The	O
291	O
-	O
nucleotide	O
clone	O
shares	O
72	O
%	O
homology	O
with	O
the	O
region	O
of	O
mouse	B-DISO
hepatitis	I-DISO
coronavirus	O
(	O
MHV	O
)	O
gene	O
1b	O
that	O
contains	O
the	O
packaging	O
signal	O
.	O

Clinical	O
and	O
physiological	O
data	O
,	O
serum	O
concentrations	O
of	O
tumour	B-DISO
necrosis	I-DISO
factor	O
(	O
TNF	O
)-	O
alpha	O
,	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
and	O
IL	O
-	O
6	O
,	O
and	O
quantitative	O
cultures	O
of	O
lower	O
respiratory	O
tract	O
specimens	O
were	O
obtained	O
from	O
46	O
patients	O
with	O
ARDS	B-DISO
and	O
20	O
with	O
severe	O
pneumonia	B-DISO
within	O
24	O
hours	O
of	O
the	O
onset	O
of	O
the	O
disease	O
and	O
from	O
10	O
control	O
subjects	O
with	O
no	O
inflammatory	O
lung	B-DISO
disease	I-DISO
.	O

The	O
frameshift	B-DISO
takes	O
place	O
at	O
the	O
slippery	O
sequence	O
with	O
the	O
two	O
ribosome	O
-	O
bound	O
tRNAs	O
slipping	O
back	O
simultaneously	O
by	O
one	O
nucleotide	O
from	O
the	O
zero	O
phase	O
(	O
U	O
UUA	O
AAC	O
)	O
to	O
the	O
-	O
1	O
phase	O
(	O
UUU	O
AAA	B-DISO
).	O

The	O
contributions	O
of	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
T	O
cells	O
in	O
the	O
pathogenesis	B-DISO
of	O
the	O
disease	O
were	O
investigated	O
.	O

Of	O
4302	O
women	O
observed	O
to	O
or	O
beyond	O
20	O
weeks	O
'	O
gestation	O
,	O
1073	O
(	O
24	O
.	O
9	O
%)	O
developed	O
mild	O
or	O
severe	O
pregnancy	O
-	O
associated	O
hypertension	B-DISO
or	O
preeclampsia	B-DISO
.	O

Adverse	O
outcomes	O
were	O
highest	O
in	O
women	O
with	O
severe	O
pregnancy	O
-	O
associated	O
hypertension	B-DISO
or	O
preeclampsia	B-DISO
.	O

Adverse	O
outcomes	O
were	O
highest	O
in	O
women	O
with	O
severe	O
pregnancy	O
-	O
associated	O
hypertension	B-DISO
or	O
preeclampsia	B-DISO
.	O

CONCLUSIONS	O
:	O
Hypertension	B-DISO
,	O
especially	O
severe	O
hypertension	B-DISO
,	O
was	O
associated	O
with	O
an	O
appreciable	O
increase	O
in	O
important	O
maternal	O
and	O
perinatal	B-DISO
morbidity	I-DISO
but	O
not	O
perinatal	O
mortality	O
.	O

The	O
study	O
constitutes	O
a	O
retrospective	O
cohort	O
of	O
80	O
consecutive	O
critically	B-DISO
ill	I-DISO
children	O
receiving	O
MV	O
for	O
severe	O
respiratory	B-DISO
diseases	I-DISO
between	O
1986	O
and	O
1993	O
.	O

The	O
full	O
-	O
length	O
N	O
protein	O
and	O
the	O
GST	O
-	O
N	O
protein	O
fusion	O
product	O
had	O
similar	O
binding	O
activities	O
with	O
a	O
dissociation	B-DISO
constant	O
(	O
K	O
(	O
d	O
))	O
of	O
14	O
nM	O
when	O
the	O
MHV	O
5	O
'-	O
leader	O
sequence	O
was	O
used	O
as	O
ligand	O
.	O

CCV	B-DISO
was	O
detected	O
by	O
EM	O
examination	O
in	O
only	O
four	O
out	O
of	O
45	O
samples	O
,	O
and	O
by	O
virus	O
isolation	O
in	O
three	O
out	O
of	O
30	O
samples	O
n	O
-	O
PCR	O
positive	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
Avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
employs	O
polyprotein	O
processing	O
as	O
a	O
strategy	O
to	O
express	O
its	O
gene	O
products	O
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
children	O
with	O
acute	O
iron	O
poisoning	O
:	O
the	O
role	O
of	O
intravenous	O
desferrioxamine	O
.	O

These	O
findings	O
indicated	O
that	O
the	O
FIPV	O
replication	O
mechanism	O
differs	O
between	O
feline	O
macrophages	O
and	O
CrFK	O
/	O
fcwf	O
-	O
4	O
cells	O
and	O
that	O
a	O
neutralizing	O
epitope	O
that	O
can	O
prevent	O
FIPV	O
infection	B-DISO
of	O
feline	O
macrophages	O
after	O
viral	O
absorption	O
is	O
present	O
on	O
M	O
protein	O
.	O

Initial	O
clinical	O
and	O
laboratory	O
data	O
were	O
collected	O
in	O
the	O
emergency	B-DISO
department	O
,	O
and	O
on	O
a	O
daily	O
basis	O
thereafter	O
during	O
the	O
patient	O
'	O
s	O
intensive	O
care	O
unit	O
stay	O
.	O

Comparison	O
with	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Within	O
the	O
overall	O
number	O
of	O
patients	O
with	O
pneumonia	B-DISO
,	O
changes	O
in	O
the	O
alveolar	O
hemostatic	O
balance	O
were	O
more	O
prominent	O
in	O
alveolar	O
and	O
interstitial	B-DISO
pneumonia	I-DISO
than	O
in	O
bronchopneumonia	B-DISO
.	O

Hence	O
,	O
PCT	B-DISO
can	O
be	O
used	O
for	O
differential	O
diagnosis	O
of	O
bacterial	O
and	O
viral	B-DISO
meningitis	I-DISO
.	O

TITLE	O
:	O
Immunogenicity	O
of	O
porcine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
virus	O
spike	O
protein	O
expressed	O
in	O
plants	O
.	O

Three	O
transgenic	O
plant	O
lines	O
were	O
generated	O
expressing	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
),	O
a	O
protein	O
crucial	O
for	O
establishing	O
mucosal	O
immunity	O
.	O

Acute	O
lung	O
injury	O
was	O
induced	O
by	O
a	O
combination	O
of	O
PLA2	O
(	O
1000	O
units	O
/	O
kg	O
/	O
hr	O
)	O
and	O
trypsin	O
(	O
5000	O
units	O
/	O
kg	O
/	O
hr	O
)	O
infused	O
intravenously	O
for	O
4	O
hrs	B-DISO
.	O

ABSTRACT	O
:	O
The	O
replicase	O
gene	O
(	O
gene	O
1	O
)	O
of	O
the	O
coronavirus	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
encodes	O
two	O
co	O
-	O
amino	O
-	O
terminal	O
polyproteins	O
presumed	O
to	O
incorporate	O
all	O
the	O
virus	O
-	O
encoded	O
proteins	O
necessary	O
for	O
viral	O
RNA	O
synthesis	O
.	O

Assays	O
have	O
been	O
developed	O
to	O
identify	O
Gray	O
strain	O
IBV	O
-	O
specific	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
responses	O
using	O
viral	O
infected	O
antigen	O
presenting	O
cells	O
(	O
APC	B-DISO
)	O
and	O
using	O
the	O
Semliki	O
Forest	O
virus	O
vector	O
infected	O
APC	B-DISO
expressing	O
individual	O
viral	O
polypeptides	O
.	O

In	O
addition	O
,	O
this	O
potential	O
DNA	O
vaccine	O
resulted	O
in	O
protection	O
of	O
chicks	O
against	O
acute	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Characterization	O
of	O
protection	O
against	O
coronavirus	B-DISO
infection	I-DISO
by	O
noninternal	O
image	O
antiidiotypic	O
antibody	O
.	O

TITLE	O
:	O
A	O
rapid	O
-	O
plate	O
hemagglutination	O
assay	O
for	O
the	O
detection	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

The	O
specificity	O
of	O
the	O
neuraminidase	O
rapid	O
-	O
plate	O
HA	O
assay	O
was	O
examined	O
with	O
other	O
avian	O
viruses	O
in	O
individual	O
and	O
dual	O
embryonic	O
infections	B-DISO
.	O

Twenty	O
-	O
two	O
consecutive	O
ventilator	O
-	O
dependent	O
patients	O
with	O
mild	O
to	O
severe	O
acute	O
lung	O
injury	O
with	O
Murray	O
scores	O
(	O
scoring	O
infiltrates	B-DISO
on	O
chest	O
radiograph	O
,	O
oxygenation	O
index	O
,	O
lung	O
compliance	O
,	O
and	O
the	O
level	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
)	O
ranging	O
from	O
0	O
.	O
5	O
to	O
3	O
.	O
0	O
without	O
history	O
of	O
preexisting	O
cardiopulmonary	B-DISO
disease	I-DISO
.	O

A	O
low	O
concentration	O
of	O
mature	O
neutrophils	O
in	O
the	O
systemic	O
circulation	O
of	O
premature	O
infants	O
within	O
2	O
hours	O
of	O
birth	O
is	O
associated	O
with	O
more	O
severe	O
respiratory	B-DISO
distress	I-DISO
during	O
the	O
first	O
postnatal	O
week	O
and	O
with	O
an	O
increased	O
risk	O
of	O
serious	O
complications	O
of	O
prematurity	O
.	O

Although	O
infectious	B-DISO
virus	O
is	O
cleared	O
by	O
CD8	O
+	O
T	O
cells	O
,	O
both	O
viral	O
RNA	O
and	O
activated	O
CD8	O
+	O
T	O
cells	O
remain	O
in	O
the	O
CNS	O
during	O
persistence	O
potentially	O
contributing	O
to	O
pathology	B-DISO
.	O

The	O
present	O
data	O
thus	O
indicate	O
that	O
in	O
immunocompetent	O
mice	O
,	O
effector	O
CD8	O
+	O
T	O
cells	O
control	O
infection	B-DISO
without	O
mediating	O
either	O
clinical	O
disease	O
or	O
demyelination	B-DISO
.	O

ABSTRACT	O
:	O
Mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)-	O
infected	O
cells	O
contain	O
full	O
-	O
length	O
and	O
subgenomic	O
-	O
length	O
positive	O
-	O
and	O
negative	O
-	O
strand	O
RNAs	O
.	O

TITLE	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
E	O
protein	O
is	O
targeted	O
to	O
the	O
Golgi	O
complex	O
and	O
directs	O
release	O
of	O
virus	O
-	O
like	O
particles	O
.	O

Among	O
mouse	O
viruses	O
,	O
high	O
positivity	O
rates	O
were	O
observed	O
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
),	O
Theiler	O
'	O
s	O
encephalomyelitis	B-DISO
virus	O
(	O
THEMV	O
),	O
minute	O
virus	O
of	O
mice	O
(	O
MVM	O
),	O
Sendai	O
virus	O
and	O
pneumonia	B-DISO
virus	O
of	O
mice	O
(	O
PVM	O
);	O
the	O
prevalence	O
rates	O
were	O
high	O
in	O
rats	O
with	O
Khilam	O
'	O
s	O
rat	O
virus	O
(	O
KRV	O
),	O
THEMV	O
,	O
Toolan	O
'	O
s	O
H	O
-	O
1	O
virus	O
,	O
Sendai	O
virus	O
,	O
Parker	O
'	O
s	O
rat	O
coronavirus	O
(	O
RCV	O
/	O
SDA	B-DISO
)	O
and	O
PVM	O
.	O

Carp	B-DISO
experimentally	O
inoculated	O
with	O
the	O
cultured	O
virus	O
showed	O
virus	O
transmission	O
,	O
and	O
the	O
same	O
pathological	O
signs	O
of	O
the	O
disease	O
and	O
mortalities	O
as	O
in	O
natural	O
infections	B-DISO
.	O

Moreover	O
,	O
the	O
recombinant	O
viruses	O
replicated	O
with	O
almost	O
the	O
same	O
efficiency	O
,	O
i	O
.	O
e	O
.,	O
reached	O
nearly	O
the	O
same	O
infectious	B-DISO
titers	O
as	O
the	O
wildtype	O
virus	O
,	O
and	O
stably	O
maintained	O
the	O
mutations	O
that	O
were	O
introduced	O
.	O

The	O
AflII	O
site	O
engineered	O
between	O
ORFs	O
5	O
and	O
6	O
was	O
subsequently	O
used	O
to	O
generate	O
a	O
virus	O
in	O
which	O
the	O
ectodomain	O
of	O
the	O
ORF	O
6	O
-	O
encoded	O
M	O
protein	O
was	O
extended	O
with	O
nine	O
amino	O
acids	O
derived	O
from	O
the	O
extreme	O
N	O
-	O
terminus	O
of	O
the	O
homologous	O
protein	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
;	O
family	O
Coronaviridae	O
,	O
order	O
Nidovirales	O
).	O

Comparison	O
with	O
a	O
first	O
-	O
generation	O
adenovirus	B-DISO
carrying	O
the	O
same	O
mIFN	O
-	O
alpha2	O
expression	O
cassette	O
indicates	O
that	O
at	O
certain	O
HD	O
-	O
IFN	O
doses	O
,	O
induction	O
of	O
antiviral	O
genes	O
can	O
be	O
achieved	O
in	O
the	O
absence	O
of	O
detectable	O
circulating	O
mIFN	O
-	O
alpha2	O
.	O

We	O
describe	O
the	O
case	O
of	O
a	O
35	O
year	O
old	O
woman	O
who	O
presented	O
with	O
dysarthria	B-DISO
,	O
weakness	B-DISO
and	O
paraesthesia	B-DISO
of	O
her	O
left	O
limbs	O
and	O
left	O
central	B-DISO
facial	I-DISO
paralysis	I-DISO
of	O
sudden	O
onset	O
.	O

We	O
consider	O
that	O
the	O
physiopathological	O
mechanisms	O
must	O
be	O
related	O
to	O
factors	O
which	O
determine	O
a	O
prothrombotic	O
state	O
in	O
the	O
arterial	O
bed	B-DISO
involved	O
.	O

SIV	B-DISO
is	O
a	O
primary	O
respiratory	O
pathogen	O
;	O
PRCV	O
and	O
PRRSV	O
,	O
on	O
the	O
contrary	O
,	O
tend	O
to	O
cause	O
subclinical	B-DISO
infections	I-DISO
if	O
uncomplicated	O
but	O
they	O
appear	O
to	O
be	O
important	O
contributors	O
to	O
multifactorial	O
respiratory	B-DISO
diseases	I-DISO
.	O

The	O
exact	O
mechanisms	O
whereby	O
these	O
viruses	O
cause	O
symptoms	O
and	O
pathology	B-DISO
,	O
however	O
,	O
remain	O
unresolved	O
.	O

The	O
biological	O
effects	O
of	O
these	O
cytokines	O
and	O
their	O
involvement	O
in	O
human	O
viral	O
respiratory	B-DISO
disease	I-DISO
are	O
discussed	O
in	O
the	O
second	O
part	O
of	O
this	O
review	O
.	O

ABSTRACT	O
:	O
A	O
bronchial	O
secretion	O
draining	O
effect	O
is	O
frequently	O
suggested	O
as	O
a	O
mechanism	O
for	O
oxygenation	O
improvement	O
during	O
prone	O
positioning	O
(	O
PP	O
)	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

The	O
study	O
included	O
15	O
consecutive	O
patients	O
with	O
severe	O
ARDS	B-DISO
(	O
PaO2	O
/	O
FIO2	O
<	O
200	O
after	O
alveolar	O
recruitment	B-DISO
,	O
Murray	O
score	O
>	O
2	O
.	O
5	O
).	O

Compared	O
with	O
the	O
baseline	O
condition	B-DISO
at	O
h0	O
,	O
PP	O
and	O
PP	O
+	O
NO	O
respectively	O
improved	O
PaO2	O
/	O
FIO2	O
by	O
102	O
+/-	O

ABSTRACT	O
:	O
To	O
profile	O
the	O
types	O
and	O
frequencies	O
of	O
cardiopulmonary	O
morbidity	O
encountered	O
in	O
patients	O
with	O
severe	B-DISO
preeclampsia	I-DISO
with	O
or	O
without	O
hemolysis	B-DISO
,	O
elevated	O
liver	O
enzymes	O
,	O
and	O
low	O
platelets	O
(	O
HELLP	B-DISO
syndrome	I-DISO
).	O

We	O
initiated	O
a	O
retrospective	O
study	O
of	O
979	O
patients	O
with	O
severe	B-DISO
preeclampsia	I-DISO
with	O
and	O
without	O
HELLP	B-DISO
syndrome	I-DISO
.	O

The	O
study	O
was	O
set	O
in	O
a	O
12	O
-	O
bed	B-DISO
multi	O
-	O
trauma	O
intensive	O
care	O
unit	O
at	O
a	O
level	O
one	O
trauma	O
center	O
and	O
hyperbaric	O
medicine	O
center	O
.	O

Serum	O
tumor	B-DISO
necrosis	I-DISO
factor	O
(	O
TNF	O
)	O
protein	O
(	O
ELISA	O
),	O
hepatic	O
TNF	O
mRNA	O
(	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
),	O
and	O
hepatic	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
kappa	O
B	O
(	O
electrophoretic	O
mobility	O
shift	O
assay	O
)	O
were	O
also	O
determined	O
.	O

There	O
are	O
trends	O
toward	O
decreases	O
in	O
CLD	B-DISO
in	O
survivors	O
at	O
28	O
-	O
30	O
days	O
,	O
'	O
death	O
or	O
CLD	B-DISO
at	O
28	O
-	O
30	O
days	O
'	O
and	O
CLD	B-DISO
in	O
survivors	O
at	O
36	O
-	O
37	O
weeks	O
postmenstrual	O
age	O
or	O
discharge	O
in	O
the	O
HFOV	O
group	O
.	O

HFOV	O
results	O
in	O
a	O
small	O
increase	O
in	O
any	O
air	O
leak	O
syndrome	B-DISO
(	O
ALS	B-DISO
),	O
[	O
summary	O
RR	O
1	O
.	O
20	O
(	O
1	O
.	O
03	O
,	O
1	O
.	O
39	O
)].	O

Subgroup	O
analyses	O
shows	O
a	O
significant	O
increase	O
in	O
risk	O
of	O
PVL	O
in	O
the	O
trial	O
by	O
Wiswell	O
1996	O
[	O
RR	O
5	O
.	O
0	O
(	O
1	O
.	O
19	O
,	O
21	O
.	O
04	O
),	O
RD	O
0	O
.	O
250	O
(	O
0	O
.	O
069	O
,	O
0	O
.	O
431	O
),	O
NNH	B-DISO
4	O
.	O
0	O
(	O
2	O
.	O
3	O
,	O
14	O
.	O
5	O
)]	O
where	O
a	O
'	O
low	O
volume	O
strategy	O
'	O
was	O
the	O
standard	O
protocol	O
for	O
HFJV	O
.	O

To	O
compare	O
the	O
effects	O
of	O
early	O
vs	O
.	O
delayed	O
selective	O
surfactant	O
therapy	O
for	O
newborns	O
intubated	O
for	O
respiratory	B-DISO
distress	I-DISO
within	O
the	O
first	O
two	O
hours	O
of	O
life	O
.	O

Infants	O
randomized	O
to	O
early	O
selective	O
surfactant	O
administration	O
also	O
demonstrated	O
a	O
decreased	O
risk	O
of	O
neonatal	O
mortality	O
(	O
Typical	O
RR	O
0	O
.	O
87	O
,	O
95	O
%	O
CI	O
0	O
.	O
77	O
,	O
0	O
.	O
99	O
;	O
Typical	O
RD	O
-	O
0	O
.	O
03	O
,	O
95	O
%	O
CI	O
-	O
0	O
.	O
06	O
,	O
-	O
0	O
.	O
00	O
),	O
chronic	B-DISO
lung	I-DISO
disease	I-DISO
(	O
Typical	O
RR	O
0	O
.	O
70	O
,	O
95	O
%	O
CI	O
0	O
.	O

55	O
,	O
0	O
.	O
88	O
;	O
Typical	O
RD	O
-	O
0	O
.	O
03	O
,	O
95	O
%	O
CI	O
-	O
0	O
.	O
05	O
,	O
-	O
0	O
.	O
01	O
),	O
and	O
chronic	B-DISO
lung	I-DISO
disease	I-DISO
or	O
death	O
at	O
36	O
weeks	O
(	O
Typical	O
RR	O
0	O
.	O
84	O
,	O
95	O
%	O
CI	O
0	O
.	O
75	O
,	O
0	O
.	O
93	O
;	O
Typical	O
RD	O
-	O
0	O
.	O
06	O
,	O
95	O
%	O
CI	O
-	O
0	O
.	O
09	O
,	O
-	O
0	O
.	O
03	O
).	O

TITLE	O
:	O
Decontamination	O
of	O
human	O
xenotransplantable	O
tumor	B-DISO
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
by	O
implantation	O
in	O
nude	O
rat	O
:	O
a	O
case	O
report	O
.	O

TITLE	O
:	O
Protection	O
studies	O
on	O
winter	B-DISO
dysentery	I-DISO
caused	O
by	O
bovine	O
coronavirus	O
in	O
cattle	O
using	O
antigens	O
prepared	O
from	O
infected	O
cell	O
lysates	O
.	O

The	O
patient	O
had	O
severe	O
gas	O
exchange	O
abnormalities	O
because	O
of	O
acute	O
lung	O
injury	O
and	O
marked	O
lung	B-DISO
collapse	I-DISO
.	O

We	O
used	O
a	O
recruitment	B-DISO
maneuver	O
using	O
40	O
cm	O
H2O	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
and	O
20	O
cm	O
H2O	O
of	O
pressure	O
controlled	O
ventilation	O
above	O
PEEP	O
for	O
2	O
mins	O
to	O
successfully	O
recruit	O
the	O
lung	O
.	O

With	O
the	O
recruitment	B-DISO
maneuvers	O
,	O
the	O
patient	O
had	O
a	O
dramatic	O
improvement	O
in	O
gas	O
exchange	O
and	O
we	O
were	O
able	O
to	O
demonstrate	O
nearly	O
complete	O
recruitment	B-DISO
of	O
the	O
lung	O
by	O
computed	O
tomography	O
.	O

SUPPORT	O
enrolled	O
2956	O
patients	O
with	O
ARF	B-DISO
or	O
MOSF	O
,	O
and	O
44	O
%	O
died	O
during	O
enrollment	O
hospitalization	O
.	O

Limitations	O
to	O
aggressive	B-DISO
treatments	O
were	O
usually	O
implemented	O
only	O
when	O
death	O
was	O
imminent	O
.	O

The	O
FIV	O
infection	B-DISO
did	O
not	O
adversely	O
affect	O
the	O
cats	O
'	O
life	O
expectancy	O
.	O

We	O
report	O
the	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
to	O
rescue	O
a	O
child	O
with	O
ARDS	B-DISO
.	O

The	O
patient	O
,	O
a	O
7	O
-	O
year	O
-	O
old	O
boy	O
,	O
underwent	O
a	O
Ross	O
procedure	O
and	O
mitral	O
valvuloplasty	O
because	O
of	O
severe	O
aortic	O
and	O
mild	O
mitral	B-DISO
regurgitation	I-DISO
.	O

TITLE	O
:	O
Isolation	O
of	O
respiratory	O
bovine	O
coronavirus	O
,	O
other	O
cytocidal	O
viruses	O
,	O
and	O
Pasteurella	O
spp	O
from	O
cattle	O
involved	O
in	O
two	O
natural	O
outbreaks	O
of	O
shipping	B-DISO
fever	I-DISO
.	O

93	O
of	O
105	O
cattle	O
and	O
106	O
of	O
120	O
cattle	O
developed	O
signs	O
of	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
during	O
1997	O
and	O
1998	O
,	O
respectively	O
,	O
and	O
RBCV	O
was	O
isolated	O
from	O
81	O
and	O
89	O
sick	O
cattle	O
,	O
respectively	O
,	O
while	O
at	O
the	O
order	O
-	O
buyer	O
'	O
s	O
barn	O
or	O
the	O
day	O
after	O
arrival	O
at	O
the	O
feedlot	O
.	O

During	O
the	O
1998	O
outbreak	O
,	O
bovine	O
herpesvirus	O
1	O
was	O
isolated	O
from	O
2	O
cattle	O
at	O
the	O
order	O
-	O
buyer	O
'	O
s	O
barn	O
and	O
on	O
arrival	O
at	O
the	O
feedlot	O
and	O
from	O
5	O
cattle	O
7	O
and	O
14	O
days	O
after	O
arrival	O
at	O
the	O
feedlot	O
,	O
and	O
parainfluenza	B-DISO
virus	O
3	O
was	O
isolated	O
from	O
1	O
animal	O
the	O
day	O
of	O
,	O
and	O
from	O
18	O
cattle	O
7	O
and	O
14	O
days	O
after	O
,	O
arrival	O
at	O
the	O
feedlot	O
.	O

Results	O
suggest	O
that	O
RBCV	O
may	O
play	O
a	O
causative	O
role	O
in	O
outbreaks	O
of	O
shipping	B-DISO
fever	I-DISO
in	O
cattle	O
.	O

ABSTRACT	O
:	O
The	O
restless	B-DISO
legs	I-DISO
syndrome	I-DISO
(	O
RLS	B-DISO
)	O
is	O
a	O
common	O
sensorimotor	B-DISO
disorder	I-DISO
which	O
leads	O
to	O
severe	O
sleep	B-DISO
disturbances	I-DISO
and	O
showed	O
a	O
prevalence	O
of	O
7	O
.	O
9	O
%	O
in	O
our	O
sleep	O
laboratory	O
.	O

As	O
a	O
rule	O
,	O
patients	O
with	O
ABO	O
with	O
severe	O
endotoxicosis	B-DISO
develop	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
presenting	O
as	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
on	O
days	O
2	O
-	O
3	O
postoperation	O
.	O

Pancreatitis	B-DISO
was	O
induced	O
by	O
either	O
0	O
.	O
5	O
mL	O
of	O
a	O
4	O
%	O
solution	O
of	O
sodium	O
taurocholate	O
(	O
TAU	O
group	O
)	O
or	O
0	O
.	O
5	O
mL	O
of	O
normal	O
saline	O
(	O
SAL	O
group	O
)	O
injection	O
into	O
the	O
biliopancreatic	O
duct	O
.	O

TITLE	O
:	O
[	O
Respiratory	B-DISO
distress	I-DISO
in	O
three	O
newborns	O
after	O
mask	O
disinfection	O
with	O
Endosporine	O
.	O

Concurrent	O
infections	B-DISO
with	O
other	O
enteropathogen	O
(	O
s	O
)	O
were	O
detected	O
in	O
31	O
.	O
3	O
%,	O
33	O
.	O
3	O
%,	O
20	O
.	O
6	O
%	O
and	O
3	O
.	O
4	O
%	O
of	O
the	O
rotavirus	O
infected	O
calves	O
in	O
the	O
age	O
-	O
groups	O
1	O
-	O
7	O
,	O
8	O
-	O
14	O
,	O
15	O
-	O
21	O
and	O
22	O
-	O
30	O
d	O
,	O
respectively	O
.	O

TITLE	O
:	O
Expression	O
of	O
reporter	O
genes	O
from	O
the	O
defective	O
RNA	O
CD	O
-	O
61	O
of	O
the	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

ABSTRACT	O
:	O
The	O
defective	O
RNA	O
(	O
D	O
-	O
RNA	O
)	O
CD	O
-	O
61	O
,	O
derived	O
from	O
the	O
Beaudette	O
strain	O
of	O
the	O
avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
),	O
was	O
used	O
as	O
an	O
RNA	O
vector	O
for	O
the	O
expression	O
of	O
two	O
reporter	O
genes	O
,	O
luciferase	O
and	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
).	O

The	O
Beaudette	O
gene	O
5	O
TAS	B-DISO
is	O
composed	O
of	O
two	O
tandem	O
repeats	O
of	O
the	O
IBV	O
canonical	O
consensus	O
sequence	O
involved	O
in	O
the	O
acquisition	O
of	O
a	O
leader	O
sequence	O
during	O
the	O
discontinuous	O
transcription	O
of	O
IBV	O
subgenomic	O
mRNAs	O
.	O

When	O
the	O
acute	B-DISO
chest	I-DISO
syndrome	I-DISO
was	O
diagnosed	O
,	O
patients	O
had	O
hypoxia	B-DISO
,	O
decreasing	O
hemoglobin	O
values	O
,	O
and	O
progressive	O
multilobar	B-DISO
pneumonia	I-DISO
.	O

Neurologic	O
events	O
occurred	O
in	O
11	O
percent	O
of	O
patients	O
,	O
among	O
whom	O
46	O
percent	O
had	O
respiratory	B-DISO
failure	I-DISO
.	O

Among	O
older	O
patients	O
and	O
those	O
with	O
neurologic	B-DISO
symptoms	I-DISO
,	O
the	O
syndrome	B-DISO
often	O
progresses	O
to	O
respiratory	B-DISO
failure	I-DISO
.	O

Treatment	O
with	O
transfusions	O
and	O
bronchodilators	O
improves	O
oxygenation	O
,	O
and	O
with	O
aggressive	B-DISO
treatment	O
,	O
most	O
patients	O
who	O
have	O
respiratory	B-DISO
failure	I-DISO
recover	O
.	O

TITLE	O
:	O
Molecular	O
screening	O
by	O
polymerase	O
chain	O
reaction	O
detects	O
panleukopenia	O
virus	O
DNA	O
in	O
formalin	O
-	O
fixed	O
hearts	O
from	O
cats	O
with	O
idiopathic	B-DISO
cardiomyopathy	I-DISO
and	O
myocarditis	B-DISO
.	O

Panleukopenia	O
virus	O
was	O
identified	O
by	O
PCR	O
in	O
10	O
of	O
31	O
cats	O
with	O
cardiomyopathy	B-DISO
but	O
in	O
none	O
of	O
the	O
controls	O
.	O

ABSTRACT	O
:	O
A	O
multiplex	O
reverse	O
-	O
transcriptase	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
procedure	O
was	O
developed	O
for	O
the	O
simultaneous	O
detection	O
of	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
(	O
PEDV	O
)	O
and	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
in	O
preweaning	O
pigs	O
with	O
diarrhoea	B-DISO
.	O

ABSTRACT	O
:	O
Abdominal	B-DISO
compartment	I-DISO
syndrome	I-DISO
(	O
ACS	O
)	O
is	O
defined	O
as	O
cardiopulmonary	O
or	O
renal	O
dysfunction	O
caused	O
by	O
an	O
acute	O
increase	O
in	O
intraabdominal	O
pressure	O
.	O

Although	O
the	O
condition	B-DISO
is	O
well	O
described	O
in	O
adults	O
,	O
particularly	O
trauma	O
patients	O
,	O
little	O
is	O
known	O
about	O
ACS	O
in	O
children	O
.	O

To	O
prevent	O
the	O
development	O
of	O
renal	O
or	O
cardiopulmonary	B-DISO
failure	I-DISO
in	O
these	O
patients	O
,	O
decompression	O
should	O
be	O
considered	O
for	O
acute	O
,	O
tense	B-DISO
abdominal	O
distension	B-DISO
.	O

TITLE	O
:	O
Identifying	O
agent	O
(	O
s	O
)	O
associated	O
with	O
poult	O
enteritis	B-DISO
mortality	O
syndrome	B-DISO
:	O
importance	O
of	O
the	O
thymus	O
.	O

Histopathologic	O
examination	O
of	O
tissues	O
from	O
PEMS	O
-	O
infected	O
poults	O
suggested	O
that	O
the	O
thymus	O
exhibited	O
the	O
earliest	O
signs	O
of	O
pathology	B-DISO
.	O

Poults	O
exposed	O
to	O
a	O
filtrate	O
composed	O
solely	O
of	O
the	O
thymus	O
from	O
PEMS	O
-	O
infected	O
birds	O
exhibited	O
diarrhea	B-DISO
,	O
growth	O
depression	B-DISO
,	O
mortality	O
,	O
pathology	B-DISO
,	O
and	O
,	O
most	O
importantly	O
,	O
immunosuppression	O
similar	O
to	O
poults	O
exposed	O
to	O
the	O
intestinal	O
filtrate	O
.	O

ABSTRACT	O
:	O
The	O
role	O
of	O
a	O
novel	O
""""	O
small	O
round	O
virus	O
""""	O
(	O
SRV	O
)	O
isolated	O
from	O
poult	O
enteritis	B-DISO
and	O
mortality	O
syndrome	B-DISO
(	O
PEMS	B-DISO
)	O
cases	O
in	O
inducing	O
PEMS	B-DISO
and	O
associated	O
immune	O
alterations	O
was	O
examined	O
in	O
this	O
study	O
.	O

TITLE	O
:	O
Viral	O
agents	O
associated	O
with	O
poult	O
enteritis	B-DISO
and	O
mortality	O
syndrome	B-DISO
:	O
the	O
role	O
of	O
a	O
small	O
round	O
virus	O
and	O
a	O
turkey	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Intestinal	O
samples	O
from	O
turkey	O
poults	O
affected	O
with	O
poult	O
enteritis	B-DISO
and	O
mortality	O
syndrome	B-DISO
(	O
PEMS	O
)	O
were	O
examined	O
for	O
viruses	O
by	O
immune	O
electron	O
microscopy	O
and	O
double	O
-	O
stranded	O
RNA	O
virus	O
genome	O
electropherotyping	O
.	O

TITLE	O
:	O
Fulminant	O
tracheobronchial	O
and	O
pulmonary	B-DISO
aspergillosis	I-DISO
complicating	O
imported	O
Plasmodium	B-DISO
falciparum	I-DISO
malaria	I-DISO
in	O
an	O
apparently	O
immunocompetent	O
woman	O
.	O

TITLE	O
:	O
A	O
potential	O
role	O
for	O
tumour	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
in	O
synergy	O
between	O
porcine	O
respiratory	O
coronavirus	O
and	O
bacterial	O
lipopolysaccharide	O
in	O
the	O
induction	O
of	O
respiratory	B-DISO
disease	I-DISO
in	O
pigs	O
.	O

Caesarian	O
-	O
derived	O
colostrum	O
-	O
deprived	O
pigs	O
were	O
inoculated	O
intratracheally	O
with	O
PRCV	O
,	O
with	O
LPS	B-DISO
from	O
Escherichia	O
coli	O
O111	O
:	O
B4	O
(	O
20	O
microg	O
/	O
kg	O
),	O
or	O
with	O
a	O
combination	O
of	O
the	O
two	O
,	O
and	O
killed	O
at	O
set	O
times	O
after	O
inoculation	O
.	O

High	O
-	O
dose	O
glucocorticoid	O
,	O
anticoagulation	O
with	O
heparin	O
,	O
plasmapheresis	O
and	O
cyclophosphamide	O
improved	O
her	O
clinical	O
condition	B-DISO
.	O

Despite	O
this	O
,	O
the	O
patient	O
died	O
several	O
days	O
later	O
of	O
spontaneous	O
intracranial	B-DISO
haemorrhage	I-DISO
.	O

All	O
presented	O
with	O
fever	O
,	O
hepatosplenomegaly	B-DISO
,	O
and	O
pancytopenia	B-DISO
;	O
5	O
were	O
previously	O
healthy	O
,	O
but	O
had	O
a	O
clinical	O
history	O
of	O
a	O
recent	O
viral	O
-	O
like	O
upper	O
respiratory	O
illness	O
(	O
1	O
week	O
to	O
2	O
months	O
),	O
and	O
1	O
patient	O
had	O
documented	O
chronic	O
active	O
EBV	B-DISO
infection	I-DISO
for	O
7	O
years	O
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
identified	O
a	O
functionally	O
essential	O
bulged	O
stem	O
-	O
loop	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
the	O
positive	O
-	O
stranded	O
RNA	O
genome	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
.	O

TITLE	O
:	O
Impaired	B-DISO
entry	O
of	O
soluble	O
receptor	O
-	O
resistant	O
mutants	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
into	O
cells	O
expressing	O
MHVR2	O
receptor	O
.	O

This	O
suggests	O
that	O
the	O
most	O
likely	O
reason	O
for	O
inefficient	O
infection	B-DISO
by	O
mutants	O
in	O
BHK	O
-	O
R2	O
is	O
impaired	B-DISO
virus	O
entry	O
into	O
cells	O
.	O

These	O
observations	O
suggest	O
that	O
inefficient	O
infections	B-DISO
in	O
BHK	O
-	O
R2	O
cells	O
by	O
srr	O
mutants	O
occur	O
in	O
the	O
absence	O
of	O
a	O
functional	O
receptor	O
MHVR1	O
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
srr	O
entry	O
into	O
cells	O
.	O

Chest	O
radiography	O
results	O
showed	O
bilateral	O
and	O
diffuse	O
infiltrate	B-DISO
.	O

ABSTRACT	O
:	O
A	O
15	O
-	O
year	O
-	O
old	O
patient	O
has	O
been	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
for	O
severe	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
that	O
developed	O
as	O
a	O
result	O
of	O
pneumonia	B-DISO
.	O

Furthermore	O
,	O
using	O
an	O
established	O
adoptive	O
transfer	O
model	O
and	O
pharmacological	O
inhibitors	O
of	O
NOS2	O
function	O
,	O
we	O
could	O
demonstrate	O
no	O
effect	O
on	O
MHV	O
-	O
induced	O
demyelination	B-DISO
.	O

A	O
reverse	O
transcription	O
(	O
RT	O
)-	O
nested	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
with	O
primers	O
targeted	O
to	O
the	O
S	O
gene	B-DISO
deletion	I-DISO
region	O
to	O
differentiate	O
TGEV	O
/	O
PRCV	O
was	O
developed	O
.	O

The	O
study	O
identified	O
1617	O
English	O
-	O
and	O
Spanish	O
-	O
speaking	O
patients	O
with	O
cancer	B-DISO
or	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
infection	I-DISO
or	O
acquired	B-DISO
immunodeficiency	I-DISO
syndrome	I-DISO
who	O
participated	O
in	O
a	O
multisite	O
validation	O
of	O
the	O
Functional	O
Assessment	O
of	O
Cancer	B-DISO
Therapy	O
Scale	O
.	O

The	O
predominant	O
clinical	O
syndromes	B-DISO
varied	O
by	O
age	O
:	O
pneumonia	B-DISO
and	O
bronchiolitis	B-DISO
in	O
children	O
aged	O
<	O
5	O
years	O
;	O
exacerbations	O
of	O
asthma	B-DISO
in	O
older	O
children	O
and	O
young	O
adults	O
;	O
and	O
pneumonia	B-DISO
and	O
exacerbations	O
of	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
and	O
congestive	B-DISO
heart	I-DISO
failure	I-DISO
in	O
older	O
adults	O
.	O

The	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
(	O
GBS	B-DISO
)	O
is	O
the	O
most	O
frequent	O
cause	O
.	O

The	O
English	O
-	O
language	O
literature	O
on	O
severe	O
cases	O
of	O
ornithosis	B-DISO
requiring	O
respiratory	O
support	O
over	O
the	O
past	O
30	O
years	O
is	O
reviewed	O
.	O

However	O
,	O
whether	O
these	O
recruitment	B-DISO
strategies	O
are	O
effective	O
as	O
rescue	O
treatment	O
after	O
established	O
lung	O
injury	O
is	O
unknown	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
each	O
lung	O
recruitment	B-DISO
strategy	O
improved	O
oxygenation	O
in	O
premature	O
lambs	O
with	O
established	O
lung	O
injury	O
.	O

Because	O
inflammatory	O
mediators	O
such	O
as	O
tumor	B-DISO
necrosis	I-DISO
factor	O
(	O
TNF	O
)-	O
alpha	O
and	O
nitric	O
oxide	O
(	O
NO	O
)	O
produced	O
within	O
the	O
lungs	O
have	O
been	O
implicated	O
in	O
sepsis	B-DISO
-	O
induced	O
ARDS	B-DISO
,	O
we	O
aimed	O
to	O
determine	O
the	O
role	O
of	O
these	O
mediators	O
in	O
pancreatitis	B-DISO
-	O
induced	O
ARDS	B-DISO
using	O
a	O
model	O
whereby	O
ascites	O
from	O
animals	O
with	O
pancreatitis	B-DISO
is	O
transferred	O
to	O
otherwise	O
healthy	O
animals	O
resulting	O
in	O
pulmonary	O
injury	O
.	O

Pathogen	O
-	O
free	O
Sprague	O
-	O
Dawley	O
rats	O
weighing	O
225	O
-	O
250	O
g	O
.	O
Sterile	B-DISO
,	O
endotoxin	O
-	O
and	O
cytokine	O
-	O
free	O
pancreatic	B-DISO
ascites	I-DISO
tested	O
for	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
,	O
TNF	O
-	O
alpha	O
,	O
interferon	O
-	O
gamma	O
,	O
and	O
IL	O
-	O
6	O
was	O
obtained	O
from	O
rats	O
18	O
hrs	B-DISO
after	O
the	O
induction	O
of	O
severe	O
,	O
acute	B-DISO
pancreatitis	I-DISO
.	O

A	O
component	O
of	O
pancreatic	B-DISO
ascites	I-DISO
other	O
than	O
endotoxin	O
,	O
bacteria	O
,	O
or	O
cytokines	O
(	O
IL	O
-	O
1beta	O
,	O
TNF	O
,	O
interferon	O
-	O
gamma	O
,	O
or	O
IL	O
-	O
6	O
)	O
is	O
capable	O
of	O
inducing	O
ARDS	B-DISO
in	O
healthy	O
animals	O
.	O

Demyelination	B-DISO
is	O
largely	O
immune	O
mediated	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
,	O
following	O
adoptive	O
transfer	O
,	O
virus	O
-	O
specific	O
CD4	O
and	O
CD8	O
T	O
cells	O
rapidly	O
infiltrate	B-DISO
the	O
CNS	O
of	O
MHV	O
-	O
JHM	O
-	O
infected	O
RAG1	O
-/-	O
mice	O
.	O

MHV	O
-	O
JHM	O
-	O
infected	O
RAG1	O
-/-	O
mice	O
receiving	O
donors	O
depleted	O
of	O
both	O
CD4	O
and	O
CD8	O
T	O
cells	O
did	O
not	O
develop	O
demyelination	B-DISO
.	O

To	O
determine	O
whether	O
a	O
patient	O
has	O
a	O
transudative	O
or	O
exudative	B-DISO
pleural	I-DISO
effusion	I-DISO
,	O
Light	O
'	O
s	O
criteria	O
should	O
be	O
applied	O
to	O
measure	O
the	O
concentrations	O
of	O
protein	O
and	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
in	O
the	O
pleural	O
fluid	O
and	O
serum	O
.	O

In	O
these	O
diseases	O
,	O
the	O
pulmonary	O
bloodflow	O
is	O
impaired	B-DISO
by	O
a	O
pathologic	B-DISO
constriction	I-DISO
of	O
blood	O
vessels	O
that	O
may	O
lead	O
to	O
right	O
ventricular	O
overloading	O
as	O
well	O
as	O
serious	O
worsening	O
of	O
gas	O
exchange	O
mainly	O
caused	O
by	O
ventilation	O
/	O
perfusion	O
mismatch	O
.	O

Infection	B-DISO
is	O
resolved	O
within	O
fourteen	O
days	O
with	O
a	O
rise	O
in	O
antibody	O
titres	O
.	O

Salmonella	B-DISO
Gallinarum	O
and	O
S	O
.	O
Pullorum	O
are	O
unknown	O
in	O
ostriches	O
.	O

Adenovirus	B-DISO
DNA	O
was	O
found	O
in	O
78	O
.	O
4	O
%	O
of	O
asthmatic	B-DISO
children	O
,	O
rhinovirus	O
RNA	O
in	O
32	O
.	O
4	O
%	O
and	O
coronavirus	O
RNA	O
in	O
2	O
.	O
7	O
%.	O

Adenovirus	B-DISO
DNA	O
was	O
detected	O
in	O
one	O
of	O
the	O
20	O
nasopharyngeal	O
swabs	O
of	O
healthy	O
controls	O
;	O
the	O
rest	O
of	O
the	O
control	O
samples	O
were	O
negative	O
.	O

Autopsy	O
revealed	O
as	O
cause	O
of	O
death	O
left	B-DISO
heart	I-DISO
failure	I-DISO
with	O
aortic	O
valvar	O
endocarditis	B-DISO
and	O
gelatinour	O
pneumonia	B-DISO
caused	O
by	O
late	O
tubercular	O
dissemination	O
from	O
the	O
tubercular	O
spondylitis	B-DISO
.	O

CONCLUSIONS	O
:	O
Tuberculosis	B-DISO
can	O
be	O
a	O
life	O
-	O
threatening	O
infection	B-DISO
.	O

Nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
including	O
aspirin	O
(	O
acetylsalicylic	O
acid	O
)	O
may	O
induce	O
asthma	B-DISO
.	O

Other	O
antibacterials	O
mainly	O
evoke	O
pneumonitis	B-DISO
,	O
pulmonary	B-DISO
infiltrates	I-DISO
and	O
eosinophilia	B-DISO
,	O
and	O
bronchiolitis	B-DISO
obliterans	I-DISO
.	O

Psychotropic	O
drugs	O
such	O
as	O
phenothiazides	O
,	O
butyrophenones	O
and	O
tricyclic	O
antidepressants	O
can	O
also	O
induce	O
pulmonary	B-DISO
oedema	I-DISO
.	O

The	O
possibility	O
of	O
the	O
occurrence	O
of	O
ARDs	B-DISO
should	O
be	O
taken	O
into	O
account	O
in	O
each	O
individual	O
patient	O
.	O

TITLE	O
:	O
Molecular	O
characterization	O
and	O
pathogenesis	B-DISO
of	O
transmissible	O
gastroenteritis	B-DISO
coronavirus	O
(	O
TGEV	O
)	O
and	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
)	O
field	O
isolates	O
co	O
-	O
circulating	O
in	O
a	O
swine	O
herd	O
.	O

TITLE	O
:	O
[	O
Retinoic	B-DISO
acid	I-DISO
syndrome	I-DISO
.	O

APL	B-DISO
was	O
diagnosed	O
and	O
he	O
underwent	O
treatment	O
with	O
idarubicin	O
and	O
ATRA	O
(	O
GIMEMA	O
protocol	O
);	O
24	O
hrs	B-DISO
after	O
ATRA	O
treatment	O
he	O
developed	O
retinoic	B-DISO
acid	I-DISO
syndrome	I-DISO
and	O
was	O
admitted	O
to	O
the	O
Intensive	O
Care	O
Unit	O
because	O
of	O
severe	O
respiratory	B-DISO
insufficiency	I-DISO
(	O
dyspnoea	B-DISO
,	O
tachypnea	B-DISO
and	O
severe	O
hypoxemia	O
(	O
SpO2	O
75	O
%).	O

Despite	O
removal	O
of	O
the	O
tumor	B-DISO
within	O
18	O
hours	O
of	O
presentation	O
,	O
the	O
patient	O
suffered	B-DISO
severe	O
complications	O
of	O
massive	O
catecholamine	O
excess	O
,	O
including	O
shock	O
,	O
cardiomyopathy	B-DISO
,	O
and	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analysis	O
identified	O
the	O
upregulation	O
of	O
Fas	B-DISO
ligand	O
(	O
FasL	O
)	O
and	O
granzyme	O
B	O
mRNAs	O
within	O
the	O
infected	O
retinas	O
.	O

The	O
development	O
of	O
apoptosis	O
,	O
regulative	O
gene	O
expression	O
,	O
and	O
viral	O
clearance	O
were	O
similar	O
in	O
both	O
retinal	B-DISO
degeneration	I-DISO
-	O
susceptible	O
(	O
BALB	O
/	O
c	O
)	O
and	O
-	O
resistant	O
(	O
CD	O
-	O
1	O
)	O
mice	O
.	O

Nasal	O
swab	O
and	O
serum	O
samples	O
were	O
collected	O
prior	O
to	O
onset	O
of	O
the	O
epizootics	O
,	O
during	O
disease	B-DISO
progression	I-DISO
,	O
and	O
after	O
death	O
,	O
when	O
necropsies	O
were	O
performed	O
and	O
lung	O
samples	O
were	O
collected	O
.	O

TITLE	O
:	O
[	O
An	O
unusual	O
cause	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
].	O

The	O
main	O
and	O
unusual	O
cause	O
of	O
ARD	O
was	O
hypophosphataemia	B-DISO
.	O

This	O
case	O
provides	O
an	O
opportunity	O
for	O
reviewing	O
the	O
main	O
causes	O
and	O
consequences	O
of	O
hypophosphataemia	B-DISO
,	O
and	O
for	O
emphasising	O
the	O
value	O
of	O
monitoring	O
serum	O
phosphate	O
levels	O
and	O
providing	O
supplemental	O
phosphate	O
in	O
ICU	O
patients	O
at	O
risk	O
for	O
phosphate	O
depletion	O
.	O

TITLE	O
:	O
Association	O
between	O
infection	B-DISO
of	O
the	O
respiratory	O
tract	O
attributable	O
to	O
bovine	O
coronavirus	O
and	O
health	O
and	O
growth	O
performance	O
of	O
cattle	O
in	O
feedlots	O
.	O

Additionally	O
,	O
cattle	O
that	O
shed	O
BCV	O
from	O
the	O
nasal	O
cavity	B-DISO
were	O
2	O
.	O
2	O
times	O
more	O
likely	O
to	O
have	O
pulmonary	O
lesions	O
at	O
slaughter	O
than	O
cattle	O
that	O
did	O
not	O
shed	O
the	O
virus	O
.	O

Confounding	O
variables	O
in	O
this	O
study	O
could	O
include	O
exposure	O
to	O
domestic	O
dogs	O
associated	O
with	O
the	O
project	O
,	O
prolonged	O
time	O
spent	O
in	O
captivity	O
,	O
and	O
concurrent	O
bacterial	O
or	O
parasitic	B-DISO
infection	I-DISO
.	O

Thus	O
,	O
MHV	O
-	O
induced	O
28S	O
rRNA	O
cleavage	O
was	O
independent	O
of	O
the	O
activation	O
of	O
RNase	O
L	O
.	O
MHV	O
-	O
induced	O
28S	O
rRNA	O
cleavage	O
was	O
also	O
different	O
from	O
apoptosis	O
-	O
related	O
rRNA	O
degradation	O
,	O
which	O
usually	O
occurs	O
concomitantly	O
with	O
DNA	O
fragmentation	B-DISO
.	O

The	O
EDI	O
-	O
ORF	O
was	O
disrupted	O
at	O
different	O
positions	O
by	O
the	O
introduction	O
of	O
frameshift	B-DISO
mutations	I-DISO
.	O

TITLE	O
:	O
Demyelination	B-DISO
determinants	O
map	O
to	O
the	O
spike	O
glycoprotein	O
gene	O
of	O
coronavirus	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
.	O

TITLE	O
:	O
Use	O
of	O
botulinum	O
toxin	O
type	O
A	O
to	O
avoid	O
tracheal	O
intubation	O
or	O
tracheostomy	O
in	O
severe	O
paradoxical	O
vocal	O
cord	B-DISO
movement	O
.	O

Using	O
an	O
infectious	B-DISO
cDNA	O
clone	O
,	O
point	O
mutations	O
and	O
deletions	O
were	O
engineered	O
in	O
the	O
EAV	O
genome	O
to	O
disrupt	O
the	O
expression	O
of	O
each	O
of	O
the	O
structural	O
genes	O
.	O

TITLE	O
:	O
Comparison	O
of	O
serologic	O
testing	O
and	O
slaughter	O
evaluation	O
for	O
assessing	O
the	O
effects	O
of	O
subclinical	B-DISO
infection	I-DISO
on	O
growth	O
in	O
pigs	O
.	O

Sera	O
were	O
tested	O
for	O
antibodies	O
to	O
porcine	B-DISO
reproductive	I-DISO
and	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
(	O
PRRSV	O
),	O
swine	B-DISO
influenza	I-DISO
virus	O
(	O
SIV	B-DISO
),	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
),	O
pseudorabies	B-DISO
virus	O
,	O
Mycoplasma	B-DISO
hyopneumoniae	O
,	O
and	O
Actinobacillus	O
pleuropneumoniae	O
.	O

Genome	O
-	O
length	O
replicative	O
intermediate	O
(	O
RI	O
)	O
RNA	O
was	O
purified	O
by	O
two	O
-	O
dimensional	O
gel	O
electrophoresis	O
of	O
intracellular	O
RNAs	O
from	O
cells	O
infected	O
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
.	O

All	O
of	O
them	O
had	O
the	O
classical	O
phenotype	O
of	O
early	O
severe	O
encefalopathy	O
,	O
associated	O
with	O
dismorphic	O
features	O
,	O
hypotomía	O
,	O
neurosensorial	O
defects	O
,	O
brain	O
dysgenesis	B-DISO
and	O
atrophy	B-DISO
,	O
anomalies	O
in	O
the	O
EEG	O
and	O
in	O
5	O
of	O
them	O
there	O
were	O
also	O
systemic	O
anomalies	O
,	O
mainly	O
cardiopathy	B-DISO
.	O

Three	O
cases	O
has	O
a	O
deficit	B-DISO
of	O
the	O
complex	O
IV	O
,	O
e	O
of	O
the	O
complex	O
I	O
-	O
IV	O
,	O
2	O
of	O
the	O
complex	O
I	O
and	O
one	O
the	O
complex	O
I	O
-	O
III	O
-	O
IV	O
.	O

ABSTRACT	O
:	O
An	O
antibody	O
-	O
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
detection	O
of	O
antibody	O
to	O
turkey	O
coronavirus	O
(	O
TCV	O
)	O
utilizing	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
antigen	O
was	O
developed	O
.	O

Ibuprofen	O
in	O
Sepsis	B-DISO
Study	O
Group	O
.	O

We	O
found	O
that	O
92	O
%	O
of	O
the	O
patients	O
developing	O
ARDS	B-DISO
had	O
low	O
or	O
borderline	O
serum	O
total	O
protein	O
levels	O
(<	O
6	O
g	O
/	O
dL	O
).	O

RHS	B-DISO
and	O
MODS	B-DISO
share	O
some	O
pathophysiologic	O
elements	O
and	O
could	O
be	O
related	O
to	O
each	O
other	O
.	O

HS	O
responded	O
to	O
the	O
acute	B-DISO
infections	I-DISO
with	O
depression	B-DISO
of	O
fibrinolysis	O
,	O
in	O
convalescence	O
platelet	O
aggregation	O
activated	O
.	O

In	O
hypertensive	O
patients	O
microcirculation	O
and	O
hemostasis	O
were	O
similar	O
to	O
those	O
with	O
IHD	B-DISO
.	O

TITLE	O
:	O
[	O
A	O
case	O
of	O
primary	B-DISO
macroglobulinemia	I-DISO
with	O
acute	B-DISO
pulmonary	I-DISO
edema	I-DISO
].	O

Acute	B-DISO
pulmonary	I-DISO
edema	I-DISO
combined	O
with	O
severe	O
pneumonia	B-DISO
was	O
strongly	O
suspected	O
,	O
and	O
treatment	O
with	O
diuretics	O
,	O
antibiotics	O
,	O
and	O
corticosteroids	O
was	O
effective	O
.	O

Survival	O
from	O
this	O
syndrome	B-DISO
has	O
improved	O
over	O
time	O
.	O

In	O
some	O
patients	O
,	O
the	O
extent	O
of	O
injury	O
to	O
the	O
alveolar	O
epithelial	O
barrier	O
may	O
be	O
too	O
severe	O
for	O
beta	O
-	O
adrenergic	O
agonists	O
to	O
enhance	O
the	O
resolution	O
of	O
alveolar	B-DISO
edema	I-DISO
,	O
although	O
some	O
experimental	O
studies	O
indicate	O
that	O
alveolar	O
fluid	O
clearance	O
can	O
be	O
augmented	O
in	O
the	O
presence	O
of	O
moderately	O
severe	O
lung	O
injury	O
.	O

Remission	B-DISO
has	O
been	O
maintained	O
with	O
azathioprine	O
.	O

The	O
advantages	O
of	O
CRRT	O
should	O
theoretically	O
translate	O
into	O
improved	O
outcomes	O
of	O
critically	B-DISO
ill	I-DISO
ARF	B-DISO
patients	O
,	O
but	O
the	O
superiority	O
of	O
continuous	O
modalities	O
in	O
terms	O
of	O
outcome	O
is	O
still	O
controversial	O
,	O
despite	O
encouraging	O
results	O
in	O
some	O
clinical	O
trials	O
.	O

TITLE	O
:	O
Disturbances	O
in	O
leptin	O
metabolism	O
are	O
related	O
to	O
energy	O
imbalance	B-DISO
during	O
acute	O
exacerbations	O
of	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
Previously	O
we	O
reported	O
an	O
impaired	B-DISO
energy	O
balance	O
in	O
patients	O
with	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
COPD	B-DISO
)	O
during	O
an	O
acute	B-DISO
disease	I-DISO
exacerbation	O
,	O
but	O
limited	O
data	O
are	O
available	O
on	O
the	O
underlying	O
mechanisms	O
.	O

Seventy	O
-	O
one	O
consecutive	O
patients	O
with	O
early	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
is	O
a	O
noncurable	O
viral	B-DISO
disease	I-DISO
affecting	O
cats	O
worldwide	O
.	O

Immune	O
complex	O
deposition	O
and	O
vasculitis	B-DISO
with	O
pyogranulomatous	O
lesions	O
are	O
the	O
hallmark	O
of	O
FIP	B-DISO
.	O

The	O
only	O
definitive	O
antemortem	O
diagnostic	O
test	O
for	O
FIP	B-DISO
is	O
histopathologic	O
examination	O
of	O
tissue	O
.	O

The	O
most	O
common	O
clinical	O
sign	O
is	O
a	O
bilateral	O
granulomatous	O
anterior	B-DISO
uveitis	I-DISO
often	O
accompanied	O
by	O
chorioretinitis	B-DISO
.	O

We	O
hypothesized	O
that	O
(	O
1	O
)	O
PCEB	O
-	O
ACE	O
alterations	O
can	O
be	O
found	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
(	O
2	O
)	O
PCEB	O
-	O
ACE	O
activity	O
correlates	O
with	O
the	O
severity	O
of	O
lung	O
injury	O
and	O
may	O
be	O
used	O
as	O
a	O
quantifiable	O
marker	O
of	O
the	O
underlying	O
pulmonary	O
capillary	O
endothelial	B-DISO
dysfunction	I-DISO
.	O

TITLE	O
:	O
Obstructive	B-DISO
sleep	I-DISO
apnea	I-DISO
syndrome	I-DISO
:	O
a	O
comparison	O
between	O
Far	O
-	O
East	O
Asian	O
and	O
white	O
men	O
.	O

There	O
may	O
be	O
differences	O
in	O
obesity	B-DISO
and	O
craniofacial	O
anatomy	O
as	O
risk	O
factors	O
in	O
these	O
two	O
groups	O
.	O

The	O
approximately	O
30	O
-	O
kb	O
genome	O
,	O
coupled	O
with	O
regions	O
of	O
genomic	B-DISO
instability	I-DISO
,	O
has	O
hindered	O
the	O
development	O
of	O
a	O
full	O
-	O
length	O
infectious	B-DISO
cDNA	O
construct	O
.	O

Plaque	B-DISO
-	O
purified	O
virus	O
derived	O
from	O
the	O
infectious	B-DISO
construct	O
replicated	O
efficiently	O
and	O
displayed	O
similar	O
plaque	B-DISO
morphology	O
in	O
permissive	O
host	O
cells	O
.	O

Data	O
of	O
all	O
ARDS	B-DISO
patients	O
were	O
prospectively	O
collected	O
between	O
1991	O
and	O
1999	O
.	O

RESULTS	O
:	O
Morbidity	O
rates	O
including	O
hyperbilirubinemia	B-DISO
,	O
anastomotic	B-DISO
leakage	I-DISO
,	O
and	O
liver	B-DISO
dysfunction	I-DISO
were	O
significantly	O
lower	O
in	O
the	O
steroid	O
group	O
than	O
in	O
the	O
control	O
group	O
.	O

Vitamin	O
A	O
supplements	O
provide	O
a	O
low	O
-	O
cost	O
intervention	O
against	O
morbidity	O
in	O
HIV	B-DISO
-	O
infected	O
and	O
undernourished	B-DISO
children	O
.	O

It	O
also	O
approximates	O
the	O
dengue	B-DISO
syndrome	B-DISO
to	O
other	O
protocols	O
and	O
medical	O
procedures	O
routinely	O
used	O
in	O
intensive	O
care	O
units	O
,	O
making	O
it	O
easier	O
to	O
be	O
followed	O
by	O
the	O
health	O
personnel	O
working	O
in	O
areas	O
subject	O
to	O
epidemic	O
bursts	O
.	O

Recently	O
,	O
we	O
have	O
generated	O
replication	O
-	O
competent	O
(	O
E3	O
deleted	O
)	O
bovine	O
adenovirus	B-DISO
-	O
3	O
(	O
BAV	B-DISO
-	O
3	O
)	O
recombinants	O
expressing	O
significant	O
amounts	O
of	O
glycoprotein	O
D	O
(	O
gD	O
)	O
of	O
bovine	O
herpesvirus	O
-	O
1	O
(	O
a	O
DNA	O
virus	O
).	O

The	O
results	O
show	O
that	O
feeding	O
milk	O
which	O
contains	O
hydrolysed	O
lactose	O
does	O
not	O
significantly	O
improve	O
lactose	O
utilization	O
in	O
calves	O
that	O
are	O
suffering	B-DISO
from	O
benign	O
infectious	B-DISO
diarrhoea	I-DISO
.	O

TITLE	O
:	O
Randomized	O
,	O
double	O
-	O
blind	B-DISO
,	O
crossover	O
challenge	O
study	O
in	O
53	O
subjects	O
reporting	O
adverse	O
reactions	O
to	O
melon	O
(	O
Cucumis	O
melo	O
).	O

About	O
one	O
third	O
of	O
reported	O
reactions	O
to	O
melon	O
are	O
confirmed	O
by	O
means	O
of	O
DBPCFC	O
,	O
which	O
has	O
been	O
proven	O
to	O
be	O
the	O
most	O
reliable	O
procedure	O
in	O
the	O
diagnosis	O
of	O
clinical	O
fruit	B-DISO
allergy	I-DISO
.	O

An	O
HFOV	O
protocol	O
was	O
established	O
with	O
the	O
following	O
inclusion	O
criteria	O
:	O
severe	O
respiratory	B-DISO
insufficiency	I-DISO
of	O
any	O
origin	O
(	O
infectious	B-DISO
,	O
inhalatory	O
,	O
etc	O
.)	O
with	O
an	O
oxygenation	O
index	O
(	O
OI	O
)	O
>	O
13	O
in	O
two	O
arterial	O
blood	O
gases	O
within	O
a	O
6	O
-	O
hour	O
interval	O
,	O
refractory	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
severe	O
respiratory	B-DISO
syncytial	I-DISO
virus	I-DISO
pneumonia	I-DISO
,	O
and	O
gross	O
airleak	O
syndromes	B-DISO
(	O
pneumothorax	B-DISO
,	O
pneumoperitoneum	B-DISO
,	O
pneumomediastinum	B-DISO
,	O
etc	O
.).	O

In	O
all	O
patients	O
HVOF	O
was	O
indicated	O
due	O
to	O
severe	O
refractory	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Severe	O
acute	O
lung	O
injury	O
caused	O
by	O
Mycoplasma	B-DISO
pneumoniae	O
:	O
potential	O
role	O
for	O
steroid	O
pulses	O
in	O
treatment	O
.	O

Randomized	O
controlled	O
trials	O
show	O
that	O
intravenous	O
immune	O
globulin	O
(	O
IVIg	O
)	O
and	O
plasma	O
exchange	O
(	O
PE	O
)	O
are	O
equally	O
effective	O
in	O
reducing	O
the	O
time	O
to	O
functional	B-DISO
recovery	I-DISO
.	O

GBS	B-DISO
patients	O
who	O
are	O
unable	O
to	O
walk	O
without	O
assistance	O
,	O
and	O
who	O
are	O
still	O
within	O
their	O
first	O
2	O
weeks	O
of	O
the	O
disease	O
,	O
need	O
to	O
be	O
treated	O
.	O

However	O
,	O
eighteen	O
months	O
ago	O
,	O
he	O
complained	O
about	O
a	O
transient	O
weakness	B-DISO
of	O
his	O
left	O
arm	O
and	O
leg	O
.	O

On	O
CT	O
and	O
diffusion	O
weighted	O
imaging	O
there	O
was	O
evidence	O
of	O
an	O
ischemic	O
infarction	B-DISO
pattern	O
.	O

Although	O
most	O
virus	O
-	O
infected	O
cells	O
,	O
except	O
KQ3E	O
-	O
infected	O
A3	O
-	O
1M	O
,	O
CMT	O
-	O
93	O
and	O
J774A	O
.	O
1	O
cells	O
,	O
produced	O
progeny	O
viruses	O
in	O
the	O
supernatants	O
when	O
assayed	O
by	O
plaque	B-DISO
formation	O
on	O
DBT	O
cells	O
,	O
the	O
kinetics	O
of	O
viral	O
replication	O
were	O
dependent	O
on	O
both	O
the	O
cell	O
line	O
and	O
virus	O
strain	O
;	O
replication	O
of	O
prototype	O
strains	O
was	O
higher	O
than	O
that	O
of	O
new	O
isolates	O
.	O

One	O
woman	O
with	O
the	O
HELLP	B-DISO
syndrome	I-DISO
had	O
a	O
liver	B-DISO
hematoma	I-DISO
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
shown	O
that	O
hepatic	O
cryoablation	O
(	O
cryo	O
),	O
but	O
not	O
partial	O
hepatectomy	O
,	O
induces	O
a	O
systemic	O
inflammatory	B-DISO
response	I-DISO
,	O
with	O
distant	O
organ	O
injury	O
and	O
overproduction	O
of	O
NF	O
-	O
kappaB	O
-	O
dependent	O
cytokines	O
.	O

Severe	O
lung	O
injury	O
,	O
as	O
evidenced	O
by	O
airspace	O
edema	B-DISO
and	O
parenchymal	B-DISO
hemorrhage	I-DISO
,	O
was	O
present	O
in	O
four	O
of	O
six	O
(	O
67	O
%)	O
animals	O
at	O
24	O
h	O
(	O
P	O
0	O
.	O
03	O
).	O

The	O
findings	O
of	O
pulmonary	O
perivascular	O
interstitial	O
macrophages	O
2	O
h	O
following	O
hepatic	O
cryo	O
suggests	O
that	O
hepatic	O
cytokine	O
production	O
may	O
induce	O
downstream	O
recruitment	B-DISO
of	O
pulmonary	O
macrophages	O
,	O
which	O
may	O
contribute	O
to	O
subsequent	O
severe	O
lung	O
injury	O
.	O

These	O
findings	O
suggest	O
that	O
a	O
lack	O
of	O
increase	O
in	O
the	O
production	O
of	O
the	O
cGMP	O
may	O
account	O
for	O
the	O
pulmonary	B-DISO
hypertension	I-DISO
seen	O
in	O
air	O
embolism	B-DISO
-	O
induced	O
ALI	O
.	O

The	O
type	O
of	O
transplantation	O
,	O
determined	O
after	O
an	O
exhaustive	O
work	O
-	O
up	O
ruling	O
out	O
all	O
contraindications	O
,	O
is	O
generally	O
a	O
single	O
lung	O
transplantation	O
if	O
there	O
is	O
no	O
bronchial	B-DISO
infection	I-DISO
or	O
two	O
-	O
lung	O
transplantation	O
or	O
heart	O
-	O
lung	O
transplantation	O
in	O
case	O
of	O
bronchiectasis	B-DISO
or	O
pulmonary	B-DISO
artery	I-DISO
hypertension	I-DISO
.	O

It	O
normalizes	O
hematosis	O
in	O
case	O
of	O
chronic	B-DISO
respiratory	I-DISO
failure	I-DISO
and	O
pulmonary	O
hemodynamics	O
in	O
case	O
of	O
pulmonary	B-DISO
hypertension	I-DISO
.	O

Chronic	O
rejection	O
or	O
obliterating	O
bronchiolitis	B-DISO
is	O
the	O
main	O
mid	O
-	O
term	O
complication	B-DISO
after	O
lung	O
transplantation	O
and	O
is	O
responsible	O
for	O
the	O
low	O
long	O
-	O
term	O
survival	O
rate	O
with	O
recurrent	O
secondary	B-DISO
infections	I-DISO
due	O
to	O
frequent	O
bronchial	O
colonization	O
with	O
Pseudomonas	O
aeruginosa	O
.	O

ABSTRACT	O
:	O
Viral	O
induced	O
demyelination	B-DISO
,	O
in	O
both	O
humans	O
and	O
rodent	O
models	O
,	O
has	O
provided	O
unique	O
insights	O
into	O
the	O
cell	O
biology	O
of	O
oligodendroglia	O
,	O
their	O
complex	O
cell	O
-	O
cell	O
interactions	O
and	O
mechanisms	O
of	O
myelin	O
destruction	O
.	O

This	O
suggests	O
that	O
demyelination	B-DISO
induced	O
by	O
viral	B-DISO
infections	I-DISO
can	O
result	O
from	O
:	O
1	O
)	O
a	O
direct	O
viral	B-DISO
infection	I-DISO
of	O
oligodendroglia	O
resulting	O
in	O
cell	O
death	O
with	O
degeneration	B-DISO
of	O
myelin	O
and	O
its	O
subsequent	O
removal	O
;	O
2	O
)	O
a	O
persistent	O
viral	B-DISO
infection	I-DISO
,	O
in	O
the	O
presence	O
or	O
absence	O
of	O
infectious	B-DISO
virus	O
,	O
resulting	O
in	O
the	O
loss	O
of	O
normal	O
cellular	O
homeostasis	O
and	O
subsequent	O
oligodendroglial	O
death	O
;	O
3	O
)	O
a	O
vigorous	O
virus	O
-	O
specific	O
inflammatory	B-DISO
response	I-DISO
wherein	O
the	O
virus	O
replicates	O
in	O
a	O
cell	O
type	O
other	O
than	O
oligodendroglia	O
,	O
but	O
cytokines	O
and	O
other	O
immune	O
mediators	O
directly	O
damage	O
the	O
oligodendroglia	O
or	O
the	O
myelin	O
sheath	O
;	O
or	O
4	O
)	O
infection	B-DISO
initiates	O
activation	O
of	O
an	O
immune	O
response	O
specific	O
for	O
either	O
oligodendroglia	O
or	O
myelin	O
components	O
.	O

Virus	O
-	O
induced	O
inflammation	B-DISO
may	O
be	O
associated	O
with	O
the	O
processing	O
of	O
myelin	O
or	O
oligodendroglial	O
components	O
and	O
their	O
presentation	O
to	O
the	O
host	O
'	O
s	O
own	O
T	O
cell	O
compartment	O
.	O

A	O
seroprevalence	O
survey	O
in	O
30	O
villages	O
using	O
haemagglutination	O
inhibition	O
(	O
HI	O
)	O
tests	O
for	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
and	O
NDV	O
antibodies	O
was	O
carried	O
out	O
from	O
December	O
1997	O
to	O
June	O
1998	O
.	O

The	O
initial	O
ISS	B-DISO
was	O
39	O
.	O
3	O
points	O
(+/-	O

The	O
LIS	O
at	O
time	O
of	O
recruitment	B-DISO
into	O
the	O
study	O
was	O
2	O
.	O
2	O
(+/-	O

On	O
all	O
of	O
the	O
occasions	O
investigated	O
,	O
plasma	O
vWf	O
:	O
Ag	O
levels	O
in	O
ARDS	B-DISO
patients	O
and	O
nonsurvivors	O
were	O
significantly	O
greater	O
than	O
those	O
in	O
patients	O
without	O
ARDS	B-DISO
and	O
survivors	O
,	O
respectively	O
.	O

but	O
not	O
early	O
(	O
day	O
2	O
)	O
or	O
late	O
(	O
day	O
35	O
)	O
in	O
the	O
infection	B-DISO
.	O

S	O
(	O
A59	O
)	O
R13	O
,	O
expressing	O
the	O
A59	O
spike	O
gene	O
,	O
replicated	O
to	O
a	O
somewhat	O
lower	O
titer	O
and	O
induced	O
moderate	O
to	O
severe	O
hepatitis	B-DISO
with	O
zonal	B-DISO
necrosis	I-DISO
,	O
similar	O
to	O
MHV	O
-	O
A59	O
.	O

ABSTRACT	O
:	O
In	O
addition	O
to	O
the	O
RI	O
(	O
replicative	O
intermediate	O
RNA	O
)	O
and	O
native	O
RF	O
(	O
replicative	O
form	O
RNA	O
),	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
-	O
infected	O
cells	O
contained	O
six	O
species	O
of	O
RNA	O
intermediates	O
active	O
in	O
transcribing	O
subgenomic	O
mRNA	O
.	O

Nine	O
patients	O
with	O
ARDS	B-DISO
and	O
severe	O
hypoxemia	O
(	O
PaO2	O
/	O
FIO2	O
ratio	O
,	O
<	O
150	O
torr	O
[	O
20	O
kPa	O
]).	O

In	O
patients	O
with	O
severe	O
hypoxemia	O
related	O
to	O
ARDS	B-DISO
,	O
high	O
-	O
dose	O
almitrine	O
infusion	O
did	O
not	O
improve	O
arterial	O
oxygenation	O
and	O
impaired	B-DISO
the	O
loading	O
conditions	O
of	O
the	O
right	O
ventricle	O
.	O

Thus	O
,	O
high	O
-	O
dose	O
almitrine	O
infusion	O
may	O
be	O
harmful	O
in	O
ARDS	B-DISO
patients	O
with	O
severe	O
hypoxemia	O
and	O
pulmonary	B-DISO
hypertension	I-DISO
.	O

Fifteen	O
consecutive	O
,	O
mechanically	O
ventilated	O
patients	O
with	O
ARDS	B-DISO
and	O
severe	O
hypoxemia	O
,	O
defined	O
as	O
PaO2	O
/	O
FIO2	O
of	O
<	O
150	O
torr	O
at	O
the	O
time	O
of	O
admission	O
.	O

ABSTRACT	O
:	O
Viral	O
agents	O
are	O
one	O
of	O
the	O
main	O
causes	O
of	O
acute	B-DISO
diarrhea	I-DISO
,	O
particularly	O
in	O
infants	O
and	O
young	O
children	O
.	O

In	O
temperate	O
climates	O
incidence	O
is	O
greater	O
in	O
winter	O
whereas	O
in	O
tropical	O
areas	O
infection	B-DISO
occurs	O
throughout	O
the	O
year	O
.	O

Our	O
final	O
diagnosis	O
was	O
ARDS	B-DISO
induced	O
by	O
fulminant	O
influenza	B-DISO
(	O
A	O
/	O
Hong	O
Kong	O
/	O
68	O
(	O
H3	O
N2	O
))	O
virus	O
pneumonia	B-DISO
,	O
because	O
the	O
antibody	O
titers	O
of	O
H3	O
N2	O
influenza	B-DISO
of	O
paired	O
sera	O
showed	O
a	O
128	O
-	O
fold	O
increase	O
.	O

Patients	O
with	O
a	O
mean	O
BD	O
of	O
less	O
than	O
-	O
6	O
mmol	O
/	O
L	O
during	O
the	O
first	O
24	O
hours	O
were	O
compared	O
with	O
patients	O
with	O
a	O
mean	O
BD	O
of	O
more	O
than	O
-	O
6	O
mmol	O
/	O
L	O
.	O
Despite	O
adequate	O
resuscitation	O
with	O
good	O
maintenance	O
of	O
urinary	O
output	O
,	O
the	O
patients	O
in	O
the	O
group	O
with	O
a	O
mean	O
BD	O
of	O
less	O
than	O
-	O
6	O
mmol	O
/	O
L	O
had	O
more	O
florid	O
systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
syndrome	I-DISO
(	O
P	O
=	O
.	O
004	O
),	O
had	O
more	O
prevalent	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
P	O
=	O
.	O
012	O
),	O
and	O
experienced	O
more	O
severe	O
multiple	O
organ	O
dysfunction	O
(	O
P	O
<	O
.	O
001	O
)	O
compared	O
with	O
patients	O
in	O
the	O
group	O
with	O
a	O
mean	O
BD	O
of	O
more	O
than	O
-	O
6	O
mmol	O
/	O
L	O
.	O
The	O
results	O
suggest	O
that	O
abnormal	O
elevation	O
of	O
the	O
BD	O
after	O
burn	O
injuries	O
represents	O
a	O
malperfusion	O
state	O
,	O
which	O
may	O
not	O
be	O
recognized	O
if	O
only	O
""""	O
traditional	O
""""	O
parameters	O
,	O
such	O
as	O
UO	O
,	O
are	O
followed	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
our	O
experience	O
with	O
inhaled	O
NO	O
in	O
10	O
adult	O
patients	O
with	O
burn	O
injuries	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
-	O
related	O
oxygenation	O
failure	O
.	O

Although	O
the	O
immediate	O
effects	O
may	O
seem	O
impressive	O
,	O
long	O
-	O
term	O
outcome	O
regarding	O
residual	O
pulmonary	B-DISO
hypertension	I-DISO
and	O
other	O
sequelae	O
has	O
been	O
studied	O
in	O
only	O
a	O
very	O
few	O
patients	O
.	O

Thus	O
36	O
paediatric	O
or	O
neonatal	O
patients	O
were	O
examined	O
for	O
circulatory	O
,	O
respiratory	O
or	O
neurological	B-DISO
disorders	I-DISO
with	O
clinical	O
examination	O
,	O
echocardiography	O
,	O
chest	O
X	O
-	O
ray	O
and	O
a	O
capillary	O
blood	O
sample	O
.	O

The	O
few	O
residual	O
circulatory	O
and	O
respiratory	B-DISO
symptoms	I-DISO
could	O
be	O
related	O
to	O
the	O
initial	O
condition	B-DISO
.	O

ABSTRACT	O
:	O
An	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
strain	O
CT	O
/	O
7852	O
/	O
97	O
was	O
isolated	O
from	O
a	O
commercial	O
layer	O
flock	O
experiencing	O
decreased	O
egg	O
production	O
and	O
poor	O
egg	O
quality	O
.	O

TITLE	O
:	O
Antibody	O
responses	O
to	O
respiratory	O
coronavirus	B-DISO
infections	I-DISO
of	O
cattle	O
during	O
shipping	B-DISO
fever	I-DISO
pathogenesis	B-DISO
.	O

Nasal	O
samples	O
and	O
lung	O
tissues	O
from	O
9	O
of	O
the	O
10	O
fatal	O
cases	O
had	O
high	O
titers	O
of	O
RBCV	O
,	O
but	O
these	O
cattle	O
had	O
only	O
IgM	O
responses	O
to	O
RBCV	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
Implementation	O
of	O
lung	O
protective	O
strategy	O
in	O
the	O
treatment	O
of	O
severe	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
improved	O
outcome	O
.	O

ABSTRACT	O
:	O
Impairment	B-DISO
of	O
alveolar	O
surfactant	O
function	O
has	O
been	O
documented	O
in	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
in	O
severe	O
pneumonia	B-DISO
(	O
PNEU	O
);	O
however	O
,	O
the	O
underlying	O
mechanisms	O
are	O
not	O
completely	O
understood	O
.	O

In	O
addition	O
,	O
the	O
minimal	O
surface	O
tension	B-DISO
(	O
gamma	O
min	O
)	O
of	O
untreated	O
LSA	B-DISO
and	O
of	O
LSA	B-DISO
after	O
supplementation	O
with	O
additional	O
dipalmitoylated	O
phosphatidylcholine	O
(	O
DPPC	O
)	O
was	O
analyzed	O
(	O
pulsating	O
bubble	O
surfactometer	O
).	O

TITLE	O
:	O
Septic	B-DISO
shock	I-DISO
and	O
acute	O
lung	O
injury	O
in	O
rabbits	O
with	O
peritonitis	B-DISO
:	O
failure	O
of	O
the	O
neutrophil	O
response	O
to	O
localized	B-DISO
infection	I-DISO
.	O

The	O
onset	O
of	O
septic	B-DISO
shock	I-DISO
was	O
associated	O
with	O
a	O
paradoxical	O
lack	O
of	O
identifiable	O
polymorphonuclear	O
leukocytes	O
(	O
PMN	O
;	O
neutrophils	O
)	O
in	O
the	O
peritoneal	O
cavity	B-DISO
.	O

Although	O
most	O
animals	O
became	O
bacteremic	O
,	O
only	O
those	O
with	O
a	O
severe	O
systemic	O
inflammation	B-DISO
response	O
developed	O
lung	O
injury	O
.	O

TITLE	O
:	O
Orchitis	B-DISO
in	O
a	O
cat	O
associated	O
with	O
coronavirus	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
A	O
case	O
of	O
severe	O
,	O
pyogranulomatous	O
and	O
necrotizing	O
orchitis	B-DISO
in	O
a	O
cat	O
,	O
which	O
later	O
succumbed	O
to	O
systemic	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
),	O
is	O
described	O
.	O

The	O
3	O
.	O
5	O
-	O
year	O
-	O
old	O
cat	O
,	O
positive	O
for	O
feline	O
immunodeficiency	B-DISO
virus	B-DISO
infection	I-DISO
,	O
presented	O
with	O
a	O
left	O
testicular	O
enlargement	B-DISO
.	O

Post	O
-	O
mortem	O
examination	O
revealed	O
inflammatory	O
lesions	O
in	O
abdominal	O
organs	O
and	O
in	O
the	O
brain	O
compatible	O
with	O
FIP	B-DISO
.	O

Each	O
mutation	O
was	O
separately	O
introduced	O
into	O
cDNA	O
encoding	O
the	O
prototype	O
JHM	O
spike	O
,	O
and	O
the	O
set	O
of	O
cDNAs	O
was	O
expressed	O
using	O
vaccinia	B-DISO
virus	O
vectors	O
.	O

Abuse	B-DISO
of	O
most	O
of	O
these	O
inhaled	O
substances	O
has	O
risen	O
in	O
recent	O
years	O
,	O
thereby	O
increasing	O
concern	O
about	O
potential	O
pulmonary	O
and	O
other	O
medical	O
complications	O
.	O

ABSTRACT	O
:	O
A	O
23	O
-	O
year	O
-	O
old	O
man	O
with	O
HIV	B-DISO
-	O
infection	B-DISO
and	O
recently	O
diagnosed	O
hepatitis	B-DISO
B	I-DISO
infection	I-DISO
developed	O
painful	B-DISO
swelling	B-DISO
and	O
palpable	O
purpura	B-DISO
in	O
the	O
limbs	O
.	O

TITLE	O
:	O
Efficacy	O
of	O
a	O
transmissible	O
gastroenteritis	B-DISO
coronavirus	O
with	O
an	O
altered	O
ORF	O
-	O
3	O
gene	O
.	O

The	O
results	O
of	O
in	O
situ	O
hybridization	O
for	O
the	O
detection	O
of	O
TGEV	O
were	O
compared	O
with	O
virus	O
isolation	O
(	O
VI	O
),	O
a	O
fluorescent	O
antibody	O
test	O
(	O
FAT	O
),	O
and	O
transmission	O
electron	O
microscopy	O
(	O
TEM	B-DISO
).	O

VI	O
,	O
FAT	O
,	O
and	O
TEM	B-DISO
were	O
tested	O
over	O
a	O
course	O
of	O
time	O
before	O
the	O
in	O
situ	O
hybridization	O
was	O
performed	O
.	O

ABSTRACT	O
:	O
A	O
nested	O
PCR	O
(	O
nPCR	O
)	O
assay	O
for	O
the	O
detection	O
of	O
canine	O
coronavirus	O
(	O
CCV	B-DISO
)	O
in	O
fecal	O
samples	O
is	O
described	O
.	O

Virus	O
isolation	O
detected	O
CCV	B-DISO
shedding	O
from	O
day	O
4	O
to	O
9	O
postchallenge	O
,	O
while	O
the	O
nPCR	O
assay	O
detected	O
CCV	B-DISO
shedding	O
from	O
day	O
4	O
to	O
13	O
postchallenge	O
.	O

The	O
simple	O
and	O
rapid	O
procedure	O
described	O
here	O
makes	O
this	O
assay	O
an	O
ideal	O
alternative	O
technique	O
to	O
electron	O
microscopy	O
and	O
viral	O
isolation	O
in	O
cell	O
culture	O
for	O
detection	O
of	O
CCV	B-DISO
shedding	O
in	O
feces	O
.	O

The	O
escape	O
mutants	O
were	O
demonstrated	O
to	O
be	O
neutralization	O
resistant	O
to	O
the	O
selecting	O
group	O
A	O
MAb	O
and	O
remained	O
sensitive	O
to	O
neutralization	O
by	O
a	O
group	B-DISO
B	I-DISO
MAb	O
.	O

Infectivity	O
-	O
neutralizing	O
(	O
IN	O
)	O
and	O
hemagglutinin	O
-	O
inhibiting	O
(	O
HAI	O
)	O
antibodies	O
induced	O
by	O
RBCV	O
infections	B-DISO
were	O
monitored	O
in	O
sequential	O
serum	O
samples	O
collected	O
from	O
cattle	O
during	O
a	O
naturally	O
evolving	O
and	O
experimentally	O
monitored	O
epizootic	O
of	O
shipping	B-DISO
fever	I-DISO
pneumonia	B-DISO
(	O
SFP	O
).	O

An	O
increase	O
in	O
serum	O
IN	O
antibody	O
after	O
day	O
7	O
led	O
to	O
reduction	O
of	O
virus	B-DISO
shedding	I-DISO
in	O
nasal	O
secretions	O
by	O
the	O
majority	O
of	O
the	O
cattle	O
between	O
days	O
7	O
and	O
14	O
.	O

ABSTRACT	O
:	O
Mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
),	O
a	O
member	O
of	O
the	O
Coronaviridae	O
,	O
contains	O
a	O
polyadenylated	O
positive	O
-	O
sense	O
single	O
-	O
stranded	O
genomic	O
RNA	O
which	O
is	O
31	O
kb	O
long	O
.	O

ABSTRACT	O
:	O
The	O
two	O
-	O
hit	O
theory	O
has	O
emerged	O
as	O
a	O
mechanism	O
to	O
explain	O
the	O
development	O
of	O
organ	B-DISO
failure	I-DISO
after	O
traumatic	O
injury	O
.	O

Further	O
clinical	O
trials	O
are	O
needed	O
to	O
define	O
the	O
optimal	O
role	O
for	O
colloids	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

The	O
development	O
and	O
characterisation	O
of	O
an	O
indirect	O
ELISA	O
for	O
the	O
detection	O
of	O
antibodies	O
(	O
IgG	O
and	O
IgM	O
)	O
to	O
CCV	B-DISO
was	O
undertaken	O
.	O

Of	O
those	O
dogs	O
that	O
were	O
presented	O
with	O
clinical	O
signs	O
of	O
gastroenteritis	B-DISO
such	O
as	O
diarrhoea	B-DISO
and	I-DISO
vomiting	I-DISO
(	O
n	O
=	O
29	O
),	O
85	O
%	O
were	O
positive	O
in	O
the	O
IgM	O
ELISA	O
and	O
85	O
.	O
7	O
%	O
in	O
the	O
IgG	O
ELISA	O
for	O
antibodies	O
to	O
CCV	B-DISO
.	O

In	O
comparison	O
,	O
for	O
those	O
dogs	O
presented	O
without	O
any	O
history	O
of	O
gastroenteritis	B-DISO
only	O
15	O
%	O
were	O
positive	O
for	O
IgM	O
and	O
30	O
%	O
positive	O
for	O
IgG	O
.	O
CONCLUSIONS	O
:	O
Serological	O
evidence	O
indicates	O
that	O
infection	B-DISO
with	O
CCV	B-DISO
in	O
dogs	O
is	O
widespread	O
throughout	O
the	O
Australian	O
mainland	O
.	O

Antigens	O
expressed	O
in	O
corn	B-DISO
are	O
particularly	O
advantageous	O
since	O
the	O
seed	O
can	O
be	O
produced	O
in	O
vast	O
quantities	O
and	O
shipped	O
over	O
long	O
distances	O
at	O
ambient	O
temperature	O
,	O
potentially	O
allowing	O
global	O
vaccination	O
.	O

The	O
patient	O
developed	O
pneumonia	B-DISO
and	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
died	O
of	O
an	O
acute	B-DISO
myocardial	I-DISO
infarction	I-DISO
.	O

TITLE	O
:	O
[	O
Clinical	B-DISO
findings	I-DISO
of	O
cows	O
who	O
originated	O
from	O
dairy	O
herds	O
with	O
chronic	B-DISO
wasting	I-DISO
disease	I-DISO
].	O

Chronic	O
wasting	B-DISO
is	O
also	O
associated	O
with	O
disorders	O
such	O
as	O
lameness	B-DISO
,	O
abortion	O
,	O
endometritis	B-DISO
,	O
mastitis	B-DISO
,	O
and	O
respiratory	B-DISO
problems	I-DISO
.	O

Ten	O
patients	O
,	O
seven	O
male	O
and	O
three	O
female	O
,	O
with	O
an	O
average	O
age	O
of	O
55	O
years	O
were	O
diagnosed	O
with	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
.	O

The	O
technique	O
can	O
be	O
used	O
to	O
determine	O
the	O
pathologic	O
extent	O
of	O
the	O
disease	O
,	O
to	O
irrigate	O
and	O
drain	O
the	O
abdominal	O
cavity	B-DISO
,	O
and	O
to	O
decompress	O
the	O
pancreas	O
.	O

Primary	O
skin	B-DISO
irritation	I-DISO
depends	O
on	O
the	O
duration	O
and	O
contact	O
site	O
,	O
occlusion	B-DISO
and	O
solvent	O
.	O

However	O
,	O
GA	O
is	O
neither	O
phototoxic	O
nor	O
photosensitizing	B-DISO
.	O

This	O
is	O
most	O
likely	O
the	O
result	O
of	O
a	O
modifying	O
effect	O
on	O
the	O
factor	O
(	O
s	O
)	O
responsible	O
for	O
the	O
expression	O
of	O
this	O
commonly	O
occurring	O
rat	O
neoplasm	B-DISO
.	O

In	O
vivo	O
genotoxicity	B-DISO
studies	O
--	O
micronucleus	O
,	O
chromosome	B-DISO
aberration	I-DISO
,	O
dominant	O
lethal	O
and	O
Drosophila	O
tests	O
--	O
generally	O
have	O
shown	O
no	O
activity	O
but	O
one	O
mouse	O
intraperitoneal	O
study	O
showed	O
bone	O
marrow	O
cell	O
chromosome	B-DISO
aberrations	I-DISO
.	O

TITLE	O
:	O
Management	O
of	O
acute	O
exacerbations	O
of	O
COPD	B-DISO
:	O
a	O
summary	O
and	O
appraisal	O
of	O
published	O
evidence	O
.	O

Further	O
high	O
-	O
quality	O
research	O
is	O
needed	O
and	O
will	O
require	O
an	O
improved	O
,	O
generally	O
acceptable	O
,	O
and	O
transportable	O
definition	O
of	O
the	O
syndrome	B-DISO
""""	O
acute	O
exacerbation	O
of	O
COPD	B-DISO
""""	O
and	O
improved	O
methods	O
for	O
observing	O
and	O
measuring	O
outcomes	O
.	O

The	O
SF	O
-	O
36	O
values	O
of	O
the	O
ARDS	B-DISO
survivors	O
indicated	O
impaired	B-DISO
health	I-DISO
status	O
on	O
seven	O
out	O
of	O
eight	O
domains	O
when	O
compared	O
to	O
normative	O
population	O
data	O
.	O

In	O
conclusion	O
,	O
long	O
-	O
term	O
ARDS	B-DISO
survivors	O
exhibit	O
impaired	B-DISO
health	I-DISO
status	O
and	O
the	O
presence	O
of	O
cognitive	B-DISO
deficits	I-DISO
is	O
associated	O
with	O
disability	O
and	O
considerable	O
impairments	O
in	O
HRQOL	O
.	O

More	O
detailed	O
psychiatric	O
research	O
is	O
required	O
to	O
establish	O
the	O
etiology	O
of	O
these	O
cognitive	B-DISO
impairments	I-DISO
.	O

ABSTRACT	O
:	O
A	O
disease	O
in	O
which	O
'	B-DISO
viremia	I-DISO
-	O
associated	O
ana	O
-	O
aki	O
-	O
byo	O
'	O
is	O
combined	O
with	O
an	O
Aeromonas	B-DISO
hydrophila	I-DISO
infection	I-DISO
currently	O
occurs	O
and	O
is	O
highly	O
transmissible	O
in	O
color	O
carp	B-DISO
Cyprinus	O
carpio	O
in	O
Japan	O
.	O

In	O
addition	O
to	O
pathological	O
changes	O
due	O
to	O
the	O
corona	O
-	O
like	O
virus	B-DISO
infection	I-DISO
,	O
various	O
changes	O
due	O
to	O
the	O
A	O
.	O
hydrophila	O
infection	B-DISO
occurred	O
.	O

The	O
ELISA	O
detected	O
antibodies	O
specific	O
for	O
TCV	O
and	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
,	O
a	O
closely	O
related	O
avian	O
coronavirus	O
,	O
but	O
did	O
not	O
detect	O
antibodies	O
specific	O
for	O
other	O
avian	O
viruses	O
(	O
avian	O
influenza	B-DISO
,	I-DISO
avian	I-DISO
reovirus	O
,	O
avian	O
paramyxovirus	O
3	O
,	O
avian	O
adenovirus	B-DISO
1	O
,	O
or	O
Newcastle	B-DISO
disease	I-DISO
virus	O
).	O

In	O
all	O
trials	O
,	O
the	O
birds	O
developed	O
clinical	O
signs	O
of	O
enteritis	B-DISO
at	O
48	O
-	O
72	O
hr	O
postinoculation	O
.	O

Birds	O
euthanatized	O
at	O
3	O
,	O
5	O
,	O
and	O
7	O
days	O
postinoculation	O
(	O
DPI	O
)	O
had	O
flaccid	O
,	O
pale	B-DISO
intestines	O
with	O
watery	O
contents	O
,	O
and	O
the	O
ceca	O
were	O
markedly	O
enlarged	O
with	O
frothy	O
contents	O
.	O

ABSTRACT	O
:	O
Chickens	O
infected	O
with	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
and	O
infectious	B-DISO
bursal	I-DISO
disease	I-DISO
virus	O
(	O
IBDV	O
)	O
commonly	O
develop	O
secondary	B-DISO
infection	I-DISO
of	O
the	O
respiratory	O
tract	O
with	O
Escherichia	O
coli	O
,	O
resulting	O
in	O
significant	O
economic	O
losses	O
.	O

We	O
observed	O
the	O
onset	O
of	O
anorexia	B-DISO
and	O
an	O
abnormal	O
feeding	O
pattern	O
during	O
an	O
opportunistic	O
SDA	B-DISO
viral	B-DISO
infection	I-DISO
in	O
our	O
rat	O
colony	O
.	O

After	O
infection	B-DISO
food	O
intake	O
decreased	O
by	O
68	O
%.	O

Anorexia	B-DISO
in	O
response	O
to	O
bacterial	O
lipopolysaccharide	O
administration	O
,	O
which	O
is	O
also	O
linked	O
to	O
plasma	O
TNF	O
-	O
alpha	O
,	O
is	O
however	O
,	O
caused	O
only	O
via	O
a	O
decrease	O
in	O
meal	O
number	O
.	O

Prevention	O
of	O
severe	O
imported	O
malaria	B-DISO
lays	O
on	O
prophylactic	O
measures	O
during	O
travel	O
,	O
as	O
well	O
as	O
adequate	O
management	O
of	O
uncomplicated	O
disease	O
after	O
return	O
.	O

ABSTRACT	O
:	O
Matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
are	O
upregulated	O
locally	O
in	O
sites	O
of	O
inflammation	B-DISO
,	O
including	O
the	O
lung	O
.	O

TITLE	O
:	O
[	O
Battered	O
baby	O
syndrome	B-DISO
.	O

A	O
previously	O
normal	O
child	O
of	O
7	O
months	O
of	O
age	O
presented	O
an	O
acute	O
picture	O
of	O
status	B-DISO
epilepticus	I-DISO
with	O
respiratory	B-DISO
problems	I-DISO
and	O
periods	O
of	O
apnea	B-DISO
.	O

The	O
shaken	O
-	O
baby	O
syndrome	B-DISO
causes	O
severe	O
encephalopathy	B-DISO
and	O
vision	O
problems	O
,	O
blindness	B-DISO
in	O
many	O
cases	O
,	O
after	O
showing	O
voluminous	O
subdural	O
and	O
/	O
or	O
epidural	O
hematomas	B-DISO
which	O
lead	O
to	O
a	O
severe	O
neuronal	O
lost	O
and	O
gliosis	B-DISO
.	O

ABSTRACT	O
:	O
Chicks	O
hatched	O
with	O
high	O
levels	O
of	O
maternal	O
antibody	O
had	O
excellent	O
protection	O
(>	O
95	O
%)	O
against	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
challenge	O
at	O
1	O
day	O
of	O
age	O
,	O
but	O
not	O
at	O
7	O
days	O
(<	O
30	O
%).	O

A	O
density	O
index	O
was	O
calculated	O
for	O
a	O
2	O
-	O
cm2	B-DISO
window	O
in	O
three	O
dorsal	O
and	O
three	O
ventral	O
lung	O
regions	O
.	O

TITLE	O
:	O
Pathophysiology	O
of	O
prone	O
positioning	O
in	O
the	O
healthy	O
lung	O
and	O
in	O
ALI	O
/	O
ARDS	B-DISO
.	O

Moreover	O
,	O
prone	O
position	O
causes	O
,	O
both	O
in	O
healthy	O
subject	O
and	O
in	O
obese	B-DISO
patients	O
,	O
an	O
improvement	O
in	O
oxygenation	O
and	O
in	O
functional	O
residual	O
capacity	O
without	O
affecting	O
respiratory	O
system	O
,	O
lung	O
and	O
chest	O
wall	O
compliance	O
.	O

In	O
ALI	O
/	O
ARDS	B-DISO
patients	O
,	O
prone	O
position	O
lead	O
to	O
a	O
reverse	O
of	O
the	O
alveolar	O
inflation	O
and	O
ventilation	O
distribution	O
,	O
due	O
to	O
the	O
reverse	O
of	O
hydrostatic	O
pressure	O
overlying	O
lung	O
parenchyma	O
,	O
the	O
reverse	O
of	O
heart	O
weight	O
,	O
and	O
the	O
changes	O
in	O
chest	O
wall	O
shape	O
and	O
mechanical	O
properties	O
.	O

Sequencing	O
analysis	O
of	O
the	O
S	O
(	O
S1	O
portion	O
),	O
HE	O
,	O
ORF4	O
and	O
ORF5	O
genes	O
of	O
BCoV	O
isolates	O
associated	O
with	O
different	O
clinical	O
syndromes	B-DISO
indicated	O
that	O
neither	O
insertions	O
or	O
deletions	O
could	O
explain	O
their	O
distinct	O
tropism	O
.	O

TITLE	O
:	O
When	O
to	O
suspect	O
and	O
how	O
to	O
monitor	O
babesiosis	B-DISO
.	O

Symptoms	O
include	O
high	O
fever	O
,	O
chills	B-DISO
,	O
diaphoresis	B-DISO
,	O
weakness	B-DISO
,	O
anorexia	B-DISO
and	O
headache	B-DISO
.	O

Mortality	O
remains	O
high	O
among	O
children	O
with	O
ARDS	B-DISO
,	O
particularly	O
when	O
serious	O
underlying	O
conditions	O
co	O
-	O
exist	O
,	O
sepsis	B-DISO
occurs	O
,	O
and	O
when	O
there	O
is	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Axonal	O
damage	O
is	O
T	O
cell	O
mediated	O
and	O
occurs	O
concomitantly	O
with	O
demyelination	B-DISO
in	O
mice	O
infected	O
with	O
a	O
neurotropic	O
coronavirus	O
.	O

In	O
patients	O
who	O
died	O
necropsy	O
confirmed	O
irreversible	O
multiorgan	B-DISO
failure	I-DISO
.	O

ABSTRACT	O
:	O
Antibodies	O
to	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
cross	O
-	O
react	O
with	O
turkey	O
coronavirus	O
(	O
TCV	O
)	O
in	O
immunofluorescence	O
assay	O
(	O
IFA	O
)	O
indicating	O
that	O
IBV	O
and	O
TCV	O
may	O
share	O
an	O
amino	O
acid	O
sequence	O
similarity	O
.	O

ABSTRACT	O
:	O
This	O
article	O
represents	O
the	O
work	O
of	O
the	O
National	O
Association	O
of	O
Medical	O
Examiners	O
Ad	O
Hoc	O
Committee	O
on	O
shaken	O
baby	O
syndrome	B-DISO
.	O

All	O
patients	O
had	O
bilateral	O
infiltrates	B-DISO
on	O
chest	O
radiography	O
,	O
a	O
PaO2	O
/	O
FIO2	O
ratio	O
less	O
than	O
200	O
mmHg	O
,	O
and	O
stable	O
hemodynamics	O
without	O
vasoactive	O
drugs	O
.	O

There	O
was	O
a	O
correlation	O
between	O
shedding	O
and	O
antibody	O
titre	O
but	O
the	O
cats	O
could	O
remain	O
seropositive	O
for	O
some	O
time	O
after	O
they	O
had	O
ceased	O
shedding	B-DISO
virus	I-DISO
.	O

If	O
unexplained	O
dyspnea	B-DISO
persists	O
for	O
more	O
than	O
a	O
few	O
hours	O
,	O
severe	O
lung	O
toxicity	O
is	O
highly	O
likely	O
and	O
gemcitabin	O
should	O
be	O
interrupted	O
.	O

TITLE	O
:	O
Recent	O
epidemiological	O
status	O
of	O
canine	O
viral	O
enteric	O
infections	B-DISO
and	O
Giardia	B-DISO
infection	I-DISO
in	O
Japan	O
.	O

Replication	O
of	O
IBV	O
in	O
Vero	O
cells	O
causes	O
extensive	O
cytopathic	B-DISO
effects	I-DISO
(	O
CPE	O
),	O
leading	O
to	O
destruction	O
of	O
the	O
entire	O
monolayer	O
and	O
the	O
death	O
of	O
infected	O
cells	O
.	O

The	O
results	O
show	O
that	O
both	O
necrosis	O
and	O
apoptosis	O
may	O
contribute	O
to	O
the	O
death	O
of	O
infected	O
cells	O
in	O
lytic	B-DISO
IBV	O
infection	B-DISO
.	O

Caspase	O
-	O
dependent	O
apoptosis	O
,	O
as	O
characterized	O
by	O
chromosomal	O
condensation	B-DISO
,	O
DNA	O
fragmentation	B-DISO
,	O
caspase	O
-	O
3	O
activation	O
,	O
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
degradation	O
,	O
was	O
detected	O
in	O
IBV	O
-	O
infected	O
Vero	O
cells	O
.	O

ABSTRACT	O
:	O
A	O
stable	O
recombinant	O
fowl	O
poxvirus	O
(	O
rFPV	O
)	O
expressing	O
the	O
C	O
-	O
terminal	O
region	O
(	O
119	O
amino	O
acids	O
)	O
of	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
an	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
strain	O
Ch3	O
was	O
constructed	O
by	O
inserting	O
the	O
coding	O
sequence	O
within	O
the	O
thymidine	O
kinase	O
gene	O
of	O
fowl	O
poxvirus	O
(	O
FPV	O
)	O
by	O
homologous	O
recombination	O
.	O

When	O
the	O
chickens	O
were	O
challenged	O
with	O
IBV	O
Ch3	O
or	O
Ch5	O
,	O
the	O
control	O
birds	O
had	O
respiratory	O
signs	O
of	O
infections	B-DISO
bronchitis	B-DISO
,	O
whereas	O
all	O
the	O
vaccinated	O
birds	O
were	O
clinically	O
normal	O
although	O
low	O
levels	O
of	O
the	O
IBV	O
infection	B-DISO
were	O
detected	O
by	O
a	O
differential	O
ELISA	O
.	O

TITLE	O
:	O
Spike	O
glycoprotein	O
cleavage	O
recognition	O
site	O
analysis	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

No	O
differences	O
were	O
found	O
between	O
the	O
ALI	O
/	O
ARDS	B-DISO
group	O
and	O
the	O
total	O
population	O
of	O
resected	O
lung	B-DISO
cancer	I-DISO
patients	O
(	O
control	O
group	O
)	O
with	O
respect	O
to	O
sex	O
,	O
mean	O
age	O
,	O
pre	O
-	O
operative	O
blood	O
gases	O
,	O
%	O
FEV1	O
,	O
surgical	O
--	O
pathologic	O
staging	O
and	O
the	O
use	O
of	O
pre	O
-	O
operative	O
radiotherapy	O
.	O

ALI	O
/	O
ARDS	B-DISO
accounted	O
for	O
41	O
%	O
of	O
our	O
hospital	O
mortality	O
.	O

TITLE	O
:	O
[	O
Neonatal	O
arteriovenous	O
thrombosis	B-DISO
:	O
report	O
of	O
a	O
case	O
].	O

CONCLUSIONS	O
:	O
Early	O
identification	O
of	O
limb	O
vascular	O
thrombosis	B-DISO
through	O
external	O
symptoms	O
is	O
very	O
important	O
,	O
as	O
it	O
can	O
avoid	O
invasive	O
surgical	O
procedures	O
.	O

Liver	O
and	O
colon	B-DISO
lesions	I-DISO
contained	O
intracellular	O
,	O
curved	O
,	O
spore	O
-	O
forming	O
,	O
gram	O
-	O
negative	O
,	O
silver	O
-	O
positive	O
rods	O
morphologically	O
consistent	O
with	O
Clostridium	O
piliforme	O
.	O

This	O
panda	O
most	O
likely	O
contracted	O
Tyzzer	B-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
subsequent	O
to	O
having	O
a	O
compromised	O
immune	O
system	O
after	O
corticosteroid	O
administration	O
and	O
concurrent	O
disease	O
.	O

Despite	O
initial	O
improvement	O
in	O
arterial	O
oxygenation	O
with	O
NIPSV	O
in	O
patients	O
with	O
ARF	B-DISO
due	O
to	O
severe	O
CAP	B-DISO
,	O
the	O
intubation	O
rate	O
is	O
high	O
.	O

After	O
induction	O
of	O
anaesthesia	B-DISO
and	O
placement	O
of	O
vascular	O
catheters	O
,	O
lung	O
injury	O
was	O
induced	O
with	O
0	O
.	O
12	O
ml	O
x	O
kg	O
(-	O
1	O
)	O
oleic	O
acid	O
.	O

The	O
lungs	O
of	O
the	O
SNO	O
group	O
had	O
significantly	O
alleviated	O
edema	B-DISO
and	O
neutrophil	O
infiltration	B-DISO
compared	O
with	O
the	O
P	O
-	O
Control	O
.	O

mAb	O
1F8	O
also	O
stains	O
Ly49	O
C	O
and	O
I	O
,	O
but	O
exclusion	O
of	O
those	O
reactivities	O
with	O
mAb	O
5E6	O
,	O
which	O
recognizes	O
Ly49	O
C	O
and	O
I	O
,	O
indicated	O
that	O
Ly49H	O
(+)	O
cells	O
infiltrated	B-DISO
the	O
peritoneal	O
cavity	B-DISO
and	O
liver	O
and	O
were	O
particularly	O
effective	O
at	O
synthesizing	O
interferon	O
gamma	O
.	O

The	O
large	O
spike	O
(	O
S	O
)	O
glycoprotein	O
is	O
an	O
important	O
determinant	O
of	O
species	O
specificity	O
,	O
tissue	O
tropism	O
and	O
virulence	O
of	O
coronavirus	B-DISO
infection	I-DISO
.	O

HFOV	O
was	O
initiated	O
in	O
patients	O
with	O
ARDS	B-DISO
after	O
varying	O
periods	O
of	O
conventional	O
ventilation	O
(	O
CV	O
).	O

Fio2	O
,	O
Paw	O
,	O
pressure	O
amplitude	O
of	O
oscillation	O
,	O
frequency	O
,	O
blood	O
pressure	O
,	O
heart	O
rate	O
,	O
and	O
arterial	O
blood	O
gases	O
were	O
monitored	O
during	O
the	O
transition	B-DISO
from	O
CV	O
to	O
HFOV	O
,	O
and	O
every	O
8	O
hrs	B-DISO
thereafter	O
for	O
72	O
hrs	B-DISO
.	O

Infections	B-DISO
accounted	O
for	O
the	O
greatest	O
number	O
of	O
deaths	O
(	O
bacterial	B-DISO
pneumonia	I-DISO
,	O
four	O
patients	O
;	O
catheter	O
-	O
related	O
bacteremia	B-DISO
,	O
one	O
patient	O
).	O

Persistent	O
pneumonia	B-DISO
confirmed	O
by	O
biopsy	O
specimen	O
was	O
usually	O
accompanied	O
by	O
histologic	O
manifestations	O
of	O
acute	O
cellular	O
rejection	O
and	O
was	O
associated	O
with	O
poor	O
patient	O
outcome	O
(	O
ie	O
,	O
death	O
or	O
subsequent	O
development	O
of	O
bronchiolitis	B-DISO
obliterans	I-DISO
syndrome	B-DISO
).	O

Other	O
causes	O
of	O
death	O
included	O
hypoxic	B-DISO
-	I-DISO
ischemic	I-DISO
encephalopathy	I-DISO
secondary	O
to	O
an	O
intraoperative	B-DISO
cardiac	I-DISO
arrest	I-DISO
(	O
one	O
patient	O
),	O
pulmonary	B-DISO
venous	I-DISO
thrombosis	I-DISO
with	O
bacterial	O
colonization	O
of	O
the	O
thrombotic	O
material	O
(	O
one	O
patient	O
),	O
and	O
ischemic	O
reperfusion	O
injury	O
(	O
one	O
patient	O
).	O

TITLE	O
:	O
Is	O
amiodarone	O
an	O
underrecognized	O
cause	O
of	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
in	O
the	O
ICU	O
?	O

After	O
reviewing	O
the	O
data	O
,	O
and	O
even	O
in	O
the	O
context	O
of	O
difficulties	O
and	O
discrepancies	O
in	O
the	O
existing	O
literature	O
,	O
we	O
contend	O
that	O
there	O
is	O
sufficient	O
evidence	O
of	O
amiodarone	O
'	O
s	O
potentially	O
serious	O
side	O
-	O
effect	O
profile	O
in	O
surgical	O
ICU	O
patients	O
to	O
advise	O
continued	O
caution	O
in	O
its	O
use	O
with	O
this	O
severely	O
ill	B-DISO
patient	O
group	O
.	O

We	O
suggest	O
that	O
amiodarone	O
has	O
a	O
potentially	O
important	O
,	O
though	O
underrecognized	O
,	O
role	O
in	O
inducing	O
an	O
APT	O
/	O
ARDS	B-DISO
in	O
some	O
patients	O
,	O
such	O
as	O
those	O
undergoing	O
cardiac	O
surgery	O
.	O

In	O
experiment	O
2	O
,	O
2	O
-	O
day	O
-	O
old	O
piglets	O
fed	O
HCC	B-DISO
containing	O
antibody	O
titers	O
of	O
1	O
:	O
512	O
,	O
1	O
:	O
128	O
and	O
1	O
:	O
32	O
,	O
and	O
UCC	O
were	O
inoculated	O
with	O
PED	O
virus	O
,	O
and	O
survival	O
rates	O
after	O
challenge	O
were	O
100	O
,	O
75	O
,	O
50	O
and	O
0	O
%,	O
respectively	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
piglets	O
fed	O
UCC	O
,	O
villous	O
atrophy	B-DISO
and	O
PED	O
virus	O
antigen	O
were	O
observed	O
in	O
epithelial	O
cells	O
of	O
the	O
jejunum	O
and	O
ileum	O
from	O
24	O
hr	O
.	O

It	O
was	O
concluded	O
that	O
oral	O
administration	O
of	O
HCC	B-DISO
to	O
piglets	O
was	O
effective	O
in	O
preventing	O
PED	O
virus	B-DISO
infection	I-DISO
and	O
reduced	O
their	O
mortality	O
.	O

Embolization	O
as	O
a	O
therapeutic	O
modality	O
to	O
address	O
this	O
tumor	B-DISO
is	O
described	O
.	O

The	O
cause	O
of	O
the	O
persistent	O
and	O
severe	O
pulmonary	B-DISO
hypertension	I-DISO
remains	O
unclear	O
,	O
but	O
may	O
be	O
related	O
to	O
the	O
tumor	B-DISO
.	O

Impaired	B-DISO
ex	O
vivo	O
cytolytic	O
activity	O
of	O
muMT	O
CNS	O
mononuclear	O
cells	O
,	O
concomitant	O
with	O
reduced	O
frequencies	O
,	O
implicated	O
IFN	O
-	O
gamma	O
as	O
the	O
primary	O
anti	O
viral	O
factor	O
early	O
in	O
infection	B-DISO
.	O

Thus	O
,	O
in	O
addition	O
to	O
the	O
lack	O
of	O
Ab	O
,	O
limited	O
CD8	O
(+)	O
and	O
CD4	O
(+)	O
T	O
cell	O
responses	O
in	O
muMT	O
mice	O
contribute	O
to	O
the	O
ultimate	O
loss	O
of	O
control	O
of	O
CNS	B-DISO
infection	I-DISO
.	O

Enterocyte	O
lesions	O
involved	O
the	O
crypts	O
in	O
cats	O
with	O
PV	O
enteritis	B-DISO
,	O
FAE	B-DISO
,	O
and	O
EUE	O
and	O
the	O
villous	O
tips	O
in	O
cats	O
with	O
CoV	O
enteritis	B-DISO
.	O

Bone	O
marrow	O
activity	O
was	O
decreased	O
in	O
cats	O
with	O
PV	O
enteritis	B-DISO
;	O
in	O
cats	O
with	O
FAE	B-DISO
or	O
EUE	O
and	O
in	O
FeLV	O
-	O
positive	O
cats	O
without	O
enterocyte	O
alterations	O
,	O
activity	O
was	O
slightly	O
increased	O
.	O

In	O
cats	O
with	O
FAE	B-DISO
and	O
PV	O
enteritis	B-DISO
,	O
a	O
T	O
-	O
cell	O
-	O
dominated	O
response	O
prevailed	O
.	O

RESULTS	O
:	O
Seventy	O
patients	O
with	O
a	O
mean	O
age	O
of	O
35	O
.	O
51	O
years	O
(	O
range	O
,	O
10	O
-	O
87	O
years	O
)	O
and	O
a	O
mean	O
ISS	B-DISO
score	O
of	O
36	O
.	O
61	O
(	O
95	O
%	O
CI	O
,	O
31	O
.	O
08	O
-	O
42	O
.	O
14	O
)	O
entered	O
the	O
study	O
.	O

Despite	O
physicians	O
'	O
ethical	O
reserves	O
concerning	O
this	O
self	O
-	O
inflicted	O
disease	O
and	O
the	O
public	O
'	O
s	O
misgivings	O
,	O
liver	O
transplantation	O
for	O
alcoholic	B-DISO
cirrhosis	I-DISO
can	O
provide	O
survival	O
rates	O
comparable	O
with	O
those	O
observed	O
for	O
other	O
chronic	O
liver	B-DISO
diseases	I-DISO
.	O

in	O
this	O
indication	O
,	O
liver	O
transplantation	O
if	O
often	O
associated	O
with	O
a	O
low	O
risk	O
of	O
acute	O
rejection	O
and	O
a	O
high	O
rate	O
cancer	B-DISO
of	O
the	O
upper	O
respiratory	O
and	O
digestive	O
tracts	O
.	O

ABSTRACT	O
:	O
An	O
outbreak	O
of	O
dual	O
infection	B-DISO
in	O
dogs	O
with	O
canine	O
adenovirus	B-DISO
type	O
1	O
(	O
CAV	O
-	O
1	O
)	O
and	O
canine	O
coronavirus	O
(	O
CCV	B-DISO
)	O
infection	B-DISO
is	O
reported	O
in	O
an	O
animal	O
shelter	O
that	O
comprised	O
approximately	O
200	O
adults	O
stray	O
dogs	O
and	O
30	O
puppies	O
.	O

Both	O
CAV	O
-	O
1	O
and	O
CCV	B-DISO
were	O
isolated	O
from	O
tissue	O
or	O
swab	O
samples	O
.	O

ABSTRACT	O
:	O
Passive	O
protection	O
experiments	O
were	O
conducted	O
to	O
determine	O
the	O
frequency	O
and	O
amounts	O
of	O
hyperimmune	O
antiserum	O
needed	O
to	O
block	O
a	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
challenge	O
infection	B-DISO
and	O
to	O
identify	O
monoclonal	O
antibodies	O
that	O
are	O
partially	O
protective	O
against	O
TGEV	O
.	O

Upon	O
resolution	O
of	O
the	O
underlying	O
pathology	B-DISO
mechanical	O
ventilation	O
may	O
be	O
withdrawn	B-DISO
.	O

ABSTRACT	O
:	O
Angioedema	B-DISO
without	O
urticaria	B-DISO
is	O
a	O
clinical	O
syndrome	B-DISO
characterised	O
by	O
self	O
-	O
limiting	O
local	O
swellings	B-DISO
involving	O
the	O
deeper	O
cutaneous	O
and	O
mucosa	O
tissue	O
layers	O
.	O

However	O
,	O
we	O
do	O
not	O
know	O
whether	O
this	O
adverse	B-DISO
effect	I-DISO
has	O
the	O
same	O
mechanism	O
with	O
the	O
2	O
classes	O
of	O
medications	O
.	O

Angioedema	B-DISO
can	O
also	O
occur	O
with	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
.	O

Epinephrine	O
(	O
adrenaline	O
),	O
diphenydramine	O
and	O
intravenous	O
methylprednisolone	O
have	O
been	O
proposed	O
for	O
the	O
medical	O
management	O
of	O
airway	B-DISO
obstruction	I-DISO
,	O
but	O
so	O
far	O
no	O
controlled	O
studies	O
have	O
demonstrated	O
their	O
efficacy	O
.	O

TITLE	O
:	O
The	O
relationship	O
between	O
the	O
occurrence	O
of	O
undifferentiated	O
bovine	O
respiratory	B-DISO
disease	I-DISO
and	O
titer	O
changes	O
to	O
bovine	O
coronavirus	O
and	O
bovine	B-DISO
viral	I-DISO
diarrhea	I-DISO
virus	O
in	O
3	O
Ontario	O
feedlots	O
.	O

The	O
method	O
could	O
provide	O
a	O
useful	O
tool	O
for	O
demonstrating	O
the	O
role	O
of	O
human	O
coronavirus	O
in	O
infections	B-DISO
of	O
the	O
respiratory	O
tract	O
.	O

ABSTRACT	O
:	O
The	O
CEACAM1	O
glycoproteins	O
(	O
formerly	O
called	O
biliary	O
glycoproteins	O
;	O
BGP	O
,	O
C	O
-	O
CAM	B-DISO
,	O
CD66a	O
,	O
or	O
MHVR	O
)	O
are	O
members	O
of	O
the	O
carcinoembryonic	O
antigen	O
family	O
of	O
cell	O
adhesion	B-DISO
molecules	O
.	O

CONCLUSIONS	O
:	O
Extent	O
of	O
contusion	O
volumes	O
measured	O
using	O
three	O
-	O
dimensional	O
reconstruction	O
allows	O
identification	O
of	O
patients	O
at	O
high	O
risk	O
of	O
pulmonary	O
dysfunction	O
as	O
characterized	O
by	O
development	O
of	O
ARDS	B-DISO
.	O

In	O
Experiment	O
2	O
,	O
Group	O
L	O
had	O
a	O
higher	O
AFA	B-DISO
and	O
AMEn	O
than	O
Group	O
S	O
.	O
AFA	B-DISO
and	O
AMEn	O
improved	O
in	O
both	O
groups	O
over	O
time	O
.	O

However	O
,	O
Fas	B-DISO
ligation	O
can	O
also	O
lead	O
to	O
cell	O
activation	O
and	O
cytokine	O
production	O
.	O

Seventy	O
-	O
five	O
consecutive	O
ARDS	B-DISO
patients	O
given	O
respiratory	O
support	O
with	O
airway	O
pressure	O
limitation	O
(	O
plateau	O
pressure	O
<	O
or	O
=	O
30	O
cm	O
H2O	O
).	O

Significant	O
impairment	B-DISO
of	O
left	O
ventricular	O
diastolic	O
function	O
was	O
also	O
seen	O
.	O

A	O
multivariate	O
analysis	O
individualized	O
Paco2	O
level	O
as	O
the	O
sole	O
factor	O
independently	O
associated	O
with	O
ACP	B-DISO
,	O
suggesting	O
that	O
ACP	B-DISO
development	O
in	O
ARDS	B-DISO
is	O
influenced	O
by	O
the	O
severity	O
of	O
lung	O
damage	O
and	O
/	O
or	O
the	O
respiratory	O
strategy	O
.	O

Pulmonary	O
hemodynamics	O
and	O
gas	O
exchange	O
are	O
related	O
to	O
changes	O
of	O
arterial	O
prostanoid	O
levels	O
in	O
ARDS	B-DISO
patients	O
,	O
depending	O
on	O
the	O
rate	O
of	O
fat	O
infusion	O
.	O

Earlier	O
use	O
of	O
the	O
drugs	O
made	O
it	O
possible	O
to	O
transfer	O
patients	O
to	O
safe	O
AV	O
regimens	O
and	O
to	O
eliminate	O
ALL	O
and	O
ARDS	B-DISO
rapidly	O
and	O
to	O
significantly	O
reduce	O
mortality	O
due	O
to	O
critical	O
states	O
.	O

The	O
viral	O
wheezers	O
with	O
colds	B-DISO
had	O
small	O
(	O
3	O
-	O
4	O
%)	O
reductions	O
in	O
FEV1	O
and	O
peak	O
expiratory	O
flow	O
on	O
days	O
with	O
LRT	O
symptoms	O
(	O
days	O
3	O
-	O
6	O
),	O
but	O
a	O
progressive	O
reduction	O
in	O
PC20	O
from	O
baseline	O
on	O
days	O
2	O
,	O
4	O
and	O
17	O
after	O
inoculation	O
(	O
by	O
0	O
.	O
82	O
,	O
1	O
.	O
35	O
and	O
1	O
.	O
82	O
doubling	O
concentrations	O
,	O
respectively	O
).	O

Thirty	O
-	O
two	O
(	O
68	O
%)	O
were	O
suicide	B-DISO
attempts	I-DISO
and	O
15	O
(	O
32	O
%)	O
were	O
accidental	O
exposure	O
.	O

Intermediate	B-DISO
syndrome	I-DISO
was	O
observed	O
in	O
9	O
(	O
19	O
.	O
1	O
%)	O
patients	O
.	O

OP	O
insecticide	O
poisoning	O
is	O
a	O
serious	O
condition	B-DISO
that	O
needs	O
rapid	O
diagnosis	O
and	O
treatment	O
.	O

TITLE	O
:	O
Airway	O
pressure	O
release	O
ventilation	O
increases	O
cardiac	O
performance	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
/	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Four	O
samples	O
,	O
collected	O
from	O
a	O
dog	O
presenting	O
a	O
long	O
-	O
duration	O
shedding	O
of	O
CCV	B-DISO
,	O
and	O
a	O
sample	O
from	O
another	O
diarrhoeic	O
dog	O
,	O
were	O
found	O
positive	O
by	O
PCR	O
but	O
negative	O
by	O
n	O
-	O
PCR	O
.	O

Normal	O
rats	O
had	O
a	O
well	O
-	O
defined	O
upper	O
inflection	O
point	O
(	O
UIP	B-DISO
)	O
at	O
low	O
airway	O
pressure	O
.	O

ventilator	O
-	O
induced	O
lung	O
injury	O
;	O
respiratory	O
mechanics	O
;	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO

ABSTRACT	O
:	O
Expression	O
of	O
negative	O
-	O
strand	O
murine	O
coronavirus	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
defective	O
interfering	O
(	O
DI	O
)	O
RNA	O
transcripts	O
in	O
MHV	O
-	O
infected	O
cells	O
results	O
in	O
the	O
accumulation	O
of	O
positive	O
-	O
strand	O
DI	O
RNAs	O
(	O
M	O
.	O
Joo	O
et	O
al	O
.,	O
1996	O
,	O
J	O
.	O
Virol	O
.	O

ABSTRACT	O
:	O
Murine	O
coronavirus	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
produces	O
a	O
genome	O
-	O
length	O
mRNA	O
,	O
mRNA	O
1	O
,	O
and	O
six	O
or	O
seven	O
species	O
of	O
subgenomic	O
mRNAs	O
in	O
infected	O
cells	O
.	O

A	O
short	O
cis	B-DISO
-	O
acting	O
MHV	O
RNA	O
packaging	O
signal	O
is	O
necessary	O
and	O
sufficient	O
for	O
packaging	O
RNA	O
into	O
MHV	O
particles	O
.	O

To	O
explore	O
the	O
events	O
which	O
couple	O
acute	B-DISO
pancreatitis	I-DISO
to	O
lung	O
injury	O
,	O
a	O
number	O
of	O
recent	O
studies	O
have	O
been	O
performed	O
in	O
the	O
author	O
'	O
s	O
laboratory	O
using	O
a	O
variety	O
of	O
experimental	O
models	O
and	O
interventions	O
including	O
gene	O
-	O
targeted	O
deletion	O
of	O
chemokines	O
,	O
cytokines	O
,	O
specific	O
receptors	O
,	O
and	O
adhesion	B-DISO
molecules	O
.	O

In	O
addition	O
,	O
infected	O
CCR5	O
(-/-)	O
mice	O
exhibited	O
reduced	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
02	O
)	O
macrophage	O
(	O
CD45	O
(	O
high	O
)	O
F4	O
/	O
80	O
(+))	O
infiltration	B-DISO
,	O
which	O
correlated	O
with	O
a	O
significant	O
reduction	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
in	O
the	O
severity	O
of	O
demyelination	B-DISO
compared	O
to	O
CCR5	O
(+/+)	O
mice	O
.	O

These	O
data	O
indicate	O
that	O
CCR5	O
contributes	O
to	O
MHV	O
-	O
induced	O
demyelination	B-DISO
by	O
allowing	O
macrophages	O
to	O
traffic	O
into	O
the	O
CNS	O
.	O

Twelve	O
-	O
bed	B-DISO
intensive	O
care	O
unit	O
in	O
a	O
1	O
,	O
100	O
-	O
bed	B-DISO
primary	O
care	O
university	O
hospital	O
.	O

PCT	B-DISO
was	O
detectable	O
in	O
BAL	O
fluids	O
of	O
all	O
14	O
patients	O
.	O

In	O
12	O
cases	O
,	O
salvage	O
of	O
above	O
-	O
knee	O
or	O
below	O
-	O
knee	O
amputated	O
stumps	B-DISO
was	O
achieved	O
with	O
a	O
plantar	O
neurovascular	O
island	O
pedicled	O
flap	O
.	O

Four	O
knee	O
joints	O
were	O
salvaged	O
and	O
one	O
above	O
-	O
knee	O
stump	B-DISO
was	O
lengthened	O
.	O

One	O
patient	O
died	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
6	O
days	O
after	O
surgery	O
.	O

Overall	O
complication	B-DISO
rate	O
,	O
including	O
wound	B-DISO
dehiscence	I-DISO
and	O
secondary	O
grafting	O
,	O
was	O
18	O
percent	O
.	O

Major	O
complications	O
such	O
as	O
flap	O
loss	O
,	O
flap	O
revision	O
,	O
or	O
severe	O
infection	B-DISO
occurred	O
in	O
only	O
7	O
.	O
5	O
percent	O
of	O
cases	O
.	O

The	O
majority	O
of	O
our	O
cases	O
resulted	O
from	O
severe	O
trauma	O
with	O
infected	O
and	O
necrotic	O
soft	O
tissues	O
,	O
disseminated	O
tumor	B-DISO
disease	O
,	O
or	O
ulcers	B-DISO
in	O
elderly	O
,	O
multimorbid	O
patients	O
.	O

TITLE	O
:	O
Complete	O
genome	O
sequence	O
of	O
transmissible	O
gastroenteritis	B-DISO
coronavirus	O
PUR46	O
-	O
MAD	O
clone	O
and	O
evolution	O
of	O
the	O
purdue	O
virus	O
cluster	O
.	O

ABSTRACT	O
:	O
The	O
complete	O
sequence	O
(	O
28580	O
nt	O
)	O
of	O
the	O
PUR46	O
-	O
MAD	O
clone	O
of	O
the	O
Purdue	O
cluster	O
of	O
transmissible	O
gastroenteritis	B-DISO
coronavirus	O
(	O
TGEV	O
)	O
has	O
been	O
determined	O
and	O
compared	O
with	O
members	O
of	O
this	O
cluster	O
and	O
other	O
coronaviruses	O
.	O

Following	O
MHV	O
infection	B-DISO
,	O
chemokines	O
including	O
CXC	O
chemokine	O
ligand	O
(	O
CXCL	O
)	O
10	O
(	O
IFN	O
inducible	O
protein	O
10	O
kDa	O
),	O
CXCL9	O
(	O
monokine	O
induced	O
by	O
IFN	O
-	O
gamma	O
),	O
and	O
CC	O
chemokine	O
ligand	O
5	O
(	O
RANTES	O
)	O
are	O
expressed	O
during	O
both	O
acute	O
and	O
chronic	O
stages	O
of	O
disease	O
suggesting	O
a	O
role	O
for	O
these	O
molecules	O
in	O
disease	O
exacerbation	O
.	O

Treatment	O
with	O
antisera	O
against	O
CXCL9	O
was	O
without	O
effect	O
,	O
demonstrating	O
a	O
critical	O
role	O
for	O
CXCL10	O
in	O
inflammatory	O
demyelination	B-DISO
in	O
this	O
model	O
.	O

These	O
findings	O
document	O
a	O
novel	O
therapeutic	O
strategy	O
using	O
Ab	O
-	O
mediated	O
neutralization	O
of	O
a	O
key	O
chemokine	O
as	O
a	O
possible	O
treatment	O
for	O
chronic	O
human	O
inflammatory	O
demyelinating	B-DISO
diseases	I-DISO
such	O
as	O
MS	O
.	O

Therefore	O
,	O
selenium	O
substitution	O
in	O
those	O
patients	O
might	O
be	O
effective	O
in	O
the	O
prevention	O
of	O
multiorgan	B-DISO
failure	I-DISO
.	O

In	O
four	O
patients	O
HFOV	O
was	O
also	O
used	O
during	O
anesthesia	B-DISO
and	O
surgery	O
,	O
where	O
a	O
total	O
of	O
10	O
procedures	O
involving	O
a	O
mean	O
excision	O
and	O
closure	O
of	O
15	O
+/-	O

In	O
three	O
patients	O
death	O
resulted	O
from	O
sepsis	B-DISO
and	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
;	O
their	O
mean	O
PaO2	O
/	O
FIO2	O
was	O
107	O
+/-	O

Prior	O
to	O
implementation	O
,	O
hemodynamic	O
and	O
acid	O
-	O
base	O
status	O
,	O
minute	O
ventilation	O
,	O
and	O
adequacy	O
of	O
sedation	B-DISO
should	O
be	O
assessed	O
to	O
minimize	O
the	O
potential	O
for	O
intolerance	O
.	O

The	O
volume	O
-	O
preset	O
,	O
assist	O
-	O
control	O
mode	O
is	O
recommended	O
for	O
better	O
control	O
of	O
V	O
(	O
T	O
),	O
and	O
the	O
respiratory	O
rate	O
should	O
be	O
increased	O
as	O
V	O
(	O
T	O
)	O
is	O
reduced	O
,	O
so	O
as	O
to	O
maintain	O
minute	O
ventilation	O
and	O
prevent	O
acute	O
hypercapnia	B-DISO
.	O

To	O
explore	O
the	O
possible	O
mechanism	O
of	O
the	O
emergence	O
of	O
acute	O
PRRS	B-DISO
,	O
the	O
open	O
reading	O
frame	O
5	O
(	O
ORF5	O
)	O
gene	O
encoding	O
the	O
major	O
envelope	O
protein	O
(	O
GP5	O
)	O
of	O
acute	O
PRRSV	O
isolates	O
was	O
characterized	O
.	O

TITLE	O
:	O
Prolonged	O
nasal	O
eosinophilia	B-DISO
in	O
allergic	O
patients	O
after	O
common	B-DISO
cold	I-DISO
.	O

Prolonged	O
nasal	O
eosinophil	O
influx	O
was	O
observed	O
in	O
allergic	O
patients	O
after	O
common	B-DISO
cold	I-DISO
.	O

What	O
immunologic	O
factors	O
can	O
induce	O
prolonged	O
eosinophil	O
influx	O
and	O
whether	O
this	O
may	O
increase	O
the	O
risk	O
of	O
subsequent	O
allergen	O
-	O
induced	O
hypersensitivity	B-DISO
reactions	I-DISO
must	O
be	O
studied	O
further	O
.	O

For	O
comparison	O
,	O
tissues	O
from	O
14	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
cats	O
and	O
seven	O
cats	O
infected	O
with	O
FIP	B-DISO
virus	O
(	O
FIPV	O
;	O
as	O
the	O
result	O
of	O
long	O
-	O
term	O
exposure	O
)	O
but	O
free	O
from	O
FIP	B-DISO
were	O
examined	O
.	O

A	O
high	O
-	O
resolution	O
CT	O
of	O
the	O
chest	O
revealed	O
a	O
low	O
attenuation	O
area	O
consistent	O
with	O
severe	O
emphysematous	O
alterations	O
and	O
progressively	O
enlarging	O
bullae	B-DISO
.	O

The	O
present	O
case	O
demonstrated	O
that	O
HIV	B-DISO
infection	I-DISO
was	O
not	O
an	O
essential	O
factor	O
in	O
the	O
development	O
of	O
bullous	O
changes	O
.	O

This	O
is	O
the	O
first	O
report	O
that	O
compares	O
the	O
neurovirulence	O
and	O
pathogenesis	B-DISO
of	O
isogenic	O
viruses	O
with	O
defined	O
alterations	O
in	O
the	O
MHV	O
spike	O
protein	O
.	O

From	O
these	O
studies	O
,	O
it	O
appears	O
that	O
the	O
interactions	O
of	O
multiple	O
regions	O
of	O
the	O
MHV	O
spike	O
,	O
including	O
the	O
HVR	O
,	O
act	O
in	O
concert	O
to	O
allow	O
for	O
efficient	O
infection	B-DISO
of	O
and	O
virulence	O
in	O
the	O
murine	O
central	O
nervous	B-DISO
system	O
.	O

Generalized	O
exfoliative	B-DISO
syndrome	I-DISO
is	O
related	O
to	O
exfoliatin	O
.	O

The	O
disease	O
may	O
occur	O
in	O
childhood	O
,	O
sometimes	O
after	O
superinfection	B-DISO
of	O
varicella	B-DISO
.	O

ABSTRACT	O
:	O
Demyelination	B-DISO
in	O
multiple	B-DISO
sclerosis	I-DISO
and	O
in	O
animal	O
models	O
is	O
associated	O
with	O
infiltrating	B-DISO
CD8	O
+	O
and	O
CD4	O
+	O
T	O
cells	O
.	O

Although	O
oligodendrocytes	O
and	O
axons	O
are	O
damaged	O
in	O
these	O
diseases	O
,	O
the	O
roles	O
T	O
cells	O
play	O
in	O
the	O
demyelination	B-DISO
process	O
are	O
not	O
completely	O
understood	O
.	O

ABSTRACT	O
:	O
Intraocular	O
coronavirus	O
inoculation	O
results	O
in	O
a	O
biphasic	O
retinal	B-DISO
disease	I-DISO
in	O
susceptible	O
mice	O
(	O
BALB	O
/	O
c	O
)	O
characterized	O
by	O
an	O
acute	B-DISO
inflammatory	I-DISO
response	I-DISO
,	O
followed	O
by	O
retinal	B-DISO
degeneration	I-DISO
associated	O
with	O
autoimmune	B-DISO
reactivity	O
.	O

A	O
female	O
patient	O
that	O
since	O
9	O
months	O
age	O
presented	O
digestive	O
symptoms	O
:	O
diarrhea	B-DISO
,	O
nauseous	B-DISO
,	O
vomits	B-DISO
,	O
slow	O
digestions	O
and	O
abdominal	B-DISO
pain	I-DISO
.	O

Infection	B-DISO
of	O
mice	O
lacking	O
CCR2	O
(	O
CCR2	O
(-/-))	O
with	O
MHV	O
resulted	O
in	O
increased	O
mortality	O
and	O
enhanced	O
viral	O
recovery	O
from	O
the	O
brain	O
that	O
correlated	O
with	O
reduced	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
04	O
)	O
T	O
cell	O
and	O
macrophage	O
/	O
microglial	O
(	O
determined	O
by	O
F4	O
/	O
80	O
Ag	O
expression	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
004	O
)	O
infiltration	B-DISO
into	O
the	O
CNS	O
.	O

Finally	O
repeated	O
intravenous	O
injections	O
of	O
various	O
drugs	O
designed	O
for	O
oral	O
intake	O
can	O
lead	O
to	O
severe	O
complications	O
such	O
as	O
pulmonary	B-DISO
hypertension	I-DISO
or	O
toxic	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
.	O

TITLE	O
:	O
[	O
Fatal	O
toxic	B-DISO
respiratory	I-DISO
epitheliolysis	I-DISO
.	O

Subacute	O
tracheo	O
-	O
bronchial	O
desquamation	O
in	O
Stevens	B-DISO
-	I-DISO
Johnson	I-DISO
syndrome	I-DISO
].	O

On	O
the	O
contrary	O
severe	O
respiratory	O
involvement	O
is	O
rare	O
in	O
post	O
-	O
infectious	B-DISO
or	O
toxic	B-DISO
Epitheliolysis	I-DISO
(	O
Stevens	B-DISO
-	I-DISO
Johnson	I-DISO
syndrome	I-DISO
).	O

ABSTRACT	O
:	O
An	O
effective	O
host	O
response	O
against	O
viral	B-DISO
infection	I-DISO
of	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
is	O
the	O
principal	O
factor	O
dictating	O
the	O
outcome	O
of	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Hand	B-DISO
,	I-DISO
foot	I-DISO
,	I-DISO
and	I-DISO
mouth	I-DISO
disease	I-DISO
(	O
HFMD	O
)	O
is	O
endemic	O
in	O
Malaysia	O
.	O

In	O
1997	O
,	O
a	O
large	O
outbreak	O
of	O
enterovirus	O
71	O
(	O
EV	O
-	O
71	O
)	O
associated	O
HFMD	O
resulted	O
in	O
41	O
deaths	O
due	O
to	O
severe	O
left	B-DISO
ventricular	I-DISO
dysfunction	I-DISO
and	O
central	B-DISO
nervous	I-DISO
system	I-DISO
infection	I-DISO
with	O
extensive	O
damage	O
to	O
the	O
medulla	O
and	O
pons	O
.	O

In	O
2000	O
,	O
an	O
outbreak	O
of	O
HFMD	O
resulted	O
in	O
the	O
deaths	O
of	O
three	O
children	O
who	O
had	O
rapid	O
cardio	O
-	O
respiratory	O
decompensation	O
and	O
one	O
child	O
who	O
survived	O
a	O
central	B-DISO
nervous	I-DISO
system	I-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
is	O
a	O
common	O
cause	O
of	O
death	O
in	O
cats	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
identified	O
GA98	O
,	O
a	O
new	O
serotype	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
),	O
which	O
is	O
closely	O
related	O
to	O
the	O
DE072	O
serotype	O
of	O
IBV	O
genetically	O
,	O
but	O
not	O
antigenically	O
.	O

ABSTRACT	O
:	O
The	O
immune	O
response	O
to	O
a	O
naked	O
plasmid	O
DNA	O
encoding	O
the	O
nucleoprotein	O
(	O
N	O
protein	O
)	O
of	O
porcine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
virus	O
(	O
TGEV	O
)	O
was	O
investigated	O
in	O
this	O
study	O
.	O

CD4	O
(+)	O
T	O
cells	O
express	O
wild	O
-	O
type	O
levels	O
of	O
CD69	O
after	O
infection	B-DISO
in	O
muMT	O
mice	O
.	O

These	O
data	O
suggest	O
that	O
clearance	O
of	O
infectious	B-DISO
mouse	B-DISO
hepatitis	I-DISO
virus	O
strain	O
A59	O
from	O
the	O
CNS	O
requires	O
Ab	O
production	O
and	O
perhaps	O
B	O
cell	O
support	O
of	O
T	O
cells	O
;	O
however	O
,	O
virus	O
is	O
cleared	O
from	O
the	O
liver	O
without	O
the	O
involvement	O
of	O
Abs	O
or	O
B	O
cells	O
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
reported	O
the	O
cloning	O
and	O
characterisation	O
of	O
the	O
heavy	O
and	O
light	O
chain	O
variable	O
domain	O
genes	O
encoding	O
three	O
monoclonal	O
antibodies	O
(	O
Mabs	O
)	O
that	O
bind	O
viral	B-DISO
haemorrhagic	I-DISO
septicaemia	I-DISO
virus	O
(	O
VHSV	O
).	O

In	O
addition	O
,	O
a	O
series	O
of	O
scAb	B-DISO
fragments	O
were	O
produced	O
using	O
the	O
3F1H10	O
variable	O
heavy	O
(	O
VH	O
)	O
chain	O
and	O
variable	O
light	O
(	O
Vkappa	O
)	O
chain	O
domains	O
but	O
containing	O
,	O
either	O
alone	O
or	O
in	O
dual	O
combination	O
,	O
each	O
of	O
the	O
four	O
different	O
residues	O
present	O
in	O
3F1A2	O
.	O

There	O
is	O
a	O
significant	O
increase	O
in	O
severe	O
(	O
grades	O
3	O
&	O
4	O
)	O
intraventricular	B-DISO
hemorrhage	I-DISO
(	O
IVH	O
)	O
and	O
in	O
any	O
pulmonary	O
air	O
leak	O
syndrome	B-DISO
[	O
summary	O
RR	O
1	O
.	O
19	O
(	O
1	O
.	O
03	O
,	O
1	O
.	O
38	O
)]	O
in	O
the	O
HFOV	O
group	O
.	O

ARDS	B-DISO
usually	O
appears	O
within	O
12	O
to	O
72	O
hours	O
of	O
an	O
identifiable	O
clinical	O
event	O
and	O
progresses	O
through	O
three	O
phases	O
:	O
1	O
.	O

background	O
general	O
therapy	O
of	O
ARDS	B-DISO
;	O
2	O
.	O

TITLE	O
:	O
Auricular	O
chondritis	B-DISO
in	O
a	O
cat	O
.	O

ABSTRACT	O
:	O
A	O
four	O
-	O
year	O
-	O
old	O
male	O
neutered	O
domestic	O
shorthaired	O
cat	O
developed	O
bilateral	O
thickening	O
of	O
the	O
pinnae	O
,	O
with	O
slight	O
curling	O
,	O
intense	O
erythema	B-DISO
and	O
pain	O
.	O

Biopsy	O
of	O
the	O
ear	O
lesion	O
revealed	O
auricular	O
chondritis	B-DISO
.	O

In	O
humans	O
,	O
histologically	O
similar	O
lesions	O
may	O
involve	O
the	O
pinnae	O
,	O
nose	O
,	O
trachea	B-DISO
,	O
joints	O
,	O
eyes	O
and	O
heart	O
,	O
and	O
the	O
disease	O
is	O
termed	O
relapsing	B-DISO
polychondritis	I-DISO
.	O

The	O
solution	O
could	O
be	O
the	O
use	O
of	O
tracheal	O
gas	O
which	O
insufflation	O
(	O
TGI	O
)	O
allows	O
the	O
reduction	O
of	O
arterial	O
carbon	O
dioxide	O
tension	B-DISO
(	O
PaCO	O
(	O
2	O
))	O
while	O
controlling	O
airway	O
pressures	O
.	O

CONCLUSIONS	O
:	O
TGI	O
appears	O
to	O
be	O
an	O
important	O
component	O
of	O
ventilatory	O
management	O
when	O
ARDS	B-DISO
is	O
associated	O
with	O
severe	O
head	O
trauma	O
.	O

TITLE	O
:	O
Neurovirulence	O
in	O
mice	O
of	O
soluble	O
receptor	O
-	O
resistant	O
(	O
srr	O
)	O
mutants	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
:	O
intensive	O
apoptosis	O
caused	O
by	O
less	O
virulent	O
srr	O
mutant	B-DISO
.	O

ABSTRACT	O
:	O
Three	O
soluble	O
receptor	O
-	O
resistant	O
(	O
srr	O
)	O
mutants	O
,	O
srr7	O
,	O
srr11	O
and	O
srr18	O
,	O
derived	O
from	O
a	O
highly	O
neurotropic	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
JHMV	O
have	O
a	O
single	O
amino	O
acid	O
mutation	O
in	O
the	O
spike	O
(	O
S	O
)	O
protein	O
.	O

ABSTRACT	O
:	O
Previously	O
,	O
we	O
characterized	O
two	O
host	O
protein	O
binding	O
elements	O
located	O
within	O
the	O
3	O
'-	O
terminal	O
166	O
nucleotides	O
of	O
the	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
genome	O
and	O
assessed	O
their	O
functions	O
in	O
defective	O
-	O
interfering	O
(	O
DI	O
)	O
RNA	O
replication	O
.	O

TITLE	O
:	O
Reverse	O
genetics	O
system	O
for	O
the	O
avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
assembly	O
of	O
a	O
full	O
-	O
length	O
cDNA	O
from	O
the	O
positive	O
-	O
sense	O
genomic	O
RNA	O
of	O
the	O
avian	O
coronavirus	O
,	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
),	O
an	O
important	O
poultry	O
pathogen	O
.	O

TITLE	O
:	O
Comparison	O
of	O
genomic	O
and	O
predicted	O
amino	O
acid	O
sequences	O
of	O
respiratory	O
and	O
enteric	O
bovine	O
coronaviruses	O
isolated	O
from	O
the	O
same	O
animal	O
with	O
fatal	O
shipping	O
pneumonia	B-DISO
.	O

We	O
report	O
a	O
severe	O
form	O
of	O
GBL	O
withdrawal	B-DISO
,	O
characterized	O
by	O
delirium	B-DISO
,	O
psychosis	B-DISO
,	O
autonomic	B-DISO
instability	I-DISO
,	O
and	O
resistance	O
to	O
benzodiazepine	O
therapy	O
.	O

GBL	O
discontinuation	O
can	O
result	O
in	O
severe	O
withdrawal	B-DISO
,	O
necessitating	O
ICU	O
admission	O
.	O

Pentobarbital	O
may	O
be	O
more	O
effective	O
than	O
benzodiazepines	O
at	O
controlling	O
delirium	B-DISO
in	O
patients	O
with	O
abnormal	O
vital	O
signs	O
,	O
paranoid	B-DISO
delusions	I-DISO
,	O
and	O
hallucinations	B-DISO
as	O
a	O
result	O
of	O
GBL	O
withdrawal	B-DISO
.	O

Acute	B-DISO
hyponatremia	I-DISO
(<	O
48	O
h	O
)	O
is	O
usually	O
observed	O
in	O
the	O
postoperative	O
period	O
,	O
these	O
patients	O
need	O
prompt	O
treatment	O
with	O
hypertonic	O
saline	O
(	O
3	O
%)	O
to	O
avoid	O
epilepsia	B-DISO
and	O
respiratory	B-DISO
arrest	I-DISO
.	O

TITLE	O
:	O
Differential	O
detection	O
of	O
transmissible	O
gastroenteritis	B-DISO
virus	O
and	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
by	O
duplex	O
RT	O
-	O
PCR	O
.	O

Primary	O
sequences	O
derived	O
from	O
these	O
products	O
were	O
used	O
to	O
design	O
additional	O
primers	O
resulting	O
in	O
the	O
amplification	B-DISO
and	O
sequencing	O
of	O
the	O
entire	O
ORF1	O
of	O
PEDV	O
.	O

ABSTRACT	O
:	O
Mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
provides	O
an	O
excellent	O
animal	O
model	O
for	O
the	O
study	O
of	O
the	O
immunopathological	O
mechanisms	O
involved	O
in	O
hepatic	O
viral	B-DISO
diseases	I-DISO
.	O

In	O
this	O
paper	O
,	O
we	O
document	O
intrahepatic	O
and	O
splenic	O
T	O
cell	O
subpopulations	O
involved	O
in	O
the	O
hepatitis	B-DISO
process	O
and	O
viral	O
elimination	O
identified	O
in	O
attenuated	O
or	O
pathogenic	O
MHV3	O
-	O
infected	O
C57BL	O
/	O
6	O
mice	O
.	O

ABSTRACT	O
:	O
The	O
present	O
study	O
was	O
to	O
characterize	O
turkey	O
coronavirus	O
associated	O
with	O
turkey	O
poult	O
enteritis	B-DISO
and	O
mortality	O
.	O

Mitogenic	O
responses	O
were	O
suppressed	O
by	O
supplemented	O
VE	O
in	O
Experiment	O
1	O
for	O
PHA	B-DISO
(	O
25	O
IU	O
/	O
kg	O
diet	O
)	O
and	O
Con	O
A	O
(	O
25	O
and	O
50	O
IU	O
/	O
kg	O
diets	O
).	O

VEGF	O
was	O
measured	O
in	O
tracheal	O
aspirates	O
from	O
31	O
preterm	O
infants	O
,	O
5	O
intubated	O
term	O
infants	O
without	O
primary	O
lung	O
injury	O
,	O
and	O
12	O
infants	O
with	O
PPHN	O
during	O
the	O
first	O
10	O
postnatal	O
days	O
,	O
and	O
from	O
8	O
infants	O
with	O
BPD	B-DISO
.	O

Early	O
screening	O
of	O
parasitemia	B-DISO
using	O
highly	O
sensitive	O
polymerase	O
chain	O
reaction	O
methods	O
in	O
seropositive	O
patients	O
with	O
unexplained	O
fever	O
may	O
be	O
needed	O
.	O

TITLE	O
:	O
Adverse	B-DISO
effects	I-DISO
of	O
feline	O
IL	O
-	O
12	O
during	O
DNA	O
vaccination	O
against	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
.	O

However	O
,	O
vaccination	O
by	O
repeated	O
injections	O
of	O
plasmids	O
encoding	O
these	O
proteins	O
did	O
not	O
protect	O
kittens	O
against	O
challenge	O
infection	B-DISO
with	O
FIPV	O
.	O

This	O
study	O
shows	O
that	O
DNA	O
vaccination	O
failed	O
to	O
protect	O
cats	O
against	O
FIP	B-DISO
and	O
that	O
IL	O
-	O
12	O
may	O
yield	O
adverse	B-DISO
effects	I-DISO
when	O
used	O
as	O
a	O
cytokine	O
adjuvant	O
.	O

By	O
reviewing	O
relevant	O
medical	O
articles	O
on	O
this	O
topic	O
,	O
we	O
tried	O
to	O
find	O
answers	O
on	O
the	O
reasons	O
why	O
many	O
surgical	O
patients	O
have	O
pain	O
in	O
the	O
postoperative	O
period	O
despite	O
implementation	O
of	O
modern	O
and	O
powerful	O
analgesic	O
therapy	O
like	O
patient	O
-	O
controlled	O
analgesia	B-DISO
(	O
PCA	B-DISO
),	O
spinal	O
/	O
epidural	O
opioids	O
and	O
regional	O
analgesia	B-DISO
.	O

No	O
differences	O
in	O
thrombosis	B-DISO
or	O
bleeding	B-DISO
were	O
noted	O
.	O

The	O
patient	O
is	O
presently	O
maintained	O
on	O
amantadine	O
therapy	O
;	O
there	O
was	O
mild	O
worsening	O
of	O
her	O
extrapyramidal	B-DISO
signs	I-DISO
following	O
unplanned	O
discontinuation	O
of	O
this	O
medication	O
,	O
and	O
on	O
follow	O
-	O
up	O
assessments	O
after	O
9	O
months	O
she	O
is	O
virtually	O
asymptomatic	O
.	O

TITLE	O
:	O
A	O
serodiagnostic	O
ELISA	O
using	O
recombinant	O
antigen	O
of	O
swine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
virus	O
nucleoprotein	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
is	O
characterised	O
by	O
capillary	O
permeability	O
and	O
pulmonary	B-DISO
oedema	I-DISO
formation	O
and	O
may	O
complicate	O
a	O
variety	O
of	O
medical	O
and	O
surgical	O
illnesses	O
.	O

However	O
,	O
an	O
N	O
-	O
terminal	O
truncation	B-DISO
containing	O
only	O
the	O
cytoplasmic	O
domain	O
(	O
CTE	B-DISO
)	O
was	O
efficiently	O
localized	O
to	O
the	O
Golgi	O
complex	O
,	O
and	O
this	O
domain	O
could	O
retain	O
a	O
reporter	O
protein	O
in	O
the	O
Golgi	O
.	O

The	O
number	O
of	O
documented	O
cases	O
of	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
(	O
ARF	B-DISO
)	O
following	O
this	O
event	O
exceeded	O
all	O
similar	O
cases	O
previously	O
reported	O
for	O
any	O
single	O
earthquake	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
639	O
patients	O
(	O
291	O
female	O
and	O
348	O
male	O
)	O
with	O
ARF	B-DISO
due	O
to	O
crush	O
injury	O
were	O
hospitalized	O
in	O
35	O
hospitals	O
.	O

TITLE	O
:	O
The	O
cell	O
biology	O
of	O
coronavirus	B-DISO
infection	I-DISO
.	O

This	O
in	O
turn	O
will	O
allow	O
new	O
approaches	O
to	O
the	O
study	O
of	O
viral	O
and	O
cellular	O
protein	O
-	O
protein	O
interactions	O
,	O
as	O
methods	O
to	O
study	O
the	O
biology	O
and	O
pathogenesis	B-DISO
of	O
MHV	O
infection	B-DISO
at	O
a	O
cellular	O
level	O
.	O

TITLE	O
:	O
Recovery	O
rate	O
and	O
prognosis	O
in	O
older	O
persons	O
who	O
develop	O
acute	O
lung	O
injury	O
and	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
The	O
incidence	O
of	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
requiring	O
mechanical	O
ventilation	O
increases	O
10	O
-	O
fold	O
from	O
the	O
ages	O
of	O
55	O
to	O
85	O
years	O
,	O
yet	O
the	O
rate	O
of	O
recovery	O
and	O
outcomes	O
in	O
older	O
persons	O
who	O
develop	O
acute	O
lung	O
injury	O
are	O
poorly	O
defined	O
.	O

TITLE	O
:	O
Proliferation	B-DISO
of	O
lung	O
macrophages	O
in	O
acute	O
fatal	O
viral	B-DISO
infections	I-DISO
in	O
chickens	O
.	O

This	O
syndrome	B-DISO
may	O
be	O
categorized	O
as	O
""""	O
virus	O
-	O
associated	O
hemophagocytic	B-DISO
syndrome	I-DISO
.	O

Both	O
the	O
one	O
-	O
step	O
RT	O
-	O
PCR	O
and	O
the	O
nested	O
PCR	O
amplified	O
cell	O
culture	O
-	O
passaged	O
isolates	O
of	O
calf	O
diarrhea	B-DISO
strains	O
of	O
BCV	O
but	O
none	O
of	O
the	O
15	O
tested	O
TOCVs	O
or	O
transmissible	O
gastroenteritis	B-DISO
coronavirus	O
of	O
swine	O
.	O

ABSTRACT	O
:	O
Patient	O
A	O
who	O
was	O
exposed	O
to	O
a	O
critical	O
dose	O
of	O
radiation	O
developed	O
skin	O
lesions	O
throughout	O
the	O
body	O
surface	O
,	O
gastrointestinal	B-DISO
disorder	I-DISO
with	O
massive	O
diarrhea	B-DISO
and	O
prominent	O
bleeding	B-DISO
,	O
which	O
caused	O
severe	O
loss	O
in	O
body	O
fluids	O
.	O

ABSTRACT	O
:	O
The	O
prevalence	O
of	O
human	O
rhino	O
-,	O
entero	O
-,	O
and	O
coronaviruses	O
was	O
investigated	O
by	O
RT	O
-	O
PCR	O
in	O
nasopharyngeal	O
aspirates	O
from	O
107	O
children	O
without	O
concurrent	O
respiratory	B-DISO
symptoms	I-DISO
.	O

Previous	O
studies	O
have	O
shown	O
that	O
CD8	O
(+)	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTL	O
)	O
are	O
critical	O
in	O
controlling	O
acute	O
IBV	O
infection	B-DISO
,	O
but	O
the	O
role	O
of	O
innate	O
immunity	O
is	O
unknown	O
.	O

RESULTS	O
:	O
After	O
2	O
or	O
6	O
hours	O
of	O
LPS	B-DISO
intravenous	O
administration	O
,	O
severe	O
lung	O
injury	O
and	O
positive	O
signals	O
of	O
NT	O
occurred	O
with	O
the	O
latter	O
located	O
in	O
the	O
pulmonary	O
macrophages	O
,	O
endothelia	O
,	O
subendothelial	O
and	O
muscular	O
layers	O
of	O
the	O
pulmonary	O
artery	O
.	O

There	O
is	O
consensus	O
that	O
severe	O
maternal	B-DISO
hypertension	I-DISO
(	O
blood	O
pressure	O
>	O
or	O
=	O
170	O
/	O
110	O
mmHg	O
)	O
should	O
be	O
treated	O
to	O
minimize	O
the	O
risk	O
of	O
acute	O
cerebrovascular	O
complications	O
.	O

In	O
contrast	O
to	O
diminished	O
T	O
cell	O
responses	O
in	O
H	O
-	O
2	O
(	O
b	O
)	O
B	O
cell	O
-	O
deficient	O
muMT	O
mice	O
,	O
the	O
absence	O
of	O
B	O
cells	O
or	O
Ab	O
in	O
the	O
H	O
-	O
2	O
(	O
d	O
)	O
mice	O
did	O
not	O
compromise	O
expansion	O
,	O
recruitment	B-DISO
into	O
the	O
CNS	O
,	O
or	O
function	O
of	O
virus	O
-	O
specific	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
.	O

Ten	O
patients	O
were	O
admitted	O
to	O
Lampoon	O
Provincial	O
Hospital	O
with	O
a	O
history	O
of	O
high	O
fever	O
,	O
watery	B-DISO
diarrhea	I-DISO
,	O
severe	O
myalgia	B-DISO
and	O
ecchymosis	O
rashes	B-DISO
.	O

Blood	O
culture	O
and	O
genetic	O
investigation	O
(	O
16	O
s	O
rRNA	O
polymerase	O
chain	O
reaction	O
with	O
restriction	O
enzyme	O
PstII	O
)	O
confirmed	O
diagnoses	O
of	O
the	O
same	O
species	O
of	O
Streptococcus	O
suis	O
infections	B-DISO
.	O

In	O
late	O
convalescence	O
severe	O
complications	O
may	O
accompany	O
leptospiral	O
jaundice	B-DISO
.	O

The	O
methods	O
of	O
choice	O
adopted	O
for	O
early	O
diagnosis	O
of	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
are	O
high	O
-	O
resolution	O
computed	O
tomography	O
scan	O
and	O
pulmonary	O
function	O
tests	O
,	O
which	O
should	O
be	O
performed	O
during	O
both	O
initial	O
evaluation	O
of	O
polymyositis	B-DISO
/	O
dermatomyositis	B-DISO
and	O
follow	O
-	O
up	O
.	O

Furthermore	O
,	O
histological	O
lung	O
findings	O
provide	O
prognostic	O
data	O
;	O
patients	O
with	O
bronchiolitis	B-DISO
obliterans	I-DISO
organizing	I-DISO
pneumonia	I-DISO
(	O
BOOP	B-DISO
)	O
indeed	O
appear	O
to	O
have	O
a	O
more	O
favorable	O
outcome	O
than	O
those	O
with	O
usual	B-DISO
interstitial	I-DISO
pneumonia	I-DISO
or	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
.	O

Finally	O
,	O
as	O
a	O
guide	O
to	O
both	O
the	O
severity	O
and	O
progress	O
of	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
,	O
the	O
significance	O
of	O
other	O
investigations	O
,	O
notably	O
bronchoalveolar	O
lavage	O
,	O
remains	O
controversial	O
.	O

Corticosteroid	O
therapy	O
is	O
considered	O
the	O
first	O
line	O
of	O
therapy	O
for	O
polymyositis	B-DISO
/	O
dermatomyositis	B-DISO
patients	O
with	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
.	O

TITLE	O
:	O
Cutting	O
edge	O
:	O
CD8	O
T	O
cell	O
-	O
mediated	O
demyelination	B-DISO
is	O
IFN	O
-	O
gamma	O
dependent	O
in	O
mice	O
infected	O
with	O
a	O
neurotropic	O
coronavirus	O
.	O

We	O
showed	O
previously	O
that	O
adoptive	O
transfer	O
of	O
MHV	O
-	O
immune	O
splenocytes	O
depleted	O
of	O
either	O
CD4	O
or	O
CD8	O
T	O
cells	O
to	O
infected	O
RAG1	O
(-/-)	O
recipients	O
(	O
mice	O
deficient	O
in	O
recombination	O
activation	O
gene	O
1	O
)	O
resulted	O
in	O
demyelination	B-DISO
.	O

PEDV	O
specific	O
IgM	O
ASC	O
occurred	O
in	O
all	O
the	O
tissues	O
between	O
PID	B-DISO
4	O
and	O
7	O
,	O
with	O
the	O
strongest	O
response	O
in	O
the	O
intestinal	O
lamina	O
propria	O
.	O

Ciliary	O
beat	O
frequency	O
was	O
determined	O
and	O
beat	O
pattern	O
analysed	O
for	O
evidence	O
of	O
dyskinesia	B-DISO
(	O
0	O
=	O
normal	O
,	O
3	O
=	O
severely	O
dyskinetic	O
)	O
using	O
digital	O
high	O
-	O
speed	O
video	O
photography	O
.	O

Expression	O
of	O
the	O
reporter	O
gene	O
beta	O
-	O
glucuronidase	O
(	O
GUS	O
)	O
(	O
2	O
-	O
8	O
microg	O
per	O
10	O
(	O
6	O
)	O
cells	O
)	O
and	O
the	O
porcine	O
respiratory	O
and	O
reproductive	O
syndrome	B-DISO
virus	O
(	O
PRRSV	O
)	O
ORF5	O
(	O
1	O
-	O
2	O
microg	O
per	O
10	O
(	O
6	O
)	O
cells	O
)	O
has	O
been	O
shown	O
using	O
a	O
TGEV	O
-	O
derived	O
minigenome	O
.	O

These	O
results	O
suggested	O
that	O
humoral	O
immunity	O
against	O
TCV	O
infection	B-DISO
may	O
be	O
important	O
in	O
turkeys	O
.	O

ABSTRACT	O
:	O
Viral	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
are	O
a	O
common	O
cause	O
of	O
asthma	B-DISO
attacks	I-DISO
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
mechanisms	O
of	O
CYP1A1	O
regulation	O
by	O
hyperoxia	B-DISO
and	O
tested	O
the	O
hypothesis	O
that	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AHR	O
)-	O
dependent	O
mechanisms	O
contribute	O
to	O
induction	O
of	O
CYP1A1	O
and	O
that	O
modulation	O
of	O
CYP1A	O
by	O
hyperoxia	B-DISO
may	O
have	O
implications	O
for	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
showed	O
that	O
an	O
intraperitoneal	O
infection	B-DISO
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
persists	O
in	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)-	O
deficient	O
C57BL	O
/	O
6	O
(	O
B6	O
-	O
GKO	O
)	O
mice	O
and	O
results	O
in	O
subacute	O
fatal	O
peritonitis	B-DISO
,	O
which	O
bears	O
a	O
resemblance	O
to	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
.	O

Expectant	O
treatment	O
in	O
women	O
with	O
PROM20	O
and	O
present	O
neonatal	O
intensive	O
care	O
has	O
improved	O
the	O
survival	O
of	O
PROM20	O
infants	O
despite	O
severe	O
initial	O
respiratory	B-DISO
failure	I-DISO
.	O

No	O
cross	O
-	O
infection	B-DISO
were	O
observed	O
from	O
community	O
-	O
acquired	O
respiratory	O
-	O
syncitial	O
virus	O
or	O
influenza	B-DISO
-	O
infected	O
children	O
to	O
neonates	O
.	O

The	O
pigs	O
exposed	O
to	O
virulent	O
PEDV	O
were	O
completely	O
protected	O
against	O
the	O
challenge	O
with	O
a	O
higher	O
dose	O
of	O
the	O
same	O
virulent	O
virus	O
on	O
PID	B-DISO
21	O
and	O
none	O
of	O
them	O
shed	O
the	O
virus	O
.	O

A	O
controlled	O
-	O
challenge	O
protocol	O
was	O
developed	O
to	O
mimic	O
natural	O
infection	B-DISO
and	O
to	O
yield	O
a	O
higher	O
rate	O
of	O
mortality	O
following	O
Escherichia	O
coli	O
(	O
EC	O
)	O
challenge	O
.	O

This	O
review	O
updates	O
the	O
indications	O
for	O
IPPV	O
in	O
adult	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
by	O
examining	O
available	O
evidence	O
from	O
clinical	O
trials	O
and	O
by	O
considering	O
new	O
management	O
alternatives	O
that	O
have	O
become	O
available	O
in	O
the	O
last	O
20	O
years	O
.	O

It	O
should	O
be	O
possible	O
to	O
avoid	O
IPPV	O
and	O
its	O
attendant	O
complications	O
in	O
many	O
cases	O
of	O
acute	O
hypercapnic	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

Four	O
-	O
week	O
-	O
old	O
female	O
chickens	O
were	O
inoculated	O
with	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
strain	O
M41	O
.	O

ABSTRACT	O
:	O
Infection	B-DISO
by	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
produces	O
an	O
acute	O
demyelinating	O
encephalomyelitis	B-DISO
.	O

Lastly	O
,	O
altered	O
antiviral	O
ASC	O
specificities	O
following	O
clearance	O
of	O
infectious	B-DISO
virus	O
suggest	O
ongoing	O
recruitment	B-DISO
of	O
peripheral	O
memory	O
cells	O
and	O
/	O
or	O
local	O
B	O
cell	O
differentiation	O
.	O

TITLE	O
:	O
The	O
spike	O
but	O
not	O
the	O
hemagglutinin	O
/	O
esterase	O
protein	O
of	O
bovine	O
coronavirus	O
is	O
necessary	O
and	O
sufficient	O
for	O
viral	B-DISO
infection	I-DISO
.	O

To	O
unequivocally	O
determine	O
their	O
roles	O
in	O
viral	O
cytopathogenicity	O
,	O
we	O
developed	O
a	O
system	O
in	O
which	O
phenotypically	O
chimeric	O
viruses	O
were	O
generated	O
by	O
infecting	O
a	O
closely	O
related	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
in	O
cells	O
that	O
stably	O
express	O
an	O
individual	O
BCV	O
protein	O
(	O
S	O
or	O
HE	O
).	O

In	O
contrast	O
,	O
chimeric	O
viruses	O
that	O
contain	O
biologically	O
active	O
and	O
functional	O
BCV	O
HE	O
protein	O
on	O
the	O
surface	O
failed	O
to	O
enter	O
HRT	O
-	O
18	O
cells	O
,	O
indicating	O
that	O
the	O
BCV	O
HE	O
protein	O
alone	O
is	O
not	O
sufficient	O
for	O
BCV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Sleep	B-DISO
apnea	I-DISO
is	O
one	O
of	O
the	O
most	O
frequent	O
manifestations	O
of	O
respiratory	B-DISO
obstruction	I-DISO
.	O

ABSTRACT	O
:	O
Transfusion	B-DISO
Related	I-DISO
Acute	I-DISO
Lung	I-DISO
Injury	I-DISO
(	O
TRALI	B-DISO
)	O
is	O
the	O
most	O
serious	O
,	O
potentially	O
lethal	O
,	O
transfusion	B-DISO
reaction	I-DISO
caused	O
by	O
anti	O
leukocyte	O
antibodies	O
carried	O
passively	O
into	O
recipient	O
'	O
s	O
circulation	O
by	O
transfused	O
haemoproduct	O
.	O

Vascular	O
immunotargeting	O
of	O
the	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)-	O
generating	O
enzyme	O
glucose	O
oxidase	O
(	O
GOX	O
)	O
to	O
the	O
pulmonary	O
endothelium	O
causes	O
an	O
acute	O
oxidative	O
lung	O
injury	O
in	O
mice	O
.(	O
1	O
)	O
In	O
the	O
present	O
study	O
we	O
compared	O
the	O
pulmonary	B-DISO
thrombosis	I-DISO
and	O
leukocyte	O
transmigration	O
caused	O
by	O
GOX	O
targeting	O
to	O
the	O
endothelial	O
antigens	O
platelet	O
-	O
endothelial	O
cell	O
adhesion	B-DISO
molecule	O
(	O
PECAM	O
)	O
and	O
thrombomodulin	O
(	O
TM	O
).	O

Both	O
anti	O
-	O
PECAM	O
and	O
anti	O
-	O
TM	O
delivered	O
similar	O
amounts	O
of	O
(	O
125	O
)	O
I	O
-	O
GOX	O
to	O
the	O
lungs	O
and	O
caused	O
a	O
dose	O
-	O
dependent	O
,	O
tissue	O
-	O
selective	O
lung	O
injury	O
manifested	O
within	O
2	O
to	O
4	O
hours	O
by	O
high	O
lethality	O
,	O
vascular	O
congestion	B-DISO
,	O
polymorphonuclear	O
neutrophil	O
(	O
PMN	O
)	O
sequestration	O
in	O
the	O
pulmonary	O
vasculature	O
,	O
severe	O
pulmonary	B-DISO
edema	I-DISO
,	O
and	O
tissue	O
oxidation	O
,	O
yet	O
at	O
an	O
equal	O
dose	O
,	O
anti	O
-	O
TM	O
/	O
GOX	O
inflicted	O
more	O
severe	O
lung	O
injury	O
than	O
anti	O
-	O
PECAM	O
/	O
GOX	O
.	O

Anti	O
-	O
TM	O
/	O
GOX	O
caused	O
markedly	O
more	O
severe	O
pulmonary	B-DISO
thrombosis	I-DISO
than	O
anti	O
-	O
PECAM	O
/	O
GOX	O
,	O
likely	O
because	O
of	O
TM	O
inhibition	O
.	O

Molecular	O
masses	O
of	O
the	O
IgE	B-DISO
-	O
binding	O
proteins	O
and	O
cross	O
-	O
reactivity	O
among	O
the	O
P	O
.	O
acerifolia	O
pollen	O
and	O
different	O
food	O
extracts	O
were	O
also	O
determined	O
.	O

Food	B-DISO
allergy	I-DISO
was	O
observed	O
in	O
32	O
(	O
52	O
.	O
45	O
%)	O
of	O
the	O
61	O
patients	O
sensitized	O
to	O
P	O
.	O
acerifolia	O
pollen	O
.	O

Furthermore	O
,	O
IP	O
-	O
10	O
(-/-)	O
mice	O
infected	O
with	O
a	O
neurotropic	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
had	O
an	O
impaired	B-DISO
ability	O
to	O
control	O
viral	O
replication	O
in	O
the	O
brain	O
.	O

The	O
DMVs	O
were	O
found	O
either	O
as	O
separate	O
entities	O
or	O
as	O
small	O
clusters	O
of	O
vesicles	B-DISO
.	O

By	O
combined	O
ISH	B-DISO
and	O
IEM	O
,	O
positive	O
-	O
stranded	O
RNA	O
and	O
viral	O
proteins	O
localized	O
to	O
the	O
same	O
DMVs	O
.	O

During	O
the	O
acute	O
phase	O
of	O
pancreatitis	B-DISO
,	O
patients	O
underwent	O
standard	O
treatment	O
.	O

TITLE	O
:	O
Quaternary	O
structure	O
of	O
coronavirus	O
spikes	O
in	O
complex	O
with	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	O
adhesion	B-DISO
molecule	O
cellular	O
receptors	O
.	O

CEACAM	O
binding	O
also	O
induced	O
separation	B-DISO
of	O
S1	O
and	O
S2	O
.	O

m	O
-	O
2	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
),	O
along	O
with	O
severe	O
intrapulmonary	O
neutrophil	O
recruitment	B-DISO
and	O
peripheral	O
neutropenia	O
.	O

Pharmacodynamics	O
of	O
iNO	O
in	O
this	O
model	O
was	O
related	O
to	O
improvement	O
in	O
gas	O
exchange	O
,	O
Cdyn	O
,	O
PVRI	O
,	O
and	O
suppression	B-DISO
of	O
proinflammatory	O
cytokine	O
expression	O
in	O
the	O
lungs	O
,	O
and	O
its	O
adverse	B-DISO
effect	I-DISO
was	O
mainly	O
confined	O
to	O
MetHb	O
at	O
higher	O
NO	O
dose	O
.	O

CONCLUSIONS	O
:	O
Pharmacodynamics	O
of	O
iNO	O
in	O
this	O
model	O
was	O
related	O
to	O
improvement	O
in	O
gas	O
exchange	O
,	O
Cdyn	O
,	O
PVRI	O
,	O
and	O
suppression	B-DISO
of	O
proinflammatory	O
cytokine	O
expression	O
in	O
the	O
lungs	O
,	O
and	O
its	O
adverse	B-DISO
effect	I-DISO
was	O
mainly	O
confined	O
to	O
MetHb	O
at	O
higher	O
NO	O
dose	O
.	O

Confusion	B-DISO
as	O
to	O
when	O
and	O
how	O
to	O
use	O
molecular	O
methods	O
abounds	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
blood	O
detoxification	O
by	O
sorbent	O
therapy	O
long	O
has	O
been	O
applied	O
in	O
treatment	O
of	O
hepatic	B-DISO
failure	I-DISO
and	O
encephalopathy	B-DISO
,	O
starting	O
with	O
hemoperfusion	O
columns	O
and	O
more	O
recently	O
with	O
the	O
currently	O
marketed	O
Liver	O
Dialysis	O
Unit	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
LPS	B-DISO
-	O
induced	O
chemokine	O
production	O
in	O
human	O
lung	O
endothelial	O
cells	O
by	O
lipid	O
conjugates	O
anchored	O
to	O
the	O
membrane	O
.	O

In	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
induced	O
by	O
endotoxins	O
,	O
a	O
high	O
production	O
of	O
inflammatory	O
mediators	O
by	O
microvascular	O
lung	O
endothelial	O
cells	O
(	O
LMVEC	O
)	O
can	O
be	O
observed	O
.	O

TITLE	O
:	O
Murine	B-DISO
hepatitis	I-DISO
virus	O
--	O
a	O
model	O
for	O
virus	O
-	O
induced	O
CNS	O
demyelination	B-DISO
.	O

ABSTRACT	O
:	O
Most	O
murine	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
strains	O
,	O
as	O
their	O
name	O
suggests	O
,	O
infect	O
the	O
liver	O
.	O

TITLE	O
:	O
Further	O
in	O
vitro	O
characterization	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
papain	O
-	O
like	O
proteinase	O
1	O
:	O
cleavage	O
sequence	O
requirements	O
within	O
pp1a	O
.	O

ABSTRACT	O
:	O
Proteolytic	O
processing	O
of	O
the	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
strain	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
replicase	O
gene	O
product	O
,	O
pp1a	O
,	O
results	O
in	O
polypeptides	O
p28	O
,	O
p65	O
,	O
p50	O
,	O
and	O
p240	O
in	O
infected	O
cells	O
.	O

Thirty	O
of	O
these	O
commercial	O
herds	O
had	O
a	O
clinical	O
history	O
of	O
TGEV	O
infection	B-DISO
and	O
a	O
positive	O
TGEV	O
fluorescent	O
antibody	O
test	O
recorded	O
at	O
necropsy	O
within	O
the	O
last	O
35	O
months	O
,	O
while	O
70	O
herds	O
had	O
no	O
history	O
of	O
clinical	O
TGEV	O
infection	B-DISO
.	O

The	O
blocking	B-DISO
ELISA	O
and	O
the	O
VN	O
showed	O
good	O
agreement	O
(	O
kappa	O
0	O
.	O
84	O
)	O
for	O
the	O
detection	O
of	O
porcine	O
coronavirus	O
antibody	O
(	O
TGEV	O
or	O
PRCV	O
).	O

TITLE	O
:	O
[	O
The	O
optimal	O
pressure	O
of	O
sustained	O
inflation	O
for	O
alveolar	O
recruitment	B-DISO
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
rabbit	O
model	O
].	O

CONCLUSIONS	O
:	O
5P	O
(	O
m	O
)	O
(	O
25	O
approximately	O
35	O
cm	O
H	O
(	O
2	O
)	O
O	O
)	O
may	O
be	O
the	O
optimal	O
pressure	O
of	O
SI	O
in	O
rabbits	O
with	O
severe	O
ARDS	B-DISO
.	O

Severe	O
combined	O
imunodeficiency	O
syndrome	B-DISO
(	O
T	O
-,	O
B	O
+,	O
NK	O
+),	O
B	O
lymphoproliferative	B-DISO
disease	I-DISO
and	O
hemophagocytic	B-DISO
lymphohistiocytosis	I-DISO
triggered	O
by	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
were	O
diagnosed	O
.	O

We	O
have	O
constructed	O
a	O
mutant	B-DISO
,	O
M	O
(	O
Delta	O
)	O
2	O
,	O
containing	O
a	O
two	O
-	O
amino	O
-	O
acid	O
truncation	B-DISO
of	O
the	O
M	O
protein	O
that	O
was	O
previously	O
thought	O
to	O
be	O
lethal	O
.	O

ABSTRACT	O
:	O
The	O
most	O
important	O
viral	B-DISO
disease	I-DISO
of	O
farmed	O
deer	O
and	O
bison	O
is	O
malignant	B-DISO
catarrhal	I-DISO
fever	I-DISO
.	O

We	O
report	O
a	O
case	O
of	O
cystic	B-DISO
fibrosis	I-DISO
with	O
hemolytic	B-DISO
uremic	I-DISO
syndrome	I-DISO
.	O

Recently	O
,	O
replacement	O
of	O
neuromuscular	O
blocking	B-DISO
agents	O
by	O
sedatives	O
has	O
notably	O
reduced	O
the	O
occurrence	O
of	O
this	O
disorder	O
.	O

TITLE	O
:	O
[	O
Therapeutic	O
impact	O
of	O
streptococcal	O
and	O
enterococcal	B-DISO
bacteremia	I-DISO
in	O
hematology	O
patients	O
].	O

TITLE	O
:	O
Viral	B-DISO
respiratory	I-DISO
infection	I-DISO
in	O
schoolchildren	O
:	O
effects	O
on	O
middle	O
ear	O
pressure	O
.	O

Eighty	O
-	O
six	O
colds	B-DISO
were	O
studied	O
,	O
82	O
in	O
schoolchildren	O
(	O
5	O
-	O
12	O
years	O
old	O
)	O
and	O
4	O
in	O
2	O
-	O
to	O
3	O
-	O
year	O
-	O
olds	O
.	O

ABSTRACT	O
:	O
Adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
not	O
a	O
specific	O
lung	B-DISO
disease	I-DISO
.	O

It	O
represents	O
an	O
acute	B-DISO
respiratory	I-DISO
insufficiency	I-DISO
syndrome	B-DISO
in	O
patients	O
with	O
non	O
-	O
injured	O
lung	O
as	O
a	O
result	O
of	O
severe	O
multiple	O
lung	O
lesions	O
of	O
different	O
etiology	O
and	O
pathogenesis	B-DISO
.	O

These	O
observations	O
indicate	O
that	O
the	O
experimental	O
virus	B-DISO
infection	I-DISO
may	O
induce	O
host	O
responses	O
that	O
provoke	O
enhanced	O
immunoglobulin	O
E	O
(	O
IgE	B-DISO
)	O
synthesis	O
.	O

During	O
ventilation	O
therapy	O
an	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
occurred	O
.	O

Tachypnea	B-DISO
,	O
hypoxia	B-DISO
,	O
and	O
respiratory	B-DISO
alkalosis	I-DISO
are	O
typical	O
early	O
clinical	O
manifestations	O
,	O
and	O
they	O
are	O
usually	O
followed	O
by	O
the	O
appearance	O
of	O
diffuse	O
pulmonary	B-DISO
infiltrates	I-DISO
and	O
respiratory	B-DISO
failure	I-DISO
within	O
48	O
hours	O
.	O

Early	O
identification	O
and	O
treatment	O
of	O
the	O
underlying	O
disorder	O
,	O
along	O
with	O
aggressive	B-DISO
supportive	O
care	O
,	O
are	O
essential	O
.	O

Many	O
patients	O
who	O
survive	O
ARDS	B-DISO
have	O
permanent	O
,	O
mild	O
to	O
moderate	O
impairment	B-DISO
of	O
lung	O
function	O
.	O

Of	O
20	O
consecutive	O
preterm	O
infants	O
(	O
27	O
-	O
35	O
weeks	O
'	O
gestation	O
)	O
with	O
severe	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
)	O
who	O
were	O
enrolled	O
14	O
with	O
bovine	O
surfactant	O
finally	O
were	O
analyzed	O
.	O

Both	O
minimum	O
(	O
gammamin	O
)	O
and	O
adsorption	O
(	O
gammaads	O
)	O
surface	O
tension	B-DISO
values	O
(	O
pulsating	O
bubble	O
surfactometer	O
)	O
were	O
dramatically	O
increased	O
.	O

Surface	O
tension	B-DISO
lowering	O
properties	O
(	O
gammamin	O
and	O
gammaads	O
)	O
significantly	O
improved	O
,	O
but	O
were	O
still	O
not	O
fully	O
normalized	O
.	O

The	O
triiodothyronine	O
and	O
respiratory	O
comparisons	O
revealed	O
modified	O
responses	O
in	O
Brahman	O
that	O
suggest	O
a	O
potential	O
benefit	O
of	O
using	O
heat	O
-	O
tolerant	O
genetics	O
to	O
reduce	O
the	O
adverse	B-DISO
effects	I-DISO
of	O
fescue	O
toxicosis	B-DISO
in	O
cattle	O
.	O

Hepatopulmonary	B-DISO
syndrome	I-DISO
(	O
HPS	B-DISO
)	O
was	O
considered	O
to	O
be	O
a	O
contraindication	O
to	O
transplantation	O
in	O
the	O
1980s	O
.	O

However	O
,	O
even	O
severe	O
cases	O
can	O
recover	O
from	O
hypoxia	B-DISO
after	O
liver	O
transplantation	O
,	O
and	O
improved	O
survival	O
data	O
were	O
reported	O
in	O
the	O
1990s	O
.	O

The	O
subjects	O
--	O
182	O
singleton	O
term	O
infants	O
with	O
no	O
major	O
congenital	B-DISO
anomalies	I-DISO
--	O
were	O
admitted	O
to	O
a	O
tertiary	O
NICU	O
for	O
mechanical	O
ventilation	O
.	O

Highest	O
mean	O
(	O
SD	O
)	O
SNAP	O
scores	O
occurred	O
in	O
infants	O
ventilated	O
for	O
meconium	B-DISO
aspiration	I-DISO
(	O
18	O
(	O
9	O
)),	O
and	O
perinatal	B-DISO
asphyxia	I-DISO
(	O
17	O
(	O
9	O
)),	O
compared	O
with	O
pulmonary	B-DISO
hypertension	I-DISO
(	O
14	O
(	O
6	O
))	O
and	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
(	O
13	O
(	O
5	O
)).	O

Escherichia	O
coli	O
isolates	O
were	O
characterized	O
on	O
the	O
basis	O
of	O
epithelial	O
cell	O
attachment	O
,	O
fluorescent	O
actin	O
staining	O
(	O
FAS	B-DISO
)	O
test	O
,	O
and	O
presence	O
of	O
E	O
.	O
coli	O
attaching	O
/	O
effacing	O
(	O
EAE	O
),	O
shigalike	O
toxin	O
(	O
SLT	O
)	O
type	O
I	O
,	O
SLT	O
II	O
,	O
and	O
bundle	O
-	O
forming	O
pilus	O
(	O
BFP	O
)	O
genes	O
by	O
polymerase	O
chain	O
reaction	O
procedures	O
.	O

Despite	O
immediate	O
life	O
support	O
,	O
the	O
postoperative	O
period	O
was	O
complicated	O
by	O
persistent	O
low	O
systolic	O
pressure	O
,	O
acute	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
,	I-DISO
acute	I-DISO
renal	B-DISO
failure	I-DISO
,	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
and	O
pancreatitis	B-DISO
,	O
leading	O
to	O
the	O
death	O
of	O
the	O
patient	O
.	O

In	O
the	O
authors	O
'	O
laboratory	O
,	O
studies	O
were	O
undertaken	O
to	O
investigate	O
the	O
relationship	O
between	O
viral	O
respiratory	B-DISO
disease	I-DISO
and	O
bioactive	O
lung	O
lavage	O
levels	O
of	O
IFN	O
-	O
alpha	O
,	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1	O
and	O
IL	O
-	O
6	O
.	O

Clostridium	O
perfringens	O
epsilon	O
-	O
toxin	O
could	O
possibly	O
be	O
aerosolized	O
to	O
produce	O
acute	B-DISO
pulmonary	I-DISO
edema	I-DISO
.	O

Ricin	O
intoxication	O
can	O
manifest	O
as	O
gastrointestinal	B-DISO
hemorrhage	I-DISO
after	O
ingestion	O
,	O
severe	O
muscle	B-DISO
necrosis	I-DISO
after	O
intramuscular	O
injection	O
,	O
and	O
acute	O
pulmonary	B-DISO
disease	I-DISO
after	O
inhalation	O
.	O

TITLE	O
:	O
Dietary	O
arginine	O
intake	O
alters	O
avian	O
leukocyte	O
population	O
distribution	O
during	O
infectious	B-DISO
bronchitis	B-DISO
challenge	O
.	O

The	O
obesity	B-DISO
-	I-DISO
hypoventilation	I-DISO
syndrome	I-DISO
is	O
generally	O
found	O
in	O
males	O
aged	O
over	O
50	O
years	O
.	O

Diagnosis	O
is	O
often	O
made	O
after	O
an	O
episode	O
of	O
severe	O
respiratory	B-DISO
failure	I-DISO
.	O

The	O
spectrum	O
of	O
disorders	O
causing	O
ARDS	B-DISO
in	O
tropical	O
countries	O
includes	O
virtually	O
all	O
conditions	O
encountered	O
in	O
the	O
West	O
.	O

Emergency	B-DISO
physicians	O
should	O
be	O
familiar	O
with	O
the	O
presentation	O
and	O
management	O
of	O
GHB	O
-	O
related	O
emergencies	B-DISO
.	O

Here	O
,	O
the	O
crystal	O
structure	O
of	O
the	O
33	O
.	O
1	O
kDa	O
transmissible	O
gastroenteritis	B-DISO
(	O
corona	O
)	O
virus	O
M	O
(	O
pro	O
)	O
is	O
reported	O
.	O

TITLE	O
:	O
[	O
A	O
case	O
of	O
miliary	B-DISO
tuberculosis	I-DISO
complicated	O
by	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
after	O
bronchofiberscopy	O
].	O

We	O
diagnosed	O
miliary	B-DISO
tuberculosis	I-DISO
because	O
the	O
transbronchial	O
lung	O
biopsy	O
specimen	O
showed	O
caseous	O
granuloma	B-DISO
and	O
the	O
PCR	O
test	O
for	O
Mycobacterium	O
tuberculosis	B-DISO
in	O
the	O
bronchoalveolar	O
lavage	O
fluid	O
was	O
positive	O
.	O

By	O
contrast	O
,	O
MMP	O
-	O
9	O
protein	O
activity	O
was	O
associated	O
with	O
the	O
infiltration	B-DISO
of	O
neutrophils	O
into	O
the	O
CNS	O
.	O

At	O
8	O
weeks	O
post	O
-	O
infection	B-DISO
,	O
mice	O
in	O
one	O
uninoculated	O
cage	O
(	O
which	O
had	O
a	O
filter	O
top	O
and	O
an	O
internal	O
valve	O
and	O
was	O
adjacent	O
to	O
a	O
cage	O
of	O
inoculated	O
mice	O
)	O
was	O
seropositive	O
.	O

GM	O
-	O
CSF	O
therapy	O
was	O
not	O
associated	O
with	O
decreased	O
30	O
-	O
day	O
survival	O
or	O
with	O
increased	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
or	O
extrapulmonary	O
organ	O
dysfunction	O
.	O

A	O
15	O
-	O
year	O
-	O
old	O
girl	O
presented	O
with	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
,	O
fever	O
,	O
seizures	B-DISO
and	O
abdominal	B-DISO
pain	I-DISO
.	O

ABSTRACT	O
:	O
Chlorine	O
gas	O
exposure	O
is	O
uncommon	O
in	O
children	O
and	O
when	O
it	O
occurs	O
usually	O
results	O
in	O
mild	O
ocular	O
,	O
oropharyngeal	O
,	O
or	O
respiratory	B-DISO
symptoms	I-DISO
.	O

ABSTRACT	O
:	O
The	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
severe	O
lung	O
injury	O
in	O
patients	O
with	O
sepsis	B-DISO
and	O
other	O
acute	O
inflammatory	O
insults	O
,	O
which	O
is	O
characterized	O
by	O
fibrin	B-DISO
deposition	I-DISO
in	O
the	O
pulmonary	O
parenchyma	O
,	O
vasculature	O
,	O
and	O
airspaces	O
.	O

New	O
interventional	O
strategies	O
directed	O
at	O
procoagulant	O
activity	O
highlight	O
the	O
importance	O
of	O
the	O
coagulation	O
system	O
to	O
acute	O
lung	O
injury	O
and	O
suggest	O
that	O
blockade	O
of	O
initiation	O
of	O
coagulation	O
may	O
have	O
therapeutic	O
benefit	O
in	O
patients	O
with	O
ARDS	B-DISO
.	O

A	O
total	O
of	O
21	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
requiring	O
prolonged	O
mechanical	O
ventilation	O
and	O
undergoing	O
thoracic	B-DISO
computed	O
tomographic	O
scanning	O
.	O

Air	O
cysts	B-DISO
prevailed	O
in	O
nondependent	O
compared	O
with	O
dependent	O
areas	O
(	O
38	O
%	O
+/-	O

With	O
mechanical	O
ventilation	O
longer	O
than	O
10	O
days	O
,	O
the	O
odds	O
ratio	O
was	O
13	O
.	O
1	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
4	O
-	O
118	O
.	O
7	O
)	O
for	O
air	O
cysts	B-DISO
and	O
for	O
bronchiectasis	B-DISO
17	O
.	O
6	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
2	O
.	O
8	O
-	O
109	O
.	O
6	O
).	O

TITLE	O
:	O
Adjunctive	O
corticosteroids	O
therapy	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
owing	O
to	O
disseminated	B-DISO
coccidioidomycosis	I-DISO
.	O

We	O
are	O
presenting	O
a	O
case	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
owing	O
to	O
a	O
fulminant	O
coccidioidomycosis	B-DISO
infection	B-DISO
that	O
responded	O
to	O
a	O
short	O
course	O
of	O
systemic	O
corticosteroids	O
in	O
addition	O
to	O
the	O
standard	O
antifungal	O
treatment	O
.	O

TITLE	O
:	O
Skin	B-DISO
necrosis	I-DISO
after	O
extravasation	B-DISO
of	O
low	O
-	O
dose	O
vasopressin	O
administered	O
for	O
septic	B-DISO
shock	I-DISO
.	O

ABSTRACT	O
:	O
Acute	O
pulmonary	O
dysfunction	O
remains	O
a	O
frequent	O
and	O
severe	O
complication	B-DISO
of	O
hematopoietic	O
stem	O
cell	O
transplantation	O
(	O
SCT	B-DISO
).	O

ABSTRACT	O
:	O
Reduction	O
in	O
tidal	O
volume	O
(	O
Vt	O
)	O
associated	O
with	O
increase	O
in	O
respiratory	O
rate	O
to	O
limit	O
hypercapnia	B-DISO
is	O
now	O
proposed	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

Long	O
-	O
distance	O
interhospital	O
ground	O
transfer	O
of	O
even	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
severe	O
unstable	O
respiratory	O
and	O
circulatory	B-DISO
failure	I-DISO
is	O
safe	O
if	O
a	O
dedicated	O
transport	O
team	O
and	O
a	O
specially	O
equipped	O
transport	O
vehicle	O
are	O
used	O
.	O

ABSTRACT	O
:	O
Venoarterial	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
VA	O
ECMO	O
)	O
has	O
become	O
a	O
valuable	O
technique	O
in	O
the	O
critical	O
care	O
of	O
children	O
with	O
congenital	B-DISO
heart	I-DISO
disease	I-DISO
who	O
require	O
mechanical	O
cardiorespiratory	O
support	O
.	O

A	O
2	O
.	O
5	O
kg	O
neonate	O
with	O
severe	O
Ebstein	B-DISO
'	I-DISO
s	I-DISO
anomaly	I-DISO
of	O
the	O
tricuspid	O
valve	O
and	O
recurrent	O
episodes	O
of	O
life	O
-	O
threatening	O
supraventricular	B-DISO
tachycardia	I-DISO
was	O
electively	O
cannulated	O
for	O
VA	O
ECMO	O
in	O
the	O
cardiac	O
intensive	O
care	O
unit	O
.	O

TITLE	O
:	O
Adult	B-DISO
onset	I-DISO
Still	I-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
as	O
a	O
cause	O
of	O
ARDS	B-DISO
and	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

She	O
developed	O
severe	O
rigors	B-DISO
,	O
peripheral	O
cyanosis	B-DISO
,	O
hypoxia	B-DISO
,	O
and	O
a	O
transient	O
diffuse	O
pulmonary	B-DISO
infiltrate	I-DISO
.	O

Thus	O
,	O
sialodacryoadenitis	O
virus	B-DISO
infection	I-DISO
mitigated	O
biological	O
processes	O
in	O
the	O
liver	O
of	O
rats	O
,	O
and	O
mtDNA	O
damage	O
was	O
modulated	O
by	O
diet	O
.	O

The	O
major	O
complications	O
were	O
severe	O
infection	B-DISO
,	O
hypotension	O
,	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
and	O
multiple	O
organ	O
disfunction	O
syndrome	B-DISO
(	O
MODS	B-DISO
).	O

ABSTRACT	O
:	O
The	O
optimal	O
treatment	O
for	O
the	O
hematological	O
toxicity	O
of	O
acute	O
radiation	B-DISO
syndrome	I-DISO
(	O
ARS	O
)	O
is	O
not	O
fully	O
established	O
,	O
especially	O
in	O
cases	O
of	O
high	O
-	O
dose	O
nonuniform	O
irradiation	O
by	O
mixed	O
neutrons	O
and	O
gamma	O
-	O
rays	O
,	O
because	O
estimation	O
of	O
the	O
irradiation	O
dose	O
(	O
dosimetry	O
)	O
and	O
prediction	O
of	O
autologous	O
hematological	O
recovery	O
are	O
complicated	O
.	O

Lung	O
lactate	O
production	O
may	O
become	O
clinically	O
evident	O
in	O
disease	O
states	O
especially	O
in	O
the	O
patients	O
with	O
acute	O
lung	O
injury	O
or	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

In	O
one	O
patient	O
withdrawal	B-DISO
from	O
NPPV	O
was	O
possible	O
after	O
2	O
months	O
.	O

Despite	O
deletion	O
of	O
NP	O
residues	O
443	O
to	O
460	O
encompassing	O
the	O
NP	O
-	O
IDE	O
,	O
the	O
mutant	B-DISO
NDV	O
propagated	O
in	O
embryonated	O
specific	O
-	O
pathogen	O
-	O
free	O
chicken	O
eggs	O
to	O
a	O
level	O
comparable	O
to	O
that	O
of	O
the	O
parent	O
virus	O
.	O

ABSTRACT	O
:	O
The	O
development	O
of	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
complicates	O
the	O
treatment	O
of	O
patients	O
with	O
severe	O
head	O
injury	O
,	O
since	O
special	O
therapeutic	O
strategies	O
for	O
both	O
conditions	O
might	O
lead	O
to	O
a	O
""""	O
conflict	O
of	O
interest	O
"""."	O

We	O
report	O
on	O
the	O
intensive	O
care	O
treatment	O
of	O
a	O
young	O
man	O
who	O
suffered	B-DISO
severe	O
brain	O
injury	O
(	O
Glasgow	O
Coma	B-DISO
Scale	O
=	O
3	O
)	O
due	O
to	O
a	O
traffic	O
accident	O
and	O
simultaneously	O
developed	O
ARDS	B-DISO
from	O
the	O
aspiration	B-DISO
of	O
gastric	O
content	O
.	O

We	O
performed	O
extensive	O
monitoring	O
of	O
cerebral	O
hemodynamics	O
and	O
metabolism	O
(	O
intracranial	O
pressure	O
measurement	O
,	O
jugular	O
bulb	O
oxymetry	O
,	O
estimation	O
of	O
arterial	O
-	O
jugular	O
bulb	O
lactate	O
concentration	O
difference	O
)	O
to	O
prevent	O
cerebral	B-DISO
hypoxia	I-DISO
and	O
to	O
control	O
cerebral	O
hyperemia	B-DISO
.	O

TITLE	O
:	O
Enteric	O
coronavirus	B-DISO
infection	I-DISO
in	O
a	O
juvenile	O
dromedary	O
(	O
Camelus	O
dromedarius	O
).	O

ABSTRACT	O
:	O
A	O
case	O
of	O
an	O
enteric	O
coronavirus	B-DISO
infection	I-DISO
in	O
a	O
6	O
-	O
week	O
-	O
old	O
dromedary	O
calf	O
is	O
described	O
.	O

This	O
dramatic	O
result	O
indicated	O
that	O
the	O
absence	O
of	O
FGF2	O
promoted	O
oligodendrocyte	O
regeneration	O
,	O
possibly	O
by	O
enhancing	O
oligodendrocyte	O
progenitor	O
proliferation	B-DISO
and	O
/	O
or	O
differentiation	O
.	O

FGF2	O
-/-	O
and	O
+/+	O
mice	O
had	O
similar	O
oligodendrocyte	O
progenitor	O
densities	O
in	O
normal	O
adult	O
CNS	O
,	O
as	O
well	O
as	O
similar	O
progenitor	O
proliferation	B-DISO
and	O
accumulation	O
during	O
demyelination	B-DISO
.	O

We	O
used	O
leukocyte	O
uptake	O
of	O
the	O
glucose	O
analog	O
[	O
18F	O
]	O
fluorodeoxyglucose	O
(	O
18FDG	O
),	O
which	O
indicates	O
postmigrational	O
neutrophil	O
activity	O
,	O
to	O
identify	O
and	O
quantify	O
the	O
relationship	O
between	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
neutrophil	O
activation	O
in	O
experimental	O
pancreatitis	B-DISO
in	O
rats	O
.	O

After	O
correction	O
for	O
blood	O
background	O
,	O
only	O
18FDG	O
in	O
lung	O
(	O
but	O
not	O
muscle	O
)	O
was	O
significantly	O
increased	O
in	O
pancreatitis	B-DISO
(	O
severe	O
>	O
mild	O
>	O
normal	O
,	O
p	O
<.	O
001	O
).	O

This	O
often	O
is	O
a	O
fatal	O
complication	B-DISO
.	O

TITLE	O
:	O
Superimposition	O
of	O
post	O
-	O
streptococcal	O
acute	B-DISO
glomerulonephritis	I-DISO
on	O
the	O
course	O
of	O
IgA	B-DISO
nephropathy	I-DISO
:	O
predominance	O
of	O
Th1	O
type	O
immune	O
response	O
.	O

On	O
admission	O
,	O
hypertension	B-DISO
,	O
nephrotic	B-DISO
syndrome	I-DISO
and	O
hypocomplementemia	B-DISO
were	O
evident	O
together	O
with	O
a	O
high	O
titer	O
of	O
anti	O
-	O
streptokinase	O
(	O
ASK	O
).	O

TITLE	O
:	O
High	O
frequency	O
oscillatory	O
ventilation	O
in	O
adult	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
--	O
a	O
retrospective	O
study	O
.	O

Ending	O
HFOV	O
after	O
6	O
.	O
6	O
(	O
SD	O
3	O
.	O
2	O
)	O
days	O
,	O
survivors	O
(	O
n	O
=	O
11	O
)	O
significantly	O
reduced	O
their	O
Sequential	O
Organ	B-DISO
Failure	I-DISO
Assessment	O
Score	O
(	O
SOFA	O
)	O
compared	O
to	O
baseline	O
.	O

TITLE	O
:	O
Virus	O
-	O
induced	O
demyelination	B-DISO
in	O
nude	O
mice	O
is	O
mediated	O
by	O
gamma	O
delta	O
T	O
cells	O
.	O

This	O
pathological	B-DISO
process	I-DISO
is	O
primarily	O
T	O
cell	O
-	O
mediated	O
and	O
MHV	O
infection	B-DISO
of	O
mice	O
lacking	O
B	O
and	O
T	O
cells	O
does	O
not	O
result	O
in	O
demyelination	B-DISO
.	O

In	O
apparent	O
contradiction	O
to	O
these	O
results	O
,	O
robust	O
demyelination	B-DISO
is	O
detected	O
in	O
MHV	O
-	O
infected	O
young	O
nude	O
(	O
athymic	O
)	O
mice	O
.	O

These	O
cells	O
,	O
but	O
not	O
conventional	O
CD4	O
or	O
CD8	O
alpha	O
beta	O
T	O
cells	O
,	O
were	O
detected	O
in	O
the	O
central	O
nervous	B-DISO
system	O
of	O
MHV	O
-	O
infected	O
nude	O
mice	O
and	O
their	O
depletion	O
with	O
neutralizing	O
antibody	O
resulted	O
in	O
an	O
80	O
%	O
reduction	O
in	O
demyelination	B-DISO
.	O

These	O
results	O
show	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
gamma	O
delta	O
T	O
cells	O
can	O
substitute	O
for	O
alpha	O
beta	O
T	O
cells	O
in	O
a	O
virus	O
model	O
of	O
demyelination	B-DISO
and	O
further	O
support	O
a	O
pathological	O
role	O
for	O
gamma	O
delta	O
T	O
cells	O
in	O
patients	O
with	O
multiple	B-DISO
sclerosis	I-DISO
.	O

TITLE	O
:	O
Systematic	O
assembly	O
of	O
a	O
full	O
-	O
length	O
infectious	B-DISO
cDNA	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
strain	O
A59	O
.	O

TITLE	O
:	O
Early	O
versus	O
delayed	O
surfactant	O
administration	O
in	O
extremely	O
premature	O
neonates	O
with	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
ventilated	O
by	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
.	O

Fewer	O
infants	O
randomized	O
to	O
the	O
EARL	O
group	O
required	O
oxygen	O
use	O
or	O
died	O
at	O
36	O
weeks	O
(	O
combined	O
outcome	O
29	O
%	O
vs	O
64	O
%,	O
p	O
=	O
0	O
.	O
021	O
),	O
and	O
there	O
was	O
a	O
lower	O
incidence	O
of	O
any	O
intraventricular	B-DISO
hemorrhage	I-DISO
in	O
this	O
group	O
(	O
43	O
vs	O
82	O
%,	O
p	O
=	O
0	O
.	O
008	O
).	O

Examination	O
of	O
postmortem	O
lungs	O
among	O
cases	O
clinically	O
diagnosed	O
as	O
ARDS	B-DISO
identified	O
a	O
cohort	O
that	O
showed	O
a	O
consistent	O
morphology	O
at	O
the	O
light	O
and	O
electron	O
microscope	O
levels	O
,	O
and	O
featured	O
pathognomonic	O
structures	O
which	O
we	O
termed	O
elastin	O
-	O
staining	O
laminar	O
structures	O
(	O
ELS	O
).	O

Remarkably	O
,	O
most	O
of	O
the	O
postmortem	O
lungs	O
with	O
ELS	O
exhibited	O
no	O
significant	O
acute	O
inflammatory	O
cellular	O
response	O
such	O
as	O
neutrophilic	O
reaction	O
,	O
and	O
little	O
evidence	O
of	O
widespread	O
edema	B-DISO
except	O
for	O
focal	O
intra	B-DISO
-	I-DISO
alveolar	I-DISO
hemorrhage	I-DISO
.	O

The	O
small	O
nonenveloped	O
viruses	O
,	O
such	O
as	O
HAV	B-DISO
and	O
parvovirus	B-DISO
B19	I-DISO
(	O
B19	O
),	O
are	O
evidently	O
more	O
difficult	O
to	O
remove	O
than	O
the	O
larger	O
enveloped	O
viruses	O
.	O

TITLE	O
:	O
Generation	O
of	O
a	O
replication	O
-	O
competent	O
,	O
propagation	O
-	O
deficient	O
virus	O
vector	O
based	O
on	O
the	O
transmissible	O
gastroenteritis	B-DISO
coronavirus	O
genome	O
.	O

ABSTRACT	O
:	O
Replication	O
-	O
competent	O
propagation	O
-	O
deficient	O
virus	O
vectors	O
based	O
on	O
the	O
transmissible	O
gastroenteritis	B-DISO
coronavirus	O
(	O
TGEV	O
)	O
genome	O
that	O
are	O
deficient	O
in	O
the	O
essential	O
E	O
gene	O
have	O
been	O
developed	O
by	O
complementation	O
within	O
E	O
(+)	O
packaging	O
cell	O
lines	O
.	O

The	O
Sindbis	O
replicon	O
vector	O
and	O
the	O
ectopic	O
TGEV	O
E	O
protein	O
did	O
not	O
interfere	O
with	O
the	O
rescue	O
of	O
infectious	B-DISO
TGEV	O
from	O
full	O
-	O
length	O
cDNA	O
.	O

ABSTRACT	O
:	O
The	O
observation	O
that	O
mice	O
infected	O
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
develop	O
autoantibodies	O
directed	O
mainly	O
to	O
liver	O
fumarylacetoacetate	O
hydrolase	O
(	O
FAH	O
)	O
enabled	O
the	O
development	O
of	O
an	O
ELISA	O
applicable	O
to	O
the	O
detection	O
of	O
MHV	O
-	O
infection	B-DISO
.	O

Bone	O
-	O
marrow	O
release	O
of	O
leukocytes	O
and	O
platelets	O
is	O
an	O
important	O
component	O
of	O
the	O
systemic	O
inflammatory	B-DISO
response	I-DISO
.	O

TITLE	O
:	O
Differential	O
induction	O
of	O
apoptosis	O
in	O
demyelinating	O
and	O
nondemyelinating	O
infection	B-DISO
by	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
.	O

At	O
1	O
month	O
,	O
TUNEL	O
staining	O
was	O
found	O
exclusively	O
in	O
areas	O
of	O
demyelination	B-DISO
in	O
the	O
spinal	O
cord	B-DISO
of	O
MHV	O
-	O
A59	O
-	O
infected	O
mice	O
;	O
however	O
,	O
it	O
was	O
not	O
found	O
in	O
nondemyelinated	O
mice	O
infected	O
with	O
MHV	O
-	O
2	O
or	O
Penn98	O
-	O
1	O
,	O
or	O
in	O
mock	O
-	O
infected	O
mice	O
.	O

ABSTRACT	O
:	O
The	O
cleavage	O
and	O
fusion	O
properties	O
of	O
recombinant	O
murine	B-DISO
hepatitis	I-DISO
viruses	O
(	O
MHV	O
)	O
were	O
examined	O
to	O
assess	O
the	O
role	O
of	O
the	O
cleavage	O
signal	O
in	O
determining	O
the	O
extent	O
of	O
S	O
protein	O
cleavage	O
,	O
and	O
the	O
correlation	O
between	O
cleavage	O
and	O
induction	O
of	O
cell	O
-	O
to	O
-	O
cell	O
fusion	O
.	O

Routine	O
cranial	O
ultrasonography	O
was	O
performed	O
and	O
the	O
occurrence	O
of	O
intraventricular	B-DISO
hemorrhage	I-DISO
(	O
IVH	O
)	O
was	O
interpreted	O
by	O
an	O
attending	O
pediatric	O
radiologist	O
unaware	O
of	O
the	O
treatment	O
group	O
assignment	O
.	O

TITLE	O
:	O
Idiopathic	O
acute	B-DISO
eosinophilic	I-DISO
pneumonia	I-DISO
:	O
a	O
study	O
of	O
22	O
patients	O
.	O

Five	O
children	O
died	O
in	O
the	O
first	O
year	O
of	O
life	O
during	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
,	O
one	O
girl	O
died	O
at	O
the	O
age	O
of	O
3	O
months	O
with	O
sudden	B-DISO
death	I-DISO
syndrome	B-DISO
,	O
only	O
one	O
boy	O
with	O
spastic	B-DISO
quadruparesis	O
and	O
severe	O
psychomotor	O
retardation	O
survived	O
to	O
the	O
age	O
of	O
8	O
years	O
.	O

Patients	O
with	O
ARDS	B-DISO
were	O
identified	O
from	O
the	O
registry	O
of	O
a	O
Level	O
I	O
trauma	O
center	O
over	O
a	O
4	O
.	O
5	O
-	O
year	O
period	O
.	O

Of	O
these	O
patients	O
200	O
(	O
4	O
.	O
5	O
%)	O
developed	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Sudden	B-DISO
infant	I-DISO
death	I-DISO
syndrome	I-DISO
(	O
SIDS	B-DISO
)	O
victims	O
were	O
regarded	O
as	O
normal	O
as	O
a	O
matter	O
of	O
definition	O
(	O
Beckwith	O
1970	O
)	O
until	O
1952	O
when	O
Kinney	O
and	O
colleagues	O
argued	O
for	O
elimination	O
of	O
the	O
clause	O
,	O
""""	O
unexpected	O
by	O
history	O
.	O

They	O
added	O
a	O
qualifier	O
,	O
""""	O
in	O
at	O
least	O
a	O
subset	O
of	O
SIDS	B-DISO
","""	O
but	O
,	O
the	O
National	O
Institute	O
of	O
Child	O
Health	O
and	O
Development	O
SIDS	B-DISO
Strategic	O
Plan	B-DISO
2000	O
,	O
quoting	O
Kinney	O
'	O
s	O
work	O
,	O
states	O
unequivocally	O
that	O
""""	O
SIDS	B-DISO
is	O
a	O
developmental	B-DISO
disorder	I-DISO
.	O

There	O
is	O
no	O
published	O
method	O
known	O
to	O
us	O
of	O
determining	O
the	O
time	O
of	O
origin	O
of	O
these	O
markers	O
except	O
that	O
the	O
injury	O
causing	O
astrogliosis	B-DISO
must	O
have	O
occurred	O
at	O
least	O
4	O
days	O
before	O
death	O
(	O
Del	O
Bigio	O
and	O
Becker	O
,	O
1994	O
).	O

These	O
cases	O
should	O
not	O
be	O
included	O
under	O
the	O
rubric	O
of	O
SIDS	B-DISO
,	O
by	O
definition	O
.	O

We	O
conclude	O
that	O
none	O
of	O
the	O
triple	O
risk	O
hypotheses	O
presented	O
so	O
far	O
have	O
significantly	O
improved	O
our	O
understanding	O
of	O
the	O
cause	O
of	O
SIDS	B-DISO
.	O

TITLE	O
:	O
Field	O
study	O
of	O
bovine	O
coronavirus	O
vaccine	O
enriched	O
with	O
hemagglutinating	O
antigen	O
for	O
winter	B-DISO
dysentery	I-DISO
in	O
dairy	O
cows	O
.	O

Conversely	O
,	O
20	O
animals	O
were	O
seropositive	O
but	O
negative	O
using	O
RT	O
/	O
nPCR	O
for	O
FCoV	O
.	O
Some	O
of	O
the	O
populations	O
in	O
which	O
virus	O
was	O
detected	O
had	O
experienced	O
health	O
problems	O
,	O
including	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
),	O
necrotizing	B-DISO
colitis	I-DISO
,	O
and	O
mild	O
enteritis	B-DISO
.	O

ABSTRACT	O
:	O
Reverse	O
-	O
transcriptase	O
polymerase	O
chain	O
reactions	O
(	O
RT	O
-	O
PCRs	O
)	O
were	O
used	O
to	O
examine	O
RNA	O
extracted	O
from	O
mouth	O
/	O
nasal	O
swabs	O
from	O
pheasants	O
exhibiting	O
signs	O
of	O
respiratory	B-DISO
disease	I-DISO
.	O

In	O
acute	B-DISO
infections	I-DISO
,	O
we	O
need	O
two	O
sera	O
samples	O
given	O
in	O
2	O
weeks	O
period	O
with	O
4	O
-	O
fold	O
rise	O
or	O
fall	O
in	O
titers	O
.	O

137	O
patients	O
had	O
mild	O
and	O
35	O
had	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
,	O
and	O
there	O
were	O
74	O
control	O
patients	O
.	O

Outcomes	O
included	O
mortality	O
,	O
pneumonia	B-DISO
(>	O
or	O
=	O
10	O
colony	O
-	O
forming	O
units	O
/	O
mL	O
in	O
bronchoalveolar	O
lavage	O
effluent	O
),	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
bacteremia	B-DISO
,	O
ventilator	O
days	O
,	O
and	O
intensive	O
care	O
unit	O
and	O
hospital	O
length	O
of	O
stay	O
.	O

Therefore	O
,	O
the	O
present	O
study	O
investigated	O
in	O
a	O
double	O
-	O
blind	B-DISO
,	O
placebo	O
-	O
controlled	O
manner	O
the	O
effect	O
of	O
severe	O
trauma	O
on	O
the	O
alveolar	O
fibrinolytic	O
/	O
coagulation	O
balance	O
,	O
and	O
the	O
effect	O
here	O
-	O
upon	O
of	O
inhalation	O
of	O
single	O
-	O
chain	O
urokinase	O
plasminogen	O
activator	O
(	O
scu	O
-	O
PA	O
)	O
in	O
pigs	O
.	O

Inhibition	O
of	O
MHV	O
-	O
induced	O
apoptosis	O
by	O
the	O
pancaspase	O
inhibitor	O
Z	O
-	O
VAD	O
-	O
FMK	O
promoted	O
virus	O
production	O
late	O
in	O
infection	B-DISO
,	O
indicating	O
that	O
apoptosis	O
could	O
be	O
a	O
host	O
response	O
to	O
limit	O
the	O
production	O
of	O
viral	O
progeny	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
identify	O
the	O
neutralizing	O
epitope	O
of	O
the	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
the	O
spike	O
protein	O
region	O
that	O
is	O
presumed	O
to	O
contain	O
the	O
virus	O
-	O
neutralizing	O
epitope	O
was	O
determined	O
.	O

TITLE	O
:	O
Pediatric	O
ARDS	B-DISO
:	O
effect	O
of	O
supine	O
-	O
prone	O
postural	O
changes	O
on	O
oxygenation	O
.	O

But	O
several	O
cases	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
related	O
to	O
Gemcitabine	O
treatment	O
have	O
been	O
reported	O
since	O
1997	O
and	O
a	O
few	O
were	O
fatal	O
.	O

ABSTRACT	O
:	O
Intracranial	O
infection	B-DISO
of	O
C57BL	O
/	O
6	O
mice	O
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
results	O
in	O
an	O
acute	O
encephalomyelitis	B-DISO
followed	O
by	O
a	O
demyelinating	B-DISO
disease	I-DISO
similar	O
in	O
pathology	B-DISO
to	O
the	O
human	O
disease	O
multiple	B-DISO
sclerosis	I-DISO
(	O
MS	O
).	O

Collectively	O
these	O
results	O
demonstrate	O
that	O
CCR5	O
signaling	O
is	O
important	O
to	O
migration	O
of	O
CD4	O
(+)	O
T	O
cells	O
to	O
the	O
CNS	O
following	O
MHV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
severe	O
form	O
of	O
respiratory	B-DISO
failure	I-DISO
that	O
is	O
characterized	O
by	O
marked	O
hypoxemia	O
,	O
bilateral	O
infiltrates	B-DISO
on	O
chest	O
radiograph	O
,	O
and	O
no	O
clinical	O
evidence	O
of	O
left	B-DISO
ventricular	I-DISO
failure	I-DISO
.	O

Transcription	O
of	O
the	O
DI	O
RNA	O
during	O
MHV	O
infection	B-DISO
was	O
greatly	O
inhibited	O
in	O
these	O
cell	O
lines	O
,	O
indicating	O
that	O
PTB	O
modulates	O
MHV	O
transcription	O
.	O

ABSTRACT	O
:	O
A	O
7	O
-	O
year	O
-	O
old	O
boy	O
with	O
Down	B-DISO
syndrome	I-DISO
developed	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
after	O
a	O
respiratory	B-DISO
infection	I-DISO
with	O
Mycoplasma	B-DISO
pneumoniae	O
with	O
an	O
unusually	O
high	O
agglutination	O
titre	O
(	O
1	O
:	O
10240	O
).	O

Extracorporeal	O
membrane	O
oxygenation	O
for	O
152	O
h	O
improved	O
the	O
lung	O
condition	B-DISO
.	O

ABSTRACT	O
:	O
Central	B-DISO
nervous	I-DISO
system	I-DISO
infection	I-DISO
by	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
JHMV	O
)	O
results	O
in	O
chronic	O
demyelination	B-DISO
characterized	O
by	O
viral	O
persistence	O
in	O
the	O
absence	O
of	O
infectious	B-DISO
virus	O
.	O

A	O
vital	O
role	O
for	O
humoral	O
immunity	O
during	O
persistence	O
is	O
supported	O
by	O
the	O
accumulation	O
and	O
retention	O
of	O
virus	O
-	O
specific	O
antibody	O
secreting	O
cells	O
following	O
clearance	O
of	O
infectious	B-DISO
virus	O
.	O

Therefore	O
,	O
although	O
the	O
central	O
nervous	B-DISO
system	O
provides	O
an	O
environment	O
for	O
prolonged	O
retention	O
of	O
both	O
T	O
cells	O
and	O
plasma	O
cells	O
,	O
plasma	O
cells	O
are	O
critical	O
in	O
maintaining	O
persistent	O
virus	O
at	O
undetectable	O
levels	O
.	O

As	O
to	O
a	O
preferred	O
method	O
of	O
immunization	O
,	O
wing	O
web	B-DISO
administration	O
appeared	O
to	O
be	O
superior	O
to	O
the	O
subcutaneous	O
route	O
because	O
a	O
greater	O
percentage	O
of	O
birds	O
vaccinated	O
by	O
the	O
former	O
protocol	O
exhibited	O
an	O
anti	O
-	O
IBV	O
humoral	O
immune	O
response	O
.	O

Chickens	O
given	O
a	O
live	O
combination	O
vaccination	O
of	O
Mass	O
+	O
Conn	O
and	O
boosted	O
with	O
an	O
inactivated	O
Mass	O
+	O
Ark	O
vaccine	O
were	O
also	O
susceptible	O
to	O
NIBV	O
challenge	O
on	O
the	O
basis	O
of	O
virus	O
isolation	O
from	O
trachea	B-DISO
and	O
kidney	O
butshowed	O
protection	O
on	O
the	O
basis	O
of	O
renal	O
microscopic	O
pathology	B-DISO
and	O
IHC	O
.	O

TITLE	O
:	O
Risk	O
factors	O
associated	O
with	O
poult	O
enteritis	B-DISO
mortality	O
syndrome	B-DISO
-	O
positive	O
turkey	O
flocks	O
.	O

ABSTRACT	O
:	O
Mechanical	O
ventilation	O
is	O
being	O
increasingly	O
used	O
in	O
many	O
disciplines	O
by	O
specialists	O
who	O
manage	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

The	O
study	O
revealed	O
that	O
the	O
GAV	O
and	O
potyvirus	O
3CL	O
(	O
pro	O
)	O
s	O
possess	B-DISO
similar	O
substrate	O
specificities	O
which	O
correlate	O
with	O
structural	O
similarities	O
in	O
their	O
respective	O
substrate	O
-	O
binding	O
sites	O
,	O
identified	O
in	O
sequence	O
comparisons	O
.	O

ABSTRACT	O
:	O
Diabetic	B-DISO
pregnancies	I-DISO
have	O
an	O
increased	O
risk	O
of	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
(	O
RDS	O
)	O
and	O
preterm	B-DISO
delivery	I-DISO
.	O

In	O
the	O
present	O
prospective	O
randomized	O
study	O
,	O
we	O
compared	O
the	O
effectiveness	O
of	O
oxygen	O
treatment	O
administered	O
by	O
a	O
face	B-DISO
mask	O
vs	O
.	O
nasal	O
continuous	O
positive	O
airway	O
pressure	O
(	O
NCPAP	O
).	O

Chest	O
X	O
-	O
ray	O
revealed	O
pleural	B-DISO
effusion	I-DISO
in	O
92	O
per	O
cent	O
and	O
showed	O
interstitial	B-DISO
oedema	I-DISO
in	O
33	O
per	O
cent	O
.	O

A	O
subset	O
of	O
samples	O
was	O
tested	O
for	O
feline	O
immunodeficiency	B-DISO
virus	O
;	O
all	O
were	O
negative	O
.	O

In	O
the	O
DIC	B-DISO
patients	O
,	O
higher	O
DIC	B-DISO
scores	O
,	O
lower	O
platelet	O
counts	O
,	O
and	O
a	O
longer	O
duration	O
of	O
SIRS	B-DISO
were	O
found	O
compared	O
with	O
the	O
non	O
-	O
DIC	B-DISO
patients	O
.	O

The	O
levels	O
of	O
sP	O
-	O
and	O
sE	O
-	O
selectins	O
,	O
sICAM	O
-	O
1	O
,	O
and	O
sVCAM	O
-	O
1	O
were	O
more	O
elevated	O
in	O
the	O
patients	O
with	O
DIC	B-DISO
than	O
in	O
those	O
without	O
DIC	B-DISO
on	O
days	O
2	O
to	O
4	O
.	O

Neutrophil	O
elastase	O
and	O
sThrombomodulin	O
levels	O
in	O
the	O
DIC	B-DISO
patients	O
persistently	O
increased	O
during	O
the	O
study	O
period	O
compared	O
to	O
those	O
in	O
the	O
non	O
-	O
DIC	B-DISO
patients	O
.	O

Highly	O
activated	O
and	O
sustained	O
inflammation	B-DISO
caused	O
by	O
neutrophil	O
-	O
endothelium	O
interaction	O
in	O
DIC	B-DISO
gives	O
rise	O
to	O
MODS	B-DISO
and	O
poor	O
outcome	O
in	O
patients	O
with	O
severe	O
trauma	O
.	O

As	O
single	O
viral	O
findings	O
,	O
rhinoviruses	O
were	O
associated	O
with	O
the	O
development	O
of	O
asthma	B-DISO
(	O
P	O
=.	O
047	O
;	O
odds	O
ratio	O
,	O
4	O
.	O
14	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
02	O
-	O
16	O
.	O
77	O
versus	O
rhinovirus	O
-	O
negative	O
cases	O
[	O
by	O
logistic	O
regression	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
and	O
atopic	B-DISO
dermatitis	I-DISO
on	O
entry	O
)].	O

To	O
investigate	O
signals	O
that	O
regulate	O
OP	O
proliferation	B-DISO
in	O
response	O
to	O
demyelination	B-DISO
we	O
used	O
murine	B-DISO
hepatitis	I-DISO
virus	O
-	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
infection	B-DISO
of	O
adult	O
mice	O
to	O
induce	O
focal	O
demyelination	B-DISO
throughout	O
the	O
spinal	O
cord	B-DISO
followed	O
by	O
spontaneous	O
remyelination	O
.	O

We	O
identify	O
PDGF	O
and	O
FGF2	O
as	O
significant	O
mitogens	O
regulating	O
this	O
proliferative	B-DISO
response	O
.	O

Inspiration	O
increased	O
alveolar	O
recruitment	B-DISO
at	O
all	O
PEEP	O
levels	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
a	O
differential	O
role	O
for	O
T	O
lymphocytes	O
in	O
the	O
development	O
of	O
fibrosis	B-DISO
associated	O
with	O
BOOP	B-DISO
versus	O
ARDS	B-DISO
.	O

In	O
contrast	O
,	O
neonatally	O
thymectomized	O
CBA	O
/	O
J	O
mice	O
infected	O
with	O
1	O
x	O
10	O
(	O
6	O
)	O
pfu	O
(	O
BOOP	B-DISO
)	O
reovirus	O
1	O
/	O
L	O
do	O
not	O
develop	O
intra	O
-	O
alveolar	O
fibrosis	B-DISO
associated	O
with	O
BOOP	B-DISO
.	O

Therefore	O
,	O
while	O
T	O
cells	O
are	O
necessary	O
for	O
the	O
development	O
of	O
intraluminal	O
fibrosis	B-DISO
associated	O
with	O
BOOP	B-DISO
,	O
they	O
are	O
not	O
necessary	O
for	O
the	O
development	O
of	O
intraluminal	O
fibrosis	B-DISO
associated	O
with	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Mechanical	O
ventilation	O
is	O
a	O
supportive	O
lifesaving	O
therapy	O
that	O
can	O
potentially	O
cause	O
lung	O
injury	O
if	O
periodic	O
alveolar	O
overdistension	O
,	O
or	O
cyclic	O
collapse	B-DISO
,	O
and	O
reopening	O
occur	O
.	O

In	O
unilateral	O
lung	O
injury	O
,	O
ventilatory	O
strategies	O
that	O
allow	O
recruitment	B-DISO
of	O
injured	O
lung	O
and	O
that	O
avoid	O
overdistension	O
of	O
uninjured	O
lung	O
parenchyma	O
should	O
be	O
applied	O
.	O

TITLE	O
:	O
Laboratory	O
changes	O
consistent	O
with	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
in	O
cats	O
from	O
multicat	O
environments	O
.	O

Moreover	O
,	O
multiple	O
small	O
frameshifting	O
insertion	O
or	O
deletion	O
mutations	O
throughout	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
open	O
reading	O
frame	O
inhibited	O
this	O
template	O
recruitment	B-DISO
,	O
while	O
an	O
in	O
-	O
frame	O
insertion	O
did	O
not	O
.	O

Both	O
experimental	O
models	O
and	O
studies	O
in	O
humans	O
suggest	O
that	O
inadequate	O
hypothalamic	O
pituitary	O
adrenal	O
axis	O
response	O
to	O
stress	O
accounts	O
,	O
at	O
least	O
partly	O
,	O
for	O
the	O
genesis	O
of	O
shock	O
and	O
organ	O
dysfunction	O
in	O
sepsis	B-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

13	O
:	O
the	O
pulmonary	O
circulation	O
and	O
right	B-DISO
ventricular	I-DISO
failure	I-DISO
in	O
the	O
ITU	O
.	O

Clinically	O
,	O
it	O
is	O
characterized	O
by	O
dyspnea	B-DISO
,	O
profound	O
hypoxemia	O
,	O
decreased	B-DISO
lung	I-DISO
compliance	I-DISO
,	O
and	O
diffuse	O
bilateral	O
infiltrates	B-DISO
on	O
chest	O
radiography	O
.	O

TITLE	O
:	O
Leptospiral	O
nephropathy	B-DISO
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
and	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
were	O
detected	O
and	O
differentiated	O
in	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissues	O
from	O
experimentally	O
and	O
naturally	O
infected	O
pigs	O
by	O
multiplex	O
reverse	O
transcription	O
-	O
nested	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
nPCR	O
).	O

TITLE	O
:	O
Acute	O
oxygenation	O
response	O
to	O
inhaled	O
nitric	O
oxide	O
when	O
combined	O
with	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
in	O
adults	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

At	O
30	O
mins	O
after	O
INO	O
initiation	O
,	O
83	O
%	O
of	O
patients	O
had	O
a	O
significant	O
increase	O
in	O
blood	O
oxygen	O
tension	B-DISO
,	O
defined	O
as	O
>	O
or	O
=	O
20	O
%	O
increase	O
in	O
Pao2	O
/	O
Fio2	O
.	O

Multicenter	O
study	O
in	O
19	O
reference	O
centers	O
for	O
ARDS	B-DISO
.	O

Anaesthesiological	O
ICU	O
,	O
referral	O
centre	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
therapy	O
,	O
university	O
hospital	O
.	O

Nevertheless	O
,	O
the	O
title	O
compounds	O
retained	O
low	O
potency	O
against	O
HIV	B-DISO
-	O
1	O
strains	O
carrying	O
mutations	O
(	O
K103R	O
,	O
Y181C	O
,	O
and	O
K103N	O
/	O
Y181C	O
)	O
responsible	O
for	O
NNRTI	O
resistance	O
.	O

TITLE	O
:	O
Ventilation	O
by	O
the	O
Open	O
Lung	O
Concept	O
in	O
spite	O
of	O
traumatic	B-DISO
lung	I-DISO
herniation	B-DISO
.	O

Collectively	O
,	O
the	O
results	O
of	O
this	O
study	O
define	O
both	O
viral	O
and	O
host	O
factors	O
necessary	O
for	O
induction	O
of	O
fgl2	O
prothrombinase	O
gene	O
transcription	O
in	O
MHV	O
infection	B-DISO
and	O
may	O
provide	O
an	O
explanation	O
for	O
the	O
hepatotrophic	O
nature	O
of	O
MHV	O
-	O
induced	O
fulminant	B-DISO
hepatic	I-DISO
failure	I-DISO
.	O

Allergy	B-DISO
was	O
suspected	O
in	O
the	O
first	O
one	O
,	O
and	O
Hemophilus	B-DISO
influenzae	I-DISO
infection	I-DISO
was	O
present	O
in	O
the	O
second	O
.	O

TITLE	O
:	O
Clinical	O
presentation	O
of	O
severe	B-DISO
anemia	I-DISO
in	O
pediatric	O
patients	O
with	O
sickle	B-DISO
cell	I-DISO
anemia	I-DISO
seen	O
in	O
Enugu	O
,	O
Nigeria	O
.	O

In	O
this	O
study	O
,	O
108	O
episodes	O
of	O
severe	B-DISO
anemia	I-DISO
were	O
prospectively	O
evaluated	O
in	O
108	O
patients	O
with	O
hemoglobin	B-DISO
SS	I-DISO
disease	I-DISO
attending	O
the	O
pediatric	O
sickle	O
cell	O
clinic	O
of	O
the	O
University	O
of	O
Nigeria	O
Teaching	O
Hospital	O
,	O
Enugu	O
,	O
Nigeria	O
.	O

Young	O
children	O
between	O
the	O
ages	O
of	O
2	O
and	O
4	O
years	O
were	O
found	O
to	O
be	O
at	O
the	O
greatest	O
risk	O
of	O
developing	O
anemic	O
crises	O
(	O
severe	B-DISO
anemia	I-DISO
).	O

We	O
experienced	O
2	O
cases	O
with	O
M	O
.	O
pneumoniae	O
pneumonia	B-DISO
from	O
identical	O
twin	O
sisters	O
.	O

Although	O
it	O
was	O
necessary	O
for	O
her	O
to	O
be	O
in	O
the	O
intensive	O
care	O
unit	O
for	O
8	O
days	O
,	O
her	O
condition	B-DISO
gradually	O
improved	O
and	O
was	O
discharged	O
on	O
the	O
30th	O
of	O
September	O
.	O

ABSTRACT	O
:	O
Bedside	O
evaluation	O
of	O
pulmonary	O
mechanics	O
and	O
thoracic	B-DISO
computed	O
axial	O
tomography	O
have	O
changed	O
the	O
ventilatory	O
management	O
of	O
patients	O
suffering	B-DISO
an	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
caused	O
by	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Mortality	O
has	O
been	O
reduced	O
limiting	O
tidal	O
volumes	O
,	O
which	O
avoids	O
alveolar	O
overdistention	O
and	O
by	O
the	O
use	O
of	O
positive	O
end	O
expiratory	O
pressure	O
(	O
PEEP	O
),	O
that	O
reduces	O
the	O
damage	O
caused	O
by	O
cyclical	O
alveolar	O
collapse	B-DISO
-	O
reopening	O
.	O

Furthermore	O
,	O
PEP	O
attenuated	O
the	O
oleic	O
acid	O
-	O
induced	O
increase	O
in	O
vascular	O
permeability	O
in	O
the	O
proximal	O
and	O
distal	O
bronchi	O
,	O
as	O
indicated	O
by	O
the	O
extravascular	O
leakage	B-DISO
of	O
Evans	O
Blue	O
dye	O
.	O

Of	O
the	O
proinflammatory	O
cytokines	O
,	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
was	O
present	O
in	O
PF	O
but	O
not	O
in	O
plasma	O
,	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
and	O
interferon	O
-	O
gamma	O
were	O
found	O
in	O
low	O
concentrations	O
in	O
both	O
PF	O
and	O
plasma	O
,	O
and	O
IL	O
-	O
12	O
(	O
p70	O
)	O
was	O
detectable	O
in	O
plasma	O
but	O
not	O
PF	O
.	O

The	O
object	O
of	O
this	O
study	O
was	O
to	O
reexamine	O
prospectively	O
the	O
relationship	O
between	O
the	O
BD	O
during	O
fluid	O
resuscitation	O
and	O
the	O
subsequent	O
development	O
of	O
SIRS	B-DISO
,	O
ARDS	B-DISO
,	O
and	O
MODS	B-DISO
by	O
undertaking	O
a	O
prospective	O
observational	O
study	O
of	O
a	O
cohort	O
of	O
consecutive	O
burn	O
patients	O
.	O

When	O
total	O
static	O
lung	O
compliance	O
decreased	O
to	O
0	O
.	O
15	O
mL	O
(	O
cm	O
H2O	O
)(-	O
1	O
)	O
x	O
kg	O
(-	O
1	O
)	O
(	O
7	O
-	O
30	O
hrs	B-DISO
),	O
the	O
sheep	O
were	O
randomized	O
to	O
two	O
groups	O
.	O

ABSTRACT	O
:	O
Recently	O
open	O
lung	O
approach	O
such	O
as	O
recruitment	B-DISO
maneuver	O
and	O
high	O
PEEP	O
has	O
been	O
applied	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

In	O
ICU	O
we	O
repeated	O
recruitment	B-DISO
maneuver	O
(	O
PEEP	O
:	O
30	O
cmH2O	O
,	O
peak	O
inspiratory	O
pressure	O
:	O
42	O
cmH2O	O
,	O
respiratory	O
rate	O
;	O
15	O
breaths	O
.	O
min	O
-	O
1	O
,	O
for	O
1	O
min	O
)	O
and	O
kept	O
high	O
PEEP	O
(	O
15	O
cmH2O	O
).	O

Histopathological	O
assessment	O
indicated	O
an	O
earlier	O
onset	O
of	O
a	O
regenerative	O
phase	O
in	O
the	O
trachea	B-DISO
of	O
W	O
chicks	O
than	O
in	O
S	O
chicks	O
.	O

The	O
results	O
indicate	O
that	O
chicken	O
lines	O
may	O
differ	O
greatly	O
in	O
their	O
susceptibility	O
to	O
fatal	O
IB	O
nephritis	B-DISO
and	O
that	O
resistance	O
is	O
likely	O
to	O
be	O
under	O
the	O
control	O
of	O
immune	O
responses	O
to	O
viral	B-DISO
infection	I-DISO
.	O

In	O
addition	O
,	O
macrophage	O
accumulation	O
within	O
the	O
CNS	O
was	O
significantly	O
decreased	O
in	O
infected	O
CCL3	O
(-/-)	O
mice	O
,	O
correlating	O
with	O
reduced	O
demyelination	B-DISO
.	O

The	O
vector	O
led	O
to	O
the	O
efficient	O
(>	O
40	O
micro	O
g	O
/	O
10	O
(	O
6	O
)	O
cells	O
)	O
and	O
stable	O
(>	O
20	O
passages	O
)	O
expression	O
of	O
a	O
heterologous	O
gene	O
(	O
green	O
fluorescent	O
protein	O
[	O
GFP	O
]),	O
driven	O
by	O
the	O
transcription	O
-	O
regulating	O
sequences	O
(	O
TRS	B-DISO
)	O
of	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
3a	O
inserted	O
in	O
the	O
site	O
previously	O
occupied	O
by	O
the	O
nonessential	O
ORFs	O
3a	O
and	O
3b	O
.	O

To	O
examine	O
this	O
,	O
we	O
stored	O
tubes	O
containing	O
embryos	O
with	O
tubes	O
containing	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
or	O
Pasteurella	O
pneumotropica	O
in	O
liquid	O
nitrogen	O
tanks	O
and	O
examined	O
whether	O
progeny	O
mice	O
derived	O
from	O
the	O
embryos	O
were	O
contaminated	O
with	O
the	O
pathogens	O
or	O
not	O
.	O

TITLE	O
:	O
Bronchiolitis	B-DISO
obliterans	I-DISO
:	O
the	O
Achilles	O
heel	O
of	O
lung	O
transplantation	O
.	O

Chronic	O
lung	B-DISO
transplant	I-DISO
rejection	I-DISO
Bronchiolitis	B-DISO
obliterans	I-DISO
(	O
BO	O
)	O
is	O
an	O
inflammatory	O
process	O
that	O
leads	O
to	O
fibrous	O
scarring	B-DISO
of	O
the	O
terminal	O
and	O
respiratory	O
bronchioles	O
and	O
subsequent	O
total	O
occlusion	B-DISO
of	O
the	O
airways	O
.	O

Particularly	O
the	O
role	O
of	O
VEGF	O
in	O
the	O
development	O
of	O
sepsis	B-DISO
-	O
induced	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
mechanically	O
ventilated	O
patients	O
suffering	B-DISO
from	O
severe	B-DISO
sepsis	I-DISO
remains	O
to	O
be	O
clarified	O
.	O

Despite	O
two	O
major	O
advances	O
in	O
treatment	O
,	O
low	O
VT	O
ventilation	O
for	O
ALI	O
/	O
ARDS	B-DISO
and	O
activated	O
protein	O
C	O
for	O
severe	B-DISO
sepsis	I-DISO
(	O
the	O
leading	O
cause	O
of	O
ALI	O
/	O
ARDS	B-DISO
),	O
additional	O
research	O
is	O
needed	O
to	O
develop	O
specific	O
treatments	O
and	O
improve	O
understanding	O
of	O
the	O
pathogenesis	B-DISO
of	O
these	O
syndromes	B-DISO
.	O

Nonneutralizing	O
monoclonal	O
Abs	O
specific	O
for	O
the	O
spike	O
,	O
matrix	O
,	O
and	O
nucleocapsid	O
proteins	O
did	O
not	O
prevent	O
recrudescence	O
,	O
demonstrating	O
that	O
neutralization	O
is	O
critical	O
for	O
maintaining	O
JHM	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
persistence	O
within	O
the	O
central	O
nervous	B-DISO
system	O
.	O

This	O
report	O
describes	O
the	O
scope	O
of	O
the	O
outbreak	O
,	O
preliminary	O
case	O
definition	O
,	O
and	O
interim	O
infection	B-DISO
control	O
guidance	O
for	O
the	O
United	O
States	O
.	O

TITLE	O
:	O
[	O
Evidence	O
-	O
based	O
medicine	O
of	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
].	O

Since	O
the	O
Norwalk	O
virus	O
was	O
identified	O
as	O
a	O
cause	O
of	O
gastroenteritis	B-DISO
,	O
the	O
number	O
of	O
viral	O
agents	O
associated	O
with	O
diarrheal	B-DISO
disease	I-DISO
in	O
humans	O
has	O
steadily	O
increased	O
.	O

Other	O
viruses	O
,	O
such	O
as	O
toroviruses	O
,	O
coronaviruses	O
,	O
picobirnaviruses	O
and	O
pestiviruses	O
,	O
are	O
increasingly	O
being	O
identified	O
as	O
causative	O
agents	O
of	O
diarrhea	B-DISO
.	O

It	O
has	O
been	O
demonstrated	O
that	O
MHV	O
-	O
specific	O
CD4	O
and	O
CD8	O
T	O
cells	O
are	O
capable	O
of	O
causing	O
demyelination	B-DISO
independent	O
of	O
the	O
other	O
T	O
cell	O
subset	O
.	O

The	O
ability	O
of	O
bystander	O
CD4	O
T	O
cells	O
to	O
mediate	O
demyelination	B-DISO
was	O
investigated	O
using	O
CD4	O
T	O
cell	O
transgenic	O
mice	O
.	O

TITLE	O
:	O
Identification	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
Canada	O
.	O

Lymphopenia	B-DISO
(	O
in	O
89	O
percent	O
of	O
those	O
for	O
whom	O
data	O
were	O
available	O
),	O
elevated	O
lactate	O
dehydrogenase	O
levels	O
(	O
in	O
80	O
percent	O
),	O
elevated	O
aspartate	O
aminotransferase	O
levels	O
(	O
in	O
78	O
percent	O
),	O
and	O
elevated	O
creatinine	O
kinase	O
levels	O
(	O
in	O
56	O
percent	O
)	O
were	O
common	O
.	O

We	O
abstracted	O
data	O
on	O
the	O
clinical	O
presentation	O
and	O
course	O
of	O
disease	O
in	O
10	O
epidemiologically	O
linked	O
Chinese	O
patients	O
(	O
5	O
men	O
and	O
5	O
women	O
38	O
to	O
72	O
years	O
old	O
)	O
in	O
whom	O
SARS	B-DISO
was	O
diagnosed	O
between	O
February	O
22	O
,	O
2003	O
,	O
and	O
March	O
22	O
,	O
2003	O
,	O
at	O
our	O
hospitals	O
in	O
Hong	O
Kong	O
,	O
China	O
.	O

Many	O
factors	O
have	O
been	O
associated	O
with	O
this	O
syndrome	B-DISO
which	O
include	O
electrolyte	B-DISO
imbalance	I-DISO
,	O
systemic	B-DISO
infection	I-DISO
,	O
drugs	O
,	O
and	O
occasionally	O
,	O
neurologic	O
disease	O
.	O

ABSTRACT	O
:	O
A	O
neonate	O
receiving	O
hyperalimentation	B-DISO
through	O
a	O
peripherally	O
inserted	O
central	O
catheter	O
(	O
PICC	O
)	O
had	O
acute	O
abdominal	O
distension	B-DISO
and	O
respiratory	B-DISO
distress	I-DISO
.	O

The	O
lesions	O
were	O
characterised	O
by	O
necrotising	B-DISO
bronchiolitis	I-DISO
,	O
septal	O
infiltration	B-DISO
with	O
mononuclear	O
cells	O
,	O
and	O
a	O
mixed	O
alveolar	O
exudate	O
.	O

ABSTRACT	O
:	O
CDC	O
continues	O
to	O
support	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
in	O
the	O
investigation	O
of	O
a	O
multicountry	O
outbreak	O
of	O
unexplained	O
atypical	B-DISO
pneumonia	I-DISO
referred	O
to	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

This	O
report	O
summarizes	O
the	O
clinical	O
description	O
of	O
patients	O
with	O
SARS	B-DISO
based	O
on	O
information	O
collected	O
since	O
mid	O
-	O
February	O
2003	O
by	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
),	O
Health	O
Canada	O
,	O
and	O
CDC	O
in	O
collaboration	O
with	O
health	O
authorities	O
and	O
clinicians	O
in	O
Hong	O
Kong	O
,	O
Taiwan	O
,	O
Bangkok	O
,	O
Singapore	O
,	O
the	O
United	O
Kingdom	O
,	O
Slovenia	O
,	O
Canada	O
,	O
and	O
the	O
United	O
States	O
.	O

SARS	B-DISO
is	O
a	O
serious	O
respiratory	O
illness	O
that	O
led	O
to	O
significant	O
morbidity	O
and	O
mortality	O
in	O
our	O
cohort	O
.	O

Neutrophils	O
and	O
their	O
cytotoxic	O
products	O
,	O
including	O
oxidants	O
and	O
proteases	O
,	O
such	O
as	O
elastase	O
,	O
have	O
been	O
implicated	O
as	O
playing	O
a	O
key	O
role	O
in	O
the	O
pathophysiology	O
of	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Chronic	B-DISO
alcohol	I-DISO
abuse	I-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
and	O
multiple	O
organ	O
dysfunction	O
.	O

A	O
summary	O
of	O
published	O
medical	O
literature	O
from	O
MEDLINE	O
search	O
files	O
and	O
other	O
reviews	O
published	O
concerning	O
chronic	B-DISO
alcohol	I-DISO
abuse	I-DISO
and	O
critical	B-DISO
illness	I-DISO
.	O

A	O
history	O
of	O
chronic	B-DISO
alcohol	I-DISO
abuse	I-DISO
is	O
associated	O
with	O
an	O
increased	O
incidence	O
and	O
severity	O
of	O
ARDS	B-DISO
in	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

In	O
two	O
separate	O
epidemiologic	O
studies	O
,	O
involving	O
571	O
intensive	O
care	O
patients	O
,	O
chronic	B-DISO
alcohol	I-DISO
abuse	I-DISO
was	O
a	O
significant	O
comorbid	O
variable	O
that	O
increased	O
the	O
incidence	O
of	O
ARDS	B-DISO
by	O
nearly	O
three	O
-	O
fold	O
and	O
was	O
associated	O
with	O
more	O
severe	O
nonpulmonary	O
organ	O
dysfunction	O
.	O

More	O
importantly	O
,	O
similar	O
changes	O
have	O
been	O
reported	O
in	O
humans	O
with	O
a	O
history	O
of	O
chronic	B-DISO
alcohol	I-DISO
abuse	I-DISO
.	O

Individuals	O
with	O
a	O
history	O
of	O
chronic	B-DISO
alcohol	I-DISO
abuse	I-DISO
have	O
decreased	O
concentrations	O
of	O
glutathione	O
in	O
the	O
epithelial	O
lining	O
fluid	O
of	O
the	O
lung	O
,	O
which	O
do	O
not	O
significantly	O
increase	O
after	O
1	O
wk	O
of	O
abstinence	O
from	O
alcohol	O
.	O

Chronic	B-DISO
alcohol	I-DISO
abuse	I-DISO
is	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
ARDS	B-DISO
and	O
the	O
severity	O
of	O
multiple	O
organ	O
dysfunction	O
.	O

This	O
research	O
has	O
implications	O
in	O
understanding	O
the	O
diagnosis	O
of	O
,	O
and	O
prognosis	O
for	O
,	O
critically	B-DISO
ill	I-DISO
patients	O
who	O
are	O
at	O
risk	O
of	O
developing	O
ARDS	B-DISO
.	O

The	O
National	O
Heart	O
,	O
Lung	O
,	O
and	O
Blood	O
Institute	O
'	O
s	O
ARDS	B-DISO
Network	O
currently	O
is	O
testing	O
the	O
use	O
of	O
methylprednisolone	O
in	O
late	O
ARDS	B-DISO
.	O

Some	O
patients	O
with	O
pressor	O
-	O
dependent	O
severe	B-DISO
sepsis	I-DISO
appear	O
to	O
have	O
relative	O
adrenal	B-DISO
insufficiency	I-DISO
and	O
benefit	O
from	O
replacement	O
glucocorticoid	O
/	O
mineralocorticoid	O
therapy	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
treatment	O
groups	O
in	O
the	O
prevalence	O
of	O
barotrauma	O
,	O
hemodynamic	B-DISO
instability	I-DISO
,	O
or	O
mucus	B-DISO
plugging	I-DISO
.	O

ABSTRACT	O
:	O
To	O
review	O
the	O
rationale	O
for	O
evaluating	O
anticoagulant	O
therapies	O
in	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
to	O
review	O
selected	O
data	O
regarding	O
the	O
effectiveness	O
of	O
anticoagulants	O
in	O
animals	O
and	O
human	O
patients	O
with	O
ALI	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

In	O
humans	O
,	O
a	O
phase	O
II	O
study	O
evaluating	O
tissue	O
factor	O
pathway	O
inhibitor	O
in	O
the	O
treatment	O
of	O
severe	B-DISO
sepsis	I-DISO
suggested	O
that	O
lung	O
function	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
was	O
improved	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
characterized	O
by	O
a	O
marked	O
maldistribution	O
of	O
pulmonary	O
perfusion	O
in	O
favor	O
of	O
nonventilated	O
,	O
atelectatic	O
areas	O
of	O
the	O
lungs	O
,	O
and	O
it	O
is	O
the	O
main	O
cause	O
of	O
pulmonary	O
right	O
-	O
to	O
-	O
left	O
shunting	O
and	O
hypoxemia	O
.	O

Clinical	O
studies	O
in	O
ARDS	B-DISO
subsequently	O
demonstrated	O
that	O
the	O
combination	O
of	O
inhaled	O
nitric	O
oxide	O
with	O
other	O
interventions	O
,	O
such	O
as	O
positive	O
end	O
-	O
expiratory	O
pressure	O
and	O
prone	O
positioning	O
,	O
yielded	O
beneficial	O
and	O
additive	O
effects	O
on	O
arterial	O
oxygenation	O
.	O

ABSTRACT	O
:	O
In	O
1914	O
,	O
Schottmueller	O
wrote	O
""""	O
Septicemia	B-DISO
is	O
a	O
state	O
of	O
microbial	O
invasion	B-DISO
from	O
a	O
portal	O
of	O
entry	O
into	O
the	O
blood	O
stream	O
which	O
causes	O
signs	O
of	O
illness	O
.	O

Sepsis	B-DISO
and	O
its	O
sequelae	O
represent	O
a	O
continuum	O
of	O
clinical	O
syndrome	B-DISO
encompassing	O
systemic	O
inflammation	B-DISO
,	O
coagulopathy	B-DISO
,	O
and	O
hemodynamic	O
abnormalities	O
.	O

Severe	B-DISO
sepsis	I-DISO
and	O
septic	B-DISO
shock	I-DISO
continue	O
to	O
be	O
the	O
major	O
causes	O
of	O
morbidity	O
and	O
mortality	O
in	O
the	O
United	O
States	O
;	O
sepsis	B-DISO
deaths	O
currently	O
match	O
mortality	O
from	O
myocardial	B-DISO
infarction	I-DISO
.	O

Despite	O
significant	O
advances	O
in	O
our	O
understanding	O
of	O
the	O
pathophysiology	O
and	O
technological	O
innovations	O
in	O
the	O
supportive	O
management	O
,	O
mortality	O
from	O
septic	B-DISO
shock	I-DISO
remains	O
excessive	O
.	O

Clinical	O
specimens	O
from	O
patients	O
with	O
SARS	B-DISO
were	O
searched	O
for	O
unknown	O
viruses	O
with	O
the	O
use	O
of	O
cell	O
cultures	O
and	O
molecular	O
techniques	O
.	O

TITLE	O
:	O
A	O
novel	O
coronavirus	O
associated	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
A	O
worldwide	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
has	O
been	O
associated	O
with	O
exposures	O
originating	O
from	O
a	O
single	O
ill	B-DISO
health	O
care	O
worker	O
from	O
Guangdong	O
Province	O
,	O
China	O
.	O

TITLE	O
:	O
Human	O
papillomavirus	O
type	O
16	O
E7	O
peptide	O
-	O
directed	O
CD8	O
+	O
T	O
cells	O
from	O
patients	O
with	O
cervical	B-DISO
cancer	I-DISO
are	O
cross	O
-	O
reactive	O
with	O
the	O
coronavirus	O
NS2	B-DISO
protein	O
.	O

As	O
of	O
April	O
2	O
,	O
2003	O
,	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
has	O
reported	O
2236	O
cases	O
and	O
78	O
deaths	O
related	O
to	O
outbreaks	O
of	O
a	O
severe	O
form	O
of	O
pneumonia	B-DISO
of	O
unknown	O
origin	O
in	O
Hong	O
Kong	O
SAR	O
,	O
Vietnam	O
,	O
Guangdong	O
province	O
in	O
southern	O
China	O
,	O
Canada	O
,	O
Singapore	O
,	O
and	O
Thailand	O
,	O
which	O
appears	O
to	O
have	O
spread	O
rapidly	O
.	O

For	O
this	O
reason	O
,	O
the	O
Director	O
General	O
of	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
issued	O
a	O
global	O
alert	O
about	O
cases	O
of	O
atypical	B-DISO
pneumonia	I-DISO
and	O
recommended	O
that	O
travelers	O
with	O
atypical	B-DISO
pneumonia	I-DISO
who	O
may	O
be	O
related	O
to	O
these	O
outbreaks	O
be	O
placed	O
into	O
isolation	O
and	O
assessed	O
by	O
quarantine	O
officials	O
.	O

In	O
addition	O
,	O
calves	O
shedding	O
>	O
or	O
=	O
2	O
enteric	O
pathogens	O
were	O
more	O
likely	O
to	O
have	O
diarrhea	B-DISO
than	O
calves	O
shedding	O
<	O
or	O
=	O
1	O
pathogen	O
.	O

Though	O
acute	B-DISO
graft	I-DISO
-	I-DISO
versus	I-DISO
-	I-DISO
host	I-DISO
disease	I-DISO
(	O
GVHD	B-DISO
)	O
of	O
systemic	O
skin	O
(	O
grade	O
II	O
)	O
and	O
pneumonia	B-DISO
were	O
observed	O
during	O
neutropenia	O
due	O
to	O
the	O
post	O
-	O
conditioning	O
regimen	O
,	O
he	O
could	O
be	O
discharged	O
from	O
our	O
hospital	O
on	O
the	O
135th	O
day	O
after	O
BMT	O
.	O

ABSTRACT	O
:	O
As	O
of	O
23	O
March	O
,	O
2003	O
,	O
11	O
cases	O
of	O
SARS	B-DISO
have	O
been	O
reported	O
in	O
Canada	O
.	O

We	O
analysed	O
case	O
notes	O
and	O
microbiological	O
findings	O
for	O
50	O
patients	O
with	O
SARS	B-DISO
,	O
representing	O
more	O
than	O
five	O
separate	O
epidemiologically	O
linked	O
transmission	O
clusters	O
.	O

Patients	O
who	O
were	O
household	O
contacts	O
of	O
other	O
infected	O
people	O
and	O
had	O
older	O
age	O
,	O
lymphopenia	B-DISO
,	O
and	O
liver	B-DISO
dysfunction	I-DISO
were	O
associated	O
with	O
severe	O
disease	O
.	O

Serological	O
and	O
molecular	O
tests	O
specific	O
for	O
the	O
virus	O
permitted	O
a	O
definitive	O
laboratory	O
diagnosis	O
to	O
be	O
made	O
and	O
allowed	O
further	O
investigation	O
to	O
define	O
whether	O
other	O
cofactors	O
play	O
a	O
part	O
in	O
disease	B-DISO
progression	I-DISO
.	O

TCV	O
infection	B-DISO
was	O
detected	O
in	O
turkeys	O
placed	O
in	O
contact	O
with	O
TCV	O
-	O
exposed	O
flies	O
at	O
densities	O
as	O
low	O
as	O
one	O
fly	O
/	O
bird	O
(	O
TCV	O
antigens	O
detected	O
at	O
3	O
days	O
post	O
fly	O
contact	O
in	O
tissues	O
of	O
3	O
/	O
12	O
turkeys	O
);	O
however	O
,	O
increased	O
rates	O
of	O
infection	B-DISO
were	O
observed	O
with	O
higher	O
fly	O
densities	O
(	O
TCV	O
antigens	O
detected	O
in	O
9	O
/	O
12	O
turkeys	O
after	O
contact	O
with	O
10	O
flies	O
/	O
bird	O
).	O

We	O
hypothesized	O
that	O
blockade	O
of	O
tissue	O
factor	O
would	O
also	O
attenuate	O
these	O
injuries	O
in	O
established	O
sepsis	B-DISO
by	O
prevention	O
of	O
further	O
fibrin	B-DISO
deposition	I-DISO
and	O
inflammation	B-DISO
.	O

Coagulopathy	B-DISO
was	O
attenuated	O
,	O
and	O
plasma	O
interleukin	O
-	O
6	O
,	O
interleukin	O
-	O
8	O
,	O
and	O
soluble	O
tumor	B-DISO
necrosis	I-DISO
factor	O
receptor	O
-	O
1	O
levels	O
were	O
significantly	O
lower	O
in	O
the	O
treated	O
animals	O
.	O

In	O
addition	O
,	O
following	O
infection	B-DISO
of	O
10	O
-	O
day	O
-	O
old	O
chicken	O
embryos	O
with	O
IBV	O
containing	O
D	O
-	O
RNAs	O
expressing	O
chIFN	O
-	O
gamma	O
,	O
the	O
allantoic	O
fluid	O
was	O
shown	O
to	O
contain	O
biologically	O
active	O
chIFN	O
-	O
gamma	O
,	O
demonstrating	O
that	O
IBV	O
D	O
-	O
RNAs	O
can	O
express	O
heterologous	O
genes	O
in	O
vivo	O
.	O

TITLE	O
:	O
Update	O
:	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
--	O
worldwide	O
,	O
2003	O
.	O

Epidemiologic	O
and	O
laboratory	O
investigations	O
of	O
SARS	B-DISO
are	O
ongoing	O
.	O

As	O
of	O
April	O
2	O
,	O
2003	O
,	O
a	O
total	O
of	O
2	O
,	O
223	O
suspected	O
and	O
/	O
or	O
probable	O
SARS	B-DISO
cases	O
have	O
been	O
reported	O
to	O
WHO	O
from	O
16	O
countries	O
,	O
including	O
the	O
United	O
States	O
.	O

TITLE	O
:	O
The	O
Genome	O
sequence	O
of	O
the	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
.	O

The	O
mortality	O
in	O
patients	O
with	O
abdominal	B-DISO
compartment	I-DISO
syndrome	I-DISO
is	O
over	O
40	O
%,	O
even	O
when	O
adequately	O
treated	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
coronavirus	O
testing	O
--	O
United	O
States	O
,	O
2003	O
.	O

ABSTRACT	O
:	O
CDC	O
and	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
are	O
continuing	O
to	O
investigate	O
the	O
multicountry	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
an	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
that	O
first	O
manifested	O
in	O
humans	O
in	O
China	O
in	O
November	O
2002	O
and	O
has	O
subsequently	O
spread	O
worldwide	O
.	O

Features	O
of	O
the	O
clinical	O
examination	O
most	O
commonly	O
found	O
in	O
these	O
patients	O
at	O
admission	O
were	O
self	O
-	O
reported	O
fever	O
(	O
99	O
%),	O
documented	O
elevated	O
temperature	O
(	O
85	O
%),	O
nonproductive	B-DISO
cough	I-DISO
(	O
69	O
%),	O
myalgia	B-DISO
(	O
49	O
%),	O
and	O
dyspnea	B-DISO
(	O
42	O
%).	O

Multivariable	O
analysis	O
showed	O
that	O
the	O
presence	O
of	O
diabetes	B-DISO
(	O
relative	O
risk	O
[	O
RR	O
],	O
3	O
.	O
1	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
4	O
-	O
7	O
.	O
2	O
;	O
P	O
=.	O
01	O
)	O
or	O
other	O
comorbid	O
conditions	O
(	O
RR	O
,	O
2	O
.	O
5	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
5	O
.	O
8	O
;	O
P	O
=.	O
03	O
)	O
were	O
independently	O
associated	O
with	O
poor	O
outcome	O
(	O
death	O
,	O
ICU	O
admission	O
,	O
or	O
mechanical	O
ventilation	O
).	O

Other	O
enteric	O
organisms	O
detected	O
alone	O
or	O
in	O
combination	O
with	O
BoTV	O
in	O
calf	O
samples	O
were	O
rotavirus	O
,	O
coronavirus	O
,	O
Salmonella	B-DISO
spp	O
.,	O
Cryptosporidium	O
spp	O
.,	O
and	O
Giardia	B-DISO
spp	O
.;	O
but	O
no	O
consistent	O
association	O
between	O
BoTV	O
and	O
these	O
organisms	O
was	O
observed	O
.	O

We	O
suggest	O
that	O
diseases	O
classified	O
as	O
IB	O
in	O
this	O
study	O
might	O
be	O
homogeneous	O
entities	O
which	O
are	O
clinically	O
and	O
radiologically	O
similar	O
to	O
DPB	B-DISO
.	O

CONCLUSIONS	O
:	O
Eclampsia	B-DISO
is	O
a	O
major	O
cause	O
of	O
both	O
maternal	O
and	O
infantile	O
mortality	O
in	O
developing	O
countries	O
.	O

Research	O
into	O
identifying	O
the	O
etiological	O
agent	O
,	O
evaluating	O
modes	O
of	O
disease	B-DISO
transmission	I-DISO
,	O
and	O
treatment	O
options	O
is	O
currently	O
ongoing	O
.	O

TITLE	O
:	O
[	O
Congenital	B-DISO
tracheal	I-DISO
stenosis	I-DISO
due	O
to	O
complete	O
cartilage	O
rings	O
with	O
right	O
pulmonary	B-DISO
agenesis	I-DISO
].	O

Chest	O
X	O
-	O
ray	O
immediately	O
after	O
the	O
operation	O
did	O
not	O
show	O
left	O
lung	O
reexpansion	O
due	O
to	O
severe	O
pulmonary	B-DISO
edema	I-DISO
.	O

He	O
died	O
from	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
due	O
to	O
infantile	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
IRDS	O
)	O
on	O
postoperative	O
day	O
3	O
.	O

The	O
outcome	O
in	O
this	O
case	O
shows	O
that	O
it	O
is	O
very	O
risky	O
to	O
repair	O
tracheal	B-DISO
stenosis	I-DISO
in	O
a	O
patient	O
with	O
pneumonia	B-DISO
using	O
PCPS	O
.	O

RESULTS	O
:	O
In	O
a	O
4	O
-	O
week	O
period	O
,	O
19	O
individuals	O
developed	O
SARS	B-DISO
,	O
including	O
11	O
health	O
care	O
workers	O
.	O

It	O
is	O
a	O
rare	O
,	O
but	O
rather	O
benign	O
pulmonary	B-DISO
edema	I-DISO
.	O

TITLE	O
:	O
Development	O
of	O
a	O
standard	O
treatment	O
protocol	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
31	O
patients	O
with	O
probable	O
SARS	B-DISO
,	O
diagnosed	O
from	O
WHO	O
criteria	O
,	O
were	O
treated	O
according	O
to	O
a	O
treatment	O
protocol	O
consisting	O
of	O
antibacterials	O
and	O
a	O
combination	O
of	O
ribavirin	O
and	O
methylprednisolone	O
.	O

Import	O
infections	B-DISO
appeared	O
in	O
many	O
other	O
parts	O
of	O
the	O
world	O
.	O

Close	O
contacts	O
with	O
SARS	B-DISO
patients	O
does	O
not	O
regularly	O
result	O
in	O
full	O
development	O
of	O
the	O
disease	O
.	O

SARS	B-DISO
is	O
a	O
new	O
and	O
highly	O
contagious	O
lung	B-DISO
disease	I-DISO
.	O

RESULTS	O
:	O
Two	O
of	O
the	O
three	O
patients	O
under	O
our	O
care	O
developed	O
SARS	B-DISO
disease	O
.	O

This	O
report	O
updates	O
information	O
on	O
reported	O
SARS	B-DISO
cases	O
worldwide	O
and	O
among	O
U	O
.	O
S	O
.	O
residents	O
and	O
summarizes	O
information	O
on	O
one	O
additional	O
case	O
with	O
laboratory	O
evidence	O
of	O
infection	B-DISO
with	O
the	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
).	O

Specific	O
fragments	O
were	O
amplified	O
from	O
the	O
sputum	O
samples	O
of	O
SARS	B-DISO
patients	O
,	O
which	O
were	O
confirmed	O
by	O
DNA	O
cloning	O
and	O
sequencing	O
to	O
belong	O
to	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
.	O

Sequence	O
analysis	O
has	O
confirmed	O
the	O
existence	O
of	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
in	O
the	O
sputum	O
samples	O
of	O
SARS	B-DISO
patients	O
,	O
and	O
nested	O
RT	O
-	O
PCR	O
is	O
a	O
quick	O
,	O
easy	O
,	O
and	O
convenient	O
way	O
for	O
the	O
detection	O
of	O
the	O
virus	O
.	O

The	O
Result	O
of	O
Blast	O
shows	O
only	O
the	O
difference	O
in	O
one	O
nucleic	O
acid	O
from	O
the	O
TOR2	O
strain	O
of	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
.	O

All	O
the	O
obtained	O
sequences	O
were	O
compared	O
with	O
the	O
sequence	O
of	O
published	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
,	O
and	O
alignment	O
was	O
proceeded	O
with	O
other	O
coronavirus	O
sequences	O
.	O

All	O
of	O
them	O
possessed	B-DISO
100	O
%	O
homology	O
with	O
the	O
published	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
sequence	O
,	O
while	O
all	O
the	O
negative	O
controls	O
were	O
RT	O
-	O
PCR	O
negative	O
.	O

The	O
polymerase	O
fragment	O
BNI109	O
of	O
SARS	B-DISO
coronavirus	O
is	O
highly	O
conservative	O
and	O
is	O
suitable	O
for	O
detecting	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
using	O
RT	O
-	O
PCR	O
method	O
.	O

This	O
catheter	O
was	O
effective	O
in	O
protecting	O
the	O
visceral	O
organs	O
and	O
the	O
spinal	O
cord	B-DISO
in	O
the	O
repair	O
of	O
an	O
aortic	B-DISO
arch	I-DISO
aneurysm	I-DISO
.	O

Initial	O
focal	O
air	O
-	O
space	O
opacity	B-DISO
in	O
44	O
of	O
59	O
patients	O
(	O
74	O
.	O
6	O
%)	O
progressed	O
to	O
unilateral	O
multifocal	O
or	O
bilateral	O
involvement	O
during	O
treatment	O
.	O

Initial	O
focal	O
air	O
-	O
space	O
opacity	B-DISO
in	O
44	O
of	O
59	O
patients	O
(	O
74	O
.	O
6	O
%)	O
progressed	O
to	O
unilateral	O
multifocal	O
or	O
bilateral	O
involvement	O
during	O
treatment	O
.	O

Among	O
the	O
new	O
-	O
onset	O
cases	O
,	O
22	O
%	O
were	O
consistent	O
with	O
reactive	B-DISO
airways	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
.	O

Further	O
work	O
to	O
characterize	O
the	O
specific	O
agents	O
and	O
the	O
circumstances	O
of	O
their	O
use	O
associated	O
with	O
asthma	B-DISO
is	O
needed	O
.	O

TITLE	O
:	O
SARS	B-DISO
:	O
current	O
knowledge	O
and	O
management	O
.	O

This	O
article	O
describes	O
current	O
knowledge	O
of	O
the	O
infection	B-DISO
and	O
outlines	O
the	O
management	O
of	O
SARS	B-DISO
in	O
the	O
UK	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
recently	O
described	O
illness	O
of	O
humans	O
that	O
has	O
spread	O
widely	O
over	O
the	O
past	O
6	O
months	O
.	O

TITLE	O
:	O
A	O
multicentre	O
collaboration	O
to	O
investigate	O
the	O
cause	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Stem	O
-	O
loop	O
III	O
in	O
the	O
5	O
'	O
untranslated	O
region	O
is	O
a	O
cis	B-DISO
-	O
acting	O
element	O
in	O
bovine	O
coronavirus	O
defective	O
interfering	O
RNA	O
replication	O
.	O

No	O
additional	O
cases	O
were	O
identified	O
after	O
infection	B-DISO
control	O
precautions	O
had	O
been	O
implemented	O
for	O
8	O
days	O
.	O

No	O
cases	O
of	O
secondary	B-DISO
transmission	I-DISO
were	O
identified	O
in	O
the	O
21	O
days	O
following	O
the	O
implementation	O
of	O
these	O
precautions	O
at	O
our	O
institution	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
is	O
a	O
frequent	O
complication	B-DISO
of	O
severe	B-DISO
sepsis	I-DISO
or	O
blood	B-DISO
loss	I-DISO
and	O
is	O
often	O
associated	O
with	O
an	O
excessive	O
inflammatory	B-DISO
response	I-DISO
requiring	O
mechanical	O
ventilation	O
.	O

The	O
levels	O
of	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
and	O
macrophage	O
inflammatory	O
protein	O
-	O
2	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
were	O
lower	O
and	O
interleukin	O
-	O
10	O
was	O
higher	O
in	O
the	O
albumin	O
-	O
treated	O
groups	O
than	O
in	O
the	O
Ringer	O
'	O
s	O
lactate	O
group	O
.	O

A	O
57	O
-	O
year	O
-	O
old	O
woman	O
had	O
a	O
typical	O
presentation	O
,	O
including	O
fever	O
,	O
non	B-DISO
-	I-DISO
productive	I-DISO
cough	I-DISO
,	O
malaise	B-DISO
,	O
lymphopenia	B-DISO
,	O
and	O
raised	O
liver	O
aminotransferases	O
.	O

The	O
government	O
has	O
taken	O
strong	O
action	O
to	O
break	O
the	O
chain	O
of	O
infection	B-DISO
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
).	O

In	O
this	O
article	O
,	O
we	O
outline	O
the	O
measures	O
taken	O
to	O
curb	B-DISO
SARS	B-DISO
in	O
Singapore	O
and	O
discuss	O
the	O
implications	O
for	O
Australasian	O
radiation	O
oncology	O
departments	O
.	O

One	O
of	O
the	O
largest	O
outbreaks	O
of	O
SARS	B-DISO
to	O
date	O
began	O
in	O
Singapore	O
in	O
March	O
2003	O
.	O

ABSTRACT	O
:	O
As	O
of	O
April	O
14	O
,	O
2003	O
,	O
Taiwan	O
had	O
had	O
23	O
probable	O
cases	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
19	O
of	O
which	O
were	O
imported	O
.	O

TITLE	O
:	O
Clinical	O
progression	O
and	O
viral	O
load	O
in	O
a	O
community	O
outbreak	O
of	O
coronavirus	O
-	O
associated	O
SARS	B-DISO
pneumonia	B-DISO
:	O
a	O
prospective	O
study	O
.	O

Fever	O
and	O
pneumonia	B-DISO
initially	O
improved	O
but	O
64	O
(	O
85	O
%)	O
patients	O
developed	O
recurrent	B-DISO
fever	I-DISO
after	O
a	O
mean	O
of	O
8	O
.	O
9	O
(	O
SD	O
3	O
.	O
1	O
)	O
days	O
,	O
55	O
(	O
73	O
%)	O
had	O
watery	B-DISO
diarrhoea	I-DISO
after	O
7	O
.	O
5	O
(	O
2	O
.	O
3	O
)	O
days	O
,	O
60	O
(	O
80	O
%)	O
had	O
radiological	O
worsening	O
after	O
7	O
.	O
4	O
(	O
2	O
.	O
2	O
)	O
days	O
,	O
and	O
respiratory	B-DISO
symptoms	I-DISO
worsened	O
in	O
34	O
(	O
45	O
%)	O
after	O
8	O
.	O
6	O
(	O
3	O
.	O
0	O
)	O
days	O
.	O

The	O
consistent	O
clinical	O
progression	O
,	O
shifting	O
radiological	O
infiltrates	B-DISO
,	O
and	O
an	O
inverted	O
V	O
viral	O
-	O
load	O
profile	O
suggest	O
that	O
worsening	O
in	O
week	O
2	O
is	O
unrelated	O
to	O
uncontrolled	O
viral	O
replication	O
but	O
may	O
be	O
related	O
to	O
immunopathological	O
damage	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
novel	O
infectious	B-DISO
disease	I-DISO
with	O
global	O
impact	O
.	O

The	O
patient	O
for	O
whom	O
full	O
autopsy	O
was	O
done	O
had	O
atrophy	B-DISO
of	O
the	O
white	O
pulp	O
of	O
the	O
spleen	O
.	O

One	O
genotype	O
was	O
linked	O
with	O
infections	B-DISO
originating	O
in	O
Hotel	O
M	O
in	O
Hong	O
Kong	O
,	O
the	O
second	O
contained	O
isolates	O
from	O
Hong	O
Kong	O
,	O
Guangzhou	O
,	O
and	O
Beijing	O
with	O
no	O
association	O
with	O
Hotel	O
M	O
(	O
p	O
<	O
0	O
.	O
0001	O
).	O

Despite	O
the	O
recent	O
onset	O
of	O
the	O
SARS	B-DISO
epidemic	O
,	O
genetic	O
signatures	O
are	O
emerging	O
that	O
partition	O
the	O
worldwide	O
SARS	B-DISO
viral	O
isolates	O
into	O
groups	O
on	O
the	O
basis	O
of	O
contact	O
source	O
history	O
and	O
geography	O
.	O

In	O
addition	O
,	O
a	O
common	O
variant	O
associated	O
with	O
a	O
non	O
-	O
conservative	O
aminoacid	O
change	O
in	O
the	O
S1	O
region	O
of	O
the	O
spike	O
protein	O
,	O
suggests	O
that	O
immunological	O
pressures	O
might	O
be	O
starting	O
to	O
influence	O
the	O
evolution	O
of	O
the	O
SARS	B-DISO
virus	O
in	O
human	O
populations	O
.	O

ABSTRACT	O
:	O
An	O
investigation	O
into	O
the	O
causes	O
of	O
canine	O
infectious	B-DISO
respiratory	B-DISO
disease	I-DISO
was	O
carried	O
out	O
in	O
a	O
large	O
rehoming	O
kennel	O
.	O

The	O
evolution	O
was	O
independent	O
of	O
tumor	B-DISO
marker	O
levels	O
and	O
the	O
type	O
of	O
chemotherapy	O
regimen	O
.	O

The	O
fnRT	O
-	O
PCR	O
assays	O
were	O
also	O
able	O
to	O
detect	O
viral	O
RNA	O
in	O
respiratory	O
tract	O
tissues	O
and	O
cage	O
swipe	O
specimens	O
collected	O
from	O
experimentally	O
inoculated	O
C	O
.	O
B	O
-	O
17	O
severe	O
combined	O
immunodeficient	B-DISO
mice	O
,	O
but	O
did	O
not	O
detect	O
viral	O
RNA	O
in	O
age	O
-	O
and	O
strain	O
-	O
matched	O
mock	O
-	O
infected	O
mice	O
.	O

In	O
conclusion	O
,	O
these	O
fnRT	O
-	O
PCR	O
assays	O
offer	O
potentially	O
high	O
-	O
throughput	O
diagnostic	O
assays	O
to	O
detect	O
Sendai	O
virus	O
and	O
PVM	O
in	O
immunodeficient	B-DISO
mice	O
,	O
and	O
to	O
detect	O
Sendai	O
virus	O
in	O
contaminated	O
biological	O
materials	O
.	O

Helicobacter	O
hepaticus	O
appeared	O
to	O
reduce	O
the	O
severity	O
of	O
MHV	O
-	O
induced	O
lesions	O
during	O
the	O
acute	O
phase	O
of	O
infection	B-DISO
,	O
and	O
exacerbated	O
hepatitis	B-DISO
and	O
meningitis	B-DISO
at	O
the	O
later	O
time	O
point	O
.	O

TITLE	O
:	O
Detection	O
of	O
feline	O
coronavirus	B-DISO
infection	I-DISO
in	O
captive	O
cheetahs	O
(	O
Acinonyx	O
jubatus	O
)	O
by	O
polymerase	O
chain	O
reaction	O
.	O

Testing	O
of	O
samples	O
from	O
one	O
population	O
over	O
a	O
1	O
-	O
yr	O
period	O
indicated	O
chronic	B-DISO
infection	I-DISO
in	O
some	O
animals	O
.	O

The	O
harmful	O
effects	O
on	O
the	O
lung	O
tissues	O
and	O
resident	O
leucocytes	O
of	O
these	O
malignant	O
factors	O
are	O
suspected	O
to	O
be	O
profoundly	O
involved	O
in	O
TRALI	B-DISO
reactions	O
.	O

However	O
,	O
the	O
precise	O
mechanisms	O
of	O
TRALI	B-DISO
development	O
remain	O
unclear	O
.	O

Furthermore	O
,	O
FcepsilonRI	O
expression	O
,	O
in	O
GM	O
-	O
CSF	O
-	O
treated	O
PMNs	O
,	O
suggests	O
the	O
involvement	O
of	O
PMNs	O
in	O
IgE	B-DISO
-	O
mediated	O
immune	O
reactions	O
.	O

The	O
tested	O
virtual	O
screening	O
indicated	O
that	O
73	O
available	O
proteinase	O
inhibitors	O
in	O
the	O
MDDR	O
database	O
might	O
dock	O
into	O
both	O
the	O
binding	O
pockets	O
of	O
the	O
TGEV	O
Mpro	O
and	O
the	O
SARS	B-DISO
-	O
CoV	O
3CL	O
proteinase	O
.	O

The	O
plasmid	O
of	O
SARS	B-DISO
E	O
protein	O
was	O
constructed	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
),	O
and	O
the	O
protein	O
was	O
expressed	O
in	O
the	O
E	O
coli	O
strain	O
.	O

Bioinformatics	O
analysis	O
indicated	O
that	O
the	O
key	O
residues	O
of	O
SARS	B-DISO
E	O
protein	O
were	O
much	O
conserved	O
compared	O
to	O
the	O
E	O
proteins	O
of	O
other	O
coronaviruses	O
.	O

RESULTS	O
:	O
The	O
pure	O
sample	O
of	O
SARS	B-DISO
E	O
protein	O
was	O
obtained	O
.	O

Demographic	O
and	O
baseline	O
clinical	O
characteristics	O
of	O
the	O
three	O
treatment	O
groups	O
were	O
similar	O
,	O
except	O
for	O
a	O
significantly	O
higher	O
prevalence	O
of	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
as	O
the	O
cause	O
of	O
severe	B-DISO
sepsis	I-DISO
in	O
patients	O
treated	O
with	O
1	O
.	O
0	O
mg	O
/	O
kg	O
rPAF	O
-	O
AH	O
.	O

Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
].	O

Case	O
1	O
(	O
father	O
case	O
):	O
79	O
-	O
year	O
-	O
old	O
male	O
visited	O
a	O
nearby	O
doctor	O
complaining	O
of	O
severe	O
chest	O
and	O
back	B-DISO
pain	I-DISO
.	O

TITLE	O
:	O
[	O
The	O
biological	O
characteristics	O
of	O
SARS	B-DISO
virus	O
and	O
its	O
related	O
coronaviruses	O
].	O

The	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
has	O
promptly	O
established	O
a	O
network	O
of	O
international	O
laboratories	O
consisting	O
of	O
13	O
members	O
around	O
the	O
10	O
countries	O
to	O
facilitate	O
the	O
identification	O
of	O
the	O
causative	O
agent	O
of	O
SARS	B-DISO
.	O

A	O
novel	O
coronavirus	O
,	O
SARS	B-DISO
virus	O
,	O
fulfilling	O
all	O
of	O
Koch	O
'	O
s	O
postulates	O
was	O
announced	O
to	O
be	O
the	O
primary	O
aetiological	O
agent	O
of	O
SARS	B-DISO
on	O
April	O
16	O
by	O
WHO	O
shortly	O
after	O
the	O
Canadian	O
scientists	O
released	O
the	O
full	O
-	O
length	O
genome	O
sequence	O
of	O
SARS	B-DISO
virus	O
(	O
Tor2	O
)	O
on	O
April	O
12	O
.	O

The	O
virus	O
was	O
proved	O
to	O
be	O
a	O
new	O
coronavirus	O
by	O
RT	O
-	O
PCR	O
and	O
it	O
responded	O
positively	O
to	O
convalescent	O
-	O
phase	O
serum	O
specimen	O
from	O
SARS	B-DISO
patients	O
,	O
which	O
is	O
the	O
evidence	O
that	O
this	O
new	O
virus	O
is	O
etiologically	O
linked	O
to	O
the	O
outbreak	O
of	O
SARS	B-DISO
.	O

In	O
birds	O
vaccinated	O
at	O
day	O
6	O
,	O
90	O
-	O
100	O
%	O
protection	O
at	O
the	O
trachea	B-DISO
was	O
induced	O
against	O
either	O
homologous	O
or	O
heterologous	O
challenge	O
.	O

Although	O
precise	O
pathogenic	O
mechanisms	O
have	O
been	O
under	O
debate	O
,	O
the	O
NE	O
-	O
mediated	O
severe	O
pulmonary	O
tissue	O
damage	O
,	O
based	O
upon	O
the	O
protease	O
-	O
antiprotease	O
imbalance	B-DISO
hypothesis	O
,	O
may	O
be	O
a	O
major	O
pathogenic	O
determinant	O
of	O
these	O
diseases	O
,	O
in	O
particular	O
COPD	B-DISO
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
its	O
lesions	O
in	O
digestive	O
system	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
an	O
infectious	B-DISO
atypical	B-DISO
pneumonia	I-DISO
that	O
has	O
recently	O
been	O
recognized	O
in	O
the	O
patients	O
in	O
32	O
countries	O
and	O
regions	O
.	O

There	O
still	O
are	O
many	O
problems	O
to	O
be	O
solved	O
in	O
the	O
course	O
of	O
conquering	O
SARS	B-DISO
.	O

TITLE	O
:	O
[	O
Neuromyalgic	O
syndrome	B-DISO
in	O
children	O
'	O
s	O
infections	B-DISO
].	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
was	O
first	O
recognized	O
in	O
Toronto	O
in	O
a	O
woman	O
who	O
returned	O
from	O
Hong	O
Kong	O
on	O
February	O
23	O
,	O
2003	O
(	O
1	O
).	O

After	O
implementation	O
of	O
provincewide	O
public	O
health	O
measures	O
that	O
included	O
strict	O
infection	B-DISO
-	O
control	O
practices	O
,	O
the	O
number	O
of	O
recognized	O
cases	O
of	O
SARS	B-DISO
declined	O
substantially	O
,	O
and	O
no	O
cases	O
were	O
detected	O
after	O
April	O
20	O
.	O

This	O
report	O
describes	O
a	O
second	O
wave	O
of	O
SARS	B-DISO
cases	O
among	O
patients	O
,	O
visitors	O
,	O
and	O
health	O
-	O
care	O
workers	O
(	O
HCWs	O
)	O
that	O
occurred	O
at	O
a	O
Toronto	O
hospital	O
approximately	O
4	O
weeks	O
after	O
SARS	B-DISO
transmission	O
was	O
thought	O
to	O
have	O
been	O
interrupted	O
.	O

CONCLUSIONS	O
:	O
Pulmonary	B-DISO
fibrosis	I-DISO
may	O
develop	O
early	O
in	O
patients	O
with	O
SARS	B-DISO
who	O
have	O
been	O
discharged	O
after	O
treatment	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
--	O
Taiwan	O
,	O
2003	O
.	O

This	O
report	O
summarizes	O
epidemiologic	O
findings	O
of	O
the	O
outbreak	O
in	O
Taiwan	O
and	O
describes	O
the	O
impact	O
of	O
health	O
-	O
care	O
--	O
associated	O
transmission	O
of	O
SARS	B-DISO
.	O

This	O
report	O
provides	O
an	O
update	O
on	O
reported	O
SARS	B-DISO
cases	O
worldwide	O
and	O
in	O
the	O
United	O
States	O
.	O

During	O
November	O
1	O
,	O
2002	O
-	O
May	O
7	O
,	O
2003	O
,	O
a	O
total	O
of	O
6	O
,	O
903	O
SARS	B-DISO
cases	O
were	O
reported	O
to	O
WHO	O
from	O
29	O
countries	O
,	O
including	O
the	O
United	O
States	O
;	O
495	O
deaths	O
(	O
case	O
-	O
fatality	O
proportion	O
:	O
7	O
.	O
2	O
%)	O
have	O
been	O
reported	O
.	O

TITLE	O
:	O
Update	O
:	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
--	O
United	O
States	O
,	O
May	O
28	O
,	O
2003	O
.	O

Consultation	O
of	O
particular	O
cases	O
involving	O
experts	O
from	O
multiple	O
medical	O
science	O
fields	O
should	O
be	O
encouraged	O
,	O
which	O
is	O
also	O
an	O
effective	O
measure	O
against	O
newly	O
emerged	O
infectious	B-DISO
diseases	I-DISO
.	O

5	O
%	O
leading	O
to	O
death	O
from	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
(	O
RDS	O
).	O

In	O
addition	O
,	O
intensifying	O
classical	O
quarantine	O
and	O
hospital	O
hygiene	O
measures	O
,	O
it	O
was	O
possible	O
to	O
limit	O
SARS	B-DISO
in	O
many	O
countries	O
to	O
sporadic	O
cases	O
,	O
and	O
to	O
reduce	O
the	O
disease	O
in	O
countries	O
such	O
as	O
Canada	O
and	O
Vietnam	O
.	O

SETTING	O
:	O
A	O
ten	O
-	O
bed	B-DISO
pediatric	O
intensive	O
care	O
unit	O
(	O
PICU	O
)	O
in	O
a	O
tertiary	O
children	O
'	O
s	O
university	O
hospital	O
.	O

The	O
disease	O
may	O
progress	O
into	O
respiratory	B-DISO
failure	I-DISO
comparable	O
with	O
an	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

556	O
hospital	O
staff	O
,	O
patients	O
,	O
and	O
relatives	O
who	O
attended	O
the	O
screening	O
clinic	O
and	O
who	O
had	O
had	O
contact	O
with	O
someone	O
with	O
SARS	B-DISO
.	O

Current	O
WHO	O
guidelines	O
for	O
diagnosing	O
suspected	O
SARS	B-DISO
may	O
not	O
be	O
sufficiently	O
sensitive	O
in	O
assessing	O
patients	O
before	O
admission	O
to	O
hospital	O
.	O

TITLE	O
:	O
Haematological	O
manifestations	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
retrospective	O
analysis	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
haematological	O
findings	O
of	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

The	O
most	O
common	O
findings	O
included	O
lymphopenia	B-DISO
in	O
153	O
(	O
98	O
%)	O
of	O
the	O
157	O
patients	O
,	O
neutrophilia	O
in	O
129	O
(	O
82	O
%),	O
thrombocytopenia	O
in	O
87	O
patients	O
(	O
55	O
%),	O
followed	O
by	O
thrombocytosis	B-DISO
in	O
77	O
(	O
49	O
%),	O
and	O
isolated	O
prolonged	O
activated	O
partial	O
thromboplastin	O
time	O
in	O
96	O
patients	O
(	O
63	O
%).	O

RESULTS	O
:	O
Between	O
November	O
16	O
,	O
2002	O
and	O
April	O
16	O
,	O
2003	O
,	O
there	O
had	O
been	O
13	O
index	O
cases	O
of	O
SARS	B-DISO
including	O
3	O
cadres	O
,	O
3	O
farmers	O
,	O
2	O
retirees	O
,	O
2	O
workers	O
and	O
1	O
shop	O
attendant	O
,	O
reported	O
from	O
13	O
cities	O
in	O
Guangdong	O
province	O
.	O

RESULTS	O
:	O
The	O
incidence	O
of	O
SARS	B-DISO
in	O
Guangdong	O
province	O
was	O
1	O
.	O
72	O
/	O
100	O
,	O
000	O
with	O
case	O
fatality	O
rate	O
as	O
3	O
.	O
64	O
%.	O

Data	O
regarding	O
the	O
clustering	O
features	O
of	O
cases	O
showed	O
that	O
there	O
were	O
42	O
families	O
having	O
2	O
or	O
more	O
cases	O
in	O
one	O
family	O
,	O
while	O
277	O
health	O
workers	O
suffered	B-DISO
from	O
SARS	B-DISO
were	O
concentrated	O
in	O
28	O
hospitals	O
.	O

The	O
disease	O
was	O
highly	O
infectious	B-DISO
,	O
suggesting	O
that	O
people	O
who	O
had	O
close	O
contact	O
with	O
patients	O
in	O
the	O
place	O
with	O
poor	O
ventilation	O
was	O
in	O
greater	O
risk	O
of	O
getting	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
has	O
only	O
recently	O
been	O
described	O
.	O

Nine	O
patients	O
had	O
hemolytic	B-DISO
anemia	I-DISO
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

SARS	B-DISO
presents	O
with	O
fever	O
,	O
cough	B-DISO
,	O
malaise	B-DISO
,	O
dyspnea	B-DISO
,	O
and	O
hypoxemia	O
.	O

Children	O
with	O
SARS	B-DISO
presented	O
with	O
fever	O
,	O
nonproductive	B-DISO
cough	I-DISO
,	O
malaise	B-DISO
,	O
chills	B-DISO
,	O
headache	B-DISO
,	O
myalgia	B-DISO
,	O
and	O
loss	B-DISO
of	I-DISO
appetite	I-DISO
.	O

Children	O
younger	O
than	O
12	O
yrs	O
seemed	O
less	O
ill	B-DISO
but	O
had	O
more	O
coughing	B-DISO
.	O

Venovenous	O
ECMO	O
can	O
effectively	O
provide	O
adequate	O
oxygenation	O
for	O
pediatric	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
receiving	O
ECMO	O
support	O
.	O

Our	O
results	O
suggest	O
that	O
multiple	O
mechanisms	O
are	O
involved	O
in	O
the	O
inhibition	O
of	O
HSV	O
-	O
1	O
infection	B-DISO
.	O

Serological	O
tests	O
indicated	O
that	O
5	O
%	O
of	O
chickens	O
tested	O
had	O
been	O
exposed	O
to	O
Newcastle	B-DISO
disease	I-DISO
,	O
43	O
%	O
to	O
infectious	B-DISO
bronchitis	B-DISO
and	O
63	O
%	O
to	O
Mycoplasma	B-DISO
gallisepticum	I-DISO
infection	I-DISO
.	O

(	O
2	O
)	O
The	O
majority	O
of	O
clinical	O
manifestations	O
were	O
fever	O
(	O
100	O
%	O
cases	O
),	O
and	O
there	O
were	O
no	O
obvious	O
respiratory	B-DISO
symptoms	I-DISO
in	O
more	O
than	O
half	O
of	O
the	O
patients	O
(	O
53	O
.	O
7	O
%)	O
at	O
early	O
SARS	B-DISO
stage	O
(	O
day	O
1	O
to	O
day	O
3	O
),	O
accompanied	O
by	O
leucopenia	B-DISO
(	O
52	O
.	O
6	O
%)	O
and	O
lymphopenia	B-DISO
(	O
68	O
.	O
4	O
%).	O

CONCLUSIONS	O
:	O
It	O
is	O
very	O
important	O
for	O
clinicians	O
to	O
pay	O
great	O
attention	O
to	O
protect	O
themselves	O
from	O
infection	B-DISO
of	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
To	O
analyze	O
the	O
clinical	O
features	O
and	O
therapy	O
experience	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Severe	O
SARS	B-DISO
might	O
develop	O
rapidly	O
.	O

In	O
addition	O
to	O
early	O
diagnosis	O
,	O
prompt	O
isolation	O
,	O
and	O
emergency	B-DISO
therapy	O
,	O
appropriate	O
use	O
of	O
corticosteroid	O
and	O
noninvasive	O
ventilation	O
should	O
be	O
recommended	O
.	O

RESULTS	O
:	O
Thirty	O
-	O
eight	O
cases	O
of	O
severe	O
SARS	B-DISO
were	O
diagnosed	O
.	O

CONCLUSIONS	O
:	O
Severe	O
SARS	B-DISO
might	O
develop	O
rapidly	O
.	O

ABSTRACT	O
:	O
To	O
value	O
of	O
glucocorticoid	O
(	O
GC	O
)	O
in	O
treatment	O
for	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
was	O
evaluated	O
.	O

The	O
case	O
definition	O
of	O
probable	O
SARS	B-DISO
cases	O
,	O
laboratory	O
investigations	O
and	O
precautions	O
for	O
prevention	O
of	O
spread	O
are	O
discussed	O
.	O

In	O
addition	O
,	O
lung	O
damage	O
in	O
SARS	B-DISO
patients	O
may	O
also	O
play	O
a	O
role	O
on	O
inducing	O
thrombocytopenia	O
by	O
(	O
1	O
)	O
increasing	O
the	O
consumption	O
of	O
platelets	O
/	O
megakaryocytes	O
;	O
and	O
/	O
or	O
(	O
2	O
)	O
reducing	O
the	O
production	O
of	O
platelets	O
in	O
the	O
lungs	O
.	O

The	O
pulmonary	O
lesions	O
included	O
bilateral	O
extensive	O
consolidation	O
,	O
localized	O
haemorrhage	B-DISO
and	O
necrosis	O
,	O
desquamative	O
pulmonary	B-DISO
alveolitis	I-DISO
and	O
bronchitis	B-DISO
,	O
proliferation	B-DISO
and	O
desquamation	O
of	O
alveolar	O
epithelial	O
cells	O
,	O
exudation	O
of	O
protein	O
and	O
monocytes	O
,	O
lymphocytes	O
and	O
plasma	O
cells	O
in	O
alveoli	O
,	O
hyaline	B-DISO
membrane	I-DISO
formation	O
,	O
and	O
viral	O
inclusion	O
bodies	O
in	O
alveolar	O
epithelial	O
cells	O
.	O

There	O
was	O
also	O
massive	B-DISO
necrosis	I-DISO
of	O
splenic	O
lymphoid	O
tissue	O
and	O
localized	O
necrosis	O
in	O
lymph	O
nodes	O
.	O

The	O
lungs	O
,	O
immune	O
organs	O
,	O
and	O
systemic	O
small	O
vessels	O
are	O
the	O
main	O
targets	O
of	O
virus	O
attack	O
,	O
so	O
that	O
extensive	O
consolidation	O
of	O
the	O
lung	O
,	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
with	O
hyaline	B-DISO
membrane	I-DISO
formation	O
,	O
respiratory	B-DISO
distress	I-DISO
,	O
and	O
decreased	O
immune	O
function	O
are	O
the	O
main	O
causes	O
of	O
death	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
transmission	O
process	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
to	O
evaluate	O
the	O
infectiveness	O
of	O
SARS	B-DISO
patients	O
in	O
different	O
periods	O
of	O
disease	O
epidemics	O
.	O

There	O
was	O
no	O
evidence	O
indicating	O
that	O
SARS	B-DISO
cases	O
were	O
infectious	B-DISO
during	O
their	O
incubation	O
period	O
.	O

The	O
epidemiological	O
characteristics	O
and	O
related	O
influential	O
factors	O
were	O
analyzed	O
with	O
EPI	B-DISO
info	O
6	O
.	O
0	O
software	O
.	O

TITLE	O
:	O
[	O
Analysis	O
on	O
the	O
trend	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
epidemic	O
in	O
Inner	O
Mongolian	O
Autonomous	O
Region	O
].	O

Up	O
to	O
May	O
20	O
,	O
there	O
were	O
446	O
cumulative	O
SARS	B-DISO
cases	O
in	O
the	O
whole	O
region	O
(	O
with	O
287	O
confirmed	O
cases	O
and	O
159	O
suspected	O
cases	O
)	O
and	O
61	O
cumulative	O
recovered	O
cases	O
had	O
been	O
discharged	O
from	O
the	O
hospitals	O
(	O
56	O
confirmed	O
cases	O
and	O
5	O
suspected	O
cases	O
).	O

To	O
generate	O
data	O
on	O
SARS	B-DISO
in	O
Sichuan	O
province	O
through	O
descriptive	O
and	O
analytical	O
studies	O
on	O
time	O
,	O
geographic	O
distribution	O
,	O
population	O
,	O
source	O
of	O
infection	B-DISO
,	O
the	O
way	O
of	O
case	O
finding	O
,	O
symptom	B-DISO
,	O
diagnosis	O
and	O
treatment	O
of	O
the	O
cases	O
.	O

Measures	O
concerning	O
the	O
prevention	O
and	O
control	O
of	O
the	O
epidemics	O
would	O
mainly	O
target	O
on	O
the	O
isolation	O
of	O
confirmed	O
and	O
suspected	O
patients	O
who	O
might	O
serve	O
as	O
the	O
sources	O
of	O
infection	B-DISO
through	O
setting	O
up	O
quarantine	O
station	O
,	O
assigned	O
hospitals	O
and	O
special	O
'	O
fever	O
-	O
clinics	O
'.	O

TITLE	O
:	O
[	O
The	O
application	O
of	O
indirect	O
immuno	O
-	O
fluorescence	O
assay	O
in	O
the	O
diagnosis	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
].	O

Clinically	O
confirmed	O
SARS	B-DISO
patients	O
,	O
suspected	O
SARS	B-DISO
patients	O
,	O
and	O
controls	O
were	O
included	O
in	O
the	O
study	O
.	O

The	O
positive	O
rates	O
of	O
specific	O
IgG	O
and	O
IgM	O
against	O
SARS	B-DISO
virus	O
within	O
10	O
days	O
after	O
onset	O
of	O
the	O
disease	O
were	O
55	O
.	O
1	O
%	O
and	O
16	O
.	O
3	O
%	O
respectively	O

Sensitivity	O
,	O
specificity	O
and	O
agreement	O
value	O
of	O
IFA	O
regarding	O
the	O
diagnosis	O
of	O
SARS	B-DISO
were	O
all	O
higher	O
than	O
90	O
%.	O

TITLE	O
:	O
[	O
Analysis	O
of	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
III	O
in	O
the	O
54	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
].	O

Some	O
of	O
the	O
technologies	O
brought	O
forward	O
during	O
the	O
SARS	B-DISO
epidemic	O
may	O
have	O
been	O
primarily	O
motivated	O
by	O
marketing	O
efforts	O
,	O
or	O
were	O
more	O
directed	O
towards	O
reassuring	O
people	O
that	O
""""	O
something	O
is	O
being	O
done	O
","""	O
ie	O
,	O
fighting	O
an	O
""""	O
epidemic	O
of	O
fear	O
.	O

A	O
significant	O
relative	O
increase	O
in	O
sputum	O
differential	O
neutrophil	O
count	O
was	O
seen	O
on	O
day	O
4	O
in	O
the	O
EVW	O
group	O
with	O
a	O
cold	B-DISO
but	O
not	O
in	O
controls	O
(	O
mean	O
difference	O
(	O
95	O
%	O
confidence	O
interval	O
)	O
20	O
.	O
4	O
(	O
9	O
.	O
6	O
,	O
31	O
.	O
1	O
)%	O
and	O
3	O
.	O
1	O
(-	O
8	O
.	O
2	O
,	O
14	O
.	O
5	O
)%,	O
respectively	O
,	O
P	O
<	O
0	O
.	O
01	O
);	O
however	O
,	O
this	O
increase	O
did	O
not	O
correlate	O
with	O
lower	O
respiratory	O
tract	O
symptom	B-DISO
scores	O
.	O

The	O
etiology	O
of	O
SARS	B-DISO
is	O
likely	O
a	O
novel	O
coronavirus	O
.	O

In	O
acute	O
(<	O
48	O
hours	O
)	O
hyponatremia	O
,	O
usually	O
observed	O
in	O
the	O
postoperative	O
period	O
,	O
prompt	O
treatment	O
with	O
hypertonic	O
saline	O
(	O
3	O
%)	O
can	O
prevent	O
seizures	B-DISO
and	O
respiratory	B-DISO
arrest	I-DISO
.	O

TITLE	O
:	O
Identification	O
of	O
an	O
epitope	O
of	O
SARS	B-DISO
-	O
coronavirus	O
nucleocapsid	O
protein	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
a	O
major	O
virion	O
structural	O
protein	O
.	O

The	O
serum	O
levels	O
of	O
IgM	O
and	O
IgG	O
antibodies	O
to	O
N	O
antigen	O
were	O
measured	O
in	O
200	O
healthy	O
blood	O
donors	O
and	O
13	O
SARS	B-DISO
patients	O
at	O
different	O
time	O
points	O
of	O
acute	O
and	O
convalescent	O
phases	O
using	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
with	O
N	O
fusion	O
proteins	O
of	O
SARS	B-DISO
-	O
associated	O
coronaviruses	O
.	O

BALB	O
/	O
c	O
mice	O
were	O
injected	O
with	O
the	O
recombinant	O
N	O
protein	O
of	O
SARS	B-DISO
-	O
Cov	O
into	O
the	O
foot	O
-	O
pads	O
for	O
the	O
immunization	O
,	O
and	O
the	O
popliteal	O
lymph	O
nodes	O
were	O
isolated	O
15	O
d	O
later	O
for	O
mAb	O
-	O
producing	O
hybridomas	O
,	O
from	O
which	O
the	O
mAbs	O
against	O
the	O
N	O
protein	O
of	O
SARS	B-DISO
-	O
Cov	O
were	O
screened	O
.	O

Of	O
196	O
patients	O
with	O
SARS	B-DISO
,	O
38	O
(	O
19	O
%)	O
became	O
critically	B-DISO
ill	I-DISO
,	O
7	O
(	O
18	O
%)	O
of	O
whom	O
were	O
HCWs	O
.	O

The	O
SARS	B-DISO
outbreak	O
greatly	O
strained	O
regional	O
critical	O
care	O
resources	O
.	O

A	O
global	O
emergency	B-DISO
was	O
declared	O
by	O
the	O
World	O
Health	O
Organization	O
,	O
bringing	O
together	O
an	O
international	O
team	O
of	O
epidemiologists	O
,	O
public	O
health	O
physicians	O
and	O
microbiologists	O
to	O
study	O
and	O
contain	O
the	O
disease	O
.	O

The	O
SARS	B-DISO
outbreak	O
in	O
Guangdong	O
province	O
and	O
the	O
outbreak	O
in	O
Guangzhou	O
associated	O
with	O
hospitals	O
in	O
the	O
city	O
are	O
described	O
,	O
documenting	O
clinical	O
and	O
laboratory	O
features	O
in	O
a	O
cohort	O
of	O
190	O
patients	O
randomly	O
allocated	O
to	O
four	O
treatment	O
regimens	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
):	O
imaging	O
findings	O
during	O
the	O
acute	O
and	O
recovery	O
phases	O
of	O
disease	O
.	O

GERD	B-DISO
is	O
frequently	O
observed	O
in	O
the	O
setting	O
of	O
type	O
1	O
(	O
sliding	O
type	O
)	O
hiatal	B-DISO
hernia	I-DISO
,	O
but	O
only	O
infrequently	O
complicates	O
the	O
course	O
of	O
type	O
2	O
(	O
paraesophageal	O
)	O
hernia	B-DISO
.	O

We	O
found	O
7	O
cases	O
(	O
14	O
%)	O
of	O
type	O
2	O
hiatal	B-DISO
hernia	I-DISO
complicated	O
by	O
pulmonary	O
manifestations	O
as	O
the	O
only	O
symptoms	O
of	O
GERD	B-DISO
.	O

The	O
SARS	B-DISO
patients	O
in	O
Shenzhen	O
were	O
infected	O
with	O
coronavirus	O
and	O
this	O
novel	O
coronavirus	O
is	O
associated	O
with	O
SARS	B-DISO
.	O

The	O
sequence	O
analysis	O
indicated	O
that	O
the	O
coronavirus	O
from	O
SARS	B-DISO
patients	O
in	O
Shenzhen	O
is	O
the	O
same	O
as	O
that	O
identified	O
from	O
other	O
areas	O
such	O
as	O
Canada	O
and	O
Hong	O
Kong	O
.	O

A	O
specific	O
diagnostic	O
nested	O
RT	O
-	O
PCR	O
was	O
developed	O
to	O
identify	O
this	O
novel	O
coronavirus	B-DISO
infection	I-DISO
.	O

The	O
overall	O
nucleotides	O
conservation	O
of	O
the	O
homologous	O
ORFs	O
is	O
low	O
(<	O
5	O
%)	O
compared	O
with	O
other	O
known	O
CoVs	O
,	O
implying	O
that	O
HK	O
-	O
39	O
is	O
a	O
newly	O
emergent	O
SARS	B-DISO
-	O
CoV	O
phylogenetically	O
distant	O
from	O
other	O
known	O
members	O
.	O

TITLE	O
:	O
Cloning	O
and	O
sequence	O
analysis	O
of	O
the	O
spike	O
gene	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
Chinju99	O
.	O

Seven	O
patients	O
who	O
developed	O
ARDS	B-DISO
complicated	O
with	O
multiple	O
organs	O
dysfunction	O
syndrome	B-DISO
(	O
MODS	B-DISO
)	O
died	O
.	O

SARS	B-DISO
appears	O
to	O
be	O
quickly	O
infectious	B-DISO
and	O
potentially	O
lethal	O
among	O
health	O
care	O
workers	O
,	O
characterized	O
by	O
acute	O
onset	O
and	O
rapid	O
progression	O
,	O
and	O
mostly	O
bilateral	O
lung	O
involvement	O
on	O
chest	O
radiographs	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
clinical	O
and	O
radiological	O
features	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

CONCLUSIONS	O
:	O
SARS	B-DISO
is	O
a	O
disease	O
with	O
high	O
infectivity	O
and	O
has	O
its	O
own	O
clinical	O
and	O
radiological	O
features	O
.	O

The	O
dominant	O
feature	O
of	O
early	O
SARS	B-DISO
patients	O
is	O
focal	O
patchy	O
opacity	B-DISO
in	O
the	O
lung	O
,	O
and	O
oval	O
small	O
ground	O
-	O
glass	O
opacities	B-DISO
are	O
the	O
common	O
morphological	O
findings	O
on	O
CT	O
.	O

The	O
numbers	O
of	O
CD	O
(	O
3	O
)(+),	O
CD	O
(	O
4	O
)(+),	O
and	O
CD	O
(	O
8	O
)(+)	O
lymphocytes	O
all	O
significantly	O
decreased	O
in	O
acute	O
phase	O
of	O
patients	O
with	O
SARS	B-DISO
[(	O
722	O
+/-	O
533	O
)/	O
microliter	O
,	O
(	O
438	O
+/-	O
353	O
)/	O
microliter	O
,	O
(	O
307	O
+/-	O

CONCLUSIONS	O
:	O
The	O
damage	O
of	O
cellular	O
immunity	O
is	O
probably	O
an	O
important	O
mechanism	O
of	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
.	O

TITLE	O
:	O
[	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
].	O

Diagnostic	O
standard	O
of	O
SARS	B-DISO
will	O
be	O
revised	O
with	O
further	O
understanding	O
of	O
the	O
disease	O
.	O

Long	O
-	O
acting	O
penicillin	O
regimen	O
given	O
for	O
3	O
-	O
5	O
years	O
for	O
the	O
prevention	O
of	O
rheumatic	B-DISO
fever	I-DISO
relapse	B-DISO
is	O
advocated	O
.	O

The	O
earliest	O
symptom	B-DISO
of	O
all	O
3	O
cases	O
was	O
hyperpyrexia	B-DISO
and	O
followed	O
by	O
progressive	O
dyspnea	B-DISO
and	O
appearance	O
of	O
lung	O
field	O
shadows	O
in	O
X	O
rays	O
findings	O
.	O

In	O
addition	O
,	O
there	O
were	O
also	O
the	O
systemic	O
poisonous	O
changes	O
including	O
:	O
degeneration	B-DISO
and	O
necrosis	O
of	O
the	O
parenchyma	O
cells	O
in	O
lungs	O
,	O
liver	O
,	O
kidneys	O
,	O
heart	O
and	O
adrenals	O
.	O

Other	O
atypical	O
pathological	O
changes	O
,	O
such	O
as	O
hydropic	B-DISO
degeneration	I-DISO
,	O
fatty	B-DISO
degeneration	I-DISO
,	O
interstitial	O
cell	O
proliferation	B-DISO
and	O
some	O
lesions	O
observed	O
in	O
liver	O
,	O
heart	O
,	O
kidney	O
,	O
pancreas	O
may	O
have	O
existed	O
before	O
the	O
hospitalization	O
.	O

Other	O
atypical	O
pathological	O
changes	O
,	O
such	O
as	O
hydropic	B-DISO
degeneration	I-DISO
,	O
fatty	B-DISO
degeneration	I-DISO
,	O
interstitial	O
cell	O
proliferation	B-DISO
and	O
some	O
lesions	O
observed	O
in	O
liver	O
,	O
heart	O
,	O
kidney	O
,	O
pancreas	O
may	O
have	O
existed	O
before	O
the	O
hospitalization	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
morphological	O
,	O
ultramicrostructural	O
and	O
pathological	O
changes	O
of	O
tissues	O
from	O
a	O
patient	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Vero	O
E6	O
cells	O
infected	O
with	O
lung	O
autopsy	O
samples	O
or	O
nasopharyngeal	O
swabs	O
from	O
SARS	B-DISO
patients	O
of	O
Beijing	O
and	O
Guangzhou	O
were	O
inoculated	O
.	O

Infectious	B-DISO
virons	O
entered	O
cells	O
by	O
endocytosis	O
or	O
membrane	O
fusion	O
and	O
released	O
through	O
a	O
budding	O
process	O
.	O

In	O
the	O
present	O
study	O
,	O
interferon	O
(	O
IFN	O
)-	O
gamma	O
production	O
during	O
ECOR	O
was	O
studied	O
and	O
its	O
role	O
evaluated	O
in	O
the	O
clearance	O
of	O
infectious	B-DISO
virus	O
from	O
the	O
retina	O
.	O

Mouse	O
eyes	O
were	O
evaluated	O
for	O
infiltrating	B-DISO
cells	O
and	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
expression	O
by	O
immunocytochemical	O
staining	O
.	O

RESULTS	O
:	O
Virus	B-DISO
infection	I-DISO
in	O
BALB	O
/	O
c	O
mice	O
was	O
associated	O
with	O
an	O
increase	O
in	O
the	O
incidence	O
and	O
levels	O
of	O
systemic	O
IFN	O
-	O
gamma	O
.	O

SARS	B-DISO
is	O
a	O
new	O
disease	O
entity	O
that	O
carries	O
significant	O
morbidity	O
and	O
mortality	O
.	O

CONCLUSIONS	O
:	O
Since	O
the	O
novel	O
Chlamydia	O
-	O
like	O
agent	O
was	O
found	O
co	O
-	O
existing	O
with	O
a	O
coronavirus	O
-	O
like	O
agent	O
in	O
the	O
dead	O
cases	O
of	O
SARS	B-DISO
,	O
it	O
looks	O
most	O
likely	O
that	O
both	O
the	O
agents	O
play	O
some	O
roles	O
in	O
the	O
disease	O
.	O

Site	O
directed	O
mutagenesis	O
of	O
cis	B-DISO
-	O
elements	O
HNF4	O
(	O
pfgl2HNF4mut	O
)	O
and	O
HNF4	O
/	O
IE1	O
.	O
2	O
(	O
pfgl2HNF4	O
/	O
IE1	O
.	O
2mut	O
)	O
mutations	O
abolished	O
over	O
75	O
%	O
of	O
transcription	O
from	O
wild	O
-	O
type	O
mfgl2	O
promoter	O
.	O

TITLE	O
:	O
Protecting	O
against	O
SARS	B-DISO
during	O
equipment	O
maintenance	O
.	O

All	O
except	O
3	O
had	O
co	O
-	O
morbid	O
conditions	O
,	O
such	O
as	O
hypertension	B-DISO
,	O
diabetes	B-DISO
mellitus	I-DISO
,	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
or	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
.	O

Patients	O
of	O
SARS	B-DISO
who	O
had	O
advanced	O
age	O
,	O
co	O
-	O
morbid	O
conditions	O
,	O
highly	O
elevated	O
LDH	O
and	O
multifocal	O
infiltration	B-DISO
over	O
chest	O
radiograph	O
should	O
be	O
closely	O
monitored	O
and	O
actively	O
treated	O
.	O

TITLE	O
:	O
Management	O
of	O
hospital	O
-	O
acquired	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
with	O
different	O
disease	O
spectrum	O
.	O

We	O
report	O
4	O
probable	O
SARS	B-DISO
cases	O
with	O
different	O
severity	O
and	O
propose	O
optimal	O
treatment	O
.	O

The	O
damage	O
is	O
light	O
and	O
related	O
to	O
SARS	B-DISO
itself	O
.	O

The	O
image	O
characteristics	O
were	O
compared	O
with	O
those	O
of	O
224	O
patients	O
with	O
common	O
SARS	B-DISO
.	O

Rapidly	O
changing	O
consolidations	O
revealed	O
in	O
chest	O
X	O
-	O
ray	O
images	O
were	O
found	O
to	O
be	O
associated	O
with	O
SARS	B-DISO
infections	B-DISO
,	O
and	O
they	O
were	O
not	O
affected	O
by	O
treatment	O
with	O
antibiotics	O
.	O

Pulmonary	O
alveoli	O
thickened	O
with	O
interstitial	O
mononuclear	O
inflammatory	O
infiltrates	B-DISO
,	O
suffered	B-DISO
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
,	O
experienced	O
desquamation	O
of	O
pneumocytes	O
and	O
had	O
hyaline	O
-	O
membrane	O
formation	O
,	O
fibrinoid	O
materials	O
,	O
and	O
erythrocytes	O
in	O
alveolar	O
spaces	O
.	O

Furthermore	O
,	O
hemorrhagic	B-DISO
necrosis	I-DISO
was	O
also	O
evident	O
in	O
lymph	O
nodes	O
and	O
spleen	O
with	O
the	O
attenuation	O
of	O
lymphocytes	O
.	O

CONCLUSIONS	O
:	O
Severe	O
damage	O
to	O
the	O
pulmonary	O
and	O
immunological	O
systems	O
is	O
responsible	O
for	O
the	O
clinical	O
features	O
of	O
SARS	B-DISO
and	O
may	O
lead	O
to	O
the	O
death	O
of	O
patients	O
.	O

The	O
level	O
of	O
IL	O
in	O
SARS	B-DISO
patients	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
patients	O
with	O
chronic	B-DISO
hepatitis	I-DISO
B	I-DISO
(	O
P	O
<	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
Rapid	O
loss	O
of	O
both	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
lymphocyte	O
subsets	O
during	O
the	O
acute	O
phase	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
alteration	O
of	O
peripheral	O
lymphocyte	O
subsets	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
and	O
to	O
help	O
improve	O
the	O
early	O
diagnosis	O
of	O
the	O
disease	O
.	O

Anti	O
-	O
coagulating	O
blood	O
samples	O
from	O
98	O
SARS	B-DISO
patients	O
in	O
the	O
acute	O
phase	O
,	O
56	O
normal	O
healthy	O
blood	O
donors	O
,	O
and	O
from	O
patients	O
infected	O
by	O
HIV	B-DISO
,	O
CMV	O
and	O
EBV	O
were	O
collected	O
.	O

A	O
significant	O
decrease	O
was	O
observed	O
in	O
all	O
SARS	B-DISO
patients	O
in	O
their	O
peripheral	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
T	O
lymphocyte	O
absolute	O
counts	O
[	O
256	O
(	O
104	O
)	O
x	O
10	O
(	O
6	O
)/	O
L	O
and	O
256	O
(	O
117	O
)	O
x	O
10	O
(	O
6	O
)/	O
L	O
,	O
respectively	O
],	O
which	O
were	O
also	O
lower	O
than	O
those	O
of	O
the	O
patients	O
infected	O
with	O
HIV	B-DISO
,	O
CMV	O
and	O
EBV	O
.	O

The	O
F	O
-	O
PCR	O
method	O
established	O
may	O
be	O
a	O
rapid	O
,	O
accurate	O
and	O
efficient	O
way	O
for	O
screening	O
and	O
for	O
the	O
early	O
diagnosis	O
of	O
SARS	B-DISO
patients	O
.	O

TITLE	O
:	O
Clinical	O
and	O
imaging	O
findings	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

Seven	O
patients	O
were	O
injured	O
in	O
motor	O
vehicle	O
collisions	O
;	O
one	O
patient	O
suffered	B-DISO
a	O
gunshot	O
wound	O
to	O
the	O
chest	O
.	O

The	O
four	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
macaques	O
excreted	O
SARS	B-DISO
-	O
CoV	O
from	O
nose	O
,	O
mouth	O
,	O
and	O
pharynx	O
from	O
2	O
days	O
after	O
infection	B-DISO
.	O

Three	O
of	O
four	O
macaques	O
developed	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
,	O
similar	O
to	O
that	O
in	O
SARS	B-DISO
patients	O
,	O
and	O
characterised	O
by	O
epithelial	O
necrosis	O
,	O
serosanguineous	O
exudate	O
,	O
formation	O
of	O
hyaline	B-DISO
membranes	I-DISO
,	O
type	O
2	O
pneumocyte	O
hyperplasia	B-DISO
,	O
and	O
the	O
presence	O
of	O
syncytia	O
.	O

Three	O
days	O
later	O
he	O
initiated	O
with	O
loss	B-DISO
of	I-DISO
strength	I-DISO
in	O
the	O
lower	O
limbs	O
(	O
LL	O
).	O

68	O
.	O
4	O
%	O
of	O
the	O
patients	O
had	O
lymphopenia	B-DISO
(	O
absolute	O
lymphocyte	O
count	O
<	O
1	O
.	O
3	O
x	O
10	O
(	O
9	O
)/	O
L	O
).	O

TITLE	O
:	O
[	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
78	O
patients	O
:	O
a	O
retrospective	O
study	O
].	O

Seven	O
patients	O
who	O
developed	O
ARDS	B-DISO
complicated	O
with	O
MODS	B-DISO
died	O
.	O

Seven	O
patients	O
who	O
developed	O
ARDS	B-DISO
complicated	O
with	O
MODS	B-DISO
died	O
.	O

Serial	O
roentgenography	O
and	O
CT	O
of	O
61	O
confirmed	O
SARS	B-DISO
patients	O
were	O
analyzed	O
.	O

The	O
onset	O
symptom	B-DISO
was	O
fever	O
in	O
all	O
patients	O
.	O

Lungs	O
complicated	B-DISO
infection	I-DISO
were	O
found	O
in	O
6	O
patients	O
with	O
a	O
prolonged	O
duration	O
of	O
the	O
illness	O
.	O

Lungs	O
fibrosis	B-DISO
was	O
found	O
in	O
some	O
patients	O
in	O
the	O
recovery	O
phase	O
.	O

The	O
levels	O
of	O
CD3	O
(+),	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
T	O
-	O
lymphocyte	O
subsets	O
in	O
peripheral	O
blood	O
of	O
SARS	B-DISO
patients	O
decrease	O
significantly	O
and	O
go	O
down	O
to	O
the	O
lowest	O
point	O
at	O
days	O
10	O
approximately	O
12	O
after	O
onset	O
of	O
the	O
disease	O
.	O

RESULTS	O
:	O
The	O
levels	O
of	O
CD3	O
(+),	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
T	O
-	O
lymphocytes	O
in	O
SARS	B-DISO
group	O
[(	O
589	O
+/-	O
435	O
)	O
x	O
10	O
(	O
6	O
)/	O
L	O
,	O
(	O
316	O
+/-	O
267	O
)	O
x	O
10	O
(	O
6	O
)/	O
L	O
and	O
(	O
215	O
+/-	O
165	O
)	O
x	O
10	O
(	O
6	O
)/	O
L	O
,	O
respectively	O
]	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
the	O
normal	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

The	O
data	O
of	O
clinical	O
presentation	O
and	O
disease	B-DISO
progression	I-DISO
of	O
all	O
the	O
patients	O
including	O
index	O
subject	O
as	O
the	O
infectious	B-DISO
SARS	B-DISO
resource	O
patient	O
,	O
her	O
family	O
infected	O
members	O
and	O
21	O
health	O
care	O
workers	O
were	O
abstracted	O
.	O

Two	O
patients	O
died	O
of	O
progressive	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
disease	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
clinical	O
manifestations	O
,	O
treatment	O
,	O
and	O
outcome	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Traditional	O
Chinese	O
medicine	O
(	O
TCM	O
)	O
regards	O
SARS	B-DISO
as	O
one	O
of	O
epidemic	O
febrile	O
diseases	O
.	O

TITLE	O
:	O
[	O
The	O
epidemiological	O
findings	O
and	O
the	O
experience	O
in	O
the	O
prevention	O
and	O
control	O
of	O
SARS	B-DISO
in	O
the	O
Hong	O
Kong	O
Special	O
Administrative	O
Region	O
].	O

Most	O
of	O
the	O
SARS	B-DISO
patients	O
are	O
health	O
care	O
workers	O
and	O
close	O
contacts	O
of	O
SARS	B-DISO
patients	O
.	O

The	O
patient	O
'	O
s	O
condition	B-DISO
may	O
be	O
most	O
serious	O
in	O
the	O
2nd	O
week	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
reveal	O
the	O
evolution	O
forces	O
of	O
SARS	B-DISO
-	O
CoV	O
virus	O
by	O
analyzing	O
the	O
nucleotide	O
mutations	O
in	O
these	O
sequences	O
.	O

These	O
results	O
provide	O
basis	O
for	O
future	O
developing	O
a	O
new	O
drug	O
and	O
vaccine	O
against	O
SARS	B-DISO
.	O

TITLE	O
:	O
[	O
SARS	B-DISO
epidemic	O
trends	O
in	O
Beijing	O
since	O
late	O
April	O
2003	O
].	O

ABSTRACT	O
:	O
To	O
study	O
the	O
morphological	O
features	O
of	O
the	O
lungs	O
obtained	O
from	O
autopsies	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
.	O

Bilateral	O
lungs	O
from	O
7	O
patients	O
died	O
from	O
SARS	B-DISO
were	O
carefully	O
studied	O
grossly	O
and	O
microscopically	O
.	O

The	O
organization	O
of	O
intra	O
-	O
alveolar	O
fibrin	O
exudates	O
along	O
with	O
the	O
interstitial	B-DISO
fibrosis	I-DISO
led	O
to	O
obliteration	O
of	O
alveoli	O
and	O
consolidation	O
of	O
lungs	O
.	O

Twenty	O
-	O
one	O
SARS	B-DISO
patients	O
who	O
reached	O
the	O
standard	O
of	O
Ministry	O
of	O
Health	O
'	O
s	O
""""	O
critical	O
level	O
""""	O
were	O
transferred	O
into	O
our	O
ICU	O
in	O
an	O
average	O
of	O
11	O
days	O
after	O
onset	O
and	O
enrolled	O
in	O
this	O
clinical	O
trial	O
.	O

Due	O
to	O
the	O
difficulty	O
of	O
SARS	B-DISO
management	O
,	O
this	O
study	O
was	O
not	O
a	O
randomized	O
controlled	O
clinical	O
trial	O
.	O

This	O
fact	O
underlines	O
the	O
importance	O
of	O
good	O
infection	B-DISO
prevention	O
measures	O
for	O
each	O
patient	O
contact	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
clinical	O
features	O
,	O
developing	O
complications	O
,	O
and	O
results	O
of	O
thirty	O
-	O
six	O
patients	O
,	O
which	O
were	O
followed	O
up	O
in	O
our	O
Obstetrics	O
and	O
Gynecology	O
and	O
Nephrology	O
departments	O
between	O
1997	O
and	O
2001	O
,	O
with	O
the	O
diagnosis	O
of	O
HELLP	B-DISO
syndrome	I-DISO
were	O
searched	O
retrospectively	O
.	O

HELLP	B-DISO
syndrome	I-DISO
was	O
diagnosed	O
on	O
average	O
in	O
the	O
32	O
.	O
6	O
+/-	O

In	O
thirteen	O
cases	O
(	O
36	O
%)	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
(	O
ARF	B-DISO
),	O
six	O
cases	O
(	O
17	O
%)	O
placenta	O
detachment	B-DISO
,	O
two	O
cases	O
disseminate	O
intravascular	O
coagulation	O
(	O
DIC	B-DISO
),	O
one	O
case	O
Adult	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
were	O
developed	O
.	O

In	O
twenty	O
-	O
three	O
cases	O
by	O
cesarian	O
section	O
(	O
64	O
%),	O
in	O
thirteen	O
cases	O
by	O
induction	O
(	O
36	O
%)	O
the	O
pregnancies	O
were	O
terminated	O
in	O
72	O
h	O
after	O
diagnosing	O
HELLP	B-DISO
syndrome	I-DISO
.	O

Two	O
patients	O
died	O
because	O
of	O
the	O
development	O
of	O
ARF	B-DISO
+	O
DIC	B-DISO
and	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
):	O
a	O
review	O
of	O
the	O
history	O
,	O
epidemiology	O
,	O
prevention	O
,	O
and	O
concerns	O
for	O
the	O
future	O
.	O

The	O
enrollment	O
of	O
inpatients	O
was	O
ruled	O
with	O
two	O
official	O
standards	O
,	O
i	O
.	O
e	O
.,	O
'	O
Clinical	O
Standards	O
for	O
Diagnosis	O
of	O
SARS	B-DISO
,	O
Trial	O
Edition	O
'	O
from	O
Health	O
Ministry	O
,	O
and	O
'	O
Diagnostic	O
Standards	O
for	O
SARS	B-DISO
'	O
from	O
Joint	O
Force	O
of	O
Prevention	O
and	O
Therapy	O
for	O
SARS	B-DISO
in	O
Beijing	O
,	O
PRC	O
.	O

The	O
characteristics	O
of	O
gender	O
,	O
age	O
,	O
occupation	O
,	O
contagious	O
history	O
and	O
previous	O
therapy	O
were	O
described	O
in	O
SARS	B-DISO
inpatients	O
when	O
they	O
visited	O
the	O
outpatient	O
department	O
for	O
SARS	B-DISO
in	O
the	O
first	O
time	O
;	O
the	O
clinical	O
symptoms	O
,	O
physical	O
signs	O
,	O
blood	O
WBC	O
counts	O
and	O
X	O
-	O
ray	O
in	O
lungs	O
were	O
also	O
analyzed	O
.	O

RESULTS	O
:	O
43	O
(	O
95	O
.	O
6	O
%)	O
of	O
all	O
45	O
patients	O
had	O
exposure	O
to	O
SARS	B-DISO
patients	O
and	O
the	O
average	O
incubation	O
time	O
was	O
(	O
7	O
.	O
3	O
+/-	O

ABSTRACT	O
:	O
To	O
primarily	O
investigate	O
the	O
changing	O
mode	O
of	O
anti	O
-	O
SARS	B-DISO
coronavirus	O
IgG	O
antibody	O
in	O
clinically	O
diagnosed	O
SARS	B-DISO
patients	O
and	O
the	O
possibility	O
of	O
subclinical	B-DISO
infection	I-DISO
in	O
physicians	O
and	O
nurses	O
through	O
close	O
association	O
with	O
SARS	B-DISO
patients	O
.	O

RESULTS	O
:	O
Plasma	O
anti	O
-	O
SARS	B-DISO
coronavirus	O
IgG	O
antibody	O
was	O
not	O
detected	O
in	O
normal	O
subjects	O
and	O
the	O
clinical	O
personnel	O
.	O

TITLE	O
:	O
[	O
Chest	O
X	O
-	O
ray	O
changes	O
after	O
discontinuation	O
of	O
glucocorticosteroids	O
treatment	O
on	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
5	O
cases	O
report	O
)].	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
glucocorticosteroids	O
on	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
chest	O
X	O
ray	O
changes	O
after	O
discontinuation	O
of	O
glucocorticosteroids	O
treatment	O
.	O

5	O
cases	O
were	O
medical	O
workers	O
and	O
had	O
exposure	O
to	O
SARS	B-DISO
patients	O
.	O

we	O
can	O
closely	O
observe	O
the	O
condition	B-DISO
of	O
the	O
disease	O
and	O
no	O
more	O
glucocortisteroids	O
needed	O
to	O
be	O
given	O
to	O
the	O
patients	O
.	O

Thoracic	B-DISO
images	O
was	O
analyzed	O
in	O
88	O
medical	O
workers	O
with	O
SARS	B-DISO
,	O
including	O
394	O
chest	O
plain	O
films	O
and	O
9	O
CT	O
scans	O
.	O

CONCLUSIONS	O
:	O
Thoracic	B-DISO
plain	O
film	O
was	O
necessary	O
for	O
diagnosis	O
of	O
SARS	B-DISO
,	O
CT	O
could	O
detect	O
the	O
pulmonary	O
abnormality	O
of	O
SARS	B-DISO
early	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
clinical	O
and	O
radiology	O
features	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
).	O

The	O
percent	O
of	O
severe	O
pneumonia	B-DISO
(	O
24	O
.	O
4	O
%)	O
is	O
higher	O
than	O
typical	O
pneumonia	B-DISO
.	O

A	O
retrospective	O
analysis	O
was	O
employed	O
to	O
study	O
the	O
prevalence	O
of	O
SARS	B-DISO
infection	B-DISO
in	O
medical	O
workers	O
who	O
contacted	O
with	O
SARS	B-DISO
patients	O
directly	O
.	O

Seven	O
hundreds	O
and	O
twenty	O
medical	O
workers	O
including	O
doctors	O
,	O
nurses	O
and	O
nurse	O
-	O
assistants	O
were	O
involved	O
in	O
the	O
medical	O
care	O
of	O
patients	O
with	O
SARS	B-DISO
.	O

TITLE	O
:	O
[	O
Primary	O
analysis	O
of	O
reasons	O
and	O
countermeasures	O
for	O
19	O
cases	O
infection	B-DISO
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
health	O
care	O
workers	O
].	O

It	O
is	O
important	O
to	O
improve	O
the	O
protection	O
even	O
for	O
the	O
health	O
care	O
workers	O
without	O
contact	O
of	O
SARS	B-DISO
patients	O
,	O
and	O
it	O
'	O
s	O
necessary	O
to	O
wear	O
mask	O
,	O
goggles	O
,	O
and	O
gloves	O
,	O
health	O
care	O
workers	O
with	O
contact	O
with	O
SARS	B-DISO
patients	O
must	O
be	O
separated	O
according	O
the	O
extent	O
of	O
contact	O
separately	O
,	O
and	O
draw	O
guideline	O
in	O
advance	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
newly	O
emerged	O
,	O
highly	O
contagious	B-DISO
disease	I-DISO
.	O

Health	O
care	O
workers	O
remain	O
the	O
majority	O
of	O
total	O
infections	B-DISO
.	O

This	O
investigation	O
is	O
aimed	O
to	O
give	O
a	O
detailed	O
report	O
on	O
infection	B-DISO
control	O
precaution	O
taken	O
by	O
this	O
medical	O
team	O
.	O

TITLE	O
:	O
[	O
Immunoinformatic	O
analysis	O
for	O
the	O
epitopes	O
on	O
SARS	B-DISO
virus	O
surface	O
protein	O
].	O

The	O
immunoinformatics	O
is	O
a	O
powerful	O
fool	O
for	O
us	O
to	O
in	O
screen	O
the	O
epitope	O
specificial	O
for	O
SARS	B-DISO
virus	O
and	O
identifying	O
the	O
candidate	O
sites	O
for	O
peptide	O
vaccine	O
of	O
SARS	B-DISO
virus	O
.	O

ABSTRACT	O
:	O
To	O
clarify	O
the	O
characteristics	O
of	O
the	O
hardware	O
and	O
software	O
in	O
the	O
emergency	B-DISO
-	O
isolation	O
-	O
radiology	O
-	O
information	O
-	O
system	O
(	O
EIRIS	O
)	O
from	O
the	O
running	O
experience	O
of	O
EIRIS	O
during	O
the	O
epidemic	O
outbreak	O
stage	O
of	O
SARS	B-DISO
(	O
serious	O
acute	O
respiratory	O
syndrom	O
).	O

The	O
incidence	O
of	O
the	O
SARS	B-DISO
in	O
medical	O
staffs	O
was	O
recorded	O
before	O
and	O
after	O
the	O
EIRIS	O
was	O
employed	O
.	O

EIRIS	O
made	O
the	O
suspected	O
and	O
the	O
diagnosed	O
SARS	B-DISO
cases	O
away	O
from	O
the	O
non	O
-	O
isolation	O
area	O
effectively	O
.	O

RESULTS	O
:	O
EIRIS	O
made	O
the	O
suspected	O
and	O
the	O
diagnosed	O
SARS	B-DISO
cases	O
away	O
from	O
the	O
non	O
-	O
isolation	O
area	O
effectively	O
.	O

RESULTS	O
:	O
In	O
group	O
A	O
,	O
the	O
infectious	B-DISO
rate	O
of	O
in	O
-	O
hospital	O
medical	O
staffs	O
showed	O
a	O
marked	O
ascending	O
trend	O
with	O
the	O
regression	O
coefficient	O
of	O
0	O
.	O
000545	O
,	O
P	O
=	O
0	O
.	O
04	O
.	O

TITLE	O
:	O
[	O
Safety	O
surveillance	O
and	O
management	O
of	O
specimen	O
associated	O
with	O
SARS	B-DISO
in	O
clinical	O
laboratory	O
].	O

ABSTRACT	O
:	O
To	O
study	O
the	O
difference	O
among	O
the	O
ratios	O
of	O
SARS	B-DISO
suspect	O
cases	O
to	O
the	O
confirmed	O
ones	O
in	O
a	O
district	O
of	O
Beijing	O
,	O
the	O
whole	O
China	O
and	O
in	O
Beijing	O
,	O
and	O
to	O
provide	O
the	O
suggestions	O
for	O
clinical	O
diagnoses	O
in	O
SARS	B-DISO
epidemic	O
areas	O
.	O

TITLE	O
:	O
[	O
Medical	O
history	O
from	O
SARS	B-DISO
to	O
pneumonia	B-DISO
].	O

From	O
the	O
end	O
of	O
2002	O
to	O
the	O
beginning	O
of	O
2003	O
,	O
SARS	B-DISO
broke	O
in	O
Guangdong	O
province	O
,	O
Hong	O
Kong	O
and	O
Beijing	O
,	O
and	O
then	O
gradually	O
spread	O
to	O
the	O
world	O
.	O

Through	O
the	O
epidemic	O
of	O
SARS	B-DISO
,	O
the	O
author	O
hopes	O
to	O
express	O
that	O
contagion	O
will	O
live	O
with	O
us	O
for	O
a	O
long	O
time	O
,	O
but	O
it	O
is	O
not	O
a	O
deadly	O
disease	O
.	O

SARS	B-DISO
is	O
swept	O
across	O
almost	O
all	O
the	O
continents	O
of	O
the	O
globe	O
,	O
and	O
has	O
currently	O
involved	O
33	O
countries	O
and	O
regions	O
,	O
including	O
the	O
mainland	O
China	O
,	O
Hong	O
Kong	O
,	O
Taiwan	O
,	O
North	O
America	O
and	O
Europe	O
.	O

The	O
treatment	O
of	O
the	O
pre	O
-	O
existing	O
diseases	O
should	O
be	O
emphasized	O
in	O
the	O
treatment	O
of	O
critical	O
SARS	B-DISO
.	O

TITLE	O
:	O
[	O
Comparison	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
with	O
community	O
-	O
acquired	O
pneumonia	B-DISO
].	O

The	O
clinical	O
features	O
of	O
35	O
patients	O
with	O
SARS	B-DISO
in	O
the	O
past	O
five	O
months	O
were	O
retrospectively	O
studied	O
,	O
and	O
compared	O
with	O
35	O
patients	O
with	O
community	O
-	O
acquired	O
pneumonia	B-DISO
.	O

RESULTS	O
:	O
The	O
most	O
common	O
symptoms	O
included	O
fever	O
(	O
in	O
100	O
.	O
0	O
percent	O
of	O
the	O
patients	O
),	O
cough	B-DISO
(	O
74	O
.	O
3	O
percent	O
),	O
headache	B-DISO
(	O
45	O
.	O
7	O
percent	O
),	O
myalgia	B-DISO
(	O
45	O
.	O
7	O
percent	O
)	O
and	O
lymphopenia	B-DISO
(	O
20	O
/	O
33	O
).	O

TITLE	O
:	O
[	O
Detection	O
of	O
cell	O
apoptosis	O
in	O
the	O
pathological	O
tissues	O
of	O
patients	O
with	O
SARS	B-DISO
and	O
its	O
significance	O
].	O

Klenow	O
-	O
FragELTM	O
DNA	O
Fragmentation	B-DISO
Detection	O
Kit	O
and	O
immunohistochemical	O
alkaline	O
phosphatase	O
detection	O
reagent	O
kit	O
were	O
used	O
to	O
detect	O
cell	O
apoptosis	O
and	O
expressions	O
of	O
CD68	O
,	O
CD20	O
,	O
CD4	O
,	O
CD8	O
and	O
CD45RA	O
in	O
the	O
pathological	O
tissues	O
of	O
SARS	B-DISO
patients	O
.	O

RESULTS	O
:	O
A	O
large	O
quantity	O
of	O
proliferated	O
macrophages	O
could	O
be	O
observed	O
in	O
the	O
lungs	O
,	O
spleens	O
and	O
lymph	O
nodes	O
of	O
the	O
SARS	B-DISO
patients	O
,	O
some	O
of	O
which	O
were	O
positive	O
for	O
CD25	O
marker	O
(	O
active	O
macrophages	O
).	O

ABSTRACT	O
:	O
Inducible	O
nitric	O
oxide	O
synthase	O
(	O
iNOS	O
)	O
is	O
implicated	O
in	O
the	O
pathogenesis	B-DISO
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

This	O
study	O
was	O
designed	O
to	O
clarify	O
the	O
role	O
of	O
iNOS	O
in	O
mediating	O
extrapulmonary	O
comorbidity	O
in	O
sheep	O
after	O
combined	O
burn	O
and	O
smoke	O
inhalation	O
injuries	O
using	O
a	O
potent	O
and	O
highly	O
selective	O
iNOS	O
dimerization	O
inhibitor	O
,	O
BBS	B-DISO
-	O
2	O
.	O

Sheep	O
were	O
divided	O
into	O
four	O
groups	O
:	O
noninjured	O
and	O
nontreated	O
(	O
sham	O
group	O
;	O
n	O
=	O
6	O
),	O
noninjured	O
but	O
treated	O
with	O
BBS	B-DISO
-	O
2	O
(	O
sham	O
/	O
BBS	B-DISO
-	O
2	O
group	O
;	O
n	O
=	O
4	O
),	O
injured	O
but	O
nontreated	O
(	O
control	O
group	O
,	O
n	O
=	O
6	O
),	O
and	O
injured	O
but	O
treated	O
with	O
100	O
microg	O
.	O
kg	O
-	O
1	O
.	O
h	O
-	O
1	O
BBS	B-DISO
-	O
2	O
(	O
BBS	B-DISO
-	O
2	O
group	O
;	O
n	O
=	O
6	O
).	O

Other	O
common	O
symptoms	O
included	O
fatigue	B-DISO
,	O
cough	B-DISO
,	O
mild	O
sputum	O
production	O
,	O
chills	B-DISO
,	O
headache	B-DISO
,	O
general	B-DISO
malaise	I-DISO
and	O
myalgia	B-DISO
.	O

SARS	B-DISO
appears	O
to	O
be	O
highly	O
contagious	O
and	O
potentially	O
lethal	O
among	O
health	O
care	O
workers	O
,	O
characterized	O
by	O
acute	O
onset	O
and	O
rapid	O
progression	O
.	O

RESULTS	O
:	O
The	O
outbreak	O
started	O
with	O
a	O
SARS	B-DISO
patient	O
from	O
the	O
community	O
on	O
30	O
January	O
2003	O
,	O
followed	O
by	O
a	O
total	O
of	O
96	O
people	O
[	O
76	O
women	O
and	O
20	O
men	O
;	O
mean	O
age	O
(	O
29	O
.	O
5	O
+/-	O

37	O
SARS	B-DISO
patients	O
fulfilled	O
the	O
Guangdong	O
provincial	O
diagnostic	O
criteria	O
for	O
infectious	B-DISO
atypical	B-DISO
pneumonia	I-DISO
and	O
35	O
health	O
controls	O
were	O
investigated	O
.	O

TITLE	O
:	O
Investigation	O
of	O
a	O
nosocomial	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
Toronto	O
,	O
Canada	O
.	O

Based	O
on	O
42	O
of	O
the	O
128	O
cases	O
with	O
a	O
single	O
known	O
contact	O
with	O
a	O
SARS	B-DISO
case	O
,	O
the	O
mean	O
incubation	O
period	O
was	O
5	O
days	O
(	O
range	O
2	O
to	O
10	O
days	O
).	O

TITLE	O
:	O
Structural	O
genomics	O
of	O
the	O
SARS	B-DISO
coronavirus	O
:	O
cloning	O
,	O
expression	O
,	O
crystallization	O
and	O
preliminary	O
crystallographic	O
study	O
of	O
the	O
Nsp9	O
protein	O
.	O

Here	O
,	O
the	O
cloning	O
,	O
Escherichia	O
coli	O
expression	O
,	O
purification	O
and	O
crystallization	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
Nsp9	O
protein	O
,	O
the	O
first	O
SARS	B-DISO
-	O
CoV	O
protein	O
to	O
be	O
crystallized	O
,	O
are	O
reported	O
.	O

The	O
synthesis	O
of	O
these	O
mRNAs	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
cells	O
was	O
confirmed	O
experimentally	O
.	O

Ill	B-DISO
-	O
defined	O
air	O
-	O
space	O
shadowing	O
was	O
the	O
common	O
finding	O
in	O
all	O
the	O
children	O
.	O

Incidence	O
,	O
mortality	O
,	O
and	O
case	O
fatality	O
of	O
SARS	B-DISO
were	O
1	O
.	O
77	O
/	O
100	O
,	O
000	O
,	O
0	O
.	O
07	O
/	O
100	O
,	O
000	O
,	O
and	O
3	O
.	O
84	O
%	O
respectively	O
.	O

The	O
most	O
effective	O
way	O
to	O
control	O
SARS	B-DISO
is	O
to	O
break	O
the	O
chain	O
of	O
transmission	O
from	O
infected	O
to	O
healthy	O
persons	O
-	O
early	O
identification	O
,	O
prompt	O
and	O
effective	O
isolation	O
,	O
and	O
vigorous	O
close	O
contact	O
tracing	O
.	O

Clinical	O
data	O
of	O
70	O
patients	O
with	O
SARS	B-DISO
admitted	O
to	O
Youan	O
Hospital	O
in	O
Beijing	O
during	O
March	O
to	O
May	O
,	O
2003	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
(	O
1	O
)	O
Sixty	O
-	O
three	O
of	O
70	O
cases	O
of	O
SARS	B-DISO
recovered	O
and	O
seven	O
cases	O
died	O
,	O
with	O
a	O
case	O
-	O
fatality	O
ratio	O
of	O
10	O
%.	O

The	O
disease	O
was	O
mainly	O
transmitted	B-DISO
through	O
air	O
droplet	O
in	O
a	O
short	O
distance	O
,	O
and	O
overwork	O
induced	O
tiredness	B-DISO
was	O
involved	O
in	O
disease	O
stimulation	O
.	O

Abnormal	B-DISO
liver	I-DISO
function	I-DISO
was	O
found	O
in	O
27	O
cases	O
(	O
mostly	O
with	O
elevated	O
serum	O
ALT	O
),	O
with	O
70	O
%	O
occurred	O
at	O
the	O
3rd	O
or	O
4th	O
week	O
.	O

Inertia	O
and	O
myalgia	B-DISO
may	O
be	O
the	O
earlier	O
symptoms	O
of	O
health	O
care	O
workers	O
with	O
SARS	B-DISO
include	O
,	O
which	O
are	O
parallel	O
to	O
CT	O
manifestations	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
influence	O
of	O
the	O
surveillance	O
system	O
and	O
preventive	O
measurements	O
on	O
the	O
control	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
a	O
university	O
in	O
Guangdong	O
Province	O
.	O

Hence	O
,	O
scIHF2	O
may	O
be	O
used	O
as	O
a	O
novel	O
regulatory	O
cofactor	O
for	O
recombination	O
or	O
other	O
DNA	O
transactions	O
in	O
mammalian	O
cells	O
that	O
require	O
or	O
benefit	O
from	O
sequence	O
-	O
specific	O
high	O
precision	O
DNA	O
bending	B-DISO
.	O

It	O
is	O
especially	O
true	O
for	O
SARS	B-DISO
as	O
the	O
treatment	O
strategies	O
remain	O
diverse	O
and	O
experimental	O
.	O

TITLE	O
:	O
[	O
Acute	O
infectious	B-DISO
gastroenteritis	I-DISO
in	O
Rio	O
Cuarto	O
:	O
clinic	O
,	O
diagnosis	O
and	O
epidemiology	O
with	O
special	O
reference	O
to	O
viral	B-DISO
infections	I-DISO
].	O

ABSTRACT	O
:	O
Porcine	O
organs	O
,	O
cells	O
and	O
tissues	O
provide	O
a	O
viable	O
source	O
of	O
transplants	O
in	O
humans	O
,	O
though	O
there	O
is	O
some	O
concern	O
of	O
public	O
health	O
risk	O
from	O
adaptation	O
of	O
swine	O
infectious	B-DISO
agents	O
in	O
humans	O
.	O

TITLE	O
:	O
Inhibiting	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
by	O
small	O
interfering	O
RNA	O
.	O

Among	O
the	O
96	O
cases	O
,	O
26	O
cases	O
(	O
27	O
%)	O
had	O
diarrhea	B-DISO
,	O
17	O
(	O
18	O
%)	O
had	O
nausea	B-DISO
,	O
6	O
(	O
6	O
%)	O
had	O
vomiting	B-DISO
,	O
16	O
(	O
17	O
%)	O
had	O
bellyache	B-DISO
,	O
and	O
8	O
(	O
8	O
%)	O
had	O
ALT	O
elevation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
clarify	O
the	O
immunohistochemical	O
distribution	O
of	O
surfactant	O
-	O
associated	O
protein	O
A	O
(	O
SP	O
-	O
A	O
)	O
for	O
early	O
diagnosis	O
of	O
ARDS	B-DISO
with	O
special	O
regard	O
to	O
hyaline	B-DISO
membrane	I-DISO
(	O
HM	O
)	O
formation	O
.	O

These	O
results	O
might	O
reflect	O
chronic	O
hypoxic	B-DISO
condition	B-DISO
before	O
death	O
,	O
because	O
ORP	O
-	O
150	O
is	O
only	O
induced	O
when	O
a	O
hypoxic	B-DISO
condition	B-DISO
exist	O
,	O
but	O
not	O
acute	O
hypoxia	B-DISO
.	O

And	O
chronic	O
hypoxic	B-DISO
state	O
is	O
likely	O
to	O
be	O
antecedent	O
to	O
SIDS	B-DISO
.	O

Prolonged	O
hospital	O
stay	O
,	O
significant	O
early	O
morbidity	O
and	O
mortality	O
,	O
and	O
long	O
-	O
term	O
pulmonary	O
parenchymal	O
changes	O
that	O
result	O
in	O
reduced	O
,	O
often	O
debilitating	O
,	O
pulmonary	O
functions	O
,	O
typify	O
the	O
outcome	O
of	O
severe	O
form	O
of	O
ARDS	B-DISO
.	O

The	O
clinical	O
and	O
some	O
laboratory	O
data	O
of	O
154	O
patients	O
suffered	B-DISO
from	O
SARS	B-DISO
were	O
collected	O
and	O
analyzed	O
,	O
who	O
were	O
admitted	O
to	O
the	O
isolation	O
wards	O
of	O
Beijing	O
You	O
-	O
an	O
Hospital	O
from	O
March	O
11	O
to	O
June	O
3	O
,	O
2003	O
.	O

It	O
may	O
be	O
beneficial	O
to	O
suppress	O
cytokines	O
storm	O
in	O
SARS	B-DISO
patients	O
in	O
early	O
stage	O
,	O
which	O
will	O
stop	O
the	O
progression	O
of	O
SIRS	B-DISO
and	O
release	O
hepatic	B-DISO
damage	I-DISO
and	O
improve	O
the	O
prognosis	O
of	O
SARS	B-DISO
patients	O
.	O

ABSTRACT	O
:	O
In	O
March	O
2003	O
,	O
SARS	B-DISO
-	O
CoV	O
,	O
a	O
novel	O
coronavirus	O
which	O
has	O
been	O
proved	O
to	O
be	O
a	O
pathogen	O
causing	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
).	O

The	O
analysis	O
indicated	O
that	O
SARS	B-DISO
-	O
CoV	O
has	O
lower	O
redundancy	O
,	O
that	O
is	O
,	O
it	O
has	O
a	O
high	O
variation	O
possibility	O
.	O

SARS	B-DISO
is	O
a	O
severe	O
form	O
of	O
the	O
epidemic	O
outbreak	O
of	O
atypical	B-DISO
pneumonia	I-DISO
which	O
remains	O
poorly	O
defined	O
regarding	O
etiology	O
and	O
special	O
therapy	O
recommendations	O
.	O

Infiltration	B-DISO
of	O
pancreatic	O
and	O
lung	O
tissue	O
with	O
neutrophils	O
(	O
measured	O
as	O
increase	O
in	O
myeloperoxidase	O
activity	O
)	O
was	O
associated	O
with	O
enhanced	O
lipid	O
peroxidation	O
(	O
increased	O
tissue	O
levels	O
of	O
malondialdehyde	O
).	O

The	O
current	O
authors	O
tested	O
a	O
therapeutic	O
intervention	O
on	O
a	O
previously	O
defined	O
pathophysiological	O
model	O
of	O
ARDS	B-DISO
.	O

In	O
these	O
studies	O
,	O
the	O
present	O
authors	O
provided	O
biological	O
and	O
morphological	O
evidence	O
indicating	O
that	O
ARDS	B-DISO
patients	O
failing	O
to	O
improve	O
after	O
1	O
week	O
of	O
mechanical	O
ventilation	O
(	O
unresolving	O
ARDS	B-DISO
)	O
have	O
intense	O
and	O
protracted	O
(	O
dysregulated	O
)	O
pulmonary	O
and	O
systemic	O
inflammatory	O
and	O
neo	O
-	O
fibrogenetic	O
activity	O
.	O

TITLE	O
:	O
High	O
-	O
dose	O
pulse	O
versus	O
nonpulse	O
corticosteroid	O
regimens	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
newly	O
described	O
and	O
highly	O
contagious	O
respiratory	B-DISO
infection	I-DISO
.	O

The	O
success	O
of	O
reducing	O
the	O
burden	O
of	O
this	O
infection	B-DISO
in	O
children	O
will	O
depend	O
on	O
proper	O
isolation	O
of	O
infected	O
adults	O
early	O
in	O
the	O
course	B-DISO
of	I-DISO
illness	I-DISO
.	O

TITLE	O
:	O
Rapidly	O
progressing	O
case	O
of	O
Mounier	B-DISO
-	I-DISO
Kuhn	I-DISO
Syndrome	I-DISO
in	O
early	O
childhood	O
.	O

ABSTRACT	O
:	O
Molecular	O
Adsorbents	O
Recirculating	O
System	O
(	O
MARS	O
)	O
is	O
a	O
new	O
promising	O
artificial	O
liver	O
support	O
therapy	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effectiveness	O
of	O
MARS	O
to	O
remove	O
nitrous	O
oxide	O
(	O
NO	O
)	O
and	O
cytokines	O
in	O
severe	O
liver	B-DISO
failure	I-DISO
patients	O
with	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
(	O
MODS	B-DISO
).	O

The	O
MARS	O
therapy	O
was	O
associated	O
with	O
a	O
significant	O
removal	O
of	O
NO	O
and	O
certain	O
cytokines	O
such	O
as	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
and	O
INF	O
-	O
gamma	O
,	O
together	O
with	O
marked	O
reduction	O
of	O
other	O
non	O
-	O
water	O
-	O
soluble	O
albumin	O
bound	O
toxins	O
and	O
water	O
-	O
soluble	O
toxins	O
,	O
these	O
were	O
associated	O
with	O
a	O
improvement	O
of	O
the	O
patients	O
'	O
clinical	O
conditions	O
including	O
hepatic	B-DISO
encephalopathy	I-DISO
,	O
deranged	O
hemodynamic	O
situation	O
and	O
as	O
well	O
as	O
renal	O
and	O
respiratory	O
function	O
,	O
thus	O
resulted	O
into	O
marked	O
decrease	O
of	O
Sequential	O
Organ	B-DISO
Failure	I-DISO
Assessment	O
(	O
SOFA	O
)	O
score	O
and	O
improved	O
outcome	O
:	O
nine	O
patients	O
were	O
able	O
to	O
be	O
discharged	O
from	O
the	O
hospital	O
or	O
bridged	O
to	O
successful	O
liver	O
transplantation	O
,	O
the	O
overall	O
survival	O
of	O
24	O
patients	O
was	O
37	O
.	O
5	O
%.	O

This	O
was	O
later	O
termed	O
by	O
the	O
World	O
Health	O
Organisation	O
as	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
).	O

A	O
preliminary	O
review	O
of	O
SARS	B-DISO
in	O
Singapore	O
shows	O
chest	O
radiographic	O
findings	O
of	O
patchy	O
airspace	O
shadowing	O
with	O
severe	O
cases	O
progressing	O
to	O
diffuse	O
air	O
-	O
space	O
shadowing	O
.	O

In	O
conclusion	O
,	O
combined	O
use	O
of	O
aerosolised	O
iloprost	O
and	O
subthreshold	O
systemic	O
phosphodiesterase	O
-	O
3	O
/	O
4	O
inhibitor	O
may	O
result	O
in	O
selective	O
intrapulmonary	O
vasodilation	B-DISO
,	O
a	O
reduction	O
in	O
oedema	B-DISO
formation	O
and	O
an	O
improvement	O
in	O
ventilation	O
-	O
perfusion	O
matching	O
in	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Antibody	O
responsiveness	O
during	O
immunization	O
and	O
challenge	O
of	O
genetically	O
modified	O
antibody	O
responder	O
mice	O
with	O
murine	B-DISO
hepatitis	I-DISO
virus	O
3	O
.	O

Although	O
mounting	O
a	O
Th2	O
response	O
as	O
indicated	O
by	O
IgG1	O
responses	O
,	O
they	O
were	O
also	O
able	O
to	O
readily	O
synthesize	O
large	O
amounts	O
of	O
IgG2a	O
antibodies	O
after	O
immunization	O
or	O
during	O
infection	B-DISO
,	O
reflecting	O
a	O
Th1	O
response	O
.	O

The	O
transfer	O
of	O
anti	O
-	O
MHV	O
antibodies	O
to	O
susceptible	O
HIII	O
mice	O
was	O
capable	O
of	O
conferring	O
resistance	O
to	O
MHV3	O
,	O
providing	O
the	O
antibodies	O
were	O
present	O
before	O
virus	B-DISO
infection	I-DISO
and	O
in	O
large	O
amounts	O
.	O

TITLE	O
:	O
[	O
Equipment	O
for	O
SARS	B-DISO
control	O
in	O
patient	O
care	O
units	O
and	O
in	O
units	O
that	O
process	O
infected	O
samples	O
.	O

It	O
emerged	O
in	O
March	O
this	O
year	O
in	O
China	O
and	O
seemed	O
to	O
be	O
apt	O
to	O
sweep	O
over	O
the	O
world	O
as	O
a	O
kind	O
of	O
Spanish	O
Flu	B-DISO
.	O

Our	O
data	O
suggested	O
that	O
these	O
patients	O
'	O
immune	O
systems	O
were	O
impaired	B-DISO
during	O
the	O
course	O
of	O
SARS	B-DISO
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
role	O
of	O
HO	O
-	O
1	O
induction	O
in	O
a	O
rat	O
model	O
of	O
CCl	B-DISO
(	O
4	O
)-	O
induced	O
acute	O
liver	O
injury	O
.	O

This	O
study	O
concentrated	O
on	O
the	O
first	O
30	O
min	O
of	O
infection	B-DISO
.	O

At	O
5	O
min	O
after	O
infection	B-DISO
,	O
several	O
virus	O
particles	O
lined	O
the	O
Vero	O
cell	O
plasma	O
membrane	O
.	O

ABSTRACT	O
:	O
We	O
analyzed	O
temporal	O
stability	O
and	O
geographic	O
trends	O
in	O
cumulative	O
case	O
-	O
fatality	O
rates	O
and	O
average	O
doubling	O
times	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

We	O
present	O
the	O
clinical	O
course	O
and	O
chest	O
radiographic	O
findings	O
of	O
a	O
case	O
of	O
SARS	B-DISO
with	O
fatal	O
outcome	O
.	O

TITLE	O
:	O
Association	O
of	O
HLA	O
class	O
I	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	B-DISO
infection	I-DISO
.	O

Woolf	O
and	O
Haldane	O
Odds	O
ratio	O
(	O
OR	O
)	O
and	O
corrected	O
P	O
-	O
value	O
(	O
Pc	O
)	O
obtained	O
from	O
two	O
tails	O
Fisher	O
exact	O
test	O
were	O
used	O
to	O
show	O
susceptibility	O
of	O
HLA	O
class	O
I	O
or	O
class	O
II	O
alleles	O
with	O
coronavirus	B-DISO
infection	I-DISO
.	O

After	O
selecting	O
only	O
a	O
""""	O
severe	O
cases	O
""""	O
patient	O
group	O
from	O
the	O
infected	O
""""	O
probable	O
SARS	B-DISO
""""	O
patient	O
group	O
and	O
comparing	O
them	O
with	O
the	O
high	O
risk	O
health	O
care	O
workers	O
group	O
,	O
the	O
severity	O
of	O
SARS	B-DISO
was	O
shown	O
to	O
be	O
significantly	O
associated	O
with	O
HLA	O
-	O
B	O
*	O
4601	O
(	O
P	O
=	O
0	O
.	O
0008	O
or	O
Pc	O
=	O
0	O
.	O
0279	O
).	O

After	O
selecting	O
only	O
a	O
""""	O
severe	O
cases	O
""""	O
patient	O
group	O
from	O
the	O
infected	O
""""	O
probable	O
SARS	B-DISO
""""	O
patient	O
group	O
and	O
comparing	O
them	O
with	O
the	O
high	O
risk	O
health	O
care	O
workers	O
group	O
,	O
the	O
severity	O
of	O
SARS	B-DISO
was	O
shown	O
to	O
be	O
significantly	O
associated	O
with	O
HLA	O
-	O
B	O
*	O
4601	O
(	O
P	O
=	O
0	O
.	O
0008	O
or	O
Pc	O
=	O
0	O
.	O
0279	O
).	O

The	O
following	O
interventions	O
were	O
systematically	O
reviewed	O
for	O
inclusion	O
in	O
the	O
guidelines	O
:	O
enteral	O
nutrition	O
(	O
EN	O
)	O
versus	O
parenteral	O
nutrition	O
(	O
PN	O
),	O
early	O
versus	O
late	O
EN	O
,	O
dose	O
of	O
EN	O
,	O
composition	O
of	O
EN	O
(	O
protein	O
,	O
carbohydrates	O
,	O
lipids	O
,	O
immune	O
-	O
enhancing	O
additives	O
),	O
strategies	O
to	O
optimize	O
delivery	O
of	O
EN	O
and	O
minimize	O
risks	O
(	O
ie	O
,	O
rate	O
of	O
advancement	O
,	O
checking	O
residuals	O
,	O
use	O
of	O
bedside	O
algorithms	O
,	O
motility	O
agents	O
,	O
small	O
bowel	O
versus	O
gastric	O
feedings	O
,	O
elevation	O
of	O
the	O
head	O
of	O
the	O
bed	B-DISO
,	O
closed	O
delivery	O
systems	O
,	O
probiotics	O
,	O
bolus	O
administration	O
),	O
enteral	O
nutrition	O
in	O
combination	O
with	O
supplemental	O
PN	O
,	O
use	O
of	O
PN	O
versus	O
standard	O
care	O
in	O
patients	O
with	O
an	O
intact	O
gastrointestinal	O
tract	O
,	O
dose	O
of	O
PN	O
and	O
composition	O
of	O
PN	O
(	O
protein	O
,	O
carbohydrates	O
,	O
IV	O
lipids	O
,	O
additives	O
,	O
vitamins	O
,	O
trace	O
elements	O
,	O
immune	O
enhancing	O
substances	O
),	O
and	O
the	O
use	O
of	O
intensive	O
insulin	O
therapy	O
.	O

The	O
major	O
potential	O
benefit	O
from	O
implementing	O
these	O
guidelines	O
is	O
improved	O
clinical	O
outcomes	O
of	O
critically	B-DISO
ill	I-DISO
patients	O
(	O
reduced	O
mortality	O
and	O
ICU	O
stay	O
).	O

TITLE	O
:	O
[	O
Relationship	O
between	O
acid	O
-	O
base	O
disturbance	O
in	O
blood	O
gas	O
analysis	O
and	O
prognosis	O
of	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
].	O

pH	O
in	O
blood	O
had	O
no	O
significant	O
influence	O
on	O
the	O
prognosis	O
of	O
SARS	B-DISO
patients	O
.	O

The	O
artery	O
blood	O
gas	O
analysis	O
is	O
useful	O
for	O
judging	O
the	O
conditions	O
and	O
prognosis	O
of	O
patients	O
with	O
SARS	B-DISO
,	O
and	O
is	O
beneficial	O
for	O
clinical	O
treatment	O
.	O

CONCLUSIONS	O
:	O
The	O
artery	O
blood	O
gas	O
analysis	O
is	O
useful	O
for	O
judging	O
the	O
conditions	O
and	O
prognosis	O
of	O
patients	O
with	O
SARS	B-DISO
,	O
and	O
is	O
beneficial	O
for	O
clinical	O
treatment	O
.	O

Thirty	O
strains	O
of	O
bacteria	O
from	O
seven	O
cases	O
of	O
SARS	B-DISO
patients	O
with	O
secondary	O
bacterial	B-DISO
infection	I-DISO
were	O
classified	O
and	O
drug	O
resistance	O
was	O
analyzed	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
risk	O
factors	O
in	O
the	O
dead	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

The	O
mean	O
age	O
was	O
67	O
years	O
old	O
in	O
12	O
dead	O
cases	O
with	O
SARS	B-DISO
and	O
was	O
42	O
in	O
recovered	O
control	O
group	O
.	O

Other	O
risk	O
factors	O
include	O
the	O
decline	O
of	O
immune	O
function	O
,	O
secondary	B-DISO
infection	I-DISO
,	O
complications	O
and	O
use	O
of	O
invasive	O
ventilation	O
.	O

RESULTS	O
:	O
The	O
mean	O
age	O
was	O
67	O
years	O
old	O
in	O
12	O
dead	O
cases	O
with	O
SARS	B-DISO
and	O
was	O
42	O
in	O
recovered	O
control	O
group	O
.	O

CONCLUSIONS	O
:	O
The	O
age	O
and	O
basic	O
diseases	O
are	O
the	O
main	O
mortal	O
risk	O
factors	O
in	O
SARS	B-DISO
.	O

TITLE	O
:	O
[	O
Analysis	O
on	O
the	O
epidemiological	O
features	O
and	O
the	O
transmission	O
of	O
an	O
imported	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
case	O
in	O
Beijing	O
].	O

RESULTS	O
:	O
The	O
first	O
imported	O
SARS	B-DISO
case	O
introduced	O
to	O
Beijing	O
had	O
infected	O
9	O
people	O
within	O
the	O
family	O
and	O
at	O
the	O
hospital	O
,	O
with	O
two	O
of	O
whom	O
died	O
of	O
the	O
same	O
disease	O
.	O

(	O
2	O
)	O
68	O
.	O
6	O
%	O
of	O
the	O
total	O
SARS	B-DISO
patients	O
were	O
concentrated	O
in	O
3	O
hospitals	O
A	O
,	O
B	O
and	O
C	O
which	O
was	O
menifastated	O
in	O
'	O
clustering	O
'.	O

Through	O
study	O
on	O
the	O
rest	O
of	O
the	O
SARS	B-DISO
patients	O
,	O
results	O
showed	O
that	O
16	O
.	O
8	O
%	O
of	O
them	O
were	O
transmitted	B-DISO
through	O
family	O
close	O
contact	O
and	O
2	O
.	O
3	O
%	O
due	O
to	O
contact	O
to	O
colleagues	O
.	O

Factors	O
that	O
influence	O
whether	O
FCoV	O
establishes	O
lifelong	O
infection	B-DISO
in	O
some	O
cats	O
and	O
not	O
others	O
are	O
determined	O
mainly	O
by	O
the	O
host	O
response	O
to	O
infection	B-DISO
.	O

TITLE	O
:	O
Cloaked	O
similarity	O
between	O
HIV	B-DISO
-	O
1	O
and	O
SARS	B-DISO
-	O
CoV	O
suggests	O
an	O
anti	O
-	O
SARS	B-DISO
strategy	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
febrile	O
respiratory	O
illness	O
.	O

The	O
exact	O
origin	O
of	O
the	O
cause	O
of	O
the	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
still	O
an	O
open	O
question	O
.	O

TITLE	O
:	O
[	O
Dynamic	O
analysis	O
of	O
TCM	O
syndrome	B-DISO
in	O
63	O
patients	O
of	O
SARS	B-DISO
].	O

TCM	O
syndrome	B-DISO
of	O
SARS	B-DISO
patients	O
has	O
its	O
characteristics	O
and	O
regularity	O
of	O
changes	O
,	O
which	O
was	O
in	O
accordance	O
with	O
the	O
laboratory	O
findings	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
characterized	O
by	O
an	O
overaggressive	O
immune	O
response	O
.	O

For	O
example	O
,	O
consideration	O
should	O
be	O
given	O
to	O
the	O
development	O
of	O
a	O
vaccine	O
that	O
will	O
protect	O
across	O
regional	O
strains	O
of	O
SARS	B-DISO
,	O
as	O
the	O
newly	O
emergent	O
coronavirus	O
SARS	B-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
proving	O
to	O
be	O
variable	O
and	O
may	O
be	O
mutating	O
in	O
response	O
to	O
immune	O
pressure	O
.	O

SARS	B-DISO
-	O
specific	O
research	O
reagents	O
should	O
also	O
be	O
collected	O
and	O
shared	O
.	O

Understanding	O
the	O
pathology	B-DISO
of	O
DAD	O
in	O
SARS	B-DISO
patients	O
may	O
provide	O
the	O
basis	O
for	O
therapeutic	O
strategies	O
.	O

The	O
syndrome	B-DISO
is	O
caused	O
by	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
,	O
a	O
novel	O
human	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
To	O
elucidate	O
the	O
mechanism	O
of	O
strong	O
inflammatory	B-DISO
response	I-DISO
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
.	O

CONCLUSIONS	O
:	O
The	O
SARS	B-DISO
-	O
associated	O
coronovirus	O
infection	B-DISO
may	O
cause	O
complex	O
cytokine	O
cascade	O
.	O

TITLE	O
:	O
Enteric	O
involvement	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
recently	O
emerged	O
infection	B-DISO
from	O
a	O
novel	O
coronavirus	O
(	O
CoV	O
).	O

Diarrhea	B-DISO
was	O
more	O
frequently	O
observed	O
during	O
the	O
first	O
week	O
of	O
illness	O
.	O

TITLE	O
:	O
Role	O
of	O
China	O
in	O
the	O
quest	O
to	O
define	O
and	O
control	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

The	O
nonspecific	O
signs	B-DISO
and	I-DISO
symptoms	I-DISO
of	O
this	O
disease	O
,	O
coupled	O
with	O
a	O
relatively	O
long	O
incubation	O
period	O
and	O
the	O
initial	O
absence	O
of	O
a	O
reliable	O
diagnostic	O
test	O
,	O
limited	O
the	O
understanding	O
of	O
the	O
magnitude	O
of	O
the	O
outbreak	O
.	O

We	O
performed	O
a	O
retrospective	O
case	O
series	O
analysis	O
to	O
assess	O
clinical	O
outcome	O
and	O
identify	O
pretreatment	O
prognostic	O
correlates	O
of	O
SARS	B-DISO
,	O
managed	O
under	O
a	O
standardized	O
treatment	O
protocol	O
.	O

Pneumonitis	B-DISO
progressed	O
rapidly	O
in	O
the	O
remaining	O
patients	O
.	O

TITLE	O
:	O
Microbiologic	O
characteristics	O
,	O
serologic	O
responses	O
,	O
and	O
clinical	O
manifestations	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
Taiwan	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
caused	O
by	O
coronavirus	O
has	O
become	O
an	O
epidemic	O
affecting	O
many	O
regions	O
worldwide	O
.	O

The	O
authors	O
carried	O
out	O
an	O
emergency	B-DISO
tracheostomy	O
and	O
changed	O
the	O
tracheostomy	O
tube	O
for	O
one	O
patient	O
and	O
performed	O
elective	O
tracheostomy	O
in	O
another	O
two	O
patients	O
.	O

All	O
patients	O
had	O
fever	O
(	O
5	O
/	O
5	O
),	O
3	O
chills	B-DISO
or	O
rigor	B-DISO
,	O
4	O
cough	B-DISO
;	O
2	O
with	O
decreased	B-DISO
lymphocyte	I-DISO
,	O
2	O
decreased	O
platelet	O
,	O
3	O
elevated	O
alanine	O
aminotransferase	O
(	O
ALT	O
),	O
4	O
hypoalbuminemia	O
,	O
5	O
abnormal	O
chest	O
radiographs	O
.	O

CONCLUSIONS	O
:	O
By	O
optimizing	O
RNA	O
extraction	O
methods	O
and	O
applying	O
quantitative	O
real	O
time	O
RT	O
-	O
PCR	O
technologies	O
,	O
the	O
sensitivity	O
of	O
tests	O
for	O
early	O
diagnosis	O
of	O
SARS	B-DISO
can	O
be	O
greatly	O
enhanced	O
.	O

TITLE	O
:	O
SARS	B-DISO
-	O
coronavirus	O
replicates	O
in	O
mononuclear	O
cells	O
of	O
peripheral	O
blood	O
(	O
PBMCs	O
)	O
from	O
SARS	B-DISO
patients	O
.	O

SARS	B-DISO
-	O
coronavirus	O
can	O
infect	O
and	O
replicate	O
within	O
PBMCs	O
of	O
SARS	B-DISO
patients	O
,	O
but	O
viral	O
replication	O
in	O
PBMCs	O
seems	O
subject	O
to	O
self	O
-	O
limitation	O
.	O

ABSTRACT	O
:	O
The	O
sudden	O
appearance	O
and	O
potential	O
lethality	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
in	O
humans	O
has	O
focused	O
attention	O
on	O
understanding	O
its	O
origins	O
.	O

Comparison	O
of	O
phylogenetic	O
trees	O
for	O
11	O
known	O
host	O
-	O
species	O
and	O
36	O
coronaviruses	O
,	O
representing	O
coronavirus	O
groups	O
1	O
-	O
3	O
and	O
SARS	B-DISO
-	O
CoV	O
,	O
based	O
on	O
N	O
showed	O
statistical	O
incongruence	O
indicating	O
multiple	O
host	O
-	O
species	O
shifts	O
for	O
coronaviruses	O
.	O

TITLE	O
:	O
Ability	O
of	O
Massachusetts	O
-	O
type	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
to	O
increase	O
colibacillosis	B-DISO
susceptibility	O
in	O
commercial	O
broilers	O
:	O
a	O
comparison	O
between	O
vaccine	O
and	O
virulent	O
field	O
virus	O
.	O

The	O
incidence	O
of	O
nasal	B-DISO
discharge	I-DISO
at	O
3	O
and	O
5	O
days	O
after	O
IB	O
virus	B-DISO
infection	I-DISO
was	O
used	O
to	O
assess	O
the	O
clinical	O
effect	O
of	O
the	O
IB	O
infection	B-DISO
,	O
while	O
mortality	O
,	O
body	O
weight	O
uniformity	O
and	O
E	O
.	O
coli	O
lesions	O
at	O
7	O
days	O
following	O
E	O
.	O
coli	O
inoculation	O
were	O
used	O
as	O
parameters	O
for	O
colibacillosis	B-DISO
.	O

TITLE	O
:	O
Infants	O
born	O
to	O
mothers	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

Mild	O
focal	O
alveolar	O
infiltrates	B-DISO
were	O
the	O
predominant	O
chest	O
radiograph	O
abnormality	O
.	O

Sixty	O
-	O
one	O
cases	O
of	O
SARS	B-DISO
with	O
positive	O
antibodies	O
to	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
were	O
classified	O
into	O
the	O
following	O
categories	O
:	O
initial	O
stage	O
(	O
3	O
-	O
7	O
days	O
),	O
peak	O
stage	O
(	O
8	O
-	O
14	O
days	O
),	O
and	O
remission	B-DISO
and	O
recovery	O
stage	O
(	O
15	O
-	O
27	O
days	O
).	O

SARS	B-DISO
patients	O
experienced	O
higher	O
concentration	O
of	O
serum	O
IL	O
-	O
13	O
compared	O
with	O
the	O
controls	O
in	O
initial	O
stage	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
but	O
returned	O
to	O
normal	O
levels	O
in	O
peak	O
stage	O
and	O
in	O
remission	B-DISO
and	O
recovery	O
stage	O
.	O

The	O
mean	O
concentration	O
of	O
serum	O
IL	O
-	O
18	O
in	O
SARS	B-DISO
patients	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
control	O
group	O
during	O
all	O
clinical	O
courses	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Although	O
TGF	O
-	O
beta1	O
in	O
serum	O
decreased	O
in	O
remission	B-DISO
and	O
recovery	O
stage	O
in	O
SARS	B-DISO
patients	O
,	O
the	O
average	O
was	O
still	O
higher	O
than	O
that	O
of	O
the	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Seventeen	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
genome	O
sequences	O
in	O
GenBank	O
were	O
compared	O
to	O
analyze	O
the	O
common	O
sequence	O
variations	O
and	O
the	O
probability	O
of	O
co	O
-	O
occurrence	O
of	O
multiple	O
polymorphisms	O
or	O
mutations	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
Hong	O
Kong	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
recently	O
recognized	O
and	O
highly	O
contagious	O
pneumonic	O
illness	O
,	O
caused	O
by	O
a	O
novel	O
coronavirus	O
.	O

40	O
hospital	O
workers	O
infected	O
with	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
over	O
a	O
6	O
-	O
week	O
period	O
(	O
25	O
March	O
through	O
5	O
May	O
2003	O
).	O

Third	O
,	O
despite	O
trends	O
toward	O
commercialization	O
,	O
easier	O
lives	O
,	O
and	O
self	O
-	O
centered	O
individualism	O
,	O
the	O
response	O
of	O
health	O
care	O
professionals	O
to	O
SARS	B-DISO
reaffirmed	O
dedication	O
to	O
caring	O
for	O
the	O
sick	O
even	O
at	O
great	O
personal	O
risks	O
as	O
the	O
core	O
ethical	O
principle	O
of	O
medicine	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
underlying	O
cellular	O
mechanisms	O
in	O
the	O
pancreas	O
after	O
acute	B-DISO
pancreatitis	I-DISO
and	O
to	O
study	O
the	O
pathogenesis	B-DISO
of	O
pancreatitis	B-DISO
-	O
associated	O
lung	O
injury	O
.	O

Of	O
the	O
6	O
imported	O
cases	O
,	O
which	O
all	O
occurred	O
before	O
screening	O
measures	O
were	O
implemented	O
at	O
the	O
airport	O
,	O
only	O
the	O
first	O
resulted	O
in	O
extensive	O
secondary	B-DISO
transmission	I-DISO
.	O

Of	O
442973	O
air	O
passengers	O
screened	O
after	O
measures	O
were	O
implemented	O
,	O
136	O
were	O
sent	O
to	O
a	O
designated	O
hospital	O
for	O
further	O
SARS	B-DISO
screening	O
;	O
none	O
was	O
diagnosed	O
as	O
having	O
SARS	B-DISO
.	O

TITLE	O
:	O
Churg	B-DISO
-	I-DISO
Strauss	I-DISO
syndrome	I-DISO
with	O
myocarditis	B-DISO
manifesting	O
as	O
acute	B-DISO
myocardial	I-DISO
infarction	I-DISO
with	O
cardiogenic	B-DISO
shock	I-DISO
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

Subsequent	O
endomyocardial	O
biopsy	O
showed	O
myocarditis	B-DISO
with	O
prominent	O
eosinophil	O
and	O
plasma	O
cell	O
components	O
.	O

Blood	O
test	O
revealed	O
deep	O
lymphopenia	B-DISO
and	O
elevated	O
LDH	O
.	O

CONCLUSIONS	O
:	O
The	O
clinical	O
symptoms	O
of	O
SARS	B-DISO
are	O
unspecific	O
and	O
its	O
evolution	O
may	O
be	O
misleading	O
.	O

ABSTRACT	O
:	O
Sixty	O
-	O
nine	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
discharged	O
from	O
Guangdong	O
Provincial	O
TCM	O
Hospital	O
were	O
followed	O
up	O
from	O
January	O
to	O
April	O
2003	O
during	O
which	O
the	O
patients	O
were	O
asked	O
to	O
fill	O
the	O
questionnaire	O
form	O
and	O
at	O
the	O
same	O
time	O
received	O
blood	O
routine	O
examination	O
,	O
hepatic	O
,	O
renal	O
,	O
pulmonary	O
and	O
immune	O
function	O
tests	O
,	O
and	O
spiral	O
computerized	O
tomography	O
(	O
CT	O
)	O
of	O
the	O
chest	O
,	O
color	O
B	O
-	O
ultrasonography	O
of	O
the	O
heart	O
with	O
the	O
collected	O
data	O
treated	O
by	O
descriptive	O
analysis	O
and	O
deductive	O
analysis	O
.	O

The	O
results	O
showed	O
that	O
in	O
the	O
69	O
followed	O
-	O
up	O
patients	O
,	O
impairment	B-DISO
of	O
the	O
hepatic	O
function	O
was	O
found	O
in	O
5	O
cases	O
,	O
hypoimmune	O
state	O
in	O
18	O
,	O
impediment	O
of	O
ventilation	O
in	O
the	O
distal	O
air	O
passages	O
with	O
normal	O
major	O
air	O
passages	O
in	O
15	O
,	O
increased	O
residual	O
volume	O
in	O
40	O
,	O
mild	O
disturbance	O
of	O
pulmonary	O
diffusion	O
function	O
in	O
14	O
,	O
incomplete	O
absorption	O
of	O
inflammatory	O
exudates	O
,	O
focal	O
or	O
multiple	O
interstitial	O
lesions	O
,	O
pulmonary	B-DISO
interstitial	I-DISO
fibrosis	I-DISO
and	O
pleural	B-DISO
adhesion	I-DISO
in	O
24	O
;	O
increased	O
resistance	O
or	O
mild	O
systolic	B-DISO
hypertension	I-DISO
in	O
the	O
pulmonary	O
circulation	O
,	O
and	O
segmental	O
ischemia	B-DISO
of	O
the	O
left	O
myocardium	O
in	O
34	O
;	O
and	O
decreased	O
visual	O
acuity	O
in	O
2	O
.	O

During	O
the	O
recovery	O
,	O
follow	O
-	O
up	O
stages	O
and	O
in	O
the	O
front	O
healthy	O
crowd	O
,	O
the	O
positive	O
ratios	O
of	O
IgG	O
were	O
all	O
higher	O
than	O
those	O
of	O
IgM	O
.	O
The	O
changeable	O
tendency	O
SARS	B-DISO
antibody	O
is	O
more	O
different	O
than	O
that	O
of	O
other	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

There	O
were	O
102	O
men	O
and	O
83	O
women	O
in	O
185	O
dead	O
cases	O
of	O
SARS	B-DISO
,	O
in	O
which	O
average	O
age	O
was	O
56	O
.	O
4	O
years	O
,	O
85	O
cases	O
were	O
older	O
than	O
60	O
years	O
.	O

Lung	O
injury	O
,	O
obstinate	O
hypoxemia	O
,	O
abnormality	O
metabolize	O
of	O
hyperglycemia	B-DISO
and	O
misusing	O
glucocorticoids	O
and	O
antibiotic	O
leading	O
to	O
secondary	B-DISO
infection	I-DISO
are	O
the	O
main	O
reasons	O
for	O
SARS	B-DISO
patients	O
dying	O
.	O

RESULTS	O
:	O
There	O
were	O
102	O
men	O
and	O
83	O
women	O
in	O
185	O
dead	O
cases	O
of	O
SARS	B-DISO
,	O
in	O
which	O
average	O
age	O
was	O
56	O
.	O
4	O
years	O
,	O
85	O
cases	O
were	O
older	O
than	O
60	O
years	O
.	O

The	O
foreign	O
gene	B-DISO
insertions	I-DISO
generally	O
reduced	O
the	O
expression	O
of	O
upstream	O
viral	O
genes	O
.	O

A	O
nonenteropathogenic	O
mutant	B-DISO
virus	O
that	O
lacked	O
a	O
sialic	O
acid	O
binding	O
activity	O
was	O
unable	O
to	O
bind	O
to	O
MGP	O
and	O
to	O
attach	O
to	O
goblet	O
cells	O
.	O

TITLE	O
:	O
Prevalence	O
of	O
IgG	O
antibody	O
to	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
in	O
animal	O
traders	O
--	O
Guangdong	O
Province	O
,	O
China	O
,	O
2003	O
.	O

Because	O
its	O
sequence	O
data	O
differ	O
from	O
that	O
of	O
known	O
human	O
coronaviruses	O
,	O
SARS	B-DISO
-	O
CoV	O
is	O
suspected	O
to	O
have	O
crossed	O
the	O
species	O
barrier	O
between	O
an	O
animal	O
host	O
and	O
humans	O
.	O

The	O
SARS	B-DISO
outbreak	O
began	O
in	O
China	O
'	O
s	O
Guangdong	O
Province	O
,	O
where	O
approximately	O
1	O
,	O
500	O
probable	O
cases	O
were	O
identified	O
during	O
November	O
2002	O
-	O
June	O
2003	O
.	O

Themes	O
were	O
:	O
(	O
a	O
)	O
changing	O
schemas	O
of	O
nursing	O
practice	O
:	O
the	O
new	O
normal	O
;	O
(	O
b	O
)	O
barriers	O
to	O
relational	O
nursing	O
work	O
;	O
(	O
c	O
)	O
work	O
life	O
concerns	O
:	O
retention	O
and	O
recruitment	B-DISO
;	O
(	O
d	O
)	O
nursing	O
virtue	O
:	O
nurses	O
as	O
heroes	O
and	O
professionals	O
;	O
(	O
e	O
)	O
paradoxical	O
responses	O
to	O
nurses	O
from	O
the	O
community	O
;	O
and	O
(	O
f	O
)	O
leadership	O
in	O
nursing	O
during	O
the	O
SARS	B-DISO
crisis	O
.	O

Establishment	O
of	O
a	O
carrier	O
state	O
in	O
IBV	O
infection	B-DISO
and	O
the	O
potential	O
for	O
the	O
persistent	O
virus	O
to	O
undergo	O
mutations	O
and	O
recombination	O
in	O
chicken	O
tissues	O
have	O
important	O
consequences	O
for	O
disease	O
management	O
.	O

Indeed	O
,	O
whether	O
or	O
not	O
IBV	O
genome	O
can	O
undergo	O
genetic	O
changes	O
during	O
in	O
vivo	O
infection	B-DISO
has	O
not	O
been	O
demonstrated	O
experimentally	O
.	O

TITLE	O
:	O
Attenuation	O
,	O
safety	O
,	O
and	O
efficacy	O
of	O
an	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
GA98	O
serotype	O
vaccine	O
.	O

Pass	O
70	O
of	O
the	O
GA98	O
/	O
0470	O
/	O
98	O
strain	O
of	O
IBV	O
when	O
given	O
at	O
1	O
day	O
of	O
age	O
by	O
coarse	O
spray	O
and	O
at	O
14	O
days	O
of	O
age	O
in	O
the	O
drinking	O
water	O
at	O
1	O
x	O
10	O
(	O
4	O
.	O
5	O
)	O
50	O
%	O
embryo	O
infectious	B-DISO
dose	O
/	O
bird	O
protected	O
against	O
the	O
homologous	O
GA98	O
challenge	O
as	O
well	O
as	O
provided	O
good	O
protection	O
against	O
the	O
DE072	O
-	O
type	O
virus	O
.	O

ABSTRACT	O
:	O
We	O
used	O
slot	O
blot	O
hybridization	O
of	O
the	O
hypervariable	O
regions	O
of	O
the	O
S1	O
subunit	O
of	O
spike	O
peplomer	O
gene	O
to	O
identify	O
and	O
characterize	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
strains	O
.	O

TITLE	O
:	O
[	O
Isolation	O
and	O
identification	O
of	O
the	O
infective	O
agent	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
from	O
a	O
patient	O
with	O
atypical	B-DISO
pneumonia	I-DISO
].	O

ABSTRACT	O
:	O
The	O
virological	O
,	O
morphological	O
,	O
molecular	O
biological	O
and	O
immunochemical	O
study	O
of	O
the	O
infective	O
agent	O
isolated	O
from	O
the	O
patient	O
with	O
the	O
symptoms	O
of	O
atypical	B-DISO
pneumonia	I-DISO
,	O
hospitalized	O
in	O
the	O
infectious	B-DISO
department	O
of	O
the	O
clinical	O
hospital	O
in	O
Blagoveshchensk	O
,	O
was	O
carried	O
out	O
.	O

TITLE	O
:	O
Detection	O
of	O
feline	O
coronavirus	B-DISO
infection	I-DISO
in	O
southern	O
African	O
nondomestic	O
felids	O
.	O

Infection	B-DISO
of	O
non	O
-	O
domestic	O
felids	O
with	O
FCoV	O
is	O
of	O
concern	O
,	O
particularly	O
in	O
endangered	O
populations	O
such	O
as	O
cheetahs	O
(	O
Acinonyx	O
jubatus	O
).	O

In	O
this	O
investigation	O
,	O
we	O
tested	O
342	O
animals	O
in	O
the	O
Republic	O
of	O
South	O
Africa	O
and	O
Namibia	O
,	O
including	O
140	O
animals	O
from	O
wild	O
populations	O
,	O
for	O
evidence	O
of	O
FCoV	O
infection	B-DISO
by	O
serology	O
and	O
/	O
or	O
reverse	O
transcription	O
/	O
nested	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
/	O
nPCR	O
)	O
on	O
feces	O
from	O
1999	O
through	O
2001	O
.	O

Of	O
these	O
,	O
195	O
animals	O
had	O
evidence	O
of	O
infection	B-DISO
and	O
included	O
41	O
animals	O
from	O
wild	O
populations	O
.	O

Important	O
lessons	O
can	O
be	O
learned	O
from	O
the	O
SARS	B-DISO
outbreak	O
about	O
both	O
the	O
scientific	O
and	O
the	O
public	O
health	O
approach	O
to	O
emerging	O
pathogens	O
.	O

TITLE	O
:	O
Reverse	O
genetics	O
with	O
a	O
full	O
-	O
length	O
infectious	B-DISO
cDNA	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

The	O
most	O
common	O
symptoms	O
were	O
cough	B-DISO
(	O
83	O
%),	O
dyspnea	B-DISO
(	O
80	O
.	O
6	O
%),	O
malaise	B-DISO
(	O
69	O
.	O
4	O
%)	O
and	O
fever	O
(	O
61	O
%).	O

In	O
addition	O
to	O
the	O
use	O
of	O
frontline	O
treatment	O
,	O
infection	B-DISO
control	O
and	O
sensitivity	O
to	O
individual	O
responses	O
to	O
sudden	O
and	O
catastrophic	B-DISO
illness	I-DISO
were	O
required	O
to	O
support	O
these	O
patients	O
.	O

The	O
diagnosis	O
was	O
made	O
at	O
the	O
first	O
visit	O
in	O
7	O
(	O
6	O
.	O
5	O
%,	O
7	O
/	O
108	O
)	O
cases	O
with	O
a	O
history	O
of	O
exposure	O
to	O
SARS	B-DISO
patients	O
and	O
infiltrates	B-DISO
on	O
chest	O
radiograph	O
.	O

Eighty	O
-	O
nine	O
(	O
82	O
.	O
4	O
%)	O
and	O
12	O
(	O
11	O
.	O
1	O
%)	O
patients	O
were	O
categorized	O
as	O
probable	O
cases	O
and	O
suspected	O
cases	O
respectively	O
at	O
their	O
first	O
visit	O
and	O
a	O
clinical	O
diagnosis	O
of	O
SARS	B-DISO
was	O
made	O
subsequently	O
.	O

The	O
final	O
diagnosis	O
was	O
made	O
in	O
0	O
-	O
14	O
days	O
(	O
median	O
,	O
2	O
days	O
)	O
for	O
those	O
(	O
n	O
=	O
59	O
,	O
54	O
.	O
6	O
%)	O
with	O
a	O
history	O
of	O
close	O
contact	O
with	O
SARS	B-DISO
patients	O
and	O
2	O
-	O
8	O
days	O
(	O
median	O
,	O
3	O
days	O
)	O
for	O
those	O
(	O
n	O
=	O
49	O
,	O
45	O
.	O
4	O
%)	O
living	O
in	O
Beijing	O
but	O
without	O
such	O
a	O
history	O
(	O
P	O
=	O
0	O
.	O
03	O
).	O

TITLE	O
:	O
Experiencing	O
SARS	B-DISO
:	O
perspectives	O
of	O
the	O
elderly	O
residents	O
and	O
health	O
care	O
professionals	O
in	O
a	O
Hong	O
Kong	O
nursing	O
home	O
.	O

Hong	O
Kong	O
and	O
China	O
have	O
been	O
most	O
severely	O
affected	O
by	O
this	O
new	O
infectious	B-DISO
disease	I-DISO
.	O

Most	O
of	O
the	O
elderly	O
residents	O
knew	O
little	O
regarding	O
SARS	B-DISO
and	O
prevention	O
strategies	O
,	O
despite	O
access	O
to	O
outside	O
news	O
by	O
TV	O
,	O
radio	O
,	O
and	O
visitors	O
.	O

TITLE	O
:	O
[	O
Controlled	O
clinical	O
study	O
on	O
49	O
patients	O
of	O
SARS	B-DISO
treated	O
by	O
integrative	O
Chinese	O
and	O
Western	O
medicine	O
].	O

To	O
use	O
a	O
back	O
projection	O
technique	O
to	O
construct	O
the	O
infection	B-DISO
curve	O
of	O
SARS	B-DISO
in	O
Hong	O
Kong	O
.	O

The	O
infections	B-DISO
among	O
the	O
medical	O
and	O
health	O
workers	O
are	O
high	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
currently	O
spreading	O
in	O
many	O
countries	O
.	O

The	O
model	O
indicates	O
that	O
SARS	B-DISO
can	O
spread	O
very	O
fast	O
when	O
there	O
are	O
no	O
interventions	O
.	O

The	O
result	O
showed	O
2	O
/	O
66	O
cases	O
(	O
3	O
.	O
0	O
%)	O
were	O
positive	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
IgG	O
antibody	O
and	O
66	O
cases	O
were	O
negative	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
IgM	O
antibody	O
in	O
the	O
66	O
cases	O
healthy	O
controls	O
;	O
in	O
31	O
cases	O
with	O
SLE	B-DISO
,	O
positive	O
rates	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
IgG	O
and	O
IgM	O
antibody	O
were	O
58	O
.	O
1	O
%	O
(	O
18	O
/	O
31	O
)	O
and	O
29	O
%	O
(	O
9	O
/	O
31	O
),	O
respectively	O
,	O
in	O
which	O
7	O
cases	O
(	O
22	O
.	O
6	O
%)	O
were	O
positive	O
of	O
both	O
SARS	B-DISO
-	O
CoV	O
-	O
IgG	O
and	O
IgM	O
antibody	O
.	O

It	O
was	O
concluded	O
that	O
not	O
all	O
SARS	B-DISO
patients	O
could	O
produce	O
the	O
anti	O
-	O
SARS	B-DISO
-	O
coronavirus	O
specific	O
antibody	O
.	O

Although	O
NO	O
is	O
important	O
in	O
maintaining	O
vasodilator	O
tone	O
,	O
hypoxia	B-DISO
-	O
induced	O
pulmonary	O
vasoconstriction	B-DISO
is	O
accompanied	O
by	O
an	O
increase	O
instead	O
of	O
a	O
decrease	O
in	O
NO	O
release	O
.	O

Our	O
early	O
and	O
recent	O
studies	O
on	O
ARDS	B-DISO
and	O
PE	O
may	O
provide	O
information	O
for	O
clinical	O
practice	O
and	O
the	O
understanding	O
of	O
the	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
.	O

The	O
purpose	O
of	O
this	O
mission	O
was	O
to	O
reinforce	O
the	O
local	O
medical	O
staff	O
,	O
to	O
bring	O
medical	O
equipment	O
,	O
and	O
to	O
assist	O
in	O
identifying	O
the	O
cause	O
of	O
the	O
SARS	B-DISO
epidemic	O
.	O

Assessment	O
of	O
the	O
toxicity	O
of	O
PCP	B-DISO
is	O
confounded	O
by	O
the	O
presence	O
of	O
contaminants	O
known	O
to	O
cause	O
effects	O
identical	O
to	O
those	O
attributed	O
to	O
PCP	B-DISO
.	O

Tachycardia	O
,	O
tachypnoea	B-DISO
,	O
sweating	O
,	O
altered	B-DISO
consciousness	I-DISO
,	O
hyperthermia	O
,	O
convulsions	B-DISO
and	O
early	O
onset	O
of	O
marked	O
rigor	B-DISO
(	O
if	O
death	O
occurs	O
)	O
are	O
the	O
most	O
notable	O
features	O
.	O

The	O
current	O
status	O
of	O
imaging	O
in	O
SARS	B-DISO
is	O
presented	O
in	O
this	O
review	O
.	O

TITLE	O
:	O
Antibody	O
-	O
mediated	O
protection	O
against	O
cytotoxic	O
T	O
-	O
cell	O
escape	O
in	O
coronavirus	O
-	O
induced	O
demyelination	B-DISO
.	O

ABSTRACT	O
:	O
C57BL	O
/	O
6	O
(	O
B6	O
)	O
mice	O
infected	O
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
strain	O
JHM	O
develop	O
a	O
clinically	O
evident	O
,	O
demyelinating	O
encephalomyelitis	B-DISO
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
a	O
hemodialysis	O
patient	O
.	O

TITLE	O
:	O
Clinical	O
presentation	O
and	O
outcome	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
dialysis	O
patients	O
.	O

ABSTRACT	O
:	O
From	O
April	O
18	O
to	O
May	O
31	O
,	O
2003	O
,	O
46	O
patients	O
with	O
probable	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
were	O
admitted	O
to	O
the	O
negative	O
-	O
pressure	O
isolation	O
rooms	O
of	O
Mackay	O
Memorial	O
Hospital	O
in	O
Taipei	O
,	O
Taiwan	O
.	O

TITLE	O
:	O
Epidemiology	O
and	O
cause	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
Guangdong	O
,	O
People	O
'	O
s	O
Republic	O
of	O
China	O
,	O
in	O
February	O
,	O
2003	O
.	O

ABSTRACT	O
:	O
A	O
newly	O
identified	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
is	O
the	O
etiological	O
agent	O
responsible	O
for	O
the	O
outbreak	O
of	O
SARS	B-DISO
.	O

The	O
SARS	B-DISO
-	O
CoV	O
main	O
protease	O
,	O
which	O
is	O
a	O
33	O
.	O
8	O
-	O
kDa	O
protease	O
(	O
also	O
called	O
the	O
3C	O
-	O
like	O
protease	O
),	O
plays	O
a	O
pivotal	O
role	O
in	O
mediating	O
viral	O
replication	O
and	O
transcription	O
functions	O
through	O
extensive	O
proteolytic	O
processing	O
of	O
two	O
replicase	O
polyproteins	O
,	O
pp1a	O
(	O
486	O
kDa	O
)	O
and	O
pp1ab	O
(	O
790	O
kDa	O
).	O

RESULTS	O
:	O
Neutrophil	O
apoptosis	O
was	O
increased	O
in	O
the	O
RDS	O
group	O
(	O
mean	O
(	O
SEM	B-DISO
)	O
neutrophil	O
apoptosis	O
on	O
day	O
7	O
BAL	O
:	O
RDS	O
17	O
.	O
0	O
(	O
8	O
.	O
6	O
)%	O
v	O
CLD	B-DISO
0	O
.	O
7	O
(	O
0	O
.	O
2	O
)%	O
(	O
p	O
<	O
0	O
.	O
05	O
)).	O

TITLE	O
:	O
Shifts	O
in	O
circulating	O
lymphocyte	O
subsets	O
in	O
cats	O
with	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
):	O
pathogenic	O
role	O
and	O
diagnostic	O
relevance	O
.	O

Blood	O
from	O
cats	O
with	O
diseases	O
other	O
than	O
FIP	B-DISO
was	O
also	O
examined	O
in	O
order	O
to	O
define	O
the	O
diagnostic	O
relevance	O
of	O
the	O
changes	O
.	O

Cats	O
with	O
diseases	O
other	O
than	O
FIP	B-DISO
also	O
had	O
decreased	O
number	O
of	O
lymphocytes	O
:	O
as	O
a	O
consequence	O
,	O
the	O
diagnostic	O
relevance	O
of	O
these	O
findings	O
is	O
very	O
low	O
.	O

ABSTRACT	O
:	O
Involvement	O
of	O
viruses	O
in	O
human	O
neurodegenerative	B-DISO
diseases	I-DISO
and	O
the	O
underlying	O
pathologic	O
mechanisms	O
remain	O
generally	O
unclear	O
.	O

Virus	O
inoculation	O
of	O
21	O
-	O
day	O
postnatal	O
C57BL	O
/	O
6	O
and	O
BALB	O
/	O
c	O
mice	O
led	O
to	O
a	O
generalized	O
infection	B-DISO
of	O
the	O
whole	O
CNS	O
,	O
demonstrating	O
HCoV	O
-	O
OC43	O
neuroinvasiveness	O
and	O
neurovirulence	O
.	O

14	O
.	O
01	O
[	O
SD	O
];	O
median	O
age	O
,	O
41	O
.	O
5	O
years	O
;	O
age	O
range	O
,	O
25	O
-	O
82	O
years	O
)	O
with	O
SARS	B-DISO
were	O
evaluated	O
.	O

SARS	B-DISO
is	O
caused	O
by	O
a	O
new	O
coronavirus	O
thought	O
to	O
be	O
of	O
animal	O
origin	O
.	O

Factors	O
contributing	O
to	O
mortality	O
were	O
respiratory	B-DISO
failure	I-DISO
,	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
and	O
nosocomial	O
sepsis	B-DISO
.	O

Here	O
we	O
performed	O
DNA	O
microarray	O
analysis	O
on	O
differential	O
gene	O
expression	O
in	O
astrocyte	O
DBT	O
cells	O
by	O
MHV	O
infection	B-DISO
and	O
found	O
that	O
the	O
mRNA	O
of	O
the	O
proapoptotic	O
gene	O
BNip3	O
was	O
significantly	O
decreased	O
following	O
MHV	O
infection	B-DISO
.	O

Most	O
of	O
the	O
respondents	O
believed	O
that	O
SARS	B-DISO
could	O
be	O
transmitted	B-DISO
via	O
direct	O
body	O
contact	O
and	O
droplets	O
.	O

Perceived	O
chance	O
of	O
infection	B-DISO
was	O
low	O
(	O
9	O
%)	O
but	O
fear	O
of	O
infection	B-DISO
in	O
public	O
places	O
was	O
high	O
(	O
48	O
%).	O

SARS	B-DISO
related	O
perceptions	O
and	O
behaviours	O
evolved	O
rapidly	O
during	O
the	O
epidemic	O
and	O
Hong	O
Kong	O
residents	O
quickly	O
adopted	O
appropriate	O
SARS	B-DISO
prevention	O
measures	O
.	O

RESULTS	O
:	O
Most	O
of	O
the	O
respondents	O
believed	O
that	O
SARS	B-DISO
could	O
be	O
transmitted	B-DISO
via	O
direct	O
body	O
contact	O
and	O
droplets	O
.	O

TITLE	O
:	O
[	O
Clinical	O
features	O
and	O
management	O
of	O
recurrence	B-DISO
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
].	O

CONCLUSIONS	O
:	O
The	O
recurrence	B-DISO
of	O
symptoms	O
in	O
SARS	B-DISO
patients	O
is	O
one	O
of	O
the	O
common	O
clinical	O
feature	O
of	O
critical	O
patients	O
with	O
SARS	B-DISO
.	O

Older	O
persons	O
and	O
those	O
taking	O
corticosteroids	O
may	O
have	O
neither	O
fever	O
nor	O
respiratory	B-DISO
symptoms	I-DISO
.	O

During	O
an	O
outbreak	O
,	O
even	O
patients	O
with	O
low	O
suspicion	O
of	O
SARS	B-DISO
should	O
be	O
promptly	O
isolated	O
,	O
and	O
all	O
contacts	O
quarantined	O
.	O

ARDS	B-DISO
patients	O
in	O
general	O
ICU	O
were	O
enrolled	O
for	O
the	O
study	O
.	O

The	O
dosage	O
of	O
GC	O
in	O
the	O
treatment	O
of	O
ARDS	B-DISO
varied	O
according	O
to	O
the	O
level	O
of	O
GR	O
and	O
clinical	O
indices	O
.	O

The	O
epidemiological	O
and	O
the	O
clinical	O
data	O
of	O
4060	O
patients	O
with	O
fever	O
admitted	O
to	O
the	O
emergency	B-DISO
department	O
of	O
the	O
Third	O
Hospital	O
affiliated	O
to	O
Peking	O
University	O
from	O
March	O
5th	O
to	O
May	O
10th	O
in	O
2003	O
were	O
analyzed	O
,	O
and	O
their	O
influential	O
factors	O
were	O
evaluated	O
.	O

Of	O
4060	O
patients	O
with	O
fever	O
275	O
cases	O
were	O
admitted	O
to	O
the	O
isolated	O
ward	O
,	O
145	O
cases	O
were	O
diagnosed	O
as	O
SARS	B-DISO
(	O
3	O
.	O
75	O
percent	O
),	O
29	O
belonged	O
to	O
suspected	O
cases	O
,	O
and	O
in	O
101	O
cases	O
SARS	B-DISO
was	O
ruled	O
out	O
.	O

These	O
results	O
indicate	O
that	O
the	O
SpaA416	O
ELISA	O
is	O
an	O
effective	O
method	O
not	O
only	O
for	O
evaluating	O
pigs	O
for	O
the	O
presence	O
of	O
protective	O
antibody	O
levels	O
resulting	O
from	O
vaccination	O
or	O
maternal	O
antibody	O
but	O
also	O
for	O
detecting	O
antibody	O
produced	O
by	O
natural	O
infection	B-DISO
.	O

Additional	O
information	O
and	O
references	O
were	O
obtained	O
from	O
the	O
Web	B-DISO
sites	O
for	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
,	O
World	O
Health	O
Organization	O
,	O
and	O
Health	O
Canada	O
.	O

According	O
to	O
the	O
time	O
of	O
the	O
occurrence	O
of	O
complications	O
,	O
we	O
divide	O
the	O
courses	O
of	O
the	O
disease	O
into	O
three	O
stages	O
:	O
early	O
phase	O
(	O
first	O
4	O
days	O
)	O
with	O
ARDS	B-DISO
,	O
kidney	B-DISO
failure	I-DISO
,	O
shock	O
,	O
encephalopathy	B-DISO
and	O
hemorrhage	B-DISO
of	O
the	O
digestive	O
tract	O
;	O
middle	O
phase	O
(	O
5	O
-	O
15	O
days	O
)	O
with	O
bacterial	B-DISO
infection	I-DISO
and	O
fungous	O
infection	B-DISO
;	O
late	O
phase	O
(	O
15	O
days	O
after	O
the	O
onset	O
)	O
with	O
abscess	B-DISO
.	O

ABSTRACT	O
:	O
A	O
transformation	B-DISO
analogous	O
to	O
the	O
well	O
-	O
known	O
conversion	O
of	O
an	O
N	O
-	O
terminal	O
glutamine	O
residue	O
to	O
pyroglutamic	O
acid	O
is	O
the	O
cyclization	O
of	O
an	O
N	O
-	O
terminal	O
carboxyamidomethylated	O
cysteine	O
residue	O
(	O
the	O
normal	O
product	O
of	O
alkylation	O
with	O
iodoacetamide	O
).	O

TITLE	O
:	O
Chemokine	O
regulation	O
of	O
inflammation	B-DISO
during	O
acute	O
viral	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Chemokines	O
are	O
important	O
inflammatory	O
mediators	O
,	O
and	O
regulate	O
disease	O
due	O
to	O
viral	B-DISO
infection	I-DISO
.	O

HSV	O
in	O
the	O
throat	O
was	O
associated	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
with	O
increased	O
length	O
of	O
stay	O
in	O
intensive	O
care	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

Our	O
data	O
suggest	O
that	O
HSV	O
reactivation	O
or	O
infection	B-DISO
of	O
the	O
upper	O
respiratory	O
tract	O
is	O
frequent	O
among	O
patients	O
in	O
intensive	O
care	O
,	O
and	O
is	O
a	O
risk	O
factor	O
for	O
development	O
of	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
with	O
this	O
virus	O
,	O
possibly	O
by	O
means	O
of	O
aspiration	B-DISO
.	O

TITLE	O
:	O
Transfusion	B-DISO
-	I-DISO
related	I-DISO
acute	I-DISO
lung	I-DISO
injury	I-DISO
or	O
acute	B-DISO
chest	I-DISO
syndrome	I-DISO
of	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
?	O

Four	O
hours	O
later	O
she	O
developed	O
progressive	O
respiratory	B-DISO
distress	I-DISO
,	O
diffuse	O
geographical	O
airspace	O
disease	O
and	O
bilateral	O
pulmonary	B-DISO
edema	I-DISO
.	O

ABSTRACT	O
:	O
Outbreaks	O
of	O
SARS	B-DISO
affected	O
more	O
than	O
8	O
,	O
400	O
people	O
,	O
and	O
caused	O
more	O
than	O
900	O
deaths	O
worldwide	O
but	O
came	O
to	O
an	O
end	O
in	O
July	O
,	O
2003	O
.	O

However	O
,	O
the	O
recurrence	B-DISO
of	O
SARS	B-DISO
epidemics	O
in	O
winter	O
is	O
possible	O
.	O

We	O
compared	O
clinical	O
symptoms	O
between	O
SARS	B-DISO
and	O
influenza	B-DISO
and	O
discussed	O
infection	B-DISO
-	O
control	O
measures	O
.	O

It	O
is	O
aimed	O
at	O
preventing	O
a	O
resurgence	O
of	O
SARS	B-DISO
,	O
but	O
it	O
also	O
contains	O
elements	O
to	O
make	O
the	O
methodology	O
developed	O
applicable	O
to	O
future	O
outbreaks	O
of	O
any	O
other	O
communicable	B-DISO
disease	I-DISO
in	O
which	O
the	O
mode	O
of	O
transmission	O
could	O
involve	O
aviation	O
and	O
/	O
or	O
the	O
need	O
to	O
prevent	O
the	O
spread	O
of	O
the	O
disease	O
by	O
air	O
travel	O
.	O

TITLE	O
:	O
Assessment	O
of	O
putative	O
protein	O
targets	O
derived	O
from	O
the	O
SARS	B-DISO
genome	O
.	O

This	O
paper	O
discusses	O
several	O
new	O
functional	O
hypotheses	O
on	O
the	O
roles	O
played	O
by	O
the	O
constituent	O
gene	O
products	O
of	O
SARS	B-DISO
,	O
and	O
will	O
serve	O
as	O
an	O
example	O
of	O
how	O
such	O
assignments	O
can	O
be	O
developed	O
or	O
extended	O
on	O
other	O
systems	O
of	O
interest	O
.	O

The	O
highest	O
concentration	O
of	O
APPs	O
was	O
detected	O
in	O
affected	O
cats	O
,	O
confirming	O
the	O
role	O
of	O
these	O
proteins	O
in	O
supporting	O
a	O
clinical	O
diagnosis	O
of	O
FIP	B-DISO
.	O

Repeated	O
samplings	O
from	O
both	O
FIP	B-DISO
affected	O
and	O
FCoV	O
-	O
exposed	O
cats	O
showed	O
that	O
when	O
FIP	B-DISO
appeared	O
in	O
the	O
group	O
,	O
all	O
the	O
cats	O
had	O
increased	O
APP	O
levels	O
.	O

TITLE	O
:	O
Inflammation	B-DISO
and	O
changes	O
in	O
cytokine	O
levels	O
in	O
neurological	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
.	O

Neurological	O
FIP	B-DISO
is	O
clinically	O
and	O
pathologically	O
more	O
homogeneous	O
than	O
systemic	O
'	O
wet	O
'	O
or	O
'	O
dry	O
'	O
FIP	B-DISO
;	O
thus	O
,	O
comparison	O
of	O
cytokine	O
profiles	O
from	O
cats	O
with	O
neurological	O
FIP	B-DISO
,	O
wet	B-DISO
FIP	I-DISO
,	O
and	O
non	O
-	O
FIP	B-DISO
neurological	B-DISO
disease	I-DISO
may	O
provide	O
insight	O
into	O
some	O
baseline	O
characteristics	O
relating	O
to	O
the	O
immunopathogenesis	O
of	O
neurological	O
FIP	B-DISO
.	O

ABSTRACT	O
:	O
In	O
March	O
2003	O
,	O
a	O
novel	O
coronavirus	O
was	O
isolated	O
from	O
patients	O
exhibiting	O
atypical	B-DISO
pneumonia	I-DISO
and	O
subsequently	O
proven	O
to	O
be	O
the	O
causative	O
agent	O
of	O
the	O
disease	O
now	O
referred	O
to	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

ABSTRACT	O
:	O
To	O
provide	O
a	O
clue	O
for	O
screening	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
a	O
highly	O
transmissible	O
disease	O
with	O
health	O
care	O
workers	O
at	O
particular	O
risk	O
,	O
in	O
the	O
early	O
stage	O
from	O
an	O
otolaryngological	O
perspective	O
.	O

When	O
presented	O
with	O
a	O
patient	O
with	O
flulike	O
symptoms	O
such	O
as	O
fever	O
and	O
/	O
or	O
cough	B-DISO
,	O
but	O
no	O
pharyngeal	O
hyperemia	B-DISO
or	O
neck	O
lymphadenopathy	O
,	O
physicians	O
should	O
be	O
alerted	O
to	O
the	O
possibility	O
of	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
is	O
a	O
new	O
,	O
sometimes	O
lethal	O
disease	O
of	O
humans	O
that	O
is	O
caused	O
by	O
a	O
novel	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
recently	O
recognized	O
condition	B-DISO
of	O
viral	O
origin	O
associated	O
with	O
substantial	O
morbidity	O
and	O
mortality	O
rates	O
in	O
adults	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
characterize	O
the	O
radiographic	O
presentation	O
of	O
children	O
with	O
SARS	B-DISO
.	O

We	O
abstracted	O
data	O
(	O
n	O
=	O
62	O
)	O
on	O
the	O
radiologic	O
appearance	O
and	O
course	O
of	O
SARS	B-DISO
in	O
pediatric	O
patients	O
with	O
suspect	O
(	O
n	O
=	O
25	O
)	O
or	O
probable	O
(	O
n	O
=	O
37	O
)	O
SARS	B-DISO
,	O
diagnosed	O
in	O
five	O
hospital	O
sites	O
located	O
in	O
three	O
cities	O
:	O
Toronto	O
,	O
Singapore	O
,	O
and	O
Hong	O
Kong	O
.	O

Other	O
findings	O
included	O
sore	B-DISO
throat	I-DISO
(	O
9	O
.	O
7	O
%),	O
gastrointestinal	B-DISO
symptoms	I-DISO
(	O
9	O
.	O
7	O
%),	O
rigor	B-DISO
(	O
8	O
.	O
1	O
%),	O
and	O
lethargy	B-DISO
(	O
6	O
.	O
5	O
%).	O

Pleural	B-DISO
effusion	I-DISO
was	O
observed	O
only	O
in	O
one	O
patient	O
(	O
age	O
17	O
years	O
and	O
11	O
.	O
5	O
months	O
),	O
whereas	O
interstitial	B-DISO
disease	I-DISO
was	O
not	O
observed	O
in	O
any	O
patient	O
.	O

In	O
pediatric	O
cases	O
,	O
SARS	B-DISO
manifests	O
with	O
nonspecific	O
radiographic	O
features	O
making	O
radiological	O
differentiation	O
difficult	O
,	O
especially	O
from	O
other	O
commonly	O
encountered	O
childhood	O
respiratory	O
viral	O
illnesses	O
causing	O
airspace	O
disease	O
.	O

The	O
radiographic	O
presentations	O
,	O
as	O
expected	O
,	O
were	O
relatively	O
more	O
pronounced	O
in	O
the	O
SARS	B-DISO
probable	O
cases	O
.	O

The	O
detection	O
of	O
SARS	B-DISO
-	O
CoV	O
in	O
the	O
sweat	O
glands	O
,	O
alimentary	O
tracts	O
and	O
epithelia	O
of	O
the	O
distal	O
convoluted	O
tubules	O
of	O
the	O
kidney	O
may	O
help	O
identify	O
the	O
transmission	O
routes	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O

Tongue	O
picture	O
is	O
one	O
of	O
the	O
objective	O
evidence	O
for	O
judging	O
state	O
of	O
illness	O
and	O
Syndrome	B-DISO
Differentiation	O
based	O
on	O
treatment	O
in	O
SARS	B-DISO
patients	O
.	O

Patients	O
with	O
affected	O
lung	O
>	O
or	O
=	O
3	O
lobules	O
mostly	O
had	O
pale	B-DISO
dark	O
proper	O
and	O
yellow	O
coating	O
on	O
root	O
,	O
but	O
those	O
with	O
involved	O
lung	O
<	O
3	O
lobules	O
mostly	O
had	O
light	O
red	O
proper	O
and	O
thin	O
white	O
coating	O
.	O

ABSTRACT	O
:	O
In	O
many	O
ways	O
SARS	B-DISO
unmasked	O
some	O
painful	B-DISO
truths	O
about	O
our	O
existing	O
system	O
.	O

In	O
-	O
flight	O
transmission	O
occurred	O
only	O
in	O
one	O
of	O
the	O
three	O
flights	O
with	O
symptomatic	O
SARS	B-DISO
patients	O
on	O
board	O
.	O

Similarly	O
,	O
SARS	B-DISO
patients	O
from	O
regions	O
with	O
high	O
APIs	O
were	O
twice	O
as	O
likely	O
to	O
die	O
from	O
SARS	B-DISO
compared	O
to	O
those	O
from	O
regions	O
with	O
low	O
APIs	O
.	O

This	O
infection	B-DISO
spreads	O
by	O
droplet	O
transmission	O
and	O
children	O
appear	O
to	O
acquire	O
SARS	B-DISO
through	O
close	O
household	O
contact	O
exposure	O
to	O
infected	O
adults	O
.	O

The	O
optimal	O
treatment	O
of	O
SARS	B-DISO
in	O
children	O
remains	O
to	O
be	O
determined	O
.	O

The	O
early	O
and	O
proper	O
isolation	O
of	O
infected	O
adults	O
,	O
meticulous	O
infection	B-DISO
control	O
measures	O
in	O
the	O
hospital	O
setting	O
,	O
exhaustive	O
contact	O
tracing	O
and	O
quarantine	O
measures	O
are	O
important	O
steps	O
in	O
preventing	O
the	O
spread	O
of	O
the	O
disease	O
among	O
health	O
care	O
workers	O
and	O
into	O
the	O
community	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
virus	O
caused	O
a	O
severe	O
outbreak	O
in	O
several	O
regions	O
of	O
the	O
world	O
in	O
2003	O
.	O

ABSTRACT	O
:	O
During	O
the	O
three	O
months	O
from	O
March	O
2003	O
the	O
economically	O
vibrant	O
city	O
of	O
Hong	O
Kong	O
was	O
seriously	O
dislocated	O
after	O
becoming	O
'	O
second	O
port	O
of	O
call	O
'	O
of	O
the	O
new	O
and	O
potentially	O
fatal	O
disease	O
,	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
).	O

RESULTS	O
:	O
The	O
results	O
showed	O
that	O
SARS	B-DISO
coronavirus	O
in	O
the	O
testing	O
condition	B-DISO
could	O
survive	O
in	O
serum	O
,	O
1	O
:	O
20	O
diluted	O
sputum	O
and	O
feces	O
for	O
at	O
least	O
96	O
h	O
,	O
whereas	O
it	O
could	O
remain	O
alive	O
in	O
urine	O
for	O
at	O
least	O
72	O
h	O
with	O
a	O
low	O
level	O
of	O
infectivity	O
.	O

0	O
.	O
20	O
,	O
which	O
was	O
also	O
significantly	O
higher	O
as	O
compared	O
with	O
those	O
in	O
community	B-DISO
acquired	I-DISO
pneumonia	I-DISO
patients	O
and	O
healthy	O
persons	O
.	O

0	O
.	O
13	O
,	O
which	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
samples	O
obtained	O
from	O
Beijing	O
in	O
2001	O
when	O
SARS	B-DISO
was	O
not	O
found	O
-	O
1	O
.	O
76	O
+/-	O

Proinflammatory	O
cytokines	O
and	O
TGF	O
-	O
beta1	O
were	O
elevated	O
during	O
the	O
early	O
phase	O
of	O
SARS	B-DISO
,	O
a	O
phenomenon	O
which	O
may	O
be	O
associated	O
with	O
lung	B-DISO
infiltration	I-DISO
and	O
proliferation	B-DISO
.	O

It	O
suggested	O
that	O
the	O
immune	O
state	O
of	O
SARS	B-DISO
was	O
obviously	O
abnormal	O
.	O

Four	O
kinds	O
of	O
isolation	O
wards	O
were	O
evaluated	O
,	O
including	O
the	O
ward	O
where	O
the	O
thirty	O
-	O
first	O
bed	B-DISO
lied	O
in	O
on	O
the	O
twelfth	O
floor	O
,	O
the	O
laminar	O
flow	O
ward	O
in	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
where	O
the	O
tenth	O
bed	B-DISO
lied	O
in	O
on	O
the	O
fifteenth	O
floor	O
,	O
the	O
ward	O
where	O
the	O
twenty	O
-	O
seventh	O
bed	B-DISO
lied	O
in	O
on	O
the	O
thirteenth	O
floor	O
of	O
Building	O
A	O
,	O
and	O
thirty	O
wards	O
on	O
the	O
fourteenth	O
to	O
eighteenth	O
floors	O
of	O
Building	O
B	O
.	O
The	O
ratios	O
(	O
m2	O
/	O
m3	O
)	O
of	O
the	O
area	O
of	O
the	O
ventilation	O
windows	O
to	O
the	O
volume	O
of	O
the	O
room	O
were	O
0	O
,	O
0	O
,	O
1	O
:	O
95	O
and	O
1	O
:	O
40	O
,	O
respectively	O
.	O

To	O
describe	O
the	O
epidemiologic	O
and	O
clinical	O
features	O
of	O
the	O
first	O
case	O
of	O
SARS	B-DISO
in	O
Foshan	O
city	O
,	O
Guangdong	O
province	O
retrospectively	O
,	O
and	O
to	O
review	O
the	O
diagnostic	O
procedure	O
.	O

Retrospective	O
analysis	O
of	O
the	O
epidemiological	O
history	O
,	O
clinical	O
presentation	O
,	O
the	O
change	O
of	O
laboratory	O
tests	O
,	O
chest	O
radiography	O
,	O
and	O
treatment	O
of	O
15	O
SARS	B-DISO
patients	O
with	O
cardiac	B-DISO
arrest	I-DISO
.	O

TITLE	O
:	O
Quantitative	O
analysis	O
and	O
prognostic	O
implication	O
of	O
SARS	B-DISO
coronavirus	O
RNA	O
in	O
the	O
plasma	O
and	O
serum	O
of	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
The	O
widespread	O
threat	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
to	O
human	O
life	O
has	O
spawned	O
challenges	O
to	O
develop	O
fast	O
and	O
accurate	O
analytical	O
methods	O
for	O
its	O
early	O
diagnosis	O
and	O
to	O
create	O
a	O
safe	O
antiviral	O
vaccine	O
for	O
preventive	O
use	O
.	O

RESULTS	O
:	O
Four	O
epitopic	O
sites	O
,	O
S599	O
,	O
M137	O
,	O
N66	O
,	O
and	O
N371	O
-	O
404	O
,	O
located	O
in	O
the	O
SARS	B-DISO
-	O
coronavirus	O
S	O
,	O
M	O
,	O
and	O
N	O
proteins	O
,	O
respectively	O
,	O
were	O
detected	O
by	O
screening	O
synthesized	O
peptides	O
.	O

Although	O
viremia	B-DISO
occurs	O
,	O
histologic	O
lesions	O
are	O
not	O
found	O
uniformly	O
throughout	O
lymphoid	O
tissues	O
.	O

ABSTRACT	O
:	O
Although	O
most	O
influenza	B-DISO
infections	B-DISO
are	O
self	O
-	O
limited	O
,	O
few	O
other	O
diseases	O
exert	O
such	O
a	O
huge	O
toll	O
of	O
suffering	B-DISO
and	O
economic	O
loss	O
.	O

Progress	O
has	O
also	O
been	O
made	O
on	O
developing	O
near	O
-	O
patient	O
testing	O
for	O
influenza	B-DISO
that	O
may	O
assist	O
individual	O
diagnosis	O
or	O
the	O
recognition	O
of	O
widespread	O
virus	O
circulation	O
,	O
and	O
so	O
optimise	O
clinical	O
management	O
.	O

The	O
contrast	O
between	O
recent	O
cases	O
of	O
H5N1	B-DISO
infection	B-DISO
,	O
associated	O
with	O
high	O
mortality	O
,	O
and	O
the	O
typically	O
mild	O
,	O
self	O
-	O
limiting	O
nature	O
of	O
human	O
infections	B-DISO
with	O
avian	O
H7N7	O
and	O
H9N2	O
influenza	B-DISO
shows	O
the	O
gaps	O
in	O
our	O
understanding	O
of	O
molecular	O
correlates	O
of	O
pathogenicity	O
and	O
underlines	O
the	O
need	O
for	O
continuing	O
international	O
research	O
into	O
pandemic	O
influenza	B-DISO
.	O

Within	O
the	O
first	O
hour	O
of	O
infection	B-DISO
,	O
the	O
most	O
obvious	O
ultrastructural	O
change	O
was	O
the	O
proliferation	B-DISO
of	O
the	O
Golgi	O
complexes	O
and	O
related	O
vesicles	B-DISO
accompanied	O
by	O
swelling	B-DISO
of	O
some	O
of	O
the	O
trans	O
-	O
Golgi	O
sacs	B-DISO
.	O

Swollen	O
Golgi	O
sacs	B-DISO
contained	O
virus	O
nucleocapsids	O
at	O
different	O
stages	O
of	O
maturation	O
.	O

TITLE	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
2	O
is	O
a	O
functional	O
receptor	O
for	O
the	O
SARS	B-DISO
coronavirus	O
.	O

ABSTRACT	O
:	O
To	O
perform	O
variation	O
and	O
phylogenetics	O
analysis	O
on	O
the	O
SARS	B-DISO
-	O
CoV	O
genome	O
sequence	O
(	O
PUMC01	O
)	O
isolated	O
in	O
the	O
Peking	O
Union	O
Medical	O
College	O
Hospital	O
.	O

According	O
to	O
the	O
published	O
SARS	B-DISO
coronavirus	O
genome	O
sequences	O
,	O
the	O
full	O
length	O
cDNA	O
of	O
N	O
protein	O
from	O
SARS	B-DISO
coronavirus	O
PUMC2	O
strain	O
was	O
cloned	O
by	O
RT	O
-	O
PCR	O
and	O
the	O
cDNA	O
was	O
cloned	O
into	O
the	O
pET32a	O
expression	O
vector	O
.	O

RESULTS	O
:	O
Prokaryoticly	O
expressed	O
and	O
purified	O
N	O
protein	O
of	O
SARS	B-DISO
coronavirus	O
PUMC2	O
strain	O
was	O
obtained	O
.	O

TITLE	O
:	O
[	O
Immunohistochemical	O
investigation	O
of	O
lungs	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
].	O

The	O
monoclonal	O
antibodies	O
of	O
CD8	O
,	O
CD20	O
,	O
CD34	O
,	O
LCA	B-DISO
,	O
CD56	O
,	O
CD68	O
,	O
and	O
AE1	O
/	O
AE3	O
are	O
used	O
to	O
demonstrate	O
the	O
different	O
cells	O
in	O
the	O
lung	O
specimens	O
of	O
SARS	B-DISO
patients	O
in	O
order	O
to	O
study	O
the	O
patterns	O
of	O
cell	O
responses	O
in	O
this	O
new	O
disease	O
.	O

The	O
patients	O
had	O
a	O
moderately	O
degree	O
physiological	O
impairment	B-DISO
and	O
increased	O
SGRQ	O
score	O
.	O

The	O
correlation	O
coefficients	O
between	O
the	O
activation	O
,	O
impaction	B-DISO
,	O
total	O
score	O
,	O
and	O
diffuse	O
capacity	O
of	O
the	O
lung	O
for	O
carbon	O
monoxide	O
/	O
alveolar	O
ventilation	O
/	O
pre	O
(	O
DLco	O
/	O
Va	O
%)	O
were	O
resembled	O
(	O
r	O
=	O
0	O
.	O
47	O
-	O
0	O
.	O
54	O
,	O
P	O
<	O
0	O
.	O
01	O
).	O

The	O
time	O
leaving	O
hospital	O
only	O
had	O
a	O
significant	O
relationship	O
with	O
the	O
symptom	B-DISO
score	O
of	O
SGRQ	O
.	O

Cytopathic	B-DISO
effect	I-DISO
(	O
CPE	O
)	O
was	O
found	O
in	O
three	O
nasal	O
swab	O
specimens	O
inoculated	O
in	O
Vero	O
cells	O
.	O

Diffusion	O
capacity	O
for	O
carbon	O
monoxide	O
(	O
DLco	O
)	O
was	O
impaired	B-DISO
in	O
38	O
patients	O
(	O
42	O
.	O
7	O
%);	O
in	O
7	O
patients	O
(	O
7	O
.	O
9	O
%),	O
lung	O
function	O
was	O
restrictive	O
defect	O
combined	O
DLco	O
impairment	B-DISO
;	O
Other	O
patterns	O
of	O
impairment	B-DISO
were	O
revealed	O
in	O
3	O
patient	O
.	O

Data	O
of	O
SARS	B-DISO
cases	O
notified	O
from	O
Dongcheng	O
District	O
Center	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
CDC	O
)	O
and	O
supplemented	O
by	O
other	O
channels	O
were	O
collected	O
.	O

And	O
,	O
7	O
.	O
4	O
%	O
(	O
attack	O
rate	O
)	O
in	O
those	O
exposed	O
to	O
SARS	B-DISO
cases	O
suffered	B-DISO
the	O
illness	O
during	O
the	O
periods	O
of	O
quarantine	O
.	O

ABSTRACT	O
:	O
To	O
discuss	O
the	O
reliability	O
of	O
SARS	B-DISO
-	O
CoV	O
antibody	O
detection	O
for	O
SARS	B-DISO
diagnosis	O
.	O

TITLE	O
:	O
[	O
Change	O
of	O
T	O
lymphocyte	O
and	O
its	O
activated	O
subsets	O
in	O
SARS	B-DISO
patients	O
].	O

Statistical	O
analysis	O
by	O
means	O
of	O
SAS	O
software	O
showed	O
that	O
there	O
was	O
significant	O
decrease	O
in	O
absolute	O
counts	O
(	O
AC	O
)	O
of	O
T	O
lymphocyte	O
and	O
its	O
subsets	O
in	O
SARS	B-DISO
patients	O
when	O
compared	O
with	O
normal	O
people	O
,	O
while	O
percentages	O
(	O
PC	O
)	O
of	O
CD3	O
+	O
CD25	O
+	O
and	O
CD3	O
+	O
HLA	O
-	O
DR	O
+	O
subsets	O
were	O
increased	O
markedly	O
.	O

Elderly	O
patients	O
had	O
more	O
coexisting	O
conditions	O
,	O
such	O
as	O
hypertension	B-DISO
,	O
diabetes	B-DISO
,	O
coronary	B-DISO
heart	I-DISO
disease	I-DISO
,	O
and	O
renal	B-DISO
disease	I-DISO
than	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Though	O
the	O
elderly	O
patients	O
have	O
a	O
lower	O
morbidity	O
of	O
SARS	B-DISO
,	O
they	O
have	O
more	O
coexisting	O
conditions	O
.	O

Univariate	O
analysis	O
showed	O
that	O
age	O
,	O
respiratory	B-DISO
failure	I-DISO
,	O
and	O
thrombocytopenia	O
were	O
risk	O
factors	O
of	O
death	O
,	O
but	O
logistic	O
analysis	O
did	O
not	O
find	O
any	O
independent	O
risk	O
factor	O
.	O

TITLE	O
:	O
[	O
Evaluation	O
of	O
tracheal	O
intubation	O
in	O
critical	O
SARS	B-DISO
patients	O
].	O

With	O
the	O
development	O
of	O
the	O
disease	O
,	O
two	O
patients	O
had	O
been	O
intubated	O
because	O
of	O
respiratory	B-DISO
failure	I-DISO
or	O
tracheotomy	O
.	O

Standard	O
protection	O
could	O
protect	O
medical	O
staff	O
from	O
infection	B-DISO
under	O
tracheal	O
intubation	O
.	O

Clinical	O
samples	O
were	O
collected	O
from	O
120	O
patients	O
diagnosed	O
as	O
suspected	O
or	O
probable	O
SARS	B-DISO
cases	O
and	O
analyzed	O
by	O
conventional	O
PCR	O
followed	O
by	O
agarose	O
gel	O
electrophoresis	O
,	O
conventional	O
TaqMan	O
real	O
-	O
time	O
PCR	O
,	O
and	O
our	O
enhanced	O
TaqMan	O
real	O
-	O
time	O
PCR	O
assays	O
.	O

The	O
increased	O
sensitivity	O
of	O
the	O
assay	O
may	O
help	O
control	O
the	O
spread	O
of	O
the	O
disease	O
during	O
future	O
SARS	B-DISO
outbreaks	O
.	O

ABSTRACT	O
:	O
The	O
emergence	O
of	O
nucleic	O
acid	O
-	O
based	O
molecular	O
techniques	O
has	O
significantly	O
enhanced	O
laboratory	O
diagnosis	O
and	O
monitoring	O
of	O
atypical	B-DISO
pneumonia	I-DISO
.	O

These	O
techniques	O
have	O
not	O
only	O
provided	O
rapid	O
and	O
sensitive	O
detection	O
of	O
fastidious	O
microbial	O
organisms	O
but	O
have	O
also	O
played	O
critical	O
roles	O
in	O
identifying	O
and	O
characterizing	O
emerging	O
pathogens	O
that	O
cause	O
atypical	B-DISO
pneumonia	I-DISO
.	O

TITLE	O
:	O
Molecular	O
model	O
of	O
SARS	B-DISO
coronavirus	O
polymerase	O
:	O
implications	O
for	O
biochemical	O
functions	O
and	O
drug	O
design	O
.	O

ABSTRACT	O
:	O
The	O
causative	O
agent	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
previously	O
unidentified	O
coronavirus	O
,	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
)	O
of	O
SARS	B-DISO
-	O
CoV	O
plays	O
a	O
pivotal	O
role	O
in	O
viral	O
replication	O
and	O
is	O
a	O
potential	O
target	O
for	O
anti	O
-	O
SARS	B-DISO
therapy	O
.	O

We	O
propose	O
that	O
the	O
clinically	O
observed	O
resistance	O
of	O
SARS	B-DISO
to	O
ribavirin	O
is	O
probably	O
due	O
to	O
perturbation	O
of	O
the	O
conserved	O
motif	O
A	O
that	O
controls	O
rNTP	O
binding	O
and	O
fidelity	O
of	O
polymerization	O
.	O

TITLE	O
:	O
[	O
Origin	O
of	O
SARS	B-DISO
from	O
accelerated	O
evolution	O
of	O
a	O
virus	O
by	O
combined	O
pollution	O
].	O

TITLE	O
:	O
Infection	B-DISO
control	O
and	O
anesthesia	B-DISO
:	O
lessons	O
learned	O
from	O
the	O
Toronto	O
SARS	B-DISO
outbreak	O
.	O

The	O
use	O
of	O
several	O
precautionary	O
measures	O
such	O
as	O
goggles	O
,	O
gloves	O
,	O
gowns	O
and	O
facemasks	O
and	O
the	O
application	O
of	O
various	O
infection	B-DISO
control	O
strategies	O
designed	O
to	O
minimize	O
the	O
spread	O
of	O
the	O
virus	O
are	O
discussed	O
.	O

In	O
containing	O
the	O
spread	O
of	O
SARS	B-DISO
,	O
vigilance	O
and	O
strict	O
infection	B-DISO
control	O
are	O
important	O
.	O

ABSTRACT	O
:	O
Influenza	B-DISO
poses	O
a	O
significant	O
threat	O
to	O
public	O
health	O
worldwide	O
.	O

The	O
World	O
Health	O
Organization	O
currently	O
estimates	O
that	O
,	O
on	O
a	O
global	O
basis	O
,	O
4	O
billion	O
annual	O
cases	O
of	O
waterborne	O
diarrhea	B-DISO
result	O
in	O
more	O
than	O
2	O
million	O
deaths	O
per	O
year	O
--	O
the	O
equivalent	O
of	O
20	O
jumbo	O
jet	O
crashes	O
per	O
day	O
.	O

Scientists	O
who	O
study	O
disease	B-DISO
transmission	I-DISO
believe	O
that	O
10	O
%-	O
30	O
%	O
of	O
the	O
vomiting	B-DISO
and	O
diarrhea	B-DISO
illness	O
in	O
North	O
America	O
,	O
including	O
Wisconsin	O
,	O
may	O
be	O
acquired	O
from	O
water	O
.	O

Diagnostic	O
utility	O
of	O
these	O
variables	O
was	O
higher	O
when	O
performed	O
on	O
effusion	B-DISO
.	O

Diagnostic	O
assays	O
on	O
the	O
fluid	O
in	O
cats	O
with	O
body	O
effusion	B-DISO
had	O
good	O
predictive	O
values	O
.	O

The	O
addition	O
of	O
lopinavir	O
/	O
ritonavir	O
to	O
a	O
standard	O
treatment	O
protocol	O
as	O
an	O
initial	O
treatment	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
appeared	O
to	O
be	O
associated	O
with	O
improved	O
clinical	O
outcome	O
.	O

Recent	O
advances	O
have	O
been	O
made	O
in	O
our	O
knowledge	O
of	O
some	O
of	O
these	O
,	O
including	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
,	O
influenza	B-DISO
A	O
virus	O
,	O
human	O
metapneumovirus	O
,	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
and	O
Ebola	O
virus	O
.	O

Antinucleocapsid	O
protein	O
antibodies	O
could	O
be	O
detected	O
in	O
68	O
.	O
4	O
%	O
of	O
probable	O
SARS	B-DISO
patients	O
6	O
to	O
10	O
days	O
after	O
illness	O
and	O
in	O
89	O
.	O
6	O
%	O
of	O
the	O
patients	O
11	O
to	O
61	O
days	O
after	O
illness	O
.	O

To	O
overcome	O
the	O
problem	O
of	O
IBV	O
amplification	B-DISO
,	O
a	O
set	O
of	O
separate	O
primers	O
was	O
designed	O
from	O
the	O
spike	O
protein	O
gene	O
of	O
IBV	O
.	O

Effective	O
human	O
-	O
to	O
-	O
human	O
transmission	O
requires	O
that	O
the	O
pathogen	O
'	O
s	O
basic	O
reproductive	O
number	O
,	O
R	O
(	O
0	O
),	O
should	O
exceed	O
one	O
,	O
where	O
R	O
(	O
0	O
)	O
is	O
the	O
average	O
number	O
of	O
secondary	B-DISO
infections	I-DISO
arising	O
from	O
one	O
infected	O
individual	O
in	O
a	O
completely	O
susceptible	O
population	O
.	O

The	O
purified	O
protein	O
will	O
be	O
used	O
for	O
the	O
studies	O
on	O
M	O
protein	O
'	O
s	O
structure	O
and	O
the	O
development	O
of	O
diagnostic	O
method	O
of	O
SARS	B-DISO
.	O

The	O
outbreak	O
dramatically	O
illustrated	O
the	O
critical	O
need	O
to	O
transform	O
healthcare	O
organizations	O
to	O
a	O
""""	O
new	O
normal	O
""""	O
state	O
of	O
operation	O
to	O
respond	O
to	O
the	O
ease	O
by	O
which	O
contagious	B-DISO
diseases	I-DISO
can	O
spread	O
globally	O
.	O

TITLE	O
:	O
Total	O
pancreatectomy	O
and	O
autologous	O
islet	O
cell	O
transplantation	O
as	O
a	O
means	O
to	O
treat	O
severe	O
chronic	B-DISO
pancreatitis	I-DISO
.	O

Sixty	O
-	O
eight	O
percent	O
of	O
the	O
patients	O
had	O
either	O
a	O
minor	O
or	O
major	O
complication	B-DISO
.	O

Major	O
complications	O
included	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
n	O
=	O
2	O
),	O
intra	B-DISO
-	I-DISO
abdominal	I-DISO
abscess	I-DISO
(	O
n	O
=	O
1	O
),	O
and	O
pulmonary	B-DISO
embolism	I-DISO
(	O
n	O
=	O
1	O
).	O

When	O
the	O
outbreak	O
of	O
this	O
apparently	O
novel	O
infectious	B-DISO
disease	I-DISO
termed	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
came	O
to	O
an	O
end	O
in	O
July	O
2003	O
,	O
it	O
had	O
caused	O
over	O
8000	O
probable	O
cases	O
worldwide	O
and	O
more	O
than	O
700	O
deaths	O
.	O

Although	O
100	O
%	O
of	O
chickens	O
may	O
be	O
protected	O
(	O
against	O
clinical	O
signs	O
and	O
loss	O
of	O
ciliary	O
activity	O
in	O
trachea	B-DISO
),	O
sometimes	O
10	O
%	O
of	O
vaccinated	O
chicks	O
do	O
not	O
respond	O
with	O
a	O
protective	O
immune	O
response	O
.	O

Prevention	O
of	O
future	O
outbreaks	O
requires	O
strengthening	O
of	O
infection	B-DISO
control	O
practices	O
in	O
hospitals	O
,	O
development	O
of	O
a	O
rapid	O
diagnostic	O
test	O
and	O
a	O
vaccine	O
,	O
and	O
removal	O
of	O
any	O
animal	O
reservoir	O
and	O
environmental	O
conditions	O
that	O
led	O
to	O
the	O
spread	O
of	O
the	O
disease	O
.	O

ABSTRACT	O
:	O
To	O
understand	O
the	O
epidemiological	O
characteristics	O
of	O
the	O
index	O
cases	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
cases	O
clusters	O
and	O
to	O
evaluate	O
their	O
importance	O
in	O
the	O
whole	O
epidemic	O
process	O
of	O
SARS	B-DISO
.	O

In	O
all	O
three	O
SARS	B-DISO
clusters	O
,	O
the	O
index	O
cases	O
all	O
had	O
chronic	B-DISO
disease	I-DISO
and	O
played	O
the	O
role	O
of	O
infection	B-DISO
source	O
that	O
transmitted	B-DISO
the	O
virus	O
to	O
the	O
patients	O
'	O
family	O
members	O
,	O
attending	O
medical	O
staff	O
as	O
well	O
as	O
other	O
non	O
-	O
SARS	B-DISO
patients	O
sharing	O
the	O
same	O
ward	O
with	O
them	O
.	O

RESULTS	O
:	O
In	O
all	O
three	O
SARS	B-DISO
clusters	O
,	O
the	O
index	O
cases	O
all	O
had	O
chronic	B-DISO
disease	I-DISO
and	O
played	O
the	O
role	O
of	O
infection	B-DISO
source	O
that	O
transmitted	B-DISO
the	O
virus	O
to	O
the	O
patients	O
'	O
family	O
members	O
,	O
attending	O
medical	O
staff	O
as	O
well	O
as	O
other	O
non	O
-	O
SARS	B-DISO
patients	O
sharing	O
the	O
same	O
ward	O
with	O
them	O
.	O

After	O
one	O
flight	O
carrying	O
a	O
symptomatic	O
person	O
and	O
119	O
other	O
persons	O
,	O
laboratory	O
-	O
confirmed	O
SARS	B-DISO
developed	O
in	O
16	O
persons	O
,	O
2	O
others	O
were	O
given	O
diagnoses	O
of	O
probable	O
SARS	B-DISO
,	O
and	O
4	O
were	O
reported	O
to	O
have	O
SARS	B-DISO
but	O
could	O
not	O
be	O
interviewed	O
.	O

HRCT	O
can	O
show	O
parenchymal	O
abnormalities	O
in	O
patients	O
with	O
SARS	B-DISO
who	O
have	O
normal	O
findings	O
on	O
radiographs	O
at	O
presentation	O
.	O

Reticulation	O
with	O
associated	O
architectural	O
distortion	B-DISO
and	O
mild	O
traction	B-DISO
bronchiectasis	I-DISO
was	O
present	O
in	O
eight	O
patients	O
.	O

CONCLUSIONS	O
:	O
HRCT	O
can	O
show	O
parenchymal	O
abnormalities	O
in	O
patients	O
with	O
SARS	B-DISO
who	O
have	O
normal	O
findings	O
on	O
radiographs	O
at	O
presentation	O
.	O

CONCLUSIONS	O
:	O
A	O
defined	O
pattern	O
of	O
HRCT	O
findings	O
is	O
observed	O
in	O
different	O
phases	O
of	O
SARS	B-DISO
,	O
which	O
is	O
characterized	O
by	O
focal	O
ground	O
-	O
glass	O
and	O
crazy	O
paving	O
patterns	O
in	O
a	O
scattered	O
distribution	O
at	O
presentation	O
,	O
followed	O
by	O
development	O
of	O
interstitial	O
thickening	O
,	O
consolidation	O
,	O
pleural	O
reaction	O
,	O
and	O
scarring	B-DISO
.	O

This	O
scanner	O
was	O
used	O
exclusively	O
for	O
patients	O
with	O
SARS	B-DISO
and	O
patients	O
with	O
other	O
illnesses	O
who	O
were	O
also	O
thought	O
to	O
have	O
SARS	B-DISO
.	O

In	O
5	O
weeks	O
,	O
90	O
studies	O
were	O
performed	O
;	O
no	O
cases	O
of	O
cross	B-DISO
infection	I-DISO
of	O
health	O
care	O
workers	O
were	O
reported	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
putative	O
cellular	O
receptor	O
150	O
kDa	O
polypeptide	O
for	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
in	O
porcine	O
enterocytes	O
.	O

PEDV	O
occupies	O
an	O
intermediate	O
position	O
between	O
two	O
well	O
characterized	O
members	O
of	O
the	O
coronavirus	O
group	O
I	O
,	O
human	O
coronavirus	O
(	O
HCoV	O
-	O
229E	O
)	O
and	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
which	O
uses	O
aminopeptidase	O
N	O
(	O
APN	O
),	O
a	O
150	O
kDa	O
protein	O
,	O
as	O
their	O
receptors	O
.	O

TITLE	O
:	O
[	O
SARS	B-DISO
surveillance	O
--	O
did	O
it	O
meet	O
the	O
demands	O
made	O
on	O
the	O
surveillance	O
of	O
new	O
infectious	B-DISO
diseases	I-DISO
?].	O

The	O
RKI	O
has	O
established	O
two	O
linked	O
databases	O
for	O
the	O
surveillance	O
of	O
SARS	B-DISO
,	O
to	O
store	O
case	O
-	O
based	O
data	O
on	O
SARS	B-DISO
and	O
to	O
keep	O
a	O
record	O
of	O
inquiries	O
by	O
the	O
public	O
health	O
system	O
.	O

TITLE	O
:	O
[	O
Evaluation	O
on	O
the	O
functions	O
and	O
cost	O
of	O
'	O
fever	O
clinics	O
'	O
during	O
the	O
period	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
epidemics	O
in	O
Beijing	O
].	O

TITLE	O
:	O
Mitochondrial	O
HSP70	O
,	O
HSP40	O
,	O
and	O
HSP60	O
bind	O
to	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
the	O
Murine	B-DISO
hepatitis	I-DISO
virus	O
genome	O
.	O

Near	O
-	O
drowning	O
in	O
the	O
Dead	O
Sea	O
is	O
expected	O
to	O
result	O
in	O
severe	O
electrolyte	O
abnormalities	O
and	O
respiratory	B-DISO
failure	I-DISO
.	O

Fecal	O
samples	O
were	O
evaluated	O
for	O
Eimeria	O
spp	O
,	O
Giardia	B-DISO
spp	O
,	O
Cryptosporidium	O
spp	O
,	O
enteric	O
viruses	O
,	O
and	O
Salmonella	B-DISO
spp	O
.	O

ABSTRACT	O
:	O
Mice	O
aged	O
1	O
,	O
4	O
or	O
8	O
weeks	O
were	O
inoculated	O
with	O
haemagglutinating	O
encephalomyelitis	B-DISO
virus	O
(	O
HEV	O
),	O
strain	O
67N	O
,	O
by	O
the	O
intracerebral	O
(	O
i	O
.	O
c	O
.	O

To	O
describe	O
and	O
evaluate	O
the	O
measures	O
undertaken	O
to	O
control	O
the	O
SARS	B-DISO
outbreak	O
.	O

Open	O
-	O
label	O
study	O
of	O
22	O
patients	O
diagnosed	O
as	O
having	O
probable	O
SARS	B-DISO
at	O
North	O
York	O
General	O
Hospital	O
,	O
Toronto	O
,	O
Ontario	O
,	O
between	O
April	O
11	O
and	O
May	O
30	O
,	O
2003	O
.	O

Development	O
of	O
a	O
set	O
of	O
legal	O
and	O
ethical	O
recommendations	O
becomes	O
even	O
more	O
essential	O
when	O
,	O
as	O
was	O
true	O
with	O
SARS	B-DISO
and	O
will	O
undoubtedly	O
be	O
the	O
case	O
with	O
future	O
epidemics	O
,	O
scientific	O
uncertainty	O
is	O
pervasive	O
and	O
urgent	O
public	O
health	O
action	O
is	O
required	O
.	O

However	O
,	O
chemokines	O
are	O
expressed	O
early	O
following	O
viral	B-DISO
infection	I-DISO
,	O
suggesting	O
an	O
important	O
role	O
in	O
coordinating	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
highly	O
contagious	O
and	O
typically	O
rapidly	O
progressive	O
form	O
of	O
atypical	B-DISO
pneumonia	I-DISO
,	O
which	O
spread	O
from	O
Asia	O
to	O
many	O
parts	O
of	O
the	O
world	O
in	O
early	O
2003	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
woman	O
who	O
had	O
undergone	O
a	O
successful	O
allogeneic	O
bone	O
marrow	O
transplant	O
for	O
acute	B-DISO
myeloid	I-DISO
leukemia	I-DISO
.	O

TITLE	O
:	O
Novel	O
N	O
-	O
thiolated	O
beta	O
-	O
lactam	O
antibiotics	O
selectively	O
induce	O
apoptosis	O
in	O
human	O
tumor	B-DISO
and	O
transformed	O
,	O
but	O
not	O
normal	O
or	O
nontransformed	O
,	O
cells	O
.	O

ABSTRACT	O
:	O
Historically	O
,	O
it	O
has	O
been	O
shown	O
that	O
the	O
beta	O
-	O
lactam	O
antibiotics	O
play	O
an	O
essential	O
role	O
in	O
treating	O
bacterial	B-DISO
infections	I-DISO
while	O
demonstrating	O
selectivity	O
for	O
prokaryotic	O
cells	O
.	O

Additionally	O
,	O
we	O
screened	O
a	O
library	O
of	O
other	O
N	O
-	O
methylthiolated	O
beta	O
-	O
lactams	O
to	O
determine	O
their	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	B-DISO
),	O
and	O
found	O
lactam	O
12	O
to	O
have	O
the	O
highest	O
apoptosis	O
-	O
inducing	O
activity	O
against	O
human	O
leukemic	O
Jurkat	O
T	O
cells	O
,	O
associated	O
with	O
increased	O
DNA	O
-	O
damaging	O
potency	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
performs	O
RNA	O
replication	O
on	O
double	O
membrane	O
vesicles	B-DISO
(	O
DMVs	O
)	O
in	O
the	O
cytoplasm	O
of	O
the	O
host	O
cell	O
.	O

Possible	O
agents	O
include	O
smallpox	B-DISO
,	O
haemorrhagic	B-DISO
fever	I-DISO
viruses	O
,	O
anthrax	B-DISO
,	O
tularaemia	B-DISO
and	O
plague	B-DISO
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
epidemiological	O
,	O
clinical	O
and	O
laboratory	O
characteristics	O
,	O
treatment	O
and	O
prognosis	O
of	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

0	O
%),	O
cough	B-DISO
(	O
72	O
.	O
8	O
%),	O
and	O
fatigue	B-DISO
(	O
70	O
.	O
0	O
%).	O

64	O
.	O
2	O
%	O
of	O
the	O
patients	O
had	O
decreased	B-DISO
lymphocytes	I-DISO
.	O

By	O
biotinylated	O
ELISA	O
and	O
Western	O
blot	O
using	O
biotin	O
-	O
labeled	O
S	O
protein	O
as	O
the	O
probe	O
,	O
we	O
identified	O
130	O
-	O
kDa	O
and	O
140	O
-	O
kDa	O
proteins	O
in	O
Vero	O
cells	O
that	O
might	O
be	O
the	O
cellular	O
receptors	O
responsible	O
for	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

RESULTS	O
:	O
Diagnostic	O
test	O
results	O
for	O
SARS	B-DISO
-	O
CoV	O
were	O
available	O
for	O
110	O
of	O
the	O
117	O
patients	O
.	O

SARS	B-DISO
-	O
CoV	O
was	O
detected	O
in	O
nasopharyngeal	O
swabs	O
in	O
33	O
(	O
32	O
.	O
4	O
%)	O
of	O
102	O
patients	O
,	O
in	O
stool	O
specimens	O
in	O
19	O
(	O
63	O
.	O
3	O
%)	O
of	O
30	O
patients	O
,	O
and	O
in	O
specimens	O
from	O
the	O
lower	O
respiratory	O
tract	O
in	O
10	O
(	O
58	O
.	O
8	O
%)	O
of	O
17	O
patients	O
.	O

In	O
nonendemic	O
areas	O
,	O
the	O
febrile	O
patients	O
with	O
recent	O
contact	O
with	O
SARS	B-DISO
or	O
travel	O
history	O
to	O
endemic	O
areas	O
could	O
be	O
screened	O
for	O
the	O
probability	O
of	O
SARS	B-DISO
by	O
the	O
use	O
of	O
clinical	O
and	O
symptom	B-DISO
scores	O
.	O

Children	O
younger	O
than	O
15	O
years	O
and	O
suspected	O
SARS	B-DISO
patients	O
with	O
negative	O
polymerase	O
chain	O
reaction	O
results	O
were	O
excluded	O
from	O
final	O
analysis	O
.	O

CONCLUSIONS	O
:	O
During	O
an	O
outbreak	O
period	O
,	O
recognition	O
of	O
possible	O
SARS	B-DISO
cases	O
depends	O
on	O
the	O
heightened	O
awareness	O
of	O
its	O
clinical	O
presentation	O
.	O

Two	O
previously	O
developed	O
SARS	B-DISO
screening	O
scores	O
were	O
applied	O
to	O
all	O
patients	O
.	O

The	O
final	O
diagnosis	O
of	O
SARS	B-DISO
was	O
made	O
by	O
the	O
Expert	O
Committee	O
of	O
the	O
Center	O
for	O
Disease	O
Control	O
Taiwan	O
,	O
Republic	O
of	O
China	O
,	O
according	O
to	O
the	O
criteria	O
of	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
,	O
Atlanta	O
,	O
GA	O
.	O

ABSTRACT	O
:	O
A	O
28	O
-	O
year	O
-	O
old	O
female	O
with	O
a	O
twin	O
pregnancy	O
at	O
29	O
6	O
/	O
7	O
weeks	O
who	O
was	O
having	O
premature	O
uterine	O
contractions	B-DISO
developed	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
due	O
to	O
sudden	O
pulmonary	B-DISO
oedema	I-DISO
requiring	O
mechanical	O
ventilation	O
.	O

Ultrasonography	O
revealed	O
oligohydramnios	B-DISO
of	O
one	O
of	O
the	O
foetuses	O
.	O

By	O
exclusion	O
of	O
other	O
causes	O
,	O
we	O
diagnosed	O
severe	O
maternal	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
due	O
to	O
the	O
amniotic	B-DISO
fluid	I-DISO
embolism	I-DISO
syndrome	B-DISO
in	O
a	O
twin	O
pregnancy	O
.	O

TITLE	O
:	O
Detection	O
of	O
SARS	B-DISO
coronavirus	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
by	O
conventional	O
and	O
real	O
-	O
time	O
quantitative	O
reverse	O
transcription	O
-	O
PCR	O
assays	O
.	O

We	O
selected	O
98	O
NPA	O
and	O
37	O
stool	O
samples	O
collected	O
at	O
different	O
times	O
after	O
the	O
onset	O
of	O
disease	O
and	O
tested	O
them	O
in	O
a	O
real	O
-	O
time	O
quantitative	O
RT	O
-	O
PCR	O
specific	O
for	O
the	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
1b	O
region	O
of	O
SARS	B-DISO
CoV	O
.	O
Detection	O
rates	O
for	O
the	O
conventional	O
and	O
real	O
-	O
time	O
quantitative	O
RT	O
-	O
PCR	O
assays	O
were	O
compared	O
.	O

The	O
objective	O
was	O
to	O
describe	O
the	O
impact	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
on	O
the	O
services	O
of	O
the	O
division	O
of	O
otorhinolaryngology	O
-	O
head	O
and	O
neck	O
surgery	O
at	O
an	O
academic	O
tertiary	O
referral	O
hospital	O
in	O
Hong	O
Kong	O
.	O

Since	O
the	O
outbreak	O
of	O
SARS	B-DISO
in	O
March	O
2003	O
,	O
the	O
weekly	O
outpatient	O
clinic	O
attendance	O
has	O
declined	O
by	O
59	O
%,	O
the	O
number	O
of	O
operations	O
performed	O
by	O
79	O
%,	O
the	O
average	O
ward	O
bed	B-DISO
occupancy	O
rate	O
by	O
79	O
%	O
and	O
the	O
daily	O
admission	O
rate	O
by	O
84	O
%.	O

The	O
temporary	O
closure	O
of	O
the	O
accident	O
and	O
emergency	B-DISO
department	O
contributed	O
to	O
the	O
decrease	O
in	O
ward	O
admissions	O
and	O
emergency	B-DISO
surgical	O
procedures	O
.	O

Dyspnea	B-DISO
appeared	O
suddenly	O
two	O
days	O
later	O
.	O

It	O
is	O
recommended	O
that	O
these	O
or	O
similar	O
protocols	O
be	O
used	O
when	O
an	O
obstetrical	O
unit	O
is	O
confronted	O
with	O
a	O
large	O
-	O
scale	O
nosocomial	O
infectious	B-DISO
outbreak	O
that	O
has	O
a	O
mechanism	O
of	O
transmission	O
similar	O
to	O
that	O
of	O
SARS	B-DISO
.	O

Interestingly	O
,	O
dogs	O
inoculated	O
with	O
the	O
ML	O
CCV	B-DISO
vaccine	O
by	O
the	O
oronasal	O
route	O
developed	O
levels	O
of	O
fecal	O
IgA	O
that	O
were	O
higher	O
than	O
those	O
observed	O
in	O
the	O
dogs	O
inoculated	O
with	O
the	O
same	O
CCV	B-DISO
vaccine	O
by	O
the	O
intramuscular	O
route	O
or	O
those	O
observed	O
in	O
dogs	O
inoculated	O
with	O
the	O
inactivated	O
vaccine	O
.	O

TITLE	O
:	O
Profile	O
of	O
antibodies	O
to	O
the	O
nucleocapsid	O
protein	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
associated	O
coronavirus	O
in	O
probable	O
SARS	B-DISO
patients	O
.	O

TITLE	O
:	O
Detection	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
in	O
blood	O
of	O
infected	O
patients	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
has	O
caused	O
major	O
outbreaks	O
worldwide	O
,	O
resulting	O
in	O
an	O
urgent	O
need	O
to	O
obtain	O
sensitive	O
and	O
accurate	O
diagnosis	O
of	O
this	O
disease	O
.	O

ABSTRACT	O
:	O
We	O
investigated	O
the	O
usefulness	O
of	O
high	O
-	O
resolution	O
computed	O
tomography	O
(	O
HRCT	O
)	O
in	O
early	O
detection	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
associated	O
coronavirus	O
pneumonia	B-DISO
and	O
analyzed	O
HRCT	O
findings	O
associated	O
with	O
potentially	O
more	O
severe	O
disease	O
.	O

Polio	B-DISO
eradication	O
and	O
elimination	O
of	O
neonatal	O
tetanus	B-DISO
are	O
making	O
slow	O
progress	O
,	O
obstacles	O
to	O
the	O
control	O
of	O
these	O
diseases	O
are	O
ongoing	O
armed	O
conflicts	O
in	O
regions	O
with	O
high	O
prevalence	O
and	O
under	O
financing	O
of	O
programs	O
.	O

The	O
numbers	O
of	O
patients	O
newly	O
identified	O
with	O
new	B-DISO
variant	I-DISO
Creutzfeldt	I-DISO
-	I-DISO
Jakob	I-DISO
disease	I-DISO
are	O
not	O
rising	O
,	O
but	O
rather	O
constant	O
or	O
even	O
declining	O
,	O
making	O
a	O
large	O
epidemic	O
of	O
vCJD	B-DISO
unlikely	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
'	B-DISO
SARS	I-DISO
'	O
or	O
'	O
not	O
SARS	B-DISO
'.	O

Contact	O
history	O
is	O
particularly	O
important	O
in	O
diagnosing	O
SARS	B-DISO
in	O
children	O
as	O
their	O
presenting	O
features	O
are	O
often	O
non	O
-	O
specific	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
epidemic	O
in	O
Asia	O
.	O

The	O
predicted	O
total	O
SARS	B-DISO
incidence	O
was	O
close	O
to	O
the	O
actual	O
number	O
of	O
cases	O
;	O
the	O
predicted	O
cessation	O
date	O
was	O
close	O
to	O
the	O
lower	O
limit	O
of	O
the	O
95	O
%	O
confidence	O
interval	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
pathologic	O
characteristics	O
and	O
pathogenesis	B-DISO
of	O
circulating	O
blood	O
leucocytes	O
infected	O
by	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
associated	O
coronavirus	O
(	O
SARS	B-DISO
CoV	O
or	O
SCV	O
)	O
in	O
SARS	B-DISO
patients	O
.	O

Blood	O
samples	O
of	O
22	O
SARS	B-DISO
patients	O
were	O
studied	O
,	O
and	O
4	O
healthy	O
blood	O
samples	O
were	O
observed	O
as	O
negative	O
controls	O
.	O

The	O
SARS	B-DISO
viral	O
sequence	O
was	O
detected	O
with	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

The	O
particles	O
were	O
located	O
in	O
the	O
cytoplasm	O
,	O
the	O
cisternae	O
of	O
endoplasmic	O
reticulum	O
,	O
Golgi	O
apparatus	O
and	O
vesicles	B-DISO
.	O

In	O
addition	O
,	O
genomes	O
of	O
viruses	O
from	O
about	O
half	O
the	O
plaques	B-DISO
that	O
retained	O
the	O
EGFP	O
gene	O
had	O
mutations	O
within	O
the	O
gp33	O
-	O
41	O
epitope	O
.	O

Nurses	O
must	O
play	O
a	O
crucial	O
role	O
in	O
the	O
prevention	O
,	O
detection	O
and	O
containment	O
of	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
To	O
prepare	O
and	O
characterize	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
against	O
S1	O
protein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

ABSTRACT	O
:	O
To	O
amplify	O
and	O
clone	O
the	O
N	O
gene	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
.	O

The	O
successful	O
amplification	B-DISO
and	O
cloning	O
of	O
N	O
gene	O
facilitates	O
further	O
investigation	O
of	O
the	O
expression	O
of	O
the	O
N	O
protein	O
and	O
study	O
of	O
its	O
structure	O
and	O
functions	O
.	O

We	O
genetically	O
sequenced	O
the	O
gene	O
for	O
the	O
S1	O
unit	O
of	O
the	O
viral	O
spike	O
protein	O
of	O
viruses	O
from	O
patients	O
with	O
SARS	B-DISO
in	O
Hong	O
Kong	O
(	O
138	O
)	O
and	O
Guangdong	O
(	O
three	O
)	O
in	O
February	O
to	O
April	O
,	O
2003	O
.	O

Atypical	O
presentation	O
of	O
SARS	B-DISO
infection	B-DISO
must	O
be	O
taken	O
into	O
consideration	O
when	O
managing	O
patients	O
with	O
a	O
history	O
of	O
contact	O
with	O
SARS	B-DISO
patients	O
.	O

RESULTS	O
:	O
The	O
index	O
patient	O
presented	O
with	O
gastrointestinal	B-DISO
bleeding	I-DISO
,	O
initially	O
without	O
changes	O
to	O
his	O
chest	O
radiograph	O
.	O

Clinical	O
manifestation	O
,	O
chest	O
X	O
-	O
ray	O
,	O
computed	O
tomography	O
(	O
CT	O
)	O
and	O
pulmonary	O
function	O
of	O
4	O
cases	O
with	O
bronchiolitis	B-DISO
obliterans	I-DISO
were	O
retrospectively	O
analyzed	O
.	O

Crackles	B-DISO
and	O
wheezing	B-DISO
were	O
the	O
most	O
common	O
signs	O
in	O
the	O
BO	O
.	O

Pulmonary	O
CT	O
showed	O
bronchial	B-DISO
wall	I-DISO
thickening	I-DISO
,	O
bronchiectasis	B-DISO
,	O
atelectasis	B-DISO
,	O
and	O
mosaic	O
perfusion	O
.	O

Pulmonary	O
function	O
tests	O
suggested	O
obstruction	B-DISO
of	O
small	O
airway	O
.	O

CONCLUSIONS	O
:	O
Clinical	O
symptoms	O
of	O
BO	O
were	O
cough	B-DISO
,	O
tachypnea	B-DISO
,	O
and	O
wheezing	B-DISO
after	O
acute	O
lung	O
injury	O
.	O

TITLE	O
:	O
Early	O
detection	O
of	O
antibodies	O
against	O
various	O
structural	O
proteins	O
of	O
the	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
in	O
SARS	B-DISO
patients	O
.	O

Finally	O
,	O
our	O
results	O
show	O
that	O
IgA	O
antibodies	O
against	O
SARS	B-DISO
-	O
CoV	O
can	O
be	O
detected	O
within	O
1	O
week	O
after	O
illness	O
onset	O
in	O
a	O
few	O
SARS	B-DISO
patients	O
.	O

ABSTRACT	O
:	O
Subacute	O
motor	B-DISO
neuropathy	I-DISO
involving	O
bulbar	O
nerves	O
is	O
an	O
unusual	O
complication	B-DISO
of	O
hyperthyroidism	B-DISO
.	O

We	O
describe	O
a	O
41	O
-	O
year	O
-	O
old	O
Colombian	O
patient	O
who	O
developed	O
respiratory	B-DISO
failure	I-DISO
associated	O
with	O
motor	B-DISO
neuropathy	I-DISO
and	O
severe	O
weight	O
loss	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
,	O
a	O
main	O
surface	O
antigen	O
of	O
SARS	B-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
is	O
one	O
of	O
the	O
most	O
important	O
antigen	O
candidates	O
for	O
vaccine	O
design	O
.	O

The	O
mouse	O
serum	O
IgG	O
antibody	O
against	O
SARS	B-DISO
-	O
CoV	O
was	O
measured	O
by	O
ELISA	O
with	O
E	O
.	O
coli	O
expressed	O
truncated	O
S	O
protein	O
or	O
SARS	B-DISO
-	O
CoV	O
lysate	O
as	O
diagnostic	O
antigen	O
.	O

TITLE	O
:	O
Comparison	O
of	O
clinical	O
course	O
of	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
among	O
the	O
multiple	O
generations	O
of	O
nosocomial	O
transmission	O
.	O

This	O
study	O
was	O
conducted	O
to	O
compare	O
the	O
clinical	O
features	O
and	O
management	O
regimens	O
of	O
patients	O
with	O
SARS	B-DISO
among	O
the	O
multiple	O
generations	O
from	O
nosocomial	O
transmission	O
initiated	O
by	O
a	O
super	O
-	O
spreader	O
.	O

There	O
is	O
no	O
evidence	O
that	O
SARS	B-DISO
infection	B-DISO
will	O
evolve	O
or	O
transmit	O
within	O
a	O
fashion	O
that	O
permits	O
it	O
to	O
become	O
less	O
powerful	O
throughout	O
the	O
successive	O
transmission	O
within	O
a	O
short	O
time	O
.	O

The	O
genotype	O
,	O
single	O
nucleotide	O
polymorphism	O
and	O
phylogeny	O
of	O
these	O
SARS	B-DISO
-	O
CoV	O
strains	O
were	O
analyzed	O
by	O
molecular	O
biological	O
,	O
bioinformatic	O
and	O
epidemiological	O
methods	O
.	O

Amplicons	O
with	O
the	O
sizes	O
of	O
368	O
bp	O
and	O
348	O
bp	O
were	O
obtained	O
from	O
a	O
throat	O
swab	O
specimen	O
collected	O
from	O
a	O
17	O
years	O
old	O
girl	O
,	O
who	O
was	O
admitted	O
to	O
the	O
isolated	O
ward	O
because	O
of	O
high	O
fever	O
(	O
39	O
.	O
5	O
degrees	O
C	O
)	O
for	O
7	O
days	O
,	O
cough	B-DISO
for	O
2	O
days	O
,	O
low	O
WBC	O
count	O
,	O
and	O
pneumonia	B-DISO
shown	O
by	O
X	O
-	O
ray	O
when	O
she	O
visited	O
the	O
""""	O
Fever	O
and	O
Cough	B-DISO
""""	O
Clinic	O
,	O
and	O
without	O
known	O
history	O
of	O
contact	O
with	O
probable	O
SARS	B-DISO
patient	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
indicate	O
that	O
the	O
patient	O
was	O
a	O
confirmed	O
case	O
of	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
To	O
explore	O
clinical	O
and	O
chest	O
X	O
-	O
ray	O
features	O
of	O
SARS	B-DISO
in	O
children	O
to	O
facilitate	O
correct	O
diagnosis	O
.	O

SARS	B-DISO
associated	O
coronavirus	O
specific	O
RNA	O
fragment	O
was	O
found	O
positive	O
by	O
RT	O
-	O
PCR	O
in	O
1	O
case	O
;	O
1	O
case	O
was	O
positive	O
for	O
both	O
IgM	O
and	O
IgG	O
antibodies	O
to	O
the	O
virus	O
;	O
1	O
case	O
was	O
positive	O
for	O
only	O
IgM	O
antibody	O
and	O
another	O
2	O
cases	O
were	O
positive	O
for	O
only	O
IgG	O
antibody	O
.	O

Findings	O
on	O
chest	O
X	O
-	O
ray	O
examination	O
:	O
4	O
cases	O
showed	O
presence	O
of	O
patchy	O
or	O
macular	O
opacities	B-DISO
with	O
cord	B-DISO
-	O
like	O
shadows	O
in	O
unilateral	O
lung	O
plates	O
while	O
1	O
case	O
each	O
showed	O
ground	O
-	O
glass	O
-	O
like	O
opacity	B-DISO
and	O
migratory	O
changes	O
;	O
1	O
case	O
showed	O
interstitial	O
changes	O
in	O
the	O
lungs	O
in	O
the	O
form	O
of	O
irregular	O
reticular	O
lattice	O
and	O
cord	B-DISO
-	O
like	O
shadows	O
.	O

Our	O
series	O
documents	O
the	O
difficulties	O
encountered	O
at	O
autopsy	O
during	O
the	O
initial	O
phases	O
of	O
the	O
SARS	B-DISO
epidemic	O
,	O
when	O
the	O
pattern	O
of	O
infection	B-DISO
and	O
definitive	O
diagnostic	O
laboratory	O
criteria	O
were	O
yet	O
to	O
be	O
established	O
.	O

In	O
4	O
of	O
the	O
8	O
SARS	B-DISO
patients	O
,	O
pulmonary	O
thromboemboli	O
were	O
also	O
recognized	O
on	O
gross	O
examination	O
,	O
while	O
one	O
patient	O
had	O
marantic	O
cardiac	O
valvular	O
vegetations	B-DISO
.	O

Although	O
nonspecific	O
by	O
itself	O
,	O
the	O
term	O
does	O
not	O
accurately	O
reflect	O
the	O
underlying	O
dangers	O
of	O
viral	B-DISO
pneumonia	I-DISO
,	O
which	O
may	O
progress	O
rapidly	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Patients	O
with	O
SARS	B-DISO
present	O
with	O
recognizable	O
patterns	O
of	O
disease	O
that	O
have	O
prognostic	O
significance	O
.	O

These	O
researchers	O
also	O
found	O
serological	O
evidence	O
of	O
infection	B-DISO
in	O
raccoon	O
dogs	O
(	O
Nyctereutes	O
procuyoinboides	O
).	O

ABSTRACT	O
:	O
To	O
document	O
the	O
outcome	O
and	O
determine	O
prognostic	O
factors	O
for	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
who	O
require	O
admission	O
to	O
an	O
intensive	O
care	O
unit	O
.	O

The	O
first	O
54	O
patients	O
admitted	O
with	O
SARS	B-DISO
to	O
an	O
intensive	O
care	O
unit	O
(	O
ICU	O
).	O

RESULTS	O
:	O
Results	O
suggest	O
that	O
despite	O
rather	O
intensive	O
efforts	O
to	O
generate	O
awareness	O
about	O
SARS	B-DISO
transmission	O
,	O
a	O
certain	O
level	O
of	O
uncertainty	O
about	O
how	O
SARS	B-DISO
can	O
be	O
transmitted	B-DISO
still	O
prevails	O
.	O

The	O
data	O
series	O
includes	O
details	O
regarding	O
sex	O
,	O
age	O
,	O
and	O
chronic	B-DISO
disease	I-DISO
history	O
.	O

TITLE	O
:	O
[	O
Clinical	O
analysis	O
of	O
pediatric	O
SARS	B-DISO
cases	O
in	O
Beijing	O
].	O

CONCLUSIONS	O
:	O
Compared	O
with	O
adults	O
,	O
pediatric	O
SARS	B-DISO
patients	O
seemed	O
to	O
have	O
their	O
own	O
clinical	O
characteristics	O
.	O

TITLE	O
:	O
Avian	B-DISO
influenza	I-DISO
A	O
virus	O
(	O
H7N7	O
)	O
associated	O
with	O
human	O
conjunctivitis	B-DISO
and	O
a	O
fatal	O
case	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Of	O
these	O
89	O
patients	O
,	O
78	O
presented	O
with	O
conjunctivitis	B-DISO
,	O
5	O
presented	O
with	O
conjunctivitis	B-DISO
and	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
,	O
2	O
presented	O
with	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
,	O
and	O
4	O
did	O
not	O
fit	B-DISO
the	O
case	O
definitions	O
.	O

Although	O
the	O
amendments	O
to	O
the	O
Health	O
Protection	O
and	O
Promotion	O
Act	O
(	O
HPPA	O
)	O
were	O
clearly	O
designed	O
to	O
address	O
emergency	B-DISO
situations	O
like	O
SARS	B-DISO
,	O
they	O
may	O
have	O
unintended	O
and	O
negative	O
consequences	O
for	O
people	O
living	O
with	O
HIV	B-DISO
/	I-DISO
AIDS	I-DISO
.	O

While	O
wt	O
CD8	O
(+)	O
T	O
cells	O
inhibited	O
virus	O
replication	O
in	O
all	O
CNS	O
cell	O
types	O
,	O
cytolytic	O
activity	O
in	O
the	O
absence	O
of	O
IFN	O
-	O
gamma	O
suppressed	O
the	O
infection	B-DISO
of	O
astrocytes	O
,	O
but	O
not	O
oligodendroglia	O
.	O

The	O
testing	O
of	O
201	O
clinical	O
specimens	O
with	O
this	O
multiplex	O
assay	O
along	O
with	O
other	O
one	O
formerly	O
described	O
by	O
our	O
group	O
to	O
simultaneously	O
detect	O
and	O
type	O
the	O
influenza	B-DISO
viruses	O
,	O
respiratory	O
syncytial	O
viruses	O
,	O
and	O
a	O
generic	O
detection	O
of	O
all	O
serotypes	O
of	O
adenovirus	B-DISO
,	O
covers	O
the	O
detection	O
of	O
most	O
viruses	O
causing	O
respiratory	O
infectious	B-DISO
disease	I-DISO
in	O
humans	O
.	O

ABSTRACT	O
:	O
From	O
geographic	O
mapping	O
at	O
different	O
scales	O
to	O
location	O
-	O
based	O
alerting	O
services	O
,	O
geoinformatics	O
plays	O
an	O
important	O
role	O
in	O
the	O
study	O
and	O
control	O
of	O
global	O
outbreaks	O
like	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

The	O
most	O
common	O
symptoms	O
in	O
this	O
cohort	O
were	O
fever	O
(	O
100	O
%)	O
and	O
cough	B-DISO
(	O
91	O
%).	O

Chest	O
radiograph	O
showed	O
patchy	O
infiltrates	B-DISO
,	O
in	O
15	O
cases	O
the	O
changes	O
were	O
unilateral	O
,	O
and	O
in	O
18	O
were	O
bilateral	O
.	O

CONCLUSIONS	O
:	O
SARS	B-DISO
in	O
children	O
may	O
have	O
its	O
own	O
characteristics	O
.	O

ABSTRACT	O
:	O
Sixty	O
-	O
one	O
SARS	B-DISO
coronavirus	O
genomic	O
sequences	O
derived	O
from	O
the	O
early	O
,	O
middle	O
,	O
and	O
late	O
phases	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
epidemic	O
were	O
analyzed	O
together	O
with	O
two	O
viral	O
sequences	O
from	O
palm	O
civets	O
.	O

Genotypes	O
characteristic	O
of	O
each	O
phase	O
were	O
discovered	O
,	O
and	O
the	O
earliest	O
genotypes	O
were	O
similar	O
to	O
the	O
animal	O
SARS	B-DISO
-	O
like	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
associated	O
with	O
significant	O
morbidity	O
and	O
mortality	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
epidemic	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
caught	O
many	O
by	O
surprise	O
.	O

Hitherto	O
,	O
infection	B-DISO
control	O
has	O
not	O
been	O
in	O
the	O
forefront	O
of	O
radiological	O
practice	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
public	O
health	O
response	O
and	O
clinical	O
practice	O
update	O
for	O
an	O
emerging	O
disease	O
.	O

ABSTRACT	O
:	O
Lower	O
respiratory	B-DISO
infections	I-DISO
threaten	O
the	O
health	O
of	O
children	O
worldwide	O
.	O

Human	O
metapneumovirus	O
is	O
now	O
recognized	O
as	O
a	O
cause	O
of	O
lower	B-DISO
respiratory	I-DISO
infection	I-DISO
disease	O
in	O
children	O
,	O
and	O
coronavirus	O
has	O
been	O
linked	O
to	O
epidemics	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Smallpox	B-DISO
and	O
bioterrorism	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
screening	O
tool	O
that	O
was	O
used	O
to	O
screen	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
the	O
three	O
revisions	O
that	O
were	O
made	O
,	O
and	O
the	O
factors	O
that	O
led	O
to	O
these	O
revisions	O
.	O

Risk	O
categorization	O
ensured	O
that	O
no	O
cross	O
-	O
infection	B-DISO
occurred	O
among	O
patients	O
and	O
that	O
no	O
one	O
contracted	O
SARS	B-DISO
in	O
the	O
ED	O
.	O

ABSTRACT	O
:	O
Theiler	O
'	O
s	O
murine	B-DISO
encephalomyelitis	I-DISO
virus	O
(	O
TMEV	O
)	O
causes	O
demyelination	B-DISO
with	O
inflammation	B-DISO
of	I-DISO
the	I-DISO
central	I-DISO
nervous	I-DISO
system	I-DISO
(	O
CNS	O
)	O
in	O
mice	O
and	O
is	O
used	O
as	O
an	O
animal	O
model	O
for	O
multiple	B-DISO
sclerosis	I-DISO
(	O
MS	O
).	O

This	O
likely	O
reflects	O
a	O
difference	O
in	O
the	O
pathogenesis	B-DISO
of	O
TMEV	O
infection	B-DISO
from	O
that	O
of	O
two	O
other	O
animal	O
models	O
for	O
MS	O
,	O
mouse	B-DISO
hepatitis	I-DISO
virus	B-DISO
infection	I-DISO
and	O
experimental	O
allergic	O
encephalomyelitis	B-DISO
(	O
EAE	O
),	O
where	O
blocking	B-DISO
of	O
IP	O
-	O
10	O
resulted	O
in	O
clinical	O
and	O
histological	O
improvement	O
with	O
suppression	B-DISO
of	O
antigen	O
specific	O
lymphoproliferation	O
.	O

The	O
alveolar	O
spaces	O
are	O
filled	O
with	O
fibrinous	O
exudates	O
and	O
lined	O
with	O
hyaline	B-DISO
membrane	I-DISO
.	O

In	O
5	O
cases	O
that	O
undergo	O
over	O
3	O
weeks	O
of	O
the	O
course	O
,	O
the	O
main	O
pattern	O
is	O
organization	O
of	O
intra	O
-	O
alveolar	O
deposit	O
,	O
along	O
with	O
fibroblastic	O
proliferation	B-DISO
in	O
the	O
alveolar	O
septa	O
,	O
which	O
leads	O
to	O
obliteration	O
of	O
alveolar	O
space	O
and	O
pulmonary	B-DISO
fibrosis	I-DISO
.	O

All	O
of	O
the	O
lungs	O
show	O
bronchopneumonia	B-DISO
,	O
scattered	O
hemorrhage	B-DISO
,	O
and	O
proliferation	B-DISO
of	O
alveolar	O
epithelial	O
cells	O
with	O
desquamation	O
.	O

In	O
immune	O
system	O
,	O
hilar	O
and	O
abdominal	O
lymph	O
nodes	O
are	O
usually	O
congested	O
and	O
hemorrhagic	O
,	O
with	O
depletion	O
of	O
lymphocytes	O
,	O
and	O
accompanied	O
with	O
subcapsular	O
sinus	B-DISO
histiocytosis	I-DISO
.	O

The	O
remaining	O
39	O
%	O
quarantinees	O
who	O
did	O
not	O
have	O
a	O
direct	O
contact	O
history	O
with	O
SARS	B-DISO
patients	O
had	O
not	O
developed	O
SARS	B-DISO
during	O
the	O
period	O
under	O
quarantine	O
.	O

The	O
overall	O
cost	O
for	O
quarantine	O
on	O
SARS	B-DISO
prevention	O
could	O
be	O
reduced	O
by	O
as	O
much	O
as	O
63	O
%	O
if	O
the	O
quarantine	O
program	O
was	O
limited	O
to	O
this	O
group	O
.	O

No	O
evidence	O
was	O
found	O
that	O
SARS	B-DISO
patient	O
was	O
infective	O
during	O
the	O
incubation	O
period	O
.	O

The	O
highest	O
incidence	O
rate	O
of	O
SARS	B-DISO
was	O
in	O
the	O
group	O
of	O
20	O
-	O
29	O
years	O
(	O
30	O
.	O
85	O
per	O
100	O
,	O
000	O
),	O
and	O
the	O
lowest	O
was	O
in	O
the	O
group	O
of	O
0	O
-	O
14	O
years	O
(	O
2	O
.	O
54	O
per	O
100	O
,	O
000	O
).	O

Beijing	O
was	O
the	O
most	O
severe	O
epidemic	O
region	O
of	O
SARS	B-DISO
in	O
the	O
world	O
,	O
but	O
the	O
fatality	O
was	O
the	O
lowest	O
.	O

METHODS	O
:	O
Database	O
of	O
the	O
2	O
521	O
probable	O
cases	O
of	O
SARS	B-DISO
in	O
Beijing	O
Center	O
for	O
Disease	O
Prevention	O
and	O
Control	O
was	O
used	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
caused	O
by	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
has	O
necessitated	O
an	O
in	O
-	O
depth	O
molecular	O
understanding	O
of	O
the	O
virus	O
to	O
identify	O
new	O
drug	O
targets	O
.	O

The	O
diarrhea	B-DISO
was	O
most	O
severe	O
at	O
a	O
mean	O
(+/-	O
SD	O
)	O
of	O
8	O
.	O
8	O
+/-	O
2	O
.	O
4	O
days	O
after	O
onset	O
,	O
with	O
a	O
maximum	O
frequency	O
of	O
24	O
episodes	O
per	O
day	O
(	O
median	O
,	O
5	O
episodes	O
;	O
range	O
,	O
3	O
-	O
24	O
episodes	O
).	O

Both	O
age	O
and	O
existence	O
of	O
other	O
diseases	O
before	O
SARS	B-DISO
were	O
significantly	O
correlated	O
with	O
prognosis	O
(	O
r	O
=	O
0	O
.	O
506	O
and	O
r	O
=	O
0	O
.	O
457	O
,	O
respectively	O
;	O
P	O
<.	O
001	O
).	O

ABSTRACT	O
:	O
We	O
have	O
expressed	O
a	O
series	O
of	O
truncated	O
spike	O
(	O
S	O
)	O
glycoproteins	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
found	O
that	O
the	O
N	O
-	O
terminus	O
14	O
-	O
502	O
residuals	O
were	O
sufficient	O
to	O
bind	O
to	O
SARS	B-DISO
-	O
CoV	O
susceptible	O
Vero	O
E6	O
cells	O
.	O

This	O
cell	O
clone	O
was	O
susceptible	O
to	O
HIV	B-DISO
/	O
SARS	B-DISO
pseudovirus	O
infection	B-DISO
and	O
the	O
presence	O
of	O
a	O
functional	O
receptor	O
for	O
S	O
protein	O
in	O
this	O
cell	O
clone	O
was	O
confirmed	O
by	O
the	O
cell	O
-	O
cell	O
fusion	O
assay	O
.	O

This	O
article	O
provides	O
critical	O
care	O
nurses	O
with	O
an	O
update	O
on	O
the	O
first	O
SARS	B-DISO
outbreak	O
,	O
its	O
origin	O
,	O
case	O
definition	O
,	O
clinical	O
manifestations	O
,	O
diagnosis	O
,	O
relevant	O
infection	B-DISO
control	O
practices	O
,	O
management	O
,	O
and	O
recommendations	O
for	O
the	O
role	O
of	O
ICU	O
nurses	O
in	O
dealing	O
with	O
future	O
outbreaks	O
.	O

Breakout	O
sessions	O
intended	O
to	O
identify	O
unmet	O
research	O
needs	O
in	O
5	O
areas	O
of	O
SARS	B-DISO
research	O
--	O
clinical	O
research	O
,	O
epidemiology	O
,	O
diagnostics	O
,	O
therapeutics	O
,	O
and	O
vaccines	O
--	O
are	O
summarized	O
here	O
.	O

Needs	O
that	O
have	O
yet	O
to	O
be	O
realized	O
include	O
reliable	O
methods	O
for	O
early	O
identification	O
of	O
individuals	O
with	O
SARS	B-DISO
,	O
a	O
full	O
description	O
of	O
SARS	B-DISO
pathogenesis	B-DISO
and	O
immune	O
response	O
,	O
and	O
animal	O
models	O
that	O
faithfully	O
mimic	O
SARS	B-DISO
respiratory	B-DISO
symptoms	I-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
newly	O
recognized	O
infectious	B-DISO
disease	I-DISO
that	O
has	O
recently	O
emerged	O
in	O
East	O
Asia	O
and	O
North	O
America	O
.	O

There	O
was	O
a	O
trend	O
towards	O
protection	O
for	O
HCWs	O
who	O
,	O
while	O
fully	O
protected	O
,	O
had	O
had	O
contact	O
with	O
patients	O
with	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
This	O
report	O
demonstrates	O
that	O
a	O
rapid	O
decrease	O
of	O
peripheral	O
T	O
cell	O
subsets	O
is	O
a	O
unique	O
characteristic	O
in	O
patients	O
with	O
SARS	B-DISO
during	O
acute	B-DISO
infection	I-DISO
,	O
although	O
total	O
white	O
blood	O
cell	O
counts	O
,	O
red	O
blood	O
cell	O
counts	O
,	O
and	O
platelet	O
counts	O
remain	O
relatively	O
normal	O
.	O

No	O
giant	B-DISO
mitochondria	I-DISO
,	O
micro	O
-	O
or	O
macro	O
-	O
vesicular	O
steatosis	B-DISO
was	O
observed	O
.	O

In	O
conclusion	O
,	O
hepatic	B-DISO
impairment	I-DISO
in	O
patients	O
with	O
SARS	B-DISO
is	O
due	O
to	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
infection	B-DISO
of	O
the	O
liver	O
.	O

We	O
determined	O
the	O
relation	O
of	O
endogenous	O
G	O
-	O
CSF	O
to	O
proinflammatory	O
and	O
anti	O
-	O
inflammatory	O
mediators	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
and	O
serum	O
of	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

Furthermore	O
,	O
the	O
assay	O
will	O
add	B-DISO
to	O
the	O
value	O
of	O
those	O
systems	O
in	O
which	O
viral	B-DISO
infections	I-DISO
of	O
the	O
cat	O
serve	O
as	O
models	O
for	O
human	O
disease	O
.	O

TITLE	O
:	O
Molecular	O
cloning	O
,	O
expression	O
,	O
purification	O
,	O
and	O
mass	O
spectrometric	O
characterization	O
of	O
3C	O
-	O
like	O
protease	O
of	O
SARS	B-DISO
coronavirus	O
.	O

TITLE	O
:	O
How	O
did	O
general	O
practitioners	O
protect	O
themselves	O
,	O
their	O
family	O
,	O
and	O
staff	O
during	O
the	O
SARS	B-DISO
epidemic	O
in	O
Hong	O
Kong	O
?	O

Exposure	O
to	O
SARS	B-DISO
,	O
the	O
infection	B-DISO
rates	O
in	O
their	O
working	O
district	O
,	O
and	O
anxiety	O
levels	O
had	O
significant	O
impact	O
on	O
the	O
level	O
of	O
protection	O
or	O
prescribing	O
behaviour	O
.	O

The	O
study	O
estimates	O
the	O
initial	O
attack	O
size	O
that	O
would	O
result	O
in	O
failed	O
invasion	B-DISO
.	O

Initial	O
attack	O
size	O
is	O
one	O
of	O
the	O
determinants	O
of	O
whether	O
SARS	B-DISO
can	O
successfully	O
invade	O
the	O
community	O
or	O
not	O
.	O

METHODS	O
:	O
Mathematical	O
modelling	O
is	O
used	O
for	O
predicting	O
the	O
epidemiological	O
outcome	O
and	O
simultaneously	O
for	O
evaluating	O
the	O
effect	O
of	O
interventions	O
on	O
SARS	B-DISO
.	O

TITLE	O
:	O
Secondary	O
structure	O
and	O
function	O
of	O
the	O
5	O
'-	O
proximal	O
region	O
of	O
the	O
equine	O
arteritis	B-DISO
virus	O
RNA	O
genome	O
.	O

After	O
purification	O
,	O
the	O
recombinant	O
protein	O
was	O
identified	O
by	O
anti	O
-	O
SARS	B-DISO
positive	O
sera	O
from	O
recovered	O
SARS	B-DISO
patients	O
.	O

The	O
sera	O
from	O
health	O
donors	O
,	O
which	O
were	O
collected	O
before	O
the	O
out	O
-	O
break	O
of	O
SARS	B-DISO
,	O
were	O
used	O
as	O
negative	O
control	O
in	O
the	O
study	O
.	O

Since	O
replication	O
of	O
HcoVs	O
depends	O
on	O
extensive	O
proteolytic	O
processing	O
,	O
the	O
main	O
proteinase	O
,	O
3CLpro	O
,	O
is	O
an	O
attractive	O
drug	O
target	O
for	O
anti	O
-	O
SARS	B-DISO
agents	O
.	O

Unlike	O
unresolving	O
MHV	O
-	O
JHM	O
infections	B-DISO
,	O
the	O
clearance	O
of	O
WTR13	O
and	O
S4R22	O
infections	B-DISO
coincided	O
with	O
strong	O
IFN	O
-	O
gamma	O
transcription	O
and	O
an	O
increase	O
in	O
the	O
number	O
of	O
CD8	O
T	O
cells	O
infiltrating	B-DISO
into	O
the	O
CNS	O
.	O

TITLE	O
:	O
Differential	O
regulation	O
of	O
innate	O
and	O
adaptive	O
immune	O
responses	O
in	O
viral	B-DISO
encephalitis	I-DISO
.	O

ABSTRACT	O
:	O
Viral	B-DISO
encephalitis	I-DISO
is	O
a	O
global	O
health	O
concern	O
.	O

Distinct	O
glial	O
cell	O
cytokine	O
and	O
chemokine	O
response	O
patterns	O
were	O
observed	O
within	O
3	O
days	O
after	O
infection	B-DISO
,	O
became	O
progressively	O
more	O
polarized	O
during	O
the	O
course	O
of	O
infection	B-DISO
and	O
with	O
the	O
infiltration	B-DISO
of	O
leukocytes	O
.	O

This	O
trend	O
was	O
reversed	O
in	O
MHV	O
-	O
A59	O
infection	B-DISO
and	O
was	O
accompanied	O
by	O
increased	O
CD8	O
T	O
cell	O
infiltration	B-DISO
into	O
brain	O
compared	O
to	O
MHV	O
-	O
JHM	O
infection	B-DISO
.	O

MHV	O
-	O
JHM	O
infection	B-DISO
also	O
induced	O
sustained	O
mRNA	O
accumulation	O
of	O
the	O
innate	B-DISO
immune	I-DISO
response	I-DISO
products	O
interleukin	O
(	O
IL	O
)-	O
6	O
and	O
IL	O
-	O
1	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
clinical	O
and	O
demographic	O
aspects	O
as	O
well	O
as	O
the	O
outcomes	O
of	O
severe	O
cases	O
of	O
malaria	B-DISO
infections	B-DISO
managed	O
in	O
the	O
intensive	O
care	O
unit	O
of	O
the	O
Sarawak	O
General	O
Hospital	O
,	O
Kuching	O
from	O
January	O
1996	O
to	O
December	O
2001	O
.	O

Fever	O
with	O
or	O
without	O
chills	B-DISO
and	O
rigors	B-DISO
,	O
headache	B-DISO
,	O
abdominal	B-DISO
pain	I-DISO
and	O
vomiting	B-DISO
were	O
the	O
four	O
commonest	O
presenting	O
complaints	O
for	O
P	O
.	O
falciparum	O
infections	B-DISO
.	O

Patients	O
with	O
both	O
abdominal	B-DISO
pain	I-DISO
and	O
hepatomegaly	B-DISO
have	O
significantly	O
higher	O
mortality	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
31	O
cases	O
of	O
malaria	B-DISO
were	O
managed	O
in	O
the	O
intensive	O
care	O
unit	O
of	O
the	O
Sarawak	O
General	O
Hospital	O
in	O
the	O
six	O
-	O
year	O
period	O
.	O

TITLE	O
:	O
[	O
Clinical	O
study	O
on	O
treatment	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
with	O
integrative	O
Chinese	O
and	O
Western	O
medicine	O
approach	O
].	O

ABSTRACT	O
:	O
To	O
summarize	O
the	O
clinical	O
characteristics	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
observe	O
the	O
therapeutic	O
effect	O
with	O
integrative	O
Chinese	O
and	O
western	O
medicine	O
(	O
ICWM	O
)	O
approach	O
in	O
treating	O
patients	O
with	O
SARS	B-DISO
.	O

CONCLUSIONS	O
:	O
Patients	O
of	O
SARS	B-DISO
are	O
mainly	O
youth	O
and	O
adults	O
in	O
the	O
prime	O
of	O
life	O
,	O
fever	O
always	O
appears	O
as	O
the	O
initiation	O
of	O
illness	O
and	O
some	O
accompanying	O
symptoms	O
would	O
appear	O
.	O

In	O
agreement	O
with	O
our	O
previous	O
results	O
,	O
the	O
number	O
of	O
different	O
clonotypes	O
responding	O
to	O
all	O
three	O
epitopes	O
fit	B-DISO
a	O
log	O
-	O
series	O
distribution	O
.	O

This	O
may	O
also	O
be	O
the	O
immunopathologic	O
basis	O
of	O
other	O
life	O
-	O
threatening	O
human	O
virus	O
infections	B-DISO
.	O

Current	O
information	O
indicates	O
that	O
most	O
transmission	O
is	O
via	O
respiratory	O
droplets	O
coming	O
from	O
a	O
person	O
who	O
is	O
symptomatic	O
with	O
SARS	B-DISO
"("""	O
close	O
contact	O
""")."	O

The	O
aim	O
of	O
our	O
study	O
is	O
to	O
evidence	O
the	O
critical	O
role	O
of	O
the	O
family	O
physician	O
,	O
the	O
first	O
health	O
-	O
care	O
worker	O
who	O
cares	O
with	O
suspected	O
/	O
probable	O
SARS	B-DISO
patients	O
,	O
underlying	O
the	O
importance	O
of	O
the	O
correct	O
use	O
and	O
management	O
of	O
the	O
personal	O
protective	O
equipment	O
.	O

TITLE	O
:	O
Pegylated	O
interferon	O
-	O
alpha	O
protects	O
type	O
1	O
pneumocytes	O
against	O
SARS	B-DISO
coronavirus	B-DISO
infection	I-DISO
in	O
macaques	O
.	O

The	O
process	O
of	O
bereavement	O
was	O
disturbed	O
,	O
as	O
traditional	O
death	O
rituals	B-DISO
could	O
not	O
be	O
performed	O
by	O
the	O
family	O
.	O

Absolute	O
contraindications	O
to	O
NPPV	O
are	O
:	O
cardiac	O
or	O
respiratory	B-DISO
arrest	I-DISO
;	O
nonrespiratory	O
organ	B-DISO
failure	I-DISO
(	O
eg	O
,	O
severe	O
encephalopathy	B-DISO
,	O
severe	O
gastrointestinal	B-DISO
bleeding	I-DISO
,	O
hemodynamic	B-DISO
instability	I-DISO
with	O
or	O
without	O
unstable	O
cardiac	B-DISO
angina	I-DISO
);	O
facial	O
surgery	O
or	O
trauma	O
;	O
upper	O
-	O
airway	B-DISO
obstruction	I-DISO
;	O
inability	O
to	O
protect	O
the	O
airway	O
and	O
/	O
or	O
high	O
risk	O
of	O
aspiration	B-DISO
;	O
and	O
inability	O
to	O
clear	O
secretions	O
.	O

With	O
patients	O
suffering	B-DISO
hypercapnic	B-DISO
respiratory	I-DISO
failure	I-DISO
the	O
best	O
NPPV	O
success	O
/	O
failure	O
predictor	O
is	O
the	O
degree	O
of	O
acidosis	B-DISO
/	O
acidemia	B-DISO
(	O
pH	O
and	O
P	O
(	O
aCO	O
(	O
2	O
))	O
at	O
admission	O
and	O
after	O
1	O
hour	O
on	O
NPPV	O
),	O
whereas	O
mental	O
status	O
and	O
severity	O
of	O
illness	O
are	O
less	O
reliable	O
predictors	O
.	O

With	O
patients	O
suffering	B-DISO
hypoxic	B-DISO
respiratory	B-DISO
failure	I-DISO
the	O
likelihood	O
of	O
NPPV	O
success	O
seems	O
to	O
be	O
related	O
to	O
the	O
underlying	O
disease	O
rather	O
than	O
to	O
the	O
degree	O
of	O
hypoxia	B-DISO
.	O

TITLE	O
:	O
Geldanamycin	O
,	O
a	O
ligand	O
of	O
heat	O
shock	O
protein	O
90	O
,	O
inhibits	O
the	O
replication	O
of	O
herpes	B-DISO
simplex	I-DISO
virus	O
type	O
1	O
in	O
vitro	O
.	O

In	O
screening	O
for	O
anti	O
-	O
herpes	B-DISO
simplex	I-DISO
virus	O
type	O
1	O
(	O
HSV	O
-	O
1	O
)	O
candidates	O
,	O
we	O
found	O
GA	O
active	O
against	O
HSV	O
-	O
1	O
.	O

The	O
first	O
stage	O
caused	O
limited	O
familial	O
or	O
hospital	B-DISO
infections	I-DISO
and	O
lasted	O
from	O
early	O
March	O
to	O
mid	O
-	O
April	O
.	O

To	O
investigate	O
the	O
origin	O
and	O
transmission	O
route	O
of	O
SARS	B-DISO
-	O
CoV	O
in	O
Taiwan	O
'	O
s	O
epidemic	O
,	O
we	O
conducted	O
a	O
systematic	O
viral	O
lineage	O
study	O
by	O
sequencing	O
the	O
entire	O
viral	O
genome	O
from	O
ten	O
SARS	B-DISO
patients	O
.	O

One	O
person	O
reported	O
as	O
a	O
probable	O
SARS	B-DISO
case	O
acknowledged	O
being	O
symptomatic	O
on	O
arrival	O
,	O
but	O
had	O
been	O
missed	O
by	O
border	O
screening	O
.	O

A	O
reduction	O
in	O
steroid	O
usage	O
and	O
nosocomial	B-DISO
infections	I-DISO
was	O
seen	O
in	O
patients	O
initially	O
treated	O
with	O
lopinavir	O
/	O
ritonavir	O
,	O
and	O
these	O
patients	O
had	O
a	O
decreasing	O
viral	O
load	O
and	O
rising	O
peripheral	O
lymphocyte	O
count	O
.	O

The	O
apparent	O
favourable	O
clinical	O
response	O
with	O
lopinavir	O
/	O
ritonavir	O
and	O
ribavirin	O
supports	O
further	O
randomised	O
placebo	O
controlled	O
trials	O
in	O
patients	O
with	O
SARS	B-DISO
.	O

Flow	O
cytometry	O
was	O
applied	O
to	O
study	O
the	O
dynamic	O
alteration	O
of	O
the	O
number	O
and	O
frequencies	O
in	O
circulating	O
DC	O
cell	O
subsets	O
in	O
30	O
SARS	B-DISO
patients	O
including	O
critical	O
SARS	B-DISO
(	O
n	O
=	O
11	O
)	O
and	O
general	O
SARS	B-DISO
(	O
n	O
=	O
19	O
).	O

The	O
frequency	O
of	O
peripheral	O
DC	O
cell	O
subsets	O
significantly	O
dropped	O
beginning	O
from	O
the	O
onset	O
of	O
symptom	B-DISO
in	O
SARS	B-DISO
patients	O
and	O
was	O
maintained	O
at	O
significant	O
low	O
levels	O
during	O
the	O
following	O
4	O
-	O
5	O
weeks	O
,	O
1	O
.	O
7	O
+/-	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
newly	O
described	O
form	O
of	O
atypical	B-DISO
pneumonia	I-DISO
linked	O
to	O
a	O
novel	O
coronavirus	O
.	O

To	O
review	O
the	O
sputum	O
cytology	O
of	O
15	O
patients	O
who	O
fulfilled	O
the	O
World	O
Health	O
Organisation	O
clinical	O
criteria	O
for	O
SARS	B-DISO
in	O
an	O
attempt	O
to	O
evaluate	O
whether	O
early	O
diagnosis	O
is	O
feasible	O
with	O
routine	O
sputum	O
examination	O
.	O

The	O
cytological	O
features	O
of	O
SARS	B-DISO
are	O
non	O
-	O
specific	O
,	O
but	O
the	O
observation	O
of	O
any	O
of	O
the	O
described	O
features	O
should	O
prompt	O
further	O
investigations	O
,	O
especially	O
in	O
patients	O
with	O
suspicious	O
clinical	O
features	O
.	O

Fibrogranulation	O
tissue	O
proliferation	B-DISO
in	O
small	O
airways	O
and	O
airspaces	O
(	O
bronchiolitis	B-DISO
obliterans	I-DISO
organising	I-DISO
pneumonia	I-DISO
-	O
like	O
lesions	O
)	O
in	O
subpleural	O
locations	O
was	O
also	O
seen	O
in	O
some	O
patients	O
.	O

Furthermore	O
,	O
engineered	O
CEACAMs	O
appended	O
to	O
glycosylphosphatidylinositol	O
anchors	O
partitioned	O
with	O
TX	O
-	O
100	O
-	O
resistant	O
lipid	O
rafts	O
,	O
but	O
cells	O
bearing	O
these	O
raft	O
-	O
associated	O
CEACAMs	O
were	O
not	O
hypersensitive	O
to	O
MHV	O
infection	B-DISO
.	O

Predominant	O
findings	O
at	O
presentation	O
are	O
ground	O
-	O
glass	O
opacities	B-DISO
and	O
consolidation	O
.	O

ABSTRACT	O
:	O
Fifteen	O
isolates	O
of	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
were	O
obtained	O
from	O
the	O
kidney	O
,	O
trachea	B-DISO
,	O
and	O
cecal	O
tonsil	O
of	O
IB	O
suspected	O
chickens	O
between	O
2001	O
and	O
2002	O
years	O
in	O
Korea	O
.	O

Other	O
agents	O
,	O
including	O
the	O
HIV	B-DISO
protease	O
inhibitor	O
glycyrrhizin	O
and	O
convalescent	O
plasma	O
,	O
remain	O
to	O
be	O
evaluated	O
.	O

ABSTRACT	O
:	O
To	O
report	O
on	O
the	O
impact	O
of	O
a	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
on	O
the	O
attendances	O
of	O
a	O
major	O
teaching	O
hospital	O
ED	O
.	O

A	O
decreased	B-DISO
lymphocyte	I-DISO
count	O
was	O
also	O
seen	O
in	O
23	O
(	O
37	O
.	O
7	O
%)	O
cases	O
of	O
the	O
61	O
patients	O
tested	O
on	O
admission	O
,	O
and	O
by	O
day	O
14	O
,	O
the	O
number	O
of	O
patients	O
with	O
decreased	B-DISO
lymphocyte	I-DISO
count	O
(	O
1	O
.	O
11	O
+/-	O

CONCLUSIONS	O
:	O
The	O
human	O
metapneumovirus	O
is	O
responsible	O
for	O
typical	O
acute	B-DISO
bronchiolitis	I-DISO
in	O
children	O
.	O

Logistic	O
regression	O
analysis	O
identified	O
4	O
factors	O
as	O
being	O
significantly	O
associated	O
with	O
increased	O
levels	O
of	O
concern	O
for	O
personal	O
or	O
family	O
health	O
:	O
perception	O
of	O
a	O
greater	O
risk	O
of	O
death	O
from	O
SARS	B-DISO
(	O
adjusted	O
odds	O
ratio	O
[	O
OR	O
]	O
5	O
.	O
0	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
2	O
.	O
6	O
-	O
9	O
.	O
6	O
),	O
living	O
with	O
children	O
(	O
adjusted	O
OR	O
1	O
.	O
8	O
,	O
95	O
%	O
CI	O
1	O
.	O
5	O
-	O
2	O
.	O
3	O
),	O
personal	O
or	O
family	O
lifestyle	O
affected	O
by	O
SARS	B-DISO
outbreak	O
(	O
adjusted	O
OR	O
3	O
.	O
3	O
,	O
95	O
%	O
CI	O
2	O
.	O
5	O
-	O
4	O
.	O
3	O
)	O
and	O
being	O
treated	O
differently	O
by	O
people	O
because	O
of	O
working	O
in	O
a	O
hospital	O
(	O
adjusted	O
OR	O
1	O
.	O
6	O
,	O
95	O
%	O
CI	O
1	O
.	O
2	O
-	O
2	O
.	O
1	O
).	O

We	O
report	O
two	O
patients	O
with	O
an	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
arising	O
during	O
the	O
course	O
of	O
pustular	B-DISO
psoriasis	I-DISO
.	O

Besides	O
infectious	B-DISO
causes	O
and	O
drug	B-DISO
hypersensitivity	I-DISO
to	O
methotrexate	O
or	O
acitretin	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
sometimes	O
due	O
to	O
a	O
pulmonary	B-DISO
capillary	I-DISO
leak	I-DISO
syndrome	I-DISO
,	O
is	O
a	O
rare	O
cause	O
of	O
pneumonitis	B-DISO
in	O
the	O
course	O
of	O
psoriasis	B-DISO
,	O
and	O
may	O
be	O
fatal	O
.	O

Its	O
pathogenesis	B-DISO
is	O
unknown	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
novel	O
epidemic	B-DISO
disease	I-DISO
.	O

The	O
present	O
study	O
reports	O
a	O
case	O
of	O
SARS	B-DISO
,	O
which	O
presented	O
as	O
acute	B-DISO
abdomen	I-DISO
,	O
warranting	O
laparotomy	O
.	O

TITLE	O
:	O
Structural	O
characterization	O
of	O
the	O
SARS	B-DISO
-	O
coronavirus	O
spike	O
S	O
fusion	O
protein	O
core	O
.	O

Here	O
we	O
describe	O
the	O
biophysical	O
analysis	O
of	O
the	O
two	O
predicted	O
heptad	O
repeat	O
regions	O
within	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
S	O
protein	O
.	O

ABSTRACT	O
:	O
In	O
some	O
nation	O
states	O
,	O
sustained	O
integrated	O
global	O
epidemiological	O
surveillance	O
has	O
been	O
weakened	O
as	O
a	O
result	O
of	O
political	O
unrest	B-DISO
,	O
disinterest	O
,	O
and	O
a	O
poorly	O
developed	O
infrastructure	O
due	O
to	O
rapidly	O
increasing	O
global	O
inequality	O
.	O

Our	O
objective	O
was	O
to	O
assess	O
exposure	O
to	O
morphine	O
as	O
an	O
etiologic	O
factor	O
for	O
acute	B-DISO
chest	I-DISO
syndrome	I-DISO
in	I-DISO
sickle	I-DISO
cell	I-DISO
disease	I-DISO
.	O

h	O
(-	O
1	O
)	O
by	O
use	O
of	O
a	O
double	O
-	O
blind	B-DISO
,	O
placebo	O
-	O
controlled	O
design	O
.	O

New	O
onset	O
of	O
acute	B-DISO
chest	I-DISO
syndrome	I-DISO
was	O
3	O
-	O
fold	O
more	O
prevalent	O
in	O
the	O
oral	O
group	O
(	O
57	O
%)	O
versus	O
the	O
continuous	O
intravenous	O
infusion	O
group	O
(	O
17	O
%)	O
(	O
P	O
<.	O
001	O
).	O

TITLE	O
:	O
[	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)--	O
present	O
status	O
].	O

TITLE	O
:	O
Infection	B-DISO
control	O
for	O
SARS	B-DISO
in	O
a	O
tertiary	O
paediatric	O
centre	O
in	O
Hong	O
Kong	O
.	O

TITLE	O
:	O
Hypoxia	B-DISO
from	O
vasculitic	O
pulmonary	B-DISO
haemorrhage	I-DISO
improved	O
by	O
prone	O
position	O
ventilation	O
.	O

ABSTRACT	O
:	O
We	O
verified	O
the	O
analytical	O
performance	O
characteristics	O
of	O
a	O
previously	O
described	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
targeting	O
the	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
1b	O
region	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
with	O
RNA	O
transcripts	O
.	O

TITLE	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
coronavirus	O
replicative	O
protein	O
nsp9	O
is	O
a	O
single	O
-	O
stranded	O
RNA	O
-	O
binding	O
subunit	O
unique	O
in	O
the	O
RNA	O
virus	O
world	O
.	O

ABSTRACT	O
:	O
Risk	O
factors	O
for	O
acute	O
wheezing	B-DISO
among	O
children	O
in	O
subtropical	O
areas	O
are	O
largely	O
unknown	O
.	O

Some	O
risk	O
factors	O
for	O
wheezing	B-DISO
previously	O
identified	O
in	O
temperate	O
climates	O
were	O
present	O
in	O
a	O
subtropical	O
area	O
,	O
including	O
respiratory	B-DISO
syncytial	I-DISO
virus	I-DISO
infection	I-DISO
in	O
infants	O
and	O
allergy	B-DISO
in	O
children	O
older	O
than	O
2	O
years	O
.	O

Patients	O
with	O
varicella	B-DISO
infection	I-DISO
requiring	O
intensive	O
care	O
carry	O
significant	O
mortality	O
.	O

Major	O
emergency	B-DISO
procedures	O
,	O
cancer	B-DISO
resections	O
and	O
complex	O
major	O
procedures	O
were	O
unaffected	O
.	O

RESULTS	O
:	O
The	O
SARS	B-DISO
epidemic	O
resulted	O
in	O
reductions	O
of	O
52	O
%	O
for	O
new	O
outpatient	O
attendances	O
,	O
59	O
%	O
for	O
review	O
attendances	O
,	O
51	O
%	O
for	O
admissions	O
,	O
32	O
%	O
for	O
surgical	O
procedures	O
and	O
48	O
%	O
for	O
colonoscopies	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
new	O
disease	O
which	O
has	O
spread	O
rapidly	O
and	O
widely	O
.	O

We	O
wished	O
to	O
know	O
whether	O
evaluation	O
of	O
in	O
vitro	O
cytokine	O
production	O
could	O
contribute	O
to	O
improved	O
understanding	O
of	O
disease	O
pathogenesis	B-DISO
and	O
to	O
better	O
patient	O
management	O
.	O

TITLE	O
:	O
Epidemiological	O
characteristics	O
of	O
an	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
Dongcheng	O
District	O
of	O
Beijing	O
from	O
March	O
to	O
May	O
2003	O
.	O

People	O
are	O
all	O
susceptible	O
to	O
infection	B-DISO
of	O
SARS	B-DISO
Co	O
-	O
V	O
,	O
which	O
mainly	O
threatens	O
the	O
young	O
adults	O
and	O
the	O
middle	O
-	O
aged	O
,	O
as	O
well	O
as	O
HCWs	O
and	O
the	O
retired	O
workers	O
.	O

Current	O
available	O
measures	O
to	O
prevent	O
and	O
control	O
SARS	B-DISO
are	O
proved	O
to	O
be	O
effective	O
.	O

And	O
7	O
.	O
4	O
%	O
(	O
attack	O
rate	O
)	O
of	O
those	O
exposed	O
to	O
SARS	B-DISO
cases	O
suffered	B-DISO
from	O
the	O
illness	O
during	O
the	O
periods	O
of	O
quarantine	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
has	O
impacted	B-DISO
heavily	O
on	O
both	O
Canada	O
'	O
s	O
society	O
and	O
its	O
health	O
care	O
system	O
.	O

Evidence	O
for	O
the	O
paper	O
comes	O
from	O
public	O
health	O
records	O
,	O
governmental	O
and	O
non	O
-	O
governmental	O
health	O
statements	O
and	O
the	O
initial	O
epidemiological	O
research	O
on	O
SARS	B-DISO
.	O

The	O
experiences	O
in	O
Toronto	O
may	O
offer	O
insights	O
to	O
other	O
cities	O
and	O
countries	O
that	O
currently	O
lack	O
such	O
strategies	O
and	O
hence	O
may	O
be	O
vulnerable	O
to	O
similar	O
outbreaks	O
of	O
dangerous	O
infectious	B-DISO
diseases	I-DISO
.	O

TITLE	O
:	O
Recombinant	O
protein	O
-	O
based	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
immunochromatographic	O
tests	O
for	O
detection	O
of	O
immunoglobulin	O
G	O
antibodies	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
in	O
SARS	B-DISO
patients	O
.	O

ABSTRACT	O
:	O
An	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
a	O
rapid	O
immunochromatographic	O
test	O
for	O
detection	O
of	O
immunoglobulin	O
G	O
(	O
IgG	O
)	O
antibodies	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
were	O
developed	O
by	O
utilizing	O
the	O
well	O
-	O
characterized	O
recombinant	O
proteins	O
Gst	O
-	O
N	O
and	O
Gst	O
-	O
U274	O
.	O

TITLE	O
:	O
Effects	O
of	O
infection	B-DISO
with	O
transmissible	O
gastroenteritis	B-DISO
virus	O
on	O
concomitant	O
immune	O
responses	O
to	O
dietary	O
and	O
injected	O
antigens	O
.	O

However	O
,	O
TGEV	O
infection	B-DISO
did	O
enhance	O
the	O
primary	O
immunoglobulin	O
M	O
(	O
IgM	O
)	O
and	O
IgG1	O
,	O
but	O
not	O
IgG2	O
,	O
antibody	O
responses	O
to	O
injected	O
soy	O
in	O
comparison	O
to	O
those	O
of	O
uninfected	O
animals	O
.	O

TITLE	O
:	O
Profiles	O
of	O
antibody	O
responses	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
recombinant	O
proteins	O
and	O
their	O
potential	O
use	O
as	O
diagnostic	O
markers	O
.	O

ABSTRACT	O
:	O
A	O
new	O
coronavirus	O
(	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
[	O
SARS	B-DISO
-	O
CoV	O
])	O
has	O
been	O
identified	O
to	O
be	O
the	O
etiological	O
agent	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

A	O
total	O
of	O
81	O
sera	O
,	O
including	O
67	O
from	O
convalescent	O
patients	O
and	O
seven	O
pairs	O
from	O
two	O
time	O
points	O
of	O
infection	B-DISO
,	O
were	O
analyzed	O
,	O
and	O
all	O
showed	O
immunoreactivity	O
towards	O
the	O
nucleocapsid	O
protein	O
(	O
N	O
).	O

TITLE	O
:	O
Development	O
of	O
a	O
Western	O
blot	O
assay	O
for	O
detection	O
of	O
antibodies	O
against	O
coronavirus	O
causing	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

RESULTS	O
:	O
ICWM	O
showed	O
better	O
effect	O
than	O
that	O
of	O
western	O
medicine	O
alone	O
in	O
improving	O
clinical	O
symptoms	O
,	O
promoting	O
the	O
absorption	O
of	O
inflammation	B-DISO
in	O
lung	O
,	O
increased	O
oxygen	O
saturation	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
decreased	O
the	O
dosage	O
of	O
corticoid	O
used	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Many	O
questions	O
remain	O
unanswered	O
,	O
including	O
the	O
origin	O
and	O
pathogenesis	B-DISO
of	O
the	O
novel	O
coronavirus	O
,	O
the	O
natural	O
history	O
and	O
the	O
best	O
specific	O
treatment	O
of	O
the	O
disease	O
.	O

It	O
is	O
probable	O
that	O
SARS	B-DISO
-	O
CoV	O
was	O
an	O
animal	O
virus	O
that	O
adapted	O
to	O
human	O
-	O
human	O
transmission	O
in	O
the	O
recent	O
past	O
.	O

Within	O
the	O
first	O
10	O
days	O
the	O
histological	O
picture	O
is	O
that	O
of	O
acute	O
phase	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
(	O
DAD	O
)	O
with	O
a	O
mixture	O
of	O
inflammatory	O
infiltrate	B-DISO
,	O
oedema	B-DISO
and	O
hyaline	B-DISO
membrane	I-DISO
formation	O
.	O

The	O
utility	O
of	O
high	O
resolution	O
computed	O
tomography	O
(	O
HRCT	O
)	O
and	O
CT	O
scans	O
lies	O
in	O
the	O
confirmation	O
of	O
airspace	O
opacities	B-DISO
in	O
cases	O
with	O
normal	O
initial	O
chest	O
radiographs	O
that	O
have	O
strong	O
contact	O
history	O
and	O
signs	B-DISO
and	I-DISO
symptoms	I-DISO
highly	O
suspicious	O
of	O
SARS	B-DISO
during	O
the	O
outbreak	O
,	O
allowing	O
early	O
treatment	O
and	O
prompt	O
isolation	O
.	O

Common	O
laboratory	O
features	O
include	O
lymphopenia	B-DISO
with	O
depletion	O
of	O
CD4	O
and	O
CD8	O
lymphocytes	O
,	O
thrombocytopenia	O
,	O
prolonged	O
activated	O
partial	O
thromboplastin	O
time	O
,	O
elevated	O
D	O
-	O
Dimer	O
,	O
elevated	O
alanine	O
transminases	O
,	O
lactate	O
dehydrogenase	O
and	O
creatinine	O
kinase	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
associated	O
with	O
considerable	O
morbidity	O
and	O
mortality	O
in	O
the	O
acute	O
phase	O
.	O

As	O
SARS	B-DISO
might	O
re	O
-	O
emerge	O
,	O
all	O
hospitals	O
should	O
take	O
advantage	O
of	O
the	O
current	O
SARS	B-DISO
-	O
free	O
interval	O
to	O
review	O
their	O
infection	B-DISO
control	O
programmes	O
,	O
alert	O
mechanisms	O
,	O
response	O
capability	O
and	O
to	O
repair	O
any	O
identified	O
inadequacies	O
.	O

ABSTRACT	O
:	O
As	O
there	O
are	O
no	O
validated	O
and	O
rapid	O
diagnostic	O
tests	O
nor	O
specific	O
treatment	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
at	O
the	O
initial	O
stage	O
of	O
the	O
outbreak	O
,	O
public	O
health	O
measures	O
are	O
vital	O
for	O
the	O
control	O
of	O
the	O
disease	O
.	O

ABSTRACT	O
:	O
Feline	O
coronaviruses	O
(	O
FCoV	O
)	O
vary	O
widely	O
in	O
virulence	O
causing	O
a	O
spectrum	O
of	O
clinical	O
manifestations	O
reaching	O
from	O
subclinical	O
course	O
to	O
fatal	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
).	O

Collectively	O
,	O
these	O
results	O
may	O
aid	O
us	O
in	O
elucidating	O
the	O
mechanism	O
pertaining	O
to	O
formation	O
of	O
viral	O
nucleocapsid	O
core	O
,	O
and	O
designing	O
molecular	O
approaches	O
to	O
intervene	O
SARS	B-DISO
-	O
CoV	O
replication	O
.	O

The	O
clinical	O
presentation	O
of	O
pneumonia	B-DISO
in	O
the	O
very	O
elderly	O
can	O
be	O
nonspecific	O
.	O

The	O
transmission	O
of	O
SARS	B-DISO
-	O
CoV	O
between	O
human	O
beings	O
is	O
mainly	O
due	O
to	O
close	O
contact	O
.	O

The	O
common	O
laboratory	O
findings	O
include	O
lymphopenia	B-DISO
,	O
thrombocytopenia	O
,	O
elevated	O
serum	O
alanine	O
and	O
aspartate	O
aminotransferase	O
,	O
lactate	O
dehydrogenase	O
,	O
creatine	O
phosphokinase	O
,	O
and	O
C	O
-	O
reactive	O
protein	O
.	O

TITLE	O
:	O
Pro	O
/	O
con	O
clinical	O
debate	O
:	O
steroids	O
are	O
a	O
key	O
component	O
in	O
the	O
treatment	O
of	O
SARS	B-DISO
.	O

A	O
large	O
percentage	O
of	O
patients	O
(	O
many	O
being	O
health	O
care	O
workers	O
themselves	O
)	O
became	O
critically	B-DISO
ill	I-DISO
.	O

Thoracic	B-DISO
computed	O
tomography	O
(	O
CT	O
)	O
is	O
more	O
sensitive	O
in	O
depicting	O
SARS	B-DISO
than	O
is	O
conventional	O
chest	O
radiography	O
,	O
and	O
CT	O
images	O
obtained	O
in	O
patients	O
with	O
normal	O
chest	O
radiographs	O
may	O
show	O
extensive	B-DISO
disease	I-DISO
and	O
airspace	O
consolidation	O
.	O

To	O
aid	O
in	O
the	O
differential	O
diagnosis	O
and	O
management	O
of	O
SARS	B-DISO
,	O
radiologists	O
must	O
be	O
familiar	O
with	O
the	O
typical	O
clinical	O
and	O
histopathologic	O
findings	O
,	O
as	O
well	O
as	O
the	O
radiologic	O
features	O
of	O
the	O
disease	O
.	O

Based	O
on	O
6	O
strains	O
with	O
accurate	O
date	O
of	O
host	O
death	O
,	O
we	O
estimated	O
a	O
time	O
of	O
the	O
last	O
common	O
ancestor	O
,	O
which	O
is	O
coincident	O
with	O
epidemic	O
investigations	O
,	O
and	O
an	O
evolution	O
rate	O
in	O
the	O
same	O
range	O
as	O
that	O
reported	O
for	O
the	O
HIV	B-DISO
-	O
1	O
virus	O
.	O

We	O
investigated	O
changes	O
in	O
plasma	O
T	O
helper	O
(	O
Th	O
)	O
cell	O
cytokines	O
,	O
inflammatory	O
cytokines	O
and	O
chemokines	O
in	O
20	O
patients	O
diagnosed	O
with	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
An	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
humans	O
,	O
associated	O
with	O
a	O
new	O
coronavirus	O
,	O
was	O
reported	O
in	O
Southeast	O
Asia	O
,	O
Europe	O
,	O
and	O
North	O
America	O
in	O
early	O
2003	O
.	O

Successes	O
and	O
limitations	O
of	O
this	O
emergency	B-DISO
surveillance	O
can	O
guide	O
preparations	O
for	O
future	O
outbreaks	O
of	O
SARS	B-DISO
or	O
respiratory	B-DISO
diseases	I-DISO
of	O
unknown	O
etiology	O
.	O

TITLE	O
:	O
Introduction	O
of	O
SARS	B-DISO
in	O
France	O
,	O
March	O
-	O
April	O
,	O
2003	O
.	O

Among	O
31	O
case	O
-	O
patients	O
for	O
whom	O
convalescent	O
-	O
phase	O
(>	O
21	O
days	O
)	O
sera	O
were	O
available	O
,	O
26	O
%	O
had	O
immunoglobulin	O
G	O
to	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
.	O

Our	O
finding	O
that	O
clinical	O
SARS	B-DISO
was	O
associated	O
with	O
visits	O
to	O
fever	O
clinics	O
supports	O
Beijing	O
'	O
s	O
strategy	O
of	O
closing	O
clinics	O
with	O
poor	O
infection	B-DISO
-	O
control	O
measures	O
.	O

ABSTRACT	O
:	O
In	O
early	O
April	O
2003	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
was	O
diagnosed	O
in	O
a	O
Pennsylvania	O
resident	O
after	O
his	O
exposure	O
to	O
persons	O
with	O
SARS	B-DISO
in	O
Toronto	O
,	O
Canada	O
.	O

Laboratory	O
evaluation	O
of	O
clinical	O
specimens	O
showed	O
no	O
evidence	O
of	O
transmission	O
of	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
)	O
infection	B-DISO
to	O
any	O
close	O
contact	O
of	O
this	O
patient	O
.	O

ABSTRACT	O
:	O
To	O
better	O
assess	O
the	O
risk	O
for	O
transmission	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
we	O
obtained	O
serial	O
specimens	O
and	O
clinical	O
and	O
exposure	O
data	O
from	O
seven	O
confirmed	O
U	O
.	O
S	O
.	O
SARS	B-DISO
patients	O
and	O
their	O
10	O
household	O
contacts	O
.	O

ABSTRACT	O
:	O
Although	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
highly	O
infectious	B-DISO
in	O
clinical	O
settings	O
,	O
SARS	B-DISO
has	O
not	O
been	O
well	O
examined	O
in	O
household	O
settings	O
.	O

SARS	B-DISO
transmission	O
at	O
the	O
household	O
level	O
was	O
not	O
negligible	O
in	O
Hong	O
Kong	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
an	O
atypical	O
presentation	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
a	O
geriatric	O
patient	O
with	O
multiple	O
coexisting	O
conditions	O
.	O

Our	O
study	O
documents	O
lack	O
of	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
transmission	O
to	O
hospital	O
B	O
workers	O
,	O
despite	O
variable	O
infection	B-DISO
control	O
measures	O
and	O
the	O
use	O
of	O
personal	O
protective	O
equipment	O
.	O

TITLE	O
:	O
Cluster	O
of	O
SARS	B-DISO
among	O
medical	O
students	O
exposed	O
to	O
single	O
patient	O
,	O
Hong	O
Kong	O
.	O

The	O
risk	O
of	O
contracting	O
SARS	B-DISO
was	O
sevenfold	O
greater	O
among	O
students	O
who	O
definitely	O
visited	O
the	O
index	O
case	O
'	O
s	O
cubicle	O
than	O
in	O
those	O
who	O
did	O
not	O
(	O
10	O
/	O
27	O
[	O
41	O
%]	O
versus	O
1	O
/	O
20	O
[	O
5	O
%],	O
relative	O
risk	O
7	O
.	O
4	O
;	O
95	O
%	O
confidence	O
interval	O
1	O
.	O
0	O
to	O
53	O
.	O
3	O
).	O

TITLE	O
:	O
Possible	O
SARS	B-DISO
coronavirus	O
transmission	O
during	O
cardiopulmonary	O
resuscitation	O
.	O

However	O
,	O
before	O
intubation	O
,	O
the	O
patient	O
was	O
ventilated	O
with	O
a	O
bag	O
-	O
valve	O
-	O
mask	O
that	O
may	O
have	O
contributed	O
to	O
aerosolization	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
On	O
the	O
basis	O
of	O
the	O
results	O
of	O
this	O
investigation	O
and	O
previous	O
reports	O
of	O
SARS	B-DISO
transmission	O
during	O
aerosol	O
-	O
generating	O
procedures	O
,	O
a	O
systematic	O
approach	O
to	O
the	O
problem	O
is	O
outlined	O
,	O
including	O
the	O
use	O
of	O
the	O
following	O
:	O
1	O
)	O
administrative	O
controls	O
,	O
2	O
)	O
environmental	O
engineering	O
controls	O
,	O
3	O
)	O
personal	O
protective	O
equipment	O
,	O
and	O
4	O
)	O
quality	O
control	O
.	O

TITLE	O
:	O
Index	O
patient	O
and	O
SARS	B-DISO
outbreak	O
in	O
Hong	O
Kong	O
.	O

TITLE	O
:	O
Possible	O
central	B-DISO
nervous	I-DISO
system	I-DISO
infection	I-DISO
by	O
SARS	B-DISO
coronavirus	O
.	O

ABSTRACT	O
:	O
Before	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
,	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
'	O
s	O
(	O
CDC	O
)	O
legal	O
authority	O
to	O
apprehend	O
,	O
detain	O
,	O
or	O
conditionally	O
release	O
persons	O
was	O
limited	O
to	O
seven	O
listed	O
diseases	O
,	O
not	O
including	O
SARS	B-DISO
,	O
and	O
could	O
only	O
be	O
changed	O
using	O
a	O
two	O
-	O
step	O
process	O
:	O
1	O
)	O
executive	O
order	O
of	O
the	O
President	O
of	O
the	O
United	O
States	O
on	O
recommendation	O
by	O
the	O
Secretary	O
,	O
U	O
.	O
S	O
.	O
Department	O
of	O
Health	O
and	O
Human	O
Services	O
(	O
HHS	B-DISO
),	O
and	O
2	O
)	O
amendment	O
to	O
CDC	O
quarantine	O
regulations	O
(	O
42	O
CFR	O
Parts	O
70	O
and	O
71	O
).	O

At	O
the	O
same	O
time	O
,	O
HHS	B-DISO
amended	O
the	O
regulations	O
to	O
streamline	O
the	O
process	O
of	O
adding	O
future	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

An	O
ELISA	O
based	O
on	O
recombinant	O
nucleocapsid	O
protein	O
for	O
IgG	O
detection	O
was	O
tested	O
with	O
serum	O
from	O
149	O
healthy	O
blood	O
donors	O
who	O
donated	O
3	O
years	O
previously	O
and	O
with	O
serum	O
positive	O
for	O
antibodies	O
against	O
SARS	B-DISO
-	O
CoV	O
(	O
by	O
indirect	O
immunofluorescence	O
assay	O
)	O
from	O
106	O
patients	O
with	O
SARS	B-DISO
-	O
CoV	O
pneumonia	B-DISO
.	O

The	O
seroprevalence	O
of	O
SARS	B-DISO
-	O
CoV	O
was	O
studied	O
with	O
the	O
ELISA	O
in	O
healthy	O
blood	O
donors	O
who	O
donated	O
during	O
the	O
SARS	B-DISO
outbreak	O
in	O
Hong	O
Kong	O
,	O
non	O
-	O
pneumonic	O
hospital	O
inpatients	O
,	O
and	O
symptom	B-DISO
-	O
free	O
health	O
-	O
care	O
workers	O
.	O

IgG	O
antibody	O
to	O
SARS	B-DISO
CoV	O
was	O
first	O
detected	O
between	O
day	O
5	O
and	O
day	O
47	O
after	O
onset	O
of	O
illness	O
(	O
mean	O
+/-	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
related	O
coronavirus	O
is	O
inhibited	O
by	O
interferon	O
-	O
alpha	O
.	O

In	O
contrast	O
,	O
IFN	O
-	O
alpha	O
showed	O
an	O
in	O
vitro	O
inhibitory	O
effect	O
starting	O
at	O
concentrations	O
of	O
1000	O
IU	O
/	O
mL	O
.	O
In	O
conclusion	O
,	O
ribavirin	O
alone	O
is	O
unlikely	O
to	O
be	O
beneficial	O
in	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
SARS	B-DISO
CoV	O
infections	B-DISO
.	O

Secretion	O
of	O
chemokines	O
within	O
the	O
CNS	O
signals	O
the	O
infiltration	B-DISO
of	O
leukocytes	O
,	O
which	O
results	O
in	O
destruction	O
of	O
white	O
matter	O
and	O
neurological	O
impairment	B-DISO
.	O

ABSTRACT	O
:	O
Using	O
data	O
from	O
13	O
surveys	O
of	O
the	O
public	O
,	O
this	O
article	O
compares	O
the	O
public	O
'	O
s	O
response	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
Ontario	O
(	O
specifically	O
,	O
Toronto	O
),	O
the	O
other	O
Canadian	O
provinces	O
,	O
and	O
the	O
United	O
States	O
,	O
which	O
had	O
substantial	O
differences	O
in	O
the	O
number	O
of	O
SARS	B-DISO
cases	O
.	O

Coincidentally	O
,	O
a	O
research	O
group	O
from	O
Hong	O
Kong	O
recently	O
reported	O
that	O
patients	O
with	O
SARS	B-DISO
who	O
received	O
treatment	O
with	O
the	O
anti	O
-	O
HIV	B-DISO
-	O
1	O
drug	O
lopinavir	O
-	O
ritonavir	O
experienced	O
significantly	O
better	O
clinical	O
outcomes	O
than	O
did	O
those	O
who	O
did	O
not	O
receive	O
lopinavir	O
-	O
ritonavir	O
.	O

TITLE	O
:	O
SARS	B-DISO
--	O
beginning	O
to	O
understand	O
a	O
new	O
virus	O
.	O

More	O
recently	O
infectious	B-DISO
disease	I-DISO
rates	O
have	O
decreased	O
,	O
with	O
corresponding	O
and	O
extended	O
morbidity	O
and	O
mortality	O
associated	O
with	O
an	O
aging	O
population	O
in	O
a	O
rapidly	O
urbanising	O
society	O
.	O

TITLE	O
:	O
Protective	O
effects	O
of	O
preischemic	O
treatment	O
with	O
pioglitazone	O
,	O
a	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
-	O
gamma	O
ligand	O
,	O
on	O
lung	B-DISO
ischemia	I-DISO
-	O
reperfusion	O
injury	O
in	O
rats	O
.	O

We	O
examined	O
the	O
effects	O
of	O
pioglitazone	O
,	O
a	O
synthetic	O
ligand	O
of	O
PPAR	O
-	O
gamma	O
,	O
against	O
lung	B-DISO
ischemia	I-DISO
-	O
reperfusion	O
injury	O
in	O
rats	O
.	O

Lung	O
injury	O
was	O
quantified	O
in	O
terms	O
of	O
lung	O
microvascular	O
permeability	O
(	O
Evans	O
blue	O
dye	O
extravasation	B-DISO
),	O
tissue	O
lipid	O
peroxidation	O
(	O
thiobarbituric	O
acid	O
reactive	O
substances	O
),	O
and	O
tissue	O
polymorphonuclear	O
leukocyte	O
accumulation	O
(	O
myeloperoxidase	O
activity	O
).	O

The	O
mechanism	O
of	O
these	O
protective	O
effects	O
involves	O
inhibition	O
of	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
,	O
polymorphonuclear	O
leukocyte	O
accumulation	O
,	O
and	O
tissue	O
lipid	O
peroxidation	O
,	O
resulting	O
in	O
reduced	O
lung	B-DISO
edema	I-DISO
.	O

Injection	O
of	O
inactivated	O
pseudorabies	B-DISO
virus	O
,	O
an	O
alphaherpesvirus	O
,	O
by	O
various	O
routes	O
into	O
mice	O
resulted	O
in	O
the	O
generation	O
of	O
T	O
helper	O
(	O
Th	O
)	O
1	O
type	O
immune	O
response	O
.	O

A	O
prospective	O
study	O
was	O
performed	O
on	O
200	O
consecutive	O
cases	O
of	O
severe	O
preeclampsia	B-DISO
and	I-DISO
eclampsia	I-DISO
referred	O
to	O
the	O
Kerman	O
University	O
Maternity	O
Center	O
from	O
June	O
2001	O
to	O
December	O
2002	O
.	O

The	O
majority	O
of	O
patients	O
were	O
young	O
and	O
primigravida	O
,	O
especially	O
in	O
the	O
eclampsia	B-DISO
group	O
.	O

72	O
.	O
7	O
%	O
of	O
eclamptic	O
patients	O
suffered	B-DISO
their	O
first	O
convulsion	B-DISO
at	O
home	O
and	O
not	O
in	O
the	O
presence	O
of	O
medical	O
help	O
.	O

The	O
data	O
indicate	O
that	O
measurement	O
of	O
sPLA2	O
can	O
be	O
useful	O
in	O
alerting	O
the	O
clinician	O
to	O
patients	O
with	O
impending	O
ACS	O
,	O
and	O
suggest	O
that	O
instituting	O
early	O
therapies	O
based	O
on	O
sPLA2	O
levels	O
,	O
including	O
inhibition	O
of	O
sPLA2	O
activity	O
,	O
may	O
be	O
useful	O
to	O
prevent	O
or	O
reduce	O
the	O
clinical	O
morbidity	O
of	O
ACS	O
in	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
.	O

Chang	O
Gung	O
University	O
experienced	O
various	O
SARS	B-DISO
-	O
related	O
episodes	O
,	O
such	O
as	O
the	O
postponement	O
of	O
classes	O
for	O
7	O
days	O
,	O
the	O
reporting	O
of	O
probable	O
SARS	B-DISO
cases	O
,	O
and	O
the	O
isolation	O
of	O
students	O
under	O
Level	O
A	O
and	O
B	O
quarantines	O
.	O

The	O
source	O
of	O
SARS	B-DISO
infection	B-DISO
was	O
identified	O
as	O
the	O
husband	O
of	O
a	O
tumor	B-DISO
patient	O
who	O
received	O
chemotherapy	O
in	O
the	O
Department	O
of	O
Oncology	O
,	O
during	O
which	O
they	O
maintained	O
intimate	O
contact	O
for	O
at	O
least	O
two	O
weeks	O
when	O
the	O
husband	O
had	O
typical	O
symptoms	O
of	O
SARS	B-DISO
.	O

Among	O
those	O
11	O
patients	O
with	O
probable	O
SARS	B-DISO
,	O
only	O
1	O
had	O
confirmed	O
SARS	B-DISO
;	O
for	O
the	O
other	O
10	O
patients	O
,	O
the	O
possibility	O
of	O
SARS	B-DISO
infection	B-DISO
was	O
ruled	O
out	O
.	O

Among	O
those	O
11	O
patients	O
with	O
probable	O
SARS	B-DISO
,	O
only	O
1	O
had	O
confirmed	O
SARS	B-DISO
;	O
for	O
the	O
other	O
10	O
patients	O
,	O
the	O
possibility	O
of	O
SARS	B-DISO
infection	B-DISO
was	O
ruled	O
out	O
.	O

TITLE	O
:	O
Respiratory	B-DISO
infections	I-DISO
:	O
SARS	B-DISO
and	O
tuberculosis	B-DISO
.	O

The	O
management	O
of	O
SARS	B-DISO
is	O
controversial	O
,	O
largely	O
due	O
to	O
the	O
lack	O
of	O
data	O
from	O
controlled	O
trials	O
,	O
which	O
were	O
logistically	O
impossible	O
to	O
design	O
or	O
execute	O
at	O
the	O
time	O
of	O
the	O
overwhelming	O
outbreak	O
between	O
March	O
and	O
June	O
2003	O
.	O

Retrospective	O
data	O
suggest	O
that	O
administration	O
of	O
the	O
anti	O
-	O
HIV	B-DISO
drug	O
Kaletra	O
in	O
combination	O
with	O
ribavirin	O
could	O
reduce	O
mortality	O
and	O
incidence	O
of	O
respiratory	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Live	O
,	O
attenuated	O
coronavirus	O
vaccines	O
through	O
the	O
directed	O
deletion	O
of	O
group	O
-	O
specific	O
genes	O
provide	O
protection	O
against	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
.	O

With	O
this	O
objective	O
,	O
we	O
deleted	O
the	O
group	O
-	O
specific	O
gene	O
cluster	O
open	O
reading	O
frame	O
3abc	O
or	O
7ab	O
and	O
obtained	O
deletion	O
mutant	B-DISO
viruses	O
that	O
not	O
only	O
multiplied	O
well	O
in	O
cell	O
culture	O
but	O
also	O
showed	O
an	O
attenuated	O
phenotype	O
in	O
the	O
cat	O
.	O

In	O
the	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
section	O
,	O
the	O
new	O
recommendation	O
is	O
to	O
determine	O
,	O
on	O
a	O
case	O
-	O
by	O
-	O
case	O
basis	O
,	O
whether	O
to	O
administer	O
monoclonal	O
antibody	O
(	O
palivizumab	O
)	O
to	O
certain	O
infants	O
and	O
children	O
aged	O
<	O
24	O
months	O
who	O
were	O
born	O
prematurely	O
and	O
are	O
at	O
high	O
risk	O
for	O
RSV	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Transfusion	B-DISO
related	I-DISO
acute	I-DISO
lung	I-DISO
injury	I-DISO
(	O
TRALI	B-DISO
)	O
is	O
a	O
relatively	O
rare	O
but	O
potentially	O
severe	O
complication	B-DISO
of	I-DISO
blood	I-DISO
transfusion	I-DISO
.	O

TITLE	O
:	O
Serum	O
LD1	O
isoenzyme	O
and	O
blood	O
lymphocyte	O
subsets	O
as	O
prognostic	O
indicators	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

They	O
were	O
either	O
involved	O
in	O
the	O
initial	O
outbreak	O
of	O
SARS	B-DISO
,	O
or	O
cases	O
from	O
the	O
community	O
outbreak	O
of	O
Amoy	O
Gardens	O
between	O
10	O
March	O
and	O
5	O
May	O
2003	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
human	O
Coronavirus	O
(	O
HCoV	O
)	O
was	O
this	O
year	O
recognized	O
as	O
the	O
etiological	O
agent	O
of	O
the	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
.	O

EP2	O
and	O
EP4	O
possessed	B-DISO
linear	O
epitopes	O
,	O
whereas	O
EP1	O
and	O
EP2	O
were	O
able	O
to	O
form	O
conformational	O
epitopes	O
that	O
could	O
react	O
with	O
most	O
(>	O
80	O
%)	O
of	O
the	O
tested	O
sera	O
.	O

TITLE	O
:	O
Effective	O
personal	O
protective	O
clothing	O
for	O
health	O
care	O
workers	O
attending	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

Findings	O
in	O
the	O
viral	O
load	O
test	O
showed	O
that	O
there	O
was	O
a	O
significant	O
difference	O
in	O
the	O
contamination	O
of	O
the	O
face	B-DISO
(	O
t	O
=	O
4	O
.	O
69	O
,	O
df	O
=	O
38	O
,	O
P	O
<.	O
00	O
)	O
between	O
1	O
and	O
2	O
strokes	B-DISO
.	O

The	O
purpose	O
of	O
this	O
meeting	O
was	O
to	O
provide	O
a	O
forum	O
for	O
expert	O
presentations	O
and	O
discussion	O
about	O
the	O
threats	O
of	O
bioterrorism	O
and	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
,	O
and	O
to	O
address	O
the	O
issues	O
relating	O
to	O
epidemics	O
,	O
prevention	O
of	O
infection	B-DISO
and	O
treatment	O
of	O
some	O
of	O
these	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
classified	O
as	O
potential	O
agents	O
of	O
bioterror	O
.	O

This	O
report	O
addresses	O
reverse	O
genetics	O
of	O
SARS	B-DISO
virus	O
,	O
as	O
well	O
as	O
its	O
epidemiology	O
,	O
and	O
a	O
host	O
of	O
different	O
recent	O
approaches	O
to	O
developing	O
antivirals	O
effective	O
against	O
SARS	B-DISO
,	O
including	O
some	O
potential	O
vaccine	O
candidates	O
.	O

TITLE	O
:	O
[	O
Central	O
issues	O
of	O
prevention	O
of	O
nosocomial	B-DISO
infections	I-DISO
--	O
status	O
in	O
2004	O
].	O

One	O
hundred	O
thirty	O
-	O
three	O
cases	O
of	O
SARS	B-DISO
admitted	O
from	O
May	O
to	O
June	O
2003	O
in	O
our	O
hospital	O
were	O
included	O
in	O
the	O
study	O
.	O

RESULTS	O
:	O
Only	O
two	O
patients	O
had	O
mild	O
elevated	O
intraocular	B-DISO
pressure	I-DISO
at	O
baseline	O
and	O
at	O
subsequent	O
follow	O
-	O
up	O
.	O

Serum	O
antibody	O
against	O
SARS	B-DISO
-	O
CoV	O
IgG	O
was	O
determined	O
cross	O
-	O
sectionally	O
and	O
symptoms	O
of	O
respiratory	B-DISO
infection	I-DISO
were	O
investigated	O
retrospectively	O
for	O
part	O
of	O
traders	O
of	O
three	O
wholesale	O
markets	O
for	O
wild	O
animals	O
in	O
Guangzhou	O
.	O

TITLE	O
:	O
[	O
Re	O
-	O
survey	O
on	O
epidemiological	O
history	O
of	O
1	O
091	O
probable	O
cases	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
Beijing	O
].	O

All	O
the	O
probable	O
SARS	B-DISO
cases	O
until	O
June	O
9	O
,	O
2003	O
without	O
definite	O
history	O
of	O
contact	O
with	O
SARS	B-DISO
patients	O
in	O
the	O
first	O
epidemiological	O
survey	O
were	O
included	O
in	O
a	O
re	O
-	O
survey	O
with	O
questionnaire	O
.	O

Comprehensive	O
judgement	O
based	O
on	O
epidemiological	O
history	O
showed	O
that	O
probale	O
history	O
of	O
contact	O
with	O
SARS	B-DISO
patients	O
could	O
be	O
found	O
in	O
72	O
.	O
9	O
%	O
of	O
1	O
,	O
091	O
probale	O
cases	O
of	O
SARS	B-DISO
in	O
the	O
second	O
survey	O
.	O

TITLE	O
:	O
[	O
An	O
investigation	O
on	O
nosocomial	B-DISO
infection	I-DISO
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
health	O
-	O
care	O
workers	O
at	O
13	O
key	O
hospitals	O
in	O
Guangdong	O
Province	O
].	O

Serum	O
levels	O
of	O
C3	O
,	O
C4	O
,	O
PA	O
and	O
CRP	O
were	O
determined	O
by	O
turbidimetry	O
in	O
54	O
cases	O
of	O
SARS	B-DISO
,	O
20	O
of	O
other	O
pneumonia	B-DISO
and	O
30	O
normal	O
persons	O
.	O

8	O
.	O
77	O
)	O
mg	O
/	O
L	O
and	O
(	O
107	O
+/-	O
54	O
)	O
mg	O
/	O
L	O
in	O
SARS	B-DISO
patients	O
,	O
(	O
1	O
.	O
30	O
+/-	O
0	O
.	O
46	O
)	O
g	O
/	O
L	O
,	O
(	O
0	O
.	O
57	O
+/-	O
0	O
.	O
31	O
)	O
g	O
/	O
L	O
,	O
(	O
0	O
.	O
88	O
+/-	O
0	O
.	O
43	O
)	O
mg	O
/	O
L	O
and	O
(	O
291	O
+/-	O
76	O
)	O
mg	O
/	O
L	O
in	O
patients	O
with	O
other	O
pneumonia	B-DISO
,	O
and	O
(	O
1	O
.	O
11	O
+/-	O
0	O
.	O
56	O
)	O
g	O
/	O
L	O
,	O
(	O
0	O
.	O
38	O
+/-	O
0	O
.	O
26	O
)	O
g	O
/	O
L	O
,	O
(	O
0	O
.	O
42	O
+/-	O
0	O
.	O
26	O
)	O
mg	O
/	O
L	O
and	O
(	O
376	O
+/-	O
74	O
)	O
mg	O
/	O
L	O
in	O
normal	O
persons	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
effectiveness	O
of	O
personal	O
protective	O
measures	O
of	O
health	O
care	O
workers	O
(	O
HCWs	O
)	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Patients	O
with	O
end	O
-	O
stage	O
liver	B-DISO
disease	I-DISO
are	O
at	O
high	O
risk	O
of	O
major	O
complications	O
and	O
death	O
following	O
surgery	O
.	O

Portal	B-DISO
hypertension	I-DISO
can	O
be	O
ameliorated	O
by	O
percutaneous	O
or	O
surgical	O
portasystemic	O
shunting	O
procedures	O
.	O

If	O
well	O
-	O
defined	O
contraindications	O
are	O
not	O
present	O
,	O
patients	O
with	O
advanced	O
liver	B-DISO
disease	I-DISO
should	O
be	O
evaluated	O
for	O
orthotopic	O
liver	O
transplantation	O
from	O
a	O
cadaver	O
donor	O
or	O
possible	O
living	O
-	O
related	O
liver	O
transplantation	O
.	O

We	O
described	O
retrospectively	O
eight	O
cases	O
of	O
sepsis	B-DISO
from	O
pneumonia	B-DISO
of	O
various	O
microbiological	O
aetiologies	O
including	O
two	O
due	O
to	O
SARS	B-DISO
,	O
compared	O
their	O
PCT	B-DISO
concentrations	O
and	O
provided	O
further	O
descriptors	O
of	O
SARS	B-DISO
as	O
a	O
viral	B-DISO
pneumonia	I-DISO
.	O

ABSTRACT	O
:	O
A	O
revolution	O
in	O
the	O
governance	O
of	O
global	O
infectious	B-DISO
disease	I-DISO
threats	O
is	O
under	O
way	O
,	O
accelerated	O
by	O
events	O
triggered	O
by	O
the	O
outbreak	O
of	O
SARS	B-DISO
in	O
2003	O
.	O

Testing	O
serial	O
dilutions	O
of	O
cultured	O
SARS	B-DISO
-	O
CoV	O
showed	O
that	O
the	O
analytical	O
sensitivity	O
of	O
the	O
assays	O
ranged	O
from	O
10	O
(-	O
8	O
)	O
to	O
10	O
(-	O
6	O
),	O
corresponding	O
to	O
1	O
and	O
100	O
copies	O
of	O
viral	O
RNA	O
,	O
respectively	O
.	O

TITLE	O
:	O
Two	O
genotypes	O
of	O
canine	O
coronavirus	O
simultaneously	O
detected	O
in	O
the	O
fecal	O
samples	O
of	O
dogs	O
with	O
diarrhea	B-DISO
.	O

Most	O
patients	O
recover	O
after	O
a	O
week	O
or	O
2	O
,	O
but	O
some	O
go	O
on	O
to	O
develop	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Up	O
-	O
to	O
-	O
date	O
knowledge	O
of	O
SARS	B-DISO
should	O
help	O
in	O
early	O
detection	O
,	O
isolation	O
of	O
high	O
-	O
risk	O
patients	O
,	O
to	O
reduce	O
mortality	O
and	O
morbidity	O
,	O
and	O
to	O
prevent	O
a	O
new	O
global	O
epidemic	O
arising	O
.	O

If	O
the	O
current	O
H5N1	B-DISO
avian	B-DISO
influenza	I-DISO
outbreak	O
ever	O
assumes	O
the	O
role	O
of	O
a	O
pandemic	O
,	O
formidable	O
technical	O
difficulties	O
relating	O
to	O
the	O
properties	O
of	O
the	O
agent	O
,	O
itself	O
,	O
will	O
ensure	O
that	O
vaccines	O
will	O
only	O
become	O
available	O
after	O
a	O
significant	O
lead	O
time	O
and	O
then	O
only	O
to	O
a	O
relatively	O
small	O
percentage	O
of	O
the	O
population	O
.	O

The	O
neuraminidase	O
inhibitors	O
zanamivir	O
and	O
oseltamivir	O
,	O
and	O
the	O
M2	O
inhibitors	O
amantadine	O
and	O
rimantadine	O
,	O
remain	O
the	O
only	O
options	O
for	O
controlling	O
respiratory	B-DISO
disease	I-DISO
caused	O
by	O
influenza	B-DISO
viruses	O
,	O
although	O
the	O
latter	O
two	O
could	O
not	O
be	O
used	O
against	O
very	O
recent	O
H5N1	B-DISO
strains	O
.	O

From	O
January	O
1	O
,	O
1999	O
,	O
to	O
December	O
31	O
,	O
2001	O
,	O
170	O
mechanically	O
ventilated	O
exposed	O
patients	O
(	O
obese	B-DISO
patients	O
with	O
body	O
mass	O
index	O
of	O
>	O
30	O
kg	O
/	O
m	O
)	O
were	O
matched	O
with	O
170	O
mechanically	O
ventilated	O
unexposed	O
patients	O
(	O
with	O
ideal	O
body	O
mass	O
index	O
of	O
18	O
.	O
5	O
-	O
24	O
.	O
9	O
kg	O
/	O
m	O
).	O

ABSTRACT	O
:	O
Glycyrrhizin	O
is	O
one	O
of	O
the	O
main	O
bioactive	O
components	O
in	O
liquorice	O
(	O
Glycyrrhiza	O
uralensis	O
Fisch	O
)	O
which	O
has	O
recently	O
been	O
found	O
to	O
be	O
highly	O
active	O
in	O
inhibiting	O
replication	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
associated	O
virus	O
.	O

The	O
separation	B-DISO
and	O
purification	O
of	O
glycyrrhizin	O
from	O
a	O
methanol	O
-	O
water	O
(	O
70	O
:	O
30	O
(	O
v	O
/	O
v	O
))	O
extract	O
of	O
liquorice	O
roots	O
was	O
achieved	O
using	O
high	O
-	O
speed	O
counter	O
-	O
current	O
chromatography	O
.	O

TITLE	O
:	O
A	O
previously	O
undescribed	O
coronavirus	O
associated	O
with	O
respiratory	B-DISO
disease	I-DISO
in	O
humans	O
.	O

Rotavirus	O
and	O
coronavirus	O
were	O
demonstrated	O
in	O
24	O
%	O
and	O
3	O
%	O
of	O
the	O
diarrhoea	B-DISO
samples	O
,	O
respectively	O
,	O
whereas	O
E	O
.	O
coli	O
K99	O
+	O
was	O
only	O
found	O
in	O
samples	O
from	O
2	O
healthy	O
calves	O
.	O

Whereas	O
in	O
the	O
past	O
,	O
reactive	O
oxygen	O
and	O
reactive	O
nitrogen	O
species	O
were	O
mainly	O
known	O
as	O
harmful	O
agents	O
,	O
recent	O
investigations	O
have	O
given	O
a	O
new	O
insight	O
into	O
the	O
(	O
patho	O
)	O
physiological	O
importance	O
of	O
these	O
substances	O
as	O
powerful	O
messenger	O
molecules	O
involved	O
in	O
gene	O
regulation	O
,	O
thereby	O
enabling	O
the	O
synthesis	O
of	O
cytokines	O
or	O
adhesion	B-DISO
molecules	O
necessary	O
for	O
defending	O
inflammatory	O
processes	O
.	O

ABSTRACT	O
:	O
A	O
22	O
-	O
yr	O
-	O
old	O
,	O
86	O
-	O
kg	O
,	O
morbidly	O
obese	B-DISO
female	O
orangutan	O
(	O
Pongo	O
pygmaeus	O
abelii	O
)	O
was	O
immobilized	O
and	O
transported	O
to	O
the	O
Denver	O
Zoological	O
Gardens	O
hospital	O
for	O
a	O
routine	O
physical	O
examination	O
.	O

A	O
large	O
volume	O
of	O
pink	O
-	O
tinged	O
frothy	O
fluid	O
flowed	O
from	O
the	O
trachea	B-DISO
when	O
the	O
laryngoscope	O
was	O
inserted	O
into	O
the	O
oropharynx	O
.	O

ABSTRACT	O
:	O
SARS	B-DISO
3C	O
-	O
like	O
proteinase	O
has	O
been	O
proposed	O
to	O
be	O
a	O
key	O
enzyme	O
for	O
drug	O
design	O
against	O
SARS	B-DISO
.	O

Beijing	O
'	O
s	O
outbreak	O
began	O
March	O
5	O
;	O
by	O
late	O
April	O
,	O
daily	O
hospital	O
admissions	O
for	O
SARS	B-DISO
exceeded	O
100	O
for	O
several	O
days	O
;	O
2	O
,	O
521	O
cases	O
of	O
probable	O
SARS	B-DISO
occurred	O
.	O

There	O
were	O
no	O
significant	O
differences	O
for	O
the	O
3	O
values	O
among	O
patients	O
with	O
SARS	B-DISO
without	O
anti	O
-	O
SARS	B-DISO
coronavirus	O
antibody	O
,	O
patients	O
with	O
M	O
.	O
pneumoniae	O
infection	B-DISO
,	O
and	O
healthy	O
subjects	O
.	O

TITLE	O
:	O
Detection	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
in	O
pneumocytes	O
of	O
the	O
lung	O
.	O

The	O
presence	O
of	O
the	O
SARS	B-DISO
virus	O
was	O
determined	O
by	O
nested	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
the	O
infected	O
cells	O
were	O
identified	O
by	O
in	O
situ	O
hybridization	O
in	O
open	O
-	O
lung	O
biopsy	O
and	O
postmortem	O
necropsy	O
specimens	O
.	O

TITLE	O
:	O
Exploring	O
the	O
binding	O
mechanism	O
of	O
the	O
main	O
proteinase	O
in	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
and	O
its	O
implication	O
to	O
anti	O
-	O
SARS	B-DISO
drug	O
design	O
.	O

ABSTRACT	O
:	O
Chronic	O
Immune	O
Dysschwannian	O
/	O
Dysneuronal	O
Polyneuropathy	B-DISO
is	O
an	O
autoimmune	B-DISO
peripheral	O
-	O
nerve	O
and	O
/	O
or	O
nerve	O
-	O
root	O
disorder	O
known	O
to	O
usually	O
respond	O
to	O
intravenous	O
immunoglobulin	O
-	O
G	O
treatment	O
.	O

Benefit	O
can	O
involve	O
any	O
combination	O
of	O
motor	O
-	O
nerve	O
fibers	O
and	O
large	O
and	O
small	O
sensory	O
-	O
nerve	O
fibers	O
responsible	O
for	O
a	O
progressively	O
crippling	O
,	O
unbalancing	O
,	O
discomforting	O
or	O
painful	B-DISO
disorder	O
.	O

The	O
genetic	O
-	O
metabolic	O
milieu	O
(	O
but	O
not	O
necessarily	O
glucose	O
dysmetabolism	O
per	O
se	O
.)	O
of	O
type	O
-	O
2	O
diabetes	B-DISO
putatively	O
predisposes	O
to	O
the	O
presumably	O
-	O
dysimmune	O
intravenous	O
immunoglobulin	O
-	O
G	O
-	O
responsive	O
polyneuropathy	B-DISO
.	O

Intravenous	O
immunoglobulin	O
-	O
G	O
might	O
:	O
a	O
)	O
combat	O
a	O
dysimmune	O
component	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
,	O
including	O
the	O
reactive	O
cytokine	O
-	O
chemokine	O
storm	O
against	O
respiratory	O
tissues	O
;	O
b	O
)	O
contain	O
some	O
antibodies	O
effective	O
against	O
the	O
coronavirus	O
non	O
-	O
specific	O
components	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
;	O
c	O
)	O
block	O
host	O
-	O
cell	O
receptors	O
for	O
the	O
virus	O
;	O
and	O
d	O
)	O
counteract	O
secondary	B-DISO
infections	I-DISO
.	O

TITLE	O
:	O
Transmission	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
dynamical	O
small	O
-	O
world	O
networks	O
.	O

ABSTRACT	O
:	O
A	O
long	O
-	O
standing	O
concern	O
for	O
international	O
spread	O
of	O
new	O
,	O
virulent	O
pathogens	O
became	O
a	O
reality	O
with	O
the	O
advent	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
).	O

TITLE	O
:	O
The	O
nucleocapsid	O
protein	O
of	O
the	O
SARS	B-DISO
coronavirus	O
is	O
capable	O
of	O
self	O
-	O
association	O
through	O
a	O
C	O
-	O
terminal	O
209	O
amino	O
acid	O
interaction	O
domain	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
new	O
respiratory	O
illness	O
due	O
to	O
a	O
novel	O
coronavirus	O
called	O
SARS	B-DISO
-	O
CoV	O
.	O
Cases	O
of	O
SARS	B-DISO
were	O
first	O
identified	O
from	O
Guangdong	O
Province	O
in	O
southern	O
China	O
in	O
November	O
2002	O
.	O

ABSTRACT	O
:	O
To	O
understand	O
the	O
time	O
-	O
course	O
of	O
viraemia	B-DISO
and	O
antibody	O
responses	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
RT	O
-	O
PCR	O
and	O
ELISA	O
were	O
used	O
to	O
assay	O
376	O
blood	O
samples	O
from	O
135	O
SARS	B-DISO
patients	O
at	O
various	O
stages	O
of	O
the	O
illness	O
,	O
including	O
samples	O
from	O
patients	O
who	O
were	O
in	O
their	O
early	O
convalescent	O
phase	O
.	O

Further	O
studies	O
indicated	O
that	O
S	O
was	O
N	O
-	O
glycosylated	O
and	O
migrated	O
in	O
SDS	B-DISO
polyacrylamide	O
gels	O
with	O
an	O
apparent	O
mass	O
of	O
approximately	O
160	O
kDa	O
after	O
treatment	O
with	O
peptide	O
N	O
-	O
glycosidase	O
F	O
.	O
The	O
acquisition	O
of	O
resistance	O
to	O
endoglycosidase	O
H	O
indicated	O
trafficking	O
of	O
S	O
to	O
the	O
medial	O
Golgi	O
compartment	O
,	O
and	O
confocal	O
microscopy	O
showed	O
that	O
S	O
was	O
transported	O
to	O
the	O
cell	O
surface	O
.	O

ABSTRACT	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
associated	O
coronavirus	O
causes	O
severe	O
disease	O
,	O
is	O
transmissible	O
to	O
the	O
community	O
and	O
there	O
is	O
no	O
effective	O
prophylaxis	O
or	O
treatment	O
--	O
perhaps	O
fulfilling	O
the	O
criteria	O
for	O
biohazard	O
group	O
3	O
or	O
4	O
.	O

ABSTRACT	O
:	O
We	O
aimed	O
to	O
evaluate	O
the	O
appearance	O
of	O
chest	O
radiographs	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
correlate	O
these	O
findings	O
with	O
clinical	O
outcomes	O
.	O

The	O
initial	O
predominant	O
radiographic	O
feature	O
of	O
SARS	B-DISO
was	O
air	O
-	O
space	O
consolidation	O
in	O
the	O
lateral	O
and	O
lower	O
lung	O
zones	O
.	O

We	O
determined	O
the	O
distribution	O
of	O
the	O
initial	O
187	O
cases	O
of	O
SARS	B-DISO
in	O
the	O
Amoy	O
Gardens	O
housing	O
complex	O
in	O
2003	O
according	O
to	O
the	O
date	O
of	O
onset	O
and	O
location	O
of	O
residence	O
.	O

We	O
then	O
studied	O
the	O
association	O
between	O
the	O
location	O
(	O
building	O
,	O
floor	O
,	O
and	O
direction	O
the	O
apartment	O
unit	O
faced	O
)	O
and	O
the	O
probability	O
of	O
infection	B-DISO
using	O
logistic	O
regression	O
.	O

This	O
report	O
summarizes	O
how	O
SARS	B-DISO
screening	O
led	O
to	O
the	O
discovery	O
of	O
60	O
cases	O
of	O
TB	O
.	O

Because	O
ALI	O
appears	O
to	O
be	O
the	O
end	O
result	O
of	O
systemic	O
hyperinflammation	O
,	O
children	O
may	O
either	O
have	O
1	O
)	O
an	O
attenuated	O
pro	O
-	O
inflammatory	B-DISO
response	I-DISO
or	O
2	O
)	O
an	O
augmented	O
anti	O
-	O
inflammatory	B-DISO
response	I-DISO
compared	O
with	O
adults	O
.	O

Old	O
age	O
,	O
high	O
white	O
blood	O
cell	O
counts	O
,	O
high	O
peak	O
grade	O
fever	O
,	O
and	O
close	O
or	O
prolonged	O
contact	O
with	O
a	O
SARS	B-DISO
patient	O
increase	O
the	O
risk	O
of	O
intubation	O
in	O
previous	O
healthy	O
SARS	B-DISO
patients	O
.	O

A	O
total	O
of	O
382	O
patients	O
were	O
fully	O
evaluated	O
for	O
suspected	O
or	O
probable	O
SARS	B-DISO
outside	O
the	O
ED	O
,	O
of	O
which	O
27	O
were	O
admitted	O
.	O

Two	O
patients	O
with	O
probable	O
SARS	B-DISO
died	O
.	O

This	O
SARS	B-DISO
outbreak	O
was	O
associated	O
with	O
substantial	O
use	O
of	O
hospital	O
and	O
ED	O
resources	O
aimed	O
at	O
infection	B-DISO
control	O
,	O
comparatively	O
less	O
use	O
of	O
resources	O
related	O
to	O
the	O
medical	O
care	O
of	O
patients	O
with	O
suspected	O
or	O
probable	O
SARS	B-DISO
,	O
and	O
decreased	O
use	O
of	O
routine	O
medical	O
services	O
.	O

Outbreaks	O
of	O
dengue	B-DISO
fever	I-DISO
in	O
endemic	O
areas	O
are	O
reflected	O
in	O
increased	O
infections	B-DISO
in	O
travelers	O
returning	O
from	O
these	O
areas	O
.	O

Analysis	O
of	O
the	O
active	O
site	O
cavity	B-DISO
reveals	O
the	O
presence	O
of	O
subsites	O
that	O
can	O
be	O
targeted	O
with	O
specific	O
chemical	O
functionalities	O
.	O

ABSTRACT	O
:	O
During	O
the	O
recent	O
global	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
thousands	O
of	O
patients	O
received	O
treatments	O
of	O
uncertain	O
efficacy	O
and	O
known	O
toxicity	O
such	O
as	O
ribavirin	O
and	O
corticosteroids	O
.	O

TITLE	O
:	O
Coronaviridae	O
and	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
strain	O
HSR1	O
.	O

Through	O
investigations	O
on	O
a	O
test	O
panel	O
of	O
whole	O
blood	O
obtained	O
from	O
30	O
SARS	B-DISO
patients	O
and	O
9	O
control	O
persons	O
,	O
the	O
specificity	O
and	O
sensitivity	O
of	O
the	O
Taqman	O
RT	O
-	O
nested	O
PCR	O
system	O
was	O
found	O
to	O
be	O
100	O
and	O
83	O
%,	O
respectively	O
,	O
which	O
suggests	O
that	O
the	O
method	O
is	O
a	O
promising	O
one	O
to	O
diagnose	O
SARS	B-DISO
in	O
early	O
stages	O
.	O

Laboratory	O
confirmation	O
of	O
SARS	B-DISO
coronavirus	B-DISO
infection	I-DISO
was	O
established	O
in	O
132	O
(	O
95	O
.	O
7	O
%).	O

In	O
suspension	O
,	O
HCoV	O
-	O
229E	O
gradually	O
lost	O
its	O
infectivity	O
completely	O
while	O
SARS	B-DISO
-	O
CoV	O
retained	O
its	O
infectivity	O
for	O
up	O
to	O
9	O
days	O
;	O
in	O
the	O
dried	O
state	O
,	O
survival	O
times	O
were	O
24	O
h	O
versus	O
6	O
days	O
.	O

Thermal	O
inactivation	B-DISO
at	O
56	O
degrees	O
C	O
was	O
highly	O
effective	O
in	O
the	O
absence	O
of	O
protein	O
,	O
reducing	O
the	O
virus	O
titre	O
to	O
below	O
detectability	O
;	O
however	O
,	O
the	O
addition	O
of	O
20	O
%	O
protein	O
exerted	O
a	O
protective	O
effect	O
resulting	O
in	O
residual	O
infectivity	O
.	O

Hendra	O
and	O
Nipah	O
viruses	O
have	O
been	O
shown	O
to	O
be	O
the	O
first	O
two	O
members	O
of	O
a	O
new	O
genus	O
,	O
Henipavirus	O
,	O
in	O
the	O
family	O
Paramyxoviridae	O
,	O
subfamily	O
Paramyxovirinae	O
,	O
whereas	O
Australian	O
bat	O
lyssavirus	O
is	O
closely	O
related	O
antigenically	O
to	O
classical	O
rabies	B-DISO
virus	O
in	O
the	O
genus	O
Lyssavirus	O
,	O
family	O
Rhabdoviridae	O
,	O
although	O
it	O
can	O
be	O
distinguished	O
on	O
genetic	O
grounds	O
.	O

Two	O
human	O
infections	B-DISO
with	O
Australian	O
bat	O
lyssavirus	O
have	O
been	O
reported	O
,	O
the	O
clinical	O
signs	O
of	O
which	O
were	O
consistent	O
with	O
classical	O
rabies	B-DISO
infection	B-DISO
and	O
included	O
a	O
diffuse	O
,	O
non	O
-	O
suppurative	B-DISO
encephalitis	B-DISO
.	O

Four	O
Clinic	O
employees	O
were	O
vaccinated	O
with	O
vaccinia	B-DISO
vaccine	O
as	O
a	O
result	O
of	O
their	O
contact	O
with	O
patients	O
or	O
lab	O
specimens	O
.	O

Naturally	O
infected	O
cats	O
were	O
positive	O
for	O
FCoV	O
antibodies	O
and	O
monocyte	O
-	O
associated	O
FCoV	O
viraemia	B-DISO
prior	O
to	O
death	O
.	O

FECV	O
shedding	O
was	O
several	O
logs	O
higher	O
in	O
young	O
kittens	O
with	O
primary	B-DISO
infection	I-DISO
than	O
adult	O
cats	O
with	O
primary	O
infections	B-DISO
.	O

The	O
infection	B-DISO
rate	O
only	O
increased	O
from	O
11	O
to	O
15	O
%	O
in	O
1	O
week	O
.	O

After	O
challenge	O
,	O
the	O
immunized	O
cats	O
demonstrated	O
one	O
of	O
four	O
clinical	O
outcomes	O
:	O
(	O
1	O
)	O
classical	O
effusive	O
FIP	B-DISO
;	O
(	O
2	O
)	O
accelerated	O
FIP	B-DISO
;	O
(	O
3	O
)	O
non	O
-	O
effusive	O
FIP	B-DISO
,	O
or	O
(	O
4	O
)	O
resistance	O
to	O
challenge	O
.	O

The	O
most	O
noteworthy	O
changes	O
were	O
in	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
interferon	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
levels	O
.	O

Our	O
preliminary	O
findings	O
suggest	O
that	O
immunity	O
against	O
FIP	B-DISO
is	O
associated	O
with	O
TNF	O
-	O
alpha	O
and	O
IFN	O
-	O
gamma	O
response	O
imbalance	B-DISO
,	O
with	O
high	O
TNF	O
-	O
alpha	O
/	O
low	O
IFN	O
-	O
gamma	O
mRNA	O
responses	O
favouring	O
disease	O
and	O
low	O
TNF	O
-	O
alpha	O
/	O
high	O
IFN	O
-	O
gamma	O
mRNA	O
responses	O
being	O
indicative	O
of	O
immunity	O
.	O

In	O
this	O
work	O
we	O
describe	O
the	O
tissue	O
distribution	O
of	O
fAGPrP	O
during	O
FIP	B-DISO
,	O
and	O
its	O
relationship	O
with	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
and	O
myeloid	O
cells	O
.	O

These	O
findings	O
did	O
not	O
depend	O
on	O
the	O
presence	O
of	O
FCoVs	O
or	O
of	O
myeloid	O
cells	O
,	O
suggesting	O
that	O
fAGPrP	O
is	O
not	O
directly	O
involved	O
in	O
the	O
pathogenesis	B-DISO
of	O
FIP	B-DISO
.	O

Those	O
that	O
survived	O
for	O
more	O
than	O
2	O
years	O
were	O
all	O
older	O
cats	O
(	O
6	O
to	O
16	O
years	O
old	O
)	O
with	O
the	O
effusive	O
form	O
of	O
FIP	B-DISO
.	O

ABSTRACT	O
:	O
In	O
August	O
2002	O
,	O
scientists	O
and	O
veterinarians	O
from	O
all	O
over	O
the	O
world	O
met	O
in	O
Scotland	O
to	O
discuss	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
and	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
).	O

Our	O
results	O
also	O
indicate	O
that	O
the	O
mechanisms	O
for	O
the	O
viral	O
fusion	O
of	O
coronaviruses	O
are	O
similar	O
to	O
those	O
of	O
influenza	B-DISO
virus	O
and	O
HIV	B-DISO
.	O

TITLE	O
:	O
Postinfectious	O
diffuse	O
proliferative	B-DISO
glomerulonephritis	I-DISO
and	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
in	O
an	O
HIV	B-DISO
patient	O
.	O

Renal	O
biopsy	O
showed	O
diffuse	B-DISO
endocapillary	I-DISO
proliferative	I-DISO
glomerulonephritis	I-DISO
,	O
with	O
mesangial	O
and	O
capillary	O
walls	O
,	O
granular	O
deposits	O
of	O
IgG	O
and	O
C3	O
by	O
immunofluorescence	O
.	O

The	O
literature	O
also	O
documents	O
that	O
airborne	O
contamination	O
can	O
be	O
minimized	O
easily	O
and	O
inexpensively	O
by	O
layering	O
several	O
infection	B-DISO
control	O
steps	O
into	O
the	O
routine	O
precautions	O
used	O
during	O
all	O
dental	O
procedures	O
.	O

TITLE	O
:	O
Acute	O
respiratory	B-DISO
symptoms	I-DISO
in	O
adults	O
in	O
general	O
practice	O
.	O

There	O
were	O
no	O
differences	O
in	O
clinical	O
presentation	O
and	O
socio	O
-	O
demographic	O
variables	O
between	O
patients	O
who	O
had	O
viral	B-DISO
infections	I-DISO
and	O
those	O
in	O
whom	O
no	O
pathogen	O
could	O
be	O
identified	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
clinical	O
characteristics	O
and	O
long	O
-	O
term	O
effects	O
of	O
SARS	B-DISO
.	O

TITLE	O
:	O
[	O
Prognostic	O
analysis	O
of	O
lung	O
function	O
and	O
chest	O
X	O
-	O
ray	O
changes	O
of	O
258	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
rehabilitation	O
after	O
discharge	O
].	O

RESULTS	O
:	O
80	O
.	O
6	O
%	O
patients	O
(	O
208	O
of	O
258	O
patients	O
)	O
were	O
positive	O
for	O
SARS	B-DISO
-	O
Co	O
virus	O
IgG	O
.	O
21	O
.	O
3	O
%	O
patients	O
(	O
55	O
of	O
258	O
patients	O
)	O
showed	O
lung	O
diffusion	O
abnormity	O
(	O
D	O
(	O
LCO	O
)	O
<	O
80	O
%	O
pred	O
).	O

ABSTRACT	O
:	O
To	O
establish	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
model	O
in	O
canine	O
after	O
inhalation	O
of	O
perfluoroisobutylene	O
(	O
PFIB	O
),	O
and	O
to	O
observe	O
the	O
progressing	O
of	O
lung	O
injury	O
,	O
and	O
to	O
study	O
the	O
mechanisms	O
of	O
injury	O
.	O

Clinical	O
manifestations	O
,	O
pathology	B-DISO
of	O
organs	O
in	O
canine	O
were	O
observed	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
two	O
second	O
-	O
generation	O
,	O
replicase	O
(	O
R	O
)	O
gene	O
-	O
based	O
,	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
test	O
kits	O
--	O
the	O
RealArt	O
HPA	O
coronavirus	O
LC	O
kit	O
(	O
Artus	O
,	O
Hamburg	O
,	O
Germany	O
)	O
and	O
the	O
LightCycler	O
SARS	B-DISO
-	O
CoV	O
quantification	O
kit	O
(	O
Roche	O
,	O
Penzberg	O
,	O
Germany	O
)--	O
and	O
a	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assay	O
for	O
the	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
.	O

A	O
total	O
of	O
812	O
people	O
died	O
due	O
to	O
respiratory	B-DISO
insufficiency	I-DISO
.	O

The	O
Artus	O
assay	O
is	O
also	O
suitable	O
for	O
detection	O
of	O
SARS	B-DISO
CoV	O
at	O
the	O
low	O
concentrations	O
found	O
in	O
serum	O
samples	O
.	O

TITLE	O
:	O
Detection	O
of	O
specific	O
antibodies	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
nucleocapsid	O
protein	O
for	O
serodiagnosis	O
of	O
SARS	B-DISO
coronavirus	O
pneumonia	B-DISO
.	O

Direct	O
reaction	O
bilirubin	O
(	O
DBil	O
),	O
total	O
bile	O
acid	O
(	O
TBA	O
),	O
gamma	O
-	O
glutamyltransferase	O
(	O
GGT	O
)	O
and	O
alkaline	O
phosphatase	O
(	O
ALP	O
)	O
showed	O
no	O
marked	O
difference	O
between	O
SARS	B-DISO
patients	O
and	O
controls	O
,	O
all	O
P	O
>	O
0	O
.	O
05	O
.	O

Histopathology	O
of	O
liver	O
was	O
non	O
-	O
specific	O
hepatitis	B-DISO
.	O

Clinical	O
date	O
of	O
30	O
SARS	B-DISO
patients	O
without	O
other	O
diseases	O
in	O
whom	O
corticosteroid	O
was	O
used	O
were	O
reviewed	O
including	O
total	O
dosage	O
,	O
duration	O
of	O
use	O
,	O
the	O
highest	O
dosage	O
and	O
its	O
duration	O
,	O
and	O
speed	O
of	O
reduction	O
in	O
dosage	O
.	O

CONCLUSIONS	O
:	O
The	O
incidence	O
of	O
pneumothorax	B-DISO
and	O
mediastinal	B-DISO
emphysema	I-DISO
in	O
serious	O
SARS	B-DISO
patients	O
with	O
NIPPV	O
is	O
significantly	O
higher	O
than	O
that	O
in	O
SARS	B-DISO
patients	O
without	O
receiving	O
MV	O
.	O

This	O
therapy	O
of	O
oxygen	O
-	O
enriched	O
liquid	O
infusion	O
could	O
be	O
quite	O
life	O
-	O
saving	O
in	O
the	O
combined	O
treatment	O
for	O
SARS	B-DISO
and	O
other	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

One	O
-	O
step	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
was	O
used	O
to	O
amplify	O
the	O
SARS	B-DISO
RNA	O
in	O
the	O
clinical	O
specimens	O
from	O
different	O
courses	O
of	O
the	O
disease	O
.	O

The	O
fragments	O
amplified	O
from	O
the	O
sputum	O
specimens	O
of	O
SARS	B-DISO
patients	O
were	O
shown	O
to	O
share	O
100	O
%	O
homology	O
with	O
the	O
published	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
.	O

Using	O
flow	O
cytometry	O
,	O
the	O
absolute	O
numbers	O
of	O
peripheral	O
blood	O
lymphocytes	O
and	O
their	O
subpopulations	O
in	O
240	O
SARS	B-DISO
patients	O
(	O
696	O
specimens	O
)	O
and	O
51	O
individuals	O
as	O
controls	O
,	O
were	O
counted	O
and	O
compared	O
.	O

The	O
absolute	O
numbers	O
of	O
peripheral	O
blood	O
lymphocytes	O
and	O
their	O
subpopulations	O
in	O
SARS	B-DISO
patients	O
might	O
be	O
used	O
as	O
one	O
of	O
the	O
methods	O
for	O
diagnosis	O
on	O
the	O
severity	O
and	O
prognosis	O
of	O
the	O
disease	O
.	O

Approximately	O
20	O
%	O
of	O
the	O
participants	O
had	O
IES	O
scores	O
>	O
or	O
=	O
30	O
,	O
indicating	O
the	O
presence	O
of	O
post	B-DISO
-	I-DISO
traumatic	I-DISO
stress	I-DISO
disorder	I-DISO
(	O
PTSD	B-DISO
).	O

ABSTRACT	O
:	O
To	O
accelerate	O
the	O
development	O
of	O
drugs	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
we	O
constructed	O
a	O
homology	O
model	O
of	O
the	O
SARS	B-DISO
coronavirus	O
main	O
protease	O
using	O
our	O
modeling	O
software	O
,	O
FAMS	O
Ligand	O
&	O
Complex	O
,	O
and	O
released	O
it	O
before	O
the	O
X	O
-	O
ray	O
structure	O
was	O
solved	O
.	O

Transmission	O
electron	O
microscope	O
(	O
TEM	B-DISO
)	O
images	O
played	O
an	O
important	O
role	O
in	O
initial	O
identification	O
of	O
the	O
pathogen	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
caused	O
by	O
a	O
novel	O
coronavirus	O
termed	O
SARS	B-DISO
-	O
CoV	O
.	O
No	O
antiviral	O
treatment	O
has	O
been	O
established	O
so	O
far	O
.	O

To	O
detect	O
false	O
negative	O
results	O
due	O
to	O
PCR	O
inhibitors	O
or	O
faulty	O
RNA	O
extraction	O
,	O
we	O
have	O
further	O
modified	O
this	O
one	O
step	O
RT	O
-	O
PCR	O
assay	O
for	O
simultaneous	O
detection	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
CoV	O
)	O
and	O
18S	O
ribosomal	O
RNA	O
(	O
rRNA	O
)	O
as	O
an	O
internal	O
positive	O
control	O
.	O

TITLE	O
:	O
Decreased	O
sialylation	O
of	O
the	O
acute	O
phase	O
protein	O
alpha1	O
-	O
acid	O
glycoprotein	O
in	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
).	O

GVHD	B-DISO
prophylaxis	O
consisted	O
of	O
cyclosporine	O
.	O

TITLE	O
:	O
[	O
On	O
the	O
rational	O
exertion	O
for	O
the	O
prescriptions	O
and	O
drugs	O
of	O
TCM	O
in	O
preventing	O
and	O
treating	O
SARS	B-DISO
].	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
):	O
a	O
review	O
.	O

Among	O
the	O
peptides	O
used	O
in	O
the	O
study	O
,	O
the	O
affinity	O
of	O
peptides	O
from	O
HCoV	O
-	O
229e	O
(	O
H77	O
and	O
H881	O
)	O
and	O
peptides	O
from	O
SARS	B-DISO
-	O
CoV	O
(	O
S978	O
and	O
S1203	O
)	O
for	O
binding	O
to	O
HLA	O
-	O
A2	O
was	O
higher	O
than	O
that	O
of	O
other	O
sequences	O
.	O

Here	O
,	O
we	O
characterized	O
the	O
enzymatic	O
activities	O
of	O
a	O
recombinant	O
form	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
helicase	O
(	O
nonstructural	O
protein	O
[	O
nsp	O
]	O
13	O
),	O
a	O
superfamily	O
1	O
helicase	O
with	O
an	O
N	O
-	O
terminal	O
zinc	O
-	O
binding	O
domain	O
.	O

TITLE	O
:	O
pH	O
-	O
dependent	O
entry	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
is	O
mediated	O
by	O
the	O
spike	O
glycoprotein	O
and	O
enhanced	O
by	O
dendritic	O
cell	O
transfer	O
through	O
DC	O
-	O
SIGN	O
.	O

Both	O
cell	O
-	O
mediated	O
infection	B-DISO
and	O
direct	O
infection	B-DISO
were	O
inhibited	O
by	O
anti	O
-	O
S	O
antisera	O
,	O
indicating	O
that	O
strategies	O
directed	O
toward	O
this	O
gene	O
product	O
are	O
likely	O
to	O
confer	O
a	O
therapeutic	O
benefit	O
for	O
antiviral	O
drugs	O
or	O
the	O
development	O
of	O
a	O
SARS	B-DISO
vaccine	O
.	O

MHV	O
infection	B-DISO
in	O
quiescent	O
17Cl	O
-	O
1	O
cells	O
prevented	O
normal	O
increases	O
in	O
Cdk4	O
,	O
Cdk6	O
,	O
cyclin	O
D1	O
,	O
and	O
cyclin	O
D3	O
levels	O
after	O
serum	O
stimulation	O
.	O

The	O
amounts	O
of	O
cyclin	O
D2	O
and	O
cyclin	O
E	O
were	O
not	O
increased	O
significantly	O
after	O
serum	O
stimulation	O
in	O
mock	O
-	O
infected	O
cells	O
,	O
whereas	O
they	O
were	O
decreased	O
in	O
MHV	O
-	O
infected	O
cells	O
,	O
suggesting	O
the	O
possibility	O
that	O
MHV	O
infection	B-DISO
may	O
induce	O
cyclin	O
D2	O
and	O
cyclin	O
E	O
degradation	O
.	O

Peptide	O
-	O
conjugated	O
morpholino	O
-	O
oligomers	O
exhibited	O
low	O
toxicity	O
in	O
DBT	O
astrocytoma	B-DISO
cells	O
used	O
for	O
culturing	O
MHV	O
.	O

ABSTRACT	O
:	O
The	O
p28	O
and	O
p65	O
proteins	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
are	O
the	O
most	O
amino	O
-	O
terminal	O
protein	O
domains	O
of	O
the	O
replicase	O
polyprotein	O
.	O

TITLE	O
:	O
Reverse	O
genetic	O
analysis	O
of	O
the	O
transcription	O
regulatory	O
sequence	O
of	O
the	O
coronavirus	O
transmissible	O
gastroenteritis	B-DISO
virus	O
.	O

Hydroxyethyl	O
starch	O
(	O
HES	B-DISO
)-	O
induced	O
pruritus	B-DISO
was	O
diagnosed	O
,	O
based	O
on	O
the	O
typical	O
history	O
and	O
clinical	O
features	O
,	O
the	O
proven	O
administration	O
of	O
HES	B-DISO
and	O
its	O
cutaneous	O
tissue	O
storage	O
by	O
electron	O
microscopy	O
.	O

Drug	B-DISO
-	I-DISO
induced	I-DISO
pruritus	I-DISO
caused	O
by	O
the	O
plasma	O
expander	O
hydroxyethyl	O
starch	O
can	O
be	O
a	O
secondary	O
consequence	O
of	O
an	O
occupational	O
accident	O
and	O
thus	O
an	O
issue	O
in	O
accident	O
compensation	O
claims	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
a	O
murine	O
monoclonal	O
antibody	O
specific	O
for	O
SARS	B-DISO
-	O
CoV	O
nucleoprotein	O
,	O
and	O
probes	O
specific	O
for	O
a	O
SARS	B-DISO
-	O
CoV	O
RNA	O
polymerase	O
gene	O
fragment	O
,	O
for	O
immunohistochemistry	O
and	O
in	O
situ	O
hybridization	O
,	O
respectively	O
,	O
to	O
detect	O
SARS	B-DISO
-	O
CoV	O
systematically	O
in	O
tissues	O
from	O
patients	O
who	O
died	O
of	O
SARS	B-DISO
.	O

TITLE	O
:	O
Tissue	O
distribution	O
of	O
ACE2	O
protein	O
,	O
the	O
functional	O
receptor	O
for	O
SARS	B-DISO
coronavirus	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
an	O
acute	B-DISO
infectious	I-DISO
disease	I-DISO
that	O
spreads	O
mainly	O
via	O
the	O
respiratory	O
route	O
.	O

In	O
conclusion	O
,	O
ACE2	O
is	O
abundantly	O
present	O
in	O
humans	O
in	O
the	O
epithelia	O
of	O
the	O
lung	O
and	O
small	O
intestine	O
,	O
which	O
might	O
provide	O
possible	O
routes	O
of	O
entry	O
for	O
the	O
SARS	B-DISO
-	O
CoV	O
.	O
This	O
epithelial	O
expression	O
,	O
together	O
with	O
the	O
presence	O
of	O
ACE2	O
in	O
vascular	O
endothelium	O
,	O
also	O
provides	O
a	O
first	O
step	O
in	O
understanding	O
the	O
pathogenesis	B-DISO
of	O
the	O
main	O
SARS	B-DISO
disease	O
manifestations	O
.	O

We	O
summarize	O
our	O
understanding	O
from	O
anecdotal	O
experience	O
and	O
limited	O
published	O
data	O
on	O
the	O
use	O
of	O
antiviral	O
and	O
corticosteroid	O
therapy	O
in	O
the	O
management	O
of	O
this	O
highly	O
contagious	B-DISO
disease	I-DISO
.	O

The	O
outbreak	O
was	O
declared	O
contained	O
on	O
July	O
5	O
,	O
2003	O
,	O
after	O
the	O
last	O
human	O
chain	O
of	O
transmission	O
of	O
SARS	B-DISO
had	O
been	O
broken	O
.	O

Many	O
procedures	O
in	O
ICUs	O
pose	O
a	O
high	O
risk	O
for	O
transmission	O
of	O
SARS	B-DISO
coronavirus	O
to	O
health	O
care	O
workers	O
.	O

ABSTRACT	O
:	O
The	O
behavior	O
and	O
myelinogenic	O
properties	O
of	O
glial	O
cells	O
have	O
been	O
well	O
documented	O
following	O
transplantation	O
into	O
regions	O
of	O
focal	O
experimental	O
demyelination	B-DISO
in	O
animal	O
models	O
.	O

This	O
study	O
demonstrates	O
for	O
the	O
first	O
time	O
that	O
transplant	O
-	O
mediated	O
remyelination	O
is	O
possible	O
in	O
the	O
pathogenic	O
environment	O
of	O
the	O
MHV	O
demyelination	B-DISO
model	O
and	O
that	O
it	O
is	O
associated	O
with	O
locomotor	O
improvement	O
.	O

TITLE	O
:	O
HIV	B-DISO
protease	O
inhibitor	O
nelfinavir	O
inhibits	O
replication	O
of	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
.	O

In	O
this	O
report	O
,	O
virus	O
-	O
like	O
particles	O
were	O
assembled	O
in	O
insect	O
cells	O
by	O
the	O
co	B-DISO
-	I-DISO
infection	I-DISO
with	O
recombinant	O
baculoviruses	O
,	O
which	O
separately	O
express	O
one	O
of	O
these	O
three	O
virion	O
proteins	O
.	O

TITLE	O
:	O
SARS	B-DISO
update	O
:	O
Winter	O
,	O
2003	O
to	O
2004	O
.	O

ABSTRACT	O
:	O
Transmission	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
related	O
coronavirus	O
(	O
CoV	O
)	O
appears	O
to	O
be	O
heterogeneous	O
.	O

Occupational	O
health	O
nurses	O
should	O
""""	O
bookmark	O
""""	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
website	O
for	O
Public	O
Health	O
Guidance	O
for	O
Community	O
-	O
Level	O
Preparedness	O
and	O
Response	O
to	O
SARS	B-DISO
:	O
www	O
.	O
cdc	O
.	O
gov	O
/	O
ncidod	O
/	O
sars	B-DISO
/	O
clinicalguidance	O
.	O
htm	O
for	O
easy	O
retrieval	O
and	O
reference	O
.	O

ABSTRACT	O
:	O
The	O
effect	O
of	O
storage	O
temperature	O
was	O
determined	O
for	O
the	O
detection	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
and	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
in	O
fecal	O
samples	O
from	O
experimentally	O
and	O
naturally	O
infected	O
pigs	O
by	O
multiplex	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

This	O
issue	O
,	O
coupled	O
with	O
recent	O
outbreaks	O
of	O
illnesses	O
that	O
pose	O
a	O
direct	O
risk	O
to	O
ICU	O
staff	O
(	O
such	O
as	O
SARS	B-DISO
[	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
]),	O
has	O
led	O
to	O
renewed	O
emphasis	O
on	O
infection	B-DISO
control	O
measures	O
and	O
practitioners	O
in	O
the	O
ICU	O
.	O

TITLE	O
:	O
Virtual	O
screening	O
for	O
SARS	B-DISO
-	O
CoV	O
protease	O
based	O
on	O
KZ7088	O
pharmacophore	O
points	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
epidemiological	O
and	O
clinical	O
features	O
of	O
paediatric	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
Singapore	O
.	O

The	O
following	O
data	O
were	O
retrospectively	O
collected	O
from	O
the	O
case	O
records	O
of	O
all	O
71	O
patients	O
(	O
aged	O
7	O
months	O
to	O
14	O
years	O
)	O
admitted	O
from	O
23	O
March	O
to	O
22	O
May	O
2003	O
to	O
the	O
SARS	B-DISO
paediatric	O
unit	O
:	O
patient	O
demographics	O
,	O
contact	O
history	O
,	O
clinical	O
features	O
,	O
physiological	O
parameters	O
,	O
investigations	O
,	O
treatment	O
,	O
and	O
outcome	O
.	O

We	O
found	O
an	O
increase	O
in	O
eGFP	O
fluorescence	O
in	O
specific	O
brain	O
areas	O
in	O
cells	O
suffering	B-DISO
or	O
reacting	O
to	O
these	O
injuries	O
.	O

This	O
may	O
be	O
the	O
cause	O
why	O
the	O
cases	O
with	O
SARS	B-DISO
in	O
children	O
is	O
much	O
less	O
than	O
in	O
adults	O
.	O

TITLE	O
:	O
Viral	B-DISO
shedding	I-DISO
patterns	O
of	O
coronavirus	O
in	O
patients	O
with	O
probable	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

The	O
main	O
goal	O
was	O
twofold	O
:	O
first	O
,	O
to	O
analyze	O
and	O
compare	O
nucleotide	O
sequences	O
and	O
to	O
identify	O
positions	O
of	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
),	O
insertions	O
and	O
deletions	O
,	O
and	O
second	O
,	O
to	O
group	O
them	O
according	O
to	O
sequence	O
similarity	O
,	O
eventually	O
pointing	O
to	O
phylogeny	O
of	O
SARS	B-DISO
-	O
CoV	O
isolates	O
.	O

Finally	O
,	O
a	O
phylogenetic	O
tree	O
for	O
the	O
SARS	B-DISO
-	O
CoV	O
isolates	O
has	O
been	O
produced	O
using	O
the	O
CLUSTALW	O
program	O
,	O
showing	O
high	O
compatibility	O
with	O
former	O
qualitative	O
classification	O
.	O

We	O
found	O
that	O
lectin	O
PHA	B-DISO
-	O
L	O
(	O
Phaseolus	O
vulgaris	O
L	O
.),	O
which	O
is	O
specific	O
for	O
a	O
defined	O
complex	O
carbohydrate	O
of	O
ASOR	O
,	O
stained	O
the	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
cells	O
specifically	O
and	O
intensively	O
.	O

TITLE	O
:	O
Structural	O
characterization	O
of	O
the	O
fusion	O
-	O
active	O
complex	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
.	O

ABSTRACT	O
:	O
The	O
causative	O
agent	O
of	O
a	O
recent	O
outbreak	O
of	O
an	O
atypical	B-DISO
pneumonia	I-DISO
,	O
known	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
has	O
been	O
identified	O
as	O
a	O
coronavirus	O
(	O
CoV	O
)	O
not	O
belonging	O
to	O
any	O
of	O
the	O
previously	O
identified	O
groups	O
.	O

HR1	O
and	O
HR2	O
of	O
SARS	B-DISO
-	O
CoV	O
associate	O
into	O
an	O
antiparallel	O
six	O
-	O
helix	O
bundle	O
,	O
with	O
structural	O
features	O
typical	O
of	O
the	O
other	O
known	O
class	O
I	O
fusion	O
proteins	O
.	O

Abnormal	O
liver	O
functions	O
were	O
common	O
in	O
patients	O
with	O
SARS	B-DISO
and	O
could	O
be	O
associated	O
with	O
virus	O
replication	O
in	O
the	O
liver	O
.	O

Specific	O
antibody	O
responses	O
to	O
the	O
purified	O
recombinant	O
N	O
protein	O
after	O
10	O
,	O
20	O
,	O
and	O
30	O
days	O
of	O
disease	O
onset	O
were	O
observed	O
in	O
13	O
of	O
16	O
(	O
81	O
.	O
3	O
%),	O
16	O
of	O
16	O
(	O
100	O
%)	O
and	O
16	O
of	O
16	O
(	O
100	O
%)	O
SARS	B-DISO
patients	O
sera	O
,	O
respectively	O
.	O

Comparison	O
of	O
detection	O
results	O
with	O
a	O
commercially	O
available	O
diagnostic	O
kit	O
coated	O
with	O
a	O
mixture	O
of	O
SARS	B-DISO
-	O
CoV	O
viral	O
proteins	O
showed	O
9	O
of	O
16	O
(	O
56	O
.	O
3	O
%),	O
13	O
of	O
16	O
(	O
81	O
.	O
3	O
%),	O
and	O
15	O
of	O
16	O
(	O
93	O
.	O
7	O
%)	O
positive	O
responses	O
,	O
respectively	O
.	O

The	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
was	O
found	O
to	O
be	O
expressed	O
at	O
the	O
cell	O
surface	O
upon	O
transient	O
transfection	O
.	O

Inhibition	O
of	O
vacuolar	O
acidification	O
impaired	B-DISO
infection	B-DISO
by	O
SARS	B-DISO
-	O
CoV	O
S	O
-	O
bearing	O
pseudotypes	O
,	O
indicating	O
that	O
S	O
-	O
mediated	O
entry	O
requires	O
low	O
pH	O
.	O
Finally	O
,	O
infection	B-DISO
by	O
SARS	B-DISO
-	O
CoV	O
S	O
pseudotypes	O
but	O
not	O
by	O
vesicular	B-DISO
stomatitis	I-DISO
virus	O
G	O
pseudotypes	O
was	O
efficiently	O
inhibited	O
by	O
a	O
rabbit	O
serum	O
raised	O
against	O
SARS	B-DISO
-	O
CoV	O
particles	O
and	O
by	O
sera	O
from	O
SARS	B-DISO
patients	O
,	O
demonstrating	O
that	O
SARS	B-DISO
-	O
CoV	O
S	O
is	O
a	O
target	O
for	O
neutralizing	O
antibodies	O
and	O
that	O
such	O
antibodies	O
are	O
generated	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
patients	O
.	O

Our	O
results	O
show	O
that	O
viral	O
pseudotyping	O
can	O
be	O
employed	O
for	O
the	O
analysis	O
of	O
SARS	B-DISO
-	O
CoV	O
S	O
function	O
.	O

Moreover	O
,	O
we	O
provide	O
evidence	O
that	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
might	O
not	O
be	O
limited	O
to	O
lung	O
tissue	O
and	O
can	O
be	O
inhibited	O
by	O
the	O
humoral	O
immune	O
response	O
in	O
infected	O
patients	O
.	O

Indeed	O
these	O
molecular	O
markers	O
are	O
very	O
useful	O
for	O
diagnosing	O
thrombus	B-DISO
formation	O
,	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
(	O
DIC	B-DISO
),	O
and	O
the	O
indicator	O
of	O
treatment	O
of	O
DIC	B-DISO
.	O

But	O
these	O
molecular	O
parameters	O
are	O
not	O
enough	O
and	O
difficult	O
for	O
prognosis	O
of	O
the	O
disease	O
or	O
predicting	O
the	O
complication	B-DISO
of	O
patients	O
as	O
the	O
most	O
important	O
subject	O
for	O
clinicians	O
.	O

Especially	O
,	O
ALI	O
followed	O
by	O
pneumoniae	O
associated	O
with	O
SIRS	B-DISO
could	O
depend	O
on	O
patient	O
'	O
s	O
prognosis	O
and	O
life	O
.	O

Neurological	B-DISO
symptoms	I-DISO
were	O
observed	O
only	O
in	O
one	O
pup	O
.	O

TITLE	O
:	O
ACE2	O
:	O
from	O
vasopeptidase	O
to	O
SARS	B-DISO
virus	O
receptor	O
.	O

We	O
have	O
used	O
a	O
replicon	O
RNA	O
-	O
containing	O
cell	O
line	O
to	O
test	O
the	O
inhibitory	O
effect	O
of	O
several	O
compounds	O
that	O
are	O
currently	O
being	O
assessed	O
for	O
SARS	B-DISO
treatment	O
.	O

TITLE	O
:	O
Infection	B-DISO
control	O
measures	O
for	O
operative	O
procedures	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
related	O
patients	O
.	O

During	O
the	O
outbreak	O
,	O
Tan	O
Tock	O
Seng	O
Hospital	O
was	O
designated	O
as	O
the	O
national	O
SARS	B-DISO
hospital	O
in	O
Singapore	O
to	O
manage	O
all	O
known	O
SARS	B-DISO
patients	O
.	O

Lessons	O
learned	O
during	O
this	O
outbreak	O
will	O
help	O
in	O
the	O
planning	O
and	O
execution	O
of	O
infection	B-DISO
control	O
measures	O
,	O
should	O
another	O
outbreak	O
occur	O
.	O

In	O
recent	O
years	O
,	O
there	O
has	O
been	O
a	O
special	O
interest	O
in	O
the	O
study	O
of	O
genetic	O
predisposition	O
to	O
development	O
ALI	O
/	O
ARDS	B-DISO
.	O

Worldwide	O
collaboration	O
led	O
to	O
the	O
rapid	O
identification	O
and	O
gene	O
sequencing	O
of	O
the	O
etiologic	O
virus	O
,	O
SARS	B-DISO
-	O
CoV	O
.	O
SARS	B-DISO
is	O
a	O
predominantly	O
respiratory	O
illness	O
,	O
spread	O
through	O
droplets	O
from	O
respiratory	O
secretions	O
and	O
possibly	O
via	O
a	O
fecal	O
-	O
oral	O
route	O
.	O

TITLE	O
:	O
Real	O
-	O
time	O
syndrome	B-DISO
surveillance	O
in	O
Ontario	O
,	O
Canada	O
:	O
the	O
potential	O
use	O
of	O
emergency	B-DISO
departments	O
and	O
Telehealth	O
.	O

The	O
purpose	O
of	O
this	O
paper	O
is	O
to	O
review	O
new	O
bioterrorist	O
and	O
emerging	O
infectious	B-DISO
threats	O
to	O
public	O
health	O
in	O
Ontario	O
,	O
Canada	O
,	O
and	O
to	O
propose	O
a	O
means	O
of	O
integrating	O
a	O
telephone	O
-	O
based	O
health	O
information	O
service	O
and	O
emergency	B-DISO
department	O
triage	O
with	O
a	O
first	O
-	O
line	O
real	O
-	O
time	O
,	O
24	O
-	O
h	O
a	O
day	O
syndrome	B-DISO
surveillance	O
system	O
.	O

TITLE	O
:	O
SARS	B-DISO
coronavirus	O
induces	O
apoptosis	O
in	O
Vero	O
E6	O
cells	O
.	O

Infection	B-DISO
-	O
induced	O
apoptosis	O
or	O
necrosis	O
is	O
suspected	O
but	O
no	O
direct	O
evidence	O
for	O
this	O
yet	O
exists	O
.	O

This	O
observation	O
has	O
some	O
implications	O
for	O
the	O
SARS	B-DISO
-	O
CoV	O
pathogenicity	O
:	O
SARS	B-DISO
-	O
CoV	O
does	O
induce	O
apoptosis	O
in	O
cell	O
cultures	O
and	O
might	O
have	O
the	O
same	O
effect	O
in	O
vivo	O
,	O
responsible	O
for	O
the	O
severe	O
damage	O
of	O
the	O
respiratory	O
system	O
.	O

Serum	O
specimens	O
from	O
40	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
patients	O
in	O
the	O
convalescent	O
phase	O
were	O
analyzed	O
by	O
Western	O
blotting	O
using	O
the	O
purified	O
antigens	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
epidemiologic	O
,	O
clinical	O
,	O
laboratory	O
,	O
and	O
radiologic	O
features	O
,	O
prognostic	O
indicators	O
,	O
and	O
short	O
-	O
term	O
to	O
medium	O
-	O
term	O
outcomes	O
for	O
children	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
to	O
validate	O
the	O
performance	O
characteristics	O
of	O
a	O
clinical	O
case	O
definition	O
,	O
calculated	O
with	O
respect	O
to	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
)	O
seroconversion	O
.	O

Children	O
<	O
18	O
years	O
of	O
age	O
,	O
from	O
a	O
single	O
-	O
site	O
outbreak	O
,	O
who	O
satisfied	O
a	O
clinical	O
case	O
definition	O
for	O
SARS	B-DISO
,	O
with	O
subsequent	O
serologic	O
confirmation	O
,	O
were	O
treated	O
according	O
to	O
a	O
standard	O
protocol	O
and	O
prospectively	O
monitored	O
.	O

The	O
kit	O
""""	O
AmpliSens	O
SARS	B-DISO
""""	O
for	O
qualitative	O
detection	O
of	O
SARS	B-DISO
-	O
related	O
coronavirus	O
RNA	O
by	O
reverse	O
transcription	O
and	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
in	O
nasopharyngeal	O
wash	O
/	O
aspirates	O
,	O
naso	O
/	O
oropharyngeal	O
swabs	O
,	O
plasma	O
,	O
and	O
extract	O
from	O
feces	O
has	O
been	O
developed	O
in	O
the	O
Central	O
Research	O
Institute	O
for	O
Epidemiology	O
of	O
the	O
RF	O
Ministry	O
of	O
Health	O
.	O

RESULTS	O
:	O
The	O
specificity	O
of	O
the	O
kit	O
was	O
determined	O
using	O
animal	O
coronaviruses	O
and	O
other	O
bacterial	O
and	O
viral	O
strains	O
,	O
causing	O
acute	O
respiratory	O
and	O
intestinal	B-DISO
infections	I-DISO
,	O
and	O
was	O
shown	O
to	O
be	O
100	O
%.	O

Detection	O
of	O
the	O
SARS	B-DISO
-	O
Cov	O
RNA	O
was	O
more	O
effective	O
in	O
feces	O
compared	O
to	O
sputum	O
990	O
and	O
40	O
%,	O
respectively	O
).	O

The	O
emergence	O
of	O
new	O
respiratory	O
viruses	O
and	O
a	O
high	O
probability	O
that	O
influenza	B-DISO
will	O
cause	O
further	O
pandemics	O
highlights	O
the	O
necessity	O
for	O
developing	O
better	O
preventative	O
strategies	O
.	O

The	O
NSW	O
law	O
can	O
also	O
be	O
applied	O
to	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
or	O
HIV	B-DISO
/	I-DISO
AIDS	I-DISO
.	O

The	O
role	O
of	O
food	B-DISO
allergy	I-DISO
in	O
otitis	B-DISO
media	I-DISO
is	O
controversial	O
,	O
probably	O
uncommon	O
,	O
and	O
further	O
studies	O
are	O
needed	O
.	O

Asthma	B-DISO
induced	O
by	O
food	B-DISO
allergy	I-DISO
is	O
considered	O
a	O
risk	O
factor	O
for	O
fatal	O
and	O
near	O
-	O
fatal	O
anaphylactic	B-DISO
reactions	I-DISO
.	O

Despite	O
concerns	O
raised	O
by	O
professional	O
societies	O
about	O
the	O
erosion	B-DISO
of	O
professionalism	O
,	O
participants	O
in	O
this	O
study	O
amply	O
demonstrated	O
the	O
necessary	O
qualities	O
during	O
the	O
recent	O
healthcare	O
crisis	O
.	O

TITLE	O
:	O
Public	O
health	O
measures	O
to	O
control	O
the	O
spread	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
during	O
the	O
outbreak	O
in	O
Toronto	O
.	O

ABSTRACT	O
:	O
Toronto	O
was	O
the	O
site	O
of	O
North	O
America	O
'	O
s	O
largest	O
outbreak	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Unrecognized	O
SARS	B-DISO
among	O
in	O
-	O
patients	O
with	O
underlying	O
illness	O
caused	O
a	O
resurgence	O
,	O
or	O
a	O
second	O
phase	O
,	O
of	O
the	O
outbreak	O
,	O
which	O
was	O
finally	O
controlled	O
through	O
active	O
surveillance	O
of	O
hospitalized	O
patients	O
.	O

For	O
every	O
case	O
of	O
SARS	B-DISO
,	O
health	O
authorities	O
should	O
expect	O
to	O
quarantine	O
up	O
to	O
100	O
contacts	O
of	O
the	O
patients	O
and	O
to	O
investigate	O
8	O
possible	O
cases	O
.	O

First	O
high	O
fever	O
,	O
parainfluenza	B-DISO
syndrome	B-DISO
followed	O
by	O
increasing	O
respiratory	B-DISO
distress	I-DISO
.	O

The	O
study	O
defines	O
172	O
nurses	O
'	O
willingness	O
to	O
provide	O
care	O
for	O
SARS	B-DISO
patients	O
as	O
a	O
professional	O
obligation	O
regardless	O
of	O
the	O
nature	O
of	O
the	O
disease	O
.	O

Several	O
proteins	O
known	O
to	O
be	O
cleaved	O
by	O
other	O
viruses	O
were	O
submitted	O
to	O
prediction	O
as	O
well	O
as	O
proteins	O
suspected	O
relevant	O
in	O
coronavirus	O
pathology	B-DISO
.	O

Cleavage	O
sites	O
were	O
predicted	O
in	O
proteins	O
such	O
as	O
the	O
cystic	B-DISO
fibrosis	I-DISO
transmembrane	O
conductance	O
regulator	O
(	O
CFTR	O
),	O
transcription	O
factors	O
CREB	O
-	O
RP	O
and	O
OCT	O
-	O
1	O
,	O
and	O
components	O
of	O
the	O
ubiquitin	O
pathway	O
.	O

Pneumomediastinum	B-DISO
should	O
be	O
considered	O
in	O
SARS	B-DISO
patients	O
as	O
a	O
possible	O
cause	O
of	O
chest	B-DISO
pain	I-DISO
and	O
ECG	O
changes	O
that	O
mimic	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
highly	O
contagious	O
and	O
sometimes	O
a	O
lethal	O
disease	O
,	O
which	O
spread	O
over	O
five	O
continents	O
in	O
2002	O
-	O
2003	O
.	O

HR1	O
-	O
1	O
and	O
HR2	O
-	O
18	O
can	O
serve	O
as	O
functional	O
probes	O
for	O
dissecting	O
the	O
fusion	O
mechanism	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
also	O
provide	O
the	O
potential	O
of	O
further	O
identifying	O
potent	O
inhibitors	O
for	O
SARS	B-DISO
-	O
CoV	O
entry	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
a	O
major	O
virion	O
structural	O
protein	O
.	O

Among	O
six	O
fusion	O
peptides	O
,	O
S5	O
reacted	O
with	O
monoclonal	O
antibody	O
D3C5	O
and	O
S2	O
reacted	O
with	O
monoclonal	O
antibody	O
D3D1	O
against	O
spike	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
epitopes	O
recognized	O
by	O
monoclonal	O
antibodies	O
D3C5	O
and	O
D3D1	O
are	O
linear	O
,	O
and	O
correspond	O
to	O
447	O
-	O
458	O
and	O
789	O
-	O
799	O
amino	O
acids	O
of	O
spike	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
a	O
sensitive	O
and	O
quantitative	O
antigen	O
capture	O
ELISA	O
was	O
established	O
for	O
the	O
early	O
diagnosis	O
and	O
disease	O
monitoring	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Altered	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
expression	O
in	O
different	O
leukocytes	O
with	O
increment	O
of	O
immunosuppressive	O
mediators	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Pneumothorax	B-DISO
is	O
a	O
frequent	O
and	O
potentially	O
fatal	O
complication	B-DISO
of	O
mechanical	O
ventilation	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

TITLE	O
:	O
[	O
Preparatory	O
guidelines	O
for	O
local	O
health	O
services	O
on	O
how	O
to	O
respond	O
to	O
new	O
cases	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)].	O

ABSTRACT	O
:	O
The	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
CDC	O
)	O
of	O
the	O
United	O
States	O
of	O
America	O
recently	O
issued	O
a	O
set	O
of	O
guidelines	O
on	O
how	O
different	O
community	O
health	O
services	O
should	O
prepare	O
for	O
and	O
respond	O
to	O
the	O
reemergence	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

If	O
cases	O
of	O
transmission	O
of	O
SARS	B-DISO
-	O
CoV	O
have	O
been	O
reported	O
,	O
the	O
aim	O
should	O
be	O
to	O
immediately	O
identify	O
and	O
notify	O
any	O
cases	O
detected	O
in	O
order	O
to	O
take	O
appropriate	O
diagnostic	O
and	O
therapeutic	O
measures	O
and	O
to	O
facilitate	O
outbreak	O
control	O
.	O

TITLE	O
:	O
A	O
corn	B-DISO
-	O
based	O
delivery	O
system	O
for	O
animal	O
vaccines	O
:	O
an	O
oral	O
transmissible	O
gastroenteritis	B-DISO
virus	O
vaccine	O
boosts	O
lactogenic	O
immunity	O
in	O
swine	O
.	O

A	O
subunit	O
vaccine	O
candidate	O
directed	O
against	O
porcine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
virus	O
and	O
expressed	O
in	O
corn	B-DISO
seed	O
has	O
been	O
developed	O
for	O
oral	O
delivery	O
to	O
swine	O
.	O

Here	O
we	O
show	O
that	O
ACE2	O
expression	O
on	O
cell	O
lines	O
correlates	O
with	O
susceptibility	O
to	O
SARS	B-DISO
-	O
CoV	O
S	O
-	O
driven	O
infection	B-DISO
,	O
suggesting	O
that	O
ACE2	O
is	O
a	O
major	O
receptor	O
for	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
soluble	O
ectodomain	O
of	O
ACE2	O
specifically	O
abrogated	O
S	O
-	O
mediated	O
infection	B-DISO
and	O
might	O
therefore	O
be	O
exploited	O
for	O
the	O
generation	O
of	O
inhibitors	O
.	O

Our	O
results	O
point	O
to	O
a	O
central	O
role	O
of	O
ACE2	O
in	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
and	O
suggest	O
a	O
minor	O
contribution	O
of	O
the	O
cytoplasmic	O
domain	O
to	O
receptor	O
function	O
.	O

However	O
,	O
most	O
of	O
the	O
diagnostic	O
methods	O
available	O
today	O
,	O
such	O
as	O
real	O
-	O
time	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
require	O
a	O
second	O
detection	O
method	O
for	O
confirmation	O
because	O
they	O
detect	O
a	O
single	O
sequence	O
region	O
of	O
the	O
SARS	B-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

To	O
investigate	O
SCoV	O
S	O
protein	O
,	O
full	O
-	O
length	O
and	O
individual	O
domains	O
of	O
S	O
protein	O
were	O
expressed	O
on	O
the	O
surface	O
of	O
insect	O
cells	O
and	O
were	O
characterized	O
for	O
cleavability	O
and	O
reactivity	O
with	O
serum	O
samples	O
obtained	O
from	O
patients	O
during	O
the	O
convalescent	O
phase	O
of	O
SARS	B-DISO
.	O

TITLE	O
:	O
Porcine	O
surfactant	O
(	O
Curosurf	O
)	O
for	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
after	O
near	O
-	O
drowning	O
in	O
12	O
year	O
old	O
.	O

Among	O
these	O
patients	O
,	O
five	O
were	O
placed	O
in	O
an	O
isolation	O
unit	O
to	O
rule	O
out	O
SARS	B-DISO
infection	B-DISO
during	O
this	O
period	O
of	O
time	O
,	O
and	O
no	O
patient	O
was	O
documented	O
to	O
have	O
suffered	B-DISO
from	O
a	O
SARS	B-DISO
infection	B-DISO
after	O
examinations	O
.	O

Thirty	O
-	O
seven	O
patients	O
(	O
63	O
.	O
8	O
%)	O
were	O
afraid	O
of	O
visiting	O
hospital	O
during	O
this	O
SARS	B-DISO
infection	B-DISO
period	O
.	O

Gas	O
insufflation	O
through	O
the	O
trachea	B-DISO
is	O
a	O
promising	O
therapeutic	O
option	O
for	O
correcting	O
hypercapnia	B-DISO
secondary	O
to	O
ventilation	O
for	O
lung	O
protection	O
in	O
such	O
patients	O
.	O

TITLE	O
:	O
SARS	B-DISO
in	O
healthcare	O
facilities	O
,	O
Toronto	O
and	O
Taiwan	O
.	O

ABSTRACT	O
:	O
The	O
healthcare	O
setting	O
was	O
important	O
in	O
the	O
early	O
spread	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
both	O
Toronto	O
and	O
Taiwan	O
.	O

Healthcare	O
workers	O
,	O
patients	O
,	O
and	O
visitors	O
were	O
at	O
increased	O
risk	O
for	O
infection	B-DISO
.	O

Unrecognized	O
SARS	B-DISO
case	O
-	O
patients	O
were	O
a	O
primary	O
source	O
of	O
transmission	O
,	O
and	O
early	O
detection	O
and	O
intervention	O
were	O
important	O
to	O
limit	O
spread	O
.	O

These	O
observations	O
indicate	O
that	O
although	O
transmission	O
by	O
direct	O
contact	O
with	O
known	O
SARS	B-DISO
patients	O
was	O
responsible	O
for	O
most	O
cases	O
,	O
environmental	O
contamination	O
with	O
the	O
SARS	B-DISO
coronavirus	O
may	O
have	O
lead	O
to	O
infection	B-DISO
among	O
healthcare	O
workers	O
without	O
documented	O
contact	O
with	O
known	O
hospitalized	O
SARS	B-DISO
patients	O
.	O

TITLE	O
:	O
Domestic	O
poultry	O
and	O
SARS	B-DISO
coronavirus	O
,	O
southern	O
China	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
an	O
infectious	B-DISO
disease	I-DISO
caused	O
by	O
a	O
newly	O
identified	O
human	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
new	O
infectious	B-DISO
disease	I-DISO
that	O
caused	O
a	O
global	O
outbreak	O
in	O
2003	O
.	O

Tear	O
samples	O
were	O
collected	O
from	O
36	O
consecutive	O
patients	O
who	O
were	O
suspected	O
of	O
having	O
SARS	B-DISO
in	O
Singapore	O
over	O
a	O
period	O
of	O
12	O
days	O
(	O
7	O
-	O
18	O
April	O
2003	O
),	O
and	O
analysed	O
by	O
PCR	O
using	O
protocols	O
developed	O
by	O
the	O
WHO	O
network	O
of	O
laboratories	O
.	O

TITLE	O
:	O
SARS	B-DISO
exposure	O
and	O
emergency	B-DISO
department	O
workers	O
.	O

TITLE	O
:	O
[	O
The	O
expression	O
and	O
activity	O
detection	O
of	O
a	O
variant	O
N	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
].	O

ABSTRACT	O
:	O
To	O
report	O
the	O
incidence	O
of	O
avascular	O
osteonecrosis	B-DISO
(	O
AVN	O
)	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
.	O

AVN	O
can	O
occur	O
in	O
the	O
patients	O
with	O
SARS	B-DISO
.	O

We	O
hypothesized	O
that	O
NO	O
production	O
from	O
NOS2	O
expressed	O
in	O
lung	O
parenchymal	O
cells	O
in	O
a	O
murine	O
model	O
of	O
ARDS	B-DISO
would	O
correlate	O
with	O
abnormal	O
surfactant	O
function	O
and	O
reduced	O
surfactant	O
protein	O
-	O
B	O
(	O
SP	O
-	O
B	O
)	O
expression	O
.	O

Chest	O
radiographs	O
demonstrated	O
severe	O
left	O
lung	O
atelectasis	B-DISO
,	O
and	O
surgery	O
was	O
postponed	O
.	O

TITLE	O
:	O
Childhood	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
coronavirus	B-DISO
infections	I-DISO
and	O
asthma	B-DISO
.	O

The	O
exact	O
reasons	O
as	O
to	O
why	O
SARS	B-DISO
preferentially	O
affects	O
adults	O
,	O
and	O
not	O
children	O
,	O
are	O
still	O
unknown	O
.	O

This	O
vector	O
provided	O
direct	O
immunization	O
of	O
the	O
respiratory	O
tract	O
,	O
the	O
major	O
site	O
of	O
SARS	B-DISO
transmission	O
,	O
replication	O
,	O
and	O
disease	O
.	O

These	O
results	O
identify	O
S	O
among	O
the	O
structural	O
proteins	O
as	O
the	O
only	O
significant	O
SARS	B-DISO
-	O
CoV	O
neutralization	O
antigen	O
and	O
protective	O
antigen	O
and	O
show	O
that	O
a	O
single	O
mucosal	O
immunization	O
is	O
highly	O
protective	O
in	O
an	O
experimental	O
animal	O
that	O
supports	O
efficient	O
replication	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O

The	O
occurence	O
of	O
hypencapnia	O
or	O
CO	O
(	O
2	O
)	O
retention	O
and	O
was	O
accompanied	O
by	O
myalgias	B-DISO
.	O

Dialysis	O
patients	O
with	O
SARS	B-DISO
often	O
require	O
prolonged	O
hospitalization	O
.	O

It	O
is	O
now	O
known	O
that	O
the	O
clinical	O
course	O
and	O
prognosis	O
are	O
different	O
between	O
paediatric	O
and	O
adult	O
SARS	B-DISO
patients	O
.	O

Young	O
children	O
(<	O
12	O
years	O
),	O
in	O
general	O
,	O
run	O
a	O
less	O
aggressive	B-DISO
clinical	O
course	O
than	O
do	O
teenage	O
and	O
adult	O
patients	O
.	O

ABSTRACT	O
:	O
Spontaneous	O
pneumomediastinum	B-DISO
(	O
SP	O
)	O
unrelated	O
to	O
assisted	O
ventilation	O
is	O
a	O
newly	O
recognised	O
complication	B-DISO
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

In	O
conclusion	O
,	O
spontaneous	O
pneumomediastinum	B-DISO
appeared	O
to	O
be	O
a	O
frequent	O
complication	B-DISO
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Human	O
monoclonal	O
antibody	O
as	O
prophylaxis	O
for	O
SARS	B-DISO
coronavirus	B-DISO
infection	I-DISO
in	O
ferrets	O
.	O

We	O
investigated	O
prophylaxis	O
of	O
SARS	B-DISO
coronavirus	B-DISO
infection	I-DISO
with	O
a	O
neutralising	O
human	O
monoclonal	O
antibody	O
in	O
ferrets	O
,	O
which	O
can	O
be	O
readily	O
infected	O
with	O
the	O
virus	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
coronavirus	O
(	O
CoV	O
)	O
has	O
been	O
identified	O
as	O
the	O
etiological	O
agent	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

We	O
conclude	O
that	O
the	O
incorporation	O
of	O
spikes	O
carrying	O
the	O
large	O
GFP	O
moiety	O
is	O
apparently	O
impaired	B-DISO
by	O
geometrical	O
constraints	O
and	O
selected	O
against	O
during	O
the	O
assembly	O
of	O
virions	O
.	O

To	O
exploit	O
the	O
possibility	O
of	O
using	O
RNA	O
interference	O
as	O
a	O
therapeutic	O
approach	O
to	O
fight	O
the	O
disease	O
,	O
plasmid	O
-	O
mediated	O
small	O
interfering	O
RNAs	O
(	O
siRNAs	O
)	O
were	O
generated	O
to	O
target	O
the	O
SARS	B-DISO
-	O
CoV	O
genome	O
.	O

Infection	B-DISO
of	O
mice	O
devoid	O
of	O
distinct	O
inflammatory	O
cells	O
revealed	O
CD4	O
(+)	O
T	O
cells	O
as	O
the	O
major	O
cell	O
type	O
influencing	O
receptor	O
expression	O
by	O
microglia	O
.	O

However	O
,	O
mortality	O
remains	O
high	O
in	O
patients	O
suffering	B-DISO
from	O
severe	O
ARDS	B-DISO
despite	O
newer	O
treatment	O
modalities	O
.	O

The	O
mean	O
duration	O
of	O
pECLA	O
therapy	O
was	O
6	O
.	O
5	O
days	O
,	O
15	O
patients	O
(	O
50	O
%)	O
died	O
due	O
to	O
ARDS	B-DISO
or	O
non	O
-	O
ARDS	B-DISO
related	O
reasons	O
.	O

Furthermore	O
,	O
studies	O
in	O
a	O
new	O
human	O
cell	O
culture	O
model	O
have	O
indicated	O
that	O
the	O
presence	O
of	O
ACE2	O
alone	O
is	O
not	O
sufficient	O
for	O
maintaining	O
viral	B-DISO
infection	I-DISO
.	O

It	O
is	O
clear	O
that	O
we	O
are	O
only	O
at	O
the	O
dawn	O
of	O
our	O
understanding	O
of	O
the	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
An	O
immunocomb	O
-	O
based	O
dot	O
-	O
ELISA	O
,	O
employing	O
specially	O
designed	O
apparatus	O
,	O
was	O
used	O
to	O
measure	O
the	O
antibody	O
status	O
for	O
the	O
three	O
major	O
poultry	B-DISO
diseases	I-DISO
--	O
Newcastle	O
disease	O
,	O
infectious	B-DISO
bursal	I-DISO
disease	I-DISO
and	O
infectious	B-DISO
bronchitis	B-DISO
--	O
in	O
single	O
test	O
sera	O
.	O

The	O
virus	O
causing	O
SARS	B-DISO
was	O
identified	O
as	O
a	O
novel	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
multiple	O
genomic	O
sequences	O
have	O
been	O
revealed	O
since	O
mid	O
-	O
April	O
,	O
2003	O
.	O

The	O
estimated	O
mutation	O
rates	O
in	O
the	O
SARS	B-DISO
-	O
CoV	O
using	O
multiple	O
strategies	O
were	O
not	O
unusual	O
among	O
coronaviruses	O
and	O
moderate	O
compared	O
to	O
those	O
in	O
other	O
RNA	O
viruses	O
.	O

TITLE	O
:	O
Significance	O
of	O
interactions	O
between	O
Escherichia	O
coli	O
and	O
respiratory	O
pathogens	O
in	O
layer	O
hen	O
flocks	O
suffering	B-DISO
from	O
colibacillosis	B-DISO
-	O
associated	O
mortality	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aimed	O
to	O
examine	O
the	O
significance	O
of	O
interactions	O
between	O
Escherichia	O
coli	O
and	O
various	O
respiratory	O
pathogens	O
during	O
outbreaks	O
of	O
colibacillosis	B-DISO
-	O
associated	O
mortality	O
in	O
layer	O
hen	O
flocks	O
under	O
field	O
conditions	O
.	O

An	O
increase	O
in	O
per	O
cent	O
reactors	O
was	O
seen	O
for	O
APV	O
(	O
one	O
control	O
flock	O
),	O
and	O
for	O
M	O
.	O
synoviae	O
(	O
one	O
control	O
and	O
two	O
colibacillosis	B-DISO
flocks	O
).	O

TITLE	O
:	O
Microwave	O
or	O
autoclave	O
treatments	O
destroy	O
the	O
infectivity	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
and	O
avian	O
pneumovirus	O
but	O
allow	O
detection	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
.	O

HFOV	O
was	O
safe	O
,	O
and	O
was	O
highly	O
effective	O
in	O
correcting	O
oxygenation	O
failure	O
associated	O
with	O
ARDS	B-DISO
in	O
burn	O
patients	O
,	O
and	O
can	O
be	O
successfully	O
used	O
as	O
an	O
intra	O
-	O
operative	O
ventilation	O
modality	O
for	O
burn	O
patients	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
pulmonary	B-DISO
tuberculosis	I-DISO
.	O

The	O
physiochemical	O
and	O
morphological	O
properties	O
of	O
the	O
isolate	O
SC021202	O
were	O
in	O
accordance	O
to	O
that	O
of	O
typical	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
).	O

TITLE	O
:	O
What	O
do	O
we	O
do	O
with	O
the	O
SARS	B-DISO
reports	O
?	O

While	O
the	O
reports	O
were	O
triggered	O
by	O
SARS	B-DISO
,	O
and	O
focus	O
on	O
many	O
issues	O
arising	O
from	O
SARS	B-DISO
,	O
they	O
all	O
clearly	O
acknowledge	O
that	O
concerns	O
regarding	O
public	O
health	O
in	O
this	O
country	O
are	O
long	O
-	O
standing	O
.	O

The	O
inactivated	O
vaccine	O
was	O
prepared	O
by	O
SARS	B-DISO
-	O
CoV	O
virus	O
propagation	O
in	O
Vero	O
cells	O
,	O
with	O
subsequent	O
beta	O
-	O
propiolactone	O
inactivation	B-DISO
and	O
Sepharose	O
4FF	O
column	O
chromatography	O
purification	O
.	O

Results	O
from	O
simple	O
factor	O
logistic	O
regression	O
analysis	O
showed	O
that	O
jobs	O
which	O
dealing	O
with	O
domestic	O
livestock	O
,	O
wild	O
livestock	O
,	O
wild	O
animals	O
,	O
aquatics	O
were	O
related	O
to	O
risk	O
factors	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

CONCLUSIONS	O
:	O
Job	O
that	O
dealing	O
with	O
palm	O
civets	O
was	O
the	O
main	O
risk	O
factor	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
in	O
animal	O
market	O
workers	O
.	O

TITLE	O
:	O
[	O
Comparison	O
among	O
four	O
kits	O
in	O
detection	O
of	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
IgG	O
in	O
sera	O
of	O
SARS	B-DISO
patients	O
].	O

Dealing	O
with	O
the	O
urgent	O
public	O
health	O
problems	O
and	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
outbreak	O
,	O
epidemiologists	O
need	O
to	O
keep	O
good	O
relations	O
with	O
media	O
,	O
and	O
making	O
use	O
of	O
modern	O
electronic	O
technologies	O
to	O
communicate	O
with	O
the	O
public	O
.	O

All	O
hospitals	O
having	O
received	O
SARS	B-DISO
inpatients	O
were	O
involved	O
in	O
the	O
project	O
.	O

RESULTS	O
:	O
The	O
database	O
involved	O
2148	O
probable	O
SARS	B-DISO
cases	O
in	O
accordant	O
with	O
the	O
clinical	O
diagnosis	O
criteria	O
,	O
including	O
1291	O
with	O
complete	O
records	O
.	O

TITLE	O
:	O
[	O
Relationship	O
between	O
the	O
severity	O
,	O
course	O
,	O
fatality	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
patients	O
and	O
the	O
timing	O
of	O
hospitalization	O
].	O

In	O
terms	O
of	O
control	O
program	O
on	O
SARS	B-DISO
,	O
emphasize	O
should	O
be	O
paid	O
on	O
decreasing	O
the	O
panic	O
of	O
patients	O
to	O
the	O
disease	O
so	O
as	O
to	O
get	O
early	O
hospitalization	O
.	O

RESULTS	O
:	O
SARS	B-DISO
cases	O
were	O
categorized	O
into	O
four	O
groups	O
,	O
according	O
to	O
the	O
time	O
of	O
hospitalization	O
after	O
onset	O
of	O
the	O
disease	O
:	O
within	O
3	O
days	O
,	O
during	O
day	O
4	O
to	O
day	O
7	O
,	O
during	O
day	O
8	O
to	O
day	O
14	O
and	O
after	O
day	O
14	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
medical	O
cost	O
and	O
its	O
related	O
factors	O
of	O
clinically	O
confirmed	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
cases	O
in	O
Beijing	O
.	O

The	O
average	O
medical	O
cost	O
per	O
person	O
/	O
day	O
was	O
calculated	O
on	O
1272	O
SARS	B-DISO
cases	O
with	O
complete	O
hospitalization	O
data	O
from	O
the	O
Beijing	O
SARS	B-DISO
clinical	O
database	O
.	O

Antiviral	O
activity	O
was	O
estimated	O
by	O
the	O
inhibition	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
cytopathic	B-DISO
effect	I-DISO
in	O
Vero	O
E6	O
cells	O
,	O
determined	O
by	O
a	O
tetrazolium	O
-	O
based	O
colorimetric	O
method	O
.	O

The	O
survival	O
rate	O
of	O
SARS	B-DISO
-	O
CoV	O
infected	O
cells	O
was	O
greatly	O
increased	O
by	O
the	O
treatment	O
with	O
SNAP	O
,	O
and	O
the	O
concentration	O
of	O
this	O
compound	O
needed	O
to	O
inhibit	O
the	O
viral	B-DISO
cytopathic	I-DISO
effect	I-DISO
to	O
50	O
%	O
was	O
222	O
microM	O
,	O
with	O
a	O
selectivity	O
index	O
of	O
3	O
.	O

No	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
effect	O
could	O
be	O
detected	O
for	O
SNP	O
and	O
NAP	O
.	O

The	O
ideal	O
amplification	B-DISO
efficiency	O
of	O
a	O
sensitive	O
SARS	B-DISO
-	O
CoV	O
RT	O
-	O
PCR	O
assay	O
should	O
yield	O
an	O
E	O
value	O
(	O
PCR	O
product	O
concentration	O
increase	O
per	O
amplification	B-DISO
cycle	O
)	O
equal	O
to	O
2	O
.	O
0	O
.	O

In	O
this	O
report	O
,	O
the	O
development	O
and	O
immunochemical	O
characterisation	O
of	O
a	O
panel	O
of	O
murine	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
against	O
the	O
SARS	B-DISO
-	O
CoV	O
is	O
presented	O
,	O
based	O
upon	O
their	O
specificity	O
,	O
binding	O
requirements	O
,	O
and	O
biological	O
activity	O
.	O

Recent	O
studies	O
have	O
documented	O
that	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
is	O
primarily	O
transmitted	B-DISO
via	O
contact	O
and	O
/	O
or	O
respiratory	O
droplets	O
and	O
that	O
the	O
combination	O
of	O
standard	O
,	O
contact	O
,	O
and	O
droplet	O
precautions	O
is	O
generally	O
effective	O
for	O
its	O
control	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
whether	O
long	O
-	O
term	O
outcome	O
differs	O
between	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
resulting	O
from	O
pulmonary	O
(	O
ARDSp	O
)	O
and	O
extrapulmonary	O
(	O
ARDSexp	O
)	O
causes	O
.	O

ABSTRACT	O
:	O
By	O
using	O
a	O
recombinant	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
nucleocapsid	O
protein	O
-	O
based	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
serum	O
specimens	O
serially	O
collected	O
(	O
from	O
day	O
0	O
to	O
day	O
240	O
after	O
symptom	B-DISO
onset	O
)	O
from	O
patients	O
with	O
pneumonia	B-DISO
due	O
to	O
SARS	B-DISO
-	O
CoV	O
,	O
we	O
analyzed	O
the	O
longitudinal	O
profiles	O
of	O
immunoglobulin	O
G	O
(	O
IgG	O
),	O
IgM	O
,	O
and	O
IgA	O
antibodies	O
against	O
the	O
SARS	B-DISO
-	O
CoV	O
nucleocapsid	O
protein	O
in	O
patients	O
with	O
pneumonia	B-DISO
due	O
to	O
SARS	B-DISO
-	O
CoV	O
.	O
For	O
IgG	O
,	O
the	O
median	O
optical	O
density	O
at	O
450	O
nm	O
(	O
OD450	O
)	O
turned	O
positive	O
at	O
day	O
17	O
and	O
a	O
biphasic	O
response	O
was	O
observed	O
.	O

ABSTRACT	O
:	O
The	O
sensitivities	O
and	O
specificities	O
of	O
an	O
immunofluorescence	O
assay	O
and	O
an	O
enzyme	O
immunoassay	O
for	O
detection	O
of	O
antibodies	O
specific	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
were	O
compared	O
for	O
148	O
laboratory	O
-	O
confirmed	O
SARS	B-DISO
cases	O
.	O

The	O
assay	O
was	O
carried	O
out	O
with	O
hyperimmune	O
polyclonal	O
nucleocapsid	O
-	O
specific	O
antibodies	O
from	O
guinea	O
pigs	O
and	O
rabbits	O
immunized	O
with	O
recombinant	O
His	O
(	O
6	O
)-	O
tagged	O
SARS	B-DISO
CoV	O
nucleocapsid	O
protein	O
.	O

Since	O
the	O
present	O
ELISA	O
is	O
more	O
convenient	O
and	O
economical	O
than	O
reverse	O
transcription	O
-	O
PCR	O
,	O
it	O
may	O
serve	O
as	O
an	O
alternative	O
tool	O
for	O
the	O
early	O
diagnosis	O
of	O
SARS	B-DISO
CoV	O
infection	B-DISO
in	O
laboratories	O
with	O
limited	O
resources	O
and	O
expertise	O
and	O
for	O
mass	O
screening	O
for	O
the	O
reservoir	O
of	O
SARS	B-DISO
CoV	O
.	O
Further	O
studies	O
on	O
serial	O
clinical	O
specimens	O
should	O
reveal	O
the	O
duration	O
of	O
nucleocapsid	O
protein	O
shedding	O
and	O
may	O
reveal	O
a	O
higher	O
detection	O
rate	O
in	O
SARS	B-DISO
patients	O
.	O

TITLE	O
:	O
Association	O
of	O
human	O
-	O
leukocyte	O
-	O
antigen	O
class	O
I	O
(	O
B	O
*	O
0703	O
)	O
and	O
class	O
II	O
(	O
DRB1	O
*	O
0301	O
)	O
genotypes	O
with	O
susceptibility	O
and	O
resistance	O
to	O
the	O
development	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

These	O
genetic	O
data	O
will	O
critically	O
affect	O
both	O
the	O
study	O
of	O
the	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
and	O
the	O
design	O
of	O
vaccination	O
programs	O
.	O

TITLE	O
:	O
Using	O
the	O
hierarchy	O
of	O
control	O
technologies	O
to	O
improve	O
healthcare	O
facility	O
infection	B-DISO
control	O
:	O
lessons	O
from	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

This	O
article	O
describes	O
the	O
classic	O
""""	O
hierarchy	O
of	O
control	O
technologies	O
""""	O
that	O
was	O
successfully	O
used	O
by	O
occupational	O
and	O
environmental	O
medicine	O
professionals	O
to	O
protect	O
workers	O
from	O
illness	O
and	O
death	O
during	O
the	O
resurgence	O
of	O
tuberculosis	B-DISO
in	O
the	O
1990s	O
.	O

This	O
model	O
for	O
review	O
of	O
pediatric	O
research	O
that	O
may	O
be	O
without	O
benefit	O
will	O
be	O
especially	O
important	O
as	O
challenging	O
studies	O
of	O
various	O
vaccines	O
against	O
a	O
range	O
of	O
infectious	B-DISO
properties	O
,	O
such	O
as	O
anthrax	B-DISO
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
emerge	O
.	O

ABSTRACT	O
:	O
Little	O
is	O
known	O
of	O
the	O
nature	O
of	O
the	O
recovery	O
period	O
after	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
infection	B-DISO
.	O

Nineteen	O
patients	O
who	O
recovered	O
from	O
SARS	B-DISO
-	O
related	O
hospitalization	O
.	O

TITLE	O
:	O
Proteomic	O
analysis	O
of	O
SARS	B-DISO
associated	O
coronavirus	O
using	O
two	O
-	O
dimensional	O
liquid	O
chromatography	O
mass	O
spectrometry	O
and	O
one	O
-	O
dimensional	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
followed	O
by	O
mass	O
spectroemtric	O
analysis	O
.	O

For	O
the	O
first	O
time	O
,	O
all	O
of	O
the	O
four	O
predicted	O
structural	O
proteins	O
of	O
SARS	B-DISO
-	O
CoV	O
were	O
identified	O
,	O
including	O
S	O
(	O
Spike	O
),	O
M	O
(	O
Membrane	O
),	O
N	O
(	O
Nucleocapsid	O
),	O
and	O
E	O
(	O
Envolope	O
)	O
proteins	O
.	O

The	O
combination	O
of	O
these	O
gel	O
-	O
base	O
and	O
non	O
-	O
gel	O
methods	O
provides	O
fast	O
and	O
complimentary	O
approaches	O
to	O
SARS	B-DISO
-	O
CoV	O
proteome	O
and	O
can	O
be	O
widely	O
used	O
in	O
the	O
analysis	O
of	O
other	O
viruses	O
.	O

Therapeutic	O
interventions	O
to	O
selectively	O
influence	O
pulmonary	O
perfusion	O
in	O
ARDS	B-DISO
became	O
possible	O
with	O
the	O
introduction	O
of	O
inhaled	O
nitric	O
oxide	O
(	O
iNO	O
),	O
which	O
provided	O
a	O
way	O
not	O
only	O
to	O
reduce	O
pulmonary	B-DISO
hypertension	I-DISO
,	O
but	O
also	O
to	O
acutely	O
improve	O
ventilation	O
-	O
perfusion	O
mismatch	O
,	O
and	O
thus	O
to	O
treat	O
severe	O
hypoxemia	O
.	O

TITLE	O
:	O
[	O
Immunological	O
reaction	O
between	O
the	O
peptides	O
from	O
S1	O
domain	O
of	O
SARS	B-DISO
coronavirus	O
S	O
-	O
protein	O
and	O
the	O
serum	O
from	O
SARS	B-DISO
patients	O
].	O

The	O
peptides	O
from	O
S1	O
domain	O
of	O
SARS	B-DISO
-	O
Cov	O
S	O
-	O
protein	O
were	O
synthesized	O
by	O
peptide	O
synthesizer	O
,	O
and	O
the	O
immunological	O
reaction	O
of	O
the	O
peptides	O
with	O
the	O
serum	O
of	O
SARS	B-DISO
patients	O
were	O
examined	O
by	O
means	O
of	O
ELISA	O
.	O

TITLE	O
:	O
Persistent	B-DISO
infection	I-DISO
of	O
SARS	B-DISO
coronavirus	O
in	O
colonic	O
cells	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
can	O
produce	O
gastrointestinal	B-DISO
symptoms	I-DISO
.	O

ABSTRACT	O
:	O
The	O
importance	O
of	O
rapid	O
diagnosis	O
of	O
influenza	B-DISO
has	O
increased	O
with	O
the	O
availability	O
of	O
neuraminidase	O
inhibitors	O
,	O
which	O
need	O
to	O
be	O
commenced	O
within	O
48	O
hr	O
of	O
symptom	B-DISO
onset	O
.	O

TITLE	O
:	O
Reexpansion	B-DISO
pulmonary	I-DISO
edema	I-DISO
after	O
resolution	O
of	O
tension	B-DISO
pneumothorax	I-DISO
in	O
the	O
contralateral	O
lung	O
of	O
a	O
previously	O
lung	O
injured	O
patient	O
.	O

It	O
is	O
postulated	O
that	O
a	O
variety	O
of	O
intraoperative	O
and	O
immediate	O
postoperative	O
maneuvers	O
may	O
have	O
contributed	O
to	O
the	O
development	O
of	O
this	O
near	O
fatal	O
complication	B-DISO
.	O

TITLE	O
:	O
Prediction	O
of	O
class	O
I	O
T	O
-	O
cell	O
epitopes	O
:	O
evidence	O
of	O
presence	O
of	O
immunological	O
hot	B-DISO
spots	I-DISO
inside	O
antigens	O
.	O

We	O
have	O
developed	O
a	O
scoring	O
scheme	O
for	O
identification	O
of	O
immunological	O
hot	B-DISO
spots	I-DISO
for	O
HLA	O
class	O
I	O
molecules	O
,	O
which	O
is	O
the	O
sum	O
of	O
the	O
highest	O
four	O
predictions	O
within	O
a	O
window	O
of	O
30	O
amino	O
acids	O
.	O

TITLE	O
:	O
How	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
affected	O
the	O
department	O
of	O
anaesthesia	B-DISO
at	O
Singapore	O
General	O
Hospital	O
.	O

Anaesthetists	O
were	O
at	O
risk	O
and	O
anaesthetic	O
practice	O
had	O
to	O
change	O
in	O
view	O
of	O
strict	O
infection	B-DISO
control	O
provisions	O
.	O

TITLE	O
:	O
Advancements	O
in	O
the	O
battle	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

This	O
paper	O
provides	O
a	O
review	O
of	O
the	O
epidemiology	O
,	O
clinical	O
features	O
and	O
possible	O
treatment	O
strategies	O
of	O
SARS	B-DISO
.	O

Epidemiological	O
evidences	O
and	O
the	O
outcomes	O
of	O
304	O
patients	O
with	O
confirmed	O
SARS	B-DISO
were	O
retrospectively	O
analyzed	O
.	O

The	O
epidemiological	O
evidence	O
is	O
an	O
independent	O
factor	O
related	O
to	O
fatality	O
rate	O
in	O
SARS	B-DISO
patients	O
.	O

By	O
observing	O
changes	O
of	O
the	O
odds	O
ratio	O
for	O
epidemic	O
evidence	O
,	O
age	O
,	O
and	O
gender	O
using	O
forward	O
method	O
,	O
we	O
found	O
epidemic	O
evidence	O
was	O
an	O
independent	O
risk	O
factor	O
related	O
to	O
fatality	O
rate	O
in	O
SARS	B-DISO
patients	O
.	O

Real	O
-	O
time	O
quantitative	O
PCR	O
was	O
performed	O
to	O
detect	O
the	O
RNA	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
,	O
and	O
results	O
were	O
analyzed	O
by	O
SPSS	O
analysis	O
software	O
.	O

Older	O
patients	O
were	O
more	O
likely	O
to	O
develop	O
secondary	O
nosocomial	B-DISO
infection	I-DISO
,	O
be	O
admitted	O
to	O
an	O
intensive	O
care	O
unit	O
,	O
and	O
require	O
mechanical	O
ventilation	O
.	O

The	O
cumulative	O
30	O
-	O
and	O
150	O
-	O
day	O
mortality	O
rates	O
were	O
3	O
.	O
8	O
%	O
and	O
7	O
.	O
6	O
%,	O
respectively	O
,	O
in	O
young	O
patients	O
with	O
SARS	B-DISO
and	O
56	O
%	O
and	O
60	O
%,	O
respectively	O
,	O
in	O
older	O
patients	O
(	O
P	O
<.	O
001	O
).	O

The	O
cumulative	O
30	O
-	O
and	O
150	O
-	O
day	O
mortality	O
rates	O
were	O
3	O
.	O
8	O
%	O
and	O
7	O
.	O
6	O
%,	O
respectively	O
,	O
in	O
young	O
patients	O
with	O
SARS	B-DISO
and	O
56	O
%	O
and	O
60	O
%,	O
respectively	O
,	O
in	O
older	O
patients	O
(	O
P	O
<.	O
001	O
).	O

TITLE	O
:	O
Analysis	O
of	O
serum	O
cytokines	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

The	O
major	O
transmission	O
mode	O
of	O
SARS	B-DISO
-	O
coronavirus	O
appears	O
to	O
be	O
through	O
droplet	O
spread	O
with	O
other	O
minor	O
subsidiary	O
modes	O
of	O
transmission	O
such	O
as	O
close	O
contact	O
and	O
fomites	O
although	O
air	O
borne	O
transmission	O
has	O
not	O
been	O
ruled	O
out	O
.	O

Our	O
epitope	O
-	O
based	O
serologic	O
test	O
may	O
be	O
useful	O
in	O
laboratory	O
detection	O
of	O
the	O
virus	O
and	O
in	O
further	O
study	O
of	O
the	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
.	O

On	O
chest	O
radiographs	O
,	O
maximal	O
SARS	B-DISO
-	O
related	O
lesion	O
extent	O
score	O
of	O
7	O
or	O
higher	O
is	O
a	O
strong	O
predictor	O
of	O
mortality	O
,	O
especially	O
in	O
patients	O
with	O
comorbid	O
lung	O
illnesses	O
and	O
involvement	O
of	O
four	O
or	O
more	O
lung	O
zones	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
the	O
delivery	O
of	O
continuing	O
medical	O
education	O
:	O
case	O
study	O
from	O
Toronto	O
.	O

The	O
predominant	O
pathological	B-DISO
process	I-DISO
of	O
SARS	B-DISO
is	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
and	O
,	O
in	O
patients	O
who	O
die	O
from	O
the	O
disease	O
,	O
there	O
is	O
evidence	O
of	O
organization	O
and	O
fibrosis	B-DISO
.	O

Of	O
SARS	B-DISO
patients	O
,	O
39	O
%	O
(	O
n	O
=	O
30	O
)	O
were	O
infected	O
health	O
care	O
workers	O
;	O
these	O
individuals	O
reported	O
significantly	O
more	O
fatigue	B-DISO
and	O
worries	O
about	O
health	O
than	O
did	O
other	O
patients	O
.	O

General	O
stress	O
and	O
negative	O
psychological	B-DISO
effects	O
are	O
increased	O
in	O
SARS	B-DISO
patients	O
,	O
particularly	O
among	O
infected	O
health	O
care	O
workers	O
.	O

Of	O
patients	O
,	O
25	O
%	O
(	O
n	O
=	O
20	O
)	O
requested	O
psychological	B-DISO
follow	O
-	O
up	O
.	O

TITLE	O
:	O
Psychological	B-DISO
effects	O
of	O
the	O
SARS	B-DISO
outbreak	O
in	O
Hong	O
Kong	O
on	O
high	O
-	O
risk	O
health	O
care	O
workers	O
.	O

In	O
HCWs	O
,	O
adaptive	O
responses	O
to	O
stress	O
and	O
the	O
positive	O
effects	O
of	O
infection	B-DISO
control	O
training	O
may	O
be	O
protective	O
in	O
future	O
outbreaks	O
.	O

Health	O
workers	O
in	O
a	O
tertiary	O
hospital	O
affected	O
by	O
SARS	B-DISO
were	O
invited	O
to	O
complete	O
a	O
questionnaire	O
designed	O
to	O
evaluate	O
exposure	O
experience	O
,	O
psychological	B-DISO
impact	O
and	O
psychiatric	O
morbidity	O
.	O

The	O
crisis	O
was	O
successfully	O
managed	O
by	O
a	O
Standard	O
Operation	O
Procedure	O
(	O
SOP	O
)	O
that	O
included	O
:	O
(	O
a	O
)	O
containment	O
of	O
SARS	B-DISO
patients	O
on	O
a	O
special	O
floor	O
and	O
evacuation	O
of	O
the	O
patients	O
from	O
the	O
infected	O
and	O
near	O
-	O
around	O
floors	O
;	O
(	O
b	O
)	O
sorting	O
of	O
the	O
hospital	O
into	O
areas	O
and	O
floors	O
to	O
avoid	O
cross	O
contact	O
of	O
people	O
;	O
(	O
c	O
)	O
triage	O
of	O
patients	O
into	O
groups	O
according	O
to	O
risks	O
;	O
(	O
d	O
)	O
closure	O
of	O
the	O
emergency	B-DISO
room	O
and	O
outpatient	O
clinics	O
;	O
and	O
(	O
e	O
)	O
set	O
up	O
of	O
an	O
outdoor	O
fever	O
screening	O
station	O
and	O
emergency	B-DISO
service	O
.	O

TITLE	O
:	O
Antibody	O
responses	O
against	O
SARS	B-DISO
-	O
coronavirus	O
and	O
its	O
nucleocaspid	O
in	O
SARS	B-DISO
patients	O
.	O

Commercial	O
antiviral	O
agents	O
and	O
pure	O
chemical	O
compounds	O
extracted	O
from	O
traditional	O
Chinese	O
medicinal	O
herbs	O
were	O
screened	O
against	O
10	O
clinical	O
isolates	O
of	O
SARS	B-DISO
coronavirus	O
by	O
neutralisation	O
tests	O
with	O
confirmation	O
by	O
plaque	B-DISO
reduction	O
assays	O
.	O

TITLE	O
:	O
Coronavirus	B-DISO
infection	I-DISO
of	O
spotted	O
hyenas	O
in	O
the	O
Serengeti	O
ecosystem	O
.	O

TITLE	O
:	O
[	O
New	O
therapeutic	O
strategies	O
in	O
severe	B-DISO
sepsis	I-DISO
and	O
septic	B-DISO
shock	I-DISO
].	O

However	O
,	O
apoptosis	O
was	O
independent	O
of	O
the	O
p53	O
and	O
Fas	B-DISO
signalling	O
pathways	O
.	O

This	O
is	O
the	O
first	O
report	O
showing	O
the	O
ability	O
of	O
the	O
N	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
to	O
induce	O
apoptosis	O
and	O
actin	O
reorganization	O
in	O
mammalian	O
cells	O
under	O
stressed	O
conditions	O
.	O

The	O
authors	O
hope	O
to	O
share	O
their	O
experience	O
in	O
the	O
implementation	O
of	O
these	O
strategies	O
by	O
the	O
Singapore	O
Civil	O
Defence	O
Force	O
and	O
stress	O
the	O
importance	O
of	O
the	O
psychological	B-DISO
preparedness	O
of	O
the	O
paramedics	O
and	O
prehospital	O
care	O
providers	O
worldwide	O
in	O
this	O
era	O
of	O
SARS	B-DISO
.	O

Visitor	O
restriction	O
to	O
decrease	O
chances	O
of	O
disease	B-DISO
transmission	I-DISO
are	O
particularly	O
difficult	O
for	O
long	O
-	O
staying	O
rehabilitation	O
patients	O
.	O

TITLE	O
:	O
Nephropathogenesis	O
of	O
chickens	O
experimentally	O
infected	O
with	O
various	O
strains	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

However	O
,	O
viral	O
nucleic	O
acid	O
and	O
antigen	O
were	O
detected	O
only	O
with	O
Wolgemuth	O
-	O
infected	O
kidneys	O
by	O
ISH	B-DISO
and	O
IHC	O
.	O

Three	O
-	O
fifths	O
(	O
60	O
.	O
1	O
%)	O
were	O
afraid	O
to	O
travel	O
for	O
fear	O
of	O
being	O
affected	O
by	O
SARS	B-DISO
.	O

The	O
level	O
of	O
knowledge	O
about	O
SARS	B-DISO
was	O
better	O
among	O
educated	O
subjects	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
rapidly	O
progressive	B-DISO
disease	I-DISO
caused	O
by	O
a	O
novel	O
coronavirus	O
(	O
CoV	O
)	O
infection	B-DISO
.	O

Eventually	O
,	O
39	O
patients	O
(	O
74	O
%)	O
developed	O
cough	B-DISO
,	O
beginning	O
at	O
a	O
mean	O
(+/-	O

1	O
.	O
9	O
days	O
after	O
fever	O
onset	O
,	O
and	O
35	O
patients	O
(	O
66	O
%)	O
had	O
diarrhea	B-DISO
beginning	O
at	O
a	O
mean	O
time	O
of	O
6	O
.	O
0	O
+/-	O

The	O
treatment	O
group	O
had	O
younger	O
women	O
with	O
more	O
symptoms	O
of	O
myalgia	B-DISO
(	O
P	O
<	O
0	O
.	O
001	O
).	O

CONCLUSIONS	O
:	O
In	O
this	O
retrospective	O
,	O
uncontrolled	O
cohort	O
analysis	O
,	O
use	O
of	O
ribavirin	O
did	O
not	O
appear	O
to	O
confer	O
any	O
benefit	O
for	O
patients	O
with	O
SARS	B-DISO
.	O

Bacterially	O
expressed	O
forms	O
of	O
NendoU	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
and	O
human	O
coronavirus	O
229E	O
were	O
revealed	O
to	O
cleave	O
single	O
-	O
stranded	O
and	O
double	O
-	O
stranded	O
RNA	O
in	O
a	O
Mn	O
(	O
2	O
+)-	O
dependent	O
manner	O
.	O

ABSTRACT	O
:	O
This	O
paper	O
reviews	O
current	O
understanding	O
of	O
the	O
epidemiology	O
,	O
transmission	O
dynamics	O
and	O
control	O
of	O
the	O
aetiological	O
agent	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

ABSTRACT	O
:	O
The	O
case	O
fatality	O
was	O
the	O
lowest	O
(	O
3	O
.	O
8	O
%)	O
among	O
1512	O
cases	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
Guangdong	O
Province	O
,	O
China	O
.	O

Strict	O
control	O
of	O
the	O
wild	O
-	O
animal	O
market	O
may	O
be	O
significant	O
in	O
preventing	O
a	O
new	O
outbreak	O
of	O
SARS	B-DISO
this	O
year	O
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
the	O
first	O
half	O
of	O
2003	O
in	O
Canada	O
was	O
unprecedented	O
in	O
several	O
respects	O
.	O

This	O
review	O
draws	O
upon	O
qualitative	O
and	O
quantitative	O
studies	O
of	O
the	O
SARS	B-DISO
outbreak	O
in	O
Toronto	O
to	O
outline	O
the	O
factors	O
that	O
contributed	O
to	O
healthcare	O
workers	O
'	O
experiencing	O
the	O
outbreak	O
as	O
a	O
psychological	B-DISO
trauma	I-DISO
.	O

TITLE	O
:	O
What	O
have	O
we	O
learnt	O
from	O
SARS	B-DISO
?	O

We	O
were	O
,	O
and	O
are	O
,	O
expecting	O
a	O
new	O
influenza	B-DISO
A	O
pandemic	O
,	O
but	O
no	O
one	O
predicted	O
the	O
emergence	O
of	O
an	O
unknown	O
coronavirus	O
(	O
CoV	O
)	O
as	O
a	O
deadly	O
human	O
pathogen	O
.	O

TITLE	O
:	O
Sequential	O
changes	O
of	O
serum	O
aminotransferase	O
levels	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

To	O
describe	O
the	O
hepatic	O
injury	O
caused	O
by	O
this	O
disease	O
,	O
we	O
report	O
the	O
sequential	O
changes	O
of	O
serum	O
transaminase	O
in	O
probable	O
SARS	B-DISO
patients	O
during	O
a	O
hospital	O
outbreak	O
in	O
southern	O
Taiwan	O
.	O

Recent	O
draft	O
guidance	O
on	O
SARS	B-DISO
preparedness	O
from	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
may	O
help	O
address	O
some	O
of	O
these	O
issues	O
.	O

TITLE	O
:	O
[	O
Study	O
on	O
the	O
psychosocial	O
status	O
and	O
related	O
factors	O
in	O
three	O
universities	O
during	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
epidemic	O
in	O
Beijing	O
].	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
psychosocial	O
status	O
and	O
related	O
factors	O
among	O
university	O
students	O
during	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
epidemic	O
in	O
Beijing	O
.	O

Psychosocial	O
status	O
of	O
students	O
was	O
influenced	O
by	O
their	O
knowledge	O
and	O
attitude	O
on	O
SARS	B-DISO
.	O

CONCLUSIONS	O
:	O
Psychosocial	O
status	O
of	O
students	O
was	O
influenced	O
by	O
their	O
knowledge	O
and	O
attitude	O
on	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
To	O
determine	O
whether	O
the	O
initial	O
chest	O
radiograph	O
is	O
helpful	O
in	O
predicting	O
the	O
clinical	O
outcome	O
of	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

TITLE	O
:	O
SARS	B-DISO
preventive	O
and	O
risk	O
behaviours	O
of	O
Hong	O
Kong	O
air	O
travellers	O
.	O

Leptospirosis	B-DISO
may	O
manifest	O
with	O
severe	O
lung	O
injury	O
characterized	O
by	O
diffuse	O
alveolar	O
hemorrhage	B-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
and	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
and	O
be	O
accompanied	O
by	O
high	O
mortality	O
rates	O
.	O

Leptospirosis	B-DISO
should	O
be	O
considered	O
in	O
patients	O
with	O
features	O
of	O
pulmonary	B-DISO
-	I-DISO
renal	I-DISO
syndrome	I-DISO
,	O
particularly	O
in	O
regions	O
known	O
to	O
be	O
endemic	O
for	O
leptospirosis	B-DISO
.	O

ABSTRACT	O
:	O
The	O
transmission	O
modes	O
of	O
SARS	B-DISO
-	O
coronavirus	O
appear	O
to	O
be	O
through	O
droplet	O
spread	O
,	O
close	O
contact	O
and	O
fomites	O
although	O
air	O
borne	O
transmission	O
has	O
not	O
been	O
ruled	O
out	O
.	O

Although	O
the	O
principle	O
of	O
universal	O
precautions	O
is	O
widely	O
advocated	O
and	O
followed	O
throughout	O
the	O
dental	O
community	O
,	O
additional	O
precautionary	O
measures	O
-	O
termed	O
standard	O
precaution	O
may	O
be	O
necessary	O
to	O
help	O
control	O
the	O
spread	O
of	O
this	O
highly	O
contagious	B-DISO
disease	I-DISO
.	O

TITLE	O
:	O
From	O
SARS	B-DISO
to	O
strategic	O
actions	O
reframing	O
systems	O
.	O

SARS	B-DISO
affected	O
people	O
on	O
three	O
continents	O
in	O
a	O
matter	O
of	O
days	O
.	O

ARDS	B-DISO
rabbit	O
models	O
were	O
established	O
by	O
injecting	O
oleic	O
acid	O
through	O
central	O
vein	O
,	O
and	O
the	O
results	O
of	O
effective	O
local	O
blood	O
perfusion	O
in	O
different	O
areas	O
of	O
rabbit	O
lung	O
(	O
upper	O
area	O
,	O
abdominal	O
area	O
,	O
and	O
dorsal	O
area	O
of	O
right	O
lung	O
)	O
with	O
PIM	O
-	O
II	O
laser	O
perfusion	O
imager	O
and	O
arterial	O
blood	O
gas	O
under	O
different	O
ventilation	O
modes	O
[	O
large	O
tidal	O
volume	O
ventilation	O
,	O
low	O
tidal	O
volume	O
ventilation	O
+	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
),	O
prone	O
position	O
+	O
large	O
tidal	O
volume	O
ventilation	O
,	O
and	O
prone	O
position	O
+	O
low	O
tidal	O
volume	O
ventilation	O
+	O
PEEP	O
]	O
were	O
measured	O
.	O

We	O
indicated	O
that	O
the	O
one	O
of	O
the	O
main	O
mechanisms	O
of	O
severe	O
hypoxemia	O
in	O
ARDS	B-DISO
might	O
be	O
caught	O
by	O
the	O
shunt	O
between	O
pulmonary	O
artery	O
and	O
pulmonary	O
vein	O
just	O
like	O
physiological	O
right	O
to	O
left	O
shunt	O
,	O
which	O
caused	O
severe	O
ventilation	O
/	O
perfusion	O
disturbance	O
.	O

CONCLUSIONS	O
:	O
We	O
indicated	O
that	O
the	O
one	O
of	O
the	O
main	O
mechanisms	O
of	O
severe	O
hypoxemia	O
in	O
ARDS	B-DISO
might	O
be	O
caught	O
by	O
the	O
shunt	O
between	O
pulmonary	O
artery	O
and	O
pulmonary	O
vein	O
just	O
like	O
physiological	O
right	O
to	O
left	O
shunt	O
,	O
which	O
caused	O
severe	O
ventilation	O
/	O
perfusion	O
disturbance	O
.	O

The	O
Cox	O
proportional	O
hazard	O
multi	O
-	O
variable	O
stepwise	O
analysis	O
showed	O
the	O
prediction	O
model	O
of	O
severe	O
SARS	B-DISO
included	O
age	O
,	O
comorbid	O
disease	O
,	O
body	O
temperature	O
being	O
still	O
abnormal	O
after	O
2	O
days	O
of	O
hospitalization	O
,	O
neutrophil	O
percentage	O
began	O
to	O
increase	O
steadily	O
to	O
more	O
than	O
80	O
%	O
after	O
3	O
days	O
of	O
hospitalization	O
,	O
counts	O
of	O
lymphocytes	O
persisted	O
<	O
0	O
.	O
9	O
x	O
10	O
(	O
9	O
)/	O
L	O
after	O
4	O
days	O
of	O
hospitalization	O
.	O

Some	O
patients	O
suffered	B-DISO
from	O
temporary	O
multiple	O
organ	O
dysfunctions	O
(	O
mainly	O
impairments	O
of	O
liver	O
and	O
myocardium	O
).	O

(	O
3	O
)	O
With	O
descending	O
in	O
infectious	B-DISO
generations	O
,	O
the	O
course	O
from	O
the	O
appearance	O
of	O
pulmonary	O
lesions	O
to	O
their	O
resolution	O
shortened	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

With	O
descending	O
in	O
infectious	B-DISO
generations	O
,	O
the	O
clinical	O
features	O
of	O
SARS	B-DISO
may	O
become	O
ameliorated	O
.	O

TITLE	O
:	O
[	O
The	O
incidence	O
and	O
prevention	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
81	O
hemodialysis	O
units	O
in	O
Beijing	O
].	O

RESULTS	O
:	O
(	O
1	O
)	O
Seven	O
hemodialysis	O
patients	O
were	O
diagnosed	O
as	O
SARS	B-DISO
clinically	O
and	O
account	O
for	O
0	O
.	O
24	O
%	O
of	O
total	O
2885	O
hemodialysis	O
patients	O
in	O
these	O
units	O
in	O
Beijing	O
.	O

TITLE	O
:	O
[	O
The	O
COX	O
regression	O
analysis	O
on	O
the	O
use	O
of	O
corticosteroids	O
in	O
the	O
treatment	O
of	O
SARS	B-DISO
].	O

TITLE	O
:	O
[	O
Detection	O
of	O
RNA	O
of	O
SARS	B-DISO
coronavirus	O
in	O
hospital	O
sewage	O
].	O

RESULTS	O
:	O
There	O
was	O
no	O
live	O
SARS	B-DISO
-	O
CoV	O
detected	O
in	O
the	O
sewage	O
in	O
this	O
study	O
.	O

TITLE	O
:	O
A	O
subcutaneously	O
injected	O
UV	O
-	O
inactivated	O
SARS	B-DISO
coronavirus	O
vaccine	O
elicits	O
systemic	O
humoral	O
immunity	O
in	O
mice	O
.	O

Notably	O
,	O
the	O
SARS	B-DISO
-	O
CoV	O
virion	O
itself	O
was	O
able	O
to	O
induce	O
long	O
-	O
term	O
antibody	O
production	O
even	O
without	O
an	O
adjuvant	O
.	O

Several	O
pulmonary	B-DISO
diseases	I-DISO
have	O
distinguishing	O
features	O
,	O
which	O
are	O
better	O
delineated	O
on	O
high	O
resolution	O
CT	O
scans	O
than	O
plain	O
chest	O
radiographs	O
.	O

The	O
radiographic	O
features	O
of	O
unusual	O
diffuse	O
lung	B-DISO
diseases	I-DISO
published	O
in	O
the	O
past	O
two	O
years	O
are	O
described	O
.	O

A	O
normal	O
HRCT	O
rules	O
out	O
the	O
diagnosis	O
of	O
Pneumocystis	B-DISO
carinii	I-DISO
pneumonia	I-DISO
while	O
a	O
normal	O
chest	O
radiograph	O
does	O
not	O
.	O

In	O
both	O
cell	O
lines	O
,	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
deregulated	O
expression	O
of	O
cellular	O
genes	O
which	O
may	O
be	O
important	O
for	O
the	O
intestinal	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
.	O

A	O
helpdesk	O
service	O
was	O
established	O
with	O
the	O
goal	O
of	O
providing	O
immediate	O
emotional	O
and	O
communication	O
support	O
to	O
relatives	O
while	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
patients	O
were	O
isolated	O
during	O
the	O
acute	O
phase	O
of	O
the	O
illness	O
.	O

This	O
study	O
describes	O
the	O
results	O
of	O
a	O
rapid	O
assessment	O
of	O
the	O
effectiveness	O
of	O
a	O
helpdesk	O
service	O
designed	O
to	O
meet	O
the	O
immediate	O
needs	O
of	O
relatives	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
patients	O
in	O
Hong	O
Kong	O
.	O

The	O
results	O
suggest	O
that	O
facilitation	O
of	O
visitation	O
of	O
patients	O
by	O
relatives	O
via	O
video	O
conferencing	O
and	O
education	O
of	O
the	O
public	O
on	O
the	O
nature	O
and	O
course	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
to	O
reduce	O
the	O
social	O
stigma	O
of	O
having	O
a	O
potentially	O
life	O
-	O
threatening	O
disease	O
should	O
be	O
introduced	O
in	O
Hong	O
Kong	O
.	O

TITLE	O
:	O
[	O
Clinical	O
impact	O
of	O
recruitment	B-DISO
maneuvers	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
].	O

Regarding	O
the	O
current	O
literature	O
,	O
recruitment	B-DISO
maneuvers	O
may	O
be	O
considered	O
as	O
a	O
rescue	O
therapy	O
in	O
the	O
early	O
stage	O
of	O
severe	O
hypoxemic	O
lung	O
failure	O
,	O
if	O
a	O
lung	O
protective	O
ventilation	O
strategy	O
and	O
other	O
additive	O
adjuncts	O
like	O
prone	O
positioning	O
or	O
the	O
application	O
of	O
inhaled	O
vasodilators	O
failed	O
to	O
induce	O
adequate	O
gas	O
exchange	O
.	O

We	O
developed	O
a	O
highly	O
sensitive	O
and	O
safe	O
neutralization	O
assay	O
using	O
the	O
SARS	B-DISO
-	O
CoV	O
pseudotyped	O
virus	O
and	O
used	O
this	O
assay	O
to	O
determine	O
the	O
titers	O
of	O
the	O
NAbs	O
in	O
serum	O
samples	O
from	O
patients	O
with	O
SARS	B-DISO
.	O

These	O
results	O
suggest	O
that	O
it	O
is	O
possible	O
to	O
develop	O
effective	O
vaccines	O
against	O
SARS	B-DISO
and	O
that	O
NAbs	O
provide	O
a	O
potential	O
strategy	O
for	O
treating	O
patients	O
with	O
SARS	B-DISO
.	O

We	O
propose	O
that	O
the	O
low	O
stability	O
of	O
N	O
protein	O
may	O
be	O
critical	O
for	O
the	O
stability	O
and	O
function	O
of	O
SARS	B-DISO
virus	O
.	O

The	O
main	O
outcome	O
measures	O
were	O
rates	O
of	O
psychiatric	O
morbidity	O
,	O
level	O
of	O
posttraumatic	O
stress	B-DISO
symptoms	I-DISO
,	O
and	O
coping	O
strategies	O
.	O

These	O
findings	O
provide	O
possible	O
foci	O
for	O
early	O
identification	O
and	O
psychological	B-DISO
support	O
.	O

CONCLUSIONS	O
:	O
SARS	B-DISO
-	O
related	O
psychiatric	O
and	O
posttraumatic	O
morbidities	O
were	O
present	O
in	O
the	O
medical	O
staff	O
within	O
a	O
primary	O
health	O
care	O
setting	O
.	O

Symptoms	O
of	O
posttraumatic	B-DISO
stress	I-DISO
disorder	I-DISO
(	O
PTSD	B-DISO
)	O
and	O
depression	B-DISO
were	O
observed	O
in	O
28	O
.	O
9	O
%	O
and	O
31	O
.	O
2	O
%	O
of	O
respondents	O
,	O
respectively	O
.	O

Acquaintance	O
with	O
or	O
direct	O
exposure	O
to	O
someone	O
with	O
a	O
diagnosis	O
of	O
SARS	B-DISO
was	O
also	O
associated	O
with	O
PTSD	B-DISO
and	O
depressive	B-DISO
symptoms	I-DISO
.	O

This	O
finding	O
,	O
with	O
the	O
high	O
detection	O
rate	O
a	O
median	O
of	O
4	O
days	O
after	O
disease	O
onset	O
and	O
before	O
the	O
development	O
of	O
lung	O
lesions	O
in	O
four	O
patients	O
,	O
suggests	O
that	O
throat	O
wash	O
and	O
saliva	O
should	O
be	O
included	O
in	O
sample	O
collection	O
guidelines	O
for	O
SARS	B-DISO
diagnosis	O
.	O

We	O
propose	O
a	O
minimum	O
dataset	O
to	O
capture	O
data	O
needed	O
to	O
examine	O
the	O
basic	O
reproduction	O
rate	O
,	O
case	O
status	O
and	O
criteria	O
,	O
symptoms	O
,	O
and	O
outcomes	O
of	O
SARS	B-DISO
.	O

TITLE	O
:	O
SARS	B-DISO
coronavirus	O
detection	O
.	O

ABSTRACT	O
:	O
We	O
developed	O
a	O
set	O
of	O
three	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
assays	O
that	O
amplify	O
three	O
different	O
regions	O
of	O
the	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
),	O
can	O
be	O
run	O
in	O
parallel	O
or	O
in	O
a	O
single	O
tube	O
,	O
and	O
can	O
detect	O
<	O
10	O
genome	O
equivalents	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
assays	O
consider	O
all	O
currently	O
available	O
SARS	B-DISO
-	O
CoV	O
sequences	O
and	O
are	O
optimized	O
for	O
two	O
prominent	O
real	O
-	O
time	O
PCR	O
platforms	O
.	O

ABSTRACT	O
:	O
High	O
mobility	O
group	O
box	O
1	O
protein	O
(	O
HMGB1	O
)	O
is	O
released	O
by	O
necrotic	O
cells	O
or	O
activated	O
macrophages	O
/	O
monocytes	O
,	O
and	O
functions	O
as	O
a	O
late	O
mediator	O
of	O
lethal	O
systemic	O
and	O
local	O
pulmonary	B-DISO
inflammation	I-DISO
.	O

This	O
article	O
focuses	O
on	O
nine	O
emerging	O
viral	O
infectious	B-DISO
agents	O
.	O

The	O
pathogenesis	B-DISO
,	O
manifestations	O
,	O
and	O
therapy	O
(	O
where	O
applicable	O
)	O
are	O
also	O
addressed	O
.	O

ABSTRACT	O
:	O
Accurate	O
,	O
objective	O
models	O
of	O
triage	O
for	O
patients	O
with	O
suspected	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
could	O
assess	O
risks	O
and	O
improve	O
decisions	O
about	O
isolation	O
and	O
inpatient	O
treatment	O
.	O

Predictors	O
for	O
SARS	B-DISO
on	O
the	O
basis	O
of	O
history	O
(	O
step	O
1	O
)	O
included	O
previous	O
contact	O
with	O
a	O
patient	O
with	O
SARS	B-DISO
and	O
the	O
presence	O
of	O
fever	O
,	O
myalgia	B-DISO
,	O
and	O
malaise	B-DISO
.	O

A	O
high	O
neutrophil	O
count	O
,	O
the	O
extremes	O
of	O
age	O
,	O
and	O
sputum	O
production	O
were	O
associated	O
with	O
a	O
lower	O
probability	O
of	O
SARS	B-DISO
.	O

Diminished	O
CD8alpha	O
-	O
DC	O
activation	O
correlated	O
with	O
reduced	O
IFN	O
-	O
gamma	O
expression	O
by	O
virus	O
-	O
specific	O
T	O
cells	O
accompanied	O
by	O
increased	O
IL	O
-	O
10	O
production	O
suggesting	O
that	O
CCL3	O
contributes	O
to	O
an	O
effective	O
host	O
response	O
to	O
viral	B-DISO
infection	I-DISO
by	O
enhancing	O
the	O
T	O
cell	O
activation	O
potential	O
of	O
DC	O
.	O

A	O
summary	O
of	O
the	O
meeting	O
highlights	O
,	O
segregated	O
by	O
infectious	B-DISO
agent	O
,	O
will	O
be	O
presented	O
in	O
this	O
review	O
.	O

Counts	O
of	O
patient	O
visits	O
meeting	O
syndrome	B-DISO
criteria	O
and	O
total	O
patient	O
visits	O
were	O
reported	O
daily	O
on	O
the	O
secure	O
regional	O
emergency	B-DISO
medicine	O
Internet	O
site	O
and	O
downloaded	O
by	O
public	O
health	O
staff	O
.	O

A	O
regional	O
emergency	B-DISO
medicine	O
Internet	O
approach	O
permitted	O
rapid	O
implementation	O
of	O
multisite	O
syndromic	O
surveillance	O
without	O
additional	O
staff	O
.	O

RESULTS	O
:	O
In	O
the	O
first	O
"("""	O
All	O
Star	B-DISO
Game	O
""")"	O
project	O
,	O
8	O
departments	O
reported	O
daily	O
counts	O
for	O
4	O
weeks	O
,	O
covering	O
more	O
than	O
26	O
,	O
000	O
patient	O
visits	O
.	O

ABSTRACT	O
:	O
The	O
emergence	O
of	O
new	O
infectious	B-DISO
diseases	I-DISO
and	O
old	O
diseases	O
with	O
new	O
pathogenic	O
properties	O
is	O
a	O
burgeoning	O
worldwide	O
problem	O
.	O

Combining	O
the	O
ancient	O
and	O
present	O
literature	O
with	O
the	O
special	O
epidemic	O
patterns	O
,	O
pathological	O
changes	O
and	O
clinical	O
symptoms	O
of	O
SARS	B-DISO
,	O
the	O
paper	O
discussed	O
the	O
methods	O
of	O
application	O
of	O
the	O
integrated	O
traditional	O
Chinese	O
and	O
western	O
medicine	O
on	O
the	O
treatment	O
of	O
SARS	B-DISO
,	O
and	O
some	O
matters	O
needing	O
attention	O
in	O
clinic	O
.	O

These	O
results	O
suggest	O
that	O
tranilast	O
may	O
be	O
a	O
candidate	O
drug	O
for	O
the	O
treatment	O
of	O
ARDS	B-DISO
/	O
ALI	O
.	O

There	O
was	O
no	O
significant	O
difference	O
among	O
positive	O
rates	O
of	O
SARS	B-DISO
-	O
CoV	O
IgG	O
for	O
generations	O
,	O
Chi	O
square	O
=	O
5	O
.	O
11	O
,	O
P	O
greater	O
than	O
0	O
.	O
05	O
.	O

The	O
positive	O
rate	O
of	O
SARS	B-DISO
-	O
CoV	O
IgG	O
in	O
cases	O
who	O
were	O
not	O
in	O
chain	O
of	O
transmission	O
was	O
12	O
.	O
59	O
%(	O
18	O
/	O
143	O
)	O
which	O
was	O
statistically	O
significantly	O
different	O
from	O
that	O
of	O
cases	O
in	O
chain	O
of	O
transmission	O
,	O
Chi	O
square	O
=	O
199	O
.	O
64	O
,	O
P	O
less	O
than	O
0	O
.	O
001	O
.	O

Compared	O
with	O
patients	O
of	O
the	O
same	O
group	O
who	O
were	O
not	O
treated	O
with	O
glucocorticoids	O
,	O
T	O
-	O
lymphocyte	O
counts	O
of	O
non	O
-	O
SARS	B-DISO
patients	O
treated	O
with	O
glucocorticoids	O
had	O
no	O
obvious	O
difference	O
.	O

Out	O
of	O
121	O
patients	O
studied	O
,	O
71	O
.	O
1	O
%	O
were	O
SARS	B-DISO
specific	O
IgG	O
positive	O
.	O

The	O
sensitivity	O
of	O
the	O
SARS	B-DISO
specific	O
IgG	O
kit	O
utilized	O
needs	O
to	O
be	O
further	O
improved	O
.	O

The	O
onset	O
symptoms	O
were	O
characterized	O
by	O
fever	O
(	O
100	O
%),	O
cough	B-DISO
(	O
49	O
.	O
1	O
%),	O
maylgia	O
(	O
24	O
.	O
5	O
%),	O
shortness	B-DISO
of	I-DISO
breath	I-DISO
(	O
20	O
.	O
8	O
%),	O
malaise	B-DISO
(	O
17	O
.	O
0	O
%),	O
and	O
diarrhea	B-DISO
(	O
5	O
.	O
7	O
%).	O

Routine	O
blood	O
test	O
during	O
the	O
first	O
to	O
the	O
fifth	O
day	O
of	O
the	O
disease	O
revealed	O
WBCs	O
less	O
than	O
4	O
.	O
0x10	O
(	O
9	O
)	O
/	O
L	O
in	O
33	O
patients	O
(	O
62	O
.	O
3	O
%),	O
4	O
.	O
0	O
-	O
10	O
.	O
0x10	O
(	O
9	O
)/	O
L	O
in	O
18	O
patients	O
(	O
34	O
.	O
0	O
%),	O
lymphopenia	B-DISO
in	O
36	O
patients	O
(	O
67	O
.	O
9	O
%),	O
and	O
PLT	O
less	O
than	O
100	O
.	O
0x10	O
(	O
9	O
)	O
in	O
7	O
patients	O
(	O
13	O
.	O
2	O
%).	O

CONCLUSIONS	O
:	O
The	O
clinical	O
manifestations	O
of	O
SARS	B-DISO
at	O
the	O
early	O
stage	O
were	O
complex	O
.	O

Low	O
counts	O
of	O
leukocytes	O
,	O
lymphocytes	O
and	O
platelets	O
were	O
common	O
among	O
patients	O
in	O
the	O
early	O
stage	O
of	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
molecular	O
mechanism	O
of	O
interferon	O
alpha2b	O
(	O
IFNalpha2b	O
)	O
inhibiting	O
the	O
SARS	B-DISO
virus	O
replication	O
.	O

Interferon	O
alpha2b	O
could	O
inhibit	O
almost	O
all	O
the	O
SARS	B-DISO
virus	O
gene	O
transcription	O
.	O

ABSTRACT	O
:	O
To	O
isolate	O
and	O
identify	O
pathogen	O
of	O
atypical	B-DISO
pneumonia	I-DISO
in	O
Guangdong	O
.	O

CONCLUSIONS	O
:	O
The	O
pathogen	O
of	O
the	O
atypical	B-DISO
pneumonia	I-DISO
in	O
Guangdong	O
province	O
was	O
a	O
novel	O
type	O
of	O
coronavirus	O
,	O
which	O
could	O
be	O
isolated	O
by	O
using	O
MDCK	O
cells	O
.	O

The	O
major	O
pathological	O
changes	O
of	O
2	O
autopsy	O
cases	O
of	O
SARS	B-DISO
in	O
lung	O
tissues	O
were	O
acute	O
pulmonary	O
interstitial	O
and	O
alveolar	O
exudative	B-DISO
inflammation	I-DISO
,	O
and	O
2	O
autopsy	O
and	O
one	O
biopsy	O
lung	O
tissues	O
showed	O
alveolar	O
hyaline	B-DISO
membrane	I-DISO
formation	O
.	O

However	O
,	O
spleen	O
and	O
bone	O
marrow	O
biopsy	O
tissue	O
samples	O
from	O
4	O
dead	O
SARS	B-DISO
cases	O
whose	O
clinical	O
course	O
lasted	O
from	O
21	O
to	O
40	O
days	O
presented	O
repairing	O
changes	O
.	O

The	O
semi	O
-	O
quantitative	O
analysis	O
of	O
lymphocyte	O
subpopulations	O
revealed	O
that	O
the	O
proportion	O
of	O
CD8	O
+	O
T	O
lymphocytes	O
were	O
about	O
80	O
%	O
of	O
the	O
total	O
infiltrative	O
inflammatory	O
cells	O
in	O
the	O
pulmonary	O
interstitium	O
,	O
with	O
a	O
few	O
CD4	O
+	O
lymphocytes	O
CD3	O
+,	O
CD4	O
+,	O
CD8	O
+	O
or	O
CD20	O
+	O
lymphocyte	O
subpopulations	O
were	O
obviously	O
decreased	O
and	O
there	O
was	O
imbalance	B-DISO
in	O
number	O
and	O
proportion	O
,	O
while	O
CD57	O
+,	O
CD68	O
+,	O
S	O
-	O
100	O
+	O
and	O
HLA	O
-	O
DR	O
+	O
cells	O
were	O
relatively	O
increased	O
in	O
lymph	O
nodes	O
and	O
spleens	O
.	O

The	O
clinical	O
data	O
of	O
60	O
SARS	B-DISO
patients	O
were	O
analyzed	O
by	O
logistic	O
regression	O
and	O
Cox	O
'	O
s	O
proportional	O
hazards	O
analysis	O
.	O

CONCLUSIONS	O
:	O
Older	O
age	O
and	O
severe	O
lymphopenia	B-DISO
seem	O
to	O
be	O
statistically	O
significant	O
for	O
predicting	O
the	O
clinical	O
deterioration	O
in	O
SARS	B-DISO
patients	O
.	O

This	O
study	O
investigated	O
the	O
physiological	O
impact	O
of	O
wearing	O
an	O
N95	O
mask	O
during	O
hemodialysis	O
(	O
HD	O
)	O
on	O
patients	O
with	O
ESRD	B-DISO
.	O

This	O
structure	O
shares	O
significant	O
similarity	O
with	O
the	O
fusion	O
core	O
structure	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
spike	O
protein	O
and	O
other	O
viral	O
fusion	O
proteins	O
,	O
suggesting	O
a	O
conserved	O
mechanism	O
of	O
membrane	O
fusion	O
.	O

ABSTRACT	O
:	O
This	O
was	O
a	O
study	O
to	O
evaluate	O
the	O
utilization	O
of	O
emergency	B-DISO
medical	O
services	O
(	O
EMS	O
)	O
systems	O
during	O
the	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
and	O
to	O
assess	O
the	O
incidence	O
of	O
infection	B-DISO
among	O
emergency	B-DISO
medical	O
technicians	O
(	O
EMTs	O
).	O

Probable	O
/	O
suspect	O
cases	O
of	O
SARS	B-DISO
were	O
defined	O
by	O
World	O
Health	O
Organization	O
criteria	O
.	O

When	O
SARS	B-DISO
-	O
related	O
transports	O
were	O
excluded	O
,	O
there	O
was	O
a	O
12	O
.	O
2	O
%	O
decrease	O
(	O
95	O
%	O
CI	O
=	O
11	O
.	O
4	O
%	O
to	O
12	O
.	O
9	O
%)	O
in	O
EMS	O
activities	O
.	O

Requests	O
from	O
hospitals	O
,	O
quarantined	O
individuals	O
,	O
and	O
febrile	O
citizens	O
accounted	O
for	O
23	O
%,	O
18	O
%,	O
and	O
59	O
%	O
of	O
SARS	B-DISO
-	O
related	O
transports	O
.	O

Combining	O
P	O
-	O
SARS	B-DISO
and	O
the	O
seropositive	O
case	O
,	O
three	O
EMTs	O
were	O
infected	O
(	O
incidence	O
1	O
.	O
3	O
%,	O
95	O
%	O
CI	O
=	O
0	O
.	O
4	O
%	O
to	O
3	O
.	O
6	O
%).	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
loss	O
of	O
paramedic	O
availability	O
to	O
Toronto	O
Emergency	B-DISO
Medical	O
Services	O
during	O
a	O
biphasic	O
(	O
SARS	B-DISO
-	O
1	O
and	O
SARS	B-DISO
-	O
2	O
)	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

During	O
the	O
SARS	B-DISO
outbreak	O
,	O
there	O
were	O
five	O
cases	O
of	O
probable	O
SARS	B-DISO
and	O
three	O
cases	O
of	O
suspect	O
SARS	B-DISO
.	O

SARS	B-DISO
-	O
2	O
lasted	O
18	O
days	O
,	O
during	O
which	O
292	O
paramedics	O
were	O
placed	O
on	O
either	O
HQ	O
or	O
WQ	O
,	O
for	O
a	O
combined	O
number	O
of	O
quarantine	O
days	O
of	O
1	O
,	O
637	O
.	O

RESULTS	O
:	O
During	O
the	O
SARS	B-DISO
outbreak	O
,	O
there	O
were	O
five	O
cases	O
of	O
probable	O
SARS	B-DISO
and	O
three	O
cases	O
of	O
suspect	O
SARS	B-DISO
.	O

In	O
this	O
context	O
,	O
naturally	O
emerging	O
diseases	O
such	O
as	O
SARS	B-DISO
,	O
monkeypox	B-DISO
or	O
West	B-DISO
Nile	I-DISO
fever	I-DISO
assume	O
new	O
importance	O
because	O
it	O
is	O
difficult	O
to	O
distinguish	O
between	O
natural	O
epidemics	O
and	O
possible	O
bioweapon	O
assaults	O
.	O

The	O
system	O
allows	O
efficient	O
cDNA	O
amplification	B-DISO
of	O
SARS	B-DISO
-	O
CoV	O
followed	O
by	O
electrophoretic	O
sizing	O
and	O
detection	O
on	O
the	O
same	O
chip	O
.	O

Since	O
Zip	O
Codes	O
have	O
no	O
homology	O
to	O
either	O
the	O
target	O
sequence	O
or	O
to	O
other	O
sequences	O
in	O
the	O
genomes	O
of	O
both	O
human	O
host	O
and	O
SARS	B-DISO
-	O
CoV	O
,	O
there	O
was	O
no	O
false	O
signal	O
due	O
to	O
mismatch	O
hybridizations	O
.	O

Virus	O
was	O
isolated	O
from	O
six	O
patients	O
with	O
encephalitis	B-DISO
and	O
was	O
identified	O
as	O
Chandipura	O
virus	O
by	O
electron	O
microscopy	O
,	O
complement	O
fixation	O
,	O
and	O
neutralisation	O
tests	O
.	O

TITLE	O
:	O
Importance	O
of	O
Akt	O
signaling	O
pathway	O
for	O
apoptosis	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
an	O
acute	O
respiratory	O
tract	O
infectious	B-DISO
disease	I-DISO
that	O
is	O
associated	O
with	O
a	O
new	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

Yet	O
,	O
little	O
sequence	O
homology	O
between	O
the	O
newly	O
identified	O
SARS	B-DISO
-	O
CoV	O
and	O
those	O
previously	O
studied	O
coronaviruses	O
suggests	O
that	O
determination	O
of	O
protein	O
-	O
protein	O
interaction	O
and	O
identification	O
of	O
amino	O
acid	O
sequences	O
,	O
responsible	O
for	O
such	O
interaction	O
in	O
SARS	B-DISO
-	O
CoV	O
,	O
are	O
necessary	O
for	O
the	O
elucidation	O
of	O
the	O
molecular	O
mechanism	O
of	O
SARS	B-DISO
-	O
CoV	O
replication	O
and	O
rationalization	O
of	O
anti	O
-	O
SARS	B-DISO
therapeutic	O
intervention	O
.	O

The	O
IC50	O
of	O
chloroquine	O
for	O
inhibition	O
of	O
SARS	B-DISO
-	O
CoV	O
in	O
vitro	O
approximates	O
the	O
plasma	O
concentrations	O
of	O
chloroquine	O
reached	O
during	O
treatment	O
of	O
acute	B-DISO
malaria	I-DISO
.	O

We	O
describe	O
two	O
patients	O
with	O
systemic	B-DISO
lupus	I-DISO
erythematosus	I-DISO
(	O
SLE	B-DISO
)	O
who	O
presented	O
with	O
fever	O
,	O
systemic	O
upset	B-DISO
and	O
pulmonary	B-DISO
infiltrates	I-DISO
between	O
April	O
and	O
June	O
,	O
2003	O
.	O

These	O
findings	O
demonstrate	O
the	O
potential	O
of	O
such	O
infections	B-DISO
to	O
be	O
transmitted	B-DISO
during	O
the	O
process	O
of	O
international	O
adoption	O
,	O
and	O
in	O
the	O
case	O
of	O
measles	B-DISO
the	O
realization	O
of	O
this	O
potential	O
in	O
recent	O
reported	O
cases	O
from	O
Chinese	O
orphanages	O
brought	O
to	O
the	O
United	O
States	O
on	O
commercial	O
airlines	O
.	O

7	O
.	O
6	O
degrees	O
C	O
,	O
suggesting	O
that	O
coronary	O
virus	B-DISO
infection	I-DISO
,	O
which	O
has	O
been	O
considered	O
to	O
cause	O
SARS	B-DISO
by	O
now	O
,	O
may	O
be	O
most	O
active	O
at	O
9	O
degrees	O
C	O
-	O
24	O
degrees	O
C	O
.	O
(	O
2	O
)	O
Occupational	O
hygiene	O
in	O
hospital	O
proved	O
to	O
be	O
an	O
important	O
socio	O
-	O
behavior	O
factor	O
for	O
SARS	B-DISO
outbreak	O
.	O

RESULTS	O
:	O
(	O
1	O
)	O
The	O
amplitude	O
of	O
air	O
temperature	O
,	O
air	O
pressure	O
and	O
diurnal	O
temperature	O
difference	O
were	O
greater	O
around	O
SARS	B-DISO
outbreaks	O
in	O
most	O
of	O
the	O
cities	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
not	O
only	O
responsible	O
for	O
receptor	O
binding	O
and	O
virus	O
fusion	O
,	O
but	O
also	O
a	O
major	O
Ag	O
among	O
the	O
SARS	B-DISO
-	O
CoV	O
proteins	O
that	O
induces	O
protective	O
Ab	O
responses	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
the	O
S	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
is	O
highly	O
immunogenic	O
during	O
infection	B-DISO
and	O
immunizations	O
,	O
and	O
contains	O
five	O
linear	O
immunodominant	O
sites	O
(	O
sites	O
I	O
to	O
V	O
)	O
as	O
determined	O
by	O
Pepscan	O
analysis	O
with	O
a	O
set	O
of	O
synthetic	O
peptides	O
overlapping	O
the	O
entire	O
S	O
protein	O
sequence	O
against	O
the	O
convalescent	O
sera	O
from	O
SARS	B-DISO
patients	O
and	O
antisera	O
from	O
small	O
animals	O
immunized	O
with	O
inactivated	O
SARS	B-DISO
-	O
CoV	O
.	O
Site	O
IV	O
located	O
in	O
the	O
middle	O
region	O
of	O
the	O
S	O
protein	O
(	O
residues	O
528	O
-	O
635	O
)	O
is	O
a	O
major	O
immunodominant	O
epitope	O
.	O

MRSA	B-DISO
screening	O
was	O
performed	O
for	O
all	O
ICU	O
patients	O
.	O

The	O
data	O
suggest	O
that	O
MRSA	B-DISO
cross	O
-	O
transmission	O
may	O
be	O
increased	O
if	O
gloves	O
and	O
gowns	O
are	O
worn	O
all	O
the	O
time	O
.	O

In	O
February	O
2004	O
,	O
Fujisawa	O
Deutschland	O
GmbH	O
,	O
a	O
subsidiary	O
of	O
Fujisawa	O
Pharmaceutical	O
Co	O
.,	O
entered	O
into	O
an	O
option	O
agreement	O
with	O
Hemispherx	O
Biopharma	O
with	O
the	O
intent	O
of	O
becoming	O
a	O
distributor	O
for	O
Ampligen	O
for	O
the	O
potential	O
treatment	O
of	O
chronic	B-DISO
fatigue	I-DISO
syndrome	I-DISO
in	O
Germany	O
,	O
Switzerland	O
and	O
Austria	O
.	O

In	O
February	O
2000	O
,	O
Crystaal	O
Corporation	O
(	O
now	O
Biovail	O
Pharmaceuticals	O
Canada	O
)	O
acquired	O
exclusive	O
marketing	O
rights	O
to	O
Ampligen	O
in	O
Canada	O
,	O
where	O
it	O
submitted	O
an	O
NDA	O
for	O
the	O
agent	O
for	O
the	O
treatment	O
of	O
chronic	B-DISO
fatigue	I-DISO
syndrome	I-DISO
.	O

In	O
the	O
meantime	O
,	O
Ampligen	O
has	O
been	O
available	O
since	O
May	O
1996	O
under	O
the	O
Canadian	O
Emergency	B-DISO
Drug	O
Release	O
Programme	O
for	O
the	O
treatment	O
of	O
chronic	B-DISO
fatigue	I-DISO
syndrome	I-DISO
and	O
immune	B-DISO
dysfunction	I-DISO
syndrome	B-DISO
by	O
Rivex	O
Pharma	O
(	O
Helix	O
BioPharma	O
).	O

Researchers	O
at	O
the	O
Rega	O
Institute	O
in	O
Belgium	O
have	O
published	O
results	O
from	O
an	O
animal	O
study	O
demonstrating	O
that	O
Ampligen	O
was	O
superior	O
at	O
protecting	O
mice	O
against	O
coxsackie	O
B3	O
virus	O
-	O
induced	O
myocarditis	B-DISO
compared	O
with	O
pegylated	O
interferon	O
.	O

The	O
identification	O
of	O
human	O
blood	O
mononuclear	O
cells	O
as	O
a	O
direct	O
target	O
of	O
SARS	B-DISO
-	O
CoV	O
in	O
the	O
model	O
system	O
described	O
here	O
provides	O
a	O
new	O
insight	O
into	O
disease	O
pathology	B-DISO
and	O
a	O
tool	O
for	O
investigating	O
the	O
host	O
response	O
and	O
mechanisms	O
of	O
pathogenesis	B-DISO
.	O

Several	O
old	O
drugs	O
that	O
bind	O
to	O
SARS	B-DISO
3CLpro	O
active	O
site	O
were	O
selected	O
and	O
in	O
silico	O
derivatized	O
to	O
generate	O
covalent	O
irreversible	O
inhibitors	O
with	O
enhanced	O
affinity	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
metal	O
-	O
conjugated	O
compounds	O
as	O
inhibitors	O
of	O
3CL	O
protease	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
ABSTRACT	O
:	O
3C	O
-	O
like	O
(	O
3CL	O
)	O
protease	O
is	O
essential	O
for	O
the	O
life	O
cycle	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
therefore	O
represents	O
a	O
key	O
anti	O
-	O
viral	O
target	O
.	O

The	O
results	O
will	O
be	O
useful	O
for	O
the	O
rational	O
development	O
of	O
the	O
anti	O
-	O
SARS	B-DISO
drugs	O
.	O

TITLE	O
:	O
Pulmonary	O
function	O
and	O
exercise	O
capacity	O
in	O
survivors	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
We	O
did	O
the	O
right	O
thing	O
:	O
an	O
intervention	O
analysis	O
approach	O
to	O
modeling	O
intervened	O
SARS	B-DISO
propagation	O
in	O
Singapore	O
.	O

These	O
measures	O
included	O
extreme	O
restrictions	O
on	O
those	O
who	O
would	O
normally	O
accompany	O
patients	O
to	O
the	O
hospital	O
,	O
screening	O
for	O
SARS	B-DISO
,	O
and	O
protective	O
attire	O
for	O
hospital	O
staff	O
,	O
including	O
masks	O
,	O
face	B-DISO
shields	O
,	O
goggles	O
,	O
gloves	O
and	O
gowns	O
.	O

According	O
to	O
the	O
morphologic	O
changes	O
,	O
lung	O
lesions	O
in	O
SARS	B-DISO
were	O
subcategorized	O
into	O
3	O
phases	O
:	O
acute	B-DISO
exudative	I-DISO
inflammation	I-DISO
,	O
fibrous	O
proliferation	B-DISO
and	O
the	O
final	O
fibrotic	O
stage	O
.	O

All	O
patients	O
with	O
the	O
diagnosis	O
of	O
probable	O
SARS	B-DISO
admitted	O
to	O
a	O
regional	O
hospital	O
in	O
Hong	O
Kong	O
from	O
March	O
9	O
to	O
April	O
28	O
,	O
2003	O
,	O
and	O
who	O
had	O
SARS	B-DISO
-	O
related	O
respiratory	B-DISO
distress	I-DISO
complications	O
were	O
recruited	O
for	O
NIPPV	O
usage	O
.	O

TITLE	O
:	O
Protein	O
chip	O
array	O
profiling	O
analysis	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
identified	O
serum	O
amyloid	B-DISO
a	O
protein	O
as	O
a	O
biomarker	O
potentially	O
useful	O
in	O
monitoring	O
the	O
extent	O
of	O
pneumonia	B-DISO
.	O

Self	O
-	O
control	O
before	O
and	O
after	O
treatment	O
examination	O
showed	O
that	O
significant	O
improvement	O
appeared	O
in	O
the	O
TCM	O
in	O
aspects	O
of	O
influenza	B-DISO
-	O
like	O
and	O
Warm	O
disease	O
symptoms	O
and	O
QOL	O
.	O

RESULTS	O
:	O
No	O
one	O
in	O
the	O
TCM	O
group	O
got	O
SARS	B-DISO
infection	B-DISO
while	O
in	O
the	O
control	O
group	O
,	O
64	O
(	O
0	O
.	O
4	O
%)	O
had	O
got	O
.	O

ABSTRACT	O
:	O
To	O
construct	O
the	O
phage	O
antibody	O
library	O
for	O
Fab	O
fragment	O
from	O
a	O
convalescent	O
patient	O
infected	O
with	O
SARS	B-DISO
coronavirus	O
.	O

Characterization	O
of	O
various	O
cellular	O
proteins	O
that	O
are	O
involved	O
in	O
regulating	O
cell	O
cycle	O
progression	O
demonstrated	O
that	O
p28	O
expression	O
resulted	O
in	O
an	O
accumulation	O
of	O
hypophosphorylated	O
retinoblastoma	B-DISO
protein	O
(	O
pRb	O
),	O
tumor	B-DISO
suppressor	O
p53	O
,	O
and	O
cyclin	O
-	O
dependent	O
kinase	O
(	O
Cdk	O
)	O
inhibitor	O
p21	O
(	O
Cip1	O
).	O

The	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
that	O
causes	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
infects	O
cells	O
expressing	O
the	O
receptor	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
).	O

Evidence	O
based	O
on	O
Bayesian	O
scanning	O
plots	O
and	O
phylogenetic	O
analysis	O
using	O
maximum	O
likelihood	O
(	O
ML	O
)	O
and	O
Bayesian	O
methods	O
indicates	O
that	O
SARS	B-DISO
-	O
CoV	O
,	O
for	O
the	O
largest	O
part	O
of	O
the	O
genome	O
(	O
approximately	O
80	O
%),	O
is	O
more	O
closely	O
related	O
to	O
Group	O
II	O
coronaviruses	O
sequences	O
,	O
whereas	O
in	O
three	O
regions	O
in	O
the	O
ORF1ab	O
gene	O
it	O
shows	O
no	O
apparent	O
similarity	O
to	O
any	O
of	O
the	O
previously	O
characterized	O
groups	O
of	O
coronaviruses	O
.	O

A	O
prospective	O
interventional	O
study	O
in	O
a	O
16	O
-	O
bed	B-DISO
intensive	O
care	O
unit	O
.	O

In	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
associated	O
human	O
corona	O
virus	O
,	O
the	O
spike	O
glycoprotein	O
and	O
nsps	O
(	O
nsp2	O
,	O
nsp5	O
,	O
nsp6	O
and	O
nsp7	O
)	O
were	O
identified	O
as	O
having	O
adhesin	O
-	O
like	O
characteristics	O
.	O

CONCLUSIONS	O
:	O
More	O
extensive	O
airspace	O
disease	O
at	O
presentation	O
is	O
an	O
independent	O
predictor	O
of	O
adverse	O
outcome	O
in	O
patients	O
with	O
SARS	B-DISO
.	O

End	O
-	O
expiratory	O
pressure	O
needed	O
to	O
prevent	O
significant	O
alveolar	O
collapse	B-DISO
in	O
severe	O
ARDS	B-DISO
resulted	O
in	O
maximal	O
safe	O
tidal	O
volumes	O
that	O
may	O
be	O
insufficient	O
for	O
adequate	O
ventilation	O
using	O
conventional	O
mechanical	O
ventilatory	O
modes	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
new	O
infectious	B-DISO
disease	I-DISO
with	O
a	O
global	O
impact	O
.	O

So	O
it	O
is	O
perhaps	O
not	O
surprising	O
that	O
the	O
ACE	O
D	O
/	O
D	O
genotype	O
is	O
associated	O
with	O
several	O
major	O
psychiatric	O
diseases	O
,	O
most	O
cancers	B-DISO
except	O
prostate	B-DISO
cancer	I-DISO
(	O
where	O
the	O
D	O
/	O
D	O
genotype	O
is	O
actually	O
protective	O
),	O
most	O
cardiovascular	B-DISO
diseases	I-DISO
,	O
most	O
autoimmune	B-DISO
diseases	I-DISO
,	O
and	O
even	O
infectious	B-DISO
diseases	I-DISO
like	O
tuberculosis	B-DISO
and	O
HIV	B-DISO
.	O

ACE1	O
might	O
be	O
one	O
of	O
the	O
candidate	O
genes	O
that	O
influence	O
the	O
progression	O
of	O
pneumonia	B-DISO
in	O
SARS	B-DISO
.	O

Sensitivity	O
,	O
specificity	O
,	O
and	O
likelihood	O
ratios	O
for	O
clinical	O
criteria	O
were	O
calculated	O
in	O
3	O
cohorts	O
by	O
using	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
at	O
autopsy	O
as	O
the	O
reference	O
standard	O
.	O

In	O
a	O
series	O
of	O
autopsy	O
patients	O
,	O
the	O
accuracy	O
of	O
the	O
American	O
-	O
European	O
Consensus	O
Conference	O
definition	O
of	O
ARDS	B-DISO
was	O
only	O
moderate	O
.	O

TITLE	O
:	O
Extracorporeal	O
life	O
support	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
adults	O
.	O

Severe	O
ARDS	B-DISO
was	O
defined	O
as	O
acute	O
onset	O
pulmonary	B-DISO
failure	I-DISO
,	O
with	O
bilateral	O
infiltrates	B-DISO
on	O
chest	O
x	O
-	O
ray	O
,	O
and	O
PaO2	O
/	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
FiO2	O
)	O
ratio	O
<	O
or	O
=	O
100	O
or	O
A	O
-	O
aDO2	O
>	O
600	O
mm	O
Hg	O
despite	O
maximal	O
ventilator	O
settings	O
.	O

Of	O
these	O
405	O
patients	O
,	O
255	O
were	O
placed	O
on	O
ECLS	O
for	O
severe	O
ARDS	B-DISO
refractory	O
to	O
all	O
other	O
treatment	O
.	O

Statistics	O
showed	O
that	O
serum	O
IgG	O
was	O
not	O
related	O
with	O
avascular	B-DISO
necrosis	I-DISO
of	I-DISO
femoral	I-DISO
head	I-DISO
and	O
osteoporosis	B-DISO
.	O

The	O
incidence	O
rates	O
of	O
critical	O
conditions	O
and	O
MODS	B-DISO
among	O
the	O
SARS	B-DISO
cases	O
without	O
underlying	O
diseases	O
,	O
with	O
other	O
comorbid	O
diseases	O
,	O
and	O
with	O
cerebrocardiovascular	O
diseases	O
were	O
28	O
.	O
10	O
%,	O
43	O
.	O
70	O
%,	O
and	O
58	O
.	O
18	O
%,	O
and	O
9	O
.	O
83	O
%,	O
18	O
.	O
52	O
%,	O
and	O
27	O
.	O
27	O
%	O
respectively	O
.	O

CONCLUSIONS	O
:	O
The	O
SARS	B-DISO
cases	O
with	O
cerebrocardiovascular	O
diseases	O
have	O
the	O
highest	O
incidence	O
rate	O
of	O
critical	O
conditions	O
and	O
MODS	B-DISO
.	O

Continuous	O
potassium	O
replacement	O
produced	O
rapid	O
and	O
complete	O
recovery	O
from	O
quadriplegia	B-DISO
and	O
respiratory	B-DISO
failure	I-DISO
without	O
requirement	O
for	O
mechanical	O
ventilation	O
.	O

ABSTRACT	O
:	O
The	O
serious	O
respiratory	B-DISO
disease	I-DISO
,	O
SARS	B-DISO
(	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
),	O
outbreaking	O
in	O
winter	O
of	O
2003	O
to	O
2004	O
remained	O
in	O
a	O
sporadic	O
patient	O
'	O
s	O
generating	O
at	O
this	O
winter	O
.	O

Our	O
results	O
showed	O
that	O
the	O
antibodies	O
could	O
efficiently	O
and	O
specifically	O
bind	O
to	O
their	O
corresponding	O
proteins	O
from	O
E	O
.	O
coli	O
expressed	O
or	O
lysate	O
of	O
SARS	B-DISO
-	O
CoV	O
infected	O
Vero	O
-	O
E6	O
cells	O
by	O
Western	O
blot	O
analysis	O
.	O

ELISPOT	O
detection	O
of	O
primary	O
B	O
cells	O
could	O
be	O
useful	O
in	O
the	O
early	O
detection	O
of	O
infection	B-DISO
following	O
infection	B-DISO
with	O
respiratory	O
coronaviruses	O
.	O

We	O
describe	O
here	O
the	O
screening	O
of	O
Chinese	O
herbal	O
medicine	O
-	O
based	O
,	O
novel	O
small	O
molecules	O
that	O
bind	O
avidly	O
with	O
the	O
surface	O
spike	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
thus	O
can	O
interfere	O
with	O
the	O
entry	O
of	O
the	O
virus	O
to	O
its	O
host	O
cells	O
.	O

Here	O
we	O
compare	O
human	O
,	O
mouse	O
,	O
and	O
rat	O
ACE2	O
molecules	O
for	O
their	O
ability	O
to	O
serve	O
as	O
receptors	O
for	O
SARS	B-DISO
-	O
CoV	O
.	O
We	O
found	O
that	O
,	O
compared	O
to	O
human	O
ACE2	O
,	O
murine	O
ACE2	O
less	O
efficiently	O
bound	O
the	O
S1	O
domain	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
supported	O
less	O
-	O
efficient	O
S	O
protein	O
-	O
mediated	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Effective	O
surveillance	O
is	O
necessary	O
for	O
the	O
successful	O
management	O
of	O
emerging	O
infection	B-DISO
.	O

TITLE	O
:	O
Six	O
month	O
radiological	O
and	O
physiological	O
outcomes	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
survivors	O
.	O

The	O
recombinant	O
enzymes	O
derived	O
from	O
influenza	B-DISO
C	O
viruses	O
specifically	O
hydrolyze	O
9	O
-	O
O	O
-	O
acetylated	O
sialic	O
acids	O
,	O
while	O
that	O
of	O
sialodacryoadenitis	O
virus	O
,	O
a	O
rat	O
coronavirus	O
related	O
to	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
,	O
is	O
specific	O
for	O
4	O
-	O
O	O
-	O
acetylated	O
sialic	O
acid	O
.	O

Two	O
hundred	O
fifty	O
-	O
four	O
patients	O
were	O
enrolled	O
over	O
a	O
36	O
-	O
month	O
period	O
,	O
of	O
whom	O
70	O
met	O
the	O
consensus	O
definitions	O
of	O
ARDS	B-DISO
.	O

Recruitment	B-DISO
of	O
trauma	O
patients	O
for	O
ARDS	B-DISO
studies	O
or	O
preemptive	O
ventilatory	O
management	O
based	O
solely	O
on	O
these	O
criteria	O
may	O
be	O
ill	B-DISO
-	O
advised	O
.	O

TITLE	O
:	O
Persistent	O
shedding	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
in	O
mouse	O
lines	O
selected	O
for	O
genetic	O
differences	O
in	O
alcohol	O
sensitivity	O
.	O

ABSTRACT	O
:	O
Two	O
replicate	O
lines	O
of	O
mice	O
,	O
selected	O
for	O
hyperactivity	O
and	O
hypoactivity	B-DISO
after	O
ethanol	O
administration	O
,	O
had	O
been	O
enzootically	O
infected	O
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
for	O
over	O
a	O
decade	O
.	O

The	O
animal	O
facility	O
we	O
describe	O
had	O
contained	O
an	O
enzootic	O
infection	B-DISO
of	O
mouse	O
coronavirus	O
for	O
more	O
than	O
a	O
decade	O
.	O

In	O
the	O
group	O
vaccinated	O
with	O
the	O
Newcastle	B-DISO
disease	I-DISO
(	O
ND	O
)	O
vaccine	O
alone	O
,	O
the	O
viral	O
genome	O
was	O
detected	O
on	O
days	O
2	O
,	O
4	O
and	O
7	O
post	O
vaccination	O
(	O
p	O
.	O
v	O
.),	O
while	O
in	O
the	O
chickens	O
given	O
the	O
infectious	B-DISO
bronchitis	B-DISO
(	O
IB	O
)	O
vaccine	O
alone	O
,	O
the	O
viral	O
genome	O
was	O
detected	O
only	O
on	O
day	O
4	O
p	O
.	O
v	O
.	O

The	O
RM	O
algorithm	O
provided	O
for	O
a	O
more	O
effective	O
prevention	O
and	O
treatment	O
of	O
APL	B-DISO
versus	O
the	O
routine	O
RM	O
--	O
it	O
cut	O
,	O
3	O
-	O
fold	O
,	O
the	O
remote	O
APL	B-DISO
.	O

The	O
ethics	O
of	O
visitation	O
restrictions	O
-	O
lessons	O
learned	O
from	O
SARS	B-DISO
.	O

TITLE	O
:	O
Longitudinal	O
study	O
of	O
viruses	O
associated	O
with	O
canine	O
infectious	B-DISO
respiratory	B-DISO
disease	I-DISO
.	O

Surprisingly	O
,	O
canine	O
adenovirus	B-DISO
was	O
not	O
detected	O
in	O
samples	O
from	O
this	O
population	O
,	O
whereas	O
19	O
.	O
4	O
%	O
of	O
tracheal	O
and	O
10	O
.	O
4	O
%	O
of	O
lung	O
samples	O
were	O
positive	O
for	O
CPIV	O
and	O
12	O
.	O
8	O
%	O
of	O
tracheal	O
and	O
9	O
.	O
6	O
%	O
of	O
lung	O
samples	O
were	O
positive	O
for	O
CHV	O
.	O

Infections	B-DISO
with	O
CRCoV	O
occurred	O
mostly	O
during	O
the	O
first	O
week	O
of	O
a	O
dog	O
'	O
s	O
stay	O
at	O
the	O
kennel	O
,	O
whereas	O
CPIV	O
and	O
CHV	O
were	O
detected	O
at	O
later	O
time	O
points	O
.	O

TITLE	O
:	O
Factors	O
associated	O
with	O
transmission	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
among	O
health	O
-	O
care	O
workers	O
in	O
Singapore	O
.	O

ABSTRACT	O
:	O
Between	O
1	O
and	O
22	O
March	O
2003	O
,	O
a	O
nosocomial	O
outbreak	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
occurred	O
at	O
the	O
Communicable	B-DISO
Disease	I-DISO
Centre	O
in	O
Tan	O
Tock	O
Seng	O
Hospital	O
,	O
Singapore	O
,	O
the	O
national	O
treatment	O
and	O
isolation	O
facility	O
for	O
patients	O
with	O
SARS	B-DISO
.	O

After	O
the	O
SARS	B-DISO
outbreak	O
,	O
a	O
total	O
of	O
750	O
staff	O
nurses	O
(	O
response	O
rate	O
90	O
%)	O
at	O
one	O
hospital	O
completed	O
a	O
questionnaire	O
assessing	O
their	O
intention	O
to	O
provide	O
care	O
to	O
SARS	B-DISO
patients	O
.	O

Four	O
factors	O
explaining	O
35	O
%	O
of	O
the	O
variance	O
in	O
nurses	O
'	O
intention	O
to	O
care	O
for	O
SARS	B-DISO
patients	O
were	O
self	O
-	O
efficacy	O
(	O
beta	O
=	O
0	O
.	O
39	O
,	O
p	O
<	O
0	O
.	O
001	O
),	O
attitude	O
(	O
beta	O
=	O
0	O
.	O
25	O
,	O
p	O
<	O
0	O
.	O
001	O
),	O
years	O
of	O
working	O
in	O
the	O
study	O
hospital	O
(	O
beta	O
=	O
-	O
0	O
.	O
15	O
,	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
receiving	O
resources	O
from	O
the	O
hospital	O
(	O
beta	O
=	O
0	O
.	O
13	O
,	O
p	O
<	O
0	O
.	O
001	O
).	O

In	O
this	O
study	O
,	O
using	O
the	O
baculovirus	O
system	O
,	O
we	O
generated	O
recombinant	O
viruses	O
that	O
expressed	O
S	O
,	O
E	O
,	O
M	O
and	O
N	O
structural	O
proteins	O
of	O
SARS	B-DISO
-	O
CoV	O
either	O
individually	O
or	O
simultaneously	O
.	O

The	O
expression	O
level	O
,	O
size	O
and	O
authenticity	O
of	O
each	O
recombinant	O
SARS	B-DISO
-	O
CoV	O
protein	O
were	O
determined	O
.	O

Co	B-DISO
-	I-DISO
infections	I-DISO
of	O
insect	O
cells	O
with	O
two	O
recombinant	O
viruses	O
demonstrated	O
that	O
M	O
and	O
E	O
could	O
assemble	O
readily	O
to	O
form	O
smooth	O
surfaced	O
VLPs	O
.	O

We	O
report	O
here	O
the	O
first	O
crystallographic	O
study	O
of	O
the	O
SARS	B-DISO
spike	O
HR	O
-	O
N	O
/	O
HR	O
-	O
C	O
complex	O
.	O

TITLE	O
:	O
Receptor	O
-	O
binding	O
domain	O
of	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
induces	O
highly	O
potent	O
neutralizing	O
antibodies	O
:	O
implication	O
for	O
developing	O
subunit	O
vaccine	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
CoV	O
),	O
a	O
type	O
I	O
transmembrane	O
envelope	O
glycoprotein	O
,	O
consists	O
of	O
S1	O
and	O
S2	O
domains	O
responsible	O
for	O
virus	O
binding	O
and	O
fusion	O
,	O
respectively	O
.	O

Every	O
emergency	B-DISO
department	O
,	O
no	O
matter	O
what	O
the	O
demographics	O
,	O
cares	O
for	O
patients	O
with	O
this	O
constellation	O
of	O
symptoms	O
.	O

Our	O
model	O
can	O
be	O
used	O
to	O
predict	O
the	O
worldwide	O
spread	O
of	O
future	O
infectious	B-DISO
diseases	I-DISO
and	O
to	O
identify	O
endangered	O
regions	O
in	O
advance	O
.	O

For	O
the	O
coronavirus	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
),	O
the	O
first	O
proteolytic	O
processing	O
event	O
of	O
the	O
replicase	O
polyprotein	O
liberates	O
an	O
amino	O
-	O
terminal	O
28	O
-	O
kDa	O
product	O
(	O
p28	O
).	O

Novel	O
infectious	B-DISO
disease	I-DISO
microbes	O
continue	O
to	O
be	O
discovered	O
because	O
they	O
are	O
new	O
or	O
newly	O
recognized	O
,	O
have	O
expanded	O
their	O
geographic	O
range	O
,	O
have	O
been	O
shown	O
to	O
cause	O
a	O
new	O
disease	O
spectrum	O
,	O
have	O
jumped	O
the	O
species	O
barrier	O
from	O
animals	O
to	O
humans	O
,	O
have	O
become	O
resistant	O
to	O
antimicrobial	O
agents	O
,	O
have	O
increased	O
in	O
incidence	O
or	O
have	O
become	O
more	O
virulent	O
.	O

In	O
2003	O
,	O
outbreaks	O
of	O
interest	O
included	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
monkeypox	B-DISO
and	O
avian	B-DISO
influenza	I-DISO
.	O

TITLE	O
:	O
Novel	O
and	O
re	O
-	O
emerging	O
respiratory	B-DISO
infections	I-DISO
.	O

The	O
performance	O
of	O
a	O
microplate	O
enzyme	O
immunoassay	O
,	O
DETECT	O
-	O
SARS	B-DISO
was	O
evaluated	O
for	O
the	O
detection	O
of	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
IgG	O
antibody	O
.	O

Strategies	O
to	O
reduce	O
the	O
rates	O
of	O
nosocomial	B-DISO
infection	I-DISO
with	O
these	O
pathogens	O
should	O
conform	O
to	O
established	O
guidelines	O
,	O
with	O
an	O
emphasis	O
on	O
thorough	O
environmental	O
cleaning	O
and	O
use	O
of	O
Environmental	O
Protection	O
Agency	O
-	O
approved	O
detergent	O
-	O
disinfectants	O
.	O

ABSTRACT	O
:	O
The	O
SARS	B-DISO
-	O
associated	O
human	O
coronavirus	O
(	O
SARS	B-DISO
-	O
HCoV	O
)	O
is	O
a	O
newly	O
described	O
,	O
emerging	O
virus	O
conclusively	O
established	O
as	O
the	O
etiologic	O
agent	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

TITLE	O
:	O
Molecular	O
mimicry	B-DISO
of	O
ACTH	O
in	O
SARS	B-DISO
-	O
implications	O
for	O
corticosteroid	O
treatment	O
and	O
prophylaxis	O
.	O

If	O
SARS	B-DISO
'	O
s	O
ACTH	O
mimic	O
strategy	O
never	O
has	O
an	O
opportunity	O
to	O
get	O
started	O
,	O
SARS	B-DISO
'	O
s	O
ability	O
to	O
evade	O
its	O
host	O
'	O
s	O
immune	O
system	O
while	O
its	O
viral	O
load	O
is	O
low	O
will	O
be	O
significantly	O
impaired	B-DISO
.	O

A	O
molecular	O
characterization	O
of	O
nine	O
monoclonal	O
antibodies	O
raised	O
in	O
immune	O
mice	O
,	O
using	O
highly	O
purified	O
,	O
inactivated	O
SARS	B-DISO
-	O
CoV	O
as	O
the	O
inoculating	O
antigen	O
,	O
is	O
presented	O
in	O
this	O
report	O
.	O

We	O
sought	O
to	O
identify	O
novel	O
inhibitors	O
of	O
3CLpro	O
to	O
advance	O
the	O
development	O
of	O
appropriate	O
therapies	O
in	O
the	O
treatment	O
of	O
SARS	B-DISO
.	O

The	O
primary	O
screen	O
identified	O
572	O
hits	O
;	O
through	O
a	O
series	O
of	O
virtual	O
and	O
experimental	O
filters	O
,	O
this	O
number	O
was	O
reduced	O
to	O
five	O
novel	O
small	O
molecules	O
that	O
show	O
potent	O
inhibitory	O
activity	O
(	O
IC50	O
=	O
0	O
.	O
5	O
-	O
7	O
microM	O
)	O
toward	O
SARS	B-DISO
-	O
CoV	O
3CLpro	O
.	O

TITLE	O
:	O
[	O
Side	O
effects	O
of	O
glucocorticosteroids	O
in	O
the	O
management	O
of	O
1291	O
patients	O
of	O
SARS	B-DISO
].	O

Hyperglycemia	B-DISO
and	O
hypokalemia	O
are	O
correlated	O
with	O
GCS	O
dosage	O
and	O
duration	O
.	O

The	O
respiratory	O
condition	B-DISO
improved	O
initially	O
after	O
mechanical	O
ventilation	O
,	O
but	O
subcutaneous	B-DISO
emphysema	I-DISO
and	O
pneumomediastinum	B-DISO
developed	O
on	O
May	O
1	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
has	O
been	O
verified	O
as	O
the	O
causative	O
agent	O
of	O
a	O
worldwide	O
outbreak	O
of	O
SARS	B-DISO
.	O

In	O
this	O
study	O
,	O
genetic	O
variation	O
of	O
SARS	B-DISO
-	O
CoV	O
is	O
analyzed	O
based	O
on	O
available	O
documented	O
data	O
and	O
our	O
study	O
.	O

It	O
suggests	O
that	O
SARS	B-DISO
-	O
CoV	O
is	O
of	O
similar	O
mutation	O
frequency	O
and	O
dynamic	O
mutant	B-DISO
distributions	O
like	O
other	O
RNA	O
viruses	O
,	O
though	O
relatively	O
less	O
identified	O
variation	O
number	O
than	O
those	O
causing	O
chronic	B-DISO
infections	I-DISO
.	O

Recently	O
solved	O
high	O
-	O
resolution	O
crystal	O
structures	O
of	O
the	O
apo	O
-	O
bound	O
and	O
inhibitor	O
-	O
bound	O
forms	O
of	O
ACE2	O
have	O
provided	O
the	O
basis	O
for	O
a	O
novel	O
molecular	O
docking	O
approach	O
in	O
an	O
attempt	O
to	O
identify	O
ACE2	O
inhibitors	O
and	O
compounds	O
that	O
block	O
SARS	B-DISO
coronavirus	O
spike	O
protein	O
-	O
mediated	O
cell	O
fusion	O
.	O

Between	O
May	O
1	O
and	O
June	O
16	O
,	O
2003	O
,	O
we	O
enrolled	O
16	O
medical	O
care	O
workers	O
who	O
fulfilled	O
the	O
definition	O
of	O
probable	O
SARS	B-DISO
.	O

Serum	O
anti	O
-	O
SARS	B-DISO
IgG	O
was	O
checked	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
at	O
the	O
convalescent	O
phase	O
.	O

In	O
contrast	O
to	O
the	O
high	O
positive	O
rate	O
of	O
feces	O
RT	O
-	O
PCR	O
(	O
97	O
%)	O
in	O
Amoy	O
Gardens	O
,	O
our	O
positive	O
rate	O
in	O
rectal	O
swab	O
RT	O
-	O
PCT	B-DISO
(	O
0	O
%)	O
was	O
significantly	O
lower	O
(	O
P	O
=	O
0	O
.	O
00000002	O
).	O

ABSTRACT	O
:	O
The	O
Authors	O
present	O
a	O
case	O
of	O
acute	B-DISO
eosinophilic	I-DISO
pneumonia	I-DISO
(	O
AEP	O
)	O
associated	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
a	O
previously	O
healthy	O
young	O
adult	O
,	O
medicated	O
with	O
nitrofurantoin	O
.	O

AEP	O
must	O
be	O
included	O
in	O
the	O
differential	O
diagnosis	O
of	O
community	O
adquired	O
pneumonia	B-DISO
,	O
as	O
well	O
as	O
a	O
cause	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
;	O
its	O
diagnosis	O
is	O
suggested	O
by	O
the	O
presence	O
of	O
eosinophilic	O
alveolitis	B-DISO
in	O
bronchoalveolar	O
lavage	O
fluid	O
.	O

The	O
significantly	O
higher	O
levels	O
of	O
IgG	O
antibodies	O
specific	O
to	O
three	O
(	O
S791	O
,	O
M207	O
and	O
N161	O
)	O
of	O
42	O
peptides	O
were	O
detectable	O
in	O
the	O
post	O
-	O
infection	B-DISO
sera	O
from	O
23	O
(	O
51	O
%),	O
27	O
(	O
60	O
%)	O
and	O
19	O
(	O
42	O
%)	O
of	O
45	O
patients	O
,	O
respectively	O
.	O

TITLE	O
:	O
SARS	B-DISO
in	O
three	O
categories	O
of	O
hospital	O
workers	O
,	O
Hong	O
Kong	O
.	O

The	O
number	O
of	O
affected	O
staff	O
and	O
attack	O
rates	O
were	O
significantly	O
correlated	O
with	O
the	O
number	O
of	O
SARS	B-DISO
patients	O
admitted	O
(	O
r	O
=	O
0	O
.	O
914	O
and	O
0	O
.	O
686	O
,	O
respectively	O
).	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
impact	O
of	O
a	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
in	O
the	O
emergency	B-DISO
department	O
(	O
ED	O
).	O

TITLE	O
:	O
Quantitation	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
genome	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
assay	O
using	O
minor	O
groove	O
binder	O
DNA	O
probe	O
technology	O
.	O

ABSTRACT	O
:	O
The	O
ability	O
to	O
rapidly	O
recognize	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
as	O
a	O
cause	O
of	O
infections	B-DISO
is	O
critical	O
to	O
quickly	O
limiting	O
further	O
spread	O
of	O
the	O
disease	O
.	O

Therefore	O
,	O
to	O
further	O
ensure	O
the	O
success	O
of	O
its	O
surveillance	O
efforts	O
,	O
the	O
DHSS	O
will	O
also	O
need	O
to	O
continue	O
educating	O
clinicians	O
about	O
its	O
surveillance	O
activities	O
and	O
the	O
importance	O
of	O
timely	O
reporting	O
of	O
patients	O
with	O
illness	O
patterns	O
that	O
might	O
suggest	O
an	O
unusual	O
infectious	B-DISO
disease	I-DISO
outbreak	O
associated	O
with	O
bioterrorism	O
or	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

Viral	O
load	O
in	O
nasopharyngeal	O
aspirates	O
(	O
n	O
=	O
142	O
)	O
from	O
day	O
10	O
to	O
day	O
15	O
after	O
onset	O
of	O
symptoms	O
was	O
associated	O
with	O
oxygen	O
desaturation	O
,	O
mechanical	O
ventilation	O
,	O
diarrhea	B-DISO
,	O
hepatic	B-DISO
dysfunction	I-DISO
,	O
and	O
death	O
.	O

1	O
.	O
6	O
(	O
0	O
-	O
10	O
)	O
days	O
after	O
onset	O
of	O
respiratory	B-DISO
failure	I-DISO
.	O

ABSTRACT	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
crisis	O
in	O
China	O
revealed	O
not	O
only	O
the	O
failures	O
of	O
the	O
Chinese	O
health	O
-	O
care	O
system	O
but	O
also	O
some	O
fundamental	O
structural	O
deficiencies	O
.	O

TITLE	O
:	O
Polyprotein	O
cleavage	O
mechanism	O
of	O
SARS	B-DISO
CoV	O
Mpro	O
and	O
chemical	O
modification	O
of	O
the	O
octapeptide	O
.	O

ABSTRACT	O
:	O
The	O
major	O
biochemical	O
and	O
thermodynamic	O
features	O
of	O
nucelocapsid	O
protein	O
of	O
SARS	B-DISO
coronavirus	O
(	O
SARS_NP	O
)	O
were	O
characterized	O
by	O
use	O
of	O
non	O
-	O
denatured	O
gel	O
electrophoresis	O
,	O
size	O
-	O
exclusion	O
chromatographic	O
and	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
)	O
techniques	O
.	O

This	O
protein	O
shows	O
its	O
maximum	O
conformational	O
stability	O
near	O
pH	O
9	O
.	O
0	O
,	O
and	O
it	O
seems	O
that	O
its	O
oligomer	O
dissociation	B-DISO
and	O
protein	O
unfolding	O
occur	O
simultaneously	O
.	O

TITLE	O
:	O
Crystallization	O
and	O
preliminary	O
crystallographic	O
analysis	O
of	O
the	O
fusion	O
core	O
of	O
the	O
spike	O
protein	O
of	O
the	O
murine	O
coronavirus	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
).	O

Although	O
SARS	B-DISO
-	O
CoV	O
was	O
not	O
isolated	O
from	O
any	O
patient	O
,	O
specimens	O
from	O
three	O
patients	O
were	O
positive	O
for	O
viral	O
RNA	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
assay	O
,	O
and	O
all	O
patients	O
had	O
detectable	O
rises	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
specific	O
antibodies	O
.	O

The	O
results	O
showed	O
that	O
the	O
cells	O
transfected	O
with	O
pEGFP	O
-	O
optS	O
expressed	O
S	O
-	O
EGFP	O
fusion	O
protein	O
at	O
a	O
higher	O
level	O
compared	O
with	O
those	O
transfected	O
with	O
pEGFP	O
-	O
S	O
,	O
which	O
contains	O
wildtype	O
SARS	B-DISO
-	O
CoV	O
spike	O
gene	O
sequence	O
.	O

For	O
some	O
coronaviruses	O
,	O
the	O
mRNA	O
cis	B-DISO
-	O
acting	O
stimulatory	O
structures	O
involved	O
in	O
this	O
process	O
have	O
been	O
characterized	O
,	O
but	O
their	O
precise	O
contribution	O
to	O
ribosomal	O
frameshifting	O
is	O
not	O
completely	O
understood	O
.	O

Despite	O
this	O
relative	O
simplicity	O
,	O
the	O
molecular	O
regulation	O
of	O
SARS	B-DISO
-	O
CoV	O
replication	O
and	O
assembly	O
is	O
not	O
understood	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
caused	O
by	O
a	O
newly	O
identified	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
a	O
serious	O
emerging	O
human	O
infectious	B-DISO
disease	I-DISO
.	O

Inflammation	B-DISO
in	O
control	O
animals	O
exposed	O
to	O
SARS	B-DISO
-	O
CoV	O
was	O
relatively	O
mild	O
.	O

The	O
need	O
for	O
oxygen	O
supplementation	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
lymphopenia	B-DISO
during	O
the	O
course	B-DISO
of	I-DISO
illness	I-DISO
(	O
P	O
=	O
0	O
.	O
012	O
)	O
were	O
significant	O
risk	O
factors	O
in	O
predicting	O
abnormal	O
HRCT	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
a	O
newly	O
emergent	O
virus	O
responsible	O
for	O
a	O
worldwide	O
epidemic	O
in	O
2003	O
.	O

Intracerebral	O
infection	B-DISO
of	O
CCL2	O
(-/-)	O
mice	O
with	O
MHV	O
did	O
not	O
result	O
in	O
increased	O
morbidity	O
or	O
mortality	O
as	O
compared	O
to	O
either	O
wild	O
type	O
or	O
CCR2	O
(-/-)	O
mice	O
and	O
CCL2	O
(-/-)	O
mice	O
cleared	O
replicating	O
virus	O
from	O
the	O
brain	O
.	O

Patients	O
20	O
years	O
or	O
younger	O
with	O
clinical	O
,	O
epidemiological	O
,	O
and	O
laboratory	O
evidence	O
of	O
SARS	B-DISO
from	O
March	O
to	O
July	O
2003	O
vs	O
children	O
with	O
virus	O
culture	O
-	O
confirmed	O
influenza	B-DISO
in	O
a	O
1	O
:	O
1	O
age	O
-	O
and	O
sex	O
-	O
matched	O
control	O
group	O
.	O

Only	O
1	O
patient	O
(	O
7	O
%)	O
had	O
sputum	O
production	O
;	O
1	O
(	O
7	O
%)	O
had	O
rhinorrhea	B-DISO
.	O

TITLE	O
:	O
The	O
epidemiology	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
the	O
2003	O
Hong	O
Kong	O
epidemic	O
:	O
an	O
analysis	O
of	O
all	O
1755	O
patients	O
.	O

TITLE	O
:	O
[	O
Severe	O
pulmonary	B-DISO
complications	I-DISO
of	O
massive	O
intoxication	O
with	O
calcium	O
channel	O
blockers	O
and	O
isosorbide	O
mononitrate	O
--	O
a	O
case	O
report	O
].	O

He	O
developed	O
shock	O
,	O
paralytic	B-DISO
ileus	I-DISO
and	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

The	O
primers	O
were	O
derived	O
from	O
the	O
corresponding	O
sequences	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
).	O

TITLE	O
:	O
The	O
aetiology	O
,	O
origins	O
,	O
and	O
diagnosis	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
The	O
epidemiology	O
and	O
virology	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
have	O
been	O
written	O
about	O
many	O
times	O
and	O
several	O
guidelines	O
on	O
the	O
infection	B-DISO
control	O
and	O
public	O
health	O
measures	O
believed	O
necessary	O
to	O
control	O
the	O
spread	O
of	O
the	O
virus	O
have	O
been	O
published	O
.	O

TITLE	O
:	O
Seasonality	O
of	O
infectious	B-DISO
diseases	I-DISO
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
what	O
we	O
don	O
'	O
t	O
know	O
can	O
hurt	O
us	O
.	O

It	O
is	O
true	O
that	O
most	O
established	O
respiratory	O
pathogens	O
of	O
human	O
beings	O
recur	O
in	O
wintertime	O
,	O
but	O
a	O
new	O
appreciation	O
for	O
the	O
high	O
burden	O
of	O
disease	O
in	O
tropical	O
areas	O
reinforces	O
questions	O
about	O
explanations	O
resting	O
solely	O
on	O
cold	B-DISO
air	O
or	O
low	O
humidity	O
.	O

TITLE	O
:	O
[	O
Human	B-DISO
metapneumovirus	I-DISO
pneumonia	I-DISO
in	O
an	O
adult	O
patient	O
hospitalized	O
for	O
suspected	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)].	O

Detection	O
of	O
the	O
novel	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
was	O
negative	O
but	O
hMPV	O
detection	O
was	O
positive	O
.	O

In	O
this	O
study	O
virological	O
and	O
serological	O
investigations	O
were	O
performed	O
to	O
demonstrate	O
the	O
existence	O
and	O
prevalence	O
of	O
CCoV	O
infection	B-DISO
in	O
a	O
Turkish	O
dog	O
population	O
.	O

Fourteen	O
(	O
15	O
.	O
5	O
%)	O
faeces	O
were	O
positive	O
for	O
CCoV	O
RNA	O
,	O
five	O
of	O
which	O
were	O
characterized	O
as	O
CCoV	O
type	O
I	O
.	O
The	O
widespread	O
CCoV	O
infection	B-DISO
in	O
the	O
Turkish	O
dog	O
population	O
may	O
be	O
attributed	O
as	O
an	O
important	O
cause	O
of	O
viral	B-DISO
diarrhoea	I-DISO
in	O
dogs	O
.	O

We	O
retrospectively	O
summarized	O
infection	B-DISO
control	O
practices	O
observed	O
in	O
hospitals	O
visited	O
by	O
mobile	O
teams	O
in	O
the	O
Lao	O
People	O
'	O
s	O
Democratic	O
Republic	O
(	O
PDR	B-DISO
),	O
Taiwan	O
,	O
and	O
Thailand	O
,	O
during	O
March	O
and	O
April	O
2003	O
.	O

Pentaglobin	O
is	O
safe	O
and	O
probably	O
effective	O
in	O
the	O
treatment	O
of	O
steroid	O
-	O
resistant	O
SARS	B-DISO
.	O

TITLE	O
:	O
Evolutional	O
insights	O
on	O
uncharacterized	O
SARS	B-DISO
coronavirus	O
genes	O
.	O

TITLE	O
:	O
Tyrosine	O
dephosphorylation	O
of	O
STAT3	O
in	O
SARS	B-DISO
coronavirus	O
-	O
infected	O
Vero	O
E6	O
cells	O
.	O

Moderate	O
to	O
high	O
titers	O
of	O
SARS	B-DISO
-	O
CoV	O
with	O
associated	O
interstitial	B-DISO
pneumonitis	I-DISO
were	O
detected	O
in	O
the	O
lungs	O
of	O
AGMs	O
on	O
day	O
2	O
and	O
were	O
resolving	O
by	O
day	O
4	O
post	O
-	O
infection	B-DISO
.	O

Several	O
monoclonal	O
antibodies	O
against	O
SARS	B-DISO
-	O
CoV	O
bound	O
to	O
the	O
N	O
-	O
or	O
C	O
-	O
terminal	O
antigenic	O
sites	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
infectious	B-DISO
bronchitis	B-DISO
variant	O
,	O
designated	O
as	O
IS	O
/	O
885	O
/	O
00	O
,	O
associated	O
with	O
nephritis	B-DISO
,	O
was	O
isolated	O
from	O
outbreaks	O
in	O
23	O
broiler	O
farms	O
in	O
Israel	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
was	O
a	O
new	O
human	O
disease	O
in	O
the	O
autumn	O
of	O
2002	O
.	O

Ten	O
secondary	O
cases	O
spread	O
the	O
infection	B-DISO
to	O
two	O
hospitals	O
in	O
Hong	O
Kong	O
and	O
to	O
Singapore	O
,	O
Toronto	O
and	O
Hanoi	O
.	O

With	O
the	O
implementation	O
of	O
effective	O
control	O
strategies	O
including	O
early	O
isolation	O
of	O
suspected	O
cases	O
,	O
strict	O
infection	B-DISO
control	O
measures	O
in	O
the	O
hospital	O
setting	O
,	O
meticulous	O
contact	O
tracing	O
and	O
quarantine	O
,	O
the	O
outbreak	O
was	O
finally	O
brought	O
under	O
control	O
by	O
July	O
2003	O
.	O

In	O
addition	O
,	O
there	O
were	O
another	O
two	O
events	O
of	O
SARS	B-DISO
in	O
China	O
between	O
the	O
end	O
of	O
December	O
2003	O
and	O
January	O
2004	O
and	O
from	O
March	O
to	O
May	O
2004	O
;	O
both	O
were	O
readily	O
controlled	O
without	O
significant	O
patient	O
spread	O
.	O

TITLE	O
:	O
Long	O
-	O
term	O
sequelae	O
of	O
SARS	B-DISO
in	O
children	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
new	O
infectious	B-DISO
disease	I-DISO
of	O
the	O
21st	O
century	O
that	O
has	O
pandemic	O
potential	O
.	O

Likewise	O
for	O
the	O
super	O
-	O
spreading	O
events	O
,	O
clarification	O
of	O
the	O
underlying	O
reasons	O
will	O
be	O
important	O
to	O
prevent	O
a	O
large	O
scale	O
outbreak	O
of	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
We	O
applied	O
cartographic	O
and	O
geostatistical	O
methods	O
in	O
analyzing	O
the	O
patterns	O
of	O
disease	O
spread	O
during	O
the	O
2003	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
in	O
Hong	O
Kong	O
using	O
geographic	O
information	O
system	O
(	O
GIS	O
)	O
technology	O
.	O

Statistical	O
surfaces	O
created	O
by	O
the	O
kernel	O
method	O
confirmed	O
that	O
SARS	B-DISO
cases	O
were	O
highly	O
clustered	O
and	O
identified	O
distinct	O
disease	O
""""	O
hot	B-DISO
spots	I-DISO
.	O

Despite	O
more	O
than	O
2	O
months	O
of	O
intensive	O
SARS	B-DISO
public	O
education	O
in	O
Singapore	O
,	O
there	O
remain	O
important	O
gaps	O
in	O
knowledge	O
and	O
appropriate	O
behaviour	O
that	O
have	O
to	O
be	O
bridged	O
.	O

Further	O
pathological	O
and	O
microbiological	O
studies	O
are	O
necessary	O
to	O
determine	O
the	O
relationship	O
between	O
SARS	B-DISO
coronavirus	O
and	O
neuromuscular	O
problems	O
.	O

Active	O
recombinant	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
nucleocapsid	O
(	O
rSCoVN	O
)	O
protein	O
can	O
be	O
successfully	O
expressed	O
in	O
recombinant	O
methylotrophic	O
yeast	O
P	O
.	O
pastoris	O
GS115	O
.	O

Turkey	O
coronavirus	O
(	O
TCV	O
)	O
from	O
two	O
sources	O
was	O
studied	O
,	O
one	O
isolate	O
(	O
NC95	O
)	O
was	O
embryo	O
propagated	O
,	O
the	O
second	O
was	O
TCV	O
infected	O
material	O
from	O
turkeys	O
diagnosed	O
with	O
poult	O
enteritis	B-DISO
mortality	O
syndrome	B-DISO
(	O
PEMS	O
).	O

SARS	B-DISO
could	O
end	O
in	O
MODS	B-DISO
and	O
the	O
mortality	O
was	O
92	O
.	O
3x	O
.	O

SARS	B-DISO
cases	O
may	O
develop	O
leucocytosis	B-DISO
,	O
low	O
lymphocyte	O
count	O
,	O
low	O
platelet	O
count	O
,	O
low	O
hemoglobin	O
level	O
and	O
abnormal	B-DISO
liver	I-DISO
function	I-DISO
.	O

TITLE	O
:	O
[	O
Comparison	O
of	O
serum	O
biochemical	O
features	O
between	O
SARS	B-DISO
and	O
other	O
viral	B-DISO
pneumonias	I-DISO
].	O

TITLE	O
:	O
Factors	O
influencing	O
the	O
wearing	O
of	O
facemasks	O
to	O
prevent	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
among	O
adult	O
Chinese	O
in	O
Hong	O
Kong	O
.	O

RESULTS	O
:	O
Overall	O
,	O
61	O
.	O
2	O
%	O
of	O
the	O
respondents	O
reported	O
consistent	O
use	O
of	O
facemasks	O
to	O
prevent	O
SARS	B-DISO
.	O

In	O
the	O
absence	O
of	O
a	O
rapid	O
diagnostic	O
test	O
,	O
therapy	O
or	O
vaccine	O
,	O
isolation	O
of	O
individuals	O
diagnosed	O
with	O
SARS	B-DISO
and	O
quarantine	O
of	O
individuals	O
feared	O
exposed	O
to	O
SARS	B-DISO
virus	O
were	O
used	O
to	O
control	O
the	O
spread	O
of	O
infection	B-DISO
.	O

TITLE	O
:	O
SYNCRIP	O
,	O
a	O
member	O
of	O
the	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
family	O
,	O
is	O
involved	O
in	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
RNA	O
synthesis	O
.	O

ABSTRACT	O
:	O
Several	O
cellular	O
proteins	O
,	O
including	O
several	O
heterogeneous	O
nuclear	O
ribonucleoproteins	O
(	O
hnRNPs	O
),	O
have	O
been	O
shown	O
to	O
function	O
as	O
regulatory	O
factors	O
for	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
RNA	O
synthesis	O
as	O
a	O
result	O
of	O
their	O
binding	O
to	O
the	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
regions	O
(	O
UTRs	O
)	O
of	O
the	O
viral	O
RNA	O
.	O

ARDS	B-DISO
survivors	O
report	O
moderate	O
to	O
severe	B-DISO
depression	I-DISO
(	O
16	O
%	O
and	O
23	O
%)	O
and	O
anxiety	O
(	O
24	O
%	O
and	O
23	O
%)	O
at	O
1	O
and	O
2	O
years	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
A	O
minimum	O
amount	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
should	O
be	O
set	O
to	O
prevent	O
lung	B-DISO
collapse	I-DISO
at	O
end	O
expiration	O
in	O
ARDS	B-DISO
.	O

Vero	O
E6	O
cells	O
were	O
transfected	O
with	O
plasmid	O
constructs	O
containing	O
exons	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
structural	O
protein	O
E	O
,	O
M	O
or	O
N	O
genes	O
or	O
their	O
exons	O
in	O
frame	O
with	O
the	O
reporter	O
protein	O
EGFP	O
.	O

This	O
8	O
-	O
month	O
prospective	O
study	O
of	O
14	O
patients	O
with	O
hospital	O
-	O
acquired	O
SARS	B-DISO
in	O
Taipei	O
,	O
Taiwan	O
,	O
was	O
conducted	O
from	O
April	O
through	O
December	O
2003	O
.	O

The	O
clinical	O
picture	O
of	O
our	O
patients	O
presenting	O
with	O
hospital	O
-	O
acquired	O
SARS	B-DISO
revealed	O
atypical	B-DISO
pneumonia	I-DISO
associated	O
with	O
lymphopenia	B-DISO
,	O
elevated	O
serum	O
levels	O
of	O
LDH	O
,	O
rapid	O
clinical	O
deterioration	O
,	O
and	O
lack	O
of	O
response	O
to	O
empirical	O
antibiotic	O
therapy	O
.	O

RESULTS	O
:	O
Optimal	O
correlations	O
were	O
found	O
between	O
conventionally	O
measured	O
body	O
temperatures	O
and	O
IRT	O
readings	O
from	O
(	O
1	O
)	O
the	O
front	O
of	O
the	O
face	B-DISO
at	O
1	O
.	O
5m	O
with	O
the	O
mouth	O
open	O
(	O
r	O
=	O
0	O
.	O
80	O
),	O
(	O
2	O
)	O
the	O
ear	O
at	O
0	O
.	O
5	O
m	O
(	O
r	O
=	O
0	O
.	O
79	O
),	O
and	O
(	O
3	O
)	O
the	O
side	O
of	O
the	O
face	B-DISO
at	O
1	O
.	O
5m	O
(	O
r	O
=	O
0	O
.	O
76	O
).	O

Multiple	O
infections	B-DISO
were	O
identified	O
in	O
20	O
(	O
27	O
%)	O
children	O
.	O

ABSTRACT	O
:	O
Inhalation	O
of	O
nitric	O
oxide	O
(	O
NO	O
)	O
improved	O
arterial	O
oxygenation	O
and	O
enabled	O
the	O
reduction	O
of	O
inspired	O
oxygen	O
therapy	O
and	O
airway	O
pressure	O
support	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

TITLE	O
:	O
SARS	B-DISO
related	O
preventive	O
and	O
risk	O
behaviours	O
practised	O
by	O
Hong	O
Kong	O
-	O
mainland	O
China	O
cross	O
border	O
travellers	O
during	O
the	O
outbreak	O
of	O
the	O
SARS	B-DISO
epidemic	O
in	O
Hong	O
Kong	O
.	O

SARS	B-DISO
-	O
CoV	O
was	O
discovered	O
in	O
the	O
early	O
spring	O
of	O
2003	O
,	O
followed	O
by	O
the	O
identification	O
of	O
HCoV	O
-	O
NL63	O
,	O
the	O
fourth	O
member	O
of	O
the	O
coronaviridae	O
family	O
that	O
infects	O
humans	O
.	O

The	O
fusion	O
protein	O
gene	O
of	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
was	O
cloned	O
and	O
characterized	O
,	O
and	O
shortly	O
thereafter	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
was	O
shown	O
to	O
be	O
its	O
functional	O
receptor	O
.	O

Identification	O
of	O
ACE2	O
as	O
a	O
receptor	O
for	O
SARS	B-DISO
-	O
CoV	O
will	O
likely	O
contribute	O
to	O
the	O
development	O
of	O
antivirals	O
and	O
vaccines	O
.	O

Thickening	O
of	O
the	O
actin	O
filaments	O
at	O
the	O
cell	O
edge	O
provided	O
the	O
bending	B-DISO
force	O
to	O
extrude	O
the	O
virus	O
particles	O
.	O

TITLE	O
:	O
Nucleocapsid	O
protein	O
as	O
early	O
diagnostic	O
marker	O
for	O
SARS	B-DISO
.	O

TITLE	O
:	O
[	O
Coronavirus	B-DISO
infection	I-DISO
in	O
immunodeficient	B-DISO
patients	O
with	O
hemoblastosis	O
and	O
deficient	O
hemopoesis	O
].	O

Their	O
blood	O
sera	O
and	O
secretions	O
of	O
the	O
nasal	O
cavity	B-DISO
were	O
examined	O
in	O
the	O
indirect	O
hemagglutination	O
(	O
IHA	O
)	O
test	O
with	O
dried	O
standard	O
erythrocyte	O
diagnostic	O
preparations	O
.	O

CVI	O
was	O
provoked	O
by	O
such	O
factors	O
as	O
the	O
course	O
of	O
the	O
main	O
disease	O
and	O
specific	O
treatment	O
,	O
previous	O
respiratory	B-DISO
infections	I-DISO
of	O
other	O
etiology	O
with	O
M	O
.	O
pneumoniae	O
infection	B-DISO
playing	O
the	O
leading	O
role	O
(	O
60	O
%).	O

By	O
using	O
the	O
analytical	O
ultracentrifuge	O
,	O
we	O
demonstrated	O
that	O
the	O
dimeric	O
SARS	B-DISO
coronavirus	O
main	O
protease	O
exists	O
as	O
the	O
major	O
form	O
in	O
solution	O
at	O
protein	O
concentration	O
as	O
low	O
as	O
0	O
.	O
10	O
mg	O
/	O
mL	O
at	O
neutral	O
pH	O
.	O
The	O
enzyme	O
started	O
to	O
dissociate	O
at	O
acidic	O
and	O
alkali	O
pH	O
values	O
.	O

This	O
information	O
is	O
useful	O
in	O
searching	O
for	O
substances	O
that	O
can	O
intervene	O
in	O
the	O
subunit	O
association	O
,	O
which	O
is	O
attractive	O
as	O
a	O
target	O
to	O
neutralize	O
the	O
virulence	O
of	O
SARS	B-DISO
coronavirus	O
.	O

TITLE	O
:	O
[	O
Comparison	O
between	O
tow	O
methods	O
of	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
III	O
and	O
acute	O
lung	O
injury	O
scale	O
to	O
evaluate	O
the	O
severity	O
and	O
prognosis	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
].	O

Out	O
of	O
the	O
2195	O
close	O
contacts	O
,	O
138	O
(	O
6	O
.	O
3	O
%)	O
were	O
diagnosed	O
as	O
SARS	B-DISO
.	O

No	O
one	O
was	O
infected	O
among	O
459	O
close	O
contacts	O
to	O
SARS	B-DISO
in	O
the	O
working	O
unit	O
.	O

The	O
absolute	O
numbers	O
of	O
peripheral	O
blood	O
B	O
lymphocytes	O
and	O
NK	O
cells	O
in	O
602	O
serial	O
samples	O
from	O
240	O
patients	O
with	O
SARS	B-DISO
were	O
counted	O
,	O
using	O
flow	O
cytometry	O
,	O
and	O
compared	O
with	O
that	O
of	O
normal	O
population	O
.	O

RESULTS	O
:	O
The	O
absolute	O
numbers	O
of	O
peripheral	O
blood	O
B	O
lymphocytes	O
and	O
NK	O
cells	O
in	O
SARS	B-DISO
patients	O
were	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
normal	O
population	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
were	O
much	O
lower	O
in	O
SARS	B-DISO
patients	O
with	O
severe	O
or	O
extremely	O
severe	O
types	O
,	O
as	O
compared	O
with	O
that	O
of	O
moderate	O
or	O
mild	O
type	O
cases	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

TITLE	O
:	O
Epidemiology	O
and	O
etiology	O
of	O
community	O
-	O
acquired	O
pneumonia	B-DISO
.	O

It	O
may	O
progress	O
to	O
respiratory	B-DISO
failure	I-DISO
,	O
and	O
a	O
significant	O
proportion	O
of	O
patients	O
die	O
.	O

We	O
prospectively	O
studied	O
an	O
inception	O
cohort	O
of	O
133	O
patients	O
with	O
virologically	O
confirmed	O
SARS	B-DISO
who	O
were	O
admitted	O
to	O
2	O
general	O
acute	O
care	O
hospitals	O
in	O
Hong	O
Kong	O
from	O
Mar	B-DISO
.	O
24	O
to	O
May	O
4	O
,	O
2003	O
.	O

Mortality	O
data	O
for	O
patients	O
with	O
SARS	B-DISO
should	O
be	O
interpreted	O
in	O
light	O
of	O
age	O
,	O
comorbidity	O
and	O
viral	O
load	O
.	O

TITLE	O
:	O
The	O
impact	O
of	O
SARS	B-DISO
on	O
a	O
tertiary	O
care	O
pediatric	O
emergency	B-DISO
department	O
.	O

There	O
were	O
significant	O
decreases	O
in	O
visits	O
and	O
length	O
of	O
stay	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
increases	O
in	O
admission	O
rates	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
during	O
the	O
periods	O
in	O
2003	O
when	O
there	O
were	O
new	O
and	O
active	O
cases	O
of	O
SARS	B-DISO
in	O
the	O
GTA	O
.	O

During	O
the	O
SARS	B-DISO
outbreak	O
in	O
the	O
GTA	O
,	O
the	O
HSC	O
emergency	B-DISO
department	O
experienced	O
significantly	O
reduced	O
volumes	O
of	O
patients	O
with	O
low	O
-	O
acuity	O
complaints	O
.	O

This	O
gives	O
insight	O
into	O
utilization	O
rates	O
of	O
a	O
pediatric	O
emergency	B-DISO
department	O
during	O
a	O
time	O
when	O
there	O
was	O
additional	O
perceived	O
risk	O
in	O
using	O
emergency	B-DISO
department	O
services	O
and	O
provides	O
a	O
foundation	O
for	O
emergency	B-DISO
department	O
preparedness	O
policies	O
for	O
SARS	B-DISO
-	O
like	O
public	O
health	O
emergencies	B-DISO
.	O

A	O
total	O
of	O
71	O
inflammation	B-DISO
-	O
associated	O
genes	O
were	O
up	O
-	O
regulated	O
in	O
LPS	B-DISO
-	O
treated	O
lungs	O
,	O
including	O
a	O
chemokine	O
,	O
LPS	B-DISO
-	O
induced	O
CXC	O
chemokine	O
(	O
LIX	O
),	O
whose	O
role	O
in	O
the	O
induction	O
of	O
ALI	O
is	O
unknown	O
.	O

Real	O
-	O
time	O
reverse	O
transcription	O
-	O
PCR	O
confirmed	O
the	O
LPS	B-DISO
-	O
induced	O
up	O
-	O
regulation	O
of	O
selected	O
genes	O
identified	O
by	O
microarray	O
analysis	O
,	O
including	O
LIX	O
.	O

TITLE	O
:	O
Early	O
containment	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
);	O
experience	O
from	O
Bamrasnaradura	O
Institute	O
,	O
Thailand	O
.	O

ABSTRACT	O
:	O
On	O
March	O
11	O
,	O
2003	O
,	O
a	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
physician	O
was	O
admitted	O
to	O
Bamrasnaradura	O
Institute	O
,	O
after	O
alerting	O
the	O
world	O
to	O
the	O
dangers	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
Vietnam	O
and	O
developing	O
a	O
fever	O
himself	O
.	O

The	O
use	O
of	O
personal	O
protective	O
equipment	O
(	O
PPE	O
)	O
was	O
consistently	O
enforced	O
by	O
nurse	O
managers	O
for	O
all	O
the	O
staff	O
and	O
visitors	O
,	O
including	O
a	O
minimum	O
of	O
N95	O
respirators	O
,	O
goggles	O
or	O
face	B-DISO
shields	O
,	O
double	O
gowns	O
,	O
double	O
gloves	O
,	O
full	O
head	O
and	O
shoe	O
covering	O
,	O
and	O
full	O
Powered	O
Air	O
Purifying	O
Respirator	O
(	O
PAPR	O
)	O
for	O
intubation	O
.	O

Exposure	O
was	O
defined	O
as	O
presence	O
on	O
the	O
SARS	B-DISO
ward	O
or	O
contact	O
with	O
laboratory	O
specimens	O
,	O
and	O
close	O
contact	O
was	O
presence	O
in	O
the	O
patient	O
'	O
s	O
room	O
.	O

Serum	O
samples	O
from	O
35	O
close	O
contacts	O
obtained	O
after	O
day	O
28	O
had	O
a	O
negative	O
result	O
for	O
SARS	B-DISO
coronavirus	O
antibody	O
.	O

Serum	O
samples	O
from	O
35	O
close	O
contacts	O
obtained	O
after	O
day	O
28	O
had	O
a	O
negative	O
result	O
for	O
SARS	B-DISO
coronavirus	O
antibody	O
.	O

Two	O
of	O
the	O
LTx	O
team	O
members	O
were	O
struck	B-DISO
by	O
SARS	B-DISO
.	O

The	O
origin	O
of	O
this	O
virus	O
is	O
uncertain	O
but	O
the	O
probability	O
of	O
zoonoses	B-DISO
is	O
being	O
seriously	O
discussed	O
.	O

These	O
frameshift	B-DISO
signals	O
originate	O
from	O
the	O
L	O
-	O
A	O
virus	O
,	O
the	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
Coronavirus	I-DISO
and	O
computationally	O
identified	O
frameshift	B-DISO
signals	O
from	O
two	O
Saccharomyces	O
cerevisiae	O
genes	O
.	O

The	O
current	O
outbreak	O
of	O
avian	B-DISO
influenza	I-DISO
in	O
South	O
East	O
Asia	O
has	O
resulted	O
in	O
a	O
small	O
number	O
of	O
human	O
deaths	O
.	O

TITLE	O
:	O
[	O
Epidemiological	O
perspectives	O
on	O
SARS	B-DISO
and	O
avian	B-DISO
influenza	I-DISO
].	O

ABSTRACT	O
:	O
SARS	B-DISO
is	O
a	O
respiratory	B-DISO
infection	I-DISO
caused	O
by	O
Coronavirus	O
(	O
Nidoviruses	O
,	O
RNA	O
)	O
from	O
which	O
3	O
groups	O
are	O
known	O
.	O

The	O
association	O
of	O
Impact	O
of	O
Event	O
Scale	O
scores	O
to	O
job	O
role	O
and	O
contact	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
patients	O
was	O
tested	O
by	O
analysis	O
of	O
variance	O
.	O

TITLE	O
:	O
Recombinant	O
infectious	B-DISO
bronchitis	B-DISO
coronavirus	O
Beaudette	O
with	O
the	O
spike	O
protein	O
gene	O
of	O
the	O
pathogenic	O
M41	O
strain	O
remains	O
attenuated	O
but	O
induces	O
protective	O
immunity	O
.	O

There	O
were	O
no	O
consistent	O
differences	O
in	O
pathogenicity	O
between	O
the	O
recombinant	O
BeauR	O
-	O
M41	O
(	O
S	O
)	O
and	O
its	O
apathogenic	O
parent	O
Beau	O
-	O
R	O
(	O
based	O
on	O
snicking	O
,	O
nasal	B-DISO
discharge	I-DISO
,	O
wheezing	B-DISO
,	O
watery	B-DISO
eyes	I-DISO
,	O
rales	B-DISO
,	O
and	O
ciliostasis	O
in	O
trachea	B-DISO
),	O
and	O
both	O
replicated	O
poorly	O
in	O
trachea	B-DISO
and	O
nose	O
compared	O
to	O
M41	O
;	O
the	O
S	O
protein	O
from	O
the	O
pathogenic	O
M41	O
had	O
not	O
altered	O
the	O
apathogenic	O
nature	O
of	O
Beau	O
-	O
R	O
.	O
Both	O
Beau	O
-	O
R	O
and	O
BeauR	O
-	O
M41	O
(	O
S	O
)	O
induced	O
protection	O
against	O
challenge	O
with	O
M41	O
as	O
assessed	O
by	O
absence	O
of	O
recovery	O
of	O
challenge	O
virus	O
and	O
nasal	O
exudate	O
.	O

Acute	O
lung	O
injury	O
/	O
ARDS	B-DISO
,	O
cardiogenic	O
edema	B-DISO
(	O
negative	O
controls	O
)	O
and	O
pulmonary	B-DISO
fibrosis	I-DISO
(	O
positive	O
controls	O
)	O
patients	O
.	O

Activation	O
of	O
circulating	O
neutrophils	O
and	O
transmigration	O
into	O
the	O
alveolar	O
airspace	O
are	O
associated	O
with	O
development	O
of	O
acute	O
lung	O
injury	O
,	O
and	O
inhibitors	O
of	O
neutrophil	O
recruitment	B-DISO
attenuate	O
lung	O
damage	O
in	O
many	O
experimental	O
models	O
.	O

Given	O
the	O
importance	O
of	O
monocytes	O
/	O
macrophages	O
to	O
the	O
immune	O
response	O
,	O
it	O
is	O
possible	O
that	O
their	O
infection	B-DISO
by	O
SARS	B-DISO
-	O
CoV	O
and	O
alteration	O
of	O
this	O
infection	B-DISO
by	O
IFN	O
-	O
alpha	O
may	O
be	O
important	O
to	O
the	O
course	O
of	O
the	O
infection	B-DISO
in	O
humans	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
dynamic	O
changes	O
of	O
the	O
antibody	O
specific	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
in	O
convalescents	O
who	O
have	O
suffered	B-DISO
from	O
SARS	B-DISO
.	O

TITLE	O
:	O
Humoral	O
immune	O
responses	O
in	O
rabbits	O
induced	O
by	O
an	O
experimental	O
inactivated	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
vaccine	O
prepared	O
from	O
F69	O
strain	O
.	O

The	O
titers	O
of	O
specific	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
IgG	O
antibody	O
were	O
determined	O
by	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
,	O
and	O
the	O
neutralizing	O
antibody	O
titers	O
were	O
detected	O
with	O
micro	O
-	O
cytopathic	B-DISO
effect	I-DISO
neutralization	O
test	O
.	O

Although	O
SARS	B-DISO
was	O
eradicated	O
by	O
isolation	O
towards	O
the	O
end	O
of	O
2003	O
,	O
sporadic	O
cases	O
have	O
been	O
reported	O
in	O
Singapore	O
,	O
Taiwan	O
and	O
mainland	O
China	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
coronavirus	O
has	O
recently	O
been	O
identified	O
as	O
the	O
cause	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
).	O

An	O
understanding	O
of	O
the	O
disease	O
and	O
its	O
pathogenesis	B-DISO
and	O
the	O
genetics	O
of	O
coronavirus	B-DISO
infections	I-DISO
,	O
as	O
well	O
as	O
strategies	O
to	O
treat	O
or	O
prevent	O
coronavirus	B-DISO
infections	I-DISO
,	O
are	O
essential	O
.	O

The	O
history	O
of	O
coronavirus	O
vaccines	O
and	O
the	O
occurrence	O
of	O
laboratory	O
-	O
associated	O
SARS	B-DISO
-	O
CoV	O
infections	B-DISO
underscore	O
the	O
need	O
for	O
stably	O
attenuated	O
strains	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
other	O
coronaviruses	O
.	O

In	O
adults	O
,	O
systemic	B-DISO
infection	I-DISO
with	O
clinical	O
and	O
biochemical	O
abnormalities	O
,	O
as	O
well	O
as	O
respiratory	B-DISO
infection	I-DISO
,	O
may	O
be	O
the	O
rule	O
.	O

RESULTS	O
:	O
Rapid	O
progress	O
has	O
been	O
made	O
in	O
understanding	O
the	O
clinical	O
disease	O
of	O
SARS	B-DISO
in	O
adults	O
and	O
children	O
.	O

TITLE	O
:	O
Research	O
on	O
infectious	B-DISO
diseases	I-DISO
requires	O
better	O
coordination	O
.	O

There	O
is	O
a	O
need	O
to	O
enhance	O
global	O
resources	O
to	O
investigate	O
,	O
detect	O
and	O
respond	O
to	O
emerging	O
infections	B-DISO
,	O
and	O
to	O
appropriately	O
coordinate	O
and	O
direct	O
research	O
efforts	O
to	O
meet	O
the	O
challenges	O
presented	O
by	O
these	O
diseases	O
.	O

ABSTRACT	O
:	O
Fifty	O
years	O
ago	O
,	O
the	O
age	O
-	O
old	O
scourge	O
of	O
infectious	B-DISO
disease	I-DISO
was	O
receding	O
in	O
the	O
developed	O
world	O
in	O
response	O
to	O
improved	O
public	O
health	O
measures	O
,	O
while	O
the	O
advent	O
of	O
antibiotics	O
,	O
better	O
vaccines	O
,	O
insecticides	O
and	O
improved	O
surveillance	O
held	O
the	O
promise	O
of	O
eradicating	O
residual	O
problems	O
.	O

TITLE	O
:	O
Use	O
of	O
simple	O
laboratory	O
features	O
to	O
distinguish	O
the	O
early	O
stage	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
from	O
dengue	B-DISO
fever	I-DISO
.	O

Postmortem	O
examination	O
revealed	O
pulmonary	B-DISO
edema	I-DISO
and	O
evidence	O
of	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
.	O

CONCLUSIONS	O
:	O
On	O
July	O
5	O
,	O
2003	O
,	O
the	O
WHO	O
declared	O
that	O
the	O
SARS	B-DISO
outbreak	O
was	O
over	O
.	O

Together	O
,	O
these	O
results	O
strongly	O
indicate	O
that	O
PBEF	O
is	O
a	O
potential	O
novel	O
biomarker	O
in	O
ALI	O
and	O
demonstrate	O
the	O
successful	O
application	O
of	O
robust	O
genomic	O
technologies	O
in	O
the	O
identification	O
of	O
candidate	O
genes	O
in	O
complex	O
lung	B-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
Resuscitation	O
from	O
hemorrhagic	B-DISO
shock	I-DISO
triggers	O
an	O
inflammatory	B-DISO
response	I-DISO
characterized	O
by	O
upregulation	O
of	O
cytokine	O
and	O
adhesion	B-DISO
molecule	O
expression	O
,	O
increased	O
leukocyte	O
activity	O
,	O
and	O
accumulation	O
of	O
polymorphonuclear	O
neutrophils	O
in	O
a	O
variety	O
of	O
tissues	O
.	O

TITLE	O
:	O
Immune	O
responses	O
against	O
SARS	B-DISO
-	O
coronavirus	O
nucleocapsid	O
protein	O
induced	O
by	O
DNA	O
vaccine	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
SARS	B-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
the	O
key	O
protein	O
for	O
the	O
formation	O
of	O
the	O
helical	O
nucleocapsid	O
during	O
virion	O
assembly	O
.	O

We	O
hypothesize	O
that	O
,	O
by	O
altering	O
lung	O
airway	O
surface	O
properties	O
through	O
an	O
inhaled	O
nontoxic	O
aerosol	O
,	O
we	O
might	O
substantially	O
diminish	O
the	O
number	O
of	O
exhaled	O
bioaerosol	O
droplets	O
and	O
thereby	O
provide	O
a	O
simple	O
means	O
to	O
potentially	O
mitigate	O
the	O
spread	O
of	O
airborne	O
infectious	B-DISO
disease	I-DISO
independently	O
of	O
the	O
identity	O
of	O
the	O
airborne	O
pathogen	O
or	O
the	O
nature	O
of	O
any	O
specific	O
therapy	O
.	O

Variously	O
described	O
as	O
postpneumonectomy	O
pulmonary	B-DISO
edema	I-DISO
,	O
noncardiogenic	O
pulmonary	B-DISO
edema	I-DISO
,	O
and	O
postlung	O
resection	O
pulmonary	B-DISO
edema	I-DISO
,	O
ALI	O
and	O
ARDS	B-DISO
may	O
be	O
considered	O
a	O
single	O
entity	O
,	O
with	O
ALI	O
being	O
the	O
less	O
severe	O
form	O
of	O
ARDS	B-DISO
.	O

Here	O
,	O
we	O
examined	O
the	O
heat	O
inactivation	B-DISO
ability	O
of	O
an	O
agent	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
SARS	B-DISO
coronavirus	O
(	O
CoV	O
).	O

However	O
,	O
the	O
different	O
composition	O
of	O
the	O
tested	O
samples	O
affected	O
the	O
heat	B-DISO
sensitivity	I-DISO
of	O
the	O
virus	O
strain	O
:	O
the	O
infectivity	O
of	O
the	O
virus	O
in	O
Antithrombin	O
III	O
preparation	O
still	O
remained	O
after	O
heating	O
for	O
30	O
min	O
at	O
60	O
degrees	O
C	O
.	O
CONCLUSIONS	O
:	O
If	O
by	O
rare	O
chance	O
SARS	B-DISO
-	O
CoV	O
contaminates	O
source	O
plasma	O
,	O
there	O
should	O
be	O
no	O
or	O
only	O
minor	O
risk	O
of	O
this	O
virus	B-DISO
infection	I-DISO
,	O
due	O
to	O
sufficient	O
inactivation	B-DISO
by	O
the	O
60	O
degrees	O
C	O
10	O
h	O
liquid	O
heating	O
step	O
,	O
although	O
we	O
must	O
pay	O
attention	O
to	O
the	O
composition	O
used	O
for	O
blood	O
product	O
preparation	O
.	O

However	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
intermediate	B-DISO
syndrome	I-DISO
,	O
relapse	B-DISO
,	O
liver	O
injury	O
(	O
all	O
P	O
>	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
A	O
characteristic	O
feature	O
of	O
all	O
inflammatory	O
disorders	O
is	O
the	O
excessive	O
recruitment	B-DISO
of	O
leukocytes	O
to	O
the	O
site	O
of	O
inflammation	B-DISO
.	O

Based	O
on	O
previous	O
experience	O
in	O
Canada	O
,	O
infection	B-DISO
control	O
resources	O
and	O
protocols	O
were	O
recommended	O
.	O

RESULTS	O
:	O
Thirty	O
-	O
two	O
patients	O
were	O
included	O
,	O
representing	O
9	O
%	O
of	O
falciparum	B-DISO
malaria	I-DISO
cases	O
diagnosed	O
in	O
the	O
same	O
period	O
.	O

Significantly	O
,	O
overexpression	O
of	O
Bcl	O
-	O
xL	O
alone	O
was	O
sufficient	O
to	O
convert	O
acute	O
to	O
persistent	O
,	O
nonproductive	O
infection	B-DISO
in	O
CG	O
-	O
4	O
cells	O
.	O

Although	O
viral	O
genomic	O
RNAs	O
continuously	O
persisted	O
in	O
Bcl	O
-	O
xL	O
-	O
expressing	O
CG	O
-	O
4	O
cells	O
over	O
10	O
passages	O
,	O
infectious	B-DISO
virus	O
could	O
no	O
longer	O
be	O
isolated	O
beyond	O
2	O
passages	O
of	O
the	O
cell	O
.	O

ABSTRACT	O
:	O
Small	O
animal	O
models	O
are	O
needed	O
in	O
order	O
to	O
evaluate	O
the	O
efficacy	O
of	O
candidate	O
vaccines	O
and	O
antivirals	O
directed	O
against	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
CoV	O
).	O

Viral	O
replication	O
in	O
epithelial	O
cells	O
of	O
the	O
respiratory	O
tract	O
was	O
accompanied	O
by	O
cellular	O
necrosis	O
early	O
in	O
infection	B-DISO
,	O
followed	O
by	O
an	O
inflammatory	B-DISO
response	I-DISO
coincident	O
with	O
viral	O
clearance	O
,	O
focal	O
consolidation	O
in	O
pulmonary	O
tissue	O
,	O
and	O
eventual	O
pulmonary	O
tissue	O
repair	O
.	O

Stress	O
-	O
dose	O
of	O
steroid	O
and	O
activated	O
protein	O
C	O
for	O
severe	B-DISO
sepsis	I-DISO
are	O
useful	O
if	O
shock	O
don	O
'	O
t	O
recover	O
by	O
aggressive	B-DISO
fluid	O
infusion	O
and	O
vasopressors	O
'	O
administration	O
.	O

One	O
female	O
patient	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
treated	O
with	O
inhaled	O
nitric	O
oxide	O
,	O
who	O
developed	O
a	O
simultaneous	O
increase	O
in	O
blood	O
methemoglobin	O
and	O
carboxyhemoglobin	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
a	O
recombinant	O
nucleocapsid	O
protein	O
-	O
based	O
assay	O
for	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
IgG	O
detection	O
.	O

ABSTRACT	O
:	O
A	O
high	O
throughput	O
accurate	O
assay	O
for	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
IgG	O
detection	O
is	O
needed	O
for	O
large	O
-	O
scale	O
epidemiological	O
studies	O
.	O

A	O
vast	O
majority	O
of	O
SARS	B-DISO
patients	O
developed	O
antibodies	O
against	O
the	O
nucleocapsid	O
protein	O
.	O

ABSTRACT	O
:	O
The	O
global	O
epidemic	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
2003	O
demonstrated	O
the	O
need	O
to	O
determine	O
control	O
strategies	O
for	O
exotic	O
infections	B-DISO
.	O

TITLE	O
:	O
Intranasal	O
immunization	O
with	O
inactivated	O
SARS	B-DISO
-	O
CoV	O
(	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
)	O
induced	O
local	O
and	O
serum	O
antibodies	O
in	O
mice	O
.	O

SARS	B-DISO
-	O
CoV	O
is	O
discussed	O
.	O

ABSTRACT	O
:	O
A	O
coronavirus	O
(	O
CoV	O
)	O
has	O
recently	O
been	O
identified	O
as	O
the	O
causative	O
agent	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
humans	O
.	O

The	O
N	O
protein	O
,	O
expressed	O
in	O
vitro	O
by	O
Ad5	B-DISO
-	O
N	O
-	O
V	O
,	O
was	O
of	O
the	O
expected	O
molecular	O
mass	O
of	O
50	O
kDa	O
and	O
was	O
phosphorylated	O
.	O

Vaccination	O
of	O
C57BL	O
/	O
6	O
mice	O
with	O
Ad5	B-DISO
-	O
N	O
-	O
V	O
generated	O
potent	O
SARS	B-DISO
-	O
CoV	O
-	O
specific	O
humoral	O
and	O
T	O
cell	O
-	O
mediated	O
immune	O
responses	O
.	O

0	O
.	O
32	O
for	O
HH	O
,	O
HL	O
and	O
LL	O
genotypes	O
,	O
respectively	O
)	O
and	O
SARS	B-DISO
patients	O
(	O
NFI	O
:	O
3	O
.	O
52	O
+/-	O
0	O
.	O
91	O
and	O
2	O
.	O
63	O
+/-	O

TITLE	O
:	O
An	O
ELISA	O
optimized	O
for	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
detection	O
in	O
faeces	O
.	O

In	O
this	O
report	O
,	O
ribavirin	O
was	O
shown	O
to	O
inhibit	O
SARS	B-DISO
-	O
CoV	O
replication	O
in	O
five	O
different	O
cell	O
types	O
of	O
animal	O
or	O
human	O
origin	O
at	O
therapeutically	O
achievable	O
concentrations	O
.	O

Since	O
clinical	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
activity	O
of	O
type	O
I	O
interferons	O
or	O
ribavirin	O
is	O
limited	O
,	O
we	O
investigated	O
the	O
combination	O
of	O
IFN	O
-	O
beta	O
and	O
ribavirin	O
.	O

Additionally	O
,	O
the	O
relative	O
strengths	O
and	O
limitations	O
of	O
targeted	O
RNA	O
recombination	O
and	O
infectious	B-DISO
cDNA	O
systems	O
are	O
contrasted	O
.	O

TITLE	O
:	O
Reverse	O
genetics	O
of	O
coronaviruses	O
using	O
vaccinia	B-DISO
virus	O
vectors	O
.	O

TITLE	O
:	O
Development	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
and	O
SARS	B-DISO
-	O
CoV	O
infectious	B-DISO
cDNA	O
constructs	O
.	O

The	O
systematic	O
assembly	O
approach	O
was	O
used	O
to	O
develop	O
an	O
infectious	B-DISO
clone	O
of	O
the	O
newly	O
identified	O
human	O
coronavirus	O
,	O
the	O
serve	O
acute	O
respiratory	O
syndrome	B-DISO
virus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

Previously	O
,	O
mutations	O
in	O
the	O
equine	O
arteritis	B-DISO
virus	O
(	O
EAV	O
)	O
nsp10	O
ZBD	O
were	O
shown	O
to	O
block	O
arterivirus	O
reproduction	O
by	O
disrupting	O
RNA	O
synthesis	O
and	O
possibly	O
virion	O
biogenesis	O
.	O

Here	O
,	O
we	O
characterized	O
the	O
ATPase	O
and	O
helicase	O
activities	O
of	O
bacterially	O
expressed	O
mutant	B-DISO
forms	O
of	O
nsp10	O
and	O
its	O
human	O
coronavirus	O
229E	O
ortholog	O
,	O
nsp13	O
,	O
and	O
correlated	O
these	O
in	O
vitro	O
activities	O
with	O
specific	O
virus	O
phenotypes	O
.	O

nsp10	O
ATPase	O
/	O
helicase	O
deficiency	O
resulting	O
from	O
single	O
-	O
residue	O
substitutions	O
in	O
the	O
ZBD	O
or	O
deletion	O
of	O
the	O
entire	O
domain	O
could	O
not	O
be	O
complemented	O
in	O
trans	O
by	O
wild	O
-	O
type	O
ZBD	O
,	O
suggesting	O
a	O
critical	O
function	O
of	O
the	O
ZBD	O
in	O
cis	B-DISO
.	O

TITLE	O
:	O
Natural	O
history	O
of	O
a	O
recurrent	O
feline	O
coronavirus	B-DISO
infection	I-DISO
and	O
the	O
role	O
of	O
cellular	O
immunity	O
in	O
survival	O
and	O
disease	O
.	O

A	O
severe	O
recurrent	O
infection	B-DISO
developed	O
,	O
typified	O
by	O
viral	O
persistence	O
and	O
acute	O
lymphopenia	B-DISO
,	O
with	O
waves	O
of	O
enhanced	O
viral	O
replication	O
coinciding	O
with	O
fever	O
,	O
weight	O
loss	O
,	O
and	O
depletion	O
of	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
.	O

Airway	O
pressure	O
release	O
ventilation	O
is	O
a	O
mode	O
of	O
mechanical	O
ventilation	O
that	O
maintains	O
lung	O
volume	O
to	O
limit	O
intra	O
tidal	O
recruitment	B-DISO
/	O
derecruitment	O
and	O
improves	O
gas	O
exchange	O
while	O
limiting	O
over	O
distension	B-DISO
.	O

Nineteen	O
years	O
later	O
,	O
acute	B-DISO
nephritic	I-DISO
syndrome	I-DISO
with	O
hypocomplementemia	B-DISO
and	O
an	O
increasing	O
anti	O
-	O
streptolysin	O
O	O
(	O
ASO	O
)	O
titer	O
developed	O
2	O
weeks	O
after	O
the	O
onset	O
of	O
an	O
upper	B-DISO
respiratory	I-DISO
infection	I-DISO
.	O

However	O
,	O
it	O
is	O
especially	O
during	O
the	O
last	O
ten	O
years	O
that	O
very	O
dangerous	O
viruses	O
for	O
mankind	O
have	O
repeatedly	O
developed	O
in	O
Asia	O
,	O
with	O
the	O
occurrence	O
of	O
Alkhurma	O
hemorrhagic	B-DISO
fever	I-DISO
in	O
Saudi	O
Arabia	O
(	O
1995	O
),	O
avian	B-DISO
flu	I-DISO
(	O
H5N1	B-DISO
)	O
in	O
Hong	O
-	O
Kong	O
(	O
1997	O
),	O
Nipah	O
virus	O
encephalitis	B-DISO
in	O
Malaysia	O
(	O
1998	O
,)	O
and	O
,	O
above	O
all	O
,	O
the	O
SARS	B-DISO
pandemic	O
fever	O
from	O
Southern	O
China	O
(	O
2002	O
).	O

TITLE	O
:	O
Generation	O
of	O
a	O
recombinant	O
avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
using	O
transient	O
dominant	O
selection	O
.	O

Recombinant	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
expressing	O
a	O
heterologous	O
spike	O
gene	O
demonstrates	O
that	O
the	O
spike	O
protein	O
is	O
a	O
determinant	O
of	O
cell	O
tropism	O
.	O

TITLE	O
:	O
Predictive	O
value	O
of	O
the	O
user	O
seal	O
check	O
in	O
determining	O
half	O
-	O
face	B-DISO
respirator	O
fit	B-DISO
.	O

The	O
results	O
of	O
the	O
documented	O
user	O
seal	O
check	O
were	O
then	O
compared	O
with	O
the	O
formal	O
fit	B-DISO
-	O
test	O
results	O
from	O
a	O
PortaCount	O
.	O

These	O
data	O
indicate	O
that	O
the	O
user	O
seal	O
check	O
should	O
not	O
be	O
used	O
as	O
a	O
surrogate	O
fit	B-DISO
test	O
.	O

Understanding	O
epidemiology	O
and	O
disease	B-DISO
transmission	I-DISO
is	O
vital	O
to	O
nursing	O
care	O
.	O

Infectious	B-DISO
disease	I-DISO
transmission	I-DISO
requires	O
three	O
components	O
:	O
an	O
agent	O
(	O
virus	O
,	O
bacterium	O
,	O
parasite	O
or	O
other	O
microbe	O
),	O
a	O
vulnerable	O
host	O
and	O
a	O
conducive	O
environment	O
.	O

Control	O
measures	O
for	O
MRSA	B-DISO
include	O
the	O
screening	O
of	O
patient	O
lesions	O
,	O
isolating	O
or	O
cohorting	O
patients	O
who	O
are	O
already	O
infected	O
,	O
covering	O
wounds	O
with	O
impermeable	O
dressings	O
,	O
treating	O
staff	O
and	O
patient	O
carriers	O
with	O
antibiotics	O
,	O
and	O
improved	O
hygiene	O
.	O

Respiratory	B-DISO
failure	I-DISO
developed	O
in	O
15	O
.	O
4	O
%	O
of	O
the	O
SARS	B-DISO
patients	O
and	O
in	O
none	O
of	O
the	O
M	O
.	O
pneumoniae	O
patients	O
.	O

Because	O
of	O
similar	O
initial	O
presentations	O
,	O
differentiating	O
SARS	B-DISO
from	O
M	O
.	O
pneumoniae	O
pneumonia	B-DISO
is	O
very	O
difficult	O
based	O
on	O
symptomatology	O
.	O

RESULTS	O
:	O
The	O
initial	O
clinical	O
manifestations	O
were	O
similar	O
in	O
patients	O
with	O
SARS	B-DISO
and	O
those	O
with	O
M	O
.	O
pneumoniae	O
infection	B-DISO
.	O

A	O
56	O
-	O
year	O
-	O
old	O
female	O
patient	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
with	O
tracheoesophageal	B-DISO
fistula	I-DISO
is	O
reported	O
.	O

Methylprednisolone	O
pulse	O
therapy	O
followed	O
by	O
a	O
maintenance	O
dosage	O
was	O
given	O
due	O
to	O
persistence	O
of	O
bilateral	O
pulmonary	B-DISO
fibrosis	I-DISO
.	O

The	O
tracheoesophageal	B-DISO
fistula	I-DISO
,	O
once	O
developed	O
,	O
can	O
be	O
repaired	O
in	O
a	O
single	O
stage	O
after	O
improvement	O
of	O
the	O
nutritional	O
status	O
.	O

ABSTRACT	O
:	O
There	O
is	O
limited	O
worldwide	O
experience	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
pregnancy	O
.	O

CONCLUSIONS	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
pregnancy	O
is	O
a	O
potentially	O
life	O
-	O
threatening	O
illness	O
with	O
complicated	O
management	O
issues	O
.	O

The	O
discovery	O
of	O
this	O
minor	O
genotype	O
,	O
GD	O
-	O
Ins29	O
,	O
suggests	O
a	O
significant	O
genetic	O
event	O
and	O
differentiates	O
it	O
from	O
the	O
previously	O
reported	O
genotype	O
,	O
the	O
dominant	O
form	O
among	O
all	O
sequenced	O
SARS	B-DISO
-	O
CoV	O
isolates	O
.	O

The	O
most	O
striking	O
physiochemical	O
feature	O
of	O
the	O
N	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
is	O
that	O
it	O
is	O
a	O
typical	O
basic	O
protein	O
with	O
a	O
high	O
predicted	O
pI	O
and	O
high	O
hydrophilicity	O
,	O
which	O
is	O
consistent	O
with	O
its	O
function	O
of	O
binding	O
to	O
the	O
ribophosphate	O
backbone	O
of	O
the	O
RNA	O
molecule	O
.	O

The	O
abundant	O
antigenic	O
sites	O
predicted	O
in	O
the	O
N	O
protein	O
,	O
as	O
well	O
as	O
experimental	O
evidence	O
with	O
synthesized	O
polypeptides	O
,	O
indicate	O
that	O
the	O
N	O
protein	O
is	O
one	O
of	O
the	O
major	O
antigens	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
.	O
Compared	O
with	O
other	O
viral	O
structural	O
proteins	O
,	O
the	O
low	O
variation	O
rate	O
of	O
the	O
N	O
protein	O
with	O
regards	O
to	O
its	O
size	O
suggests	O
its	O
importance	O
to	O
the	O
survival	O
of	O
the	O
virus	O
.	O

TITLE	O
:	O
Complete	O
genome	O
sequences	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
:	O
the	O
BJ	O
Group	O
(	O
Isolates	O
BJ01	O
-	O
BJ04	O
).	O

To	O
determine	O
its	O
antigenicity	O
,	O
the	O
fusion	O
protein	O
was	O
challenged	O
with	O
serum	O
samples	O
from	O
SARS	B-DISO
patients	O
and	O
normal	O
controls	O
.	O

TITLE	O
:	O
The	O
epitope	O
study	O
on	O
the	O
SARS	B-DISO
-	O
CoV	O
nucleocapsid	O
protein	O
.	O

In	O
order	O
to	O
understand	O
the	O
origin	O
and	O
evolution	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
(	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
),	O
we	O
collected	O
complete	O
genome	O
sequences	O
of	O
all	O
viruses	O
available	O
in	O
GenBank	O
,	O
and	O
made	O
comparative	O
analyses	O
with	O
the	O
SARS	B-DISO
-	O
CoV	O
.	O
Genomic	O
signature	O
analysis	O
demonstrates	O
that	O
the	O
coronaviruses	O
all	O
take	O
the	O
TGTT	O
as	O
their	O
richest	O
tetranucleotide	O
except	O
the	O
SARS	B-DISO
-	O
CoV	O
.	O
A	O
detailed	O
analysis	O
of	O
the	O
forty	O
-	O
two	O
complete	O
SARS	B-DISO
-	O
CoV	O
genome	O
sequences	O
revealed	O
the	O
existence	O
of	O
two	O
distinct	O
genotypes	O
,	O
and	O
showed	O
that	O
these	O
isolates	O
could	O
be	O
classified	O
into	O
four	O
groups	O
.	O

We	O
have	O
performed	O
a	O
full	O
annotation	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
genome	O
sequences	O
by	O
using	O
annotation	O
programs	O
publicly	O
available	O
or	O
developed	O
by	O
ourselves	O
.	O

The	O
binding	O
specificity	O
of	O
phage	O
antibody	O
to	O
SARS	B-DISO
virus	O
was	O
detected	O
by	O
ELISA	O
.	O

After	O
three	O
rounds	O
of	O
panning	O
with	O
SARS	B-DISO
virus	O
antigen	O
,	O
phage	O
antibodies	O
against	O
SARS	B-DISO
virus	O
were	O
specifically	O
enriched	O
.	O

Besides	O
,	O
the	O
expressions	O
of	O
TCR	O
Vbeta1	O
,	O
Vbeta5	O
.	O
2	O
,	O
Vbeta5	O
.	O
3	O
,	O
Vbeta7	O
.	O
2	O
,	O
Vbeta9	O
,	O
Vbeta11	O
,	O
Vbeta13	O
.	O
1	O
,	O
Vbeta13	O
.	O
2	O
,	O
Vbeta17	O
,	O
Vbeta18	O
,	O
Vbeta22	O
and	O
Vbeta23	O
in	O
SARS	B-DISO
group	O
were	O
all	O
significantly	O
higher	O
than	O
those	O
in	O
normal	O
group	O
.	O

CONCLUSIONS	O
:	O
Increased	O
Ts	O
cell	O
may	O
lead	O
to	O
increased	O
CD8	O
(+)	O
T	O
cells	O
in	O
convalescent	O
SARS	B-DISO
patients	O
.	O

(	O
2	O
)	O
The	O
proportion	O
of	O
the	O
patients	O
who	O
had	O
close	O
contact	O
to	O
SARS	B-DISO
patients	O
was	O
7	O
/	O
8	O
among	O
the	O
antibody	O
-	O
positive	O
group	O
vs	O
.	O
1	O
/	O
13	O
for	O
the	O
antibody	O
-	O
negative	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

(	O
4	O
)	O
Among	O
23	O
parents	O
of	O
children	O
with	O
SARS	B-DISO
,	O
one	O
was	O
positive	O
for	O
IgG	O
and	O
the	O
mixed	O
antibodies	O
,	O
whose	O
grandson	O
and	O
husband	O
suffered	B-DISO
from	O
SARS	B-DISO
;	O
The	O
IgG	O
antibody	O
and	O
the	O
mixed	O
antibodies	O
were	O
also	O
positive	O
in	O
another	O
adult	O
who	O
had	O
close	O
contact	O
with	O
adult	O
SARS	B-DISO
cases	O
(	O
3	O
%).	O

The	O
positive	O
rates	O
of	O
IgM	O
,	O
IgG	O
and	O
total	O
antibodies	O
to	O
SARS	B-DISO
-	O
CoV	O
in	O
146	O
sera	O
of	O
SARS	B-DISO
patients	O
collected	O
in	O
different	O
phases	O
of	O
the	O
disease	O
were	O
61	O
.	O
64	O
%,	O
53	O
.	O
43	O
%	O
and	O
69	O
.	O
86	O
%,	O
respectively	O
.	O

The	O
specific	O
IgM	O
disappeared	O
as	O
early	O
as	O
42	O
days	O
after	O
the	O
onset	O
of	O
SARS	B-DISO
.	O

Specific	O
IgG	O
antibody	O
against	O
SARS	B-DISO
-	O
CoV	O
in	O
serum	O
samples	O
from	O
contacts	O
to	O
patients	O
,	O
five	O
months	O
before	O
an	O
SARS	B-DISO
outbreak	O
in	O
Beijing	O
.	O

All	O
SARS	B-DISO
cases	O
were	O
positive	O
except	O
one	O
by	O
immunity	O
adherence	O
test	O
.	O

,	O
there	O
was	O
no	O
latent	B-DISO
infection	I-DISO
among	O
close	O
contacts	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
risk	O
of	O
aerosol	O
transmission	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
admitted	O
to	O
Hospital	O
through	O
testing	O
the	O
air	O
samples	O
.	O

Indirect	O
immunofluorescence	O
assay	O
showed	O
positive	O
from	O
serum	O
of	O
a	O
SARS	B-DISO
patient	O
.	O

SARS	B-DISO
-	O
CoV	O
existed	O
in	O
the	O
air	O
hospital	O
,	O
where	O
SARS	B-DISO
patients	O
were	O
admitted	O
to	O
,	O
but	O
the	O
activity	O
of	O
SARS	B-DISO
-	O
CoV	O
in	O
air	O
samples	O
was	O
rather	O
low	O
.	O

Monoclonal	O
antibodies	O
we	O
made	O
were	O
specific	O
to	O
the	O
SARS	B-DISO
-	O
CoV	O
,	O
and	O
they	O
had	O
been	O
used	O
to	O
detect	O
SARS	B-DISO
-	O
CoV	O
in	O
autopsy	O
lung	O
tissues	O
specimens	O
with	O
positive	O
results	O
.	O

TITLE	O
:	O
[	O
Report	O
on	O
the	O
investigation	O
of	O
lower	O
extremity	O
osteonecrosis	B-DISO
with	O
magnetic	O
resonance	O
imaging	O
in	O
recovered	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
Guangzhou	O
].	O

124	O
health	O
care	O
workers	O
with	O
recovered	O
SARS	B-DISO
from	O
four	O
hospitals	O
in	O
Guangzhou	O
were	O
examined	O
with	O
MR	O
imaging	O
of	O
the	O
lower	O
extremity	O
including	O
bilateral	O
hips	O
and	O
knees	O
.	O

The	O
full	O
examination	O
was	O
defined	O
as	O
images	O
from	O
the	O
screening	O
examination	O
plus	O
three	O
additional	O
imaging	O
sequences	O
:	O
transverse	O
and	O
coronal	O
T2	O
-	O
weighted	O
imaging	O
and	O
short	O
tau	O
inversion	B-DISO
recovery	O
sequence	O
.	O

TITLE	O
:	O
Foundations	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
preparedness	O
and	O
response	O
plan	B-DISO
for	O
healthcare	O
facilities	O
.	O

Of	O
the	O
196	O
patients	O
,	O
34	O
(	O
17	O
.	O
3	O
%)	O
met	O
the	O
World	O
Health	O
Organization	O
criteria	O
for	O
probable	O
SARS	B-DISO
with	O
positive	O
results	O
of	O
serologic	O
testing	O
for	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
),	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
from	O
nasopharyngeal	O
or	O
throat	O
swabs	O
for	O
SARS	B-DISO
-	O
CoV	O
,	O
or	O
both	O
.	O

Seventy	O
-	O
four	O
patients	O
had	O
suspected	O
SARS	B-DISO
based	O
on	O
unprotected	O
exposure	O
to	O
SARS	B-DISO
patients	O
;	O
three	O
of	O
them	O
had	O
positive	O
results	O
on	O
RT	O
-	O
PCR	O
but	O
negative	O
serologic	O
results	O
.	O

During	O
the	O
study	O
period	O
,	O
one	O
nurse	O
developed	O
probable	O
SARS	B-DISO
due	O
to	O
violation	O
of	O
infection	B-DISO
control	O
measures	O
,	O
but	O
there	O
was	O
no	O
evidence	O
of	O
cross	O
-	O
transmission	O
to	O
other	O
HCWs	O
.	O

TITLE	O
:	O
A	O
tale	O
of	O
two	O
cities	O
:	O
community	O
psychobehavioral	O
surveillance	O
and	O
related	O
impact	O
on	O
outbreak	O
control	O
in	O
Hong	O
Kong	O
and	O
Singapore	O
during	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
epidemic	O
.	O

Comparative	O
psychobehavioral	O
surveillance	O
and	O
analysis	O
could	O
yield	O
important	O
insights	O
into	O
generic	O
versus	O
population	O
-	O
specific	O
issues	O
that	O
could	O
be	O
used	O
to	O
inform	O
,	O
design	O
,	O
and	O
evaluate	O
public	O
health	O
infection	B-DISO
control	O
policy	O
measures	O
.	O

TITLE	O
:	O
A	O
large	O
-	O
volume	O
nebulizer	O
would	O
not	O
be	O
an	O
infectious	B-DISO
source	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

In	O
spontaneously	O
breathing	O
patients	O
,	O
auto	B-DISO
-	I-DISO
PEEP	I-DISO
is	O
measured	O
by	O
simultaneous	O
recordings	O
of	O
esophageal	O
and	O
flow	O
waveforms	O
.	O

TITLE	O
:	O
Psychological	B-DISO
distress	I-DISO
of	O
nurses	O
in	O
Taiwan	O
who	O
worked	O
during	O
the	O
outbreak	O
of	O
SARS	B-DISO
.	O

This	O
study	O
was	O
conducted	O
in	O
Taiwan	O
during	O
the	O
peak	O
of	O
the	O
SARS	B-DISO
outbreak	O
in	O
2003	O
.	O

TITLE	O
:	O
Arginine	O
metabolism	O
during	O
macrophage	O
autocrine	O
activation	O
and	O
infection	B-DISO
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
3	O
.	O

TITLE	O
:	O
Prevalence	O
of	O
diseases	O
of	O
the	O
spinal	O
cord	B-DISO
of	O
cats	O
.	O

FIP	B-DISO
was	O
the	O
most	O
common	O
disease	O
of	O
cats	O
younger	O
than	O
2	O
years	O
of	O
age	O
.	O

Nucleic	O
acid	O
amplification	B-DISO
tests	O
(	O
NAATs	O
)	O
have	O
been	O
evaluated	O
for	O
detecting	O
most	O
respiratory	O
pathogens	O
,	O
and	O
commercial	O
assays	O
are	O
available	O
for	O
some	O
pathogens	O
.	O

Although	O
less	O
sensitive	O
than	O
culture	O
-	O
based	O
methods	O
,	O
several	O
commercial	O
molecular	O
diagnostic	O
assays	O
have	O
been	O
developed	O
for	O
tuberculosis	B-DISO
and	O
are	O
useful	O
rapid	O
tests	O
for	O
selected	O
patients	O
.	O

Of	O
all	O
the	O
subjects	O
,	O
81	O
.	O
2	O
%	O
(	O
311	O
of	O
383	O
patients	O
)	O
tested	O
positive	O
for	O
serum	O
SARS	B-DISO
-	O
CoV	O
IgG	O
.	O
Of	O
those	O
testing	O
positive	O
,	O
27	O
.	O
3	O
%	O
(	O
85	O
of	O
311	O
patients	O
)	O
were	O
suffering	B-DISO
from	O
lung	O
diffusion	O
abnormities	O
(	O
DLCO	O
<	O
80	O
%	O
pred	O
)	O
and	O
21	O
.	O
5	O
%	O
(	O
67	O
of	O
311	O
patients	O
)	O
exhibited	O
lung	O
fibrotic	O
changes	O
.	O

The	O
lack	O
of	O
sero	O
-	O
positive	O
SARS	B-DISO
-	O
CoV	O
in	O
some	O
individuals	O
suggests	O
that	O
there	O
may	O
have	O
been	O
some	O
misdiagnosed	O
cases	O
among	O
the	O
subjects	O
included	O
in	O
this	O
study	O
.	O

TITLE	O
:	O
HMGB1	O
contributes	O
to	O
the	O
development	O
of	O
acute	O
lung	O
injury	O
after	O
hemorrhage	B-DISO
.	O

Similarly	O
,	O
both	O
the	O
accumulation	O
of	O
neutrophils	O
in	O
the	O
lung	O
as	O
well	O
as	O
enhanced	O
lung	O
permeability	O
were	O
reduced	O
when	O
anti	O
-	O
HMGB1	O
antibodies	O
were	O
injected	O
after	O
hemorrhage	B-DISO
.	O

Communication	O
and	O
leadership	O
strategies	O
were	O
key	O
components	O
in	O
the	O
critical	O
care	O
response	O
to	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
To	O
summarize	O
the	O
clinical	O
experience	O
from	O
treatment	O
of	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

The	O
treatment	O
regiments	O
included	O
oxygen	O
,	O
small	O
dosage	O
and	O
short	O
period	O
of	O
methylprednisolone	O
(	O
1	O
to	O
2	O
mg	O
/	O
kg	O
),	O
use	O
of	O
ventilator	O
,	O
psychological	B-DISO
intervention	O
,	O
and	O
treatment	O
of	O
underlying	O
diseases	O
,	O
after	O
which	O
,	O
all	O
the	O
7	O
patients	O
recovered	O
.	O

The	O
ELISA	O
for	O
detection	O
of	O
SARS	B-DISO
virus	O
antigen	O
was	O
developed	O
with	O
McAb	O
7	O
.	O

The	O
monoclonal	O
antibody	O
has	O
good	O
specificity	O
and	O
may	O
be	O
used	O
to	O
detect	O
SARS	B-DISO
virus	O
antigen	O
.	O

However	O
,	O
its	O
sensitivity	O
is	O
to	O
be	O
evaluated	O
further	O
with	O
clinical	O
samples	O
from	O
SARS	B-DISO
patients	O
,	O
especially	O
at	O
acute	O
phase	O
.	O

BALB	O
/	O
c	O
mice	O
were	O
immunized	O
with	O
a	O
plasmid	O
bearing	O
codon	O
-	O
optimized	O
SARS	B-DISO
-	O
CoV	O
(	O
Tor2	O
strain	O
)	O
S1	O
domain	O
and	O
then	O
boosted	O
with	O
purified	O
S1	O
protein	O
;	O
the	O
SARS	B-DISO
-	O
CoV	O
specific	O
IgG	O
antibody	O
was	O
tested	O
by	O
ELISA	O
and	O
neutralization	O
antibody	O
was	O
determined	O
by	O
in	O
vitro	O
microneutralization	O
assay	O
.	O

S1	O
domain	O
of	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
,	O
which	O
is	O
responsible	O
for	O
receptor	O
binding	O
,	O
can	O
efficiently	O
and	O
sufficiently	O
induce	O
highly	O
potent	O
neutralizing	O
antibody	O
in	O
mice	O
.	O

This	O
result	O
suggested	O
that	O
S1	O
domain	O
could	O
be	O
an	O
effective	O
subunit	O
vaccines	O
against	O
SARS	B-DISO
-	O
CoV	O
.	O
RESULTS	O
:	O
S1	O
domain	O
of	O
SARS	B-DISO
-	O
CoV	O
spike	O
,	O
which	O
has	O
been	O
demonstrated	O
harboring	O
the	O
receptor	O
binding	O
domain	O
,	O
successfully	O
elicited	O
SARS	B-DISO
-	O
CoV	O
specific	O
IgG	O
antibody	O
in	O
mouse	O
after	O
combined	O
immunization	O
with	O
DNA	O
and	O
purified	O
S1	O
protein	O
;	O
the	O
antibody	O
elicited	O
solely	O
by	O
S1	O
could	O
potently	O
neutralize	O
SARS	B-DISO
-	O
CoV	O
(	O
HKU	O
-	O
39849	O
)	O
in	O
vitro	O
,	O
50	O
%	O
of	O
1	O
000	O
TCID50	O
SARS	B-DISO
-	O
CoV	O
challenged	O
cells	O
were	O
protected	O
from	O
viral	B-DISO
infection	I-DISO
by	O
a	O
1	O
:	O
1499	O
.	O
68	O
dilution	O
of	O
mice	O
sera	O
immunized	O
with	O
S1	O
protein	O
,	O
but	O
negative	O
control	O
sera	O
showed	O
no	O
protection	O
.	O

This	O
result	O
suggested	O
that	O
S1	O
domain	O
could	O
be	O
an	O
effective	O
subunit	O
vaccines	O
against	O
SARS	B-DISO
-	O
CoV	O
.	O

TITLE	O
:	O
[	O
Analysis	O
on	O
factors	O
related	O
to	O
X	O
-	O
ray	O
outcomes	O
in	O
93	O
SARS	B-DISO
patients	O
].	O

TITLE	O
:	O
[	O
Application	O
of	O
fluorescent	O
real	O
-	O
time	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
in	O
detecting	O
influenza	B-DISO
viruses	O
].	O

ABSTRACT	O
:	O
To	O
construct	O
a	O
recombinant	O
plasmid	O
Pet23a	O
-	O
M	O
,	O
the	O
gene	O
encoding	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
membrane	O
protein	O
was	O
amplified	O
by	O
RT	O
-	O
PCR	O
and	O
cloned	O
into	O
the	O
expression	O
plasmid	O
Pet23a	O
.	O

ABSTRACT	O
:	O
Noninvasive	O
ventilation	O
(	O
NIV	O
)	O
combined	O
with	O
heliox	O
therapy	O
(	O
Hx	O
)	O
constitutes	O
a	O
therapeutic	O
option	O
in	O
the	O
management	O
of	O
adult	O
patients	O
with	O
acute	O
exacerbations	O
of	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
The	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
7a	O
of	O
the	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
)	O
encodes	O
a	O
unique	O
type	O
I	O
transmembrane	O
protein	O
of	O
unknown	O
function	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
provide	O
a	O
structural	O
and	O
cellular	O
framework	O
in	O
which	O
to	O
explore	O
the	O
role	O
of	O
orf7a	O
in	O
SARS	B-DISO
-	O
CoV	O
pathogenesis	B-DISO
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
pharmacophore	O
model	O
for	O
the	O
main	O
proteinase	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

Among	O
them	O
are	O
six	O
compounds	O
that	O
already	O
exhibited	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
activity	O
experimentally	O
.	O

TITLE	O
:	O
Evasion	O
of	O
antibody	O
neutralization	O
in	O
emerging	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronaviruses	O
.	O

Furthermore	O
,	O
of	O
16	O
sera	O
collected	O
from	O
four	O
patients	O
during	O
the	O
SARS	B-DISO
recurrence	B-DISO
in	O
Guangzhou	O
,	O
5	O
sera	O
collected	O
from	O
7	O
to	O
9	O
days	O
after	O
the	O
onset	O
of	O
symptoms	O
were	O
positive	O
for	O
the	O
N	O
protein	O
.	O

In	O
conclusion	O
,	O
an	O
antigen	O
capture	O
ELISA	O
reveals	O
a	O
high	O
N	O
protein	O
detection	O
rate	O
in	O
acute	O
-	O
phase	O
sera	O
of	O
patients	O
with	O
SARS	B-DISO
,	O
which	O
makes	O
it	O
useful	O
for	O
early	O
diagnosis	O
of	O
SARS	B-DISO
.	O

CONCLUSIONS	O
:	O
Proper	O
disposal	O
of	O
patient	O
excreta	O
is	O
important	O
to	O
prevent	O
the	O
spread	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
High	O
-	O
dose	O
hydrocortisone	O
reduces	O
expression	O
of	O
the	O
pro	O
-	O
inflammatory	O
chemokines	O
CXCL8	O
and	O
CXCL10	O
in	O
SARS	B-DISO
coronavirus	O
-	O
infected	O
intestinal	O
cells	O
.	O

Ribavirin	O
that	O
does	O
not	O
inhibit	O
SARS	B-DISO
-	O
CoV	O
replication	O
in	O
Vero	O
cells	O
inhibited	O
SARS	B-DISO
-	O
CoV	O
replication	O
in	O
Caco2	O
cells	O
at	O
therapeutical	O
concentrations	O
.	O

The	O
virus	O
has	O
been	O
also	O
detected	O
in	O
immunocompromised	O
adults	O
with	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
.	O

A	O
total	O
of	O
118	O
nasopharyngeal	O
swab	O
samples	O
from	O
118	O
hospitalized	O
young	O
children	O
aged	O
less	O
than	O
2	O
years	O
with	O
bronchiolitis	B-DISO
who	O
were	O
not	O
infected	O
with	O
human	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	B-DISO
A	O
or	O
B	O
,	O
or	O
human	O
metaneumovirus	O
were	O
selected	O
.	O

ABSTRACT	O
:	O
One	O
year	O
after	O
the	O
first	O
outbreak	O
infections	B-DISO
with	O
SARS	B-DISO
associated	O
coronavirus	O
were	O
again	O
reported	O
and	O
the	O
clinical	O
picture	O
varied	O
.	O

TITLE	O
:	O
Identification	O
of	O
two	O
neutralizing	O
regions	O
on	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
spike	O
glycoprotein	O
produced	O
from	O
the	O
mammalian	O
expression	O
system	O
.	O

TITLE	O
:	O
Nitric	O
oxide	O
inhibits	O
the	O
replication	O
cycle	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

ABSTRACT	O
:	O
Nitric	O
oxide	O
(	O
NO	O
)	O
is	O
an	O
important	O
signaling	O
molecule	O
between	O
cells	O
which	O
has	O
been	O
shown	O
to	O
have	O
an	O
inhibitory	O
effect	O
on	O
some	O
virus	O
infections	B-DISO
.	O

We	O
found	O
that	O
an	O
organic	O
NO	O
donor	O
,	O
S	O
-	O
nitroso	O
-	O
N	O
-	O
acetylpenicillamine	O
,	O
significantly	O
inhibited	O
the	O
replication	O
cycle	O
of	O
SARS	B-DISO
CoV	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
NO	O
generated	O
by	O
inducible	O
nitric	O
oxide	O
synthase	O
,	O
an	O
enzyme	O
that	O
produces	O
NO	O
,	O
inhibits	O
the	O
SARS	B-DISO
CoV	O
replication	O
cycle	O
.	O

The	O
levels	O
of	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
IgG	O
antibody	O
were	O
measured	O
by	O
ELISA	O
.	O

TITLE	O
:	O
[	O
A	O
case	O
of	O
Legionella	B-DISO
pneumonia	I-DISO
complicated	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
treated	O
with	O
methylprednisolone	O
and	O
sivelestat	O
sodium	O
in	O
combination	O
with	O
intravenous	O
erythromycin	O
and	O
ciprofloxacin	O
].	O

ABSTRACT	O
:	O
A	O
64	O
-	O
year	O
-	O
old	O
man	O
was	O
referred	O
to	O
us	O
because	O
of	O
pneumonia	B-DISO
refractory	O
to	O
panipenem	O
/	O
betamipron	O
.	O

His	O
chest	O
radiography	O
showed	O
patchy	O
consolidations	O
in	O
the	O
lower	O
lobe	O
of	O
the	O
right	O
lung	O
and	O
in	O
the	O
middle	O
field	O
of	O
the	O
left	O
lung	O
,	O
and	O
severe	O
hypoxia	B-DISO
was	O
present	O
.	O

Dental	O
personnel	O
are	O
urged	O
to	O
make	O
the	O
control	O
of	O
aerosols	O
a	O
standard	O
part	O
of	O
their	O
infection	B-DISO
control	O
procedures	O
.	O

There	O
is	O
currently	O
an	O
urgent	O
need	O
to	O
identify	O
effective	O
antiviral	O
agents	O
that	O
will	O
prevent	O
and	O
treat	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
infection	B-DISO
.	O

The	O
data	O
,	O
however	O
,	O
suggest	O
that	O
the	O
antiviral	O
activity	O
of	O
IFN	O
against	O
SARS	B-DISO
-	O
CoV	O
virus	O
is	O
independent	O
of	O
MxA	O
expression	O
.	O

We	O
demonstrate	O
that	O
siRNAs	O
directed	O
against	O
Spike	O
sequences	O
and	O
the	O
3	O
'-	O
UTR	O
can	O
inhibit	O
the	O
replication	O
of	O
SARS	B-DISO
-	O
CoV	O
in	O
Vero	O
-	O
E6	O
cells	O
,	O
and	O
holds	O
out	O
promise	O
for	O
the	O
development	O
of	O
an	O
effective	O
antiviral	O
agent	O
against	O
SARS	B-DISO
-	O
CoV	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
burden	O
of	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)-	O
associated	O
lower	O
respiratory	B-DISO
infections	I-DISO
(	O
LRI	O
)	O
in	O
children	O
in	O
four	O
developing	O
countries	O
.	O

We	O
performed	O
seven	O
SARS	B-DISO
autopsies	O
in	O
which	O
samples	O
of	O
alimentary	O
tract	O
and	O
digestive	O
glands	O
were	O
examined	O
with	O
routine	O
pathology	B-DISO
,	O
electron	O
microscopy	O
(	O
EM	O
),	O
in	O
situ	O
hybridization	O
(	O
ISH	B-DISO
),	O
immunohistochemistry	O
,	O
and	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
).	O

SARS	B-DISO
-	O
coronavirus	O
(	O
CoV	O
)-	O
like	O
particles	O
were	O
found	O
in	O
the	O
mucosal	O
epithelial	O
cells	O
under	O
EM	O
and	O
mild	O
focal	O
inflammation	B-DISO
was	O
detected	O
in	O
the	O
alimentary	O
tract	O
.	O

Fatty	B-DISO
degeneration	I-DISO
and	O
central	O
lobular	O
necrosis	O
were	O
observed	O
in	O
the	O
liver	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
emerged	O
in	O
later	O
February	O
2003	O
,	O
as	O
a	O
new	O
epidemic	O
form	O
of	O
life	O
-	O
threatening	O
infection	B-DISO
caused	O
by	O
a	O
novel	O
coronavirus	O
.	O

ABSTRACT	O
:	O
The	O
etiological	O
agents	O
responsible	O
for	O
a	O
substantial	O
proportion	O
of	O
respiratory	B-DISO
tract	I-DISO
diseases	I-DISO
have	O
not	O
been	O
identified	O
.	O

Thereafter	O
,	O
we	O
designed	O
specific	O
probes	O
to	O
screen	O
respiratory	O
specimens	O
from	O
children	O
<	O
5	O
years	O
old	O
for	O
this	O
novel	O
HCoV	O
.	O
Clinical	O
features	O
associated	O
with	O
HCoV	O
-	O
NH	O
infection	B-DISO
were	O
identified	O
.	O

We	O
identified	O
evidence	O
of	O
a	O
novel	O
human	O
coronavirus	O
,	O
designated	O
""""	O
New	O
Haven	O
coronavirus	O
""""	O
(	O
HCoV	O
-	O
NH	O
),	O
in	O
respiratory	O
secretions	O
from	O
a	O
6	O
-	O
month	O
-	O
old	O
infant	O
with	O
classic	O
Kawasaki	B-DISO
disease	I-DISO
.	O

To	O
further	O
investigate	O
the	O
possible	O
association	O
between	O
HCoV	O
-	O
NH	O
infection	B-DISO
and	O
Kawasaki	B-DISO
disease	I-DISO
,	O
we	O
conducted	O
a	O
case	O
-	O
control	O
study	O
.	O

Specimens	O
of	O
respiratory	O
secretions	O
from	O
8	O
(	O
72	O
.	O
7	O
%)	O
of	O
11	O
children	O
with	O
Kawasaki	B-DISO
disease	I-DISO
and	O
from	O
1	O
(	O
4	O
.	O
5	O
%)	O
of	O
22	O
control	O
subjects	O
(	O
children	O
without	O
Kawasaki	B-DISO
disease	I-DISO
matched	O
by	O
age	O
and	O
the	O
time	O
the	O
specimens	O
were	O
obtained	O
)	O
tested	O
positive	O
for	O
HCoV	O
-	O
NH	O
by	O
reverse	O
-	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
Mantel	O
-	O
Haenszel	O
matched	O
odds	O
ratio	O
,	O
16	O
.	O
0	O
[	O
95	O
%	O
confidence	O
interval	O
,	O
3	O
.	O
4	O
-	O
74	O
.	O
4	O
];	O
P	O
=.	O
0015	O
).	O

These	O
data	O
suggest	O
that	O
HCoV	O
-	O
NH	O
infection	B-DISO
is	O
associated	O
with	O
Kawasaki	B-DISO
disease	I-DISO
.	O

TITLE	O
:	O
Human	O
coronavirus	O
NL63	O
infection	B-DISO
in	O
Canada	O
.	O

Two	O
neutralizing	O
epitopes	O
were	O
defined	O
for	O
MAbs	O
to	O
SARS	B-DISO
-	O
CoV	O
S	O
glycoprotein	O
.	O

ABSTRACT	O
:	O
This	O
paper	O
describes	O
the	O
reflective	O
practice	O
of	O
a	O
nurse	O
manager	O
in	O
Hong	O
Kong	O
in	O
supporting	O
frontline	O
nurses	O
to	O
overcome	O
the	O
crisis	O
of	O
SARS	B-DISO
.	O

Moreover	O
,	O
IP	O
-	O
10	O
was	O
highly	O
expressed	O
in	O
both	O
lung	O
and	O
lymphoid	O
tissues	O
,	O
where	O
monocyte	O
-	O
macrophage	O
infiltration	B-DISO
and	O
depletion	O
of	O
lymphocytes	O
were	O
observed	O
.	O

Based	O
on	O
the	O
fluorescence	O
resonance	O
energy	O
transfer	O
(	O
FRET	O
)	O
principle	O
using	O
5	O
-[(	O
2	O
'-	O
aminoethyl	O
)-	O
amino	O
]	O
naphthelenesulfonic	O
acid	O
(	O
EDANS	O
)	O
and	O
4	O
-[[	O
4	O
-(	O
dimethylamino	O
)	O
phenyl	O
]	O
azo	O
]	O
benzoic	O
acid	O
(	O
Dabcyl	O
)	O
as	O
the	O
energy	O
transfer	O
pair	O
,	O
one	O
fluorogenic	O
substrate	O
was	O
designed	O
for	O
the	O
evaluation	O
of	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
proteolytic	O
activity	O
.	O

TITLE	O
:	O
Assisted	O
breathing	O
is	O
better	O
in	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

In	O
addition	O
,	O
by	O
increasing	O
end	O
-	O
expiratory	O
lung	O
volume	O
,	O
as	O
will	O
occur	O
when	O
airway	O
pressure	O
release	O
ventilation	O
is	O
used	O
,	O
recruitment	B-DISO
of	O
collapsed	O
or	O
consolidated	O
lung	O
is	O
likely	O
to	O
occur	O
,	O
especially	O
in	O
juxtadiaphragmatic	O
lung	O
regions	O
.	O

The	O
rate	O
of	O
myocardial	B-DISO
infarction	I-DISO
seems	O
to	O
be	O
no	O
higher	O
when	O
patients	O
with	O
cardiogenic	B-DISO
pulmonary	I-DISO
edema	I-DISO
are	O
treated	O
with	O
noninvasive	O
ventilation	O
rather	O
than	O
continuous	O
positive	O
airway	O
pressure	O
,	O
although	O
caution	O
is	O
still	O
advised	O
in	O
patients	O
with	O
acute	B-DISO
coronary	I-DISO
syndromes	I-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
emerged	O
from	O
China	O
as	O
an	O
untreatable	O
and	O
rapidly	O
spreading	O
respiratory	O
illness	O
of	O
unknown	O
etiology	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
new	O
infectious	B-DISO
disease	I-DISO
caused	O
by	O
a	O
novel	O
coronavirus	O
that	O
leads	O
to	O
deleterious	O
pulmonary	O
pathological	O
features	O
.	O

The	O
rescued	O
recombinant	O
virus	O
,	O
expressing	O
EGFP	O
(	O
GIBV	O
),	O
replicated	O
to	O
lower	O
viral	O
titers	O
and	O
formed	O
smaller	O
plaques	B-DISO
compared	O
to	O
the	O
parental	O
virus	O
and	O
the	O
MIBV	O
.	O

After	O
six	O
passages	O
of	O
GIBV	O
,	O
a	O
minority	O
of	O
plaques	B-DISO
were	O
observed	O
that	O
had	O
reverted	O
to	O
the	O
larger	O
plaque	B-DISO
size	O
and	O
virus	O
from	O
these	O
plaques	B-DISO
no	O
longer	O
expressed	O
EGFP	O
.	O

The	O
assay	O
is	O
evaluated	O
as	O
a	O
diagnostic	O
test	O
for	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
).	O

The	O
initial	O
study	O
consisted	O
of	O
Yorkshire	O
swine	O
[	O
group	O
1	O
,	O
fecal	O
clot	B-DISO
(	O
FC	O
),	O
n	O
=	O
4	O
]	O
that	O
were	O
followed	O
clinically	O
after	O
intraperitoneal	O
placement	O
of	O
a	O
fecal	O
(	O
0	O
.	O
5	O
mL	O
/	O
kg	O
)	O
blood	O
(	O
2	O
mL	O
/	O
kg	O
)	O
clot	B-DISO
.	O

A	O
second	O
group	O
of	O
Yorkshire	O
swine	O
[	O
group	O
2	O
,	O
superior	O
mesenteric	O
artery	O
(	O
SMA	B-DISO
)	O
+	O
FC	O
,	O
n	O
=	O
4	O
]	O
underwent	O
SMA	B-DISO
occlusion	B-DISO
for	O
30	O
min	O
(	O
I	O
/	O
R	O
)	O
followed	O
by	O
intraperitoneal	O
placement	O
of	O
a	O
FC	O
as	O
in	O
the	O
initial	O
group	O
.	O

Forty	O
compounds	O
were	O
purchased	O
and	O
tested	O
by	O
HPLC	O
and	O
colorimetric	O
assay	O
against	O
SARS	B-DISO
3C	O
-	O
like	O
proteinase	O
.	O

Presumptive	O
treatment	O
for	O
leptospirosis	B-DISO
should	O
be	O
initiated	O
immediately	O
in	O
the	O
appropriate	O
epidemiological	O
and	O
clinical	O
context	O
.	O

TITLE	O
:	O
Structure	O
-	O
based	O
preliminary	O
analysis	O
of	O
immunity	O
and	O
virulence	O
of	O
SARS	B-DISO
coronavirus	O
.	O

Data	O
suggest	O
that	O
the	O
proteins	O
of	O
SARS	B-DISO
-	O
CoV	O
with	O
toxic	O
motifs	O
might	O
play	O
crucial	O
roles	O
in	O
targeting	O
host	O
cells	O
and	O
interfering	O
with	O
the	O
immune	O
system	O
.	O

This	O
study	O
provides	O
new	O
information	O
for	O
drug	O
and	O
vaccine	O
design	O
,	O
as	O
well	O
as	O
therapeutic	O
strategies	O
against	O
SARS	B-DISO
.	O

(	O
2	O
)	O
The	O
evidence	O
for	O
immune	O
implication	O
in	O
distress	O
strongly	O
supports	O
immunomodulators	O
for	O
therapy	O
:	O
phosphodiesterase	O
inhibitors	O
(	O
due	O
to	O
their	O
down	O
-	O
modulating	O
activity	O
on	O
proinflammatory	O
cytokines	O
);	O
inhaled	O
corticoids	O
(	O
aimed	O
at	O
producing	O
a	O
local	O
immunomodulation	O
);	O
teophylline	O
or	O
nedocromil	O
sodium	O
(	O
which	O
prevents	O
inflammatory	O
cell	O
recruitment	B-DISO
into	O
the	O
airway	O
wall	O
).	O

Eventually	O
,	O
33	O
SARS	B-DISO
patients	O
(	O
91	O
.	O
7	O
%)	O
with	O
acute	B-DISO
renal	I-DISO
impairment	I-DISO
died	O
.	O

CONCLUSIONS	O
:	O
Acute	B-DISO
renal	I-DISO
impairment	I-DISO
is	O
uncommon	O
in	O
SARS	B-DISO
but	O
carries	O
a	O
high	O
mortality	O
.	O

CONCLUSIONS	O
:	O
Chinese	O
herbal	O
medicine	O
combined	O
with	O
conventional	O
medicine	O
may	O
have	O
beneficial	O
effects	O
in	O
patients	O
with	O
SARS	B-DISO
.	O

She	O
was	O
transferred	O
to	O
the	O
intensive	O
care	O
unit	O
with	O
a	O
diagnosis	O
of	O
respiratory	B-DISO
failure	I-DISO
,	O
probably	O
due	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
and	O
was	O
intubated	O
and	O
ventilated	O
.	O

On	O
the	O
24th	O
day	O
her	O
Glascow	O
Coma	B-DISO
Score	O
was	O
2	O
(	O
1	O
+	O
1	O
+	O
E	O
)	O
and	O
severe	O
hypotension	O
developed	O
.	O

TITLE	O
:	O
Pathogenesis	B-DISO
of	O
enterotropic	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
in	O
immunocompetent	O
and	O
immunodeficient	B-DISO
mice	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
SARS	B-DISO
-	O
CoV	O
escapes	O
IFN	O
-	O
mediated	O
growth	O
inhibition	O
by	O
preventing	O
the	O
induction	O
of	O
IFN	O
-	O
beta	O
.	O

Transcription	O
-	O
regulating	O
sequences	O
(	O
TRSs	O
)	O
precede	O
each	O
gene	O
and	O
include	O
a	O
conserved	O
core	O
sequence	O
(	O
CS	O
)	O
surrounded	O
by	O
relatively	O
variable	O
sequences	O
(	O
5	O
'	O
TRS	B-DISO
and	O
3	O
'	O
TRS	B-DISO
).	O

The	O
presence	O
of	O
a	O
canonical	O
CS	O
was	O
not	O
sufficient	O
to	O
drive	O
transcription	O
,	O
but	O
subgenomic	O
synthesis	O
requires	O
a	O
minimum	O
base	O
pairing	O
between	O
the	O
leader	O
TRS	B-DISO
(	O
TRS	B-DISO
-	O
L	O
)	O
and	O
the	O
complement	O
of	O
the	O
body	O
TRS	B-DISO
(	O
cTRS	O
-	O
B	O
)	O
provided	O
by	O
the	O
CS	O
and	O
its	O
adjacent	O
nucleotides	O
.	O

A	O
good	O
correlation	O
was	O
observed	O
between	O
the	O
free	O
energy	O
of	O
TRS	B-DISO
-	O
L	O
and	O
cTRS	O
-	O
B	O
duplex	O
formation	O
and	O
the	O
levels	O
of	O
subgenomic	O
mRNA	O
S2	O
,	O
demonstrating	O
that	O
base	O
pairing	O
between	O
the	O
leader	O
and	O
body	O
beyond	O
the	O
CS	O
is	O
a	O
determinant	O
regulation	O
factor	O
in	O
coronavirus	O
transcription	O
.	O

TITLE	O
:	O
Haematological	O
parameters	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

White	O
cell	O
(	O
WCC	O
),	O
absolute	O
neutrophil	O
,	O
absolute	O
lymphocyte	O
(	O
ALC	O
)	O
and	O
platelet	O
counts	O
followed	O
a	O
v	O
-	O
shaped	O
trend	O
with	O
the	O
nadir	O
at	O
day	O
6	O
or	O
7	O
after	O
symptom	B-DISO
onset	O
except	O
for	O
ALC	O
in	O
the	O
ICU	O
group	O
that	O
had	O
not	O
reached	O
the	O
nadir	O
by	O
day	O
12	O
.	O

Further	O
research	O
showed	O
that	O
HAb18G	O
/	O
CD147	O
,	O
a	O
transmembrane	O
molecule	O
,	O
was	O
highly	O
expressed	O
on	O
293	O
cells	O
and	O
that	O
CyPA	O
was	O
integrated	O
with	O
SARS	B-DISO
-	O
CoV	O
.	O
HAb18G	O
/	O
CD147	O
-	O
antagonistic	O
peptide	O
(	O
AP	O
)-	O
9	O
,	O
an	O
AP	O
of	O
HAb18G	O
/	O
CD147	O
,	O
had	O
a	O
high	O
rate	O
of	O
binding	O
to	O
293	O
cells	O
and	O
an	O
inhibitory	O
effect	O
on	O
SARS	B-DISO
-	O
CoV	O
.	O
These	O
results	O
show	O
that	O
HAb18G	O
/	O
CD147	O
,	O
mediated	O
by	O
CyPA	O
bound	O
to	O
SARS	B-DISO
-	O
CoV	O
N	O
protein	O
,	O
plays	O
a	O
functional	O
role	O
in	O
facilitating	O
invasion	B-DISO
of	O
host	O
cells	O
by	O
SARS	B-DISO
-	O
CoV	O
.	O
Our	O
findings	O
provide	O
some	O
evidence	O
for	O
the	O
cytologic	O
mechanism	O
of	O
invasion	B-DISO
by	O
SARS	B-DISO
-	O
CoV	O
and	O
provide	O
a	O
molecular	O
basis	O
for	O
screening	O
anti	O
-	O
SARS	B-DISO
drugs	O
.	O

The	O
inactivated	O
viral	O
vaccine	O
induced	O
milder	O
granulomatous	B-DISO
myositis	I-DISO
with	O
intralesional	O
lipid	O
and	O
scant	O
fibrosis	B-DISO
.	O

TITLE	O
:	O
Global	O
Initiative	O
for	O
Chronic	B-DISO
Obstructive	I-DISO
Lung	I-DISO
Disease	I-DISO
strategy	O
for	O
the	O
diagnosis	O
,	O
management	O
and	O
prevention	O
of	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
:	O
an	O
Asia	O
-	O
Pacific	O
perspective	O
.	O

The	O
Asia	O
-	O
Pacific	O
COPD	B-DISO
Roundtable	O
Group	O
,	O
a	O
taskforce	O
of	O
expert	O
respirologists	O
from	O
the	O
Asia	O
-	O
Pacific	O
region	O
,	O
has	O
recently	O
formulated	O
a	O
consensus	O
statement	O
on	O
implementation	O
of	O
the	O
GOLD	O
strategy	O
for	O
COPD	B-DISO
in	O
the	O
Asia	O
-	O
Pacific	O
region	O
.	O

The	O
key	O
issues	O
identified	O
by	O
the	O
COPD	B-DISO
Roundtable	O
Group	O
for	O
comment	O
are	O
:	O
(	O
i	O
)	O
where	O
there	O
is	O
no	O
access	O
to	O
spirometry	O
,	O
diagnosis	O
of	O
COPD	B-DISO
could	O
be	O
suspected	O
on	O
the	O
basis	O
of	O
history	O
,	O
symptoms	O
and	O
physical	O
signs	O
;	O
(	O
ii	O
)	O
inhaled	O
bronchodilators	O
are	O
the	O
preferred	O
regular	O
treatment	O
for	O
COPD	B-DISO
in	O
the	O
region	O
,	O
but	O
oral	O
bronchodilators	O
may	O
be	O
considered	O
if	O
the	O
cost	O
of	O
inhaled	O
bronchodilators	O
is	O
a	O
barrier	O
to	O
treatment	O
;	O
(	O
iii	O
)	O
the	O
use	O
of	O
a	O
Metered	O
Dose	O
Inhaler	O
with	O
spacer	O
in	O
place	O
of	O
a	O
nebulizer	O
is	O
recommended	O
in	O
the	O
treatment	O
of	O
acute	O
airflow	O
obstruction	B-DISO
in	O
patients	O
with	O
COPD	B-DISO
;	O
(	O
iv	O
)	O
influenza	B-DISO
vaccination	O
is	O
recommended	O
for	O
all	O
patients	O
with	O
COPD	B-DISO
in	O
communities	O
where	O
there	O
is	O
a	O
high	O
likelihood	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
;	O
and	O
(	O
v	O
)	O
simplified	O
pulmonary	O
rehabilitation	O
programmes	O
should	O
be	O
established	O
in	O
areas	O
where	O
comprehensive	O
programmes	O
are	O
unavailable	O
.	O

TITLE	O
:	O
The	O
changing	O
face	B-DISO
of	O
healthcare	O
worker	O
perceptions	O
on	O
powered	O
air	O
-	O
purifying	O
respirators	O
during	O
the	O
SARS	B-DISO
outbreak	O
.	O

A	O
questionnaire	O
-	O
based	O
survey	O
was	O
conducted	O
of	O
HCWs	O
who	O
had	O
used	O
the	O
PAPR	O
in	O
clinical	O
practice	O
during	O
the	O
SARS	B-DISO
outbreak	O
,	O
when	O
use	O
of	O
the	O
PAPR	O
was	O
mandatory	O
and	O
widespread	O
.	O

In	O
this	O
study	O
,	O
the	O
cleavage	O
mechanism	O
of	O
the	O
SARS	B-DISO
coronavirus	O
main	O
proteinase	O
(	O
Mpro	O
or	O
3CLpro	O
)	O
on	O
the	O
octapeptide	O
NH2	O
-	O
AVLQ	O
downward	O
arrowSGFR	O
-	O
COOH	O
was	O
investigated	O
using	O
molecular	O
mechanics	O
and	O
quantum	O
mechanics	O
simulations	O
based	O
on	O
the	O
experimental	O
structure	O
of	O
the	O
proteinase	O
.	O

It	O
has	O
been	O
found	O
that	O
the	O
chemical	O
bond	O
between	O
Gln	O
and	O
Ser	O
will	O
become	O
much	O
stronger	O
and	O
no	O
longer	O
cleavable	O
by	O
the	O
SARS	B-DISO
enzyme	O
after	O
either	O
changing	O
the	O
carbonyl	O
group	O
CO	O
of	O
Gln	O
to	O
CH2	O
or	O
CF2	O
or	O
changing	O
the	O
NH	O
of	O
Ser	O
to	O
CH2	O
or	O
CF2	O
.	O

The	O
octapeptide	O
thus	O
modified	O
might	O
become	O
an	O
effective	O
inhibitor	O
or	O
a	O
potential	O
drug	O
candidate	O
against	O
SARS	B-DISO
.	O

One	O
-	O
day	O
-	O
old	O
chicks	O
were	O
immunized	O
with	O
killed	O
or	O
high	O
[	O
10	O
(	O
5	O
)	O
50	O
%	O
embryo	O
infectious	B-DISO
dose	O
(	O
EID50	O
)]	O
or	O
low	O
(	O
10	O
(	O
3	O
)	O
EID50	O
)	O
doses	O
of	O
live	O
IBV	O
viruses	O
and	O
challenged	O
with	O
homologous	O
or	O
heterologous	O
IBV	O
strains	O
.	O

Of	O
course	O
,	O
children	O
younger	O
than	O
24	O
months	O
also	O
are	O
at	O
high	O
risk	O
for	O
complications	O
from	O
influenza	B-DISO
.	O

TITLE	O
:	O
Clinical	O
characteristics	O
of	O
chronic	B-DISO
lung	I-DISO
disease	I-DISO
without	O
preceding	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
in	O
preterm	O
infants	O
.	O

Of	O
the	O
117	O
infants	O
analyzed	O
,	O
CLD	B-DISO
developed	O
in	O
44	O
infants	O
(	O
38	O
%).	O

Among	O
these	O
44	O
infants	O
,	O
CLD	B-DISO
with	O
RDS	O
developed	O
in	O
27	O
infants	O
(	O
23	O
%)	O
and	O
CLD	B-DISO
without	O
RDS	O
developed	O
in	O
17	O
infants	O
(	O
15	O
%).	O

TITLE	O
:	O
Cross	O
-	O
host	O
evolution	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
in	O
palm	O
civet	O
and	O
human	O
.	O

Major	O
genetic	O
variations	O
in	O
some	O
critical	O
genes	O
,	O
particularly	O
the	O
Spike	O
gene	O
,	O
seemed	O
essential	O
for	O
the	O
transition	B-DISO
from	O
animal	O
-	O
to	O
-	O
human	O
transmission	O
to	O
human	O
-	O
to	O
-	O
human	O
transmission	O
,	O
which	O
eventually	O
caused	O
the	O
first	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreak	O
of	O
2002	O
/	O
2003	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
the	O
emergence	O
of	O
a	O
nephropathogenic	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
with	O
a	O
novel	O
genotype	O
in	O
India	O
.	O

Analysis	O
of	O
sequential	O
SARS	B-DISO
-	O
CoV	O
load	O
in	O
plasma	O
from	O
six	O
cases	O
revealed	O
different	O
patterns	O
of	O
viremia	B-DISO
,	O
with	O
the	O
peak	O
between	O
day	O
4	O
and	O
day	O
8	O
.	O

Urine	O
UA	O
and	O
creatinine	O
levels	O
were	O
available	O
for	O
43	O
patients	O
;	O
the	O
serum	O
cytokines	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
),	O
IL	O
-	O
8	O
,	O
and	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
were	O
measured	O
in	O
16	O
patients	O
.	O

Negative	O
appraisals	O
at	O
the	O
acute	O
phase	O
and	O
1	O
-	O
month	O
recovery	O
significantly	O
accounted	O
for	O
substantial	O
portions	O
of	O
variances	O
for	O
anxiety	O
and	O
depressive	B-DISO
symptoms	I-DISO
,	O
after	O
the	O
effects	O
of	O
other	O
psychosocial	O
variables	O
were	O
controlled	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
Hong	O
Kong	O
in	O
2003	O
:	O
stress	O
and	O
psychological	B-DISO
impact	O
among	O
frontline	O
healthcare	O
workers	O
.	O

About	O
57	O
%	O
were	O
found	O
to	O
have	O
experienced	O
psychological	B-DISO
distress	I-DISO
.	O

Although	O
many	O
parents	O
feared	O
transmitting	O
HIV	B-DISO
to	O
their	O
children	O
or	O
catching	B-DISO
an	O
infection	B-DISO
from	O
their	O
children	O
,	O
few	O
were	O
avoiding	O
the	O
most	O
routine	O
forms	O
of	O
physical	O
affection	O
.	O

Clinicians	O
may	O
be	O
able	O
to	O
provide	O
education	O
to	O
HIV	B-DISO
-	O
infected	O
parents	O
and	O
reassurance	O
about	O
HIV	B-DISO
transmission	O
and	O
the	O
safety	O
of	O
various	O
activities	O
.	O

RESULTS	O
:	O
Forty	O
-	O
two	O
percent	O
of	O
parents	O
feared	O
catching	B-DISO
an	O
infection	B-DISO
from	O
their	O
children	O
,	O
and	O
36	O
.	O
1	O
%	O
of	O
parents	O
feared	O
transmitting	O
HIV	B-DISO
to	O
their	O
children	O
.	O

An	O
IFA	O
based	O
on	O
Sf9	O
cells	O
producing	O
the	O
fusion	O
protein	O
was	O
standardized	O
with	O
23	O
serum	O
samples	O
from	O
patients	O
with	O
SARS	B-DISO
,	O
20	O
serum	O
samples	O
from	O
patients	O
with	O
autoimmune	B-DISO
diseases	I-DISO
,	O
and	O
43	O
serum	O
samples	O
from	O
healthy	O
blood	O
donors	O
.	O

We	O
present	O
a	O
patient	O
in	O
Thailand	O
who	O
was	O
infected	O
with	O
influenza	B-DISO
A	O
(	O
H5N1	B-DISO
)	O
virus	O
.	O

Prominent	O
features	O
included	O
the	O
progression	O
from	O
fever	O
and	O
dyspnea	B-DISO
to	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
a	O
short	O
period	O
,	O
lymphopenia	B-DISO
and	O
thrombocytopenia	O
.	O

In	O
one	O
pattern	O
,	O
actual	O
transmission	O
of	O
the	O
pathogen	O
to	O
humans	O
is	O
a	O
rare	O
event	O
but	O
,	O
once	O
it	O
has	O
occurred	O
,	O
human	O
-	O
to	O
-	O
human	O
transmission	O
maintains	O
the	O
infection	B-DISO
for	O
some	O
period	O
of	O
time	O
or	O
permanently	O
.	O

Some	O
examples	O
of	O
pathogens	O
with	O
this	O
pattern	O
of	O
transmission	O
are	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
/	O
acquired	B-DISO
immune	I-DISO
deficiency	I-DISO
syndrome	I-DISO
,	O
influenza	B-DISO
A	O
,	O
Ebola	O
virus	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

In	O
the	O
second	O
pattern	O
,	O
direct	O
or	O
vector	O
-	O
mediated	O
animal	O
-	O
to	O
-	O
human	O
transmission	O
is	O
the	O
usual	O
source	O
of	O
human	O
infection	B-DISO
.	O

Wild	O
animal	O
populations	O
are	O
the	O
principal	O
reservoirs	O
of	O
the	O
pathogen	O
and	O
human	O
-	O
to	O
-	O
human	O
disease	B-DISO
transmission	I-DISO
is	O
rare	O
.	O

This	O
review	O
focuses	O
on	O
the	O
comparative	O
pathogenesis	B-DISO
of	O
CoV	O
infections	B-DISO
,	O
including	O
the	O
factors	O
that	O
accentuate	O
CoV	O
respiratory	B-DISO
disease	I-DISO
,	O
with	O
emphasis	O
on	O
livestock	O
and	O
poultry	O
.	O

Measures	O
to	O
prevent	O
nosocomial	B-DISO
infection	I-DISO
included	O
establishing	O
isolation	O
wards	O
for	O
triage	O
,	O
SARS	B-DISO
patients	O
,	O
and	O
step	O
-	O
down	O
;	O
training	O
and	O
monitoring	O
hospital	O
staff	O
in	O
infection	B-DISO
-	O
control	O
procedures	O
;	O
active	O
and	O
passive	O
screening	O
of	O
HCWs	O
;	O
enforcement	O
of	O
droplet	O
and	O
contact	O
precautions	O
;	O
and	O
compliance	O
with	O
the	O
use	O
of	O
PPE	O
.	O

The	O
interaction	O
between	O
3a	O
and	O
S	O
,	O
which	O
are	O
expressed	O
from	O
separate	O
subgenomic	O
RNA	O
,	O
would	O
be	O
important	O
for	O
controlling	O
the	O
trafficking	O
properties	O
of	O
S	O
.	O
The	O
cell	O
surface	O
expression	O
of	O
S	O
in	O
infected	O
cells	O
significantly	O
impacts	O
viral	O
assembly	O
,	O
viral	O
spread	O
and	O
viral	B-DISO
pathogenesis	I-DISO
.	O

The	O
risk	O
of	O
osteonecrosis	B-DISO
was	O
0	O
.	O
6	O
%	O
for	O
patients	O
receiving	O
less	O
than	O
3	O
g	O
and	O
13	O
%	O
for	O
patients	O
receiving	O
more	O
than	O
3	O
g	O
prednisolone	O
-	O
equivalent	O
dose	O
.	O

RESULTS	O
:	O
One	O
hundred	O
thirty	O
-	O
four	O
(	O
53	O
%)	O
of	O
254	O
patients	O
had	O
recent	O
onset	O
of	O
large	O
joint	B-DISO
pain	I-DISO
,	O
but	O
211	O
(	O
80	O
%)	O
of	O
264	O
painful	B-DISO
joints	I-DISO
were	O
not	O
associated	O
with	O
abnormality	O
on	O
MR	O
images	O
.	O

SARS	B-DISO
has	O
an	O
extremely	O
low	O
prevalence	O
,	O
and	O
the	O
positive	O
predictive	O
value	O
of	O
screening	O
is	O
essentially	O
zero	O
.	O

As	O
a	O
reference	O
group	O
,	O
709	O
healthcare	O
workers	O
who	O
worked	O
in	O
2	O
hospitals	O
that	O
never	O
admitted	O
any	O
SARS	B-DISO
patients	O
were	O
similarly	O
tested	O
.	O

The	O
seroprevalence	O
rate	O
was	O
88	O
.	O
9	O
%	O
(	O
80	O
/	O
90	O
)	O
for	O
healthcare	O
workers	O
with	O
SARS	B-DISO
and	O
1	O
.	O
4	O
%	O
(	O
15	O
/	O
1	O
,	O
057	O
)	O
for	O
healthcare	O
workers	O
who	O
were	O
apparently	O
healthy	O
.	O

HEICS	O
provides	O
a	O
flexible	O
framework	O
that	O
seems	O
to	O
have	O
assisted	O
NCKUH	O
in	O
the	O
organization	O
of	O
its	O
emergency	B-DISO
response	O
to	O
the	O
SARS	B-DISO
outbreak	O
in	O
Taiwan	O
,	O
ROC	O
.	O

ABSTRACT	O
:	O
This	O
report	O
aims	O
to	O
describe	O
the	O
epidemiology	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
Taiwan	O
between	O
March	O
and	O
July	O
2003	O
,	O
and	O
to	O
examine	O
the	O
public	O
health	O
response	O
.	O

Surveillance	O
for	O
SARS	B-DISO
was	O
initiated	O
on	O
14	O
March	O
2003	O
.	O

At	O
the	O
time	O
of	O
the	O
mobile	O
team	O
assessments	O
,	O
46	O
(	O
53	O
%)	O
hospitals	O
had	O
implemented	O
WHO	O
infection	B-DISO
control	O
recommendations	O
.	O

The	O
signs	B-DISO
and	I-DISO
symptoms	I-DISO
are	O
often	O
attributed	O
to	O
other	O
clinical	O
aspects	O
of	O
a	O
patient	O
'	O
s	O
condition	B-DISO
,	O
and	O
therefore	O
,	O
TRALI	B-DISO
may	O
go	O
unrecognised	O
.	O

CONCLUSIONS	O
:	O
Current	O
knowledge	O
based	O
on	O
case	O
studies	O
of	O
the	O
SARS	B-DISO
outbreak	O
in	O
the	O
four	O
cities	O
suggested	O
that	O
the	O
SARS	B-DISO
outbreaks	O
were	O
significantly	O
associated	O
with	O
the	O
temperature	O
and	O
its	O
variations	O
.	O

TITLE	O
:	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
infection	I-DISO
:	O
MR	O
imaging	O
findings	O
in	O
the	O
nervous	B-DISO
system	O
.	O

CONCLUSIONS	O
:	O
Histopathology	O
suggests	O
that	O
acid	O
aspiration	B-DISO
induced	O
acute	O
lung	O
injury	O
can	O
be	O
effectively	O
treated	O
by	O
lidocaine	O
and	O
methylprednisolone	O
,	O
if	O
applied	O
early	O
.	O

Thus	O
,	O
this	O
protein	O
microarray	O
can	O
be	O
alternatively	O
used	O
as	O
a	O
high	O
throughput	O
screening	O
method	O
for	O
rapid	O
detection	O
against	O
SARS	B-DISO
CoV	O
3CLpro	O
and	O
/	O
or	O
efficient	O
purification	O
of	O
other	O
Tagged	O
proteins	O
.	O

Thirty	O
-	O
two	O
acute	O
-	O
care	O
hospitals	O
were	O
required	O
to	O
report	O
their	O
previous	O
day	O
'	O
s	O
unscheduled	O
admissions	O
for	O
11	O
syndromes	B-DISO
(	O
pneumonia	B-DISO
,	O
hemoptysis	B-DISO
,	O
respiratory	B-DISO
distress	I-DISO
,	O
acute	O
neurologic	O
illness	O
,	O
nontraumatic	O
paralysis	O
,	O
sepsis	B-DISO
and	O
nontraumatic	O
shock	O
,	O
fever	B-DISO
with	I-DISO
rash	I-DISO
,	O
fever	O
of	O
unknown	O
cause	O
,	O
acute	O
gastrointestinal	O
illness	O
,	O
and	O
possible	O
cutaneous	B-DISO
anthrax	I-DISO
,	O
and	O
suspected	O
illness	O
clusters	O
).	O

A	O
method	O
for	O
determining	O
the	O
difference	O
between	O
random	O
and	O
systemic	O
variation	O
was	O
used	O
to	O
identify	O
differences	O
of	O
>/=	O
3	O
standard	O
deviations	O
for	O
each	O
syndrome	B-DISO
from	O
a	O
6	O
-	O
month	O
moving	O
average	O
.	O

Amides	O
of	O
GL	O
and	O
conjugates	O
of	O
GL	O
with	O
two	O
amino	O
acid	O
residues	O
and	O
a	O
free	O
30	O
-	O
COOH	O
function	O
presented	O
up	O
to	O
70	O
-	O
fold	O
increased	O
activity	O
against	O
SARS	B-DISO
-	O
CoV	O
but	O
also	O
increased	O
cytotoxicity	B-DISO
resulting	O
in	O
decreased	O
selectivity	O
index	O
.	O

Computed	O
tomographs	O
(	O
CTs	B-DISO
)	O
are	O
better	O
than	O
normal	O
chest	O
radiographs	O
in	O
the	O
detection	O
of	O
other	O
pulmonary	O
lesions	O
such	O
as	O
pulmonary	O
contusion	O
(	O
9	O
,	O
10	O
).	O

The	O
importance	O
of	O
CT	O
scans	O
in	O
patients	O
with	O
ARDS	B-DISO
has	O
been	O
reviewed	O
recently	O
(	O
9	O
),	O
but	O
unfortunately	O
there	O
has	O
been	O
no	O
experience	O
of	O
CT	O
in	O
patients	O
with	O
smoke	O
inhalation	O
injury	O
.	O

EDs	B-DISO
then	O
were	O
invited	O
to	O
report	O
visit	O
frequencies	O
with	O
various	O
SARS	B-DISO
syndrome	B-DISO
elements	O
to	O
local	O
public	O
health	O
authorities	O
by	O
using	O
the	O
REMI	O
Internet	O
application	O
(	O
first	O
in	O
one	O
metropolitan	O
area	O
,	O
and	O
later	O
in	O
four	O
).	O

A	O
total	O
of	O
27	O
EDs	B-DISO
reported	O
syndrome	B-DISO
frequencies	O
from	O
>	O
146	O
,	O
000	O
patient	O
encounters	O
.	O

Screening	O
to	O
detect	O
a	O
potential	O
SARS	B-DISO
infected	O
person	O
plays	O
an	O
important	O
role	O
in	O
preventing	O
the	O
spread	O
of	O
SARS	B-DISO
.	O

As	O
elevation	O
of	O
body	O
temperature	O
is	O
a	O
common	O
presenting	O
symptom	B-DISO
for	O
many	O
illnesses	O
including	O
infectious	B-DISO
diseases	I-DISO
,	O
thermal	O
imagers	O
are	O
useful	O
tools	O
for	O
mass	O
screening	O
of	O
body	O
temperature	O
not	O
only	O
for	O
SARS	B-DISO
but	O
also	O
during	O
other	O
public	O
health	O
crisis	O
where	O
widespread	O
transmission	O
of	O
infection	B-DISO
is	O
a	O
concern	O
.	O

The	O
following	O
article	O
reports	O
how	O
a	O
young	O
girl	O
suffering	B-DISO
from	O
pulmonary	B-DISO
tuberculosis	I-DISO
was	O
erroneously	O
diagnosed	O
as	O
SARS	B-DISO
in	O
an	O
outbreak	O
.	O

Histopathologically	O
,	O
thickening	O
of	O
the	O
alveolar	O
walls	O
and	O
lymphocytic	B-DISO
infiltration	I-DISO
around	O
the	O
bronchioles	O
were	O
observed	O
in	O
mice	O
and	O
rats	O
from	O
microbiologically	O
contaminated	O
facilities	O
.	O

Many	O
valuable	O
lessons	O
have	O
been	O
learned	O
through	O
the	O
SARS	B-DISO
epidemic	O
.	O

(	O
1	O
)	O
The	O
delay	O
in	O
diagnosis	O
of	O
this	O
SARS	B-DISO
case	O
was	O
largely	O
associated	O
with	O
unclear	O
epidemiologic	O
history	O
;	O
(	O
2	O
)	O
The	O
SARS	B-DISO
patient	O
showed	O
characteristics	O
of	O
typical	O
pneumonia	B-DISO
in	O
the	O
early	O
stage	O
.	O

It	O
is	O
very	O
important	O
for	O
physicians	O
to	O
be	O
alert	O
to	O
the	O
epidemiological	O
data	O
for	O
an	O
early	O
diagnosis	O
of	O
SARS	B-DISO
,	O
and	O
therefore	O
early	O
isolation	O
and	O
initiation	O
of	O
appropriate	O
treatment	O
.	O

TITLE	O
:	O
Increased	O
epitope	O
-	O
specific	O
CD8	O
+	O
T	O
cells	O
prevent	O
murine	O
coronavirus	O
spread	O
to	O
the	O
spinal	O
cord	B-DISO
and	O
subsequent	O
demyelination	B-DISO
.	O

TITLE	O
:	O
B	O
-	O
cell	O
responses	O
in	O
patients	O
who	O
have	O
recovered	O
from	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
target	O
a	O
dominant	O
site	O
in	O
the	O
S2	O
domain	O
of	O
the	O
surface	O
spike	O
glycoprotein	O
.	O

Examination	O
of	O
the	O
immune	O
responses	O
of	O
patients	O
who	O
have	O
recovered	O
from	O
SARS	B-DISO
should	O
provide	O
important	O
information	O
for	O
design	O
of	O
a	O
safe	O
and	O
effective	O
vaccine	O
.	O

We	O
determined	O
the	O
continuous	O
viral	O
epitopes	O
targeted	O
by	O
antibodies	O
in	O
plasma	O
samples	O
from	O
convalescent	O
SARS	B-DISO
patients	O
through	O
biopanning	O
with	O
a	O
vast	O
M13	O
phage	O
display	O
dodecapeptide	O
library	O
.	O

These	O
S2	O
-	O
targeting	O
antibodies	O
were	O
shown	O
to	O
effectively	O
neutralize	O
the	O
coronavirus	O
,	O
indicating	O
that	O
they	O
provided	O
protective	O
immunity	O
to	O
help	O
the	O
patients	O
recover	O
from	O
the	O
viral	B-DISO
infection	I-DISO
.	O

These	O
results	O
suggest	O
that	O
the	O
SARS	B-DISO
coronavirus	O
might	O
have	O
an	O
antigenic	O
profile	O
distinct	O
from	O
those	O
of	O
other	O
human	O
or	O
animal	O
coronaviruses	O
.	O

Due	O
to	O
the	O
tested	O
safety	O
and	O
protective	O
effects	O
of	O
the	O
convalescent	O
-	O
phase	O
serological	O
antibodies	O
,	O
identification	O
of	O
their	O
complementary	O
antigens	O
may	O
enable	O
the	O
design	O
of	O
an	O
epitope	O
-	O
based	O
vaccine	O
to	O
prevent	O
potential	O
antibody	O
-	O
mediated	O
immunopathology	B-DISO
.	O

Multistep	O
growth	O
kinetics	O
were	O
identical	O
in	O
Vero	O
E6	O
and	O
MA104	O
cells	O
,	O
with	O
maximum	O
titer	O
reached	O
24	O
h	O
postinoculation	O
(	O
hpi	B-DISO
).	O

Expression	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
receptor	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
resulted	O
in	O
SARS	B-DISO
-	O
CoV	O
replication	O
in	O
all	O
refractory	O
cell	O
lines	O
examined	O
.	O

ABSTRACT	O
:	O
Recently	O
,	O
several	O
previously	O
unrecognized	O
respiratory	O
viral	O
pathogens	O
have	O
been	O
identified	O
and	O
several	O
influenza	B-DISO
A	O
virus	O
subtypes	O
,	O
previously	O
known	O
to	O
infect	O
poultry	O
and	O
wild	O
birds	O
,	O
were	O
transmitted	B-DISO
to	O
humans	O
.	O

ABSTRACT	O
:	O
Epidemiological	O
investigations	O
of	O
infectious	B-DISO
disease	I-DISO
are	O
mainly	O
dependent	O
on	O
indirect	O
contact	O
information	O
and	O
only	O
occasionally	O
assisted	O
by	O
characterization	O
of	O
pathogen	O
sequence	O
variation	O
from	O
clinical	O
isolates	O
.	O

Analysis	O
of	O
13	O
SARS	B-DISO
-	O
CoV	O
isolates	O
from	O
the	O
different	O
stages	O
of	O
the	O
Singapore	O
outbreak	O
identified	O
nine	O
sequence	O
variations	O
that	O
could	O
define	O
the	O
molecular	O
relationship	O
between	O
them	O
and	O
pointed	O
to	O
a	O
new	O
,	O
previously	O
unidentified	O
,	O
primary	O
route	O
of	O
introduction	O
of	O
SARS	B-DISO
-	O
CoV	O
into	O
the	O
Singapore	O
population	O
.	O

The	O
study	O
has	O
implications	O
to	O
public	O
health	O
in	O
,	O
for	O
example	O
,	O
the	O
control	O
of	O
other	O
airborne	O
respiratory	O
infectious	B-DISO
diseases	I-DISO
such	O
as	O
influenza	B-DISO
,	O
and	O
in	O
bio	O
-	O
terror	O
safety	O
in	O
buildings	O
.	O

When	O
M	O
.	O
gallisepticum	O
could	O
no	O
longer	O
be	O
re	O
-	O
isolated	O
from	O
chickens	O
,	O
birds	O
were	O
stressed	O
by	O
inoculation	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
or	O
avian	O
pneumovirus	O
.	O

Then	O
,	O
the	O
binding	O
ability	O
of	O
SA59B	O
-	O
HRP	O
to	O
SARS	B-DISO
-	O
CoV	O
was	O
evaluated	O
by	O
ELISA	O
with	O
S	O
/	O
N	O
of	O
11	O
.	O
6	O
,	O
indicating	O
higher	O
binding	O
specificity	O
between	O
them	O
.	O

These	O
factors	O
included	O
perceived	O
threat	O
of	O
SARS	B-DISO
,	O
perceived	O
benefits	O
and	O
barriers	O
in	O
practicing	O
SARS	B-DISO
preventive	O
health	O
behaviors	O
,	O
cues	O
to	O
action	O
,	O
knowledge	O
of	O
SARS	B-DISO
,	O
and	O
self	O
-	O
efficacy	O
.	O

TITLE	O
:	O
Prone	O
position	O
reduces	O
lung	O
stress	O
and	O
strain	O
in	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Compared	O
with	O
SR	O
(	O
BAS	O
),	O
pronation	O
/	O
SR	O
(	O
PP	O
)	O
resulted	O
in	O
reduced	O
peak	O
/	O
plateau	O
P	O
(	O
L	O
)	O
at	O
V	O
(	O
T	O
)	O
s	O
>	O
or	O
=	O
0	O
.	O
6	O
L	O
;	O
static	O
lung	O
elastance	O
and	O
additional	O
lung	O
resistance	O
decreased	O
and	O
chest	O
wall	O
elastance	O
(	O
in	O
prone	O
position	O
)	O
increased	O
;	O
EELV	O
increased	O
(	O
23	O
-	O
33	O
%);	O
V	O
(	O
T	O
)/	O
EELV	O
decreased	O
(	O
27	O
-	O
33	O
%);	O
arterial	O
oxygen	O
tension	B-DISO
/	O
inspiratory	O
oxygen	O
fraction	O
and	O
arterial	O
carbon	O
dioxide	O
tension	B-DISO
improved	O
(	O
21	O
-	O
43	O
/	O
10	O
-	O
14	O
%,	O
respectively	O
),	O
and	O
shunt	O
fraction	O
/	O
physiological	O
dead	O
space	O
decreased	O
(	O
21	O
-	O
50	O
/	O
20	O
-	O
47	O
%,	O
respectively	O
).	O

Both	O
organizations	O
subsequently	O
conducted	O
quality	O
management	O
reviews	O
of	O
their	O
handling	O
of	O
these	O
emergency	B-DISO
situations	O
.	O

A	O
similar	O
report	O
was	O
published	O
in	O
the	O
Spring	O
2004	O
edition	O
of	O
Quality	O
Management	O
in	O
Health	O
Care	O
on	O
the	O
way	O
SARS	B-DISO
was	O
managed	O
at	O
the	O
BCCDC	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
surgical	O
patients	O
:	O
a	O
diagnostic	O
dilemma	O
.	O

This	O
study	O
was	O
conducted	O
to	O
demonstrate	O
whether	O
the	O
protein	O
X4	O
was	O
expressed	O
and	O
its	O
essential	O
function	O
in	O
the	O
process	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

Western	O
blot	O
was	O
employed	O
to	O
evaluate	O
the	O
expression	O
of	O
protein	O
X4	O
in	O
SARS	B-DISO
-	O
CoV	O
particles	O
.	O

The	O
results	O
provide	O
the	O
evidence	O
of	O
protein	O
X4	O
expression	O
following	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
,	O
and	O
may	O
facilitate	O
further	O
investigation	O
of	O
the	O
immunopathological	O
mechanism	O
of	O
SARS	B-DISO
.	O

Because	O
of	O
its	O
public	O
health	O
impact	O
,	O
major	O
efforts	O
are	O
focused	O
on	O
development	O
of	O
SARS	B-DISO
vaccines	O
.	O

The	O
clinical	O
manifestations	O
of	O
SARS	B-DISO
showed	O
high	O
variability	O
,	O
and	O
were	O
related	O
to	O
the	O
underlying	O
health	O
status	O
of	O
individual	O
patients	O
.	O

ABSTRACT	O
:	O
Catastrophic	O
antiphospholipid	B-DISO
syndrome	I-DISO
(	O
CAPS	O
)	O
is	O
a	O
severe	O
and	O
rare	O
variant	O
of	O
antiphospholipid	B-DISO
syndrome	I-DISO
(	O
APS	B-DISO
)	O
characterized	O
by	O
acute	O
multiorgan	B-DISO
failure	I-DISO
due	O
to	O
small	O
vessel	O
thrombi	B-DISO
in	O
patients	O
with	O
positive	O
antiphospholipid	O
antibodies	O
.	O

Doppler	O
ultrasonography	O
showed	O
evidence	O
of	O
arterial	B-DISO
ischemia	I-DISO
of	O
the	O
both	O
lower	O
extremities	O
.	O

The	O
mouse	O
disease	O
is	O
primarily	O
immune	O
-	O
mediated	O
because	O
demyelination	B-DISO
is	O
not	O
detected	O
in	O
JHM	O
-	O
infected	O
mice	O
lacking	O
T	O
or	O
B	O
cells	O
but	O
does	O
occur	O
after	O
transfer	O
of	O
JHM	O
-	O
specific	O
T	O
cells	O
.	O

Demyelination	B-DISO
was	O
reduced	O
by	O
85	O
to	O
90	O
%	O
in	O
infected	O
RAG1	O
(-/-)	O
mice	O
lacking	O
normal	O
expression	O
of	O
activating	O
Fc	O
receptors	O
(	O
FcRgamma	O
(-/-))	O
and	O
by	O
approximately	O
76	O
%	O
when	O
complement	O
was	O
depleted	O
by	O
treatment	O
with	O
cobra	O
venom	O
factor	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
caused	O
by	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
a	O
fatal	O
disease	O
.	O

Virus	O
was	O
isolated	O
followed	O
by	O
the	O
determination	O
of	O
its	O
genome	O
sequences	O
,	O
which	O
were	O
then	O
analyzed	O
by	O
comparing	O
with	O
other	O
46	O
SARS	B-DISO
-	O
CoV	O
genomes	O
.	O

TITLE	O
:	O
[	O
Amendment	O
to	O
the	O
infectious	B-DISO
disease	I-DISO
control	O
law	O
].	O

In	O
this	O
paper	O
,	O
we	O
determine	O
the	O
effect	O
of	O
a	O
number	O
of	O
different	O
interventions	O
on	O
the	O
effective	O
reproduction	O
number	O
and	O
estimate	O
requirements	O
to	O
achieve	O
elimination	O
of	O
the	O
infectious	B-DISO
disease	I-DISO
.	O

It	O
is	O
somewhat	O
unexpected	O
that	O
no	O
N	O
-	O
specific	O
mAbs	O
were	O
identified	O
albeit	O
anti	O
-	O
N	O
IgG	O
was	O
easily	O
identified	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
patients	O
.	O

TITLE	O
:	O
Detection	O
and	O
isolation	O
of	O
winter	B-DISO
dysentery	I-DISO
bovine	O
coronavirus	O
circulated	O
in	O
Korea	O
during	O
2002	O
-	O
2004	O
.	O

None	O
of	O
the	O
health	O
care	O
workers	O
who	O
used	O
the	O
supplement	O
subsequently	O
contracted	O
SARS	B-DISO
compared	O
to	O
0	O
.	O
4	O
%	O
of	O
the	O
health	O
care	O
workers	O
who	O
did	O
not	O
use	O
the	O
supplement	O
(	O
p	O
=	O
0	O
.	O
014	O
).	O

RESULTS	O
:	O
None	O
of	O
the	O
health	O
care	O
workers	O
who	O
used	O
the	O
supplement	O
subsequently	O
contracted	O
SARS	B-DISO
compared	O
to	O
0	O
.	O
4	O
%	O
of	O
the	O
health	O
care	O
workers	O
who	O
did	O
not	O
use	O
the	O
supplement	O
(	O
p	O
=	O
0	O
.	O
014	O
).	O

Patients	O
with	O
HELLP	B-DISO
syndrome	I-DISO
are	O
also	O
at	O
greater	O
risk	O
of	O
pulmonary	B-DISO
edema	I-DISO
,	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
abruptio	B-DISO
placentae	I-DISO
,	O
intracerebral	B-DISO
hemorrhage	I-DISO
,	O
eclamptic	O
convulsions	B-DISO
,	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
,	O
ruptured	O
liver	O
hematomas	B-DISO
and	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
.	O

The	O
anesthetic	O
technique	O
is	O
critical	O
for	O
these	O
patients	O
with	O
a	O
high	O
risk	O
of	O
uncontrollable	O
hypertension	B-DISO
,	O
bleeding	B-DISO
and	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
.	O

SARS	B-DISO
testing	O
with	O
existing	O
polymerase	O
chain	O
reaction	O
assays	O
would	O
have	O
harmful	O
public	O
health	O
and	O
economic	O
consequences	O
if	O
SARS	B-DISO
made	O
up	O
<	O
0	O
.	O
1	O
%	O
of	O
circulating	O
FRIs	O
.	O

ABSTRACT	O
:	O
During	O
the	O
2003	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
Taiwan	O
,	O
>	O
150	O
,	O
000	O
persons	O
were	O
quarantined	O
,	O
24	O
of	O
whom	O
were	O
later	O
found	O
to	O
have	O
laboratory	O
-	O
confirmed	O
SARS	B-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
infection	B-DISO
.	O

Thus	O
,	O
quarantine	O
for	O
SARS	B-DISO
in	O
Taiwan	O
screened	O
potentially	O
infective	O
persons	O
for	O
swift	O
diagnosis	O
and	O
hospitalization	O
after	O
onset	O
,	O
thereby	O
indirectly	O
reducing	O
infections	B-DISO
.	O

TITLE	O
:	O
The	O
substrate	O
specificity	O
of	O
SARS	B-DISO
coronavirus	O
3C	O
-	O
like	O
proteinase	O
.	O

ABSTRACT	O
:	O
Vero	O
E6	O
cells	O
are	O
commonly	O
used	O
for	O
in	O
vitro	O
studies	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
for	O
antiviral	O
evaluation	O
purposes	O
.	O

A	O
better	O
understanding	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
growth	O
kinetics	O
in	O
Vero	O
E6	O
cells	O
is	O
crucial	O
to	O
help	O
elucidate	O
the	O
mechanism	O
of	O
antiviral	O
activity	O
of	O
selective	O
antiviral	O
agents	O
.	O

HFOV	O
seems	O
to	O
be	O
safe	O
and	O
effective	O
for	O
adults	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
who	O
have	O
failed	O
conventional	O
ventilation	O
.	O

Published	O
studies	O
evaluating	O
the	O
use	O
of	O
iNO	O
,	O
PP	O
,	O
and	O
HFOV	O
in	O
adult	O
patients	O
with	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Sedation	B-DISO
,	O
analgesia	B-DISO
,	O
and	O
neuromuscular	B-DISO
blockade	I-DISO
for	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
.	O

ABSTRACT	O
:	O
To	O
provide	O
a	O
comprehensive	O
review	O
of	O
the	O
issue	O
related	O
to	O
the	O
administration	O
of	O
sedative	O
,	O
analgesic	O
,	O
and	O
neuromuscular	O
blocking	B-DISO
agents	O
(	O
NMBA	O
)	O
to	O
patients	O
who	O
are	O
receiving	O
ventilatory	O
support	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
with	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
.	O

In	O
particular	O
,	O
the	O
use	O
of	O
NMBA	O
has	O
been	O
higher	O
than	O
for	O
other	O
ARDS	B-DISO
populations	O
.	O

After	O
a	O
mean	O
of	O
12	O
hrs	B-DISO
of	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
,	O
the	O
mean	O
Fio2	O
was	O
significantly	O
reduced	O
compared	O
with	O
prestudy	O
levels	O
(	O
0	O
.	O
5	O
+/-	O
0	O
.	O
2	O
vs	O
.	O
0	O
.	O
9	O
+/-	O

Additionally	O
PMNL	O
diapedesis	O
and	O
interstitial	O
lung	B-DISO
oedema	I-DISO
were	O
determined	O
by	O
histological	O
analysis	O
.	O

The	O
Web	B-DISO
viewer	O
of	O
this	O
system	O
integrates	O
multi	O
-	O
media	O
display	O
modules	O
and	O
remote	O
control	O
module	O
together	O
to	O
provide	O
interactive	O
EPR	O
display	O
and	O
manipulation	O
functions	O
for	O
collaborative	O
applications	O
.	O

We	O
have	O
successfully	O
used	O
this	O
system	O
two	O
times	O
to	O
provide	O
teleconsultation	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
in	O
Shanghai	O
Infection	B-DISO
Hospital	O
and	O
Xinhua	O
Hospital	O
.	O

ABSTRACT	O
:	O
We	O
have	O
the	O
knowledge	O
and	O
tools	O
to	O
eliminate	O
the	O
threat	O
of	O
canine	O
rabies	B-DISO
but	O
this	O
disease	O
,	O
nevertheless	O
,	O
remains	O
a	O
public	O
health	O
threat	O
in	O
many	O
parts	O
of	O
the	O
world	O
.	O

Rabies	B-DISO
immunoglobulin	O
,	O
injected	O
into	O
and	O
around	O
bite	O
wounds	O
,	O
provides	O
added	O
safety	O
for	O
the	O
severely	O
exposed	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
nosocomial	O
acquisition	O
of	O
MRSA	B-DISO
decreased	O
in	O
these	O
hospitals	O
during	O
an	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
when	O
barrier	O
precautions	O
were	O
routinely	O
used	O
for	O
all	O
patients	O
.	O

Three	O
tertiary	O
-	O
care	O
hospitals	O
(	O
a	O
1100	O
-	O
bed	B-DISO
hospital	O
;	O
a	O
500	O
-	O
bed	B-DISO
hospital	O
;	O
and	O
an	O
823	O
-	O
bed	B-DISO
hospital	O
)	O
and	O
a	O
430	O
-	O
bed	B-DISO
community	O
hospital	O
,	O
each	O
located	O
in	O
Toronto	O
,	O
Ontario	O
,	O
Canada	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
a	O
new	O
approach	O
for	O
infectious	B-DISO
disease	I-DISO
surveillance	O
that	O
facilitates	O
rapid	O
identification	O
of	O
known	O
and	O
emerging	O
pathogens	O
.	O

Polyclonal	O
antibodies	O
against	O
the	O
SARS	B-DISO
N	O
protein	O
have	O
been	O
produced	O
and	O
the	O
strong	O
binding	O
sites	O
of	O
the	O
anti	O
-	O
nucleocapsid	O
protein	O
(	O
NP	O
)	O
antibodies	O
produced	O
were	O
mapped	O
to	O
aa	O
1	O
-	O
20	O
,	O
aa	O
150	O
-	O
170	O
and	O
aa	O
390	O
-	O
410	O
.	O

Very	O
little	O
research	O
into	O
these	O
factors	O
has	O
been	O
conducted	O
with	O
regard	O
to	O
preventing	O
exposures	O
to	O
respiratory	O
tract	O
pathogens	O
,	O
but	O
there	O
was	O
evidence	O
from	O
the	O
SARS	B-DISO
outbreaks	O
that	O
training	O
programs	O
and	O
the	O
availability	O
of	O
adequate	O
PPE	O
were	O
associated	O
with	O
a	O
decrease	O
risk	O
of	O
infection	B-DISO
.	O

SARS	B-DISO
focused	O
attention	O
on	O
the	O
adequacy	O
of	O
and	O
compliance	O
with	O
infection	B-DISO
control	O
practices	O
in	O
preventing	O
airborne	O
and	O
droplet	O
-	O
spread	O
transmission	O
of	O
infectious	B-DISO
agents	O
.	O

Recent	O
studies	O
revealed	O
that	O
3a	O
could	O
interact	O
specifically	O
with	O
many	O
SARS	B-DISO
-	O
CoV	O
structural	O
proteins	O
,	O
such	O
as	O
M	O
,	O
E	O
and	O
S	O
protein	O
.	O

ABSTRACT	O
:	O
Oxymatrine	O
is	O
one	O
of	O
the	O
alkaloids	O
extracted	O
from	O
Chinese	O
herb	O
Sophora	O
japonica	O
(	O
Sophora	O
flavescens	O
Ait	O
.)	O
with	O
activities	O
of	O
anti	O
-	O
inflammation	B-DISO
,	O
inhibiting	O
immune	O
reaction	O
,	O
antivirus	O
,	O
protecting	O
hepatocytes	O
and	O
antihepatic	O
fibrosis	B-DISO
.	O

ABSTRACT	O
:	O
The	O
H	O
strain	O
of	O
infectious	B-DISO
bronchitis	B-DISO
(	O
IB	B-DISO
)	O
was	O
one	O
of	O
the	O
earliest	O
live	O
attenuated	O
IB	B-DISO
vaccines	O
to	O
be	O
developed	O
and	O
has	O
continued	O
to	O
be	O
use	O
in	O
most	O
parts	O
of	O
the	O
world	O
for	O
almost	O
50	O
years	O
.	O

TITLE	O
:	O
Aerosol	O
-	O
induced	O
Mycoplasma	B-DISO
synoviae	O
arthritis	B-DISO
:	O
the	O
synergistic	O
effect	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	B-DISO
infection	I-DISO
.	O

Mycoplasma	B-DISO
-	O
free	O
brown	O
layer	O
pullets	O
,	O
approximately	O
5	O
weeks	O
old	O
,	O
were	O
exposed	O
to	O
an	O
aerosol	O
dose	O
of	O
>	O
or	O
=	O
10	O
(	O
2	O
-	O
3	O
)	O
colony	O
-	O
forming	O
units	O
(	O
CFU	O
)	O
of	O
M	O
.	O
synoviae	O
alone	O
or	O
3	O
days	O
after	O
inoculation	O
of	O
a	O
field	O
strain	O
of	O
IBV	O
(	O
D1466	O
)	O
by	O
the	O
ocular	O
-	O
nasal	O
route	O
.	O

Ninety	O
-	O
five	O
per	O
cent	O
of	O
positive	O
control	O
birds	O
developed	O
arthritis	B-DISO
.	O

Twenty	O
-	O
one	O
per	O
cent	O
of	O
chicks	O
infected	O
with	O
M	O
.	O
synoviae	O
aerosol	O
developed	O
arthritis	B-DISO
compared	O
with	O
33	O
%	O
of	O
those	O
co	O
-	O
infected	O
with	O
IBV	O
D1466	O
,	O
and	O
55	O
%	O
of	O
those	O
co	O
-	O
infected	O
with	O
IBV	O
M41	O
.	O

TITLE	O
:	O
Psychological	B-DISO
responses	O
to	O
the	O
SARS	B-DISO
outbreak	O
in	O
healthcare	O
students	O
in	O
Hong	O
Kong	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
characterized	O
by	O
fever	O
with	O
rapid	O
progression	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
and	O
it	O
is	O
associated	O
with	O
substantial	O
morbidity	O
and	O
mortality	O
.	O

In	O
the	O
third	O
patient	O
,	O
biopsy	O
specimen	O
taken	O
17	O
days	O
after	O
symptom	B-DISO
onset	O
showed	O
patches	O
of	O
organizing	B-DISO
pneumonia	I-DISO
with	O
reactive	O
fibroblastic	O
proliferation	B-DISO
,	O
more	O
abundant	O
type	O
II	O
pneumocytes	O
and	O
clustering	O
of	O
CD68	O
-	O
positive	O
macrophages	O
within	O
the	O
alveolar	O
spaces	O
.	O

The	O
lung	O
biopsy	O
specimen	O
from	O
patient	O
4	O
taken	O
21	O
days	O
after	O
symptom	B-DISO
onset	O
showed	O
characteristics	O
of	O
the	O
fibrotic	O
stage	O
,	O
with	O
significant	O
myofibroblastic	O
proliferation	B-DISO
in	O
the	O
alveolar	O
space	O
and	O
interstitium	O
resulting	O
in	O
loss	O
of	O
pulmonary	O
architecture	O
.	O

RESULTS	O
:	O
The	O
autopsy	O
lung	O
tissue	O
from	O
patient	O
1	O
,	O
who	O
died	O
7	O
days	O
after	O
symptoms	O
onset	O
due	O
to	O
the	O
complication	B-DISO
of	O
acute	B-DISO
myocardial	I-DISO
infarction	I-DISO
,	O
revealed	O
mild	O
histologic	O
change	O
in	O
the	O
lung	O
.	O

TITLE	O
:	O
Polymorphisms	O
of	O
interferon	O
-	O
inducible	O
genes	O
OAS	B-DISO
-	O
1	O
and	O
MxA	O
associated	O
with	O
SARS	B-DISO
in	O
the	O
Vietnamese	O
population	O
.	O

ABSTRACT	O
:	O
We	O
hypothesized	O
that	O
host	O
antiviral	O
genes	O
induced	O
by	O
type	O
I	O
interferons	O
might	O
affect	O
the	O
natural	O
course	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Efforts	O
should	O
be	O
made	O
to	O
evaluate	O
the	O
most	O
promising	O
treatments	O
and	O
vaccines	O
in	O
controlled	O
clinical	O
trials	O
,	O
should	O
another	O
SARS	B-DISO
outbreak	O
occur	O
.	O

TITLE	O
:	O
Transmission	O
of	O
infectious	B-DISO
diseases	I-DISO
during	O
commercial	O
air	O
travel	O
.	O

TITLE	O
:	O
Viral	O
induction	O
of	O
central	O
nervous	B-DISO
system	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
.	O

ABSTRACT	O
:	O
The	O
ability	O
of	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
to	O
generate	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
was	O
investigated	O
in	O
an	O
in	O
vitro	O
model	O
of	O
CNS	B-DISO
infection	I-DISO
.	O

RESULTS	O
:	O
Of	O
these	O
populations	O
,	O
the	O
detective	O
rate	O
of	O
Ab	O
-	O
IgG	O
for	O
the	O
clinic	O
diagnosed	O
SARS	B-DISO
patients	O
,	O
which	O
was	O
53	O
.	O
7	O
%;	O
That	O
for	O
the	O
wild	O
animal	O
salesman	O
and	O
community	O
common	O
people	O
were	O
16	O
.	O
7	O
%	O
and	O
0	O
.	O
9	O
%,	O
respectively	O
.	O

Severe	O
psychological	B-DISO
symptoms	I-DISO
such	O
as	O
obsession	B-DISO
,	O
depression	B-DISO
and	O
anxiety	O
were	O
found	O
in	O
a	O
minority	O
of	O
patients	O
with	O
SARS	B-DISO
and	O
the	O
psychological	B-DISO
symptoms	I-DISO
were	O
not	O
related	O
with	O
the	O
change	O
of	O
physical	O
parameters	O
.	O

Whether	O
or	O
not	O
psychological	B-DISO
symptoms	I-DISO
were	O
related	O
to	O
their	O
personality	B-DISO
needs	O
further	O
study	O
.	O

Cats	O
with	O
URI	O
tended	O
to	O
be	O
housed	O
in	O
isolation	O
,	O
dehydrated	B-DISO
,	O
and	O
younger	O
than	O
cats	O
without	O
URI	O
,	O
and	O
infected	O
with	O
FHV	O
,	O
Mycoplasma	B-DISO
species	O
,	O
FCV	O
,	O
or	O
C	O
felis	O
.	O

Therefore	O
,	O
we	O
cloned	O
the	O
Leader	O
sequence	O
from	O
SARS	B-DISO
-	O
CoV	O
(	O
BJ01	O
),	O
which	O
is	O
identical	O
to	O
that	O
identified	O
from	O
SARS	B-DISO
-	O
CoV	O
(	O
HKU	O
-	O
39849	O
),	O
and	O
constructed	O
specific	O
siRNA	O
targeting	O
the	O
Leader	O
sequence	O
.	O

Twenty	O
-	O
five	O
of	O
the	O
29	O
patients	O
(	O
86	O
%)	O
were	O
mechanically	O
ventilated	O
,	O
15	O
of	O
the	O
29	O
patients	O
(	O
52	O
%)	O
developed	O
ARDS	B-DISO
,	O
and	O
overall	O
28	O
-	O
day	O
mortality	O
was	O
41	O
%.	O

Follow	O
-	O
up	O
lung	O
function	O
tests	O
and	O
chest	O
high	O
-	O
resolution	O
computerized	O
tomography	O
(	O
HRCT	O
)	O
were	O
performed	O
in	O
medical	O
staff	O
with	O
SARS	B-DISO
from	O
Dec	O
.	O
2003	O
to	O
Feb	O
.	O
2004	O
.	O

Of	O
the	O
434	O
patients	O
who	O
had	O
received	O
HRCT	O
scans	O
,	O
151	O
(	O
34	O
.	O
79	O
%)	O
showed	O
abnormalities	O
including	O
subpleural	O
and	O
basal	O
ground	O
-	O
glass	O
and	O
reticular	O
attenuation	O
,	O
nodular	O
septal	O
thickening	O
and	O
bronchiectasis	B-DISO
.	O

Reported	O
data	O
showed	O
that	O
this	O
was	O
a	O
relatively	O
high	O
degree	O
of	O
sensitivity	O
and	O
specificity	O
for	O
SARS	B-DISO
-	O
CoV	O
antibody	O
testing	O
.	O

ABSTRACT	O
:	O
Assuming	O
a	O
synergistic	O
or	O
additive	O
effect	O
of	O
Chlamydiaceae	O
in	O
coexistence	O
with	O
other	O
enteropathogenic	O
agents	O
,	O
the	O
viral	O
/	O
bacterial	O
interaction	O
between	O
a	O
cell	O
culture	O
adapted	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
ca	O
-	O
PEDV	O
)	O
and	O
different	O
Chlamydiaceae	O
strains	O
was	O
studied	O
in	O
vitro	O
.	O

TITLE	O
:	O
[	O
Emergent	O
infectious	B-DISO
diseases	I-DISO
:	O
importance	O
for	O
public	O
health	O
,	O
epidemiology	O
,	O
promoting	O
factors	O
,	O
and	O
prevention	O
].	O

Qualitative	O
changes	O
of	O
infectious	B-DISO
agents	O
such	O
as	O
the	O
resistance	O
to	O
anti	O
-	O
infectious	B-DISO
agents	O
may	O
also	O
contribute	O
,	O
through	O
a	O
selection	O
mechanism	O
,	O
to	O
the	O
emergence	O
of	O
new	O
infectious	B-DISO
threat	O
.	O

ABSTRACT	O
:	O
The	O
immune	O
spectrum	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
poorly	O
understood	O
.	O

CONCLUSIONS	O
:	O
SARS	B-DISO
-	O
CoV	O
seemed	O
to	O
elicit	O
effective	O
humoral	O
immunity	O
but	O
inhibited	O
cellular	O
immunity	O
,	O
especially	O
CD8	O
+	O
memory	O
T	O
lymphocytes	O
over	O
time	O
.	O

ABSTRACT	O
:	O
We	O
present	O
the	O
first	O
proteomic	O
analysis	O
on	O
the	O
cellular	O
response	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
infection	B-DISO
.	O

Statistically	O
significant	O
differences	O
were	O
found	O
for	O
gender	O
(	O
73	O
.	O
9	O
%	O
women	O
),	O
nurses	O
(	O
24	O
.	O
7	O
%)	O
vs	O
.	O
others	O
,	O
doctors	O
(	O
20	O
.	O
3	O
%)	O
vs	O
.	O
others	O
,	O
older	O
(	O
40	O
years	O
or	O
older	O
,	O
60	O
.	O
0	O
%)	O
vs	O
.	O
younger	O
persons	O
,	O
emergency	B-DISO
or	O
intensive	O
care	O
unit	O
workers	O
(	O
8	O
.	O
0	O
%)	O
vs	O
.	O
others	O
,	O
and	O
those	O
employed	O
fewer	O
years	O
at	O
the	O
hospital	O
(	O
less	O
than	O
5	O
years	O
:	O
46	O
.	O
2	O
%)	O
vs	O
.	O
five	O
or	O
more	O
years	O
.	O

The	O
clear	O
differences	O
between	O
groups	O
defined	O
by	O
demographics	O
,	O
professions	O
and	O
clinical	O
roles	O
suggest	O
a	O
subtle	O
and	O
pervasive	O
secondary	O
impact	O
of	O
the	O
SARS	B-DISO
outbreak	O
,	O
with	O
repercussions	O
health	O
care	O
facilities	O
must	O
contend	O
with	O
while	O
maintaining	O
increased	O
levels	O
of	O
vigilance	O
in	O
the	O
wake	O
of	O
SARS	B-DISO
.	O

Two	O
methods	O
,	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
indirect	O
immunofluorescent	O
assay	O
(	O
IFA	O
),	O
were	O
used	O
to	O
detect	O
specific	O
serum	O
IgG	O
and	O
IgM	O
against	O
SARS	B-DISO
-	O
CoV	O
in	O
98	O
SARS	B-DISO
patients	O
and	O
250	O
controls	O
consisting	O
of	O
patients	O
with	O
pneumonia	B-DISO
,	O
health	O
-	O
care	O
professionals	O
and	O
healthy	O
subjects	O
.	O

Cytopathic	B-DISO
effect	I-DISO
was	O
extensive	O
after	O
initial	O
inoculation	O
but	O
diminished	O
with	O
serial	O
passages	O
.	O

Infectious	B-DISO
virus	O
was	O
detected	O
after	O
each	O
passage	O
and	O
viral	O
growth	O
curves	O
were	O
identical	O
for	O
parental	O
virus	O
stock	O
and	O
virus	O
obtained	O
from	O
passage	O
11	O
cells	O
.	O

Persistence	O
is	O
associated	O
with	O
selected	O
mutations	O
in	O
the	O
SARS	B-DISO
-	O
CoV	O
genome	O
.	O

The	O
dimeric	O
three	O
-	O
dimensional	O
structure	O
of	O
the	O
C145A	O
mutant	B-DISO
protease	O
shows	O
that	O
the	O
active	O
site	O
of	O
one	O
protomer	O
binds	O
with	O
the	O
C	O
-	O
terminal	O
six	O
amino	O
acids	O
of	O
the	O
protomer	O
from	O
another	O
asymmetric	O
unit	O
,	O
mimicking	O
the	O
product	O
-	O
bound	O
form	O
and	O
suggesting	O
a	O
possible	O
mechanism	O
for	O
maturation	O
.	O

TITLE	O
:	O
Can	O
routine	O
laboratory	O
tests	O
discriminate	O
between	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
other	O
causes	O
of	O
community	O
-	O
acquired	O
pneumonia	B-DISO
?	O

ABSTRACT	O
:	O
The	O
clinical	O
presentation	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
resembles	O
that	O
of	O
other	O
etiologies	O
of	O
community	O
-	O
acquired	O
pneumonia	B-DISO
,	O
making	O
diagnosis	O
difficult	O
.	O

The	O
SARS	B-DISO
database	O
contained	O
data	O
for	O
144	O
patients	O
with	O
SARS	B-DISO
from	O
the	O
2003	O
Toronto	O
SARS	B-DISO
outbreak	O
.	O

The	O
community	O
-	O
acquired	O
pneumonia	B-DISO
database	O
contained	O
data	O
for	O
8044	O
patients	O
with	O
community	O
-	O
acquired	O
pneumonia	B-DISO
from	O
Edmonton	O
,	O
Canada	O
.	O

These	O
techniques	O
represent	O
valuable	O
laboratory	O
diagnostic	O
modalities	O
and	O
provide	O
insights	O
into	O
the	O
pathogenesis	B-DISO
of	O
this	O
emerging	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
The	O
recombinant	O
nucleocapsid	O
protein	O
(	O
rNP	O
)	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
was	O
expressed	O
in	O
a	O
baculovirus	O
system	O
.	O

The	O
purified	O
SARS	B-DISO
-	O
CoV	O
rNP	O
was	O
used	O
as	O
an	O
antigen	O
for	O
detection	O
of	O
SARS	B-DISO
-	O
CoV	O
antibodies	O
in	O
IgG	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

ABSTRACT	O
:	O
Neurotropic	O
coronavirus	O
-	O
induced	O
encephalitis	B-DISO
was	O
used	O
to	O
evaluate	O
recruitment	B-DISO
,	O
functional	O
activation	O
,	O
and	O
retention	O
of	O
peripheral	O
bystander	O
memory	O
CD8	O
+	O
T	O
cells	O
.	O

Furthermore	O
,	O
in	O
contrast	O
to	O
highly	O
activated	O
pN	O
-	O
specific	O
CD8	O
+	O
T	O
cells	O
,	O
bystander	O
p18	O
-	O
specific	O
CD8	O
+	O
T	O
cells	O
recruited	O
to	O
the	O
site	O
of	O
inflammation	B-DISO
maintained	O
a	O
nonactivated	O
memory	O
phenotype	O
and	O
did	O
not	O
express	O
ex	O
vivo	O
cytolytic	O
activity	O
.	O

By	O
contrast	O
,	O
protein	O
expression	O
was	O
undetectable	O
in	O
astrocytes	O
or	O
CD8	O
+	O
T	O
cells	O
,	O
the	O
primary	O
antiviral	O
effectors	O
that	O
localize	O
to	O
the	O
CNS	O
parenchyma	O
in	O
response	O
to	O
infection	B-DISO
.	O

TITLE	O
:	O
Fear	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
among	O
health	O
care	O
workers	O
.	O

Sample	O
1	O
participants	O
had	O
stronger	O
fear	O
related	O
to	O
infection	B-DISO
than	O
Sample	O
2	O
participants	O
,	O
who	O
seemed	O
to	O
be	O
concerned	O
more	O
about	O
other	O
health	O
problems	O
and	O
discrimination	O
.	O

TITLE	O
:	O
The	O
adamantane	O
-	O
derived	O
bananins	O
are	O
potent	O
inhibitors	O
of	O
the	O
helicase	O
activities	O
and	O
replication	O
of	O
SARS	B-DISO
coronavirus	O
.	O

TITLE	O
:	O
Genosensor	O
on	O
gold	O
films	O
with	O
enzymatic	O
electrochemical	O
detection	O
of	O
a	O
SARS	B-DISO
virus	O
sequence	O
.	O

A	O
30	O
-	O
mer	O
sequence	O
that	O
encodes	O
a	O
short	O
lysine	O
-	O
rich	O
region	O
,	O
unique	O
to	O
SARS	B-DISO
(	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
)	O
virus	O
,	O
was	O
chosen	O
as	O
target	O
.	O

RESULTS	O
:	O
The	O
S450	O
-	O
650	O
-	O
based	O
ELISA	O
detected	O
IgG	O
Abs	O
in	O
41	O
out	O
of	O
51	O
serum	O
samples	O
from	O
22	O
hospitalized	O
patients	O
with	O
probable	O
SARS	B-DISO
,	O
a	O
result	O
closely	O
correlated	O
with	O
that	O
obtained	O
with	O
a	O
virus	O
-	O
based	O
ELISA	O
(	O
r	O
=	O
0	O
.	O
75	O
,	O
k	O
=	O
0	O
.	O
8	O
).	O

ABSTRACT	O
:	O
On	O
22	O
March	O
2003	O
,	O
the	O
Ministry	O
of	O
Health	O
,	O
Singapore	O
,	O
designated	O
Tan	O
Tock	O
Seng	O
Hospital	O
as	O
the	O
nationwide	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
hospital	O
and	O
its	O
Emergency	B-DISO
Department	O
(	O
ED	O
)	O
took	O
over	O
the	O
role	O
as	O
the	O
screening	O
center	O
for	O
SARS	B-DISO
on	O
26	O
March	O
2003	O
.	O

A	O
retrospective	O
study	O
of	O
patients	O
who	O
were	O
admitted	O
through	O
the	O
ED	O
and	O
subsequently	O
diagnosed	O
to	O
have	O
probable	O
SARS	B-DISO
and	O
suspect	O
SARS	B-DISO
was	O
done	O
.	O

Surveillance	O
data	O
on	O
medical	O
sick	O
leave	O
of	O
staff	O
,	O
all	O
inpatient	O
fevers	O
,	O
all	O
febrile	O
(	O
temperature	O
greater	O
than	O
or	O
equal	O
to	O
38	O
degrees	O
Celsius	O
)	O
inpatient	O
pneumonia	B-DISO
,	O
including	O
atypical	B-DISO
pneumonia	I-DISO
,	O
and	O
deaths	O
from	O
pneumonia	B-DISO
were	O
collected	O
from	O
sick	O
leave	O
reports	O
,	O
ward	O
reports	O
,	O
isolation	O
room	O
rounds	O
and	O
mortuary	O
reports	O
from	O
1	O
to	O
28	O
September	O
2003	O
.	O

Baseline	O
results	O
show	O
167	O
(	O
1	O
.	O
4	O
/	O
1000	O
staff	O
-	O
days	O
)	O
observed	O
in	O
staff	O
sick	O
leave	O
for	O
febrile	O
illnesses	O
,	O
and	O
1798	O
(	O
71	O
.	O
3	O
/	O
1000	O
bed	B-DISO
-	O
days	O
)	O
observed	O
for	O
inpatient	O
fever	O
.	O

The	O
large	O
amount	O
of	O
patients	O
shifting	O
from	O
the	O
maternity	O
wards	O
of	O
more	O
advanced	O
hospitals	O
to	O
those	O
of	O
less	O
advanced	O
hospitals	O
,	O
coupled	O
with	O
the	O
substantial	O
reduction	O
in	O
their	O
length	O
of	O
maternity	O
stay	O
due	O
to	O
their	O
fears	O
of	O
SARS	B-DISO
could	O
also	O
lead	O
to	O
serious	O
concerns	O
for	O
quality	O
of	O
care	O
,	O
especially	O
regarding	O
a	O
patient	O
'	O
s	O
accessibility	O
to	O
quality	O
providers	O
and	O
continuity	O
of	O
care	O
.	O

RESULTS	O
:	O
Compared	O
to	O
the	O
pre	O
-	O
SARS	B-DISO
period	O
,	O
medical	O
centers	O
and	O
regional	O
hospitals	O
dropped	O
5	O
.	O
2	O
%	O
and	O
4	O
.	O
1	O
%	O
in	O
market	O
share	O
for	O
childbirth	O
services	O
during	O
the	O
peak	O
SARS	B-DISO
period	O
,	O
while	O
district	O
hospitals	O
and	O
clinics	O
increased	O
2	O
.	O
1	O
%	O
and	O
7	O
.	O
1	O
%,	O
respectively	O
.	O

Using	O
methods	O
consistent	O
with	O
Husserl	O
'	O
s	O
philosophy	O
,	O
eight	O
Registered	O
Nurses	O
working	O
in	O
three	O
regional	O
hospitals	O
in	O
Hong	O
Kong	O
were	O
invited	O
to	O
participate	O
in	O
sharing	O
their	O
lived	O
experience	O
of	O
caring	O
for	O
SARS	B-DISO
patients	O
and	O
data	O
were	O
analysed	O
using	O
Colaizzi	O
'	O
s	O
approach	O
.	O

The	O
findings	O
of	O
this	O
study	O
indicate	O
that	O
extensive	O
and	O
ongoing	O
support	O
is	O
needed	O
to	O
prepare	O
and	O
enable	O
nurses	O
to	O
care	O
for	O
SARS	B-DISO
patients	O
during	O
a	O
crisis	O
and	O
make	O
it	O
easier	O
for	O
nurses	O
to	O
deal	O
with	O
the	O
various	O
uncertainties	O
.	O

TITLE	O
:	O
[	O
Bronchiolitis	B-DISO
treated	O
with	O
mechanical	O
ventilation	O
:	O
prognosis	O
factors	O
and	O
outcome	O
in	O
a	O
series	O
of	O
135	O
children	O
].	O

Only	O
few	O
studies	O
reported	O
severe	O
bronchiolitis	B-DISO
requiring	O
mechanical	O
ventilation	O
,	O
and	O
respiratory	O
outcome	O
is	O
not	O
well	O
described	O
.	O

Serial	O
assay	O
of	O
serum	O
ALT	O
was	O
followed	O
in	O
patients	O
who	O
fulfilled	O
the	O
WHO	O
criteria	O
of	O
SARS	B-DISO
.	O

Serology	O
for	O
hepatitis	B-DISO
B	I-DISO
virus	O
(	O
HBV	B-DISO
)	O
infection	B-DISO
was	O
checked	O
.	O

Reactive	O
hepatitis	B-DISO
is	O
a	O
common	O
complication	B-DISO
of	O
SARS	B-DISO
-	O
coronavirus	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
caused	O
by	O
a	O
new	O
coronavirus	O
.	O

TITLE	O
:	O
Keeping	O
SARS	B-DISO
out	O
:	O
an	O
education	O
program	O
for	O
SARS	B-DISO
screeners	O
in	O
one	O
Ontario	O
hospital	O
.	O

ABSTRACT	O
:	O
On	O
March	O
14	O
,	O
2003	O
,	O
the	O
Ontario	O
(	O
Canada	O
)	O
Ministry	O
of	O
Health	O
and	O
Long	O
-	O
Term	O
Care	O
alerted	O
healthcare	O
providers	O
about	O
four	O
cases	O
of	O
atypical	B-DISO
pneumonia	I-DISO
resulting	O
in	O
two	O
deaths	O
within	O
a	O
single	O
family	O
in	O
Toronto	O
,	O
Ontario	O
.	O

TITLE	O
:	O
Annulling	O
a	O
dangerous	O
liaison	O
:	O
vaccination	O
strategies	O
against	O
AIDS	O
and	O
tuberculosis	B-DISO
.	O

Last	O
year	O
,	O
600	O
,	O
000	O
individuals	O
,	O
doubly	O
infected	O
with	O
HIV	B-DISO
and	O
M	O
.	O
tuberculosis	B-DISO
,	O
died	O
.	O

Last	O
year	O
,	O
5	O
million	O
and	O
50	O
million	O
were	O
newly	O
infected	O
with	O
HIV	B-DISO
or	O
M	O
.	O
tuberculosis	B-DISO
,	O
respectively	O
,	O
with	O
2	O
million	O
new	O
double	O
infections	B-DISO
.	O

Univariate	O
and	O
multivariate	O
analyses	O
were	O
performed	O
to	O
determine	O
factors	O
associated	O
with	O
respiratory	B-DISO
failure	I-DISO
and	O
intubation	O
.	O

All	O
patients	O
initially	O
received	O
empiric	O
antibacterial	O
therapy	O
against	O
common	O
causative	O
pathogens	O
of	O
atypical	B-DISO
pneumonia	I-DISO
.	O

A	O
higher	O
body	O
temperature	O
at	O
presentation	O
(	O
median	O
39	O
.	O
5	O
vs	O
38	O
.	O
6	O
degrees	O
C	O
),	O
and	O
higher	O
peak	O
values	O
of	O
lactate	O
dehydrogenase	O
(	O
410	O
vs	O
282	O
U	O
/	O
L	O
)	O
and	O
C	O
-	O
reactive	O
protein	O
(	O
10	O
.	O
2	O
vs	O
2	O
.	O
5	O
mg	O
/	O
dL	O
),	O
were	O
associated	O
with	O
subsequent	O
respiratory	B-DISO
failure	I-DISO
.	O

All	O
patients	O
with	O
probable	O
SARS	B-DISO
who	O
were	O
admitted	O
to	O
hospital	O
presented	O
with	O
fever	O
and	O
lymphopenia	B-DISO
.	O

Multivariate	O
analysis	O
showed	O
that	O
peak	O
level	O
of	O
C	O
-	O
reactive	O
protein	O
was	O
the	O
only	O
independent	O
predictor	O
of	O
respiratory	B-DISO
failure	I-DISO
and	O
intubation	O
(	O
odds	O
ratio	O
for	O
every	O
increment	O
of	O
1	O
mg	O
/	O
dL	O
=	O
1	O
.	O
45	O
;	O
95	O
%	O
confidence	O
interval	O
=	O
1	O
.	O
003	O
,	O
2	O
.	O
097	O
;	O
p	O
=	O
0	O
.	O
048	O
).	O

TITLE	O
:	O
[	O
Treatment	O
of	O
West	B-DISO
syndrome	I-DISO
].	O

The	O
mean	O
age	O
at	O
spasm	B-DISO
onset	O
was	O
5	O
.	O
8	O
months	O
,	O
and	O
mean	O
age	O
at	O
diagnosis	O
and	O
treatment	O
7	O
.	O
2	O
months	O
.	O

There	O
was	O
no	O
recurrence	B-DISO
of	O
WS	O
.	O

Vigabatrin	O
can	O
be	O
suggested	O
as	O
the	O
first	O
drug	O
for	O
WS	O
;	O
if	O
spasms	B-DISO
persist	O
after	O
15	O
days	O
with	O
a	O
dose	O
of	O
150	O
mg	O
/	O
kg	O
,	O
synthetic	O
ACTH	O
should	O
be	O
considered	O
.	O

We	O
found	O
that	O
,	O
surprisingly	O
,	O
militaristic	O
language	O
was	O
largely	O
absent	O
,	O
as	O
was	O
the	O
judgemental	O
discourse	O
of	O
plague	B-DISO
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
a	O
major	O
antigenic	O
determinant	O
capable	O
of	O
inducing	O
protective	O
immunity	O
.	O

ABSTRACT	O
:	O
A	O
Saccharomyces	O
cerevisiae	O
-	O
expressed	O
nucleocapsid	O
(	O
N	O
)	O
polypeptide	O
of	O
the	O
M41	O
strain	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
was	O
used	O
as	O
antigen	O
in	O
a	O
recombinant	O
yeast	O
-	O
expressed	O
N	O
protein	O
-	O
based	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
Y	O
-	O
N	O
-	O
ELISA	O
).	O

ABSTRACT	O
:	O
Acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
or	O
perimyocarditis	O
?	O

The	O
patient	O
recently	O
recovered	O
from	O
upper	B-DISO
respiratory	I-DISO
infection	I-DISO
.	O

Recent	O
experiences	O
of	O
emerging	O
microbial	O
threats	O
,	O
including	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
new	O
influenza	B-DISO
variants	O
affecting	O
humans	O
,	O
the	O
re	O
-	O
emergence	O
of	O
infectious	B-DISO
disease	I-DISO
problems	O
and	O
the	O
possibility	O
of	O
bioterrorism	O
have	O
evidenced	O
the	O
need	O
for	O
implementation	O
of	O
infectious	B-DISO
disease	I-DISO
surveillance	O
programmes	O
.	O

ABSTRACT	O
:	O
Three	O
outbreaks	O
of	O
respiratory	O
illness	O
associated	O
with	O
human	O
coronavirus	O
HCoV	O
-	O
OC43	O
infection	B-DISO
occurred	O
in	O
geographically	O
unrelated	O
aged	O
-	O
care	O
facilities	O
in	O
Melbourne	O
,	O
Australia	O
during	O
August	O
and	O
September	O
2002	O
.	O

On	O
clinical	O
and	O
epidemiological	O
grounds	O
the	O
outbreaks	O
were	O
first	O
thought	O
to	O
be	O
caused	O
by	O
influenza	B-DISO
virus	O
.	O

These	O
outbreaks	O
establish	O
this	O
virus	O
as	O
a	O
cause	O
of	O
morbidity	O
in	O
aged	O
-	O
care	O
facilities	O
and	O
add	B-DISO
to	O
increasing	O
evidence	O
of	O
the	O
significance	O
of	O
coronavirus	B-DISO
infections	I-DISO
.	O

All	O
clinical	O
settings	O
,	O
including	O
rehabilitative	O
and	O
infirmary	O
setting	O
,	O
have	O
actively	O
involved	O
in	O
fighting	O
against	O
the	O
infection	B-DISO
.	O

They	O
were	O
assessment	O
of	O
risk	O
,	O
formulation	O
of	O
operational	O
guidelines	O
,	O
implementation	O
of	O
infection	B-DISO
control	O
measures	O
,	O
education	O
and	O
training	O
of	O
staff	O
,	O
conducting	O
audits	O
and	O
carrying	O
out	O
environmental	O
improvement	O
work	O
.	O

A	O
newly	O
described	O
lesion	O
,	O
isolated	O
ductular	O
hyperplasia	B-DISO
(	O
IDH	O
)	O
was	O
found	O
in	O
patients	O
with	O
prolonged	O
abnormalities	O
of	O
liver	O
function	O
tests	O
of	O
uncertain	O
origin	O
.	O

In	O
some	O
of	O
these	O
heritable	O
forms	O
of	O
primary	O
iron	B-DISO
overload	I-DISO
,	O
stainable	O
iron	O
is	O
present	O
in	O
both	O
hepatocytes	O
and	O
Kupffer	O
cells	O
.	O

TITLE	O
:	O
Community	O
-	O
acquired	O
pneumonia	B-DISO
in	O
children	O
.	O

ABSTRACT	O
:	O
This	O
review	O
highlights	O
recent	O
developments	O
in	O
the	O
diagnosis	O
,	O
etiology	O
,	O
therapy	O
,	O
and	O
prevention	O
of	O
community	O
-	O
acquired	O
pneumonia	B-DISO
in	O
children	O
.	O

TITLE	O
:	O
Progressive	O
and	O
nonresolving	O
pneumonia	B-DISO
.	O

This	O
review	O
will	O
glean	O
from	O
the	O
recent	O
literature	O
clinical	O
,	O
laboratory	O
,	O
and	O
radiologic	O
findings	O
that	O
help	O
identify	O
patients	O
at	O
risk	O
for	O
such	O
complications	O
of	O
their	O
pneumonia	B-DISO
.	O

The	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
cells	O
had	O
a	O
patchy	O
distribution	O
and	O
tended	O
to	O
be	O
present	O
in	O
the	O
periphery	O
of	O
the	O
lung	O
.	O

The	O
skeletal	O
muscle	O
specimens	O
of	O
2	O
patients	O
who	O
had	O
rhabdomyolysis	B-DISO
were	O
also	O
negative	O
for	O
SARS	B-DISO
-	O
CoV	O
.	O
SARS	B-DISO
-	O
CoV	O
is	O
mainly	O
present	O
in	O
the	O
cytoplasm	O
of	O
type	O
II	O
pneumocytes	O
and	O
can	O
only	O
be	O
detected	O
in	O
the	O
lung	O
tissue	O
during	O
the	O
early	O
stage	O
of	O
the	O
disease	O
.	O

Log	O
reduction	O
of	O
nonenveloped	O
viruses	O
for	O
human	O
adenovirus	B-DISO
5	O
was	O
>	O
5	O
.	O
2	O
;	O
for	O
parvovirus	B-DISO
B19	I-DISO
,	O
3	O
.	O
5	O
->	O
5	O
.	O
0	O
;	O
for	O
bluetongue	B-DISO
virus	O
,	O
5	O
.	O
6	O
-	O
5	O
.	O
9	O
;	O
for	O
feline	O
conjunctivitis	B-DISO
virus	O
,	O
1	O
.	O
7	O
-	O
2	O
.	O
4	O
;	O
and	O
for	O
simian	O
adenovirus	B-DISO
15	O
,	O
0	O
.	O
7	O
-	O
2	O
.	O
3	O
.	O

Inactivation	B-DISO
of	O
viruses	O
in	O
PLT	O
concentrates	O
with	O
amotosalen	O
and	O
UVA	O
offers	O
the	O
potential	O
to	O
prospectively	O
prevent	O
the	O
majority	O
of	O
PLT	O
transfusion	O
-	O
associated	O
viral	B-DISO
diseases	I-DISO
.	O

CONCLUSIONS	O
:	O
PCT	B-DISO
inactivates	O
a	O
broad	O
spectrum	O
of	O
pathogenic	O
,	O
blood	O
-	O
borne	O
viruses	O
.	O

TITLE	O
:	O
Absence	O
of	O
association	O
between	O
angiotensin	O
converting	O
enzyme	O
polymorphism	O
and	O
development	O
of	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
a	O
case	O
control	O
study	O
.	O

RESULTS	O
:	O
There	O
is	O
no	O
significant	O
difference	O
in	O
the	O
genotypic	O
distributions	O
and	O
the	O
allelic	O
frequencies	O
of	O
the	O
ACE	O
I	O
/	O
D	O
polymorphism	O
between	O
the	O
SARS	B-DISO
patients	O
and	O
the	O
healthy	O
control	O
subjects	O
.	O

The	O
internal	O
consistency	O
,	O
construct	O
validity	O
and	O
convergent	O
validity	O
of	O
the	O
instrument	O
were	O
examined	O
in	O
a	O
sample	O
of	O
128	O
nurses	O
during	O
the	O
SARS	B-DISO
outbreak	O
in	O
Taiwan	O
.	O

Overlapping	O
peptides	O
were	O
used	O
to	O
identify	O
major	O
histocompatibility	O
complex	O
class	O
I	O
-	O
restricted	O
epitopes	O
in	O
mice	O
immunized	O
with	O
vectors	O
encoding	O
codon	O
-	O
optimized	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
.	O

The	O
overall	O
attack	O
rate	O
of	O
SARS	B-DISO
was	O
41	O
%	O
(	O
30	O
of	O
74	O
subjects	O
).	O

RESULTS	O
:	O
The	O
overall	O
attack	O
rate	O
of	O
SARS	B-DISO
was	O
41	O
%	O
(	O
30	O
of	O
74	O
subjects	O
).	O

Finally	O
,	O
many	O
will	O
have	O
suffered	B-DISO
psychological	B-DISO
trauma	I-DISO
in	O
either	O
institutions	O
or	O
refugee	O
camps	O
.	O

A	O
recurrent	O
Candida	O
septicemia	B-DISO
with	O
prolonged	O
respiratory	B-DISO
failure	I-DISO
and	O
severe	O
liver	B-DISO
dysfunction	I-DISO
in	O
form	O
of	O
cholestatic	O
hepatosis	B-DISO
,	O
that	O
improved	O
several	O
times	O
with	O
antimycotic	O
therapy	O
in	O
combination	O
with	O
evidence	O
based	O
intensive	O
care	O
measures	O
and	O
artificial	O
organ	O
support	O
is	O
a	O
comparatively	O
rare	O
event	O
.	O

It	O
comprises	O
mucocutaneous	O
,	O
rhinocerebral	O
,	O
pulmonary	O
,	O
urological	O
and	O
disseminated	O
infections	B-DISO
.	O

Predisposing	O
factors	O
are	O
immunosuppression	O
owing	O
to	O
severe	O
diseases	B-DISO
,	I-DISO
immunological	I-DISO
defects	O
or	O
metabolic	O
disturbances	O
like	O
diabetic	B-DISO
ketoacidosis	I-DISO
.	O

TITLE	O
:	O
Suspected	O
SARS	B-DISO
patients	O
hospitalised	O
in	O
French	O
isolation	O
units	O
during	O
the	O
early	O
SARS	B-DISO
epidemic	O
:	O
the	O
French	O
experience	O
.	O

Only	O
3	O
.	O
4	O
%	O
had	O
been	O
in	O
close	O
contact	O
with	O
a	O
SARS	B-DISO
patient	O
but	O
73	O
.	O
5	O
%	O
came	O
from	O
an	O
affected	O
area	O
.	O

Information	O
on	O
signs	B-DISO
and	I-DISO
symptoms	I-DISO
of	O
SARS	B-DISO
as	O
well	O
as	O
the	O
current	O
suggested	O
treatment	O
will	O
be	O
presented	O
.	O

Over	O
the	O
past	O
decade	O
,	O
the	O
global	O
effort	O
to	O
identify	O
and	O
characterize	O
infectious	B-DISO
agents	O
,	O
decipher	O
the	O
underlying	O
pathways	O
by	O
which	O
they	O
cause	O
disease	O
,	O
and	O
develop	O
preventive	O
measures	O
and	O
treatments	O
for	O
many	O
of	O
the	O
world	O
'	O
s	O
most	O
dangerous	O
pathogens	O
has	O
resulted	O
in	O
considerable	O
progress	O
.	O

ABSTRACT	O
:	O
By	O
the	O
end	O
of	O
year	O
2002	O
there	O
was	O
an	O
outbreak	O
of	O
atypical	B-DISO
pneumonia	I-DISO
in	O
Southeast	O
Asia	O
which	O
soon	O
spread	O
to	O
other	O
continents	O
.	O

This	O
new	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
was	O
produced	O
by	O
a	O
novel	O
coronavirus	O
.	O

ABSTRACT	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
CoV	O
)	O
main	O
protease	O
represents	O
an	O
attractive	O
target	O
for	O
the	O
development	O
of	O
novel	O
anti	O
-	O
SARS	B-DISO
agents	O
.	O

Coronaviruses	O
,	O
like	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
virus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
bud	O
from	O
the	O
endoplasmic	O
reticulum	O
-	O
Golgi	O
intermediate	O
compartment	O
.	O

Immunofluorescence	O
analysis	O
shows	O
that	O
S	O
is	O
detected	O
in	O
several	O
compartments	O
along	O
the	O
secretory	O
pathway	O
from	O
the	O
endoplasmic	O
reticulum	O
to	O
the	O
plasma	O
membrane	O
while	O
M	O
predominantly	O
localizes	O
in	O
the	O
Golgi	O
,	O
where	O
it	O
accumulates	O
,	O
and	O
in	O
trafficking	O
vesicles	B-DISO
.	O

In	O
conclusion	O
,	O
SARS	B-DISO
-	O
CoV	O
surface	O
proteins	O
S	O
,	O
M	O
and	O
E	O
show	O
differential	O
subcellular	O
localizations	O
when	O
expressed	O
alone	O
suggesting	O
that	O
additional	O
cellular	O
or	O
viral	O
factors	O
might	O
be	O
required	O
for	O
coordinated	O
trafficking	O
to	O
the	O
virus	O
assembly	O
site	O
in	O
the	O
endoplasmic	O
reticulum	O
-	O
Golgi	O
intermediate	O
compartment	O
.	O

ABSTRACT	O
:	O
Foreign	O
viral	O
proteins	O
expressed	O
by	O
rabies	B-DISO
virus	O
(	O
RV	O
)	O
have	O
been	O
shown	O
to	O
induce	O
potent	O
humoral	O
and	O
cellular	O
immune	O
responses	O
in	O
immunized	O
animals	O
.	O

Now	O
the	O
SARS	B-DISO
-	O
CoV	O
story	O
has	O
entered	O
a	O
new	O
phase	O
,	O
a	O
search	O
for	O
preventive	O
strategies	O
and	O
a	O
cure	O
for	O
the	O
disease	O
.	O

Authors	O
conclude	O
that	O
development	O
of	O
successful	O
SARS	B-DISO
-	O
CoV	O
vaccines	O
and	O
antivirals	O
depends	O
on	O
the	O
progress	O
we	O
make	O
in	O
these	O
areas	O
in	O
the	O
immediate	O
future	O
.	O

Using	O
cDNA	O
arrays	O
,	O
analysis	O
of	O
gene	O
expression	O
profile	O
in	O
the	O
brain	O
revealed	O
a	O
modulation	O
of	O
80	O
different	O
genes	O
following	O
infection	B-DISO
,	O
with	O
at	O
least	O
27	O
of	O
these	O
genes	O
having	O
previously	O
been	O
directly	O
related	O
to	O
innate	O
or	O
acquired	O
immune	O
responses	O
.	O

TITLE	O
:	O
Mutations	O
in	O
Sendai	O
virus	O
variant	O
F1	O
-	O
R	O
that	O
correlate	O
with	O
plaque	B-DISO
formation	O
in	O
the	O
absence	O
of	O
trypsin	O
.	O

ABSTRACT	O
:	O
With	O
the	O
emergence	O
of	O
new	O
viruses	O
,	O
such	O
as	O
the	O
SARS	B-DISO
virus	O
and	O
the	O
avian	B-DISO
influenza	I-DISO
virus	O
,	O
the	O
importance	O
of	O
investigations	O
on	O
the	O
genetic	O
basis	O
of	O
viral	B-DISO
infections	I-DISO
becomes	O
clear	O
.	O

ABSTRACT	O
:	O
A	O
new	O
Coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
the	O
aetiological	O
agent	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

The	O
proportions	O
of	O
patients	O
requiring	O
ventilatory	O
care	O
and	O
mortality	O
in	O
the	O
diarrhea	B-DISO
group	O
were	O
8	O
.	O
2	O
%	O
and	O
2	O
%,	O
respectively	O
,	O
which	O
were	O
significantly	O
lower	O
than	O
those	O
in	O
the	O
non	O
-	O
diarrhea	B-DISO
group	O
(	O
27	O
.	O
6	O
%	O
and	O
16	O
.	O
2	O
%,	O
P	O
<	O
0	O
.	O
005	O
).	O

A	O
total	O
of	O
20	O
.	O
4	O
%	O
of	O
SARS	B-DISO
patients	O
had	O
the	O
complication	B-DISO
of	O
diarrhea	B-DISO
after	O
hospital	O
admission	O
.	O

SARS	B-DISO
patients	O
with	O
an	O
initially	O
normal	O
chest	O
X	O
-	O
ray	O
study	O
developed	O
infiltrates	B-DISO
at	O
a	O
mean	O
of	O
5	O
+/-	O

Pleural	B-DISO
effusion	I-DISO
was	O
not	O
present	O
in	O
any	O
SARS	B-DISO
patients	O
but	O
was	O
seen	O
in	O
6	O
of	O
26	O
non	O
-	O
SARS	B-DISO
cases	O
(	O
p	O
<	O
0	O
.	O
0001	O
).	O

Initial	O
lymphopenia	B-DISO
,	O
thrombocytopenia	O
,	O
and	O
elevated	O
lactate	O
dehydrogenase	O
were	O
all	O
more	O
common	O
in	O
SARS	B-DISO
than	O
non	O
-	O
SARS	B-DISO
(	O
p	O
<	O
0	O
.	O
0001	O
).	O

ABSTRACT	O
:	O
The	O
immunogenicity	O
of	O
a	O
candidate	O
-	O
inactivated	O
vaccine	O
prepared	O
from	O
SARS	B-DISO
-	O
CoV	O
F69	O
strain	O
was	O
evaluated	O
in	O
Balb	O
/	O
c	O
mice	O
.	O

The	O
potent	O
adjuvanticity	O
of	O
rOv	O
-	O
ASP	O
-	O
1	O
was	O
confirmed	O
in	O
mice	O
vaccinated	O
with	O
a	O
37	O
-	O
mer	O
peptide	O
from	O
the	O
S	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
an	O
HIV	B-DISO
-	O
1	O
gp120	O
-	O
CD4	O
chimeric	O
polypeptide	O
antigen	O
.	O

These	O
results	O
suggest	O
that	O
MBL	O
contributes	O
to	O
the	O
first	O
-	O
line	O
host	O
defense	O
against	O
SARS	B-DISO
-	O
CoV	O
and	O
that	O
MBL	B-DISO
deficiency	I-DISO
is	O
a	O
susceptibility	O
factor	O
for	O
acquisition	O
of	O
SARS	B-DISO
.	O

TITLE	O
:	O
[	O
Detection	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
probable	O
patients	O
'	O
virus	O
RNA	O
in	O
Hangzhou	O
by	O
using	O
a	O
two	O
loci	O
and	O
a	O
modified	O
nested	O
real	O
-	O
time	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
].	O

The	O
results	O
of	O
the	O
hemi	O
-	O
nested	O
RT	O
-	O
PCR	O
,	O
the	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
and	O
the	O
modified	O
nested	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
in	O
the	O
3	O
SARS	B-DISO
patients	O
were	O
consistent	O
with	O
the	O
one	O
of	O
the	O
nested	O
RT	O
-	O
PCR	O
.	O

RESULTS	O
:	O
Two	O
positives	O
were	O
found	O
in	O
the	O
3	O
SARS	B-DISO
probable	O
patients	O
,	O
and	O
none	O
positive	O
in	O
4	O
SARS	B-DISO
suspect	O
patients	O
and	O
other	O
27	O
patients	O
with	O
fever	O
,	O
using	O
the	O
nested	O
RT	O
-	O
PCR	O
.	O

Among	O
these	O
cases	O
,	O
664	O
cases	O
were	O
classified	O
as	O
probable	O
SARS	B-DISO
based	O
on	O
the	O
clinical	O
case	O
definitions	O
and	O
346	O
had	O
a	O
positive	O
result	O
for	O
the	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
).	O

The	O
poor	O
prognostic	O
factors	O
are	O
preponderance	O
of	O
male	O
sex	O
,	O
alcohol	B-DISO
dependence	I-DISO
,	O
age	O
group	O
>	O
50	O
years	O
,	O
MODS	B-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
presence	O
of	O
acidosis	B-DISO
and	O
need	O
for	O
mechanical	O
ventilation	O
.	O

The	O
determinants	O
of	O
health	O
-	O
be	O
they	O
a	O
SARS	B-DISO
virus	O
or	O
a	O
predilection	O
for	O
fatty	O
foods	O
-	O
have	O
joined	O
us	O
in	O
our	O
global	O
mobility	O
.	O

ABSTRACT	O
:	O
Three	O
multiplex	O
hemi	O
-	O
nested	O
RT	O
-	O
PCR	O
assays	O
were	O
developed	O
to	O
detect	O
simultaneously	O
12	O
RNA	O
respiratory	O
viruses	O
:	O
influenza	B-DISO
viruses	O
A	O
,	O
B	O
and	O
C	O
,	O
human	O
respiratory	O
syncytial	O
virus	O
(	O
hRSV	O
),	O
human	O
metapneumovirus	O
(	O
hMPV	O
),	O
parainfluenza	B-DISO
virus	O
types	O
1	O
-	O
4	O
(	O
PIV	O
-	O
1	O
,	O
-	O
2	O
,	O
-	O
3	O
and	O
-	O
4	O
),	O
human	O
coronavirus	O
OC43	O
and	O
229E	O
(	O
HCoV	O
)	O
and	O
rhinovirus	O
(	O
hRV	O
).	O

TITLE	O
:	O
Effects	O
of	O
cold	B-DISO
storage	O
on	O
detection	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
in	O
chicken	O
carcasses	O
and	O
local	O
antibodies	O
in	O
tracheal	O
washes	O
.	O

Free	O
chlorine	O
was	O
found	O
to	O
inactivate	O
SARS	B-DISO
-	O
CoV	O
better	O
than	O
chlorine	O
dioxide	O
.	O

ABSTRACT	O
:	O
SARS	B-DISO
-	O
CoV	O
is	O
a	O
newly	O
identified	O
coronavirus	O
that	O
causes	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

APHS	O
did	O
not	O
affect	O
the	O
replication	O
of	O
feline	O
immunodeficiency	B-DISO
virus	O
,	O
HIV	B-DISO
-	O
2	O
and	O
a	O
HIV	B-DISO
-	O
1	O
strain	O
resistant	O
to	O
non	O
-	O
nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
(	O
NNRTI	O
).	O

Chemokines	O
are	O
important	O
inflammatory	O
mediators	O
and	O
regulate	O
disease	O
due	O
to	O
viral	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Prediction	O
of	O
smallpox	B-DISO
outbreak	O
and	O
evaluation	O
of	O
control	O
-	O
measure	O
policy	O
in	O
Japan	O
,	O
using	O
a	O
mathematical	O
model	O
.	O

Concerning	O
the	O
important	O
parameters	O
,	O
such	O
as	O
the	O
number	O
of	O
initial	O
-	O
exposure	O
cases	O
,	O
R0	O
(	O
infectious	B-DISO
power	O
,	O
or	O
natural	O
history	O
)	O
and	O
,	O
the	O
starting	O
day	O
of	O
intervention	O
after	O
the	O
initial	O
exposure	O
,	O
we	O
checked	O
the	O
robustness	O
of	O
our	O
conclusions	O
by	O
sensitivity	O
analysis	O
.	O

Except	O
for	O
two	O
,	O
all	O
other	O
patients	O
improved	O
after	O
aggressive	B-DISO
blood	O
transfusions	O
.	O

Except	O
for	O
two	O
,	O
all	O
other	O
patients	O
improved	O
after	O
aggressive	B-DISO
blood	O
transfusions	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
human	O
monoclonal	O
antibody	O
80R	O
for	O
immunoprophylaxis	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
by	O
an	O
animal	O
study	O
,	O
epitope	O
mapping	O
,	O
and	O
analysis	O
of	O
spike	O
variants	O
.	O

We	O
propose	O
that	O
by	O
establishing	O
the	O
susceptibility	O
and	O
resistance	O
profiles	O
of	O
newly	O
emerging	O
SARS	B-DISO
-	O
CoVs	O
through	O
early	O
S1	O
genotyping	O
of	O
the	O
core	O
180	O
-	O
amino	O
-	O
acid	O
neutralizing	O
epitope	O
of	O
80R	O
,	O
an	O
effective	O
immunoprophylaxis	O
strategy	O
with	O
80R	O
should	O
be	O
possible	O
in	O
an	O
outbreak	O
setting	O
.	O

These	O
results	O
show	O
that	O
microglia	O
express	O
functional	O
MHVR	O
that	O
mediates	O
JHMV	O
infection	B-DISO
.	O

TITLE	O
:	O
Chemokine	O
up	O
-	O
regulation	O
in	O
SARS	B-DISO
-	O
coronavirus	O
-	O
infected	O
,	O
monocyte	O
-	O
derived	O
human	O
dendritic	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
focused	O
on	O
dendritic	O
cells	O
(	O
DCs	B-DISO
)	O
which	O
play	O
important	O
roles	O
in	O
linking	O
the	O
innate	O
and	O
adaptive	O
immunity	O
.	O

There	O
was	O
impairment	B-DISO
of	O
HRQoL	O
at	O
6	O
months	O
.	O

The	O
daily	O
mortality	O
of	O
SARS	B-DISO
might	O
be	O
associated	O
with	O
certain	O
air	O
pollutants	O
in	O
Beijing	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
SARS	B-DISO
coronavirus	O
(	O
SARS_CoV	O
)	O
is	O
a	O
major	O
structural	O
component	O
of	O
virions	O
,	O
which	O
appears	O
to	O
be	O
a	O
multifunctional	O
protein	O
involved	O
in	O
viral	O
RNA	O
replication	O
and	O
translation	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
an	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
caused	O
by	O
a	O
novel	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
).	O

The	O
clinical	O
characteristics	O
are	O
high	O
fever	O
,	O
rapidly	O
progressive	O
diffuse	O
pneumonitis	B-DISO
and	O
respiratory	B-DISO
distress	I-DISO
.	O

Peptides	O
corresponding	O
to	O
six	O
regions	O
in	O
the	O
S1	O
(	O
Sp1	O
-	O
Sp6	O
),	O
one	O
in	O
the	O
S2	O
(	O
Sp7	O
)	O
and	O
four	O
in	O
the	O
N	O
protein	O
(	O
Np1	O
-	O
Np4	O
)	O
were	O
synthesized	O
and	O
coupled	O
to	O
either	O
diphtheria	B-DISO
toxoid	O
(	O
dt	O
)	O
or	O
biotin	O
(	O
bt	O
).	O

TITLE	O
:	O
Development	O
and	O
evaluation	O
of	O
a	O
multitarget	O
real	O
-	O
time	O
Taqman	O
reverse	O
transcription	O
-	O
PCR	O
assay	O
for	O
detection	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
and	O
surveillance	O
for	O
an	O
apparently	O
related	O
coronavirus	O
found	O
in	O
masked	O
palm	O
civets	O
.	O

It	O
could	O
be	O
an	O
alternative	O
for	O
early	O
and	O
rapid	O
diagnosis	O
,	O
should	O
SARS	B-DISO
return	O
in	O
the	O
future	O
.	O

Monocyte	O
-	O
associated	O
FCoV	O
viremia	B-DISO
was	O
demonstrated	O
by	O
immunohistology	O
,	O
RNA	O
in	O
situ	O
hybridization	O
,	O
and	O
electron	O
micropscopy	O
.	O

These	O
results	O
confirm	O
FIP	B-DISO
as	O
a	O
monocyte	O
-	O
triggered	O
systemic	B-DISO
disease	I-DISO
and	O
demonstrate	O
the	O
central	O
role	O
of	O
activated	O
monocytes	O
in	O
FIP	B-DISO
vasculitis	B-DISO
.	O

Full	O
recovery	O
of	O
the	O
syndrome	B-DISO
was	O
observed	O
in	O
6	O
days	O
,	O
while	O
chest	O
X	O
-	O
ray	O
returned	O
to	O
normal	O
findings	O
within	O
4	O
days	O
.	O

TRALI	B-DISO
syndrome	B-DISO
is	O
an	O
immune	O
-	O
mediated	O
transfusion	B-DISO
reaction	I-DISO
which	O
can	O
cause	O
severe	O
complications	O
or	O
even	O
death	O
.	O

TRALI	B-DISO
remains	O
a	O
clinical	O
diagnosis	O
in	O
an	O
appropriate	O
setting	O
,	O
supported	O
by	O
serologic	O
studies	O
if	O
these	O
are	O
available	O
.	O

The	O
competitive	O
blocking	B-DISO
ELISA	O
format	O
showed	O
the	O
highest	O
sensitivity	O
,	O
allowing	O
detection	O
of	O
10	O
(	O
3	O
)	O
TCID50	O
TGEV	O
/	O
ml	O
in	O
culture	O
medium	O
.	O

Ninety	O
-	O
nine	O
porcine	O
field	O
faecal	O
samples	O
obtained	O
from	O
37	O
herds	O
affected	O
with	O
diarrhoea	B-DISO
were	O
examined	O
,	O
and	O
various	O
TGEV	O
levels	O
were	O
found	O
in	O
nine	O
samples	O
from	O
six	O
herds	O
.	O

The	O
relationship	O
between	O
incidence	O
of	O
TGEV	O
gastroenteritis	B-DISO
and	O
the	O
spread	O
of	O
porcine	O
respiratory	O
coronavirus	B-DISO
infection	I-DISO
in	O
pig	O
farms	O
is	O
discussed	O
.	O

Being	O
the	O
Ophthalmology	O
Department	O
of	O
the	O
only	O
hospital	O
in	O
the	O
world	O
that	O
has	O
just	O
gone	O
through	O
the	O
largest	O
outbreak	O
of	O
SARS	B-DISO
,	O
we	O
would	O
like	O
to	O
share	O
our	O
strategy	O
,	O
measures	O
,	O
and	O
experiences	O
of	O
preventing	O
contracting	O
or	O
spreading	O
of	O
SARS	B-DISO
infection	B-DISO
as	O
an	O
infection	B-DISO
control	O
model	O
.	O

ABSTRACT	O
:	O
A	O
new	O
disease	O
,	O
the	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
caused	O
by	O
the	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
emerged	O
at	O
the	O
beginning	O
of	O
2003	O
and	O
rapidly	O
spread	O
throughout	O
the	O
world	O
.	O

Since	O
2002	O
,	O
all	O
recipients	O
of	O
lung	O
and	O
heart	O
-	O
lung	O
transplantation	O
at	O
our	O
institution	O
have	O
been	O
routinely	O
investigated	O
for	O
GERD	B-DISO
.	O

Of	O
10	O
patients	O
tested	O
,	O
2	O
had	O
severe	O
GERD	B-DISO
(	O
Ft	O
>	O
20	O
%),	O
5	O
had	O
moderate	O
GERD	B-DISO
(	O
Ft	O
10	O
-	O
20	O
%),	O
2	O
had	O
mild	O
GERD	B-DISO
(	O
Ft	O
5	O
-	O
10	O
%),	O
and	O
1	O
had	O
no	O
GERD	B-DISO
.	O

All	O
patients	O
with	O
episodes	O
of	O
rejection	O
had	O
moderate	O
to	O
severe	O
GERD	B-DISO
posttransplant	O
.	O

ABSTRACT	O
:	O
Morbidity	O
and	O
mortality	O
due	O
to	O
infectious	B-DISO
disease	I-DISO
is	O
greater	O
in	O
the	O
elderly	O
than	O
in	O
the	O
young	O
,	O
at	O
least	O
partly	O
because	O
of	O
age	O
-	O
associated	O
decreased	O
immune	O
competence	O
,	O
which	O
renders	O
individuals	O
more	O
susceptible	O
to	O
pathogens	O
.	O

ABSTRACT	O
:	O
Monoclonal	O
antibodies	O
(	O
Mabs	O
)	O
against	O
the	O
Urbani	O
strain	O
of	O
the	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
)	O
were	O
developed	O
and	O
characterized	O
for	O
reactivity	O
to	O
SARS	B-DISO
-	O
CoV	O
and	O
SARS	B-DISO
-	O
CoV	O
S	O
,	O
N	O
,	O
M	O
,	O
and	O
E	O
proteins	O
using	O
enzyme	O
-	O
linked	O
immunoabsorbent	O
(	O
ELISA	O
),	O
radioimmunoprecipitation	O
,	O
immunofluorescence	O
,	O
Western	O
Blot	O
and	O
microneutralization	O
assays	O
.	O

Twenty	O
-	O
six	O
mAbs	O
were	O
reactive	O
to	O
SARS	B-DISO
-	O
CoV	O
by	O
ELISA	O
,	O
and	O
nine	O
were	O
chosen	O
for	O
detailed	O
characterization	O
.	O

Two	O
of	O
five	O
S	O
protein	O
mAbs	O
neutralized	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
of	O
Vero	O
E6	O
cells	O
and	O
reacted	O
to	O
an	O
epitope	O
within	O
amino	O
acids	O
490	O
-	O
510	O
in	O
the	O
S	O
protein	O
.	O

The	O
results	O
suggested	O
that	O
four	O
herbal	O
extracts	O
and	O
the	O
compound	O
lycorine	O
are	O
candidates	O
for	O
the	O
development	O
of	O
new	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
drugs	O
in	O
the	O
treatment	O
of	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
One	O
of	O
the	O
most	O
challenging	O
problems	O
in	O
critical	O
care	O
medicine	O
is	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
the	O
most	O
severe	O
form	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

To	O
determine	O
further	O
the	O
time	O
course	O
of	O
recovery	O
of	O
lung	B-DISO
inflammation	I-DISO
,	O
we	O
investigated	O
the	O
HRCT	O
and	O
inflammatory	O
profiles	O
,	O
and	O
coronavirus	O
persistence	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
of	O
12	O
patients	O
at	O
recovery	O
at	O
60	O
and	O
90	O
days	O
.	O

RESULTS	O
:	O
At	O
60	O
days	O
,	O
compared	O
to	O
normal	O
controls	O
,	O
SARS	B-DISO
patients	O
had	O
increased	O
cellularity	O
of	O
BALF	O
with	O
increased	O
alveolar	O
macrophages	O
(	O
AM	O
)	O
and	O
CD8	O
cells	O
.	O

Pulse	O
steroid	O
therapy	O
and	O
prolonged	O
fever	O
were	O
two	O
independent	O
factors	O
associated	O
with	O
delayed	O
resolution	O
of	O
pneumonitis	B-DISO
,	O
in	O
this	O
non	O
-	O
randomized	O
,	O
retrospective	O
analysis	O
.	O

TITLE	O
:	O
Change	O
in	O
infection	B-DISO
control	O
practices	O
and	O
awareness	O
of	O
hospital	O
medical	O
staff	O
in	O
the	O
aftermath	O
of	O
SARS	B-DISO
.	O

We	O
conducted	O
an	O
interview	O
survey	O
of	O
121	O
medical	O
staff	O
145	O
doctors	O
,	O
46	O
staff	O
nurses	O
and	O
30	O
medical	O
assistants	O
)	O
in	O
a	O
state	O
hospital	O
in	O
Malaysia	O
three	O
months	O
after	O
the	O
end	O
of	O
SARS	B-DISO
epidemic	O
(	O
from	O
October	O
to	O
December	O
2003	O
).	O

On	O
wearing	O
masks	O
,	O
gloves	O
,	O
and	O
aprons	O
when	O
meeting	O
potentially	O
infectious	B-DISO
patients	O
,	O
the	O
proportions	O
that	O
reported	O
an	O
increase	O
were	O
39	O
.	O
7	O
%,	O
47	O
.	O
1	O
%	O
and	O
32	O
.	O
2	O
%	O
respectively	O
.	O

Regarding	O
infection	B-DISO
isolation	O
ward	O
,	O
Infectious	B-DISO
Control	O
Nurse	O
and	O
Infection	B-DISO
Control	O
Committee	O
Chairman	O
in	O
the	O
hospital	O
,	O
the	O
proportions	O
of	O
staff	O
that	O
could	O
correctly	O
name	O
them	O
were	O
39	O
.	O
7	O
%,	O
38	O
.	O
3	O
%	O
and	O
15	O
.	O
7	O
%	O
respectively	O
.	O

TITLE	O
:	O
Media	O
effects	O
on	O
students	O
during	O
SARS	B-DISO
outbreak	O
.	O

Binding	O
of	O
both	O
cinanserin	O
and	O
its	O
hydrochloride	O
to	O
bacterially	O
expressed	O
3CLpro	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
the	O
related	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
was	O
demonstrated	O
by	O
surface	O
plasmon	O
resonance	O
technology	O
.	O

TITLE	O
:	O
Viral	O
expression	O
of	O
CCL2	O
is	O
sufficient	O
to	O
induce	O
demyelination	B-DISO
in	O
RAG1	O
-/-	O
mice	O
infected	O
with	O
a	O
neurotropic	O
coronavirus	O
.	O

Thus	O
,	O
these	O
results	O
suggest	O
that	O
the	O
minimal	O
requirement	O
for	O
demyelination	B-DISO
is	O
increased	O
expression	O
of	O
a	O
single	O
macrophage	O
-	O
attracting	O
chemokine	O
in	O
the	O
context	O
of	O
an	O
inflammatory	O
milieu	O
,	O
such	O
as	O
that	O
induced	O
by	O
a	O
viral	B-DISO
infection	I-DISO
.	O

Although	O
the	O
SARS	B-DISO
-	O
CoV	O
fusion	O
protein	O
heptad	O
repeats	O
have	O
been	O
well	O
characterized	O
,	O
the	O
fusion	O
peptide	O
has	O
yet	O
to	O
be	O
identified	O
.	O

ABSTRACT	O
:	O
A	O
new	O
SARS	B-DISO
animal	O
model	O
was	O
established	O
by	O
inoculating	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
into	O
rhesus	O
macaques	O
(	O
Macaca	O
mulatta	O
)	O
through	O
the	O
nasal	O
cavity	B-DISO
.	O

Immunological	O
,	O
molecular	O
biological	O
,	O
and	O
pathological	O
studies	O
support	O
the	O
establishment	O
of	O
this	O
SARS	B-DISO
animal	O
model	O
.	O

Mp	O
-	O
and	O
Dp	O
-	O
MART	O
(	O
anti	O
-	O
melanoma	B-DISO
lipopeptides	O
)	O
induce	O
strong	O
CTL	O
(	O
cytolytic	O
T	O
lymphocyte	O
)	O
response	O
.	O

TITLE	O
:	O
Characterization	O
of	O
monoclonal	O
antibody	O
against	O
SARS	B-DISO
coronavirus	O
nucleocapsid	O
antigen	O
and	O
development	O
of	O
an	O
antigen	O
capture	O
ELISA	O
.	O

Specific	O
binding	O
of	O
the	O
MAb	O
S	O
-	O
A5D5	O
to	O
both	O
purified	O
N195	O
and	O
SARS	B-DISO
CoV	O
nucleocapsid	O
antigen	O
was	O
effectively	O
inhibited	O
by	O
human	O
SARS	B-DISO
positive	O
serum	O
and	O
guinea	O
pig	O
anti	O
-	O
N195	O
serum	O
.	O

No	O
false	O
positive	O
results	O
were	O
given	O
when	O
60	O
samples	O
from	O
healthy	O
individuals	O
were	O
tested	O
,	O
and	O
no	O
cross	O
-	O
reaction	O
occurred	O
when	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
),	O
chicken	O
coronavirus	O
,	O
was	O
tested	O
.	O

In	O
this	O
study	O
,	O
we	O
selected	O
one	O
fragment	O
of	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
(	O
S1	O
-(	O
3	O
))	O
as	O
antigenic	O
determinant	O
by	O
immunoinformatics	O
.	O

We	O
established	O
one	O
hybridoma	O
cell	O
line	O
secreting	O
specific	O
mAb	O
and	O
evaluated	O
this	O
mAb	O
with	O
murine	O
leukemia	B-DISO
virus	O
pseudotyped	O
with	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
(	O
MLV	O
/	O
SARS	B-DISO
-	O
CoV	O
).	O

ABSTRACT	O
:	O
Accurate	O
assessment	O
of	O
neutralizing	O
antibody	O
activities	O
is	O
important	O
either	O
for	O
patients	O
infected	O
with	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
or	O
for	O
animals	O
and	O
volunteers	O
immunized	O
with	O
the	O
experimental	O
vaccines	O
against	O
the	O
SARS	B-DISO
associated	O
coronavirus	O
(	O
SCV	O
).	O

The	O
NRS	O
neutralization	O
assay	O
was	O
adopted	O
from	O
a	O
similar	O
system	O
used	O
for	O
detecting	O
neutralizing	O
antibody	O
responses	O
against	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
type	O
1	O
(	O
HIV	B-DISO
-	O
1	O
).	O

In	O
contrast	O
,	O
oleic	O
acid	O
caused	O
severe	O
alveolar	O
damage	O
with	O
the	O
development	O
of	O
alveolar	B-DISO
edema	I-DISO
of	O
the	O
increased	O
-	O
permeability	O
type	O
with	O
associated	O
abnormalities	O
in	O
gas	O
exchange	O
.	O

Overall	O
,	O
serum	O
samples	O
from	O
convalescent	O
patients	O
who	O
had	O
SARS	B-DISO
had	O
a	O
1	O
-	O
way	O
cross	O
-	O
reactivity	O
with	O
the	O
2	O
known	O
HCoVs	O
.	O

TITLE	O
:	O
Variation	O
analysis	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
putative	O
non	O
-	O
structural	O
protein	O
2	O
gene	O
and	O
construction	O
of	O
three	O
-	O
dimensional	O
model	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
an	O
infectious	B-DISO
disease	I-DISO
caused	O
by	O
SARS	B-DISO
-	O
CoV	O
.	O
There	O
are	O
no	O
effective	O
antiviral	O
drugs	O
for	O
SARS	B-DISO
although	O
the	O
epidemic	O
of	O
SARS	B-DISO
was	O
controlled	O
.	O

RESULTS	O
:	O
The	O
vector	O
,	O
pshRNA	O
-	O
N	O
expressing	O
shRNA	O
which	O
targeted	O
the	O
N	O
gene	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
was	O
successfully	O
constructed	O
.	O

Retrospective	O
cases	O
involving	O
801	O
patients	O
admitted	O
to	O
hospitals	O
in	O
Beijing	O
between	O
March	O
and	O
June	O
2003	O
,	O
with	O
a	O
diagnosis	O
of	O
probable	O
SARS	B-DISO
,	O
moderate	O
type	O
.	O

RESULTS	O
:	O
One	O
to	O
three	O
days	O
after	O
the	O
onset	O
of	O
SARS	B-DISO
,	O
the	O
major	O
clinical	O
symptoms	O
were	O
fever	O
(	O
in	O
88	O
.	O
14	O
%	O
of	O
patients	O
),	O
fatigue	B-DISO
,	O
headache	B-DISO
,	O
myalgia	B-DISO
,	O
arthralgia	B-DISO
(	O
25	O
-	O
36	O
%),	O
etc	O
.	O

TITLE	O
:	O
A	O
case	O
report	O
of	O
an	O
extremely	O
low	O
birthweight	O
infant	O
with	O
circulatory	B-DISO
collapse	I-DISO
accompanied	O
by	O
cerebral	B-DISO
infarction	I-DISO
after	O
the	O
acute	O
period	O
.	O

ABSTRACT	O
:	O
A	O
male	O
infant	O
(	O
gestational	O
age	O
,	O
26	O
weeks	O
and	O
1	O
day	O
;	O
birthweight	O
,	O
752	O
g	O
)	O
was	O
treated	O
for	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
and	O
thereafter	O
required	O
mechanical	O
ventilation	O
due	O
to	O
chronic	O
pulmonary	B-DISO
insufficiency	I-DISO
.	O

There	O
has	O
been	O
no	O
previous	O
report	O
of	O
a	O
case	O
accompanied	O
by	O
cerebral	B-DISO
infarction	I-DISO
.	O

More	O
than	O
90	O
%	O
of	O
the	O
SARS	B-DISO
cases	O
and	O
death	O
were	O
reported	O
from	O
China	O
.	O

SARS	B-DISO
,	O
as	O
an	O
emergency	B-DISO
of	O
Public	O
Health	O
System	O
(	O
PHS	B-DISO
),	O
alarmed	O
health	O
workers	O
throughout	O
the	O
world	O
proving	O
there	O
is	O
still	O
the	O
potential	O
for	O
an	O
epidemic	O
of	O
an	O
emerging	O
infection	B-DISO
both	O
in	O
developed	O
and	O
developing	O
areas	O
.	O

Here	O
,	O
we	O
weigh	O
the	O
economic	O
costs	O
and	O
benefits	O
associated	O
with	O
implementing	O
widespread	O
quarantine	O
in	O
Toronto	O
during	O
the	O
SARS	B-DISO
outbreaks	O
of	O
2003	O
.	O

This	O
had	O
a	O
dramatic	O
impact	O
on	O
healthcare	O
provision	O
for	O
non	O
-	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
patients	O
during	O
this	O
period	O
.	O

Coronavirus	B-DISO
infections	I-DISO
were	O
detected	O
in	O
26	O
(	O
4	O
.	O
4	O
%)	O
of	O
587	O
children	O
studied	O
;	O
15	O
(	O
2	O
.	O
6	O
%)	O
were	O
positive	O
for	O
HCoV	O
-	O
NL63	O
,	O
9	O
(	O
1	O
.	O
5	O
%)	O
were	O
positive	O
for	O
HCoV	O
-	O
OC43	O
,	O
and	O
2	O
(	O
0	O
.	O
3	O
%)	O
were	O
positive	O
for	O
HCoV	O
-	O
229E	O
.	O

1	O
,	O
524	O
mL	O
for	O
the	O
non	O
-	O
ARDS	B-DISO
group	O
(	O
P	O
=	O
.	O
079	O
),	O
and	O
by	O
the	O
fourth	O
day	O
the	O
respective	O
values	O
were	O
1	O
,	O
992	O
+/-	O

TITLE	O
:	O
Interferon	O
alfacon1	O
is	O
an	O
inhibitor	O
of	O
SARS	B-DISO
-	O
corona	O
virus	O
in	O
cell	O
-	O
based	O
models	O
.	O

ABSTRACT	O
:	O
The	O
activity	O
of	O
inosine	O
-	O
5	O
'-	O
monophosphate	O
dehydrogenase	O
(	O
IMPDH	O
)	O
inhibitors	O
,	O
mizoribine	O
and	O
ribavirin	O
,	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
was	O
determined	O
by	O
plaque	B-DISO
reduction	O
and	O
yield	O
reduction	O
assays	O
.	O

Mizoribine	O
and	O
ribavirin	O
selectively	O
inhibited	O
replication	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
50	O
%	O
inhibitory	O
concentration	O
(	O
IC50	O
)	O
of	O
mizoribine	O
for	O
SARS	B-DISO
-	O
CoV	O
Frankfurt	O
-	O
1	O
and	O
SARS	B-DISO
-	O
CoV	O
HKU39849	O
,	O
as	O
determined	O
by	O
plaque	B-DISO
reduction	O
was	O
3	O
.	O
5	O
microg	O
/	O
ml	O
and	O
16	O
microg	O
/	O
ml	O
,	O
respectively	O
,	O
and	O
the	O
IC50	O
of	O
ribavirin	O
for	O
SARS	B-DISO
-	O
CoV	O
Frankfurt	O
-	O
1	O
and	O
SARS	B-DISO
-	O
CoV	O
HKU39849	O
was	O
20	O
microg	O
/	O
ml	O
and	O
80	O
microg	O
/	O
ml	O
,	O
while	O
the	O
50	O
%	O
cytotoxic	O
concentration	O
of	O
mizoribine	O
and	O
ribavirin	O
for	O
Vero	O
E6	O
cells	O
exceeded	O
200	O
microg	O
/	O
ml	O
.	O

In	O
a	O
yield	O
reduction	O
assay	O
,	O
mizoribine	O
(	O
10	O
microg	O
/	O
ml	O
)	O
and	O
ribavirin	O
(	O
40	O
microg	O
/	O
ml	O
)	O
inhibited	O
the	O
replication	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
reduced	O
the	O
infectious	B-DISO
SARS	B-DISO
-	O
CoV	O
titers	O
to	O
one	O
-	O
tenth	O
or	O
less	O
.	O

ABSTRACT	O
:	O
SARS	B-DISO
coronavirus	O
has	O
been	O
identified	O
as	O
the	O
cause	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

A	O
blind	B-DISO
-	O
test	O
of	O
both	O
peripheral	O
blood	O
and	O
sputum	O
specimens	O
lead	O
to	O
the	O
positive	O
detection	O
of	O
SARS	B-DISO
-	O
CoV	O
in	O
31	O
out	O
of	O
34	O
patients	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
gene	O
chip	O
-	O
based	O
molecular	O
test	O
is	O
specific	O
for	O
SARS	B-DISO
-	O
CoV	O
and	O
allows	O
early	O
detection	O
of	O
patients	O
with	O
SARS	B-DISO
with	O
detection	O
rate	O
about	O
8	O
%	O
higher	O
than	O
the	O
single	O
PCR	O
test	O
when	O
the	O
sputum	O
sample	O
is	O
available	O
.	O

The	O
current	O
study	O
was	O
undertaken	O
to	O
clarify	O
whether	O
furosemide	O
attenuates	O
the	O
inflammatory	B-DISO
response	I-DISO
by	O
changing	O
the	O
epidermal	O
growth	O
factor	O
level	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
.	O

In	O
some	O
of	O
these	O
patients	O
,	O
the	O
clinical	O
course	O
can	O
progress	O
relentlessly	O
to	O
septic	B-DISO
shock	I-DISO
and	O
/	O
or	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
(	O
MODS	B-DISO
).	O

Measures	O
to	O
prevent	O
epidemic	O
VAP	O
include	O
rigorous	O
disinfection	O
of	O
respiratory	O
equipment	O
and	O
bronchoscopes	O
,	O
and	O
infection	B-DISO
-	O
control	O
measures	O
to	O
prevent	O
contamination	O
of	O
medical	O
aerosols	O
.	O

Case	O
studies	O
of	O
two	O
residents	O
who	O
lived	O
in	O
Block	O
E	O
,	O
the	O
heart	O
of	O
the	O
SARS	B-DISO
epidemic	O
at	O
AG	O
,	O
complement	O
the	O
survey	O
data	O
.	O

While	O
recognizing	O
the	O
intrinsically	O
stigmatizing	O
nature	O
of	O
public	O
health	O
measures	O
to	O
control	O
SARS	B-DISO
,	O
we	O
recommend	O
that	O
a	O
consistent	O
inter	O
-	O
sectoral	O
approach	O
is	O
needed	O
to	O
minimize	O
stigma	O
and	O
to	O
make	O
an	O
effective	O
health	O
response	O
to	O
future	O
outbreaks	O
.	O

ABSTRACT	O
:	O
In	O
light	O
of	O
the	O
finding	O
of	O
a	O
previously	O
unknown	O
coronavirus	O
as	O
the	O
aetiology	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
it	O
is	O
probable	O
that	O
other	O
coronaviruses	O
,	O
than	O
those	O
recognized	O
to	O
date	O
,	O
are	O
circulating	O
in	O
animal	O
populations	O
.	O

Lessons	O
need	O
to	O
be	O
learned	O
from	O
the	O
SARS	B-DISO
epidemic	O
.	O

Enforced	O
implementation	O
of	O
stringent	O
droplet	O
precautions	O
during	O
the	O
SARS	B-DISO
crisis	O
should	O
be	O
maintained	O
;	O
and	O
this	O
will	O
most	O
likely	O
have	O
a	O
major	O
additional	O
impact	O
on	O
other	O
nosocomial	B-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
Persistence	O
was	O
established	O
after	O
most	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	O
died	O
.	O

G418	O
-	O
selected	O
clones	O
established	O
from	O
parent	O
Vero	O
E6	O
cells	O
,	O
which	O
were	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
neomycin	O
resistance	O
gene	O
,	O
were	O
infected	O
with	O
SARS	B-DISO
-	O
CoV	O
,	O
resulting	O
in	O
a	O
potential	O
cell	O
population	O
capable	O
of	O
persistence	O
in	O
Vero	O
E6	O
cells	O
.	O

This	O
was	O
observed	O
in	O
different	O
dimensions	O
:	O
health	O
services	O
seeking	O
,	O
adoption	O
of	O
healthier	O
lifestyle	O
,	O
spending	O
more	O
resources	O
on	O
health	O
,	O
adoption	O
of	O
good	O
personal	O
hygiene	O
,	O
mask	O
use	O
when	O
ill	B-DISO
with	O
influenza	B-DISO
,	O
and	O
avoidance	O
of	O
risk	O
behaviors	O
.	O

We	O
previously	O
isolated	O
and	O
characterized	O
SARS	B-DISO
-	O
CoV	O
and	O
SARS	B-DISO
-	O
CoV	O
-	O
like	O
viruses	O
from	O
human	O
and	O
animals	O
,	O
respectively	O
,	O
suggesting	O
that	O
SARS	B-DISO
could	O
be	O
transmitted	B-DISO
from	O
wild	O
/	O
farmed	O
animals	O
to	O
humans	O
.	O

SARS	B-DISO
-	O
CoV	O
infectivity	O
was	O
reduced	O
over	O
10	O
000	O
-	O
fold	O
through	O
pre	O
-	O
incubation	O
with	O
two	O
of	O
these	O
peptides	O
,	O
while	O
it	O
was	O
completely	O
inhibited	O
in	O
the	O
presence	O
of	O
three	O
peptides	O
.	O

Molecular	O
modelling	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
peplomer	O
suggests	O
that	O
three	O
of	O
these	O
antiviral	O
peptides	O
map	O
to	O
the	O
interfaces	O
between	O
the	O
three	O
monomers	O
of	O
the	O
trimeric	O
peplomer	O
rather	O
than	O
the	O
heptad	O
repeat	O
region	O
from	O
which	O
short	O
peptides	O
are	O
known	O
to	O
inhibit	O
viral	O
entry	O
.	O

TITLE	O
:	O
Overview	O
of	O
antiviral	O
and	O
anti	O
-	O
inflammatory	O
treatment	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
In	O
2003	O
,	O
an	O
outbreak	O
of	O
a	O
novel	O
respiratory	O
virus	O
exploded	O
from	O
mainland	O
China	O
into	O
an	O
international	O
issue	O
,	O
catching	B-DISO
the	O
world	O
by	O
surprise	O
.	O

The	O
""""	O
catastrophic	O
""""	O
variant	O
of	O
the	O
antiphospholipid	B-DISO
syndrome	I-DISO
(	O
APS	B-DISO
)	O
is	O
an	O
accelerated	O
form	O
of	O
this	O
systemic	O
autoimmune	B-DISO
condition	B-DISO
which	O
results	O
in	O
multiorgan	B-DISO
failure	I-DISO
because	O
of	O
multiple	O
small	O
vessel	O
occlusions	B-DISO
.	O

There	O
were	O
no	O
differences	O
in	O
age	O
,	O
sex	O
,	O
precipitating	O
factors	O
,	O
clinical	O
manifestations	O
,	O
or	O
mortality	O
between	O
catastrophic	O
APS	B-DISO
patients	O
with	O
and	O
without	O
ARDS	B-DISO
.	O

RESULTS	O
:	O
Pulmonary	B-DISO
involvement	I-DISO
was	O
reported	O
in	O
150	O
of	O
220	O
patients	O
with	O
catastrophic	O
APS	B-DISO
(	O
68	O
%)	O
and	O
47	O
patients	O
(	O
21	O
%)	O
were	O
diagnosed	O
as	O
having	O
ARDS	B-DISO
.	O

There	O
were	O
no	O
differences	O
in	O
age	O
,	O
sex	O
,	O
precipitating	O
factors	O
,	O
clinical	O
manifestations	O
,	O
or	O
mortality	O
between	O
catastrophic	O
APS	B-DISO
patients	O
with	O
and	O
without	O
ARDS	B-DISO
.	O

We	O
have	O
previously	O
shown	O
that	O
mutants	O
of	O
A59	O
,	O
unable	O
to	O
induce	O
hepatitis	B-DISO
,	O
may	O
be	O
selected	O
by	O
persistent	B-DISO
infection	I-DISO
of	O
primary	O
glial	O
cells	O
in	O
vitro	O
.	O

Primary	O
human	O
monocyte	O
-	O
derived	O
macrophages	O
were	O
infected	O
with	O
SARS	B-DISO
-	O
CoV	O
in	O
vitro	O
.	O

The	O
gene	O
expression	O
profiles	O
of	O
macrophages	O
infected	O
with	O
SARS	B-DISO
-	O
CoV	O
,	O
human	O
coronavirus	O
229E	O
,	O
and	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
virus	O
were	O
compared	O
by	O
using	O
microarrays	O
and	O
real	O
-	O
time	O
quantitative	O
reverse	O
transcriptase	O
PCR	O
.	O

Little	O
is	O
known	O
about	O
the	O
biology	O
and	O
pathophysiology	O
of	O
the	O
novel	O
coronavirus	O
that	O
causes	O
SARS	B-DISO
.	O

TITLE	O
:	O
[	O
The	O
effects	O
of	O
4	O
laboratory	O
test	O
kits	O
in	O
early	O
detecting	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
].	O

Three	O
enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
kits	O
were	O
used	O
to	O
detect	O
SARS	B-DISO
-	O
CoV	O
IgG	O
,	O
IgM	O
and	O
N	O
protein	O
and	O
fluorescent	O
polymerase	O
chain	O
reaction	O
(	O
F	O
-	O
PCR	O
)	O
kit	O
was	O
used	O
to	O
detect	O
SARS	B-DISO
-	O
CoV	O
RNA	O
.	O

In	O
31	O
animals	O
sampled	O
in	O
January	O
5	O
2004	O
before	O
culling	O
of	O
wild	O
animals	O
at	O
Guangdong	O
Province	O
,	O
including	O
20	O
cats	O
(	O
Felis	O
catus	O
),	O
5	O
red	O
fox	O
(	O
Vulpes	O
vulpes	O
)	O
and	O
6	O
Lesser	O
rice	O
field	O
rats	O
(	O
Rattus	O
losea	O
),	O
8	O
(	O
25	O
.	O
8	O
%)	O
animals	O
were	O
tested	O
positive	O
for	O
SARS	B-DISO
-	O
CoV	O
like	O
virus	O
by	O
RT	O
-	O
PCR	O
methods	O
,	O
of	O
which	O
4	O
cats	O
,	O
3	O
red	O
fox	O
and	O
one	O
Lesser	O
rice	O
field	O
rats	O
were	O
included	O
.	O

RESULTS	O
:	O
In	O
31	O
animals	O
sampled	O
in	O
January	O
5	O
2004	O
before	O
culling	O
of	O
wild	O
animals	O
at	O
Guangdong	O
Province	O
,	O
including	O
20	O
cats	O
(	O
Felis	O
catus	O
),	O
5	O
red	O
fox	O
(	O
Vulpes	O
vulpes	O
)	O
and	O
6	O
Lesser	O
rice	O
field	O
rats	O
(	O
Rattus	O
losea	O
),	O
8	O
(	O
25	O
.	O
8	O
%)	O
animals	O
were	O
tested	O
positive	O
for	O
SARS	B-DISO
-	O
CoV	O
like	O
virus	O
by	O
RT	O
-	O
PCR	O
methods	O
,	O
of	O
which	O
4	O
cats	O
,	O
3	O
red	O
fox	O
and	O
one	O
Lesser	O
rice	O
field	O
rats	O
were	O
included	O
.	O

PTH	O
positive	O
cells	O
were	O
seen	O
in	O
the	O
normal	O
thyroid	O
glands	O
and	O
those	O
of	O
the	O
SARS	B-DISO
patients	O
with	O
a	O
slightly	O
weaker	O
intensity	O
of	O
reaction	O
,	O
however	O
,	O
with	O
significant	O
difference	O
in	O
IOD	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
without	O
significant	O
difference	O
in	O
mean	O
slight	O
absorption	O
MOD	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

Health	O
care	O
practitioners	O
need	O
to	O
be	O
aware	O
of	O
infection	B-DISO
control	O
measures	O
to	O
prevent	O
the	O
spread	O
of	O
SARS	B-DISO
.	O

TITLE	O
:	O
The	O
effects	O
of	O
disease	O
severity	O
,	O
use	O
of	O
corticosteroids	O
and	O
social	O
factors	O
on	O
neuropsychiatric	O
complaints	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
at	O
acute	O
and	O
convalescent	O
phases	O
.	O

Self	O
-	O
administered	O
mail	O
questionnaires	O
survey	O
to	O
308	O
SARS	B-DISO
patients	O
after	O
discharging	O
from	O
hospital	O
.	O

Severity	O
of	O
symptoms	O
,	O
corticosteroids	O
and	O
social	O
factors	O
explained	O
about	O
half	O
of	O
the	O
variances	O
(	O
R	O
(	O
2	O
)	O
=	O
52	O
)	O
in	O
anxiety	O
-	O
depression	B-DISO
at	O
acute	O
phase	O
and	O
33	O
%	O
at	O
convalescent	O
phase	O
.	O

TITLE	O
:	O
Pulmonary	B-DISO
artery	I-DISO
thrombosis	I-DISO
in	O
a	O
patient	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

Its	O
mode	O
(	O
intermittent	O
or	O
low	O
-	O
flow	O
continuous	O
)	O
was	O
determined	O
by	O
the	O
severity	O
of	O
renal	B-DISO
failure	I-DISO
and	O
the	O
general	O
condition	B-DISO
of	O
patients	O
.	O

Twenty	O
patients	O
(	O
46	O
.	O
51	O
%)	O
were	O
diagnosed	O
as	O
having	O
ARDS	B-DISO
based	O
on	O
the	O
lung	O
injury	O
score	O
,	O
while	O
23	O
patients	O
(	O
53	O
.	O
48	O
%)	O
were	O
diagnosed	O
with	O
acute	O
lung	O
injury	O
.	O

TRALI	B-DISO
is	O
characterized	O
by	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
and	O
non	O
-	O
cardiogenic	O
lung	B-DISO
oedema	I-DISO
developing	O
during	O
,	O
or	O
within	O
6	O
h	O
of	O
,	O
transfusion	O
.	O

By	O
virtue	O
of	O
its	O
morbidity	O
and	O
mortality	O
,	O
TRALI	B-DISO
has	O
become	O
one	O
of	O
the	O
most	O
serious	O
current	O
complications	O
of	O
transfusion	O
.	O

RESULTS	O
:	O
TRALI	B-DISO
is	O
characterized	O
by	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
and	O
non	O
-	O
cardiogenic	O
lung	B-DISO
oedema	I-DISO
developing	O
during	O
,	O
or	O
within	O
6	O
h	O
of	O
,	O
transfusion	O
.	O

TITLE	O
:	O
Serum	O
C	O
-	O
reactive	O
protein	O
elevation	O
predicts	O
poor	O
clinical	O
outcome	O
in	O
patients	O
with	O
distal	O
type	O
acute	B-DISO
aortic	I-DISO
dissection	I-DISO
:	O
association	O
with	O
the	O
occurrence	O
of	O
oxygenation	O
impairment	B-DISO
.	O

Systemic	O
activation	O
of	O
the	O
inflammatory	O
system	O
after	O
aortic	O
injury	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
oxygenation	O
impairment	B-DISO
.	O

TITLE	O
:	O
SARS	B-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
the	O
safety	O
of	O
a	O
solvent	O
/	O
detergent	O
(	O
S	O
/	O
D	O
)	O
treated	O
immunoglobulin	O
preparation	O
.	O

The	O
ability	O
to	O
express	O
and	O
purify	O
SARS	B-DISO
-	O
CoV	O
proteins	O
in	O
large	O
quantities	O
is	O
critical	O
for	O
basic	O
research	O
and	O
for	O
development	O
of	O
pharmaceutical	O
agents	O
.	O

This	O
study	O
not	O
only	O
first	O
made	O
a	O
human	O
neutralizing	O
antibody	O
,	O
which	O
recognized	O
an	O
epitope	O
on	O
S2	O
protein	O
like	O
natural	O
antibody	O
in	O
sera	O
,	O
but	O
also	O
may	O
help	O
us	O
to	O
better	O
understand	O
the	O
immunological	O
characteristics	O
of	O
SARS	B-DISO
protein	O
and	O
SARS	B-DISO
vaccine	O
design	O
.	O

TITLE	O
:	O
[	O
The	O
application	O
of	O
a	O
systematic	O
-	O
dynamic	O
model	O
to	O
study	O
the	O
computer	O
simulation	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
transmission	O
and	O
the	O
impact	O
of	O
control	O
measures	O
].	O

(	O
2	O
)	O
Physician	O
'	O
s	O
alertness	O
/	O
sense	O
and	O
practice	O
of	O
self	O
-	O
protection	O
on	O
SARS	B-DISO
,	O
measures	O
on	O
quarantine	O
and	O
isolation	O
to	O
the	O
patients	O
,	O
ventilation	O
and	O
disinfection	O
process	O
in	O
the	O
wards	O
appeared	O
to	O
be	O
the	O
key	O
variables	O
for	O
the	O
control	O
of	O
epidemics	O
.	O

RESULTS	O
:	O
(	O
1	O
)	O
The	O
mean	O
duration	O
between	O
disease	O
onset	O
and	O
hospital	O
admission	O
,	O
rate	O
of	O
contacts	O
of	O
each	O
infectious	B-DISO
individual	O
as	O
well	O
as	O
the	O
rate	O
of	O
contacts	O
in	O
hospital	O
of	O
each	O
infectious	B-DISO
individual	O
appeared	O
to	O
be	O
the	O
key	O
variables	O
in	O
the	O
process	O
of	O
SARS	B-DISO
transmission	O
.	O

Cluster	O
detection	O
of	O
close	O
contacts	O
of	O
SARS	B-DISO
infective	O
in	O
Beijing	O
revealed	O
the	O
spatial	O
characters	O
of	O
urban	O
population	O
flow	O
and	O
having	O
important	O
implications	O
in	O
the	O
prevention	O
and	O
control	O
of	O
this	O
communicable	B-DISO
diseases	I-DISO
.	O

The	O
predictable	O
number	O
of	O
SARS	B-DISO
cases	O
evolving	O
with	O
time	O
were	O
also	O
calculated	O
.	O

TITLE	O
:	O
[	O
Study	O
on	O
the	O
dynamics	O
of	O
IgG	O
antibody	O
in	O
311	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
].	O

RNA	O
was	O
extracted	O
and	O
nested	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
was	O
carried	O
out	O
using	O
SARS	B-DISO
-	O
CoV	O
specific	O
primers	O
.	O

RESULTS	O
:	O
Among	O
the	O
276	O
samples	O
,	O
SARS	B-DISO
-	O
CoV	O
RNA	O
was	O
detected	O
in	O
6	O
cases	O
(	O
38	O
.	O
8	O
%)	O
by	O
nested	O
RT	O
-	O
PCR	O
.	O

Capturing	O
and	O
detecting	O
antibodies	O
were	O
selected	O
by	O
pairing	O
the	O
mAbs	O
and	O
polyclonal	O
antibodies	O
one	O
by	O
one	O
and	O
an	O
antibodies	O
-	O
based	O
sandwich	O
antigen	O
capture	O
ELISA	O
was	O
used	O
for	O
detecting	O
N	O
antigen	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
Nine	O
mAbs	O
and	O
hyperimmune	O
rabbit	O
polyclonal	O
antibodies	O
,	O
specifically	O
against	O
SARS	B-DISO
-	O
CoV	O
nucleocapsid	O
protein	O
were	O
obtained	O
.	O

RESULTS	O
:	O
Nine	O
mAbs	O
and	O
hyperimmune	O
rabbit	O
polyclonal	O
antibodies	O
,	O
specifically	O
against	O
SARS	B-DISO
-	O
CoV	O
nucleocapsid	O
protein	O
were	O
obtained	O
.	O

TITLE	O
:	O
Use	O
of	O
quarantine	O
in	O
the	O
control	O
of	O
SARS	B-DISO
in	O
Singapore	O
.	O

With	O
emerging	O
diseases	O
,	O
health	O
authorities	O
need	O
to	O
rethink	O
the	O
value	O
of	O
quarantine	O
to	O
reduce	O
opportunities	O
for	O
spread	O
from	O
potential	O
reservoirs	O
of	O
infection	B-DISO
.	O

Immunofluorescence	O
assay	O
(	O
IFA	O
)	O
technique	O
and	O
plaque	B-DISO
reduction	O
neutralization	O
test	O
(	O
PRNT	O
)	O
were	O
used	O
to	O
detect	O
7	O
samples	O
of	O
sera	O
of	O
4	O
newly	O
diagnosed	O
SARS	B-DISO
patients	O
collected	O
in	O
different	O
days	O
,	O
48	O
samples	O
of	O
convalescent	O
sera	O
of	O
SARS	B-DISO
patients	O
,	O
24	O
serum	O
samples	O
of	O
healthy	O
person	O
undergoing	O
physical	O
examination	O
,	O
and	O
40	O
serum	O
samples	O
from	O
non	O
-	O
SARS	B-DISO
patients	O
with	O
fever	O
by	O
double	O
blind	B-DISO
test	O
.	O

TITLE	O
:	O
Screening	O
of	O
drugs	O
by	O
FRET	O
analysis	O
identifies	O
inhibitors	O
of	O
SARS	B-DISO
-	O
CoV	O
3CL	O
protease	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
established	O
a	O
high	O
-	O
throughput	O
FRET	O
technique	O
for	O
screening	O
for	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
3CL	O
protease	O
drugs	O
.	O

ABSTRACT	O
:	O
At	O
the	O
end	O
of	O
2002	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
emerged	O
and	O
spread	O
worldwide	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
highly	O
infectious	B-DISO
disease	I-DISO
,	O
with	O
high	O
potential	O
for	O
transmission	O
to	O
close	O
contacts	O
,	O
particularly	O
among	O
healthcare	O
workers	O
.	O

Nurses	O
in	O
moderate	O
-	O
risk	O
areas	O
appeared	O
to	O
have	O
more	O
stress	B-DISO
symptoms	I-DISO
than	O
those	O
working	O
in	O
high	O
-	O
risk	O
areas	O
.	O

TITLE	O
:	O
Acute	B-DISO
quadriplegic	I-DISO
myopathy	I-DISO
in	O
a	O
16	O
-	O
month	O
-	O
old	O
child	O
.	O

The	O
results	O
show	O
that	O
these	O
assays	O
can	O
be	O
applied	O
to	O
high	O
-	O
throughput	O
screening	O
for	O
identification	O
of	O
inhibitors	O
selectively	O
active	O
against	O
SARS	B-DISO
-	O
CoV	O
.	O

TITLE	O
:	O
Emergency	B-DISO
management	O
and	O
infection	B-DISO
control	O
in	O
a	O
radiology	O
department	O
during	O
an	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

The	O
goal	O
of	O
this	O
program	O
was	O
to	O
reduce	O
the	O
infection	B-DISO
rate	O
and	O
distribute	O
materials	O
efficiently	O
in	O
the	O
department	O
.	O

TITLE	O
:	O
Genetic	O
lesions	O
within	O
the	O
3a	O
gene	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
ABSTRACT	O
:	O
A	O
series	O
of	O
frameshift	B-DISO
mutations	I-DISO
within	O
the	O
3a	O
gene	O
has	O
been	O
observed	O
in	O
culture	O
-	O
derived	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

No	O
infectious	B-DISO
SARS	B-DISO
-	O
CoV	O
contamination	O
was	O
found	O
in	O
any	O
of	O
the	O
samples	O
collected	O
,	O
but	O
the	O
nucleic	O
acid	O
of	O
SARS	B-DISO
-	O
CoV	O
could	O
be	O
detected	O
in	O
the	O
sewage	O
from	O
the	O
two	O
hospitals	O
before	O
disinfection	O
.	O

The	O
study	O
showed	O
that	O
the	O
overall	O
knowledge	O
about	O
SARS	B-DISO
and	O
control	O
measures	O
undertaken	O
was	O
low	O
(	O
mean	O
per	O
cent	O
score	O
of	O
24	O
.	O
5	O
+/-	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
use	O
and	O
perceptions	O
of	O
a	O
local	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
Extranet	O
and	O
its	O
potential	O
to	O
support	O
future	O
information	O
and	O
communication	O
applications	O
.	O

Despite	O
higher	O
rankings	O
of	O
various	O
communication	O
strategies	O
during	O
the	O
SARS	B-DISO
outbreak	O
,	O
such	O
as	O
email	O
,	O
meetings	O
,	O
teleconferences	O
,	O
and	O
other	O
web	B-DISO
sites	O
,	O
users	O
generally	O
perceived	O
a	O
local	O
Extranet	O
as	O
a	O
useful	O
support	O
for	O
the	O
dissemination	O
of	O
local	O
information	O
during	O
public	O
health	O
emergencies	B-DISO
.	O

The	O
continuing	O
danger	O
of	O
seasonal	O
recurrence	B-DISO
,	O
particularly	O
in	O
the	O
winter	O
,	O
cannot	O
be	O
ignored	O
.	O

Three	O
of	O
SARS	B-DISO
genes	O
,	O
RNA	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
),	O
spike	O
and	O
nucleocapsid	O
,	O
were	O
amplified	O
with	O
T7	O
promoter	O
-	O
flanked	O
primers	O
.	O

RdRp	O
,	O
spike	O
and	O
nucleocapsid	O
DNA	O
fragments	O
were	O
inserted	O
into	O
the	O
plasmid	O
pGL3	B-DISO
-	O
Control	O
,	O
obtained	O
plasmids	O
pGL	B-DISO
-	O
R	O
,	O
pGL	B-DISO
-	O
S	O
and	O
pGL	B-DISO
-	O
N	O
can	O
express	O
hybrid	O
mRNAs	O
luciferase	O
-	O
RdRp	O
,	O
spike	O
and	O
-	O
nucleocapsid	O
in	O
cells	O
.	O

RNase	O
III	O
-	O
prepared	O
short	O
interfering	O
RNAs	O
induce	O
robust	O
and	O
specific	O
degradation	O
of	O
SARS	B-DISO
-	O
coronavirus	O
mRNAs	O
in	O
HEK293F	O
cells	O
.	O

TITLE	O
:	O
[	O
Changes	O
in	O
pulmonary	O
function	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
patients	O
during	O
convalescent	O
period	O
].	O

The	O
laboratory	O
findings	O
of	O
the	O
4	O
cases	O
with	O
SARS	B-DISO
occurring	O
in	O
Guangzhou	O
,	O
People	O
'	O
s	O
Republic	O
of	O
China	O
,	O
in	O
2004	O
were	O
analyzed	O
and	O
compared	O
with	O
that	O
during	O
epidemic	O
.	O

RESULTS	O
:	O
Leukopenia	B-DISO
and	O
lymphocytopenia	B-DISO
were	O
seen	O
in	O
all	O
the	O
patients	O
.	O

During	O
the	O
6	O
months	O
after	O
discharge	O
,	O
the	O
titers	O
of	O
SARS	B-DISO
-	O
antibodies	O
were	O
high	O
,	O
but	O
they	O
lowered	O
along	O
with	O
passage	O
of	O
time	O
.	O

Therefore	O
,	O
it	O
is	O
necessary	O
to	O
follow	O
up	O
the	O
changes	O
in	O
the	O
levels	O
of	O
SARS	B-DISO
-	O
antibodies	O
.	O

A	O
definitive	O
contact	O
history	O
was	O
the	O
most	O
important	O
predictor	O
for	O
SARS	B-DISO
.	O

Raised	O
serum	O
lactate	O
dehydrogenase	O
concentration	O
in	O
the	O
presence	O
of	O
low	O
neutrophil	O
count	O
and	O
serum	O
creatine	O
phosphokinase	O
level	O
at	O
presentation	O
also	O
indicated	O
an	O
increased	O
likelihood	O
of	O
SARS	B-DISO
-	O
coronavirus	B-DISO
infection	I-DISO
in	O
young	O
children	O
.	O

We	O
measured	O
risk	O
perception	O
and	O
impact	O
on	O
personal	O
and	O
work	O
life	O
of	O
15	O
,	O
025	O
HCWs	O
from	O
9	O
major	O
healthcare	O
institutions	O
during	O
the	O
SARS	B-DISO
epidemic	O
in	O
Singapore	O
using	O
a	O
self	O
-	O
administered	O
questionnaire	O
and	O
Impact	O
of	O
Events	O
Scale	O
and	O
analyzed	O
the	O
results	O
with	O
bivariate	O
and	O
multivariate	O
statistics	O
.	O

From	O
10	O
,	O
511	O
valid	O
questionnaires	O
(	O
70	O
%	O
response	O
),	O
we	O
found	O
that	O
although	O
the	O
majority	O
(	O
76	O
%)	O
perceived	O
a	O
great	O
personal	O
risk	O
of	O
falling	O
ill	B-DISO
with	O
SARS	B-DISO
,	O
they	O
(	O
69	O
.	O
5	O
%)	O
also	O
accepted	O
the	O
risk	O
as	O
part	O
of	O
their	O
job	O
.	O

A	O
case	O
of	O
severe	O
TRALI	B-DISO
secondary	O
to	O
infusion	O
of	O
fresh	O
frozen	O
plasma	O
in	O
the	O
intensive	O
care	O
unit	O
is	O
discussed	O
.	O

This	O
anilide	O
is	O
a	O
competitive	O
inhibitor	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
3CL	O
protease	O
with	O
K	O
(	O
i	O
)	O
=	O
0	O
.	O
03	O
muM	O
.	O
The	O
molecular	O
docking	O
experiment	O
indicates	O
that	O
the	O
P1	O
residue	O
of	O
this	O
anilide	O
inhibitor	O
is	O
distant	O
from	O
the	O
nucleophilic	O
SH	O
of	O
Cys145	O
in	O
the	O
active	O
site	O
.	O

TITLE	O
:	O
The	O
probability	O
of	O
failing	O
in	O
detecting	O
an	O
infectious	B-DISO
disease	I-DISO
at	O
entry	O
points	O
into	O
a	O
country	O
.	O

Using	O
the	O
single	O
-	O
round	O
infection	B-DISO
assay	O
,	O
we	O
found	O
that	O
a	O
two	O
-	O
amino	O
acid	O
substitution	O
(	O
N479K	O
/	O
T487S	O
)	O
of	O
a	O
huSARS	O
-	O
CoV	O
for	O
those	O
of	O
pcSARS	O
-	O
CoV	O
almost	O
abolished	O
its	O
infection	B-DISO
of	O
human	O
cells	O
expressing	O
the	O
SARS	B-DISO
-	O
CoV	O
receptor	O
ACE2	O
but	O
no	O
effect	O
upon	O
the	O
infection	B-DISO
of	O
mouse	O
ACE2	O
cells	O
.	O

In	O
January	O
2000	O
,	O
we	O
instituted	O
a	O
protocol	O
for	O
aggressive	B-DISO
management	O
of	O
children	O
with	O
dengue	B-DISO
shock	I-DISO
syndrome	I-DISO
.	O

The	O
number	O
of	O
patients	O
with	O
upper	O
airway	O
infections	B-DISO
and	O
suicide	B-DISO
attempts	I-DISO
from	O
drug	O
overdoses	O
increased	O
,	O
but	O
not	O
statistically	O
significantly	O
.	O

ABSTRACT	O
:	O
In	O
2003	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
came	O
to	O
be	O
recognized	O
as	O
a	O
newly	O
emergent	O
form	O
of	O
disease	O
that	O
is	O
highly	O
contagious	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
perceptions	O
of	O
nurses	O
with	O
SARS	B-DISO
in	O
Hong	O
Kong	O
,	O
as	O
the	O
perceptions	O
of	O
nurses	O
who	O
have	O
suffered	B-DISO
from	O
SARS	B-DISO
have	O
not	O
been	O
studied	O
.	O

Ten	O
nurses	O
who	O
had	O
suffered	B-DISO
from	O
SARS	B-DISO
were	O
interviewed	O
,	O
either	O
face	B-DISO
-	O
to	O
-	O
face	B-DISO
or	O
by	O
telephone	O
,	O
about	O
their	O
subjective	O
experiences	O
.	O

Our	O
aim	O
was	O
to	O
explore	O
liver	O
proinflammatory	O
mediator	O
production	O
after	O
a	O
'	O
second	O
hit	O
'	O
of	O
portal	O
lipopolysaccharide	O
(	O
LPS	B-DISO
)	O
during	O
AP	O
.	O

Transplant	O
patients	O
are	O
uniquely	O
predisposed	O
to	O
emerging	O
infections	B-DISO
.	O

Total	O
RNA	O
was	O
isolated	O
from	O
the	O
lymphocytes	O
of	O
6	O
patients	O
recovered	O
from	O
SARS	B-DISO
.	O

The	O
first	O
radiographic	O
study	O
showed	O
a	O
mass	O
filling	O
the	O
whole	O
left	O
thorax	O
cage	O
causing	O
erosion	B-DISO
of	O
the	O
inferior	O
edge	O
of	O
the	O
third	O
rib	O
.	O

Computed	O
tomography	O
scan	O
confirmed	O
a	O
homogeneous	O
tumor	B-DISO
that	O
filled	O
the	O
left	O
thorax	O
and	O
displaced	O
the	O
mediastinum	O
to	O
the	O
right	O
without	O
invasion	B-DISO
.	O

On	O
immunohistochemistry	O
,	O
the	O
tumor	B-DISO
showed	O
positive	O
staining	O
for	O
vimentin	O
,	O
whereas	O
antidesmin	O
antibodies	O
and	O
S	O
-	O
100	O
protein	O
were	O
negative	O
.	O

The	O
aim	O
of	O
this	O
article	O
is	O
to	O
present	O
an	O
extremely	O
uncommon	O
case	O
of	O
neonatal	O
distress	O
caused	O
by	O
an	O
intrathoracic	O
,	O
extrapulmonary	O
myofibroblastic	B-DISO
tumor	I-DISO
.	O

TITLE	O
:	O
Nuclear	O
/	O
nucleolar	O
localization	O
properties	O
of	O
C	O
-	O
terminal	O
nucleocapsid	O
protein	O
of	O
SARS	B-DISO
coronavirus	O
.	O

TITLE	O
:	O
SARS	B-DISO
coronavirus	O
spike	O
polypeptide	O
DNA	O
vaccine	O
priming	O
with	O
recombinant	O
spike	O
polypeptide	O
from	O
Escherichia	O
coli	O
as	O
booster	O
induces	O
high	O
titer	O
of	O
neutralizing	O
antibody	O
against	O
SARS	B-DISO
coronavirus	O
.	O

S	O
-	O
peptide	O
,	O
mice	O
primed	O
with	O
oral	O
live	O
-	O
attenuated	O
S	O
.	O
typhimurium	O
that	O
contained	O
tPA	O
-	O
optimize800	O
DNA	O
vaccine	O
(	O
Salmonella	B-DISO
-	O
tPA	O
-	O
S	O
-	O
DNA	O
)	O
and	O
boosted	O
with	O
i	O
.	O
p	O
.	O

ABSTRACT	O
:	O
The	O
proteolytic	O
processing	O
of	O
polyproteins	O
by	O
the	O
3CL	O
protease	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
is	O
essential	O
for	O
the	O
viral	O
propagation	O
.	O

The	O
cell	O
-	O
based	O
assays	O
also	O
indicate	O
that	O
18c	O
is	O
a	O
nontoxic	O
anti	O
-	O
SARS	B-DISO
agent	O
with	O
an	O
EC50	O
value	O
of	O
0	O
.	O
18	O
microM	O
.	O

TITLE	O
:	O
Pulmonary	O
manifestations	O
of	O
multicentric	B-DISO
Castleman	I-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
in	O
HIV	B-DISO
infection	I-DISO
:	O
a	O
clinical	O
,	O
biological	O
and	O
radiological	O
study	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
report	O
clinical	O
,	O
radiological	O
and	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
findings	O
in	O
patients	O
with	O
pulmonary	O
manifestations	O
of	O
HIV	B-DISO
-	O
associated	O
multicentric	B-DISO
Castleman	I-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
(	O
MCD	B-DISO
).	O

Clinical	O
manifestations	O
were	O
as	O
follows	O
:	O
dyspnoea	B-DISO
(	O
nine	O
out	O
of	O
12	O
cases	O
),	O
cough	B-DISO
(	O
n	O
=	O
10	O
),	O
bilateral	O
crackles	B-DISO
(	O
n	O
=	O
10	O
),	O
together	O
with	O
high	O
fever	O
,	O
malaise	B-DISO
,	O
peripheral	B-DISO
lymphadenopathy	I-DISO
(	O
n	O
=	O
12	O
),	O
and	O
hepatosplenomegaly	B-DISO
(	O
n	O
=	O
10	O
).	O

In	O
conclusion	O
,	O
the	O
pulmonary	O
manifestation	O
of	O
HIV	B-DISO
-	O
related	O
multicentric	B-DISO
Castleman	I-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
is	O
an	O
acute	O
reticulo	O
-	O
nodular	O
interstitial	B-DISO
pneumonitis	I-DISO
,	O
associated	O
with	O
severe	O
systemic	O
symptoms	O
and	O
peripheral	B-DISO
lymphadenopathy	I-DISO
.	O

TITLE	O
:	O
New	O
approaches	O
to	O
quantifying	O
the	O
spread	O
of	O
infection	B-DISO
.	O

In	O
this	O
study	O
,	O
bioinformatics	O
methods	O
were	O
employed	O
to	O
predict	O
the	O
secondary	O
structure	O
and	O
construct	O
3	O
-	O
D	O
models	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
GD	O
strain	O
nsp5	O
.	O

TITLE	O
:	O
Short	O
-	O
term	O
effects	O
of	O
prone	O
position	O
in	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
patients	O
with	O
severe	O
acute	O
hypoxemic	O
and	O
hypercapnic	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

However	O
,	O
no	O
recombinant	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
(	O
S	O
)-	O
based	O
ELISA	O
is	O
currently	O
available	O
.	O

Results	O
indicate	O
that	O
HCWs	O
were	O
most	O
able	O
to	O
report	O
to	O
work	O
for	O
a	O
mass	O
casualty	O
incident	O
(	O
MCI	B-DISO
)	O
(	O
83	O
%),	O
environmental	O
disaster	O
(	O
81	O
%),	O
and	O
chemical	O
event	O
(	O
71	O
%)	O
and	O
least	O
able	O
to	O
report	O
during	O
a	O
smallpox	B-DISO
epidemic	O
(	O
69	O
%),	O
radiological	O
event	O
(	O
64	O
%),	O
sudden	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
(	O
64	O
%),	O
or	O
severe	O
snow	O
storm	O
(	O
49	O
%).	O

Hypocapnia	B-DISO
was	O
significantly	O
more	O
evident	O
in	O
Child	O
C	O
than	O
in	O
A	O
and	O
B	O
(	O
31	O
.	O
2	O
+/-	O
3	O
.	O
1	O
vs	O
.	O
38	O
.	O
1	O
+/-	O

To	O
identify	O
inapparent	O
SARS	B-DISO
-	O
CoV	O
infections	B-DISO
,	O
serum	O
samples	O
collected	O
from	O
health	O
care	O
workers	O
(	O
HCWs	O
)	O
in	O
Vietnam	O
were	O
screened	O
by	O
the	O
(	O
N	O
)	O
Delta	O
(	O
121	O
)	O
protein	O
-	O
based	O
ELISA	O
,	O
and	O
positive	O
samples	O
were	O
confirmed	O
by	O
a	O
virus	O
neutralization	O
test	O
.	O

Four	O
out	O
of	O
149	O
HCWs	O
were	O
identified	O
to	O
have	O
inapparent	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
in	O
Vietnam	O
,	O
indicating	O
that	O
subclinical	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
in	O
Vietnam	O
is	O
rare	O
but	O
does	O
exist	O
.	O

TITLE	O
:	O
Adverse	B-DISO
effects	I-DISO
of	O
ribavirin	O
and	O
outcome	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
experience	O
in	O
two	O
medical	O
centers	O
.	O

The	O
hemoglobin	O
began	O
decreasing	O
in	O
two	O
thirds	O
of	O
SARS	B-DISO
patients	O
(	O
32	O
of	O
44	O
patients	O
;	O
73	O
%)	O
who	O
were	O
receiving	O
ribavirin	O
3	O
days	O
after	O
therapy	O
with	O
the	O
antiviral	O
drug	O
was	O
started	O
.	O

Only	O
one	O
of	O
seven	O
SARS	B-DISO
patients	O
(	O
14	O
%)	O
who	O
was	O
not	O
receiving	O
ribavirin	O
became	O
anemic	O
,	O
but	O
this	O
individual	O
was	O
not	O
hypoxemic	O
.	O

ABSTRACT	O
:	O
The	O
efficacy	O
of	O
contact	O
tracing	O
,	O
be	O
it	O
between	O
individuals	O
(	O
e	O
.	O
g	O
.	O
sexually	B-DISO
transmitted	I-DISO
diseases	I-DISO
or	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
)	O
or	O
between	O
groups	O
of	O
individuals	O
(	O
e	O
.	O
g	O
.	O
foot	B-DISO
-	I-DISO
and	I-DISO
-	I-DISO
mouth	I-DISO
disease	I-DISO
;	O
FMD	B-DISO
),	O
is	O
difficult	O
to	O
evaluate	O
without	O
precise	O
knowledge	O
of	O
the	O
underlying	O
contact	O
structure	O
;	O
i	O
.	O
e	O
.	O
who	O
is	O
connected	O
to	O
whom	O
?	O

Motivated	O
by	O
the	O
2001	O
FMD	B-DISO
epidemic	O
in	O
the	O
UK	O
,	O
we	O
determine	O
,	O
using	O
stochastic	O
simulations	O
and	O
deterministic	O
'	O
moment	O
closure	O
'	O
models	O
of	O
disease	B-DISO
transmission	I-DISO
on	O
networks	O
of	O
premises	O
(	O
nodes	O
),	O
network	O
and	O
disease	O
properties	O
that	O
are	O
important	O
for	O
contact	O
tracing	O
efficiency	O
.	O

In	O
this	O
case	O
,	O
isolation	O
of	O
infected	O
nodes	O
is	O
the	O
dominant	O
factor	O
in	O
determining	O
disease	B-DISO
epidemic	I-DISO
size	O
and	O
duration	O
.	O

TITLE	O
:	O
A	O
crucial	O
role	O
of	O
angiotensin	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
in	O
SARS	B-DISO
coronavirus	O
-	O
induced	O
lung	O
injury	O
.	O

A	O
new	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
was	O
identified	O
as	O
the	O
SARS	B-DISO
pathogen	O
,	O
which	O
triggered	O
severe	O
pneumonia	B-DISO
and	O
acute	O
,	O
often	O
lethal	O
,	O
lung	O
failure	O
.	O

These	O
results	O
provide	O
a	O
molecular	O
explanation	O
why	O
SARS	B-DISO
-	O
CoV	O
infections	B-DISO
cause	O
severe	O
and	O
often	O
lethal	O
lung	O
failure	O
and	O
suggest	O
a	O
rational	O
therapy	O
for	O
SARS	B-DISO
and	O
possibly	O
other	O
respiratory	B-DISO
disease	I-DISO
viruses	O
.	O

Retrospective	O
analysis	O
of	O
187	O
patients	O
admitted	O
with	O
a	O
diagnosis	O
of	O
ARDS	B-DISO
over	O
the	O
previous	O
7	O
years	O
.	O

Human	B-DISO
influenza	I-DISO
A	O
consists	O
of	O
many	O
sub	O
-	O
types	O
of	O
coronaviruses	O
including	O
the	O
SARS	B-DISO
virus	O
and	O
the	O
avian	B-DISO
influenza	I-DISO
(	O
H5N1	B-DISO
)	O
that	O
are	O
all	O
variants	O
of	O
RNA	O
of	O
avian	O
coronavirus	O
.	O

There	O
is	O
an	O
urgent	O
necessity	O
of	O
improving	O
human	O
and	O
ecological	O
health	O
in	O
South	O
East	O
Asia	O
to	O
control	O
viral	B-DISO
infection	I-DISO
among	O
birds	O
,	O
mammals	O
and	O
human	O
beings	O
.	O

RESULTS	O
:	O
Salmonella	B-DISO
enterica	O
and	O
Brachyspira	O
spp	O
were	O
not	O
common	O
,	O
whereas	O
other	O
pathogens	O
such	O
as	O
canine	O
coronavirus	O
and	O
Helicobacter	O
spp	O
were	O
common	O
among	O
the	O
dogs	O
that	O
were	O
surveyed	O
.	O

Spatial	O
analysis	O
of	O
case	O
specimens	O
by	O
use	O
of	O
GIS	O
indicated	O
that	O
diarrhea	B-DISO
was	O
widespread	O
throughout	O
the	O
entire	O
shelter	O
,	O
and	O
spatial	O
statistical	O
analysis	O
revealed	O
no	O
evidence	O
of	O
spatial	O
clustering	O
of	O
case	O
specimens	O
.	O

There	O
is	O
a	O
spectrum	O
of	O
myopathic	O
changes	O
associated	O
with	O
a	O
SARS	B-DISO
infection	B-DISO
.	O

The	O
introduction	O
of	O
the	O
nucleic	O
acid	O
amplification	B-DISO
can	O
avoid	O
the	O
window	O
period	O
of	O
these	O
viral	B-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
The	O
incubation	O
period	O
of	O
SARS	B-DISO
is	O
the	O
time	O
between	O
infection	B-DISO
of	O
disease	O
and	O
onset	O
of	O
symptoms	O
.	O

ABSTRACT	O
:	O
This	O
article	O
provides	O
an	O
overview	O
of	O
pneumonia	B-DISO
as	O
a	O
high	O
-	O
incidence	O
respiratory	B-DISO
disease	I-DISO
of	O
varying	O
severity	O
in	O
the	O
21st	O
century	O
.	O

ABSTRACT	O
:	O
Based	O
on	O
the	O
genomic	O
sequence	O
of	O
SARS	B-DISO
-	O
CoV	O
strain	O
BJ101	O
,	O
antigenic	O
immunodominant	O
genes	O
coding	O
for	O
the	O
structure	O
proteins	O
of	O
SARS	B-DISO
-	O
CoV	O
were	O
predicted	O
by	O
bio	O
-	O
informatics	O
methods	O
,	O
and	O
two	O
chimeric	O
genes	O
A	O
and	O
B	O
with	O
multi	O
-	O
immunodominants	O
lined	O
up	O
by	O
Gly	O
-	O
Pro	O
-	O
Gly	O
linker	O
were	O
synthesized	O
.	O

The	O
specificity	O
of	O
monoclonal	O
antibodies	O
were	O
tested	O
with	O
a	O
commercial	O
ELISA	O
kit	O
for	O
detecting	O
antibody	O
against	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
results	O
showed	O
that	O
two	O
peptides	O
with	O
molecular	O
weights	O
of	O
34kD	O
and	O
35kD	O
expressed	O
by	O
the	O
two	O
chimeric	O
genes	O
could	O
be	O
recognized	O
by	O
SARS	B-DISO
patient	O
convalescent	O
serum	O
in	O
Western	O
blot	O
.	O

Most	O
strikingly	O
,	O
our	O
results	O
also	O
show	O
a	O
major	O
role	O
for	O
NKG2D	O
,	O
expressed	O
on	O
gammadelta	O
T	O
cells	O
,	O
in	O
the	O
demyelinating	O
process	O
with	O
in	O
vivo	O
blockade	O
of	O
NKG2D	O
interactions	O
resulting	O
in	O
a	O
60	O
%	O
reduction	O
in	O
demyelination	B-DISO
.	O

A	O
lung	O
epithelial	O
cell	O
-	O
line	O
,	O
A549	O
,	O
was	O
chosen	O
for	O
this	O
study	O
because	O
the	O
lung	O
is	O
the	O
primary	O
organ	O
infected	O
by	O
SARS	B-DISO
-	O
CoV	O
and	O
fatalities	O
resulted	O
mainly	O
from	O
pulmonary	B-DISO
complications	I-DISO
.	O

Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
as	O
a	O
component	O
of	O
MOFS	O
was	O
diagnosed	O
in	O
39	O
(	O
26	O
.	O
2	O
%)	O
patients	O
.	O

The	O
inactivated	O
SARS	B-DISO
-	O
CoV	O
vaccine	O
may	O
be	O
the	O
first	O
one	O
available	O
for	O
clinical	O
use	O
because	O
it	O
is	O
easy	O
to	O
generate	O
;	O
however	O
,	O
safety	O
is	O
the	O
main	O
concern	O
.	O

TITLE	O
:	O
Emergency	B-DISO
department	O
response	O
to	O
SARS	B-DISO
,	O
Taiwan	O
.	O

ABSTRACT	O
:	O
We	O
conducted	O
a	O
study	O
among	O
healthcare	O
workers	O
(	O
HCWs	O
)	O
exposed	O
to	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
before	O
infection	B-DISO
control	O
measures	O
were	O
instituted	O
.	O

TITLE	O
:	O
Thermal	O
aggregation	O
of	O
SARS	B-DISO
-	O
CoV	O
membrane	O
protein	O
.	O

Boiling	O
treatment	O
,	O
causing	O
the	O
aggregation	O
of	O
SARS	B-DISO
-	O
CoV	O
membrane	O
protein	O
in	O
the	O
stacking	O
gels	O
,	O
results	O
in	O
the	O
failure	O
to	O
detect	O
the	O
membrane	O
protein	O
in	O
the	O
separating	O
gels	O
.	O

However	O
,	O
SARS	B-DISO
-	O
CoV	O
membrane	O
protein	O
seems	O
to	O
be	O
more	O
sensitive	B-DISO
to	I-DISO
heat	I-DISO
treatment	O
,	O
since	O
the	O
membrane	O
protein	O
of	O
MHV	O
-	O
JHM	O
,	O
another	O
member	O
of	O
the	O
Coronaviridae	O
,	O
would	O
not	O
aggregate	O
after	O
the	O
same	O
treatment	O
.	O

Therefore	O
,	O
if	O
SARS	B-DISO
-	O
CoV	O
membrane	O
protein	O
needs	O
to	O
be	O
analyzed	O
using	O
SDS	B-DISO
-	O
PAGE	O
,	O
boiling	O
should	O
be	O
avoided	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
an	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
that	O
first	O
occurred	O
in	O
humans	O
in	O
the	O
People	O
'	O
s	O
Republic	O
of	O
China	O
in	O
November	O
2002	O
and	O
has	O
subsequently	O
spread	O
worldwide	O
.	O

RESULTS	O
:	O
A	O
real	O
-	O
time	O
quantitative	O
RT	O
-	O
PCR	O
was	O
designed	O
in	O
the	O
nsp11	O
region	O
of	O
the	O
replicase	O
1B	O
domain	O
of	O
the	O
SARS	B-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
genome	O
.	O

The	O
information	O
obtained	O
would	O
help	O
prepare	O
us	O
for	O
future	O
infectious	B-DISO
disease	I-DISO
outbreaks	O
.	O

Of	O
149	O
patients	O
,	O
97	O
%	O
had	O
heard	O
of	O
SARS	B-DISO
,	O
92	O
%	O
believed	O
SARS	B-DISO
precautions	O
necessary	O
,	O
and	O
54	O
%	O
believed	O
contracting	O
SARS	B-DISO
was	O
possible	O
despite	O
the	O
precautions	O
.	O

Most	O
(	O
94	O
%)	O
of	O
patients	O
were	O
satisfied	O
with	O
doctor	O
-	O
patient	O
interaction	O
,	O
despite	O
implementation	O
of	O
infectious	B-DISO
disease	I-DISO
prevention	O
measures	O
.	O

Chest	O
radiograph	O
showed	O
bilateral	O
alveolar	O
infiltrates	B-DISO
.	O

Twenty	O
-	O
six	O
of	O
27	O
SARS	B-DISO
patients	O
and	O
5	O
of	O
18	O
healthy	O
controls	O
had	O
strongly	O
stained	O
columnar	O
epithelia	O
of	O
the	O
bronchiole	O
,	O
especially	O
the	O
lumen	O
border	O
of	O
the	O
epithelia	O
?	O
the	O
difference	O
between	O
two	O
groups	O
was	O
significant	O
.	O

The	O
simple	O
nested	O
RT	O
-	O
PCR	O
method	O
was	O
a	O
rapid	O
,	O
efficient	O
and	O
sensitive	O
one	O
for	O
SARS	B-DISO
early	O
diagnosis	O
.	O

CONCLUSIONS	O
:	O
The	O
simple	O
nested	O
RT	O
-	O
PCR	O
method	O
was	O
a	O
rapid	O
,	O
efficient	O
and	O
sensitive	O
one	O
for	O
SARS	B-DISO
early	O
diagnosis	O
.	O

TITLE	O
:	O
An	O
update	O
on	O
aspects	O
of	O
viral	O
gastrointestinal	B-DISO
diseases	I-DISO
of	O
dogs	O
and	O
cats	O
.	O

Although	O
parvoviruses	O
,	O
coronaviruses	O
and	O
retroviruses	O
are	O
the	O
most	O
important	O
known	O
viral	O
causes	O
of	O
canine	O
and	O
feline	O
gastrointestinal	B-DISO
disease	I-DISO
,	O
other	O
viruses	O
play	O
a	O
role	O
.	O

We	O
retrospectively	O
analyzed	O
all	O
patients	O
who	O
attended	O
an	O
Emergency	B-DISO
Department	O
SARS	B-DISO
screening	O
clinic	O
during	O
the	O
outbreak	O
in	O
Hong	O
Kong	O
,	O
from	O
March	O
10	O
to	O
June	O
5	O
,	O
2003	O
.	O

In	O
this	O
study	O
,	O
the	O
development	O
of	O
autoantibodies	O
against	O
human	O
epithelial	O
cells	O
and	O
endothelial	O
cells	O
in	O
patients	O
with	O
SARS	B-DISO
at	O
different	O
time	O
periods	O
(	O
the	O
first	O
week	O
:	O
phase	O
I	O
,	O
1	O
month	O
after	O
the	O
disease	O
onset	O
:	O
phase	O
II	O
/	O
phase	O
III	O
)	O
were	O
investigated	O
.	O

ABSTRACT	O
:	O
A	O
consensus	O
sequence	O
of	O
the	O
Feline	O
coronavirus	O
(	O
FCoV	O
)	O
(	O
strain	O
FIPV	O
WSU	O
-	O
79	O
/	O
1146	O
)	O
genome	O
was	O
determined	O
from	O
overlapping	O
cDNA	O
fragments	O
produced	O
by	O
RT	O
-	O
PCR	O
amplification	B-DISO
of	O
viral	O
RNA	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
is	O
the	O
only	O
phosphorylated	O
structural	O
protein	O
of	O
the	O
coronavirus	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
).	O

These	O
results	O
indicated	O
that	O
VSV	O
-	O
SARS	B-DISO
-	O
St19	O
infection	B-DISO
is	O
mediated	O
by	O
SARS	B-DISO
-	O
CoV	O
-	O
S	O
protein	O
in	O
an	O
ACE2	O
-	O
dependent	O
manner	O
.	O

Recent	O
studies	O
suggest	O
that	O
SARS	B-DISO
-	O
CoV	O
is	O
zoonotic	O
and	O
may	O
have	O
a	O
broad	O
host	O
range	O
besides	O
humans	O
.	O

ABSTRACT	O
:	O
To	O
observe	O
initial	O
radiographic	O
manifestations	O
and	O
evaluate	O
its	O
value	O
for	O
the	O
diagnosis	O
and	O
differential	O
diagnosis	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Since	O
TNF	O
-	O
alpha	O
plays	O
a	O
role	O
in	O
immune	O
-	O
mediated	O
processes	O
we	O
evaluated	O
the	O
levels	O
of	O
TNF	O
-	O
alpha	O
/	O
TNF	O
-	O
alpha	O
receptors	O
and	O
the	O
downstream	O
signaling	O
molecule	O
nitric	O
oxide	O
(	O
NO	O
)	O
during	O
disease	O
in	O
both	O
retinal	B-DISO
degeneration	I-DISO
susceptible	O
BALB	O
/	O
c	O
and	O
degeneration	B-DISO
resistant	O
CD	O
-	O
1	O
mice	O
.	O

These	O
studies	O
demonstrate	O
that	O
retinal	B-DISO
degeneration	I-DISO
following	O
viral	B-DISO
infection	I-DISO
is	O
associated	O
with	O
increased	O
release	O
of	O
TNF	O
-	O
alpha	O
/	O
TNF	O
receptors	O
combined	O
with	O
a	O
down	O
-	O
regulation	O
of	O
NO	O
.	O

Furthermore	O
they	O
suggest	O
that	O
these	O
molecules	O
are	O
involved	O
in	O
alterations	O
in	O
immune	O
response	O
leading	O
to	O
autoimmune	B-DISO
reactivity	O
.	O

In	O
addition	O
,	O
we	O
provided	O
evidence	O
for	O
evolutionary	O
reclassification	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
results	O
provide	O
important	O
insights	O
into	O
the	O
biochemical	O
properties	O
of	O
the	O
coronaviral	O
PLP	O
family	O
and	O
a	O
promising	O
therapeutic	O
way	O
to	O
fight	O
SARS	B-DISO
-	O
CoV	O
.	O

Due	O
to	O
the	O
threat	O
of	O
re	O
-	O
emergence	O
,	O
the	O
overall	O
fatality	O
rate	O
of	O
approximately	O
10	O
%,	O
and	O
the	O
rapid	O
dispersion	O
of	O
the	O
virus	O
via	O
international	O
travel	O
,	O
viable	O
vaccine	O
candidates	O
providing	O
protection	O
from	O
SARS	B-DISO
are	O
clearly	O
needed	O
.	O

We	O
evaluated	O
white	O
blood	O
cells	O
from	O
22	O
confirmed	O
SARS	B-DISO
patients	O
at	O
various	O
stages	O
of	O
the	O
disease	O
.	O

To	O
reduce	O
the	O
risk	O
of	O
nosocomial	O
cross	B-DISO
infections	I-DISO
,	O
screening	O
all	O
patients	O
and	O
visitors	O
who	O
visit	O
hospitals	O
and	O
clinics	O
for	O
fever	O
at	O
the	O
entrance	O
of	O
every	O
hospital	O
building	O
has	O
become	O
a	O
standard	O
protocol	O
in	O
Taiwan	O
during	O
the	O
SARS	B-DISO
epidemic	O
from	O
mid	O
-	O
April	O
to	O
mid	O
-	O
June	O
2003	O
.	O

The	O
findings	O
suggests	O
that	O
infrared	O
thermography	O
was	O
an	O
effective	O
and	O
reliable	O
tool	O
ideal	O
for	O
mass	O
-	O
screening	O
patients	O
with	O
fever	O
in	O
the	O
initial	O
phase	O
of	O
screening	O
for	O
SARS	B-DISO
patients	O
at	O
a	O
busy	O
hospital	O
which	O
sees	O
approximately	O
3	O
,	O
000	O
outpatients	O
every	O
weekday	O
during	O
the	O
SARS	B-DISO
epidemic	O
.	O

Taken	O
together	O
,	O
we	O
have	O
demonstrated	O
that	O
the	O
anti	O
-	O
S2	O
Abs	O
in	O
SARS	B-DISO
patient	O
sera	O
cause	O
cytotoxic	O
injury	O
as	O
well	O
as	O
enhance	O
immune	O
cell	O
adhesion	B-DISO
to	O
epithelial	O
cells	O
.	O

TITLE	O
:	O
[	O
Bacterial	B-DISO
tracheitis	I-DISO
:	O
an	O
infectious	B-DISO
cause	O
of	O
upper	B-DISO
airway	I-DISO
obstruction	I-DISO
to	O
be	O
considered	O
in	O
children	O
].	O

Four	O
children	O
had	O
a	O
history	O
of	O
acute	B-DISO
laryngotracheitis	I-DISO
,	O
one	O
had	O
Down	B-DISO
syndrome	I-DISO
and	O
another	O
had	O
interauricular	B-DISO
communication	I-DISO
.	O

Three	O
children	O
(	O
25	O
%)	O
developed	O
lobar	B-DISO
pneumonia	I-DISO
and	O
one	O
developed	O
congestive	O
cardiac	B-DISO
insufficiency	I-DISO
as	O
a	O
complication	B-DISO
of	O
bacterial	B-DISO
tracheitis	I-DISO
.	O

TITLE	O
:	O
Nucleolar	O
localization	O
of	O
non	O
-	O
structural	O
protein	O
3b	O
,	O
a	O
protein	O
specifically	O
encoded	O
by	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

TITLE	O
:	O
Early	O
open	O
thoracotomy	O
and	O
mediastinopleural	O
irrigation	O
for	O
severe	O
descending	O
necrotizing	B-DISO
mediastinitis	I-DISO
.	O

Early	O
detection	O
of	O
DNM	O
,	O
and	O
immediate	O
thoracotomy	O
and	O
irrigation	O
of	O
the	O
mediastinum	O
and	O
thoracic	B-DISO
cavity	B-DISO
,	O
are	O
recommended	O
.	O

During	O
the	O
SARS	B-DISO
outbreak	O
,	O
herbal	O
preparations	O
had	O
been	O
used	O
jointly	O
with	O
standard	O
modern	O
treatment	O
in	O
China	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
a	O
cDNA	O
encoding	O
SARS	B-DISO
-	O
CoV	O
E	O
protein	O
was	O
created	O
using	O
whole	O
gene	O
synthesis	O
.	O

ABSTRACT	O
:	O
A	O
67	O
-	O
year	O
-	O
old	O
man	O
is	O
presented	O
with	O
longstanding	O
and	O
severe	O
Darier	B-DISO
disease	I-DISO
treated	O
by	O
topical	O
antiseptics	O
and	O
potent	O
corticosteroids	O
,	O
in	O
combination	O
with	O
oral	O
glucocorticoids	O
and	O
etretinate	O
.	O

The	O
different	O
risk	O
factors	O
for	O
HSV	B-DISO
infection	I-DISO
in	O
this	O
patient	O
are	O
reviewed	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
significant	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
.	O

Humans	O
infected	O
with	O
the	O
etiological	O
agent	O
,	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
),	O
primarily	O
present	O
with	O
pneumonitis	B-DISO
but	O
may	O
also	O
develop	O
hepatic	O
,	O
gastrointestinal	O
,	O
and	O
renal	O
pathology	B-DISO
.	O

Besides	O
intensive	O
,	O
multidirectional	O
treatment	O
of	O
severe	B-DISO
sepsis	I-DISO
,	O
Xigris	O
(	O
activated	O
drotrecogin	O
alfa	O
)	O
was	O
administered	O
on	O
the	O
second	O
day	O
in	O
both	O
cases	O
.	O

During	O
treatment	O
the	O
patients	O
'	O
general	O
condition	B-DISO
and	O
respiratory	O
efficiency	O
improved	O
,	O
allowing	O
respirator	O
weaning	O
on	O
days	O
5	O
and	O
8	O
of	O
therapy	O
.	O

These	O
cases	O
of	O
severe	B-DISO
sepsis	I-DISO
and	O
immunosuppression	O
indicate	O
a	O
high	O
therapeutic	O
efficacy	O
of	O
drotrecogin	O
alfa	O
(	O
activated	O
).	O

These	O
cases	O
confirm	O
the	O
effectiveness	O
of	O
drotrecogin	O
alfa	O
in	O
severe	B-DISO
sepsis	I-DISO
as	O
part	O
of	O
multidirectional	O
therapy	O
.	O

TITLE	O
:	O
Are	O
the	O
World	O
Health	O
Organisation	O
case	O
definitions	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
sufficient	O
at	O
initial	O
assessment	O
?	O

To	O
determine	O
whether	O
nsp1	O
is	O
required	O
for	O
MHV	O
replication	O
and	O
to	O
identify	O
residues	O
critical	O
for	O
protein	O
function	O
,	O
mutant	B-DISO
viruses	O
that	O
contained	O
deletions	O
or	O
point	O
mutations	O
within	O
the	O
nsp1	O
-	O
coding	O
region	O
were	O
generated	O
and	O
assayed	O
for	O
defects	O
in	O
viral	O
replication	O
,	O
viral	O
protein	O
expression	O
,	O
protein	O
localization	O
,	O
and	O
RNA	O
synthesis	O
.	O

ABSTRACT	O
:	O
Cellular	O
attachment	O
factors	O
like	O
the	O
C	O
-	O
type	O
lectins	O
DC	O
-	O
SIGN	O
and	O
DC	O
-	O
SIGNR	O
(	O
collectively	O
referred	O
to	O
as	O
DC	O
-	O
SIGN	O
/	O
R	O
)	O
can	O
augment	O
viral	B-DISO
infection	I-DISO
and	O
might	O
promote	O
viral	O
dissemination	O
in	O
and	O
between	O
hosts	O
.	O

Monocytes	O
from	O
1	O
cat	O
were	O
resistant	O
to	O
both	O
FIPV	O
-	O
and	O
FECV	O
-	O
infection	B-DISO
.	O

In	O
CrFK	O
cells	O
,	O
FIPV	O
and	O
FECV	O
infection	B-DISO
kinetics	O
did	O
not	O
differ	O
.	O

In	O
monocytes	O
of	O
a	O
larger	O
cat	O
population	O
(	O
n	O
=	O
19	O
)	O
the	O
3	O
infection	B-DISO
patterns	O
were	O
also	O
found	O
.	O

The	O
rest	O
could	O
be	O
infected	O
with	O
FECV	O
and	O
FIPV	O
but	O
10	O
/	O
22	O
cats	O
had	O
monocytes	O
that	O
only	O
sustained	O
FIPV	O
infection	B-DISO
and	O
9	O
/	O
22	O
sustained	O
neither	O
FIPV	O
nor	O
FECV	O
infection	B-DISO
.	O

Late	O
pulmonary	B-DISO
hypertension	I-DISO
(	O
weeks	O
to	O
months	O
after	O
birth	O
)	O
is	O
increasingly	O
recognized	O
in	O
this	O
population	O
,	O
and	O
chronic	O
pulmonary	O
vascular	O
abnormalities	O
(	O
months	O
to	O
years	O
after	O
birth	O
)	O
are	O
now	O
being	O
discovered	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
discuss	O
the	O
pathophysiology	O
of	O
acute	O
,	O
late	O
,	O
and	O
chronic	O
pulmonary	B-DISO
hypertension	I-DISO
in	O
patients	O
with	O
congenital	B-DISO
diaphragmatic	I-DISO
hernia	I-DISO
.	O

The	O
role	O
of	O
enzymes	O
,	O
adhesion	B-DISO
molecules	O
,	O
neutrophils	O
,	O
fibronectin	O
and	O
various	O
inflammatory	O
mediators	O
has	O
been	O
emphasized	O
.	O

The	O
skin	O
lesions	O
were	O
caused	O
by	O
a	O
pyogranulomatous	O
-	O
necrotising	O
dermal	O
phlebitis	B-DISO
and	O
periphlebitis	B-DISO
.	O

The	O
pathogenesis	B-DISO
of	O
FIP	B-DISO
involves	O
a	O
viral	O
associated	O
,	O
disseminated	O
phlebitis	B-DISO
and	O
periphlebitis	B-DISO
which	O
can	O
arise	O
at	O
many	O
sites	O
.	O

Target	O
organs	O
frequently	O
include	O
the	O
eyes	O
,	O
abdominal	O
organs	O
,	O
pleural	O
and	O
peritoneal	O
membranes	O
,	O
and	O
central	O
nervous	B-DISO
tissues	O
,	O
but	O
cutaneous	O
lesions	O
have	O
not	O
previously	O
been	O
reported	O
.	O

ABSTRACT	O
:	O
To	O
prospectively	O
evaluate	O
lung	O
parenchyma	O
on	O
paired	O
inspiration	O
-	O
expiration	O
thin	O
-	O
section	O
computed	O
tomographic	O
(	O
CT	O
)	O
scans	O
in	O
patients	O
recovering	O
from	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

A	O
comparison	O
of	O
scores	O
for	O
the	O
serial	O
thin	O
-	O
section	O
CT	O
examinations	O
indicated	O
a	O
significant	O
reduction	O
in	O
the	O
extent	O
of	O
ground	O
-	O
glass	O
opacity	B-DISO
(	O
P	O
<	O
.	O
001	O
)	O
and	O
interstitial	O
opacity	B-DISO
(	O
P	O
<	O
.	O
001	O
)	O
but	O
not	O
in	O
that	O
of	O
air	B-DISO
trapping	I-DISO
(	O
P	O
=	O
.	O
38	O
)	O
at	O
follow	O
-	O
up	O
examination	O
.	O

At	O
initial	O
thin	O
-	O
section	O
CT	O
,	O
scores	O
for	O
ground	O
-	O
glass	O
opacity	B-DISO
,	O
interstitial	O
opacity	B-DISO
,	O
and	O
air	B-DISO
trapping	I-DISO
correlated	O
with	O
age	O
;	O
those	O
for	O
ground	O
-	O
glass	O
opacity	B-DISO
and	O
air	B-DISO
trapping	I-DISO
,	O
with	O
peak	O
C	O
-	O
reactive	O
protein	O
level	O
.	O

Four	O
(	O
6	O
.	O
7	O
%)	O
were	O
biochemically	O
hypothyroid	B-DISO
,	O
being	O
comprised	O
of	O
three	O
with	O
central	B-DISO
hypothyroidism	I-DISO
and	O
one	O
with	O
primary	B-DISO
hypothyroidism	I-DISO
.	O

ENIVD	O
presently	O
comprises	O
,	O
as	O
permanent	O
members	O
,	O
44	O
expert	O
laboratories	O
in	O
21	O
European	O
Union	O
(	O
EU	O
)	O
member	O
states	O
and	O
4	O
non	O
-	O
EU	O
countries	O
and	O
is	O
one	O
of	O
the	O
networks	O
on	O
infectious	B-DISO
diseases	I-DISO
funded	O
by	O
the	O
European	O
Commission	O
.	O

Here	O
,	O
we	O
summarise	O
the	O
data	O
generated	O
by	O
recent	O
EQA	O
activities	O
focussed	O
on	O
the	O
diagnostics	O
of	O
infections	B-DISO
with	O
hantavirus	O
,	O
dengue	B-DISO
virus	O
,	O
filovirus	O
,	O
Lassa	O
virus	O
,	O
orthopox	O
virus	O
and	O
the	O
SARS	B-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

TITLE	O
:	O
[	O
Severe	O
ARDS	B-DISO
following	O
perioperative	O
aspiration	B-DISO
of	O
gastric	O
content	O
associated	O
with	O
the	O
use	O
of	O
a	O
""""	O
ProSeal	O
""""	O
laryngeal	O
mask	O
airway	O
].	O

Prospective	O
observational	O
study	O
to	O
compare	O
PCT	B-DISO
levels	O
in	O
infected	O
and	O
uninfected	O
patients	O
.	O

PCT	B-DISO
may	O
be	O
useful	O
to	O
identify	O
severely	O
ill	B-DISO
elderly	O
patients	O
admitted	O
to	O
an	O
acute	O
geriatric	O
ward	O
but	O
not	O
to	O
discriminate	O
patients	O
with	O
infection	B-DISO
from	O
those	O
without	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
caused	O
by	O
an	O
emergent	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
for	O
which	O
there	O
is	O
currently	O
no	O
effective	O
treatment	O
.	O

These	O
findings	O
provide	O
important	O
information	O
for	O
developing	O
SARS	B-DISO
diagnostics	O
and	O
vaccines	O
.	O

In	O
this	O
article	O
,	O
the	O
authors	O
address	O
the	O
following	O
questions	O
for	O
a	O
number	O
of	O
infectious	B-DISO
disease	I-DISO
threats	O
:	O
(	O
1	O
)	O
does	O
pregnancy	O
affect	O
the	O
clinical	O
course	O
of	O
these	O
novel	O
infectious	B-DISO
diseases	I-DISO
?,	O
(	O
2	O
)	O
what	O
are	O
the	O
implications	O
for	O
prophylaxis	O
and	O
treatment	O
of	O
exposed	O
or	O
infected	O
pregnant	O
women	O
?,	O
and	O
(	O
3	O
)	O
are	O
these	O
novel	O
infectious	B-DISO
diseases	I-DISO
transmitted	B-DISO
during	O
pregnancy	O
,	O
labor	O
and	O
delivery	O
,	O
or	O
breastfeeding	O
?	O

Still	O
,	O
ARDS	B-DISO
is	O
feared	O
(	O
mortality	O
30	O
-	O
40	O
%)	O
and	O
relatively	O
frequent	O
(	O
incidence	O
between	O
13	O
.	O
5	O
per	O
100	O
,	O
000	O
to	O
75	O
per	O
100	O
,	O
000	O
).	O

This	O
review	O
therefore	O
summarizes	O
the	O
current	O
pathophysiological	O
concepts	O
underlying	O
the	O
evolution	O
of	O
acute	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
and	O
focuses	O
on	O
:	O
(	O
1	O
)	O
possible	O
reasons	O
for	O
the	O
development	O
of	O
ALI	O
/	O
ARDS	B-DISO
;	O
(	O
2	O
)	O
cellular	O
and	O
humoral	O
mediator	O
responses	O
leading	O
to	O
a	O
sustained	O
and	O
self	O
-	O
perpetuating	O
inflammation	B-DISO
of	O
the	O
lung	O
;	O
(	O
3	O
)	O
consequences	O
with	O
regard	O
to	O
fluid	O
balance	O
,	O
pulmonary	O
perfusion	O
,	O
ventilation	O
,	O
and	O
efficiency	O
of	O
gas	O
exchange	O
;	O
and	O
(	O
4	O
)	O
mechanisms	O
underlying	O
the	O
aggravating	O
complications	O
commonly	O
seen	O
in	O
ARDS	B-DISO
,	O
especially	O
ventilator	O
-	O
associated	O
lung	O
injury	O
,	O
ventilator	B-DISO
-	I-DISO
associated	I-DISO
pneumonia	I-DISO
,	O
and	O
lung	B-DISO
fibrosis	I-DISO
.	O

In	O
the	O
mid	O
-	O
1970s	O
,	O
the	O
development	O
of	O
the	O
sheep	O
model	O
of	O
ARDS	B-DISO
and	O
later	O
,	O
the	O
porcine	O
model	O
,	O
led	O
to	O
the	O
discovery	O
of	O
a	O
wide	O
variety	O
of	O
inflammatory	O
lipid	O
mediators	O
,	O
cytokines	O
,	O
and	O
proteases	O
,	O
to	O
name	O
but	O
a	O
few	O
.	O

Recognition	O
of	O
the	O
presence	O
of	O
such	O
highly	O
toxic	O
mediators	O
associated	O
with	O
the	O
development	O
of	O
ARDS	B-DISO
has	O
led	O
to	O
numerous	O
potential	O
targets	O
for	O
drug	O
development	O
toward	O
therapeutic	O
intervention	O
.	O

Over	O
the	O
last	O
decade	O
,	O
a	O
collection	O
of	O
new	O
studies	O
with	O
improved	O
methodology	O
and	O
novel	O
questions	O
has	O
improved	O
our	O
understanding	O
of	O
life	O
after	O
ARDS	B-DISO
.	O

(	O
5	O
)	O
Significant	O
numbers	O
of	O
ARDS	B-DISO
survivors	O
suffer	B-DISO
from	O
posttraumatic	O
stress	O
syndrome	B-DISO
.	O

SARS	B-DISO
-	O
CoV	O
virus	O
is	O
able	O
to	O
induce	O
both	O
IFN	O
-	O
alpha	O
and	O
-	O
gamma	O
mRNA	O
accumulation	O
and	O
protein	O
release	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
MOI	O
10	O
being	O
the	O
most	O
effective	O
.	O

This	O
study	O
provides	O
evidence	O
that	O
SARS	B-DISO
-	O
CoV	O
is	O
able	O
to	O
induce	O
in	O
normal	O
PBMC	O
a	O
coordinate	O
induction	O
of	O
IFN	O
-	O
alpha	O
and	O
-	O
gamma	O
gene	O
expression	O
.	O

TITLE	O
:	O
Effects	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	B-DISO
infection	I-DISO
on	O
peripheral	O
blood	O
lymphocytes	O
and	O
their	O
subsets	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
caused	O
large	O
outbreaks	O
of	O
atypical	B-DISO
pneumonia	I-DISO
in	O
2003	O
,	O
with	O
the	O
largest	O
localized	O
outbreak	O
occurring	O
in	O
Beijing	O
,	O
China	O
.	O

Lymphopenia	B-DISO
was	O
prominent	O
amongst	O
the	O
laboratory	O
abnormalities	O
reported	O
in	O
acute	O
SARS	B-DISO
.	O

There	O
was	O
a	O
significant	O
decrease	O
in	O
the	O
CD45	O
+,	O
CD3	O
+,	O
CD4	O
+,	O
CD8	O
+,	O
CD19	O
+	O
and	O
CD16	O
+/	O
56	O
+	O
cell	O
counts	O
over	O
the	O
five	O
weeks	O
of	O
the	O
SARS	B-DISO
illness	O
although	O
CD4	O
+/	O
CD8	O
+	O
ratios	O
did	O
not	O
change	O
significantly	O
.	O

However	O
,	O
these	O
studies	O
are	O
difficult	O
to	O
interpret	O
because	O
of	O
small	O
sample	O
size	O
,	O
inclusion	O
of	O
severely	O
injured	O
patients	O
in	O
traumatic	B-DISO
shock	I-DISO
,	O
and	O
combination	O
of	O
a	O
variety	O
of	O
unrelated	O
low	O
-	O
morbidity	O
/	O
mortality	O
infections	B-DISO
,	O
such	O
as	O
wound	O
,	O
catheter	O
-	O
related	O
,	O
and	O
urinary	B-DISO
tract	I-DISO
infection	I-DISO
as	O
outcomes	O
.	O

To	O
date	O
,	O
molecular	O
assays	O
for	O
the	O
detection	O
of	O
SARS	B-DISO
-	O
CoV	O
has	O
focused	O
mainly	O
on	O
reverse	O
transcriptase	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
analysis	O
of	O
specimens	O
.	O

It	O
was	O
shown	O
that	O
,	O
when	O
applied	O
to	O
SARS	B-DISO
RNA	O
samples	O
,	O
the	O
sensitivity	O
of	O
nucleic	O
acid	O
capture	O
RTPCR	O
was	O
about	O
10	O
-	O
fold	O
greater	O
than	O
routine	O
RT	O
-	O
PCR	O
.	O

ABSTRACT	O
:	O
Guinea	O
pigs	O
were	O
inoculated	O
with	O
a	O
reovirus	O
(	O
ReoV	O
)	O
and	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
isolated	O
from	O
SARS	B-DISO
patients	O
to	O
determine	O
their	O
potential	O
role	O
in	O
the	O
etiology	O
of	O
SARS	B-DISO
.	O

The	O
titer	O
of	O
neutralizing	O
antibodies	O
against	O
ReoV	O
and	O
SARS	B-DISO
-	O
CoV	O
ranged	O
from	O
80	O
to	O
160	O
when	O
the	O
animals	O
were	O
inoculated	O
with	O
the	O
two	O
viruses	O
,	O
respectively	O
,	O
while	O
the	O
titer	O
of	O
the	O
antibodies	O
was	O
just	O
below	O
10	O
in	O
coinfections	B-DISO
.	O

The	O
animal	O
inoculated	O
with	O
ReoV	O
developed	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
similar	O
to	O
the	O
exudative	O
and	O
leakage	B-DISO
inflammation	B-DISO
found	O
in	O
SARS	B-DISO
patients	O
,	O
and	O
was	O
characterized	O
by	O
diffuse	B-DISO
hemorrhage	I-DISO
,	O
fibroid	B-DISO
exudation	O
,	O
hyaline	B-DISO
membrane	I-DISO
formation	O
,	O
and	O
type	O
II	O
pneumocytes	O
hyperplasia	B-DISO
in	O
alveolar	O
interstitia	O
.	O

The	O
pulmonary	O
epithelial	O
necrosis	O
,	O
excoriation	O
,	O
and	O
early	O
fibrosis	B-DISO
of	O
pulmonary	O
tissue	O
were	O
only	O
observed	O
in	O
ReoV	O
-	O
SARS	B-DISO
-	O
CoV	O
groups	O
and	O
in	O
SARS	B-DISO
-	O
CoV	O
/	O
ReoV	O
groups	O
.	O

ABSTRACT	O
:	O
Experimental	O
studies	O
were	O
performed	O
to	O
determine	O
the	O
role	O
of	O
a	O
newly	O
isolated	O
reovirus	O
(	O
ReoV	O
)	O
from	O
a	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patient	O
in	O
the	O
etiology	O
of	O
this	O
newly	O
described	O
serious	O
respiratory	O
syndrome	B-DISO
.	O

ABSTRACT	O
:	O
The	O
pathogenesis	B-DISO
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
a	O
newly	O
emerging	O
life	O
-	O
threatening	O
disease	O
in	O
humans	O
,	O
remains	O
unknown	O
.	O

The	O
results	O
indicated	O
that	O
the	O
SARS	B-DISO
-	O
CoV	O
-	O
induced	O
apoptosis	O
in	O
Vero	O
cells	O
in	O
a	O
virus	O
replication	O
-	O
dependent	O
manner	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
,	O
a	O
main	O
surface	O
antigen	O
of	O
the	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
is	O
considered	O
to	O
be	O
one	O
of	O
the	O
most	O
important	O
protective	O
antigen	O
candidates	O
for	O
targets	O
for	O
vaccine	O
design	O
against	O
the	O
virus	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
humoral	O
immunity	O
against	O
the	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
),	O
we	O
studied	O
the	O
profiles	O
of	O
IgG	O
antibodies	O
to	O
the	O
nucleocapsid	O
(	O
N	O
)	O
and	O
spike	O
(	O
S	O
)	O
proteins	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
Serum	O
specimens	O
from	O
10	O
SARS	B-DISO
patients	O
were	O
analyzed	O
by	O
Western	O
blotting	O
and	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
using	O
purified	O
recombinant	O
N	O
and	O
truncated	O
S	O
(	O
S1	O
,	O
S2	O
,	O
and	O
S3	O
)	O
proteins	O
as	O
antigens	O
.	O

Following	O
photochemical	O
treatment	O
,	O
SARS	B-DISO
-	O
CoV	O
was	O
consistently	O
inactivated	O
to	O
the	O
limit	O
of	O
detection	O
in	O
seven	O
independent	O
APC	B-DISO
units	O
.	O

We	O
studied	O
HCoV	O
-	O
NL63	O
infection	B-DISO
in	O
hospitalized	O
children	O
diagnosed	O
with	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
.	O

The	O
main	O
symptoms	O
were	O
fever	O
(	O
61	O
%),	O
rhinitis	B-DISO
(	O
39	O
%),	O
bronchiolitis	B-DISO
(	O
39	O
%),	O
digestive	B-DISO
problems	I-DISO
(	O
33	O
%),	O
otitis	B-DISO
(	O
28	O
%),	O
pharyngitis	B-DISO
(	O
22	O
%),	O
and	O
conjunctivitis	B-DISO
(	O
17	O
%).	O

TITLE	O
:	O
CXC	O
chemokine	O
expression	O
and	O
synthesis	O
in	O
skeletal	O
muscle	O
during	O
ischemia	B-DISO
/	O
reperfusion	O
.	O

The	O
persistent	O
increase	O
in	O
muscle	O
chemokine	O
levels	O
at	O
24	O
hours	O
of	O
reperfusion	O
was	O
not	O
associated	O
with	O
increased	O
edema	B-DISO
or	O
injury	O
.	O

This	O
observation	O
may	O
underestimate	O
the	O
degree	O
of	O
the	O
systemic	O
response	O
to	O
ischemia	B-DISO
because	O
the	O
single	O
mouse	O
hind	O
limb	O
represents	O
only	O
7	O
%	O
of	O
the	O
mouse	O
total	O
body	O
area	O
,	O
whereas	O
the	O
human	O
limb	O
represents	O
nearly	O
18	O
%	O
of	O
the	O
adult	O
body	O
area	O
.	O

To	O
develop	O
an	O
alternative	O
system	O
for	O
the	O
study	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
we	O
introduced	O
individual	O
SARS	B-DISO
-	O
CoV	O
genes	O
(	O
open	O
reading	O
frames	O
[	O
ORFs	O
])	O
into	O
the	O
genome	O
of	O
an	O
attenuated	O
murine	O
coronavirus	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
several	O
members	O
within	O
the	O
order	O
Nidovirales	O
localizes	O
to	O
the	O
nucleolus	O
during	O
infection	B-DISO
and	O
after	O
transfection	O
of	O
cells	O
with	O
N	O
genes	O
.	O

According	O
to	O
the	O
official	O
files	O
of	O
reported	O
cases	O
of	O
SARS	B-DISO
from	O
February	O
21	O
to	O
June	O
19	O
,	O
2003	O
,	O
there	O
were	O
586	O
cases	O
in	O
southern	O
Taiwan	O
.	O

Symptom	B-DISO
onset	O
occurred	O
between	O
February	O
21	O
and	O
June	O
19	O
in	O
reported	O
cases	O
,	O
between	O
March	O
13	O
and	O
May	O
30	O
in	O
probable	O
cases	O
,	O
and	O
between	O
March	O
17	O
and	O
May	O
23	O
in	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)-	O
positive	O
probable	O
cases	O
.	O

Imported	O
cases	O
following	O
nosocomial	B-DISO
infection	I-DISO
were	O
the	O
major	O
cause	O
of	O
SARS	B-DISO
infections	B-DISO
in	O
southern	O
Taiwan	O
.	O

ABSTRACT	O
:	O
During	O
the	O
outbreak	O
of	O
the	O
emergent	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
infection	B-DISO
,	O
>	O
30	O
%	O
of	O
the	O
approximately	O
8000	O
infected	O
persons	O
were	O
health	O
care	O
workers	O
.	O

A	O
total	O
of	O
16	O
complete	O
postmortem	O
examinations	O
for	O
probable	O
and	O
suspected	O
SARS	B-DISO
were	O
performed	O
during	O
a	O
2	O
-	O
month	O
period	O
.	O

The	O
results	O
showed	O
that	O
,	O
all	O
five	O
species	O
of	O
small	O
animals	O
chosed	O
were	O
not	O
susceptible	O
to	O
SARS	B-DISO
-	O
CoV	O
,	O
no	O
characterized	O
changes	O
in	O
clinical	O
sign	O
and	O
histopathology	O
were	O
observed	O
after	O
infection	B-DISO
,	O
but	O
from	O
the	O
lung	O
samples	O
of	O
large	O
rat	O
and	O
pig	O
guinea	O
,	O
the	O
genomic	O
RNA	O
of	O
SARS	B-DISO
-	O
CoV	O
could	O
be	O
detected	O
by	O
RT	O
-	O
PCR	O
at	O
day	O
14	O
post	O
infection	B-DISO
,	O
this	O
suggested	O
that	O
SARS	B-DISO
-	O
CoV	O
could	O
replicate	O
in	O
these	O
animals	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
pancreatitis	I-DISO
is	O
an	O
inflammatory	B-DISO
disorder	I-DISO
,	O
and	O
inflammation	B-DISO
not	O
only	O
affects	O
the	O
pathogenesis	B-DISO
but	O
also	O
the	O
course	O
of	O
the	O
disease	O
.	O

Higher	O
IgG	O
levels	O
were	O
detected	O
in	O
patients	O
who	O
required	O
supplemental	O
oxygen	O
(	O
Mann	O
-	O
Whitney	O
;	O
p	O
=	O
0	O
.	O
002	O
),	O
ICU	O
-	O
admission	O
(	O
p	O
=	O
0	O
.	O
001	O
),	O
had	O
negative	O
pre	O
-	O
discharge	O
fecal	O
RT	O
-	O
PCR	O
results	O
(	O
p	O
=	O
0	O
.	O
004	O
),	O
and	O
lymphopenia	B-DISO
at	O
presentation	O
(	O
p	O
=	O
0	O
.	O
028	O
).	O

Severe	O
SARS	B-DISO
is	O
associated	O
with	O
a	O
more	O
robust	O
IgG	O
response	O
.	O

TITLE	O
:	O
Characterization	O
and	O
application	O
of	O
monoclonal	O
antibodies	O
against	O
N	O
protein	O
of	O
SARS	B-DISO
-	O
coronavirus	O
.	O

In	O
this	O
study	O
,	O
we	O
raised	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
against	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
mapped	O
epitopes	O
by	O
using	O
different	O
truncated	O
N	O
protein	O
fragments	O
.	O

This	O
may	O
negatively	O
influence	O
the	O
virus	O
-	O
receptor	O
binding	O
and	O
abrogate	O
the	O
infection	B-DISO
,	O
with	O
further	O
ramifications	O
by	O
the	O
elevation	O
of	O
vesicular	O
pH	O
,	O
resulting	O
in	O
the	O
inhibition	O
of	O
infection	B-DISO
and	O
spread	O
of	O
SARS	B-DISO
CoV	O
at	O
clinically	O
admissible	O
concentrations	O
.	O

TITLE	O
:	O
Protease	O
-	O
mediated	O
enhancement	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Cloning	O
of	O
a	O
human	B-DISO
parvovirus	I-DISO
by	O
molecular	O
screening	O
of	O
respiratory	O
tract	O
samples	O
.	O

We	O
developed	O
a	O
system	O
for	O
large	O
-	O
scale	O
molecular	O
virus	O
screening	O
of	O
clinical	O
samples	O
based	O
on	O
host	O
DNA	O
depletion	O
,	O
random	O
PCR	O
amplification	B-DISO
,	O
large	O
-	O
scale	O
sequencing	O
,	O
and	O
bioinformatics	O
.	O

Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
and	O
the	O
Hong	O
Kong	O
health	O
system	O
.	O

This	O
article	O
reviews	O
events	O
in	O
the	O
immediate	O
period	O
following	O
the	O
SARS	B-DISO
outbreak	O
.	O

These	O
two	O
plasmids	O
pET28a	O
(+)-	O
S	O
and	O
pPIC9K	O
-	O
S	O
were	O
transformed	O
to	O
E	O
.	O
coli	O
strain	O
BL21	O
(	O
DE3	O
)-	O
star	B-DISO
and	O
Pichia	O
pastoris	O
,	O
respectively	O
.	O

TITLE	O
:	O
Rapid	O
and	O
sensitive	O
detection	O
of	O
multiple	O
genes	O
from	O
the	O
SARS	B-DISO
-	O
coronavirus	O
using	O
quantitative	O
RT	O
-	O
PCR	O
with	O
dual	O
systems	O
.	O

The	O
relative	O
sensitivities	O
for	O
detecting	O
cell	O
culture	O
-	O
derived	O
SARS	B-DISO
-	O
CoV	O
were	O
0	O
.	O
01	O
,	O
0	O
.	O
01	O
,	O
and	O
0	O
.	O
001	O
PFU	O
/	O
test	O
,	O
respectively	O
.	O

It	O
showed	O
that	O
SARS	B-DISO
-	O
N	O
has	O
comparable	O
detection	O
efficiencies	O
to	O
SARS2	O
and	O
SARS3	O
which	O
are	O
primers	O
sets	O
designed	O
by	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
.	O

In	O
addition	O
,	O
SARS	B-DISO
-	O
S	O
and	O
SARS	B-DISO
-	O
M	O
also	O
demonstrated	O
equivalent	O
sensitivity	O
to	O
the	O
commercially	O
available	O
RealArt	O
HPA	O
-	O
Coronavirus	O
reagents	O
(	O
Artus	O
).	O

ABSTRACT	O
:	O
Detection	O
of	O
viral	O
antigens	O
and	O
isolation	O
methods	O
has	O
long	O
been	O
used	O
for	O
the	O
diagnosis	O
of	O
respiratory	O
virus	O
infections	B-DISO
.	O

However	O
,	O
the	O
replication	O
of	O
influenza	B-DISO
A	O
and	O
B	O
viruses	O
was	O
more	O
rapid	O
and	O
intense	O
on	O
MDCK	O
cells	O
than	O
on	O
HuH7	O
cells	O
.	O

Patients	O
had	O
the	O
rapid	O
onset	O
of	O
dyspnea	B-DISO
refractory	O
to	O
oxygen	O
therapy	O
.	O

TITLE	O
:	O
Gene	O
expression	O
profiles	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
SARS	B-DISO
patients	O
.	O

cDNA	O
microarrays	O
were	O
used	O
to	O
screen	O
the	O
gene	O
expression	O
profiles	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
in	O
two	O
SARS	B-DISO
patients	O
(	O
one	O
in	O
the	O
acute	O
severe	O
phase	O
and	O
the	O
other	O
in	O
the	O
convalescent	O
phase	O
)	O
and	O
a	O
healthy	O
donor	O
.	O

Many	O
inflammatory	O
and	O
anti	O
-	O
viral	O
genes	O
were	O
differentially	O
expressed	O
in	O
SARS	B-DISO
patients	O
.	O

ABSTRACT	O
:	O
This	O
paper	O
introduces	O
the	O
difficulties	O
ever	O
facing	O
the	O
hospital	O
radiology	O
during	O
the	O
earlier	O
prevention	O
and	O
treatment	O
times	O
of	O
SARS	B-DISO
and	O
a	O
RIS	O
/	O
PACS	O
system	O
based	O
on	O
the	O
DICOM	O
standard	O
and	O
its	O
actual	O
functions	O
in	O
that	O
condition	B-DISO
is	O
described	O
,	O
and	O
a	O
typical	O
system	O
project	O
and	O
its	O
related	O
analysis	O
and	O
explanation	O
are	O
put	O
forward	O
.	O

ABSTRACT	O
:	O
Twenty	O
antiviral	O
drugs	O
,	O
that	O
is	O
about	O
half	O
of	O
those	O
that	O
are	O
currently	O
approved	O
,	O
are	O
formally	O
licensed	O
for	O
clinical	O
use	O
in	O
the	O
treatment	O
of	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
infections	B-DISO
(	O
acquired	B-DISO
immune	I-DISO
deficiency	I-DISO
syndrome	I-DISO
).	O

In	O
addition	O
,	O
both	O
epithelial	O
and	O
fibroblastic	O
cell	O
lines	O
were	O
able	O
to	O
secrete	O
large	O
quantities	O
of	O
T	O
cell	O
-	O
targeting	O
chemokines	O
,	O
similar	O
to	O
the	O
ones	O
detected	O
in	O
SARS	B-DISO
patients	O
.	O

Results	O
implicated	O
that	O
the	O
second	O
heptad	O
repeat	O
region	O
of	O
spike	O
protein	O
could	O
be	O
a	O
good	O
target	O
for	O
vaccine	O
development	O
against	O
SARS	B-DISO
-	O
CoV	O
.	O

ABSTRACT	O
:	O
A	O
prospective	O
study	O
was	O
undertaken	O
to	O
identify	O
clinical	O
,	O
radiographical	O
,	O
haematological	O
and	O
biochemical	O
profiles	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
.	O

ABSTRACT	O
:	O
Abdominal	B-DISO
compartment	I-DISO
syndrome	I-DISO
has	O
been	O
described	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
,	O
but	O
its	O
clinical	O
impact	O
remains	O
unclear	O
.	O

The	O
incidence	O
of	O
organ	O
dysfunction	O
was	O
high	O
in	O
patients	O
with	O
IAH	O
:	O
respiratory	B-DISO
failure	I-DISO
95	O
%,	O
cardiovascular	O
failure	O
91	O
%,	O
and	O
renal	B-DISO
failure	I-DISO
86	O
%.	O

TITLE	O
:	O
Differential	O
detection	O
of	O
turkey	O
coronavirus	O
,	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
,	O
and	O
bovine	O
coronavirus	O
by	O
a	O
multiplex	O
polymerase	O
chain	O
reaction	O
.	O

ABSTRACT	O
:	O
Neutralizing	O
antibodies	O
(	O
NAbs	O
)	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
glycoprotein	O
confer	O
protection	O
to	O
animals	O
experimentally	O
infected	O
with	O
the	O
pathogenic	O
virus	O
.	O

ABSTRACT	O
:	O
Massive	O
numbers	O
of	O
palm	O
civets	O
were	O
culled	O
to	O
remove	O
sources	O
for	O
the	O
reemergence	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
Guangdong	O
Province	O
,	O
China	O
,	O
in	O
January	O
2004	O
,	O
following	O
SARS	B-DISO
coronavirus	O
detection	O
in	O
market	O
animals	O
.	O

Knowledge	O
of	O
the	O
survival	O
characteristics	O
of	O
the	O
virus	O
is	O
essential	O
for	O
formulating	O
appropriate	O
infection	B-DISO
-	O
control	O
measures	O
.	O

ABSTRACT	O
:	O
A	O
cross	O
-	O
sectional	O
anonymous	O
survey	O
was	O
administered	O
to	O
all	O
directory	O
-	O
listed	O
physicians	O
within	O
a	O
network	O
of	O
three	O
large	O
teaching	O
hospitals	O
that	O
provided	O
care	O
to	O
SARS	B-DISO
patients	O
in	O
Toronto	O
.	O

The	O
diagnosis	O
of	O
sleep	B-DISO
apnea	I-DISO
syndrome	I-DISO
is	O
based	O
on	O
polysomnography	O
,	O
and	O
severity	O
is	O
measured	O
with	O
an	O
apnea	B-DISO
-	O
hypopnea	O
index	O
that	O
counts	O
the	O
total	O
number	O
of	O
apneas	B-DISO
per	O
hour	O
of	O
sleep	O
.	O

Recent	O
large	O
epidemiologic	O
studies	O
have	O
shown	O
that	O
sleep	B-DISO
apnea	I-DISO
affects	O
about	O
16	O
%	O
of	O
men	O
and	O
5	O
%	O
of	O
women	O
between	O
30	O
and	O
65	O
years	O
of	O
age	O
.	O

Many	O
studies	O
have	O
shown	O
that	O
patients	O
with	O
obstructive	O
apnea	B-DISO
have	O
an	O
increased	O
incidence	O
of	O
daytime	O
hypertension	B-DISO
,	O
and	O
this	O
syndrome	B-DISO
is	O
recognized	O
as	O
an	O
independent	O
risk	O
factor	O
for	O
hypertension	B-DISO
.	O

Central	B-DISO
sleep	I-DISO
apnea	I-DISO
is	O
frequent	O
in	O
severe	O
heart	B-DISO
failure	I-DISO
.	O

Apnea	B-DISO
,	O
hypoxia	B-DISO
,	O
CO2	B-DISO
retention	I-DISO
and	O
arousals	O
provoke	O
elevated	O
sympathetic	O
activity	O
,	O
increased	O
afterload	O
and	O
elevated	O
left	O
ventricular	O
transmural	O
pressure	O
,	O
and	O
promote	O
the	O
progression	O
of	O
heart	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Hematopoietic	O
stem	O
cell	O
transplantation	O
for	O
Shwachman	B-DISO
-	I-DISO
Diamond	I-DISO
syndrome	I-DISO
:	O
experience	O
of	O
the	O
French	O
neutropenia	O
registry	O
.	O

One	O
patient	O
had	O
an	O
MDS	B-DISO
relapse	B-DISO
4	O
months	O
after	O
HSCT	O
and	O
died	O
10	O
months	O
later	O
.	O

We	O
conclude	O
that	O
HSCT	O
is	O
feasible	O
for	O
patients	O
with	O
SDS	B-DISO
who	O
develop	O
bone	B-DISO
marrow	I-DISO
failure	I-DISO
or	O
malignant	B-DISO
transformation	I-DISO
.	O

The	O
results	O
showed	O
the	O
neutralization	O
titres	O
of	O
F	O
(	O
ab	O
')	O
2	O
from	O
three	O
horses	O
all	O
reached	O
at	O
least	O
1	O
:	O
1600	O
,	O
and	O
50	O
microg	O
of	O
the	O
F	O
(	O
ab	O
')	O
2	O
fragments	O
could	O
completely	O
neutralize	O
1x10	O
(	O
4	O
)	O
TCID50	O
-	O
SARS	B-DISO
-	O
CoV	O
in	O
vivo	O
.	O

Most	O
interestingly	O
,	O
S	O
(	O
471	O
-	O
503	O
),	O
a	O
peptide	O
located	O
at	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
could	O
specifically	O
block	O
the	O
binding	O
between	O
the	O
RBD	O
and	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
,	O
resulting	O
in	O
the	O
inhibition	O
of	O
SARS	B-DISO
-	O
CoV	O
entrance	O
into	O
host	O
cells	O
in	O
vitro	O
.	O

The	O
study	O
demonstrated	O
that	O
S	O
(	O
471	O
-	O
503	O
)	O
peptide	O
was	O
a	O
potential	O
immunoantigen	O
for	O
the	O
development	O
of	O
peptide	O
-	O
based	O
vaccine	O
or	O
a	O
candidate	O
for	O
further	O
drug	O
evaluation	O
against	O
the	O
SARS	B-DISO
-	O
CoV	O
virus	O
-	O
cell	O
fusion	O
.	O

Two	O
HCWs	O
contracted	O
SARS	B-DISO
in	O
the	O
study	O
hospital	O
(	O
0	O
.	O
03	O
cases	O
/	O
bed	B-DISO
)	O
compared	O
with	O
93	O
HCWs	O
in	O
the	O
other	O
hospitals	O
(	O
0	O
.	O
13	O
cases	O
/	O
bed	B-DISO
)	O
during	O
the	O
same	O
three	O
-	O
week	O
period	O
.	O

We	O
injected	O
a	O
multifrequency	O
broad	O
-	O
band	O
sound	O
signal	O
into	O
the	O
airway	O
while	O
recording	O
transmitted	B-DISO
sound	O
at	O
three	O
locations	O
bilaterally	O
on	O
the	O
chest	O
wall	O
.	O

The	O
usefulness	O
of	O
this	O
method	O
was	O
illustrated	O
by	O
analyzing	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
RNA	O
.	O

ABSTRACT	O
:	O
Viral	B-DISO
infection	I-DISO
can	O
result	O
in	O
alterations	O
to	O
the	O
host	O
subcellular	O
membrane	O
.	O

The	O
TEM	B-DISO
image	O
for	O
our	O
purposes	O
is	O
defined	O
on	O
2	O
-	O
D	O
information	O
,	O
such	O
as	O
the	O
membrane	O
having	O
undergone	O
proliferation	B-DISO
and	O
from	O
pattern	O
recognition	O
suggesting	O
that	O
the	O
membrane	O
-	O
described	O
pattern	O
is	O
possibly	O
a	O
gyroid	O
type	O
of	O
membrane	O
.	O

A	O
total	O
of	O
145	O
neonates	O
received	O
ECMO	O
for	O
treatment	O
of	O
respiratory	B-DISO
failure	I-DISO
.	O

Eighty	O
two	O
were	O
classed	O
as	O
normal	O
,	O
seven	O
as	O
having	O
""""	O
impairment	B-DISO
""","	O
and	O
four	O
as	O
having	O
""""	O
severe	O
disability	O
"""."	O

However	O
,	O
after	O
several	O
more	O
days	O
,	O
the	O
patient	O
'	O
s	O
condition	B-DISO
deteriorated	O
,	O
and	O
she	O
ultimately	O
died	O
.	O

Our	O
patient	O
'	O
s	O
renal	O
function	O
remained	O
stable	O
throughout	O
the	O
hospital	O
course	O
,	O
which	O
caused	O
us	O
to	O
look	O
further	O
for	O
an	O
explanation	O
for	O
the	O
propylene	O
glycol	O
-	O
induced	O
lactic	B-DISO
acidosis	I-DISO
.	O

Based	O
on	O
the	O
Naranjo	O
probability	O
scale	O
,	O
propylene	O
glycol	O
was	O
determined	O
to	O
be	O
the	O
probable	O
cause	O
of	O
lactic	B-DISO
acidosis	I-DISO
.	O

ABSTRACT	O
:	O
More	O
often	O
we	O
are	O
faced	O
with	O
the	O
cases	O
of	O
young	O
people	O
(	O
who	O
are	O
in	O
a	O
serious	O
condition	B-DISO
)	O
who	O
land	O
in	O
ICU	O
,	O
because	O
of	O
severe	O
narcotics	O
intoxication	O
,	O
which	O
they	O
took	O
occasionally	O
on	O
the	O
concerts	O
,	O
discotheques	O
and	O
social	O
events	O
.	O

We	O
observed	O
many	O
petechias	O
and	O
ecchymoses	O
which	O
suggested	O
vascular	O
haemorrhagic	B-DISO
diathesis	I-DISO
.	O

The	O
health	O
status	O
of	O
SARS	B-DISO
survivors	O
was	O
also	O
significantly	O
worse	O
compared	O
with	O
the	O
healthy	O
population	O
.	O

A	O
condition	B-DISO
closely	O
meeting	O
the	O
human	O
criteria	O
for	O
ALI	O
/	O
ARDS	B-DISO
exists	O
in	O
foals	O
age	O
1	O
-	O
12	O
months	O
and	O
may	O
be	O
identical	O
to	O
previously	O
described	O
acute	O
bronchointerstitial	O
pneumonia	B-DISO
in	O
young	O
horses	O
.	O

Treatment	O
with	O
systemic	O
corticosteroids	O
,	O
intranasal	O
oxygen	O
and	O
antimicrobials	O
may	O
be	O
beneficial	O
in	O
foals	O
with	O
clinical	O
signs	O
compatible	O
with	O
ALI	O
/	O
ARDS	B-DISO
.	O

We	O
present	O
profiling	O
examples	O
for	O
several	O
positive	O
individuals	O
,	O
including	O
those	O
vaccinated	O
with	O
the	O
smallpox	B-DISO
and	O
anthrax	B-DISO
vaccines	O
.	O

TITLE	O
:	O
Facing	O
SARS	B-DISO
:	O
psychological	B-DISO
impacts	O
on	O
SARS	B-DISO
team	O
nurses	O
and	O
psychiatric	O
services	O
in	O
a	O
Taiwan	O
general	O
hospital	O
.	O

The	O
frequencies	O
of	O
1	O
mutation	O
in	O
codon	O
54	O
and	O
3	O
promoter	O
polymorphisms	O
at	O
nt	O
-	O
550	O
,	O
-	O
221	O
,	O
and	O
4	O
were	O
ascertained	O
in	O
352	O
patients	O
with	O
SARS	B-DISO
and	O
392	O
control	O
subjects	O
,	O
by	O
means	O
of	O
polymerase	O
chain	O
reaction	O
direct	O
sequencing	O
.	O

Of	O
352	O
patients	O
with	O
SARS	B-DISO
and	O
392	O
control	O
subjects	O
,	O
120	O
(	O
34	O
.	O
4	O
%)	O
and	O
91	O
(	O
23	O
.	O
2	O
%)	O
were	O
carriers	O
of	O
the	O
codon	O
54	O
variant	O
,	O
respectively	O
(	O
odds	O
ratio	O
[	O
OR	O
],	O
1	O
.	O
73	O
[	O
95	O
%	O
confidence	O
interval	O
{	O
CI	O
},	O
1	O
.	O
25	O
-	O
2	O
.	O
39	O
];	O
P	O
=.	O
00086	O
).	O

TITLE	O
:	O
Treatment	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

Ribavirin	O
and	O
corticosteroids	O
were	O
used	O
extensively	O
during	O
the	O
SARS	B-DISO
outbreak	O
.	O

Noninvasive	O
positive	O
pressure	O
ventilation	O
is	O
a	O
sound	O
treatment	O
for	O
SARS	B-DISO
patients	O
with	O
respiratory	B-DISO
failure	I-DISO
if	O
administered	O
with	O
due	O
precaution	O
in	O
the	O
correct	O
environment	O
.	O

ABSTRACT	O
:	O
Taiwan	O
suffered	B-DISO
from	O
the	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
2003	O
.	O

ELISA	O
and	O
a	O
neutralization	O
test	O
were	O
used	O
to	O
measure	O
anti	O
-	O
SARS	B-DISO
antibodies	O
.	O

The	O
findings	O
that	O
antibody	O
to	O
HTLV	O
can	O
be	O
detected	O
in	O
blood	O
samples	O
collected	O
from	O
SARS	B-DISO
patients	O
provide	O
important	O
information	O
for	O
safe	O
handling	O
of	O
blood	O
products	O
.	O

RESULTS	O
:	O
Based	O
on	O
changes	O
in	O
gene	O
expression	O
of	O
peripheral	O
blood	O
,	O
we	O
identified	O
52	O
signature	O
genes	O
that	O
accurately	O
discriminated	O
acute	O
SARS	B-DISO
patients	O
from	O
non	O
-	O
SARS	B-DISO
controls	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
patterns	O
of	O
temperature	O
changes	O
of	O
patients	O
with	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
the	O
effect	O
of	O
glucocorticoid	O
hormone	O
on	O
the	O
temperature	O
of	O
these	O
patients	O
.	O

The	O
control	O
groups	O
consisted	O
of	O
65	O
patients	O
with	O
interstitial	B-DISO
pneumonia	I-DISO
,	O
78	O
with	O
bacterial	B-DISO
pneumonia	I-DISO
and	O
57	O
with	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
.	O

The	O
results	O
showed	O
that	O
the	O
FBS	B-DISO
medium	O
was	O
optimal	O
for	O
recombinant	O
N	O
protein	O
expression	O
and	O
growth	O
of	O
the	O
recombinant	O
strain	O
.	O

SARS	B-DISO
is	O
a	O
serious	O
respiratory	O
illness	O
,	O
and	O
its	O
aetiology	O
is	O
a	O
novel	O
coronavirus	O
.	O

TITLE	O
:	O
Experience	O
of	O
using	O
convalescent	O
plasma	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
among	O
healthcare	O
workers	O
in	O
a	O
Taiwan	O
hospital	O
.	O

All	O
infected	O
HCW	O
whose	O
condition	B-DISO
had	O
progressed	O
severely	O
and	O
who	O
had	O
failed	O
to	O
respond	O
to	O
the	O
available	O
treatment	O
,	O
survived	O
after	O
transfusion	O
with	O
convalescent	O
plasma	O
.	O

ABSTRACT	O
:	O
Polymorphisms	O
of	O
human	O
Fc	O
gamma	O
-	O
receptor	O
IIA	O
(	O
FcgammaRIIA	O
)	O
and	O
mannose	O
-	O
binding	O
lectin	O
(	O
MBL	O
)	O
genes	O
have	O
been	O
associated	O
with	O
susceptibility	O
to	O
or	O
severity	O
of	O
some	O
infectious	B-DISO
diseases	I-DISO
.	O

TITLE	O
:	O
Structural	O
genomics	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
:	O
nuclear	O
magnetic	O
resonance	O
structure	O
of	O
the	O
protein	O
nsP7	O
.	O

An	O
18	O
-	O
yr	O
-	O
old	O
woman	O
injected	O
the	O
oil	O
and	O
developed	O
fulminant	O
pulmonary	B-DISO
edema	I-DISO
requiring	O
ventilator	O
support	O
.	O

The	O
patient	O
rapidly	O
developed	O
severe	O
fluid	B-DISO
overload	I-DISO
of	O
the	O
lung	O
and	O
subsequent	O
lung	O
injury	O
that	O
required	O
intubation	O
,	O
mechanical	O
ventilation	O
,	O
and	O
intensive	O
care	O
therapy	O
for	O
13	O
days	O
.	O

We	O
report	O
a	O
suicidal	O
39	O
-	O
year	O
-	O
old	O
woman	O
with	O
stage	B-DISO
II	I-DISO
cervical	I-DISO
cancer	I-DISO
who	O
drank	O
a	O
potentially	O
lethal	O
dose	O
of	O
OPP	O
in	O
the	O
form	O
of	O
a	O
commercial	O
antiseptic	O
,	O
which	O
led	O
to	O
the	O
complication	B-DISO
of	O
liver	O
and	O
renal	O
function	O
impairment	B-DISO
,	O
severe	O
lung	O
damage	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
subsequent	O
severe	O
lung	B-DISO
fibrosis	I-DISO
.	O

TITLE	O
:	O
Diffusion	O
-	O
weighted	O
MR	O
study	O
of	O
femoral	B-DISO
head	I-DISO
avascular	I-DISO
necrosis	I-DISO
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
patients	O
.	O

Osteonecrosis	B-DISO
was	O
detected	O
in	O
176	O
patients	O
(	O
32	O
.	O
7	O
percent	O
)	O
among	O
539	O
patients	O
.	O

ABSTRACT	O
:	O
Exaggerated	O
activation	O
of	O
cytokines	O
/	O
chemokines	O
has	O
been	O
proposed	O
as	O
a	O
factor	O
in	O
adverse	O
outcome	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Increased	O
plasma	O
IP	O
-	O
10	O
during	O
the	O
first	O
week	O
of	O
SARS	B-DISO
symptoms	O
is	O
an	O
independent	O
predictor	O
of	O
outcome	O
.	O

Oxidative	B-DISO
stress	I-DISO
was	O
assessed	O
by	O
measuring	O
the	O
levels	O
of	O
erythrocyte	O
reduced	O
glutathione	O
(	O
GSH	B-DISO
),	O
tissue	O
malondialdehyde	O
(	O
MDA	O
),	O
myeloperoxidase	O
(	O
MPO	O
)	O
and	O
Na	O
(+)-	O
K	O
(+)	O
ATPase	O
.	O

In	O
the	O
ethanol	O
group	O
,	O
serum	O
and	O
tissue	O
MDA	O
levels	O
and	O
MPO	O
activities	O
were	O
increased	O
(	O
p	O
=	O
0	O
.	O
007	O
,	O
p	O
=	O
0	O
.	O
001	O
and	O
p	O
=	O
0	O
.	O
000	O
),	O
and	O
lung	O
tissue	O
Na	O
(+)-	O
K	O
(+)	O
ATPase	O
activities	O
and	O
erythrocyte	O
GSH	B-DISO
were	O
decreased	O
(	O
p	O
=	O
0	O
.	O
001	O
and	O
p	O
=	O
0	O
.	O
000	O
)	O
compared	O
to	O
the	O
controls	O
.	O

PCR	O
-	O
based	O
detection	O
of	O
MHV	O
did	O
not	O
reveal	O
any	O
contamination	O
of	O
the	O
tumour	B-DISO
examined	O
by	O
this	O
technique	O
,	O
indicating	O
that	O
this	O
murine	O
tumour	B-DISO
apparently	O
did	O
not	O
transmit	O
MHV	O
or	O
that	O
MHV	O
was	O
eliminated	O
from	O
the	O
tissue	O
so	O
fast	O
after	O
the	O
infection	B-DISO
that	O
it	O
could	O
not	O
be	O
transmitted	B-DISO
by	O
the	O
tumour	B-DISO
tissue	O
.	O

In	O
patients	O
receiving	O
anti	O
-	O
TNF	O
-	O
alpha	O
therapy	O
,	O
especially	O
in	O
combination	O
with	O
corticosteroids	O
,	O
signs	O
of	O
pulmonary	B-DISO
infection	I-DISO
should	O
be	O
regarded	O
as	O
very	O
serious	O
,	O
as	O
fulminant	O
pneumonia	B-DISO
with	O
ARDS	B-DISO
and	O
severe	B-DISO
sepsis	I-DISO
may	O
develop	O
within	O
24	O
h	O
.	O

TITLE	O
:	O
[	O
Molecular	O
cloning	O
and	O
expression	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
nucleocapsid	O
protein	O
and	O
its	O
clinical	O
application	O
].	O

TITLE	O
:	O
Anthrax	B-DISO
:	O
pathological	O
aspects	O
in	O
autopsy	O
cases	O
in	O
Shiraz	O
,	O
Islamic	O
Republic	O
of	O
Iran	O
,	O
1960	O
-	O
2001	O
.	O

We	O
reviewed	O
all	O
the	O
pathology	B-DISO
slides	O
of	O
these	O
cases	O
and	O
classified	O
the	O
organs	O
involved	O
in	O
a	O
search	O
for	O
unrecognized	O
microscopic	O
findings	O
.	O

The	O
most	O
common	O
cause	O
of	O
death	O
was	O
sepsis	B-DISO
,	O
caused	O
by	O
organ	O
involvement	O
and	O
direct	O
cytotoxicity	B-DISO
of	O
Bacillus	O
anthracis	O
,	O
in	O
addition	O
to	O
its	O
exotoxin	O
production	O
.	O

MEDLINE	O
(	O
1985	O
-	O
2005	O
),	O
the	O
Cochrane	O
Controlled	O
Trials	O
Registry	O
(	O
1988	O
-	O
2005	O
),	O
the	O
National	O
Institutes	O
of	O
Health	O
ClinicalTrials	O
.	O
gov	O
database	O
,	O
and	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
Web	B-DISO
site	O
for	O
RCTs	O
in	O
which	O
patients	O
were	O
randomly	O
assigned	O
to	O
PAC	B-DISO
or	O
no	O
PAC	B-DISO
were	O
searched	O
.	O

TITLE	O
:	O
Simulating	O
public	O
health	O
response	O
to	O
a	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
event	O
:	O
a	O
comprehensive	O
and	O
systematic	O
approach	O
to	O
designing	O
,	O
implementing	O
,	O
and	O
evaluating	O
a	O
tabletop	O
exercise	O
.	O

This	O
is	O
likely	O
to	O
result	O
in	O
a	O
fragmentation	B-DISO
of	O
intellectual	O
property	O
(	O
IP	O
)	O
rights	O
which	O
in	O
turn	O
may	O
adversely	O
affect	O
the	O
development	O
of	O
products	O
,	O
such	O
as	O
vaccines	O
,	O
to	O
combat	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
The	O
complete	O
genome	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
reveals	O
the	O
existence	O
of	O
putative	O
proteins	O
unique	O
to	O
SARS	B-DISO
-	O
CoV	O
.	O
Identification	O
of	O
their	O
function	O
facilitates	O
a	O
mechanistic	O
understanding	O
of	O
SARS	B-DISO
infection	B-DISO
and	O
drug	O
development	O
for	O
its	O
treatment	O
.	O

Our	O
study	O
suggests	O
that	O
the	O
SARS	B-DISO
-	O
CoV	O
genome	O
possibly	O
contains	O
a	O
putative	O
voltage	O
-	O
gated	O
ion	O
channel	O
,	O
structural	O
proteins	O
,	O
a	O
carbon	O
-	O
oxygen	O
lyase	O
,	O
oxidoreductases	O
acting	O
on	O
the	O
CH	O
-	O
OH	O
group	O
of	O
donors	O
,	O
and	O
an	O
ATP	O
-	O
binding	O
cassette	O
transporter	O
.	O

A	O
web	B-DISO
version	O
of	O
our	O
software	O
,	O
SVMProt	O
,	O
is	O
accessible	O
at	O
http	O
://	O
jing	O
.	O
cz3	O
.	O
nus	O
.	O
edu	O
.	O
sg	O
/	O
cgi	O
-	O
bin	O
/	O
svmprot	O
.	O
cgi	O
.	O

It	O
is	O
likely	O
that	O
the	O
immune	O
responses	O
induced	O
by	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
could	O
also	O
cause	O
pathological	O
damage	O
to	O
the	O
host	O
,	O
especially	O
in	O
the	O
case	O
of	O
proinflammatory	O
cytokines	O
.	O

TITLE	O
:	O
In	O
vivo	O
functional	O
characterization	O
of	O
the	O
SARS	B-DISO
-	O
Coronavirus	O
3a	O
protein	O
in	O
Drosophila	O
.	O

ABSTRACT	O
:	O
To	O
measure	O
the	O
spatial	O
contagion	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
Beijing	O
and	O
to	O
test	O
the	O
different	O
epidemic	O
factors	O
of	O
the	O
spread	O
of	O
SARS	B-DISO
in	O
different	O
periods	O
.	O

The	O
geographical	O
relationships	O
were	O
important	O
during	O
the	O
early	O
phase	O
of	O
the	O
SARS	B-DISO
epidemic	O
in	O
Beijing	O
.	O

Moreover	O
,	O
the	O
vaccine	O
confers	O
protective	O
immunity	O
as	O
demonstrated	O
by	O
prevention	O
of	O
SARS	B-DISO
-	O
CoV	O
replication	O
in	O
the	O
respiratory	O
tract	O
of	O
mice	O
after	O
intranasal	O
challenge	O
with	O
SARS	B-DISO
-	O
CoV	O
.	O
Protection	O
of	O
mice	O
was	O
correlated	O
to	O
antibody	O
titre	O
against	O
the	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
and	O
neutralising	O
antibody	O
titre	O
.	O

This	O
article	O
reviews	O
the	O
alterations	O
in	O
the	O
immune	O
response	O
that	O
underlie	O
ARDS	B-DISO
,	O
discusses	O
the	O
physiology	O
of	O
dietary	O
oils	O
as	O
immunonutrients	O
,	O
summarizes	O
animal	O
and	O
human	O
studies	O
that	O
explore	O
the	O
therapeutic	O
effects	O
of	O
dietary	O
oils	O
,	O
and	O
provides	O
clinical	O
recommendations	O
for	O
their	O
use	O
.	O

Intestinal	O
epithelial	B-DISO
proliferation	I-DISO
and	O
death	O
were	O
also	O
examined	O
in	O
animals	O
with	O
differing	O
degrees	O
of	O
lung	B-DISO
inflammation	I-DISO
(	O
n	O
=	O
24	O
)	O
as	O
well	O
as	O
in	O
a	O
time	O
course	O
analysis	O
following	O
a	O
fixed	O
injury	O
(	O
n	O
=	O
18	O
).	O

Overexpression	O
of	O
Bcl	O
-	O
2	O
did	O
not	O
change	O
proliferation	B-DISO
despite	O
decreasing	O
gut	O
apoptosis	O
.	O

Acute	O
lung	O
injury	O
causes	O
disparate	O
effects	O
on	O
crypt	O
proliferation	B-DISO
and	O
apoptosis	O
,	O
which	O
occur	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
differing	O
mechanisms	O
involving	O
Toll	O
-	O
like	O
receptor	O
4	O
and	O
Bcl	O
-	O
2	O
.	O

Severity	O
of	O
lung	O
injury	O
does	O
not	O
correlate	O
with	O
perturbations	O
in	O
proliferation	B-DISO
or	O
death	O
in	O
the	O
gut	O
epithelium	O
,	O
and	O
acute	O
lung	O
injury	O
-	O
induced	O
changes	O
in	O
intestinal	O
epithelial	B-DISO
proliferation	I-DISO
persist	O
longer	O
than	O
those	O
in	O
apoptosis	O
.	O

A	O
mutant	B-DISO
in	O
the	O
N	O
terminus	O
of	O
Nsp15	O
was	O
impaired	B-DISO
in	O
hexamer	O
formation	O
and	O
had	O
low	O
endoribonuclease	O
activity	O
,	O
suggesting	O
that	O
oligomerization	O
is	O
required	O
for	O
endoribonuclease	O
activity	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
the	O
first	O
global	O
epidemic	O
in	O
the	O
21st	O
century	O
,	O
affected	O
over	O
8500	O
people	O
in	O
approximately	O
30	O
countries	O
.	O

SARS	B-DISO
-	O
specific	O
IgG	O
antibody	O
is	O
generated	O
in	O
the	O
second	O
week	O
and	O
persists	O
for	O
a	O
long	O
time	O
,	O
whereas	O
IgM	O
is	O
expressed	O
transiently	O
.	O

The	O
spike	O
protein	O
and	O
neucleocapsid	O
protein	O
are	O
most	O
abundant	O
in	O
SARS	B-DISO
-	O
Cov	O
and	O
contribute	O
dominantly	O
to	O
the	O
antibody	O
production	O
during	O
the	O
course	O
of	O
disease	O
.	O

Therefore	O
,	O
applications	O
with	O
spike	O
subunit	O
,	O
neucleocapsid	O
subunit	O
as	O
well	O
as	O
inactivated	O
SARS	B-DISO
-	O
Cov	O
are	O
three	O
prospective	O
vaccination	O
strategies	O
for	O
SARS	B-DISO
.	O

This	O
study	O
seeks	O
to	O
explore	O
whether	O
this	O
epidemic	O
has	O
altered	O
the	O
willingness	O
of	O
Hong	O
Kong	O
medical	O
students	O
to	O
perform	O
basic	O
life	O
support	O
and	O
mouth	O
-	O
to	O
-	O
mouth	O
ventilation	O
during	O
an	O
out	B-DISO
-	I-DISO
of	I-DISO
-	I-DISO
hospital	I-DISO
cardiac	I-DISO
arrest	I-DISO
.	O

The	O
majority	O
of	O
practices	O
reported	O
that	O
they	O
had	O
policies	O
or	O
procedures	O
in	O
place	O
to	O
isolate	O
potentially	O
infectious	B-DISO
patients	O
from	O
others	O
in	O
the	O
waiting	O
room	O
.	O

For	O
this	O
purpose	O
,	O
infectious	B-DISO
mouse	B-DISO
hepatitis	I-DISO
virus	O
,	O
a	O
common	O
viral	O
pathogen	O
in	O
mouse	O
facilities	O
,	O
was	O
used	O
.	O

Oocytes	O
having	O
an	O
intact	O
or	O
laser	O
-	O
microdissected	O
zona	B-DISO
pellucida	O
were	O
incubated	O
for	O
fertilization	O
in	O
media	O
containing	O
MHV	O
-	O
A59	O
and	O
resulting	O
embryos	O
were	O
transferred	O
to	O
the	O
oviduct	O
of	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
Swiss	O
recipients	O
.	O

ABSTRACT	O
:	O
The	O
seriousness	O
of	O
the	O
risk	O
that	O
healthcare	O
workers	O
faced	O
during	O
SARS	B-DISO
,	O
and	O
their	O
response	O
of	O
service	O
in	O
the	O
face	B-DISO
of	O
this	O
risk	O
,	O
brings	O
to	O
light	O
unrealistic	O
assumptions	O
about	O
duty	O
and	O
risk	O
that	O
informed	O
the	O
debate	O
on	O
duty	O
to	O
care	O
in	O
the	O
early	O
years	O
of	O
HIV	B-DISO
/	I-DISO
AIDS	I-DISO
.	O

As	O
of	O
10	O
May	O
2003	O
,	O
a	O
cumulative	O
7296	O
probable	O
SARS	B-DISO
cases	O
with	O
526	O
deaths	O
have	O
been	O
reported	O
from	O
30	O
countries	O
on	O
three	O
continents	O
(	O
WHO	O
,	O
ProMED	O
).	O

According	O
to	O
SARS	B-DISO
-	O
CoV	O
genome	O
sequence	O
,	O
the	O
cDNA	O
probe	O
was	O
synthesized	O
and	O
labelled	O
by	O
digoxin	O
.	O

Indirect	O
Immunofluorescence	O
assay	O
indicated	O
that	O
they	O
could	O
specifically	O
bind	O
to	O
protein	O
X4	O
expressed	O
in	O
SARS	B-DISO
-	O
CoV	O
infected	O
Vero	O
E6	O
cells	O
.	O

The	O
results	O
of	O
ELISA	O
showed	O
that	O
among	O
114	O
sera	O
from	O
healthy	O
controls	O
,	O
4	O
(	O
3	O
.	O
5	O
%)	O
were	O
positive	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
IgG	O
antibody	O
and	O
114	O
(	O
100	O
%)	O
were	O
all	O
negative	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
IgM	O
antibody	O
;	O
the	O
specificity	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
IgG	O
antibody	O
for	O
SARS	B-DISO
patients	O
was	O
96	O
.	O
5	O
%,	O
but	O
the	O
specificity	O
of	O
both	O
SARS	B-DISO
-	O
CoV	O
-	O
IgG	O
and	O
-	O
IgM	O
antibodies	O
for	O
SARS	B-DISO
patients	O
was	O
100	O
%.	O

ABSTRACT	O
:	O
The	O
pathogenesis	B-DISO
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
an	O
important	O
issue	O
for	O
treatment	O
and	O
prevention	O
of	O
SARS	B-DISO
.	O

Recently	O
,	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
protease	O
has	O
been	O
implied	O
to	O
be	O
possible	O
relevance	O
to	O
SARS	B-DISO
-	O
CoV	O
pathogenesis	B-DISO
.	O

TITLE	O
:	O
Contribution	O
of	O
trafficking	O
signals	O
in	O
the	O
cytoplasmic	O
tail	O
of	O
the	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
spike	O
protein	O
to	O
virus	B-DISO
infection	I-DISO
.	O

We	O
constructed	O
infectious	B-DISO
cDNA	O
clones	O
lacking	O
the	O
ER	O
retrieval	O
signal	O
,	O
the	O
endocytosis	O
signal	O
,	O
or	O
both	O
.	O

Analysis	O
of	O
multiple	O
second	O
-	O
site	O
revertants	O
of	O
CCA4	B-DISO
revealed	O
mutations	O
in	O
both	O
the	O
M	O
protein	O
and	O
the	O
N	O
protein	O
that	O
could	O
compensate	O
for	O
the	O
original	O
lesion	O
in	O
N	O
.	O
These	O
data	O
more	O
precisely	O
define	O
the	O
region	O
of	O
the	O
N	O
protein	O
that	O
interacts	O
with	O
the	O
M	O
protein	O
.	O

TITLE	O
:	O
Insights	O
into	O
SARS	B-DISO
-	O
CoV	O
transcription	O
and	O
replication	O
from	O
the	O
structure	O
of	O
the	O
nsp7	O
-	O
nsp8	O
hexadecamer	O
.	O

This	O
study	O
provides	O
information	O
on	O
the	O
domain	O
structure	O
partition	O
of	O
SARS	B-DISO
-	O
CoV	O
N	O
protein	O
and	O
insights	O
into	O
the	O
differing	O
roles	O
of	O
structured	O
and	O
disordered	O
regions	O
in	O
coronavirus	O
nucleocapsid	O
proteins	O
.	O

ABSTRACT	O
:	O
To	O
find	O
the	O
most	O
suitable	O
RT	O
-	O
PCR	O
detection	O
method	O
for	O
SARS	B-DISO
-	O
Coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
detection	O
in	O
both	O
human	O
and	O
animals	O
,	O
and	O
to	O
study	O
the	O
source	O
of	O
SARS	B-DISO
virus	O
by	O
investigating	O
the	O
condition	B-DISO
of	O
virus	O
carried	O
by	O
wild	O
,	O
domestic	O
animals	O
and	O
animals	O
sold	O
in	O
market	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
the	O
modified	O
molecular	O
beacon	O
-	O
based	O
dual	O
fluorescent	O
PCR	O
assays	O
for	O
detection	O
of	O
SARS	B-DISO
virus	O
.	O

Then	O
fluorescent	O
PCR	O
assays	O
for	O
specific	O
and	O
sensitive	O
detection	O
of	O
the	O
SARS	B-DISO
virus	O
was	O
established	O
,	O
while	O
the	O
ELISA	O
&	O
the	O
traditional	O
method	O
were	O
used	O
as	O
control	O
.	O

TITLE	O
:	O
A	O
simple	O
and	O
rapid	O
approach	O
for	O
screening	O
of	O
SARS	B-DISO
-	O
coronavirus	O
genotypes	O
:	O
an	O
evaluation	O
study	O
.	O

In	O
a	O
randomized	O
controlled	O
trial	O
,	O
nasopharyngeal	O
and	O
oropharyngeal	O
swab	O
specimens	O
from	O
patients	O
admitted	O
for	O
antibiotic	O
treatment	O
of	O
LRTI	B-DISO
were	O
evaluated	O
by	O
means	O
of	O
real	O
-	O
time	O
PCR	O
for	O
respiratory	O
viruses	O
and	O
atypical	O
pathogens	O
,	O
as	O
well	O
as	O
by	O
conventional	O
diagnostic	O
procedures	O
.	O

The	O
detection	O
of	O
viral	O
pathogens	O
by	O
PCR	O
was	O
associated	O
with	O
the	O
winter	O
season	O
,	O
less	O
infiltrates	B-DISO
on	O
chest	O
radiographs	O
,	O
lower	O
C	O
-	O
reactive	O
protein	O
levels	O
,	O
and	O
shorter	O
duration	O
of	O
symptoms	O
.	O

This	O
month	O
'	O
s	O
article	O
considers	O
whether	O
those	O
who	O
act	O
recklessly	O
and	O
put	O
others	O
at	O
risk	O
of	O
infection	B-DISO
should	O
be	O
held	O
criminally	O
liable	O
and	O
prosecuted	O
for	O
their	O
actions	O
.	O

TITLE	O
:	O
Human	O
coronavirus	O
NL63	O
is	O
not	O
detected	O
in	O
the	O
respiratory	O
tracts	O
of	O
children	O
with	O
acute	O
Kawasaki	B-DISO
disease	I-DISO
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
failure	I-DISO
due	O
to	O
hypokalaemic	O
muscular	O
paralysis	O
from	O
renal	B-DISO
tubular	I-DISO
acidosis	I-DISO
.	O

ABSTRACT	O
:	O
Syndromic	O
surveillance	O
has	O
been	O
developed	O
in	O
order	O
to	O
detect	O
outbreaks	O
of	O
unusual	O
infectious	B-DISO
diseases	I-DISO
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
or	O
anthrax	B-DISO
at	O
an	O
early	O
stage	O
.	O

ABSTRACT	O
:	O
To	O
examine	O
pulmonary	O
function	O
,	O
exercise	O
capacity	O
,	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
among	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
survivors	O
.	O

Blinded	O
studies	O
using	O
RNA	O
extracted	O
from	O
various	O
tissues	O
of	O
a	O
SARS	B-DISO
-	O
infected	O
individual	O
showed	O
that	O
STAR	B-DISO
correctly	O
identified	O
all	O
samples	O
containing	O
SARS	B-DISO
virus	O
and	O
yielded	O
negative	O
results	O
for	O
non	O
-	O
SARS	B-DISO
control	O
samples	O
.	O

Increased	O
activation	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
protein	O
38	O
,	O
Akt	O
,	O
and	O
nuclear	O
factor	O
(	O
NF	O
)-	O
kappa	O
B	O
in	O
neutrophils	O
and	O
other	O
cell	O
populations	O
obtained	O
at	O
early	O
time	O
points	O
in	O
the	O
clinical	O
course	O
of	O
sepsis	B-DISO
-	O
induced	O
acute	O
lung	O
injury	O
or	O
after	O
accidental	O
trauma	O
is	O
associated	O
with	O
a	O
more	O
-	O
severe	O
clinical	O
course	O
,	O
suggesting	O
that	O
a	O
proinflammatory	O
cellular	O
phenotype	O
contributes	O
to	O
organ	O
system	O
dysfunction	O
in	O
such	O
settings	O
.	O

TITLE	O
:	O
pH	O
-	O
dependent	O
conformational	O
flexibility	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
main	O
proteinase	O
(	O
M	O
(	O
pro	O
))	O
dimer	O
:	O
molecular	O
dynamics	O
simulations	O
and	O
multiple	O
X	O
-	O
ray	O
structure	O
analyses	O
.	O

ABSTRACT	O
:	O
The	O
SARS	B-DISO
coronavirus	O
main	O
proteinase	O
(	O
M	O
(	O
pro	O
))	O
is	O
a	O
key	O
enzyme	O
in	O
the	O
processing	O
of	O
the	O
viral	O
polyproteins	O
and	O
thus	O
an	O
attractive	O
target	O
for	O
the	O
discovery	O
of	O
drugs	O
directed	O
against	O
SARS	B-DISO
.	O

Twenty	O
-	O
three	O
patients	O
presented	O
only	O
with	O
jaundice	B-DISO
,	O
hyperparasitemia	O
,	O
or	O
prostration	B-DISO
in	O
isolation	O
,	O
or	O
in	O
combination	O
.	O

This	O
outcome	O
appears	O
to	O
compare	O
favourably	O
to	O
conventional	O
ventilation	O
techniques	O
and	O
may	O
have	O
a	O
role	O
in	O
patients	O
who	O
develop	O
acute	O
severe	O
respiratory	B-DISO
distress	I-DISO
associated	O
with	O
trauma	O
.	O

Infants	O
born	O
to	O
mothers	O
with	O
the	O
disease	O
did	O
not	O
acquire	O
the	O
infection	B-DISO
through	O
vertical	B-DISO
transmission	I-DISO
.	O

Intubation	O
can	O
be	O
avoided	O
for	O
some	O
patients	O
with	O
neuromuscular	B-DISO
disease	I-DISO
in	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
by	O
some	O
combination	O
of	O
noninvasive	O
mechanical	O
ventilation	O
and	O
mechanically	O
assisted	O
coughing	B-DISO
.	O

TITLE	O
:	O
Hypercoagulant	O
states	O
in	O
malignant	B-DISO
lymphoma	I-DISO
.	O

Plasma	O
concentrations	O
of	O
granulocyte	O
elastase	O
derived	O
-	O
XDP	B-DISO
(	O
GEXDP	O
)	O
levels	O
correlated	O
with	O
D	O
-	O
dimer	O
levels	O
,	O
suggesting	O
that	O
almost	O
all	O
elevated	O
D	O
-	O
dimer	O
is	O
GE	O
-	O
XDP	B-DISO
.	O

The	O
glycodendrons	O
were	O
elaborated	O
onto	O
the	O
N	O
-	O
or	O
C	O
-	O
terminus	O
of	O
sequences	O
derived	O
from	O
HIV	B-DISO
-	O
1	O
gp41	O
,	O
SARS	B-DISO
-	O
CoV	O
S2	O
protein	O
,	O
and	O
Influenza	B-DISO
Hemagglutinin	O
(	O
consisting	O
of	O
15	O
-	O
44	O
residues	O
).	O

In	O
early	O
/	O
severe	O
/	O
diffuse	O
ARDS	B-DISO
prone	O
position	O
reduces	O
lower	O
inflection	O
point	O
pressure	O
and	O
increases	O
upper	O
inflection	O
point	O
UIP	B-DISO
volume	O
of	O
the	O
lung	O
PV	O
curve	O
.	O

These	O
neuromuscular	B-DISO
disorders	I-DISO
in	O
SARS	B-DISO
patients	O
were	O
considered	O
as	O
critical	B-DISO
illness	I-DISO
neuropathy	B-DISO
and	O
myopathy	B-DISO
,	O
but	O
the	O
possibility	O
of	O
direct	O
attack	O
by	O
SARS	B-DISO
coronavirus	O
on	O
the	O
nerve	O
and	O
muscle	O
could	O
not	O
be	O
excluded	O
.	O

Large	O
artery	O
ischemic	B-DISO
stroke	I-DISO
were	O
described	O
in	O
five	O
SARS	B-DISO
patients	O
with	O
poor	O
prognosis	O
.	O

Among	O
them	O
were	O
the	O
trials	O
that	O
tested	O
the	O
infusion	O
of	O
activated	O
protein	O
C	O
in	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
,	O
tight	O
glycemic	O
control	O
in	O
surgical	O
intensive	O
care	O
patients	O
,	O
and	O
use	O
of	O
lung	O
protective	O
mechanical	O
ventilation	O
by	O
using	O
small	O
tidal	O
volumes	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
.	O

Because	O
both	O
cellular	O
and	O
humoral	O
immune	O
responses	O
are	O
generated	O
by	O
gene	O
-	O
based	O
vaccination	O
and	O
inactivated	O
viral	O
boosting	O
,	O
this	O
strategy	O
may	O
prove	O
useful	O
in	O
the	O
generation	O
of	O
SARS	B-DISO
-	O
CoV	O
vaccines	O
.	O

Whereas	O
FECV	O
79	O
-	O
1683	O
causes	O
at	O
the	O
most	O
a	O
mild	O
enteritis	B-DISO
in	O
young	O
kittens	O
,	O
FIPV	O
79	O
-	O
1146	O
almost	O
invariably	O
induces	O
a	O
lethal	O
peritonitis	B-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
exhibits	O
a	O
high	O
mortality	O
rate	O
and	O
the	O
potential	O
for	O
rapid	O
epidemic	O
spread	O
.	O

Molecular	O
tests	O
have	O
been	O
developed	O
to	O
detect	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
RNA	O
using	O
real	O
time	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
with	O
varying	O
levels	O
of	O
sensitivity	O
.	O

RESULTS	O
:	O
Recombinant	O
N	O
protein	O
reacted	O
strongly	O
and	O
specifically	O
with	O
the	O
sera	O
from	O
immunized	O
mice	O
and	O
SARS	B-DISO
patients	O
.	O

TITLE	O
:	O
AIDS	O
vaccine	O
:	O
Intranasal	O
immunization	O
using	O
inactivated	O
HIV	B-DISO
-	O
1	O
-	O
capturing	O
core	O
-	O
corona	O
type	O
polymeric	O
nanospheres	O
.	O

TITLE	O
:	O
Molecular	O
diagnosis	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
the	O
state	O
of	O
the	O
art	O
.	O

Commercially	O
available	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
tests	O
for	O
SARS	B-DISO
have	O
recently	O
appeared	O
;	O
however	O
,	O
meaningful	O
evaluations	O
of	O
these	O
assays	O
have	O
not	O
yet	O
been	O
performed	O
and	O
their	O
true	O
performance	O
has	O
not	O
been	O
determined	O
.	O

Recombinant	O
IFN	O
-	O
alpha2b	O
could	O
effectively	O
interdict	O
or	O
weaken	O
SARS	B-DISO
-	O
CoV	O
injury	O
in	O
monkeys	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
symptoms	O
of	O
cough	B-DISO
and	O
expectoration	O
between	O
the	O
experimental	O
group	O
and	O
the	O
control	O
group	O
.	O

The	O
side	B-DISO
effect	I-DISO
of	O
bloody	O
nasal	O
mucus	O
was	O
not	O
observed	O
in	O
experimental	O
group	O
,	O
which	O
had	O
been	O
reported	O
by	O
other	O
authors	O
in	O
several	O
volunteer	O
studies	O
.	O

A	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	B-DISO
field	O
trial	O
study	O
in	O
populations	O
with	O
14	O
,	O
391	O
persons	O
from	O
SARS	B-DISO
prevalent	O
cities	O
or	O
provinces	O
in	O
China	O
during	O
May	O
-	O
Jun	O
,	O
2003	O
and	O
Dec	O
-	O
Apr	O
,	O
2004	O
.	O

No	O
statistically	O
significant	O
difference	O
in	O
serum	O
SARS	B-DISO
IgG	O
antibody	O
positive	O
rate	O
was	O
found	O
between	O
the	O
interferon	O
and	O
control	O
groups	O
among	O
2	O
,	O
757	O
serum	O
samples	O
.	O

Among	O
them	O
there	O
were	O
statistically	O
significant	O
differences	O
between	O
the	O
interferon	O
and	O
control	O
groups	O
for	O
parainfluenza	B-DISO
virus	O
,	O
influenza	B-DISO
B	O
and	O
adenovirus	B-DISO
.	O

SARS	B-DISO
-	O
CoV	O
receptor	O
ACE	O
-	O
2	O
gene	O
was	O
successfully	O
cloned	O
and	O
eukaryotic	O
expressed	O
,	O
and	O
used	O
to	O
establish	O
syncytia	O
inhibition	O
assay	O
for	O
SARS	B-DISO
-	O
CoV	O
neutralizing	O
antibody	O
assay	O
.	O

Western	O
Blot	O
and	O
ELISA	O
analysis	O
showed	O
that	O
the	O
S1c	O
protein	O
could	O
be	O
specifically	O
recognized	O
by	O
the	O
sera	O
from	O
SARS	B-DISO
patients	O
.	O

Diarrhea	B-DISO
also	O
occurs	O
in	O
patients	O
with	O
community	O
-	O
acquired	O
pneumonia	B-DISO
,	O
when	O
it	O
is	O
suggestive	O
of	O
legionellosis	B-DISO
.	O

Unfortunately	O
,	O
it	O
is	O
often	O
not	O
established	O
whether	O
diarrhea	B-DISO
is	O
an	O
initial	O
symptom	B-DISO
or	O
develops	O
during	O
the	O
course	O
of	O
the	O
disease	O
.	O

Her	O
respiratory	O
condition	B-DISO
deteriorated	O
despite	O
administration	O
of	O
pulse	O
corticosteroids	O
.	O

ABSTRACT	O
:	O
In	O
patients	O
with	O
severe	O
malaria	B-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
usually	O
develops	O
after	O
the	O
start	O
of	O
drug	O
treatment	O
and	O
is	O
a	O
major	O
cause	O
of	O
death	O
.	O

Cough	B-DISO
was	O
frequent	O
in	O
both	O
patients	O
with	O
uncomplicated	O
malaria	B-DISO
(	O
50	O
%)	O
and	O
those	O
with	O
severe	O
malaria	B-DISO
(	O
30	O
%)	O
and	O
resolved	O
by	O
day	O
14	O
.	O

Gas	O
transfer	O
was	O
significantly	O
impaired	B-DISO
in	O
patients	O
with	O
severe	O
malaria	B-DISO
.	O

Our	O
results	O
suggest	O
that	O
pulmonary	O
vascular	B-DISO
occlusion	I-DISO
occurs	O
in	O
both	O
patients	O
with	O
uncomplicated	O
malaria	B-DISO
and	O
those	O
with	O
severe	O
malaria	B-DISO
,	O
likely	O
from	O
sequestration	O
of	O
both	O
red	O
blood	O
cells	O
(	O
RBCs	O
)	O
and	O
white	O
blood	O
cells	O
.	O

Among	O
the	O
157	O
patients	O
with	O
leptospirosis	B-DISO
,	O
eight	O
patients	O
had	O
pulmonary	B-DISO
complications	I-DISO
.	O

One	O
patient	O
had	O
congestive	B-DISO
heart	I-DISO
failure	I-DISO
and	O
pulmonary	B-DISO
oedema	I-DISO
.	O

One	O
patient	O
had	O
only	O
ARF	B-DISO
.	O

RESULTS	O
:	O
Among	O
the	O
157	O
patients	O
with	O
leptospirosis	B-DISO
,	O
eight	O
patients	O
had	O
pulmonary	B-DISO
complications	I-DISO
.	O

Three	O
patients	O
developed	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
one	O
died	O
from	O
respiratory	B-DISO
failure	I-DISO
.	O

ABSTRACT	O
:	O
A	O
reference	O
antiserum	O
for	O
SARS	B-DISO
is	O
in	O
urgent	O
need	O
in	O
the	O
development	O
of	O
SARS	B-DISO
vaccine	O
and	O
other	O
serological	O
test	O
of	O
SARS	B-DISO
research	O
.	O

ABSTRACT	O
:	O
Little	O
information	O
is	O
available	O
on	O
persistent	B-DISO
infection	I-DISO
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
CoV	O
).	O

In	O
this	O
study	O
,	O
we	O
established	O
persistent	B-DISO
infection	I-DISO
of	O
SARS	B-DISO
-	O
CoV	O
in	O
the	O
Vero	O
E6	O
cell	O
line	O
.	O

TITLE	O
:	O
Sensitivity	O
of	O
Tru	O
-	O
cut	O
and	O
fine	O
needle	O
aspiration	B-DISO
biopsies	O
of	O
liver	O
and	O
kidney	O
for	O
diagnosis	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
.	O

TITLE	O
:	O
Microcirculation	O
disturbance	O
affects	O
rats	O
with	O
acute	O
severe	O
pancreatitis	B-DISO
following	O
lung	O
injury	O
.	O

We	O
developed	O
ASP	O
rat	O
models	O
,	O
and	O
anatomized	O
separately	O
after	O
1	O
,	O
3	O
,	O
5	O
,	O
7	O
,	O
and	O
9	O
h	O
.	O
We	O
took	O
out	O
blood	O
and	O
did	O
hemorrheologic	O
examination	O
and	O
erythrocyte	O
osmotic	O
fragility	B-DISO
test	O
,	O
checked	O
up	O
the	O
water	O
content	O
,	O
capillary	O
permeability	O
,	O
and	O
genetic	O
expression	O
of	O
intercellular	O
adhesion	B-DISO
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
in	O
lung	O
tissues	O
,	O
examined	O
the	O
apoptosis	O
degree	O
of	O
blood	O
vessel	O
endothelium	O
while	O
we	O
tested	O
related	O
gene	O
expression	O
of	O
Bax	O
and	O
Bcl	O
-	O
2	O
in	O
lung	O
tissues	O
.	O

Data	O
of	O
SARS	B-DISO
cases	O
were	O
collected	O
from	O
daily	O
notification	O
of	O
China	O
Ministry	O
of	O
Health	O
and	O
a	O
database	O
of	O
infectious	B-DISO
diseases	I-DISO
was	O
established	O
by	O
the	O
Beijing	O
Municipal	O
Center	O
for	O
Disease	O
Prevention	O
and	O
Control	O
(	O
BCDC	O
).	O

Case	O
patients	O
were	O
from	O
Xuanwu	O
Hospital	O
(	O
Capital	O
University	O
of	O
Medical	O
Sciences	O
,	O
Beijing	O
,	O
China	O
),	O
and	O
all	O
of	O
them	O
met	O
clinical	O
criteria	O
for	O
SARS	B-DISO
.	O

SARS	B-DISO
patients	O
might	O
need	O
anticoagulant	O
therapy	O
or	O
fibrinolytic	O
therapy	O
in	O
order	O
to	O
reverse	O
intraalveolar	O
coagulation	O
,	O
microthrombi	O
formation	O
,	O
alveolar	O
and	O
interstitial	O
fibrin	B-DISO
deposition	I-DISO
.	O

Search	O
of	O
pertinent	O
articles	O
within	O
Ovid	O
MEDLINE	O
from	O
1975	O
to	O
2005	O
,	O
CINAHL	O
from	O
1982	O
to	O
2005	O
,	O
EMBASE	O
from	O
1988	O
to	O
2005	O
,	O
and	O
Web	B-DISO
of	O
Science	O
from	O
1993	O
to	O
2005	O
.	O

ABSTRACT	O
:	O
This	O
study	O
examines	O
the	O
psychological	B-DISO
impact	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
195	O
adult	O
patients	O
in	O
Hong	O
Kong	O
.	O

ABSTRACT	O
:	O
Studies	O
of	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
demonstrate	O
that	O
the	O
respiratory	O
tract	O
is	O
a	O
major	O
site	O
of	O
SARS	B-DISO
-	O
coronavirus	O
(	O
CoV	O
)	O
infection	B-DISO
and	O
disease	O
morbidity	O
.	O

ABSTRACT	O
:	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
encodes	O
several	O
unique	O
group	O
-	O
specific	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
relative	O
to	O
other	O
known	O
coronaviruses	O
.	O

It	O
seems	O
likely	O
,	O
but	O
it	O
was	O
not	O
proved	O
,	O
that	O
the	O
parvovirus	B-DISO
infection	I-DISO
caused	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
The	O
world	O
was	O
shocked	B-DISO
in	O
early	O
2003	O
when	O
a	O
pandemic	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
was	O
imminent	O
.	O

ABSTRACT	O
:	O
This	O
study	O
was	O
done	O
to	O
develop	O
and	O
test	O
validity	O
and	O
reliability	O
of	O
on	O
instrument	O
for	O
predicting	O
nursing	O
intention	O
for	O
SARS	B-DISO
patient	O
care	O
.	O

TITLE	O
:	O
A	O
novel	O
fingerprint	O
map	O
for	O
detecting	O
SARS	B-DISO
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Spike	O
(	O
S	O
)	O
protein	O
is	O
the	O
most	O
important	O
membrane	O
protein	O
on	O
the	O
surface	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

As	O
an	O
outcome	O
,	O
a	O
novel	O
method	O
for	O
visualizing	O
the	O
characteristic	O
of	O
SARS	B-DISO
-	O
CoV	O
is	O
suggested	O
.	O

An	O
extensive	O
comparison	O
among	O
a	O
large	O
number	O
of	O
genome	O
sequences	O
has	O
proved	O
that	O
the	O
characteristic	O
thus	O
revealed	O
is	O
unique	O
for	O
SARS	B-DISO
-	O
CoV	O
.	O
As	O
such	O
,	O
the	O
characteristic	O
can	O
be	O
regarded	O
as	O
the	O
fingerprint	O
map	O
of	O
SARS	B-DISO
-	O
CoV	O
for	O
diagnostic	O
usage	O
.	O

ABSTRACT	O
:	O
The	O
envelope	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
mediates	O
the	O
entry	O
of	O
the	O
virus	O
into	O
target	O
cells	O
.	O

It	O
is	O
a	O
matter	O
of	O
discussion	O
if	O
the	O
HIV	B-DISO
-	O
1	O
gp41	O
HR2	O
-	O
derived	O
peptide	O
T20	O
(	O
enfuvirtide	O
)	O
could	O
be	O
a	O
possible	O
SARS	B-DISO
-	O
CoV	O
inhibitor	O
given	O
the	O
similarities	O
between	O
the	O
two	O
viruses	O
.	O

We	O
tested	O
the	O
possibility	O
of	O
interaction	O
between	O
both	O
T20	O
(	O
HIV	B-DISO
-	O
1	O
gp41	O
HR2	O
-	O
derived	O
peptide	O
)	O
and	O
T	O
-	O
1249	O
with	O
S	O
protein	O
HR1	O
-	O
and	O
HR2	O
-	O
derived	O
peptides	O
.	O

SARS	B-DISO
'	O
clinical	O
description	O
is	O
presented	O
,	O
including	O
its	O
common	O
signs	O
/	O
symptoms	O
,	O
diagnosis	O
,	O
and	O
treatment	O
.	O

Potential	O
neonatal	O
outcomes	O
include	O
complications	O
related	O
to	O
premature	B-DISO
birth	I-DISO
,	O
intrauterine	B-DISO
growth	I-DISO
restriction	I-DISO
,	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
,	O
and	O
severe	O
gastrointestinal	O
manifestations	O
.	O

A	O
prominent	O
example	O
,	O
central	O
to	O
our	O
current	O
understanding	O
of	O
epidemic	O
spread	O
,	O
is	O
the	O
basic	O
reproductive	O
number	O
,	O
R	O
(	O
0	O
),	O
which	O
is	O
defined	O
as	O
the	O
mean	O
number	O
of	O
infections	B-DISO
caused	O
by	O
an	O
infected	O
individual	O
in	O
a	O
susceptible	O
population	O
.	O

ABSTRACT	O
:	O
An	O
indirect	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	B-DISO
)	O
virus	O
(	O
PEDV	O
)	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
was	O
compared	O
with	O
the	O
serum	O
neutralization	O
(	O
SN	O
)	O
test	O
by	O
testing	O
46	O
samples	O
from	O
experimentally	O
infected	O
sows	O
,	O
73	O
samples	O
from	O
naive	O
sows	O
,	O
and	O
1	O
,	O
024	O
field	O
sow	O
samples	O
from	O
48	O
commercial	O
swine	O
farms	O
of	O
undefined	O
PED	B-DISO
status	O
.	O

ABSTRACT	O
:	O
The	O
Hospital	O
Emergency	B-DISO
Incident	O
Command	O
System	O
(	O
HEICS	O
),	O
now	O
in	O
its	O
third	O
edition	O
,	O
has	O
emerged	O
as	O
a	O
popular	O
incident	O
command	O
system	O
model	O
for	O
hospital	O
emergency	B-DISO
response	O
in	O
the	O
United	O
States	O
and	O
other	O
countries	O
.	O

ABSTRACT	O
:	O
Recent	O
years	O
have	O
witnessed	O
the	O
emergence	O
of	O
new	O
pathogens	O
linked	O
to	O
community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
CAP	B-DISO
)	O
along	O
with	O
new	O
antibiotics	O
designed	O
to	O
combat	O
them	O
.	O

Such	O
events	O
illustrated	O
that	O
lack	O
of	O
infection	B-DISO
control	O
(	O
IC	O
)	O
measures	O
or	O
failure	O
to	O
comply	O
with	O
IC	O
precautions	O
could	O
lead	O
to	O
large	O
-	O
scale	O
hospital	O
outbreaks	O
.	O

ABSTRACT	O
:	O
The	O
SARS	B-DISO
outbreak	O
hit	O
Singapore	O
between	O
March	O
and	O
May	O
2003	O
.	O

Nosocomial	O
spread	O
composed	O
majority	O
of	O
SARS	B-DISO
cases	O
in	O
Singapore	O
.	O

At	O
all	O
air	O
,	O
sea	O
and	O
land	O
points	O
-	O
of	O
-	O
entry	O
,	O
exit	O
and	O
entry	O
screening	O
took	O
place	O
that	O
resulted	O
in	O
zero	O
importation	O
and	O
exportation	O
of	O
SARS	B-DISO
cases	O
after	O
implementation	O
of	O
screening	O
.	O

ABSTRACT	O
:	O
Transplantation	O
of	O
remyelination	O
-	O
competent	O
cells	O
represents	O
a	O
promising	O
strategy	O
for	O
the	O
treatment	O
of	O
demyelinating	B-DISO
diseases	I-DISO
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
severity	O
of	O
neuroinflammation	O
following	O
transplantation	O
of	O
glial	O
-	O
committed	O
progenitor	O
cells	O
into	O
the	O
spinal	O
cords	O
of	O
mice	O
chronically	O
infected	O
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
),	O
a	O
model	O
in	O
which	O
T	O
cells	O
and	O
macrophages	O
are	O
critical	O
in	O
amplifying	O
the	O
severity	O
of	O
demyelination	B-DISO
.	O

TITLE	O
:	O
Anti	O
-	O
SARS	B-DISO
-	O
CoV	O
immunity	O
induced	O
by	O
a	O
novel	O
CpG	O
oligodeoxynucleotide	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
CpG	O
oligodeoxynucleotides	O
(	O
CpG	O
ODNs	O
)	O
based	O
therapy	O
for	O
prevention	O
and	O
treatment	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
we	O
selected	O
a	O
novel	O
CpG	O
ODN	O
(	O
BW001	O
),	O
which	O
displays	O
B	O
-	O
type	O
CpG	O
ODN	O
structure	O
feature	O
at	O
the	O
5	O
'	O
and	O
A	O
-	O
type	O
CpG	O
ODN	O
structure	O
feature	O
at	O
the	O
3	O
',	O
and	O
tested	O
for	O
its	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
activity	O
.	O

However	O
,	O
only	O
54	O
%	O
of	O
respondents	O
knew	O
the	O
incubation	O
period	O
of	O
SARS	B-DISO
.	O

The	O
results	O
obtained	O
suggest	O
that	O
knowledge	O
of	O
SARS	B-DISO
was	O
generally	O
good	O
although	O
obtained	O
from	O
both	O
medical	O
and	O
non	O
-	O
medical	O
sources	O
.	O

ARDS	B-DISO
has	O
been	O
associated	O
with	O
the	O
administration	O
of	O
other	O
monoclonal	O
antibodies	O
,	O
such	O
as	O
infliximab	O
,	O
gemtuzumab	O
ozogamicin	O
,	O
and	O
OKT3	O
and	O
is	O
believed	O
to	O
be	O
directly	O
mediated	O
by	O
release	O
of	O
proinflammatory	O
cytokines	O
.	O

TITLE	O
:	O
Subcellular	O
localization	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
nucleocapsid	O
protein	O
.	O

Four	O
patients	O
died	O
during	O
further	O
treatment	O
due	O
to	O
multiple	O
trauma	O
or	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Use	O
of	O
an	O
internal	O
control	O
in	O
a	O
quantitative	O
RT	O
-	O
PCR	O
assay	O
for	O
quantitation	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	B-DISO
shedding	I-DISO
in	O
pigs	O
.	O

ABSTRACT	O
:	O
Epidemiologic	O
data	O
suggested	O
that	O
there	O
was	O
an	O
obvious	O
predominance	O
of	O
young	O
adult	O
patients	O
with	O
a	O
slight	O
female	O
proneness	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

TITLE	O
:	O
SARS	B-DISO
coronavirus	O
7a	O
protein	O
blocks	O
cell	O
cycle	O
progression	O
at	O
G0	O
/	O
G1	O
phase	O
via	O
the	O
cyclin	O
D3	O
/	O
pRb	O
pathway	O
.	O

Selected	O
serial	O
chest	O
radiographs	O
obtained	O
from	O
the	O
time	O
of	O
presentation	O
until	O
discharge	O
or	O
death	O
in	O
1373	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
SARS	B-DISO
were	O
scored	O
.	O

TITLE	O
:	O
SARS	B-DISO
:	O
understanding	O
the	O
virus	O
and	O
development	O
of	O
rational	O
therapy	O
.	O

ABSTRACT	O
:	O
Public	O
health	O
officials	O
once	O
suggested	O
that	O
it	O
might	O
someday	O
be	O
possible	O
to	O
""""	O
close	O
the	O
book	O
""""	O
on	O
the	O
study	O
and	O
treatment	O
of	O
infectious	B-DISO
diseases	I-DISO
.	O

The	O
spike	O
glycoprotein	O
,	O
S	O
,	O
which	O
mediates	O
receptor	O
binding	O
and	O
membrane	O
fusion	O
,	O
plays	O
a	O
critical	O
role	O
in	O
MHV	O
pathogenesis	B-DISO
.	O

Molecular	O
modeling	O
of	O
SARS	B-DISO
-	O
CoV	O
PLpro	O
suggested	O
that	O
this	O
catalytic	O
core	O
may	O
also	O
have	O
deubiquitinating	O
activity	O
.	O

TITLE	O
:	O
The	O
papain	O
-	O
like	O
protease	O
from	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
is	O
a	O
deubiquitinating	O
enzyme	O
.	O

ABSTRACT	O
:	O
The	O
mouse	B-DISO
hepatitis	I-DISO
coronavirus	O
(	O
MHV	O
)	O
infects	O
murine	O
cells	O
by	O
binding	O
of	O
its	O
spike	O
(	O
S	O
)	O
protein	O
to	O
murine	O
CEACAM1a	O
.	O

SARS	B-DISO
-	O
CoV	O
structural	O
proteins	O
and	O
virions	O
localized	O
to	O
ciliated	O
epithelial	O
cells	O
.	O

Epithelial	O
cell	B-DISO
injury	I-DISO
,	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
and	O
surfactant	O
dysfunction	O
ensue	O
leading	O
to	O
refractory	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
The	O
putative	O
protein	O
6	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
:	O
expression	O
and	O
functional	O
characterization	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
confirmed	O
the	O
SARS	B-DISO
6	O
protein	O
expression	O
in	O
lung	O
and	O
intestine	O
tissues	O
of	O
the	O
SARS	B-DISO
patients	O
and	O
in	O
SARS	B-DISO
-	O
CoV	O
infected	O
Vero	O
E6	O
cells	O
by	O
immunohistochemistry	O
.	O

ABSTRACT	O
:	O
In	O
the	O
last	O
years	O
our	O
country	O
has	O
been	O
affected	O
by	O
several	O
outbreaks	O
of	O
infectious	B-DISO
diseases	I-DISO
such	O
as	O
Cholera	B-DISO
and	O
Hanta	O
virus	O
and	O
recently	O
,	O
by	O
pathogens	O
associated	O
to	O
red	O
tide	O
.	O

The	O
new	O
threat	O
that	O
may	O
emerge	O
and	O
could	O
eventually	O
overcome	O
that	O
capacity	O
,	O
is	O
the	O
possible	O
H5N1	B-DISO
influenza	I-DISO
virus	O
outbreak	O
.	O

It	O
is	O
possible	O
that	O
we	O
may	O
have	O
a	O
vaccine	O
before	O
the	O
outbreak	O
;	O
this	O
development	O
is	O
even	O
faster	O
than	O
for	O
SARS	B-DISO
.	O

Respiratory	B-DISO
failure	I-DISO
is	O
the	O
major	O
complication	B-DISO
of	O
SARS	B-DISO
;	O
at	O
least	O
half	O
of	O
the	O
patients	O
require	O
supplemental	O
oxygen	O
during	O
the	O
acute	O
phase	O
whereas	O
about	O
20	O
%	O
of	O
patients	O
progress	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
requiring	O
invasive	O
mechanical	O
ventilatory	O
support	O
.	O

Over	O
8439	O
SARS	B-DISO
cases	O
and	O
812	O
SARS	B-DISO
-	O
related	O
deaths	O
were	O
reported	O
to	O
the	O
World	O
Health	O
Organization	O
from	O
32	O
countries	O
around	O
the	O
world	O
up	O
to	O
5	O
July	O
2003	O
.	O

We	O
showed	O
that	O
in	O
vitro	O
and	O
in	O
vivo	O
infections	B-DISO
across	O
the	O
species	O
barrier	O
differ	O
in	O
their	O
requirements	O
.	O

Future	O
genetic	O
engineering	O
approaches	O
are	O
suggested	O
to	O
provide	O
animal	O
models	O
for	O
the	O
better	O
understanding	O
of	O
human	O
infectious	B-DISO
diseases	I-DISO
.	O

Pooled	O
tissue	O
samples	O
(	O
trachea	B-DISO
,	O
kidney	O
,	O
caecal	O
tonsils	O
and	O
cloacal	O
swabs	O
)	O
from	O
164	O
broiler	O
and	O
53	O
layer	O
flocks	O
located	O
throughout	O
New	O
Zealand	O
were	O
collected	O
in	O
transport	O
medium	O
containing	O
antibiotics	O
.	O

On	O
the	O
basis	O
of	O
similarities	O
with	O
other	O
coronavirus	B-DISO
infections	I-DISO
,	O
SARS	B-DISO
might	O
,	O
in	O
part	O
,	O
be	O
immune	O
mediated	O
.	O

TITLE	O
:	O
[	O
Intermittent	O
asphyxia	B-DISO
syndrome	B-DISO
caused	O
by	O
a	O
bronchial	O
cast	O
in	O
the	O
subglottic	O
region	O
].	O

SDS	B-DISO
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	B-DISO
-	O
PAGE	O
),	O
Western	O
blot	O
and	O
neutralization	O
test	O
results	O
showed	O
that	O
the	O
IgY	O
obtained	O
was	O
of	O
a	O
high	O
purity	O
and	O
had	O
a	O
strong	O
reactive	O
activity	O
with	O
a	O
neutralization	O
titer	O
of	O
1	O
:	O
640	O
.	O

TITLE	O
:	O
From	O
genome	O
to	O
drug	O
lead	O
:	O
identification	O
of	O
a	O
small	O
-	O
molecule	O
inhibitor	O
of	O
the	O
SARS	B-DISO
virus	O
.	O

Acad	B-DISO
.	O

A	O
short	O
historical	O
overview	O
of	O
the	O
antiphospholipid	B-DISO
syndrome	I-DISO
(	O
APS	B-DISO
)	O
is	O
followed	O
by	O
a	O
description	O
of	O
the	O
""""	O
triggering	O
""""	O
factors	O
,	O
associated	O
autoimmune	B-DISO
diseases	I-DISO
,	O
clinical	O
presentation	O
,	O
presumed	O
pathogenesis	B-DISO
,	O
prognosis	O
,	O
mode	O
of	O
death	O
and	O
suggested	O
therapies	O
.	O

Parenteral	O
antibiotics	O
may	O
be	O
indicated	O
where	O
an	O
underlying	B-DISO
infection	I-DISO
is	O
suspected	O
.	O

The	O
per	O
-	O
1	O
,	O
000	O
positivity	O
rates	O
were	O
influenza	B-DISO
virus	O
66	O
,	O
RSV	O
49	O
,	O
rhinovirus	O
33	O
,	O
metapneumovirus	O
16	O
,	O
and	O
coronavirus	O
8	O
.	O

TITLE	O
:	O
The	O
N	O
-	O
terminal	O
octapeptide	O
acts	O
as	O
a	O
dimerization	O
inhibitor	O
of	O
SARS	B-DISO
coronavirus	O
3C	O
-	O
like	O
proteinase	O
.	O

Accurate	O
determination	O
of	O
the	O
dimer	O
dissociation	B-DISO
constant	O
and	O
the	O
role	O
of	O
the	O
N	O
-	O
finger	O
(	O
residues	O
1	O
-	O
7	O
)	O
will	O
provide	O
more	O
insights	O
into	O
the	O
enzyme	O
catalytic	O
mechanism	O
of	O
SARS	B-DISO
3CL	O
proteinase	O
.	O

ABSTRACT	O
:	O
Influenza	O
pneumonia	B-DISO
and	I-DISO
influenza	I-DISO
-	O
associated	O
severe	O
exacerbation	O
of	O
pre	O
-	O
existing	O
heart	O
and	O
lung	B-DISO
disease	I-DISO
are	O
responsible	O
for	O
major	O
complications	O
that	O
may	O
require	O
intensive	O
care	O
unit	O
admission	O
.	O

Influenza	B-DISO
pneumonia	I-DISO
is	O
a	O
significant	O
cause	O
of	O
morbidity	O
and	O
mortality	O
,	O
especially	O
during	O
influenza	B-DISO
epidemics	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
an	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
caused	O
by	O
a	O
novel	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

Besides	O
,	O
determinants	O
of	O
the	O
SARS	B-DISO
incubation	O
period	O
remain	O
unclear	O
.	O

In	O
this	O
study	O
,	O
209	O
probable	O
SARS	B-DISO
cases	O
with	O
documented	O
episodes	O
of	O
exposure	O
between	O
March	O
1	O
and	O
May	O
31	O
,	O
2003	O
,	O
in	O
mainland	O
China	O
were	O
included	O
.	O

Expression	O
of	O
exogenous	O
cathepsin	O
L	O
substantially	O
enhanced	O
infection	B-DISO
mediated	O
by	O
the	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
and	O
by	O
filovirus	O
GP	O
proteins	O
but	O
not	O
by	O
the	O
HCoV	O
-	O
NL63	O
S	O
protein	O
or	O
the	O
vesicular	B-DISO
stomatitis	I-DISO
virus	O
G	O
protein	O
.	O

We	O
report	O
a	O
24	O
years	O
old	O
male	O
with	O
HPS	B-DISO
that	O
was	O
successfully	O
managed	O
when	O
an	O
arterio	O
-	O
venous	O
shunt	O
was	O
added	O
to	O
a	O
conventional	O
veno	O
-	O
arterial	O
ECLS	O
technique	O
.	O

These	O
items	O
were	O
,	O
in	O
general	O
,	O
negatively	O
associated	O
with	O
post	O
-	O
traumatic	O
stress	O
,	O
perception	O
of	O
stress	O
and	O
other	O
perceptions	O
that	O
were	O
related	O
to	O
SARS	B-DISO
.	O

TITLE	O
:	O
Vasculitis	B-DISO
and	O
systemic	B-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
In	O
recent	O
years	O
,	O
many	O
investigators	O
have	O
focused	O
on	O
potential	O
associations	O
between	O
infections	B-DISO
and	O
vascular	B-DISO
inflammation	I-DISO
.	O

We	O
review	O
the	O
principal	O
pathogenic	O
mechanisms	O
that	O
have	O
been	O
implicated	O
for	O
possible	O
roles	O
in	O
the	O
vascular	B-DISO
inflammation	I-DISO
initiated	O
by	O
infectious	B-DISO
agents	O
.	O

A	O
single	O
molecule	O
detection	O
(	O
SMD	B-DISO
)	O
based	O
technique	O
was	O
developed	O
for	O
simultaneously	O
measuring	O
both	O
bulk	O
flow	O
and	O
near	O
-	O
wall	O
flow	O
velocity	O
in	O
the	O
microchannels	O
.	O

ABSTRACT	O
:	O
Gene	O
3	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
is	O
tricistronic	O
;	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
3a	O
and	O
3b	O
encode	O
two	O
small	O
nonstructural	O
(	O
ns	O
)	O
proteins	O
,	O
3a	O
and	O
3b	O
,	O
of	O
unknown	O
function	O
,	O
and	O
a	O
third	O
,	O
structural	O
protein	O
E	O
,	O
is	O
encoded	O
by	O
ORF	O
3c	O
.	O

Errors	O
in	O
infection	B-DISO
control	O
as	O
well	O
as	O
in	O
medical	O
management	O
of	O
advanced	O
cardiac	O
life	O
support	O
(	O
ACLS	B-DISO
)	O
were	O
corrected	O
.	O

Errors	O
in	O
infection	B-DISO
control	O
as	O
well	O
as	O
in	O
medical	O
management	O
of	O
advanced	O
cardiac	O
life	O
support	O
(	O
ACLS	B-DISO
)	O
were	O
corrected	O
.	O

ABSTRACT	O
:	O
Critical	O
care	O
myopathy	B-DISO
(	O
CCM	B-DISO
)	O
is	O
an	O
important	O
,	O
often	O
unrecognized	O
cause	O
of	O
weakness	B-DISO
in	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
).	O

Risk	O
factors	O
that	O
may	O
have	O
predisposed	O
this	O
patient	O
to	O
CCM	B-DISO
include	O
underlying	O
liver	B-DISO
dysfunction	I-DISO
,	O
presence	O
of	O
acute	O
lung	O
injury	O
,	O
use	O
of	O
corticosteroids	O
,	O
and	O
use	O
of	O
neuromuscular	B-DISO
blockade	I-DISO
.	O

Subsequently	O
,	O
the	O
technique	O
was	O
employed	O
in	O
the	O
diagnosis	O
of	O
other	O
viral	B-DISO
infections	I-DISO
,	O
such	O
as	O
hepatitis	B-DISO
B	I-DISO
and	O
parvovirus	B-DISO
B19	I-DISO
.	O

Furthermore	O
,	O
EM	O
forms	O
a	O
vital	O
part	O
of	O
the	O
national	O
emergency	B-DISO
response	O
programme	O
of	O
many	O
countries	O
and	O
will	O
provide	O
a	O
frontline	O
diagnostic	O
service	O
in	O
the	O
event	O
of	O
a	O
bioterrorism	O
incident	O
,	O
particularly	O
in	O
the	O
scenario	O
of	O
a	O
deliberate	O
release	O
of	O
smallpox	B-DISO
virus	O
.	O

TITLE	O
:	O
SARS	B-DISO
coronavirus	O
E	O
protein	O
in	O
phospholipid	O
bilayers	O
:	O
an	O
x	O
-	O
ray	O
study	O
.	O

CONCLUSIONS	O
:	O
In	O
severely	O
injured	O
trauma	O
patients	O
who	O
require	O
administration	O
of	O
packed	O
red	O
blood	O
cells	O
,	O
the	O
amount	O
of	O
transfused	O
blood	O
is	O
independently	O
associated	O
with	O
both	O
the	O
development	O
of	O
ARDS	B-DISO
and	O
hospital	O
mortality	O
.	O

TITLE	O
:	O
How	O
the	O
SARS	B-DISO
coronavirus	O
causes	O
disease	O
:	O
host	O
or	O
organism	O
?	O

However	O
,	O
many	O
questions	O
concerning	O
how	O
the	O
aetiological	O
agent	O
,	O
the	O
novel	O
SARS	B-DISO
coronavirus	O
(	O
CoV	O
),	O
causes	O
illness	O
in	O
humans	O
remain	O
unanswered	O
.	O

For	O
the	O
host	O
cells	O
,	O
the	O
outcome	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
,	O
whether	O
there	O
are	O
cytopathic	B-DISO
effects	I-DISO
or	O
not	O
,	O
depends	O
on	O
the	O
cell	O
types	O
that	O
are	O
infected	O
.	O

At	O
the	O
whole	O
-	O
body	O
level	O
,	O
immune	O
-	O
mediated	O
damage	O
,	O
due	O
to	O
activation	O
of	O
cytokines	O
and	O
/	O
or	O
chemokines	O
and	O
,	O
perhaps	O
,	O
autoimmunity	B-DISO
,	O
may	O
play	O
key	O
roles	O
in	O
the	O
clinical	O
and	O
pathological	O
features	O
of	O
SARS	B-DISO
.	O

TITLE	O
:	O
[	O
Present	O
situation	O
and	O
control	O
on	O
emerging	O
respiratory	O
infectious	B-DISO
diseases	I-DISO
such	O
as	O
SARS	B-DISO
and	O
avian	B-DISO
influenza	I-DISO
].	O

The	O
outbreaks	O
of	O
avian	B-DISO
influenza	I-DISO
among	O
fowls	O
have	O
been	O
occurred	O
since	O
2004	O
,	O
and	O
some	O
fatal	O
human	O
cases	O
infected	O
with	O
avian	B-DISO
influenza	I-DISO
virus	O
are	O
detected	O
in	O
Viet	O
Nam	O
,	O
Thailand	O
,	O
Cambodia	O
and	O
Indonesia	O
.	O

Recently	O
,	O
many	O
outbreaks	O
of	O
virus	O
zoonoses	B-DISO
are	O
reported	O
in	O
the	O
world	O
,	O
which	O
include	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
disease	O
,	O
avian	B-DISO
influenza	I-DISO
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

It	O
covers	O
the	O
taxonomy	O
,	O
structure	O
of	O
virion	O
,	O
viral	O
genome	O
and	O
proteins	O
,	O
unique	O
replication	O
strategy	O
,	O
receptors	O
and	O
viral	B-DISO
pathogenesis	I-DISO
.	O

L	O
-	O
SIGN	O
,	O
encoded	O
by	O
CLEC4M	O
(	O
also	O
known	O
as	O
CD209L	O
),	O
is	O
a	O
SARS	B-DISO
-	O
CoV	O
binding	O
receptor	O
that	O
has	O
polymorphism	O
in	O
its	O
extracellular	O
neck	O
region	O
encoded	O
by	O
the	O
tandem	O
repeat	O
domain	O
in	O
exon	O
4	O
.	O

TITLE	O
:	O
Intestinal	O
invasion	B-DISO
and	O
disseminated	O
disease	O
associated	O
with	O
Penicillium	O
chrysogenum	O
.	O

They	O
are	O
a	O
rarely	O
identified	O
cause	O
of	O
infection	B-DISO
in	O
immunocompetent	O
hosts	O
.	O

A	O
51	O
year	O
old	O
African	O
-	O
American	O
female	O
presented	O
with	O
an	O
acute	B-DISO
abdomen	I-DISO
and	O
underwent	O
an	O
exploratory	O
laparotomy	O
which	O
revealed	O
an	O
incarcerated	O
peristomal	O
hernia	B-DISO
.	O

In	O
this	O
report	O
we	O
summarized	O
the	O
results	O
from	O
an	O
epidemiological	O
investigation	O
of	O
a	O
SARS	B-DISO
outbreak	O
in	O
a	O
hospital	O
in	O
Tianjin	O
,	O
between	O
April	O
and	O
May	O
2003	O
.	O

The	O
overall	O
case	O
fatality	O
in	O
the	O
SARS	B-DISO
outbreak	O
was	O
11	O
.	O
7	O
%	O
(	O
13	O
/	O
111	O
).	O

SARS	B-DISO
is	O
a	O
highly	O
contagious	O
condition	B-DISO
associated	O
with	O
substantial	O
case	O
fatality	O
;	O
an	O
outbreak	O
can	O
result	O
from	O
one	O
patient	O
in	O
a	O
relatively	O
short	O
period	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
use	O
of	O
a	O
pumpless	O
extracorporeal	O
lung	O
assist	O
device	O
in	O
the	O
treatment	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

A	O
15	O
-	O
yr	O
-	O
old	O
girl	O
developed	O
severe	O
post	O
-	O
traumatic	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Acute	O
lung	O
injury	O
in	O
patients	O
with	O
subarachnoid	B-DISO
hemorrhage	I-DISO
:	O
incidence	O
,	O
risk	O
factors	O
,	O
and	O
outcome	O
.	O

ABSTRACT	O
:	O
Pulmonary	B-DISO
complications	I-DISO
account	O
for	O
significant	O
morbidity	O
and	O
mortality	O
following	O
aneurysmal	B-DISO
subarachnoid	I-DISO
hemorrhage	I-DISO
;	O
however	O
,	O
the	O
effect	O
of	O
acute	O
lung	O
injury	O
is	O
largely	O
unknown	O
.	O

Six	O
-	O
hundred	O
and	O
twenty	O
patients	O
with	O
aneurysmal	B-DISO
subarachnoid	I-DISO
hemorrhage	I-DISO
documented	O
on	O
computed	O
tomography	O
or	O
angiography	O
.	O

On	O
multivariate	O
analysis	O
,	O
severity	O
of	O
illness	O
,	O
clinical	O
grade	O
of	O
hemorrhage	B-DISO
,	O
packed	O
red	O
blood	O
cell	O
transfusions	O
,	O
and	O
severe	B-DISO
sepsis	I-DISO
in	O
the	O
intensive	O
care	O
unit	O
were	O
independently	O
associated	O
with	O
development	O
of	O
acute	O
lung	O
injury	O
.	O

Acute	O
lung	O
injury	O
is	O
common	O
in	O
patients	O
with	O
subarachnoid	B-DISO
hemorrhage	I-DISO
and	O
is	O
independently	O
associated	O
with	O
a	O
worse	O
clinical	O
outcome	O
.	O

TITLE	O
:	O
Time	O
course	O
and	O
cellular	O
localization	O
of	O
SARS	B-DISO
-	O
CoV	O
nucleoprotein	O
and	O
RNA	O
in	O
lungs	O
from	O
fatal	O
cases	O
of	O
SARS	B-DISO
.	O

Fourteen	O
hospitalized	O
patients	O
with	O
a	O
diagnosis	O
of	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
infection	B-DISO
at	O
National	O
Taiwan	O
University	O
Hospital	O
from	O
March	O
to	O
May	O
2003	O
were	O
included	O
.	O

The	O
abnormality	O
in	O
pulmonary	O
functions	O
manifests	O
mainly	O
as	O
impairment	B-DISO
of	O
diffusion	O
function	O
.	O

Both	O
the	O
low	O
and	O
high	O
intensity	O
of	O
UV	O
-	O
B	O
exposure	O
increased	O
the	O
concentration	O
of	O
glycyrrhizin	O
in	O
the	O
root	O
tissues	O
of	O
3	O
-	O
month	O
-	O
old	O
pot	B-DISO
plants	O
,	O
the	O
values	O
being	O
nearly	O
X1	O
.	O
5	O
those	O
of	O
the	O
control	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
the	O
spectrum	O
of	O
immune	O
responses	O
of	O
mice	O
to	O
three	O
different	O
forms	O
of	O
the	O
SARS	B-DISO
coronavirus	O
nucleocapsid	O
(	O
N	O
):	O
(	O
1	O
)	O
exogenous	O
recombinant	O
protein	O
(	O
N	O
-	O
GST	O
)	O
with	O
Freund	O
'	O
s	O
adjuvant	O
;	O
(	O
2	O
)	O
DNA	O
encoding	O
unmodified	O
N	O
as	O
an	O
endogenous	O
cytoplasmic	O
protein	O
(	O
pN	O
);	O
and	O
(	O
3	O
)	O
DNA	O
encoding	O
N	O
as	O
a	O
LAMP	O
-	O
1	O
chimera	B-DISO
targeted	O
to	O
the	O
lysosomal	O
MHC	O
II	O
compartment	O
(	O
p	O
-	O
LAMP	O
-	O
N	O
).	O

The	O
pronounced	O
Th	O
-	O
2	O
and	O
humoral	O
response	O
to	O
N	O
protein	O
plus	O
adjuvant	O
are	O
in	O
contrast	O
to	O
the	O
balanced	O
IFN	O
-	O
gamma	O
and	O
IL	O
-	O
4	O
responses	O
and	O
strong	O
memory	O
CTL	O
responses	O
to	O
the	O
LAMP	O
-	O
N	O
chimera	B-DISO
.	O

The	O
most	O
selective	O
compounds	O
were	O
active	O
in	O
the	O
higher	O
microgram	O
per	O
litre	O
range	O
,	O
being	O
non	O
-	O
toxic	O
at	O
50	O
-	O
100	O
mg	O
/	O
L	O
.	O
There	O
was	O
a	O
poor	O
structure	O
-	O
antiviral	O
activity	O
relationship	O
(	O
SAR	O
)	O
for	O
the	O
pyridine	O
N	O
-	O
oxide	O
derivatives	O
against	O
Fe	O
-	O
CoV	O
and	O
SARS	B-DISO
-	O
CoV	O
.	O
One	O
of	O
the	O
most	O
active	O
and	O
selective	O
compounds	O
was	O
shown	O
to	O
inhibit	O
Fe	O
-	O
CoV	O
replication	O
at	O
the	O
transcriptional	O
level	O
.	O

Antibody	O
titers	O
were	O
measured	O
by	O
plaque	B-DISO
reduction	O
neutralization	O
test	O
.	O

TITLE	O
:	O
[	O
A	O
case	O
-	O
control	O
study	O
on	O
the	O
mxA	O
polymorphisms	O
and	O
susceptibility	O
to	O
severe	O
acute	O
respiratory	O
syndromes	B-DISO
].	O

Multivariate	O
logistic	O
regression	O
analysis	O
revealed	O
that	O
the	O
significant	O
association	O
remained	O
after	O
factors	O
as	O
wearing	O
masks	O
,	O
protection	O
gowns	O
and	O
eye	O
-	O
protection	O
when	O
contacting	O
with	O
SARS	B-DISO
patient	O
etc	O
.	O

Together	O
with	O
the	O
long	O
-	O
term	O
gene	O
expression	O
after	O
gene	O
transfer	O
,	O
these	O
findings	O
supported	O
the	O
initiation	O
of	O
clinical	O
trials	O
to	O
assess	O
the	O
safety	O
of	O
AAV2	O
(	O
CU	O
)	O
hCLN2	O
administration	O
to	O
individuals	O
with	O
LINCL	B-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
was	O
discovered	O
during	O
a	O
recent	O
global	O
outbreak	O
of	O
atypical	B-DISO
pneumonia	I-DISO
.	O

The	O
present	O
study	O
was	O
carried	O
out	O
to	O
evaluate	O
the	O
performance	O
of	O
SARS	B-DISO
resequencing	O
GeneChips	O
.	O

Based	O
on	O
their	O
mechanism	O
,	O
these	O
procedures	O
are	O
grouped	O
into	O
three	O
classes	O
:	O
partitioning	O
,	O
inactivation	B-DISO
,	O
and	O
removal	O
based	O
on	O
size	O
.	O

ABSTRACT	O
:	O
Unwitnessed	O
gastric	O
aspiration	B-DISO
can	O
be	O
a	O
diagnostic	O
dilemma	O
,	O
and	O
early	O
discrimination	O
of	O
different	O
forms	O
may	O
help	O
to	O
identify	O
individuals	O
with	O
increased	O
risk	O
of	O
development	O
of	O
severe	O
clinical	O
acute	O
lung	O
injury	O
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
We	O
have	O
examined	O
studies	O
published	O
since	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreak	O
that	O
elucidate	O
the	O
mode	O
of	O
transmission	O
of	O
respiratory	O
pathogens	O
and	O
the	O
optimal	O
means	O
of	O
interrupting	O
their	O
transmission	O
,	O
focusing	O
on	O
transmission	O
in	O
the	O
intensive	O
care	O
unit	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
experience	O
of	O
being	O
on	O
quarantine	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
with	O
a	O
focus	O
on	O
the	O
relationship	O
between	O
perceived	O
risk	O
of	O
contracting	O
SARS	B-DISO
and	O
reported	O
compliance	O
with	O
the	O
quarantine	O
order	O
and	O
protocols	O
.	O

TITLE	O
:	O
Novel	O
five	O
-	O
membered	O
iminocyclitol	O
derivatives	O
as	O
selective	O
and	O
potent	O
glycosidase	O
inhibitors	O
:	O
new	O
structures	O
for	O
antivirals	O
and	O
osteoarthritis	B-DISO
.	O

Electronic	O
and	O
manual	O
searches	O
was	O
conducted	O
to	O
identify	O
randomised	O
controlled	O
trials	O
(	O
RCTs	O
)	O
for	O
comparing	O
the	O
effects	O
of	O
integrative	O
traditional	O
Chinese	O
and	O
Western	O
medicine	O
versus	O
the	O
effects	O
of	O
Western	O
medicine	O
alone	O
in	O
treating	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
The	O
recent	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
the	O
growing	O
potential	O
of	O
an	O
influenza	B-DISO
pandemic	O
force	O
us	O
to	O
consider	O
the	O
fact	O
that	O
despite	O
great	O
advances	O
in	O
critical	O
care	O
medicine	O
,	O
we	O
lack	O
the	O
capacity	O
to	O
provide	O
intensive	O
care	O
to	O
the	O
large	O
number	O
of	O
patients	O
that	O
may	O
be	O
generated	O
in	O
an	O
epidemic	O
or	O
multisite	O
bioterrorism	O
event	O
.	O

The	O
GeneMark	O
systems	O
for	O
gene	O
-	O
finding	O
in	O
virus	O
and	O
phage	O
genomes	O
suffer	B-DISO
from	O
some	O
basic	O
drawbacks	O
.	O

TITLE	O
:	O
Data	O
from	O
11	O
years	O
of	O
molecular	O
typing	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
field	O
isolates	O
.	O

ABSTRACT	O
:	O
In	O
1993	O
,	O
a	O
new	O
molecular	O
typing	O
method	O
for	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
was	O
introduced	O
.	O

The	O
data	O
were	O
obtained	O
from	O
clinical	O
samples	O
submitted	O
to	O
our	O
laboratory	O
from	O
birds	O
with	O
clinical	O
signs	O
characteristic	O
of	O
IBV	O
infection	B-DISO
.	O

Our	O
observations	O
highlight	O
the	O
importance	O
of	O
constantly	O
monitoring	O
IBV	O
as	O
well	O
as	O
other	O
coronaviruses	O
like	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
coronavirus	O
that	O
have	O
the	O
ability	O
to	O
change	O
and	O
emerge	O
to	O
cause	O
disease	O
in	O
a	O
susceptible	O
host	O
.	O

Another	O
substance	O
,	O
such	O
as	O
interleukin	O
10	O
,	O
was	O
efficacious	O
in	O
decreasing	O
the	O
severity	O
and	O
mortality	O
of	O
lethal	O
pancreatitis	B-DISO
in	O
rats	O
,	O
but	O
seems	O
to	O
have	O
no	O
effect	O
on	O
human	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
.	O

Thus	O
,	O
the	O
main	O
problem	O
in	O
acute	B-DISO
pancreatitis	I-DISO
,	O
especially	O
in	O
the	O
severe	O
form	O
of	O
the	O
disease	O
,	O
is	O
the	O
difficulty	O
of	O
planning	O
clinical	O
studies	O
capable	O
of	O
giving	O
hard	O
statistically	O
significant	O
answers	O
regarding	O
the	O
benefits	O
of	O
the	O
various	O
proposed	O
therapeutic	O
agents	O
previously	O
tested	O
in	O
experimental	O
settings	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
pulmonary	O
inflammatory	B-DISO
reaction	I-DISO
induced	O
by	O
N	O
-	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
in	O
rat	O
models	O
and	O
the	O
effects	O
of	O
glucocorticoids	O
on	O
the	O
inflammatory	B-DISO
reaction	I-DISO
.	O

Among	O
the	O
11	O
previous	O
cases	O
of	O
vivax	O
-	O
related	O
severe	O
respiratory	O
involvement	O
described	O
in	O
the	O
literature	O
,	O
all	O
except	O
one	O
developed	O
it	O
after	O
the	O
beginning	O
of	O
anti	O
-	O
malarial	O
treatment	O
;	O
these	O
appear	O
to	O
correspond	O
to	O
an	O
exacerbation	O
of	O
the	O
inflammatory	B-DISO
response	I-DISO
.	O

TITLE	O
:	O
SARS	B-DISO
:	O
clinical	O
presentation	O
,	O
transmission	O
,	O
pathogenesis	B-DISO
and	O
treatment	O
options	O
.	O

Although	O
the	O
rapidly	O
evolving	O
outbreak	O
did	O
not	O
allow	O
the	O
conducting	O
of	O
systematic	O
clinical	O
trails	O
to	O
evaluate	O
treatment	O
options	O
,	O
the	O
accumulated	O
experience	O
on	O
managing	O
SARS	B-DISO
patients	O
will	O
improve	O
the	O
clinical	O
outcome	O
should	O
SARS	B-DISO
return	O
.	O

Although	O
SARS	B-DISO
led	O
to	O
more	O
than	O
700	O
deaths	O
worldwide	O
,	O
the	O
lessons	O
learnt	O
have	O
prepared	O
healthcare	O
systems	O
worldwide	O
to	O
face	B-DISO
future	O
emerging	O
and	O
re	O
-	O
emerging	O
infections	B-DISO
.	O

Similarly	O
,	O
HCoV	O
-	O
OC43	O
,	O
likely	O
a	O
member	O
of	O
the	O
same	O
coronavirus	O
group	O
as	O
SARS	B-DISO
-	O
CoV	O
,	O
readily	O
crossed	O
the	O
species	O
barrier	O
as	O
evidenced	O
by	O
its	O
rapid	O
adaptation	O
to	O
the	O
murine	O
brain	O
[	O
McIntosh	O
,	O
K	O
.,	O
Becker	O
,	O
W	O
.	O
B	O
.,	O
Chanock	O
,	O
R	O
.	O
M	O
.,	O
1967	O
.	O

Growth	O
in	O
suckling	O
-	O
mouse	O
brain	O
of	O
""""	O
IBV	O
-	O
like	O
""""	O
viruses	O
from	O
patients	O
with	O
upper	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
.	O

TITLE	O
:	O
Bidirectional	O
virus	O
secretion	O
and	O
nonciliated	O
cell	O
tropism	O
following	O
Andes	O
virus	B-DISO
infection	I-DISO
of	O
primary	O
airway	O
epithelial	O
cell	O
cultures	O
.	O

There	O
is	O
no	O
obvious	O
cytopathology	O
associated	O
with	O
infection	B-DISO
,	O
and	O
beta	O
(	O
3	O
)	O
integrins	O
do	O
not	O
appear	O
to	O
be	O
critical	O
for	O
respiratory	O
epithelial	O
cell	O
monolayer	O
integrity	O
.	O

To	O
demonstrate	O
that	O
MHV	O
can	O
be	O
retargeted	O
to	O
a	O
nonnative	O
receptor	O
on	O
human	O
cells	O
,	O
we	O
produced	O
bispecific	O
adapter	O
proteins	O
composed	O
of	O
the	O
N	O
-	O
terminal	O
D1	O
domain	O
of	O
mCEACAM1a	O
linked	O
to	O
a	O
short	O
targeting	O
peptide	O
,	O
the	O
six	O
-	O
amino	O
-	O
acid	O
His	O
tag	B-DISO
.	O

TITLE	O
:	O
Important	O
role	O
for	O
the	O
transmembrane	O
domain	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
spike	O
protein	O
during	O
entry	O
.	O

Here	O
,	O
the	O
roles	O
of	O
the	O
transmembrane	O
and	O
cytoplasmic	O
domains	O
of	O
S	O
in	O
the	O
infectivity	O
and	O
membrane	O
fusion	O
activity	O
of	O
SARS	B-DISO
-	O
CoV	O
have	O
been	O
studied	O
.	O

ABSTRACT	O
:	O
Several	O
viruses	O
infect	O
the	O
mammalian	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
),	O
some	O
with	O
devastating	O
consequences	O
,	O
others	O
resulting	O
in	O
chronic	O
or	O
persistent	O
infections	B-DISO
associated	O
with	O
little	O
or	O
no	O
overt	O
pathology	B-DISO
.	O

The	O
two	O
recombinant	O
proteins	O
were	O
separately	O
verified	O
by	O
Western	O
blot	O
,	O
purified	O
by	O
nickel	O
-	O
affinity	O
chromatography	O
,	O
and	O
incubated	O
with	O
Vero	O
cells	O
,	O
a	O
susceptible	O
cell	O
line	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
,	O
for	O
cell	O
binding	O
assay	O
.	O

The	O
appropriate	O
expression	O
of	O
the	O
proteins	O
was	O
confirmed	O
by	O
Western	O
blotting	O
using	O
both	O
SARS	B-DISO
patients	O
'	O
sera	O
and	O
anti	O
-	O
6	O
x	O
histidine	O
antibody	O
.	O

Thus	O
,	O
lithium	O
intoxication	O
is	O
a	O
frequent	O
complication	B-DISO
of	O
chronic	O
lithium	O
therapy	O
.	O

However	O
,	O
she	O
was	O
unable	O
to	O
follow	O
commands	O
and	O
she	O
expressed	O
rigidity	B-DISO
of	O
extremities	O
,	O
mild	O
tachycardia	O
,	O
and	O
stupor	O
.	O

We	O
examined	O
the	O
relationship	O
between	O
the	O
redox	O
state	O
of	O
the	O
20	O
cysteine	O
residues	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
(	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
)	O
Spike	O
glycoprotein	O
S1	O
subdomain	O
and	O
its	O
functional	O
properties	O
.	O

Two	O
sets	O
of	O
4	O
photographs	O
-	O
the	O
same	O
man	O
in	O
formal	O
attire	O
,	O
a	O
white	O
coat	O
,	O
greens	O
,	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
standard	O
precautions	O
attire	O
,	O
and	O
the	O
same	O
woman	O
in	O
formal	O
attire	O
,	O
a	O
white	O
coat	O
,	O
greens	O
,	O
and	O
SARS	B-DISO
standard	O
precautions	O
attire	O
-	O
were	O
shown	O
to	O
the	O
children	O
and	O
their	O
caregiver	O
.	O

TITLE	O
:	O
Impact	O
of	O
human	O
metapneumovirus	O
and	O
human	O
cytomegalovirus	O
versus	O
other	O
respiratory	O
viruses	O
on	O
the	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
of	O
lung	O
transplant	O
recipients	O
.	O

With	O
the	O
exuberant	O
development	O
of	O
mouse	O
genetics	O
and	O
the	O
constant	O
generation	O
of	O
new	O
mutant	B-DISO
alleles	O
,	O
it	O
is	O
likely	O
that	O
many	O
more	O
genes	O
with	O
an	O
impact	O
on	O
the	O
phenotype	O
of	O
resistance	O
or	O
susceptibility	O
will	O
be	O
identified	O
in	O
the	O
forthcoming	O
years	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
effects	O
of	O
embryo	O
transfer	O
on	O
the	O
ethanol	O
phenotype	O
(	O
ethanol	O
-	O
induced	O
locomotor	O
depression	B-DISO
).	O

TITLE	O
:	O
Longitudinal	O
profile	O
of	O
antibodies	O
against	O
SARS	B-DISO
-	O
coronavirus	O
in	O
SARS	B-DISO
patients	O
and	O
their	O
clinical	O
significance	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
newly	O
discovered	O
disease	O
caused	O
by	O
a	O
novel	O
coronavirus	O
.	O

Two	O
methods	O
,	O
ELISA	O
and	O
indirect	O
immunofluorescent	O
assay	O
,	O
were	O
used	O
for	O
the	O
detection	O
of	O
the	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
IgG	O
and	O
IgM	O
in	O
335	O
serial	O
sera	O
from	O
98	O
SARS	B-DISO
patients	O
.	O

Neutralizing	O
viral	O
antibodies	O
were	O
demonstrated	O
in	O
the	O
convalescence	O
sera	O
from	O
SARS	B-DISO
patients	O
.	O

TITLE	O
:	O
Colonization	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
among	O
health	O
-	O
care	O
workers	O
screened	O
by	O
nasopharyngeal	O
swab	O
.	O

The	O
findings	O
suggest	O
that	O
the	O
SARS	B-DISO
outbreak	O
had	O
a	O
psychosocial	O
impact	O
on	O
the	O
Chinese	O
students	O
living	O
in	O
Japan	O
,	O
even	O
though	O
none	O
of	O
them	O
had	O
SARS	B-DISO
.	O

The	O
article	O
also	O
gives	O
an	O
overview	O
of	O
the	O
2003	O
SARS	B-DISO
epidemic	O
in	O
Taiwan	O
,	O
and	O
discusses	O
people	O
'	O
s	O
general	O
perceptions	O
towards	O
infectious	B-DISO
diseases	I-DISO
,	O
their	O
coping	O
strategies	O
concerning	O
disease	O
,	O
and	O
their	O
spiritual	O
beliefs	O
,	O
the	O
psychological	B-DISO
impact	O
of	O
the	O
2003	O
SARS	B-DISO
outbreak	O
in	O
Chinese	O
communities	O
,	O
Chinese	O
myths	O
about	O
infectious	B-DISO
disease	I-DISO
,	O
and	O
the	O
religious	O
activities	O
of	O
a	O
SARS	B-DISO
-	O
infected	O
intern	O
in	O
Taiwan	O
.	O

The	O
SMART	O
debriefing	O
(	O
1	O
)	O
aimed	O
at	O
boosting	O
resilience	O
and	O
catalyzing	O
transformation	B-DISO
among	O
persons	O
undergoing	O
stressful	O
events	O
,	O
(	O
2	O
)	O
adopted	O
a	O
growth	O
-	O
oriented	O
and	O
holistic	O
approach	O
of	O
health	O
promotion	O
,	O
and	O
(	O
3	O
)	O
employed	O
methods	O
drawn	O
from	O
various	O
indigenous	O
sources	O
(	O
e	O
.	O
g	O
.	O
Asian	O
philosophies	O
and	O
Traditional	O
Chinese	O
Medicine	O
).	O

This	O
review	O
provides	O
an	O
overview	O
of	O
current	O
information	O
on	O
coronavirus	O
and	O
the	O
application	O
of	O
small	O
interfering	O
RNA	O
in	O
viral	O
therapeutics	O
,	O
with	O
particular	O
reference	O
to	O
SARS	B-DISO
-	O
CoV	O
.	O

ABSTRACT	O
:	O
This	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
personal	O
protective	O
equipment	O
(	O
PPE	O
)	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Thirty	O
-	O
three	O
HCWs	O
who	O
performed	O
39	O
intubations	O
on	O
35	O
SARS	B-DISO
patients	O
were	O
interviewed	O
.	O

TITLE	O
:	O
[	O
Late	O
mediastinitis	B-DISO
with	O
bilateral	O
hydrothorax	B-DISO
after	O
vessel	B-DISO
perforation	I-DISO
by	O
a	O
central	O
venous	O
catheter	O
].	O

A	O
total	O
of	O
654	O
SARS	B-DISO
patients	O
and	O
12	O
Chinese	O
herbs	O
were	O
identified	O
.	O

Five	O
herbs	O
may	O
improve	O
lung	O
infiltrate	B-DISO
absorption	O
.	O

Whereas	O
cellular	O
immunity	O
controls	O
acute	B-DISO
infection	I-DISO
,	O
humoral	O
immunity	O
regulates	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
persistence	O
.	O

We	O
postulate	O
that	O
the	O
administration	O
of	O
the	O
innovative	O
TCM	O
may	O
have	O
beneficial	O
immunomodulatory	O
effects	O
for	O
preventing	O
viral	B-DISO
infections	I-DISO
including	O
SARS	B-DISO
.	O

The	O
SARS	B-DISO
outbreak	O
resulted	O
in	O
a	O
marked	O
reduction	O
in	O
the	O
number	O
of	O
ED	O
visits	O
which	O
persisted	O
for	O
3	O
months	O
after	O
the	O
end	O
of	O
the	O
epidemic	O
.	O

The	O
increased	O
total	O
cost	O
for	O
each	O
patient	O
was	O
attributed	O
to	O
the	O
increased	O
number	O
of	O
diagnostic	O
procedures	O
to	O
screen	O
for	O
possible	O
SARS	B-DISO
in	O
the	O
ED	O
.	O

The	O
humanized	O
mAb	O
Synagis	O
(	O
palivizumab	O
),	O
which	O
is	O
still	O
the	O
only	O
mAb	O
against	O
a	O
viral	B-DISO
disease	I-DISO
approved	O
by	O
the	O
US	O
FDA	O
,	O
has	O
been	O
widely	O
used	O
as	O
a	O
prophylactic	O
measure	O
against	O
respiratory	B-DISO
syncytial	I-DISO
virus	I-DISO
infections	I-DISO
in	O
neonates	O
and	O
immunocompromised	O
individuals	O
.	O

Shorter	O
duration	O
of	O
face	B-DISO
-	O
mask	O
wear	O
may	O
reduce	O
the	O
frequency	O
and	O
severity	O
of	O
these	O
headaches	B-DISO
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
HKU1	O
(	O
HCoV	O
-	O
HKU1	O
),	O
a	O
new	O
group	O
2	O
coronavirus	O
,	O
was	O
first	O
characterized	O
in	O
2005	O
from	O
2	O
adults	O
with	O
pneumonia	B-DISO
in	O
Hong	O
Kong	O
,	O
China	O
.	O

The	O
clinical	O
presentation	O
of	O
these	O
6	O
patients	O
was	O
as	O
follows	O
:	O
3	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
acute	O
enteric	O
disease	O
resulting	O
in	O
severe	B-DISO
dehydration	I-DISO
associated	O
with	O
upper	O
respiratory	B-DISO
symptoms	I-DISO
;	O
1	O
had	O
fever	O
,	O
otitis	B-DISO
,	O
and	O
febrile	B-DISO
seizure	I-DISO
;	O
1	O
had	O
a	O
sample	O
obtained	O
to	O
investigate	O
failure	B-DISO
to	I-DISO
thrive	I-DISO
;	O
and	O
1	O
had	O
a	O
sample	O
obtained	O
for	O
exploration	O
of	O
X	B-DISO
-	I-DISO
linked	I-DISO
agammaglobulinemia	I-DISO
and	O
hyperleucocytosis	O
.	O

TITLE	O
:	O
Longer	O
term	O
follow	O
up	O
of	O
aerobic	O
capacity	O
in	O
children	O
affected	O
by	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Our	O
study	O
confirmed	O
that	O
type	O
II	O
CCVs	O
infection	B-DISO
is	O
very	O
common	O
in	O
domestic	O
dog	O
,	O
fox	O
,	O
and	O
raccoon	O
dog	O
populations	O
in	O
China	O
.	O

TITLE	O
:	O
Changes	O
in	O
respiratory	O
mechanics	O
and	O
gas	O
exchange	O
during	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

We	O
assessed	O
the	O
changes	O
in	O
respiratory	O
mechanics	O
and	O
gas	O
exchange	O
during	O
ARDS	B-DISO
.	O

Pressure	O
-	O
volume	O
(	O
PV	O
)	O
curves	O
of	O
the	O
respiratory	O
system	O
were	O
obtained	O
,	O
and	O
upper	O
and	O
lower	O
inflection	O
points	O
(	O
UIP	B-DISO
,	O
LIP	B-DISO
)	O
and	O
recruitment	B-DISO
were	O
estimated	O
.	O

If	O
applied	O
to	O
our	O
data	O
,	O
the	O
inspiratory	O
pressure	O
limit	O
advocated	O
by	O
the	O
ARDSnet	O
(	O
30	O
cmH2O	O
)	O
would	O
produce	O
ventilation	O
over	O
the	O
UIP	B-DISO
,	O
with	O
a	O
consequent	O
increased	O
risk	O
of	O
overdistension	O
in	O
12	O
%,	O
43	O
%	O
and	O
65	O
%	O
of	O
our	O
patients	O
during	O
the	O
acute	O
,	O
intermediate	O
and	O
late	O
phases	O
of	O
ARDS	B-DISO
,	O
respectively	O
.	O

Two	O
to	O
7	O
days	O
after	O
infection	B-DISO
,	O
the	O
hamsters	O
were	O
killed	O
,	O
and	O
their	O
lungs	O
were	O
collected	O
for	O
evaluation	O
of	O
viral	O
titers	O
and	O
pathological	O
findings	O
.	O

Postexposure	O
treatment	O
with	O
MAb	O
201	O
can	O
alleviate	O
the	O
viral	O
burden	O
and	O
associated	O
pathological	O
findings	O
in	O
a	O
golden	O
Syrian	O
hamster	O
model	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

The	O
demonstration	O
of	O
successful	O
postexposure	O
MAb	O
201	O
therapy	O
in	O
an	O
animal	O
model	O
that	O
demonstrates	O
viral	O
replication	O
and	O
associated	O
pulmonary	O
pathological	O
findings	O
suggests	O
that	O
MAb	O
201	O
may	O
be	O
useful	O
in	O
the	O
arsenal	O
of	O
tools	O
to	O
combat	O
SARS	B-DISO
.	O

After	O
a	O
hamster	O
is	O
treated	O
with	O
MAb	O
201	O
,	O
its	O
viral	O
burden	O
is	O
reduced	O
by	O
102	O
.	O
4	O
-	O
103	O
.	O
9	O
50	O
%	O
tissue	O
-	O
culture	O
infectious	B-DISO
doses	O
per	O
gram	O
of	O
tissue	O
,	O
and	O
the	O
severity	O
of	O
associated	O
pathological	O
findings	O
,	O
including	O
interstitial	B-DISO
pneumonitis	I-DISO
and	O
consolidation	O
,	O
is	O
also	O
remarkably	O
reduced	O
.	O

Transfusion	B-DISO
-	I-DISO
Related	I-DISO
Acute	I-DISO
Lung	I-DISO
Injury	I-DISO
or	O
TRALI	B-DISO
is	O
one	O
of	O
the	O
most	O
frequent	O
severe	O
transfusion	B-DISO
reactions	I-DISO
(	O
one	O
third	O
of	O
Non	O
Hemolytic	O
Febrile	O
Transfusion	B-DISO
Reactions	I-DISO
).	O

It	O
presents	O
as	O
a	O
generally	O
mild	O
form	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
occurring	O
1	O
to	O
2	O
hours	O
after	O
transfusion	O
of	O
a	O
plasma	O
-	O
containing	O
blood	O
component	O
.	O

Although	O
it	O
is	O
highly	O
possible	O
that	O
direct	O
pulmonary	O
damage	O
might	O
be	O
the	O
cause	O
of	O
ARDS	B-DISO
,	O
there	O
is	O
no	O
preclinical	O
information	O
about	O
the	O
pulmonary	B-DISO
toxicity	I-DISO
of	O
CHX	O
.	O

The	O
odds	O
ratio	O
for	O
contracting	O
a	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
among	O
persons	O
with	O
either	O
a	O
homozygous	O
or	O
a	O
heterozygous	O
Cw	O
*	O
0801	O
genotype	O
was	O
4	O
.	O
4	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
to	O
12	O
.	O
9	O
;	O
P	O
=	O
0	O
.	O
007	O
).	O

Although	O
infants	O
with	O
severe	O
respiratory	B-DISO
insufficiency	I-DISO
may	O
sometimes	O
show	O
morphological	O
features	O
similar	O
to	O
DIP	B-DISO
or	O
NSIP	O
,	O
this	O
entity	O
should	O
rather	O
be	O
classified	O
as	O
chronic	O
pneumonitis	B-DISO
of	O
infancy	O
(	O
CPI	B-DISO
)	O
because	O
of	O
differences	O
in	O
etiology	O
,	O
pathogenesis	B-DISO
and	O
prognostic	O
outcome	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
phosphorylation	O
status	O
of	O
p90RSK	O
,	O
which	O
is	O
a	O
well	O
-	O
known	O
substrate	O
of	O
these	O
signaling	O
pathways	O
,	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
cells	O
.	O

ABSTRACT	O
:	O
Patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
who	O
die	O
usually	O
succumb	O
to	O
multiorgan	B-DISO
failure	I-DISO
as	O
opposed	O
to	O
hypoxia	B-DISO
.	O

By	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
antibodies	O
against	O
ADV	O
were	O
detected	O
in	O
55	O
sera	O
(	O
31	O
%),	O
against	O
PRCV	O
in	O
five	O
sera	O
(	O
3	O
%),	O
PPV	O
in	O
87	O
sera	O
(	O
49	O
%),	O
APP	O
in	O
93	O
sera	O
(	O
52	O
%),	O
M	O
.	O
hyopneumoniae	O
in	O
38	O
sera	O
(	O
21	O
%),	O
Salmonella	B-DISO
spp	O
.	O

in	O
85	O
sera	O
(	O
47	O
%)	O
and	O
HPS	B-DISO
in	O
33	O
sera	O
(	O
18	O
%).	O

TITLE	O
:	O
Prevalence	O
of	O
psychiatric	O
morbidity	O
and	O
psychological	B-DISO
adaptation	O
of	O
the	O
nurses	O
in	O
a	O
structured	O
SARS	B-DISO
caring	O
unit	O
during	O
outbreak	O
:	O
a	O
prospective	O
and	O
periodic	O
assessment	O
study	O
in	O
Taiwan	O
.	O

This	O
study	O
examined	O
if	O
SARS	B-DISO
may	O
result	O
in	O
cardiovascular	O
complications	O
.	O

Only	O
one	O
patient	O
who	O
had	O
transient	O
echocardiographic	O
evidence	O
of	O
impaired	B-DISO
left	O
ventricular	O
systolic	O
function	O
required	O
temporary	O
inotropic	O
support	O
.	O

To	O
analyse	O
the	O
antigenicity	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
genome	O
and	O
identify	O
potential	O
antigenic	O
epitopes	O
in	O
the	O
structural	O
proteins	O
.	O

Laboratory	O
tests	O
revealed	O
an	O
inflammation	B-DISO
probably	O
due	O
to	O
bacterial	B-DISO
infection	I-DISO
,	O
anemia	B-DISO
,	O
acute	O
renal	O
failure	B-DISO
,	I-DISO
acute	I-DISO
hepatic	I-DISO
dysfunction	O
,	O
coagulopathy	B-DISO
and	O
lactic	B-DISO
acidosis	I-DISO
,	O
indicating	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
and	O
septic	B-DISO
shock	I-DISO
.	O

Chest	O
X	O
-	O
Ray	O
and	O
computed	O
tomography	O
revealed	O
bilateral	B-DISO
pneumonia	I-DISO
.	O

In	O
addition	O
to	O
a	O
chronic	O
venous	B-DISO
ulcer	I-DISO
-	O
necrotizing	O
hemorrhagic	O
erysipelas	B-DISO
had	O
developed	O
in	O
the	O
right	O
lower	O
leg	O
.	O

This	O
unusual	O
and	O
fulminant	O
case	O
emphasizes	O
the	O
importance	O
of	O
considering	O
Streptococcus	O
dysgalactiae	O
as	O
a	O
causative	O
agent	O
in	O
septicemia	B-DISO
with	O
multiple	O
predisposing	O
factors	O
and	O
soft	O
-	O
tissue	O
infections	B-DISO
.	O

However	O
,	O
the	O
automated	O
method	O
was	O
found	O
to	O
be	O
less	O
sensitive	O
,	O
less	O
precise	O
and	O
led	O
to	O
consistently	O
lower	O
serum	O
SARS	B-DISO
-	O
coronavirus	O
concentrations	O
when	O
compared	O
with	O
the	O
column	O
-	O
based	O
extraction	O
method	O
.	O

CONCLUSIONS	O
:	O
As	O
the	O
diagnostic	O
efficiency	O
and	O
prognostic	O
value	O
of	O
the	O
serum	O
SARS	B-DISO
-	O
CoV	O
RNA	O
RT	O
-	O
PCR	O
test	O
is	O
critically	O
associated	O
with	O
the	O
analytical	O
sensitivity	O
and	O
quantitative	O
performance	O
contributed	O
both	O
by	O
the	O
RNA	O
extraction	O
and	O
RT	O
-	O
PCR	O
components	O
of	O
the	O
test	O
,	O
we	O
recommend	O
the	O
use	O
of	O
the	O
column	O
-	O
based	O
manual	O
RNA	O
extraction	O
method	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
5	O
'	O
UTR	O
sequence	O
in	O
different	O
SARS	B-DISO
-	O
CoV	O
isolates	O
,	O
to	O
identify	O
the	O
secondary	O
structure	O
,	O
and	O
to	O
test	O
the	O
promoter	O
activity	O
of	O
the	O
cDNA	O
sequence	O
corresponding	O
to	O
SARS	B-DISO
-	O
CoV	O
5	O
'	O
UTR	O
in	O
eukaryotic	O
cells	O
.	O

A	O
set	O
of	O
deletion	O
mutant	B-DISO
plasmids	O
,	O
of	O
which	O
pGL3	B-DISO
-	O
5	O
'	O
UTR	O
-	O
1	O
,	O
pGL3	B-DISO
-	O
5	O
'	O
UTR	O
-	O
2	O
,	O
pGL3	B-DISO
-	O
5	O
'	O
UTR	O
-	O
3	O
and	O
pGL3	B-DISO
-	O
5	O
'	O
UTR	O
-	O
4	O
are	O
with	O
3	O
,	O
2	O
,	O
1	O
,	O
and	O
0	O
residual	O
stem	O
-	O
loops	O
of	O
3	O
'	O
termini	O
respectively	O
,	O
were	O
constructed	O
from	O
pGL3	B-DISO
-	O
5	O
'	O
UTR	O
and	O
were	O
transfected	O
into	O
HepG2	O
cells	O
to	O
express	O
reporter	O
gene	O
luc	O
+,	O
with	O
pGL3	B-DISO
-	O
5	O
'	O
UTR	O
containing	O
full	O
sequence	O
as	O
control	O
.	O

The	O
full	O
sequence	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
5	O
'	O
UTR	O
is	O
a	O
264nt	O
,	O
and	O
18	O
deletion	O
mutants	O
were	O
found	O
.	O

ABSTRACT	O
:	O
In	O
the	O
past	O
2	O
years	O
,	O
at	O
least	O
three	O
distinct	O
human	O
coronaviruses	O
have	O
been	O
discovered	O
,	O
including	O
the	O
etiological	O
agent	O
associated	O
with	O
severe	O
acquired	O
respiratory	O
syndrome	B-DISO
(	O
SARS	B-DISO
).	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
caused	O
the	O
first	O
epidemic	O
of	O
the	O
21st	O
century	O
and	O
continues	O
to	O
threaten	O
the	O
global	O
community	O
.	O

Coinfection	B-DISO
with	O
other	O
pulmonary	O
pathogens	O
occurred	O
in	O
patients	O
with	O
SARS	B-DISO
.	O

The	O
SARS	B-DISO
-	O
CoV	O
3a	O
protein	O
,	O
however	O
,	O
was	O
demonstrated	O
to	O
contain	O
sialic	O
acids	O
,	O
indicating	O
the	O
presence	O
of	O
oligosaccharides	O
.	O

Gross	O
pathology	B-DISO
revealed	O
an	O
enteritis	B-DISO
suggestive	O
of	O
CPV	O
-	O
2	O
.	O

These	O
cases	O
emphasize	O
the	O
importance	O
of	O
pursuing	O
a	O
diagnosis	O
of	O
CCV	B-DISO
in	O
young	O
puppies	O
when	O
CPV	O
-	O
2	O
disease	O
has	O
been	O
ruled	O
out	O
by	O
IHC	O
.	O

ABSTRACT	O
:	O
Mathematical	O
models	O
are	O
used	O
to	O
quantify	O
the	O
effect	O
of	O
border	O
control	O
measures	O
in	O
reducing	O
the	O
international	O
spread	O
of	O
SARS	B-DISO
.	O

Rapid	O
reductions	O
in	O
the	O
time	O
to	O
diagnosis	O
and	O
effective	O
facilities	O
for	O
the	O
isolation	O
of	O
cases	O
are	O
essential	O
to	O
ensure	O
that	O
there	O
will	O
not	O
be	O
a	O
large	O
outbreak	O
,	O
and	O
each	O
week	O
of	O
delay	O
in	O
responding	O
to	O
imported	O
infection	B-DISO
approximately	O
doubles	O
the	O
total	O
number	O
of	O
cases	O
.	O

ABSTRACT	O
:	O
Serum	O
samples	O
from	O
214	O
Swedish	O
cats	O
with	O
no	O
signs	O
of	O
infectious	B-DISO
disease	I-DISO
were	O
analysed	O
for	O
the	O
presence	O
of	O
antibodies	O
against	O
Chlamydophila	O
felis	O
(	O
Cp	O
felis	O
),	O
while	O
209	O
of	O
these	O
were	O
also	O
analysed	O
for	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
antibodies	O
.	O

The	O
whole	O
killed	O
virus	O
(	O
WKV	O
)	O
vaccine	O
given	O
subcutaneously	O
to	O
129S6	O
/	O
SvEv	O
mice	O
was	O
more	O
effective	O
than	O
the	O
Ad	O
S	O
/	O
N	O
vaccine	O
administered	O
either	O
intranasally	O
or	O
intramuscularly	O
in	O
inhibiting	O
SARS	B-DISO
-	O
CoV	O
replication	O
in	O
the	O
murine	O
respiratory	O
tract	O
.	O

However	O
,	O
Ad	O
S	O
/	O
N	O
administered	O
intranasally	O
,	O
but	O
not	O
intramuscularly	O
,	O
significantly	O
limited	O
SARS	B-DISO
-	O
CoV	O
replication	O
in	O
the	O
lungs	O
.	O

ABSTRACT	O
:	O
The	O
3C	O
-	O
like	O
protease	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
has	O
a	O
C	O
-	O
terminal	O
extra	O
domain	O
in	O
addition	O
to	O
the	O
chymotrypsin	O
-	O
fold	O
adopted	O
by	O
picornavirus	O
3C	O
proteases	O
hosting	O
the	O
complete	O
catalytic	O
machinery	O
.	O

Interestingly	O
,	O
Asn214Ala	O
mutant	B-DISO
with	O
a	O
significant	O
tendency	O
to	O
form	O
a	O
monomer	O
still	O
retained	O
approximately	O
30	O
%	O
activity	O
,	O
indicating	O
that	O
the	O
relationship	O
between	O
the	O
activity	O
and	O
dimerization	O
might	O
be	O
very	O
complex	O
.	O

These	O
preliminary	O
data	O
suggest	O
that	O
a	O
severe	O
reduction	O
in	O
compliance	O
in	O
the	O
early	O
phase	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
is	O
associated	O
with	O
both	O
collagen	O
deposition	O
and	O
surfactant	O
degradation	O
.	O

Administration	O
of	O
anti	O
-	O
CXCR3	O
antibody	O
reduced	O
CD4	O
+	O
T	O
cell	O
infiltration	B-DISO
(	O
p	O
<	O
or	O
=	O
0	O
.	O
05	O
),	O
while	O
CD8	O
+	O
T	O
cell	O
trafficking	O
was	O
not	O
affected	O
.	O

ABSTRACT	O
:	O
Severe	O
tuberculosis	B-DISO
(	O
TB	O
)	O
requiring	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
care	O
is	O
rare	O
but	O
commonly	O
known	O
to	O
be	O
of	O
markedly	O
bad	O
prognosis	O
.	O

These	O
data	O
indicate	O
a	O
high	O
mortality	O
of	O
patients	O
with	O
tuberculosis	B-DISO
requiring	O
intensive	O
care	O
unit	O
care	O
and	O
identifies	O
new	O
independently	O
associated	O
risk	O
factors	O
.	O

Therefore	O
,	O
SARS	B-DISO
-	O
CoV	O
replication	O
was	O
suppressed	O
by	O
pretreatment	O
with	O
IFN	O
.	O

Collectively	O
,	O
overinduction	O
of	O
inflammatory	O
cytokine	O
and	O
dysregulation	O
of	O
cytokine	O
signaling	O
may	O
contribute	O
to	O
the	O
immunopathology	B-DISO
associated	O
with	O
""""	O
severe	O
""""	O
inflammation	B-DISO
in	O
SARS	B-DISO
.	O

Partial	O
spike	O
(	O
S	O
)	O
gene	O
sequences	O
of	O
SARS	B-DISO
-	O
CoV	O
from	O
the	O
2	O
patients	O
were	O
identical	O
to	O
4	O
of	O
5	O
Sgene	O
viral	O
sequences	O
from	O
palm	O
civets	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
caused	O
by	O
SARS	B-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

Our	O
previous	O
study	O
indicated	O
that	O
Akt	O
,	O
which	O
is	O
poorly	O
phosphorylated	O
in	O
confluent	O
cultures	O
of	O
Vero	O
E6	O
cells	O
,	O
is	O
phosphorylated	O
and	O
then	O
dephosphorylated	O
upon	O
infection	B-DISO
by	O
SARS	B-DISO
-	O
CoV	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
showed	O
that	O
a	O
serine	O
residue	O
of	O
Akt	O
was	O
phosphorylated	O
in	O
Vero	O
E6	O
cells	O
in	O
subconfluent	O
culture	O
and	O
that	O
Akt	O
was	O
dephosphorylated	O
rapidly	O
after	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
without	O
up	O
-	O
regulation	O
of	O
its	O
phosphorylation	O
.	O

The	O
study	O
included	O
a	O
total	O
of	O
17	O
highly	O
-	O
suspected	O
and	O
49	O
suspected	O
SARS	B-DISO
paediatric	O
patients	O
(	O
age	O
:	O
1	O
-	O
16	O
).	O

Infection	B-DISO
control	O
overshadowed	O
the	O
family	O
-	O
centred	O
nursing	O
practices	O
in	O
the	O
management	O
of	O
SARS	B-DISO
paediatric	O
patients	O
.	O

The	O
current	O
philosophy	O
and	O
practice	O
of	O
family	O
-	O
centred	O
nursing	O
model	O
neglect	O
the	O
special	O
needs	O
of	O
children	O
with	O
infectious	B-DISO
diseases	I-DISO
and	O
predominantly	O
apply	O
to	O
children	O
with	O
non	O
-	O
infectious	B-DISO
diseases	I-DISO
that	O
family	O
visits	O
are	O
allowed	O
and	O
nursing	O
care	O
by	O
parents	O
are	O
encouraged	O
.	O

RESULTS	O
:	O
The	O
study	O
included	O
a	O
total	O
of	O
17	O
highly	O
-	O
suspected	O
and	O
49	O
suspected	O
SARS	B-DISO
paediatric	O
patients	O
(	O
age	O
:	O
1	O
-	O
16	O
).	O

Potential	O
epidemiological	O
and	O
laboratory	O
pitfalls	O
are	O
also	O
discussed	O
as	O
they	O
may	O
give	O
rise	O
to	O
false	O
or	O
inconsistent	O
results	O
in	O
measuring	O
the	O
seroprevalence	O
of	O
IgG	O
antibodies	O
to	O
SARS	B-DISO
-	O
CoV	O
.	O

TITLE	O
:	O
Inactivation	B-DISO
of	O
SARS	B-DISO
coronavirus	O
by	O
means	O
of	O
povidone	O
-	O
iodine	O
,	O
physical	O
conditions	O
and	O
chemical	O
reagents	O
.	O

TITLE	O
:	O
Pandemic	O
influenza	B-DISO
threat	O
and	O
preparedness	O
.	O

We	O
describe	O
recent	O
research	O
progress	O
in	O
preparing	O
for	O
pandemic	O
influenza	B-DISO
.	O

ABSTRACT	O
:	O
We	O
used	O
a	O
single	O
equation	O
with	O
discrete	O
phases	O
to	O
fit	B-DISO
the	O
daily	O
cumulative	O
case	O
data	O
from	O
the	O
2003	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreak	O
in	O
Toronto	O
.	O

TITLE	O
:	O
Coordinated	O
response	O
to	O
SARS	B-DISO
,	O
Vancouver	O
,	O
Canada	O
.	O

Exhaled	O
NO	O
concentration	O
in	O
asthma	B-DISO
is	O
a	O
sensitive	O
marker	O
of	O
airway	O
inflammation	B-DISO
that	O
reacts	O
rapidly	O
in	O
response	O
to	O
treatment	O
or	O
exacerbation	O
of	O
disease	O
.	O

TITLE	O
:	O
The	O
rationale	O
of	O
fever	O
surveillance	O
to	O
identify	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
Taiwan	O
.	O

The	O
distribution	O
of	O
median	O
Coronase	O
antibody	O
titres	O
by	O
breed	O
was	O
very	O
similar	O
to	O
the	O
pattern	O
of	O
breed	O
predisposition	O
to	O
FIP	B-DISO
recently	O
reported	O
in	O
Sydney	O
.	O

ABSTRACT	O
:	O
Rapid	O
differentiation	O
of	O
vaccine	O
strains	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
from	O
wild	O
type	O
strains	O
would	O
enhance	O
investigations	O
of	O
disease	O
outbreaks	O
.	O

By	O
using	O
the	O
polycentric	O
nonrandomized	O
concurrent	O
controled	O
trial	O
and	O
under	O
the	O
condition	B-DISO
of	O
glucocorticoid	O
use	O
,	O
the	O
patierts	O
were	O
divided	O
into	O
two	O
groups	O
:	O
the	O
integrated	O
traditional	O
Chinese	O
and	O
western	O
mendicine	O
(	O
ITCWM	O
)	O
and	O
simplicity	O
western	O
mendicine	O
alone	O
(	O
WM	O
).	O

In	O
the	O
ITCWM	O
group	O
,	O
average	O
time	O
in	O
hospital	O
was	O
shortened	O
(	O
P	O
=	O
0	O
.	O
058	O
),	O
pneumonia	B-DISO
duration	O
was	O
shortened	O
(	O
P	O
=	O
0	O
.	O
057	O
),	O
mortality	O
fell	O
(	O
P	O
=	O
-	O
0	O
.	O
001	O
).	O

AdV	O
hepatitis	B-DISO
did	O
not	O
occur	O
,	O
and	O
graft	O
function	O
was	O
preserved	O
,	O
although	O
acute	O
rejection	O
occurred	O
in	O
both	O
patients	O
.	O

ABSTRACT	O
:	O
Pulmonary	B-DISO
infections	I-DISO
are	O
among	O
the	O
most	O
common	O
causes	O
of	O
morbidity	O
and	O
mortality	O
worldwide	O
,	O
and	O
contribute	O
substantially	O
to	O
annual	O
medical	O
expenditures	O
in	O
the	O
United	O
States	O
.	O

Mutagenesis	O
studies	O
led	O
to	O
the	O
identification	O
of	O
the	O
hepta	O
-	O
and	O
octo	O
-	O
uridine	O
stretches	B-DISO
as	O
slippery	O
sequences	O
for	O
efficient	O
frameshifting	O
.	O

When	O
the	O
hepta	O
-	O
and	O
octo	O
-	O
uridine	O
stretches	B-DISO
were	O
used	O
to	O
replace	O
the	O
original	O
slippery	O
sequence	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
ORF	O
1a	O
and	O
1b	O
,	O
efficient	O
frameshift	B-DISO
events	O
were	O
observed	O
.	O

To	O
study	O
the	O
cellular	O
response	O
in	O
the	O
acute	O
phase	O
of	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)-	O
host	O
cell	O
interaction	O
,	O
we	O
investigated	O
the	O
induction	O
of	O
chemokines	O
,	O
adhesion	B-DISO
molecules	O
,	O
and	O
DC	O
-	O
SIGN	O
(	O
dendritic	O
cell	O
-	O
specific	O
ICAM	O
-	O
3	O
-	O
grabbing	O
nonintegrin	O
)	O
by	O
SARS	B-DISO
-	O
CoV	O
.	O
Immunohistochemistry	O
revealed	O
neutrophil	O
,	O
macrophage	O
,	O
and	O
CD8	O
T	O
-	O
cell	O
infiltration	B-DISO
in	O
the	O
lung	O
autopsy	O
of	O
a	O
SARS	B-DISO
patient	O
who	O
died	O
during	O
the	O
acute	O
phase	O
of	O
illness	O
.	O

Moreover	O
,	O
SARS	B-DISO
-	O
CoV	O
induced	O
THP	O
-	O
1	O
cells	O
to	O
express	O
CCL2	O
/	O
MCP	O
-	O
1	O
,	O
CXCL8	O
/	O
IL	O
-	O
8	O
,	O
CCL3	O
/	O
MIP	B-DISO
-	O
1alpha	O
,	O
CXCL10	O
/	O
IP	O
-	O
10	O
,	O
CCL4	O
/	O
MIP	B-DISO
-	O
1beta	O
,	O
and	O
CCL5	O
/	O
RANTES	O
,	O
which	O
attracted	O
neutrophils	O
,	O
monocytes	O
,	O
and	O
activated	O
T	O
cells	O
in	O
a	O
chemotaxis	O
assay	O
.	O

Our	O
in	O
vitro	O
experiments	O
modeling	O
infection	B-DISO
in	O
humans	O
together	O
with	O
the	O
study	O
of	O
a	O
lung	O
biopsy	O
of	O
a	O
patient	O
who	O
died	O
during	O
the	O
early	O
phase	O
of	O
infection	B-DISO
demonstrated	O
that	O
SARS	B-DISO
-	O
CoV	O
,	O
through	O
a	O
dynamic	O
interaction	O
with	O
lung	O
epithelial	O
cells	O
and	O
monocytic	O
cells	O
,	O
creates	O
an	O
environment	O
conducive	O
for	O
immune	O
cell	O
migration	O
and	O
accumulation	O
that	O
eventually	O
leads	O
to	O
lung	O
injury	O
.	O

Serum	O
IgG	O
antibody	O
against	O
SARS	B-DISO
coronavirus	O
is	O
positive	O
in	O
a	O
small	O
proportion	O
(	O
around	O
10	O
%)	O
of	O
the	O
medical	O
staff	O
members	O
exposed	O
to	O
the	O
virus	O
in	O
our	O
hospital	O
,	O
but	O
may	O
not	O
cause	O
obvious	O
symptoms	O
,	O
suggesting	O
SARS	B-DISO
coronavirus	B-DISO
infection	I-DISO
might	O
in	O
some	O
cases	O
have	O
mild	O
or	O
even	O
no	O
clinical	O
manifestations	O
.	O

The	O
animals	O
were	O
then	O
observed	O
for	O
4	O
hrs	B-DISO
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
extent	O
and	O
temporal	O
pattern	O
of	O
transmission	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
to	O
intensive	O
care	O
unit	O
staff	O
.	O

ABSTRACT	O
:	O
A	O
diverse	O
group	O
of	O
cytolytic	O
animal	O
viruses	O
encodes	O
small	O
,	O
hydrophobic	O
proteins	O
to	O
modify	O
host	O
cell	O
membrane	O
permeability	O
to	O
ions	O
and	O
small	O
molecules	O
during	O
their	O
infection	B-DISO
cycles	O
.	O

Alanine	O
scanning	O
mutagenesis	O
analysis	O
was	O
performed	O
to	O
identify	O
determinants	O
on	O
ACE2	O
critical	O
for	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

To	O
reveal	O
a	O
role	O
for	O
innate	O
effectors	O
in	O
anti	O
-	O
viral	O
immunity	O
and	O
neurological	B-DISO
disease	I-DISO
,	O
JHMV	O
pathogenesis	B-DISO
was	O
studied	O
in	O
mice	O
deficient	O
in	O
interleukin	O
-	O
15	O
(	O
IL	O
-	O
15	O
-/-)	O
and	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
.	O

IL	O
-	O
15	O
and	O
NK	O
cells	O
thus	O
appear	O
dispensable	O
for	O
anti	O
-	O
viral	O
immunity	O
and	O
CNS	O
pathogenesis	B-DISO
during	O
acute	O
JHMV	O
infection	B-DISO
.	O

Like	O
avian	B-DISO
influenza	I-DISO
,	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
was	O
a	O
zoonotic	B-DISO
infection	I-DISO
,	O
perhaps	O
derived	O
from	O
related	O
coronaviruses	O
in	O
bats	O
.	O

A	O
total	O
of	O
43	O
samples	O
from	O
outbreaks	O
in	O
both	O
countries	O
were	O
used	O
for	O
PCR	O
amplification	B-DISO
and	O
direct	O
sequencing	O
of	O
a	O
624	O
-	O
nucleotide	O
fragment	O
of	O
the	O
BCoV	O
S	O
gene	O
.	O

TITLE	O
:	O
Furin	O
cleavage	O
of	O
the	O
SARS	B-DISO
coronavirus	O
spike	O
glycoprotein	O
enhances	O
cell	O
-	O
cell	O
fusion	O
but	O
does	O
not	O
affect	O
virion	O
entry	O
.	O

Although	O
the	O
coronavirus	O
(	O
CoV	O
)	O
S	O
glycoproteins	O
share	O
membership	O
in	O
this	O
class	O
of	O
envelope	O
glycoproteins	O
,	O
cleavage	O
to	O
generate	O
the	O
respective	O
S1	O
and	O
S2	O
subunits	O
appears	O
absent	O
in	O
a	O
subset	O
of	O
CoV	O
species	O
,	O
including	O
that	O
responsible	O
for	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Alveolar	O
fibrin	B-DISO
deposition	I-DISO
is	O
an	O
important	O
feature	O
of	O
ALI	O
/	O
ARDS	B-DISO
and	O
pulmonary	B-DISO
infection	I-DISO
.	O

We	O
evaluated	O
and	O
followed	O
all	O
patients	O
with	O
a	O
diagnosis	O
of	O
GBS	B-DISO
admitted	O
to	O
three	O
referral	O
neurology	O
centers	O
in	O
East	O
Azerbaijan	O
province	O
over	O
a	O
1	O
-	O
year	O
period	O
(	O
2003	O
).	O

It	O
can	O
lead	O
to	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
and	O
may	O
diminish	O
the	O
effectiveness	O
of	O
the	O
dialytic	O
therapy	O
.	O

In	O
this	O
paper	O
we	O
have	O
analyzed	O
total	O
number	O
of	O
acute	B-DISO
polyradiculoneuritis	I-DISO
cases	O
within	O
the	O
period	O
since	O
April	O
1992	O
until	O
April	O
1996	O
,	O
when	O
the	O
city	O
of	O
Sarajevo	O
was	O
completely	O
under	O
siege	O
.	O

Motor	O
weakness	B-DISO
and	O
parestesias	O
was	O
most	O
dominant	O
in	O
clinical	O
image	O
.	O

Previous	O
infections	B-DISO
were	O
noted	O
in	O
6	O
cases	O
,	O
and	O
5	O
of	O
those	O
respiratory	O
,	O
and	O
one	O
case	O
of	O
gastrointestinal	O
.	O

ABSTRACT	O
:	O
Despite	O
advances	O
in	O
antimicrobial	O
therapy	O
and	O
supportive	O
measures	O
,	O
mortality	O
for	O
patients	O
with	O
severe	O
community	O
-	O
acquired	O
pneumonia	B-DISO
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
remains	O
high	O
,	O
especially	O
in	O
case	O
of	O
development	O
of	O
sepsis	B-DISO
with	O
its	O
complications	O
.	O

In	O
case	O
of	O
severe	O
community	O
-	O
acquired	O
pneumonia	B-DISO
inflammation	B-DISO
spill	O
over	O
from	O
the	O
lungs	O
,	O
particularly	O
there	O
is	O
a	O
persistent	O
increase	O
of	O
IL	O
-	O
6	O
and	O
CRP	O
in	O
serum	O
,	O
and	O
this	O
is	O
associated	O
with	O
a	O
worst	O
prognosis	O
and	O
possible	O
development	O
of	O
sepsis	B-DISO
-	O
related	O
complications	O
.	O

Post	O
-	O
mortem	O
lung	O
samples	O
from	O
six	O
patients	O
who	O
died	O
from	O
SARS	B-DISO
from	O
April	O
to	O
July	O
2003	O
were	O
studied	O
by	O
light	O
and	O
electron	O
microscopy	O
,	O
Masson	O
trichromal	O
staining	O
and	O
immunohistochemistry	O
.	O

Evidence	O
of	O
infection	B-DISO
with	O
the	O
SARS	B-DISO
-	O
CoV	O
was	O
determined	O
by	O
reverse	O
-	O
transcription	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
,	O
serological	O
examination	O
and	O
electron	O
microscopy	O
.	O

Four	O
of	O
six	O
patients	O
had	O
serological	O
and	O
RT	O
-	O
PCR	O
evidence	O
of	O
recent	O
infection	B-DISO
of	O
SARS	B-DISO
-	O
CoV	O
.	O
Morphologic	O
changes	O
are	O
summarized	O
as	O
follows	O
:	O
(	O
1	O
)	O
Diffuse	O
and	O
bilateral	O
lung	B-DISO
consolidation	I-DISO
was	O
seen	O
in	O
all	O
patients	O
(	O
6	O
/	O
6	O
)	O
with	O
increasing	O
lung	O
weight	O
.	O

(	O
2	O
)	O
Diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
was	O
universal	O
(	O
6	O
/	O
6	O
)	O
with	O
hyaline	B-DISO
membrane	I-DISO
formation	O
(	O
6	O
/	O
6	O
),	O
intra	O
-	O
alveolar	B-DISO
edema	I-DISO
/	O
hemorrhage	B-DISO
(	O
6	O
/	O
6	O
),	O
fibrin	B-DISO
deposition	I-DISO
(	O
6	O
/	O
6	O
),	O
pneumocyte	O
desquamation	O
(	O
6	O
/	O
6	O
).	O

(	O
4	O
)	O
Giant	B-DISO
cells	O
in	O
the	O
alveoli	O
were	O
seen	O
in	O
five	O
of	O
6	O
patients	O
(	O
5	O
/	O
6	O
)	O
,	O
most	O
of	O
which	O
were	O
positive	O
for	O
the	O
epithelial	O
marker	O
AE1	O
/	O
AE3	O
(	O
5	O
/	O
6	O
),	O
but	O
some	O
cells	O
were	O
positive	O
for	O
the	O
macrophage	O
marker	O
CD68	O
(	O
2	O
/	O
6	O
).	O

Proliferation	B-DISO
of	O
collagen	O
was	O
confirmed	O
by	O
Masson	O
trichromal	O
staining	O
,	O
most	O
of	O
which	O
was	O
type	O
III	O
collagen	O
by	O
immunostaining	O
.	O

(	O
9	O
)	O
Thrombi	B-DISO
was	O
seen	O
in	O
all	O
patients	O
(	O
6	O
/	O
6	O
).	O

Direct	O
injury	O
of	O
SARS	B-DISO
-	O
CoV	O
on	O
alveolar	O
epithelium	O
,	O
prominent	O
macrophage	O
infiltration	B-DISO
and	O
distinctive	O
fibroblast	O
/	O
myofibroblast	O
proliferation	B-DISO
may	O
play	O
major	O
roles	O
in	O
the	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
.	O

Early	O
postoperative	O
intensive	O
care	O
significantly	O
decreased	O
the	O
occurrence	O
of	O
ARDS	B-DISO
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Clinicians	O
need	O
to	O
be	O
aware	O
that	O
ARDS	B-DISO
can	O
cause	O
significant	O
long	O
-	O
term	O
brain	O
-	O
related	O
morbidity	O
manifest	O
by	O
brain	B-DISO
atrophy	I-DISO
,	O
lesions	O
and	O
neurocognitive	O
impairments	O
.	O

Here	O
,	O
we	O
examined	O
coronavirus	O
-	O
cell	O
fusion	O
and	O
entry	O
employing	O
the	O
avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
).	O

TITLE	O
:	O
Recovery	O
of	O
a	O
neurovirulent	O
human	O
coronavirus	O
OC43	O
from	O
an	O
infectious	B-DISO
cDNA	O
clone	O
.	O

ABSTRACT	O
:	O
A	O
67	O
-	O
year	O
-	O
old	O
patient	O
with	O
newly	O
diagnosed	O
acute	B-DISO
myeloid	I-DISO
leukemia	I-DISO
developed	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
with	O
high	O
-	O
grade	O
fever	O
and	O
bilateral	B-DISO
pulmonary	I-DISO
infiltrates	I-DISO
.	O

In	O
this	O
study	O
,	O
novel	O
bifunctional	O
quinolonyl	O
diketo	O
acid	O
derivatives	O
were	O
designed	O
,	O
synthesized	O
,	O
and	O
tested	O
for	O
their	O
inhibitory	O
ability	O
against	O
HIV	B-DISO
-	O
1	O
integrase	O
.	O

ABSTRACT	O
:	O
Pump	O
-	O
driven	O
extracorporeal	O
gas	O
exchange	O
systems	O
have	O
been	O
advocated	O
in	O
patients	O
suffering	B-DISO
from	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
who	O
are	O
at	O
risk	O
for	O
life	O
-	O
threatening	O
hypoxemia	O
and	O
/	O
or	O
hypercapnia	B-DISO
.	O

Interventional	O
lung	O
assist	O
was	O
inserted	O
in	O
90	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Thirty	O
-	O
seven	O
of	O
90	O
patients	O
survived	O
,	O
creating	O
a	O
lower	O
mortality	O
rate	O
than	O
expected	O
from	O
the	O
Sequential	O
Organ	B-DISO
Failure	I-DISO
Assessment	O
score	O
.	O

TITLE	O
:	O
Corticosteroid	O
treatment	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
Hong	O
Kong	O
.	O

Patients	O
receiving	O
corticosteroids	O
beyond	O
15	O
days	O
or	O
other	O
investigational	O
treatment	O
within	O
21	O
days	O
from	O
symptom	B-DISO
onset	O
were	O
excluded	O
.	O

METHODS	O
:	O
Patients	O
>	O
or	O
=	O
18	O
years	O
old	O
who	O
either	O
had	O
not	O
received	O
corticosteroid	O
or	O
had	O
taken	O
corticosteroids	O
within	O
14	O
days	O
from	O
symptom	B-DISO
onset	O
were	O
included	O
.	O

Patients	O
suffered	B-DISO
from	O
sepsis	B-DISO
(	O
n	O
=	O
99	O
),	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
n	O
=	O
31	O
),	O
severe	O
head	O
injury	O
(	O
n	O
=	O
38	O
),	O
hemorrhagic	B-DISO
shock	I-DISO
(	O
n	O
=	O
19	O
),	O
intracranial	B-DISO
hemorrhage	I-DISO
(	O
n	O
=	O
19	O
),	O
and	O
cerebral	B-DISO
infarction	I-DISO
(	O
n	O
=	O
3	O
).	O

CONCLUSIONS	O
:	O
ICG	O
-	O
PDR	B-DISO
does	O
reflect	O
ICG	O
blood	O
clearance	O
with	O
sufficient	O
accuracy	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
and	O
may	O
be	O
used	O
as	O
a	O
surrogate	O
.	O

Hypercoagulation	O
and	O
hypofibrinolysis	O
were	O
found	O
in	O
patients	O
with	O
post	O
-	O
SARS	B-DISO
ON	O
.	O

This	O
mutation	O
allowed	O
an	O
enzootic	O
,	O
equine	O
-	O
avirulent	O
VEEV	O
strain	O
,	O
which	O
circulates	O
among	O
rodents	O
in	O
nearby	O
forests	O
to	O
adapt	O
for	O
equine	O
amplification	B-DISO
.	O

ABSTRACT	O
:	O
Replication	O
of	O
the	O
giant	B-DISO
RNA	O
genome	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
CoV	O
)	O
and	O
synthesis	O
of	O
as	O
many	O
as	O
eight	O
subgenomic	O
(	O
sg	O
)	O
mRNAs	O
are	O
mediated	O
by	O
a	O
viral	O
replicase	O
-	O
transcriptase	O
of	O
outstanding	O
complexity	O
that	O
includes	O
an	O
essential	O
endoribonuclease	O
activity	O
.	O

When	O
part	O
of	O
dsRNA	O
or	O
in	O
the	O
presence	O
of	O
nonlabeled	O
dsRNA	O
,	O
the	O
5	O
'-	O
labeled	O
RNA	O
substrates	O
were	O
processed	O
to	O
significantly	O
smaller	O
products	O
,	O
indicating	O
that	O
binding	O
to	O
dsRNA	O
in	O
cis	B-DISO
or	O
trans	O
modulates	O
the	O
exonucleolytic	O
activity	O
of	O
nsp14	O
.	O

Septic	B-DISO
shock	I-DISO
in	O
turn	O
,	O
implies	O
severe	B-DISO
sepsis	I-DISO
that	O
has	O
led	O
to	O
circulatory	B-DISO
shock	I-DISO
refractory	O
to	O
fluid	O
resuscitation	O
alone	O
.	O

The	O
proteins	O
possess	B-DISO
the	O
biologic	O
activity	O
,	O
which	O
lays	O
a	O
foundation	O
for	O
further	O
investigation	O
of	O
S	O
-	O
protein	O
biological	O
function	O
.	O

TITLE	O
:	O
Nurses	O
'	O
perceptions	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
relationship	O
between	O
commitment	O
and	O
intention	O
to	O
leave	O
nursing	O
.	O

Our	O
data	O
evidenced	O
largely	O
identical	O
topology	O
for	O
all	O
of	O
the	O
obtained	O
phylogenetic	O
trees	O
,	O
thus	O
supporting	O
the	O
hypothesis	O
that	O
the	O
relationship	O
existing	O
between	O
SARS	B-DISO
-	O
CoV	O
and	O
group	O
2	O
coronavirus	O
is	O
a	O
monophyletic	O
one	O
.	O

ABSTRACT	O
:	O
The	O
advantages	O
of	O
nucleic	O
acid	O
amplification	B-DISO
tests	O
(	O
NAT	O
)	O
over	O
conventional	O
methods	O
for	O
the	O
detection	O
of	O
pathogens	O
in	O
lower	O
respiratory	O
tract	O
samples	O
have	O
not	O
been	O
established	O
.	O

ABSTRACT	O
:	O
i	O
)	O
To	O
establish	O
the	O
seroprevalence	O
of	O
Feline	O
Coronavirus	O
(	O
FCoV	O
)	O
infection	B-DISO
in	O
two	O
defined	O
groups	O
of	O
cats	O
in	O
Sydney	O
:	O
owned	O
and	O
feral	O
cats	O
;	O
ii	O
)	O
to	O
identify	O
factors	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
infection	B-DISO
with	O
FCoV	O
;	O
and	O
iii	O
)	O
to	O
establish	O
the	O
seroprevalence	O
and	O
FCoV	O
antibody	O
titres	O
of	O
owned	O
cats	O
with	O
immunohistochemically	O
confirmed	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
).	O

The	O
median	O
Immunocomb	O
score	O
of	O
cats	O
with	O
immunohistochemically	O
confirmed	O
FIP	B-DISO
was	O
significantly	O
higher	O
than	O
cats	O
in	O
the	O
sample	O
population	O
of	O
owned	O
cats	O
but	O
there	O
was	O
sufficient	O
overlap	O
between	O
these	O
two	O
groups	O
to	O
make	O
definitive	O
diagnosis	O
of	O
FIP	B-DISO
by	O
serology	O
impossible	O
.	O

In	O
immunohistochemistry	O
analyses	O
,	O
lung	O
tissues	O
of	O
patients	O
with	O
severe	O
versus	O
mild	O
ARDS	B-DISO
had	O
a	O
higher	O
intensity	O
of	O
NF	O
-	O
kappaB	O
nuclear	O
staining	O
(	O
13	O
+/-	O
1	O
.	O
3	O
vs	O
.	O
7	O
+/-	O

In	O
conclusion	O
,	O
we	O
demonstrated	O
that	O
the	O
ability	O
of	O
GC	O
-	O
GRalpha	O
to	O
downregulate	O
NF	O
-	O
kappaB	O
activation	O
is	O
critical	O
for	O
the	O
resolution	O
of	O
systemic	O
and	O
pulmonary	B-DISO
inflammation	I-DISO
in	O
ARDS	B-DISO
.	O

The	O
findings	O
provide	O
a	O
rationale	O
for	O
the	O
use	O
of	O
prolonged	O
GC	O
treatment	O
in	O
early	O
ARDS	B-DISO
.	O

Acute	B-DISO
pancreatitis	I-DISO
is	O
an	O
acute	B-DISO
inflammatory	I-DISO
disorder	I-DISO
of	O
the	O
pancreas	O
caused	O
by	O
an	O
intracellular	O
activation	O
of	O
pancreatic	O
digestive	O
enzymes	O
.	O

The	O
destruction	O
of	O
pancreatic	O
parenchyma	O
induces	O
a	O
systemic	O
activation	O
of	O
coagulation	O
,	O
kinin	O
,	O
complement	O
and	O
fibrinolytic	O
cascades	O
with	O
liberation	O
of	O
cytokines	O
and	O
reactive	O
oxygen	O
metabolites	O
which	O
,	O
if	O
severe	O
and	O
overwhelming	O
,	O
can	O
lead	O
to	O
shock	O
,	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
and	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

With	O
the	O
rise	O
in	O
global	O
travel	O
,	O
preventing	O
disease	B-DISO
transmission	I-DISO
has	O
become	O
paramount	O
to	O
avoid	O
the	O
spread	O
of	O
infectious	B-DISO
diseases	I-DISO
,	O
including	O
SARS	B-DISO
(	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
),	O
avian	B-DISO
influenza	I-DISO
,	O
and	O
haemorrhagic	B-DISO
fever	I-DISO
.	O

Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
associated	O
coronavirus	O
persists	O
in	O
the	O
lung	O
up	O
to	O
the	O
second	O
month	O
,	O
whereas	O
H5N1	B-DISO
persists	O
in	O
the	O
lung	O
up	O
to	O
the	O
third	O
week	O
.	O

The	O
infectious	B-DISO
nature	O
,	O
severity	O
and	O
clinical	O
manifestations	O
of	O
the	O
disease	O
and	O
its	O
potential	O
for	O
pandemic	O
spread	O
have	O
considerable	O
implications	O
for	O
intensive	O
care	O
in	O
terms	O
of	O
infection	B-DISO
control	O
,	O
patient	O
management	O
,	O
staff	O
morale	O
and	O
intensive	O
care	O
expansion	O
.	O

TITLE	O
:	O
Toxicological	O
safety	O
evaluation	O
of	O
DNA	O
plasmid	O
vaccines	O
against	O
HIV	B-DISO
-	O
1	O
,	O
Ebola	O
,	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
,	O
or	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
is	O
similar	O
despite	O
differing	O
plasmid	O
backbones	O
or	O
gene	O
-	O
inserts	O
.	O

These	O
data	O
build	O
on	O
the	O
biodistribution	O
studies	O
performed	O
(	O
see	O
companion	O
article	O
,	O
Sheets	O
et	O
al	O
.,	O
2006	O
)	O
to	O
demonstrate	O
the	O
safety	O
and	O
suitability	O
for	O
investigational	O
human	O
use	O
of	O
DNA	O
plasmid	O
vaccine	O
candidates	O
for	O
a	O
variety	O
of	O
infectious	B-DISO
disease	I-DISO
prevention	O
indications	O
.	O

TITLE	O
:	O
Thymoglobulin	O
-	O
induced	O
severe	O
cardiovascular	O
reaction	O
and	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
in	O
a	O
patient	O
scheduled	O
for	O
orthotopic	O
liver	O
transplantation	O
.	O

TITLE	O
:	O
Expanding	O
ICU	O
facilities	O
in	O
an	O
epidemic	O
:	O
recommendations	O
based	O
on	O
experience	O
from	O
the	O
SARS	B-DISO
epidemic	O
in	O
Hong	O
Kong	O
and	O
Singapore	O
.	O

TITLE	O
:	O
Functional	O
diversity	O
of	O
chemokines	O
and	O
chemokine	O
receptors	O
in	O
response	O
to	O
viral	B-DISO
infection	I-DISO
of	O
the	O
central	O
nervous	B-DISO
system	O
.	O

It	O
is	O
the	O
role	O
of	O
the	O
immune	O
system	O
to	O
contain	O
and	O
control	O
the	O
spread	O
of	O
virus	B-DISO
infection	I-DISO
in	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
),	O
and	O
paradoxically	O
,	O
this	O
response	O
may	O
also	O
be	O
pathologic	O
.	O

Indeed	O
,	O
studies	O
with	O
a	O
neurotropic	O
murine	O
coronavirus	O
,	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
),	O
have	O
provided	O
important	O
insight	O
into	O
the	O
functional	O
roles	O
of	O
chemokines	O
and	O
chemokine	O
receptors	O
in	O
participating	O
in	O
various	O
aspects	O
of	O
host	O
defense	O
as	O
well	O
as	O
disease	O
development	O
within	O
the	O
CNS	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
cytokine	O
response	O
of	O
two	O
human	O
non	O
-	O
lymphatic	O
cell	O
lines	O
,	O
Caco	O
-	O
2	O
and	O
HEK	O
293	O
,	O
which	O
are	O
fully	O
permissive	O
for	O
SARS	B-DISO
-	O
CoV	O
.	O
A	O
comparison	O
with	O
established	O
cytokine	O
-	O
inducing	O
viruses	O
revealed	O
that	O
SARS	B-DISO
-	O
CoV	O
only	O
weakly	O
triggered	O
a	O
cytokine	O
response	O
.	O

Our	O
data	O
indicate	O
that	O
SARS	B-DISO
-	O
CoV	O
suppresses	O
the	O
antiviral	O
cytokine	O
system	O
of	O
non	O
-	O
immune	O
cells	O
to	O
a	O
large	O
extent	O
,	O
thus	O
buying	O
time	O
for	O
dissemination	O
in	O
the	O
host	O
.	O

Interestingly	O
,	O
however	O
,	O
SARS	B-DISO
-	O
CoV	O
strongly	O
induced	O
the	O
chemokines	O
IP	O
-	O
10	O
and	O
IL	O
-	O
8	O
in	O
the	O
colon	B-DISO
carcinoma	I-DISO
cell	O
line	O
Caco	O
-	O
2	O
,	O
but	O
not	O
in	O
the	O
embryonic	O
kidney	O
cell	O
line	O
293	O
.	O

TITLE	O
:	O
Mucosal	O
immunization	O
with	O
surface	O
-	O
displayed	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
spike	O
protein	O
on	O
Lactobacillus	O
casei	O
induces	O
neutralizing	O
antibodies	O
in	O
mice	O
.	O

ABSTRACT	O
:	O
Induction	O
of	O
mucosal	O
immunity	O
may	O
be	O
important	O
for	O
preventing	O
SARS	B-DISO
-	O
CoV	O
infections	B-DISO
.	O

Patients	O
with	O
severe	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
should	O
be	O
managed	O
in	O
an	O
intensive	O
care	O
unit	O
and	O
given	O
intravenous	O
immune	O
globulin	O
.	O

Another	O
coronavirus	O
,	O
porcine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
virus	O
(	O
TGEV	O
)	O
preferentially	O
recognizes	O
N	O
-	O
glycolylneuraminic	O
acid	O
.	O

Coronaviruses	O
related	O
to	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
express	O
a	O
hemagglutinin	O
-	O
esterase	O
surface	O
glycoprotein	O
,	O
which	O
specifically	O
hydrolyses	O
either	O
5	O
-	O
N	O
-	O
acetyl	O
-	O
4	O
-	O
O	O
-	O
acetyl	O
neuraminic	O
acid	O
(	O
Neu4	O
,	O
5Ac	O
(	O
2	O
))	O
or	O
5	O
-	O
N	O
-	O
acetyl	O
-	O
9	O
-	O
O	O
-	O
acetyl	O
neuraminic	O
acid	O
(	O
Neu5	O
,	O
9Ac	O
(	O
2	O
)).	O

United	O
States	O
Forces	O
Korea	O
'	O
s	O
campaign	O
plan	B-DISO
.	O

In	O
this	O
study	O
,	O
we	O
report	O
the	O
interaction	O
of	O
a	O
SARS	B-DISO
-	O
CoV	O
7a	O
and	O
small	O
glutamine	O
-	O
rich	O
tetratricopeptide	O
repeat	O
-	O
containing	O
protein	O
(	O
SGT	O
).	O

SARS	B-DISO
full	O
-	O
length	O
Nsp15	O
(	O
346	O
amino	O
acids	O
)	O
has	O
been	O
cloned	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
with	O
an	O
N	O
-	O
terminal	O
hexahistidine	O
tag	B-DISO
and	O
has	O
been	O
purified	O
to	O
homogeneity	O
.	O

Direct	O
exposure	O
,	O
fever	O
on	O
the	O
first	O
day	O
of	O
illness	O
,	O
and	O
elevated	O
temperature	O
,	O
pulmonary	B-DISO
infiltrates	I-DISO
,	O
lymphopenia	B-DISO
and	O
thrombocytopenia	O
at	O
admission	O
were	O
associated	O
with	O
confirmed	O
cases	O
.	O

Rhinorrhea	B-DISO
,	O
sore	B-DISO
throat	I-DISO
,	O
and	O
an	O
elevated	O
neutrophil	O
count	O
at	O
admission	O
were	O
associated	O
with	O
excluded	O
cases	O
.	O

In	O
the	O
absence	O
of	O
fever	O
or	O
significant	O
exposure	O
,	O
SARS	B-DISO
is	O
unlikely	O
.	O

Analyses	O
of	O
T	O
cell	O
repertoires	O
in	O
health	O
care	O
workers	O
who	O
survived	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
during	O
the	O
2003	O
outbreak	O
revealed	O
that	O
their	O
effector	O
memory	O
V	O
gamma	O
9V	O
delta	O
2	O
T	O
cell	O
populations	O
were	O
selectively	O
expanded	O
~	O
3	O
months	O
after	O
the	O
onset	O
of	O
disease	O
.	O

In	O
addition	O
,	O
in	O
vitro	O
experiments	O
demonstrated	O
that	O
stimulated	O
V	O
gamma	O
9V	O
delta	O
2	O
T	O
cells	O
display	O
an	O
interferon	O
-	O
gamma	O
-	O
dependent	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
activity	O
and	O
are	O
able	O
to	O
directly	O
kill	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
target	O
cells	O
.	O

ABSTRACT	O
:	O
As	O
part	O
of	O
an	O
epidemiological	O
surveillance	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
in	O
Spain	O
,	O
four	O
Spanish	O
field	O
isolates	O
showed	O
high	O
S1	O
spike	O
sequence	O
similarities	O
with	O
an	O
IBV	O
sequence	O
from	O
the	O
GenBank	O
database	O
named	O
Italy	O
02	O
.	O

Several	O
other	O
oligonucleotide	O
primer	O
pairs	O
that	O
give	O
PCR	O
products	O
corresponding	O
to	O
genes	O
3	O
,	O
5	O
,	O
N	O
and	O
the	O
3	O
'-	O
untranslated	O
region	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
,	O
turkey	O
coronavirus	O
and	O
pheasant	O
coronavirus	O
(	O
all	O
in	O
group	O
3	O
)	O
failed	O
to	O
do	O
so	O
with	O
RNA	O
from	O
the	O
parrot	O
coronavirus	O
.	O

ABSTRACT	O
:	O
There	O
are	O
a	O
number	O
of	O
antivirals	O
as	O
well	O
as	O
antiviral	O
strategies	O
that	O
could	O
be	O
envisaged	O
to	O
prevent	O
or	O
treat	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
(	O
or	O
similar	O
)	O
coronavirus	O
(	O
CoV	O
)	O
infections	B-DISO
.	O

Various	O
other	O
compounds	O
,	O
often	O
with	O
an	O
ill	B-DISO
-	O
defined	O
mode	O
of	O
action	O
but	O
selectivity	O
indexes	O
up	O
to	O
100	O
,	O
have	O
been	O
reported	O
to	O
exhibit	O
in	O
vitro	O
activity	O
against	O
SARS	B-DISO
-	O
CoV	O
:	O
valinomycin	O
,	O
glycopeptide	O
antibiotics	O
,	O
plant	O
lectins	O
,	O
hesperetin	O
,	O
glycyrrhizin	O
,	O
aurintricarboxylic	O
acid	O
,	O
chloroquine	O
,	O
niclosamide	O
,	O
nelfinavir	O
and	O
calpain	O
inhibitors	O
.	O

TITLE	O
:	O
Inhaled	O
nitric	O
oxide	O
improves	O
pulmonary	O
functions	O
following	O
massive	O
pulmonary	B-DISO
embolism	I-DISO
:	O
a	O
report	O
of	O
four	O
patients	O
and	O
review	O
of	O
the	O
literature	O
.	O

ABSTRACT	O
:	O
This	O
case	O
was	O
a	O
27	O
years	O
old	O
female	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Peripheral	B-DISO
neuropathy	I-DISO
and	O
myopathy	B-DISO
have	O
been	O
reported	O
as	O
a	O
concomitant	O
problem	O
during	O
the	O
convalescent	O
stage	O
of	O
SARS	B-DISO
,	O
while	O
the	O
sequel	O
of	O
permanent	O
ansomia	O
in	O
SARS	B-DISO
was	O
not	O
reported	O
before	O
.	O

The	O
clinical	O
experiments	O
were	O
conducted	O
in	O
three	O
appointed	O
hospital	O
for	O
fighting	O
against	O
SARS	B-DISO
.	O

The	O
binding	O
interface	O
of	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
that	O
is	O
facing	O
the	O
P1	O
'	O
position	O
is	O
suggested	O
to	O
be	O
occupied	O
by	O
acidic	O
amino	O
acids	O
,	O
thus	O
the	O
P1	O
'	O
position	O
is	O
intolerant	O
to	O
acidic	O
residue	O
substitution	O
,	O
owing	O
to	O
electrostatic	O
repulsion	O
.	O

This	O
study	O
generates	O
a	O
comprehensive	O
overview	O
of	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
substrate	O
specificity	O
,	O
which	O
serves	O
as	O
the	O
design	O
basis	O
of	O
synthetic	O
peptide	O
-	O
based	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
inhibitors	O
.	O

ABSTRACT	O
:	O
A	O
four	O
-	O
month	O
-	O
old	O
infant	O
was	O
hospitalized	O
because	O
of	O
RSV	O
bronchiolitis	B-DISO
.	O

The	O
first	O
group	O
included	O
only	O
RBCV	O
,	O
while	O
the	O
second	O
group	O
contained	O
calf	O
diarrhea	B-DISO
BCoV	O
,	O
RBCV	O
,	O
WD	O
and	O
EBCV	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Volume	O
replacement	O
was	O
studied	O
prospectively	O
in	O
208	O
infants	O
with	O
dengue	B-DISO
hemorrhagic	I-DISO
fever	I-DISO
/	O
dengue	B-DISO
shock	I-DISO
syndrome	I-DISO
(	O
DHF	O
/	O
DSS	B-DISO
).	O

To	O
improve	O
case	O
fatality	O
rates	O
,	O
special	O
efforts	O
need	O
to	O
be	O
directed	O
to	O
infants	O
with	O
DHF	O
/	O
DSS	B-DISO
accompanied	O
by	O
severe	O
complications	O
.	O

The	O
wet	O
-	O
to	O
-	O
dry	O
lung	O
weight	O
ratio	O
and	O
bronchial	O
obstruction	B-DISO
scores	O
were	O
lower	O
for	O
sheep	O
receiving	O
albuterol	O
.	O

TITLE	O
:	O
Acute	B-DISO
renal	I-DISO
failure	I-DISO
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

Acute	B-DISO
renal	I-DISO
failure	I-DISO
(	O
ARF	B-DISO
)	O
may	O
also	O
occur	O
and	O
/	O
or	O
complicate	O
the	O
disease	O
course	O
,	O
however	O
,	O
its	O
incidence	O
,	O
causes	O
and	O
impact	O
in	O
SARS	B-DISO
patients	O
are	O
not	O
known	O
.	O

Of	O
the	O
16	O
medical	O
staff	O
performing	O
renal	O
replacement	O
therapy	O
,	O
none	O
was	O
subsequently	O
infected	O
with	O
SARS	B-DISO
coronavirus	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
an	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
caused	O
by	O
a	O
novel	O
human	O
coronavirus	O
(	O
CoV	O
).	O

A	O
chymotrypsin	O
-	O
like	O
cysteine	O
protease	O
named	O
3C	O
-	O
like	O
protease	O
(	O
3CLpro	O
)	O
is	O
essential	O
for	O
the	O
life	O
cycle	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
.	O
This	O
main	O
protease	O
is	O
responsible	O
for	O
maturation	O
of	O
functional	O
proteins	O
and	O
represents	O
a	O
key	O
anti	O
-	O
viral	O
target	O
.	O

These	O
viruses	O
exhibited	O
a	O
small	O
-	O
plaque	B-DISO
phenotype	O
and	O
produced	O
significantly	O
less	O
virus	O
.	O

Overall	O
,	O
results	O
from	O
our	O
analysis	O
of	O
a	O
large	O
panel	O
of	O
plaque	B-DISO
-	O
purified	O
recovered	O
viruses	O
indicate	O
that	O
the	O
negatively	O
charged	O
residues	O
at	O
positions	O
440	O
and	O
441	O
are	O
key	O
residues	O
that	O
appear	O
to	O
be	O
involved	O
in	O
virus	O
assembly	O
.	O

ABSTRACT	O
:	O
A	O
significant	O
number	O
of	O
drugs	O
and	O
toxins	O
have	O
been	O
associated	O
with	O
eosinophilic	B-DISO
pneumonia	I-DISO
.	O

Toxins	O
suspected	O
to	O
cause	O
eosinophilic	B-DISO
pneumonia	I-DISO
include	O
cigarette	O
smoke	O
and	O
illicit	O
drugs	O
.	O

Pulmonary	B-DISO
artery	I-DISO
hypertension	I-DISO
has	O
a	O
high	O
prevalence	O
in	O
patients	O
with	O
severe	O
ARDS	B-DISO
.	O

Taken	O
together	O
,	O
these	O
data	O
provide	O
direct	O
evidence	O
to	O
show	O
that	O
a	O
single	O
amino	O
acid	O
residue	O
at	O
key	O
position	O
in	O
the	O
RBD	O
can	O
determine	O
the	O
major	O
function	O
of	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
and	O
imply	O
for	O
designing	O
SARS	B-DISO
vaccines	O
and	O
therapeutics	O
.	O

ABSTRACT	O
:	O
An	O
enhanced	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
ERT	O
-	O
PCR	O
)	O
assay	O
to	O
detect	O
the	O
coronavirus	O
associated	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
-	O
Cov	O
)	O
has	O
been	O
designed	O
for	O
detection	O
of	O
SARS	B-DISO
-	O
Cov	O
with	O
high	O
sensitivity	O
and	O
easy	O
-	O
to	O
-	O
interpret	O
results	O
,	O
in	O
which	O
a	O
target	O
gene	O
pre	O
-	O
amplification	B-DISO
step	O
preceded	O
TaqMan	O
real	O
-	O
time	O
fluorescent	O
PCR	O
.	O

Subjects	O
were	O
evaluated	O
with	O
a	O
specially	O
designed	O
questionnaire	O
and	O
a	O
modified	O
form	O
of	O
the	O
Spielberger	O
Scale	O
for	O
State	B-DISO
Anxiety	I-DISO
.	O

TITLE	O
:	O
The	O
relevance	O
of	O
psychosocial	O
variables	O
and	O
working	O
conditions	O
in	O
predicting	O
nurses	O
'	O
coping	O
strategies	O
during	O
the	O
SARS	B-DISO
crisis	O
:	O
an	O
online	O
questionnaire	O
survey	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
examine	O
the	O
relationship	O
between	O
psychosocial	O
variables	O
and	O
working	O
conditions	O
,	O
and	O
nurses	O
'	O
coping	O
methods	O
and	O
distress	O
in	O
response	O
to	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
crisis	O
in	O
Canada	O
.	O

Three	O
multiple	O
regression	O
analysis	O
revealed	O
that	O
the	O
model	O
we	O
evolved	O
--	O
including	O
higher	O
levels	O
of	O
vigor	O
,	O
organizational	O
support	O
,	O
and	O
trust	O
in	O
equipment	O
/	O
infection	B-DISO
control	O
initiative	O
;	O
and	O
lower	O
levels	O
of	O
contact	O
with	O
SARS	B-DISO
patients	O
,	O
and	O
time	O
spent	O
in	O
quarantine	O
--	O
predicted	O
to	O
lower	O
levels	O
of	O
avoidance	O
behavior	O
,	O
emotional	O
exhaustion	B-DISO
,	O
and	O
state	O
anger	O
.	O

A	O
minority	O
of	O
cats	O
,	O
however	O
,	O
develop	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
),	O
a	O
fatal	O
systemic	B-DISO
granulomatous	I-DISO
disease	I-DISO
.	O

In	O
cats	O
with	O
FIP	B-DISO
,	O
however	O
,	O
IL	O
-	O
12	O
p40	O
levels	O
were	O
significantly	O
lower	O
in	O
lymphatic	O
tissues	O
in	O
comparison	O
to	O
both	O
SPF	O
cats	O
and	O
FCoV	O
-	O
infected	O
cats	O
without	O
FIP	B-DISO
.	O

By	O
not	O
inhibiting	O
viral	O
replication	O
in	O
the	O
lungs	O
of	O
infected	O
mice	O
,	O
ribavirin	O
treatment	O
may	O
have	O
provided	O
a	O
continual	O
source	O
of	O
stimulation	O
for	O
the	O
inflammatory	B-DISO
response	I-DISO
thought	O
to	O
contribute	O
to	O
the	O
pathogenesis	B-DISO
of	O
the	O
infection	B-DISO
.	O

PSV	O
affected	O
the	O
pattern	O
of	O
breathing	O
and	O
deadspace	O
to	O
a	O
greater	O
degree	O
than	O
did	O
P	O
-	O
ACV	B-DISO
.	O

ABSTRACT	O
:	O
As	O
a	O
number	O
of	O
commentators	O
have	O
noted	O
,	O
SARS	B-DISO
exposed	O
the	O
vulnerabilities	O
of	O
our	O
health	O
care	O
systems	O
and	O
governance	O
structures	O
.	O

Solutions	O
to	O
limiting	O
the	O
spread	O
of	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
will	O
require	O
cooperative	O
efforts	O
among	O
many	O
disciplines	O
and	O
entities	O
worldwide	O
.	O

Seven	O
agents	O
that	O
have	O
made	O
a	O
significant	O
appearance	O
,	O
particularly	O
in	O
the	O
21st	O
century	O
,	O
are	O
reviewed	O
,	O
including	O
:	O
Ebola	O
and	O
Marburg	O
hemorrhagic	B-DISO
fevers	I-DISO
,	O
human	B-DISO
monkeypox	I-DISO
,	O
bovine	B-DISO
spongiform	I-DISO
encephalopathy	I-DISO
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
,	O
and	O
avian	B-DISO
influenza	I-DISO
.	O

Interferon	O
-	O
alpha	O
(	O
IFN	O
-	O
alpha	O
)	O
alone	O
was	O
a	O
poor	O
inducer	O
of	O
MoDC	O
maturation	O
,	O
but	O
in	O
association	O
with	O
tumour	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
),	O
or	O
TLR	O
ligands	O
such	O
as	O
lipopolysaccharide	O
and	O
polyinosinic	O
-	O
polycytidylic	O
acid	O
I	O
:	O
C	O
,	O
an	O
up	O
-	O
regulation	O
of	O
major	O
histocompatibility	O
complex	O
II	O
and	O
CD80	O
/	O
86	O
expression	O
was	O
noted	O
,	O
along	O
with	O
reduced	O
endocytic	O
activity	O
.	O

SARS	B-DISO
-	O
3CL	O
(	O
pro	O
)	O
has	O
been	O
shown	O
to	O
be	O
essential	O
for	O
replication	O
and	O
is	O
thus	O
a	O
target	O
for	O
drug	O
discovery	O
.	O

ICE	O
provided	O
high	O
quality	O
2D	O
imaging	O
of	O
the	O
prosthesis	O
demonstrating	O
thrombus	B-DISO
-	O
like	O
material	O
coating	O
the	O
inner	O
surfaces	O
of	O
the	O
prosthetic	O
valve	O
stents	O
effectively	O
forming	O
a	O
tunnel	O
-	O
like	O
obstruction	B-DISO
.	O

ABSTRACT	O
:	O
A	O
highly	O
neurovirulent	O
murine	O
coronavirus	O
JHMV	O
(	O
wild	O
-	O
type	O
[	O
wt	O
]	O
JHMV	O
)	O
is	O
known	O
to	O
spread	O
from	O
cells	O
infected	O
via	O
the	O
murine	O
coronavirus	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
receptor	O
(	O
MHVR	O
)	O
to	O
cells	O
without	O
MHVR	O
(	O
MHVR	O
-	O
independent	O
infection	B-DISO
),	O
whereas	O
a	O
mutant	B-DISO
virus	O
isolated	O
from	O
wt	O
JHMV	O
,	O
srr7	O
,	O
spread	O
only	O
in	O
an	O
MHVR	O
-	O
dependent	O
fashion	O
.	O

MHVR	O
-	O
independent	O
infection	B-DISO
is	O
hypothetically	O
thought	O
to	O
be	O
attributed	O
to	O
a	O
naturally	O
occurring	O
fusion	O
activation	O
of	O
the	O
wt	O
JHMV	O
S	O
protein	O
,	O
which	O
did	O
not	O
occur	O
in	O
the	O
case	O
of	O
srr7	O
.	O

The	O
patient	O
was	O
stable	O
with	O
normoxia	O
by	O
day	O
20	O
,	O
in	O
spite	O
of	O
pulmonary	B-DISO
congestion	I-DISO
-	O
like	O
infiltrates	B-DISO
on	O
chest	O
X	O
-	O
ray	O
.	O

On	O
day	O
21	O
,	O
he	O
was	O
complicated	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

However	O
,	O
glucocorticoid	O
therapy	O
induced	O
hyperglycemia	B-DISO
with	O
an	O
increase	O
in	O
plasma	O
osmolality	O
,	O
complicated	O
with	O
hypoalbuminemia	O
,	O
and	O
gastrointestinal	B-DISO
bleeding	I-DISO
.	O

ABSTRACT	O
:	O
Beginning	O
in	O
late	O
2003	O
,	O
a	O
substantial	O
outbreak	O
of	O
influenza	B-DISO
A	O
(	O
H5N1	B-DISO
)	O
virus	O
spread	O
among	O
poultry	O
in	O
Thailand	O
.	O

ABSTRACT	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
epidemic	O
,	O
the	O
growing	O
fear	O
of	O
an	O
influenza	B-DISO
pandemic	O
and	O
the	O
recent	O
shortage	O
of	O
flu	B-DISO
vaccine	O
highlight	O
the	O
need	O
for	O
surveillance	O
systems	O
able	O
to	O
provide	O
early	O
,	O
quantitative	O
predictions	O
of	O
epidemic	O
events	O
.	O

Serological	O
testing	O
on	O
samples	O
obtained	O
in	O
August	O
,	O
November	O
and	O
January	O
indicated	O
that	O
bovine	O
parainfluenza	B-DISO
virus	O
3	O
(	O
PIV	O
-	O
3	O
)	O
infections	B-DISO
occurred	O
each	O
year	O
before	O
November	O
after	O
entry	O
.	O

ABSTRACT	O
:	O
Little	O
is	O
known	O
about	O
the	O
long	O
-	O
term	O
consequence	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Forty	O
-	O
one	O
percent	O
had	O
scores	O
indicative	O
of	O
a	O
posttraumatic	B-DISO
stress	I-DISO
disorder	I-DISO
(	O
PTSD	B-DISO
);	O
about	O
30	O
%	O
had	O
likely	O
anxiety	O
and	O
depression	B-DISO
.	O

The	O
nationwide	O
SARS	B-DISO
database	O
in	O
Taiwan	O
was	O
analyzed	O
,	O
and	O
genotyping	O
of	O
281	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
of	O
65	O
genes	O
was	O
performed	O
for	O
94	O
patients	O
with	O
SARS	B-DISO
,	O
to	O
identify	O
SNPs	O
for	O
which	O
distribution	O
between	O
patients	O
with	O
or	O
without	O
detectable	O
nasopharyngeal	O
shedding	O
of	O
SARS	B-DISO
-	O
CoV	O
was	O
biased	O
.	O

Detectable	O
nasopharyngeal	O
shedding	O
of	O
SARS	B-DISO
-	O
CoV	O
was	O
associated	O
with	O
polymorphic	O
alleles	O
of	O
interleukins	O
18	O
(	O
P	O
=.	O
014	O
)	O
and	O
1A	O
(	O
P	O
=.	O
031	O
)	O
and	O
a	O
member	O
of	O
NF	O
kappa	O
B	O
complex	O
(	O
reticuloendotheliosis	B-DISO
viral	O
oncogene	O
homolog	O
B	O
[	O
RelB	O
])	O
(	O
P	O
=.	O
034	O
),	O
all	O
of	O
which	O
are	O
proinflammatory	O
in	O
nature	O
,	O
as	O
well	O
as	O
the	O
procoagulation	O
molecule	O
fibrinogen	O
-	O
like	O
protein	O
2	O
(	O
P	O
=.	O
008	O
).	O

A	O
total	O
of	O
55	O
cases	O
of	O
SARS	B-DISO
were	O
identified	O
,	O
and	O
227	O
hospital	O
workers	O
were	O
quarantined	O
.	O

As	O
the	O
number	O
of	O
cases	O
of	O
nosocomial	O
SARS	B-DISO
increased	O
,	O
the	O
hospital	O
closed	O
the	O
affected	O
ward	O
and	O
expedited	O
construction	O
of	O
negative	O
-	O
pressure	O
rooms	O
on	O
other	O
vacated	O
floors	O
for	O
patient	O
cohorting	O
,	O
and	O
the	O
last	O
case	O
in	O
the	O
hospital	O
was	O
identified	O
1	O
week	O
later	O
.	O

Timely	O
recognition	O
of	O
SARS	B-DISO
is	O
extremely	O
important	O
.	O

Eight	O
(	O
54	O
%)	O
reported	O
that	O
they	O
were	O
aware	O
of	O
a	O
breach	O
in	O
infection	B-DISO
control	O
precautions	O
.	O

HCWs	O
reported	O
fatigue	B-DISO
due	O
to	O
an	O
increased	O
number	O
and	O
length	O
of	O
shifts	O
;	O
participants	O
worked	O
a	O
median	O
of	O
10	O
shifts	O
during	O
the	O
10	O
days	O
before	O
onset	O
of	O
symptoms	O
.	O

Multiple	O
factors	O
were	O
likely	O
responsible	O
for	O
SARS	B-DISO
in	O
these	O
HCWs	O
,	O
including	O
the	O
performance	O
of	O
high	O
-	O
risk	O
patient	O
care	O
procedures	O
,	O
inconsistent	O
use	O
of	O
personal	O
protective	O
equipment	O
,	O
fatigue	B-DISO
,	O
and	O
lack	O
of	O
adequate	O
infection	B-DISO
control	O
training	O
.	O

A	O
case	O
-	O
control	O
study	O
was	O
carried	O
out	O
in	O
476	O
Chinese	O
SARS	B-DISO
patients	O
and	O
449	O
healthy	O
controls	O
.	O

We	O
tested	O
the	O
polymorphisms	O
of	O
IFN	O
-	O
gamma	O
,	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
10	O
for	O
their	O
associations	O
with	O
SARS	B-DISO
.	O

RESULTS	O
:	O
IFN	O
-	O
gamma	O
+	O
874A	O
allele	O
was	O
associated	O
with	O
susceptibility	O
to	O
SARS	B-DISO
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

Thus	O
,	O
there	O
still	O
exists	O
a	O
significant	O
unmet	O
medical	O
need	O
to	O
find	O
agents	O
that	O
can	O
shorten	O
the	O
duration	O
of	O
HRV	O
-	O
induced	O
illness	O
,	O
lessen	O
the	O
severity	O
of	O
symptoms	O
,	O
minimize	O
secondary	O
bacterial	B-DISO
infections	I-DISO
and	O
exacerbations	O
of	O
underlying	O
disease	O
and	O
reduce	O
virus	O
transmission	O
.	O

Although	O
effective	O
over	O
-	O
the	O
-	O
counter	O
products	O
have	O
been	O
described	O
that	O
alleviate	O
symptoms	O
associated	O
with	O
the	O
common	B-DISO
cold	I-DISO
[	O
Anzueto	O
,	O
A	O
.,	O
Niederman	O
,	O
M	O
.	O
S	O
.,	O
2003	O
.	O

ABSTRACT	O
:	O
To	O
screen	O
the	O
severe	O
acute	O
respiratory	O
syndromes	B-DISO
(	O
SARS	B-DISO
)	O
mimotopes	O
with	O
random	O
phage	O
peptide	O
library	O
and	O
to	O
investigate	O
their	O
immunogenicity	O
.	O

The	O
DNA	O
sequencing	O
data	O
showed	O
no	O
homology	O
between	O
the	O
sequences	O
of	O
the	O
deduced	O
amino	O
acid	O
of	O
the	O
two	O
mimic	O
antigen	O
peptides	O
and	O
the	O
sequence	O
of	O
SARS	B-DISO
.	O

CONCLUSIONS	O
:	O
SARS	B-DISO
mimotopes	O
were	O
obtained	O
by	O
phage	O
peptide	O
library	O
screening	O
.	O

TITLE	O
:	O
Apertura	O
pyriformis	O
stenosis	B-DISO
in	O
the	O
newborn	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
clinical	O
manifestations	O
and	O
the	O
chest	O
imaging	O
characteristics	O
of	O
an	O
epidemic	O
outbreak	O
of	O
respiratory	B-DISO
infection	I-DISO
caused	O
by	O
Chlamydia	O
pneumoniae	O
(	O
CP	O
).	O

Acute	B-DISO
cough	I-DISO
was	O
often	O
associated	O
with	O
chest	B-DISO
pain	I-DISO
.	O

CONCLUSIONS	O
:	O
Trends	O
of	O
hypercoagulation	O
and	O
hypofibrinolysis	O
exist	O
in	O
the	O
post	O
-	O
SARS	B-DISO
patients	O
with	O
osteonecrosis	B-DISO
.	O

These	O
rDIs	O
elicited	O
SARS	B-DISO
-	O
CoV	O
-	O
specific	O
serum	O
IgG	O
antibody	O
and	O
T	O
-	O
cell	O
responses	O
in	O
vaccinated	O
mice	O
following	O
intranasal	O
or	O
subcutaneous	O
administration	O
.	O

ABSTRACT	O
:	O
Taiwan	O
experienced	O
one	O
of	O
the	O
most	O
serious	O
outbreaks	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
during	O
the	O
2003	O
epidemic	O
.	O

RESULTS	O
:	O
Most	O
public	O
health	O
nurses	O
(	O
71	O
.	O
9	O
%)	O
expressed	O
a	O
general	O
lack	O
of	O
confidence	O
in	O
handling	O
the	O
SARS	B-DISO
epidemic	O
.	O

The	O
peak	O
spread	O
of	O
SARS	B-DISO
occurred	O
at	O
a	O
mean	O
temperature	O
of	O
16	O
.	O
9	O
degrees	O
C	O
(	O
95	O
%	O
CI	O
,	O
10	O
.	O
7	O
degrees	O
C	O
to	O
23	O
.	O
1	O
degrees	O
C	O
),	O
with	O
a	O
mean	O
relative	O
humidity	O
of	O
52	O
.	O
2	O
%	O
(	O
95	O
%	O
CI	O
,	O
33	O
.	O
0	O
%	O
to	O
71	O
.	O
4	O
%)	O
and	O
wind	B-DISO
speed	O
of	O
2	O
.	O
8	O
ms	O
(-	O
1	O
)	O
(	O
95	O
%	O
CI	O
,	O
2	O
.	O
0	O
to	O
3	O
.	O
6	O
ms	O
(-	O
1	O
)).	O

TITLE	O
:	O
A	O
pandemic	O
flu	B-DISO
:	O
not	O
if	O
,	O
but	O
when	O
.	O

SARS	B-DISO
was	O
the	O
wake	O
-	O
up	O
call	O
we	O
slept	O
through	O
.	O

Two	O
(	O
0	O
.	O
57	O
%)	O
of	O
353	O
asymptomatic	O
children	O
from	O
the	O
high	O
-	O
risk	O
area	O
were	O
tested	O
positive	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
antibody	O
compared	O
with	O
0	O
of	O
361	O
in	O
the	O
low	O
-	O
risk	O
region	O
.	O

As	O
in	O
adults	O
,	O
subclinical	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	B-DISO
infection	I-DISO
was	O
rare	O
in	O
children	O
in	O
the	O
2003	O
epidemic	O
.	O

TITLE	O
:	O
The	O
effect	O
of	O
alcohol	B-DISO
abuse	I-DISO
on	O
ARDS	B-DISO
and	O
multiple	O
organ	O
dysfunction	O
.	O

The	O
consequences	O
of	O
alcohol	B-DISO
abuse	I-DISO
are	O
multifactorial	O
,	O
and	O
it	O
is	O
associated	O
with	O
excessive	O
morbidity	O
and	O
increased	O
mortality	O
.	O

At	O
present	O
new	O
devices	O
are	O
developed	O
for	O
chronic	B-DISO
respiratory	I-DISO
failure	I-DISO
or	O
bridge	O
to	O
lung	O
transplant	O
.	O

Earlier	O
treatment	O
with	O
drotrecogin	O
alfa	O
(	O
activated	O
)	O
(	O
DrotAA	O
)	O
may	O
also	O
improve	O
outcomes	O
in	O
severe	B-DISO
sepsis	I-DISO
.	O

The	O
database	O
comprises	O
data	O
from	O
4	O
,	O
459	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
(	O
DrotAA	O
,	O
n	O
=	O
3	O
,	O
228	O
;	O
placebo	O
,	O
n	O
=	O
1	O
,	O
231	O
)	O
included	O
in	O
five	O
clinical	O
trials	O
conducted	O
in	O
tertiary	O
care	O
institutions	O
in	O
28	O
countries	O
.	O

In	O
contrast	O
,	O
parallel	O
experiments	O
showed	O
that	O
the	O
E	O
protein	O
from	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
spanned	O
the	O
membranes	O
once	O
,	O
with	O
the	O
N	O
-	O
terminus	O
exposed	O
luminally	O
and	O
the	O
C	O
-	O
terminus	O
exposed	O
cytoplasmically	O
(	O
N	O
(	O
exo	O
(	O
lum	O
)-)	O
C	O
(	O
cyto	O
)).	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
high	O
-	O
volume	O
continuous	O
hemofiltration	O
on	O
experimental	O
pancreatitis	B-DISO
associated	O
lung	O
injury	O
(	O
PALI	O
)	O
in	O
pigs	O
.	O

CVVH	O
can	O
reduce	O
pulmonary	B-DISO
edema	I-DISO
and	O
the	O
severity	O
of	O
PALI	O
in	O
pigs	O
with	O
high	O
-	O
volume	O
CVVH	O
being	O
significantly	O
better	O
than	O
low	O
-	O
volume	O
CVVH	O
.	O

ABSTRACT	O
:	O
To	O
the	O
authors	O
'	O
knowledge	O
,	O
no	O
satisfactory	O
therapy	O
is	O
available	O
for	O
patients	O
with	O
refractory	O
germ	B-DISO
cell	I-DISO
neoplasms	I-DISO
.	O

Three	O
patients	O
died	O
as	O
a	O
result	O
of	O
adverse	O
events	O
believed	O
to	O
be	O
possibly	O
related	O
to	O
treatment	O
:	O
ventricular	B-DISO
arrhythmia	I-DISO
,	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
and	O
pneumonitis	B-DISO
.	O

TITLE	O
:	O
SARS	B-DISO
-	O
CoV	O
virus	O
-	O
host	O
interactions	O
and	O
comparative	O
etiologies	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
as	O
determined	O
by	O
transcriptional	O
and	O
cytokine	O
profiling	O
of	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
tissues	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
is	O
a	O
structural	O
component	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
can	O
induce	O
antibody	O
responses	O
in	O
SARS	B-DISO
patients	O
during	O
infection	B-DISO
.	O

These	O
data	O
will	O
help	O
us	O
to	O
understand	O
the	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

The	O
prevalence	O
of	O
subclinical	O
udder	O
infection	B-DISO
in	O
camels	O
can	O
reach	O
very	O
high	O
proportions	O
in	O
dairy	O
camels	O
.	O

This	O
paper	O
reviews	O
the	O
etio	O
-	O
pathogenesis	B-DISO
of	O
these	O
causes	O
of	O
reproductive	O
losses	O
,	O
as	O
well	O
as	O
the	O
major	O
risk	O
factors	O
and	O
strategies	O
to	O
prevent	O
their	O
occurrence	O
.	O

Overall	O
,	O
these	O
results	O
clearly	O
demonstrate	O
that	O
the	O
two	O
-	O
stranded	O
coiled	O
-	O
coil	O
template	O
acts	O
as	O
an	O
excellent	O
presentation	O
system	O
for	O
eliciting	O
helix	O
-	O
specific	O
antibodies	O
against	O
highly	O
conserved	O
viral	O
antigens	O
and	O
HRC1	O
and	O
HRC2	O
peptides	O
may	O
represent	O
potential	O
candidates	O
for	O
use	O
in	O
a	O
peptide	O
vaccine	O
against	O
the	O
SARS	B-DISO
-	O
CoV	O
.	O

TITLE	O
:	O
Effect	O
of	O
porcine	O
respiratory	O
coronavirus	B-DISO
infection	I-DISO
on	O
lipopolysaccharide	O
recognition	O
proteins	O
and	O
haptoglobin	O
levels	O
in	O
the	O
lungs	O
.	O

This	O
study	O
aimed	O
to	O
quantify	O
LPS	B-DISO
-	O
binding	O
protein	O
(	O
LBP	B-DISO
),	O
CD14	O
and	O
haptoglobin	O
in	O
the	O
lungs	O
throughout	O
a	O
PRCV	O
infection	B-DISO
.	O

Cell	O
-	O
associated	O
CD14	O
in	O
lung	O
tissue	O
increased	O
up	O
to	O
15	O
times	O
throughout	O
the	O
infection	B-DISO
,	O
due	O
to	O
an	O
increase	O
in	O
highly	O
CD14	O
+	O
monocyte	O
-	O
macrophages	O
from	O
1	O
to	O
12DPI	O
and	O
CD14	O
+	O
type	O
2	O
pneumocytes	O
from	O
7	O
to	O
9DPI	O
.	O

The	O
presence	O
of	O
A	O
/	O
H5N1	B-DISO
virus	O
is	O
confirmed	O
by	O
viral	O
isolation	O
or	O
RNA	O
detection	O
by	O
RT	O
-	O
PCR	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
responsible	O
for	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
contains	O
a	O
small	O
envelope	O
protein	O
,	O
E	O
,	O
with	O
putative	O
involvement	O
in	O
host	O
apoptosis	O
and	O
virus	O
morphogenesis	O
.	O

Children	O
who	O
had	O
HCoV	O
-	O
HKU1	O
infection	B-DISO
had	O
evidence	O
of	O
either	O
upper	O
or	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
or	O
both	O
.	O

We	O
identified	O
6	O
patients	O
with	O
a	O
verified	O
histopathologic	O
diagnosis	O
of	O
OP	O
and	O
antecedent	O
or	O
concomitant	O
diagnosis	O
of	O
a	O
hematologic	B-DISO
malignancy	I-DISO
from	O
the	O
Mayo	O
Clinic	O
database	O
(	O
1995	O
-	O
2003	O
).	O

TITLE	O
:	O
Phase	O
I	O
trial	O
of	O
the	O
trifunctional	O
anti	O
-	O
HER2	O
x	O
anti	O
-	O
CD3	O
antibody	O
ertumaxomab	O
in	O
metastatic	B-DISO
breast	I-DISO
cancer	I-DISO
.	O

Most	O
drug	O
-	O
related	O
adverse	O
events	O
were	O
mild	O
and	O
transient	O
including	O
fever	O
(	O
94	O
%),	O
rigors	B-DISO
(	O
47	O
%),	O
headache	B-DISO
(	O
35	O
%),	O
nausea	B-DISO
(	O
29	O
%),	O
vomiting	B-DISO
(	O
29	O
%).	O

It	O
has	O
been	O
shown	O
that	O
KKS	O
activation	O
in	O
the	O
systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
syndrome	I-DISO
results	O
in	O
decrease	O
of	O
its	O
component	O
plasma	O
proteins	O
.	O

We	O
model	O
the	O
detection	O
limits	O
of	O
a	O
potential	O
system	O
based	O
on	O
primary	O
care	O
consults	O
for	O
the	O
detection	O
of	O
an	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

HIV	B-DISO
-	O
infected	O
parents	O
often	O
worry	O
about	O
the	O
emotional	O
consequences	O
of	O
disclosure	O
to	O
their	O
children	O
and	O
that	O
their	O
children	O
may	O
tell	O
others	O
.	O

Reasons	O
children	O
did	O
not	O
know	O
their	O
parent	O
'	O
s	O
HIV	B-DISO
status	O
included	O
that	O
the	O
parent	O
was	O
worried	O
about	O
the	O
emotional	O
consequences	O
of	O
disclosure	O
(	O
67	O
%),	O
was	O
worried	O
the	O
child	O
would	O
tell	O
other	O
people	O
(	O
36	O
%),	O
and	O
did	O
not	O
know	O
how	O
to	O
tell	O
their	O
child	O
(	O
28	O
%).	O

Parenchymal	O
scars	B-DISO
remained	O
unchanged	O
from	O
the	O
6	O
-	O
to	O
12	O
-	O
month	O
follow	O
-	O
up	O
in	O
all	O
six	O
patients	O
with	O
that	O
finding	O
.	O

TITLE	O
:	O
Anti	O
-	O
SARS	B-DISO
drug	O
screening	O
by	O
molecular	O
docking	O
.	O

Further	O
,	O
the	O
kinetic	O
process	O
of	O
interaction	O
between	O
the	O
antibodies	O
and	O
SARS	B-DISO
-	O
CoV	O
was	O
studied	O
using	O
the	O
real	O
-	O
time	O
function	O
of	O
the	O
biosensor	O
.	O

In	O
addition	O
,	O
the	O
detection	O
of	O
still	O
untypeable	O
hCoV	O
strains	O
suggests	O
that	O
the	O
number	O
of	O
hCoVs	O
involved	O
in	O
human	O
pathology	B-DISO
might	O
further	O
increase	O
.	O

These	O
data	O
provide	O
important	O
information	O
for	O
understanding	O
the	O
antigenicity	O
and	O
immunogenicity	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
and	O
this	O
panel	O
of	O
novel	O
mAbs	O
can	O
be	O
used	O
as	O
tools	O
for	O
studying	O
the	O
structure	O
of	O
S	O
protein	O
and	O
for	O
guiding	O
SARS	B-DISO
vaccine	O
design	O
.	O

He	O
was	O
admitted	O
to	O
the	O
Intensive	O
Care	O
Unit	O
(	O
ICU	O
)	O
due	O
to	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
evolving	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

TITLE	O
:	O
Oral	O
efficacy	O
of	O
Vero	O
cell	O
attenuated	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
DR13	O
strain	O
.	O

In	O
addition	O
,	O
a	O
LacZ	O
reporter	O
gene	O
was	O
introduced	O
into	O
the	O
universal	O
transfer	O
vector	O
named	O
pUGS	O
-	O
LacZ	O
.	O
Subsequently	O
,	O
a	O
PRV	B-DISO
genome	O
-	O
based	O
virus	O
live	O
vector	O
was	O
generated	O
via	O
homologous	O
recombination	O
.	O

TITLE	O
:	O
Emerging	B-DISO
infectious	I-DISO
disease	I-DISO
outbreaks	O
:	O
old	O
lessons	O
and	O
new	O
challenges	O
for	O
obstetrician	O
-	O
gynecologists	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
summarize	O
3	O
recent	O
high	O
-	O
profile	O
infectious	B-DISO
disease	I-DISO
threats	O
that	O
have	O
affected	O
the	O
United	O
States	O
:	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
,	O
and	O
anthrax	B-DISO
.	O

TITLE	O
:	O
Antigenic	O
and	O
immunogenic	O
characterization	O
of	O
recombinant	O
baculovirus	O
-	O
expressed	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
spike	O
protein	O
:	O
implication	O
for	O
vaccine	O
design	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
mediates	O
the	O
receptor	O
interaction	O
and	O
immune	O
recognition	O
and	O
is	O
considered	O
a	O
major	O
target	O
for	O
vaccine	O
design	O
.	O

Strikingly	O
,	O
all	O
of	O
the	O
RBD	O
-	O
specific	O
MAbs	O
had	O
potent	O
neutralizing	O
activity	O
,	O
6	O
of	O
which	O
efficiently	O
blocked	O
the	O
receptor	O
binding	O
,	O
confirming	O
that	O
the	O
RBD	O
contains	O
the	O
main	O
neutralizing	O
epitopes	O
and	O
that	O
blockage	O
of	O
the	O
receptor	O
association	O
is	O
the	O
major	O
mechanism	O
of	O
SARS	B-DISO
-	O
CoV	O
neutralization	O
.	O

TITLE	O
:	O
Endosomal	O
proteolysis	O
by	O
cathepsins	O
is	O
necessary	O
for	O
murine	O
coronavirus	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
type	O
2	O
spike	O
-	O
mediated	O
entry	O
.	O

We	O
show	O
here	O
that	O
while	O
infection	B-DISO
of	O
the	O
prototype	O
MHV	O
-	O
A59	O
strain	O
is	O
not	O
sensitive	O
to	O
pretreatment	O
with	O
lysosomotropic	O
agents	O
,	O
MHV	O
-	O
2	O
replication	O
is	O
significantly	O
inhibited	O
by	O
these	O
agents	O
.	O

Here	O
,	O
using	O
a	O
panel	O
of	O
replicase	O
-	O
specific	O
antisera	O
,	O
we	O
have	O
analyzed	O
the	O
earlier	O
stages	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
infection	B-DISO
in	O
Vero	O
E6	O
cells	O
,	O
in	O
particular	O
focusing	O
on	O
the	O
subcellular	O
localization	O
of	O
the	O
replicase	O
and	O
the	O
ultrastructure	O
of	O
the	O
associated	O
membranes	O
.	O

Similar	O
morphological	O
studies	O
and	O
labeling	O
experiments	O
argued	O
against	O
the	O
previously	O
proposed	O
involvement	O
of	O
the	O
autophagic	O
pathway	O
as	O
the	O
source	O
for	O
the	O
vesicles	B-DISO
with	O
which	O
the	O
replicase	O
is	O
associated	O
and	O
instead	O
suggested	O
the	O
endoplasmic	O
reticulum	O
to	O
be	O
the	O
most	O
likely	O
donor	O
of	O
the	O
membranes	O
that	O
carry	O
the	O
SARS	B-DISO
-	O
CoV	O
replication	O
complex	O
.	O

Sequential	O
anti	O
-	O
coagulated	O
blood	O
samples	O
were	O
collected	O
from	O
62	O
seropositive	O
SARS	B-DISO
patients	O
during	O
the	O
first	O
week	O
,	O
the	O
second	O
week	O
,	O
the	O
first	O
month	O
,	O
the	O
2nd	O
-	O
3rd	O
month	O
,	O
and	O
1	O
year	O
after	O
disease	O
onset	O
.	O

RESULTS	O
:	O
A	O
rapid	O
restoration	O
in	O
T	O
-	O
lymphocyte	O
subsets	O
was	O
observed	O
during	O
a	O
short	O
period	O
after	O
infection	B-DISO
.	O

UC	O
should	O
at	O
times	O
be	O
viewed	O
within	O
the	O
context	O
of	O
a	O
more	O
generalized	O
immune	O
imbalance	B-DISO
affecting	O
multiple	O
organs	O
,	O
and	O
not	O
as	O
an	O
isolated	O
pathological	O
entity	O
.	O

In	O
three	O
placentas	O
delivered	O
in	O
the	O
acute	O
stage	O
of	O
SARS	B-DISO
,	O
there	O
were	O
increases	O
in	O
intervillous	O
or	O
subchorionic	O
fibrin	O
which	O
might	O
be	O
related	O
to	O
disturbances	O
in	O
maternal	O
placental	O
blood	O
flow	O
due	O
to	O
the	O
hypoxic	B-DISO
respiratory	B-DISO
disease	I-DISO
.	O

The	O
aetiology	O
of	O
the	O
FTV	O
might	O
be	O
related	O
to	O
thrombotic	O
tendency	O
due	O
to	O
SARS	B-DISO
or	O
placental	O
hypoxia	B-DISO
.	O

TITLE	O
:	O
Steroid	O
-	O
induced	O
osteonecrosis	B-DISO
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
a	O
retrospective	O
analysis	O
of	O
biochemical	O
markers	O
of	O
bone	O
metabolism	O
and	O
corticosteroid	O
therapy	O
.	O

With	O
tapering	O
down	O
of	O
corticosteroid	O
dosage	O
,	O
CTx	B-DISO
started	O
to	O
return	O
to	O
previous	O
baseline	O
level	O
from	O
Day	O
51	O
onwards	O
,	O
while	O
other	O
bone	O
formation	O
markers	O
,	O
serum	O
osteocalcin	O
and	O
bone	O
-	O
specific	O
alkaline	O
phosphatase	O
concentrations	O
(	O
OC	O
and	O
BALP	O
,	O
respectively	O
),	O
started	O
to	O
increase	O
.	O

Seven	O
patients	O
developed	O
radiological	O
evidence	O
of	O
osteonecrosis	B-DISO
.	O

Both	O
bone	O
resorption	O
and	O
formation	O
markers	O
were	O
unable	O
to	O
predict	O
the	O
subsequent	O
development	O
of	O
osteonecrosis	B-DISO
.	O

TITLE	O
:	O
Coronavirus	O
HKU1	O
and	O
other	O
coronavirus	B-DISO
infections	I-DISO
in	O
Hong	O
Kong	O
.	O

CoV	O
-	O
HKU1	O
and	O
HCoV	O
-	O
OC43	O
infections	B-DISO
peaked	O
in	O
winter	O
,	O
although	O
cases	O
of	O
the	O
former	O
also	O
occurred	O
in	O
spring	O
to	O
early	O
summer	O
.	O

This	O
was	O
the	O
first	O
time	O
that	O
a	O
case	O
of	O
asymptomatic	O
SARS	B-DISO
was	O
noted	O
in	O
an	O
individual	O
with	O
antigenemia	O
and	O
seroconversion	O
.	O

The	O
asymptomatic	O
case	O
patient	O
and	O
the	O
second	O
index	O
case	O
patient	O
with	O
SARS	B-DISO
in	O
the	O
2003	O
-	O
2004	O
outbreak	O
both	O
worked	O
in	O
the	O
same	O
restaurant	O
,	O
where	O
they	O
served	O
palm	O
civets	O
,	O
which	O
were	O
found	O
to	O
carry	O
SARS	B-DISO
-	O
associated	O
coronaviruses	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
viruses	O
in	O
the	O
aetiology	O
of	O
community	O
-	O
acquired	O
pneumonia	B-DISO
in	O
adults	O
.	O

Consecutive	O
adult	O
patients	O
diagnosed	O
of	O
CAP	B-DISO
from	O
January	O
2003	O
to	O
March	O
2004	O
were	O
included	O
.	O

TITLE	O
:	O
Isatin	O
compounds	O
as	O
noncovalent	O
SARS	B-DISO
coronavirus	O
3C	O
-	O
like	O
protease	O
inhibitors	O
.	O

0	O
.	O
305	O
,	O
P	O
=	O
0	O
.	O
025	O
,	O
general	O
estimation	O
equation	O
model	O
)	O
in	O
SARS	B-DISO
patients	O
.	O

Metabolic	O
control	O
may	O
improve	O
the	O
prognosis	O
of	O
SARS	B-DISO
patients	O
.	O

TITLE	O
:	O
Management	O
of	O
acute	B-DISO
pancreatitis	I-DISO
:	O
current	O
knowledge	O
and	O
future	O
perspectives	O
.	O

TITLE	O
:	O
Transcriptional	O
profiling	O
of	O
acute	O
cytopathic	O
murine	B-DISO
hepatitis	I-DISO
virus	B-DISO
infection	I-DISO
in	O
fibroblast	O
-	O
like	O
cells	O
.	O

Microarray	O
analysis	O
was	O
applied	O
to	O
assess	O
changes	O
in	O
cellular	O
expression	O
profiles	O
during	O
different	O
stages	O
of	O
two	O
independent	O
,	O
highly	O
controlled	O
murine	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
infections	B-DISO
in	O
vitro	O
.	O

Interferon	O
responses	O
are	O
not	O
triggered	O
during	O
infection	B-DISO
,	O
although	O
the	O
L	O
cells	O
can	O
be	O
readily	O
stimulated	O
to	O
produce	O
interferon	O
by	O
dsRNA	O
,	O
a	O
known	O
potent	O
inducer	O
of	O
interferon	O
.	O

Nonetheless	O
the	O
close	O
working	O
and	O
living	O
conditions	O
for	O
staff	O
and	O
residents	O
in	O
such	O
a	O
home	O
may	O
facilitate	O
transmission	O
of	O
SARS	B-DISO
despite	O
vigilant	O
precautionary	O
measures	O
.	O

Laboratory	O
testing	O
identified	O
influenza	B-DISO
A	O
for	O
44	O
%;	O
sequence	O
analysis	O
demonstrated	O
that	O
these	O
were	O
Fujian	O
-	O
like	O
influenza	B-DISO
strains	O
,	O
which	O
represented	O
the	O
predominant	O
strain	O
found	O
globally	O
in	O
2003	O
/	O
2004	O
.	O

TITLE	O
:	O
The	O
effect	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
on	O
emergency	B-DISO
airway	O
management	O
.	O

ABSTRACT	O
:	O
From	O
early	O
March	O
2003	O
to	O
late	O
May	O
2003	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
was	O
detected	O
in	O
Singapore	O
.	O

Our	O
aim	O
was	O
to	O
study	O
the	O
effects	O
of	O
wearing	O
of	O
personal	O
protective	O
equipment	O
(	O
PPE	O
)	O
and	O
powered	O
air	O
-	O
purifying	O
respirator	O
(	O
PAPR	O
)	O
and	O
the	O
restriction	O
in	O
the	O
number	O
of	O
resuscitation	O
personnel	O
on	O
airway	O
management	O
during	O
the	O
SARS	B-DISO
crisis	O
.	O

The	O
resident	O
medical	O
officer	O
intubation	O
rate	O
decreased	O
from	O
45	O
.	O
1	O
%	O
pre	O
-	O
SARS	B-DISO
to	O
35	O
.	O
2	O
%	O
during	O
SARS	B-DISO
and	O
17	O
.	O
7	O
%	O
post	O
-	O
SARS	B-DISO
.	O

The	O
exposure	O
of	O
junior	O
medical	O
officers	O
in	O
emergency	B-DISO
airway	O
management	O
during	O
SARS	B-DISO
and	O
the	O
immediate	O
post	O
-	O
SARS	B-DISO
period	O
was	O
decreased	O
.	O

The	O
majority	O
of	O
EDs	B-DISO
would	O
isolate	O
patients	O
with	O
potential	O
infectious	B-DISO
diseases	I-DISO
,	O
however	O
,	O
47	O
(	O
23	O
%)	O
would	O
not	O
isolate	O
patients	O
with	O
suspected	O
chickenpox	B-DISO
,	O
37	O
(	O
18	O
%)	O
EDS	B-DISO
would	O
not	O
isolate	O
patients	O
with	O
suspected	O
TB	O
,	O
12	O
(	O
6	O
%)	O
EDS	B-DISO
would	O
not	O
isolate	O
patients	O
with	O
suspected	O
SARS	B-DISO
and	O
55	O
(	O
27	O
%)	O
EDS	B-DISO
would	O
not	O
isolate	O
patients	O
with	O
other	O
suspicious	O
infections	B-DISO
.	O

The	O
majority	O
of	O
EDs	B-DISO
would	O
isolate	O
patients	O
with	O
potential	O
infectious	B-DISO
diseases	I-DISO
,	O
however	O
,	O
47	O
(	O
23	O
%)	O
would	O
not	O
isolate	O
patients	O
with	O
suspected	O
chickenpox	B-DISO
,	O
37	O
(	O
18	O
%)	O
EDS	B-DISO
would	O
not	O
isolate	O
patients	O
with	O
suspected	O
TB	O
,	O
12	O
(	O
6	O
%)	O
EDS	B-DISO
would	O
not	O
isolate	O
patients	O
with	O
suspected	O
SARS	B-DISO
and	O
55	O
(	O
27	O
%)	O
EDS	B-DISO
would	O
not	O
isolate	O
patients	O
with	O
other	O
suspicious	O
infections	B-DISO
.	O

New	O
insight	O
into	O
the	O
physiology	O
of	O
lung	O
recruitment	B-DISO
suggests	O
that	O
the	O
shape	O
of	O
the	O
pressure	O
-	O
volume	O
curve	O
is	O
defined	O
by	O
the	O
change	O
in	O
rate	O
of	O
alveolar	O
opening	O
and	O
closing	O
.	O

This	O
study	O
may	O
provide	O
an	O
effective	O
way	O
to	O
interfere	O
with	O
the	O
potential	O
therapeutic	O
target	O
fgl2	O
gene	O
for	O
fulminant	O
viral	B-DISO
hepatitis	I-DISO
and	O
other	O
diseases	O
with	O
similar	O
pathological	O
characteristics	O
of	O
microcirculation	O
disorders	O
,	O
including	O
acute	O
rejection	O
of	O
xeno	O
-	O
or	O
allograft	O
transplantation	O
and	O
fetal	O
loss	O
syndrome	B-DISO
,	O
in	O
which	O
studies	O
show	O
fgl2	O
plays	O
an	O
important	O
role	O
.	O

TITLE	O
:	O
Ageing	O
and	O
psychological	B-DISO
response	O
during	O
the	O
post	O
-	O
SARS	B-DISO
period	O
.	O

After	O
controlling	O
for	O
depression	B-DISO
,	O
residents	O
in	O
high	O
SARS	B-DISO
-	O
prevalent	O
regions	O
,	O
regardless	O
of	O
age	O
,	O
consistently	O
developed	O
more	O
intense	O
post	O
-	O
traumatic	O
disturbance	O
than	O
residents	O
in	O
low	O
SARS	B-DISO
-	O
prevalent	O
regions	O
.	O

RESULTS	O
:	O
Among	O
the	O
401	O
SARS	B-DISO
patients	O
studied	O
,	O
147	O
of	O
249	O
noncritical	O
patients	O
(	O
59	O
.	O
0	O
%)	O
received	O
corticosteroids	O
(	O
mean	O
daily	O
dose	O
,	O
105	O
.	O
3	O
+/-	O

Corticosteroid	O
pulse	O
-	O
therapy	O
resulted	O
in	O
prompt	O
improvement	O
of	O
chest	O
infiltrates	B-DISO
and	O
his	O
symptoms	O
.	O

RESULTS	O
:	O
The	O
positive	O
rates	O
of	O
specific	O
IgG	O
and	O
whole	O
antibodies	O
against	O
SARS	B-DISO
-	O
CoV	O
ranged	O
from	O
39	O
.	O
1	O
%	O
to	O
43	O
.	O
5	O
%	O
in	O
the	O
children	O
who	O
had	O
been	O
clinically	O
diagnosed	O
as	O
SARS	B-DISO
,	O
zero	O
in	O
children	O
and	O
6	O
.	O
0	O
%	O
to	O
9	O
.	O
0	O
%	O
in	O
adults	O
who	O
had	O
closely	O
contacted	O
with	O
the	O
clinically	O
diagnosed	O
SARS	B-DISO
children	O
.	O

ABSTRACT	O
:	O
A	O
synthetic	O
peptide	O
corresponding	O
to	O
amino	O
acids	O
(	O
aa	O
)	O
15	O
-	O
28	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
3a	O
protein	O
was	O
used	O
to	O
raise	O
polyclonal	O
antibodies	O
in	O
rabbits	O
.	O

Flow	O
cytometric	O
analysis	O
showed	O
that	O
both	O
CD4	O
(+)	O
and	O
CD8	O
(+)	O
T	O
cells	O
were	O
involved	O
in	O
cellular	O
responses	O
against	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Systemic	O
activation	O
of	O
complement	O
is	O
a	O
pathophysiological	O
response	O
common	O
to	O
severe	O
disturbances	O
such	O
as	O
hemorrhagic	B-DISO
shock	I-DISO
,	O
major	O
burn	O
injury	O
and	O
sepsis	B-DISO
.	O

Intravenous	O
infusion	O
of	O
cobra	O
venom	O
factor	O
(	O
CVF	O
)	O
has	O
been	O
used	O
as	O
an	O
animal	O
model	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
and	O
reliably	O
and	O
selectively	O
induces	O
rapid	O
intravascular	O
activation	O
of	O
the	O
complement	O
system	O
,	O
leading	O
to	O
acute	O
organ	O
damage	O
.	O

Intravenous	O
CVF	O
resulted	O
in	O
hallmark	O
events	O
evident	O
in	O
the	O
development	O
of	O
ARDS	B-DISO
,	O
including	O
systemic	O
neutropenia	O
followed	O
by	O
neutrophil	B-DISO
migration	I-DISO
to	O
the	O
lung	O
and	O
bronchoalveolar	O
vascular	O
leakage	B-DISO
,	O
blood	O
pressure	O
alterations	O
,	O
and	O
an	O
increase	O
in	O
TNFalpha	O
levels	O
in	O
both	O
serum	O
and	O
bronchoalveolar	O
lavage	O
fluid	O
.	O

TITLE	O
:	O
[	O
Effects	O
of	O
different	O
modes	O
of	O
artificial	O
ventilation	O
on	O
lung	O
injury	O
in	O
dog	O
model	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
].	O

Thirty	O
-	O
six	O
healthy	O
dogs	O
were	O
randomly	O
divided	O
into	O
normal	O
control	O
group	O
(	O
N	O
group	O
),	O
ARDS	B-DISO
group	O
(	O
M	O
group	O
)	O
and	O
ventilation	O
group	O
(	O
A	O
-	O
D	O
groups	O
)	O
based	O
on	O
a	O
series	O
of	O
random	O
number	O
.	O

TITLE	O
:	O
The	O
lung	O
in	O
sepsis	B-DISO
:	O
guilty	O
or	O
innocent	O
?	O

Analytical	O
Biochemistry	O
,	O
1996	O
,	O
233	O
,	O
1	O
-	O
14	O
),	O
the	O
knowledge	O
of	O
the	O
cleavable	O
peptides	O
by	O
SARS	B-DISO
-	O
CoV	O
M	O
(	O
pro	O
)	O
(	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
main	O
proteinase	O
)	O
can	O
provide	O
very	O
useful	O
insights	O
on	O
developing	O
drugs	O
against	O
SARS	B-DISO
.	O

A	O
possible	O
strategy	O
to	O
convert	O
a	O
cleavable	O
octapeptide	O
by	O
SARS	B-DISO
enzyme	O
into	O
a	O
drug	O
candidate	O
against	O
SARS	B-DISO
is	O
elucidated	O
.	O

ABSTRACT	O
:	O
A	O
38	O
-	O
year	O
-	O
old	O
Japanese	O
man	O
was	O
referred	O
to	O
our	O
hospital	O
in	O
June	O
2003	O
for	O
treatment	O
of	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
with	O
severe	O
eosinophilia	B-DISO
.	O

Idiopathic	B-DISO
hypereosinophilic	I-DISO
syndrome	I-DISO
had	O
been	O
diagnosed	O
in	O
1994	O
.	O

Despite	O
treatment	O
with	O
steroid	O
pulse	O
therapy	O
and	O
cytarabine	O
,	O
the	O
blood	O
eosinophil	O
count	O
did	O
not	O
decrease	O
,	O
and	O
the	O
patient	O
'	O
s	O
respiratory	O
condition	B-DISO
worsened	O
.	O

The	O
blood	O
eosinophil	O
count	O
decreased	O
dramatically	O
over	O
5	O
days	O
,	O
and	O
the	O
patient	O
'	O
s	O
condition	B-DISO
rapidly	O
improved	O
,	O
such	O
that	O
the	O
patient	O
could	O
be	O
discharged	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
multiplex	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
multiplex	O
RT	O
-	O
PCR	O
)	O
that	O
can	O
detect	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
),	O
and	O
porcine	O
group	O
A	O
rotavirus	O
(	O
GAR	O
)	O
was	O
developed	O
.	O

PEDV	O
,	O
porcine	O
GAR	O
,	O
and	O
TGEV	O
infection	B-DISO
were	O
26	O
.	O
3	O
%,	O
13	O
.	O
2	O
%,	O
and	O
2	O
.	O
7	O
%	O
respectively	O
.	O

This	O
multiplex	O
RT	O
-	O
PCR	O
is	O
a	O
simple	O
assay	O
and	O
may	O
be	O
a	O
potentially	O
useful	O
for	O
rapid	O
,	O
sensitive	O
,	O
and	O
cost	O
-	O
effective	O
etiological	O
diagnostic	O
tool	O
for	O
acute	O
viral	B-DISO
gastroenteritis	I-DISO
in	O
piglets	O
.	O

and	O
Scrophularia	O
scorodonia	O
have	O
been	O
reported	O
to	O
possess	B-DISO
various	O
biological	O
activities	O
,	O
specifically	O
antihepatitis	O
,	O
antinephritis	O
,	O
antihepatoma	O
,	O
anti	O
-	O
inflammation	B-DISO
,	O
immunomodulation	O
and	O
antibacterial	O
effects	O
.	O

Interestingly	O
,	O
both	O
saikosaponins	O
A	O
(	O
50	O
%	O
cellular	O
cytotoxicity	B-DISO
(	O
CC50	B-DISO
)	O
concentration	O
=	O
228	O
.	O
1	O
+/-	O

In	O
the	O
time	O
-	O
of	O
-	O
addition	O
studies	O
,	O
saikosaponin	O
B2	O
,	O
at	O
6	O
micromol	O
/	O
L	O
,	O
significantly	O
inhibited	O
human	O
coronavirus	O
229E	O
infection	B-DISO
following	O
its	O
addition	O
at	O
various	O
time	O
pre	O
-	O
infection	B-DISO
(-	O
4	O
to	O
-	O
1	O
h	O
),	O
coinfection	B-DISO
(	O
0	O
h	O
)	O
and	O
post	O
-	O
infection	B-DISO
(	O
1	O
-	O
4	O
h	O
).	O

We	O
therefore	O
screened	O
an	O
antibody	O
-	O
phage	O
library	O
derived	O
from	O
blood	O
of	O
a	O
convalescent	O
SARS	B-DISO
patient	O
for	O
antibodies	O
complementary	O
to	O
CR3014	O
.	O

ABSTRACT	O
:	O
It	O
has	O
been	O
shown	O
that	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
3a	O
and	O
7a	O
proteins	O
,	O
but	O
not	O
membrane	O
(	O
M	O
)	O
protein	O
,	O
induce	O
apoptosis	O
in	O
mammalian	O
cells	O
.	O

This	O
is	O
the	O
first	O
report	O
describing	O
the	O
induction	O
of	O
apoptosis	O
by	O
SARS	B-DISO
-	O
CoV	O
M	O
protein	O
in	O
animal	O
cells	O
and	O
possible	O
implications	O
are	O
discussed	O
.	O

There	O
were	O
8	O
fistulae	O
,	O
7	O
of	O
which	O
occurred	O
out	O
of	O
9	O
patients	O
treated	O
between	O
July	O
2003	O
and	O
January	O
2004	O
when	O
operations	O
were	O
resumed	O
after	O
the	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
Hong	O
Kong	O
;	O
1	O
minute	O
fistula	B-DISO
occurred	O
after	O
this	O
period	O
and	O
closed	O
spontaneously	O
.	O

The	O
high	O
incidence	O
and	O
cluster	O
occurrence	O
immediately	O
after	O
SARS	B-DISO
could	O
be	O
related	O
to	O
changes	O
in	O
the	O
provision	O
of	O
nursing	O
care	O
and	O
the	O
level	O
of	O
parental	O
supervision	O
,	O
in	O
addition	O
to	O
more	O
difficult	O
operations	O
encountered	O
as	O
reflected	O
by	O
more	O
extensive	O
clefts	O
and	O
longer	O
operation	O
time	O
.	O

Factors	O
significantly	O
associated	O
with	O
initial	O
CRP	O
concentration	O
>	O
47	O
.	O
5	O
mg	O
/	O
L	O
included	O
dyspnea	B-DISO
(	O
OR	O
=	O
4	O
.	O
3	O
),	O
red	O
blood	O
cell	O
count	O
<	O
4	O
.	O
1	O
x	O
106	O
/	O
microL	O
(	O
OR	O
=	O
4	O
.	O
3	O
)	O
and	O
serum	O
aspartate	O
aminotransferase	O
>	O
57	O
IU	O
/	O
L	O
(	O
OR	O
=	O
3	O
.	O
1	O
).	O

Seven	O
of	O
the	O
20	O
patients	O
with	O
nonauthorized	O
requests	O
were	O
not	O
known	O
to	O
have	O
SARS	B-DISO
at	O
the	O
time	O
of	O
request	O
.	O

Within	O
ten	O
days	O
,	O
three	O
of	O
seven	O
were	O
under	O
investigation	O
for	O
,	O
a	O
suspect	O
case	O
of	O
,	O
or	O
a	O
probable	O
case	O
of	O
SARS	B-DISO
.	O

Community	O
SARS	B-DISO
cases	O
caused	O
transmission	O
to	O
others	O
at	O
an	O
estimated	O
rate	O
of	O
0	O
.	O
4	O
per	O
infective	O
per	O
day	O
during	O
the	O
early	O
part	O
of	O
the	O
epidemic	O
,	O
reducing	O
to	O
0	O
.	O
2	O
in	O
the	O
later	O
part	O
of	O
the	O
epidemic	O
.	O

To	O
compare	O
the	O
reduction	O
in	O
hospitalizations	O
resulting	O
from	O
widespread	O
nonurgent	O
hospital	O
admission	O
restrictions	O
during	O
the	O
Toronto	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
with	O
the	O
expected	O
increase	O
in	O
admissions	O
resulting	O
from	O
an	O
influenza	B-DISO
pandemic	O
in	O
Toronto	O
.	O

Therefore	O
,	O
influenza	B-DISO
-	O
related	O
admissions	O
could	O
exceed	O
the	O
reduction	O
in	O
admissions	O
resulting	O
from	O
restricted	O
hospital	O
utilization	O
by	O
1	O
,	O
165	O
to	O
7	O
,	O
591	O
patient	O
admissions	O
,	O
depending	O
on	O
pandemic	O
severity	O
,	O
which	O
corresponds	O
to	O
an	O
excess	O
of	O
0	O
.	O
44	O
to	O
2	O
.	O
91	O
influenza	B-DISO
-	O
related	O
admissions	O
per	O
1	O
,	O
000	O
population	O
per	O
eight	O
weeks	O
,	O
and	O
an	O
increase	O
of	O
4	O
%	O
to	O
25	O
%	O
in	O
the	O
overall	O
number	O
of	O
admissions	O
,	O
when	O
compared	O
with	O
nonpandemic	O
conditions	O
.	O

Therefore	O
,	O
influenza	B-DISO
-	O
related	O
admissions	O
could	O
exceed	O
the	O
reduction	O
in	O
admissions	O
resulting	O
from	O
restricted	O
hospital	O
utilization	O
by	O
1	O
,	O
165	O
to	O
7	O
,	O
591	O
patient	O
admissions	O
,	O
depending	O
on	O
pandemic	O
severity	O
,	O
which	O
corresponds	O
to	O
an	O
excess	O
of	O
0	O
.	O
44	O
to	O
2	O
.	O
91	O
influenza	B-DISO
-	O
related	O
admissions	O
per	O
1	O
,	O
000	O
population	O
per	O
eight	O
weeks	O
,	O
and	O
an	O
increase	O
of	O
4	O
%	O
to	O
25	O
%	O
in	O
the	O
overall	O
number	O
of	O
admissions	O
,	O
when	O
compared	O
with	O
nonpandemic	O
conditions	O
.	O

In	O
the	O
context	O
of	O
the	O
armed	O
forces	O
,	O
aggressive	B-DISO
containment	O
measures	O
are	O
essential	O
to	O
prevent	O
an	O
outbreak	O
.	O

In	O
the	O
early	O
recovery	O
period	O
,	O
potential	O
problems	O
during	O
diving	O
are	O
caused	O
by	O
inadequate	O
lung	O
ventilation	O
in	O
relation	O
to	O
exercise	O
level	O
and	O
increased	O
breathing	O
resistance	O
attributable	O
to	O
weak	O
respiratory	O
muscles	O
,	O
with	O
corresponding	O
risk	O
of	O
hypoxia	B-DISO
and	O
hypercapnia	B-DISO
,	O
as	O
well	O
as	O
decreased	O
ability	O
to	O
respond	O
to	O
nonrespiratory	O
problems	O
during	O
diving	O
.	O

TITLE	O
:	O
Mechanisms	O
of	O
establishment	O
of	O
persistent	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
cells	O
.	O

Protease	O
cleavage	O
of	O
the	O
trimer	O
occurs	O
at	O
the	O
S1	O
-	O
S2	O
boundary	O
;	O
an	O
ensuing	O
S1	O
dissociation	B-DISO
leads	O
to	O
a	O
major	O
rearrangement	O
of	O
the	O
trimeric	O
S2	O
and	O
to	O
formation	O
of	O
rosettes	O
likely	O
to	O
represent	O
clusters	O
of	O
elongated	O
,	O
postfusion	O
trimers	O
of	O
S2	O
associated	O
through	O
their	O
fusion	O
peptides	O
.	O

Infection	B-DISO
with	O
the	O
A59	O
strain	O
of	O
MHV	O
induces	O
both	O
encephalitis	B-DISO
and	O
hepatitis	B-DISO
,	O
while	O
the	O
highly	O
neurovirulent	O
JHM	O
strain	O
induces	O
a	O
fatal	O
encephalitis	B-DISO
with	O
little	O
,	O
if	O
any	O
,	O
hepatitis	B-DISO
.	O

TITLE	O
:	O
Enhanced	O
induction	O
of	O
SARS	B-DISO
-	O
CoV	O
nucleocapsid	O
protein	O
-	O
specific	O
immune	O
response	O
using	O
DNA	O
vaccination	O
followed	O
by	O
adenovirus	B-DISO
boosting	O
in	O
BALB	O
/	O
c	O
mice	O
.	O

The	O
humoral	O
immune	O
response	O
was	O
induced	O
more	O
effectively	O
by	O
the	O
DNA	O
priming	O
and	O
recombinant	O
adenovirus	B-DISO
boosting	O
regimen	O
and	O
the	O
reverse	O
sequence	O
of	O
heterogeneous	O
combinations	O
.	O

However	O
,	O
the	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
response	O
was	O
not	O
significantly	O
altered	O
by	O
the	O
different	O
prime	O
-	O
boost	O
immunizations	O
or	O
the	O
recombinant	O
adenovirus	B-DISO
of	O
pcDNA3	O
.	O
1	O
-	O
N	O
prime	O
-	O
rAd	O
-	O
N	O
boost	O
regimen	O
alone	O
,	O
but	O
lymphoproliferation	O
and	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
secretion	O
were	O
all	O
enhanced	O
by	O
heterologous	O
combination	O
immunizations	O
compared	O
to	O
homologous	O
combinations	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
E	O
protein	O
from	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
forms	O
cation	O
-	O
selective	O
ion	O
channels	O
in	O
planar	O
lipid	O
bilayers	O
(	O
Wilson	O
,	O
L	O
.,	O
McKinlay	O
,	O
C	O
.,	O
Gage	O
,	O
P	O
.,	O
Ewart	O
,	O
G	O
.,	O
2004	O
.	O

TITLE	O
:	O
Pathogenic	O
role	O
for	O
virus	O
-	O
specific	O
CD4	O
T	O
cells	O
in	O
mice	O
with	O
coronavirus	O
-	O
induced	O
acute	O
encephalitis	B-DISO
.	O

Infection	B-DISO
of	O
naïve	O
B6	O
mice	O
with	O
this	O
virus	O
resulted	O
in	O
mild	O
disease	O
with	O
no	O
mortality	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
existence	O
status	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
,	O
retrovirus	O
,	O
and	O
the	O
poliovirus	O
in	O
the	O
bodies	O
of	O
the	O
patients	O
with	O
SARS	B-DISO
and	O
the	O
possible	O
relationship	O
between	O
the	O
three	O
viruses	O
and	O
SARS	B-DISO
.	O

No	O
positive	O
results	O
for	O
antibody	O
to	O
SARS	B-DISO
-	O
CoV	O
were	O
detected	O
in	O
the	O
25	O
healthy	O
persons	O
.	O

Susceptible	O
populations	O
develop	O
the	O
syndrome	B-DISO
more	O
often	O
and	O
have	O
worse	O
outcomes	O
.	O

Additionally	O
,	O
the	O
SARS	B-DISO
Grid	O
project	O
can	O
be	O
viewed	O
and	O
further	O
studied	O
as	O
an	O
outstanding	O
model	O
of	O
epidemic	B-DISO
disease	I-DISO
prevention	O
and	O
/	O
or	O
containment	O
.	O

Among	O
the	O
behavioral	O
beliefs	O
,	O
""""	O
SARS	B-DISO
-	O
patient	O
caring	O
would	O
be	O
a	O
new	O
experience	O
""","	O
""""	O
during	O
SARS	B-DISO
-	O
patient	O
caring	O
,	O
I	O
should	O
be	O
apart	O
from	O
my	O
family	O
""","	O
""""	O
after	O
completing	O
SARS	B-DISO
-	O
patient	O
caring	O
,	O
I	O
would	O
be	O
proud	O
of	O
myself	O
being	O
able	O
to	O
cope	O
with	O
a	O
stressful	O
event	O
""""	O
and	O
""""	O
with	O
my	O
SARS	B-DISO
-	O
patient	O
caring	O
,	O
patients	O
could	O
recover	O
from	O
SARS	B-DISO
""""	O
were	O
the	O
significant	O
determinants	O
.	O

TITLE	O
:	O
Surge	O
capacity	O
and	O
casualization	O
:	O
Human	O
resource	O
issues	O
in	O
the	O
post	O
-	O
SARS	B-DISO
health	O
system	O
.	O

The	O
article	O
ends	O
with	O
a	O
discussion	O
of	O
how	O
practice	O
and	O
regulations	O
have	O
changed	O
in	O
Canada	O
since	O
SARS	B-DISO
and	O
some	O
suggestions	O
on	O
how	O
practice	O
or	O
regulations	O
could	O
further	O
improve	O
.	O

During	O
the	O
period	O
between	O
March	O
and	O
May	O
2003	O
,	O
238	O
probable	O
SARS	B-DISO
cases	O
,	O
including	O
8	O
imported	O
cases	O
and	O
33	O
deaths	O
,	O
were	O
reported	O
.	O

Eighty	O
-	O
nine	O
per	O
cent	O
had	O
exposures	O
to	O
7	O
wards	O
which	O
had	O
cases	O
of	O
SARS	B-DISO
that	O
were	O
not	O
isolated	O
on	O
admission	O
.	O

The	O
outbreak	O
of	O
SARS	B-DISO
at	O
TTSH	O
showed	O
the	O
challenges	O
of	O
dealing	O
with	O
an	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
with	O
efficient	O
nosocomial	O
spread	O
.	O

Advanced	O
age	O
,	O
neutrophilia	O
and	O
high	O
LDH	O
predict	O
poor	O
outcomes	O
in	O
patients	O
with	O
SARS	B-DISO
.	O

TITLE	O
:	O
Clinical	O
and	O
laboratory	O
findings	O
of	O
SARS	B-DISO
in	O
Singapore	O
.	O

At	O
presentation	O
,	O
the	O
common	O
symptoms	O
were	O
fever	O
,	O
myalgia	B-DISO
,	O
cough	B-DISO
and	O
headache	B-DISO
;	O
rhinorrhoea	B-DISO
was	O
uncommon	O
.	O

On	O
admission	O
,	O
21	O
%	O
had	O
leukopenia	B-DISO
,	O
18	O
%	O
had	O
thrombocytopaenia	O
,	O
29	O
%	O
had	O
hyponatraemia	O
,	O
31	O
%	O
had	O
hypokalaemia	O
,	O
21	O
%	O
had	O
transaminitis	O
.	O

Patients	O
infected	O
with	O
the	O
SARS	B-DISO
coronavirus	O
had	O
a	O
wide	O
clinical	O
presentation	O
with	O
non	O
-	O
specific	O
symptoms	O
.	O

TITLE	O
:	O
Radiographic	O
features	O
of	O
SARS	B-DISO
in	O
paediatric	O
patients	O
:	O
a	O
review	O
of	O
cases	O
in	O
Singapore	O
.	O

The	O
SARS	B-DISO
outbreak	O
clearly	O
demonstrated	O
that	O
it	O
is	O
no	O
longer	O
the	O
exclusive	O
privilege	O
of	O
countries	O
to	O
report	O
and	O
respond	O
to	O
infectious	B-DISO
diseases	I-DISO
occurring	O
in	O
their	O
own	O
territories	O
,	O
but	O
that	O
the	O
global	O
community	O
has	O
also	O
assumed	O
this	O
role	O
,	O
aided	O
by	O
the	O
ease	O
and	O
power	O
of	O
electronic	O
communication	O
through	O
the	O
World	O
Wide	O
Web	B-DISO
.	O

It	O
was	O
agreed	O
that	O
an	O
inventory	O
of	O
all	O
specimens	O
with	O
the	O
potential	O
presence	O
of	O
SARS	B-DISO
-	O
CoV	O
collected	O
for	O
any	O
diagnostic	O
or	O
research	O
purposes	O
from	O
November	O
2002	O
to	O
July	O
2003	O
should	O
be	O
established	O
in	O
each	O
laboratory	O
.	O

By	O
January	O
2004	O
,	O
all	O
clinical	O
laboratories	O
performing	O
SARS	B-DISO
-	O
CoV	O
testing	O
in	O
Hong	O
Kong	O
set	O
up	O
inventories	O
to	O
document	O
location	O
and	O
types	O
of	O
SARS	B-DISO
-	O
CoV	O
containing	O
materials	O
retained	O
in	O
their	O
laboratory	O
.	O

After	O
the	O
World	O
Health	O
Organization	O
declared	O
the	O
world	O
SARS	B-DISO
-	O
free	O
on	O
5	O
July	O
2003	O
,	O
there	O
were	O
episodic	O
recurrences	B-DISO
of	O
SARS	B-DISO
between	O
September	O
2003	O
and	O
May	O
2004	O
,	O
including	O
4	O
cases	O
of	O
laboratory	O
-	O
acquired	O
SARS	B-DISO
.	O

SARS	B-DISO
posed	O
a	O
mammoth	O
challenge	O
because	O
of	O
the	O
impact	O
of	O
nosocomial	O
transmission	O
on	O
healthcare	O
manpower	O
and	O
facilities	O
,	O
and	O
the	O
resources	O
needed	O
for	O
controlling	O
and	O
preventing	O
further	O
spread	O
.	O

SARS	B-DISO
preparedness	O
and	O
response	O
planning	O
must	O
be	O
flexible	O
and	O
dynamic	O
so	O
that	O
appropriate	O
measures	O
can	O
be	O
implemented	O
as	O
an	O
outbreak	O
progresses	O
.	O

TITLE	O
:	O
SARS	B-DISO
plague	B-DISO
:	O
duty	O
of	O
care	O
or	O
medical	O
heroism	O
?	O

Indeed	O
,	O
HCWs	O
had	O
lost	O
their	O
lives	O
to	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
The	O
INTERCEPT	O
Blood	O
System	O
,	O
a	O
photochemical	O
treatment	O
(	O
PCT	B-DISO
)	O
process	O
,	O
has	O
been	O
developed	O
to	O
inactivate	O
pathogens	O
in	O
platelet	O
concentrates	O
.	O

PCT	B-DISO
has	O
the	O
potential	O
to	O
reduce	O
the	O
risk	O
of	O
transfusion	O
-	O
transmitted	B-DISO
diseases	O
in	O
patients	O
requiring	O
plasma	O
transfusion	O
support	O
.	O

However	O
,	O
the	O
emergence	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
has	O
prompted	O
the	O
discovery	O
of	O
such	O
drugs	O
.	O

Moreover	O
,	O
progress	O
in	O
the	O
drug	O
development	O
based	O
on	O
different	O
molecular	O
targets	O
is	O
also	O
summarized	O
,	O
including	O
1	O
)	O
Compounds	O
that	O
block	O
the	O
S	O
protein	O
-	O
ACE2	O
-	O
mediated	O
viral	O
entry	O
;	O
2	O
)	O
Compounds	O
targeting	O
SARS	B-DISO
-	O
CoV	O
M	O
(	O
pro	O
);	O
3	O
)	O
Compounds	O
targeting	O
papain	O
-	O
like	O
protease	O
2	O
(	O
PLP2	O
);	O
4	O
)	O
Compounds	O
targeting	O
SARS	B-DISO
-	O
CoV	O
RdRp	O
;	O
5	O
)	O
Compounds	O
targeting	O
SARS	B-DISO
-	O
CoV	O
helicase	O
;	O
6	O
)	O
Active	O
compounds	O
with	O
unspecified	O
targets	O
;	O
and	O
7	O
)	O
Research	O
on	O
siRNA	O
.	O

It	O
also	O
blocked	O
beta	O
arrestin	O
translocation	B-DISO
and	O
receptor	O
downregulation	O
induced	O
by	O
formyl	O
-	O
Nle	O
-	O
Leu	O
-	O
Phe	O
.	O

We	O
have	O
also	O
shown	O
that	O
griffithsin	O
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
coronavirus	O
responsible	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Analysis	O
of	O
the	O
immune	O
responses	O
by	O
flow	O
cytometry	O
showed	O
that	O
both	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
were	O
involved	O
in	O
the	O
SARS	B-DISO
-	O
CoV	O
E	O
-	O
specific	O
immune	O
responses	O
after	O
stimulation	O
with	O
SARS	B-DISO
-	O
CoV	O
E	O
peptides	O
.	O

We	O
then	O
studied	O
the	O
severity	O
of	O
acute	B-DISO
pancreatitis	I-DISO
-	O
associated	O
lung	O
injury	O
over	O
18h	O
in	O
rats	O
that	O
had	O
taurocholic	O
acid	O
injection	O
in	O
the	O
pancreatic	O
duct	O
and	O
determined	O
whether	O
blood	O
collected	O
from	O
rats	O
with	O
pancreatitis	B-DISO
is	O
toxic	O
enough	O
to	O
induce	O
injury	O
in	O
normal	O
lungs	O
.	O

The	O
cases	O
were	O
classified	O
as	O
dry	O
-	O
bite	O
(	O
n	O
=	O
1	O
,	O
caused	O
by	O
M	O
.	O
lemniscatus	O
;	O
did	O
not	O
receive	O
antivenom	O
),	O
mild	O
(	O
n	O
=	O
2	O
,	O
local	O
manifestations	O
with	O
no	O
acute	O
myasthenic	B-DISO
syndrome	I-DISO
;	O
M	O
.	O
frontalis	O
and	O
Micrurus	O
spp	O
.),	O
moderate	O
(	O
n	O
=	O
5	O
,	O
mild	O
myasthenia	B-DISO
)	O
or	O
severe	O
(	O
n	O
=	O
3	O
,	O
important	O
myasthenia	B-DISO
;	O
one	O
of	O
them	O
caused	O
by	O
M	O
.	O
frontalis	O
).	O

TITLE	O
:	O
Frequent	O
detection	O
of	O
human	O
rhinoviruses	O
,	O
paramyxoviruses	O
,	O
coronaviruses	O
,	O
and	O
bocavirus	O
during	O
acute	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
.	O

HRVs	O
were	O
the	O
sole	O
microbe	O
detected	O
in	O
37	O
.	O
8	O
%	O
(	O
n	O
=	O
31	O
)	O
of	O
patients	O
with	O
suspected	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
(	O
LRTI	B-DISO
).	O

Most	O
importantly	O
,	O
R0	O
often	O
serves	O
as	O
a	O
threshold	O
parameter	O
that	O
predicts	O
whether	O
an	O
infection	B-DISO
will	O
spread	O
.	O

Telephone	O
contact	O
appears	O
to	O
be	O
a	O
practical	O
way	O
of	O
providing	O
health	O
education	O
to	O
vulnerable	O
groups	O
when	O
face	B-DISO
-	O
to	O
-	O
face	B-DISO
measure	O
is	O
not	O
feasible	O
and	O
may	O
be	O
useful	O
in	O
raising	O
health	O
awareness	O
during	O
future	O
outbreaks	O
of	O
emerging	O
infections	B-DISO
.	O

Chart	O
review	O
identified	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
managed	O
with	O
HFPV	O
.	O

TITLE	O
:	O
An	O
episulfide	O
cation	O
(	O
thiiranium	O
ring	O
)	O
trapped	O
in	O
the	O
active	O
site	O
of	O
HAV	B-DISO
3C	O
proteinase	O
inactivated	O
by	O
peptide	O
-	O
based	O
ketone	O
inhibitors	O
.	O

ABSTRACT	O
:	O
We	O
have	O
solved	O
the	O
crystal	O
and	O
molecular	O
structures	O
of	O
hepatitis	B-DISO
A	I-DISO
viral	O
(	O
HAV	B-DISO
)	O
3C	O
proteinase	O
,	O
a	O
cysteine	O
peptidase	O
having	O
a	O
chymotrypsin	O
-	O
like	O
protein	O
fold	O
,	O
in	O
complex	O
with	O
each	O
of	O
three	O
tetrapeptidyl	O
-	O
based	O
methyl	O
ketone	O
inhibitors	O
to	O
resolutions	O
beyond	O
1	O
.	O
4	O
A	O
,	O
the	O
highest	O
resolution	O
to	O
date	O
for	O
a	O
3C	O
or	O
a	O
3C	O
-	O
Like	O
(	O
e	O
.	O
g	O
.	O
SARS	B-DISO
viral	O
main	O
proteinase	O
)	O
peptidase	O
.	O

These	O
findings	O
suggest	O
that	O
IL	O
-	O
4	O
and	O
IFN	O
-	O
gamma	O
inhibit	O
SARS	B-DISO
-	O
CoV	O
replication	O
partly	O
through	O
downregulation	O
of	O
ACE2	O
.	O

TITLE	O
:	O
Clinical	O
prognostic	O
rules	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
low	O
-	O
and	O
high	O
-	O
resource	O
settings	O
.	O

The	O
model	O
performs	O
well	O
and	O
could	O
be	O
useful	O
in	O
assessing	O
prognosis	O
for	O
patients	O
who	O
are	O
infected	O
with	O
re	O
-	O
emergent	O
SARS	B-DISO
.	O

TITLE	O
:	O
Understanding	O
the	O
super	O
-	O
spreading	O
events	O
of	O
SARS	B-DISO
in	O
Singapore	O
.	O

Premenstrual	B-DISO
symptom	I-DISO
frequency	O
was	O
significantly	O
associated	O
with	O
a	O
maternal	O
history	O
of	O
premenstrual	B-DISO
syndrome	I-DISO
,	O
self	O
-	O
perception	O
of	O
mental	B-DISO
stress	I-DISO
,	O
physical	O
activity	O
,	O
consumption	O
of	O
sweet	O
-	O
tasting	O
foods	O
,	O
and	O
coffee	O
,	O
but	O
these	O
factors	O
only	O
explained	O
14	O
%	O
of	O
the	O
variability	O
in	O
the	O
multiple	O
regression	O
model	O
.	O

TITLE	O
:	O
Supramolecular	O
architecture	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
revealed	O
by	O
electron	O
cryomicroscopy	O
.	O

TITLE	O
:	O
Prognostic	O
value	O
of	O
increased	O
plasma	O
levels	O
of	O
brain	O
natriuretic	O
peptide	O
in	O
patients	O
with	O
septic	B-DISO
shock	I-DISO
.	O

This	O
is	O
a	O
prospective	O
case	O
series	O
study	O
of	O
22	O
patients	O
with	O
septic	B-DISO
shock	I-DISO
,	O
11	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
,	O
and	O
20	O
healthy	O
volunteers	O
at	O
the	O
Department	O
of	O
Emergency	B-DISO
and	O
Critical	O
Care	O
Medicine	O
,	O
Nara	O
Medical	O
University	O
Hospital	O
,	O
Japan	O
.	O

Right	O
atrial	O
pressure	O
,	O
mean	O
pulmonary	O
arterial	O
pressure	O
,	O
pulmonary	O
arterial	O
wedge	O
pressure	O
,	O
and	O
left	O
ventricular	O
stroke	B-DISO
work	O
index	O
were	O
determined	O
using	O
a	O
thermodilution	O
catheter	O
.	O

In	O
patients	O
with	O
septic	B-DISO
shock	I-DISO
,	O
both	O
BNP	O
and	O
ANP	O
peaked	O
on	O
day	O
2	O
(	O
BNP	O
,	O
987	O
+/-	O

Increased	O
plasma	O
levels	O
of	O
BNP	O
may	O
reflect	O
not	O
only	O
the	O
severity	O
of	O
myocardial	B-DISO
depression	I-DISO
but	O
also	O
the	O
disease	O
severity	O
and	O
could	O
be	O
of	O
prognostic	O
value	O
in	O
patients	O
with	O
septic	B-DISO
shock	I-DISO
.	O

RESULTS	O
:	O
All	O
patients	O
were	O
hypertensive	O
,	O
with	O
mean	O
Glasgow	O
coma	B-DISO
score	O
(	O
GCS	O
)	O
of	O
11	O
+/-	O

The	O
population	O
comprised	O
34	O
patients	O
including	O
17	O
with	O
valvular	O
disease	O
and	O
revascularisable	O
coronary	O
lesions	O
(	O
15	O
symptomatic	O
severe	O
aortic	O
stenoses	B-DISO
and	O
two	O
acute	O
mitral	O
insufficiencies	O
)	O
plus	O
17	O
multitrunk	O
coronary	O
patients	O
without	O
valvular	O
disease	O
but	O
with	O
an	O
indication	O
for	O
revascularisation	O
.	O

We	O
observed	O
4	O
in	O
-	O
hospital	O
deaths	O
,	O
one	O
of	O
which	O
was	O
due	O
to	O
an	O
infarct	B-DISO
and	O
three	O
due	O
to	O
extra	O
-	O
cardiac	O
causes	O
(	O
1	O
non	O
-	O
cardiogenic	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
1	O
respiratory	B-DISO
tract	I-DISO
infection	I-DISO
and	O
1	O
pyelonephritis	B-DISO
).	O

There	O
were	O
no	O
additional	O
deaths	O
,	O
coronary	O
events	O
nor	O
haemorrhage	B-DISO
at	O
the	O
end	O
of	O
an	O
average	O
follow	O
-	O
up	O
of	O
15	O
+/-	O

TITLE	O
:	O
Synthesis	O
,	O
crystal	O
structure	O
,	O
structure	O
-	O
activity	O
relationships	O
,	O
and	O
antiviral	O
activity	O
of	O
a	O
potent	O
SARS	B-DISO
coronavirus	O
3CL	O
protease	O
inhibitor	O
.	O

ABSTRACT	O
:	O
A	O
potent	O
SARS	B-DISO
coronavirus	O
(	O
CoV	O
)	O
3CL	O
protease	O
inhibitor	O
(	O
TG	O
-	O
0205221	O
,	O
Ki	O
=	O
53	O
nM	O
)	O
has	O
been	O
developed	O
.	O

TG	O
-	O
0205221	O
showed	O
remarkable	O
activity	O
against	O
SARS	B-DISO
CoV	O
and	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
229E	O
replications	O
by	O
reducing	O
the	O
viral	O
titer	O
by	O
4	O
.	O
7	O
log	O
(	O
at	O
5	O
microM	O
)	O
for	O
SARS	B-DISO
CoV	O
and	O
5	O
.	O
2	O
log	O
(	O
at	O
1	O
.	O
25	O
microM	O
)	O
for	O
HCoV	O
229E	O
.	O

Additional	O
investigations	O
are	O
required	O
to	O
define	O
the	O
role	O
of	O
HBoV	O
in	O
LRTI	B-DISO
.	O

TITLE	O
:	O
A	O
loophole	O
in	O
international	O
quarantine	O
procedures	O
disclosed	O
during	O
the	O
SARS	B-DISO
crisis	O
.	O

The	O
low	O
yield	O
in	O
detecting	O
SARS	B-DISO
is	O
most	O
likely	O
due	O
to	O
a	O
combination	O
of	O
factors	O
,	O
such	O
as	O
travel	O
advisories	O
which	O
resulted	O
in	O
reduced	O
travel	O
to	O
and	O
from	O
SARS	B-DISO
affected	O
areas	O
,	O
implementation	O
of	O
effective	O
pre	O
-	O
departure	O
screening	O
at	O
airports	O
in	O
SARS	B-DISO
-	O
hit	O
countries	O
,	O
and	O
a	O
rapid	O
decline	O
in	O
new	O
cases	O
at	O
the	O
time	O
when	O
screening	O
was	O
finally	O
introduced	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
highly	O
contagious	O
and	O
life	O
-	O
threatening	O
disease	O
that	O
emerged	O
in	O
China	O
in	O
November	O
2002	O
.	O

The	O
antigenicity	O
of	O
nine	O
peptides	O
which	O
could	O
refold	O
with	O
HLA	O
-	O
A	O
*	O
0201	O
molecules	O
was	O
assessed	O
with	O
an	O
IFN	O
-	O
gamma	O
ELISPOT	O
assay	O
to	O
determine	O
the	O
capacity	O
to	O
stimulate	O
CTLs	O
from	O
PBMCs	O
of	O
HLA	O
-	O
A2	O
(+)	O
SARS	B-DISO
-	O
recovered	O
donors	O
.	O

Thus	O
,	O
P15	O
may	O
be	O
a	O
novel	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
-	O
specific	O
CTL	O
epitope	O
and	O
a	O
potential	O
target	O
for	O
characterization	O
of	O
virus	O
control	O
mechanisms	O
and	O
evaluation	O
of	O
candidate	O
SARS	B-DISO
vaccines	O
.	O

Two	O
additional	O
Giardiosis	B-DISO
cases	O
with	O
negative	O
results	O
upon	O
parasitological	O
and	O
histopathological	O
examinations	O
were	O
diagnosed	O
by	O
means	O
of	O
immunohistochemical	O
examination	O
.	O

TITLE	O
:	O
[	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
pediatric	O
cardiosurgery	O
].	O

ABSTRACT	O
:	O
The	O
prognosis	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
poor	O
;	O
its	O
mortality	O
is	O
generally	O
40	O
-	O
60	O
%.	O

The	O
incidence	O
of	O
delayed	B-DISO
graft	I-DISO
function	I-DISO
was	O
0	O
%,	O
and	O
the	O
incidence	O
of	O
posttransplant	O
insulin	B-DISO
-	I-DISO
dependent	I-DISO
diabetes	I-DISO
mellitus	I-DISO
was	O
0	O
.	O
5	O
%.	O

ABSTRACT	O
:	O
Live	O
virus	O
vaccines	O
provide	O
significant	O
protection	O
against	O
many	O
detrimental	O
human	O
and	O
animal	B-DISO
diseases	I-DISO
,	O
but	O
reversion	O
to	O
virulence	O
by	O
mutation	O
and	O
recombination	O
has	O
reduced	O
appeal	O
.	O

TITLE	O
:	O
Multicenter	O
comparison	O
of	O
nucleic	O
acid	O
extraction	O
methods	O
for	O
detection	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
RNA	O
in	O
stool	O
specimens	O
.	O

ABSTRACT	O
:	O
The	O
preparedness	O
levels	O
of	O
front	O
-	O
line	O
clinicians	O
including	O
physicians	O
,	O
nurses	O
,	O
emergency	B-DISO
medical	O
responders	O
(	O
EMRs	O
),	O
and	O
other	O
medical	O
staff	O
working	O
in	O
clinics	O
,	O
offices	O
and	O
ambulatory	O
care	O
centers	O
must	O
be	O
assessed	O
,	O
so	O
these	O
personnel	O
are	O
able	O
to	O
deal	O
with	O
communicable	O
and	O
potentially	O
lethal	O
diseases	O
,	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Both	O
major	O
camps	O
in	O
the	O
argument	O
presume	O
that	O
humans	O
are	O
normally	O
free	O
of	O
such	O
viruses	O
and	O
assume	O
that	O
once	O
the	O
simian	O
virus	O
was	O
transmitted	B-DISO
,	O
it	O
immediately	O
infected	O
some	O
T	O
-	O
cells	O
and	O
caused	O
the	O
release	O
of	O
toxic	O
agents	O
that	O
killed	O
off	O
bystander	O
(	O
uninfected	O
)	O
T	O
-	O
cells	O
resulting	O
in	O
AIDS	O
.	O

SARS	B-DISO
and	O
Ebola	O
also	O
fit	B-DISO
this	O
pattern	O
.	O

Recent	O
examples	O
include	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
avian	B-DISO
influenza	I-DISO
,	O
and	O
monkeypox	B-DISO
.	O

The	O
microneutralizing	O
test	O
showed	O
that	O
one	O
clone	O
,	O
designated	O
M1A	O
,	O
had	O
neutralizing	O
activity	O
on	O
Vero	O
E6	O
cells	O
against	O
SARS	B-DISO
-	O
CoV	O
.	O
DNA	O
sequence	O
analysis	O
indicated	O
that	O
the	O
light	O
-	O
and	O
heavy	O
-	O
chain	O
genes	O
of	O
M1A	O
Fab	O
belong	O
to	O
the	O
kappa2a	O
and	O
4f	O
families	O
,	O
respectively	O
.	O

A	O
neutralizing	O
test	O
on	O
purified	O
M1A	O
demonstrated	O
that	O
0	O
.	O
5	O
mg	O
/	O
ml	O
of	O
M1A	O
completely	O
inhibited	O
SARS	B-DISO
-	O
CoV	O
activity	O
,	O
with	O
an	O
absence	O
of	O
cytopathic	B-DISO
effect	I-DISO
for	O
7	O
days	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
3a	O
protein	O
forms	O
an	O
ion	O
channel	O
and	O
modulates	O
virus	O
release	O
.	O

This	O
finding	O
will	O
help	O
to	O
explain	O
the	O
highly	O
pathogenic	O
nature	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
to	O
develop	O
new	O
strategies	O
for	O
treatment	O
of	O
SARS	B-DISO
infection	B-DISO
.	O

Bat	O
-	O
CoV	O
1A	O
and	O
1B	O
were	O
detected	O
in	O
apparently	O
healthy	O
Miniopterus	O
magnater	O
and	O
Miniopterus	O
pusillus	O
,	O
respectively	O
,	O
on	O
repeated	O
sampling	O
occasions	O
at	O
a	O
single	O
habitat	O
,	O
suggesting	O
that	O
these	O
viruses	O
have	O
established	O
a	O
persistent	B-DISO
infection	I-DISO
in	O
these	O
populations	O
.	O

We	O
have	O
synthesised	O
and	O
characterised	O
the	O
first	O
generation	O
of	O
a	O
red	O
-	O
shifted	O
internally	O
quenched	O
fluorogenic	O
substrate	O
(	O
RS	O
-	O
IQFS	O
)	O
for	O
3CLpro	O
based	O
on	O
resonance	O
energy	O
transfer	O
between	O
the	O
donor	O
and	O
acceptor	O
pair	O
CAL	O
Fluor	B-DISO
Red	O
610	O
and	O
Black	O
Hole	O
Quencher	O
-	O
1	O
(	O
Km	O
and	O
kcat	O
values	O
of	O
14	O
microM	O
and	O
0	O
.	O
65	O
min	O
-	O
1	O
).	O

The	O
RS	O
-	O
IQFS	O
primary	O
sequence	O
was	O
selected	O
based	O
on	O
the	O
results	O
of	O
our	O
screening	O
analysis	O
of	O
3CLpro	O
performed	O
using	O
a	O
series	O
of	O
blue	O
-	O
shifted	O
(	O
BS	O
)-	O
IQFSs	O
corresponding	O
to	O
the	O
3CLpro	O
-	O
mediated	O
cleavage	O
junctions	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
polyproteins	O
.	O

HCW	O
with	O
onset	O
of	O
illness	O
in	O
the	O
same	O
10	O
-	O
day	O
period	O
were	O
contacted	O
and	O
asked	O
whether	O
they	O
have	O
been	O
diagnosed	O
with	O
pneumonia	B-DISO
.	O

The	O
occurrence	O
of	O
clusters	O
of	O
two	O
or	O
more	O
cases	O
of	O
pneumonia	B-DISO
in	O
HCW	O
in	O
the	O
same	O
hospital	O
unit	O
appears	O
to	O
be	O
an	O
uncommon	O
event	O
,	O
and	O
thus	O
the	O
alert	O
system	O
proposed	O
is	O
not	O
likely	O
to	O
result	O
in	O
large	O
numbers	O
of	O
false	O
positive	O
alerts	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
adrenal	O
function	O
in	O
severe	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
(	O
WNV	B-DISO
)	O
infection	B-DISO
.	O

All	O
patients	O
had	O
fever	O
(	O
mean	O
body	O
temperature	O
39	O
+/-	O
1	O
degrees	O
C	O
)	O
and	O
altered	B-DISO
mental	I-DISO
status	I-DISO
(	O
mean	O
Glasgow	O
Coma	B-DISO
Score	O
11	O
+/-	O
2	O
).	O

ABSTRACT	O
:	O
Aggressive	B-DISO
behaviours	I-DISO
represent	O
major	O
obstacles	O
to	O
the	O
integration	O
into	O
society	O
of	O
individuals	O
with	O
intellectual	B-DISO
disability	I-DISO
(	O
ID	O
)	O
and	O
pose	O
significant	O
management	O
issues	O
for	O
carers	O
.	O

RESULTS	O
:	O
The	O
12	O
-	O
month	O
prevalence	O
of	O
aggressive	B-DISO
behaviour	I-DISO
was	O
51	O
.	O
8	O
%:	O
24	O
%	O
property	O
damage	O
,	O
37	O
.	O
6	O
%	O
verbal	O
,	O
24	O
.	O
4	O
%	O
self	O
-	O
oriented	O
and	O
24	O
.	O
4	O
%	O
physical	O
aggression	B-DISO
,	O
and	O
9	O
.	O
8	O
%	O
sexually	O
aggressive	B-DISO
behaviour	I-DISO
,	O
most	O
of	O
which	O
being	O
mild	O
in	O
severity	O
.	O

Additionally	O
,	O
serum	O
specimens	O
were	O
collected	O
and	O
assayed	O
for	O
antibody	O
to	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
)	O
antibody	O
and	O
job	O
-	O
specific	O
attack	O
rates	O
were	O
calculated	O
.	O

Within	O
12	O
to	O
16	O
hours	O
after	O
infusion	O
,	O
they	O
became	O
critically	B-DISO
ill	I-DISO
,	O
with	O
pulmonary	B-DISO
infiltrates	I-DISO
and	O
lung	O
injury	O
,	O
renal	B-DISO
failure	I-DISO
,	O
and	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
.	O

Mortality	O
rates	O
for	O
ARDS	B-DISO
range	O
from	O
30	O
to	O
75	O
%,	O
and	O
most	O
deaths	O
are	O
a	O
consequence	O
of	O
multiorgan	B-DISO
failure	I-DISO
(	O
MOF	B-DISO
).	O

This	O
review	O
summarizes	O
our	O
current	O
understanding	O
of	O
the	O
pathophysiology	O
of	O
what	O
is	O
now	O
termed	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
its	O
less	O
severe	O
form	O
acute	O
lung	O
injury	O
(	O
ALI	O
),	O
with	O
an	O
emphasis	O
on	O
cellular	O
and	O
molecular	O
mechanisms	O
of	O
injury	O
that	O
may	O
represent	O
potential	O
therapeutic	O
targets	O
.	O

The	O
crystal	O
structure	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
macro	O
domain	O
was	O
determined	O
at	O
1	O
.	O
8	O
-	O
Angstroms	O
resolution	O
in	O
complex	O
with	O
ADP	O
-	O
ribose	O
.	O

Here	O
,	O
we	O
show	O
that	O
expression	O
of	O
DC	O
-	O
SIGN	O
augments	O
NL63	O
spike	O
(	O
S	O
)-	O
protein	O
-	O
driven	O
infection	B-DISO
of	O
susceptible	O
cells	O
,	O
while	O
only	O
expression	O
of	O
ACE2	O
but	O
not	O
DC	O
-	O
SIGN	O
is	O
sufficient	O
for	O
entry	O
into	O
nonpermissive	O
cells	O
,	O
indicating	O
that	O
ACE2	O
fulfills	O
the	O
criteria	O
of	O
a	O
bona	O
fide	O
hCoV	O
-	O
NL63	O
receptor	O
.	O

In	O
contrast	O
,	O
several	O
amino	O
acid	O
exchanges	O
in	O
human	O
ACE2	O
which	O
diminish	O
SARS	B-DISO
-	O
S	O
-	O
driven	O
entry	O
do	O
not	O
interfere	O
with	O
NL63	O
-	O
S	O
-	O
mediated	O
infection	B-DISO
,	O
suggesting	O
that	O
SARS	B-DISO
-	O
S	O
and	O
NL63	O
-	O
S	O
might	O
engage	O
human	O
ACE2	O
differentially	O
.	O

The	O
individual	O
role	O
of	O
specific	O
pathogens	O
for	O
the	O
development	O
of	O
ARDS	B-DISO
is	O
difficult	O
to	O
assess	O
,	O
because	O
prospective	O
studies	O
are	O
missing	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
main	O
protease	O
(	O
M	O
(	O
pro	O
)),	O
a	O
protein	O
required	O
for	O
the	O
maturation	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
is	O
vital	O
for	O
its	O
life	O
cycle	O
,	O
making	O
it	O
an	O
attractive	O
target	O
for	O
structure	O
-	O
based	O
drug	O
design	O
of	O
anti	O
-	O
SARS	B-DISO
drugs	O
.	O

The	O
structure	O
-	O
based	O
virtual	O
screening	O
of	O
a	O
chemical	O
database	O
containing	O
58	O
,	O
855	O
compounds	O
followed	O
by	O
the	O
testing	O
of	O
potential	O
compounds	O
for	O
SARS	B-DISO
-	O
CoV	O
M	O
(	O
pro	O
)	O
inhibition	O
leads	O
to	O
two	O
hit	O
compounds	O
.	O

Mycobacteria	O
,	O
including	O
Mycobacterium	O
tuberculosis	B-DISO
,	O
and	O
spore	O
-	O
forming	O
bacteria	O
,	O
including	O
Clostridium	O
difficile	O
,	O
can	O
also	O
survive	O
for	O
months	O
on	O
surfaces	O
.	O

Although	O
the	O
SARS	B-DISO
epidemic	O
has	O
subsided	O
,	O
many	O
authorities	O
,	O
including	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
and	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
CDC	O
),	O
have	O
warned	O
of	O
the	O
possible	O
re	O
-	O
emergence	O
of	O
this	O
highly	O
infectious	B-DISO
disease	I-DISO
.	O

Although	O
antibody	O
-	O
based	O
diagnosis	O
of	O
SARS	B-DISO
has	O
been	O
demonstrated	O
to	O
be	O
a	O
reliable	O
proof	O
of	O
SARS	B-DISO
infection	B-DISO
,	O
it	O
is	O
not	O
sensitive	O
enough	O
for	O
detection	O
during	O
the	O
early	O
phase	O
of	O
the	O
disease	O
.	O

During	O
the	O
epidemic	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
2003	O
,	O
PCR	O
not	O
only	O
offered	O
a	O
rapid	O
way	O
to	O
diagnose	O
SARS	B-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
infection	B-DISO
,	O
but	O
also	O
made	O
the	O
molecular	O
analysis	O
of	O
its	O
genomic	O
sequence	O
possible	O
.	O

With	O
current	O
concerns	O
about	O
a	O
possible	O
approaching	O
influenza	B-DISO
pandemic	O
,	O
the	O
control	O
of	O
transmission	O
via	O
infectious	B-DISO
air	O
has	O
become	O
more	O
important	O
.	O

On	O
this	O
basis	O
,	O
recommendations	O
are	O
made	O
to	O
improve	O
the	O
control	O
of	O
aerosol	O
-	O
transmitted	B-DISO
infections	B-DISO
in	O
hospitals	O
as	O
well	O
as	O
in	O
the	O
design	O
and	O
construction	O
of	O
future	O
isolation	O
facilities	O
.	O

ABSTRACT	O
:	O
Severe	O
respiratory	B-DISO
failure	I-DISO
(	O
including	O
acute	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
)	O
continues	O
to	O
be	O
associated	O
with	O
significant	O
mortality	O
and	O
morbidity	O
in	O
patients	O
of	O
all	O
ages	O
.	O

Our	O
understanding	O
of	O
lung	O
pathophysiology	O
and	O
the	O
role	O
of	O
ventilator	O
-	O
induced	O
lung	O
injury	O
through	O
basic	O
science	O
investigation	O
has	O
led	O
to	O
advances	O
in	O
lung	O
protective	O
strategies	O
for	O
the	O
mechanical	O
ventilation	O
support	O
of	O
patients	O
with	O
severe	O
respiratory	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Immunogenicity	O
of	O
a	O
receptor	O
-	O
binding	O
domain	O
of	O
SARS	B-DISO
coronavirus	O
spike	O
protein	O
in	O
mice	O
:	O
implications	O
for	O
a	O
subunit	O
vaccine	O
.	O

ABSTRACT	O
:	O
Consensus	O
covariation	O
-	O
based	O
secondary	O
structural	O
models	O
for	O
the	O
5	O
'	O
140	O
nucleotides	O
of	O
the	O
5	O
'	O
untranslated	O
regions	O
(	O
5	O
'	O
UTRs	O
)	O
from	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SCoV	O
)	O
were	O
developed	O
and	O
predicted	O
three	O
major	O
helical	O
stem	O
-	O
loop	O
structures	O
,	O
designated	O
stem	O
-	O
loop	O
1	O
(	O
SL1	O
),	O
SL2	O
,	O
and	O
SL4	O
.	O

Replacing	O
the	O
SCoV	O
TRS	B-DISO
with	O
the	O
MHV	O
TRS	B-DISO
in	O
the	O
MHV	O
/	O
5	O
'	O
UTR	O
SCoV	O
chimera	B-DISO
permitted	O
the	O
synthesis	O
of	O
minus	O
-	O
sense	O
genome	O
-	O
sized	O
RNA	O
but	O
did	O
not	O
support	O
the	O
production	O
of	O
positive	O
-	O
or	O
minus	O
-	O
sense	O
subgenomic	O
RNA7	O
.	O

TITLE	O
:	O
Genotypic	O
and	O
phenotypic	O
characterization	O
of	O
the	O
California	O
99	O
(	O
Cal99	O
)	O
variant	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

Finally	O
,	O
we	O
performed	O
a	O
challenge	O
study	O
with	O
Cal99	O
and	O
demonstrated	O
that	O
the	O
virus	O
causes	O
late	O
-	O
onset	O
respiratory	B-DISO
disease	I-DISO
,	O
with	O
a	O
severity	O
comparable	O
to	O
that	O
of	O
the	O
M41	O
IBV	O
challenge	O
strain	O
.	O

In	O
the	O
absence	O
of	O
clinical	O
cases	O
of	O
SARS	B-DISO
,	O
candidate	O
vaccines	O
should	O
be	O
evaluated	O
for	O
efficacy	O
in	O
animal	O
models	O
,	O
and	O
although	O
it	O
is	O
uncertain	O
whether	O
the	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
'	O
s	O
""""	O
animal	O
rule	O
""""	O
would	O
apply	O
to	O
licensure	O
of	O
a	O
SARS	B-DISO
vaccine	O
,	O
it	O
is	O
important	O
to	O
develop	O
standardized	O
animal	O
models	O
and	O
immunological	O
assays	O
in	O
preparation	O
for	O
this	O
eventuality	O
.	O

Several	O
mechanisms	O
are	O
involved	O
in	O
the	O
pathogenesis	B-DISO
of	O
virus	O
-	O
related	O
nephropathy	B-DISO
,	O
including	O
tropism	O
of	O
the	O
virus	O
in	O
the	O
kidney	O
,	O
induction	O
of	O
abnormal	O
immune	O
complexes	O
,	O
direct	O
cytopathogenic	O
effects	O
,	O
and	O
multiorgan	B-DISO
failure	I-DISO
.	O

ABSTRACT	O
:	O
Estimates	O
of	O
seropositivity	O
to	O
a	O
new	O
infectious	B-DISO
agent	O
in	O
a	O
community	O
are	O
useful	O
to	O
public	O
health	O
.	O

For	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
the	O
figures	O
are	O
conflicting	O
.	O

The	O
remaining	O
person	O
,	O
as	O
well	O
as	O
the	O
46	O
other	O
individuals	O
(	O
group	O
2	O
),	O
were	O
healthy	O
and	O
had	O
no	O
history	O
of	O
SARS	B-DISO
.	O

Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
uses	O
ER	O
as	O
a	O
site	O
for	O
synthesis	O
and	O
processing	O
of	O
viral	O
proteins	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
infection	B-DISO
with	O
SARS	B-DISO
-	O
CoV	O
induces	O
the	O
UPR	O
in	O
cultured	O
cells	O
.	O

Severe	O
leptospirosis	B-DISO
manifests	O
as	O
pulmonary	B-DISO
edema	I-DISO
leading	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
polyuric	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
(	O
ARF	B-DISO
).	O

The	O
polyuria	B-DISO
might	O
also	O
be	O
attributed	O
to	O
reduced	O
aquaporin	O
2	O
expression	O
and	O
the	O
attendant	O
urinary	O
concentrating	O
defect	O
.	O

The	O
primers	O
,	O
designed	O
in	O
the	O
open	O
reading	O
frame	O
1b	O
,	O
enabled	O
the	O
detection	O
of	O
32	O
animal	O
coronaviruses	O
including	O
strains	O
of	O
canine	O
coronavirus	O
,	O
feline	O
coronavirus	O
,	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
),	O
bovine	O
coronavirus	O
(	O
BCoV	O
),	O
murine	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
and	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
).	O

In	O
addition	O
,	O
ascites	O
was	O
detected	O
in	O
all	O
women	O
patients	O
associated	O
with	O
subcutaneous	O
edema	B-DISO
in	O
five	O
of	O
them	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
coronavirus	O
nucleocapsid	O
(	O
SARS	B-DISO
-	O
CoV	O
N	O
)	O
protein	O
has	O
been	O
found	O
to	O
be	O
important	O
to	O
the	O
processes	O
related	O
to	O
viral	B-DISO
pathogenesis	I-DISO
,	O
such	O
as	O
virus	O
replication	O
,	O
interference	O
of	O
the	O
cell	O
process	O
and	O
modulation	O
of	O
host	O
immune	O
response	O
;	O
detection	O
of	O
the	O
antigen	O
has	O
been	O
used	O
for	O
the	O
early	O
diagnosis	O
of	O
infection	B-DISO
.	O

The	O
assays	O
'	O
sensitivities	O
were	O
highest	O
(	O
58	O
%	O
to	O
75	O
%)	O
for	O
specimens	O
obtained	O
8	O
to	O
21	O
days	O
after	O
symptom	B-DISO
onset	O
.	O

In	O
contrast	O
,	O
emergence	O
or	O
re	O
-	O
emergence	O
of	O
severe	O
viral	B-DISO
infections	I-DISO
,	O
including	O
tick	B-DISO
borne	I-DISO
encephalitis	I-DISO
virus	O
,	O
and	O
viral	B-DISO
haemorrhagic	I-DISO
fever	I-DISO
caused	O
by	O
Hantavirus	O
and	O
dengue	B-DISO
virus	O
have	O
been	O
frequently	O
reported	O
in	O
several	O
European	O
countries	O
.	O

UV	O
irradiation	O
had	O
good	O
efficiency	O
on	O
microorganism	O
inactivation	B-DISO
and	O
good	O
future	O
of	O
application	O
in	O
China	O
.	O

And	O
it	O
is	O
of	O
fairly	O
low	O
toxicological	O
hazard	O
due	O
to	O
the	O
transformation	B-DISO
of	O
monochloramine	O
.	O

ABSTRACT	O
:	O
When	O
considering	O
how	O
people	O
are	O
infected	O
and	O
what	O
can	O
be	O
done	O
to	O
prevent	O
the	O
infections	B-DISO
,	O
answers	O
from	O
many	O
disciplines	O
are	O
sought	O
:	O
microbiology	O
,	O
epidemiology	O
,	O
medicine	O
,	O
engineering	O
,	O
and	O
physics	O
.	O

Every	O
day	O
tens	O
of	O
millions	O
of	O
people	O
worldwide	O
suffer	B-DISO
from	O
viral	B-DISO
infections	I-DISO
of	O
different	O
severity	O
at	O
immense	O
economic	O
cost	O
.	O

ABSTRACT	O
:	O
Patients	O
with	O
systemic	O
rheumatic	B-DISO
disease	I-DISO
constitute	O
a	O
small	O
percentage	O
of	O
admissions	O
to	O
the	O
medical	O
intensive	O
care	O
units	O
(	O
ICUs	O
).	O

The	O
medical	O
records	O
of	O
nine	O
patients	O
with	O
diagnosis	O
of	O
scleroderma	B-DISO
(	O
8	O
female	O
,	O
1	O
male	O
),	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
of	O
Sheba	O
Medical	O
Center	O
during	O
the	O
11	O
-	O
year	O
interval	O
between	O
1991	O
and	O
2002	O
,	O
were	O
reviewed	O
.	O

CONCLUSIONS	O
:	O
The	O
outcome	O
of	O
scleroderma	B-DISO
patients	O
admitted	O
to	O
the	O
ICU	O
was	O
extremely	O
poor	O
.	O

We	O
identified	O
19	O
CEAs	O
published	O
through	O
2003	O
with	O
48	O
cost	O
-	O
effectiveness	O
ratios	O
pertaining	O
to	O
treatment	O
of	O
severe	B-DISO
sepsis	I-DISO
,	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
,	O
and	O
general	O
critical	O
care	O
interventions	O
.	O

ABSTRACT	O
:	O
Patients	O
with	O
toxic	B-DISO
epidermal	I-DISO
necrolysis	I-DISO
(	O
TEN	O
)	O
have	O
been	O
known	O
to	O
have	O
various	O
complications	O
.	O

Such	O
cases	O
are	O
usually	O
classified	O
into	O
chronic	B-DISO
bronchitis	I-DISO
/	O
bronchiolitis	B-DISO
with	O
obstructive	O
change	O
(	O
including	O
bronchiolitis	B-DISO
obliterans	I-DISO
and	O
bronchiolitis	B-DISO
obliterans	I-DISO
organizing	I-DISO
pneumonia	I-DISO
),	O
respiratory	O
tract	O
obstruction	B-DISO
and	O
bronchiectasis	B-DISO
.	O

The	O
relationship	O
between	O
TEN	O
and	O
these	O
chronic	O
pulmonary	B-DISO
complications	I-DISO
remains	O
to	O
be	O
elucidated	O
.	O

TITLE	O
:	O
Exercise	O
capacity	O
and	O
pulmonary	O
function	O
in	O
hospital	O
workers	O
recovered	O
from	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Airflows	O
around	O
oxygen	O
masks	O
:	O
A	O
potential	O
source	O
of	O
infection	B-DISO
?	O

The	O
3bDelta124	O
-	O
154	O
mutant	B-DISO
behaves	O
in	O
a	O
similar	O
manner	O
indicating	O
that	O
the	O
localization	O
of	O
the	O
3b	O
protein	O
does	O
not	O
seems	O
to	O
be	O
important	O
for	O
the	O
cell	O
-	O
death	O
pathways	O
since	O
full	O
-	O
length	O
3b	O
is	O
localized	O
predominantly	O
to	O
the	O
nucleolus	O
,	O
while	O
the	O
mutant	B-DISO
is	O
found	O
to	O
be	O
concentrated	O
in	O
the	O
peri	O
-	O
nuclear	O
regions	O
.	O

ABSTRACT	O
:	O
The	O
present	O
study	O
was	O
performed	O
to	O
elucidate	O
the	O
clinical	O
outcome	O
,	O
and	O
etiology	O
of	O
acute	B-DISO
otitis	I-DISO
media	I-DISO
(	O
AOM	B-DISO
)	O
in	O
children	O
based	O
on	O
virologic	O
and	O
bacteriologic	O
tests	O
.	O

The	O
study	O
group	O
consisted	O
of	O
120	O
children	O
aged	O
6	O
to	O
144	O
months	O
with	O
AOM	B-DISO
.	O

The	O
findings	O
highlight	O
the	O
importance	O
of	O
common	O
respiratory	O
viruses	O
and	O
bacterial	O
pathogens	O
,	O
particularly	O
RSV	O
,	O
HRV	O
,	O
S	O
.	O
pneumoniae	O
and	O
H	O
.	O
influenzae	O
,	O
in	O
predisposing	O
to	O
and	O
causing	O
AOM	B-DISO
in	O
children	O
.	O

Within	O
in	O
vitro	O
studies	O
,	O
ribavirin	O
,	O
lopinavir	O
,	O
and	O
type	O
I	O
IFN	O
showed	O
inhibition	O
of	O
SARS	B-DISO
-	O
CoV	O
in	O
tissue	O
culture	O
.	O

TITLE	O
:	O
Replication	O
of	O
murine	B-DISO
hepatitis	I-DISO
virus	O
is	O
regulated	O
by	O
papain	O
-	O
like	O
proteinase	O
1	O
processing	O
of	O
nonstructural	O
proteins	O
1	O
,	O
2	O
,	O
and	O
3	O
.	O

Fecal	O
and	O
nasal	O
virus	B-DISO
shedding	I-DISO
were	O
first	O
detected	O
by	O
reverse	O
transcription	O
-	O
PCR	O
at	O
PID	B-DISO
3	O
to	O
4	O
and	O
at	O
PID	B-DISO
2	O
to	O
4	O
,	O
respectively	O
.	O

An	O
additional	O
two	O
gnotobiotic	O
calves	O
were	O
inoculated	O
with	O
HECV	O
-	O
4408	O
and	O
euthanized	O
at	O
PID	B-DISO
5	O
.	O

This	O
information	O
would	O
be	O
useful	O
in	O
development	O
of	O
preventive	O
and	O
treatment	O
approaches	O
against	O
coronavirus	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Cloning	O
and	O
sequence	O
analysis	O
of	O
the	O
N	O
gene	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
LJB	O
/	O
03	O
.	O

As	O
the	O
elevation	O
of	O
body	O
temperature	O
is	O
a	O
common	O
presenting	O
symptom	B-DISO
for	O
many	O
illnesses	O
,	O
including	O
infectious	B-DISO
diseases	I-DISO
such	O
as	O
SARS	B-DISO
,	O
thermal	O
imagers	O
are	O
useful	O
and	O
essential	O
tools	O
for	O
mass	O
screening	O
of	O
body	O
temperature	O
.	O

This	O
is	O
true	O
not	O
only	O
for	O
SARS	B-DISO
but	O
also	O
during	O
other	O
public	O
health	O
crises	O
where	O
widespread	O
transmission	O
of	O
infection	B-DISO
such	O
as	O
the	O
danger	O
of	O
avian	B-DISO
flu	I-DISO
pandemic	O
is	O
a	O
concern	O
,	O
in	O
particular	O
at	O
places	O
like	O
hospitals	O
and	O
cross	O
-	O
border	O
checkpoints	O
.	O

Using	O
an	O
in	O
vivo	O
assay	O
,	O
we	O
found	O
that	O
the	O
SCoV	O
spike	O
protein	O
TMD	B-DISO
is	O
oligomeric	O
and	O
that	O
this	O
oligomerization	O
is	O
driven	O
by	O
the	O
GxxxG	O
motif	O
.	O

Of	O
the	O
29	O
patients	O
who	O
had	O
HCoV	O
identified	O
in	O
their	O
bronchoalveolar	O
lavage	O
fluid	O
specimens	O
,	O
9	O
(	O
31	O
%)	O
were	O
hospitalized	O
in	O
the	O
intensive	O
care	O
unit	O
,	O
22	O
(	O
76	O
%)	O
presented	O
to	O
the	O
hospital	O
with	O
acute	O
respiratory	B-DISO
symptoms	I-DISO
,	O
16	O
(	O
55	O
%)	O
presented	O
with	O
cough	B-DISO
and	O
/	O
or	O
sputum	O
,	O
13	O
(	O
45	O
%)	O
presented	O
with	O
dyspnea	B-DISO
,	O
16	O
(	O
55	O
%)	O
had	O
experienced	O
prior	O
respiratory	B-DISO
infection	I-DISO
,	O
and	O
18	O
(	O
62	O
%)	O
had	O
a	O
new	O
infiltrate	B-DISO
that	O
was	O
visible	O
on	O
chest	O
radiograph	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
consequences	O
of	O
consanguineous	O
unions	O
between	O
first	O
cousins	O
on	O
the	O
severity	O
of	O
pre	B-DISO
-	I-DISO
eclampsia	I-DISO
and	O
associated	O
perinatal	B-DISO
morbidity	I-DISO
.	O

Respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
was	O
more	O
frequent	O
(	O
P	O
=	O
0	O
.	O
043	O
)	O
in	O
infants	O
of	O
unrelated	O
couples	O
.	O

Third	O
-	O
degree	O
consanguinity	O
in	O
terms	O
of	O
a	O
union	O
between	O
first	O
cousins	O
seems	O
to	O
have	O
no	O
effect	O
on	O
the	O
development	O
of	O
maternal	O
and	O
perinatal	O
complications	O
in	O
established	O
pre	B-DISO
-	I-DISO
eclampsia	I-DISO
.	O

TITLE	O
:	O
Control	O
of	O
coronavirus	B-DISO
infection	I-DISO
through	O
plasmacytoid	O
dendritic	O
-	O
cell	O
-	O
derived	O
type	O
I	O
interferon	O
.	O

TITLE	O
:	O
Tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
genetic	O
predisposing	O
factors	O
can	O
influence	O
clinical	O
severity	O
in	O
nephropathia	B-DISO
epidemica	I-DISO
.	O

ABSTRACT	O
:	O
Severe	O
human	O
infection	B-DISO
with	O
Hantavirus	O
is	O
characterized	O
by	O
high	O
fever	O
,	O
cold	B-DISO
chills	B-DISO
,	O
thrombocytopenia	O
,	O
arterial	O
hypotension	O
,	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
and	O
/	O
or	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)-	O
like	O
pulmonary	B-DISO
involvement	I-DISO
,	O
but	O
the	O
clinical	O
course	O
varies	O
greatly	O
between	O
individuals	O
.	O

We	O
investigated	O
whether	O
genetically	O
determined	O
differences	O
in	O
tumor	B-DISO
necrosis	I-DISO
factor	O
(	O
TNF	O
)-	O
alpha	O
production	O
can	O
influence	O
the	O
severity	O
of	O
Hantavirus	O
disease	O
.	O

In	O
our	O
study	O
,	O
genetically	O
determined	O
low	O
production	O
of	O
TNF	O
-	O
alpha	O
was	O
associated	O
with	O
some	O
parameters	O
indicating	O
a	O
more	O
severe	O
clinical	O
course	O
of	O
Puumala	O
Hantavirus	B-DISO
infection	I-DISO
in	O
humans	O
,	O
possibly	O
by	O
impaired	B-DISO
activation	O
of	O
TNF	O
-	O
alpha	O
-	O
dependent	O
antiviral	O
mechanisms	O
,	O
which	O
could	O
in	O
turn	O
result	O
in	O
decreased	O
clearance	O
of	O
Hantavirus	O
.	O

Transmission	O
of	O
SARS	B-DISO
-	O
associated	O
CoV	O
was	O
not	O
observed	O
,	O
suggesting	O
that	O
the	O
risk	O
of	O
transmission	O
is	O
not	O
amplified	O
aboard	O
aircraft	O
.	O

TITLE	O
:	O
S1	O
gene	O
sequence	O
analysis	O
of	O
a	O
nephropathogenic	O
strain	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
in	O
Egypt	O
.	O

Future	O
licensure	O
of	O
these	O
and	O
other	O
candidate	O
vaccines	O
will	O
depend	O
on	O
their	O
safety	O
and	O
immunogenicity	O
profiles	O
in	O
humans	O
,	O
and	O
their	O
ability	O
to	O
confer	O
protection	O
in	O
animal	O
models	O
of	O
inhalational	B-DISO
anthrax	I-DISO
.	O

TITLE	O
:	O
Quantitative	O
comparison	O
of	O
the	O
efficiency	O
of	O
antibodies	O
against	O
S1	O
and	O
S2	O
subunit	O
of	O
SARS	B-DISO
coronavirus	O
spike	O
protein	O
in	O
virus	O
neutralization	O
and	O
blocking	B-DISO
of	O
receptor	O
binding	O
:	O
implications	O
for	O
the	O
functional	O
roles	O
of	O
S2	O
subunit	O
.	O

The	O
efficiency	O
of	O
these	O
purified	O
IgGs	O
in	O
virus	O
neutralization	O
and	O
blocking	B-DISO
of	O
receptor	O
binding	O
were	O
compared	O
quantitatively	O
using	O
virus	O
neutralization	O
assay	O
and	O
a	O
previously	O
developed	O
cell	O
-	O
based	O
receptor	O
binding	O
assay	O
,	O
respectively	O
.	O

TITLE	O
:	O
Early	O
markers	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
development	O
in	O
severe	O
trauma	O
patients	O
.	O

Patients	O
with	O
ARDS	B-DISO
required	O
more	O
colloids	O
(	O
P	O
=	O
.	O
005	O
)	O
and	O
red	O
blood	O
cell	O
units	O
(	O
P	O
=	O
.	O
02	O
)	O
than	O
patients	O
without	O
ARDS	B-DISO
during	O
the	O
first	O
24	O
hours	O
.	O

Risk	O
of	O
ARDS	B-DISO
development	O
is	O
related	O
to	O
the	O
first	O
24	O
-	O
hour	O
admission	O
variables	O
,	O
including	O
severe	O
physiologic	O
derangements	O
and	O
specific	O
ICD	B-DISO
-	O
9	O
-	O
classified	O
injuries	O
.	O

TITLE	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
:	O
S1	O
gene	O
characteristics	O
of	O
vaccines	O
used	O
in	O
China	O
and	O
efficacy	O
of	O
vaccination	O
against	O
heterologous	O
strains	O
from	O
China	O
.	O

ABSTRACT	O
:	O
The	O
causative	O
agent	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
has	O
been	O
identified	O
as	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
).	O

Collectively	O
,	O
these	O
results	O
indicate	O
that	O
S	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
induces	O
the	O
expression	O
of	O
COX	O
-	O
2	O
and	O
an	O
N	O
-	O
terminal	O
fragment	O
of	O
the	O
Spike	O
protein	O
is	O
crucial	O
for	O
the	O
induction	O
.	O

TITLE	O
:	O
Pathology	B-DISO
of	O
the	O
thyroid	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

No	O
distinct	O
calcitonin	O
-	O
positive	O
cells	O
were	O
detectable	O
in	O
the	O
SARS	B-DISO
thyroids	O
.	O

Molecular	O
simulation	O
indicates	O
that	O
the	O
MOL376	O
(	O
a	O
compound	O
derived	O
from	O
a	O
Chinese	O
medicine	O
herb	O
with	O
the	O
therapeutic	O
efficacy	O
on	O
the	O
human	O
body	O
such	O
as	O
relieving	O
cough	B-DISO
,	O
removing	O
the	O
phlegm	O
,	O
and	O
relieving	O
asthma	B-DISO
)	O
has	O
not	O
only	O
the	O
highest	O
binding	O
energy	O
with	O
the	O
receptor	O
but	O
also	O
the	O
good	O
match	O
in	O
geometric	O
conformation	O
.	O

TITLE	O
:	O
SARS	B-DISO
-	O
CoV	O
nucleocapsid	O
protein	O
binds	O
to	O
hUbc9	O
,	O
a	O
ubiquitin	O
conjugating	O
enzyme	O
of	O
the	O
sumoylation	O
system	O
.	O

The	O
m	O
-	O
PCR	O
detected	O
124	O
viruses	O
which	O
were	O
not	O
found	O
by	O
conventional	O
methods	O
:	O
68	O
rhinovirus	O
,	O
17	O
human	O
metapneumovirus	O
,	O
15	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
8	O
parainfluenza	B-DISO
virus	O
(	O
PIV	O
),	O
5	O
coronavirus	O
229E	O
,	O
3	O
OC43	O
and	O
3	O
NL63	O
,	O
4	O
enterovirus	O
,	O
2	O
influenza	B-DISO
virus	O
B	O
and	O
C	O
virus	O
.	O

ABSTRACT	O
:	O
A	O
negative	O
-	O
pressure	O
operating	O
theater	O
is	O
required	O
to	O
limit	O
the	O
spread	O
of	O
respiratory	B-DISO
diseases	I-DISO
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
tuberculosis	B-DISO
,	I-DISO
avian	I-DISO
influenza	B-DISO
,	O
or	O
similar	O
infectious	B-DISO
diseases	I-DISO
.	O

The	O
fact	O
that	O
nucleic	O
acid	O
binding	O
could	O
promote	O
the	O
SARS	B-DISO
-	O
CoV	O
N	O
protein	O
C	O
-	O
terminus	O
to	O
form	O
high	O
-	O
order	O
oligomers	O
implies	O
that	O
the	O
oligomeric	O
SARS	B-DISO
-	O
CoV	O
N	O
protein	O
probably	O
combines	O
with	O
the	O
viral	O
genomic	O
RNA	O
in	O
triggering	O
long	O
nucleocapsid	O
formation	O
.	O

The	O
frequency	O
of	O
HCoV	O
-	O
NL63	O
infection	B-DISO
increased	O
from	O
1	O
%	O
in	O
2003	O
-	O
2004	O
to	O
10	O
%	O
in	O
2004	O
-	O
2005	O
.	O

Heat	O
,	O
UVC	O
irradiation	O
,	O
and	O
S	O
/	O
D	O
treatments	O
effectively	O
inactivate	O
SARS	B-DISO
-	O
CoV	O
,	O
whereas	O
octanoic	O
acid	O
treatment	O
is	O
insufficient	O
for	O
inactivation	B-DISO
of	O
the	O
virus	O
.	O

S	O
/	O
D	O
treatment	O
required	O
2	O
,	O
4	O
,	O
and	O
up	O
to	O
24	O
hours	O
for	O
Triton	O
X	O
-	O
100	O
,	O
Tween	O
80	O
,	O
and	O
sodium	O
cholate	O
inactivation	B-DISO
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
Heat	O
,	O
UVC	O
irradiation	O
,	O
and	O
S	O
/	O
D	O
treatments	O
effectively	O
inactivate	O
SARS	B-DISO
-	O
CoV	O
,	O
whereas	O
octanoic	O
acid	O
treatment	O
is	O
insufficient	O
for	O
inactivation	B-DISO
of	O
the	O
virus	O
.	O

There	O
is	O
considerable	O
effort	O
directed	O
towards	O
understanding	O
and	O
negating	O
the	O
proliferation	B-DISO
of	O
infectious	B-DISO
diseases	I-DISO
.	O

Eight	O
small	O
group	O
interviews	O
were	O
conducted	O
with	O
a	O
total	O
of	O
twenty	O
-	O
one	O
nurses	O
with	O
experience	O
caring	O
for	O
SARS	B-DISO
patients	O
.	O

At	O
least	O
101	O
studies	O
have	O
reported	O
controlling	O
MRSA	B-DISO
infection	I-DISO
and	O
38	O
have	O
reported	O
controlling	O
VRE	O
infection	B-DISO
by	O
means	O
of	O
active	O
detection	O
by	O
surveillance	O
culture	O
and	O
use	O
of	O
isolation	O
for	O
all	O
colonized	O
patients	O
in	O
healthcare	O
settings	O
where	O
the	O
pathogens	O
are	O
epidemic	O
or	O
endemic	O
,	O
in	O
academic	O
and	O
nonacademic	O
hospitals	O
,	O
and	O
in	O
acute	O
care	O
,	O
intensive	O
care	O
,	O
and	O
long	O
-	O
term	O
care	O
settings	O
.	O

MRSA	B-DISO
colonization	O
and	O
infection	B-DISO
have	O
been	O
controlled	O
to	O
exceedingly	O
low	O
levels	O
in	O
multiple	O
nations	O
and	O
in	O
the	O
state	O
of	O
Western	O
Australia	O
for	O
decades	O
by	O
use	O
of	O
active	O
detection	O
and	O
isolation	O
.	O

A	O
33	O
-	O
year	O
-	O
old	O
pregnant	O
woman	O
at	O
23	O
weeks	O
of	O
gestation	O
presented	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
unresponsive	O
to	O
conventional	O
mechanical	O
ventilation	O
.	O

CONCLUSIONS	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
can	O
be	O
life	O
saving	O
when	O
initiated	O
early	O
in	O
pregnant	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
insufficiency	I-DISO
unresponsive	O
to	O
conventional	O
mechanical	O
ventilation	O
.	O

Pneumonia	B-DISO
was	O
diagnosed	O
based	O
on	O
predefined	O
criteria	O
and	O
retrospectively	O
confirmed	O
by	O
two	O
observers	O
.	O

Based	O
on	O
phylogenetic	O
tree	O
and	O
epidemiological	O
investigation	O
,	O
SARS	B-DISO
outbreak	O
was	O
divided	O
into	O
three	O
epidemic	O
groups	O
:	O
02	O
-	O
04	O
interspecies	O
,	O
03	O
-	O
early	O
-	O
mid	O
,	O
and	O
03	O
-	O
late	O
epidemic	O
groups	O
in	O
the	O
present	O
study	O
.	O

TITLE	O
:	O
Preparation	O
of	O
His	O
-	O
tagged	O
armored	O
RNA	O
phage	O
particles	O
as	O
a	O
control	O
for	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
PCR	O
detection	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

A	O
fragment	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
genome	O
targeted	O
for	O
SARS	B-DISO
-	O
CoV	O
detection	O
was	O
chosen	O
for	O
an	O
external	O
positive	O
control	O
preparation	O
.	O

ABSTRACT	O
:	O
The	O
present	O
study	O
investigated	O
the	O
presence	O
and	O
location	O
of	O
fluorescent	O
microspheres	O
having	O
the	O
size	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
and	O
of	O
mouse	O
minute	O
virus	O
(	O
MMV	O
)	O
in	O
the	O
zona	B-DISO
pellucida	O
(	O
ZP	O
)	O
of	O
in	O
vivo	O
-	O
produced	O
murine	O
embryos	O
,	O
the	O
transmission	O
of	O
these	O
viruses	O
by	O
embryos	O
during	O
embryo	O
transfer	O
,	O
and	O
the	O
time	O
of	O
seroconversion	O
of	O
recipients	O
and	O
pups	O
.	O

TITLE	O
:	O
New	O
and	O
re	B-DISO
-	I-DISO
emerging	I-DISO
infectious	I-DISO
diseases	I-DISO
:	O
epidemics	O
in	O
waiting	O
.	O

ABSTRACT	O
:	O
The	O
observations	O
that	O
Lymphopenia	B-DISO
is	O
common	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
and	O
that	O
peripheral	O
blood	O
mononuclear	O
cell	O
(	O
PBMC	O
)	O
could	O
be	O
infected	O
by	O
SARS	B-DISO
-	O
CoV	O
indicate	O
that	O
PBMC	O
could	O
be	O
useful	O
in	O
identifying	O
the	O
gene	O
expression	O
profile	O
in	O
convalescent	O
patients	O
and	O
tracing	O
the	O
host	O
response	O
to	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

The	O
identification	O
of	O
a	O
viral	O
gene	O
,	O
M	O
,	O
in	O
SSH	O
cDNA	O
library	O
shows	O
the	O
long	O
-	O
term	O
existence	O
of	O
SARS	B-DISO
-	O
CoV	O
in	O
vivo	O
.	O

ABSTRACT	O
:	O
Communicable	O
respiratory	O
viruses	O
as	O
a	O
causative	O
factor	O
of	O
infectious	B-DISO
complication	B-DISO
in	O
hemoblastosis	O
and	O
myelodepression	O
were	O
investigated	O
in	O
51	O
patients	O
(	O
aplastic	B-DISO
anemia	I-DISO
--	O
3	O
,	O
multiple	B-DISO
myeloma	I-DISO
--	O
10	O
,	O
different	O
patterns	O
of	O
acute	B-DISO
leukemia	I-DISO
--	O
16	O
,	O
chronic	B-DISO
leukemia	I-DISO
--	O
8	O
and	O
non	B-DISO
-	I-DISO
Hodgkin	I-DISO
'	I-DISO
s	I-DISO
lymphoma	I-DISO
--	O
14	O
).	O

Similarly	O
,	O
the	O
important	O
cause	O
of	O
mortality	O
in	O
2001	O
was	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
(	O
71	O
.	O
10	O
%)	O
with	O
predominant	O
presentation	O
of	O
jaundice	B-DISO
and	O
renal	B-DISO
failure	I-DISO
,	O
whereas	O
in	O
1994	O
,	O
it	O
was	O
cerebral	B-DISO
malaria	I-DISO
(	O
77	O
.	O
96	O
%).	O

RESULTS	O
:	O
In	O
a	O
prospective	O
study	O
in	O
1994	O
the	O
spectrum	O
of	O
complication	B-DISO
was	O
dominated	O
by	O
cerebral	B-DISO
malaria	I-DISO
(	O
25	O
.	O
75	O
%)	O
followed	O
by	O
jaundice	B-DISO
(	O
11	O
.	O
47	O
%),	O
bleeding	B-DISO
tendencies	I-DISO
(	O
9	O
.	O
59	O
%),	O
severe	O
anaemia	B-DISO
(	O
5	O
.	O
83	O
%),	O
shock	O
(	O
5	O
.	O
26	O
%),	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
-	O
ARDS	B-DISO
(	O
3	O
.	O
01	O
%),	O
renal	B-DISO
failure	I-DISO
(	O
2	O
.	O
07	O
%)	O
and	O
hypoglycemia	B-DISO
(	O
2	O
.	O
07	O
%)	O
whereas	O
in	O
2001	O
it	O
was	O
dominated	O
by	O
jaundice	B-DISO
(	O
58	O
.	O
85	O
%)	O
followed	O
by	O
severe	O
anaemia	B-DISO
(	O
26	O
.	O
04	O
%),	O
bleeding	B-DISO
tendencies	I-DISO
(	O
25	O
.	O
52	O
%),	O
shock	O
(	O
10	O
.	O
94	O
%),	O
cerebral	B-DISO
malaria	I-DISO
(	O
10	O
.	O
94	O
%),	O
renal	B-DISO
failure	I-DISO
(	O
6	O
.	O
25	O
%),	O
ARDS	B-DISO
(	O
2	O
.	O
08	O
%)	O
and	O
hypoglycemia	B-DISO
(	O
1	O
.	O
56	O
%).	O

64	O
(	O
21	O
.	O
4	O
%)	O
of	O
the	O
299	O
who	O
used	O
gloves	O
regularly	O
reported	O
dry	B-DISO
skin	I-DISO
(	O
73	O
.	O
4	O
%),	O
itch	B-DISO
(	O
56	O
.	O
3	O
%),	O
and	O
rash	B-DISO
(	O
37	O
.	O
5	O
%).	O

During	O
infection	B-DISO
animals	O
experience	O
a	O
characteristic	O
transient	O
leucopenia	B-DISO
and	O
the	O
number	O
of	O
cells	O
per	O
volume	O
of	O
blood	O
changes	O
over	O
time	O
;	O
so	O
quantitation	O
of	O
viral	O
load	O
by	O
reference	O
to	O
a	O
cellular	O
housekeeping	O
gene	O
is	O
not	O
ideal	O
as	O
this	O
may	O
hide	O
significant	O
animal	O
to	O
animal	O
variation	O
.	O

This	O
study	O
demonstrates	O
encouraging	O
results	O
for	O
rapid	O
,	O
sensitive	O
and	O
reliable	O
detection	O
of	O
acute	O
BVDV	O
infection	B-DISO
and	O
provides	O
an	O
alternative	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
method	O
for	O
use	O
on	O
whole	O
blood	O
samples	O
or	O
samples	O
where	O
suitable	O
housekeeping	O
genes	O
are	O
not	O
available	O
.	O

In	O
the	O
present	O
study	O
,	O
immunohistochemistry	O
(	O
IHC	O
)	O
and	O
in	O
situ	O
hybridization	O
(	O
ISH	B-DISO
)	O
assays	O
were	O
used	O
to	O
analyse	O
the	O
expression	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
SARS	B-DISO
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
,	O
and	O
some	O
pro	O
-	O
inflammatory	O
cytokines	O
(	O
PICs	O
)	O
including	O
MCP	O
-	O
1	O
,	O
TGF	O
-	O
beta1	O
,	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1beta	O
,	O
and	O
IL	O
-	O
6	O
in	O
autopsy	O
tissues	O
from	O
four	O
patients	O
who	O
died	O
of	O
SARS	B-DISO
.	O

SARS	B-DISO
-	O
CoV	O
S	O
protein	O
and	O
its	O
RNA	O
were	O
only	O
detected	O
in	O
ACE2	O
+	O
cells	O
in	O
the	O
lungs	O
and	O
other	O
organs	O
,	O
indicating	O
that	O
ACE2	O
-	O
expressing	O
cells	O
are	O
the	O
primary	O
targets	O
for	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
in	O
vivo	O
in	O
humans	O
.	O

High	O
levels	O
of	O
PICs	O
were	O
expressed	O
in	O
the	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
ACE2	O
+	O
cells	O
,	O
but	O
not	O
in	O
the	O
uninfected	O
cells	O
.	O

Therefore	O
application	O
of	O
PIC	B-DISO
antagonists	O
may	O
reduce	O
the	O
severity	O
and	O
mortality	O
of	O
SARS	B-DISO
.	O

TITLE	O
:	O
Perception	O
of	O
benefits	O
and	O
costs	O
during	O
SARS	B-DISO
outbreak	O
:	O
An	O
18	O
-	O
month	O
prospective	O
study	O
.	O

AU	O
was	O
induced	O
by	O
renal	B-DISO
ischemia	I-DISO
-	O
reperfusion	O
(	O
inflammatory	O
AU	O
)	O
or	O
bilateral	O
nephrectomy	O
(	O
noninflammatory	O
AU	O
).	O

After	O
the	O
third	O
panning	O
,	O
20	O
phage	O
-	O
plague	B-DISO
clones	O
were	O
randomly	O
picked	O
and	O
analyzed	O
for	O
the	O
binding	O
ability	O
with	O
the	O
MAb	O
2C5	O
by	O
ELISA	O
.	O

TITLE	O
:	O
Effects	O
of	O
mutagenesis	O
of	O
murine	B-DISO
hepatitis	I-DISO
virus	O
nsp1	O
and	O
nsp14	O
on	O
replication	O
in	O
culture	O
.	O

ABSTRACT	O
:	O
The	O
results	O
presented	O
here	O
demonstrate	O
that	O
the	O
MHV	O
and	O
SARS	B-DISO
-	O
CoV	O
nsp2	O
proteins	O
are	O
not	O
required	O
for	O
the	O
production	O
of	O
infectious	B-DISO
virus	O
,	O
for	O
polyprotein	O
expression	O
or	O
processing	O
,	O
or	O
for	O
viral	O
replication	O
complex	O
formation	O
in	O
cell	O
culture	O
.	O

Importantly	O
,	O
the	O
viruses	O
produced	O
in	O
this	O
study	O
provide	O
a	O
system	O
by	O
which	O
the	O
role	O
of	O
the	O
nsp2	O
protein	O
in	O
viral	B-DISO
infection	I-DISO
can	O
be	O
characterized	O
.	O

ABSTRACT	O
:	O
We	O
have	O
investigated	O
novel	O
vaccines	O
strategies	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
CoV	O
infection	B-DISO
using	O
cDNA	O
constructs	O
encoding	O
the	O
structural	O
antigens	O
;	O
spike	O
(	O
S	O
),	O
membrane	O
(	O
M	O
),	O
envelope	O
(	O
E	O
),	O
or	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
,	O
derived	O
from	O
SARS	B-DISO
CoV	O
(	O
strain	O
HKU39849	O
,	O
TW1	O
,	O
or	O
FFM	B-DISO
-	O
1	O
).	O

into	O
IL	O
-	O
2	O
receptor	O
gamma	O
-	O
chain	O
-	O
disrupted	O
NOD	B-DISO
-	O
SCID	B-DISO
mice	O
[	O
IL	O
-	O
2R	O
(-/-)	O
NOD	B-DISO
-	O
SCID	B-DISO
].	O

The	O
M	O
DNA	O
vaccine	O
enhanced	O
CTL	O
activity	O
and	O
proliferation	B-DISO
in	O
the	O
presence	O
of	O
M	O
peptide	O
in	O
SCID	B-DISO
-	O
PBL	O
/	O
hu	O
mice	O
.	O

Although	O
a	O
SARS	B-DISO
-	O
like	O
coronavirus	O
isolated	O
from	O
a	O
bat	O
is	O
thought	O
to	O
be	O
the	O
progenitor	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
a	O
lack	O
of	O
genomic	O
sequences	O
for	O
the	O
animal	O
coronaviruses	O
has	O
prevented	O
elucidation	O
of	O
the	O
true	O
origin	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
Sequence	O
analysis	O
of	O
SARS	B-DISO
-	O
CoV	O
shows	O
that	O
the	O
5	O
'	O
polymerase	O
gene	O
has	O
a	O
mammalian	O
ancestry	O
;	O
whereas	O
the	O
3	O
'	O
end	O
structural	O
genes	O
(	O
excluding	O
the	O
spike	O
glycoprotein	O
)	O
have	O
an	O
avian	O
origin	O
.	O

TITLE	O
:	O
Zoonotic	O
viral	B-DISO
diseases	I-DISO
and	O
the	O
frontier	O
of	O
early	O
diagnosis	O
,	O
control	O
and	O
prevention	O
.	O

This	O
study	O
describes	O
a	O
potentially	O
useful	O
small	O
animal	O
model	O
of	O
human	O
SARS	B-DISO
,	O
defines	O
its	O
pathogenesis	B-DISO
,	O
and	O
suggests	O
treatment	O
strategies	O
.	O

TITLE	O
:	O
Early	O
recovery	O
from	O
post	O
-	O
traumatic	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

After	O
alveolar	O
recruitment	B-DISO
,	O
PEEP	O
was	O
titrated	O
to	O
the	O
lowest	O
level	O
which	O
prevented	O
alveolar	O
derecruitment	O
.	O

Patients	O
with	O
early	O
post	O
-	O
traumatic	O
respiratory	B-DISO
failure	I-DISO
seem	O
to	O
most	O
readily	O
respond	O
to	O
alveolar	O
recruitment	B-DISO
manoeuvres	O
and	O
could	O
thus	O
benefit	O
from	O
the	O
gain	O
in	O
functional	O
lung	O
volume	O
and	O
oxygenation	O
.	O

We	O
wished	O
to	O
evaluate	O
the	O
influence	O
of	O
PTSD	B-DISO
on	O
HRQoL	O
and	O
to	O
investigate	O
the	O
influence	O
of	O
perceived	O
social	O
support	O
during	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
treatment	O
on	O
both	O
PTSD	B-DISO
symptoms	O
and	O
HRQoL	O
.	O
In	O
ARDS	B-DISO
patients	O
we	O
prospectively	O
measured	O
HRQoL	O
(	O
Medical	O
Outcomes	O
Study	O
36	O
-	O
Item	O
Short	O
Form	O
;	O
SF	O
-	O
36	O
),	O
symptoms	O
of	O
PTSD	B-DISO
(	O
Post	B-DISO
-	I-DISO
Traumatic	I-DISO
Stress	I-DISO
Syndrome	I-DISO
10	O
-	O
Questions	O
Inventory	O
;	O
PTSS	O
-	O
10	O
),	O
perceived	O
social	O
support	O
(	O
Questionnaire	O
for	O
Social	O
Support	O
;	O
F	O
-	O
Sozu	O
)	O
and	O
symptoms	O
of	O
psychopathology	O
(	O
Symptom	B-DISO
Checklist	O
-	O
90	O
-	O
R	O
);	O
and	O
collected	O
sociodemographic	O
data	O
including	O
current	O
employment	O
status	O
.	O

Perceived	O
social	O
support	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
PTSD	B-DISO
symptoms	O
(	O
Pearson	O
correlation	O
;	O
p	O
<	O
0	O
.	O
05	O
).	O

It	O
is	O
currently	O
used	O
for	O
treatment	O
of	O
suspected	O
or	O
confirmed	O
airborne	O
infection	B-DISO
cases	O
,	O
and	O
was	O
built	O
in	O
anticipation	O
of	O
a	O
return	O
of	O
SARS	B-DISO
,	O
an	O
outbreak	O
of	O
avian	B-DISO
influenza	I-DISO
or	O
other	O
respiratory	O
epidemics	O
.	O

TITLE	O
:	O
A	O
""""	O
possible	O
""""	O
involvement	O
of	O
TNF	O
-	O
alpha	O
in	O
apoptosis	O
induction	O
in	O
peripheral	O
blood	O
lymphocytes	O
of	O
cats	O
with	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
.	O

Using	O
a	O
case	O
-	O
control	O
approach	O
,	O
index	O
patients	O
who	O
had	O
probable	O
SARS	B-DISO
who	O
subsequently	O
transmitted	B-DISO
the	O
disease	O
to	O
at	O
least	O
one	O
other	O
patient	O
were	O
analysed	O
as	O
""""	O
cases	O
""""	O
against	O
patients	O
with	O
no	O
transmission	O
as	O
""""	O
controls	O
""","	O
using	O
multivariate	O
logistic	O
regression	O
analysis	O
.	O

Covariates	O
positively	O
associated	O
with	O
transmission	O
in	O
univariate	O
analysis	O
at	O
p	O
<	O
0	O
.	O
05	O
included	O
delay	O
to	O
isolation	O
(	O
Day	O
7	O
of	O
illness	O
or	O
later	O
),	O
admission	O
to	O
a	O
non	O
-	O
isolation	O
facility	O
,	O
pre	O
-	O
existing	O
chronic	B-DISO
respiratory	I-DISO
disease	I-DISO
and	O
immunosuppressive	O
disease	O
,	O
need	O
for	O
oxygen	O
,	O
shortness	B-DISO
of	I-DISO
breath	I-DISO
,	O
vomiting	B-DISO
,	O
and	O
higher	O
lactate	O
dehydrogenase	O
levels	O
and	O
higher	O
neutrophil	O
counts	O
.	O

SARS	B-DISO
-	O
CoV	O
-	O
specific	O
serum	O
and	O
mucosal	O
immunoglobulins	O
were	O
readily	O
detected	O
in	O
immunized	O
animals	O
.	O

The	O
mean	O
ratio	O
of	O
IL	O
-	O
6	O
to	O
IL	O
-	O
10	O
in	O
SARS	B-DISO
patients	O
(	O
4	O
.	O
84	O
;	O
range	O
0	O
.	O
41	O
-	O
21	O
)	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
CAP	B-DISO
patients	O
(	O
2	O
.	O
95	O
;	O
range	O
0	O
.	O
02	O
-	O
10	O
.	O
57	O
)	O
(	O
P	O
=	O
0	O
.	O
04	O
).	O

The	O
early	O
induction	O
of	O
IP	O
-	O
10	O
and	O
IL	O
-	O
2	O
,	O
as	O
well	O
as	O
the	O
subsequent	O
over	O
-	O
production	O
of	O
IL	O
-	O
6	O
and	O
lack	O
of	O
IL	O
-	O
10	O
production	O
,	O
probably	O
contribute	O
to	O
the	O
main	O
immuno	O
-	O
pathological	B-DISO
processes	I-DISO
involved	O
in	O
lung	O
injury	O
in	O
SARS	B-DISO
.	O

These	O
changes	O
in	O
cytokine	O
/	O
chemokine	O
profile	O
are	O
remarkably	O
different	O
from	O
those	O
observed	O
in	O
CAP	B-DISO
patients	O
.	O

TITLE	O
:	O
Respiratory	O
hygiene	O
in	O
the	O
emergency	B-DISO
department	O
.	O

The	O
possible	O
predisposing	O
and	O
perpetuating	O
factors	O
in	O
developing	O
mental	B-DISO
symptoms	I-DISO
were	O
investigated	O
.	O

Both	O
neuroticism	B-DISO
and	O
maternal	O
attachment	O
influenced	O
the	O
mental	O
health	O
of	O
health	O
care	O
workers	O
during	O
the	O
SARS	B-DISO
epidemic	O
.	O

Twenty	O
-	O
one	O
consecutive	O
mechanically	O
ventilated	O
patients	O
with	O
severe	O
brain	O
damage	O
and	O
no	O
acute	O
lung	O
injury	O
were	O
randomly	O
assigned	O
to	O
be	O
ventilated	O
with	O
ZEEP	O
(	O
n	O
=	O
10	O
)	O
or	O
with	O
8	O
cmH	B-DISO
(	O
2	O
)	O
O	O
of	O
PEEP	O
(	O
n	O
=	O
11	O
).	O

1	O
.	O
9	O
cmH	B-DISO
(	O
2	O
)	O
O	O
/	O
l	O
per	O
second	O
,	O
respectively	O
).	O

Using	O
the	O
phage	O
-	O
displayed	O
peptide	O
library	O
screening	O
method	O
and	O
purified	O
Fab	O
fragments	O
of	O
immunoglobulin	O
G	O
(	O
IgG	O
Fab	O
)	O
from	O
normal	O
human	O
sera	O
and	O
convalescent	O
sera	O
from	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
patients	O
as	O
targets	O
,	O
11	O
B	O
cell	O
epitopes	O
of	O
SARS	B-DISO
-	O
CoV	O
spike	O
glycoprotein	O
(	O
S	O
protein	O
)	O
and	O
membrane	O
protein	O
(	O
M	O
protein	O
)	O
were	O
screened	O
.	O

TITLE	O
:	O
Impact	O
of	O
quarantine	O
on	O
the	O
2003	O
SARS	B-DISO
outbreak	O
:	O
a	O
retrospective	O
modeling	O
study	O
.	O

The	O
effects	O
of	O
some	O
crucial	O
parameters	O
,	O
such	O
as	O
buffer	O
type	O
,	O
pH	O
,	O
wavelength	O
and	O
running	O
voltage	O
on	O
the	O
separation	B-DISO
were	O
studied	O
systematically	O
.	O

A	O
previously	O
unrecognized	O
coronavirus	O
was	O
identified	O
as	O
the	O
causative	O
agent	O
,	O
and	O
health	O
officials	O
throughout	O
the	O
world	O
struggled	O
to	O
implement	O
measures	O
to	O
contain	O
its	O
spread	O
,	O
including	O
isolation	O
of	O
suspect	O
SARS	B-DISO
cases	O
and	O
quarantine	O
of	O
exposed	O
persons	O
.	O

TITLE	O
:	O
Where	O
do	O
pets	O
fit	B-DISO
into	O
human	O
quarantines	O
?	O

Sepsis	B-DISO
syndrome	I-DISO
often	O
induces	O
severe	O
pulmonary	O
lesions	O
with	O
a	O
picture	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

After	O
the	O
SARS	B-DISO
(	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
)	O
scares	O
[	O
1	O
],	O
attention	O
has	O
turned	O
towards	O
the	O
possibility	O
of	O
an	O
avian	B-DISO
influenza	I-DISO
virus	O
hybridizing	O
with	O
a	O
human	B-DISO
influenza	I-DISO
virus	O
to	O
create	O
a	O
highly	O
virulent	O
,	O
as	O
yet	O
unknown	O
,	O
killer	O
,	O
on	O
a	O
scale	O
unseen	O
since	O
the	O
Spanish	O
flu	B-DISO
outbreak	O
of	O
1918	O
,	O
which	O
produced	O
more	O
fatalities	O
than	O
the	O
Great	O
War	O
.	O

The	O
SARS	B-DISO
spleens	O
all	O
had	O
severe	O
damage	O
to	O
the	O
white	O
pulp	O
and	O
showed	O
an	O
alteration	O
of	O
the	O
normal	O
distribution	O
of	O
various	O
cell	O
types	O
.	O

The	O
etiological	O
agent	O
of	O
CAP	B-DISO
was	O
identified	O
retrospectively	O
in	O
only	O
39	O
%	O
of	O
cases	O
,	O
the	O
majority	O
being	O
bacterial	O
pathogens	O
.	O

Recombinant	O
N	O
protein	O
was	O
extracted	O
from	O
infected	O
cells	O
,	O
analysed	O
by	O
SDS	B-DISO
-	O
PAGE	O
and	O
Western	O
blot	O
,	O
and	O
purified	O
by	O
Ni2	O
+	O
affinity	O
procedure	O
.	O

TITLE	O
:	O
Mouse	B-DISO
hepatitis	I-DISO
virus	O
does	O
not	O
induce	O
Beta	O
interferon	O
synthesis	O
and	O
does	O
not	O
inhibit	O
its	O
induction	O
by	O
double	O
-	O
stranded	O
RNA	O
.	O

Further	O
,	O
MHV	O
infection	B-DISO
did	O
not	O
inhibit	O
IFN	O
-	O
beta	O
production	O
mediated	O
by	O
known	O
host	O
pattern	O
recognition	O
receptors	O
(	O
PRRs	B-DISO
)	O
(	O
RIG	O
-	O
I	O
,	O
Mda	O
-	O
5	O
,	O
and	O
TLR3	O
).	O

These	O
results	O
are	O
consistent	O
with	O
the	O
notion	O
that	O
double	O
-	O
stranded	O
RNA	O
,	O
produced	O
during	O
MHV	O
infection	B-DISO
,	O
is	O
not	O
accessible	O
to	O
cellular	O
PRRs	B-DISO
.	O

We	O
therefore	O
conclude	O
that	O
the	O
ORF7b	O
protein	O
is	O
not	O
only	O
an	O
accessory	O
protein	O
but	O
a	O
structural	O
component	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
virion	O
.	O

TITLE	O
:	O
Suppression	B-DISO
of	O
coronavirus	O
replication	O
by	O
inhibition	O
of	O
the	O
MEK	O
signaling	O
pathway	O
.	O

After	O
adjusting	O
for	O
Simplified	O
Acute	O
Physiology	O
Score	O
II	O
,	O
oliguria	B-DISO
(	O
odds	O
ratio	O
,	O
30	O
.	O
8	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
7	O
.	O
7	O
-	O
123	O
.	O
0	O
)	O
remained	O
as	O
a	O
strong	O
risk	O
factor	O
for	O
mortality	O
.	O

ABSTRACT	O
:	O
Synthetic	O
decapeptides	O
(	O
N	O
=	O
206	O
)	O
covering	O
the	O
entire	O
sequence	O
of	O
mouse	O
liver	O
fumarylacetoacetate	O
hydrolase	O
(	O
FAH	O
)	O
were	O
used	O
to	O
analyze	O
the	O
specificities	O
of	O
the	O
autoantibodies	O
(	O
autoAb	O
)	O
elicited	O
towards	O
this	O
enzyme	O
in	O
mice	O
infected	O
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
).	O

TITLE	O
:	O
Quantification	O
of	O
repertoire	O
diversity	O
of	O
influenza	B-DISO
-	O
specific	O
epitopes	O
with	O
predominant	O
public	O
or	O
private	O
TCR	O
usage	O
.	O

Of	O
the	O
9	O
children	O
,	O
2	O
died	O
of	O
MODS	B-DISO
(	O
1	O
intussusception	B-DISO
complicated	O
with	O
intestine	B-DISO
necrosis	I-DISO
,	O
1	O
severe	O
scald	O
)	O
and	O
1	O
was	O
given	O
up	O
because	O
of	O
severe	O
intestinal	B-DISO
fistula	I-DISO
,	O
the	O
other	O
6	O
children	O
recovered	O
at	O
the	O
end	O
.	O

Tracheobronchial	O
lavage	O
(	O
TBL	O
)	O
and	O
paired	O
serum	O
samples	O
were	O
analysed	O
for	O
bacteria	O
,	O
mycoplasmas	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
parainfluenza	B-DISO
virus	O
3	O
(	O
PIV3	O
),	O
bovine	O
corona	O
virus	O
(	O
BCV	O
)	O
and	O
bovine	O
adenovirus	B-DISO
(	O
BAV	B-DISO
).	O

TITLE	O
:	O
Mechanisms	O
of	O
acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Conventional	O
mechanical	O
ventilation	O
in	O
acute	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

The	O
preadministration	O
of	O
TJ	O
-	O
41	O
significantly	O
inhibited	O
increases	O
in	O
the	O
serum	O
level	O
of	O
keratinocyte	O
chemoattractant	O
(	O
KC	O
),	O
which	O
is	O
a	O
murine	O
chemotaxin	O
for	O
neutrophils	O
that	O
corresponds	O
to	O
human	O
interleukin	O
-	O
8	O
,	O
with	O
respect	O
to	O
its	O
concentration	O
at	O
24	O
h	O
after	O
LPS	B-DISO
challenge	O
.	O

His	O
respiratory	O
condition	B-DISO
rapidly	O
improved	O
during	O
HFOV	O
.	O

HFOV	O
seem	O
to	O
be	O
safe	O
and	O
effective	O
for	O
patients	O
with	O
severe	O
ARDS	B-DISO
who	O
failed	O
conventional	O
ventilation	O
support	O
.	O

Of	O
858	O
patients	O
with	O
dengue	B-DISO
fever	I-DISO
/	O
DHF	O
admitted	O
to	O
the	O
hospital	O
during	O
the	O
study	O
period	O
,	O
109	O
cases	O
with	O
severe	O
forms	O
of	O
disease	O
required	O
PICU	O
admission	O
,	O
of	O
which	O
9	O
patients	O
died	O
.	O

Six	O
deaths	O
of	O
refractory	B-DISO
shock	I-DISO
included	O
4	O
who	O
had	O
ARDS	B-DISO
and	O
DIC	B-DISO
and	O
2	O
who	O
had	O
shock	O
with	O
DIC	B-DISO
3	O
patients	O
had	O
abdominal	B-DISO
compartment	I-DISO
syndrome	I-DISO
(	O
ACS	O
)	O
has	O
not	O
been	O
previously	O
described	O
in	O
children	O
with	O
DSS	B-DISO
and	O
may	O
lead	O
to	O
fluid	O
refractory	B-DISO
shock	I-DISO
if	O
not	O
corrected	O
.	O

2	O
children	O
had	O
features	O
of	O
Acute	B-DISO
Disseminated	I-DISO
Encephalomyelitis	I-DISO
(	O
ADEM	O
),	O
previously	O
only	O
described	O
in	O
adults	O
with	O
dengue	B-DISO
.	O

It	O
was	O
found	O
that	O
complications	O
such	O
as	O
DIC	B-DISO
,	O
diastolic	B-DISO
dysfunction	I-DISO
,	O
abdominal	B-DISO
compartment	I-DISO
syndrome	I-DISO
,	O
ARDS	B-DISO
and	O
hepatic	B-DISO
dysfunction	I-DISO
were	O
more	O
frequent	O
in	O
severe	O
established	O
shock	O
.	O

RESULTS	O
:	O
Of	O
858	O
patients	O
with	O
dengue	B-DISO
fever	I-DISO
/	O
DHF	O
admitted	O
to	O
the	O
hospital	O
during	O
the	O
study	O
period	O
,	O
109	O
cases	O
with	O
severe	O
forms	O
of	O
disease	O
required	O
PICU	O
admission	O
,	O
of	O
which	O
9	O
patients	O
died	O
.	O

2	O
children	O
had	O
features	O
of	O
Acute	B-DISO
Disseminated	I-DISO
Encephalomyelitis	I-DISO
(	O
ADEM	O
),	O
previously	O
only	O
described	O
in	O
adults	O
with	O
dengue	B-DISO
.	O

Mice	O
induced	O
with	O
SARS	B-DISO
-	O
CoV	O
alone	O
did	O
not	O
display	O
clinical	O
signs	O
,	O
characteristically	O
hyaline	B-DISO
membrane	I-DISO
formation	O
,	O
hemorrhage	B-DISO
and	O
early	O
pulmonary	B-DISO
fibrosis	I-DISO
in	O
lung	O
tissue	O
.	O

Acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHEII	O
)	O
scores	O
,	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
(	O
MODS	B-DISO
)	O
evaluation	O
scores	O
and	O
PaO	O
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
were	O
observed	O
before	O
and	O
after	O
HVHF	O
.	O

ABSTRACT	O
:	O
Development	O
of	O
effective	O
vaccines	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
still	O
a	O
priority	O
in	O
prevention	O
of	O
re	O
-	O
emergence	O
of	O
SARS	B-DISO
.	O

Four	O
of	O
five	O
vaccinated	O
mice	O
were	O
protected	O
from	O
subsequent	O
SARS	B-DISO
-	O
CoV	O
challenge	O
because	O
no	O
significant	O
virus	O
replication	O
,	O
and	O
no	O
obvious	O
histopathological	O
changes	O
were	O
found	O
in	O
the	O
lung	O
tissues	O
of	O
the	O
vaccinated	O
mice	O
challenged	O
with	O
SARS	B-DISO
-	O
CoV	O
.	O
Only	O
one	O
vaccinated	O
mouse	O
had	O
mild	O
alveolar	O
damage	O
in	O
the	O
lung	O
tissues	O
.	O

In	O
contrast	O
,	O
high	O
copies	O
of	O
SARS	B-DISO
-	O
CoV	O
RNA	O
and	O
virus	O
replication	O
were	O
detected	O
,	O
and	O
pathological	O
changes	O
were	O
observed	O
in	O
the	O
lung	O
tissues	O
of	O
the	O
control	O
mice	O
.	O

ABSTRACT	O
:	O
Serum	O
samples	O
from	O
14	O
lions	O
(	O
Panthera	O
leo	O
)	O
from	O
Queen	O
Elizabeth	O
National	O
Park	B-DISO
,	O
Uganda	O
,	O
were	O
collected	O
during	O
1998	O
and	O
1999	O
to	O
determine	O
infectious	B-DISO
disease	I-DISO
exposure	O
in	O
this	O
threatened	O
population	O
.	O

Through	O
SPR	O
technology	O
-	O
based	O
assay	O
,	O
52	O
from	O
these	O
256	O
compounds	O
were	O
discovered	O
to	O
show	O
binding	O
to	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
).	O

Most	O
striking	O
,	O
a	O
mutant	B-DISO
deleted	O
of	O
the	O
entire	O
HVR	O
was	O
only	O
minimally	O
impaired	B-DISO
in	O
tissue	O
culture	O
relative	O
to	O
the	O
wild	O
type	O
.	O

TITLE	O
:	O
[	O
Mental	B-DISO
disorders	I-DISO
in	O
general	O
hospital	O
patients	O
].	O

The	O
most	O
prevalent	O
groups	O
of	O
psychiatric	B-DISO
disorders	I-DISO
among	O
general	O
hospital	O
inpatients	O
are	O
organic	O
mental	B-DISO
illness	I-DISO
,	O
depressive	B-DISO
disorders	I-DISO
,	O
and	O
alcohol	B-DISO
dependence	I-DISO
or	O
abuse	B-DISO
.	O

One	O
follow	O
-	O
up	O
study	O
of	O
long	O
-	O
term	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
survivors	O
using	O
the	O
Structural	O
Clinical	O
Interview	O
for	O
the	O
DSM	O
-	O
IV	O
(	O
SCID	B-DISO
)	O
has	O
shown	O
that	O
43	O
.	O
5	O
%	O
of	O
these	O
patients	O
met	O
the	O
criteria	O
for	O
a	O
full	O
posttraumatic	B-DISO
stress	I-DISO
disorder	I-DISO
(	O
PTSD	B-DISO
),	O
8	O
.	O
9	O
%	O
of	O
these	O
patients	O
for	O
a	O
subthreshold	O
or	O
partial	O
PTSD	B-DISO
(	O
sub	O
-	O
PTSD	B-DISO
)	O
at	O
hospital	O
discharge	O
,	O
and	O
23	O
.	O
9	O
%	O
of	O
them	O
still	O
suffered	B-DISO
from	O
full	O
PTSD	B-DISO
,	O
17	O
.	O
8	O
%	O
of	O
them	O
from	O
sub	O
-	O
PTSD	B-DISO
.	O

Short	O
-	O
term	O
consequences	O
of	O
cardiac	O
surgery	O
included	O
adjustment	B-DISO
disorders	I-DISO
with	O
depressed	O
features	O
(	O
32	O
.	O
4	O
%),	O
acute	O
full	O
in	O
-	O
hospital	O
PTSD	B-DISO
(	O
17	O
.	O
6	O
%),	O
and	O
in	O
-	O
hospital	O
major	B-DISO
depression	I-DISO
(	O
17	O
.	O
6	O
%).	O

ABSTRACT	O
:	O
Recently	O
developed	O
control	O
measure	O
modeling	O
approaches	O
for	O
containing	O
airborne	O
infections	B-DISO
,	O
including	O
engineering	O
controls	O
with	O
respiratory	O
protection	O
and	O
public	O
health	O
interventions	O
,	O
are	O
readily	O
amenable	O
to	O
an	O
integrated	O
-	O
scale	O
analysis	O
.	O

Practical	O
Implications	O
We	O
have	O
developed	O
a	O
flexible	O
mathematical	O
model	O
that	O
can	O
help	O
determine	O
the	O
best	O
intervention	O
strategies	O
for	O
containing	O
indoor	O
airborne	O
infections	B-DISO
.	O

Pulsed	O
methylprednisolone	O
,	O
gamma	O
-	O
globulin	O
,	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
and	O
sivelestat	O
sodium	O
hydrate	O
were	O
administrated	O
,	O
and	O
thereafter	O
the	O
patient	O
recovered	O
from	O
cytopenia	B-DISO
and	O
organ	B-DISO
failure	I-DISO
.	O

ABSTRACT	O
:	O
A	O
deletion	O
mutant	B-DISO
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
has	O
been	O
engineered	O
by	O
deleting	O
the	O
structural	O
E	O
gene	O
in	O
an	O
infectious	B-DISO
cDNA	O
clone	O
that	O
was	O
constructed	O
as	O
a	O
bacterial	O
artificial	O
chromosome	O
(	O
BAC	O
).	O

The	O
rJ	O
.	O
6	O
infections	B-DISO
were	O
also	O
set	O
apart	O
by	O
early	O
viral	O
protein	O
accumulation	O
and	O
by	O
robust	O
expansion	O
via	O
syncytia	O
,	O
a	O
characteristic	O
feature	O
of	O
JHM	O
virus	O
dissemination	O
.	O

We	O
found	O
no	O
evidence	O
for	O
protein	O
6	O
operating	O
at	O
the	O
virus	O
entry	O
or	O
assembly	O
stage	O
,	O
as	O
virions	O
from	O
either	O
infection	B-DISO
were	O
indistinguishable	O
.	O

ABSTRACT	O
:	O
We	O
conducted	O
a	O
blinded	O
,	O
case	O
-	O
control	O
,	O
retrospective	O
study	O
in	O
pediatric	O
patients	O
hospitalized	O
at	O
The	O
Children	O
'	O
s	O
Hospital	O
,	O
Denver	O
,	O
Colorado	O
,	O
to	O
determine	O
whether	O
human	O
coronavirus	O
(	O
HCoV	O
)-	O
NL63	O
infection	B-DISO
is	O
associated	O
with	O
Kawasaki	B-DISO
syndrome	I-DISO
(	O
KS	O
).	O

ABSTRACT	O
:	O
The	O
STAT	O
pathways	O
are	O
integral	O
to	O
the	O
inflammatory	B-DISO
response	I-DISO
and	O
these	O
proteins	O
provide	O
a	O
direct	O
link	O
between	O
the	O
cytokine	O
receptors	O
and	O
cytokine	O
-	O
induced	O
gene	O
transcription	O
.	O

TITLE	O
:	O
Radiology	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
):	O
the	O
emerging	O
pathologic	O
-	O
radiologic	O
correlates	O
of	O
an	O
emerging	O
disease	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
caused	O
by	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
a	O
systemic	B-DISO
infection	I-DISO
that	O
clinically	O
manifests	O
as	O
progressive	O
pneumonia	B-DISO
.	O

Severe	O
SARS	B-DISO
cases	O
can	O
develop	O
radiologic	O
and	O
pathologic	O
findings	O
of	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
.	O

Long	O
-	O
term	O
follow	O
-	O
up	O
imaging	O
of	O
survivors	O
shows	O
gradual	O
decrease	O
of	O
GGO	O
and	O
reticulation	O
with	O
persistent	O
air	B-DISO
trapping	I-DISO
in	O
some	O
patients	O
.	O

Thus	O
,	O
siRNA	O
could	O
be	O
designed	O
so	O
as	O
to	O
knockdown	O
the	O
expression	O
of	O
viral	O
protein	O
(	O
s	O
)	O
from	O
a	O
targeted	O
sgRNA	O
during	O
viral	B-DISO
infection	I-DISO
,	O
thereby	O
allowing	O
the	O
contribution	O
of	O
individual	O
viral	O
proteins	O
to	O
viral	B-DISO
infection	I-DISO
to	O
be	O
delineated	O
.	O

Analysis	O
with	O
the	O
other	O
sequences	O
,	O
showed	O
three	O
distinct	O
SARS	B-DISO
clusters	O
,	O
closely	O
correlated	O
to	O
previously	O
defined	O
early	O
,	O
middle	O
and	O
late	O
phases	O
of	O
the	O
2003	O
international	O
SARS	B-DISO
outbreaks	O
.	O

ABSTRACT	O
:	O
This	O
study	O
analysed	O
the	O
consequences	O
of	O
deviation	O
from	O
the	O
WHO	O
case	O
definition	O
for	O
the	O
assessment	O
of	O
patients	O
with	O
suspected	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
The	O
Netherlands	O
during	O
2003	O
.	O

Collectively	O
,	O
these	O
results	O
indicate	O
that	O
viral	O
immunodeficiency	B-DISO
most	O
probably	O
plays	O
a	O
relevant	O
role	O
in	O
the	O
epidemiology	O
and	O
outcome	O
of	O
IBV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Canine	O
parvovirus	B-DISO
type	O
2	O
(	O
CPV	O
-	O
2	O
),	O
the	O
aetiological	O
agent	O
of	O
haemorrhagic	B-DISO
enteritis	I-DISO
in	O
dogs	O
,	O
includes	O
three	O
antigenic	O
variants	O
,	O
types	O
2a	O
,	O
2b	O
and	O
2c	O
.	O

The	O
phenyl	O
methyl	O
alaninyl	O
parent	O
ProTide	O
of	O
L	O
-	O
Cd4A	O
was	O
prepared	O
by	O
Grignard	O
-	O
mediated	O
phosphorochloridate	O
reaction	O
and	O
resulted	O
in	O
a	O
compound	O
with	O
significantly	O
improved	O
anti	O
-	O
HIV	B-DISO
(	O
2600	O
-	O
fold	O
)	O
and	O
HBV	B-DISO
activity	O
.	O

Oxygen	O
supplementation	O
,	O
recent	O
chemotherapy	O
,	O
and	O
presence	O
of	O
peripheral	O
edema	B-DISO
were	O
independent	O
predictors	O
of	O
a	O
combined	O
outcome	O
of	O
ALI	O
or	O
severe	O
hypoxemia	O
after	O
VATS	O
talc	O
pleurodesis	O
.	O

In	O
multivariate	O
analysis	O
,	O
the	O
presence	O
of	O
peripheral	O
edema	B-DISO
before	O
pleurodesis	O
(	O
p	O
=	O
0	O
.	O
005	O
),	O
any	O
preoperative	O
requirement	O
for	O
supplemental	O
oxygen	O
(	O
p	O
=	O
0	O
.	O
032	O
),	O
and	O
chemotherapy	O
within	O
14	O
days	O
before	O
pleurodesis	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
were	O
identified	O
as	O
predictors	O
of	O
ALI	O
or	O
severe	O
postoperative	O
hypoxemia	O
.	O

The	O
preferentially	O
type	O
2	O
cell	O
expressed	O
genes	O
involved	O
in	O
critical	O
functions	O
(	O
such	O
as	O
ATP	O
-	O
binding	O
cassette	O
transporter	O
,	O
ABCA3	O
),	O
those	O
involved	O
in	O
susceptibility	O
to	O
acute	O
lung	O
damage	O
,	O
and	O
those	O
with	O
known	O
susceptibility	O
to	O
other	O
severe	O
lung	B-DISO
diseases	I-DISO
(	O
such	O
as	O
G	O
protein	O
-	O
coupled	O
receptor	O
for	O
asthma	B-DISO
susceptibility	O
,	O
GPR154	O
alias	O
GPRA	O
)	O
will	O
possibly	O
serve	O
as	O
candidate	O
genes	O
in	O
future	O
studies	O
.	O

TITLE	O
:	O
Structural	O
studies	O
of	O
algal	O
lectins	O
with	O
anti	O
-	O
HIV	B-DISO
activity	O
.	O

ABSTRACT	O
:	O
A	O
number	O
of	O
antiviral	O
lectins	O
,	O
small	O
proteins	O
that	O
bind	O
carbohydrates	O
found	O
on	O
viral	O
envelopes	O
,	O
are	O
currently	O
in	O
pre	O
-	O
clinical	O
trials	O
as	O
potential	O
drugs	O
for	O
prevention	O
of	O
transmission	O
of	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
(	O
HIV	B-DISO
)	O
and	O
other	O
enveloped	O
viruses	O
,	O
such	O
as	O
the	O
Ebola	O
virus	O
and	O
the	O
coronavirus	O
responsible	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Spike	O
glycoprotein	O
of	O
SARS	B-DISO
-	O
CoV	O
was	O
recombined	O
by	O
using	O
insect	O
-	O
baculovirus	O
expression	O
system	O
and	O
Nickel	O
affinity	O
Magnet	O
Beads	O
,	O
and	O
then	O
used	O
to	O
stimulate	O
cultured	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
).	O

(	O
1	O
)	O
A	O
significant	O
increase	O
of	O
IP	O
-	O
10	O
activity	O
in	O
the	O
blood	O
was	O
found	O
in	O
patients	O
with	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
,	O
and	O
remained	O
at	O
a	O
high	O
level	O
until	O
the	O
stage	O
of	O
convalescence	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
clinical	O
efficacy	O
and	O
safety	O
of	O
specific	O
immunotherapy	O
(	O
SIT	O
)	O
with	O
standardized	O
house	O
dust	O
mite	O
(	O
HDM	O
)	O
vaccine	O
on	O
allergic	O
asthmatic	B-DISO
patients	O
.	O

Dropouts	O
included	O
three	O
females	O
because	O
of	O
poor	O
compliance	O
,	O
being	O
afraid	O
of	O
the	O
epidemic	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
emigration	O
respectively	O
.	O

The	O
hope	O
is	O
that	O
future	O
management	O
of	O
acute	B-DISO
pancreatitis	I-DISO
with	O
a	O
better	O
understanding	O
of	O
the	O
pathogenesis	B-DISO
of	O
lung	O
injury	O
will	O
be	O
directed	O
against	O
the	O
production	O
of	O
noxious	O
cytokines	O
.	O

Pigs	O
represent	O
an	O
important	O
animal	O
reservoir	O
for	O
influenza	B-DISO
virus	B-DISO
infection	I-DISO
of	O
human	O
populations	O
and	O
are	O
also	O
naturally	O
infected	O
by	O
coronaviruses	O
,	O
an	O
important	O
group	O
of	O
viruses	O
,	O
which	O
includes	O
the	O
recently	O
emerged	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
virus	O
.	O

Pigs	O
infected	O
by	O
a	O
respiratory	O
coronavirus	O
(	O
PRCV	O
)	O
showed	O
virus	O
-	O
specific	O
IgG	O
Ab	O
-	O
secreting	O
cells	O
in	O
the	O
bronchial	O
lymph	O
nodes	O
,	O
whereas	O
the	O
transmissible	O
gastroenteritis	B-DISO
coronavirus	O
(	O
TGEV	O
)	O
induced	O
more	O
IgA	O
Ab	O
-	O
secreting	O
cells	O
in	O
gut	O
tissues	O
,	O
which	O
illustrates	O
the	O
importance	O
of	O
the	O
route	O
of	O
antigen	O
administration	O
for	O
inducing	O
local	O
immune	O
effector	O
mechanisms	O
.	O

Porcine	O
viral	B-DISO
infections	I-DISO
provide	O
,	O
therefore	O
,	O
valuable	O
models	O
for	O
evaluating	O
the	O
immune	O
parameters	O
that	O
are	O
important	O
for	O
controlling	O
transmission	O
of	O
important	O
viral	O
zoonotic	O
infections	B-DISO
.	O

The	O
neutralization	O
and	O
infection	B-DISO
blocking	B-DISO
tests	O
showed	O
that	O
the	O
VSV	O
Delta	O
G	O
*	O
SG	O
and	O
SARS	B-DISO
-	O
CoV	O
reacted	O
similarly	O
to	O
SARS	B-DISO
-	O
CoV	O
specific	O
antiserum	O
,	O
suggesting	O
the	O
VSVDelta	O
G	O
*	O
SG	O
can	O
be	O
a	O
safe	O
replacement	O
of	O
the	O
live	O
SARS	B-DISO
-	O
CoV	O
for	O
neutralization	O
test	O
and	O
cell	O
-	O
entry	O
assay	O
.	O

The	O
current	O
study	O
presents	O
a	O
case	O
of	O
a	O
13	O
-	O
yr	O
-	O
old	O
female	O
with	O
T	O
-	O
cell	O
acute	B-DISO
lymphocytic	I-DISO
leukaemia	I-DISO
who	O
developed	O
persistent	O
,	O
severe	O
,	O
obstructive	B-DISO
lung	I-DISO
disease	I-DISO
following	O
an	O
episode	O
of	O
SJS	B-DISO
.	O

A	O
lung	O
biopsy	O
demonstrated	O
bronchiolar	O
submucosal	B-DISO
fibrosis	I-DISO
consistent	O
with	O
constrictive	B-DISO
bronchiolitis	I-DISO
,	O
as	O
well	O
as	O
eosinophilic	O
micro	O
-	O
abscesses	B-DISO
,	O
which	O
,	O
to	O
the	O
current	O
authors	O
'	O
knowledge	O
,	O
has	O
not	O
been	O
previously	O
described	O
.	O

The	O
effects	O
of	O
adenovirus	B-DISO
-	O
delivered	O
small	O
hairpin	O
RNA	O
on	O
SARS	B-DISO
-	O
CoV	O
gene	O
expression	O
were	O
determined	O
by	O
RT	O
-	O
PCR	O
,	O
Western	O
blot	O
,	O
and	O
luciferase	O
activity	O
assays	O
.	O

Four	O
of	O
the	O
five	O
patients	O
had	O
renal	B-DISO
failure	I-DISO
(	O
median	O
peak	O
creatinine	O
3	O
.	O
8	O
+/-	O

ABSTRACT	O
:	O
Emerging	O
and	O
re	B-DISO
-	I-DISO
emerging	I-DISO
infectious	I-DISO
diseases	I-DISO
have	O
again	O
entered	O
the	O
public	O
arena	O
in	O
recent	O
years	O
.	O

Other	O
viruses	O
detected	O
included	O
human	O
metapneumovirus	O
(	O
4	O
.	O
6	O
%	O
in	O
patients	O
with	O
acute	B-DISO
asthma	I-DISO
vs	O
2	O
.	O
6	O
%	O
in	O
control	O
subjects	O
),	O
enteroviruses	O
(	O
4	O
.	O
6	O
%	O
vs	O
0	O
%),	O
coronavirus	O
229E	O
(	O
0	O
%	O
vs	O
1	O
.	O
3	O
%),	O
and	O
respiratory	O
syncytial	O
virus	O
(	O
1	O
.	O
5	O
%	O
vs	O
0	O
%).	O

TITLE	O
:	O
Reversible	O
unfolding	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
main	O
protease	O
in	O
guanidinium	O
chloride	O
.	O

Subsequent	O
analysis	O
revealed	O
no	O
differences	O
in	O
T	O
cell	O
proliferation	B-DISO
,	O
IFN	O
-	O
gamma	O
secretion	O
by	O
virus	O
-	O
specific	O
T	O
cells	O
,	O
or	O
CD8	O
+	O
T	O
cell	O
cytolytic	O
activity	O
.	O

ABSTRACT	O
:	O
Important	O
epidemiological	O
modifications	O
have	O
been	O
registered	O
in	O
respiratory	B-DISO
infections	I-DISO
,	O
both	O
in	O
immunocompetent	O
and	O
immunocompromised	O
hosts	O
.	O

The	O
study	O
aimed	O
to	O
describe	O
the	O
experience	O
and	O
behaviour	O
of	O
family	O
physicians	O
and	O
the	O
use	O
of	O
personal	O
protection	O
equipment	O
(	O
PPE	O
)	O
in	O
their	O
encounters	O
with	O
SARS	B-DISO
patients	O
.	O

They	O
highlighted	O
the	O
difficulties	O
in	O
procuring	O
PPE	O
due	O
to	O
severe	O
shortage	O
,	O
the	O
discomfort	B-DISO
and	O
inconvenience	O
associated	O
with	O
its	O
use	O
.	O

It	O
fits	B-DISO
into	O
the	O
Becker	O
Health	O
Belief	O
Model	O
,	O
which	O
explains	O
that	O
behaviour	O
change	O
depends	O
on	O
the	O
balance	O
of	O
perceived	O
vulnerability	O
,	O
severity	O
,	O
effectiveness	O
,	O
and	O
barriers	O
.	O

The	O
vulnerability	O
and	O
severity	O
of	O
SARS	B-DISO
to	O
healthcare	O
workers	O
were	O
verified	O
by	O
the	O
hospital	O
experience	O
.	O

Malaria	B-DISO
must	O
always	O
be	O
suspected	O
in	O
a	O
returning	O
traveler	O
or	O
a	O
visitor	O
from	O
a	O
malaria	B-DISO
-	O
endemic	O
country	O
with	O
an	O
acute	O
febrile	B-DISO
illness	I-DISO
.	O

Malaria	B-DISO
must	O
be	O
treated	O
with	O
effective	O
drugs	O
,	O
but	O
current	O
choices	O
are	O
few	O
:	O
e	O
.	O
g	O
.	O
parenteral	O
artemisinins	O
,	O
intravenous	O
quinine	O
or	O
quinidine	O
(	O
in	O
the	O
US	O
only	O
).	O

ALI	O
/	O
ARDS	B-DISO
in	O
pediatric	O
malaria	B-DISO
appears	O
to	O
be	O
rare	O
.	O

These	O
results	O
demonstrate	O
that	O
oligodendrocyte	O
apoptosis	O
is	O
triggered	O
by	O
MHV	O
infection	B-DISO
during	O
cell	O
entry	O
through	O
the	O
activation	O
of	O
the	O
Fas	B-DISO
signaling	O
pathway	O
.	O

RESULTS	O
:	O
We	O
were	O
able	O
to	O
perform	O
all	O
detection	O
processes	O
in	O
the	O
encapsulated	O
system	O
without	O
opening	O
the	O
cap	B-DISO
.	O

TITLE	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
serotypes	O
in	O
poultry	O
flocks	O
in	O
Jordan	O
.	O

Its	O
pathogenesis	B-DISO
is	O
closely	O
linked	O
with	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
).	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
whether	O
dipyridamole	O
(	O
DIP	B-DISO
),	O
delivered	O
as	O
a	O
liposomal	O
preparation	O
,	O
can	O
ameliorate	O
the	O
lipopolysaccharides	O
(	O
LPS	B-DISO
)-	O
induced	O
ALI	O
due	O
to	O
the	O
changes	O
of	O
its	O
biodistribution	O
.	O

To	O
prove	O
the	O
therapeutic	O
efficiency	O
,	O
the	O
effects	O
of	O
DIP	B-DISO
liposomes	O
on	O
LPS	B-DISO
-	O
induced	O
ALI	O
were	O
studied	O
compared	O
with	O
DIP	B-DISO
injection	O
.	O

Furthermore	O
,	O
DIP	B-DISO
liposomes	O
alleviated	O
the	O
ALI	O
induced	O
by	O
LPS	B-DISO
significantly	O
.	O

World	O
Health	O
Organization	O
defined	O
the	O
new	O
disease	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

ABSTRACT	O
:	O
Chinese	O
medicine	O
(	O
CM	O
)	O
has	O
been	O
used	O
to	O
control	O
infectious	B-DISO
diseases	I-DISO
for	O
thousands	O
of	O
years	O
.	O

In	O
2003	O
outbreaks	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
occurred	O
in	O
China	O
,	O
Hong	O
Kong	O
and	O
Taiwan	O
.	O

Using	O
CM	O
as	O
a	O
supplementary	O
treatment	O
of	O
severe	O
SARS	B-DISO
seems	O
to	O
indicate	O
that	O
natural	O
herbal	O
medicine	O
can	O
be	O
used	O
against	O
avian	B-DISO
influenza	I-DISO
.	O

This	O
study	O
aimed	O
to	O
find	O
the	O
symptom	B-DISO
combinations	O
associated	O
with	O
adverse	O
outcome	O
and	O
the	O
therapeutic	O
effects	O
in	O
a	O
cohort	O
of	O
patients	O
with	O
probable	O
SARS	B-DISO
retrospectively	O
.	O

In	O
2003	O
,	O
123	O
SARS	B-DISO
cases	O
in	O
Beijing	O
were	O
subjected	O
to	O
a	O
strictly	O
western	O
medicine	O
(	O
WM	O
)	O
treatment	O
,	O
or	O
a	O
combined	O
treatment	O
(	O
WM	O
plus	O
Herba	O
houttuyniae	O
injection	O
,	O
addition	O
of	O
individualized	O
herbal	O
treatments	O
when	O
necessary	O
),	O
of	O
which	O
115	O
were	O
followed	O
till	O
death	O
or	O
discharge	O
;	O
8	O
were	O
transferred	O
and	O
lost	O
to	O
follow	O
-	O
up	O
.	O

TITLE	O
:	O
The	O
cytoplasmic	O
tail	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
spike	O
protein	O
contains	O
a	O
novel	O
endoplasmic	O
reticulum	O
retrieval	O
signal	O
that	O
binds	O
COPI	O
and	O
promotes	O
interaction	O
with	O
membrane	O
protein	O
.	O

Due	O
to	O
the	O
lack	O
of	O
potential	O
drugs	O
for	O
the	O
treatment	O
of	O
SARS	B-DISO
,	O
the	O
discovery	O
of	O
inhibitors	O
against	O
SARS	B-DISO
3C	O
-	O
like	O
proteinase	O
,	O
which	O
can	O
potentially	O
be	O
optimized	O
as	O
drugs	O
appears	O
to	O
be	O
highly	O
desirable	O
.	O

TITLE	O
:	O
Recombinant	O
dimeric	O
small	O
immunoproteins	O
neutralize	O
transmissible	O
gastroenteritis	B-DISO
virus	O
infectivity	O
efficiently	O
in	O
vitro	O
and	O
confer	O
passive	O
immunity	O
in	O
vivo	O
.	O

We	O
propose	O
that	O
prediction	O
markets	O
may	O
be	O
useful	O
for	O
tracking	O
and	O
forecasting	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
,	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
avian	B-DISO
influenza	I-DISO
,	O
by	O
aggregating	O
expert	O
opinion	O
quickly	O
,	O
accurately	O
,	O
and	O
inexpensively	O
.	O

Data	O
from	O
a	O
pilot	O
study	O
in	O
the	O
state	O
of	O
Iowa	O
suggest	O
that	O
these	O
markets	O
can	O
accurately	O
predict	O
statewide	O
seasonal	O
influenza	B-DISO
activity	O
2	O
-	O
4	O
weeks	O
in	O
advance	O
by	O
using	O
clinical	O
data	O
volunteered	O
from	O
participating	O
health	O
care	O
workers	O
.	O

ABSTRACT	O
:	O
Compounds	O
approved	O
for	O
therapeutic	O
use	O
and	O
in	O
vitro	O
inhibitors	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
were	O
evaluated	O
for	O
inhibition	O
in	O
the	O
mouse	O
SARS	B-DISO
-	O
CoV	O
replication	O
model	O
.	O

Anti	O
-	O
inflammatory	O
agents	O
,	O
chloroquine	O
,	O
amodiaquin	O
and	O
pentoxifylline	O
,	O
were	O
also	O
inactive	O
in	O
vivo	O
,	O
suggesting	O
that	O
although	O
they	O
may	O
be	O
useful	O
in	O
ameliorating	O
the	O
hyperinflammatory	O
response	O
induced	O
by	O
the	O
virus	B-DISO
infection	I-DISO
,	O
they	O
will	O
not	O
significantly	O
reduce	O
the	O
replication	O
of	O
the	O
virus	O
,	O
the	O
inducer	O
of	O
inflammatory	B-DISO
response	I-DISO
.	O

TITLE	O
:	O
[	O
Survival	O
by	O
a	O
young	O
woman	O
with	O
malnutrition	B-DISO
due	O
to	O
alcoholism	B-DISO
and	O
eating	B-DISO
disorders	I-DISO
and	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
due	O
to	O
severe	O
pneumonia	B-DISO
who	O
showed	O
increased	O
serum	O
neutrophil	O
elastase	O
activity	O
].	O

TITLE	O
:	O
Mouse	B-DISO
hepatitis	I-DISO
coronavirus	O
A59	O
nucleocapsid	O
protein	O
is	O
a	O
type	O
I	O
interferon	O
antagonist	O
.	O

These	O
results	O
are	O
consistent	O
with	O
lack	O
of	O
protein	O
translation	O
shutoff	O
early	O
following	O
infection	B-DISO
.	O

We	O
have	O
now	O
constructed	O
an	O
E	O
knockout	O
mutant	B-DISO
that	O
confirms	O
that	O
the	O
highly	O
defective	O
phenotype	O
of	O
the	O
DeltaE	O
mutant	B-DISO
is	O
due	O
to	O
loss	O
of	O
the	O
E	O
gene	O
.	O

The	O
DTS	B-DISO
-	O
C	O
scores	O
of	O
staff	O
in	O
the	O
emergency	B-DISO
department	O
and	O
in	O
the	O
psychiatric	O
ward	O
were	O
significantly	O
different	O
(	O
p	O
=	O
0	O
.	O
04	O
).	O

Emergency	B-DISO
department	O
staff	O
had	O
more	O
severe	O
PTSD	B-DISO
symptoms	O
than	O
staff	O
in	O
the	O
psychiatric	O
ward	O
.	O

We	O
investigate	O
contact	O
tracing	O
in	O
a	O
model	O
of	O
an	O
emerging	O
epidemic	O
that	O
is	O
flexible	O
enough	O
to	O
use	O
for	O
most	O
infections	B-DISO
.	O

We	O
estimated	O
that	O
if	O
societal	O
learning	O
had	O
occurred	O
at	O
half	O
the	O
actual	O
rate	O
,	O
the	O
expected	O
final	O
size	O
of	O
the	O
outbreak	O
would	O
have	O
reached	O
nearly	O
800	O
cases	O
,	O
more	O
than	O
three	O
times	O
the	O
observed	O
number	O
of	O
infections	B-DISO
.	O

In	O
summary	O
,	O
our	O
study	O
has	O
,	O
for	O
the	O
first	O
time	O
,	O
characterized	O
the	O
temporal	O
and	O
dynamic	O
changes	O
of	O
humoral	O
and	O
CTL	O
responses	O
in	O
the	O
natural	O
history	O
of	O
SARS	B-DISO
-	O
recovered	O
individuals	O
,	O
and	O
strongly	O
supports	O
the	O
notion	O
that	O
high	O
and	O
sustainable	O
levels	O
of	O
immune	O
responses	O
correlate	O
strongly	O
with	O
the	O
disease	O
outcome	O
.	O

TITLE	O
:	O
Baculovirus	O
surface	O
display	O
of	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
spike	O
protein	O
and	O
immunogenicity	O
of	O
the	O
displayed	O
protein	O
in	O
mice	O
models	O
.	O

rFVIIa	O
reduced	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
and	O
/	O
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
the	O
coagulopathic	O
patients	O
(	O
3	O
%	O
versus	O
20	O
%,	O
P	O
=	O
0	O
.	O
004	O
),	O
whereas	O
thromboembolic	B-DISO
events	I-DISO
were	O
equally	O
present	O
in	O
both	O
groups	O
(	O
3	O
%	O
versus	O
4	O
%,	O
P	O
=	O
1	O
.	O
00	O
).	O

TITLE	O
:	O
Bench	O
-	O
to	O
-	O
bedside	O
review	O
:	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
in	O
adults	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

High	O
-	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
is	O
an	O
unconventional	O
form	O
of	O
ventilation	O
that	O
may	O
improve	O
oxygenation	O
in	O
patients	O
with	O
ARDS	B-DISO
,	O
while	O
limiting	O
further	O
lung	O
injury	O
associated	O
with	O
high	O
ventilatory	O
pressures	O
and	O
volumes	O
delivered	O
during	O
conventional	O
ventilation	O
.	O

Several	O
studies	O
suggest	O
that	O
HFOV	O
may	O
improve	O
outcomes	O
if	O
used	O
early	O
in	O
the	O
course	O
of	O
ARDS	B-DISO
,	O
or	O
if	O
used	O
in	O
certain	O
populations	O
.	O

ABSTRACT	O
:	O
Cytomegalovirus	O
(	O
CMV	O
)	O
infection	B-DISO
is	O
associated	O
with	O
significant	O
morbidity	O
and	O
mortality	O
in	O
immunocompromised	O
patients	O
.	O

TITLE	O
:	O
Expression	O
,	O
purification	O
and	O
characterization	O
of	O
recombinant	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
non	O
-	O
structural	O
protein	O
1	O
.	O

One	O
such	O
protein	O
is	O
SARS	B-DISO
-	O
CoV	O
nsp1	O
,	O
which	O
is	O
processed	O
from	O
the	O
N	O
-	O
terminus	O
of	O
both	O
pp1a	O
and	O
pp1ab	O
.	O

ABSTRACT	O
:	O
The	O
viral	O
proteases	O
have	O
proven	O
to	O
be	O
the	O
most	O
selective	O
and	O
useful	O
for	O
removing	O
the	O
fusion	O
tags	O
in	O
fusion	B-DISO
protein	I-DISO
expression	I-DISO
systems	O
.	O

We	O
report	O
a	O
new	O
method	O
to	O
produce	O
wild	O
-	O
type	O
(	O
WT	O
)	O
SARS	B-DISO
-	O
CoV	O
M	O
(	O
pro	O
)	O
with	O
authentic	O
N	O
and	O
C	O
termini	O
,	O
and	O
compare	O
the	O
activity	O
of	O
WT	O
protease	O
with	O
those	O
of	O
three	O
different	O
types	O
of	O
SARS	B-DISO
-	O
CoV	O
M	O
(	O
pro	O
)	O
with	O
additional	O
residues	O
at	O
the	O
N	O
or	O
C	O
terminus	O
.	O

To	O
explain	O
this	O
,	O
the	O
crystal	O
structures	O
of	O
WT	O
SARS	B-DISO
-	O
CoV	O
M	O
(	O
pro	O
)	O
and	O
its	O
complex	O
with	O
a	O
Michael	O
acceptor	O
inhibitor	O
were	O
determined	O
to	O
1	O
.	O
6	O
Angstroms	O
and	O
1	O
.	O
95	O
Angstroms	O
resolution	O
respectively	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
potential	O
risk	O
factors	O
for	O
severe	O
acute	O
respiratory	O
syndromes	B-DISO
(	O
SARS	B-DISO
)-	O
related	O
deaths	O
in	O
Beijing	O
.	O

TITLE	O
:	O
The	O
synergistic	O
interaction	O
of	O
interferon	O
types	O
I	O
and	O
II	O
leads	O
to	O
marked	O
reduction	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
replication	O
and	O
increase	O
in	O
the	O
expression	O
of	O
mRNAs	O
for	O
interferon	O
-	O
induced	O
proteins	O
.	O

TITLE	O
:	O
Vaccine	O
efficacy	O
in	O
senescent	O
mice	O
challenged	O
with	O
recombinant	O
SARS	B-DISO
-	O
CoV	O
bearing	O
epidemic	O
and	O
zoonotic	O
spike	O
variants	O
.	O

ABSTRACT	O
:	O
In	O
2003	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
was	O
identified	O
as	O
the	O
etiological	O
agent	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
a	O
disease	O
characterized	O
by	O
severe	O
pneumonia	B-DISO
that	O
sometimes	O
results	O
in	O
death	O
.	O

VRP	O
-	O
N	O
-	O
induced	O
pathology	B-DISO
presented	O
at	O
day	O
4	O
,	O
peaked	O
around	O
day	O
7	O
,	O
and	O
persisted	O
through	O
day	O
14	O
,	O
and	O
was	O
likely	O
mediated	O
by	O
cellular	O
immune	O
responses	O
.	O

The	O
histopathology	O
examination	O
revealed	O
the	O
development	O
of	O
alveolar	O
interstitial	O
thickening	O
and	O
vasculitis	B-DISO
,	O
and	O
an	O
aggravation	O
of	O
the	O
mainstem	O
bronchial	O
exudates	O
and	O
bronchial	O
inflammation	B-DISO
.	O

TITLE	O
:	O
Lipid	O
rafts	O
play	O
an	O
important	O
role	O
in	O
the	O
early	O
stage	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
coronavirus	O
life	O
cycle	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
lipid	O
rafts	O
also	O
play	O
an	O
important	O
role	O
in	O
the	O
life	O
cycle	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
coronavirus	O
(	O
CoV	O
).	O

In	O
contrast	O
,	O
cholesterol	B-DISO
depletion	I-DISO
at	O
the	O
post	O
-	O
entry	O
stage	O
(	O
3h	O
post	O
-	O
infection	B-DISO
)	O
caused	O
only	O
a	O
limited	O
effect	O
on	O
virus	O
particle	O
release	O
.	O

There	O
is	O
only	O
1	O
published	O
report	O
of	O
transmission	O
of	O
SARS	B-DISO
virus	O
from	O
a	O
pediatric	O
patient	O
.	O

However	O
,	O
the	O
extent	O
to	O
which	O
the	O
pathogenesis	B-DISO
of	O
leptospirosis	B-DISO
mimics	O
sepsis	B-DISO
caused	O
by	O
Gram	O
-	O
negative	O
bacteria	O
remains	O
unknown	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
serum	O
levels	O
of	O
nitric	O
oxide	O
(	O
NO	O
)	O
in	O
patients	O
diagnosed	O
with	O
severe	O
leptospirosis	B-DISO
.	O

CONCLUSIONS	O
:	O
The	O
lethality	O
of	O
severe	O
imported	O
malaria	B-DISO
is	O
still	O
high	O
despite	O
optimal	O
management	O
in	O
ICUs	O
.	O

Mass	O
casualty	O
respiratory	B-DISO
failure	I-DISO
remains	O
a	O
largely	O
unstudied	O
field	O
,	O
but	O
we	O
believe	O
informed	O
decisions	O
about	O
equipment	O
stockpiling	O
and	O
use	O
,	O
the	O
development	O
of	O
creative	O
operational	O
concepts	O
to	O
increase	O
staffing	O
,	O
and	O
the	O
careful	O
implementation	O
of	O
rational	O
infection	B-DISO
control	O
practices	O
can	O
lay	O
a	O
foundation	O
for	O
an	O
appropriate	O
response	O
until	O
additional	O
data	O
become	O
available	O
.	O

Although	O
AV	O
-	O
ECLA	O
is	O
highly	O
effective	O
in	O
eliminating	O
CO2	O
,	O
if	O
combined	O
with	O
apnoeic	B-DISO
oxygenation	O
,	O
normocapnia	O
was	O
not	O
achievable	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
localizes	O
to	O
the	O
cytoplasm	O
and	O
nucleolus	O
and	O
contains	O
an	O
eight	O
-	O
amino	O
-	O
acid	O
nucleolar	O
retention	O
motif	O
.	O

TITLE	O
:	O
Recombinant	O
truncated	O
nucleocapsid	O
protein	O
as	O
antigen	O
in	O
a	O
novel	O
immunoglobulin	O
M	O
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
diagnosis	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Delayed	O
presentation	O
of	O
amniotic	B-DISO
fluid	I-DISO
embolism	I-DISO
:	O
lessons	O
from	O
a	O
case	O
diagnosed	O
at	O
autopsy	O
.	O

The	O
variables	O
pertaining	O
to	O
oxygen	O
metabolism	O
were	O
analyzed	O
,	O
and	O
the	O
data	O
were	O
compared	O
between	O
patients	O
with	O
risky	O
trauma	O
and	O
those	O
with	O
severe	O
trauma	O
,	O
between	O
patients	O
complicated	O
with	O
MODS	B-DISO
and	O
non	O
--	O
MODS	B-DISO
(	O
NMODS	O
),	O
and	O
between	O
survivors	O
and	O
nonsurvivors	O
.	O

It	O
was	O
more	O
intense	O
in	O
the	O
patients	O
with	O
MODS	B-DISO
.	O

There	O
was	O
marked	O
difference	O
in	O
the	O
ratio	O
of	O
change	O
in	O
oxygen	O
metabolism	O
between	O
MODS	B-DISO
and	O
NMODS	O
groups	O
.	O

Oxygen	B-DISO
deficiency	I-DISO
metabolic	O
variables	O
tended	O
to	O
deteriorate	O
in	O
the	O
non	O
survival	O
group	O
.	O

RESULTS	O
:	O
Oxygen	O
metabolism	O
abnormality	O
was	O
found	O
after	O
trauma	O
,	O
and	O
it	O
was	O
correlated	O
with	O
ISS	B-DISO
,	O
RTS	B-DISO
,	O
injured	O
organ	O
or	O
region	O
and	O
number	O
of	O
injured	O
organs	O
,	O
shock	O
,	O
systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
syndrome	I-DISO
(	O
SIRS	B-DISO
)	O
and	O
respiratory	B-DISO
complications	I-DISO
.	O

CONCLUSIONS	O
:	O
Changes	O
in	O
level	O
of	O
oxygen	O
metabolism	O
might	O
be	O
closely	O
correlated	O
with	O
development	O
of	O
MODS	B-DISO
in	O
trauma	O
patients	O
.	O

Sequence	O
analysis	O
of	O
the	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
genome	O
predicts	O
several	O
proteins	O
that	O
are	O
unique	O
to	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
search	O
to	O
understand	O
the	O
high	O
virulence	O
of	O
SARS	B-DISO
-	O
CoV	O
compared	O
with	O
related	O
coronaviruses	O
,	O
which	O
cause	O
lesser	O
respiratory	O
illnesses	O
,	O
has	O
recently	O
focused	O
on	O
the	O
unique	O
nsp1	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
suggests	O
evolution	O
of	O
a	O
possible	O
new	O
virulence	O
mechanism	O
in	O
coronaviruses	O
.	O

Severe	O
falciparum	B-DISO
malaria	I-DISO
,	O
or	O
infections	B-DISO
complicated	O
by	O
a	O
relatively	O
high	O
parasite	O
count	O
(	O
more	O
than	O
2	O
%	O
of	O
red	O
blood	O
cells	O
parasitized	O
),	O
should	O
be	O
treated	O
with	O
intravenous	O
therapy	O
until	O
the	O
patient	O
is	O
well	O
enough	O
to	O
continue	O
with	O
oral	O
treatment	O
.	O

Malaria	B-DISO
in	O
children	O
(	O
and	O
sometimes	O
in	O
adults	O
)	O
may	O
present	O
with	O
misleading	O
symptoms	O
such	O
as	O
gastrointestinal	O
features	O
,	O
sore	B-DISO
throat	I-DISO
or	O
lower	O
respiratory	O
complaints	O
;	O
the	O
diagnosis	O
must	O
always	O
be	O
sought	O
in	O
a	O
feverish	O
or	O
very	O
sick	O
child	O
who	O
has	O
visited	O
malaria	B-DISO
-	O
endemic	O
areas	O
.	O

ABSTRACT	O
:	O
Canine	O
respiratory	O
coronavirus	O
(	O
CRCoV	O
)	O
is	O
a	O
group	O
II	O
coronavirus	O
that	O
was	O
firstly	O
identified	O
in	O
lung	O
samples	O
of	O
dogs	O
with	O
canine	O
infectious	B-DISO
respiratory	B-DISO
disease	I-DISO
(	O
CIRD	O
)	O
in	O
UK	O
in	O
2003	O
.	O

Positive	O
results	O
were	O
obtained	O
from	O
the	O
lungs	O
of	O
a	O
dog	O
of	O
the	O
Apulia	O
region	O
that	O
was	O
co	O
-	O
infected	O
with	O
canine	O
parvovirus	B-DISO
type	O
2	O
.	O

Separate	O
measures	O
of	O
time	O
and	O
distance	O
from	O
source	O
cases	O
should	O
be	O
added	O
to	O
minimum	O
datasets	O
for	O
the	O
assessment	O
of	O
interventions	O
for	O
SARS	B-DISO
and	O
other	O
emerging	O
diseases	O
.	O

Among	O
the	O
non	O
-	O
SARS	B-DISO
patients	O
,	O
235	O
(	O
93	O
%)	O
were	O
diagnosed	O
as	O
having	O
influenza	B-DISO
infections	B-DISO
(	O
primarily	O
H3N2	O
subtype	O
)	O
and	O
77	O
(	O
30	O
%)	O
had	O
radiological	O
evidence	O
of	O
pneumonia	B-DISO
.	O

The	O
potential	O
for	O
H5N1	B-DISO
influenza	I-DISO
to	O
cause	O
a	O
pandemic	O
of	O
human	O
disease	O
continues	O
to	O
be	O
the	O
subject	O
of	O
intense	O
scrutiny	O
by	O
both	O
the	O
media	O
and	O
the	O
scientific	O
community	O
.	O

Experimental	O
models	O
and	O
clinical	O
studies	O
are	O
beginning	O
to	O
elucidate	O
the	O
mechanisms	O
underlying	O
this	O
previously	O
unrecognized	O
association	O
and	O
are	O
revealing	O
for	O
the	O
first	O
time	O
that	O
chronic	B-DISO
alcohol	I-DISO
abuse	I-DISO
causes	O
discrete	O
changes	O
,	O
particularly	O
within	O
the	O
alveolar	O
epithelium	O
,	O
that	O
render	O
the	O
lung	O
susceptible	O
to	O
acute	O
edematous	B-DISO
injury	O
in	O
response	O
to	O
sepsis	B-DISO
,	O
trauma	O
,	O
and	O
other	O
inflammatory	O
insults	O
.	O

Of	O
these	O
,	O
10	O
(	O
19	O
.	O
2	O
%)	O
were	O
caused	O
by	O
HKU1	O
(	O
6	O
single	O
infections	B-DISO
and	O
4	O
coinfections	B-DISO
)	O
during	O
the	O
period	O
January	O
-	O
May	O
2006	O
.	O

ABSTRACT	O
:	O
Mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
is	O
a	O
member	O
of	O
the	O
family	O
Coronaviridae	O
.	O

TITLE	O
:	O
Use	O
of	O
anti	O
-	O
coronavirus	O
antibody	O
testing	O
of	O
cerebrospinal	O
fluid	O
for	O
diagnosis	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
involving	O
the	O
central	O
nervous	B-DISO
system	O
in	O
cats	O
.	O

CSF	O
and	O
serum	O
samples	O
were	O
allocated	O
into	O
4	O
groups	O
:	O
cats	O
with	O
FIP	B-DISO
involving	O
the	O
CNS	O
(	O
n	O
=	O
10	O
),	O
cats	O
with	O
FIP	B-DISO
not	O
involving	O
the	O
CNS	O
(	O
13	O
),	O
cats	O
with	O
CNS	B-DISO
disorders	I-DISO
caused	O
by	O
diseases	O
other	O
than	O
FIP	B-DISO
(	O
29	O
),	O
and	O
cats	O
with	O
diseases	O
other	O
than	O
FIP	B-DISO
and	O
not	O
involving	O
the	O
CNS	O
(	O
15	O
).	O

Synthetic	O
versions	O
of	O
predominant	O
IgA	O
antibodies	O
in	O
acute	O
Kawasaki	B-DISO
disease	I-DISO
arterial	O
tissue	O
bind	O
to	O
an	O
antigen	O
present	O
in	O
acute	O
Kawasaki	B-DISO
disease	I-DISO
ciliated	O
bronchial	O
epithelium	O
and	O
in	O
a	O
subset	O
of	O
macrophages	O
in	O
acute	O
inflamed	O
Kawasaki	B-DISO
disease	I-DISO
tissues	O
.	O

Light	O
and	O
electron	O
microscopic	O
studies	O
of	O
the	O
antigen	O
in	O
acute	O
Kawasaki	B-DISO
disease	I-DISO
ciliated	O
bronchial	O
epithelium	O
indicate	O
that	O
the	O
Kawasaki	B-DISO
disease	I-DISO
-	O
associated	O
antigen	O
localizes	O
to	O
cytoplasmic	O
inclusion	O
bodies	O
that	O
are	O
consistent	O
with	O
aggregates	O
of	O
viral	O
protein	O
and	O
associated	O
nucleic	O
acid	O
.	O

The	O
identification	O
of	O
cytoplasmic	O
inclusion	O
bodies	O
in	O
acute	O
Kawasaki	B-DISO
disease	I-DISO
ciliated	O
bronchial	O
epithelium	O
has	O
provided	O
direction	O
for	O
future	O
Kawasaki	B-DISO
disease	I-DISO
etiology	O
studies	O
.	O

We	O
constructed	O
a	O
database	O
of	O
248	O
syndromes	B-DISO
,	O
each	O
syndrome	B-DISO
having	O
an	O
estimated	O
probability	O
of	O
producing	O
any	O
of	O
85	O
symptoms	O
,	O
with	O
some	O
two	O
-	O
way	O
,	O
three	O
-	O
way	O
,	O
and	O
five	O
-	O
way	O
probabilities	O
reflecting	O
correlations	O
among	O
symptoms	O
.	O

Physical	O
examination	O
showed	O
dilated	B-DISO
pupils	I-DISO
and	O
coma	B-DISO
with	O
no	O
focal	O
neurological	O
signs	O
.	O

TITLE	O
:	O
Recombinant	O
protein	O
-	O
based	O
assays	O
for	O
detection	O
of	O
antibodies	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
spike	O
and	O
nucleocapsid	O
proteins	O
.	O

The	O
vitality	O
and	O
mental	O
health	O
status	O
of	O
SARS	B-DISO
HCWs	O
1	O
month	O
after	O
self	O
-	O
quarantine	O
and	O
off	O
-	O
duty	O
shifts	O
remained	O
inferior	O
to	O
those	O
of	O
the	O
control	O
group	O
.	O

Our	O
findings	O
suggest	O
subtle	O
but	O
important	O
heterogeneities	O
in	O
the	O
incubation	O
period	O
of	O
SARS	B-DISO
among	O
different	O
strata	O
of	O
patients	O
.	O

TITLE	O
:	O
Development	O
of	O
an	O
empirical	O
model	O
to	O
aid	O
in	O
designing	O
airborne	O
infection	B-DISO
isolation	O
rooms	O
.	O

Data	O
collected	O
in	O
health	O
care	O
facilities	O
showed	O
that	O
the	O
model	O
accurately	O
predicted	O
the	O
leakage	B-DISO
area	O
44	O
of	O
48	O
times	O
.	O

The	O
NIOSH	O
model	O
is	O
an	O
effective	O
,	O
cost	O
-	O
cutting	O
tool	O
that	O
can	O
be	O
used	O
by	O
HVAC	O
engineers	O
and	O
designers	O
to	O
estimate	O
leakage	B-DISO
area	O
and	O
select	O
an	O
appropriate	O
DeltaQ	O
in	O
AIIRs	O
to	O
reduce	O
the	O
airborne	O
transmission	B-DISO
of	I-DISO
disease	I-DISO
.	O

189	O
-	O
193	O
from	O
ASAYQ	O
to	O
PPFPF	O
)	O
is	O
more	O
efficient	O
than	O
the	O
A	O
/	O
F	O
mutant	B-DISO
(	O
mutate	O
a	O
.	O
a	O
189	O
and	O
191	O
from	O
A	O
to	O
F	O
)	O
in	O
blocking	B-DISO
the	O
cleavage	O
of	O
signal	O
peptide	O
by	O
signal	O
peptidase	O
.	O

Three	O
animal	O
viruses	O
;	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
),	O
avian	O
pneumovirus	O
(	O
APV	O
),	O
and	O
fowlpox	B-DISO
virus	O
were	O
chosen	O
as	O
surrogates	O
for	O
three	O
human	O
viruses	O
;	O
SARS	B-DISO
coronavirus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
and	O
smallpox	B-DISO
virus	O
;	O
respectively	O
.	O

TITLE	O
:	O
Spatial	O
dynamics	O
of	O
an	O
epidemic	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
an	O
urban	O
area	O
.	O

ABSTRACT	O
:	O
To	O
map	O
risk	O
of	O
exposure	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
an	O
urban	O
area	O
and	O
assess	O
the	O
ability	O
of	O
traditional	O
interventions	O
to	O
control	O
dispersion	O
of	O
the	O
disease	O
.	O

Traditional	O
control	O
measures	O
can	O
be	O
very	O
effective	O
at	O
reducing	O
transmission	O
of	O
SARS	B-DISO
.	O

The	O
sudden	O
appearance	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
2003	O
demonstrated	O
that	O
an	O
emerging	O
and	O
highly	O
infectious	B-DISO
disease	I-DISO
caused	O
by	O
a	O
hitherto	O
unknown	O
virus	O
was	O
able	O
to	O
spread	O
rapidly	O
,	O
but	O
could	O
finally	O
be	O
contained	O
by	O
stringent	O
measures	O
.	O

Morphologic	O
and	O
biochemical	O
features	O
of	O
apoptosis	O
,	O
such	O
as	O
blebbing	O
of	O
the	O
plasma	O
membrane	O
,	O
translocation	B-DISO
of	O
phosphatidilserine	O
to	O
cell	O
surface	O
and	O
annexin	O
V	O
positive	O
staining	O
,	O
nuclear	O
fragmentation	B-DISO
,	O
apoptotic	O
bodies	O
formation	O
and	O
DNA	O
laddering	O
,	O
were	O
detected	O
in	O
CCoV	O
-	O
infected	O
cells	O
.	O

TITLE	O
:	O
Using	O
models	O
to	O
identify	O
routes	O
of	O
nosocomial	B-DISO
infection	I-DISO
:	O
a	O
large	O
hospital	O
outbreak	O
of	O
SARS	B-DISO
in	O
Hong	O
Kong	O
.	O

We	O
propose	O
that	O
in	O
future	O
outbreaks	O
of	O
SARS	B-DISO
or	O
other	O
directly	O
transmissible	O
respiratory	O
pathogens	O
,	O
simple	O
mathematical	O
models	O
could	O
be	O
used	O
to	O
validate	O
preliminary	O
conclusions	O
concerning	O
the	O
relative	O
importance	O
of	O
different	O
routes	O
of	O
transmission	O
with	O
important	O
implications	O
for	O
infection	B-DISO
control	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
novel	O
infectious	B-DISO
disease	I-DISO
with	O
disastrous	O
clinical	O
consequences	O
,	O
in	O
which	O
the	O
lungs	O
are	O
the	O
major	O
target	O
organs	O
.	O

We	O
found	O
that	O
SARS	B-DISO
-	O
CoV	O
was	O
present	O
in	O
bronchial	O
epithelium	O
,	O
type	O
I	O
and	O
II	O
pneumocytes	O
,	O
T	O
lymphocytes	O
,	O
and	O
macrophages	O
/	O
monocytes	O
.	O

From	O
each	O
calf	O
,	O
a	O
paired	O
blood	O
sample	O
was	O
obtained	O
for	O
serological	O
studies	O
of	O
bovine	O
parainfluenza	B-DISO
virus	O
-	O
3	O
,	O
bovine	O
respiratory	O
syncytial	O
virus	O
,	O
bovine	O
coronavirus	O
,	O
bovine	O
adenovirus	B-DISO
-	O
3	O
and	O
bovine	O
adenovirus	B-DISO
-	O
7	O
.	O

International	O
collaboration	O
by	O
teams	O
of	O
epidemiologists	O
as	O
well	O
as	O
virologists	O
was	O
the	O
key	O
to	O
success	O
against	O
SARS	B-DISO
(	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
).	O

SARS	B-DISO
provided	O
a	O
good	O
""""	O
dress	O
rehearsal	O
""""	O
and	O
educated	O
the	O
public	O
authorities	O
about	O
the	O
issues	O
of	O
infectious	B-DISO
pandemics	O
.	O

Human	O
bocavirus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
and	O
Legionella	O
,	O
Mycoplasma	B-DISO
,	O
and	O
Chlamydophila	O
species	O
were	O
absent	O
or	O
appeared	O
at	O
frequencies	O
of	O
<	O
1	O
%.	O

In	O
2003	O
outbreaks	O
included	O
monkeypox	B-DISO
,	O
SARS	B-DISO
and	O
avian	B-DISO
influenza	I-DISO
.	O

Most	O
commercial	O
mAbs	O
studied	O
as	O
antiviral	O
agents	O
in	O
the	O
clinic	O
have	O
either	O
directly	O
or	O
indirectly	O
targeted	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
,	O
respiratory	O
syncytial	O
virus	O
,	O
or	O
hepatitis	B-DISO
C	I-DISO
virus	O
infections	B-DISO
.	O

Public	O
sector	O
research	O
into	O
the	O
use	O
of	O
mAbs	O
against	O
emerging	O
pathogens	O
,	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
,	O
may	O
have	O
already	O
provided	O
candidates	O
for	O
further	O
development	O
.	O

Numerous	O
studies	O
have	O
reported	O
the	O
therapeutic	O
potential	O
of	O
RNA	O
interference	O
for	O
the	O
treatment	O
of	O
various	O
human	O
diseases	O
ranging	O
from	O
cancers	B-DISO
to	O
infectious	B-DISO
diseases	I-DISO
such	O
as	O
HIV	B-DISO
and	O
hepatitis	B-DISO
.	O

One	O
study	O
using	O
siRNAs	O
to	O
inhibit	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
in	O
Rhesus	O
macaques	O
demonstrated	O
that	O
siRNAs	O
were	O
effective	O
both	O
prophylactically	O
and	O
therapeutically	O
with	O
no	O
adverse	B-DISO
effects	I-DISO
in	O
the	O
animals	O
.	O

Challenges	O
remaining	O
for	O
the	O
application	O
of	O
siRNA	O
in	O
vivo	O
for	O
SARS	B-DISO
prevention	O
and	O
treatment	O
include	O
the	O
specificity	O
of	O
the	O
siRNAs	O
and	O
the	O
efficiency	O
of	O
delivery	O
.	O

However	O
,	O
with	O
improvements	O
in	O
siRNA	O
design	O
and	O
delivery	O
methods	O
,	O
RNA	O
interference	O
has	O
the	O
potential	O
to	O
become	O
another	O
major	O
weapon	O
for	O
combating	O
dangerous	O
infections	B-DISO
due	O
to	O
viruses	O
such	O
as	O
SARS	B-DISO
-	O
CoV	O
.	O

The	O
approach	O
developed	O
in	O
this	O
study	O
and	O
the	O
findings	O
thus	O
obtained	O
might	O
stimulate	O
new	O
strategies	O
and	O
provide	O
useful	O
information	O
for	O
drug	O
design	O
against	O
SARS	B-DISO
.	O

We	O
describe	O
three	O
cases	O
of	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
with	O
sepsis	B-DISO
,	O
shock	O
and	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
in	O
patients	O
with	O
severe	O
liver	B-DISO
failure	I-DISO
among	O
whom	O
two	O
had	O
positive	O
Aspergillus	O
antigenemia	O
and	O
one	O
had	O
a	O
positive	O
Aspergillus	O
serology	O
.	O

PKC	B-DISO
epsilon	O
-	O
specific	O
siRNA	O
also	O
attenuated	O
the	O
phosphorylation	O
of	O
JNK	O
.	O

These	O
HIV	B-DISO
-	O
1	O
-	O
capturing	O
nanospheres	O
and	O
protein	O
-	O
loaded	O
gamma	O
-	O
PGA	B-DISO
nanoparticles	O
have	O
shown	O
unique	O
potential	O
as	O
vaccine	O
carriers	O
.	O

ABSTRACT	O
:	O
This	O
paper	O
helps	O
define	O
infrared	O
(	O
IR	O
)	O
imaging	O
as	O
a	O
complementary	O
tool	O
to	O
high	O
-	O
speed	O
computer	O
tomography	O
(	O
CT	O
)	O
in	O
the	O
diagnosis	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

The	O
impact	O
of	O
SARS	B-DISO
on	O
hospital	O
procedures	O
is	O
also	O
described	O
.	O

TITLE	O
:	O
Molecular	O
analysis	O
of	O
Brazilian	O
infectious	B-DISO
bronchitis	B-DISO
field	O
isolates	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
,	O
restriction	O
fragment	O
length	O
polymorphism	O
,	O
and	O
partial	O
sequencing	O
of	O
the	O
N	O
gene	O
.	O

By	O
phylogenetic	O
analysis	O
of	O
the	O
structural	O
proteins	O
,	O
the	O
spike	O
(	O
S	O
)	O
protein	O
was	O
found	O
to	O
cluster	O
with	O
feline	O
coronavirus	O
type	O
II	O
strain	O
79	O
-	O
1683	O
,	O
whereas	O
,	O
the	O
envelope	O
(	O
E	O
),	O
membrane	O
(	O
M	O
)	O
and	O
nucleocapsid	O
(	O
N	O
)	O
proteins	O
segregated	O
together	O
with	O
the	O
reference	O
strain	O
Purdue	O
of	O
transmissible	O
gastroenteritis	B-DISO
virus	O
of	O
swine	O
.	O

Infections	B-DISO
were	O
diagnosed	O
according	O
to	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
CDC	O
)	O
criteria	O
.	O

Sharing	O
the	O
""""	O
lessons	O
learned	O
""""	O
in	O
different	O
regions	O
during	O
a	O
SARS	B-DISO
outbreak	O
will	O
help	O
prepare	O
for	O
the	O
next	O
epidemic	O
.	O

Aged	O
BALB	O
/	O
c	O
mice	O
displayed	O
a	O
high	O
susceptibility	O
to	O
SARS	B-DISO
-	O
CoV	O
and	O
have	O
been	O
a	O
valuable	O
platform	O
for	O
evaluation	O
of	O
strategies	O
against	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

Thus	O
,	O
this	O
antibody	O
should	O
be	O
a	O
potential	O
candidate	O
for	O
treatment	O
of	O
elderly	O
patients	O
suffering	B-DISO
from	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
Long	O
pentraxin	O
3	O
(	O
PTX3	O
)	O
is	O
a	O
newly	O
discovered	O
acute	O
phase	O
protein	O
produced	O
at	O
the	O
sites	O
of	O
infection	B-DISO
and	O
inflammation	B-DISO
by	O
tissue	O
cells	O
,	O
macrophages	O
,	O
monocytes	O
,	O
and	O
dendritic	O
cells	O
.	O

PTX3	O
plays	O
an	O
important	O
role	O
in	O
preventing	O
infection	B-DISO
of	O
certain	O
fungi	O
,	O
bacteria	O
,	O
and	O
viruses	O
in	O
the	O
lung	O
.	O

These	O
studies	O
will	O
provide	O
insight	O
into	O
the	O
pathological	B-DISO
processes	I-DISO
of	O
pulmonary	B-DISO
infection	I-DISO
and	O
acute	O
lung	O
injury	O
and	O
provide	O
potential	O
novel	O
therapeutic	O
strategies	O
to	O
control	O
pulmonary	B-DISO
infections	I-DISO
without	O
severe	O
lung	O
injury	O
.	O

Nasal	B-DISO
discharge	I-DISO
was	O
collected	O
from	O
24	O
patients	O
with	O
PVOD	B-DISO
.	O

We	O
investigated	O
the	O
presence	O
of	O
10	O
viruses	O
in	O
nasal	B-DISO
discharge	I-DISO
and	O
examined	O
the	O
time	O
course	O
,	O
with	O
regard	O
to	O
changes	O
in	O
olfactory	O
dysfunction	O
and	O
nasal	O
obstruction	B-DISO
in	O
patients	O
with	O
PVOD	B-DISO
,	O
using	O
questionnaires	O
,	O
acoustic	O
rhinometry	O
,	O
and	O
olfactory	O
tests	O
.	O

These	O
results	O
indicated	O
that	O
M	O
.	O
fermentans	O
enhances	O
apoptosis	O
in	O
surviving	O
cells	O
that	O
have	O
escaped	O
from	O
SARS	B-DISO
-	O
CoV	O
-	O
induced	O
apoptosis	O
.	O

Bats	O
have	O
been	O
identified	O
as	O
the	O
reservoir	O
hosts	O
of	O
newly	O
emergent	O
viruses	O
such	O
as	O
Nipah	O
virus	O
,	O
Hendra	O
virus	O
,	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
like	O
coronaviruses	O
.	O

Family	O
physicians	O
appear	O
to	O
be	O
unprepared	O
for	O
,	O
but	O
willing	O
to	O
address	O
,	O
serious	O
public	O
health	O
emergencies	B-DISO
.	O

ABSTRACT	O
:	O
This	O
paper	O
introduces	O
our	O
work	O
on	O
how	O
to	O
use	O
image	O
mining	O
techniques	O
to	O
detect	O
SARS	B-DISO
,	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
automatically	O
as	O
the	O
prototype	O
of	O
computer	O
aided	O
detection	O
/	O
diagnosis	O
(	O
CAD	B-DISO
)	O
system	O
.	O

The	O
etiologic	O
agent	O
of	O
this	O
disease	O
was	O
found	O
to	O
be	O
a	O
previously	O
unknown	O
coronavirus	O
,	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
detailed	O
pathology	B-DISO
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
and	O
the	O
host	O
response	O
to	O
the	O
viral	B-DISO
infection	I-DISO
are	O
still	O
not	O
known	O
.	O

Our	O
data	O
show	O
that	O
over	O
-	O
expression	O
of	O
a	O
single	O
SARS	B-DISO
-	O
CoV	O
protein	O
can	O
induce	O
apoptosis	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
ICU	O
nurses	O
who	O
are	O
involved	O
in	O
pandemic	O
planning	O
must	O
advocate	O
for	O
the	O
education	O
and	O
training	O
they	O
need	O
to	O
assume	O
clinical	O
leadership	O
roles	O
in	O
emergency	B-DISO
situations	O
such	O
as	O
an	O
infectious	B-DISO
disease	I-DISO
outbreak	O
.	O

Our	O
results	O
suggest	O
that	O
RNAi	O
might	O
be	O
a	O
promising	O
new	O
strategy	O
against	O
TGEV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Severe	O
immunosuppression	O
is	O
a	O
hallmark	O
of	O
Morbillivirus	B-DISO
infections	I-DISO
.	O

TITLE	O
:	O
[	O
The	O
prone	O
position	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
a	O
critical	O
systematic	O
review	O
].	O

Increased	O
levels	O
of	O
measured	O
molecules	O
(	O
TGF	O
-	O
beta1	O
,	O
p	O
<	O
0	O
.	O
02	O
,	O
sE	O
-	O
Selectin	O
,	O
p	O
<	O
0	O
.	O
02	O
,	O
sL	O
-	O
Selectin	O
,	O
p	O
=	O
0	O
.	O
06	O
,	O
sICAM	O
-	O
1	O
,	O
p	O
<	O
0	O
.	O
03	O
)	O
were	O
demonstrated	O
among	O
survivors	O
in	O
the	O
sepsis	B-DISO
and	O
ARDS	B-DISO
groups	O
of	O
patients	O
and	O
were	O
positively	O
correlated	O
with	O
length	O
of	O
stay	O
(	O
p	O
<	O
0	O
.	O
04	O
)	O
and	O
mechanical	O
ventilation	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
its	O
presentation	O
with	O
more	O
severe	O
hypoxemia	O
,	O
the	O
ARDS	B-DISO
,	O
is	O
a	O
challenging	O
entity	O
for	O
clinical	O
investigation	O
because	O
,	O
like	O
many	O
critical	B-DISO
illness	I-DISO
syndromes	B-DISO
,	O
it	O
lacks	O
an	O
accepted	O
diagnostic	O
test	O
and	O
relies	O
on	O
a	O
constellation	O
of	O
clinical	B-DISO
findings	I-DISO
for	O
diagnosis	O
.	O

The	O
most	O
common	O
symptoms	O
/	O
signs	O
of	O
HCoV	O
-	O
NL63	O
infection	B-DISO
were	O
cough	B-DISO
,	O
fever	O
,	O
and	O
inspiratory	B-DISO
stridor	I-DISO
.	O

METHODS	O
:	O
We	O
developed	O
a	O
mathematical	O
model	O
to	O
investigate	O
the	O
effects	O
of	O
hospital	O
admission	O
and	O
targeted	O
antibody	O
prophylaxis	O
on	O
the	O
reproduction	O
number	O
R	O
,	O
defined	O
as	O
the	O
number	O
of	O
secondary	O
cases	O
generated	O
by	O
an	O
index	O
case	O
,	O
during	O
different	O
SARS	B-DISO
outbreak	O
scenarios	O
.	O

He	O
developed	O
severe	O
airway	B-DISO
obstruction	I-DISO
in	O
the	O
early	O
postoperative	O
period	O
.	O

The	O
anesthetic	O
difficulties	O
that	O
arise	O
in	O
these	O
cases	O
include	O
acute	O
airway	O
occlusion	B-DISO
,	O
superior	B-DISO
vena	I-DISO
cava	I-DISO
syndrome	I-DISO
,	O
pulmonary	O
artery	O
or	O
cardiac	O
compression	O
,	O
acute	B-DISO
pulmonary	I-DISO
edema	I-DISO
,	O
and	O
cardiopulmonary	O
collapse	B-DISO
.	O

TITLE	O
:	O
[	O
Construction	O
of	O
genomic	O
full	O
-	O
length	O
cDNA	O
of	O
SARS	B-DISO
coronavirus	O
BJ01	O
strain	O
and	O
identification	O
of	O
its	O
biological	O
characteristics	O
].	O

Antiviral	O
activity	O
was	O
analysed	O
by	O
determining	O
infective	O
virus	O
titres	O
by	O
TCID50	O
,	O
viral	O
RNA	O
synthesis	O
by	O
Northern	O
blot	O
analysis	O
and	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
,	O
and	O
viral	O
protein	O
synthesis	O
by	O
SDS	B-DISO
-	O
PAGE	O
analysis	O
after	O
35S	O
-	O
methionine	O
-	O
labelling	O
.	O

The	O
results	O
identify	O
INDO	O
as	O
a	O
potent	O
inhibitor	O
of	O
coronavirus	O
replication	O
and	O
suggest	O
that	O
,	O
having	O
both	O
anti	O
-	O
inflammatory	O
and	O
antiviral	O
activity	O
,	O
INDO	O
could	O
be	O
beneficial	O
in	O
SARS	B-DISO
therapy	O
.	O

TITLE	O
:	O
The	O
SARS	B-DISO
-	O
Coronavirus	O
Membrane	O
protein	O
induces	O
apoptosis	O
through	O
modulating	O
the	O
Akt	O
survival	O
pathway	O
.	O

In	O
order	O
to	O
develop	O
an	O
evidence	O
-	O
based	O
plan	B-DISO
for	O
ED	O
and	O
hospital	O
management	O
of	O
contaminated	O
patients	O
,	O
a	O
review	O
was	O
conducted	O
of	O
the	O
most	O
effective	O
strategies	O
developed	O
during	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
epidemic	O
,	O
as	O
well	O
as	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
and	O
military	O
guidelines	O
on	O
biowarfare	O
.	O

The	O
daily	O
meteorological	O
data	O
and	O
daily	O
air	O
pollution	O
data	O
during	O
the	O
same	O
SARS	B-DISO
outbreak	O
period	O
in	O
mainland	O
China	O
were	O
used	O
in	O
the	O
data	O
analysis	O
.	O

In	O
univariate	O
analyses	O
,	O
daily	O
average	O
temperature	O
(	O
DAT	O
),	O
daily	O
average	O
air	O
pressure	O
(	O
DAAP	O
),	O
and	O
daily	O
average	O
relative	O
humidity	O
(	O
DARH	O
)	O
were	O
inversely	O
associated	O
with	O
secondary	O
attack	O
rate	O
(	O
P	O
<	O
0	O
.	O
001	O
);	O
a	O
significant	O
positive	O
association	O
was	O
found	O
for	O
daily	O
hours	O
of	O
sunshine	O
(	O
DHS	B-DISO
)	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

ABSTRACT	O
:	O
Detection	O
of	O
a	O
broad	O
number	O
of	O
respiratory	O
viruses	O
is	O
not	O
undertaken	O
currently	O
for	O
the	O
diagnosis	O
of	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
due	O
to	O
the	O
large	O
and	O
always	O
increasing	O
list	O
of	O
pathogens	O
involved	O
.	O

HMPV	O
infected	O
children	O
below	O
3	O
years	O
in	O
two	O
peaks	O
in	O
March	O
and	O
June	O
causing	O
bronchiolitis	B-DISO
and	O
pneumonia	B-DISO
.	O

ABSTRACT	O
:	O
In	O
the	O
period	O
1991	O
-	O
2005	O
,	O
169	O
patients	O
with	O
the	O
diagnosis	O
of	O
malaria	B-DISO
were	O
hospitalized	O
in	O
the	O
Department	O
of	O
Tropical	O
and	O
Parasitic	B-DISO
Diseases	I-DISO
,	O
Institute	O
of	O
Maritime	O
and	O
Tropical	O
Medicine	O
in	O
Gdynia	O
(	O
from	O
2003	O
--	O
the	O
Academic	O
Centre	O
of	O
Maritime	O
and	O
Tropical	O
Medicine	O
,	O
Medical	O
University	O
of	O
Gdańsk	O
).	O

Moreover	O
,	O
meningoencephalitis	B-DISO
was	O
diagnosed	O
in	O
two	O
patients	O
--	O
in	O
one	O
of	O
them	O
concurrently	O
with	O
symptoms	B-DISO
and	I-DISO
signs	I-DISO
of	O
malaria	B-DISO
,	O
while	O
in	O
the	O
other	O
one	O
-	O
3	O
weeks	O
after	O
the	O
symptoms	O
subsided	O
.	O

TITLE	O
:	O
Reviewing	O
lessons	O
learnt	O
of	O
SARS	B-DISO
in	O
Singapore	O
during	O
planning	O
for	O
influenza	B-DISO
pandemic	O
.	O

ABSTRACT	O
:	O
To	O
survey	O
the	O
dynamic	O
changing	O
and	O
persistence	O
of	O
the	O
special	O
antibodies	O
,	O
including	O
total	O
IgM	O
,	O
IgG	O
,	O
nucleocapsid	O
protein	O
and	O
spike	O
protein	O
antibodies	O
,	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
in	O
patients	O
with	O
SARS	B-DISO
.	O

146	O
cases	O
,	O
all	O
clinically	O
diagnosed	O
as	O
SARS	B-DISO
with	O
positive	O
SARS	B-DISO
-	O
CoV	O
IgG	O
,	O
were	O
followed	O
up	O
.	O

Fifty	O
percent	O
or	O
more	O
of	O
the	O
cats	O
sampled	O
were	O
seropositive	O
for	O
feline	O
herpesvirus	O
(	O
22	O
of	O
30	O
),	O
feline	B-DISO
panleukopenia	I-DISO
(	O
15	O
of	O
30	O
),	O
and	O
T	O
.	O
gondii	O
(	O
16	O
of	O
30	O
).	O

Data	O
of	O
SARS	B-DISO
cases	O
were	O
officially	O
reported	O
by	O
Beijing	O
Municipal	O
Center	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
BCDC	O
)	O
and	O
Anhui	O
Provincial	O
Center	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
APCDC	O
)	O
and	O
results	O
of	O
epidemiological	O
investigations	O
were	O
collected	O
and	O
analyzed	O
.	O

(	O
2	O
)	O
Management	O
systems	O
of	O
occupational	O
exposure	O
to	O
virus	O
and	O
disease	O
surveillance	O
need	O
to	O
be	O
strengthened	O
to	O
take	O
all	O
risk	O
factors	O
into	O
account	O
so	O
as	O
to	O
detect	O
potential	O
patients	O
with	O
infectious	B-DISO
disease	I-DISO
as	O
early	O
as	O
possible	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
thrombotic	O
risk	O
,	O
assessed	O
by	O
platelet	O
aggregation	O
and	O
aspirin	O
non	O
-	O
responsiveness	O
,	O
in	O
patients	O
with	O
an	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
complicated	O
by	O
an	O
infection	B-DISO
.	O

Aspirin	O
non	O
-	O
responsiveness	O
was	O
more	O
frequent	O
in	O
the	O
group	O
of	O
subjects	O
with	O
pneumonia	B-DISO
compared	O
with	O
those	O
without	O
an	O
infection	B-DISO
,	O
90	O
%	O
vs	O
.	O
46	O
%	O
(	O
P	O
=	O
0	O
.	O
006	O
).	O

China	O
has	O
the	O
world	O
'	O
s	O
second	O
largest	O
tuberculosis	B-DISO
epidemic	O
,	O
but	O
progress	O
in	O
tuberculosis	B-DISO
control	O
was	O
slow	O
during	O
the	O
1990s	O
.	O

After	O
the	O
SARS	B-DISO
epidemic	O
was	O
brought	O
under	O
control	O
,	O
the	O
government	O
increased	O
its	O
commitment	O
and	O
leadership	O
to	O
tackle	O
public	O
-	O
health	O
problems	O
and	O
,	O
among	O
other	O
efforts	O
,	O
increased	O
public	O
-	O
health	O
funding	O
,	O
revised	O
laws	O
that	O
concerned	O
the	O
control	O
of	O
infectious	B-DISO
diseases	I-DISO
,	O
implemented	O
the	O
world	O
'	O
s	O
largest	O
internet	O
-	O
based	O
disease	O
reporting	O
system	O
,	O
and	O
started	O
a	O
programme	O
to	O
rebuild	O
local	O
public	O
-	O
health	O
facilities	O
.	O

These	O
measures	O
contributed	O
to	O
acceleration	O
in	O
efforts	O
to	O
control	O
tuberculosis	B-DISO
.	O

An	O
additional	O
threat	O
to	O
the	O
conservation	O
of	O
maned	O
wolves	O
is	O
the	O
risk	O
of	O
morbidity	O
and	O
mortality	O
due	O
to	O
infectious	B-DISO
and	I-DISO
parasitic	I-DISO
diseases	I-DISO
.	O

Alfacell	O
expanded	O
a	O
research	O
agreement	O
with	O
the	O
National	O
Cancer	B-DISO
Institute	O
in	O
September	O
2002	O
,	O
allowing	O
the	O
NCI	O
to	O
examine	O
the	O
effects	O
of	O
ranpirnase	O
as	O
a	O
radiation	O
enhancer	O
.	O

The	O
targeted	O
treatment	O
group	O
in	O
this	O
trial	O
represents	O
90	O
%	O
of	O
malignant	B-DISO
mesothelioma	I-DISO
patients	O
at	O
the	O
time	O
of	O
diagnosis	O
.	O

Inhibition	O
of	O
iNOS	O
is	O
effective	O
in	O
mitigating	O
the	O
endotoxaemic	O
changes	O
and	O
lung	O
pathology	B-DISO
.	O

ABSTRACT	O
:	O
Because	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
in	O
Taiwan	O
in	O
2003	O
was	O
worsened	O
by	O
hospital	B-DISO
infections	I-DISO
,	O
we	O
analyzed	O
229	O
questionnaires	O
(	O
84	O
.	O
8	O
%	O
of	O
270	O
sent	O
)	O
completed	O
by	O
surveyed	O
healthcare	O
workers	O
who	O
cared	O
for	O
patients	O
with	O
SARS	B-DISO
in	O
3	O
types	O
of	O
hospitals	O
,	O
to	O
identify	O
surveillance	O
problems	O
.	O

ABSTRACT	O
:	O
Bats	O
have	O
been	O
identified	O
as	O
a	O
natural	O
reservoir	O
for	O
an	O
increasing	O
number	O
of	O
emerging	O
zoonotic	O
viruses	O
,	O
including	O
henipaviruses	O
and	O
variants	O
of	O
rabies	B-DISO
viruses	O
.	O

Recently	O
,	O
we	O
and	O
another	O
group	O
independently	O
identified	O
several	O
horseshoe	O
bat	O
species	O
(	O
genus	O
Rhinolophus	O
)	O
as	O
the	O
reservoir	O
host	O
for	O
a	O
large	O
number	O
of	O
viruses	O
that	O
have	O
a	O
close	O
genetic	O
relationship	O
with	O
the	O
coronavirus	O
associated	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Toronto	O
HCWs	O
reported	O
significantly	O
higher	O
levels	O
of	O
burnout	O
(	O
p	O
=	O
0	O
.	O
019	O
),	O
psychological	B-DISO
distress	I-DISO
(	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
posttraumatic	O
stress	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

This	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
exploited	O
opportunities	O
provided	O
by	O
'	O
wet	O
markets	O
'	O
in	O
southern	O
China	O
to	O
adapt	O
to	O
the	O
palm	O
civet	O
and	O
human	O
.	O

Significantly	O
,	O
most	O
of	O
the	O
second	O
site	O
changes	O
in	O
the	O
R227E	O
mutant	B-DISO
viruses	O
were	O
previously	O
shown	O
to	O
compensate	O
for	O
the	O
removal	O
of	O
negative	O
charges	O
in	O
the	O
N	O
protein	O
.	O

Myt1	O
expressing	O
cells	O
proliferated	O
most	O
extensively	O
during	O
active	O
demyelination	B-DISO
and	O
subsequently	O
accumulated	O
to	O
maximal	O
levels	O
during	O
early	O
remyelination	O
.	O

These	O
results	O
suggesta	O
potential	O
role	O
for	O
Myt1	O
in	O
the	O
regeneration	O
of	O
oligodendrocyte	O
lineage	O
cells	O
in	O
response	O
to	O
demyelination	B-DISO
.	O

This	O
is	O
the	O
first	O
description	O
of	O
respiratory	B-DISO
tract	I-DISO
infection	I-DISO
with	O
coronavirus	O
in	O
HIV	B-DISO
patients	O
.	O

TITLE	O
:	O
Heterologous	O
viral	O
RNA	O
export	O
elements	O
improve	O
expression	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
spike	O
protein	O
and	O
protective	O
efficacy	O
of	O
DNA	O
vaccines	O
against	O
SARS	B-DISO
.	O

The	O
presence	O
of	O
both	O
splice	O
sites	O
and	O
WPRE	O
markedly	O
improved	O
the	O
immunogenicity	O
of	O
S	O
-	O
based	O
DNA	O
vaccines	O
against	O
SARS	B-DISO
.	O

Upon	O
immunization	O
of	O
mice	O
with	O
low	O
doses	O
(	O
2	O
microg	O
)	O
of	O
naked	O
DNA	O
,	O
only	O
intron	O
and	O
WPRE	O
-	O
containing	O
vectors	O
could	O
induce	O
neutralizing	O
anti	O
-	O
S	O
antibodies	O
and	O
provide	O
protection	O
against	O
challenge	O
with	O
SARS	B-DISO
-	O
CoV	O
.	O
Our	O
observations	O
are	O
likely	O
to	O
be	O
useful	O
for	O
the	O
construction	O
of	O
plasmid	O
and	O
viral	O
vectors	O
designed	O
for	O
optimal	O
expression	O
of	O
intronless	O
genes	O
derived	O
from	O
cytoplasmic	O
RNA	O
viruses	O
.	O

TITLE	O
:	O
[	O
Further	O
analysis	O
and	O
study	O
based	O
on	O
a	O
visualized	O
method	O
for	O
SARS	B-DISO
RNA	O
sequences	O
].	O

TITLE	O
:	O
Factors	O
predicting	O
nurses	O
'	O
consideration	O
of	O
leaving	O
their	O
job	O
during	O
the	O
SARS	B-DISO
outbreak	O
.	O

Twenty	O
-	O
one	O
nurses	O
who	O
had	O
taken	O
care	O
of	O
SARS	B-DISO
patients	O
were	O
interviewed	O
in	O
focus	O
groups	O
.	O

In	O
order	O
to	O
verify	O
the	O
pathogenic	O
role	O
of	O
these	O
purified	O
antibodies	O
,	O
we	O
injected	O
patient	O
IgG	O
intrathecally	O
into	O
cisterna	O
magna	O
of	O
C57BL	O
/	O
6	O
mice	O
pre	O
-	O
implanted	O
with	O
EEG	O
electrodes	O
and	O
we	O
observed	O
severe	O
ataxia	B-DISO
followed	O
by	O
breathing	O
depression	B-DISO
and	O
total	O
suppression	B-DISO
of	O
slow	O
wave	O
sleep	O
,	O
as	O
evidenced	O
by	O
EEG	O
recording	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

RESULTS	O
:	O
During	O
the	O
SARS	B-DISO
outbreak	O
in	O
2003	O
,	O
ED	O
visits	O
declined	O
by	O
21	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
18	O
%-	O
24	O
%)	O
over	O
the	O
4	O
-	O
week	O
study	O
period	O
.	O

TITLE	O
:	O
Does	O
the	O
implementation	O
of	O
radiation	O
oncology	O
outpatient	O
infection	B-DISO
control	O
measures	O
adversely	O
affect	O
patient	O
satisfaction	O
with	O
doctor	O
-	O
patient	O
interaction	O
?	O

There	O
are	O
worldwide	O
concerns	O
of	O
an	O
impending	O
avian	B-DISO
influenza	I-DISO
outbreak	O
,	O
with	O
nations	O
formulating	O
infection	B-DISO
control	O
strategies	O
to	O
prepare	O
for	O
such	O
an	O
event	O
.	O

At	O
T1	O
more	O
patients	O
indicated	O
satisfaction	O
for	O
understanding	O
the	O
doctor	O
'	O
s	O
plans	O
(	O
p	O
-	O
value	O
is	O
0	O
.	O
001	O
),	O
while	O
at	O
T2	O
,	O
more	O
patients	O
indicated	O
satisfaction	O
for	O
being	O
told	O
how	O
to	O
care	O
for	O
their	O
condition	B-DISO
(	O
p	O
-	O
value	O
is	O
0	O
.	O
04	O
).	O

This	O
is	O
the	O
first	O
report	O
of	O
the	O
isolation	O
and	O
detailed	O
genetic	O
,	O
biologic	O
,	O
and	O
antigenic	O
characterization	O
of	O
a	O
bovine	O
-	O
like	O
CoV	O
from	O
a	O
giraffe	O
(	O
Giraffa	O
camelopardalis	O
)	O
in	O
a	O
wild	O
-	O
animal	O
park	B-DISO
in	O
the	O
United	O
States	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
accessory	O
protein	O
6	O
is	O
a	O
virion	O
-	O
associated	O
protein	O
and	O
is	O
released	O
from	O
6	O
protein	O
-	O
expressing	O
cells	O
.	O

We	O
have	O
used	O
several	O
strains	O
of	O
murine	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
in	O
cell	O
culture	O
and	O
in	O
vivo	O
in	O
mouse	O
models	O
to	O
investigate	O
the	O
antiviral	O
characteristics	O
of	O
peptide	O
-	O
conjugated	O
antisense	O
phosphorodiamidate	O
morpholino	O
oligomers	O
(	O
P	O
-	O
PMOs	O
).	O

TITLE	O
:	O
Recent	O
developments	O
in	O
the	O
virology	O
and	O
antiviral	O
research	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

The	O
outbreak	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
the	O
danger	O
of	O
its	O
re	O
-	O
introduction	O
into	O
the	O
human	O
population	O
,	O
as	O
well	O
as	O
the	O
danger	O
of	O
the	O
emergence	O
of	O
other	O
zoonotic	O
coronaviral	O
infections	B-DISO
triggered	O
an	O
intense	O
survey	O
for	O
an	O
efficient	O
treatment	O
that	O
resulted	O
in	O
the	O
evaluation	O
of	O
several	O
anticoronaviral	O
compounds	O
.	O

TITLE	O
:	O
Reliability	O
of	O
soiled	O
bedding	O
transfer	O
for	O
detection	O
of	O
mouse	O
parvovirus	B-DISO
and	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
and	O
sepsis	B-DISO
.	O

Ongoing	O
refinements	O
in	O
circuit	O
technology	O
and	O
widening	O
global	O
experience	O
have	O
led	O
to	O
ECMO	O
being	O
applied	O
to	O
a	O
broader	O
group	O
of	O
conditions	O
than	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
and	O
cardiogenic	B-DISO
shock	I-DISO
.	O

Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
bacterial	B-DISO
pneumonia	I-DISO
are	O
the	O
most	O
common	O
conditions	O
in	O
sepsis	B-DISO
that	O
may	O
require	O
ECMO	O
,	O
although	O
septic	B-DISO
shock	I-DISO
with	O
refractory	O
hypotension	O
may	O
also	O
be	O
an	O
indication	O
under	O
certain	O
circumstances	O
.	O

This	O
review	O
describes	O
the	O
basic	O
technique	O
and	O
application	O
of	O
ECMO	O
in	O
neonates	O
,	O
older	O
children	O
,	O
and	O
adults	O
with	O
sepsis	B-DISO
.	O

All	O
women	O
who	O
intend	O
to	O
become	O
pregnant	O
or	O
are	O
pregnant	O
should	O
receive	O
the	O
influenza	B-DISO
vaccine	O
.	O

If	O
a	O
pregnant	O
woman	O
develops	O
influenza	B-DISO
she	O
should	O
be	O
treated	O
with	O
supportive	O
care	O
.	O

Avian	B-DISO
influenza	I-DISO
(	O
H5N1	B-DISO
)	O
is	O
a	O
new	O
emerging	O
virus	O
usually	O
contracted	O
from	O
direct	O
contact	O
with	O
diseased	O
birds	O
.	O

The	O
treatment	O
of	O
pregnant	O
women	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
should	O
be	O
without	O
ribavirin	O
.	O

Long	O
-	O
term	O
exposure	O
of	O
HIV	B-DISO
to	O
CBAs	O
in	O
cell	O
culture	O
results	O
in	O
the	O
progressive	O
deletion	O
of	O
N	O
-	O
glycans	O
of	O
HIV	B-DISO
gpl20	O
in	O
an	O
attempt	O
of	O
the	O
virus	O
to	O
escape	O
drug	O
pressure	O
.	O

The	O
latter	O
phenomenon	O
will	O
result	O
in	O
creating	O
'	O
holes	O
'	O
in	O
the	O
protective	O
glycan	O
shield	O
of	O
the	O
HIV	B-DISO
envelope	O
,	O
whereby	O
the	O
immune	O
system	O
may	O
become	O
triggered	O
to	O
produce	O
neutralizing	O
antibodies	O
against	O
previously	O
hidden	O
immunogenic	O
epitopes	O
of	O
gp120	O
.	O

In	O
pulmonary	B-DISO
fibrosis	I-DISO
and	O
in	O
the	O
postinjury	O
phase	O
of	O
acute	O
lung	O
injury	O
,	O
the	O
angiogenic	O
/	O
angiostatic	O
balance	O
is	O
also	O
affected	O
.	O

The	O
computed	O
tomography	O
severe	O
index	O
(	O
CTSI	O
)	O
was	O
used	O
to	O
assess	O
the	O
severity	O
of	O
the	O
pancreatitis	B-DISO
.	O

The	O
development	O
of	O
consolidation	O
during	O
the	O
course	O
of	O
the	O
disease	O
correlated	O
with	O
the	O
occurrence	O
of	O
respiratory	B-DISO
failure	I-DISO
(	O
P	O
=	O
0	O
.	O
068	O
)	O
but	O
not	O
with	O
mortality	O
(	O
P	O
=	O
0	O
.	O
193	O
).	O

Similarly	O
,	O
the	O
onset	O
of	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
also	O
correlated	O
with	O
respiratory	B-DISO
failure	I-DISO
(	O
P	O
<	O
0	O
.	O
001	O
)	O
but	O
,	O
unlike	O
consolidation	O
,	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
correlated	O
with	O
mortality	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

At	O
presentation	O
,	O
the	O
presence	O
of	O
pleural	B-DISO
effusion	I-DISO
but	O
not	O
atelectasis	B-DISO
and	O
consolidation	O
correlates	O
with	O
the	O
development	O
of	O
respiratory	B-DISO
failure	I-DISO
and	O
mortality	O
.	O

RESULTS	O
:	O
The	O
mean	O
age	O
was	O
42	O
.	O
9	O
+/-	O
15	O
.	O
9	O
years	O
(	O
range	O
:	O
18	O
-	O
80	O
years	O
)	O
and	O
the	O
etiology	O
of	O
the	O
pancreatitis	B-DISO
was	O
gallstones	B-DISO
in	O
29	O
patients	O
,	O
alcohol	O
in	O
22	O
patients	O
while	O
no	O
cause	O
could	O
be	O
ascertained	O
in	O
9	O
.	O

Multivariate	O
analyses	O
indicated	O
that	O
factors	O
related	O
to	O
age	O
,	O
full	O
-	O
time	O
employment	O
,	O
perceived	O
susceptibility	O
,	O
perceived	O
efficacy	O
of	O
preventive	O
measures	O
,	O
perceived	O
higher	O
fatality	O
as	O
compared	O
to	O
SARS	B-DISO
,	O
perceived	O
chance	O
of	O
a	O
major	O
local	O
outbreak	O
,	O
and	O
being	O
worried	O
about	O
self	O
/	O
family	O
members	O
contracting	O
the	O
virus	O
were	O
significantly	O
associated	O
with	O
the	O
inclination	O
to	O
adopt	O
self	O
-	O
protective	O
measures	O
.	O

RESULTS	O
:	O
The	O
public	O
in	O
Hong	O
Kong	O
is	O
likely	O
to	O
adopt	O
self	O
-	O
protective	O
behaviors	O
(	O
e	O
.	O
g	O
.,	O
wearing	O
face	B-DISO
mask	O
in	O
public	O
venues	O
(	O
73	O
.	O
8	O
%),	O
increasing	O
the	O
frequency	O
of	O
handwashing	O
(	O
86	O
.	O
7	O
%))	O
and	O
behaviors	O
that	O
protect	O
others	O
(	O
e	O
.	O
g	O
.,	O
wearing	O
face	B-DISO
masks	O
when	O
experiencing	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
(	O
ILI	O
,	O
92	O
.	O
4	O
%),	O
immediately	O
seeking	O
medical	O
consultation	O
(	O
94	O
.	O
2	O
%),	O
making	O
declarations	O
when	O
crossing	O
the	O
border	O
with	O
ILI	O
(	O
87	O
.	O
1	O
%),	O
complying	O
to	O
quarantine	O
policies	O
(	O
88	O
.	O
3	O
%)).	O

CONCLUSIONS	O
:	O
In	O
the	O
event	O
of	O
a	O
human	O
-	O
to	O
-	O
human	O
H5N1	B-DISO
outbreak	O
,	O
the	O
public	O
in	O
Hong	O
Kong	O
is	O
likely	O
to	O
adopt	O
preventive	O
measures	O
that	O
may	O
help	O
contain	O
the	O
spread	O
of	O
the	O
virus	O
in	O
the	O
community	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
newly	O
emergent	O
human	O
disease	O
,	O
which	O
requires	O
rapid	O
diagnosis	O
and	O
effective	O
therapy	O
.	O

In	O
sequence	O
analysis	O
with	O
chicken	O
germline	O
gene	O
,	O
five	O
phage	O
clones	O
reacted	O
,	O
with	O
large	O
dissimilarities	O
of	O
between	O
31	O
and	O
62	O
%,	O
in	O
the	O
complementarity	O
-	O
determining	O
regions	O
,	O
one	O
dominant	O
phage	O
4S1	O
had	O
strong	O
binding	O
to	O
fragment	O
Se	O
-	O
e	O
,	O
located	O
between	O
amino	O
acid	O
residues	O
456	O
-	O
650	O
of	O
the	O
spike	O
protein	O
and	O
this	O
particular	O
phage	O
had	O
significantly	O
strong	O
binding	O
to	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	O
.	O

The	O
authors	O
discuss	O
possible	O
mechanisms	O
of	O
ALI	O
development	O
by	O
multiple	O
defibrillation	O
shocks	B-DISO
.	O

To	O
date	O
,	O
its	O
effectiveness	O
in	O
cancer	B-DISO
clinical	O
trials	O
has	O
been	O
minimal	O
.	O

Thus	O
,	O
the	O
anti	O
-	O
cancer	B-DISO
utility	O
of	O
suppressing	O
Bcl	O
-	O
2	O
in	O
cancer	B-DISO
cells	O
is	O
limited	O
.	O

ABSTRACT	O
:	O
Attenuated	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
vaccines	O
are	O
available	O
but	O
the	O
relationship	O
between	O
sequence	O
and	O
virulence	O
is	O
not	O
clear	O
.	O

TITLE	O
:	O
Why	O
did	O
outbreaks	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
occur	O
in	O
some	O
hospital	O
wards	O
but	O
not	O
in	O
others	O
?	O

ABSTRACT	O
:	O
Most	O
documented	O
""""	O
superspreading	O
events	O
""""	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
occurred	O
in	O
hospitals	O
,	O
but	O
the	O
underlying	O
causes	O
remain	O
unclear	O
.	O

Case	O
wards	O
were	O
hospital	O
wards	O
in	O
which	O
superspreading	O
events	O
of	O
SARS	B-DISO
occurred	O
,	O
and	O
control	O
wards	O
were	O
wards	O
in	O
which	O
patients	O
with	O
SARS	B-DISO
were	O
admitted	O
,	O
but	O
no	O
subsequent	O
nosocomial	O
outbreaks	O
occurred	O
.	O

Our	O
results	O
revealed	O
that	O
factors	O
that	O
were	O
associated	O
with	O
the	O
ward	O
environment	O
and	O
administration	O
were	O
important	O
in	O
nosocomial	O
outbreaks	O
of	O
SARS	B-DISO
.	O

The	O
lessons	O
learned	O
from	O
this	O
study	O
remain	O
very	O
important	O
and	O
highly	O
relevant	O
to	O
the	O
daily	O
operation	O
of	O
hospital	O
wards	O
if	O
we	O
are	O
to	O
prevent	O
nosocomial	O
outbreaks	O
of	O
other	O
respiratory	B-DISO
infections	I-DISO
in	O
the	O
future	O
.	O

TITLE	O
:	O
Identification	O
of	O
mouse	B-DISO
hepatitis	I-DISO
coronavirus	O
A59	O
nucleocapsid	O
protein	O
phosphorylation	O
sites	O
.	O

TITLE	O
:	O
Computational	O
simulation	O
of	O
interactions	O
between	O
SARS	B-DISO
coronavirus	O
spike	O
mutants	O
and	O
host	O
species	O
-	O
specific	O
receptors	O
.	O

And	O
the	O
predictions	O
further	O
indicate	O
that	O
some	O
viral	O
prototypes	O
might	O
utilize	O
the	O
rat	O
ACE2	O
while	O
rats	O
might	O
serve	O
as	O
a	O
vector	O
or	O
reservoir	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O

Here	O
we	O
review	O
recent	O
advances	O
in	O
SARS	B-DISO
immunopathogenesis	O
research	O
and	O
present	O
a	O
summary	O
of	O
our	O
findings	O
regarding	O
host	O
responses	O
in	O
SARS	B-DISO
patients	O
.	O

TITLE	O
:	O
Inhaled	O
nitric	O
oxide	O
in	O
newborns	O
with	O
severe	O
hypoxic	B-DISO
respiratory	B-DISO
failure	I-DISO
.	O

Inhaled	O
nitric	O
oxide	O
(	O
iNO	O
)	O
is	O
currently	O
used	O
as	O
a	O
pulmonary	O
vasodilator	O
to	O
improve	O
oxygenation	O
in	O
neonates	O
with	O
severe	O
respiratory	B-DISO
failure	I-DISO
.	O

No	O
acute	O
complication	B-DISO
was	O
found	O
during	O
nitric	O
oxide	O
administration	O
.	O

Chronic	O
lung	B-DISO
diseases	I-DISO
,	O
delayed	B-DISO
development	I-DISO
and	O
severe	O
hearing	B-DISO
loss	I-DISO
in	O
long	O
-	O
term	O
follow	O
up	O
were	O
found	O
in	O
10	O
,	O
5	O
,	O
and	O
2	O
cases	O
,	O
respectively	O
.	O

TITLE	O
:	O
[	O
Aspiration	B-DISO
of	O
milk	O
in	O
healthy	O
infant	O
--	O
cause	O
of	O
acute	O
respiratory	B-DISO
arrest	I-DISO
?].	O

Furthermore	O
,	O
the	O
positively	O
charged	O
surface	O
area	O
is	O
larger	O
in	O
the	O
SARS	B-DISO
-	O
CoV	O
construct	O
than	O
in	O
the	O
IBV	O
.	O

This	O
paper	O
proposes	O
an	O
on	O
-	O
line	O
real	O
-	O
time	O
mechanism	O
,	O
named	O
EDICTS	O
,	O
for	O
emerging	O
/	O
notifiable	O
infectious	B-DISO
diseases	I-DISO
control	O
,	O
tracking	O
and	O
surveillance	O
.	O

Corticosteroids	O
were	O
introduced	O
in	O
the	O
treatment	O
of	O
severe	O
infection	B-DISO
as	O
early	O
as	O
in	O
the	O
1940s	O
.	O

Recently	O
,	O
a	O
link	O
between	O
septic	B-DISO
shock	I-DISO
and	O
adrenal	B-DISO
insufficiency	I-DISO
,	O
or	O
systemic	O
inflammation	B-DISO
-	O
induced	O
glucocorticoid	O
receptor	O
resistance	O
has	O
been	O
established	O
.	O

A	O
series	O
of	O
tetrapeptide	O
phthalhydrazide	O
ketones	O
,	O
pyridinyl	O
esters	O
,	O
and	O
their	O
analogs	O
have	O
been	O
designed	O
,	O
synthesized	O
,	O
and	O
evaluated	O
as	O
potential	O
SARS	B-DISO
3CLpro	O
inhibitors	O
.	O

TITLE	O
:	O
Adverse	O
events	O
associated	O
with	O
high	O
-	O
dose	O
ribavirin	O
:	O
evidence	O
from	O
the	O
Toronto	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
To	O
distinguish	O
adverse	O
events	O
related	O
to	O
ribavirin	O
therapy	O
from	O
those	O
attributable	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
and	O
to	O
determine	O
the	O
rate	O
of	O
potential	O
ribavirin	O
-	O
related	O
adverse	O
events	O
.	O

Ribavirin	O
should	O
not	O
be	O
used	O
empirically	O
for	O
the	O
treatment	O
of	O
viral	O
syndromes	B-DISO
of	O
unknown	O
origin	O
.	O

TITLE	O
:	O
TNF	O
-	O
alpha	O
,	O
produced	O
by	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
)-	O
infected	O
macrophages	O
,	O
upregulates	O
expression	O
of	O
type	O
II	O
FIPV	O
receptor	O
feline	O
aminopeptidase	O
N	O
in	O
feline	O
macrophages	O
.	O

For	O
upregulation	O
of	O
TNF	O
-	O
alpha	O
and	O
fAPN	O
in	O
macrophages	O
,	O
viral	O
replication	O
in	O
macrophages	O
is	O
necessary	O
,	O
and	O
their	O
expressions	O
were	O
increased	O
by	O
ADE	O
of	O
FIPV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
NL63	O
(	O
HCoV	O
-	O
NL63	O
),	O
a	O
common	O
human	O
respiratory	O
pathogen	O
,	O
is	O
associated	O
with	O
both	O
upper	O
and	O
lower	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
in	O
children	O
and	O
adults	O
.	O

ABSTRACT	O
:	O
By	O
using	O
a	O
series	O
of	O
overlapping	O
synthetic	O
peptides	O
covering	O
98	O
%	O
of	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
nucleocapsid	O
protein	O
(	O
NP	O
)	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
four	O
helper	O
T	O
-	O
cell	O
(	O
Th	O
)	O
epitopes	O
(	O
NP11	O
,	O
residues	O
11	O
to	O
25	O
;	O
NP51	O
,	O
residues	O
51	O
to	O
65	O
;	O
NP61	O
,	O
residues	O
61	O
to	O
75	O
;	O
and	O
NP111	O
,	O
residues	O
111	O
to	O
125	O
)	O
in	O
C57BL	O
mice	O
(	O
H	O
-	O
2	O
(	O
b	O
)),	O
four	O
(	O
NP21	O
,	O
residues	O
21	O
to	O
35	O
;	O
NP91	O
,	O
residues	O
91	O
to	O
105	O
;	O
NP331	O
,	O
residues	O
331	O
to	O
345	O
;	O
and	O
NP351	O
,	O
residues	O
351	O
to	O
365	O
)	O
in	O
C3H	O
mice	O
(	O
H	O
-	O
2	O
(	O
k	O
)),	O
and	O
two	O
(	O
NP81	O
,	O
residues	O
81	O
to	O
95	O
;	O
and	O
NP351	O
,	O
residues	O
351	O
to	O
365	O
)	O
in	O
BALB	O
/	O
c	O
mice	O
(	O
H	O
-	O
2	O
(	O
d	O
))	O
have	O
been	O
identified	O
.	O

All	O
of	O
these	O
peptides	O
were	O
able	O
to	O
stimulate	O
the	O
proliferation	B-DISO
of	O
NP	O
-	O
specific	O
T	O
-	O
cell	O
lines	O
or	O
freshly	O
isolated	O
lymph	O
node	O
cells	O
from	O
mice	O
immunized	O
with	O
recombinant	O
NP	O
.	O

When	O
fused	O
with	O
a	O
conserved	O
neutralizing	O
epitope	O
(	O
SP1143	O
-	O
1157	O
)	O
from	O
the	O
spike	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
NP111	O
and	O
NP351	O
assisted	O
in	O
the	O
production	O
of	O
high	O
-	O
titer	O
neutralizing	O
antibodies	O
in	O
vivo	O
.	O

ABSTRACT	O
:	O
Although	O
the	O
initial	O
outbreaks	O
of	O
the	O
deadly	O
coronavirus	O
that	O
causes	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
)	O
were	O
controlled	O
by	O
public	O
health	O
measures	O
,	O
the	O
development	O
of	O
vaccines	O
and	O
antiviral	O
agents	O
for	O
SARS	B-DISO
-	O
CoV	O
is	O
essential	O
for	O
improving	O
control	O
and	O
treatment	O
of	O
future	O
outbreaks	O
.	O

One	O
potential	O
target	O
for	O
SARS	B-DISO
-	O
CoV	O
antiviral	O
drug	O
development	O
is	O
the	O
3C	O
-	O
like	O
protease	O
(	O
3CLpro	O
).	O

As	O
a	O
result	O
,	O
SARS	B-DISO
-	O
CoV	O
3CLpro	O
has	O
become	O
the	O
focus	O
of	O
numerous	O
drug	O
discovery	O
efforts	O
worldwide	O
,	O
but	O
as	O
a	O
consequence	O
,	O
a	O
variety	O
of	O
different	O
3CLpro	O
expression	O
constructs	O
and	O
kinetic	O
assays	O
have	O
been	O
independently	O
developed	O
making	O
evaluation	O
and	O
comparison	O
between	O
potential	O
inhibitors	O
problematic	O
.	O

HIV	B-DISO
and	O
influenza	B-DISO
,	O
two	O
clear	O
threats	O
to	O
human	O
health	O
,	O
have	O
been	O
shown	O
to	O
rely	O
on	O
expression	O
of	O
specific	O
oligosaccharides	O
to	O
evade	O
detection	O
by	O
the	O
host	O
immune	O
system	O
.	O

TITLE	O
:	O
[	O
Study	O
on	O
the	O
dynamic	O
prevalence	O
of	O
serum	O
antibody	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
in	O
employees	O
from	O
wild	O
animal	O
market	O
in	O
Guangzhou	O
].	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
dynamic	O
trend	O
of	O
specific	O
antibody	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
CoV	O
in	O
serum	O
collected	O
at	O
various	O
periods	O
among	O
employees	O
in	O
Guangzhou	O
Xinyuan	O
animal	O
market	O
.	O

Volunteers	O
from	O
employees	O
of	O
the	O
animal	O
market	O
were	O
recruited	O
and	O
their	O
serum	O
specific	O
antibody	O
against	O
SARS	B-DISO
-	O
CoV	O
were	O
determined	O
by	O
enzyme	O
linked	O
immunesorbent	O
assay	O
(	O
ELISA	O
)	O
method	O
.	O

This	O
data	O
indicated	O
that	O
the	O
SARS	B-DISO
-	O
CoV	O
might	O
have	O
been	O
from	O
the	O
palm	O
civets	O
and	O
raccoon	O
dog	O
,	O
and	O
the	O
animal	O
market	O
seemed	O
to	O
serve	O
as	O
one	O
of	O
the	O
sources	O
of	O
infection	B-DISO
.	O

Unlike	O
SARS	B-DISO
,	O
direct	O
contact	O
with	O
patient	O
contracted	O
with	O
avian	B-DISO
influenza	I-DISO
at	O
the	O
end	O
of	O
incubation	O
period	O
and	O
in	O
the	O
stage	O
of	O
illness	O
through	O
flying	O
droplets	O
,	O
saliva	O
,	O
mucous	O
membrane	O
and	O
skin	O
injuries	O
will	O
not	O
lead	O
to	O
human	O
-	O
to	O
-	O
human	O
transmission	O
,	O
indicating	O
the	O
virus	O
'	O
ability	O
to	O
pass	O
from	O
human	O
to	O
human	O
is	O
limited	O
.	O

A	O
total	O
of	O
56	O
close	O
contacts	O
,	O
including	O
his	O
girl	O
friend	O
,	O
relatives	O
,	O
friends	O
and	O
medical	O
staff	O
who	O
had	O
taken	O
care	O
of	O
him	O
,	O
were	O
brought	O
under	O
medical	O
observation	O
for	O
7	O
days	O
but	O
none	O
of	O
them	O
showed	O
signs	O
of	O
infection	B-DISO
.	O

TITLE	O
:	O
Qigong	O
practice	O
among	O
chronically	B-DISO
ill	I-DISO
patients	O
during	O
the	O
SARS	B-DISO
outbreak	O
.	O

Both	O
the	O
underlying	O
and	O
trigger	O
motivations	O
could	O
motivate	O
these	O
chronically	B-DISO
ill	I-DISO
participants	O
to	O
practise	O
qigong	O
.	O

She	O
died	O
6	O
months	O
later	O
from	O
respiratory	B-DISO
insufficiency	I-DISO
and	O
hypercapnic	B-DISO
coma	B-DISO
.	O

The	O
study	O
provides	O
system	O
-	O
level	O
insights	O
into	O
the	O
interaction	O
of	O
SARS	B-DISO
CoV	O
3CLpro	O
with	O
host	O
cells	O
,	O
which	O
will	O
be	O
helpful	O
in	O
elucidating	O
the	O
molecular	O
basis	O
of	O
SARS	B-DISO
CoV	O
pathogenesis	B-DISO
.	O

Here	O
,	O
we	O
report	O
the	O
structure	O
of	O
a	O
trimmed	O
,	O
monomeric	O
form	O
of	O
SARS	B-DISO
-	O
CoV	O
nsp15	O
(	O
residues	O
28	O
to	O
335	O
)	O
determined	O
to	O
a	O
resolution	O
of	O
2	O
.	O
9	O
A	O
.	O
The	O
catalytic	O
loop	O
(	O
residues	O
234	O
to	O
249	O
)	O
with	O
its	O
two	O
reactive	O
histidines	O
(	O
His	O
234	O
and	O
His	O
249	O
)	O
is	O
dramatically	O
flipped	O
by	O
approximately	O
120	O
degrees	O
into	O
the	O
active	O
site	O
cleft	O
.	O

However	O
,	O
no	O
clinical	O
symptoms	O
such	O
as	O
respiratory	B-DISO
symptoms	I-DISO
and	O
diarrhea	B-DISO
were	O
observed	O
.	O

Here	O
we	O
expressed	O
the	O
SARS	B-DISO
-	O
CoV	O
S	O
-	O
protein	O
to	O
investigate	O
its	O
interactions	O
with	O
innate	O
immune	O
mechanisms	O
in	O
the	O
lung	O
.	O

ABSTRACT	O
:	O
SARS	B-DISO
-	O
CoV	O
3a	O
is	O
a	O
structural	O
protein	O
,	O
mainly	O
localizing	O
to	O
Golgi	O
apparatus	O
and	O
co	O
-	O
localizing	O
with	O
SARS	B-DISO
-	O
CoV	O
M	O
in	O
co	O
-	O
transfected	O
cells	O
.	O

SARS	B-DISO
also	O
brought	O
to	O
light	O
how	O
scientific	O
uncertainty	O
can	O
permeate	O
public	O
health	O
decisionmaking	O
,	O
leading	O
us	O
to	O
think	O
about	O
the	O
relationship	O
between	O
the	O
adequacy	O
of	O
evidence	O
of	O
the	O
effectiveness	O
of	O
an	O
intervention	O
and	O
its	O
role	O
in	O
the	O
justification	O
of	O
public	O
health	O
action	O
.	O

We	O
reviewed	O
English	O
-	O
language	O
publications	O
pertaining	O
to	O
clinical	O
presentation	O
,	O
diagnosis	O
,	O
and	O
management	O
of	O
AI	O
H5N1	B-DISO
and	O
infection	B-DISO
control	O
expressly	O
relating	O
to	O
the	O
intensive	O
care	O
setting	O
.	O

Multiorgan	B-DISO
failure	I-DISO
occurs	O
in	O
a	O
large	O
proportion	O
.	O

Strict	O
infection	B-DISO
control	O
procedures	O
are	O
paramount	O
to	O
staff	O
safety	O
,	O
although	O
human	O
-	O
to	O
-	O
human	O
transmission	O
is	O
rare	O
as	O
of	O
this	O
time	O
.	O

Parasitic	O
pneumonia	B-DISO
can	O
sometimes	O
be	O
life	O
threatening	O
.	O

ABSTRACT	O
:	O
The	O
timing	O
of	O
fixation	O
of	O
femoral	O
fractures	O
in	O
multiply	O
injured	O
patients	O
with	O
severe	O
thoracic	B-DISO
trauma	O
is	O
discussed	O
controversially	O
.	O

Both	O
cohorts	O
were	O
comparable	O
with	O
regard	O
to	O
demographic	O
data	O
,	O
ISS	B-DISO
,	O
AIS	B-DISO
score	O
in	O
the	O
thoracic	B-DISO
region	O
,	O
and	O
incidence	O
and	O
severity	O
of	O
brain	O
injury	O
.	O

RESULTS	O
:	O
Both	O
cohorts	O
were	O
comparable	O
with	O
regard	O
to	O
demographic	O
data	O
,	O
ISS	B-DISO
,	O
AIS	B-DISO
score	O
in	O
the	O
thoracic	B-DISO
region	O
,	O
and	O
incidence	O
and	O
severity	O
of	O
brain	O
injury	O
.	O

CONCLUSIONS	O
:	O
Early	O
unreamed	O
IMN	O
of	O
femoral	O
fractures	O
in	O
multiply	O
injured	O
patients	O
with	O
severe	O
thoracic	B-DISO
trauma	O
is	O
a	O
safe	O
procedure	O
and	O
seems	O
to	O
be	O
justified	O
to	O
achieve	O
early	O
definitive	O
care	O
.	O

ABSTRACT	O
:	O
Both	O
persistent	O
accumulation	O
and	O
activation	O
of	O
neutrophils	O
may	O
contribute	O
to	O
the	O
most	O
severe	O
form	O
of	O
acute	O
lung	O
injury	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

We	O
analyzed	O
the	O
expression	O
of	O
neutrophil	O
-	O
derived	O
S100A12	O
and	O
the	O
proinflammatory	O
receptor	O
for	O
advanced	O
glycation	O
end	O
products	O
(	O
RAGE	O
)	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Recent	O
papers	O
on	O
disorders	O
of	O
the	O
liver	O
and	O
biliary	O
tract	O
which	O
clarify	O
their	O
pathogenesis	B-DISO
and	O
attendant	O
morphologic	O
changes	O
are	O
highlighted	O
.	O

The	O
concept	O
of	O
'	O
bystander	O
hepatitis	B-DISO
'	O
was	O
cited	O
in	O
studies	O
showing	O
hepatic	O
infiltration	B-DISO
of	O
CD8	O
-	O
positive	O
T	O
cells	O
in	O
the	O
setting	O
of	O
extrahepatic	O
infections	B-DISO
such	O
as	O
influenza	B-DISO
virus	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
coronavirus	O
(	O
IBV	O
)	O
is	O
the	O
cause	O
of	O
the	O
single	O
most	O
economically	O
costly	O
infectious	B-DISO
disease	I-DISO
of	O
domestic	O
fowl	O
in	O
the	O
UK	O
--	O
and	O
probably	O
so	O
in	O
many	O
countries	O
that	O
have	O
a	O
developed	O
poultry	O
industry	O
.	O

Av	O
-	O
ECLA	O
was	O
initiated	O
to	O
achieve	O
a	O
less	O
aggressive	B-DISO
ventilation	O
strategy	O
.	O

The	O
authors	O
prospectively	O
investigated	O
avian	B-DISO
flu	I-DISO
and	O
SARS	B-DISO
between	O
March	O
2005	O
and	O
April	O
2006	O
.	O

Vaccination	O
remains	O
the	O
primary	O
strategy	O
for	O
the	O
prevention	O
of	O
influenza	B-DISO
,	O
and	O
the	O
broadened	O
recommendations	O
should	O
lead	O
to	O
protection	O
of	O
a	O
larger	O
portion	O
of	O
the	O
population	O
.	O

This	O
may	O
be	O
due	O
to	O
the	O
mass	O
campaign	O
of	O
influenza	B-DISO
vaccination	O
or	O
seasonal	O
variation	O
.	O

TITLE	O
:	O
Blastomycosis	B-DISO
in	O
solid	O
organ	O
transplant	O
recipients	O
.	O

From	O
1986	O
to	O
2004	O
,	O
we	O
identified	O
11	O
cases	O
of	O
post	O
-	O
transplant	O
blastomycosis	B-DISO
with	O
64	O
%	O
occurring	O
between	O
2000	O
and	O
2004	O
.	O

Blastomycosis	B-DISO
is	O
an	O
uncommon	O
infection	B-DISO
following	O
solid	O
organ	O
transplantation	O
that	O
is	O
frequently	O
complicated	O
by	O
ARDS	B-DISO
,	O
dissemination	O
,	O
and	O
opportunistic	O
co	B-DISO
-	I-DISO
infection	I-DISO
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
TS	O
mutant	B-DISO
variant	O
of	O
nsp10	O
inhibits	O
the	O
main	O
protease	O
,	O
3CLpro	O
,	O
blocking	B-DISO
its	O
function	O
completely	O
at	O
the	O
nonpermissive	O
temperature	O
.	O

TITLE	O
:	O
Different	O
genotypes	O
of	O
nephropathogenic	O
infectious	B-DISO
bronchitis	B-DISO
viruses	O
co	O
-	O
circulating	O
in	O
chicken	O
population	O
in	O
China	O
.	O

TITLE	O
:	O
Experiences	O
and	O
implications	O
of	O
social	O
workers	O
practicing	O
in	O
a	O
pediatric	O
hospital	O
environment	O
affected	O
by	O
SARS	B-DISO
.	O

The	O
sudden	O
onset	O
of	O
SARS	B-DISO
in	O
hospital	O
settings	O
created	O
an	O
immediate	O
necessity	O
to	O
study	O
this	O
phenomenon	O
as	O
hospitals	O
and	O
health	O
care	O
professionals	O
struggle	O
to	O
adapt	O
to	O
this	O
new	O
epidemic	O
environment	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
association	O
of	O
diagnostic	O
predictors	O
available	O
in	O
the	O
emergency	B-DISO
department	O
(	O
ED	O
)	O
with	O
the	O
outcome	O
diagnosis	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
patient	O
with	O
Down	B-DISO
'	I-DISO
s	I-DISO
syndrome	I-DISO
(	O
DS	O
)	O
who	O
died	O
of	O
a	O
fulminant	O
NMO	O
.	O

TITLE	O
:	O
Acute	O
effects	O
of	O
combined	O
high	O
-	O
frequency	O
oscillation	O
and	O
tracheal	O
gas	O
insufflation	O
in	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
In	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
high	O
-	O
frequency	O
oscillation	O
(	O
HFO	O
)	O
improves	O
oxygenation	O
relative	O
to	O
conventional	O
mechanical	O
ventilation	O
(	O
CMV	O
).	O

To	O
illustrate	O
this	O
problem	O
,	O
the	O
Transfusion	O
Requirements	O
in	O
Critical	O
Care	O
(	O
TRICC	O
)	O
trial	O
and	O
the	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
Network	O
low	O
tidal	O
volume	O
(	O
ARMA	O
)	O
trial	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
Publications	O
before	O
TRICC	O
indicated	O
that	O
clinicians	O
used	O
higher	O
transfusion	O
thresholds	O
in	O
patients	O
with	O
ischemic	B-DISO
heart	I-DISO
disease	I-DISO
compared	O
with	O
younger	O
,	O
healthier	O
patients	O
(	O
p	O
=	O
.	O
001	O
).	O

Consequently	O
,	O
TNF	O
production	O
is	O
enhanced	O
,	O
leading	O
to	O
the	O
development	O
of	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
in	O
sepsis	B-DISO
.	O

TITLE	O
:	O
Weather	O
:	O
driving	O
force	O
behind	O
the	O
transmission	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
China	O
?	O

Pearson	O
'	O
s	O
correlation	O
analyses	O
and	O
negative	O
binomial	O
regression	O
analyses	O
were	O
used	O
to	O
quantify	O
the	O
correlations	O
between	O
the	O
daily	O
newly	O
reported	O
number	O
of	O
SARS	B-DISO
cases	O
and	O
weather	O
variables	O
,	O
using	O
daily	O
disease	O
notification	O
data	O
and	O
meteorological	O
data	O
from	O
the	O
two	O
locations	O
.	O

The	O
results	O
indicate	O
that	O
there	O
were	O
inverse	O
association	O
between	O
the	O
number	O
of	O
daily	O
cases	O
and	O
maximum	O
and	O
/	O
or	O
minimum	O
temperatures	O
whereas	O
air	O
pressure	O
was	O
found	O
to	O
be	O
positively	O
associated	O
with	O
SARS	B-DISO
transmission	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
disease	O
categories	O
with	O
the	O
smallest	O
reduction	O
were	O
allergic	B-DISO
reactions	I-DISO
(-	O
4	O
%),	O
skin	B-DISO
infections	I-DISO
(-	O
6	O
%),	O
and	O
anxiety	O
(-	O
10	O
%)	O
in	O
ambulatory	O
care	O
and	O
respiratory	B-DISO
failure	I-DISO
(+	O
40	O
%),	O
delivery	O
(-	O
2	O
%),	O
and	O
fractures	O
of	O
lower	O
limbs	O
(-	O
5	O
%)	O
in	O
inpatient	O
care	O
.	O

Interestingly	O
,	O
twelve	O
human	O
milk	O
samples	O
were	O
positive	O
for	O
IgA	O
against	O
porcine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
coronavirus	O
,	O
and	O
this	O
represented	O
5	O
%.	O

ABSTRACT	O
:	O
Autoimmune	B-DISO
reactions	I-DISO
associated	O
with	O
MS	O
involve	O
genetic	O
and	O
environmental	O
factors	O
.	O

To	O
investigate	O
antigenic	O
cross	O
-	O
reactivity	O
at	O
the	O
molecular	O
level	O
,	O
155	O
long	O
-	O
term	O
T	O
-	O
cell	O
clones	O
(	O
TCC	B-DISO
)	O
were	O
derived	O
from	O
32	O
MS	O
patients	O
by	O
in	O
vitro	O
selection	O
with	O
MBP	O
,	O
proteolipid	O
protein	O
(	O
PLP	O
)	O
or	O
HCoV	O
(	O
strains	O
229E	O
and	O
OC43	O
).	O

RACE	O
RT	O
-	O
PCR	O
amplification	B-DISO
of	O
the	O
Vbeta	O
chains	O
of	O
five	O
of	O
ten	O
the	O
cross	O
-	O
reactive	O
TCC	B-DISO
confirmed	O
clonality	O
and	O
sequencing	O
identified	O
the	O
CDR3	O
region	O
associated	O
with	O
cross	O
-	O
reactivity	O
.	O

Indications	O
for	O
LTx	O
were	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
(	O
15	O
%),	O
cystic	B-DISO
fibrosis	I-DISO
(	O
15	O
%),	O
idiopathic	B-DISO
pulmonary	I-DISO
fibrosis	I-DISO
(	O
8	O
%),	O
primary	B-DISO
pulmonary	I-DISO
hypertension	I-DISO
,	O
(	O
10	O
%),	O
emphysema	B-DISO
(	O
15	O
%),	O
acute	O
lung	O
failure	O
(	O
11	O
%),	O
other	O
(	O
23	O
%),	O
and	O
unknown	O
(	O
3	O
%).	O

Alignment	O
of	O
10	O
complete	O
viral	O
genome	O
sequences	O
from	O
masked	O
palm	O
civets	O
with	O
those	O
of	O
human	O
SARS	B-DISO
-	O
CoVs	O
revealed	O
26	O
conserved	O
single	O
-	O
nucleotide	O
variations	O
(	O
SNVs	O
)	O
in	O
the	O
viruses	O
from	O
masked	O
palm	O
civets	O
.	O

These	O
conserved	O
SNVs	O
were	O
gradually	O
lost	O
from	O
the	O
genomes	O
of	O
viruses	O
isolated	O
from	O
the	O
early	O
phase	O
to	O
late	O
phase	O
human	O
patients	O
of	O
the	O
2003	O
SARS	B-DISO
epidemic	O
.	O

Apart	O
from	O
masked	O
palm	O
civets	O
and	O
bats	O
,	O
29	O
other	O
animal	O
species	O
had	O
been	O
tested	O
for	O
the	O
SARS	B-DISO
-	O
CoV	O
,	O
and	O
the	O
results	O
are	O
summarized	O
in	O
this	O
paper	O
.	O

Patients	O
who	O
are	O
infants	O
or	O
elderly	O
,	O
have	O
asthma	B-DISO
or	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
COPD	B-DISO
),	O
or	O
are	O
immunosuppressed	O
have	O
increased	O
frequency	O
of	O
rhinovirus	O
-	O
related	O
respiratory	B-DISO
complications	I-DISO
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
.	O

Although	O
the	O
outbreak	O
was	O
successfully	O
controlled	O
,	O
evidence	O
that	O
SARS	B-DISO
emerged	O
from	O
an	O
animal	O
reservoir	O
has	O
raised	O
concerns	O
that	O
another	O
pandemic	O
could	O
occur	O
.	O

In	O
order	O
to	O
understand	O
this	O
infection	B-DISO
,	O
one	O
of	O
the	O
coronavirus	O
isolates	O
was	O
sequenced	O
and	O
analyzed	O
.	O

In	O
addition	O
,	O
MHV	O
was	O
able	O
to	O
significantly	O
decrease	O
the	O
level	O
of	O
IFN	O
-	O
beta	O
protein	O
induced	O
by	O
both	O
Newcastle	B-DISO
disease	I-DISO
virus	O
(	O
NDV	O
)	O
and	O
Sendai	O
virus	O
infections	B-DISO
,	O
without	O
targeting	O
it	O
for	O
proteasomal	O
degradation	O
and	O
without	O
altering	O
the	O
nuclear	O
translocation	B-DISO
of	O
IRF	O
-	O
3	O
or	O
IFN	O
-	O
beta	O
mRNA	O
production	O
or	O
stability	O
.	O

TITLE	O
:	O
SARS	B-DISO
wars	O
:	O
an	O
examination	O
of	O
the	O
quantity	O
and	O
construction	O
of	O
health	O
information	O
in	O
the	O
news	O
media	O
.	O

The	O
purpose	O
of	O
this	O
article	O
is	O
to	O
describe	O
an	O
examination	O
of	O
the	O
construction	O
of	O
news	O
reports	O
on	O
health	O
topics	O
using	O
aspects	O
of	O
the	O
social	O
amplification	B-DISO
of	O
risk	O
model	O
and	O
the	O
elaboration	O
likelihood	O
model	O
of	O
persuasion	O
for	O
theoretical	O
direction	O
.	O

The	O
major	O
infection	B-DISO
control	O
measures	O
taken	O
by	O
the	O
Taiwanese	O
government	O
over	O
the	O
course	O
of	O
the	O
SARS	B-DISO
epidemic	O
,	O
particularly	O
those	O
regarding	O
infection	B-DISO
control	O
in	O
hospitals	O
,	O
played	O
a	O
crucial	O
role	O
in	O
containing	O
the	O
outbreak	O
.	O

RESULTS	O
:	O
During	O
the	O
study	O
period	O
,	O
818	O
patients	O
presented	O
with	O
SARS	B-DISO
-	O
like	O
symptoms	O
,	O
including	O
205	O
confirmed	O
SARS	B-DISO
,	O
35	O
undetermined	O
SARS	B-DISO
and	O
578	O
non	O
-	O
SARS	B-DISO
.	O

In	O
conclusion	O
,	O
BNoV	O
infections	B-DISO
are	O
endemic	O
and	O
there	O
are	O
two	O
distinct	O
genotypes	O
with	O
GIII	O
-	O
2	O
being	O
the	O
main	O
genotype	O
circulating	O
in	O
the	O
calf	O
population	O
in	O
South	O
Korea	O
.	O

TITLE	O
:	O
Insertion	O
/	O
deletion	O
polymorphism	O
in	O
the	O
promoter	O
of	O
NFKB1	O
influences	O
severity	O
but	O
not	O
mortality	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
The	O
future	O
of	O
the	O
endangered	O
red	O
panda	O
(	O
Ailurusfulgens	O
)	O
depends	O
in	O
part	O
on	O
the	O
development	O
of	O
protective	O
measures	O
against	O
infectious	B-DISO
diseases	I-DISO
.	O

However	O
,	O
we	O
cannot	O
exclude	O
the	O
possibility	O
of	O
reemergence	O
of	O
SARS	B-DISO
.	O

TITLE	O
:	O
Signal	O
transduction	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
cells	O
.	O

Both	O
Akt	O
and	O
p38	O
MAPK	O
are	O
keys	O
for	O
determination	O
of	O
cell	O
survival	O
or	O
death	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
cells	O
in	O
vitro	O
.	O

Agents	O
being	O
developed	O
to	O
target	O
these	O
signaling	O
cascades	O
may	O
be	O
important	O
for	O
the	O
design	O
of	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
drugs	O
.	O

The	O
16	O
-	O
year	O
-	O
old	O
patient	O
had	O
a	O
history	O
of	O
smoking	O
and	O
therapy	O
-	O
refractant	O
hemoptysis	B-DISO
and	O
,	O
later	O
,	O
acute	O
macrohematuria	O
with	O
renal	B-DISO
insufficiency	I-DISO
necessitating	O
hemodialysis	O
(	O
initial	O
creatinine	O
4	O
.	O
2	O
mg	O
/	O
dl	O
).	O

After	O
treatment	O
with	O
prednisone	O
,	O
oral	O
cyclophosphamide	O
and	O
plasmapheresis	O
,	O
chest	O
X	O
-	O
ray	O
and	O
hemoptysis	B-DISO
improved	O
,	O
but	O
renal	B-DISO
failure	I-DISO
persisted	O
.	O

The	O
prognosis	O
of	O
anti	O
-	O
GBM	B-DISO
glomerulonephritis	B-DISO
depends	O
on	O
serum	O
creatinine	O
and	O
the	O
need	O
of	O
dialysis	O
at	O
initial	O
presentation	O
.	O

Here	O
we	O
formulate	O
how	O
to	O
integrate	O
those	O
three	O
different	O
types	O
of	O
functional	O
relationship	O
to	O
construct	O
easy	O
-	O
to	O
-	O
use	O
and	O
easy	O
-	O
to	O
-	O
interpret	O
critical	O
-	O
control	O
lines	O
that	O
help	O
determine	O
optimally	O
the	O
intervention	O
strategies	O
for	O
containing	O
airborne	O
infections	B-DISO
.	O

We	O
suggest	O
that	O
integrated	O
analysis	O
to	O
enhance	O
modelling	O
the	O
impact	O
of	O
potential	O
control	O
measures	O
against	O
airborne	O
infections	B-DISO
presents	O
an	O
opportunity	O
to	O
assess	O
risks	O
and	O
benefits	O
.	O

All	O
33	O
serum	O
samples	O
from	O
set	O
2	O
were	O
strongly	O
positive	O
for	O
N	O
-	O
protein	O
-	O
specific	O
IgG	O
,	O
while	O
27	O
(	O
82	O
%)	O
were	O
positive	O
for	O
anti	O
-	O
S450	O
-	O
650	O
IgG	O
.	O
Two	O
of	O
the	O
serum	O
samples	O
from	O
set	O
3	O
were	O
strongly	O
positive	O
for	O
anti	O
-	O
N	O
-	O
protein	O
IgG	O
but	O
not	O
anti	O
-	O
S450	O
-	O
650	O
IgG	O
.	O
Similar	O
levels	O
of	O
IgG	O
responses	O
to	O
the	O
S	O
and	O
N	O
proteins	O
were	O
observed	O
in	O
SARS	B-DISO
patients	O
during	O
the	O
manifestation	O
and	O
convalescent	O
stages	O
.	O

Like	O
many	O
other	O
countries	O
,	O
Canada	O
must	O
face	B-DISO
the	O
challenge	O
of	O
building	O
and	O
sustaining	O
the	O
capacity	O
to	O
respond	O
to	O
this	O
broad	O
range	O
of	O
challenges	O
.	O

This	O
is	O
a	O
case	O
study	O
of	O
severe	O
pneumococcal	B-DISO
peritonitis	I-DISO
in	O
a	O
young	O
woman	O
with	O
no	O
predisposing	O
features	O
.	O

A	O
review	O
of	O
studies	O
of	O
hand	O
-	O
washing	O
practices	O
in	O
the	O
community	O
during	O
and	O
after	O
the	O
SARS	B-DISO
outbreak	O
in	O
2003	O
.	O

Consecutive	O
adult	O
trauma	O
patients	O
from	O
July	O
2001	O
to	O
November	O
2005	O
with	O
Injury	O
Severity	O
Score	O
(	O
ISS	B-DISO
)	O
>	O
or	O
=	O
16	O
and	O
blunt	O
mechanism	O
were	O
evaluated	O
using	O
the	O
National	O
Trauma	O
Registry	O
of	O
the	O
American	O
College	O
of	O
Surgeons	O
.	O

ABSTRACT	O
:	O
To	O
review	O
the	O
literature	O
relevant	O
to	O
diagnosis	O
and	O
management	O
of	O
meningococcal	B-DISO
disease	I-DISO
(	O
MD	O
).	O

MD	O
is	O
a	O
leading	O
cause	O
of	O
death	O
due	O
to	O
infection	B-DISO
in	O
children	O
.	O

Early	O
intervention	O
with	O
aggressive	B-DISO
fluid	O
resuscitation	O
and	O
antibiotic	O
therapy	O
can	O
significantly	O
improve	O
outcome	O
.	O

Meningitis	B-DISO
is	O
often	O
not	O
diagnosed	O
in	O
MD	O
because	O
of	O
the	O
severity	O
of	O
illness	O
and	O
the	O
inability	O
to	O
perform	O
a	O
lumbar	O
puncture	O
safely	O
in	O
a	O
patient	O
with	O
coagulopathy	B-DISO
,	O
coma	B-DISO
,	O
or	O
hemodynamic	B-DISO
instability	I-DISO
.	O

TITLE	O
:	O
The	O
3a	O
accessory	O
protein	O
of	O
SARS	B-DISO
coronavirus	O
specifically	O
interacts	O
with	O
the	O
5	O
'	O
UTR	O
of	O
its	O
genomic	O
RNA	O
,	O
Using	O
a	O
unique	O
75	O
amino	O
acid	O
interaction	O
domain	O
.	O

The	O
detrimental	O
effects	O
of	O
O2	O
have	O
established	O
hyperoxic	O
ALI	O
(	O
HALI	O
)	O
as	O
a	O
conventional	O
model	O
to	O
study	O
neonatal	O
and	O
adult	O
forms	O
of	O
respiratory	B-DISO
distress	I-DISO
syndromes	B-DISO
in	O
experimental	O
animals	O
.	O

TITLE	O
:	O
Mycoplasma	B-DISO
pneumoniae	O
infection	B-DISO
complicated	O
by	O
pneumomediastinum	B-DISO
and	O
severe	O
mucositis	B-DISO
.	O

ABSTRACT	O
:	O
We	O
report	O
an	O
8	O
-	O
year	O
-	O
old	O
boy	O
with	O
Mycoplasma	B-DISO
pneumoniae	O
respiratory	B-DISO
infection	I-DISO
complicated	O
by	O
pneumomediastinum	B-DISO
and	O
severe	O
oral	O
and	O
conjunctival	O
mucositis	B-DISO
.	O

However	O
,	O
MHV	O
replication	O
per	O
se	O
does	O
not	O
appear	O
to	O
benefit	O
from	O
the	O
inhibition	O
of	O
host	O
protein	O
synthesis	O
,	O
at	O
least	O
in	O
vitro	O
,	O
since	O
viral	O
replication	O
was	O
not	O
negatively	O
affected	O
but	O
rather	O
enhanced	O
in	O
cells	O
with	O
impaired	B-DISO
translational	O
shutoff	O
.	O

TITLE	O
:	O
Nucleocapsid	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
activates	O
interleukin	O
-	O
6	O
expression	O
through	O
cellular	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O
ABSTRACT	O
:	O
High	O
levels	O
of	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
in	O
the	O
acute	O
stage	O
associated	O
with	O
lung	O
lesions	O
were	O
found	O
in	O
SARS	B-DISO
patients	O
.	O

These	O
results	O
provided	O
new	O
insights	O
into	O
understanding	O
the	O
mechanism	O
involved	O
in	O
the	O
function	O
of	O
SARS	B-DISO
-	O
CoV	O
N	O
protein	O
and	O
pathogenesis	B-DISO
of	O
the	O
virus	O
.	O

ABSTRACT	O
:	O
Many	O
emerging	O
diseases	O
(	O
AIDS	O
,	O
SARS	B-DISO
,	O
avian	B-DISO
flu	I-DISO
)	O
are	O
related	O
to	O
viral	O
zoonoses	B-DISO
,	O
which	O
have	O
crossed	O
the	O
interspecies	O
barrier	O
.	O

Our	O
findings	O
indicate	O
endemic	O
infections	B-DISO
with	O
enteric	O
viruses	O
in	O
monkeys	O
of	O
both	O
colonies	O
.	O

In	O
addition	O
,	O
apoptosis	O
induced	O
by	O
IBV	O
at	O
late	O
stages	O
of	O
the	O
infection	B-DISO
cycle	O
in	O
cultured	O
cells	O
was	O
shown	O
to	O
be	O
p53	O
-	O
independent	O
.	O

This	O
conclusion	O
was	O
drawn	O
based	O
on	O
the	O
observations	O
that	O
apoptosis	O
occurred	O
in	O
both	O
IBV	O
-	O
infected	O
H1299	O
and	O
Vero	O
cells	O
,	O
and	O
that	O
IBV	O
infection	B-DISO
did	O
not	O
affect	O
the	O
expression	O
of	O
p53	O
in	O
host	O
cells	O
.	O

This	O
study	O
provides	O
basic	O
information	O
for	O
the	O
design	O
of	O
DNA	O
vaccines	O
against	O
SARS	B-DISO
-	O
CoV	O
.	O

ABSTRACT	O
:	O
An	O
enteric	O
syndrome	B-DISO
was	O
observed	O
in	O
quail	O
(	O
Coturnix	O
coturnix	O
)	O
semi	O
-	O
intensively	O
reared	O
for	O
restocking	O
in	O
Apulia	O
(	O
southern	O
Italy	O
).	O

Pulmonary	B-DISO
aspiration	I-DISO
and	O
lethal	O
respiratory	B-DISO
distress	I-DISO
occurred	O
only	O
in	O
patients	O
with	O
myogenic	O
dysphagia	B-DISO
.	O

Local	O
infection	B-DISO
was	O
the	O
main	O
complication	B-DISO
in	O
those	O
with	O
pharyngo	O
-	O
oesophageal	B-DISO
diverticulum	I-DISO
.	O

Persistent	O
aspiration	B-DISO
can	O
lead	O
to	O
laryngeal	O
exclusion	O
or	O
resection	O
with	O
permanent	O
tracheostomy	O
.	O

TITLE	O
:	O
Animal	O
models	O
and	O
vaccines	O
for	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

In	O
2004	O
,	O
SARS	B-DISO
survivors	O
also	O
showed	O
worrying	O
levels	O
of	O
depression	B-DISO
,	O
anxiety	O
,	O
and	O
posttraumatic	O
symptoms	O
.	O

During	O
the	O
outbreak	O
,	O
health	O
care	O
worker	O
SARS	B-DISO
survivors	O
had	O
stress	O
levels	O
similar	O
to	O
those	O
of	O
non	O
-	O
health	O
care	O
workers	O
,	O
but	O
health	O
care	O
workers	O
showed	O
significantly	O
higher	O
stress	O
levels	O
in	O
2004	O
(	O
PSS	B-DISO
-	O
10	O
score	O
=	O
22	O
.	O
8	O
,	O
compared	O
with	O
PSS	B-DISO
-	O
10	O
score	O
=	O
18	O
.	O
4	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
had	O
higher	O
depression	B-DISO
,	O
anxiety	O
,	O
posttraumatic	O
symptoms	O
,	O
and	O
GHQ	O
-	O
12	O
scores	O
.	O

TITLE	O
:	O
Immediate	O
and	O
sustained	O
psychological	B-DISO
impact	O
of	O
an	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
outbreak	O
on	O
health	O
care	O
workers	O
.	O

More	O
high	O
-	O
risk	O
health	O
care	O
workers	O
reported	O
fatigue	B-DISO
,	O
poor	B-DISO
sleep	I-DISO
,	O
worry	O
about	O
health	O
,	O
and	O
fear	O
of	O
social	O
contact	O
,	O
despite	O
their	O
confidence	O
in	O
infection	B-DISO
-	O
control	O
measures	O
.	O

Respiratory	O
deficiency	O
and	O
renal	B-DISO
impairment	I-DISO
are	O
often	O
reported	O
in	O
patients	O
suffering	B-DISO
from	O
Lemierre	B-DISO
'	I-DISO
s	I-DISO
syndrome	I-DISO
.	O

The	O
main	O
goal	O
of	O
the	O
present	O
study	O
,	O
was	O
to	O
first	O
determine	O
the	O
values	O
of	O
RBC	O
'	O
s	O
deformability	O
,	O
in	O
the	O
course	O
of	O
patients	O
treated	O
in	O
an	O
Intensive	O
Care	O
Unit	O
(	O
ICU	O
)	O
for	O
basically	O
sepsis	B-DISO
and	O
then	O
deteriorated	O
states	O
and	O
secondly	O
to	O
establish	O
the	O
prognostic	O
efficiency	O
of	O
the	O
test	O
.	O

ABSTRACT	O
:	O
Chemical	O
,	O
Biological	O
,	O
Radiological	O
and	O
Nuclear	O
incidents	O
are	O
rare	O
,	O
but	O
the	O
likelihood	O
of	O
any	O
medical	O
facility	O
having	O
to	O
deal	O
with	O
contaminated	O
or	O
contagious	O
casualties	O
is	O
not	O
,	O
Health	O
Care	O
Workers	O
(	O
HCW	O
)	O
often	O
being	O
exposed	O
to	O
infectious	B-DISO
or	O
toxic	O
substances	O
.	O

ABSTRACT	O
:	O
We	O
have	O
developed	O
the	O
loop	O
-	O
mediated	O
isothermal	O
amplification	B-DISO
(	O
LAMP	O
)	O
method	O
,	O
an	O
innovative	O
gene	B-DISO
amplification	I-DISO
technique	O
,	O
which	O
has	O
the	O
potential	O
to	O
become	O
important	O
in	O
genetic	O
testing	O
.	O

ABSTRACT	O
:	O
Canine	O
coronavirus	O
(	O
CCoV	O
)	O
is	O
responsible	O
for	O
mild	O
or	O
moderate	O
enteritis	B-DISO
in	O
puppies	O
.	O

Since	O
no	O
studies	O
have	O
yet	O
focused	O
on	O
the	O
sensitivity	O
of	O
CCoV	O
to	O
chemical	O
biocides	O
the	O
present	O
investigation	O
examined	O
the	O
efficiency	O
of	O
physical	O
and	O
chemical	O
methods	O
of	O
viral	O
inactivation	B-DISO
.	O

Analysis	O
of	O
the	O
immunogenicity	O
of	O
the	O
UV	O
-	O
F	O
-	O
V	O
+	O
alum	O
vaccine	O
in	O
mice	O
revealed	O
that	O
it	O
generated	O
comparable	O
neutralizing	O
serum	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
IgG	O
antibody	O
levels	O
as	O
the	O
UV	O
-	O
V	O
+	O
alum	O
vaccine	O
.	O

Spike	O
-	O
pseudotyped	O
HIV	B-DISO
vector	O
was	O
generated	O
and	O
evaluated	O
in	O
vitro	O
on	O
well	O
-	O
differentiated	O
human	O
airway	O
epithelial	O
cells	O
and	O
bronchial	O
explants	O
and	O
in	O
vivo	O
in	O
murine	O
airways	O
.	O

In	O
addition	O
,	O
this	O
study	O
shows	O
that	O
spike	O
-	O
pseudotyped	O
HIV	B-DISO
-	O
based	O
vector	O
can	O
efficiently	O
transduce	O
human	O
dendritic	O
cells	O
and	O
epithelial	O
cells	O
of	O
the	O
esophagus	O
,	O
which	O
may	O
have	O
implications	O
in	O
investigating	O
mechanisms	O
of	O
SARS	B-DISO
-	O
CoV	O
pathogenesis	B-DISO
.	O

TITLE	O
:	O
Analysis	O
of	O
intraviral	O
protein	O
-	O
protein	O
interactions	O
of	O
the	O
SARS	B-DISO
coronavirus	O
ORFeome	O
.	O

ABSTRACT	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
genome	O
is	O
predicted	O
to	O
encode	O
14	O
functional	O
open	O
reading	O
frames	O
,	O
leading	O
to	O
the	O
expression	O
of	O
up	O
to	O
30	O
structural	O
and	O
non	O
-	O
structural	O
protein	O
products	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
failure	I-DISO
is	O
a	O
major	O
complication	B-DISO
of	O
severe	O
pneumococcal	B-DISO
pneumonia	I-DISO
,	O
characterized	O
by	O
impairment	B-DISO
of	O
pulmonary	O
microvascular	O
barrier	O
function	O
and	O
pulmonary	B-DISO
hypertension	I-DISO
.	O

We	O
hypothesized	O
that	O
platelet	O
-	O
activating	O
factor	O
(	O
PAF	B-DISO
)	O
and	O
associated	O
downstream	O
signaling	O
pathways	O
play	O
a	O
role	O
in	O
the	O
PLY	O
-	O
induced	O
development	O
of	O
acute	O
lung	O
injury	O
.	O

The	O
pressor	O
response	O
was	O
reduced	O
in	O
lungs	O
of	O
PAF	B-DISO
receptor	O
-	O
deficient	O
mice	O
and	O
after	O
PAF	B-DISO
receptor	O
blockade	O
by	O
BN	O
50730	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
the	O
interaction	O
between	O
a	O
SARS	B-DISO
-	O
CoV	O
accessory	O
protein	O
and	O
nsp8	O
and	O
our	O
findings	O
suggest	O
that	O
ORF6	O
protein	O
may	O
play	O
a	O
role	O
in	O
virus	O
replication	O
.	O

Early	O
death	O
is	O
mainly	O
linked	O
to	O
an	O
overwhelming	O
inflammatory	B-DISO
response	I-DISO
leading	O
to	O
cardiovascular	B-DISO
collapse	I-DISO
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
whereas	O
late	O
death	O
is	O
associated	O
with	O
infected	B-DISO
pancreatic	I-DISO
necrosis	I-DISO
and	O
sepsis	B-DISO
.	O

However	O
,	O
other	O
functions	O
of	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
such	O
as	O
proteolytic	O
cleavage	O
and	O
its	O
implications	O
to	O
viral	B-DISO
infection	I-DISO
are	O
incompletely	O
understood	O
.	O

The	O
rate	O
ratio	O
for	O
all	O
-	O
cause	O
mortality	O
during	O
the	O
SARS	B-DISO
outbreak	O
was	O
0	O
.	O
99	O
[	O
95	O
%	O
Confidence	O
Interval	O
(	O
CI	O
)	O
0	O
.	O
93	O
-	O
1	O
.	O
06	O
]	O
compared	O
to	O
2002	O
and	O
0	O
.	O
96	O
[	O
95	O
%	O
CI	O
0	O
.	O
90	O
-	O
1	O
.	O
03	O
]	O
compared	O
to	O
2001	O
.	O

Limitations	O
on	O
access	O
to	O
medical	O
services	O
during	O
the	O
2003	O
SARS	B-DISO
outbreak	O
in	O
Toronto	O
had	O
no	O
observable	O
impact	O
on	O
short	O
-	O
term	O
population	O
mortality	O
.	O

As	O
acute	O
illness	O
progressed	O
,	O
SARS	B-DISO
patients	O
entered	O
a	O
crisis	O
phase	O
linked	O
to	O
oxygen	O
saturation	O
profiles	O
.	O

However	O
,	O
-	O
28	O
CG	O
(	O
OR	O
=	O
4	O
.	O
27	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
64	O
-	O
11	O
.	O
1	O
)	O
and	O
GG	O
(	O
OR	O
=	O
3	O
.	O
34	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
37	O
-	O
30	O
.	O
7	O
)	O
were	O
associated	O
with	O
admission	O
to	O
intensive	O
care	O
units	O
or	O
death	O
due	O
to	O
SARS	B-DISO
(	O
P	O
=	O
0	O
.	O
011	O
).	O

Recent	O
studies	O
of	O
anticoagulants	O
have	O
shown	O
positive	O
outcomes	O
in	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
.	O

TITLE	O
:	O
Proteinase	O
dysbalance	O
in	O
pathology	B-DISO
:	O
the	O
neprilysin	O
(	O
NEP	O
)	O
and	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
families	O
.	O

Some	O
approaches	O
to	O
dealing	O
with	O
these	O
questions	O
and	O
addressing	O
functional	O
correlates	O
of	O
proteolytic	O
activity	O
at	O
the	O
level	O
of	O
molecular	O
cell	O
biology	O
are	O
provided	O
in	O
this	O
review	O
focusing	O
on	O
two	O
spheres	O
of	O
interest	O
:	O
neurodegeneration	B-DISO
and	O
cardiovascular	O
regulation	O
.	O

Finally	O
,	O
the	O
serendipitous	O
discovery	O
of	O
ACE2	O
as	O
the	O
SARS	B-DISO
virus	O
receptor	O
illustrates	O
the	O
surprises	O
always	O
in	O
store	O
from	O
nature	O
.	O

Sera	O
of	O
cats	O
which	O
were	O
clinically	O
and	O
serologically	O
diagnosed	O
as	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
possessed	B-DISO
significantly	O
higher	O
VN	O
titers	O
to	O
type	O
I	O
FCoV	O
,	O
and	O
sera	O
from	O
cats	O
experimentally	O
infected	O
with	O
FIPV	O
type	O
II	O
had	O
high	O
VN	O
titers	O
to	O
type	O
II	O
but	O
not	O
type	O
I	O
viruses	O
.	O

These	O
results	O
indicate	O
that	O
the	O
VN	O
test	O
described	O
here	O
can	O
be	O
used	O
for	O
serological	O
differentiation	O
of	O
FCoV	O
infections	B-DISO
of	O
cats	O
,	O
and	O
that	O
FCoV	O
type	O
I	O
is	O
a	O
dominant	O
type	O
in	O
recent	O
years	O
of	O
Japan	O
.	O

Pulmonary	O
-	O
renal	O
syndromes	B-DISO
are	O
not	O
a	O
single	O
entity	O
,	O
but	O
are	O
caused	O
by	O
a	O
wide	O
variety	O
of	O
diseases	O
,	O
including	O
various	O
forms	O
of	O
primary	B-DISO
systemic	I-DISO
vasculitis	I-DISO
(	O
especially	O
Wegener	B-DISO
'	I-DISO
s	I-DISO
granulomatosis	I-DISO
and	O
microscopic	B-DISO
polyangiitis	I-DISO
),	O
Goodpasture	B-DISO
'	I-DISO
s	I-DISO
syndrome	I-DISO
(	O
associated	O
with	O
autoantibodies	O
to	O
the	O
alveolar	O
and	O
glomerular	O
basement	O
membrane	O
)	O
and	O
systemic	B-DISO
lupus	I-DISO
erythematosus	I-DISO
.	O

In	O
the	O
clinical	O
setting	O
of	O
an	O
acute	B-DISO
nephritis	I-DISO
syndrome	B-DISO
,	O
percutaneous	O
renal	O
biopsy	O
is	O
commonly	O
performed	O
for	O
histopathology	O
and	O
immunofluorescence	O
studies	O
.	O

The	O
combination	O
of	O
plasmapheresis	O
with	O
these	O
cytotoxic	O
agents	O
and	O
steroids	O
is	O
effective	O
in	O
patients	O
with	O
Goodpasture	B-DISO
'	I-DISO
s	I-DISO
syndrome	I-DISO
,	O
especially	O
if	O
instituted	O
early	O
in	O
the	O
course	O
of	O
the	O
disease	O
.	O

A	O
single	O
chain	O
variable	O
fragment	O
antibody	O
(	O
N18	O
)	O
with	O
high	O
affinity	O
against	O
N	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
was	O
isolated	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
and	O
protracted	O
inflammation	B-DISO
that	O
characterizes	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
is	O
driven	O
by	O
the	O
ongoing	O
recruitment	B-DISO
of	O
neutrophils	O
to	O
the	O
lung	O
.	O

Given	O
its	O
previously	O
described	O
chemoattractant	O
effects	O
on	O
marrow	O
neutrophils	O
,	O
we	O
investigated	O
whether	O
stromal	O
-	O
derived	O
factor	O
-	O
1	O
(	O
SDF	O
-	O
1	O
)	O
(	O
CXCL12	O
)	O
might	O
participate	O
in	O
this	O
later	O
phase	O
of	O
recruitment	B-DISO
.	O

Lastly	O
,	O
we	O
found	O
that	O
expression	O
of	O
the	O
SDF	O
-	O
1	O
receptor	O
CXCR4	O
rises	O
in	O
a	O
similar	O
temporal	O
pattern	O
on	O
neutrophils	O
in	O
both	O
the	O
blood	O
and	O
airspace	O
of	O
LPS	B-DISO
-	O
injured	O
mice	O
and	O
that	O
Ab	O
-	O
mediated	O
SDF	O
-	O
1	O
blockade	O
significantly	O
attenuates	O
late	O
but	O
not	O
early	O
pulmonary	O
neutrophilia	O
in	O
this	O
model	O
.	O

The	O
penile	O
shaft	O
was	O
the	O
site	O
most	O
likely	O
to	O
be	O
HPV	O
positive	O
and	O
harbored	O
the	O
greatest	O
proportion	O
of	O
multiple	O
type	O
and	O
oncogenic	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
In	O
this	O
report	O
,	O
we	O
describe	O
a	O
case	O
of	O
pneumonia	B-DISO
due	O
to	O
an	O
infection	B-DISO
with	O
human	O
coronaviruses	O
(	O
HCoVs	O
)-	O
OC43	O
in	O
a	O
pediatric	O
leukemia	B-DISO
patient	O
with	O
Down	B-DISO
syndrome	I-DISO
and	O
febrile	B-DISO
neutropenia	I-DISO
.	O

Not	O
only	O
the	O
recently	O
discovered	O
HCoVs	O
NL63	O
or	O
HKU1	O
but	O
also	O
the	O
prototype	O
strains	O
HCoV	O
-	O
OC43	O
and	O
HCoV	O
-	O
229E	O
have	O
to	O
be	O
considered	O
as	O
respiratory	O
pathogens	O
in	O
immunocompromised	O
pediatric	B-DISO
cancer	I-DISO
patients	O
.	O

The	O
routine	O
utilization	O
of	O
polymerase	O
chain	O
reaction	O
-	O
based	O
diagnostic	O
tools	O
would	O
certainly	O
elucidate	O
the	O
etiology	O
of	O
a	O
relevant	O
proportion	O
of	O
""""	O
pneumonias	B-DISO
of	O
unknown	O
origin	O
""""	O
in	O
immunocompromised	O
pediatric	O
patients	O
and	O
would	O
contribute	O
to	O
a	O
better	O
understanding	O
of	O
the	O
role	O
of	O
HCoVs	O
in	O
this	O
setting	O
.	O

The	O
factors	O
associated	O
with	O
the	O
presence	O
of	O
coagulopathy	B-DISO
were	O
the	O
following	O
:	O
severity	O
of	O
the	O
traumatic	O
brain	O
injury	O
(	O
OR	O
=	O
2	O
.	O
83	O
;	O
95	O
%	O
CI	O
1	O
.	O
58	O
-	O
5	O
.	O
07	O
),	O
diagnosis	O
of	O
brain	B-DISO
swelling	I-DISO
on	O
cranial	O
computed	O
tomography	O
(	O
OR	O
=	O
2	O
.	O
11	O
;	O
95	O
%	O
CI	O
1	O
.	O
13	O
-	O
4	O
.	O
07	O
)	O
and	O
occurrence	O
of	O
chest	O
and	O
/	O
or	O
abdominal	O
injury	O
(	O
OR	O
=	O
2	O
.	O
07	O
;	O
95	O
%	O
CI	O
1	O
.	O
11	O
-	O
4	O
.	O
00	O
).	O

The	O
development	O
of	O
coagulopathy	B-DISO
is	O
a	O
frequent	O
complication	B-DISO
in	O
patients	O
with	O
moderate	O
to	O
severe	O
traumatic	O
brain	O
injury	O
.	O

The	O
multivariate	O
analysis	O
showed	O
that	O
the	O
factors	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death	O
were	O
presence	O
of	O
sodium	O
disorders	O
(	O
OR	O
=	O
5	O
.	O
56	O
;	O
95	O
%	O
CI	O
2	O
.	O
90	O
-	O
10	O
.	O
65	O
),	O
hypotension	O
in	O
the	O
intensive	O
care	O
unit	O
(	O
OR	O
=	O
12	O
.	O
58	O
;	O
95	O
%	O
CI	O
4	O
.	O
40	O
-	O
35	O
.	O
00	O
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
OR	O
=	O
13	O
.	O
57	O
;	O
95	O
%	O
CI	O
1	O
.	O
51	O
-	O
121	O
.	O
66	O
).	O

TITLE	O
:	O
Sickle	B-DISO
cell	I-DISO
disease	I-DISO
caused	O
by	O
Hb	O
S	O
/	O
Québec	O
-	O
CHORI	O
:	O
treatment	O
with	O
hydroxyurea	O
and	O
response	O
.	O

ABSTRACT	O
:	O
Glycoprotein	O
Si	O
was	O
the	O
major	O
protein	O
to	O
determine	O
infection	B-DISO
and	O
immunogenicity	O
of	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
).	O

TITLE	O
:	O
[	O
Construction	O
of	O
recombinant	O
Lactococcus	O
lactis	O
expressing	O
porcine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
spike	O
glycoprotein	O
and	O
analysis	O
of	O
immunogenicity	O
].	O

This	O
system	O
was	O
applied	O
to	O
develop	O
a	O
quantitative	O
measurement	O
of	O
cell	O
-	O
cell	O
fusion	O
using	O
hepatitis	B-DISO
C	I-DISO
virus	O
(	O
HCV	O
)	O
NS3	B-DISO
/	O
4A	O
protease	O
and	O
a	O
secretion	O
-	O
blocked	O
EGFP	O
-	O
4A	O
/	O
4B	O
-	O
SEAP	O
(	O
EGFP	O
:	O
enhanced	O
green	O
fluorescent	O
protein	O
;	O
4A	O
/	O
4B	O
:	O
a	O
decapeptide	O
substrate	O
of	O
NS3	B-DISO
/	O
4A	O
protease	O
;	O
SEAP	O
:	O
secreted	O
alkaline	O
phosphatase	O
)	O
fusion	O
gene	O
.	O

As	O
cryptogenic	B-DISO
organizing	I-DISO
pneumonia	I-DISO
was	O
suspected	O
,	O
she	O
was	O
then	O
treated	O
with	O
intravenously	O
pulsed	O
methylprednisolone	O
followed	O
by	O
prednisolone	O
.	O

Sequential	O
chest	O
computed	O
tomography	O
scans	O
in	O
this	O
case	O
indicate	O
that	O
absorption	O
of	O
marginal	O
air	O
-	O
space	O
consolidation	O
with	O
extended	O
central	O
ground	O
glass	O
attenuation	O
in	O
concordance	O
with	O
a	O
new	O
infiltrate	B-DISO
on	O
another	O
lung	O
field	O
appeared	O
to	O
create	O
wandering	O
infiltrate	B-DISO
.	O

Here	O
we	O
investigated	O
the	O
role	O
of	O
COXs	O
in	O
the	O
mouse	B-DISO
hepatitis	I-DISO
coronavirus	O
(	O
MHV	O
)	O
infection	B-DISO
cycle	O
.	O

32	O
patients	O
,	O
15	O
(	O
47	O
%)	O
presenting	O
with	O
acute	O
onset	O
and	O
associated	O
respiratory	B-DISO
insufficiency	I-DISO
(	O
group	O
A	O
)	O
and	O
17	O
(	O
53	O
%)	O
with	O
gradual	O
onset	O
(	O
group	O
G	O
)	O
were	O
examined	O
.	O

Then	O
we	O
measured	O
the	O
numbers	O
of	O
total	O
cells	O
and	O
neutrophils	O
and	O
the	O
levels	O
of	O
tumor	B-DISO
necrosis	I-DISO
factor	O
(	O
TNF	O
)-	O
alpha	O
and	O
cytokine	O
-	O
induced	O
neutrophil	O
chemoattractant	O
(	O
CINC	O
)	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
).	O

However	O
,	O
AM	O
infusion	O
attenuated	O
these	O
LPS	B-DISO
-	O
induced	O
abnormalities	O
.	O

TITLE	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
2	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Intriguingly	O
,	O
the	O
SARS	B-DISO
coronavirus	O
,	O
the	O
cause	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
utilizes	O
ACE2	O
as	O
an	O
essential	O
receptor	O
for	O
cell	O
fusion	O
and	O
in	O
vivo	O
infections	B-DISO
.	O

Pathological	O
examinations	O
revealed	O
alveolar	O
haemorrhage	B-DISO
and	O
necrotic	O
lesions	O
in	O
various	O
organs	O
.	O

TITLE	O
:	O
Adenovirus	B-DISO
-	O
based	O
vaccine	O
prevents	O
pneumonia	B-DISO
in	O
ferrets	O
challenged	O
with	O
the	O
SARS	B-DISO
coronavirus	O
and	O
stimulates	O
robust	O
immune	O
responses	O
in	O
macaques	O
.	O

The	O
presence	O
of	O
carbohydrate	O
-	O
binding	O
agents	O
strongly	O
inhibited	O
coronaviruses	O
(	O
transmissible	O
gastroenteritis	B-DISO
virus	O
,	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
,	O
feline	O
coronaviruses	O
serotypes	O
I	O
and	O
II	O
,	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
),	O
arteriviruses	O
(	O
equine	O
arteritis	B-DISO
virus	O
and	O
porcine	O
respiratory	O
and	O
reproductive	O
syndrome	B-DISO
virus	O
)	O
and	O
torovirus	O
(	O
equine	O
Berne	O
virus	O
).	O

The	O
role	O
of	O
oral	O
corticosteroids	O
is	O
highly	O
debatable	O
in	O
young	O
children	O
with	O
virus	O
-	O
associated	O
wheeze	B-DISO
.	O

Lung	O
injury	O
score	O
and	O
Sequential	O
Organ	B-DISO
Failure	I-DISO
Assessment	O
scores	O
were	O
serially	O
determined	O
.	O

Intra	B-DISO
-	I-DISO
abdominal	I-DISO
hypertension	I-DISO
induced	O
acute	O
lung	O
injury	O
and	O
MODS	B-DISO
with	O
IL	O
-	O
8	O
elevation	O
,	O
even	O
though	O
AD	O
improved	O
hemodynamic	O
parameters	O
in	O
extensively	O
burned	O
patients	O
.	O

Plasma	O
concentration	O
of	O
IL	O
-	O
8	O
was	O
elevated	O
in	O
intra	B-DISO
-	I-DISO
abdominal	I-DISO
hypertension	I-DISO
patients	O
3	O
days	O
postburn	O
.	O

TITLE	O
:	O
Dual	O
enteric	O
and	O
respiratory	O
tropisms	O
of	O
winter	B-DISO
dysentery	I-DISO
bovine	O
coronavirus	O
in	O
calves	O
.	O

The	O
WD	O
-	O
BCoV	O
-	O
infected	O
animals	O
showed	O
epithelial	O
damage	O
in	O
nasal	O
turbinates	O
,	O
trachea	B-DISO
and	O
lungs	O
,	O
and	O
interstitial	B-DISO
pneumonia	I-DISO
.	O

The	O
WD	O
-	O
BCoV	O
antigen	O
was	O
detected	O
in	O
the	O
epithelium	O
of	O
the	O
small	O
and	O
large	O
intestines	O
,	O
nasal	O
turbinates	O
,	O
trachea	B-DISO
and	O
lungs	O
.	O

Both	O
groups	O
were	O
matched	O
for	O
spirometry	O
,	O
BMI	O
,	O
and	O
AHI	O
,	O
but	O
oxygen	O
desaturation	O
was	O
worse	O
in	O
the	O
OSA	B-DISO
-	O
plus	O
-	O
OHS	B-DISO
group	O
.	O

Further	O
long	O
-	O
term	O
studies	O
assessing	O
the	O
comparative	O
role	O
of	O
CPAP	O
and	O
bilevel	O
ventilatory	O
support	O
in	O
such	O
subjects	O
with	O
OHS	B-DISO
is	O
warranted	O
.	O

CONCLUSIONS	O
:	O
The	O
organ	O
derived	O
microvascular	O
endothelial	O
cells	O
are	O
the	O
important	O
target	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
pathological	O
injury	O
of	O
lung	O
and	O
lymph	O
system	O
induced	O
by	O
SARS	B-DISO
-	O
CoV	O
may	O
be	O
mediated	O
respectively	O
by	O
different	O
receptors	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O

ABSTRACT	O
:	O
The	O
clinical	O
features	O
of	O
propofol	O
infusion	O
syndrome	B-DISO
(	O
PRIS	O
)	O
are	O
acute	O
refractory	O
bradycardia	B-DISO
leading	O
to	O
asystole	B-DISO
,	O
in	O
the	O
presence	O
of	O
one	O
or	O
more	O
of	O
the	O
following	O
:	O
metabolic	B-DISO
acidosis	I-DISO
(	O
base	O
deficit	B-DISO
>	O
10	O
mmol	O
.	O
l	O
(-	O
1	O
)),	O
rhabdomyolysis	B-DISO
,	O
hyperlipidaemia	B-DISO
,	O
and	O
enlarged	O
or	O
fatty	B-DISO
liver	I-DISO
.	O

TITLE	O
:	O
Effectiveness	O
of	O
control	O
measures	O
during	O
the	O
SARS	B-DISO
epidemic	O
in	O
Beijing	O
:	O
a	O
comparison	O
of	O
the	O
Rt	O
curve	O
and	O
the	O
epidemic	O
curve	O
.	O

No	O
significant	O
association	O
to	O
susceptibility	O
to	O
SARS	B-DISO
infection	B-DISO
caused	O
by	O
the	O
novel	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
was	O
found	O
for	O
the	O
FCER2	O
and	O
the	O
ICAM3	O
single	O
nucleotide	O
polymorphisms	O
.	O

Histologically	O
,	O
the	O
ratio	O
of	O
villous	O
height	O
:	O
crypt	O
depth	O
of	O
PEDV	O
+	O
EGF	O
piglets	O
was	O
significantly	O
higher	O
than	O
PEDV	O
only	O
piglets	O
at	O
36	O
and	O
48	O
hpi	B-DISO
.	O

ABSTRACT	O
:	O
This	O
study	O
was	O
conducted	O
to	O
investigate	O
the	O
incidence	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
in	O
commercial	O
broiler	O
and	O
layer	O
flocks	O
in	O
Pakistan	O
.	O

ABSTRACT	O
:	O
A	O
focus	O
formation	O
assay	O
(	O
FFA	O
)	O
for	O
detection	O
and	O
titration	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
in	O
a	O
micro	O
-	O
culture	O
system	O
using	O
Vero	O
cells	O
and	O
PAP	B-DISO
staining	O
technique	O
was	O
evaluated	O
.	O

ABSTRACT	O
:	O
Restrictions	O
on	O
the	O
nonurgent	O
use	O
of	O
hospital	O
services	O
were	O
imposed	O
in	O
March	O
2003	O
to	O
control	O
an	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
Toronto	O
,	O
Ont	O
.	O

Steroids	O
have	O
been	O
used	O
for	O
many	O
decades	O
in	O
a	O
wide	O
variety	O
of	O
inflammatory	O
conditions	O
in	O
which	O
hypercytokinaemia	O
plays	O
a	O
role	O
,	O
such	O
as	O
sepsis	B-DISO
and	O
viral	B-DISO
infections	I-DISO
,	O
including	O
severe	O
acquired	O
respiratory	O
syndromes	B-DISO
and	O
avian	B-DISO
influenza	I-DISO
.	O

Adrenal	B-DISO
insufficiency	I-DISO
can	O
be	O
overcome	O
,	O
however	O
,	O
with	O
prolonged	O
(	O
7	O
-	O
10	O
or	O
more	O
days	O
)	O
supraphysiological	O
steroid	O
treatment	O
at	O
a	O
sufficiently	O
high	O
dose	O
to	O
address	O
the	O
excess	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
but	O
low	O
enough	O
to	O
avoid	O
immune	B-DISO
suppression	I-DISO
.	O

Although	O
steroids	O
cannot	O
be	O
used	O
as	O
a	O
monotherapy	O
in	O
the	O
treatment	O
of	O
avian	B-DISO
influenza	I-DISO
,	O
there	O
might	O
be	O
a	O
potential	O
role	O
for	O
their	O
use	O
as	O
an	O
adjunct	O
treatment	O
to	O
antiviral	O
therapy	O
if	O
appropriate	O
dosages	O
can	O
be	O
determined	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
caused	O
by	O
a	O
novel	O
coronavirus	O
(	O
CoV	O
),	O
SARS	B-DISO
-	O
CoV	O
.	O
In	O
previous	O
studies	O
,	O
we	O
showed	O
that	O
a	O
SARS	B-DISO
-	O
CoV	O
spike	O
(	O
S	O
)	O
glycoprotein	O
-	O
based	O
modified	O
vaccinia	B-DISO
Ankara	O
(	O
MVA	O
-	O
S	O
)	O
vaccine	O
could	O
induce	O
strong	O
neutralizing	O
antibody	O
(	O
Nab	O
)	O
response	O
which	O
might	O
have	O
played	O
a	O
critical	O
role	O
in	O
protecting	O
Chinese	O
rhesus	O
monkeys	O
from	O
the	O
pathogenic	O
viral	O
challenge	O
.	O

Thus	O
,	O
our	O
data	O
provides	O
a	O
promising	O
optimal	O
regimen	O
for	O
vaccine	O
development	O
in	O
humans	O
against	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

Presence	O
of	O
anti	O
-	O
KC	O
:	O
KC	O
complexes	O
was	O
associated	O
with	O
development	O
of	O
severe	O
pulmonary	B-DISO
inflammation	I-DISO
that	O
was	O
,	O
however	O
,	O
dramatically	O
suppressed	O
in	O
gamma	O
-	O
chain	O
-	O
deficient	O
mice	O
.	O

ABSTRACT	O
:	O
The	O
susceptibility	O
of	O
the	O
chicken	O
embryo	O
related	O
(	O
CER	O
)	O
cell	O
line	O
to	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
M41	O
)	O
was	O
characterized	O
after	O
five	O
consecutive	O
passages	O
in	O
CER	O
cells	O
.	O

TITLE	O
:	O
Prognostication	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
:	O
a	O
retrospective	O
time	O
-	O
course	O
analysis	O
of	O
1312	O
laboratory	O
-	O
confirmed	O
patients	O
in	O
Hong	O
Kong	O
.	O

Demographic	O
,	O
clinical	O
and	O
laboratory	O
data	O
at	O
presentation	O
and	O
investigative	O
data	O
during	O
the	O
first	O
10	O
days	O
of	O
illness	O
from	O
the	O
time	O
of	O
symptom	B-DISO
onset	O
were	O
compiled	O
.	O

ABSTRACT	O
:	O
Glucocorticoids	O
have	O
been	O
shown	O
to	O
improve	O
survival	O
when	O
used	O
in	O
patients	O
with	O
septic	B-DISO
shock	I-DISO
.	O

Blood	O
samples	O
were	O
obtained	O
for	O
the	O
determination	O
of	O
amylase	O
,	O
lipase	O
,	O
tumor	B-DISO
necrosis	I-DISO
factor	O
(	O
TNF	O
)-	O
alpha	O
,	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
,	O
macrophage	O
inflammatory	O
peptide	O
(	O
MIP	B-DISO
)-	O
2	O
and	O
soluble	O
intercellular	O
adhesion	B-DISO
molecule	O
(	O
sICAM	O
)-	O
1	O
levels	O
,	O
while	O
pancreatic	O
and	O
lung	O
tissues	O
were	O
removed	O
for	O
myeloperoxidase	O
(	O
MPO	O
)	O
activity	O
,	O
nitric	O
oxide	O
(	O
NOx	O
)	O
level	O
,	O
CD40	O
expression	O
and	O
histological	O
evaluation	O
.	O

To	O
study	O
M	O
protein	O
function	O
,	O
three	O
candidate	O
small	O
interfering	O
RNAs	O
(	O
siRNAs	O
)	O
corresponding	O
to	O
M	O
gene	O
sequences	O
were	O
designed	O
,	O
transcribed	O
in	O
vitro	O
,	O
and	O
then	O
tested	O
for	O
their	O
ability	O
to	O
silence	B-DISO
M	O
protein	O
expression	O
.	O

During	O
the	O
SARS	B-DISO
epidemic	O
,	O
informal	O
caregivers	O
reported	O
a	O
decline	O
of	O
1	O
.	O
6	O
SD	O
below	O
normal	O
on	O
the	O
mental	O
component	O
score	O
of	O
the	O
SF	O
-	O
36	O
.	O

ABSTRACT	O
:	O
The	O
host	O
innate	B-DISO
immune	I-DISO
response	I-DISO
is	O
an	O
important	O
deterrent	O
of	O
severe	O
viral	B-DISO
infection	I-DISO
in	O
humans	O
and	O
animals	O
.	O

Recombinant	O
SARS	B-DISO
-	O
CoV	O
lacking	O
ORF6	O
did	O
not	O
tether	O
karyopherin	O
alpha	O
2	O
to	O
the	O
ER	O
/	O
Golgi	O
membrane	O
and	O
allowed	O
the	O
import	O
of	O
the	O
STAT1	O
complex	O
into	O
the	O
nucleus	O
.	O

The	O
RVP	O
test	O
should	O
improve	O
the	O
capabilities	O
of	O
hospital	O
and	O
public	O
health	O
laboratories	O
for	O
diagnosing	O
viral	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
and	O
should	O
assist	O
public	O
health	O
agencies	O
in	O
identifying	O
etiologic	O
agents	O
in	O
respiratory	B-DISO
tract	I-DISO
infection	I-DISO
outbreaks	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
prevalence	O
of	O
recently	O
identified	O
viruses	O
,	O
including	O
human	O
metapneumovirus	O
(	O
hMPV	O
),	O
human	O
bocavirus	O
(	O
hBoV	O
),	O
human	O
coronavirus	O
NL63	O
(	O
hCoV	O
-	O
NL63	O
),	O
and	O
human	O
coronavirus	O
HKU1	O
(	O
hCoV	O
-	O
HKU1	O
)	O
in	O
children	O
with	O
acute	O
wheezing	B-DISO
.	O

hMPV	O
and	O
hCoV	O
-	O
NL63	O
were	O
detected	O
in	O
7	O
.	O
8	O
%	O
and	O
1	O
.	O
3	O
%	O
of	O
wheezing	B-DISO
children	O
,	O
respectively	O
.	O

Nevertheless	O
,	O
such	O
information	O
is	O
useful	O
in	O
providing	O
clinical	O
management	O
guidelines	O
and	O
directing	O
future	O
research	O
in	O
case	O
SARS	B-DISO
recurs	O
.	O

Prolonged	O
therapy	O
with	O
high	O
-	O
dose	O
steroids	O
,	O
in	O
the	O
absence	O
of	O
an	O
effective	O
antimicrobial	O
agent	O
,	O
could	O
predispose	O
patients	O
to	O
complications	O
such	O
as	O
disseminated	O
fungal	B-DISO
infection	I-DISO
,	O
and	O
avascular	B-DISO
necrosis	I-DISO
.	O

Dysfunction	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
with	O
decreased	O
glucocorticoid	O
activity	O
is	O
being	O
increasingly	O
recognized	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
,	O
particularly	O
those	O
with	O
sepsis	B-DISO
.	O

ABSTRACT	O
:	O
This	O
work	O
was	O
conducted	O
to	O
investigate	O
calf	O
-	O
level	O
factors	O
that	O
influence	O
the	O
risk	O
of	O
neonatal	B-DISO
diarrhea	I-DISO
and	O
shedding	O
of	O
Cryptosporidium	O
parvum	O
oocysts	O
in	O
calves	O
,	O
on	O
dairy	O
farms	O
in	O
Ontario	O
with	O
histories	O
of	O
calf	O
diarrhea	B-DISO
or	O
cryptosporidiosis	B-DISO
.	O

Using	O
the	O
GLLAMM	O
function	O
in	O
Stata	O
9	O
.	O
0	O
,	O
multilevel	O
regression	O
techniques	O
were	O
employed	O
to	O
investigate	O
associations	O
between	O
management	O
practices	O
and	O
the	O
risk	O
of	O
C	O
.	O
parvum	O
shedding	O
or	O
diarrhea	B-DISO
.	O

Factors	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
diarrhea	B-DISO
were	O
leaving	O
the	O
calf	O
with	O
the	O
dam	O
for	O
more	O
than	O
an	O
hour	O
after	O
birth	O
,	O
and	O
the	O
birth	O
of	O
a	O
calf	O
in	O
the	O
summer	O
as	O
opposed	O
to	O
winter	O
.	O

Electrophysiological	O
examination	O
showed	O
demyelination	B-DISO
in	O
74	O
%,	O
and	O
26	O
%	O
of	O
these	O
presented	O
with	O
very	O
low	O
amplitude	O
compound	O
action	O
potentials	O
.	O

Transient	O
deterioration	O
after	O
immunoglobulin	O
treatment	O
occurred	O
in	O
seven	O
patients	O
,	O
two	O
suffered	B-DISO
relapsing	O
GBS	B-DISO
,	O
and	O
three	O
developed	O
CIDP	B-DISO
.	O

Besides	O
pareses	B-DISO
and	O
respiratory	O
compromise	O
,	O
severe	O
neuropathic	B-DISO
pain	I-DISO
frequently	O
is	O
a	O
therapeutic	O
challenge	O
during	O
the	O
acute	O
phase	O
of	O
the	O
disease	O
.	O

TITLE	O
:	O
Quantitative	O
temporal	O
-	O
spatial	O
distribution	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
in	O
post	O
-	O
mortem	O
tissues	O
.	O

Occupationally	O
acquired	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
(	O
HIV	B-DISO
)	O
infection	B-DISO
could	O
also	O
result	O
in	O
life	O
-	O
threatening	O
,	O
opportunistic	O
lung	O
infections	B-DISO
as	O
a	O
result	O
of	O
host	O
immunosuppression	O
.	O

ABSTRACT	O
:	O
A	O
46	O
-	O
year	O
-	O
old	O
woman	O
presented	O
to	O
a	O
local	O
hospital	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
and	O
a	O
2	O
-	O
year	O
progressive	O
history	O
of	O
fatigue	B-DISO
,	O
personality	B-DISO
changes	I-DISO
,	O
increased	B-DISO
sweating	I-DISO
,	O
dysphagia	B-DISO
with	O
substantial	O
weight	O
loss	O
,	O
dysarthria	B-DISO
,	O
and	O
intermittent	O
ptosis	B-DISO
and	O
diplopia	B-DISO
.	O

Mice	O
pretreated	O
with	O
vehicle	O
and	O
receiving	O
endotoxin	O
exhibited	O
100	O
%	O
24	O
-	O
hour	O
lethality	O
,	O
a	O
dramatic	O
increase	O
in	O
all	O
parameters	O
of	O
systemic	O
and	O
pulmonary	B-DISO
inflammation	I-DISO
,	O
increased	O
capillary	O
leak	O
,	O
and	O
reduced	O
lung	O
function	O
.	O

Hsp90	O
inhibitors	O
may	O
offer	O
a	O
new	O
pharmacological	O
tool	O
in	O
the	O
management	O
of	O
severe	B-DISO
sepsis	I-DISO
and	O
severe	B-DISO
sepsis	I-DISO
-	O
induced	O
ALI	O
.	O

This	O
spike	O
protein	O
,	O
sharing	O
similar	O
deletions	O
with	O
other	O
group	O
2	O
coronaviruses	O
in	O
its	O
C	O
-	O
terminus	O
,	O
also	O
contained	O
a	O
15	O
-	O
amino	O
acid	O
peptide	O
homologous	O
to	O
a	O
corresponding	O
peptide	O
within	O
the	O
RBM	O
of	O
spike	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
which	O
was	O
absent	O
in	O
other	O
coronaviruses	O
except	O
bat	O
-	O
SARS	B-DISO
-	O
CoV	O
.	O
These	O
suggest	O
a	O
common	O
evolutionary	O
origin	O
in	O
the	O
spike	O
protein	O
of	O
bat	O
-	O
CoV	O
HKU2	O
,	O
bat	O
-	O
SARS	B-DISO
-	O
CoV	O
,	O
and	O
SARS	B-DISO
-	O
CoV	O
.	O

CXCL10	O
-	O
mediated	O
protection	O
within	O
the	O
liver	O
was	O
not	O
dependent	O
on	O
CXC	O
-	O
chemokine	O
receptor	O
2	O
(	O
CXCR2	O
)	O
signaling	O
as	O
anti	O
-	O
CXCR2	O
treatment	O
of	O
MHV	O
-	O
CXCL10	O
-	O
infected	O
mice	O
did	O
not	O
modulate	O
viral	O
clearance	O
or	O
liver	O
pathology	B-DISO
.	O

Demographic	O
,	O
clinical	O
and	O
cancer	B-DISO
-	O
related	O
data	O
were	O
collected	O
.	O

Here	O
we	O
report	O
that	O
two	O
hmAbs	O
,	O
m396	O
and	O
S230	O
.	O
15	O
,	O
potently	O
neutralized	O
GD03	O
and	O
representative	O
isolates	O
from	O
the	O
first	O
SARS	B-DISO
outbreak	O
(	O
Urbani	O
,	O
Tor2	O
)	O
and	O
from	O
palm	O
civets	O
(	O
SZ3	O
,	O
SZ16	O
).	O

TITLE	O
:	O
Medical	O
referral	O
of	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
:	O
lessons	O
learned	O
from	O
a	O
large	O
outbreak	O
of	O
botulism	O
in	O
northern	O
Thailand	O
.	O

Infection	B-DISO
of	O
cells	O
assessed	O
by	O
plaque	B-DISO
reduction	O
assay	O
was	O
strongly	O
inhibited	O
by	O
lysosomotropic	O
compounds	O
and	O
substances	O
that	O
interfere	O
with	O
clathrin	O
-	O
dependent	O
endocytosis	O
,	O
suggesting	O
that	O
MHV	O
-	O
A59	O
is	O
taken	O
up	O
via	O
endocytosis	O
and	O
delivered	O
to	O
acidic	O
endosomal	O
compartments	O
.	O

The	O
adaptation	O
of	O
animal	O
viruses	O
to	O
the	O
human	O
host	O
,	O
as	O
recently	O
exemplified	O
by	O
influenza	B-DISO
viruses	O
and	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
,	O
is	O
also	O
a	O
continuous	O
threat	O
.	O

Passage	O
of	O
the	O
attenuated	O
nsp9	O
-	O
nsp10	O
cleavage	O
mutant	B-DISO
increased	O
fitness	O
to	O
near	O
-	O
wild	O
-	O
type	O
kinetics	O
without	O
reversion	O
to	O
a	O
virus	O
capable	O
of	O
processing	O
nsp9	O
-	O
nsp10	O
.	O

An	O
(	O
R	O
-	O
Ahx	B-DISO
-	O
R	O
)(	O
4	O
)	O
AhxB	O
-	O
PMO	O
conjugate	O
was	O
the	O
most	O
effective	O
compound	O
in	O
inducing	O
the	O
correction	O
of	O
mutant	B-DISO
dystrophin	O
transcripts	O
in	O
myoblasts	O
derived	O
from	O
a	O
canine	O
model	O
of	O
DMD	B-DISO
.	O

Similarly	O
,	O
normal	O
levels	O
of	O
dystrophin	O
expression	O
were	O
restored	O
in	O
the	O
diaphragms	O
of	O
mdx	B-DISO
mice	O
,	O
with	O
treatment	O
starting	O
at	O
the	O
neonatal	O
stage	O
,	O
and	O
protein	O
was	O
still	O
detecTable	O
22	O
weeks	O
after	O
the	O
last	O
dose	O
of	O
an	O
(	O
R	O
-	O
Ahx	B-DISO
-	O
R	O
)(	O
4	O
)	O
AhxB	O
-	O
PMO	O
conjugate	O
.	O

TITLE	O
:	O
Unusual	O
presentation	O
of	O
leptospirosis	B-DISO
in	O
the	O
late	O
stage	O
of	O
pregnancy	O
.	O

Hitherto	O
,	O
the	O
SARS	B-DISO
-	O
CoV	O
,	O
as	O
a	O
viral	O
paradigm	O
of	O
emerging	O
infectious	B-DISO
entities	O
,	O
has	O
been	O
extensively	O
studied	O
that	O
has	O
ranged	O
from	O
epidemiology	O
,	O
molecular	O
virology	O
/	O
immunology	O
to	O
structural	O
genomics	O
.	O

ABSTRACT	O
:	O
The	O
feasibility	O
of	O
developing	O
a	O
prophylactic	O
vaccine	O
against	O
SARS	B-DISO
was	O
assessed	O
by	O
comparing	O
the	O
immune	O
responses	O
elicited	O
by	O
immunizing	O
mice	O
with	O
a	O
recombinant	O
SARS	B-DISO
spike	O
glycoprotein	O
(	O
S	O
-	O
protein	O
)	O
formulated	O
with	O
different	O
adjuvants	O
,	O
given	O
by	O
different	O
routes	O
.	O

Measures	O
currently	O
used	O
for	O
the	O
management	O
of	O
patients	O
with	O
SARS	B-DISO
include	O
isolation	O
,	O
ribavirin	O
,	O
corticosteroid	O
therapy	O
and	O
mechanical	O
ventilation	O
.	O

Other	O
recorded	O
variables	O
included	O
age	O
,	O
sex	O
,	O
biochemical	O
indicators	O
,	O
blood	O
gas	O
analysis	O
,	O
length	O
of	O
stay	O
in	O
ICU	O
,	O
length	O
of	O
ventilation	O
,	O
presence	O
or	O
absence	O
of	O
tracheostomy	O
,	O
ventilation	O
variables	O
,	O
elective	O
operation	O
or	O
emergency	B-DISO
operation	O
.	O

ABSTRACT	O
:	O
To	O
clarify	O
the	O
molecular	O
basis	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
adaptation	O
to	O
different	O
host	O
species	O
,	O
we	O
serially	O
passaged	O
SARS	B-DISO
-	O
CoV	O
in	O
rat	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)-	O
expressing	O
cells	O
.	O

TITLE	O
:	O
Expression	O
of	O
feline	O
angiotensin	O
converting	O
enzyme	O
2	O
and	O
its	O
interaction	O
with	O
SARS	B-DISO
-	O
CoV	O
S1	O
protein	O
.	O

Applications	O
are	O
given	O
to	O
specific	O
models	O
for	O
influenza	B-DISO
and	O
SARS	B-DISO
.	O

Improvements	O
in	O
compliance	O
and	O
reduced	O
psychological	B-DISO
distress	I-DISO
may	O
be	O
possible	O
by	O
minimizing	O
duration	O
,	O
revising	O
requirements	O
,	O
and	O
providing	O
enhanced	O
education	O
and	O
support	O
.	O

Ten	O
diterpenoids	O
(	O
1	O
-	O
10	O
),	O
two	O
sesquiterpenoids	O
(	O
11	O
and	O
12	O
),	O
two	O
triterpenoids	O
(	O
13	O
and	O
14	O
),	O
five	O
lignoids	O
(	O
15	O
-	O
19	O
),	O
curcumin	O
(	O
20	O
),	O
and	O
reference	O
controls	O
niclosamide	O
(	O
21	O
)	O
and	O
valinomycin	O
(	O
22	O
)	O
were	O
potent	O
inhibitors	O
at	O
concentrations	O
between	O
3	O
.	O
3	O
and	O
10	O
microM	O
.	O
The	O
concentrations	O
of	O
the	O
22	O
compounds	O
to	O
inhibit	O
50	O
%	O
of	O
Vero	O
E6	O
cell	O
proliferation	B-DISO
(	O
CC50	O
)	O
and	O
viral	O
replication	O
(	O
EC50	O
)	O
were	O
measured	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
first	O
appeared	O
in	O
Southern	O
China	O
in	O
November	O
2002	O
,	O
and	O
then	O
quickly	O
spread	O
to	O
33	O
countries	O
on	O
five	O
continents	O
along	O
international	O
air	O
travel	O
routes	O
.	O

The	O
clinical	O
evolution	O
is	O
gradual	O
:	O
from	O
mild	O
non	O
-	O
specific	O
manifestations	O
of	O
acute	B-DISO
tracheobronchitis	I-DISO
against	O
the	O
background	O
of	O
a	O
prolonged	O
fever	O
unaffected	O
by	O
antibiotic	O
therapy	O
to	O
the	O
onset	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
insufficiency	I-DISO
and	O
unilateral	O
bronchial	O
obstruction	B-DISO
syndrome	B-DISO
.	O

TITLE	O
:	O
Activation	O
of	O
human	O
monocytes	O
after	O
infection	B-DISO
by	O
human	O
coronavirus	O
229E	O
.	O

Additional	O
experiments	O
with	O
UV	O
-	O
inactivated	O
virus	O
,	O
cell	O
-	O
cell	O
fusion	O
-	O
blocking	B-DISO
antibodies	O
,	O
and	O
an	O
MHV	O
mutant	B-DISO
with	O
a	O
defect	O
in	O
spike	O
protein	O
maturation	O
demonstrated	O
that	O
spike	O
-	O
host	O
interactions	O
in	O
the	O
ER	O
are	O
responsible	O
for	O
the	O
induction	O
of	O
ER	O
stress	O
and	O
subsequent	O
Cxcl2	O
mRNA	O
transcription	O
.	O

Three	O
patients	O
died	O
,	O
one	O
from	O
compromised	O
cardiac	O
function	O
,	O
one	O
from	O
overwhelming	O
sepsis	B-DISO
and	O
one	O
from	O
respiratory	B-DISO
failure	I-DISO
due	O
to	O
severe	O
bilateral	O
CCAM	O
;	O
the	O
rest	O
of	O
the	O
patients	O
made	O
a	O
satisfactory	O
recovery	O
.	O

TITLE	O
:	O
[	O
New	O
infections	B-DISO
:	O
myths	O
and	O
reality	O
].	O

A	O
31	O
-	O
year	O
-	O
old	O
female	O
patient	O
at	O
30	O
weeks	O
of	O
amenorrhea	B-DISO
was	O
admitted	O
to	O
the	O
obstetrics	O
department	O
with	O
40	O
degrees	O
C	O
hyperthermia	O
and	O
New	O
York	O
Heart	O
Association	O
(	O
NYHA	O
)	O
class	O
4	O
dyspnea	B-DISO
.	O

Blood	O
gases	O
showed	O
severe	O
hypoxemia	O
associated	O
with	O
hypocapnia	B-DISO
.	O

This	O
study	O
evaluated	O
the	O
incidence	O
of	O
ALI	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
mechanically	O
ventilated	O
CDS	B-DISO
.	O

The	O
main	O
outcome	O
measure	O
was	O
the	O
incidence	O
of	O
ALI	O
and	O
ARDS	B-DISO
.	O

Magnetic	O
resonance	O
imaging	O
was	O
performed	O
,	O
and	O
an	O
enlargement	B-DISO
of	O
the	O
lateral	O
,	O
third	O
,	O
and	O
fourth	O
ventricles	O
and	O
syringomyelia	B-DISO
were	O
detected	O
.	O

Mice	O
immunized	O
four	O
times	O
with	O
VLPs	O
developed	O
high	O
antibody	O
titres	O
against	O
SARS	B-DISO
CoV	O
.	O
In	O
addition	O
,	O
VLPs	O
elicited	O
cell	O
-	O
mediated	O
immunity	O
as	O
demonstrated	O
by	O
enhanced	O
interferon	O
-	O
gamma	O
and	O
interleukin	O
-	O
4	O
production	O
.	O

ABSTRACT	O
:	O
The	O
acute	B-DISO
phase	I-DISO
reaction	I-DISO
(	O
APR	O
)	O
is	O
a	O
response	O
to	O
potentially	O
pathogenic	O
stimuli	O
.	O

It	O
begins	O
with	O
the	O
release	O
of	O
interleukin	O
(	O
IL	O
)-	O
1	O
,	O
IL	O
-	O
6	O
and	O
tumour	B-DISO
necrosis	I-DISO
factor	O
(	O
TNF	O
)-	O
alpha	O
from	O
inflammatory	O
cells	O
.	O

These	O
cytokines	O
induce	O
fever	O
,	O
leucocytosis	B-DISO
and	O
release	O
of	O
serum	O
acute	O
phase	O
proteins	O
(	O
APPs	O
).	O

In	O
cats	O
with	O
inflammatory	O
conditions	O
,	O
fever	O
is	O
a	O
common	O
finding	O
,	O
with	O
leucocytosis	B-DISO
due	O
to	O
the	O
release	O
of	O
cells	O
from	O
the	O
marginal	O
pool	O
,	O
followed	O
by	O
activation	O
of	O
myelopoiesis	O
.	O

ABSTRACT	O
:	O
The	O
proteins	O
encoded	O
by	O
gene	O
7	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
have	O
been	O
demonstrated	O
to	O
have	O
proapoptotic	O
activity	O
when	O
expressed	O
from	O
cDNA	O
but	O
appear	O
to	O
be	O
dispensable	O
for	O
virus	O
replication	O
.	O

The	O
data	O
indicate	O
that	O
open	O
reading	O
frames	O
7a	O
and	O
7b	O
contribute	O
to	O
but	O
are	O
not	O
solely	O
responsible	O
for	O
the	O
apoptosis	O
seen	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
cells	O
.	O

ABSTRACT	O
:	O
Little	O
is	O
known	O
about	O
CD4	O
(+)	O
T	O
-	O
cell	O
immunity	O
to	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Pulmonary	B-DISO
complication	I-DISO
in	O
severe	O
Plasmodium	B-DISO
falciparum	I-DISO
malaria	I-DISO
is	O
manifested	O
as	O
a	O
prolonged	O
impairment	B-DISO
of	O
gas	O
transfer	O
or	O
the	O
more	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

In	O
either	O
clinical	O
presentation	O
,	O
vascular	O
permeability	O
is	O
a	O
major	O
component	O
of	O
the	O
pathologic	B-DISO
process	I-DISO
.	O

Replication	O
and	O
spread	O
of	O
the	O
nsp1	O
mutant	B-DISO
virus	O
was	O
restored	O
almost	O
to	O
wild	O
-	O
type	O
levels	O
in	O
type	O
I	O
interferon	O
(	O
IFN	O
)	O
receptor	O
-	O
deficient	O
mice	O
,	O
indicating	O
that	O
nsp1	O
interferes	O
efficiently	O
with	O
the	O
type	O
I	O
IFN	O
system	O
.	O

Analysis	O
of	O
gene	O
signatures	O
revealed	O
induction	O
of	O
a	O
strong	O
innate	B-DISO
immune	I-DISO
response	I-DISO
characterized	O
by	O
the	O
stimulation	O
of	O
various	O
cytokine	O
and	O
chemokine	O
genes	O
,	O
including	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
IL	O
-	O
8	O
,	O
and	O
IP	O
-	O
10	O
,	O
which	O
corresponds	O
to	O
the	O
host	O
response	O
seen	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Samples	O
obtained	O
from	O
farms	O
experiencing	O
PED	O
or	O
TGE	B-DISO
were	O
quantified	O
between	O
10	O
(	O
2	O
)	O
and	O
10	O
(	O
5	O
)	O
RNA	O
copies	O
.	O

TITLE	O
:	O
Attachment	O
and	O
internalization	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
in	O
feline	O
blood	O
monocytes	O
and	O
Crandell	O
feline	O
kidney	O
cells	O
.	O

ABSTRACT	O
:	O
To	O
review	O
the	O
literature	O
on	O
retention	O
strategies	O
in	O
follow	O
-	O
up	O
studies	O
and	O
their	O
relevance	O
to	O
critical	O
care	O
and	O
to	O
comment	O
on	O
the	O
Toronto	O
experience	O
with	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
follow	O
-	O
up	O
studies	O
.	O

ABSTRACT	O
:	O
We	O
propose	O
a	O
compartmental	O
disease	B-DISO
transmission	I-DISO
model	O
with	O
an	O
asymptomatic	O
(	O
or	O
subclinical	O
)	O
infective	O
class	O
to	O
study	O
the	O
role	O
of	O
asymptomatic	B-DISO
infection	I-DISO
in	O
the	O
transmission	O
dynamics	O
of	O
infectious	B-DISO
diseases	I-DISO
with	O
asymptomatic	O
infectives	O
,	O
e	O
.	O
g	O
.,	O
influenza	B-DISO
.	O

TITLE	O
:	O
Pan	O
-	O
viral	O
screening	O
of	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
in	O
adults	O
with	O
and	O
without	O
asthma	B-DISO
reveals	O
unexpected	O
human	O
coronavirus	O
and	O
human	O
rhinovirus	O
diversity	O
.	O

All	O
together	O
,	O
these	O
results	O
show	O
that	O
CBA	O
exhibit	O
promising	O
capabilities	O
to	O
inhibit	O
coronavirus	B-DISO
infections	I-DISO
.	O

TITLE	O
:	O
The	O
membrane	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
suppresses	O
NF	O
-	O
kappaB	O
activation	O
.	O

Analysis	O
of	O
the	O
sequence	O
identified	O
11	O
open	O
reading	O
frames	O
which	O
encode	O
two	O
replicase	O
polyproteins	O
,	O
five	O
structural	O
proteins	O
(	O
hemagglutinin	O
esterase	O
,	O
spike	O
,	O
envelope	O
,	O
membrane	O
,	O
and	O
nucleocapsid	O
)	O
and	O
four	O
accessory	O
proteins	O
(	O
NS2	B-DISO
,	O
p4	O
.	O
7	O
,	O
p12	O
.	O
7	O
,	O
and	O
I	O
).	O

Identification	O
of	O
functional	O
dominant	O
epitopes	O
in	O
SARS	B-DISO
CoV	O
S	O
protein	O
for	O
T	O
cells	O
is	O
crucial	O
for	O
further	O
understanding	O
of	O
cellular	O
immune	O
responses	O
elicited	O
by	O
SARS	B-DISO
CoV	O
S	O
DNA	O
vaccine	O
.	O

Pneumonia	B-DISO
was	O
diagnosed	O
in	O
71	O
%	O
and	O
Acute	O
Lung	O
Injury	O
(	O
ALI	O
)/	O
Adult	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
26	O
%	O
of	O
the	O
patients	O
.	O

During	O
intensive	O
care	O
treatment	O
,	O
hypotension	O
,	O
elevated	B-DISO
blood	I-DISO
sugar	I-DISO
and	O
hypoalbuminemia	O
are	O
possible	O
independent	O
predictors	O
of	O
an	O
unfavourable	O
outcome	O
.	O

TITLE	O
:	O
Lopinavir	O
-	O
ritonavir	O
dramatically	O
affects	O
the	O
pharmacokinetics	O
of	O
irinotecan	O
in	O
HIV	B-DISO
patients	O
with	O
Kaposi	B-DISO
'	I-DISO
s	I-DISO
sarcoma	I-DISO
.	O

Expeditious	O
research	O
on	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
,	O
one	O
of	O
the	O
latest	O
discovered	O
coronaviruses	O
that	O
infect	O
humans	O
,	O
has	O
provided	O
valuable	O
insights	O
into	O
the	O
molecular	O
aspects	O
of	O
cell	O
-	O
death	O
regulation	O
during	O
infection	B-DISO
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
evades	O
antiviral	O
signaling	O
:	O
role	O
of	O
nsp1	O
and	O
rational	O
design	O
of	O
an	O
attenuated	O
strain	O
.	O

ABSTRACT	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
epidemic	O
was	O
caused	O
by	O
the	O
spread	O
of	O
a	O
previously	O
unrecognized	O
infectious	B-DISO
agent	O
,	O
the	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
).	O

TITLE	O
:	O
Acute	B-DISO
chest	I-DISO
syndrome	I-DISO
in	O
Omani	O
children	O
with	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
:	O
epidemiology	O
and	O
clinical	O
profile	O
.	O

Prevention	O
of	O
VOCs	O
,	O
prompt	O
and	O
effective	O
treatment	O
of	O
respiratory	B-DISO
infections	I-DISO
and	O
caution	O
in	O
the	O
use	O
of	O
morphine	O
during	O
a	O
VOC	O
should	O
reduce	O
the	O
incidence	O
of	O
ACS	O
.	O

RESULTS	O
:	O
Of	O
240	O
patients	O
registered	O
with	O
SCD	B-DISO
,	O
52	O
(	O
22	O
%)	O
developed	O
55	O
episodes	O
of	O
ACS	O
.	O

ABSTRACT	O
:	O
Noninvasive	O
ventilation	O
has	O
assumed	O
an	O
important	O
role	O
in	O
the	O
management	O
of	O
respiratory	B-DISO
failure	I-DISO
in	O
critical	O
care	O
units	O
,	O
but	O
it	O
must	O
be	O
used	O
selectively	O
depending	O
on	O
the	O
patient	O
'	O
s	O
diagnosis	O
and	O
clinical	O
characteristics	O
.	O

There	O
are	O
important	O
gaps	O
in	O
our	O
understanding	O
of	O
the	O
epidemiology	O
of	O
respiratory	O
virus	O
infections	B-DISO
in	O
tropical	O
countries	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
pancreatitis	I-DISO
represents	O
a	O
spectrum	O
of	O
disease	O
,	O
ranging	O
from	O
a	O
mild	O
,	O
transitory	O
illness	O
to	O
a	O
severe	O
,	O
rapidly	O
progressive	O
hemorrhagic	O
form	O
,	O
with	O
massive	B-DISO
necrosis	I-DISO
and	O
mortality	O
rates	O
of	O
up	O
to	O
24	O
%.	O

The	O
reported	O
incidence	O
of	O
acute	B-DISO
pancreatitis	I-DISO
diagnosed	O
first	O
at	O
clinicopathologic	O
autopsy	O
ranges	O
between	O
30	O
%	O
and	O
42	O
%.	O

Many	O
prior	O
studies	O
have	O
suggested	O
that	O
the	O
majority	O
of	O
deaths	O
in	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
occur	O
in	O
the	O
late	O
phase	O
of	O
the	O
disease	O
as	O
a	O
result	O
of	O
pancreatic	O
sepsis	B-DISO
.	O

HRCT	O
images	O
revealed	O
smooth	O
septal	O
thickening	O
and	O
intralobular	O
lines	O
superimposed	O
on	O
ground	O
glass	O
opacities	B-DISO
in	O
both	O
upper	O
lobes	O
.	O

TITLE	O
:	O
[	O
Acute	B-DISO
severe	I-DISO
asthma	I-DISO
in	O
infants	O
.	O

Greater	O
knowledge	O
regarding	O
TRALI	B-DISO
on	O
the	O
part	O
of	O
clinicians	O
could	O
be	O
crucial	O
in	O
preventing	O
and	O
treating	O
this	O
severe	O
complication	B-DISO
of	I-DISO
blood	I-DISO
transfusion	I-DISO
.	O

Piglets	O
naturally	O
co	O
-	O
infected	O
with	O
PEDV	O
and	O
PGAR	O
appeared	O
to	O
have	O
severe	O
and	O
prolonged	O
diarrhea	B-DISO
that	O
was	O
distinct	O
from	O
that	O
commonly	O
observed	O
.	O

These	O
findings	O
failed	O
to	O
detect	O
any	O
interaction	O
between	O
PEDV	O
and	O
porcine	O
rotavirus	O
in	O
the	O
small	O
intestines	O
of	O
piglets	O
,	O
suggesting	O
that	O
concurrent	O
infection	B-DISO
of	O
PGAR	O
may	O
not	O
synergistically	O
enhance	O
intestinal	O
villous	O
atrophy	B-DISO
of	O
piglets	O
with	O
PEDV	O
disease	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
a	O
novel	O
coronavirus	O
that	O
causes	O
a	O
highly	O
contagious	O
respiratory	B-DISO
disease	I-DISO
,	O
SARS	B-DISO
,	O
with	O
significant	O
mortality	O
.	O

Upper	O
and	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
were	O
equally	O
common	O
.	O

A	O
single	O
lineage	O
of	O
HBoV	O
was	O
associated	O
with	O
both	O
respiratory	O
tract	O
and	O
enteric	O
infections	B-DISO
.	O

This	O
renewed	O
interest	O
follows	O
the	O
re	O
-	O
emergence	O
of	O
communicable	B-DISO
diseases	I-DISO
,	O
largely	O
thought	O
to	O
have	O
disappeared	O
and	O
therefore	O
irrelevant	O
to	O
modern	O
day	O
practitioners	O
.	O

The	O
2003	O
SARS	B-DISO
outbreak	O
particularly	O
presented	O
propitious	O
circumstances	O
for	O
reconsidering	O
this	O
issue	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
perform	O
a	O
retrospective	O
analysis	O
of	O
neurological	O
signs	O
in	O
a	O
population	O
of	O
55	O
cats	O
with	O
a	O
histopathologically	O
confirmed	O
neurological	O
form	O
of	O
FIP	B-DISO
.	O

Seizure	B-DISO
patterns	O
were	O
determined	O
and	O
it	O
was	O
attempted	O
to	O
relate	O
occurrence	O
of	O
seizures	B-DISO
with	O
age	O
,	O
breed	O
,	O
sex	O
and	O
neuropathological	O
features	O
.	O

The	O
exact	O
type	O
of	O
seizure	B-DISO
could	O
not	O
be	O
determined	O
in	O
one	O
cat	O
.	O

Thus	O
,	O
the	O
occurrence	O
of	O
seizures	B-DISO
in	O
FIP	B-DISO
indicates	O
extensive	O
brain	O
damage	O
and	O
can	O
,	O
therefore	O
,	O
be	O
considered	O
to	O
be	O
an	O
unfavourable	O
prognostic	O
sign	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
the	O
association	O
of	O
Bartonella	O
species	O
,	O
feline	O
herpesvirus	O
1	O
,	O
feline	O
calicivirus	O
,	O
feline	B-DISO
leukemia	I-DISO
virus	O
and	O
feline	O
immunodeficiency	B-DISO
virus	O
with	O
chronic	O
feline	O
gingivostomatitis	B-DISO
.	O

Serum	O
was	O
tested	O
for	O
feline	B-DISO
leukemia	I-DISO
virus	O
(	O
FeLV	O
)	O
antigen	O
and	O
antibodies	O
against	O
feline	O
immunodeficiency	B-DISO
virus	O
,	O
feline	O
calicivirus	O
(	O
FCV	O
),	O
feline	O
herpesvirus	O
1	O
(	O
FHV	O
-	O
1	O
),	O
and	O
Bartonella	O
species	O
(	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
Western	O
blot	O
immunoassay	O
).	O

We	O
consider	O
this	O
in	O
a	O
prominent	O
test	O
case	O
:	O
the	O
eusocial	O
naked	O
mole	B-DISO
-	O
rat	O
(	O
Heterocephalus	O
glaber	O
),	O
one	O
of	O
the	O
most	O
inbred	O
of	O
all	O
free	O
-	O
living	O
mammals	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
patterns	O
of	O
pulmonary	O
function	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
during	O
three	O
-	O
year	O
convalescent	O
period	O
,	O
and	O
to	O
investigate	O
the	O
changes	O
and	O
the	O
medium	O
and	O
long	O
term	O
effects	O
on	O
pulmonary	O
function	O
of	O
SARS	B-DISO
patients	O
.	O

Compared	O
with	O
the	O
healthy	O
controls	O
,	O
there	O
were	O
significant	O
decrease	O
in	O
forced	O
vital	O
capacity	O
(	O
FVC	O
),	O
vital	O
capacity	O
(	O
VC	O
),	O
one	O
second	O
forced	O
expiratory	O
volume	O
(	O
FEV1	O
),	O
25	O
%-	O
75	O
%	O
forced	O
expiratory	O
flow	O
(	O
25	O
%-	O
75	O
%	O
FEF	O
)	O
of	O
SARS	B-DISO
patients	O
within	O
three	O
years	O
after	O
their	O
discharge	O
from	O
hospital	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
lung	O
functions	O
of	O
most	O
patients	O
have	O
recovered	O
gradually	O
,	O
but	O
in	O
a	O
minority	O
of	O
patients	O
they	O
may	O
be	O
impaired	B-DISO
.	O

RESULTS	O
:	O
Compared	O
with	O
the	O
healthy	O
controls	O
,	O
there	O
were	O
significant	O
decrease	O
in	O
forced	O
vital	O
capacity	O
(	O
FVC	O
),	O
vital	O
capacity	O
(	O
VC	O
),	O
one	O
second	O
forced	O
expiratory	O
volume	O
(	O
FEV1	O
),	O
25	O
%-	O
75	O
%	O
forced	O
expiratory	O
flow	O
(	O
25	O
%-	O
75	O
%	O
FEF	O
)	O
of	O
SARS	B-DISO
patients	O
within	O
three	O
years	O
after	O
their	O
discharge	O
from	O
hospital	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Prevention	O
of	O
LPS	B-DISO
-	O
induced	O
acute	O
lung	O
injury	O
in	O
mice	O
by	O
mesenchymal	O
stem	O
cells	O
overexpressing	O
angiopoietin	O
1	O
.	O

High	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
is	O
a	O
developing	O
therapy	O
for	O
the	O
treatment	O
of	O
ARDS	B-DISO
in	O
adult	O
patients	O
that	O
can	O
be	O
life	O
saving	O
.	O

However	O
,	O
often	O
patients	O
with	O
acute	O
,	O
severe	O
brain	O
injury	O
demonstrate	O
intracranial	B-DISO
hypertension	I-DISO
(	O
hICP	O
)	O
due	O
to	O
a	O
variety	O
of	O
injuries	O
(	O
e	O
.	O
g	O
.,	O
traumatic	O
brain	O
injury	O
,	O
mass	B-DISO
lesion	I-DISO
,	O
acute	O
hydrocephalus	B-DISO
).	O

Hence	O
,	O
we	O
characterized	O
the	O
UV	O
disinfection	O
of	O
viral	O
aerosols	O
using	O
the	O
bacteriophage	O
MS2	O
,	O
adenovirus	B-DISO
,	O
and	O
coronavirus	O
.	O

Analysis	O
of	O
data	O
from	O
3	O
,	O
665	O
intensive	O
care	O
unit	O
admissions	O
identified	O
318	O
(	O
8	O
.	O
68	O
%)	O
cases	O
of	O
severe	B-DISO
sepsis	I-DISO
,	O
64	O
.	O
8	O
%	O
of	O
which	O
were	O
men	O
.	O

The	O
median	O
age	O
(	O
interquartile	O
range	O
)	O
of	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
was	O
64	O
(	O
47	O
-	O
74	O
)	O
yrs	O
.	O

Histopathological	O
evaluation	O
and	O
indirect	O
immunohistochemistry	O
confirmed	O
a	O
diagnosis	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
,	O
hepatic	B-DISO
lipidosis	I-DISO
and	O
feline	O
skin	O
fragility	B-DISO
syndrome	B-DISO
.	O

Feline	O
skin	O
fragility	B-DISO
syndrome	B-DISO
has	O
not	O
previously	O
been	O
reported	O
in	O
association	O
with	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
).	O

TITLE	O
:	O
Bats	O
,	O
civets	O
and	O
the	O
emergence	O
of	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
The	O
extent	O
to	O
which	O
coronaviruses	O
are	O
associated	O
with	O
lower	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
in	O
previously	O
healthy	O
children	O
without	O
underlying	O
medical	O
conditions	O
is	O
unknown	O
.	O

We	O
investigated	O
instances	O
of	O
radiographically	O
confirmed	O
lower	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
among	O
symptomatic	O
children	O
with	O
coronavirus	B-DISO
infection	I-DISO
.	O

The	O
SARS	B-DISO
-	O
CoV	O
specific	O
antibody	O
was	O
detected	O
for	O
all	O
of	O
them	O
by	O
ELISA	O
and	O
neutralized	O
test	O
simultaneously	O
.	O

The	O
findings	O
discussed	O
include	O
the	O
impact	O
of	O
infection	B-DISO
control	O
practices	O
on	O
social	O
work	O
intervention	O
,	O
the	O
range	O
of	O
interventions	O
undertaken	O
,	O
respondents	O
'	O
reflections	O
and	O
self	O
-	O
awareness	O
,	O
the	O
role	O
of	O
values	O
and	O
ethics	O
,	O
creativity	O
and	O
training	O
,	O
and	O
their	O
recommendations	O
for	O
future	O
emergencies	B-DISO
.	O

TITLE	O
:	O
Genetic	O
analysis	O
of	O
Murine	B-DISO
hepatitis	I-DISO
virus	O
nsp4	O
in	O
virus	O
replication	O
.	O

ABSTRACT	O
:	O
To	O
retrospectively	O
evaluate	O
the	O
efficacy	O
of	O
total	O
lymphoid	O
irradiation	O
(	O
TLI	O
)-	O
based	O
reconditioning	O
regimens	O
in	O
patients	O
with	O
graft	B-DISO
failure	I-DISO
or	O
graft	O
rejection	O
after	O
allogeneic	O
hematopoietic	O
stem	O
cell	O
transplantation	O
.	O

Four	O
major	O
themes	O
were	O
identified	O
from	O
the	O
interviews	O
:	O
1	O
)	O
fear	O
of	O
immediate	O
isolation	O
and	O
infection	B-DISO
control	O
procedures	O
,	O
2	O
)	O
sources	O
of	O
anxiety	O
,	O
3	O
)	O
coping	O
,	O
and	O
4	O
)	O
communication	O
with	O
children	O
and	O
health	O
care	O
professionals	O
.	O

RESULTS	O
:	O
Four	O
major	O
themes	O
were	O
identified	O
from	O
the	O
interviews	O
:	O
1	O
)	O
fear	O
of	O
immediate	O
isolation	O
and	O
infection	B-DISO
control	O
procedures	O
,	O
2	O
)	O
sources	O
of	O
anxiety	O
,	O
3	O
)	O
coping	O
,	O
and	O
4	O
)	O
communication	O
with	O
children	O
and	O
health	O
care	O
professionals	O
.	O

This	O
data	O
may	O
have	O
important	O
implication	O
for	O
developing	O
SARS	B-DISO
vaccines	O
.	O

Differences	O
in	O
viral	O
structure	O
and	O
clinical	O
outcome	O
prompted	O
us	O
to	O
postulate	O
that	O
innate	O
mucosal	O
immune	O
responses	O
would	O
be	O
markedly	O
different	O
following	O
rotavirus	O
and	O
coronavirus	B-DISO
infections	I-DISO
.	O

Although	O
several	O
adverse	O
events	O
have	O
been	O
described	O
with	O
its	O
use	O
,	O
acute	O
and	O
subacute	O
interstitial	B-DISO
pneumonitis	I-DISO
leading	O
to	O
pulmonary	B-DISO
fibrosis	I-DISO
is	O
rare	O
and	O
potentially	O
fatal	O
.	O

TITLE	O
:	O
Preparing	O
for	O
pandemic	O
influenza	B-DISO
:	O
revisit	O
the	O
basics	O
.	O

A	O
self	O
-	O
administered	O
questionnaire	O
was	O
delivered	O
to	O
nurses	O
in	O
Hong	O
Kong	O
to	O
assess	O
their	O
attitude	O
towards	O
avian	B-DISO
influenza	I-DISO
;	O
risk	O
perception	O
,	O
and	O
their	O
relationships	O
with	O
previous	O
level	O
of	O
exposure	O
to	O
SARS	B-DISO
patients	O
.	O

Infection	B-DISO
with	O
these	O
viruses	O
is	O
common	O
in	O
childhood	O
though	O
the	O
prevalence	O
of	O
these	O
viruses	O
may	O
vary	O
from	O
year	O
to	O
year	O
.	O

ABSTRACT	O
:	O
Devic	B-DISO
'	I-DISO
s	I-DISO
neuromyelitis	I-DISO
optica	I-DISO
was	O
orginally	O
described	O
as	O
an	O
acute	O
severe	O
monophasic	O
syndrome	B-DISO
characterised	O
by	O
myelitis	B-DISO
and	O
optic	B-DISO
neuritis	I-DISO
.	O

BPD	B-DISO
is	O
a	O
multifactorial	O
condition	B-DISO
,	O
where	O
the	O
degree	O
of	O
prematurity	O
plays	O
an	O
important	O
role	O
.	O

Here	O
we	O
describe	O
a	O
rapid	O
and	O
sensitive	O
genotyping	O
assay	O
and	O
microarray	O
for	O
URI	O
identification	O
using	O
standard	O
amplification	B-DISO
and	O
hybridization	O
techniques	O
,	O
with	O
electrochemical	O
detection	O
(	O
ECD	B-DISO
)	O
on	O
a	O
semiconductor	O
-	O
based	O
oligonucleotide	O
microarray	O
.	O

Here	O
,	O
the	O
author	O
performs	O
a	O
further	O
analysis	O
to	O
document	O
the	O
frequency	O
of	O
the	O
lymphopenia	B-DISO
in	O
SARS	B-DISO
by	O
the	O
way	O
of	O
metanalysis	O
study	O
.	O

CAS	B-DISO
characteristically	O
occurs	O
in	O
middle	O
-	O
aged	O
or	O
elderly	O
persons	O
,	O
often	O
with	O
signs	B-DISO
and	I-DISO
symptoms	I-DISO
exacerbated	O
by	O
cold	B-DISO
.	O

Twenty	O
-	O
two	O
patients	O
with	O
severe	O
CAP	B-DISO
and	O
ARDS	B-DISO
were	O
included	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
SARS	B-DISO
epidemic	O
has	O
boosted	O
interest	O
in	O
the	O
discovery	O
of	O
novel	O
human	O
and	O
animal	O
coronaviruses	O
.	O

We	O
analyzed	O
this	O
cross	O
-	O
reactivity	O
by	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
Western	O
blot	O
analysis	O
using	O
specific	O
antisera	O
to	O
animal	O
CoVs	O
and	O
SARS	B-DISO
-	O
CoV	O
and	O
SARS	B-DISO
patient	O
convalescent	O
-	O
phase	O
or	O
negative	O
sera	O
.	O

The	O
N	O
-	O
protein	O
fragments	O
comprising	O
aa	O
360	O
to	O
412	O
and	O
aa	O
1	O
to	O
213	O
reacted	O
specifically	O
with	O
SARS	B-DISO
convalescent	O
-	O
phase	O
sera	O
but	O
not	O
with	O
negative	O
human	O
sera	O
in	O
ELISA	O
;	O
the	O
fragment	O
comprising	O
aa	O
1	O
to	O
213	O
cross	O
-	O
reacted	O
with	O
antisera	O
to	O
animal	O
CoVs	O
,	O
whereas	O
the	O
fragment	O
comprising	O
aa	O
360	O
to	O
412	O
did	O
not	O
cross	O
-	O
react	O
and	O
could	O
be	O
a	O
potential	O
candidate	O
for	O
SARS	B-DISO
diagnosis	O
.	O

TITLE	O
:	O
High	O
prevalence	O
of	O
the	O
CD14	O
-	O
159CC	O
genotype	O
in	O
patients	O
infected	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
.	O

The	O
incidence	O
of	O
ARDS	B-DISO
was	O
31	O
.	O
9	O
%	O
(	O
90	O
/	O
282	O
)	O
in	O
patients	O
with	O
serious	O
thoracoabdominal	O
injuries	O
.	O

There	O
are	O
many	O
high	O
risk	O
factors	O
related	O
to	O
ARDS	B-DISO
following	O
severe	O
thoracoabdominal	O
injuries	O
,	O
which	O
should	O
be	O
detected	O
early	O
and	O
treated	O
timely	O
to	O
decrease	O
the	O
incidence	O
and	O
mortality	O
of	O
A	O
RDS	O
.	O

The	O
univariate	O
analysis	O
and	O
multivariate	O
analysis	O
demonstrated	O
that	O
the	O
clinical	O
conditions	O
such	O
as	O
elder	O
age	O
,	O
shock	O
,	O
dyspnea	B-DISO
,	O
abnormal	O
arterial	O
blood	O
gas	O
,	O
hemopneumothorax	B-DISO
,	O
pulmonary	O
contusion	O
,	O
flail	B-DISO
chest	I-DISO
,	O
coexisting	O
pulmonary	B-DISO
diseases	I-DISO
,	O
multiple	O
abdominal	O
injury	O
and	O
high	O
ISS	B-DISO
score	O
were	O
the	O
independent	O
high	O
risk	O
factors	O
related	O
to	O
ARDS	B-DISO
.	O

HCoV	O
infections	B-DISO
were	O
infrequently	O
detected	O
in	O
rural	O
Thailand	O
by	O
use	O
of	O
sensitive	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assays	O
.	O

HCoV	O
infections	B-DISO
were	O
detected	O
throughout	O
both	O
study	O
years	O
;	O
93	O
.	O
6	O
%	O
of	O
OC43	O
infections	B-DISO
in	O
the	O
first	O
year	O
occurred	O
from	O
January	O
through	O
March	O
.	O

We	O
evaluated	O
the	O
humoral	O
immune	O
response	O
and	O
pathological	O
end	O
points	O
in	O
ferrets	O
challenged	O
with	O
the	O
Urbani	O
strain	O
of	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
)	O
after	O
having	O
received	O
formalin	O
-	O
inactivated	O
whole	O
-	O
virus	O
vaccine	O
or	O
mock	O
vaccine	O
.	O

These	O
putative	O
lung	O
stem	O
/	O
progenitor	O
cells	O
can	O
also	O
be	O
identified	O
in	O
some	O
non	O
-	O
SARS	B-DISO
individuals	O
and	O
can	O
be	O
infected	O
by	O
SARS	B-DISO
-	O
coronavirus	O
ex	O
vivo	O
.	O

In	O
group	O
1	O
,	O
this	O
produced	O
a	O
significant	O
decrease	O
in	O
mean	O
(+/-	O
SD	O
)	O
RV	O
enlargement	B-DISO
(	O
from	O
0	O
.	O
91	O
+/-	O
0	O
.	O
22	O
to	O
0	O
.	O
61	O
+/-	O
0	O
.	O
21	O
)	O
after	O
18	O
h	O
of	O
PP	O
(	O
p	O
=	O
0	O
.	O
000	O
)	O
and	O
a	O
significant	O
reduction	O
in	O
mean	O
septal	O
dyskinesia	B-DISO
(	O
from	O
1	O
.	O
5	O
+/-	O
0	O
.	O
2	O
to	O
1	O
.	O
1	O
+/-	O
0	O
.	O
1	O
)	O
after	O
18	O
h	O
of	O
PP	O
(	O
p	O
=	O
0	O
.	O
000	O
).	O

Serology	O
for	O
human	O
herpes	B-DISO
virus	O
(	O
HHV6	O
)	O
was	O
initially	O
negative	O
but	O
became	O
positive	O
.	O

TITLE	O
:	O
Information	O
control	O
in	O
time	O
of	O
crisis	O
:	O
the	O
framing	O
of	O
SARS	B-DISO
in	O
China	O
-	O
based	O
newspapers	O
and	O
Internet	O
sources	O
.	O

It	O
was	O
found	O
to	O
contain	O
a	O
cleavable	O
signal	O
sequence	O
,	O
which	O
directs	O
the	O
precursor	O
to	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
and	O
mediates	O
its	O
translocation	B-DISO
into	O
the	O
lumen	O
.	O

TITLE	O
:	O
Protection	O
from	O
infection	B-DISO
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
in	O
a	O
Chinese	O
hamster	O
model	O
by	O
equine	O
neutralizing	O
F	O
(	O
ab	O
')	O
2	O
.	O

All	O
animals	O
were	O
protected	O
from	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
in	O
preventive	O
settings	O
.	O

The	O
docking	O
results	O
suggest	O
two	O
major	O
modes	O
for	O
the	O
initial	O
binding	O
of	O
these	O
inhibitors	O
to	O
the	O
active	O
site	O
of	O
SARS	B-DISO
-	O
CoV	O
M	O
(	O
pro	O
).	O

TITLE	O
:	O
Cloning	O
and	O
further	O
sequence	O
analysis	O
of	O
the	O
ORF3	O
gene	O
of	O
wild	O
-	O
and	O
attenuated	O
-	O
type	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
viruses	O
.	O

ABSTRACT	O
:	O
The	O
open	O
reading	O
frame	O
(	O
ORF3	O
)	O
genes	O
of	O
the	O
parent	O
DR13	O
,	O
attenuated	O
DR13	O
,	O
KPED	O
-	O
9	O
,	O
P	O
-	O
5V	O
,	O
and	O
12	O
field	O
samples	O
were	O
cloned	O
and	O
sequenced	O
to	O
further	O
explore	O
the	O
functions	O
of	O
wild	O
-	O
and	O
attenuated	O
-	O
type	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
viruses	O
(	O
PEDVs	O
).	O

TITLE	O
:	O
The	O
ethics	O
of	O
infection	B-DISO
control	O
:	O
philosophical	O
frameworks	O
.	O

Frameworks	O
for	O
the	O
ethics	O
of	O
infection	B-DISO
control	O
resemble	O
those	O
of	O
public	O
health	O
more	O
than	O
those	O
of	O
clinical	O
medicine	O
but	O
embrace	O
elements	O
of	O
both	O
.	O

In	O
recent	O
years	O
their	O
significance	O
has	O
increased	O
because	O
of	O
the	O
appearence	O
of	O
""""	O
bird	B-DISO
flu	I-DISO
""""	O
caused	O
by	O
a	O
highly	O
virulent	O
strain	O
H5N1	B-DISO
subtype	O
.	O

Although	O
influenza	B-DISO
type	O
A	O
viruses	O
that	O
cause	O
infections	B-DISO
in	O
the	O
birds	O
(	O
avian	B-DISO
influenza	I-DISO
)	O
are	O
species	O
-	O
specific	O
,	O
some	O
may	O
cross	O
the	O
species	O
barrier	O
to	O
infect	O
humans	O
.	O

After	O
a	O
mean	O
incubation	O
period	O
of	O
2	O
-	O
5	O
days	O
,	O
infection	B-DISO
onsets	O
with	O
high	O
fever	O
,	O
lower	O
respiratory	O
tract	O
symptoms	O
and	O
diarrhea	B-DISO
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
as	O
an	O
agent	O
of	O
emerging	O
and	O
reemerging	O
infection	B-DISO
.	O

The	O
marked	O
increase	O
in	O
the	O
understanding	O
of	O
the	O
virus	O
and	O
the	O
disease	O
within	O
such	O
a	O
short	O
time	O
has	O
allowed	O
the	O
development	O
of	O
diagnostic	O
tests	O
,	O
animal	O
models	O
,	O
antivirals	O
,	O
vaccines	O
,	O
and	O
epidemiological	O
and	O
infection	B-DISO
control	O
measures	O
,	O
which	O
could	O
prove	O
to	O
be	O
useful	O
in	O
randomized	O
control	O
trials	O
if	O
SARS	B-DISO
should	O
return	O
.	O

TITLE	O
:	O
Maturation	O
and	O
localization	O
of	O
macrophages	O
and	O
microglia	O
during	O
infection	B-DISO
with	O
a	O
neurotropic	O
murine	O
coronavirus	O
.	O

Herein	O
,	O
we	O
show	O
that	O
""""	O
immature	O
""""	O
F4	O
/	O
80	O
(+)	O
Ly	O
-	O
6C	O
(	O
hi	O
)	O
monocytes	O
are	O
the	O
first	O
cells	O
,	O
along	O
with	O
neutrophils	O
,	O
to	O
enter	O
the	O
MHV	O
-	O
JHM	O
-	O
infected	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
).	O

These	O
results	O
suggest	O
that	O
chronic	O
CNS	B-DISO
infection	I-DISO
results	O
in	O
the	O
appearance	O
of	O
CD11c	O
-	O
expressing	O
macrophages	O
from	O
the	O
blood	O
that	O
exhibit	O
properties	O
of	O
immature	O
APCs	B-DISO
,	O
are	O
closely	O
associated	O
with	O
areas	O
of	O
demyelination	B-DISO
,	O
and	O
may	O
act	O
as	O
final	O
effectors	O
of	O
myelin	O
destruction	O
.	O

HCW	O
status	O
(	O
OR	O
2	O
.	O
72	O
,	O
95	O
%	O
CI	O
1	O
.	O
11	O
-	O
6	O
.	O
68	O
;	O
p	O
=	O
0	O
.	O
029	O
)	O
or	O
epidemiological	O
linkage	O
to	O
the	O
SARS	B-DISO
outbreak	O
ward	O
(	O
OR	O
3	O
.	O
59	O
,	O
95	O
%	O
CI	O
1	O
.	O
42	O
-	O
9	O
.	O
05	O
;	O
p	O
=	O
0	O
.	O
007	O
)	O
were	O
independent	O
factors	O
associated	O
with	O
hMPV	O
infection	B-DISO
.	O

A	O
major	O
nosocomial	O
hMPV	O
outbreak	O
involving	O
HCWs	O
occurred	O
during	O
the	O
early	O
SARS	B-DISO
epidemic	O
.	O

RESULTS	O
:	O
An	O
hMPV	O
outbreak	O
occurred	O
during	O
6	O
-	O
16	O
March	O
2003	O
(	O
first	O
week	O
of	O
the	O
Hong	O
Kong	O
SARS	B-DISO
epidemic	O
).	O

Medical	O
personnel	O
in	O
the	O
ED	O
reported	O
that	O
they	O
would	O
be	O
willing	O
to	O
pay	O
substantial	O
monetary	O
amounts	O
for	O
preventing	O
nosocomial	O
SARS	B-DISO
.	O

TITLE	O
:	O
Possible	O
meteorological	O
influence	O
on	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
community	O
outbreak	O
at	O
Amoy	O
Gardens	O
,	O
Hong	O
Kong	O
.	O

If	O
that	O
hypothesis	O
is	O
correct	O
,	O
meteorological	O
factors	O
may	O
have	O
played	O
a	O
contributory	O
role	O
;	O
the	O
virus	O
-	O
laden	O
aerosols	O
may	O
have	O
been	O
transported	O
between	O
apartment	O
blocks	O
by	O
the	O
ambient	O
wind	B-DISO
,	O
low	O
mixing	O
heights	O
may	O
have	O
prevented	O
the	O
efficient	O
dispersion	O
of	O
the	O
aerosols	O
,	O
and	O
a	O
fall	O
in	O
temperature	O
may	O
have	O
fostered	O
the	O
survival	O
of	O
the	O
virus	O
or	O
increased	O
the	O
susceptibility	O
of	O
the	O
exposed	O
population	O
.	O

Recently	O
our	O
research	O
showed	O
that	O
some	O
proteases	O
facilitated	O
SCoV	O
'	O
s	O
direct	O
entry	O
from	O
the	O
cell	O
surface	O
,	O
resulting	O
in	O
a	O
more	O
efficient	O
infection	B-DISO
than	O
the	O
previously	O
known	O
infection	B-DISO
via	O
endosomal	O
entry	O
.	O

This	O
finding	O
suggests	O
that	O
sHRPs	O
may	O
effectively	O
prevent	O
infection	B-DISO
in	O
the	O
lungs	O
,	O
where	O
SCoV	O
infection	B-DISO
could	O
be	O
enhanced	O
by	O
proteases	O
produced	O
in	O
this	O
organ	O
.	O

In	O
PRCV	O
/	O
DEX	O
pigs	O
,	O
significantly	O
milder	O
pneumonia	B-DISO
,	O
fewer	O
PRCV	O
-	O
positive	O
cells	O
,	O
and	O
lower	O
viral	O
RNA	O
titers	O
were	O
present	O
in	O
lungs	O
early	O
at	O
PID	B-DISO
2	O
;	O
however	O
,	O
at	O
PID	B-DISO
4	O
,	O
10	O
,	O
and	O
21	O
,	O
severe	O
bronchointerstitial	O
pneumonia	B-DISO
,	O
significantly	O
higher	O
numbers	O
of	O
PRCV	O
-	O
positive	O
cells	O
,	O
and	O
higher	O
viral	O
RNA	O
titers	O
were	O
observed	O
compared	O
to	O
results	O
for	O
PRCV	O
/	O
PBS	B-DISO
pigs	O
.	O

Significantly	O
lower	O
numbers	O
of	O
CD2	O
(+),	O
CD3	O
(+),	O
CD4	O
(+),	O
and	O
CD8	O
(+)	O
T	O
cells	O
were	O
also	O
observed	O
in	O
lungs	O
of	O
PRCV	O
/	O
DEX	O
pigs	O
than	O
in	O
those	O
of	O
PRCV	O
/	O
PBS	B-DISO
pigs	O
at	O
PID	B-DISO
8	O
and	O
10	O
,	O
coincident	O
with	O
fewer	O
gamma	O
interferon	O
(	O
IFN	O
-	O
gamma	O
)-	O
secreting	O
cells	O
in	O
the	O
tracheobronchial	O
lymph	O
nodes	O
as	O
determined	O
by	O
enzyme	O
-	O
linked	O
immunospot	O
assay	O
.	O

The	O
incremental	O
effect	O
of	O
adding	O
virucidals	O
or	O
antiseptics	O
to	O
normal	O
handwashing	O
to	O
decrease	O
respiratory	B-DISO
disease	I-DISO
remains	O
uncertain	O
.	O

In	O
contrast	O
,	O
markers	O
of	O
acute	O
inflammation	B-DISO
,	O
except	O
for	O
interleukin	O
-	O
6	O
,	O
and	O
disordered	O
coagulation	O
were	O
similar	O
in	O
trauma	O
and	O
nontrauma	O
patients	O
.	O

Mortality	O
,	O
development	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
and	O
number	O
of	O
failing	O
organs	O
were	O
determined	O
for	O
each	O
group	O
.	O

The	O
objectives	O
were	O
to	O
describe	O
and	O
analyze	O
the	O
impact	O
of	O
2	O
major	O
crises	O
(	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
[	O
SARS	B-DISO
]	O
outbreak	O
,	O
and	O
the	O
electrical	O
system	O
failure	O
"["""	O
blackout	B-DISO
"""])"	O
on	O
pharmacy	O
practice	O
and	O
pharmacists	O
in	O
Toronto	O
,	O
Canada	O
.	O

In	O
April	O
2005	O
,	O
CDC	O
received	O
reports	O
of	O
two	O
cases	O
of	O
severe	O
TBRF	O
associated	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
residents	O
of	O
California	O
and	O
Nevada	O
.	O

The	O
findings	O
indicate	O
that	O
ARDS	B-DISO
might	O
occur	O
more	O
frequently	O
in	O
patients	O
with	O
TBRF	O
than	O
previously	O
recognized	O
.	O

It	O
was	O
previously	O
found	O
that	O
cockerels	O
vaccinated	O
with	O
live	O
attenuated	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
AIBV	O
)	O
have	O
decreased	O
serum	O
testosterone	O
concentrations	O
,	O
epididymal	O
stones	O
and	O
reduced	O
fertility	B-DISO
.	O

TITLE	O
:	O
[	O
Ischemic	O
rhabdomyolysis	B-DISO
and	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
].	O

ABSTRACT	O
:	O
Rhabdomyolysis	B-DISO
is	O
a	O
clinical	O
syndrome	B-DISO
characterized	O
by	O
the	O
breakdown	B-DISO
and	O
later	O
necrosis	O
of	O
skeletal	O
muscle	O
,	O
leading	O
to	O
the	O
release	O
of	O
various	O
intracellular	O
components	O
into	O
the	O
blood	O
stream	O
.	O

ABSTRACT	O
:	O
The	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
spike	O
is	O
the	O
largest	O
known	O
viral	O
spike	O
molecule	O
,	O
and	O
shares	O
a	O
similar	O
function	O
with	O
all	O
class	O
1	O
viral	O
fusion	O
proteins	O
.	O

The	O
correlation	O
coefficient	O
of	O
scores	O
of	O
health	O
related	O
behavior	O
during	O
and	O
after	O
SARS	B-DISO
was	O
0	O
.	O
782	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Multiple	O
linear	O
regression	O
indicated	O
that	O
the	O
scores	O
of	O
health	O
related	O
behavior	O
were	O
significantly	O
related	O
to	O
the	O
perceived	O
stress	O
,	O
demographic	O
characteristics	O
and	O
recognition	O
of	O
SARS	B-DISO
.	O

To	O
further	O
investigate	O
the	O
possible	O
roles	O
of	O
S2	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
induced	O
apoptosis	O
and	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
,	O
we	O
characterized	O
the	O
host	O
expression	O
profiles	O
induced	O
upon	O
S2	O
over	O
-	O
expression	O
in	O
Vero	O
E6	O
cells	O
by	O
oligonucleotide	O
microarray	O
analysis	O
.	O

ABSTRACT	O
:	O
The	O
contribution	O
of	O
DRAK2	O
[	O
death	O
-	O
associated	O
protein	O
kinase	O
(	O
DAPK	O
)-	O
related	O
apoptosis	O
-	O
inducing	O
kinase	O
2	O
]	O
to	O
anti	O
-	O
viral	O
memory	O
T	O
cell	O
responses	O
following	O
infection	B-DISO
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
was	O
examined	O
.	O

Memory	O
T	O
cells	O
derived	O
from	O
MHV	O
-	O
immunized	O
Drak2	O
(-/-)	O
mice	O
exhibited	O
amplified	O
proliferation	B-DISO
and	O
IFN	O
-	O
gamma	O
secretion	O
following	O
stimulation	O
with	O
viral	O
epitopes	O
.	O

After	O
induction	O
of	O
severe	O
lung	O
injury	O
by	O
repeated	O
saline	O
lung	O
lavage	O
,	O
18	O
adult	O
white	O
Japanese	O
rabbits	O
were	O
randomly	O
assigned	O
to	O
3	O
groups	O
:	O
Group	O
1	O
,	O
CNEP	O
(	O
extra	O
thoracic	B-DISO
negative	O
pressure	O
,	O
-	O
10	O
cmH2O	O
)	O
with	O
HFO	O
(	O
mean	O
airway	O
pressure	O
(	O
MAP	O
),	O
10	O
cmH2O	O
);	O
Group	O
2	O
,	O
HFO	O
(	O
MAP	O
,	O
10	O
cmH2O	O
);	O
and	O
Group	O
3	O
,	O
HFO	O
(	O
MAP	O
,	O
15	O
cmH2O	O
).	O

CONCLUSIONS	O
:	O
Adequate	O
CNEP	O
combined	O
with	O
HFO	O
improves	O
oxygenation	O
with	O
less	O
impact	O
on	O
blood	O
pressure	O
than	O
high	O
-	O
frequency	O
oscillation	O
alone	O
in	O
an	O
animal	O
model	O
of	O
respiratory	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Mice	O
transgenic	O
for	O
human	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
provide	O
a	O
model	O
for	O
SARS	B-DISO
coronavirus	B-DISO
infection	I-DISO
.	O

Other	O
pathologic	O
changes	O
,	O
including	O
vasculitis	B-DISO
,	O
degeneration	B-DISO
,	O
and	O
necrosis	O
,	O
were	O
found	O
in	O
the	O
extrapulmonary	O
organs	O
of	O
transgenic	O
mice	O
,	O
and	O
viral	O
antigen	O
was	O
found	O
in	O
brain	O
.	O

A	O
few	O
such	O
segments	O
are	O
present	O
in	O
the	O
SARS	B-DISO
-	O
CoV	O
genome	O
,	O
but	O
also	O
in	O
mRNAs	O
of	O
host	O
proteins	O
involved	O
in	O
the	O
regulation	O
of	O
signaling	O
pathways	O
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
disease	I-DISO
syndrome	B-DISO
with	O
preoperative	O
chronomodulated	O
chemoradiotherapy	O
in	O
patients	O
with	O
esophageal	B-DISO
cancer	I-DISO
.	O

Moreover	O
,	O
domain	O
III	O
rotates	O
dramatically	O
against	O
the	O
chymotrypsin	O
fold	O
compared	O
with	O
the	O
dimer	O
,	O
from	O
which	O
we	O
proposed	O
a	O
putative	O
dimerization	O
model	O
for	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
).	O

To	O
explore	O
the	O
mechanistic	O
basis	O
of	O
mucosal	O
protective	O
immunity	O
,	O
gene	O
transcriptional	O
profiling	O
in	O
mucosal	O
tissues	O
was	O
evaluated	O
after	O
the	O
primary	O
and	O
secondary	O
immunization	O
of	O
animals	O
with	O
an	O
attenuated	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
),	O
a	O
prototype	O
of	O
Coronavirus	O
and	O
a	O
well	O
-	O
characterized	O
mucosal	O
pathogen	O
.	O

During	O
closer	O
contact	O
,	O
they	O
can	O
transmit	O
rabies	B-DISO
and	O
probably	O
other	O
nonviral	O
infectious	B-DISO
diseases	I-DISO
.	O

Bats	O
get	O
closer	O
to	O
man	O
due	O
to	O
ecological	O
modifications	O
like	O
deforestation	O
,	O
so	O
that	O
transmission	O
of	O
new	O
infectious	B-DISO
agents	O
might	O
provoke	O
dramatic	O
epidemics	O
.	O

Then	O
the	O
antigenic	O
property	O
of	O
Z	O
protein	O
to	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
was	O
analyzed	O
by	O
dot	O
-	O
blot	O
and	O
ELISA	O
assay	O
.	O

ELISA	O
analysis	O
indicated	O
the	O
SARS	B-DISO
-	O
CoV	O
antigen	O
prepared	O
from	O
SARS	B-DISO
-	O
CoV	O
lysates	O
can	O
be	O
detected	O
by	O
anti	O
-	O
Z	O
sera	O
.	O

The	O
predicted	O
epitopes	O
of	O
Z	O
protein	O
can	O
induce	O
the	O
development	O
of	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
antibody	O
in	O
rabbits	O
,	O
which	O
provides	O
a	O
new	O
protein	O
for	O
developing	O
vaccine	O
against	O
SARS	B-DISO
-	O
CoV	O
.	O
RESULTS	O
:	O
Z	O
gene	O
was	O
successfully	O
designed	O
and	O
expressed	O
in	O
E	O
.	O
coli	O
BL21	O
(	O
DE3	O
).	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
iNO	O
therapy	O
leads	O
to	O
an	O
improvement	O
in	O
oxygenation	O
without	O
short	O
-	O
term	O
side	O
effects	O
(	O
such	O
as	O
pulmonary	O
hemorrhage	B-DISO
,	I-DISO
intracranial	I-DISO
hemorrhage	B-DISO
,	O
pneumothorax	B-DISO
or	O
acute	O
deterioration	O
)	O
in	O
premature	O
infants	O
with	O
severe	O
RDS	O
and	O
respiratory	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Sequence	O
analysis	O
of	O
the	O
S1	O
glycoprotein	O
gene	O
of	O
infectious	B-DISO
bronchitis	B-DISO
viruses	O
:	O
identification	O
of	O
a	O
novel	O
phylogenetic	O
group	O
in	O
Korea	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
pharmacokinetics	O
,	O
tolerance	B-DISO
and	O
immunity	O
of	O
this	O
kind	O
of	O
antibody	O
in	O
macaques	O
and	O
rats	O
.	O

TITLE	O
:	O
[	O
Management	O
of	O
90	O
patients	O
presenting	O
with	O
suspected	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
The	O
characteristics	O
of	O
patients	O
with	O
a	O
suspected	O
SARS	B-DISO
hospitalized	O
in	O
a	O
Paris	O
hospital	O
were	O
studied	O
to	O
analyze	O
the	O
hypothetic	O
differences	O
between	O
epidemiologic	O
and	O
clinical	O
teams	O
in	O
the	O
management	O
of	O
an	O
epidemic	O
emerging	O
disease	O
,	O
and	O
to	O
gather	O
experience	O
for	O
the	O
management	O
of	O
the	O
next	O
outbreak	O
.	O

The	O
risk	O
assessment	O
was	O
different	O
in	O
almost	O
40	O
%	O
of	O
the	O
cases	O
,	O
with	O
no	O
impact	O
on	O
epidemic	O
diffusion	O
or	O
hospital	O
-	O
borne	O
exposure	O
as	O
no	O
probable	O
case	O
of	O
SARS	B-DISO
was	O
diagnosed	O
among	O
these	O
patients	O
or	O
their	O
households	O
.	O

The	O
multiplex	O
RT	O
-	O
PCR	O
enabled	O
a	O
sensitive	O
one	O
-	O
time	O
detection	O
and	O
the	O
characterisation	O
of	O
all	O
of	O
the	O
known	O
HCoV	O
types	O
with	O
the	O
exception	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Despite	O
recent	O
advances	O
in	O
intensive	O
care	O
medicine	O
,	O
acute	O
lung	O
injury	O
and	O
its	O
more	O
severe	O
form	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
pose	O
major	O
therapeutic	O
problems	O
.	O

Concerns	O
about	O
SARS	B-DISO
adversely	O
affected	O
the	O
willingness	O
of	O
respondents	O
to	O
perform	O
SCPR	O
or	O
CCPR	O
on	O
strangers	O
and	O
to	O
perform	O
SCPR	O
on	O
family	O
members	O
.	O

It	O
is	O
described	O
to	O
be	O
expressed	O
during	O
infection	B-DISO
and	O
to	O
be	O
a	O
component	O
of	O
the	O
virus	O
particle	O
surface	O
.	O

These	O
observations	O
are	O
confirmed	O
by	O
direct	O
in	O
vitro	O
binding	O
of	O
recombinant	O
protein	O
7a	O
to	O
the	O
wild	O
type	O
and	O
mutant	B-DISO
K287C	O
/	O
K294C	O
I	O
domain	O
showing	O
that	O
the	O
I	O
domain	O
is	O
the	O
7a	O
binding	O
site	O
in	O
the	O
alpha	O
(	O
L	O
)	O
chain	O
of	O
LFA	O
-	O
1	O
.	O

The	O
patient	O
was	O
diagnosed	O
with	O
pneumonia	B-DISO
due	I-DISO
to	I-DISO
Pseudomonas	I-DISO
aeruginosa	O
.	O

Type	O
B	O
insulin	B-DISO
resistance	I-DISO
syndrome	I-DISO
.	O

Acute	B-DISO
respiratory	I-DISO
failure	I-DISO
and	O
hypotension	O
combined	O
with	O
seizures	B-DISO
were	O
the	O
initial	O
symptoms	O
.	O

Aggressive	B-DISO
management	O
was	O
practiced	O
with	O
continuous	O
transfusion	O
of	O
blood	O
products	O
and	O
administration	O
of	O
vasocopressors	O
.	O

CONCLUSIONS	O
:	O
Amniotic	B-DISO
fluid	I-DISO
embolism	I-DISO
or	O
anaphylactoid	B-DISO
syndrome	I-DISO
of	I-DISO
pregnancy	I-DISO
is	O
a	O
life	O
-	O
threatening	O
condition	B-DISO
.	O

These	O
included	O
the	O
emergence	O
of	O
effective	O
'	O
champions	O
'	O
for	O
such	O
policies	O
,	O
an	O
ethos	O
of	O
pragmatism	O
and	O
receptivity	O
to	O
evidence	O
,	O
growing	O
collaboration	O
across	O
public	O
health	O
,	O
police	O
and	O
other	O
sectors	O
,	O
the	O
influence	O
of	O
contingent	O
events	O
such	O
as	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
epidemic	O
and	O
pressure	O
from	O
donors	O
and	O
international	O
organizations	O
to	O
adopt	O
best	O
practice	O
in	O
HIV	B-DISO
prevention	O
.	O

The	O
results	O
showed	O
that	O
astragalus	O
polysaccharide	O
and	O
isatis	O
root	O
polysaccharide	O
at	O
low	O
dosages	O
,	O
and	O
achyranthes	O
root	O
polysaccharide	O
and	O
Chinese	O
yam	O
polysaccharide	O
at	O
high	O
dosages	O
significantly	O
enhanced	O
the	O
ND	O
antibody	O
titers	O
,	O
concanavalin	O
A	O
-	O
induced	O
proliferation	B-DISO
of	O
peripheral	O
blood	O
lymphocytes	O
,	O
and	O
ratio	O
of	O
CD4	O
(+)	O
to	O
CD8	O
(+)	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Simulation	O
results	O
are	O
in	O
agreement	O
with	O
the	O
empirical	O
data	O
of	O
the	O
SARS	B-DISO
worldwide	O
epidemic	O
.	O

TITLE	O
:	O
Sensitive	O
and	O
specific	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
using	O
chemiluminescence	O
for	O
detection	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
viral	B-DISO
infection	I-DISO
.	O

These	O
extracts	O
also	O
significantly	O
decreased	O
PEDV	O
production	O
and	O
less	O
dramatically	O
decreased	O
vesicular	B-DISO
stomatitis	I-DISO
virus	O
(	O
VSV	O
)	O
production	O
in	O
vitro	O
.	O

RESULTS	O
:	O
Based	O
on	O
data	O
from	O
Shenzhen	O
,	O
Hongkong	O
and	O
Taiwan	O
,	O
the	O
maximum	O
and	O
mean	O
risk	O
(	O
per	O
million	O
)	O
of	O
SARS	B-DISO
-	O
CoV	O
transmission	O
from	O
donors	O
in	O
Shenzhen	O
were	O
estimated	O
as	O
23	O
.	O
57	O
(	O
95	O
%	O
CI	O
:	O
6	O
.	O
83	O
-	O
47	O
.	O
69	O
)	O
and	O
14	O
.	O
11	O
(	O
95	O
%	O
CI	O
:	O
11	O
.	O
00	O
-	O
17	O
.	O
22	O
),	O
respectively	O
.	O

PTSD	B-DISO
has	O
been	O
described	O
in	O
patients	O
after	O
multiple	O
trauma	O
,	O
burns	O
,	O
or	O
myocardial	B-DISO
infarction	I-DISO
with	O
a	O
particularly	O
high	O
incidence	O
in	O
survivors	O
of	O
acute	O
pulmonary	B-DISO
failure	I-DISO
(	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
)	O
or	O
septic	B-DISO
shock	I-DISO
.	O

A	O
high	O
number	O
of	O
these	O
traumatic	O
memories	O
from	O
the	O
ICU	O
has	O
been	O
shown	O
to	O
be	O
a	O
significant	O
risk	O
factor	O
for	O
the	O
later	O
development	O
of	O
PTSD	B-DISO
in	O
long	O
-	O
term	O
survivors	O
.	O

ABSTRACT	O
:	O
Mouse	B-DISO
hepatitis	I-DISO
virus	O
induces	O
a	O
biphasic	B-DISO
disease	I-DISO
in	O
BALB	O
/	O
c	O
mice	O
that	O
consists	O
of	O
an	O
acute	O
retinitis	B-DISO
followed	O
by	O
progression	O
to	O
a	O
chronic	O
retinal	B-DISO
degeneration	I-DISO
with	O
autoimmune	B-DISO
reactivity	O
.	O

The	O
pathogenic	O
mechanisms	O
of	O
SARS	B-DISO
-	O
CoV	O
remain	O
poorly	O
understood	O
.	O

SARS	B-DISO
lung	O
lesions	O
are	O
only	O
generated	O
in	O
monkeys	O
by	O
i	O
.	O
t	O
.	O

TITLE	O
:	O
Molecular	O
epidemiology	O
and	O
disease	O
severity	O
of	O
respiratory	O
syncytial	O
virus	O
in	O
relation	O
to	O
other	O
potential	O
pathogens	O
in	O
children	O
hospitalized	O
with	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
in	O
Jordan	O
.	O

ABSTRACT	O
:	O
Human	O
respiratory	O
syncytial	O
virus	O
(	O
HRSV	O
)	O
is	O
the	O
major	O
viral	O
cause	O
of	O
acute	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
in	O
children	O
.	O

The	O
frequency	O
and	O
severity	O
of	O
infections	B-DISO
caused	O
by	O
HRSV	O
were	O
assessed	O
in	O
hospitalized	O
Jordanian	O
children	O
<	O
5	O
years	O
of	O
age	O
compared	O
with	O
other	O
potential	O
etiological	O
agents	O
.	O

Mild	O
adverse	O
reactions	O
,	O
both	O
hematologic	O
and	O
nonhematologic	O
,	O
are	O
not	O
uncommon	O
;	O
however	O
,	O
severe	O
adverse	B-DISO
effects	I-DISO
are	O
rare	O
.	O

In	O
this	O
review	O
,	O
we	O
have	O
compiled	O
the	O
current	O
knowledge	O
about	O
SARS	B-DISO
-	O
CoV	O
accessory	O
proteins	O
,	O
obtained	O
from	O
studies	O
in	O
cell	O
culture	O
systems	O
,	O
reverse	O
genetics	O
and	O
animal	O
models	O
,	O
to	O
shed	O
some	O
light	O
into	O
the	O
possible	O
role	O
of	O
these	O
proteins	O
in	O
the	O
propagation	O
and	O
virulence	O
of	O
SARS	B-DISO
-	O
CoV	O
in	O
its	O
natural	O
host	O
.	O

ABSTRACT	O
:	O
Since	O
there	O
are	O
more	O
than	O
150	O
000	O
Italians	O
(	O
about	O
25	O
for	O
every	O
10	O
,	O
000	O
inhabitants	O
)	O
infected	O
with	O
HIV	B-DISO
,	O
Intensive	O
Care	O
Units	O
(	O
ICU	O
)	O
often	O
come	O
across	O
patients	O
who	O
are	O
HIV	B-DISO
positive	O
.	O

TITLE	O
:	O
A	O
test	O
for	O
constant	O
fatality	O
rate	O
of	O
an	O
emerging	O
epidemic	O
:	O
with	O
applications	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
Hong	O
Kong	O
and	O
Beijing	O
.	O

The	O
proposed	O
test	O
is	O
applied	O
to	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
data	O
in	O
Hong	O
Kong	O
and	O
Beijing	O
.	O

TITLE	O
:	O
[	O
Optimization	O
of	O
expression	O
condition	B-DISO
of	O
SARS	B-DISO
-	O
CoV	O
PUPs	O
genes	O
in	O
E	O
.	O
coli	O
].	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
)	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
potentiates	O
transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
beta	O
)-	O
induced	O
expression	O
of	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
but	O
attenuates	O
Smad3	O
/	O
Smad4	O
-	O
mediated	O
apoptosis	O
of	O
human	O
peripheral	O
lung	O
epithelial	O
HPL1	O
cells	O
.	O

These	O
findings	O
provide	O
evidence	O
of	O
a	O
novel	O
mechanism	O
whereby	O
N	O
protein	O
modulates	O
TGF	O
-	O
beta	O
signaling	O
to	O
block	O
apoptosis	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
host	O
cells	O
and	O
meanwhile	O
promote	O
tissue	O
fibrosis	B-DISO
.	O

Our	O
results	O
reveal	O
a	O
novel	O
mode	O
of	O
Smad3	O
action	O
in	O
a	O
Smad4	O
-	O
independent	O
manner	O
and	O
may	O
lead	O
to	O
successful	O
strategies	O
for	O
SARS	B-DISO
treatment	O
by	O
targeting	O
the	O
TGF	O
-	O
beta	O
signaling	O
molecules	O
.	O

Recommendations	O
are	O
grouped	O
into	O
those	O
directly	O
targeting	O
severe	B-DISO
sepsis	I-DISO
,	O
recommendations	O
targeting	O
general	O
care	O
of	O
the	O
critically	B-DISO
ill	I-DISO
patient	O
that	O
are	O
considered	O
high	O
priority	O
in	O
severe	B-DISO
sepsis	I-DISO
,	O
and	O
pediatric	O
considerations	O
.	O

Recommendations	O
specific	O
to	O
pediatric	O
severe	B-DISO
sepsis	I-DISO
include	O
:	O
greater	O
use	O
of	O
physical	O
examination	O
therapeutic	O
end	O
points	O
(	O
2C	O
);	O
dopamine	O
as	O
the	O
first	O
drug	O
of	O
choice	O
for	O
hypotension	O
(	O
2C	O
);	O
steroids	O
only	O
in	O
children	O
with	O
suspected	O
or	O
proven	O
adrenal	B-DISO
insufficiency	I-DISO
(	O
2C	O
);	O
a	O
recommendation	O
against	O
the	O
use	O
of	O
recombinant	O
activated	O
protein	O
C	O
in	O
children	O
(	O
1B	O
).	O

ABSTRACT	O
:	O
The	O
insertion	O
/	O
deletion	O
(	O
I	O
/	O
D	O
)	O
of	O
a	O
289	O
base	O
pair	O
Alu	O
repeat	O
sequence	O
polymorphism	O
in	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
gene	O
(	O
ACE	O
)	O
has	O
been	O
shown	O
to	O
predict	O
susceptibility	O
and	O
outcome	O
in	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

We	O
hypothesized	O
that	O
the	O
I	O
/	O
D	O
polymorphism	O
also	O
confers	O
susceptibility	O
to	O
sepsis	B-DISO
and	O
is	O
a	O
predisposing	O
factor	O
for	O
morbidity	O
and	O
mortality	O
of	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
.	O

TITLE	O
:	O
Intermediate	B-DISO
syndrome	I-DISO
following	O
organophosphate	O
insecticide	O
poisoning	O
.	O

ABSTRACT	O
:	O
Acute	O
organophosphate	O
insecticide	O
poisoning	O
can	O
manifest	O
3	O
different	O
phases	O
of	O
toxic	O
effects	O
,	O
namely	O
,	O
acute	O
cholinergic	B-DISO
crisis	I-DISO
,	O
intermediate	B-DISO
syndrome	I-DISO
(	O
IMS	O
),	O
and	O
delayed	O
neuropathy	B-DISO
.	O

Previously	O
proposed	O
mechanisms	O
of	O
IMS	O
include	O
different	O
susceptibility	O
of	O
various	O
cholinergic	O
receptors	O
,	O
muscle	B-DISO
necrosis	I-DISO
,	O
prolonged	O
acetylcholinesterase	O
inhibition	O
,	O
inadequate	O
oxime	O
therapy	O
,	O
downregulation	O
or	O
desensitization	O
of	O
postsynaptic	O
acetylcholine	O
receptors	O
,	O
failure	O
of	O
postsynaptic	O
acetylcholine	O
release	O
,	O
and	O
oxidative	B-DISO
stress	I-DISO
-	O
related	O
myopathy	B-DISO
.	O

Nevertheless	O
,	O
because	O
IMS	O
generally	O
concurs	O
with	O
severe	O
organophosphate	O
toxicity	O
and	O
persistent	O
inhibition	O
of	O
acetylcholinesterase	O
,	O
early	O
aggressive	B-DISO
decontamination	O
,	O
appropriate	O
antidotal	O
therapy	O
,	O
and	O
prompt	O
institution	O
of	O
ventilatory	O
support	O
should	O
be	O
helpful	O
in	O
ameliorating	O
the	O
magnitude	O
and	O
/	O
or	O
the	O
incidence	O
of	O
IMS	O
.	O

The	O
most	O
common	O
cause	O
of	O
death	O
in	O
the	O
surgical	O
group	O
was	O
brain	B-DISO
death	I-DISO
in	O
severe	O
traumatic	O
patients	O
.	O

TITLE	O
:	O
Comparison	O
of	O
acute	O
non	O
-	O
haemolytic	O
transfusion	B-DISO
reactions	I-DISO
in	O
female	O
and	O
male	O
patients	O
receiving	O
female	O
or	O
male	O
blood	O
components	O
.	O

TITLE	O
:	O
Identification	O
of	O
group	O
1	O
coronavirus	O
antigen	O
in	O
multisystemic	O
granulomatous	B-DISO
lesions	I-DISO
in	O
ferrets	O
(	O
Mustela	O
putorius	O
furo	O
).	O

ABSTRACT	O
:	O
In	O
previous	O
studies	O
a	O
variety	O
of	O
novel	O
accessory	O
genes	O
has	O
been	O
identified	O
that	O
were	O
interspersed	O
among	O
the	O
structural	O
genes	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
(	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
)	O
genome	O
.	O

SDS	B-DISO
-	O
PAGE	O
and	O
Western	O
blot	O
revealed	O
that	O
the	O
ORF10	O
and	O
X5	O
genes	O
have	O
been	O
expressed	O
in	O
the	O
two	O
hosts	O
.	O

ABSTRACT	O
:	O
To	O
analyze	O
antigenic	O
structure	O
of	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
the	O
gene	O
encoding	O
its	O
major	O
immunodominant	O
region	O
S1	O
was	O
amplified	O
by	O
PCR	O
.	O

Furthermore	O
,	O
a	O
reverse	O
genetic	O
system	O
was	O
established	O
for	O
this	O
FCoV	O
strain	O
by	O
cloning	O
a	O
full	O
-	O
length	O
cDNA	O
copy	O
into	O
vaccinia	B-DISO
virus	O
.	O

In	O
addition	O
,	O
we	O
showed	O
that	O
feline	O
CD14	O
(+)	O
blood	O
monocytes	O
and	O
dendritic	O
cells	O
can	O
be	O
easily	O
detected	O
after	O
infection	B-DISO
with	O
recFCoV	O
-	O
GFP	O
.	O

TITLE	O
:	O
Difference	O
in	O
receptor	O
usage	O
between	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
and	O
SARS	B-DISO
-	O
like	O
coronavirus	O
of	O
bat	O
origin	O
.	O

A	O
group	O
of	O
SARS	B-DISO
-	O
like	O
CoVs	O
(	O
SL	O
-	O
CoVs	O
)	O
has	O
been	O
identified	O
in	O
horseshoe	O
bats	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
1980s	O
,	O
a	O
number	O
of	O
key	O
events	O
have	O
significantly	O
altered	O
our	O
ideas	O
on	O
biosecurity	O
and	O
the	O
role	O
of	O
biocontainment	O
laboratories	O
,	O
such	O
as	O
the	O
bovine	B-DISO
spongiform	I-DISO
encephalopathy	I-DISO
(	O
BSE	B-DISO
)	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreaks	O
and	O
the	O
anthrax	B-DISO
episode	O
of	O
2001	O
in	O
the	O
USA	O
.	O

Corticotherapy	O
,	O
even	O
for	O
a	O
short	O
period	O
,	O
may	O
aggravate	O
this	O
immunodeficiency	B-DISO
and	O
predispose	O
these	O
patients	O
to	O
severe	O
opportunistic	B-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
spike	O
protein	O
(	O
S	O
)	O
is	O
a	O
major	O
target	O
for	O
neutralizing	O
antibody	O
.	O

TITLE	O
:	O
[	O
Epidemiology	O
of	O
acute	O
upper	O
and	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
in	O
children	O
].	O

The	O
structure	O
-	O
based	O
optimization	O
of	O
N3	O
has	O
yielded	O
two	O
more	O
efficacious	O
lead	O
compounds	O
,	O
N27	O
and	O
H16	O
,	O
with	O
potent	O
inhibition	O
against	O
SARS	B-DISO
-	O
CoV	O
M	O
(	O
pro	O
).	O

ABSTRACT	O
:	O
We	O
have	O
analyzed	O
the	O
intracellular	O
transport	O
of	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
),	O
an	O
avian	O
coronavirus	O
.	O

CD4	O
(+)	O
T	O
cells	O
provide	O
an	O
auxiliary	O
function	O
(	O
s	O
)	O
for	O
CD8	O
(+)	O
T	O
-	O
cell	O
survival	O
;	O
however	O
,	O
their	O
direct	O
contribution	O
to	O
control	O
of	O
virus	O
replication	O
and	O
pathology	B-DISO
is	O
unclear	O
.	O

CD4	O
(+)	O
T	O
-	O
cell	O
-	O
mediated	O
antiviral	O
activity	O
correlated	O
with	O
diminished	O
clinical	O
symptoms	O
,	O
pathology	B-DISO
,	O
and	O
demyelination	B-DISO
.	O

These	O
data	O
support	O
a	O
direct	O
,	O
if	O
limited	O
,	O
antiviral	O
role	O
for	O
CD4	O
(+)	O
T	O
cells	O
early	O
during	O
acute	O
JHMV	O
encephalomyelitis	B-DISO
.	O

Seropositivity	O
for	O
leptospirosis	B-DISO
,	O
patient	O
demographics	O
,	O
risk	O
factors	O
,	O
complications	O
,	O
treatment	O
and	O
survival	O
.	O

In	O
an	O
inhibition	O
assay	O
of	O
EA	O
-	O
rosette	O
formation	O
as	O
a	O
representation	O
of	O
immune	O
phagocytosis	O
,	O
FcgammaRIII	O
-	O
specific	O
MoAbs	O
,	O
TAG1	O
,	O
TAG2	O
and	O
TAG3	O
inhibited	O
EA	O
-	O
rosette	O
formation	O
,	O
but	O
HNA	B-DISO
-	O
2a	O
-	O
specific	O
MoAb	O
,	O
TAG4	O
,	O
did	O
not	O
markedly	O
inhibit	O
EA	O
-	O
rosette	O
formation	O
.	O

0	O
.	O
36	O
L	O
/	O
min	O
of	O
the	O
cardiac	O
output	O
perfused	O
the	O
device	O
,	O
without	O
hemodynamic	O
impairment	B-DISO
.	O

The	O
integration	O
of	O
this	O
device	O
to	O
near	O
static	O
mechanical	O
ventilation	O
of	O
the	O
residual	O
native	O
lung	O
(	O
s	O
)	O
is	O
feasible	O
and	O
highly	O
effective	O
in	O
patients	O
with	O
severe	O
and	O
unresponsive	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
after	O
pulmonary	O
resection	O
.	O

TITLE	O
:	O
Peripheral	O
cell	O
wall	O
lipids	O
of	O
Mycobacterium	O
tuberculosis	B-DISO
are	O
inhibitory	O
to	O
surfactant	O
function	O
.	O

Concentration	O
dependence	B-DISO
studies	O
showed	O
that	O
LS	O
was	O
also	O
inhibited	O
significantly	O
by	O
total	O
TB	O
lipids	O
at	O
0	O
.	O
075	O
mg	O
/	O
ml	O
,	O
with	O
a	O
smaller	O
activity	O
decrease	O
apparent	O
even	O
at	O
0	O
.	O
00375	O
mg	O
/	O
ml	O
.	O

ABSTRACT	O
:	O
The	O
epidemic	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
2003	O
was	O
caused	O
by	O
a	O
novel	O
coronavirus	O
(	O
CoV	O
),	O
designated	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
RNA	O
genome	O
of	O
SARS	B-DISO
-	O
CoV	O
is	O
complexed	O
by	O
the	O
nucleocapsid	O
protein	O
(	O
N	O
)	O
to	O
form	O
a	O
helical	O
nucleocapsid	O
.	O

Caco	O
-	O
2	O
and	O
N2a	O
cells	O
served	O
as	O
models	O
for	O
persistent	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
,	O
whereas	O
Vero	O
E6	O
and	O
A549	O
cells	O
did	O
as	O
prototype	O
cell	O
lines	O
lytically	O
infected	O
by	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
experiments	O
revealed	O
that	O
N	O
induces	O
the	O
intrinsic	O
apoptotic	O
pathway	O
,	O
resulting	O
in	O
processing	O
of	O
N	O
at	O
residues	O
400	O
and	O
403	O
by	O
caspase	O
-	O
6	O
and	O
/	O
or	O
caspase	O
-	O
3	O
.	O

These	O
data	O
suggest	O
a	O
correlation	O
among	O
the	O
replication	O
cycle	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
subcellular	O
localization	O
of	O
N	O
,	O
induction	O
of	O
apoptosis	O
,	O
and	O
the	O
subsequent	O
activation	O
of	O
caspases	O
leading	O
to	O
cleavage	O
of	O
N	O
.	O

But	O
philosophical	O
accounts	O
of	O
the	O
duty	O
to	O
treat	O
that	O
were	O
developed	O
in	O
the	O
context	O
of	O
HIV	B-DISO
did	O
not	O
adequately	O
address	O
some	O
of	O
the	O
ethical	O
issues	O
raised	O
by	O
SARS	B-DISO
.	O

Recommendations	O
specific	O
to	O
pediatric	O
severe	B-DISO
sepsis	I-DISO
include	O
greater	O
use	O
of	O
physical	O
examination	O
therapeutic	O
end	O
points	O
(	O
2C	O
);	O
dopamine	O
as	O
the	O
first	O
drug	O
of	O
choice	O
for	O
hypotension	O
(	O
2C	O
);	O
steroids	O
only	O
in	O
children	O
with	O
suspected	O
or	O
proven	O
adrenal	B-DISO
insufficiency	I-DISO
(	O
2C	O
);	O
and	O
a	O
recommendation	O
against	O
the	O
use	O
of	O
recombinant	O
activated	O
protein	O
C	O
in	O
children	O
(	O
1B	O
).	O

ABSTRACT	O
:	O
Although	O
the	O
local	O
public	O
health	O
response	O
to	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreak	O
in	O
Canada	O
was	O
critical	O
to	O
the	O
diagnosis	O
,	O
management	O
and	O
treatment	O
of	O
patients	O
,	O
such	O
a	O
rapid	O
research	O
response	O
required	O
a	O
national	O
effort	O
to	O
engage	O
the	O
research	O
and	O
stakeholder	O
communities	O
.	O

Pulmonary	B-DISO
toxicity	I-DISO
is	O
rare	O
and	O
usually	O
mild	O
and	O
self	O
-	O
limiting	O
with	O
acute	B-DISO
dyspnea	I-DISO
.	O

It	O
is	O
associated	O
with	O
absence	O
of	O
left	B-DISO
heart	I-DISO
failure	I-DISO
and	O
a	O
PaO2	O
/	O
FiO2	O
ratio	O
of	O
<	O
or	O
=	O
200	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
responses	O
of	O
Chinese	O
elderly	O
living	O
in	O
Edmonton	O
,	O
Canada	O
,	O
during	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
pandemic	O
,	O
and	O
their	O
use	O
of	O
Western	O
and	O
/	O
or	O
traditional	O
Chinese	O
medicine	O
.	O

The	O
main	O
agents	O
of	O
febrile	O
respiratory	O
illness	O
that	O
would	O
lead	O
to	O
an	O
epidemic	O
include	O
influenza	B-DISO
,	O
the	O
coronavirus	O
that	O
causes	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
smallpox	B-DISO
,	O
viral	B-DISO
hemorrhagic	I-DISO
fever	I-DISO
,	O
plague	B-DISO
,	O
tularemia	B-DISO
,	O
and	O
anthrax	B-DISO
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
changes	O
in	O
pulmonary	O
pressures	O
and	O
cardiac	O
biomarkers	O
during	O
severe	O
acute	B-DISO
chest	I-DISO
syndrome	I-DISO
and	O
their	O
associations	O
with	O
mortality	O
.	O

vaccination	O
may	O
be	O
the	O
preferred	O
route	O
of	O
administration	O
due	O
to	O
its	O
ability	O
to	O
induce	O
SARS	B-DISO
-	O
CoV	O
-	O
specific	O
systemic	O
and	O
mucosal	O
immune	O
responses	O
and	O
its	O
better	O
safety	O
profile	O
.	O

TITLE	O
:	O
Learning	O
from	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
epidemic	O
.	O

ABSTRACT	O
:	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
pro	O
)	O
plays	O
pivotal	O
roles	O
in	O
the	O
life	O
cycle	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
only	O
the	O
dimeric	O
protease	O
is	O
proposed	O
as	O
the	O
functional	O
form	O
.	O

In	O
preparation	O
for	O
future	O
events	O
,	O
such	O
as	O
pandemic	O
influenza	B-DISO
,	O
training	O
and	O
support	O
may	O
bolster	O
the	O
resilience	O
of	O
health	O
care	O
workers	O
who	O
are	O
at	O
higher	O
risk	O
by	O
virtue	O
of	O
their	O
psychiatric	O
history	O
and	O
fewer	O
years	O
of	O
health	O
care	O
experience	O
.	O

RESULTS	O
:	O
The	O
lifetime	O
prevalence	O
of	O
any	O
depressive	O
,	O
anxiety	O
,	O
or	O
substance	B-DISO
use	I-DISO
diagnosis	O
was	O
30	O
%.	O

New	O
episodes	O
of	O
psychiatric	B-DISO
disorders	I-DISO
were	O
directly	O
associated	O
with	O
a	O
history	O
of	O
having	O
a	O
psychiatric	B-DISO
disorder	I-DISO
before	O
the	O
SARS	B-DISO
outbreak	O
(	O
p	O
=.	O
02	O
)	O
and	O
inversely	O
associated	O
with	O
years	O
of	O
health	O
care	O
experience	O
(	O
p	O
=.	O
03	O
)	O
and	O
the	O
perceived	O
adequacy	O
of	O
training	O
and	O
support	O
(	O
p	O
=.	O
03	O
).	O

Single	O
-	O
substitution	O
viruses	O
exhibited	O
growth	O
characteristics	O
virtually	O
identical	O
to	O
those	O
of	O
the	O
wild	O
-	O
type	O
virus	O
,	O
while	O
the	O
double	O
-	O
substitution	O
mutations	O
gave	O
rise	O
to	O
viruses	O
with	O
less	O
robust	O
growth	O
phenotypes	O
indicated	O
by	O
smaller	O
plaques	B-DISO
and	O
decreased	O
virus	O
yields	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
assembly	O
process	O
encloses	O
a	O
ribonucleoprotein	O
genome	O
into	O
vesicles	B-DISO
containing	O
the	O
lipid	O
-	O
embedded	O
proteins	O
S	O
(	O
spike	O
),	O
E	O
(	O
envelope	O
),	O
and	O
M	O
(	O
membrane	O
).	O

To	O
determine	O
whether	O
specific	O
palmitoylations	O
influence	O
coronavirus	O
assembly	O
,	O
we	O
introduced	O
plasmid	O
DNAs	O
encoding	O
mouse	B-DISO
hepatitis	I-DISO
coronavirus	O
(	O
MHV	O
)	O
S	O
,	O
E	O
,	O
M	O
,	O
and	O
N	O
(	O
nucleocapsid	O
)	O
into	O
293T	O
cells	O
and	O
found	O
that	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
were	O
robustly	O
assembled	O
and	O
secreted	O
into	O
culture	O
medium	O
.	O

Coexpression	O
of	O
SCoV	O
S	O
protein	O
and	O
E	O
,	O
M	O
and	O
N	O
proteins	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
in	O
293T	O
or	O
CHO	O
cells	O
resulted	O
in	O
the	O
efficient	O
production	O
of	O
chimeric	O
VLPs	O
carrying	O
SCoV	O
S	O
protein	O
.	O

Our	O
results	O
show	O
that	O
chimeric	O
VLP	O
can	O
be	O
an	O
effective	O
vaccine	O
strategy	O
against	O
SCoV	O
infection	B-DISO
.	O

TITLE	O
:	O
Influenza	B-DISO
C	O
virus	O
and	O
bovine	O
coronavirus	O
esterase	O
reveal	O
a	O
similar	O
catalytic	O
mechanism	O
:	O
new	O
insights	O
for	O
drug	O
discovery	O
.	O

This	O
study	O
provides	O
valuable	O
insights	O
towards	O
the	O
design	O
of	O
drugs	O
to	O
combat	O
INF	O
-	O
C	O
virus	O
and	O
coronavirus	B-DISO
infections	I-DISO
causing	O
outbreaks	O
of	O
upper	B-DISO
respiratory	I-DISO
infections	I-DISO
and	O
severe	B-DISO
diarrhea	I-DISO
in	O
calves	O
,	O
respectively	O
.	O

Elevation	O
of	O
serum	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
was	O
observed	O
before	O
treatment	O
with	O
antibiotics	O
and	O
glucocorticoids	O
,	O
but	O
the	O
elevation	O
of	O
transforming	O
growth	O
factor	O
-	O
beta	O
(	O
1	O
)	O
was	O
delayed	O
for	O
2	O
to	O
4	O
weeks	O
after	O
the	O
accident	O
.	O

The	O
respiratory	O
sequela	O
of	O
restrictive	O
ventilation	O
impairment	B-DISO
developed	O
in	O
the	O
most	O
severely	O
affected	O
patients	O
,	O
whereas	O
other	O
tissue	O
toxicities	O
were	O
mostly	O
transient	O
.	O

A	O
proper	O
ventilation	O
strategy	O
,	O
early	O
pharmacologic	O
therapy	O
including	O
glucocorticoids	O
,	O
and	O
complication	B-DISO
prevention	O
may	O
contribute	O
to	O
good	O
treatment	O
outcomes	O
after	O
white	O
smoke	O
inhalation	O
.	O

RESULTS	O
:	O
All	O
patients	O
initially	O
presented	O
with	O
fever	O
,	O
dry	B-DISO
cough	I-DISO
,	O
chest	B-DISO
tightness	I-DISO
,	O
and	O
shortness	B-DISO
of	I-DISO
breath	I-DISO
.	O

Seventy	O
-	O
six	O
public	O
health	O
staff	O
completed	O
the	O
emergency	B-DISO
preparedness	O
training	O
programme	O
.	O

We	O
generated	O
a	O
recombinant	O
Newcastle	B-DISO
disease	I-DISO
virus	O
(	O
NDV	O
)	O
possessing	O
a	O
two	O
-	O
segmented	O
genome	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
are	O
a	O
major	O
cause	O
of	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
in	O
the	O
critically	B-DISO
ill	I-DISO
patient	O
.	O

The	O
infection	B-DISO
rate	O
(	O
7	O
.	O
9	O
%	O
vs	O
26	O
.	O
3	O
%,	O
P	O
<	O
0	O
.	O
05	O
),	O
operation	O
rate	O
(	O
13	O
.	O
2	O
%	O
vs	O
34	O
.	O
2	O
%,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
mortality	O
(	O
5	O
.	O
3	O
%	O
vs	O
21	O
.	O
1	O
%,	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
early	O
treatment	O
group	O
were	O
lower	O
than	O
in	O
the	O
late	O
treatment	O
group	O
.	O

Infection	B-DISO
induced	I-DISO
modest	O
mRNA	O
increases	O
in	O
microglia	O
,	O
but	O
dramatic	O
transcriptional	O
upregulation	O
in	O
oligodendroglia	O
coincident	O
with	O
IFN	O
alpha	O
or	O
IFN	O
gamma	O
mRNA	O
increases	O
in	O
infected	O
tissue	O
.	O

These	O
data	O
suggest	O
an	O
innate	O
immune	O
preparedness	O
of	O
microglia	O
to	O
present	O
antigen	O
and	O
engage	O
CD8	O
T	O
cells	O
early	O
following	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
rate	O
of	O
influenza	B-DISO
vaccination	O
and	O
the	O
factors	O
associated	O
with	O
the	O
vaccination	O
'	O
s	O
acceptance	O
among	O
nurses	O
in	O
Hong	O
Kong	O
.	O

Concern	O
about	O
contracting	O
avian	B-DISO
influenza	I-DISO
was	O
a	O
predictor	O
of	O
the	O
vaccination	O
rate	O
in	O
2006	O
but	O
not	O
in	O
2007	O
(	O
OR	O
,	O
1	O
.	O
47	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
03	O
-	O
2	O
.	O
09	O
];	O
P	O
<.	O
05	O
),	O
as	O
was	O
the	O
perceived	O
lack	O
of	O
control	O
over	O
avian	B-DISO
influenza	I-DISO
infection	B-DISO
(	O
OR	O
,	O
1	O
.	O
52	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
06	O
-	O
2	O
.	O
18	O
];	O
P	O
<.	O
05	O
).	O

TITLE	O
:	O
[	O
Pulmonary	O
function	O
in	O
children	O
after	O
neonatal	O
meconium	B-DISO
aspiration	I-DISO
syndrome	I-DISO
].	O

ABSTRACT	O
:	O
Meconium	B-DISO
aspiration	I-DISO
syndrome	I-DISO
is	O
a	O
disease	O
of	O
the	O
newborn	O
mature	O
or	O
post	O
mature	O
.	O

CONCLUSIONS	O
:	O
Children	O
surviving	O
meconium	B-DISO
aspiration	I-DISO
syndrome	I-DISO
tend	O
to	O
develop	O
alveolar	O
hyperinflation	B-DISO
and	O
airway	B-DISO
hyperreactivity	I-DISO
to	O
exercise	O
.	O

On	O
the	O
basis	O
of	O
experience	O
in	O
the	O
fields	O
of	O
AIDS	O
,	O
BSE	B-DISO
,	O
SARS	B-DISO
and	O
bird	B-DISO
flu	I-DISO
,	O
this	O
study	O
discusses	O
the	O
strong	O
and	O
weak	O
points	O
of	O
governance	O
procedures	O
for	O
health	O
risks	O
.	O

ABSTRACT	O
:	O
The	O
Cox	O
model	O
has	O
been	O
the	O
mainstay	O
of	O
survival	O
analysis	O
in	O
the	O
critically	B-DISO
ill	I-DISO
and	O
time	O
-	O
dependent	O
covariates	O
have	O
infrequently	O
been	O
incorporated	O
into	O
survival	O
analysis	O
.	O

Peak	O
mortality	O
hazard	O
occurred	O
at	O
days	O
7	O
-	O
8	O
after	O
onset	O
of	O
ALI	O
/	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Molecular	O
characterization	O
and	O
phylogenetic	O
analysis	O
of	O
membrane	O
protein	O
genes	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
isolates	O
in	O
China	O
.	O

During	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
epidemic	O
in	O
Toronto	O
,	O
airway	O
manipulation	O
was	O
clearly	O
identified	O
as	O
the	O
procedure	O
most	O
associated	O
with	O
risk	O
to	O
health	O
care	O
workers	O
.	O

ABSTRACT	O
:	O
A	O
new	O
strain	O
of	O
coronavirus	O
has	O
caused	O
an	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
from	O
2002	O
to	O
2003	O
resulting	O
in	O
774	O
deaths	O
worldwide	O
.	O

After	O
washing	O
and	O
addition	O
of	O
sinapinic	O
acid	O
,	O
the	O
chips	O
were	O
read	O
in	O
a	O
Protein	O
Biological	O
System	O
(	O
PBS	B-DISO
)	O
IIc	O
mass	O
spectrometer	O
.	O

The	O
comparison	O
group	O
consisted	O
of	O
clinical	O
units	O
that	O
had	O
no	O
contact	O
with	O
patients	O
infected	O
with	O
SARS	B-DISO
.	O

Nevertheless	O
,	O
more	O
prospective	O
studies	O
are	O
needed	O
to	O
evaluate	O
optimal	O
ventilator	O
management	O
strategies	O
for	O
patients	O
not	O
suffering	B-DISO
from	O
ALI	O
/	O
ARDS	B-DISO
.	O

Except	O
for	O
3	O
in	O
47	O
cases	O
whose	O
parents	O
refused	O
treatment	O
,	O
dyspnea	B-DISO
in	O
other	O
44	O
cases	O
were	O
relieved	O
with	O
inhaling	O
oxygen	O
and	O
drug	O
treatment	O
,	O
37	O
case	O
received	O
tracheal	O
intubation	O
and	O
sputum	O
suction	O
,	O
19	O
cases	O
received	O
direct	O
laryngoscope	O
or	O
self	O
-	O
retaining	O
laryngoscope	O
operation	O
.	O

RESULTS	O
:	O
Among	O
47	O
neonates	O
,	O
41	O
cases	O
were	O
congenital	B-DISO
diseases	I-DISO
,	O
accounting	O
for	O
87	O
.	O
2	O
%	O
(	O
41	O
/	O
47	O
).	O

Seroassays	O
also	O
included	O
samples	O
obtained	O
in	O
2003	O
from	O
eight	O
red	O
pandas	B-DISO
(	O
Ailurus	O
fulgens	O
)	O
housed	O
at	O
the	O
same	O
institution	O
.	O

Research	O
in	O
this	O
area	O
is	O
imperative	O
to	O
sustaining	O
a	O
viable	O
population	O
of	O
giant	B-DISO
pandas	B-DISO
and	O
other	O
endangered	O
species	O
.	O

Interestingly	O
,	O
IBV	O
-	O
infected	O
cells	O
stably	O
expressing	O
a	O
Flag	O
-	O
tagged	O
eIF3f	O
showed	O
much	O
higher	O
translation	O
of	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
,	O
suggesting	O
that	O
the	O
interaction	O
between	O
coronavirus	O
S	O
protein	O
and	O
eIF3f	O
plays	O
a	O
functional	O
role	O
in	O
controlling	O
the	O
expression	O
of	O
host	O
genes	O
,	O
especially	O
genes	O
that	O
are	O
induced	O
during	O
coronavirus	B-DISO
infection	I-DISO
cycles	O
.	O

TITLE	O
:	O
Transverse	O
laparostomy	O
is	O
feasible	O
and	O
effective	O
in	O
the	O
treatment	O
of	O
abdominal	B-DISO
compartment	I-DISO
syndrome	I-DISO
in	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
.	O

SARS	B-DISO
-	O
CoV	O
was	O
detected	O
up	O
to	O
7	O
d	O
.	O
p	O
.	O
i	O
.	O

This	O
study	O
supports	O
the	O
validity	O
of	O
the	O
ferret	O
model	O
for	O
use	O
in	O
evaluating	O
efficacy	O
of	O
potential	O
therapeutics	O
to	O
treat	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
Necrotizing	B-DISO
enterocolitis	I-DISO
(	O
NEC	O
)	O
is	O
a	O
clinical	O
syndrome	B-DISO
of	O
ischemic	B-DISO
necrosis	I-DISO
of	O
the	O
bowel	O
of	O
multiple	O
etiological	O
factors	O
that	O
include	O
the	O
presence	O
of	O
intestinal	B-DISO
ischemia	I-DISO
,	O
abnormal	O
bacterial	O
flora	O
,	O
and	O
intestinal	O
mucosal	O
immaturity	O
.	O

Indications	O
for	O
surgery	O
include	O
clinical	O
deterioration	O
,	O
perforation	O
,	O
peritonitis	B-DISO
,	O
obstruction	B-DISO
,	O
and	O
abdominal	O
mass	O
.	O

All	O
infants	O
had	O
a	O
severe	O
acute	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
(	O
D	O
(	O
A	O
-	O
a	O
)	O
O2	O
=	O
468	O
+/-	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
was	O
a	O
worldwide	O
epidemic	O
caused	O
by	O
a	O
coronavirus	O
that	O
has	O
a	O
cysteine	O
protease	O
(	O
3CLpro	O
)	O
essential	O
to	O
its	O
life	O
cycle	O
.	O

Finally	O
,	O
the	O
pH	O
-	O
inactivation	B-DISO
profile	O
of	O
3CLpro	O
with	O
iodoacetamide	O
is	O
indicative	O
of	O
an	O
ion	O
-	O
pair	O
mechanism	O
.	O

Recently	O
,	O
both	O
fulvic	O
acid	O
and	O
pomegranate	O
juice	O
have	O
been	O
shown	O
to	O
inactivate	O
genetically	O
diverse	O
strains	O
of	O
influenza	B-DISO
including	O
H5N1	B-DISO
,	O
further	O
confirming	O
the	O
broad	O
spectrum	O
nature	O
of	O
these	O
agents	O
.	O

TITLE	O
:	O
Unilateral	O
neurogenic	B-DISO
pulmonary	I-DISO
oedema	I-DISO
and	O
severe	O
left	B-DISO
ventricular	I-DISO
dysfunction	I-DISO
secondary	O
to	O
acute	O
multiple	B-DISO
sclerosis	I-DISO
exacerbation	I-DISO
.	O

Whatever	O
the	O
case	O
,	O
neurogenic	B-DISO
pulmonary	I-DISO
oedema	I-DISO
should	O
always	O
be	O
in	O
the	O
differential	O
diagnosis	O
when	O
patients	O
with	O
presumed	O
neurogenic	O
pathology	B-DISO
develop	O
cardiopulmonary	O
compromise	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
failure	I-DISO
is	O
a	O
common	O
,	O
life	O
-	O
threatening	O
complication	B-DISO
after	O
severe	O
trauma	O
.	O

We	O
conclude	O
that	O
the	O
IL	O
-	O
10	O
-	O
1082	O
genotype	O
may	O
be	O
a	O
risk	O
marker	O
for	O
development	O
of	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
after	O
trauma	O
.	O

Although	O
the	O
pathological	O
characteristics	O
of	O
ECoV	O
are	O
largely	O
unknown	O
,	O
apoptosis	O
may	O
be	O
the	O
pathological	O
basis	O
of	O
lesions	O
of	O
the	O
digestive	O
system	O
in	O
ECoV	O
infection	B-DISO
.	O

We	O
,	O
therefore	O
,	O
conclude	O
that	O
although	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
provides	O
an	O
excellent	O
method	O
for	O
detecting	O
the	O
presence	O
of	O
viral	B-DISO
shedding	I-DISO
,	O
quantification	O
of	O
FCoV	O
RNA	O
in	O
faecal	O
material	O
has	O
to	O
take	O
into	O
account	O
the	O
possible	O
effects	O
of	O
RT	O
-	O
PCR	O
inhibitors	O
.	O

We	O
designed	O
a	O
retrospective	O
study	O
examining	O
the	O
experience	O
with	O
respiratory	B-DISO
syncytial	I-DISO
virus	I-DISO
infection	I-DISO
in	O
pediatric	O
patients	O
with	O
underlying	O
malignancies	B-DISO
and	O
hematopoietic	O
stem	O
cell	O
transplant	O
recipients	O
seen	O
between	O
1997	O
and	O
2005	O
.	O

All	O
deaths	O
occurred	O
in	O
patients	O
with	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
who	O
were	O
before	O
or	O
after	O
hematopoietic	O
stem	O
cell	O
transplants	O
or	O
were	O
<	O
2	O
years	O
of	O
age	O
and	O
receiving	O
treatment	O
for	O
acute	B-DISO
myeloid	I-DISO
leukemia	I-DISO
.	O

This	O
study	O
identified	O
profound	O
lymphopenia	B-DISO
and	O
young	O
age	O
as	O
independent	O
predictors	O
of	O
respiratory	O
syncytial	O
virus	O
-	O
related	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
in	O
immunocompromised	O
children	O
.	O

ABSTRACT	O
:	O
We	O
argue	O
that	O
traditional	O
health	O
economic	O
analysis	O
is	O
ill	B-DISO
-	O
equipped	O
to	O
estimate	O
the	O
cost	O
effectiveness	O
and	O
cost	O
benefit	O
of	O
interventions	O
that	O
aim	O
at	O
controlling	O
and	O
/	O
or	O
preventing	O
public	O
health	O
emergencies	B-DISO
of	O
international	O
concern	O
(	O
such	O
as	O
pandemic	O
influenza	B-DISO
or	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
).	O

TITLE	O
:	O
[	O
Procalcitonin	O
-	O
marker	O
of	O
severe	O
infection	B-DISO
and	O
sepsis	B-DISO
].	O

But	O
the	O
pathophysiological	O
role	O
of	O
PCT	B-DISO
in	O
sepsis	B-DISO
is	O
not	O
definitely	O
clear	O
yet	O
.	O

TITLE	O
:	O
Molecular	O
characterization	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
strains	O
isolated	O
from	O
the	O
enteric	O
contents	O
of	O
Brazilian	O
laying	O
hens	O
and	O
broilers	O
.	O

TITLE	O
:	O
Precautionary	O
behavior	O
in	O
response	O
to	O
perceived	O
threat	O
of	O
pandemic	O
influenza	B-DISO
.	O

ABSTRACT	O
:	O
Faced	O
with	O
an	O
epidemic	O
of	O
an	O
infectious	B-DISO
disease	I-DISO
,	O
persons	O
may	O
take	O
precautionary	O
actions	O
to	O
try	O
to	O
reduce	O
their	O
risk	O
.	O

ABSTRACT	O
:	O
Highly	O
pathogenic	O
avian	B-DISO
influenza	I-DISO
A	O
(	O
HPAI	O
)	O
subtype	O
H5N1	B-DISO
has	O
caused	O
family	O
case	O
clusters	O
,	O
mostly	O
in	O
Southeast	O
Asia	O
,	O
that	O
could	O
be	O
due	O
to	O
human	O
-	O
to	O
-	O
human	O
transmission	O
.	O

Effective	O
HPAI	O
(	O
H5N1	B-DISO
)	O
surveillance	O
,	O
containment	O
response	O
,	O
and	O
field	O
evaluation	O
are	O
essential	O
to	O
monitor	O
and	O
contain	O
potential	O
pandemic	O
strains	O
.	O

ABSTRACT	O
:	O
Asian	O
bats	O
have	O
been	O
identified	O
as	O
potential	O
reservoir	O
hosts	O
of	O
coronaviruses	O
associated	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
).	O

We	O
detected	O
antibody	O
reactive	O
with	O
SARS	B-DISO
-	O
CoV	O
antigen	O
in	O
47	O
(	O
6	O
.	O
7	O
%)	O
of	O
705	O
bat	O
serum	O
specimens	O
comprising	O
26	O
species	O
collected	O
in	O
Africa	O
;	O
thus	O
,	O
African	O
bats	O
may	O
harbor	O
agents	O
related	O
to	O
putative	O
group	O
4	O
CoV	O
.	O

TITLE	O
:	O
[	O
Traumatic	B-DISO
shock	I-DISO
--	O
physiopathologic	O
aspects	O
].	O

Hypoxia	B-DISO
causes	O
capillary	O
injury	O
and	O
increased	O
permeability	O
,	O
resulting	O
in	O
the	O
formation	O
of	O
edema	B-DISO
and	O
finally	O
in	O
loss	O
of	O
the	O
self	O
-	O
regulating	O
power	O
of	O
the	O
microcirculation	O
.	O

ABSTRACT	O
:	O
In	O
late	O
2002	O
,	O
cases	O
of	O
life	O
-	O
threatening	O
respiratory	B-DISO
disease	I-DISO
with	O
no	O
identifiable	O
cause	O
were	O
reported	O
from	O
Guangdong	O
Province	O
,	O
China	O
,	O
and	O
they	O
were	O
followed	O
by	O
reports	O
from	O
other	O
countries	O
.	O

Thus	O
,	O
SARS	B-DISO
patients	O
might	O
be	O
susceptible	O
to	O
reinfection	O
>	O
or	O
=	O
3	O
years	O
after	O
initial	O
exposure	O
.	O

The	O
enzyme	O
loaded	O
column	O
captures	O
the	O
desired	O
bispecific	O
anti	O
-	O
SARS	B-DISO
-	O
CoVxanti	O
-	O
HRPO	O
species	O
with	O
the	O
elimination	O
of	O
the	O
monospecific	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
MAb	O
to	O
result	O
in	O
a	O
high	O
specific	O
activity	O
diagnostic	O
probe	O
.	O

ABSTRACT	O
:	O
ALI	O
/	O
ARDS	B-DISO
(	O
acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
)	O
is	O
a	O
severe	O
inflammatory	O
lung	B-DISO
disease	I-DISO
associated	O
with	O
very	O
high	O
mortality	O
.	O

Correlating	O
the	O
autopsy	O
,	O
leptospirosis	B-DISO
can	O
be	O
visualized	O
as	O
an	O
infective	O
systemic	O
vasculitis	B-DISO
.	O

TITLE	O
:	O
Avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
attenuated	O
live	O
vaccines	O
undergo	O
selection	O
of	O
subpopulations	O
and	O
mutations	O
following	O
vaccination	O
.	O

We	O
assessed	O
the	O
role	O
of	O
lymphocytic	O
bronchiolitis	B-DISO
as	O
a	O
risk	O
factor	O
for	O
bronchiolitis	B-DISO
obliterans	I-DISO
syndrome	B-DISO
(	O
BOS	B-DISO
)	O
and	O
death	O
after	O
lung	O
transplantation	O
.	O

Multivariable	O
Cox	O
proportional	O
hazards	O
analysis	O
showed	O
significant	O
risks	O
for	O
BOS	B-DISO
were	O
highest	O
B	O
grade	O
(	O
relative	O
risk	O
[	O
RR	O
],	O
1	O
.	O
62	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
1	O
.	O
31	O
-	O
2	O
.	O
00	O
)	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
longer	O
ischemic	O
time	O
(	O
RR	O
,	O
1	O
.	O
00	O
;	O
CI	O
,	O
1	O
.	O
00	O
-	O
1	O
.	O
00	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
recent	O
year	O
of	O
transplant	O
(	O
RR	O
,	O
0	O
.	O
93	O
;	O
CI	O
,	O
0	O
.	O
87	O
-	O
1	O
.	O
00	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
whereas	O
risks	O
for	O
death	O
were	O
BOS	B-DISO
as	O
a	O
time	O
-	O
dependent	O
covariable	O
(	O
RR	O
,	O
19	O
.	O
10	O
;	O
CI	O
,	O
11	O
.	O
07	O
-	O
32	O
.	O
96	O
)	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
highest	O
B	O
grade	O
(	O
RR	O
,	O
1	O
.	O
36	O
;	O
CI	O
,	O
1	O
.	O
07	O
-	O
1	O
.	O
72	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Clinical	O
aspects	O
of	O
systemic	O
granulomatous	O
inflammatory	O
syndrome	B-DISO
in	O
ferrets	O
(	O
Mustela	O
putorius	O
furo	O
).	O

Common	O
signs	O
included	O
diarrhoea	B-DISO
,	O
lethargy	B-DISO
,	O
weight	O
loss	O
,	O
and	O
weakness	B-DISO
in	O
the	O
hindlimbs	O
.	O

Pathological	O
findings	O
consisted	O
of	O
mesenteric	B-DISO
lymphadenopathy	I-DISO
,	O
splenomegaly	O
,	O
hypergammaglobulinaemia	B-DISO
and	O
non	O
-	O
regenerative	B-DISO
anaemia	I-DISO
.	O

In	O
patients	O
suffering	B-DISO
from	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
with	O
life	O
-	O
threatening	O
hypoxaemia	O
,	O
a	O
pump	O
-	O
driven	O
,	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
has	O
been	O
established	O
.	O

TITLE	O
:	O
China	O
'	O
s	O
heath	O
care	O
system	O
and	O
avian	B-DISO
influenza	I-DISO
preparedness	O
.	O

SI	O
gene	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
and	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
gene	O
from	O
chicken	O
were	O
inserted	O
into	O
the	O
bicistronic	O
pIRES	O
-	O
EGFP	O
/	O
DsRed	O
plasmid	O
.	O

In	O
fact	O
,	O
in	O
transmissible	O
gastroenteritis	B-DISO
CoV	O
,	O
a	O
good	O
correlation	O
has	O
been	O
observed	O
between	O
subgenomic	O
mRNA	O
(	O
sg	O
mRNA	O
)	O
levels	O
and	O
the	O
free	O
energy	O
(	O
DeltaG	O
)	O
of	O
TRS	B-DISO
-	O
L	O
and	O
cTRS	O
-	O
B	O
duplex	O
formation	O
.	O

Global	O
analysis	O
of	O
the	O
combined	O
results	O
showed	O
that	O
truncation	B-DISO
of	O
C	O
-	O
terminus	O
from	O
306	O
to	O
300	O
had	O
no	O
appreciable	O
effect	O
on	O
the	O
quaternary	O
structure	O
,	O
and	O
the	O
enzyme	O
remained	O
catalytically	O
active	O
.	O

TITLE	O
:	O
Politics	O
and	O
the	O
management	O
of	O
public	O
health	O
disasters	O
:	O
reflections	O
on	O
the	O
SARS	B-DISO
epidemic	O
in	O
greater	O
China	O
.	O

Rhinovirus	O
and	O
adenovirus	B-DISO
were	O
most	O
frequently	O
detected	O
during	O
URI	O
.	O

Young	O
age	O
was	O
the	O
most	O
important	O
predictor	O
of	O
AOM	B-DISO
that	O
complicated	O
URI	O
.	O

The	O
strategy	O
may	O
be	O
more	O
effective	O
if	O
the	O
priority	O
is	O
given	O
to	O
development	O
of	O
means	O
to	O
prevent	O
URI	O
associated	O
with	O
adenovirus	B-DISO
and	O
respiratory	O
syncytial	O
virus	O
.	O

Collapse	B-DISO
,	O
convulsions	B-DISO
,	O
or	O
coma	B-DISO
may	O
be	O
caused	O
in	O
different	O
circumstances	O
by	O
opioids	O
,	O
MDMA	O
,	O
or	O
gamma	O
hydroxybutyrate	O
and	O
may	O
be	O
aggravated	O
by	O
other	O
sedatives	O
,	O
especially	O
alcohol	O
and	O
benzodiazepines	O
.	O

A	O
Logistic	O
regression	O
model	O
was	O
applied	O
to	O
investigate	O
the	O
outcome	O
variables	O
:	O
death	O
,	O
complications	O
,	O
subsequent	O
lung	B-DISO
infection	I-DISO
and	O
other	O
infections	B-DISO
and	O
COX	O
regression	O
was	O
made	O
.	O

There	O
is	O
no	O
significant	O
difference	O
in	O
mortality	O
,	O
instant	O
death	O
incidence	O
between	O
steroid	O
treatment	O
and	O
non	O
-	O
steroid	O
treatment	O
group	O
of	O
SARS	B-DISO
patients	O
diagnosed	O
with	O
the	O
diagnostic	O
criteria	O
issued	O
by	O
Ministry	O
of	O
Health	O
.	O

But	O
attention	O
should	O
be	O
paid	O
that	O
infection	B-DISO
rate	O
could	O
be	O
increased	O
in	O
such	O
cases	O
.	O

TITLE	O
:	O
Lipid	O
rafts	O
are	O
involved	O
in	O
SARS	B-DISO
-	O
CoV	O
entry	O
into	O
Vero	O
E6	O
cells	O
.	O

Long	O
-	O
term	O
mechanical	O
ventilation	O
was	O
necessary	O
,	O
and	O
both	O
patients	O
developed	O
aspiration	B-DISO
pneumonia	I-DISO
.	O

Feline	B-DISO
leukemia	I-DISO
virus	O
antigen	O
,	O
feline	O
immunodeficiency	B-DISO
virus	O
antibody	O
,	O
or	O
coronavirus	O
antibodies	O
were	O
not	O
detected	O
.	O

Bartonella	O
sp	O
.	O
(	O
44	O
%)	O
infections	B-DISO
were	O
common	O
in	O
cats	O
,	O
but	O
only	O
one	O
was	O
infected	O
with	O
M	O
.	O
haemofelis	O
.	O

We	O
used	O
reverse	O
genetics	O
to	O
generate	O
infectious	B-DISO
clone	O
viruses	O
(	O
icv	O
)	O
with	O
an	O
alanine	O
substitution	O
at	O
nsp4	O
glycosylation	O
site	O
N176	O
or	O
N237	O
,	O
or	O
an	O
asparagine	O
to	O
threonine	O
substitution	O
(	O
nsp4	O
-	O
N258T	O
),	O
which	O
is	O
proposed	O
to	O
confer	O
a	O
temperature	O
sensitive	O
phenotype	O
.	O

Data	O
were	O
collected	O
for	O
patient	O
age	O
,	O
neurological	O
diagnosis	O
,	O
associated	O
comorbidities	O
,	O
index	O
of	O
respiratory	B-DISO
insufficiency	I-DISO
in	O
the	O
immediate	O
postoperative	O
period	O
and	O
period	O
of	O
hospitalization	O
.	O

ABSTRACT	O
:	O
The	O
sequence	O
of	O
a	O
6	O
.	O
0	O
-	O
kb	O
fragment	O
was	O
compared	O
in	O
the	O
3	O
'-	O
encoding	O
region	O
of	O
the	O
genome	O
in	O
27	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
strains	O
.	O

This	O
enzyme	O
is	O
a	O
target	O
for	O
the	O
design	O
of	O
potential	O
anti	O
-	O
SARS	B-DISO
drugs	O
.	O

ABSTRACT	O
:	O
A	O
prospective	O
2	O
-	O
year	O
analysis	O
including	O
322	O
infant	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
disease	I-DISO
(	O
ARD	O
)	O
hospitalized	O
in	O
a	O
pediatric	O
department	O
in	O
northern	O
Italy	O
was	O
carried	O
out	O
to	O
evaluate	O
the	O
role	O
as	O
respiratory	O
pathogens	O
or	O
co	O
-	O
pathogens	O
of	O
recently	O
identified	O
viruses	O
.	O

TITLE	O
:	O
Chemokine	O
expression	O
during	O
mouse	O
-	O
hepatitis	B-DISO
-	O
virus	O
-	O
induced	O
encephalitis	B-DISO
:	O
contributions	O
of	O
the	O
spike	O
and	O
background	O
genes	O
.	O

ABSTRACT	O
:	O
Infection	B-DISO
of	O
mice	O
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
strain	O
JHM	O
(	O
RJHM	O
)	O
induces	O
lethal	O
encephalitis	B-DISO
,	O
with	O
high	O
macrophage	O
and	O
neutrophil	O
,	O
but	O
minimal	O
T	O
-	O
cell	O
,	O
infiltration	B-DISO
into	O
the	O
brain	O
when	O
compared	O
to	O
the	O
neuroattenuated	O
strain	O
RA59	O
.	O

Thus	O
,	O
chemokine	O
patterns	O
correspond	O
with	O
the	O
cellular	B-DISO
infiltrate	I-DISO
,	O
and	O
the	O
spike	O
protein	O
influences	O
levels	O
of	O
macrophage	O
,	O
but	O
not	O
T	O
-	O
cell	O
,	O
chemokines	O
.	O

ABSTRACT	O
:	O
Chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
is	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
worldwide	O
.	O

Rhinovirus	O
,	O
the	O
organism	O
most	O
often	O
responsible	O
for	O
causing	O
the	O
common	B-DISO
cold	I-DISO
,	O
is	O
also	O
the	O
most	O
common	O
infectious	B-DISO
cause	O
of	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
exacerbations	O
.	O

Although	O
PCR	O
technology	O
has	O
dramatically	O
increased	O
the	O
detection	O
rate	O
of	O
viruses	O
in	O
patients	O
with	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
,	O
it	O
does	O
not	O
differentiate	O
infection	B-DISO
from	O
colonization	O
.	O

Translation	O
initiation	O
factor	O
eIF2alpha	O
is	O
highly	O
phosphorylated	O
during	O
MHV	O
infection	B-DISO
,	O
and	O
translation	O
of	O
cellular	O
mRNAs	O
is	O
attenuated	O
.	O

TITLE	O
:	O
Without	O
its	O
N	O
-	O
finger	O
,	O
the	O
main	O
protease	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
can	O
form	O
a	O
novel	O
dimer	O
through	O
its	O
C	O
-	O
terminal	O
domain	O
.	O

Our	O
study	O
results	O
help	O
to	O
clarify	O
previously	O
published	O
controversial	O
claims	O
about	O
the	O
role	O
of	O
the	O
N	O
-	O
finger	O
in	O
SARS	B-DISO
-	O
CoV	O
M	O
(	O
pro	O
)	O
dimerization	O
.	O

Both	O
viruses	O
accumulated	O
similar	O
amounts	O
of	O
virus	O
-	O
specific	O
mRNAs	O
and	O
nsp1	O
protein	O
in	O
infected	O
cells	O
,	O
whereas	O
the	O
amounts	O
of	O
endogenous	O
host	O
mRNAs	O
were	O
clearly	O
higher	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
mt	O
-	O
infected	O
cells	O
than	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
WT	O
-	O
infected	O
cells	O
,	O
in	O
both	O
the	O
presence	O
and	O
absence	O
of	O
actinomycin	O
D	O
.	O
Further	O
,	O
SARS	B-DISO
-	O
CoV	O
-	O
WT	O
replication	O
strongly	O
inhibited	O
host	O
protein	O
synthesis	O
,	O
whereas	O
host	O
protein	O
synthesis	O
inhibition	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
mt	O
-	O
infected	O
cells	O
was	O
not	O
as	O
efficient	O
as	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
WT	O
-	O
infected	O
cells	O
.	O

A	O
3V	O
armored	O
L	O
-	O
RNA	O
of	O
2	O
,	O
248	O
bases	O
containing	O
six	O
gene	O
fragments	O
-	O
hepatitis	B-DISO
C	I-DISO
virus	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV1	O
,	O
SARS	B-DISO
-	O
CoV2	O
,	O
and	O
SARS	B-DISO
-	O
CoV3	O
),	O
avian	B-DISO
influenza	I-DISO
virus	O
matrix	O
gene	O
(	O
M300	O
),	O
and	O
H5N1	B-DISO
avian	B-DISO
influenza	I-DISO
virus	O
(	O
HA300	O
)-	O
was	O
successfully	O
expressed	O
by	O
the	O
two	O
-	O
plasmid	O
coexpression	O
system	O
and	O
was	O
demonstrated	O
to	O
have	O
all	O
of	O
the	O
characteristics	O
of	O
armored	O
RNA	O
.	O

We	O
should	O
keep	O
in	O
mind	O
that	O
,	O
especially	O
following	O
sepsis	B-DISO
,	O
sudden	O
massive	O
pulmonary	O
capillary	O
leak	O
can	O
occur	O
during	O
elective	O
surgery	O
,	O
even	O
though	O
the	O
patient	O
'	O
s	O
condition	B-DISO
is	O
well	O
controlled	O
.	O

This	O
indicates	O
that	O
these	O
CCV	B-DISO
stains	O
may	O
have	O
the	O
same	O
ancestor	O
.	O

The	O
association	O
between	O
genetic	O
polymorphisms	O
of	O
TNF	O
-	O
alpha	O
gene	O
and	O
susceptibility	O
to	O
severe	O
acute	O
respiratory	O
syndromes	B-DISO
(	O
SARS	B-DISO
)	O
was	O
conducted	O
in	O
a	O
hospital	O
-	O
based	O
case	O
-	O
control	O
study	O
including	O
75	O
SARS	B-DISO
patients	O
,	O
41	O
health	O
care	O
workers	O
and	O
92	O
healthy	O
controls	O
.	O

SNPs	O
of	O
TNF	O
-	O
alpha	O
gene	O
of	O
promoter	O
region	O
may	O
not	O
associate	O
with	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

RESULTS	O
:	O
Compared	O
to	O
TT	O
genotype	O
,	O
the	O
CT	O
genotype	O
at	O
the	O
-	O
204	O
locus	O
was	O
found	O
associated	O
with	O
a	O
protective	O
effect	O
on	O
SARS	B-DISO
with	O
OR	O
(	O
95	O
%	O
CI	O
)	O
of	O
0	O
.	O
95	O
(	O
0	O
.	O
90	O
-	O
0	O
.	O
99	O
).	O

We	O
have	O
identified	O
6MP	O
and	O
6TG	O
as	O
reversible	O
and	O
slow	O
-	O
binding	O
inhibitors	O
of	O
SARS	B-DISO
-	O
CoV	O
PLpro	O
,	O
which	O
is	O
the	O
first	O
report	O
about	O
small	O
molecule	O
reversible	O
inhibitors	O
of	O
PLpro	O
.	O

TITLE	O
:	O
Peptide	O
mimicrying	O
between	O
SARS	B-DISO
coronavirus	O
spike	O
protein	O
and	O
human	O
proteins	O
reacts	O
with	O
SARS	B-DISO
patient	O
serum	O
.	O

The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
plays	O
an	O
important	O
role	O
in	O
the	O
virus	O
entry	O
into	O
a	O
cell	O
.	O

However	O
,	O
repetitive	O
administration	O
of	O
endotoxin	O
can	O
cause	O
tolerance	B-DISO
.	O

ABSTRACT	O
:	O
We	O
describe	O
an	O
outbreak	O
of	O
vomiting	B-DISO
,	O
wasting	B-DISO
,	O
and	O
encephalomyelitis	B-DISO
syndrome	B-DISO
in	O
piglets	O
in	O
Argentina	O
,	O
caused	O
by	O
porcine	O
hemagglutinating	O
encephalomyelitis	B-DISO
coronavirus	O
(	O
PHE	O
-	O
CoV	O
)	O
infection	B-DISO
.	O

TITLE	O
:	O
Clinical	O
and	O
genetic	O
characterization	O
of	O
severe	O
influenza	B-DISO
B	O
-	O
associated	O
diseases	O
during	O
an	O
outbreak	O
in	O
Taiwan	O
.	O

A	O
comprehensive	O
clinical	O
and	O
genetic	O
analysis	O
of	O
influenza	B-DISO
B	O
viruses	O
-	O
associated	O
important	O
diseases	O
was	O
lacking	O
.	O

Severe	O
influenza	B-DISO
B	O
-	O
associated	O
disease	O
in	O
children	O
was	O
not	O
rare	O
and	O
might	O
be	O
fatal	O
.	O

TITLE	O
:	O
[	O
Ovarian	O
overstimulation	O
syndrome	B-DISO
:	O
problem	O
of	O
intensive	O
care	O
].	O

The	O
clinical	O
picture	O
of	O
OHSS	B-DISO
is	O
characterized	O
by	O
a	O
broad	O
spectrum	O
of	O
clinical	O
and	O
laboratory	O
manifestations	O
:	O
increased	O
vascular	O
permeability	O
resulting	O
in	O
the	O
excess	O
release	O
of	O
liquid	O
into	O
the	O
third	O
space	O
and	O
its	O
storage	O
with	O
the	O
development	O
of	O
hypovolemia	O
,	O
hemoconcentration	O
,	O
oliguria	B-DISO
,	O
hypoproteinemia	B-DISO
,	O
electrolyte	B-DISO
imbalance	I-DISO
,	O
polyserositis	B-DISO
;	O
in	O
severe	O
cases	O
,	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
thromboembolic	B-DISO
events	I-DISO
,	O
and	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
develop	O
.	O

ABSTRACT	O
:	O
A	O
DNA	O
vaccine	O
against	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
can	O
induce	O
specific	O
humoral	O
and	O
cell	O
-	O
mediated	O
immunity	O
.	O

Nasal	O
samples	O
obtained	O
at	O
admission	O
and	O
weekly	O
thereafter	O
for	O
all	O
hospitalised	O
children	O
,	O
as	O
well	O
as	O
monthly	O
nasal	O
samples	O
from	O
staff	O
,	O
were	O
analysed	O
using	O
immunofluorescence	O
for	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
influenza	B-DISO
viruses	O
A	O
and	O
B	O
,	O
paramyxoviruses	O
1	O
,	O
2	O
,	O
3	O
and	O
adenoviruses	O
.	O

TITLE	O
:	O
Pulmonary	O
coagulopathy	B-DISO
as	O
a	O
new	O
target	O
in	O
lung	O
injury	O
--	O
a	O
review	O
of	O
available	O
pre	O
-	O
clinical	O
models	O
.	O

In	O
ALI	O
/	O
ARDS	B-DISO
similar	O
but	O
local	O
disturbances	O
in	O
fibrin	O
turnover	O
occur	O
,	O
leading	O
to	O
excessive	O
alveolar	O
fibrin	B-DISO
deposition	I-DISO
compromising	O
pulmonary	O
integrity	O
and	O
function	O
.	O

Therapies	O
in	O
patients	O
with	O
sepsis	B-DISO
have	O
specifically	O
focused	O
on	O
coagulation	O
disturbances	O
.	O

A	O
solid	O
base	O
has	O
to	O
be	O
provided	O
by	O
preclinical	O
studies	O
to	O
justify	O
clinical	O
studies	O
on	O
new	O
pharmacologic	O
therapies	O
for	O
ALI	O
/	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
During	O
acute	B-DISO
viral	I-DISO
hepatitis	I-DISO
,	O
the	O
intrahepatic	O
tolerance	B-DISO
sustained	O
by	O
immunosuppressive	O
cytokines	O
such	O
as	O
interleukin	O
(	O
IL	O
)-	O
4	O
,	O
IL	O
-	O
10	O
,	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)-	O
beta	O
and	O
prostaglandin	O
E2	O
(	O
PGE2	O
),	O
produced	O
by	O
Kupffer	O
cells	O
(	O
KC	O
),	O
liver	O
sinusoidal	O
endothelial	O
cells	O
(	O
LSEC	O
),	O
natural	O
killer	O
(	O
NK	O
)	O
T	O
cells	O
and	O
natural	O
regulatory	O
T	O
cells	O
may	O
be	O
disturbed	O
.	O

Strikingly	O
,	O
immunofluorescence	O
assays	O
reveal	O
that	O
mimicyp	O
localizes	O
to	O
the	O
surface	O
of	O
the	O
mature	O
virion	O
,	O
as	O
recently	O
proposed	O
for	O
several	O
viruses	O
that	O
recruit	O
host	O
cell	O
cyclophilins	O
such	O
as	O
SARS	B-DISO
and	O
HIV	B-DISO
-	O
1	O
.	O

These	O
results	O
indicate	O
that	O
SARS	B-DISO
-	O
CoV	O
causes	O
multi	O
-	O
organ	O
pathology	B-DISO
in	O
civets	O
,	O
similar	O
to	O
that	O
observed	O
in	O
human	O
SARS	B-DISO
patients	O
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
NL63	O
(	O
NL63	O
),	O
a	O
member	O
of	O
the	O
group	O
I	O
coronaviruses	O
,	O
may	O
cause	O
acute	O
respiratory	B-DISO
diseases	I-DISO
in	O
young	O
children	O
and	O
immunocompromised	O
adults	O
.	O

We	O
investigated	O
the	O
following	O
unclear	O
points	O
concerning	O
ADE	O
of	O
FIPV	O
infection	B-DISO
:	O
(	O
i	O
)	O
involvement	O
of	O
the	O
virus	O
receptor	O
,	O
feline	O
aminopeptidase	O
N	O
(	O
fAPN	O
),	O
in	O
ADE	O
activity	O
in	O
FIPV	O
infection	B-DISO
;	O
(	O
ii	O
)	O
necessity	O
of	O
acidification	O
of	O
the	O
endosome	O
in	O
cellular	O
invasion	B-DISO
of	O
FIPV	O
.	O

We	O
conducted	O
key	O
informant	O
interviews	O
with	O
homeless	O
service	O
providers	O
and	O
public	O
health	O
officials	O
(	O
n	O
=	O
17	O
)	O
and	O
identified	O
challenges	O
specific	O
to	O
the	O
homeless	O
population	O
in	O
the	O
areas	O
of	O
communication	O
,	O
infection	B-DISO
control	O
,	O
isolation	O
and	O
quarantine	O
,	O
and	O
resource	O
allocation	O
.	O

Antibodies	O
against	O
rat	O
coronavirus	O
/	O
sialodacryoadenitis	O
virus	O
(	O
91	O
.	O
7	O
%),	O
Mycoplasma	B-DISO
pulmonis	O
(	O
72	O
.	O
9	O
%),	O
cilia	O
-	O
associated	O
respiratory	O
bacillus	O
(	O
52	O
.	O
1	O
%),	O
rat	O
parvovirus	B-DISO
/	O
rat	O
minute	O
virus	O
(	O
29	O
.	O
2	O
%),	O
Kilham	O
rat	O
virus	O
(	O
10	O
.	O
4	O
%),	O
Toolan	O
'	O
s	O
H	O
-	O
1	O
virus	O
(	O
10	O
.	O
4	O
%),	O
Sendai	O
virus	O
(	O
4	O
.	O
2	O
%)	O
and	O
Theiler	B-DISO
'	I-DISO
s	I-DISO
mouse	I-DISO
encephalomyelitis	I-DISO
virus	O
(	O
4	O
.	O
2	O
%),	O
were	O
detected	O
in	O
wild	O
-	O
caught	O
Norway	O
rats	O
.	O

The	O
risk	O
of	O
pathogen	B-DISO
transmission	I-DISO
from	O
wild	O
-	O
caught	O
rats	O
to	O
laboratory	O
colonies	O
needs	O
to	O
be	O
mitigated	O
by	O
minimizing	O
exposures	O
rather	O
than	O
assuming	O
wild	O
animals	O
represent	O
a	O
minimal	O
hazard	O
.	O

39	O
.	O
5	O
%	O
had	O
complications	O
,	O
with	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
being	O
the	O
most	O
common	O
(	O
25	O
.	O
5	O
%).	O

Study	O
participants	O
were	O
HIV	B-DISO
-	O
infected	O
patients	O
who	O
underwent	O
a	O
bronchoalveolar	O
lavage	O
to	O
rule	O
out	O
an	O
opportunistic	O
event	O
.	O

Parainfluenza	B-DISO
virus	O
(	O
PIV	O
)	O
2	O
,	O
PIV	O
3	O
,	O
PIV	O
4	O
,	O
bocavirus	O
,	O
human	O
rhinovirus	O
A	O
and	O
human	O
metapneumovirus	O
were	O
each	O
identified	O
in	O
one	O
case	O
(	O
9	O
%).	O

Clinical	O
investigation	O
of	O
respiratory	O
viral	B-DISO
infections	I-DISO
in	O
HIV	B-DISO
-	O
infected	O
patients	O
should	O
not	O
be	O
restricted	O
to	O
prototype	O
viruses	O
and	O
also	O
need	O
to	O
target	O
all	O
the	O
different	O
family	O
of	O
viruses	O
as	O
it	O
seems	O
likely	O
that	O
these	O
viruses	O
contribute	O
to	O
pulmonary	B-DISO
complications	I-DISO
and	O
morbidity	O
in	O
this	O
population	O
.	O

TITLE	O
:	O
Platypnea	B-DISO
-	O
orthodeoxia	O
syndrome	B-DISO
in	O
interatrial	O
right	O
to	O
left	O
shunt	O
postpneumonectomy	O
.	O

We	O
describe	O
the	O
case	O
of	O
a	O
64	O
-	O
year	O
-	O
old	O
patient	O
who	O
had	O
developed	O
an	O
acute	B-DISO
respiratory	I-DISO
insufficiency	I-DISO
due	O
to	O
right	O
-	O
to	O
-	O
left	O
shunt	O
in	O
a	O
patent	B-DISO
foramen	I-DISO
ovale	I-DISO
one	O
month	O
after	O
right	O
intrapericardiac	O
pneumonectomy	O
.	O

ABSTRACT	O
:	O
We	O
developed	O
a	O
new	O
system	O
for	O
detection	O
of	O
viral	O
nucleic	O
acids	O
because	O
rapid	O
detection	O
of	O
pathogens	O
is	O
necessary	O
to	O
prevent	O
potential	O
outbreaks	O
of	O
infectious	B-DISO
diseases	I-DISO
.	O

The	O
nucleic	O
acid	O
sequences	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
,	O
which	O
represent	O
emerging	O
and	O
re	O
-	O
emerging	O
infectious	B-DISO
viruses	O
,	O
were	O
determined	O
from	O
infectious	B-DISO
viral	O
culture	O
supernatant	O
by	O
the	O
RDV	O
method	O
.	O

Three	O
biomarkers	O
-	O
IL	O
-	O
8	O
,	O
intercellular	O
adhesion	B-DISO
molecule	O
1	O
and	O
protein	O
C	O
-	O
remained	O
significantly	O
different	O
by	O
multivariate	O
analysis	O
that	O
included	O
age	O
,	O
gender	O
,	O
Simplified	O
Acute	O
Physiology	O
Score	O
II	O
and	O
all	O
biomarkers	O
that	O
were	O
significant	O
on	O
bivariate	O
analysis	O
.	O

CONCLUSIONS	O
:	O
Despite	O
lung	O
-	O
protective	O
ventilation	O
,	O
abnormalities	O
in	O
plasma	O
levels	O
of	O
markers	O
of	O
inflammation	B-DISO
,	O
coagulation	O
and	O
fibrinolysis	O
predict	O
mortality	O
in	O
ALI	O
patients	O
,	O
indicating	O
more	O
severe	O
activation	O
of	O
these	O
biologic	O
pathways	O
in	O
nonsurvivors	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
phagocytic	O
cells	O
in	O
enhanced	O
susceptibility	O
of	O
broilers	O
to	O
colibacillosis	B-DISO
after	O
Infectious	B-DISO
Bronchitis	B-DISO
Virus	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Colibacillosis	B-DISO
results	O
from	O
infection	B-DISO
with	O
avian	O
pathogenic	O
Escherichia	O
coli	O
bacteria	O
.	O

A	O
PBS	B-DISO
control	O
and	O
E	O
.	O
coli	O
group	O
without	O
previous	O
virus	O
inoculation	O
were	O
also	O
included	O
.	O

At	O
4dpi	O
,	O
the	O
number	O
of	O
KUL	O
-	O
01	O
(+)	O
PBMC	O
in	O
all	O
E	O
.	O
coli	O
-	O
inoculated	O
groups	O
was	O
significantly	O
higher	O
than	O
in	O
PBS	B-DISO
-	O
inoculated	O
birds	O
,	O
which	O
correlated	O
with	O
lesion	O
scores	O
.	O

TITLE	O
:	O
Role	O
of	O
human	O
metapneumovirus	O
,	O
human	O
coronavirus	O
NL63	O
and	O
human	O
bocavirus	O
in	O
infants	O
and	O
young	O
children	O
with	O
acute	O
wheezing	B-DISO
.	O

Respiratory	O
syncytial	O
virus	O
may	O
be	O
an	O
underestimated	O
cause	O
of	O
severe	O
respiratory	B-DISO
failure	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
the	O
immunocompromised	O
adult	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
.	O

The	O
""""	O
recipient	O
""""	O
twin	O
exhibits	O
lethal	O
abnormalities	O
,	O
such	O
as	O
acardia	B-DISO
and	O
acephaly	B-DISO
.	O

Both	O
feet	O
demonstrated	O
talipes	O
varus	B-DISO
deformity	I-DISO
.	O

In	O
addition	O
to	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
(	O
acute	O
lung	O
injury	O
,	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
),	O
she	O
developed	O
tenderness	B-DISO
in	O
the	O
right	O
neck	O
followed	O
by	O
septic	B-DISO
arthritis	I-DISO
of	O
the	O
right	O
sternoclavicular	O
joint	O
a	O
few	O
days	O
later	O
.	O

Progression	O
of	O
primary	O
pulmonary	B-DISO
disease	I-DISO
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
can	O
also	O
qualify	O
as	O
a	O
complication	B-DISO
.	O

ABSTRACT	O
:	O
Thailand	O
has	O
been	O
struggling	O
to	O
control	O
and	O
prevent	O
H5N1	B-DISO
avian	B-DISO
influenza	I-DISO
on	O
both	O
the	O
animal	O
health	O
and	O
public	O
health	O
fronts	O
.	O

A	O
complete	O
characterization	O
of	O
virion	O
components	O
is	O
therefore	O
important	O
to	O
understanding	O
the	O
dynamics	O
of	O
early	O
stages	O
of	O
infection	B-DISO
.	O

In	O
Chenopodium	O
quinoa	O
plants	O
inoculated	O
with	O
GFP	O
-	O
ALSV	O
,	O
the	O
infection	B-DISO
foci	O
first	O
appeared	O
as	O
small	O
fluorescent	O
spots	B-DISO
2	O
-	O
3	O
days	O
post	O
inoculation	O
(	O
dpi	O
).	O

Among	O
the	O
complications	O
(	O
47	O
.	O
7	O
%)	O
there	O
were	O
respiratory	B-DISO
insufficiency	I-DISO
of	O
degree	O
I	O
-	O
II	O
(	O
n	O
=	O
29	O
),	O
exudative	B-DISO
pleurisy	I-DISO
(	O
n	O
=	O
7	O
),	O
toxic	B-DISO
shock	I-DISO
(	O
n	O
=	O
6	O
),	O
abscess	B-DISO
of	O
the	O
lung	O
(	O
n	O
=	O
5	O
),	O
acute	O
vascular	O
failure	O
(	O
n	O
=	O
5	O
),	O
chronic	B-DISO
renal	I-DISO
failure	I-DISO
(	O
n	O
=	O
5	O
),	O
DIC	B-DISO
syndrome	I-DISO
(	O
n	O
=	O
3	O
),	O
myocarditis	B-DISO
(	O
n	O
=	O
2	O
).	O

Every	O
infectious	B-DISO
agent	O
spreads	O
easier	O
when	O
its	O
hosts	O
are	O
closer	O
together	O
.	O

ABSTRACT	O
:	O
The	O
sudden	O
emergence	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
at	O
the	O
end	O
of	O
2002	O
resulted	O
in	O
774	O
reported	O
deaths	O
from	O
more	O
than	O
8000	O
cases	O
worldwide	O
.	O

Epitope	O
mapping	O
analysis	O
indicated	O
that	O
monoclonal	O
antibody	O
SN5	O
-	O
25	O
recognized	O
the	O
amino	O
acid	O
sequence	O
Q	O
(	O
245	O
)	O
TVTKK	O
(	O
250	O
)	O
On	O
SARS	B-DISO
-	O
NP	O
.	O

Mice	O
co	O
-	O
infected	O
with	O
SARS	B-DISO
-	O
CoV	O
and	O
Pp	O
developed	O
severe	O
respiratory	B-DISO
disease	I-DISO
with	O
extensive	O
weight	O
loss	O
,	O
resulting	O
in	O
a	O
33	O
~	O
90	O
%	O
mortality	O
rate	O
.	O

Mice	O
with	O
exacerbated	O
pneumonia	B-DISO
showed	O
enhanced	O
virus	B-DISO
infection	I-DISO
in	O
the	O
lungs	O
and	O
histopathological	O
lesions	O
similar	O
to	O
those	O
found	O
in	O
human	O
SARS	B-DISO
cases	O
.	O

Thus	O
,	O
this	O
study	O
shows	O
that	O
exacerbated	O
pneumonia	B-DISO
in	O
mice	O
results	O
from	O
co	B-DISO
-	I-DISO
infection	I-DISO
with	O
SARS	B-DISO
-	O
CoV	O
and	O
a	O
respiratory	O
bacterium	O
that	O
induces	O
elastase	O
production	O
in	O
the	O
lungs	O
,	O
suggesting	O
a	O
possible	O
role	O
for	O
elastase	O
in	O
the	O
exacerbation	O
of	O
pneumonia	B-DISO
.	O

Because	O
these	O
findings	O
are	O
incompatible	O
with	O
social	O
justice	O
and	O
fairness	O
,	O
we	O
examine	O
strategic	O
interventions	O
targeting	O
upstream	O
causes	O
of	O
communicable	B-DISO
disease	I-DISO
transmission	I-DISO
keeping	O
in	O
mind	O
10	O
indispensable	O
public	O
health	O
functions	O
essential	O
to	O
reach	O
marginalized	O
groups	O
.	O

ABSTRACT	O
:	O
In	O
summer	O
2003	O
,	O
a	O
respiratory	O
outbreak	O
was	O
investigated	O
in	O
British	O
Columbia	O
,	O
during	O
which	O
nucleic	O
acid	O
tests	O
and	O
serology	O
unexpectedly	O
indicated	O
reactivity	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

Serological	O
cross	O
-	O
reactivity	O
between	O
SARS	B-DISO
-	O
CoV	O
and	O
human	O
CoV	O
-	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
)	O
was	O
investigated	O
by	O
peptide	O
spot	O
assay	O
.	O

No	O
staff	O
members	O
developed	O
pneumonia	B-DISO
.	O

Findings	O
on	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
assays	O
for	O
SARS	B-DISO
-	O
CoV	O
at	O
a	O
national	O
reference	O
laboratory	O
were	O
suspected	O
to	O
represent	O
false	O
positives	O
,	O
but	O
this	O
was	O
confounded	O
by	O
concurrent	O
identification	O
of	O
antibody	O
to	O
N	O
protein	O
on	O
serology	O
.	O

The	O
results	O
indicate	O
this	O
preferred	O
polypeptide	O
can	O
be	O
used	O
as	O
a	O
lead	O
compound	O
of	O
potent	O
inhibitor	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
mechanism	O
study	O
suggests	O
the	O
specific	O
recognition	O
between	O
the	O
DP	O
and	O
the	O
target	O
peptide	O
was	O
due	O
to	O
sequence	O
-	O
dependent	O
and	O
multi	O
-	O
modal	O
affinity	O
interaction	O
.	O

The	O
introduction	O
of	O
the	O
T10651C	O
mutation	O
into	O
the	O
infectious	B-DISO
MHV	O
clone	O
resulted	O
in	O
the	O
recovery	O
of	O
a	O
mutant	B-DISO
virus	O
,	O
the	O
nsp5	O
/	O
V148A	O
virus	O
,	O
that	O
demonstrated	O
reduced	O
growth	O
and	O
nsp5	O
proteinase	O
activity	O
identical	O
to	O
that	O
of	O
Alb	O
/	O
ts	O
/	O
nsp5	O
/	O
V148A	O
at	O
the	O
nonpermissive	O
temperature	O
.	O

The	O
introduction	O
of	O
the	O
Ser133Asn	O
or	O
His134Tyr	O
substitution	O
into	O
the	O
cloned	O
nsp5	O
/	O
V148A	O
mutant	B-DISO
virus	O
background	O
resulted	O
in	O
the	O
recovery	O
of	O
viruses	O
with	O
increased	B-DISO
growth	I-DISO
fitness	O
and	O
the	O
partial	O
restoration	O
of	O
nsp5	O
activity	O
at	O
the	O
nonpermissive	O
temperature	O
.	O

ABSTRACT	O
:	O
Some	O
strains	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
can	O
induce	O
chronic	O
inflammatory	O
demyelination	B-DISO
in	O
mice	O
that	O
mimics	O
certain	O
pathological	O
features	O
of	O
multiple	B-DISO
sclerosis	I-DISO
.	O

Previous	O
studies	O
demonstrated	O
that	O
recombinant	O
MHV	O
strains	O
,	O
isogenic	O
other	O
than	O
for	O
the	O
spike	O
gene	O
,	O
differ	O
in	O
the	O
extent	O
of	O
neurovirulence	O
and	O
the	O
ability	O
to	O
induce	O
demyelination	B-DISO
.	O

Viral	O
antigen	O
from	O
demyelinating	O
strains	O
is	O
detected	O
initially	O
in	O
both	O
gray	O
and	O
white	O
matter	O
,	O
with	O
subsequent	O
localization	O
to	O
white	O
matter	O
of	O
the	O
spinal	O
cord	B-DISO
,	O
whereas	O
viral	O
antigen	O
localization	O
of	O
nondemyelinating	O
strains	O
is	O
restricted	O
mainly	O
to	O
gray	O
matter	O
.	O

Overall	O
,	O
these	O
observations	O
suggest	O
that	O
isogenic	O
demyelinating	O
and	O
nondemyelinating	O
strains	O
of	O
MHV	O
,	O
differing	O
in	O
the	O
spike	O
protein	O
expressed	O
,	O
infect	O
neurons	O
and	O
glial	O
cells	O
in	O
different	O
proportions	O
and	O
that	O
differential	O
tropism	O
to	O
a	O
particular	O
CNS	O
cell	O
type	O
may	O
play	O
a	O
significant	O
role	O
in	O
mediating	O
the	O
onset	O
and	O
mechanisms	O
of	O
demyelination	B-DISO
.	O

An	O
important	O
viral	O
factor	O
which	O
gives	O
bronchiolitis	B-DISO
in	O
children	O
is	O
HMPV	O
(	O
11	O
%).	O

We	O
also	O
find	O
respiratory	B-DISO
infections	I-DISO
with	O
triple	O
viral	O
etiology	O
:	O
RSV	B-DISO
+	I-DISO
Influenza	I-DISO
A	O
virus	O
+	O
Rhinovirus	O
.	O

ABSTRACT	O
:	O
Fibrin	B-DISO
deposition	I-DISO
was	O
universal	O
in	O
the	O
lungs	O
of	O
SARS	B-DISO
patients	O
and	O
fgl2	O
prothrombinase	O
gene	O
,	O
a	O
novel	O
procoagulant	O
,	O
was	O
demonstrated	O
to	O
express	O
highly	O
in	O
a	O
clinically	O
relevant	O
SARS	B-DISO
model	O
.	O

In	O
nearly	O
every	O
published	O
case	O
report	O
of	O
attempted	O
therapy	O
for	O
clinical	O
FIP	B-DISO
,	O
glucocorticoids	O
have	O
been	O
used	O
;	O
there	O
are	O
,	O
however	O
,	O
no	O
controlled	O
studies	O
that	O
evaluate	O
the	O
effect	O
of	O
glucocorticoids	O
as	O
a	O
therapy	O
for	O
FIP	B-DISO
.	O

Long	O
-	O
term	O
protection	O
from	O
SARS	B-DISO
coronavirus	B-DISO
infection	I-DISO
conferred	O
by	O
a	O
single	O
immunization	O
with	O
an	O
attenuated	O
VSV	O
-	O
based	O
vaccine	O
.	O

Because	O
it	O
is	O
difficult	O
to	O
obtain	O
regulatory	O
approval	O
of	O
vaccine	O
based	O
on	O
live	O
viruses	O
,	O
we	O
constructed	O
a	O
replication	O
-	O
defective	O
single	O
-	O
cycle	O
VSV	O
vector	O
in	O
which	O
we	O
replaced	O
the	O
VSV	O
glycoprotein	O
(	O
G	O
)	O
gene	O
with	O
the	O
SARS	B-DISO
-	O
CoV	O
S	O
gene	O
.	O

These	O
results	O
indicate	O
that	O
alpha2	O
,	O
3	O
-	O
linked	O
sialic	O
acid	O
plays	O
an	O
important	O
role	O
for	O
infection	B-DISO
of	O
the	O
respiratory	O
epithelium	O
by	O
IBV	O
.	O

105	O
of	O
the	O
12	O
018	O
patients	O
(	O
1	O
.	O
44	O
%)	O
were	O
diagnosed	O
as	O
with	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
This	O
study	O
was	O
designated	O
to	O
investigate	O
whether	O
extravascular	O
lung	O
water	O
index	O
(	O
EVLI	O
)	O
is	O
an	O
independent	O
predictor	O
for	O
mortality	O
outcome	O
in	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
.	O

Similar	O
to	O
other	O
N	O
-	O
glycosylated	O
proteins	O
,	O
glycosylation	O
of	O
SARS	B-DISO
-	O
CoV	O
M	O
protein	O
was	O
occurred	O
co	O
-	O
translationally	O
in	O
the	O
presence	O
of	O
microsomes	O
.	O

TITLE	O
:	O
Anticomplementary	O
principles	O
of	O
a	O
Chinese	O
multiherb	O
remedy	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
SARS	B-DISO
.	O

Vascular	B-DISO
lesions	I-DISO
,	O
e	O
.	O
g	O
.	O
degeneration	B-DISO
of	O
endothelial	O
cells	O
,	O
perivascular	O
and	O
intramural	O
oedema	B-DISO
,	O
fibrinoid	B-DISO
necrosis	I-DISO
,	O
vasculitis	B-DISO
,	O
perivasculitis	B-DISO
,	O
and	O
vascular	O
thrombi	B-DISO
were	O
observed	O
in	O
all	O
cases	O
,	O
associated	O
with	O
the	O
presence	O
of	O
PCV2	O
antigen	O
.	O

This	O
report	O
describes	O
the	O
outbreak	O
investigation	O
of	O
nosocomial	O
transmission	O
of	O
SARS	B-DISO
at	O
Hospital	O
X	O
.	O
An	O
investigation	O
of	O
90	O
probable	O
and	O
suspect	O
cases	O
of	O
SARS	B-DISO
associated	O
with	O
a	O
hospital	O
outbreak	O
was	O
performed	O
.	O

Twelve	O
of	O
17	O
(	O
70	O
.	O
6	O
%)	O
nursing	O
staff	O
who	O
developed	O
SARS	B-DISO
worked	O
with	O
another	O
nursing	O
staff	O
who	O
was	O
symptomatic	O
for	O
SARS	B-DISO
.	O

These	O
relaxations	O
of	O
precautions	O
were	O
temporally	O
associated	O
with	O
the	O
nosocomial	O
transmission	O
of	O
SARS	B-DISO
to	O
hospital	O
staff	O
,	O
other	O
patients	O
and	O
visitors	O
at	O
Hospital	O
X	O
.	O
As	O
a	O
result	O
of	O
this	O
outbreak	O
significant	O
changes	O
have	O
been	O
made	O
with	O
respect	O
to	O
infection	B-DISO
-	O
control	O
practices	O
within	O
Canada	O
.	O

ARDS	B-DISO
and	O
hyperglycosemia	O
may	O
be	O
the	O
high	O
risk	O
factors	O
for	O
PE	O
.	O

The	O
data	O
might	O
provide	O
an	O
important	O
insight	O
into	O
the	O
mechanism	O
of	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
-	O
CoV	O
allowing	O
further	O
development	O
of	O
antiviral	O
therapies	O
for	O
treating	O
SARS	B-DISO
infections	B-DISO
.	O

TITLE	O
:	O
Heteroaromatic	O
ester	O
inhibitors	O
of	O
hepatitis	B-DISO
A	I-DISO
virus	O
3C	O
proteinase	O
:	O
Evaluation	O
of	O
mode	O
of	O
action	O
.	O

Modeling	O
studies	O
indicated	O
that	O
the	O
halopyridinyl	O
moiety	O
of	O
the	O
inhibitor	O
fits	B-DISO
tightly	O
into	O
the	O
S1	O
-	O
binding	O
pocket	O
,	O
consistent	O
with	O
the	O
lack	O
of	O
tolerance	B-DISO
of	O
the	O
inhibitors	O
to	O
modification	O
in	O
this	O
portion	O
of	O
the	O
molecule	O
.	O

Virus	B-DISO
infection	I-DISO
was	O
documented	O
in	O
80	O
%	O
of	O
patients	O
with	O
croup	B-DISO
and	O
71	O
%	O
of	O
control	O
subjects	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
frequency	O
of	O
influenza	B-DISO
A	O
virus	O
or	O
human	O
bocavirus	O
.	O

Rhinovirus	O
and	O
enterovirus	O
appeared	O
equally	O
often	O
in	O
croup	B-DISO
and	O
in	O
wheezing	B-DISO
illness	O
.	O

RESULTS	O
:	O
Virus	B-DISO
infection	I-DISO
was	O
documented	O
in	O
80	O
%	O
of	O
patients	O
with	O
croup	B-DISO
and	O
71	O
%	O
of	O
control	O
subjects	O
.	O

TITLE	O
:	O
The	O
analysis	O
of	O
risk	O
factors	O
of	O
impacting	O
mortality	O
rate	O
in	O
severe	O
multiple	O
trauma	O
patients	O
with	O
posttraumatic	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Sepsis	B-DISO
is	O
still	O
a	O
vital	O
risk	O
factor	O
referring	O
to	O
systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
syndrome	I-DISO
,	O
infection	B-DISO
,	I-DISO
secondary	I-DISO
multiple	O
organ	O
dysfunction	O
,	O
etc	O
.	O

TITLE	O
:	O
[	O
Case	O
of	O
severe	O
transfusion	B-DISO
-	I-DISO
related	I-DISO
acute	I-DISO
lung	I-DISO
injury	I-DISO
during	O
coronary	O
artery	O
bypass	O
surgery	O
].	O

Notably	O
,	O
the	O
weak	O
CD8	O
(+)	O
T	O
-	O
cell	O
response	O
elicited	O
by	O
RJHM	O
was	O
unique	O
to	O
CNS	B-DISO
infection	I-DISO
,	O
since	O
peripheral	O
inoculation	O
induced	O
a	O
robust	O
CD8	O
(+)	O
T	O
-	O
cell	O
response	O
in	O
the	O
spleen	O
.	O

CONCLUSIONS	O
:	O
PCT	B-DISO
analysed	O
within	O
72	O
h	O
of	O
the	O
onset	O
of	O
ARDS	B-DISO
predicted	O
mortality	O
of	O
patients	O
with	O
ARDS	B-DISO
caused	O
by	O
severe	O
CAP	B-DISO
.	O

Here	O
we	O
report	O
that	O
Toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR4	O
)	O
mutant	B-DISO
mice	O
display	O
natural	O
resistance	O
to	O
acid	O
-	O
induced	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

We	O
observed	O
OxPL	O
production	O
in	O
the	O
lungs	O
of	O
humans	O
and	O
animals	O
infected	O
with	O
SARS	B-DISO
,	O
Anthrax	B-DISO
,	O
or	O
H5N1	B-DISO
.	O

Therefore	O
,	O
treating	O
SARS	B-DISO
infections	B-DISO
with	O
compounds	O
like	O
promazine	O
is	O
not	O
warranted	O
.	O

TITLE	O
:	O
Clinicopathologic	O
features	O
of	O
a	O
systemic	O
coronavirus	O
-	O
associated	O
disease	O
resembling	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
in	O
the	O
domestic	O
ferret	O
(	O
Mustela	O
putorius	O
).	O

One	O
ferret	O
had	O
a	O
serous	O
abdominal	O
effusion	B-DISO
.	O

In	O
5	O
trials	O
(	O
n	O
=	O
1004	O
),	O
prone	O
positioning	O
was	O
associated	O
with	O
a	O
reduced	O
risk	O
of	O
ventilator	B-DISO
-	I-DISO
associated	I-DISO
pneumonia	I-DISO
(	O
RR	O
0	O
.	O
81	O
,	O
95	O
%	O
CI	O
0	O
.	O
66	O
-	O
0	O
.	O
99	O
;	O
p	O
=	O
0	O
.	O
04	O
)	O
but	O
not	O
with	O
a	O
reduced	O
duration	O
of	O
ventilation	O
.	O

Healthcare	O
workers	O
should	O
take	O
adequate	O
respiratory	O
protection	O
in	O
addition	O
to	O
strict	O
contact	O
and	O
droplet	O
precautions	O
when	O
managing	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

Four	O
years	O
after	O
the	O
SARS	B-DISO
-	O
CoV	O
epidemic	O
,	O
several	O
compounds	O
with	O
an	O
anticoronaviral	O
activity	O
have	O
been	O
identified	O
.	O

Gross	O
inspection	O
revealed	O
oedematous	B-DISO
and	O
haemorrhagic	O
lungs	O
.	O

Microscopic	O
examination	O
revealed	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
with	O
hyaline	B-DISO
membrane	I-DISO
formation	O
and	O
interstitial	B-DISO
pneumonitis	I-DISO
with	O
infiltration	B-DISO
of	O
inflammatory	O
cells	O
.	O

The	O
protein	O
was	O
named	O
human	O
embryo	O
lung	O
cellular	O
protein	O
interacting	O
with	O
SARS	B-DISO
-	O
CoV	O
nsp	O
-	O
10	O
(	O
HEPIS	O
),	O
and	O
it	O
is	O
composed	O
of	O
147	O
amino	O
acids	O
with	O
several	O
CK	O
II	O
phosphorylation	O
sites	O
.	O

Furthermore	O
,	O
we	O
co	O
-	O
immunoprecipitated	O
HEPIS	O
with	O
BTF3	O
,	O
a	O
component	O
of	O
the	O
RNA	O
pol	O
II	O
initiation	O
complex	O
,	O
and	O
observed	O
reduced	O
proliferation	B-DISO
of	O
HeLa	O
cells	O
transfected	O
with	O
the	O
HEPIS	O
gene	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
),	O
including	O
its	O
more	O
severe	O
subcategory	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
is	O
a	O
critical	B-DISO
illness	I-DISO
associated	O
with	O
considerable	O
morbidity	O
and	O
mortality	O
.	O

Our	O
objective	O
was	O
to	O
summarize	O
data	O
on	O
the	O
prevalence	O
of	O
depressive	O
,	O
posttraumatic	B-DISO
stress	I-DISO
disorder	I-DISO
(	O
PTSD	B-DISO
),	O
and	O
other	O
anxiety	O
syndromes	B-DISO
amongst	O
survivors	O
of	O
ALI	O
/	O
ARDS	B-DISO
,	O
potential	O
risk	O
factors	O
for	O
these	O
syndromes	B-DISO
,	O
and	O
their	O
relationships	O
to	O
quality	O
of	O
life	O
.	O

Scrub	B-DISO
typhus	I-DISO
was	O
diagnosed	O
on	O
the	O
basis	O
of	O
serology	O
tests	O
or	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
examination	O
in	O
fifteen	O
children	O
.	O

Nine	O
(	O
60	O
%)	O
patients	O
had	O
headache	B-DISO
and	O
six	O
(	O
40	O
%)	O
complained	O
of	O
abdominal	B-DISO
pain	I-DISO
.	O

RESULTS	O
:	O
Fever	O
and	O
chigger	O
bite	O
history	O
were	O
presented	O
in	O
all	O
15	O
cases	O
,	O
and	O
eschar	B-DISO
lesion	O
was	O
identified	O
in	O
12	O
patients	O
(	O
80	O
%).	O

TITLE	O
:	O
Utilization	O
of	O
the	O
lower	O
inflection	O
point	O
of	O
the	O
pressure	O
-	O
volume	O
curve	O
results	O
in	O
protective	O
conventional	O
ventilation	O
comparable	O
to	O
high	O
frequency	O
oscillatory	O
ventilation	O
in	O
an	O
animal	O
model	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

To	O
compare	O
conventional	O
and	O
high	O
frequency	O
ventilation	O
using	O
the	O
lower	O
inflection	O
point	O
of	O
the	O
pressure	O
-	O
volume	O
curve	O
as	O
the	O
determinant	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
to	O
obtain	O
similar	O
levels	O
of	O
recruitment	B-DISO
and	O
alveolar	O
stability	O
.	O

ABSTRACT	O
:	O
Negative	O
public	O
reactions	O
to	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
can	O
adversely	O
affect	O
population	O
health	O
.	O

ABSTRACT	O
:	O
Progressive	B-DISO
supranuclear	I-DISO
palsy	I-DISO
(	O
PSP	B-DISO
)	O
is	O
classically	O
characterized	O
by	O
supranuclear	B-DISO
ophthalmoplegia	I-DISO
,	O
paroxysmal	O
imbalance	B-DISO
with	O
backward	O
falling	O
,	O
axial	O
dystonia	B-DISO
,	O
rigidity	B-DISO
,	O
pseudobulbar	B-DISO
palsy	I-DISO
and	O
cognitive	B-DISO
dysfunction	I-DISO
.	O

A	O
few	O
months	O
later	O
she	O
developed	O
severe	O
swallowing	B-DISO
disorders	I-DISO
,	O
caused	O
by	O
achalasia	B-DISO
of	O
the	O
upper	O
esophageal	O
sphincter	O
,	O
and	O
responsible	O
for	O
recurrent	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
and	O
pneumonia	B-DISO
,	O
prevailing	O
to	O
tracheotomy	O
and	O
gastrostomy	B-DISO
.	O

This	O
case	O
suggests	O
that	O
the	O
initial	O
neuropathological	O
changes	O
in	O
PSP	B-DISO
is	O
located	O
in	O
the	O
dorsal	O
brainstem	O
.	O

In	O
addition	O
,	O
the	O
immune	O
response	O
levels	O
in	O
N3	O
were	O
significantly	O
higher	O
for	O
antibody	O
responses	O
(	O
IgG	O
and	O
IgG1	O
but	O
not	O
IgG2a	O
)	O
and	O
cell	O
proliferation	B-DISO
but	O
not	O
in	O
CD4	O
(+):	O
CD8	O
(+)	O
assay	O
compared	O
to	O
N1	O
vaccine	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
was	O
first	O
reported	O
in	O
November	O
2002	O
in	O
China	O
,	O
and	O
spreads	O
to	O
about	O
30	O
countries	O
over	O
the	O
next	O
few	O
months	O
.	O

The	O
study	O
of	O
associations	O
between	O
important	O
SARS	B-DISO
characteristics	O
considerably	O
enhanced	O
the	O
mainstream	O
epidemic	O
analysis	O
and	O
improved	O
the	O
understanding	O
of	O
the	O
relationships	O
between	O
the	O
observed	O
epidemic	O
determinants	O
.	O

The	O
concerted	O
protein	O
-	O
protein	O
interactions	O
among	O
the	O
HR	O
helices	O
are	O
responsible	O
for	O
the	O
fusion	O
event	O
that	O
leads	O
to	O
the	O
release	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
nucleocapsid	O
into	O
the	O
target	O
host	O
-	O
cell	O
.	O

ADS	O
-	O
J1	O
,	O
which	O
has	O
been	O
used	O
to	O
interfere	O
with	O
the	O
fusogenesis	O
of	O
HIV	B-DISO
-	O
1	O
onto	O
CD4	O
+	O
cells	O
,	O
demonstrated	O
the	O
highest	O
HIV	B-DISO
-	O
luc	O
/	O
SARS	B-DISO
pseudotyped	O
virus	O
-	O
entry	O
inhibition	O
activity	O
among	O
the	O
other	O
small	O
-	O
molecule	O
drugs	O
.	O

ABSTRACT	O
:	O
In	O
Bangladesh	O
,	O
4	O
outbreaks	O
of	O
Nipah	B-DISO
virus	I-DISO
infection	I-DISO
were	O
identified	O
during	O
the	O
period	O
2001	O
-	O
2004	O
.	O

Patients	O
were	O
considered	O
to	O
have	O
probable	O
cases	O
of	O
Nipah	B-DISO
virus	I-DISO
infection	I-DISO
if	O
they	O
had	O
symptoms	O
consistent	O
with	O
Nipah	B-DISO
virus	I-DISO
infection	I-DISO
during	O
the	O
same	O
time	O
and	O
in	O
the	O
same	O
community	O
as	O
patients	O
with	O
confirmed	O
cases	O
.	O

Among	O
patients	O
with	O
Nipah	B-DISO
virus	I-DISO
infection	I-DISO
who	O
had	O
well	O
-	O
defined	O
exposure	O
to	O
another	O
patient	O
infected	O
with	O
Nipah	O
virus	O
,	O
the	O
median	O
incubation	O
period	O
was	O
9	O
days	O
(	O
range	O
,	O
6	O
-	O
11	O
days	O
).	O

The	O
most	O
common	O
indication	O
for	O
HFOV	O
was	O
oxygenation	O
failure	O
,	O
which	O
was	O
due	O
to	O
pneumonia	B-DISO
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
15	O
(	O
45	O
.	O
5	O
%),	O
severe	O
lobar	B-DISO
pneumonia	I-DISO
in	O
nine	O
(	O
27	O
.	O
3	O
%),	O
pulmonary	B-DISO
hemorrhage	I-DISO
in	O
eight	O
(	O
24	O
.	O
2	O
%)	O
and	O
pneumothorax	B-DISO
in	O
one	O
(	O
3	O
%).	O

However	O
,	O
conventional	O
treatment	O
for	O
severe	O
respiratory	B-DISO
failure	I-DISO
is	O
also	O
one	O
of	O
the	O
more	O
costly	O
forms	O
of	O
care	O
in	O
any	O
health	O
system	O
.	O

Direct	O
infestation	B-DISO
of	O
lymphocytes	O
,	O
neutrophils	O
and	O
macrophages	O
by	O
SARS	B-DISO
coronavirus	O
(	O
CoV	O
)	O
has	O
been	O
debated	O
as	O
a	O
cause	O
of	O
lymphopenia	B-DISO
,	O
but	O
there	O
is	O
no	O
convincing	O
data	O
.	O

Because	O
of	O
the	O
insidious	O
presentation	O
,	O
SARS	B-DISO
was	O
treated	O
with	O
antibacterial	O
,	O
antiviral	O
and	O
supra	O
-	O
physiological	O
doses	O
of	O
glucocorticoids	O
.	O

SARS	B-DISO
-	O
CoV	O
protein	O
6	O
increases	O
MHV	O
neurovirulence	O
and	O
accelerates	O
MHV	O
infection	B-DISO
kinetics	O
in	O
tissue	O
culture	O
.	O

In	O
this	O
study	O
,	O
protein	O
6	O
was	O
expressed	O
from	O
plasmid	O
DNAs	O
and	O
accumulated	O
in	O
cells	O
prior	O
to	O
infection	B-DISO
by	O
wild	O
-	O
type	O
MHV	O
.	O

TITLE	O
:	O
Structural	O
analysis	O
of	O
major	O
species	O
barriers	O
between	O
humans	O
and	O
palm	O
civets	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	B-DISO
infections	I-DISO
.	O

They	O
show	O
that	O
the	O
major	O
species	O
barriers	O
are	O
determined	O
by	O
interactions	O
between	O
four	O
ACE2	O
residues	O
(	O
residues	O
31	O
,	O
35	O
,	O
38	O
,	O
and	O
353	O
)	O
and	O
two	O
RBD	O
residues	O
(	O
residues	O
479	O
and	O
487	O
),	O
that	O
early	O
civet	O
SARS	B-DISO
-	O
CoV	O
isolates	O
were	O
prevented	O
from	O
infecting	O
human	O
cells	O
due	O
to	O
imbalanced	O
salt	O
bridges	O
at	O
the	O
hydrophobic	O
virus	O
/	O
receptor	O
interface	O
,	O
and	O
that	O
SARS	B-DISO
-	O
CoV	O
has	O
evolved	O
to	O
gain	O
sustained	O
infectivity	O
for	O
human	O
cells	O
by	O
eliminating	O
unfavorable	O
free	O
charges	O
at	O
the	O
interface	O
through	O
stepwise	O
mutations	O
at	O
positions	O
479	O
and	O
487	O
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
2002	O
-	O
2003	O
has	O
had	O
a	O
significant	O
impact	O
worldwide	O
.	O

There	O
were	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
in	O
age	O
,	O
body	O
mass	O
index	O
,	O
length	O
of	O
stay	O
,	O
APACHE	O
II	O
score	O
,	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
(	O
MODS	B-DISO
)	O
and	O
abdominal	B-DISO
compartment	I-DISO
syndrome	I-DISO
(	O
ACS	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Total	O
hepatectomy	O
with	O
temporary	O
portocaval	O
shunt	O
was	O
employed	O
as	O
a	O
bridging	O
procedure	O
before	O
liver	O
transplantation	O
,	O
in	O
the	O
setting	O
of	O
fulminant	B-DISO
hepatic	I-DISO
failure	I-DISO
with	O
""""	O
toxic	O
liver	O
syndrome	B-DISO
""";"	O
acute	O
,	O
severe	O
,	O
and	O
extensive	O
liver	B-DISO
necrosis	I-DISO
associated	O
with	O
cardiovascular	O
shock	O
and	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
with	O
or	O
without	O
respiratory	B-DISO
failure	I-DISO
.	O

This	O
procedure	O
sought	O
to	O
improve	O
metabolic	B-DISO
acidosis	I-DISO
and	O
hemodynamic	B-DISO
instability	I-DISO
related	O
to	O
advanced	O
liver	B-DISO
necrosis	I-DISO
.	O

Despite	O
the	O
passage	O
of	O
time	O
since	O
the	O
last	O
diagnosed	O
case	O
of	O
SARS	B-DISO
in	O
April	O
2004	O
,	O
researchers	O
have	O
warned	O
the	O
global	O
community	O
to	O
be	O
prepared	O
for	O
future	O
outbreaks	O
of	O
SARS	B-DISO
or	O
other	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

Human	O
coronaviruses	O
may	O
be	O
also	O
involved	O
in	O
enteric	O
and	O
neurologic	B-DISO
diseases	I-DISO
.	O

Although	O
at	O
the	O
present	O
time	O
we	O
do	O
not	O
have	O
a	O
test	O
that	O
will	O
definitively	O
rule	O
in	O
or	O
rule	O
out	O
SARS	B-DISO
at	O
the	O
time	O
of	O
initial	O
presentation	O
of	O
a	O
patient	O
with	O
a	O
respiratory	B-DISO
infection	I-DISO
,	O
modifications	O
of	O
existing	O
assays	O
will	O
hopefully	O
result	O
in	O
our	O
ability	O
to	O
make	O
this	O
diagnosis	O
with	O
a	O
high	O
degree	O
of	O
accuracy	O
in	O
the	O
future	O
.	O

The	O
postulated	O
disease	B-DISO
progression	I-DISO
comprises	O
(	O
1	O
)	O
active	O
viral	B-DISO
infection	I-DISO
,	O
(	O
2	O
)	O
hyperactive	O
immune	O
response	O
,	O
and	O
(	O
3	O
)	O
recovery	O
or	O
pulmonary	O
destruction	O
and	O
death	O
.	O

TITLE	O
:	O
Acute	O
febrile	O
respiratory	O
illness	O
in	O
the	O
ICU	O
:	O
reducing	O
disease	B-DISO
transmission	I-DISO
.	O

A	O
small	O
number	O
of	O
viral	O
agents	O
lead	O
to	O
acute	O
FRI	O
,	O
respiratory	B-DISO
failure	I-DISO
,	O
and	O
ARDS	B-DISO
:	O
seasonal	O
influenza	B-DISO
,	I-DISO
avian	I-DISO
influenza	B-DISO
,	O
coronavirus	O
associated	O
with	O
severe	O
ARDS	B-DISO
,	O
respiratory	O
syncytial	O
virus	O
,	O
adenovirus	B-DISO
,	O
varicella	B-DISO
,	O
human	O
metapneumovirus	O
,	O
and	O
hantavirus	O
.	O

The	O
analysis	O
showed	O
that	O
early	O
case	O
detection	O
followed	O
by	O
strict	O
isolation	O
could	O
control	O
a	O
SARS	B-DISO
outbreak	O
.	O

The	O
study	O
emphasizes	O
the	O
importance	O
of	O
early	O
identification	O
and	O
isolation	O
of	O
SARS	B-DISO
cases	O
to	O
reduce	O
the	O
number	O
of	O
people	O
getting	O
infected	O
.	O

A	O
44	O
-	O
year	O
-	O
old	O
,	O
small	O
-	O
statured	O
female	O
with	O
cretinism	B-DISO
had	O
a	O
traffic	O
accident	O
.	O

Anti	O
-	O
EN	O
antibody	O
was	O
positive	O
in	O
the	O
sera	O
of	O
40	O
.	O
9	O
%	O
of	O
SARS	B-DISO
patients	O
.	O

TITLE	O
:	O
Combination	O
of	O
functionalized	O
nanoparticles	O
and	O
polymerase	O
chain	O
reaction	O
-	O
based	O
method	O
for	O
SARS	B-DISO
-	O
CoV	O
gene	O
detection	O
.	O

ABSTRACT	O
:	O
Rapid	O
and	O
sensitive	O
detection	O
of	O
SARS	B-DISO
associated	O
coronavirus	O
is	O
critical	O
for	O
early	O
diagnosis	O
and	O
control	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

Each	O
year	O
our	O
country	O
is	O
stricken	O
by	O
flu	B-DISO
epidemics	O
,	O
but	O
at	O
some	O
points	O
of	O
time	O
unexpected	O
new	O
flu	B-DISO
viruses	O
may	O
cause	O
a	O
worldwide	O
pandemic	O
.	O

Results	O
showed	O
that	O
HC	O
water	O
extract	O
could	O
stimulate	O
the	O
proliferation	B-DISO
of	O
mouse	O
splenic	O
lymphocytes	O
significantly	O
and	O
dose	O
-	O
dependently	O
.	O

TITLE	O
:	O
Staff	O
perception	O
and	O
institutional	O
reporting	O
:	O
two	O
views	O
of	O
infection	B-DISO
control	O
compliance	O
in	O
British	O
Columbia	O
and	O
Ontario	O
three	O
years	O
after	O
an	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
The	O
fetal	O
brain	O
in	O
bovine	B-DISO
viral	I-DISO
diarrhea	I-DISO
virus	O
-	O
infected	O
calves	O
:	O
lesions	O
,	O
distribution	O
,	O
and	O
cellular	O
heterogeneity	O
of	O
viral	O
antigen	O
at	O
190	O
days	O
gestation	O
.	O

ABSTRACT	O
:	O
In	O
response	O
to	O
the	O
2003	O
global	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
and	O
the	O
threat	O
of	O
pandemic	O
influenza	B-DISO
,	O
Canadian	O
hospitals	O
have	O
been	O
actively	O
developing	O
and	O
revising	O
their	O
emergency	B-DISO
plans	O
.	O

Approximately	O
one	O
third	O
of	O
Canadian	O
nurses	O
identified	O
job	B-DISO
strain	I-DISO
and	O
poor	O
health	O
,	O
related	O
to	O
their	O
work	O
environment	O
.	O

Three	O
years	O
after	O
SARS	B-DISO
,	O
this	O
article	O
presents	O
a	O
critical	O
analysis	O
of	O
the	O
gaps	O
of	O
three	O
hospital	O
pandemic	O
influenza	B-DISO
plans	O
in	O
the	O
context	O
of	O
established	O
organizational	O
supports	O
for	O
healthcare	O
workers	O
.	O

Hospital	O
pandemic	O
influenza	B-DISO
plans	O
were	O
obtained	O
from	O
institutional	O
representatives	O
in	O
three	O
Ontario	O
cities	O
.	O

Organizational	O
support	O
mechanisms	O
for	O
healthcare	O
workers	O
were	O
included	O
in	O
these	O
hospital	O
plans	O
;	O
however	O
,	O
the	O
gaps	O
identified	O
here	O
may	O
have	O
serious	O
implications	O
for	O
employee	O
health	O
and	O
safety	O
,	O
and	O
overall	O
response	O
during	O
a	O
large	O
scale	O
infectious	B-DISO
disease	I-DISO
outbreak	O
.	O

In	O
the	O
proposed	O
model	O
of	O
respiratory	B-DISO
failure	I-DISO
,	O
SARS	B-DISO
-	O
CoV	O
down	O
-	O
regulates	O
its	O
receptor	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
but	O
the	O
mechanism	O
involved	O
is	O
unknown	O
.	O

Intriguingly	O
,	O
viral	B-DISO
infection	I-DISO
,	O
judged	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
analysis	O
of	O
SARS	B-DISO
-	O
CoV	O
mRNA	O
expression	O
,	O
was	O
significantly	O
attenuated	O
by	O
deletion	O
of	O
the	O
cytoplasmic	O
tail	O
of	O
ACE2	O
or	O
knock	O
-	O
down	O
of	O
TACE	O
expression	O
by	O
siRNA	O
.	O

These	O
data	O
suggest	O
that	O
cellular	O
signals	O
triggered	O
by	O
the	O
interaction	O
of	O
SARS	B-DISO
-	O
CoV	O
with	O
ACE2	O
are	O
positively	O
involved	O
in	O
viral	O
entry	O
but	O
lead	O
to	O
tissue	O
damage	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	B-DISO
infection	I-DISO
causes	O
neuronal	O
death	O
in	O
the	O
absence	O
of	O
encephalitis	B-DISO
in	O
mice	O
transgenic	O
for	O
human	O
ACE2	O
.	O

This	O
extensive	O
neuronal	O
infection	B-DISO
is	O
the	O
main	O
cause	O
of	O
death	O
because	O
intracranial	O
inoculation	O
with	O
low	O
doses	O
of	O
virus	O
results	O
in	O
a	O
uniformly	O
lethal	O
disease	O
even	O
though	O
little	O
infection	B-DISO
is	O
detected	O
in	O
the	O
lungs	O
.	O

HCoV	O
-	O
229E	O
is	O
a	O
close	O
relative	O
of	O
HCoV	O
-	O
NL63	O
,	O
and	O
infection	B-DISO
with	O
either	O
virus	O
can	O
lead	O
to	O
the	O
hospitalization	O
of	O
young	O
children	O
,	O
immunocompromised	O
persons	O
,	O
and	O
the	O
elderly	O
.	O

TITLE	O
:	O
Recommendations	O
for	O
the	O
diagnosis	O
and	O
management	O
of	O
corticosteroid	O
insufficiency	O
in	O
critically	B-DISO
ill	I-DISO
adult	O
patients	O
:	O
consensus	O
statements	O
from	O
an	O
international	O
task	O
force	O
by	O
the	O
American	O
College	O
of	O
Critical	O
Care	O
Medicine	O
.	O

Adrenal	B-DISO
insufficiency	I-DISO
in	O
critically	B-DISO
ill	I-DISO
patients	O
is	O
best	O
made	O
by	O
a	O
delta	O
total	O
serum	O
cortisol	O
of	O
<	O
9	O
microg	O
/	O
dL	O
after	O
adrenocorticotrophic	O
hormone	O
(	O
250	O
microg	O
)	O
administration	O
or	O
a	O
random	O
total	O
cortisol	O
of	O
<	O
10	O
microg	O
/	O
dL	O
.	O
The	O
benefit	O
of	O
treatment	O
with	O
glucocorticoids	O
at	O
this	O
time	O
seems	O
to	O
be	O
limited	O
to	O
patients	O
with	O
vasopressor	O
-	O
dependent	O
septic	B-DISO
shock	I-DISO
and	O
patients	O
with	O
early	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
PaO2	O
/	O
FiO2	O
of	O
<	O
200	O
and	O
within	O
14	O
days	O
of	O
onset	O
).	O

RESULTS	O
:	O
The	O
task	O
force	O
coined	O
the	O
term	O
critical	B-DISO
illness	I-DISO
-	O
related	O
corticosteroid	O
insufficiency	O
to	O
describe	O
the	O
dysfunction	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
that	O
occurs	O
during	O
critical	B-DISO
illness	I-DISO
.	O

Poisson	O
Regression	O
Models	O
were	O
used	O
to	O
examine	O
impact	O
of	O
the	O
SARS	B-DISO
epidemic	O
on	O
older	O
adults	O
suicides	O
in	O
Hong	O
Kong	O
.	O

TITLE	O
:	O
Canine	O
respiratory	O
coronavirus	O
:	O
an	O
emerging	O
pathogen	O
in	O
the	O
canine	O
infectious	B-DISO
respiratory	B-DISO
disease	I-DISO
complex	O
.	O

TITLE	O
:	O
H5N1	B-DISO
influenza	I-DISO
marker	O
vaccine	O
for	O
serological	O
differentiation	O
between	O
vaccinated	O
and	O
infected	O
chickens	O
.	O

Chickens	O
immunized	O
with	O
the	O
H5N1	B-DISO
/	O
PR8	O
-	O
5B19	O
inactivated	O
vaccine	O
produced	O
high	O
levels	O
of	O
HI	O
antibody	O
and	O
a	O
measurable	O
antibody	O
response	O
against	O
the	O
MHV	O
5B19	O
epitope	O
,	O
and	O
were	O
fully	O
protected	O
against	O
subsequent	O
challenge	O
with	O
different	O
highly	O
pathogenic	O
H5N1	B-DISO
avian	B-DISO
influenza	I-DISO
viruses	O
.	O

The	O
findings	O
of	O
hepatic	B-DISO
failure	I-DISO
resolved	O
immediately	O
after	O
LRLT	O
,	O
but	O
severe	O
respiratory	B-DISO
complications	I-DISO
and	O
chylous	B-DISO
ascites	I-DISO
were	O
observed	O
during	O
the	O
follow	O
-	O
up	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
capacity	O
of	O
alveolar	O
type	O
II	O
(	O
AT	O
II	O
)	O
cells	O
for	O
water	O
and	O
sodium	O
transport	O
in	O
rats	O
with	O
early	O
-	O
stage	O
oleic	O
acid	O
-	O
induced	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

ABSTRACT	O
:	O
Although	O
some	O
previously	O
common	O
infections	B-DISO
,	O
such	O
as	O
Sendai	O
virus	O
and	O
Mycoplasma	B-DISO
pulmonis	O
,	O
have	O
become	O
rare	O
in	O
laboratory	O
rodents	O
in	O
North	O
American	O
research	O
facilities	O
,	O
others	O
continue	O
to	O
plague	B-DISO
researchers	O
and	O
those	O
responsible	O
for	O
providing	O
biomedical	O
scientists	O
with	O
animals	O
free	O
of	O
adventitious	O
disease	O
.	O

In	O
this	O
condition	B-DISO
,	O
DCO	B-DISO
is	O
an	O
effective	O
and	O
safe	O
option	O
.	O

Studies	O
with	O
a	O
neurotropic	O
murine	O
coronavirus	O
,	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
have	O
provided	O
important	O
insights	O
into	O
how	O
the	O
immune	O
system	O
combats	O
neuroinvasive	O
viruses	O
,	O
and	O
have	O
identified	O
molecular	O
and	O
cellular	O
mechanisms	O
contributing	O
to	O
chronic	B-DISO
disease	I-DISO
in	O
persistently	O
infected	O
mice	O
.	O

A	O
programmed	O
-	O
1	O
ribosomal	O
frameshift	B-DISO
is	O
required	O
by	O
coronaviruses	O
for	O
the	O
production	O
of	O
the	O
RNA	O
dependent	O
RNA	O
polymerase	O
which	O
in	O
turn	O
is	O
essential	O
for	O
viral	O
replication	O
.	O

Other	O
symptoms	O
are	O
non	O
specific	O
and	O
they	O
may	O
include	O
:	O
sore	B-DISO
throat	I-DISO
,	O
myalgia	B-DISO
and	O
nausea	B-DISO
.	O

However	O
,	O
direct	O
contact	O
with	O
the	O
maternal	O
body	O
fluid	O
which	O
contained	O
SARS	B-DISO
-	O
CoV	O
,	O
has	O
put	O
the	O
infants	O
in	O
great	O
danger	O
of	O
perinatal	B-DISO
infection	I-DISO
.	O

His	O
situation	O
further	O
declined	O
with	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
(	O
DIC	B-DISO
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Of	O
83	O
patients	O
,	O
considering	O
IAP	O
(	O
max	O
),	O
31	O
%	O
had	O
intra	B-DISO
-	I-DISO
abdominal	I-DISO
hypertension	I-DISO
on	O
admission	O
and	O
another	O
33	O
%	O
developed	O
it	O
after	O
(	O
23	O
%	O
and	O
31	O
%	O
with	O
IAP	O
(	O
mean	O
)).	O

Main	O
risk	O
factors	O
were	O
mechanical	O
ventilation	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
and	O
fluid	O
resuscitation	O
(	O
relative	O
risk	O
,	O
5	O
.	O
26	O
,	O
3	O
.	O
19	O
,	O
and	O
2	O
.	O
50	O
,	O
respectively	O
).	O

Abdominal	B-DISO
compartment	I-DISO
syndrome	I-DISO
developed	O
in	O
12	O
%;	O
20	O
%	O
survived	O
.	O

The	O
prevalence	O
of	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
was	O
possible	O
to	O
evaluate	O
in	O
the	O
deceased	O
patients	O
with	O
SPRF	O
(	O
n	O
=	O
52	O
).	O

TITLE	O
:	O
A	O
chimeric	O
multi	O
-	O
epitope	O
DNA	O
vaccine	O
elicited	O
specific	O
antibody	O
response	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
which	O
attenuated	O
the	O
virulence	O
of	O
SARS	B-DISO
-	O
CoV	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
are	O
different	O
stages	O
of	O
the	O
same	O
disease	O
,	O
the	O
aggravated	O
stage	O
of	O
ALI	O
leading	O
to	O
ARDS	B-DISO
.	O

TITLE	O
:	O
[	O
Evaluation	O
of	O
the	O
protection	O
conferred	O
by	O
several	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
attenuated	O
vaccines	O
against	O
the	O
field	O
strain	O
CK	O
/	O
CH	O
/	O
LDL	O
/	O
97	O
I	O
in	O
China	O
].	O

ABSTRACT	O
:	O
The	O
entire	O
S1	O
protein	O
gene	O
of	O
five	O
infectious	B-DISO
bronchitis	B-DISO
(	O
IB	B-DISO
)	O
vaccine	O
strains	O
(	O
JAAS	O
,	O
IBN	O
,	O
Jilin	O
,	O
J9	O
,	O
H120	O
)	O
used	O
in	O
China	O
were	O
compared	O
with	O
that	O
of	O
the	O
IB	B-DISO
field	O
isolate	O
CK	O
/	O
CH	O
/	O
LDL	O
/	O
97	O
I	O
present	O
in	O
China	O
.	O

TITLE	O
:	O
Pathogenesis	B-DISO
of	O
feline	O
enteric	O
coronavirus	B-DISO
infection	I-DISO
.	O

After	O
stabilization	O
,	O
pigs	O
belonging	O
to	O
group	O
II	O
were	O
observed	O
only	O
,	O
whereas	O
in	O
those	O
belonging	O
to	O
groups	O
III	O
to	O
V	O
,	O
a	O
surfactant	O
-	O
depletion	O
severe	O
(	O
Pao	O
(	O
2	O
)/	O
Fio	O
(	O
2	O
)	O
<	O
100	O
)	O
postpneumonectomy	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
was	O
induced	O
.	O

Thirty	O
-	O
two	O
New	O
Zealand	O
rabbits	O
were	O
randomly	O
divided	O
into	O
four	O
groups	O
,	O
and	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
model	O
was	O
reproduced	O
by	O
severe	O
steam	O
inhalation	O
injury	O
.	O

TITLE	O
:	O
Mouse	B-DISO
hepatitis	I-DISO
coronavirus	O
RNA	O
replication	O
depends	O
on	O
GBF1	O
-	O
mediated	O
ARF1	O
activation	O
.	O

Consistently	O
,	O
expression	O
of	O
a	O
dominant	B-DISO
-	I-DISO
negative	I-DISO
mutant	I-DISO
of	O
ARF1	O
,	O
known	O
to	O
mimic	O
the	O
action	O
of	O
the	O
drug	O
,	O
inhibited	O
MHV	O
infection	B-DISO
profoundly	O
.	O

A	O
complete	O
analytical	O
microfluidic	O
system	O
was	O
developed	O
by	O
integrating	O
various	O
functional	O
modules	O
into	O
a	O
single	O
chip	O
,	O
thus	O
allowing	O
cell	O
lysis	B-DISO
,	O
sample	O
preparation	O
,	O
purification	O
of	O
intracellular	O
molecules	O
,	O
and	O
subsequent	O
analysis	O
.	O

TITLE	O
:	O
Endocytosis	O
of	O
the	O
receptor	O
-	O
binding	O
domain	O
of	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
together	O
with	O
virus	O
receptor	O
ACE2	O
.	O

TITLE	O
:	O
Intra	B-DISO
-	I-DISO
abdominal	I-DISO
hypertension	I-DISO
:	O
pulmonary	O
and	O
cerebral	O
complications	O
.	O

ABSTRACT	O
:	O
Intra	B-DISO
-	I-DISO
abdominal	I-DISO
hypertension	I-DISO
causes	O
many	O
physiologic	O
changes	O
,	O
primarily	O
by	O
reducing	O
thoracic	B-DISO
compliance	O
and	O
secondarily	O
causing	O
organ	B-DISO
failure	I-DISO
,	O
which	O
is	O
the	O
body	O
'	O
s	O
normal	O
response	O
to	O
trauma	O
or	O
acute	B-DISO
inflammatory	I-DISO
response	I-DISO
.	O

ABSTRACT	O
:	O
Transmission	O
electron	O
microscopy	O
(	O
of	O
ultrathin	O
sections	O
)	O
was	O
used	O
to	O
examine	O
the	O
biomass	O
of	O
lung	O
tissue	O
in	O
the	O
immunodeficiency	B-DISO
minipigs	O
experimentally	O
infected	O
with	O
Pneumocystis	B-DISO
carinii	O
.	O

ABSTRACT	O
:	O
To	O
test	O
whether	O
an	O
acute	O
transfusion	O
practice	O
of	O
packed	O
red	O
blood	O
cells	O
(	O
pRBC	O
)	O
:	O
fresh	O
-	O
frozen	O
plasma	O
(	O
FFP	O
)	O
1	O
:	O
1	O
would	O
be	O
associated	O
with	O
reduced	O
mortality	O
in	O
acute	B-DISO
bleeding	I-DISO
multiply	O
injury	O
.	O

Further	O
investigation	O
is	O
necessary	O
prior	O
to	O
recommending	O
routine	O
1	O
:	O
1	O
or	O
more	O
aggressive	B-DISO
FFP	O
use	O
in	O
exsanguinating	O
patients	O
.	O

The	O
occurrence	O
of	O
bronchitis	B-DISO
(	O
P	O
=.	O
007	O
),	O
pneumonia	B-DISO
(	O
P	O
=.	O
02	O
),	O
and	O
any	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
(	O
P	O
=.	O
002	O
)	O
was	O
significantly	O
associated	O
with	O
having	O
a	O
viral	O
diagnosis	O
.	O

TITLE	O
:	O
Role	O
of	O
respiratory	O
pathogens	O
in	O
infants	O
hospitalized	O
for	O
a	O
first	O
episode	O
of	O
wheezing	B-DISO
and	O
their	O
impact	O
on	O
recurrences	B-DISO
.	O

A	O
high	O
viral	O
load	O
seems	O
to	O
be	O
strictly	O
related	O
to	O
the	O
likelihood	O
of	O
recurrence	B-DISO
.	O

TITLE	O
:	O
A	O
structural	O
view	O
of	O
the	O
inactivation	B-DISO
of	O
the	O
SARS	B-DISO
coronavirus	O
main	O
proteinase	O
by	O
benzotriazole	O
esters	O
.	O

TITLE	O
:	O
Cathepsin	O
L	O
functionally	O
cleaves	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
class	O
I	O
fusion	O
protein	O
upstream	O
of	O
rather	O
than	O
adjacent	O
to	O
the	O
fusion	O
peptide	O
.	O

TITLE	O
:	O
Peptides	O
from	O
the	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
as	O
tags	O
for	O
protein	O
expression	O
and	O
purification	O
.	O

This	O
report	O
describes	O
the	O
usage	O
of	O
two	O
short	O
peptides	O
from	O
the	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
nucleocapsid	O
(	O
SARS	B-DISO
-	O
N	O
)	O
protein	O
as	O
protein	O
tags	O
.	O

Shedding	O
of	O
SARS	B-DISO
-	O
CoV	O
peaks	O
at	O
day	O
10	O
after	O
the	O
onset	O
of	O
symptoms	O
,	O
which	O
theoretically	O
allows	O
ample	O
time	O
for	O
antiviral	O
treatment	O
.	O

The	O
role	O
of	O
immunomodulators	O
to	O
decrease	O
excessive	O
inflammation	B-DISO
remains	O
elusive	O
.	O

TITLE	O
:	O
Rapid	O
selection	O
in	O
chickens	O
of	O
subpopulations	O
within	O
ArkDPI	O
-	O
derived	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
vaccines	O
.	O

ABSTRACT	O
:	O
Muscular	B-DISO
weakness	I-DISO
affecting	O
predominantly	O
the	O
proximal	O
limb	O
muscles	O
and	O
neck	O
flexors	O
is	O
the	O
cardinal	O
feature	O
of	O
intermediate	B-DISO
syndrome	I-DISO
with	O
cranial	B-DISO
nerve	I-DISO
palsies	I-DISO
occasionally	O
accompanied	O
.	O

ABSTRACT	O
:	O
A	O
34	O
-	O
year	O
old	O
woman	O
who	O
developed	O
persistent	O
and	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
with	O
underlying	O
myelomonocytic	B-DISO
leukemia	I-DISO
(	O
M4FAB	O
)	O
is	O
described	O
.	O

The	O
patient	O
remained	O
on	O
P	O
-	O
ELA	O
for	O
nine	O
days	O
;	O
one	O
week	O
later	O
she	O
was	O
extubated	O
and	O
ten	O
days	O
after	O
she	O
was	O
discharged	O
from	O
the	O
Intensive	O
Care	O
Unit	O
the	O
patient	O
left	O
the	O
hospital	O
in	O
good	O
health	O
condition	B-DISO
.	O

Risk	O
factors	O
for	O
perinatal	O
death	O
as	O
assessed	O
by	O
multivariable	O
logistic	O
regression	O
included	O
preterm	B-DISO
delivery	I-DISO
(	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
11	O
.	O
9	O
,	O
[	O
95	O
%	O
CI	O
6	O
.	O
7	O
,	O
21	O
.	O
2	O
]),	O
antepartum	B-DISO
haemorrhage	I-DISO
(	O
OR	O
=	O
5	O
.	O
6	O
,	O
[	O
95	O
%	O
CI	O
1	O
.	O
5	O
,	O
20	O
.	O
9	O
]),	O
any	O
severe	O
pregnancy	B-DISO
complication	I-DISO
(	O
OR	O
=	O
3	O
.	O
4	O
,	O
[	O
95	O
%	O
CI	O
1	O
.	O
8	O
,	O
6	O
.	O
6	O
]),	O
term	O
delivery	O
in	O
a	O
government	O
hospital	O
and	O
having	O
a	O
labour	O
and	O
delivery	B-DISO
complication	I-DISO
(	O
OR	O
=	O
3	O
.	O
8	O
,	O
[	O
95	O
%	O
CI	O
1	O
.	O
2	O
,	O
12	O
.	O
0	O
]),	O
more	O
than	O
one	O
delivery	B-DISO
complication	I-DISO
(	O
OR	O
=	O
4	O
.	O
4	O
,	O
[	O
95	O
%	O
CI	O
1	O
.	O
8	O
,	O
10	O
.	O
5	O
]),	O
mother	O
'	O
s	O
age	O
>	O
35	O
years	O
(	O
OR	O
=	O
2	O
.	O
9	O
,	O
[	O
95	O
%	O
CI	O
1	O
.	O
3	O
,	O
6	O
.	O
8	O
])	O
and	O
primiparity	O
in	O
a	O
full	O
-	O
term	O
pregnancy	O
(	O
OR	O
=	O
2	O
.	O
6	O
,	O
[	O
1	O
.	O
1	O
,	O
6	O
.	O
3	O
]).	O

CONCLUSIONS	O
:	O
Our	O
large	O
study	O
suggests	O
that	O
MBL	O
plays	O
a	O
redundant	O
role	O
in	O
human	O
defenses	O
against	O
primary	B-DISO
infection	I-DISO
,	O
at	O
least	O
in	O
adults	O
with	O
CAP	B-DISO
,	O
and	O
provides	O
,	O
for	O
the	O
first	O
time	O
,	O
evidence	O
that	O
MBL	O
insufficiency	O
predisposes	O
to	O
higher	O
severity	O
and	O
fatal	O
outcome	O
in	O
patients	O
with	O
CAP	B-DISO
,	O
irrespective	O
of	O
the	O
causal	O
microorganisms	O
.	O

To	O
prevent	O
the	O
potential	O
serious	O
consequences	O
of	O
pandemic	O
influenza	B-DISO
,	O
timely	O
implementation	O
of	O
pharmaceutical	O
and	O
non	O
-	O
pharmaceutical	O
interventions	O
locally	O
within	O
the	O
outbreak	O
area	O
is	O
the	O
key	O
to	O
minimizing	O
global	O
spread	O
.	O

ABSTRACT	O
:	O
The	O
causative	O
agent	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
has	O
been	O
identified	O
as	O
a	O
novel	O
coronavirus	O
,	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
development	O
of	O
rapid	O
screening	O
assays	O
is	O
essential	O
for	O
antiviral	O
drug	O
discovery	O
.	O

We	O
demonstrate	O
that	O
the	O
compounds	O
inhibited	O
SARS	B-DISO
-	O
CoV	O
replication	O
-	O
dependent	O
GFP	O
expression	O
in	O
the	O
replicon	O
cells	O
and	O
reduced	O
SARS	B-DISO
-	O
CoV	O
viral	O
protein	O
accumulation	O
and	O
viral	O
RNA	O
copy	O
number	O
in	O
the	O
replicon	O
cells	O
.	O

SARS	B-DISO
-	O
CoV	O
antigen	O
expression	O
occurred	O
mainly	O
in	O
type	O
I	O
and	O
II	O
pneumocytes	O
and	O
serous	O
cells	O
of	O
tracheo	O
-	O
bronchial	O
submucosal	O
glands	O
of	O
cats	O
and	O
in	O
type	O
II	O
pneumocytes	O
of	O
ferrets	O
.	O

The	O
identification	O
of	O
tracheo	O
-	O
bronchoadenitis	O
in	O
cats	O
has	O
potential	O
implications	O
for	O
SARS	B-DISO
pathogenesis	B-DISO
and	O
SARS	B-DISO
-	O
CoV	O
excretion	O
.	O

All	O
fatalities	O
caused	O
by	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

All	O
fatalities	O
caused	O
by	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
following	O
thoracic	B-DISO
spinal	O
cord	B-DISO
trauma	O
.	O

Lower	B-DISO
extremity	I-DISO
weakness	I-DISO
rapidly	O
worsened	O
to	O
paraplegia	B-DISO
and	O
new	O
weakness	B-DISO
developed	O
affecting	O
bilateral	O
upper	O
extremities	O
and	O
face	B-DISO
.	O

Malarial	O
ARF	B-DISO
is	O
commonly	O
found	O
in	O
non	O
-	O
immune	O
adults	O
and	O
older	O
children	O
with	O
falciparum	B-DISO
malaria	I-DISO
.	O

Increased	O
fluid	O
administration	O
,	O
oxygen	O
toxicity	O
,	O
and	O
yet	O
unidentified	O
factors	O
may	O
contribute	O
to	O
pulmonary	B-DISO
edema	I-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
multiorgan	B-DISO
failure	I-DISO
and	O
death	O
.	O

Loop	O
diuretics	O
can	O
convert	O
an	O
oliguric	O
renal	B-DISO
failure	I-DISO
to	O
non	O
-	O
oliguric	O
renal	B-DISO
failure	I-DISO
without	O
affecting	O
outcome	O
of	O
the	O
disease	O
though	O
the	O
conversion	O
reduces	O
the	O
risk	O
of	O
volume	B-DISO
overload	I-DISO
.	O

TITLE	O
:	O
[	O
Vegetable	O
oil	O
-	O
induced	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
near	O
drowning	O
:	O
evaluation	O
based	O
on	O
extravascular	O
lung	O
water	O
index	O
].	O

We	O
concluded	O
that	O
lipoid	B-DISO
pneumonia	I-DISO
is	O
characterized	O
by	O
prolonged	O
elevatation	O
of	O
pulmonary	O
vascular	O
permeability	O
.	O

ABSTRACT	O
:	O
DC	O
-	O
SIGN	O
,	O
a	O
C	O
-	O
type	O
lectin	O
receptor	O
expressed	O
in	O
dendritic	O
cells	O
(	O
DCs	B-DISO
),	O
has	O
been	O
identified	O
as	O
a	O
receptor	O
for	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
type	O
1	O
,	O
hepatitis	B-DISO
C	I-DISO
virus	O
,	O
Ebola	O
virus	O
,	O
cytomegalovirus	O
,	O
dengue	B-DISO
virus	O
,	O
and	O
the	O
SARS	B-DISO
coronavirus	O
.	O

RESULTS	O
:	O
HCoV	O
-	O
NL63	O
was	O
detected	O
in	O
10	O
patients	O
(	O
2	O
.	O
0	O
%)	O
with	O
symptomatic	O
respiratory	B-DISO
diseases	I-DISO
,	O
mainly	O
during	O
winter	O
.	O

SARS	B-DISO
IFP	O
peptide	O
specifically	O
decreases	O
the	O
mobility	O
of	O
the	O
phospholipid	O
acyl	O
chains	O
of	O
negatively	O
charged	O
phospholipids	O
and	O
adopts	O
different	O
conformations	O
in	O
the	O
membrane	O
depending	O
upon	O
their	O
composition	O
.	O

From	O
January	O
2003	O
to	O
March	O
2007	O
,	O
a	O
total	O
of	O
45	O
patients	O
(	O
mean	O
age	O
:	O
48	O
years	O
)	O
were	O
placed	O
on	O
ECLS	O
for	O
acute	O
cardiopulmonary	B-DISO
failure	I-DISO
and	O
survived	O
longer	O
than	O
24h	O
.	O

ABSTRACT	O
:	O
This	O
paper	O
explores	O
the	O
difficulties	O
in	O
managing	O
risk	O
communications	O
in	O
the	O
face	B-DISO
of	O
uncertainty	O
of	O
an	O
avian	B-DISO
flu	I-DISO
pandemic	O
over	O
a	O
protracted	O
period	O
.	O

TITLE	O
:	O
A	O
rapid	O
point	O
of	O
care	O
immunoswab	O
assay	O
for	O
SARS	B-DISO
-	O
CoV	O
detection	O
.	O

Results	O
show	O
that	O
the	O
robust	O
immunoswab	O
method	O
of	O
detecting	O
SARS	B-DISO
-	O
CoV	O
NP	O
antigen	O
can	O
be	O
developed	O
into	O
an	O
easy	O
and	O
effective	O
way	O
of	O
identifying	O
SARS	B-DISO
suspected	O
individuals	O
during	O
a	O
future	O
SARS	B-DISO
epidemic	O
,	O
thereby	O
reducing	O
and	O
containing	O
the	O
transmission	O
.	O

The	O
key	O
feature	O
of	O
this	O
simple	O
immunoswab	O
diagnostic	O
assay	O
is	O
its	O
ability	O
to	O
detect	O
the	O
presence	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
antigen	O
within	O
45	O
-	O
60	O
min	O
with	O
the	O
availability	O
of	O
the	O
body	O
fluid	O
samples	O
.	O

There	O
was	O
no	O
significant	O
change	O
in	O
the	O
tumor	B-DISO
type	O
or	O
reason	O
for	O
referral	O
.	O

RNS	B-DISO
was	O
done	O
on	O
the	O
right	O
and	O
left	O
median	O
and	O
ulnar	O
nerves	O
at	O
1	O
,	O
3	O
,	O
10	O
,	O
15	O
,	O
20	O
,	O
and	O
30	O
Hz	O
.	O

TITLE	O
:	O
Phosphorylation	O
of	O
the	O
arginine	O
/	O
serine	O
dipeptide	O
-	O
rich	O
motif	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
nucleocapsid	O
protein	O
modulates	O
its	O
multimerization	O
,	O
translation	O
inhibitory	O
activity	O
and	O
cellular	O
localization	O
.	O

ABSTRACT	O
:	O
The	O
emergence	O
of	O
human	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
incited	O
renewed	O
interest	O
in	O
animal	O
coronaviruses	O
(	O
CoVs	O
)	O
as	O
potential	O
agents	O
of	O
direct	O
and	O
indirect	O
zoonoses	B-DISO
.	O

Reovirus	O
,	O
birnavirus	O
,	O
and	O
adenovirus	B-DISO
have	O
also	O
been	O
detected	O
.	O

Such	O
overt	O
features	O
are	O
seen	O
in	O
10	O
-	O
15	O
%	O
of	O
cases	O
of	O
sudden	O
severe	O
,	O
but	O
sub	O
-	O
lethal	O
,	O
upper	O
-	O
airway	B-DISO
obstruction	I-DISO
.	O

Catastrophic	O
antiphospholipid	B-DISO
syndrome	I-DISO
(	O
CAPS	O
)	O
is	O
a	O
small	O
subset	O
of	O
APS	B-DISO
characterized	O
by	O
widespread	O
systemic	O
thrombotic	O
disease	O
with	O
multiorgan	B-DISO
failure	I-DISO
.	O

We	O
herein	O
describe	O
an	O
autopsy	O
case	O
of	O
CAPS	O
who	O
developed	O
severe	O
respiratory	B-DISO
failure	I-DISO
due	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
as	O
the	O
initial	O
manifestation	O
.	O

ABSTRACT	O
:	O
In	O
recent	O
year	O
a	O
frequency	O
of	O
viral	B-DISO
infections	I-DISO
during	O
pregnancy	O
has	O
increased	O
.	O

In	O
1918	O
-	O
1919	O
the	O
so	O
-	O
called	O
Spanish	O
flu	B-DISO
spread	O
like	O
wildfire	O
through	O
all	O
five	O
continents	O
,	O
killing	O
between	O
25	O
and	O
40	O
million	O
people	O
.	O

Even	O
more	O
worrying	O
is	O
the	O
fact	O
that	O
emerging	O
and	O
re	O
-	O
emerging	O
viral	B-DISO
diseases	I-DISO
have	O
had	O
a	O
tendency	O
to	O
spread	O
more	O
quickly	O
and	O
more	O
widely	O
during	O
the	O
last	O
decade	O
,	O
invading	O
whole	O
countries	O
and	O
continents	O
;	O
witness	O
the	O
recent	O
outbreaks	O
of	O
Nipah	O
virus	O
,	O
West	O
Nile	O
,	O
Rift	B-DISO
Valley	I-DISO
fever	I-DISO
,	O
SARS	B-DISO
,	O
monkeypox	B-DISO
,	O
avian	B-DISO
flu	I-DISO
(	O
H5N1	B-DISO
)	O
and	O
Chikungunya	B-DISO
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
induces	O
a	O
minimal	O
type	O
I	O
interferon	O
(	O
IFN	O
)	O
response	O
in	O
several	O
cell	O
types	O
in	O
vitro	O
despite	O
the	O
fact	O
that	O
the	O
type	O
I	O
IFN	O
response	O
is	O
important	O
in	O
protecting	O
the	O
mouse	O
from	O
infection	B-DISO
in	O
vivo	O
.	O

To	O
determine	O
the	O
pathway	O
by	O
which	O
MHV	O
is	O
recognized	O
in	O
macrophages	O
,	O
IFN	O
-	O
beta	O
mRNA	O
expression	O
was	O
quantified	O
following	O
MHV	O
infection	B-DISO
of	O
a	O
panel	O
of	O
primary	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
generated	O
from	O
mice	O
lacking	O
different	O
pattern	O
recognition	O
receptors	O
(	O
PRRs	B-DISO
).	O

ABSTRACT	O
:	O
Viral	B-DISO
infections	I-DISO
are	O
common	O
causes	O
of	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
in	O
the	O
outpatient	O
setting	O
but	O
much	O
less	O
common	O
in	O
the	O
intensive	O
care	O
unit	O
.	O

Recent	O
studies	O
on	O
murine	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
showed	O
that	O
processing	O
of	O
the	O
1a	O
polyprotein	O
at	O
the	O
position	O
between	O
nsp10	O
-	O
nsp11	O
is	O
essential	O
for	O
viral	O
replication	O
.	O

In	O
this	O
report	O
,	O
we	O
investigated	O
the	O
requirement	O
of	O
processing	O
at	O
the	O
equivalent	O
position	O
for	O
replication	O
of	O
avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
),	O
using	O
an	O
infectious	B-DISO
cloning	O
system	O
.	O

In	O
addition	O
,	O
abnormal	O
distributions	O
of	O
radioactivity	O
were	O
observed	O
in	O
other	O
bones	O
on	O
the	O
whole	O
-	O
body	O
bone	O
scans	O
of	O
29	O
patients	O
,	O
including	O
osteonecrosis	B-DISO
of	O
knees	O
in	O
15	O
patients	O
.	O

ABSTRACT	O
:	O
The	O
potential	O
role	O
of	O
respiratory	O
viruses	O
in	O
the	O
natural	O
history	O
of	O
community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
CAP	B-DISO
)	O
in	O
adults	O
has	O
not	O
been	O
well	O
described	O
since	O
the	O
advent	O
of	O
nucleic	O
amplification	B-DISO
tests	O
(	O
NATs	O
).	O

ABSTRACT	O
:	O
Studies	O
to	O
date	O
have	O
shown	O
no	O
survival	O
benefit	O
for	O
the	O
use	O
of	O
exogenous	O
surfactant	O
to	O
treat	O
patients	O
with	O
the	O
ARDS	B-DISO
.	O

ARDS	B-DISO
was	O
most	O
often	O
associated	O
with	O
pneumonia	B-DISO
or	O
aspiration	B-DISO
,	O
sepsis	B-DISO
,	O
and	O
trauma	O
or	O
surgery	O
.	O

The	O
biological	O
and	O
physiological	O
complexity	O
of	O
ALI	O
/	O
ARDS	B-DISO
requires	O
the	O
consideration	O
of	O
combined	O
-	O
agent	O
treatments	O
in	O
addition	O
to	O
single	O
-	O
agent	O
therapies	O
.	O

The	O
versatility	O
of	O
the	O
system	O
was	O
demonstrated	O
by	O
successful	O
detection	O
of	O
SARS	B-DISO
viral	O
DNA	O
and	O
ATP	O
.	O

Our	O
results	O
suggested	O
that	O
the	O
delivery	O
of	O
NAC	O
as	O
a	O
liposomal	O
formulation	O
improved	O
its	O
prophylactic	O
effectiveness	O
against	O
LPS	B-DISO
-	O
induced	O
lung	O
injuries	O
.	O

Because	O
cystatins	O
added	O
to	O
cell	O
cultures	O
can	O
inhibit	O
polio	B-DISO
,	O
herpes	B-DISO
simplex	I-DISO
and	O
coronavirus	O
replication	O
,	O
which	O
are	O
intracellular	O
processes	O
,	O
the	O
internalization	O
and	O
intracellular	O
regulation	O
of	O
cysteine	O
proteases	O
by	O
cystatin	O
C	O
should	O
be	O
considered	O
.	O

The	O
chest	O
radiograph	O
and	O
chest	O
CT	O
scan	O
showed	O
diffuse	O
ground	O
-	O
glass	O
-	O
opacities	B-DISO
and	O
reticular	O
shadows	O
in	O
both	O
lung	O
fields	O
.	O

TITLE	O
:	O
Disaster	O
and	O
emergency	B-DISO
management	O
:	O
Canadian	O
nurses	O
'	O
perceptions	O
of	O
preparedness	O
on	O
hospital	O
front	O
lines	O
.	O

TITLE	O
:	O
Risk	O
factors	O
of	O
mortality	O
in	O
road	O
traffic	O
injury	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Twenty	O
-	O
three	O
items	O
of	O
potential	O
risk	O
impacting	O
mortality	O
were	O
calculated	O
by	O
univariate	O
and	O
multivariate	O
Logistic	O
analyses	O
in	O
order	O
to	O
find	O
distinctive	O
items	O
in	O
these	O
severe	O
RTI	B-DISO
patients	O
.	O

There	O
were	O
247	O
RTI	B-DISO
patients	O
with	O
post	O
-	O
traumatic	O
ARDS	B-DISO
admitted	O
to	O
EICU	O
during	O
the	O
study	O
period	O
.	O

The	O
unadjusted	O
odds	O
ratio	O
(	O
OR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
of	O
mortality	O
were	O
associated	O
with	O
six	O
risk	O
factors	O
out	O
of	O
23	O
:	O
APACHE	O
II	O
score	O
,	O
duration	O
of	O
trauma	O
factor	O
,	O
pulmonary	O
contusion	O
,	O
aspiration	B-DISO
of	O
gastric	O
contents	O
,	O
sepsis	B-DISO
and	O
duration	O
of	O
mechanical	O
ventilation	O
.	O

We	O
have	O
retrospectively	O
demonstrated	O
an	O
adverse	B-DISO
effect	I-DISO
of	O
six	O
different	O
risk	O
factors	O
out	O
of	O
23	O
items	O
in	O
mortality	O
of	O
post	O
-	O
traumatic	O
ARDS	B-DISO
within	O
severe	O
RTI	B-DISO
patients	O
and	O
,	O
moreover	O
,	O
gained	O
distinct	O
outcomes	O
in	O
stratified	O
patients	O
under	O
real	O
emergency	B-DISO
trauma	O
circumstance	O
.	O

Sepsis	B-DISO
is	O
still	O
a	O
vital	O
risk	O
factor	O
referring	O
to	O
systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
syndrome	I-DISO
,	O
infection	B-DISO
,	O
and	O
secondary	O
multiple	O
organs	O
dysfunction	O
.	O

The	O
results	O
show	O
that	O
flap	O
closing	O
was	O
clearly	O
observed	O
when	O
the	O
inhibitors	O
bind	O
to	O
the	O
active	O
site	O
of	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
).	O

The	O
binding	O
affinities	O
of	O
LPV	O
and	O
RTV	O
to	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
do	O
not	O
show	O
any	O
significant	O
difference	O
.	O

CoV	O
primarily	O
infects	O
the	O
upper	O
respiratory	O
and	O
gastrointestinal	O
tract	O
;	O
however	O
,	O
SARS	B-DISO
-	O
CoV	O
has	O
a	O
unique	O
pathogenesis	B-DISO
because	O
it	O
infects	O
both	O
the	O
upper	O
and	O
lower	O
respiratory	O
tracts	O
and	O
leads	O
to	O
human	O
respiratory	B-DISO
diseases	I-DISO
.	O

SARS	B-DISO
coronavirus	O
has	O
low	O
transmissibility	O
at	O
the	O
community	O
level	O
.	O

Intranasal	O
vaccination	O
using	O
inactivated	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
vaccine	O
with	O
adjuvant	O
can	O
induce	O
strong	O
systemic	O
(	O
serum	O
immunoglobulin	O
[	O
Ig	O
]	O
G	O
)	O
and	O
respiratory	O
tract	O
local	O
(	O
tracheal	O
-	O
lung	O
wash	O
fluid	O
IgA	O
)	O
antibody	O
responses	O
with	O
neutralising	O
activity	O
.	O

Intranasal	O
vaccination	O
with	O
RBD	O
-	O
rAAV	O
induced	O
local	O
IgA	O
and	O
systemic	O
IgG	O
neutralising	O
antibodies	O
and	O
specific	O
T	O
-	O
cell	O
responses	O
,	O
able	O
to	O
protect	O
against	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
in	O
animal	O
models	O
.	O

This	O
study	O
has	O
identified	O
several	O
structures	O
and	O
infection	B-DISO
control	O
practice	O
areas	O
that	O
need	O
strengthening	O
,	O
including	O
improving	O
the	O
clarity	O
of	O
some	O
guidelines	O
and	O
minimising	O
barriers	O
to	O
their	O
implementation	O
.	O

ABSTRACT	O
:	O
Four	O
new	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
strains	O
(	O
T6	O
,	O
K32	O
,	O
K43	O
,	O
and	O
K87	O
)	O
were	O
isolated	O
from	O
clinically	O
infected	O
chickens	O
in	O
New	O
Zealand	O
.	O

ABSTRACT	O
:	O
Influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
(	O
ILI	O
)	O
definitions	O
have	O
been	O
used	O
worldwide	O
for	O
influenza	B-DISO
surveillance	O
.	O

DFA	O
and	O
RT	O
-	O
PCR	O
for	O
influenza	B-DISO
,	O
parainfluenza	B-DISO
,	O
respiratory	O
syncytial	O
virus	O
,	O
adenovirus	B-DISO
,	O
enterovirus	O
,	O
coronavirus	O
,	O
rhinovirus	O
,	O
and	O
metapneumovirus	O
were	O
performed	O
on	O
nasal	O
washes	O
and	O
61	O
.	O
8	O
%	O
resulted	O
positive	O
.	O

Members	O
of	O
the	O
Herpesviridae	O
family	O
,	O
cytomegalovirus	O
(	O
CMV	O
),	O
and	O
human	O
herpesvirus	O
6	O
(	O
HHV	O
-	O
6	O
)	O
have	O
been	O
associated	O
occasionally	O
with	O
myocarditis	B-DISO
.	O

During	O
an	O
atypical	O
outbreak	O
of	O
acute	O
febrile	B-DISO
syndrome	I-DISO
,	O
eight	O
children	O
,	O
with	O
ages	O
from	O
5	O
months	O
to	O
15	O
years	O
,	O
died	O
in	O
cardiogenic	B-DISO
shock	I-DISO
due	O
to	O
myocarditis	B-DISO
in	O
July	O
-	O
August	O
2005	O
,	O
in	O
the	O
city	O
of	O
Havana	O
,	O
Cuba	O
.	O

Histological	O
examination	O
was	O
undertaken	O
to	O
detect	O
myocardial	B-DISO
inflammation	I-DISO
.	O

This	O
important	O
control	O
center	O
of	O
cellular	O
responses	O
is	O
differently	O
employed	O
to	O
support	O
the	O
replication	O
of	O
several	O
important	O
human	O
pathogenic	O
RNA	O
viruses	O
including	O
influenza	B-DISO
,	O
Ebola	O
,	O
hepatitis	B-DISO
C	I-DISO
and	O
SARS	B-DISO
corona	O
viruses	O
.	O

TITLE	O
:	O
Detection	O
of	O
an	O
antigenic	O
group	O
2	O
coronavirus	O
in	O
an	O
adult	O
alpaca	O
with	O
enteritis	B-DISO
.	O

We	O
conclude	O
that	O
nutritional	O
stress	O
may	O
have	O
predisposed	O
the	O
alpaca	O
to	O
severe	O
ApCoV	O
infection	B-DISO
.	O

The	O
diagnosis	O
of	O
haemophagocytic	B-DISO
lymphohistiocytosis	I-DISO
should	O
be	O
considered	O
in	O
young	O
patients	O
with	O
marked	O
bone	O
marrow	O
dysfunction	O
and	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
.	O

Bacterial	O
bronchopneumonia	B-DISO
was	O
present	O
in	O
36	O
%	O
(	O
91	O
cases	O
)	O
and	O
Pneumocystis	B-DISO
jiroveci	I-DISO
pneumonia	I-DISO
in	O
27	O
%	O
(	O
68	O
)	O
of	O
patients	O
.	O

Multivariate	O
analysis	O
showed	O
a	O
significant	O
and	O
positive	O
association	O
between	O
Pneumocystis	B-DISO
jiroveci	I-DISO
pneumonia	I-DISO
and	O
acute	B-DISO
interstitial	I-DISO
pneumonia	I-DISO
(	O
Odds	O
ratio	O
,	O
4	O
.	O
51	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
46	O
-	O
8	O
.	O
24	O
;	O
p	O
<	O
0	O
.	O
001	O
),	O
severe	B-DISO
sepsis	I-DISO
and	O
/	O
or	O
septic	B-DISO
shock	I-DISO
and	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
(	O
Odds	O
ratio	O
,	O
3	O
.	O
60	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
78	O
-	O
7	O
.	O
27	O
;	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
cytomegalovirus	O
and	O
acute	B-DISO
interstitial	I-DISO
pneumonia	I-DISO
(	O
Odds	O
ratio	O
,	O
2	O
.	O
22	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
01	O
-	O
4	O
.	O
93	O
;	O
p	O
=	O
0	O
.	O
05	O
).	O

ALI	O
and	O
in	O
particular	O
ARDS	B-DISO
,	O
are	O
usually	O
accompanied	O
by	O
refractory	O
hypoxemia	O
and	O
the	O
need	O
for	O
mechanical	O
ventilation	O
.	O

In	O
most	O
cases	O
,	O
an	O
exaggerated	O
inflammatory	O
and	O
pro	O
-	O
thrombotic	O
reaction	O
to	O
an	O
initial	O
stimulus	O
,	O
such	O
as	O
systemic	B-DISO
infection	I-DISO
,	O
elicits	O
disruption	O
of	O
the	O
alveolo	O
-	O
capillary	O
membrane	O
and	O
vascular	O
fluid	O
leak	O
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
caused	O
by	O
a	O
distinct	O
coronavirus	O
,	O
in	O
2003	O
greatly	O
threatened	O
public	O
health	O
in	O
China	O
,	O
Southeast	O
Asia	O
as	O
well	O
as	O
North	O
America	O
.	O

ABSTRACT	O
:	O
Restrictions	O
on	O
non	O
-	O
urgent	O
hospital	O
care	O
imposed	O
to	O
control	O
the	O
2003	O
Toronto	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreak	O
led	O
to	O
substantial	O
disruptions	O
in	O
hospital	O
clinical	O
practice	O
,	O
admission	O
,	O
and	O
transfer	O
patterns	O
.	O

Although	O
still	O
preliminary	O
,	O
a	O
few	O
recent	O
observations	O
also	O
substantiate	O
a	O
possible	O
role	O
for	O
OAS1	O
in	O
human	O
susceptibility	O
to	O
viral	B-DISO
infections	I-DISO
(	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
,	O
SARS	B-DISO
,	O
etc	O
.)	O
and	O
its	O
possible	O
involvement	O
in	O
some	O
other	O
diseases	O
such	O
as	O
type	B-DISO
1	I-DISO
diabetes	I-DISO
and	O
multiple	B-DISO
sclerosis	I-DISO
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
we	O
addressed	O
the	O
question	O
whether	O
cholesterol	O
is	O
important	O
for	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
),	O
a	O
porcine	O
coronavirus	O
,	O
in	O
the	O
initiation	O
of	O
an	O
infection	B-DISO
.	O

The	O
vaccines	O
also	O
diminished	O
haemorrhage	B-DISO
in	O
the	O
thymus	O
and	O
reduced	O
the	O
severity	O
and	O
extent	O
of	O
pneumonia	B-DISO
and	O
damage	O
to	O
lung	O
epithelium	O
.	O

The	O
ferret	O
may	O
be	O
a	O
good	O
model	O
for	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
because	O
it	O
is	O
the	O
only	O
model	O
that	O
replicates	O
the	O
fever	O
seen	O
in	O
human	O
patients	O
,	O
as	O
well	O
as	O
replicating	O
other	O
SARS	B-DISO
disease	O
features	O
including	O
infection	B-DISO
by	O
the	O
respiratory	O
route	O
,	O
clinical	O
signs	O
,	O
viral	O
replication	O
in	O
upper	O
and	O
lower	O
respiratory	O
tract	O
and	O
lung	O
damage	O
.	O

In	O
this	O
study	O
,	O
the	O
pathway	O
of	O
internalization	O
is	O
characterized	O
by	O
evaluating	O
the	O
effect	O
of	O
chemical	O
inhibitors	O
and	O
/	O
or	O
expression	O
of	O
dominant	O
-	O
negative	O
(	O
DN	O
)	O
proteins	O
on	O
the	O
percentage	O
of	O
internalized	O
virions	O
per	O
cell	O
and	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Experimental	O
studies	O
of	O
arbidol	O
and	O
arbidol	O
mesylate	O
versus	O
ribavirin	O
suggest	O
that	O
insertion	O
of	O
these	O
agents	O
into	O
the	O
nutrient	O
medium	O
of	O
the	O
cultured	O
cells	O
GMK	O
-	O
AH	O
-	O
1	O
(	O
D	O
)	O
after	O
infection	B-DISO
at	O
concentrations	O
of	O
50	O
,	O
25	O
,	O
and	O
100	O
microg	O
/	O
ml	O
,	O
respectively	O
,	O
is	O
effective	O
in	O
suppressing	O
the	O
reproduction	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
virus	O
.	O

Although	O
obesity	B-DISO
-	I-DISO
hypoventilation	I-DISO
syndrome	I-DISO
occurs	O
in	O
only	O
a	O
minority	O
of	O
morbidly	O
obese	B-DISO
patients	O
,	O
it	O
is	O
important	O
because	O
the	O
consequences	O
of	O
respiratory	B-DISO
failure	I-DISO
can	O
be	O
severe	O
if	O
not	O
recognized	O
and	O
anticipated	O
.	O

CONCLUSIONS	O
:	O
Although	O
obesity	B-DISO
-	I-DISO
hypoventilation	I-DISO
syndrome	I-DISO
occurs	O
in	O
only	O
a	O
minority	O
of	O
morbidly	O
obese	B-DISO
patients	O
,	O
it	O
is	O
important	O
because	O
the	O
consequences	O
of	O
respiratory	B-DISO
failure	I-DISO
can	O
be	O
severe	O
if	O
not	O
recognized	O
and	O
anticipated	O
.	O

Of	O
these	O
,	O
43	O
with	O
osteonecrosis	B-DISO
received	O
a	O
significantly	O
higher	O
cumulative	O
and	O
peak	O
methylprednisolone	O
-	O
equivalent	O
dose	O
than	O
71	O
patients	O
with	O
no	O
osteonecrosis	B-DISO
identified	O
by	O
MRI	O
.	O

Patients	O
with	O
diaphyseal	O
osteonecrosis	B-DISO
received	O
a	O
significantly	O
higher	O
cumulative	O
methylprednisolone	O
-	O
equivalent	O
dose	O
than	O
those	O
with	O
epiphyseal	O
osteonecrosis	B-DISO
.	O

Infection	B-DISO
with	O
recombinant	O
SARS	B-DISO
-	O
CoV	O
viruses	O
bearing	O
disruptions	O
in	O
the	O
gene	O
7	O
coding	O
region	O
showed	O
no	O
significant	O
change	O
in	O
replication	O
kinetics	O
,	O
tissue	O
tropism	O
,	O
morbidity	O
,	O
or	O
mortality	O
suggesting	O
that	O
the	O
ORF7a	O
(	O
7a	O
)	O
and	O
ORF7b	O
(	O
7b	O
)	O
proteins	O
are	O
not	O
required	O
for	O
virus	O
replication	O
in	O
immunosuppressed	O
hamsters	O
.	O

Applications	O
of	O
the	O
proposed	O
approach	O
to	O
modeling	O
the	O
effects	O
of	O
immunological	O
heterogeneity	O
on	O
the	O
dynamics	O
of	O
bat	O
rabies	B-DISO
are	O
presented	O
.	O

This	O
paper	O
reports	O
for	O
the	O
first	O
time	O
that	O
extract	O
from	O
a	O
vegetable	O
,	O
the	O
tender	O
leaf	O
of	O
Toona	O
sinensis	O
Roem	O
,	O
can	O
inhibit	O
SARS	B-DISO
-	O
CoV	O
in	O
vitro	O
.	O

CONCLUSIONS	O
:	O
This	O
paper	O
reports	O
for	O
the	O
first	O
time	O
that	O
extract	O
from	O
a	O
vegetable	O
,	O
the	O
tender	O
leaf	O
of	O
Toona	O
sinensis	O
Roem	O
,	O
can	O
inhibit	O
SARS	B-DISO
-	O
CoV	O
in	O
vitro	O
.	O

This	O
animal	O
was	O
referred	O
for	O
examination	O
with	O
progressive	B-DISO
paralysis	I-DISO
and	O
shown	O
to	O
be	O
free	O
from	O
feline	O
immunodeficiency	B-DISO
virus	O
,	O
feline	O
leukaemia	B-DISO
virus	O
,	O
feline	O
coronavirus	O
and	O
Toxoplasma	O
gondii	O
.	O

The	O
addition	O
of	O
an	O
eight	O
amino	O
acid	O
HIV	B-DISO
-	O
1	O
gp41	O
envelope	O
incorporation	O
motif	O
further	O
increased	O
scFvFc	O
expression	O
on	O
human	O
cells	O
and	O
incorporation	O
into	O
lentiviral	O
particles	O
.	O

RESULTS	O
:	O
Viruses	O
were	O
detected	O
in	O
168	O
(	O
93	O
%)	O
of	O
the	O
180	O
children	O
with	O
bronchiolitis	B-DISO
.	O

A	O
heptad	O
repeat	O
peptide	O
,	O
derived	O
from	O
a	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
that	O
is	O
known	O
to	O
efficiently	O
block	O
infections	B-DISO
from	O
the	O
cell	O
surface	O
,	O
blocked	O
the	O
infection	B-DISO
by	O
a	O
pseudotype	O
with	O
a	O
cleaved	O
S	O
protein	O
but	O
not	O
that	O
with	O
an	O
uncleaved	O
S	O
protein	O
.	O

TITLE	O
:	O
Alcohol	B-DISO
abuse	I-DISO
/	O
dependence	B-DISO
symptoms	O
among	O
hospital	O
employees	O
exposed	O
to	O
a	O
SARS	B-DISO
outbreak	O
.	O

A	O
survey	O
was	O
conducted	O
among	O
549	O
randomly	O
selected	O
hospital	O
employees	O
in	O
Beijing	O
,	O
China	O
,	O
concerning	O
the	O
psychological	B-DISO
impact	O
of	O
the	O
2003	O
SARS	B-DISO
outbreak	O
.	O

RESULTS	O
:	O
Current	O
alcohol	B-DISO
abuse	I-DISO
/	O
dependence	B-DISO
symptom	B-DISO
counts	O
3	O
years	O
after	O
the	O
outbreak	O
were	O
positively	O
associated	O
with	O
having	O
been	O
quarantined	O
,	O
or	O
worked	O
in	O
high	O
-	O
risk	O
locations	O
such	O
as	O
SARS	B-DISO
wards	O
,	O
during	O
the	O
outbreak	O
.	O

Recombinant	O
plasmid	O
named	O
T	O
-	O
vector	O
-	O
M	O
was	O
constructed	O
via	O
inserting	O
the	O
M	O
gene	O
into	O
the	O
TA	O
cloning	O
vector	O
,	O
pMD	B-DISO
18	O
-	O
T	O
.	O
The	O
sequenced	O
M	O
gene	O
and	O
its	O
deduced	O
amino	O
acid	O
(	O
aa	O
)	O
sequences	O
were	O
compared	O
with	O
the	O
published	O
sequences	O
of	O
reference	O
strains	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
structural	O
proteins	O
(	O
S	O
,	O
E	O
,	O
M	O
,	O
and	O
NC	O
)	O
localize	O
in	O
different	O
subcellular	O
positions	O
when	O
expressed	O
individually	O
.	O

A	O
model	O
for	O
the	O
interactions	O
between	O
SARS	B-DISO
-	O
CoV	O
M	O
protein	O
and	O
other	O
structural	O
proteins	O
is	O
proposed	O
.	O

According	O
to	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
experience	O
,	O
anticipation	O
of	O
the	O
pandemic	O
may	O
have	O
impact	O
on	O
behaviors	O
related	O
to	O
influenza	B-DISO
vaccination	O
(	O
IV	O
)	O
and	O
relevant	O
public	O
health	O
behaviors	O
such	O
as	O
wearing	O
a	O
face	B-DISO
mask	O
when	O
having	O
influenza	B-DISO
-	O
like	O
-	O
illnesses	O
(	O
ILI	O
),	O
which	O
would	O
play	O
an	O
important	O
role	O
in	O
the	O
control	O
of	O
human	O
avian	B-DISO
influenza	I-DISO
outbreaks	O
.	O

Exposure	O
to	O
live	O
birds	O
,	O
perceived	O
similar	O
symptoms	O
between	O
influenza	B-DISO
and	O
bird	O
-	O
to	O
-	O
human	O
H5N1	B-DISO
avian	B-DISO
influenza	I-DISO
,	O
that	O
bird	O
-	O
to	O
-	O
human	O
avian	B-DISO
influenza	I-DISO
was	O
more	O
lethal	O
than	O
SARS	B-DISO
were	O
predictive	O
use	O
of	O
face	B-DISO
mask	O
when	O
having	O
ILI	O
symptoms	O
(	O
OR	O
=	O
4	O
.	O
25	O
-	O
8	O
.	O
34	O
,	O
p	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Design	O
,	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
a	O
series	O
of	O
5	O
-	O
chloropyridine	O
ester	O
-	O
derived	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
coronavirus	O
chymotrypsin	O
-	O
like	O
protease	O
inhibitors	O
is	O
described	O
.	O

TITLE	O
:	O
Evaluating	O
pulmonary	B-DISO
complications	I-DISO
in	O
childhood	O
acute	B-DISO
leukemias	I-DISO
.	O

Pulmonary	B-DISO
infections	I-DISO
in	O
the	O
maintenance	O
phase	O
of	O
the	O
therapy	O
were	O
frequently	O
treated	O
with	O
oral	O
antibiotics	O
,	O
and	O
they	O
were	O
generally	O
rapidly	O
taken	O
under	O
control	O
.	O

ABSTRACT	O
:	O
The	O
aims	O
of	O
this	O
study	O
were	O
firstly	O
to	O
evaluate	O
the	O
pathogenicity	O
of	O
an	O
Italian	O
isolate	O
of	O
the	O
QX	O
strain	O
of	O
infectious	B-DISO
bronchitis	B-DISO
(	O
IB	B-DISO
)	O
virus	O
using	O
1	O
-	O
day	O
-	O
old	O
female	O
specific	O
pathogen	O
free	O
chicks	O
(	O
layer	O
type	O
)	O
and	O
1	O
-	O
day	O
-	O
old	O
female	O
commercial	O
broiler	O
type	O
chickens	O
,	O
and	O
secondly	O
to	O
assess	O
the	O
level	O
of	O
protection	O
induced	O
in	O
these	O
birds	O
by	O
a	O
vaccination	O
programme	O
including	O
the	O
IB	B-DISO
Massachusetts	O
and	O
4	O
/	O
91	O
serotype	O
live	O
attenuated	O
vaccines	O
.	O

Vaccinated	O
birds	O
appeared	O
healthy	O
,	O
with	O
the	O
exception	O
of	O
a	O
very	O
mild	O
conjunctivitis	B-DISO
affecting	O
a	O
limited	O
number	O
of	O
the	O
broilers	O
.	O

TITLE	O
:	O
SARS	B-DISO
-	O
coronavirus	O
replication	O
is	O
supported	O
by	O
a	O
reticulovesicular	O
network	O
of	O
modified	O
endoplasmic	O
reticulum	O
.	O

Membrane	O
structures	O
supporting	O
viral	O
RNA	O
synthesis	O
range	O
from	O
distinct	O
spherular	O
membrane	O
invaginations	B-DISO
to	O
more	O
elaborate	O
webs	O
of	O
packed	O
membranes	O
and	O
vesicles	B-DISO
.	O

Since	O
we	O
could	O
not	O
discern	O
a	O
connection	O
between	O
DMV	O
interior	O
and	O
cytosol	O
,	O
our	O
analysis	O
raises	O
several	O
questions	O
about	O
the	O
mechanism	O
of	O
DMV	O
formation	O
and	O
the	O
actual	O
site	O
of	O
SARS	B-DISO
-	O
CoV	O
RNA	O
synthesis	O
.	O

Since	O
Chinese	O
rhesus	O
(	O
rh	O
)	O
macaques	O
do	O
not	O
usually	O
develop	O
SARS	B-DISO
after	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
,	O
it	O
has	O
been	O
suggested	O
that	O
rh	O
-	O
ACE2	O
probably	O
does	O
not	O
support	O
viral	O
entry	O
efficiently	O
.	O

The	O
SARS	B-DISO
epidemic	O
in	O
Vietnam	O
resulted	O
in	O
numerous	O
secondary	B-DISO
infections	I-DISO
due	O
to	O
its	O
unknown	O
etiology	O
and	O
delayed	O
recognition	O
at	O
the	O
beginning	O
of	O
the	O
epidemic	O
.	O

The	O
consistent	O
and	O
proper	O
use	O
of	O
a	O
mask	O
was	O
shown	O
to	O
be	O
crucial	O
for	O
constant	O
protection	O
against	O
infection	B-DISO
with	O
SARS	B-DISO
.	O

Malarial	O
ALI	O
/	O
ARDS	B-DISO
is	O
more	O
common	O
in	O
adults	O
than	O
in	O
children	O
.	O

Respiratory	B-DISO
failure	I-DISO
requires	O
endotracheal	O
intubation	O
and	O
assisted	O
mechanical	O
ventilation	O
.	O

TITLE	O
:	O
[	O
Postinfectious	O
acute	B-DISO
glomerulonephritis	I-DISO
].	O

ABSTRACT	O
:	O
Right	B-DISO
ventricular	I-DISO
failure	I-DISO
may	O
result	O
from	O
an	O
newly	O
developed	O
disease	O
(	O
e	O
.	O
g	O
.	O
as	O
a	O
consequence	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
[	O
ARDS	B-DISO
]	O
or	O
of	O
severe	O
pulmonary	B-DISO
embolism	I-DISO
)	O
or	O
of	O
already	O
present	O
pulmonary	B-DISO
hypertension	I-DISO
(	O
PHT	B-DISO
).	O

Alternate	O
encoding	O
or	O
duplication	B-DISO
of	O
the	O
nsp2	O
gene	O
sequence	O
resulted	O
in	O
differences	O
in	O
nsp2	O
expression	O
,	O
processing	O
,	O
and	O
localization	O
,	O
was	O
neutral	O
or	O
detrimental	O
to	O
replication	O
,	O
and	O
did	O
not	O
complement	O
an	O
ORF1a	O
Deltansp2	O
replication	O
defect	O
.	O

TITLE	O
:	O
Systematic	O
assembly	O
of	O
a	O
full	O
-	O
length	O
infectious	B-DISO
clone	O
of	O
human	O
coronavirus	O
NL63	O
.	O

In	O
order	O
to	O
more	O
fully	O
appreciate	O
the	O
potential	O
effect	O
of	O
the	O
ABO	O
polymorphism	O
on	O
the	O
epidemiology	O
of	O
SARS	B-DISO
,	O
we	O
built	O
a	O
mathematical	O
model	O
of	O
the	O
virus	O
transmission	O
dynamics	O
that	O
takes	O
into	O
account	O
the	O
protective	O
effect	O
of	O
ABO	O
natural	O
antibodies	O
.	O

TITLE	O
:	O
Hepatitis	B-DISO
C	I-DISO
is	O
a	O
predictor	O
of	O
acute	O
liver	O
injury	O
among	O
hospitalizations	O
for	O
acetaminophen	O
overdose	O
in	O
the	O
United	O
States	O
:	O
a	O
nationwide	O
analysis	O
.	O

TITLE	O
:	O
[	O
The	O
functions	O
of	O
liver	O
natural	O
killer	O
cells	O
in	O
murine	O
fulminant	B-DISO
hepatitis	I-DISO
induced	O
by	O
murine	B-DISO
hepatitis	I-DISO
virus	O
strain	O
3	O
].	O

The	O
proportion	O
of	O
NK	O
cells	O
in	O
the	O
peripheral	O
blood	O
also	O
significantly	O
increased	O
and	O
reached	O
the	O
peak	O
(	O
18	O
.	O
0	O
%+/-	O
5	O
.	O
4	O
%)	O
at	O
48	O
h	O
.	O
However	O
,	O
there	O
were	O
few	O
NK	O
cells	O
in	O
the	O
peripheral	O
blood	O
at	O
70	O
h	O
after	O
infection	B-DISO
;	O
the	O
ratio	O
was	O
only	O
1	O
.	O
3	O
%+/-	O
0	O
.	O
6	O
%.	O

Resilient	O
and	O
recovered	O
individuals	O
had	O
greater	O
social	O
support	O
and	O
less	O
SARS	B-DISO
-	O
related	O
worry	O
,	O
and	O
resilient	O
individuals	O
were	O
more	O
likely	O
to	O
be	O
male	O
.	O

TITLE	O
:	O
Respiratory	O
pathogens	O
in	O
children	O
with	O
and	O
without	O
respiratory	B-DISO
symptoms	I-DISO
.	O

Respiratory	O
pathogens	O
are	O
frequently	O
detected	O
in	O
samples	O
from	O
children	O
with	O
no	O
respiratory	B-DISO
symptoms	I-DISO
.	O

TITLE	O
:	O
Bovine	O
and	O
human	O
-	O
derived	O
passive	O
immunization	O
could	O
help	O
slow	O
a	O
future	O
avian	B-DISO
influenza	I-DISO
pandemic	O
.	O

ABSTRACT	O
:	O
An	O
epidemic	O
of	O
human	O
transmitted	B-DISO
avian	B-DISO
influenza	I-DISO
could	O
have	O
casualties	O
on	O
a	O
scale	O
seen	O
in	O
the	O
great	O
Spanish	O
influenza	B-DISO
pandemic	O
of	O
1918	O
.	O

TITLE	O
:	O
Genome	O
-	O
wide	O
analysis	O
of	O
protein	O
-	O
protein	O
interactions	O
and	O
involvement	O
of	O
viral	O
proteins	O
in	O
SARS	B-DISO
-	O
CoV	O
replication	O
.	O

ABSTRACT	O
:	O
Single	O
nucleotide	O
polymorphisms	O
in	O
the	O
myosin	O
light	O
chain	O
kinase	O
(	O
MYLK	O
)	O
gene	O
have	O
been	O
implicated	O
in	O
the	O
risk	O
of	O
sepsis	B-DISO
-	O
related	O
acute	O
lung	O
injury	O
and	O
asthma	B-DISO
.	O

ABSTRACT	O
:	O
Effective	O
vaccines	O
should	O
confer	O
long	O
-	O
term	O
protection	O
against	O
future	O
outbreaks	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
caused	O
by	O
a	O
novel	O
zoonotic	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
with	O
unknown	O
animal	O
reservoirs	O
.	O

Approximately	O
50	O
%	O
of	O
convalescent	O
SARS	B-DISO
patients	O
were	O
positive	O
for	O
T	O
cell	O
responses	O
,	O
and	O
90	O
%	O
possessed	B-DISO
strongly	O
neutralizing	O
Abs	O
.	O

TITLE	O
:	O
A	O
comparison	O
of	O
infection	B-DISO
control	O
program	O
resources	O
,	O
activities	O
,	O
and	O
antibiotic	O
resistant	O
organism	O
rates	O
in	O
Canadian	O
acute	O
care	O
hospitals	O
in	O
1999	O
and	O
2005	O
:	O
pre	O
-	O
and	O
post	O
-	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

Methicillin	B-DISO
-	I-DISO
resistant	I-DISO
Staphylococcus	I-DISO
aureus	I-DISO
(	O
MRSA	B-DISO
)	O
rates	O
increased	O
from	O
1999	O
to	O
2005	O
(	O
F	O
=	O
9	O
.	O
4	O
,	O
P	O
=	O
.	O
003	O
).	O

In	O
2005	O
,	O
the	O
mean	O
MRSA	B-DISO
rate	O
was	O
5	O
.	O
2	O
(	O
standard	O
deviation	O
[	O
SD	O
],	O
6	O
.	O
1	O
)	O
per	O
1000	O
admissions	O
,	O
and	O
,	O
in	O
1999	O
,	O
it	O
was	O
2	O
.	O
0	O
(	O
SD	O
,	O
2	O
.	O
9	O
).	O

In	O
the	O
face	B-DISO
of	O
substantial	O
increases	O
in	O
ARO	O
rates	O
in	O
Canada	O
,	O
continued	O
efforts	O
to	O
train	O
ICPs	O
and	O
support	O
hospital	B-DISO
infection	I-DISO
control	O
programs	O
are	O
necessary	O
.	O

ABSTRACT	O
:	O
Between	O
mid	O
-	O
century	O
and	O
1992	O
,	O
there	O
was	O
a	O
consensus	O
that	O
the	O
battle	O
against	O
infectious	B-DISO
diseases	I-DISO
had	O
been	O
won	O
,	O
and	O
the	O
Surgeon	O
General	O
announced	O
that	O
it	O
was	O
time	O
to	O
close	O
the	O
book	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
whether	O
the	O
variable	O
nucleotide	O
tandem	O
repeat	O
polymorphism	O
in	O
intron	O
2	O
of	O
the	O
interleukin	O
-	O
1	O
receptor	O
antagonist	O
gene	O
is	O
associated	O
with	O
lung	O
injury	O
in	O
children	O
with	O
community	O
-	O
acquired	O
pneumonia	B-DISO
.	O

Eight	O
hundred	O
fifty	O
pediatric	O
patients	O
with	O
community	O
-	O
acquired	O
pneumonia	B-DISO
were	O
enrolled	O
.	O

In	O
children	O
with	O
community	O
-	O
acquired	O
pneumonia	B-DISO
,	O
absence	O
of	O
the	O
A1	O
allele	O
at	O
the	O
interleukin	O
-	O
1	O
receptor	O
antagonist	O
intron	O
2	O
polymorphic	O
site	O
is	O
associated	O
with	O
increased	O
risk	O
for	O
more	O
severe	O
lung	O
injury	O
,	O
as	O
measured	O
by	O
the	O
need	O
for	O
positive	O
pressure	O
ventilation	O
or	O
the	O
development	O
of	O
acute	O
lung	O
injury	O
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
We	O
detected	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
antibodies	O
in	O
pig	O
farms	O
in	O
Tochigi	O
prefecture	O
,	O
although	O
the	O
farms	O
had	O
no	O
past	O
record	O
of	O
TGEV	O
vaccination	O
or	O
TGE	B-DISO
.	O

Furthermore	O
,	O
dyspnea	B-DISO
and	O
evidence	O
of	O
acute	O
lung	O
injury	O
may	O
not	O
occur	O
for	O
several	O
hours	O
after	O
exposure	O
and	O
can	O
lead	O
to	O
rapidly	O
progressive	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

How	O
these	O
structures	O
are	O
assembled	O
is	O
still	O
largely	O
unknown	O
,	O
but	O
it	O
is	O
likely	O
that	O
the	O
membrane	O
-	O
spanning	O
members	O
of	O
these	O
nonstructural	O
proteins	O
(	O
nsps	O
)	O
are	O
responsible	O
for	O
the	O
induction	O
of	O
the	O
double	O
-	O
membrane	O
vesicles	B-DISO
and	O
for	O
anchoring	O
the	O
replication	O
complexes	O
to	O
these	O
membranes	O
.	O

To	O
distinguish	O
bystander	O
from	O
direct	O
antiviral	O
contributions	O
of	O
CD4	O
(+)	O
T	O
cells	O
in	O
virus	O
clearance	O
and	O
pathology	B-DISO
,	O
memory	O
CD4	O
(+)	O
T	O
cells	O
purified	O
from	O
wild	O
type	O
(	O
wt	O
),	O
perforin	O
-	O
deficient	O
(	O
PKO	O
),	O
and	O
IFN	O
-	O
gamma	O
-	O
deficient	O
(	O
GKO	O
)	O
immune	O
donors	O
were	O
transferred	O
to	O
immunodeficient	B-DISO
SCID	B-DISO
mice	O
prior	O
to	O
CNS	O
challenge	O
.	O

ABSTRACT	O
:	O
Apolipoprotein	O
D	O
(	O
apoD	O
)	O
is	O
a	O
lipocalin	O
upregulated	O
in	O
the	O
nervous	B-DISO
system	O
after	O
injury	O
or	O
pathologies	O
such	O
as	O
Alzheimer	B-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
,	O
Parkinson	B-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
,	O
and	O
multiple	B-DISO
sclerosis	I-DISO
.	O

Our	O
results	O
show	O
that	O
apoD	O
transcript	O
and	O
protein	O
are	O
upregulated	O
during	O
acute	O
encephalitis	B-DISO
induced	O
by	O
the	O
human	O
coronavirus	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
)	O
infection	B-DISO
.	O

These	O
data	O
reveal	O
a	O
role	O
for	O
apoD	O
in	O
the	O
regulation	O
of	O
inflammation	B-DISO
and	O
suggest	O
that	O
it	O
protects	O
from	O
HCoV	O
-	O
OC43	O
-	O
induced	O
encephalitis	B-DISO
,	O
most	O
likely	O
through	O
the	O
phospholipase	O
A2	O
signaling	O
pathways	O
.	O

ABSTRACT	O
:	O
It	O
is	O
now	O
recognized	O
that	O
a	O
significant	O
portion	O
of	O
patients	O
with	O
idiopathic	B-DISO
pulmonary	I-DISO
fibrosis	I-DISO
(	O
IPF	O
)	O
can	O
have	O
sudden	O
and	O
rapid	O
deteriorations	O
in	O
disease	O
course	O
that	O
cannot	O
be	O
explained	O
by	O
infection	B-DISO
,	O
heart	B-DISO
failure	I-DISO
,	O
or	O
thromboembolic	B-DISO
disease	I-DISO
.	O

There	O
are	O
numerous	O
causes	O
that	O
can	O
lead	O
to	O
acute	O
rhabdomyolysis	B-DISO
and	O
many	O
of	O
patients	O
present	O
with	O
multiple	O
causes	O
.	O

The	O
peak	O
of	O
creatine	O
phosphokinase	O
level	O
can	O
be	O
predictive	O
for	O
the	O
development	O
of	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
because	O
myoglobin	O
level	O
may	O
return	O
to	O
normal	O
within	O
6	O
hours	O
after	O
muscle	O
injury	O
.	O

Novel	O
peptide	O
-	O
aldehyde	O
derivatives	O
containing	O
a	O
side	O
-	O
chain	O
-	O
protected	O
C	O
-	O
terminal	O
Gln	O
efficiently	O
inhibited	O
the	O
catalytic	O
activity	O
of	O
the	O
R188I	O
mutant	B-DISO
.	O

The	O
resulting	O
compound	O
,	O
GRL0617	O
,	O
inhibited	O
SARS	B-DISO
-	O
CoV	O
viral	O
replication	O
in	O
Vero	O
E6	O
cells	O
with	O
an	O
EC	O
(	O
50	O
)	O
of	O
15	O
microM	O
and	O
had	O
no	O
associated	O
cytotoxicity	B-DISO
.	O

Some	O
of	O
these	O
emerging	O
pathogens	O
may	O
have	O
the	O
potential	O
to	O
cause	O
pandemics	O
or	O
global	O
spread	O
of	O
a	O
severe	O
disease	O
,	O
as	O
exemplified	O
by	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
avian	B-DISO
influenza	I-DISO
.	O

Antiviral	O
therapy	O
of	O
viral	O
respiratory	B-DISO
infections	I-DISO
is	O
often	O
unnecessary	O
in	O
the	O
competent	O
hosts	O
because	O
most	O
of	O
them	O
are	O
selflimiting	O
and	O
effective	O
agents	O
are	O
not	O
always	O
available	O
.	O

In	O
the	O
20	O
ng	O
/	O
mL	O
Ag	O
group	O
,	O
systolic	O
blood	O
pressure	O
decreased	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
respiratory	B-DISO
rate	I-DISO
increased	I-DISO
(	O
p	O
<	O
0	O
.	O
05	O
)	O
post	O
-	O
challenge	O
.	O

We	O
found	O
that	O
the	O
mutant	B-DISO
virus	O
replicated	O
to	O
slightly	O
reduced	O
titers	O
in	O
livers	O
but	O
,	O
strikingly	O
,	O
did	O
not	O
induce	O
liver	B-DISO
disease	I-DISO
.	O

TITLE	O
:	O
Risk	O
factors	O
for	O
pulmonary	B-DISO
embolism	I-DISO
after	O
hip	O
and	O
knee	O
arthroplasty	O
:	O
a	O
population	O
-	O
based	O
study	O
.	O

ABSTRACT	O
:	O
Pulmonary	B-DISO
embolism	I-DISO
(	O
PE	O
)	O
is	O
a	O
cause	O
of	O
death	O
after	O
total	O
hip	O
and	O
knee	O
arthroplasty	O
(	O
THA	O
,	O
TKA	O
).	O

We	O
characterised	O
the	O
patient	O
population	O
suffering	B-DISO
from	O
in	O
-	O
hospital	O
PE	O
and	O
identified	O
perioperative	O
risk	O
factors	O
associated	O
with	O
PE	O
using	O
nationally	O
representative	O
data	O
.	O

Factors	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
the	O
diagnosis	O
of	O
PE	O
included	O
:	O
revision	O
THA	O
,	O
female	O
gender	O
,	O
dementia	B-DISO
,	O
obesity	B-DISO
,	O
renal	O
and	O
cerebrovascular	B-DISO
disease	I-DISO
.	O

CONCLUSIONS	O
:	O
In	O
pigs	O
with	O
ARDS	B-DISO
,	O
prone	O
position	O
improves	O
PaO2	O
/	O
FiO2	O
significantly	O
without	O
influence	O
on	O
respiratory	O
mechanics	O
and	O
hemodynamics	O
.	O

TITLE	O
:	O
Papular	O
cutaneous	O
lesions	O
in	O
a	O
cat	O
associated	O
with	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
.	O

The	O
case	O
was	O
classified	O
as	O
a	O
mixed	O
form	O
of	O
FIP	B-DISO
.	O

Recognition	O
of	O
associated	O
cutaneous	O
lesions	O
may	O
facilitate	O
a	O
diagnosis	O
of	O
FIP	B-DISO
in	O
suspicious	O
cases	O
.	O

A	O
lower	O
-	O
affinity	O
interaction	O
with	O
ACE	O
-	O
2	O
might	O
partly	O
explain	O
the	O
different	O
pathological	O
consequences	O
of	O
infection	B-DISO
by	O
SARS	B-DISO
-	O
CoV	O
and	O
NL63	O
.	O

ABSTRACT	O
:	O
Human	O
PP11	O
(	O
placental	O
protein	O
11	O
)	O
was	O
previously	O
described	O
as	O
a	O
serine	O
protease	O
specifically	O
expressed	O
in	O
the	O
syncytiotrophoblast	O
and	O
in	O
numerous	O
tumor	B-DISO
tissues	O
.	O

Awareness	O
and	O
concern	O
about	O
bird	B-DISO
flu	I-DISO
is	O
low	O
(	O
lower	O
than	O
a	O
recent	O
survey	O
of	O
U	O
.	O
S	O
.	O
residents	O
).	O

There	O
appears	O
to	O
be	O
widespread	O
support	O
for	O
bird	B-DISO
flu	I-DISO
control	O
measures	O
initiated	O
by	O
the	O
federal	O
government	O
,	O
although	O
less	O
agreement	O
regarding	O
personal	O
protective	O
behaviors	O
.	O

Gastric	O
juice	O
from	O
intensive	O
care	O
unit	O
patients	O
,	O
even	O
buffered	O
at	O
pH	O
7	O
.	O
4	O
,	O
stimulated	O
human	O
type	O
II	O
-	O
like	O
A549	O
epithelial	O
cells	O
to	O
up	O
-	O
regulate	O
intercellular	O
adhesion	B-DISO
molecule	O
-	O
1	O
and	O
interleukin	O
-	O
8	O
,	O
significantly	O
more	O
than	O
juice	O
obtained	O
in	O
controls	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
quantify	O
transmission	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
H120	O
vaccine	O
strain	O
among	O
broilers	O
,	O
and	O
to	O
assess	O
whether	O
birds	O
that	O
have	O
been	O
exposed	O
to	O
vaccine	O
strain	O
-	O
shedding	O
birds	O
were	O
protected	O
against	O
clinical	O
signs	O
after	O
infection	B-DISO
with	O
a	O
virulent	O
strain	O
of	O
the	O
same	O
serotype	O
.	O

Nasal	B-DISO
discharge	I-DISO
was	O
recorded	O
,	O
and	O
antibody	O
response	O
and	O
virus	B-DISO
shedding	I-DISO
were	O
measured	O
.	O

In	O
addition	O
,	O
the	O
differences	O
in	O
socioeconomic	O
and	O
health	O
-	O
care	O
infrastructures	O
limit	O
the	O
usefulness	O
of	O
Western	O
management	O
guidelines	O
for	O
pneumonia	B-DISO
in	O
Asia	O
.	O

History	O
of	O
varicella	B-DISO
zoster	I-DISO
virus	O
(	O
VZV	O
)	O
infection	B-DISO
was	O
positive	O
in	O
42	O
%	O
of	O
controls	O
and	O
66	O
%	O
of	O
MS	O
cases	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
).	O

Docking	O
simulations	O
helped	O
to	O
rationalize	O
the	O
SARs	B-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
lifethreatening	O
emerging	O
respiratory	B-DISO
disease	I-DISO
caused	O
by	O
the	O
coronavirus	O
,	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
is	O
highly	O
antigenic	O
and	O
may	O
be	O
a	O
suitable	O
candidate	O
for	O
diagnostic	O
applications	O
.	O

ABSTRACT	O
:	O
Descending	O
necrotising	B-DISO
mediastinitis	I-DISO
is	O
a	O
severe	O
infection	B-DISO
spreading	O
from	O
the	O
cervical	O
region	O
to	O
the	O
mediastinal	O
connective	O
tissue	O
.	O

Complication	B-DISO
rates	O
and	O
outcomes	O
are	O
reviewed	O
and	O
our	O
experience	O
at	O
The	O
Epworth	O
Hospital	O
is	O
summarized	O
.	O

In	O
this	O
work	O
,	O
the	O
method	O
for	O
fabrication	O
of	O
poly	O
(	O
methyl	O
methacrylate	O
)	O
(	O
PMMA	O
)	O
chip	O
was	O
described	O
,	O
and	O
conditions	O
for	O
DNA	O
separation	B-DISO
were	O
investigated	O
with	O
the	O
chip	O
.	O

A	O
nosocomial	O
outbreak	O
of	O
SARS	B-DISO
occurred	O
at	O
Kaohsiung	O
Chang	O
Gung	O
Memorial	O
Hospital	O
(	O
CGMH	O
)	O
in	O
May	O
2003	O
.	O

CONCLUSIONS	O
:	O
There	O
was	O
low	O
post	O
-	O
epidemic	O
seroprevalence	O
of	O
SARS	B-DISO
-	O
CoV	O
in	O
a	O
community	O
adjacent	O
to	O
a	O
hospital	O
which	O
had	O
a	O
nosocomial	O
SARS	B-DISO
outbreak	O
.	O

We	O
found	O
that	O
cathepsin	O
L	O
(	O
CPL	B-DISO
)	O
inhibitors	O
blocked	O
229E	O
infection	B-DISO
the	O
most	O
remarkably	O
among	O
a	O
variety	O
of	O
protease	O
inhibitors	O
tested	O
.	O

RESULTS	O
:	O
The	O
emergency	B-DISO
preparedness	O
training	O
resulted	O
in	O
positive	O
shifts	O
in	O
knowledge	O
,	O
self	O
-	O
assessment	O
of	O
skills	O
for	O
public	O
health	O
leaders	O
.	O

These	O
observations	O
indicate	O
that	O
CXCL9	O
promotes	O
protection	O
from	O
coronavirus	O
-	O
induced	O
neurological	O
and	O
liver	B-DISO
disease	I-DISO
.	O

Sections	O
of	O
trachea	B-DISO
,	O
lung	O
and	O
airsacs	O
were	O
stained	O
for	O
CD4	O
,	O
CD8	O
,	O
gammadelta	O
-	O
TCR	O
,	O
alphabeta1	O
-	O
TCR	O
,	O
and	O
for	O
macrophages	O
(	O
KUL	O
-	O
01	O
)	O
and	O
both	O
pathogens	O
.	O

The	O
presence	O
of	O
high	O
numbers	O
of	O
T	O
cells	O
and	O
macrophages	O
in	O
IBV	O
infected	O
birds	O
most	O
likely	O
induced	O
an	O
altered	O
immune	O
response	O
,	O
which	O
is	O
responsible	O
for	O
the	O
enhanced	O
clinical	O
signs	O
of	O
colibacillosis	B-DISO
.	O

The	O
mechanism	O
for	O
this	O
is	O
unknown	O
,	O
however	O
the	O
suppression	B-DISO
of	O
a	O
key	O
antiviral	O
strategy	O
during	O
a	O
period	O
of	O
physiologic	O
and	O
immunological	O
stress	O
,	O
such	O
as	O
on	O
entry	O
to	O
a	O
kennel	O
,	O
could	O
potentially	O
predispose	O
a	O
dog	O
to	O
further	O
pathogenic	O
challenge	O
and	O
the	O
development	O
of	O
respiratory	B-DISO
disease	I-DISO
.	O

Peri	O
-	O
partum	O
and	O
post	O
-	O
collapse	B-DISO
data	O
were	O
collated	O
with	O
clinical	O
,	O
electrophysiological	O
,	O
neuroimaging	O
and	O
autopsy	O
data	O
and	O
neurodevelopmental	O
outcome	O
.	O

Ten	O
were	O
born	O
vaginally	O
(	O
including	O
occipitoposterior	O
(	O
1	O
),	O
breech	O
(	O
2	O
),	O
water	O
birth	O
(	O
2	O
),	O
ventouse	O
/	O
forceps	O
(	O
3	O
)),	O
and	O
two	O
by	O
emergency	B-DISO
caesarean	O
section	O
.	O

Four	O
infants	O
had	O
severe	O
respiratory	O
illness	O
,	O
normal	O
background	O
EEG	O
,	O
and	O
MRI	O
showing	O
slight	O
white	O
matter	O
change	O
(	O
n	O
=	O
3	O
)	O
or	O
a	O
small	O
infarction	B-DISO
(	O
n	O
=	O
1	O
).	O

ABSTRACT	O
:	O
The	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
on	O
spike	O
protein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
the	O
main	O
region	O
interacting	O
with	O
the	O
viral	O
receptor	O
-	O
ACE2	O
and	O
is	O
a	O
useful	O
target	O
for	O
induction	O
of	O
neutralizing	O
antibodies	O
against	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

We	O
identified	O
human	O
alveolar	O
epithelial	O
A549	O
cells	O
as	O
the	O
most	O
susceptible	O
cell	O
line	O
among	O
those	O
tested	O
to	O
infection	B-DISO
by	O
HCoV	O
-	O
HKU1	O
S	O
pseudotypes	O
.	O

However	O
,	O
the	O
long	O
-	O
term	O
impact	O
of	O
SARS	B-DISO
on	O
hospital	O
performance	O
needs	O
to	O
be	O
further	O
discussed	O
.	O

A	O
municipal	O
hospital	O
in	O
Taipei	O
City	O
was	O
shut	O
down	O
for	O
a	O
month	O
due	O
to	O
SARS	B-DISO
and	O
then	O
became	O
the	O
designated	O
SARS	B-DISO
and	O
infectious	B-DISO
disease	I-DISO
hospital	O
for	O
the	O
city	O
.	O

The	O
ARIMA	O
model	O
of	O
outpatient	O
volume	O
in	O
the	O
pre	O
-	O
SARS	B-DISO
year	O
was	O
developed	O
.	O

Furthermore	O
,	O
the	O
ashes	O
contained	O
high	O
concentrations	O
of	O
heavy	O
metals	O
such	O
as	O
Ag	O
,	O
As	O
,	O
Ba	O
,	O
Bi	O
,	O
Cd	O
,	O
Cr	O
,	O
Cu	O
,	O
Mn	O
,	O
Ni	O
,	O
Pb	O
,	O
Ti	O
,	O
Sb	O
,	O
Sn	O
,	O
Sr	O
,	O
Zn	O
with	O
a	O
vast	O
range	O
of	O
1	O
.	O
1	O
-	O
121	O
,	O
411mgkg	O
(-	O
1	O
),	O
with	O
higher	O
concentrations	O
found	O
in	O
the	O
fly	O
ash	B-DISO
samples	O
.	O

TITLE	O
:	O
Emerging	O
infections	B-DISO
:	O
a	O
perpetual	O
challenge	O
.	O

TITLE	O
:	O
Antiviral	O
activity	O
of	O
quercetin	O
7	O
-	O
rhamnoside	O
against	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
.	O

TITLE	O
:	O
Progression	O
of	O
lesions	O
in	O
the	O
respiratory	O
tract	O
of	O
broilers	O
after	O
single	O
infection	B-DISO
with	O
Escherichia	O
coli	O
compared	O
to	O
superinfection	B-DISO
with	O
E	O
.	O
coli	O
after	O
infection	B-DISO
with	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

In	O
the	O
present	O
study	O
it	O
is	O
shown	O
that	O
4	O
-	O
week	O
-	O
old	O
broilers	O
are	O
not	O
resistant	O
to	O
intratracheal	O
E	O
.	O
coli	O
inoculation	O
,	O
however	O
,	O
these	O
birds	O
can	O
overcome	O
the	O
induced	O
E	B-DISO
.	I-DISO
coli	I-DISO
infection	I-DISO
within	O
a	O
short	O
time	O
span	O
.	O

This	O
plan	B-DISO
has	O
been	O
formulated	O
as	O
a	O
consequence	O
of	O
:	O
(	O
1	O
)	O
experiences	O
gained	O
through	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
and	O
comments	O
of	O
the	O
members	O
of	O
the	O
Expert	O
Panel	O
on	O
SARS	B-DISO
and	O
Infectious	B-DISO
Disease	I-DISO
Control	O
(	O
i	O
.	O
e	O
.,	O
the	O
Walker	O
report	O
);	O
(	O
2	O
)	O
a	O
review	O
of	O
pandemic	O
preparedness	O
literature	O
;	O
(	O
3	O
)	O
historical	O
and	O
epidemiologic	O
discussions	O
about	O
previous	O
pandemics	O
;	O
and	O
(	O
4	O
)	O
suggestions	O
made	O
by	O
various	O
pandemic	O
working	O
committees	O
.	O

The	O
ORF7b	O
from	O
the	O
peritoneal	O
/	O
pleural	B-DISO
effusions	I-DISO
of	O
FIP	B-DISO
cats	O
and	O
from	O
the	O
rectal	O
swabs	O
of	O
healthy	O
cats	O
was	O
amplified	O
.	O

Surprisingly	O
,	O
among	O
the	O
eight	O
viruses	O
with	O
deletions	O
,	O
three	O
were	O
from	O
FIP	B-DISO
diseased	O
cats	O
.	O

TITLE	O
:	O
Plaque	B-DISO
assay	O
for	O
human	O
coronavirus	O
NL63	O
using	O
human	O
colon	B-DISO
carcinoma	I-DISO
cells	O
.	O

12	O
different	O
cell	O
cultures	O
were	O
tested	O
for	O
susceptibility	O
to	O
hCoV	O
-	O
NL63	O
infection	B-DISO
.	O

The	O
utility	O
of	O
plaque	B-DISO
assays	O
with	O
agrose	O
overlay	O
was	O
demonstrated	O
for	O
purifying	O
virus	O
,	O
thereby	O
increasing	O
viral	O
infectivity	O
by	O
1	O
log	O
10	O
PFU	O
/	O
mL	O
.	O
CaCo	O
-	O
2	O
cells	O
support	O
hCoV	O
-	O
NL63	O
better	O
than	O
LLC	O
-	O
MK2	O
cells	O
and	O
enable	O
cytopathogenic	O
plaque	B-DISO
assays	O
.	O

Avicel	O
overlay	O
is	O
favourable	O
for	O
plaque	B-DISO
quantification	O
,	O
and	O
agarose	O
overlay	O
is	O
preferred	O
for	O
plaque	B-DISO
purification	O
.	O

ABSTRACT	O
:	O
For	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
techniques	O
of	O
extracorporeal	O
lung	O
support	O
have	O
been	O
established	O
thirty	O
years	O
ago	O
.	O

In	O
the	O
beginning	O
of	O
such	O
a	O
strategy	O
a	O
roller	O
-	O
pump	O
-	O
driven	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
was	O
used	O
,	O
which	O
was	O
characterized	O
by	O
high	O
complication	B-DISO
rate	O
.	O

TCoV	O
nsp15	O
consists	O
of	O
338	O
residues	O
and	O
shares	O
40	O
%	O
sequence	O
similarity	O
to	O
U	O
-	O
specific	O
Nidovirales	O
endoribonuclease	O
(	O
NendoU	O
)	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

This	O
study	O
used	O
a	O
broad	O
capture	O
,	O
rapid	O
and	O
sensitive	O
method	O
(	O
multiplex	O
PCR	O
assay	O
)	O
to	O
detect	O
20	O
different	O
respiratory	O
pathogens	O
including	O
influenza	B-DISO
A	O
subtypes	O
H1	O
,	O
H3	O
,	O
and	O
H5	O
;	O
influenza	B-DISO
B	O
;	O
parainfluenza	B-DISO
types	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
4	O
;	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
groups	O
A	O
and	O
B	O
;	O
adenoviruses	O
;	O
human	O
rhinoviruses	O
;	O
enteroviruses	O
;	O
human	O
metapneumoviruses	O
;	O
human	O
coronaviruses	O
OC43	O
,	O
229E	O
,	O
and	O
SARS	B-DISO
-	O
CoV	O
;	O
Chlamydophila	O
pneumoniae	O
;	O
Legionella	O
pneumophila	O
;	O
and	O
Mycoplasma	B-DISO
pneumoniae	O
;	O
from	O
respiratory	O
specimens	O
of	O
475	O
children	O
hospitalized	O
over	O
a	O
12	O
-	O
month	O
period	O
for	O
acute	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
.	O

RSV	B-DISO
infection	I-DISO
was	O
associated	O
with	O
bronchiolitis	B-DISO
,	O
and	O
parainfluenza	B-DISO
was	O
associated	O
with	O
croup	B-DISO
;	O
otherwise	O
the	O
clinical	O
manifestations	O
were	O
largely	O
nonspecific	O
.	O

In	O
view	O
of	O
the	O
increasing	O
concern	O
about	O
unexpected	O
outbreaks	O
of	O
severe	O
viral	B-DISO
infections	I-DISO
,	O
a	O
rapid	O
multiplex	O
PCR	O
assay	O
is	O
a	O
valuable	O
tool	O
to	O
enhance	O
the	O
management	O
of	O
hospitalized	O
patients	O
,	O
and	O
for	O
the	O
surveillance	O
for	O
viral	B-DISO
infections	I-DISO
circulating	O
in	O
the	O
community	O
.	O

ELISA	O
method	O
was	O
used	O
to	O
detect	O
serum	O
amyloid	B-DISO
P	O
component	O
in	O
individual	O
serum	O
;	O
specificity	O
and	O
sensitivity	O
of	O
serum	O
amyloid	B-DISO
P	O
component	O
were	O
analyzed	O
.	O

The	O
serum	O
amyloid	B-DISO
P	O
component	O
in	O
3	O
groups	O
were	O
0	O
.	O
54	O
+/-	O

ABSTRACT	O
:	O
Defining	O
prospective	O
pathways	O
by	O
which	O
zoonoses	B-DISO
evolve	O
and	O
emerge	O
as	O
human	O
pathogens	O
is	O
critical	O
for	O
anticipating	O
and	O
controlling	O
both	O
natural	O
and	O
deliberate	O
pandemics	O
.	O

Here	O
,	O
we	O
report	O
the	O
design	O
,	O
synthesis	O
,	O
and	O
recovery	O
of	O
the	O
largest	O
synthetic	O
replicating	O
life	O
form	O
,	O
a	O
29	O
.	O
7	O
-	O
kb	O
bat	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
like	O
coronavirus	O
(	O
Bat	O
-	O
SCoV	O
),	O
a	O
likely	O
progenitor	O
to	O
the	O
SARS	B-DISO
-	O
CoV	O
epidemic	O
.	O

Serological	O
results	O
showed	O
that	O
the	O
diagnostic	O
sensitivity	O
and	O
specificity	O
of	O
the	O
truncated	O
S	O
-	O
N	O
fusion	O
protein	O
derived	O
the	O
SARS	B-DISO
virus	O
were	O
>	O
99	O
%	O
(	O
457	O
/	O
460	O
)	O
and	O
100	O
.	O
00	O
%	O
(	O
650	O
/	O
650	O
),	O
respectively	O
.	O

TITLE	O
:	O
Development	O
of	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
-	O
based	O
test	O
with	O
a	O
cocktail	O
of	O
nucleocapsid	O
and	O
spike	O
proteins	O
for	O
detection	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
-	O
specific	O
antibody	O
.	O

The	O
degree	O
of	O
discomfort	B-DISO
reported	O
was	O
2	O
.	O
54	O
for	O
swabs	O
,	O
2	O
.	O
63	O
for	O
washes	O
,	O
2	O
.	O
68	O
for	O
aspirates	O
and	O
3	O
.	O
61	O
for	O
brushings	O
.	O

In	O
contrast	O
,	O
nasal	O
brushes	O
produced	O
the	O
lowest	O
detection	O
rates	O
and	O
demonstrated	O
the	O
highest	O
level	O
of	O
discomfort	B-DISO
.	O

Hypoxia	B-DISO
on	O
room	O
air	O
and	O
PO2	O
/	O
FiO2	O
ratio	O
predicted	O
severity	O
of	O
outcome	O
as	O
assessed	O
by	O
the	O
duration	O
of	O
hospitalization	O
and	O
the	O
need	O
for	O
intensive	O
care	O
support	O
.	O

However	O
,	O
only	O
a	O
few	O
studies	O
on	O
the	O
B	O
-	O
cell	O
activation	O
mechanism	O
after	O
FIP	B-DISO
virus	O
(	O
FIPV	O
)	O
infection	B-DISO
have	O
been	O
reported	O
.	O

Although	O
some	O
authors	O
reported	O
its	O
efficacy	O
in	O
ALI	O
,	O
it	O
is	O
unclear	O
whether	O
sivelestat	O
has	O
good	O
effects	O
in	O
ALI	O
,	O
especially	O
in	O
cases	O
due	O
to	O
severe	O
bacterial	B-DISO
pneumonia	I-DISO
.	O

We	O
performed	O
a	O
retrospective	O
study	O
of	O
28	O
patients	O
who	O
were	O
admitted	O
for	O
severe	O
bacterial	B-DISO
pneumonia	I-DISO
(	O
pneumonia	B-DISO
severity	O
index	O
;	O
PSI	O
class	O
V	O
).	O

In	O
pneumonia	B-DISO
severity	O
score	O
,	O
chest	O
X	O
-	O
ray	O
film	O
score	O
was	O
higher	O
in	O
the	O
group	O
of	O
fatalities	O
than	O
in	O
the	O
survival	O
group	O
.	O

ABSTRACT	O
:	O
Identification	O
of	O
dominant	O
T	O
cell	O
epitopes	O
within	O
newly	O
emerging	O
and	O
re	O
-	O
emerging	O
infectious	B-DISO
organisms	O
is	O
valuable	O
in	O
understanding	O
pathogenic	O
immune	O
responses	O
and	O
potential	O
vaccine	O
designs	O
.	O

Small	O
-	O
angle	O
X	O
-	O
ray	O
scattering	O
data	O
show	O
that	O
the	O
protein	O
is	O
in	O
an	O
extended	O
conformation	O
and	O
that	O
the	O
two	O
structural	O
domains	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
N	O
protein	O
are	O
far	O
apart	O
.	O

ABSTRACT	O
:	O
The	O
innate	O
immune	O
system	O
guards	O
against	O
virus	B-DISO
infection	I-DISO
through	O
a	O
variety	O
of	O
mechanisms	O
including	O
mobilization	O
of	O
the	O
host	O
interferon	O
system	O
,	O
which	O
attacks	O
viral	O
products	O
mainly	O
at	O
a	O
posttranscriptional	O
level	O
.	O

Interestingly	O
,	O
cells	O
lacking	O
an	O
interferon	O
response	O
were	O
drug	O
resistant	O
,	O
suggesting	O
that	O
the	O
compounds	O
block	O
interactions	O
between	O
NS1	B-DISO
and	O
the	O
interferon	O
system	O
.	O

The	O
emergence	O
of	O
the	O
highly	O
pathogenic	O
coronavirus	O
severe	O
acute	O
respiratory	O
virus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
serves	O
as	O
a	O
robust	O
model	O
system	O
to	O
elucidate	O
the	O
virus	O
-	O
host	O
interactions	O
that	O
mediate	O
severe	O
end	O
-	O
stage	O
lung	B-DISO
disease	I-DISO
in	O
humans	O
and	O
animals	O
.	O

The	O
highest	O
leukocyte	O
and	O
neutrophil	O
counts	O
,	O
lactate	O
dehydrogenase	O
,	O
and	O
creatine	O
kinase	O
;	O
positive	O
end	O
-	O
expiratory	O
pressure	O
;	O
and	O
use	O
of	O
corticosteroids	O
,	O
ribavirin	O
,	O
and	O
intravenous	O
immunoglobulin	O
were	O
higher	O
in	O
the	O
SARS	B-DISO
group	O
.	O

Neuroendocrine	O
and	O
metabolic	O
responses	O
may	O
result	O
in	O
insufficient	O
adaptive	O
immune	O
response	O
and	O
the	O
development	O
of	O
nosocomial	B-DISO
infections	I-DISO
,	O
which	O
may	O
further	O
threaten	O
host	O
homeostasis	O
.	O

ABSTRACT	O
:	O
Chicken	O
tracheal	O
organ	O
cultures	O
(	O
TOCs	O
),	O
comprising	O
transverse	O
sections	O
of	O
chick	O
embryo	O
trachea	B-DISO
with	O
beating	O
cilia	O
,	O
have	O
proved	O
useful	O
in	O
the	O
isolation	O
of	O
several	O
respiratory	O
viruses	O
and	O
as	O
a	O
viral	O
assay	O
system	O
,	O
using	O
ciliostasis	O
as	O
the	O
criterion	O
for	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Calculation	O
of	O
infectious	B-DISO
viral	O
titers	O
represents	O
a	O
basic	O
and	O
essential	O
experimental	O
approach	O
for	O
virologists	O
.	O

The	O
primer	O
combinations	O
were	O
:	O
oligonucleotide	O
pair	O
2Bp	O
/	O
4Bm	O
,	O
which	O
is	O
in	O
a	O
region	O
of	O
gene	O
1	O
that	O
is	O
moderately	O
conserved	O
among	O
all	O
species	O
of	O
coronavirus	O
(	O
1	O
);	O
and	O
UTR11	O
-/	O
UTR41	O
+,	O
which	O
are	O
in	O
a	O
highly	O
conserved	O
part	O
of	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
avian	O
coronaviruses	O
related	O
to	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
2	O
).	O

ABSTRACT	O
:	O
We	O
have	O
developed	O
a	O
DNA	O
assembly	O
platform	O
that	O
utilizes	O
the	O
nonspecific	O
,	O
highly	O
variable	O
sequence	O
signatures	O
of	O
type	O
IIs	O
restriction	O
enzymes	O
to	O
assemble	O
a	O
full	O
-	O
length	O
molecular	O
clone	O
of	O
murine	B-DISO
hepatitis	I-DISO
coronavirus	O
(	O
MHV	O
)	O
strain	O
A59	O
.	O

Vaccinia	B-DISO
virus	O
as	O
a	O
vector	O
for	O
the	O
full	O
-	O
length	O
IBV	O
cDNA	O
has	O
the	O
advantage	O
that	O
modifications	O
can	O
be	O
introduced	O
into	O
the	O
IBV	O
cDNA	O
using	O
homologous	O
recombination	O
,	O
a	O
method	O
frequently	O
used	O
to	O
insert	O
and	O
delete	O
sequences	O
from	O
the	O
vaccinia	B-DISO
virus	O
genome	O
.	O

Thus	O
the	O
monoclonal	O
antibody	O
approach	O
provides	O
useful	O
tools	O
for	O
rapid	O
and	O
specific	O
diagnosis	O
of	O
SARS	B-DISO
,	O
as	O
well	O
as	O
for	O
possible	O
antibody	O
-	O
based	O
treatment	O
of	O
the	O
disease	O
.	O

TITLE	O
:	O
Generating	O
antibodies	O
to	O
the	O
gene	O
3	O
proteins	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

Within	O
the	O
family	O
Coronaviridae	O
,	O
the	O
embryonated	O
egg	O
has	O
been	O
used	O
as	O
a	O
host	O
system	O
primarily	O
for	O
two	O
group	O
3	O
coronaviruses	O
,	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
and	O
turkey	O
coronavirus	O
(	O
TCoV	O
),	O
but	O
it	O
also	O
has	O
been	O
shown	O
to	O
be	O
suitable	O
for	O
pheasant	O
coronavirus	O
.	O

Docking	O
simulations	O
were	O
carried	O
out	O
to	O
rationalize	O
the	O
most	O
relevant	O
SARs	B-DISO
.	O

TITLE	O
:	O
The	O
role	O
of	O
the	O
traveler	O
in	O
emerging	O
infections	B-DISO
and	O
magnitude	O
of	O
travel	O
.	O

The	O
patient	O
then	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
requiring	O
intubation	O
and	O
ventilatory	O
support	O
.	O

TITLE	O
:	O
Fraction	O
of	O
all	O
hospital	O
admissions	O
and	O
deaths	O
attributable	O
to	O
malnutrition	B-DISO
among	O
children	O
in	O
rural	O
Kenya	O
.	O

TITLE	O
:	O
Beyond	O
SARS	B-DISO
:	O
ethnic	O
community	O
organization	O
'	O
s	O
role	O
in	O
public	O
health	O
--	O
a	O
Toronto	O
experience	O
.	O

Breathing	O
room	O
air	O
arterial	O
blood	O
gases	O
,	O
revealed	O
severe	O
hypoxemia	O
(	O
P	O
/	O
F	O
ratio	O
185	O
mmHg	O
)	O
and	O
Chest	O
CT	O
showed	O
diffuse	O
ground	O
glass	O
opacities	B-DISO
in	O
both	O
lung	O
fields	O
.	O

Phylogenetic	O
trees	O
of	O
25	O
viruses	O
including	O
SARS	B-DISO
-	O
CoVs	O
are	O
constructed	O
to	O
illustrate	O
our	O
approach	O
.	O

The	O
mortality	O
rate	O
for	O
medical	O
personnel	O
during	O
the	O
SARS	B-DISO
outbreak	O
in	O
Taiwan	O
,	O
which	O
began	O
in	O
April	O
2003	O
,	O
was	O
the	O
highest	O
among	O
Asian	O
countries	O
.	O

That	O
is	O
,	O
knowledge	O
sharing	O
was	O
an	O
antecedent	O
variable	O
for	O
both	O
SARS	B-DISO
impact	O
and	O
professional	O
commitment	O
.	O

RESULTS	O
:	O
The	O
results	O
showed	O
that	O
knowledge	O
sharing	O
correlated	O
positively	O
with	O
professional	O
commitment	O
but	O
negatively	O
with	O
the	O
impact	O
of	O
SARS	B-DISO
.	O

Here	O
,	O
we	O
report	O
that	O
mice	O
deficient	O
in	O
MyD88	O
(	O
MyD88	O
(-/-)),	O
an	O
adapter	O
protein	O
that	O
mediates	O
Toll	O
-	O
like	O
receptor	O
(	O
TLR	O
),	O
IL	O
-	O
1R	O
,	O
and	O
IL	O
-	O
18R	O
signaling	O
,	O
are	O
far	O
more	O
susceptible	O
to	O
rMA15	O
infection	B-DISO
.	O

Despite	O
increased	O
viral	O
loads	O
,	O
the	O
expression	O
of	O
multiple	O
proinflammatory	O
cytokines	O
and	O
chemokines	O
within	O
lung	O
tissue	O
and	O
recruitment	B-DISO
of	O
inflammatory	O
monocytes	O
/	O
macrophages	O
to	O
the	O
lung	O
was	O
severely	O
impaired	B-DISO
in	O
MyD88	O
(-/-)	O
mice	O
compared	O
to	O
wild	O
-	O
type	O
mice	O
.	O

The	O
rationalization	O
and	O
contraction	B-DISO
of	O
the	O
plasma	O
products	O
industry	O
may	O
be	O
viewed	O
as	O
one	O
aspect	O
of	O
globalisation	O
imposed	O
by	O
the	O
remorseless	O
inevitability	O
of	O
the	O
market	O
;	O
the	O
effect	O
of	O
this	O
development	O
on	O
the	O
safety	O
and	O
supply	O
of	O
products	O
has	O
yet	O
to	O
be	O
seen	O
,	O
but	O
the	O
oversight	O
and	O
assurance	O
of	O
a	O
shrinking	O
number	O
of	O
players	O
will	O
present	O
particular	O
challenges	O
.	O

Here	O
,	O
we	O
present	O
insight	O
into	O
the	O
immunological	O
mechanisms	O
involved	O
in	O
FH	O
caused	O
by	O
murine	B-DISO
hepatitis	I-DISO
virus	O
strain	O
3	O
(	O
MHV	O
-	O
3	O
),	O
indicating	O
a	O
critical	O
role	O
for	O
CD4	O
(+)	O
CD25	O
(+)	O
regulatory	O
T	O
cells	O
(	O
Tregs	O
)	O
and	O
production	O
of	O
the	O
novel	O
Treg	O
effector	O
molecule	O
FGL2	O
.	O

TITLE	O
:	O
Associations	O
between	O
male	O
anogenital	B-DISO
human	I-DISO
papillomavirus	I-DISO
infection	I-DISO
and	O
circumcision	O
by	O
anatomic	O
site	O
sampled	O
and	O
lifetime	O
number	O
of	O
female	O
sex	O
partners	O
.	O

Reported	O
associations	O
between	O
circumcision	O
and	O
HPV	O
infection	B-DISO
in	O
men	O
have	O
been	O
inconsistent	O
.	O

Circumcision	O
may	O
be	O
protective	O
against	O
HPV	O
infection	B-DISO
of	O
the	O
urethra	O
,	O
glans	O
/	O
corona	O
,	O
and	O
penile	O
shaft	O
.	O

The	O
breakdown	B-DISO
of	O
suspected	O
causative	O
pathogens	O
was	O
as	O
follows	O
:	O
24	O
.	O
4	O
%	O
were	O
Streptococcus	O
pneumoniae	O
,	O
14	O
.	O
8	O
%	O
were	O
Mycoplasma	B-DISO
pneumoniae	O
,	O
11	O
.	O
3	O
%	O
were	O
Haemophilus	O
influenzae	O
,	O
and	O
1	O
.	O
4	O
%	O
were	O
Chlamydophila	O
pneumoniae	O
.	O

One	O
of	O
these	O
proteins	O
,	O
protein	O
6	O
(	O
p6	O
),	O
which	O
is	O
encoded	O
by	O
ORF6	O
,	O
enhances	O
virus	O
replication	O
when	O
introduced	O
into	O
a	O
heterologous	O
murine	O
coronavirus	O
(	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
[	O
MHV	O
])	O
but	O
is	O
not	O
essential	O
for	O
optimal	O
SARS	B-DISO
-	O
CoV	O
replication	O
after	O
infection	B-DISO
at	O
a	O
relatively	O
high	O
multiplicity	O
of	O
infection	B-DISO
(	O
MOI	O
).	O

Here	O
,	O
we	O
reconcile	O
these	O
apparently	O
conflicting	O
results	O
by	O
showing	O
that	O
p6	O
enhances	O
SARS	B-DISO
-	O
CoV	O
replication	O
to	O
nearly	O
the	O
same	O
extent	O
as	O
when	O
expressed	O
in	O
the	O
context	O
of	O
MHV	O
if	O
cells	O
are	O
infected	O
at	O
a	O
low	O
MOI	O
and	O
accelerates	O
disease	O
in	O
mice	O
transgenic	O
for	O
the	O
human	O
SARS	B-DISO
-	O
CoV	O
receptor	O
.	O

TITLE	O
:	O
Identification	O
of	O
Taiwan	O
and	O
China	O
-	O
like	O
recombinant	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
viruses	O
in	O
Taiwan	O
.	O

TITLE	O
:	O
Complete	O
genomic	O
sequence	O
analysis	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
Ark	O
DPI	O
strain	O
and	O
its	O
evolution	O
by	O
recombination	O
.	O

At	O
day	O
4	O
(	O
D4	O
),	O
a	O
cardiogenic	B-DISO
shock	I-DISO
occurred	O
and	O
,	O
despite	O
epinephrine	O
and	O
norepinephrine	O
infusion	O
,	O
fluid	O
expansion	O
,	O
the	O
hemodynamic	O
condition	B-DISO
worsened	O
with	O
two	O
episodes	O
of	O
cardiac	B-DISO
arrest	I-DISO
.	O

Five	O
hundred	O
and	O
twenty	O
-	O
nine	O
adult	O
patients	O
with	O
CAP	B-DISO
requiring	O
ICU	O
admission	O
.	O

To	O
explore	O
the	O
correlation	O
between	O
different	O
types	O
of	O
FCoV	O
and	O
FIP	B-DISO
,	O
clinical	O
specimens	O
collected	O
from	O
363	O
naturally	O
infected	O
cats	O
during	O
2003	O
-	O
2007	O
were	O
analyzed	O
.	O

All	O
of	O
the	O
children	O
admitted	O
to	O
the	O
Hospital	O
for	O
Sick	O
Children	O
between	O
March	O
14	O
and	O
June	O
15	O
,	O
2003	O
,	O
with	O
suspect	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	B-DISO
infection	I-DISO
were	O
included	O
.	O

This	O
serves	O
to	O
reinforce	O
the	O
importance	O
of	O
routinely	O
obtaining	O
a	O
thorough	O
epidemiologic	O
travel	O
and	O
exposure	O
history	O
for	O
all	O
subjects	O
with	O
suspected	O
infectious	B-DISO
diseases	I-DISO
.	O

IRF3	O
translocation	B-DISO
was	O
independent	O
of	O
p38	O
kinase	O
activity	O
,	O
indicating	O
that	O
IRF3	O
and	O
p38	O
kinase	O
are	O
distinct	O
pathways	O
leading	O
to	O
cytokine	O
production	O
by	O
H5N1	B-DISO
virus	O
.	O

We	O
conclude	O
that	O
IRF3	O
and	O
p38	O
kinase	O
separately	O
and	O
predominantly	O
contribute	O
to	O
H5N1	B-DISO
-	O
mediated	O
induction	O
of	O
IFN	O
-	O
beta	O
,	O
IFN	O
-	O
lambda1	O
,	O
and	O
MCP	O
-	O
1	O
but	O
only	O
partly	O
control	O
TNF	O
-	O
alpha	O
induction	O
.	O

This	O
genetic	O
analysis	O
revealed	O
that	O
IFNAR	O
expression	O
on	O
LysM	O
+	O
macrophages	O
and	O
CD11c	O
+	O
dendritic	O
cells	O
was	O
most	O
important	O
for	O
the	O
early	O
containment	O
of	O
MHV	O
within	O
secondary	O
lymphoid	O
organs	O
and	O
to	O
prevent	O
lethal	O
liver	B-DISO
disease	I-DISO
.	O

Perceived	O
threat	O
for	O
SARS	B-DISO
varied	O
between	O
countries	O
in	O
Europe	O
and	O
Asia	O
with	O
a	O
higher	O
perceived	O
severity	O
of	O
SARS	B-DISO
in	O
Europe	O
and	O
a	O
higher	O
perceived	O
vulnerability	O
in	O
Asia	O
.	O

The	O
relatively	O
high	O
perceived	O
threat	O
for	O
SARS	B-DISO
indicates	O
that	O
it	O
is	O
seen	O
as	O
a	O
public	O
health	O
risk	O
and	O
offers	O
a	O
basis	O
for	O
communication	O
in	O
case	O
of	O
an	O
outbreak	O
.	O

ABSTRACT	O
:	O
Although	O
known	O
as	O
respiratory	O
pathogens	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
its	O
sister	O
coronaviruses	O
frequently	O
cause	O
enteric	O
symptoms	O
.	O

These	O
effects	O
can	O
be	O
due	O
to	O
direct	O
infection	B-DISO
of	O
the	O
gut	O
mucosa	O
,	O
but	O
can	O
also	O
be	O
because	O
of	O
decreased	O
antibacterial	O
defenses	O
,	O
increased	O
mucosal	O
permeability	O
,	O
bacterial	O
translocation	B-DISO
,	O
and	O
systemic	O
leak	O
of	O
endotoxin	O
.	O

In	O
the	O
Emergency	B-DISO
Department	O
two	O
patients	O
were	O
comatose	B-DISO
and	O
required	O
intubation	O
.	O

To	O
combat	O
SARS	B-DISO
,	O
we	O
previously	O
had	O
developed	O
peptidomimetic	O
and	O
zinc	O
-	O
coordinating	O
inhibitors	O
of	O
3CL	O
(	O
pro	O
).	O

TITLE	O
:	O
Applying	O
the	O
lessons	O
of	O
SARS	B-DISO
to	O
pandemic	O
influenza	B-DISO
:	O
an	O
evidence	O
-	O
based	O
approach	O
to	O
mitigating	O
the	O
stress	O
experienced	O
by	O
healthcare	O
workers	O
.	O

Consequently	O
,	O
the	O
antisera	O
exhibited	O
neutralization	O
activity	O
in	O
an	O
in	O
vitro	O
infection	B-DISO
inhibition	O
assay	O
.	O

ABSTRACT	O
:	O
Using	O
HIV	B-DISO
/	I-DISO
AIDS	I-DISO
,	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
),	O
and	O
avian	B-DISO
influenza	I-DISO
as	O
case	O
studies	O
,	O
this	O
paper	O
discusses	O
the	O
processes	O
and	O
dilemmas	O
of	O
China	O
'	O
s	O
participation	O
in	O
health	O
governance	O
,	O
both	O
at	O
the	O
domestic	O
level	O
and	O
the	O
global	O
level	O
.	O

Infectious	B-DISO
disease	I-DISO
outbreaks	O
are	O
among	O
the	O
most	O
dramatic	O
aspects	O
of	O
systems	O
failure	O
,	O
and	O
the	O
Canadian	O
cases	O
of	O
SARS	B-DISO
(	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
)	O
in	O
Toronto	O
,	O
and	O
the	O
E	O
.	O
coli	O
outbreak	O
in	O
Walkerton	O
,	O
serve	O
as	O
useful	O
illustrative	O
examples	O
.	O

TITLE	O
:	O
Comparative	O
analysis	O
of	O
the	O
sialic	O
acid	O
binding	O
activity	O
and	O
the	O
tropism	O
for	O
the	O
respiratory	O
epithelium	O
of	O
four	O
different	O
strains	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
.	O

Our	O
data	O
have	O
implications	O
for	O
people	O
who	O
maintain	O
low	O
levels	O
of	O
anti	O
-	O
VTT	O
Nabs	O
after	O
historical	O
smallpox	B-DISO
vaccination	O
.	O

To	O
investigate	O
any	O
differences	O
in	O
attitudes	O
toward	O
influenza	B-DISO
vaccination	O
among	O
Hong	O
Kong	O
elderly	O
people	O
with	O
different	O
levels	O
of	O
cognitive	O
and	O
physical	O
functioning	O
.	O

ABSTRACT	O
:	O
Newcastle	B-DISO
disease	I-DISO
virus	O
(	O
NDV	O
),	O
an	O
avian	O
virus	O
,	O
is	O
being	O
evaluated	O
for	O
the	O
development	O
of	O
vectored	O
human	O
vaccines	O
against	O
emerging	O
pathogens	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
that	O
antioxidants	O
reduced	O
pulmonary	B-DISO
inflammation	I-DISO
in	O
different	O
models	O
of	O
lung	O
damage	O
.	O

100	O
mg	O
/	O
kg	O
)	O
or	O
placebo	O
(	O
PBS	B-DISO
)	O
30	O
,	O
60	O
min	O
and	O
24	O
h	O
after	O
exposure	O
.	O

We	O
have	O
used	O
a	O
vaccinia	B-DISO
virus	O
-	O
based	O
reverse	O
genetic	O
system	O
to	O
produce	O
recombinant	O
viruses	O
encoding	O
ns2	B-DISO
proteins	O
with	O
single	O
-	O
amino	O
-	O
acid	O
substitutions	O
in	O
,	O
or	O
adjacent	O
to	O
,	O
these	O
conserved	O
motifs	O
,	O
namely	O
,	O
inf	O
-	O
ns2	B-DISO
H46A	O
,	O
inf	O
-	O
ns2	B-DISO
S48A	O
,	O
inf	O
-	O
ns2	B-DISO
-	O
S120A	O
,	O
and	O
inf	O
-	O
ns2	B-DISO
-	O
H126R	O
.	O

Interestingly	O
,	O
none	O
of	O
the	O
mutant	B-DISO
viruses	O
were	O
attenuated	O
for	O
replication	O
in	O
mouse	O
brain	O
following	O
intracranial	O
inoculation	O
.	O

TITLE	O
:	O
Demonstration	O
of	O
passive	O
protection	O
in	O
neonatal	O
calves	O
against	O
colibacillosis	B-DISO
following	O
immunization	O
of	O
pregnant	O
heifers	O
at	O
3	O
months	O
of	O
gestation	O
.	O

However	O
,	O
the	O
incidence	O
of	O
AE	O
in	O
CVD	B-DISO
-	O
IP	O
and	O
its	O
clinical	O
characteristics	O
remain	O
to	O
be	O
fully	O
determined	O
.	O

ABSTRACT	O
:	O
Pumpless	O
interventional	O
lung	O
assist	O
(	O
iLA	O
)	O
is	O
used	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
aimed	O
at	O
improving	O
extracorporeal	O
gas	O
exchange	O
with	O
a	O
membrane	O
integrated	O
in	O
a	O
passive	O
arteriovenous	B-DISO
shunt	I-DISO
.	O

We	O
report	O
the	O
effects	O
of	O
extracorporeal	O
CO	O
(	O
2	O
)	O
removal	O
by	O
means	O
of	O
a	O
novel	O
pumpless	O
extracorporeal	O
lung	O
assist	O
(	O
p	O
-	O
ECLA	O
)	O
on	O
tidal	O
volumes	O
,	O
airway	O
pressures	O
,	O
breathing	O
patterns	O
and	O
sedation	B-DISO
management	O
in	O
pneumonia	B-DISO
patients	O
during	O
late	O
-	O
phase	O
ARDS	B-DISO
.	O

Gas	O
exchange	O
,	O
tidal	O
volumes	O
,	O
airway	O
pressures	O
,	O
breathing	O
patterns	O
and	O
sedation	B-DISO
requirements	O
before	O
(	O
baseline	O
)	O
and	O
after	O
(	O
2	O
-	O
4	O
days	O
)	O
initiation	O
of	O
treatment	O
with	O
p	O
-	O
ECLA	O
were	O
analysed	O
.	O

The	O
participants	O
of	O
the	O
study	O
,	O
who	O
used	O
a	O
modified	O
SARS	B-DISO
Psychosocial	O
Research	O
Consortium	O
survey	O
,	O
were	O
drawn	O
from	O
Internet	O
panels	O
in	O
Finland	O
(	O
n	O
=	O
308	O
)	O
and	O
the	O
Netherlands	O
(	O
n	O
=	O
373	O
)	O
in	O
June	O
2003	O
.	O

While	O
the	O
epidemiology	O
and	O
pathogenesis	B-DISO
of	O
TCoV	O
have	O
been	O
extensively	O
studied	O
,	O
TCoV	O
remains	O
one	O
of	O
the	O
least	O
characterized	O
of	O
the	O
known	O
coronaviruses	O
.	O

Histological	O
examination	O
revealed	O
amphophilic	O
intranuclear	O
inclusion	O
bodies	O
in	O
the	O
superficial	O
epithelial	O
cells	O
of	O
the	O
trachea	B-DISO
and	O
bronchi	O
.	O

The	O
presence	O
of	O
EDS	B-DISO
virus	O
DNA	O
in	O
different	O
organs	O
of	O
the	O
naturally	O
and	O
experimentally	O
infected	O
goslings	O
was	O
detected	O
by	O
polymerase	O
chain	O
reaction	O
.	O

The	O
most	O
recent	O
suggests	O
a	O
beneficial	O
effect	O
on	O
proinflammatory	O
response	O
associated	O
with	O
ARDS	B-DISO
and	O
mechanical	O
ventilation	O
.	O

The	O
role	O
of	O
NMBAs	O
in	O
the	O
occurrence	O
of	O
ICU	O
-	O
acquired	O
neuromyopathies	B-DISO
and	O
lung	O
atelectasis	B-DISO
in	O
ARDS	B-DISO
patients	O
remains	O
largely	O
questioned	O
.	O

The	O
use	O
of	O
NMBAs	O
in	O
the	O
early	O
phase	O
of	O
ARDS	B-DISO
could	O
reinforce	O
the	O
beneficial	O
effects	O
of	O
a	O
lung	O
-	O
protective	O
ventilation	O
.	O

APC	B-DISO
-	O
treated	O
rabbits	O
showed	O
no	O
significant	O
difference	O
in	O
platelet	O
count	O
and	O
antithrombin	O
but	O
exhibited	O
less	O
D	O
-	O
dimer	O
production	O
than	O
did	O
the	O
controls	O
.	O

0	O
.	O
6	O
in	O
APC	B-DISO
group	O
,	O
P	O
<	O
0	O
.	O
01	O
).	O

ABSTRACT	O
:	O
Epidemiologic	O
studies	O
and	O
clinical	O
description	O
of	O
severe	O
Plasmodium	B-DISO
vivax	I-DISO
malaria	I-DISO
in	O
adults	O
living	O
in	O
malaria	B-DISO
-	O
endemic	O
areas	O
are	O
rare	O
and	O
more	O
attention	O
is	O
needed	O
to	O
understand	O
the	O
dynamics	O
and	O
its	O
interaction	O
with	O
the	O
immune	O
system	O
.	O

Complications	O
observed	O
were	O
hepatic	B-DISO
dysfunction	I-DISO
and	O
jaundice	B-DISO
in	O
23	O
(	O
57	O
.	O
5	O
%)	O
patients	O
,	O
renal	B-DISO
failure	I-DISO
in	O
18	O
(	O
45	O
%)	O
patients	O
,	O
severe	B-DISO
anemia	I-DISO
in	O
13	O
(	O
32	O
.	O
5	O
%)	O
patients	O
,	O
cerebral	B-DISO
malaria	I-DISO
in	O
5	O
patients	O
(	O
12	O
.	O
5	O
%),	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
4	O
patients	O
(	O
10	O
%),	O
shock	O
in	O
3	O
patients	O
(	O
7	O
.	O
5	O
%),	O
and	O
hypoglycemia	B-DISO
in	O
1	O
(	O
2	O
.	O
5	O
%)	O
patient	O
.	O

Using	O
the	O
social	O
amplification	B-DISO
of	O
risk	O
framework	O
,	O
we	O
show	O
that	O
,	O
while	O
other	O
countries	O
displayed	O
social	O
amplification	B-DISO
of	O
risk	O
,	O
Canada	O
experienced	O
a	O
social	O
attenuation	O
of	O
risk	O
.	O

Multivariate	O
analysis	O
showed	O
that	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
pulmonary	O
artery	O
catheter	O
placement	O
,	O
comorbidities	O
,	O
hospital	O
-	O
acquired	O
infection	B-DISO
,	O
APACHE	O
II	O
score	O
and	O
maximum	O
LOD	O
score	O
,	O
were	O
independent	O
risk	O
factors	O
for	O
hospital	O
mortality	O
.	O

In	O
conclusion	O
,	O
severe	B-DISO
sepsis	I-DISO
and	O
septic	B-DISO
shock	I-DISO
are	O
common	O
causes	O
of	O
ICU	O
admission	O
.	O

TITLE	O
:	O
[	O
Application	O
of	O
molecular	O
methods	O
in	O
the	O
diagnosis	O
and	O
epidemiological	O
study	O
of	O
viral	O
respiratory	B-DISO
infections	I-DISO
].	O

Aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
by	O
immunohistochemistry	O
(	O
IHC	O
)	O
the	O
tissue	O
tropism	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
strain	O
M41	O
in	O
experimentally	O
infected	O
chicken	O
embryos	O
.	O

Most	O
importantly	O
,	O
we	O
found	O
infection	B-DISO
of	O
vasculature	O
and	O
smooth	O
muscle	O
of	O
the	O
proventriculus	O
which	O
has	O
not	O
seen	O
before	O
with	O
IBV	O
strain	O
M41	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
newly	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
caused	O
by	O
a	O
novel	O
coronavirus	O
,	O
SARS	B-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

The	O
S	O
protein	O
plays	O
key	O
parts	O
in	O
the	O
induction	O
of	O
neutralizing	O
-	O
antibody	O
and	O
T	O
-	O
cell	O
responses	O
,	O
as	O
well	O
as	O
protective	O
immunity	O
,	O
during	O
infection	B-DISO
with	O
SARS	B-DISO
-	O
CoV	O
.	O
In	O
this	O
Review	O
,	O
we	O
highlight	O
recent	O
advances	O
in	O
the	O
development	O
of	O
vaccines	O
and	O
therapeutics	O
based	O
on	O
the	O
S	O
protein	O
.	O

This	O
article	O
discusses	O
the	O
history	O
,	O
epidemiology	O
,	O
and	O
pathogenesis	B-DISO
of	O
infection	B-DISO
;	O
control	O
of	O
infection	B-DISO
;	O
clinical	B-DISO
findings	I-DISO
;	O
diagnosis	O
;	O
and	O
,	O
where	O
applicable	O
,	O
treatment	O
of	O
the	O
agents	O
of	O
healthcare	O
-	O
associated	O
atypical	B-DISO
pneumonia	I-DISO
.	O

ABSTRACT	O
:	O
We	O
present	O
the	O
case	O
of	O
a	O
26	O
-	O
year	O
-	O
old	O
man	O
with	O
a	O
bland	O
medical	O
history	O
,	O
who	O
presented	O
to	O
the	O
general	O
practitioner	O
because	O
of	O
severe	O
cough	B-DISO
and	O
dyspnea	B-DISO
.	O

The	O
right	O
-	O
sided	O
pneumonectomy	O
revealed	O
an	O
intrapulmonary	O
tumor	B-DISO
with	O
cystic	O
and	O
solid	O
components	O
,	O
hemorrhage	B-DISO
,	O
and	O
necrosis	O
with	O
a	O
tumor	B-DISO
diameter	O
of	O
18cm	O
.	O

n	O
-	O
3	O
PUFA	O
targets	O
this	O
inflammatory	B-DISO
response	I-DISO
.	O

This	O
review	O
describes	O
the	O
specific	O
molecular	O
targets	O
for	O
diagnostics	O
and	O
therapeutics	O
of	O
viral	B-DISO
infection	I-DISO
.	O

Subsequent	O
management	O
included	O
a	O
thoracotomy	O
,	O
defunctioning	O
oesophagectomy	O
,	O
and	O
gastrostomy	B-DISO
with	O
ventilatory	O
and	O
inotropic	O
support	O
.	O

On	O
several	O
continents	O
in	O
2002	O
-	O
2003	O
,	O
the	O
highly	O
infectious	B-DISO
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
overwhelmed	O
health	O
care	O
systems	O
and	O
health	O
professionals	O
who	O
had	O
to	O
provide	O
care	O
in	O
situations	O
involving	O
high	O
personal	O
risk	O
and	O
stress	O
,	O
some	O
becoming	O
infected	O
and	O
dying	O
.	O

The	O
active	O
site	O
region	O
of	O
SARS	B-DISO
CoVMpro	O
is	O
divided	O
into	O
8	O
subsites	O
.	O

RESULTS	O
:	O
The	O
one	O
turn	O
alpha	O
-	O
helix	O
chain	O
(	O
residues	O
47	O
-	O
54	O
)	O
of	O
the	O
SARS	B-DISO
CoVMpro	O
was	O
directly	O
involved	O
in	O
the	O
induced	O
-	O
fit	B-DISO
model	O
of	O
the	O
enzyme	O
-	O
substrate	O
complex	O
.	O

Mutational	O
analysis	O
in	O
a	O
replicon	O
system	O
showed	O
that	O
the	O
N7	O
-	O
MTase	O
activity	O
was	O
important	O
for	O
SARS	B-DISO
virus	O
replication	O
/	O
transcription	O
and	O
can	O
thus	O
be	O
used	O
as	O
an	O
attractive	O
drug	O
target	O
to	O
develop	O
antivirals	O
for	O
control	O
of	O
coronaviruses	O
including	O
the	O
deadly	O
SARS	B-DISO
virus	O
.	O

dengue	B-DISO
,	O
Japanese	B-DISO
encephalitis	I-DISO
,	O
chikungunya	B-DISO
,	O
west	O
Nile	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
(	O
SARS	B-DISO
)	O
etc	O
.	O

Individuals	O
with	O
psychological	B-DISO
disorders	O
were	O
classified	O
on	O
the	O
basis	O
of	O
scores	O
on	O
the	O
30	O
-	O
item	O
General	O
Health	O
Questionnaire	O
during	O
the	O
recovery	O
period	O
.	O

The	O
one	O
patient	O
with	O
detection	O
of	O
hMPV	O
and	O
clinical	O
diagnosis	O
of	O
atypical	B-DISO
pneumonia	I-DISO
died	O
of	O
pulmonary	B-DISO
failure	I-DISO
.	O

RESULTS	O
:	O
P	O
.	O
jirovecii	O
was	O
detected	O
in	O
26	O
/	O
128	O
,	O
bacteria	O
in	O
10	O
,	O
fungi	O
in	O
four	O
,	O
Influenza	B-DISO
A	O
in	O
two	O
patients	O
.	O

The	O
present	O
article	O
aims	O
to	O
review	O
theoretical	O
models	O
and	O
concepts	O
underlying	O
current	O
empirical	O
research	O
on	O
pandemic	O
influenza	B-DISO
risk	O
perception	O
.	O

Here	O
we	O
used	O
this	O
method	O
to	O
monitor	O
the	O
spatial	O
and	O
temporal	O
progression	O
of	O
mouse	B-DISO
hepatitis	I-DISO
coronavirus	O
(	O
MHV	O
)	O
infection	B-DISO
in	O
mice	O
using	O
luciferase	O
-	O
expressing	O
viruses	O
.	O

To	O
examine	O
,	O
compare	O
and	O
contrast	O
the	O
functional	O
characteristics	O
of	O
hmAbs	O
with	O
the	O
potential	O
for	O
prophylaxis	O
and	O
treatment	O
of	O
diseases	O
caused	O
by	O
SARS	B-DISO
CoV	O
,	O
HeV	O
and	O
NiV	O
.	O
A	O
review	O
of	O
relevant	O
literature	O
.	O

We	O
propose	O
that	O
INO	O
may	O
decrease	O
the	O
inflammatory	B-DISO
response	I-DISO
in	O
patients	O
with	O
increased	B-DISO
intracranial	I-DISO
pressure	I-DISO
caused	O
by	O
traumatic	O
brain	O
injury	O
accompanied	O
by	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
thereby	O
contributing	O
to	O
improved	O
outcomes	O
.	O

Positively	O
interacting	O
proteins	O
were	O
further	O
tested	O
using	O
a	O
mammalian	O
cell	O
hybrid	O
system	O
and	O
co	O
-	O
immunoprecipitation	O
in	O
the	O
human	O
A549	O
cell	O
line	O
,	O
which	O
has	O
been	O
shown	O
to	O
support	O
SARS	B-DISO
coronavirus	O
replication	O
.	O

Out	O
of	O
the	O
seven	O
positive	O
clones	O
observed	O
by	O
yeast	O
two	O
-	O
hybrid	O
assay	O
,	O
only	O
the	O
Ddx5	O
(	O
Asp	O
-	O
Glu	O
-	O
Ala	O
-	O
Asp	O
box	O
polypeptide	O
5	O
)	O
protein	O
showed	O
specific	O
interaction	O
with	O
SARS	B-DISO
-	O
CoV	O
helicase	O
.	O

TITLE	O
:	O
ECMO	O
in	O
ARDS	B-DISO
:	O
a	O
long	O
-	O
term	O
follow	O
-	O
up	O
study	O
regarding	O
pulmonary	O
morphology	O
and	O
function	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
.	O

Most	O
patients	O
had	O
reduced	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
),	O
according	O
to	O
the	O
SGRQ	O
,	O
but	O
were	O
stating	O
less	O
respiratory	B-DISO
symptoms	I-DISO
than	O
conventionally	O
treated	O
ARDS	B-DISO
patients	O
in	O
previous	O
studies	O
.	O

Moreover	O
,	O
adult	O
SARS	B-DISO
infected	O
BALB	O
/	O
c	O
mice	O
showed	O
elevated	O
levels	O
of	O
IFN	O
-	O
gamma	O
while	O
IFN	O
-	O
gamma	O
levels	O
in	O
weanling	O
and	O
young	O
groups	O
had	O
no	O
obvious	O
association	O
with	O
lung	B-DISO
inflammation	I-DISO
.	O

Moreover	O
,	O
adult	O
SARS	B-DISO
infected	O
BALB	O
/	O
c	O
mice	O
showed	O
elevated	O
levels	O
of	O
IFN	O
-	O
gamma	O
while	O
IFN	O
-	O
gamma	O
levels	O
in	O
weanling	O
and	O
young	O
groups	O
had	O
no	O
obvious	O
association	O
with	O
lung	B-DISO
inflammation	I-DISO
.	O

MRI	O
showed	O
a	O
trend	O
of	O
reduction	O
in	O
bone	B-DISO
marrow	I-DISO
edema	I-DISO
and	O
the	O
size	O
of	O
the	O
lesion	O
,	O
but	O
no	O
changes	O
in	O
the	O
stage	O
of	O
the	O
lesion	O
.	O

TITLE	O
:	O
Sequence	O
and	O
phylogenetic	O
analysis	O
of	O
S1	O
,	O
S2	O
,	O
M	O
,	O
and	O
N	O
genes	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
isolates	O
from	O
Malaysia	O
.	O

TITLE	O
:	O
Fatal	O
outcome	O
after	O
insufficient	O
spine	O
fixation	O
for	O
pyogenic	O
thoracic	B-DISO
spondylodiscitis	B-DISO
:	O
an	O
imperative	O
for	O
360	O
degrees	O
fusion	O
of	O
the	O
infected	O
spine	O
.	O

An	O
emergent	O
MRI	O
revealed	O
a	O
kyphotic	O
wedge	O
compression	B-DISO
fracture	I-DISO
at	O
T7	O
/	O
T8	O
with	O
significant	O
spinal	B-DISO
cord	I-DISO
compression	I-DISO
,	O
paravertebral	O
and	O
epidural	B-DISO
abscess	I-DISO
,	O
and	O
signs	O
of	O
myelopathy	B-DISO
.	O

She	O
underwent	O
antero	O
-	O
posterior	O
revision	O
fixation	O
with	O
hardware	O
removal	O
,	O
correction	O
of	O
kyphotic	O
malunion	O
,	O
evacuation	O
of	O
a	O
recurrent	O
epidural	B-DISO
abscess	I-DISO
,	O
decompression	O
of	O
the	O
spinal	O
canal	O
,	O
and	O
360	O
degrees	O
fusion	O
from	O
T2	O
-	O
T11	O
.	O

To	O
assess	O
potential	O
risks	O
from	O
this	O
pathway	O
,	O
there	O
is	O
a	O
need	O
for	O
surrogates	O
for	O
SARS	B-DISO
coronavirus	O
to	O
provide	O
representative	O
data	O
on	O
viral	O
survival	O
in	O
contaminated	O
water	O
.	O

Coronaviruses	O
can	O
remain	O
infectious	B-DISO
for	O
long	O
periods	O
in	O
water	O
and	O
pasteurized	O
settled	O
sewage	O
,	O
suggesting	O
contaminated	O
water	O
is	O
a	O
potential	O
vehicle	O
for	O
human	O
exposure	O
if	O
aerosols	O
are	O
generated	O
.	O

Life	O
-	O
threatening	O
and	O
daily	O
-	O
life	B-DISO
stress	I-DISO
show	O
two	O
different	O
patterns	O
of	O
influence	O
on	O
mental	O
health	O
.	O

ABSTRACT	O
:	O
Differential	O
scanning	O
calorimetry	O
,	O
circular	O
dichroism	O
spectroscopy	O
,	O
nuclear	O
magnetic	O
resonance	O
spectroscopy	O
,	O
and	O
numerical	O
simulations	O
were	O
used	O
to	O
study	O
the	O
thermostability	O
of	O
the	O
N	O
-	O
terminal	O
RNA	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
nucleocapsid	O
protein	O
.	O

Those	O
results	O
show	O
that	O
liver	O
injury	O
after	O
viral	B-DISO
infection	I-DISO
may	O
lead	O
to	O
the	O
spreading	O
of	O
the	O
immune	O
response	O
and	O
to	O
an	O
increase	O
of	O
serum	O
IgG	O
,	O
suggesting	O
that	O
the	O
procedure	O
used	O
herein	O
could	O
simulate	O
the	O
onset	O
of	O
autoimmune	B-DISO
hepatitis	I-DISO
.	O

A	O
recombinant	O
adenovirus	B-DISO
encoding	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
nucleocapsid	O
protein	O
(	O
rAd	O
-	O
N	O
)	O
was	O
constructed	O
.	O

When	O
different	O
forms	O
of	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
spike	O
protein	O
-	O
based	O
vaccines	O
for	O
generation	O
of	O
a	O
neutralising	O
antibody	O
response	O
to	O
SARS	B-DISO
-	O
CoV	O
were	O
injected	O
into	O
a	O
mouse	O
model	O
,	O
all	O
the	O
mice	O
immunised	O
with	O
intramuscular	O
tPA	O
-	O
optimised	O
800	O
DNA	O
vaccine	O
boosted	O
with	O
intraperitoneal	O
recombinant	O
spike	O
polypeptide	O
generated	O
by	O
Escherichia	O
coli	O
and	O
intramuscular	O
CTLA4Hinge	O
SARS800	O
DNA	O
vaccine	O
boosted	O
with	O
intraperitoneal	O
S	O
-	O
peptide	O
had	O
neutralising	O
antibody	O
titres	O
of	O
>	O
1	O
:	O
1280	O
.	O
2	O
.	O

TITLE	O
:	O
Association	O
of	O
cytokine	O
and	O
chemokine	O
gene	O
polymorphisms	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
whether	O
the	O
phase	O
of	O
sepsis	B-DISO
is	O
related	O
to	O
the	O
effects	O
of	O
PMX	O
-	O
DHP	O
treatment	O
on	O
oxygenation	O
in	O
patients	O
with	O
ALI	O
and	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Differential	O
stepwise	O
evolution	O
of	O
SARS	B-DISO
coronavirus	O
functional	O
proteins	O
in	O
different	O
host	O
species	O
.	O

ABSTRACT	O
:	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
was	O
identified	O
as	O
the	O
etiological	O
agent	O
of	O
SARS	B-DISO
,	O
and	O
extensive	O
investigations	O
indicated	O
that	O
it	O
originated	O
from	O
an	O
animal	O
source	O
(	O
probably	O
bats	O
)	O
and	O
was	O
recently	O
introduced	O
into	O
the	O
human	O
population	O
via	O
wildlife	O
animals	O
from	O
wet	O
markets	O
in	O
southern	O
China	O
.	O

These	O
results	O
support	O
the	O
hypothesis	O
that	O
SARS	B-DISO
-	O
CoV	O
originated	O
from	O
bats	O
and	O
that	O
the	O
spill	O
over	O
into	O
civets	O
and	O
humans	O
were	O
more	O
recent	O
events	O
.	O

TITLE	O
:	O
Critical	B-DISO
illness	I-DISO
polyneuromyopathy	O
in	O
a	O
child	O
with	O
severe	O
demyelinating	O
myelitis	B-DISO
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
child	O
presenting	O
with	O
severe	O
demyelinating	O
myelitis	B-DISO
complicated	O
with	O
critical	B-DISO
illness	I-DISO
polyneuropathy	I-DISO
.	O

This	O
case	O
highlights	O
the	O
possible	O
occurrence	O
of	O
critical	B-DISO
illness	I-DISO
polyneuromyopathy	O
when	O
treatment	O
with	O
corticosteroids	O
are	O
used	O
in	O
patients	O
with	O
acute	O
demyelinating	O
myelitis	B-DISO
.	O

The	O
host	O
mRNA	O
degradation	O
and	O
translational	O
suppression	B-DISO
activities	O
of	O
nsp1	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
Rm1	O
nsp1	O
were	O
similar	O
and	O
stronger	O
than	O
the	O
activities	O
of	O
the	O
nsp1	O
proteins	O
of	O
133	O
and	O
HKU9	O
-	O
1	O
.	O

We	O
examined	O
transfers	O
of	O
critically	B-DISO
ill	I-DISO
Medicare	O
patients	O
in	O
Connecticut	O
in	O
2005	O
as	O
a	O
model	O
system	O
.	O

In	O
addition	O
to	O
the	O
HIV	B-DISO
pandemic	O
,	O
the	O
smaller	O
epidemic	O
outbreaks	O
of	O
Legionnaire	B-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
,	O
hantavirus	B-DISO
pulmonary	I-DISO
syndrome	I-DISO
,	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
among	O
many	O
others	O
,	O
points	O
out	O
the	O
potential	O
risk	O
associated	O
with	O
a	O
lack	O
of	O
preplanning	O
and	O
preparedness	O
.	O

Experiences	O
of	O
European	O
Chinese	O
communities	O
suggest	O
that	O
practical	O
and	O
timely	O
information	O
,	O
and	O
consistent	O
implementation	O
of	O
protective	O
measures	O
from	O
central	O
governments	O
are	O
essential	O
to	O
protect	O
vulnerable	O
populations	O
in	O
unaffected	O
regions	O
from	O
unnecessary	O
alarm	O
and	O
harm	O
during	O
outbreaks	O
of	O
emerging	O
infections	B-DISO
.	O

The	O
symptoms	O
of	O
ARDS	B-DISO
also	O
subsided	O
and	O
ALI	O
did	O
not	O
occur	O
.	O

TITLE	O
:	O
Helminthic	O
eosinophilic	B-DISO
meningitis	I-DISO
:	O
emerging	O
zoonotic	O
diseases	O
in	O
the	O
South	O
.	O

Baylisascariasis	O
,	O
a	O
raccoon	O
zoonosis	B-DISO
,	O
caused	O
by	O
the	O
raccoon	O
roundworm	B-DISO
,	O
Baylisascaris	O
procyonis	O
,	O
has	O
extended	O
its	O
US	O
distribution	O
range	O
from	O
suburban	O
neighborhoods	O
in	O
the	O
northern	O
US	O
to	O
the	O
Southeast	O
and	O
West	O
Coast	O
since	O
the	O
1980s	O
.	O

Disruption	O
of	O
actin	O
filaments	O
with	O
cell	O
-	O
permeable	O
agent	O
cytochalasin	O
D	O
at	O
early	O
stages	O
of	O
the	O
infection	B-DISO
cycle	O
led	O
to	O
the	O
detection	O
of	O
viral	O
protein	O
synthesis	O
in	O
infected	O
cells	O
but	O
not	O
release	O
of	O
virus	O
particles	O
to	O
the	O
cultured	O
media	O
.	O

We	O
modeled	O
a	O
generic	O
disease	O
caused	O
by	O
a	O
pathogen	O
apparently	O
transmitted	B-DISO
by	O
close	O
interpersonal	O
contact	O
,	O
but	O
about	O
which	O
little	O
else	O
is	O
known	O
.	O

In	O
our	O
model	O
,	O
people	O
may	O
be	O
infectious	B-DISO
while	O
incubating	O
or	O
during	O
their	O
prodrome	B-DISO
or	O
acute	O
illness	O
.	O

RESULTS	O
:	O
Stage	O
-	O
specific	O
infection	B-DISO
rate	O
estimates	O
from	O
cases	O
hospitalized	O
before	O
quarantine	O
began	O
exceed	O
those	O
from	O
the	O
entire	O
outbreak	O
,	O
but	O
are	O
qualitatively	O
similar	O
:	O
infectiousness	O
was	O
negligible	O
until	O
symptom	B-DISO
onset	O
,	O
and	O
increased	O
10	O
-	O
fold	O
from	O
prodrome	B-DISO
to	O
acute	O
illness	O
.	O

ABSTRACT	O
:	O
We	O
evaluated	O
the	O
efficacy	O
of	O
three	O
SARS	B-DISO
vaccine	O
candidates	O
in	O
a	O
murine	O
SARS	B-DISO
model	O
utilizing	O
low	O
-	O
virulence	O
Pp	O
and	O
SARS	B-DISO
-	O
CoV	O
coinfection	B-DISO
.	O

We	O
found	O
that	O
while	O
both	O
lineages	O
were	O
permissive	O
to	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
,	O
causing	O
elevated	O
secretion	O
of	O
many	O
inflammatory	O
mediators	O
within	O
the	O
lungs	O
and	O
brains	O
,	O
viral	B-DISO
infection	I-DISO
appeared	O
to	O
be	O
more	O
intense	O
in	O
AC70	O
than	O
in	O
AC22	O
mice	O
,	O
especially	O
in	O
the	O
brain	O
.	O

TITLE	O
:	O
Recombinant	O
Ov	O
-	O
ASP	O
-	O
1	O
,	O
a	O
Th1	O
-	O
biased	O
protein	O
adjuvant	O
derived	O
from	O
the	O
helminth	O
Onchocerca	O
volvulus	B-DISO
,	O
can	O
directly	O
bind	O
and	O
activate	O
antigen	O
-	O
presenting	O
cells	O
.	O

TITLE	O
:	O
Institutional	O
trust	O
as	O
a	O
determinant	O
of	O
anxiety	O
during	O
the	O
SARS	B-DISO
crisis	O
in	O
Hong	O
Kong	O
.	O

The	O
outcome	O
measures	O
of	O
interest	O
included	O
mortality	O
and	O
adverse	B-DISO
effects	I-DISO
of	O
high	O
FFP	O
:	O
PRBC	O
ratios	O
.	O

The	O
results	O
indicate	O
that	O
the	O
DVE	O
infection	B-DISO
can	O
stimulate	O
both	O
IgA	O
-	O
dominated	O
antibody	O
immune	O
responses	O
in	O
the	O
intestinal	O
tract	O
,	O
and	O
IgG	O
-	O
dominated	O
antibody	O
systemic	O
immunity	O
in	O
the	O
serum	O
of	O
ducklings	O
orally	O
inoculated	O
with	O
virulent	O
DEV	O
.	O

Our	O
case	O
indicated	O
that	O
PMX	O
might	O
be	O
an	O
effective	O
supportive	O
therapy	O
in	O
severe	O
cases	O
of	O
Lemierre	B-DISO
'	I-DISO
s	I-DISO
syndrome	I-DISO
with	O
ARDS	B-DISO
that	O
possessed	B-DISO
no	O
indication	O
of	O
surgical	O
interventions	O
.	O

A	O
remaining	O
contentious	O
question	O
is	O
whether	O
there	O
is	O
a	O
need	O
for	O
new	O
federal	O
emergency	B-DISO
public	O
health	O
powers	O
.	O

The	O
legislation	O
should	O
also	O
consider	O
providing	O
the	O
federal	O
government	O
with	O
the	O
authority	O
to	O
devote	O
the	O
nation	O
'	O
s	O
resources	O
to	O
the	O
management	O
of	O
an	O
emergency	B-DISO
at	O
its	O
earliest	O
stages	O
.	O

We	O
report	O
this	O
outbreak	O
in	O
a	O
mental	O
hospital	O
to	O
alert	O
the	O
medical	O
profession	O
that	O
this	O
unusual	O
infection	B-DISO
of	O
hMPV	O
can	O
occur	O
as	O
an	O
outbreak	O
in	O
an	O
adult	O
setting	O
and	O
is	O
an	O
occupational	O
hazard	O
for	O
healthcare	O
personnel	O
.	O

ABSTRACT	O
:	O
Human	O
papillomavirus	O
(	O
HPV	O
)	O
causes	O
cervical	B-DISO
cancer	I-DISO
and	O
is	O
strongly	O
associated	O
with	O
other	O
anogenital	O
cancers	B-DISO
.	O

TITLE	O
:	O
[	O
Preterm	O
and	O
term	O
infants	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
):	O
what	O
is	O
the	O
role	O
of	O
surfactant	O
substitution	O
?].	O

ABSTRACT	O
:	O
The	O
coronavirus	O
spike	O
protein	O
(	O
S	O
)	O
plays	O
a	O
key	O
role	O
in	O
the	O
early	O
steps	O
of	O
viral	B-DISO
infection	I-DISO
,	O
with	O
the	O
S1	O
domain	O
responsible	O
for	O
receptor	O
binding	O
and	O
the	O
S2	O
domain	O
mediating	O
membrane	O
fusion	O
.	O

Similar	O
to	O
other	O
N	O
-	O
glycosylated	O
proteins	O
,	O
the	O
glycosylation	O
of	O
SARS	B-DISO
-	O
CoV	O
E	O
protein	O
occurred	O
co	O
-	O
translationally	O
in	O
the	O
presence	O
of	O
microsomes	O
.	O

TITLE	O
:	O
Molecular	O
characterization	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
strains	O
from	O
outbreaks	O
in	O
Argentina	O
(	O
2001	O
-	O
2008	O
).	O

ABSTRACT	O
:	O
The	O
course	O
of	O
turkey	O
coronavirus	O
(	O
TCoV	O
)	O
infection	B-DISO
in	O
young	O
turkey	O
poults	O
was	O
examined	O
using	O
a	O
field	O
isolate	O
(	O
TCoV	O
-	O
MG10	O
)	O
from	O
a	O
diarrhoeal	B-DISO
disease	I-DISO
outbreak	O
on	O
a	O
commercial	O
turkey	O
farm	O
in	O
Ontario	O
,	O
Canada	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
responsible	O
for	O
host	O
cell	O
attachment	O
and	O
fusion	O
of	O
the	O
viral	O
and	O
host	O
cell	O
membranes	O
.	O

ABSTRACT	O
:	O
Clinical	O
use	O
of	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
(	O
BMMSCs	O
)	O
holds	O
great	O
promise	O
for	O
regenerative	O
medicine	O
in	O
intractable	O
lung	B-DISO
diseases	I-DISO
,	O
such	O
as	O
lung	B-DISO
fibrosis	I-DISO
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

This	O
study	O
was	O
to	O
determine	O
whether	O
the	O
damage	O
was	O
correlated	O
with	O
expression	O
of	O
the	O
SARS	B-DISO
coronavirus	O
receptor	O
,	O
angiotensin	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
in	O
different	O
organs	O
,	O
especially	O
in	O
the	O
endocrine	O
tissues	O
of	O
the	O
pancreas	O
,	O
and	O
to	O
elucidate	O
the	O
pathogenesis	B-DISO
of	O
glucose	B-DISO
intolerance	I-DISO
in	O
SARS	B-DISO
patients	O
.	O

Infectious	B-DISO
bronchitis	B-DISO
virus	O
nucleic	O
acid	O
was	O
detected	O
in	O
16	O
broiler	O
(	O
64	O
%),	O
8	O
layer	O
(	O
53	O
%),	O
and	O
6	O
broiler	O
breeder	O
(	O
54	O
.	O
54	O
%)	O
flocks	O
affected	O
with	O
respiratory	B-DISO
disease	I-DISO
.	O

IL	O
-	O
12p40	O
mRNA	O
rapidly	O
increases	O
after	O
neurotropic	O
coronavirus	B-DISO
infection	I-DISO
.	O

To	O
investigate	O
the	O
seroepidemiology	O
of	O
HKU1	O
infections	B-DISO
in	O
our	O
local	O
population	O
.	O

Neutrophil	O
adhesion	B-DISO
to	O
,	O
surface	O
expression	O
of	O
ICAM	O
-	O
1	O
and	O
VCAM	O
-	O
1	O
on	O
,	O
and	O
release	O
of	O
IL	O
-	O
8	O
and	O
G	O
-	O
CSF	O
from	O
A549	O
cells	O
were	O
measured	O
by	O
ELISA	O
after	O
stimulation	O
with	O
IL	O
-	O
1	O
beta	O
or	O
TNFalpha	O
.	O

After	O
treatment	O
of	O
A549	O
cells	O
with	O
EtP	O
,	O
a	O
substantial	O
reduction	O
in	O
the	O
cytokine	O
-	O
induced	O
adhesion	B-DISO
of	O
neutrophils	O
to	O
monolayers	O
was	O
noted	O
,	O
whereas	O
sodium	O
pyruvate	O
(	O
NaP	O
)	O
conferred	O
no	O
reduction	O
.	O

These	O
are	O
reactions	O
of	O
significance	O
for	O
early	O
inflammatory	B-DISO
responses	I-DISO
in	O
the	O
lung	O
,	O
suggesting	O
a	O
role	O
for	O
EtP	O
as	O
a	O
treatment	O
for	O
acute	O
pulmonary	O
conditions	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
reported	O
that	O
replacing	O
HIV	B-DISO
-	O
1	O
nucleocapsid	O
(	O
NC	O
)	O
domain	O
with	O
SARS	B-DISO
-	O
CoV	O
nucleocapsid	O
(	O
N	O
)	O
residues	O
2	O
-	O
213	O
,	O
215	O
-	O
421	O
,	O
or	O
234	O
-	O
421	O
results	O
in	O
efficient	O
virus	O
-	O
like	O
particle	O
(	O
VLP	O
)	O
production	O
at	O
a	O
level	O
comparable	O
to	O
that	O
of	O
wild	O
-	O
type	O
HIV	B-DISO
-	O
1	O
.	O

PaO2	O
/	O
FiO2	O
ratio	O
improved	O
but	O
X	O
-	O
ray	O
findings	O
showed	O
no	O
improvement	O
and	O
a	O
blood	O
test	O
revealed	O
pancytopenia	B-DISO
.	O

Bone	O
marrow	O
biopsy	O
revealed	O
necrotizing	O
epithelioid	B-DISO
granuloma	I-DISO
and	O
acid	O
-	O
fast	O
bacilli	O
.	O

TITLE	O
:	O
[	O
Intracardiac	O
hemodynamic	O
changes	O
in	O
the	O
newborns	O
with	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
].	O

Using	O
current	O
definitions	O
,	O
the	O
incidence	O
of	O
the	O
clinical	O
manifestation	O
,	O
abdominal	B-DISO
compartment	I-DISO
syndrome	I-DISO
(	O
ACS	O
),	O
has	O
been	O
reported	O
as	O
27	O
%	O
in	O
the	O
largest	O
study	O
so	O
far	O
.	O

The	O
onset	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
the	O
AP	O
patients	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
the	O
level	O
of	O
anti	O
-	O
inflammatory	O
cytokines	O
,	O
especially	O
IL	O
-	O
10	O
.	O

TITLE	O
:	O
Bovine	O
coronavirus	O
nonstructural	O
protein	O
1	O
(	O
p28	O
)	O
is	O
an	O
RNA	O
binding	O
protein	O
that	O
binds	O
terminal	O
genomic	O
cis	B-DISO
-	O
replication	O
elements	O
.	O

ABSTRACT	O
:	O
Nonstructural	O
protein	O
1	O
(	O
nsp1	O
),	O
a	O
28	O
-	O
kDa	O
protein	O
in	O
the	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
and	O
closely	O
related	O
mouse	B-DISO
hepatitis	I-DISO
coronavirus	O
,	O
is	O
the	O
first	O
protein	O
cleaved	O
from	O
the	O
open	O
reading	O
frame	O
1	O
(	O
ORF	O
1	O
)	O
polyprotein	O
product	O
of	O
genome	O
translation	O
.	O

TITLE	O
:	O
[	O
Scleroedema	B-DISO
adultorum	O
Buschke	O
in	O
a	O
diabetic	O
subject	O
:	O
intravenous	O
immunoglobulin	O
therapy	O
].	O

We	O
report	O
the	O
case	O
of	O
a	O
type	O
2	O
diabetic	O
patient	O
presenting	O
with	O
progressive	O
,	O
oedematous	B-DISO
timbering	O
of	O
the	O
trunk	O
associated	O
with	O
impaired	B-DISO
mobility	O
,	O
dysphagia	B-DISO
and	O
restrictive	O
respiratory	O
syndrome	B-DISO
.	O

Cutaneous	O
rigidity	B-DISO
improved	O
steadily	O
until	O
the	O
end	O
of	O
treatment	O
(	O
eight	O
cycles	O
).	O

ABSTRACT	O
:	O
The	O
3	O
'-	O
one	O
-	O
third	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
genome	O
contains	O
genes	O
for	O
four	O
essential	O
structural	O
proteins	O
and	O
eight	O
virus	O
-	O
specific	O
genes	O
.	O

These	O
results	O
will	O
be	O
helpful	O
for	O
further	O
studies	O
to	O
reveal	O
the	O
biological	O
functions	O
and	O
translation	O
regulatory	O
mechanisms	O
of	O
sgRNAs	O
in	O
the	O
coronavirus	O
life	O
cycle	O
and	O
pathogenesis	B-DISO
.	O

Seven	O
of	O
the	O
selected	O
intrabodies	O
tested	O
do	O
not	O
perturb	O
cellular	O
function	O
when	O
expressed	O
singly	O
in	O
vivo	O
and	O
inhibit	O
virus	O
replication	O
from	O
11	O
-	O
to	O
5900	O
-	O
fold	O
when	O
expressed	O
in	O
cells	O
prior	O
to	O
infection	B-DISO
.	O

TITLE	O
:	O
The	O
SR	O
-	O
rich	O
motif	O
in	O
SARS	B-DISO
-	O
CoV	O
nucleocapsid	O
protein	O
is	O
important	O
for	O
virus	O
replication	O
.	O

The	O
mutated	O
infectious	B-DISO
clone	O
showed	O
reduced	O
level	O
of	O
genome	O
transcription	O
and	O
significantly	O
reduced	O
levels	O
of	O
the	O
infectious	B-DISO
virions	O
.	O

Both	O
a	O
rapid	O
viral	O
culture	O
with	O
direct	O
fluorescence	O
antibody	O
(	O
DFA	O
)	O
staining	O
and	O
a	O
PCR	O
-	O
based	O
assay	O
(	O
MultiCode	O
-	O
PLx	O
Respiratory	O
Virus	O
Panel	O
)	O
were	O
performed	O
on	O
patients	O
with	O
hematologic	B-DISO
malignancies	I-DISO
,	O
who	O
underwent	O
collection	O
of	O
a	O
nasopharyngeal	O
swab	O
or	O
bronchoalveolar	O
lavage	O
from	O
October	O
2006	O
to	O
April	O
2007	O
.	O

The	O
data	O
of	O
the	O
patient	O
infected	O
by	O
the	O
influenza	B-DISO
A	O
(	O
H5N1	B-DISO
)	O
admitted	O
to	O
People	O
'	O
s	O
Hospital	O
of	O
Guizhou	O
Province	O
on	O
January	O
15	O
,	O
2009	O
,	O
were	O
analyzed	O
and	O
summarized	O
.	O

RESULTS	O
:	O
The	O
patient	O
,	O
a	O
29	O
-	O
year	O
-	O
old	O
man	O
,	O
had	O
been	O
healthy	O
in	O
the	O
past	O
,	O
but	O
had	O
exposed	O
to	O
the	O
environment	O
of	O
bird	B-DISO
flu	I-DISO
before	O
illness	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
1	O
-	O
year	O
-	O
old	O
child	O
born	O
with	O
agenesis	B-DISO
of	O
the	O
right	O
lung	O
who	O
sustained	O
an	O
episode	O
of	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
related	O
to	O
a	O
postpneumonectomy	O
-	O
like	O
syndrome	B-DISO
,	O
with	O
severe	O
mediastinal	O
shift	O
and	O
subsequent	O
stretching	O
and	O
stenosis	B-DISO
of	O
the	O
left	O
main	O
bronchus	O
.	O

The	O
insertion	O
of	O
an	O
expandable	O
prosthesis	O
in	O
the	O
right	O
empty	O
pleural	O
space	O
markedly	O
improved	O
the	O
patient	O
'	O
s	O
clinical	O
condition	B-DISO
.	O

TITLE	O
:	O
Target	O
-	O
dependent	O
B7	O
-	O
H1	O
regulation	O
contributes	O
to	O
clearance	O
of	O
central	B-DISO
nervous	I-DISO
system	I-DISO
infection	I-DISO
and	O
dampens	O
morbidity	O
.	O

Oligodendroglia	O
and	O
microglia	O
up	O
-	O
regulated	O
B7	O
-	O
H1	O
following	O
infection	B-DISO
;	O
however	O
,	O
although	O
B7	O
-	O
H1	O
expression	O
on	O
oligodendroglia	O
was	O
prominent	O
and	O
sustained	O
,	O
it	O
was	O
significantly	O
reduced	O
and	O
transient	O
on	O
microglia	O
.	O

ABSTRACT	O
:	O
Mediastinal	O
mass	B-DISO
syndrome	I-DISO
remains	O
an	O
anaesthetic	O
challenge	O
that	O
cannot	O
be	O
underestimated	O
.	O

Depending	O
on	O
the	O
localization	O
and	O
the	O
size	O
of	O
the	O
mediastinal	O
tumour	B-DISO
,	O
the	O
clinical	O
presentation	O
is	O
variable	O
ranging	O
from	O
a	O
complete	O
lack	O
of	O
symptoms	O
to	O
severe	O
cardiorespiratory	O
problems	O
.	O

Proper	O
anaesthetic	O
management	O
of	O
patients	O
with	O
mediastinal	O
mass	B-DISO
syndrome	I-DISO
begins	O
with	O
an	O
assessment	O
of	O
the	O
preoperative	O
status	O
,	O
directed	O
foremost	O
at	O
establishing	O
the	O
localization	O
of	O
the	O
tumour	B-DISO
and	O
on	O
the	O
basis	O
of	O
the	O
clinical	O
and	O
radiological	O
findings	O
,	O
discerning	O
whether	O
any	O
vital	O
mediastinal	O
structures	O
are	O
affected	O
.	O

Tumour	B-DISO
compression	I-DISO
on	O
the	O
airways	O
or	O
the	O
great	O
vessels	O
may	O
create	O
a	O
critical	O
respiratory	O
and	O
/	O
or	O
haemodynamic	O
situation	O
,	O
and	O
therefore	O
the	O
standard	O
of	O
intraoperative	O
management	O
includes	O
induction	O
of	O
anaesthesia	B-DISO
in	O
the	O
operating	O
theatre	O
on	O
an	O
adjustable	O
surgical	O
table	O
,	O
the	O
use	O
of	O
short	O
-	O
acting	O
anaesthetics	O
,	O
avoidance	O
of	O
muscle	O
relaxants	O
and	O
maintenance	O
of	O
spontaneous	O
respiration	O
.	O

TITLE	O
:	O
"["""	O
Liquid	O
ecstasy	O
""":"	O
gamma	O
-	O
butyrolactone	O
withdrawal	B-DISO
delirium	B-DISO
with	O
rhabdomyolysis	B-DISO
and	O
dialysis	O
dependent	O
renal	B-DISO
failure	I-DISO
].	O

Primary	O
care	O
physicians	O
treating	O
patients	O
with	O
a	O
coma	B-DISO
of	O
unknown	O
cause	O
always	O
have	O
to	O
think	O
of	O
the	O
possibility	O
of	O
GBL	O
withdrawal	B-DISO
.	O

Most	O
systemic	O
diseases	O
that	O
impact	O
on	O
the	O
nervous	B-DISO
system	O
result	O
in	O
multifocal	O
neurological	O
signs	O
;	O
however	O
,	O
isolated	O
deficits	O
can	O
also	O
be	O
observed	O
.	O

Talpha	O
(	O
1	O
)	O
is	O
approved	O
in	O
over	O
35	O
countries	O
for	O
the	O
treatment	O
of	O
hepatitis	B-DISO
B	I-DISO
and	O
C	O
,	O
and	O
as	O
an	O
immune	O
stimulant	O
and	O
adjuvant	O
.	O

Talpha	O
(	O
1	O
)	O
is	O
also	O
in	O
late	O
-	O
stage	O
clinical	O
testing	O
in	O
the	O
United	O
States	O
and	O
Europe	O
for	O
hepatitis	B-DISO
C	I-DISO
and	O
stage	B-DISO
IV	I-DISO
melanoma	I-DISO
.	O

Novel	O
applications	O
and	O
other	O
recently	O
completed	O
trials	O
point	O
to	O
much	O
broader	O
clinical	O
applications	O
of	O
Talpha	O
(	O
1	O
)	O
in	O
the	O
treatment	O
of	O
life	O
-	O
threatening	O
and	O
chronic	B-DISO
diseases	I-DISO
,	O
and	O
are	O
the	O
subject	O
of	O
this	O
review	O
.	O

This	O
outcome	O
suggests	O
that	O
drotrecogin	O
alfa	O
(	O
activated	O
)	O
may	O
be	O
useful	O
therapy	O
for	O
transplant	O
recipients	O
who	O
develop	O
severe	B-DISO
sepsis	I-DISO
or	O
septic	B-DISO
shock	I-DISO
secondary	O
to	O
potentially	O
lethal	O
opportunistic	B-DISO
infections	I-DISO
.	O

In	O
a	O
systematic	O
review	O
of	O
the	O
literature	O
on	O
nine	O
respiratory	O
viral	B-DISO
infections	I-DISO
of	O
public	O
-	O
health	O
importance	O
,	O
we	O
identified	O
436	O
articles	O
with	O
statements	O
of	O
incubation	O
period	O
and	O
38	O
with	O
data	O
for	O
pooled	O
analysis	O
.	O

ABSTRACT	O
:	O
A	O
cohort	O
of	O
67	O
confirmed	O
SARS	B-DISO
patients	O
were	O
prospectively	O
followed	O
for	O
16	O
months	O
and	O
were	O
compared	O
with	O
a	O
control	O
population	O
.	O

Protein	O
sequence	O
analysis	O
reveals	O
that	O
3a	O
possesses	B-DISO
three	O
major	O
protein	O
signatures	O
,	O
the	O
cysteine	O
-	O
rich	O
,	O
Yxx	O
phi	O
and	O
diacidic	O
domains	O
.	O

It	O
was	O
previously	O
reported	O
that	O
3a	O
possesses	B-DISO
potassium	O
ion	O
channel	O
activity	O
.	O

Various	O
pre	O
-	O
and	O
postnatal	O
factors	O
,	O
such	O
as	O
exposure	O
to	O
chorioamnionitis	B-DISO
,	O
pneumonia	B-DISO
,	O
sepsis	B-DISO
and	O
asphyxia	B-DISO
,	O
induce	O
an	O
injurious	O
inflammatory	B-DISO
response	I-DISO
in	O
the	O
lungs	O
of	O
preterm	O
infants	O
,	O
which	O
may	O
subsequently	O
affect	O
surfactant	O
function	O
,	O
synthesis	O
and	O
alveolar	O
stability	O
.	O

ABSTRACT	O
:	O
Viruses	O
such	O
as	O
hepatitis	B-DISO
C	I-DISO
and	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
encode	O
proteins	O
that	O
are	O
distributed	O
between	O
mitochondria	O
and	O
the	O
nucleus	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
factors	O
that	O
control	O
partitioning	O
between	O
these	O
sites	O
.	O

One	O
case	O
-	O
control	O
study	O
has	O
reported	O
an	O
association	O
between	O
susceptibility	O
to	O
SARS	B-DISO
and	O
mannan	O
-	O
binding	O
lectin	O
(	O
MBL	O
)	O
in	O
China	O
.	O

It	O
provides	O
a	O
broadly	O
targeted	O
and	O
rational	O
single	O
tube	O
real	O
-	O
time	O
reverse	O
transcription	O
PCR	O
"("""	O
NQPCR	O
""")"	O
for	O
the	O
generic	O
detection	O
and	O
discovery	O
of	O
CoV	O
.	O
Degenerate	B-DISO
primers	O
,	O
previously	O
published	O
,	O
and	O
the	O
new	O
probes	O
,	O
were	O
from	O
a	O
conserved	O
stretch	O
of	O
open	O
reading	O
frame	O
1b	O
,	O
encoding	O
the	O
replicase	O
.	O

TITLE	O
:	O
Development	O
of	O
animal	O
models	O
for	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Clinical	O
improvements	O
were	O
realized	O
in	O
the	O
subgroups	O
of	O
patients	O
with	O
shock	O
and	O
ALI	O
/	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Towards	O
construction	O
of	O
viral	O
vectors	O
based	O
on	O
avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
for	O
gene	O
delivery	O
and	O
vaccine	O
development	O
.	O

Here	O
we	O
discovered	O
that	O
two	O
adjacent	O
mutations	O
(	O
Ser139_Ala	O
and	O
Phe140_Ala	O
)	O
on	O
the	O
dimer	O
interface	O
resulted	O
in	O
completely	O
different	O
crystal	O
structures	O
of	O
the	O
enzyme	O
,	O
demonstrating	O
the	O
distinct	O
roles	O
of	O
these	O
two	O
residues	O
in	O
maintaining	O
the	O
active	O
conformation	O
of	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
).	O

TITLE	O
:	O
Molecular	O
screening	O
and	O
risk	O
factors	O
of	O
enterotoxigenic	O
Escherichia	O
coli	O
and	O
Salmonella	B-DISO
spp	O
.	O

ETEC	O
K99	O
was	O
recovered	O
from	O
20	O
(	O
10	O
.	O
36	O
%)	O
out	O
of	O
193	O
isolates	O
,	O
whereas	O
Salmonella	B-DISO
spp	O
.	O
was	O
recovered	O
from	O
nine	O
calves	O
(	O
4	O
.	O
09	O
%).	O

Infection	B-DISO
with	O
Salmonella	B-DISO
spp	O
.	O
was	O
found	O
to	O
be	O
significantly	O
affected	O
by	O
the	O
animal	O
age	O
(	O
P	O
<	O
0	O
.	O
05	O
;	O
OR	O
:	O
0	O
.	O
376	O
;	O
CI	O
95	O
%:	O
0	O
.	O
511	O
-	O
1	O
.	O
369	O
),	O
Hygiene	O
(	O
P	O
<	O
0	O
.	O
05	O
;	O
OR	O
:	O
0	O
.	O
628	O
;	O
CI	O
95	O
%:	O
1	O
.	O
729	O
-	O
5	O
.	O
612	O
),	O
and	O
region	O
(	O
P	O
<	O
0	O
.	O
01	O
;	O
OR	O
:	O
0	O
.	O
970	O
;	O
CI	O
95	O
%:	O
0	O
.	O
841	O
-	O
1	O
.	O
624	O
).	O

Previous	O
work	O
with	O
the	O
prototype	O
coronavirus	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
has	O
shown	O
that	O
a	O
major	O
determinant	O
of	O
the	O
N	O
-	O
M	O
interaction	O
maps	O
to	O
the	O
carboxy	O
-	O
terminal	O
domain	O
3	O
of	O
the	O
N	O
protein	O
.	O

Advanced	O
age	O
was	O
significantly	O
associated	O
with	O
increased	O
SARS	B-DISO
-	O
related	O
deaths	O
,	O
primarily	O
due	O
to	O
the	O
onset	O
of	O
early	O
-	O
and	O
late	O
-	O
stage	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
pulmonary	B-DISO
fibrosis	I-DISO
.	O

ABSTRACT	O
:	O
The	O
first	O
report	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
was	O
published	O
in	O
1967	O
,	O
and	O
even	O
now	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
ARDS	B-DISO
are	O
severe	O
forms	O
of	O
diffuse	O
lung	B-DISO
disease	I-DISO
that	O
impose	O
a	O
substantial	O
health	O
burden	O
all	O
over	O
the	O
world	O
.	O

There	O
has	O
been	O
intense	O
investigation	O
into	O
the	O
pathophysiologic	O
events	O
relevant	O
to	O
each	O
stage	O
of	O
ALI	O
/	O
ARDS	B-DISO
,	O
and	O
much	O
has	O
been	O
learned	O
in	O
the	O
alveolar	O
epithelial	O
,	O
endobronchial	O
homeostasis	O
,	O
and	O
alveolar	O
cell	O
immune	O
responses	O
,	O
especially	O
neutrophils	O
and	O
alveolar	O
macrophages	O
in	O
an	O
animal	O
model	O
.	O

Here	O
,	O
we	O
review	O
the	O
recent	O
randomized	O
,	O
clinical	O
trials	O
of	O
ALI	O
/	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Analysis	O
of	O
the	O
properties	O
of	O
neutralizing	O
monoclonal	O
antibodies	O
against	O
the	O
hemagglutinating	O
encephalomyelitis	B-DISO
virus	O
and	O
inhibition	O
of	O
HEV	O
infection	B-DISO
by	O
specific	O
MAb	O
.	O

Effects	O
of	O
the	O
chimeric	O
ribozyme	O
on	O
expression	O
of	O
SARS	B-DISO
-	O
CoV	O
were	O
evaluated	O
in	O
cultured	O
3T3	O
cells	O
.	O

N	O
protein	O
is	O
thought	O
to	O
dysregulate	O
cell	O
signalling	O
and	O
the	O
transcription	O
of	O
cellular	O
genes	O
,	O
including	O
FGL2	O
,	O
which	O
encodes	O
a	O
prothrombinase	O
implicated	O
in	O
vascular	O
thrombosis	B-DISO
,	O
fibrin	B-DISO
deposition	I-DISO
and	O
pneumocyte	O
necrosis	O
.	O

Here	O
,	O
we	O
present	O
an	O
overview	O
of	O
recently	O
identified	O
substances	O
that	O
inhibit	O
and	O
/	O
or	O
reverse	O
endothelial	O
barrier	O
disruption	O
and	O
permeability	O
or	O
alveolar	O
epithelial	O
dysfunction	O
:	O
(	O
1	O
)	O
zinc	O
chelators	O
,	O
which	O
were	O
shown	O
to	O
attenuate	O
the	O
effects	O
of	O
oxidative	B-DISO
stress	I-DISO
on	O
the	O
pulmonary	O
endothelium	O
;	O
(	O
2	O
)	O
peroxisome	O
proliferator	O
activated	O
receptor	O
(	O
PPAR	O
)	O
ligands	O
,	O
which	O
have	O
been	O
shown	O
to	O
exert	O
anti	O
-	O
inflammatory	O
effects	O
,	O
by	O
decreasing	O
the	O
expression	O
of	O
pro	O
-	O
inflammatory	O
genes	O
;	O
(	O
3	O
)	O
extracellular	O
ATP	O
,	O
produced	O
during	O
inflammation	B-DISO
,	O
which	O
induces	O
a	O
rapid	O
and	O
dose	O
-	O
dependent	O
increase	O
in	O
transendothelial	O
electrical	O
resistance	O
(	O
TER	O
)	O
across	O
pulmonary	O
endothelial	O
cells	O
;	O
(	O
4	O
)	O
the	O
lectin	O
-	O
like	O
domain	O
of	O
TNF	O
,	O
which	O
is	O
spatially	O
distinct	O
from	O
the	O
receptor	O
binding	O
sites	O
and	O
which	O
protects	O
from	O
hydrostatic	O
and	O
permeability	O
edema	B-DISO
and	O
(	O
5	O
)	O
Hsp90	O
inhibitors	O
,	O
which	O
prevent	O
and	O
repair	O
toxin	O
-	O
induced	O
hyperpermeability	O
.	O

Unraveling	O
the	O
mechanism	O
of	O
action	O
of	O
these	O
agents	O
could	O
contribute	O
to	O
the	O
development	O
of	O
novel	O
therapeutic	O
strategies	O
to	O
combat	O
permeability	O
edema	B-DISO
.	O

The	O
cytopathic	B-DISO
effect	I-DISO
(	O
CPE	O
)	O
reduction	O
,	O
plaque	B-DISO
reduction	O
and	O
inhibition	O
assays	O
on	O
viral	O
replication	O
,	O
and	O
virucidal	O
activity	O
were	O
further	O
conducted	O
to	O
investigate	O
the	O
anti	O
-	O
PrV	B-DISO
activity	O
.	O

Extracts	O
from	O
roots	O
and	O
leaves	O
of	O
Isatis	O
indigotica	O
also	O
presented	O
CPE	O
inhibition	O
either	O
before	O
or	O
after	O
infection	B-DISO
of	O
PrV	B-DISO
on	O
porcine	O
kidney	O
(	O
PK	O
-	O
15	O
)	O
cells	O
.	O

This	O
Review	O
focuses	O
on	O
recent	O
advances	O
in	O
our	O
understanding	O
of	O
the	O
mechanisms	O
of	O
coronavirus	O
replication	O
,	O
interactions	O
with	O
the	O
host	O
immune	O
response	O
and	O
disease	O
pathogenesis	B-DISO
.	O

ABSTRACT	O
:	O
Four	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
isolates	O
were	O
recovered	O
from	O
commercial	O
broiler	O
chicken	O
flocks	O
located	O
on	O
the	O
Delmarva	O
Peninsula	O
(	O
east	O
coast	O
of	O
the	O
United	O
States	O
)	O
in	O
the	O
spring	O
of	O
2006	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
validate	O
a	O
colorimetric	O
method	O
to	O
measure	O
total	O
sialic	O
acid	O
(	O
TSA	O
)	O
in	O
feline	O
serum	O
and	O
to	O
investigate	O
the	O
serum	O
concentration	O
of	O
TSA	O
in	O
clinically	O
healthy	O
cats	O
seronegative	O
(	O
n	O
=	O
9	O
)	O
and	O
seropositive	O
(	O
n	O
=	O
48	O
)	O
for	O
feline	O
coronavirus	O
(	O
FCoV	O
),	O
and	O
in	O
cats	O
affected	O
by	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
,	O
n	O
=	O
28	O
),	O
tumors	B-DISO
(	O
n	O
=	O
20	O
),	O
or	O
inflammation	B-DISO
(	O
n	O
=	O
16	O
).	O

294	O
.	O
4	O
mg	O
/	O
L	O
,	O
P	O
=	O
0	O
.	O
028	O
),	O
and	O
inflammation	B-DISO
(	O
546	O
.	O
8	O
+/-	O

Each	O
monomer	O
consists	O
of	O
two	O
subdomains	O
,	O
SUD	O
-	O
N	O
and	O
SUD	O
-	O
M	O
,	O
with	O
a	O
macrodomain	O
fold	O
similar	O
to	O
the	O
SARS	B-DISO
-	O
CoV	O
X	O
-	O
domain	O
.	O

TITLE	O
:	O
Elevated	O
plasma	O
surfactant	O
protein	O
D	O
(	O
SP	O
-	O
D	O
)	O
levels	O
and	O
a	O
direct	O
correlation	O
with	O
anti	O
-	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
-	O
specific	O
IgG	O
antibody	O
in	O
SARS	B-DISO
patients	O
.	O

Plasma	O
SP	O
-	O
D	O
and	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
N	O
protein	O
IgG	O
were	O
measured	O
using	O
ELISA	O
.	O

SP	O
-	O
D	O
significantly	O
correlated	O
with	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
N	O
protein	O
IgG	O
(	O
r	O
(	O
2	O
)	O
=	O
0	O
.	O
5995	O
,	O
P	O
=	O
0	O
.	O
02	O
).	O

Treatment	O
of	O
mice	O
bearing	O
a	O
lethal	O
intracranial	O
U87DeltaEGFR	O
tumor	B-DISO
by	O
injection	O
with	O
MHVsoR	O
-	O
EGF	O
significantly	O
prolonged	O
survival	O
compared	O
to	O
phosphate	O
-	O
buffered	O
saline	O
-	O
treated	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
and	O
control	O
virus	O
-	O
treated	O
(	O
P	O
=	O
0	O
.	O
004	O
)	O
animals	O
,	O
and	O
no	O
recurrent	B-DISO
tumor	I-DISO
load	O
was	O
observed	O
.	O

In	O
order	O
to	O
achieve	O
a	O
pseudo	O
-	O
infection	B-DISO
condition	B-DISO
,	O
the	O
subjects	O
maintained	O
an	O
ergo	O
-	O
meter	O
exercise	O
load	O
(	O
100	O
W	O
,	O
10	O
minutes	O
).	O

Over	O
the	O
past	O
decade	O
,	O
new	O
viruses	O
have	O
been	O
discovered	O
through	O
both	O
more	O
specific	O
testing	O
and	O
the	O
finding	O
of	O
new	O
agents	O
causing	O
infection	B-DISO
.	O

Other	O
agents	O
responsible	O
for	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
include	O
Coronavirus	O
(	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
),	O
Bocavirus	O
,	O
and	O
others	O
.	O

This	O
review	O
serves	O
to	O
focus	O
on	O
some	O
of	O
the	O
recent	O
literature	O
on	O
these	O
agents	O
and	O
the	O
clinical	O
impact	O
they	O
have	O
on	O
pediatric	O
lung	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Association	O
of	O
human	O
leukocyte	O
antigen	O
class	O
II	O
alleles	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
the	O
Vietnamese	O
population	O
.	O

ABSTRACT	O
:	O
Excessive	O
immune	O
response	O
is	O
believed	O
to	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Inhomogeneous	O
spread	O
of	O
SARS	B-DISO
led	O
one	O
to	O
think	O
of	O
an	O
Asian	O
genetic	O
predisposition	O
and	O
contribution	O
of	O
human	O
leukocyte	O
antigen	O
(	O
HLA	O
)	O
to	O
the	O
disease	O
susceptibility	O
.	O

HLA	O
-	O
DRB1	O
*	O
12	O
was	O
more	O
frequently	O
shown	O
in	O
SARS	B-DISO
patients	O
than	O
in	O
controls	O
(	O
corrected	O
p	O
=	O
0	O
.	O
042	O
).	O

The	O
approaches	O
to	O
combating	O
coronaviral	O
infections	B-DISO
are	O
built	O
on	O
the	O
foundation	O
of	O
antivirals	O
against	O
other	O
viruses	O
and	O
the	O
fundamental	O
insights	O
gained	O
by	O
dissection	O
of	O
the	O
coronaviral	O
lifecycle	O
.	O

TITLE	O
:	O
SARS	B-DISO
-	O
coronavirus	O
modulation	O
of	O
myocardial	O
ACE2	O
expression	O
and	O
inflammation	B-DISO
in	O
patients	O
with	O
SARS	B-DISO
.	O

Autopsy	O
heart	O
samples	O
from	O
patients	O
who	O
succumbed	O
to	O
the	O
SARS	B-DISO
crisis	O
in	O
Toronto	O
(	O
Canada	O
)	O
were	O
used	O
to	O
investigate	O
the	O
impact	O
of	O
SARS	B-DISO
on	O
myocardial	O
structure	O
,	O
inflammation	B-DISO
and	O
ACE2	O
protein	O
expression	O
.	O

Pulmonary	B-DISO
infection	I-DISO
with	O
the	O
human	O
SARS	B-DISO
-	O
CoV	O
in	O
mice	O
led	O
to	O
an	O
ACE2	O
-	O
dependent	O
myocardial	O
infection	B-DISO
with	O
a	O
marked	O
decrease	O
in	O
ACE2	O
expression	O
confirming	O
a	O
critical	O
role	O
of	O
ACE2	O
in	O
mediating	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
in	O
the	O
heart	O
.	O

Macrophage	O
-	O
specific	O
staining	O
showed	O
a	O
marked	O
increase	O
in	O
macrophage	O
infiltration	B-DISO
with	O
evidence	O
of	O
myocardial	O
damage	O
in	O
patients	O
who	O
had	O
SARS	B-DISO
-	O
CoV	O
in	O
their	O
hearts	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
characterised	O
by	O
lung	B-DISO
inflammation	I-DISO
with	O
severe	O
hypoxia	B-DISO
,	O
which	O
usually	O
develops	O
over	O
4	O
-	O
48	O
hours	O
and	O
persists	O
for	O
days	O
or	O
weeks	O
.	O

The	O
main	O
causes	O
of	O
ARDS	B-DISO
are	O
infections	B-DISO
,	O
aspiration	B-DISO
of	O
gastric	O
contents	O
,	O
and	O
trauma	O
.	O

ABSTRACT	O
:	O
The	O
overview	O
presents	O
the	O
currently	O
available	O
data	O
on	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
)	O
and	O
its	O
etiological	O
agent	O
,	O
a	O
coronarovirus	O
of	O
swine	O
.	O

Most	O
of	O
our	O
recipients	O
exhibited	O
a	O
high	O
-	O
risk	O
HPV	O
genotype	O
,	O
which	O
suggests	O
higher	O
aggressiveness	B-DISO
of	O
such	O
infection	B-DISO
in	O
immunosuppressed	O
patients	O
.	O

Overall	O
,	O
hospitalizations	O
with	O
hypertensive	O
disorders	O
were	O
associated	O
with	O
57	O
%	O
of	O
hospitalizations	O
with	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
27	O
%	O
of	O
hospitalizations	O
with	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
syndrome	B-DISO
,	O
and	O
30	O
%	O
or	O
more	O
of	O
hospitalizations	O
with	O
ventilation	O
,	O
pulmonary	B-DISO
edema	I-DISO
,	O
puerperal	O
cerebrovascular	B-DISO
disorders	I-DISO
,	O
and	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
.	O

At	O
1	O
year	O
,	O
43	O
new	O
cases	O
of	O
BOS	B-DISO
developed	O
.	O

Symptomatic	O
CARV	O
-	O
infection	B-DISO
increases	O
the	O
risk	O
for	O
new	O
onset	O
of	O
BOS	B-DISO
,	O
but	O
not	O
progression	O
.	O

Risk	O
to	O
develop	O
BOS	B-DISO
was	O
especially	O
increased	O
after	O
paramyxovirus	O
infection	B-DISO
.	O

After	O
paramyxovirus	O
infection	B-DISO
,	O
8	O
of	O
24	O
patients	O
developed	O
new	O
-	O
onset	O
BOS	B-DISO
,	O
whereas	O
no	O
case	O
was	O
recorded	O
after	O
rhinovirus	O
and	O
coronavirus	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
[	O
An	O
update	O
on	O
viral	B-DISO
diseases	I-DISO
of	O
the	O
dog	O
and	O
cat	O
].	O

In	O
the	O
dog	O
,	O
infection	B-DISO
with	O
the	O
coronavirus	O
type	O
2	O
is	O
associated	O
with	O
respiratory	O
signs	O
,	O
while	O
infection	B-DISO
of	O
a	O
highly	O
pathogenic	O
strain	O
of	O
the	O
coronavirus	O
type	O
1	O
has	O
been	O
identified	O
as	O
the	O
cause	O
of	O
mortality	O
in	O
puppies	O
.	O

TITLE	O
:	O
[	O
Acute	B-DISO
respiratory	I-DISO
failure	I-DISO
in	O
a	O
16	O
-	O
yr	O
-	O
old	O
girl	O
with	O
alveolar	B-DISO
soft	I-DISO
part	I-DISO
sarcoma	I-DISO
].	O

Recognition	O
and	O
treatment	O
of	O
pulmonary	B-DISO
aspergillosis	I-DISO
is	O
difficult	O
and	O
may	O
require	O
multi	O
drug	O
therapy	O
.	O

CONCLUSIONS	O
:	O
Fungal	B-DISO
infection	I-DISO
should	O
always	O
be	O
considered	O
in	O
immunocompromised	O
patients	O
with	O
clinical	O
signs	O
of	O
systemic	B-DISO
infection	I-DISO
.	O

Th2	O
cell	O
polarization	O
,	O
Smad4	O
and	O
Smad7	O
should	O
be	O
the	O
crucial	O
molecular	O
mechanism	O
of	O
ALI	O
-	O
induced	O
rapid	O
fibrosis	B-DISO
.	O

Patient	O
was	O
taken	O
to	O
the	O
hospital	O
,	O
evolved	O
with	O
respiratory	B-DISO
failure	I-DISO
,	O
bradyarrhythmia	B-DISO
,	O
arterial	O
hypotension	O
and	O
cardiac	B-DISO
arrest	I-DISO
,	O
being	O
resuscitated	O
.	O

These	O
theoretical	O
results	O
should	O
be	O
kept	O
in	O
mind	O
when	O
analyzing	O
data	O
for	O
emerging	O
vector	O
-	O
borne	O
diseases	O
(	O
West	O
-	O
Nile	O
,	O
dengue	B-DISO
,	O
chikungunya	B-DISO
)	O
or	O
air	O
-	O
borne	O
diseases	O
(	O
SARS	B-DISO
,	O
pandemic	O
influenza	B-DISO
);	O
all	O
these	O
diseases	O
being	O
influenced	O
by	O
seasonality	O
.	O

At	O
the	O
time	O
of	O
writing	O
,	O
there	O
is	O
no	O
non	O
-	O
invasive	O
confirmatory	O
test	O
available	O
for	O
cats	O
without	O
effusion	B-DISO
.	O

At	O
present	O
,	O
only	O
one	O
(	O
intranasal	O
)	O
FIP	B-DISO
vaccine	O
is	O
available	O
,	O
which	O
is	O
considered	O
as	O
being	O
non	O
-	O
core	O
.	O

Before	O
(	O
normal	O
condition	B-DISO
)	O
and	O
after	O
(	O
pseudo	O
-	O
infection	B-DISO
condition	B-DISO
)	O
exercise	O
,	O
a	O
significant	O
linear	O
discriminant	O
function	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
was	O
determined	O
to	O
distinguish	O
pseudo	O
-	O
infection	B-DISO
condition	B-DISO
from	O
normal	O
condition	B-DISO
(	O
Mahalanobis	O
D	O
-	O
square	O
=	O
20	O
.	O
3	O
,	O
classification	O
error	O
rate	O
<	O
5	O
%).	O

A	O
4	O
-	O
fold	O
classification	O
of	O
emerging	O
zoonoses	B-DISO
was	O
proposed	O
:	O
Type	O
1	O
:	O
from	O
wild	O
animals	O
to	O
humans	O
(	O
Hanta	O
);	O
Type	O
1	O
plus	O
:	O
from	O
wild	O
animals	O
to	O
humans	O
with	O
further	O
human	O
-	O
to	O
-	O
human	O
transmission	O
(	O
AIDS	O
);	O
Type	O
2	O
:	O
from	O
wild	O
animals	O
to	O
domestic	O
animals	O
to	O
humans	O
(	O
Avian	B-DISO
flu	I-DISO
)	O
and	O
Type	O
2	O
plus	O
:	O
from	O
wild	O
animals	O
to	O
domestic	O
animals	O
to	O
humans	O
,	O
with	O
further	O
human	O
-	O
to	O
-	O
human	O
transmission	O
(	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
,	O
SARS	B-DISO
).	O

The	O
resulting	O
holistic	O
approach	O
to	O
emerging	O
infections	B-DISO
links	O
microbiology	O
,	O
veterinary	O
medicine	O
,	O
human	O
medicine	O
,	O
ecology	O
,	O
public	O
health	O
and	O
epidemiology	O
.	O

Animal	O
models	O
that	O
mimic	O
certain	O
diseases	O
are	O
key	O
elements	O
for	O
understanding	O
the	O
underlying	O
mechanisms	O
of	O
disease	O
pathogenesis	B-DISO
,	O
as	O
well	O
as	O
for	O
the	O
development	O
and	O
efficacy	O
testing	O
of	O
therapeutics	O
and	O
vaccines	O
.	O

The	O
occurrences	O
of	O
scarlet	B-DISO
fever	I-DISO
in	O
central	O
Taiwan	O
in	O
2000	O
-	O
2006	O
were	O
primarily	O
caused	O
by	O
five	O
emm	O
types	O
,	O
which	O
accounted	O
for	O
96	O
.	O
8	O
%	O
of	O
the	O
isolates	O
collected	O
.	O

ABSTRACT	O
:	O
Systemic	O
administration	O
of	O
corticosteroid	O
,	O
plasmapheresis	O
and	O
high	O
-	O
dose	O
immunoglobulin	O
therapy	O
(	O
IVIG	O
)	O
are	O
the	O
main	O
treatment	O
of	O
Stevens	B-DISO
-	I-DISO
Johnson	I-DISO
syndrome	I-DISO
(	O
SJS	B-DISO
)	O
and	O
toxic	B-DISO
epidermal	I-DISO
necrolysis	I-DISO
(	O
TEN	O
).	O

Combination	O
of	O
plasmapheresis	O
or	O
IVIG	O
with	O
corticosteroid	O
therapy	O
was	O
performed	O
in	O
3	O
cases	O
of	O
SJS	B-DISO
and	O
8	O
cases	O
of	O
TEN	O
.	O

The	O
mortality	O
rate	O
of	O
patient	O
with	O
SJS	B-DISO
was	O
3	O
.	O
7	O
%	O
(	O
1	O
case	O
),	O
and	O
with	O
TEN	O
was	O
21	O
.	O
1	O
%	O
(	O
4	O
cases	O
).	O

ABSTRACT	O
:	O
Neutrophil	O
elastase	O
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
(	O
DIC	B-DISO
)	O
in	O
sepsis	B-DISO
.	O

A	O
retrospective	O
data	O
analysis	O
of	O
septic	O
patients	O
associated	O
with	O
ARDS	B-DISO
and	O
DIC	B-DISO
was	O
conducted	O
to	O
investigate	O
the	O
effects	O
of	O
sivelestat	O
.	O

ABSTRACT	O
:	O
The	O
relative	O
lack	O
of	O
efficient	O
methods	O
for	O
evaluating	O
antiseptic	O
antiviral	O
activity	O
,	O
together	O
with	O
weaknesses	B-DISO
in	O
the	O
existing	O
European	O
Standard	O
(	O
i	O
.	O
e	O
.	O
NF	O
EN	O
14476	O
+	O
A1	O
),	O
underlines	O
the	O
need	O
to	O
seek	O
a	O
new	O
method	O
which	O
could	O
allow	O
a	O
more	O
precise	O
evaluation	O
of	O
the	O
antiseptic	O
antiviral	O
activity	O
of	O
chemical	O
agents	O
.	O

Human	O
coronaviruses	O
cause	O
respiratory	B-DISO
infections	I-DISO
that	O
range	O
in	O
seriousness	O
from	O
common	B-DISO
colds	I-DISO
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

To	O
test	O
for	O
associations	O
between	O
coronaviruses	O
and	O
serious	O
mental	B-DISO
disorders	I-DISO
,	O
we	O
utilized	O
a	O
recently	O
developed	O
assay	O
and	O
measured	O
immunoglobulin	O
G	O
(	O
IgG	O
)	O
response	O
against	O
4	O
human	O
coronavirus	O
strains	O
(	O
229E	O
,	O
HKU1	O
,	O
NL63	O
,	O
and	O
OC43	O
)	O
in	O
106	O
patients	O
with	O
a	O
recent	O
onset	O
of	O
psychotic	B-DISO
symptoms	I-DISO
and	O
196	O
nonpsychiatric	O
controls	O
.	O

Inhibition	O
of	O
MMP	O
-	O
9	O
activity	O
with	O
doxycycline	O
reduced	O
pancreatitis	B-DISO
-	O
associated	O
lung	O
injury	O
and	O
expression	O
of	O
MMP	O
-	O
9	O
in	O
pulmonary	O
tissue	O
.	O

Owing	O
to	O
their	O
affinity	O
towards	O
intestinal	O
cells	O
and	O
immunoglobulin	O
G	O
,	O
the	O
Slayer	O
fusion	O
proteins	O
enabled	O
the	O
adhesion	B-DISO
of	O
antibodies	O
to	O
human	O
epithelial	O
cells	O
.	O

All	O
health	O
care	O
personnel	O
,	O
trainees	O
,	O
and	O
support	O
staff	O
should	O
be	O
trained	O
in	O
infection	B-DISO
control	O
management	O
and	O
containment	O
to	O
prevent	O
spread	O
of	O
the	O
SARS	B-DISO
virus	O
.	O

About	O
10	O
%	O
of	O
the	O
respondents	O
had	O
experienced	O
high	O
levels	O
of	O
posttraumatic	O
stress	O
(	O
PTS	O
)	O
symptoms	O
since	O
the	O
SARS	B-DISO
outbreak	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
infectivity	O
and	O
propagation	O
of	O
HEV	O
in	O
comparison	O
with	O
those	O
of	O
pseudorabies	B-DISO
virus	O
(	O
PRV	B-DISO
),	O
another	O
neurotropic	O
virus	O
,	O
using	O
dorsal	O
root	O
ganglia	O
cells	O
of	O
newborn	O
mice	O
containing	O
nerve	O
cells	O
and	O
non	O
-	O
neuronal	O
cells	O
.	O

By	O
using	O
cytoskeletal	O
inhibitors	O
,	O
it	O
was	O
suggested	O
that	O
propagation	O
of	O
HEV	O
and	O
PRV	B-DISO
within	O
and	O
among	O
nerve	O
cells	O
depended	O
on	O
microtubules	O
and	O
intermediate	O
filaments	O
of	O
nerve	O
cells	O
,	O
indicating	O
that	O
the	O
viruses	O
may	O
be	O
transported	O
between	O
the	O
cell	O
body	O
and	O
axonal	O
terminals	O
of	O
neurons	O
by	O
fast	O
axonal	O
flow	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
(	O
PED	O
)	O
is	O
a	O
contagious	O
enteric	O
disease	O
of	O
pigs	O
caused	O
by	O
a	O
coronavirus	O
.	O

We	O
also	O
compared	O
adult	O
and	O
cord	B-DISO
blood	O
(	O
CB	O
)	O
DCs	B-DISO
to	O
find	O
a	O
possible	O
explanation	O
for	O
the	O
age	O
-	O
dependent	O
severity	O
of	O
SARS	B-DISO
.	O

There	O
was	O
also	O
strong	O
induction	O
of	O
TNF	O
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	O
(	O
TRAIL	O
),	O
but	O
not	O
Fas	B-DISO
ligand	O
gene	O
expression	O
in	O
SARS	B-DISO
-	O
CoV	O
infected	O
DCs	B-DISO
.	O

The	O
upregulation	O
of	O
chemokines	O
and	O
CCRs	O
may	O
facilitate	O
DC	O
migration	O
from	O
the	O
infection	B-DISO
site	I-DISO
to	O
the	O
lymph	O
nodes	O
,	O
whereas	O
the	O
increase	O
of	O
TRAIL	O
may	O
induce	O
lymphocyte	O
apoptosis	O
.	O

CONCLUSIONS	O
:	O
The	O
upregulation	O
of	O
chemokines	O
and	O
CCRs	O
may	O
facilitate	O
DC	O
migration	O
from	O
the	O
infection	B-DISO
site	I-DISO
to	O
the	O
lymph	O
nodes	O
,	O
whereas	O
the	O
increase	O
of	O
TRAIL	O
may	O
induce	O
lymphocyte	O
apoptosis	O
.	O

During	O
the	O
SARS	B-DISO
epidemic	O
,	O
pregnant	O
women	O
avoided	O
using	O
maternity	O
services	O
in	O
advanced	O
hospitals	O
.	O

We	O
compared	O
the	O
differences	O
between	O
observed	O
mortality	O
rates	O
of	O
the	O
SARS	B-DISO
period	O
and	O
predicted	O
rates	O
to	O
examine	O
whether	O
the	O
shifting	O
in	O
maternity	O
services	O
during	O
the	O
SARS	B-DISO
epidemic	O
significantly	O
affected	O
neonatal	O
mortality	O
rates	O
.	O

With	O
an	O
analysis	O
of	O
a	O
total	O
of	O
1	O
,	O
848	O
observations	O
between	O
1998	O
and	O
2004	O
,	O
an	O
insignificantly	O
negative	O
mean	O
of	O
standardized	O
predicted	O
errors	O
during	O
the	O
SARS	B-DISO
period	O
was	O
found	O
.	O

We	O
herein	O
report	O
detailed	O
SARs	B-DISO
for	O
each	O
of	O
the	O
regions	O
of	O
the	O
ProTide	O
.	O

This	O
knowledge	O
may	O
be	O
important	O
for	O
the	O
control	O
of	O
re	O
-	O
emerging	O
SARS	B-DISO
,	O
or	O
other	O
future	O
emerging	O
human	O
-	O
to	O
-	O
human	O
transmittable	O
infections	B-DISO
.	O

RESULTS	O
:	O
The	O
SARS	B-DISO
epidemic	O
in	O
mainland	O
China	O
spanned	O
a	O
large	O
geographical	O
extent	O
but	O
clustered	O
in	O
two	O
areas	O
:	O
first	O
in	O
Guangdong	O
Province	O
,	O
and	O
about	O
3	O
months	O
later	O
in	O
Beijing	O
with	O
its	O
surrounding	O
areas	O
in	O
Shanxi	O
Province	O
,	O
Inner	O
Mongolia	O
Autonomic	O
Region	O
,	O
Hebei	O
Province	O
and	O
Tianjin	O
.	O

Being	O
intersected	O
by	O
a	O
railway	O
did	O
not	O
significantly	O
associate	O
with	O
risk	O
of	O
SARS	B-DISO
.	O

Longitudinal	O
study	O
of	O
71	O
former	O
SARS	B-DISO
patients	O
(	O
mainly	O
health	O
care	O
workers	O
)	O
who	O
had	O
been	O
treated	O
with	O
corticosteroids	O
,	O
with	O
an	O
observation	O
time	O
of	O
36	O
months	O
.	O

Magnetic	O
resonance	O
images	O
(	O
MRI	O
)	O
and	O
X	O
-	O
rays	O
of	O
hips	O
,	O
knees	O
,	O
shoulders	O
,	O
ankles	O
and	O
wrists	O
were	O
taken	O
as	O
part	O
of	O
the	O
post	O
-	O
SARS	B-DISO
follow	O
-	O
up	O
assessments	O
.	O

The	O
data	O
of	O
all	O
probable	O
SARS	B-DISO
cases	O
were	O
derived	O
from	O
the	O
Infectious	B-DISO
Disease	I-DISO
Reporting	O
System	O
of	O
the	O
Center	O
of	O
Diseases	O
Control	O
and	O
Hospital	O
Information	O
Systems	O
,	O
during	O
the	O
2003	O
epidemic	O
in	O
mainland	O
China	O
.	O

The	O
relatively	O
young	O
age	O
of	O
the	O
cases	O
partly	O
explains	O
the	O
low	O
CFR	O
in	O
mainland	O
China	O
compared	O
with	O
other	O
countries	O
and	O
areas	O
affected	O
by	O
SARS	B-DISO
.	O

SARS	B-DISO
became	O
a	O
notifiable	O
disease	O
in	O
China	O
in	O
mid	O
-	O
April	O
2003	O
,	O
after	O
which	O
introduction	O
of	O
efficient	O
nationwide	O
control	O
measures	O
led	O
to	O
containment	O
within	O
2	O
months	O
.	O

SARS	B-DISO
challenged	O
the	O
political	O
and	O
public	O
health	O
systems	O
of	O
all	O
affected	O
countries	O
.	O

ABSTRACT	O
:	O
To	O
document	O
and	O
verify	O
the	O
number	O
of	O
cases	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
during	O
the	O
2002	O
-	O
2003	O
epidemic	O
in	O
mainland	O
China	O
.	O

SARS	B-DISO
-	O
CoV	O
protein	O
eukaryotic	O
expression	O
plasmids	O
were	O
transfected	O
respectively	O
into	O
CHO	O
cells	O
.	O

M	O
,	O
N	O
and	O
S2	O
proteins	O
of	O
SARS	B-DISO
-	O
CoV	O
were	O
detected	O
in	O
the	O
cytoplasm	O
of	O
transfected	O
CHO	O
cells	O
.	O

Rats	O
with	O
LC	O
+	O
CASP	O
also	O
had	O
distinct	O
aspects	O
of	O
inflammation	B-DISO
compared	O
with	O
CASP	O
alone	O
,	O
i	O
.	O
e	O
.,	O
significantly	O
higher	O
levels	O
of	O
IL	O
-	O
10	O
(	O
5	O
and	O
24	O
h	O
),	O
IL	O
-	O
1beta	O
(	O
24	O
h	O
),	O
CINC	O
-	O
1	O
(	O
24	O
h	O
),	O
and	O
MCP	O
-	O
1	O
(	O
24	O
h	O
),	O
and	O
significantly	O
lower	O
levels	O
of	O
MPO	O
(	O
5	O
h	O
),	O
MIP	B-DISO
-	O
2	O
(	O
5	O
h	O
),	O
and	O
CINC	O
-	O
1	O
(	O
5	O
h	O
).	O

Multiplex	O
PCR	O
tests	O
sentinel	O
the	O
appearance	O
of	O
pandemic	O
influenza	B-DISO
viruses	O
including	O
H1N1	O
swine	B-DISO
influenza	I-DISO
.	O

Both	O
SARS	B-DISO
Coronavirus	O
which	O
quickly	O
spread	O
to	O
29	O
countries	O
in	O
February	O
2003	O
and	O
H1N1	O
swine	B-DISO
influenza	I-DISO
that	O
recently	O
spread	O
from	O
Mexico	O
to	O
30	O
countries	O
in	O
three	O
weeks	O
represent	O
major	O
pandemic	O
threats	O
for	O
mankind	O
.	O

In	O
this	O
report	O
we	O
evaluate	O
the	O
ability	O
of	O
a	O
multiplex	O
PCR	O
test	O
(	O
xTAG	O
RVP	O
)	O
to	O
detect	O
new	O
,	O
""""	O
non	O
-	O
seasonal	O
""""	O
influenza	B-DISO
viruses	O
including	O
the	O
H1N1	O
swine	B-DISO
influenza	I-DISO
A	O
/	O
swine	O
/	O
California	O
/	O
04	O
/	O
2009	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
years	O
have	O
seen	O
the	O
emergence	O
of	O
diseases	O
which	O
have	O
spread	O
very	O
quickly	O
all	O
around	O
the	O
world	O
either	O
through	O
human	O
travels	O
like	O
SARS	B-DISO
or	O
animal	O
migration	O
like	O
avian	B-DISO
flu	I-DISO
.	O

Another	O
challenge	O
is	O
related	O
to	O
the	O
early	O
detection	O
and	O
surveillance	O
of	O
the	O
diseases	O
as	O
new	O
cases	O
can	O
appear	O
just	O
anywhere	O
due	O
to	O
the	O
globalization	O
of	O
exchanges	O
and	O
the	O
circulation	O
of	O
people	O
and	O
animals	O
around	O
the	O
earth	O
,	O
as	O
recently	O
demonstrated	O
by	O
the	O
avian	B-DISO
flu	I-DISO
epidemics	O
.	O

In	O
the	O
present	O
case	O
,	O
a	O
child	O
manifested	O
transient	O
mutism	B-DISO
and	O
pathologic	O
laughter	O
during	O
a	O
severe	O
cerebellitis	B-DISO
.	O

Headache	B-DISO
,	O
vertigo	B-DISO
,	O
and	O
impaired	B-DISO
consciousness	I-DISO
developed	O
during	O
an	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
.	O

TITLE	O
:	O
[	O
Effect	O
of	O
an	O
early	O
application	O
of	O
chaiqin	O
chengqi	O
decoction	O
in	O
treating	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
complicated	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
].	O

The	O
Acute	O
Physiology	O
and	O
Chronic	O
Heath	O
Evaluation	O
II	O
(	O
APACHE	O
I	O
)	O
scores	O
,	O
the	O
incidence	O
and	O
sustained	O
time	O
of	O
complications	O
,	O
the	O
occurrence	O
of	O
infection	B-DISO
,	O
requirement	O
of	O
operation	O
shifting	O
on	O
day	O
7	O
,	O
as	O
well	O
as	O
the	O
duration	O
resided	O
in	O
hospital	O
and	O
mortality	O
in	O
patients	O
were	O
observed	O
and	O
compared	O
.	O

4	O
.	O
3	O
scores	O
,	O
P	O
<	O
0	O
.	O
01	O
);	O
the	O
incidence	O
of	O
shock	O
was	O
lesser	O
(	O
1	O
/	O
20	O
vs	O
7	O
/	O
19	O
);	O
the	O
duration	O
of	O
ARDS	B-DISO
,	O
renal	B-DISO
failure	I-DISO
,	O
cardiac	O
insufficiency	B-DISO
,	I-DISO
hepatic	I-DISO
dysfunction	O
,	O
cerebropathy	O
and	O
enteroplegia	O
,	O
as	O
well	O
as	O
the	O
duration	O
in	O
hospital	O
and	O
the	O
requirement	O
of	O
operation	O
shifting	O
were	O
all	O
shorter	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
ET	O
group	O
than	O
those	O
in	O
the	O
LT	O
group	O
,	O
but	O
no	O
statistical	O
difference	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
was	O
shown	O
in	O
terms	O
of	O
the	O
infection	B-DISO
incidence	O
and	O
the	O
mortality	O
.	O

4	O
.	O
3	O
scores	O
,	O
P	O
<	O
0	O
.	O
01	O
);	O
the	O
incidence	O
of	O
shock	O
was	O
lesser	O
(	O
1	O
/	O
20	O
vs	O
7	O
/	O
19	O
);	O
the	O
duration	O
of	O
ARDS	B-DISO
,	O
renal	B-DISO
failure	I-DISO
,	O
cardiac	O
insufficiency	B-DISO
,	I-DISO
hepatic	I-DISO
dysfunction	O
,	O
cerebropathy	O
and	O
enteroplegia	O
,	O
as	O
well	O
as	O
the	O
duration	O
in	O
hospital	O
and	O
the	O
requirement	O
of	O
operation	O
shifting	O
were	O
all	O
shorter	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
ET	O
group	O
than	O
those	O
in	O
the	O
LT	O
group	O
,	O
but	O
no	O
statistical	O
difference	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
was	O
shown	O
in	O
terms	O
of	O
the	O
infection	B-DISO
incidence	O
and	O
the	O
mortality	O
.	O

Strengthening	O
surveillance	O
systems	O
at	O
the	O
international	O
level	O
,	O
to	O
allow	O
the	O
timely	O
monitoring	O
of	O
infectious	B-DISO
agents	O
and	O
outbreaks	O
is	O
essential	O
.	O

RESULTS	O
:	O
A	O
lack	O
of	O
knowledge	O
and	O
delayed	O
international	O
communication	O
resulted	O
in	O
the	O
rapid	O
spread	O
of	O
SARS	B-DISO
,	O
highlighting	O
the	O
importance	O
of	O
a	O
global	O
system	O
for	O
rapid	O
and	O
transparent	O
information	O
transfer	O
.	O

To	O
provide	O
the	O
clinician	O
with	O
a	O
summary	O
of	O
the	O
literature	O
on	O
the	O
epidemiology	O
,	O
diagnosis	O
,	O
and	O
an	O
evidence	O
-	O
base	O
for	O
management	O
of	O
ALI	O
/	O
ARDS	B-DISO
in	O
children	O
.	O

Based	O
on	O
expert	O
opinion	O
,	O
the	O
following	O
are	O
recommended	O
:	O
1	O
)	O
avoid	O
tidal	O
volumes	O
>	O
or	O
=	O
10	O
mL	O
/	O
kg	O
body	O
weight	O
;	O
2	O
)	O
keep	O
plateau	O
pressure	O
<	O
or	O
=	O
30	O
cm	O
H2O	O
,	O
arterial	O
pH	O
at	O
7	O
.	O
30	O
to	O
7	O
.	O
45	O
,	O
and	O
Pao2	O
60	O
to	O
80	O
torr	O
(	O
8	O
to	O
10	O
.	O
7	O
kPa	O
)	O
(	O
Spo2	O
>	O
or	O
=	O
90	O
%);	O
3	O
)	O
provide	O
sedation	B-DISO
,	O
analgesia	B-DISO
,	O
and	O
stress	B-DISO
ulcer	I-DISO
prophylaxis	O
;	O
and	O
4	O
)	O
use	O
a	O
10	O
g	O
/	O
dL	O
hemoglobin	O
threshold	O
for	O
packed	O
red	O
blood	O
cell	O
transfusion	O
in	O
unstable	O
patients	O
(	O
shock	O
or	O
profound	O
hypoxia	B-DISO
).	O

In	O
this	O
study	O
,	O
we	O
used	O
MRI	O
to	O
observe	O
the	O
lesion	O
size	O
changes	O
of	O
ONFH	O
induced	O
by	O
corticosteroid	O
administration	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
.	O

The	O
study	O
included	O
51	O
SARS	B-DISO
patients	O
(	O
84	O
hips	O
)	O
with	O
early	O
-	O
stage	O
ONFH	O
who	O
did	O
not	O
receive	O
any	O
operative	O
treatment	O
and	O
were	O
diagnosed	O
by	O
MRI	O
.	O

The	O
5	O
-	O
Acetyl	O
-	O
2	O
-(	O
4	O
'-	O
nitrobiphenyl	O
-	O
4	O
-	O
yl	O
)-	O
1H	O
-	O
benzimidazole	O
(	O
24	O
)	O
emerged	O
as	O
potent	O
active	O
lead	O
compound	O
against	O
Yellow	B-DISO
Fever	I-DISO
Virus	O
(	O
a	O
Flavivirus	O
)	O
(	O
EC	O
(	O
50	O
)	O
=	O
0	O
.	O
5	O
microM	O
)	O
and	O
CVB	O
-	O
2	O
at	O
1	O
microM	O
and	O
was	O
not	O
cytotoxic	O
,	O
whereas	O
the	O
other	O
title	O
benzimidazoles	O
showed	O
no	O
antiviral	O
activity	O
at	O
concentrations	O
not	O
cytotoxic	O
for	O
the	O
resting	O
cell	O
monolayers	O
.	O

While	O
there	O
is	O
much	O
evidence	O
that	O
various	O
vaccine	O
strategies	O
against	O
SARS	B-DISO
are	O
safe	O
and	O
immunogenic	O
,	O
vaccinated	O
animals	O
still	O
display	O
significant	O
disease	O
upon	O
challenge	O
.	O

The	O
univariate	O
analysis	O
showed	O
that	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
(	O
p	O
<	O
0	O
.	O
001	O
),	O
leukopenia	B-DISO
(	O
p	O
<	O
0	O
.	O
001	O
),	O
admission	O
to	O
ICU	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
mechanical	O
ventilation	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
use	O
of	O
aminoglycosides	O
after	O
culture	O
results	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
shock	O
(	O
p	O
=	O
0	O
.	O
001	O
),	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
p	O
=	O
0	O
.	O
001	O
),	O
influenza	B-DISO
like	I-DISO
symptoms	I-DISO
(	O
p	O
=	O
0	O
.	O
008	O
),	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
(	O
p	O
=	O
0	O
.	O
042	O
)	O
and	O
rash	B-DISO
(	O
p	O
=	O
0	O
.	O
04	O
)	O
were	O
the	O
factors	O
associated	O
with	O
death	O
.	O

CONCLUSIONS	O
:	O
It	O
is	O
suggested	O
that	O
N	O
protein	O
may	O
be	O
related	O
to	O
the	O
excessive	O
secretion	O
of	O
proinflammatory	O
cytokines	O
during	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
at	O
the	O
acute	O
phase	O
.	O

ABSTRACT	O
:	O
The	O
SARS	B-DISO
epidemic	O
has	O
boosted	O
interest	O
in	O
research	O
on	O
coronavirus	O
biodiversity	O
and	O
genomics	O
.	O

Acute	B-DISO
pancreatitis	I-DISO
accounted	O
for	O
2	O
.	O
29	O
%	O
of	O
all	O
admissions	O
and	O
4	O
.	O
9	O
%	O
of	O
all	O
deaths	O
in	O
the	O
department	O
of	O
surgery	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
the	O
coronavirus	O
(	O
CoV	O
)	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
is	O
cleaved	O
into	O
S1	O
and	O
S2	O
subunits	O
at	O
the	O
furin	O
consensus	O
motif	O
RRFRR	O
(	O
537	O
)/	O
S	O
in	O
virus	O
-	O
infected	O
cells	O
.	O

ABSTRACT	O
:	O
3	O
-	O
Chlorobenzofuran	O
-	O
2	O
-	O
carbaldehyde	O
was	O
condensed	O
with	O
substituted	O
acetophenone	O
by	O
using	O
the	O
Claisen	O
-	O
Schmidt	O
condensation	B-DISO
to	O
obtain	O
3	O
-(	O
3	O
-	O
chlorobenzofuran	O
-	O
2	O
-	O
yl	O
)-	O
1	O
-(	O
substituted	O
phenyl	O
)-	O
2	O
-	O
propen	O
-	O
1	O
-	O
one	O
(	O
2a	O
-	O
m	O
)	O
which	O
upon	O
further	O
treatment	O
with	O
hydrazine	O
hydrate	O
gave	O
2	O
-[	O
3	O
-(	O
substituted	O
phenyl	O
)-	O
4	O
,	O
5	O
-	O
dihydro	O
-	O
1H	O
-	O
5	O
-	O
pyrazolyl	O
)	O
benzofuran	O
-	O
3	O
-	O
yl	O
chloride	O
derivatives	O
(	O
3a	O
-	O
m	O
).	O

We	O
examined	O
the	O
distribution	O
of	O
respiratory	O
viruses	O
and	O
their	O
association	O
with	O
seasons	O
in	O
acute	O
and	O
stable	O
asthmatic	B-DISO
children	O
in	O
Trinidad	O
.	O

Emergent	O
wheezing	B-DISO
illnesses	O
during	O
childhood	O
can	O
be	O
linked	O
to	O
infection	B-DISO
with	O
rhinovirus	O
in	O
Trinidad	O
'	O
s	O
tropical	O
environment	O
.	O

TITLE	O
:	O
A	O
test	O
of	O
syndromic	O
surveillance	O
using	O
a	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
model	O
.	O

The	O
clinical	O
picture	O
was	O
modeled	O
on	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
symptoms	O
.	O

TITLE	O
:	O
Phenobarbital	O
treatment	O
in	O
a	O
patient	O
with	O
resistant	O
alcohol	B-DISO
withdrawal	I-DISO
syndrome	I-DISO
.	O

We	O
also	O
conducted	O
interviews	O
with	O
50	O
nurses	O
who	O
had	O
experience	O
in	O
administering	O
bronchodilators	O
via	O
both	O
nebulizer	O
and	O
MDI	B-DISO
with	O
spacer	O
.	O

Forty	O
-	O
six	O
patients	O
(	O
92	O
%)	O
were	O
able	O
to	O
use	O
MDI	B-DISO
with	O
spacer	O
effectively	O
.	O

The	O
agents	O
isolated	O
were	O
the	O
following	O
:	O
Mannheimia	O
haemolytica	O
(	O
25	O
.	O
0	O
%),	O
Pasteurella	O
multocida	O
(	O
24	O
.	O
5	O
%),	O
Histophilus	O
somni	O
(	O
10	O
.	O
0	O
%),	O
Arcanobacterium	O
pyogenes	O
(	O
35	O
.	O
0	O
%),	O
Salmonella	B-DISO
spp	O
.	O

Bovine	B-DISO
viral	I-DISO
diarrhea	I-DISO
virus	O
IHC	O
testing	O
was	O
positive	O
in	O
5	O
.	O
3	O
%	O
of	O
the	O
animals	O
.	O

Lesions	O
included	O
the	O
following	O
:	O
1	O
)	O
duration	O
:	O
acute	O
(	O
21	O
%),	O
subacute	O
(	O
15	O
%),	O
chronic	O
(	O
40	O
.	O
2	O
%),	O
healing	O
(	O
2	O
.	O
8	O
%),	O
normal	O
(	O
18	O
.	O
1	O
%),	O
and	O
autolyzed	O
(	O
2	O
.	O
8	O
%);	O
2	O
)	O
type	O
of	O
pneumonia	B-DISO
:	O
lobar	O
bronchopneumonia	B-DISO
(	O
LBP	B-DISO
;	O
27	O
.	O
1	O
%),	O
LBP	B-DISO
with	O
pleuritis	B-DISO
(	O
49	O
.	O
1	O
%),	O
interstitial	B-DISO
pneumonia	I-DISO
(	O
5	O
.	O
1	O
%),	O
bronchointerstitial	O
pneumonia	B-DISO
(	O
1	O
.	O
4	O
%),	O
septic	O
(	O
0	O
.	O
9	O
%),	O
embolic	O
foci	O
(	O
0	O
.	O
5	O
%),	O
other	O
(	O
2	O
.	O
8	O
%),	O
normal	O
(	O
10	O
.	O
3	O
%),	O
and	O
autolyzed	O
(	O
2	O
.	O
8	O
%);	O
and	O
3	O
)	O
bronchiolar	O
lesions	O
:	O
bronchiolitis	B-DISO
obliterans	I-DISO
(	O
39	O
.	O
7	O
%),	O
bronchiolar	O
necrosis	O
(	O
26	O
.	O
6	O
%),	O
bronchiolitis	B-DISO
obliterans	I-DISO
/	O
bronchiolar	O
necrosis	O
(	O
1	O
.	O
4	O
%),	O
other	O
bronchiolar	O
lesions	O
(	O
6	O
.	O
5	O
%),	O
and	O
bronchiolar	O
lesion	O
negative	O
(	O
25	O
.	O
7	O
%).	O

TITLE	O
:	O
Pneumonia	B-DISO
and	O
respiratory	B-DISO
failure	I-DISO
from	O
swine	O
-	O
origin	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
in	O
Mexico	O
.	O

All	O
patients	O
had	O
fever	O
,	O
cough	B-DISO
,	O
dyspnea	B-DISO
or	O
respiratory	B-DISO
distress	I-DISO
,	O
increased	O
serum	O
lactate	O
dehydrogenase	O
levels	O
,	O
and	O
bilateral	O
patchy	O
pneumonia	B-DISO
.	O

None	O
of	O
the	O
secondary	B-DISO
infections	I-DISO
among	O
health	O
care	O
workers	O
were	O
severe	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
successful	O
use	O
of	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
in	O
a	O
53	O
-	O
year	O
-	O
old	O
patient	O
with	O
Legionella	B-DISO
pneumonia	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
with	O
severe	O
barotraumas	O
.	O

TITLE	O
:	O
Survey	O
of	O
feline	B-DISO
leukemia	I-DISO
virus	O
and	O
feline	O
coronaviruses	O
in	O
captive	O
neotropical	O
wild	O
felids	O
from	O
Southern	O
Brazil	O
.	O

TITLE	O
:	O
Protective	O
and	O
pathologic	O
roles	O
of	O
the	O
immune	O
response	O
to	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
type	O
1	O
:	O
implications	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

It	O
has	O
also	O
been	O
suggested	O
that	O
immunopathology	B-DISO
may	O
represent	O
an	O
important	O
clinical	O
feature	O
of	O
SARS	B-DISO
.	O

Logistic	O
regression	O
was	O
used	O
to	O
adjust	O
for	O
the	O
effects	O
of	O
other	O
known	O
risk	O
factors	O
for	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Obesity	B-DISO
is	O
an	O
independent	O
predictor	O
of	O
increased	O
morbidity	O
and	O
mortality	O
in	O
critically	O
injured	O
trauma	O
patients	O
.	O

TITLE	O
:	O
Structure	O
and	O
inhibition	O
of	O
the	O
SARS	B-DISO
coronavirus	O
envelope	O
protein	O
ion	O
channel	O
.	O

In	O
animal	O
models	O
,	O
vagal	O
-	O
mediated	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
have	O
been	O
shown	O
to	O
modulate	O
proinflammatory	O
cytokine	O
release	O
in	O
response	O
to	O
trauma	O
or	O
sepsis	B-DISO
.	O

Our	O
aim	O
was	O
to	O
assess	O
the	O
clinical	O
and	O
nutritional	O
efficacy	O
of	O
a	O
probiotic	O
and	O
prebiotic	O
functional	O
food	O
for	O
the	O
treatment	O
of	O
severe	O
acute	O
malnutrition	B-DISO
in	O
a	O
HIV	B-DISO
-	O
prevalent	O
setting	O
.	O

In	O
Malawi	O
,	O
Synbiotic2000	O
Forte	O
did	O
not	O
improve	O
severe	O
acute	O
malnutrition	B-DISO
outcomes	O
.	O

In	O
those	O
returning	O
from	O
the	O
tropics	O
malaria	B-DISO
must	O
always	O
be	O
excluded	O
,	O
and	O
HIV	B-DISO
considered	O
,	O
from	O
all	O
settings	O
.	O

Common	O
causes	O
of	O
non	O
-	O
malarial	B-DISO
fever	I-DISO
include	O
from	O
Africa	O
rickettsial	B-DISO
diseases	I-DISO
,	O
amoebic	B-DISO
liver	I-DISO
abscess	I-DISO
and	O
Katayama	O
syndrome	B-DISO
;	O
from	O
South	O
and	O
South	O
East	O
Asia	O
,	O
enteric	B-DISO
fever	I-DISO
and	O
arboviral	B-DISO
infection	I-DISO
;	O
from	O
the	O
Middle	O
East	O
,	O
brucellosis	B-DISO
and	O
from	O
the	O
Horn	O
of	O
Africa	O
visceral	B-DISO
leishmaniasis	I-DISO
.	O

The	O
sera	O
had	O
low	O
cross	O
-	O
reactivity	O
,	O
but	O
no	O
neutralization	O
activity	O
,	O
for	O
the	O
HIV	B-DISO
-	O
pseudotyped	O
S	O
(	O
SARS	B-DISO
).	O

We	O
report	O
a	O
case	O
with	O
crush	B-DISO
syndrome	I-DISO
and	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
(	O
MODS	B-DISO
)	O
successfully	O
treated	O
with	O
hybrid	O
continuous	O
renal	O
replacement	O
therapy	O
(	O
CRRT	O
).	O

Hybrid	O
CRRT	O
is	O
an	O
effective	O
treatment	O
for	O
patients	O
with	O
severe	O
crush	B-DISO
syndrome	I-DISO
complicated	O
with	O
MODS	B-DISO
.	O

TITLE	O
:	O
[	O
A	O
case	O
of	O
Legionella	B-DISO
pneumonia	I-DISO
with	O
diabetic	B-DISO
ketoacidosis	I-DISO
rescued	O
despite	O
the	O
development	O
of	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
and	O
ARDS	B-DISO
].	O

Concomitant	O
diabetic	B-DISO
ketoacidosis	I-DISO
was	O
treated	O
with	O
hydration	O
and	O
rapid	O
-	O
acting	O
insulin	O
.	O

Mouse	B-DISO
hepatitis	I-DISO
virus	O
is	O
used	O
as	O
well	O
studied	O
examplar	O
to	O
re	O
-	O
evaluate	O
the	O
theoretical	O
basis	O
of	O
the	O
mouse	O
haystack	O
model	O
of	O
M	O
Smith	O
.	O

This	O
report	O
summarizes	O
the	O
clinical	O
characteristics	O
of	O
a	O
series	O
of	O
10	O
patients	O
with	O
novel	O
influenza	B-DISO
A	I-DISO
(	I-DISO
H1N1	I-DISO
)	I-DISO
virus	I-DISO
infection	I-DISO
and	O
ARDS	B-DISO
at	O
a	O
tertiary	O
-	O
care	O
ICU	O
in	O
Michigan	O
.	O

Of	O
the	O
10	O
patients	O
,	O
nine	O
were	O
obese	B-DISO
(	O
body	O
mass	O
index	O
[	O
BMI	O
]	O
>	O
or	O
=	O
30	O
),	O
including	O
seven	O
who	O
were	O
extremely	O
obese	B-DISO
(	O
BMI	O
=	O
40	O
);	O
five	O
had	O
pulmonary	O
emboli	O
;	O
and	O
nine	O
had	O
multiorgan	O
dysfunction	O
syndrome	B-DISO
(	O
MODS	B-DISO
).	O

TITLE	O
:	O
Interferon	O
priming	O
enables	O
cells	O
to	O
partially	O
overturn	O
the	O
SARS	B-DISO
coronavirus	O
-	O
induced	O
block	O
in	O
innate	O
immune	O
activation	O
.	O

Here	O
,	O
we	O
show	O
that	O
pretreatment	O
of	O
non	O
-	O
lymphatic	O
cells	O
with	O
small	O
amounts	O
of	O
IFN	O
-	O
alpha	O
(	O
IFN	O
priming	O
)	O
partially	O
overturns	O
the	O
block	O
in	O
IFN	O
induction	O
imposed	O
by	O
SARS	B-DISO
-	O
CoV	O
.	O
IFN	O
priming	O
combined	O
with	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
substantially	O
induced	O
genes	O
for	O
IFN	O
induction	O
,	O
IFN	O
signalling	O
,	O
antiviral	O
effector	O
proteins	O
,	O
ubiquitination	O
and	O
ISGylation	O
,	O
antigen	O
presentation	O
and	O
other	O
cytokines	O
and	O
chemokines	O
,	O
whereas	O
each	O
individual	O
treatment	O
had	O
no	O
major	O
effect	O
.	O

ABSTRACT	O
:	O
Raccoon	O
dog	O
is	O
one	O
of	O
the	O
suspected	O
intermediate	O
hosts	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

TITLE	O
:	O
Detection	O
of	O
four	O
human	O
coronaviruses	O
in	O
respiratory	B-DISO
infections	I-DISO
in	O
children	O
:	O
a	O
one	O
-	O
year	O
study	O
in	O
Colorado	O
.	O

The	O
majority	O
of	O
HCoV	O
infections	B-DISO
occurred	O
during	O
winter	O
months	O
,	O
and	O
over	O
62	O
%	O
were	O
in	O
previously	O
healthy	O
children	O
.	O

Our	O
findings	O
show	O
that	O
introduction	O
of	O
IBV	O
vaccines	O
into	O
a	O
commercial	O
broiler	O
flock	O
do	O
not	O
necessarily	O
follow	O
a	O
seemingly	O
logical	O
pattern	O
of	O
a	O
high	O
number	O
of	O
birds	O
infected	O
followed	O
by	O
clearance	O
from	O
the	O
trachea	B-DISO
,	O
but	O
resembled	O
either	O
a	O
parabolic	O
curve	O
or	O
a	O
sinusoidal	O
-	O
type	O
wave	O
.	O

ABSTRACT	O
:	O
The	O
understanding	O
of	O
innate	O
immune	O
modulation	O
by	O
pathogens	O
and	O
immune	O
-	O
modulating	O
agents	O
,	O
including	O
synthetic	O
oligodeoxynucleotides	O
(	O
CpG	O
ODNs	O
),	O
has	O
offered	O
several	O
new	O
approaches	O
to	O
improve	O
prophylactic	O
and	O
therapeutic	O
strategies	O
against	O
infectious	B-DISO
diseases	I-DISO
in	O
humans	O
and	O
animals	O
.	O

In	O
addition	O
,	O
CpG	O
ODN	O
administration	O
to	O
chicken	O
embryos	O
24	O
hr	O
before	O
the	O
challenge	O
with	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
was	O
capable	O
of	O
limiting	O
IBV	O
propagation	O
in	O
different	O
embryonic	O
tissues	O
.	O

ABSTRACT	O
:	O
Patients	O
who	O
are	O
diagnosed	O
with	O
acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ALI	O
/	O
ARDS	B-DISO
)	O
usually	O
have	O
ventilation	O
-	O
perfusion	O
mismatch	O
,	O
severe	O
decrease	O
in	O
lung	O
capacity	O
,	O
and	O
gas	O
exchange	O
abnormalities	O
.	O

By	O
rotating	O
patients	O
with	O
ALI	O
/	O
ARDS	B-DISO
between	O
the	O
supine	O
and	O
prone	O
position	O
,	O
it	O
is	O
possible	O
to	O
achieve	O
a	O
significant	O
improvement	O
in	O
PaO2	O
/	O
FiO2	O
,	O
decrease	O
shunting	O
and	O
therefore	O
improve	O
oxygenation	O
without	O
use	O
of	O
expensive	O
,	O
invasive	O
and	O
experimental	O
procedures	O
.	O

Based	O
on	O
current	O
data	O
,	O
a	O
trial	O
of	O
prone	O
positioning	O
ventilation	O
should	O
be	O
offered	O
to	O
the	O
patients	O
who	O
have	O
ALI	O
/	O
ARDS	B-DISO
in	O
the	O
early	O
course	O
of	O
the	O
disease	O
.	O

Primary	O
group	O
A	O
streptococcal	O
peritonitis	B-DISO
in	O
women	O
:	O
case	O
report	O
.	O

Abdominal	O
computed	O
tomography	O
showed	O
perirectal	O
edema	B-DISO
.	O

Blood	O
cultures	O
revealed	O
group	O
A	O
streptococci	O
,	O
usually	O
a	O
common	O
cause	O
of	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
or	O
erysipelas	B-DISO
.	O

Median	O
admission	O
CRS	B-DISO
of	O
2	O
,	O
progressed	O
to	O
4	O
before	O
RCE	O
and	O
declined	O
to	O
2	O
within	O
24	O
hr	O
afterwards	O
.	O

TITLE	O
:	O
[	O
Severe	O
complications	O
and	O
their	O
outcomes	O
in	O
65	O
patients	O
with	O
Legionella	B-DISO
pneumonia	I-DISO
].	O

ABSTRACT	O
:	O
The	O
patient	O
was	O
a	O
70	O
-	O
year	O
-	O
old	O
man	O
who	O
had	O
been	O
given	O
a	O
diagnosis	O
of	O
remitting	B-DISO
seronegative	I-DISO
symmetrical	I-DISO
synovitis	I-DISO
with	I-DISO
pitting	I-DISO
edema	I-DISO
(	O
RS3PE	O
)	O
syndrome	B-DISO
and	O
had	O
been	O
placed	O
on	O
low	O
-	O
dose	O
steroid	O
therapy	O
in	O
the	O
Department	O
of	O
Orthopedics	O
.	O

RS3PE	O
complicated	O
by	O
interstitial	B-DISO
pneumonia	I-DISO
was	O
diagnosed	O
,	O
and	O
steroid	O
pulse	O
therapy	O
and	O
immunosuppressant	O
therapy	O
were	O
initiated	O
.	O

Primary	O
cultures	O
of	O
differentiated	O
alveolar	O
epithelial	O
cells	O
will	O
be	O
useful	O
for	O
identifying	O
the	O
interactions	O
between	O
coronaviruses	O
and	O
alveolar	O
epithelial	O
cells	O
that	O
influence	O
the	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
to	O
infection	B-DISO
in	O
the	O
lung	O
.	O

Here	O
we	O
expand	O
this	O
range	O
of	O
the	O
spectral	O
density	O
to	O
low	O
fields	O
through	O
field	O
cycling	O
using	O
the	O
nucleocapsid	O
protein	O
of	O
the	O
SARS	B-DISO
coronavirus	O
as	O
a	O
model	O
system	O
.	O

ABSTRACT	O
:	O
The	O
term	O
""""	O
cor	B-DISO
pulmonale	I-DISO
""""	O
is	O
still	O
popular	O
but	O
there	O
is	O
presently	O
no	O
consensual	O
definition	O
and	O
it	O
seems	O
more	O
appropriate	O
to	O
define	O
the	O
condition	B-DISO
by	O
the	O
presence	O
of	O
pulmonary	B-DISO
hypertension	I-DISO
(	O
PH	B-DISO
)	O
resulting	O
from	O
diseases	O
affecting	O
the	O
structure	O
and	O
/	O
or	O
the	O
function	O
of	O
the	O
lungs	O
:	O
PH	B-DISO
results	O
in	O
right	B-DISO
ventricular	I-DISO
enlargement	I-DISO
and	O
may	O
lead	O
with	O
time	O
to	O
right	B-DISO
heart	I-DISO
failure	I-DISO
(	O
RHF	O
).	O

The	O
main	O
characteristic	O
of	O
PH	O
in	O
CRD	B-DISO
and	O
particularly	O
in	O
COPD	B-DISO
is	O
its	O
mild	O
to	O
moderate	O
degree	O
,	O
resting	O
pulmonary	O
artery	O
mean	O
pressure	O
(	O
PAP	B-DISO
)	O
in	O
a	O
stable	O
state	O
of	O
the	O
disease	O
usually	O
ranging	O
between	O
20	O
and	O
35	O
mmHg	O
.	O

At	O
present	O
long	O
-	O
term	O
oxygen	O
therapy	O
(	O
LTOT	O
)	O
is	O
the	O
logical	O
treatment	O
of	O
PH	O
since	O
alveolar	O
hypoxia	B-DISO
is	O
considered	O
to	O
be	O
the	O
major	O
determinant	O
of	O
the	O
elevation	O
of	O
PAP	B-DISO
and	O
PVR	B-DISO
.	O

With	O
VT	O
<	O
6	O
ml	O
/	O
kg	O
,	O
severe	O
acidosis	B-DISO
could	O
only	O
be	O
avoided	O
if	O
PCV	O
was	O
combined	O
with	O
av	O
-	O
ECLA	O
.	O

RESULTS	O
:	O
After	O
lung	O
recruitment	B-DISO
,	O
oxygenation	O
remained	O
significantly	O
improved	O
although	O
VTs	O
were	O
minimized	O
to	O
0	O
ml	O
/	O
kg	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Upon	O
the	O
basis	O
of	O
the	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
inhibitor	O
24	O
-	O
bound	O
to	O
SARS	B-DISO
-	O
CoV	O
PLpro	O
,	O
a	O
drug	O
design	O
template	O
was	O
created	O
.	O

The	O
pathology	B-DISO
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
involves	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
,	O
which	O
comprises	O
severe	O
alveolar	O
epithelial	O
cell	B-DISO
damage	I-DISO
,	O
hyaline	B-DISO
membrane	I-DISO
formation	O
,	O
and	O
festinate	O
myofibroblast	O
proliferation	B-DISO
and	O
fibrosis	B-DISO
in	O
the	O
intra	O
-	O
alveolar	O
spaces	O
.	O

ABSTRACT	O
:	O
Nonthrombotic	O
pulmonary	B-DISO
embolism	I-DISO
(	O
NTPE	O
)	O
is	O
defined	O
as	O
embolisation	O
to	O
the	O
pulmonary	O
circulation	O
of	O
different	O
cell	O
types	O
(	O
adipocytes	O
,	O
haematopoietic	O
,	O
amniotic	O
,	O
trophoblastic	O
or	O
tumour	B-DISO
),	O
bacteria	O
,	O
fungi	O
,	O
foreign	O
material	O
or	O
gas	O
.	O

Increased	O
awareness	O
of	O
NTPE	O
as	O
an	O
underestimated	O
cause	O
of	O
acute	O
and	O
chronic	O
embolism	B-DISO
,	O
which	O
may	O
result	O
in	O
acute	O
and	O
chronic	O
pulmonary	B-DISO
hypertension	I-DISO
,	O
is	O
needed	O
.	O

We	O
speculate	O
that	O
the	O
additional	O
type	O
I	O
IFN	O
-	O
dependent	O
genes	O
that	O
we	O
discovered	O
may	O
also	O
be	O
important	O
for	O
protection	O
against	O
MHV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Over	O
the	O
last	O
year	O
there	O
have	O
been	O
more	O
studies	O
determining	O
predisposition	O
to	O
severe	O
bronchiolitis	B-DISO
and	O
its	O
consequences	O
.	O

Others	O
have	O
examined	O
the	O
long	O
-	O
term	O
outcome	O
of	O
viral	B-DISO
infection	I-DISO
in	O
infancy	O
.	O

Compared	O
to	O
low	O
PEEP	O
,	O
PaO	O
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
and	O
alveolar	O
recruitment	B-DISO
were	O
increased	O
with	O
high	O
PEEP	O
.	O

Both	O
high	O
-	O
PEEP	O
strategies	O
induced	O
higher	O
PaCO	O
(	O
2	O
)	O
levels	O
[	O
71	O
(	O
60	O
-	O
94	O
)	O
and	O
75	O
(	O
53	O
-	O
84	O
),	O
vs	O
.	O
52	O
(	O
43	O
-	O
68	O
)	O
mmHg	O
]	O
and	O
lower	O
pH	O
values	O
[	O
7	O
.	O
17	O
(	O
7	O
.	O
12	O
-	O
7	O
.	O
23	O
)	O
and	O
7	O
.	O
20	O
(	O
7	O
.	O
16	O
-	O
7	O
.	O
25	O
)	O
vs	O
.	O
7	O
.	O
30	O
(	O
7	O
.	O
24	O
-	O
7	O
.	O
35	O
)],	O
as	O
well	O
as	O
RV	O
dilatation	B-DISO
,	O
LV	O
deformation	O
and	O
a	O
significant	O
decrease	O
in	O
cardiac	O
index	O
.	O

The	O
decrease	O
in	O
stroke	B-DISO
index	O
tended	O
to	O
be	O
negatively	O
correlated	O
to	O
the	O
increase	O
in	O
alveolar	O
recruitment	B-DISO
with	O
high	O
PEEP	O
.	O

Significant	O
suppression	B-DISO
of	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
[	O
reduced	O
alpha	O
interferon	O
(	O
IFN	O
-	O
alpha	O
)	O
levels	O
in	O
the	O
lungs	O
and	O
reduced	O
blood	O
natural	O
killer	O
cell	O
cytotoxicity	B-DISO
]	O
by	O
the	O
ongoing	O
PRRSV	O
infection	B-DISO
was	O
observed	O
in	O
dual	O
-	O
infected	O
pigs	O
,	O
which	O
coincided	O
with	O
exacerbated	O
pneumonia	B-DISO
during	O
early	O
PRCV	O
infection	B-DISO
.	O

This	O
study	O
provides	O
new	O
insights	O
into	O
host	O
-	O
pathogen	O
interactions	O
related	O
to	O
co	B-DISO
-	I-DISO
infection	I-DISO
by	O
CoVs	O
and	O
other	O
respiratory	O
viruses	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
enhance	O
the	O
sensitivity	O
of	O
conventional	O
immunoassay	O
technology	O
for	O
the	O
detection	O
of	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
nucleocapsid	O
protein	O
(	O
N	O
protein	O
),	O
we	O
developed	O
a	O
localized	O
surface	O
plasmon	O
coupled	O
fluorescence	O
(	O
LSPCF	O
)	O
fiber	O
-	O
optic	O
biosensor	O
that	O
combines	O
sandwich	O
immunoassay	O
with	O
the	O
LSP	O
technique	O
.	O

RCIM	O
should	O
not	O
be	O
used	O
in	O
case	O
of	O
acute	O
streptococcal	O
glomerulonephritis	B-DISO
,	O
acquired	B-DISO
immune	I-DISO
deficiency	I-DISO
syndrome	I-DISO
,	O
severe	O
viral	B-DISO
disease	I-DISO
,	O
or	O
severe	O
autoimmune	B-DISO
disease	I-DISO
.	O

Preference	O
will	O
be	O
given	O
to	O
rRBD	O
expressed	O
in	O
mammalian	O
cells	O
for	O
future	O
evaluation	O
of	O
the	O
vaccine	O
efficacy	O
in	O
a	O
non	O
-	O
human	O
primate	O
model	O
of	O
SARS	B-DISO
because	O
of	O
its	O
ability	O
to	O
refold	O
into	O
a	O
native	O
conformation	O
more	O
readily	O
and	O
to	O
induce	O
higher	O
level	O
of	O
neutralizing	O
antibody	O
responses	O
than	O
those	O
expressed	O
in	O
E	O
.	O
coli	O
and	O
insect	O
cells	O
.	O

Using	O
a	O
SELEX	O
(	O
systematic	O
evolution	O
of	O
ligand	O
by	O
exponential	O
enrichment	O
)	O
procedure	O
and	O
recombinant	O
N	O
protein	O
,	O
we	O
selected	O
a	O
high	O
-	O
affinity	O
RNA	O
aptamer	O
capable	O
of	O
binding	O
to	O
N	O
protein	O
with	O
a	O
dissociation	B-DISO
constant	O
of	O
1	O
.	O
65	O
nM	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
RNA	O
competition	O
experiments	O
showed	O
that	O
the	O
selected	O
aptamer	O
recognized	O
selectively	O
the	O
C	O
-	O
terminal	O
region	O
of	O
N	O
protein	O
with	O
high	O
specificity	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
causes	O
a	O
lung	B-DISO
disease	I-DISO
with	O
high	O
mortality	O
.	O

ABSTRACT	O
:	O
Hyperinfection	O
syndrome	B-DISO
with	O
Strongyloides	O
stercoralis	O
is	O
not	O
uncommon	O
in	O
immunocompromised	O
patients	O
.	O

We	O
present	O
2	O
fatal	O
cases	O
of	O
Strongyloides	O
hyperinfection	O
with	O
initial	O
presentation	O
mimicking	O
acute	O
exacerbation	O
of	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
COPD	B-DISO
).	O

Both	O
cases	O
had	O
a	O
history	O
of	O
COPD	B-DISO
and	O
had	O
received	O
systemic	O
steroid	O
treatment	O
before	O
or	O
during	O
admission	O
.	O

Clinical	O
manifestations	O
of	O
unexplained	O
wheezing	B-DISO
and	O
respiratory	B-DISO
failure	I-DISO
,	O
increased	O
infiltration	B-DISO
on	O
chest	O
radiograph	O
,	O
Gram	B-DISO
-	I-DISO
negative	I-DISO
bacteremia	I-DISO
,	O
and	O
aseptic	B-DISO
meningitis	I-DISO
may	O
all	O
be	O
clues	O
of	O
Strongyloides	O
hyperinfection	O
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
and	O
spread	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
and	O
the	O
subsequent	O
identification	O
of	O
its	O
animal	O
origin	O
study	O
have	O
heightened	O
the	O
world	O
'	O
s	O
awareness	O
of	O
animal	O
-	O
borne	O
or	O
zoonotic	O
pathogens	O
.	O

TITLE	O
:	O
Inflammation	B-DISO
-	O
associated	O
repression	O
of	O
vasodilator	O
-	O
stimulated	O
phosphoprotein	O
(	O
VASP	O
)	O
reduces	O
alveolar	O
-	O
capillary	O
barrier	O
function	O
during	O
acute	O
lung	O
injury	O
.	O

The	O
World	O
Health	O
Organization	O
recommended	O
the	O
use	O
of	O
household	O
disinfectants	O
,	O
which	O
have	O
not	O
been	O
previously	O
tested	O
against	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
to	O
disinfect	O
potentially	O
contaminated	O
environmental	O
surfaces	O
.	O

Legal	O
medicine	O
autopsy	O
identified	O
aggressive	B-DISO
Candida	O
famata	O
mycosis	B-DISO
.	O

This	O
study	O
attempted	O
to	O
quantify	O
the	O
effect	O
of	O
such	O
changes	O
on	O
the	O
risk	O
of	O
infection	B-DISO
in	O
different	O
settings	O
,	O
i	O
.	O
e	O
.,	O
the	O
community	O
and	O
hospitals	O
.	O

Data	O
augmentation	O
techniques	O
and	O
Markov	O
chain	O
Monte	O
Carlo	O
(	O
MCMC	O
)	O
methods	O
were	O
applied	O
to	O
estimate	O
SARS	B-DISO
epidemiological	O
parameters	O
.	O

In	O
the	O
meantime	O
,	O
the	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
and	O
the	O
concern	O
over	O
pandemic	O
influenza	B-DISO
have	O
stimulated	O
considerable	O
government	O
and	O
healthcare	O
institutional	O
efforts	O
to	O
improve	O
infection	B-DISO
control	O
systems	O
in	O
Canada	O
.	O

Methicillin	B-DISO
-	I-DISO
resistant	I-DISO
Staphylococcus	I-DISO
aureus	I-DISO
(	O
MRSA	B-DISO
)	O
rates	O
increased	O
from	O
1999	O
to	O
2005	O
(	O
F	O
=	O
9	O
.	O
4	O
,	O
P	O
=	O
0	O
.	O
003	O
).	O

Meanwhile	O
,	O
Nosocomial	O
MRSA	B-DISO
rates	O
more	O
than	O
doubled	O
between	O
1999	O
and	O
2005	O
and	O
hospitals	O
reporting	O
new	O
nosocomial	O
VRE	O
cases	O
increased	O
77	O
%	O
over	O
the	O
same	O
period	O
.	O

TITLE	O
:	O
[	O
An	O
autopsy	O
case	O
of	O
fulminant	O
community	O
-	O
acquired	O
pneumonia	B-DISO
due	O
to	O
Acinetobacter	O
baumannii	O
].	O

Acinetobacter	O
baumannii	O
was	O
cultured	O
from	O
bronchoalveolar	O
lavage	O
fluid	O
and	O
the	O
postmortem	O
lung	O
specimen	O
,	O
indicating	O
that	O
his	O
severe	O
community	O
-	O
acquired	O
pneumonia	B-DISO
was	O
due	O
to	O
A	O
.	O
baumannii	O
.	O

In	O
Syrian	O
Golden	O
Hamsters	O
inoculated	O
intranasally	O
with	O
10e4	O
plaque	B-DISO
forming	O
units	O
of	O
either	O
virus	O
,	O
mean	O
titers	O
of	O
infectious	B-DISO
virus	O
and	O
viral	O
RNA	O
in	O
the	O
lungs	O
after	O
24	O
h	O
were	O
increased	O
23	O
-	O
and	O
94	O
.	O
8	O
-	O
fold	O
,	O
respectively	O
,	O
with	O
the	O
deleted	O
virus	O
.	O

On	O
physical	O
examination	O
,	O
the	O
patient	O
presented	O
malnourished	B-DISO
with	O
pale	B-DISO
skin	I-DISO
,	O
cervical	B-DISO
lymphadenitis	I-DISO
,	O
frequent	O
fever	O
and	O
generalized	B-DISO
pain	I-DISO
.	O

Thirty	O
-	O
two	O
months	O
after	O
presentation	O
of	O
the	O
initial	O
symptoms	O
,	O
the	O
patient	O
died	O
due	O
to	O
complications	O
related	O
to	O
leukaemia	B-DISO
recurrence	B-DISO
(	O
haemorrhage	B-DISO
,	O
sepsis	B-DISO
and	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
).	O

BALB	O
/	O
c	O
mice	O
exposed	O
to	O
a	O
mouse	O
-	O
adapted	O
strain	O
of	O
SARS	B-DISO
-	O
CoV	O
demonstrated	O
100	O
%	O
survival	O
and	O
modest	O
reductions	O
in	O
lung	O
pathology	B-DISO
without	O
reductions	O
in	O
virus	O
titer	O
when	O
treated	O
with	O
two	O
intranasal	O
doses	O
of	O
RTD	B-DISO
-	O
1	O
,	O
while	O
mortality	O
in	O
untreated	O
mice	O
was	O
approximately	O
75	O
%.	O

Here	O
we	O
analyse	O
,	O
for	O
the	O
first	O
time	O
,	O
the	O
heterogeneous	O
patterns	O
of	O
related	O
cellular	O
activities	O
,	O
namely	O
virus	B-DISO
infection	I-DISO
,	O
endocytosis	O
and	O
membrane	O
lipid	O
composition	O
in	O
adherent	O
human	O
cells	O
.	O

Finally	O
,	O
we	O
reveal	O
that	O
synergy	O
between	O
two	O
molecular	O
components	O
,	O
focal	O
adhesion	B-DISO
kinase	O
and	O
the	O
sphingolipid	O
GM1	O
,	O
enhances	O
the	O
population	O
-	O
determined	O
pattern	O
of	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
infection	B-DISO
.	O

Severe	B-DISO
sepsis	I-DISO
and	O
septic	B-DISO
shock	I-DISO
accounts	O
for	O
25	O
.	O
4	O
%	O
of	O
admission	O
to	O
the	O
ICU	O
during	O
Hajj	O
.	O

RESULTS	O
:	O
Severe	B-DISO
sepsis	I-DISO
and	O
septic	B-DISO
shock	I-DISO
accounts	O
for	O
25	O
.	O
4	O
%	O
of	O
admission	O
to	O
the	O
ICU	O
during	O
Hajj	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
importance	O
of	O
this	O
well	O
conserved	O
region	O
for	O
SARS	B-DISO
-	O
CoV	O
S	O
-	O
mediated	O
fusion	O
activation	O
.	O

Mutagenic	O
analysis	O
of	O
SARS	B-DISO
-	O
CoV	O
S	O
,	O
combined	O
with	O
cell	O
-	O
cell	O
fusion	O
and	O
pseudotyped	O
virion	O
infectivity	O
assays	O
,	O
showed	O
a	O
critical	O
role	O
for	O
the	O
core	O
-	O
conserved	O
residues	O
C822	O
,	O
D830	O
,	O
L831	O
,	O
and	O
C833	O
.	O

The	O
estimates	O
for	O
influenza	B-DISO
suggest	O
that	O
the	O
virulence	O
is	O
comparable	O
to	O
the	O
early	O
estimate	O
in	O
Mexico	O
.	O

We	O
performed	O
a	O
prospective	O
,	O
multicenter	O
,	O
observational	O
study	O
to	O
investigate	O
the	O
time	O
-	O
course	O
of	O
lipopolysaccharide	O
binding	O
protein	O
(	O
LBP	B-DISO
)	O
serum	O
levels	O
in	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
and	O
examined	O
whether	O
serial	O
serum	O
levels	O
of	O
LBP	B-DISO
could	O
be	O
used	O
as	O
a	O
marker	O
of	O
outcome	O
.	O

ADCML	O
consists	O
of	O
virus	O
-	O
specific	O
antibodies	O
that	O
bind	O
to	O
cell	O
surface	O
expressed	O
viral	O
proteins	O
which	O
result	O
in	O
complement	O
activation	O
and	O
cell	O
lysis	B-DISO
.	O

ADCML	O
assays	O
,	O
using	O
FIPV	O
strain	O
79	O
-	O
1146	O
and	O
its	O
deletion	O
mutant	B-DISO
strain	O
Delta	O
3abc	O
/	O
Delta	O
7ab	O
,	O
were	O
performed	O
on	O
:	O
(	O
i	O
)	O
CrFK	O
cells	O
that	O
show	O
surface	O
-	O
expressed	O
viral	O
antigens	O
,	O
(	O
ii	O
)	O
monocytes	O
without	O
surface	O
-	O
expressed	O
viral	O
proteins	O
due	O
to	O
retention	O
and	O
(	O
iii	O
)	O
monocytes	O
with	O
surface	O
-	O
expressed	O
viral	O
proteins	O
since	O
the	O
antibody	O
-	O
mediated	O
internalization	O
of	O
these	O
proteins	O
was	O
blocked	O
.	O

Here	O
we	O
present	O
crystal	O
structures	O
of	O
porcine	O
and	O
bovine	O
torovirus	O
HEs	B-DISO
in	O
complex	O
with	O
receptor	O
analogs	O
.	O

TITLE	O
:	O
Revisiting	O
steroid	O
treatment	O
for	O
septic	B-DISO
shock	I-DISO
:	O
molecular	O
actions	O
and	O
clinical	O
effects	O
--	O
a	O
review	O
.	O

The	O
spectrum	O
of	O
interferon	O
(	O
IFN	O
)-	O
gamma	O
responses	O
of	O
Balb	O
/	O
c	O
mice	O
immunized	O
against	O
two	O
different	O
forms	O
of	O
SARS	B-DISO
CoV	O
-	O
N	O
plasmid	O
was	O
then	O
analyzed	O
.	O

ABSTRACT	O
:	O
Airborne	O
virus	O
capture	O
and	O
inactivation	B-DISO
were	O
studied	O
in	O
an	O
electrostatic	O
precipitator	O
(	O
ESP	O
)	O
at	O
applied	O
voltages	O
from	O
-	O
10	O
to	O
+	O
10	O
kV	O
using	O
aerosolized	O
bacteriophages	O
T3	O
and	O
MS2	O
.	O

For	O
each	O
charging	O
scenario	O
,	O
samples	O
were	O
collected	O
from	O
the	O
effluent	O
air	O
stream	O
and	O
assayed	O
for	O
viable	O
phages	O
using	O
plaque	B-DISO
assays	O
and	O
for	O
nucleic	O
acids	O
using	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
qPCR	O
)	O
assays	O
.	O

At	O
higher	O
applied	O
voltages	O
,	O
more	O
virus	O
particles	O
were	O
captured	O
from	O
air	O
with	O
maximum	O
log	O
reductions	O
of	O
6	O
.	O
8	O
and	O
6	O
.	O
3	O
for	O
the	O
plaque	B-DISO
assay	O
and	O
4	O
.	O
2	O
and	O
3	O
.	O
5	O
for	O
the	O
qPCR	O
assay	O
at	O
-	O
10	O
kV	O
for	O
T3	O
and	O
MS2	O
,	O
respectively	O
.	O

Beyond	O
corona	O
inception	O
(	O
i	O
.	O
e	O
.,	O
at	O
applied	O
voltages	O
of	O
-	O
10	O
,	O
-	O
8	O
,	O
+	O
8	O
,	O
and	O
+	O
10	O
kV	O
),	O
log	O
reduction	O
values	O
obtained	O
with	O
the	O
plaque	B-DISO
assay	O
were	O
much	O
higher	O
compared	O
to	O
those	O
of	O
the	O
qPCR	O
assay	O
because	O
nonviable	O
particles	O
,	O
while	O
present	O
in	O
the	O
effluent	O
were	O
unaccounted	O
for	O
in	O
the	O
plaque	B-DISO
assay	O
.	O

ABSTRACT	O
:	O
Intravascular	O
volume	O
status	O
and	O
volume	O
responsiveness	O
continue	O
to	O
be	O
important	O
questions	O
for	O
the	O
management	O
of	O
critically	B-DISO
ill	I-DISO
or	O
injured	O
patients	O
.	O

Static	O
measures	O
of	O
fluid	O
status	O
,	O
central	O
venous	O
pressure	O
(	O
CVP	O
),	O
and	O
pulmonary	O
artery	B-DISO
occlusion	I-DISO
pressure	O
(	O
PAOP	O
)	O
are	O
not	O
useful	O
in	O
predicting	O
volume	O
responsiveness	O
.	O

TITLE	O
:	O
[	O
Study	O
on	O
interaction	O
between	O
SARS	B-DISO
-	O
CoV	O
N	O
and	O
MAP19	O
].	O

CONCLUSIONS	O
:	O
SARS	B-DISO
-	O
CoV	O
N	O
can	O
bind	O
with	O
MAP19	O
in	O
cells	O
.	O

TITLE	O
:	O
Antigen	O
-	O
capture	O
blocking	B-DISO
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
based	O
on	O
a	O
baculovirus	O
recombinant	O
antigen	O
to	O
differentiate	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
from	O
Porcine	O
respiratory	O
coronavirus	O
antibodies	O
.	O

These	O
results	O
suggest	O
that	O
control	O
of	O
acute	B-DISO
hepatitis	I-DISO
by	O
IFN	O
-	O
gamma	O
-	O
producing	O
NK	O
cells	O
may	O
depend	O
on	O
both	O
production	O
of	O
IL	O
-	O
12	O
and	O
IL	O
-	O
18	O
in	O
the	O
liver	O
environment	O
and	O
viral	B-DISO
infection	I-DISO
of	O
NK	O
cells	O
.	O

ABSTRACT	O
:	O
To	O
identify	O
instructive	O
messages	O
to	O
guide	O
nursing	O
practice	O
in	O
future	O
epidemics	O
by	O
examining	O
the	O
stories	O
of	O
Chinese	O
nurses	O
who	O
cared	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
.	O

Researchers	O
expect	O
that	O
global	O
infections	B-DISO
,	O
like	O
SARS	B-DISO
,	O
will	O
persist	O
and	O
escalate	O
in	O
the	O
future	O
.	O

It	O
is	O
important	O
to	O
access	O
the	O
guidance	O
from	O
nurses	O
who	O
cared	O
for	O
SARS	B-DISO
patients	O
in	O
China	O
and	O
to	O
uncover	O
instructive	O
messages	O
which	O
can	O
be	O
useful	O
when	O
facing	O
global	O
infections	B-DISO
in	O
the	O
future	O
.	O

Data	O
were	O
collected	O
in	O
2003	O
,	O
within	O
the	O
three	O
months	O
following	O
the	O
nurses	O
'	O
quarantine	O
necessitated	O
by	O
caring	O
for	O
SARS	B-DISO
patients	O
.	O

These	O
instructive	O
messages	O
come	O
from	O
China	O
,	O
where	O
the	O
SARS	B-DISO
epidemic	O
inflicted	O
an	O
unparalleled	O
health	O
impact	O
.	O

TITLE	O
:	O
Efficient	O
induction	O
of	O
cytotoxic	O
T	O
lymphocytes	O
specific	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
associated	O
coronavirus	O
by	O
immunization	O
with	O
surface	O
-	O
linked	O
liposomal	O
peptides	O
derived	O
from	O
a	O
non	O
-	O
structural	O
polyprotein	O
1a	O
.	O

These	O
data	O
suggest	O
that	O
surface	O
-	O
linked	O
liposomal	O
peptides	O
derived	O
from	O
pp1a	O
might	O
offer	O
an	O
efficient	O
CTL	O
-	O
based	O
vaccine	O
against	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
Stem	O
-	O
loop	O
2	O
(	O
SL2	O
)	O
of	O
the	O
5	O
'-	O
untranslated	O
region	O
of	O
the	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
contains	O
a	O
highly	O
conserved	O
pentaloop	O
(	O
C47	O
-	O
U48	O
-	O
U49	O
-	O
G50	O
-	O
U51	O
)	O
stacked	O
on	O
a	O
5	O
-	O
bp	O
stem	O
.	O

ABSTRACT	O
:	O
Reminiscent	O
of	O
the	O
Severe	O
Acquired	O
Respiratory	O
Syndrome	B-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
during	O
the	O
spring	O
and	O
fall	O
of	O
2003	O
,	O
an	O
outbreak	O
of	O
Severe	O
Respiratory	O
Illness	O
(	O
SRI	O
)	O
in	O
Mexico	O
has	O
world	O
health	O
officials	O
in	O
a	O
state	O
of	O
concern	O
.	O

Potential	O
risk	O
factors	O
for	O
diarrhea	B-DISO
were	O
analyzed	O
by	O
using	O
Cox	O
regression	O
analysis	O
adjusted	O
for	O
herd	O
frailty	O
effect	O
.	O

A	O
high	O
level	O
of	O
Cryptosporidium	O
shedding	O
or	O
BCoV	O
seropositive	O
calves	O
in	O
a	O
herd	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
diarrhea	B-DISO
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
clinical	O
and	O
treatment	O
factors	O
for	O
patients	O
recorded	O
in	O
the	O
Extracorporeal	O
Life	O
Support	O
Organization	O
(	O
ELSO	O
)	O
registry	O
and	O
survival	O
of	O
adult	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
respiratory	B-DISO
failure	I-DISO
patients	O
.	O

Mortality	O
:	O
14	O
/	O
28	O
;	O
7	O
/	O
14	O
with	O
confirmed	O
A	O
(	O
H1N1	O
)	O
infection	B-DISO
.	O

The	O
children	O
'	O
s	O
median	O
age	O
was	O
11	O
months	O
;	O
61	O
.	O
8	O
%	O
presented	O
comorbidities	O
(	O
prematurity	O
,	O
asthma	B-DISO
,	O
broncho	O
-	O
pulmonary	O
dysplasia	B-DISO
and	O
congenital	B-DISO
heart	I-DISO
disease	I-DISO
).	O

TITLE	O
:	O
The	O
making	O
of	O
a	O
Chinese	O
head	O
of	O
the	O
WHO	O
:	O
a	O
study	O
of	O
the	O
media	O
discourse	O
on	O
Margaret	O
Chan	O
'	O
s	O
contest	O
for	O
the	O
WHO	O
director	O
-	O
generalship	O
and	O
its	O
implications	O
for	O
the	O
collective	O
memory	O
of	O
SARS	B-DISO
.	O

TITLE	O
:	O
Acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
triggered	O
by	O
honeybee	O
sting	O
:	O
a	O
case	O
report	O
.	O

He	O
did	O
not	O
have	O
any	O
allergic	B-DISO
symptoms	I-DISO
and	O
there	O
was	O
no	O
cutaneous	O
or	O
respiratory	O
evidence	O
of	O
allergy	B-DISO
on	O
physical	O
examination	O
.	O

Using	O
inhibitors	O
specific	O
for	O
three	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
,	O
we	O
showed	O
that	O
induction	O
of	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
6	O
by	O
MHV	O
-	O
A59	O
infection	B-DISO
was	O
mediated	O
through	O
activation	O
of	O
the	O
Janus	B-DISO
N	O
-	O
terminal	O
kinase	O
signaling	O
pathway	O
,	O
but	O
not	O
through	O
the	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
or	O
p38	O
signaling	O
pathway	O
.	O

Interestingly	O
,	O
while	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
),	O
a	O
key	O
transcription	O
factor	O
required	O
for	O
the	O
expression	O
of	O
proinflammatory	O
cytokines	O
in	O
most	O
cell	O
types	O
,	O
was	O
activated	O
in	O
astrocytes	O
during	O
MHV	O
-	O
A59	O
infection	B-DISO
,	O
disruption	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
by	O
peptide	O
inhibitors	O
did	O
not	O
significantly	O
inhibit	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
6	O
expression	O
.	O

Statistical	O
significant	O
difference	O
was	O
observed	O
among	O
the	O
spleen	O
lymphocyte	O
proliferation	B-DISO
index	O
(	O
LPI	B-DISO
)	O
among	O
the	O
immunization	O
groups	O
of	O
mice	O
and	O
control	O
groups	O
.	O

We	O
show	O
here	O
that	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
of	O
N	O
protein	O
from	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
),	O
a	O
virus	O
most	O
closely	O
related	O
to	O
SARS	B-DISO
-	O
CoV	O
,	O
employs	O
aromatic	O
amino	O
acid	O
-	O
nucleobase	O
stacking	O
interactions	O
with	O
a	O
triple	O
adenosine	O
motif	O
to	O
mediate	O
high	O
-	O
affinity	O
binding	O
to	O
single	O
-	O
stranded	O
RNAs	O
containing	O
the	O
transcriptional	O
regulatory	O
sequence	O
(	O
TRS	B-DISO
)	O
or	O
its	O
complement	O
(	O
cTRS	O
).	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
in	O
the	O
literature	O
to	O
show	O
a	O
causal	O
relationship	O
between	O
ARDS	B-DISO
and	O
RA	O
.	O

TITLE	O
:	O
Protection	O
of	O
chickens	O
against	O
infectious	B-DISO
bronchitis	B-DISO
by	O
a	O
recombinant	O
fowlpox	B-DISO
virus	O
co	O
-	O
expressing	O
IBV	O
-	O
S1	O
and	O
chicken	O
IFNgamma	O
.	O

The	O
serum	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
level	O
recovered	O
more	O
quickly	O
in	O
patients	O
in	O
the	O
PCD	B-DISO
group	O
compared	O
to	O
those	O
in	O
the	O
surgery	O
group	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

Patients	O
with	O
SAP	O
and	O
a	O
CTSI	O
<	O
or	O
=	O
8	O
.	O
0	O
could	O
be	O
treated	O
with	O
conservative	O
therapy	O
,	O
while	O
patients	O
with	O
a	O
CTSI	O
>	O
8	O
.	O
0	O
should	O
be	O
treated	O
with	O
surgery	O
or	O
PCD	B-DISO
therapy	O
if	O
the	O
life	O
-	O
threatening	O
complications	O
of	O
extensive	O
fluid	O
collection	O
or	O
necrosis	O
are	O
a	O
factor	O
.	O

These	O
findings	O
may	O
have	O
potential	O
as	O
diagnostic	O
markers	O
for	O
virulent	O
FIP	B-DISO
-	O
associated	O
FCoV	O
.	O

APRV	O
may	O
have	O
particular	O
utility	O
in	O
pregnant	O
patients	O
with	O
ARDS	B-DISO
.	O

TITLE	O
:	O
RNase	O
L	O
mediated	O
protection	O
from	O
virus	O
induced	O
demyelination	B-DISO
.	O

Infection	B-DISO
of	O
RNase	O
L	O
deficient	O
(	O
RL	O
(-/-))	O
mice	O
with	O
a	O
sub	O
-	O
lethal	O
,	O
demyelinating	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
variant	O
revealed	O
that	O
the	O
majority	O
of	O
mice	O
succumbed	O
to	O
infection	B-DISO
by	O
day	O
12	O
p	O
.	O
i	O
.	O

However	O
,	O
RNase	O
L	O
deficiency	O
did	O
not	O
affect	O
overall	O
control	O
of	O
infectious	B-DISO
virus	O
,	O
or	O
diminish	O
IFN	O
-	O
alpha	O
/	O
beta	O
expression	O
in	O
the	O
CNS	O
.	O

Furthermore	O
,	O
increased	O
morbidity	O
and	O
mortality	O
could	O
not	O
be	O
attributed	O
to	O
altered	O
proinflammatory	O
signals	O
or	O
composition	O
of	O
cells	O
infiltrating	B-DISO
the	O
CNS	O
.	O

These	O
data	O
demonstrate	O
a	O
novel	O
protective	O
role	O
for	O
RNase	O
L	O
in	O
viral	O
induced	O
CNS	O
encephalomyelitis	B-DISO
,	O
which	O
is	O
not	O
reflected	O
in	O
overall	O
viral	O
control	O
or	O
propagation	O
of	O
IFN	O
-	O
alpha	O
/	O
beta	O
mediated	O
signals	O
.	O

Protective	O
function	O
is	O
rather	O
associated	O
with	O
cell	O
type	O
specific	O
and	O
regional	O
restriction	O
of	O
viral	O
replication	O
in	O
grey	O
matter	O
and	O
ameliorated	O
neurodegeneration	B-DISO
and	O
demyelination	B-DISO
.	O

The	O
patient	O
'	O
s	O
condition	B-DISO
became	O
stable	O
after	O
the	O
management	O
.	O

After	O
A	O
/	O
H5N1	B-DISO
infection	B-DISO
was	O
confirmed	O
,	O
antiviral	O
treatment	O
with	O
oseltamivir	O
and	O
A	O
/	O
H5N1	B-DISO
vaccinated	O
plasma	O
were	O
used	O
on	O
day	O
11	O
.	O

Human	O
A	O
/	O
H5N1	B-DISO
infection	B-DISO
is	O
a	O
severe	O
and	O
rapidly	O
progressive	B-DISO
disease	I-DISO
mostly	O
manifested	O
as	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
To	O
summarize	O
the	O
clinical	O
characteristics	O
and	O
therapeutic	O
experience	O
of	O
A	O
/	O
H5N1	B-DISO
infected	O
patient	O
with	O
intractable	O
bronchopleural	B-DISO
fistula	I-DISO
.	O

The	O
data	O
of	O
a	O
patient	O
with	O
A	O
/	O
H5N1	B-DISO
infection	B-DISO
complicated	O
with	O
bronchopleural	B-DISO
fistula	I-DISO
was	O
collected	O
and	O
analyzed	O
.	O

TITLE	O
:	O
Phylogenetic	O
perspectives	O
on	O
the	O
epidemiology	O
and	O
origins	O
of	O
SARS	B-DISO
and	O
SARS	B-DISO
-	O
like	O
coronaviruses	O
.	O

The	O
origins	O
of	O
SCoV	O
have	O
been	O
mysterious	O
and	O
controversial	O
,	O
until	O
the	O
recent	O
discovery	O
of	O
SARS	B-DISO
-	O
like	O
CoV	O
(	O
SLCoV	O
)	O
in	O
bats	O
and	O
the	O
proposal	O
of	O
bats	O
as	O
the	O
natural	O
reservior	O
of	O
the	O
Coronaviridae	O
family	O
.	O

Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
belongs	O
to	O
the	O
family	O
Coronaviridae	O
,	O
was	O
first	O
identified	O
during	O
2002	O
-	O
2003	O
.	O

Secondly	O
,	O
NO	O
or	O
its	O
derivatives	O
cause	O
a	O
reduction	O
in	O
viral	O
RNA	O
production	O
in	O
the	O
early	O
steps	O
of	O
viral	O
replication	O
,	O
and	O
this	O
could	O
possibly	O
be	O
due	O
to	O
an	O
effect	O
on	O
one	O
or	O
both	O
of	O
the	O
cysteine	O
proteases	O
encoded	O
in	O
Orf1a	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O

TITLE	O
:	O
Hantavirus	B-DISO
pulmonary	I-DISO
syndrome	I-DISO
in	O
Brasilia	O
periphery	O
:	O
a	O
diagnostic	O
challenge	O
.	O

Reports	O
of	O
moderate	O
or	O
less	O
typical	O
cases	O
can	O
raise	O
the	O
suspicion	O
index	O
among	O
primary	O
care	O
and	O
hospital	O
-	O
based	O
physicians	O
about	O
this	O
uncommon	O
but	O
severe	O
condition	B-DISO
that	O
often	O
affects	O
previously	O
healthy	O
young	O
individuals	O
from	O
developing	O
countries	O
,	O
and	O
subjects	O
who	O
interact	O
with	O
rodent	O
-	O
infested	O
environments	O
in	O
North	O
America	O
.	O

Veterinarians	O
should	O
consider	O
CRCoV	O
as	O
a	O
differential	O
diagnosis	O
in	O
cases	O
of	O
respiratory	B-DISO
disease	I-DISO
in	O
dogs	O
in	O
New	O
Zealand	O
.	O

TITLE	O
:	O
Ascaris	B-DISO
lumbricoides	I-DISO
infection	I-DISO
causing	O
respiratory	B-DISO
distress	I-DISO
after	O
coronary	O
artery	O
bypass	O
grafting	O
.	O

CONCLUSIONS	O
:	O
Although	O
infection	B-DISO
with	O
A	O
.	O
lumbricoides	O
is	O
rare	O
in	O
the	O
United	O
States	O
,	O
it	O
may	O
become	O
manifest	O
with	O
severe	O
consequences	O
in	O
the	O
postoperative	O
period	O
.	O

ABSTRACT	O
:	O
We	O
have	O
shown	O
that	O
mice	O
infected	O
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
develop	O
autoantibodies	O
(	O
autoAb	O
)	O
to	O
liver	O
and	O
kidney	O
fumarylacetoacetate	O
hydrolase	O
(	O
FAH	O
).	O

Our	O
study	O
showed	O
no	O
evidence	O
of	O
over	O
-	O
reporting	O
of	O
SARS	B-DISO
in	O
mainland	O
China	O
,	O
nor	O
in	O
Guangdong	O
,	O
where	O
the	O
SARS	B-DISO
epidemic	O
started	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
clinical	O
characteristics	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
in	O
a	O
hospital	O
in	O
Tianjin	O
,	O
China	O
,	O
thereby	O
comparing	O
probable	O
and	O
suspected	O
cases	O
;	O
to	O
study	O
risk	O
factors	O
associated	O
with	O
the	O
death	O
of	O
cases	O
;	O
to	O
describe	O
the	O
implementation	O
of	O
preventive	O
interventions	O
during	O
the	O
hospital	O
outbreak	O
.	O

Differences	O
in	O
clinical	O
symptoms	O
between	O
probable	O
and	O
suspected	O
SARS	B-DISO
cases	O
were	O
tested	O
by	O
Fisher	O
'	O
s	O
exact	O
test	O
.	O

Risk	O
factors	O
for	O
dying	O
among	O
probable	O
SARS	B-DISO
cases	O
were	O
tested	O
by	O
logistic	O
regression	O
.	O

After	O
the	O
last	O
SARS	B-DISO
case	O
left	O
the	O
hospital	O
on	O
6	O
June	O
,	O
protective	O
materials	O
were	O
dispensed	O
at	O
substantially	O
lower	O
rates	O
,	O
but	O
not	O
to	O
zero	O
,	O
as	O
was	O
the	O
case	O
during	O
the	O
first	O
days	O
of	O
the	O
outbreak	O
.	O

The	O
dynamic	O
properties	O
of	O
the	O
different	O
states	O
,	O
which	O
are	O
stabilized	O
under	O
different	O
experimental	O
conditions	O
,	O
extend	O
the	O
current	O
model	O
of	O
viral	O
membrane	O
fusion	O
and	O
give	O
insight	O
into	O
the	O
design	O
of	O
structure	O
-	O
based	O
antagonists	O
of	O
SARS	B-DISO
-	O
CoV	O
in	O
particular	O
,	O
as	O
well	O
as	O
other	O
enveloped	O
viruses	O
such	O
as	O
HIV	B-DISO
.	O

Activation	O
of	O
coagulation	O
and	O
immune	O
system	O
as	O
well	O
as	O
blood	O
cell	B-DISO
damage	I-DISO
was	O
measured	O
.	O

In	O
all	O
groups	O
,	O
hemolysis	B-DISO
remained	O
negligible	O
,	O
indicated	O
by	O
low	O
plasma	O
hemoglobin	O
concentration	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
prevalence	O
of	O
14	O
viruses	O
in	O
infants	O
with	O
bronchiolitis	B-DISO
and	O
to	O
study	O
demographic	O
and	O
clinical	O
differences	O
in	O
those	O
with	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
human	O
bocavirus	O
(	O
hBoV	O
)	O
and	O
rhinovirus	O
(	O
RV	O
)	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
In	O
March	O
2009	O
,	O
novel	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
was	O
first	O
reported	O
in	O
the	O
southwestern	O
United	O
States	O
and	O
Mexico	O
.	O

Time	O
from	O
hospital	O
to	O
ICU	O
admission	O
was	O
short	O
(	O
median	O
,	O
1	O
day	O
[	O
interquartile	O
range	O
{	O
IQR	O
},	O
0	O
-	O
3	O
days	O
]),	O
and	O
all	O
patients	O
but	O
2	O
received	O
mechanical	O
ventilation	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
refractory	O
hypoxemia	O
(	O
median	O
day	O
1	O
ratio	O
of	O
Pao	O
(	O
2	O
)	O
to	O
fraction	O
of	O
inspired	O
oxygen	O
,	O
83	O
[	O
IQR	O
,	O
59	O
-	O
145	O
]	O
mm	O
Hg	O
).	O

Critical	B-DISO
illness	I-DISO
from	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
in	O
Mexico	O
occurred	O
in	O
young	O
individuals	O
,	O
was	O
associated	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
shock	O
,	O
and	O
had	O
a	O
high	O
case	O
-	O
fatality	O
rate	O
.	O

To	O
describe	O
the	O
characteristics	O
of	O
all	O
patients	O
with	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)-	O
associated	O
ARDS	B-DISO
treated	O
with	O
ECMO	O
and	O
to	O
report	O
incidence	O
,	O
resource	O
utilization	O
,	O
and	O
patient	O
outcomes	O
.	O

Sixty	O
-	O
eight	O
patients	O
with	O
severe	O
influenza	B-DISO
-	O
associated	O
ARDS	B-DISO
were	O
treated	O
with	O
ECMO	O
,	O
of	O
whom	O
61	O
had	O
either	O
confirmed	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
(	O
n	O
=	O
53	O
)	O
or	O
influenza	B-DISO
A	O
not	O
subtyped	O
(	O
n	O
=	O
8	O
),	O
representing	O
an	O
incidence	O
rate	O
of	O
2	O
.	O
6	O
ECMO	O
cases	O
per	O
million	O
population	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
remains	O
a	O
challenging	O
disease	O
leading	O
to	O
increased	O
mortality	O
in	O
burn	O
patients	O
,	O
and	O
inhalation	O
injury	O
may	O
contribute	O
to	O
the	O
development	O
of	O
severe	O
ARDS	B-DISO
.	O

Forty	O
-	O
eight	O
hours	O
after	O
presentation	O
,	O
the	O
patient	O
developed	O
respiratory	B-DISO
failure	I-DISO
and	O
hemodynamic	B-DISO
instability	I-DISO
refractory	O
to	O
conventional	O
therapy	O
,	O
and	O
ECLS	O
was	O
initiated	O
on	O
hospital	O
day	O
2	O
.	O

Sexually	O
intact	O
dogs	O
and	O
frequent	O
exposure	O
to	O
dogs	O
outside	O
the	O
household	O
were	O
positively	O
associated	O
with	O
viral	O
detection	O
in	O
the	O
conjunctivitis	B-DISO
group	O
.	O

Lowering	O
of	O
body	O
temperature	O
,	O
however	O
,	O
may	O
be	O
a	O
major	O
clinical	O
problem	O
because	O
hyperthermia	O
in	O
neuroleptic	B-DISO
malignant	I-DISO
syndrome	I-DISO
is	O
typically	O
unresponsive	O
to	O
antipyretic	O
agents	O
while	O
manual	O
cooling	O
proves	O
difficult	O
due	O
to	O
peripheral	O
vasoconstriction	B-DISO
.	O

In	O
addition	O
to	O
intensive	O
care	O
standard	O
therapy	O
for	O
coma	B-DISO
and	O
shock	O
,	O
a	O
non	O
-	O
invasive	O
cooling	O
device	O
(	O
Arctic	O
Sun	O
2000	O
((	O
R	O
)),	O
Medivance	O
Inc	O
.,	O
USA	O
),	O
originally	O
designed	O
to	O
induce	O
mild	O
therapeutic	O
hypothermia	O
in	O
patients	O
after	O
cardiopulmonary	O
resuscitation	O
,	O
was	O
used	O
to	O
lower	O
body	O
temperature	O
.	O

This	O
case	O
shows	O
that	O
aggressive	B-DISO
combined	O
immunosuppressive	O
therapy	O
may	O
lead	O
to	O
a	O
sustained	O
complete	O
remission	B-DISO
in	O
children	O
with	O
refractory	O
autoimmune	B-DISO
hemolytic	I-DISO
anemia	I-DISO
.	O

In	O
this	O
article	O
,	O
we	O
discuss	O
the	O
mechanical	O
and	O
chemical	O
effects	O
of	O
meconium	O
on	O
a	O
newborn	O
'	O
s	O
airway	O
,	O
meconium	O
-	O
induced	O
inflammation	B-DISO
,	O
mediated	O
by	O
proinflammatory	O
cytokines	O
and	O
chemokines	O
,	O
the	O
complement	O
system	O
and	O
the	O
proinflammatory	O
enzyme	O
phospholipase	O
A2	O
.	O

ABSTRACT	O
:	O
A	O
reverse	O
transcription	O
loop	O
-	O
mediated	O
isothermal	O
amplification	B-DISO
(	O
RT	O
-	O
LAMP	O
)	O
assay	O
targeting	O
the	O
nucleocapsid	O
phosphoprotein	O
gene	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
was	O
developed	O
.	O

A	O
total	O
of	O
26	O
ventilated	O
patients	O
with	O
severe	O
thoracic	B-DISO
trauma	O
and	O
an	O
abbreviated	O
injury	O
scale	O
score	O
(	O
AIS	B-DISO
thorax	O
)	O
>	O
3	O
were	O
included	O
in	O
the	O
study	O
.	O

The	O
development	O
and	O
progression	O
of	O
ALI	O
/	O
ARDS	B-DISO
may	O
be	O
triggered	O
by	O
various	O
intrahospital	O
exposures	O
including	O
but	O
not	O
limited	O
to	O
transfusion	O
,	O
aspiration	B-DISO
,	O
mechanical	O
ventilation	O
,	O
certain	O
medications	O
and	O
delayed	O
treatment	O
of	O
shock	O
and	O
infection	B-DISO
.	O

Pleomorphic	O
double	O
membrane	O
-	O
bound	O
vesicles	B-DISO
(	O
DMV	O
),	O
measuring	O
roughly	O
140	O
to	O
210	O
nm	O
in	O
diameter	O
,	O
were	O
observed	O
.	O

The	O
virus	O
was	O
released	O
via	O
exocytosis	O
and	O
cell	O
lysis	B-DISO
.	O

The	O
N176A	O
,	O
N237A	O
,	O
and	O
N176A	O
/	O
N237A	O
mutant	B-DISO
viruses	O
were	O
viable	O
,	O
and	O
N176	O
and	O
N237	O
were	O
glycosylated	O
during	O
infection	B-DISO
of	O
wild	O
-	O
type	O
(	O
wt	O
)	O
and	O
mutant	B-DISO
viruses	O
.	O

In	O
relation	O
to	O
gene	O
3	O
,	O
samples	O
showed	O
a	O
greater	O
relationship	O
with	O
chicken	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
),	O
while	O
gene	O
5	O
showed	O
greater	O
identity	O
with	O
pheasant	O
coronavirus	O
(	O
PhCoV	O
).	O

Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
was	O
induced	O
by	O
lipopolysaccharide	O
infusion	O
.	O

TITLE	O
:	O
Evasion	O
by	O
stealth	O
:	O
inefficient	O
immune	O
activation	O
underlies	O
poor	O
T	O
cell	O
response	O
and	O
severe	O
disease	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
mice	O
.	O

Many	O
of	O
the	O
features	O
of	O
the	O
human	O
disease	O
are	O
duplicated	O
in	O
BALB	O
/	O
c	O
mice	O
infected	O
with	O
a	O
mouse	O
-	O
adapted	O
version	O
of	O
the	O
virus	O
(	O
MA15	O
),	O
which	O
develop	O
respiratory	B-DISO
disease	I-DISO
with	O
high	O
morbidity	O
and	O
mortality	O
.	O

The	O
inhibitory	O
effects	O
of	O
AM	O
can	O
also	O
be	O
nullified	O
if	O
mice	O
or	O
AMs	B-DISO
are	O
pretreated	O
with	O
poly	O
I	O
:	O
C	O
,	O
which	O
directly	O
activate	O
AMs	B-DISO
and	O
rDCs	O
through	O
toll	O
-	O
like	O
receptors	O
3	O
(	O
TLR3	O
).	O

ABSTRACT	O
:	O
This	O
report	O
describes	O
the	O
identification	O
of	O
a	O
novel	O
linear	O
B	O
-	O
cell	O
epitope	O
at	O
the	O
C	O
-	O
terminus	O
of	O
the	O
membrane	O
(	O
M	O
)	O
protein	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
).	O

Strain	O
v2163	O
increased	O
IL	O
-	O
1alpha	O
,	O
IL	O
-	O
6	O
,	O
MIP	B-DISO
-	O
1alpha	O
,	O
MCP	O
-	O
1	O
,	O
and	O
RANTES	O
in	O
mice	O
,	O
and	O
high	O
IL	O
-	O
6	O
expression	O
correlated	O
with	O
mortality	O
.	O

In	O
vitro	O
efficacy	O
against	O
v2163	O
was	O
shown	O
with	O
known	O
inhibitors	O
of	O
SARS	B-DISO
-	O
CoV	O
replication	O
.	O

The	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
virus	O
caused	O
a	O
global	O
pandemia	O
91	O
years	O
ago	O
,	O
with	O
sporadic	O
outbreaks	O
afterward	O
.	O

ABSTRACT	O
:	O
Interspecies	O
transmission	O
of	O
pathogens	O
may	O
result	O
in	O
the	O
emergence	O
of	O
new	O
infectious	B-DISO
diseases	I-DISO
in	O
humans	O
as	O
well	O
as	O
in	O
domestic	O
and	O
wild	O
animals	O
.	O

The	O
ultimate	O
challenge	O
is	O
to	O
link	O
pathogen	O
and	O
host	O
genomics	O
data	O
with	O
biological	O
outcomes	O
of	O
zoonotic	O
transmission	O
and	O
to	O
translate	O
the	O
integrated	O
data	O
into	O
novel	O
intervention	O
strategies	O
that	O
eventually	O
will	O
allow	O
the	O
effective	O
control	O
of	O
newly	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

TITLE	O
:	O
Age	O
-	O
dependent	O
resistance	O
to	O
Porcine	B-DISO
reproductive	I-DISO
and	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
replication	O
in	O
swine	O
.	O

Existing	O
theories	O
of	O
virulence	O
evolution	O
based	O
on	O
a	O
tradeoff	O
between	O
high	O
transmission	O
rates	O
and	O
long	O
infectious	B-DISO
periods	O
imply	O
that	O
epidemic	O
growth	O
conditions	O
will	O
select	O
for	O
higher	O
virulence	O
,	O
possibly	O
leading	O
to	O
a	O
transient	O
peak	O
in	O
virulence	O
near	O
the	O
beginning	O
of	O
an	O
epidemic	O
.	O

A	O
brain	O
MRI	O
nearly	O
4	O
years	O
after	O
ICU	O
discharge	O
demonstrated	O
interval	O
development	O
of	O
profound	O
and	O
generalized	O
atrophy	B-DISO
with	O
sulcal	O
widening	O
and	O
ventricular	O
enlargement	B-DISO
.	O

We	O
recruited	O
consecutively	O
31	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
survivors	O
and	O
their	O
informal	O
caregivers	O
.	O

We	O
have	O
identified	O
symptom	B-DISO
domains	O
important	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
who	O
are	O
not	O
well	O
represented	O
in	O
existing	O
health	O
outcomes	O
measures	O
.	O

TITLE	O
:	O
The	O
RNA	O
polymerase	O
activity	O
of	O
SARS	B-DISO
-	O
coronavirus	O
nsp12	O
is	O
primer	O
dependent	O
.	O

We	O
also	O
classify	O
SARS	B-DISO
coronavirus	O
to	O
verify	O
the	O
effectiveness	O
of	O
the	O
new	O
method	O
.	O

Most	O
of	O
the	O
patients	O
presented	O
during	O
the	O
rainy	O
season	O
,	O
correlating	O
with	O
the	O
relatively	O
high	O
incidence	O
of	O
skin	B-DISO
infections	I-DISO
at	O
this	O
time	O
.	O

The	O
C3	O
fraction	O
was	O
lower	O
in	O
severe	O
presentations	O
,	O
but	O
the	O
type	O
of	O
haematuria	O
,	O
level	O
of	O
proteinuria	O
and	O
inflammatory	O
syndrome	B-DISO
were	O
not	O
correlated	O
with	O
immediate	O
severe	O
forms	O
or	O
with	O
initial	O
renal	B-DISO
failure	I-DISO
.	O

Despite	O
a	O
high	O
incidence	O
of	O
skin	B-DISO
infections	I-DISO
,	O
however	O
,	O
the	O
predominance	O
of	O
respiratory	B-DISO
infections	I-DISO
potentially	O
indicates	O
that	O
French	O
Polynesia	O
is	O
on	O
the	O
way	O
to	O
become	O
a	O
low	O
-	O
incidence	O
area	O
.	O

TITLE	O
:	O
An	O
ELISA	O
based	O
on	O
recombinant	O
spike	O
protein	O
S	O
for	O
the	O
detection	O
of	O
antibodies	O
to	O
transmissible	O
gastroenteritis	B-DISO
virus	O
of	O
swine	O
-	O
like	O
canine	O
coronaviruses	O
.	O

Bleeding	B-DISO
occurred	O
six	O
and	O
12	O
days	O
in	O
male	O
and	O
female	O
mice	O
,	O
respectively	O
,	O
after	O
the	O
initiation	O
of	O
dosing	O
suggesting	O
that	O
mtPA	O
accumulated	O
in	O
the	O
lungs	O
.	O

TITLE	O
:	O
Plasmodium	B-DISO
vivax	I-DISO
malaria	I-DISO
:	O
an	O
unusual	O
presentation	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
(	O
DIC	B-DISO
),	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
hypoglycemia	B-DISO
,	O
coma	B-DISO
,	O
or	O
epileptic	B-DISO
seizures	I-DISO
are	O
manifestations	O
of	O
severe	O
Plasmodium	B-DISO
falciparum	I-DISO
malaria	I-DISO
.	O

A	O
diagnosis	O
of	O
Plasmodium	B-DISO
vivax	I-DISO
malaria	I-DISO
was	O
established	O
by	O
a	O
positive	O
Plasmodium	O
LDH	O
immunochromatographic	O
assay	O
while	O
a	O
negative	O
PfHRP2	O
based	O
assay	O
ruled	O
out	O
P	O
.	O
falciparum	B-DISO
malaria	I-DISO
.	O

TITLE	O
:	O
Leptospirosis	B-DISO
in	O
a	O
European	O
intensive	O
care	O
unit	O
.	O

Antibiotic	O
therapy	O
does	O
not	O
significantly	O
benefit	O
most	O
patients	O
with	O
AOM	B-DISO
,	O
but	O
long	O
-	O
term	O
prophylactic	O
antibiotic	O
therapy	O
can	O
reduce	O
the	O
risk	O
of	O
otitis	B-DISO
media	I-DISO
recurrence	B-DISO
among	O
children	O
at	O
high	O
risk	O
.	O

Therefore	O
,	O
the	O
functional	O
implication	O
of	O
interferon	O
production	O
during	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
remains	O
to	O
be	O
re	O
-	O
investigated	O
.	O

When	O
the	O
secretory	O
pathway	O
was	O
disrupted	O
by	O
brefeldin	O
A	O
(	O
BFA	O
)	O
treatment	O
at	O
the	O
start	O
of	O
infection	B-DISO
,	O
RVN	O
formation	O
and	O
viral	O
RTC	O
activity	O
were	O
not	O
blocked	O
and	O
continued	O
up	O
to	O
11	O
h	O
postinfection	O
,	O
although	O
RNA	O
synthesis	O
was	O
reduced	O
by	O
ca	O
.	O

We	O
therefore	O
conclude	O
that	O
early	O
secretory	O
pathway	O
proteins	O
do	O
not	O
play	O
a	O
direct	O
role	O
in	O
RVN	O
morphogenesis	O
or	O
the	O
functionality	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
RTC	O
.	O

TITLE	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
:	O
insights	O
into	O
feline	O
coronavirus	O
pathobiogenesis	O
and	O
epidemiology	O
based	O
on	O
genetic	O
analysis	O
of	O
the	O
viral	O
3c	O
gene	O
.	O

TITLE	O
:	O
Hyperimmunoglobulin	B-DISO
E	I-DISO
syndrome	I-DISO
with	O
a	O
novel	O
STAT3	O
mutation	O
.	O

ABSTRACT	O
:	O
A	O
35	O
-	O
year	O
-	O
old	O
man	O
with	O
severe	O
eczematous	B-DISO
dermatitis	I-DISO
and	O
recurrent	O
staphylococcal	B-DISO
skin	I-DISO
infections	I-DISO
,	O
some	O
of	O
which	O
required	O
hospitalization	O
,	O
is	O
presented	O
.	O

Laboratory	O
data	O
showed	O
an	O
eosinophil	O
count	O
of	O
2	O
,	O
400	O
cells	O
/	O
ml	O
;	O
the	O
highest	O
IgE	B-DISO
level	O
was	O
17	O
,	O
028	O
IU	O
/	O
mL	O
.	O
Considering	O
the	O
clinical	O
and	O
laboratory	O
findings	O
,	O
the	O
diagnosis	O
of	O
hyperimmunoglobulin	B-DISO
E	I-DISO
syndrome	I-DISO
was	O
made	O
.	O

To	O
study	O
the	O
impact	O
of	O
PTSD	B-DISO
,	O
we	O
used	O
the	O
Impact	O
of	O
Event	O
Scale	O
(	O
IES	O
),	O
Zung	O
Self	O
-	O
Rating	O
Anxiety	O
Scale	O
(	O
SAS	O
),	O
Zung	O
Self	O
-	O
Rating	O
Depression	B-DISO
Scale	O
(	O
SDS	B-DISO
),	O
Symptom	B-DISO
Checklist	O
90	O
(	O
SCL	O
-	O
90	O
),	O
Short	O
Form	O
-	O
36	O
(	O
SF	O
-	O
36	O
Health	O
Survey	O
)	O
and	O
Social	O
Disability	O
Screening	O
Schedule	O
(	O
SDSS	O
).	O

Scores	O
on	O
IES	O
,	O
SAS	O
,	O
SDS	B-DISO
and	O
SCL	O
-	O
90	O
(	O
P	O
<.	O
0001	O
)	O
were	O
higher	O
,	O
and	O
functional	O
impairment	B-DISO
as	O
measured	O
by	O
SF	O
-	O
36	O
(	O
P	O
<.	O
0001	O
)	O
and	O
SDSS	O
was	O
more	O
severe	O
(	O
P	O
=.	O
0073	O
)	O
for	O
subjects	O
with	O
PTSD	B-DISO
.	O

Treatment	O
of	O
JHMV	O
-	O
infected	O
mice	O
with	O
anti	O
-	O
CXCR2	O
blocking	B-DISO
antibody	O
reduced	O
PMN	O
trafficking	O
into	O
the	O
CNS	O
by	O
>	O
95	O
%,	O
dampened	O
MMP	O
-	O
9	O
activity	O
,	O
and	O
abrogated	O
blood	O
-	O
brain	O
-	O
barrier	O
(	O
BBB	O
)	O
breakdown	B-DISO
.	O

Blocking	B-DISO
CXCR2	O
signaling	O
did	O
not	O
impair	O
the	O
generation	O
of	O
virus	O
-	O
specific	O
T	O
cells	O
,	O
indicating	O
that	O
CXCR2	O
is	O
not	O
required	O
to	O
tailor	O
anti	O
-	O
JHMV	O
T	O
cell	O
responses	O
.	O

Collectively	O
,	O
these	O
findings	O
highlight	O
a	O
previously	O
unappreciated	O
role	O
for	O
ELR	O
-	O
positive	O
chemokines	O
in	O
enhancing	O
host	O
defense	O
during	O
acute	O
viral	B-DISO
infections	I-DISO
of	O
the	O
CNS	O
.	O

They	O
characteristically	O
form	O
promiscuous	O
associations	O
with	O
one	O
another	O
and	O
with	O
other	O
membrane	O
proteins	O
and	O
lipids	O
to	O
generate	O
a	O
specialized	O
type	O
of	O
microdomain	O
:	O
the	O
tetraspanin	B-DISO
-	I-DISO
enriched	I-DISO
microdomain	I-DISO
(	O
TEM	B-DISO
).	O

The	O
secondary	B-DISO
infections	I-DISO
were	O
rare	O
(	O
1	O
case	O
was	O
suspected	O
and	O
another	O
probable	O
).	O

In	O
addition	O
,	O
143	O
of	O
226	O
FIV	O
-	O
infected	O
animals	O
(	O
63	O
%)	O
also	O
expressed	O
antibodies	O
to	O
the	O
primary	O
binding	O
receptor	O
,	O
CD134	O
,	O
whereas	O
cats	O
infected	O
with	O
other	O
feline	O
RNA	O
viruses	O
,	O
including	O
calicivirus	O
,	O
coronavirus	O
,	O
herpesvirus	O
,	O
and	O
feline	B-DISO
leukemia	I-DISO
virus	O
,	O
did	O
not	O
.	O

Anti	O
-	O
CD134	O
binding	O
caused	O
displacement	O
of	O
SU	O
from	O
the	O
surface	O
of	O
the	O
cell	O
and	O
inhibition	O
of	O
infection	B-DISO
.	O

TITLE	O
:	O
Prone	O
positioning	O
in	O
patients	O
with	O
moderate	O
and	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

To	O
assess	O
possible	O
outcome	O
benefits	O
of	O
prone	O
positioning	O
in	O
patients	O
with	O
moderate	O
and	O
severe	O
hypoxemia	O
who	O
are	O
affected	O
by	O
ARDS	B-DISO
.	O

Patients	O
were	O
342	O
adults	O
with	O
ARDS	B-DISO
receiving	O
mechanical	O
ventilation	O
,	O
enrolled	O
from	O
February	O
2004	O
through	O
June	O
2008	O
and	O
prospectively	O
stratified	O
into	O
subgroups	O
with	O
moderate	O
(	O
n	O
=	O
192	O
)	O
and	O
severe	O
(	O
n	O
=	O
150	O
)	O
hypoxemia	O
.	O

By	O
day	O
7	O
,	O
histopathologic	O
evidence	O
of	O
pneumonitis	B-DISO
was	O
seen	O
in	O
the	O
lungs	O
when	O
viral	O
clearance	O
occurred	O
.	O

The	O
dry	O
lung	O
-	O
to	O
-	O
body	O
weight	O
ratio	O
was	O
significantly	O
increased	O
in	O
infected	O
group	O
,	O
which	O
might	O
be	O
associated	O
with	O
the	O
formation	O
of	O
PF	O
in	O
H5N1	B-DISO
-	O
infected	O
mice	O
.	O

ABSTRACT	O
:	O
As	O
one	O
of	O
the	O
most	O
important	O
endogenous	O
chemotactic	O
factors	O
for	O
neutrophils	O
,	O
the	O
chemokine	O
CXCL8	O
(	O
IL	O
-	O
8	O
)	O
is	O
involved	O
in	O
the	O
pathogenesis	B-DISO
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
characterized	O
by	O
massive	O
neutrophil	O
infiltration	B-DISO
in	O
the	O
lung	O
.	O

We	O
used	O
a	O
'	O
two	O
-	O
hit	O
'	O
protocol	O
to	O
induce	O
ALI	O
in	O
rabbits	O
that	O
showed	O
extensive	O
edema	B-DISO
in	O
the	O
alveolar	O
lumina	O
,	O
marked	O
infiltration	B-DISO
of	O
neutrophils	O
in	O
the	O
lung	O
tissue	O
,	O
fibrin	B-DISO
deposition	I-DISO
in	O
alveolar	O
space	O
,	O
and	O
destruction	O
of	O
pulmonary	O
architecture	O
,	O
culminating	O
in	O
severe	O
hypoxemia	O
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
insights	O
gained	O
from	O
clinical	O
and	O
translational	O
research	O
.	O

ABSTRACT	O
:	O
Serum	O
samples	O
from	O
92	O
giant	B-DISO
pandas	B-DISO
in	O
three	O
captive	O
facilities	O
were	O
tested	O
for	O
antibodies	O
against	O
five	O
viruses	O
of	O
carnivores	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
vaccines	O
used	O
for	O
these	O
giant	B-DISO
pandas	B-DISO
do	O
not	O
elicit	O
consistent	O
antibody	O
titers	O
.	O

Almost	O
half	O
of	O
sera	O
were	O
CPV	O
antibody	O
positive	O
,	O
and	O
CPV	O
titers	O
were	O
high	O
enough	O
to	O
suggest	O
infection	B-DISO
with	O
the	O
virus	O
.	O

ABSTRACT	O
:	O
Turkey	O
coronavirus	O
(	O
TCoV	O
)	O
infection	B-DISO
causes	O
acute	O
atrophic	B-DISO
enteritis	B-DISO
in	O
the	O
turkey	O
poults	O
,	O
leading	O
to	O
significant	O
economic	O
loss	O
in	O
the	O
U	O
.	O
S	O
.	O
turkey	O
industry	O
.	O

TITLE	O
:	O
Cleavage	O
of	O
the	O
SARS	B-DISO
coronavirus	O
spike	O
glycoprotein	O
by	O
airway	O
proteases	O
enhances	O
virus	O
entry	O
into	O
human	O
bronchial	O
epithelial	O
cells	O
in	O
vitro	O
.	O

In	O
order	O
to	O
gain	O
insight	O
into	O
the	O
molecular	O
basis	O
of	O
protease	O
cleavage	O
and	O
its	O
impact	O
on	O
the	O
efficiency	O
of	O
viral	O
entry	O
,	O
we	O
investigated	O
the	O
susceptibility	O
of	O
a	O
recombinant	O
native	O
full	O
-	O
length	O
S	O
-	O
protein	O
trimer	O
(	O
triSpike	O
)	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
to	O
cleavage	O
by	O
various	O
airway	O
proteases	O
.	O

Patients	O
with	O
and	O
without	O
confirmed	O
H1N1	B-DISO
influenza	I-DISO
had	O
similar	O
disease	O
severity	O
at	O
presentation	O
and	O
a	O
comparable	O
response	O
to	O
treatment	O
.	O

ABSTRACT	O
:	O
A	O
52	O
-	O
year	O
-	O
old	O
man	O
presented	O
with	O
unproductive	B-DISO
cough	I-DISO
,	O
fever	O
and	O
chill	B-DISO
in	O
our	O
emergency	B-DISO
department	O
.	O

CONCLUSIONS	O
:	O
The	O
incidence	O
of	O
influenza	B-DISO
(	O
A	O
/	O
H1N1	O
)	O
has	O
increased	O
in	O
Germany	O
and	O
severe	O
and	O
lethal	O
courses	O
have	O
occurred	O
.	O

The	O
clinical	O
course	O
of	O
the	O
disease	O
in	O
these	O
patients	O
suggests	O
that	O
nosocomial	B-DISO
pneumonia	I-DISO
caused	O
by	O
this	O
agent	O
can	O
lead	O
to	O
profound	O
respiratory	B-DISO
insufficiency	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
particularly	O
in	O
patients	O
with	O
significant	O
comorbidities	O
and	O
during	O
the	O
postoperative	O
period	O
.	O

Overall	O
mortality	O
of	O
critically	B-DISO
ill	I-DISO
HIV	B-DISO
-	O
infected	O
patients	O
in	O
ICU	O
has	O
decreased	O
in	O
the	O
HAART	O
era	O
and	O
patients	O
are	O
more	O
commonly	O
admitted	O
with	O
non	O
-	O
HIV	B-DISO
-	O
related	O
illnesses	O
.	O

In	O
dogs	O
,	O
infectious	B-DISO
respiratory	B-DISO
disease	I-DISO
is	O
a	O
common	O
problem	O
,	O
particularly	O
in	O
housed	O
animals	O
.	O

TITLE	O
:	O
Update	O
on	O
cutaneous	O
manifestations	O
of	O
infectious	B-DISO
diseases	I-DISO
.	O

In	O
addition	O
,	O
blood	O
cultures	O
collected	O
at	O
Hospital	O
A	O
yielded	O
Streptococcus	O
pneumoniae	O
,	O
and	O
beta	O
-	O
hemolytic	O
Streptococcus	O
other	O
than	O
group	O
A	O
,	O
B	O
or	O
D	O
.	O
Hospital	O
course	O
was	O
uneventful	O
and	O
he	O
was	O
discharged	O
26	O
days	O
after	O
transfer	O
to	O
Hospital	O
B	O
.	O
This	O
experience	O
showed	O
that	O
ECMO	O
can	O
be	O
life	O
-	O
saving	O
for	O
severe	O
novel	O
H1N1	O
infection	B-DISO
.	O

Volume	B-DISO
overload	I-DISO
that	O
may	O
occur	O
during	O
renal	B-DISO
impairment	I-DISO
increases	O
pulmonary	O
capillary	O
hydrostatic	O
pressure	O
.	O

Extracorporeal	O
CO2	O
removal	O
and	O
renal	O
replacement	O
associated	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
might	O
be	O
interesting	O
options	O
for	O
a	O
future	O
approach	O
to	O
pulmonary	O
/	O
renal	O
syndrome	B-DISO
.	O

TITLE	O
:	O
Comparison	O
of	O
the	O
pathogenicity	O
of	O
QX	O
-	O
like	O
,	O
M41	O
and	O
793	O
/	O
B	O
infectious	B-DISO
bronchitis	B-DISO
strains	O
from	O
different	O
pathological	O
conditions	O
.	O

In	O
addition	O
to	O
being	O
a	O
potent	O
source	O
of	O
IFN	O
-	O
alpha	O
,	O
other	O
properties	O
of	O
these	O
porcine	O
CD4	O
(	O
hi	O
)	O
CD172	O
(	O
lo	O
)	O
cells	O
including	O
their	O
morphological	O
transition	B-DISO
from	O
a	O
plasma	O
cell	O
-	O
like	O
shape	O
during	O
quiescence	O
to	O
one	O
resembling	O
a	O
dendritic	O
cell	O
(	O
DC	O
)	O
after	O
activation	O
by	O
TGEV	O
and	O
their	O
relatively	O
strong	O
constitutive	O
expression	O
of	O
interferon	O
regulatory	O
factor	O
-	O
7	O
(	O
IRF	O
-	O
7	O
)	O
conformed	O
to	O
the	O
expectations	O
of	O
genuine	O
pDCs	O
.	O

TITLE	O
:	O
Evidence	O
lost	O
to	O
treatment	O
of	O
critically	O
-	O
ill	B-DISO
patients	O
?	O

We	O
discuss	O
difficulties	O
with	O
grading	O
the	O
evidence	O
for	O
and	O
the	O
implementation	O
of	O
lung	O
protective	O
mechanical	O
ventilation	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
glucocorticosteroid	O
therapy	O
in	O
refractory	O
septic	B-DISO
shock	I-DISO
,	O
glucocorticosteroid	O
therapy	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
goal	O
directed	O
fluid	O
therapy	O
in	O
shock	O
,	O
activated	O
protein	O
C	O
in	O
severe	B-DISO
sepsis	I-DISO
and	O
intensive	O
insulin	O
therapy	O
in	O
critical	B-DISO
illness	I-DISO
.	O

ABSTRACT	O
:	O
H9N2	O
avian	B-DISO
influenza	I-DISO
viruses	O
have	O
repeatedly	O
caused	O
infections	B-DISO
in	O
swine	O
and	O
humans	O
in	O
some	O
countries	O
.	O

Major	O
histopathological	O
changes	O
in	O
infected	O
lungs	O
included	O
diffuse	O
pneumonia	B-DISO
and	O
alveolar	O
damage	O
,	O
with	O
neutrophil	O
-	O
dominant	O
inflammatory	O
cellular	O
infiltration	B-DISO
,	O
interstitial	O
and	O
alveolar	B-DISO
edema	I-DISO
,	O
hemorrhage	B-DISO
,	O
and	O
severe	O
bronchiolitis	B-DISO
/	O
peribronchiolitis	O
.	O

In	O
addition	O
,	O
H9N2	O
viral	B-DISO
infection	I-DISO
resulted	O
in	O
severe	O
progressive	O
hypoxemia	O
,	O
lymphopenia	B-DISO
,	O
and	O
a	O
significant	O
increase	O
in	O
neutrophils	O
,	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
and	O
interleukin	O
-	O
6	O
in	O
BALF	O
.	O

Our	O
data	O
show	O
that	O
H9N2	O
viral	B-DISO
infection	I-DISO
resulted	O
in	O
ARDS	B-DISO
in	O
mice	O
,	O
and	O
this	O
may	O
facilitate	O
studies	O
of	O
the	O
pathogenesis	B-DISO
of	O
future	O
potential	O
H9N2	O
disease	O
in	O
humans	O
.	O

TITLE	O
:	O
[	O
24	O
-	O
year	O
old	O
male	O
with	O
fever	O
,	O
multi	O
-	O
organ	O
dysfunction	O
and	O
fast	O
progressing	O
ARDS	B-DISO
].	O

This	O
system	O
,	O
which	O
uses	O
a	O
percutaneous	O
approach	O
and	O
autopriming	O
devices	O
,	O
can	O
be	O
rapidly	O
applied	O
in	O
emergency	B-DISO
situations	O
.	O

TITLE	O
:	O
Antibody	O
binding	O
site	O
mapping	O
of	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
receptor	O
-	O
binding	O
domain	O
by	O
a	O
combination	O
of	O
yeast	O
surface	O
display	O
and	O
phage	O
peptide	O
library	O
screening	O
.	O

It	O
is	O
increasingly	O
evident	O
that	O
only	O
integration	O
of	O
physiological	O
,	O
clinical	O
and	O
technological	O
approaches	O
will	O
lead	O
to	O
improvement	O
in	O
the	O
outcome	O
of	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

RESULTS	O
:	O
169	O
patients	O
with	O
a	O
laboratory	O
-	O
confirmed	O
diagnosis	O
of	O
leptospirosis	B-DISO
were	O
investigated	O
.	O

Exogenous	O
PS	O
replacement	O
therapy	O
can	O
improve	O
oxygenation	O
and	O
the	O
compliance	O
of	O
the	O
respiratory	O
system	O
in	O
ARDS	B-DISO
rabbits	O
.	O

Treatment	O
of	O
trauma	O
-	O
related	O
hemorrhage	B-DISO
.	O

Analysis	O
of	O
data	O
for	O
the	O
117	O
blunt	O
trauma	O
patients	O
who	O
survived	O
at	O
least	O
48	O
hours	O
after	O
receiving	O
study	O
treatment	O
shows	O
that	O
,	O
in	O
addition	O
to	O
reducing	O
RBC	O
requirement	O
,	O
rFVIIa	O
significantly	O
reduced	O
the	O
need	O
for	O
massive	O
transfusion	O
over	O
48	O
hours	O
(>	O
20	O
RBC	O
units	O
)	O
(	O
relative	O
risk	O
reduction	O
of	O
56	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
:	O
9	O
%-	O
79	O
%];	O
p	O
=	O
0	O
.	O
03	O
),	O
and	O
the	O
fresh	O
-	O
frozen	O
plasma	O
(	O
p	O
=	O
0	O
.	O
036	O
),	O
platelet	O
(	O
p	O
=	O
0	O
.	O
023	O
),	O
and	O
cryoprecipitate	O
(	O
p	O
=	O
0	O
.	O
053	O
)	O
requirements	O
within	O
48	O
hours	O
,	O
and	O
was	O
associated	O
with	O
a	O
significant	O
reduction	O
in	O
the	O
30	O
-	O
day	O
risk	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
(	O
p	O
=	O
0	O
.	O
05	O
)	O
and	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
and	O
/	O
or	O
ARDS	B-DISO
(	O
p	O
=	O
0	O
.	O
05	O
).	O

We	O
determined	O
seroprevalences	O
to	O
nine	O
key	O
viruses	O
(	O
feline	O
herpesvirus	O
1	O
,	O
feline	O
calicivirus	O
,	O
feline	O
parvovirus	B-DISO
,	O
feline	O
coronavirus	O
,	O
canine	B-DISO
distemper	I-DISO
virus	O
,	O
feline	O
immunodeficiency	B-DISO
virus	O
[	O
FIV	O
],	O
puma	O
lentivirus	O
,	O
feline	B-DISO
leukemia	I-DISO
virus	O
,	O
and	O
rabies	B-DISO
virus	O
)	O
in	O
68	O
free	O
-	O
ranging	O
cheetahs	O
on	O
east	O
-	O
central	O
Namibian	O
farmland	O
,	O
24	O
nonvaccinated	O
Namibian	O
captive	O
cheetahs	O
,	O
and	O
several	O
other	O
wild	O
carnivore	O
species	O
and	O
conducted	O
necropsies	O
of	O
cheetahs	O
and	O
other	O
wild	O
carnivores	O
.	O

Eight	O
of	O
11	O
other	O
wild	O
carnivores	O
were	O
seropositive	O
for	O
at	O
least	O
one	O
of	O
the	O
viruses	O
,	O
including	O
the	O
first	O
record	O
of	O
an	O
FIV	O
-	O
like	O
infection	B-DISO
in	O
a	O
wild	O
felid	O
west	O
of	O
the	O
Kalahari	O
,	O
the	O
caracal	O
(	O
Felis	O
caracal	O
).	O

Low	O
-	O
dose	O
heparin	O
can	O
decrease	O
the	O
mortality	O
rate	O
of	O
sepsis	B-DISO
and	O
improve	O
the	O
prognosis	O
of	O
patients	O
.	O

RESULTS	O
:	O
The	O
rates	O
of	O
DIC	B-DISO
,	O
ARF	B-DISO
and	O
MODS	B-DISO
in	O
heparin	O
group	O
decreased	O
significantly	O
after	O
therapy	O
:	O
rate	O
of	O
DIC	B-DISO
,	O
15	O
.	O
4	O
%	O
vs	O
38	O
.	O
7	O
%	O
(	O
P	O
=	O
0	O
.	O
03	O
);	O
rate	O
of	O
ARF	B-DISO
,	O
25	O
.	O
0	O
%	O
vs	O
51	O
.	O
9	O
%	O
(	O
P	O
=	O
0	O
.	O
04	O
);	O
rate	O
of	O
MODS	B-DISO
,	O
26	O
.	O
3	O
%	O
vs	O
50	O
.	O
0	O
%	O
(	O
P	O
=	O
0	O
.	O
04	O
).	O

Plasma	O
CC16	O
had	O
a	O
good	O
diagnostic	O
capacity	O
for	O
ALI	O
/	O
ARDS	B-DISO
as	O
shown	O
by	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
with	O
an	O
area	O
under	O
the	O
curve	O
of	O
0	O
.	O
91	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0	O
.	O
79	O
-	O
1	O
.	O
00	O
;	O
p	O
<	O
0	O
.	O
001	O
).	O

First	O
,	O
different	O
SARS	B-DISO
-	O
CoV	O
sequences	O
were	O
analyzed	O
to	O
predict	O
eight	O
candidate	O
peptides	O
from	O
conserved	O
regions	O
of	O
the	O
S	O
protein	O
based	O
upon	O
HLA	O
-	O
A	O
*	O
0201	O
binding	O
and	O
proteosomal	O
cleavage	O
.	O

The	O
immunized	O
mice	O
released	O
IFN	O
-	O
gamma	O
and	O
lysed	B-DISO
target	O
cells	O
upon	O
stimulation	O
with	O
Sp8	O
peptide	O
-	O
pulsed	O
autologous	O
dendritic	O
cells	O
in	O
comparison	O
to	O
other	O
candidates	O
.	O

SARS	B-DISO
and	O
Spanish	O
influenza	B-DISO
favored	O
more	O
stringent	O
measures	O
.	O

The	O
multihost	O
ecology	O
of	O
zoonoses	B-DISO
leads	O
to	O
complex	O
dynamics	O
,	O
and	O
analytical	O
tools	O
,	O
such	O
as	O
mathematical	O
modeling	O
,	O
are	O
vital	O
to	O
the	O
development	O
of	O
effective	O
control	O
policies	O
and	O
research	O
agendas	O
.	O

TITLE	O
:	O
[	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
induced	O
by	O
hydrogen	O
fluoride	O
gas	O
inhalation	O
].	O

He	O
felt	O
sick	O
immediately	O
after	O
exposure	O
and	O
experienced	O
respiratory	B-DISO
distress	I-DISO
within	O
a	O
few	O
hours	O
.	O

Expression	O
of	O
the	O
cGM	O
-	O
CSF	O
protein	O
in	O
the	O
recombinant	O
Lactobacillus	O
was	O
confirmed	O
by	O
SDS	B-DISO
-	O
PAGE	O
and	O
Western	O
blotting	O
methods	O
.	O

Indiscriminate	O
application	O
of	O
recruitment	B-DISO
maneuver	O
in	O
unselected	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
population	O
does	O
not	O
provide	O
benefits	O
.	O

ABSTRACT	O
:	O
Many	O
viruses	O
,	O
including	O
bovine	O
herpesvirus	O
-	O
1	O
(	O
BHV	O
-	O
1	O
),	O
bovine	O
respiratory	O
syncytial	O
virus	O
(	O
BRSV	O
),	O
parainfluenzavirus	O
-	O
3	O
(	O
PI3	O
),	O
bovine	O
coronavirus	O
,	O
bovine	B-DISO
viral	I-DISO
diarrhea	I-DISO
virus	O
and	O
bovine	O
reovirus	O
,	O
have	O
been	O
etiologically	O
associated	O
with	O
respiratory	B-DISO
disease	I-DISO
in	O
cattle	O
.	O

Our	O
data	O
show	O
a	O
remarkable	O
resemblance	O
to	O
results	O
obtained	O
recently	O
by	O
others	O
with	O
hepatitis	B-DISO
C	I-DISO
virus	O
.	O

TITLE	O
:	O
A	O
single	O
tyrosine	O
in	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
membrane	O
protein	O
cytoplasmic	O
tail	O
is	O
important	O
for	O
efficient	O
interaction	O
with	O
spike	O
protein	O
.	O

These	O
results	O
suggest	O
that	O
Y	O
(	O
195	O
)	O
is	O
necessary	O
for	O
efficient	O
SARS	B-DISO
-	O
CoV	O
S	O
-	O
M	O
interaction	O
and	O
,	O
thus	O
,	O
has	O
a	O
significant	O
involvement	O
in	O
assembly	O
of	O
infectious	B-DISO
virus	O
.	O

Logistic	O
regression	O
analysis	O
suggested	O
that	O
being	O
a	O
health	O
care	O
worker	O
at	O
the	O
time	O
of	O
SARS	B-DISO
infection	B-DISO
(	O
odds	O
ratio	O
[	O
OR	O
],	O
3	O
.	O
24	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
1	O
.	O
12	O
-	O
9	O
.	O
39	O
;	O
P	O
=	O
.	O
03	O
),	O
being	O
unemployed	O
at	O
follow	O
-	O
up	O
(	O
OR	O
,	O
4	O
.	O
71	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
50	O
-	O
14	O
.	O
78	O
;	O
P	O
=	O
.	O
008	O
),	O
having	O
a	O
perception	O
of	O
social	O
stigmatization	O
(	O
OR	O
,	O
3	O
.	O
03	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
20	O
-	O
7	O
.	O
60	O
;	O
P	O
=	O
.	O
02	O
),	O
and	O
having	O
applied	O
to	O
the	O
SARS	B-DISO
survivors	O
'	O
fund	O
(	O
OR	O
,	O
2	O
.	O
92	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
18	O
-	O
7	O
.	O
22	O
;	O
P	O
=	O
.	O
02	O
)	O
were	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
psychiatric	O
morbidities	O
at	O
follow	O
-	O
up	O
,	O
whereas	O
application	O
to	O
the	O
SARS	B-DISO
survivors	O
'	O
fund	O
(	O
OR	O
,	O
2	O
.	O
64	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
07	O
-	O
6	O
.	O
51	O
;	O
P	O
=	O
.	O
04	O
)	O
was	O
associated	O
with	O
increased	O
risk	O
of	O
chronic	O
fatigue	B-DISO
problems	O
.	O

TITLE	O
:	O
Predictive	O
modeling	O
and	O
inflammatory	O
biomarkers	O
in	O
rats	O
with	O
lung	O
contusion	O
and	O
gastric	O
aspiration	B-DISO
.	O

Specific	O
parameters	O
assessed	O
in	O
the	O
innate	O
pulmonary	O
inflammatory	B-DISO
response	I-DISO
were	O
leukocytes	O
,	O
macrophages	O
,	O
and	O
polymorphonuclear	O
neutrophils	O
(	O
PMNs	O
)	O
in	O
BAL	O
;	O
whole	O
lung	O
myeloperoxidase	O
activity	O
;	O
and	O
a	O
series	O
of	O
cytokines	O
or	O
chemokines	O
present	O
in	O
BAL	O
at	O
5	O
or	O
24	O
hours	O
after	O
injury	O
:	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
,	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
,	O
IL	O
-	O
6	O
,	O
interferon	O
-	O
gamma	O
,	O
IL	O
-	O
10	O
,	O
macrophage	O
inflammatory	O
protein	O
-	O
2	O
,	O
cytokine	O
-	O
induced	O
neutrophil	O
chemoattractant	O
-	O
1	O
,	O
and	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
.	O

ABSTRACT	O
:	O
Bats	O
are	O
the	O
suspected	O
natural	O
reservoir	O
hosts	O
for	O
a	O
number	O
of	O
new	O
and	O
emerging	O
zoonotic	O
viruses	O
including	O
Nipah	O
virus	O
,	O
Hendra	O
virus	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
and	O
Ebola	O
virus	O
.	O

We	O
previously	O
showed	O
that	O
antibodies	O
against	O
SARS	B-DISO
-	O
CoV	O
spike	O
domain	O
2	O
(	O
S2	O
)	O
in	O
the	O
patient	O
sera	O
can	O
cross	O
-	O
react	O
with	O
human	O
lung	O
epithelial	O
cells	O
;	O
however	O
,	O
the	O
autoantigen	O
is	O
not	O
yet	O
identified	O
.	O

Mild	O
hyperglycemia	B-DISO
and	O
hyperlactatemia	O
was	O
common	O
in	O
both	O
survivors	O
and	O
nonsurvivors	O
.	O

Nonsurvivors	O
were	O
significantly	O
more	O
likely	O
to	O
have	O
had	O
head	O
trauma	O
(	O
P	O
=	O
0	O
.	O
008	O
),	O
cranium	O
fractures	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
recumbency	O
at	O
admission	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
development	O
of	O
hematochezia	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
clinical	O
suspicion	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
P	O
<	O
0	O
.	O
001	O
),	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
(	O
P	O
<	O
0	O
.	O
001	O
),	O
multiorgan	O
dysfunction	O
syndrome	B-DISO
(	O
P	O
<	O
0	O
.	O
001	O
),	O
development	O
of	O
pneumonia	B-DISO
(	O
P	O
<	O
0	O
.	O
001	O
),	O
positive	O
-	O
pressure	O
ventilation	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
vasopressor	O
use	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
cardiopulmonary	B-DISO
arrest	I-DISO
(	O
P	O
<	O
0	O
.	O
001	O
).	O

TITLE	O
:	O
A	O
new	O
miniaturized	O
system	O
for	O
extracorporeal	O
membrane	O
oxygenation	O
in	O
adult	O
respiratory	B-DISO
failure	I-DISO
.	O

These	O
results	O
provide	O
further	O
mechanistic	O
details	O
of	O
the	O
pro	O
-	O
apoptotic	O
effects	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
3a	O
protein	O
,	O
and	O
suggest	O
a	O
potential	O
role	O
for	O
it	O
in	O
attenuating	O
interferon	O
responses	O
and	O
innate	O
immunity	O
.	O

A	O
retrospective	O
cohort	O
study	O
was	O
performed	O
examining	O
112	O
patients	O
admitted	O
through	O
an	O
ICU	O
between	O
2002	O
and	O
2006	O
,	O
with	O
diagnosis	O
of	O
secondary	B-DISO
peritonitis	I-DISO
and	O
managed	O
with	O
staged	O
laparotomies	O
whom	O
required	O
small	O
-	O
or	O
large	O
-	O
bowel	O
segment	O
resections	O
.	O

Fistulas	B-DISO
/	O
leakages	O
developed	O
in	O
three	O
patients	O
(	O
8	O
.	O
8	O
%)	O
with	O
DPA	O
and	O
four	O
patients	O
(	O
5	O
.	O
1	O
%)	O
with	O
diversion	O
(	O
p	O
=	O
0	O
.	O
359	O
).	O

ARDS	B-DISO
was	O
present	O
in	O
6	O
patients	O
(	O
17	O
.	O
6	O
%)	O
with	O
DPA	O
and	O
24	O
patients	O
(	O
30	O
.	O
8	O
%)	O
with	O
diversion	O
(	O
p	O
=	O
0	O
.	O
149	O
).	O

TITLE	O
:	O
Clinical	O
management	O
of	O
pandemic	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
infection	B-DISO
.	O

Nonpharmacologic	O
measures	O
,	O
such	O
as	O
early	O
case	O
isolation	O
,	O
household	O
quarantine	O
,	O
school	O
/	O
workplace	O
closure	O
,	O
good	O
community	O
hygiene	O
,	O
and	O
restrictions	O
on	O
travel	O
are	O
useful	O
measures	O
in	O
controlling	O
an	O
influenza	B-DISO
pandemic	O
at	O
its	O
early	O
phase	O
.	O

Adequate	O
,	O
transparent	O
,	O
and	O
targeted	O
communication	O
on	O
the	O
part	O
of	O
public	O
health	O
authorities	O
would	O
be	O
also	O
of	O
crucial	O
importance	O
in	O
the	O
event	O
of	O
a	O
serious	O
influenza	B-DISO
pandemic	O
.	O

TITLE	O
:	O
Retrospective	O
analysis	O
of	O
the	O
risk	O
factors	O
and	O
pathogens	O
associated	O
with	O
early	O
-	O
onset	O
ventilator	B-DISO
-	I-DISO
associated	I-DISO
pneumonia	I-DISO
in	O
surgical	O
-	O
ICU	O
head	O
-	O
trauma	O
patients	O
.	O

Vitamin	O
K3	O
may	O
be	O
an	O
effective	O
therapeutic	O
strategy	O
against	O
acute	O
lung	O
injury	O
including	O
ARDS	B-DISO
.	O

Since	O
the	O
publicized	O
outbreaks	O
of	O
SARS	B-DISO
in	O
China	O
and	O
Canada	O
in	O
2002	O
-	O
2003	O
,	O
significant	O
efforts	O
successfully	O
identified	O
the	O
causative	O
agent	O
,	O
host	O
cell	O
receptor	O
(	O
s	O
),	O
and	O
many	O
of	O
the	O
pathogenic	O
mechanisms	O
underlying	O
SARS	B-DISO
.	O

Specifically	O
,	O
0	O
-	O
1	O
infections	B-DISO
could	O
occur	O
during	O
a	O
5	O
hour	O
flight	O
,	O
1	O
-	O
3	O
during	O
an	O
11	O
hour	O
flight	O
and	O
2	O
-	O
5	O
during	O
a	O
17	O
hour	O
flight	O
.	O

Secondary	O
Case	O
Count	O
Difference	O
(	O
SCCD	B-DISO
)	O
reflects	O
reduction	O
in	O
the	O
average	O
number	O
of	O
transmissions	O
arising	O
from	O
a	O
SARS	B-DISO
case	O
in	O
quarantine	O
,	O
relative	O
to	O
not	O
in	O
quarantine	O
,	O
at	O
onset	O
of	O
symptoms	O
.	O

SCCD	B-DISO
was	O
estimated	O
using	O
Poisson	O
and	O
negative	O
binomial	O
regression	O
models	O
(	O
with	O
identity	O
link	O
function	O
)	O
comparing	O
the	O
number	O
of	O
secondary	O
cases	O
to	O
each	O
index	O
case	O
for	O
quarantine	O
relative	O
to	O
non	O
-	O
quarantined	O
index	O
cases	O
.	O

An	O
overall	O
10	O
.	O
37	O
%	O
incidence	O
of	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
was	O
found	O
,	O
in	O
addition	O
to	O
tidal	O
volumes	O
>	O
8	O
ml	O
/	O
kg	O
,	O
as	O
well	O
as	O
normo	O
-	O
or	O
hypocapnia	B-DISO
.	O

ABSTRACT	O
:	O
The	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
characterized	O
by	O
intense	O
inflammation	B-DISO
and	O
alveolar	O
-	O
capillary	O
disruption	O
that	O
can	O
progress	O
to	O
a	O
state	O
of	O
unresolving	O
inflammation	B-DISO
and	O
disordered	O
fibrosis	B-DISO
,	O
referred	O
to	O
as	O
fibroproliferative	O
,	O
late	O
-	O
stage	O
,	O
or	O
persistent	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Prone	O
positioning	O
has	O
been	O
known	O
for	O
decades	O
to	O
improve	O
oxygenation	O
in	O
animals	O
with	O
acute	O
lung	O
injury	O
and	O
in	O
most	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

However	O
,	O
several	O
randomized	O
trials	O
have	O
failed	O
to	O
show	O
improvements	O
in	O
clinical	O
outcomes	O
of	O
ARDS	B-DISO
patients	O
,	O
other	O
than	O
consistently	O
better	O
oxygenation	O
.	O

Lower	B-DISO
respiratory	I-DISO
infection	I-DISO
developed	O
in	O
2	O
patients	O
with	O
HRV	O
before	O
day	O
100	O
,	O
and	O
1	O
each	O
with	O
HRV	O
and	O
HCoV	O
after	O
day	O
100	O
.	O

TITLE	O
:	O
Multivalent	O
DNA	O
vaccine	O
enhanced	O
protection	O
efficacy	O
against	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
in	O
chickens	O
.	O

ABSTRACT	O
:	O
Viral	O
spread	O
during	O
the	O
early	O
stages	O
after	O
infection	B-DISO
was	O
compared	O
between	O
a	O
highly	O
neurovirulent	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
),	O
JHMV	O
cl	O
-	O
2	O
strain	O
(	O
cl	O
-	O
2	O
),	O
and	O
its	O
low	O
-	O
virulent	O
mutant	B-DISO
,	O
soluble	O
-	O
receptor	O
-	O
resistant	O
(	O
srr	O
)	O
7	O
.	O

Syncytial	O
giant	B-DISO
cells	O
(	O
SGCs	O
)	O
expressing	O
viral	O
and	O
CD11b	O
antigens	O
were	O
also	O
detected	O
among	O
these	O
inflammatory	O
cells	O
.	O

These	O
antigen	O
-	O
positive	O
cells	O
appeared	O
in	O
the	O
subarachnoidal	O
space	O
prior	O
to	O
viral	O
antigen	O
spread	O
into	O
the	O
brain	O
parenchyma	O
,	O
indicating	O
that	O
viral	B-DISO
encephalitis	I-DISO
starts	O
with	O
the	O
infection	B-DISO
of	O
infiltrating	B-DISO
monocytes	O
which	O
express	O
MHVR	O
.	O

The	O
study	O
covered	O
all	O
of	O
the	O
183	O
primary	O
schools	O
and	O
only	O
83	O
of	O
the	O
165	O
secondary	O
schools	O
due	O
to	O
a	O
disruption	O
of	O
health	O
screening	O
in	O
schools	O
during	O
the	O
outbreak	O
of	O
SARS	B-DISO
(	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
).	O

In	O
mid	O
-	O
2003	O
,	O
schools	O
in	O
Singapore	O
were	O
closed	O
because	O
Singapore	O
was	O
one	O
of	O
the	O
countries	O
affected	O
by	O
SARS	B-DISO
.	O

GeneOrder	O
,	O
CoreGenes	O
and	O
CGUG	O
are	O
web	B-DISO
-	O
based	O
'	O
on	O
-	O
the	O
-	O
fly	O
'	O
tools	O
that	O
examine	O
gene	O
order	O
and	O
synteny	O
,	O
as	O
well	O
as	O
proteomes	O
for	O
comparative	O
genomics	O
and	O
for	O
drug	O
discovery	O
and	O
design	O
targets	O
.	O

Paradoxically	O
,	O
prolonged	O
administration	O
of	O
immunosuppressive	O
agents	O
because	O
of	O
acute	B-DISO
graft	I-DISO
-	I-DISO
versus	I-DISO
-	I-DISO
host	I-DISO
disease	I-DISO
had	O
a	O
protective	O
effect	O
on	O
the	O
development	O
of	O
allo	O
-	O
LS	O
(	O
P	O
=	O
.	O
004	O
).	O

TITLE	O
:	O
Relapsing	O
macrophage	O
activating	O
syndrome	B-DISO
in	O
a	O
15	O
-	O
year	O
-	O
old	O
girl	O
with	O
Still	B-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
:	O
a	O
case	O
report	O
.	O

ABSTRACT	O
:	O
Macrophage	O
activating	O
syndrome	B-DISO
is	O
a	O
severe	O
,	O
potentially	O
life	O
-	O
threatening	O
condition	B-DISO
that	O
may	O
accompany	O
Still	B-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
Two	O
newborn	O
infants	O
presented	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
.	O

Patients	O
who	O
developed	O
acute	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ALI	O
/	O
ARDS	B-DISO
)	O
typically	O
presented	O
with	O
normal	O
leukocyte	O
count	O
,	O
lymphopenia	B-DISO
,	O
raised	O
C	O
-	O
reactive	O
protein	O
,	O
creatinkinase	O
,	O
transaminases	O
but	O
normal	O
urea	O
and	O
creatinine	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
pAPN	O
receptor	O
density	O
appears	O
to	O
be	O
an	O
important	O
factor	O
in	O
contributing	O
to	O
efficient	O
PEDV	O
infection	B-DISO
.	O

The	O
study	O
used	O
a	O
retrospective	O
single	O
-	O
center	O
analysis	O
of	O
21	O
consecutive	O
adult	O
patients	O
with	O
severe	O
ARDS	B-DISO
,	O
ventilated	O
with	O
HFOV	O
/	O
iLA	O
.	O

ABSTRACT	O
:	O
The	O
hypokalemic	O
paralysis	O
is	O
a	O
disease	O
characterized	O
by	O
the	O
development	O
of	O
acute	O
muscular	B-DISO
weakness	I-DISO
,	O
associated	O
to	O
low	O
levels	O
of	O
blood	O
potassium	O
(<	O
3	O
.	O
5	O
meq	O
/	O
L	O
).	O

Her	O
pregnancy	O
got	O
complicated	O
with	O
a	O
severe	B-DISO
preeclampsia	I-DISO
,	O
enough	O
reason	O
for	O
interrumpting	O
the	O
pregnancy	O
at	O
29	O
.	O
1	O
weeks	O
of	O
gestation	O
.	O

It	O
becomes	O
a	O
true	O
viral	B-DISO
pneumonia	I-DISO
,	O
which	O
can	O
evolve	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

This	O
is	O
why	O
trivalent	O
vaccination	O
against	O
seasonal	O
flu	B-DISO
appears	O
to	O
be	O
somewhat	O
protective	O
against	O
severe	O
presentations	O
of	O
the	O
disease	O
.	O

Nasopharyngeal	O
swab	O
samples	O
were	O
prospectively	O
collected	O
from	O
209	O
adult	O
outpatients	O
with	O
respiratory	B-DISO
infections	I-DISO
and	O
100	O
asymptomatic	O
controls	O
.	O

An	O
infectious	B-DISO
agent	O
was	O
identified	O
in	O
43	O
%	O
of	O
samples	O
from	O
patients	O
and	O
2	O
%	O
of	O
asymptomatic	O
controls	O
.	O

For	O
human	O
corona	O
viruses	O
,	O
and	O
influenza	B-DISO
virus	O
A	O
and	O
B	O
there	O
was	O
a	O
correlation	O
between	O
the	O
amount	O
of	O
virus	O
in	O
each	O
patient	O
sample	O
as	O
measured	O
Ct	O
values	O
and	O
duration	O
of	O
symptoms	O
.	O

TITLE	O
:	O
Lessons	O
learned	O
from	O
the	O
anti	O
-	O
SARS	B-DISO
quarantine	O
experience	O
in	O
a	O
hospital	O
-	O
based	O
fever	O
screening	O
station	O
in	O
Taiwan	O
.	O

These	O
results	O
will	O
contribute	O
to	O
sensitizing	O
health	O
care	O
professionals	O
to	O
empathize	O
with	O
quarantined	O
persons	O
while	O
providing	O
quality	O
quarantine	O
care	O
and	O
other	O
infection	B-DISO
control	O
measures	O
.	O

The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreak	O
was	O
too	O
short	O
to	O
allow	O
management	O
protocols	O
to	O
be	O
tested	O
in	O
a	O
research	O
environment	O
.	O

Other	O
common	O
seasonal	O
viruses	O
,	O
such	O
as	O
respiratory	O
syncytial	O
virus	O
and	O
parainfluenza	B-DISO
,	O
as	O
well	O
as	O
previously	O
poorly	O
recognized	O
viruses	O
such	O
as	O
hantavirus	O
,	O
have	O
the	O
ability	O
to	O
cause	O
significant	O
respiratory	B-DISO
morbidity	I-DISO
and	O
mortality	O
.	O

This	O
article	O
addresses	O
the	O
global	O
aspects	O
of	O
the	O
outbreak	O
of	O
this	O
new	O
pandemic	O
influenza	B-DISO
,	O
starting	O
from	O
the	O
first	O
event	O
of	O
""""	O
Avian	B-DISO
Flu	I-DISO
""""	O
in	O
1997	O
in	O
Hong	O
Kong	O
,	O
through	O
the	O
outbreaks	O
of	O
SARS	B-DISO
in	O
2003	O
,	O
and	O
the	O
Avian	B-DISO
Flu	I-DISO
,	O
which	O
also	O
began	O
in	O
2003	O
,	O
and	O
is	O
still	O
endemic	O
in	O
some	O
countries	O
.	O

ABSTRACT	O
:	O
ALI	O
(	O
acute	O
lung	O
injury	O
)	O
and	O
its	O
more	O
severe	O
form	O
ARDS	B-DISO
(	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
)	O
are	O
inflammatory	O
diseases	B-DISO
of	I-DISO
the	I-DISO
lung	I-DISO
characterized	O
by	O
hypoxaemia	O
and	O
diffuse	O
bilateral	O
infiltrates	B-DISO
.	O

By	O
combining	O
these	O
data	O
with	O
quantitative	O
analyses	O
on	O
viral	O
RNA	O
,	O
protein	O
synthesis	O
and	O
virion	O
release	O
,	O
this	O
study	O
generates	O
an	O
integrated	O
molecular	O
and	O
ultrastructural	O
overview	O
of	O
CoV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Alpaca	O
respiratory	O
syndrome	B-DISO
(	O
ARS	O
)	O
was	O
first	O
recognized	O
in	O
California	O
in	O
October	O
2007	O
.	O

This	O
syndrome	B-DISO
is	O
characterized	O
by	O
acute	O
respiratory	O
signs	O
,	O
high	O
fever	O
,	O
and	O
occasional	O
sudden	B-DISO
death	I-DISO
,	O
and	O
has	O
mostly	O
been	O
observed	O
in	O
pregnant	O
alpacas	O
(	O
Vicugna	O
pacos	O
),	O
although	O
all	O
signalments	O
have	O
been	O
affected	O
.	O

This	O
is	O
the	O
second	O
autopsy	O
case	O
of	O
influenza	B-DISO
(	O
A	O
/	O
H1N1pdm	O
)	O
virus	B-DISO
infection	I-DISO
in	O
Japan	O
,	O
and	O
the	O
findings	O
indicated	O
that	O
the	O
patient	O
died	O
due	O
to	O
an	O
exceptionally	O
rapid	O
progression	O
of	O
viral	B-DISO
pneumonia	I-DISO
.	O

CONCLUSIONS	O
:	O
H1N1	B-DISO
influenza	I-DISO
is	O
especially	O
dangerous	O
to	O
pregnant	O
women	O
.	O

A	O
literature	O
review	O
was	O
undertaken	O
for	O
evidence	O
of	O
superior	O
protective	O
value	O
of	O
N95	O
masks	O
or	O
surgical	O
masks	O
for	O
healthcare	O
workers	O
against	O
influenza	B-DISO
and	O
extraneous	O
factors	O
influencing	O
conferred	O
protection	O
.	O

In	O
the	O
majority	O
of	O
studies	O
,	O
important	O
confounders	O
included	O
the	O
unrecognized	O
impact	O
of	O
concurrent	O
bundling	O
of	O
other	O
infection	B-DISO
control	O
measures	O
,	O
mask	O
compliance	O
,	O
contamination	O
from	O
improper	O
doffing	O
of	O
masks	O
,	O
and	O
ocular	O
inoculation	O
.	O

Evidence	O
from	O
laboratory	O
studies	O
of	O
potential	O
airborne	O
spread	O
of	O
influenza	B-DISO
from	O
shedding	O
patients	O
indicate	O
that	O
guidelines	O
related	O
to	O
the	O
current	O
1	O
-	O
meter	O
respiratory	O
zone	O
may	O
need	O
to	O
be	O
extended	O
to	O
a	O
larger	O
respiratory	O
zone	O
and	O
include	O
protection	O
from	O
ocular	O
inoculation	O
.	O

The	O
disease	O
occurs	O
more	O
often	O
in	O
immunocompromised	O
persons	O
and	O
can	O
be	O
manifested	O
by	O
severe	O
pneumonia	B-DISO
,	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
and	O
has	O
a	O
high	O
mortality	O
.	O

Pathohistological	O
analysis	O
of	O
the	O
samples	O
retrieved	O
by	O
bronchoscopy	O
pointed	O
to	O
a	O
pneumonia	B-DISO
,	O
and	O
diagnosis	O
of	O
LD	O
was	O
confirmed	O
by	O
positive	O
urine	O
test	O
for	O
LP	O
antigen	O
.	O

Later	O
,	O
the	O
disease	O
was	O
complicated	O
by	O
acute	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

TITLE	O
:	O
Avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
susceptibility	O
to	O
botanical	O
oleoresins	O
and	O
essential	O
oils	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
report	O
on	O
18	O
patients	O
initially	O
provided	O
with	O
venoarterial	O
extracorporeal	O
membrane	O
oxygenation	O
and	O
then	O
downgraded	O
to	O
a	O
pumpless	O
arteriovenous	B-DISO
shunt	I-DISO
with	O
a	O
membrane	O
oxygenator	O
by	O
removal	O
of	O
the	O
pump	O
from	O
the	O
circuit	O
after	O
hemodynamic	O
stabilization	O
in	O
the	O
face	B-DISO
of	O
persisting	O
pulmonary	B-DISO
failure	I-DISO
.	O

43	O
mg	O
/	O
dL	O
.	O
The	O
sequential	O
organ	B-DISO
failure	I-DISO
assessment	O
score	O
averaged	O
11	O
.	O
8	O
+/-	O

Components	O
from	O
the	O
Rheum	O
palmatum	O
L	O
.	O
had	O
a	O
high	O
level	O
of	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
3CL	O
protease	O
activity	O
.	O

No	O
outcome	O
studies	O
have	O
been	O
reported	O
on	O
the	O
use	O
of	O
prostacyclin	O
in	O
patients	O
with	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Psychosocial	O
and	O
coping	O
responses	O
within	O
the	O
community	O
health	O
care	O
setting	O
towards	O
a	O
national	O
outbreak	O
of	O
an	O
infectious	B-DISO
disease	I-DISO
.	O

These	O
findings	O
could	O
potentially	O
inform	O
the	O
development	O
of	O
practical	O
community	O
mental	O
health	O
programs	O
for	O
future	O
infectious	B-DISO
disease	I-DISO
outbreaks	O
.	O

To	O
this	O
end	O
,	O
LAB	O
strains	O
selected	O
on	O
the	O
basis	O
of	O
previous	O
in	O
vitro	O
trials	O
were	O
co	O
-	O
incubated	O
with	O
cell	O
line	O
monolayers	O
,	O
which	O
were	O
subsequently	O
challenged	O
with	O
rotavirus	O
(	O
RV	O
)	O
and	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
).	O

We	O
want	O
to	O
underline	O
,	O
within	O
the	O
current	O
context	O
of	O
severe	O
respiratory	O
distresses	O
due	O
to	O
Influenza	B-DISO
A	O
pandemic	O
,	O
the	O
necessity	O
to	O
develop	O
a	O
multidisciplinary	O
care	O
network	O
,	O
or	O
to	O
reinforce	O
the	O
existing	O
channels	O
between	O
well	O
-	O
trained	O
medical	O
crews	O
familiar	O
with	O
ECMO	O
'	O
s	O
technics	O
and	O
the	O
ICU	O
that	O
are	O
not	O
.	O

Web	B-DISO
of	O
Science	O
and	O
PubMed	O
databases	O
were	O
searched	O
for	O
references	O
to	O
papers	O
on	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
avian	B-DISO
influenza	I-DISO
/	O
flu	B-DISO
,	O
H5N1	B-DISO
,	O
swine	B-DISO
influenza	I-DISO
/	O
flu	B-DISO
,	O
H1N1	O
,	O
and	O
pandemics	O
.	O

There	O
is	O
also	O
evidence	O
that	O
greater	O
levels	O
of	O
state	B-DISO
anxiety	I-DISO
and	O
greater	O
trust	O
in	O
authorities	O
are	O
associated	O
with	O
behaviour	O
.	O

TITLE	O
:	O
Effects	O
of	O
coronavirus	B-DISO
infections	I-DISO
in	O
children	O
.	O

ABSTRACT	O
:	O
The	O
isolation	O
of	O
the	O
coronavirus	O
(	O
CoV	O
)	O
identified	O
as	O
the	O
cause	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
the	O
detection	O
of	O
2	O
new	O
human	O
CoVs	O
(	O
HCoV	O
-	O
NL63	O
and	O
HCoV	O
-	O
HKU1	O
)	O
have	O
led	O
to	O
studies	O
of	O
the	O
epidemiology	O
and	O
clinical	O
and	O
socioeconomic	O
effects	O
of	O
infections	B-DISO
caused	O
by	O
all	O
HCoVs	O
,	O
including	O
those	O
known	O
since	O
the	O
late	O
1960s	O
(	O
HCoV	O
-	O
229E	O
and	O
HCoV	O
-	O
OC43	O
).	O

TITLE	O
:	O
[	O
Intensive	O
care	O
patients	O
with	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
infection	B-DISO
in	O
Iceland	O
2009	O
].	O

TITLE	O
:	O
Nephrotic	B-DISO
syndrome	I-DISO
complicated	O
by	O
life	O
-	O
threatening	O
pulmonary	B-DISO
embolism	I-DISO
in	O
an	O
adult	O
patient	O
.	O

Assessment	O
of	O
a	O
pulmonary	B-DISO
embolism	I-DISO
by	O
radioisotope	O
imaging	O
was	O
not	O
possible	O
because	O
of	O
his	O
dependence	B-DISO
on	I-DISO
mechanical	O
ventilation	O
.	O

Until	O
recently	O
,	O
intravenous	O
quinine	O
was	O
the	O
standard	O
treatment	O
;	O
however	O
,	O
artemisin	O
derivatives	O
are	O
now	O
regarded	O
as	O
the	O
first	O
-	O
line	O
treatment	O
for	O
multidrug	O
-	O
resistant	O
falciparum	B-DISO
malaria	I-DISO
.	O

TITLE	O
:	O
Heterogeneity	O
in	O
spike	O
protein	O
genes	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
viruses	O
isolated	O
in	O
Korea	O
.	O

Furthermore	O
,	O
the	O
recent	O
explosion	O
of	O
research	O
into	O
the	O
ACE2	O
homolog	O
,	O
collectrin	O
,	O
has	O
revealed	O
a	O
new	O
physiological	O
function	O
of	O
ACE2	O
as	O
an	O
amino	O
acid	O
transporter	O
,	O
which	O
explains	O
the	O
pathogenic	O
role	O
of	O
gene	O
mutations	O
in	O
Hartnup	B-DISO
disorder	I-DISO
.	O

Patients	O
with	O
severe	O
disease	O
were	O
older	O
,	O
more	O
likely	O
to	O
be	O
obese	B-DISO
or	O
having	O
underlying	O
diseases	O
,	O
and	O
had	O
lower	O
respiratory	O
tract	O
symptoms	O
,	O
especially	O
dyspnea	B-DISO
at	O
presentation	O
.	O

TITLE	O
:	O
Exacerbated	O
innate	O
host	O
response	O
to	O
SARS	B-DISO
-	O
CoV	O
in	O
aged	O
non	O
-	O
human	O
primates	O
.	O

The	O
molecular	O
pathways	O
,	O
however	O
,	O
that	O
cause	O
virus	O
-	O
induced	O
ALI	O
/	O
ARDS	B-DISO
in	O
aged	O
individuals	O
are	O
ill	B-DISO
-	O
defined	O
.	O

Comprehensive	O
genomic	O
analyses	O
indicate	O
that	O
aged	O
macaques	O
have	O
a	O
stronger	O
host	O
response	O
to	O
virus	B-DISO
infection	I-DISO
than	O
young	O
adult	O
macaques	O
,	O
with	O
an	O
increase	O
in	O
differential	O
expression	O
of	O
genes	O
associated	O
with	O
inflammation	B-DISO
,	O
with	O
NF	O
-	O
kappaB	O
as	O
central	O
player	O
,	O
whereas	O
expression	O
of	O
type	O
I	O
interferon	O
(	O
IFN	O
)-	O
beta	O
is	O
reduced	O
.	O

Thus	O
,	O
ALI	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
aged	O
macaques	O
developed	O
as	O
a	O
result	O
of	O
an	O
exacerbated	O
innate	O
host	O
response	O
.	O

ABSTRACT	O
:	O
A	O
typical	O
feature	O
of	O
Parkinson	B-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
is	O
the	O
progressive	O
loss	O
of	O
dopaminergic	O
neurons	O
in	O
the	O
substantia	O
nigra	O
,	O
in	O
which	O
inhibition	O
of	O
mitochondrial	O
complex	O
I	O
activity	O
may	O
play	O
an	O
important	O
role	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
emerged	O
as	O
a	O
human	O
disease	O
in	O
2002	O
.	O

Detailed	O
phylogenetic	O
analysis	O
and	O
epidemiologic	O
studies	O
have	O
suggested	O
that	O
the	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
originated	O
from	O
animals	O
.	O

Ap4A	O
-	O
hydrolase	O
is	O
responsible	O
for	O
metabolizing	O
the	O
""""	O
allarmone	O
""""	O
nucleotide	O
Ap4A	O
and	O
therefore	O
likely	O
involved	O
in	O
regulation	O
of	O
cell	O
proliferation	B-DISO
,	O
DNA	O
replication	O
,	O
RNA	O
processing	O
,	O
apoptosis	O
and	O
DNA	O
repair	O
.	O

Installation	O
of	O
fever	O
screening	O
stations	O
outside	O
of	O
the	O
hospital	O
and	O
implementing	O
traffic	O
control	O
in	O
the	O
emergency	B-DISO
department	O
contributed	O
to	O
70	O
%	O
of	O
the	O
effectiveness	O
in	O
the	O
prevention	O
of	O
SARS	B-DISO
transmission	O
.	O

Unlike	O
the	O
parent	O
strain	O
,	O
the	O
attenuated	O
strain	O
(	O
K2p170	O
)	O
was	O
safe	O
in	O
day	O
-	O
old	O
specific	O
-	O
pathogen	O
-	O
free	O
chicks	O
since	O
replication	O
of	O
the	O
virus	O
did	O
not	O
induce	O
mortality	O
and	O
nephritis	B-DISO
,	O
and	O
rarely	O
induced	O
histological	O
changes	O
in	O
the	O
trachea	B-DISO
and	O
kidney	O
after	O
intraocular	O
administration	O
.	O

ABSTRACT	O
:	O
Campylobacter	O
jejuni	O
enteritis	B-DISO
is	O
the	O
predominant	O
bacterial	B-DISO
infection	I-DISO
preceding	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
(	O
GBS	B-DISO
),	O
an	O
acute	O
postinfectious	O
immune	O
-	O
mediated	O
polyradiculoneuropathy	B-DISO
.	O

We	O
performed	O
a	O
prospective	O
matched	O
case	O
-	O
control	O
hospital	O
surveillance	O
including	O
100	O
patients	O
fulfilling	O
the	O
National	O
Institute	O
of	O
Neurological	B-DISO
Disorders	I-DISO
and	O
Stroke	B-DISO
criteria	O
for	O
GBS	B-DISO
from	O
2006	O
to	O
2007	O
in	O
the	O
Dhaka	O
area	O
of	O
Bangladesh	O
.	O

ABSTRACT	O
:	O
The	O
objective	O
of	O
the	O
SARSControl	O
Delphi	O
study	O
was	O
to	O
develop	O
options	O
for	O
national	O
and	O
international	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
policies	O
.	O

Lymphocytic	O
inflammation	B-DISO
was	O
present	O
in	O
these	O
tissues	O
.	O

We	O
report	O
a	O
case	O
of	O
life	O
-	O
threatening	O
amniotic	B-DISO
fluid	I-DISO
embolism	I-DISO
,	O
where	O
chest	O
CT	O
in	O
the	O
acute	O
phase	O
was	O
obtained	O
.	O

Many	O
of	O
these	O
glycoproteins	O
,	O
including	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
protein	O
form	O
trimeric	O
units	O
in	O
the	O
membrane	O
of	O
the	O
native	O
virion	O
.	O

Multiplex	O
nested	O
RT	O
-	O
PCR	O
can	O
detect	O
TGEV	O
,	O
PRV	B-DISO
-	O
A	O
,	O
and	O
PEDV	O
up	O
to	O
concentration	O
10	O
(	O
2	O
)	O
TCID	O
(	O
50	O
)/	O
mL	O
,	O
10	O
(	O
1	O
)	O
TCID	O
(	O
50	O
)/	O
mL	O
,	O
and	O
27	O
.	O
2	O
microg	O
/	O
microl	O
of	O
RNA	O
,	O
respectively	O
.	O

However	O
,	O
early	O
prophylactic	O
use	O
of	O
iNO	O
in	O
preterm	O
infants	O
with	O
respiratory	B-DISO
distress	I-DISO
seems	O
to	O
improve	O
survival	O
without	O
BPD	B-DISO
or	O
severe	O
cerebral	O
damage	O
.	O

A	O
complex	O
interaction	O
between	O
the	O
coronavirus	O
and	O
the	O
feline	O
immune	O
system	O
causes	O
disseminated	O
vasculitis	B-DISO
,	O
which	O
is	O
the	O
hallmark	O
of	O
FIP	B-DISO
.	O

Minimizing	O
exposure	O
is	O
the	O
best	O
method	O
of	O
preventing	O
infection	B-DISO
.	O

Specifically	O
,	O
this	O
paper	O
will	O
examine	O
the	O
perspectives	O
and	O
recommendations	O
of	O
children	O
hospitalised	O
during	O
SARS	B-DISO
in	O
a	O
large	O
paediatric	O
hospital	O
in	O
Canada	O
.	O

The	O
lung	O
samples	O
were	O
cultured	O
for	O
bacteria	O
and	O
tested	O
by	O
multiplex	O
polymerase	O
chain	O
reaction	O
for	O
presence	O
of	O
swine	B-DISO
influenza	I-DISO
virus	O
(	O
type	O
A	O
),	O
porcine	B-DISO
reproductive	I-DISO
and	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
(	O
both	O
European	O
and	O
US	O
type	O
),	O
porcine	O
circovirus	O
type	O
2	O
(	O
PCV2	O
),	O
porcine	O
respiratory	O
coronavirus	O
,	O
porcine	O
cytomegalovirus	O
,	O
Mycoplasma	B-DISO
hyopneumoniae	O
and	O
Mycoplasma	B-DISO
hyorhinis	O
.	O

Five	O
bacterial	O
species	O
,	O
five	O
viruses	O
and	O
two	O
Mycoplasma	B-DISO
spp	O
.	O
were	O
detected	O
in	O
different	O
combinations	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
encode	O
multifunctional	O
proteins	O
that	O
are	O
critical	O
for	O
viral	O
replication	O
and	O
for	O
blocking	B-DISO
the	O
innate	B-DISO
immune	I-DISO
response	I-DISO
to	O
viral	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Identification	O
of	O
intertypic	O
recombinant	O
infectious	B-DISO
bronchitis	B-DISO
viruses	O
from	O
slaughtered	O
chickens	O
.	O

Infectious	B-DISO
bronchitis	B-DISO
viruses	O
from	O
slaughtered	O
chickens	O
revealed	O
intertypic	O
genetic	O
recombination	O
and	O
antigenic	O
diversity	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
),	O
the	O
causative	O
agent	O
of	O
infectious	B-DISO
bronchitis	B-DISO
,	O
results	O
in	O
respiratory	B-DISO
disease	I-DISO
,	O
nephritis	B-DISO
,	O
and	O
poor	O
egg	O
production	O
and	O
quality	O
in	O
chicken	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
case	O
of	O
severe	O
neonatal	B-DISO
infection	I-DISO
on	O
day	O
6	O
of	O
life	O
due	O
to	O
Toxoplasma	O
gondii	O
mimicking	O
septic	O
shock	B-DISO
syndrome	I-DISO
associated	O
with	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
such	O
as	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
with	O
persistent	B-DISO
pulmonary	I-DISO
hypertension	I-DISO
,	O
neurological	O
distress	O
,	O
thrombocytopenia	O
with	O
disseminated	O
intravascular	O
coagulopathy	B-DISO
and	O
transaminitis	O
.	O

The	O
morbidity	O
and	O
mortality	O
associated	O
with	O
ALI	O
and	O
ARDS	B-DISO
are	O
significant	O
and	O
the	O
treatment	O
of	O
these	O
conditions	O
presents	O
a	O
formidable	O
challenge	O
.	O

Controlling	O
hyperglycemia	B-DISO
with	O
insulin	O
is	O
a	O
core	O
component	O
of	O
patient	O
management	O
in	O
the	O
critically	B-DISO
ill	I-DISO
.	O

ABSTRACT	O
:	O
The	O
study	O
tested	O
the	O
model	O
of	O
perceived	O
support	O
from	O
medical	O
staff	O
and	O
family	O
/	O
friends	O
on	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
survivors	O
'	O
mental	O
health	O
as	O
mediated	O
by	O
self	O
-	O
care	O
self	O
-	O
efficacy	O
.	O

The	O
patient	O
responded	O
to	O
pulse	O
steroid	O
therapy	O
and	O
recovered	O
from	O
severe	O
respiratory	B-DISO
failure	I-DISO
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
describing	O
the	O
details	O
of	O
ARDS	B-DISO
following	O
PCT	B-DISO
.	O

ABSTRACT	O
:	O
The	O
role	O
of	O
coronaviruses	O
in	O
paediatric	O
gastro	O
-	O
enteritis	B-DISO
is	O
not	O
well	O
defined	O
.	O

Coronaviruses	O
were	O
detected	O
in	O
63	O
(	O
6	O
%)	O
of	O
984	O
children	O
with	O
acute	O
gastro	O
-	O
enteritis	B-DISO
and	O
were	O
more	O
commonly	O
detected	O
in	O
outpatients	O
(	O
47	O
/	O
423	O
,	O
11	O
%)	O
than	O
in	O
inpatients	O
(	O
16	O
/	O
561	O
,	O
3	O
%).	O

This	O
discrepancy	O
can	O
only	O
be	O
explained	O
by	O
the	O
fact	O
,	O
that	O
hypoxemia	O
is	O
not	O
equivalent	O
to	O
tissue	O
hypoxia	B-DISO
.	O

Five	O
patients	O
(	O
14	O
.	O
7	O
%)	O
with	O
a	O
lower	O
lobe	O
tumor	B-DISO
required	O
PA	O
reconstruction	O
with	O
artery	O
flap	O
.	O

CONCLUSIONS	O
:	O
In	O
our	O
department	O
,	O
PA	O
reconstruction	O
has	O
been	O
more	O
frequently	O
and	O
actively	O
performed	O
for	O
patients	O
with	O
central	O
lung	B-DISO
cancer	I-DISO
,	O
especially	O
for	O
some	O
patients	O
with	O
a	O
lower	O
lobe	O
tumor	B-DISO
.	O

TITLE	O
:	O
Chickenpox	B-DISO
:	O
presentation	O
and	O
complications	O
in	O
adults	O
.	O

Whereas	O
,	O
the	O
most	O
common	O
complications	O
observed	O
were	O
raised	O
Alanine	O
aminotransferases	O
(	O
ALT	O
)	O
levels	O
(	O
51	O
.	O
9	O
%)	O
and	O
the	O
levels	O
were	O
greater	O
than	O
10	O
-	O
folds	O
of	O
normal	O
value	O
in	O
4	O
.	O
9	O
%,	O
thrombocytopenia	O
(	O
42	O
.	O
1	O
%),	O
varicella	B-DISO
pneumonia	I-DISO
(	O
28	O
.	O
4	O
%),	O
skin	B-DISO
infection	I-DISO
(	O
25	O
.	O
4	O
%),	O
septicaemia	B-DISO
(	O
10	O
.	O
7	O
%),	O
Encephalitis	B-DISO
/	O
Meningitis	B-DISO
(	O
8	O
.	O
8	O
%),	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
(	O
6	O
.	O
8	O
%),	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
(	O
2	O
.	O
9	O
%)	O
and	O
acute	B-DISO
hepatic	I-DISO
failure	I-DISO
(	O
1	O
.	O
9	O
%).	O

Total	O
five	O
(	O
4	O
.	O
9	O
%)	O
patients	O
expired	O
,	O
whereas	O
,	O
mortality	O
rate	O
was	O
17	O
.	O
2	O
%	O
in	O
varicella	B-DISO
pneumonia	I-DISO
patients	O
and	O
45	O
.	O
5	O
%	O
in	O
mechanically	O
ventilated	O
patients	O
.	O

Children	O
usually	O
have	O
mild	O
-	O
to	O
-	O
severe	O
respiratory	B-DISO
symptoms	I-DISO
and	O
occasionally	O
die	O
of	O
respiratory	B-DISO
failure	I-DISO
.	O

Herein	O
,	O
we	O
describe	O
an	O
infant	O
with	O
a	O
constitutional	O
14q12	O
-	O
21	O
.	O
3	O
haploid	O
deletion	O
encompassing	O
the	O
TTF	O
-	O
1	O
gene	O
locus	O
who	O
had	O
cerebral	B-DISO
dysgenesis	I-DISO
,	O
thyroidal	O
dysfunction	O
,	O
and	O
respiratory	B-DISO
insufficiency	I-DISO
.	O

To	O
describe	O
these	O
characteristics	O
in	O
patients	O
with	O
confirmed	O
,	O
probable	O
,	O
and	O
suspected	O
viral	B-DISO
pneumonia	I-DISO
caused	O
by	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
admitted	O
to	O
35	O
intensive	O
care	O
units	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
requiring	O
mechanical	O
ventilation	O
in	O
Argentina	O
,	O
between	O
June	O
3	O
and	O
September	O
7	O
.	O

Late	O
reactions	O
due	O
to	O
cow	B-DISO
'	I-DISO
s	I-DISO
milk	I-DISO
allergy	I-DISO
are	O
atopic	B-DISO
dermatitis	I-DISO
,	O
chronic	B-DISO
diarrhoea	I-DISO
,	O
blood	O
in	O
the	O
stools	O
,	O
iron	B-DISO
deficiency	I-DISO
anaemia	I-DISO
,	O
gastroesophageal	B-DISO
reflux	I-DISO
disease	I-DISO
,	O
constipation	B-DISO
,	I-DISO
chronic	I-DISO
vomiting	B-DISO
,	O
colic	B-DISO
,	O
poor	O
growth	O
(	O
food	O
refusal	O
),	O
enterocolitis	B-DISO
syndrome	B-DISO
,	O
protein	B-DISO
-	I-DISO
losing	I-DISO
enteropathy	I-DISO
with	O
hypoalbuminemia	O
,	O
eosinophilic	O
oesophagogastroenteropathy	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
identify	O
similarities	O
and	O
differences	O
in	O
SARS	B-DISO
epidemiology	O
in	O
three	O
populations	O
with	O
similar	O
host	O
and	O
viral	O
genotype	O
.	O

Our	O
findings	O
underline	O
the	O
importance	O
of	O
a	O
common	O
data	O
collection	O
platform	O
,	O
especially	O
in	O
an	O
emerging	O
epidemic	O
,	O
in	O
order	O
to	O
identify	O
and	O
explain	O
consistencies	O
and	O
differences	O
in	O
the	O
eventual	O
clinical	O
and	O
public	O
health	O
outcomes	O
of	O
infectious	B-DISO
disease	I-DISO
outbreaks	O
,	O
which	O
is	O
becoming	O
increasingly	O
important	O
in	O
our	O
highly	O
interconnected	O
world	O
.	O

One	O
feature	O
of	O
our	O
analysis	O
is	O
the	O
incorporation	O
of	O
time	O
-	O
dependent	O
functions	O
into	O
the	O
model	O
to	O
reflect	O
the	O
progressive	O
refinement	O
of	O
these	O
SARS	B-DISO
control	O
measures	O
over	O
time	O
.	O

RESULTS	O
:	O
The	O
incidences	O
of	O
the	O
two	O
severe	O
complications	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
intestinal	B-DISO
paralysis	I-DISO
,	O
in	O
the	O
treated	O
group	O
was	O
3	O
.	O
6	O
%	O
and	O
5	O
.	O
4	O
%	O
respectively	O
,	O
while	O
in	O
the	O
control	O
group	O
,	O
12	O
.	O
7	O
%	O
and	O
18	O
.	O
2	O
%,	O
showing	O
statistical	O
significance	O
between	O
groups	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

On	O
testing	O
of	O
263	O
VN	O
antibody	O
-	O
positive	O
sera	O
from	O
27	O
farms	O
with	O
a	O
commercial	O
blocking	B-DISO
ELISA	O
to	O
distinguish	O
TGEV	O
and	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
)	O
antibodies	O
,	O
78	O
.	O
3	O
%	O
were	O
positive	O
for	O
PRCV	O
antibody	O
only	O
,	O
while	O
12	O
.	O
5	O
%	O
were	O
positive	O
for	O
TGEV	O
antibody	O
only	O
or	O
both	O
TGEV	O
and	O
PRCV	O
antibodies	O
.	O

3	O
.	O
126	O
APL	B-DISO
,	O
IgG	O
at	O
5	O
.	O
184	O
+/-	O

The	O
entry	O
pathway	O
of	O
SARS	B-DISO
-	O
CoV	O
could	O
influence	O
the	O
severity	O
of	O
the	O
disease	O
.	O

Murine	O
coronavirus	O
,	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
infection	B-DISO
of	O
the	O
mouse	O
,	O
provides	O
animal	O
models	O
for	O
the	O
study	O
of	O
central	B-DISO
nervous	I-DISO
system	I-DISO
disease	I-DISO
,	O
including	O
encephalitis	B-DISO
and	O
demyelinating	B-DISO
diseases	I-DISO
such	O
as	O
Multiple	B-DISO
Sclerosis	I-DISO
and	O
for	O
hepatitis	B-DISO
.	O

Other	O
primary	O
cell	O
types	O
such	O
as	O
neurons	O
,	O
astrocytes	O
and	O
hepatocytes	O
fail	O
to	O
produce	O
IFN	O
following	O
infection	B-DISO
and	O
,	O
in	O
vivo	O
,	O
likely	O
depend	O
on	O
IFN	O
produced	O
by	O
pDCs	O
and	O
macrophages	O
for	O
protection	O
from	O
MHV	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
murine	O
norovirus	O
(	O
MNV	O
)	O
infection	B-DISO
in	O
laboratory	O
mice	O
,	O
we	O
attempted	O
to	O
develop	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
system	O
and	O
an	O
indirect	O
immunofluorescent	O
antibody	O
(	O
IFA	O
)	O
assay	O
for	O
detecting	O
the	O
anti	O
-	O
MNV	O
-	O
S7	O
antibody	O
in	O
mice	O
.	O

ABSTRACT	O
:	O
The	O
severity	O
of	O
an	O
outbreak	O
is	O
a	O
priority	O
in	O
decision	O
-	O
making	O
for	O
human	O
infection	B-DISO
control	O
.	O

TITLE	O
:	O
Molecular	O
characterization	O
of	O
a	O
Chinese	O
vaccine	O
strain	O
of	O
transmissible	O
gastroenteritis	B-DISO
virus	O
:	O
mutations	O
that	O
may	O
contribute	O
to	O
attenuation	O
.	O

ABSTRACT	O
:	O
The	O
pathogenesis	B-DISO
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
poorly	O
understood	O
.	O

Interestingly	O
,	O
IP	O
-	O
10	O
expression	O
was	O
shown	O
to	O
be	O
significantly	O
increased	O
when	O
SARS	B-DISO
-	O
CoV	O
-	O
infected	O
Calu	O
-	O
3	O
cells	O
were	O
treated	O
with	O
IFN	O
alfacon	O
-	O
1	O
.	O

Our	O
data	O
might	O
provide	O
an	O
important	O
insight	O
into	O
the	O
mechanism	O
of	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
-	O
CoV	O
and	O
these	O
properties	O
might	O
be	O
therapeutically	O
advantageous	O
.	O

TITLE	O
:	O
Detection	O
of	O
human	O
coronaviruses	O
in	O
children	O
with	O
acute	B-DISO
gastroenteritis	I-DISO
.	O

878	O
stool	O
specimens	O
from	O
children	O
with	O
acute	B-DISO
gastroenteritis	I-DISO
and	O
112	O
from	O
control	O
children	O
were	O
tested	O
by	O
RT	O
-	O
PCR	O
to	O
detect	O
HCoV	O
groups	O
1B	O
,	O
2A	O
and	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
widely	O
accepted	O
as	O
a	O
rescue	O
therapy	O
in	O
patients	O
with	O
acute	O
life	O
-	O
threatening	O
hypoxemia	O
in	O
the	O
course	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

After	O
institutional	O
review	O
board	O
approval	O
,	O
knowledge	O
of	O
personal	O
protection	O
measures	O
among	O
emergency	B-DISO
medicine	O
(	O
n	O
=	O
28	O
)	O
and	O
anesthetics	O
(	O
n	O
=	O
47	O
)	O
specialty	O
registrars	O
in	O
the	O
South	O
Thames	O
Region	O
of	O
the	O
United	O
Kingdom	O
was	O
surveyed	O
using	O
a	O
standardized	O
questionnaire	O
.	O

Little	O
is	O
known	O
about	O
kidney	O
outcomes	O
and	O
dialytic	O
requirements	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
infected	O
with	O
pandemic	O
H1N1	O
.	O

In	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
pandemic	O
H1N1	O
,	O
kidney	O
injury	O
,	O
kidney	B-DISO
failure	I-DISO
,	O
and	O
the	O
need	O
for	O
dialysis	O
are	O
common	O
and	O
associated	O
with	O
an	O
increase	O
in	O
mortality	O
and	O
length	O
of	O
intensive	O
care	O
unit	O
stay	O
.	O

RESULTS	O
:	O
The	O
pandemic	O
H1N1	O
group	O
was	O
composed	O
of	O
50	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
pandemic	O
H1N1	O
with	O
severe	O
respiratory	O
syndrome	B-DISO
(	O
47	O
confirmed	O
cases	O
,	O
3	O
probable	O
).	O

ABSTRACT	O
:	O
To	O
summarize	O
the	O
experience	O
with	O
surgical	O
treatment	O
of	O
constrictive	B-DISO
pericarditis	I-DISO
.	O

Relapse	B-DISO
occurred	O
in	O
one	O
case	O
because	O
of	O
incomplete	O
pericardial	O
resection	O
.	O

TITLE	O
:	O
Lambda	O
interferon	O
renders	O
epithelial	O
cells	O
of	O
the	O
respiratory	O
and	O
gastrointestinal	O
tracts	O
resistant	O
to	O
viral	B-DISO
infections	I-DISO
.	O

Using	O
mice	O
lacking	O
functional	O
receptors	O
for	O
type	O
I	O
IFN	O
,	O
type	O
III	O
IFN	O
,	O
or	O
both	O
,	O
we	O
found	O
that	O
IFN	O
-	O
lambda	O
plays	O
an	O
important	O
role	O
in	O
the	O
defense	O
against	O
several	O
human	O
pathogens	O
that	O
infect	O
the	O
respiratory	O
tract	O
,	O
such	O
as	O
influenza	B-DISO
A	O
virus	O
,	O
influenza	B-DISO
B	O
virus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
human	O
metapneumovirus	O
,	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
.	O

Recently	O
,	O
we	O
demonstrated	O
that	O
a	O
recombinant	O
MVTT	O
expressing	O
the	O
spike	O
glycoprotein	O
of	O
SARS	B-DISO
-	O
CoV	O
(	O
namely	O
MVTT	O
-	O
S	O
)	O
is	O
superior	O
to	O
the	O
non	O
-	O
replicating	O
modified	O
vaccinia	B-DISO
Ankara	O
(	O
MVA	O
-	O
S	O
)	O
for	O
inducing	O
high	O
level	O
of	O
neutralizing	O
antibodies	O
through	O
mucosal	O
vaccination	O
.	O

TITLE	O
:	O
Infectivity	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
during	O
its	O
incubation	O
period	O
.	O

Individuals	O
related	O
with	O
the	O
two	O
SARS	B-DISO
chains	O
of	O
transmission	O
in	O
Beijing	O
in	O
2003	O
and	O
a	O
group	O
of	O
individuals	O
isolated	O
for	O
medical	O
observation	O
in	O
Haidian	O
district	O
of	O
Beijing	O
during	O
the	O
SARS	B-DISO
outbreak	O
were	O
selected	O
as	O
subjects	O
of	O
study	O
.	O

Samples	O
collected	O
from	O
the	O
asymptomatic	O
contactors	O
were	O
all	O
negative	O
for	O
SARS	B-DISO
-	O
CoV	O
antibody	O
.	O

ABSTRACT	O
:	O
Inhaled	O
nitric	O
oxide	O
(	O
iNO	O
)	O
improves	O
gas	O
exchange	O
in	O
about	O
60	O
%	O
of	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

TITLE	O
:	O
The	O
long	O
-	O
term	O
impact	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
on	O
pulmonary	O
function	O
,	O
exercise	O
capacity	O
and	O
health	O
status	O
.	O

A	O
prospective	O
cohort	O
study	O
of	O
SARS	B-DISO
patients	O
at	O
the	O
Prince	O
of	O
Wales	O
Hospital	O
,	O
Hong	O
Kong	O
was	O
conducted	O
,	O
with	O
serial	O
assessments	O
of	O
lung	O
function	O
,	O
6MWD	O
and	O
36	O
item	O
Short	O
Form	O
General	O
Health	O
Survey	O
at	O
3	O
,	O
6	O
,	O
12	O
,	O
18	O
and	O
24	O
months	O
after	O
disease	O
onset	O
.	O

A	O
significant	O
reduction	O
in	O
milk	O
yield	O
was	O
observed	O
for	O
cows	O
in	O
presumably	O
BRSV	O
recently	O
infected	O
herds	O
,	O
as	O
well	O
as	O
in	O
herds	O
having	O
a	O
presumably	O
BRSV	O
-	O
related	O
clinical	O
outbreak	O
(	O
of	O
0	O
.	O
57	O
and	O
0	O
.	O
91	O
kg	O
/	O
d	O
,	O
respectively	O
),	O
compared	O
with	O
cows	O
in	O
presumably	O
infection	B-DISO
-	O
free	O
herds	O
.	O

Based	O
on	O
the	O
number	O
of	O
children	O
with	O
high	O
HCoV	O
-	O
NL63	O
infection	B-DISO
and	O
no	O
additional	O
infection	B-DISO
,	O
the	O
overall	O
annual	O
incidence	O
in	O
outpatients	O
was	O
7	O
per	O
1000	O
children	O
per	O
year	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
3	O
-	O
13	O
per	O
1000	O
children	O
per	O
year	O
),	O
which	O
can	O
be	O
extrapolated	O
to	O
an	O
absolute	O
number	O
of	O
16	O
,	O
929	O
visits	O
to	O
the	O
physician	O
due	O
to	O
an	O
HCoV	O
-	O
NL63	O
infection	B-DISO
in	O
Germany	O
per	O
year	O
.	O

TITLE	O
:	O
Respiratory	O
virus	O
pneumonia	B-DISO
after	O
hematopoietic	O
cell	O
transplantation	O
(	O
HCT	O
):	O
associations	O
between	O
viral	O
load	O
in	O
bronchoalveolar	O
lavage	O
samples	O
,	O
viral	O
RNA	O
detection	O
in	O
serum	O
samples	O
,	O
and	O
clinical	O
outcomes	O
of	O
HCT	O
.	O

We	O
retrospectively	O
identified	O
HCT	O
recipients	O
with	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
parainfluenza	B-DISO
virus	O
,	O
influenza	B-DISO
virus	O
,	O
metapneumovirus	O
(	O
MPV	O
),	O
and	O
coronavirus	O
(	O
CoV	O
)	O
detected	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
samples	O
,	O
and	O
we	O
tested	O
stored	O
BAL	O
and	O
/	O
or	O
serum	O
samples	O
by	O
quantitative	O
polymerase	O
chain	O
reaction	O
.	O

The	O
sPLA2	O
activity	O
and	O
tumor	B-DISO
necrosis	I-DISO
factor	O
(	O
TNF	O
)-	O
α	O
were	O
significantly	O
higher	O
in	O
the	O
bronchoalveolar	O
lavage	O
of	O
ARDS	B-DISO
infants	O
.	O

Despite	O
improved	O
surveillance	O
and	O
quarantine	O
measures	O
,	O
we	O
find	O
ourselves	O
in	O
the	O
midst	O
of	O
a	O
H1N1	B-DISO
influenza	I-DISO
pandemic	O
.	O

Marked	O
renal	B-DISO
tubular	I-DISO
necrosis	I-DISO
was	O
also	O
seen	O
.	O

We	O
present	O
evidence	O
that	O
MHV	O
infection	B-DISO
can	O
delay	O
interferon	O
-	O
stimulated	O
gene	O
(	O
ISG	O
)	O
induction	O
mediated	O
by	O
both	O
SeV	O
and	O
IFN	O
-	O
beta	O
but	O
only	O
when	O
MHV	O
infection	B-DISO
precedes	O
SeV	O
or	O
IFN	O
-	O
beta	O
exposure	O
.	O

TITLE	O
:	O
From	O
neurogenic	B-DISO
pulmonary	I-DISO
edema	I-DISO
to	O
fat	B-DISO
embolism	I-DISO
syndrome	I-DISO
:	O
a	O
brief	O
review	O
of	O
experimental	O
and	O
clinical	O
investigations	O
of	O
acute	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Hence	O
,	O
SARS	B-DISO
patients	O
with	O
the	O
CD209	O
-	O
336	O
AA	O
genotype	O
carry	O
a	O
60	O
%	O
chance	O
of	O
having	O
a	O
poorer	O
prognosis	O
.	O

It	O
allows	O
us	O
to	O
show	O
that	O
the	O
SARS	B-DISO
-	O
CoV	O
is	O
most	O
closely	O
related	O
to	O
a	O
coronavirus	O
from	O
the	O
palm	O
civet	O
not	O
from	O
a	O
bird	O
as	O
initially	O
suspected	O
,	O
and	O
the	O
newly	O
discovered	O
human	O
coronavirus	O
HCoV	O
-	O
HKU1	O
is	O
more	O
closely	O
related	O
to	O
SARS	B-DISO
than	O
to	O
any	O
other	O
known	O
member	O
of	O
group	O
2	O
coronavirus	O
.	O

This	O
review	O
attempts	O
to	O
bridge	O
this	O
gap	O
by	O
presenting	O
conceptual	O
,	O
technical	O
,	O
and	O
practical	O
aspects	O
of	O
applying	O
phylogenetic	O
methods	O
in	O
studies	O
of	O
influenza	B-DISO
,	O
HIV	B-DISO
,	O
and	O
SCoV	O
.	O
It	O
aims	O
to	O
provide	O
,	O
with	O
minimal	O
mathematics	O
and	O
statistics	O
,	O
a	O
practical	O
overview	O
of	O
how	O
phylogenetic	O
methods	O
can	O
be	O
incorporated	O
into	O
virological	O
studies	O
by	O
clinical	O
and	O
laboratory	O
specialists	O
.	O

Seventeen	O
patients	O
had	O
primary	O
viral	B-DISO
pneumonia	I-DISO
and	O
1	O
patient	O
had	O
an	O
asthma	B-DISO
exacerbation	O
and	O
3	O
patients	O
experienced	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
(	O
MODS	B-DISO
).	O

In	O
Qinghai	O
Province	O
,	O
cases	O
with	O
influenza	B-DISO
A	O
H1N1	O
peaked	O
early	O
with	O
relative	O
high	O
incidence	O
of	O
severe	O
cases	O
.	O

TITLE	O
:	O
Pathogenesis	B-DISO
of	O
murine	O
coronavirus	O
in	O
the	O
central	O
nervous	B-DISO
system	O
.	O

Type	O
I	O
interferon	O
is	O
essential	O
to	O
prevent	O
very	O
early	O
mortality	O
after	O
infection	B-DISO
.	O

The	O
use	O
of	O
oseltamivir	O
for	O
treatment	O
and	O
prophylaxis	O
of	O
infection	B-DISO
is	O
recommended	O
and	O
its	O
use	O
has	O
climbed	O
steeply	O
although	O
there	O
is	O
little	O
data	O
available	O
on	O
its	O
benefit	O
in	O
critically	O
unwell	B-DISO
patients	O
with	O
H1N1	B-DISO
influenza	I-DISO
.	O

Plasma	O
exchange	O
should	O
be	O
considered	O
early	O
in	O
Guillain	O
-	O
Barrć	O
syndrome	B-DISO
cases	O
with	O
axonal	O
involvement	O
,	O
and	O
in	O
the	O
recurrent	O
or	O
familial	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
forms	O
.	O

The	O
present	O
review	O
highlights	O
the	O
drug	O
design	O
approaches	O
utilized	O
to	O
understand	O
the	O
mechanism	O
of	O
inhibition	O
and	O
discovery	O
of	O
inhibitors	O
against	O
protozoal	O
cysteine	O
protease	O
,	O
falcipain	O
(	O
a	O
cysteine	O
protease	O
of	O
P	O
.	O
falciparum	O
which	O
causes	O
malaria	B-DISO
),	O
and	O
viral	O
cysteine	O
protease	O
,	O
SARS	B-DISO
-	O
CoV	O
M	O
(	O
pro	O
)	O
(	O
a	O
cysteine	O
protease	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
corona	O
virus	O
).	O

Our	O
studies	O
indicate	O
that	O
mutation	O
of	O
Glu	O
-	O
166	O
in	O
the	O
R298A	O
mutant	B-DISO
indeed	O
blocks	O
the	O
substrate	O
-	O
induced	O
dimerization	O
.	O

A	O
prevailing	O
hypothesis	O
is	O
that	O
the	O
highly	O
pathogenic	O
virus	O
isolates	O
cause	O
a	O
severe	O
cytokinemia	O
precipitating	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
.	O

Cynomolgus	O
macaques	O
(	O
Macaca	O
fascicularis	O
)	O
infected	O
with	O
a	O
human	O
highly	O
pathogenic	O
avian	B-DISO
influenza	I-DISO
(	O
HPAI	O
)	O
H5N1	B-DISO
virus	O
isolate	O
(	O
A	O
/	O
Vietnam	O
/	O
1203	O
/	O
2004	O
)	O
or	O
reassortants	O
of	O
human	B-DISO
influenza	I-DISO
virus	O
A	O
/	O
Texas	O
/	O
36	O
/	O
91	O
(	O
H1N1	O
)	O
containing	O
genes	O
from	O
the	O
1918	O
pandemic	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
virus	O
developed	O
severe	O
pneumonia	B-DISO
within	O
24	O
h	O
postinfection	O
.	O

Extrapulmonary	O
pathology	B-DISO
may	O
thus	O
contribute	O
to	O
the	O
morbidities	O
induced	O
by	O
H5N1	B-DISO
viruses	O
.	O

Administrative	O
,	O
personal	O
and	O
engineering	O
measures	O
to	O
control	O
respiratory	B-DISO
infection	I-DISO
are	O
effective	O
and	O
should	O
be	O
implemented	O
in	O
healthcare	O
facilities	O
.	O

TITLE	O
:	O
Identification	O
of	O
SARS	B-DISO
-	O
COV	O
spike	O
protein	O
-	O
derived	O
and	O
HLA	O
-	O
A2	O
-	O
restricted	O
human	O
CTL	O
epitopes	O
by	O
using	O
a	O
new	O
muramyl	O
dipeptidederivative	O
adjuvant	O
.	O

The	O
present	O
study	O
provides	O
a	O
strategy	O
to	O
rapidly	O
identify	O
SARS	B-DISO
-	O
CoV	O
-	O
derived	O
antigenic	O
peptides	O
recognized	O
by	O
HLA	O
-	O
A2	O
-	O
restricted	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTLs	O
).	O

The	O
method	O
was	O
useful	O
,	O
convenient	O
and	O
efficient	O
for	O
rapid	O
identification	O
of	O
CTL	O
epitopes	O
derived	O
from	O
SARS	B-DISO
-	O
CoV	O
proteins	O
and	O
will	O
be	O
possibly	O
applicable	O
for	O
other	O
pathogens	O
to	O
develop	O
a	O
peptide	O
-	O
based	O
vaccine	O
.	O

RESULTS	O
:	O
The	O
emergency	B-DISO
preparedness	O
training	O
resulted	O
in	O
positive	O
shifts	O
in	O
knowledge	O
and	O
skills	O
for	O
rural	O
public	O
health	O
personnel	O
.	O

Moreover	O
,	O
more	O
than	O
90	O
%	O
of	O
participants	O
reported	O
that	O
this	O
training	O
provided	O
a	O
valuable	O
learning	O
experience	O
and	O
reinforced	O
the	O
importance	O
of	O
emergency	B-DISO
preparedness	O
.	O

From	O
June	O
2006	O
to	O
June	O
2009	O
we	O
treated	O
adult	O
trauma	O
patients	O
(	O
n	O
=	O
10	O
,	O
mean	O
age	O
:	O
32	O
+/-	O
14	O
years	O
,	O
mean	O
ISS	B-DISO
score	O
73	O
+/-	O
4	O
)	O
with	O
percutaneous	O
veno	O
-	O
venous	O
(	O
v	O
-	O
v	O
)	O
ECMO	O
for	O
pulmonary	B-DISO
failure	I-DISO
(	O
n	O
=	O
7	O
)	O
and	O
with	O
veno	O
-	O
arterial	O
(	O
v	O
-	O
a	O
)	O
ECMO	O
in	O
cardiopulmonary	B-DISO
failure	I-DISO
(	O
n	O
=	O
3	O
).	O

To	O
address	O
this	O
question	O
,	O
we	O
evaluated	O
the	O
role	O
of	O
innate	O
immune	O
signaling	O
in	O
protection	O
from	O
human	O
(	O
Urbani	O
)	O
and	O
a	O
recombinant	O
mouse	O
adapted	O
SARS	B-DISO
-	O
CoV	O
,	O
designated	O
rMA15	O
.	O

TITLE	O
:	O
[	O
Characterization	O
of	O
human	O
coronavirus	O
229E	O
infection	B-DISO
among	O
patients	O
with	O
respiratory	B-DISO
symptom	I-DISO
in	O
Beijing	O
,	O
Oct	O
-	O
Dec	O
,	O
2007	O
].	O

ABSTRACT	O
:	O
To	O
know	O
the	O
etiology	O
,	O
prevalence	O
,	O
clinical	O
symptoms	O
associated	O
with	O
the	O
infection	B-DISO
of	O
the	O
HCoV	O
-	O
229E	O
in	O
the	O
respiratory	O
specimens	O
sampled	O
from	O
adult	O
patients	O
in	O
Beijing	O
.	O

At	O
meantime	O
,	O
we	O
also	O
screened	O
the	O
HCoV	O
-	O
229E	O
positive	O
samples	O
for	O
the	O
co	B-DISO
-	I-DISO
infection	I-DISO
with	O
HCoV	O
-	O
NL63	O
,	O
HCoV	O
-	O
HKU1	O
and	O
HMPV	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

TITLE	O
:	O
In	O
Vitro	O
Antiviral	O
Activity	O
of	O
some	O
Novel	O
Isatin	O
Derivatives	O
against	O
HCV	O
and	O
SARS	B-DISO
-	O
CoV	O
Viruses	O
.	O

at	O
19	O
weeks	O
of	O
age	O
and	O
infected	O
5	O
days	O
earlier	O
with	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
D1466	O
(	O
IBV	O
),	O
and	O
a	O
fifth	O
group	O
similar	O
to	O
the	O
former	O
but	O
inoculated	O
i	O
.	O
t	O
.	O

Our	O
results	O
show	O
that	O
inhibition	O
of	O
BAG3	O
expression	O
by	O
RNA	O
interference	O
led	O
to	O
significant	O
suppression	B-DISO
of	O
SARS	B-DISO
-	O
CoV	O
replication	O
,	O
suggesting	O
the	O
possibility	O
that	O
upregulation	O
of	O
BAG3	O
may	O
be	O
part	O
of	O
the	O
machinery	O
that	O
SARS	B-DISO
-	O
CoV	O
relies	O
on	O
for	O
replication	O
.	O

The	O
temporal	O
and	O
spatial	O
evolution	O
of	O
the	O
SARS	B-DISO
epidemic	O
in	O
Hong	O
Kong	O
is	O
described	O
.	O

The	O
characteristics	O
of	O
those	O
who	O
contracted	O
the	O
disease	O
are	O
determined	O
including	O
factors	O
associated	O
with	O
the	O
likelihood	O
of	O
mortality	O
as	O
a	O
result	O
of	O
SARS	B-DISO
coronavirus	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
During	O
the	O
early	O
stages	O
of	O
infection	B-DISO
,	O
SARS	B-DISO
-	O
CoV	O
produces	O
more	O
severe	O
perturbation	O
of	O
host	O
cell	O
gene	O
expression	O
in	O
a	O
human	O
epithelial	O
cell	O
line	O
of	O
liver	O
origin	O
than	O
the	O
HCoV	O
-	O
229E	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
understand	O
the	O
significance	O
of	O
CoV	O
-	O
HKU1	O
in	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
and	O
its	O
potential	O
to	O
cause	O
outbreaks	O
of	O
acute	O
viral	O
respiratory	O
illnesses	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
salmon	O
anaemia	B-DISO
virus	O
(	O
ISAV	O
)	O
is	O
a	O
piscine	O
orthomyxovirus	O
causing	O
a	O
serious	O
disease	O
in	O
farmed	O
Atlantic	O
salmon	O
(	O
Salmo	O
salar	O
L	O
.).	O

In	O
summary	O
,	O
our	O
study	O
indicates	O
that	O
mucosal	O
immunization	O
with	O
rBV	O
SARS	B-DISO
-	O
CoV	O
VLPs	O
represent	O
an	O
effective	O
means	O
for	O
eliciting	O
protective	O
systemic	O
and	O
mucosal	O
immune	O
responses	O
against	O
SARS	B-DISO
-	O
CoV	O
,	O
providing	O
important	O
information	O
for	O
vaccine	O
design	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
novel	O
coronavirus	B-DISO
infection	I-DISO
which	O
broke	O
out	O
in	O
Hong	O
Kong	O
in	O
March	O
2003	O
.	O

TITLE	O
:	O
The	O
envelope	O
protein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
interacts	O
with	O
the	O
non	O
-	O
structural	O
protein	O
3	O
and	O
is	O
ubiquitinated	O
.	O

Moreover	O
,	O
NO	O
levels	O
in	O
cell	O
culture	O
medium	O
of	O
PRRSV	O
-	O
infected	O
alveolar	O
macrophages	O
(	O
AMs	B-DISO
)	O
did	O
not	O
differ	O
from	O
that	O
of	O
mock	O
-	O
infected	O
AMs	B-DISO
.	O

Primary	O
prevention	O
,	O
epidemiological	O
surveillance	O
and	O
health	O
education	O
in	O
the	O
framework	O
of	O
intersectoral	O
and	O
international	O
collaboration	O
remain	O
the	O
cornerstone	O
for	O
response	O
to	O
and	O
control	O
of	O
zoonoses	B-DISO
in	O
the	O
context	O
of	O
tourism	O
and	O
immigration	O
.	O

ATF3	O
protein	O
expression	O
and	O
nuclear	O
translocation	B-DISO
is	O
increased	O
in	O
the	O
lung	O
after	O
mechanical	O
ventilation	O
in	O
wild	O
-	O
type	O
mice	O
.	O

TITLE	O
:	O
Prevalence	O
of	O
viral	B-DISO
infection	I-DISO
detected	O
by	O
PCR	O
and	O
RT	O
-	O
PCR	O
in	O
patients	O
with	O
acute	O
exacerbation	O
of	O
COPD	B-DISO
:	O
a	O
systematic	O
review	O
.	O

ABSTRACT	O
:	O
Viruses	O
are	O
important	O
aetiological	O
agents	O
of	O
acute	O
exacerbation	O
of	O
COPD	B-DISO
(	O
AECOPD	O
).	O

Picorna	O
was	O
the	O
most	O
common	O
virus	O
detected	O
in	O
Western	O
countries	O
whereas	O
influenza	B-DISO
was	O
most	O
common	O
in	O
Asia	O
.	O

In	O
this	O
paper	O
we	O
examine	O
the	O
mechanism	O
of	O
how	O
the	O
SARS	B-DISO
outbreak	O
resulted	O
in	O
a	O
higher	O
completed	B-DISO
suicide	I-DISO
rate	O
especially	O
among	O
older	O
adults	O
in	O
Hong	O
Kong	O
.	O

Furthermore	O
,	O
we	O
used	O
a	O
qualitative	O
study	O
based	O
on	O
the	O
Coroner	O
Court	O
reports	O
to	O
provide	O
empirical	O
evidence	O
about	O
the	O
relationship	O
between	O
SARS	B-DISO
and	O
the	O
excessive	O
number	O
of	O
suicide	O
deaths	O
among	O
the	O
elderly	O
.	O

Nasopharyngeal	O
aspirates	O
from	O
465	O
patients	O
with	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
were	O
collected	O
in	O
2006	O
and	O
2007	O
.	O

Dimerization	O
is	O
an	O
indispensable	O
requirement	O
for	O
the	O
function	O
of	O
SARS	B-DISO
3CL	O
(	O
pro	O
)	O
and	O
is	O
regulated	O
through	O
mechanisms	O
involving	O
both	O
direct	O
and	O
long	O
-	O
range	O
interactions	O
in	O
the	O
enzyme	O
.	O

Here	O
we	O
report	O
that	O
Asn28	O
,	O
a	O
residue	O
11	O
A	O
from	O
the	O
closest	O
residue	O
in	O
the	O
opposing	O
monomer	O
,	O
is	O
essential	O
for	O
the	O
enzymatic	O
activity	O
and	O
dimerization	O
of	O
SARS	B-DISO
3CL	O
(	O
pro	O
).	O

When	O
the	O
2009	O
H1N1	B-DISO
influenza	I-DISO
A	O
virus	O
emerged	O
in	O
the	O
United	O
States	O
,	O
epidemiologic	O
and	O
clinical	O
information	O
about	O
severe	O
and	O
fatal	O
cases	O
was	O
limited	O
.	O

Many	O
(	O
79	O
%)	O
had	O
underlying	O
risk	O
conditions	O
for	O
severe	O
seasonal	O
influenza	B-DISO
,	O
and	O
58	O
%	O
were	O
obese	B-DISO
according	O
to	O
their	O
body	O
mass	O
index	O
.	O

TITLE	O
:	O
Alveolar	O
dead	O
-	O
space	O
response	O
to	O
activated	O
protein	O
C	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
complicated	O
case	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
from	O
severe	B-DISO
sepsis	I-DISO
,	O
in	O
which	O
we	O
measured	O
the	O
ratio	O
of	O
physiologic	O
dead	O
space	O
to	O
tidal	O
volume	O
(	O
V	O
(	O
D	O
)/	O
V	O
(	O
T	O
))	O
with	O
volumetric	O
capnography	O
prior	O
to	O
,	O
during	O
,	O
and	O
after	O
therapy	O
with	O
human	O
recombinant	O
activated	O
protein	O
C	O
.	O
Previous	O
studies	O
hypothesized	O
that	O
early	O
in	O
ARDS	B-DISO
,	O
elevated	O
V	O
(	O
D	O
)/	O
V	O
(	O
T	O
)	O
primarily	O
reflects	O
increased	O
alveolar	O
V	O
(	O
D	O
),	O
probably	O
caused	O
by	O
pronounced	O
thrombi	B-DISO
formation	O
in	O
the	O
pulmonary	O
microvasculature	O
.	O

We	O
show	O
that	O
mRNA	O
cap	B-DISO
methylation	O
requires	O
a	O
third	O
viral	O
protein	O
,	O
nsp10	O
,	O
which	O
acts	O
as	O
an	O
essential	O
trigger	O
to	O
complete	O
RNA	O
cap	B-DISO
-	O
1	O
formation	O
.	O

This	O
patient	O
'	O
s	O
clinical	O
features	O
were	O
published	O
as	O
a	O
newly	O
described	O
syndrome	B-DISO
:	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
only	O
reported	O
surgical	O
management	O
of	O
thoracic	B-DISO
insufficiency	O
syndrome	B-DISO
demonstrating	O
a	O
statistical	O
improvement	O
in	O
chest	O
wall	O
compliance	O
and	O
tidal	O
volume	O
.	O

Murine	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
PLP2	O
and	O
orthologs	O
recognize	O
and	O
cleave	O
at	O
a	O
position	O
following	O
a	O
p4	O
-	O
Leu	O
-	O
X	O
-	O
Gly	O
-	O
Gly	O
-	O
p1	O
tetrapeptide	O
,	O
but	O
it	O
is	O
unknown	O
whether	O
these	O
residues	O
are	O
sufficient	O
to	O
result	O
in	O
processing	O
by	O
PLP2	O
at	O
sites	O
normally	O
cleaved	O
by	O
PLP1	O
.	O

TITLE	O
:	O
Acute	O
kidney	O
injury	O
and	O
2009	O
H1N1	B-DISO
influenza	I-DISO
-	O
related	O
critical	B-DISO
illness	I-DISO
.	O

All	O
patients	O
with	O
severe	O
falciparum	B-DISO
malaria	I-DISO
above	O
the	O
age	O
of	O
14	O
years	O
admitted	O
to	O
the	O
ICU	O
were	O
included	O
in	O
this	O
study	O
.	O

Jaundice	B-DISO
with	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
(	O
ARF	B-DISO
)	O
was	O
the	O
most	O
common	O
presentation	O
(	O
13	O
.	O
28	O
percent	O
),	O
followed	O
by	O
cerebral	B-DISO
malaria	I-DISO
with	O
jaundice	B-DISO
and	O
ARF	B-DISO
(	O
6	O
.	O
37	O
percent	O
),	O
and	O
jaundice	B-DISO
,	O
ARF	B-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
(	O
5	O
.	O
31	O
percent	O
).	O

28	O
-	O
year	O
-	O
old	O
white	O
female	O
was	O
admitted	O
to	O
our	O
Intensive	O
Care	O
Unit	O
during	O
the	O
influenza	B-DISO
pandemic	O
because	O
of	O
severe	O
ARDS	B-DISO
due	O
to	O
bilateral	B-DISO
pneumonia	I-DISO
.	O

This	O
was	O
demonstrated	O
by	O
the	O
2000	O
-	O
2001	O
foot	B-DISO
and	I-DISO
mouth	I-DISO
disease	I-DISO
(	O
FMD	B-DISO
)	O
outbreaks	O
that	O
occurred	O
in	O
Europe	O
,	O
South	O
America	O
,	O
Asia	O
and	O
Africa	O
and	O
by	O
the	O
recent	O
increased	O
occurrence	O
of	O
emerging	O
diseases	O
transmitted	B-DISO
from	O
animals	O
to	O
humans	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
clinical	O
features	O
of	O
patients	O
admitted	O
to	O
the	O
pediatric	O
intensive	O
care	O
unit	O
(	O
PICU	O
)	O
with	O
acute	B-DISO
lower	I-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
(	O
LRTI	B-DISO
)	O
attributable	O
to	O
influenza	B-DISO
A	O
pH1N1	O
virus	O
and	O
compare	O
them	O
with	O
those	O
admitted	O
with	O
LRTI	B-DISO
due	O
to	O
other	O
viral	O
pathogens	O
.	O

No	O
amplification	B-DISO
was	O
achieved	O
for	O
uninfected	O
cells	O
,	O
or	O
cells	O
infected	O
with	O
Newcastle	B-DISO
disease	I-DISO
virus	O
(	O
NDV	O
),	O
canine	O
parvovirus	B-DISO
(	O
CPV	O
),	O
canine	O
coronavirus	O
(	O
CCV	B-DISO
),	O
rabies	B-DISO
virus	O
(	O
RV	O
),	O
or	O
canine	O
adenovirus	B-DISO
(	O
CAV	O
).	O

ABSTRACT	O
:	O
The	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
)	O
is	O
a	O
mutated	O
form	O
of	O
the	O
feline	O
enteric	O
coronavirus	O
(	O
FeCV	O
)	O
that	O
can	O
present	O
with	O
a	O
variety	O
of	O
clinical	O
signs	O
.	O

The	O
purpose	O
of	O
this	O
retrospective	O
study	O
was	O
to	O
analyze	O
abdominal	O
ultrasonographic	O
findings	O
associated	O
with	O
cats	O
with	O
confirmed	O
FIPV	O
infection	B-DISO
.	O

Abdominal	B-DISO
lymphadenopathy	I-DISO
was	O
noted	O
in	O
nine	O
cats	O
.	O

In	O
post	O
-	O
surgical	O
patients	O
and	O
in	O
those	O
with	O
mild	O
sepsis	B-DISO
or	O
trauma	O
,	O
there	O
is	O
clinical	O
benefit	O
from	O
a	O
formula	O
including	O
fish	O
oil	O
and	O
arginine	O
.	O

Here	O
,	O
we	O
investigate	O
the	O
effects	O
of	O
amino	O
acid	O
substitution	O
at	O
the	O
P1	O
position	O
of	O
3CLpro	O
cleavage	O
sites	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
on	O
the	O
cleavage	O
efficiency	O
and	O
viral	O
replication	O
by	O
in	O
vitro	O
cleavage	O
assays	O
and	O
reverse	O
genetic	O
approaches	O
.	O

In	O
contrast	O
,	O
a	O
P1	O
-	O
Asn	O
substitution	O
at	O
the	O
nsp6	O
-	O
7	O
/	O
Q3379	O
,	O
nsp12	O
-	O
13	O
/	O
Q4868	O
,	O
nsp13	O
-	O
14	O
/	O
Q5468	O
,	O
and	O
nsp14	O
-	O
15	O
/	O
Q5989	O
sites	O
,	O
as	O
well	O
as	O
a	O
P1	O
-	O
Pro	O
substitution	O
at	O
the	O
nsp15	O
-	O
16	O
/	O
Q6327	O
site	O
,	O
abolished	O
3CLpro	O
-	O
mediated	O
cleavage	O
at	O
the	O
corresponding	O
position	O
and	O
blocked	O
the	O
recovery	O
of	O
infectious	B-DISO
viruses	O
.	O

More	O
interestingly	O
,	O
a	O
mutant	B-DISO
3CLpro	O
with	O
either	O
a	O
P166S	O
or	O
P166L	O
mutation	O
was	O
selected	O
when	O
an	O
IBV	O
infectious	B-DISO
cDNA	O
clone	O
carrying	O
the	O
Q6327N	O
mutation	O
at	O
the	O
nsp15	O
-	O
16	O
site	O
was	O
introduced	O
into	O
cells	O
.	O

On	O
0	O
,	O
7	O
,	O
14	O
,	O
21	O
,	O
28	O
and	O
35	O
post	O
first	O
vaccination	O
,	O
the	O
dynamic	O
changes	O
of	O
peripheral	O
lymphocyte	O
proliferation	B-DISO
,	O
cytokine	O
assays	O
and	O
serum	O
antibody	O
titers	O
were	O
assayed	O
respectively	O
by	O
MTT	O
method	O
,	O
ELISA	O
and	O
hemagglutination	O
inhibition	O
assay	O
(	O
HI	O
).	O

In	O
this	O
small	O
series	O
of	O
patients	O
with	O
H1N1	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
hemodynamic	O
compromise	O
,	O
therapeutic	O
plasma	O
exchange	O
appeared	O
to	O
benefit	O
as	O
a	O
method	O
of	O
mitigating	O
the	O
associated	O
cytokine	B-DISO
storm	I-DISO
.	O

ABSTRACT	O
:	O
Outbreaks	O
of	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
,	O
especially	O
those	O
of	O
a	O
global	O
nature	O
,	O
require	O
rapid	O
epidemiological	O
analysis	O
and	O
information	O
dissemination	O
.	O

We	O
identified	O
and	O
analyzed	O
all	O
published	O
articles	O
on	O
the	O
epidemiology	O
of	O
the	O
SARS	B-DISO
outbreak	O
in	O
Hong	O
Kong	O
or	O
Toronto	O
.	O

A	O
majority	O
of	O
the	O
epidemiological	O
articles	O
on	O
SARS	B-DISO
were	O
submitted	O
after	O
the	O
epidemic	O
had	O
ended	O
,	O
although	O
the	O
corresponding	O
studies	O
had	O
relevance	O
to	O
public	O
health	O
authorities	O
during	O
the	O
epidemic	O
.	O

This	O
suggests	O
that	O
-	O
123C	O
>	O
A	O
plays	O
a	O
more	O
important	O
role	O
in	O
modulating	O
basal	O
MxA	O
expression	O
,	O
thus	O
contributing	O
more	O
significantly	O
to	O
innate	B-DISO
immune	I-DISO
response	I-DISO
against	O
viral	B-DISO
infections	I-DISO
that	O
suppress	O
endogenous	O
IFN	O
-	O
alpha	O
and	O
IFN	O
-	O
beta	O
induction	O
such	O
as	O
SARS	B-DISO
coronavirus	O
.	O

TITLE	O
:	O
Blastomycosis	B-DISO
.	O

Rarely	O
,	O
patients	O
develop	O
severe	O
pulmonary	B-DISO
infection	I-DISO
that	O
progresses	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
which	O
has	O
a	O
high	O
mortality	O
rate	O
.	O

Using	O
novel	O
bioinformatic	O
tools	O
and	O
deep	O
sequencing	O
across	O
the	O
full	O
-	O
length	O
genome	O
following	O
10	O
population	O
passages	O
in	O
vitro	O
,	O
we	O
demonstrate	O
retention	O
of	O
ExoN	O
mutations	O
and	O
continued	O
increased	O
diversity	O
and	O
mutational	O
load	O
compared	O
to	O
wild	O
-	O
type	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
results	O
define	O
a	O
novel	O
genetic	O
and	O
bioinformatics	O
model	O
for	O
introduction	O
and	O
identification	O
of	O
multi	O
-	O
allelic	O
mutations	O
in	O
replication	O
competent	O
viruses	O
that	O
will	O
be	O
powerful	O
tools	O
for	O
testing	O
the	O
effects	O
of	O
decreased	O
fidelity	O
and	O
increased	O
quasispecies	O
diversity	O
on	O
viral	O
replication	O
,	O
pathogenesis	B-DISO
,	O
and	O
evolution	O
.	O

ABSTRACT	O
:	O
Tumour	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
many	O
inflammatory	O
conditions	O
.	O

They	O
were	O
inoculated	O
intratracheally	O
with	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
)	O
followed	O
by	O
lipopolysaccharide	O
(	O
LPS	B-DISO
)	O
24h	O
later	O
.	O

ABSTRACT	O
:	O
A	O
survey	O
of	O
infectious	B-DISO
and	I-DISO
parasitic	I-DISO
diseases	I-DISO
of	O
stray	O
cats	O
was	O
carried	O
out	O
using	O
biological	O
samples	O
collected	O
from	O
animals	O
captured	O
during	O
a	O
catch	B-DISO
-	O
neuter	O
-	O
release	O
programme	O
in	O
four	O
counties	O
of	O
the	O
Lisbon	O
Metropolitan	O
Area	O
.	O

Ingenuity	O
Pathway	O
Analysis	O
revealed	O
that	O
proteins	O
that	O
changed	O
in	O
response	O
to	O
infection	B-DISO
could	O
be	O
grouped	O
into	O
different	O
functional	O
categories	O
.	O

This	O
research	O
is	O
the	O
first	O
application	O
of	O
SILAC	O
to	O
study	O
total	O
host	O
cell	O
proteome	O
changes	O
in	O
response	O
to	O
positive	O
sense	O
RNA	B-DISO
virus	I-DISO
infection	I-DISO
and	O
illustrates	O
the	O
versatility	O
of	O
this	O
technique	O
as	O
applied	O
to	O
infectious	B-DISO
disease	I-DISO
research	O
.	O

Although	O
cases	O
of	O
TSS	B-DISO
due	O
to	O
GBS	B-DISO
are	O
very	O
rare	O
,	O
we	O
must	O
be	O
aware	O
of	O
the	O
potential	O
risk	O
of	O
OPSI	O
in	O
a	O
splenectomized	O
patient	O
.	O

Compounds	O
were	O
tested	O
in	O
cell	O
-	O
based	O
assays	O
against	O
viruses	O
representative	O
of	O
:	O
i	O
)	O
two	O
of	O
the	O
three	O
genera	O
of	O
the	O
Flaviviridae	O
family	O
,	O
i	O
.	O
e	O
.	O
Pestiviruses	O
and	O
Flaviviruses	O
;	O
ii	O
)	O
other	O
RNA	O
virus	O
families	O
,	O
such	O
as	O
Retroviridae	O
,	O
Picornaviridae	O
,	O
Paramyxoviridae	O
,	O
Rhabdoviridae	O
and	O
Reoviridae	O
;	O
iii	O
)	O
two	O
DNA	O
virus	O
families	O
(	O
Herpesviridae	O
and	O
Poxviridae	O
)	O
as	O
well	O
as	O
for	O
cytotoxicity	B-DISO
tests	O
,	O
run	O
in	O
parallel	O
with	O
antiviral	O
assays	O
,	O
against	O
MDBK	O
,	O
BHK	O
and	O
Vero	O
76	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
term	O
pulmonary	O
renal	B-DISO
vasculitis	I-DISO
syndrome	B-DISO
describes	O
a	O
clinical	O
syndrome	B-DISO
of	O
diffuse	O
alveolar	O
haemorrhage	B-DISO
(	O
DAH	O
)	O
complicating	O
acute	B-DISO
glomerulonephritis	I-DISO
that	O
often	O
heralds	O
severe	O
,	O
life	O
-	O
threatening	O
systemic	O
vasculitis	B-DISO
requiring	O
urgent	O
,	O
aggressive	B-DISO
therapy	O
.	O

This	O
maneuver	O
has	O
consistently	O
proven	O
capable	O
of	O
improving	O
oxygenation	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

Estimates	O
of	O
the	O
number	O
of	O
cases	O
of	O
H1N1	O
-	O
2009	O
were	O
made	O
using	O
the	O
number	O
of	O
polyclinic	O
attendances	O
for	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
and	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
and	O
the	O
weekly	O
prevalence	O
of	O
H1N1	O
-	O
2009	O
.	O

For	O
hospitalised	O
children	O
,	O
the	O
most	O
common	O
risk	O
factors	O
were	O
being	O
under	O
5	O
years	O
of	O
age	O
and	O
asthma	B-DISO
.	O

This	O
devastating	O
form	O
of	O
lung	O
injury	O
strikes	O
individuals	O
of	O
any	O
age	O
following	O
insults	O
,	O
such	O
as	O
major	O
trauma	O
or	O
sepsis	B-DISO
,	O
and	O
even	O
with	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
medical	O
care	O
it	O
has	O
a	O
mortality	O
as	O
high	O
as	O
50	O
%.	O

This	O
review	O
summarizes	O
human	O
and	O
animal	O
studies	O
on	O
biomarkers	O
in	O
primary	B-DISO
graft	I-DISO
dysfunction	I-DISO
,	O
including	O
cytokines	O
and	O
markers	O
of	O
acute	O
inflammation	B-DISO
,	O
VEGF	O
,	O
endothelial	O
markers	O
and	O
adhesion	B-DISO
molecules	O
,	O
markers	O
of	O
coagulation	O
and	O
fibrinolysis	O
and	O
markers	O
of	O
lung	O
epithelial	O
injury	O
.	O

The	O
nucleocapsid	O
protein	O
(	O
NP	O
)	O
of	O
SARS	B-DISO
-	O
CoV	O
may	O
be	O
critical	O
for	O
pathogenicity	O
.	O

p42	O
is	O
a	O
subunit	O
of	O
the	O
26S	O
proteasome	O
;	O
this	O
large	O
,	O
multi	O
-	O
protein	O
complex	O
is	O
a	O
component	O
of	O
the	O
ubiquitin	O
-	O
proteasome	O
pathway	O
,	O
which	O
is	O
involved	O
in	O
a	O
variety	O
of	O
basic	O
cellular	O
processes	O
and	O
inflammatory	B-DISO
responses	I-DISO
.	O

This	O
review	O
summarizes	O
the	O
recent	O
advances	O
in	O
viral	O
encoded	O
ion	O
channel	O
proteins	O
(	O
or	O
viroporins	O
),	O
including	O
PBCV	O
-	O
1	O
KcV	O
,	O
influenza	B-DISO
M2	O
,	O
HIV	B-DISO
-	O
1	O
Vpu	O
,	O
HCV	O
p7	O
,	O
picornavirus	O
2B	O
,	O
and	O
coronavirus	O
E	O
and	O
3a	O
.	O

Exposure	O
of	O
NSCLC	B-DISO
cells	O
to	O
TSL	O
-	O
1	O
caused	O
cell	O
-	O
cycle	O
arrest	O
in	O
subG1	O
phase	O
and	O
caused	O
apoptosis	O
.	O

Additionally	O
,	O
the	O
tumoricidal	O
effect	O
of	O
TSL	O
-	O
1	O
was	O
measured	O
using	O
a	O
xenograft	O
model	O
,	O
after	O
5	O
weeks	O
of	O
TSL	O
-	O
1	O
treatment	O
by	O
various	O
regimen	O
caused	O
regression	O
of	O
tumor	B-DISO
.	O

TITLE	O
:	O
Early	O
intermittent	O
noninvasive	O
ventilation	O
for	O
acute	B-DISO
chest	I-DISO
syndrome	I-DISO
in	O
adults	O
with	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
:	O
a	O
pilot	O
study	O
.	O

ABSTRACT	O
:	O
The	O
apparent	O
association	O
between	O
varicella	B-DISO
zoster	I-DISO
virus	O
(	O
VZV	O
)	O
and	O
multiple	B-DISO
sclerosis	I-DISO
(	O
MS	O
)	O
has	O
been	O
described	O
.	O

In	O
these	O
cases	O
,	O
the	O
virus	O
may	O
produce	O
a	O
chronic	O
,	O
relentless	O
infection	B-DISO
or	O
trigger	O
a	O
process	O
of	O
immune	O
-	O
mediated	O
demyelination	B-DISO
.	O

We	O
constructed	O
a	O
large	O
protein	O
containing	O
the	O
cyan	O
fluorescent	O
protein	O
(	O
C	O
),	O
the	O
N	O
-	O
terminal	O
flanking	O
substrate	O
peptide	O
of	O
SARS	B-DISO
3CL	O
(	O
pro	O
)	O
(	O
XX	O
),	O
SARS	B-DISO
3CL	O
(	O
pro	O
)	O
(	O
3CLP	O
),	O
and	O
the	O
yellow	O
fluorescent	O
protein	O
(	O
Y	O
)	O
to	O
study	O
the	O
autoprocessing	O
of	O
3CL	O
(	O
pro	O
)	O
using	O
fluorescence	O
resonance	O
energy	O
transfer	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
form	O
a	O
basis	O
for	O
further	O
investigations	O
of	O
between	O
-	O
herds	O
dynamics	O
and	O
risk	O
factors	O
for	O
these	O
infections	B-DISO
in	O
order	O
to	O
design	O
effective	O
control	O
strategies	O
.	O

ABSTRACT	O
:	O
Nonstructural	O
protein	O
3	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
includes	O
a	O
""""	O
SARS	B-DISO
-	O
unique	O
domain	O
""""	O
(	O
SUD	O
)	O
consisting	O
of	O
three	O
globular	O
domains	O
separated	O
by	O
short	O
linker	O
peptide	O
segments	O
.	O

TITLE	O
:	O
Synthesis	O
,	O
docking	O
studies	O
,	O
and	O
evaluation	O
of	O
pyrimidines	O
as	O
inhibitors	O
of	O
SARS	B-DISO
-	O
CoV	O
3CL	O
protease	O
.	O

ABSTRACT	O
:	O
Nitric	O
oxide	O
(	O
NO	O
)	O
plays	O
an	O
important	O
role	O
in	O
acute	O
lung	O
injury	O
(	O
ALI	O
),	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
and	O
in	O
ventilator	O
-	O
induced	O
lung	O
injury	O
(	O
VILI	O
).	O

Illness	O
-	O
related	O
fatalities	O
have	O
been	O
recorded	O
among	O
individuals	O
hospitalized	O
in	O
The	O
Hospital	O
For	O
Infectious	B-DISO
Diseases	I-DISO
in	O
Warsaw	O
,	O
Poland	O
.	O

In	O
this	O
article	O
have	O
shown	O
cases	O
of	O
H1N1	B-DISO
influenza	I-DISO
-	O
related	O
complications	O
.	O

Among	O
109	O
hospitalized	O
individuals	O
with	O
A	O
/	O
H1N1	O
infection	B-DISO
,	O
eight	O
(	O
7	O
%)	O
developed	O
severe	O
pulmonary	B-DISO
complications	I-DISO
,	O
and	O
one	O
of	O
this	O
patient	O
died	O
.	O

Considerable	O
controversy	O
resulted	O
regarding	O
which	O
procedures	O
and	O
behaviours	O
were	O
associated	O
with	O
the	O
greatest	O
risk	O
of	O
SARS	B-DISO
-	O
CoV	O
transmission	O
.	O

Rodent	O
models	O
that	O
mimic	O
human	O
CM	O
,	O
PAM	B-DISO
and	O
SA	O
syndromes	B-DISO
have	O
been	O
established	O
.	O

Here	O
,	O
we	O
show	O
that	O
DBA	B-DISO
/	O
2	O
mice	O
infected	O
with	O
P	O
.	O
berghei	O
ANKA	O
constitute	O
a	O
new	O
model	O
for	O
malaria	B-DISO
-	O
associated	O
ALI	O
.	O

Application	O
of	O
CAB	O
to	O
the	O
field	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
research	O
is	O
presented	O
.	O

Radiographic	O
findings	O
showed	O
agenesis	B-DISO
of	O
12	O
permanent	O
teeth	O
(	O
all	O
canines	O
and	O
premolars	O
).	O

Those	O
who	O
perceived	O
high	O
severity	O
and	O
susceptibility	O
of	O
getting	O
H1N1	O
and	O
doubted	O
the	O
adequacy	O
of	O
governmental	O
preparedness	O
were	O
more	O
likely	O
than	O
others	O
to	O
feel	O
emotionally	O
distressed	B-DISO
.	O

TITLE	O
:	O
Duodenal	B-DISO
perforation	I-DISO
due	O
to	O
a	O
kink	O
in	O
a	O
nasojejunal	O
feeding	O
tube	O
in	O
a	O
patient	O
with	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
:	O
a	O
case	O
report	O
.	O

Significant	O
complications	O
due	O
to	O
nasojejunal	O
feeding	O
tube	O
placement	O
,	O
such	O
as	O
hydrothorax	B-DISO
,	O
duodenal	B-DISO
perforation	I-DISO
and	O
retroperitoneal	O
emphysema	B-DISO
,	O
are	O
very	O
rare	O
.	O

Clinical	O
data	O
from	O
all	O
patients	O
admitted	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
due	O
to	O
novel	O
viral	O
H1N1	O
infection	B-DISO
were	O
reviewed	O
.	O

Other	O
lung	O
findings	O
were	O
necrotizing	B-DISO
bronchiolitis	I-DISO
or	O
extensive	O
hemorrhage	B-DISO
.	O

Rhinovirus	O
and	O
adenovirus	B-DISO
were	O
detected	O
in	O
two	O
-	O
thirds	O
of	O
hospitalized	O
children	O
,	O
but	O
their	O
frequent	O
detection	O
in	O
control	O
children	O
made	O
their	O
role	O
in	O
respiratory	O
hospitalization	O
uncertain	O
.	O

The	O
recent	O
pandemic	O
of	O
H1N1	B-DISO
influenza	I-DISO
A	O
provided	O
an	O
opportunity	O
to	O
study	O
echocardiographic	O
findings	O
in	O
critically	B-DISO
ill	I-DISO
infected	O
patients	O
.	O

We	O
hypothesised	O
that	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
H1N1	O
infection	B-DISO
would	O
have	O
a	O
higher	O
incidence	O
of	O
right	O
and	O
left	B-DISO
heart	I-DISO
failure	I-DISO
than	O
is	O
seen	O
in	O
unselected	O
populations	O
of	O
patients	O
with	O
septic	B-DISO
shock	I-DISO
and	O
/	O
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

We	O
retrospectively	O
studied	O
all	O
patients	O
admitted	O
to	O
four	O
intensive	O
care	O
units	O
at	O
three	O
hospitals	O
in	O
Salt	O
Lake	O
County	O
,	O
UT	O
,	O
USA	O
,	O
with	O
laboratory	O
-	O
confirmed	O
H1N1	O
infection	B-DISO
in	O
whom	O
a	O
clinical	O
echocardiogram	O
was	O
available	O
.	O

Conversely	O
,	O
insertion	O
of	O
gene	O
5a	O
,	O
or	O
its	O
homologs	O
from	O
related	O
group	O
2	O
coronaviruses	O
,	O
at	O
an	O
upstream	O
genomic	O
position	O
in	O
an	O
MHV	O
-	O
A59	O
/	O
S	O
chimera	B-DISO
restored	O
IFN	O
resistance	O
.	O

Understanding	O
how	O
the	O
outbreak	O
control	O
measures	O
affected	O
use	O
of	O
health	O
services	O
and	O
ultimately	O
the	O
health	O
of	O
the	O
population	O
,	O
is	O
an	O
important	O
part	O
of	O
understanding	O
the	O
impact	O
of	O
SARS	B-DISO
restrictions	O
.	O

TITLE	O
:	O
Proteomic	O
analysis	O
of	O
purified	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
particles	O
.	O

The	O
recent	O
outbreaks	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
the	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pandemic	O
provide	O
evidence	O
of	O
the	O
benefits	O
of	O
the	O
new	O
global	O
monitoring	O
and	O
of	O
the	O
importance	O
of	O
the	O
World	O
Health	O
Organization	O
in	O
its	O
coordinating	O
role	O
in	O
the	O
multilateral	O
response	O
of	O
the	O
global	O
public	O
health	O
community	O
.	O

However	O
,	O
the	O
news	O
media	O
coverage	O
did	O
vary	O
in	O
accordance	O
with	O
the	O
mortality	O
of	O
'	B-DISO
cancer	I-DISO
,'	O
'	B-DISO
diabetes	I-DISO
,'	O
and	O
'	B-DISO
hypertension	I-DISO
.'	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
is	O
an	O
avian	O
coronavirus	O
affecting	O
the	O
respiratory	O
tract	O
of	O
chickens	O
.	O

To	O
analyze	O
IBV	O
infection	B-DISO
of	O
the	O
lower	O
respiratory	O
tract	O
,	O
we	O
applied	O
a	O
technique	O
that	O
uses	O
precision	O
-	O
cut	O
lung	O
slices	O
(	O
PCLSs	O
).	O

MHV	O
infection	B-DISO
causes	O
accumulation	O
of	O
EDEM1	O
and	O
OS	O
-	O
9	O
,	O
another	O
short	O
-	O
living	O
ER	O
chaperone	O
,	O
in	O
the	O
DMVs	O
.	O

Severe	O
viral	B-DISO
pneumonia	I-DISO
predominated	O
in	O
these	O
patients	O
,	O
mean	O
APACHE	O
was	O
18	O
,	O
average	O
PaO	O
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
on	O
admission	O
was	O
74	O
.	O
9	O
,	O
100	O
%	O
had	O
multisystemic	O
involvement	O
.	O

However	O
,	O
adverse	B-DISO
effects	I-DISO
,	O
especially	O
potentially	O
fatal	O
and	O
non	O
-	O
reversible	O
acute	O
and	O
chronic	O
pulmonary	B-DISO
toxicity	I-DISO
,	O
continue	O
to	O
be	O
observed	O
.	O

Thus	O
,	O
identification	O
of	O
novel	O
CD4	O
and	O
CD8	O
T	O
cell	O
epitopes	O
for	O
MHV	O
-	O
1	O
permitted	O
high	O
-	O
resolution	O
analyses	O
of	O
pulmonary	O
T	O
cell	O
responses	O
in	O
a	O
mouse	O
model	O
of	O
SARS	B-DISO
.	O

PIV1	O
infections	B-DISO
occurred	O
every	O
2	O
years	O
in	O
the	O
fall	O
.	O

The	O
prolonged	O
depletion	O
of	O
peripheral	O
CD4	O
(+)	O
T	O
cells	O
did	O
not	O
alter	O
the	O
levels	O
of	O
serum	O
IgG	O
or	O
IgM	O
.	O
The	O
impact	O
of	O
CB	O
/	O
05	O
infection	B-DISO
on	O
the	O
immune	O
performance	O
of	O
infected	O
pups	O
is	O
discussed	O
.	O

TITLE	O
:	O
Characteristics	O
of	O
crush	B-DISO
syndrome	I-DISO
caused	O
by	O
prolonged	O
limb	O
compression	O
longer	O
than	O
24	O
h	O
in	O
the	O
Sichuan	O
earthquake	O
.	O

Multiple	B-DISO
organ	I-DISO
failure	I-DISO
and	O
sepsis	B-DISO
developed	O
in	O
eight	O
patients	O
,	O
but	O
no	O
patients	O
died	O
.	O

Thus	O
,	O
in	O
principle	O
,	O
the	O
longer	O
-	O
nested	O
sgmRNAs	O
in	O
a	O
natural	O
infection	B-DISO
,	O
all	O
of	O
which	O
contain	O
potential	O
internal	O
template	O
-	O
switching	O
donor	O
signals	O
,	O
can	O
function	O
to	O
increase	O
the	O
number	O
of	O
the	O
shorter	O
3	O
'-	O
nested	O
sgmRNAs	O
.	O

TITLE	O
:	O
Malaria	B-DISO
in	O
pregnancy	O
:	O
update	O
on	O
emergency	B-DISO
management	O
.	O

This	O
case	O
illustrates	O
the	O
serious	O
nature	O
of	O
malaria	B-DISO
in	O
the	O
pregnant	O
patient	O
.	O

SARS	B-DISO
galvanized	O
the	O
world	O
to	O
the	O
threat	O
of	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
and	O
provided	O
a	O
dress	O
rehearsal	O
for	O
subsequent	O
challenges	O
such	O
as	O
H5N1	B-DISO
and	O
H1N1	B-DISO
influenza	I-DISO
.	O

Among	O
the	O
insights	O
gained	O
were	O
the	O
following	O
:	O
SARS	B-DISO
reminded	O
us	O
that	O
health	O
care	O
work	O
can	O
be	O
hazardous	O
;	O
the	O
effects	O
of	O
SARS	B-DISO
extended	O
beyond	O
the	O
infection	B-DISO
;	O
general	O
principles	O
for	O
prevention	O
and	O
control	O
were	O
effective	O
against	O
SARS	B-DISO
;	O
and	O
SARS	B-DISO
posed	O
both	O
a	O
public	O
health	O
and	O
an	O
occupational	O
health	O
threat	O
.	O

The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreak	O
in	O
2003	O
highlighted	O
that	O
healthcare	O
workers	O
were	O
under	O
-	O
prepared	O
for	O
such	O
an	O
epidemic	O
.	O

A	O
quasi	O
-	O
experimental	O
design	O
was	O
used	O
and	O
a	O
16	O
-	O
hour	O
,	O
purpose	O
-	O
designed	O
infection	B-DISO
control	O
education	O
programme	O
was	O
implemented	O
for	O
preservice	O
nursing	O
students	O
in	O
southern	O
Taiwan	O
.	O

We	O
used	O
the	O
incubation	O
period	O
of	O
9	O
respiratory	O
viruses	O
to	O
derive	O
decision	O
rules	O
for	O
distinguishing	O
between	O
community	O
-	O
and	O
hospital	O
-	O
acquired	O
infection	B-DISO
.	O

Sources	O
of	O
infection	B-DISO
suggested	O
by	O
analysis	O
of	O
the	O
symptom	B-DISO
onset	O
times	O
of	O
individual	O
patients	O
are	O
consistent	O
with	O
those	O
from	O
detailed	O
investigations	O
.	O

ABSTRACT	O
:	O
Human	O
toxocarosis	B-DISO
is	O
a	O
helminthozoonosis	O
due	O
to	O
the	O
migration	O
of	O
toxocara	O
species	O
larvae	O
throughout	O
the	O
human	O
body	O
.	O

Lung	O
manifestations	O
vary	O
and	O
range	O
from	O
asymptomatic	B-DISO
infection	I-DISO
to	O
severe	O
disease	O
.	O

We	O
report	O
a	O
case	O
of	O
bilateral	B-DISO
pneumonia	I-DISO
in	O
an	O
80	O
year	O
old	O
caucasian	O
man	O
who	O
developed	O
very	O
rapidly	O
an	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
with	O
a	O
PaO2	O
/	O
FiO2	O
ratio	O
of	O
55	O
,	O
requiring	O
mechanical	O
ventilation	O
and	O
adrenergic	O
support	O
.	O

For	O
coronaviruses	O
,	O
it	O
was	O
long	O
speculated	O
that	O
replication	O
of	O
the	O
giant	B-DISO
RNA	O
genome	O
and	O
transcription	O
of	O
multiple	O
subgenomic	O
mRNA	O
species	O
by	O
a	O
unique	O
discontinuous	O
transcription	O
mechanism	O
may	O
require	O
host	O
cofactors	O
.	O

Thus	O
,	O
binding	O
of	O
MBL	O
to	O
SARS	B-DISO
-	O
S	O
may	O
interfere	O
with	O
other	O
early	O
pre	O
-	O
or	O
postreceptor	O
-	O
binding	O
events	O
necessary	O
for	O
efficient	O
viral	O
entry	O
.	O

ABSTRACT	O
:	O
A	O
classical	O
epidemiological	O
framework	O
is	O
used	O
to	O
provide	O
a	O
preliminary	O
cost	O
analysis	O
of	O
the	O
effects	O
of	O
quarantine	O
and	O
isolation	O
on	O
the	O
dynamics	O
of	O
infectious	B-DISO
diseases	I-DISO
for	O
which	O
no	O
treatment	O
or	O
immediate	O
diagnosis	O
tools	O
are	O
available	O
.	O

Surprisingly	O
,	O
however	O
,	O
palmitoylation	O
of	O
S	O
was	O
not	O
required	O
for	O
interaction	O
with	O
SARS	B-DISO
-	O
CoV	O
M	O
protein	O
.	O

The	O
SARS	B-DISO
experience	O
and	O
unconfirmed	O
beliefs	O
about	O
the	O
transmission	O
modes	O
were	O
associated	O
with	O
variables	O
on	O
anticipated	O
preventive	O
behaviors	O
and	O
emotional	B-DISO
distress	I-DISO
.	O

In	O
105	O
patients	O
with	O
SIRS	B-DISO
score	O
3	O
and	O
higher	O
,	O
initial	O
measured	O
IL	O
-	O
6	O
levels	O
were	O
significantly	O
higher	O
than	O
in	O
the	O
group	O
of	O
remaining	O
129	O
patients	O
(	O
72	O
+/-	O

Furthermore	O
,	O
telbivudine	O
treatment	O
enhanced	O
the	O
ability	O
of	O
T	O
cells	O
to	O
undergo	O
proliferation	B-DISO
and	O
secrete	O
cytokines	O
but	O
did	O
not	O
affect	O
cytotoxicity	B-DISO
of	O
infected	O
hepatocytes	O
.	O

The	O
results	O
demonstrate	O
the	O
immunomodulatory	O
properties	O
of	O
telbivudine	O
,	O
independent	O
of	O
its	O
antiviral	O
activity	O
,	O
in	O
a	O
mouse	O
model	O
of	O
MHV	O
-	O
3	O
-	O
induced	O
hepatitis	B-DISO
.	O

ABSTRACT	O
:	O
Public	O
health	O
administrators	O
do	O
not	O
have	O
effective	O
models	O
to	O
predict	O
excess	O
influenza	B-DISO
-	O
associated	O
mortality	O
and	O
monitor	O
viral	O
changes	O
associated	O
with	O
it	O
.	O

A	O
negative	O
binomial	O
model	O
was	O
developed	O
to	O
estimate	O
Taiwan	O
'	O
s	O
monthly	O
influenza	B-DISO
-	O
associated	O
mortality	O
among	O
the	O
elderly	O
.	O

Inoculation	O
of	O
the	O
neuroattenuated	O
JHM	O
strain	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
JHMV	O
)	O
into	O
the	O
CNS	O
of	O
susceptible	O
mice	O
results	O
in	O
an	O
acute	O
encephalomyelitis	B-DISO
that	O
evolves	O
into	O
a	O
chronic	O
demyelinating	B-DISO
disease	I-DISO
,	O
modeling	O
white	O
matter	O
pathology	B-DISO
observed	O
in	O
the	O
human	O
demyelinating	B-DISO
disease	I-DISO
Multiple	B-DISO
Sclerosis	I-DISO
.	O

TITLE	O
:	O
Trilogy	O
of	O
ACE2	O
:	O
a	O
peptidase	O
in	O
the	O
renin	O
-	O
angiotensin	O
system	O
,	O
a	O
SARS	B-DISO
receptor	O
,	O
and	O
a	O
partner	O
for	O
amino	O
acid	O
transporters	O
.	O

These	O
results	O
suggest	O
that	O
the	O
combined	O
use	O
of	O
GNA	O
and	O
nelfinavir	O
has	O
therapeutic	O
potential	O
in	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
cats	O
with	O
early	O
-	O
diagnosed	O
FIP	B-DISO
.	O

ABSTRACT	O
:	O
Communicable	B-DISO
disease	I-DISO
crises	O
can	O
endanger	O
the	O
health	O
care	O
system	O
and	O
often	O
require	O
special	O
guidelines	O
.	O

To	O
improve	O
adherence	O
to	O
crisis	O
guidelines	O
,	O
the	O
generic	O
barriers	O
should	O
be	O
addressed	O
when	O
developing	O
guidelines	O
,	O
irrespective	O
of	O
the	O
infectious	B-DISO
agent	O
.	O

Significant	O
differences	O
were	O
detected	O
in	O
the	O
incidence	O
of	O
some	O
distinct	O
IBV	O
predominant	O
populations	O
in	O
tissues	O
and	O
fluids	O
;	O
e	O
.	O
g	O
.,	O
phenotype	O
C1	O
showed	O
the	O
highest	O
incidence	O
in	O
the	O
reproductive	O
tract	O
of	O
the	O
chickens	O
,	O
achieving	O
a	O
significant	O
difference	O
versus	O
its	O
incidence	O
in	O
the	O
trachea	B-DISO
(	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Multiple	O
lineages	O
of	O
Brazilian	O
strains	O
from	O
2007	O
to	O
2008	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
were	O
detected	O
in	O
flocks	O
of	O
breeders	O
,	O
broilers	O
,	O
and	O
layers	O
.	O

We	O
demonstrated	O
that	O
T	O
cells	O
are	O
responsible	O
for	O
virus	O
clearance	O
,	O
as	O
intravenous	O
adoptive	O
transfer	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
immune	O
splenocytes	O
or	O
in	O
vitro	O
-	O
generated	O
T	O
cells	O
to	O
SCID	B-DISO
or	O
BALB	O
/	O
c	O
mice	O
enhanced	O
survival	O
and	O
reduced	O
virus	O
titers	O
in	O
the	O
lung	O
.	O

ABSTRACT	O
:	O
Bats	O
are	O
reservoirs	O
for	O
a	O
wide	O
range	O
of	O
zoonotic	O
agents	O
including	O
lyssa	B-DISO
-,	O
henipah	O
-,	O
SARS	B-DISO
-	O
like	O
corona	O
-,	O
Marburg	O
-,	O
Ebola	O
-,	O
and	O
astroviruses	O
.	O

In	O
an	O
effort	O
to	O
survey	O
for	O
the	O
presence	O
of	O
other	O
infectious	B-DISO
agents	O
,	O
known	O
and	O
unknown	O
,	O
we	O
screened	O
sera	O
from	O
16	O
Pteropus	O
giganteus	O
bats	O
from	O
Faridpur	O
,	O
Bangladesh	O
,	O
using	O
high	O
-	O
throughput	O
pyrosequencing	O
.	O

At	O
present	O
,	O
there	O
are	O
no	O
BCoV	O
vaccines	O
to	O
prevent	O
respiratory	O
BCoV	O
infections	B-DISO
in	O
cattle	O
,	O
and	O
the	O
correlates	O
of	O
immunity	O
to	O
respiratory	O
BCoV	O
infections	B-DISO
are	O
unknown	O
.	O

However	O
,	O
the	O
enhanced	O
effects	O
of	O
combinations	O
of	O
growth	O
factors	O
,	O
such	O
as	O
the	O
synergistic	O
effect	O
of	O
HGF	B-DISO
upon	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)-	O
mediated	O
endothelial	O
cell	O
activity	O
,	O
and	O
the	O
combined	O
effect	O
of	O
HGF	B-DISO
and	O
KGF	O
in	O
tissue	O
repair	O
should	O
be	O
investigated	O
,	O
particularly	O
as	O
the	O
latter	O
pair	O
of	O
growth	O
factors	O
are	O
frequently	O
implicated	O
in	O
processes	O
associated	O
with	O
the	O
repair	O
of	O
lung	O
damage	O
.	O

ABSTRACT	O
:	O
Calf	O
diarrhea	B-DISO
is	O
a	O
major	O
economic	O
burden	O
to	O
the	O
bovine	O
industry	O
.	O

Survivor	O
long	O
-	O
term	O
morbidity	O
was	O
often	O
related	O
to	O
the	O
sequelae	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
hypoxic	B-DISO
encephalopathy	I-DISO
.	O

from	O
porcine	O
gastrointestinal	O
tract	O
inhibit	O
transmissible	O
gastroenteritis	B-DISO
coronavirus	O
and	O
enteric	O
bacterial	O
pathogens	O
.	O

Although	O
extensive	O
demyelination	B-DISO
occurs	O
in	O
mice	O
persistently	O
infected	O
with	O
MHV	O
there	O
is	O
only	O
limited	O
remyelination	O
.	O

As	O
such	O
,	O
understanding	O
mechanisms	O
associated	O
with	O
promoting	O
repair	O
within	O
the	O
CNS	O
in	O
the	O
context	O
of	O
a	O
persistent	O
viral	B-DISO
infection	I-DISO
is	O
critical	O
given	O
the	O
possible	O
viral	O
etiology	O
of	O
MS	O
.	O

39	O
respiratory	O
viruses	O
were	O
detected	O
in	O
37	O
(	O
13	O
.	O
1	O
%	O
of	O
total	O
)	O
patients	O
by	O
molecular	O
testing	O
,	O
including	O
rhinovirus	O
(	O
n	O
=	O
13	O
),	O
influenza	B-DISO
virus	O
(	O
n	O
=	O
8	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
n	O
=	O
6	O
),	O
human	O
metapneumovirus	O
(	O
n	O
=	O
3	O
),	O
coronavirus	O
NL63	O
(	O
n	O
=	O
2	O
),	O
parainfluenza	B-DISO
virus	O
(	O
n	O
=	O
2	O
),	O
adenovirus	B-DISO
(	O
n	O
=	O
1	O
)	O
and	O
newly	O
discovered	O
viruses	O
(	O
n	O
=	O
4	O
).	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
complicating	O
generalized	B-DISO
pustular	I-DISO
psoriasis	I-DISO
(	O
psoriasis	B-DISO
-	O
associated	O
aseptic	O
pneumonitis	B-DISO
).	O

This	O
complication	B-DISO
has	O
rarely	O
been	O
reported	O
but	O
should	O
be	O
more	O
widely	O
known	O
as	O
the	O
differential	O
diagnoses	O
include	O
congestive	B-DISO
heart	I-DISO
failure	I-DISO
,	O
acute	O
lung	B-DISO
infection	I-DISO
related	O
or	O
unrelated	O
to	O
immunosuppressive	O
therapy	O
,	O
and	O
drug	O
hypersensitivity	B-DISO
reaction	I-DISO
.	O

ABSTRACT	O
:	O
The	O
etiology	O
of	O
most	O
neurodegenerative	B-DISO
diseases	I-DISO
of	O
the	O
central	O
nervous	B-DISO
system	O
remains	O
unknown	O
and	O
likely	O
involves	O
a	O
combination	O
of	O
genetic	O
susceptibility	O
and	O
environmental	O
triggering	O
factors	O
.	O

The	O
binding	O
ability	O
of	O
the	O
proteins	O
to	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
),	O
a	O
porcine	O
coronavirus	O
,	O
was	O
analyzed	O
by	O
ELISA	O
.	O

TITLE	O
:	O
Lessons	O
from	O
SARS	B-DISO
:	O
a	O
retrospective	O
study	O
of	O
outpatient	O
care	O
during	O
an	O
infectious	B-DISO
disease	I-DISO
outbreak	O
.	O

There	O
was	O
a	O
significant	O
under	O
identification	O
of	O
developmental	B-DISO
delay	I-DISO
during	O
SARS	B-DISO
(	O
18	O
%	O
versus	O
45	O
%).	O

There	O
was	O
no	O
difference	O
in	O
the	O
overall	O
rate	O
of	O
developmental	B-DISO
delay	I-DISO
in	O
the	O
two	O
groups	O
as	O
identified	O
at	O
the	O
'	O
after	O
'	O
visit	O
.	O

TITLE	O
:	O
Endocrine	O
cells	O
of	O
the	O
adenohypophysis	O
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

The	O
immunohistochemistry	O
and	O
quantitative	O
image	O
results	O
showed	O
that	O
compared	O
with	O
control	O
cases	O
,	O
both	O
the	O
number	O
of	O
positive	O
cells	O
and	O
the	O
staining	O
intensity	O
of	O
immunoreactivity	O
for	O
growth	O
hormone	O
,	O
TSH	O
,	O
and	O
adrenocorticotrophic	O
hormone	O
in	O
these	O
cells	O
were	O
remarkably	O
decreased	O
,	O
while	O
that	O
of	O
PRL	O
,	O
FSH	O
,	O
and	O
LH	O
were	O
significantly	O
increased	O
in	O
all	O
SARS	B-DISO
cases	O
studied	O
.	O

TITLE	O
:	O
Population	O
-	O
based	O
post	O
-	O
crisis	O
psychological	B-DISO
distress	I-DISO
:	O
an	O
example	O
from	O
the	O
SARS	B-DISO
outbreak	O
in	O
Taiwan	O
.	O

The	O
correlates	O
of	O
symptomatic	O
cases	O
,	O
as	O
indicated	O
by	O
the	O
five	O
-	O
item	O
Brief	O
Symptom	B-DISO
Rating	O
Scale	O
,	O
included	O
age	O
>	O
or	O
=	O
50	O
years	O
,	O
senior	O
high	O
school	O
graduate	O
,	O
and	O
worries	O
about	O
recurrence	B-DISO
of	O
SARS	B-DISO
.	O

It	O
is	O
suggested	O
that	O
marketing	O
of	O
mental	O
health	O
education	O
should	O
be	O
segmented	O
according	O
to	O
age	O
and	O
education	O
level	O
,	O
which	O
should	O
enhance	O
crisis	O
communication	O
for	O
newly	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
among	O
community	O
populations	O
.	O

ABSTRACT	O
:	O
In	O
July	O
2009	O
,	O
a	O
pandemic	O
influenza	B-DISO
(	O
H1N1	B-DISO
)	O
(	O
pdm	O
H1N1	B-DISO
)	O
virus	O
epidemic	O
emerged	O
rapidly	O
in	O
Phitsanulok	O
,	O
Thailand	O
.	O

Twenty	O
-	O
four	O
cases	O
of	O
pdm	O
H1N1	O
virus	O
-	O
associated	O
CAP	B-DISO
were	O
confirmed	O
,	O
and	O
their	O
clinical	O
features	O
including	O
bacterial	B-DISO
infection	I-DISO
,	O
severity	O
of	O
disease	O
,	O
course	O
of	O
admission	O
,	O
treatment	O
,	O
and	O
outcome	O
were	O
investigated	O
.	O

Most	O
cases	O
appeared	O
to	O
be	O
primary	O
viral	B-DISO
pneumonia	I-DISO
,	O
but	O
only	O
one	O
case	O
was	O
positive	O
for	O
a	O
urinary	O
pneumococcal	O
antigen	O
.	O

CONCLUSIONS	O
:	O
Unlike	O
patients	O
of	O
seasonal	O
influenza	B-DISO
,	O
our	O
severe	O
H1N1	O
patients	O
were	O
of	O
a	O
younger	O
age	O
.	O

However	O
,	O
such	O
a	O
strategy	O
may	O
result	O
in	O
alveolar	O
collapse	B-DISO
,	O
leading	O
to	O
cyclic	O
opening	O
and	O
closing	O
of	O
atelectatic	O
alveoli	O
and	O
distal	O
airways	O
.	O

Thenar	O
oxygen	O
saturation	O
(	O
StO	O
(	O
2	O
))	O
was	O
also	O
measured	O
with	O
near	O
-	O
infrared	O
spectroscopy	O
(	O
NIRS	O
)	O
during	O
a	O
vascular	B-DISO
occlusion	I-DISO
test	O
.	O

The	O
microcirculation	O
as	O
assessed	O
by	O
SDF	O
imaging	O
and	O
NIRS	O
techniques	O
was	O
compromised	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
infection	B-DISO
.	O

Necropsy	O
of	O
5	O
fresh	O
carcasses	O
revealed	O
pulmonary	B-DISO
congestion	I-DISO
,	O
consolidation	O
,	O
and	O
hemorrhage	B-DISO
.	O

The	O
survey	O
included	O
questions	O
regarding	O
individual	O
perceptions	O
,	O
motivating	O
factors	O
,	O
and	O
behaviors	O
associated	O
with	O
hand	O
washing	O
for	O
the	O
prevention	O
of	O
H1N1	B-DISO
influenza	I-DISO
transmission	O
.	O

TITLE	O
:	O
Pathogenic	O
characteristics	O
of	O
persistent	O
feline	O
enteric	O
coronavirus	B-DISO
infection	I-DISO
in	O
cats	O
.	O

Yet	O
,	O
most	O
of	O
our	O
knowledge	O
about	O
FCoV	O
infections	B-DISO
relates	O
to	O
serotype	O
II	O
viruses	O
,	O
particularly	O
about	O
the	O
FIPV	O
,	O
mainly	O
because	O
type	O
I	O
viruses	O
grow	O
poorly	O
in	O
cell	O
culture	O
.	O

TITLE	O
:	O
Studies	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
pathology	B-DISO
in	O
human	O
cases	O
and	O
animal	O
models	O
.	O

SSDRB	O
-	O
mediated	O
changes	O
in	O
gene	O
expression	O
profiles	O
of	O
B	O
lymphoma	B-DISO
cells	O
were	O
analyzed	O
by	O
microarray	O
.	O

Its	O
tertiary	O
structure	O
is	O
compared	O
with	O
that	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
PL2	O
(	O
pro	O
),	O
a	O
downstream	O
paralog	O
that	O
is	O
conserved	O
in	O
the	O
nsp3	O
'	O
s	O
of	O
all	O
coronaviruses	O
.	O

Serum	O
DNA	O
,	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
),	O
and	O
malonaldehyde	O
(	O
MDA	O
)	O
concentrations	O
were	O
measured	O
and	O
were	O
found	O
to	O
be	O
significantly	O
higher	O
in	O
patients	O
with	O
moderate	O
and	O
severe	O
OSAHS	B-DISO
groups	O
than	O
those	O
in	O
the	O
mild	O
OSAHS	B-DISO
and	O
control	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

The	O
strong	O
pathogenicity	O
of	O
the	O
virus	O
is	O
still	O
not	O
completely	O
explained	O
,	O
but	O
the	O
deep	O
location	O
of	O
infection	B-DISO
in	O
the	O
lungs	O
and	O
the	O
deregulation	O
of	O
cytokine	O
production	O
by	O
the	O
target	O
cells	O
,	O
particularly	O
macrophages	O
,	O
may	O
be	O
part	O
of	O
the	O
explanation	O
.	O

TITLE	O
:	O
Emerging	O
,	O
novel	O
,	O
and	O
known	O
influenza	B-DISO
virus	O
infections	B-DISO
in	O
humans	O
.	O

ABSTRACT	O
:	O
Influenza	B-DISO
viruses	O
continue	O
to	O
cause	O
yearly	O
epidemics	O
and	O
occasional	O
pandemics	O
in	O
humans	O
.	O

The	O
recent	O
emergence	O
of	O
the	O
pandemic	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
2009	O
virus	O
from	O
the	O
Americas	O
in	O
early	O
2009	O
,	O
although	O
surprising	O
in	O
its	O
geographic	O
and	O
zoonotic	O
origins	O
,	O
has	O
tested	O
these	O
preparedness	O
programs	O
and	O
revealed	O
areas	O
in	O
which	O
further	O
work	O
is	O
necessary	O
.	O

Nevertheless	O
,	O
the	O
plethora	O
of	O
epidemiologic	O
,	O
diagnostic	O
,	O
mathematical	O
and	O
phylogenetic	O
modeling	O
,	O
and	O
investigative	O
methodologies	O
developed	O
since	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreak	O
of	O
2003	O
and	O
the	O
subsequent	O
sporadic	O
human	O
cases	O
of	O
avian	B-DISO
influenza	I-DISO
have	O
been	O
applied	O
effectively	O
and	O
rapidly	O
to	O
the	O
emergence	O
of	O
this	O
novel	O
pandemic	O
virus	O
.	O

TITLE	O
:	O
Occupation	O
-	O
related	O
respiratory	B-DISO
infections	I-DISO
revisited	O
.	O

Rhinolophids	O
carried	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
related	O
CoV	O
at	O
high	O
frequencies	O
and	O
concentrations	O
(	O
26	O
%	O
of	O
animals	O
are	O
positive	O
;	O
up	O
to	O
2	O
.	O
4	O
×	O
10	O
(	O
8	O
)	O
copies	O
per	O
gram	O
of	O
feces	O
),	O
as	O
well	O
as	O
two	O
Alphacoronavirus	O
clades	O
,	O
one	O
novel	O
and	O
one	O
related	O
to	O
the	O
HKU2	O
clade	O
.	O

It	O
is	O
predicted	O
that	O
proteins	O
3b	O
and	O
6	O
were	O
highly	O
divergent	O
from	O
those	O
proteins	O
in	O
all	O
known	O
SARS	B-DISO
-	O
related	O
CoV	O
.	O
Open	O
reading	O
frame	O
8	O
(	O
ORF8	O
)	O
was	O
surprisingly	O
absent	O
.	O

One	O
group	O
of	O
primers	O
was	O
designed	O
to	O
detect	O
wild	O
-	O
type	O
strains	O
(	O
i	O
.	O
e	O
.,	O
strains	O
with	O
the	O
gE	O
gene	O
)	O
and	O
the	O
other	O
group	O
of	O
primers	O
was	O
designed	O
to	O
detect	O
both	O
PRV	B-DISO
gE	O
-	O
vaccine	O
and	O
wild	O
-	O
type	O
strains	O
(	O
i	O
.	O
e	O
.,	O
strains	O
with	O
the	O
gG	O
gene	O
and	O
with	O
or	O
without	O
the	O
gE	O
gene	O
).	O

ARDS	B-DISO
-	O
like	O
syndrome	B-DISO
was	O
produced	O
by	O
lung	O
lavage	O
in	O
eight	O
pigs	O
(	O
ARDS	B-DISO
group	O
).	O

In	O
contrast	O
,	O
in	O
the	O
ARDS	B-DISO
group	O
,	O
DeltaPP	O
was	O
an	O
unreliable	O
hypovolemia	O
marker	O
at	O
low	O
VT	O
ventilation	O
,	O
regardless	O
of	O
the	O
RR	O
value	O
(	O
p	O
=	O
not	O
statistically	O
significant	O
).	O

Electrophoretic	O
separation	B-DISO
was	O
also	O
performed	O
on	O
supernatants	O
of	O
homogenized	O
brain	O
,	O
skeletal	O
muscle	O
,	O
and	O
cardiac	O
muscle	O
from	O
both	O
species	O
,	O
to	O
assess	O
the	O
tissue	O
distribution	O
of	O
isoenyzmes	O
in	O
dogs	O
and	O
cats	O
.	O

ABSTRACT	O
:	O
Several	O
protein	O
-	O
protein	O
interactions	O
within	O
the	O
SARS	B-DISO
-	O
CoV	O
proteome	O
have	O
been	O
identified	O
,	O
one	O
of	O
them	O
being	O
between	O
non	O
-	O
structural	O
proteins	O
nsp10	O
and	O
nsp16	O
.	O

In	O
fact	O
,	O
HCoV	O
-	O
NL63	O
is	O
the	O
aetiological	O
agent	O
for	O
up	O
to	O
10	O
%	O
of	O
all	O
respiratory	B-DISO
diseases	I-DISO
.	O

TITLE	O
:	O
Non	O
-	O
invasive	O
mechanical	O
ventilation	O
with	O
spinal	O
anesthesia	B-DISO
for	O
cesarean	O
delivery	O
.	O

In	O
contrast	O
,	O
STAT1	O
-/-	O
mice	O
exhibited	O
a	O
defect	O
in	O
the	O
expression	O
of	O
interferon	O
-	O
stimulated	O
genes	O
and	O
were	O
unable	O
to	O
clear	O
the	O
infection	B-DISO
,	O
resulting	O
in	O
a	O
lethal	O
outcome	O
.	O

The	O
infection	B-DISO
was	O
complicated	O
by	O
severe	O
respiratory	B-DISO
failure	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
requiring	O
ventilatory	O
support	O
,	O
including	O
extra	O
-	O
corporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
).	O

Several	O
human	O
HLA	O
-	O
A	O
*	O
0201	O
restricted	O
CTL	O
epitopes	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
spike	O
(	O
S	O
)	O
protein	O
have	O
been	O
identified	O
in	O
HLA	O
-	O
A	O
*	O
0201	O
transgenic	O
(	O
Tg	O
)	O
mice	O
,	O
but	O
the	O
mechanisms	O
and	O
properties	O
of	O
immune	O
responses	O
are	O
still	O
not	O
well	O
understood	O
.	O

In	O
this	O
study	O
,	O
HLA	O
-	O
A	O
*	O
0201	O
Tg	O
mice	O
were	O
primed	O
intramuscularly	O
with	O
SARS	B-DISO
S	O
DNA	O
and	O
boosted	O
subcutaneously	O
with	O
HLA	O
-	O
A	O
*	O
0201	O
restricted	O
peptides	O
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
immunization	O
with	O
SARS	B-DISO
S	O
DNA	O
and	O
HLA	O
-	O
A	O
*	O
0201	O
restricted	O
peptides	O
can	O
elicit	O
antigen	O
-	O
specific	O
CD8	O
(+)	O
T	O
cell	O
immune	O
responses	O
which	O
may	O
have	O
a	O
significant	O
implication	O
in	O
the	O
long	O
-	O
term	O
protection	O
.	O

However	O
,	O
studies	O
on	O
the	O
interactions	O
between	O
MBL	O
and	O
CMV	B-DISO
infection	I-DISO
are	O
limited	O
.	O

Thus	O
we	O
can	O
speculate	O
that	O
as	O
an	O
acute	O
response	O
protein	O
and	O
a	O
pattern	O
-	O
recognition	O
molecule	O
of	O
the	O
innate	O
immune	O
system	O
,	O
MBL	O
may	O
play	O
a	O
role	O
in	O
protecting	O
against	O
HCMV	O
infection	B-DISO
in	O
children	O
,	O
and	O
MBL	O
gene	O
mutations	O
may	O
be	O
a	O
significant	O
risk	O
factor	O
for	O
the	O
development	O
of	O
infantile	O
HCMV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
The	O
infectious	B-DISO
origin	O
of	O
fatal	O
cases	O
of	O
calf	O
pneumonia	B-DISO
was	O
studied	O
in	O
48	O
calves	O
from	O
27	O
different	O
herds	O
on	O
postmortem	O
examination	O
.	O

The	O
presence	O
of	O
multiple	O
respiratory	O
pathogens	O
in	O
23	O
/	O
40	O
(	O
57	O
.	O
5	O
%)	O
cases	O
indicated	O
the	O
complex	O
origin	O
of	O
fatal	O
calf	O
pneumonia	B-DISO
.	O

Cryptosporidium	B-DISO
infection	I-DISO
was	O
diagnosed	O
in	O
all	O
herds	O
,	O
with	O
equal	O
prevalence	O
in	O
case	O
and	O
control	O
herds	O
in	O
all	O
three	O
age	O
groups	O
.	O

ABSTRACT	O
:	O
Infection	B-DISO
of	O
pancreatic	B-DISO
necrosis	I-DISO
,	O
although	O
present	O
in	O
less	O
than	O
10	O
%	O
of	O
acute	B-DISO
pancreatitis	I-DISO
,	O
carries	O
a	O
high	O
risk	O
of	O
mortality	O
;	O
debridment	O
and	O
drainage	O
of	O
necrosis	O
is	O
the	O
treatment	O
of	O
choice	O
,	O
followed	O
by	O
'	O
open	O
'	O
or	O
'	O
close	O
'	O
abdomen	O
management	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
N	O
-	O
aryl	O
-	O
2	O
-	O
arylthioacetamide	O
derivatives	O
(	O
2	O
-	O
4	O
)	O
designed	O
as	O
non	O
-	O
nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
was	O
synthesized	O
and	O
evaluated	O
for	O
their	O
inhibitory	O
activity	O
against	O
HIV	B-DISO
-	O
1	O
(	O
IIIB	O
)	O
replication	O
in	O
MT	O
-	O
4	O
cell	O
cultures	O
.	O

TITLE	O
:	O
Antiviral	O
treatment	O
for	O
severe	O
EBV	B-DISO
infections	I-DISO
in	O
apparently	O
immunocompetent	O
patients	O
.	O

The	O
role	O
of	O
antivirals	O
in	O
the	O
management	O
of	O
severe	O
EBV	B-DISO
infections	I-DISO
is	O
debatable	O
.	O

45	O
patients	O
with	O
severe	O
manifestations	O
of	O
infectious	B-DISO
mononucleosis	I-DISO
received	O
antivirals	O
(	O
as	O
an	O
adjunct	O
to	O
steroids	O
in	O
26	O
of	O
them	O
).	O

Given	O
the	O
low	O
levels	O
of	O
neuronal	O
expression	O
of	O
ceacam1a	O
,	O
primary	O
neurons	O
from	O
wild	O
-	O
type	O
and	O
ceacam1a	O
knockout	O
mice	O
were	O
inoculated	O
with	O
MHV	O
to	O
determine	O
the	O
extent	O
to	O
which	O
CEACAM1a	O
-	O
independent	O
infection	B-DISO
might	O
contribute	O
to	O
CNS	B-DISO
infection	I-DISO
.	O

With	O
aggressive	B-DISO
hydration	O
her	O
renal	O
function	O
remained	O
normal	O
throughout	O
the	O
entire	O
disease	O
course	O
,	O
and	O
she	O
steadily	O
improved	O
clinically	O
.	O

While	O
there	O
is	O
neither	O
an	O
effective	O
vaccine	O
,	O
nor	O
a	O
curative	O
treatment	O
for	O
FIP	B-DISO
,	O
a	O
diagnostic	O
protocol	O
for	O
FCoV	O
would	O
greatly	O
assist	O
in	O
the	O
management	O
and	O
control	O
of	O
the	O
virus	O
.	O

Loop	O
-	O
mediated	O
isothermal	O
amplification	B-DISO
(	O
LAMP	O
)	O
was	O
developed	O
to	O
detect	O
the	O
TGEV	O
by	O
incubation	O
at	O
60	O
°	O
C	O
for	O
1	O
h	O
and	O
the	O
product	O
specificity	O
was	O
confirmed	O
by	O
HphI	O
digestion	O
.	O

There	O
was	O
also	O
an	O
intensive	O
and	O
very	O
productive	O
research	O
effort	O
to	O
identify	O
the	O
aetiological	O
agent	O
,	O
characterise	O
the	O
clinical	O
and	O
epidemiological	O
features	O
of	O
the	O
disease	O
,	O
understand	O
the	O
pathogenesis	B-DISO
of	O
the	O
disease	O
and	O
the	O
molecular	O
biology	O
of	O
the	O
virus	O
,	O
and	O
design	O
antiviral	O
drugs	O
and	O
vaccines	O
to	O
treat	O
and	O
prevent	O
the	O
disease	O
.	O

TITLE	O
:	O
C	O
-	O
arm	O
CT	O
-	O
guided	O
foam	O
sclerotherapy	O
for	O
the	O
treatment	O
of	O
gastric	B-DISO
varices	I-DISO
.	O

TITLE	O
:	O
Intra	B-DISO
-	I-DISO
abdominal	I-DISO
hypertension	I-DISO
in	O
fulminant	O
Clostridium	B-DISO
difficile	I-DISO
infection	I-DISO
--	O
an	O
under	O
-	O
recognized	O
treatable	O
complication	B-DISO
.	O

The	O
results	O
confirm	O
the	O
vulnerability	O
of	O
HCWs	O
,	O
whether	O
clinical	O
or	O
nonclinical	O
,	O
to	O
emerging	O
H1N1	B-DISO
influenza	I-DISO
.	O

In	O
contrast	O
,	O
these	O
lung	O
injury	O
indexes	O
were	O
attenuated	O
in	O
rats	O
that	O
received	O
a	O
subcutaneous	O
injection	O
of	O
GHRP	O
-	O
2	O
(	O
100	O
microg	O
/	O
kg	O
)	O
0	O
.	O
5	O
h	O
prior	O
to	O
LPS	B-DISO
administration	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
represent	O
a	O
spectrum	O
of	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
with	O
diffuse	O
,	O
bilateral	O
lung	O
injury	O
and	O
severe	O
hypoxemia	O
caused	O
by	O
non	B-DISO
-	I-DISO
cardiogenic	I-DISO
pulmonary	I-DISO
edema	I-DISO
.	O

Painful	B-DISO
and	O
repetitive	O
spasms	B-DISO
interfere	O
with	O
respiration	O
and	O
may	O
cause	O
metabolic	O
disturbances	O
such	O
as	O
hyperpyrexia	B-DISO
,	O
dehydration	B-DISO
,	O
respiratory	B-DISO
insufficiency	I-DISO
,	O
and	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
secondary	O
to	O
rhabdomyolysis	B-DISO
.	O

Abrupt	O
cessation	O
of	O
intrathecal	O
baclofen	O
infusion	O
has	O
been	O
associated	O
with	O
a	O
severe	O
withdrawal	B-DISO
syndrome	I-DISO
comprised	O
of	O
dystonia	B-DISO
,	O
autonomic	B-DISO
dysfunction	I-DISO
,	O
hyperthermia	O
,	O
end	O
-	O
organ	B-DISO
failure	I-DISO
and	O
sometimes	O
death	O
.	O

The	O
similarity	O
between	O
the	O
life	O
-	O
threatening	O
dystonic	O
episode	O
experienced	O
by	O
our	O
patient	O
,	O
and	O
those	O
reported	O
in	O
intrathecal	O
baclofen	O
withdrawal	B-DISO
,	O
highlights	O
the	O
possibility	O
that	O
,	O
rather	O
than	O
representing	O
a	O
true	O
physiological	O
withdrawal	B-DISO
syndrome	I-DISO
,	O
abrupt	O
withdrawal	B-DISO
of	O
intrathecal	O
baclofen	O
may	O
simply	O
precipitate	O
an	O
episode	O
of	O
status	O
dystonicus	O
in	O
susceptible	O
individuals	O
.	O

Some	O
states	O
propose	O
use	O
of	O
emergency	B-DISO
powers	O
that	O
might	O
potentially	O
override	O
human	O
rights	O
protections	O
while	O
other	O
states	O
propose	O
to	O
limit	O
interventions	O
to	O
those	O
authorized	O
by	O
public	O
health	O
laws	O
.	O

CONCLUSIONS	O
:	O
These	O
differences	O
could	O
create	O
problems	O
for	O
European	O
strategies	O
if	O
an	O
evolving	O
influenza	B-DISO
pandemic	O
results	O
in	O
more	O
serious	O
public	O
health	O
challenges	O
or	O
,	O
indeed	O
,	O
if	O
a	O
novel	O
disease	O
other	O
than	O
influenza	B-DISO
emerges	O
with	O
pandemic	O
potential	O
.	O

TITLE	O
:	O
Sequential	O
introduction	O
of	O
single	O
room	O
isolation	O
and	O
hand	O
hygiene	O
campaign	O
in	O
the	O
control	O
of	O
methicillin	B-DISO
-	I-DISO
resistant	I-DISO
Staphylococcus	I-DISO
aureus	I-DISO
in	O
intensive	O
care	O
unit	O
.	O

Since	O
the	O
ICU	O
renovation	O
,	O
all	O
patients	O
colonized	O
or	O
infected	O
with	O
MRSA	B-DISO
were	O
nursed	O
in	O
single	O
rooms	O
with	O
contact	O
precautions	O
.	O

The	O
incidence	O
of	O
MRSA	B-DISO
infection	I-DISO
in	O
the	O
ICU	O
was	O
monitored	O
during	O
3	O
different	O
phases	O
:	O
the	O
baseline	O
period	O
(	O
phase	O
1	O
);	O
after	O
ICU	O
renovation	O
(	O
phase	O
2	O
)	O
and	O
after	O
implementation	O
of	O
a	O
hand	O
hygiene	O
campaign	O
with	O
alcohol	O
-	O
based	O
hand	O
rub	O
(	O
phase	O
3	O
).	O

Infection	B-DISO
due	O
to	O
ESBL	O
-	O
producing	O
organisms	O
did	O
not	O
show	O
a	O
corresponding	O
reduction	O
.	O

This	O
suggests	O
that	O
the	O
deaths	O
of	O
fellow	O
healthcare	O
workers	O
from	O
an	O
occupational	O
acquired	O
infection	B-DISO
had	O
an	O
overwhelming	O
effect	O
on	O
their	O
compliance	O
with	O
infection	B-DISO
control	O
measures	O
.	O

However	O
compliance	O
with	O
infection	B-DISO
control	O
measures	O
relies	O
largely	O
on	O
a	O
personal	O
commitment	O
,	O
which	O
may	O
increase	O
when	O
personal	O
safety	O
is	O
threatened	O
.	O

RESULTS	O
:	O
Without	O
a	O
major	O
change	O
in	O
bed	B-DISO
occupancy	O
rate	O
,	O
nursing	O
workforce	O
,	O
or	O
the	O
protocol	O
of	O
environmental	O
cleansing	O
throughout	O
the	O
study	O
period	O
,	O
a	O
stepwise	O
reduction	O
in	O
ICU	O
onset	O
nonbacteraemic	O
MRSA	B-DISO
infection	I-DISO
was	O
observed	O
:	O
from	O
3	O
.	O
54	O
(	O
phase	O
1	O
)	O
to	O
2	O
.	O
26	O
(	O
phase	O
2	O
,	O
p	O
=	O
0	O
.	O
042	O
)	O
and	O
1	O
.	O
02	O
(	O
phase	O
3	O
,	O
p	O
=	O
0	O
.	O
006	O
)	O
per	O
1000	O
-	O
patient	O
-	O
days	O
.	O

we	O
have	O
developed	O
VIGOR	O
(	O
Viral	O
Genome	O
ORF	O
Reader	O
),	O
a	O
web	B-DISO
application	O
tool	O
for	O
gene	O
prediction	O
in	O
influenza	B-DISO
virus	O
,	O
rotavirus	O
,	O
rhinovirus	O
and	O
coronavirus	O
subtypes	O
.	O

Using	O
known	O
kinetic	O
rate	O
constants	O
,	O
the	O
individual	O
contributions	O
of	O
different	O
steps	O
of	O
the	O
translation	O
elongation	O
cycle	O
to	O
-	O
1	O
PRF	O
and	O
the	O
ratio	O
between	O
two	O
types	O
of	O
frameshift	B-DISO
products	O
were	O
evaluated	O
.	O

The	O
first	O
patient	O
received	O
TMP	O
6	O
.	O
4	O
mg	O
/	O
kg	O
/	O
day	O
and	O
SMX	O
32	O
mg	O
/	O
kg	O
/	O
day	O
,	O
corresponding	O
to	O
50	O
%	O
of	O
the	O
recommended	O
high	O
-	O
dose	O
TMP	O
/	O
SMX	O
regimen	O
in	O
PCP	B-DISO
patients	O
.	O

Accordingly	O
,	O
peak	O
TMP	O
serum	O
concentrations	O
were	O
within	O
the	O
recommended	O
range	O
in	O
the	O
patient	O
treated	O
with	O
a	O
reduced	O
TMP	O
/	O
SMX	O
dose	O
for	O
PCP	B-DISO
,	O
whereas	O
her	O
SMX	O
peak	O
concentrations	O
were	O
only	O
one	O
third	O
of	O
recommended	O
target	O
concentrations	O
.	O

ABSTRACT	O
:	O
We	O
aimed	O
to	O
review	O
the	O
impact	O
of	O
introducing	O
binasal	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
in	O
newborns	O
≥	O
32	O
weeks	O
gestation	O
during	O
retrieval	O
in	O
Western	O
Australia	O
.	O

Retrospective	O
review	O
of	O
newborns	O
≥	O
32	O
weeks	O
gestation	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
,	O
transported	O
by	O
the	O
Western	O
Australian	O
Neonatal	O
Transport	O
Service	O
between	O
February	O
2002	O
and	O
December	O
2004	O
.	O

This	O
clinical	O
trial	O
,	O
as	O
well	O
as	O
following	O
large	O
-	O
scale	O
trials	O
in	O
ARDS	B-DISO
patients	O
,	O
led	O
to	O
significant	O
changes	O
of	O
ventilation	O
therapy	O
and	O
therapeutic	O
strategies	O
that	O
improve	O
the	O
outcome	O
of	O
this	O
disease	O
entity	O
.	O

In	O
this	O
study	O
,	O
the	O
avian	O
nucleolar	O
proteome	O
was	O
defined	O
in	O
the	O
absence	O
and	O
presence	O
of	O
virus	O
,	O
in	O
this	O
case	O
the	O
positive	O
strand	O
RNA	O
virus	O
,	O
avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

TITLE	O
:	O
Use	O
of	O
a	O
multiplex	O
PCR	O
/	O
RT	O
-	O
PCR	O
approach	O
to	O
assess	O
the	O
viral	O
causes	O
of	O
influenza	B-DISO
-	O
like	O
illnesses	O
in	O
Cambodia	O
during	O
three	O
consecutive	O
dry	O
seasons	O
.	O

Rhinoviruses	O
(	O
43	O
.	O
4	O
%),	O
parainfluenza	B-DISO
(	O
31	O
.	O
3	O
%)	O
viruses	O
and	O
coronaviruses	O
(	O
21	O
.	O
7	O
%)	O
were	O
the	O
most	O
frequently	O
detected	O
viruses	O
.	O

The	O
M	O
protein	O
of	O
SARS	B-DISO
-	O
CoV	O
holds	O
dominant	O
cellular	O
immunogenicity	O
.	O

The	O
incidence	O
of	O
ALI	O
/	O
ARDS	B-DISO
was	O
similar	O
by	O
race	O
(	O
P	O
=	O
.	O
99	O
).	O

Among	O
patients	O
who	O
developed	O
ALI	O
/	O
ARDS	B-DISO
,	O
there	O
was	O
no	O
evidence	O
to	O
support	O
a	O
difference	O
in	O
partial	O
pressure	O
of	O
oxygen	O
in	O
arterial	O
blood	O
to	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
Pao	O
(	O
2	O
)/	O
Fio	O
(	O
2	O
))	O
(	O
P	O
=	O
.	O
33	O
),	O
lung	O
injury	O
score	O
(	O
P	O
=	O
.	O
67	O
),	O
or	O
mortality	O
(	O
P	O
=	O
.	O
78	O
)	O
by	O
race	O
.	O

However	O
,	O
there	O
is	O
still	O
significant	O
mortality	O
associated	O
with	O
antineutrophil	O
cytoplasmic	O
antibody	O
-	O
associated	O
vasculitis	B-DISO
.	O

TITLE	O
:	O
[	O
Consecutive	O
five	O
-	O
year	O
follow	O
-	O
up	O
analysis	O
of	O
specific	O
IgG	O
antibody	O
of	O
22	O
cases	O
of	O
SARS	B-DISO
patients	O
after	O
recovery	O
].	O

In	O
conclusion	O
,	O
SARS	B-DISO
-	O
CoV	O
IgG	O
Ab	O
can	O
be	O
maintained	O
for	O
more	O
than	O
3	O
years	O
post	O
infection	B-DISO
,	O
however	O
,	O
the	O
titer	O
of	O
IgG	O
Ab	O
has	O
declined	O
markedly	O
4	O
years	O
later	O
.	O

This	O
study	O
tests	O
the	O
hypothesis	O
that	O
muscarinic	O
receptor	O
antagonist	O
therapy	O
with	O
tiotropium	O
bromide	O
,	O
an	O
M1	O
and	O
M3	O
muscarinic	O
receptor	O
antagonist	O
,	O
will	O
decrease	O
the	O
airway	O
constrictive	O
response	O
and	O
acute	O
bronchial	O
obstruction	B-DISO
to	O
improve	O
pulmonary	O
function	O
compared	O
to	O
injured	O
animals	O
without	O
treatment	O
.	O

TITLE	O
:	O
Brachial	B-DISO
neuritis	I-DISO
masquerading	O
as	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
.	O

He	O
also	O
developed	O
severe	O
orthopnoea	B-DISO
.	O

Severe	O
ARDS	B-DISO
was	O
defined	O
as	O
a	O
ratio	O
of	O
the	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
(	O
PaO2	O
)	O
to	O
the	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
FIO2	O
)	O
of	O
less	O
than	O
150	O
,	O
with	O
a	O
positive	O
end	O
-	O
expiratory	O
pressure	O
of	O
5	O
cm	O
or	O
more	O
of	O
water	O
and	O
a	O
tidal	O
volume	O
of	O
6	O
to	O
8	O
ml	O
per	O
kilogram	O
of	O
predicted	O
body	O
weight	O
.	O

Taken	O
together	O
,	O
this	O
novel	O
vaccine	O
platform	O
is	O
well	O
suited	O
to	O
deliver	O
antigens	O
and	O
immunostimulatory	O
cytokines	O
to	O
DCs	B-DISO
and	O
to	O
initiate	O
and	O
maintain	O
protective	O
immunity	O
.	O

Moreover	O
,	O
the	O
fusion	O
of	O
the	O
GM	O
-	O
CSF	O
markedly	O
increased	O
spleen	O
cell	O
proliferation	B-DISO
and	O
IFN	O
-	O
γ	O
production	O
while	O
mild	O
increased	O
in	O
IL	O
-	O
4	O
production	O
,	O
which	O
demonstrated	O
the	O
enhancement	O
of	O
cell	O
-	O
mediated	O
immune	O
responses	O
.	O

In	O
most	O
patients	O
over	O
70	O
years	O
of	O
age	O
hospitalized	O
with	O
acute	B-DISO
heart	I-DISO
failure	I-DISO
it	O
is	O
possible	O
to	O
identify	O
one	O
or	O
more	O
precipitating	O
factors	O
of	O
decompensation	O
,	O
some	O
of	O
which	O
are	O
independently	O
associated	O
with	O
hospital	O
mortality	O
.	O

The	O
variables	O
independently	O
associated	O
with	O
hospital	O
mortality	O
were	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
severe	O
hypoalbuminemia	O
,	O
systolic	O
blood	O
pressure	O
<	O
110mmHg	O
,	O
white	O
blood	O
cell	O
count	O
>	O
10	O
.	O
000	O
per	O
mm³	O
and	O
valvular	B-DISO
heart	I-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
A	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)/	O
high	O
-	O
resolution	O
melt	O
(	O
HRM	O
)	O
curve	O
analysis	O
protocol	O
was	O
developed	O
in	O
our	O
laboratory	O
to	O
differentiate	O
infectious	B-DISO
bronchitis	B-DISO
(	O
IB	O
)	O
virus	O
reference	O
strains	O
.	O

Comparing	O
these	O
results	O
with	O
some	O
obtained	O
previously	O
with	O
chlorhexidine	O
and	O
hexamidine	O
,	O
(	O
i	O
)	O
these	O
two	O
calixarenes	O
did	O
not	O
show	O
any	O
cytotoxicity	B-DISO
contrary	O
to	O
chlorhexidine	O
and	O
hexamidine	O
,	O
(	O
ii	O
)	O
C	O
[	O
4	O
]	O
S	O
showed	O
as	O
did	O
hexamidine	O
,	O
a	O
very	O
weak	O
activity	O
against	O
HCoV	O
229E	O
,	O
and	O
(	O
iii	O
)	O
the	O
C	O
[	O
4	O
]	O
S	O
-	O
BTZ	O
showed	O
a	O
stronger	O
activity	O
than	O
chlorhexidine	O
,	O
i	O
.	O
e	O
.	O
2	O
.	O
7	O
and	O
1	O
.	O
4log₁₀	O
reduction	O
in	O
viral	O
titer	O
after	O
5min	O
of	O
contact	O
with	O
10	O
⁻	O
³mol	O
L	O
⁻	O
¹	O
solutions	O
of	O
C	O
[	O
4	O
]	O
S	O
-	O
BTZ	O
and	O
chlorhexidine	O
,	O
respectively	O
.	O

TITLE	O
:	O
Spontaneous	O
pnemomedastinum	O
in	O
acute	B-DISO
severe	I-DISO
asthma	I-DISO
.	O

To	O
explore	O
the	O
link	O
between	O
coronavirus	B-DISO
infection	I-DISO
and	O
the	O
ubiquitin	O
system	O
,	O
we	O
asked	O
whether	O
protein	O
degradation	O
by	O
the	O
26S	O
proteasome	O
plays	O
a	O
role	O
in	O
severe	O
coronavirus	B-DISO
infections	I-DISO
using	O
a	O
murine	O
model	O
of	O
SARS	B-DISO
-	O
like	O
pneumonitis	B-DISO
induced	O
by	O
murine	B-DISO
hepatitis	I-DISO
virus	O
strain	O
1	O
(	O
MHV	O
-	O
1	O
).	O

In	O
vivo	O
,	O
intranasal	O
inoculation	O
of	O
MHV	O
-	O
1	O
results	O
in	O
a	O
lethal	O
pneumonitis	B-DISO
in	O
A	O
/	O
J	O
mice	O
.	O

The	O
results	O
further	O
suggest	O
that	O
targeting	O
the	O
proteasome	O
may	O
be	O
an	O
effective	O
new	O
treatment	O
for	O
severe	O
coronavirus	B-DISO
infections	I-DISO
.	O

According	O
to	O
the	O
result	O
of	O
the	O
culture	O
,	O
the	O
suitable	O
antibiotic	O
targeting	O
the	O
pathogen	O
(	O
e	O
.	O
g	O
.,	O
MRSA	B-DISO
,	O
Pseudomonas	O
aeruginosa	O
,	O
Klebsiella	O
oxytoca	O
)	O
that	O
had	O
grown	O
most	O
predominantly	O
in	O
the	O
culture	O
was	O
used	O
until	O
clinical	O
resolution	O
of	O
VAP	O
,	O
leading	O
to	O
avoidance	O
of	O
overusing	O
broad	O
-	O
spectrum	O
antibiotics	O
and	O
ultimately	O
a	O
favorable	O
outcome	O
.	O

After	O
the	O
change	O
from	O
VCM	O
to	O
linezolid	O
(	O
LZD	O
),	O
the	O
VAP	O
improved	O
promptly	O
,	O
indicating	O
that	O
LZD	O
is	O
superior	O
to	O
VCM	O
in	O
the	O
treatment	O
of	O
MRSA	B-DISO
pneumonia	I-DISO
.	O

This	O
time	O
-	O
consuming	O
procedure	O
is	O
unacceptable	O
,	O
especially	O
when	O
highly	O
fatal	O
and	O
infectious	B-DISO
virus	O
arises	O
such	O
as	O
SARS	B-DISO
and	O
H1N1	O
,	O
which	O
forces	O
the	O
scoring	O
task	O
to	O
be	O
done	O
in	O
a	O
limited	O
time	O
.	O

An	O
1	O
-	O
year	O
prospective	O
,	O
observational	O
study	O
was	O
conducted	O
in	O
adults	O
(	O
age	O
>	O
16	O
years	O
)	O
who	O
presented	O
with	O
an	O
undifferentiated	O
febrile	B-DISO
illness	I-DISO
of	O
duration	O
5	O
-	O
21	O
days	O
,	O
requiring	O
hospitalization	O
.	O

Molecular	O
pharmacologic	O
studies	O
focused	O
on	O
the	O
molecular	O
and	O
the	O
biochemical	O
mechanisms	O
underlying	O
the	O
protective	O
effects	O
of	O
caffeine	B-DISO
are	O
also	O
being	O
done	O
to	O
optimize	O
treatment	O
regimes	O
and	O
to	O
target	O
potential	O
molecular	O
pathways	O
leading	O
to	O
further	O
decreases	O
in	O
acute	O
and	O
long	O
term	O
neonatal	O
morbidities	O
.	O

B7	O
-	O
H1	O
(-/-)	O
mice	O
exhibited	O
extensive	O
loss	O
of	O
axonal	O
integrity	O
,	O
although	O
demyelination	B-DISO
,	O
a	O
hallmark	O
of	O
virus	O
-	O
induced	O
tissue	O
damage	O
,	O
was	O
not	O
increased	O
.	O

TITLE	O
:	O
Elevated	O
plasma	O
and	O
alveolar	O
levels	O
of	O
soluble	O
receptor	O
for	O
advanced	O
glycation	O
endproducts	O
are	O
associated	O
with	O
severity	O
of	O
lung	O
dysfunction	O
in	O
ARDS	B-DISO
patients	O
.	O

ABSTRACT	O
:	O
Serious	O
pulmonary	O
and	O
cardiac	B-DISO
failure	I-DISO
may	O
be	O
treated	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
when	O
the	O
conventional	O
treatment	O
fails	O
.	O

Causes	O
of	O
cardiac	O
shock	O
were	O
:	O
myocarditis	B-DISO
(	O
28	O
.	O
1	O
%),	O
acute	B-DISO
heart	I-DISO
failure	I-DISO
of	O
unknown	O
aetiology	O
(	O
21	O
.	O
9	O
%),	O
drug	O
-	O
induced	O
cardiovascular	O
failure	O
(	O
18	O
.	O
8	O
%),	O
post	O
-	O
infarction	B-DISO
cardiac	B-DISO
failure	I-DISO
(	O
12	O
.	O
5	O
%),	O
post	O
-	O
cardiac	O
surgery	O
(	O
12	O
.	O
5	O
%)	O
and	O
refractory	O
cardiac	B-DISO
arrest	I-DISO
(	O
6	O
.	O
2	O
%).	O

The	O
incidence	O
of	O
influenza	B-DISO
admissions	O
had	O
not	O
increased	O
significantly	O
in	O
2009	O
(	O
H1N1	O
pandemic	O
)	O
when	O
compared	O
with	O
2003	O
(	O
SARS	B-DISO
epidemic	O
)	O
(	O
p	O
=	O
0	O
.	O
3	O
).	O

The	O
annual	O
incidence	O
of	O
severe	O
PICU	O
cases	O
of	O
influenza	B-DISO
and	O
parainfluenza	B-DISO
were	O
0	O
.	O
94	O
and	O
0	O
.	O
88	O
per	O
100	O
,	O
000	O
children	O
per	O
annum	O
,	O
respectively	O
.	O

Thus	O
measurements	O
of	O
cytokines	O
and	O
frequencies	O
of	O
immune	O
cells	O
may	O
serve	O
as	O
indicators	O
of	O
the	O
progression	O
of	O
respiratory	O
viral	O
co	B-DISO
-	I-DISO
infections	I-DISO
,	O
and	O
provide	O
more	O
definitive	O
approaches	O
for	O
treatment	O
.	O

TITLE	O
:	O
Immunogenicity	O
and	O
protective	O
efficacy	O
in	O
mice	O
and	O
hamsters	O
of	O
a	O
β	O
-	O
propiolactone	O
inactivated	O
whole	O
virus	O
SARS	B-DISO
-	O
CoV	O
vaccine	O
.	O

ABSTRACT	O
:	O
The	O
immunogenicity	O
and	O
efficacy	O
of	O
β	O
-	O
propiolactone	O
(	O
BPL	O
)	O
inactivated	O
whole	O
virion	O
SARS	B-DISO
-	O
CoV	O
(	O
WI	O
-	O
SARS	B-DISO
)	O
vaccine	O
was	O
evaluated	O
in	O
BALB	O
/	O
c	O
mice	O
and	O
golden	O
Syrian	O
hamsters	O
.	O

Influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
(	O
fever	O
and	O
cough	B-DISO
or	O
sore	B-DISO
throat	I-DISO
)	O
developed	O
in	O
29	O
%	O
(	O
95	O
%	O
CI	O
,	O
20	O
.	O
5	O
%-	O
36	O
.	O
7	O
%)	O
of	O
household	O
contacts	O
.	O

CD4	O
(+)	O
CD25	O
(+)	O
Foxp3	O
(+)	O
regulatory	O
T	O
Cells	O
(	O
Foxp3	O
(+)	O
Tregs	O
),	O
iNOS	O
and	O
cytokines	O
may	O
affect	O
these	O
severe	O
conditions	O
such	O
as	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
after	O
hemorrhagic	B-DISO
shock	I-DISO
and	O
resuscitation	O
.	O

This	O
study	O
seeks	O
to	O
describe	O
attitudes	O
and	O
perceived	O
practices	O
of	O
pediatric	O
intensivists	O
regarding	O
the	O
use	O
of	O
noninvasive	O
positive	O
-	O
pressure	O
ventilation	O
in	O
children	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

Factors	O
such	O
as	O
severe	O
defects	O
in	O
oxygenation	O
and	O
ventilation	O
,	O
disease	B-DISO
progression	I-DISO
,	O
and	O
patient	O
tolerability	O
decreased	O
the	O
likelihood	O
of	O
use	O
.	O

The	O
ΔE	O
virus	O
formed	O
tiny	O
plaques	B-DISO
and	O
reached	O
optimal	O
infectious	B-DISO
titers	O
many	O
orders	O
of	O
magnitude	O
below	O
those	O
of	O
wild	O
-	O
type	O
virus	O
.	O

Coinfection	B-DISO
was	O
associated	O
with	O
increased	O
ICU	O
mortality	O
(	O
26	O
.	O
2	O
%	O
vs	O
15	O
.	O
5	O
%;	O
OR	O
,	O
1	O
.	O
94	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
21	O
-	O
3	O
.	O
09	O
),	O
but	O
Cox	O
regression	O
analysis	O
adjusted	O
by	O
potential	O
confounders	O
did	O
not	O
confirm	O
a	O
significant	O
association	O
between	O
coinfection	B-DISO
and	O
ICU	O
mortality	O
.	O

From	O
January	O
2003	O
to	O
December	O
2008	O
,	O
eleven	O
patients	O
in	O
our	O
hospital	O
required	O
VV	O
ECMO	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

The	O
pre	O
-	O
ECMO	O
ventilator	O
time	O
was	O
shorter	O
in	O
group	O
A	O
than	O
in	O
group	B-DISO
B	I-DISO
.	O
Significant	O
differences	O
were	O
found	O
between	O
the	O
two	O
groups	O
in	O
the	O
P	O
/	O
F	O
ratio	O
and	O
LIS	O
from	O
pre	O
-	O
ECMO	O
introduction	O
to	O
72	O
hours	O
after	O
.	O

RESULTS	O
:	O
ECMO	O
could	O
be	O
removed	O
from	O
six	O
patients	O
(	O
55	O
%,	O
group	O
A	O
),	O
but	O
in	O
five	O
(	O
45	O
%,	O
group	B-DISO
B	I-DISO
)	O
could	O
not	O
.	O

ABSTRACT	O
:	O
Plasmodium	O
(	O
P	O
.)	O
vivax	B-DISO
malaria	I-DISO
is	O
rarely	O
associated	O
with	O
severe	O
complications	O
like	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

ABSTRACT	O
:	O
As	O
part	O
of	O
our	O
search	O
for	O
botanical	O
sources	O
of	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
inhibitors	O
,	O
we	O
selected	O
Torreya	O
nucifera	O
,	O
which	O
is	O
traditionally	O
used	O
as	O
a	O
medicinal	O
plant	O
in	O
Asia	O
.	O

Patients	O
with	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
,	O
porphyria	B-DISO
,	O
polio	B-DISO
and	O
non	O
-	O
polio	B-DISO
enterovirus	B-DISO
infection	I-DISO
and	O
myositis	B-DISO
were	O
excluded	O
.	O

43	O
.	O
3	O
%	O
of	O
patients	O
with	O
hypokalaemic	O
paralysis	O
had	O
a	O
secondary	O
cause	O
for	O
their	O
condition	B-DISO
.	O

CONCLUSIONS	O
:	O
43	O
.	O
3	O
%	O
of	O
patients	O
with	O
hypokalaemic	O
paralysis	O
had	O
a	O
secondary	O
cause	O
for	O
their	O
condition	B-DISO
.	O

TITLE	O
:	O
The	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
pathogenesis	B-DISO
and	O
treatment	O
.	O

ABSTRACT	O
:	O
The	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
causes	O
40	O
%	O
mortality	O
in	O
approximately	O
200	O
,	O
000	O
critically	B-DISO
ill	I-DISO
patients	O
annually	O
in	O
the	O
United	O
States	O
.	O

Composite	O
end	O
point	O
of	O
30	O
-	O
day	O
all	O
-	O
cause	O
mortality	O
and	O
severe	O
morbidity	O
(	O
cardiogenic	B-DISO
shock	I-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
or	O
acute	O
renal	O
injury	O
requiring	O
dialysis	O
or	O
hemofiltration	O
)	O
occurring	O
during	O
the	O
hospital	O
stay	O
.	O

However	O
,	O
the	O
revertant	O
viruses	O
displayed	O
different	O
plaque	B-DISO
sizes	O
and	O
whole	O
genome	O
sequencing	O
of	O
two	O
revertants	O
showed	O
that	O
they	O
were	O
isogenic	O
apart	O
from	O
a	O
mutation	O
in	O
nsp13	O
.	O

ABSTRACT	O
:	O
Little	O
is	O
known	O
about	O
the	O
induction	O
of	O
humoral	O
responses	O
directed	O
against	O
human	O
autoantigens	O
during	O
acute	O
inflammation	B-DISO
.	O

Available	O
longitudinal	O
samples	O
from	O
different	O
seropositive	O
ARDS	B-DISO
and	O
sepsis	B-DISO
patient	O
samples	O
,	O
starting	O
from	O
within	O
the	O
first	O
two	O
days	O
after	O
admission	O
to	O
the	O
intensive	O
care	O
,	O
were	O
then	O
analyzed	O
for	O
changes	O
in	O
autoantibody	O
over	O
time	O
.	O

From	O
screening	O
patient	O
plasma	O
,	O
57	O
%	O
of	O
ARDS	B-DISO
and	O
46	O
%	O
of	O
septic	O
patients	O
without	O
ARDS	B-DISO
demonstrated	O
at	O
least	O
one	O
statistically	O
significant	O
elevated	O
autoantibody	O
compared	O
to	O
the	O
controls	O
.	O

TITLE	O
:	O
Synthesis	O
and	O
evaluation	O
of	O
pyrazolone	O
compounds	O
as	O
SARS	B-DISO
-	O
coronavirus	O
3C	O
-	O
like	O
protease	O
inhibitors	O
.	O

TITLE	O
:	O
Profiling	O
of	O
substrate	O
specificity	O
of	O
SARS	B-DISO
-	O
CoV	O
3CL	O
.	O

Though	O
S	O
protein	O
was	O
not	O
solubilized	O
by	O
cold	B-DISO
non	O
-	O
ionic	O
detergents	O
,	O
this	O
behavior	O
was	O
unchanged	O
when	O
cholesterol	O
was	O
depleted	O
from	O
viral	O
membrane	O
by	O
methyl	O
-	O
β	O
-	O
cyclodextrin	O
(	O
MβCD	O
)	O
and	O
the	O
protein	O
did	O
not	O
comigrate	O
with	O
cellular	O
DRM	B-DISO
marker	O
proteins	O
in	O
flotation	O
analyses	O
.	O

Recombinant	O
plasmid	O
pSY	O
-	O
S1	O
/	O
IL18	O
was	O
constructed	O
by	O
cloning	O
chicken	O
IL	O
-	O
18	O
into	O
fowlpox	B-DISO
virus	O
transfer	O
plasmid	O
containing	O
S1	O
gene	O
and	O
transfected	O
into	O
the	O
chicken	O
embryo	O
fibroblasts	O
cell	O
pre	O
-	O
infected	O
with	O
S	O
-	O
FPV	O
-	O
017	O
to	O
generate	O
rFPV	O
-	O
S1	O
/	O
IL18	O
.	O

TITLE	O
:	O
Use	O
of	O
the	O
Aerosol	O
Rabbitpox	B-DISO
Virus	O
Model	O
for	O
Evaluation	O
of	O
Anti	O
-	O
Poxvirus	O
Agents	O
.	O

Many	O
laboratory	O
animal	O
models	O
of	O
poxviral	O
disease	O
have	O
been	O
developed	O
over	O
the	O
years	O
to	O
study	O
host	O
response	O
and	O
to	O
evaluate	O
new	O
therapeutics	O
and	O
vaccines	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
human	O
smallpox	B-DISO
.	O

Thus	O
,	O
our	O
results	O
indicate	O
that	O
SARS	B-DISO
-	O
CoV	O
M	O
gene	O
specific	O
siRNA	O
might	O
function	O
in	O
a	O
sequence	O
-	O
dependent	O
manner	O
.	O

Positive	O
cell	O
clones	O
were	O
selected	O
by	O
cotransfecting	O
pTRE	O
-	O
Tight	O
-	O
SARS	B-DISO
-	O
N	O
with	O
the	O
linear	O
marker	O
pPUR	O
to	O
BHK	O
-	O
21	O
Tet	O
-	O
on	O
cells	O
in	O
the	O
presence	O
of	O
puromycin	O
.	O

A	O
set	O
of	O
double	O
-	O
stable	O
eukaryotic	O
cell	O
lines	O
(	O
BHK	O
-	O
Tet	O
-	O
SARS	B-DISO
-	O
N	O
)	O
with	O
inducible	O
control	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
neucleocapsid	O
gene	O
expression	O
was	O
identified	O
by	O
using	O
SDS	B-DISO
-	O
PAGE	O
and	O
Western	O
-	O
blot	O
analysis	O
.	O

ABSTRACT	O
:	O
A	O
group	O
of	O
SARS	B-DISO
-	O
like	O
coronaviruses	O
(	O
SL	O
-	O
CoV	O
)	O
have	O
been	O
identified	O
in	O
horseshoe	O
bats	O
.	O

TITLE	O
:	O
Complete	O
genomic	O
sequence	O
of	O
transmissible	O
gastroenteritis	B-DISO
virus	O
TS	O
and	O
3	O
'	O
end	O
sequence	O
characterization	O
following	O
cell	O
culture	O
.	O

TITLE	O
:	O
Dilemmas	O
of	O
securitization	O
and	O
health	O
risk	O
management	O
in	O
the	O
People	O
'	O
s	O
Republic	O
of	O
China	O
:	O
the	O
cases	O
of	O
SARS	B-DISO
and	O
avian	B-DISO
influenza	I-DISO
.	O

ABSTRACT	O
:	O
Since	O
the	O
SARS	B-DISO
epidemic	O
in	O
2003	O
,	O
the	O
international	O
community	O
has	O
urged	O
Chinese	O
leaders	O
to	O
do	O
more	O
to	O
address	O
infectious	B-DISO
diseases	I-DISO
.	O

A	O
retrospective	O
study	O
of	O
data	O
from	O
chest	O
X	O
-	O
ray	O
,	O
CT	O
and	O
MRI	O
exam	O
of	O
29	O
pediatric	O
patients	O
treated	O
in	O
intensive	O
care	O
unit	O
for	O
severe	O
Influenza	B-DISO
-	O
A	O
(	O
H1N1	O
)	O
disease	O
.	O

In	O
these	O
cases	O
we	O
determined	O
H1N1	O
Inf	O
A	O
pandemic	O
variant	O
by	O
detection	O
of	O
Inf	O
A	O
Matrix	O
Protein	O
2	O
gene	O
M2	O
and	O
the	O
specific	O
H1	O
gene	O
for	O
influenza	B-DISO
pandemic	O
H1N1	O
2009	O
with	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
Inf	O
A	O
/	O
H1N1	O
(	O
Roche	O
).	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
encodes	O
a	O
highly	O
basic	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
which	O
can	O
inhibit	O
the	O
synthesis	O
of	O
type	O
I	O
interferon	O
(	O
IFN	O
),	O
but	O
the	O
molecular	O
mechanism	O
of	O
this	O
antagonism	O
remains	O
to	O
be	O
identified	O
.	O

ABSTRACT	O
:	O
Studies	O
of	O
the	O
host	O
response	O
to	O
virus	B-DISO
infection	I-DISO
typically	O
focus	O
on	O
protein	O
-	O
coding	O
genes	O
.	O

We	O
observed	O
differential	O
expression	O
of	O
approximately	O
500	O
annotated	O
,	O
long	O
ncRNAs	O
and	O
1	O
,	O
000	O
nonannotated	O
genomic	O
regions	O
during	O
infection	B-DISO
.	O

TITLE	O
:	O
Goal	O
-	O
directed	O
therapy	O
for	O
severely	O
hypoxic	B-DISO
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
permissive	O
hypoxemia	O
.	O

TITLE	O
:	O
[	O
Clinical	O
features	O
of	O
severe	O
new	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
in	O
pregnant	O
women	O
].	O

ABSTRACT	O
:	O
Severe	O
leptospirosis	B-DISO
usually	O
associates	O
shock	O
,	O
jaundice	B-DISO
,	O
renal	B-DISO
failure	I-DISO
,	O
and	O
thrombocytopenia	O
.	O

Pearson	O
'	O
s	O
χ²	O
tests	O
and	O
logistic	O
regression	O
models	O
were	O
used	O
to	O
analyze	O
associations	O
between	O
seropositivity	O
for	O
coronaviruses	O
,	O
influenza	B-DISO
A	O
and	O
B	O
viruses	O
and	O
the	O
following	O
:	O
a	O
)	O
history	O
of	O
recurrent	O
mood	B-DISO
disorders	I-DISO
b	O
)	O
having	O
attempted	B-DISO
suicide	I-DISO
in	O
the	O
past	O
c	O
)	O
uni	O
-	O
vs	O
.	O
bi	O
-	O
polarity	O
and	O
d	O
)	O
presence	O
of	O
psychotic	B-DISO
symptoms	I-DISO
during	O
mood	O
episodes	O
.	O

Seropositivity	O
for	O
influenza	B-DISO
B	O
was	O
significantly	O
associated	O
with	O
a	O
history	O
of	O
suicide	B-DISO
attempt	I-DISO
(	O
p	O
=	O
0	O
.	O
001	O
)	O
and	O
history	O
of	O
psychotic	B-DISO
symptoms	I-DISO
(	O
p	O
=	O
0	O
.	O
005	O
).	O

ABSTRACT	O
:	O
The	O
severity	O
of	O
respiratory	B-DISO
distress	I-DISO
was	O
associated	O
with	O
neonatal	O
prognosis	O
.	O

Neonatal	B-DISO
respiratory	I-DISO
distress	I-DISO
is	O
still	O
a	O
common	O
cause	O
of	O
hospitalization	O
in	O
China	O
.	O

TITLE	O
:	O
Clinical	O
characteristics	O
,	O
diagnosis	O
and	O
management	O
of	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
in	O
full	O
-	O
term	O
neonates	O
.	O

TITLE	O
:	O
Antiviral	O
activities	O
of	O
ISG20	O
in	O
positive	O
-	O
strand	O
RNA	B-DISO
virus	I-DISO
infections	I-DISO
.	O

This	O
prospective	O
study	O
was	O
done	O
on	O
303	O
admitted	O
children	O
of	O
malaria	B-DISO
.	O

ABSTRACT	O
:	O
To	O
use	O
evidence	O
-	O
based	O
principles	O
to	O
develop	O
infection	B-DISO
control	O
algorithms	O
to	O
ensure	O
the	O
protection	O
of	O
healthcare	O
workers	O
and	O
the	O
continuity	O
of	O
health	O
service	O
provision	O
during	O
a	O
pandemic	O
.	O
:	O
Evidence	O
-	O
based	O
algorithms	O
were	O
developed	O
from	O
published	O
research	O
as	O
well	O
as	O
""""	O
needs	O
and	O
values	O
""""	O
assessments	O
.	O

Two	O
international	O
infection	B-DISO
control	O
teams	O
responsible	O
for	O
healthcare	O
worker	O
safety	O
during	O
the	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
outbreak	O
reviewed	O
the	O
evidence	O
-	O
based	O
algorithms	O
.	O

Despite	O
the	O
equivocal	O
evidence	O
for	O
the	O
efficacy	O
of	O
surgical	O
and	O
N95	O
masks	O
and	O
the	O
provision	O
of	O
algorithms	O
appropriate	O
for	O
the	O
level	O
of	O
risk	O
according	O
to	O
clinical	O
care	O
during	O
a	O
pandemic	O
,	O
clinicians	O
still	O
demanded	O
N95	O
masks	O
plus	O
face	B-DISO
shields	O
in	O
combination	O
with	O
prophylaxis	O
and	O
novel	O
vaccination	O
.	O

SARS	B-DISO
event	O
has	O
highlighted	O
the	O
inadequate	O
interface	O
between	O
primary	O
and	O
secondary	O
care	O
and	O
valuable	O
health	O
care	O
resources	O
were	O
thus	O
inappropriately	O
matched	O
to	O
community	O
needs	O
.	O

ALI	O
/	O
ARDS	B-DISO
are	O
characterized	O
by	O
lung	B-DISO
edema	I-DISO
due	O
to	O
increased	O
permeability	O
of	O
the	O
alveolar	O
-	O
capillary	O
barrier	O
and	O
subsequent	O
impairment	B-DISO
of	O
arterial	O
oxygenation	O
.	O

Unlike	O
the	O
nsp1	O
protein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
,	O
a	O
betacoronavirus	O
,	O
the	O
TGEV	O
nsp1	O
protein	O
was	O
unable	O
to	O
bind	O
40S	O
ribosomal	O
subunits	O
or	O
promote	O
host	O
mRNA	O
degradation	O
.	O

Our	O
data	O
suggested	O
that	O
HeLa	O
cell	O
extracts	O
and	O
cultured	O
host	O
cells	O
,	O
but	O
not	O
RRL	O
,	O
contain	O
a	O
host	O
factor	O
(	O
s	O
)	O
that	O
is	O
essential	O
for	O
TGEV	O
nsp1	O
-	O
induced	O
translational	O
suppression	B-DISO
.	O

However	O
,	O
a	O
role	O
in	O
infection	B-DISO
for	O
the	O
unincorporated	O
E	O
or	O
its	O
ion	O
channel	O
activity	O
has	O
not	O
been	O
described	O
.	O

TITLE	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
viruses	O
with	O
naturally	O
occurring	O
genomic	O
rearrangement	O
and	O
gene	B-DISO
deletion	I-DISO
.	O

Here	O
,	O
we	O
combine	O
electrospray	O
differential	O
mobility	O
analysis	O
(	O
ES	O
-	O
DMA	O
),	O
which	O
rapidly	O
measures	O
the	O
size	O
of	O
the	O
entire	O
cluster	O
,	O
with	O
transmission	O
electron	O
microscopy	O
(	O
TEM	B-DISO
),	O
which	O
detects	O
the	O
hard	O
components	O
,	O
to	O
determine	O
the	O
presence	O
and	O
composition	O
of	O
the	O
softer	O
components	O
.	O

The	O
xTAG	O
additionally	O
subtypes	O
influenza	B-DISO
A	O
as	O
seasonal	O
H1	O
and	O
H3	O
.	O

Co	B-DISO
-	I-DISO
infection	I-DISO
was	O
detected	O
in	O
a	O
small	O
subset	O
of	O
patient	O
specimens	O
.	O

RESULTS	O
:	O
The	O
PRV	B-DISO
assays	O
detected	O
more	O
viruses	O
than	O
culture	O
.	O

The	O
patients	O
might	O
be	O
easily	O
misdiagnosed	O
as	O
sepsis	B-DISO
at	O
early	O
stage	O
.	O

We	O
used	O
in	O
-	O
house	O
TaqMan	O
multiplex	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
to	O
test	O
nasopharyngeal	O
samples	O
from	O
536	O
RTI	B-DISO
episodes	O
in	O
452	O
children	O
who	O
were	O
admitted	O
during	O
the	O
2006	O
-	O
2007	O
winter	O
.	O

After	O
adjusting	O
for	O
age	O
,	O
chronic	B-DISO
disease	I-DISO
,	O
LRTI	B-DISO
,	O
and	O
co	O
-	O
detection	O
of	O
other	O
viruses	O
in	O
a	O
multiple	O
logistic	O
regression	O
analysis	O
,	O
HCoV	O
was	O
associated	O
with	O
a	O
shorter	O
fever	O
period	O
and	O
shorter	O
hospitalization	O
time	O
than	O
RSV	O
.	O

HCoV	O
-	O
OC43	O
and	O
HCoV	O
-	O
NL63	O
are	O
common	O
among	O
hospitalized	O
Norwegian	O
children	O
with	O
RTI	B-DISO
.	O

After	O
adjusting	O
for	O
age	O
,	O
chronic	B-DISO
disease	I-DISO
,	O
LRTI	B-DISO
,	O
and	O
co	O
-	O
detection	O
of	O
other	O
viruses	O
in	O
a	O
multiple	O
logistic	O
regression	O
analysis	O
,	O
HCoV	O
was	O
associated	O
with	O
a	O
shorter	O
fever	O
period	O
and	O
shorter	O
hospitalization	O
time	O
than	O
RSV	O
.	O

Thirty	O
-	O
two	O
patients	O
hospitalized	O
with	O
confirmed	O
nvA	O
(	O
H1N1	O
)	O
infection	B-DISO
were	O
enrolled	O
in	O
the	O
study	O
:	O
21	O
patients	O
with	O
nvA	O
(	O
H1N1	O
)-	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
11	O
patients	O
with	O
mild	O
disease	O
.	O

In	O
obese	B-DISO
patients	O
with	O
influenza	B-DISO
disease	O
,	O
a	O
significant	O
increased	O
level	O
of	O
IL	O
-	O
8	O
was	O
found	O
.	O

ABSTRACT	O
:	O
Health	O
care	O
workers	O
(	O
HCWs	O
)	O
presented	O
frequent	O
concerns	O
regarding	O
their	O
health	O
and	O
their	O
families	O
'	O
health	O
and	O
high	O
levels	O
of	O
psychological	B-DISO
distress	I-DISO
during	O
previous	O
disease	O
outbreaks	O
,	O
such	O
as	O
the	O
SARS	B-DISO
outbreak	O
,	O
which	O
was	O
associated	O
with	O
social	O
isolation	O
and	O
intentional	O
absenteeism	O
.	O

The	O
most	O
frequent	O
concern	O
was	O
infection	B-DISO
of	O
family	O
and	O
friends	O
and	O
the	O
health	O
consequences	O
of	O
the	O
disease	O
(	O
54	O
.	O
9	O
%).	O

METHODS	O
:	O
Between	O
September	O
1st	O
and	O
30th	O
,	O
2009	O
,	O
469	O
health	O
-	O
care	O
workers	O
(	O
HCWs	O
)	O
of	O
a	O
tertiary	O
teaching	O
hospital	O
completed	O
a	O
20	O
-	O
item	O
questionnaire	O
regarding	O
concerns	O
and	O
worries	O
about	O
the	O
new	O
A	O
/	O
H1N1	B-DISO
influenza	I-DISO
pandemic	O
,	O
along	O
with	O
Cassileth	O
'	O
s	O
Information	O
Styles	O
Questionnaire	O
(	O
part	O
-	O
I	O
)	O
and	O
the	O
GHQ	O
-	O
28	O
.	O

Coronavirus	O
consensus	O
PCR	O
and	O
unbiased	O
high	O
-	O
throughput	O
pyrosequencing	O
revealed	O
the	O
presence	O
of	O
coronavirus	O
sequences	O
related	O
to	O
those	O
of	O
SARS	B-DISO
-	O
CoV	O
in	O
a	O
Commerson	O
'	O
s	O
leaf	O
-	O
nosed	O
bat	O
(	O
Hipposideros	O
commersoni	O
).	O

CONCLUSIONS	O
:	O
This	O
study	O
underlines	O
that	O
diseases	O
such	O
as	O
malaria	B-DISO
,	O
viral	B-DISO
hepatitis	I-DISO
and	O
enteric	B-DISO
fever	I-DISO
occur	O
in	O
Singapore	O
mainly	O
because	O
of	O
importation	O
.	O

TITLE	O
:	O
H1N1	O
infection	B-DISO
and	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
:	O
can	O
we	O
give	O
non	O
-	O
invasive	O
ventilation	O
a	O
chance	O
?	O

Although	O
all	O
the	O
cubicles	O
were	O
in	O
'	O
positive	O
pressure	O
'	O
towards	O
the	O
corridor	O
,	O
the	O
virus	O
-	O
containing	O
bioaerosols	O
generated	O
from	O
the	O
index	O
patient	O
'	O
s	O
cubicle	O
were	O
still	O
transmitted	B-DISO
to	O
other	O
cubicles	O
,	O
which	O
cannot	O
be	O
explained	O
in	O
a	O
traditional	O
manner	O
.	O

TITLE	O
:	O
Murine	O
coronavirus	O
neuropathogenesis	B-DISO
:	O
determinants	O
of	O
virulence	O
.	O

The	O
observation	O
that	O
JHM	O
.	O
SD	O
infects	O
more	O
cells	O
and	O
expresses	O
more	O
antigen	O
,	O
but	O
produces	O
less	O
infectious	B-DISO
virus	O
per	O
cell	O
than	O
A59	O
,	O
implies	O
that	O
efficient	O
replication	O
is	O
not	O
always	O
a	O
correlate	O
of	O
high	O
neurovirulence	O
.	O

JHM	O
.	O
SD	O
induces	O
a	O
generally	O
protective	O
innate	B-DISO
immune	I-DISO
response	I-DISO
;	O
however	O
,	O
the	O
strong	O
neutrophil	O
response	O
may	O
be	O
more	O
pathogenic	O
than	O
protective	O
.	O

Inadequate	O
analgesia	B-DISO
may	O
delay	O
or	O
prevent	O
patient	O
discharge	O
and	O
can	O
result	O
in	O
readmission	O
.	O

More	O
frequently	O
,	O
postoperative	B-DISO
pain	I-DISO
produces	O
discomfort	B-DISO
and	O
interrupts	O
sleep	O
,	O
contributing	O
to	O
postoperative	O
fatigue	B-DISO
.	O

The	O
development	O
of	O
effective	O
analgesic	O
regimens	O
for	O
the	O
management	O
of	O
postoperative	B-DISO
pain	I-DISO
is	O
a	O
priority	O
especially	O
in	O
patients	O
with	O
impaired	B-DISO
cardiorespiratory	O
,	O
hepatic	O
,	O
or	O
renal	O
function	O
.	O

TITLE	O
:	O
Perioperative	O
pulmonary	O
outcomes	O
in	O
patients	O
with	O
sleep	B-DISO
apnea	I-DISO
after	O
noncardiac	O
surgery	O
.	O

SA	O
was	O
associated	O
with	O
a	O
significantly	O
higher	O
adjusted	O
OR	O
of	O
developing	O
pulmonary	B-DISO
complications	I-DISO
after	O
both	O
orthopedic	O
and	O
general	O
surgical	O
procedures	O
,	O
respectively	O
,	O
with	O
the	O
exception	O
of	O
PE	O
(	O
OR	O
for	O
aspiration	B-DISO
pneumonia	I-DISO
:	O
1	O
.	O
41	O
[	O
1	O
.	O
35	O
,	O
1	O
.	O
47	O
]	O
and	O
1	O
.	O
37	O
[	O
1	O
.	O
33	O
,	O
1	O
.	O
41	O
];	O
for	O
ARDS	B-DISO
:	O
2	O
.	O
39	O
[	O
2	O
.	O
28	O
,	O
2	O
.	O
51	O
]	O
and	O
1	O
.	O
58	O
[	O
1	O
.	O
54	O
,	O
1	O
.	O
62	O
];	O
for	O
PE	O
:	O
OR	O
1	O
.	O
22	O
[	O
1	O
.	O
15	O
,	O
1	O
.	O
29	O
]	O
and	O
0	O
.	O
90	O
[	O
0	O
.	O
84	O
,	O
0	O
.	O
97	O
];	O
for	O
intubation	O
/	O
mechanical	O
ventilation	O
:	O
5	O
.	O
20	O
[	O
5	O
.	O
05	O
,	O
5	O
.	O
37	O
]	O
and	O
1	O
.	O
95	O
[	O
1	O
.	O
91	O
,	O
1	O
.	O
98	O
]).	O

Globally	O
,	O
approximately	O
5	O
%	O
of	O
all	O
upper	O
and	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
in	O
hospitalized	O
children	O
are	O
caused	O
by	O
HCoV	O
-	O
229E	O
and	O
HCoV	O
-	O
NL63	O
.	O

Animals	O
treated	O
with	O
CMV	O
became	O
progressively	O
hypoxic	B-DISO
and	O
hypercarbic	O
despite	O
maximum	O
ventilatory	O
support	O
.	O

ABSTRACT	O
:	O
Cellular	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
of	O
higher	O
eukaryotes	O
and	O
many	O
viral	O
RNAs	O
are	O
methylated	O
at	O
the	O
N	O
-	O
7	O
and	O
2	O
'-	O
O	O
positions	O
of	O
the	O
5	O
'	O
guanosine	O
cap	B-DISO
by	O
specific	O
nuclear	O
and	O
cytoplasmic	O
methyltransferases	O
(	O
MTases	O
),	O
respectively	O
.	O

Here	O
we	O
show	O
that	O
a	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
(	O
WNV	B-DISO
)	O
mutant	B-DISO
(	O
E218A	O
)	O
that	O
lacks	O
2	O
'-	O
O	O
MTase	O
activity	O
was	O
attenuated	O
in	O
wild	O
-	O
type	O
primary	O
cells	O
and	O
mice	O
but	O
was	O
pathogenic	O
in	O
the	O
absence	O
of	O
type	O
I	O
interferon	O
(	O
IFN	O
)	O
signalling	O
.	O

To	O
investigate	O
predictors	O
for	O
pandemic	O
(	O
H1N1	O
)	O
2009	O
virus	B-DISO
infection	I-DISO
among	O
hospitalized	O
patients	O
with	O
a	O
flu	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
and	O
to	O
identify	O
parameters	O
suggesting	O
a	O
severe	O
clinical	O
course	O
.	O

We	O
analyzed	O
a	O
cohort	O
of	O
all	O
patients	O
hospitalized	O
during	O
a	O
2	O
month	O
period	O
with	O
a	O
flu	B-DISO
-	O
like	O
syndrome	B-DISO
who	O
were	O
tested	O
for	O
pandemic	O
(	O
H1N1	O
)	O
2009	O
infection	B-DISO
.	O

Of	O
the	O
179	O
examined	O
hospitalized	O
patients	O
suspected	O
of	O
having	O
pandemic	O
(	O
H1N1	O
)	O
2009	O
infection	B-DISO
65	O
(	O
36	O
%)	O
were	O
found	O
positive	O
.	O

TITLE	O
:	O
Chronic	B-DISO
heart	I-DISO
disease	I-DISO
and	O
severe	O
obstetric	O
morbidity	O
among	O
hospitalisations	O
for	O
pregnancy	O
in	O
the	O
USA	O
:	O
1995	O
-	O
2006	O
.	O

The	O
contribution	O
of	O
chronic	B-DISO
heart	I-DISO
disease	I-DISO
to	O
severe	O
morbidity	O
was	O
estimated	O
using	O
adjusted	O
population	O
-	O
attributable	O
fractions	O
.	O

No	O
substantial	O
changes	O
in	O
the	O
overall	O
prevalence	O
of	O
chronic	B-DISO
heart	I-DISO
disease	I-DISO
among	O
hospitalisations	O
for	O
delivery	O
were	O
observed	O
from	O
1995	O
-	O
1997	O
to	O
2004	O
-	O
2006	O
.	O

During	O
this	O
same	O
period	O
the	O
rate	O
of	O
postpartum	O
hospitalisations	O
with	O
chronic	B-DISO
heart	I-DISO
disease	I-DISO
tripled	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Severe	O
complications	O
during	O
hospitalisations	O
for	O
delivery	O
among	O
women	O
with	O
chronic	B-DISO
heart	I-DISO
disease	I-DISO
were	O
more	O
common	O
in	O
2004	O
-	O
2006	O
than	O
in	O
1995	O
-	O
1997	O
.	O

RESULTS	O
:	O
in	O
2004	O
-	O
2006	O
,	O
about	O
1	O
.	O
4	O
%	O
of	O
delivery	O
hospitalisations	O
were	O
complicated	O
with	O
chronic	B-DISO
heart	I-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
)	O
may	O
cause	O
a	O
lethal	O
infection	B-DISO
in	O
cats	O
.	O

Antibody	O
-	O
dependent	O
enhancement	O
(	O
ADE	O
)	O
of	O
FIPV	O
infection	B-DISO
has	O
been	O
recognized	O
,	O
and	O
cellular	O
immunity	O
is	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
preventing	O
the	O
onset	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
.	O

TITLE	O
:	O
SARS	B-DISO
--	O
my	O
personal	O
battle	O
.	O

The	O
blood	O
test	O
for	O
toxoplasmosis	B-DISO
,	O
syphilis	B-DISO
,	O
varicella	B-DISO
-	O
zoster	B-DISO
,	O
rubella	B-DISO
,	O
cytomegalovirus	O
,	O
and	O
herpes	B-DISO
simplex	I-DISO
virus	O
(	O
TORCH	O
)	O
complex	O
and	O
various	O
metabolic	O
tests	O
of	O
blood	O
and	O
urine	O
specimens	O
yielded	O
unremarkable	O
results	O
.	O

Partial	O
protection	O
against	O
rotavirus	O
-	O
induced	O
diarrhea	B-DISO
was	O
achieved	O
in	O
suckling	O
BALB	O
/	O
c	O
mice	O
born	O
to	O
dams	O
immunized	O
with	O
the	O
recombinant	O
virus	O
expressing	O
VP7	O
when	O
they	O
were	O
orally	O
challenged	O
with	O
the	O
homotypic	O
rotavirus	O
strain	O
.	O

The	O
pathogenesis	B-DISO
of	O
ARDS	B-DISO
is	O
still	O
poorly	O
understood	O
,	O
and	O
therapeutic	O
options	O
remain	O
limited	O
.	O

Investigating	O
the	O
cellular	O
functions	O
of	O
cav	O
-	O
1	O
may	O
provide	O
new	O
insights	O
for	O
understanding	O
the	O
pathogenesis	B-DISO
of	O
ALI	O
and	O
provide	O
novel	O
targets	O
for	O
therapeutic	O
interventions	O
in	O
the	O
future	O
.	O

All	O
relevant	O
meta	O
-	O
analyses	O
were	O
identified	O
by	O
a	O
computerized	O
search	O
of	O
PubMed	O
using	O
combinations	O
of	O
the	O
following	O
terms	O
:	O
acute	O
lung	O
injury	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
positive	O
end	O
-	O
expiratory	O
pressure	O
,	O
mechanical	O
ventilation	O
,	O
prone	O
position	O
,	O
drotrecogin	O
,	O
activated	O
protein	O
C	O
,	O
sepsis	B-DISO
,	O
and	O
septic	O
patients	O
.	O

A	O
high	O
level	O
of	O
PEEP	O
and	O
prone	O
ventilation	O
was	O
shown	O
to	O
reduce	O
the	O
mortality	O
in	O
patients	O
with	O
severe	O
acute	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
.	O

In	O
this	O
study	O
,	O
we	O
detected	O
PHEV	O
from	O
clinically	O
ill	B-DISO
pigs	O
in	O
conventional	O
pig	O
farms	O
in	O
South	O
Korea	O
.	O

ABSTRACT	O
:	O
Fisher	B-DISO
syndrome	I-DISO
is	O
characterized	O
by	O
the	O
clinical	O
triad	O
of	O
ophthalmoplegia	B-DISO
,	O
ataxia	B-DISO
,	O
and	O
areflexia	O
.	O

Exams	O
for	O
the	O
etiologic	O
diagnosis	O
of	O
intra	B-DISO
-	I-DISO
alveolar	I-DISO
hemorrhage	I-DISO
were	O
negative	O
:	O
renal	O
function	O
,	O
24	O
-	O
hour	O
proteinuria	O
,	O
antinuclear	O
antibodies	O
,	O
antineutrophil	O
cytoplasmic	O
antibodies	O
.	O

It	O
is	O
mandatory	O
to	O
eliminate	O
the	O
other	O
causes	O
of	O
alveolar	O
hemorrhage	B-DISO
before	O
holding	O
the	O
diagnosis	O
of	O
fat	B-DISO
embolism	I-DISO
.	O

ABSTRACT	O
:	O
We	O
developed	O
a	O
two	O
-	O
layer	O
,	O
four	O
-	O
channel	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)-	O
capillary	O
electrophoresis	O
microdevice	O
that	O
integrates	O
nucleic	O
acid	O
amplification	B-DISO
,	O
sample	O
cleanup	O
and	O
concentration	O
,	O
capillary	O
electrophoretic	O
separation	B-DISO
,	O
and	O
detection	O
for	O
multiplex	O
analysis	O
of	O
four	O
human	O
respiratory	O
viral	O
pathogens	O
,	O
influenza	B-DISO
A	O
,	O
influenza	B-DISO
B	O
,	O
coronavirus	O
OC43	O
,	O
and	O
human	O
metapneumovirus	O
.	O

The	O
survival	O
of	O
the	O
SC	O
-	O
CIP	O
patients	O
after	O
LT	O
was	O
comparable	O
with	O
that	O
of	O
patients	O
transplanted	O
due	O
to	O
alcoholic	B-DISO
liver	I-DISO
cirrhosis	I-DISO
.	O

In	O
a	O
clinical	O
study	O
,	O
we	O
measured	O
plasma	O
NEP	O
activity	O
in	O
patients	O
who	O
developed	O
postoperative	O
ALI	O
/	O
ARDS	B-DISO
,	O
using	O
a	O
HPLC	O
fluorometric	O
system	O
.	O

ABSTRACT	O
:	O
The	O
increasing	O
number	O
of	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
events	O
that	O
have	O
spread	O
internationally	O
,	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
the	O
2009	O
pandemic	O
A	O
/	O
H1N1	O
,	O
highlight	O
the	O
need	O
for	O
improvements	O
in	O
global	O
outbreak	O
surveillance	O
.	O

It	O
is	O
expected	O
that	O
the	O
proliferation	B-DISO
of	O
Internet	O
-	O
based	O
reports	O
has	O
resulted	O
in	O
greater	O
communication	O
and	O
improved	O
surveillance	O
and	O
reporting	O
frameworks	O
,	O
especially	O
with	O
the	O
revision	O
of	O
the	O
World	O
Health	O
Organization	O
'	O
s	O
(	O
WHO	O
)	O
International	O
Health	O
Regulations	O
(	O
IHR	O
2005	O
),	O
which	O
went	O
into	O
force	O
in	O
2007	O
.	O

These	O
assays	O
were	O
routinely	O
used	O
for	O
clinical	O
diagnosis	O
during	O
the	O
SARS	B-DISO
outbreak	O
.	O

This	O
is	O
the	O
first	O
study	O
demonstrating	O
the	O
utility	O
of	O
clonazepam	O
in	O
the	O
treatment	O
of	O
AWS	B-DISO
syndrome	B-DISO
.	O

TITLE	O
:	O
Engaging	O
hospitals	O
to	O
meet	O
tuberculosis	B-DISO
control	O
targets	O
in	O
China	O
:	O
using	O
the	O
Internet	O
as	O
a	O
tool	O
to	O
put	O
policy	O
into	O
practice	O
.	O

Thrombolysis	O
during	O
spontaneous	O
circulation	O
only	O
for	O
myocardial	B-DISO
infarction	I-DISO
or	O
massive	O
pulmonary	B-DISO
embolism	I-DISO
;	O
during	O
on	O
-	O
going	O
cardiopulmonary	O
resuscitation	O
(	O
CPR	O
)	O
only	O
when	O
indications	O
of	O
massive	O
pulmonary	B-DISO
embolism	I-DISO
.	O

Foreign	O
body	O
airway	B-DISO
obstruction	I-DISO
with	O
insufficient	O
cough	B-DISO
:	O
alternate	O
back	O
blows	O
and	O
chest	O
compressions	O
(	O
infants	O
),	O
or	O
abdominal	O
compressions	O
(	O
children	O
>	O
1	O
year	O
).	O

ACUTE	B-DISO
CORONARY	I-DISO
SYNDROME	I-DISO
:	O
Even	O
if	O
only	O
a	O
weak	O
suspicion	O
of	O
an	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
is	O
present	O
,	O
record	O
a	O
prehospital	O
12	O
-	O
lead	O
ECG	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
first	O
3	O
cases	O
of	O
inflammatory	B-DISO
myopathy	I-DISO
with	O
abundant	O
macrophages	O
(	O
IMAM	O
)	O
to	O
be	O
found	O
in	O
an	O
Asian	O
country	O
.	O

All	O
patients	O
presenting	O
in	O
Medical	O
College	O
Hospital	O
during	O
three	O
months	O
from	O
1st	O
August	O
to	O
31st	O
October	O
who	O
tested	O
IgM	O
positive	O
or	O
borderline	O
or	O
PCR	O
positive	O
for	O
leptospirosis	B-DISO
were	O
taken	O
into	O
the	O
study	O
.	O

Applying	O
Faine	O
'	O
s	O
criteria	O
only	O
7	O
were	O
positive	O
,	O
but	O
using	O
modified	O
Faine	O
'	O
s	O
criteria	O
all	O
13	O
were	O
positive	O
for	O
leptospirosis	B-DISO
.	O

Applying	O
Faine	O
'	O
s	O
criteria	O
only	O
7	O
were	O
positive	O
,	O
but	O
using	O
modified	O
Faine	O
'	O
s	O
criteria	O
all	O
13	O
were	O
positive	O
for	O
leptospirosis	B-DISO
.	O

We	O
report	O
a	O
unique	O
case	O
of	O
a	O
60	O
-	O
year	O
-	O
old	O
Hispanic	O
woman	O
with	O
myasthenia	B-DISO
gravis	I-DISO
who	O
developed	O
takotsubo	B-DISO
cardiomyopathy	I-DISO
and	O
concomitant	O
myasthenic	B-DISO
crisis	I-DISO
that	O
appear	O
to	O
have	O
been	O
triggered	O
by	O
a	O
stressful	O
life	O
event	O
.	O

Shortly	O
after	O
cardiac	O
catheterization	O
,	O
she	O
developed	O
bilateral	O
ophthalmoparesis	B-DISO
and	O
significant	O
bulbar	O
and	O
respiratory	O
muscle	B-DISO
weakness	I-DISO
.	O

Forced	O
vital	O
capacity	O
values	O
were	O
persistently	O
less	O
than	O
1	O
L	O
.	O
The	O
patient	O
developed	O
respiratory	B-DISO
failure	I-DISO
and	O
required	O
endotracheal	O
intubation	O
.	O

TITLE	O
:	O
On	O
the	O
mechanisms	O
of	O
bananin	O
activity	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

The	O
S259	O
/	O
L	O
mutation	O
of	O
SARS	B-DISO
-	O
CoV	O
helicase	O
is	O
always	O
found	O
in	O
all	O
the	O
identified	O
bananin	O
-	O
resistant	O
variants	O
,	O
suggesting	O
a	O
primary	O
role	O
of	O
this	O
mutation	O
site	O
for	O
bananin	O
activity	O
.	O

In	O
these	O
patients	O
,	O
physicians	O
may	O
consider	O
a	O
number	O
of	O
therapies	O
(	O
eg	O
,	O
recruitment	B-DISO
maneuvers	O
,	O
prone	O
positioning	O
,	O
inhaled	O
nitric	O
oxide	O
,	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
,	O
extracorporeal	O
membrane	O
oxygenation	O
)	O
to	O
alleviate	O
hypoxemia	O
in	O
patients	O
unable	O
to	O
maintain	O
reasonable	O
oxygenation	O
while	O
being	O
supported	O
with	O
conventional	O
mechanical	O
ventilation	O
.	O

The	O
sensitivity	O
of	O
this	O
method	O
for	O
BCoV	O
and	O
group	O
A	O
BRV	B-DISO
was	O
10	O
PFU	O
/	O
100	O
µl	O
and	O
1	O
PFU	O
/	O
100	O
µl	O
,	O
respectively	O
.	O

Twenty	O
-	O
eight	O
diarrhea	B-DISO
fecal	O
samples	O
were	O
detected	O
with	O
this	O
method	O
,	O
the	O
result	O
showed	O
that	O
2	O
samples	O
were	O
identified	O
as	O
co	O
-	O
infected	O
with	O
BCoV	O
and	O
group	O
A	O
BRV	B-DISO
,	O
26	O
samples	O
were	O
group	O
A	O
BRV	B-DISO
positive	O
,	O
and	O
2	O
samples	O
were	O
negative	O
.	O

Discharge	O
conditions	O
such	O
as	O
applied	O
voltage	O
and	O
storage	O
capacitance	O
significantly	O
affected	O
the	O
inactivation	B-DISO
efficiency	O
of	O
MS2	O
phage	O
,	O
whereas	O
the	O
influence	O
of	O
water	O
quality	O
parameters	O
was	O
minor	O
.	O

The	O
shockwave	O
generated	O
upon	O
plasma	O
channel	O
formation	O
appears	O
to	O
be	O
the	O
most	O
important	O
factor	O
responsible	O
for	O
MS2	O
phage	O
inactivation	B-DISO
.	O

TITLE	O
:	O
Clinical	O
manifestations	O
of	O
influenza	B-DISO
caused	O
by	O
A	O
/	O
H1N1v	O
virus	O
among	O
children	O
and	O
teenagers	O
consulted	O
in	O
general	O
practice	O
.	O

There	O
are	O
some	O
publications	O
concerning	O
the	O
course	O
of	O
the	O
pandemic	O
influenza	B-DISO
among	O
pediatric	O
population	O
but	O
mostly	O
from	O
hospital	O
or	O
from	O
emergency	B-DISO
units	O
.	O

This	O
article	O
reviews	O
data	O
used	O
to	O
derive	O
potential	O
clinical	O
management	O
strategies	O
for	O
chemically	B-DISO
induced	I-DISO
lung	O
injury	O
.	O

To	O
this	O
end	O
,	O
we	O
implement	O
a	O
memetic	O
algorithm	O
for	O
the	O
problem	O
and	O
demonstrate	O
the	O
effectiveness	O
of	O
the	O
arithmetic	O
-	O
harmonic	O
cut	O
on	O
a	O
number	O
of	O
datasets	O
including	O
a	O
cancer	B-DISO
type	O
dataset	O
and	O
a	O
corona	O
virus	O
dataset	O
.	O

TITLE	O
:	O
Expression	O
of	O
a	O
cholera	B-DISO
toxin	O
B	O
subunit	O
-	O
neutralizing	O
epitope	O
of	O
the	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
fusion	O
gene	O
in	O
transgenic	O
lettuce	O
(	O
Lactuca	O
sativa	O
L	O
.).	O

The	O
results	O
of	O
western	O
blot	O
analysis	O
with	O
anti	O
-	O
cholera	B-DISO
toxin	O
and	O
anti	O
-	O
COE	O
antibody	O
showed	O
the	O
synthesis	O
and	O
assembly	O
of	O
CTB	O
-	O
COE	O
fusion	O
protein	O
into	O
oligomeric	O
structures	O
with	O
pentameric	O
sizing	O
.	O

In	O
view	O
of	O
the	O
relationship	O
between	O
ARDS	B-DISO
and	O
MOF	B-DISO
,	O
two	O
different	O
but	O
complementary	O
pathophysiological	O
perspectives	O
will	O
be	O
developed	O
in	O
this	O
article	O
:	O
ARDS	B-DISO
as	O
a	O
consequence	O
of	O
MOF	B-DISO
,	O
and	O
ARDS	B-DISO
as	O
the	O
cause	O
of	O
MOF	B-DISO
.	O

ABSTRACT	O
:	O
To	O
review	O
the	O
literature	O
on	O
novel	O
swine	O
origin	O
influenza	B-DISO
A	O
(	O
H1N1	O
2009	O
)	O
as	O
a	O
cause	O
of	O
respiratory	B-DISO
failure	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Chest	O
radiographs	O
and	O
pathology	B-DISO
resembled	O
ARDS	B-DISO
and	O
most	O
patients	O
were	O
treated	O
with	O
low	O
tidal	O
volume	O
ventilation	O
,	O
high	O
positive	O
end	O
expiratory	O
pressure	O
and	O
at	O
times	O
,	O
rescue	O
therapies	O
.	O

TITLE	O
:	O
[	O
Two	O
adult	O
cases	O
of	O
influenza	B-DISO
A	O
/	O
H1N1v	O
virus	O
pneumonia	B-DISO
hospitalized	O
in	O
the	O
Intensive	O
Care	O
Unit	O
of	O
the	O
Reims	O
University	O
Medical	O
Centre	O
].	O

Here	O
we	O
report	O
two	O
of	O
these	O
14	O
cases	O
who	O
were	O
suffering	B-DISO
from	O
a	O
bilateral	B-DISO
pneumonia	I-DISO
related	O
to	O
S	O
-	O
OIV	O
infection	B-DISO
and	O
who	O
were	O
hospitalized	O
in	O
the	O
Intensive	O
Care	O
Unit	O
(	O
ICU	O
)	O
of	O
the	O
Reims	O
University	O
Medical	O
Centre	O
during	O
December	O
2009	O
.	O

These	O
two	O
patients	O
were	O
male	O
with	O
at	O
least	O
one	O
known	O
risk	O
factor	O
for	O
severe	O
S	O
-	O
OIV	O
infection	B-DISO
(	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
COPD	B-DISO
)	O
and	O
morbid	B-DISO
obesity	I-DISO
,	O
respectively	O
);	O
the	O
COPD	B-DISO
patient	O
developed	O
an	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

The	O
cats	O
presented	O
with	O
signs	O
of	O
CHF	B-DISO
including	O
acute	B-DISO
collapse	I-DISO
,	O
tachypnea	B-DISO
,	O
increased	O
respiratory	O
effort	O
,	O
and	O
pulmonary	O
crackles	B-DISO
.	O

ABSTRACT	O
:	O
We	O
evaluated	O
the	O
clinical	O
data	O
in	O
patients	O
who	O
required	O
mechanical	O
ventilation	O
for	O
severe	O
community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
CAP	B-DISO
)	O
and	O
compared	O
survival	O
with	O
and	O
without	O
the	O
use	O
of	O
systemic	O
corticosteroids	O
.	O

TITLE	O
:	O
Transient	O
diabetes	B-DISO
mellitus	I-DISO
in	O
a	O
neonatal	O
Thoroughbred	O
foal	O
.	O

This	O
is	O
a	O
prospective	O
study	O
of	O
all	O
children	O
with	O
GBS	B-DISO
(	O
no	O
=	O
50	O
)	O
admitted	O
to	O
pediatric	O
Cairo	O
University	O
Hospital	O
between	O
January	O
2006	O
and	O
June	O
2007	O
(	O
70	O
.	O
42	O
%	O
of	O
all	O
acute	O
flaccid	B-DISO
paralysis	I-DISO
patients	O
during	O
this	O
period	O
).	O

Nasopharyngeal	O
aspiration	B-DISO
(	O
NPA	O
)	O
samples	O
were	O
collected	O
from	O
301	O
children	O
with	O
ARTI	O
at	O
the	O
First	O
Hospital	O
of	O
Lanzhou	O
University	O
,	O
Gansu	O
Province	O
,	O
China	O
,	O
between	O
November	O
2007	O
and	O
October	O
2008	O
.	O

The	O
phylogenetic	O
analysis	O
revealed	O
that	O
the	O
HCoV	O
-	O
HKU1	O
strain	O
pol	O
gene	O
clustered	O
with	O
the	O
HCoV	O
-	O
HKU1	O
strain	O
N15	O
genotype	O
B	O
(	O
no	O
.	O
DQ415911	O
);	O
11	O
of	O
15	O
HCoV	O
-	O
HKU1	O
positive	O
sample	O
tested	O
were	O
mixed	O
-	O
infection	B-DISO
.	O

Children	O
with	O
HCoV	O
-	O
HKU1	O
infection	B-DISO
varied	O
in	O
age	O
from	O
15	O
day	O
to	O
12	O
-	O
years	O
(	O
median	O
age	O
,	O
10	O
months	O
).	O

The	O
symptoms	O
and	O
clinical	O
diagnoses	O
of	O
those	O
infected	O
with	O
HCoV	O
-	O
HKU1	O
had	O
no	O
specificity	O
as	O
compared	O
with	O
patients	O
with	O
other	O
common	O
respiratory	O
viruses	O
infection	B-DISO
.	O

Three	O
chemically	O
synthesized	O
peptides	O
recognizing	O
the	O
pAPN	O
showed	O
effective	O
inhibition	O
ability	O
to	O
TGEV	O
infection	B-DISO
in	O
vitro	O
.	O

Compared	O
to	O
the	O
90	O
children	O
admitted	O
during	O
the	O
2008	O
-	O
09	O
season	O
,	O
children	O
admitted	O
with	O
2009	O
H1N1	B-DISO
influenza	I-DISO
were	O
significantly	O
older	O
,	O
had	O
a	O
shorter	O
length	O
of	O
hospitalization	O
,	O
more	O
use	O
of	O
antivirals	O
,	O
and	O
a	O
higher	O
incidence	O
of	O
ARDS	B-DISO
.	O

Indeed	O
,	O
depletion	O
of	O
a	O
small	O
subset	O
of	O
the	O
affected	O
proteins	O
by	O
using	O
small	O
interfering	O
RNAs	O
identified	O
several	O
host	O
factors	O
involved	O
in	O
coronavirus	B-DISO
infection	I-DISO
.	O

Therefore	O
,	O
the	O
factors	O
associated	O
with	O
ASC	O
migration	O
,	O
differentiation	O
,	O
and	O
survival	O
are	O
all	O
induced	O
during	O
acute	O
viral	O
encephalomyelitis	B-DISO
,	O
prior	O
to	O
ASC	O
accumulation	O
in	O
the	O
CNS	O
.	O

TITLE	O
:	O
Interferon	O
-	O
gamma	O
negatively	O
regulates	O
Th17	O
-	O
mediated	O
immunopathology	B-DISO
during	O
mouse	B-DISO
hepatitis	I-DISO
virus	B-DISO
infection	I-DISO
.	O

Using	O
the	O
same	O
filters	O
as	O
normal	O
surgical	O
masks	O
,	O
facemasks	O
A	O
and	O
B	O
provided	O
more	O
effective	O
respiratory	O
protection	O
against	O
communicable	O
respiratory	B-DISO
infections	I-DISO
such	O
as	O
influenza	B-DISO
and	O
SARS	B-DISO
by	O
the	O
location	O
of	O
the	O
breathing	O
pathway	O
to	O
the	O
back	O
of	O
the	O
facemasks	O
.	O

A	O
total	O
of	O
34	O
patients	O
with	O
ARDS	B-DISO
underwent	O
TEE	O
in	O
PP	O
.	O

TEE	O
can	O
be	O
performed	O
safely	O
and	O
efficiently	O
in	O
severe	O
ARDS	B-DISO
patients	O
in	O
PP	O
.	O

One	O
example	O
is	O
SARS	B-DISO
,	O
which	O
caused	O
a	O
worldwide	O
health	O
threat	O
in	O
2003	O
.	O

Furthermore	O
,	O
the	O
mature	O
E290R	O
mutant	B-DISO
can	O
resume	O
N	O
-	O
terminal	O
autocleavage	O
activity	O
when	O
mixed	O
with	O
the	O
""""	O
immature	O
""""	O
C145A	O
/	O
E290R	O
double	O
mutant	B-DISO
whereas	O
its	O
trans	O
-	O
cleavage	O
activity	O
remains	O
absent	O
.	O

China	O
'	O
s	O
surveillance	O
system	O
for	O
endemic	O
infectious	B-DISO
diseases	I-DISO
has	O
improved	O
greatly	O
since	O
2003	O
,	O
but	O
the	O
country	O
'	O
s	O
ability	O
to	O
conduct	O
surveillance	O
for	O
laboratory	O
-	O
confirmed	O
infections	B-DISO
remains	O
underdeveloped	O
.	O

This	O
is	O
dangerous	O
for	O
China	O
,	O
the	O
world	O
'	O
s	O
most	O
populous	O
country	O
,	O
which	O
has	O
been	O
the	O
focus	O
of	O
global	O
attention	O
since	O
outbreaks	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
avian	B-DISO
influenza	I-DISO
.	O

We	O
describe	O
China	O
'	O
s	O
public	O
health	O
advances	O
since	O
the	O
2003	O
SARS	B-DISO
outbreak	O
and	O
conclude	O
that	O
China	O
must	O
now	O
invest	O
far	O
more	O
in	O
pathogen	O
-	O
based	O
surveillance	O
.	O

We	O
examined	O
whether	O
sRAGE	O
level	O
was	O
independently	O
associated	O
with	O
death	O
in	O
20	O
ARDS	B-DISO
patients	O
with	O
severe	O
infection	B-DISO
.	O

Compared	O
with	O
age	O
-	O
and	O
sex	O
-	O
matched	O
control	O
subjects	O
,	O
blood	O
pressure	O
levels	O
were	O
lower	O
and	O
KL	O
-	O
6	O
,	O
high	O
mobility	O
group	O
box	O
1	O
(	O
HMGB1	O
),	O
interleukin	O
-	O
6	O
and	O
sRAGE	O
levels	O
were	O
higher	O
in	O
ARDS	B-DISO
patients	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
was	O
isolated	O
from	O
trachea	B-DISO
and	O
kidney	O
tissues	O
of	O
eight	O
broiler	O
farms	O
in	O
Kurdistan	O
region	O
of	O
North	O
Iraq	O
from	O
2008	O
to	O
2010	O
.	O

Highly	O
significant	O
decreases	O
in	O
haematocrit	O
and	O
albumin	O
levels	O
and	O
an	O
increase	O
in	O
total	O
bilirubin	O
level	O
were	O
noted	O
in	O
both	O
effusive	O
and	O
non	O
-	O
effusive	O
FIP	B-DISO
,	O
at	O
first	O
presentation	O
and	O
before	O
death	O
.	O

The	O
plasma	O
level	O
of	O
sRAGE	O
was	O
correlated	O
with	O
clinical	O
and	O
radiographic	O
severity	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
and	O
decreased	O
over	O
time	O
,	O
suggesting	O
resolution	O
of	O
the	O
injury	O
to	O
the	O
alveolar	O
epithelium	O
.	O

This	O
study	O
aimed	O
to	O
develop	O
a	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
detection	O
assay	O
specific	O
for	O
SARS	B-DISO
-	O
CoV	O
,	O
taking	O
into	O
account	O
its	O
intrinsic	O
polymorphic	O
nature	O
due	O
to	O
genetic	O
drift	O
and	O
recombination	O
and	O
the	O
possibility	O
of	O
continuous	O
and	O
multiple	O
introductions	O
of	O
genetically	O
non	O
-	O
identical	O
strains	O
into	O
the	O
human	O
population	O
,	O
by	O
using	O
mismatch	O
-	O
tolerant	O
molecular	O
beacons	O
designed	O
to	O
specifically	O
detect	O
the	O
SARS	B-DISO
-	O
CoV	O
S	O
,	O
E	O
,	O
M	O
and	O
N	O
genes	O
.	O

Hantavirus	B-DISO
pulmonary	I-DISO
syndrome	I-DISO
caused	O
by	O
European	O
hantavirus	O
.	O

However	O
,	O
increasing	O
evidence	O
suggests	O
that	O
this	O
dichotomy	O
is	O
no	O
longer	O
fruitful	O
when	O
recognising	O
human	O
hantavirus	O
disease	O
and	O
understanding	O
the	O
pathogenesis	B-DISO
.	O

Consequently	O
,	O
hantavirus	B-DISO
infection	I-DISO
should	O
be	O
considered	O
as	O
a	O
cause	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
in	O
all	O
endemic	O
areas	O
worldwide	O
.	O

A	O
previously	O
healthy	O
18	O
-	O
year	O
-	O
old	O
woman	O
experienced	O
malaise	B-DISO
,	O
diarrhea	B-DISO
,	O
and	O
fever	O
for	O
several	O
days	O
prior	O
to	O
a	O
sudden	O
collapse	B-DISO
at	O
home	O
.	O

ABSTRACT	O
:	O
We	O
postulate	O
that	O
most	O
patients	O
with	O
chronic	B-DISO
cough	I-DISO
have	O
a	O
single	O
discrete	O
clinical	O
entity	O
:	O
cough	B-DISO
hypersensitivity	B-DISO
syndrome	I-DISO
.	O

To	O
examine	O
if	O
nasal	O
LTB4	O
can	O
produce	O
neutrophil	O
activity	O
and	O
to	O
explore	O
whether	O
or	O
not	O
LTB4	O
can	O
condition	B-DISO
neutrophils	O
to	O
exert	O
virucidal	O
effects	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Common	O
cold	B-DISO
symptoms	I-DISO
and	O
incidence	O
of	O
seroconversion	O
were	O
unaffected	O
.	O

Trypsin	O
treatment	O
of	O
receptor	O
-	O
associated	O
SARS	B-DISO
-	O
CoV	O
pseudovirions	O
,	O
which	O
bypasses	O
their	O
dependence	B-DISO
on	I-DISO
lysosomal	O
cathepsin	O
L	O
,	O
also	O
bypassed	O
IFITM	O
-	O
mediated	O
restriction	O
.	O

Germicides	O
must	O
be	O
chosen	O
carefully	O
to	O
ensure	O
they	O
are	O
effective	O
against	O
viruses	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

Eighty	O
-	O
three	O
children	O
with	O
confirmed	O
infection	B-DISO
attributable	O
to	O
pandemic	O
influenza	B-DISO
detected	O
by	O
reverse	O
-	O
transcriptase	O
polymerase	O
chain	O
reaction	O
assay	O
between	O
November	O
1	O
and	O
December	O
31	O
,	O
2009	O
who	O
were	O
admitted	O
to	O
critical	O
care	O
units	O
.	O

The	O
cause	O
of	O
death	O
was	O
primary	O
pandemic	O
influenza	B-DISO
infection	B-DISO
in	O
16	O
(	O
64	O
%),	O
nosocomial	B-DISO
infection	I-DISO
in	O
four	O
(	O
16	O
%),	O
and	O
primary	O
disease	B-DISO
progression	I-DISO
in	O
five	O
(	O
20	O
%)	O
patients	O
.	O

The	O
odds	O
ratio	O
for	O
respiratory	B-DISO
failure	I-DISO
was	O
14	O
.	O
7	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
85	O
-	O
111	O
.	O
11	O
),	O
and	O
odds	O
ratio	O
for	O
mechanical	O
ventilation	O
was	O
27	O
.	O
7	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
.	O
003	O
-	O
200	O
).	O

The	O
regional	O
challenges	O
in	O
control	O
of	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
are	O
formidable	O
and	O
range	O
from	O
influencing	O
the	O
factors	O
that	O
drive	O
disease	O
emergence	O
,	O
to	O
making	O
surveillance	O
systems	O
fit	B-DISO
for	O
purpose	O
,	O
and	O
ensuring	O
that	O
regional	O
governance	O
mechanisms	O
work	O
effectively	O
to	O
improve	O
control	O
interventions	O
.	O

ABSTRACT	O
:	O
Lung	O
-	O
protective	O
ventilation	O
with	O
a	O
low	O
tidal	O
volume	O
,	O
plateau	O
pressure	O
<	O
30	O
cm	O
H	O
(	O
2	O
)	O
O	O
.	O
oxygen	O
saturation	O
>	O
90	O
%	O
and	O
permissive	O
hypercapnia	B-DISO
results	O
in	O
reduction	O
of	O
the	O
mortality	O
rate	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Patients	O
are	O
sometimes	O
admitted	O
to	O
ICUs	O
for	O
hypercapnic	B-DISO
respiratory	I-DISO
failure	I-DISO
or	O
cor	B-DISO
pulmonale	I-DISO
,	O
but	O
more	O
often	O
,	O
they	O
are	O
admitted	O
for	O
pneumonia	B-DISO
,	O
excessive	B-DISO
daytime	I-DISO
sleepiness	I-DISO
,	O
heart	B-DISO
failure	I-DISO
,	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
COPD	B-DISO
),	O
asthma	B-DISO
attacks	I-DISO
or	O
pulmonary	B-DISO
embolism	I-DISO
,	O
and	O
hypercapnic	B-DISO
respiratory	I-DISO
failure	I-DISO
is	O
coincidentally	O
noticed	O
during	O
this	O
period	O
.	O

For	O
the	O
obese	B-DISO
patients	O
,	O
the	O
reason	O
for	O
ICU	O
admission	O
was	O
more	O
frequently	O
pulmonary	B-DISO
edema	I-DISO
and	O
less	O
frequently	O
pulmonary	B-DISO
infections	I-DISO
,	O
which	O
was	O
significantly	O
different	O
(	O
P	O
=	O
0	O
.	O
003	O
and	O
0	O
.	O
043	O
,	O
respectively	O
)	O
than	O
the	O
rates	O
for	O
the	O
non	O
-	O
obese	B-DISO
patients	O
.	O

These	O
results	O
suggest	O
that	O
improvement	O
in	O
hypercapnia	B-DISO
in	O
obese	B-DISO
patients	O
may	O
require	O
higher	O
PEEP	O
levels	O
and	O
longer	O
times	O
than	O
that	O
of	O
non	O
-	O
obese	B-DISO
patients	O
during	O
acute	O
hypercapnic	B-DISO
respiratory	I-DISO
failure	I-DISO
attack	O
.	O

With	O
anticonvulsant	O
therapy	O
and	O
antibiotics	O
there	O
was	O
complete	O
resolution	O
of	O
neurological	B-DISO
symptoms	I-DISO
.	O

TITLE	O
:	O
The	O
multicenter	O
Italian	O
birth	O
cohort	O
study	O
on	O
incidence	O
and	O
determinants	O
of	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
hospitalization	O
in	O
infants	O
at	O
33	O
weeks	O
GA	O
or	O
more	O
:	O
preliminary	O
results	O
.	O

TITLE	O
:	O
Induction	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
rats	O
by	O
lipopolysaccharide	O
and	O
its	O
effect	O
on	O
oxidative	B-DISO
stress	I-DISO
and	O
antioxidant	O
status	O
in	O
lung	O
.	O

Bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
neutrophil	O
content	O
and	O
protein	O
concentration	O
in	O
LPS	B-DISO
-	O
treated	O
rats	O
were	O
significantly	O
elevated	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
.	O

Genotyping	O
was	O
performed	O
on	O
seven	O
linkage	O
disequilibrium	B-DISO
-	O
tag	B-DISO
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
surfactant	O
protein	O
B	O
gene	O
.	O

There	O
was	O
a	O
higher	O
increase	O
in	O
the	O
percentage	O
of	O
HIV	B-DISO
-	O
uninfected	O
subjects	O
with	O
protective	O
A	O
/	O
H1N1	O
antibodies	O
(	O
96	O
.	O
6	O
%)	O
compared	O
to	O
HIV	B-DISO
-	O
infected	O
vaccinees	O
(	O
67	O
.	O
6	O
%)	O
at	O
T1	O
(	O
p	O
=	O
0	O
.	O
004	O
).	O

The	O
results	O
showed	O
that	O
the	O
optimal	O
reaction	O
condition	B-DISO
for	O
RT	O
-	O
LAMP	O
amplifying	O
PEDV	O
N	O
gene	O
was	O
achieved	O
at	O
63	O
°	O
C	O
for	O
50	O
min	O
.	O

TITLE	O
:	O
[	O
The	O
past	O
decade	O
'	O
s	O
infectious	B-DISO
diseases	I-DISO
].	O

There	O
will	O
also	O
be	O
unknown	O
challenges	O
:	O
We	O
have	O
not	O
faced	O
the	O
last	O
HIV	B-DISO
,	O
ebola	O
,	O
SARS	B-DISO
or	O
avian	O
or	O
swine	B-DISO
flu	I-DISO
epidemic	O
.	O

The	O
most	O
obvious	O
example	O
is	O
anti	O
-	O
AIDS	O
research	O
,	O
where	O
HIV	B-DISO
protease	O
and	O
reverse	O
transcriptase	O
have	O
triggered	O
enormous	O
efforts	O
in	O
developing	O
and	O
improving	O
computational	O
methods	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
prognostic	O
value	O
of	O
corpus	O
callosum	O
lesions	O
(	O
CCL	B-DISO
)	O
and	O
brain	O
stem	O
lesions	O
(	O
BSL	O
)	O
in	O
diffuse	O
axonal	O
injury	O
(	O
DAI	O
)	O
patients	O
.	O

Time	O
to	O
recovery	O
of	O
consciousness	O
is	O
predicted	O
by	O
age	O
,	O
bilateral	O
absence	O
of	O
light	O
reflexes	O
,	O
multiplicity	O
of	O
CCL	B-DISO
on	O
MRI	O
,	O
and	O
GCS	O
on	O
admission	O
.	O

ABSTRACT	O
:	O
To	O
detect	O
the	O
presence	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
or	O
avian	O
coronavirus	O
,	O
a	O
nested	O
reverse	O
transcriptase	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
method	O
was	O
developed	O
with	O
the	O
aim	O
of	O
amplifying	O
a	O
fragment	O
of	O
530	O
bases	O
,	O
comprising	O
the	O
gene	O
coding	O
S1	O
protein	O
.	O

Among	O
the	O
factors	O
that	O
may	O
influence	O
the	O
efficiency	O
of	O
ILTV	O
live	O
attenuated	O
vaccines	O
is	O
a	O
possible	O
interference	O
of	O
Newcastle	B-DISO
Disease	I-DISO
virus	O
(	O
NDV	O
)	O
and	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
vaccines	O
with	O
the	O
protection	O
induced	O
by	O
ILTV	O
vaccines	O
.	O

TITLE	O
:	O
[	O
New	O
challenges	O
in	O
community	O
-	O
acquired	O
pneumonia	B-DISO
].	O

The	O
most	O
widely	O
used	O
scales	O
are	O
the	O
PSI	O
/	O
Fine	O
and	O
CURB	B-DISO
-	O
65	O
scales	O
,	O
which	O
have	O
been	O
widely	O
validated	O
and	O
are	O
easy	O
to	O
calculate	O
in	O
clinical	O
practice	O
.	O

Etiologic	O
diagnosis	O
of	O
pneumonia	B-DISO
continues	O
to	O
pose	O
a	O
challenge	O
to	O
clinicians	O
.	O

ABSTRACT	O
:	O
The	O
traffic	O
control	O
bundle	O
consists	O
of	O
procedures	O
designed	O
to	O
help	O
prevent	O
epidemic	O
nosocomial	B-DISO
infection	I-DISO
.	O

We	O
retrospectively	O
studied	O
the	O
serial	O
infection	B-DISO
control	O
measures	O
to	O
determine	O
factors	O
most	O
effective	O
in	O
preventing	O
nosocomial	B-DISO
infections	I-DISO
of	O
healthcare	O
workers	O
(	O
HCWs	O
)	O
during	O
the	O
2003	O
Taiwanese	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
epidemic	O
.	O

Fever	O
screening	O
stations	O
,	O
triage	O
of	O
fever	O
patients	O
,	O
separating	O
SARS	B-DISO
patients	O
from	O
other	O
patients	O
,	O
separation	B-DISO
of	O
entrances	O
and	O
passageways	O
between	O
patients	O
and	O
HCWs	O
,	O
and	O
increasing	O
hand	O
-	O
washing	O
facilities	O
all	O
demonstrated	O
a	O
protective	O
effect	O
for	O
HCWs	O
(	O
univariate	O
analysis	O
;	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
differences	O
remained	O
significant	O
when	O
adjusting	O
for	O
pneumonia	B-DISO
severity	O
index	O
,	O
hospital	O
of	O
origin	O
,	O
and	O
intensive	O
care	O
unit	O
admission	O
(	O
p	O
=	O
.	O
0012	O
,	O
odds	O
ratio	O
=	O
2	O
.	O
83	O
,	O
95	O
%	O
confidence	O
interval	O
1	O
.	O
51	O
-	O
5	O
.	O
32	O
).	O

Our	O
results	O
do	O
not	O
support	O
a	O
role	O
of	O
FCGR2A	O
-	O
H131R	O
polymorphism	O
in	O
susceptibility	O
to	O
CAP	B-DISO
or	O
PCAP	B-DISO
.	O

TITLE	O
:	O
Identification	O
and	O
characterization	O
of	O
three	O
novel	O
small	O
interference	O
RNAs	O
that	O
effectively	O
down	O
-	O
regulate	O
the	O
isolated	O
nucleocapsid	O
gene	O
expression	O
of	O
SARS	B-DISO
coronavirus	O
.	O

Furthermore	O
,	O
we	O
provide	O
evidence	O
to	O
show	O
that	O
N	O
gene	O
can	O
effectively	O
up	O
-	O
regulate	O
M	O
gene	O
mediated	O
interferon	O
b	O
(	O
IFNb	O
)	O
production	O
,	O
while	O
blocking	B-DISO
N	O
gene	O
expression	O
by	O
specific	O
siRNA	O
significantly	O
reduces	O
IFNb	O
gene	O
expression	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
severe	O
respiratory	O
illness	O
caused	O
by	O
a	O
novel	O
virus	O
,	O
the	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

Because	O
African	O
green	O
monkeys	O
developed	O
more	O
severe	O
ALI	O
than	O
macaques	O
,	O
with	O
hyaline	B-DISO
membrane	I-DISO
formation	O
,	O
some	O
of	O
these	O
differentially	O
expressed	O
proinflammatory	O
genes	O
may	O
be	O
critically	O
involved	O
in	O
development	O
of	O
the	O
observed	O
pathological	O
changes	O
.	O

In	O
contrast	O
,	O
it	O
is	O
largely	O
unknown	O
whether	O
host	O
cell	O
proteases	O
located	O
in	O
the	O
secretory	O
pathway	O
of	O
infected	O
cells	O
and	O
/	O
or	O
on	O
the	O
surface	O
of	O
target	O
cells	O
can	O
cleave	O
SARS	B-DISO
S	O
.	O
We	O
along	O
with	O
others	O
could	O
previously	O
show	O
that	O
the	O
type	O
II	O
transmembrane	O
protease	O
TMPRSS2	O
activates	O
the	O
influenza	B-DISO
virus	O
hemagglutinin	O
and	O
the	O
human	O
metapneumovirus	O
F	O
protein	O
by	O
cleavage	O
.	O

Here	O
,	O
we	O
assessed	O
whether	O
SARS	B-DISO
S	O
is	O
proteolytically	O
processed	O
by	O
TMPRSS2	O
.	O

In	O
summary	O
,	O
we	O
show	O
that	O
TMPRSS2	O
might	O
promote	O
viral	O
spread	O
and	O
pathogenesis	B-DISO
by	O
diminishing	O
viral	O
recognition	O
by	O
neutralizing	O
antibodies	O
and	O
by	O
activating	O
SARS	B-DISO
S	O
for	O
cell	O
-	O
cell	O
and	O
virus	O
-	O
cell	O
fusion	O
.	O

ABSTRACT	O
:	O
While	O
endemic	O
malaria	B-DISO
has	O
been	O
eliminated	O
in	O
the	O
United	O
States	O
,	O
approximately	O
1200	O
mostly	O
imported	O
cases	O
are	O
reported	O
annually	O
in	O
the	O
country	O
,	O
with	O
fewer	O
than	O
20	O
recorded	O
deaths	O
.	O

Plasmodium	O
falciparum	O
can	O
lead	O
to	O
a	O
particularly	O
severe	O
type	O
of	O
malaria	B-DISO
complicated	O
by	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
and	O
physicians	O
must	O
be	O
alert	O
to	O
the	O
possibility	O
of	O
this	O
diagnosis	O
in	O
immigrants	O
and	O
returning	O
travelers	O
.	O

We	O
report	O
a	O
case	O
of	O
successfully	O
treated	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
complicating	O
imported	O
P	O
falciparum	B-DISO
malaria	I-DISO
at	O
a	O
large	O
teaching	O
hospital	O
in	O
Washington	O
,	O
DC	O
.	O

A	O
vaccination	O
-	O
challenge	O
test	O
that	O
was	O
performed	O
using	O
the	O
three	O
QX	O
-	O
like	O
strains	O
showed	O
that	O
the	O
commercially	O
available	O
H120	O
vaccine	O
did	O
not	O
provide	O
sufficient	O
protection	O
against	O
challenge	O
with	O
the	O
QX	O
-	O
like	O
isolates	O
,	O
as	O
demonstrated	O
by	O
comparison	O
of	O
the	O
clinical	O
signs	O
,	O
pathological	O
lesions	O
and	O
virus	O
recovery	O
from	O
the	O
trachea	B-DISO
and	O
kidney	O
of	O
unvaccinated	O
-	O
challenged	O
and	O
vaccinated	O
-	O
challenged	O
birds	O
.	O

This	O
case	O
demonstrates	O
the	O
complex	O
decision	O
making	O
process	O
regarding	O
initiation	O
of	O
ECMO	O
in	O
patients	O
with	O
severe	O
immunodeficiency	B-DISO
.	O

This	O
makes	O
the	O
attribution	O
of	O
acquired	O
respiratory	O
muscle	B-DISO
weakness	I-DISO
and	O
ventilator	O
-	O
dependence	B-DISO
to	O
either	O
ventilator	O
-	O
induced	O
diaphragmatic	O
dysfunction	O
or	O
loaded	O
breathing	O
extremely	O
difficult	O
.	O

TITLE	O
:	O
Development	O
of	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
to	O
feline	O
interferon	O
(	O
fIFN	O
)-	O
γ	O
as	O
tools	O
to	O
evaluate	O
cellular	O
immune	O
responses	O
to	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
).	O

These	O
results	O
suggest	O
that	O
cellular	O
immunity	O
plays	O
an	O
important	O
role	O
in	O
preventing	O
the	O
development	O
of	O
FIP	B-DISO
.	O

In	O
conclusion	O
,	O
these	O
new	O
assays	O
will	O
greatly	O
improve	O
the	O
use	O
of	O
the	O
hamster	O
as	O
an	O
important	O
small	O
animal	O
model	O
in	O
infectious	B-DISO
disease	I-DISO
research	O
.	O

Subjects	O
enrolled	O
in	O
six	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
Clinical	O
Trials	O
Network	O
trials	O
occurring	O
between	O
1996	O
and	O
2005	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
whether	O
prehospital	O
statin	O
use	O
is	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
sepsis	B-DISO
,	O
acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
and	O
mortality	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

Both	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
(	O
DIC	B-DISO
)	O
and	O
CAPS	O
share	O
similar	O
characteristics	O
encompassing	O
thrombotic	B-DISO
microangiopathy	I-DISO
,	O
bleeding	B-DISO
,	O
thromboembolism	B-DISO
,	O
and	O
multiple	O
organ	O
dysfunction	O
.	O

The	O
lupus	B-DISO
flare	B-DISO
initiated	O
a	O
pathological	O
immunological	O
cascade	O
and	O
resulted	O
in	O
the	O
CAPS	O
and	O
the	O
vascular	O
damage	O
.	O

To	O
establish	O
the	O
reciprocal	O
binding	O
of	O
CCoV	O
on	O
plasma	O
membrane	O
,	O
A72	O
cells	O
on	O
a	O
permeable	O
support	O
were	O
preincubated	O
with	O
a	O
mAb	O
specific	O
for	O
CCoV	O
.	O
Infection	B-DISO
from	O
the	O
apical	O
side	O
was	O
blocked	O
by	O
mAb	O
applied	O
to	O
that	O
side	O
;	O
in	O
contrast	O
,	O
such	O
treatment	O
on	O
the	O
basolateral	O
side	O
had	O
no	O
effect	O
on	O
the	O
infectious	B-DISO
process	I-DISO
.	O

TITLE	O
:	O
Community	O
under	O
stress	O
:	O
trust	O
,	O
reciprocity	O
,	O
and	O
community	O
collective	O
efficacy	O
during	O
SARS	B-DISO
outbreak	O
.	O

Specifically	O
,	O
we	O
focus	O
on	O
how	O
the	O
collective	O
efficacy	O
of	O
a	O
community	O
,	O
measured	O
by	O
trust	O
and	O
reciprocal	O
relations	O
,	O
is	O
related	O
to	O
collective	O
action	O
in	O
places	O
where	O
SARS	B-DISO
occurred	O
and	O
those	O
where	O
SARS	B-DISO
did	O
not	O
occur	O
.	O

The	O
study	O
is	O
based	O
on	O
a	O
unique	O
data	O
set	O
,	O
the	O
2003	O
Taiwan	O
Social	O
Image	O
Survey	O
,	O
collected	O
during	O
the	O
outbreak	O
of	O
SARS	B-DISO
in	O
Taiwan	O
.	O

Although	O
all	O
RT	O
inhibitors	O
approved	O
for	O
therapy	O
target	O
DNA	O
polymerase	O
activity	O
,	O
the	O
search	O
for	O
new	O
RT	O
inhibitors	O
that	O
target	O
the	O
RNase	O
H	O
function	O
and	O
are	O
possibly	O
active	O
on	O
RTs	B-DISO
resistant	O
to	O
the	O
known	O
non	O
-	O
nucleoside	O
inhibitors	O
(	O
NNRTI	O
)	O
is	O
a	O
viable	O
approach	O
for	O
anti	O
-	O
HIV	B-DISO
drug	O
development	O
.	O

NIV	O
should	O
not	O
be	O
considered	O
as	O
an	O
alternative	O
to	O
ETI	O
in	O
severe	O
communicable	O
airborne	O
infections	B-DISO
likely	O
to	O
progress	O
to	O
ARDS	B-DISO
.	O

NIV	O
is	O
being	O
used	O
increasingly	O
as	O
an	O
alternative	O
to	O
ETI	O
in	O
end	O
-	O
stage	O
symptomatic	O
patients	O
,	O
especially	O
to	O
relieve	O
dyspnoea	B-DISO
.	O

TITLE	O
:	O
Comparative	O
anti	O
-	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
activity	O
of	O
(-)-	O
pinene	O
:	O
effect	O
on	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
.	O

Results	O
presented	O
here	O
may	O
suggest	O
that	O
(-)-	O
α	O
-	O
pinene	O
and	O
(-)-	O
β	O
-	O
pinene	O
possess	B-DISO
anti	O
-	O
IBV	O
properties	O
,	O
and	O
therefore	O
are	O
a	O
potential	O
source	O
of	O
anti	O
-	O
IBV	O
ingredients	O
for	O
the	O
pharmaceutical	O
industry	O
.	O

Here	O
we	O
demonstrate	O
that	O
emodin	O
can	O
inhibit	O
the	O
3a	O
ion	O
channel	O
of	O
coronavirus	O
SARS	B-DISO
-	O
CoV	O
and	O
HCoV	O
-	O
OC43	O
as	O
well	O
as	O
virus	O
release	O
from	O
HCoV	O
-	O
OC43	O
with	O
a	O
K1	O
/	O
2	O
value	O
of	O
about	O
20	O
μM	O
.	O
We	O
suggest	O
that	O
viral	O
ion	O
channels	O
,	O
in	O
general	O
,	O
may	O
be	O
a	O
good	O
target	O
for	O
the	O
development	O
of	O
antiviral	O
agents	O
.	O

TITLE	O
:	O
Cutting	O
edge	O
:	O
attrition	B-DISO
of	O
Plasmodium	O
-	O
specific	O
memory	O
CD8	O
T	O
cells	O
results	O
in	O
decreased	O
protection	O
that	O
is	O
rescued	O
by	O
booster	O
immunization	O
.	O

Attrition	B-DISO
was	O
associated	O
with	O
preferential	O
loss	O
of	O
effector	O
memory	O
CD8	O
T	O
cells	O
and	O
reduced	O
immunity	O
to	O
P	O
.	O
berghei	O
sporozoite	O
challenge	O
.	O

PubMed	O
was	O
searched	O
using	O
the	O
terms	O
toxic	B-DISO
epidermal	I-DISO
necrolysis	I-DISO
,	O
Stevens	B-DISO
-	I-DISO
Johnson	I-DISO
syndrome	I-DISO
,	O
drug	O
toxicity	O
,	O
drug	O
interaction	O
,	O
and	O
skin	B-DISO
diseases	I-DISO
.	O

TITLE	O
:	O
Routine	O
prone	O
positioning	O
in	O
patients	O
with	O
severe	O
ARDS	B-DISO
:	O
feasibility	O
and	O
impact	O
on	O
prognosis	O
.	O

We	O
report	O
here	O
the	O
characteristics	O
and	O
prognosis	O
of	O
this	O
subgroup	O
of	O
patients	O
with	O
severe	O
lung	O
injury	O
to	O
illustrate	O
the	O
feasibility	O
,	O
role	O
,	O
and	O
impact	O
of	O
routine	O
PP	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

These	O
systematic	O
findings	O
provide	O
valuable	O
information	O
on	O
natural	O
humoral	O
memory	O
responses	O
,	O
and	O
the	O
data	O
will	O
be	O
helpful	O
for	O
understanding	O
the	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
coronavirus	B-DISO
infection	I-DISO
and	O
for	O
the	O
rational	O
design	O
of	O
vaccines	O
.	O

In	O
this	O
article	O
,	O
the	O
current	O
knowledge	O
of	O
human	O
coronavirus	O
HCoV	O
-	O
NL63	O
,	O
with	O
special	O
reference	O
to	O
the	O
clinical	O
features	O
,	O
prevalence	O
and	O
seasonal	O
incidence	O
,	O
and	O
coinfection	B-DISO
with	O
other	O
respiratory	O
viruses	O
,	O
will	O
be	O
discussed	O
.	O

ABSTRACT	O
:	O
Virus	O
-	O
associated	O
hemophagocytic	B-DISO
syndrome	I-DISO
(	O
VAHS	O
)	O
is	O
a	O
severe	O
complication	B-DISO
of	O
various	O
viral	B-DISO
infections	I-DISO
often	O
resulting	O
in	O
multiorgan	B-DISO
failure	I-DISO
and	O
death	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
describe	O
baseline	O
characteristics	O
,	O
development	O
of	O
VAHS	O
,	O
related	O
treatments	O
and	O
associated	O
mortality	O
rate	O
of	O
consecutive	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
confirmed	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
infection	B-DISO
and	O
respiratory	B-DISO
failure	I-DISO
.	O

After	O
transfection	O
of	O
PK	O
-	O
15	O
cells	O
with	O
each	O
of	O
the	O
siRNAs	O
followed	O
by	O
infection	B-DISO
with	O
PHE	O
-	O
CoV	O
,	O
the	O
cytopathic	B-DISO
effect	I-DISO
(	O
CPE	O
)	O
was	O
examined	O
by	O
phase	O
-	O
contrast	O
microscope	O
,	O
and	O
viral	O
proliferation	B-DISO
within	O
cells	O
was	O
examined	O
by	O
indirect	O
immunofluorescence	O
microscopy	O
,	O
hemagglutination	O
(	O
HA	O
)	O
test	O
,	O
TCID	O
(	O
50	O
)	O
assay	O
and	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

Pathomorphologically	O
,	O
patients	O
with	O
central	B-DISO
nervous	I-DISO
system	I-DISO
disease	I-DISO
and	O
cardiopulmonary	B-DISO
failure	I-DISO
were	O
found	O
to	O
have	O
acute	O
inflammation	B-DISO
of	O
the	O
grey	O
matter	O
of	O
the	O
brain	O
stem	O
(	O
medulla	O
oblongata	O
,	O
pons	O
)	O
and	O
spinal	O
cord	B-DISO
.	O

ABSTRACT	O
:	O
The	O
transcription	O
and	O
replication	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
regulated	O
by	O
specific	O
viral	O
genome	O
sequences	O
within	O
5	O
'-	O
and	O
3	O
'-	O
untranslated	O
regions	O
(	O
5	O
'-	O
UTR	O
and	O
3	O
'-	O
UTR	O
).	O

Multiple	O
observational	O
studies	O
have	O
suggested	O
that	O
HMGCoA	O
reductase	O
inhibitors	O
(	O
statins	O
)	O
can	O
exert	O
a	O
class	O
effect	O
in	O
attenuating	O
inflammation	B-DISO
.	O

The	O
fatal	O
ending	O
in	O
this	O
bone	O
marrow	O
transplant	O
recipient	O
supports	O
recommendations	O
that	O
call	O
for	O
education	O
measures	O
,	O
S	O
-	O
OIV	O
vaccination	O
,	O
early	O
diagnosis	O
and	O
aggressive	B-DISO
treatment	O
in	O
the	O
transplant	O
population	O
.	O

ILIs	O
were	O
defined	O
as	O
body	O
temperature	O
≥	O
38	O
°	O
C	O
and	O
cough	B-DISO
and	O
at	O
least	O
two	O
of	O
the	O
following	O
symptoms	O
:	O
sore	B-DISO
throat	I-DISO
,	O
rhinorrhea	B-DISO
,	O
headache	B-DISO
and	O
muscular	B-DISO
pain	I-DISO
,	O
for	O
a	O
maximum	O
duration	O
of	O
3	O
days	O
.	O

While	O
rhinovirus	O
and	O
adenovirus	B-DISO
infections	I-DISO
occurred	O
year	O
round	O
,	O
RSV	O
,	O
influenza	B-DISO
virus	O
A	O
and	O
coronavirus	O
OC43	O
had	O
defined	O
period	O
of	O
circulation	O
.	O

Based	O
on	O
the	O
high	O
specificity	O
,	O
sensitivity	O
,	O
and	O
stability	O
of	O
the	O
immunochromatographic	O
strip	O
,	O
it	O
would	O
be	O
suitable	O
for	O
on	O
-	O
site	O
detection	O
of	O
PHEV	O
antibodies	O
in	O
order	O
to	O
monitor	O
PHEV	O
infections	B-DISO
in	O
an	O
animal	O
population	O
.	O

Other	B-DISO
respiratory	I-DISO
complications	I-DISO
such	O
as	O
sleep	B-DISO
disorders	I-DISO
and	O
nocturnal	O
hypoxemia	O
,	O
infiltrative	O
lung	B-DISO
disease	I-DISO
and	O
exertional	B-DISO
dyspnea	I-DISO
are	O
described	O
and	O
should	O
be	O
considered	O
.	O

The	O
health	O
and	O
safety	O
risks	O
to	O
emergency	B-DISO
service	O
personnel	O
were	O
highlighted	O
by	O
the	O
deaths	O
of	O
firefighters	O
,	O
paramedics	O
,	O
and	O
police	O
during	O
the	O
September	O
11	O
,	O
2001	O
,	O
terrorist	O
attacks	O
,	O
and	O
the	O
infection	B-DISO
,	O
illness	O
,	O
and	O
deaths	O
of	O
paramedics	O
and	O
emergency	B-DISO
health	O
care	O
staff	O
during	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
outbreak	O
in	O
2003	O
.	O

The	O
results	O
indicate	O
that	O
paramedics	O
ranked	O
nuclear	O
and	O
radiological	O
events	O
and	O
outbreaks	O
of	O
new	O
and	O
highly	O
infectious	B-DISO
disasters	O
highest	O
for	O
fear	O
and	O
unfamiliarity	O
.	O

Partial	O
exchange	O
transfusion	O
should	O
be	O
reserved	O
for	O
children	O
with	O
only	O
mild	O
anemia	B-DISO
(	O
Hb	O
>	O
9	O
g	O
/	O
dL	O
)	O
but	O
deteriorating	O
respiratory	O
status	O
.	O

TITLE	O
:	O
A	O
virus	O
-	O
binding	O
hot	B-DISO
spot	I-DISO
on	O
human	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
is	O
critical	O
for	O
binding	O
of	O
two	O
different	O
coronaviruses	O
.	O

A	O
small	O
number	O
of	O
samples	O
positive	O
for	O
influenza	B-DISO
A	O
virus	O
,	O
respiratory	O
syncytial	O
virus	O
B	O
,	O
human	O
metapneumovirus	O
,	O
and	O
parainfluenza	B-DISO
virus	O
type	O
1	O
were	O
not	O
detected	O
by	O
the	O
RVP	O
Classic	O
assay	O
and	O
in	O
general	O
had	O
low	O
viral	O
loads	O
.	O

TITLE	O
:	O
Vomiting	B-DISO
and	O
wasting	B-DISO
disease	I-DISO
associated	O
with	O
hemagglutinating	O
encephalomyelitis	B-DISO
viruses	O
infection	B-DISO
in	O
piglets	O
in	O
Jilin	O
,	O
China	O
.	O

Major	O
pathological	O
changes	O
included	O
meningeal	O
hyperemia	B-DISO
,	O
meningeal	B-DISO
hemorrhage	I-DISO
and	O
cortical	B-DISO
hemorrhage	I-DISO
.	O

Their	O
histopathological	O
changes	O
were	O
similar	O
to	O
those	O
symptoms	O
observed	O
in	O
the	O
piglets	O
,	O
exhibiting	O
typical	O
changes	O
for	O
non	O
-	O
suppurative	B-DISO
encephalitis	B-DISO
.	O

ABSTRACT	O
:	O
The	O
author	O
reflects	O
on	O
her	O
personal	O
experiences	O
during	O
the	O
2009	O
H1N1	B-DISO
influenza	I-DISO
,	O
acquired	B-DISO
immune	I-DISO
deficiency	I-DISO
syndrome	I-DISO
(	O
AIDS	O
),	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
pandemics	O
.	O

Modelers	O
published	O
thoughtful	O
articles	O
after	O
the	O
2003	O
SARS	B-DISO
crisis	O
,	O
but	O
had	O
limited	O
if	O
any	O
real	O
-	O
time	O
impact	O
on	O
the	O
global	O
response	O
and	O
may	O
even	O
have	O
inadvertently	O
contributed	O
to	O
a	O
lingering	O
misunderstanding	O
of	O
the	O
means	O
by	O
which	O
the	O
epidemic	O
was	O
controlled	O
.	O

TITLE	O
:	O
Fulminant	O
myocarditis	B-DISO
in	O
an	O
adult	O
with	O
2009	O
pandemic	O
influenza	B-DISO
A	O
(	O
H1N1	B-DISO
influenza	I-DISO
)	O
infection	B-DISO
.	O

The	O
management	O
of	O
veno	O
-	O
venous	O
ECMO	O
without	O
systemic	O
anticoagulation	O
in	O
a	O
patient	O
suffering	B-DISO
from	O
traumatic	B-DISO
lung	I-DISO
failure	O
and	O
severe	O
traumatic	O
brain	O
injury	O
is	O
reported	O
.	O

TITLE	O
:	O
A	O
case	O
of	O
Goodpasture	B-DISO
syndrome	I-DISO
positive	O
for	O
anti	O
-	O
GBM	B-DISO
antibody	O
and	O
MPO	O
-	O
ANCA	O
complicated	O
by	O
a	O
variety	O
of	O
serious	O
infections	B-DISO
.	O

Mechanical	O
ventilation	O
support	O
was	O
provided	O
and	O
continuous	O
hemodiafiltration	O
was	O
carried	O
out	O
,	O
following	O
which	O
the	O
respiratory	B-DISO
failure	I-DISO
improved	O
immediately	O
.	O

We	O
suspected	O
severe	O
immunosuppression	O
caused	O
by	O
various	O
factors	O
,	O
such	O
as	O
predonisolone	O
administration	O
,	O
chronic	B-DISO
renal	I-DISO
failure	I-DISO
on	O
maintenance	O
hemodialysis	O
,	O
depression	B-DISO
,	O
and	O
malnutrition	B-DISO
due	O
to	O
chronic	B-DISO
inflammation	I-DISO
and	O
granulocytopenia	B-DISO
as	O
a	O
side	B-DISO
effect	I-DISO
of	O
ganciclovir	O
.	O

When	O
treating	O
rapidly	B-DISO
progressive	I-DISO
glomerulonephritis	I-DISO
,	O
immunosuppressive	O
status	O
should	O
be	O
carefully	O
monitored	O
regarding	O
not	O
only	O
the	O
dosage	O
of	O
therapeutic	O
regimen	O
but	O
also	O
the	O
mental	O
health	O
status	O
and	O
nutrition	O
of	O
the	O
patient	O
.	O

Using	O
cycloheximide	O
and	O
puromycin	O
,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
translation	O
inhibition	O
on	O
the	O
RNA	O
synthesis	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
and	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
.	O

The	O
inter	O
-	O
stem	O
-	O
loop	O
domain	O
(	O
nt	O
142	O
to	O
173	O
between	O
SLs	B-DISO
III	O
and	O
IV	O
)	O
enabled	O
small	O
plaques	B-DISO
only	O
after	O
genetic	O
adaptation	O
.	O

ABSTRACT	O
:	O
In	O
early	O
February	O
2003	O
,	O
a	O
previously	O
unknown	O
disease	O
causing	O
severe	O
pneumonia	B-DISO
was	O
recognised	O
.	O

Pleural	B-DISO
effusion	I-DISO
and	O
lymphadenopathy	O
were	O
of	O
consistent	O
rare	O
features	O
in	O
both	O
groups	O
.	O

Moreover	O
,	O
this	O
system	O
using	O
the	O
bioinspired	O
PCs	B-DISO
allows	O
specific	O
target	O
detection	O
in	O
biosensor	O
chip	O
fields	O
through	O
control	O
of	O
the	O
PCs	B-DISO
.	O

ABSTRACT	O
:	O
We	O
performed	O
a	O
prospective	O
cohort	O
study	O
from	O
September	O
2003	O
to	O
December	O
2004	O
to	O
delineate	O
attributing	O
the	O
effect	O
of	O
different	O
respiratory	O
viral	B-DISO
infections	I-DISO
including	O
newly	O
discovered	O
ones	O
to	O
asthma	B-DISO
exacerbations	O
in	O
children	O
in	O
Hong	O
Kong	O
.	O

Although	O
newly	O
discovered	O
respiratory	O
viruses	O
were	O
identified	O
in	O
these	O
episodes	O
,	O
rhinovirus	O
was	O
the	O
commonest	O
organism	O
associated	O
with	O
both	O
asthma	B-DISO
exacerbations	O
and	O
non	O
-	O
asthma	B-DISO
related	O
episodes	O
.	O

Infection	B-DISO
by	O
other	O
viruses	O
employing	O
similar	O
viral	O
entry	O
mechanisms	O
(	O
such	O
as	O
HIV	B-DISO
-	O
1	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
)	O
can	O
be	O
inhibited	O
with	O
synthetic	O
peptides	O
corresponding	O
to	O
the	O
native	O
CHR	B-DISO
sequence	O
"("""	O
C	O
-	O
peptides	O
""")."	O

TITLE	O
:	O
Viral	O
etiologies	O
of	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
among	O
hospitalized	O
Vietnamese	O
children	O
in	O
Ho	O
Chi	O
Minh	O
City	O
,	O
2004	O
-	O
2008	O
.	O

Notably	O
,	O
the	O
patient	O
had	O
fever	O
,	O
severe	O
abdominal	B-DISO
pain	I-DISO
,	O
hematuria	O
,	O
arthritis	B-DISO
,	O
and	O
purpuric	O
manifestations	O
associated	O
with	O
a	O
normal	O
platelet	O
count	O
.	O

TITLE	O
:	O
[	O
Expression	O
of	O
green	O
fluorescent	O
protein	O
using	O
an	O
infectious	B-DISO
cDNA	O
clone	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
].	O

One	O
of	O
the	O
most	O
serious	O
complications	O
of	O
the	O
treatment	O
with	O
this	O
drug	O
is	O
metformin	O
-	O
induced	O
lactic	B-DISO
acidosis	I-DISO
.	O

It	O
is	O
a	O
rare	O
but	O
dangerous	O
metabolic	O
complication	B-DISO
with	O
a	O
mortality	O
rate	O
of	O
up	O
to	O
50	O
%	O
that	O
can	O
result	O
from	O
the	O
accumulation	O
of	O
lactates	O
.	O

The	O
rate	O
of	O
lactic	B-DISO
acidosis	I-DISO
in	O
patients	O
receiving	O
metformin	O
is	O
not	O
precisely	O
known	O
.	O

However	O
,	O
in	O
the	O
majority	O
of	O
cases	O
,	O
lactic	B-DISO
acidosis	I-DISO
is	O
diagnosed	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
which	O
itself	O
can	O
cause	O
lactic	B-DISO
acidosis	I-DISO
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
intraperitoneal	O
and	O
intranasal	O
co	O
-	O
administration	O
of	O
inactivated	O
SARS	B-DISO
-	O
CoV	O
vaccine	O
together	O
with	O
this	O
improved	O
Poly	O
(	O
I	O
:	O
C	O
)	O
derivative	O
induced	O
strong	O
anti	O
-	O
SARS	B-DISO
-	O
CoV	O
mucosal	O
and	O
systemic	O
humoral	O
immune	O
responses	O
with	O
neutralizing	O
activity	O
against	O
pseudotyped	O
virus	O
.	O

Although	O
intraperitoneal	O
immunization	O
of	O
inactivated	O
SARS	B-DISO
-	O
CoV	O
vaccine	O
alone	O
could	O
induce	O
a	O
certain	O
level	O
of	O
neutralizing	O
activity	O
in	O
serum	O
as	O
well	O
as	O
in	O
mucosal	O
sites	O
,	O
co	O
-	O
administration	O
of	O
inactivated	O
SARS	B-DISO
-	O
CoV	O
vaccine	O
with	O
PIKA	O
as	O
adjuvant	O
could	O
induce	O
a	O
much	O
higher	O
neutralizing	O
activity	O
.	O

TITLE	O
:	O
Functional	O
disability	O
5	O
years	O
after	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

We	O
evaluated	O
109	O
survivors	O
of	O
ARDS	B-DISO
at	O
3	O
,	O
6	O
,	O
and	O
12	O
months	O
and	O
at	O
2	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
years	O
after	O
discharge	O
from	O
the	O
intensive	O
care	O
unit	O
.	O

To	O
analyze	O
the	O
impact	O
of	O
corticosteroid	O
therapy	O
on	O
outcomes	O
of	O
patients	O
having	O
ARDS	B-DISO
associated	O
with	O
influenza	B-DISO
A	O
/	O
H1N1	O
pneumonia	B-DISO
.	O

Patients	O
from	O
the	O
French	O
registry	O
of	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
influenza	B-DISO
A	O
/	O
H1N1v	O
2009	O
infection	B-DISO
were	O
selected	O
if	O
fulfilling	O
criteria	O
for	O
ARDS	B-DISO
,	O
excluding	O
patients	O
having	O
other	O
indication	O
for	O
corticosteroids	O
,	O
or	O
decompensated	O
underlying	O
disease	O
as	O
the	O
primary	O
cause	O
for	O
intensive	O
care	O
unit	O
admission	O
.	O

The	O
contents	O
of	O
tumor	B-DISO
necrosis	I-DISO
factor	O
α	O
(	O
TNF	O
-	O
α	O
)	O
and	O
interleukin	O
6	O
(	O
IL	O
-	O
6	O
)	O
in	O
plasma	O
and	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
were	O
also	O
increased	O
distinctly	O
compared	O
with	O
the	O
control	O
group	O
[	O
TNF	O
-	O
α	O
(	O
ng	O
/	O
L	O
)	O
in	O
plasma	O
:	O
328	O
.	O
89	O
±	O
6	O
.	O
26	O
vs	O
.	O
62	O
.	O
12	O
±	O
2	O
.	O
98	O
,	O
TNF	O
-	O
α	O
(	O
ng	O
/	O
L	O
)	O
in	O
BALF	O
:	O
164	O
.	O
87	O
±	O
4	O
.	O
59	O
vs	O
.	O
29	O
.	O
51	O
±	O
1	O
.	O
12	O
;	O
IL	O
-	O
6	O
(	O
ng	O
/	O
L	O
)	O
in	O
plasma	O
:	O
128	O
.	O
51	O
±	O
4	O
.	O
13	O
vs	O
.	O
19	O
.	O
32	O
±	O
1	O
.	O
53	O
,	O
IL	O
-	O
6	O
(	O
ng	O
/	O
L	O
)	O
in	O
BALF	O
:	O
94	O
.	O
97	O
±	O
1	O
.	O
14	O
vs	O
.	O
22	O
.	O
72	O
±	O
0	O
.	O
19	O
,	O
all	O
P	O
<	O
0	O
.	O
05	O
].	O

In	O
an	O
airtight	O
environment	O
,	O
rabbit	O
ARDS	B-DISO
model	O
can	O
be	O
reproduced	O
successfully	O
by	O
blast	O
injury	O
with	O
1	O
917	O
.	O
3	O
mm	O
Hg	O
explosion	O
pressure	O
;	O
TNF	O
-	O
α	O
and	O
IL	O
-	O
6	O
are	O
involved	O
in	O
the	O
pathogenesis	B-DISO
and	O
development	O
of	O
ARDS	B-DISO
in	O
blast	O
injury	O
.	O

I	O
also	O
use	O
the	O
example	O
of	O
HIV	B-DISO
and	O
CMV	O
to	O
illustrate	O
how	O
two	O
unrelated	O
enveloped	O
viruses	O
use	O
a	O
similar	O
SCHOOL	O
mechanism	O
to	O
modulate	O
the	O
host	O
immune	O
response	O
mediated	O
by	O
two	O
functionally	O
different	O
receptors	O
:	O
T	O
cell	O
antigen	O
receptor	O
and	O
natural	O
killer	O
cell	O
receptor	O
,	O
NKp30	O
.	O

Subjects	O
were	O
assessed	O
on	O
sociodemographic	O
factors	O
,	O
on	O
types	O
of	O
exposure	O
to	O
the	O
outbreak	O
,	O
and	O
on	O
symptoms	O
of	O
posttraumatic	B-DISO
stress	I-DISO
disorder	I-DISO
and	O
depression	B-DISO
.	O

Such	O
an	O
approach	O
may	O
be	O
suitable	O
for	O
gene	O
rescue	O
strategies	O
in	O
neurological	B-DISO
disease	I-DISO
,	O
such	O
as	O
FRDA	B-DISO
.	O

We	O
report	O
an	O
unusual	O
clinical	O
manifestation	O
of	O
neuralgic	B-DISO
amyotrophy	I-DISO
,	O
namely	O
bilateral	O
phrenic	B-DISO
nerve	I-DISO
palsy	I-DISO
with	O
concomitant	O
laryngeal	O
paresis	B-DISO
.	O

After	O
treatment	O
with	O
prednisolone	O
,	O
vocal	O
cord	B-DISO
function	O
markedly	O
improved	O
within	O
8	O
weeks	O
,	O
whereas	O
paresis	B-DISO
of	O
the	O
diaphragm	O
persisted	O
.	O

ABSTRACT	O
:	O
To	O
analyze	O
the	O
epidemiological	O
data	O
for	O
pandemic	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
v	O
in	O
the	O
Autonomous	O
Province	O
of	O
Vojvodina	O
,	O
Serbia	O
,	O
during	O
the	O
season	O
of	O
2009	O
/	O
2010	O
and	O
to	O
assess	O
whether	O
including	O
severe	O
acute	O
respiratory	O
illness	O
(	O
SARI	O
)	O
hospitalization	O
data	O
to	O
the	O
surveillance	O
system	O
gives	O
a	O
more	O
complete	O
picture	O
of	O
the	O
impact	O
of	O
influenza	B-DISO
during	O
the	O
pandemic	O
.	O

PubMed	O
,	O
Google	O
Scholar	O
,	O
ISI	O
Web	B-DISO
of	O
Knowledge	O
,	O
Scirus	O
,	O
and	O
Scielo	O
were	O
searched	O
(	O
to	O
December	O
2008	O
)	O
for	O
reports	O
of	O
accidental	O
viral	B-DISO
infections	I-DISO
,	O
written	O
in	O
English	O
,	O
Portuguese	O
,	O
Spanish	O
,	O
or	O
German	O
;	O
the	O
authors	O
'	O
personal	O
file	O
of	O
scientific	O
articles	O
and	O
references	O
from	O
the	O
articles	O
retrieved	O
in	O
the	O
initial	O
search	O
were	O
also	O
used	O
.	O

For	O
airborne	O
viruses	O
,	O
81	O
%	O
of	O
the	O
infections	B-DISO
occurred	O
in	O
laboratories	O
,	O
with	O
hantavirus	O
the	O
leading	O
causative	O
agent	O
.	O

The	O
Brazilian	O
isolates	O
branched	O
into	O
one	O
unique	O
cluster	O
,	O
separate	O
from	O
the	O
reference	O
serotypes	O
used	O
for	O
infectious	B-DISO
bronchitis	B-DISO
control	O
in	O
other	O
countries	O
.	O

TITLE	O
:	O
Repeated	O
virus	O
identification	O
in	O
the	O
airways	O
of	O
patients	O
with	O
mild	O
and	O
severe	O
asthma	B-DISO
during	O
prospective	O
follow	O
-	O
up	O
.	O

ABSTRACT	O
:	O
Certain	O
Staphylococcus	O
aureus	O
strains	O
produce	O
Panton	O
-	O
Valentine	O
leukocidin	O
,	O
a	O
toxin	O
that	O
lyses	B-DISO
white	O
blood	O
cells	O
causing	O
extensive	O
tissue	O
necrosis	O
and	O
chronic	O
,	O
recurrent	O
or	O
severe	O
infection	B-DISO
.	O

About	O
two	O
weeks	O
later	O
he	O
was	O
re	O
-	O
admitted	O
to	O
our	O
hospital	O
complaining	O
of	O
pain	O
and	O
weakness	B-DISO
affecting	O
his	O
left	O
leg	O
,	O
where	O
he	O
had	O
received	O
an	O
intramuscular	O
injection	O
of	O
an	O
anti	O
-	O
emetic	O
drug	O
.	O

He	O
deteriorated	O
and	O
developed	O
septic	B-DISO
arthritis	I-DISO
,	O
necrotizing	B-DISO
fasciitis	I-DISO
and	O
septic	B-DISO
shock	I-DISO
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
leading	O
to	O
death	O
within	O
48	O
hours	O
of	O
admission	O
despite	O
intensive	O
care	O
treatment	O
.	O

The	O
infection	B-DISO
was	O
caused	O
by	O
S	O
.	O
aureus	O
.	O

Among	O
843	O
cases	O
,	O
90	O
were	O
HboV	O
positive	O
(	O
10	O
.	O
7	O
%),	O
131	O
were	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
positive	O
(	O
15	O
.	O
5	O
%),	O
117	O
were	O
influenza	B-DISO
virus	O
positive	O
(	O
13	O
.	O
9	O
%),	O
84	O
were	O
parainfluenza	B-DISO
virus	O
positive	O
(	O
10	O
.	O
0	O
%),	O
55	O
were	O
rhinovirus	O
positive	O
(	O
6	O
.	O
5	O
%),	O
48	O
were	O
coronavirus	O
positive	O
(	O
5	O
.	O
7	O
%),	O
and	O
33	O
were	O
human	O
metapneumovirus	O
positive	O
(	O
3	O
.	O
7	O
%).	O

HBoV	O
positive	O
rate	O
detected	O
from	O
children	O
with	O
wheezing	B-DISO
is	O
higher	O
than	O
from	O
children	O
without	O
wheezing	B-DISO
,	O
suggesting	O
that	O
apart	O
from	O
RSV	O
,	O
HBoV	O
is	O
another	O
virus	O
causing	O
wheezing	B-DISO
in	O
children	O
with	O
respiratory	B-DISO
tract	I-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Immunoglobulin	O
in	O
cerebral	O
spinal	O
fluid	O
and	O
antibody	O
secreting	O
cells	O
(	O
ASC	O
)	O
within	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
parenchyma	O
are	O
common	O
hallmarks	O
of	O
microbial	O
infections	B-DISO
and	O
autoimmune	B-DISO
disorders	I-DISO
.	O

This	O
study	O
demonstrates	O
that	O
CXCR3	O
mediates	O
CNS	O
accumulation	O
of	O
ASC	O
during	O
neurotropic	O
coronavirus	O
-	O
induced	O
encephalomyelitis	B-DISO
.	O

The	O
following	O
recommendations	O
are	O
the	O
result	O
of	O
evidence	O
-	O
based	O
consensus	O
by	O
the	O
American	O
College	O
of	O
Radiology	O
Appropriateness	O
Criteria	O
Expert	O
Panel	O
on	O
Thoracic	B-DISO
Radiology	O
.	O

Chest	O
radiographs	O
are	O
usually	O
appropriate	O
in	O
(	O
1	O
)	O
patients	O
with	O
positive	O
physical	O
examination	O
or	O
risk	O
factors	O
for	O
pneumonia	B-DISO
,	O
(	O
2	O
)	O
for	O
the	O
assessment	O
of	O
complicated	O
pneumonia	B-DISO
,	O
or	O
(	O
3	O
)	O
in	O
cases	O
of	O
emerging	O
infections	B-DISO
and	O
biological	O
warfare	O
agents	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
H1N1	O
,	O
and	O
anthrax	B-DISO
.	O

ABSTRACT	O
:	O
In	O
the	O
Southern	O
hemisphere	O
,	O
Réunion	O
Island	O
acts	O
as	O
a	O
sentinel	O
for	O
infections	B-DISO
preferentially	O
occurring	O
during	O
the	O
austral	O
winter	O
that	O
are	O
likely	O
to	O
reach	O
the	O
Northern	O
hemisphere	O
a	O
few	O
months	O
later	O
.	O

Most	O
of	O
them	O
(	O
22	O
/	O
25	O
)	O
had	O
comorbidities	O
such	O
as	O
:	O
chronic	B-DISO
diseases	I-DISO
,	O
overweight	B-DISO
,	O
obesity	B-DISO
,	O
pregnancy	O
,	O
and	O
Down	B-DISO
syndrome	I-DISO
.	O

Within	O
the	O
study	O
period	O
,	O
12	O
patients	O
died	O
(	O
48	O
%)	O
mainly	O
of	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
.	O

In	O
2010	O
,	O
the	O
failure	O
of	O
the	O
mass	O
immunization	O
campaign	O
,	O
particularly	O
among	O
the	O
at	O
-	O
risk	O
groups	O
,	O
led	O
to	O
severe	O
cases	O
of	O
A	O
(	O
H1N1	O
)	O
v2009	O
infections	B-DISO
,	O
particularly	O
among	O
patients	O
with	O
comorbidities	O
.	O

Our	O
data	O
may	O
contribute	O
toward	O
better	O
management	O
of	O
influenza	B-DISO
virus	O
pandemics	O
in	O
the	O
future	O
.	O

ABSTRACT	O
:	O
The	O
nephropathogenic	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
(	O
IB	O
)	O
caused	O
unprecedented	O
economic	O
losses	O
to	O
the	O
commercial	O
chicken	O
industry	O
of	O
China	O
in	O
2008	O
-	O
2009	O
.	O

To	O
investigate	O
the	O
prevalence	O
of	O
nephropathogenic	O
IB	O
in	O
China	O
,	O
eighty	O
IBV	O
isolates	O
from	O
different	O
provinces	O
during	O
2008	O
-	O
2009	O
were	O
identified	O
by	O
dwarf	B-DISO
embryo	O
test	O
and	O
RT	O
-	O
PCR	O
.	O

By	O
the	O
virus	O
recovery	O
trials	O
,	O
70	O
/	O
80	O
of	O
the	O
strains	O
resulted	O
in	O
the	O
deaths	O
or	O
distresses	O
of	O
birds	O
from	O
nephritis	B-DISO
.	O

Better	O
understanding	O
of	O
the	O
pathophysiology	O
of	O
ARDS	B-DISO
has	O
lead	O
to	O
the	O
development	O
of	O
novel	O
therapies	O
,	O
pharmacological	O
strategies	O
,	O
and	O
advances	O
in	O
mechanical	O
ventilation	O
.	O

The	O
availability	O
of	O
TGEV	O
RdRp	O
mAbs	O
will	O
be	O
instrumental	O
to	O
study	O
coronavirus	O
replication	O
and	O
to	O
analyze	O
the	O
function	O
of	O
RdRp	O
in	O
pathogenesis	B-DISO
.	O

Examples	O
include	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
or	O
influenza	B-DISO
A	O
virus	O
H3N2	O
.	O

The	O
link	O
with	O
BOS	B-DISO
needs	O
also	O
to	O
be	O
reassessed	O
in	O
appropriate	O
prospective	O
studies	O
.	O

Therefore	O
,	O
the	O
information	O
about	O
clinical	O
spectrum	O
of	O
manifestations	O
,	O
risk	O
factors	O
for	O
severe	O
form	O
of	O
the	O
disease	O
,	O
treatment	O
and	O
outcome	O
in	O
patients	O
with	O
novel	O
flu	B-DISO
are	O
still	O
collected	O
.	O

15	O
years	O
,	O
range	O
14	O
-	O
88	O
years	O
)	O
with	O
the	O
signs	B-DISO
and	I-DISO
symptoms	I-DISO
of	O
novel	O
influenza	B-DISO
were	O
treated	O
in	O
the	O
Clinic	O
for	O
Infectious	B-DISO
and	O
Tropical	B-DISO
Diseases	I-DISO
,	O
Military	O
Medical	O
Academy	O
.	O

A	O
total	O
of	O
21	O
(	O
21	O
.	O
4	O
%)	O
patients	O
were	O
with	O
underlying	O
disease	O
,	O
18	O
(	O
18	O
.	O
4	O
%)	O
were	O
obese	B-DISO
,	O
19	O
(	O
19	O
.	O
4	O
)	O
were	O
cigarette	O
smokers	O
.	O

CONCLUSIONS	O
:	O
Novel	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
is	O
most	O
commonly	O
manifested	O
as	O
a	O
mild	O
acute	B-DISO
respiratory	I-DISO
disease	I-DISO
,	O
which	O
usually	O
affects	O
young	O
healthy	O
adults	O
.	O

Children	O
younger	O
than	O
36	O
months	O
old	O
,	O
hospitalized	O
at	O
a	O
medical	O
center	O
in	O
Northern	O
Taiwan	O
with	O
acute	B-DISO
bronchiolitis	I-DISO
or	O
pneumonia	B-DISO
from	O
April	O
to	O
December	O
2007	O
,	O
were	O
prospectively	O
enrolled	O
.	O

However	O
,	O
the	O
hMPV	O
group	O
had	O
a	O
higher	O
mixed	B-DISO
infection	I-DISO
rate	O
(	O
p	O
=	O
0	O
.	O
038	O
).	O

Patients	O
with	O
H1N1	O
associated	O
with	O
ARDS	B-DISO
may	O
be	O
given	O
a	O
trial	O
of	O
IV	O
IgG	O
.	O
More	O
case	O
reports	O
and	O
trials	O
are	O
required	O
to	O
ascertain	O
the	O
efficacy	O
of	O
IV	O
IgG	O
and	O
the	O
best	O
dosage	O
and	O
timing	O
of	O
starting	O
IV	O
IgG	O
in	O
relation	O
to	O
antiviral	O
therapy	O
.	O

Infection	B-DISO
of	O
transgenic	O
IL	O
-	O
10	O
/	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
reporter	O
mice	O
revealed	O
that	O
CNS	O
-	O
infiltrating	B-DISO
T	O
cells	O
were	O
the	O
major	O
source	O
of	O
IL	O
-	O
10	O
,	O
with	O
minimal	O
IL	O
-	O
10	O
production	O
by	O
macrophages	O
and	O
resident	O
microglia	O
.	O

Moreover	O
,	O
a	O
shift	O
from	O
predominant	O
IL	O
-	O
10	O
production	O
by	O
CD25	O
(+)	O
CD4	O
(+)	O
T	O
cells	O
to	O
CD25	O
(-)	O
CD4	O
(+)	O
T	O
cells	O
suggests	O
that	O
a	O
transition	B-DISO
to	O
nonclassical	O
regulatory	O
T	O
cells	O
precedes	O
and	O
is	O
retained	O
during	O
CNS	O
viral	O
persistence	O
.	O

ABSTRACT	O
:	O
Pandemic	O
of	O
A	O
H1N1	B-DISO
influenza	I-DISO
is	O
noted	O
for	O
its	O
rapid	O
spreading	O
and	O
life	O
-	O
threatening	O
consequences	O
like	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
which	O
requires	O
mechanical	O
ventilation	O
(	O
MV	O
)	O
and	O
intensive	O
therapy	O
(	O
IT	O
).	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
the	O
significance	O
of	O
mechanical	O
ventilation	O
application	O
in	O
the	O
presence	O
of	O
comorbidities	O
on	O
the	O
outcome	O
of	O
the	O
disease	O
and	O
patients	O
with	O
severe	O
forms	O
of	O
acute	O
influenza	B-DISO
caused	O
by	O
A	O
H1N1	O
virus	O
.	O

CONCLUSIONS	O
:	O
Intensive	O
therapy	O
of	O
patients	O
with	O
ARDS	B-DISO
due	O
to	O
A	O
H1N1	B-DISO
influenza	I-DISO
virus	O
requires	O
MV	O
which	O
should	O
be	O
carried	O
out	O
according	O
to	O
guidelines	O
of	O
international	O
expert	O
forums	O
.	O

TITLE	O
:	O
Construction	O
and	O
characterization	O
of	O
Lactobacillus	O
pentosus	O
expressing	O
the	O
D	O
antigenic	O
site	O
of	O
the	O
spike	O
protein	O
of	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
.	O

ABSTRACT	O
:	O
The	O
criteria	O
that	O
define	O
acute	O
lung	O
injury	O
and	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
include	O
PaO₂	O
/	O
Fio₂	O
but	O
not	O
positive	O
end	O
-	O
expiratory	O
pressure	O
or	O
Fio2	O
.	O

TITLE	O
:	O
Development	O
of	O
loop	O
-	O
mediated	O
isothermal	O
amplification	B-DISO
assay	O
for	O
detection	O
of	O
human	O
coronavirus	O
-	O
NL63	O
.	O

Nine	O
of	O
the	O
64	O
filters	O
tested	O
were	O
positive	O
for	O
influenza	B-DISO
A	O
virus	O
,	O
2	O
filters	O
were	O
positive	O
for	O
influenza	B-DISO
B	O
virus	O
,	O
and	O
1	O
filter	O
was	O
positive	O
for	O
parainfluenza	B-DISO
virus	O
1	O
.	O

ABSTRACT	O
:	O
The	O
natural	O
history	O
of	O
cystic	B-DISO
fibrosis	I-DISO
(	O
CF	O
)	O
may	O
be	O
associated	O
both	O
with	O
acute	O
respiratory	B-DISO
complications	I-DISO
(	O
respiratory	O
exacerbations	O
,	O
haemoptysis	B-DISO
,	O
pneumothorax	B-DISO
)	O
and	O
with	O
non	O
-	O
respiratory	B-DISO
complications	I-DISO
(	O
distal	B-DISO
intestinal	I-DISO
obstruction	I-DISO
syndrome	I-DISO
,	O
dehydration	B-DISO
)	O
that	O
may	O
result	O
in	O
hospitalizations	O
.	O

TITLE	O
:	O
Bronchopleural	O
fistulae	O
and	O
pulmonary	B-DISO
ossification	I-DISO
in	O
posttraumatic	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
successful	O
treatment	O
with	O
extracorporeal	O
support	O
.	O

TITLE	O
:	O
Mutations	O
in	O
the	O
spike	O
gene	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
associated	O
with	O
growth	O
adaptation	O
in	O
vitro	O
and	O
attenuation	O
of	O
virulence	O
in	O
vivo	O
.	O

ABSTRACT	O
:	O
Previously	O
,	O
we	O
have	O
reported	O
that	O
a	O
serial	O
passage	O
of	O
83P	O
-	O
5	O
strain	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
in	O
Vero	O
cells	O
resulted	O
in	O
a	O
growth	O
adaptation	O
of	O
the	O
virus	O
in	O
cultured	O
cells	O
at	O
the	O
22nd	O
passage	O
.	O

TITLE	O
:	O
Respiratory	B-DISO
disorders	I-DISO
in	O
the	O
Middle	O
East	O
:	O
a	O
review	O
.	O

We	O
shed	O
light	O
on	O
the	O
diverse	O
conditions	O
commonly	O
encountered	O
in	O
the	O
region	O
,	O
from	O
the	O
centuries	O
-	O
old	O
illnesses	O
of	O
tuberculosis	B-DISO
,	O
to	O
contemporary	O
problems	O
such	O
as	O
lung	O
complications	O
from	O
chemical	O
warfare	O
.	O

ABSTRACT	O
:	O
After	O
intracranial	O
inoculation	O
,	O
neurovirulent	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
strains	O
induce	O
acute	O
inflammation	B-DISO
,	O
demyelination	B-DISO
,	O
and	O
axonal	O
loss	O
in	O
the	O
central	O
nervous	B-DISO
system	O
.	O

Recombinant	O
demyelinating	O
MHV	O
induced	O
macrophage	O
infiltration	B-DISO
of	O
optic	O
nerves	O
,	O
demyelination	B-DISO
,	O
and	O
axonal	O
loss	O
,	O
whereas	O
optic	B-DISO
neuritis	I-DISO
and	O
axonal	O
injury	O
were	O
minimal	O
in	O
mice	O
infected	O
with	O
the	O
nondemyelinating	O
MHV	O
strain	O
that	O
differs	O
in	O
the	O
spike	O
gene	O
.	O

CONCLUSIONS	O
:	O
The	O
del	O
/	O
del	O
genotype	O
is	O
associated	O
with	O
an	O
age	O
-	O
dependent	O
increase	O
in	O
odds	O
of	O
developing	O
ARDS	B-DISO
.	O

The	O
inhibitory	O
effect	O
of	O
LiCl	O
was	O
also	O
observed	O
with	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
coronavirus	O
.	O

ABSTRACT	O
:	O
This	O
study	O
examined	O
the	O
main	O
and	O
interactive	O
relations	O
of	O
stressors	O
and	O
coping	O
related	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
with	O
Chinese	O
college	O
students	O
'	O
psychological	B-DISO
adjustment	O
(	O
psychological	B-DISO
symptoms	I-DISO
,	O
perceived	O
general	O
health	O
,	O
and	O
life	O
satisfaction	O
)	O
during	O
the	O
2003	O
Beijing	O
SARS	B-DISO
epidemic	O
.	O

A	O
multidimensional	O
battery	O
of	O
psychological	B-DISO
adjustment	O
should	O
be	O
used	O
to	O
monitor	O
clients	O
'	O
psychological	B-DISO
adjustment	O
to	O
stressors	O
and	O
evaluate	O
the	O
efficacy	O
of	O
intervention	O
.	O

It	O
is	O
critical	O
to	O
find	O
out	O
whether	O
a	O
potential	O
anamnestic	O
response	O
,	O
as	O
seen	O
with	O
other	O
viral	B-DISO
infections	I-DISO
,	O
exists	O
to	O
protect	O
a	O
person	O
from	O
reinfection	O
in	O
case	O
of	O
another	O
SARS	B-DISO
outbreak	O
.	O

TITLE	O
:	O
Protocol	O
for	O
recombinant	O
RBD	O
-	O
based	O
SARS	B-DISO
vaccines	O
:	O
protein	O
preparation	O
,	O
animal	O
vaccination	O
and	O
neutralization	O
detection	O
.	O

Therefore	O
,	O
in	O
this	O
protocol	O
,	O
we	O
describe	O
novel	O
methods	O
for	O
developing	O
a	O
RBD	O
-	O
based	O
subunit	O
vaccine	O
against	O
SARS	B-DISO
.	O

The	O
antibody	O
5H10	O
was	O
obtained	O
by	O
vaccination	O
of	O
KM	O
mice	O
bearing	O
human	O
immunoglobulin	O
genes	O
with	O
Escherichia	O
coli	O
-	O
producing	O
recombinant	O
peptide	O
containing	O
the	O
dominant	O
epitope	O
of	O
the	O
viral	O
spike	O
protein	O
found	O
in	O
convalescent	O
serum	O
samples	O
from	O
patients	O
with	O
SARS	B-DISO
.	O

Outcomes	O
with	O
ventilatory	O
and	O
rescue	O
therapies	O
for	O
H1N1	B-DISO
influenza	I-DISO
-	O
related	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
have	O
been	O
varied	O
.	O

A	O
single	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
experience	O
with	O
management	O
of	O
laboratory	O
-	O
confirmed	O
2009	O
pandemic	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
ARDS	B-DISO
with	O
a	O
combination	O
of	O
proning	O
and	O
airway	O
pressure	O
release	O
ventilation	O
(	O
APRV	O
)	O
is	O
described	O
.	O

A	O
retrospective	O
review	O
of	O
medical	O
records	O
of	O
ICU	O
patients	O
seen	O
at	O
Utah	O
Valley	O
Regional	O
Medical	O
Center	O
during	O
the	O
first	O
and	O
second	O
waves	O
of	O
the	O
H1N1	B-DISO
influenza	I-DISO
pandemic	O
was	O
done	O
.	O

Mortality	O
in	O
intubated	O
patients	O
receiving	O
a	O
combination	O
of	O
proning	O
and	O
APRV	O
was	O
27	O
.	O
3	O
%	O
(	O
3	O
/	O
11	O
)	O
with	O
2	O
of	O
these	O
dying	O
during	O
the	O
first	O
wave	O
of	O
the	O
H1N1	B-DISO
influenza	I-DISO
pandemic	O
.	O

Further	O
,	O
they	O
suggest	O
that	O
early	O
treatment	O
with	O
IL	O
-	O
10	O
may	O
be	O
useful	O
adjunct	O
therapy	O
in	O
some	O
types	O
of	O
viral	B-DISO
encephalitis	I-DISO
.	O

TITLE	O
:	O
Effect	O
of	O
Da	O
-	O
Cheng	O
-	O
Qi	O
decoction	O
on	O
pancreatitis	B-DISO
-	O
associated	O
lung	O
injury	O
in	O
patients	O
and	O
anti	O
-	O
inflammatory	B-DISO
responses	I-DISO
in	O
rat	O
models	O
.	O

In	O
this	O
study	O
,	O
the	O
role	O
of	O
fAPN	O
and	O
fDC	B-DISO
-	O
SIGN	O
was	O
studied	O
at	O
different	O
stages	O
in	O
FIPV	O
infection	B-DISO
of	O
monocytes	O
.	O

First	O
,	O
the	O
effects	O
of	O
blocking	B-DISO
the	O
potential	O
receptor	O
(	O
s	O
)	O
were	O
studied	O
for	O
the	O
processes	O
of	O
attachment	O
and	O
infection	B-DISO
.	O

Newcastle	B-DISO
disease	I-DISO
virus	O
(	O
NDV	O
)	O
and	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
),	O
serious	O
threats	O
to	O
the	O
poultry	O
industry	O
,	O
can	O
give	O
rise	O
to	O
complex	O
mixed	B-DISO
infections	I-DISO
that	O
hinder	O
diagnosis	O
and	O
prevention	O
.	O

The	O
novel	O
peptides	O
completely	O
inhibited	O
single	O
virus	O
infections	B-DISO
and	O
mixed	B-DISO
infections	I-DISO
caused	O
by	O
NDV	O
and	O
IBV	O
.	O

ABSTRACT	O
:	O
Upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
(	O
URTI	B-DISO
)	O
occurs	O
commonly	O
in	O
both	O
children	O
and	O
adults	O
and	O
is	O
a	O
major	O
cause	O
of	O
mild	O
morbidity	O
.	O

ABSTRACT	O
:	O
We	O
have	O
shown	O
that	O
mice	O
infected	O
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
A59	O
develop	O
autoantibodies	O
(	O
autoAb	O
)	O
to	O
liver	O
and	O
kidney	O
fumarylacetoacetate	O
hydrolase	O
(	O
FAH	O
).	O

ABSTRACT	O
:	O
Pneumonia	B-DISO
is	O
still	O
one	O
of	O
the	O
most	O
frequent	O
causes	O
of	O
death	O
in	O
the	O
elderly	O
.	O

TITLE	O
:	O
Role	O
of	O
proteases	O
in	O
the	O
release	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
from	O
infected	O
cells	O
.	O

TITLE	O
:	O
Characterization	O
of	O
splenic	O
cells	O
during	O
the	O
early	O
phase	O
of	O
infection	B-DISO
with	O
neuropathogenic	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
.	O

ABSTRACT	O
:	O
The	O
highly	O
neuropathogenic	O
cl	O
-	O
2	O
and	O
less	O
virulent	O
srr7	O
viruses	O
isolated	O
from	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
the	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
exhibit	O
super	O
acute	O
spread	O
of	O
virus	O
(	O
SAS	O
),	O
a	O
term	O
applied	O
when	O
rapid	O
viral	O
spread	O
from	O
an	O
organ	O
or	O
part	O
of	O
the	O
initially	O
infected	O
site	O
to	O
another	O
non	O
-	O
adjacent	O
organ	O
or	O
part	O
is	O
detected	O
within	O
12	O
h	O
after	O
infection	B-DISO
.	O

TITLE	O
:	O
Long	O
-	O
term	O
extracorporeal	O
membrane	O
oxygenation	O
with	O
minimal	O
ventilatory	O
support	O
:	O
a	O
new	O
paradigm	O
for	O
severe	O
ARDS	B-DISO
?	O

On	O
the	O
other	O
hand	O
,	O
current	O
scientific	O
evidence	O
supports	O
a	O
link	O
between	O
VILI	O
and	O
the	O
development	O
of	O
extrapulmonary	O
organ	O
dysfunction	O
,	O
similar	O
to	O
how	O
most	O
severe	O
cases	O
of	O
sepsis	B-DISO
are	O
clinically	O
manifested	O
.	O

A	O
higher	O
number	O
of	O
lung	O
zones	O
involved	O
and	O
consolidation	O
on	O
the	O
initial	O
chest	O
radiograph	O
as	O
well	O
as	O
a	O
rapid	O
progression	O
of	O
the	O
radiological	O
abnormalities	O
were	O
identified	O
in	O
patients	O
requiring	O
ICU	O
admission	O
and	O
development	O
of	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Hepatitis	B-DISO
B	I-DISO
virus	O
core	O
antibody	O
(	O
HBcAb	O
)-	O
positive	O
organ	O
donors	O
have	O
the	O
potential	O
to	O
transmit	O
infection	B-DISO
to	O
transplant	O
recipients	O
.	O

Among	O
the	O
other	O
42	O
patients	O
,	O
5	O
(	O
11	O
.	O
9	O
%)	O
seroconverted	O
from	O
HBcAb	O
-	O
negative	O
to	O
HBcAb	O
-	O
positive	O
,	O
whereas	O
one	O
HBcAb	O
-	O
positive	O
recipient	O
became	O
hepatitis	B-DISO
B	I-DISO
virus	O
surface	O
antigen	O
-	O
positive	O
with	O
clinical	O
signs	O
of	O
active	O
hepatitis	B-DISO
6	O
years	O
after	O
transplantation	O
.	O

Effective	O
antiviral	O
agents	O
are	O
lacking	O
that	O
specifically	O
target	O
RNA	O
viruses	O
such	O
as	O
measles	B-DISO
,	O
SARS	B-DISO
-	O
CoV	O
and	O
influenza	B-DISO
H5N1	B-DISO
viruses	O
,	O
and	O
available	O
vaccinations	O
have	O
demonstrated	O
variable	O
efficacy	O
.	O

Therefore	O
,	O
the	O
development	O
of	O
novel	O
antiviral	O
agents	O
is	O
needed	O
to	O
close	O
the	O
vaccination	O
gap	O
and	O
silence	B-DISO
outbreaks	O
.	O

Surprisingly	O
,	O
we	O
found	O
that	O
the	O
antiviral	O
activities	O
of	O
mucroporin	O
-	O
M1	O
against	O
measles	B-DISO
,	O
SARS	B-DISO
-	O
CoV	O
and	O
influenza	B-DISO
H5N1	B-DISO
viruses	O
were	O
notably	O
increased	O
with	O
an	O
EC₅₀	O
of	O
7	O
.	O
15	O
μg	O
/	O
ml	O
(	O
3	O
.	O
52	O
μM	O
)	O
and	O
a	O
CC₅₀	O
of	O
70	O
.	O
46	O
μg	O
/	O
ml	O
(	O
34	O
.	O
70	O
μM	O
)	O
against	O
measles	B-DISO
virus	O
,	O
an	O
EC₅₀	O
of	O
14	O
.	O
46	O
μg	O
/	O
ml	O
(	O
7	O
.	O
12	O
μM	O
)	O
against	O
SARS	B-DISO
-	O
CoV	O
and	O
an	O
EC₅₀	O
of	O
2	O
.	O
10	O
μg	O
/	O
ml	O
(	O
1	O
.	O
03	O
μM	O
)	O
against	O
H5N1	B-DISO
,	O
while	O
the	O
original	O
peptide	O
mucroporin	O
showed	O
no	O
antiviral	O
activity	O
against	O
any	O
of	O
these	O
three	O
viruses	O
.	O

ABSTRACT	O
:	O
Stepwise	O
recruitment	B-DISO
maneuvers	O
(	O
RM	O
)	O
applied	O
with	O
high	O
airway	O
pressures	O
may	O
optimize	O
lung	O
recruitment	B-DISO
,	O
but	O
this	O
kind	O
of	O
intervention	O
may	O
lead	O
to	O
widely	O
heterogeneous	O
responses	O
with	O
possible	O
side	O
effects	O
.	O

The	O
PEEP	O
was	O
then	O
progressively	O
reduced	O
until	O
the	O
PaO	O
(	O
2	O
)	O
decreased	O
by	O
more	O
than	O
10	O
%	O
of	O
the	O
maximum	O
PaO	O
(	O
2	O
);	O
the	O
PEEP	O
was	O
subsequently	O
set	O
to	O
2	O
cmH	B-DISO
(	O
2	O
)	O
O	O
above	O
this	O
level	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
clinical	O
presentation	O
,	O
case	O
management	O
,	O
and	O
outcome	O
in	O
2	O
foals	O
with	O
Rhodococcus	B-DISO
equi	I-DISO
infection	I-DISO
associated	O
with	O
presumptive	O
severe	O
immune	O
-	O
mediated	O
hemolytic	B-DISO
anemia	I-DISO
.	O

Two	O
foals	O
diagnosed	O
with	O
R	O
.	O
equi	O
pneumonia	B-DISO
on	O
the	O
basis	O
of	O
tracheal	O
wash	O
cultures	O
,	O
thoracic	B-DISO
radiographs	O
,	O
and	O
thoracic	B-DISO
ultrasonography	O
were	O
concurrently	O
diagnosed	O
with	O
hemolytic	B-DISO
anemia	I-DISO
.	O

Although	O
extra	O
-	O
pulmonary	B-DISO
disorders	I-DISO
are	O
commonly	O
diagnosed	O
in	O
foals	O
infected	O
with	O
R	O
.	O
equi	O
,	O
hemolytic	B-DISO
anemia	I-DISO
is	O
rarely	O
described	O
.	O

Following	O
admission	O
to	O
the	O
intensive	O
care	O
unit	O
,	O
hypoxia	B-DISO
became	O
critical	O
,	O
with	O
a	O
PaO	O
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
)	O
value	O
of	O
52	O
even	O
after	O
recruitment	B-DISO
maneuvers	O
.	O

All	O
patients	O
were	O
young	O
children	O
with	O
associated	O
invasive	O
Streptococcus	O
pneumoniae	O
pulmonary	B-DISO
infection	I-DISO
.	O

The	O
classical	O
post	O
-	O
diarrhoeal	O
form	O
associated	O
with	O
Escherichia	O
coli	O
(	O
O157	O
:	O
H7	O
)	O
infection	B-DISO
was	O
not	O
seen	O
.	O

The	O
acute	O
clinical	O
picture	O
is	O
similar	O
to	O
that	O
reported	O
in	O
the	O
western	O
literature	O
,	O
except	O
for	O
an	O
uncommon	O
association	O
with	O
meningitis	B-DISO
.	O

TITLE	O
:	O
Crystal	O
structure	O
and	O
functional	O
analysis	O
of	O
the	O
SARS	B-DISO
-	O
coronavirus	O
RNA	O
cap	B-DISO
2	O
'-	O
O	O
-	O
methyltransferase	O
nsp10	O
/	O
nsp16	O
complex	O
.	O

Intranasal	O
inoculation	O
of	O
ferrets	O
with	O
influenza	B-DISO
A	I-DISO
/	I-DISO
H5N1	I-DISO
virus	O
causes	O
lesions	O
in	O
both	O
the	O
respiratory	O
tract	O
and	O
extrarespiratory	O
organs	O
(	O
primarily	O
brain	O
).	O

The	O
method	O
of	O
virus	O
inoculation	O
requires	O
careful	O
consideration	O
in	O
the	O
design	O
of	O
ferret	O
experiments	O
as	O
a	O
model	O
for	O
influenza	B-DISO
A	I-DISO
/	I-DISO
H5N1	I-DISO
in	O
humans	O
.	O

Pathologically	O
ARDS	B-DISO
is	O
characterised	O
by	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
,	O
alveolar	O
capillary	O
leakage	B-DISO
,	O
and	O
protein	O
rich	O
pulmonary	B-DISO
oedema	I-DISO
leading	O
to	O
the	O
clinical	O
manifestation	O
of	O
poor	O
lung	O
compliance	O
,	O
severe	O
hypoxaemia	O
,	O
and	O
bilateral	O
infiltrates	B-DISO
on	O
chest	O
radiograph	O
.	O

Moreover	O
,	O
advances	O
in	O
general	O
supportive	O
measures	O
such	O
as	O
appropriate	O
antimicrobial	O
therapy	O
,	O
early	O
enteral	O
nutrition	O
,	O
prophylaxis	O
against	O
venous	B-DISO
thromboembolism	I-DISO
and	O
gastrointestinal	O
ulceration	B-DISO
are	O
likely	O
contributory	O
reasons	O
for	O
the	O
improved	O
outcomes	O
.	O

CT	O
of	O
the	O
abdomen	O
showed	O
a	O
large	O
retroperitoneal	O
hematoma	B-DISO
compressing	O
the	O
inferior	O
vena	O
cava	O
(	O
IVC	O
)	O
associated	O
with	O
contrast	O
blush	B-DISO
indicating	O
active	O
bleeding	B-DISO
.	O

TITLE	O
:	O
Host	O
and	O
viral	O
ecology	O
determine	O
bat	O
rabies	B-DISO
seasonality	O
and	O
maintenance	O
.	O

Within	O
viable	O
bat	O
populations	O
,	O
sufficiently	O
long	O
incubation	O
periods	O
allow	O
enough	O
infected	O
individuals	O
to	O
enter	O
hibernation	O
and	O
survive	O
until	O
the	O
following	O
year	O
,	O
and	O
hence	O
avoid	O
an	O
epizootic	O
fadeout	O
of	O
rabies	B-DISO
virus	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
otitis	I-DISO
media	I-DISO
with	O
perforation	O
(	O
AOMwiP	O
)	O
affects	O
40	O
%	O
of	O
remote	O
Indigenous	O
children	O
during	O
the	O
first	O
18	O
months	O
of	O
life	O
.	O

The	O
higher	O
number	O
of	O
PCR	O
-	O
positive	O
cases	O
was	O
possibly	O
attributed	O
to	O
amplification	B-DISO
of	O
viral	O
DNA	O
from	O
a	O
live	O
attenuated	O
vaccination	O
,	O
but	O
a	O
previous	O
FHV	O
-	O
1	O
infection	B-DISO
with	O
subsequent	O
amplification	B-DISO
of	O
latently	O
inserted	O
FHV	O
-	O
1	O
could	O
not	O
be	O
excluded	O
.	O

ABSTRACT	O
:	O
Africa	O
,	O
as	O
the	O
rest	O
of	O
the	O
world	O
,	O
was	O
touched	O
by	O
the	O
2009	O
pandemic	O
influenza	B-DISO
A	O
(	O
H1N1	O
).	O

From	O
29	O
November	O
2009	O
through	O
21	O
January	O
2010	O
,	O
32	O
patients	O
with	O
confirmed	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
were	O
admitted	O
to	O
our	O
ICU	O
.	O

TITLE	O
:	O
Increased	O
risk	O
of	O
multiple	B-DISO
sclerosis	I-DISO
following	O
herpes	B-DISO
zoster	I-DISO
:	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
study	O
.	O

The	O
goal	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
frequency	O
and	O
risk	O
for	O
MS	O
following	O
occurrence	O
of	O
herpes	B-DISO
zoster	I-DISO
.	O

A	O
total	O
of	O
315	O
,	O
550	O
patients	O
with	O
herpes	B-DISO
zoster	I-DISO
were	O
included	O
as	O
the	O
study	O
group	O
,	O
and	O
the	O
control	O
group	O
consisted	O
of	O
946	O
,	O
650	O
randomly	O
selected	O
subjects	O
.	O

We	O
found	O
a	O
significantly	O
higher	O
risk	O
for	O
MS	O
within	O
1	O
year	O
of	O
herpes	B-DISO
zoster	I-DISO
attack	O
compared	O
with	O
the	O
control	O
population	O
.	O

It	O
is	O
therefore	O
important	O
that	O
all	O
physicians	O
on	O
acute	O
medical	O
take	O
are	O
familiar	O
with	O
the	O
acute	O
management	O
of	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
.	O

This	O
review	O
encompasses	O
the	O
initial	O
management	O
which	O
is	O
subdivided	O
into	O
analgesia	B-DISO
,	O
investigations	O
and	O
supportive	O
care	O
.	O

A	O
total	O
of	O
115	O
patients	O
in	O
the	O
early	O
stages	O
of	O
sepsis	B-DISO
requiring	O
EN	O
were	O
included	O
,	O
among	O
whom	O
106	O
were	O
considered	O
evaluable	B-DISO
.	O

The	O
percentage	O
of	O
patients	O
fed	O
the	O
EPA	O
/	O
GLA	O
diet	O
requiring	O
invasive	O
mechanical	O
ventilation	O
was	O
reduced	O
compared	O
with	O
controls	O
(	O
ITT	O
patients	O
:	O
18	O
.	O
9	O
%	O
versus	O
33	O
.	O
9	O
%,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
394	O
;	O
evaluable	B-DISO
patients	O
:	O
17	O
.	O
5	O
%	O
versus	O
34	O
.	O
5	O
%,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
295	O
).	O

Patients	O
nourished	O
with	O
the	O
EPA	O
/	O
GLA	O
diet	O
remained	O
in	O
the	O
ICU	O
fewer	O
days	O
than	O
the	O
control	O
population	O
(	O
ITT	O
patients	O
:	O
21	O
.	O
1	O
ICU	O
-	O
free	O
days	O
versus	O
14	O
.	O
7	O
ICU	O
-	O
free	O
days	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
0001	O
;	O
evaluable	B-DISO
patients	O
:	O
20	O
.	O
8	O
ICU	O
-	O
free	O
days	O
versus	O
14	O
.	O
3	O
ICU	O
-	O
free	O
days	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
fewer	O
days	O
at	O
the	O
hospital	O
(	O
ITT	O
patients	O
:	O
19	O
.	O
5	O
hospital	O
-	O
free	O
days	O
versus	O
10	O
.	O
3	O
hospital	O
-	O
free	O
days	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
0001	O
;	O
evaluable	B-DISO
patients	O
:	O
19	O
.	O
1	O
hospital	O
-	O
free	O
days	O
versus	O
10	O
.	O
2	O
hospital	O
-	O
free	O
days	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
(	O
all	O
numbers	O
expressed	O
as	O
means	O
).	O

No	O
significant	O
differences	O
in	O
28	O
-	O
day	O
all	O
-	O
cause	O
mortality	O
were	O
observed	O
(	O
ITT	O
patients	O
:	O
26	O
.	O
2	O
%	O
EPA	O
/	O
GLA	O
diet	O
versus	O
27	O
.	O
6	O
%	O
control	O
diet	O
,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
72	O
;	O
evaluable	B-DISO
:	O
26	O
.	O
4	O
EPA	O
/	O
GLA	O
diet	O
versus	O
30	O
.	O
18	O
control	O
diet	O
,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
79	O
).	O

A	O
tandem	O
alkylation	O
,	O
γ	O
-	O
lactonization	O
,	O
a	O
chemoselective	O
reduction	O
of	O
ester	O
in	O
the	O
presence	O
of	O
γ	O
-	O
lactone	O
functional	O
group	O
,	O
a	O
RCM	B-DISO
reaction	O
,	O
and	O
a	O
Mitsunobu	O
coupling	O
reaction	O
were	O
used	O
as	O
key	O
reactions	O
.	O

Pneumonia	B-DISO
caused	O
by	O
HSV1	O
is	O
a	O
rare	O
finding	O
in	O
immunocompetent	O
individuals	O
;	O
it	O
occurs	O
more	O
often	O
in	O
immunosuppressed	O
and	O
ventilated	O
patients	O
.	O

In	O
the	O
absence	O
of	O
clinical	O
tamponade	O
,	O
examination	O
of	O
the	O
pericardial	B-DISO
fluid	I-DISO
is	O
indicated	O
when	O
there	O
is	O
a	O
clinical	O
suspicion	O
of	O
purulent	B-DISO
pericarditis	I-DISO
and	O
in	O
patients	O
with	O
underlying	O
neoplasia	B-DISO
.	O

Neoplastic	O
pericardial	B-DISO
effusion	I-DISO
constitutes	O
a	O
more	O
difficult	O
challenge	O
because	O
reaccumulation	O
of	O
pericardial	B-DISO
fluid	I-DISO
is	O
a	O
concern	O
.	O

Trypsin	O
treatment	O
during	O
the	O
budding	O
stage	O
of	O
virus	B-DISO
infection	I-DISO
induces	O
an	O
obvious	O
cytopathic	B-DISO
effect	I-DISO
in	O
infected	O
cells	O
.	O

Mouse	B-DISO
hepatitis	I-DISO
coronavirus	O
(	O
MHV	O
)	O
uses	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
of	O
its	O
spike	O
protein	O
as	O
its	O
receptor	O
-	O
binding	O
domain	O
.	O

ACS	O
appears	O
to	O
be	O
less	O
severe	O
in	O
children	O
with	O
hemoglobin	B-DISO
SC	I-DISO
disease	I-DISO
compared	O
to	O
that	O
in	O
children	O
with	O
SS	O
disease	O
.	O

Asthma	B-DISO
and	O
wheezing	B-DISO
may	O
represent	O
more	O
significant	O
risk	O
factors	O
for	O
the	O
development	O
of	O
ACS	O
in	O
children	O
with	O
hemoglobin	B-DISO
SC	I-DISO
disease	I-DISO
.	O

Sudden	O
severe	B-DISO
headache	I-DISO
had	O
progressed	O
and	O
developed	O
bilateral	O
lower	O
visual	O
fields	O
defect	O
along	O
with	O
mild	O
weakness	B-DISO
of	O
her	O
right	O
leg	O
on	O
the	O
next	O
day	O
.	O

Most	O
cases	O
with	O
adenovirus	B-DISO
,	O
influenza	B-DISO
A	O
,	O
hMPV	O
,	O
hBoV	O
,	O
coronaviruses	O
,	O
and	O
WU	O
virus	O
occurred	O
as	O
co	B-DISO
-	I-DISO
infections	I-DISO
while	O
RSV	O
,	O
PIV	O
-	O
3	O
,	O
and	O
rhinovirus	O
were	O
identified	O
most	O
frequently	O
as	O
the	O
only	O
respiratory	O
pathogen	O
.	O

Tachypnoea	B-DISO
,	O
low	O
grade	O
fever	O
,	O
clubbed	B-DISO
fingers	I-DISO
,	O
palmar	O
erythaema	O
,	O
spider	B-DISO
angioma	I-DISO
,	O
wheezing	B-DISO
and	O
severe	O
hypoxaemia	O
were	O
found	O
.	O

However	O
,	O
dyspnoea	B-DISO
and	O
hypoxaemia	O
recurred	O
with	O
widened	O
alveolar	O
-	O
arterial	O
gradient	O
,	O
which	O
was	O
unusual	O
in	O
COPD	B-DISO
.	O

Both	O
the	O
mutant	B-DISO
and	O
the	O
parental	O
(	O
rTGEV	O
-	O
wt	O
)	O
viruses	O
showed	O
the	O
same	O
growth	O
and	O
viral	O
RNA	O
accumulation	O
kinetics	O
in	O
tissue	O
cultures	O
.	O

TITLE	O
:	O
Neonatal	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
an	O
inflammatory	B-DISO
disease	I-DISO
?	O

From	O
4	O
to	O
6	O
days	O
postinfection	O
,	O
interstitial	B-DISO
pneumonia	I-DISO
with	O
alveolar	O
collapse	B-DISO
expanded	O
throughout	O
the	O
lungs	O
.	O

TITLE	O
:	O
Beyond	O
the	O
black	O
box	O
:	O
drug	O
-	O
and	O
device	O
-	O
associated	O
hypersensitivity	B-DISO
events	O
.	O

The	O
recent	O
increased	O
incidence	O
of	O
severe	O
respiratory	B-DISO
failure	I-DISO
due	O
to	O
H1N1	B-DISO
influenza	I-DISO
pandemic	O
has	O
led	O
to	O
an	O
increased	O
use	O
of	O
ECMO	O
.	O

In	O
this	O
article	O
,	O
we	O
reviewed	O
the	O
usefulness	O
of	O
ECMO	O
in	O
patients	O
with	O
severe	O
ARDS	B-DISO
in	O
the	O
light	O
of	O
current	O
evidence	O
.	O

Patients	O
with	O
ALI	O
or	O
ARDS	B-DISO
typically	O
experience	O
respiratory	B-DISO
failure	I-DISO
and	O
thus	O
require	O
mechanical	O
ventilation	O
for	O
support	O
,	O
which	O
itself	O
can	O
aggravate	O
lung	O
injury	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
fulminant	O
blastomycosis	B-DISO
in	O
Germany	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
establish	O
whether	O
HFOV	O
can	O
be	O
safely	O
applied	O
in	O
patients	O
with	O
acute	O
exacerbation	O
of	O
COPD	B-DISO
and	O
hypercapnic	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

Our	O
study	O
indicates	O
that	O
short	O
-	O
term	O
HFOV	O
,	O
using	O
lower	O
mean	O
airway	O
pressures	O
than	O
recommended	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
appears	O
safe	O
in	O
patients	O
with	O
COPD	B-DISO
while	O
securing	O
adequate	O
pulmonary	O
gas	O
exchange	O
.	O

RESULTS	O
:	O
High	O
-	O
frequency	O
oscillatory	O
ventilation	O
was	O
tolerated	O
well	O
;	O
no	O
adverse	B-DISO
effects	I-DISO
or	O
severe	O
hyperinflation	B-DISO
and	O
hemodynamic	O
compromise	O
were	O
observed	O
.	O

The	O
exclusion	O
criteria	O
include	O
patients	O
aged	O
under	O
15	O
years	O
,	O
a	O
history	O
of	O
hypersensitivity	B-DISO
to	O
the	O
use	O
of	O
corticosteroids	O
,	O
the	O
presence	O
of	O
active	O
infection	B-DISO
of	O
fungal	O
,	O
tuberculous	B-DISO
or	O
bacterial	O
origin	O
apart	O
from	O
the	O
infection	B-DISO
by	O
leptospira	O
itself	O
,	O
the	O
presence	O
of	O
hemoconcentration	O
or	O
atypical	O
lymphocyte	O
count	O
on	O
admission	O
to	O
hospital	O
,	O
the	O
presence	O
of	O
co	O
-	O
morbidities	O
that	O
could	O
be	O
responsible	O
for	O
the	O
radiological	O
and	O
gasometric	O
alterations	O
used	O
to	O
diagnose	O
leptospirotic	O
pneumonitis	B-DISO
,	O
evidence	O
of	O
recent	O
cranial	O
trauma	O
,	O
neurosurgery	O
,	O
peptic	B-DISO
ulcer	I-DISO
,	O
and	O
participation	O
in	O
another	O
clinical	O
trial	O
.	O

The	O
primary	O
end	O
-	O
point	O
is	O
mortality	O
from	O
leptospirotic	O
pneumonitis	B-DISO
.	O

ABSTRACT	O
:	O
The	O
management	O
of	O
bronchial	B-DISO
fistula	I-DISO
associated	O
with	O
acute	O
lung	O
injury	O
raises	O
two	O
major	O
concerns	O
:	O
(	O
1	O
)	O
high	O
ventilation	O
pressures	O
are	O
necessary	O
for	O
lung	O
recruitment	B-DISO
but	O
detrimental	O
for	O
fistula	B-DISO
healing	O
,	O
and	O
(	O
2	O
)	O
adequate	O
lung	O
recruitment	B-DISO
is	O
prevented	O
by	O
large	O
air	O
leak	O
.	O

During	O
a	O
1	O
-	O
year	O
period	O
,	O
this	O
protocol	O
management	O
was	O
used	O
in	O
5	O
patients	O
with	O
refractory	O
respiratory	B-DISO
failure	I-DISO
associated	O
with	O
bronchial	B-DISO
fistula	I-DISO
after	O
thoracic	B-DISO
operations	O
.	O

This	O
study	O
demonstrates	O
the	O
enhanced	O
protection	O
of	O
oral	O
co	O
-	O
administration	O
of	O
swine	O
interferon	O
-	O
α	O
(	O
swIFN	O
-	O
α	O
)	O
and	O
interleukin	O
-	O
18	O
(	O
swIL	O
-	O
18	O
)	O
against	O
infection	B-DISO
with	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
in	O
piglets	O
using	O
attenuated	O
Salmonella	B-DISO
enterica	O
serovar	O
Typhimurium	O
as	O
carrier	O
of	O
cytokine	O
proteins	O
.	O

The	O
results	O
suggest	O
that	O
the	O
combined	O
administration	O
of	O
the	O
swIFN	O
-	O
α	O
and	O
swIL	O
-	O
18	O
cytokines	O
using	O
attenuated	O
S	O
.	O
enterica	O
serovar	O
Typhimurium	O
as	O
an	O
oral	O
carrier	O
provides	O
enhanced	O
protection	O
against	O
intestinal	O
tract	O
infection	B-DISO
with	O
TGEV	O
.	O

TITLE	O
:	O
Genetic	O
determinants	O
of	O
pathogenesis	B-DISO
by	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
.	O

ABSTRACT	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
is	O
a	O
fatal	O
,	O
immune	O
-	O
augmented	O
,	O
and	O
progressive	O
viral	B-DISO
disease	I-DISO
of	O
cats	O
associated	O
with	O
feline	O
coronavirus	O
(	O
FCoV	O
).	O

Further	O
studies	O
exploring	O
both	O
viral	O
and	O
host	O
genetic	O
determinants	O
of	O
disease	O
in	O
FIP	B-DISO
offer	O
specific	O
opportunities	O
for	O
the	O
management	O
of	O
this	O
disease	O
.	O

If	O
their	O
'	O
fresh	O
'	O
host	O
had	O
no	O
defences	O
,	O
the	O
viruses	O
could	O
cause	O
a	O
serious	O
pandemic	O
,	O
as	O
seen	O
with	O
HIV	B-DISO
,	O
SARS	B-DISO
(	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
)	O
and	O
avian	B-DISO
influenza	I-DISO
virus	O
that	O
originated	O
from	O
chimpanzees	O
,	O
the	O
common	O
palm	O
civet	O
and	O
birds	O
,	O
respectively	O
.	O

More	O
specifically	O
,	O
it	O
documents	O
the	O
current	O
evidence	O
on	O
the	O
effects	O
of	O
higher	O
PEEP	O
in	O
preventing	O
(	O
or	O
attenuating	O
)	O
lung	O
damage	O
during	O
the	O
ventilatory	O
management	O
of	O
patients	O
with	O
severely	O
hypoxemic	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Since	O
its	O
discovery	O
in	O
the	O
western	O
hemisphere	O
in	O
1999	O
,	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
(	O
WNv	B-DISO
)	O
has	O
caused	O
extensive	O
bird	O
mortality	O
across	O
North	O
America	O
,	O
especially	O
in	O
American	O
crows	O
(	O
Corvus	O
brachyrhynchos	O
)	O
which	O
are	O
highly	O
susceptible	O
to	O
WNv	B-DISO
.	O

In	O
this	O
study	O
,	O
antigenic	O
distribution	O
of	O
WNv	B-DISO
among	O
different	O
organs	O
of	O
American	O
crows	O
was	O
studied	O
,	O
using	O
the	O
immunohistochemistry	O
technique	O
(	O
IHC	O
).	O

More	O
than	O
one	O
tissue	O
sample	O
is	O
suggested	O
to	O
screen	O
WNv	B-DISO
infection	B-DISO
using	O
IHC	O
technique	O
.	O

TITLE	O
:	O
The	O
NS1	B-DISO
glycoprotein	O
can	O
generate	O
dramatic	O
antibody	O
-	O
enhanced	O
dengue	B-DISO
viral	O
replication	O
in	O
normal	O
out	O
-	O
bred	O
mice	O
resulting	O
in	O
lethal	O
multi	O
-	O
organ	O
disease	O
.	O

These	O
AER	O
/	O
AED	O
mice	O
developed	O
life	O
-	O
threatening	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
displayed	O
by	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
(	O
DAD	O
)	O
resulting	O
from	O
i	O
)	O
dramatic	O
interstitial	O
alveolar	O
septa	O
-	O
thickening	O
with	O
mononuclear	O
cells	O
,	O
ii	O
)	O
some	O
hyperplasia	B-DISO
of	O
alveolar	O
type	O
-	O
II	O
pneumocytes	O
,	O
iii	O
)	O
copious	O
intra	O
-	O
alveolar	O
protein	O
secretion	O
,	O
iv	O
)	O
some	O
hyaline	B-DISO
membrane	I-DISO
-	O
covered	O
alveolar	O
walls	O
,	O
and	O
v	O
)	O
DENV	O
-	O
2	O
antigen	O
-	O
positive	O
alveolar	O
macrophages	O
.	O

Their	O
infections	B-DISO
were	O
confirmed	O
by	O
DENV	O
-	O
2	O
isolations	O
from	O
their	O
lungs	O
,	O
spleens	O
and	O
livers	O
.	O

This	O
DENV	O
-	O
2	O
AER	O
/	O
AED	O
was	O
blocked	O
by	O
high	O
concentrations	O
of	O
only	O
the	O
NG	O
-	O
C	O
NS1	B-DISO
glycoprotein	O
.	O

ABSTRACT	O
:	O
In	O
view	O
of	O
the	O
expected	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pandemic	O
,	O
the	O
Italian	O
Health	O
Authorities	O
set	O
up	O
a	O
national	O
referral	O
network	O
of	O
selected	O
intensive	O
care	O
units	O
(	O
ICU	O
)	O
able	O
to	O
provide	O
advanced	O
respiratory	O
care	O
up	O
to	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
for	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

TITLE	O
:	O
A	O
rare	O
case	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
secondary	O
to	O
acute	O
lithium	O
intoxication	O
.	O

The	O
patients	O
were	O
treated	O
with	O
saline	O
hydration	O
(	O
50	O
%)	O
or	O
hemodialysis	O
(	O
50	O
%),	O
indicating	O
that	O
hemodialysis	O
may	O
be	O
a	O
permissive	O
factor	O
in	O
lithium	O
-	O
associated	O
ARDS	B-DISO
development	O
rather	O
than	O
a	O
required	O
component	O
.	O

Adding	O
virucidals	O
or	O
antiseptics	O
to	O
normal	O
handwashing	O
to	O
decrease	O
respiratory	O
disease	B-DISO
transmission	I-DISO
remains	O
uncertain	O
.	O

Hospitals	O
are	O
often	O
the	O
epicentres	O
of	O
newly	O
circulating	O
infections	B-DISO
.	O

RESULTS	O
:	O
HCWs	O
perceived	O
risk	O
factors	O
for	O
occupationally	O
acquired	O
infectious	B-DISO
diseases	I-DISO
to	O
be	O
1	O
.)	O
exposure	O
to	O
patients	O
with	O
undiagnosed	O
infections	B-DISO
2	O
.)	O

ABSTRACT	O
:	O
Legionellosis	B-DISO
is	O
a	O
systemic	B-DISO
disease	I-DISO
that	O
primarily	O
affects	O
the	O
lungs	O
.	O

Although	O
her	O
respiratory	B-DISO
symptoms	I-DISO
responded	O
well	O
to	O
antibiotic	O
treatment	O
,	O
her	O
renal	O
function	O
worsened	O
,	O
with	O
severe	O
proteinuria	O
and	O
edema	B-DISO
.	O

TITLE	O
:	O
Sixty	O
-	O
two	O
severe	O
and	O
critical	O
patients	O
with	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
in	O
Shanghai	O
,	O
China	O
.	O

ABSTRACT	O
:	O
Pandemic	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
emerged	O
rapidly	O
in	O
China	O
in	O
May	O
2009	O
.	O

Severe	O
illness	O
from	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
infection	B-DISO
in	O
Shanghai	O
occurred	O
among	O
young	O
individuals	O
.	O

Four	O
death	O
reports	O
(	O
6	O
.	O
5	O
%)	O
were	O
filed	O
within	O
the	O
first	O
14	O
days	O
from	O
the	O
onset	O
of	O
critical	B-DISO
illness	I-DISO
with	O
the	O
primary	O
causes	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
hypoxemia	O
,	O
or	O
complications	O
,	O
secondary	B-DISO
infection	I-DISO
and	O
sepsis	B-DISO
,	O
pyopneumothorax	B-DISO
and	O
stroke	B-DISO
.	O

The	O
pathogenesis	B-DISO
is	O
still	O
unknown	O
.	O

We	O
sequenced	O
the	O
TSFM	O
gene	O
,	O
encoding	O
the	O
mitochondrial	O
translation	O
factor	O
EFTs	B-DISO
and	O
identified	O
a	O
homozygous	O
mutation	O
changing	O
a	O
highly	O
conserved	O
arginine	O
into	O
a	O
tryptophan	O
(	O
R312W	O
).	O

We	O
sequenced	O
the	O
TSFM	O
gene	O
,	O
encoding	O
the	O
mitochondrial	O
translation	O
factor	O
EFTs	B-DISO
and	O
identified	O
a	O
homozygous	O
mutation	O
changing	O
a	O
highly	O
conserved	O
arginine	O
into	O
a	O
tryptophan	O
(	O
R312W	O
).	O

Chest	O
radiography	O
shows	O
diffuse	O
pulmonary	O
opacities	B-DISO
.	O

TITLE	O
:	O
Cerebral	B-DISO
edema	I-DISO
and	O
a	O
transtentorial	O
brain	B-DISO
herniation	I-DISO
syndrome	B-DISO
associated	O
with	O
pandemic	O
swine	O
influenza	B-DISO
A	I-DISO
(	I-DISO
H1N1	I-DISO
)	I-DISO
virus	I-DISO
infection	I-DISO
.	O

SARS	B-DISO
-	O
CoV	O
S	O
peptide	O
-	O
specific	O
IFN	O
-	O
γ	O
(+)	O
CD8	O
(+)	O
T	O
cells	O
were	O
distributed	O
throughout	O
the	O
lymphoid	O
and	O
non	O
-	O
lymphoid	O
tissues	O
.	O

TITLE	O
:	O
IFN	O
-	O
γ	O
-	O
and	O
IL	O
-	O
10	O
-	O
expressing	O
virus	O
epitope	O
-	O
specific	O
Foxp3	O
(+)	O
T	O
reg	O
cells	O
in	O
the	O
central	O
nervous	B-DISO
system	O
during	O
encephalomyelitis	B-DISO
.	O

ABSTRACT	O
:	O
Foxp3	O
(+)	O
CD4	O
regulatory	O
T	O
cells	O
(	O
T	O
reg	O
cells	O
)	O
are	O
important	O
in	O
limiting	O
immunopathology	B-DISO
in	O
infections	B-DISO
.	O

Using	O
MHC	O
class	O
II	O
/	O
peptide	O
tetramers	O
and	O
intracellular	O
cytokine	O
staining	O
,	O
we	O
identify	O
T	O
reg	O
cells	O
recognizing	O
two	O
virus	O
-	O
specific	O
CD4	O
T	O
cell	O
epitopes	O
in	O
the	O
coronavirus	O
-	O
infected	O
central	O
nervous	B-DISO
system	O
as	O
well	O
as	O
naive	O
T	O
cell	O
precursor	O
pools	O
.	O

Although	O
human	O
CoV	O
HKU1	O
infection	B-DISO
is	O
not	O
usually	O
severe	O
,	O
in	O
highly	O
immunocompromised	O
patients	O
,	O
it	O
can	O
be	O
associated	O
with	O
fatal	O
pneumonia	B-DISO
.	O

Here	O
,	O
we	O
investigated	O
the	O
functional	O
mechanisms	O
of	O
PD	O
-	O
1	O
as	O
related	O
to	O
FH	O
pathogenesis	B-DISO
induced	O
by	O
the	O
murine	B-DISO
hepatitis	I-DISO
virus	O
strain	O
-	O
3	O
(	O
MHV	O
-	O
3	O
).	O

ABSTRACT	O
:	O
Previous	O
studies	O
have	O
demonstrated	O
that	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
hepatotropism	O
is	O
determined	O
largely	O
by	O
postentry	O
events	O
rather	O
than	O
by	O
availability	O
of	O
the	O
viral	O
receptor	O
.	O

These	O
data	O
imply	O
that	O
the	O
ability	O
of	O
MHV	O
to	O
replicate	O
in	O
macrophages	O
is	O
a	O
prerequisite	O
for	O
replication	O
in	O
the	O
liver	O
and	O
induction	O
of	O
hepatitis	B-DISO
but	O
not	O
for	O
replication	O
or	O
disease	O
in	O
the	O
CNS	O
,	O
underscoring	O
the	O
importance	O
of	O
IFN	O
signaling	O
in	O
macrophages	O
in	O
vivo	O
for	O
protection	O
of	O
the	O
host	O
from	O
hepatitis	B-DISO
.	O

ABSTRACT	O
:	O
Low	O
micromolar	O
,	O
non	O
-	O
cytotoxic	O
concentrations	O
of	O
cyclosporin	O
A	O
(	O
CsA	B-DISO
)	O
strongly	O
affected	O
the	O
replication	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
human	O
coronavirus	O
229E	O
and	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
in	O
cell	O
culture	O
,	O
as	O
was	O
evident	O
from	O
the	O
strong	O
inhibition	O
of	O
GFP	O
reporter	O
gene	O
expression	O
and	O
a	O
reduction	O
of	O
up	O
to	O
4	O
logs	O
in	O
progeny	O
titres	O
.	O

ABSTRACT	O
:	O
Superoxide	O
is	O
produced	O
by	O
activated	O
neutrophils	O
during	O
the	O
inflammatory	B-DISO
response	I-DISO
to	O
stimuli	O
such	O
as	O
endotoxin	O
,	O
can	O
directly	O
or	O
indirectly	O
injure	O
host	O
cells	O
,	O
and	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	B-DISO
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

The	O
AAV	O
vector	O
itself	O
did	O
not	O
contribute	O
to	O
inflammation	B-DISO
or	O
to	O
lung	O
injury	O
.	O

The	O
AAV	O
vector	O
itself	O
did	O
not	O
contribute	O
to	O
inflammation	B-DISO
or	O
to	O
lung	O
injury	O
.	O

TITLE	O
:	O
Local	O
renin	O
-	O
angiotensin	O
II	O
systems	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
and	O
its	O
homologue	O
ACE2	O
:	O
their	O
potential	O
role	O
in	O
the	O
pathogenesis	B-DISO
of	O
chronic	O
obstructive	B-DISO
pulmonary	I-DISO
diseases	I-DISO
,	O
pulmonary	B-DISO
hypertension	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ACE	O
and	O
ACE2	O
also	O
appear	O
to	O
modify	O
the	O
severity	O
of	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
with	O
ACE2	O
playing	O
a	O
protective	O
role	O
.	O

Since	O
1997	O
,	O
several	O
new	O
respiratory	O
viruses	O
and	O
their	O
subgroups	O
have	O
been	O
discovered	O
:	O
influenza	B-DISO
A	O
viruses	O
H5N1	B-DISO
and	O
H1N1	O
,	O
human	O
metapneumovirus	O
,	O
coronaviruses	O
SARS	B-DISO
,	O
NL63	O
and	O
HKU1	O
,	O
human	O
bocavirus	O
,	O
human	O
rhinoviruses	O
C	O
and	O
D	O
and	O
potential	O
respiratory	O
pathogens	O
,	O
the	O
KI	O
and	O
WU	O
polyomaviruses	O
and	O
the	O
torque	O
teno	O
virus	O
.	O

P	O
.	O
knowlesi	O
is	O
a	O
major	O
cause	O
of	O
severe	O
and	O
fatal	O
malaria	B-DISO
in	O
Sabah	O
.	O

TITLE	O
:	O
Chimeric	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
S	O
glycoprotein	O
and	O
influenza	B-DISO
matrix	O
1	O
efficiently	O
form	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
that	O
protect	O
mice	O
against	O
challenge	O
with	O
SARS	B-DISO
-	O
CoV	O
.	O
ABSTRACT	O
:	O
SARS	B-DISO
-	O
CoV	O
was	O
the	O
cause	O
of	O
the	O
global	O
pandemic	O
in	O
2003	O
that	O
infected	O
over	O
8000	O
people	O
in	O
8	O
months	O
.	O

SARS	B-DISO
-	O
CoV	O
VLPs	O
are	O
highly	O
immunogenic	O
and	O
induce	O
neutralizing	O
antibodies	O
and	O
provide	O
protection	O
against	O
lethal	O
challenge	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
Eosinophilic	I-DISO
Pneumonia	I-DISO
(	O
AEP	O
)	O
is	O
a	O
severe	O
syndrome	B-DISO
which	O
can	O
be	O
potentially	O
induced	O
by	O
many	O
reasons	O
,	O
including	O
drugs	O
.	O

TITLE	O
:	O
SARS	B-DISO
-	O
Coronavirus	O
ancestor	O
'	O
s	O
foot	O
-	O
prints	O
in	O
South	O
-	O
East	O
Asian	O
bat	O
colonies	O
and	O
the	O
refuge	O
theory	O
.	O

To	O
elucidate	O
the	O
biogeographic	O
origin	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
investigate	O
the	O
role	O
that	O
bats	O
played	O
in	O
its	O
emergence	O
,	O
we	O
amplified	O
coronavirus	O
sequences	O
from	O
bat	O
species	O
captured	O
throughout	O
Thailand	O
and	O
assessed	O
the	O
phylogenetic	O
relationships	O
to	O
each	O
other	O
and	O
to	O
other	O
published	O
coronavirus	O
sequences	O
.	O

Patients	O
(	O
60	O
.	O
0	O
%	O
male	O
;	O
mean	O
age	O
,	O
52	O
;	O
sd	O
17	O
)	O
had	O
predominantly	O
acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
89	O
.	O
8	O
%)	O
and	O
were	O
severely	O
ill	B-DISO
(	O
mean	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
score	O
,	O
28	O
;	O
sd	O
,	O
9	O
)	O
and	O
hypoxemic	O
(	O
mean	O
Pao2	O
/	O
Fio2	O
,	O
80	O
;	O
sd	O
,	O
42	O
).	O

During	O
high	O
-	O
frequency	O
oscillation	O
,	O
adjunctive	O
treatments	O
(	O
neuromuscular	B-DISO
blockade	I-DISO
,	O
75	O
.	O
6	O
%;	O
recruitment	B-DISO
maneuvers	O
,	O
49	O
.	O
5	O
%;	O
nitric	O
oxide	O
,	O
34	O
.	O
0	O
%;	O
steroids	O
,	O
63	O
.	O
1	O
%)	O
and	O
new	O
barotrauma	O
or	O
chest	O
tube	O
placement	O
(	O
23	O
.	O
5	O
%)	O
were	O
common	O
.	O

TITLE	O
:	O
Recent	O
developments	O
in	O
anti	O
-	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
chemotherapy	O
.	O

Thus	O
,	O
it	O
seems	O
prudent	O
to	O
continue	O
to	O
explore	O
and	O
develop	O
antiviral	O
chemotherapies	O
to	O
treat	O
SARS	B-DISO
-	O
CoV	O
infections	B-DISO
.	O

TITLE	O
:	O
The	O
advent	O
of	O
ECMO	O
and	O
pumpless	O
extracorporeal	O
lung	O
assist	O
in	O
ARDS	B-DISO
.	O

The	O
condition	B-DISO
can	O
stem	O
from	O
a	O
multitude	O
of	O
causes	O
including	O
pneumonia	B-DISO
,	O
septicemia	B-DISO
and	O
trauma	O
ultimately	O
resulting	O
in	O
ARDS	B-DISO
.	O

The	O
expressions	O
of	O
four	O
segments	O
of	O
spike	O
proteins	O
in	O
recombinant	O
vaccinia	B-DISO
viruses	O
were	O
showed	O
at	O
appropriate	O
level	O
and	O
with	O
posttranslational	O
modification	O
(	O
glycosylation	O
),	O
and	O
S1	O
,	O
RL	O
and	O
RS	O
were	O
mainly	O
distributed	O
in	O
the	O
cell	O
membrane	O
,	O
while	O
the	O
S2	O
was	O
mainly	O
distributed	O
in	O
the	O
cytoplasm	O
.	O

ABSTRACT	O
:	O
Public	O
health	O
measures	O
successfully	O
contained	O
outbreaks	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
infection	B-DISO
.	O

Our	O
results	O
suggest	O
a	O
novel	O
mechanism	O
by	O
which	O
SARS	B-DISO
-	O
CoV	O
can	O
enter	O
target	O
cells	O
and	O
illustrate	O
the	O
potential	O
pitfalls	O
associated	O
with	O
immunization	O
against	O
it	O
.	O

ABSTRACT	O
:	O
Mice	O
infected	O
with	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
develop	O
pathological	O
and	O
clinical	O
outcomes	O
similar	O
to	O
patients	O
with	O
the	O
demyelinating	B-DISO
disease	I-DISO
Multiple	B-DISO
Sclerosis	I-DISO
(	O
MS	O
).	O

It	O
is	O
important	O
for	O
mangers	O
to	O
provide	O
a	O
support	O
to	O
healthcare	O
workers	O
during	O
influenza	B-DISO
pandemic	O
by	O
providing	O
a	O
clear	O
guideline	O
/	O
policy	O
for	O
case	O
management	O
and	O
demonstrating	O
appreciation	O
for	O
the	O
frontline	O
healthcare	O
workers	O
to	O
minimise	O
the	O
risk	O
for	O
high	O
staff	O
turnover	O
rates	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
outbreaks	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
H5N1	B-DISO
(	O
avian	B-DISO
influenza	I-DISO
),	O
and	O
,	O
most	O
recently	O
,	O
the	O
novel	B-DISO
H1N1	I-DISO
influenza	I-DISO
pandemic	O
of	O
2009	O
have	O
raised	O
awareness	O
of	O
the	O
danger	O
of	O
new	O
and	O
emerging	O
infections	B-DISO
.	O

Only	O
6	O
(	O
14	O
.	O
3	O
%)	O
of	O
the	O
schools	O
with	O
influenza	B-DISO
specific	O
Web	B-DISO
sites	O
had	O
information	O
for	O
parents	O
,	O
with	O
23	O
(	O
54	O
.	O
8	O
%)	O
providing	O
information	O
specifically	O
for	O
faculty	O
and	O
staff	O
,	O
and	O
24	O
(	O
57	O
.	O
1	O
%)	O
providing	O
information	O
specifically	O
to	O
students	O
.	O

A	O
series	O
of	O
wind	B-DISO
tunnel	O
experiments	O
were	O
conducted	O
using	O
a	O
1	O
:	O
30	O
scale	O
model	O
that	O
represented	O
the	O
real	O
structures	O
under	O
study	O
.	O

Recently	O
,	O
the	O
combination	O
of	O
cell	O
and	O
gene	O
therapy	O
which	O
has	O
been	O
demonstrated	O
to	O
provide	O
additive	O
benefit	O
has	O
opened	O
up	O
a	O
new	O
chapter	O
in	O
therapeutic	O
strategy	O
and	O
provides	O
a	O
basis	O
for	O
the	O
development	O
of	O
an	O
innovative	O
approach	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
ALI	O
/	O
ARDS	B-DISO
.	O

The	O
most	O
common	O
clinical	O
diagnosis	O
was	O
bronchopneumonia	B-DISO
(	O
83	O
.	O
33	O
%).	O

Coronavirus	O
HKU1	O
may	O
be	O
important	O
pathogens	O
in	O
children	O
with	O
acute	B-DISO
lower	I-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
the	O
aetiological	O
agent	O
of	O
the	O
highly	O
infectious	B-DISO
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

TITLE	O
:	O
Cytokine	O
levels	O
in	O
bronchoalveolar	O
lavage	O
and	O
serum	O
in	O
3	O
patients	O
with	O
2009	O
Influenza	B-DISO
A	O
(	O
H1N1	O
)	O
v	O
severe	O
pneumonia	B-DISO
.	O

In	O
this	O
study	O
,	O
we	O
assess	O
the	O
inflammatory	B-DISO
response	I-DISO
mediated	O
by	O
cytokines	O
at	O
the	O
local	O
and	O
systemic	O
levels	O
in	O
three	O
cases	O
of	O
severe	O
pneumonia	B-DISO
caused	O
by	O
Influenza	B-DISO
A	O
(	O
H1N1	O
)	O
virus	O
.	O

RESULTS	O
:	O
High	O
levels	O
of	O
C	O
Reactive	O
Protein	O
,	O
Procalcitonin	O
below	O
1	O
ng	O
/	O
ml	O
and	O
absence	O
of	O
leukocytosis	B-DISO
were	O
common	O
findings	O
in	O
all	O
patients	O
.	O

This	O
method	O
of	O
rapid	O
heat	O
transfer	O
has	O
enabled	O
30	O
cycles	O
of	O
PCR	O
amplification	B-DISO
to	O
be	O
completed	O
in	O
as	O
little	O
as	O
two	O
minutes	O
and	O
eighteen	O
seconds	O
.	O

Our	O
results	O
showed	O
that	O
:	O
(	O
i	O
)	O
deletion	O
of	O
18aa	O
from	O
the	O
C	O
-	O
terminus	O
enhanced	O
the	O
S	O
protein	O
accumulation	O
and	O
virus	O
entry	O
,	O
which	O
might	O
be	O
due	O
to	O
the	O
deletion	O
of	O
intracellular	O
retention	O
signals	O
;	O
(	O
ii	O
)	O
further	O
deletion	O
to	O
residue	O
29	O
also	O
enhanced	O
the	O
amount	O
of	O
S	O
protein	O
on	O
the	O
cell	O
surface	O
and	O
in	O
virion	O
,	O
but	O
reduced	O
virus	O
entry	O
by	O
25	O
%,	O
suggesting	O
that	O
residues	O
19	O
-	O
29	O
contributes	O
to	O
membrane	O
fusion	O
;	O
(	O
iii	O
)	O
a	O
29aa	O
-	O
deletion	O
mutant	B-DISO
had	O
a	O
defect	O
in	O
anchoring	O
on	O
the	O
plasma	O
membrane	O
,	O
which	O
led	O
to	O
a	O
dramatic	O
decrease	O
of	O
S	O
protein	O
in	O
virion	O
and	O
virus	O
entry	O
;	O
(	O
iv	O
)	O
a	O
total	O
of	O
15	O
residues	O
(	O
Y498	O
,	O
V499	O
,	O
V531	O
,	O
G534	O
,	O
G537	O
,	O
D538	O
,	O
S540	O
,	O
G575	O
,	O
S576	O
,	O
E582	O
,	O
W585	O
,	O
Y590	O
,	O
T591	O
,	O
V593	O
and	O
G594	O
)	O
within	O
RBD	O
were	O
important	O
for	O
receptor	O
binding	O
and	O
virus	O
entry	O
.	O

We	O
find	O
that	O
an	O
RNA	O
capable	O
of	O
forming	O
only	O
the	O
predicted	O
PK	O
(	O
58	O
nt	O
;	O
3	O
'	O
nucleotides	O
241	O
-	O
185	O
)	O
adopts	O
the	O
P2	O
stem	O
-	O
loop	O
with	O
little	O
evidence	O
for	O
P1	O
(	O
pk	O
)	O
pairing	O
in	O
0	O
.	O
1	O
M	O
KCl	O
and	O
the	O
absence	O
of	O
Mg	O
(	O
2	O
+);	O
as	O
Mg	O
(	O
2	O
+)	O
or	O
1	O
M	O
KCl	O
is	O
added	O
,	O
a	O
new	O
thermal	O
unfolding	O
transition	B-DISO
is	O
induced	O
and	O
assignable	O
to	O
P1	O
(	O
pk	O
)	O
pairing	O
.	O

Degradation	O
through	O
autophagy	O
can	O
provide	O
an	O
innate	O
defence	O
against	O
virus	B-DISO
infection	I-DISO
,	O
or	O
conversely	O
autophagosomes	O
can	O
promote	O
infection	B-DISO
by	O
facilitating	O
assembly	O
of	O
replicase	O
proteins	O
.	O

TITLE	O
:	O
MMP9	O
deficiency	O
does	O
not	O
decrease	O
blood	O
-	O
brain	O
barrier	O
disruption	O
,	O
but	O
increases	O
astrocyte	O
MMP3	O
expression	O
during	O
viral	O
encephalomyelitis	B-DISO
.	O

Moreover	O
,	O
significantly	O
enhanced	O
MMP3	O
expression	O
by	O
astrocytes	O
in	O
infected	O
MMP9	O
(-/-)	O
mice	O
suggests	O
an	O
active	O
role	O
of	O
resident	O
cells	O
in	O
participating	O
and	O
potentially	O
collaborating	O
with	O
infiltrating	B-DISO
cells	O
in	O
regulating	O
BBB	O
permeability	O
.	O

To	O
evaluate	O
the	O
clinical	O
utility	O
of	O
the	O
ELISA	O
,	O
serum	O
samples	O
collected	O
from	O
patients	O
during	O
an	O
outbreak	O
of	O
HCoV	O
-	O
OC43	O
infection	B-DISO
and	O
previously	O
identified	O
as	O
positive	O
by	O
HCoV	O
-	O
OC43	O
whole	O
N	O
ELISA	O
were	O
screened	O
resulting	O
in	O
100	O
%	O
diagnosis	O
agreement	O
between	O
the	O
testing	O
methods	O
.	O

Five	O
patients	O
showed	O
abnormal	B-DISO
behavior	I-DISO
as	O
a	O
complication	B-DISO
of	O
encephalopathy	B-DISO
.	O

We	O
found	O
that	O
respiratory	B-DISO
failure	I-DISO
progressed	O
rapidly	O
.	O

TITLE	O
:	O
[	O
The	O
community	O
health	O
team	O
:	O
roles	O
and	O
responsibilities	O
in	O
infection	B-DISO
control	O
].	O

Objectives	O
of	O
this	O
study	O
were	O
to	O
determine	O
if	O
asthma	B-DISO
characteristics	O
are	O
present	O
in	O
adults	O
with	O
a	O
doctor	O
-	O
diagnosis	O
of	O
asthma	B-DISO
and	O
/	O
or	O
wheezing	B-DISO
,	O
and	O
to	O
examine	O
the	O
relationship	O
between	O
doctor	O
-	O
diagnosis	O
of	O
asthma	B-DISO
,	O
wheezing	B-DISO
and	O
SCD	B-DISO
morbidity	O
.	O

This	O
was	O
an	O
observational	O
cohort	O
study	O
of	O
114	O
adults	O
with	O
SCD	B-DISO
who	O
completed	O
respiratory	B-DISO
symptom	I-DISO
questionnaires	O
and	O
had	O
serum	O
IgE	B-DISO
measurements	O
.	O

Adults	O
reporting	O
a	O
doctor	O
-	O
diagnosis	O
of	O
asthma	B-DISO
(	O
N	O
=	O
34	O
)	O
were	O
more	O
likely	O
to	O
have	O
features	O
of	O
asthma	B-DISO
including	O
wheeze	B-DISO
,	O
eczema	B-DISO
,	O
family	O
history	O
of	O
asthma	B-DISO
,	O
and	O
an	O
elevated	O
IgE	B-DISO
level	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

However	O
,	O
there	O
was	O
no	O
difference	O
in	O
pain	O
or	O
ACS	O
rate	O
,	O
lung	O
function	O
,	O
or	O
risk	O
of	O
death	O
between	O
adults	O
with	O
and	O
without	O
a	O
doctor	O
-	O
diagnosis	O
of	O
asthma	B-DISO
.	O

They	O
were	O
able	O
to	O
degranulate	O
and	O
produce	O
gamma	O
interferon	O
,	O
tumor	B-DISO
necrosis	I-DISO
factor	O
alpha	O
,	O
and	O
macrophage	O
inflammatory	O
proteins	O
1α	O
and	O
1β	O
after	O
antigenic	O
stimulation	O
.	O

One	O
of	O
the	O
least	O
understood	O
prognosticators	O
is	O
generalised	O
status	O
myoclonus	B-DISO
(	O
GSM	B-DISO
),	O
with	O
case	O
reports	O
confusing	O
GSM	B-DISO
,	O
isolated	O
myoclonic	B-DISO
jerks	I-DISO
and	O
post	O
-	O
hypoxic	B-DISO
intention	B-DISO
myoclonus	I-DISO
(	O
Lance	B-DISO
Adams	I-DISO
syndrome	I-DISO
[	O
LAS	O
]).	O

In	O
the	O
most	O
severe	O
case	O
,	O
extensive	O
embolization	O
was	O
associated	O
pulmonary	O
damage	O
consistent	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
emerged	O
as	O
the	O
causal	O
agent	O
of	O
an	O
endemic	O
atypical	B-DISO
pneumonia	I-DISO
,	O
infecting	O
thousands	O
of	O
people	O
worldwide	O
.	O

More	O
than	O
30	O
%	O
of	O
cases	O
are	O
idiopathic	O
,	O
but	O
they	O
are	O
commonly	O
related	O
to	O
a	O
dental	O
or	O
oropharyngeal	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
To	O
report	O
the	O
management	O
of	O
a	O
38	O
-	O
yr	O
-	O
old	O
patient	O
with	O
known	O
Marfan	B-DISO
syndrome	I-DISO
who	O
presented	O
with	O
acute	O
Stanford	O
type	O
A	O
dissection	O
of	O
the	O
aorta	O
in	O
the	O
34	O
(	O
th	O
)	O
week	O
of	O
pregnancy	O
.	O

Bleeding	B-DISO
because	O
of	O
absent	O
synthesis	O
of	O
various	O
coagulation	O
factors	O
and	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
,	O
acute	O
kidney	O
failure	B-DISO
,	I-DISO
circulatory	I-DISO
failure	O
with	O
vasopressor	O
dependence	B-DISO
,	O
respiratory	B-DISO
failure	I-DISO
with	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
neurological	O
failure	O
up	O
to	O
coma	B-DISO
because	O
of	O
hepatic	B-DISO
encephalopathy	I-DISO
,	O
and	O
a	O
very	O
high	O
risk	O
of	O
infection	B-DISO
and	O
sepsis	B-DISO
frequently	O
result	O
from	O
the	O
initial	O
state	O
of	O
isolated	O
liver	B-DISO
failure	I-DISO
.	O

However	O
,	O
increasing	O
the	O
rate	O
of	O
spontaneous	O
recovery	O
of	O
the	O
patients	O
'	O
own	O
liver	O
,	O
and	O
reducing	O
the	O
need	O
for	O
liver	O
transplantation	O
is	O
preferable	O
and	O
would	O
further	O
improve	O
the	O
outcome	O
of	O
acute	B-DISO
liver	I-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Current	O
therapeutic	O
uses	O
,	O
pharmacology	O
,	O
and	O
clinical	O
considerations	O
of	O
neuromuscular	O
blocking	B-DISO
agents	O
for	O
critically	B-DISO
ill	I-DISO
adults	O
.	O

Moreover	O
,	O
HR1	O
and	O
HR2	O
derived	O
free	O
peptides	O
are	O
inhibitors	O
of	O
SARS	B-DISO
-	O
CoV	O
entry	O
.	O

TITLE	O
:	O
Microwave	O
assisted	O
organic	O
synthesis	O
(	O
MAOS	O
)	O
of	O
small	O
molecules	O
as	O
potential	O
HIV	B-DISO
-	O
1	O
integrase	O
inhibitors	O
.	O

In	O
recent	O
years	O
our	O
research	O
group	O
has	O
been	O
engaged	O
in	O
the	O
stucture	O
-	O
function	O
study	O
of	O
this	O
enzyme	O
and	O
in	O
the	O
development	O
of	O
some	O
three	O
-	O
dimensional	O
pharmacophore	O
models	O
which	O
have	O
led	O
to	O
the	O
identification	O
of	O
a	O
large	O
series	O
of	O
potent	O
HIV	B-DISO
-	O
1	O
integrase	O
strand	O
-	O
transfer	O
inhibitors	O
(	O
INSTIs	O
)	O
bearing	O
an	O
indole	O
core	O
.	O

ABSTRACT	O
:	O
The	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
severe	O
and	O
frequently	O
seen	O
complication	B-DISO
in	O
multi	O
-	O
trauma	O
patients	O
.	O

None	O
of	O
the	O
patients	O
developed	O
ARDS	B-DISO
.	O

Influenza	B-DISO
virus	O
predominated	O
in	O
children	O
older	O
than	O
1	O
year	O
old	O
,	O
with	O
type	O
B	O
being	O
the	O
dominant	O
type	O
for	O
the	O
first	O
season	O
and	O
subtypes	O
A	O
/	O
H3N2	O
and	O
A	O
/	O
H1N1	O
the	O
following	O
two	O
winter	O
seasons	O
,	O
respectively	O
.	O

This	O
is	O
the	O
most	O
comprehensive	O
study	O
of	O
the	O
epidemiology	O
of	O
respiratory	O
viruses	O
in	O
Greece	O
,	O
indicating	O
influenza	B-DISO
,	O
rhinovirus	O
and	O
respiratory	O
syncytial	O
virus	O
as	O
major	O
contributors	O
to	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
in	O
children	O
.	O

TACO	B-DISO
and	O
TRALI	B-DISO
are	O
less	O
frequent	O
;	O
they	O
have	O
been	O
reported	O
according	O
to	O
the	O
number	O
of	O
transfusions	O
:	O
one	O
in	O
1275	O
to	O
6000	O
for	O
TRALI	B-DISO
and	O
one	O
in	O
356	O
transfusions	O
for	O
TACO	B-DISO
.	O

TITLE	O
:	O
Mutation	O
in	O
the	O
cytoplasmic	O
retrieval	O
signal	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
spike	O
(	O
S	O
)	O
protein	O
is	O
responsible	O
for	O
enhanced	O
fusion	O
activity	O
.	O

This	O
study	O
aimed	O
to	O
determine	O
the	O
prevalence	O
of	O
avian	B-DISO
influenza	I-DISO
virus	O
,	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
,	O
and	O
Newcastle	B-DISO
disease	I-DISO
virus	O
among	O
domestic	O
and	O
wild	O
birds	O
in	O
highly	O
pathogenic	O
avian	B-DISO
influenza	I-DISO
(	O
HPAI	O
)	O
H5N1	B-DISO
outbreaks	O
areas	O
.	O

Total	O
RNA	O
extracted	O
from	O
samples	O
were	O
subjected	O
to	O
reverse	O
transcription	O
and	O
resulting	O
cDNA	O
amplified	O
by	O
PCR	O
using	O
specific	O
primers	O
for	O
detection	O
of	O
Avian	B-DISO
Influenza	I-DISO
Virus	O
(	O
AIV	O
mainly	O
highly	O
pathogenic	O
H5N1	B-DISO
),	O
Infectious	B-DISO
Bronchitis	B-DISO
Virus	O
(	O
IBV	O
),	O
and	O
Newcastle	B-DISO
Disease	I-DISO
Virus	O
(	O
NDV	O
)	O
for	O
the	O
first	O
time	O
in	O
Burkina	O
Faso	O
.	O

The	O
attribution	O
of	O
stigma	O
during	O
the	O
SARS	B-DISO
outbreak	O
occurred	O
in	O
multiple	O
and	O
overlapping	O
ways	O
informed	O
by	O
:	O
(	O
i	O
)	O
the	O
depiction	O
of	O
images	O
of	O
individuals	O
donning	O
respiratory	O
masks	O
;	O
(	O
ii	O
)	O
employment	O
status	O
in	O
the	O
health	O
sector	O
;	O
and	O
(	O
iii	O
)	O
Asian	O
-	O
Canadian	O
and	O
Chinese	O
-	O
Canadian	O
ethnicity	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effect	O
of	O
HC	O
on	O
cell	O
infection	B-DISO
by	O
IBV	O
was	O
determined	O
using	O
plaque	B-DISO
assay	O
and	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
.	O

During	O
the	O
study	O
period	O
178	O
patients	O
with	O
diffuse	O
viral	B-DISO
pneumonitis	I-DISO
requiring	O
MV	O
were	O
admitted	O
.	O

TITLE	O
:	O
Update	O
on	O
rhinovirus	O
and	O
coronavirus	B-DISO
infections	I-DISO
.	O

Here	O
we	O
describe	O
the	O
effectiveness	O
of	O
SHEDD	O
-	O
fA	O
,	O
which	O
makes	O
the	O
best	O
use	O
of	O
three	O
principles	O
:	O
dialysis	O
,	O
filtration	O
and	O
adsorption	O
,	O
for	O
mediator	O
removal	O
in	O
the	O
treatment	O
of	O
severe	B-DISO
sepsis	I-DISO
.	O

The	O
average	O
sequential	O
organ	B-DISO
failure	I-DISO
assessment	O
score	O
of	O
patients	O
was	O
10	O
.	O
1	O
and	O
the	O
mortality	O
at	O
28	O
days	O
was	O
16	O
.	O
4	O
%	O
(	O
46	O
survived	O
,	O
9	O
died	O
).	O

Active	O
SDAV	O
infection	B-DISO
severely	O
impaired	B-DISO
nerve	O
regeneration	O
and	O
negated	O
the	O
positive	O
effect	O
of	O
FK506	O
on	O
nerve	O
regeneration	O
in	O
rats	O
.	O

The	O
high	O
sensitivity	O
of	O
these	O
tests	O
affects	O
our	O
understanding	O
of	O
the	O
epidemiology	O
of	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
.	O

Seven	O
thousand	O
eight	O
hundred	O
and	O
fifty	O
-	O
three	O
nasopharyngeal	O
samples	O
from	O
7220	O
patients	O
(	O
age	O
range	O
0	O
-	O
98	O
y	O
,	O
median	O
22	O
y	O
)	O
obtained	O
during	O
36	O
consecutive	O
months	O
(	O
November	O
2006	O
-	O
October	O
2009	O
),	O
were	O
analyzed	O
with	O
a	O
multiplex	O
PCR	O
panel	O
including	O
influenza	B-DISO
A	O
(	O
IfA	O
)	O
and	O
B	O
(	O
IfB	O
)	O
virus	O
,	O
parainfluenza	B-DISO
virus	O
(	O
PIV	O
)	O
1	O
-	O
3	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
human	O
rhinovirus	O
(	O
HRV	O
),	O
human	O
coronavirus	O
(	O
CoV	O
)	O
OC43	O
,	O
NL63	O
,	O
and	O
229E	O
,	O
human	O
metapneumovirus	O
(	O
HMPV	O
),	O
adenovirus	B-DISO
(	O
AdV	O
),	O
enterovirus	O
(	O
EV	O
),	O
and	O
2	O
bacteria	O
--	O
Mycoplasma	B-DISO
pneumoniae	O
and	O
Chlamydophila	O
pneumoniae	O
.	O

ABSTRACT	O
:	O
Viruses	O
cause	O
a	O
high	O
percentage	O
of	O
community	O
-	O
acquired	O
pneumonias	B-DISO
.	O

TITLE	O
:	O
Complementary	O
roles	O
of	O
Fas	B-DISO
-	O
associated	O
death	O
domain	O
(	O
FADD	O
)	O
and	O
receptor	O
interacting	O
protein	O
kinase	O
-	O
3	O
(	O
RIPK3	O
)	O
in	O
T	O
-	O
cell	O
homeostasis	O
and	O
antiviral	O
immunity	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
that	O
receptor	O
-	O
interacting	O
protein	O
kinases	O
(	O
RIPKs	O
)	O
RIPK1	O
and	O
RIPK3	O
together	O
facilitate	O
TNF	O
-	O
induced	O
necroptosis	B-DISO
,	O
but	O
the	O
precise	O
role	O
of	O
RIPKs	O
in	O
the	O
demise	O
of	O
T	O
cells	O
lacking	O
FADD	O
or	O
casp8	O
activity	O
is	O
unknown	O
.	O

TITLE	O
:	O
Neuroleptic	B-DISO
malignant	I-DISO
syndrome	I-DISO
versus	O
serotonin	B-DISO
syndrome	I-DISO
:	O
the	O
search	O
for	O
a	O
diagnostic	O
tool	O
.	O

It	O
is	O
mainly	O
characterized	O
by	O
hyperthermia	O
,	O
altered	O
mental	O
state	O
,	O
hemodynamic	O
dysregulation	O
,	O
elevated	O
serum	O
creatine	O
kinase	O
,	O
and	O
rigors	B-DISO
.	O

It	O
has	O
been	O
associated	O
with	O
multisystem	B-DISO
organ	I-DISO
failure	I-DISO
potentially	O
leading	O
to	O
rhabdomyolysis	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
and	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
.	O

TITLE	O
:	O
Thioacetamide	O
-	O
induced	O
fulminant	B-DISO
hepatic	I-DISO
failure	I-DISO
induces	O
cerebral	O
mitochondrial	O
dysfunction	O
by	O
altering	O
the	O
electron	O
transport	O
chain	O
complexes	O
.	O

FHF	B-DISO
also	O
occurs	O
in	O
acute	B-DISO
disorders	I-DISO
like	O
Reye	B-DISO
'	I-DISO
s	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Patients	O
with	O
severe	B-DISO
chronic	I-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
COPD	B-DISO
)	O
often	O
exhale	O
along	O
the	O
same	O
flow	O
-	O
volume	O
curve	O
during	O
quiet	O
breathing	O
as	O
they	O
do	O
during	O
the	O
forced	O
expiratory	O
vital	O
capacity	O
manoeuvre	O
,	O
and	O
this	O
has	O
been	O
taken	O
as	O
an	O
indicator	O
of	O
expiratory	O
flow	O
limitation	O
at	O
rest	O
(	O
EFL	O
(	O
T	O
)).	O

In	O
fact	O
,	O
EFL	O
(	O
T	O
)	O
occurs	O
commonly	O
in	O
COPD	B-DISO
patients	O
(	O
mainly	O
in	O
Global	O
Initiative	O
for	O
Chronic	B-DISO
Obstructive	I-DISO
Lung	I-DISO
Disease	I-DISO
III	O
and	O
IV	O
stage	O
),	O
in	O
whom	O
the	O
latter	O
symptoms	O
are	O
common	O
,	O
but	O
is	O
not	O
exclusive	O
to	O
COPD	B-DISO
,	O
since	O
it	O
can	O
also	O
be	O
detected	O
in	O
other	O
pulmonary	O
and	O
nonpulmonary	O
diseases	O
like	O
asthma	B-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
heart	B-DISO
failure	I-DISO
and	O
obesity	B-DISO
,	O
etc	O
.	O

CONCLUSIONS	O
:	O
Ventilation	O
with	O
low	O
tidal	O
volumes	O
and	O
associated	O
hypercapnia	B-DISO
was	O
lung	O
protective	O
.	O

We	O
further	O
investigated	O
the	O
role	O
of	O
LF	O
in	O
the	O
entry	O
of	O
SARS	B-DISO
pseudovirus	O
into	O
HEK293E	O
/	O
ACE2	O
-	O
Myc	O
cells	O
.	O

RESULTS	O
:	O
Occupational	O
health	O
and	O
safety	O
issues	O
anticipated	O
by	O
Canadian	O
nurses	O
for	O
future	O
infectious	B-DISO
respiratory	B-DISO
disease	I-DISO
outbreaks	O
were	O
grouped	O
into	O
four	O
major	O
themes	O
:	O
(	O
1	O
)	O
apprehension	O
about	O
occupational	O
risks	O
to	O
pregnant	O
nurses	O
;	O
(	O
2	O
)	O
unknown	O
pregnancy	O
risks	O
of	O
anti	O
-	O
infective	O
therapy	O
/	O
prophylaxis	O
;	O
(	O
3	O
)	O
occupational	O
risk	O
communication	O
for	O
pregnant	O
nurses	O
;	O
and	O
(	O
4	O
)	O
human	O
resource	O
strategies	O
required	O
for	O
pregnant	O
nurses	O
during	O
outbreaks	O
.	O

We	O
found	O
several	O
proteins	O
that	O
could	O
interact	O
with	O
the	O
nucleocapsid	O
protein	O
of	O
the	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

To	O
further	O
validate	O
the	O
association	O
,	O
the	O
ten	O
tag	B-DISO
SNPs	O
were	O
genotyped	O
in	O
the	O
Beijing	O
cohort	O
.	O

Several	O
different	O
methods	O
have	O
been	O
used	O
to	O
generate	O
SARS	B-DISO
-	O
CoV	O
specific	O
neutralizing	O
hmAbs	O
including	O
the	O
immunization	O
of	O
transgenic	O
mice	O
,	O
cloning	O
of	O
small	O
chain	O
variable	O
regions	O
from	O
naïve	O
and	O
convalescent	O
patients	O
,	O
and	O
the	O
immortalization	O
of	O
convalescent	O
B	O
cells	O
.	O

While	O
antibodies	O
against	O
Feline	O
parvovirus	B-DISO
and	O
Feline	O
coronavirus	O
(	O
FCoV	O
),	O
Feline	O
calicivirus	O
and	O
Bartonella	O
spp	O
.	O
were	O
frequently	O
detected	O
by	O
serologic	O
tests	O
,	O
antibodies	O
against	O
Felid	O
herpesvirus	O
1	O
or	O
infection	B-DISO
with	O
hemotropic	O
mycoplasmas	O
were	O
less	O
prevalent	O
.	O

Serologic	O
evidence	O
of	O
exposure	O
to	O
Ehrlichia	O
spp	O
.,	O
Feline	O
immunodeficiency	B-DISO
virus	O
,	O
and	O
Feline	B-DISO
leukemia	I-DISO
virus	O
(	O
FeLV	O
)	O
was	O
detected	O
rarely	O
,	O
and	O
infections	B-DISO
with	O
FeLV	O
,	O
Ehrlichia	O
spp	O
.,	O
and	O
Cytauxzoon	O
spp	O
.	O
were	O
found	O
infrequently	O
.	O

TITLE	O
:	O
The	O
sialic	O
acid	O
binding	O
activity	O
of	O
the	O
S	O
protein	O
facilitates	O
infection	B-DISO
by	O
porcine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
coronavirus	O
.	O

Prior	O
to	O
infection	B-DISO
,	O
cultured	O
cells	O
were	O
either	O
treated	O
with	O
neuraminidase	O
to	O
deplete	O
sialic	O
acids	O
from	O
the	O
cell	O
surface	O
,	O
or	O
mock	O
-	O
treated	O
.	O

Both	O
viruses	O
were	O
found	O
among	O
Saudi	O
children	O
with	O
upper	O
and	O
lower	O
respiratory	B-DISO
tract	I-DISO
diseases	I-DISO
during	O
the	O
autumn	O
and	O
winter	O
of	O
2007	O
and	O
2008	O
,	O
contributing	O
to	O
11	O
.	O
1	O
%	O
of	O
all	O
viral	O
diagnoses	O
,	O
with	O
individual	O
incidences	O
of	O
8	O
.	O
3	O
%	O
(	O
hMPV	O
)	O
and	O
2	O
.	O
8	O
%	O
(	O
HCoV	O
-	O
NL63	O
)	O
among	O
489	O
specimens	O
.	O

Initial	O
symptoms	O
included	O
fever	O
,	O
cough	B-DISO
,	O
and	O
nasal	B-DISO
congestion	I-DISO
.	O

RESULTS	O
:	O
Polymicrobial	B-DISO
infection	I-DISO
was	O
present	O
in	O
39	O
(	O
11	O
%)	O
cases	O
(	O
20	O
%	O
of	O
those	O
with	O
defined	O
aetiology	O
):	O
33	O
cases	O
with	O
two	O
pathogens	O
,	O
and	O
six	O
cases	O
with	O
three	O
pathogens	O
.	O

Given	O
the	O
relative	O
paucity	O
of	O
data	O
regarding	O
its	O
use	O
in	O
CABG	O
patients	O
,	O
and	O
given	O
entrenched	O
practice	O
patterns	O
,	O
we	O
assessed	O
the	O
impact	O
of	O
PAC	B-DISO
use	O
on	O
fatal	O
and	O
nonfatal	O
CABG	O
outcomes	O
as	O
practiced	O
at	O
a	O
diverse	O
set	O
of	O
medical	O
centers	O
.	O

Use	O
of	O
a	O
PAC	B-DISO
during	O
CABG	O
surgery	O
was	O
associated	O
with	O
increased	O
mortality	O
and	O
a	O
higher	O
risk	O
of	O
severe	O
end	O
-	O
organ	O
complications	O
in	O
this	O
propensity	O
-	O
matched	O
observational	O
study	O
.	O

Use	O
of	O
PAC	B-DISO
was	O
also	O
associated	O
with	O
prolonged	O
intensive	O
care	O
unit	O
stay	O
(	O
14	O
.	O
5	O
%	O
vs	O
10	O
.	O
1	O
%;	O
AOR	O
,	O
1	O
.	O
55	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
06	O
to	O
2	O
.	O
27	O
;	O
P	O
=	O
0	O
.	O
02	O
).	O

Here	O
,	O
we	O
identified	O
ANXA2	O
as	O
a	O
RNA	O
binding	O
protein	O
(	O
RBP	O
)	O
that	O
binds	O
IBV	O
(	O
Infectious	B-DISO
Bronchitis	B-DISO
Virus	O
)	O
pseudoknot	O
RNA	O
.	O

TITLE	O
:	O
Corticosteroids	O
in	O
respiratory	B-DISO
diseases	I-DISO
in	O
children	O
.	O

Disturbances	O
of	O
lipid	O
metabolism	O
are	O
supposed	O
to	O
be	O
major	O
risk	O
factors	O
of	O
severe	O
influenza	B-DISO
and	O
its	O
fatal	O
outcome	O
that	O
may	O
be	O
related	O
to	O
obesity	B-DISO
through	O
common	O
pathogenetic	O
pathways	O
.	O

TITLE	O
:	O
Effectiveness	O
of	O
facemasks	O
to	O
reduce	O
exposure	O
hazards	O
for	O
airborne	O
infections	B-DISO
among	O
general	O
populations	O
.	O

ABSTRACT	O
:	O
Facemasks	O
are	O
widely	O
used	O
as	O
a	O
protective	O
measure	O
by	O
general	O
public	O
to	O
prevent	O
inhalation	O
of	O
airborne	O
pathogens	O
including	O
seasonal	O
,	O
swine	O
and	O
other	O
forms	O
of	O
influenza	B-DISO
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
etc	O
.	O

TITLE	O
:	O
A	O
double	O
-	O
inactivated	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
vaccine	O
provides	O
incomplete	O
protection	O
in	O
mice	O
and	O
induces	O
increased	O
eosinophilic	O
proinflammatory	O
pulmonary	O
response	O
upon	O
challenge	O
.	O

All	O
recorded	O
bronchoscopy	O
examinations	O
were	O
reviewed	O
and	O
categorized	O
injury	O
according	O
to	O
the	O
published	O
abbreviated	O
injury	O
score	O
(	O
AIS	B-DISO
0	O
:	O
no	O
injury	O
,	O
1	O
:	O
mild	O
,	O
2	O
:	O
moderate	O
,	O
3	O
:	O
severe	O
,	O
and	O
4	O
:	O
massive	O
injury	O
).	O

TITLE	O
:	O
[	O
Fatal	O
alveolar	O
haemorrhage	B-DISO
following	O
a	O
""""	O
bang	O
""""	O
of	O
cannabis	B-DISO
].	O

ABSTRACT	O
:	O
The	O
new	O
methods	O
of	O
cannabis	B-DISO
consumption	O
(	O
home	O
made	O
water	O
pipe	O
or	O
""""	O
bang	O
""")"	O
may	O
be	O
responsible	O
for	O
fatal	O
respiratory	B-DISO
complications	I-DISO
.	O

Investigations	O
for	O
infection	B-DISO
and	O
immunological	O
disorder	O
were	O
negative	O
and	O
toxicology	O
was	O
negative	O
except	O
for	O
cannabis	B-DISO
.	O

We	O
draw	O
attention	O
to	O
the	O
extremely	O
serious	O
potential	O
consequences	O
of	O
new	O
methods	O
of	O
using	O
cannabis	B-DISO
,	O
particularly	O
the	O
use	O
of	O
""""	O
bang	O
""""	O
in	O
homemade	O
plastic	O
materials	O
.	O

22	O
cases	O
of	O
GBS	B-DISO
were	O
reported	O
in	O
the	O
pediatric	O
department	O
of	O
Ibn	O
El	O
Jazzar	O
'	O
s	O
hospital	O
of	O
Kairouan	O
from	O
January	O
1990	O
to	O
September	O
2009	O
.	O

The	O
prodromic	O
infectious	B-DISO
manifestations	O
were	O
observed	O
in	O
54	O
.	O
5	O
%	O
of	O
cases	O
.	O

The	O
clinic	O
symptomatology	O
was	O
the	O
muscular	O
deficiency	O
observed	O
in	O
all	O
cases	O
with	O
absence	O
of	O
deep	O
reflex	O
an	O
albumincytologic	O
dissociation	B-DISO
was	O
observed	O
in	O
12	O
cases	O
.	O

The	O
evolution	O
was	O
favourable	O
in	O
10	O
cases	O
with	O
total	O
recovery	O
three	O
cases	O
of	O
drop	B-DISO
foot	I-DISO
gait	I-DISO
were	O
observed	O
,	O
seven	O
patients	O
were	O
lost	O
to	O
follow	O
up	O
and	O
two	O
patients	O
are	O
dead	O
.	O

TITLE	O
:	O
Distinguishing	O
characteristics	O
between	O
pandemic	O
2009	O
-	O
2010	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
and	O
other	O
viruses	O
in	O
patients	O
hospitalized	O
with	O
respiratory	O
illness	O
.	O

ABSTRACT	O
:	O
Differences	O
in	O
clinical	O
presentation	O
and	O
outcomes	O
among	O
patients	O
infected	O
with	O
pandemic	O
2009	O
influenza	B-DISO
A	O
H1N1	O
(	O
pH1N1	O
)	O
compared	O
to	O
other	O
respiratory	O
viruses	O
have	O
not	O
been	O
fully	O
elucidated	O
.	O

The	O
inhibitory	O
activity	O
was	O
concomitant	O
with	O
an	O
inhibition	O
of	O
NF	O
-	O
κB	O
activation	O
by	O
HSV	O
-	O
2	O
infection	B-DISO
.	O

Furthermore	O
,	O
we	O
show	O
that	O
treatment	O
with	O
quercetin	O
,	O
quercitrin	O
or	O
isoquercitrin	O
,	O
major	O
water	O
extractable	O
flavonoids	O
from	O
H	O
.	O
cordata	O
,	O
significantly	O
blocked	O
HSV	O
-	O
2	O
infection	B-DISO
.	O

These	O
results	O
together	O
demonstrated	O
that	O
H	O
.	O
cordata	O
blocks	O
HSV	O
-	O
2	O
infection	B-DISO
through	O
inhibition	O
of	O
NF	O
-	O
κB	O
activation	O
.	O

Fourteen	O
cats	O
were	O
FCoV	O
-	O
positive	O
,	O
including	O
infections	B-DISO
with	O
type	O
I	O
FCoV	O
(	O
n	O
=	O
8	O
),	O
type	O
II	O
FCoV	O
(	O
n	O
=	O
4	O
),	O
and	O
types	O
I	O
and	O
II	O
co	B-DISO
-	I-DISO
infection	I-DISO
(	O
n	O
=	O
2	O
).	O

Although	O
the	O
prevalence	O
of	O
FCoV	O
infection	B-DISO
was	O
not	O
high	O
in	O
comparison	O
to	O
other	O
countries	O
,	O
there	O
was	O
a	O
higher	O
prevalence	O
of	O
type	O
I	O
FCoV	O
in	O
Korean	O
felines	O
.	O

RESULTS	O
:	O
Fourteen	O
cats	O
were	O
FCoV	O
-	O
positive	O
,	O
including	O
infections	B-DISO
with	O
type	O
I	O
FCoV	O
(	O
n	O
=	O
8	O
),	O
type	O
II	O
FCoV	O
(	O
n	O
=	O
4	O
),	O
and	O
types	O
I	O
and	O
II	O
co	B-DISO
-	I-DISO
infection	I-DISO
(	O
n	O
=	O
2	O
).	O

Interleukin	O
6	O
and	O
IL	O
-	O
8	O
levels	O
were	O
significantly	O
higher	O
in	O
patients	O
who	O
developed	O
renal	O
,	O
respiratory	O
,	O
and	O
circulatory	B-DISO
failure	I-DISO
,	O
as	O
was	O
the	O
case	O
for	O
patients	O
with	O
multiorgan	B-DISO
failure	I-DISO
.	O

Tumor	B-DISO
necrosis	I-DISO
factor	O
α	O
was	O
significantly	O
elevated	O
in	O
all	O
types	O
of	O
organ	O
failures	O
,	O
except	O
for	O
intestinal	O
failure	O
.	O

TITLE	O
:	O
Glutamate	O
excitotoxicity	O
is	O
involved	O
in	O
the	O
induction	O
of	O
paralysis	O
in	O
mice	O
after	O
infection	B-DISO
by	O
a	O
human	O
coronavirus	O
with	O
a	O
single	O
point	O
mutation	O
in	O
its	O
spike	O
protein	O
.	O

TITLE	O
:	O
Human	O
-	O
leukocyte	O
antigen	O
class	O
I	O
Cw	O
1502	O
and	O
class	O
II	O
DR	O
0301	O
genotypes	O
are	O
associated	O
with	O
resistance	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
One	O
-	O
hundred	O
and	O
thirty	O
confirmed	O
cases	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
were	O
recruited	O
to	O
evaluate	O
their	O
anti	O
-	O
SARS	B-DISO
-	O
coronavirus	O
(	O
CoV	O
)	O
antibody	O
status	O
and	O
human	O
leukocyte	O
antigen	O
(	O
HLA	O
)	O
types	O
in	O
September	O
2006	O
,	O
3	O
y	O
after	O
the	O
SARS	B-DISO
outbreaks	O
in	O
Taiwan	O
.	O

ABSTRACT	O
:	O
Combined	O
with	O
massive	O
lung	O
aeration	O
loss	O
resulting	O
from	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
hepatopulmonary	B-DISO
syndrome	I-DISO
,	O
a	O
liver	O
-	O
induced	O
vascular	O
lung	B-DISO
disorder	I-DISO
characterized	O
by	O
diffuse	O
or	O
localized	O
dilated	O
pulmonary	O
capillaries	O
,	O
may	O
induce	O
hypoxaemia	O
and	O
death	O
in	O
patients	O
with	O
end	O
-	O
stage	O
liver	B-DISO
disease	I-DISO
.	O

RESULTS	O
:	O
A	O
51	O
-	O
year	O
-	O
old	O
man	O
with	O
a	O
five	O
-	O
year	O
history	O
of	O
alcoholic	B-DISO
cirrhosis	I-DISO
was	O
admitted	O
for	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
,	O
platypnoea	B-DISO
and	O
severe	O
hypoxaemia	O
requiring	O
emergency	B-DISO
tracheal	O
intubation	O
.	O

ABSTRACT	O
:	O
Public	O
health	O
situations	O
faced	O
by	O
family	O
physicians	O
and	O
other	O
primary	O
care	O
practitioners	O
,	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
more	O
recently	O
H1N1	O
,	O
have	O
resulted	O
in	O
an	O
increased	O
interest	O
to	O
identify	O
the	O
public	O
health	O
competencies	O
relevant	O
to	O
family	O
medicine	O
.	O

At	O
present	O
there	O
is	O
no	O
agreed	O
-	O
on	O
set	O
of	O
public	O
health	O
competencies	O
delineating	O
the	O
knowledge	O
and	O
skills	O
that	O
family	O
physicians	O
should	O
possess	B-DISO
to	O
effectively	O
face	B-DISO
diverse	O
public	O
health	O
challenges	O
.	O

TITLE	O
:	O
Male	O
circumcision	O
and	O
human	B-DISO
papillomavirus	I-DISO
infection	I-DISO
in	O
men	O
:	O
a	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
.	O

ABSTRACT	O
:	O
We	O
systematically	O
reviewed	O
the	O
evidence	O
for	O
an	O
association	O
between	O
male	O
circumcision	O
and	O
Human	O
Papillomavirus	O
(	O
HPV	O
)	O
infection	B-DISO
and	O
genital	B-DISO
warts	I-DISO
in	O
men	O
.	O

TITLE	O
:	O
The	O
value	O
of	O
pulmonary	O
contusion	O
volume	O
measurement	O
with	O
three	O
-	O
dimensional	O
computed	O
tomography	O
in	O
predicting	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
development	O
.	O

The	O
partial	O
pressure	O
of	O
oxygen	O
/	O
fraction	O
of	O
inspired	O
oxygen	O
ratio	O
,	O
the	O
needed	O
maximal	O
positive	O
end	O
-	O
expiratory	O
pressure	O
level	O
,	O
and	O
ARDS	B-DISO
incidence	O
between	O
the	O
severe	O
group	O
and	O
the	O
general	O
group	O
was	O
significantly	O
different	O
(	O
p	O
<.	O
05	O
).	O

The	O
presence	O
of	O
gross	O
vulva	O
oedema	B-DISO
in	O
pre	B-DISO
-	I-DISO
eclampsia	I-DISO
may	O
be	O
an	O
indicator	O
of	O
severity	O
of	O
disease	O
and	O
or	O
deteriorating	O
fetomaternal	O
condition	B-DISO
.	O

Further	O
studies	O
are	O
required	O
to	O
demonstrate	O
the	O
significance	O
of	O
gross	O
vulva	O
edema	B-DISO
in	O
pre	B-DISO
-	I-DISO
eclampsia	I-DISO
.	O

ABSTRACT	O
:	O
Previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
SARS	B-DISO
-	O
CoV	O
S	O
protein	O
requires	O
proteolytic	O
cleavage	O
by	O
elastase	O
,	O
cathepsin	O
or	O
TMPRSS2	O
for	O
S	O
-	O
mediated	O
cell	O
-	O
cell	O
or	O
virus	O
-	O
cell	O
membrane	O
fusion	O
.	O

There	O
were	O
timely	O
reports	O
on	O
promising	O
compounds	O
against	O
adenoviruses	O
,	O
cytomegalovirus	O
,	O
HCV	O
and	O
HIV	B-DISO
in	O
clinical	O
trials	O
.	O

ABSTRACT	O
:	O
Pulmonary	B-DISO
complications	I-DISO
together	O
with	O
surgical	O
complications	O
are	O
the	O
most	O
frequent	O
causes	O
for	O
morbidity	O
and	O
mortality	O
after	O
thoracoabdominal	O
esophagectomy	O
.	O

Thus	O
,	O
the	O
choice	O
of	O
the	O
thoracotomy	O
method	O
during	O
the	O
thoracoabdominal	O
esophagectomy	O
and	O
the	O
resultant	O
cytokine	O
levels	O
may	O
contribute	O
to	O
the	O
occurrence	O
of	O
postoperative	O
pulmonary	B-DISO
complications	I-DISO
and	O
may	O
have	O
an	O
impact	O
on	O
the	O
extent	O
and	O
severity	O
of	O
the	O
surgical	O
stress	O
.	O

ABSTRACT	O
:	O
The	O
highly	O
pathogenic	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
poses	O
a	O
constant	O
threat	O
to	O
human	O
health	O
.	O

TITLE	O
:	O
Significance	O
of	O
coronavirus	O
mutants	O
in	O
feces	O
and	O
diseased	O
tissues	O
of	O
cats	O
suffering	B-DISO
from	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
.	O

Compartmentalization	O
of	O
the	O
parental	O
and	O
mutant	B-DISO
forms	O
was	O
not	O
absolute	O
;	O
virus	O
of	O
lesional	O
type	O
was	O
sometimes	O
found	O
in	O
feces	O
of	O
affected	O
cats	O
and	O
virus	O
identical	O
to	O
fecal	O
type	O
was	O
occasionally	O
identified	O
in	O
diseased	O
tissues	O
.	O

Moreover	O
we	O
review	O
the	O
clinical	O
presentation	O
,	O
laboratory	O
findings	O
and	O
outcome	O
of	O
influenza	B-DISO
-	O
related	O
GBS	B-DISO
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
causes	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
,	O
an	O
important	O
disease	O
that	O
produces	O
severe	O
economic	O
losses	O
in	O
the	O
poultry	O
industry	O
worldwide	O
.	O

The	O
findings	O
underscore	O
the	O
importance	O
of	O
continuous	O
monitoring	O
to	O
control	O
spread	O
of	O
infections	B-DISO
,	O
as	O
well	O
as	O
to	O
timely	O
adjust	O
diagnostic	O
methods	O
,	O
molecular	O
epidemiological	O
studies	O
,	O
development	O
and	O
use	O
of	O
vaccines	O
that	O
are	O
adapted	O
to	O
the	O
changing	O
disease	O
scenario	O
.	O

TITLE	O
:	O
Modification	O
of	O
a	O
high	O
frequency	O
oscillator	O
circuit	O
with	O
a	O
heated	O
expiratory	O
filter	O
to	O
prevent	O
infectious	B-DISO
pathogen	B-DISO
transmission	I-DISO
:	O
a	O
bench	O
study	O
.	O

Sixty	O
patients	O
with	O
ARDS	B-DISO
and	O
60	O
controls	O
were	O
included	O
.	O

ACE	O
I	O
/	O
D	O
polymorphism	O
modified	O
angiotensin	O
-	O
II	O
levels	O
in	O
pediatric	O
ARDS	B-DISO
,	O
but	O
its	O
pathogenic	O
role	O
is	O
not	O
well	O
understood	O
and	O
needs	O
to	O
be	O
addressed	O
in	O
future	O
studies	O
.	O

TITLE	O
:	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
following	O
sepsis	B-DISO
after	O
stereotactic	O
aspiration	B-DISO
for	O
spontaneous	O
pontine	B-DISO
hemorrhage	I-DISO
.	O

ABSTRACT	O
:	O
A	O
52	O
-	O
year	O
-	O
old	O
female	O
was	O
treated	O
with	O
CT	O
-	O
guided	O
stereotactic	O
aspiration	B-DISO
for	O
acute	O
spontaneous	O
pontine	B-DISO
hemorrhage	I-DISO
.	O

This	O
panel	O
of	O
anti	O
-	O
N	O
MAbs	O
may	O
be	O
used	O
as	O
a	O
tool	O
for	O
rapid	O
and	O
specific	O
diagnosis	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O

TITLE	O
:	O
Approaches	O
to	O
refractory	O
hypoxemia	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
current	O
understanding	O
,	O
evidence	O
,	O
and	O
debate	O
.	O

The	O
use	O
of	O
NIV	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
other	O
airborne	O
diseases	O
has	O
generated	O
debate	O
,	O
despite	O
encouraging	O
clinical	O
results	O
,	O
mainly	O
because	O
of	O
safety	O
issues	O
.	O

The	O
present	O
study	O
shows	O
that	O
serum	O
MBL	O
levels	O
influence	O
the	O
ability	O
of	O
chickens	O
to	O
clear	O
the	O
respiratory	O
tract	O
of	O
virus	O
genomes	O
after	O
an	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
infection	B-DISO
.	O

Moreover	O
,	O
addition	O
of	O
mannose	O
to	O
an	O
IBV	O
vaccine	O
altered	O
both	O
vaccine	O
-	O
induced	O
changes	O
in	O
circulating	O
T	O
-	O
cell	O
populations	O
and	O
IBV	O
specific	O
vaccine	O
and	O
infection	B-DISO
-	O
induced	O
antibody	O
responses	O
in	O
chickens	O
with	O
high	O
serum	O
MBL	O
levels	O
.	O

HFOV	O
was	O
instituted	O
for	O
48	O
h	O
,	O
resulting	O
in	O
a	O
marked	O
improvement	O
in	O
gas	O
exchange	O
,	O
however	O
any	O
manipulations	O
caused	O
immediate	O
deterioration	O
in	O
the	O
patient	O
'	O
s	O
condition	B-DISO
.	O

We	O
now	O
report	O
on	O
underlying	O
mechanisms	O
associated	O
with	O
the	O
induction	O
of	O
programmed	O
cell	O
death	O
(	O
PCD	B-DISO
)	O
after	O
infection	B-DISO
by	O
the	O
reference	O
HCoV	O
-	O
OC43	O
virus	O
(	O
rOC	O
/	O
ATCC	O
)	O
and	O
a	O
more	O
neurovirulent	O
and	O
cytotoxic	O
HCoV	O
-	O
OC43	O
variant	O
harboring	O
two	O
point	O
mutations	O
in	O
the	O
S	O
glycoprotein	O
(	O
rOC	O
/	O
U	O
(	O
S183	O
-	O
241	O
)).	O

On	O
the	O
other	O
hand	O
,	O
CsA	B-DISO
and	O
CypD	O
knockdown	O
had	O
moderate	O
effects	O
on	O
rOC	O
/	O
U	O
(	O
S183	O
-	O
241	O
)-	O
induced	O
PCD	B-DISO
.	O

To	O
help	O
in	O
the	O
evaluation	O
of	O
each	O
case	O
we	O
used	O
a	O
decision	O
-	O
support	O
tool	O
that	O
was	O
previously	O
developed	O
for	O
ventilator	O
allocation	O
during	O
an	O
influenza	B-DISO
pandemic	O
.	O

Moreover	O
,	O
in	O
one	O
patient	O
with	O
a	O
CT	O
diagnosis	O
of	O
pulmonary	B-DISO
fibrosis	I-DISO
,	O
we	O
observed	O
progressive	O
regression	O
of	O
radiological	O
findings	O
over	O
4	O
months	O
of	O
follow	O
-	O
up	O
.	O

TITLE	O
:	O
Diagnostic	O
value	O
of	O
urine	O
sTREM	O
-	O
1	O
for	O
sepsis	B-DISO
and	O
relevant	O
acute	O
kidney	O
injuries	O
:	O
a	O
prospective	O
study	O
.	O

On	O
the	O
day	O
of	O
admission	O
to	O
the	O
ICU	O
,	O
and	O
compared	O
with	O
the	O
SIRS	B-DISO
group	O
,	O
the	O
sepsis	B-DISO
group	O
exhibited	O
higher	O
levels	O
of	O
urine	O
sTREM	O
-	O
1	O
and	O
Acute	O
Physiologic	O
Assessment	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
(	O
APACHE	O
II	O
)	O
scores	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

It	O
can	O
also	O
provide	O
an	O
early	O
warning	O
of	O
possible	O
secondary	O
AKI	O
in	O
sepsis	B-DISO
patients	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
is	O
a	O
condition	B-DISO
characterized	O
by	O
acute	O
onset	O
of	O
severe	O
hypoxemia	O
and	O
bilateral	B-DISO
pulmonary	I-DISO
infiltrates	I-DISO
.	O

This	O
recommendation	O
was	O
based	O
on	O
the	O
results	O
of	O
the	O
ARMA	O
study	O
,	O
a	O
randomized	O
clinical	O
trial	O
designed	O
to	O
compare	O
low	O
vs	O
.	O
high	O
tidal	O
volume	O
strategies	O
(	O
The	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
Network	O
,	O
2000	O
)	O
.	O

Our	O
previous	O
study	O
revealed	O
that	O
ORF6	O
localized	O
to	O
vesicular	O
structures	O
in	O
SARS	B-DISO
-	O
CoV	O
infected	O
Vero	O
E6	O
cells	O
.	O

We	O
undertook	O
a	O
prospective	O
study	O
to	O
investigate	O
the	O
determinants	O
of	O
mortality	O
and	O
the	O
sequential	O
evolution	O
of	O
organ	O
failures	O
in	O
HFOV	O
-	O
treated	O
adult	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
envelope	O
protein	O
regulates	O
cell	O
stress	O
response	O
and	O
apoptosis	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
that	O
lacks	O
the	O
envelope	O
(	O
E	O
)	O
gene	O
(	O
rSARS	O
-	O
CoV	O
-	O
ΔE	O
)	O
is	O
attenuated	O
in	O
vivo	O
.	O

In	O
addition	O
,	O
genes	O
involved	O
in	O
signal	O
transduction	O
,	O
transcription	O
,	O
cell	O
metabolism	O
,	O
immunoregulation	O
,	O
inflammation	B-DISO
,	O
apoptosis	O
and	O
cell	O
cycle	O
and	O
differentiation	O
were	O
differentially	O
regulated	O
in	O
cells	O
infected	O
with	O
rSARS	O
-	O
CoV	O
with	O
or	O
without	O
the	O
E	O
gene	O
.	O

During	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
a	O
continuous	O
enteral	O
diet	O
with	O
high	O
-	O
dose	O
omega	O
-	O
3	O
fatty	O
acids	O
,	O
gamma	O
-	O
linolenic	O
acid	O
,	O
and	O
antioxidants	O
improved	O
clinical	O
outcome	O
.	O

RESULTS	O
:	O
Non	O
-	O
responders	O
to	O
pandemic	O
H1N1	O
(	O
2009	O
)	O
vaccination	O
more	O
often	O
had	O
cGvHD	B-DISO
(	O
65	O
vs	O
.	O
53	O
%)	O
and	O
received	O
second	O
-	O
or	O
third	O
-	O
line	O
therapy	O
(	O
53	O
vs	O
.	O
11	O
%),	O
while	O
responders	O
mostly	O
had	O
first	O
-	O
line	O
therapy	O
for	O
cGvHD	B-DISO
.	O

Little	O
is	O
known	O
about	O
the	O
epidemiology	O
of	O
this	O
syndrome	B-DISO
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
defined	O
as	O
severe	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
resulting	O
from	O
diffuse	O
lung	O
injury	O
and	O
secondary	O
to	O
direct	O
and	O
indirect	O
insults	O
.	O

Exclusion	O
criteria	O
included	O
patients	O
already	O
receiving	O
NMBA	O
at	O
enrolment	O
;	O
those	O
who	O
had	O
increased	B-DISO
intracranial	I-DISO
pressure	I-DISO
,	O
severe	O
chronic	B-DISO
respiratory	I-DISO
disease	I-DISO
,	O
or	O
severe	O
chronic	B-DISO
liver	I-DISO
disease	I-DISO
;	O
those	O
who	O
had	O
received	O
a	O
bone	O
marrow	O
transplant	O
or	O
had	O
chemotherapy	B-DISO
-	I-DISO
induced	I-DISO
neutropenia	I-DISO
;	O
those	O
who	O
had	O
a	O
pneumothorax	B-DISO
;	O
and	O
those	O
who	O
were	O
expected	O
to	O
require	O
mechanical	O
ventilation	O
for	O
<	O
48	O
hr	O
or	O
were	O
enrolled	O
in	O
another	O
trial	O
within	O
30	O
days	O
.	O

Prior	O
to	O
either	O
infusion	O
,	O
patients	O
were	O
sedated	O
to	O
a	O
Ramsay	O
sedation	B-DISO
score	O
of	O
6	O
.	O

The	O
rate	O
of	O
ICU	O
-	O
acquired	O
weakness	B-DISO
at	O
day	O
28	O
or	O
at	O
ICU	O
discharge	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
groups	O
.	O

To	O
observe	O
the	O
clinical	O
manifestations	O
of	O
the	O
2009	O
pandemic	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
and	O
the	O
epidemic	O
waves	O
of	O
hospitalized	O
children	O
for	O
a	O
period	O
of	O
one	O
year	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
83	O
pandemic	O
influenza	B-DISO
infected	O
children	O
were	O
admitted	O
during	O
a	O
one	O
-	O
year	O
period	O
.	O

After	O
exposure	O
to	O
hyperoxia	B-DISO
,	O
the	O
wet	O
/	O
dry	O
weight	O
ratio	O
remained	O
stable	O
before	O
day	O
2	O
but	O
increased	O
significantly	O
after	O
day	O
3	O
.	O

Rotaviruses	O
have	O
been	O
identified	O
in	O
numerous	O
animal	O
species	O
and	O
are	O
generally	O
host	O
-	O
specific	O
,	O
but	O
zoonotic	O
transmission	O
has	O
been	O
suggested	O
by	O
cross	O
-	O
infection	B-DISO
(	O
especially	O
in	O
experimental	O
models	O
),	O
by	O
genetic	O
studies	O
showing	O
a	O
close	O
relationship	O
between	O
certain	O
human	O
and	O
animal	O
rotaviruses	O
,	O
and	O
by	O
the	O
discovery	O
of	O
new	O
animal	O
genotypes	O
during	O
epidemiological	O
surveillance	O
of	O
human	O
rotaviroses	O
.	O

The	O
2003	O
SARS	B-DISO
outbreak	O
exposed	O
weaknesses	B-DISO
in	O
global	O
governance	O
that	O
caused	O
uncoordinated	B-DISO
public	O
health	O
and	O
economic	O
responses	O
.	O

TITLE	O
:	O
Cell	O
-	O
based	O
therapies	O
for	O
lung	O
vascular	B-DISO
diseases	I-DISO
:	O
lessons	O
for	O
the	O
future	O
.	O

Pulmonary	B-DISO
arterial	I-DISO
hypertension	I-DISO
is	O
a	O
progressive	O
and	O
debilitating	O
lung	B-DISO
disorder	I-DISO
,	O
which	O
is	O
characterized	O
by	O
hallmark	O
pathological	O
features	O
in	O
the	O
small	O
peripheral	O
pulmonary	O
arteries	O
,	O
including	O
intimal	O
hyperplasia	B-DISO
and	O
fibrosis	B-DISO
,	O
medial	O
hypertrophy	B-DISO
,	O
increased	O
deposition	O
of	O
extracellular	O
matrix	O
,	O
infiltration	B-DISO
of	O
inflammatory	O
mediators	O
,	O
and	O
in	O
many	O
instances	O
of	O
advanced	O
disease	O
,	O
plexiform	O
lesions	O
.	O

Emergency	B-DISO
management	O
is	O
a	O
relatively	O
new	O
research	O
field	O
in	O
China	O
.	O

The	O
search	O
identified	O
2548	O
articles	O
potentially	O
involving	O
hospital	O
emergency	B-DISO
management	O
.	O

Adjusted	O
logistic	O
regression	O
analysis	O
suggested	O
that	O
the	O
odds	O
of	O
HAIs	O
were	O
2	O
.	O
2	O
times	O
higher	O
in	O
the	O
pre	O
-	O
SARS	B-DISO
period	O
as	O
compared	O
to	O
the	O
SARS	B-DISO
period	O
(	O
OR	O
=	O
2	O
.	O
2	O
;	O
95	O
%	O
CI	O
=	O
1	O
.	O
08	O
-	O
4	O
.	O
49	O
).	O

Adjusted	O
logistic	O
regression	O
analysis	O
suggested	O
that	O
the	O
odds	O
of	O
HAIs	O
were	O
2	O
.	O
2	O
times	O
higher	O
in	O
the	O
pre	O
-	O
SARS	B-DISO
period	O
as	O
compared	O
to	O
the	O
SARS	B-DISO
period	O
(	O
OR	O
=	O
2	O
.	O
2	O
;	O
95	O
%	O
CI	O
=	O
1	O
.	O
08	O
-	O
4	O
.	O
49	O
).	O

Studies	O
,	O
however	O
,	O
have	O
focused	O
on	O
the	O
mechanism	O
of	O
specific	O
diseases	O
or	O
have	O
used	O
animals	O
whose	O
immunological	O
condition	B-DISO
could	O
be	O
biased	O
-	O
by	O
vaccination	O
or	O
environmental	O
stressors	O
,	O
for	O
example	O
.	O

However	O
,	O
the	O
exact	O
phenotype	O
of	O
central	O
nervous	B-DISO
system	O
-	O
infiltrating	B-DISO
CD8	O
(+)	O
T	O
lymphocytes	O
and	O
the	O
mechanism	O
by	O
which	O
these	O
cells	O
cross	O
the	O
blood	O
-	O
brain	O
barrier	O
remain	O
largely	O
unknown	O
.	O

We	O
further	O
show	O
that	O
purified	O
human	O
effector	O
memory	O
CD8	O
(+)	O
T	O
lymphocytes	O
transmigrate	O
more	O
readily	O
across	O
blood	O
-	O
brain	O
barrier	O
-	O
endothelial	O
cells	O
than	O
non	O
-	O
effector	O
memory	O
CD8	O
(+)	O
T	O
lymphocytes	O
,	O
and	O
that	O
blood	O
-	O
brain	O
barrier	O
endothelium	O
promotes	O
the	O
selective	O
recruitment	B-DISO
of	O
effector	O
memory	O
CD8	O
(+)	O
T	O
lymphocytes	O
.	O

The	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	B-DISO
)	O
of	O
thiazolides	O
against	O
HCV	O
are	O
less	O
predictable	O
than	O
against	O
hepatitis	B-DISO
B	I-DISO
virus	O
(	O
HBV	B-DISO
),	O
though	O
an	O
electron	O
-	O
withdrawing	O
group	O
at	O
C	O
(	O
5	O
')	O
generally	O
correlates	O
with	O
potency	O
.	O

ABSTRACT	O
:	O
A	O
study	O
published	O
in	O
the	O
previous	O
issue	O
of	O
Critical	O
Care	O
demonstrates	O
that	O
measurement	O
of	O
the	O
pulmonary	O
dead	O
-	O
space	O
fraction	O
is	O
superior	O
to	O
hypoxemia	O
as	O
an	O
indicator	O
of	O
a	O
favorable	O
physiologic	O
response	O
to	O
prone	O
positioning	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Hospitals	O
must	O
be	O
prepared	O
to	O
diagnose	O
and	O
treat	O
malaria	B-DISO
patients	O
-	O
or	O
have	O
a	O
standard	O
operating	O
procedure	O
for	O
transferring	O
the	O
patient	O
to	O
a	O
specialized	O
center	O
.	O

TITLE	O
:	O
Molecular	O
determinants	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
pathogenesis	B-DISO
and	O
virulence	O
in	O
young	O
and	O
aged	O
mouse	O
models	O
of	O
human	O
disease	O
.	O

ABSTRACT	O
:	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
causes	O
severe	O
acute	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
characterized	O
by	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
and	O
hyaline	B-DISO
membrane	I-DISO
formation	O
.	O

The	O
mutations	O
in	O
S	O
likely	O
increase	O
recognition	O
of	O
the	O
mouse	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
receptor	O
not	O
only	O
in	O
MA15	O
but	O
also	O
in	O
two	O
additional	O
,	O
independently	O
isolated	O
mouse	O
-	O
adapted	O
SARS	B-DISO
-	O
CoVs	O
.	O

The	O
compounds	O
were	O
tested	O
for	O
antiparasitic	O
activities	O
against	O
Leishmania	O
major	O
and	O
Trypanosoma	O
brucei	O
,	O
and	O
for	O
protease	O
inhibition	O
against	O
several	O
cysteine	O
proteases	O
such	O
as	O
falcipain	O
,	O
rhodesain	O
,	O
cathepsin	O
L	O
,	O
cathepsin	O
B	O
,	O
and	O
viral	O
proteases	O
SARS	B-DISO
-	O
CoV	O
M	O
(	O
pro	O
),	O
and	O
PL	O
(	O
pro	O
).	O

Their	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
)),	O
which	O
catalyzes	O
the	O
proteolytic	O
processing	O
of	O
the	O
polyproteins	O
for	O
viral	O
replication	O
,	O
is	O
a	O
potential	O
target	O
for	O
anti	O
-	O
coronaviral	O
infection	B-DISO
.	O

Six	O
of	O
the	O
eight	O
patients	O
had	O
no	O
relevant	O
underlying	O
disease	O
;	O
one	O
had	O
a	O
pre	O
-	O
existing	O
idiopathic	O
lung	B-DISO
fibrosis	I-DISO
and	O
another	O
had	O
a	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
COPD	B-DISO
),	O
an	O
abuse	B-DISO
of	O
alcohol	O
and	O
an	O
adiposities	O
grade	O
3	O
.	O

Four	O
patients	O
needed	O
an	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
due	O
to	O
severe	O
respiratory	B-DISO
failure	I-DISO
with	O
global	O
respiratory	B-DISO
insufficiency	I-DISO
that	O
could	O
not	O
be	O
treated	O
by	O
conservative	O
ventilatory	O
support	O
.	O

RESULTS	O
:	O
Six	O
of	O
the	O
eight	O
patients	O
had	O
no	O
relevant	O
underlying	O
disease	O
;	O
one	O
had	O
a	O
pre	O
-	O
existing	O
idiopathic	O
lung	B-DISO
fibrosis	I-DISO
and	O
another	O
had	O
a	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
COPD	B-DISO
),	O
an	O
abuse	B-DISO
of	O
alcohol	O
and	O
an	O
adiposities	O
grade	O
3	O
.	O

TITLE	O
:	O
Prone	O
positioning	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
):	O
when	O
and	O
how	O
?	O

TITLE	O
:	O
The	O
role	O
of	O
type	O
-	O
2	O
turkey	O
astrovirus	O
in	O
poult	O
enteritis	B-DISO
syndrome	B-DISO
.	O

Clinical	O
signs	O
of	O
diarrhea	B-DISO
,	O
depression	B-DISO
,	O
and	O
dullness	O
were	O
observed	O
in	O
group	O
A	O
.	O
Birds	O
in	O
group	B-DISO
B	I-DISO
also	O
showed	O
clinical	O
signs	O
similar	O
to	O
those	O
in	O
group	O
A	O
,	O
although	O
the	O
signs	O
were	O
milder	O
in	O
nature	O
.	O

SARS	B-DISO
patients	O
were	O
almost	O
universally	O
steroid	O
naive	O
with	O
no	O
other	O
known	O
predisposition	O
to	O
osteonecrosis	B-DISO
.	O

TITLE	O
:	O
Supportive	O
therapy	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

An	O
integrative	O
sequencing	O
analysis	O
of	O
both	O
small	O
RNAs	O
and	O
long	O
transcripts	O
from	O
the	O
same	O
samples	O
showed	O
that	O
the	O
results	O
revealing	O
differential	O
expression	O
of	O
miRNAs	O
during	O
infection	B-DISO
were	O
largely	O
due	O
to	O
transcriptional	O
regulation	O
and	O
that	O
the	O
predicted	O
miRNA	O
-	O
mRNA	O
network	O
could	O
modulate	O
global	O
host	O
responses	O
to	O
virus	B-DISO
infection	I-DISO
in	O
a	O
combinatorial	O
fashion	O
.	O

Using	O
this	O
approach	O
,	O
we	O
recently	O
discovered	O
widespread	O
differential	O
expression	O
of	O
host	O
long	O
(>	O
200	O
nucleotide	O
[	O
nt	O
])	O
ncRNAs	O
in	O
response	O
to	O
virus	B-DISO
infection	I-DISO
.	O

Management	O
of	O
this	O
condition	B-DISO
has	O
been	O
difficult	O
and	O
effective	O
therapies	O
have	O
not	O
yet	O
been	O
established	O
.	O

Our	O
results	O
demonstrated	O
that	O
mitochondrial	O
SIRT3	O
and	O
SIRT4	O
protein	O
expression	O
increased	O
from	O
12	O
and	O
24	O
h	O
post	O
infection	B-DISO
(	O
p	O
.	O
i	O
.)	O
onwards	O
,	O
respectively	O
,	O
whereas	O
the	O
nuclear	O
SIRT1	O
expression	O
increased	O
during	O
the	O
first	O
12	O
h	O
p	O
.	O
i	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
virus	B-DISO
infection	I-DISO
increased	O
both	O
bax	O
translocation	B-DISO
into	O
mitochondria	O
and	O
decreased	O
bcl	O
-	O
2	O
expression	O
in	O
cytosol	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
.	O

She	O
is	O
placed	O
in	O
the	O
prone	O
position	O
and	O
a	O
neuromuscular	O
blocking	B-DISO
agent	O
is	O
administered	O
,	O
without	O
improvement	O
in	O
her	O
Pao2	O
.	O

Compared	O
with	O
injured	O
controls	O
,	O
the	O
treatment	O
group	O
had	O
a	O
significantly	O
higher	O
PaO₂	O
/	O
FIO₂	O
ratio	O
,	O
and	O
the	O
onset	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
was	O
prevented	O
.	O

Retrospectively	O
,	O
the	O
archive	O
of	O
all	O
patients	O
with	O
a	O
diagnosis	O
of	O
2009	O
H1N1	B-DISO
influenza	I-DISO
A	O
were	O
reviewed	O
,	O
in	O
Al	O
-	O
Zahra	O
Hospital	O
in	O
Isfahan	O
,	O
central	O
Iran	O
,	O
between	O
September	O
23	O
(	O
rd	O
)	O
2009	O
to	O
February	O
20	O
(	O
th	O
)	O
2010	O
.	O

Out	O
of	O
216	O
patients	O
with	O
confirmed	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
virus	O
,	O
26	O
cases	O
with	O
abnormal	O
CT	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

Therefore	O
,	O
PPF	O
does	O
not	O
appear	O
to	O
be	O
an	O
effective	O
treatment	O
option	O
in	O
cats	O
with	O
a	O
late	O
stage	O
of	O
the	O
disease	O
FIP	B-DISO
.	O

Institutions	O
need	O
to	O
ensure	O
that	O
appropriate	O
infection	B-DISO
control	O
safeguards	O
are	O
in	O
place	O
to	O
protect	O
workers	O
and	O
their	O
families	O
.	O

TITLE	O
:	O
Coronavirus	O
pathogenesis	B-DISO
.	O

ABSTRACT	O
:	O
Coronaviruses	O
infect	O
many	O
species	O
of	O
animals	O
including	O
humans	O
,	O
causing	O
acute	O
and	O
chronic	B-DISO
diseases	I-DISO
.	O

We	O
review	O
the	O
pathogenesis	B-DISO
of	O
both	O
viruses	O
and	O
the	O
several	O
reverse	O
genetics	O
systems	O
that	O
made	O
much	O
of	O
these	O
studies	O
possible	O
.	O

Nonstructural	O
proteins	O
include	O
the	O
small	O
accessory	O
proteins	O
that	O
are	O
not	O
at	O
all	O
conserved	O
between	O
MHV	O
and	O
SARS	B-DISO
-	O
CoV	O
and	O
the	O
16	O
conserved	O
proteins	O
encoded	O
in	O
the	O
replicase	O
locus	O
,	O
many	O
of	O
which	O
have	O
enzymatic	O
activities	O
in	O
RNA	O
metabolism	O
or	O
protein	O
processing	O
in	O
addition	O
to	O
functions	O
in	O
antagonizing	O
host	O
response	O
.	O

However	O
,	O
other	O
viruses	O
can	O
cause	O
severe	O
ARDS	B-DISO
.	O

Other	O
than	O
antiviral	O
drug	O
(	O
mainly	O
oseltamivir	O
)	O
administration	O
and	O
avoidance	O
of	O
corticosteroids	O
,	O
management	O
of	O
ARDS	B-DISO
due	O
to	O
these	O
viruses	O
does	O
not	O
differ	O
from	O
that	O
for	O
ARDS	B-DISO
caused	O
by	O
other	O
diseases	O
.	O

Ganciclovir	O
can	O
be	O
considered	O
for	O
patients	O
with	O
ARDS	B-DISO
and	O
histology	O
-	O
or	O
cytology	O
-	O
proven	O
CMV	O
pneumonia	B-DISO
.	O

TITLE	O
:	O
The	O
impact	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
on	O
survival	O
in	O
pediatric	O
patients	O
with	O
respiratory	O
and	O
heart	B-DISO
failure	I-DISO
:	O
review	O
of	O
our	O
experience	O
.	O

We	O
retrospectively	O
evaluated	O
the	O
efficacy	O
of	O
ECMO	O
support	O
for	O
respiratory	O
and	O
heart	B-DISO
failure	I-DISO
in	O
infants	O
and	O
children	O
.	O

ECMO	O
was	O
introduced	O
in	O
a	O
patient	O
with	O
severe	O
heart	B-DISO
failure	I-DISO
caused	O
by	O
fulminant	O
myocarditis	B-DISO
.	O

Decreased	O
rDC	B-DISO
migration	O
resulted	O
in	O
diminished	O
T	O
cell	O
responses	O
and	O
more	O
severe	O
clinical	O
disease	O
in	O
older	O
mice	O
infected	O
with	O
respiratory	O
viruses	O
.	O

Sensitivity	O
of	O
the	O
DSS	B-DISO
'	O
s	O
advice	O
to	O
variations	O
in	O
cardiac	O
output	O
(	O
CO	O
)	O
was	O
evaluated	O
.	O

TITLE	O
:	O
Lessons	O
from	O
the	O
response	O
to	O
A	O
H1N1	B-DISO
influenza	I-DISO
,	O
2009	O
,	O
India	O
:	O
ethics	O
in	O
pandemic	O
planning	O
.	O

This	O
is	O
a	O
pilot	O
study	O
intended	O
to	O
assess	O
hospital	O
emergency	B-DISO
management	O
in	O
the	O
Beijing	O
area	O
,	O
make	O
recommendations	O
to	O
government	O
health	O
authorities	O
and	O
hospital	O
managers	O
,	O
and	O
offer	O
references	O
for	O
similar	O
studies	O
.	O

RESULTS	O
:	O
We	O
surveyed	O
1131	O
(	O
94	O
%)	O
households	O
and	O
5449	O
residents	O
between	O
October	O
and	O
December	O
2006	O
and	O
identified	O
323	O
(	O
6	O
%)	O
cases	O
of	O
pneumonia	B-DISO
and	O
628	O
(	O
13	O
%)	O
cases	O
of	O
ILI	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
an	O
acute	O
life	O
-	O
threatening	O
form	O
of	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
with	O
a	O
high	O
mortality	O
rate	O
,	O
and	O
there	O
is	O
still	O
a	O
great	O
need	O
for	O
more	O
effective	O
therapies	O
for	O
such	O
a	O
severe	O
and	O
lethal	O
disease	O
.	O

KGF	O
-	O
2	O
,	O
a	O
potent	O
alveolar	O
epithelial	O
cell	O
mitogen	O
,	O
plays	O
an	O
important	O
role	O
in	O
organ	O
morphogenesis	O
and	O
epithelial	O
differentiation	O
,	O
and	O
modulates	O
a	O
variety	O
of	O
mechanisms	O
recognized	O
to	O
be	O
important	O
in	O
alveolar	O
repair	O
and	O
resolution	O
in	O
ALI	O
/	O
ARDS	B-DISO
.	O

Preclinical	O
and	O
clinical	O
studies	O
have	O
suggested	O
that	O
KGF	O
-	O
2	O
may	O
be	O
the	O
candidate	O
of	O
novel	O
therapies	O
for	O
alveolar	O
epithelial	O
damage	O
during	O
ALI	O
/	O
ARDS	B-DISO
.	O

The	O
presence	O
of	O
stress	O
factors	O
in	O
the	O
history	O
of	O
CFS	B-DISO
patients	O
is	O
associated	O
with	O
severe	O
oxidative	B-DISO
stress	I-DISO
and	O
the	O
suppression	B-DISO
of	O
protective	O
HSP27	O
and	O
HSP70	O
responses	O
to	O
exercise	O
.	O

This	O
case	O
highlights	O
the	O
importance	O
of	O
biochemical	O
profiling	O
in	O
patients	O
presenting	O
with	O
possible	O
drug	B-DISO
use	I-DISO
,	O
even	O
in	O
the	O
absence	O
of	O
significant	O
symptoms	O
.	O

To	O
confirm	O
MHVR	O
-	O
independence	O
in	O
vitro	O
,	O
we	O
used	O
a	O
combination	O
of	O
spinoculation	O
and	O
ultraviolet	O
radiation	O
to	O
detect	O
distinct	O
plaque	B-DISO
formation	O
(	O
SpinoPlaque	O
(	O
UV	O
+))	O
afrer	O
infection	B-DISO
of	O
BHK	O
cells	O
,	O
which	O
do	O
not	O
express	O
MHVR	O
.	O

Research	O
has	O
investigated	O
the	O
efficacy	O
of	O
intravenous	O
hyperoxygenated	O
solutions	O
(	O
HOS	B-DISO
)	O
as	O
auxiliary	O
oxygen	O
supplies	O
in	O
several	O
hypoxic	B-DISO
states	O
including	O
cardiopulmonary	O
resuscitation	O
,	O
respiratory	B-DISO
failure	I-DISO
,	O
cerebrovascular	B-DISO
disease	I-DISO
,	O
myocardial	B-DISO
ischaemia	I-DISO
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
poisoning	O
,	O
neonatal	B-DISO
hypoxia	I-DISO
,	O
altitude	B-DISO
sickness	I-DISO
,	O
large	O
burns	O
and	O
traumatic	O
haemorrhagic	B-DISO
shock	I-DISO
.	O

Much	O
of	O
the	O
research	O
has	O
taken	O
place	O
in	O
China	O
and	O
more	O
than	O
3	O
.	O
5	O
million	O
hypoxic	B-DISO
patients	O
have	O
received	O
HOS	B-DISO
,	O
with	O
good	O
therapeutic	O
effects	O
.	O

These	O
other	O
viruses	O
were	O
rapidly	O
lost	O
upon	O
passages	O
in	O
MDCK	O
33016PF	O
cells	O
and	O
under	O
conditions	O
as	O
applied	O
to	O
influenza	B-DISO
virus	O
passaging	O
.	O

In	O
combination	O
with	O
their	O
superior	O
isolation	O
efficiency	O
,	O
MDCK	O
cells	O
appear	O
highly	O
suitable	O
to	O
be	O
used	O
as	O
an	O
alternative	O
to	O
embryonated	O
eggs	O
to	O
isolate	O
and	O
propagate	O
influenza	B-DISO
vaccine	O
candidate	O
viruses	O
.	O

These	O
investigations	O
have	O
contributed	O
to	O
detecting	O
and	O
characterizing	O
new	O
pathogens	O
(	O
e	O
.	O
g	O
.,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
)	O
and	O
conditions	O
,	O
provided	O
insights	O
regarding	O
factors	O
that	O
cause	O
or	O
contribute	O
to	O
disease	O
acquisition	O
(	O
e	O
.	O
g	O
.,	O
Ebola	B-DISO
hemorrhagic	I-DISO
fever	I-DISO
),	O
led	O
to	O
development	O
of	O
new	O
diagnostics	O
and	O
surveillance	O
technologies	O
,	O
and	O
provided	O
information	O
upon	O
which	O
global	O
health	O
policies	O
and	O
regulations	O
can	O
be	O
based	O
.	O

ABSTRACT	O
:	O
Pneumonia	B-DISO
is	O
a	O
leading	O
cause	O
of	O
death	O
in	O
adults	O
in	O
the	O
industrialised	O
countries	O
and	O
in	O
the	O
rest	O
of	O
the	O
world	O
in	O
infants	O
.	O

ABSTRACT	O
:	O
The	O
cessation	O
of	O
sedation	B-DISO
in	O
brain	O
-	O
injured	O
patients	O
may	O
result	O
in	O
severe	O
agitation	B-DISO
and	O
/	O
or	O
acute	O
withdrawal	B-DISO
syndrome	I-DISO
related	O
to	O
the	O
prolonged	O
administration	O
of	O
large	O
doses	O
of	O
benzodiazepines	O
and	O
/	O
or	O
opioids	O
.	O

TITLE	O
:	O
Novel	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
virus	O
-	O
induced	O
hemophagocytosis	B-DISO
:	O
first	O
case	O
reported	O
in	O
Saudi	O
Arabia	O
.	O

ABSTRACT	O
:	O
H1N1	O
is	O
a	O
novel	O
subtype	O
of	O
the	O
influenza	B-DISO
A	O
virus	O
.	O

It	O
also	O
highlights	O
the	O
fact	O
that	O
the	O
virus	O
is	O
still	O
very	O
virulent	O
and	O
will	O
pose	O
a	O
major	O
annual	O
health	O
risk	O
along	O
with	O
the	O
seasonal	O
influenza	B-DISO
for	O
at	O
least	O
the	O
next	O
few	O
years	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
in	O
the	O
treatment	O
of	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
in	O
adults	O
.	O

Prone	O
position	O
and	O
extended	O
prone	O
position	O
ventilation	O
have	O
been	O
shown	O
to	O
increase	O
end	O
-	O
expiratory	O
lung	O
volume	O
,	O
alveolar	O
recruitment	B-DISO
,	O
and	O
oxygenation	O
in	O
patients	O
with	O
severe	O
hypoxemic	O
and	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

Prone	O
positioning	O
is	O
a	O
viable	O
,	O
inexpensive	O
therapy	O
for	O
the	O
treatment	O
of	O
severe	O
ARDS	B-DISO
.	O

This	O
maneuver	O
consistently	O
improves	O
systemic	O
oxygenation	O
in	O
70	O
%	O
to	O
80	O
%	O
of	O
patients	O
with	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Meconium	B-DISO
aspiration	I-DISO
syndrome	I-DISO
(	O
MAS	B-DISO
)	O
is	O
a	O
common	O
cause	O
of	O
severe	O
respiratory	B-DISO
distress	I-DISO
in	O
term	O
infants	O
,	O
with	O
an	O
associated	O
highly	O
variable	O
morbidity	O
and	O
mortality	O
.	O

Approaches	O
to	O
the	O
prevention	O
of	O
MAS	B-DISO
have	O
changed	O
over	O
time	O
with	O
collaboration	O
between	O
obstetricians	O
and	O
pediatricians	O
forming	O
the	O
foundations	O
for	O
care	O
.	O

The	O
identification	O
of	O
these	O
inhibitors	O
demonstrated	O
a	O
strong	O
functional	O
connection	O
between	O
the	O
PLP	O
-	O
based	O
yeast	O
assay	O
,	O
the	O
inhibitory	O
compounds	O
,	O
and	O
SARS	B-DISO
-	O
CoV	O
biology	O
.	O

ABSTRACT	O
:	O
Bovine	O
torovirus	O
(	O
BToV	O
)	O
is	O
recognized	O
as	O
an	O
enteric	O
pathogen	O
of	O
calves	O
,	O
but	O
its	O
etiological	O
role	O
in	O
diarrhea	B-DISO
and	O
epidemiological	O
characterization	O
in	O
adult	O
cows	O
remain	O
unclear	O
.	O

ABSTRACT	O
:	O
High	O
frequency	O
of	O
epidemiological	O
threats	O
(	O
H5N1	B-DISO
influenza	I-DISO
,	O
SARS	B-DISO
,	O
etc	O
.)	O
in	O
modern	O
world	O
calls	O
for	O
the	O
development	O
of	O
new	O
flexible	O
technologies	O
for	O
manufacturing	O
efficacious	O
vaccines	O
and	O
rapid	O
reorientation	O
of	O
their	O
production	O
as	O
appropriate	O
.	O

ABSTRACT	O
:	O
SARS	B-DISO
coronavirus	O
(	O
SCoV	O
)	O
nonstructural	O
protein	O
(	O
nsp	O
)	O
1	O
,	O
a	O
potent	O
inhibitor	O
of	O
host	O
gene	O
expression	O
,	O
possesses	B-DISO
a	O
unique	O
mode	O
of	O
action	O
:	O
it	O
binds	O
to	O
40S	O
ribosomes	O
to	O
inactivate	O
their	O
translation	O
functions	O
and	O
induces	O
host	O
mRNA	O
degradation	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
pathogens	O
of	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
(	O
ARI	O
)	O
in	O
Guangzhou	O
from	O
2006	O
to	O
2009	O
.	O

HPIV	O
and	O
HCoV	O
shared	O
a	O
similar	O
infection	B-DISO
ratio	O
among	O
different	O
age	O
groups	O
.	O

Supported	O
by	O
robust	O
time	O
-	O
ordered	O
sequence	O
variation	O
,	O
structural	O
biology	O
,	O
well	O
-	O
characterized	O
patient	O
pools	O
,	O
and	O
biological	O
data	O
,	O
the	O
emergence	O
of	O
SARS	B-DISO
-	O
CoV	O
represents	O
one	O
of	O
the	O
best	O
-	O
studied	O
natural	O
models	O
of	O
viral	B-DISO
disease	I-DISO
emergence	O
from	O
zoonotic	O
sources	O
.	O

ABSTRACT	O
:	O
Transfer	O
of	O
severely	O
hypoxic	B-DISO
patients	O
is	O
a	O
high	O
-	O
risk	O
procedure	O
.	O

Criteria	O
for	O
ECMO	O
center	O
activation	O
were	O
:	O
potentially	O
reversibile	O
respiratory	B-DISO
failure	I-DISO
,	O
PaO₂	O
<	O
50	O
mmHg	O
with	O
FiO₂	O
>	O
0	O
.	O
6	O
for	O
>	O
12	O
hours	O
,	O
PEEP	O
>	O
5	O
cmH₂0	O
,	O
Lung	O
Injury	O
Score	O
(	O
LIS	O
)	O
≥	O
3	O
or	O
respiratory	B-DISO
acidosis	I-DISO
with	O
pH	O
<	O
7	O
.	O
2	O
,	O
no	O
intracranial	B-DISO
bleeding	I-DISO
,	O
and	O
no	O
absolute	O
contraindication	O
to	O
anticoagulation	O
.	O

Nucleic	O
acid	O
based	O
amplification	B-DISO
tests	O
(	O
NATs	O
)	O
for	O
respiratory	O
viruses	O
were	O
first	O
introduced	O
two	O
decades	O
ago	O
and	O
today	O
are	O
utilized	O
for	O
the	O
detection	O
of	O
both	O
conventional	O
and	O
emerging	O
viruses	O
.	O

These	O
resistance	O
assays	O
,	O
together	O
with	O
viral	O
load	O
assays	O
,	O
will	O
enable	O
clinical	O
laboratories	O
to	O
provide	O
physicians	O
with	O
new	O
and	O
important	O
information	O
for	O
optimal	O
treatment	O
of	O
respiratory	O
virus	O
infections	B-DISO
.	O

Led	O
by	O
Dr	O
.	O
Yin	O
,	O
Sinovac	O
successfully	O
developed	O
the	O
vaccine	O
prducts	O
against	O
SARS	B-DISO
,	O
H5N1	B-DISO
,	O
H1N1	O
,	O
hepatitis	B-DISO
A	I-DISO
and	O
B	O
and	O
infleunza	O
.	O

Inclusion	O
criteria	O
included	O
randomised	O
controlled	O
trials	O
and	O
quasi	O
-	O
experimental	O
and	O
observational	O
studies	O
of	O
humans	O
published	O
in	O
English	O
with	O
an	O
outcome	O
of	O
laboratory	O
-	O
confirmed	O
or	O
clinically	O
-	O
diagnosed	O
influenza	B-DISO
and	O
other	O
viral	O
respiratory	B-DISO
infections	I-DISO
.	O

One	O
household	O
trial	O
found	O
that	O
mask	O
wearing	O
coupled	O
with	O
hand	O
sanitiser	O
use	O
reduced	O
secondary	B-DISO
transmission	I-DISO
of	O
upper	B-DISO
respiratory	I-DISO
infection	I-DISO
/	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
/	O
laboratory	O
-	O
confirmed	O
influenza	B-DISO
compared	O
with	O
education	O
;	O
hand	O
sanitiser	O
alone	O
resulted	O
in	O
no	O
reduction	O
.	O

TITLE	O
:	O
A	O
chemokine	O
gene	O
expression	O
signature	O
derived	O
from	O
meta	O
-	O
analysis	O
predicts	O
the	O
pathogenicity	O
of	O
viral	O
respiratory	B-DISO
infections	I-DISO
.	O

From	O
a	O
compendium	O
of	O
12	O
studies	O
that	O
included	O
responses	O
to	O
influenza	B-DISO
A	O
subtype	O
H5N1	B-DISO
,	O
reconstructed	O
1918	O
influenza	B-DISO
A	O
virus	O
,	O
and	O
SARS	B-DISO
coronavirus	O
,	O
we	O
used	O
meta	O
-	O
analysis	O
to	O
derive	O
multiple	O
gene	O
expression	O
signatures	O
.	O

TITLE	O
:	O
The	O
prevalance	O
of	O
respiratory	O
viruses	O
among	O
healthcare	O
workers	O
serving	O
pilgrims	O
in	O
Makkah	O
during	O
the	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pandemic	O
.	O

Lung	O
injury	O
(	O
lavage	O
LDH	O
levels	O
)	O
and	O
lung	B-DISO
inflammation	I-DISO
(	O
lavage	O
neutrophil	O
numbers	O
)	O
were	O
measured	O
24h	O
after	O
cytokine	O
insufflation	O
.	O

RESULTS	O
:	O
Ergothioneine	O
pre	O
-	O
and	O
post	O
-	O
treatment	O
generally	O
decreased	O
lung	O
injury	O
and	O
lung	B-DISO
inflammation	I-DISO
in	O
cytokine	O
insufflated	O
rats	O
.	O

TITLE	O
:	O
Overview	O
of	O
plant	O
-	O
derived	O
vaccine	O
antigens	O
:	O
Dengue	B-DISO
virus	O
.	O

ABSTRACT	O
:	O
CD4	O
T	O
cell	O
activation	O
during	O
peripheral	O
infections	B-DISO
not	O
only	O
is	O
essential	O
in	O
inducing	O
protective	O
CD8	O
T	O
cell	O
memory	O
but	O
also	O
promotes	O
CD8	O
T	O
cell	O
function	O
and	O
survival	O
.	O

The	O
effects	O
of	O
an	O
ambient	O
airflow	O
,	O
as	O
an	O
infection	B-DISO
control	O
,	O
are	O
incorporated	O
leading	O
to	O
a	O
delay	O
equation	O
,	O
with	O
droplet	O
density	O
dependent	O
on	O
the	O
infectious	B-DISO
density	O
at	O
a	O
previous	O
time	O
.	O

A	O
diagnosis	O
of	O
IgA	O
and	O
IgG2	B-DISO
deficiency	I-DISO
and	O
SLE	B-DISO
was	O
made	O
on	O
the	O
basis	O
of	O
severe	O
proteinuria	O
,	O
hematuria	O
,	O
hypocomplementemia	B-DISO
,	O
high	O
anti	O
-	O
DNA	O
antibody	O
and	O
antinuclear	O
antibody	O
(	O
ANA	O
)	O
titers	O
,	O
and	O
malar	O
rash	B-DISO
.	O

Using	O
a	O
national	O
sample	O
of	O
suspect	O
patients	O
,	O
we	O
found	O
that	O
thrombocytopenia	O
was	O
a	O
highly	O
sensitive	O
indicator	O
of	O
HPS	B-DISO
and	O
should	O
be	O
included	O
in	O
surveillance	O
definitions	O
for	O
suspected	O
HPS	B-DISO
.	O

Combining	O
increased	O
EVLW	O
and	O
a	O
diagnosis	O
of	O
ALI	O
,	O
ARDS	B-DISO
or	O
sLI	O
increases	O
the	O
posttest	O
odds	O
of	O
ICU	O
mortality	O
.	O

She	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
within	O
a	O
short	O
time	O
after	O
the	O
symptoms	O
commenced	O
and	O
she	O
died	O
within	O
4	O
days	O
.	O

TITLE	O
:	O
Single	O
site	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
as	O
an	O
alternative	O
to	O
invasive	O
ventilation	O
in	O
post	O
-	O
pneumonectomy	O
fistula	B-DISO
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

Cellular	O
pyruvate	O
kinase	O
activity	O
in	O
hepatoma	B-DISO
cells	O
was	O
repressed	O
by	O
SARS	B-DISO
-	O
CoV	O
nucleocapsid	O
protein	O
in	O
either	O
transiently	O
transfected	O
or	O
stably	O
transfected	O
cells	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
is	O
prevented	O
primarily	O
by	O
the	O
use	O
of	O
live	O
attenuated	O
vaccines	O
,	O
which	O
are	O
known	O
to	O
have	O
a	O
limited	O
strain	O
range	O
of	O
protection	O
.	O

Non	O
-	O
aerated	O
parenchyma	O
decreased	O
significantly	O
from	O
53	O
.	O
6	O
%	O
(	O
interquartile	O
range	O
(	O
IQR	O
):	O
42	O
.	O
5	O
to	O
62	O
.	O
4	O
)	O
to	O
12	O
.	O
7	O
%	O
(	O
IQR	O
:	O
4	O
.	O
9	O
to	O
24	O
.	O
2	O
)	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
after	O
MRS	B-DISO
.	O

ABSTRACT	O
:	O
We	O
aimed	O
at	O
providing	O
the	O
most	O
recent	O
and	O
relevant	O
evidence	O
regarding	O
spontaneous	O
breathing	O
activity	O
during	O
mechanical	O
ventilation	O
in	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

In	O
our	O
opinion	O
,	O
spontaneous	O
breathing	O
activity	O
should	O
be	O
avoided	O
in	O
the	O
first	O
48	O
h	O
of	O
mechanical	O
ventilation	O
in	O
patients	O
with	O
severe	O
ARDS	B-DISO
(	O
PaO2	O
/	O
FIO2	O
<	O
120	O
mmHg	O
),	O
but	O
it	O
may	O
be	O
useful	O
in	O
less	O
severe	O
ARDS	B-DISO
and	O
ALI	O
.	O

Clearly	O
,	O
further	O
clinical	O
and	O
experimental	O
investigations	O
on	O
the	O
use	O
of	O
different	O
ventilation	O
modes	O
of	O
supported	O
/	O
unsupported	O
spontaneous	O
breathing	O
in	O
ALI	O
/	O
ARDS	B-DISO
are	O
needed	O
.	O

These	O
data	O
imply	O
that	O
enveloped	O
virus	O
can	O
deviate	O
Th2	O
responses	O
in	O
human	O
cord	B-DISO
T	O
cells	O
.	O

Clinical	O
atypical	O
cases	O
of	O
malaria	B-DISO
are	O
more	O
frequent	O
than	O
published	O
in	O
the	O
indexed	O
literature	O
,	O
probably	O
due	O
to	O
a	O
publication	O
bias	O
.	O

Indeed	O
,	O
HSA	B-DISO
represents	O
the	O
main	O
carrier	O
for	O
fatty	O
acids	O
,	O
affects	O
pharmacokinetics	O
of	O
many	O
drugs	O
,	O
provides	O
the	O
metabolic	O
modification	O
of	O
some	O
ligands	O
,	O
renders	O
potential	O
toxins	O
harmless	O
,	O
accounts	O
for	O
most	O
of	O
the	O
anti	O
-	O
oxidant	O
capacity	O
of	O
human	O
plasma	O
,	O
and	O
displays	O
(	O
pseudo	O
-)	O
enzymatic	O
properties	O
.	O

Here	O
,	O
genetic	O
,	O
biochemical	O
,	O
biomedical	O
,	O
and	O
biotechnological	O
aspects	O
of	O
HSA	B-DISO
are	O
reviewed	O
.	O

Infection	B-DISO
of	O
the	O
CNS	O
with	O
the	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
provides	O
a	O
unique	O
model	O
situation	O
in	O
which	O
the	O
extent	O
of	O
inflammatory	O
CNS	B-DISO
disease	I-DISO
is	O
determined	O
by	O
the	O
balance	O
between	O
antiviral	O
immune	O
control	O
,	O
viral	O
replication	O
,	O
and	O
immune	O
-	O
mediated	O
damage	O
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
induced	O
by	O
a	O
swine	O
2009	O
H1N1	O
variant	O
in	O
mice	O
.	O

We	O
also	O
summarise	O
existing	O
pre	O
-	O
clinical	O
evidence	O
,	O
evaluate	O
the	O
potential	O
and	O
pitfalls	O
of	O
using	O
mesenchymal	O
stem	O
cells	O
for	O
treatment	O
,	O
and	O
examine	O
the	O
likely	O
future	O
directions	O
for	O
mesenchymal	O
stem	O
cells	O
in	O
ARDS	B-DISO
.	O

We	O
show	O
here	O
that	O
three	O
residues	O
on	O
the	O
β3	O
(	O
Arg	O
-	O
125	O
and	O
Tyr	O
-	O
127	O
)	O
and	O
β5	O
(	O
Tyr	O
-	O
190	O
)	O
strands	O
play	O
key	O
roles	O
in	O
TRS	B-DISO
RNA	O
binding	O
and	O
helix	O
destabilization	O
with	O
Ala	O
substitutions	O
of	O
these	O
residues	O
lethal	O
to	O
the	O
virus	O
.	O

While	O
mortality	O
in	O
the	O
first	O
two	O
is	O
exceptional	O
,	O
the	O
mortality	O
of	O
the	O
chylothorax	B-DISO
is	O
common	O
,	O
especially	O
when	O
it	O
is	O
bilateral	O
and	O
does	O
not	O
respond	O
to	O
different	O
therapies	O
.	O

The	O
publications	O
do	O
not	O
specify	O
the	O
ultimate	O
cause	O
of	O
respiratory	B-DISO
failure	I-DISO
.	O

Patients	O
with	O
a	O
high	O
suspicion	O
of	O
influenza	B-DISO
A	O
/	O
H1N1	O
infection	B-DISO
must	O
continue	O
with	O
antiviral	O
treatment	O
,	O
regardless	O
of	O
the	O
negative	O
results	O
of	O
initial	O
tests	O
,	O
unless	O
an	O
alternative	O
diagnosis	O
can	O
be	O
established	O
or	O
clinical	O
criteria	O
suggest	O
a	O
low	O
probability	O
of	O
influenza	B-DISO
.	O

Pneumococcal	O
vaccination	O
is	O
recommended	O
as	O
a	O
preventive	O
measure	O
in	O
the	O
population	O
at	O
risk	O
of	O
suffering	B-DISO
severe	O
complications	O
.	O

Clinical	B-DISO
findings	I-DISO
show	O
50	O
-	O
60	O
%	O
survival	O
rates	O
in	O
patients	O
treated	O
with	O
this	O
technique	O
.	O

The	O
increase	O
in	O
right	O
ventricular	O
(	O
RV	O
)	O
afterload	O
causes	O
RV	O
dysfunction	O
and	O
failure	O
in	O
some	O
patients	O
,	O
with	O
associated	O
adverse	B-DISO
effects	I-DISO
on	O
oxygen	O
delivery	O
.	O

There	O
is	O
no	O
effective	O
treatment	O
for	O
ARDS	B-DISO
/	O
ALI	O
.	O

Male	O
ACE2	O
(-/	O
y	O
)	O
BLM	B-DISO
injured	O
mice	O
exhibited	O
poorer	O
exercise	O
capacity	O
,	O
worse	O
lung	O
function	O
and	O
exacerbated	O
lung	B-DISO
fibrosis	I-DISO
and	O
collagen	O
deposition	O
compared	O
with	O
WT	O
.	O

Conversely	O
,	O
ACE2	O
protects	O
against	O
BLM	B-DISO
-	O
induced	O
fibrosis	B-DISO
.	O

In	O
comparison	O
to	O
three	O
other	O
cases	O
of	O
influenza	B-DISO
pneumonia	I-DISO
in	O
the	O
same	O
outbreak	O
with	O
known	O
risk	O
factors	O
for	O
severe	O
influenza	B-DISO
,	O
such	O
as	O
pregnancy	B-DISO
and	I-DISO
diabetes	I-DISO
mellitus	O
,	O
a	O
much	O
higher	O
viral	O
load	O
was	O
detected	O
in	O
the	O
lungs	O
of	O
this	O
patient	O
despite	O
antiviral	O
treatment	O
.	O

TITLE	O
:	O
Complicated	O
secondary	O
pneumonia	B-DISO
after	O
swine	O
-	O
origin	O
influenza	B-DISO
A	I-DISO
virus	I-DISO
infection	I-DISO
in	O
an	O
immunocompetent	O
patient	O
.	O

Although	O
ARDS	B-DISO
would	O
be	O
caused	O
by	O
the	O
influenza	B-DISO
virus	O
pneumonia	B-DISO
itself	O
,	O
it	O
has	O
remained	O
unclear	O
whether	O
other	O
respiratory	O
viral	O
or	O
bacterial	B-DISO
infections	I-DISO
coexist	O
with	O
S	O
-	O
OIV	O
pneumonia	B-DISO
.	O

Administration	O
of	O
an	O
antiviral	O
agent	O
(	O
acyclovir	O
),	O
an	O
antibacterial	O
agent	O
(	O
linezolid	O
),	O
and	O
a	O
corticosteroid	O
(	O
methylprednisolone	O
)	O
successfully	O
improved	O
the	O
pneumonia	B-DISO
and	O
ARDS	B-DISO
.	O

HSV	O
pneumonia	B-DISO
can	O
scarcely	O
be	O
seen	O
in	O
healthy	O
people	O
.	O

We	O
propose	O
that	O
a	O
possibility	O
of	O
hidden	O
HSV	O
pneumonia	B-DISO
should	O
be	O
taken	O
into	O
consideration	O
in	O
patients	O
with	O
prolonged	O
severe	O
pneumonia	B-DISO
due	O
to	O
influenza	B-DISO
infection	B-DISO
.	O

Using	O
gene	O
knockdown	O
technology	O
,	O
we	O
demonstrate	O
that	O
phosphatidylinositol	O
4	O
-	O
kinase	O
IIIβ	O
(	O
PI4KB	O
)	O
is	O
required	O
for	O
cellular	O
entry	O
by	O
pseudoviruses	O
bearing	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
spike	O
protein	O
and	O
that	O
the	O
cell	O
entry	O
mediated	O
by	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
is	O
strongly	O
inhibited	O
by	O
knockdown	O
of	O
PI4KB	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
a	O
new	O
function	O
for	O
PI4KB	O
and	O
suggest	O
a	O
new	O
drug	O
target	O
for	O
preventing	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
The	O
causative	O
agent	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
genome	O
encodes	O
several	O
unique	O
group	O
specific	O
accessory	O
proteins	O
with	O
unknown	O
functions	O
.	O

Chromatin	O
immunoprecipitaion	O
(	O
ChIP	O
)	O
and	O
reporter	O
gene	O
assays	O
in	O
3b	O
expressing	O
jurkat	O
cells	O
showed	O
recruitment	B-DISO
of	O
3b	O
on	O
the	O
RUNX1	O
binding	O
element	O
that	O
led	O
to	O
an	O
increase	O
in	O
RUNX1b	O
transactivation	O
potential	O
on	O
the	O
IL2	O
promoter	O
.	O

These	O
results	O
unveil	O
a	O
novel	O
interaction	O
of	O
SARS	B-DISO
-	O
CoV	O
3b	O
with	O
the	O
host	O
factor	O
,	O
RUNX1b	O
,	O
and	O
speculate	O
its	O
physiological	O
relevance	O
in	O
upregulating	O
cytokines	O
and	O
chemokine	O
levels	O
in	O
state	O
of	O
SARS	B-DISO
virus	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Obstructive	B-DISO
Sleep	I-DISO
Apnea	I-DISO
Syndrome	I-DISO
(	O
OSAS	B-DISO
)	O
is	O
defined	O
as	O
a	O
sleep	O
related	O
breathing	B-DISO
disorder	I-DISO
that	O
causes	O
the	O
body	O
to	O
stop	O
breathing	O
for	O
about	O
10	O
seconds	O
and	O
mostly	O
ends	O
with	O
a	O
loud	O
sound	O
due	O
to	O
the	O
opening	O
of	O
the	O
airway	O
.	O

Chemically	O
modified	O
tetracycline	O
3	O
treatment	O
prevented	O
ARDS	B-DISO
as	O
indicated	O
by	O
PaO	O
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
ratio	O
,	O
static	O
compliance	O
,	O
and	O
plateau	O
airway	O
pressure	O
(	O
P	O
<	O
0	O
.	O
05	O
vs	O
.	O
placebo	O
).	O

In	O
this	O
paper	O
,	O
the	O
association	O
between	O
two	O
network	O
analysis	O
measures	O
,	O
i	O
.	O
e	O
.	O
'	O
in	O
-	O
degree	O
'	O
and	O
'	O
ingoing	O
infection	B-DISO
chain	O
',	O
and	O
signs	O
of	O
infection	B-DISO
is	O
investigated	O
.	O

It	O
is	O
shown	O
that	O
based	O
on	O
regression	O
analysis	O
of	O
combined	O
data	O
from	O
a	O
recent	O
cross	O
-	O
sectional	O
study	O
for	O
endemic	O
viral	B-DISO
infections	I-DISO
and	O
network	O
analysis	O
of	O
animal	O
movements	O
,	O
a	O
positive	O
serological	O
result	O
for	O
bovine	O
coronavirus	O
(	O
BCV	O
)	O
and	O
bovine	O
respiratory	O
syncytial	O
virus	O
(	O
BRSV	O
)	O
is	O
significantly	O
associated	O
with	O
the	O
purchase	O
of	O
animals	O
.	O

TITLE	O
:	O
A	O
hexapeptide	O
of	O
the	O
receptor	O
-	O
binding	O
domain	O
of	O
SARS	B-DISO
corona	O
virus	O
spike	O
protein	O
blocks	O
viral	O
entry	O
into	O
host	O
cells	O
via	O
the	O
human	O
receptor	O
ACE2	O
.	O

(	O
438	O
)	O
YKYRYL	O
(	O
443	O
)	O
carries	O
the	O
dominant	O
binding	O
epitope	O
and	O
binds	O
to	O
ACE2	O
with	O
K	O
(	O
D	O
)=	O
46	O
μM	O
.	O
The	O
binding	O
mode	O
was	O
further	O
characterized	O
by	O
saturation	O
transfer	O
difference	O
(	O
STD	B-DISO
)	O
NMR	O
spectroscopy	O
and	O
molecular	O
dynamic	O
simulations	O
.	O

TITLE	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
:	O
role	O
of	O
the	O
feline	O
coronavirus	O
3c	O
gene	O
in	O
intestinal	O
tropism	O
and	O
pathogenicity	O
based	O
upon	O
isolates	O
from	O
resident	O
and	O
adopted	O
shelter	O
cats	O
.	O

Coronavirus	O
from	O
FIP	B-DISO
diseased	O
tissues	O
consistently	O
induced	O
FIP	B-DISO
when	O
given	O
either	O
oronasally	O
or	O
intraperitoneally	O
(	O
i	O
.	O
p	O
.),	O
regardless	O
of	O
the	O
functional	O
status	O
of	O
their	O
3c	O
genes	O
,	O
thus	O
confirming	O
them	O
to	O
be	O
FIPVs	O
.	O

ABSTRACT	O
:	O
To	O
recognize	O
the	O
etiological	O
agent	O
responsible	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
(	O
ARF	B-DISO
)	O
in	O
patients	O
in	O
mechanical	O
ventilation	O
(	O
MV	O
)	O
is	O
important	O
to	O
determine	O
their	O
treatment	O
and	O
prognosis	O
,	O
and	O
to	O
avoid	O
the	O
excessive	O
use	O
of	O
antibiotics	O
.	O

There	O
is	O
clear	O
overlap	O
between	O
the	O
pathogenesis	B-DISO
of	O
CRS	B-DISO
and	O
asthma	B-DISO
.	O

Infections	B-DISO
with	O
respiratory	O
viruses	O
in	O
childhood	O
increase	O
the	O
risk	O
of	O
subsequently	O
developing	O
asthma	B-DISO
.	O

TITLE	O
:	O
Eculizumab	O
safely	O
reverses	O
neurologic	O
impairment	B-DISO
and	O
eliminates	O
need	O
for	O
dialysis	O
in	O
severe	O
atypical	B-DISO
hemolytic	I-DISO
uremic	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
The	O
hemagglutinin	O
-	O
esterases	O
(	O
HEs	B-DISO
),	O
envelope	O
glycoproteins	O
of	O
corona	O
-,	O
toro	O
-	O
and	O
orthomyxoviruses	O
,	O
mediate	O
reversible	O
virion	O
attachment	O
to	O
O	O
-	O
acetylated	O
sialic	O
acids	O
(	O
O	O
-	O
Ac	O
-	O
Sias	O
).	O

Here	O
we	O
present	O
the	O
crystal	O
structure	O
of	O
the	O
lectin	O
domain	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
strain	O
S	O
HE	O
,	O
resolved	O
both	O
in	O
its	O
native	O
state	O
and	O
in	O
complex	O
with	O
a	O
receptor	O
analogue	O
.	O

Our	O
findings	O
illustrate	O
the	O
ease	O
with	O
which	O
viruses	O
can	O
change	O
receptor	O
-	O
binding	O
specificity	O
with	O
potential	O
consequences	O
for	O
host	O
-,	O
organ	O
and	O
/	O
or	O
cell	O
tropism	O
,	O
and	O
for	O
pathogenesis	B-DISO
.	O

STUDY	O
DESIGN	O
&	O
DESCRIPTION	O
OF	O
THE	O
PATIENTS	O
:	O
Our	O
study	O
was	O
conducted	O
during	O
2007	O
to	O
2009	O
in	O
200	O
cases	O
of	O
severe	O
malaria	B-DISO
[	O
Pf	O
,	O
Pv	O
,	O
and	O
mixed	O
(	O
Pf	O
+	O
Pv	O
)]	O
with	O
pulmonary	B-DISO
involvement	I-DISO
.	O

Pulmonary	B-DISO
involvement	I-DISO
was	O
observed	O
in	O
30	O
%	O
(	O
60	O
/	O
200	O
)	O
patients	O
among	O
which	O
cough	B-DISO
in	O
24	O
%	O
,	O
dyspnea	B-DISO
in	O
12	O
%,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
7	O
%	O
,	O
bronchitis	B-DISO
in	O
3	O
%	O
and	O
pneumonia	B-DISO
in	O
1	O
.	O
5	O
%	O
were	O
the	O
major	O
clinical	O
manifestations	O
of	O
malaria	B-DISO
.	O

The	O
endoribonuclease	O
activity	O
of	O
the	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
A59	O
Nsp15	O
was	O
also	O
increased	O
by	O
pRb	O
in	O
vitro	O
,	O
and	O
an	O
MHV	O
with	O
mutations	O
in	O
the	O
LXCXE	O
/	O
D	O
-	O
motif	O
,	O
named	O
vLC	O
,	O
exhibited	O
a	O
smaller	O
plaque	B-DISO
diameter	O
and	O
reduced	O
the	O
virus	O
titer	O
by	O
∼	O
1	O
log	O
.	O

The	O
administration	O
of	O
fusing	O
CEA	O
-	O
SARS	B-DISO
-	O
CoV	O
fragments	O
may	O
provide	O
a	O
promising	O
strategy	O
for	O
strengthening	O
the	O
anti	O
-	O
tumor	B-DISO
efficacy	O
against	O
low	O
-	O
immunogenic	O
endogenous	O
tumor	B-DISO
antigens	O
.	O

TITLE	O
:	O
[	O
Guidelines	O
for	O
specialized	O
nutritional	O
and	O
metabolic	O
support	O
in	O
the	O
critically	O
-	O
ill	B-DISO
patient	O
.	O

Among	O
the	O
most	O
frequent	O
causes	O
for	O
admission	O
are	O
exacerbation	O
of	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
with	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
or	O
with	O
criteria	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

We	O
demonstrate	O
the	O
feasibility	O
of	O
using	O
GSH	B-DISO
for	O
in	O
vitro	O
HTS	B-DISO
assays	O
with	O
these	O
three	O
target	O
enzymes	O
.	O

Coronaviruses	O
accounted	O
for	O
1	O
.	O
6	O
%	O
(	O
98	O
/	O
6272	O
)	O
of	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
based	O
on	O
nasopharyngeal	O
aspirate	O
samples	O
.	O

3	O
.	O
Although	O
CoV	O
-	O
HKU1	O
infections	B-DISO
were	O
most	O
often	O
associated	O
with	O
the	O
upper	O
respiratory	O
tract	O
,	O
more	O
severe	O
illness	O
(	O
pneumonia	B-DISO
,	O
acute	B-DISO
bronchiolitis	I-DISO
,	O
and	O
asthmatic	B-DISO
exacerbation	O
)	O
may	O
occur	O
,	O
especially	O
in	O
those	O
with	O
underlying	O
disease	O
.	O

Most	O
differences	O
between	O
the	O
bat	O
-	O
SARS	B-DISO
-	O
CoV	O
and	O
SARS	B-DISO
-	O
CoV	O
genomes	O
were	O
observed	O
in	O
the	O
spike	O
gene	O
.	O

Neutralising	O
antibody	O
to	O
human	O
SARS	B-DISO
-	O
CoV	O
was	O
also	O
detected	O
in	O
those	O
with	O
lower	O
viral	O
loads	O
.	O
5	O
.	O

Antibody	O
-	O
mediated	O
infection	B-DISO
of	O
SARS	B-DISO
-	O
CoV	O
triggers	O
entry	O
into	O
human	O
haematopoietic	O
cells	O
via	O
an	O
FcγR	O
-	O
dependent	O
and	O
ACE2	O
-,	O
pH	O
-,	O
cysteine	O
-	O
protease	O
-	O
independent	O
pathways	O
.	O

Occurrence	O
of	O
immune	O
-	O
mediated	O
enhancement	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
raises	O
safety	O
concerns	O
regarding	O
the	O
use	O
of	O
SARS	B-DISO
-	O
CoV	O
vaccine	O
in	O
humans	O
and	O
enables	O
new	O
ways	O
to	O
investigate	O
SARS	B-DISO
pathogenesis	B-DISO
(	O
tropism	O
and	O
immune	O
response	O
deregulation	O
).	O

Rat	O
coronavirus	O
(	O
RCoV	O
)	O
is	O
used	O
as	O
a	O
model	O
to	O
study	O
the	O
immune	O
response	O
to	O
viral	B-DISO
infection	I-DISO
in	O
the	O
lung	O
of	O
the	O
natural	O
host	O
.	O

We	O
have	O
developed	O
an	O
in	O
vitro	O
model	O
to	O
characterize	O
the	O
response	O
of	O
PMNs	O
to	O
RCoV	O
-	O
infected	O
type	O
I	O
-	O
like	O
alveolar	O
epithelial	O
(	O
AT1	B-DISO
)	O
cells	O
,	O
the	O
primary	O
target	O
for	O
RCoV	O
infection	B-DISO
in	O
the	O
alveoli	O
.	O

Multiple	O
CXC	O
chemokines	O
that	O
signal	O
through	O
CXCR2	O
were	O
required	O
for	O
PMN	O
chemotaxis	O
toward	O
medium	O
from	O
RCoV	O
-	O
infected	O
AT1	B-DISO
-	O
like	O
cells	O
(	O
RCoV	O
-	O
AT1	B-DISO
).	O

Use	O
of	O
a	O
selective	O
inhibitor	O
of	O
CXCR2	O
,	O
SB265610	O
,	O
demonstrated	O
that	O
CXCR2	O
signaling	O
was	O
required	O
for	O
RCoV	O
-	O
AT1	B-DISO
-	O
mediated	O
inhibition	O
of	O
PMN	O
apoptosis	O
.	O

These	O
studies	O
provide	O
new	O
insight	O
into	O
the	O
molecular	O
mechanisms	O
whereby	O
alveolar	O
epithelial	O
cells	O
direct	O
the	O
functions	O
of	O
PMNs	O
during	O
viral	B-DISO
infection	I-DISO
of	O
the	O
lung	O
.	O

Although	O
the	O
precise	O
cause	O
of	O
FIP	B-DISO
pathogenesis	B-DISO
remains	O
unclear	O
,	O
some	O
hypotheses	O
have	O
been	O
suggested	O
.	O

In	O
this	O
review	O
we	O
present	O
results	O
from	O
different	O
FCoV	O
studies	O
and	O
attempt	O
to	O
elucidate	O
existing	O
theories	O
on	O
the	O
pathogenesis	B-DISO
of	O
FCoV	O
infection	B-DISO
.	O

Nevertheless	O
,	O
coronaviruses	O
have	O
been	O
known	O
for	O
about	O
50	O
years	O
to	O
be	O
major	O
agents	O
of	O
respiratory	O
,	O
enteric	O
,	O
or	O
systemic	B-DISO
infections	I-DISO
of	O
domestic	O
and	O
companion	O
animals	O
.	O

In	O
this	O
paper	O
,	O
different	O
aspects	O
of	O
the	O
genetics	O
,	O
host	O
cell	O
tropism	O
,	O
and	O
pathogenesis	B-DISO
of	O
the	O
feline	O
and	O
canine	O
coronaviruses	O
(	O
FCoV	O
and	O
CCoV	O
)	O
will	O
be	O
discussed	O
,	O
with	O
a	O
view	O
to	O
illustrating	O
how	O
study	O
of	O
FCoVs	O
and	O
CCoVs	O
can	O
improve	O
our	O
general	O
understanding	O
of	O
the	O
pathobiology	O
of	O
coronaviruses	O
.	O

TITLE	O
:	O
The	O
Effects	O
of	O
Temperature	O
and	O
Relative	O
Humidity	O
on	O
the	O
Viability	O
of	O
the	O
SARS	B-DISO
Coronavirus	O
.	O

The	O
better	O
stability	O
of	O
SARS	B-DISO
coronavirus	O
at	O
low	O
temperature	O
and	O
low	O
humidity	O
environment	O
may	O
facilitate	O
its	O
transmission	O
in	O
community	O
in	O
subtropical	O
area	O
(	O
such	O
as	O
Hong	O
Kong	O
)	O
during	O
the	O
spring	O
and	O
in	O
air	O
-	O
conditioned	O
environments	O
.	O

TITLE	O
:	O
Coronavirus	O
papain	O
-	O
like	O
proteases	O
negatively	O
regulate	O
antiviral	O
innate	B-DISO
immune	I-DISO
response	I-DISO
through	O
disruption	O
of	O
STING	O
-	O
mediated	O
signaling	O
.	O

We	O
found	O
that	O
expression	O
of	O
the	O
membrane	O
anchored	O
PLP	O
domain	O
from	O
human	O
HCoV	O
-	O
NL63	O
(	O
PLP2	O
-	O
TM	O
)	O
or	O
SARS	B-DISO
-	O
CoV	O
(	O
PLpro	O
-	O
TM	O
)	O
inhibits	O
STING	O
-	O
mediated	O
activation	O
of	O
IRF	O
-	O
3	O
nuclear	O
translocation	B-DISO
and	O
induction	O
of	O
IRF	O
-	O
3	O
dependent	O
promoters	O
.	O

The	O
current	O
investigation	O
presents	O
a	O
comprehensive	O
approach	O
to	O
assessing	O
the	O
spatial	O
and	O
temporal	O
distributions	O
of	O
airborne	O
infection	B-DISO
risk	O
in	O
an	O
aircraft	O
cabin	O
.	O

A	O
case	O
of	O
influenza	B-DISO
outbreak	O
was	O
evaluated	O
in	O
a	O
4	O
-	O
h	O
flight	O
in	O
a	O
twin	O
-	O
aisle	O
,	O
fully	O
occupied	O
aircraft	O
cabin	O
with	O
the	O
index	O
passenger	O
seated	O
at	O
the	O
center	O
of	O
the	O
cabin	O
.	O

The	O
approach	O
and	O
methods	O
developed	O
can	O
easily	O
be	O
implemented	O
in	O
other	O
enclosed	O
spaces	O
such	O
as	O
buildings	O
,	O
trains	O
,	O
and	O
buses	O
to	O
assess	O
the	O
infection	B-DISO
risk	O
.	O

Airborne	O
infectious	B-DISO
disease	I-DISO
transmission	I-DISO
could	O
take	O
place	O
in	O
enclosed	O
environments	O
such	O
as	O
buildings	O
and	O
transport	O
vehicles	O
.	O

This	O
failure	O
was	O
associated	O
with	O
reduced	O
numbers	O
and	O
functionality	O
of	O
LCMV	O
-	O
specific	O
CD4	O
(+)	O
helper	O
T	O
cells	O
and	O
impaired	B-DISO
antiviral	O
CD8	O
(+)	O
T	O
-	O
cell	O
responses	O
.	O

Considering	O
the	O
widespread	O
nature	O
of	O
CCoV	O
infections	B-DISO
among	O
dog	O
populations	O
,	O
several	O
studies	O
have	O
been	O
carried	O
out	O
,	O
focusing	O
upon	O
the	O
epidemiological	O
relevance	O
of	O
these	O
viruses	O
and	O
underlining	O
the	O
need	O
for	O
further	O
investigation	O
into	O
the	O
biology	O
of	O
CCoVs	O
and	O
into	O
the	O
pathogenetic	O
role	O
of	O
the	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
Recruitment	B-DISO
maneuvers	O
and	O
the	O
application	O
of	O
high	O
levels	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
combined	O
with	O
lung	O
protective	O
mechanical	O
ventilation	O
strategies	O
have	O
been	O
proposed	O
to	O
improve	O
pulmonary	O
function	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Of	O
6	O
cases	O
,	O
2	O
patients	O
with	O
severe	O
influenza	B-DISO
A	O
/	O
H1N1	O
pneumonia	B-DISO
finally	O
died	O
of	O
shock	O
;	O
1	O
patient	O
with	O
severe	O
influenza	B-DISO
A	O
/	O
H1N1	O
pneumonia	B-DISO
and	O
1	O
patient	O
with	O
Klebsiella	B-DISO
pneumoniae	I-DISO
pneumonia	I-DISO
were	O
withdrawn	B-DISO
from	O
ECMO	O
treatment	O
because	O
of	O
deterioration	O
of	O
the	O
disease	O
.	O

Meta	O
-	O
analysis	O
of	O
the	O
use	O
of	O
ECMO	O
in	O
the	O
treatment	O
of	O
ARDS	B-DISO
patients	O
was	O
conducted	O
using	O
the	O
methods	O
recommended	O
by	O
the	O
Cochrane	O
Collaboration	O
'	O
s	O
software	O
RevMan	O
5	O
.	O
0	O
.	O

Two	O
patients	O
were	O
treated	O
with	O
veno	O
-	O
arterial	O
(	O
V	O
-	O
A	O
)	O
ECMO	O
for	O
severe	O
heart	B-DISO
failure	I-DISO
,	O
and	O
7	O
with	O
veno	O
-	O
venous	O
(	O
V	O
-	O
V	O
)	O
ECMO	O
due	O
to	O
refractory	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
ARDS	B-DISO
caused	O
by	O
2009	O
novel	O
H1N1	B-DISO
virus	I-DISO
infection	I-DISO
.	O

We	O
prospectively	O
assessed	O
184	O
consecutive	O
patients	O
;	O
102	O
had	O
""""	O
de	O
novo	O
""""	O
ARF	B-DISO
,	O
and	O
82	O
previous	O
cardiac	O
or	O
respiratory	B-DISO
disease	I-DISO
.	O

If	O
predictors	O
for	O
NIV	O
failure	O
are	O
present	O
,	O
avoiding	O
delayed	O
intubation	O
of	O
patients	O
with	O
""""	O
de	O
novo	O
""""	O
ARF	B-DISO
would	O
potentially	O
minimise	O
mortality	O
.	O

This	O
was	O
concurrent	O
in	O
most	O
cases	O
with	O
canine	O
parvovirus	B-DISO
2c	O
.	O

One	O
outbreak	O
was	O
a	O
deadly	O
acute	O
systemic	B-DISO
disease	I-DISO
with	O
a	O
single	O
pantropic	O
canine	O
coronavirus	B-DISO
infection	I-DISO
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
the	O
mixed	B-DISO
infection	I-DISO
rate	O
among	O
different	O
age	O
groups	O
(	O
χ²	O
=	O
1346	O
.	O
00	O
,	O
P	O
=	O
0	O
.	O
000	O
).	O

Young	O
dogs	O
are	O
more	O
likely	O
to	O
suffer	B-DISO
from	O
viral	B-DISO
enteritis	I-DISO
.	O

Besides	O
the	O
young	O
age	O
,	O
parvovirus	B-DISO
infection	I-DISO
is	O
associated	O
with	O
typical	O
changes	O
in	O
laboratory	O
parameters	O
,	O
but	O
not	O
with	O
specific	O
clinical	O
signs	O
.	O

RESULTS	O
:	O
Virus	O
was	O
detected	O
in	O
44	O
.	O
2	O
%	O
of	O
the	O
dogs	O
presented	O
with	O
acute	O
bloody	B-DISO
diarrhea	I-DISO
.	O

No	O
significant	O
differences	O
were	O
seen	O
when	O
evaluating	O
sex	O
,	O
clinical	O
parameters	O
,	O
character	O
of	O
diarrhea	B-DISO
or	O
vomiting	B-DISO
among	O
all	O
groups	O
.	O

With	O
the	O
appearance	O
of	O
multidrug	O
-	O
resistant	O
TB	O
and	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
H1N1	B-DISO
influenza	I-DISO
viruses	O
,	O
engineering	O
controls	O
using	O
254	O
nm	O
UV	O
-	O
C	O
lamps	O
within	O
specialized	O
luminaires	O
,	O
herein	O
designated	O
UVGI	O
fixtures	O
,	O
are	O
being	O
installed	O
in	O
high	O
-	O
risk	O
settings	O
such	O
as	O
homeless	O
shelters	O
,	O
hospitals	O
,	O
jails	O
and	O
prisons	O
,	O
and	O
schools	O
.	O

All	O
ECMO	O
cases	O
with	O
severe	O
ARDS	B-DISO
associated	O
with	O
novel	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
virus	O
were	O
analyzed	O
in	O
5	O
intensive	O
care	O
units	O
(	O
ICUs	O
)	O
from	O
5	O
different	O
hospitals	O
in	O
Beijing	O
and	O
Tianjin	O
.	O

A	O
physician	O
experienced	O
in	O
ECMO	O
handling	O
collected	O
the	O
relevant	O
data	O
,	O
including	O
general	O
conditions	O
pre	O
and	O
post	O
-	O
EMCO	O
,	O
efficacy	O
and	O
complication	B-DISO
parameters	O
,	O
ventilator	O
settings	O
of	O
mechanical	O
ventilation	O
and	O
clinical	O
outcomes	O
.	O

Full	O
-	O
length	O
NP	O
was	O
used	O
for	O
the	O
preparation	O
of	O
mouse	O
monoclonal	O
antibody	O
and	O
chicken	O
polyclonal	O
IgY	O
antibodies	O
for	O
the	O
development	O
of	O
heterosandwich	O
ELISA	O
for	O
early	O
diagnostics	O
of	O
SARS	B-DISO
-	O
suspected	O
individuals	O
.	O

One	O
of	O
the	O
most	O
important	O
findings	O
was	O
the	O
use	O
of	O
inexpensive	O
polyclonal	O
IgY	O
antibody	O
to	O
increase	O
the	O
sensitivity	O
of	O
the	O
detection	O
system	O
for	O
SARS	B-DISO
-	O
CoV	O
at	O
the	O
picogram	O
level	O
.	O

In	O
contrast	O
,	O
no	O
positive	O
CSF	O
was	O
detected	O
among	O
the	O
340	O
patients	O
with	O
neurologic	O
syndromes	B-DISO
.	O

Ten	O
of	O
the	O
14	O
HPeV	O
patients	O
with	O
respiratory	O
syndrome	B-DISO
were	O
co	O
-	O
infected	O
with	O
other	O
respiratory	O
viruses	O
(	O
eight	O
with	O
rhinovirus	O
and	O
two	O
with	O
coronavirus	O
OC43	O
).	O

TITLE	O
:	O
Design	O
and	O
validation	O
of	O
a	O
questionnaire	O
to	O
measure	O
the	O
attitudes	O
of	O
hospital	O
staff	O
concerning	O
pandemic	O
influenza	B-DISO
.	O

With	O
the	O
changes	O
proposed	O
in	O
this	O
article	O
,	O
the	O
questionnaire	O
for	O
measuring	O
staff	O
attitudes	O
concerning	O
pandemic	O
influenza	B-DISO
can	O
be	O
converted	O
to	O
a	O
standardized	O
and	O
validated	O
questionnaire	O
to	O
properly	O
measure	O
the	O
expectations	O
and	O
attendance	O
of	O
healthcare	O
staff	O
in	O
the	O
event	O
of	O
pandemic	O
flu	B-DISO
.	O

ABSTRACT	O
:	O
Increasing	O
concerns	O
about	O
the	O
spread	O
of	O
airborne	O
pathogens	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
novel	O
swine	O
-	O
origin	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
have	O
attracted	O
public	O
attention	O
to	O
bioaerosols	O
and	O
protection	O
against	O
them	O
.	O

Replacement	O
with	O
the	O
BCoV	O
32	O
-	O
nucleotide	O
(	O
nt	O
)	O
inter	O
-	O
stem	O
-	O
loop	O
fourth	O
domain	O
between	O
stem	O
-	O
loops	O
III	O
and	O
IV	O
,	O
however	O
,	O
required	O
blind	B-DISO
cell	O
passaging	O
for	O
virus	O
recovery	O
.	O

TITLE	O
:	O
Primary	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	B-DISO
infection	I-DISO
limits	O
replication	O
but	O
not	O
lung	B-DISO
inflammation	I-DISO
upon	O
homologous	O
rechallenge	O
.	O

In	O
SARS	B-DISO
-	O
CoV	O
homologous	O
rechallenge	O
studies	O
,	O
11	O
of	O
the	O
12	O
animals	O
were	O
free	O
of	O
replicating	O
virus	O
at	O
day	O
5	O
after	O
rechallenge	O
.	O

This	O
study	O
represents	O
one	O
of	O
the	O
first	O
comprehensive	O
analyses	O
of	O
lung	O
immunity	O
,	O
including	O
changes	O
in	O
leukocyte	O
populations	O
,	O
lung	O
-	O
specific	O
cytokines	O
,	O
and	O
antibody	O
responses	O
following	O
SARS	B-DISO
-	O
CoV	O
rechallenge	O
in	O
AGMs	O
.	O

TITLE	O
:	O
Hapivirins	O
and	O
diprovirins	O
:	O
novel	O
θ	O
-	O
defensin	O
analogs	O
with	O
potent	O
activity	O
against	O
influenza	B-DISO
A	O
virus	O
.	O

The	O
new	O
peptides	O
acted	O
at	O
an	O
early	O
phase	O
of	O
viral	B-DISO
infection	I-DISO
,	O
and	O
,	O
when	O
combined	O
with	O
pulmonary	O
surfactant	O
protein	O
D	O
,	O
their	O
antiviral	O
effects	O
were	O
additive	O
.	O

Antecedent	O
illness	O
was	O
found	O
in	O
66	O
.	O
7	O
%	O
of	O
cases	O
in	O
the	O
preceding	O
two	O
weeks	O
,	O
which	O
included	O
nonspecific	O
illness	O
,	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
,	O
diarrhea	B-DISO
,	O
and	O
chickenpox	B-DISO
.	O

At	O
onset	O
,	O
sensory	O
symptoms	O
(	O
pain	O
and	O
paresthesia	B-DISO
)	O
were	O
noted	O
in	O
59	O
%	O
of	O
the	O
cases	O
and	O
limb	B-DISO
weakness	I-DISO
in	O
77	O
%.	O

The	O
histopathologic	O
study	O
of	O
the	O
lung	O
showed	O
findings	O
typical	O
of	O
an	O
acute	O
fibrinous	O
and	O
organizing	B-DISO
pneumonia	I-DISO
.	O

A	O
review	O
of	O
the	O
literature	O
reveals	O
that	O
the	O
role	O
of	O
noninvasive	O
ventilation	O
(	O
NIV	O
)	O
in	O
ARDS	B-DISO
after	O
lung	O
resection	O
is	O
unclear	O
,	O
in	O
contrast	O
to	O
its	O
well	O
established	O
benefits	O
in	O
other	O
types	O
of	O
respiratory	B-DISO
failure	I-DISO
.	O

The	O
detection	O
specificity	O
of	O
the	O
new	O
assay	O
was	O
proven	O
by	O
positive	O
amplification	B-DISO
from	O
a	O
set	O
of	O
nine	O
different	O
FCoV	O
strains	O
and	O
negative	O
from	O
the	O
tested	O
non	O
-	O
coronaviral	O
targets	O
.	O

TITLE	O
:	O
Flavonoid	O
-	O
mediated	O
inhibition	O
of	O
SARS	B-DISO
coronavirus	O
3C	O
-	O
like	O
protease	O
expressed	O
in	O
Pichia	O
pastoris	O
.	O

ABSTRACT	O
:	O
A	O
72	O
-	O
year	O
-	O
old	O
man	O
was	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
of	O
our	O
hospital	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

However	O
,	O
he	O
had	O
a	O
fever	O
on	O
day	O
28	O
,	O
pleural	B-DISO
pain	I-DISO
and	O
dyspnea	B-DISO
on	O
day	O
29	O
,	O
and	O
exacerbation	O
of	O
the	O
infiltration	B-DISO
as	O
demonstrated	O
on	O
chest	O
CT	O
on	O
day	O
30	O
.	O

Currently	O
,	O
the	O
use	O
of	O
corticosteroid	O
therapy	O
for	O
severe	O
pandemic	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pneumonia	B-DISO
is	O
controversial	O
,	O
but	O
even	O
the	O
late	O
administration	O
of	O
corticosteroid	O
therapy	O
may	O
be	O
effective	O
.	O

ABSTRACT	O
:	O
In	O
2011	O
,	O
outbreaks	O
of	O
viral	B-DISO
diarrhea	I-DISO
were	O
observed	O
on	O
most	O
swine	O
-	O
breeding	O
farms	O
in	O
most	O
of	O
the	O
provinces	O
of	O
China	O
.	O

TITLE	O
:	O
Dendritic	O
cell	O
targeted	O
chitosan	O
nanoparticles	O
for	O
nasal	O
DNA	O
immunization	O
against	O
SARS	B-DISO
CoV	O
nucleocapsid	O
protein	O
.	O

Tuberculosis	B-DISO
,	O
as	O
a	O
bacterial	B-DISO
infection	I-DISO
,	O
has	O
re	O
-	O
emerged	O
since	O
the	O
1990s	O
and	O
has	O
become	O
prevalent	O
in	O
the	O
country	O
.	O

TITLE	O
:	O
[	O
Experience	O
with	O
empirical	O
treatment	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
due	O
to	O
coronavirus	O
,	O
genotype	O
IV	O
].	O

The	O
efficacy	O
of	O
two	O
chemotherapeutics	O
,	O
i	O
.	O
e	O
.	O
lopinavir	O
and	O
ritonavir	O
used	O
in	O
the	O
SARS	B-DISO
foci	O
is	O
confirmed	O
.	O

TITLE	O
:	O
Rapid	O
detection	O
of	O
Betacoronavirus	O
1	O
from	O
clinical	O
fecal	O
specimens	O
by	O
a	O
novel	O
reverse	O
transcription	O
loop	O
-	O
mediated	O
isothermal	O
amplification	B-DISO
assay	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
timely	O
peritoneal	O
dialysis	O
(	O
PD	O
)	O
catheter	O
in	O
children	O
with	O
abdominal	B-DISO
compartment	I-DISO
syndrome	I-DISO
(	O
ACS	O
)	O
while	O
supported	O
on	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
).	O

Timely	O
placement	O
of	O
a	O
PD	O
catheter	O
in	O
patients	O
who	O
develop	O
abdominal	O
distension	B-DISO
and	O
ACS	O
can	O
substantially	O
improve	O
venous	O
return	O
and	O
thus	O
help	O
maintain	O
adequate	O
tissue	O
perfusion	O
by	O
improving	O
ECMO	O
flows	O
.	O

To	O
define	O
the	O
epidemiological	O
profile	O
and	O
the	O
clinical	O
characteristics	O
associated	O
with	O
HBoV	O
infection	B-DISO
in	O
a	O
population	O
of	O
children	O
hospitalized	O
with	O
respiratory	B-DISO
tract	I-DISO
infection	I-DISO
.	O

MP	O
infection	B-DISO
is	O
usually	O
a	O
mild	O
and	O
self	O
-	O
limiting	O
disease	O
without	O
specific	O
treatment	O
,	O
and	O
if	O
needed	O
,	O
macrolides	O
are	O
generally	O
used	O
as	O
a	O
first	O
-	O
choice	O
drug	O
for	O
children	O
.	O

TITLE	O
:	O
The	O
SARS	B-DISO
-	O
like	O
coronaviruses	O
:	O
the	O
role	O
of	O
bats	O
and	O
evolutionary	O
relationships	O
with	O
SARS	B-DISO
coronavirus	O
.	O

Bats	O
are	O
the	O
natural	O
reservoir	O
for	O
several	O
viruses	O
genetically	O
closely	O
related	O
to	O
the	O
SARScoronavirus	O
which	O
is	O
the	O
etiological	O
agent	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
a	O
human	O
epidemic	O
which	O
emerged	O
in	O
China	O
in	O
2002	O
-	O
2003	O
.	O

This	O
review	O
analyzes	O
the	O
role	O
of	O
bats	O
as	O
a	O
reservoir	O
of	O
zoonotic	O
viruses	O
focusing	O
more	O
extensively	O
on	O
SARS	B-DISO
-	O
related	O
coronaviruses	O
and	O
taking	O
into	O
account	O
the	O
role	O
of	O
African	O
and	O
European	O
strains	O
in	O
the	O
evolutionary	O
history	O
of	O
these	O
viruses	O
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
pathophysiology	O
and	O
therapeutic	O
options	O
.	O

These	O
were	O
corona	O
virus	O
(	O
CoV	O
),	O
rhinovirus	O
(	O
RhV	O
)	O
and	O
respiratory	O
syncytial	O
virus	O
combined	O
with	O
CoV	O
;	O
AdV	O
combined	O
with	O
RhV	O
;	O
and	O
parainfluenza	B-DISO
virus	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
describe	O
the	O
experience	O
of	O
a	O
referral	O
ECMO	O
center	O
using	O
portable	O
miniaturized	O
ECMO	O
systems	O
for	O
H1N1	O
-	O
related	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

In	O
our	O
experience	O
,	O
ECMO	O
support	O
was	O
a	O
valuable	O
therapeutic	O
option	O
for	O
H1N1	O
-	O
related	O
severe	O
ARDS	B-DISO
.	O

RESULTS	O
:	O
Ten	O
adult	O
patients	O
with	O
severe	O
ARDS	B-DISO
secondary	O
to	O
H1N1	O
infection	B-DISO
(	O
Pao	O
(	O
2	O
)/	O
fraction	O
of	O
inspired	O
oxygen	O
,	O
69	O
mm	O
Hg	O
[	O
56	O
-	O
84	O
];	O
Murray	O
score	O
,	O
3	O
.	O
5	O
[	O
3	O
.	O
5	O
-	O
3	O
.	O
8	O
])	O
were	O
included	O
,	O
and	O
60	O
%	O
survived	O
to	O
hospital	O
discharge	O
.	O

The	O
patient	O
signalment	O
of	O
382	O
FIP	B-DISO
confirmed	O
cases	O
were	O
compared	O
with	O
the	O
Companion	O
Animal	O
Register	O
of	O
NSW	O
and	O
the	O
general	O
cat	O
population	O
of	O
Sydney	O
.	O

Domestic	O
crossbred	O
,	O
Persian	O
and	O
Himalayan	O
cats	O
were	O
significantly	O
under	O
-	O
represented	O
in	O
the	O
FIP	B-DISO
cohort	O
,	O
while	O
several	O
breeds	O
were	O
over	O
-	O
represented	O
,	O
including	O
British	O
Shorthair	O
,	O
Devon	O
Rex	O
and	O
Abyssinian	O
.	O

A	O
significantly	O
higher	O
proportion	O
of	O
male	O
cats	O
had	O
FIP	B-DISO
compared	O
with	O
female	O
cats	O
.	O

This	O
opens	O
further	O
avenues	O
to	O
investigate	O
the	O
role	O
of	O
genetic	O
factors	O
in	O
FIP	B-DISO
.	O

ABSTRACT	O
:	O
Although	O
acute	O
mycotoxicoses	O
are	O
rare	O
in	O
poultry	O
production	O
,	O
chronic	O
exposure	O
to	O
low	O
levels	O
of	O
mycotoxins	O
is	O
responsible	O
for	O
reduced	O
productivity	O
and	O
increased	O
susceptibility	O
to	O
infectious	B-DISO
diseases	I-DISO
.	O

ABSTRACT	O
:	O
To	O
discuss	O
a	O
case	O
of	O
scrub	B-DISO
typhus	I-DISO
complicated	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
a	O
67	O
-	O
year	O
-	O
old	O
female	O
.	O

ABSTRACT	O
:	O
A	O
one	O
-	O
step	O
multiplex	O
reverse	O
transcription	O
(	O
RT	O
)-	O
PCR	O
method	O
was	O
developed	O
for	O
the	O
simultaneous	O
detection	O
of	O
five	O
viruses	O
causing	O
diarrhea	B-DISO
in	O
adult	O
cattle	O
:	O
bovine	O
group	O
A	O
rotavirus	O
(	O
GAR	O
),	O
bovine	O
group	B-DISO
B	I-DISO
rotavirus	O
(	O
GBR	O
),	O
bovine	O
group	O
C	O
rotavirus	O
(	O
GCR	O
),	O
bovine	O
coronavirus	O
(	O
BCV	O
),	O
and	O
bovine	O
torovirus	O
(	O
BToV	O
).	O

Initial	O
metabolic	O
screening	O
was	O
normal	O
,	O
except	O
for	O
a	O
cyclic	B-DISO
neutropenia	I-DISO
.	O

Cytogenetic	O
analysis	O
showed	O
mosaicism	B-DISO
for	O
monosomy	B-DISO
X	I-DISO
and	O
for	O
a	O
ring	O
X	O
chromosome	O
with	O
a	O
large	O
deletion	O
of	O
the	O
long	O
arm	O
including	O
the	O
Xq28	O
region	O
.	O

CONCLUSIONS	O
:	O
This	O
case	O
highlights	O
that	O
the	O
diagnosis	O
of	O
BTHS	B-DISO
should	O
also	O
be	O
suspected	O
in	O
female	O
patients	O
presenting	O
a	O
phenotype	O
similar	O
to	O
affected	O
boys	O
.	O

Consensus	O
SEMICYUC	O
-	O
SENPE	O
:	O
respiratory	B-DISO
failure	I-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
zoonotic	O
disease	O
caused	O
by	O
SARS	B-DISO
-	O
related	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
that	O
emerged	O
in	O
2002	O
to	O
become	O
a	O
global	O
health	O
concern	O
.	O

The	O
SARS	B-DISO
-	O
CoV	O
genome	O
was	O
cloned	O
in	O
separate	O
vaccinia	B-DISO
virus	O
vectors	O
,	O
(	O
vSARS	O
-	O
CoV	O
-	O
5prime	O
and	O
vSARS	O
-	O
CoV	O
-	O
3prime	O
)	O
as	O
two	O
cDNAs	O
that	O
were	O
subsequently	O
ligated	O
to	O
create	O
a	O
genome	O
-	O
length	O
SARS	B-DISO
-	O
CoV	O
cDNA	O
template	O
for	O
in	O
vitro	O
transcription	O
of	O
SARS	B-DISO
-	O
CoV	O
infectious	B-DISO
RNA	O
transcripts	O
.	O

Using	O
this	O
approach	O
,	O
we	O
demonstrate	O
that	O
,	O
in	O
contrast	O
to	O
HCoV	O
-	O
229E	O
,	O
SARS	B-DISO
-	O
CoV	O
is	O
not	O
able	O
to	O
mediate	O
efficient	O
heterologous	O
gene	O
expression	O
in	O
hDCs	O
.	O

The	O
condition	B-DISO
of	O
the	O
patient	O
did	O
not	O
improve	O
and	O
he	O
was	O
referred	O
for	O
liver	O
transplantation	O
,	O
which	O
is	O
the	O
only	O
treatment	O
option	O
with	O
documented	O
efficacy	O
.	O

Finally	O
50	O
,	O
000	O
-	O
100	O
,	O
000	O
patients	O
may	O
be	O
falsely	O
categorized	O
as	O
having	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
/	O
acute	O
lung	O
injury	O
(	O
ARDS	B-DISO
/	O
ALI	O
)	O
because	O
DAH	O
and	O
ARDS	B-DISO
cannot	O
be	O
separated	O
clinically	O
.	O

FVIIa	O
administrated	O
via	O
pulmonary	O
route	O
is	O
""""	O
drug	O
of	O
choice	O
""","	O
because	O
it	O
stops	O
bleeding	B-DISO
in	O
the	O
life	O
-	O
threatening	O
syndrome	B-DISO
DAH	O
.	O

The	O
effects	O
of	O
DOX	O
on	O
ALI	O
were	O
determined	O
by	O
measuring	O
inflammation	B-DISO
,	O
capillary	O
leakage	B-DISO
,	O
and	O
MMP	O
activities	O
.	O

TITLE	O
:	O
Characterization	O
and	O
analysis	O
of	O
the	O
full	O
-	O
length	O
genome	O
of	O
a	O
strain	O
of	O
the	O
European	O
QX	O
-	O
like	O
genotype	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

ABSTRACT	O
:	O
In	O
recent	O
years	O
,	O
strains	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
belonging	O
to	O
the	O
QX	O
-	O
like	O
genotype	O
have	O
been	O
causing	O
huge	O
economic	O
losses	O
in	O
commercial	O
chicken	O
flocks	O
in	O
different	O
countries	O
in	O
Europe	O
.	O

Feline	B-DISO
leukemia	I-DISO
virus	O
p27	O
antigen	O
was	O
detected	O
in	O
13	O
/	O
50	O
serum	O
/	O
lung	O
tissue	O
extract	O
samples	O
(	O
26	O
%),	O
canine	B-DISO
distemper	I-DISO
virus	O
antibodies	O
were	O
detected	O
in	O
2	O
/	O
26	O
serum	O
/	O
lung	O
tissue	O
extract	O
samples	O
(	O
7	O
.	O
7	O
%),	O
feline	O
coronavirus	O
RNA	O
was	O
present	O
in	O
6	O
/	O
29	O
stool	O
samples	O
(	O
20	O
.	O
7	O
%)	O
and	O
feline	O
parvovirus	B-DISO
DNA	O
in	O
2	O
/	O
29	O
stool	O
samples	O
(	O
6	O
.	O
9	O
%).	O

Feline	O
immunodeficiency	B-DISO
virus	O
and	O
feline	O
coronavirus	O
antibodies	O
were	O
not	O
detected	O
.	O

Nonobstetric	O
and	O
obstetric	O
female	O
New	O
Zealand	O
white	O
rabbits	O
underwent	O
fixed	O
-	O
pressure	O
or	O
fixed	O
-	O
volume	O
hemorrhagic	B-DISO
shock	I-DISO
for	O
30	O
mins	O
and	O
then	O
were	O
rapidly	O
resuscitated	O
with	O
the	O
shed	O
blood	O
and	O
Ringer	O
'	O
s	O
solution	O
.	O

The	O
case	O
records	O
of	O
all	O
confirmed	O
cases	O
of	O
malaria	B-DISO
over	O
the	O
period	O
of	O
one	O
year	O
were	O
studied	O
.	O

Two	O
cases	O
had	O
mixed	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
mechanisms	O
of	O
a	O
novel	O
potassium	O
channel	O
gene	O
named	O
KCTD9	O
(	O
potassium	O
channel	O
tetramerization	O
domain	O
containing	O
9	O
)	O
in	O
model	O
of	O
fulminant	O
viral	B-DISO
hepatitis	I-DISO
induced	O
by	O
murine	B-DISO
hepatitis	I-DISO
virus	O
3	O
(	O
MHV	O
-	O
3	O
).	O

In	O
contrast	O
,	O
in	O
model	O
mice	O
of	O
chronic	B-DISO
viral	I-DISO
hepatitis	I-DISO
the	O
expressions	O
of	O
KCTD9	O
mRNA	O
were	O
down	O
-	O
regulated	O
by	O
71	O
%	O
and	O
51	O
%	O
in	O
hepatic	O
CD4	O
+	O
T	O
cells	O
and	O
NK	O
cells	O
,	O
respectively	O
.	O

TITLE	O
:	O
Nurses	O
'	O
perceptions	O
of	O
risk	O
from	O
emerging	O
respiratory	O
infectious	B-DISO
diseases	I-DISO
:	O
a	O
Singapore	O
study	O
.	O

Compared	O
with	O
256	O
patients	O
without	O
pneumonia	B-DISO
,	O
these	O
195	O
patients	O
with	O
pneumonia	B-DISO
were	O
more	O
likely	O
to	O
be	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
(	O
52	O
%	O
vs	O
16	O
%),	O
have	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
;	O
26	O
%	O
vs	O
2	O
%),	O
have	O
sepsis	B-DISO
(	O
18	O
%	O
vs	O
3	O
%),	O
and	O
die	O
(	O
17	O
%	O
vs	O
2	O
%;	O
P	O
<	O
.	O
0001	O
).	O

Bacterial	B-DISO
infections	I-DISO
were	O
reported	O
in	O
13	O
patients	O
with	O
pneumonia	B-DISO
and	O
2	O
patients	O
without	O
pneumonia	B-DISO
.	O

Late	O
in	O
infection	B-DISO
,	O
the	O
correlation	O
between	O
dsRNA	O
dots	O
,	O
then	O
found	O
dispersed	O
throughout	O
the	O
cytoplasm	O
,	O
and	O
nsp	O
'	O
s	O
and	O
nascent	O
RNAs	O
was	O
less	O
obvious	O
.	O

ABSTRACT	O
:	O
In	O
2002	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
coronavirus	O
(	O
CoV	O
)	O
appeared	O
as	O
a	O
novel	O
human	O
virus	O
with	O
high	O
similarity	O
to	O
bat	O
coronaviruses	O
.	O

Here	O
we	O
show	O
that	O
signatures	O
of	O
recurrent	O
positive	O
selection	O
in	O
the	O
bat	O
ACE2	O
gene	O
map	O
almost	O
perfectly	O
to	O
known	O
SARS	B-DISO
-	O
CoV	O
interaction	O
surfaces	O
.	O

ABSTRACT	O
:	O
The	O
full	O
-	O
length	O
genome	O
of	O
the	O
highly	O
lethal	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
)	O
strain	O
DF	O
-	O
2	O
was	O
sequenced	O
and	O
cloned	O
into	O
a	O
bacterial	O
artificial	O
chromosome	O
(	O
BAC	O
)	O
to	O
study	O
the	O
role	O
of	O
ORF3abc	O
in	O
the	O
FIPV	O
-	O
feline	O
enteric	O
coronavirus	O
(	O
FECV	O
)	O
transition	B-DISO
.	O

The	O
SARS	B-DISO
coronavirus	O
,	O
henipaviruses	O
and	O
filoviruses	O
are	O
zoonotic	O
RNA	O
viruses	O
that	O
use	O
bats	O
as	O
their	O
reservoir	O
.	O

ECMO	O
requires	O
establishment	O
of	O
an	O
appropriate	O
management	O
system	O
to	O
minimize	O
fatal	O
complications	O
(	O
e	O
.	O
g	O
.,	O
hemorrhage	B-DISO
),	O
which	O
requires	O
a	O
multidisciplinary	O
team	O
.	O

This	O
is	O
in	O
contrast	O
with	O
the	O
late	O
respiratory	B-DISO
failure	I-DISO
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
neuromuscular	O
dysfunction	O
.	O

Five	O
other	O
patients	O
developed	O
late	O
respiratory	B-DISO
failure	I-DISO
after	O
24	O
hours	O
of	O
ingestion	O
,	O
and	O
all	O
of	O
them	O
showed	O
progressive	O
RNS	B-DISO
changes	O
indicating	O
severe	O
IMS	O
prior	O
to	O
intubation	O
.	O

TITLE	O
:	O
Proteomics	O
analysis	O
of	O
differentially	O
expressed	O
proteins	O
in	O
chicken	O
trachea	B-DISO
and	O
kidney	O
after	O
infection	B-DISO
with	O
the	O
highly	O
virulent	O
and	O
attenuated	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
in	O
vivo	O
.	O

Results	O
demonstrated	O
that	O
some	O
proteins	O
which	O
had	O
functions	O
in	O
cytoskeleton	O
organization	O
,	O
anti	O
-	O
oxidative	B-DISO
stress	I-DISO
,	O
and	O
stress	O
response	O
,	O
showed	O
different	O
change	O
patterns	O
in	O
abundance	O
from	O
chicken	O
infected	O
with	O
the	O
highly	O
virulent	O
ck	O
/	O
CH	O
/	O
LDL	O
/	O
97I	O
P5	O
strain	O
and	O
those	O
given	O
the	O
embryo	O
-	O
passaged	O
,	O
attenuated	O
P115	O
stain	O
.	O

In	O
addition	O
,	O
the	O
dynamic	O
transcriptional	O
alterations	O
of	O
12	O
selected	O
proteins	O
were	O
analyzed	O
by	O
the	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
,	O
and	O
western	O
blot	O
analysis	O
confirmed	O
the	O
change	O
in	O
abundance	O
of	O
heat	O
shock	O
proteins	O
(	O
HSP	B-DISO
)	O
beta	O
-	O
1	O
,	O
annexin	O
A2	O
,	O
and	O
annexin	O
A5	O
.	O

Cat	O
viruses	O
that	O
cause	O
these	O
diseases	O
have	O
been	O
studied	O
for	O
decades	O
revealing	O
detailed	O
insight	O
concerning	O
transmission	O
,	O
virulence	O
,	O
origins	O
and	O
pathogenesis	B-DISO
.	O

Among	O
the	O
tested	O
compounds	O
,	O
six	O
compounds	O
(	O
2e	O
-	O
2h	O
,	O
2l	O
,	O
2r	O
)	O
exhibited	O
significantly	O
inhibitory	O
activity	O
against	O
HBV	B-DISO
DNA	O
replication	O
with	O
IC	O
(	O
50	O
)	O
values	O
in	O
the	O
range	O
of	O
2	O
.	O
82	O
-	O
7	O
.	O
48	O
μM	O
.	O
Interestingly	O
,	O
two	O
compounds	O
(	O
2e	O
,	O
2f	O
)	O
had	O
potent	O
activity	O
inhibiting	O
not	O
only	O
the	O
secretion	O
of	O
HBsAg	O
(	O
IC	O
(	O
50	O
)=	O
18	O
.	O
68	O
μM	O
,	O
21	O
.	O
71	O
μM	O
),	O
HBeAg	O
(	O
IC	O
(	O
50	O
)=	O
13	O
.	O
16	O
μM	O
,	O
33	O
.	O
73	O
μM	O
),	O
but	O
also	O
HBV	B-DISO
DNA	O
replication	O
(	O
IC	O
(	O
50	O
)=	O
7	O
.	O
48	O
μM	O
,	O
3	O
.	O
63	O
μM	O
).	O

Five	O
groups	O
of	O
day	O
-	O
old	O
broilers	O
of	O
15	O
birds	O
each	O
were	O
housed	O
in	O
isolators	O
and	O
were	O
inoculated	O
at	O
29	O
days	O
of	O
age	O
with	O
Infectious	B-DISO
Bronchitis	B-DISO
Virus	O
strain	O
M41	O
by	O
the	O
oculo	O
-	O
nasal	O
and	O
IT	O
(	O
intratracheal	O
)	O
route	O
(	O
10	O
(	O
5	O
.	O
4	O
)	O
EID	O
(	O
50	O
)	O
(	O
egg	O
infectious	B-DISO
dosis	O
50	O
)/	O
broiler	O
)	O
and	O
at	O
33	O
days	O
of	O
age	O
with	O
Escherichia	O
coli	O
strain	O
506	O
by	O
the	O
IT	O
route	O
(	O
10	O
(	O
7	O
.	O
6	O
)	O
colony	O
forming	O
units	O
/	O
broiler	O
).	O

At	O
40	O
days	O
of	O
age	O
,	O
the	O
experiment	O
was	O
ended	O
and	O
at	O
post	O
-	O
mortem	O
examination	O
,	O
colibacillosis	B-DISO
lesions	O
were	O
assessed	O
.	O

TITLE	O
:	O
Vitamin	B-DISO
D	I-DISO
deficiency	I-DISO
and	O
comorbidities	O
in	O
children	O
with	O
sickle	B-DISO
cell	I-DISO
anemia	I-DISO
.	O

ABSTRACT	O
:	O
Vitamin	B-DISO
D	I-DISO
deficiency	I-DISO
is	O
known	O
to	O
be	O
common	O
among	O
patients	O
with	O
sickle	B-DISO
cell	I-DISO
anemia	I-DISO
(	O
SCA	O
).	O

Vitamin	O
D	O
levels	O
were	O
associated	O
with	O
pulmonary	O
function	O
(	O
forced	O
expiratory	O
volume	O
in	O
1	O
second	O
[	O
FEV	O
(	O
1	O
)]),	O
but	O
not	O
associated	O
with	O
either	O
rates	O
of	O
acute	B-DISO
pain	I-DISO
or	O
acute	B-DISO
chest	I-DISO
syndrome	I-DISO
episodes	O
.	O

This	O
syndrome	B-DISO
is	O
characterized	O
by	O
noncardiogenic	O
pulmonary	B-DISO
edema	I-DISO
,	O
diffuse	O
pulmonary	B-DISO
infiltrates	I-DISO
,	O
and	O
hypoxemia	O
refractory	O
to	O
oxygen	O
delivery	O
.	O

RESULTS	O
:	O
The	O
results	O
demonstrate	O
that	O
(	O
1	O
)	O
STAT3	O
is	O
activated	O
by	O
P	O
.	O
berghei	O
ANKA	O
(	O
PBA	O
)	O
infection	B-DISO
in	O
vivo	O
and	O
Heme	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
Porcine	O
aminopeptidase	O
N	O
(	O
pAPN	O
)	O
is	O
a	O
common	O
cellular	O
receptor	O
for	O
swine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
virus	O
(	O
TGEV	O
)	O
and	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
).	O

TITLE	O
:	O
Effect	O
of	O
pulmonary	O
support	O
using	O
extracorporeal	O
membrane	O
oxygenation	O
for	O
adult	O
liver	O
transplant	O
recipients	O
with	O
respiratory	B-DISO
failure	I-DISO
.	O

ABSTRACT	O
:	O
The	O
type	O
II	O
transmembrane	O
protease	O
TMPRSS2	O
activates	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
on	O
the	O
cell	O
surface	O
following	O
receptor	O
binding	O
during	O
viral	O
entry	O
into	O
cells	O
.	O

These	O
observations	O
suggest	O
camostat	O
as	O
a	O
candidate	O
antiviral	O
drug	O
to	O
prevent	O
or	O
depress	O
TMPRSS2	O
-	O
dependent	O
infection	B-DISO
by	O
SARS	B-DISO
-	O
CoV	O
.	O

After	O
the	O
2003	O
SARS	B-DISO
epidemic	O
,	O
the	O
pressure	O
in	O
Shenzhen	O
to	O
contain	O
infectious	B-DISO
disease	I-DISO
has	O
been	O
considerable	O
.	O

TITLE	O
:	O
Plasmodium	B-DISO
vivax	I-DISO
malaria	I-DISO
-	O
associated	O
acute	O
kidney	O
injury	O
,	O
India	O
,	O
2010	O
-	O
2011	O
.	O

ABSTRACT	O
:	O
Porcine	O
hemagglutinating	O
encephalomyelitis	B-DISO
(	O
PHE	B-DISO
)	O
is	O
caused	O
by	O
the	O
coronavirus	O
hemagglutinating	O
encephalomyelitis	B-DISO
virus	O
(	O
PHE	B-DISO
-	O
CoV	O
),	O
and	O
the	O
recent	O
,	O
rapid	O
spread	O
of	O
PHE	B-DISO
-	O
CoV	O
in	O
piglets	O
from	O
many	O
countries	O
emphasizes	O
the	O
urgent	O
need	O
for	O
a	O
PHE	B-DISO
-	O
CoV	O
vaccine	O
.	O

The	O
IPV	B-DISO
induced	O
the	O
IgG1	O
subclass	O
of	O
serum	O
antibodies	O
and	O
expression	O
of	O
the	O
cytokine	O
interleukin	O
-	O
4	O
(	O
IL	O
-	O
4	O
),	O
suggesting	O
that	O
the	O
IPV	B-DISO
generated	O
a	O
predominantly	O
Th2	O
-	O
type	O
immune	O
response	O
.	O

The	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	B-DISO
)	O
of	O
GA	O
derivatives	O
were	O
discussed	O
for	O
exploring	O
novel	O
anti	O
-	O
HBV	B-DISO
agents	O
.	O

ABSTRACT	O
:	O
Ventilator	B-DISO
-	I-DISO
associated	I-DISO
pneumonia	I-DISO
(	O
VAP	O
)	O
may	O
contribute	O
to	O
the	O
mortality	O
associated	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Factors	O
independently	O
associated	O
with	O
an	O
increased	O
risk	O
to	O
develop	O
a	O
VAP	O
were	O
male	O
sex	O
and	O
worse	O
admission	O
Glasgow	O
Coma	B-DISO
Scale	O
score	O
.	O

In	O
patients	O
with	O
severe	O
ARDS	B-DISO
receiving	O
lung	O
-	O
protective	O
ventilation	O
,	O
VAP	O
was	O
associated	O
with	O
an	O
increased	O
crude	O
ICU	O
mortality	O
which	O
did	O
not	O
remain	O
significant	O
after	O
adjustment	O
.	O

In	O
recent	O
years	O
ventilation	O
of	O
patients	O
with	O
acute	O
hypoxic	B-DISO
lung	O
injury	O
has	O
changed	O
fundamentally	O
.	O

Additionally	O
computed	O
tomography	O
techniques	O
to	O
assess	O
the	O
pulmonary	O
situation	O
and	O
recruitment	B-DISO
potential	O
as	O
well	O
as	O
bed	B-DISO
-	O
side	O
techniques	O
to	O
adjust	O
PEEP	O
on	O
the	O
ward	O
have	O
been	O
modified	O
and	O
improved	O
.	O

The	O
objective	O
of	O
this	O
paper	O
was	O
to	O
develop	O
a	O
prognostic	O
index	O
for	O
severe	O
complications	O
among	O
hospitalized	O
patients	O
with	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
2009	O
virus	B-DISO
infection	I-DISO
.	O

From	O
the	O
β	O
parameter	O
obtained	O
in	O
the	O
multivariate	O
model	O
,	O
a	O
weight	O
was	O
assigned	O
to	O
each	O
factor	O
to	O
compute	O
the	O
individual	O
influenza	B-DISO
risk	O
score	O
.	O

Effective	O
mucosal	O
immunity	O
by	O
vaccination	O
should	O
provide	O
protection	O
at	O
this	O
primary	B-DISO
infection	I-DISO
site	O
.	O

We	O
previously	O
identified	O
the	O
antiviral	O
activities	O
of	O
the	O
scorpion	O
-	O
venom	O
-	O
peptide	O
-	O
derived	O
mucroporin	O
-	O
M1	O
for	O
three	O
RNA	O
viruses	O
(	O
measles	B-DISO
viruses	O
,	O
SARS	B-DISO
-	O
CoV	O
,	O
and	O
H5N1	B-DISO
).	O

In	O
this	O
investigation	O
,	O
a	O
panel	O
of	O
scorpion	O
venom	O
peptides	O
and	O
their	O
derivatives	O
were	O
designed	O
and	O
chosen	O
for	O
assessment	O
of	O
their	O
anti	O
-	O
HIV	B-DISO
activities	O
.	O

TITLE	O
:	O
Targeting	O
matrix	O
metalloproteinases	O
in	O
acute	O
inflammatory	O
shock	O
syndromes	B-DISO
.	O

These	O
severe	O
conditions	O
with	O
high	O
mortality	O
rates	O
are	O
characterized	O
by	O
intravascular	O
neutrophil	O
degranulation	O
,	O
permeability	O
changes	O
of	O
endothelia	O
and	O
disintegration	B-DISO
of	O
basement	O
membranes	O
and	O
lead	O
to	O
almost	O
uncontrollable	O
edema	B-DISO
,	O
coagulation	O
changes	O
and	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
.	O

After	O
experimental	O
infection	B-DISO
with	O
the	O
new	O
pantropic	O
isolate	O
,	O
most	O
inoculated	O
dogs	O
showed	O
diarrhoea	B-DISO
and	O
acute	O
lymphopenia	B-DISO
.	O

TITLE	O
:	O
Cross	O
sectional	O
and	O
longitudinal	O
surveys	O
of	O
canine	O
enteric	O
coronavirus	B-DISO
infection	I-DISO
in	O
kennelled	O
dogs	O
:	O
a	O
molecular	O
marker	O
for	O
biosecurity	O
.	O

TITLE	O
:	O
Genetic	O
diversity	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
coronavirus	O
in	O
recent	O
years	O
in	O
China	O
.	O

TITLE	O
:	O
Suppression	B-DISO
of	O
feline	O
coronavirus	O
replication	O
in	O
vitro	O
by	O
cyclosporin	O
A	O
.	O
ABSTRACT	O
:	O
The	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
)	O
is	O
a	O
member	O
of	O
the	O
feline	O
coronavirus	O
family	O
that	O
causes	O
FIP	B-DISO
,	O
which	O
is	O
incurable	O
and	O
fatal	O
in	O
cats	O
.	O

Neither	O
cell	O
growth	O
nor	O
viability	O
changed	O
in	O
the	O
presence	O
of	O
either	O
CsA	B-DISO
or	O
FK506	O
,	O
and	O
these	O
factors	O
did	O
not	O
affect	O
the	O
NF	O
-	O
AT	O
pathway	O
in	O
fcwf	O
-	O
4	O
cells	O
.	O

Therefore	O
,	O
CsA	B-DISO
does	O
not	O
seem	O
to	O
exert	O
inhibitory	O
effects	O
via	O
the	O
NF	O
-	O
AT	O
pathway	O
.	O

ABSTRACT	O
:	O
Right	O
ventricular	O
(	O
RV	O
)	O
failure	O
is	O
characterized	O
by	O
an	O
inability	O
to	O
pump	O
blood	O
into	O
the	O
pulmonary	O
circulation	O
and	O
can	O
often	O
lead	O
to	O
hemodynamic	B-DISO
instability	I-DISO
.	O

ABSTRACT	O
:	O
The	O
organization	O
of	O
the	O
response	O
to	O
infectious	B-DISO
disease	I-DISO
outbreaks	O
by	O
public	O
health	O
agencies	O
at	O
the	O
federal	O
,	O
state	O
,	O
and	O
local	O
levels	O
has	O
historically	O
been	O
based	O
on	O
traditional	O
public	O
health	O
functions	O
(	O
e	O
.	O
g	O
.,	O
epidemiology	O
,	O
surveillance	O
,	O
laboratory	O
,	O
infection	B-DISO
control	O
,	O
and	O
health	O
communications	O
).	O

ABSTRACT	O
:	O
Human	O
coronaviruses	O
are	O
associated	O
with	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
that	O
occasionally	O
spread	O
to	O
the	O
lungs	O
and	O
other	O
organs	O
.	O

TITLE	O
:	O
Influenza	B-DISO
and	O
SARS	B-DISO
-	O
coronavirus	O
activating	O
proteases	O
TMPRSS2	O
and	O
HAT	O
are	O
expressed	O
at	O
multiple	O
sites	O
in	O
human	O
respiratory	O
and	O
gastrointestinal	O
tracts	O
.	O

Here	O
,	O
we	O
show	O
that	O
both	O
HAT	O
and	O
TMPRSS2	O
are	O
coexpressed	O
with	O
2	O
,	O
6	O
-	O
linked	O
sialic	O
acids	O
,	O
the	O
major	O
receptor	O
determinant	O
of	O
human	B-DISO
influenza	I-DISO
viruses	O
,	O
throughout	O
the	O
human	O
respiratory	O
tract	O
.	O

Similarly	O
,	O
coexpression	O
of	O
ACE2	O
,	O
the	O
SARS	B-DISO
-	O
coronavirus	O
receptor	O
,	O
and	O
TMPRSS2	O
was	O
frequently	O
found	O
in	O
the	O
upper	O
and	O
lower	O
aerodigestive	O
tract	O
,	O
with	O
the	O
exception	O
of	O
the	O
vocal	O
folds	O
,	O
epiglottis	O
and	O
trachea	B-DISO
.	O

For	O
this	O
paper	O
,	O
we	O
chose	O
Bombyx	O
mori	O
cypovirus	O
1	O
(	O
BmCPV	O
-	O
1	O
)	O
interactions	O
with	O
midgut	O
cells	O
from	O
silkworm	O
,	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
associated	O
coronavirus	O
interactions	O
with	O
Vero	O
E6	O
cells	O
,	O
as	O
examples	O
to	O
demonstrate	O
the	O
response	O
of	O
eukaryotic	O
cells	O
to	O
two	O
different	O
types	O
of	O
virus	O
from	O
our	O
previous	O
studies	O
.	O

TITLE	O
:	O
Emergency	B-DISO
extracorporeal	O
membrane	O
oxygenation	O
to	O
treat	O
massive	O
aspiration	B-DISO
during	O
anaesthesia	B-DISO
induction	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
two	O
isolates	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
from	O
field	O
outbreaks	O
in	O
2008	O
(	O
India	O
/	O
LKW	O
/	O
56	O
/	O
IVRI	O
/	O
08	O
)	O
and	O
2010	O
(	O
India	O
/	O
NMK	O
/	O
72	O
/	O
IVRI	O
/	O
10	O
)	O
from	O
broiler	O
chickens	O
in	O
India	O
were	O
isolated	O
and	O
characterized	O
.	O

Our	O
study	O
demonstrates	O
for	O
the	O
first	O
time	O
that	O
selected	O
naturally	O
-	O
occurring	O
flavonoids	O
,	O
including	O
myricetin	O
and	O
scultellarein	O
might	O
serve	O
as	O
SARS	B-DISO
-	O
CoV	O
chemical	O
inhibitors	O
.	O

With	O
close	O
monitoring	O
of	O
cerebral	O
and	O
systemic	O
haemodynamics	O
,	O
PEEP	O
can	O
be	O
safely	O
applied	O
and	O
titrated	O
to	O
an	O
optimal	O
level	O
in	O
the	O
management	O
of	O
ARDS	B-DISO
following	O
traumatic	O
brain	O
injury	O
.	O

TITLE	O
:	O
The	O
viral	O
etiology	O
of	O
an	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
during	O
the	O
2009	O
pandemic	O
.	O

TITLE	O
:	O
[	O
Present	O
state	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
on	O
efficacy	O
of	O
medical	O
nonspecific	O
protective	O
agents	O
with	O
respect	O
to	O
genotype	O
IV	O
coronavirus	O
causing	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
].	O

He	O
presented	O
with	O
a	O
2	O
-	O
week	O
history	O
of	O
increasing	O
abdominal	B-DISO
pain	I-DISO
,	O
nausea	B-DISO
,	O
diminished	O
appetite	O
and	O
longstanding	O
encopresis	B-DISO
.	O

Although	O
ACS	O
secondary	O
to	O
constipation	B-DISO
is	O
extremely	O
unusual	O
,	O
this	O
case	O
illustrates	O
the	O
need	O
to	O
actively	O
treat	O
constipation	B-DISO
and	O
what	O
can	O
happen	O
if	O
it	O
is	O
not	O
.	O

TITLE	O
:	O
Human	O
parechovirus	O
infections	B-DISO
,	O
Lyon	O
,	O
France	O
,	O
2008	O
-	O
10	O
:	O
evidence	O
for	O
severe	O
cases	O
.	O

Patients	O
with	O
adenovirus	B-DISO
pneumonia	B-DISO
typically	O
reported	O
flu	B-DISO
-	I-DISO
like	I-DISO
symptoms	I-DISO
.	O

Within	O
this	O
genus	O
of	O
coronaviruses	O
,	O
the	O
avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
causes	O
a	O
highly	O
infectious	B-DISO
upper	O
-	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
in	O
commercial	O
poultry	O
.	O

Genomic	O
analysis	O
shows	O
that	O
CCoV	O
-	O
A76	O
possesses	B-DISO
a	O
distinct	O
spike	O
,	O
which	O
is	O
the	O
result	O
of	O
a	O
recombination	O
between	O
type	O
I	O
and	O
type	O
II	O
CCoV	O
,	O
that	O
occurred	O
between	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
domains	O
(	O
NTD	O
and	O
C	O
-	O
domain	O
)	O
of	O
the	O
S1	O
subunit	O
.	O

In	O
contrast	O
,	O
SARS	B-DISO
-	O
CoV	O
and	O
TGEV	O
EGFP	O
-	O
nsp15s	O
distributed	O
smoothly	O
in	O
the	O
whole	O
cell	O
and	O
did	O
not	O
form	O
speckles	O
.	O

Collectively	O
these	O
results	O
thus	O
underscore	O
the	O
differential	O
biochemical	O
and	O
biological	O
functions	O
among	O
the	O
nsp15s	O
of	O
MHV	O
,	O
TGEV	O
and	O
SARS	B-DISO
-	O
CoV	O
in	O
host	O
cells	O
.	O

TITLE	O
:	O
A	O
facile	O
inhibitor	O
screening	O
of	O
SARS	B-DISO
coronavirus	O
N	O
protein	O
using	O
nanoparticle	O
-	O
based	O
RNA	O
oligonucleotide	O
.	O

Hence	O
,	O
the	O
development	O
of	O
efficient	O
drug	O
treatments	O
for	O
the	O
biological	O
effects	O
of	O
SARS	B-DISO
is	O
highly	O
needed	O
.	O

The	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
subverts	O
ERAD	O
tuning	O
for	O
replication	O
.	O

The	O
clinical	O
files	O
of	O
women	O
having	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
attending	O
the	O
Monica	O
Pretelini	O
maternal	O
-	O
perinatal	O
hospital	O
'	O
s	O
(	O
HMPMP	O
)	O
intensive	O
care	O
unit	O
in	O
Toluca	O
,	O
Mexico	O
,	O
were	O
reviewed	O
.	O

No	O
new	O
case	O
of	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
was	O
found	O
after	O
the	O
first	O
eight	O
months	O
of	O
2010	O
.	O

ABSTRACT	O
:	O
The	O
replication	O
/	O
transcription	O
complex	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
is	O
composed	O
of	O
at	O
least	O
16	O
nonstructural	O
proteins	O
(	O
nsp1	O
-	O
16	O
)	O
encoded	O
by	O
the	O
ORF	O
-	O
1a	O
/	O
1b	O
.	O

TITLE	O
:	O
Expression	O
of	O
B	O
and	O
T	O
lymphocyte	O
attenuator	O
(	O
BTLA	O
)	O
in	O
macrophages	O
contributes	O
to	O
the	O
fulminant	B-DISO
hepatitis	I-DISO
caused	O
by	O
murine	B-DISO
hepatitis	I-DISO
virus	O
strain	O
-	O
3	O
.	O

By	O
contrast	O
,	O
IL	O
-	O
17	O
depletion	O
rescued	O
recipients	O
of	O
GKO	O
CD4	O
+	O
T	O
cells	O
from	O
rapid	O
mortality	O
without	O
diminishing	O
neutrophils	O
or	O
reducing	O
GM	O
-	O
CSF	O
,	O
associated	O
with	O
pathogenic	O
Th17	O
cells	O
in	O
CNS	O
autoimmune	B-DISO
models	O
.	O

Numerous	O
studies	O
have	O
been	O
carried	O
out	O
to	O
identify	O
new	O
bat	O
viruses	O
related	O
to	O
SARS	B-DISO
-	O
coronavirus	O
(	O
bat	O
-	O
SARS	B-DISO
-	O
like	O
CoVs	O
)	O
using	O
a	O
reverse	O
-	O
transcribed	O
-	O
polymerase	O
chain	O
reaction	O
assay	O
.	O

CONCLUSIONS	O
:	O
The	O
development	O
of	O
a	O
severe	O
and	O
acute	O
methemoglobinemia	B-DISO
following	O
the	O
administration	O
of	O
MCP	O
is	O
described	O
in	O
this	O
case	O
report	O
.	O

TITLE	O
:	O
Cryptococccal	O
meningoencephalitis	B-DISO
after	O
H1N1	B-DISO
influenza	I-DISO
.	O

While	O
prolonged	O
corticosteroid	O
use	O
is	O
a	O
known	O
risk	O
factor	O
for	O
development	O
of	O
invasive	O
fungal	B-DISO
disease	I-DISO
,	O
the	O
authors	O
postulate	O
that	O
by	O
causing	O
immunologic	O
defects	O
and	O
FLAARDS	O
,	O
the	O
2009	O
-	O
pandemic	O
H1N1	O
virus	O
may	O
represent	O
an	O
additional	O
independent	O
risk	O
for	O
the	O
development	O
of	O
C	O
neoformans	O
meningitis	B-DISO
in	O
a	O
previously	O
healthy	O
individual	O
.	O

TITLE	O
:	O
Successful	O
treatment	O
of	O
a	O
case	O
of	O
extensive	O
radiation	O
burns	O
with	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
.	O

The	O
authors	O
suggest	O
that	O
deeper	O
excision	O
of	O
necrotic	O
tissue	O
and	O
skin	O
grafting	O
as	O
well	O
as	O
appropriate	O
antibiotics	O
are	O
principal	O
measures	O
to	O
counteract	O
systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
syndrome	I-DISO
.	O

To	O
describe	O
the	O
characteristics	O
of	O
ICU	O
patients	O
with	O
pH1N1	O
virus	B-DISO
infection	I-DISO
in	O
the	O
United	O
States	O
during	O
the	O
spring	O
and	O
fall	O
of	O
2009	O
and	O
to	O
describe	O
the	O
factors	O
associated	O
with	O
severe	O
complications	O
including	O
ARDS	B-DISO
and	O
death	O
.	O

RESULTS	O
:	O
The	O
majority	O
(	O
77	O
%)	O
of	O
154	O
patients	O
hospitalized	O
in	O
an	O
ICU	O
were	O
<	O
50	O
years	O
of	O
age	O
,	O
and	O
65	O
%	O
had	O
at	O
least	O
one	O
underlying	O
medical	O
condition	B-DISO
.	O

Based	O
on	O
our	O
experience	O
,	O
we	O
recommend	O
the	O
use	O
of	O
heparin	O
-	O
free	O
ECMO	O
in	O
multiple	O
injured	O
patients	O
with	O
pulmonary	B-DISO
failure	I-DISO
that	O
is	O
not	O
successfully	O
controlled	O
by	O
lung	O
-	O
protective	O
ventilation	O
even	O
if	O
severe	O
TBI	O
is	O
present	O
.	O

ABSTRACT	O
:	O
Carcinoembryonic	O
antigen	O
-	O
related	O
cell	O
adhesion	B-DISO
molecule	O
1	O
(	O
CEACAM1	O
)	O
is	O
the	O
sole	O
known	O
receptor	O
of	O
murine	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
A59	O
,	O
but	O
the	O
available	O
,	O
often	O
qualitative	O
,	O
data	O
about	O
CEACAM1	O
expression	O
does	O
not	O
explain	O
MHV	O
organ	O
tropism	O
.	O

TITLE	O
:	O
Postinfection	O
A77	O
-	O
1726	O
treatment	O
improves	O
cardiopulmonary	O
function	O
in	O
H1N1	B-DISO
influenza	I-DISO
-	O
infected	O
mice	O
.	O

Because	O
antiviral	O
drugs	O
are	O
only	O
effective	O
early	O
in	O
infection	B-DISO
,	O
new	O
agents	O
are	O
needed	O
to	O
treat	O
nonvaccinated	O
patients	O
presenting	O
with	O
late	O
-	O
stage	O
disease	O
,	O
particularly	O
those	O
who	O
develop	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Nebulized	O
A77	O
-	O
1726	O
also	O
reversed	O
influenza	B-DISO
-	O
induced	O
increases	O
in	O
lung	O
water	O
content	O
and	O
volume	O
,	O
improved	O
pulmonary	O
mechanics	O
,	O
reduced	O
bronchoalveolar	O
lavage	O
fluid	O
ATP	O
and	O
neutrophil	O
content	O
,	O
and	O
increased	O
IL	O
-	O
6	O
concentrations	O
.	O

ABSTRACT	O
:	O
Avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
is	O
a	O
member	O
of	O
the	O
group	O
III	O
coronaviruses	O
,	O
which	O
differ	O
from	O
the	O
other	O
groups	O
of	O
coronaviruses	O
in	O
that	O
they	O
do	O
not	O
encode	O
the	O
essential	O
pathogenic	O
factor	O
nonstructural	O
protein	O
1	O
(	O
nsp1	O
)	O
and	O
instead	O
start	O
with	O
nsp2	O
.	O

We	O
hypothesize	O
that	O
PP	O
improves	O
oxygenation	O
and	O
can	O
be	O
performed	O
safely	O
in	O
burn	O
patients	O
with	O
ARDS	B-DISO
.	O

Mean	O
PFR	O
before	O
PP	O
was	O
87	O
(±	O
38	O
)	O
with	O
a	O
mean	O
sequential	O
organ	B-DISO
failure	I-DISO
assessment	O
score	O
of	O
11	O
(±	O
4	O
).	O

Throughout	O
these	O
years	O
,	O
an	O
unusual	O
entity	O
of	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
(	O
DIC	B-DISO
)	O
was	O
known	O
to	O
complicate	O
the	O
resuscitation	O
of	O
seriously	O
injured	O
patients	O
with	O
HS	O
.	O

The	O
theoretical	O
benefits	O
of	O
administering	O
heparin	O
to	O
prevent	O
the	O
thrombosis	B-DISO
and	O
epsilon	O
-	O
aminocaproic	O
acid	O
to	O
enhance	O
lysis	B-DISO
have	O
not	O
proven	O
beneficial	O
.	O

As	O
expected	O
,	O
antigen	O
affinity	O
was	O
shown	O
to	O
correlate	O
directly	O
with	O
neutralization	O
potency	O
toward	O
the	O
icUrbani	O
strain	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
Additionally	O
,	O
the	O
highest	O
-	O
affinity	O
antibody	O
fragment	O
displayed	O
10	O
-	O
fold	O
-	O
increased	O
broad	O
neutralization	O
in	O
vitro	O
and	O
completely	O
protected	O
against	O
several	O
SARS	B-DISO
-	O
CoV	O
strains	O
containing	O
substitutions	O
associated	O
with	O
antibody	O
escape	O
.	O

Importantly	O
,	O
higher	O
affinity	O
also	O
led	O
to	O
the	O
suppression	B-DISO
of	O
viral	O
escape	O
mutants	O
in	O
vitro	O
.	O

All	O
tracheal	O
aspirate	O
(	O
TA	O
)	O
samples	O
sent	O
to	O
the	O
microbiology	O
department	O
were	O
systematically	O
screened	O
for	O
influenza	B-DISO
.	O

Influenza	B-DISO
was	O
detected	O
in	O
31	O
patients	O
and	O
was	O
classified	O
as	O
unsuspected	O
in	O
15	O
(	O
48	O
.	O
4	O
%)	O
patients	O
,	O
and	O
as	O
hospital	O
acquired	O
in	O
13	O
(	O
42	O
%)	O
patients	O
.	O

However	O
,	O
disorder	O
shows	O
a	O
sharp	O
increase	O
associated	O
with	O
the	O
transition	B-DISO
from	O
prokaryotic	O
to	O
eukaryotic	O
cells	O
.	O

Ns2	B-DISO
cleaves	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
,	O
the	O
product	O
of	O
OAS	B-DISO
,	O
to	O
prevent	O
activation	O
of	O
the	O
cellular	O
endoribonuclease	O
RNase	O
L	O
and	O
consequently	O
block	O
viral	O
RNA	O
degradation	O
.	O

Twelve	O
cases	O
exhibited	O
biphasic	O
seizures	B-DISO
;	O
one	O
-	O
half	O
of	O
these	O
had	O
sequelae	O
,	O
but	O
none	O
was	O
fatal	O
.	O

Abnormal	O
behaviors	O
,	O
especially	O
delirium	B-DISO
and	O
visual	B-DISO
hallucinations	I-DISO
,	O
were	O
observed	O
more	O
frequently	O
in	O
cases	O
without	O
sequelae	O
.	O

ABSTRACT	O
:	O
In	O
addition	O
to	O
SARS	B-DISO
associated	O
coronaviruses	O
,	O
4	O
non	O
-	O
SARS	B-DISO
related	O
human	O
coronaviruses	O
(	O
HCoVs	O
)	O
are	O
recognized	O
as	O
common	O
respiratory	O
pathogens	O
.	O

The	O
etiology	O
and	O
clinical	O
impact	O
of	O
HCoVs	O
in	O
Chinese	O
adults	O
with	O
acute	B-DISO
upper	I-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
(	O
URTI	B-DISO
)	O
needs	O
to	O
be	O
characterized	O
systematically	O
by	O
molecular	O
detection	O
with	O
excellent	O
sensitivity	O
.	O

Respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
human	O
parainfluenza	B-DISO
virus	O
(	O
PIV	O
)	O
and	O
HBoV	O
were	O
detected	O
in	O
very	O
low	O
rate	O
(	O
less	O
than	O
1	O
%)	O
among	O
adult	O
patients	O
with	O
URTI	B-DISO
.	O

This	O
review	O
summarizes	O
current	O
knowledge	O
on	O
the	O
formation	O
and	O
potential	O
functional	O
role	O
of	O
different	O
MPs	O
in	O
inflammatory	O
diseases	O
with	O
a	O
specific	O
focus	O
on	O
ALI	O
/	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
(	O
HCoV	O
)	O
NL63	O
,	O
a	O
newly	O
discovered	O
coronavirus	O
,	O
has	O
been	O
associated	O
with	O
acute	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
(	O
ALRTI	O
).	O

We	O
examined	O
the	O
role	O
of	O
PTX3	O
in	O
coronavirus	O
murine	B-DISO
hepatitis	I-DISO
virus	O
strain	O
1	O
(	O
MHV	O
-	O
1	O
)-	O
induced	O
acute	O
lung	O
injury	O
,	O
a	O
previously	O
reported	O
animal	O
model	O
for	O
SARS	B-DISO
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
replication	O
inhibitor	O
that	O
interferes	O
with	O
the	O
nucleic	O
acid	O
unwinding	O
of	O
the	O
viral	O
helicase	O
.	O

Twenty	O
consecutively	O
registered	O
patients	O
with	O
gastric	B-DISO
varices	I-DISO
underwent	O
balloon	O
-	O
occluded	B-DISO
retrograde	O
transvenous	O
obliteration	O
with	O
polidocanol	O
foam	O
.	O

Except	O
in	O
one	O
instance	O
of	O
recanalization	O
,	O
full	O
variceal	O
thrombosis	B-DISO
was	O
confirmed	O
at	O
contrast	O
-	O
enhanced	O
CT	O
1	O
week	O
after	O
transvenous	O
obliteration	O
(	O
success	O
rate	O
,	O
95	O
%).	O

This	O
disease	O
is	O
one	O
of	O
the	O
most	O
important	O
infectious	B-DISO
diseases	I-DISO
in	O
the	O
Asia	O
-	O
Pacific	O
area	O
;	O
however	O
,	O
a	O
severe	O
infant	O
case	O
has	O
not	O
yet	O
been	O
reported	O
.	O

ABSTRACT	O
:	O
To	O
increase	O
immune	O
responses	O
of	O
plant	O
-	O
based	O
vaccines	O
in	O
intestine	O
mucosal	O
immune	O
systems	O
,	O
a	O
synthetic	O
neutralizing	O
epitope	O
(	O
sCOE	O
)	O
gene	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
was	O
fused	O
with	O
M	O
cell	O
-	O
targeting	O
ligand	O
(	O
Co1	O
)	O
and	O
introduced	O
into	O
a	O
plant	O
expression	O
vector	O
under	O
the	O
control	O
of	O
rice	O
amylase	O
3D	O
promoter	O
.	O

ABSTRACT	O
:	O
The	O
shortage	O
of	O
isolation	O
facilities	O
in	O
hospitals	O
was	O
highlighted	O
during	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
pandemic	O
in	O
2003	O
.	O

TITLE	O
:	O
Evidence	O
and	O
ethics	O
in	O
public	O
health	O
:	O
the	O
experience	O
of	O
SARS	B-DISO
in	O
Canada	O
.	O

All	O
patients	O
presented	O
with	O
fever	O
,	O
hemoptysis	B-DISO
,	O
bilateral	B-DISO
pulmonary	I-DISO
infiltrates	I-DISO
in	O
chest	O
radiographs	O
,	O
and	O
thrombocytopenia	O
and	O
had	O
compatible	O
epidemiological	O
history	O
with	O
leptospirosis	B-DISO
;	O
3	O
patients	O
had	O
anemia	B-DISO
,	O
3	O
had	O
renal	B-DISO
failure	I-DISO
,	O
2	O
had	O
increased	O
creatine	O
kinase	O
,	O
whereas	O
bilirubin	O
was	O
slightly	O
increased	O
in	O
only	O
1	O
patient	O
.	O

Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
,	O
Simplified	O
Acute	O
Physiology	O
Score	O
II	O
and	O
Sepsis	B-DISO
-	O
Related	O
Organ	B-DISO
Failure	I-DISO
Assessment	O
scoring	O
systems	O
were	O
unable	O
to	O
predict	O
the	O
outcome	O
of	O
the	O
patients	O
with	O
leptospirosis	B-DISO
-	O
associated	O
severe	O
pulmonary	O
hemorrhagic	O
syndrome	B-DISO
.	O

ABSTRACT	O
:	O
The	O
mechanisms	O
of	O
each	O
subset	O
of	O
immune	O
cells	O
contributing	O
to	O
the	O
pathogenesis	B-DISO
of	O
viral	B-DISO
hepatitis	I-DISO
remain	O
incompletely	O
understood	O
.	O

TITLE	O
:	O
Tracing	O
the	O
transmission	O
of	O
bovine	O
coronavirus	B-DISO
infections	I-DISO
in	O
cattle	O
herds	O
based	O
on	O
S	O
gene	O
diversity	O
.	O

ABSTRACT	O
:	O
Regulatory	O
T	O
cells	O
(	O
T	O
(	O
regs	O
))	O
are	O
a	O
subset	O
of	O
T	O
cells	O
that	O
are	O
responsible	O
for	O
maintaining	O
peripheral	O
immune	B-DISO
tolerance	I-DISO
and	O
homeostasis	O
.	O

Induction	O
of	O
T	O
(	O
regs	O
)	O
in	O
coronaviral	O
infections	B-DISO
protects	O
against	O
the	O
more	O
severe	O
forms	O
of	O
the	O
disease	O
attributable	O
to	O
the	O
host	O
response	O
.	O

This	O
review	O
discusses	O
the	O
development	O
and	O
biology	O
of	O
regulatory	O
T	O
cells	O
in	O
the	O
context	O
of	O
arteriviral	O
and	O
coronaviral	O
infection	B-DISO
.	O

Triggering	O
of	O
TLRs	O
with	O
selected	O
ligands	O
can	O
be	O
beneficial	O
against	O
some	O
viral	B-DISO
infections	I-DISO
.	O

Investigation	O
of	O
the	O
interplay	O
between	O
CoVs	O
and	O
PRRs	B-DISO
is	O
in	O
its	O
infancy	O
.	O

Human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
-	O
exposed	O
infants	O
with	O
respiratory	B-DISO
failure	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
were	O
recruited	O
into	O
the	O
study	O
.	O

Only	O
7	O
.	O
9	O
%	O
of	O
infants	O
had	O
a	O
positive	O
tuberculosis	B-DISO
culture	O
.	O

High	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
is	O
a	O
rescue	O
therapy	O
for	O
hypoxemic	O
patients	O
who	O
deteriorate	O
in	O
conventional	O
mechanical	O
ventilation	O
and	O
/	O
or	O
for	O
the	O
air	O
-	O
leak	O
syndrome	B-DISO
treatment	O
.	O

A	O
single	O
-	O
center	O
post	O
hoc	O
analysis	O
of	O
a	O
cohort	O
of	O
intensive	O
care	O
unit	O
patients	O
admitted	O
with	O
SARI	O
due	O
to	O
2009	O
Influenza	B-DISO
A	O
/	O
H1N1v	O
was	O
done	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
five	O
nonintubated	O
adult	O
patients	O
were	O
admitted	O
for	O
SARI	O
(	O
21	O
pneumonia	B-DISO
).	O

ABSTRACT	O
:	O
Oral	O
antiviral	O
agents	O
to	O
treat	O
influenza	B-DISO
are	O
challenging	O
to	O
administer	O
in	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
).	O

Common	O
clinical	O
complications	O
included	O
pneumonia	B-DISO
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
requiring	O
mechanical	O
ventilation	O
(	O
54	O
;	O
95	O
%),	O
sepsis	B-DISO
requiring	O
vasopressor	O
support	O
(	O
34	O
/	O
53	O
;	O
64	O
%),	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
requiring	O
hemodialysis	O
(	O
19	O
/	O
53	O
;	O
36	O
%)	O
and	O
secondary	O
bacterial	B-DISO
infection	I-DISO
(	O
14	O
;	O
25	O
%).	O

In	O
13	O
of	O
17	O
deceased	O
patients	O
,	O
P	O
.	O
vivax	O
infection	B-DISO
was	O
the	O
plausible	O
cause	O
of	O
death	O
.	O

However	O
,	O
more	O
studies	O
are	O
needed	O
to	O
understand	O
pathogenesis	B-DISO
related	O
to	O
severe	O
disease	O
.	O

In	O
fact	O
,	O
m	O
-	O
calpain	O
inhibition	O
with	O
MDL28170	O
resulted	O
in	O
an	O
even	O
more	O
pronounced	O
inhibition	O
of	O
SARS	B-DISO
-	O
CoV	O
replication	O
(>	O
7	O
orders	O
of	O
magnitude	O
)	O
than	O
did	O
MG132	O
.	O

Taken	O
together	O
,	O
we	O
provide	O
strong	O
experimental	O
evidence	O
that	O
SARS	B-DISO
-	O
CoV	O
has	O
unique	O
replication	O
requirements	O
which	O
are	O
independent	O
of	O
functional	O
UPS	O
or	O
autophagy	O
pathways	O
compared	O
to	O
other	O
coronaviruses	O
.	O

Consumption	O
of	O
decoctions	O
of	O
C	O
.	O
collinus	O
leaves	O
,	O
hypokalemia	O
,	O
renal	B-DISO
failure	I-DISO
,	O
severe	O
metabolic	B-DISO
acidosis	I-DISO
,	O
ARDS	B-DISO
and	O
cardiac	B-DISO
arrhythmias	I-DISO
occur	O
in	O
severe	O
poisonings	O
and	O
predict	O
mortality	O
.	O

ABSTRACT	O
:	O
A	O
few	O
months	O
into	O
the	O
2009	O
influenza	B-DISO
pandemic	O
,	O
nine	O
European	O
countries	O
implemented	O
case	O
-	O
based	O
surveillance	O
of	O
hospitalised	O
severe	O
influenza	B-DISO
infections	B-DISO
.	O

TITLE	O
:	O
Biochemical	O
characterization	O
of	O
a	O
recombinant	O
SARS	B-DISO
coronavirus	O
nsp12	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
capable	O
of	O
copying	O
viral	O
RNA	O
templates	O
.	O

Our	O
previous	O
observation	O
revealed	O
a	O
partial	O
relief	O
of	O
lung	B-DISO
fibrosis	I-DISO
in	O
patients	O
suffering	B-DISO
from	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

A	O
draft	O
definition	O
proposed	O
3	O
mutually	O
exclusive	O
categories	O
of	O
ARDS	B-DISO
based	O
on	O
degree	O
of	O
hypoxemia	O
:	O
mild	O
(	O
200	O
mm	O
Hg	O
&	O
lt	O
;	O
PaO2	O
/	O
FIO2	O
≤	O
300	O
mm	O
Hg	O
),	O
moderate	O
(	O
100	O
mm	O
Hg	O
&	O
lt	O
;	O
PaO2	O
/	O
FIO2	O
≤	O
200	O
mm	O
Hg	O
),	O
and	O
severe	O
(	O
PaO2	O
/	O
FIO2	O
≤	O
100	O
mm	O
Hg	O
)	O
and	O
4	O
ancillary	O
variables	O
for	O
severe	O
ARDS	O
:	O
radiographic	O
severity	O
,	O
respiratory	O
system	O
compliance	O
(≤	O
40	O
mL	O
/	O
cm	O
H2O	O
),	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(≥	O
10	O
cm	O
H2O	O
),	O
and	O
corrected	O
expired	O
volume	O
per	O
minute	O
(≥	O
10	O
L	O
/	O
min	O
).	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
efficacy	O
of	O
continuous	O
blood	O
purification	O
(	O
CBP	O
)	O
in	O
the	O
treatment	O
of	O
acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ALI	O
/	O
ARDS	B-DISO
)	O
in	O
children	O
.	O

The	O
use	O
of	O
vasoactive	O
drugs	O
in	O
patients	O
with	O
MODS	B-DISO
and	O
shock	O
gradually	O
declined	O
.	O

Demographics	O
(	O
body	O
weigh	O
,	O
age	O
,	O
gender	O
,	O
VSD	B-DISO
diameter	O
)	O
and	O
clinical	O
characteristics	O
(	O
CPB	O
time	O
,	O
oxygenation	O
index	O
,	O
mean	O
airway	O
pressure	O
,	O
pH	O
and	O
PCO2	O
)	O
of	O
all	O
the	O
patients	O
were	O
collected	O
,	O
and	O
statistical	O
analysis	O
was	O
done	O
to	O
compare	O
the	O
data	O
between	O
treatment	O
and	O
control	O
group	O
.	O

ABSTRACT	O
:	O
Veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
VV	O
-	O
ECMO	O
)	O
has	O
been	O
indicated	O
in	O
patients	O
with	O
severe	O
refractory	O
respiratory	B-DISO
failure	I-DISO
from	O
various	O
causes	O
for	O
more	O
than	O
30	O
years	O
,	O
even	O
for	O
the	O
small	O
infant	O
.(	O
1	O
)	O

Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
occurred	O
in	O
79	O
subjects	O
(	O
35	O
%)	O
belonging	O
to	O
the	O
development	O
cohort	O
and	O
in	O
423	O
subjects	O
(	O
24	O
%)	O
from	O
the	O
validation	O
cohort	O
.	O

ABSTRACT	O
:	O
Low	O
albumin	O
to	O
globulin	O
ratio	O
has	O
been	O
found	O
previously	O
to	O
have	O
a	O
high	O
positive	O
predictive	O
value	O
for	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
in	O
cats	O
with	O
clinical	O
signs	O
highly	O
suggestive	O
of	O
the	O
disease	O
.	O

However	O
,	O
FIP	B-DISO
can	O
have	O
a	O
more	O
vague	O
clinical	O
presentation	O
.	O

ABSTRACT	O
:	O
Pleural	B-DISO
effusions	I-DISO
are	O
rarely	O
observed	O
in	O
patients	O
with	O
acute	B-DISO
myelogenous	I-DISO
leukemia	I-DISO
(	O
AML	B-DISO
),	O
acute	B-DISO
lymphocytic	I-DISO
leukemia	I-DISO
(	O
ALL	O
)	O
and	O
myelodysplastic	B-DISO
syndrome	I-DISO
(	O
MDS	B-DISO
)/	O
myeloproliferative	B-DISO
neoplasm	I-DISO
(	O
MPN	O
).	O

Herein	O
we	O
have	O
used	O
a	O
novel	O
fusion	O
protein	O
consisting	O
of	O
a	O
modified	O
β	O
-	O
barrel	O
to	O
purify	O
both	O
wild	O
type	O
and	O
cysteine	O
-	O
less	O
mutants	O
of	O
two	O
representatives	O
of	O
coronavirus	O
E	O
proteins	O
:	O
the	O
shortest	O
(	O
76	O
residues	O
),	O
from	O
SARS	B-DISO
-	O
CoV	O
E	O
,	O
and	O
one	O
of	O
the	O
longest	O
(	O
109	O
residues	O
),	O
from	O
the	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
E	O
).	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
accessory	O
proteins	O
6	O
and	O
9b	O
interact	O
in	O
vivo	O
.	O

Pancreatic	O
debridement	O
can	O
be	O
performed	O
during	O
ECLS	O
,	O
using	O
a	O
comprehensive	O
protocol	O
to	O
minimize	O
bleeding	B-DISO
complications	O
.	O

To	O
analyze	O
possible	O
competitive	O
amplification	B-DISO
reactions	O
between	O
the	O
different	O
viruses	O
,	O
samples	O
were	O
further	O
inoculated	O
with	O
only	O
4	O
different	O
viruses	O
in	O
one	O
sample	O
.	O

Multiple	O
infections	B-DISO
were	O
detected	O
in	O
16	O
TS	O
samples	O
(	O
32	O
%)	O
by	O
RespiFinder	O
-	O
19	O
.	O

Bioterrorist	O
use	O
of	O
anthrax	B-DISO
spores	O
in	O
2001	O
raised	O
awareness	O
of	O
the	O
value	O
of	O
public	O
health	O
surveillance	O
for	O
national	O
security	O
.	O

In	O
particular	O
,	O
in	O
2003	O
,	O
SARS	B-DISO
precipitated	O
changes	O
in	O
awareness	O
of	O
the	O
world	O
'	O
s	O
collective	O
economic	O
vulnerability	O
to	O
epidemic	O
shocks	B-DISO
.	O

Infants	O
who	O
progressed	O
to	O
stage	O
3	O
ROP	B-DISO
were	O
given	O
laser	O
therapy	O
.	O

TITLE	O
:	O
The	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Based	O
on	O
both	O
experimental	O
and	O
clinical	O
studies	O
,	O
progress	O
has	O
been	O
made	O
in	O
understanding	O
the	O
mechanisms	O
responsible	O
for	O
the	O
pathogenesis	B-DISO
and	O
the	O
resolution	O
of	O
lung	O
injury	O
,	O
including	O
the	O
contribution	O
of	O
environmental	O
and	O
genetic	O
factors	O
.	O

HCoVs	O
can	O
cause	O
lower	O
respiratory	B-DISO
infections	I-DISO
and	O
hospitalisation	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
SCoV	O
)	O
is	O
an	O
enveloped	O
virus	O
containing	O
a	O
single	O
-	O
stranded	O
,	O
positive	O
-	O
sense	O
RNA	O
genome	O
.	O

Genetically	O
stable	O
exoribonuclease	O
mutants	O
will	O
allow	O
direct	O
testing	O
of	O
viral	O
mutational	O
tolerance	B-DISO
to	O
RNA	O
mutagens	O
and	O
other	O
selective	O
pressures	O
.	O

One	O
clinical	O
diagnostic	O
criterion	O
for	O
ARDS	B-DISO
is	O
the	O
P	O
(	O
a	O
)	O
O	O
(	O
2	O
):	O
F	O
(	O
i	O
)	O
O	O
(	O
2	O
)	O
ratio	O
,	O
which	O
is	O
an	O
index	O
of	O
alveolar	O
gas	O
exchange	O
.	O

To	O
determine	O
influenza	B-DISO
effects	O
on	O
P	O
(	O
a	O
)	O
O	O
(	O
2	O
):	O
F	O
(	O
i	O
)	O
O	O
(	O
2	O
),	O
mice	O
were	O
challenged	O
with	O
10	O
,	O
000	O
p	O
.	O
f	O
..	O

Influenza	B-DISO
infection	B-DISO
of	O
mice	O
results	O
in	O
impairment	B-DISO
of	O
alveolar	O
gas	O
exchange	O
consistent	O
with	O
rapid	O
development	O
of	O
acute	O
lung	O
injury	O
and	O
progression	O
to	O
ARDS	B-DISO
.	O

TITLE	O
:	O
[	O
Preparation	O
and	O
identification	O
of	O
monoclonal	O
antibodies	O
against	O
recombinant	O
N	O
protein	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
].	O

Whether	O
these	O
biomarkers	O
have	O
predictive	O
value	O
in	O
a	O
less	O
severely	O
ill	B-DISO
population	O
that	O
excludes	O
septic	O
patients	O
with	O
high	O
APACHE	O
II	O
scores	O
is	O
currently	O
unknown	O
.	O

ABSTRACT	O
:	O
In	O
patients	O
with	O
severe	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
the	O
prone	O
position	O
has	O
been	O
shown	O
to	O
improve	O
survival	O
of	O
patients	O
who	O
are	O
severely	O
hypoxemic	O
with	O
an	O
arterial	O
oxygen	O
tension	B-DISO
to	O
inspiratory	O
oxygen	O
fraction	O
ratio	O
(	O
PaO	O
(	O
2	O
)/	O
FiO	O
(	O
2	O
))<	O
100	O
.	O

The	O
role	O
of	O
parasite	O
sequestration	O
in	O
the	O
pulmonary	O
microvasculature	O
is	O
unclear	O
,	O
because	O
sequestration	O
occurs	O
intensely	O
in	O
P	B-DISO
falciparum	I-DISO
,	O
less	O
so	O
in	O
P	O
knowlesi	O
,	O
and	O
has	O
not	O
been	O
shown	O
convincingly	O
in	O
P	B-DISO
vivax	I-DISO
.	O

Because	O
early	O
markers	O
of	O
ALI	O
/	O
ARDS	B-DISO
are	O
lacking	O
,	O
fluid	O
resuscitation	O
in	O
severe	O
malaria	B-DISO
should	O
follow	O
the	O
old	O
adage	O
to	O
""""	O
keep	O
them	O
dry	O
.	O

Bacteremia	B-DISO
and	O
hospital	O
-	O
acquired	O
pneumonia	B-DISO
can	O
complicate	O
severe	O
malaria	B-DISO
and	O
may	O
contribute	O
to	O
ALI	O
/	O
ARDS	B-DISO
.	O

The	O
use	O
of	O
lung	O
-	O
protective	O
ventilation	O
has	O
helped	O
to	O
reduce	O
mortality	O
from	O
malaria	B-DISO
-	O
induced	O
ALI	O
/	O
ARDS	B-DISO
,	O
but	O
permissive	O
hypercapnia	B-DISO
in	O
unconscious	O
patients	O
is	O
not	O
recommended	O
because	O
increased	B-DISO
intracranial	I-DISO
pressure	I-DISO
and	O
cerebral	O
swelling	B-DISO
may	O
occur	O
in	O
cerebral	B-DISO
malaria	I-DISO
.	O

The	O
best	O
antimalarial	O
treatment	O
of	O
severe	O
malaria	B-DISO
is	O
IV	O
artesunate	O
.	O

In	O
this	O
report	O
,	O
using	O
molecular	O
methods	O
,	O
we	O
show	O
the	O
chronological	O
association	O
between	O
human	O
coronavirus	O
--	O
HKU1	O
infection	B-DISO
and	O
asthma	B-DISO
exacerbation	O
in	O
a	O
two	O
years	O
and	O
seven	O
months	O
old	O
asthmatic	B-DISO
girl	O
who	O
was	O
not	O
under	O
treatment	O
and	O
was	O
otherwise	O
healthy	O
.	O

Long	O
-	O
term	O
virus	B-DISO
shedding	I-DISO
,	O
lasting	O
from	O
one	O
to	O
12	O
months	O
,	O
was	O
observed	O
for	O
adenoviruses	O
,	O
anelloviruses	O
,	O
bocaviruses	O
,	O
enteroviruses	O
,	O
parechoviruses	O
,	O
and	O
picobirnaviruses	O
.	O

APN	O
is	O
also	O
considered	O
a	O
target	O
for	O
cancer	B-DISO
therapy	O
and	O
its	O
structure	O
,	O
reported	O
here	O
,	O
could	O
facilitate	O
the	O
development	O
of	O
anti	O
-	O
cancer	B-DISO
drugs	O
.	O

To	O
further	O
explore	O
our	O
hypothesis	O
,	O
we	O
used	O
the	O
454	O
sequence	O
analysis	O
of	O
a	O
large	O
naïve	O
library	O
of	O
human	O
IgM	O
antibodies	O
which	O
had	O
been	O
used	O
for	O
selecting	O
antibodies	O
against	O
SARS	B-DISO
CoV	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
),	O
and	O
soluble	O
G	O
proteins	O
(	O
sG	O
)	O
of	O
henipaviruses	O
.	O

These	O
results	O
elucidate	O
that	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
regulates	O
immune	O
-	O
related	O
genes	O
in	O
monocytes	O
/	O
macrophages	O
,	O
which	O
may	O
be	O
important	O
to	O
the	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
.	O

Here	O
,	O
we	O
present	O
an	O
unusual	O
case	O
of	O
TM	O
from	O
C	O
difficile	O
infection	B-DISO
induced	I-DISO
by	O
topical	O
silver	O
sulphadiazine	O
in	O
a	O
60	O
-	O
year	O
-	O
old	O
man	O
with	O
immune	O
-	O
bullous	O
pemphigus	B-DISO
vulgaris	I-DISO
.	O

Additionally	O
,	O
the	O
inhibition	O
is	O
selective	O
because	O
these	O
compounds	O
do	O
not	O
exert	O
significant	O
inhibitory	O
effects	O
against	O
other	O
proteases	O
including	O
chymotrysin	O
,	O
papain	O
,	O
and	O
HIV	B-DISO
protease	O
.	O

Th17	O
associated	O
cytokines	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
21	O
and	O
IL	O
-	O
22	O
,	O
were	O
also	O
increased	O
significantly	O
at	O
72	O
h	O
post	O
-	O
infection	B-DISO
.	O

It	O
was	O
concluded	O
that	O
IL	O
-	O
17	O
may	O
contribute	O
to	O
the	O
pathogenesis	B-DISO
of	O
MHV	O
-	O
3	O
-	O
induced	O
acute	B-DISO
liver	I-DISO
failure	I-DISO
.	O

Finally	O
,	O
we	O
introduce	O
a	O
constraint	O
in	O
Richards	O
model	O
to	O
address	O
over	O
fitting	B-DISO
problem	O
observed	O
in	O
the	O
existing	O
studies	O
and	O
then	O
apply	O
our	O
method	O
with	O
constraint	O
to	O
conduct	O
some	O
validation	O
analysis	O
using	O
the	O
data	O
of	O
recent	O
outbreaks	O
of	O
prototype	O
infectious	B-DISO
diseases	I-DISO
such	O
as	O
Canada	O
2009	O
H1N1	O
outbreak	O
,	O
GTA	O
2003	O
SARS	B-DISO
outbreak	O
,	O
Singapore	O
2005	O
dengue	B-DISO
outbreak	O
,	O
and	O
Taiwan	O
2003	O
SARS	B-DISO
outbreak	O
.	O

The	O
following	O
representatives	O
of	O
polytopic	O
viral	O
channel	O
proteins	O
are	O
chosen	O
:	O
(	O
i	O
)	O
p7	O
of	O
HCV	O
and	O
2B	O
of	O
Polio	B-DISO
virus	O
(	O
two	O
TMDs	O
)	O
and	O
(	O
ii	O
)	O
3a	O
of	O
SARS	B-DISO
-	O
CoV	O
(	O
three	O
TMDs	O
).	O

The	O
analysis	O
reveals	O
that	O
p7	O
and	O
2B	O
TMDs	O
align	O
with	O
the	O
pore	O
-	O
facing	O
TMD	B-DISO
of	O
MscL	O
,	O
and	O
3a	O
-	O
TMDs	O
align	O
with	O
those	O
of	O
ligand	O
-	O
gated	O
ion	O
channels	O
.	O

ABSTRACT	O
:	O
We	O
followed	O
changes	O
in	O
a	O
portion	O
of	O
the	O
S1	O
gene	O
sequence	O
of	O
the	O
dominant	O
populations	O
of	O
an	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
Arkansas	O
(	O
Ark	O
)	O
vaccine	O
strain	O
during	O
serial	O
passage	O
in	O
chickens	O
infected	O
with	O
the	O
immunosuppressive	O
chicken	O
anaemia	B-DISO
virus	O
(	O
CAV	O
)	O
and	O
/	O
or	O
infectious	B-DISO
bursal	I-DISO
disease	I-DISO
virus	O
(	O
IBDV	O
)	O
as	O
well	O
as	O
in	O
immunocompetent	O
chickens	O
.	O

The	O
correlation	O
between	O
CC16	O
serum	O
levels	O
and	O
severe	O
lung	O
injury	O
,	O
onset	O
of	O
nosocomial	B-DISO
pneumonia	I-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
or	O
acute	O
lung	O
injury	O
,	O
and	O
organ	B-DISO
failure	I-DISO
was	O
measured	O
.	O

In	O
patients	O
with	O
lung	O
injury	O
,	O
initial	O
""""	O
time	O
0	O
""""	O
median	O
CC16	O
values	O
were	O
significantly	O
elevated	O
(	O
11	O
.	O
2	O
ng	O
/	O
mL	O
)	O
compared	O
with	O
patients	O
without	O
severe	O
thoracic	B-DISO
injury	O
(	O
6	O
.	O
9	O
ng	O
/	O
mL	O
)	O
and	O
controls	O
(	O
6	O
.	O
3	O
ng	O
/	O
mL	O
).	O

The	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
for	O
serum	O
CC16	O
and	O
pneumonia	B-DISO
was	O
0	O
.	O
79	O
(	O
0	O
.	O
62	O
-	O
0	O
.	O
97	O
;	O
p	O
=	O
0	O
.	O
0011	O
).	O

In	O
three	O
experiments	O
moderate	O
predispositions	O
were	O
applied	O
:	O
coinfections	B-DISO
with	O
enterotoxigenic	O
E	O
.	O
coli	O
(	O
ETEC	O
)	O
or	O
with	O
low	O
-	O
virulence	O
TGE	B-DISO
coronavirus	O
,	O
application	O
of	O
fumonisin	O
B1	O
with	O
a	O
normal	O
therapeutic	O
dose	O
of	O
dexamethasone	O
,	O
and	O
the	O
increase	O
of	O
soybean	O
protein	O
concentration	O
in	O
the	O
feed	O
.	O

ABSTRACT	O
:	O
Five	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
isolates	O
were	O
isolated	O
from	O
broiler	O
chickens	O
showing	O
respiratory	O
and	O
renal	O
lesions	O
.	O

Similar	O
strategies	O
have	O
led	O
to	O
the	O
understanding	O
of	O
the	O
emergence	O
of	O
SARS	B-DISO
and	O
provided	O
options	O
for	O
preventing	O
the	O
re	O
-	O
emergence	O
of	O
this	O
disease	O
.	O

A	O
CT	O
scan	O
revealed	O
the	O
presence	O
of	O
patchy	O
bilateral	O
lung	O
opacities	B-DISO
at	O
the	O
level	O
of	O
superior	O
and	O
parahilar	O
zones	O
;	O
follow	O
-	O
up	O
CT	O
scans	O
three	O
days	O
later	O
and	O
10	O
days	O
later	O
are	O
also	O
reported	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
show	O
that	O
this	O
is	O
a	O
common	O
condition	B-DISO
among	O
experienced	O
BHDs	O
.	O

TITLE	O
:	O
[	O
Epidemiological	O
profile	O
of	O
pandemic	O
influenza	B-DISO
A	O
cases	O
in	O
the	O
south	O
of	O
Santa	O
Catarina	O
state	O
,	O
Brazil	O
,	O
in	O
2009	O
].	O

During	O
the	O
pandemic	O
period	O
,	O
1	O
149	O
suspected	O
cases	O
of	O
influenza	B-DISO
A	O
were	O
notified	O
,	O
of	O
which	O
560	O
(	O
48	O
.	O
6	O
%)	O
were	O
confirmed	O
.	O

The	O
prevalence	O
of	O
FIP	B-DISO
in	O
this	O
population	O
was	O
determined	O
,	O
and	O
sensitivity	O
,	O
specificity	O
,	O
and	O
PPV	O
and	O
NPV	O
of	O
the	O
Rivalta	O
test	O
were	O
calculated	O
.	O

Variables	O
measured	O
in	O
effusion	B-DISO
fluid	O
and	O
peripheral	O
blood	O
were	O
compared	O
between	O
cats	O
that	O
had	O
positive	O
or	O
negative	O
Rivalta	O
tests	O
using	O
the	O
Mann	O
-	O
Whitney	O
U	O
-	O
test	O
and	O
multivariate	O
analysis	O
.	O

Prevalence	O
of	O
FIP	B-DISO
in	O
cats	O
with	O
effusion	B-DISO
and	O
a	O
conclusive	O
Rivalta	O
test	O
result	O
was	O
34	O
.	O
6	O
%.	O

The	O
Rivalta	O
test	O
had	O
a	O
sensitivity	O
of	O
91	O
.	O
3	O
%,	O
specificity	O
of	O
65	O
.	O
5	O
%,	O
PPV	O
of	O
58	O
.	O
4	O
%,	O
and	O
NPV	O
of	O
93	O
.	O
4	O
%	O
for	O
the	O
diagnosis	O
of	O
FIP	B-DISO
.	O

The	O
results	O
demonstrate	O
that	O
the	O
newly	O
developed	O
assay	O
can	O
purify	O
and	O
subsequently	O
detect	O
BCV	O
,	O
BRV	B-DISO
,	O
and	O
Cryptosporidium	O
spp	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
the	O
etiological	O
agent	O
of	O
SARS	B-DISO
,	O
a	O
fatal	O
pulmonary	B-DISO
disorder	I-DISO
with	O
no	O
effective	O
treatment	O
.	O

Intranasal	O
pretreatment	O
of	O
aged	O
mice	O
with	O
poly	O
(	O
I	O
·	O
C	O
)	O
(	O
a	O
TLR3	O
agonist	O
)	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
CpG	O
,	O
R848	O
,	O
or	O
lipopolysaccharide	O
(	O
TLR9	O
,	O
TLR7	O
/	O
8	O
,	O
or	O
TLR4	O
agonists	O
),	O
provided	O
a	O
high	O
level	O
of	O
protection	O
[	O
90	O
%	O
to	O
100	O
%	O
survival	O
rate	O
after	O
poly	O
(	O
I	O
·	O
C	O
)	O
treatment	O
]	O
against	O
lethal	O
MA15	O
or	O
IAV	O
challenge	O
and	O
reduced	O
pathological	O
changes	O
and	O
virus	O
loads	O
in	O
the	O
lungs	O
at	O
early	O
times	O
after	O
infection	B-DISO
.	O

We	O
developed	O
Western	O
-	O
Bolt	O
and	O
ELISA	O
to	O
detect	O
antibody	O
reactivity	O
between	O
truncated	O
N	O
fragments	O
with	O
sera	O
from	O
SARS	B-DISO
-	O
CoV	O
-	O
negative	O
normal	O
adults	O
or	O
SARS	B-DISO
-	O
CoV	O
patient	O
convalescent	O
sera	O
.	O

The	O
ALI	O
model	O
was	O
developed	O
through	O
the	O
intra	O
-	O
tracheal	O
(	O
IT	O
)	O
administration	O
of	O
LPS	B-DISO
(	O
16mg	O
/	O
kg	O
)	O
to	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
,	O
which	O
formed	O
the	O
LPS	B-DISO
group	O
.	O

The	O
results	O
of	O
this	O
experiment	O
indicate	O
that	O
the	O
number	O
of	O
total	O
cells	O
and	O
neutrophils	O
and	O
the	O
concentration	O
of	O
protein	O
exudation	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
significantly	O
decreased	O
in	O
the	O
MCR	O
-	O
LPS	B-DISO
group	O
.	O

Myeloperoxidase	O
(	O
MPO	O
)	O
activity	O
in	O
lung	O
tissue	O
was	O
reduced	O
in	O
the	O
MCR	O
-	O
LPS	B-DISO
and	O
LPS	B-DISO
-	O
MCR	O
groups	O
at	O
16h	O
after	O
LPS	B-DISO
administration	O
.	O

The	O
suckling	O
piglets	O
are	O
particularly	O
susceptible	O
to	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
with	O
a	O
high	O
mortality	O
rate	O
(	O
90	O
%).	O

Overcrowded	O
shelters	O
and	O
breeding	O
kennels	O
create	O
the	O
perfect	O
environment	O
for	O
amplified	O
infectious	B-DISO
disease	I-DISO
transmission	I-DISO
among	O
dogs	O
and	O
present	O
a	O
critical	O
opportunity	O
for	O
zoonotic	O
pathogens	O
to	O
emerge	O
and	O
infect	O
people	O
who	O
work	O
in	O
close	O
contact	O
with	O
dogs	O
.	O

TITLE	O
:	O
Acute	O
viral	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
in	O
Cambodian	O
children	O
:	O
clinical	O
and	O
epidemiologic	O
characteristics	O
.	O

Similar	O
to	O
other	O
tropical	O
countries	O
,	O
rhinovirus	O
and	O
respiratory	O
syncytial	O
virus	O
were	O
the	O
principal	O
viral	O
pathogens	O
detected	O
among	O
children	O
hospitalized	O
for	O
lower	O
tract	O
respiratory	B-DISO
infection	I-DISO
in	O
Cambodia	O
.	O

The	O
European	O
Society	O
of	O
Intensive	O
Care	O
Medicine	O
identified	O
three	O
chairs	O
with	O
broad	O
expertise	O
in	O
ARDS	B-DISO
who	O
selected	O
the	O
participants	O
and	O
created	O
the	O
agenda	O
.	O

RESULTS	O
:	O
The	O
Berlin	O
Definition	O
of	O
ARDS	B-DISO
maintains	O
a	O
link	O
to	O
prior	O
definitions	O
with	O
diagnostic	O
criteria	O
of	O
timing	O
,	O
chest	O
imaging	O
,	O
origin	O
of	O
edema	B-DISO
,	O
and	O
hypoxemia	O
.	O

Hot	B-DISO
spots	I-DISO
of	O
substitutions	O
were	O
situated	O
in	O
the	O
S1	O
region	O
of	O
the	O
Spike	O
,	O
the	O
nucleocapsid	O
gene	O
,	O
and	O
the	O
non	O
-	O
structural	O
protein	O
3	O
gene	O
,	O
whereas	O
several	O
deletions	O
were	O
detected	O
in	O
the	O
3	O
'	O
UTR	O
.	O

Currently	O
,	O
the	O
vaccines	O
for	O
it	O
are	O
only	O
partially	O
effective	O
and	O
no	O
specific	O
drug	O
is	O
available	O
for	O
treatment	O
of	O
TGE	B-DISO
virus	O
(	O
TGEV	O
)	O
infection	B-DISO
.	O

A	O
retrospective	O
review	O
was	O
conducted	O
that	O
included	O
patients	O
admitted	O
to	O
the	O
Cleveland	O
Clinic	O
MICU	O
with	O
ALI	O
/	O
ARDS	B-DISO
and	O
confirmed	O
influenza	B-DISO
A	O
infection	B-DISO
,	O
and	O
all	O
patients	O
admitted	O
with	O
ALI	O
/	O
ARDS	B-DISO
from	O
any	O
other	O
etiology	O
from	O
September	O
2009	O
to	O
March	O
2010	O
.	O

SOFA	O
scores	O
over	O
the	O
first	O
2	O
weeks	O
in	O
the	O
ICU	O
indicate	O
more	O
severe	O
organ	B-DISO
failure	I-DISO
in	O
the	O
noninfluenza	O
group	O
(	O
p	O
=	O
0	O
.	O
017	O
).	O

An	O
observational	O
cohort	O
study	O
of	O
HIV	B-DISO
-	O
negative	O
adults	O
with	O
PJP	O
documented	O
by	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
through	O
Gomori	O
-	O
Grocott	O
staining	O
or	O
immunofluorescence	O
,	O
admitted	O
to	O
one	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
for	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
,	O
was	O
undertaken	O
.	O

Endotracheal	O
intubation	O
(	O
ETI	O
)	O
was	O
required	O
in	O
42	O
patients	O
(	O
60	O
.	O
0	O
%),	O
including	O
38	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

In	O
the	O
univariate	O
analysis	O
,	O
in	O
-	O
ICU	O
mortality	O
was	O
associated	O
with	O
SAPS	O
-	O
II	O
(	O
p	O
=	O
0	O
.	O
0131	O
),	O
ARDS	B-DISO
(	O
p	O
<	O
0	O
.	O
0001	O
),	O
shock	O
(	O
p	O
<	O
0	O
.	O
0001	O
),	O
and	O
herpes	B-DISO
simplex	I-DISO
virus	O
(	O
HSV	O
)	O
or	O
cytomegalovirus	O
(	O
CMV	O
)	O
on	O
BAL	O
(	O
p	O
=	O
0	O
.	O
0031	O
).	O

Meanwhile	O
,	O
the	O
levels	O
of	O
CK	O
and	O
CK	O
-	O
MB	O
were	O
elevated	O
in	O
patients	O
with	O
respiratory	B-DISO
failure	I-DISO
compared	O
by	O
non	O
-	O
failure	O
ones	O
,	O
but	O
decreased	O
in	O
the	O
ratios	O
of	O
CK	O
-	O
MB	O
to	O
CK	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Increasing	O
incidences	O
of	O
emerging	O
and	O
re	O
-	O
emerging	O
diseases	O
that	O
are	O
mostly	O
zoonotic	O
(	O
e	O
.	O
g	O
.	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
avian	B-DISO
influenza	I-DISO
H5N1	B-DISO
,	O
pandemic	O
influenza	B-DISO
)	O
has	O
led	O
to	O
the	O
need	O
for	O
a	O
multidisciplinary	O
approach	O
to	O
tackling	O
these	O
threats	O
to	O
public	O
and	O
animal	O
health	O
.	O

Recently	O
,	O
a	O
range	O
of	O
mathematical	O
and	O
computer	O
simulation	O
modelling	O
methods	O
and	O
tools	O
have	O
increasingly	O
been	O
applied	O
to	O
improve	O
our	O
understanding	O
of	O
disease	B-DISO
transmission	I-DISO
dynamics	O
,	O
contingency	O
planning	O
and	O
to	O
support	O
policy	O
decisions	O
on	O
disease	O
outbreak	O
management	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
need	O
to	O
direct	O
additional	O
research	O
to	O
the	O
study	O
of	O
influenza	B-DISO
transmission	O
dynamics	O
in	O
animals	O
and	O
at	O
the	O
animal	O
-	O
human	O
interface	O
.	O

NMBAs	O
have	O
not	O
been	O
shown	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
of	O
neuromyopathy	B-DISO
in	O
most	O
studies	O
.	O

The	O
emergence	O
or	O
re	O
-	O
emergence	O
of	O
bacterial	O
(	O
Mycobacterium	O
bovis	O
and	O
Brucella	O
spp	O
)	O
or	O
viral	O
(	O
hepatitis	B-DISO
E	I-DISO
virus	O
)	O
infections	B-DISO
shows	O
that	O
zoonoses	B-DISO
should	O
be	O
considered	O
as	O
emerging	O
risks	O
in	O
agricultural	O
and	O
animal	O
breeding	O
and	O
should	O
be	O
addressed	O
by	O
specific	O
preventive	O
interventions	O
.	O

TITLE	O
:	O
Combined	O
action	O
of	O
type	O
I	O
and	O
type	O
III	O
interferon	O
restricts	O
initial	O
replication	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
in	O
the	O
lung	O
but	O
fails	O
to	O
inhibit	O
systemic	O
virus	O
spread	O
.	O

An	O
early	O
extensive	O
clinical	O
,	O
laboratory	O
,	O
and	O
imaging	O
evaluation	O
of	O
""""	O
at	O
risk	O
patients	O
""""	O
allows	O
a	O
correct	O
diagnosis	O
of	O
ARDS	B-DISO
,	O
assessment	O
of	O
comorbidities	O
,	O
and	O
calculation	O
of	O
prognostic	O
indices	O
,	O
so	O
that	O
a	O
careful	O
treatment	O
can	O
be	O
planned	O
.	O

TITLE	O
:	O
Impact	O
of	O
a	O
hospital	O
-	O
wide	O
hand	O
hygiene	O
promotion	O
strategy	O
on	O
healthcare	O
-	O
associated	O
infections	B-DISO
.	O

However	O
,	O
the	O
post	O
-	O
SARS	B-DISO
period	O
confirmed	O
that	O
this	O
practice	O
was	O
not	O
sustainable	O
.	O

Gene	O
expression	O
levels	O
for	O
the	O
neutrophil	O
chemoattractants	O
CXCL1	O
and	O
CXCL2	O
are	O
elevated	O
in	O
the	O
lungs	O
of	O
ps20	O
(-/-)	O
mice	O
post	O
-	O
MHV	O
-	O
1	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
RNA	O
viruses	O
are	O
the	O
causative	O
agents	O
for	O
AIDS	O
,	O
influenza	B-DISO
,	O
SARS	B-DISO
,	O
and	O
other	O
serious	O
health	O
threats	O
.	O

With	O
5	O
million	O
reads	O
,	O
we	O
capture	O
96	O
to	O
100	O
%	O
of	O
the	O
viral	O
protein	O
coding	O
region	O
of	O
HIV	B-DISO
,	O
respiratory	O
syncytial	O
and	O
West	O
Nile	O
viral	O
samples	O
from	O
as	O
little	O
as	O
100	O
copies	O
of	O
viral	O
RNA	O
.	O

TITLE	O
:	O
Residue	O
analysis	O
of	O
a	O
CTL	O
epitope	O
of	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
by	O
IFN	O
-	O
gamma	O
production	O
and	O
bioinformatics	O
prediction	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
an	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
caused	O
by	O
the	O
novel	O
coronavirus	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
T	O
cell	O
epitopes	O
of	O
the	O
SARS	B-DISO
CoV	O
spike	O
protein	O
are	O
well	O
known	O
,	O
but	O
no	O
systematic	O
evaluation	O
of	O
the	O
functional	O
and	O
structural	O
roles	O
of	O
each	O
residue	O
has	O
been	O
reported	O
for	O
these	O
antigenic	O
epitopes	O
.	O

RESULTS	O
:	O
We	O
demonstrated	O
that	O
N50	O
could	O
induce	O
significant	O
IFN	O
-	O
gamma	O
response	O
from	O
SARS	B-DISO
-	O
CoV	O
S	O
DNA	O
immunized	O
mice	O
splenocytes	O
by	O
the	O
means	O
of	O
ELISA	O
,	O
ELISPOT	O
and	O
FACS	O
.	O

ABSTRACT	O
:	O
We	O
were	O
able	O
to	O
treat	O
a	O
patient	O
with	O
acute	O
exacerbation	O
of	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
who	O
also	O
suffered	B-DISO
from	O
sleep	B-DISO
-	I-DISO
disordered	I-DISO
breathing	I-DISO
by	O
using	O
the	O
average	O
volume	O
-	O
assured	O
pressure	O
support	O
mode	O
of	O
a	O
Respironics	O
V60	O
Ventilator	O
(	O
Philips	O
Respironics	O
:	O
United	O
States	O
).	O

The	O
Respironics	O
V60	O
Ventilator	O
,	O
in	O
the	O
average	O
volume	O
-	O
assured	O
pressure	O
support	O
mode	O
,	O
was	O
attached	O
to	O
our	O
patient	O
and	O
improved	O
and	O
stabilized	O
his	O
sleep	O
-	O
related	O
hypoventilation	B-DISO
by	O
automatically	O
adjusting	O
force	O
to	O
within	O
an	O
acceptable	O
range	O
.	O

Upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
preceded	O
HSP	B-DISO
in	O
over	O
half	O
of	O
the	O
patients	O
and	O
antistreptolyzin	O
O	O
(	O
ASO	O
)	O
titer	O
was	O
positive	O
in	O
11	O
of	O
the	O
24	O
(	O
46	O
%)	O
children	O
tested	O
at	O
presentation	O
.	O

TITLE	O
:	O
Complete	O
genome	O
sequences	O
of	O
two	O
Chinese	O
virulent	O
avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
variants	O
.	O

TITLE	O
:	O
Isolation	O
and	O
characterization	O
of	O
a	O
variant	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
in	O
China	O
.	O

ABSTRACT	O
:	O
An	O
outbreak	O
of	O
diarrhea	B-DISO
in	O
pigs	O
started	O
in	O
Guangdong	O
,	O
South	O
China	O
in	O
January	O
2011	O
.	O

Cases	O
were	O
characterized	O
by	O
watery	B-DISO
diarrhea	I-DISO
,	O
dehydration	B-DISO
and	O
vomiting	B-DISO
,	O
with	O
80	O
-	O
100	O
%	O
morbidity	O
and	O
50	O
-	O
90	O
%	O
mortality	O
in	O
suckling	O
piglets	O
.	O

Plasma	O
albumin	O
level	O
was	O
higher	O
in	O
treatment	O
group	O
than	O
in	O
control	O
group	O
from	O
PBD	B-DISO
3	O
to	O
10	O
,	O
with	O
statistically	O
significant	O
differences	O
observed	O
on	O
PBD	B-DISO
4	O
,	O
9	O
,	O
and	O
10	O
(	O
with	O
F	O
values	O
from	O
5	O
.	O
691	O
to	O
10	O
.	O
551	O
,	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

We	O
have	O
used	O
the	O
JHMV	O
-	O
induced	O
demyelination	B-DISO
model	O
to	O
evaluate	O
the	O
antigenicity	O
of	O
transplanted	O
allogeneic	O
NPCs	O
within	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
of	O
mice	O
with	O
established	O
immune	O
-	O
mediated	O
demyelination	B-DISO
.	O

Finally	O
,	O
we	O
showed	O
that	O
PGRN	O
/	O
TNFR2	O
interaction	O
was	O
crucial	O
for	O
the	O
protective	O
effect	O
of	O
PGRN	O
on	O
the	O
LPS	B-DISO
-	O
induced	O
ALI	O
.	O

Our	O
findings	O
strongly	O
demonstrated	O
that	O
PGRN	O
could	O
effectively	O
ameliorate	O
the	O
LPS	B-DISO
-	O
induced	O
ALI	O
in	O
mice	O
,	O
suggesting	O
a	O
potential	O
application	O
for	O
PGRN	O
-	O
based	O
therapy	O
to	O
treat	O
clinical	O
ARDS	B-DISO
.	O

A	O
high	O
frequency	O
of	O
respiratory	B-DISO
infections	I-DISO
(	O
78	O
.	O
7	O
%)	O
and	O
co	B-DISO
-	I-DISO
infections	I-DISO
(	O
29	O
.	O
9	O
%)	O
was	O
detected	O
in	O
children	O
with	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
symptoms	O
in	O
Shanghai	O
.	O

RESULTS	O
:	O
Viruses	O
were	O
detected	O
in	O
84	O
(	O
51	O
.	O
2	O
%)	O
patients	O
by	O
VRDAL	O
multiplex	O
PCR	O
,	O
and	O
8	O
(	O
4	O
.	O
9	O
%)	O
of	O
cases	O
were	O
mixed	B-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
A	O
multiplex	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
mRT	O
-	O
PCR	O
)	O
assay	O
was	O
developed	O
for	O
the	O
simultaneous	O
detection	O
of	O
canine	B-DISO
distemper	I-DISO
virus	O
(	O
CDV	O
),	O
canine	O
respiratory	O
coronavirus	O
(	O
CRCoV	O
)	O
and	O
canine	O
influenza	B-DISO
virus	O
(	O
CIV	O
).	O

Of	O
the	O
isolated	O
diarylheptanoids	O
,	O
hirsutenone	O
(	O
2	O
)	O
showed	O
the	O
most	O
potent	O
PL	O
(	O
pro	O
)	O
inhibitory	O
activity	O
,	O
with	O
an	O
inhibitory	O
concentration	O
(	O
IC	O
(	O
50	O
))	O
value	O
of	O
4	O
.	O
1	O
µM	O
.	O
Structure	O
-	O
activity	O
analysis	O
showed	O
that	O
catechol	O
and	O
α	O
,	O
β	O
-	O
unsaturated	O
carbonyl	O
moiety	O
in	O
the	O
molecule	O
were	O
the	O
key	O
requirement	O
for	O
SARS	B-DISO
-	O
CoV	O
cysteine	O
protease	O
inhibition	O
.	O

ABSTRACT	O
:	O
Young	O
adults	O
with	O
underlying	O
medical	O
conditions	O
who	O
are	O
infected	O
with	O
the	O
H1N1	O
virus	O
are	O
at	O
risk	O
of	O
quickly	O
progressing	O
from	O
mild	O
upper	O
airways	O
infection	B-DISO
to	O
severe	O
ARDS	B-DISO
within	O
4	O
to	O
5	O
days	O
after	O
the	O
onset	O
of	O
the	O
illness	O
.	O

The	O
susceptibility	O
,	O
immune	O
responses	O
,	O
pathogenesis	B-DISO
,	O
and	O
pharmacokinetics	O
may	O
differ	O
between	O
the	O
various	O
animal	O
models	O
.	O

Within	O
these	O
constraints	O
,	O
animal	O
models	O
are	O
very	O
informative	O
for	O
studying	O
virus	O
immunopathology	B-DISO
and	O
transmission	O
modes	O
and	O
for	O
translation	O
of	O
virus	O
research	O
into	O
clinical	O
benefit	O
.	O

Here	O
,	O
we	O
report	O
the	O
case	O
of	O
a	O
7	O
-	O
year	O
-	O
old	O
child	O
who	O
suffered	B-DISO
a	O
prolonged	O
history	O
of	O
abuse	B-DISO
and	O
died	O
from	O
a	O
systemic	O
Pseudomonas	B-DISO
aeruginosa	I-DISO
infection	I-DISO
.	O

An	O
initial	O
local	O
chronic	B-DISO
infection	I-DISO
propagated	O
to	O
the	O
pelvic	O
lymph	O
nodes	O
in	O
an	O
immunologically	O
weak	O
body	O
and	O
evolved	O
into	O
abscesses	B-DISO
/	O
phlegmons	O
of	O
the	O
pelvic	O
tissue	O
,	O
sepsis	B-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
and	O
finally	O
,	O
death	O
.	O

RESULTS	O
:	O
all	O
sera	O
samples	O
from	O
patients	O
with	O
SARS	B-DISO
positive	O
were	O
the	O
ELISA	O
positive	O
(	O
100	O
%	O
sensitivity	O
).	O

Single	O
infections	B-DISO
were	O
detected	O
in	O
56	O
samples	O
,	O
50	O
of	O
those	O
were	O
caused	O
by	O
RNA	O
viruses	O
:	O
33	O
samples	O
tested	O
positive	O
for	O
rhinovirus	O
,	O
five	O
for	O
influenza	B-DISO
A	O
,	O
five	O
for	O
metapneumovirus	O
,	O
four	O
for	O
coronavirus	O
and	O
,	O
three	O
for	O
respiratory	O
syncytial	O
virus	O
.	O

For	O
the	O
DNA	O
viruses	O
,	O
five	O
samples	O
were	O
positive	O
for	O
bocavirus	O
and	O
one	O
for	O
adenovirus	B-DISO
.	O

TITLE	O
:	O
Prevalence	O
of	O
viral	B-DISO
infections	I-DISO
in	O
Norwegian	O
cats	O
with	O
and	O
without	O
feline	B-DISO
lower	I-DISO
urinary	I-DISO
tract	I-DISO
disease	I-DISO
.	O

Six	O
adult	O
patients	O
were	O
detected	O
as	O
HBoV	O
positive	O
and	O
5	O
were	O
emergency	B-DISO
cases	O
.	O

ABSTRACT	O
:	O
Detection	O
of	O
respiratory	O
viruses	O
by	O
molecular	O
methods	O
,	O
in	O
children	O
without	O
respiratory	B-DISO
symptoms	I-DISO
undergoing	O
hematopoietic	O
cell	O
transplantation	O
(	O
HCT	O
),	O
has	O
not	O
been	O
well	O
described	O
.	O

Of	O
the	O
11	O
asymptomatic	O
patients	O
where	O
respiratory	O
virus	O
was	O
detected	O
,	O
3	O
(	O
27	O
%)	O
later	O
developed	O
an	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
,	O
from	O
the	O
same	O
virus	O
.	O

It	O
is	O
shown	O
that	O
patients	O
with	O
moderately	O
severe	O
and	O
severe	O
forms	O
of	O
the	O
disease	O
exhibit	O
early	O
clinical	O
and	O
X	O
-	O
ray	O
signs	O
of	O
pulmonary	O
lesions	O
and	O
respiratory	B-DISO
insufficiency	I-DISO
Some	O
of	O
them	O
suffer	B-DISO
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
confirmed	O
by	O
morphological	O
findings	O
at	O
autopsy	O
.	O

Cleavage	O
of	O
IBV	O
spike	O
protein	O
by	O
furin	O
may	O
contribute	O
to	O
the	O
productive	O
IBV	O
infection	B-DISO
in	O
these	O
cells	O
.	O

The	O
findings	O
that	O
IBV	O
could	O
productively	O
infect	O
multiple	O
human	O
and	O
animal	O
cells	O
of	O
diverse	O
tissue	O
and	O
organ	O
origins	O
would	O
provide	O
a	O
useful	O
system	O
for	O
studying	O
the	O
pathogenesis	B-DISO
of	O
coronavirus	O
.	O

ABSTRACT	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
spike	O
protein	O
is	O
known	O
to	O
mediate	O
receptor	O
interaction	O
and	O
immune	O
recognition	O
and	O
thus	O
it	O
is	O
considered	O
as	O
a	O
major	O
target	O
for	O
vaccine	O
design	O
.	O

In	O
conclusion	O
,	O
the	O
method	O
described	O
in	O
this	O
study	O
allows	O
sensitive	O
detection	O
of	O
a	O
recombinant	O
SARS	B-DISO
spike	O
protein	O
by	O
sandwich	O
ELISA	O
with	O
bi	O
-	O
specific	O
monoclonal	O
antibody	O
and	O
could	O
be	O
used	O
for	O
the	O
diagnosis	O
of	O
patients	O
suspected	O
with	O
SARS	B-DISO
.	O

TITLE	O
:	O
Establishment	O
of	O
reverse	O
genetics	O
system	O
for	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
attenuated	O
vaccine	O
strain	O
H120	O
.	O

The	O
clinical	O
diagnosis	O
was	O
bronchopneumonia	B-DISO
(	O
60	O
%),	O
bronchiolitis	B-DISO
(	O
30	O
%),	O
and	O
acute	O
laryngotracheal	O
bronchitis	B-DISO
(	O
10	O
%).	O

Four	O
of	O
the	O
10	O
cases	O
had	O
critical	B-DISO
illness	I-DISO
,	O
4	O
cases	O
had	O
underlying	O
diseases	O
,	O
and	O
7	O
cases	O
had	O
mixed	B-DISO
infection	I-DISO
with	O
other	O
viruses	O
.	O

Coronavirus	O
NL63	O
infections	B-DISO
are	O
common	O
in	O
children	O
under	O
3	O
years	O
of	O
age	O
.	O

CONCLUSIONS	O
:	O
Coronavirus	O
NL63	O
infection	B-DISO
exists	O
in	O
hospitalized	O
children	O
with	O
acute	B-DISO
lower	I-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
in	O
Changsha	O
.	O

Moreover	O
,	O
the	O
severe	B-DISO
sepsis	I-DISO
group	O
appeared	O
to	O
have	O
a	O
higher	O
level	O
of	O
sCD163	O
compared	O
with	O
that	O
in	O
the	O
sepsis	B-DISO
group	O
(	O
76	O
.	O
2	O
;	O
47	O
.	O
2	O
-	O
167	O
.	O
5	O
ng	O
/	O
ml	O
vs	O
.	O
74	O
.	O
2	O
;	O
46	O
.	O
2	O
-	O
131	O
.	O
6	O
ng	O
/	O
ml	O
),	O
but	O
this	O
was	O
not	O
significant	O
.	O

TITLE	O
:	O
Repeated	O
lung	O
lavage	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
treating	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
due	O
to	O
nasogastric	O
tube	O
malposition	O
for	O
enternal	O
nutrition	O
:	O
a	O
case	O
report	O
.	O

After	O
institutional	O
review	O
board	O
approval	O
was	O
obtained	O
,	O
the	O
records	O
of	O
mechanically	O
ventilated	O
surgical	O
intensive	O
care	O
unit	O
patients	O
who	O
received	O
epoprostenol	O
as	O
a	O
therapy	O
for	O
severe	O
hypoxia	B-DISO
(	O
SaO₂	O
<	O
90	O
%)	O
in	O
a	O
tertiary	O
care	O
referral	O
center	O
were	O
retrospectively	O
reviewed	O
.	O

In	O
penehyclidine	O
hydrochloride	O
sequential	O
to	O
atropine	O
group	O
,	O
except	O
for	O
1	O
case	O
of	O
cancer	B-DISO
of	I-DISO
gastric	I-DISO
cardia	I-DISO
with	O
poisoning	O
after	O
operation	O
showing	O
intermediate	B-DISO
syndrome	I-DISO
of	O
poisoning	O
,	O
the	O
remaining	O
patients	O
did	O
not	O
have	O
any	O
complication	B-DISO
,	O
and	O
the	O
incidence	O
of	O
complications	O
was	O
1	O
.	O
67	O
％.	O
No	O
death	O
occurred	O
in	O
all	O
the	O
patients	O
,	O
and	O
the	O
cure	O
rate	O
was	O
100	O
.	O
00	O
％.	O
Time	O
of	O
recovery	O
from	O
ChE	O
activity	O
to	O
70	O
％	O
was	O

TITLE	O
:	O
Fourth	O
European	O
Conference	O
on	O
Infections	B-DISO
in	O
Leukaemia	B-DISO
(	O
ECIL	O
-	O
4	O
):	O
guidelines	O
for	O
diagnosis	O
and	O
treatment	O
of	O
human	O
respiratory	O
syncytial	O
virus	O
,	O
parainfluenza	B-DISO
virus	O
,	O
metapneumovirus	O
,	O
rhinovirus	O
,	O
and	O
coronavirus	O
.	O

Owing	O
to	O
differences	O
in	O
screening	O
,	O
clinical	O
presentation	O
,	O
and	O
therapy	O
for	O
influenza	B-DISO
and	O
adenovirus	B-DISO
,	O
ECIL	O
-	O
4	O
recommendations	O
are	O
summarized	O
for	O
CARVs	O
other	O
than	O
influenza	B-DISO
and	O
adenovirus	B-DISO
.	O

TITLE	O
:	O
Effect	O
of	O
infection	B-DISO
route	O
and	O
concurrent	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
vaccination	O
on	O
Mycoplasma	B-DISO
gallisepticum	O
disease	O
pathology	B-DISO
in	O
an	O
experimental	O
model	O
.	O

Reinfected	O
ferrets	O
,	O
however	O
,	O
lacked	O
the	O
integrated	O
expression	O
of	O
IRGs	O
that	O
was	O
prevalent	O
during	O
acute	B-DISO
infection	I-DISO
.	O

An	O
effective	O
public	O
health	O
response	O
to	O
an	O
influenza	B-DISO
public	O
health	O
emergency	B-DISO
depends	O
on	O
the	O
majority	O
of	O
uninfected	O
health	O
care	O
personnel	O
(	O
HCP	B-DISO
)	O
continuing	O
to	O
report	O
to	O
work	O
.	O

Search	O
strategies	O
included	O
the	O
Cochrane	O
Library	O
,	O
PubMed	O
,	O
PubMed	O
Central	O
,	O
EBSCO	O
Psychological	B-DISO
and	O
Behavioral	O
Sciences	O
Collection	O
,	O
Google	O
Scholar	O
,	O
ancestry	O
searching	O
of	O
citations	O
in	O
relevant	O
publications	O
,	O
and	O
information	O
from	O
individuals	O
with	O
a	O
known	O
interest	O
in	O
the	O
topic	O
.	O

Information	O
from	O
this	O
review	O
can	O
guide	O
emergency	B-DISO
policy	O
makers	O
,	O
planners	O
,	O
and	O
implementers	O
in	O
both	O
understanding	O
and	O
influencing	O
the	O
willingness	O
of	O
HCP	B-DISO
to	O
work	O
during	O
an	O
influenza	B-DISO
public	O
health	O
emergency	B-DISO
.	O

Available	O
evidence	O
supports	O
an	O
early	O
,	O
short	O
course	O
of	O
continuous	O
-	O
infusion	O
cisatracurium	O
in	O
patients	O
presenting	O
with	O
severe	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
protein	O
nsp1	O
is	O
a	O
novel	O
eukaryotic	O
translation	O
inhibitor	O
that	O
represses	O
multiple	O
steps	O
of	O
translation	O
initiation	O
.	O

TITLE	O
:	O
Viral	O
etiology	O
of	O
bronchiolitis	B-DISO
among	O
pediatric	O
inpatients	O
in	O
northern	O
Taiwan	O
with	O
emphasis	O
on	O
newly	O
identified	O
respiratory	O
viruses	O
.	O

ABSTRACT	O
:	O
Two	O
cases	O
of	O
rapidly	O
progressive	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
in	O
adults	O
associated	O
with	O
a	O
novel	O
coronavirus	O
have	O
generated	O
an	O
international	O
public	O
health	O
response	O
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
strain	O
AYU	O
was	O
isolated	O
in	O
Shanghai	O
.	O

SDS	B-DISO
-	O
PAGE	O
and	O
Western	O
blot	O
results	O
indicated	O
that	O
EpiC	O
was	O
successfully	O
expressed	O
and	O
had	O
good	O
immunoreactivity	O
with	O
chicken	O
anti	O
-	O
IBV	O
serum	O
.	O

ABSTRACT	O
:	O
Conventional	O
and	O
molecular	O
epidemiologic	O
studies	O
have	O
confirmed	O
the	O
ability	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
to	O
rapidly	O
evolve	O
and	O
successfully	O
circumvent	O
extensive	O
vaccination	O
programs	O
implemented	O
since	O
the	O
early	O
1950s	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
examined	O
changes	O
occurring	O
in	O
a	O
wild	O
Arkansas	O
(	O
Ark	O
)	O
challenge	O
strain	O
in	O
chickens	O
that	O
were	O
vaccinated	O
either	O
ocularly	O
with	O
commercially	O
available	O
attenuated	O
ArkDPI	O
-	O
derived	O
vaccines	O
or	O
in	O
ovo	O
with	O
a	O
replication	O
-	O
defective	O
recombinant	O
adenovirus	B-DISO
expressing	O
a	O
codon	O
-	O
optimized	O
IBV	O
Ark	O
S1	O
gene	O
(	O
AdArkIBV	O
.	O
S1	O
(	O
ck	O
)).	O

Subsequently	O
,	O
infections	B-DISO
with	O
this	O
genotype	O
were	O
found	O
in	O
several	O
other	O
European	O
countries	O
such	O
as	O
France	O
,	O
Italy	O
,	O
Germany	O
,	O
United	O
Kingdom	O
,	O
Slovenia	O
,	O
and	O
Sweden	O
.	O

Trauma	O
and	O
severe	O
inflammation	B-DISO
may	O
be	O
good	O
indications	O
for	O
en	O
masse	O
lobectomy	O
.	O

The	O
common	B-DISO
cold	I-DISO
and	O
otitis	B-DISO
media	I-DISO
are	O
two	O
such	O
disease	O
states	O
,	O
and	O
much	O
has	O
been	O
learned	O
about	O
the	O
various	O
effects	O
of	O
cytokines	O
in	O
each	O
disease	O
.	O

Real	O
time	O
PCR	O
,	O
DFA	O
and	O
cell	O
culture	O
method	O
were	O
used	O
for	O
detection	O
of	O
C	O
.	O
pneumoniae	O
,	O
RSV	O
antigen	O
and	O
influenza	B-DISO
virus	O
respectively	O
.	O

ABSTRACT	O
:	O
αB	O
-	O
crystallin	O
(	O
HspB5	O
)	O
is	O
a	O
chaperone	O
whose	O
role	O
as	O
a	O
marker	O
of	O
innate	O
immunity	O
activation	O
as	O
well	O
as	O
its	O
therapeutic	O
potential	O
have	O
recently	O
been	O
investigated	O
in	O
several	O
inflammatory	O
diseases	O
:	O
multiple	B-DISO
sclerosis	I-DISO
,	O
myocardial	B-DISO
ischemia	I-DISO
,	O
and	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
.	O

Forty	O
-	O
eight	O
patients	O
were	O
diagnosed	O
with	O
acute	O
inflammatory	O
respiratory	B-DISO
disease	I-DISO
.	O

The	O
mean	O
level	O
of	O
anti	O
-	O
αB	O
-	O
crystallin	O
antibodies	O
in	O
non	O
-	O
COPD	B-DISO
smokers	O
was	O
0	O
.	O
291	O
nm	O
.	O

RESULTS	O
:	O
The	O
mean	O
level	O
of	O
anti	O
-	O
αB	O
-	O
crystallin	O
antibodies	O
in	O
non	O
-	O
COPD	B-DISO
smokers	O
was	O
0	O
.	O
291	O
nm	O
.	O

When	O
used	O
in	O
early	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
NMBAs	O
assist	O
to	O
establish	O
a	O
lung	O
protective	O
strategy	O
,	O
which	O
leads	O
to	O
improved	O
oxygenation	O
,	O
decreased	O
pulmonary	O
and	O
systemic	O
inflammation	B-DISO
,	O
and	O
potentially	O
improved	O
mortality	O
.	O

It	O
also	O
is	O
increasingly	O
recognized	O
that	O
NMBAs	O
can	O
cause	O
harm	O
,	O
particularly	O
critical	B-DISO
illness	I-DISO
polyneuromyopathy	O
(	O
CIPM	O
),	O
when	O
used	O
for	O
prolonged	O
periods	O
or	O
in	O
septic	B-DISO
shock	I-DISO
.	O

The	O
use	O
of	O
the	O
prone	O
position	O
for	O
patients	O
with	O
traumatic	O
brain	O
injury	O
and	O
lung	O
impairment	B-DISO
has	O
been	O
reported	O
only	O
in	O
selected	O
cases	O
.	O

Here	O
we	O
report	O
our	O
experience	O
with	O
the	O
use	O
of	O
both	O
inhaled	O
nitric	O
oxide	O
and	O
the	O
prone	O
position	O
together	O
in	O
the	O
operating	O
room	O
in	O
a	O
patient	O
with	O
head	O
injury	O
and	O
ARDS	B-DISO
who	O
underwent	O
column	O
stabilization	O
.	O

Patients	O
with	O
severe	B-DISO
sepsis	I-DISO
(	O
N	O
=	O
20	O
)	O
and	O
septic	B-DISO
shock	I-DISO
(	O
N	O
=	O
10	O
)	O
were	O
compared	O
using	O
Fisher	O
'	O
s	O
Exact	O
and	O
Mann	O
-	O
Whitney	O
U	O
tests	O
.	O

A	O
total	O
of	O
640	O
SARS	B-DISO
patients	O
and	O
12	O
Chinese	O
herbs	O
were	O
identified	O
.	O

We	O
describe	O
here	O
the	O
clinical	O
and	O
virological	O
features	O
of	O
a	O
novel	O
coronavirus	B-DISO
infection	I-DISO
causing	O
severe	O
respiratory	O
illness	O
in	O
a	O
patient	O
transferred	O
to	O
London	O
,	O
United	O
Kingdom	O
,	O
from	O
the	O
Gulf	O
region	O
of	O
the	O
Middle	O
East	O
.	O

Current	O
guidelines	O
foresee	O
mandatory	O
vaccination	O
with	O
quadrivalent	O
meningococcal	O
vaccine	O
for	O
all	O
pilgrims	O
,	O
and	O
yellow	B-DISO
fever	I-DISO
and	O
poliomyelitis	B-DISO
vaccine	O
for	O
pilgrims	O
from	O
high	O
-	O
risk	O
countries	O
.	O

TITLE	O
:	O
Complete	O
genome	O
sequence	O
of	O
a	O
variant	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
strain	O
isolated	O
in	O
China	O
.	O

Here	O
we	O
report	O
the	O
complete	O
genome	O
sequence	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
strain	O
LC	O
,	O
which	O
was	O
recently	O
isolated	O
from	O
sucking	O
piglets	O
that	O
suffered	B-DISO
from	O
severe	O
watery	B-DISO
diarrhea	I-DISO
in	O
Guangdong	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
protein	O
N	O
-	O
terminal	O
domains	O
(	O
NTDs	O
)	O
of	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
and	O
mouse	B-DISO
hepatitis	I-DISO
coronavirus	O
(	O
MHV	O
)	O
recognize	O
sugar	O
and	O
protein	O
receptors	O
,	O
respectively	O
,	O
despite	O
their	O
significant	O
sequence	O
homology	O
.	O

Concomitantly	O
,	O
the	O
threat	O
of	O
epidemics	O
,	O
ranging	O
from	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
to	O
the	O
resurgence	O
of	O
vector	O
-	O
borne	O
diseases	O
as	O
well	O
as	O
the	O
rise	O
of	O
modern	O
lifestyle	O
-	O
related	O
outbreaks	O
,	O
have	O
worsened	O
difficulties	O
in	O
safeguarding	O
public	O
health	O
amidst	O
much	O
elusiveness	O
and	O
unpredictability	O
.	O

Positivity	O
only	O
for	O
influenza	B-DISO
A	O
virus	O
(	O
OR	O
=	O
4	O
.	O
3	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
3	O
-	O
14	O
.	O
6	O
)	O
was	O
significantly	O
associated	O
with	O
fatal	O
outcome	O
.	O

ABSTRACT	O
:	O
The	O
HIV	B-DISO
-	O
1	O
reverse	O
transcriptase	O
(	O
RT	O
)	O
is	O
one	O
of	O
the	O
most	O
attracting	O
targets	O
for	O
the	O
development	O
of	O
early	O
phase	O
infection	B-DISO
inhibitors	O
.	O

Although	O
many	O
RT	O
inhibitors	O
have	O
been	O
approved	O
for	O
the	O
treatment	O
of	O
HIV	B-DISO
-	I-DISO
1	I-DISO
infection	I-DISO
,	O
they	O
all	O
target	O
the	O
polymerase	O
function	O
of	O
this	O
enzyme	O
.	O

During	O
a	O
5	O
-	O
year	O
period	O
(	O
2004	O
-	O
2009	O
),	O
133	O
patients	O
with	O
severe	O
TBI	O
[	O
Glasgow	O
Coma	B-DISO
Scale	O
(	O
GCS	O
)	O
score	O
≤	O
8	O
]	O
were	O
prospectively	O
included	O
.	O

Hydrocortisone	O
(	O
100	O
mg	O
)	O
given	O
over	O
three	O
doses	O
,	O
each	O
eight	O
hours	O
apart	O
,	O
decreased	O
and	O
maintained	O
a	O
lower	O
degree	O
of	O
inflammation	B-DISO
with	O
bilateral	O
total	O
knee	O
replacement	O
as	O
measured	O
by	O
IL	O
-	O
6	O
level	O
.	O

DAMPs	O
can	O
function	O
as	O
either	O
toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
agonists	O
or	O
antagonists	O
,	O
and	O
can	O
modulate	O
both	O
TLR	O
and	O
nod	B-DISO
-	O
like	O
receptor	O
(	O
NLR	O
)	O
signalling	O
cascades	O
.	O

ABSTRACT	O
:	O
In	O
patients	O
with	O
the	O
most	O
severe	O
forms	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
refractory	O
to	O
conventional	O
mechanical	O
ventilation	O
and	O
adjunctive	O
or	O
rescue	O
therapies	O
like	O
kinetic	O
therapy	O
,	O
inhaled	O
vasodilators	O
or	O
extracorporeal	O
CO2	O
-	O
elimination	O
(	O
extracorporeal	O
lung	O
assist	O
),	O
the	O
use	O
of	O
the	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
can	O
secure	O
gas	O
exchange	O
.	O

Recent	O
data	O
suggests	O
,	O
that	O
outcome	O
of	O
patients	O
with	O
severe	O
ARDS	B-DISO
treated	O
with	O
ECMO	O
may	O
improve	O
.	O

The	O
incubation	O
period	O
helps	O
differential	O
diagnosis	O
,	O
and	O
up	O
to	O
two	O
days	O
is	O
suggestive	O
of	O
influenza	B-DISO
.	O

Based	O
on	O
these	O
premises	O
,	O
the	O
main	O
aim	O
of	O
this	O
report	O
was	O
to	O
assess	O
the	O
benefit	O
of	O
screening	O
for	O
impaired	B-DISO
glucose	I-DISO
tolerance	I-DISO
during	O
pregnancy	O
with	O
regard	O
to	O
patient	O
-	O
relevant	O
outcomes	O
.	O

the	O
relationship	O
between	O
the	O
results	O
of	O
an	O
oral	O
glucose	O
tolerance	B-DISO
test	O
(	O
oGTT	O
)	O
and	O
maternal	O
/	O
baby	O
outcomes	O
,	O
and	O
4	O
.	O

These	O
data	O
demonstrate	O
a	O
regulatory	O
role	O
for	O
EBI3	O
-	O
associated	O
cytokines	O
in	O
controlling	O
host	O
responses	O
following	O
CNS	O
viral	B-DISO
infection	I-DISO
.	O

This	O
study	O
provides	O
new	O
insight	O
for	O
designing	O
vaccine	O
and	O
therapeutic	O
reagents	O
against	O
coronavirus	B-DISO
infections	I-DISO
.	O

Particularly	O
in	O
high	O
incidence	O
regions	O
such	O
as	O
sub	O
-	O
Saharan	O
Africa	O
,	O
concurrent	O
infections	B-DISO
with	O
more	O
than	O
one	O
pathogen	O
represent	O
a	O
widely	O
underappreciated	O
public	O
health	O
problem	O
.	O

In	O
addition	O
to	O
respiratory	B-DISO
complications	I-DISO
,	O
several	O
complications	O
due	O
to	O
direct	O
and	O
indirect	O
effects	O
on	O
other	O
body	O
systems	O
were	O
associated	O
with	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pdm09	O
virus	B-DISO
infection	I-DISO
.	O

Pathological	O
studies	O
in	O
autopsy	O
specimens	O
indicated	O
that	O
the	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pdm09	O
virus	O
mainly	O
targeted	O
the	O
lower	O
respiratory	O
tract	O
,	O
resulting	O
in	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
(	O
edema	B-DISO
,	O
hyaline	B-DISO
membranes	I-DISO
,	O
inflammation	B-DISO
,	O
and	O
fibrosis	B-DISO
),	O
manifested	O
clinically	O
by	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
with	O
refractory	O
hypoxemia	O
.	O

Influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pdm09	O
ILI	O
rates	O
per	O
100	O
py	O
ranged	O
between	O
1	O
.	O
6	O
among	O
children	O
aged	O
<	O
5	O
to	O
17	O
.	O
1	O
among	O
persons	O
aged	O
45	O
-	O
64	O
years	O
.	O

TITLE	O
:	O
Reverse	O
transcription	O
-	O
loop	O
-	O
mediated	O
isothermal	O
amplification	B-DISO
for	O
the	O
detection	O
of	O
rodent	O
coronaviruses	O
.	O

A	O
reverse	O
transcription	O
-	O
loop	O
-	O
mediated	O
isothermal	O
amplification	B-DISO
(	O
RT	O
-	O
LAMP	O
)	O
technique	O
was	O
developed	O
for	O
the	O
detection	O
of	O
rodent	O
coronaviruses	O
within	O
90	O
min	O
.	O

ABSTRACT	O
:	O
The	O
degradative	O
activity	O
of	O
the	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
type	O
1	O
(	O
HIV	B-DISO
-	O
1	O
)	O
reverse	O
transcriptase	O
(	O
RT	O
),	O
termed	O
ribonuclease	O
H	O
(	O
RNase	O
H	O
),	O
which	O
hydrolyzes	O
the	O
RNA	O
component	O
of	O
the	O
heteroduplex	O
RNA	O
:	O
DNA	O
replication	O
intermediate	O
,	O
is	O
an	O
excellent	O
target	O
for	O
drug	O
discovery	O
.	O

We	O
have	O
assayed	O
new	O
AQ	O
derivatives	O
on	O
HIV	B-DISO
-	O
1	O
RNase	O
H	O
activities	O
in	O
biochemical	O
assays	O
.	O

Six	O
series	O
of	O
new	O
AQ	O
derivatives	O
with	O
various	O
substituents	O
at	O
positions	O
1	O
,	O
2	O
,	O
3	O
and	O
4	O
of	O
the	O
AQ	O
ring	O
were	O
tested	O
,	O
and	O
new	O
analogs	O
able	O
to	O
inhibit	O
HIV	B-DISO
-	O
1	O
RT	O
-	O
associated	O
RNase	O
H	O
activity	O
in	O
the	O
low	O
micromolar	O
range	O
were	O
found	O
.	O

RESULTS	O
:	O
The	O
limit	O
of	O
detection	O
(	O
LOD	O
)	O
was	O
1	O
.	O
31	O
plaque	B-DISO
-	O
forming	O
units	O
(	O
PFU	O
)/	O
mL	O
for	O
human	O
rhinoviruses	O
(	O
hRVs	O
),	O
4	O
.	O
93	O
PFU	O
/	O
mL	O
for	O
human	O
coronavirus	O
HCoV	O
-	O
229E	O
/	O
NL63	O
,	O
2	O
.	O
67	O
PFU	O
/	O
mL	O
for	O
human	O
coronavirus	O
HCoV	O
-	O
OC43	O
,	O
18	O
.	O
20	O
PFU	O
/	O
mL	O
for	O
parainfluenza	B-DISO
virus	O
1	O
(	O
PIV	O
)-	O
1	O
,	O
24	O
.	O
57	O
PFU	O
/	O
mL	O
for	O
PIV	O
-	O
2	O
,	O
1	O
.	O
73	O
PFU	O
/	O
mL	O
for	O
PIV	O
-	O
3	O
,	O
1	O
.	O
79	O
PFU	O
/	O
mL	O
for	O
influenza	B-DISO
virus	O
group	O
(	O
Flu	B-DISO
)	O
A	O
,	O
59	O
.	O
51	O
PFU	O
/	O
mL	O
for	O
FluB	O
,	O
5	O
.	O
46	O
PFU	O
/	O
mL	O
for	O
human	O
respiratory	O
syncytial	O
virus	O
(	O
hRSV	O
)-	O
A	O
,	O
17	O
.	O
23	O
PFU	O
/	O
mL	O
for	O
hRSV	O
-	O
B	O
,	O
9	O
.	O
99	O
PFU	O
/	O
mL	O
for	O
human	O
adenovirus	B-DISO
(	O
ADVs	O
).	O

ABSTRACT	O
:	O
Three	O
cases	O
of	O
acute	B-DISO
intermittent	I-DISO
porphyria	I-DISO
are	O
reported	O
.	O

In	O
addition	O
,	O
she	O
developed	O
severe	O
and	O
fluctuating	O
dysautonomia	B-DISO
leading	O
to	O
cardiac	B-DISO
arrest	I-DISO
and	O
fatal	O
termination	O
.	O

After	O
administering	O
chemotherapy	O
,	O
the	O
patient	O
developed	O
an	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

TITLE	O
:	O
Expected	O
and	O
observed	O
mortality	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
receiving	O
initial	O
antibiotic	O
therapy	O
.	O

The	O
low	O
incidence	O
of	O
complications	O
and	O
favorable	O
patient	O
'	O
s	O
satisfaction	O
suggest	O
that	O
non	O
-	O
stimulation	O
needle	O
with	O
an	O
external	O
indwelling	O
cannula	O
is	O
a	O
useful	O
and	O
safe	O
anesthetic	O
tool	O
in	O
brachial	O
nerve	O
block	O
and	O
acute	O
postoperative	B-DISO
pain	I-DISO
management	O
.	O

There	O
was	O
no	O
nerve	O
injury	O
related	O
complication	B-DISO
after	O
withdrawing	O
the	O
external	O
indwelling	O
catheter	O
.	O

TITLE	O
:	O
A	O
live	O
,	O
impaired	B-DISO
-	O
fidelity	O
coronavirus	O
vaccine	O
protects	O
in	O
an	O
aged	O
,	O
immunocompromised	O
mouse	O
model	O
of	O
lethal	O
disease	O
.	O

We	O
investigated	O
the	O
contribution	O
of	O
CXCL10	O
and	O
its	O
receptor	O
CXCR3	O
axis	O
to	O
the	O
pathogenesis	B-DISO
of	O
ARDS	B-DISO
with	O
nonviral	O
and	O
viral	O
origins	O
.	O

Histopathology	O
revealed	O
dermal	O
granulomatous	B-DISO
dermatitis	I-DISO
,	O
focally	O
suppurative	B-DISO
,	O
dominated	O
by	O
epitheloid	O
cells	O
with	O
brownish	O
round	O
fungi	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
Chaiqinchengqi	O
decoction	O
(	O
CQCQD	O
)	O
on	O
serum	O
amyloid	B-DISO
A	O
(	O
SAA	O
)	O
in	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
(	O
SAP	O
)	O
patients	O
.	O

Our	O
findings	O
suggest	O
that	O
a	O
novel	O
PEDV	O
with	O
a	O
characteristic	O
variant	O
S	O
gene	O
is	O
responsible	O
for	O
recent	O
outbreaks	O
of	O
clinical	O
diarrhea	B-DISO
in	O
piglets	O
in	O
China	O
.	O

None	O
of	O
patients	O
without	O
cirrhosis	B-DISO
died	O
.	O

Severe	O
hyperkalemia	O
and	O
the	O
development	O
of	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
require	O
urgent	O
therapeutic	O
measures	O
,	O
which	O
imply	O
the	O
application	O
of	O
either	O
conventional	O
treatment	O
or	O
a	O
form	O
of	O
dialysis	O
.	O

The	O
routine	O
laboratory	O
diagnostics	O
,	O
which	O
implies	O
determining	O
of	O
the	O
levels	O
of	O
potassium	O
,	O
urea	O
,	O
creatinine	O
and	O
CK	O
in	O
the	O
serum	O
of	O
all	O
hospitalized	O
heroin	O
addicts	O
can	O
contribute	O
to	O
timely	O
detection	O
of	O
hyperkalemia	O
and	O
acute	O
kidney	O
weakness	B-DISO
and	O
undertaking	O
of	O
appropriate	O
therapeutic	O
measures	O
.	O

CONCLUSIONS	O
:	O
The	O
routine	O
laboratory	O
diagnostics	O
,	O
which	O
implies	O
determining	O
of	O
the	O
levels	O
of	O
potassium	O
,	O
urea	O
,	O
creatinine	O
and	O
CK	O
in	O
the	O
serum	O
of	O
all	O
hospitalized	O
heroin	O
addicts	O
can	O
contribute	O
to	O
timely	O
detection	O
of	O
hyperkalemia	O
and	O
acute	O
kidney	O
weakness	B-DISO
and	O
undertaking	O
of	O
appropriate	O
therapeutic	O
measures	O
.	O

An	O
emergency	B-DISO
operation	O
of	O
mediastinum	O
drainage	O
by	O
thoracotomy	O
was	O
performed	O
.	O

ABSTRACT	O
:	O
Abdominal	B-DISO
compartment	I-DISO
syndrome	I-DISO
is	O
an	O
under	O
-	O
recognized	O
cause	O
of	O
acute	O
kidney	O
injury	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

Infection	B-DISO
was	O
documented	O
in	O
3	O
cases	O
,	O
hyperbilirubinemia	B-DISO
in	O
2	O
cases	O
,	O
lower	B-DISO
limb	I-DISO
ischemia	I-DISO
in	O
1	O
case	O
,	O
hyperglycemia	B-DISO
in	O
3	O
cases	O
,	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
in	O
1	O
case	O
,	O
membrane	O
lung	O
leakage	B-DISO
in	O
2	O
cases	O
,	O
systemic	O
hemolysis	B-DISO
in	O
3	O
cases	O
,	O
oxygenator	O
failure	O
in	O
2	O
cases	O
and	O
oxygenator	O
thrombosis	B-DISO
in	O
one	O
case	O
.	O

During	O
the	O
follow	O
-	O
up	O
between	O
6	O
months	O
and	O
4	O
.	O
5	O
years	O
,	O
5	O
patients	O
survived	O
with	O
good	O
quality	O
of	O
life	O
,	O
without	O
any	O
documented	O
central	B-DISO
nervous	I-DISO
system	I-DISO
disorders	I-DISO
.	O

CONCLUSIONS	O
:	O
ECMO	O
is	O
a	O
justifiable	O
alternative	O
treatment	O
for	O
reversible	O
severe	O
cardiopulmonary	B-DISO
failure	I-DISO
in	O
critically	B-DISO
ill	I-DISO
children	O
.	O

Two	O
patients	O
were	O
also	O
suffering	B-DISO
from	O
the	O
Currarino	B-DISO
syndrome	I-DISO
associated	O
with	O
Hirschsprung	B-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
and	O
other	O
,	O
multiple	O
malformations	B-DISO
and	O
a	O
cloacal	O
anomaly	O
with	O
anal	O
imperforation	O
,	O
respectively	O
.	O

Being	O
congenital	O
tumors	B-DISO
,	O
prenatal	O
diagnosis	O
by	O
US	O
scan	O
is	O
extremely	O
important	O
in	O
order	O
to	O
decide	O
either	O
for	O
an	O
anticipated	O
delivery	O
or	O
to	O
perform	O
,	O
in	O
critical	O
fetuses	O
,	O
prenatal	O
treatment	O
within	O
highly	O
specialized	O
facilities	O
,	O
or	O
to	O
organize	O
proper	O
perinatal	O
care	O
,	O
always	O
in	O
appropriate	O
facilities	O
where	O
it	O
is	O
possible	O
to	O
define	O
the	O
diagnosis	O
and	O
carry	O
out	O
emergency	B-DISO
surgery	O
.	O

The	O
major	O
clinical	O
symptoms	O
associated	O
with	O
HCoV	O
-	O
HKU1	O
infection	B-DISO
were	O
examined	O
statistically	O
and	O
sequence	O
variations	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
),	O
spike	O
,	O
and	O
nucleocapsid	O
genes	O
were	O
also	O
analyzed	O
.	O

Thirty	O
-	O
five	O
of	O
the	O
patients	O
had	O
a	O
positive	O
malaria	B-DISO
blood	O
smear	O
.	O

CPAP	O
decreases	O
respiratory	O
rate	O
in	O
children	O
with	O
respiratory	B-DISO
distress	I-DISO
compared	O
with	O
children	O
not	O
receiving	O
CPAP	O
.	O

CPAP	O
is	O
a	O
relatively	O
low	O
-	O
cost	O
,	O
low	O
-	O
technology	O
that	O
is	O
a	O
safe	O
method	O
to	O
decrease	O
respiratory	O
rate	O
in	O
children	O
with	O
nonspecific	O
respiratory	B-DISO
distress	I-DISO
.	O

Here	O
we	O
reported	O
the	O
complete	O
genomic	O
sequence	O
of	O
the	O
IBV	O
-	O
YX10	O
which	O
was	O
a	O
natural	O
recombinant	O
nephropathogenic	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
strain	O
.	O

ABSTRACT	O
:	O
In	O
recent	O
years	O
,	O
acute	O
outbreaks	O
of	O
epizootic	O
diarrhea	B-DISO
have	O
occurred	O
on	O
many	O
swine	O
farms	O
in	O
China	O
.	O

ABSTRACT	O
:	O
Limited	O
information	O
exists	O
about	O
influenza	B-DISO
viruses	O
in	O
Africa	O
.	O

Seasonal	O
influenza	B-DISO
virus	B-DISO
infection	I-DISO
was	O
found	O
to	O
be	O
associated	O
with	O
both	O
mild	O
and	O
severe	O
respiratory	O
illness	O
in	O
Zambia	O
.	O

HCoV	O
-	O
EMC	B-DISO
/	O
2012	O
may	O
be	O
most	O
closely	O
related	O
to	O
a	O
coronavirus	O
detected	O
in	O
Pipistrellus	O
pipistrellus	O
in	O
The	O
Netherlands	O
,	O
but	O
because	O
only	O
a	O
short	O
sequence	O
from	O
the	O
most	O
conserved	O
part	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
-	O
encoding	O
region	O
of	O
the	O
genome	O
was	O
reported	O
for	O
this	O
bat	O
virus	O
,	O
its	O
genetic	O
distance	O
from	O
HCoV	O
-	O
EMC	B-DISO
remains	O
uncertain	O
.	O

We	O
have	O
determined	O
the	O
complete	O
genome	O
of	O
HCoV	O
-	O
EMC	B-DISO
/	O
2012	O
using	O
an	O
unbiased	O
virus	O
discovery	O
approach	O
involving	O
next	O
-	O
generation	O
sequencing	O
techniques	O
,	O
which	O
enabled	O
subsequent	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
bioinformatics	O
,	O
phylogenetics	O
,	O
and	O
taxonomic	O
analyses	O
.	O

Supportive	O
measures	O
including	O
protective	O
lung	O
ventilation	O
confer	O
a	O
survival	O
advantage	O
in	O
patients	O
with	O
ARDS	B-DISO
,	O
but	O
management	O
is	O
otherwise	O
limited	O
by	O
the	O
lack	O
of	O
effective	O
pharmacological	O
therapies	O
.	O

Crucially	O
,	O
the	O
mechanism	O
of	O
lung	O
injury	O
in	O
neonates	O
is	O
different	O
from	O
that	O
in	O
ARDS	B-DISO
:	O
surfactant	O
inhibition	O
by	O
plasma	O
constituents	O
is	O
a	O
typical	O
feature	O
of	O
ARDS	B-DISO
,	O
whereas	O
the	O
primary	O
pathology	B-DISO
in	O
neonates	O
is	O
the	O
deficiency	O
of	O
surfactant	O
material	O
due	O
to	O
reduced	O
synthesis	O
.	O

The	O
YN	O
isolate	O
caused	O
severe	O
lesions	O
and	O
resulted	O
in	O
deaths	O
of	O
65	O
%	O
in	O
experimental	O
infections	B-DISO
of	O
30	O
-	O
day	O
-	O
old	O
specific	O
-	O
pathogen	O
-	O
free	O
chickens	O
.	O

Tracheal	O
and	O
severe	O
kidney	O
lesions	O
developed	O
in	O
all	O
infected	O
birds	O
,	O
confirming	O
the	O
ability	O
of	O
YN	O
strain	O
to	O
induce	O
both	O
respiratory	O
and	O
renal	B-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
Previous	O
studies	O
have	O
reported	O
that	O
a	O
prokaryotic	O
-	O
expressed	O
recombinant	O
nucleocapsid	O
protein	O
(	O
NP	O
)	O
is	O
a	O
suitable	O
reagent	O
for	O
the	O
epidemiological	O
screening	O
of	O
coronavirus	B-DISO
infection	I-DISO
.	O

Sera	O
from	O
26	O
young	O
adults	O
,	O
17	O
middle	O
-	O
aged	O
and	O
elderly	O
patients	O
with	O
respiratory	B-DISO
infection	I-DISO
,	O
and	O
15	O
cord	B-DISO
blood	O
samples	O
were	O
also	O
tested	O
.	O

Three	O
different	O
patterns	O
for	O
the	O
immunoreactivities	O
of	O
the	O
three	O
structural	O
regions	O
of	O
HCoV	O
-	O
OC43	O
NP	O
were	O
observed	O
in	O
human	O
serum	O
,	O
suggesting	O
variability	O
in	O
the	O
immune	O
responses	O
that	O
occur	O
during	O
HCoV	O
-	O
OC43	O
infection	B-DISO
in	O
humans	O
.	O

Despite	O
therapy	O
,	O
the	O
patient	O
developed	O
disseminated	O
intravascular	O
coagulopathy	B-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

IBV	O
Gray	O
strain	O
infection	B-DISO
of	O
MHC	O
homozygous	O
B12	O
and	O
B19	O
haplotype	O
chicks	O
resulted	O
in	O
severe	O
respiratory	B-DISO
disease	I-DISO
compared	O
to	O
chicks	O
with	O
B2	O
/	O
B2	O
and	O
B5	O
/	O
B5	O
haplotypes	O
.	O

mRNA	O
expression	O
for	O
selected	O
markers	O
of	O
viral	B-DISO
infection	I-DISO
was	O
measured	O
using	O
RT	O
-	O
PCR	O
.	O

Viral	B-DISO
infections	I-DISO
were	O
detected	O
in	O
3	O
of	O
the	O
'	O
well	O
'	O
weeks	O
and	O
17	O
of	O
the	O
'	O
sick	O
'	O
weeks	O
(	O
10	O
rhinovirus	O
,	O
three	O
coronavirus	O
,	O
two	O
influenza	B-DISO
A	O
,	O
two	O
influenza	B-DISO
B	O
,	O
two	O
respiratory	O
syncytial	O
virus	O
,	O
one	O
parainfluenza	B-DISO
).	O

TITLE	O
:	O
Ezrin	O
interacts	O
with	O
the	O
SARS	B-DISO
coronavirus	O
Spike	O
protein	O
and	O
restrains	O
infection	B-DISO
at	O
the	O
entry	O
stage	O
.	O

TITLE	O
:	O
Human	O
monoclonal	O
antibodies	O
against	O
highly	O
conserved	O
HR1	O
and	O
HR2	O
domains	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
are	O
more	O
broadly	O
neutralizing	O
.	O

These	O
data	O
indicate	O
that	O
HmAbs	O
which	O
bind	O
to	O
conserved	O
regions	O
of	O
the	O
S	O
protein	O
are	O
more	O
suitable	O
for	O
conferring	O
protection	O
against	O
a	O
wide	O
range	O
of	O
SARS	B-DISO
-	O
CoV	O
variants	O
and	O
have	O
implications	O
for	O
generating	O
therapeutic	O
antibodies	O
or	O
subunit	O
vaccines	O
against	O
other	O
enveloped	O
viruses	O
.	O

A	O
respiratory	O
virus	O
was	O
detected	O
in	O
193	O
(	O
76	O
%)	O
patients	O
;	O
156	O
(	O
81	O
%)	O
patients	O
had	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
.	O

RESULTS	O
:	O
:	O
We	O
enrolled	O
253	O
children	O
with	O
upper	O
or	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
(	O
LRTI	B-DISO
)	O
during	O
a	O
1	O
-	O
year	O
period	O
.	O

TITLE	O
:	O
Patient	O
-	O
ventilator	O
interaction	O
in	O
ARDS	B-DISO
patients	O
with	O
extremely	O
low	O
compliance	O
undergoing	O
ECMO	O
:	O
a	O
novel	O
approach	O
based	O
on	O
diaphragm	O
electrical	O
activity	O
.	O

Life	O
expectancy	O
soared	O
by	O
around	O
30	O
years	O
,	O
infant	O
mortality	O
plummeted	O
and	O
smallpox	B-DISO
,	O
sexually	B-DISO
transmitted	I-DISO
diseases	I-DISO
and	O
many	O
other	O
infections	B-DISO
were	O
either	O
eliminated	O
or	O
decreased	O
massively	O
in	O
incidence	O
,	O
largely	O
as	O
a	O
result	O
of	O
CDC	O
.	O

In	O
addition	O
,	O
China	O
'	O
s	O
laissez	O
-	O
faire	O
approach	O
to	O
public	O
health	O
placed	O
it	O
at	O
great	O
risk	O
,	O
as	O
evidenced	O
by	O
the	O
outbreak	O
in	O
2003	O
of	O
the	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
.	O

CHDF	O
and	O
PMX	O
hemoperfusion	O
are	O
possible	O
candidates	O
for	O
effective	O
treatment	O
of	O
ARDS	B-DISO
with	O
H5N1	B-DISO
if	O
applied	O
earlier	O
.	O

It	O
has	O
been	O
previously	O
shown	O
that	O
HCoV	O
-	O
NL63	O
is	O
also	O
one	O
of	O
the	O
most	O
important	O
causes	O
of	O
croup	B-DISO
in	O
children	O
.	O

In	O
2002	O
-	O
2003	O
,	O
the	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
due	O
to	O
a	O
newly	O
discovered	O
coronavirus	O
,	O
the	O
SARS	B-DISO
-	I-DISO
associated	I-DISO
coronavirus	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
);	O
led	O
to	O
a	O
new	O
awareness	O
of	O
the	O
medical	O
importance	O
of	O
the	O
Coronaviridae	O
family	O
.	O

This	O
pathogen	O
,	O
responsible	O
for	O
an	O
emerging	O
disease	O
in	O
humans	O
,	O
with	O
high	O
risk	O
of	O
fatal	O
outcome	O
;	O
underline	O
the	O
pressing	O
need	O
for	O
new	O
approaches	O
to	O
the	O
management	O
of	O
the	O
infection	B-DISO
,	O
and	O
primarily	O
to	O
its	O
prevention	O
.	O

Double	O
-	O
stranded	O
RNA	O
,	O
presumably	O
functioning	O
as	O
replicative	O
intermediate	O
during	O
viral	O
RNA	O
synthesis	O
,	O
has	O
been	O
detected	O
at	O
the	O
double	O
-	O
membrane	O
vesicle	B-DISO
interior	O
.	O

TITLE	O
:	O
Sequencing	O
,	O
phylogenetic	O
analysis	O
,	O
and	O
potential	O
recombination	O
events	O
of	O
infectious	B-DISO
bronchitis	B-DISO
viruses	O
isolated	O
in	O
Korea	O
.	O

Little	O
is	O
known	O
about	O
the	O
different	O
phenotypes	O
of	O
patients	O
with	O
BOS	B-DISO
and	O
their	O
outcomes	O
.	O

We	O
identified	O
103	O
patients	O
(	O
BOS	B-DISO
(	O
n	O
=	O
77	O
),	O
asthma	B-DISO
(	O
n	O
=	O
11	O
)	O
and	O
chronic	B-DISO
bronchitis	I-DISO
(	O
n	O
=	O
15	O
)).	O

TITLE	O
:	O
Characteristics	O
and	O
outcome	O
of	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
2009	O
H1N1	B-DISO
influenza	I-DISO
infection	B-DISO
in	O
Syria	O
.	O

Retrospectively	O
,	O
we	O
collected	O
clinical	O
data	O
on	O
all	O
patients	O
who	O
were	O
admitted	O
to	O
the	O
ICU	O
with	O
confirmed	O
or	O
suspected	O
diagnosis	O
of	O
severe	O
2009	O
H1N1	B-DISO
influenza	I-DISO
A	O
with	O
respiratory	B-DISO
failure	I-DISO
at	O
4	O
major	O
tertiary	O
care	O
hospitals	O
in	O
Damascus	O
,	O
Syria	O
.	O

ABSTRACT	O
:	O
Inoculation	O
with	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
into	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
of	O
susceptible	O
strains	O
of	O
mice	O
results	O
in	O
an	O
acute	O
encephalomyelitis	B-DISO
in	O
which	O
virus	O
preferentially	O
replicates	O
within	O
glial	O
cells	O
while	O
excluding	O
neurons	O
.	O

Currently	O
,	O
there	O
is	O
no	O
specific	O
treatment	O
approved	O
for	O
FIP	B-DISO
despite	O
the	O
importance	O
of	O
FIP	B-DISO
as	O
the	O
leading	O
infectious	B-DISO
cause	O
of	O
death	O
in	O
young	O
cats	O
.	O

Previously	O
,	O
we	O
reported	O
the	O
generation	O
of	O
broad	O
-	O
spectrum	O
peptidyl	O
inhibitors	O
against	O
viruses	O
that	O
possess	B-DISO
a	O
3C	O
or	O
3CL	O
protease	O
.	O

The	O
technique	O
relies	O
on	O
the	O
addition	O
of	O
synthetic	O
oligonucleotides	O
to	O
both	O
termini	O
of	O
RNA	O
fragments	O
in	O
a	O
sequence	O
-	O
dependent	O
manner	O
during	O
first	O
-	O
and	O
second	O
-	O
strand	O
DNA	O
synthesis	O
;	O
these	O
oligonucleotides	O
are	O
used	O
subsequently	O
for	O
amplification	B-DISO
of	O
the	O
viral	O
nucleic	O
acids	O
of	O
interest	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
is	O
a	O
common	O
complication	B-DISO
after	O
severe	O
trauma	O
,	O
which	O
predisposes	O
patients	O
to	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
.	O

Pathological	O
examinations	O
showed	O
that	O
lungs	O
were	O
the	O
predominantly	O
affected	O
organ	O
with	O
edema	B-DISO
,	O
hemorrhage	B-DISO
,	O
microvascular	O
thrombosis	B-DISO
,	O
and	O
neutrophil	O
congestion	B-DISO
.	O

In	O
severe	B-DISO
sepsis	I-DISO
and	O
septic	B-DISO
shock	I-DISO
should	O
be	O
early	O
goal	O
-	O
directed	O
resuscitation	O
of	O
the	O
septic	O
patient	O
during	O
the	O
first	O
6	O
hrs	B-DISO
after	O
recognition	O
;	O
-	O
appropriate	O
diagnostic	O
studies	O
to	O
ascertain	O
causative	O
organisms	O
before	O
starting	O
antibiotics	O
;	O
-	O
early	O
administration	O
of	O
broad	O
-	O
spectrum	O
antibiotic	O
therapy	O
;	O
-	O
reassessment	O
of	O
antibiotic	O
therapy	O
with	O
microbiology	O
and	O
clinical	O
data	O
to	O
narrow	O
coverage	O
,	O
when	O
appropriate	O
;	O
-	O
a	O
usual	O
7	O
-	O
10	O
days	O
of	O
antibiotic	O
therapy	O
guided	O
by	O
clinical	O
response	O
;	O
-	O
source	O
control	O
with	O
attention	O
to	O
the	O
method	O
that	O
balances	O
risks	O
and	O
benefits	O
;	O
-	O
equivalence	O
of	O
crystalloid	O
and	O
colloid	O
resuscitation	O
;	O
aggressive	B-DISO
fluid	O
challenge	O
to	O
restore	O
mean	O
circulating	O
filling	O
pressure	O
;	O
-	O
vasopressor	O
preference	O
for	O
norepinephrine	O
and	O
dopamine	O
;	O
-	O
cautious	O
use	O
of	O
vasopressin	O
pending	O
further	O
studies	O
;	O
-	O
avoiding	O
low	O
-	O
dose	O
dopamine	O
administration	O
for	O
renal	O
protection	O
;	O
consideration	O
of	O
dobutamine	O
inotropic	O
therapy	O
in	O
some	O
clinical	O
situations	O
;	O
-	O
stress	O
-	O
dose	O
steroid	O
therapy	O
for	O
septic	B-DISO
shock	I-DISO
;	O
use	O
of	O
recombinant	O
activated	O
protein	O
C	O
in	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
and	O
high	O
risk	O
for	O
death	O
;	O
-	O
with	O
resolution	O
of	O
tissue	O
hypoperfusion	O
and	O
in	O
the	O
absence	O
of	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
or	O
acute	B-DISO
hemorrhage	I-DISO
,	O
targeting	O
a	O
hemoglobin	O
of	O
7	O
-	O
9	O
g	O
/	O
dL	O
;	O
-	O
a	O
low	O
tidal	O
volume	O
and	O
limitation	O
of	O
inspiratory	O
plateau	O
pressure	O
strategy	O
for	O
acute	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
;	O
-	O
application	O
of	O
a	O
minimal	O
amount	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
in	O
acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
;	O
-	O
protocols	O
for	O
weaning	O
and	O
sedation	B-DISO
,	O
using	O
either	O
intermittent	O
bolus	O
sedation	B-DISO
or	O
continuous	O
infusion	O
sedation	B-DISO
with	O
daily	O
interruptions	O
/	O
lightening	O
;	O
-	O
avoidance	O
of	O
neuromuscular	O
blockers	O
,	O
if	O
at	O
all	O
possible	O
;	O
-	O
maintenance	O
of	O
blood	O
glucose	O
<	O
150	O
mg	O
/	O
dL	O
after	O
initial	O
stabilization	O
.	O

Several	O
gammacoronaviruses	O
including	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
contain	O
a	O
putative	O
open	O
reading	O
frame	O
(	O
ORF	O
),	O
localized	O
between	O
the	O
M	O
gene	O
and	O
gene	O
5	O
,	O
which	O
is	O
controversial	O
due	O
to	O
the	O
perceived	O
absence	O
of	O
a	O
TRS	B-DISO
.	O

The	O
trachea	B-DISO
and	O
the	O
spleen	O
can	O
be	O
used	O
as	O
references	O
for	O
histological	O
diagnosis	O
,	O
but	O
they	O
are	O
not	O
suitable	O
for	O
antigen	O
detection	O
;	O
proventriculus	O
might	O
be	O
an	O
important	O
target	O
in	O
IBV	O
infection	B-DISO
;	O
the	O
thymus	O
and	O
the	O
bursa	O
of	O
Fabricius	O
were	O
not	O
sensitive	O
organs	O
in	O
IBV	O
infection	B-DISO
.	O

In	O
toddlers	O
,	O
it	O
may	O
lead	O
to	O
acute	O
gastric	B-DISO
dilatation	I-DISO
,	O
which	O
,	O
if	O
severe	O
enough	O
,	O
may	O
lead	O
to	O
respiratory	B-DISO
distress	I-DISO
.	O

Multivariate	O
logistic	O
regression	O
analysis	O
found	O
that	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
score	O
,	O
solid	B-DISO
tumor	I-DISO
,	O
severe	B-DISO
sepsis	I-DISO
/	O
septic	B-DISO
shock	I-DISO
,	O
acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
and	O
acute	O
kidney	O
injury	O
were	O
independent	O
risk	O
factors	O
for	O
hospital	O
mortality	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
therapy	O
for	O
patients	O
with	O
influenza	B-DISO
A	O
(	O
H1N1	O
)-	O
related	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
has	O
been	O
described	O
once	O
all	O
other	O
therapeutic	O
options	O
have	O
been	O
exhausted	B-DISO
.	O

ABSTRACT	O
:	O
A	O
high	O
-	O
throughput	O
screen	O
of	O
the	O
NIH	O
molecular	O
libraries	O
sample	O
collection	O
and	O
subsequent	O
optimization	O
of	O
a	O
lead	O
dipeptide	O
-	O
like	O
series	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
main	O
protease	O
(	O
3CLpro	O
)	O
inhibitors	O
led	O
to	O
the	O
identification	O
of	O
probe	O
compound	O
ML188	O
(	O
16	O
-(	O
R	O
),	O
(	O
R	O
)-	O
N	O
-(	O
4	O
-(	O
tert	O
-	O
butyl	O
)	O
phenyl	O
)-	O
N	O
-(	O
2	O
-(	O
tert	O
-	O
butylamino	O
)-	O
2	O
-	O
oxo	O
-	O
1	O
-(	O
pyridin	O
-	O
3	O
-	O
yl	O
)	O
ethyl	O
)	O
furan	O
-	O
2	O
-	O
carboxamide	O
,	O
Pubchem	O
CID	O
:	O
46897844	O
).	O

Our	O
patient	O
presented	O
,	O
as	O
did	O
2	O
prior	O
cases	O
,	O
with	O
severe	O
pneumonia	B-DISO
and	O
renal	O
dysfunction	O
requiring	O
intensive	O
care	O
support	O
including	O
assisted	O
ventilation	O
.	O

As	O
human	O
CoV	O
normally	O
cannot	O
replicate	O
in	O
bat	O
cells	O
from	O
different	O
families	O
,	O
this	O
suggests	O
that	O
hCoV	O
-	O
EMC	B-DISO
might	O
use	O
a	O
receptor	O
molecule	O
that	O
is	O
conserved	O
in	O
bats	O
,	O
pigs	O
,	O
and	O
humans	O
,	O
implicating	O
a	O
low	O
barrier	O
against	O
cross	O
-	O
host	O
transmission	O
.	O

The	O
disease	O
resembled	O
SARS	B-DISO
(	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
),	O
causing	O
a	O
fatal	O
epidemic	O
in	O
2002	O
/	O
2003	O
.	O

Our	O
data	O
show	O
that	O
hCoV	O
-	O
EMC	B-DISO
does	O
not	O
need	O
the	O
SARS	B-DISO
-	O
CoV	O
receptor	O
to	O
infect	O
human	O
cells	O
.	O

TITLE	O
:	O
[	O
Myasthenic	B-DISO
crisis	I-DISO
and	O
Takotsubo	B-DISO
syndrome	I-DISO
:	O
a	O
non	O
-	O
chance	O
relationship	O
].	O

An	O
echocardiography	O
scan	O
showed	O
severe	O
ventricular	B-DISO
dysfunction	I-DISO
with	O
apical	O
dyskinesia	B-DISO
.	O

Unfortunately	O
,	O
amantadine	O
forfeited	O
most	O
of	O
its	O
therapeutic	O
potential	O
because	O
of	O
resistance	O
development	O
in	O
recent	O
influenza	B-DISO
A	O
virus	O
isolates	O
.	O

TITLE	O
:	O
[	O
Clinical	O
and	O
laboratory	O
profile	O
of	O
Plasmodium	B-DISO
vivax	I-DISO
malaria	I-DISO
patients	O
hospitalized	O
in	O
Apartadó	O
,	O
Colombia	O
].	O

Only	O
4	O
.	O
82	O
%	O
(	O
4	O
/	O
83	O
)	O
of	O
patients	O
with	O
complicated	B-DISO
malaria	I-DISO
were	O
treated	O
with	O
intravenous	O
quinine	O
,	O
no	O
one	O
died	O
.	O

The	O
decision	O
of	O
when	O
to	O
start	O
HFOV	O
in	O
the	O
pediatric	O
burn	O
victim	O
with	O
ARDS	B-DISO
is	O
debatable	O
.	O

The	O
relationships	O
between	O
swapping	O
kinetics	O
and	O
folding	O
/	O
unfolding	O
thermodynamics	O
were	O
established	O
,	O
which	O
were	O
further	O
adopted	O
as	O
criteria	O
to	O
show	O
that	O
the	O
proposed	O
mechanism	O
dominates	O
in	O
three	O
representative	O
proteins	O
:	O
Cyanovirin	O
-	O
N	O
(	O
CV	O
-	O
N	O
),	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
SARS	B-DISO
-	O
CoV	O
main	O
protease	O
(	O
M	O
(	O
pro	O
)-	O
C	O
),	O
and	O
a	O
single	O
mutant	B-DISO
of	O
oxidized	O
thioredoxin	O
(	O
Trx_W28A	O
(	O
ox	O
)).	O

ABSTRACT	O
:	O
Human	O
metapneumovirus	O
(	O
hMPV	O
)	O
is	O
considered	O
an	O
important	O
cause	O
of	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
A	O
mouse	O
-	O
adapted	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
,	O
MK	O
-	O
p10	O
,	O
showed	O
higher	O
neurovirulence	O
in	O
suckling	O
mice	O
than	O
a	O
non	O
-	O
adapted	O
MK	O
strain	O
.	O

In	O
this	O
study	O
we	O
focussed	O
on	O
NK	O
cell	O
and	O
interferon	O
(	O
IFN	O
)	O
responses	O
after	O
infection	B-DISO
with	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
).	O

ABSTRACT	O
:	O
Acute	O
viral	O
respiratory	B-DISO
infections	I-DISO
are	O
an	O
important	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
humans	O
worldwide	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
prevalence	O
of	O
human	O
coronavirus	B-DISO
infections	I-DISO
in	O
a	O
series	O
of	O
children	O
hospitalized	O
with	O
symptoms	O
of	O
acute	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
in	O
a	O
one	O
-	O
year	O
period	O
in	O
Slovenia	O
.	O

ABSTRACT	O
:	O
Intra	B-DISO
-	I-DISO
abdominal	I-DISO
hypertension	I-DISO
is	O
frequent	O
in	O
surgical	O
and	O
medical	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
causes	O
diarrhea	B-DISO
of	O
pigs	O
age	O
-	O
independently	O
and	O
death	O
of	O
young	O
piglets	O
,	O
resulting	O
in	O
economic	O
loss	O
of	O
porcine	O
industry	O
.	O

TITLE	O
:	O
Multiplex	O
nested	O
RT	O
-	O
PCR	O
for	O
detecting	O
avian	B-DISO
influenza	I-DISO
virus	O
,	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
and	O
Newcastle	B-DISO
disease	I-DISO
virus	O
.	O

In	O
short	O
,	O
our	O
study	O
identified	O
DN	O
T	O
cells	O
contributing	O
to	O
viral	O
persistence	O
in	O
MHV	O
-	O
3	O
induced	O
hepatitis	B-DISO
in	O
C3H	O
/	O
HeJ	O
mice	O
,	O
which	O
provides	O
a	O
rationale	O
for	O
modulating	O
DN	O
T	O
cells	O
for	O
the	O
management	O
of	O
viral	B-DISO
hepatitis	I-DISO
.	O

ABSTRACT	O
:	O
The	O
management	O
of	O
hypoxemia	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
is	O
challenging	O
.	O

This	O
review	O
sets	O
out	O
to	O
discuss	O
the	O
strengths	O
and	O
limitations	O
of	O
precise	O
control	O
of	O
arterial	O
oxygenation	O
and	O
permissive	O
hypoxemia	O
as	O
candidate	O
management	O
strategies	O
in	O
hypoxemic	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

We	O
searched	O
PubMed	O
for	O
references	O
to	O
""""	O
permissive	O
hypoxemia	O
/	O
hypoxaemia	O
""""	O
and	O
""""	O
precise	O
control	O
of	O
arterial	O
oxygenation	O
""""	O
as	O
well	O
as	O
reference	O
to	O
""""	O
profound	O
hypoxemia	O
/	O
hypoxaemia	O
/	O
hypoxia	B-DISO
","""	O
""""	O
severe	O
hypoxemia	O
/	O
hypoxaemia	O
/	O
hypoxia	B-DISO
.	O

ABSTRACT	O
:	O
Protection	O
of	O
the	O
human	O
lung	O
from	O
infectious	B-DISO
agents	O
,	O
allergens	O
,	O
and	O
ultrafine	O
particles	O
is	O
difficult	O
with	O
current	O
technologies	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
focus	O
on	O
the	O
public	O
health	O
implications	O
of	O
bat	O
derived	O
zoonotic	O
viral	B-DISO
disease	I-DISO
outbreaks	O
,	O
examine	O
the	O
drivers	O
and	O
risk	O
factors	O
of	O
past	O
disease	O
outbreaks	O
and	O
outline	O
research	O
directions	O
for	O
better	O
control	O
of	O
future	O
disease	O
events	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
successfully	O
established	O
a	O
mouse	O
model	O
of	O
hepatic	B-DISO
steatosis	I-DISO
induced	O
by	O
chronic	B-DISO
viral	I-DISO
hepatitis	I-DISO
,	O
which	O
provides	O
the	O
basis	O
for	O
further	O
study	O
of	O
the	O
disease	O
mechanism	O
.	O

Analysis	O
of	O
mutant	B-DISO
viruses	O
resistant	O
to	O
neutralization	O
by	O
4H4	O
revealed	O
that	O
the	O
antigenic	O
site	O
of	O
the	O
Kakegawa	O
strain	O
maps	O
to	O
amino	O
acid	O
position	O
284	O
of	O
the	O
S	O
glycoprotein	O
.	O

CCL2	O
has	O
been	O
implicated	O
in	O
both	O
proinflammatory	O
and	O
anti	O
-	O
inflammatory	B-DISO
responses	I-DISO
and	O
has	O
been	O
suggested	O
as	O
a	O
target	O
for	O
therapy	O
in	O
some	O
inflammatory	O
disorders	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
nsp1	O
has	O
been	O
shown	O
to	O
induce	O
suppression	B-DISO
of	O
host	O
gene	O
expression	O
and	O
to	O
interfere	O
with	O
the	O
host	O
immune	O
response	O
.	O

Here	O
we	O
present	O
the	O
first	O
nsp1	O
structure	O
from	O
an	O
alphacoronavirus	O
,	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
nsp1	O
.	O

Sixteen	O
patients	O
(	O
30	O
%)	O
presented	O
with	O
one	O
or	O
more	O
chronic	O
medical	O
condition	B-DISO
:	O
8	O
(	O
16	O
%)	O
with	O
chronic	B-DISO
lung	I-DISO
disease	I-DISO
,	O
5	O
(	O
10	O
%)	O
with	O
chronic	B-DISO
heart	I-DISO
failure	I-DISO
,	O
and	O
3	O
(	O
6	O
%)	O
with	O
diabetes	B-DISO
mellitus	I-DISO
.	O

Forty	O
-	O
eight	O
patients	O
(	O
96	O
%)	O
experienced	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
28	O
(	O
56	O
%)	O
septic	B-DISO
shock	I-DISO
,	O
and	O
27	O
(	O
54	O
%)	O
multiorgan	B-DISO
failure	I-DISO
.	O

ABSTRACT	O
:	O
Canine	O
infectious	B-DISO
respiratory	B-DISO
disease	I-DISO
(	O
CIRD	O
)	O
occurs	O
frequently	O
in	O
densely	O
housed	O
dog	O
populations	O
.	O

TITLE	O
:	O
The	O
acetyl	O
-	O
esterase	O
activity	O
of	O
the	O
hemagglutinin	O
-	O
esterase	O
protein	O
of	O
human	O
coronavirus	O
OC43	O
strongly	O
enhances	O
the	O
production	O
of	O
infectious	B-DISO
virus	O
.	O

Indeed	O
,	O
after	O
transfecting	O
BHK	O
-	O
21	O
cells	O
with	O
various	O
cDNA	O
infectious	B-DISO
clones	O
of	O
HCoV	O
-	O
OC43	O
,	O
either	O
lacking	O
the	O
HE	O
protein	O
or	O
bearing	O
an	O
HE	O
protein	O
with	O
a	O
nonfunctional	O
acetyl	O
-	O
esterase	O
enzymatic	O
activity	O
,	O
we	O
were	O
reproducibly	O
unable	O
to	O
detect	O
recombinant	O
infectious	B-DISO
viruses	O
compared	O
to	O
the	O
reference	O
infectious	B-DISO
HCoV	O
-	O
OC43	O
clone	O
pBAC	O
-	O
OC43	O
(	O
FL	O
).	O

Patients	O
had	O
severe	O
respiratory	B-DISO
failure	I-DISO
despite	O
advanced	O
mechanical	O
ventilator	O
support	O
.	O

Ten	O
mechanically	O
ventilated	O
ARDS	B-DISO
patients	O
(	O
mean	O
age	O
44	O
±	O
16	O
years	O
;	O
6	O
males	O
;	O
mean	O
hemoglobin	O
8	O
.	O
0	O
±	O
1	O
.	O
8	O
g	O
/	O
dL	O
)	O
on	O
ECMO	O
for	O
a	O
mean	O
of	O
9	O
.	O
0	O
±	O
3	O
.	O
8	O
days	O
)	O
receiving	O
femoro	O
-	O
jugular	O
vv	O
-	O
ECMO	O
were	O
evaluated	O
.	O

Decreasing	O
the	O
ECMO	O
flow	O
from	O
its	O
baseline	O
maximum	O
value	O
(	O
5	O
.	O
8	O
±	O
0	O
.	O
8	O
L	O
/	O
min	O
)	O
to	O
40	O
%	O
less	O
(	O
2	O
.	O
4	O
±	O
0	O
.	O
3	O
L	O
/	O
min	O
)	O
significantly	O
decreased	O
mean	O
PaO2	O
(	O
arterial	O
oxygen	O
tension	B-DISO
;	O
88	O
±	O
24	O
to	O
45	O
±	O
9	O
mm	O
Hg	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
SaO2	O
(	O
oxygen	O
saturation	O
;	O
97	O
±	O
2	O
to	O
82	O
±	O
10	O
%;	O
p	O
<	O
0	O
.	O
001	O
).	O

TITLE	O
:	O
The	O
new	O
age	O
of	O
virus	O
discovery	O
:	O
genomic	O
analysis	O
of	O
a	O
novel	O
human	O
betacoronavirus	O
isolated	O
from	O
a	O
fatal	O
case	O
of	O
pneumonia	B-DISO
.	O

Comparisons	O
between	O
the	O
18	O
patients	O
with	O
positive	O
RT	O
-	O
PCR	O
results	O
and	O
the	O
other	O
37	O
KD	O
patients	O
revealed	O
no	O
significant	O
differences	O
in	O
terms	O
of	O
clinical	B-DISO
findings	I-DISO
(	O
including	O
the	O
prevalence	O
of	O
incomplete	O
presentation	O
of	O
the	O
disease	O
)	O
and	O
coronary	O
artery	O
diameter	O
.	O

These	O
viruses	O
were	O
not	O
associated	O
with	O
the	O
incomplete	O
presentation	O
of	O
KD	O
and	O
coronary	B-DISO
artery	I-DISO
dilatation	I-DISO
.	O

Impaired	B-DISO
ASC	O
recruitment	B-DISO
in	O
CXCL10	O
(-/-)	O
but	O
not	O
CXCL9	O
(-/-)	O
mice	O
was	O
consistent	O
with	O
reduced	O
CNS	O
IgG	O
and	O
κ	O
-	O
light	O
chain	O
mRNA	O
and	O
virus	O
-	O
specific	O
Ab	O
.	O

TITLE	O
:	O
Solution	O
structure	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
nsp3a	O
and	O
determinants	O
of	O
the	O
interaction	O
with	O
MHV	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
.	O

TITLE	O
:	O
Lower	O
tidal	O
volume	O
strategy	O
(≈	O
3	O
ml	O
/	O
kg	O
)	O
combined	O
with	O
extracorporeal	O
CO2	O
removal	O
versus	O
'	O
conventional	O
'	O
protective	O
ventilation	O
(	O
6	O
ml	O
/	O
kg	O
)	O
in	O
severe	O
ARDS	B-DISO
:	O
the	O
prospective	O
randomized	O
Xtravent	O
-	O
study	O
.	O

Intravenous	O
carbohydrate	O
infusion	O
prior	O
to	O
artificial	O
nutrition	O
support	O
may	O
have	O
precipitated	O
the	O
onset	O
of	O
the	O
syndrome	B-DISO
.	O

After	O
a	O
long	O
period	O
of	O
very	O
severe	O
respiratory	O
impairment	B-DISO
,	O
the	O
evolution	O
was	O
progressively	O
favourable	O
and	O
the	O
patient	O
was	O
discharged	O
from	O
ICU	O
with	O
full	O
respiratory	O
recovery	O
43	O
days	O
after	O
admission	O
.	O

Polymorphonuclear	O
leucocytes	O
(	O
PMNs	O
)	O
are	O
activated	O
after	O
trauma	O
and	O
there	O
is	O
substantial	O
evidence	O
of	O
their	O
involvement	O
in	O
the	O
development	O
of	O
ARDS	B-DISO
.	O

HBP	B-DISO
is	O
a	O
potential	O
biomarker	O
candidate	O
for	O
early	O
detection	O
of	O
ARDS	B-DISO
development	O
after	O
trauma	O
.	O

TITLE	O
:	O
Human	O
coronavirus	O
EMC	B-DISO
is	O
not	O
the	O
same	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

Of	O
these	O
patients	O
,	O
56	O
%	O
had	O
underlying	O
neurological	O
diseases	O
,	O
50	O
%	O
experienced	O
fever	O
higher	O
than	O
40	O
°	O
C	O
and	O
69	O
%	O
suffered	B-DISO
fever	O
longer	O
than	O
one	O
week	O
.	O

Adenovirus	B-DISO
serotype	O
7	O
and	O
3	O
can	O
cause	O
severe	O
disease	O
-	O
even	O
death	O
-	O
in	O
children	O
,	O
especially	O
those	O
with	O
underlying	O
neurological	O
diseases	O
.	O

We	O
hypothesized	O
that	O
NOS	O
substrate	O
levels	O
are	O
low	O
in	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
and	O
that	O
low	O
levels	O
of	O
the	O
NOS	O
substrate	O
citrulline	O
would	O
be	O
associated	O
with	O
end	B-DISO
organ	I-DISO
damage	I-DISO
including	O
ARDS	B-DISO
in	O
severe	B-DISO
sepsis	I-DISO
.	O

In	O
multivariable	O
analyses	O
,	O
citrulline	O
levels	O
were	O
associated	O
with	O
ARDS	B-DISO
even	O
after	O
adjustment	O
for	O
covariates	O
including	O
severity	O
of	O
illness	O
.	O

ABSTRACT	O
:	O
Autophagy	O
is	O
a	O
highly	O
conserved	O
cellular	O
response	O
to	O
starvation	O
that	O
leads	O
to	O
the	O
degradation	O
of	O
organelles	O
and	O
long	O
-	O
lived	O
proteins	O
in	O
lysosomes	O
and	O
is	O
important	O
for	O
cellular	O
homeostasis	O
,	O
tissue	O
development	O
and	O
as	O
a	O
defense	O
against	O
aggregated	O
proteins	O
,	O
damaged	O
organelles	O
and	O
infectious	B-DISO
agents	O
.	O

ABSTRACT	O
:	O
Interferon	O
-	O
α	O
(	O
IFNα	O
)	O
has	O
enormous	O
potential	O
for	O
anti	O
-	O
proliferative	B-DISO
and	O
anti	O
-	O
viral	O
treatments	O
.	O

Neutropenia	O
was	O
present	O
in	O
24	O
(	O
27	O
.	O
0	O
%)	O
episodes	O
and	O
lymphopenia	B-DISO
was	O
in	O
31	O
(	O
34	O
.	O
8	O
%)	O
episodes	O
.	O

Three	O
patients	O
died	O
of	O
respiratory	B-DISO
failure	I-DISO
caused	O
by	O
respiratory	O
viral	B-DISO
infections	I-DISO
.	O

The	O
adjuvanticity	O
of	O
Sargassum	O
pallidum	O
polysaccharides	O
in	O
Newcastle	B-DISO
disease	I-DISO
(	O
ND	O
),	O
infectious	B-DISO
bronchitis	B-DISO
(	O
IB	O
)	O
and	O
avian	B-DISO
influenza	I-DISO
(	O
AI	O
)	O
was	O
investigated	O
by	O
examining	O
the	O
antibody	O
titers	O
and	O
lymphocyte	O
proliferation	B-DISO
following	O
immunization	O
in	O
chickens	O
.	O

The	O
ND	O
,	O
IB	O
and	O
AI	O
antibody	O
titers	O
and	O
the	O
lymphocyte	O
proliferation	B-DISO
were	O
enhanced	O
at	O
30	O
mg	O
/	O
mL	O
SPP	O
.	O

TITLE	O
:	O
Lessons	O
from	O
the	O
history	O
of	O
quarantine	O
,	O
from	O
plague	B-DISO
to	O
influenza	B-DISO
A	O
.	O
ABSTRACT	O
:	O
In	O
the	O
new	O
millennium	O
,	O
the	O
centuries	O
-	O
old	O
strategy	O
of	O
quarantine	O
is	O
becoming	O
a	O
powerful	O
component	O
of	O
the	O
public	O
health	O
response	O
to	O
emerging	O
and	O
reemerging	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

In	O
a	O
globalized	O
world	O
that	O
is	O
becoming	O
ever	O
more	O
vulnerable	O
to	O
communicable	B-DISO
diseases	I-DISO
,	O
a	O
historical	O
perspective	O
can	O
help	O
clarify	O
the	O
use	O
and	O
implications	O
of	O
a	O
still	O
-	O
valid	O
public	O
health	O
strategy	O
.	O

Data	O
from	O
193	O
patients	O
(	O
44	O
±	O
18	O
y	O
;	O
77	O
%	O
male	O
;	O
admission	O
Glasgow	O
Coma	B-DISO
Scale	O
score	O
4	O
±	O
2	O
)	O
were	O
reviewed	O
.	O

TITLE	O
:	O
Chronic	O
-	O
alcohol	O
-	O
abuse	B-DISO
-	O
induced	O
oxidative	B-DISO
stress	I-DISO
in	O
the	O
development	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
[	O
Non	O
-	O
invasive	O
ventilation	O
:	O
indication	O
for	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
].	O

This	O
technique	O
is	O
also	O
proposed	O
for	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
,	O
with	O
more	O
various	O
results	O
.	O

Wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
ADORA2A	O
(-/-)	O
mice	O
received	O
intratracheal	O
lipopolysaccharide	O
(	O
IT	O
LPS	B-DISO
),	O
followed	O
12	O
hours	O
later	O
by	O
continuous	O
exposure	O
to	O
21	O
%	O
oxygen	O
(	O
control	O
mice	O
)	O
or	O
60	O
%	O
oxygen	O
for	O
1	O
to	O
3	O
days	O
.	O

We	O
determined	O
the	O
specific	O
effects	O
of	O
myeloid	O
ADORA2A	O
,	O
using	O
chimera	B-DISO
experiments	O
.	O

ADORA2A	O
is	O
protective	O
against	O
lung	O
injury	O
after	O
LPS	B-DISO
and	O
oxygen	O
.	O

The	O
patient	O
'	O
s	O
condition	B-DISO
gradually	O
improved	O
and	O
she	O
was	O
weaned	O
from	O
ventilation	O
on	O
day	O
30	O
.	O

TITLE	O
:	O
Preliminary	O
study	O
of	O
ventilation	O
with	O
4	O
ml	O
/	O
kg	O
tidal	O
volume	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
feasibility	O
and	O
effects	O
on	O
cyclic	O
recruitment	B-DISO
-	O
derecruitment	O
and	O
hyperinflation	B-DISO
.	O

Decreasing	O
Vt	O
from	O
6	O
to	O
4	O
ml	O
/	O
kg	O
reduces	O
cyclic	O
recruitment	B-DISO
-	O
derecruitment	O
and	O
hyperinflation	B-DISO
.	O

TITLE	O
:	O
Surviving	O
sepsis	B-DISO
campaign	O
:	O
international	O
guidelines	O
for	O
management	O
of	O
severe	B-DISO
sepsis	I-DISO
and	O
septic	B-DISO
shock	I-DISO
:	O
2012	O
.	O

Key	O
recommendations	O
and	O
suggestions	O
,	O
listed	O
by	O
category	O
,	O
include	O
:	O
early	O
quantitative	O
resuscitation	O
of	O
the	O
septic	O
patient	O
during	O
the	O
first	O
6	O
hrs	B-DISO
after	O
recognition	O
(	O
1C	O
);	O
blood	O
cultures	O
before	O
antibiotic	O
therapy	O
(	O
1C	O
);	O
imaging	O
studies	O
performed	O
promptly	O
to	O
confirm	O
a	O
potential	O
source	O
of	O
infection	B-DISO
(	O
UG	O
);	O
administration	O
of	O
broad	O
-	O
spectrum	O
antimicrobials	O
therapy	O
within	O
1	O
hr	O
of	O
recognition	O
of	O
septic	B-DISO
shock	I-DISO
(	O
1B	O
)	O
and	O
severe	B-DISO
sepsis	I-DISO
without	I-DISO
septic	I-DISO
shock	I-DISO
(	O
1C	O
)	O
as	O
the	O
goal	O
of	O
therapy	O
;	O
reassessment	O
of	O
antimicrobial	O
therapy	O
daily	O
for	O
de	O
-	O
escalation	O
,	O
when	O
appropriate	O
(	O
1B	O
);	O
infection	B-DISO
source	O
control	O
with	O
attention	O
to	O
the	O
balance	O
of	O
risks	O
and	O
benefits	O
of	O
the	O
chosen	O
method	O
within	O
12	O
hrs	B-DISO
of	O
diagnosis	O
(	O
1C	O
);	O
initial	O
fluid	O
resuscitation	O
with	O
crystalloid	O
(	O
1B	O
)	O
and	O
consideration	O
of	O
the	O
addition	O
of	O
albumin	O
in	O
patients	O
who	O
continue	O
to	O
require	O
substantial	O
amounts	O
of	O
crystalloid	O
to	O
maintain	O
adequate	O
mean	O
arterial	O
pressure	O
(	O
2C	O
)	O
and	O
the	O
avoidance	O
of	O
hetastarch	O
formulations	O
(	O
1C	O
);	O
initial	O
fluid	O
challenge	O
in	O
patients	O
with	O
sepsis	B-DISO
-	O
induced	O
tissue	O
hypoperfusion	O
and	O
suspicion	O
of	O
hypovolemia	O
to	O
achieve	O
a	O
minimum	O
of	O
30	O
mL	O
/	O
kg	O
of	O
crystalloids	O
(	O
more	O
rapid	O
administration	O
and	O
greater	O
amounts	O
of	O
fluid	O
may	O
be	O
needed	O
in	O
some	O
patients	O
)	O
(	O
1C	O
);	O
fluid	O
challenge	O
technique	O
continued	O
as	O
long	O
as	O
hemodynamic	O
improvement	O
,	O
as	O
based	O
on	O
either	O
dynamic	O
or	O
static	O
variables	O
(	O
UG	O
);	O
norepinephrine	O
as	O
the	O
first	O
-	O
choice	O
vasopressor	O
to	O
maintain	O
mean	O
arterial	O
pressure	O
≥	O
65	O
mm	O
Hg	O
(	O
1B	O
);	O
epinephrine	O
when	O
an	O
additional	O
agent	O
is	O
needed	O
to	O
maintain	O
adequate	O
blood	O
pressure	O
(	O
2B	O
);	O
vasopressin	O
(	O
0	O
.	O
03	O
U	O
/	O
min	O
)	O
can	O
be	O
added	O
to	O
norepinephrine	O
to	O
either	O
raise	O
mean	O
arterial	O
pressure	O
to	O
target	O
or	O
to	O
decrease	O
norepinephrine	O
dose	O
but	O
should	O
not	O
be	O
used	O
as	O
the	O
initial	O
vasopressor	O
(	O
UG	O
);	O
dopamine	O
is	O
not	O
recommended	O
except	O
in	O
highly	O
selected	O
circumstances	O
(	O
2C	O
);	O
dobutamine	O
infusion	O
administered	O
or	O
added	O
to	O
vasopressor	O
in	O
the	O
presence	O
of	O
a	O
)	O
myocardial	B-DISO
dysfunction	I-DISO
as	O
suggested	O
by	O
elevated	O
cardiac	O
filling	O
pressures	O
and	O
low	O
cardiac	O
output	O
,	O
or	O
b	O
)	O
ongoing	O
signs	O
of	O
hypoperfusion	O
despite	O
achieving	O
adequate	O
intravascular	O
volume	O
and	O
adequate	O
mean	O
arterial	O
pressure	O
(	O
1C	O
);	O
avoiding	O
use	O
of	O
intravenous	O
hydrocortisone	O
in	O
adult	O
septic	B-DISO
shock	I-DISO
patients	O
if	O
adequate	O
fluid	O
resuscitation	O
and	O
vasopressor	O
therapy	O
are	O
able	O
to	O
restore	O
hemodynamic	O
stability	O
(	O
2C	O
);	O
hemoglobin	O
target	O
of	O
7	O
-	O
9	O
g	O
/	O
dL	O
in	O
the	O
absence	O
of	O
tissue	O
hypoperfusion	O
,	O
ischemic	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
,	O
or	O
acute	B-DISO
hemorrhage	I-DISO
(	O
1B	O
);	O
low	O
tidal	O
volume	O
(	O
1A	O
)	O
and	O
limitation	O
of	O
inspiratory	O
plateau	O
pressure	O
(	O
1B	O
)	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
);	O
application	O
of	O
at	O
least	O
a	O
minimal	O
amount	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
in	O
ARDS	B-DISO
(	O
1B	O
);	O
higher	O
rather	O
than	O
lower	O
level	O
of	O
PEEP	O
for	O
patients	O
with	O
sepsis	B-DISO
-	O
induced	O
moderate	O
or	O
severe	O
ARDS	B-DISO
(	O
2C	O
);	O
recruitment	B-DISO
maneuvers	O
in	O
sepsis	B-DISO
patients	O
with	O
severe	O
refractory	O
hypoxemia	O
due	O
to	O
ARDS	B-DISO
(	O
2C	O
);	O
prone	O
positioning	O
in	O
sepsis	B-DISO
-	O
induced	O
ARDS	B-DISO
patients	O
with	O
a	O
PaO2	O
/	O
FIO2	O
ratio	O
of	O
≤	O
100	O
mm	O
Hg	O
in	O
facilities	O
that	O
have	O
experience	O
with	O
such	O
practices	O
(	O
2C	O
);	O
head	O
-	O
of	O
-	O
bed	B-DISO
elevation	O
in	O
mechanically	O
ventilated	O
patients	O
unless	O
contraindicated	O
(	O
1B	O
);	O
a	O
conservative	O
fluid	O
strategy	O
for	O
patients	O
with	O
established	O
ARDS	B-DISO
who	O
do	O
not	O
have	O
evidence	O
of	O
tissue	O
hypoperfusion	O
(	O
1C	O
);	O
protocols	O
for	O
weaning	O
and	O
sedation	B-DISO
(	O
1A	O
);	O
minimizing	O
use	O
of	O
either	O
intermittent	O
bolus	O
sedation	B-DISO
or	O
continuous	O
infusion	O
sedation	B-DISO
targeting	O
specific	O
titration	O
endpoints	O
(	O
1B	O
);	O
avoidance	O
of	O
neuromuscular	O
blockers	O
if	O
possible	O
in	O
the	O
septic	O
patient	O
without	O
ARDS	B-DISO
(	O
1C	O
);	O
a	O
short	O
course	O
of	O
neuromuscular	O
blocker	O
(	O
no	O
longer	O
than	O
48	O
hrs	B-DISO
)	O
for	O
patients	O
with	O
early	O
ARDS	B-DISO
and	O
a	O
Pao2	O
/	O
Fio2	O
<	O
150	O
mm	O
Hg	O
(	O
2C	O
);	O
a	O
protocolized	O
approach	O
to	O
blood	O
glucose	O
management	O
commencing	O
insulin	O
dosing	O
when	O
two	O
consecutive	O
blood	O
glucose	O
levels	O
are	O
>	O
180	O
mg	O
/	O
dL	O
,	O
targeting	O
an	O
upper	O
blood	O
glucose	O
≤	O
180	O
mg	O
/	O
dL	O
(	O
1A	O
);	O
equivalency	O
of	O
continuous	O
veno	O
-	O
venous	O
hemofiltration	O
or	O
intermittent	O
hemodialysis	O
(	O
2B	O
);	O
prophylaxis	O
for	O
deep	B-DISO
vein	I-DISO
thrombosis	I-DISO
(	O
1B	O
);	O
use	O
of	O
stress	B-DISO
ulcer	I-DISO
prophylaxis	O
to	O
prevent	O
upper	B-DISO
gastrointestinal	I-DISO
bleeding	I-DISO
in	O
patients	O
with	O
bleeding	B-DISO
risk	O
factors	O
(	O
1B	O
);	O
oral	O
or	O
enteral	O
(	O
if	O
necessary	O
)	O
feedings	O
,	O
as	O
tolerated	O
,	O
rather	O
than	O
either	O
complete	O
fasting	O
or	O
provision	O
of	O
only	O
intravenous	O
glucose	O
within	O
the	O
first	O
48	O
hrs	B-DISO
after	O
a	O
diagnosis	O
of	O
severe	B-DISO
sepsis	I-DISO
/	O
septic	B-DISO
shock	I-DISO
(	O
2C	O
);	O
and	O
addressing	O
goals	O
of	O
care	O
,	O
including	O
treatment	O
plans	O
and	O
end	O
-	O
of	O
-	O
life	O
planning	O
(	O
as	O
appropriate	O
)	O
(	O
1B	O
),	O
as	O
early	O
as	O
feasible	O
,	O
but	O
within	O
72	O
hrs	B-DISO
of	O
intensive	O
care	O
unit	O
admission	O
(	O
2C	O
).	O

RESULTS	O
:	O
Key	O
recommendations	O
and	O
suggestions	O
,	O
listed	O
by	O
category	O
,	O
include	O
:	O
early	O
quantitative	O
resuscitation	O
of	O
the	O
septic	O
patient	O
during	O
the	O
first	O
6	O
hrs	B-DISO
after	O
recognition	O
(	O
1C	O
);	O
blood	O
cultures	O
before	O
antibiotic	O
therapy	O
(	O
1C	O
);	O
imaging	O
studies	O
performed	O
promptly	O
to	O
confirm	O
a	O
potential	O
source	O
of	O
infection	B-DISO
(	O
UG	O
);	O
administration	O
of	O
broad	O
-	O
spectrum	O
antimicrobials	O
therapy	O
within	O
1	O
hr	O
of	O
recognition	O
of	O
septic	B-DISO
shock	I-DISO
(	O
1B	O
)	O
and	O
severe	B-DISO
sepsis	I-DISO
without	I-DISO
septic	I-DISO
shock	I-DISO
(	O
1C	O
)	O
as	O
the	O
goal	O
of	O
therapy	O
;	O
reassessment	O
of	O
antimicrobial	O
therapy	O
daily	O
for	O
de	O
-	O
escalation	O
,	O
when	O
appropriate	O
(	O
1B	O
);	O
infection	B-DISO
source	O
control	O
with	O
attention	O
to	O
the	O
balance	O
of	O
risks	O
and	O
benefits	O
of	O
the	O
chosen	O
method	O
within	O
12	O
hrs	B-DISO
of	O
diagnosis	O
(	O
1C	O
);	O
initial	O
fluid	O
resuscitation	O
with	O
crystalloid	O
(	O
1B	O
)	O
and	O
consideration	O
of	O
the	O
addition	O
of	O
albumin	O
in	O
patients	O
who	O
continue	O
to	O
require	O
substantial	O
amounts	O
of	O
crystalloid	O
to	O
maintain	O
adequate	O
mean	O
arterial	O
pressure	O
(	O
2C	O
)	O
and	O
the	O
avoidance	O
of	O
hetastarch	O
formulations	O
(	O
1C	O
);	O
initial	O
fluid	O
challenge	O
in	O
patients	O
with	O
sepsis	B-DISO
-	O
induced	O
tissue	O
hypoperfusion	O
and	O
suspicion	O
of	O
hypovolemia	O
to	O
achieve	O
a	O
minimum	O
of	O
30	O
mL	O
/	O
kg	O
of	O
crystalloids	O
(	O
more	O
rapid	O
administration	O
and	O
greater	O
amounts	O
of	O
fluid	O
may	O
be	O
needed	O
in	O
some	O
patients	O
)	O
(	O
1C	O
);	O
fluid	O
challenge	O
technique	O
continued	O
as	O
long	O
as	O
hemodynamic	O
improvement	O
,	O
as	O
based	O
on	O
either	O
dynamic	O
or	O
static	O
variables	O
(	O
UG	O
);	O
norepinephrine	O
as	O
the	O
first	O
-	O
choice	O
vasopressor	O
to	O
maintain	O
mean	O
arterial	O
pressure	O
≥	O
65	O
mm	O
Hg	O
(	O
1B	O
);	O
epinephrine	O
when	O
an	O
additional	O
agent	O
is	O
needed	O
to	O
maintain	O
adequate	O
blood	O
pressure	O
(	O
2B	O
);	O
vasopressin	O
(	O
0	O
.	O
03	O
U	O
/	O
min	O
)	O
can	O
be	O
added	O
to	O
norepinephrine	O
to	O
either	O
raise	O
mean	O
arterial	O
pressure	O
to	O
target	O
or	O
to	O
decrease	O
norepinephrine	O
dose	O
but	O
should	O
not	O
be	O
used	O
as	O
the	O
initial	O
vasopressor	O
(	O
UG	O
);	O
dopamine	O
is	O
not	O
recommended	O
except	O
in	O
highly	O
selected	O
circumstances	O
(	O
2C	O
);	O
dobutamine	O
infusion	O
administered	O
or	O
added	O
to	O
vasopressor	O
in	O
the	O
presence	O
of	O
a	O
)	O
myocardial	B-DISO
dysfunction	I-DISO
as	O
suggested	O
by	O
elevated	O
cardiac	O
filling	O
pressures	O
and	O
low	O
cardiac	O
output	O
,	O
or	O
b	O
)	O
ongoing	O
signs	O
of	O
hypoperfusion	O
despite	O
achieving	O
adequate	O
intravascular	O
volume	O
and	O
adequate	O
mean	O
arterial	O
pressure	O
(	O
1C	O
);	O
avoiding	O
use	O
of	O
intravenous	O
hydrocortisone	O
in	O
adult	O
septic	B-DISO
shock	I-DISO
patients	O
if	O
adequate	O
fluid	O
resuscitation	O
and	O
vasopressor	O
therapy	O
are	O
able	O
to	O
restore	O
hemodynamic	O
stability	O
(	O
2C	O
);	O
hemoglobin	O
target	O
of	O
7	O
-	O
9	O
g	O
/	O
dL	O
in	O
the	O
absence	O
of	O
tissue	O
hypoperfusion	O
,	O
ischemic	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
,	O
or	O
acute	B-DISO
hemorrhage	I-DISO
(	O
1B	O
);	O
low	O
tidal	O
volume	O
(	O
1A	O
)	O
and	O
limitation	O
of	O
inspiratory	O
plateau	O
pressure	O
(	O
1B	O
)	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
);	O
application	O
of	O
at	O
least	O
a	O
minimal	O
amount	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
in	O
ARDS	B-DISO
(	O
1B	O
);	O
higher	O
rather	O
than	O
lower	O
level	O
of	O
PEEP	O
for	O
patients	O
with	O
sepsis	B-DISO
-	O
induced	O
moderate	O
or	O
severe	O
ARDS	B-DISO
(	O
2C	O
);	O
recruitment	B-DISO
maneuvers	O
in	O
sepsis	B-DISO
patients	O
with	O
severe	O
refractory	O
hypoxemia	O
due	O
to	O
ARDS	B-DISO
(	O
2C	O
);	O
prone	O
positioning	O
in	O
sepsis	B-DISO
-	O
induced	O
ARDS	B-DISO
patients	O
with	O
a	O
PaO2	O
/	O
FIO2	O
ratio	O
of	O
≤	O
100	O
mm	O
Hg	O
in	O
facilities	O
that	O
have	O
experience	O
with	O
such	O
practices	O
(	O
2C	O
);	O
head	O
-	O
of	O
-	O
bed	B-DISO
elevation	O
in	O
mechanically	O
ventilated	O
patients	O
unless	O
contraindicated	O
(	O
1B	O
);	O
a	O
conservative	O
fluid	O
strategy	O
for	O
patients	O
with	O
established	O
ARDS	B-DISO
who	O
do	O
not	O
have	O
evidence	O
of	O
tissue	O
hypoperfusion	O
(	O
1C	O
);	O
protocols	O
for	O
weaning	O
and	O
sedation	B-DISO
(	O
1A	O
);	O
minimizing	O
use	O
of	O
either	O
intermittent	O
bolus	O
sedation	B-DISO
or	O
continuous	O
infusion	O
sedation	B-DISO
targeting	O
specific	O
titration	O
endpoints	O
(	O
1B	O
);	O
avoidance	O
of	O
neuromuscular	O
blockers	O
if	O
possible	O
in	O
the	O
septic	O
patient	O
without	O
ARDS	B-DISO
(	O
1C	O
);	O
a	O
short	O
course	O
of	O
neuromuscular	O
blocker	O
(	O
no	O
longer	O
than	O
48	O
hrs	B-DISO
)	O
for	O
patients	O
with	O
early	O
ARDS	B-DISO
and	O
a	O
Pao2	O
/	O
Fio2	O
<	O
150	O
mm	O
Hg	O
(	O
2C	O
);	O
a	O
protocolized	O
approach	O
to	O
blood	O
glucose	O
management	O
commencing	O
insulin	O
dosing	O
when	O
two	O
consecutive	O
blood	O
glucose	O
levels	O
are	O
>	O
180	O
mg	O
/	O
dL	O
,	O
targeting	O
an	O
upper	O
blood	O
glucose	O
≤	O
180	O
mg	O
/	O
dL	O
(	O
1A	O
);	O
equivalency	O
of	O
continuous	O
veno	O
-	O
venous	O
hemofiltration	O
or	O
intermittent	O
hemodialysis	O
(	O
2B	O
);	O
prophylaxis	O
for	O
deep	B-DISO
vein	I-DISO
thrombosis	I-DISO
(	O
1B	O
);	O
use	O
of	O
stress	B-DISO
ulcer	I-DISO
prophylaxis	O
to	O
prevent	O
upper	B-DISO
gastrointestinal	I-DISO
bleeding	I-DISO
in	O
patients	O
with	O
bleeding	B-DISO
risk	O
factors	O
(	O
1B	O
);	O
oral	O
or	O
enteral	O
(	O
if	O
necessary	O
)	O
feedings	O
,	O
as	O
tolerated	O
,	O
rather	O
than	O
either	O
complete	O
fasting	O
or	O
provision	O
of	O
only	O
intravenous	O
glucose	O
within	O
the	O
first	O
48	O
hrs	B-DISO
after	O
a	O
diagnosis	O
of	O
severe	B-DISO
sepsis	I-DISO
/	O
septic	B-DISO
shock	I-DISO
(	O
2C	O
);	O
and	O
addressing	O
goals	O
of	O
care	O
,	O
including	O
treatment	O
plans	O
and	O
end	O
-	O
of	O
-	O
life	O
planning	O
(	O
as	O
appropriate	O
)	O
(	O
1B	O
),	O
as	O
early	O
as	O
feasible	O
,	O
but	O
within	O
72	O
hrs	B-DISO
of	O
intensive	O
care	O
unit	O
admission	O
(	O
2C	O
).	O

RV16	O
was	O
more	O
sensitive	O
than	O
xTAG	O
for	O
coronavirus	O
OC43	O
/	O
HKU1	O
(	O
100	O
%	O
versus	O
26	O
.	O
1	O
%;	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
adenovirus	B-DISO
(	O
100	O
%	O
versus	O
79	O
.	O
5	O
%;	O
P	O
<	O
0	O
.	O
01	O
)	O
but	O
was	O
less	O
sensitive	O
than	O
xTAG	O
for	O
rhinovirus	O
/	O
enterovirus	O
(	O
89	O
.	O
4	O
%	O
versus	O
97	O
.	O
9	O
%;	O
P	O
<	O
0	O
.	O
05	O
).	O

RV16	O
demonstrated	O
higher	O
sensitivity	O
than	O
RV15	O
for	O
the	O
detection	O
of	O
adenovirus	B-DISO
(	O
100	O
%	O
versus	O
82	O
.	O
1	O
%;	O
P	O
<	O
0	O
.	O
05	O
).	O

Variables	O
included	O
in	O
the	O
maximal	O
multivariate	O
model	O
were	O
male	O
sex	O
,	O
chronic	B-DISO
alcoholism	I-DISO
,	O
use	O
of	O
ACE	O
inhibitors	O
or	O
angiotensin	O
-	O
receptor	O
blockers	O
,	O
Simplified	O
Acute	O
Physiology	O
Score	O
II	O
score	O
,	O
serum	O
glucose	O
concentration	O
at	O
ICU	O
admission	O
,	O
and	O
the	O
presence	O
of	O
the	O
allele	O
D	O
of	O
the	O
ACE	O
gene	O
.	O

After	O
adjustment	O
for	O
those	O
variables	O
,	O
the	O
presence	O
of	O
the	O
allele	O
D	O
of	O
the	O
ACE	O
gene	O
(	O
odds	O
ratio	O
,	O
4	O
.	O
75	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
02	O
-	O
22	O
.	O
20	O
;	O
P	O
=	O
0	O
.	O
048	O
)	O
was	O
significantly	O
associated	O
with	O
the	O
diagnosis	O
of	O
ARDS	B-DISO
.	O

The	O
presence	O
of	O
the	O
allele	O
D	O
of	O
the	O
ACE	O
gene	O
is	O
associated	O
with	O
ARDS	B-DISO
in	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
.	O

TITLE	O
:	O
Asthma	B-DISO
in	O
patients	O
hospitalized	O
with	O
pandemic	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pdm09	O
virus	B-DISO
infection	I-DISO
-	O
United	O
States	O
,	O
2009	O
.	O

ABSTRACT	O
:	O
Asthma	B-DISO
was	O
the	O
most	O
common	O
co	O
-	O
morbidity	O
among	O
patients	O
hospitalized	O
with	O
pandemic	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pdm09	O
[	O
pH1N1	O
]	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
The	O
PaO2	O
/	O
FiO2	O
is	O
an	O
integral	O
part	O
of	O
the	O
assessment	O
of	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

We	O
studied	O
452	O
ARDS	B-DISO
patients	O
enrolled	O
prospectively	O
in	O
two	O
independent	O
,	O
multicenter	O
cohorts	O
treated	O
with	O
protective	O
mechanical	O
ventilation	O
.	O

At	O
the	O
time	O
of	O
ARDS	B-DISO
diagnosis	O
,	O
patients	O
had	O
a	O
PaO2	O
/	O
FiO2	O
≤	O
200	O
.	O

RESULTS	O
:	O
The	O
only	O
standard	O
ventilatory	O
setting	O
that	O
identified	O
the	O
three	O
PaO2	O
/	O
FiO2	O
risk	O
categories	O
in	O
the	O
derivation	O
cohort	O
was	O
PEEP	O
≥	O
10	O
cmH2O	O
and	O
FiO2	O
≥	O
0	O
.	O
5	O
at	O
24	O
h	O
after	O
ARDS	B-DISO
onset	O
(	O
p	O
=	O
0	O
.	O
0001	O
).	O

DAD	O
was	O
more	O
frequent	O
in	O
patients	O
who	O
met	O
clinical	O
criteria	O
for	O
ARDS	B-DISO
during	O
more	O
than	O
72	O
hours	O
and	O
was	O
found	O
in	O
69	O
%	O
of	O
those	O
with	O
severe	O
ARDS	B-DISO
for	O
72	O
hours	O
or	O
longer	O
.	O

Glucocorticoids	O
are	O
the	O
natural	O
regulators	O
of	O
inflammation	B-DISO
,	O
and	O
their	O
production	O
increases	O
during	O
infection	B-DISO
.	O

The	O
authors	O
examined	O
the	O
literature	O
regarding	O
general	O
health	O
protections	O
that	O
breastfeeding	O
confers	O
to	O
infants	O
and	O
mothers	O
and	O
explored	O
associations	O
between	O
breastfeeding	O
,	O
occlusion	B-DISO
in	O
the	O
primary	O
dentition	O
and	O
early	B-DISO
childhood	I-DISO
caries	I-DISO
.	O

Recent	O
advances	O
in	O
the	O
understanding	O
of	O
the	O
immunologic	O
and	O
molecular	O
mechanisms	O
of	O
inflammation	B-DISO
support	O
,	O
in	O
part	O
,	O
the	O
conceptual	O
use	O
of	O
corticosteroids	O
as	O
an	O
adjunct	O
immunomodulatory	O
therapy	O
.	O

TITLE	O
:	O
Protection	O
of	O
chickens	O
against	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
with	O
a	O
multivalent	O
DNA	O
vaccine	O
and	O
boosting	O
with	O
an	O
inactivated	O
vaccine	O
.	O

TITLE	O
:	O
The	O
required	O
sample	O
size	O
in	O
vaccination	O
-	O
challenge	O
experiments	O
with	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
,	O
a	O
meta	O
-	O
analysis	O
.	O

One	O
hundred	O
fifty	O
-	O
nine	O
critically	B-DISO
ill	I-DISO
patients	O
,	O
including	O
50	O
patients	O
with	O
sepsis	B-DISO
,	O
57	O
patients	O
with	O
severe	O
trauma	O
and	O
52	O
resuscitated	O
after	O
out	B-DISO
-	I-DISO
of	I-DISO
-	I-DISO
hospital	I-DISO
cardiac	I-DISO
arrest	I-DISO
,	O
were	O
divided	O
into	O
three	O
subgroups	O
:	O
including	O
25	O
ALI	O
patients	O
,	O
101	O
ARDS	B-DISO
patients	O
and	O
22	O
non	O
-	O
ALI	O
/	O
ARDS	B-DISO
patients	O
.	O

Angiogenic	O
factors	O
and	O
their	O
soluble	O
receptors	O
,	O
particularly	O
sVEGFR2	O
and	O
Ang2	O
,	O
are	O
thus	O
considered	O
to	O
be	O
valuable	O
predictive	O
biomarkers	O
in	O
the	O
development	O
of	O
ALI	O
/	O
ARDS	B-DISO
associated	O
with	O
critical	B-DISO
illness	I-DISO
and	O
mortality	O
in	O
ALI	O
/	O
ARDS	B-DISO
patients	O
.	O

These	O
results	O
suggest	O
that	O
kallistatin	O
may	O
serve	O
as	O
a	O
novel	O
marker	O
for	O
severe	O
CAP	B-DISO
prognosis	O
and	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	B-DISO
of	O
CAP	B-DISO
through	O
antiinflammatory	O
and	O
anticoagulation	O
effects	O
.	O

TITLE	O
:	O
Review	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
around	O
the	O
world	O
.	O

Genetic	O
typing	O
of	O
IBV	O
,	O
which	O
involves	O
reverse	O
transcription	O
-	O
PCR	O
amplification	B-DISO
and	O
sequence	O
analysis	O
of	O
the	O
S1	O
glycoprotein	O
gene	O
,	O
has	O
revolutionized	O
diagnosis	O
and	O
identification	O
of	O
this	O
virus	O
by	O
making	O
it	O
possible	O
to	O
type	O
and	O
compare	O
the	O
relatedness	O
of	O
a	O
large	O
number	O
of	O
virus	O
isolates	O
in	O
a	O
short	O
period	O
of	O
time	O
.	O

These	O
discrepancies	O
suggest	O
that	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
load	O
in	O
tears	O
may	O
not	O
always	O
predict	O
degree	O
of	O
tracheal	O
damage	O
and	O
that	O
phenotypic	O
characteristics	O
other	O
than	O
S1	O
may	O
also	O
be	O
involved	O
in	O
severity	O
of	O
vaccine	O
reactions	O
following	O
ArkDPI	O
vaccine	O
administration	O
.	O

Possible	O
involvement	O
of	O
infectious	B-DISO
bronchitis	B-DISO
(	O
IB	B-DISO
)	O
and	O
egg	B-DISO
drop	I-DISO
syndrome	I-DISO
(	O
EDS	B-DISO
)	O
viruses	O
that	O
could	O
have	O
caused	O
loss	O
of	O
egg	O
production	O
we	O
ruled	O
out	O
for	O
IB	B-DISO
virus	O
by	O
RT	O
-	O
PCR	O
,	O
and	O
EDS	B-DISO
virus	O
was	O
ruled	O
out	O
by	O
hemagglutination	O
-	O
inhibition	O
(	O
HI	O
).	O

Accordingly	O
,	O
we	O
studied	O
the	O
HBP	B-DISO
levels	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
infection	B-DISO
of	O
influenza	B-DISO
A	O
(	O
H1N1	O
).	O
Critically	B-DISO
ill	I-DISO
patients	O
in	O
four	O
intensive	O
care	O
units	O
(	O
ICUs	O
)	O
with	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
confirmed	O
infection	B-DISO
of	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
were	O
prospectively	O
evaluated	O
.	O

TITLE	O
:	O
Postpneumonectomy	O
-	O
like	O
syndrome	B-DISO
presenting	O
in	O
a	O
patient	O
with	O
treated	O
pulmonary	B-DISO
tuberculosis	I-DISO
:	O
a	O
case	O
report	O
.	O

Plain	O
X	O
-	O
ray	O
and	O
computed	O
tomography	O
scans	O
confirmed	O
the	O
presence	O
of	O
postpneumonectomy	O
-	O
like	O
syndrome	B-DISO
secondary	O
to	O
his	O
parenchymal	O
lung	O
destruction	O
.	O

SF	O
-	O
aero	O
induced	O
less	O
alveolar	O
hemorrhage	B-DISO
and	O
inflammation	B-DISO
.	O

IAH	O
and	O
ACS	O
are	O
relatively	O
frequent	O
findings	O
in	O
patiens	O
with	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
(	O
SAP	O
)	O
and	O
are	O
associated	O
with	O
deterioration	O
in	O
organ	O
functions	O
.	O

However	O
,	O
the	O
management	O
of	O
necrotizing	B-DISO
pancreatitis	I-DISO
has	O
changed	O
over	O
the	O
last	O
decade	O
.	O

However	O
,	O
OSA	B-DISO
continues	O
to	O
be	O
an	O
important	O
risk	O
because	O
a	O
substantial	O
proportion	O
of	O
patients	O
in	O
the	O
contemporary	O
surgical	O
population	O
have	O
undiagnosed	O
OSA	B-DISO
.	O

ARDS	B-DISO
is	O
another	O
serious	O
postoperative	B-DISO
complication	I-DISO
associated	O
with	O
high	O
mortality	O
rate	O
and	O
limited	O
treatment	O
options	O
,	O
and	O
its	O
prevention	O
is	O
critical	O
.	O

Furthermore	O
,	O
IFN	O
-	O
γ	O
production	O
in	O
the	O
lungs	O
was	O
significantly	O
reduced	O
in	O
IFN	O
-	O
α	O
-	O
treated	O
mice	O
,	O
compared	O
with	O
control	O
mice	O
,	O
but	O
tumor	B-DISO
necrosis	I-DISO
factor	O
(	O
TNF	O
)-	O
α	O
production	O
was	O
almost	O
equivalent	O
for	O
both	O
groups	O
.	O

ABSTRACT	O
:	O
Critical	B-DISO
illness	I-DISO
polyneuropathy	I-DISO
(	O
CIP	O
)	O
and	O
critical	B-DISO
illness	I-DISO
myopathy	I-DISO
(	O
CIM	O
)	O
are	O
complications	O
causing	O
weakness	B-DISO
of	O
respiratory	O
and	O
limb	O
muscles	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

ABSTRACT	O
:	O
Canine	O
coronavirus	O
(	O
CCoV	O
)	O
is	O
an	O
etiologic	O
agent	O
of	O
diarrhea	B-DISO
in	O
dogs	O
and	O
is	O
known	O
to	O
have	O
spread	O
worldwide	O
.	O

The	O
structure	O
activity	O
relationships	O
(	O
SARs	B-DISO
)	O
were	O
discussed	O
and	O
rationalized	O
by	O
docking	O
simulations	O
.	O

Multiple	O
respiratory	O
viruses	O
beyond	O
influenza	B-DISO
are	O
associated	O
with	O
significant	O
morbidity	O
and	O
mortality	O
among	O
adults	O
and	O
children	O
in	O
Mexico	O
City	O
.	O

Viral	O
antigens	O
were	O
detected	O
in	O
the	O
cytoplasm	O
of	O
infected	O
type	O
II	O
cells	O
,	O
electron	O
micrographs	O
demonstrated	O
secretory	O
vesicles	B-DISO
filled	O
with	O
virions	O
,	O
virus	O
RNA	O
concentrations	O
increased	O
with	O
time	O
,	O
and	O
infectious	B-DISO
virions	O
were	O
released	O
by	O
exocytosis	O
from	O
the	O
apical	O
surface	O
of	O
polarized	O
type	O
II	O
cells	O
.	O

Amongst	O
ICU	O
survivors	O
,	O
obese	B-DISO
patients	O
had	O
longer	O
ICU	O
LOS	O
(	O
median	O
11	O
.	O
9	O
vs	O
.	O
6	O
.	O
8	O
days	O
,	O
p	O
=	O
0	O
.	O
017	O
).	O

Using	O
the	O
EMA	B-DISO
dossiers	O
(	O
all	O
three	O
agents	O
),	O
the	O
FDA	O
dossier	O
(	O
Tevagrastim	O
),	O
and	O
journal	O
publications	O
,	O
this	O
article	O
reviews	O
clinical	O
safety	O
data	O
for	O
these	O
products	O
with	O
emphasis	O
on	O
serious	O
/	O
severe	O
adverse	O
events	O
and	O
special	O
consideration	O
of	O
immunogenicity	O
,	O
bone	B-DISO
pain	I-DISO
,	O
splenomegaly	O
,	O
allergic	B-DISO
reactions	I-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
mortality	O
.	O

The	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
virus	O
caused	O
a	O
global	O
pandemic	O
and	O
also	O
affected	O
New	O
Zealand	O
during	O
that	O
winter	O
.	O

The	O
survey	O
identified	O
issues	O
including	O
the	O
acuity	O
and	O
high	O
mortality	O
rate	O
of	O
those	O
affected	O
,	O
nurses	O
working	O
in	O
an	O
isolated	O
environment	O
because	O
of	O
infection	B-DISO
control	O
requirements	O
,	O
limited	O
support	O
and	O
being	O
asked	O
to	O
work	O
extra	O
shifts	O
.	O

Here	O
,	O
we	O
show	O
that	O
pseudostratified	O
HAE	O
cultures	O
derived	O
from	O
different	O
donors	O
are	O
highly	O
permissive	O
to	O
HCoV	O
-	O
EMC	B-DISO
infection	B-DISO
,	O
and	O
by	O
using	O
reverse	O
transcription	O
(	O
RT	O
)-	O
PCR	O
and	O
RNAseq	O
data	O
,	O
we	O
experimentally	O
determined	O
the	O
identity	O
of	O
seven	O
HCoV	O
-	O
EMC	B-DISO
subgenomic	O
mRNAs	O
.	O

We	O
show	O
that	O
human	O
bronchial	O
epithelia	O
are	O
highly	O
susceptible	O
to	O
HCoV	O
-	O
EMC	B-DISO
infection	B-DISO
.	O

TITLE	O
:	O
Plasmodium	B-DISO
vivax	I-DISO
malaria	I-DISO
complicated	O
by	O
acute	O
kidney	O
injury	O
:	O
experience	O
at	O
a	O
referral	O
hospital	O
in	O
Uttarakhand	O
,	O
India	O
.	O

Acute	O
rejection	O
,	O
lymphocytic	O
bronchiolitis	B-DISO
,	O
colonization	O
with	O
pseudomonas	O
,	O
infection	B-DISO
,	O
and	O
BAL	O
eosinophilia	B-DISO
and	O
neutrophilia	O
are	O
risk	O
factors	O
for	O
the	O
later	O
development	O
not	O
only	O
of	O
RAS	O
but	O
also	O
of	O
BOS	B-DISO
.	O

RESULTS	O
:	O
There	O
were	O
103	O
patients	O
suffering	B-DISO
from	O
chronic	O
rejection	O
,	O
of	O
which	O
79	O
had	O
BOS	B-DISO
and	O
24	O
were	O
diagnosed	O
with	O
RAS	O
.	O

Studies	O
of	O
the	O
fundamental	O
aspects	O
of	O
these	O
HCoV	O
infections	B-DISO
at	O
the	O
primary	O
entry	O
port	O
,	O
such	O
as	O
cell	O
tropism	O
,	O
are	O
seriously	O
hampered	O
by	O
the	O
lack	O
of	O
a	O
universal	O
culture	O
system	O
or	O
suitable	O
animal	O
models	O
.	O

TITLE	O
:	O
High	O
-	O
frequency	O
oscillatory	O
ventilation	O
for	O
cardiac	O
surgery	O
children	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

This	O
report	O
aims	O
to	O
describe	O
a	O
single	O
-	O
center	O
experience	O
with	O
HFOV	O
in	O
the	O
management	O
of	O
ARDS	B-DISO
after	O
open	O
heart	O
surgery	O
with	O
respect	O
to	O
mortality	O
.	O

Nearly	O
10	O
,	O
843	O
patients	O
underwent	O
surgery	O
during	O
the	O
study	O
period	O
,	O
and	O
the	O
ARDS	B-DISO
incidence	O
rate	O
was	O
0	O
.	O
76	O
%	O
(	O
83	O
/	O
10	O
,	O
843	O
),	O
with	O
64	O
patients	O
(	O
77	O
%,	O
64	O
/	O
83	O
)	O
receiving	O
HFOV	O
.	O

The	O
findings	O
show	O
that	O
HFOV	O
is	O
an	O
effective	O
and	O
safe	O
method	O
for	O
ventilating	O
severe	O
ARDS	B-DISO
patients	O
after	O
corrective	O
cardiac	O
surgery	O
.	O

Pulmonary	B-DISO
hypertension	I-DISO
and	O
RRTIs	O
before	O
surgery	O
were	O
risk	O
factors	O
for	O
in	O
-	O
hospital	O
mortality	O
.	O

However	O
,	O
these	O
results	O
will	O
also	O
open	O
possibilities	O
for	O
new	O
therapies	O
targeting	O
specifically	O
NK	O
cells	O
and	O
Tregs	O
to	O
enhance	O
their	O
numbers	O
and	O
/	O
or	O
functionality	O
during	O
FIPV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
The	O
nucleotide	O
sequences	O
of	O
a	O
region	O
including	O
S1	O
,	O
S2	O
,	O
3a	O
,	O
3b	O
and	O
E	O
genes	O
of	O
twenty	O
-	O
seven	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
isolates	O
in	O
Korea	O
between	O
1990	O
-	O
2011	O
were	O
determined	O
and	O
phylogenetic	O
and	O
computational	O
recombination	O
analyses	O
were	O
conducted	O
.	O

ABSTRACT	O
:	O
Molecular	O
typing	O
is	O
a	O
valuable	O
tool	O
for	O
gaining	O
insight	O
into	O
spread	O
of	O
Mycobacterium	O
tuberculosis	B-DISO
.	O

A	O
possible	O
explanation	O
for	O
this	O
skewness	O
is	O
the	O
concept	O
of	O
""""	O
superspreading	O
""":"	O
a	O
high	O
heterogeneity	O
in	O
the	O
number	O
of	O
secondary	O
cases	O
caused	O
per	O
infectious	B-DISO
individual	O
.	O

We	O
quantified	O
heterogeneity	O
in	O
secondary	B-DISO
infections	I-DISO
per	O
infectious	B-DISO
individual	O
by	O
describing	O
this	O
number	O
as	O
a	O
negative	O
binomial	O
distribution	O
.	O

We	O
estimated	O
this	O
negative	O
binomial	O
dispersion	O
parameter	O
for	O
TB	O
in	O
the	O
Netherlands	O
,	O
using	O
the	O
genotypic	O
cluster	O
size	O
distribution	O
for	O
all	O
8330	O
cases	O
of	O
culture	O
confirmed	O
,	O
pulmonary	B-DISO
TB	I-DISO
diagnosed	O
between	O
1993	O
and	O
2007	O
in	O
the	O
Netherlands	O
.	O

ABSTRACT	O
:	O
Acute	O
inhalational	O
exposure	O
leads	O
to	O
rapidly	O
progressive	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

However	O
,	O
HCoV	O
-	O
EMC	B-DISO
was	O
markedly	O
more	O
sensitive	O
to	O
the	O
antiviral	O
state	O
established	O
by	O
ectopic	O
IFN	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
14	O
kDa	O
endocan	O
fragment	O
generated	O
by	O
cathepsin	O
G	O
,	O
a	O
novel	O
circulating	O
biomarker	O
in	O
patients	O
with	O
sepsis	B-DISO
.	O

Taken	O
together	O
,	O
the	O
p14	O
endocan	O
fragment	O
represents	O
a	O
novel	O
interesting	O
biomarker	O
which	O
could	O
participate	O
to	O
the	O
pathogenesis	B-DISO
of	O
sepsis	B-DISO
.	O

ABSTRACT	O
:	O
Granuloma	B-DISO
formation	O
occurs	O
in	O
the	O
human	O
body	O
if	O
there	O
is	O
a	O
particle	O
which	O
persists	O
in	O
phagocytes	O
and	O
which	O
the	O
immune	O
system	O
cannot	O
eliminate	O
.	O

Pulmonary	B-DISO
granuloma	I-DISO
also	O
evolve	O
in	O
the	O
context	O
of	O
autoimmune	B-DISO
diseases	I-DISO
such	O
as	O
rheumatoid	B-DISO
arthritis	I-DISO
,	O
granulomatosis	B-DISO
with	O
polyangiitis	O
(	O
GBA	O
,	O
Wegener	O
'	O
s	O
)	O
and	O
eosinophilic	O
granulomatosis	B-DISO
with	O
polyangiitis	O
(	O
EGPA	O
,	O
Churg	B-DISO
-	I-DISO
Strauss	I-DISO
syndrome	I-DISO
).	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
on	O
S	O
.	O
agalactiae	O
natural	O
infection	B-DISO
in	O
domestic	O
rabbits	O
.	O

TITLE	O
:	O
The	O
spike	O
protein	O
of	O
the	O
emerging	O
betacoronavirus	O
EMC	B-DISO
uses	O
a	O
novel	O
coronavirus	O
receptor	O
for	O
entry	O
,	O
can	O
be	O
activated	O
by	O
TMPRSS2	O
,	O
and	O
is	O
targeted	O
by	O
neutralizing	O
antibodies	O
.	O

We	O
found	O
that	O
the	O
spike	O
protein	O
of	O
hCoV	O
-	O
EMC	B-DISO
(	O
EMC	B-DISO
-	O
S	O
)	O
is	O
incorporated	O
into	O
lentiviral	O
particles	O
and	O
mediates	O
transduction	O
of	O
human	O
cell	O
lines	O
derived	O
from	O
different	O
organs	O
,	O
including	O
the	O
lungs	O
,	O
kidneys	O
,	O
and	O
colon	O
,	O
as	O
well	O
as	O
primary	O
human	O
macrophages	O
.	O

In	O
addition	O
,	O
they	O
define	O
TMPRSS2	O
and	O
cathepsins	O
B	O
and	O
L	O
as	O
potential	O
targets	O
for	O
intervention	O
and	O
suggest	O
that	O
neutralizing	O
antibodies	O
contribute	O
to	O
the	O
control	O
of	O
hCoV	O
-	O
EMC	B-DISO
infection	B-DISO
.	O

While	O
species	O
D	O
adenoviruses	O
and	O
subtype	O
H7	O
influenza	B-DISO
viruses	O
are	O
known	O
to	O
possess	B-DISO
an	O
ocular	O
tropism	O
,	O
documented	O
human	O
ocular	O
disease	O
has	O
been	O
reported	O
following	O
infection	B-DISO
with	O
all	O
principal	O
respiratory	O
viruses	O
.	O

TITLE	O
:	O
Enteric	O
viruses	O
in	O
Brazilian	O
turkey	O
flocks	O
:	O
single	O
and	O
multiple	O
virus	B-DISO
infection	I-DISO
frequency	O
according	O
to	O
age	O
and	O
clinical	O
signs	O
of	O
intestinal	B-DISO
disease	I-DISO
.	O

Prevaccination	O
antibody	O
titers	O
to	O
Newcastle	O
disease	B-DISO
,	I-DISO
infectious	I-DISO
bronchitis	B-DISO
,	O
and	O
infectious	B-DISO
bursal	I-DISO
disease	I-DISO
virus	O
were	O
higher	O
in	O
HYPER	O
chicks	O
during	O
1	O
wk	O
of	O
age	O
,	O
although	O
not	O
different	O
in	O
their	O
dams	O
.	O

Higher	O
cutaneous	O
basophilic	O
hypersensitivity	B-DISO
response	I-DISO
in	O
HYPER	O
chicks	O
(	O
d	O
10	O
)	O
was	O
not	O
observed	O
at	O
35	O
d	O
of	O
age	O
.	O

CONCLUSIONS	O
:	O
Early	O
OI	O
(	O
within	O
3	O
days	O
)	O
and	O
SOFA	O
score	O
were	O
predictors	O
of	O
mortality	O
in	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Pathophysiology	O
of	O
leptospirosis	B-DISO
.	O

TITLE	O
:	O
A	O
longitudinal	O
study	O
of	O
the	O
dynamics	O
of	O
bovine	O
corona	O
virus	O
and	O
respiratory	B-DISO
syncytial	I-DISO
virus	I-DISO
infections	I-DISO
in	O
dairy	O
herds	O
.	O

A	O
myocardial	O
biopsy	O
was	O
taken	O
to	O
exclude	O
giant	B-DISO
cell	I-DISO
myocarditis	I-DISO
.	O

Recently	O
,	O
another	O
coronavirus	O
(	O
human	O
coronavirus	O
-	O
Erasmus	O
Medical	O
Center	O
(	O
hCoV	O
-	O
EMC	B-DISO
))	O
was	O
identified	O
in	O
patients	O
with	O
severe	O
and	O
sometimes	O
lethal	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
.	O

This	O
publication	O
addresses	O
the	O
clinical	O
and	O
radiological	O
features	O
of	O
ARDS	B-DISO
,	O
a	O
review	O
of	O
the	O
imaging	O
technology	O
with	O
illustrations	O
and	O
differential	O
diagnosis	O
.	O

The	O
predictive	O
value	O
of	O
the	O
MSA	B-DISO
and	O
CAM	B-DISO
score	O
were	O
calculated	O
.	O

Cerebral	B-DISO
malaria	I-DISO
and	O
acute	O
kidney	O
injury	O
occurred	O
earlier	O
(	O
median	O
day	O
1	O
)	O
than	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
median	O
day	O
3	O
).	O

Co	B-DISO
-	I-DISO
infection	I-DISO
with	O
HIV	B-DISO
was	O
relatively	O
common	O
but	O
compared	O
to	O
studies	O
in	O
children	O
,	O
bacteraemia	B-DISO
was	O
uncommon	O
.	O

HFOV	O
is	O
effective	O
in	O
improving	O
oxygenation	O
in	O
adults	O
with	O
ARDS	B-DISO
,	O
particularly	O
when	O
instituted	O
early	O
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
)	O
is	O
a	O
causative	O
agent	O
of	O
the	O
common	B-DISO
cold	I-DISO
.	O

TITLE	O
:	O
Continuous	O
veno	O
-	O
venous	O
hemofiltration	O
for	O
massive	O
rhabdomyolysis	B-DISO
after	O
malignant	B-DISO
hyperthermia	I-DISO
:	O
report	O
of	O
2	O
cases	O
.	O

CVVH	O
is	O
a	O
valuable	O
therapeutic	O
application	O
in	O
the	O
initial	O
/	O
critical	O
management	O
of	O
severe	O
rhabdomyolysis	B-DISO
.	O

Total	O
47	O
patients	O
fulfilling	O
criterion	O
of	O
complicated	B-DISO
malaria	I-DISO
due	O
to	O
P	O
.	O
falciparum	O
who	O
presented	O
with	O
fever	O
having	O
positive	O
trophozoites	O
of	O
P	O
.	O
falciparum	O
in	O
blood	O
smear	O
were	O
included	O
in	O
this	O
study	O
.	O

Total	O
three	O
(	O
6	O
.	O
38	O
%)	O
patients	O
had	O
hypoglycemia	B-DISO
at	O
the	O
time	O
of	O
admission	O
.	O

The	O
case	O
fatality	O
rate	O
for	O
isolated	O
ARDS	B-DISO
was	O
50	O
%	O
(	O
2	O
/	O
4	O
),	O
with	O
ARF	B-DISO
was	O
20	O
%	O
(	O
1	O
/	O
5	O
)	O
and	O
with	O
cerebral	B-DISO
malaria	I-DISO
it	O
was	O
16	O
.	O
66	O
%	O
(	O
1	O
/	O
6	O
).	O

Case	O
fatality	O
rate	O
was	O
highest	O
in	O
patients	O
with	O
ARDS	B-DISO
compared	O
to	O
ARF	B-DISO
and	O
cerebral	B-DISO
malaria	I-DISO
with	O
'	O
P	O
'	O
=	O
0	O
.	O
0221	O
.	O

The	O
use	O
of	O
antiplatelet	O
therapy	O
before	O
the	O
diagnosis	O
of	O
severe	B-DISO
sepsis	I-DISO
or	O
septic	B-DISO
shock	I-DISO
was	O
not	O
associated	O
with	O
decreased	O
hospital	O
mortality	O
.	O

(	O
1	O
)	O
Patients	O
with	O
complications	O
had	O
a	O
decreased	O
initial	O
Glasgow	O
Coma	B-DISO
Scale	O
and	O
tended	O
to	O
have	O
a	O
lower	O
ISS	B-DISO
.	O

The	O
notice	O
of	O
229E	O
/	O
NL63	O
coronavirus	O
and	O
its	O
relationship	O
to	O
the	O
recent	O
outbreaks	O
of	O
avian	O
influenza	B-DISO
in	I-DISO
humans	I-DISO
and	O
the	O
clinical	O
presentation	O
of	O
the	O
case	O
were	O
the	O
epidemiological	O
circumstances	O
that	O
prevented	O
the	O
nation	O
epidemiology	O
system	O
to	O
establish	O
global	O
containment	O
strategies	O
to	O
prevent	O
the	O
spread	O
of	O
this	O
emerging	O
infection	B-DISO
.	O

Its	O
behavior	O
in	O
pregnancy	O
,	O
reported	O
by	O
Assistant	O
General	O
Direction	O
of	O
Epidemiology	O
in	O
Mexico	O
,	O
has	O
placed	O
this	O
infection	B-DISO
as	O
a	O
risk	O
factor	O
for	O
women	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
of	O
somatostatin	O
,	O
ulinastatin	O
and	O
Salvia	O
miltiorrhiza	O
for	O
treatment	O
of	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
.	O

Three	O
hundred	O
six	O
patients	O
with	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
were	O
divided	O
randomly	O
into	O
5	O
groups	O
:	O
basic	O
treatment	O
,	O
somatostatin	O
,	O
somatostatin	O
+	O
ulinastatin	O
,	O
somatostatin	O
+	O
S	O
miltiorrhiza	O
and	O
somatostatin	O
+	O
ulinastatin	O
+	O
S	O
miltiorrhiza	O
.	O

ABSTRACT	O
:	O
Conventional	O
therapy	O
against	O
acute	O
pediatric	O
cardiopulmonary	B-DISO
failure	I-DISO
(	O
APCPF	O
)	O
caused	O
by	O
a	O
variety	O
of	O
disease	O
entities	O
remains	O
unsatisfactory	O
with	O
extremely	O
high	O
morbidity	O
and	O
mortality	O
.	O

ABSTRACT	O
:	O
Feline	O
coronavirus	O
(	O
FCoV	O
)	O
infection	B-DISO
is	O
common	O
.	O

This	O
article	O
reviews	O
our	O
current	O
understanding	O
of	O
the	O
contribution	O
of	O
pulmonary	O
dysfunction	O
to	O
mortality	O
and	O
to	O
quality	O
of	O
life	O
in	O
survivors	O
of	O
ARDS	B-DISO
,	O
the	O
mechanisms	O
driving	O
pathological	O
fibroproliferation	O
and	O
potential	O
therapeutic	O
approaches	O
to	O
prevent	O
or	O
attenuate	O
fibroproliferative	O
lung	B-DISO
disease	I-DISO
.	O

TITLE	O
:	O
Histophilus	O
somni	O
-	O
induced	B-DISO
infections	I-DISO
in	O
cattle	O
from	O
southern	O
Brazil	O
.	O

Two	O
Histophilus	O
somni	O
-	O
associated	O
syndromes	B-DISO
were	O
identified	O
:	O
systemic	O
histophilosis	O
(	O
n	O
=	O
4	O
)	O
and	O
abortion	O
(	O
n	O
=	O
1	O
).	O

ABSTRACT	O
:	O
TMPRSS2	O
(	O
transmembrane	O
serine	O
proteinase	O
2	O
)	O
is	O
a	O
multidomain	O
type	O
II	O
transmembrane	O
serine	O
protease	O
that	O
cleaves	O
the	O
surface	O
glycoprotein	O
HA	O
(	O
haemagglutinin	O
)	O
of	O
influenza	B-DISO
viruses	O
with	O
a	O
monobasic	O
cleavage	O
site	O
,	O
which	O
is	O
a	O
prerequisite	O
for	O
virus	O
fusion	O
and	O
propagation	O
.	O

The	O
first	O
series	O
comprises	O
substrate	O
analogue	O
inhibitors	O
containing	O
a	O
4	O
-	O
amidinobenzylamide	O
moiety	O
at	O
the	O
P1	O
position	O
,	O
whereby	O
some	O
of	O
these	O
analogues	O
possess	B-DISO
inhibition	O
constants	O
of	O
approximately	O
20	O
nM	O
.	O
An	O
improved	O
potency	O
was	O
found	O
for	O
a	O
second	O
type	O
derived	O
from	O
sulfonylated	O
3	O
-	O
amindinophenylalanylamide	O
derivatives	O
.	O

This	O
range	O
of	O
human	O
tissue	O
tropism	O
is	O
broader	O
than	O
that	O
for	O
all	O
other	O
HCoVs	O
,	O
including	O
SARS	B-DISO
coronavirus	O
,	O
HCoV	O
-	O
OC43	O
,	O
HCoV	O
-	O
HKU1	O
,	O
HCoV	O
-	O
229E	O
,	O
and	O
HCoV	O
-	O
NL63	O
,	O
which	O
may	O
explain	O
the	O
high	O
mortality	O
associated	O
with	O
this	O
disease	O
.	O

We	O
found	O
that	O
HCoV	O
-	O
EMC	B-DISO
can	O
also	O
infect	O
civet	O
lung	O
fibroblast	O
and	O
rabbit	O
kidney	O
cell	O
lines	O
.	O

The	O
other	O
10	O
critical	O
residues	O
were	O
distributed	O
throughout	O
the	O
N7	O
-	O
MTase	O
domain	O
but	O
localized	O
mainly	O
in	O
the	O
S	O
-	O
adenosyl	O
-	O
l	O
-	O
methionine	O
(	O
SAM	B-DISO
)-	O
binding	O
pocket	O
and	O
key	O
structural	O
elements	O
of	O
the	O
MTase	O
fold	O
of	O
nsp14	O
.	O

Alcohol	O
misuse	O
was	O
common	O
with	O
70	O
(	O
7	O
%)	O
of	O
patients	O
having	O
Alcohol	B-DISO
Use	I-DISO
Disorders	I-DISO
Identification	O
Test	O
scores	O
in	O
zone	O
3	O
and	O
129	O
(	O
12	O
%)	O
patients	O
in	O
zone	O
4	O
.	O

The	O
synthesized	O
2	O
-(	O
3	O
-	O
amino	O
-	O
4	O
-	O
piperazinylphenyl	O
)-	O
chromones	O
showed	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
corona	O
virus	O
(	O
SARS	B-DISO
-	O
CoV	O
)-	O
specific	O
antiviral	O
activity	O
.	O

Polymyxin	O
B	O
-	O
immobilized	O
fiber	O
column	O
direct	O
hemoperfusion	O
(	O
PMX	O
-	O
DHP	O
)	O
is	O
a	O
medical	O
device	O
that	O
reduces	O
blood	O
endotoxin	O
levels	O
in	O
sepsis	B-DISO
.	O

The	O
patient	O
rapidly	O
developed	O
respiratory	B-DISO
failure	I-DISO
and	O
required	O
mechanical	O
ventilation	O
.	O

The	O
aim	O
is	O
to	O
report	O
the	O
cases	O
and	O
look	O
for	O
malaria	B-DISO
conditions	O
that	O
may	O
affect	O
the	O
incidence	O
of	O
this	O
unusual	O
malaria	B-DISO
complication	B-DISO
.	O

Patients	O
with	O
AAC	O
have	O
significantly	O
more	O
commonly	O
five	O
or	O
more	O
criteria	O
of	O
severe	O
malaria	B-DISO
:	O
renal	B-DISO
insufficiency	I-DISO
,	O
pulmonary	B-DISO
oedema	I-DISO
/	O
ARDS	B-DISO
,	O
parasitaemia	O
higher	O
than	O
30	O
%,	O
nosocomial	B-DISO
infection	I-DISO
and	O
a	O
prolonged	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
stay	O
.	O

Use	O
of	O
combination	O
of	O
bronchodilators	O
and	O
inhaled	O
corticosteroids	O
was	O
more	O
frequent	O
in	O
younger	O
patients	O
with	O
more	O
severe	O
airways	B-DISO
obstruction	I-DISO
and	O
lower	O
CCI	O
.	O

The	O
predictors	O
of	O
NIV	O
failure	O
were	O
the	O
severity	O
of	O
associated	O
organ	O
dysfunctions	O
(	O
OR	O
,	O
1	O
.	O
20	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
05	O
to	O
1	O
.	O
34	O
),	O
ARDS	B-DISO
(	O
OR	O
,	O
2	O
.	O
31	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
10	O
to	O
4	O
.	O
82	O
)	O
and	O
positive	O
fluid	O
balance	O
(	O
OR	O
,	O
2	O
.	O
09	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
02	O
to	O
4	O
.	O
30	O
).	O

In	O
a	O
retrospective	O
study	O
167	O
long	O
-	O
term	O
survivors	O
of	O
severe	O
ARDS	B-DISO
who	O
were	O
transferred	O
to	O
the	O
clinic	O
for	O
anesthesiology	O
of	O
the	O
University	O
of	O
Munich	O
,	O
Campus	O
Großhadern	O
by	O
means	O
of	O
specialized	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
transport	O
teams	O
and	O
treated	O
over	O
a	O
period	O
of	O
20	O
years	O
(	O
1985	O
-	O
2005	O
)	O
were	O
evaluated	O
to	O
investigate	O
whether	O
significant	O
improvements	O
in	O
outcome	O
as	O
a	O
consequence	O
of	O
the	O
above	O
mentioned	O
progress	O
in	O
ARDS	B-DISO
therapy	O
have	O
occurred	O
.	O

The	O
ARDS	B-DISO
patient	O
cohort	O
studied	O
was	O
characterized	O
with	O
regard	O
to	O
demographic	O
variables	O
,	O
initial	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
(	O
APACHE	O
)	O
II	O
score	O
,	O
duration	O
of	O
ICU	O
treatment	O
,	O
the	O
duration	O
of	O
mechanical	O
ventilation	O
and	O
mortality	O
.	O

ABSTRACT	O
:	O
The	O
role	O
of	O
mast	O
cells	O
(	O
MCs	B-DISO
)	O
in	O
allergic	B-DISO
reactions	I-DISO
and	O
parasitic	O
infections	B-DISO
is	O
well	O
established	O
.	O

Thirty	O
-	O
four	O
patients	O
with	O
at	O
least	O
5	O
years	O
of	O
HIV	B-DISO
infection	I-DISO
and	O
27	O
healthy	O
controls	O
underwent	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
in	O
a	O
1	O
.	O
5	O
T	O
scanner	O
.	O

This	O
hypothesis	O
should	O
be	O
tested	O
in	O
a	O
double	O
blind	B-DISO
randomized	O
controlled	O
trial	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
)	O
is	O
an	O
acute	O
and	O
highly	O
contagious	O
enteric	O
disease	O
of	O
swine	O
caused	O
by	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
).	O

TITLE	O
:	O
Metagenomic	O
study	O
of	O
the	O
viruses	O
of	O
African	O
straw	O
-	O
coloured	O
fruit	O
bats	O
:	O
detection	O
of	O
a	O
chiropteran	O
poxvirus	O
and	O
isolation	O
of	O
a	O
novel	O
adenovirus	B-DISO
.	O

We	O
identified	O
a	O
great	O
abundance	O
and	O
diversity	O
of	O
novel	O
herpes	B-DISO
and	O
papillomaviruses	O
,	O
described	O
the	O
isolation	O
of	O
a	O
novel	O
adenovirus	B-DISO
,	O
and	O
detected	O
,	O
for	O
the	O
first	O
time	O
,	O
sequences	O
of	O
a	O
chiropteran	O
poxvirus	O
closely	O
related	O
with	O
Molluscum	B-DISO
contagiosum	I-DISO
.	O

ABSTRACT	O
:	O
The	O
primary	O
challenge	O
to	O
mountain	O
lion	O
population	O
viability	O
in	O
California	O
is	O
habitat	O
loss	O
and	O
fragmentation	B-DISO
.	O

Combined	O
with	O
other	O
stressors	O
,	O
such	O
as	O
ongoing	O
habitat	O
loss	O
,	O
infectious	B-DISO
disease	I-DISO
deserves	O
recognition	O
for	O
potential	O
negative	O
impact	O
on	O
mountain	O
lion	O
health	O
and	O
population	O
viability	O
.	O

TITLE	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
in	O
a	O
mountain	O
lion	O
(	O
Puma	O
concolor	O
),	O
California	O
,	O
USA	O
.	O

Regardless	O
of	O
presentation	O
,	O
FIP	B-DISO
is	O
ultimately	O
fatal	O
and	O
often	O
presents	O
a	O
diagnostic	O
challenge	O
.	O

RESULTS	O
:	O
CMV	O
is	O
frequent	O
and	O
severe	O
in	O
immunosuppressed	O
infants	O
but	O
infrequent	O
in	O
full	O
-	O
term	O
neonates	O
and	O
occurs	O
more	O
frequently	O
after	O
perinatal	O
than	O
after	O
congenital	B-DISO
infection	I-DISO
,	O
particularly	O
in	O
premature	O
infants	O
.	O

TITLE	O
:	O
Pandemic	O
planning	O
and	O
response	O
in	O
academic	O
pediatric	O
emergency	B-DISO
departments	O
during	O
the	O
2009	O
H1N1	B-DISO
influenza	I-DISO
pandemic	O
.	O

Pediatric	O
emergency	B-DISO
departments	O
(	O
EDs	B-DISO
)	O
were	O
disproportionately	O
burdened	O
by	O
the	O
2009	O
H1N1	B-DISO
influenza	I-DISO
pandemic	O
and	O
therefore	O
serve	O
as	O
a	O
robust	O
context	O
for	O
evaluation	O
of	O
pandemic	O
preparedness	O
.	O

ABSTRACT	O
:	O
To	O
report	O
two	O
cases	O
of	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
(	O
GBS	B-DISO
)	O
which	O
occurred	O
following	O
traumatic	O
bone	O
injuries	O
.	O

These	O
cases	O
highlight	O
the	O
importance	O
of	O
considering	O
GBS	B-DISO
as	O
a	O
differential	O
diagnosis	O
when	O
patients	O
with	O
traumatic	O
bone	O
injuries	O
develop	O
acute	O
neuromuscular	B-DISO
weakness	I-DISO
.	O

An	O
oxygenator	O
used	O
in	O
conjunction	O
with	O
a	O
VAD	O
may	O
be	O
a	O
life	O
-	O
saving	O
therapy	O
,	O
allowing	O
adequate	O
oxygenation	O
and	O
ventilation	O
in	O
severe	O
respiratory	O
and	O
cardiac	B-DISO
failure	I-DISO
.	O

ABSTRACT	O
:	O
A	O
novel	O
betacoronavirus	O
,	O
human	O
coronavirus	O
(	O
HCoV	O
-	O
EMC	B-DISO
),	O
has	O
recently	O
been	O
detected	O
in	O
humans	O
with	O
severe	O
respiratory	B-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
a	O
newly	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
,	O
and	O
an	O
effective	O
vaccine	O
is	O
not	O
available	O
.	O

However	O
,	O
in	O
the	O
last	O
decade	O
novel	O
potent	O
mAbs	O
have	O
been	O
discovered	O
and	O
characterized	O
with	O
potential	O
as	O
therapeutics	O
against	O
viruses	O
of	O
major	O
importance	O
for	O
public	O
health	O
and	O
biosecurity	O
including	O
Hendra	O
virus	O
(	O
HeV	O
),	O
Nipah	O
virus	O
(	O
NiV	O
),	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
Ebola	O
virus	O
(	O
EBOV	O
),	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
(	O
WNV	B-DISO
),	O
influenza	B-DISO
virus	O
(	O
IFV	O
)	O
and	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
type	O
1	O
(	O
HIV	B-DISO
-	O
1	O
).	O

Respiratory	O
specimens	O
were	O
tested	O
for	O
influenza	B-DISO
and	O
other	O
respiratory	O
viruses	O
by	O
means	O
of	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	O
-	O
polymerase	O
-	O
chain	O
-	O
reaction	O
assays	O
,	O
viral	O
culturing	O
,	O
and	O
sequence	O
analyses	O
.	O

Complications	O
included	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
multiorgan	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Acute	O
-	O
phase	O
concentrations	O
of	O
soluble	O
fibrinogen	O
inhibit	O
neutrophil	O
adhesion	B-DISO
under	O
flow	O
conditions	O
in	O
vitro	O
through	O
interactions	O
with	O
ICAM	O
-	O
1	O
and	O
MAC	O
-	O
1	O
(	O
CD11b	O
/	O
CD18	O
).	O

The	O
level	O
of	O
soluble	O
fibrinogen	O
is	O
increased	O
during	O
chronic	O
and	O
acute	O
inflammation	B-DISO
,	O
but	O
the	O
function	O
of	O
this	O
increase	O
is	O
unknown	O
.	O

To	O
study	O
the	O
effect	O
of	O
soluble	O
fibrinogen	O
in	O
concentrations	O
found	O
in	O
severe	O
acute	O
inflammation	B-DISO
on	O
leukocyte	O
adhesion	B-DISO
.	O

Importantly	O
soluble	O
fibrinogen	O
in	O
acute	O
-	O
phase	O
concentrations	O
(	O
4	O
-	O
10	O
mg	O
mL	O
(-	O
1	O
)	O
)	O
dose	O
-	O
dependently	O
reduced	O
neutrophil	O
firm	O
adhesion	B-DISO
to	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
α	O
-	O
activated	O
endothelium	O
to	O
40	O
%	O
under	O
flow	O
conditions	O
.	O

The	O
localization	O
of	O
ORT	O
within	O
the	O
lung	O
tissue	O
was	O
demonstrated	O
by	O
fluorescent	O
in	O
-	O
situ	O
hybridization	O
in	O
the	O
bronchial	O
exudate	O
of	O
three	O
cases	O
,	O
although	O
not	O
within	O
the	O
granulomatous	B-DISO
lesions	I-DISO
themselves	O
.	O

Diffuse	B-DISO
infiltrative	I-DISO
lung	I-DISO
disease	I-DISO
(	O
DILD	O
)	O
is	O
rare	O
and	O
occurs	O
most	O
often	O
in	O
the	O
course	O
of	O
the	O
disease	O
.	O

We	O
analyzed	O
seven	O
cases	O
of	O
DILO	O
of	O
SD	O
recorded	O
between	O
2003	O
and	O
2010	O
among	O
196	O
PID	B-DISO
(	O
3	O
.	O
6	O
%).	O

Clinical	O
examination	O
found	O
crackles	B-DISO
in	O
the	O
bases	O
of	O
the	O
thorax	O
in	O
all	O
cases	O
and	O
specific	O
cutaneous	O
signs	O
in	O
six	O
cases	O
.	O

The	O
chest	O
radiograph	O
showed	O
that	O
interstitial	B-DISO
disease	I-DISO
predominates	O
at	O
the	O
lung	O
bases	O
in	O
all	O
cases	O
with	O
a	O
large	O
aspect	O
of	O
the	O
pulmonary	O
arteries	O
in	O
two	O
cases	O
.	O

The	O
chest	O
CT	O
scan	O
confirmed	O
the	O
predominance	O
of	O
basal	O
and	O
peripheral	O
damage	O
with	O
signs	O
of	O
fibrosis	B-DISO
in	O
six	O
cases	O
.	O

ABSTRACT	O
:	O
The	O
study	O
investigates	O
the	O
ability	O
of	O
subtype	O
A	O
Avian	O
metapneumovirus	O
(	O
AMPV	O
)	O
to	O
accept	O
foreign	O
genes	O
and	O
be	O
used	O
as	O
a	O
vector	O
for	O
delivery	O
of	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
QX	O
genes	O
to	O
chickens	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
correlation	O
between	O
post	O
-	O
severe	O
acute	O
respiratory	B-DISO
symptom	I-DISO
(	O
SARS	B-DISO
)	O
patients	O
with	O
osteonecrosis	B-DISO
,	O
investigate	O
the	O
etiology	O
of	O
post	O
-	O
SARS	B-DISO
osteonecrosis	B-DISO
and	O
select	O
the	O
sensitive	O
molecular	O
symbols	O
for	O
early	O
diagnosis	O
and	O
distinguish	O
the	O
high	O
-	O
risk	O
population	O
.	O

Plasminogen	O
activator	O
inhibitor	O
(	O
PAI	O
)	O
by	O
means	O
of	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
PAI	B-DISO
-	I-DISO
1	I-DISO
4G	I-DISO
/	I-DISO
5G	I-DISO
polymorphism	I-DISO
was	O
detected	O
by	O
polymerase	O
chain	O
reaction	O
and	O
solid	O
phase	O
oligonucleotide	O
assay	O
.	O

The	O
blood	O
agents	O
of	O
post	O
-	O
SARS	B-DISO
patients	O
changed	O
obviously	O
with	O
15	O
.	O
64	O
±	O
13	O
.	O
85	O
U	O
/	O
ml	O
while	O
the	O
control	O
group	O
7	O
.	O
96	O
±	O
4	O
.	O
27	O
U	O
/	O
ml	O
;	O
4G	O
/	O
4G	O
genotype	O
for	O
the	O
PAI	B-DISO
-	I-DISO
1	I-DISO
polymorphism	I-DISO
detected	O
in	O
post	O
-	O
SARS	B-DISO
group	O
was	O
more	O
than	O
that	O
of	O
the	O
control	O
group	O
,	O
but	O
had	O
no	O
statistical	O
significance	O
.	O

In	O
conclusion	O
,	O
the	O
in	O
vivo	O
mutation	O
transition	B-DISO
hypothesis	O
and	O
the	O
circulating	O
high	O
virulent	O
-	O
low	O
virulent	O
FCoV	O
hypothesis	O
have	O
been	O
found	O
to	O
be	O
plausible	O
according	O
to	O
the	O
results	O
obtained	O
from	O
sequencing	O
the	O
M	O
gene	O
.	O

Respiratory	B-DISO
symptoms	I-DISO
were	O
noted	O
in	O
18	O
participants	O
.	O

TITLE	O
:	O
Adult	O
refractory	O
hypoxemic	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
treated	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
:	O
the	O
role	O
of	O
a	O
regional	O
referral	O
center	O
.	O

Human	O
-	O
to	O
-	O
human	O
transmission	O
has	O
not	O
been	O
observed	O
,	O
but	O
zoonotic	O
infections	B-DISO
of	O
nrH7N9	O
from	O
birds	O
to	O
humans	O
appear	O
to	O
be	O
associated	O
with	O
live	O
poultry	O
markets	O
.	O

To	O
assess	O
the	O
function	O
of	O
a	O
relatively	O
conserved	O
domain	O
(	O
LLRKxGxKG	O
)	O
of	O
MHV	O
nsp1	O
,	O
a	O
mutant	B-DISO
virus	O
,	O
MHV	O
-	O
nsp1	O
-	O
27D	O
,	O
with	O
a	O
27	O
nts	O
(	O
LLRKxGxKG	O
)	O
deletion	O
in	O
nsp1	O
,	O
was	O
constructed	O
using	O
a	O
reverse	O
genetic	O
system	O
with	O
a	O
vaccinia	B-DISO
virus	O
vector	O
.	O

The	O
mutant	B-DISO
virus	O
had	O
similar	O
growth	O
kinetics	O
to	O
MHV	O
-	O
A59	O
wild	O
-	O
type	O
virus	O
in	O
17CI	O
-	O
1	O
cells	O
,	O
but	O
was	O
highly	O
attenuated	O
in	O
vivo	O
.	O

ABSTRACT	O
:	O
We	O
present	O
a	O
serological	O
assay	O
for	O
the	O
specific	O
detection	O
of	O
IgM	O
and	O
IgG	O
antibodies	O
against	O
the	O
emerging	O
human	O
coronavirus	O
hCoV	O
-	O
EMC	B-DISO
and	O
the	O
SARS	B-DISO
-	O
CoV	O
based	O
on	O
protein	O
microarray	O
technology	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
the	O
cause	O
of	O
an	O
economically	O
important	O
swine	B-DISO
disease	I-DISO
.	O

Previous	O
studies	O
suggested	O
that	O
PEDV	O
does	O
not	O
elicit	O
a	O
robust	O
IFN	O
response	O
,	O
but	O
the	O
mechanism	O
(	O
s	O
)	O
used	O
to	O
evade	O
or	O
block	O
this	O
innate	B-DISO
immune	I-DISO
response	I-DISO
was	O
not	O
known	O
.	O

These	O
results	O
show	O
that	O
PEDV	O
infection	B-DISO
suppresses	O
production	O
of	O
IFN	O
-	O
β	O
and	O
provides	O
evidence	O
indicating	O
that	O
the	O
PEDV	O
papain	O
-	O
like	O
protease	O
2	O
acts	O
as	O
a	O
viral	O
DUB	O
to	O
interfere	O
with	O
the	O
RIG	O
-	O
I	O
-	O
and	O
STING	O
-	O
mediated	O
signalling	O
pathway	O
.	O

The	O
amplified	O
product	O
of	O
the	O
FIP	B-DISO
virus	O
(	O
223	O
-	O
bp	O
)	O
was	O
analyzed	O
within	O
10s	O
by	O
single	O
-	O
channel	O
ME	O
under	O
a	O
sieving	O
gel	O
of	O
0	O
.	O
3	O
%	O
poly	O
(	O
ethylene	O
oxide	O
)	O
(	O
Mr	O
=	O
8	O
,	O
000	O
,	O
000	O
)	O
in	O
1x	O
TBE	O
buffer	O
(	O
pH	O
8	O
.	O
33	O
)	O
and	O
a	O
short	O
effective	O
channel	O
length	O
of	O
1	O
.	O
3	O
cm	O
with	O
a	O
programmed	O
step	O
electric	O
field	O
strength	O
(	O
PSEFS	O
)	O
condition	B-DISO
as	O
follows	O
:	O
470	O
.	O
6	O
V	O
/	O
cm	O
for	O
9	O
s	O
,	O
294	O
.	O
1	O
V	O
/	O
cm	O
1	O
.	O
5	O
s	O
,	O
and	O
470	O
.	O
6	O
V	O
/	O
cm	O
for	O
9	O
.	O
5	O
s	O
.	O
The	O
single	O
-	O
channel	O
ME	O
/	O
PSEFS	O
method	O
was	O
50	O
times	O
faster	O
than	O
that	O
obtained	O
with	O
conventional	O
slab	O
gel	O
electrophoresis	O
.	O

This	O
phenomenon	O
is	O
called	O
ventilator	O
induced	O
lung	O
injury	O
(	O
VILI	O
),	O
and	O
plays	O
a	O
significant	O
role	O
in	O
morbidity	O
and	O
mortality	O
associated	O
with	O
ARDS	B-DISO
.	O

The	O
patients	O
were	O
randomly	O
treated	O
with	O
normal	O
saline	O
(	O
NS	O
group	O
),	O
combination	O
of	O
normal	O
saline	O
and	O
hydroxyethyl	O
starch	O
(	O
HES	B-DISO
)	O
(	O
SH	O
group	O
),	O
combination	O
of	O
normal	O
saline	O
,	O
hydroxyethyl	O
starch	O
and	O
glutamine	O
(	O
SHG	O
group	O
)	O
in	O
resuscitation	O
.	O

TITLE	O
:	O
Monoclonal	O
antibody	O
against	O
membrane	O
protein	O
of	O
transmissible	O
gastroenteritis	B-DISO
virus	O
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
is	O
a	O
porcine	O
coronavirus	O
that	O
can	O
cause	O
piglet	O
diarrhea	B-DISO
with	O
high	O
mortality	O
rates	O
.	O

After	O
sequence	O
analysis	O
,	O
the	O
scFv	O
/	O
6E6	O
gene	O
was	O
cloned	O
into	O
the	O
prokaryotic	O
expression	O
vector	O
pGEX	O
-	O
6p	O
-	O
1	O
with	O
a	O
GST	O
-	O
tag	B-DISO
.	O

ABSTRACT	O
:	O
The	O
efficacy	O
of	O
systemic	O
corticosteroids	O
in	O
many	O
critical	B-DISO
illnesses	I-DISO
remains	O
uncertain	O
.	O

These	O
competing	O
indications	O
will	O
complicate	O
the	O
design	O
and	O
interpretation	O
of	O
any	O
future	O
large	O
-	O
scale	O
trial	O
of	O
corticosteroids	O
in	O
critical	B-DISO
illness	I-DISO
.	O

However	O
,	O
infectious	B-DISO
virus	O
was	O
still	O
detected	O
after	O
20	O
days	O
storage	O
at	O
the	O
cooler	O
temperatures	O
,	O
a	O
finding	O
that	O
suggests	O
prolonged	O
survival	O
of	O
Fr	O
TCoV	O
and	O
easier	O
transmission	O
between	O
poultry	O
farms	O
in	O
a	O
cool	O
environment	O
are	O
possible	O
.	O

T	O
regulatory	O
(	O
T	O
(	O
reg	O
))	O
cells	O
in	O
the	O
lungs	O
are	O
reported	O
to	O
modify	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
during	O
resolution	O
of	O
acute	O
lung	O
injury	O
.	O

HMGB1	O
was	O
expressed	O
in	O
the	O
infiltrating	B-DISO
neutrophils	O
and	O
macrophages	O
in	O
lungs	O
.	O

Immunohistochemistry	O
for	O
intracellular	O
feline	O
coronavirus	O
(	O
FeCoV	O
)	O
antigen	O
demonstrated	O
positive	O
staining	O
in	O
dermal	O
macrophages	O
providing	O
an	O
antemortem	O
diagnosis	O
of	O
a	O
moderate	O
,	O
nodular	O
to	O
diffuse	O
,	O
pyogranulomatous	O
perivascular	B-DISO
dermatitis	I-DISO
due	O
to	O
FIP	B-DISO
infection	B-DISO
.	O

Logistic	O
regression	O
modeling	O
demonstrates	O
that	O
the	O
presence	O
of	O
an	O
operative	O
fracture	O
increased	O
the	O
odds	O
of	O
developing	O
at	O
least	O
one	O
complication	B-DISO
approximately	O
three	O
times	O
(	O
odds	O
ratio	O
,	O
2	O
.	O
88	O
,	O
p	O
=	O
0	O
.	O
006	O
),	O
after	O
controlling	O
for	O
presence	O
of	O
chest	O
injury	O
and	O
type	O
of	O
injured	O
abdominal	O
organ	O
.	O

The	O
procoagulant	O
phenotype	O
and	O
perhaps	O
also	O
certain	O
pregnancy	B-DISO
complications	I-DISO
follow	O
from	O
activated	O
protein	O
C	O
(	O
APC	B-DISO
)	O
resistance	O
.	O

However	O
,	O
the	O
patient	O
again	O
developed	O
persistent	O
hypoxaemia	O
and	O
,	O
after	O
unsuccessful	O
treatment	O
for	O
a	O
hospital	O
-	O
acquired	O
pneumonia	B-DISO
,	O
the	O
problems	O
further	O
expanded	O
to	O
include	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
(	O
ILD	O
).	O

Five	O
candidate	O
genes	O
ELMO1	O
,	O
RRAGA	O
,	O
TNFSF10	O
,	O
ERAP1	O
and	O
ERAP2	O
,	O
all	O
relevant	O
to	O
what	O
is	O
known	O
about	O
FIP	B-DISO
virus	B-DISO
pathogenesis	I-DISO
,	O
were	O
identified	O
but	O
no	O
single	O
association	O
was	O
fully	O
concordant	O
with	O
the	O
disease	O
phenotype	O
.	O

TITLE	O
:	O
Anti	B-DISO
-	I-DISO
NMDA	I-DISO
receptor	I-DISO
encephalitis	I-DISO
in	O
children	O
:	O
the	O
disorder	O
,	O
its	O
diagnosis	O
,	O
and	O
treatment	O
.	O

ABSTRACT	O
:	O
Anti	B-DISO
-	I-DISO
NMDA	I-DISO
receptor	I-DISO
encephalitis	I-DISO
is	O
a	O
newly	O
characterized	O
severe	O
neuroautoimmune	O
syndrome	B-DISO
with	O
a	O
progressive	O
,	O
clinical	O
course	O
.	O

Thus	O
,	O
myofibroblasic	O
FRC	O
precursors	O
are	O
able	O
to	O
generate	O
the	O
basic	O
T	O
cell	O
zone	O
infrastructure	O
,	O
whereas	O
LTβR	O
-	O
dependent	O
maturation	O
of	O
FRCs	O
guarantees	O
full	O
immunocompetence	O
and	O
hence	O
optimal	O
LN	O
function	O
during	O
infection	B-DISO
.	O

TITLE	O
:	O
Geranylated	O
flavonoids	O
displaying	O
SARS	B-DISO
-	O
CoV	O
papain	O
-	O
like	O
protease	O
inhibition	O
from	O
the	O
fruits	O
of	O
Paulownia	O
tomentosa	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
and	O
optimize	O
the	O
molecular	O
detection	O
assays	O
for	O
recently	O
identified	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
infection	B-DISO
.	O

Bronchiolitis	B-DISO
and	O
pneumonia	B-DISO
were	O
the	O
most	O
frequent	O
diagnoses	O
in	O
NL63	O
positive	O
patients	O
and	O
the	O
major	O
symptoms	O
were	O
fever	O
and	O
cough	B-DISO
in	O
our	O
study	O
.	O

TITLE	O
:	O
Risk	O
factors	O
for	O
severe	O
acute	O
lower	O
respiratory	B-DISO
infections	I-DISO
in	O
children	O
:	O
a	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
.	O

ABSTRACT	O
:	O
To	O
estimate	O
the	O
proportional	O
contribution	O
of	O
influenza	B-DISO
viruses	O
(	O
IV	O
),	O
parainfluenza	B-DISO
viruses	O
(	O
PIV	O
),	O
adenoviruses	O
(	O
AV	O
),	O
and	O
coronaviruses	O
(	O
CV	O
)	O
to	O
the	O
burden	O
of	O
severe	O
acute	O
lower	O
respiratory	B-DISO
infections	I-DISO
(	O
ALRI	O
).	O

Later	O
in	O
infection	B-DISO
,	O
HCoV	O
-	O
EMC	B-DISO
induced	O
a	O
massive	O
dysregulation	O
of	O
the	O
host	O
transcriptome	O
,	O
to	O
a	O
much	O
greater	O
extent	O
than	O
SARS	B-DISO
-	O
CoV	O
.	O
Both	O
viruses	O
induced	O
a	O
similar	O
activation	O
of	O
pattern	O
recognition	O
receptors	O
and	O
the	O
interleukin	O
17	O
(	O
IL	O
-	O
17	O
)	O
pathway	O
,	O
but	O
HCoV	O
-	O
EMC	B-DISO
specifically	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
several	O
genes	O
within	O
the	O
antigen	O
presentation	O
pathway	O
,	O
including	O
both	O
type	O
I	O
and	O
II	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
genes	O
.	O

Identification	O
of	O
a	O
novel	O
coronavirus	O
causing	O
fatal	O
respiratory	B-DISO
infection	I-DISO
in	O
humans	O
raises	O
concerns	O
about	O
a	O
possible	O
widespread	O
outbreak	O
of	O
severe	O
respiratory	B-DISO
infection	I-DISO
similar	O
to	O
the	O
one	O
caused	O
by	O
SARS	B-DISO
-	O
CoV	O
.	O
Using	O
a	O
human	O
lung	O
epithelial	O
cell	O
line	O
and	O
global	O
transcriptomic	O
profiling	O
,	O
we	O
identified	O
differences	O
in	O
the	O
host	O
response	O
between	O
HCoV	O
-	O
EMC	B-DISO
and	O
SARS	B-DISO
-	O
CoV	O
.	O
This	O
enables	O
rapid	O
assessment	O
of	O
viral	O
properties	O
and	O
the	O
ability	O
to	O
anticipate	O
possible	O
differences	O
in	O
human	O
clinical	O
responses	O
to	O
HCoV	O
-	O
EMC	B-DISO
and	O
SARS	B-DISO
-	O
CoV	O
.	O
We	O
used	O
this	O
information	O
to	O
predict	O
potential	O
effective	O
drugs	O
against	O
HCoV	O
-	O
EMC	B-DISO
,	O
a	O
method	O
that	O
could	O
be	O
more	O
generally	O
used	O
to	O
identify	O
candidate	O
therapeutics	O
in	O
future	O
disease	O
outbreaks	O
.	O

TITLE	O
:	O
[	O
ARDS	B-DISO
--	O
an	O
update	O
].	O

The	O
mortality	O
in	O
severe	O
ARDS	B-DISO
is	O
as	O
high	O
as	O
50	O
%.	O

The	O
fundamental	O
basis	O
of	O
therapy	O
is	O
to	O
treat	O
the	O
underlying	O
cause	O
of	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Severe	O
respiratory	O
viral	B-DISO
infections	I-DISO
are	O
associated	O
with	O
spread	O
to	O
the	O
alveoli	O
of	O
the	O
lungs	O
.	O

In	O
this	O
study	O
,	O
we	O
established	O
an	O
in	O
vitro	O
model	O
to	O
compare	O
the	O
responses	O
of	O
type	O
I	O
(	O
ATI	O
)	O
and	O
type	O
II	O
(	O
ATII	O
)	O
alveolar	O
epithelial	O
cells	O
to	O
infection	B-DISO
by	O
respiratory	O
viruses	O
used	O
in	O
murine	O
models	O
:	O
mouse	O
-	O
adapted	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
,	O
v2163	O
),	O
murine	O
coronavirus	O
MHV	O
-	O
1	O
,	O
and	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
virus	O
,	O
strain	O
PR8	O
.	O

Murine	O
alveolar	O
cells	O
cultured	O
to	O
maintain	O
an	O
ATII	O
cell	O
phenotype	O
,	O
determined	O
by	O
expression	O
of	O
LBP180	O
,	O
were	O
susceptible	O
to	O
infection	B-DISO
by	O
all	O
three	O
viruses	O
.	O

However	O
,	O
clinicians	O
seeing	O
pet	O
rabbits	O
in	O
North	O
America	O
infrequently	O
encounter	O
viral	B-DISO
diseases	I-DISO
although	O
myxomatosis	O
may	O
be	O
seen	O
occasionally	O
.	O

Between	O
2000	O
and	O
2010	O
,	O
19	O
patients	O
with	O
severe	O
respiratory	B-DISO
failure	I-DISO
caused	O
by	O
Legionella	O
were	O
managed	O
with	O
ECMO	O
after	O
failure	O
to	O
respond	O
to	O
conventional	O
intensive	O
care	O
management	O
.	O

TITLE	O
:	O
Dieckol	O
,	O
a	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
inhibitor	O
,	O
isolated	O
from	O
the	O
edible	O
brown	O
algae	O
Ecklonia	O
cava	O
.	O

The	O
main	O
clinical	O
signs	O
of	O
affected	O
horses	O
were	O
anorexia	B-DISO
,	O
pyrexia	O
and	O
leucopenia	B-DISO
;	O
gastrointestinal	B-DISO
disease	I-DISO
was	O
observed	O
in	O
about	O
10	O
%	O
of	O
affected	O
horses	O
.	O

Clinicians	O
should	O
consider	O
the	O
diagnosis	O
of	O
avian	B-DISO
influenza	I-DISO
A	O
(	O
H7N9	O
)	O
virus	B-DISO
infection	I-DISO
in	O
persons	O
with	O
acute	O
respiratory	O
illness	O
and	O
relevant	O
exposure	O
history	O
and	O
should	O
contact	O
their	O
state	O
health	O
departments	O
regarding	O
specimen	O
collection	O
and	O
facilitation	O
of	O
confirmatory	O
testing	O
.	O

ABSTRACT	O
:	O
Dengue	B-DISO
is	O
a	O
mosquito	O
-	O
borne	O
viral	B-DISO
disease	I-DISO
endemic	O
in	O
many	O
countries	O
in	O
the	O
tropics	O
and	O
sub	O
-	O
tropics	O
.	O

In	O
comparisons	O
with	O
the	O
control	O
subjects	O
(	O
n	O
=	O
18	O
)	O
and	O
convalescent	O
SARS	B-DISO
patients	O
without	O
PTSD	B-DISO
(	O
n	O
=	O
26	O
),	O
the	O
SARS	B-DISO
-	O
related	O
PTSD	B-DISO
group	O
(	O
n	O
=	O
18	O
)	O
had	O
significantly	O
lower	O
N	O
-	O
acetylaspartate	O
/	O
creatine	O
(	O
NAA	O
/	O
Cr	O
)	O
in	O
4	O
regions	O
of	O
interest	O
while	O
the	O
NAA	O
/	O
Cr	O
of	O
the	O
convalescent	O
SARS	B-DISO
patients	O
was	O
significantly	O
lower	O
than	O
controls	O
in	O
3	O
regions	O
of	O
interest	O
(	O
ACG	O
,	O
PCG	O
and	O
LAPWM	O
).	O

CONCLUSIONS	O
:	O
The	O
changes	O
of	O
brain	O
metabolism	O
in	O
PTSD	B-DISO
are	O
caused	O
by	O
SARS	B-DISO
.	O

TITLE	O
:	O
Life	O
-	O
threatening	O
hypokalemia	O
following	O
rapid	O
correction	O
of	O
respiratory	B-DISO
acidosis	I-DISO
.	O

We	O
conclude	O
that	O
rapid	O
correction	O
of	O
respiratory	B-DISO
acidosis	I-DISO
,	O
especially	O
in	O
the	O
setting	O
of	O
hypotension	O
,	O
can	O
lead	O
to	O
life	O
-	O
threatening	O
hypokalemia	O
.	O

Admission	O
pneumonia	B-DISO
scores	O
were	O
calculated	O
,	O
and	O
clinical	O
variables	O
were	O
registered	O
during	O
the	O
first	O
24h	O
.	O

ABSTRACT	O
:	O
Puumala	O
virus	O
(	O
PUUV	O
)	O
is	O
considered	O
a	O
classic	O
Old	O
World	O
etiologic	O
agent	O
of	O
nephropathia	B-DISO
epidemica	I-DISO
(	O
NE	O
),	O
or	O
hemorrhagic	B-DISO
fever	I-DISO
with	I-DISO
renal	I-DISO
syndrome	I-DISO
(	O
HFRS	B-DISO
).	O

Adjunctive	O
therapies	O
discussed	O
include	O
pharmacologic	O
techniques	O
(	O
for	O
example	O
,	O
vasodilators	O
,	O
diuretics	O
,	O
neuromuscular	B-DISO
blockade	I-DISO
)	O
and	O
nonpharmacologic	O
techniques	O
(	O
for	O
example	O
,	O
prone	O
position	O
,	O
alternative	O
modes	O
of	O
ventilation	O
).	O

Cell	O
therapy	O
,	O
particularly	O
with	O
allogeneic	O
mesenchymal	O
stem	O
/	O
stromal	O
cells	O
(	O
MSCs	O
),	O
has	O
emerged	O
as	O
a	O
promising	O
therapeutic	O
strategy	O
for	O
ARDS	B-DISO
,	O
favorably	O
modulating	O
the	O
immune	O
response	O
to	O
reduce	O
lung	O
injury	O
,	O
while	O
facilitating	O
lung	O
regeneration	O
and	O
repair	O
.	O

Despite	O
improvement	O
in	O
these	O
strategies	O
,	O
recent	O
data	O
indicate	O
that	O
the	O
mortality	O
of	O
ALI	O
/	O
ARDS	B-DISO
is	O
still	O
as	O
high	O
as	O
30	O
to	O
50	O
%.	O

Thus	O
,	O
there	O
is	O
a	O
need	O
for	O
innovative	O
therapies	O
to	O
further	O
improve	O
clinical	O
outcomes	O
of	O
ALI	O
/	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Prevalence	O
and	O
prognosis	O
of	O
cor	B-DISO
pulmonale	I-DISO
during	O
protective	O
ventilation	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Two	O
hundred	O
and	O
twenty	O
-	O
six	O
consecutive	O
patients	O
with	O
moderate	O
to	O
severe	O
ARDS	B-DISO
(	O
Berlin	O
definition	O
)	O
ventilated	O
with	O
plateau	O
pressure	O
limited	O
at	O
30	O
cmH₂O	O
(	O
mean	O
PEEP	O
of	O
8	O
.	O
8	O
±	O
3	O
.	O
6	O
cmH₂O	O
)	O
underwent	O
transesophageal	O
echocardiography	O
(	O
TEE	O
)	O
within	O
the	O
first	O
3	O
days	O
after	O
the	O
diagnosis	O
of	O
ARDS	B-DISO
.	O

Multivariate	O
logistic	O
regression	O
identified	O
McCabe	O
and	O
Jackson	O
class	O
,	O
lung	O
injury	O
not	O
related	O
to	O
pneumonia	B-DISO
,	I-DISO
aspiration	I-DISO
,	O
or	O
sepsis	B-DISO
,	O
lactic	B-DISO
acidosis	I-DISO
,	O
driving	O
pressure	O
,	O
and	O
cor	B-DISO
pulmonale	I-DISO
as	O
independent	O
risk	O
factors	O
for	O
28	O
-	O
day	O
mortality	O
.	O

Cor	B-DISO
pulmonale	I-DISO
occurrence	O
is	O
not	O
negligible	O
in	O
ARDS	B-DISO
patients	O
ventilated	O
with	O
airway	O
pressure	O
limitation	O
.	O

Serum	O
IgG	O
antibodies	O
has	O
diagnostic	O
value	O
for	O
SARS	B-DISO
in	O
the	O
late	O
course	O
of	O
disease	O
and	O
the	O
antibodies	O
present	O
more	O
than	O
48	O
months	O
.	O

The	O
HLH	B-DISO
continued	O
to	O
progress	O
after	O
discontinuation	O
of	O
blinatumomab	O
;	O
however	O
,	O
he	O
had	O
rapid	O
improvement	O
after	O
IL	O
-	O
6	O
receptor	O
-	O
directed	O
therapy	O
with	O
tocilizumab	O
.	O

This	O
study	O
provides	O
solid	O
evidence	O
that	O
induction	O
of	O
GADD153	O
by	O
PERK	O
and	O
PKR	O
plays	O
an	O
important	O
regulatory	O
role	O
in	O
the	O
apoptotic	O
process	O
triggered	O
by	O
IBV	O
infection	B-DISO
.	O

DMV	O
/	O
1639	O
/	O
11	O
and	O
PA	O
/	O
9579A	O
/	O
10	O
were	O
determined	O
to	O
be	O
nephropathogenic	O
in	O
susceptible	O
chickens	O
,	O
yielding	O
virus	O
reisolations	O
from	O
kidney	O
and	O
inducing	O
characteristic	O
interstitial	B-DISO
nephritis	I-DISO
microscopic	O
lesions	O
.	O

Adenovirus	B-DISO
was	O
recovered	O
with	O
efficiencies	O
of	O
56	O
.	O
5	O
,	O
31	O
.	O
8	O
,	O
and	O
34	O
.	O
8	O
%	O
from	O
lettuce	O
,	O
strawberries	O
,	O
and	O
raspberries	O
,	O
respectively	O
.	O

In	O
this	O
paper	O
,	O
we	O
review	O
evidence	O
that	O
lung	O
endothelial	O
activation	O
and	O
vascular	O
leak	O
are	O
a	O
""""	O
final	O
common	O
pathway	O
""""	O
in	O
severe	O
influenza	B-DISO
,	O
as	O
has	O
been	O
reported	O
in	O
bacterial	B-DISO
sepsis	I-DISO
,	O
and	O
that	O
enhancing	O
endothelial	O
barrier	O
function	O
may	O
improve	O
the	O
outcome	O
of	O
illness	O
.	O

We	O
describe	O
a	O
number	O
of	O
experimental	O
therapies	O
that	O
have	O
shown	O
promise	O
in	O
preventing	O
or	O
reversing	O
increased	O
vascular	O
leak	O
in	O
animal	O
models	O
of	O
sepsis	B-DISO
or	O
influenza	B-DISO
.	O

TITLE	O
:	O
Epidemiological	O
survey	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
in	O
swine	O
farms	O
in	O
Shanghai	O
,	O
China	O
.	O

In	O
patients	O
with	O
severe	O
ARDS	B-DISO
,	O
early	O
application	O
of	O
prolonged	O
prone	O
-	O
positioning	O
sessions	O
significantly	O
decreased	O
28	O
-	O
day	O
and	O
90	O
-	O
day	O
mortality	O
.	O

Overall	O
,	O
the	O
whole	O
set	O
of	O
experiments	O
supports	O
the	O
proteolipidic	O
structure	O
of	O
SARS	B-DISO
-	O
CoV	O
E	O
channels	O
and	O
explains	O
the	O
large	O
difference	O
in	O
channel	O
conductance	O
observed	O
between	O
neutral	O
and	O
charged	O
membranes	O
.	O

TITLE	O
:	O
[	O
The	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
malaria	B-DISO
:	O
is	O
it	O
always	O
the	O
prerogative	O
of	O
Plasmodium	O
falciparum	O
?].	O

We	O
report	O
the	O
case	O
of	O
a	O
young	O
Moroccan	O
soldier	O
who	O
died	O
in	O
an	O
array	O
of	O
ARDS	B-DISO
related	O
to	O
malaria	B-DISO
of	O
Plasmodium	O
ovale	O
7	O
months	O
after	O
his	O
return	O
from	O
an	O
endemic	O
country	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
infections	I-DISO
(	O
ARIs	O
)	O
are	O
the	O
leading	O
cause	O
of	O
children	O
and	O
their	O
leading	O
killer	O
.	O

Influenza	B-DISO
B	O
(	O
Flu	B-DISO
B	O
)	O
and	O
seasonal	O
influenza	B-DISO
A	O
H1N1	O
(	O
sH1N1	O
)	O
were	O
not	O
detected	O
.	O

Single	O
-	O
infections	B-DISO
were	O
detected	O
in	O
30	O
.	O
5	O
%	O
(	O
85	O
/	O
279	O
)	O
of	O
cases	O
.	O

Compared	O
to	O
controls	O
,	O
ARDS	B-DISO
demonstrates	O
increased	O
serum	O
endotoxin	O
and	O
IL	O
-	O
6	O
levels	O
,	O
and	O
decreased	O
HDL	O
,	O
apoA	O
-	O
I	O
and	O
activity	O
of	O
anti	O
-	O
oxidant	O
HDL	O
-	O
associated	O
paraoxanase	O
-	O
1	O
.	O

ABSTRACT	O
:	O
Prospective	O
data	O
on	O
viral	O
etiology	O
and	O
clinical	O
characteristics	O
of	O
bronchiolitis	B-DISO
and	O
upper	O
respiratory	O
illness	O
(	O
URI	O
)	O
in	O
infants	O
are	O
limited	O
.	O

Among	O
infants	O
with	O
URI	O
,	O
46	O
%	O
had	O
HRV	O
,	O
14	O
%	O
RSV	O
,	O
12	O
%	O
influenza	B-DISO
,	O
7	O
%	O
coronavirus	O
,	O
6	O
%	O
parainfluenza	B-DISO
virus	O
and	O
4	O
%	O
human	O
metapneumovirus	O
.	O

The	O
most	O
common	O
infections	B-DISO
among	O
infants	O
seeking	O
care	O
in	O
unscheduled	O
medical	O
visits	O
for	O
URI	O
or	O
bronchiolitis	B-DISO
were	O
RSV	O
and	O
HRV	O
.	O

Demographic	O
differences	O
were	O
observed	O
between	O
patients	O
with	O
different	O
viruses	O
,	O
suggesting	O
that	O
host	O
and	O
viral	O
factors	O
play	O
a	O
role	O
in	O
phenotypic	O
expression	O
of	O
viral	B-DISO
illness	I-DISO
.	O

A	O
total	O
of	O
61	O
.	O
3	O
%	O
of	O
the	O
patients	O
had	O
at	O
least	O
one	O
underlying	O
medical	O
condition	B-DISO
.	O

Activation	O
of	O
RNase	O
L	O
correlated	O
with	O
the	O
induction	O
of	O
type	O
I	O
interferon	O
and	O
the	O
consequent	O
high	O
levels	O
of	O
OAS	B-DISO
mRNA	O
induced	O
in	O
these	O
cell	O
types	O
.	O

It	O
has	O
been	O
reported	O
that	O
a	O
cyclophilin	O
inhibitor	O
,	O
cyclosporin	O
A	O
(	O
CsA	B-DISO
),	O
could	O
inhibit	O
the	O
replication	O
of	O
coronaviruses	O
.	O

CsA	B-DISO
is	O
a	O
well	O
-	O
known	O
immunosuppressive	O
drug	O
that	O
binds	O
to	O
cellular	O
cyclophilins	O
to	O
inhibit	O
calcineurin	O
,	O
a	O
calcium	O
-	O
calmodulin	O
-	O
activated	O
serine	O
/	O
threonine	O
-	O
specific	O
phosphatase	O
.	O

TITLE	O
:	O
Identifying	O
SARS	B-DISO
-	O
CoV	O
membrane	O
protein	O
amino	O
acid	O
residues	O
linked	O
to	O
virus	O
-	O
like	O
particle	O
assembly	O
.	O

TITLE	O
:	O
Anaesthesia	B-DISO
and	O
intensive	O
care	O
management	O
of	O
face	B-DISO
transplantation	O
.	O

ABSTRACT	O
:	O
The	O
face	B-DISO
-	O
grafting	O
techniques	O
are	O
innovative	O
and	O
highly	O
complex	O
,	O
requiring	O
well	O
-	O
defined	O
organization	O
of	O
all	O
the	O
teams	O
involved	O
.	O

Anaesthesia	B-DISO
for	O
this	O
long	O
procedure	O
involves	O
advanced	O
planning	O
for	O
airway	O
management	O
,	O
vascular	O
access	O
,	O
technique	O
of	O
anaesthesia	B-DISO
,	O
and	O
fluid	O
management	O
.	O

Opportunistic	O
bacterial	B-DISO
infections	I-DISO
were	O
a	O
feature	O
during	O
the	O
postoperative	O
period	O
in	O
these	O
highly	O
immunosuppressed	O
patients	O
.	O

This	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
distribution	O
of	O
respiratory	O
viruses	O
in	O
patients	O
with	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
(	O
ILI	B-DISO
)	O
through	O
the	O
first	O
teaching	O
hospital	O
-	O
based	O
surveillance	O
scheme	O
for	O
ILI	B-DISO
in	O
South	O
Korea	O
.	O

TITLE	O
:	O
Experimental	O
study	O
on	O
histopathological	O
changes	O
and	O
tissue	O
tropism	O
of	O
Iranian	O
infectious	B-DISO
bronchitis	B-DISO
serotype	O
793	O
/	O
B	O
-	O
like	O
virus	O
in	O
SPF	O
chickens	O
.	O

Serum	O
tests	O
for	O
feline	O
immunodeficiency	B-DISO
virus	O
(	O
FIV	O
)	O
and	O
feline	O
leukaemia	B-DISO
virus	O
(	O
FeLV	O
)	O
were	O
negative	O
.	O

Broad	O
-	O
spectrum	O
antibiotic	O
treatment	O
for	O
infectious	B-DISO
hepatitis	I-DISO
was	O
to	O
no	O
avail	O
;	O
the	O
cat	O
deteriorated	O
and	O
died	O
72	O
h	O
after	O
admission	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
its	O
most	O
severe	O
form	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
were	O
presciently	O
described	O
nearly	O
two	O
centuries	O
ago	O
by	O
René	O
Laennec	O
,	O
later	O
to	O
be	O
described	O
clinically	O
in	O
the	O
1950s	O
and	O
1960s	O
.	O

No	O
secondary	B-DISO
transmission	I-DISO
was	O
documented	O
in	O
hospital	O
staff	O
despite	O
the	O
absence	O
of	O
specific	O
protective	O
measures	O
before	O
the	O
diagnosis	O
of	O
MERS	O
-	O
CoV	O
was	O
suspected	O
.	O

French	O
Institute	O
for	O
Public	O
Health	O
Surveillance	O
,	O
ANR	O
grant	O
Labex	O
Integrative	O
Biology	O
of	O
Emerging	B-DISO
Infectious	I-DISO
Diseases	I-DISO
,	O
and	O
the	O
European	O
Community	O
'	O
s	O
Seventh	O
Framework	O
Programme	O
projects	O
EMPERIE	O
and	O
PREDEMICS	O
.	O

Examples	O
include	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
,	O
and	O
Nipah	O
,	O
lymphocytic	B-DISO
choriomeningitis	I-DISO
,	O
West	O
Nile	O
,	O
Cache	O
Valley	O
,	O
and	O
Heartland	O
viruses	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
its	O
more	O
severe	O
form	O
of	O
clinical	O
manifestation	O
,	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
is	O
associated	O
with	O
significant	O
dysfunction	O
in	O
air	O
exchange	O
due	O
to	O
inflammation	B-DISO
of	O
the	O
lung	O
parenchyma	O
.	O

The	O
region	O
is	O
certainly	O
a	O
hot	B-DISO
spot	I-DISO
of	O
socioeconomic	O
and	O
environmental	O
change	O
,	O
and	O
although	O
some	O
changes	O
(	O
e	O
.	O
g	O
.,	O
urbanization	O
and	O
agricultural	O
intensification	O
)	O
may	O
reduce	O
the	O
probability	O
of	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
,	O
the	O
effect	O
of	O
any	O
individual	O
emergence	O
event	O
may	O
be	O
increased	O
by	O
the	O
greater	O
concentration	O
and	O
connectivity	O
of	O
livestock	O
,	O
persons	O
,	O
and	O
products	O
.	O

Specific	O
CT	O
images	O
of	O
GC	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
included	O
enlarged	O
and	O
high	O
-	O
tensioned	O
gallbladder	O
,	O
wall	O
thickening	O
,	O
lumenal	O
emphysema	B-DISO
,	O
discontinuous	O
and	O
/	O
or	O
irregular	O
enhancement	O
of	O
mucosa	O
,	O
and	O
pericholecystic	O
effusion	B-DISO
.	O

RESULTS	O
:	O
Specific	O
CT	O
images	O
of	O
GC	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
included	O
enlarged	O
and	O
high	O
-	O
tensioned	O
gallbladder	O
,	O
wall	O
thickening	O
,	O
lumenal	O
emphysema	B-DISO
,	O
discontinuous	O
and	O
/	O
or	O
irregular	O
enhancement	O
of	O
mucosa	O
,	O
and	O
pericholecystic	O
effusion	B-DISO
.	O

Sensitivities	O
of	O
RV16	O
,	O
RV15	O
,	O
and	O
culture	O
for	O
virus	O
tested	O
were	O
as	O
follows	O
:	O
100	O
/	O
93	O
/	O
63	O
%	O
for	O
influenza	B-DISO
A	O
,	O
90	O
/	O
80	O
/	O
69	O
%	O
for	O
influenza	B-DISO
B	O
,	O
98	O
/	O
94	O
/	O
63	O
%	O
for	O
RSV	O
,	O
98	O
/	O
52	O
/	O
23	O
%	O
for	O
adenovirus	B-DISO
,	O
and	O
100	O
/	O
75	O
/	O
46	O
%	O
for	O
PIV	O
.	O

Lungs	O
are	O
most	O
commonly	O
affected	O
organs	O
(	O
with	O
exception	O
of	O
muscles	O
and	O
skin	O
)	O
in	O
polymyositis	B-DISO
and	O
dermatomyositis	B-DISO
.	O

These	O
results	O
suggest	O
that	O
compounds	O
isolated	O
from	O
E	O
.	O
cava	O
have	O
strong	O
antiviral	O
activity	O
against	O
PEDV	O
,	O
inhibiting	O
viral	O
entry	O
and	O
/	O
or	O
viral	O
replication	O
,	O
and	O
may	O
be	O
developed	O
into	O
natural	O
therapeutic	O
drugs	O
against	O
coronavirus	B-DISO
infection	I-DISO
.	O

Management	O
challenges	O
included	O
sedation	B-DISO
,	O
weaning	O
from	O
sedation	B-DISO
,	O
and	O
liberation	O
from	O
mechanical	O
ventilation	O
.	O

We	O
confirmed	O
the	O
chylomicronemia	B-DISO
syndrome	I-DISO
with	O
a	O
triglyceride	O
assay	O
.	O

RESULTS	O
:	O
A	O
49	O
-	O
year	O
-	O
old	O
man	O
developed	O
acute	O
hypercapneic	O
respiratory	B-DISO
failure	I-DISO
during	O
an	O
episode	O
of	O
community	O
-	O
acquired	O
pneumonia	B-DISO
.	O

His	O
condition	B-DISO
became	O
complicated	O
with	O
pneumonia	B-DISO
,	O
septic	B-DISO
shock	I-DISO
,	O
ARDS	B-DISO
,	O
coagulation	O
dysfunction	O
,	O
and	O
renal	B-DISO
failure	I-DISO
.	O

The	O
expressed	O
products	O
were	O
purified	O
by	O
affinity	O
chromatography	O
then	O
analyzed	O
by	O
SDS	B-DISO
-	O
PAGE	O
and	O
Western	O
blotting	O
.	O

TITLE	O
:	O
[	O
Molecular	O
characterization	O
and	O
phylogenetic	O
analysis	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
field	O
strains	O
in	O
central	O
China	O
during	O
2010	O
-	O
2012	O
outbreaks	O
].	O

Besides	O
lung	O
-	O
protective	O
ventilation	O
as	O
a	O
confirmed	O
therapeutic	O
option	O
,	O
supportive	O
therapy	O
is	O
an	O
integral	O
part	O
of	O
ARDS	B-DISO
management	O
.	O

The	O
febrile	O
respiratory	O
illness	O
screening	O
tool	O
missed	O
26	O
%	O
of	O
active	O
influenza	B-DISO
cases	O
,	O
while	O
67	O
%	O
of	O
noninfluenza	O
patients	O
were	O
unnecessarily	O
placed	O
under	O
respiratory	O
isolation	O
.	O

It	O
is	O
thought	O
that	O
mutations	O
in	O
FECV	O
enable	O
infection	B-DISO
of	O
macrophages	O
,	O
causing	O
FIP	B-DISO
.	O

Although	O
the	O
pathological	O
characteristics	O
of	O
PHEV	O
are	O
largely	O
unknown	O
,	O
apoptosis	O
may	O
be	O
the	O
pathological	O
basis	O
of	O
the	O
lesions	O
resulting	O
from	O
PHEV	O
infection	B-DISO
.	O

The	O
prevalence	O
of	O
infectious	B-DISO
pathogens	O
under	O
study	O
was	O
between	O
0	O
%	O
(	O
Lawsonia	O
intracellularis	O
)	O
and	O
34	O
.	O
6	O
%	O
(	O
equine	O
rotavirus	O
).	O

Six	O
of	O
the	O
8	O
infectious	B-DISO
agents	O
were	O
associated	O
with	O
the	O
GI	O
-	O
diseased	O
group	O
,	O
the	O
other	O
2	O
were	O
not	O
(	O
equine	O
coronavirus	O
and	O
R	O
.	O
equi	O
).	O

In	O
this	O
study	O
we	O
have	O
compared	O
the	O
complications	O
in	O
vivax	B-DISO
malaria	I-DISO
with	O
those	O
in	O
falciparum	O
or	O
mixed	B-DISO
malaria	I-DISO
.	O

2	O
)	O
To	O
compare	O
the	O
incidence	O
of	O
complications	O
in	O
vivax	O
,	O
falciparum	O
and	O
mixed	B-DISO
malaria	I-DISO
.	O

31	O
%	O
cases	O
of	O
severe	O
malaria	B-DISO
had	O
vivax	O
monoinfection	O
.	O

Morbidity	O
odds	O
ratios	O
(	O
95	O
%	O
confidence	O
interval	O
)	O
for	O
complications	O
were	O
not	O
significant	O
for	O
HRR	O
but	O
were	O
for	O
crystalloids	O
:	O
bacteremia	B-DISO
,	O
1	O
.	O
05	O
(	O
1	O
.	O
0	O
-	O
1	O
.	O
1	O
);	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
1	O
.	O
13	O
(	O
1	O
.	O
0	O
-	O
1	O
.	O
2	O
),	O
and	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
1	O
.	O
05	O
(	O
1	O
.	O
0	O
-	O
1	O
.	O
1	O
).	O

Morbidity	O
odds	O
ratios	O
(	O
95	O
%	O
confidence	O
interval	O
)	O
for	O
complications	O
were	O
not	O
significant	O
for	O
HRR	O
but	O
were	O
for	O
crystalloids	O
:	O
bacteremia	B-DISO
,	O
1	O
.	O
05	O
(	O
1	O
.	O
0	O
-	O
1	O
.	O
1	O
);	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
1	O
.	O
13	O
(	O
1	O
.	O
0	O
-	O
1	O
.	O
2	O
),	O
and	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
1	O
.	O
05	O
(	O
1	O
.	O
0	O
-	O
1	O
.	O
1	O
).	O

During	O
early	O
resuscitation	O
(	O
0	O
-	O
6	O
h	O
),	O
logistic	O
regression	O
revealed	O
age	O
(	O
odd	O
ratio	O
[	O
OR	O
],	O
1	O
.	O
02	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
1	O
.	O
00	O
-	O
1	O
.	O
04	O
),	O
chest	O
AIS	B-DISO
score	O
(	O
OR	O
,	O
1	O
.	O
31	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
10	O
-	O
1	O
.	O
57	O
),	O
and	O
intravenously	O
administered	O
crystalloid	O
fluids	O
given	O
in	O
500	O
mL	O
increments	O
(	O
OR	O
,	O
1	O
.	O
12	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
01	O
-	O
1	O
.	O
25	O
)	O
as	O
predictive	O
of	O
moderate	O
or	O
severe	O
hypoxemia	O
.	O

MERS	O
-	O
CoV	O
might	O
have	O
shedding	O
patterns	O
that	O
are	O
different	O
from	O
those	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
so	O
might	O
need	O
alternative	O
diagnostic	O
approaches	O
.	O

Infectious	B-DISO
agent	O
detection	O
by	O
PCR	O
provided	O
greater	O
sensitivity	O
than	O
conventional	O
techniques	O
.	O

TITLE	O
:	O
Transmission	O
scenarios	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
how	O
to	O
tell	O
them	O
apart	O
.	O

In	O
particular	O
,	O
our	O
data	O
show	O
that	O
DC	O
-	O
SIGNR	O
has	O
a	O
different	O
binding	O
mode	O
for	O
glycans	O
on	O
the	O
HIV	B-DISO
viral	O
envelope	O
compared	O
with	O
the	O
smaller	O
glycans	O
previously	O
observed	O
in	O
the	O
crystalline	O
state	O
.	O

However	O
,	O
a	O
large	O
proportion	O
of	O
HSA	B-DISO
prescription	O
is	O
inappropriate	O
.	O

As	O
a	O
result	O
,	O
a	O
more	O
appropriate	O
HSA	B-DISO
use	O
can	O
be	O
achieved	O
maintaining	O
the	O
health	O
care	O
expenditure	O
under	O
control	O
.	O

As	O
of	O
14	O
June	O
2013	O
,	O
58	O
human	O
cases	O
of	O
MERS	O
CoV	O
infection	B-DISO
have	O
been	O
confirmed	O
,	O
including	O
33	O
deaths	O
(	O
case	O
fatality	O
rate	O
of	O
57	O
%).	O

MERS	O
CoV	O
is	O
a	O
beta	O
-	O
coronavirus	O
,	O
in	O
the	O
same	O
family	O
as	O
SARS	B-DISO
-	O
CoV	O
,	O
and	O
shares	O
a	O
probable	O
origin	O
from	O
bats	O
.	O

ABSTRACT	O
:	O
A	O
sudden	O
increase	O
in	O
the	O
number	O
of	O
novel	O
influenza	B-DISO
A	O
virus	O
(	O
pH1N1	O
-	O
2009	O
)	O
infection	B-DISO
prompted	O
us	O
to	O
compare	O
the	O
clinical	O
presentation	O
and	O
outcomes	O
of	O
patients	O
infected	O
with	O
pH1N1	O
-	O
2009	O
and	O
seasonal	O
influenza	B-DISO
A	O
virus	O
during	O
the	O
post	O
-	O
pandemic	O
phase	O
.	O

Patients	O
with	O
severe	O
hypoxia	B-DISO
,	O
hypertension	B-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
shock	O
required	O
ICU	O
care	O
.	O

182	O
patients	O
had	O
died	O
because	O
of	O
a	O
pandemic	O
influenza	B-DISO
in	O
Poland	O
by	O
31st	O
July	O
2010	O
.	O

Autopsies	O
were	O
performed	O
in	O
5	O
cases	O
and	O
revealed	O
haemorrhagic	B-DISO
pneumonia	I-DISO
in	O
2	O
patients	O
.	O

CONCLUSIONS	O
:	O
Delayed	O
diagnosis	O
and	O
antiviral	O
treatment	O
initiation	O
has	O
a	O
significant	O
impact	O
on	O
mortality	O
in	O
A	O
(	O
H1N1	O
)	O
influenza	B-DISO
.	O

TITLE	O
:	O
Exchange	O
transfusion	O
for	O
severe	O
malaria	B-DISO
:	O
evidence	O
base	O
and	O
literature	O
review	O
.	O

ABSTRACT	O
:	O
Exchange	O
transfusion	O
(	O
ET	O
)	O
has	O
biologic	O
plausibility	O
as	O
an	O
adjunct	O
to	O
antimalarial	O
drugs	O
in	O
treating	O
severe	O
malaria	B-DISO
and	O
has	O
been	O
used	O
for	O
decades	O
despite	O
limited	O
evidence	O
of	O
its	O
efficacy	O
in	O
improving	O
survival	O
.	O

Patients	O
with	O
severe	O
malaria	B-DISO
reported	O
to	O
the	O
US	O
national	O
malaria	B-DISO
surveillance	O
system	O
during	O
1985	O
-	O
2010	O
were	O
matched	O
,	O
and	O
survival	O
outcomes	O
were	O
compared	O
between	O
patients	O
receiving	O
and	O
not	O
receiving	O
ET	O
.	O

The	O
literature	O
review	O
used	O
search	O
terms	O
""""	O
severe	O
malaria	B-DISO
""""	O
and	O
""""	O
exchange	O
transfusion	O
.	O

Although	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
strains	O
are	O
frequently	O
circulating	O
in	O
cattle	O
farms	O
worldwide	O
,	O
causing	O
both	O
enteric	O
and	O
respiratory	B-DISO
disease	I-DISO
,	O
little	O
is	O
known	O
about	O
their	O
genomic	O
evolution	O
.	O

Tidal	O
volumes	O
,	O
positive	O
end	O
-	O
expiratory	O
pressure	O
,	O
and	O
mean	O
airway	O
pressure	O
were	O
higher	O
in	O
those	O
with	O
a	O
clinical	O
diagnosis	O
of	O
ARDS	B-DISO
.	O

TITLE	O
:	O
[	O
Fatal	O
course	O
of	O
virus	O
-	O
associated	O
pneumonia	B-DISO
in	O
patient	O
with	O
influenza	B-DISO
A	O
(	O
H1N1	O
)].	O

Due	O
to	O
the	O
continuous	O
emergence	O
of	O
new	O
variants	O
of	O
the	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
,	O
the	O
identification	O
of	O
the	O
type	O
of	O
IBV	O
causing	O
an	O
outbreak	O
in	O
commercial	O
poultry	O
is	O
important	O
in	O
the	O
selection	O
of	O
the	O
appropriate	O
vaccine	O
(	O
s	O
)	O
capable	O
of	O
inducing	O
a	O
protective	O
immune	O
response	O
.	O

The	O
screening	O
of	O
antitrypanosomal	O
and	O
antiviral	O
activities	O
of	O
5	O
-(	O
3	O
-	O
naphthalen	O
-	O
2	O
-	O
yl	O
-	O
5	O
-	O
aryl	O
-	O
4	O
,	O
5	O
-	O
dihydropyrazol	O
-	O
1	O
-	O
yl	O
)-	O
thiazolidine	O
-	O
2	O
,	O
4	O
-	O
diones	O
was	O
carried	O
out	O
with	O
the	O
promising	O
influence	O
of	O
the	O
mentioned	O
compounds	O
on	O
Trypanosoma	O
brucei	O
,	O
but	O
minimal	O
effect	O
on	O
SARS	B-DISO
coronavirus	O
and	O
influenza	B-DISO
types	O
A	O
and	O
B	O
viruses	O
.	O

TITLE	O
:	O
A	O
new	O
approach	O
for	O
diagnosis	O
of	O
bovine	O
coronavirus	O
using	O
a	O
reverse	O
transcription	O
recombinase	O
polymerase	O
amplification	B-DISO
assay	O
.	O

TITLE	O
:	O
Severe	O
parainfluenza	B-DISO
pneumonia	B-DISO
in	O
a	O
case	O
of	O
transient	O
hypogammalobulinemia	O
of	O
infancy	O
.	O

ABSTRACT	O
:	O
Human	O
parainfluenza	B-DISO
viruses	O
(	O
HPIVs	O
)	O
infection	B-DISO
,	O
largely	O
known	O
to	O
cause	O
self	O
-	O
limiting	O
bronchiolitis	B-DISO
and	O
pneumonia	B-DISO
in	O
immune	O
competent	O
patients	O
,	O
can	O
lead	O
to	O
severe	O
to	O
fatal	O
pulmonary	B-DISO
disease	I-DISO
in	O
immune	B-DISO
disorders	I-DISO
,	O
such	O
as	O
primary	O
or	O
acquired	O
-	O
immune	O
deficiencies	O
.	O

ABSTRACT	O
:	O
The	O
prevalence	O
of	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
(	O
SCD	B-DISO
)	O
is	O
extremely	O
high	O
in	O
the	O
Democratic	O
Republic	O
of	O
Congo	O
(	O
DRC	O
).	O

Blackwater	B-DISO
fever	I-DISO
was	O
a	O
rare	O
event	O
.	O

We	O
conclude	O
that	O
the	O
acute	O
crisis	O
related	O
to	O
SCD	B-DISO
is	O
more	O
common	O
in	O
children	O
less	O
than	O
5	O
years	O
of	O
age	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
the	O
acute	O
crisis	O
related	O
to	O
SCD	B-DISO
is	O
more	O
common	O
in	O
children	O
less	O
than	O
5	O
years	O
of	O
age	O
.	O

Based	O
on	O
the	O
etiology	O
,	O
children	O
were	O
categorized	O
into	O
three	O
groups	O
:	O
P	B-DISO
.	I-DISO
vivax	I-DISO
,	O
Plasmodium	O
falciparum	O
(	O
P	O
.	O
falciparum	O
)	O
and	O
mixed	B-DISO
infection	I-DISO
.	O

The	O
clinical	O
presentation	O
and	O
outcome	O
of	O
severe	O
vivax	B-DISO
malaria	I-DISO
was	O
found	O
to	O
be	O
similar	O
to	O
severe	O
malaria	B-DISO
caused	O
by	O
P	O
.	O
falciparum	O
and	O
mixed	B-DISO
infection	I-DISO
,	O
except	O
for	O
higher	O
chances	O
of	O
severe	O
anaemia	B-DISO
among	O
the	O
children	O
infected	O
with	O
P	O
.	O
falciparum	O
(	O
P	O
=	O
0	O
·	O
04	O
).	O

ABSTRACT	O
:	O
A	O
32	O
-	O
year	O
-	O
old	O
female	O
with	O
epilepsy	B-DISO
presented	O
at	O
our	O
hospital	O
with	O
high	O
-	O
grade	O
fever	O
,	O
seizures	B-DISO
,	O
and	O
unconsciousness	O
.	O

The	O
clinical	O
features	O
are	O
essentially	O
the	O
same	O
as	O
for	O
any	O
respiratory	O
viral	B-DISO
infections	I-DISO
or	O
pneumonitis	B-DISO
.	O

In	O
medicine	O
,	O
a	O
definition	O
or	O
syndrome	B-DISO
representing	O
""""	O
a	O
constellation	O
of	O
symptomatology	O
seen	O
in	O
association	O
""""	O
should	O
stand	O
the	O
trial	O
of	O
time	O
after	O
it	O
is	O
coined	O
.	O

Fluid	O
management	O
with	O
the	O
goal	O
to	O
obtain	O
zero	O
fluid	O
balance	O
in	O
ARDS	B-DISO
patients	O
without	O
shock	O
or	O
renal	B-DISO
failure	I-DISO
significantly	O
increases	O
the	O
number	O
of	O
days	O
without	O
mechanical	O
ventilation	O
.	O

Aerosolized	O
β2	O
-	O
agonists	O
do	O
not	O
improve	O
outcome	O
in	O
patients	O
with	O
ARDS	B-DISO
and	O
one	O
study	O
strongly	O
suggests	O
that	O
intravenous	O
salbutamol	O
may	O
worsen	O
outcome	O
in	O
those	O
patients	O
.	O

Here	O
we	O
show	O
that	O
the	O
emerging	O
H7N9	O
avian	B-DISO
influenza	I-DISO
virus	O
poses	O
a	O
potentially	O
high	O
risk	O
to	O
humans	O
.	O

An	O
increase	O
in	O
macrophage	O
recruitment	B-DISO
and	O
activation	O
in	O
lung	O
tissues	O
infected	O
with	O
rTGEV	O
-	O
Δ7	O
virus	O
was	O
observed	O
compared	O
to	O
cells	O
infected	O
with	O
the	O
parental	O
virus	O
.	O

Such	O
facilities	O
were	O
essential	O
for	O
the	O
management	O
of	O
highly	O
contagious	O
patients	O
during	O
the	O
2003	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreaks	O
and	O
the	O
more	O
recent	O
2009	O
A	O
/	O
H1N1	B-DISO
influenza	I-DISO
pandemic	O
.	O

Adalimumab	O
is	O
a	O
recombinant	O
human	O
monoclonal	O
antibody	O
that	O
blocks	O
the	O
effects	O
of	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
alpha	O
.	O

Adalimumab	O
related	O
acute	O
lung	O
injury	O
is	O
a	O
rare	O
form	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
of	O
possible	O
immune	O
etiology	O
that	O
develops	O
immediately	O
after	O
an	O
infusion	O
.	O

ABSTRACT	O
:	O
Sepsis	B-DISO
accounts	O
for	O
approximately	O
10	O
%	O
of	O
all	O
maternal	O
deaths	O
.	O

Increasing	O
evidence	O
from	O
pre	O
-	O
clinical	O
studies	O
supports	O
preventive	O
and	O
therapeutic	O
effects	O
of	O
mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
,	O
also	O
called	O
mesenchymal	O
stromal	O
cells	O
)	O
in	O
ALI	O
/	O
ARDS	B-DISO
(	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
).	O

MSCs	O
could	O
reduce	O
the	O
over	O
-	O
production	O
of	O
inflammatory	O
mediators	O
,	O
leucocyte	O
infiltration	B-DISO
,	O
tissue	O
injury	O
and	O
pulmonary	B-DISO
failure	I-DISO
,	O
and	O
produce	O
a	O
number	O
of	O
benefit	O
factors	O
through	O
interaction	O
with	O
other	O
cells	O
in	O
the	O
process	O
of	O
lung	O
tissue	O
repair	O
.	O

In	O
four	O
western	O
Panama	O
clinics	O
,	O
we	O
tested	O
individuals	O
presenting	O
with	O
a	O
severe	O
febrile	O
prodrome	B-DISO
for	O
acute	O
hantavirus	O
(	O
HV	O
)	O
infection	B-DISO
by	O
immunoglobulin	O
M	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
as	O
well	O
as	O
clinically	O
similar	O
infections	B-DISO
,	O
such	O
as	O
dengue	B-DISO
and	O
leptospirosis	B-DISO
.	O

HV	O
infection	B-DISO
caused	O
by	O
Choclo	O
virus	O
in	O
Panama	O
presents	O
often	O
as	O
HF	O
,	O
which	O
contrasts	O
with	O
HV	O
in	O
the	O
Americas	O
but	O
is	O
consistent	O
with	O
the	O
high	O
seroprevalence	O
in	O
endemic	O
regions	O
.	O

Another	O
patient	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
was	O
admitted	O
to	O
the	O
ICU	O
.	O

The	O
emergence	O
of	O
this	O
novel	O
coronavirus	O
prompts	O
the	O
need	O
for	O
a	O
small	O
animal	O
model	O
to	O
study	O
the	O
pathogenesis	B-DISO
of	O
this	O
virus	O
and	O
to	O
test	O
the	O
efficacy	O
of	O
potential	O
intervention	O
strategies	O
.	O

Clinical	O
signs	O
of	O
disease	B-DISO
,	I-DISO
virus	I-DISO
replication	O
,	O
histological	O
lesions	O
,	O
cytokine	O
upregulation	O
nor	O
seroconversion	O
were	O
observed	O
in	O
any	O
of	O
the	O
inoculated	O
animals	O
,	O
indicating	O
that	O
MERS	O
-	O
CoV	O
does	O
not	O
replicate	O
in	O
Syrian	O
hamsters	O
.	O

Patients	O
with	O
severe	O
ARDS	B-DISO
had	O
higher	O
EVLWi	O
(	O
mild	O
,	O
16	O
.	O
1	O
;	O
moderate	O
,	O
17	O
.	O
2	O
;	O
severe	O
,	O
19	O
.	O
1	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
PVPI	O
(	O
2	O
.	O
7	O
;	O
3	O
.	O
0	O
;	O
3	O
.	O
2	O
;	O
P	O
<	O
0	O
.	O
05	O
).	O

RESULTS	O
:	O
Compared	O
to	O
patients	O
with	O
mild	O
ARDS	B-DISO
,	O
patients	O
with	O
moderate	O
and	O
severe	O
ARDS	B-DISO
had	O
higher	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
and	O
sequential	O
organ	B-DISO
failure	I-DISO
assessment	O
scores	O
on	O
the	O
day	O
of	O
enrollment	O
.	O

ABSTRACT	O
:	O
In	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
combined	O
high	O
-	O
frequency	O
oscillation	O
(	O
HFO	O
)	O
and	O
tracheal	O
gas	O
insufflation	O
(	O
TGI	O
)	O
improves	O
gas	O
exchange	O
compared	O
with	O
conventional	O
mechanical	O
ventilation	O
(	O
CMV	O
).	O

Transient	O
improvements	O
were	O
observed	O
after	O
4	O
hours	O
of	O
HFO	O
-	O
TGI	O
versus	O
pre	O
-	O
HFO	O
-	O
TGI	O
CMV	O
in	O
PaCO2	O
(	O
37	O
.	O
7	O
±	O
9	O
.	O
9	O
versus	O
41	O
.	O
2	O
±	O
10	O
.	O
8	O
mm	O
Hg	O
;	O
P	O
<	O
0	O
.	O
01	O
),	O
ICP	B-DISO
(	O
17	O
.	O
2	O
±	O
5	O
.	O
4	O
versus	O
19	O
.	O
7	O
±	O
5	O
.	O
9	O
mm	O
Hg	O
;	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
CPP	O
(	O
77	O
.	O
2	O
±	O
14	O
.	O
6	O
versus	O
71	O
.	O
9	O
±	O
14	O
.	O
8	O
mm	O
Hg	O
;	O
P	O
<	O
0	O
.	O
05	O
).	O

These	O
findings	O
support	O
the	O
use	O
of	O
HFO	O
-	O
TGI	O
as	O
a	O
rescue	O
ventilatory	O
strategy	O
in	O
patients	O
with	O
severe	O
TBI	O
and	O
imminent	O
oxygenation	O
failure	O
due	O
to	O
severe	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
effects	O
of	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
as	O
a	O
rescue	O
ventilatory	O
support	O
in	O
pediatric	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Twenty	O
eight	O
days	O
after	O
the	O
onset	O
of	O
ARDS	B-DISO
,	O
the	O
mortality	O
rate	O
was	O
52	O
%	O
(	O
13	O
/	O
25	O
).	O

Furthermore	O
,	O
we	O
explored	O
the	O
preferential	O
association	O
patterns	O
between	O
respiratory	O
viruses	O
in	O
multiple	O
infections	B-DISO
.	O

To	O
investigate	O
the	O
frequency	O
and	O
clinical	O
features	O
of	O
AGEP	B-DISO
systemic	O
involvement	O
.	O

AGEP	B-DISO
systemic	O
involvement	O
was	O
observed	O
in	O
17	O
%	O
of	O
cases	O
studied	O
,	O
including	O
liver	O
,	O
kidney	O
,	O
bone	O
-	O
marrow	O
and	O
lung	O
involvement	O
.	O

Outcomes	O
were	O
favourable	O
after	O
drug	B-DISO
withdrawal	I-DISO
,	O
and	O
symptomatic	O
and	O
topical	O
steroid	O
treatments	O
.	O

Outcomes	O
were	O
favourable	O
after	O
drug	B-DISO
withdrawal	I-DISO
,	O
and	O
symptomatic	O
and	O
topical	O
steroid	O
treatments	O
.	O

33	O
differentially	O
expressed	O
protein	O
spots	B-DISO
,	O
of	O
which	O
23	O
were	O
up	O
-	O
regulated	O
and	O
10	O
were	O
down	O
-	O
regulated	O
were	O
identified	O
.	O

To	O
our	O
knowledge	O
,	O
we	O
have	O
performed	O
the	O
first	O
analysis	O
of	O
the	O
proteomic	O
changes	O
in	O
host	O
cell	O
during	O
TGEV	O
infection	B-DISO
.	O

A	O
dynamic	O
respiratory	O
control	O
system	O
is	O
critical	O
to	O
successful	O
adaptation	O
in	O
the	O
face	B-DISO
of	O
progressive	O
pulmonary	B-DISO
pathology	I-DISO
.	O

Recent	O
infectious	B-DISO
disease	I-DISO
threats	O
,	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
avian	B-DISO
influenza	I-DISO
(	O
H5N1	B-DISO
)	O
and	O
pandemic	O
influenza	B-DISO
(	O
H1N1	O
),	O
have	O
all	O
highlighted	O
the	O
need	O
for	O
countries	O
to	O
be	O
rapidly	O
aware	O
of	O
the	O
spread	O
of	O
infectious	B-DISO
diseases	I-DISO
within	O
a	O
region	O
and	O
across	O
the	O
globe	O
.	O

All	O
treatment	O
regimens	O
reduced	O
neutrophil	O
influx	O
in	O
the	O
BALF	O
compared	O
with	O
LPS	B-DISO
controls	O
(	O
high	O
-	O
dose	O
ASA	O
75	O
%	O
±	O
2	O
%	O
[	O
mean	O
±	O
SD	O
],	O
low	O
-	O
dose	O
ASA	O
86	O
%	O
±	O
3	O
%,	O
clopidogrel	O
82	O
%	O
±	O
1	O
%,	O
and	O
low	O
-	O
dose	O
ASA	O
-	O
clopidogrel	O
82	O
%	O
±	O
3	O
%	O
vs	O
.	O
LPS	B-DISO
control	O
88	O
%	O
±	O
2	O
%;	O
P	O
≤	O
0	O
.	O
05	O
).	O

High	O
-	O
dose	O
ASA	O
reduced	O
BALF	O
levels	O
of	O
protein	O
compared	O
with	O
LPS	B-DISO
controls	O
(	O
median	O
[	O
interquartile	O
range	O
],	O
0	O
.	O
2	O
[	O
15	O
]	O
vs	O
.	O
75	O
[	O
20	O
]	O
pg	O
/	O
mL	O
;	O
P	O
<	O
0	O
.	O
01	O
),	O
to	O
a	O
greater	O
extent	O
than	O
after	O
low	O
-	O
dose	O
ASA	O
(	O
48	O
[	O
32	O
]	O
pg	O
/	O
mL	O
),	O
clopidogrel	O
(	O
37	O
[	O
23	O
]	O
pg	O
/	O
mL	O
),	O
or	O
low	O
-	O
dose	O
ASA	O
-	O
clopidogrel	O
(	O
57	O
[	O
8	O
]	O
pg	O
/	O
mL	O
).	O

Safety	O
was	O
measured	O
based	O
on	O
28	O
-	O
day	O
mortality	O
and	O
survival	O
free	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Factors	O
associated	O
with	O
ACP	B-DISO
,	O
PFO	O
,	O
and	O
28	O
-	O
day	O
mortality	O
were	O
identified	O
using	O
multivariate	O
regression	O
analysis	O
.	O

There	O
was	O
a	O
rapid	O
release	O
of	O
endothelial	O
progenitor	O
cells	O
from	O
bone	O
marrow	O
into	O
circulation	O
in	O
moderate	O
acute	O
lung	O
injury	O
,	O
and	O
endothelial	O
progenitor	O
cell	O
mobilization	O
was	O
impaired	B-DISO
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Changes	O
of	O
several	O
acute	O
phase	O
factors	O
in	O
broiler	O
chickens	O
in	O
response	O
to	O
infectious	B-DISO
bronchitis	B-DISO
virus	B-DISO
infection	I-DISO
.	O

At	O
the	O
age	O
of	O
20	O
d	O
,	O
all	O
birds	O
in	O
the	O
infected	O
group	O
were	O
challenged	O
intranasally	O
with	O
allantoic	O
fluid	O
containing	O
10	O
(	O
5	O
)	O
embryo	O
lethal	O
dose	O
(	O
ELD50	O
)/	O
0	O
.	O
1	O
mL	O
of	O
the	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

TITLE	O
:	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
:	O
natural	O
history	O
and	O
prognostic	O
factors	O
:	O
a	O
retrospective	O
review	O
of	O
106	O
cases	O
.	O

ABSTRACT	O
:	O
Efficient	O
and	O
productive	O
virus	B-DISO
infection	I-DISO
often	O
requires	O
viral	O
countermeasures	O
that	O
block	O
innate	O
immunity	O
.	O

In	O
the	O
years	O
since	O
the	O
initial	O
SARS	B-DISO
outbreak	O
,	O
the	O
arsenal	O
to	O
fight	O
this	O
virus	O
family	O
has	O
been	O
significantly	O
increased	O
by	O
the	O
rapid	O
growth	O
of	O
coronavirus	O
research	O
.	O

ABSTRACT	O
:	O
Respiratory	B-DISO
tract	I-DISO
infections	I-DISO
(	O
RTIs	O
)	O
are	O
a	O
leading	O
cause	O
of	O
mortality	O
and	O
morbidity	O
.	O

We	O
conducted	O
a	O
retrospective	O
analysis	O
of	O
the	O
incidence	O
of	O
respiratory	O
pathogens	O
at	O
a	O
500	O
-	O
bed	B-DISO
adult	O
and	O
154	O
-	O
bed	B-DISO
pediatric	O
hospital	O
tertiary	O
care	O
center	O
.	O

Physicians	O
should	O
be	O
cognizant	O
of	O
the	O
possible	O
association	O
of	O
serious	O
pulmonary	B-DISO
toxicity	I-DISO
with	O
gemcitabine	O
treatment	O
.	O

A	O
case	O
-	O
control	O
study	O
was	O
conducted	O
to	O
assess	O
infectious	B-DISO
etiologies	O
associated	O
with	O
calf	O
diarrhea	B-DISO
in	O
Midwest	O
cattle	O
farms	O
.	O

Statistically	O
,	O
BRV	B-DISO
-	O
A	O
,	O
BCoV	O
,	O
BNoV	O
,	O
Nebovirus	O
,	O
Salmonella	B-DISO
,	O
E	O
.	O
coli	O
K99	O
(+),	O
and	O
C	O
.	O
parvum	O
were	O
significantly	O
associated	O
with	O
calf	O
diarrhea	B-DISO
(	O
p	O
<	O
0	O
.	O
05	O
).	O

This	O
paper	O
describes	O
the	O
epidemiological	O
findings	O
of	O
retrospective	O
investigation	O
carried	O
out	O
in	O
November	O
2012	O
and	O
highlights	O
the	O
likelihood	O
of	O
nosocomial	O
transmission	O
of	O
nCoV	O
infection	B-DISO
in	O
a	O
health	O
-	O
care	O
setting	O
.	O

The	O
Region	O
has	O
already	O
witnessed	O
a	O
number	O
of	O
emerging	O
zoonoses	B-DISO
with	O
epidemic	O
potential	O
.	O

Laboratory	O
analyses	O
showed	O
raised	O
concentrations	O
of	O
lactate	O
dehydrogenase	O
(	O
23	O
[	O
49	O
%])	O
and	O
aspartate	O
aminotransferase	O
(	O
seven	O
[	O
15	O
%])	O
and	O
thrombocytopenia	O
(	O
17	O
[	O
36	O
%])	O
and	O
lymphopenia	B-DISO
(	O
16	O
[	O
34	O
%]).	O

Furthermore	O
,	O
these	O
studies	O
demonstrate	O
that	O
human	O
alveolar	O
cells	O
can	O
be	O
used	O
to	O
isolate	O
and	O
study	O
novel	O
human	O
respiratory	O
viruses	O
that	O
cause	O
lower	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
.	O

We	O
show	O
that	O
HLH	B-DISO
may	O
present	O
by	O
masquerading	O
as	O
surgical	O
disease	O
or	O
as	O
a	O
postoperative	B-DISO
complication	I-DISO
leading	O
to	O
delays	O
in	O
diagnosis	O
and	O
treatment	O
.	O

All	O
developed	O
signs	O
of	O
prolonged	O
postoperative	O
sepsis	B-DISO
with	O
hepatosplenomegaly	B-DISO
and	O
pancytopenia	B-DISO
,	O
requiring	O
intensive	O
care	O
support	O
.	O

Whereas	O
sialic	O
acid	O
is	O
the	O
only	O
receptor	O
determinant	O
known	O
so	O
far	O
for	O
IBV	O
,	O
TGEV	O
requires	O
interaction	O
with	O
its	O
receptor	O
aminopeptidase	O
N	O
to	O
initiate	O
infection	B-DISO
of	O
cells	O
.	O

RESULTS	O
:	O
Acute	B-DISO
renal	I-DISO
failure	I-DISO
(	O
55	O
.	O
0	O
%	O
vs	O
.	O
7	O
.	O
5	O
%,	O
p	O
=	O
0	O
.	O
0001	O
),	O
low	O
cardiac	O
out	O
-	O
put	O
syndrome	B-DISO
(	O
43	O
.	O
1	O
%	O
vs	O
.	O
8	O
.	O
8	O
%,	O
p	O
=	O
0	O
.	O
0001	O
),	O
sepsis	B-DISO
(	O
52	O
.	O
0	O
%	O
vs	O
.	O
10	O
.	O
3	O
%,	O
p	O
=	O
0	O
.	O
0001	O
),	O
prolonged	O
respiratory	B-DISO
failure	I-DISO
with	O
tracheotomy	O
(	O
29	O
.	O
0	O
%	O
vs	O
.	O
11	O
.	O
0	O
%,	O
p	O
=	O
0	O
.	O
002	O
),	O
re	O
-	O
thoracotomy	O
due	O
to	O
bleeding	B-DISO
(	O
26	O
.	O
9	O
%	O
vs	O
.	O
10	O
.	O
6	O
%,	O
p	O
=	O
0	O
.	O
0001	O
),	O
and	O
postoperative	O
laparotomy	O
(	O
30	O
.	O
8	O
%	O
vs	O
.	O
11	O
.	O
5	O
%,	O
p	O
=	O
0	O
.	O
033	O
)	O
had	O
a	O
significant	O
impact	O
on	O
mortality	O
.	O

TITLE	O
:	O
Crystal	O
structure	O
of	O
the	O
receptor	O
-	O
binding	O
domain	O
from	O
newly	O
emerged	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
.	O

To	O
date	O
,	O
no	O
study	O
has	O
directly	O
examined	O
the	O
epidemiology	O
of	O
ARDS	B-DISO
in	O
severe	B-DISO
sepsis	I-DISO
from	O
the	O
earliest	O
presentation	O
to	O
the	O
health	O
care	O
system	O
,	O
the	O
emergency	B-DISO
department	O
(	O
ED	O
).	O

This	O
was	O
a	O
single	O
-	O
center	O
retrospective	O
,	O
observational	O
cohort	O
study	O
of	O
778	O
adults	O
with	O
severe	B-DISO
sepsis	I-DISO
presenting	O
to	O
the	O
ED	O
.	O

Elevated	O
serum	O
lactate	O
levels	O
in	O
the	O
ED	O
and	O
a	O
recently	O
validated	O
clinical	O
prediction	O
score	O
were	O
independently	O
associated	O
with	O
the	O
development	O
of	O
ARDS	B-DISO
in	O
severe	B-DISO
sepsis	I-DISO
.	O

RESULTS	O
:	O
Main	O
ARDS	B-DISO
etiologies	O
were	O
bacterial	O
(	O
45	O
%),	O
influenza	B-DISO
A	O
[	O
H₁N₁	O
]	O
(	O
26	O
%)	O
and	O
post	O
-	O
operative	O
(	O
17	O
%)	O
pneumonias	B-DISO
.	O

Disease	O
duration	O
prior	O
to	O
aqueocentesis	O
was	O
not	O
significantly	O
different	O
between	O
dogs	O
with	O
idiopathic	B-DISO
anterior	I-DISO
uveitis	I-DISO
and	O
those	O
with	O
an	O
etiologic	O
diagnosis	O
,	O
but	O
was	O
shorter	O
in	O
cats	O
with	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
than	O
those	O
with	O
idiopathic	O
uveitis	B-DISO
.	O

As	O
changes	O
in	O
the	O
expression	O
of	O
adhesion	B-DISO
molecules	O
on	O
circulating	O
leukocytes	O
precede	O
their	O
margination	O
and	O
emigration	O
,	O
we	O
reasoned	O
that	O
the	O
expression	O
of	O
leukocyte	O
adhesion	B-DISO
molecules	O
may	O
be	O
altered	O
in	O
FIP	B-DISO
.	O

Thus	O
,	O
following	O
positive	O
results	O
of	O
preclinical	O
studies	O
,	O
a	O
clinical	O
trial	O
(	O
PROWESS	O
)	O
with	O
high	O
continuous	O
doses	O
of	O
recombinant	O
human	O
aPC	B-DISO
given	O
for	O
4	O
days	O
demonstrated	O
a	O
survival	O
benefit	O
in	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
.	O

ABSTRACT	O
:	O
Infection	B-DISO
of	O
conventional	O
mice	O
with	O
a	O
mouse	O
adapted	O
(	O
MA15	O
)	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
CoV	O
)	O
reproduces	O
many	O
aspects	O
of	O
human	O
SARS	B-DISO
such	O
as	O
pathological	O
changes	O
in	O
lung	O
,	O
viremia	B-DISO
,	O
neutrophilia	O
,	O
and	O
lethality	O
.	O

These	O
cells	O
yielded	O
high	O
SARS	B-DISO
-	O
CoV	O
-	O
MA15	O
titers	O
and	O
also	O
served	O
as	O
excellent	O
tools	O
for	O
plaque	B-DISO
assays	O
.	O

No	O
hospital	O
or	O
other	O
social	O
contacts	O
are	O
known	O
to	O
have	O
acquired	O
the	O
infection	B-DISO
.	O

This	O
is	O
an	O
open	O
,	O
controlled	O
,	O
non	O
-	O
randomized	O
interventional	O
study	O
of	O
ten	O
patients	O
with	O
acute	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

RESULTS	O
:	O
Increasing	O
levels	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
were	O
correlated	O
with	O
increased	O
recruitment	B-DISO
and	O
global	O
strain	O
(	O
p	O
<	O
0	O
.	O
01	O
),	O
which	O
was	O
significantly	O
correlated	O
with	O
plateau	O
pressure	O
(	O
r²	O
=	O
0	O
.	O
97	O
,	O
p	O
<	O
0	O
.	O
01	O
).	O

ABSTRACT	O
:	O
Bats	O
play	O
important	O
roles	O
as	O
pollen	O
disseminators	O
and	O
pest	B-DISO
predators	O
.	O

Serious	O
infectious	B-DISO
diseases	I-DISO
caused	O
by	O
previously	O
identified	O
bat	O
viruses	O
continue	O
to	O
emerge	O
throughout	O
in	O
Asia	O
,	O
Australia	O
,	O
Africa	O
and	O
America	O
.	O

The	O
pathogenesis	B-DISO
and	O
potential	O
threat	O
of	O
bat	O
-	O
borne	O
viruses	O
to	O
public	O
health	O
remains	O
largely	O
unknown	O
.	O

ABSTRACT	O
:	O
In	O
2012	O
,	O
a	O
novel	O
coronavirus	O
,	O
initially	O
named	O
as	O
human	O
coronavirus	O
EMC	B-DISO
(	O
HCoV	O
-	O
EMC	B-DISO
)	O
but	O
recently	O
renamed	O
as	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
human	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
was	O
identified	O
in	O
patients	O
who	O
suffered	B-DISO
severe	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
and	O
subsequent	O
renal	B-DISO
failure	I-DISO
that	O
resulted	O
in	O
death	O
.	O

TITLE	O
:	O
[	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
septic	O
cardiomyopathy	B-DISO
:	O
successful	O
application	O
of	O
veno	O
-	O
venoarterial	O
extracorporeal	O
membrane	O
oxygenation	O
].	O

ABSTRACT	O
:	O
A	O
30	O
-	O
year	O
-	O
old	O
patient	O
was	O
admitted	O
to	O
hospital	O
with	O
fever	O
and	O
respiratory	B-DISO
insufficiency	I-DISO
due	O
to	O
community	B-DISO
acquired	I-DISO
pneumonia	I-DISO
.	O

TITLE	O
:	O
Mechanisms	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
-	O
induced	O
acute	O
lung	O
injury	O
.	O

With	O
these	O
data	O
,	O
we	O
predicted	O
that	O
the	O
urokinase	O
and	O
other	O
wound	O
repair	O
pathways	O
would	O
regulate	O
lethal	O
versus	O
sublethal	O
disease	O
following	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
in	O
mice	O
.	O

We	O
identified	O
sets	O
of	O
differentially	O
expressed	O
genes	O
that	O
contribute	O
to	O
ALI	O
and	O
ARDS	B-DISO
using	O
lethal	O
and	O
sublethal	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
models	O
.	O

Three	O
hundred	O
ninety	O
-	O
eight	O
CoV	O
infections	B-DISO
were	O
identified	O
,	O
with	O
annual	O
infection	B-DISO
rates	O
ranging	O
from	O
2	O
.	O
8	O
%	O
to	O
26	O
%	O
in	O
prospective	O
cohorts	O
,	O
and	O
prevalence	O
ranging	O
from	O
3	O
.	O
3	O
%	O
to	O
11	O
.	O
1	O
%	O
in	O
the	O
hospitalized	O
cohort	O
.	O

Surprisingly	O
,	O
this	O
length	O
was	O
found	O
to	O
vary	O
throughout	O
infection	B-DISO
from	O
~	O
45	O
nt	O
immediately	O
after	O
virus	O
entry	O
(	O
at	O
0	O
to	O
4	O
hpi	B-DISO
)	O
to	O
~	O
65	O
nt	O
later	O
on	O
(	O
at	O
6	O
h	O
to	O
9	O
hpi	B-DISO
)	O
and	O
from	O
~	O
65	O
nt	O
(	O
at	O
6	O
h	O
to	O
9	O
hpi	B-DISO
)	O
to	O
~	O
30	O
nt	O
(	O
at	O
120	O
-	O
144	O
hpi	B-DISO
).	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
increasingly	O
applied	O
in	O
adults	O
with	O
acute	O
refractory	O
respiratory	B-DISO
failure	I-DISO
that	O
is	O
deemed	O
reversible	O
.	O

ABSTRACT	O
:	O
A	O
new	O
betacoronavirus	O
-	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)-	O
has	O
been	O
identified	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
.	O

Cattle	O
(	O
n	O
=	O
80	O
),	O
sheep	O
(	O
n	O
=	O
40	O
),	O
goats	O
(	O
n	O
=	O
40	O
),	O
dromedary	O
camels	O
(	O
n	O
=	O
155	O
),	O
and	O
various	O
other	O
camelid	O
species	O
(	O
n	O
=	O
34	O
)	O
were	O
tested	O
for	O
specific	O
serum	O
IgG	O
by	O
protein	O
microarray	O
using	O
the	O
receptor	O
-	O
binding	O
S1	O
subunits	O
of	O
spike	O
proteins	O
of	O
MERS	O
-	O
CoV	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
,	O
and	O
human	O
coronavirus	O
OC43	O
.	O

The	O
inflammatory	O
host	O
immune	O
response	O
to	O
H1N1	O
infection	B-DISO
is	O
a	O
major	O
contributor	O
to	O
lung	O
injury	O
.	O

We	O
predicted	O
a	O
small	O
set	O
of	O
regulatory	O
factors	O
with	O
conserved	O
behavior	O
for	O
consideration	O
as	O
important	O
components	O
of	O
viral	B-DISO
pathogenesis	I-DISO
that	O
might	O
also	O
serve	O
as	O
therapeutic	O
targets	O
for	O
intervention	O
.	O

His	O
renal	O
function	O
was	O
restored	O
after	O
appropriate	O
therapy	O
for	O
rhabdomyolysis	B-DISO
.	O

Although	O
these	O
double	O
-	O
membrane	O
vesicles	B-DISO
have	O
been	O
well	O
characterized	O
,	O
the	O
mechanism	O
behind	O
their	O
formation	O
remains	O
unclear	O
,	O
including	O
which	O
viral	O
proteins	O
are	O
responsible	O
.	O

This	O
induced	O
a	O
lymphocyte	O
expansion	O
in	O
head	O
-	O
associated	O
lymphoid	O
tissues	O
(	O
HALT	O
)	O
and	O
to	O
a	O
lesser	O
extent	O
in	O
the	O
spleen	O
,	O
followed	O
by	O
a	O
rapid	O
decline	O
,	O
probably	O
due	O
to	O
homing	O
of	O
lymphocytes	O
out	O
of	O
these	O
organs	O
and	O
contraction	B-DISO
of	O
the	O
lymphocyte	O
population	O
.	O

TITLE	O
:	O
Emerging	O
indications	O
for	O
extracorporeal	O
membrane	O
oxygenation	O
in	O
adults	O
with	O
respiratory	B-DISO
failure	I-DISO
.	O

Patients	O
with	O
less	O
severe	O
forms	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
for	O
instance	O
,	O
may	O
benefit	O
from	O
enhanced	O
lung	O
-	O
protective	O
ventilation	O
with	O
the	O
very	O
low	O
tidal	O
volumes	O
made	O
possible	O
by	O
direct	O
carbon	O
dioxide	O
removal	O
from	O
the	O
blood	O
.	O

In	O
addition	O
,	O
ACE2	O
has	O
functions	O
independent	O
of	O
the	O
RAS	O
:	O
ACE2	O
is	O
the	O
receptor	O
for	O
the	O
SARS	B-DISO
coronavirus	O
and	O
ACE2	O
is	O
essential	O
for	O
expression	O
of	O
neutral	O
amino	O
acid	O
transporters	O
in	O
the	O
gut	O
.	O

Infection	B-DISO
with	O
the	O
virus	O
has	O
so	O
far	O
resulted	O
in	O
only	O
91	O
cases	O
and	O
46	O
deaths	O
(	O
as	O
of	O
29	O
July	O
2013	O
),	O
but	O
it	O
is	O
nonetheless	O
setting	O
off	O
alarm	O
bells	O
among	O
public	O
health	O
officials	O
,	O
including	O
Margaret	O
Chan	O
,	O
Director	O
-	O
General	O
of	O
the	O
World	O
Health	O
Organization	O
,	O
who	O
called	O
MERS	O
-	O
CoV	O
""""	O
a	O
threat	O
to	O
the	O
entire	O
world	O
.	O

ABSTRACT	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
is	O
the	O
most	O
feared	O
infectious	B-DISO
cause	O
of	O
death	O
in	O
cats	O
,	O
induced	O
by	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
).	O

TITLE	O
:	O
Transmissible	O
gastroenteritis	B-DISO
coronavirus	O
genome	O
packaging	O
signal	O
is	O
located	O
at	O
the	O
5	O
'	O
end	O
of	O
the	O
genome	O
and	O
promotes	O
viral	O
RNA	O
incorporation	O
into	O
virions	O
in	O
a	O
replication	O
-	O
independent	O
process	O
.	O

TITLE	O
:	O
Acute	B-DISO
myeloid	I-DISO
leukemia	I-DISO
in	O
a	O
38	O
-	O
year	O
-	O
old	O
hemodialyzed	O
patient	O
with	O
von	B-DISO
Hippel	I-DISO
-	I-DISO
Lindau	I-DISO
disease	I-DISO
.	O

Clinical	O
hallmarks	O
of	O
von	B-DISO
Hippel	I-DISO
-	I-DISO
Lindau	I-DISO
disease	I-DISO
are	O
the	O
development	O
of	O
central	O
nervous	B-DISO
system	O
hemangioblastomas	B-DISO
,	O
renal	B-DISO
cell	I-DISO
carcinoma	I-DISO
,	O
pheochromocytoma	B-DISO
,	O
neuroendocrine	B-DISO
tumors	I-DISO
and	O
endolymphatic	O
sac	O
tumors	B-DISO
.	O

After	O
cytostatic	O
treatment	O
the	O
patient	O
went	O
into	O
complete	O
hematologic	O
remission	B-DISO
but	O
there	O
was	O
still	O
residual	B-DISO
disease	I-DISO
at	O
the	O
genetic	O
level	O
.	O

After	O
consolidation	O
therapy	O
patient	O
developed	O
bone	B-DISO
marrow	I-DISO
aplasia	I-DISO
and	O
severe	O
pneumonia	B-DISO
.	O

Despite	O
the	O
fact	O
that	O
there	O
is	O
an	O
increased	O
risk	O
of	O
cancer	B-DISO
development	O
in	O
hemodialyzed	O
patients	O
,	O
cancer	B-DISO
is	O
a	O
relatively	O
rare	O
cause	O
of	O
death	O
in	O
the	O
dialysed	O
population	O
,	O
and	O
the	O
most	O
common	O
malignancies	B-DISO
are	O
genitourinary	B-DISO
cancers	I-DISO
.	O

These	O
spatial	O
models	O
are	O
individual	O
-	O
level	O
models	O
which	O
account	O
for	O
the	O
spatio	O
-	O
temporal	O
dynamics	O
of	O
infectious	B-DISO
disease	I-DISO
.	O

The	O
incidence	O
of	O
the	O
disease	O
had	O
been	O
decreasing	O
since	O
the	O
late	O
1980s	O
when	O
deletion	O
mutant	B-DISO
variants	O
(	O
porcine	O
respiratory	O
coronavirus	O
,	O
PRCoV	O
)	O
of	O
the	O
virus	O
emerged	O
,	O
repressing	O
TGE	B-DISO
gradually	O
.	O

Novel	O
viruses	O
from	O
the	O
families	O
Picorna	O
-,	O
Papilloma	B-DISO
-,	O
and	O
Anelloviridae	O
as	O
well	O
as	O
known	O
viruses	O
from	O
the	O
families	O
Astro	O
-,	O
Corona	O
-,	O
Parvo	O
-,	O
and	O
Hepeviridae	O
were	O
identified	O
in	O
different	O
ferret	O
cohorts	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
):	O
lessons	O
learnt	O
in	O
Hong	O
Kong	O
.	O

N95	O
mask	O
was	O
more	O
effective	O
than	O
surgical	O
mask	O
in	O
preventing	O
expelled	O
air	B-DISO
leakage	I-DISO
during	O
patient	O
'	O
s	O
coughing	B-DISO
but	O
there	O
was	O
still	O
significant	O
sideway	O
leakage	B-DISO
to	O
15	O
cm	O
.	O

ABSTRACT	O
:	O
A	O
decade	O
ago	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
caused	O
a	O
global	O
pandemic	O
with	O
a	O
mortality	O
rate	O
of	O
10	O
%.	O

Reports	O
of	O
recent	O
outbreaks	O
of	O
a	O
SARS	B-DISO
-	O
like	O
disease	O
caused	O
by	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
have	O
raised	O
serious	O
concerns	O
of	O
a	O
possible	O
reemergence	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
either	O
by	O
laboratory	O
escape	O
or	O
the	O
presence	O
of	O
a	O
natural	O
reservoir	O
.	O

This	O
review	O
will	O
discuss	O
key	O
advances	O
in	O
the	O
development	O
of	O
RBD	O
-	O
based	O
SARS	B-DISO
vaccines	O
and	O
the	O
possibility	O
of	O
using	O
a	O
similar	O
strategy	O
to	O
develop	O
vaccines	O
against	O
MERS	O
-	O
CoV	O
.	O

Furthermore	O
,	O
one	O
small	O
molecule	O
HIV	B-DISO
entry	O
inhibitor	O
targeting	O
gp41	O
(	O
ADS	O
-	O
J1	O
)	O
and	O
the	O
3	O
-	O
hydroxyphthalic	O
anhydride	O
-	O
modified	O
human	O
serum	O
albumin	O
(	O
HP	O
-	O
HSA	B-DISO
)	O
could	O
significantly	O
inhibit	O
MERS	O
-	O
CoV	O
pseudovirus	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Microglia	O
,	O
the	O
major	O
resident	O
immune	O
cells	O
in	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
are	O
considered	O
as	O
the	O
key	O
cellular	O
mediators	O
of	O
neuroinflammatory	O
processes	O
.	O

Baseline	O
D	O
-	O
dimer	O
values	O
were	O
3	O
.	O
4	O
(±	O
3	O
.	O
0	O
)	O
mg	O
/	O
l	O
and	O
rose	O
significantly	O
to	O
19	O
.	O
5	O
(±	O
11	O
.	O
5	O
)	O
mg	O
/	O
l	O
during	O
MCS	B-DISO
(	O
P	O
<	O
0	O
.	O
001	O
).	O

The	O
use	O
of	O
the	O
Deltastream	O
DP3	O
seems	O
to	O
be	O
safe	O
and	O
effective	O
for	O
MCS	B-DISO
in	O
children	O
and	O
may	O
show	O
a	O
low	O
degree	O
of	O
haemolysis	B-DISO
.	O

ABSTRACT	O
:	O
Recent	O
trials	O
suggest	O
that	O
treatment	O
with	O
neuromuscular	O
blocking	B-DISO
agents	O
may	O
improve	O
survival	O
in	O
patients	O
requiring	O
mechanical	O
ventilation	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

We	O
used	O
propensity	O
score	O
matching	O
and	O
instrumental	O
variable	O
methods	O
to	O
compare	O
the	O
outcomes	O
of	O
patients	O
treated	O
with	O
neuromuscular	O
blocking	B-DISO
agents	O
within	O
the	O
first	O
2	O
hospital	O
days	O
to	O
those	O
who	O
were	O
not	O
.	O

Underlying	O
comorbid	O
conditions	O
included	O
chronic	B-DISO
respiratory	I-DISO
disease	I-DISO
in	O
9	O
patients	O
,	O
immunosuppression	O
in	O
7	O
patients	O
,	O
and	O
obesity	B-DISO
in	O
3	O
patients	O
,	O
while	O
measles	B-DISO
affected	O
5	O
pregnant	O
women	O
.	O

Of	O
11	O
patients	O
who	O
required	O
mechanical	O
ventilation	O
,	O
9	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Measles	B-DISO
-	O
associated	O
pneumonitis	B-DISO
and	O
its	O
complications	O
,	O
and	O
less	O
commonly	O
postinfectious	B-DISO
encephalomyelitis	I-DISO
,	O
are	O
the	O
main	O
source	O
of	O
morbidity	O
and	O
mortality	O
.	O

Measles	B-DISO
pneumonitis	B-DISO
may	O
predispose	O
to	O
air	O
leak	O
disease	O
in	O
patients	O
using	O
mechanical	O
ventilation	O
.	O

Awareness	O
of	O
these	O
complications	O
,	O
their	O
detection	O
and	O
management	O
,	O
may	O
help	O
limit	O
the	O
morbidity	O
of	O
GBS	B-DISO
.	O

Complications	O
related	O
to	O
positioning	O
therapy	O
were	O
facial	O
oedema	B-DISO
(	O
n	O
=	O
9	O
);	O
complications	O
related	O
to	O
vvECMO	O
were	O
entrance	O
of	O
air	O
(	O
n	O
=	O
1	O
)	O
and	O
pump	O
failure	O
(	O
n	O
=	O
1	O
).	O

The	O
reported	O
cases	O
suggest	O
that	O
positioning	O
therapy	O
can	O
be	O
performed	O
safely	O
in	O
ARDS	B-DISO
patients	O
treated	O
with	O
vvECMO	O
,	O
providing	O
appropriate	O
precautions	O
are	O
in	O
place	O
and	O
a	O
very	O
experienced	O
team	O
is	O
present	O
.	O

Vaccinated	O
mice	O
produced	O
high	O
levels	O
of	O
serum	O
antibodies	O
neutralizing	O
MERS	O
-	O
CoV	O
.	O
Thus	O
,	O
MVA	O
-	O
MERS	O
-	O
S	O
may	O
serve	O
for	O
further	O
development	O
of	O
an	O
emergency	B-DISO
vaccine	O
against	O
MERS	O
-	O
CoV	O
.	O

TITLE	O
:	O
Assessing	O
activity	O
and	O
inhibition	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
papain	O
-	O
like	O
and	O
3C	O
-	O
like	O
proteases	O
using	O
luciferase	O
-	O
based	O
biosensors	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
associated	O
with	O
an	O
outbreak	O
of	O
more	O
than	O
90	O
cases	O
of	O
severe	O
pneumonia	B-DISO
with	O
high	O
mortality	O
(	O
greater	O
than	O
50	O
%).	O

ABSTRACT	O
:	O
Stevens	B-DISO
-	I-DISO
Johnson	I-DISO
syndrome	I-DISO
and	O
toxic	B-DISO
epidermal	I-DISO
necrolysis	I-DISO
are	O
severe	O
adverse	O
cutaneous	O
drug	O
reactions	O
characterized	O
by	O
widespread	O
skin	O
and	O
mucous	O
membrane	O
detachments	B-DISO
,	O
including	O
bronchial	O
mucosa	O
,	O
which	O
may	O
be	O
associated	O
with	O
respiratory	B-DISO
failure	I-DISO
requiring	O
mechanical	O
ventilation	O
.	O

Patients	O
requiring	O
mechanical	O
ventilation	O
had	O
a	O
larger	O
baseline	O
detached	O
body	O
surface	O
area	O
,	O
higher	O
Logistic	O
Organ	O
Dysfunction	O
score	O
,	O
and	O
Simplified	O
Acute	O
Physiology	O
Score	O
II	O
,	O
and	O
they	O
presented	O
more	O
often	O
with	O
shock	O
,	O
pulmonary	B-DISO
infiltrates	I-DISO
,	O
and	O
renal	O
dysfunction	O
(	O
p	O
<	O
0	O
.	O
0001	O
for	O
all	O
comparisons	O
).	O

TITLE	O
:	O
Prevalence	O
,	O
risk	O
factors	O
of	O
infection	B-DISO
and	O
molecular	O
characterization	O
of	O
trichomonads	O
in	O
puppies	O
from	O
French	O
breeding	O
kennels	O
.	O

It	O
is	O
phylogenetically	O
related	O
to	O
the	O
SARS	B-DISO
coronavirus	O
and	O
has	O
also	O
been	O
associated	O
with	O
severe	O
respiratory	O
illness	O
as	O
well	O
as	O
nosocomial	O
transmission	O
in	O
healthcare	O
settings	O
.	O

This	O
paper	O
forms	O
part	O
of	O
a	O
series	O
of	O
invited	O
articles	O
in	O
Antiviral	O
Research	O
on	O
""""	O
From	O
SARS	B-DISO
to	O
MERS	O
:	O
10years	O
of	O
research	O
on	O
highly	O
pathogenic	O
human	O
coronaviruses	O
"""."	O

TITLE	O
:	O
Clinical	O
management	O
and	O
infection	B-DISO
control	O
of	O
SARS	B-DISO
:	O
lessons	O
learned	O
.	O

Responding	O
to	O
the	O
epidemic	O
provided	O
clinicians	O
with	O
extensive	O
experience	O
in	O
diagnosing	O
and	O
treating	O
a	O
novel	O
respiratory	O
viral	B-DISO
disease	I-DISO
.	O

A	O
docking	O
study	O
involving	O
binding	O
between	O
the	O
dipeptidic	O
lead	O
compound	O
4	O
and	O
3CLpro	O
suggested	O
the	O
modification	O
of	O
a	O
structurally	O
flexible	O
P3	O
N	O
-(	O
3	O
-	O
methoxyphenyl	O
)	O
glycine	O
with	O
various	O
rigid	B-DISO
P3	O
moieties	O
in	O
4	O
.	O

The	O
clinical	O
picture	O
mimicked	O
bacterial	B-DISO
infection	I-DISO
for	O
its	O
prolonged	O
high	O
fever	O
and	O
neutrophilic	O
blood	O
picture	O
.	O

The	O
majority	O
of	O
acute	B-DISO
bronchiolitis	I-DISO
(	O
71	O
.	O
4	O
%)	O
were	O
associated	O
with	O
serotype	O
2	O
infection	B-DISO
,	O
and	O
this	O
association	O
was	O
statistically	O
significant	O
(	O
p	O
<	O
0	O
.	O
0001	O
).	O

Serotype	O
3	O
infection	B-DISO
accounted	O
for	O
over	O
half	O
of	O
the	O
pneumonia	B-DISO
cases	O
(	O
57	O
-	O
75	O
%)	O
in	O
those	O
aged	O
3	O
-	O
5	O
years	O
old	O
.	O

ABSTRACT	O
:	O
Explore	O
information	O
about	O
the	O
incidence	O
of	O
employees	O
of	O
enterprises	O
of	O
the	O
oil	O
and	O
gas	O
industry	O
with	O
the	O
influenza	B-DISO
(	O
SARS	B-DISO
).	O

ABSTRACT	O
:	O
Despite	O
a	O
significant	O
amount	O
of	O
progress	O
in	O
the	O
past	O
decade	O
,	O
global	O
infectious	B-DISO
disease	I-DISO
surveillance	O
still	O
often	O
falters	O
,	O
as	O
in	O
the	O
case	O
of	O
the	O
emerging	O
novel	O
coronavirus	O
that	O
has	O
killed	O
at	O
least	O
17	O
people	O
in	O
Saudi	O
Arabia	O
.	O

Suggestions	O
are	O
also	O
offered	O
for	O
ways	O
to	O
improve	O
infectious	B-DISO
disease	I-DISO
surveillance	O
strategies	O
in	O
resource	O
-	O
limited	O
settings	O
.	O

ABSTRACT	O
:	O
Protective	O
mechanical	O
ventilation	O
is	O
currently	O
accepted	O
as	O
a	O
key	O
strategy	O
for	O
the	O
management	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
its	O
most	O
severe	O
form	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Drug	O
repurposing	O
:	O
a	O
better	O
approach	O
for	O
infectious	B-DISO
disease	I-DISO
drug	O
discovery	O
?	O

TITLE	O
:	O
From	O
SARS	B-DISO
to	O
MERS	O
:	O
10	O
years	O
of	O
research	O
on	O
highly	O
pathogenic	O
human	O
coronaviruses	O
.	O

The	O
γ	O
-	O
PGA	B-DISO
with	O
high	O
molecular	O
weights	O
(	O
2000	O
and	O
5000	O
kDa	O
)	O
was	O
able	O
to	O
activate	O
the	O
subsequent	O
signals	O
through	O
TLR4	O
/	O
MD2	O
to	O
result	O
in	O
dimerization	O
of	O
IRF	O
-	O
3	O
,	O
a	O
transcription	O
factor	O
required	O
for	O
IFN	O
gene	O
expression	O
,	O
leading	O
to	O
increases	O
in	O
mRNA	O
levels	O
of	O
the	O
type	O
I	O
IFN	O
-	O
response	O
genes	O
,	O
2	O
'-	O
5	O
'	O
OAS	B-DISO
and	O
ISG56	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
an	O
emerging	O
coronavirus	O
infecting	O
humans	O
that	O
is	O
associated	O
with	O
acute	B-DISO
pneumonia	I-DISO
,	O
occasional	O
renal	B-DISO
failure	I-DISO
,	O
and	O
a	O
high	O
mortality	O
rate	O
and	O
is	O
considered	O
a	O
threat	O
to	O
public	O
health	O
.	O

This	O
article	O
describes	O
the	O
development	O
of	O
the	O
first	O
reverse	O
genetics	O
system	O
for	O
MERS	O
-	O
CoV	O
,	O
based	O
on	O
the	O
construction	O
of	O
an	O
infectious	B-DISO
cDNA	O
clone	O
inserted	O
into	O
a	O
bacterial	O
artificial	O
chromosome	O
.	O

This	O
virus	O
constitutes	O
a	O
vaccine	O
candidate	O
that	O
may	O
represent	O
a	O
balance	O
between	O
safety	O
and	O
efficacy	O
for	O
the	O
induction	O
of	O
mucosal	O
immunity	O
,	O
which	O
is	O
needed	O
to	O
prevent	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

Viral	B-DISO
infections	I-DISO
contribute	O
significantly	O
to	O
this	O
population	O
'	O
s	O
respiratory	O
symptomatology	O
.	O

No	O
temporal	O
association	O
was	O
observed	O
between	O
infection	B-DISO
and	O
acute	O
rejection	O
.	O

Acute	O
rejection	O
was	O
not	O
associated	O
with	O
viral	B-DISO
infection	I-DISO
(	O
OR	O
0	O
.	O
4	O
,	O
95	O
%	O
CI	O
0	O
.	O
1	O
to	O
1	O
.	O
3	O
).	O

Finally	O
,	O
and	O
a	O
series	O
of	O
clinical	O
trials	O
led	O
to	O
the	O
conclusion	O
that	O
in	O
patients	O
with	O
severe	O
ARDS	B-DISO
,	O
the	O
prone	O
position	O
provides	O
a	O
significant	O
survival	O
advantage	O
.	O

This	O
study	O
aims	O
to	O
examine	O
the	O
effects	O
of	O
vaporized	O
PFC	O
on	O
gas	O
exchange	O
and	O
lung	O
mechanics	O
in	O
a	O
piglet	O
model	O
with	O
ARDS	B-DISO
.	O

PMN	O
hypotonic	B-DISO
challenge	O
resulted	O
in	O
a	O
transient	O
increase	O
of	O
the	O
relative	O
cell	O
volume	O
,	O
which	O
returned	O
to	O
baseline	O
after	O
600	O
seconds	O
,	O
while	O
incubation	O
in	O
the	O
presence	O
of	O
LPS	B-DISO
resulted	O
in	O
persistently	O
increased	O
cell	O
volume	O
.	O

TITLE	O
:	O
Beta	O
-	O
Agonist	O
Lung	O
injury	O
TrIal	O
-	O
2	O
(	O
BALTI	O
-	O
2	O
):	O
a	O
multicentre	O
,	O
randomised	O
,	O
double	O
-	O
blind	B-DISO
,	O
placebo	O
-	O
controlled	O
trial	O
and	O
economic	O
evaluation	O
of	O
intravenous	O
infusion	O
of	O
salbutamol	O
versus	O
placebo	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

The	O
Beta	O
-	O
Agonist	O
Lung	O
injury	O
TrIal	O
-	O
2	O
(	O
BALTI	O
-	O
2	O
)	O
was	O
initiated	O
to	O
evaluate	O
the	O
effects	O
of	O
this	O
intervention	O
on	O
mortality	O
in	O
patients	O
with	O
ARDS	B-DISO
.	O

Severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
was	O
presents	O
.	O

ABSTRACT	O
:	O
Healthcare	O
workers	O
(	O
HCWs	O
)	O
are	O
at	O
increased	O
risk	O
of	O
exposure	O
to	O
respiratory	O
pathogens	O
and	O
may	O
transmit	O
infection	B-DISO
to	O
vulnerable	O
patients	O
.	O

Adenovirus	B-DISO
and	O
norovirus	O
were	O
the	O
most	O
common	O
viruses	O
in	O
this	O
cohort	O
,	O
while	O
aichi	O
virus	O
was	O
the	O
only	O
gastrointestinal	O
agent	O
not	O
detected	O
.	O

TITLE	O
:	O
Epidemiological	O
and	O
genetic	O
characteristics	O
associated	O
with	O
the	O
severity	O
of	O
acute	B-DISO
viral	I-DISO
bronchiolitis	I-DISO
by	O
respiratory	O
syncytial	O
virus	O
.	O

Polymorphisms	O
of	O
the	O
TLRs	O
,	O
RANTES	O
,	O
JUN	O
,	O
IFNA5	O
,	O
NOS2	O
,	O
CX3CR1	O
,	O
ILs	B-DISO
,	O
and	O
VDR	O
genes	O
have	O
been	O
shown	O
to	O
be	O
associated	O
with	O
more	O
severe	O
evolution	O
of	O
AVB	O
by	O
RSV	O
.	O

ABSTRACT	O
:	O
Endothelial	O
cell	O
(	O
EC	O
)	O
inflammation	B-DISO
is	O
a	O
central	O
event	O
in	O
the	O
pathogenesis	B-DISO
of	O
many	O
pulmonary	B-DISO
diseases	I-DISO
such	O
as	O
acute	O
lung	O
injury	O
and	O
its	O
more	O
severe	O
form	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Previously	O
,	O
we	O
have	O
described	O
a	O
role	O
of	O
actin	O
binding	O
protein	O
cofilin	O
in	O
mediating	O
cytoskeletal	O
alterations	O
essential	O
for	O
NF	O
-	O
κB	O
activation	O
and	O
EC	O
inflammation	B-DISO
.	O

Thus	O
this	O
study	O
provides	O
evidence	O
for	O
a	O
novel	O
role	O
of	O
LIMK1	O
and	O
SSH	O
-	O
1L	O
in	O
selectively	O
regulating	O
EC	O
inflammation	B-DISO
associated	O
with	O
intravascular	O
coagulation	O
.	O

Both	O
are	O
enveloped	O
,	O
single	O
-	O
stranded	O
,	O
negative	O
-	O
sense	O
RNA	O
viruses	O
and	O
cause	O
similar	O
symptoms	O
,	O
ranging	O
from	O
sub	O
-	O
clinical	B-DISO
infections	I-DISO
to	O
severe	O
diseases	O
,	O
including	O
decrease	O
in	O
egg	O
production	O
,	O
acute	O
respiratory	O
syndrome	B-DISO
,	O
and	O
high	O
mortality	O
.	O

Swabs	O
from	O
cloaca	O
and	O
trachea	B-DISO
were	O
collected	O
and	O
examined	O
.	O

Hence	O
,	O
further	O
research	O
is	O
required	O
regarding	O
the	O
long	O
-	O
term	O
benefits	O
and	O
adverse	B-DISO
effects	I-DISO
of	O
TRT	O
in	O
LOH	O
.	O

ABSTRACT	O
:	O
In	O
acute	O
glufosinate	O
poisoning	O
,	O
sudden	O
respiratory	B-DISO
arrest	I-DISO
and	O
convulsion	B-DISO
can	O
occur	O
after	O
a	O
latent	O
period	O
of	O
4	O
-	O
60	O
h	O
.	O
There	O
is	O
still	O
no	O
factor	O
that	O
accurately	O
predicts	O
the	O
occurrence	O
of	O
these	O
symptoms	O
.	O

ABSTRACT	O
:	O
Feline	O
coronavirus	O
(	O
FCoV	O
)	O
can	O
cause	O
either	O
asymptomatic	O
enteric	O
infection	B-DISO
or	O
fatal	O
peritonitis	B-DISO
in	O
cats	O
.	O

High	O
-	O
throughput	O
sequencing	O
of	O
the	O
host	O
transcriptome	O
revealed	O
that	O
demyelination	B-DISO
is	O
accompanied	O
by	O
numerous	O
transcriptional	O
changes	O
indicative	O
of	O
immune	O
infiltration	B-DISO
as	O
well	O
as	O
changes	O
in	O
the	O
cytokine	O
milieu	O
and	O
lipid	O
metabolism	O
.	O

In	O
July	O
2013	O
,	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
International	O
Health	O
Regulations	O
Emergency	B-DISO
Committee	O
determined	O
that	O
MERS	O
-	O
CoV	O
did	O
not	O
meet	O
criteria	O
for	O
a	O
""""	O
public	O
health	O
emergency	B-DISO
of	O
international	O
concern	O
","""	O
but	O
was	O
nevertheless	O
of	O
""""	O
serious	O
and	O
great	O
concern	O
"""."	O

ABSTRACT	O
:	O
We	O
identified	O
the	O
domains	O
of	O
CD26	O
involved	O
in	O
the	O
binding	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
using	O
distinct	O
clones	O
of	O
anti	O
-	O
CD26	O
monoclonal	O
antibodies	O
(	O
MAbs	O
).	O

The	O
mortality	O
was	O
higher	O
among	O
patients	O
who	O
had	O
an	O
accompanying	O
malignancy	B-DISO
or	O
immune	B-DISO
deficiency	I-DISO
(	O
72	O
.	O
2	O
%).	O

TITLE	O
:	O
Severe	O
influenza	B-DISO
outbreak	O
in	O
Western	O
Ukraine	O
in	O
2009	O
--	O
a	O
molecular	O
-	O
epidemiological	O
study	O
.	O

RESULTS	O
:	O
Among	O
the	O
124	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
cases	O
,	O
~	O
50	O
%	O
(	O
58	O
)	O
were	O
positive	O
for	O
influenza	B-DISO
A	O
virus	O
in	O
WHO	O
-	O
CDC	O
molecular	O
assay	O
,	O
including	O
subtyping	O
.	O

ABSTRACT	O
:	O
The	O
earliest	O
definition	O
of	O
transfusion	B-DISO
-	I-DISO
related	I-DISO
acute	I-DISO
lung	I-DISO
injury	I-DISO
(	O
TRALI	B-DISO
)	O
included	O
all	O
patients	O
who	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
,	O
moderate	O
to	O
severe	O
hypoxemia	O
,	O
rapid	O
onset	O
of	O
pulmonary	B-DISO
edema	I-DISO
,	O
mild	O
to	O
moderate	O
hypotension	O
,	O
and	O
fever	O
within	O
6	O
hours	O
of	O
receiving	O
a	O
plasma	O
containing	O
blood	O
transfusion	O
.	O

Among	O
the	O
eight	O
cytokine	O
genes	O
,	O
IL	O
-	O
1β	O
,	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
induced	O
by	O
MERS	O
-	O
CoV	O
were	O
markedly	O
higher	O
than	O
those	O
induced	O
by	O
SARS	B-DISO
-	O
CoV	O
at	O
30	O
h	O
,	O
whilst	O
TNF	O
-	O
α	O
,	O
IFN	O
-	O
β	O
and	O
IP	O
-	O
10	O
induced	O
by	O
SARS	B-DISO
-	O
CoV	O
were	O
markedly	O
higher	O
than	O
those	O
induced	O
by	O
MERS	O
-	O
CoV	O
at	O
24	O
and	O
30	O
h	O
in	O
infected	O
Calu	O
-	O
3	O
cells	O
.	O

The	O
activation	O
of	O
IL	O
-	O
8	O
and	O
attenuated	O
IFN	O
-	O
β	O
response	O
by	O
MERS	O
-	O
CoV	O
were	O
also	O
confirmed	O
by	O
protein	O
measurements	O
in	O
the	O
culture	O
supernatant	O
when	O
compared	O
with	O
SARS	B-DISO
-	O
CoV	O
and	O
Sendai	O
virus	O
.	O

To	O
further	O
confirm	O
the	O
attenuated	O
antiviral	O
response	O
,	O
cytokine	O
response	O
was	O
compared	O
with	O
human	O
HCoV	O
-	O
229E	O
in	O
embryonal	O
lung	O
fibroblast	O
HFL	O
cells	O
,	O
which	O
also	O
revealed	O
higher	O
IFN	O
-	O
β	O
and	O
IP	O
-	O
10	O
levels	O
induced	O
by	O
HCoV	O
-	O
229E	O
than	O
MERS	O
-	O
CoV	O
at	O
24	O
and	O
30	O
h	O
.	O
Whilst	O
our	O
data	O
supported	O
recent	O
findings	O
that	O
MERS	O
-	O
CoV	O
elicits	O
attenuated	O
innate	O
immunity	O
,	O
this	O
represents	O
the	O
first	O
report	O
to	O
demonstrate	O
delayed	O
proinflammatory	O
cytokine	O
induction	O
by	O
MERS	O
-	O
CoV	O
.	O
Our	O
results	O
provide	O
insights	O
into	O
the	O
pathogenesis	B-DISO
and	O
treatment	O
of	O
MERS	O
-	O
CoV	O
infections	B-DISO
.	O

Due	O
to	O
multiple	O
episodes	O
of	O
respiratory	B-DISO
distress	I-DISO
the	O
cat	O
subsequently	O
had	O
tracheal	O
surgeries	O
.	O

Infiltrating	B-DISO
cells	O
were	O
phenotypically	O
CD11b	O
(	O
hi	O
),	O
F4	O
/	O
80	O
(	O
lo	O
).	O

Moreover	O
,	O
the	O
28	O
-	O
day	O
mortality	O
rate	O
(	O
P	O
=	O
0	O
.	O
017	O
),	O
60	O
-	O
day	O
mortality	O
rate	O
(	O
P	O
=	O
0	O
.	O
003	O
),	O
and	O
survival	O
rate	O
(	O
78	O
%	O
vs	O
.	O
19	O
%;	O
P	O
=	O
0	O
.	O
003	O
)	O
significantly	O
improved	O
in	O
patients	O
undergoing	O
IPSI	O
,	O
which	O
therefore	O
appears	O
to	O
be	O
an	O
easily	O
implemented	O
and	O
highly	O
effective	O
treatment	O
for	O
patients	O
with	O
severe	O
ARDS	B-DISO
in	O
combination	O
with	O
MODS	B-DISO
,	O
particularly	O
in	O
patients	O
who	O
fail	O
to	O
respond	O
to	O
conventional	O
treatment	O
.	O

Over	O
the	O
past	O
decades	O
,	O
inhaled	O
NO	O
remains	O
the	O
central	O
therapy	O
for	O
PPHN	O
and	O
is	O
commonly	O
used	O
for	O
acute	O
pulmonary	O
vasoreactivity	O
testing	O
during	O
right	O
heart	O
catheterization	O
and	O
for	O
treating	O
pediatric	O
and	O
adult	O
patients	O
with	O
PAH	B-DISO
associated	O
with	O
postoperative	O
cardiac	O
surgery	O
,	O
severe	O
respiratory	B-DISO
failure	I-DISO
,	O
pulmonary	B-DISO
hypertension	I-DISO
crises	O
,	O
and	O
other	O
disorders	O
.	O

Management	O
of	O
individual	O
cases	O
is	O
mainly	O
supportive	O
and	O
requires	O
institution	O
of	O
appropriate	O
infection	B-DISO
control	O
measures	O
.	O

Influenza	B-DISO
is	O
the	O
most	O
common	O
virus	O
associated	O
with	O
severe	O
viral	B-DISO
pneumonia	I-DISO
,	O
although	O
other	O
important	O
causes	O
include	O
respiratory	O
syncytial	O
virus	O
,	O
adenovirus	B-DISO
,	O
metapneumonia	O
virus	O
,	O
and	O
coronaviruses	O
.	O

The	O
50	O
%	O
inhibitory	O
concentrations	O
(	O
IC50	O
)	O
of	O
the	O
MAbs	O
for	O
the	O
cytotoxicity	B-DISO
of	O
recombinant	O
TNF	O
-	O
alpha	O
were	O
5	O
-	O
684	O
ng	O
/	O
ml	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggested	O
that	O
TGEV	O
infection	B-DISO
induced	I-DISO
S	O
and	O
G2	O
/	O
M	O
phase	O
arrest	O
in	O
host	O
cells	O
,	O
which	O
might	O
provide	O
a	O
favorable	O
condition	B-DISO
for	O
viral	O
replication	O
.	O

TITLE	O
:	O
Broad	O
-	O
spectrum	O
antivirals	O
for	O
the	O
emerging	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
has	O
emerged	O
to	O
cause	O
fatal	O
infections	B-DISO
in	O
patients	O
in	O
the	O
Middle	O
East	O
and	O
traveler	O
-	O
associated	O
secondary	O
cases	O
in	O
Europe	O
and	O
Africa	O
.	O

At	O
that	O
time	O
,	O
he	O
also	O
was	O
treated	O
for	O
syphilis	B-DISO
.	O

He	O
had	O
no	O
risk	O
factors	O
of	O
atherosclerosis	B-DISO
including	O
hypertension	B-DISO
,	O
diabetes	B-DISO
and	O
hyperlipidemia	B-DISO
.	O

He	O
had	O
neither	O
coagulation	O
abnormality	O
nor	O
autoimmune	B-DISO
disease	I-DISO
.	O

TITLE	O
:	O
Role	O
of	O
the	O
spike	O
glycoprotein	O
of	O
human	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
virus	O
entry	O
and	O
syncytia	O
formation	O
.	O

When	O
293T	O
cells	O
producing	O
MERS	O
pseudotypes	O
co	O
-	O
expressed	O
serine	O
proteases	O
TMPRSS	O
-	O
2	O
or	O
-	O
4	O
,	O
large	O
syncytia	O
formed	O
at	O
neutral	O
pH	O
,	O
and	O
the	O
pseudovirions	O
produced	O
were	O
non	O
-	O
infectious	B-DISO
and	O
deficient	O
in	O
S	O
protein	O
.	O

Mortality	O
(	O
13	O
.	O
9	O
%	O
for	O
mild	O
ARDS	B-DISO
;	O
11	O
.	O
3	O
%	O
for	O
moderate	O
ARDS	B-DISO
;	O
25	O
%	O
for	O
severe	O
ARDS	B-DISO
,	O
p	O
=	O
0	O
.	O
04	O
)	O
and	O
the	O
composite	O
outcome	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)/	O
mortality	O
(	O
13	O
.	O
9	O
%	O
for	O
mild	O
ARDS	B-DISO
;	O
11	O
.	O
3	O
%	O
for	O
moderate	O
ARDS	B-DISO
;	O
28	O
.	O
4	O
%	O
for	O
severe	O
ARDS	B-DISO
,	O
p	O
<	O
0	O
.	O
01	O
)	O
were	O
different	O
across	O
the	O
BD	O
classes	O
,	O
whereas	O
they	O
were	O
similar	O
using	O
the	O
previous	O
definition	O
.	O

BD	O
validity	O
for	O
children	O
is	O
similar	O
to	O
that	O
already	O
reported	O
in	O
adults	O
and	O
mainly	O
due	O
to	O
the	O
introduction	O
of	O
a	O
""""	O
severe	O
ARDS	B-DISO
""""	O
category	O
.	O

There	O
was	O
significant	O
concordance	O
between	O
raters	O
evaluating	O
radiographs	O
[	O
ICC	B-DISO
0	O
.	O
6	O
(	O
95	O
%	O
CI	O
0	O
.	O
2	O
-	O
0	O
.	O
8	O
)]	O
and	O
risk	O
factors	O
[	O
ICC	B-DISO
0	O
.	O
92	O
(	O
95	O
%	O
CI	O
0	O
.	O
8	O
-	O
0	O
.	O
97	O
)].	O

TITLE	O
:	O
Requirement	O
for	O
safety	O
monitoring	O
for	O
approved	O
multiple	B-DISO
sclerosis	I-DISO
therapies	O
:	O
an	O
overview	O
.	O

ABSTRACT	O
:	O
Dedicator	O
of	O
cytokinesis	O
8	O
(	O
DOCK8	O
)	O
deficiency	O
is	O
an	O
autosomal	O
recessive	O
type	O
of	O
combined	B-DISO
immunodeficiency	I-DISO
with	O
elevated	O
IgE	B-DISO
.	O
In	O
this	O
report	O
,	O
we	O
describe	O
a	O
Japanese	O
girl	O
of	O
non	O
-	O
consanguineous	O
family	O
suffering	B-DISO
from	O
acute	B-DISO
eosinophilic	I-DISO
pneumonia	I-DISO
(	O
AEP	O
)	O
as	O
a	O
presenting	O
feature	O
of	O
DOCK8	O
deficiency	O
.	O

We	O
show	O
that	O
bat	O
DPP4	O
genes	O
have	O
been	O
subject	O
to	O
significant	O
adaptive	O
evolution	O
,	O
suggestive	O
of	O
a	O
long	O
-	O
term	O
arms	B-DISO
-	O
race	O
between	O
bats	O
and	O
MERS	O
related	O
CoVs	O
.	O

We	O
tested	O
the	O
system	O
on	O
13	O
influenza	B-DISO
patients	O
and	O
33	O
normal	O
subjects	O
.	O

ABSTRACT	O
:	O
Gene	O
encoding	O
the	O
N	O
-	O
terminal	O
half	O
of	O
spike	O
protein	O
(	O
S1	O
)	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
was	O
cloned	O
and	O
expressed	O
as	O
a	O
recombinant	O
protein	O
in	O
Escherichia	O
coli	O
BL21	O
(	O
DE3	O
).	O

The	O
incidence	O
of	O
ARDS	B-DISO
amounted	O
to	O
32	O
per	O
100	O
,	O
000	O
population	O
per	O
year	O
,	O
with	O
values	O
for	O
mild	O
,	O
moderate	O
,	O
and	O
severe	O
ARDS	B-DISO
of	O
5	O
.	O
6	O
,	O
16	O
.	O
3	O
,	O
and	O
10	O
per	O
100	O
,	O
000	O
population	O
per	O
year	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
05	O
between	O
the	O
three	O
groups	O
).	O

However	O
,	O
since	O
2008	O
it	O
seems	O
that	O
a	O
new	O
neonatal	O
diarrhoeic	O
syndrome	B-DISO
unresponsive	O
to	O
antibiotics	O
and	O
common	O
management	O
practices	O
has	O
emerged	O
.	O

The	O
primary	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
if	O
well	O
-	O
known	O
enteric	O
pathogens	O
could	O
be	O
associated	O
with	O
outbreaks	O
of	O
neonatal	B-DISO
diarrhoea	I-DISO
,	O
thus	O
question	O
the	O
hypotheses	O
of	O
a	O
new	O
syndrome	B-DISO
.	O

ABSTRACT	O
:	O
To	O
explore	O
perception	O
of	O
spokespersons	O
'	O
performance	O
and	O
characteristics	O
in	O
response	O
to	O
the	O
2003	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
.	O

TITLE	O
:	O
Infection	B-DISO
of	O
cats	O
with	O
atypical	O
feline	O
coronaviruses	O
harbouring	O
a	O
truncated	O
form	O
of	O
the	O
canine	O
type	O
I	O
non	O
-	O
structural	O
ORF3	O
gene	O
.	O

Nasopharyngeal	O
wash	O
specimens	O
were	O
prospectively	O
collected	O
from	O
60	O
children	O
with	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
and	O
acute	O
respiratory	O
illness	O
,	O
over	O
a	O
1	O
-	O
year	O
period	O
.	O

Co	B-DISO
-	I-DISO
infection	I-DISO
with	O
at	O
least	O
one	O
additional	O
respiratory	O
virus	O
was	O
seen	O
in	O
14	O
(	O
30	O
%)	O
infected	O
patients	O
,	O
and	O
was	O
not	O
significantly	O
higher	O
in	O
patients	O
with	O
ACS	O
(	O
P	O
=	O
0	O
.	O
10	O
).	O

Tripeptidyls	O
2	O
and	O
6	O
possess	B-DISO
antiviral	O
activities	O
against	O
noroviruses	O
,	O
human	O
rhinovirus	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
,	O
and	O
coronavirus	O
229E	O
,	O
suggesting	O
a	O
broad	O
range	O
of	O
antiviral	O
activities	O
.	O

Only	O
little	O
information	O
on	O
the	O
influence	O
of	O
sample	O
storage	O
and	O
reaction	O
conditions	O
on	O
test	O
results	O
is	O
available	O
,	O
and	O
diagnostic	O
sensitivity	O
and	O
specificity	O
to	O
diagnose	O
FIP	B-DISO
vary	O
considerably	O
between	O
few	O
available	O
studies	O
.	O

In	O
the	O
present	O
report	O
,	O
a	O
series	O
of	O
three	O
cases	O
of	O
imported	O
malaria	B-DISO
complicated	O
by	O
refractory	O
severe	O
ARDS	B-DISO
supported	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
presented	O
.	O

ECMO	O
referral	O
should	O
be	O
considered	O
early	O
in	O
malaria	B-DISO
complicated	O
by	O
severe	O
ARDS	B-DISO
refractory	O
to	O
conventional	O
treatment	O
.	O

Therefore	O
,	O
polymorphism	O
of	O
X	O
-	O
linked	O
genes	O
would	O
result	O
in	O
the	O
presence	O
of	O
two	O
cell	O
populations	O
with	O
distinct	O
regulatory	O
arsenals	O
,	O
providing	O
females	O
with	O
greater	O
diversity	O
to	O
fight	O
against	O
infectious	B-DISO
challenges	O
,	O
in	O
comparison	O
with	O
the	O
uniform	O
cell	O
populations	O
in	O
hemizygous	O
males	O
.	O

Here	O
we	O
report	O
the	O
emergence	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
in	O
the	O
United	O
States	O
and	O
determination	O
of	O
its	O
origin	O
,	O
evolution	O
,	O
and	O
genotypes	O
based	O
on	O
temporal	O
and	O
geographical	O
evidence	O
.	O

Viral	O
pathogen	O
is	O
a	O
major	O
cause	O
of	O
infectious	B-DISO
disease	I-DISO
in	O
pediatric	O
critical	B-DISO
illnesses	I-DISO
and	O
virus	B-DISO
infection	I-DISO
may	O
lead	O
to	O
severe	O
illness	O
.	O

Nitric	O
oxide	O
did	O
not	O
reduce	O
mortality	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
risk	O
ratio	O
,	O
1	O
.	O
01	O
[	O
95	O
%	O
CI	O
,	O
0	O
.	O
78	O
-	O
1	O
.	O
32	O
];	O
p	O
=	O
0	O
.	O
93	O
;	O
n	O
=	O
329	O
,	O
six	O
trials	O
)	O
or	O
mild	O
-	O
moderate	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
risk	O
ratio	O
,	O
1	O
.	O
12	O
[	O
95	O
%	O
CI	O
,	O
0	O
.	O
89	O
-	O
1	O
.	O
42	O
];	O
p	O
=	O
0	O
.	O
33	O
;	O
n	O
=	O
740	O
,	O
seven	O
trials	O
).	O

TITLE	O
:	O
Hajj	O
pilgrims	O
knowledge	O
about	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
,	O
August	O
to	O
September	O
2013	O
.	O

We	O
hypothesized	O
that	O
a	O
loss	O
of	O
5	O
-	O
HT	O
for	O
∼	O
1	O
day	O
would	O
compromise	O
MAP	O
during	O
episodic	O
anoxia	B-DISO
.	O

Despite	O
normal	O
gasp	B-DISO
latency	O
,	O
breathing	O
frequency	O
and	O
a	O
larger	O
tidal	O
volume	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
5	O
-	O
HT	O
-	O
deficient	O
pups	O
survived	O
one	O
-	O
half	O
the	O
number	O
of	O
episodes	O
as	O
controls	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

These	O
data	O
may	O
help	O
explain	O
why	O
some	O
sudden	B-DISO
infant	I-DISO
death	I-DISO
syndrome	I-DISO
cases	O
die	O
from	O
what	O
appears	O
to	O
be	O
cardiovascular	B-DISO
collapse	I-DISO
during	O
apparent	O
severe	O
hypoxia	B-DISO
.	O

It	O
is	O
preceded	O
by	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
(	O
RDS	O
),	O
characterized	O
by	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
due	O
to	O
deficiency	O
of	O
surfactant	O
at	O
birth	O
.	O

Pulmonary	O
biomarkers	O
are	O
needed	O
to	O
predict	O
the	O
clinical	O
course	O
of	O
lung	B-DISO
disease	I-DISO
,	O
status	O
,	O
progression	O
and	O
response	O
to	O
treatment	O
.	O

Risk	O
factors	O
with	O
pooled	O
evidence	O
supporting	O
an	O
increased	O
risk	O
for	O
IAH	O
among	O
mixed	O
ICU	O
patients	O
included	O
obesity	B-DISO
(	O
four	O
studies	O
;	O
odds	O
ratio	O
(	O
OR	O
)	O
5	O
.	O
10	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
),	O
1	O
.	O
92	O
to	O
13	O
.	O
58	O
),	O
sepsis	B-DISO
(	O
two	O
studies	O
;	O
OR	O
2	O
.	O
38	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
34	O
to	O
4	O
.	O
23	O
),	O
abdominal	O
surgery	O
(	O
four	O
studies	O
;	O
OR	O
1	O
.	O
93	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
30	O
to	O
2	O
.	O
85	O
),	O
ileus	B-DISO
(	O
two	O
studies	O
;	O
OR	O
2	O
.	O
05	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
40	O
to	O
2	O
.	O
98	O
),	O
and	O
large	O
volume	O
fluid	O
resuscitation	O
(	O
two	O
studies	O
;	O
OR	O
2	O
.	O
17	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
30	O
to	O
3	O
.	O
63	O
).	O

These	O
studies	O
support	O
further	O
development	O
of	O
GRFT	O
as	O
a	O
systemic	O
antiviral	O
therapeutic	O
agent	O
against	O
enveloped	O
viruses	O
,	O
although	O
deimmunizing	O
the	O
molecule	O
may	O
be	O
necessary	O
if	O
it	O
is	O
to	O
be	O
used	O
in	O
long	O
-	O
term	O
treatment	O
of	O
chronic	O
viral	B-DISO
infections	I-DISO
.	O

The	O
majority	O
of	O
patients	O
presented	O
with	O
fever	O
98	O
%,	O
fever	O
with	O
cough	B-DISO
83	O
%,	O
and	O
shortness	B-DISO
of	I-DISO
breath	I-DISO
72	O
%.	O

The	O
prevalence	O
of	O
lung	O
injury	O
is	O
relatively	O
low	O
in	O
acute	B-DISO
liver	I-DISO
failure	I-DISO
,	O
where	O
21	O
%	O
fulfilled	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
criteria	O
.	O

In	O
response	O
,	O
we	O
developed	O
two	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
PCR	O
(	O
rRT	O
-	O
PCR	O
)	O
assays	O
targeting	O
the	O
MERS	O
-	O
CoV	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
and	O
evaluated	O
these	O
assays	O
as	O
a	O
panel	O
with	O
a	O
previously	O
published	O
assay	O
targeting	O
the	O
region	O
upstream	O
of	O
the	O
MERS	O
-	O
CoV	O
envelope	O
gene	O
(	O
upE	O
)	O
for	O
the	O
detection	O
and	O
confirmation	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

TITLE	O
:	O
Brain	O
-	O
type	O
natriuretic	O
peptide	O
and	O
right	O
ventricular	O
end	O
-	O
diastolic	O
volume	O
index	O
measurements	O
are	O
imprecise	O
estimates	O
of	O
circulating	O
blood	O
volume	O
in	O
critically	B-DISO
ill	I-DISO
subjects	O
.	O

TITLE	O
:	O
Cardiopulmonary	O
involvement	O
in	O
Puumala	O
hantavirus	B-DISO
infection	I-DISO
.	O

Infections	B-DISO
with	O
American	O
hantaviruses	O
may	O
lead	O
to	O
hantavirus	B-DISO
pulmonary	I-DISO
syndrome	I-DISO
characterised	O
by	O
severe	O
cardiopulmonary	O
distress	O
with	O
high	O
mortality	O
.	O

We	O
aimed	O
to	O
comprehensively	O
investigate	O
cardiopulmonary	O
involvement	O
in	O
patients	O
with	O
PUUV	O
-	O
infection	B-DISO
.	O

Pathological	O
ECG	O
,	O
atrial	B-DISO
fibrillation	I-DISO
or	O
T	O
-	O
wave	O
changes	O
,	O
was	O
demonstrated	O
in	O
26	O
%	O
of	O
patients	O
.	O

Furthermore	O
,	O
patients	O
experiencing	O
impaired	B-DISO
general	O
condition	B-DISO
at	O
follow	O
-	O
up	O
had	O
significantly	O
lower	O
gas	O
diffusing	O
capacity	O
and	O
higher	O
pulmonary	O
vascular	O
resistance	O
,	O
compared	O
to	O
those	O
feeling	O
fully	O
recovered	O
.	O

ABSTRACT	O
:	O
The	O
present	O
article	O
analyzes	O
the	O
main	O
presentations	O
on	O
acute	B-DISO
pancreatitis	I-DISO
(	O
AP	O
)	O
in	O
Digestive	B-DISO
Disease	I-DISO
Week	O
2013	O
.	O

True	O
pseudocysts	B-DISO
(	O
fluid	O
collections	O
without	O
necrosis	O
for	O
more	O
than	O
4	O
weeks	O
)	O
are	O
a	O
highly	O
infrequent	O
complication	B-DISO
in	O
AP	O
.	O

ABSTRACT	O
:	O
Pertussis	B-DISO
is	O
an	O
illness	O
that	O
causes	O
significant	O
morbidity	O
and	O
mortality	O
,	O
especially	O
in	O
infants	O
younger	O
than	O
3	O
months	O
old	O
.	O

However	O
,	O
the	O
mortality	O
of	O
ECMO	O
with	O
pertussis	B-DISO
is	O
higher	O
than	O
with	O
other	O
causes	O
of	O
pediatric	O
respiratory	B-DISO
failure	I-DISO
.	O

We	O
report	O
here	O
the	O
case	O
of	O
a	O
2	O
-	O
month	O
-	O
old	O
boy	O
with	O
severe	O
respiratory	B-DISO
failure	I-DISO
and	O
pulmonary	B-DISO
hypertension	I-DISO
who	O
satisfied	O
ECMO	O
criteria	O
but	O
was	O
successfully	O
treated	O
with	O
repeated	O
bronchoscopy	O
with	O
instillation	O
of	O
N	O
-	O
acetylcysteine	O
.	O

Gene	O
ontology	O
category	O
,	O
KEGG	O
pathway	O
,	O
and	O
gene	O
interaction	O
networks	O
(	O
STRING	O
analysis	O
)	O
were	O
analyzed	O
to	O
identify	O
relationships	O
among	O
differentially	O
expressed	O
genes	O
involved	O
in	O
signal	O
transduction	O
,	O
cell	O
adhesion	B-DISO
,	O
immune	O
responses	O
,	O
apoptosis	O
regulation	O
,	O
positive	O
regulation	O
of	O
the	O
I	O
-	O
kappaB	O
kinase	O
/	O
NF	O
-	O
kappaB	O
cascade	O
and	O
response	O
to	O
cytokine	O
stimulus	O
.	O

This	O
study	O
was	O
designed	O
to	O
identify	O
early	O
factors	O
associated	O
with	O
hospital	O
mortality	O
in	O
ARDS	B-DISO
patients	O
treated	O
with	O
ECMO	O
and	O
retrieved	O
from	O
referring	O
hospitals	O
.	O

RESULTS	O
:	O
The	O
main	O
ARDS	B-DISO
etiologies	O
were	O
community	O
-	O
acquired	O
bacterial	B-DISO
pneumonia	I-DISO
(	O
35	O
%),	O
influenza	B-DISO
pneumonia	I-DISO
(	O
23	O
%)	O
(	O
with	O
12	O
patients	O
having	O
been	O
treated	O
during	O
the	O
first	O
half	O
of	O
the	O
study	O
period	O
),	O
and	O
nosocomial	B-DISO
pneumonia	I-DISO
(	O
14	O
%).	O

TITLE	O
:	O
Long	O
lasting	O
dysautonomia	B-DISO
due	O
to	O
botulinum	O
toxin	O
B	O
poisoning	O
:	O
clinical	O
-	O
laboratory	O
follow	O
up	O
and	O
difficulties	O
in	O
initial	O
diagnosis	O
.	O

Botulism	O
(	O
especially	O
type	O
B	O
)	O
should	O
be	O
considered	O
in	O
any	O
case	O
of	O
acute	O
or	O
predominant	O
isolated	O
autonomic	B-DISO
dysfunction	I-DISO
.	O

At	O
present	O
,	O
there	O
are	O
no	O
established	O
national	O
criteria	O
for	O
when	O
to	O
consider	O
futility	O
or	O
lung	O
transplantation	O
in	O
adult	O
patients	O
requiring	O
ECMO	O
for	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Clinical	O
features	O
of	O
patients	O
with	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
at	O
seven	O
hospitals	O
on	O
the	O
East	O
Coast	O
of	O
Australia	O
.	O

There	O
were	O
168	O
cases	O
of	O
acute	B-DISO
inflammatory	I-DISO
demyelinating	I-DISO
polyneuropathy	I-DISO
(	O
AIDP	B-DISO
),	O
17	O
of	O
acute	O
motor	O
axonal	B-DISO
neuropathy	I-DISO
(	O
AMAN	O
),	O
4	O
of	O
acute	O
motor	O
and	O
sensory	O
axonal	B-DISO
neuropathy	I-DISO
(	O
AMSAN	O
),	O
and	O
35	O
of	O
Miller	B-DISO
-	I-DISO
Fisher	I-DISO
syndrome	I-DISO
(	O
MFS	B-DISO
).	O

GBS	B-DISO
affects	O
adults	O
of	O
all	O
ages	O
and	O
usually	O
follows	O
a	O
severe	O
clinical	O
course	O
.	O

A	O
wide	O
variety	O
of	O
triggering	O
factors	O
leads	O
to	O
a	O
relatively	O
stereotypical	O
clinical	O
syndrome	B-DISO
.	O

Personalized	O
pharmacotherapy	O
is	O
necessary	O
to	O
prevent	O
the	O
next	O
acute	B-DISO
severe	I-DISO
asthma	I-DISO
exacerbation	O
,	O
not	O
just	O
the	O
control	O
of	O
symptoms	O
.	O

The	O
2007	O
National	O
Asthma	B-DISO
Education	O
and	O
Prevention	O
Program	O
Expert	O
Panel	O
3	O
provides	O
guidelines	O
for	O
the	O
treatment	O
of	O
uncontrolled	O
asthma	B-DISO
.	O

Besides	O
hepatomegaly	B-DISO
and	O
splenomegaly	O
which	O
were	O
the	O
most	O
common	O
symptoms	O
,	O
which	O
were	O
seen	O
in	O
81	O
.	O
5	O
%	O
and	O
72	O
.	O
2	O
%	O
children	O
respectively	O
,	O
the	O
various	O
unusual	O
manifestations	O
seen	O
were	O
severe	O
thrombocytopaenia	O
(	O
37	O
%),	O
jaundice	B-DISO
with	O
deranged	O
LFT	O
values	O
(	O
25	O
.	O
9	O
%),	O
abnormal	B-DISO
bleeding	I-DISO
(	O
18	O
.	O
5	O
%),	O
impaired	B-DISO
consciousness	I-DISO
with	O
a	O
GCS	O
of	O
<	O
9	O
(	O
18	O
.	O
5	O
%),	O
severe	O
anaemia	B-DISO
(	O
14	O
.	O
8	O
%),	O
hypotension	O
(	O
11	O
.	O
1	O
%),	O
repeated	O
convulsions	B-DISO
(	O
7	O
.	O
6	O
%),	O
pulmonary	B-DISO
oedema	I-DISO
/	O
ARDS	B-DISO
(	O
5	O
.	O
6	O
%)	O
and	O
ascites	O
(	O
5	O
.	O
6	O
%).	O

One	O
case	O
each	O
showed	O
haemoglobinuria	B-DISO
,	O
and	O
pleural	B-DISO
effusion	I-DISO
.	O

Due	O
to	O
its	O
lower	O
morbidity	O
,	O
P	O
.	O
ovale	O
receives	O
little	O
attention	O
in	O
malaria	B-DISO
research	O
.	O

Monitoring	O
of	O
respiratory	O
and	O
renal	O
function	O
of	O
malaria	B-DISO
patients	O
,	O
regardless	O
of	O
the	O
species	O
of	O
malaria	B-DISO
parasites	O
involved	O
is	O
crucial	O
during	O
the	O
course	O
of	O
hospital	O
admission	O
.	O

We	O
aimed	O
to	O
show	O
that	O
e	O
-	O
commerce	O
concepts	O
and	O
software	O
tools	O
can	O
be	O
readily	O
adapted	O
to	O
enable	O
rapid	O
collection	O
of	O
data	O
after	O
an	O
infectious	B-DISO
disease	I-DISO
outbreak	O
or	O
environmental	O
disaster	O
.	O

This	O
virus	O
,	O
termed	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
CoV	O
was	O
linked	O
to	O
a	O
zoonotic	O
origin	O
from	O
rhinolophid	O
bats	O
in	O
2005	O
.	O

Since	O
then	O
,	O
numerous	O
studies	O
have	O
described	O
novel	O
bat	O
CoVs	O
,	O
including	O
close	O
relatives	O
of	O
the	O
newly	O
emerging	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)-	O
CoV	O
.	O
In	O
this	O
paper	O
we	O
discuss	O
CoV	O
genomic	O
properties	O
and	O
compare	O
different	O
taxonomic	O
approaches	O
in	O
light	O
of	O
the	O
technical	O
difficulties	O
of	O
obtaining	O
full	O
genomic	O
sequences	O
directly	O
from	O
bat	O
specimens	O
.	O

TITLE	O
:	O
Biochemical	O
analysis	O
and	O
application	O
of	O
molecular	O
display	O
technology	O
on	O
Candida	O
albicans	O
for	O
diagnosing	O
and	O
preventing	O
candidiasis	B-DISO
.	O

However	O
,	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
AIDS	O
,	O
as	O
well	O
as	O
re	B-DISO
-	I-DISO
emerging	I-DISO
infectious	I-DISO
diseases	I-DISO
such	O
as	O
Japanese	B-DISO
encephalitis	I-DISO
and	O
dengue	B-DISO
fever	I-DISO
,	O
have	O
been	O
spreading	O
in	O
recent	O
times	O
.	O

In	O
addition	O
,	O
vaccines	O
against	O
these	O
diseases	O
often	O
cannot	O
prevent	O
infections	B-DISO
,	O
because	O
pathogenic	O
viruses	O
or	O
bacteria	O
evade	O
the	O
immune	O
system	O
of	O
the	O
host	O
.	O

This	O
renders	O
IFN	O
-	O
λ	O
a	O
better	O
choice	O
for	O
the	O
treatment	O
against	O
many	O
diseases	O
including	O
viral	B-DISO
hepatitis	I-DISO
and	O
human	O
coronavirus	O
(	O
HCoV	O
-	O
EMC	B-DISO
).	O

Patients	O
were	O
classified	O
in	O
mild	O
,	O
moderate	O
and	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

The	O
development	O
of	O
a	O
small	O
-	O
animal	O
model	O
is	O
critical	O
for	O
the	O
understanding	O
of	O
this	O
virus	O
and	O
to	O
aid	O
in	O
development	O
of	O
countermeasures	O
against	O
MERS	O
-	O
CoV	O
.	O
We	O
found	O
that	O
BALB	O
/	O
c	O
,	O
129	O
/	O
SvEv	O
and	O
129	O
/	O
SvEv	O
STAT1	O
knockout	O
mice	O
are	O
not	O
permissive	O
to	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

TITLE	O
:	O
Inhibition	O
of	O
NF	O
-	O
κB	O
-	O
mediated	O
inflammation	B-DISO
in	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
-	O
infected	O
mice	O
increases	O
survival	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
is	O
the	O
etiological	O
agent	O
of	O
a	O
respiratory	B-DISO
disease	I-DISO
that	O
has	O
a	O
10	O
%	O
mortality	O
rate	O
.	O

This	O
study	O
demonstrates	O
a	O
protective	O
role	O
of	O
the	O
ISG	O
Ifit2	O
in	O
encephalitis	B-DISO
induced	O
by	O
the	O
dual	O
hepato	O
-	O
and	O
neurotropic	O
MHV	O
-	O
A59	O
.	O

Currently	O
,	O
the	O
viruses	O
virulence	O
determinants	O
and	O
host	O
gene	O
expressions	O
during	O
FIPV	O
infection	B-DISO
are	O
not	O
fully	O
understood	O
.	O

Real	O
time	O
RT	O
-	O
qPCR	O
developed	O
focusing	O
on	O
2	O
up	O
-	O
regulated	O
genes	O
(	O
PD	O
-	O
L1	O
and	O
A3H	O
)	O
together	O
with	O
an	O
apoptosis	O
associated	O
gene	O
PD	O
-	O
1	O
expressions	O
in	O
FIPV	O
infected	O
CRFK	O
cells	O
and	O
in	O
PBMCs	O
from	O
healthy	O
and	O
FIP	B-DISO
diagnosed	O
cats	O
produced	O
concordant	O
results	O
with	O
transcriptome	O
data	O
.	O

CONCLUSIONS	O
:	O
The	O
possible	O
roles	O
of	O
these	O
genes	O
,	O
and	O
their	O
importance	O
in	O
feline	O
coronaviruses	O
infection	B-DISO
,	O
are	O
discussed	O
.	O

TITLE	O
:	O
Neurally	O
adjusted	O
ventilatory	O
assist	O
vs	O
pressure	O
support	O
ventilation	O
in	O
infants	O
recovering	O
from	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
nested	O
study	O
.	O

Controls	O
(	O
2	O
:	O
1	O
ratio	O
)	O
were	O
ARDS	B-DISO
infants	O
weaned	O
with	O
pressure	O
support	O
ventilation	O
(	O
PSV	O
)	O
during	O
2008	O
-	O
2009	O
matched	O
for	O
age	O
,	O
gas	B-DISO
exchange	I-DISO
impairment	I-DISO
,	O
and	O
weight	O
.	O

TITLE	O
:	O
Definition	O
of	O
critical	O
asthma	B-DISO
syndromes	B-DISO
.	O

Existing	O
national	O
guidelines	O
do	O
not	O
present	O
consistent	O
or	O
specific	O
recommendations	O
for	O
the	O
evaluation	O
and	O
treatment	O
of	O
individual	O
asthma	B-DISO
patients	O
in	O
respiratory	B-DISO
distress	I-DISO
.	O

Acute	B-DISO
severe	I-DISO
asthma	I-DISO
,	O
refractory	O
asthma	B-DISO
,	O
status	B-DISO
asthmaticus	I-DISO
,	O
and	O
near	O
-	O
fatal	O
asthma	B-DISO
all	O
describe	O
CAS	B-DISO
where	O
physical	O
exhaustion	B-DISO
from	O
the	O
overwhelming	O
work	O
of	O
breathing	O
leads	O
to	O
respiratory	B-DISO
arrest	I-DISO
and	O
death	O
from	O
hypoxia	B-DISO
or	O
related	O
complications	O
.	O

We	O
recommend	O
that	O
primary	O
care	O
physicians	O
refer	O
patients	O
promptly	O
to	O
an	O
asthma	B-DISO
specialist	O
for	O
consultation	O
to	O
reduce	O
the	O
frequency	O
of	O
acute	O
exacerbations	O
and	O
prevent	O
the	O
development	O
of	O
CAS	B-DISO
.	O

Non	O
-	O
randomized	O
studies	O
suggest	O
that	O
convalescent	O
plasma	O
appears	O
useful	O
as	O
add	B-DISO
-	O
on	O
therapy	O
for	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
avian	B-DISO
influenza	I-DISO
A	O
(	O
H5N1	B-DISO
),	O
and	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
2009	O
pandemic	O
[	O
A	O
(	O
H1N1	O
)	O
pdm09	O
),	O
but	O
it	O
is	O
limited	O
by	O
its	O
availability	O
.	O

For	O
17	O
/	O
25	O
samples	O
,	O
single	O
infections	B-DISO
were	O
detected	O
as	O
follows	O
:	O
six	O
CCoV	O
-	O
I	O
,	O
nine	O
CCoV	O
-	O
IIa	O
and	O
two	O
CCoV	O
-	O
IIb	O
.	O

TITLE	O
:	O
A	O
decade	O
after	O
SARS	B-DISO
:	O
strategies	O
for	O
controlling	O
emerging	O
coronaviruses	O
.	O

E2	O
treatment	O
during	O
intestinal	B-DISO
ischemia	I-DISO
was	O
effective	O
to	O
reduce	O
the	O
levels	O
of	O
IL	O
-	O
10	O
and	O
IL	O
-	O
1β	O
in	O
explant	O
supernatant	O
,	O
but	O
only	O
IL	O
-	O
10	O
levels	O
were	O
reduced	O
by	O
E2	O
at	O
reperfusion	O
phase	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
estradiol	O
modulates	O
the	O
lung	O
inflammatory	B-DISO
response	I-DISO
induced	O
by	O
lung	O
injury	O
,	O
likely	O
by	O
acute	O
effects	O
.	O

TITLE	O
:	O
Respiratory	B-DISO
failure	I-DISO
due	O
to	O
blastomycosis	B-DISO
infection	B-DISO
in	O
a	O
patient	O
with	O
hypertension	B-DISO
,	O
cirrhosis	B-DISO
and	O
chronic	B-DISO
pancreatitis	I-DISO
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
),	O
an	O
enteropathogenic	O
coronavirus	O
,	O
causes	O
severe	O
lethal	O
watery	B-DISO
diarrhea	I-DISO
and	O
dehydration	B-DISO
in	O
piglets	O
.	O

The	O
results	O
showed	O
that	O
TGEV	O
infection	B-DISO
induced	I-DISO
ROS	O
accumulation	O
,	O
whereas	O
UV	O
-	O
irradiated	O
TGEV	O
did	O
not	O
promote	O
ROS	O
accumulation	O
.	O

In	O
addition	O
,	O
TGEV	O
infection	B-DISO
lowered	O
mitochondrial	O
transmembrane	O
potential	O
in	O
PK	O
-	O
15	O
cell	O
line	O
,	O
which	O
could	O
be	O
inhibited	O
by	O
ROS	O
scavengers	O
,	O
pyrrolidinedithiocarbamic	O
(	O
PDTC	O
)	O
and	O
N	O
-	O
acetyl	O
-	O
l	O
-	O
cysteine	O
(	O
NAC	O
).	O

Finally	O
,	O
TMPRSS2	O
was	O
found	O
to	O
compete	O
with	O
the	O
metalloprotease	O
ADAM17	O
for	O
ACE2	O
processing	O
,	O
but	O
only	O
cleavage	O
by	O
TMPRSS2	O
resulted	O
in	O
augmented	O
SARS	B-DISO
-	O
S	O
-	O
driven	O
entry	O
.	O

Collectively	O
,	O
our	O
results	O
in	O
conjunction	O
with	O
those	O
of	O
previous	O
studies	O
indicate	O
that	O
TMPRSS2	O
and	O
potentially	O
related	O
proteases	O
promote	O
SARS	B-DISO
-	O
CoV	O
entry	O
by	O
two	O
separate	O
mechanisms	O
:	O
ACE2	O
cleavage	O
,	O
which	O
might	O
promote	O
viral	O
uptake	O
,	O
and	O
SARS	B-DISO
-	O
S	O
cleavage	O
,	O
which	O
activates	O
the	O
S	O
protein	O
for	O
membrane	O
fusion	O
.	O

Their	O
genome	O
size	O
is	O
about	O
32	O
,	O
000	O
nucleotides	O
,	O
the	O
largest	O
among	O
all	O
CoVs	O
,	O
as	O
a	O
result	O
of	O
multiple	O
unique	O
open	O
reading	O
frames	O
(	O
NS5a	O
,	O
NS5b	O
,	O
NS5c	O
,	O
NS6	B-DISO
,	O
NS7	B-DISO
,	O
NS8	O
,	O
NS9	O
,	O
and	O
NS10	O
)	O
between	O
their	O
membrane	O
(	O
M	O
)	O
and	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
genes	O
.	O

HCoV	O
strain	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
)	O
can	O
infect	O
and	O
persist	O
in	O
human	O
neural	O
cells	O
and	O
activate	O
neuroinflammatory	O
and	O
neurodegenerative	O
mechanisms	O
,	O
suggesting	O
that	O
it	O
could	O
be	O
involved	O
in	O
neurological	B-DISO
disease	I-DISO
of	O
unknown	O
etiology	O
in	O
humans	O
.	O

Mutations	O
in	O
the	O
surface	O
spike	O
(	O
S	O
)	O
protein	O
of	O
human	O
respiratory	O
coronavirus	O
OC43	O
appear	O
after	O
persistent	B-DISO
infection	I-DISO
of	O
human	O
cells	O
of	O
the	O
central	O
nervous	B-DISO
system	O
,	O
a	O
possible	O
viral	O
adaptation	O
to	O
this	O
environment	O
.	O

This	O
suggests	O
that	O
memantine	O
could	O
be	O
used	O
as	O
an	O
antiviral	O
agent	O
while	O
improving	O
neurological	B-DISO
symptoms	I-DISO
in	O
various	O
neurological	O
diseases	O
with	O
a	O
viral	O
involvement	O
.	O

This	O
review	O
presents	O
a	O
summary	O
of	O
6	O
viruses	O
(	O
canine	O
respiratory	O
coronavirus	O
,	O
canine	O
pneumovirus	O
,	O
canine	O
influenza	B-DISO
virus	O
,	O
pantropic	O
canine	O
coronavirus	O
,	O
canine	O
bocavirus	O
,	O
and	O
canine	O
hepacivirus	O
)	O
and	O
2	O
bacteria	O
(	O
Streptococcus	O
zooepidemicus	O
and	O
Mycoplasma	B-DISO
cynos	O
)	O
that	O
have	O
been	O
associated	O
with	O
respiratory	B-DISO
disease	I-DISO
in	O
dogs	O
.	O

TITLE	O
:	O
Apnea	B-DISO
testing	O
for	O
brain	B-DISO
death	I-DISO
in	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
a	O
possible	O
solution	O
.	O

ABSTRACT	O
:	O
A	O
42	O
-	O
year	O
-	O
old	O
man	O
with	O
a	O
subarachnoid	B-DISO
hemorrhage	I-DISO
complicated	O
by	O
anoxic	B-DISO
brain	I-DISO
injury	I-DISO
,	O
respiratory	B-DISO
failure	I-DISO
requiring	O
mechanical	O
ventilation	O
,	O
and	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
presented	O
a	O
clinical	O
conundrum	O
for	O
safe	O
apnea	B-DISO
testing	O
in	O
brain	B-DISO
death	I-DISO
determination	O
due	O
to	O
profound	O
hypoxemia	O
.	O

The	O
detailed	O
clinical	O
features	O
of	O
cases	O
with	O
SFTSV	O
infection	B-DISO
have	O
not	O
been	O
well	O
described	O
,	O
and	O
the	O
risk	O
factors	O
for	O
severity	O
among	O
patients	O
and	O
fatality	O
among	O
severe	O
patients	O
remain	O
to	O
be	O
determined	O
.	O

One	O
hundred	O
and	O
three	O
(	O
89	O
.	O
6	O
%)	O
of	O
115	O
patients	O
presented	O
with	O
multiple	O
organ	O
dysfunction	O
,	O
and	O
22	O
(	O
19	O
.	O
1	O
%)	O
of	O
115	O
proceeded	O
to	O
the	O
stage	O
of	O
life	O
threatening	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
.	O

In	O
this	O
issue	O
,	O
Klaus	O
et	O
al	O
.	O
(	O
2013	O
)	O
identify	O
the	O
cargo	O
receptor	O
endoplasmic	O
reticulum	O
(	O
ER	O
)-	O
Golgi	O
intermediate	O
compartment	O
53	O
kDa	O
protein	O
(	O
ERGIC	O
-	O
53	O
)	O
as	O
a	O
binding	O
partner	O
for	O
viral	O
GPs	B-DISO
and	O
a	O
crucial	O
cellular	O
factor	O
required	O
for	O
infectious	B-DISO
virus	O
production	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
serologic	O
and	O
antigenic	O
relationships	O
between	O
middle	O
eastern	O
respiratory	O
syndrome	B-DISO
coronavirus	O
and	O
other	O
coronaviruses	O
to	O
develop	O
vaccine	O
platforms	O
for	O
the	O
rapid	O
response	O
to	O
emerging	O
coronaviruses	O
.	O

No	O
complication	B-DISO
related	O
to	O
PP	O
was	O
detected	O
.	O

No	O
complication	B-DISO
related	O
to	O
PP	O
was	O
detected	O
.	O

TITLE	O
:	O
Adenosine	O
deaminase	O
acts	O
as	O
a	O
natural	O
antagonist	O
for	O
dipeptidyl	O
peptidase	O
4	O
-	O
mediated	O
entry	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
.	O

TITLE	O
:	O
Spatio	O
-	O
temporal	O
and	O
stochastic	O
modelling	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
In	O
the	O
era	O
of	O
global	O
travel	O
,	O
clinicians	O
can	O
no	O
longer	O
consider	O
just	O
influenza	B-DISO
and	O
Respiratory	O
Synctial	O
Virus	O
(	O
RSV	O
)	O
and	O
ignore	O
other	O
causes	O
of	O
presumptive	O
viral	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
.	O

Retrospective	O
quantitative	O
analysis	O
of	O
CT	O
scan	O
images	O
of	O
148	O
patients	O
with	O
ARDS	B-DISO
and	O
100	O
control	O
subjects	O
.	O

The	O
extent	O
of	O
lung	O
inhomogeneities	O
increased	O
with	O
the	O
severity	O
of	O
ARDS	B-DISO
(	O
14	O
±	O
5	O
,	O
18	O
±	O
8	O
,	O
and	O
23	O
±	O
10	O
%	O
of	O
lung	O
volume	O
in	O
mild	O
,	O
moderate	O
,	O
and	O
severe	O
ARDS	B-DISO
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
correlated	O
with	O
the	O
physiologic	O
dead	O
space	O
(	O
r	O
(	O
2	O
)	O
=	O
0	O
.	O
34	O
;	O
P	O
<	O
0	O
.	O
0001	O
).	O

Radiological	O
and	O
pulmonary	O
function	O
test	O
were	O
consistent	O
with	O
an	O
acute	O
infectious	B-DISO
bronchiolitis	B-DISO
.	O

CONCLUSIONS	O
:	O
Mycoplasma	B-DISO
pneumoniae	O
may	O
be	O
responsible	O
for	O
severe	O
respiratory	O
illness	O
in	O
the	O
form	O
of	O
bronchiolitis	B-DISO
.	O

CONCLUSIONS	O
:	O
The	O
Proteus	B-DISO
syndrome	I-DISO
is	O
a	O
very	O
rare	O
cause	O
of	O
pulmonary	B-DISO
emphysema	I-DISO
.	O

ABSTRACT	O
:	O
The	O
SARS	B-DISO
(	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
)	O
pandemic	O
caused	O
ten	O
years	O
ago	O
by	O
the	O
SARS	B-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
has	O
stimulated	O
a	O
number	O
of	O
studies	O
on	O
the	O
molecular	O
biology	O
of	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
Though	O
respiratory	O
viruses	O
are	O
thought	O
to	O
cause	O
substantial	O
morbidity	O
globally	O
in	O
children	O
aged	O
<	O
5	O
years	O
,	O
the	O
incidence	O
of	O
severe	O
respiratory	O
virus	O
infections	B-DISO
in	O
children	O
is	O
unknown	O
in	O
India	O
where	O
20	O
%	O
of	O
the	O
world	O
'	O
s	O
children	O
live	O
.	O

Of	O
245	O
hospitalized	O
children	O
,	O
respiratory	O
viruses	O
were	O
detected	O
among	O
98	O
(	O
40	O
%),	O
of	O
whom	O
92	O
(	O
94	O
%)	O
had	O
fever	O
or	O
respiratory	B-DISO
symptoms	I-DISO
.	O

Public	O
health	O
research	O
and	O
prevention	O
in	O
India	O
should	O
consider	O
targeting	O
RSV	O
and	O
influenza	B-DISO
in	O
young	O
children	O
.	O

Outbreaks	O
have	O
been	O
extinguished	O
without	O
overly	O
aggressive	B-DISO
isolation	O
and	O
quarantine	O
suggesting	O
that	O
transmission	O
of	O
virus	O
may	O
be	O
stopped	O
with	O
implementation	O
of	O
appropriate	O
infection	B-DISO
control	O
measures	O
.	O

Nearly	O
all	O
symptomatic	O
patients	O
presented	O
with	O
respiratory	B-DISO
symptoms	I-DISO
and	O
1	O
/	O
3	O
of	O
patients	O
also	O
had	O
gastrointestinal	B-DISO
symptoms	I-DISO
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
major	O
cause	O
of	O
respiratory	B-DISO
failure	I-DISO
,	O
with	O
limited	O
effective	O
treatments	O
available	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
emergence	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
2012	O
,	O
many	O
questions	O
remain	O
on	O
modes	O
of	O
transmission	O
and	O
sources	O
of	O
virus	O
.	O

The	O
aptamer	O
selection	O
process	O
will	O
be	O
described	O
,	O
followed	O
by	O
an	O
explanation	O
of	O
the	O
potential	O
for	O
treating	O
virus	B-DISO
infection	I-DISO
by	O
aptamers	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
has	O
become	O
endemic	O
in	O
the	O
Thai	O
swine	O
industry	O
,	O
causing	O
economic	O
losses	O
and	O
repeated	O
outbreaks	O
since	O
its	O
first	O
emergence	O
in	O
2007	O
.	O

TITLE	O
:	O
Phylogenetic	O
analysis	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
field	O
strains	O
in	O
central	O
China	O
based	O
on	O
the	O
ORF3	O
gene	O
and	O
the	O
main	O
neutralization	O
epitopes	O
.	O

Mortality	O
was	O
the	O
primary	O
outcome	O
;	O
resolution	O
of	O
infection	B-DISO
and	O
hospitalization	O
costs	O
were	O
the	O
secondary	O
outcomes	O
.	O

The	O
median	O
time	O
until	O
resolution	O
of	O
infection	B-DISO
was	O
5	O
days	O
in	O
both	O
arms	B-DISO
.	O

TITLE	O
:	O
Definitions	O
and	O
pathophysiology	O
of	O
sepsis	B-DISO
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
commonly	O
associated	O
with	O
severe	B-DISO
sepsis	I-DISO
.	O

Sepsis	B-DISO
-	O
related	O
ARDS	B-DISO
has	O
a	O
generally	O
higher	O
disease	O
severity	O
and	O
poorer	O
recovery	O
period	O
from	O
lung	O
injury	O
with	O
an	O
increased	O
mortality	O
rate	O
.	O

The	O
incidence	O
of	O
ARDS	B-DISO
was	O
0	O
.	O
61	O
%,	O
with	O
a	O
mortality	O
of	O
40	O
.	O
5	O
%	O
(	O
15	O
patients	O
).	O

Multivariate	O
regression	O
analysis	O
identified	O
previous	O
cardiac	O
surgery	O
,	O
complex	O
cardiac	O
surgery	O
,	O
and	O
more	O
than	O
three	O
transfusions	O
with	O
packed	O
red	O
blood	O
cells	O
(	O
PRBC	O
)	O
were	O
independent	O
predictors	O
for	O
developing	O
ARDS	B-DISO
.	O

Multivariate	O
regression	O
analysis	O
identified	O
previous	O
cardiac	O
surgery	O
,	O
complex	O
cardiac	O
surgery	O
,	O
and	O
more	O
than	O
three	O
transfusions	O
with	O
packed	O
red	O
blood	O
cells	O
(	O
PRBC	O
)	O
were	O
independent	O
predictors	O
for	O
developing	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Molecular	O
characterization	O
of	O
major	O
structural	O
protein	O
genes	O
of	O
avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
isolates	O
in	O
southern	O
china	O
.	O

TITLE	O
:	O
Adjuvant	O
effects	O
of	O
mannose	O
-	O
binding	O
lectin	O
ligands	O
on	O
the	O
immune	O
response	O
to	O
infectious	B-DISO
bronchitis	B-DISO
vaccine	O
in	O
chickens	O
with	O
high	O
or	O
low	O
serum	O
mannose	O
-	O
binding	O
lectin	O
concentrations	O
.	O

All	O
patients	O
were	O
middle	O
to	O
old	O
aged	O
(	O
mean	O
age	O
62	O
years	O
)	O
and	O
overweight	B-DISO
(	O
mean	O
body	O
mass	O
index	O
31	O
)	O
patients	O
.	O

Pulmonary	B-DISO
fibrosis	I-DISO
can	O
be	O
seen	O
at	O
late	O
stage	O
of	O
the	O
disease	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
the	O
synthetic	O
peptide	O
FP5	O
could	O
serve	O
as	O
a	O
valuable	O
addition	O
to	O
the	O
current	O
FIP	B-DISO
prevention	O
methods	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
not	O
detected	O
in	O
children	O
hospitalized	O
with	O
acute	O
respiratory	O
illness	O
in	O
Amman	O
,	O
Jordan	O
,	O
March	O
2010	O
to	O
September	O
2012	O
.	O

TITLE	O
:	O
Trends	O
in	O
influenza	B-DISO
vaccination	O
coverage	O
in	O
Portugal	O
from	O
1998	O
to	O
2010	O
:	O
effect	O
of	O
major	O
pandemic	O
threats	O
.	O

ABSTRACT	O
:	O
Vaccination	O
is	O
the	O
key	O
measure	O
available	O
for	O
prevention	O
of	O
the	O
public	O
health	O
burden	O
of	O
annual	O
influenza	B-DISO
epidemics	O
.	O

The	O
effect	O
of	O
SARS	B-DISO
,	O
A	O
(	O
H5N1	B-DISO
),	O
and	O
the	O
A	O
(	O
H1N1	O
)	O
2009	O
pandemic	O
was	O
tested	O
using	O
a	O
meta	O
-	O
regression	O
model	O
.	O

This	O
result	O
indicates	O
that	O
influenza	B-DISO
vaccination	O
strategy	O
should	O
be	O
improved	O
to	O
meet	O
the	O
ambitious	O
WHO	O
coverage	O
goals	O
.	O

ABSTRACT	O
:	O
The	O
infection	B-DISO
of	O
the	O
avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
is	O
initiated	O
by	O
the	O
binding	O
of	O
the	O
spike	O
glycoprotein	O
S	O
to	O
sialic	O
acids	O
on	O
the	O
chicken	O
host	O
cell	O
.	O

Our	O
results	O
may	O
help	O
to	O
understand	O
the	O
differences	O
between	O
IBV	O
S1	O
genotypes	O
and	O
the	O
ultimate	O
pathogenesis	B-DISO
of	O
IBV	O
in	O
chickens	O
.	O

3CL	O
(	O
pro	O
)	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
viral	O
replication	O
cycle	O
and	O
is	O
a	O
potential	O
target	O
for	O
SARS	B-DISO
inhibitor	O
development	O
.	O

A	O
series	O
of	O
isatin	O
derivatives	O
as	O
possible	O
SARS	B-DISO
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
inhibitors	O
was	O
designed	O
,	O
synthesized	O
,	O
and	O
evaluated	O
by	O
in	O
vitro	O
protease	O
assay	O
using	O
fluorogenic	O
substrate	O
peptide	O
,	O
in	O
which	O
several	O
showed	O
potent	O
inhibition	O
against	O
the	O
3CL	O
(	O
pro	O
).	O

TITLE	O
:	O
Interferon	O
-	O
β	O
and	O
mycophenolic	O
acid	O
are	O
potent	O
inhibitors	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
in	O
cell	O
-	O
based	O
assays	O
.	O

Administration	O
of	O
IFN	O
-	O
α2b	O
and	O
ribavirin	O
has	O
improved	O
outcomes	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
in	O
rhesus	O
macaques	O
when	O
administered	O
within	O
8	O
h	O
post	O
-	O
challenge	O
.	O

TITLE	O
:	O
Neutrophils	O
are	O
needed	O
for	O
an	O
effective	O
immune	O
response	O
against	O
pulmonary	O
rat	O
coronavirus	B-DISO
infection	I-DISO
,	O
but	O
also	O
contribute	O
to	O
pathology	B-DISO
.	O

ABSTRACT	O
:	O
Polymorphonuclear	O
neutrophils	O
(	O
PMN	O
)	O
infiltrate	B-DISO
the	O
respiratory	O
tract	O
early	O
after	O
viral	B-DISO
infection	I-DISO
and	O
can	O
contribute	O
to	O
both	O
host	O
defence	O
and	O
pathology	B-DISO
.	O

Coronaviruses	O
are	O
important	O
causes	O
of	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
,	O
ranging	O
from	O
mild	O
to	O
severe	O
depending	O
on	O
the	O
viral	O
strain	O
.	O

To	O
determine	O
their	O
role	O
during	O
RCoV	O
infection	B-DISO
,	O
PMN	O
were	O
depleted	O
and	O
the	O
effects	O
on	O
disease	B-DISO
progression	I-DISO
,	O
viral	O
replication	O
,	O
inflammatory	B-DISO
response	I-DISO
and	O
lung	O
pathology	B-DISO
were	O
analysed	O
.	O

TITLE	O
:	O
A	O
truncated	O
receptor	O
-	O
binding	O
domain	O
of	O
MERS	O
-	O
CoV	O
spike	O
protein	O
potently	O
inhibits	O
MERS	O
-	O
CoV	O
infection	B-DISO
and	O
induces	O
strong	O
neutralizing	O
antibody	O
responses	O
:	O
implication	O
for	O
developing	O
therapeutics	O
and	O
vaccines	O
.	O

ABSTRACT	O
:	O
An	O
emerging	O
respiratory	O
infectious	B-DISO
disease	I-DISO
with	O
high	O
mortality	O
,	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	B-DISO
),	O
is	O
caused	O
by	O
a	O
novel	O
coronavirus	O
(	O
MERS	B-DISO
-	O
CoV	O
).	O

These	O
findings	O
indicate	O
that	O
this	O
truncated	O
RBD	O
protein	O
shows	O
promise	O
for	O
further	O
development	O
as	O
an	O
effective	O
and	O
safe	O
vaccine	O
for	O
the	O
prevention	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

An	O
emerging	O
theme	O
is	O
that	O
polymorphisms	O
in	O
the	O
genes	O
encoding	O
these	O
factors	O
can	O
influence	O
the	O
host	O
response	O
to	O
infection	B-DISO
and	O
the	O
course	O
of	O
disease	O
.	O

Respiratory	B-DISO
tract	I-DISO
infections	I-DISO
,	O
particularly	O
pneumonia	B-DISO
,	O
are	O
the	O
most	O
common	O
site	O
of	O
infection	B-DISO
,	O
and	O
associated	O
with	O
the	O
highest	O
mortality	O
.	O

Recent	O
studies	O
suggest	O
that	O
acute	B-DISO
infections	I-DISO
worsen	O
pre	O
-	O
existing	O
chronic	B-DISO
diseases	I-DISO
or	O
result	O
in	O
new	O
chronic	B-DISO
diseases	I-DISO
,	O
leading	O
to	O
poor	O
long	O
-	O
term	O
outcomes	O
in	O
acute	O
illness	O
survivors	O
.	O

People	O
of	O
older	O
age	O
,	O
male	O
gender	O
,	O
black	O
race	O
,	O
and	O
preexisting	O
chronic	O
health	O
conditions	O
are	O
particularly	O
prone	O
to	O
develop	O
severe	B-DISO
sepsis	I-DISO
;	O
hence	O
prevention	O
strategies	O
should	O
be	O
targeted	O
at	O
these	O
vulnerable	O
populations	O
in	O
future	O
studies	O
.	O

ABSTRACT	O
:	O
This	O
review	O
summarizes	O
the	O
most	O
recent	O
clinical	O
and	O
experimental	O
data	O
on	O
the	O
impact	O
of	O
spontaneous	O
breathing	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

ABSTRACT	O
:	O
Combination	O
of	O
prone	O
positioning	O
(	O
PrP	O
)	O
and	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
might	O
be	O
beneficial	O
in	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
because	O
both	O
approaches	O
are	O
recommended	O
.	O

Progress	O
has	O
been	O
made	O
in	O
designing	O
novel	O
and	O
efficient	O
candidate	O
vaccines	O
to	O
control	O
IBV	O
infection	B-DISO
.	O

BacMam	O
virus	O
-	O
based	O
surface	O
display	O
strategies	O
could	O
serve	O
as	O
effective	O
tools	O
in	O
designing	O
vaccines	O
against	O
IB	O
and	O
other	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

ABSTRACT	O
:	O
Between	O
June	O
and	O
September	O
2013	O
,	O
sera	O
from	O
11	O
dromedary	O
camels	O
,	O
150	O
goats	O
,	O
126	O
sheep	O
and	O
91	O
cows	O
were	O
collected	O
in	O
Jordan	O
,	O
where	O
the	O
first	O
human	O
Middle	O
-	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
cluster	O
appeared	O
in	O
2012	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
coronavirus	O
seroprevalence	O
in	O
domestic	O
livestock	O
in	O
Saudi	O
Arabia	O
,	O
2010	O
to	O
2013	O
.	O

Given	O
that	O
BCoV	O
is	O
better	O
studied	O
than	O
equine	O
coronaviruses	O
and	O
given	O
the	O
possibility	O
of	O
interspecies	O
transmission	O
of	O
these	O
viruses	O
,	O
this	O
research	O
was	O
designed	O
to	O
compare	O
the	O
partial	O
sequences	O
of	O
the	O
spike	O
glycoprotein	O
(	O
S	O
),	O
hemagglutinin	O
-	O
esterase	O
protein	O
(	O
HE	O
),	O
and	O
nucleoprotein	O
(	O
N	O
)	O
genes	O
from	O
coronaviruses	O
from	O
adult	O
cattle	O
with	O
winter	B-DISO
dysentery	I-DISO
,	O
calves	O
with	O
neonatal	B-DISO
diarrhea	I-DISO
,	O
and	O
horses	O
.	O

Whether	O
the	O
leaderless	O
genome	O
contributes	O
to	O
the	O
establishment	O
of	O
persistent	B-DISO
infection	I-DISO
remains	O
to	O
be	O
determined	O
.	O

The	O
primary	O
end	O
-	O
point	O
was	O
the	O
incidence	O
(	O
with	O
reference	O
to	O
1	O
,	O
000	O
days	O
of	O
invasive	O
mechanical	O
ventilation	O
or	O
1	O
,	O
000	O
days	O
of	O
ICU	O
stay	O
)	O
of	O
new	O
patients	O
with	O
pressure	B-DISO
ulcers	I-DISO
at	O
stage	O
2	O
or	O
higher	O
from	O
randomisation	O
to	O
ICU	O
discharge	O
.	O

Position	O
group	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
1	O
.	O
5408	O
,	O
P	O
=	O
0	O
.	O
0653	O
],	O
age	O
>	O
60	O
years	O
(	O
OR	O
1	O
.	O
5340	O
,	O
P	O
=	O
0	O
.	O
0019	O
),	O
female	O
gender	O
(	O
OR	O
0	O
.	O
5075	O
,	O
P	O
=	O
0	O
.	O
019	O
),	O
body	O
mass	O
index	O
of	O
>	O
28	O
.	O
4	O
kg	O
/	O
m	O
(	O
2	O
)	O
(	O
OR	O
1	O
.	O
9804	O
,	O
P	O
=	O
0	O
.	O
0037	O
),	O
and	O
a	O
Simplified	O
Acute	O
Physiology	O
Score	O
II	O
at	O
inclusion	O
of	O
>	O
46	O
(	O
OR	O
1	O
.	O
2765	O
,	O
P	O
=	O
0	O
.	O
3158	O
)	O
were	O
the	O
covariates	O
independently	O
associated	O
to	O
the	O
acquisition	O
of	O
pressure	B-DISO
ulcers	I-DISO
.	O

ABSTRACT	O
:	O
The	O
international	O
response	O
to	O
SARS	B-DISO
-	O
CoV	O
has	O
produced	O
an	O
outstanding	O
number	O
of	O
protein	O
structures	O
in	O
a	O
very	O
short	O
time	O
.	O

The	O
high	O
percentage	O
of	O
novel	O
protein	O
folds	O
identified	O
among	O
SARS	B-DISO
-	O
CoV	O
proteins	O
is	O
discussed	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
causes	O
severe	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
in	O
people	O
.	O

We	O
tested	O
swabs	O
with	O
RT	O
-	O
PCR	O
,	O
with	O
amplification	B-DISO
targeting	O
the	O
E	O
gene	O
(	O
upE	O
),	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
,	O
and	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
1a	O
.	O

TITLE	O
:	O
Yeast	O
-	O
expressed	O
recombinant	O
protein	O
of	O
the	O
receptor	O
-	O
binding	O
domain	O
in	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
with	O
deglycosylated	O
forms	O
as	O
a	O
SARS	B-DISO
vaccine	O
candidate	O
.	O

TITLE	O
:	O
High	O
-	O
frequency	O
oscillatory	O
ventilation	O
for	O
early	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
adults	O
.	O

TITLE	O
:	O
Vascular	O
endothelial	O
growth	O
factor	O
in	O
acute	O
lung	O
injury	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Chinese	O
social	O
media	O
reaction	O
to	O
the	O
MERS	O
-	O
CoV	O
and	O
avian	B-DISO
influenza	I-DISO
A	O
(	O
H7N9	O
)	O
outbreaks	O
.	O

Our	O
objective	O
was	O
to	O
systematically	O
review	O
original	O
research	O
studies	O
evaluating	O
organ	O
-	O
specific	O
outcomes	O
at	O
28	O
days	O
or	O
greater	O
in	O
patients	O
surviving	O
severe	B-DISO
sepsis	I-DISO
.	O

Our	O
review	O
found	O
variable	O
rates	O
of	O
organ	O
dysfunction	O
at	O
1	O
month	O
after	O
severe	B-DISO
sepsis	I-DISO
.	O

Future	O
studies	O
should	O
attempt	O
to	O
characterize	O
organ	O
dysfunction	O
at	O
greater	O
than	O
1	O
month	O
after	O
an	O
acute	O
severe	B-DISO
sepsis	I-DISO
episode	O
to	O
determine	O
the	O
true	O
prevalence	O
long	O
-	O
term	O
organ	O
dysfunction	O
and	O
treatments	O
for	O
prevention	O
.	O

Among	O
the	O
influenza	B-DISO
viruses	O
type	O
A	O
,	O
B	O
and	O
C	O
,	O
the	O
A	O
type	O
virus	O
shows	O
the	O
most	O
pathogenic	O
potential	O
.	O

In	O
this	O
randomized	O
,	O
controlled	O
,	O
double	O
-	O
blind	B-DISO
trial	O
,	O
48	O
patients	O
with	O
severe	O
burn	O
injury	O
were	O
assigned	O
to	O
receive	O
either	O
lactated	O
Ringer	O
'	O
s	O
solution	O
plus	O
6	O
%	O
HES	B-DISO
130	O
/	O
0	O
.	O
4	O
in	O
a	O
ratio	O
of	O
2	O
:	O
1	O
or	O
lactated	O
Ringer	O
'	O
s	O
solution	O
with	O
no	O
colloid	O
supplement	O
for	O
the	O
first	O
72	O
hours	O
.	O

Length	O
of	O
ICU	O
stay	O
(	O
HES	B-DISO
vs	O
.	O
lactated	O
Ringer	O
'	O
s	O
:	O
28	O
vs	O
.	O
24	O
days	O
;	O
P	O
=	O
0	O
.	O
80	O
)	O
and	O
length	O
of	O
hospital	O
stay	O
(	O
31	O
vs	O
.	O
29	O
days	O
;	O
P	O
=	O
0	O
.	O
57	O
)	O
were	O
similar	O
.	O

From	O
the	O
combined	O
results	O
of	O
the	O
two	O
meta	O
-	O
analyses	O
and	O
the	O
last	O
randomized	O
controlled	O
trial	O
,	O
there	O
is	O
a	O
very	O
strong	O
signal	O
to	O
use	O
prone	O
position	O
in	O
patients	O
with	O
severe	O
ARDS	B-DISO
,	O
as	O
early	O
as	O
possible	O
and	O
for	O
long	O
sessions	O
.	O

ABSTRACT	O
:	O
The	O
survival	O
benefit	O
of	O
prone	O
positioning	O
during	O
mechanical	O
ventilation	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
has	O
been	O
a	O
matter	O
of	O
debate	O
.	O

Randomized	O
controlled	O
trial	O
comparing	O
overall	O
mortality	O
of	O
prone	O
-	O
versus	O
-	O
supine	O
positioning	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Each	O
OSA	B-DISO
subject	O
was	O
assigned	O
to	O
CPAP	O
or	O
APAP	O
treatment	O
and	O
underwent	O
a	O
sleep	O
study	O
after	O
1	O
week	O
of	O
treatment	O
.	O

The	O
use	O
of	O
anti	O
-	O
inflammatory	O
agents	O
to	O
attenuate	O
inflammatory	B-DISO
response	I-DISO
during	O
acute	O
systemic	O
inflammatory	O
reactions	O
may	O
improve	O
survival	O
rates	O
.	O

Fatal	O
respiratory	B-DISO
diseases	I-DISO
in	O
humans	O
have	O
recently	O
been	O
caused	O
by	O
coronaviruses	O
of	O
animal	O
origin	O
.	O

These	O
results	O
demonstrate	O
that	O
chimeric	O
VLPs	O
have	O
the	O
potential	O
for	O
use	O
in	O
vaccines	O
against	O
IBV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Few	O
studies	O
have	O
examined	O
the	O
epidemiology	O
of	O
respiratory	O
viral	B-DISO
infections	I-DISO
in	O
large	O
tertiary	O
centres	O
over	O
more	O
than	O
one	O
season	O
in	O
the	O
era	O
of	O
molecular	O
diagnosis	O
.	O

The	O
patient	O
developed	O
respiratory	B-DISO
failure	I-DISO
due	O
to	O
diffuse	O
alveolar	O
hemorrhage	B-DISO
.	O

Serologic	O
tests	O
disclosed	O
hypocomplementemia	B-DISO
and	O
autoantibodies	O
directed	O
against	O
several	O
nuclear	O
antigens	O
.	O

ABSTRACT	O
:	O
Severe	O
bronchial	O
obstruction	B-DISO
due	O
to	O
one	O
of	O
the	O
major	O
pulmonary	B-DISO
diseases	I-DISO
:	O
asthma	B-DISO
,	O
COPD	B-DISO
,	O
or	O
emphysema	B-DISO
often	O
requires	O
mechanical	O
ventilation	O
support	O
.	O

We	O
observed	O
a	O
significant	O
decrease	O
in	O
metabolic	B-DISO
syndrome	I-DISO
scores	O
(	O
P	O
for	O
trend	O
=	O
0	O
.	O
003	O
)	O
for	O
AER	O
(-	O
0	O
.	O
59	O
,	O
95	O
%	O
CI	O
=	O
-	O
1	O
.	O
00	O
to	O
-	O
0	O
.	O
21	O
)	O
and	O
AER	O
+	O
RES	O
(-	O
0	O
.	O
79	O
,	O
95	O
%	O
CI	O
=	O
-	O
1	O
.	O
40	O
to	O
-	O
0	O
.	O
35	O
),	O
both	O
being	O
significant	O
(	O
P	O
≤	O
0	O
.	O
02	O
)	O
versus	O
control	O
(	O
0	O
.	O
26	O
,	O
95	O
%	O
CI	O
=	O
-	O
0	O
.	O
58	O
to	O
0	O
.	O
40	O
)	O
and	O
RES	O
(-	O
0	O
.	O
13	O
,	O
95	O
%	O
CI	O
=	O
-	O
1	O
.	O
00	O
to	O
0	O
.	O
24	O
).	O

Results	O
indicated	O
that	O
the	O
current	O
mechanism	O
for	O
emergency	B-DISO
responses	O
to	O
emerging	B-DISO
communicable	I-DISO
diseases	I-DISO
in	O
China	O
has	O
made	O
great	O
achievements	O
in	O
terms	O
of	O
command	O
and	O
decision	O
-	O
making	O
,	O
organization	O
and	O
collaboration	O
,	O
monitoring	O
and	O
early	O
warning	O
systems	O
,	O
protection	O
,	O
and	O
international	O
communication	O
and	O
cooperation	O
.	O

The	O
previous	O
SARS	B-DISO
outbreak	O
in	O
this	O
country	O
was	O
accompanied	O
by	O
contradictory	O
information	O
,	O
while	O
worries	O
about	O
wide	O
-	O
spread	O
influenza	B-DISO
led	O
to	O
discrimination	O
worldwide	O
.	O

Findings	O
emphasise	O
the	O
need	O
to	O
manage	O
public	O
communications	O
early	O
during	O
new	O
influenza	B-DISO
outbreaks	O
.	O

RESULTS	O
:	O
High	O
levels	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
IL	O
-	O
1β	O
,-	O
6	O
,-	O
8	O
,-	O
12	O
,	O
tumour	B-DISO
necrosis	I-DISO
factor	O
alpha	O
and	O
interferon	O
gamma	O
were	O
found	O
in	O
all	O
injured	O
patients	O
compared	O
to	O
healthy	O
controls	O
.	O

TITLE	O
:	O
Probabilistic	O
differential	O
diagnosis	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
using	O
the	O
time	O
from	O
immigration	O
to	O
illness	O
onset	O
among	O
imported	O
cases	O
.	O

It	O
is	O
vital	O
to	O
collect	O
the	O
information	O
of	O
the	O
incubation	O
period	O
upon	O
emergence	O
of	O
a	O
novel	O
infectious	B-DISO
disease	I-DISO
,	O
and	O
moreover	O
,	O
in	O
our	O
model	O
,	O
the	O
fundamental	O
transmission	O
dynamics	O
including	O
the	O
initial	O
growth	O
rate	O
has	O
to	O
be	O
explored	O
to	O
differentiate	O
the	O
disease	O
diagnoses	O
with	O
non	O
-	O
specific	O
symptoms	O
.	O

In	O
this	O
retrospective	O
evaluation	O
,	O
we	O
included	O
64	O
patients	O
with	O
ARDS	B-DISO
following	O
esophagectomy	O
for	O
esophageal	B-DISO
cancer	I-DISO
between	O
January	O
2009	O
and	O
December	O
2011	O
.	O

Highly	O
significant	O
correlations	O
were	O
found	O
between	O
probing	O
depth	O
,	O
CAL	O
measures	O
,	O
and	O
indicators	O
of	O
OSAS	B-DISO
severity	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Prevalence	O
of	O
Co	O
,	O
Gi	O
and	O
Tr	O
was	O
higher	O
in	O
pedigree	O
cats	O
compared	O
to	O
non	O
-	O
pedigree	O
cats	O
(	O
DSH	B-DISO
)	O
and	O
prevalence	O
decreased	O
with	O
increasing	O
age	O
for	O
Co	O
,	O
Pa	O
,	O
Gi	O
,	O
Cr	O
and	O
Tr	O
.	O

These	O
data	O
suggest	O
that	O
NIMV	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
atelectasis	B-DISO
is	O
some	O
critical	O
patients	O
.	O

ABSTRACT	O
:	O
Neural	O
precursor	O
cells	O
(	O
NPCs	O
)	O
are	O
the	O
subject	O
of	O
intense	O
investigation	O
for	O
their	O
potential	O
to	O
treat	O
neurodegenerative	B-DISO
disorders	I-DISO
,	O
yet	O
the	O
consequences	O
of	O
neuroinvasive	O
virus	B-DISO
infection	I-DISO
of	O
NPCs	O
remain	O
unclear	O
.	O

Importantly	O
,	O
cytokines	O
secreted	O
by	O
CD4	O
+	O
T	O
cells	O
inhibit	O
JHMV	O
replication	O
in	O
NPCs	O
,	O
and	O
CD8	O
+	O
T	O
cells	O
specifically	O
target	O
viral	O
peptide	O
-	O
pulsed	O
NPCs	O
for	O
lysis	B-DISO
.	O

TITLE	O
:	O
The	O
SARS	B-DISO
coronavirus	O
nucleocapsid	O
protein	O
--	O
forms	O
and	O
functions	O
.	O

The	O
seroprevalence	O
to	O
BRSV	O
in	O
Norwegian	O
cattle	O
herds	O
is	O
high	O
,	O
but	O
its	O
role	O
in	O
epidemics	O
of	O
respiratory	B-DISO
disease	I-DISO
is	O
unclear	O
.	O

When	O
serology	O
indicated	O
that	O
bovine	O
coronavirus	O
and	O
/	O
or	O
bovine	O
parainfluenza	B-DISO
virus	O
3	O
were	O
present	O
,	O
the	O
number	O
of	O
BRSV	O
positive	O
animals	O
in	O
the	O
herd	O
was	O
always	O
higher	O
,	O
supporting	O
the	O
view	O
of	O
BRSV	O
as	O
the	O
main	O
pathogen	O
.	O

Several	O
viral	B-DISO
diseases	I-DISO
of	O
livestock	O
such	O
as	O
bluetongue	B-DISO
,	O
peste	B-DISO
des	I-DISO
petits	I-DISO
ruminants	I-DISO
,	O
camel	O
pox	O
,	O
equine	B-DISO
infectious	I-DISO
anaemia	I-DISO
,	O
chicken	O
anaemia	B-DISO
and	O
sheep	O
-	O
associated	O
malignant	B-DISO
catarrhal	I-DISO
fever	I-DISO
are	O
crossing	O
their	O
traditional	O
boundaries	O
.	O

The	O
increased	O
incidence	O
of	O
emerging	O
and	O
reemerging	O
viral	B-DISO
diseases	I-DISO
could	O
be	O
attributed	O
to	O
several	O
factors	O
including	O
deforestation	O
and	O
surge	O
in	O
direct	O
contact	O
of	O
livestock	O
and	O
humans	O
with	O
wild	O
animals	O
and	O
birds	O
.	O

The	O
difference	O
in	O
emergency	B-DISO
surgery	O
timing	O
between	O
Group	O
I	O
and	O
II	O
was	O
not	O
significant	O
(	O
p	O
>	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Presence	O
of	O
infectious	B-DISO
agents	O
and	O
co	B-DISO
-	I-DISO
infections	I-DISO
in	O
diarrheic	O
dogs	O
determined	O
with	O
a	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
-	O
based	O
panel	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
diarrhea	I-DISO
can	O
be	O
caused	O
by	O
bacteria	O
,	O
viruses	O
,	O
or	O
protozoan	O
organisms	O
,	O
or	O
a	O
combination	O
of	O
these	O
.	O

Therefore	O
,	O
multiple	O
pathogens	O
should	O
be	O
investigated	O
in	O
dogs	O
presenting	O
with	O
diarrhea	B-DISO
.	O

TITLE	O
:	O
[	O
Complicated	O
form	O
of	O
A	O
/	O
HINI	O
(	O
2009	O
)	O
influenza	B-DISO
in	O
pregnant	O
women	O
].	O

TITLE	O
:	O
Successful	O
treatment	O
of	O
cardiogenic	B-DISO
shock	I-DISO
with	O
an	O
intraaortic	O
balloon	O
pump	O
following	O
aluminium	O
phosphide	O
poisoning	O
.	O

In	O
contrast	O
,	O
in	O
cl	O
-	O
2	O
infection	B-DISO
,	O
10	O
-	O
20	O
%	O
of	O
the	O
infected	O
mice	O
exhibited	O
apoptosis	O
in	O
the	O
hippocampus	O
,	O
which	O
was	O
primarily	O
observed	O
in	O
the	O
CA1	O
subregion	O
.	O

Specifically	O
,	O
we	O
have	O
shown	O
that	O
Epac	O
-	O
specific	O
inhibitor	O
treatment	O
or	O
silencing	O
Epac	O
-	O
1	O
gene	O
expression	O
rendered	O
cells	O
resistant	O
to	O
viral	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
antibody	O
reactors	O
among	O
camels	O
in	O
Dubai	O
,	O
United	O
Arab	O
Emirates	O
,	O
in	O
2005	O
.	O

Using	O
a	O
standard	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
neutralization	O
test	O
,	O
serial	O
sera	O
from	O
three	O
sheep	O
and	O
three	O
horses	O
were	O
all	O
negative	O
while	O
sera	O
from	O
9	O
of	O
11	O
dromedary	O
camels	O
from	O
Dubai	O
were	O
positive	O
for	O
antibodies	O
supported	O
by	O
similar	O
results	O
in	O
a	O
MERS	O
-	O
CoV	O
recombinant	O
partial	O
spike	O
protein	O
antibody	O
ELISA	O
.	O

However	O
,	O
immune	B-DISO
tolerance	I-DISO
was	O
suggested	O
to	O
be	O
induced	O
by	O
the	O
high	O
dose	O
and	O
frequency	O
of	O
NP7	O
and	O
NP8	O
with	O
fCpG	O
-	O
ODNs	O
.	O

RESULTS	O
:	O
Prevention	O
against	O
type	O
II	O
FIPV	O
79	O
-	O
1146	O
strain	O
-	O
induced	O
FIP	B-DISO
was	O
slightly	O
better	O
in	O
specific	O
pathogen	O
-	O
free	O
cats	O
treated	O
with	O
NP7	O
and	O
NP8	O
with	O
fCpG	O
-	O
ODNs	O
.	O

TITLE	O
:	O
Flail	B-DISO
chest	I-DISO
injuries	O
:	O
a	O
review	O
of	O
outcomes	O
and	O
treatment	O
practices	O
from	O
the	O
National	O
Trauma	O
Data	O
Bank	O
.	O

Patients	O
with	O
a	O
flail	B-DISO
chest	I-DISO
injury	O
admitted	O
from	O
2007	O
to	O
2009	O
were	O
included	O
in	O
the	O
analysis	O
.	O

Given	O
the	O
high	O
rates	O
of	O
morbidity	O
and	O
mortality	O
in	O
patients	O
with	O
a	O
flail	B-DISO
chest	I-DISO
injury	O
,	O
alternate	O
methods	O
of	O
treatment	O
including	O
more	O
consistent	O
use	O
of	O
epidural	O
catheters	O
for	O
pain	O
or	O
surgical	O
fixation	O
need	O
to	O
be	O
investigated	O
with	O
large	O
randomized	O
controlled	O
trials	O
.	O

Heroin	B-DISO
addiction	I-DISO
is	O
common	O
,	O
with	O
an	O
estimated	O
3	O
.	O
7	O
million	O
Americans	O
reporting	O
to	O
have	O
used	O
it	O
at	O
some	O
point	O
in	O
their	O
lives	O
.	O

ABSTRACT	O
:	O
The	O
emergence	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
the	O
eastern	O
Mediterranean	O
and	O
imported	O
cases	O
to	O
Europe	O
has	O
alerted	O
public	O
health	O
authorities	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
the	O
development	O
of	O
a	O
reverse	O
transcription	O
isothermal	O
Recombinase	O
Polymerase	O
Amplification	B-DISO
(	O
RT	O
-	O
RPA	O
)	O
assay	O
for	O
the	O
identification	O
of	O
MERS	O
-	O
CoV	O
.	O
A	O
partial	O
nucleocapsid	O
gene	O
RNA	O
molecular	O
standard	O
of	O
MERS	O
-	O
coronavirus	O
was	O
used	O
to	O
determine	O
the	O
assay	O
sensitivity	O
.	O

ABSTRACT	O
:	O
Granulocyte	O
colony	O
-	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)-	O
producing	O
lung	B-DISO
cancers	I-DISO
are	O
known	O
to	O
cause	O
extreme	O
leukocytosis	B-DISO
.	O

There	O
were	O
108	O
cases	O
(	O
99	O
adults	O
and	O
nine	O
children	O
)	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
detected	O
during	O
the	O
12	O
-	O
month	O
period	O
(	O
108	O
/	O
5065	O
,	O
2	O
%	O
case	O
detection	O
rate	O
).	O

Our	O
approach	O
identifies	O
likely	O
transmission	O
events	O
and	O
infers	O
dates	O
of	O
infections	B-DISO
,	O
unobserved	O
cases	O
and	O
separate	O
introductions	O
of	O
the	O
disease	O
.	O

This	O
approach	O
to	O
analysing	O
symptom	B-DISO
patterns	O
has	O
potential	O
utility	O
in	O
other	O
clinical	O
syndromes	B-DISO
.	O

A	O
laboratory	O
analysis	O
of	O
her	O
complement	O
system	O
suggested	O
the	O
presence	O
of	O
C1	B-DISO
inhibitor	I-DISO
deficiency	I-DISO
as	O
the	O
cause	O
for	O
systemic	O
capillary	O
leakage	B-DISO
.	O

An	O
important	O
finding	O
from	O
a	O
cohort	O
study	O
was	O
that	O
many	O
former	O
SARS	B-DISO
patients	O
currently	O
suffer	B-DISO
from	O
avascular	O
osteonecrosis	B-DISO
,	O
as	O
a	O
consequence	O
of	O
the	O
treatment	O
with	O
corticosteroids	O
during	O
their	O
infection	B-DISO
.	O

Additionally	O
,	O
the	O
fibrosis	B-DISO
of	I-DISO
lung	I-DISO
was	O
observed	O
in	O
the	O
HP	O
-	O
PRRSV	O
-	O
infected	O
pigs	O
.	O

This	O
case	O
series	O
report	O
showed	O
that	O
lung	O
injury	O
and	O
respiratory	B-DISO
failure	I-DISO
can	O
occur	O
as	O
a	O
result	O
of	O
inhaling	O
humidifier	O
disinfectants	O
.	O

ABSTRACT	O
:	O
Since	O
September	O
2012	O
,	O
170	O
confirmed	O
infections	B-DISO
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
have	O
been	O
reported	O
to	O
the	O
World	O
Health	O
Organization	O
,	O
including	O
72	O
deaths	O
.	O

All	O
12	O
patients	O
had	O
underlying	O
comorbid	O
conditions	O
and	O
presented	O
with	O
acute	O
severe	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
.	O

Community	O
-	O
acquired	O
and	O
health	O
care	O
-	O
associated	O
MERS	O
-	O
CoV	O
infection	B-DISO
occurs	O
in	O
patients	O
with	O
chronic	O
comorbid	O
conditions	O
.	O

ABSTRACT	O
:	O
We	O
conducted	O
an	O
epidemiologic	O
investigation	O
among	O
survivors	O
of	O
an	O
outbreak	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
in	O
Jordan	O
.	O

A	O
second	O
-	O
trimester	O
stillbirth	B-DISO
occurred	O
during	O
the	O
course	O
of	O
an	O
acute	O
respiratory	O
illness	O
that	O
was	O
attributed	O
to	O
MERS	O
-	O
CoV	O
on	O
the	O
basis	O
of	O
exposure	O
history	O
and	O
positive	O
results	O
of	O
MERS	O
-	O
CoV	O
serologic	O
testing	O
.	O

Mutations	O
were	O
introduced	O
into	O
SARS	B-DISO
-	O
CoV	O
NSP16	O
within	O
the	O
conserved	O
KDKE	O
motif	O
and	O
effectively	O
attenuated	O
the	O
resulting	O
SARS	B-DISO
-	O
CoV	O
mutant	B-DISO
viruses	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

ABSTRACT	O
:	O
Few	O
studies	O
have	O
prospectively	O
assessed	O
viral	O
etiologies	O
of	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
in	O
community	O
-	O
based	O
elderly	O
individuals	O
.	O

Multiplex	O
reverse	O
-	O
transcriptase	O
polymerase	O
chain	O
reaction	O
identified	O
viral	O
pathogens	O
in	O
nasal	O
/	O
throat	O
swabs	O
from	O
556	O
episodes	O
of	O
moderate	O
-	O
to	O
-	O
severe	O
ILI	O
,	O
defined	O
as	O
ILI	O
with	O
pneumonia	B-DISO
,	O
hospitalization	O
,	O
or	O
maximum	O
daily	O
influenza	B-DISO
symptom	B-DISO
severity	O
score	O
(	O
ISS	B-DISO
)	O
>	O
2	O
.	O

RSV	O
prevalence	O
was	O
7	O
.	O
1	O
%	O
(	O
2	O
/	O
28	O
)	O
in	O
ILI	O
with	O
pneumonia	B-DISO
,	O
12	O
.	O
5	O
%	O
(	O
8	O
/	O
64	O
)	O
in	O
ILI	O
with	O
hospitalization	O
,	O
and	O
6	O
.	O
7	O
%	O
(	O
32	O
/	O
480	O
)	O
in	O
ILI	O
with	O
maximum	O
ISS	B-DISO
>	O
2	O
.	O

TITLE	O
:	O
Persistent	O
pulmonary	B-DISO
arterial	I-DISO
hypertension	I-DISO
in	O
the	O
newborn	O
(	O
PPHN	O
):	O
a	O
frequent	O
manifestation	O
of	O
TMEM70	O
defective	O
patients	O
.	O

Pulmonary	B-DISO
hypertension	I-DISO
has	O
rarely	O
been	O
reported	O
in	O
mitochondrial	B-DISO
disorders	I-DISO
and	O
,	O
so	O
far	O
,	O
it	O
has	O
been	O
described	O
in	O
association	O
with	O
TMEM70	O
deficiency	O
only	O
in	O
one	O
patient	O
.	O

ABSTRACT	O
:	O
The	O
5	O
'	O
end	O
of	O
eukaryotic	O
mRNA	O
contains	O
the	O
type	O
-	O
1	O
(	O
m7GpppNm	O
)	O
or	O
type	O
-	O
2	O
(	O
m7GpppNmNm	O
)	O
cap	B-DISO
structure	O
.	O

Such	O
mutant	B-DISO
viruses	O
could	O
be	O
rationally	O
designed	O
as	O
live	O
attenuated	O
vaccines	O
.	O

Forty	O
two	O
Wistar	O
rats	O
were	O
randomly	O
divided	O
into	O
three	O
groups	O
:	O
6	O
rats	O
were	O
treated	O
with	O
saline	O
solution	O
by	O
intratracheal	O
instillation	O
(	O
control	O
group	O
),	O
18	O
rats	O
were	O
treated	O
with	O
LPS	B-DISO
by	O
intratracheal	O
instillation	O
(	O
LPS	B-DISO
group	O
)	O
and	O
the	O
other	O
18	O
rats	O
received	O
PFC	O
through	O
femoral	O
vein	O
prior	O
to	O
LPS	B-DISO
instillation	O
(	O
LPS	O
+	O
PFC	O
group	O
).	O

TITLE	O
:	O
Clinical	O
Manifestations	O
,	O
Treatment	O
,	O
and	O
Outcome	O
of	O
Hospitalized	O
Patients	O
with	O
Plasmodium	B-DISO
vivax	I-DISO
Malaria	I-DISO
in	O
Two	O
Indian	O
States	O
:	O
A	O
Retrospective	O
Study	O
.	O

As	O
per	O
WHO	O
criteria	O
for	O
severity	O
,	O
19	O
of	O
110	O
patients	O
had	O
severe	O
disease	O
-	O
six	O
patients	O
had	O
clinical	O
jaundice	B-DISO
with	O
hepatic	B-DISO
dysfunction	I-DISO
,	O
three	O
patients	O
had	O
severe	B-DISO
anemia	I-DISO
,	O
three	O
had	O
spontaneous	O
bleeding	B-DISO
,	O
two	O
had	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
and	O
one	O
had	O
cerebral	B-DISO
malaria	I-DISO
,	O
hyperparasitemia	O
,	O
renal	O
failure	O
,	O
circulatory	B-DISO
collapse	I-DISO
,	O
and	O
metabolic	B-DISO
acidosis	I-DISO
.	O

The	O
fact	O
that	O
MSCs	O
are	O
in	O
clinical	O
studies	O
for	O
a	O
wide	O
range	O
of	O
disease	O
processes	O
is	O
a	O
clear	O
advantage	O
for	O
translating	O
MSCs	O
to	O
clinical	O
testing	O
in	O
patients	O
with	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Viral	B-DISO
infections	I-DISO
associated	O
with	O
Kawasaki	B-DISO
disease	I-DISO
.	O

Compared	O
with	O
the	O
control	O
group	O
,	O
cases	O
of	O
KD	O
were	O
more	O
likely	O
to	O
have	O
overall	O
positive	O
rates	O
of	O
viral	O
PCR	O
(	O
50	O
.	O
4	O
%	O
vs	O
.	O
16	O
.	O
4	O
%,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
for	O
various	O
viruses	O
including	O
enterovirus	O
(	O
16	O
.	O
8	O
%	O
vs	O
.	O
4	O
.	O
4	O
%,	O
p	O
<	O
0	O
.	O
001	O
),	O
adenovirus	B-DISO
(	O
8	O
.	O
0	O
%	O
vs	O
.	O
1	O
.	O
8	O
%,	O
p	O
=	O
0	O
.	O
007	O
),	O
human	O
rhinovirus	O
(	O
26	O
.	O
5	O
%	O
vs	O
.	O
9	O
.	O
7	O
%,	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
coronavirus	O
(	O
7	O
.	O
1	O
%	O
vs	O
.	O
0	O
.	O
9	O
%,	O
p	O
=	O
0	O
.	O
003	O
).	O

ABSTRACT	O
:	O
Advances	O
in	O
molecular	O
diagnostics	O
have	O
implicated	O
newly	O
-	O
discovered	O
respiratory	O
viruses	O
in	O
the	O
pathogenesis	B-DISO
of	O
pneumonia	B-DISO
.	O

The	O
newly	O
tested	O
viruses	O
were	O
detected	O
at	O
high	O
frequency	O
in	O
association	O
with	O
other	O
respiratory	O
viruses	O
,	O
including	O
previously	O
-	O
investigated	O
viruses	O
(	O
22	O
.	O
8	O
%	O
in	O
HIV	B-DISO
-	O
infected	O
and	O
28	O
.	O
5	O
%	O
in	O
HIV	B-DISO
-	O
uninfected	O
children	O
).	O

The	O
high	O
frequency	O
of	O
viral	O
co	B-DISO
-	I-DISO
infections	I-DISO
illustrates	O
the	O
complexities	O
in	O
attributing	O
causality	O
to	O
specific	O
viruses	O
in	O
the	O
aetiology	O
of	O
LRTI	B-DISO
and	O
may	O
indicate	O
a	O
synergetic	O
role	O
of	O
viral	O
co	B-DISO
-	I-DISO
infections	I-DISO
in	O
the	O
pathogenesis	B-DISO
of	O
childhood	O
LRTI	B-DISO
.	O

Among	O
the	O
265	O
patients	O
included	O
,	O
150	O
(	O
56	O
.	O
6	O
%)	O
reported	O
at	O
least	O
one	O
respiratory	B-DISO
symptom	I-DISO
of	O
which	O
13	O
(	O
8	O
.	O
7	O
%)	O
had	O
positive	O
swabs	O
for	O
at	O
least	O
one	O
respiratory	O
virus	O
,	O
and	O
115	O
patients	O
reported	O
any	O
respiratory	B-DISO
symptom	I-DISO
of	O
which	O
10	O
(	O
8	O
.	O
7	O
%)	O
had	O
positive	O
swabs	O
for	O
respiratory	O
virus	O
.	O

No	O
influenza	B-DISO
viruses	O
were	O
found	O
despite	O
the	O
fact	O
that	O
one	O
half	O
of	O
the	O
patients	O
were	O
investigated	O
during	O
the	O
peak	O
of	O
the	O
seasonal	O
influenza	B-DISO
epidemic	I-DISO
in	O
Marseille	O
.	O

We	O
identified	O
a	O
novel	O
broad	O
-	O
spectrum	O
small	O
molecule	O
that	O
could	O
block	O
cathepsin	O
L	O
-	O
mediated	O
cleavage	O
and	O
thus	O
inhibit	O
the	O
entry	O
of	O
pseudotypes	O
bearing	O
the	O
glycoprotein	O
derived	O
from	O
SARS	B-DISO
-	O
CoV	O
or	O
Ebola	O
,	O
Hendra	O
,	O
or	O
Nipah	O
virus	O
.	O

This	O
work	O
describes	O
the	O
interactions	O
of	O
the	O
two	O
RNA	O
-	O
binding	O
domains	O
of	O
the	O
nucleocapsid	O
protein	O
of	O
a	O
model	O
coronavirus	O
,	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
.	O

Further	O
,	O
we	O
compared	O
the	O
ability	O
of	O
MERS	O
-	O
CoV	O
PLpro	O
and	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
PLpro	O
to	O
block	O
innate	O
immune	O
signaling	O
of	O
proinflammatory	O
cytokines	O
.	O

This	O
initial	O
down	O
-	O
regulation	O
followed	O
by	O
the	O
induction	O
of	O
innate	B-DISO
immune	I-DISO
response	I-DISO
to	O
IBV	O
infection	B-DISO
appears	O
to	O
be	O
inadequate	O
for	O
the	O
control	O
of	O
IBV	O
genome	O
accumulation	O
and	O
consequent	O
histopathological	O
changes	O
in	O
these	O
tissues	O
.	O

Moreover	O
,	O
how	O
to	O
select	O
patients	O
and	O
the	O
timing	O
and	O
indications	O
for	O
ECLS	O
in	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
remain	O
unclear	O
.	O

Only	O
Sepsis	B-DISO
-	O
Related	O
Organ	B-DISO
Failure	I-DISO
Assessment	O
score	O
could	O
be	O
identified	O
as	O
an	O
independent	O
predictor	O
of	O
extracorporeal	O
lung	O
support	O
.	O

HCPS	O
starts	O
as	O
a	O
dengue	B-DISO
-	O
like	O
acute	O
febrile	B-DISO
illness	I-DISO
but	O
after	O
about	O
3	O
days	O
progresses	O
to	O
respiratory	B-DISO
failure	I-DISO
and	O
cardiogenic	B-DISO
shock	I-DISO
,	O
leading	O
to	O
a	O
high	O
fatality	O
rate	O
that	O
reaches	O
50	O
%	O
for	O
patients	O
infected	O
with	O
ARQV	O
.	O

Structural	O
and	O
enzymatic	O
studies	O
revealed	O
that	O
SARS	B-DISO
-	O
CoV	O
PLpro	O
can	O
act	O
as	O
both	O
a	O
protease	O
to	O
cleave	O
peptide	O
bonds	O
and	O
also	O
as	O
a	O
deubiquitinating	O
(	O
DUB	O
)	O
enzyme	O
to	O
cleave	O
the	O
isopeptide	O
bonds	O
found	O
in	O
polyubiquitin	O
chains	O
.	O

Overexpression	O
studies	O
revealed	O
that	O
viral	O
protease	O
/	O
DUB	O
activity	O
can	O
modulate	O
or	O
block	O
activation	O
of	O
the	O
innate	B-DISO
immune	I-DISO
response	I-DISO
pathway	O
.	O

Importantly	O
,	O
mutations	O
that	O
alter	O
DUB	O
activity	O
but	O
not	O
viral	O
protease	O
activity	O
have	O
been	O
identified	O
and	O
arteriviruses	O
expressing	O
DUB	O
mutants	O
stimulated	O
higher	O
levels	O
of	O
acute	O
inflammatory	O
cytokines	O
after	O
infection	B-DISO
.	O

In	O
the	O
present	O
study	O
,	O
we	O
provide	O
data	O
of	O
immunisation	O
experiments	O
with	O
a	O
recombinant	O
FCoV	O
pair	O
differing	O
only	O
in	O
the	O
truncation	B-DISO
(	O
PBFIPV	O
-	O
DF	O
-	O
2	O
)	O
or	O
completion	O
(	O
PBFIPV	O
-	O
DF	O
-	O
2	O
-	O
R3i	O
)	O
of	O
their	O
ORF3abc	O
regions	O
.	O

ABSTRACT	O
:	O
The	O
cause	O
of	O
death	O
in	O
215	O
cattle	O
on	O
20	O
long	O
-	O
haul	O
live	O
export	O
voyages	O
from	O
Australia	O
to	O
the	O
Middle	O
East	O
,	O
Russia	O
,	O
and	O
China	O
was	O
investigated	O
between	O
2010	O
and	O
2012	O
using	O
gross	O
,	O
histologic	O
,	O
and	O
/	O
or	O
molecular	O
pathology	B-DISO
techniques	O
.	O

Two	O
thirds	O
(	O
130	O
/	O
195	O
)	O
of	O
animals	O
from	O
which	O
lung	O
samples	O
were	O
collected	O
had	O
histologic	O
changes	O
and	O
/	O
or	O
positive	O
qRT	O
-	O
PCR	O
results	O
indicative	O
of	O
infectious	B-DISO
lung	I-DISO
disease	I-DISO
:	O
93	O
out	O
of	O
130	O
(	O
72	O
%)	O
had	O
evidence	O
of	O
bacterial	B-DISO
infection	I-DISO
,	O
4	O
(	O
3	O
%)	O
had	O
viral	B-DISO
infection	I-DISO
,	O
and	O
29	O
(	O
22	O
%)	O
had	O
mixed	O
bacterial	O
and	O
viral	B-DISO
infections	I-DISO
,	O
and	O
for	O
4	O
(	O
3	O
%)	O
the	O
causative	O
organism	O
could	O
not	O
be	O
identified	O
.	O

A	O
3	O
-	O
year	O
-	O
old	O
girl	O
was	O
admitted	O
to	O
the	O
Emergency	B-DISO
Department	O
suspected	O
of	O
having	O
ingested	O
one	O
or	O
two	O
pills	O
of	O
rivastigmine	O
.	O

The	O
child	O
was	O
hyporeactive	O
,	O
with	O
symptoms	O
of	O
altered	B-DISO
mental	I-DISO
status	I-DISO
,	O
sialorrhea	B-DISO
,	O
sweating	O
,	O
and	O
diarrhea	B-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
an	O
acute	B-DISO
respiratory	I-DISO
disease	I-DISO
caused	O
by	O
the	O
SARS	B-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

The	O
24	O
hours	O
urine	O
protein	O
analysis	O
revealed	O
significant	O
proteinuria	O
and	O
renal	O
biopsy	O
showed	O
global	O
and	O
seg	O
-	O
mental	O
sclerosis	B-DISO
in	O
glomeruli	O
,	O
mesangial	O
arteritis	B-DISO
,	O
proliferations	B-DISO
in	O
visceral	O
epithelial	O
cells	O
(	O
IgA	B-DISO
nephropathy	I-DISO
).	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
such	O
a	O
complication	B-DISO
will	O
be	O
presented	O
for	O
the	O
first	O
time	O
in	O
the	O
literature	O
.	O

In	O
recent	O
years	O
,	O
the	O
broad	O
-	O
spectrum	O
antiviral	O
activity	O
of	O
many	O
triterpenoids	O
in	O
licorice	O
was	O
confirmed	O
,	O
and	O
these	O
findings	O
have	O
become	O
a	O
hot	B-DISO
spot	I-DISO
of	O
antiviral	O
immunity	O
.	O

TITLE	O
:	O
Middle	O
east	O
respiratory	O
syndrome	B-DISO
coronavirus	O
4a	O
protein	O
is	O
a	O
double	O
-	O
stranded	O
RNA	O
-	O
binding	O
protein	O
that	O
suppresses	O
PACT	B-DISO
-	O
induced	O
activation	O
of	O
RIG	O
-	O
I	O
and	O
MDA5	O
in	O
the	O
innate	O
antiviral	O
response	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
a	O
new	O
mechanism	O
through	O
which	O
MERS	O
-	O
CoV	O
employs	O
a	O
viral	O
double	O
-	O
stranded	O
RNA	O
-	O
binding	O
protein	O
to	O
circumvent	O
the	O
innate	O
antiviral	O
response	O
by	O
perturbing	O
the	O
function	O
of	O
cellular	O
double	O
-	O
stranded	O
RNA	O
-	O
binding	O
protein	O
PACT	B-DISO
.	O

Why	O
MERS	O
-	O
CoV	O
causes	O
severe	O
disease	O
in	O
human	O
is	O
unclear	O
,	O
and	O
one	O
possibility	O
is	O
that	O
MERS	O
-	O
CoV	O
is	O
particularly	O
efficient	O
in	O
counteracting	O
host	O
immunity	O
,	O
including	O
the	O
sensing	O
of	O
virus	O
invasion	B-DISO
.	O

RESULTS	O
:	O
Of	O
54	O
patients	O
,	O
there	O
were	O
18	O
ARDS	B-DISO
patients	O
in	O
mild	O
group	O
,	O
22	O
in	O
moderate	O
group	O
and	O
14	O
in	O
severe	O
group	O
.	O

Moreover	O
,	O
further	O
results	O
showed	O
that	O
Ag	O
NPs	B-DISO
and	O
silver	O
nanowires	O
decreased	O
the	O
number	O
of	O
apoptotic	O
cells	O
induced	O
by	O
TGEV	O
through	O
regulating	O
p38	O
/	O
mitochondria	O
-	O
caspase	O
-	O
3	O
signaling	O
pathway	O
.	O

TITLE	O
:	O
Screening	O
and	O
identification	O
of	O
T	O
helper	O
1	O
and	O
linear	O
immunodominant	O
antibody	O
-	O
binding	O
epitopes	O
in	O
spike	O
1	O
domain	O
and	O
membrane	O
protein	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
.	O

ABSTRACT	O
:	O
The	O
5	O
'-	O
cap	B-DISO
structure	O
is	O
a	O
distinct	O
feature	O
of	O
eukaryotic	O
mRNAs	O
and	O
is	O
important	O
for	O
RNA	O
stability	O
and	O
protein	O
translation	O
by	O
providing	O
a	O
molecular	O
signature	O
for	O
the	O
distinction	O
of	O
self	O
or	O
non	O
-	O
self	O
mRNA	O
.	O

TITLE	O
:	O
Structural	O
basis	O
for	O
catalysis	O
and	O
ubiquitin	O
recognition	O
by	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
papain	O
-	O
like	O
protease	O
.	O

These	O
IgG	O
subclasses	O
were	O
purified	O
from	O
the	O
serum	O
of	O
174	O
GBS	B-DISO
patients	O
before	O
and	O
in	O
150	O
patients	O
2	O
weeks	O
after	O
standard	O
IVIg	O
treatment	O
regimen	O
.	O

Further	O
studies	O
showed	O
that	O
p53	O
inhibitor	O
attenuated	O
TGEV	O
N	O
protein	O
induced	O
cell	O
cycle	O
arrest	O
at	O
S	O
and	O
G2	O
/	O
M	O
phases	O
and	O
apoptosis	O
through	O
reversing	O
the	O
expression	O
changes	O
of	O
cdc2	O
,	O
cdk2	O
and	O
cyclin	O
B1	O
and	O
the	O
translocation	B-DISO
changes	O
of	O
Bax	O
and	O
cytochrome	O
c	O
induced	O
by	O
TGEV	O
N	O
protein	O
.	O

Until	O
specific	O
guidelines	O
are	O
developed	O
for	O
patients	O
receiving	O
ECMO	O
,	O
it	O
appears	O
that	O
the	O
guidelines	O
for	O
the	O
provision	O
and	O
assessment	O
of	O
nutrition	O
support	O
therapy	O
in	O
the	O
adult	O
critically	B-DISO
ill	I-DISO
patient	O
provide	O
the	O
best	O
guidance	O
for	O
the	O
nutrition	O
support	O
clinician	O
who	O
is	O
caring	O
for	O
the	O
patient	O
receiving	O
ECMO	O
support	O
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
was	O
first	O
documented	O
in	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
(	O
KSA	O
)	O
in	O
2012	O
and	O
,	O
to	O
date	O
,	O
has	O
been	O
identified	O
in	O
180	O
cases	O
with	O
43	O
%	O
mortality	O
.	O

Host	O
recognition	O
of	O
viral	O
dsRNA	O
determines	O
outcome	O
in	O
the	O
early	O
stage	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
recently	O
spread	O
from	O
an	O
animal	O
reservoir	O
to	O
infect	O
humans	O
,	O
causing	O
sporadic	O
severe	O
and	O
frequently	O
fatal	O
respiratory	B-DISO
disease	I-DISO
.	O

TITLE	O
:	O
""""	O
Don	O
'	O
t	O
forget	B-DISO
the	O
migrants	O
""":"	O
exploring	O
preparedness	O
and	O
response	O
strategies	O
to	O
combat	O
the	O
potential	O
spread	O
of	O
MERS	O
-	O
CoV	O
virus	O
through	O
migrant	O
workers	O
in	O
Sri	O
Lanka	O
.	O

The	O
aims	O
of	O
the	O
current	O
study	O
were	O
to	O
identify	O
Mycoplasma	B-DISO
suis	O
antigens	O
and	O
develop	O
a	O
multiplex	O
microbead	O
immunoassay	O
(	O
MIA	O
).	O

Prophylaxis	O
of	O
recurrent	O
cellulitis	B-DISO
with	O
penicillin	O
250	O
mg	O
2	O
x	O
/	O
d	O
PO	O
may	O
be	O
considered	O
.	O

RESULTS	O
:	O
25	O
-	O
OHD	B-DISO
levels	O
did	O
not	O
differ	O
between	O
cases	O
with	O
ALI	O
/	O
ARDS	B-DISO
and	O
controls	O
in	O
either	O
the	O
sepsis	B-DISO
or	O
trauma	O
cohorts	O
.	O

Rates	O
of	O
pneumonia	B-DISO
decrease	O
with	O
the	O
use	O
of	O
antiretroviral	O
therapy	O
but	O
continue	O
to	O
be	O
higher	O
than	O
in	O
HIV	B-DISO
uninfected	O
individuals	O
.	O

Diabetic	O
patients	O
with	O
chronic	B-DISO
kidney	I-DISO
disease	I-DISO
stage	O
Vd	O
are	O
prone	O
to	O
develop	O
this	O
complication	B-DISO
.	O

The	O
presenting	O
symptom	B-DISO
is	O
a	O
localized	O
painful	B-DISO
swelling	B-DISO
of	O
the	O
affected	O
limb	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
cause	O
numerous	O
diseases	O
,	O
including	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
generating	O
significant	O
health	O
-	O
related	O
and	O
economic	O
consequences	O
.	O

This	O
tripeptidic	O
acylsulfonamide	O
inhibitor	O
of	O
the	O
NS3	B-DISO
/	O
4A	O
enzyme	O
is	O
currently	O
in	O
phase	O
III	O
clinical	O
trials	O
for	O
the	O
treatment	O
of	O
hepatitis	B-DISO
C	I-DISO
virus	B-DISO
infection	I-DISO
.	O

We	O
have	O
shown	O
before	O
that	O
CsA	B-DISO
and	O
FK506	O
inhibit	O
coronavirus	O
replication	O
(	O
Carbajo	O
-	O
Lozoya	O
,	O
J	O
.,	O
Müller	O
,	O
M	O
.	O
A	O
.,	O
Kallies	O
,	O
S	O
.,	O
Thiel	O
,	O
V	O
.,	O
Drosten	O
,	O
C	O
.,	O
von	O
Brunn	O
,	O
A	O
.	O
Replication	O
of	O
human	O
coronaviruses	O
SARS	B-DISO
-	O
CoV	O
,	O
HCoV	O
-	O
NL63	O
and	O
HCoV	O
-	O
229E	O
is	O
inhibited	O
by	O
the	O
drug	O
FK506	O
.	O

Studies	O
were	O
considered	O
if	O
a	O
statistically	O
significant	O
association	O
was	O
declared	O
with	O
either	O
susceptibility	O
or	O
outcomes	O
of	O
all	O
-	O
cause	O
ARDS	B-DISO
.	O

Giardia	B-DISO
spp	O
.	O

TITLE	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
:	O
still	O
an	O
enigma	O
?	O

ABSTRACT	O
:	O
African	B-DISO
trypanosomiasis	I-DISO
is	O
a	O
parasitic	B-DISO
infection	I-DISO
sporadically	O
imported	O
to	O
Europe	O
by	O
tourists	O
or	O
immigrants	O
returning	O
from	O
endemic	O
areas	O
.	O

TITLE	O
:	O
Detection	O
of	O
common	O
respiratory	O
viruses	O
in	O
tonsillar	O
tissue	O
of	O
children	O
with	O
obstructive	B-DISO
sleep	I-DISO
apnea	I-DISO
.	O

ABSTRACT	O
:	O
Few	O
studies	O
have	O
investigated	O
high	O
-	O
frequency	O
percussive	O
ventilation	O
(	O
HFPV	O
)	O
in	O
adult	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

We	O
retrospectively	O
analyzed	O
data	O
from	O
critically	B-DISO
ill	I-DISO
-	O
patients	O
with	O
moderate	O
and	O
severe	O
ARDS	B-DISO
who	O
received	O
HFPV	O
.	O

HFPV	O
caused	O
rapid	O
and	O
sustained	O
improvement	O
of	O
oxygenation	O
and	O
ventilation	O
in	O
patients	O
with	O
moderate	O
to	O
severe	O
ARDS	B-DISO
.	O

Weil	O
'	O
s	O
syndrome	B-DISO
is	O
defined	O
as	O
liver	B-DISO
damage	I-DISO
with	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
and	O
bleeding	B-DISO
diathesis	I-DISO
,	O
has	O
a	O
high	O
mortality	O
rate	O
.	O

The	O
influenza	B-DISO
A	O
/	O
Hong	O
Kong	O
/	O
470129	O
/	O
2013	O
virus	O
strain	O
was	O
detected	O
in	O
a	O
patient	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
deranged	O
liver	O
function	O
and	O
coagulation	O
profile	O
,	O
cytopenia	B-DISO
,	O
and	O
rhabdomyolysis	B-DISO
.	O

Coinfections	B-DISO
were	O
detected	O
in	O
35	O
%	O
and	O
38	O
%	O
of	O
children	O
with	O
HCoV	O
-	O
OC43	O
and	O
HCoV	O
-	O
NL63	O
,	O
respectively	O
.	O

Severe	O
illness	O
was	O
less	O
common	O
in	O
HCoV	O
-	O
NL63	O
,	O
HCoV	O
-	O
OC43	O
and	O
parainfluenza	B-DISO
virus	O
(	O
14	O
%,	O
each	O
)	O
compared	O
with	O
respiratory	O
syncytial	O
virus	O
(	O
30	O
%)	O
and	O
picornaviruses	O
(	O
26	O
%;	O
P	O
=	O
0	O
.	O
055	O
for	O
HCoVs	O
combined	O
compared	O
with	O
the	O
other	O
respiratory	O
viruses	O
)	O
and	O
occurred	O
mainly	O
in	O
those	O
with	O
underlying	O
medical	O
conditions	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
initial	O
description	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
-	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
the	O
disease	O
has	O
been	O
associated	O
with	O
a	O
high	O
case	O
-	O
fatality	O
rate	O
.	O

TITLE	O
:	O
The	O
pathology	B-DISO
and	O
pathogenesis	B-DISO
of	O
experimental	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
influenza	B-DISO
in	O
animal	O
models	O
.	O

Firstly	O
,	O
the	O
pathology	B-DISO
and	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
and	O
influenza	B-DISO
are	O
compared	O
.	O

Both	O
diseases	O
are	O
similar	O
in	O
that	O
they	O
affect	O
mainly	O
the	O
respiratory	O
tract	O
and	O
cause	O
inflammation	B-DISO
and	O
necrosis	O
centred	O
on	O
the	O
pulmonary	O
alveoli	O
and	O
bronchioles	O
.	O

Consistent	O
with	O
the	O
media	O
attention	O
generated	O
,	O
and	O
with	O
results	O
from	O
other	O
studies	O
,	O
the	O
reporting	O
rates	O
of	O
syncope	B-DISO
or	O
loss	O
of	O
consciousness	O
and	O
seizures	B-DISO
were	O
higher	O
for	O
the	O
HPV	O
vaccine	O
than	O
for	O
other	O
vaccines	O
given	O
in	O
adolescence	O
.	O

AdvanSure	O
assay	O
demonstrated	O
exquisite	O
performance	O
for	O
the	O
detection	O
of	O
RVs	O
and	O
will	O
be	O
a	O
valuable	O
tool	O
for	O
the	O
management	O
of	O
RV	O
infection	B-DISO
.	O

TITLE	O
:	O
Longitudinal	O
field	O
studies	O
of	O
avian	O
metapneumovirus	O
and	O
turkey	B-DISO
hemorrhagic	I-DISO
enteritis	I-DISO
virus	O
in	O
turkeys	O
suffering	B-DISO
from	O
colibacillosis	B-DISO
associated	O
mortality	O
.	O

Less	O
clear	O
appears	O
the	O
role	O
of	O
THEV	O
because	O
the	O
endemicity	O
of	O
aMPV	O
makes	O
difficult	O
to	O
evaluate	O
its	O
role	O
in	O
predisposing	O
colibacillosis	B-DISO
in	O
absence	O
of	O
aMPV	O
.	O

Over	O
a	O
year	O
after	O
the	O
emergence	O
of	O
this	O
novel	O
coronavirus	O
--	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)--	O
it	O
has	O
caused	O
178	O
laboratory	O
-	O
confirmed	O
cases	O
and	O
76	O
deaths	O
.	O

While	O
parent	O
virus	O
FIPV	O
DF	O
-	O
2	O
developed	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
in	O
all	O
the	O
infected	O
cats	O
,	O
its	O
recombinant	O
virus	O
PBFIPV	O
-	O
DF	O
-	O
2	O
,	O
differing	O
only	O
in	O
seven	O
nucleotides	O
,	O
proved	O
to	O
be	O
surprisingly	O
low	O
virulent	O
,	O
although	O
caused	O
an	O
acute	O
febrile	O
episode	O
similarly	O
to	O
the	O
original	O
FIPV	O
DF	O
-	O
2	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
prevalence	O
,	O
characteristics	O
,	O
risk	O
factors	O
and	O
impact	O
on	O
mortality	O
of	O
hospitalized	O
patients	O
with	O
CAP	B-DISO
according	O
to	O
the	O
presence	O
of	O
ARF	B-DISO
and	O
SS	O
on	O
admission	O
.	O

Three	O
groups	O
of	O
patients	O
were	O
identified	O
:	O
those	O
with	O
neither	O
ARF	B-DISO
nor	O
SS	O
(	O
Group	O
A	O
),	O
those	O
with	O
only	O
ARF	B-DISO
(	O
Group	B-DISO
B	I-DISO
)	O
and	O
those	O
with	O
both	O
ARF	B-DISO
and	O
SS	O
(	O
Group	O
C	O
)	O
on	O
admission	O
.	O

TITLE	O
:	O
Development	O
and	O
evaluation	O
of	O
reverse	O
transcription	O
loop	O
-	O
mediated	O
isothermal	O
amplification	B-DISO
assay	O
for	O
the	O
detection	O
of	O
the	O
fathead	O
minnow	O
nidovirus	O
.	O

No	O
small	O
-	O
animal	O
model	O
for	O
this	O
infection	B-DISO
is	O
currently	O
available	O
,	O
but	O
studies	O
suggest	O
that	O
virus	O
entry	O
factors	O
can	O
confer	O
virus	O
susceptibility	O
.	O

Using	O
these	O
mice	O
,	O
we	O
demonstrated	O
the	O
efficacy	O
of	O
a	O
therapeutic	O
intervention	O
(	O
poly	O
I	O
:	O
C	O
)	O
and	O
a	O
potential	O
vaccine	O
[	O
Venezuelan	B-DISO
equine	I-DISO
encephalitis	I-DISO
replicon	O
particles	O
expressing	O
MERS	O
-	O
CoV	O
spike	O
protein	O
].	O

METHODS	O
:	O
This	O
was	O
an	O
autopsy	O
study	O
of	O
dengue	B-DISO
-	O
associated	O
deaths	O
at	O
a	O
large	O
tertiary	O
care	O
hospital	O
.	O

Adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
bleeding	B-DISO
diathesis	I-DISO
,	O
hypotension	O
,	O
hepatic	B-DISO
failure	I-DISO
and	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
were	O
the	O
common	O
causes	O
of	O
death	O
despite	O
early	O
hospitalization	O
,	O
intravenous	O
fluid	O
,	O
and	O
blood	O
-	O
product	O
support	O
.	O

He	O
had	O
a	O
history	O
of	O
two	O
previous	O
operations	O
:	O
parapharyngeal	O
tumor	B-DISO
removal	O
with	O
temporal	O
tracheotomy	O
14	O
years	O
ago	O
and	O
,	O
two	O
years	O
later	O
,	O
a	O
sinus	B-DISO
surgery	O
when	O
,	O
according	O
to	O
our	O
anesthesia	B-DISO
registry	O
,	O
intubation	O
was	O
extremely	O
difficult	O
due	O
to	O
stricture	B-DISO
of	O
the	O
trachea	B-DISO
underneath	O
the	O
tracheotomy	O
scar	B-DISO
.	O

ABSTRACT	O
:	O
Mechanical	O
ventilation	O
(	O
MV	O
)	O
is	O
the	O
main	O
supportive	O
treatment	O
in	O
respiratory	B-DISO
failure	I-DISO
due	O
to	O
different	O
etiologies	O
.	O

TITLE	O
:	O
Imported	O
falciparum	B-DISO
malaria	I-DISO
among	O
adults	O
requiring	O
intensive	O
care	O
:	O
analysis	O
of	O
the	O
literature	O
.	O

ABSTRACT	O
:	O
Malaria	B-DISO
is	O
the	O
most	O
important	O
imported	O
tropical	B-DISO
disease	I-DISO
.	O

Data	O
were	O
extracted	O
on	O
the	O
epidemiology	O
,	O
management	O
,	O
rates	O
of	O
concomitant	O
community	O
-	O
acquired	O
bacterial	B-DISO
infection	I-DISO
and	O
outcomes	O
.	O

Acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
(	O
36	O
%),	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
(	O
31	O
%)	O
and	O
impaired	B-DISO
consciousness	I-DISO
(	O
25	O
%)	O
were	O
common	O
.	O

Most	O
notably	O
,	O
the	O
compound	O
7b	O
was	O
identified	O
as	O
the	O
most	O
promising	O
candidate	O
in	O
inhibiting	O
HIV	B-DISO
-	O
1	O
replication	O
with	O
an	O
EC50	O
value	O
of	O
0	O
.	O
056	O
μM	O
and	O
a	O
selective	O
index	O
(	O
SI	O
)	O
of	O
1251	O
,	O
which	O
were	O
much	O
better	O
than	O
those	O
of	O
NVP	O
(	O
EC₅₀	O
=	O
0	O
.	O
23	O
μM	O
)	O
and	O
DLV	O
(	O
EC₅₀	O
=	O
0	O
.	O
51	O
μM	O
).	O

Lacking	O
understanding	O
of	O
FH	O
pathogenesis	B-DISO
has	O
in	O
essence	O
hindered	O
efficient	O
clinical	O
treatment	O
.	O

Furthermore	O
,	O
Trolox	O
specifically	O
attenuated	O
the	O
increased	O
hypoxia	B-DISO
susceptibility	O
of	O
Mecp2	O
(-)	O
(/	O
y	O
)	O
slices	O
.	O

Dual	O
expression	O
vectors	O
containing	O
IBV	O
N	O
and	O
spike	O
(	O
S	O
)	O
proteins	O
of	O
the	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
were	O
engineered	O
under	O
the	O
control	O
of	O
human	O
and	O
murine	O
cytomegalovirus	O
immediate	O
-	O
early	O
enhancer	O
/	O
promoter	O
elements	O
in	O
combination	O
with	O
the	O
baculoviral	O
polyhedrin	O
and	O
p10	O
promoters	O
for	O
simultaneous	O
expression	O
in	O
both	O
vertebrate	O
and	O
insect	O
cells	O
.	O

However	O
,	O
the	O
pathogenesis	B-DISO
of	O
pulmonary	O
coronavirus	B-DISO
infections	I-DISO
is	O
poorly	O
understood	O
.	O

However	O
,	O
cachectic	B-DISO
muscle	O
'	O
s	O
metabolic	O
signaling	O
response	O
to	O
a	O
novel	O
,	O
acute	O
bout	O
of	O
low	O
-	O
frequency	O
contraction	B-DISO
has	O
not	O
been	O
determined	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
mechanism	O
by	O
which	O
the	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
affects	O
eggshell	O
formation	O
.	O

ABSTRACT	O
:	O
Recombination	O
among	O
infectious	B-DISO
bronchitis	B-DISO
viruses	O
(	O
IBVs	O
),	O
coupled	O
with	O
point	O
mutations	O
,	O
insertions	O
,	O
and	O
deletions	O
that	O
occur	O
in	O
the	O
genome	O
,	O
is	O
thought	O
to	O
contribute	O
to	O
the	O
emergence	O
of	O
new	O
IBV	O
variants	O
.	O

She	O
had	O
vomiting	B-DISO
,	O
excessive	O
retching	B-DISO
,	O
diarrhoea	B-DISO
,	O
miosis	O
,	O
hypersalivation	B-DISO
and	O
bilateral	O
crepitation	B-DISO
on	O
chest	O
during	O
admission	O
.	O

Although	O
animal	O
models	O
of	O
ALI	O
/	O
ARDS	B-DISO
have	O
pointed	O
out	O
a	O
variety	O
of	O
new	O
ideas	O
for	O
study	O
,	O
there	O
are	O
still	O
limited	O
data	O
regarding	O
the	O
initiating	O
factors	O
,	O
the	O
critical	O
steps	O
in	O
the	O
progression	O
of	O
the	O
disease	O
,	O
and	O
the	O
central	O
mechanisms	O
dictating	O
its	O
resolution	O
or	O
progression	O
to	O
lung	O
scarring	B-DISO
.	O

The	O
lack	O
of	O
a	O
clear	O
human	O
epidemic	O
suggests	O
that	O
the	O
basic	O
reproductive	O
number	O
R0	O
is	O
below	O
or	O
very	O
close	O
to	O
one	O
for	O
all	O
three	O
infections	B-DISO
.	O

Human	O
Coronaviruses	O
(	O
HCoV	O
)	O
usually	O
infect	O
the	O
upper	O
respiratory	O
tract	O
,	O
where	O
they	O
are	O
mainly	O
associated	O
with	O
common	B-DISO
colds	I-DISO
.	O

Only	O
22	O
%	O
of	O
the	O
pilgrims	O
(	O
17	O
.	O
5	O
%	O
of	O
those	O
≥	O
65	O
years	O
and	O
36	O
.	O
3	O
%	O
of	O
diabetics	O
)	O
had	O
flu	B-DISO
vaccination	O
,	O
and	O
4	O
.	O
4	O
%	O
had	O
pneumococcal	O
vaccination	O
.	O

While	O
rates	O
of	O
compulsory	O
vaccinations	O
uptake	O
were	O
high	O
,	O
uptake	O
of	O
pneumococcal	O
and	O
flu	B-DISO
seasonal	O
vaccinations	O
were	O
low	O
,	O
including	O
among	O
the	O
high	O
-	O
risk	O
population	O
.	O

Acute	O
and	O
chronic	O
CD4	O
(+)	O
T	O
cell	O
-	O
mediated	O
experimental	O
autoimmune	B-DISO
encephalomyelitis	B-DISO
lesions	O
showed	O
transient	O
expression	O
of	O
p22phox	O
and	O
iNOS	O
associated	O
with	O
inflammation	B-DISO
.	O

The	O
amplification	B-DISO
of	O
oxidative	O
injury	O
,	O
which	O
has	O
been	O
suggested	O
in	O
MS	O
,	O
is	O
only	O
reflected	O
to	O
a	O
limited	O
degree	O
in	O
the	O
studied	O
rodent	O
models	O
.	O

We	O
found	O
that	O
expression	O
of	O
the	O
membrane	O
-	O
anchored	O
PLpro	O
domain	O
(	O
PLpro	O
-	O
TM	O
)	O
from	O
SARS	B-DISO
-	O
CoV	O
inhibits	O
STING	O
/	O
TBK1	O
/	O
IKKε	O
-	O
mediated	O
activation	O
of	O
type	O
I	O
IFNs	O
and	O
disrupts	O
the	O
phosphorylation	O
and	O
dimerization	O
of	O
IRF3	O
,	O
which	O
are	O
activated	O
by	O
STING	O
and	O
TBK1	O
.	O

The	O
role	O
of	O
ECMO	O
used	O
primarily	O
for	O
extracorporeal	O
carbon	O
dioxide	O
removal	O
(	O
ECCO2R	O
)	O
in	O
the	O
support	O
of	O
patients	O
with	O
hypercapnic	B-DISO
respiratory	I-DISO
failure	I-DISO
and	O
less	O
severe	O
forms	O
of	O
ARDS	B-DISO
is	O
also	O
evolving	O
.	O

TITLE	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
vs	O
.	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
.	O

Both	O
SARS	B-DISO
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
may	O
cause	O
severe	O
respiratory	B-DISO
failure	I-DISO
and	O
extrapulmonary	O
features	O
such	O
as	O
diarrhoea	B-DISO
,	O
whereas	O
mild	O
or	O
asymptomatic	O
cases	O
also	O
occur	O
in	O
both	O
conditions	O
.	O

ABSTRACT	O
:	O
Neonatal	B-DISO
diarrhea	I-DISO
is	O
a	O
multifactorial	O
condition	B-DISO
commonly	O
present	O
on	O
pig	O
farms	O
and	O
leads	O
to	O
economic	O
losses	O
due	O
to	O
increased	O
morbidity	O
and	O
mortality	O
of	O
piglets	O
.	O

Potentially	O
pathogenic	O
bacteria	O
have	O
recently	O
received	O
focus	O
in	O
the	O
research	O
on	O
the	O
possible	O
etiology	O
of	O
neonatal	B-DISO
diarrhea	I-DISO
not	O
caused	O
by	O
common	O
pathogens	O
.	O

A	O
(	O
H7N9	O
)	O
infection	B-DISO
has	O
usually	O
presented	O
with	O
severe	O
pneumonia	B-DISO
,	O
often	O
complicated	O
by	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
multiorgan	B-DISO
failure	I-DISO
.	O

We	O
used	O
an	O
aged	O
African	O
green	O
monkey	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
model	O
to	O
better	O
understand	O
age	O
-	O
related	O
mechanisms	O
of	O
increased	O
susceptibility	O
to	O
viral	O
respiratory	B-DISO
infections	I-DISO
.	O

Significant	O
age	O
-	O
and	O
infection	B-DISO
-	O
dependent	O
differences	O
were	O
observed	O
in	O
both	O
systemic	O
and	O
mucosal	O
immune	O
compartments	O
.	O

RESULTS	O
:	O
Significant	O
age	O
-	O
and	O
infection	B-DISO
-	O
dependent	O
differences	O
were	O
observed	O
in	O
both	O
systemic	O
and	O
mucosal	O
immune	O
compartments	O
.	O

TITLE	O
:	O
PKR	O
mediated	O
regulation	O
of	O
inflammation	B-DISO
and	O
IL	O
-	O
10	O
during	O
viral	O
encephalomyelitis	B-DISO
.	O

Here	O
we	O
use	O
data	O
from	O
daily	O
underground	O
ridership	O
in	O
Taipei	O
City	O
and	O
daily	O
reported	O
new	O
SARS	B-DISO
cases	O
in	O
Taiwan	O
to	O
model	O
the	O
dynamics	O
of	O
the	O
public	O
fear	O
of	O
the	O
SARS	B-DISO
virus	O
during	O
the	O
wax	O
and	O
wane	O
of	O
the	O
SARS	B-DISO
period	O
.	O

These	O
daily	O
loss	O
rates	O
dissipate	O
to	O
the	O
following	O
days	O
with	O
an	O
e	O
-	O
folding	O
time	O
of	O
about	O
28	O
days	O
,	O
reflecting	O
the	O
public	O
perception	O
on	O
the	O
risk	O
of	O
contacting	O
SARS	B-DISO
virus	O
when	O
traveling	O
with	O
the	O
underground	O
system	O
(	O
the	O
residual	O
fear	O
).	O

Real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
was	O
used	O
to	O
detect	O
hMPV	O
infection	B-DISO
.	O

The	O
viruses	O
studied	O
were	O
:	O
feline	O
calicivirus	O
(	O
FCV	O
,	O
a	O
norovirus	O
surrogate	O
);	O
human	O
adenovirus	B-DISO
type	O
1	O
;	O
transmissible	O
gastroenteritis	B-DISO
coronavirus	O
of	O
pigs	O
(	O
TGEV	O
,	O
a	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
[	O
SARS	B-DISO
-	O
CoV	O
]	O
surrogate	O
);	O
avian	B-DISO
influenza	I-DISO
virus	O
(	O
AIV	O
);	O
and	O
swine	B-DISO
influenza	I-DISO
virus	O
(	O
SwIV	O
).	O

Deceased	O
donors	O
with	O
previous	O
hepatitis	B-DISO
C	I-DISO
infection	I-DISO
may	O
represent	O
a	O
safe	O
resource	O
to	O
expand	O
the	O
donor	O
pool	O
.	O

Because	O
the	O
PEDV	O
host	O
cell	O
receptor	O
(	O
CD13	O
or	O
aminopeptidase	O
N	O
)	O
stimulates	O
cellular	O
signaling	O
pathways	O
in	O
the	O
absence	O
of	O
PEDV	O
infection	B-DISO
,	O
we	O
suspect	O
that	O
PEDV	O
co	B-DISO
-	I-DISO
infection	I-DISO
might	O
alter	O
CD13	O
function	O
and	O
induce	O
the	O
chlamydiae	O
to	O
enter	O
the	O
persistent	O
state	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
apoptosis	O
induced	O
by	O
BYD1	O
,	O
its	O
outer	O
capsid	O
protein	O
μ1	O
,	O
and	O
its	O
cell	O
-	O
attachment	O
protein	O
σ1	O
to	O
understand	O
the	O
pathogenesis	B-DISO
of	O
BYD1	O
.	O

TITLE	O
:	O
Role	O
of	O
alveolar	O
macrophages	O
in	O
the	O
inflammatory	B-DISO
response	I-DISO
after	O
trauma	O
.	O

In	O
the	O
course	O
of	O
ALI	O
/	O
ARDS	B-DISO
,	O
mediators	O
released	O
from	O
resident	O
cells	O
,	O
such	O
as	O
alveolar	O
macrophages	O
,	O
may	O
act	O
as	O
chemoattractants	O
for	O
invading	O
cells	O
and	O
stimulate	O
local	O
cells	O
to	O
build	O
up	O
a	O
proinflammatory	O
micromilieu	O
.	O

Fifty	O
-	O
six	O
mechanically	O
ventilated	O
patients	O
with	O
septic	B-DISO
shock	I-DISO
criteria	O
were	O
studied	O
.	O

We	O
excluded	O
trials	O
of	O
newborns	O
and	O
children	O
;	O
and	O
those	O
on	O
short	O
-	O
term	O
interventions	O
,	O
ARDS	B-DISO
prevention	O
,	O
or	O
post	O
-	O
traumatic	B-DISO
lung	I-DISO
injury	O
.	O

A	O
statistically	O
significant	O
survival	O
benefit	O
was	O
observed	O
in	O
eight	O
trials	O
(	O
seven	O
interventions	O
)	O
and	O
two	O
trials	O
reported	O
an	O
adverse	B-DISO
effect	I-DISO
on	O
survival	O
.	O

While	O
low	O
tidal	O
volumes	O
and	O
prone	O
positioning	O
in	O
severe	O
ARDS	B-DISO
seem	O
effective	O
,	O
most	O
sporadic	O
findings	O
of	O
interventions	O
suggesting	O
reduced	O
mortality	O
are	O
not	O
corroborated	O
consistently	O
in	O
large	O
-	O
scale	O
evidence	O
including	O
meta	O
-	O
analyses	O
.	O

Clinical	O
examination	O
and	O
chest	O
radiography	O
may	O
be	O
misleading	O
in	O
these	O
patients	O
as	O
tracheobronchomegaly	B-DISO
is	O
easily	O
overlooked	O
on	O
radiographs	O
.	O

TITLE	O
:	O
Human	O
adult	O
bone	O
marrow	O
-	O
derived	O
stem	O
cells	O
decrease	O
severity	O
of	O
lipopolysaccharide	O
-	O
induced	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
sheep	O
.	O

Perceived	O
A	O
/	O
H1N1	O
severity	O
relative	O
to	O
SARS	B-DISO
had	O
stronger	O
associations	O
with	O
adoption	O
of	O
protective	O
behaviors	O
in	O
the	O
late	O
epidemic	O
periods	O
than	O
in	O
the	O
early	O
epidemic	O
periods	O
.	O

Interestingly	O
,	O
we	O
also	O
found	O
that	O
2	O
-	O
DG	O
treatment	O
could	O
affect	O
virus	O
assembly	O
,	O
which	O
is	O
similar	O
to	O
previous	O
studies	O
on	O
influenza	B-DISO
virus	O
.	O

TITLE	O
:	O
Complete	O
genome	O
sequence	O
of	O
a	O
novel	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
strain	O
circulating	O
in	O
China	O
with	O
a	O
distinct	O
S	O
gene	O
.	O

ABSTRACT	O
:	O
An	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
was	O
isolated	O
and	O
identified	O
from	O
a	O
commercial	O
layer	O
flock	O
vaccinated	O
with	O
live	O
attenuated	O
H120	O
vaccine	O
in	O
China	O
,	O
designed	O
as	O
ck	O
/	O
CH	O
/	O
IBTZ	O
/	O
2012	O
.	O

To	O
study	O
intratonsillar	O
/	O
nasopharyngeal	O
virus	O
detections	O
and	O
in	O
vivo	O
expressions	O
of	O
T	O
-	O
cell	O
-	O
and	O
innate	B-DISO
immune	I-DISO
response	I-DISO
-	O
specific	O
cytokines	O
,	O
transcription	O
factors	O
,	O
and	O
type	O
I	O
/	O
II	O
/	O
III	O
interferons	O
in	O
human	O
tonsils	O
.	O

Adenovirus	B-DISO
,	O
bocavirus	O
-	O
1	O
,	O
coronavirus	O
,	O
enteroviruses	O
,	O
influenza	B-DISO
virus	O
,	O
metapneumovirus	O
,	O
parainfluenza	B-DISO
virus	O
,	O
rhinovirus	O
,	O
and	O
respiratory	O
syncytial	O
virus	O
were	O
detected	O
using	O
PCR	O
.	O

TITLE	O
:	O
Comparison	O
of	O
the	O
Berlin	O
definition	O
with	O
the	O
American	O
European	O
consensus	O
definition	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
burn	O
patients	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
leading	O
cause	O
of	O
mortality	O
in	O
burn	O
patients	O
.	O

According	O
to	O
the	O
Berlin	O
definition	O
,	O
all	O
patients	O
met	O
criteria	O
for	O
ARDS	B-DISO
:	O
4	O
(	O
10	O
%)	O
for	O
a	O
severe	O
ARDS	B-DISO
,	O
25	O
(	O
62	O
.	O
5	O
%)	O
for	O
a	O
moderate	O
ARDS	B-DISO
,	O
11	O
(	O
27	O
.	O
5	O
%)	O
for	O
a	O
mild	O
ARDS	B-DISO
.	O

Clinical	O
and	O
laboratory	O
evaluation	O
revealed	O
that	O
the	O
child	O
also	O
had	O
hypopigmented	O
hair	O
and	O
skin	O
,	O
splenohepatomegaly	O
,	O
pancytopenia	B-DISO
and	O
hypoalbuminaemia	O
.	O

The	O
coexistence	O
of	O
hypopigmentation	B-DISO
and	O
suspected	O
low	O
immunity	O
prompted	O
us	O
to	O
investigate	O
the	O
child	O
'	O
s	O
hair	O
,	O
peripheral	O
blood	O
smear	O
and	O
bone	O
marrow	O
.	O

The	O
child	O
'	O
s	O
investigations	O
revealed	O
coexistent	O
hemophagocytic	B-DISO
lymphohistiocytosis	I-DISO
,	O
confirming	O
the	O
diagnosis	O
of	O
CHS	B-DISO
in	O
'	O
accelerated	O
phase	O
',	O
which	O
is	O
fatal	O
if	O
not	O
treated	O
.	O

The	O
mechanisms	O
how	O
viral	O
agents	O
affect	O
the	O
pathogenesis	B-DISO
as	O
well	O
as	O
the	O
inflammatory	O
and	O
immune	O
response	O
of	O
CF	O
are	O
discussed	O
.	O

Possible	O
harmful	O
effects	O
of	O
further	O
viruses	O
like	O
adenovirus	B-DISO
,	O
bocavirus	O
,	O
coronavirus	O
,	O
metapneumovirus	O
,	O
parainfluenzavirus	O
on	O
the	O
lung	O
function	O
of	O
CF	O
patients	O
are	O
discussed	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
causes	O
an	O
upper	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
in	O
chickens	O
and	O
is	O
highly	O
contagious	O
.	O

The	O
demonstration	O
of	O
an	O
endogeneous	O
in	O
vitro	O
growth	O
of	O
myeloid	O
progenitors	O
although	O
not	O
very	O
specific	O
can	O
help	O
JMML	B-DISO
diagnosis	O
.	O

JMML	B-DISO
have	O
a	O
poor	O
prognosis	O
.	O

JMML	B-DISO
clinical	O
course	O
is	O
highly	O
heterogeneous	O
and	O
unpredictable	O
.	O

TITLE	O
:	O
Predicting	O
survival	O
after	O
extracorporeal	O
membrane	O
oxygenation	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

Two	O
liquid	O
chip	O
panels	O
were	O
developed	O
which	O
used	O
a	O
target	O
-	O
enriched	O
multiplexed	O
RT	O
-	O
PCR	O
amplification	B-DISO
followed	O
by	O
Luminex	O
liquid	O
chip	O
hybridization	O
based	O
on	O
xMAP	O
technology	O
.	O

108	O
throat	O
swabs	O
from	O
influenza	B-DISO
-	O
like	O
-	O
illness	O
(	O
ILI	O
)	O
cases	O
and	O
88	O
nasopharyngeal	O
aspirates	O
(	O
NPA	O
)	O
from	O
hospitalized	O
children	O
with	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
(	O
LRTI	B-DISO
)	O
were	O
used	O
to	O
evaluate	O
the	O
two	O
panels	O
.	O

The	O
exercise	O
took	O
place	O
over	O
2	O
days	O
and	O
included	O
the	O
TripCom	O
Point	O
-	O
of	O
-	O
Dispensing	O
(	O
POD	O
)	O
Management	O
Team	O
,	O
volunteers	O
from	O
the	O
TripCom	O
MRC	O
,	O
and	O
neighboring	O
public	O
health	O
departments	O
and	O
MRCs	B-DISO
.	O

He	O
was	O
placed	O
on	O
extracorporeal	O
membrane	O
oxygenation	O
to	O
stabilise	O
his	O
condition	B-DISO
.	O

However	O
,	O
a	O
single	O
PCT	B-DISO
determination	O
is	O
not	O
sufficient	O
,	O
only	O
consecutive	O
measurements	O
can	O
give	O
feedback	O
of	O
the	O
appropriateness	O
and	O
success	O
of	O
the	O
antibacterial	O
therapy	O
.	O

Examples	O
are	O
calcitonin	O
-	O
producing	O
tumors	B-DISO
,	I-DISO
medullary	I-DISO
C	O
-	O
cell	O
thyroid	B-DISO
carcinoma	I-DISO
,	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

TITLE	O
:	O
Acute	O
respiratory	O
viral	B-DISO
infections	I-DISO
in	O
pediatric	B-DISO
cancer	I-DISO
patients	O
undergoing	O
chemotherapy	O
.	O

the	O
prevalence	O
of	O
respiratory	O
viruses	O
was	O
relevant	O
in	O
the	O
infectious	B-DISO
episode	O
,	O
with	O
no	O
increase	O
in	O
morbidity	O
and	O
mortality	O
.	O

In	O
conclusion	O
,	O
the	O
circular	O
TFOs	O
have	O
the	O
potential	O
to	O
be	O
further	O
developed	O
as	O
antiviral	O
agents	O
against	O
FIPV	O
infection	B-DISO
.	O

Articles	O
related	O
that	O
Chinese	O
herbs	O
preventing	O
and	O
treating	O
infections	B-DISO
in	O
respiratory	O
tract	O
were	O
retrieved	O
and	O
reviewed	O
.	O

Based	O
on	O
the	O
theory	O
of	O
traditional	O
Chinese	O
medicine	O
,	O
mix	O
-	O
using	O
herbs	O
provide	O
a	O
synergistic	O
benefit	O
on	O
preventing	O
and	O
healing	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
.	O

Many	O
commercial	O
herbal	O
medicines	O
containing	O
one	O
or	O
more	O
compounds	O
have	O
been	O
successfully	O
applied	O
to	O
prevent	O
and	O
treat	O
viral	B-DISO
infections	I-DISO
of	O
respiratory	O
tract	O
clinically	O
.	O

The	O
concentrations	O
of	O
the	O
six	O
extracts	O
needed	O
to	O
inhibit	O
50	O
%	O
of	O
Vero	O
E6	O
cell	O
proliferation	B-DISO
(	O
CC50	O
)	O
and	O
50	O
%	O
of	O
viral	O
replication	O
(	O
EC50	O
)	O
were	O
determined	O
.	O

Consequently	O
,	O
a	O
post	O
-	O
recovery	O
diagnosis	O
of	O
fat	B-DISO
emboli	I-DISO
syndrome	B-DISO
was	O
made	O
.	O

Our	O
findings	O
support	O
the	O
clinical	O
perception	O
that	O
chronic	O
health	O
condition	B-DISO
,	O
high	O
comorbidity	O
and	O
reduced	O
functional	O
reserves	O
are	O
strongly	O
related	O
to	O
survival	O
during	O
and	O
following	O
ECMO	O
support	O
.	O

We	O
found	O
that	O
both	O
of	O
the	O
indirubin	O
derivatives	O
strongly	O
suppress	O
the	O
pro	O
-	O
inflammatory	O
cytokines	O
including	O
IP	O
-	O
10	O
(	O
CXCL10	O
),	O
one	O
of	O
the	O
key	O
factors	O
which	O
contribute	O
to	O
the	O
lung	B-DISO
inflammation	I-DISO
during	O
H5N1	B-DISO
virus	B-DISO
infection	I-DISO
.	O

If	O
humanized	O
,	O
this	O
antibody	O
may	O
be	O
used	O
as	O
a	O
prophylactic	O
and	O
therapeutic	O
agent	O
against	O
MERS	O
-	O
CoV	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
Mycoplasma	B-DISO
pneumoniae	O
(	O
MP	O
)	O
is	O
a	O
common	O
childhood	O
pathogen	O
associated	O
with	O
atypical	B-DISO
pneumonia	I-DISO
(	O
AP	O
).	O

No	O
statistical	O
differences	O
were	O
observed	O
in	O
relation	O
to	O
sex	O
,	O
the	O
presence	O
of	O
a	O
fever	O
or	O
cough	B-DISO
,	O
and	O
the	O
presence	O
of	O
a	O
single	O
or	O
multilobar	O
infiltrate	B-DISO
on	O
chest	O
radiography	O
.	O

TITLE	O
:	O
Impact	O
of	O
serum	O
biomarkers	O
and	O
clinical	O
factors	O
on	O
intensive	O
care	O
unit	O
mortality	O
and	O
6	O
-	O
month	O
outcome	O
in	O
relatively	O
healthy	O
patients	O
with	O
severe	O
pneumonia	B-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Interestingly	O
,	O
we	O
also	O
found	O
that	O
a	O
low	O
day	O
1	O
albumin	O
level	O
was	O
an	O
independent	O
biomarker	O
for	O
predicting	O
patient	O
life	O
dependence	B-DISO
6	O
months	O
after	O
a	O
pneumonia	B-DISO
event	O
.	O

A	O
61	O
-	O
year	O
-	O
old	O
female	O
who	O
had	O
rapidly	O
progressive	O
pneumonia	B-DISO
with	O
respiratory	B-DISO
distress	I-DISO
and	O
bilateral	O
exduation	O
and	O
consolidation	O
changes	O
on	O
chest	O
X	O
-	O
ray	O
and	O
computerized	O
tomography	O
(	O
CT	O
)	O
scan	O
that	O
did	O
not	O
respond	O
to	O
ordinary	O
antibiotics	O
was	O
diagnosed	O
with	O
influenza	B-DISO
A	O
(	O
H7N9	O
)	O
infection	B-DISO
in	O
our	O
hospital	O
on	O
July	O
19	O
,	O
2013	O
.	O

Whether	O
or	O
not	O
the	O
influenza	B-DISO
season	O
in	O
north	O
China	O
,	O
the	O
influenza	B-DISO
screening	O
should	O
be	O
carried	O
out	O
as	O
a	O
conventional	O
test	O
for	O
the	O
patients	O
who	O
are	O
suspected	O
of	O
viral	B-DISO
pneumonia	I-DISO
.	O

TITLE	O
:	O
Phagocytic	O
cells	O
contribute	O
to	O
the	O
antibody	O
-	O
mediated	O
elimination	O
of	O
pulmonary	O
-	O
infected	O
SARS	B-DISO
coronavirus	O
.	O

The	O
objective	O
of	O
the	O
present	O
work	O
was	O
to	O
identify	O
,	O
using	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
mouse	O
infection	B-DISO
models	O
,	O
immune	O
factors	O
responsible	O
for	O
clearing	O
of	O
the	O
virus	O
.	O

TITLE	O
:	O
Performance	O
and	O
clinical	O
validation	O
of	O
the	O
RealStar	O
MERS	O
-	O
CoV	O
Kit	O
for	O
detection	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
RNA	O
.	O

And	O
to	O
validate	O
this	O
kit	O
(	O
RealStar	O
MERS	O
-	O
CoV	O
RT	O
-	O
PCR	O
kit	O
1	O
.	O
0	O
,	O
Altona	O
Diagnostics	O
GmbH	O
,	O
Hamburg	O
,	O
Germany	O
)	O
using	O
clinical	O
samples	O
of	O
one	O
MERS	O
-	O
CoV	O
case	O
from	O
Munich	O
and	O
respiratory	O
samples	O
of	O
patients	O
with	O
other	O
respiratory	B-DISO
diseases	I-DISO
.	O

A	O
total	O
of	O
55	O
patients	O
hospitalized	O
with	O
CAP	B-DISO
were	O
enrolled	O
into	O
the	O
prospective	O
study	O
between	O
February	O
2010	O
and	O
December	O
2010	O
.	O

Advanced	O
age	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
higher	O
CURB	B-DISO
-	O
65	O
score	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
were	O
found	O
to	O
be	O
associated	O
with	O
increased	O
mortality	O
.	O

ABSTRACT	O
:	O
Cytokine	B-DISO
storm	I-DISO
defines	O
a	O
dysregulation	O
of	O
and	O
an	O
excessively	O
exaggerated	O
immune	O
response	O
most	O
often	O
accompanying	O
selected	O
viral	B-DISO
infections	I-DISO
and	O
several	O
autoimmune	B-DISO
diseases	I-DISO
.	O

ABSTRACT	O
:	O
This	O
essay	O
examines	O
how	O
Chinese	O
governments	O
,	O
local	O
communities	O
,	O
and	O
overseas	O
Chinese	O
in	O
North	O
America	O
responded	O
to	O
the	O
perceived	O
health	O
risks	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
H1N1	B-DISO
flu	I-DISO
through	O
the	O
use	O
of	O
public	O
and	O
participatory	O
rhetoric	O
about	O
risk	O
and	O
quarantines	O
.	O

Focusing	O
on	O
modes	O
of	O
security	O
and	O
quarantine	O
practices	O
,	O
I	O
examine	O
how	O
globalization	O
and	O
the	O
social	O
crises	O
surrounding	O
SARS	B-DISO
and	O
H1N1	B-DISO
flu	I-DISO
operated	O
to	O
regulate	O
differently	O
certain	O
bodies	O
and	O
areas	O
.	O

In	O
pneumococcal	B-DISO
pneumonia	I-DISO
,	O
MV	O
increased	O
lung	O
permeability	O
,	O
and	O
worsened	O
lung	O
mechanics	O
and	O
oxygenation	O
failure	O
.	O

MV	O
induced	O
systemic	O
leukocytopenia	B-DISO
and	O
liver	O
,	O
gut	O
and	O
kidney	O
injury	O
in	O
mice	O
with	O
pneumonia	B-DISO
.	O

RESULTS	O
:	O
In	O
pneumococcal	B-DISO
pneumonia	I-DISO
,	O
MV	O
increased	O
lung	O
permeability	O
,	O
and	O
worsened	O
lung	O
mechanics	O
and	O
oxygenation	O
failure	O
.	O

TITLE	O
:	O
Synthesis	O
,	O
structure	O
-	O
activity	O
relationships	O
and	O
biological	O
evaluation	O
of	O
dehydroandrographolide	O
and	O
andrographolide	O
derivatives	O
as	O
novel	O
anti	O
-	O
hepatitis	B-DISO
B	I-DISO
virus	O
agents	O
.	O

Furthermore	O
,	O
the	O
most	O
active	O
compound	O
2c	O
with	O
SI	O
value	O
higher	O
than	O
165	O
.	O
1	O
inhibiting	O
HBV	B-DISO
DNA	O
replication	O
was	O
revealed	O
with	O
the	O
optimal	O
logP	O
value	O
of	O
1	O
.	O
78	O
and	O
logD	O
values	O
.	O

Risk	O
factors	O
for	O
death	O
were	O
lymphocytopenia	B-DISO
and	O
high	O
steroid	O
dosage	O
.	O

TITLE	O
:	O
Investigation	O
of	O
the	O
role	O
of	O
major	O
respiratory	O
viruses	O
in	O
the	O
aetiology	O
of	O
nasal	B-DISO
polyps	I-DISO
using	O
polymerase	O
chain	O
reaction	O
technique	O
.	O

Thus	O
,	O
most	O
coronaviruses	O
exit	O
through	O
the	O
apical	O
surface	O
,	O
several	O
through	O
the	O
basolateral	O
one	O
,	O
although	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
appears	O
to	O
use	O
both	O
sides	O
.	O

However	O
,	O
only	O
SHXB	O
inhibited	O
Mo	O
-	O
DCs	B-DISO
to	O
activate	O
T	O
-	O
cell	O
proliferation	B-DISO
by	O
down	O
-	O
regulating	O
the	O
expression	O
of	O
cell	O
-	O
surface	O
markers	O
and	O
the	O
secretion	O
of	O
cytokines	O
in	O
vitro	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
show	O
that	O
SHXB	O
significantly	O
impaired	B-DISO
the	O
functions	O
of	O
Mo	O
-	O
DCs	B-DISO
and	O
intestinal	O
DCs	B-DISO
in	O
vitro	O
and	O
in	O
vivo	O
,	O
while	O
STC3	O
had	O
the	O
opposite	O
effect	O
.	O

These	O
differences	O
may	O
underlie	O
the	O
pathogenesis	B-DISO
of	O
virulent	O
and	O
attenuated	O
TGEV	O
in	O
piglets	O
,	O
and	O
could	O
help	O
us	O
to	O
develop	O
a	O
better	O
strategy	O
to	O
prevent	O
virulent	O
TGEV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
In	O
2011	O
,	O
autochthonous	O
Plasmodium	B-DISO
vivax	I-DISO
malaria	I-DISO
emerged	O
in	O
a	O
focal	O
geographical	O
area	O
in	O
Greece	O
after	O
importation	O
by	O
immigrants	O
from	O
the	O
Indian	O
subcontinent	O
.	O

Data	O
from	O
two	O
American	O
College	O
of	O
Surgeons	O
-	O
verified	O
Level	O
1	O
trauma	O
centers	O
,	O
which	O
maintain	O
detailed	O
records	O
of	O
patients	O
with	O
acute	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
(	O
AHRF	O
),	O
were	O
evaluated	O
retrospectively	O
.	O

Infection	B-DISO
with	O
this	O
pathogen	O
is	O
associated	O
with	O
upper	O
and	O
lower	O
respiratory	B-DISO
tract	I-DISO
diseases	I-DISO
of	O
mild	O
to	O
moderate	O
severity	O
.	O

Intriguingly	O
,	O
we	O
show	O
here	O
that	O
all	O
three	O
types	O
of	O
interferons	O
,	O
IFN	O
-	O
α	O
,	O
IFN	O
-	O
γ	O
,	O
and	O
IFN	O
-	O
λ	O
,	O
efficiently	O
promote	O
infection	B-DISO
by	O
a	O
human	O
coronavirus	O
,	O
HCoV	O
-	O
OC43	O
,	O
one	O
of	O
the	O
major	O
etiological	O
agents	O
of	O
common	B-DISO
cold	I-DISO
,	O
through	O
the	O
induction	O
of	O
IFN	O
-	O
inducible	O
transmembrane	O
(	O
IFITM	O
)	O
proteins	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
was	O
detected	O
in	O
185	O
samples	O
originating	O
from	O
chicken	O
flocks	O
of	O
various	O
commodity	O
groups	O
in	O
Canada	O
.	O

Antibodies	O
against	O
canine	O
parvovirus	B-DISO
were	O
detected	O
in	O
71	O
.	O
6	O
%	O
(	O
63	O
/	O
88	O
)	O
blood	O
samples	O
and	O
the	O
seroprevalence	O
found	O
for	O
canine	B-DISO
distemper	I-DISO
virus	O
was	O
51	O
.	O
1	O
%	O
(	O
45	O
/	O
88	O
).	O

These	O
results	O
may	O
provide	O
some	O
insights	O
into	O
the	O
genotype	O
of	O
the	O
etiological	O
agent	O
responsible	O
for	O
the	O
porcine	O
hemagglutinating	O
encephalomyelitis	B-DISO
outbreak	O
and	O
could	O
also	O
provide	O
a	O
comparative	O
view	O
of	O
the	O
genomics	O
of	O
the	O
five	O
structural	O
proteins	O
of	O
PHEV	O
.	O

Immunofluorescence	O
assays	O
detected	O
no	O
difference	O
in	O
HCoV	O
-	O
NL63	O
antibody	O
positivity	O
between	O
the	O
patients	O
with	O
Kawasaki	B-DISO
disease	I-DISO
and	O
controls	O
,	O
whereas	O
the	O
rate	O
of	O
HCoV	O
-	O
229E	O
antibody	O
positivity	O
was	O
higher	O
in	O
the	O
patients	O
with	O
Kawasaki	B-DISO
disease	I-DISO
than	O
that	O
in	O
controls	O
.	O

The	O
serological	O
test	O
supported	O
no	O
involvement	O
of	O
HCoV	O
-	O
NL63	O
but	O
suggested	O
the	O
possible	O
involvement	O
of	O
HCoV	O
-	O
229E	O
in	O
the	O
development	O
of	O
Kawasaki	B-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
In	O
the	O
initial	O
description	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
,	O
many	O
affected	O
patients	O
were	O
adults	O
with	O
underlying	O
medical	O
comorbidities	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
is	O
a	O
coronavirus	O
of	O
the	O
chicken	O
.	O

Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
M	O
co	O
-	O
expression	O
with	O
either	O
N	O
or	O
E	O
is	O
sufficient	O
for	O
producing	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
),	O
although	O
at	O
a	O
lower	O
level	O
compared	O
to	O
M	O
,	O
N	O
and	O
E	O
co	O
-	O
expression	O
.	O

The	O
eNose	O
was	O
trained	O
to	O
recognize	O
ARDS	B-DISO
in	O
a	O
training	O
cohort	O
and	O
the	O
diagnostic	O
performance	O
was	O
evaluated	O
in	O
a	O
temporal	O
external	O
validation	O
cohort	O
.	O

The	O
exhaled	O
breath	O
profile	O
from	O
patients	O
with	O
cardiopulmonary	O
edema	B-DISO
and	O
pneumonia	B-DISO
was	O
different	O
from	O
that	O
of	O
patients	O
with	O
moderate	O
/	O
severe	O
ARDS	B-DISO
.	O

This	O
identified	O
a	O
methionine	O
codon	O
at	O
position	O
1058	O
,	O
consistent	O
with	O
the	O
shedding	O
of	O
an	O
enteric	O
form	O
of	O
FCoV	O
,	O
in	O
77	O
%	O
of	O
the	O
faecal	O
samples	O
from	O
cats	O
with	O
FIP	B-DISO
,	O
and	O
in	O
100	O
%	O
of	O
the	O
samples	O
from	O
cats	O
without	O
FIP	B-DISO
.	O

TITLE	O
:	O
Is	O
abdomen	O
release	O
really	O
necessary	O
for	O
prone	O
ventilation	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
?	O

ABSTRACT	O
:	O
Some	O
patients	O
with	O
idiopathic	B-DISO
pulmonary	I-DISO
fibrosis	I-DISO
(	O
IPF	O
)	O
develop	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
(	O
ARF	B-DISO
)	O
requiring	O
admission	O
to	O
an	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
and	O
ventilatory	O
support	O
.	O

This	O
study	O
aimed	O
to	O
retrospectively	O
investigate	O
the	O
clinical	O
status	O
and	O
outcomes	O
in	O
IPF	O
patients	O
receiving	O
NIV	O
for	O
ARF	B-DISO
and	O
to	O
identify	O
those	O
clinical	O
and	O
laboratory	O
characteristics	O
,	O
which	O
could	O
be	O
considered	O
risk	O
factors	O
for	O
its	O
failure	O
.	O

This	O
study	O
was	O
conducted	O
in	O
a	O
4	O
-	O
bed	B-DISO
respiratory	O
ICU	O
(	O
RICU	O
)	O
in	O
a	O
university	O
hospital	O
.	O

Preliminary	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	B-DISO
)	O
and	O
molecular	O
modeling	O
of	O
these	O
new	O
analogues	O
were	O
also	O
discussed	O
in	O
detail	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
Th2	O
-	O
type	O
inflammation	B-DISO
in	O
H7N9	O
-	O
infected	O
patients	O
with	O
pre	O
-	O
existing	O
chronic	B-DISO
diseases	I-DISO
likely	O
contributes	O
to	O
the	O
pathogenesis	B-DISO
of	O
H7N9	O
infection	B-DISO
and	O
is	O
linked	O
to	O
poor	O
clinical	O
outcomes	O
.	O

There	O
are	O
growing	O
concerns	O
about	O
spread	O
of	O
infection	B-DISO
.	O

TITLE	O
:	O
Pathophysiology	O
of	O
hantavirus	B-DISO
pulmonary	I-DISO
syndrome	I-DISO
in	O
rhesus	O
macaques	O
.	O

ABSTRACT	O
:	O
ABSTRACT	O
Complete	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
genome	O
sequences	O
were	O
obtained	O
from	O
nasal	O
swabs	O
of	O
dromedary	O
camels	O
sampled	O
in	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
through	O
direct	O
analysis	O
of	O
nucleic	O
acid	O
extracts	O
or	O
following	O
virus	O
isolation	O
in	O
cell	O
culture	O
.	O

Antibodies	O
to	O
and	O
viral	O
nucleic	O
acids	O
of	O
MERS	O
-	O
CoV	O
have	O
been	O
found	O
in	O
dromedaries	O
,	O
suggesting	O
the	O
possibility	O
that	O
they	O
may	O
serve	O
as	O
a	O
reservoir	O
or	O
vector	O
for	O
human	O
infection	B-DISO
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
dromedary	O
camels	O
,	O
Oman	O
,	O
2013	O
.	O

To	O
test	O
the	O
contribution	O
of	O
E	O
protein	O
IC	O
activity	O
in	O
virus	B-DISO
pathogenesis	I-DISO
,	O
two	O
recombinant	O
mouse	O
-	O
adapted	O
SARS	B-DISO
-	O
CoVs	O
,	O
each	O
containing	O
one	O
single	O
amino	O
acid	O
mutation	O
that	O
suppressed	O
ion	O
conductivity	O
,	O
were	O
engineered	O
.	O

Reduced	O
edema	B-DISO
correlated	O
with	O
lung	O
epithelia	O
integrity	O
and	O
proper	O
localization	O
of	O
Na	O
+/	O
K	O
+	O
ATPase	O
,	O
which	O
participates	O
in	O
edema	B-DISO
resolution	O
.	O

In	O
conclusion	O
,	O
E	O
protein	O
IC	O
activity	O
represents	O
a	O
new	O
determinant	O
for	O
SARS	B-DISO
-	O
CoV	O
virulence	O
.	O

TITLE	O
:	O
Exceptionally	O
potent	O
neutralization	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
by	O
human	O
monoclonal	O
antibodies	O
.	O

The	O
exceptionally	O
high	O
neutralization	O
activity	O
of	O
these	O
antibodies	O
and	O
especially	O
m336	O
suggests	O
that	O
they	O
have	O
great	O
potential	O
for	O
prophylaxis	O
and	O
therapy	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
in	O
humans	O
and	O
as	O
a	O
tool	O
for	O
development	O
of	O
vaccine	O
immunogens	O
.	O

Adults	O
who	O
were	O
admitted	O
or	O
presented	O
to	O
the	O
clinics	O
of	O
Gil	O
Medical	O
Center	O
with	O
acute	O
respiratory	B-DISO
symptoms	I-DISO
were	O
recruited	O
from	O
1	O
November	O
2012	O
to	O
31	O
March	O
2013	O
.	O

Influenza	B-DISO
A	O
virus	O
,	O
RSV	O
A	O
,	O
HRV	O
,	O
coronavirus	O
OC43	O
,	O
and	O
adenovirus	B-DISO
were	O
detected	O
more	O
frequently	O
in	O
sputum	O
samples	O
than	O
in	O
nasopharyngeal	O
swabs	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

Using	O
these	O
assays	O
,	O
the	O
expression	O
of	O
each	O
of	O
the	O
tested	O
genes	O
could	O
be	O
detected	O
in	O
ferret	O
lymph	O
node	O
cells	O
stimulated	O
with	O
mitogens	O
or	O
infected	O
with	O
influenza	B-DISO
virus	O
in	O
vitro	O
.	O

However	O
,	O
the	O
identification	O
of	O
HIV	B-DISO
-	O
1	O
RNase	O
H	O
inhibitors	O
(	O
RHIs	O
)	O
has	O
been	O
hampered	O
by	O
the	O
open	O
morphology	O
of	O
its	O
active	O
site	O
,	O
the	O
limited	O
number	O
of	O
available	O
RNase	O
H	O
crystal	O
structures	O
in	O
complex	O
with	O
inhibitors	O
,	O
and	O
the	O
fact	O
that	O
,	O
due	O
to	O
the	O
high	O
concentrations	O
of	O
Mg	O
(	O
2	O
+)	O
needed	O
for	O
protein	O
stability	O
,	O
HIV	B-DISO
-	O
1	O
RNase	O
H	O
is	O
not	O
suitable	O
for	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
inhibitor	O
studies	O
.	O

Thus	O
,	O
we	O
examined	O
whether	O
PFV	O
RNase	O
H	O
can	O
serve	O
as	O
an	O
HIV	B-DISO
-	O
1	O
RNase	O
H	O
model	O
for	O
inhibitor	O
interaction	O
studies	O
.	O

He	O
got	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
but	O
recovered	O
after	O
treatment	O
in	O
Intensive	O
Care	O
Unit	O
for	O
24	O
days	O
.	O

A	O
T	O
-	O
tube	O
drainage	O
and	O
wrapping	O
with	O
the	O
intercostal	O
muscle	O
flap	O
is	O
a	O
useful	O
choice	O
of	O
treatment	O
for	O
intrathoracic	O
anastomotic	B-DISO
leakage	I-DISO
with	O
severe	O
inflammation	B-DISO
.	O

Our	O
study	O
focused	O
on	O
the	O
role	O
of	O
protease	O
activity	O
on	O
infection	B-DISO
by	O
investigating	O
the	O
spike	O
protein	O
of	O
a	O
PEDV	O
isolate	O
(	O
wtPEDV	O
)	O
using	O
a	O
reverse	O
genetics	O
system	O
based	O
on	O
the	O
trypsin	O
-	O
independent	O
cell	O
culture	O
-	O
adapted	O
strain	O
DR13	O
(	O
caPEDV	O
).	O

96	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
and	O
ARDS	B-DISO
admitted	O
from	O
July	O
2012	O
to	O
September	O
2013	O
to	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
of	O
Liuzhou	O
People	O
'	O
s	O
Hospital	O
in	O
Guangxi	O
Zhuang	O
Autonomous	O
Region	O
were	O
enrolled	O
and	O
divided	O
into	O
severe	O
ARDS	B-DISO
group	O
(	O
n	O
=	O
48	O
)	O
and	O
moderate	O
ARDS	B-DISO
group	O
(	O
n	O
=	O
48	O
)	O
according	O
to	O
the	O
Berlin	O
definition	O
of	O
ARDS	B-DISO
.	O

In	O
moderate	O
or	O
severe	O
ARDS	B-DISO
group	O
,	O
there	O
were	O
no	O
statistically	O
significant	O
difference	O
in	O
APACHEII	O
score	O
,	O
SOFA	O
score	O
,	O
PaO2	O
/	O
FiO2	O
,	O
ScvO2	O
,	O
Lac	O
and	O
CRP	O
before	O
treatment	O
between	O
two	O
groups	O
.	O

In	O
moderate	O
ARDS	B-DISO
group	O
,	O
each	O
of	O
the	O
above	O
clinical	O
parameters	O
were	O
improved	O
in	O
both	O
groups	O
expect	O
for	O
CRP	O
at	O
48	O
hours	O
after	O
treatment	O
,	O
but	O
the	O
indexes	O
showed	O
no	O
statistically	O
significant	O
difference	O
between	O
two	O
groups	O
(	O
all	O
P	O
>	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
[	O
The	O
influence	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
on	O
cerebral	O
blood	O
flow	O
and	O
cerebrovascular	O
autoregulation	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
].	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
influence	O
of	O
different	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
levels	O
on	O
cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
and	O
cerebrovascular	O
autoregulation	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

RESULTS	O
:	O
35	O
patients	O
with	O
ARDS	B-DISO
were	O
included	O
.	O

ABSTRACT	O
:	O
Pulmonary	B-DISO
aspiration	I-DISO
is	O
an	O
important	O
recognized	O
cause	O
of	O
ARDS	B-DISO
.	O

Neither	O
obesity	B-DISO
nor	O
gastroesophageal	B-DISO
reflux	I-DISO
was	O
associated	O
with	O
aspiration	B-DISO
.	O

Findings	O
from	O
this	O
study	O
may	O
facilitate	O
the	O
design	O
of	O
future	O
clinical	O
studies	O
of	O
aspiration	B-DISO
-	O
induced	O
lung	O
injury	O
.	O

Neither	O
obesity	B-DISO
nor	O
gastroesophageal	B-DISO
reflux	I-DISO
was	O
associated	O
with	O
aspiration	B-DISO
.	O

TITLE	O
:	O
Plasmodium	B-DISO
falciparum	I-DISO
Malaria	I-DISO
Complicated	O
by	O
Symmetrical	O
Peripheral	B-DISO
Gangrene	I-DISO
,	O
Bowel	B-DISO
Ischemia	I-DISO
,	O
Repeated	O
Candidemia	B-DISO
,	O
and	O
Bacteraemia	B-DISO
.	O

The	O
overall	O
rate	O
of	O
pneumothorax	B-DISO
by	O
GA	O
was	O
bimodal	O
with	O
estimates	O
of	O
4	O
.	O
0	O
%,	O
2	O
.	O
6	O
%,	O
and	O
6	O
.	O
7	O
%	O
respectively	O
.	O

In	O
early	O
preterm	O
neonates	O
,	O
pneumothorax	B-DISO
was	O
associated	O
with	O
mortality	O
,	O
bronchopulmonary	B-DISO
dysplasia	I-DISO
,	O
severe	O
intraventricular	B-DISO
hemorrhage	I-DISO
,	O
and	O
prolonged	O
NICU	O
stay	O
.	O

However	O
,	O
this	O
M2	O
polarization	O
also	O
resulted	O
in	O
increased	O
lung	O
bacterial	O
load	O
following	O
infection	B-DISO
with	O
Pseudomonas	O
aeruginosa	O
.	O

NIV	O
failed	O
to	O
reverse	O
ARF	B-DISO
in	O
only	O
13	O
patients	O
.	O

In	O
the	O
NIV	O
success	O
group	O
(	O
n	O
=	O
63	O
),	O
33	O
patients	O
(	O
53	O
%)	O
experienced	O
a	O
delayed	O
response	O
to	O
NIV	O
(	O
with	O
persistent	O
hypercapnic	B-DISO
acidosis	I-DISO
during	O
the	O
first	O
6	O
hours	O
).	O

A	O
total	O
of	O
62	O
children	O
(	O
45	O
male	O
,	O
17	O
female	O
;	O
age	O
range	O
:	O
0	O
-	O
2	O
years	O
)	O
with	O
the	O
initial	O
diagnosis	O
of	O
acute	B-DISO
bronchiolitis	I-DISO
and	O
33	O
healthy	O
children	O
(	O
21	O
male	O
,	O
12	O
female	O
;	O
age	O
range	O
:	O
0	O
-	O
2	O
years	O
)	O
as	O
control	O
group	O
who	O
were	O
admitted	O
to	O
the	O
Pediatrics	O
Department	O
of	O
Mersin	O
University	O
Hospital	O
,	O
southern	O
Turkey	O
,	O
from	O
January	O
to	O
July	O
2010	O
were	O
included	O
in	O
the	O
study	O
.	O

Of	O
the	O
62	O
samples	O
collected	O
from	O
bronchiolitis	B-DISO
cases	O
,	O
at	O
least	O
one	O
virus	O
was	O
detected	O
in	O
52	O
(	O
83	O
.	O
9	O
%)	O
and	O
viral	O
co	B-DISO
-	I-DISO
infections	I-DISO
were	O
detected	O
in	O
31	O
(	O
50	O
%)	O
of	O
them	O
.	O

Including	O
the	O
co	B-DISO
-	I-DISO
infections	I-DISO
,	O
RSV	O
was	O
the	O
most	O
commonly	O
identified	O
virus	O
(	O
n	O
=	O
21	O
;	O
33	O
.	O
9	O
%),	O
followed	O
by	O
influenza	B-DISO
A	O
[	O
H1N1	O
]	O
(	O
n	O
=	O
18	O
;	O
29	O
%),	O
RV	O
(	O
n	O
=	O
18	O
;	O
29	O
%),	O
hMPV	O
(	O
n	O
=	O
13	O
;	O
21	O
%),	O
PIV	O
(	O
n	O
=	O
10	O
;	O
16	O
.	O
1	O
%),	O
AdV	O
(	O
n	O
=	O
5	O
;	O
8	O
%),	O
HBoV	O
(	O
n	O
=	O
3	O
;	O
4	O
.	O
8	O
%)	O
and	O
EV	O
(	O
n	O
=	O
1	O
;	O
1	O
.	O
6	O
%).	O

Including	O
the	O
co	B-DISO
-	I-DISO
infections	I-DISO
,	O
the	O
most	O
commonly	O
detected	O
virus	O
was	O
RV	O
(	O
n	O
=	O
10	O
;	O
30	O
.	O
3	O
%),	O
followed	O
by	O
influenza	B-DISO
A	O
[	O
H1N1	O
]	O
(	O
n	O
=	O
6	O
;	O
18	O
.	O
1	O
%),	O
AdV	O
(	O
n	O
=	O
6	O
;	O
18	O
.	O
1	O
%),	O
RSV	O
(	O
n	O
=	O
4	O
;	O
12	O
.	O
1	O
%)	O
and	O
PIV	O
(	O
n	O
=	O
3	O
;	O
9	O
%),	O
however	O
HBoV	O
and	O
hMPV	O
were	O
not	O
detected	O
in	O
the	O
control	O
group	O
.	O

The	O
most	O
common	O
findings	O
on	O
physical	O
examination	O
were	O
prolonged	O
expirium	O
(	O
98	O
.	O
4	O
%),	O
rhonchi	B-DISO
(	O
98	O
.	O
4	O
%),	O
rales	B-DISO
(	O
80	O
.	O
6	O
%),	O
tachypnea	B-DISO
(	O
71	O
%)	O
and	O
tachycardia	O
(	O
67	O
.	O
7	O
%).	O

Pulmonary	O
graphies	O
revealed	O
that	O
diffuse	O
air	O
trappings	O
were	O
more	O
common	O
in	O
virus	O
-	O
associated	O
bronchiolitis	B-DISO
(	O
36	O
/	O
52	O
;	O
69	O
.	O
2	O
%)	O
cases	O
,	O
on	O
the	O
other	O
hand	O
infiltrations	O
were	O
more	O
common	O
(	O
6	O
/	O
10	O
;	O
60	O
%)	O
in	O
patients	O
who	O
were	O
virus	O
-	O
negative	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

The	O
demographic	O
features	O
,	O
clinical	O
and	O
laboratory	O
findings	O
,	O
clinical	O
severity	O
scores	O
,	O
hospitalization	O
rates	O
and	O
duration	O
of	O
hospitalizations	O
in	O
bronchiolitis	B-DISO
cases	O
did	O
not	O
show	O
statistically	O
significant	O
differences	O
between	O
the	O
viral	O
agents	O
(	O
p	O
>	O
0	O
.	O
05	O
for	O
each	O
parameter	O
).	O

ABSTRACT	O
:	O
Respiratory	O
viral	B-DISO
infections	I-DISO
precipitate	O
exacerbations	O
of	O
chronic	O
respiratory	B-DISO
diseases	I-DISO
such	O
as	O
asthma	B-DISO
and	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
though	O
similar	O
data	O
in	O
non	O
-	O
cystic	B-DISO
fibrosis	I-DISO
(	O
CF	O
)	O
bronchiectasis	B-DISO
are	O
missing	O
.	O

Respiratory	O
viruses	O
were	O
detected	O
during	O
37	O
(	O
48	O
%)	O
exacerbations	O
:	O
human	O
rhinovirus	O
(	O
HRV	O
)	O
in	O
20	O
;	O
an	O
enterovirus	O
or	O
bocavirus	O
in	O
four	O
each	O
;	O
adenoviruses	O
,	O
metapneumovirus	O
,	O
influenza	B-DISO
A	O
virus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
parainfluenza	B-DISO
virus	O
3	O
or	O
4	O
in	O
two	O
each	O
;	O
coronavirus	O
or	O
parainfluenza	B-DISO
virus	O
1	O
and	O
2	O
in	O
one	O
each	O
.	O

ABSTRACT	O
:	O
Influenza	B-DISO
A	O
viruses	O
recruit	O
components	O
of	O
the	O
nuclear	O
import	O
pathway	O
to	O
enter	O
the	O
host	O
cell	O
nucleus	O
and	O
promote	O
viral	O
replication	O
.	O

Here	O
,	O
we	O
analyzed	O
the	O
role	O
of	O
the	O
nuclear	O
import	O
factor	O
importin	O
-	O
α7	O
in	O
H1N1	B-DISO
influenza	I-DISO
virus	O
pulmonary	O
tropism	O
by	O
using	O
various	O
ex	O
vivo	O
imaging	O
techniques	O
(	O
magnetic	O
resonance	O
imaging	O
,	O
confocal	O
laser	O
scanning	O
microscopy	O
,	O
and	O
correlative	O
light	O
-	O
electron	O
microscopy	O
).	O

Accordingly	O
,	O
extensive	O
mononuclear	O
infiltration	B-DISO
and	O
alveolar	O
destruction	O
were	O
present	O
in	O
the	O
lungs	O
of	O
infected	O
WT	O
mice	O
,	O
followed	O
by	O
100	O
%	O
lethality	O
.	O

Conversely	O
,	O
in	O
α7	O
(-/-)	O
mice	O
,	O
virus	O
replication	O
was	O
restricted	O
mostly	O
to	O
the	O
bronchial	O
epithelium	O
with	O
marginal	O
alveolar	O
infection	B-DISO
,	O
resulting	O
in	O
significantly	O
reduced	O
lung	O
damage	O
and	O
enhanced	O
animal	O
survival	O
.	O

In	O
summary	O
,	O
these	O
data	O
show	O
that	O
a	O
cellular	O
factor	O
,	O
importin	O
-	O
α7	O
,	O
is	O
required	O
for	O
enhanced	O
virus	O
replication	O
in	O
the	O
alveolar	O
epithelium	O
,	O
resulting	O
in	O
elevated	O
cytokine	O
and	O
chemokine	O
levels	O
,	O
extensive	O
mononuclear	O
infiltration	B-DISO
,	O
and	O
thus	O
,	O
severe	O
pneumonia	B-DISO
and	O
enhanced	O
virulence	O
in	O
mice	O
.	O

ABSTRACT	O
:	O
The	O
evidence	O
saying	O
that	O
the	O
rate	O
of	O
Systemic	B-DISO
Inflammatory	I-DISO
Response	I-DISO
Syndrome	I-DISO
(	O
SIRS	B-DISO
)	O
is	O
high	O
in	O
patients	O
with	O
advanced	B-DISO
cirrhosis	I-DISO
and	O
portal	B-DISO
hypertension	I-DISO
,	O
this	O
could	O
have	O
negative	O
outcome	O
on	O
patients	O
prognosis	O
.	O

Of	O
the	O
109	O
patients	O
,	O
76	O
(	O
69	O
.	O
8	O
%)	O
were	O
SIRS	B-DISO
-	O
negative	O
and	O
33	O
(	O
30	O
.	O
2	O
%)	O
were	O
SIRS	B-DISO
-	O
positive	O
.	O

There	O
was	O
a	O
correlation	O
noted	O
between	O
SIRS	B-DISO
and	O
high	O
serum	O
creatinine	O
levels	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
and	O
between	O
SIRS	B-DISO
and	O
a	O
high	O
MELD	O
score	O
(	O
p	O
=	O
0	O
.	O
00	O
).	O

SIRS	B-DISO
was	O
correlated	O
with	O
death	O
(	O
p	O
<	O
0	O
.	O
00	O
)	O
on	O
multivariate	O
analysis	O
,	O
SIRS	B-DISO
was	O
independently	O
associated	O
with	O
hospital	O
death	O
.	O

SIRS	B-DISO
independently	O
and	O
adversely	O
affects	O
the	O
in	O
-	O
hospital	O
outcome	O
in	O
patients	O
with	O
liver	B-DISO
cirrhosis	I-DISO
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
for	O
the	O
first	O
time	O
use	O
of	O
this	O
combination	O
as	O
a	O
primary	O
treatment	O
for	O
a	O
patient	O
with	O
MERS	O
-	O
CoV	O
infection	B-DISO
and	O
as	O
prophylaxis	O
for	O
his	O
spouse	O
and	O
discuss	O
its	O
possible	O
role	O
.	O

Prompt	O
diagnosis	O
,	O
multidisciplinary	O
management	O
,	O
including	O
aggressive	B-DISO
resuscitation	O
,	O
cardiorespiratory	O
support	O
,	O
intravenous	O
immunoglobulin	O
therapy	O
,	O
and	O
daily	O
wound	O
care	O
resulted	O
in	O
a	O
positive	O
outcome	O
despite	O
a	O
predicted	O
mortality	O
greater	O
than	O
60	O
%.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
,	O
antiviral	O
activity	O
,	O
and	O
SARs	B-DISO
of	O
13a	O
-	O
substituted	O
phenanthroindolizidine	O
alkaloid	O
derivatives	O
.	O

Preliminary	O
SARs	B-DISO
showed	O
that	O
the	O
substituted	O
groups	O
with	O
hydrogen	O
donor	O
at	O
13a	O
position	O
were	O
found	O
to	O
be	O
favorable	O
for	O
keeping	O
high	O
antiviral	O
activity	O
.	O

We	O
analyzed	O
samples	O
from	O
112	O
patients	O
infected	O
with	O
the	O
recently	O
discovered	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

Respiratory	O
tract	O
samples	O
from	O
cases	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
confirmed	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
were	O
investigated	O
to	O
determine	O
the	O
MERS	O
-	O
CoV	O
load	O
and	O
fraction	O
of	O
the	O
MERS	O
-	O
CoV	O
genome	O
.	O

ABSTRACT	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
continues	O
to	O
be	O
one	O
of	O
the	O
most	O
researched	O
infectious	B-DISO
diseases	I-DISO
of	O
cats	O
.	O

After	O
a	O
half	O
century	O
,	O
FIP	B-DISO
remains	O
one	O
of	O
the	O
last	O
important	O
infections	B-DISO
of	O
cats	O
for	O
which	O
we	O
have	O
no	O
single	O
diagnostic	O
test	O
,	O
no	O
vaccine	O
and	O
no	O
definitive	O
explanations	O
for	O
how	O
virus	O
and	O
host	O
interact	O
to	O
cause	O
disease	O
.	O

Why	O
is	O
it	O
so	O
difficult	O
,	O
and	O
perhaps	O
impossible	O
,	O
to	O
develop	O
a	O
vaccine	O
for	O
FIP	B-DISO
?	O

TITLE	O
:	O
Screening	O
of	O
an	O
FDA	O
-	O
approved	O
compound	O
library	O
identifies	O
four	O
small	O
-	O
molecule	O
inhibitors	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
replication	O
in	O
cell	O
culture	O
.	O

ABSTRACT	O
:	O
Outbreaks	O
of	O
emerging	O
infections	B-DISO
present	O
health	O
professionals	O
with	O
the	O
unique	O
challenge	O
of	O
trying	O
to	O
select	O
appropriate	O
pharmacologic	O
treatments	O
in	O
the	O
clinic	O
with	O
little	O
time	O
available	O
for	O
drug	O
testing	O
and	O
development	O
.	O

The	O
compounds	O
belong	O
to	O
13	O
different	O
classes	O
of	O
pharmaceuticals	O
,	O
including	O
inhibitors	O
of	O
estrogen	O
receptors	O
used	O
for	O
cancer	B-DISO
treatment	O
and	O
inhibitors	O
of	O
dopamine	O
receptor	O
used	O
as	O
antipsychotics	O
.	O

Using	O
two	O
-	O
photon	O
imaging	O
of	O
a	O
newly	O
developed	O
ventral	O
spinal	O
cord	B-DISO
preparation	O
and	O
a	O
viral	O
model	O
of	O
demyelination	B-DISO
,	O
we	O
describe	O
the	O
motility	O
and	O
intercellular	O
interactions	O
of	O
transplanted	O
mouse	O
NPCs	O
expressing	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
with	O
damaged	O
axons	O
expressing	O
yellow	O
fluorescent	O
protein	O
(	O
YFP	O
).	O

TITLE	O
:	O
Pathogenic	O
influenza	B-DISO
viruses	O
and	O
coronaviruses	O
utilize	O
similar	O
and	O
contrasting	O
approaches	O
to	O
control	O
interferon	O
-	O
stimulated	O
gene	O
responses	O
.	O

Using	O
a	O
novel	O
screening	O
approach	O
,	O
specific	O
comparison	O
between	O
highly	O
pathogenic	O
influenza	B-DISO
viruses	O
and	O
coronaviruses	O
revealed	O
similarities	O
and	O
differences	O
in	O
strategies	O
to	O
control	O
the	O
interferon	O
and	O
innate	B-DISO
immune	I-DISO
response	I-DISO
.	O

In	O
moderate	O
and	O
severe	O
ARDS	B-DISO
tracheal	O
intubation	O
associated	O
with	O
heavy	O
sedation	B-DISO
/	O
muscle	B-DISO
relaxation	I-DISO
allows	O
to	O
fully	O
characterize	O
the	O
patient	O
.	O

We	O
report	O
the	O
case	O
of	O
an	O
18	O
-	O
year	O
-	O
old	O
male	O
driver	O
who	O
strayed	O
from	O
the	O
road	O
and	O
fell	O
15	O
m	O
into	O
a	O
backyard	O
by	O
landing	O
on	O
the	O
roof	O
of	O
its	O
car	B-DISO
.	O

However	O
,	O
whole	O
inactivated	O
SARS	B-DISO
vaccine	O
that	O
includes	O
nucleocapsid	O
protein	O
is	O
reported	O
to	O
induce	O
eosinophilic	B-DISO
infiltration	I-DISO
in	O
mouse	O
lungs	O
after	O
challenge	O
with	O
live	O
SARS	B-DISO
-	O
CoV	O
.	O
In	O
this	O
study	O
,	O
an	O
ability	O
of	O
Toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
agonists	O
to	O
reduce	O
the	O
side	O
effects	O
of	O
UV	O
-	O
V	O
vaccination	O
in	O
a	O
6	O
-	O
month	O
-	O
old	O
adult	O
BALB	O
/	O
c	O
mouse	O
model	O
was	O
investigated	O
,	O
using	O
the	O
mouse	O
-	O
passaged	O
Frankfurt	O
1	O
isolate	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
Immunization	O
of	O
adult	O
mice	O
with	O
UV	O
-	O
V	O
,	O
with	O
or	O
without	O
alum	O
,	O
resulted	O
in	O
partial	O
protection	O
from	O
lethal	O
doses	O
of	O
SARS	B-DISO
-	O
CoV	O
challenge	O
,	O
but	O
extensive	O
eosinophil	O
infiltration	B-DISO
in	O
the	O
lungs	O
was	O
observed	O
.	O

In	O
this	O
study	O
,	O
the	O
ability	O
of	O
adjuvant	O
Toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
agonists	O
to	O
reduce	O
the	O
side	O
effects	O
of	O
UV	O
-	O
inactivated	O
SARS	B-DISO
-	O
CoV	O
vaccination	O
in	O
a	O
BALB	O
/	O
c	O
mouse	O
model	O
was	O
tested	O
,	O
using	O
the	O
mouse	O
-	O
passaged	O
Frankfurt	O
1	O
isolate	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
We	O
found	O
that	O
TLR	O
stimulation	O
reduced	O
the	O
high	O
level	O
of	O
eosinophilic	B-DISO
infiltration	I-DISO
that	O
occurred	O
in	O
the	O
lungs	O
of	O
mice	O
immunized	O
with	O
UV	O
-	O
inactivated	O
SARS	B-DISO
-	O
CoV	O
.	O
Microarray	O
analysis	O
revealed	O
that	O
genes	O
associated	O
with	O
chemotaxis	O
,	O
eosinophil	O
migration	O
,	O
eosinophilia	B-DISO
,	O
and	O
cell	O
movement	O
and	O
the	O
polarization	O
of	O
Th2	O
cells	O
were	O
upregulated	O
in	O
UV	O
-	O
inactivated	O
SARS	B-DISO
-	O
CoV	O
-	O
immunized	O
mice	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
1	O
,	O
3	O
-	O
diarylpropenones	O
as	O
dual	O
inhibitors	O
of	O
HIV	B-DISO
-	O
1	O
reverse	O
transcriptase	O
.	O

TITLE	O
:	O
Sonographic	O
dynamic	O
assessment	O
of	O
lung	O
injury	O
in	O
a	O
child	O
with	O
hypoplastic	B-DISO
left	I-DISO
heart	I-DISO
syndrome	I-DISO
undergoing	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

A	O
1	O
-	O
year	O
-	O
old	O
male	O
with	O
hypoplastic	B-DISO
left	I-DISO
heart	I-DISO
syndrome	I-DISO
underwent	O
bidirectional	O
Glenn	O
procedure	O
and	O
systemic	O
-	O
to	O
-	O
left	O
pulmonary	O
artery	O
shunt	O
for	O
heart	O
palliation	O
.	O

The	O
identification	O
of	O
cis	B-DISO
-	O
acting	O
elements	O
required	O
for	O
(-)-	O
strand	O
RNA	O
synthesis	O
in	O
coronaviruses	O
,	O
however	O
,	O
has	O
been	O
hampered	O
due	O
to	O
insufficiencies	O
in	O
the	O
techniques	O
used	O
to	O
detect	O
the	O
(-)-	O
strand	O
RNA	O
species	O
.	O

Commonly	O
detected	O
viruses	O
were	O
human	O
rhinovirus	O
(	O
HRV	O
,	O
15	O
.	O
4	O
%),	O
coronavirus	O
(	O
CoV	O
,	O
10	O
.	O
4	O
%),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
,	O
8	O
.	O
4	O
%),	O
human	O
metapneumovirus	O
(	O
hMPV	O
,	O
8	O
.	O
3	O
%),	O
and	O
influenza	B-DISO
(	O
6	O
%).	O

ABSTRACT	O
:	O
Subphenotypes	O
have	O
been	O
identified	O
within	O
heterogeneous	O
diseases	O
such	O
as	O
asthma	B-DISO
and	O
breast	B-DISO
cancer	I-DISO
,	O
with	O
important	O
therapeutic	O
implications	O
.	O

However	O
,	O
a	O
select	O
number	O
of	O
these	O
mutants	O
have	O
a	O
significantly	O
reduced	O
ability	O
to	O
hydrolyze	O
the	O
substrate	O
ISG15	O
-	O
AMC	B-DISO
,	O
or	O
be	O
inhibited	O
by	O
K48	O
-	O
linked	O
diubuiquitin	O
.	O

ABSTRACT	O
:	O
Since	O
about	O
a	O
year	O
,	O
a	O
new	O
pulmonary	B-DISO
pathology	I-DISO
occurred	O
in	O
Saudi	O
Arabia	O
and	O
some	O
cases	O
are	O
imported	O
in	O
Europa	O
.	O

Immunization	O
using	O
vaccines	O
is	O
routine	O
practice	O
;	O
however	O
,	O
to	O
combat	O
infectious	B-DISO
diseases	I-DISO
,	O
conventional	O
vaccines	O
as	O
well	O
as	O
new	O
-	O
generation	O
recombinant	O
vaccines	O
alone	O
,	O
due	O
to	O
relatively	O
weak	O
immunogenicity	O
,	O
may	O
not	O
be	O
effective	O
enough	O
to	O
provide	O
optimum	O
immunity	O
.	O

ABSTRACT	O
:	O
We	O
identified	O
the	O
near	O
-	O
full	O
-	O
genome	O
sequence	O
(	O
29	O
,	O
908	O
nt	O
,	O
>	O
99	O
%)	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
from	O
a	O
nasal	O
swab	O
specimen	O
from	O
a	O
dromedary	O
camel	O
in	O
Egypt	O
.	O

Mild	O
and	O
moderate	O
cases	O
can	O
be	O
efficiently	O
treated	O
by	O
NIV	O
,	O
but	O
this	O
is	O
contra	O
-	O
indicated	O
with	O
severe	O
ARDS	B-DISO
.	O

Progress	O
in	O
the	O
treatment	O
of	O
ARDS	B-DISO
must	O
be	O
addressed	O
toward	O
the	O
new	O
paradigm	O
of	O
the	O
disease	O
pathobiology	O
to	O
be	O
applied	O
to	O
the	O
disease	O
definition	O
and	O
to	O
predict	O
the	O
treatment	O
outcome	O
,	O
also	O
with	O
the	O
perspective	O
to	O
develop	O
predictive	O
and	O
personalized	O
medicine	O
that	O
highlights	O
new	O
and	O
challenging	O
opportunities	O
in	O
terms	O
of	O
benefit	O
for	O
patient	O
'	O
s	O
safety	O
and	O
doctor	O
'	O
s	O
responsibility	O
,	O
with	O
further	O
medico	O
-	O
legal	O
implication	O
.	O

Camels	O
may	O
act	O
as	O
a	O
direct	O
source	O
of	O
human	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Emerging	O
and	O
re	O
-	O
emerging	O
zoonoses	B-DISO
are	O
a	O
significant	O
public	O
health	O
concern	O
and	O
cause	O
considerable	O
socioeconomic	O
problems	O
globally	O
.	O

These	O
studies	O
clearly	O
identified	O
both	O
antibody	O
and	O
CD4	O
T	O
cell	O
reactivities	O
to	O
α	O
-	O
fodrin	O
in	O
sera	O
from	O
virus	O
infected	O
,	O
retinal	O
degenerative	B-DISO
susceptible	O
BALB	O
/	O
c	O
mice	O
.	O

A	O
large	O
-	O
scale	O
outbreak	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
occurred	O
in	O
China	O
in	O
2010	O
,	O
and	O
the	O
virus	O
emerged	O
in	O
the	O
United	O
States	O
in	O
2013	O
and	O
spread	O
rapidly	O
,	O
posing	O
significant	O
economic	O
and	O
public	O
health	O
concerns	O
.	O

We	O
expect	O
this	O
mode	O
of	O
action	O
to	O
serve	O
as	O
a	O
paradigm	O
for	O
the	O
development	O
of	O
potent	O
antiviral	O
drugs	O
to	O
combat	O
many	O
animal	O
and	O
human	O
virus	O
infections	B-DISO
.	O

TITLE	O
:	O
Severe	O
nocturnal	O
and	O
postexercise	O
hypoxia	B-DISO
in	O
children	O
and	O
adolescents	O
with	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
.	O

To	O
assess	O
the	O
prevalence	O
and	O
risk	O
factors	O
of	O
hypoxia	B-DISO
,	O
we	O
recorded	O
daytime	O
,	O
nocturnal	O
,	O
and	O
postexercise	O
pulse	O
oximetry	O
(	O
SpO2	O
)	O
values	O
in	O
39	O
SCD	B-DISO
patients	O
with	O
a	O
median	O
age	O
of	O
10	O
.	O
8	O
years	O
.	O

Median	O
nocturnal	O
SpO2	O
was	O
94	O
.	O
7	O
%	O
(	O
range	O
,	O
87	O
.	O
7	O
%-	O
99	O
.	O
5	O
%),	O
50	O
%	O
of	O
patients	O
had	O
nocturnal	O
hypoxia	B-DISO
defined	O
as	O
SpO2	O
≤	O
93	O
%,	O
and	O
11	O
(	O
37	O
%)	O
patients	O
spent	O
more	O
than	O
10	O
%	O
of	O
their	O
total	O
sleep	O
time	O
with	O
SpO2	O
<	O
90	O
%.	O

Of	O
32	O
evaluable	B-DISO
patients	O
,	O
6	O
(	O
18	O
.	O
8	O
%)	O
had	O
a	O
tricuspid	B-DISO
regurgitation	I-DISO
velocity	O
≥	O
2	O
.	O
6	O
m	O
/	O
s	O
,	O
and	O
this	O
feature	O
was	O
associated	O
with	O
anemia	B-DISO
(	O
P	O
=	O
0	O
.	O
044	O
).	O

TITLE	O
:	O
The	O
first	O
reported	O
case	O
of	O
ureteral	O
perforation	O
in	O
a	O
patient	O
with	O
severe	O
toxic	B-DISO
epidermal	I-DISO
necrolysis	I-DISO
syndrome	B-DISO
.	O

The	O
patient	O
in	O
question	O
suffered	B-DISO
a	O
severe	O
case	O
of	O
TENS	O
with	O
extensive	O
mucocutaneous	O
involvement	O
.	O

SJS	B-DISO
and	O
TENS	O
are	O
two	O
different	O
presentations	O
in	O
the	O
spectrum	O
of	O
the	O
same	O
disease	O
process	O
.	O

From	O
the	O
currently	O
available	O
data	O
,	O
prone	O
positioning	O
should	O
be	O
used	O
as	O
a	O
first	O
-	O
line	O
therapy	O
in	O
patients	O
with	O
severe	O
ALI	O
/	O
ARDS	B-DISO
.	O

However	O
,	O
in	O
the	O
1980s	O
several	O
investigators	O
provided	O
novel	O
evidence	O
that	O
the	O
primary	O
mechanism	O
for	O
removal	O
of	O
alveolar	B-DISO
edema	I-DISO
fluid	O
depended	O
on	O
active	O
ion	O
transport	O
across	O
the	O
alveolar	O
epithelium	O
.	O

From	O
1960	O
,	O
six	O
strains	O
of	O
human	O
coronaviruses	O
have	O
emerged	O
that	O
includes	O
SARS	B-DISO
-	O
CoV	O
and	O
the	O
recent	O
infection	B-DISO
by	O
deadly	O
MERS	O
-	O
CoV	O
which	O
is	O
now	O
going	O
to	O
cause	O
another	O
outbreak	O
.	O

Overexpression	O
of	O
activin	O
A	O
in	O
the	O
lung	O
causes	O
similar	O
histopathological	O
changes	O
as	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

No	O
difference	O
in	O
baseline	O
or	O
highest	O
activin	O
A	O
or	O
activin	O
B	O
was	O
found	O
in	O
patients	O
with	O
or	O
without	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
or	O
ARDS	B-DISO
(	O
P	O
>	O
0	O
.	O
05	O
for	O
all	O
).	O

Assuming	O
this	O
death	O
was	O
caused	O
by	O
P	O
.	O
vivax	O
,	O
the	O
risk	O
of	O
ARDS	B-DISO
-	O
related	O
maternal	O
mortality	O
in	O
this	O
setting	O
did	O
not	O
differ	O
significantly	O
between	O
Plasmodium	O
falciparum	O
and	O
P	O
.	O
vivax	O
(	O
0	O
.	O
24	O
per	O
1	O
,	O
000	O
(	O
1	O
/	O
4	O
,	O
158	O
)	O
versus	O
0	O
.	O
23	O
per	O
1	O
,	O
000	O
(	O
1	O
/	O
4	O
,	O
298	O
),	O
contrary	O
to	O
the	O
increased	O
risk	O
of	O
maternal	O
mortality	O
from	O
P	O
.	O
falciparum	O
compared	O
to	O
P	O
.	O
vivax	O
,	O
2	O
.	O
89	O
per	O
1	O
,	O
000	O
(	O
12	O
/	O
4	O
,	O
158	O
)	O
versus	O
0	O
.	O
23	O
per	O
1	O
,	O
000	O
(	O
1	O
/	O
4	O
,	O
298	O
),	O
P	O
=	O
0	O
.	O
003	O
.	O

TITLE	O
:	O
Severe	O
flucloxacillin	O
-	O
induced	O
acute	B-DISO
generalized	I-DISO
exanthematous	I-DISO
pustulosis	I-DISO
(	O
AGEP	B-DISO
),	O
with	O
toxic	B-DISO
epidermal	I-DISO
necrolysis	I-DISO
(	O
TEN	B-DISO
)-	O
like	O
features	O
:	O
does	O
overlap	O
between	O
AGEP	B-DISO
and	O
TEN	B-DISO
exist	O
?	O

Although	O
AGEP	B-DISO
and	O
SJS	B-DISO
/	O
TEN	O
are	O
distinct	O
entities	O
with	O
a	O
different	O
clinical	O
picture	O
,	O
pathogenesis	B-DISO
,	O
prognosis	O
and	O
treatment	O
,	O
they	O
may	O
share	O
some	O
features	O
,	O
raising	O
the	O
hypothesis	O
of	O
overlap	O
between	O
both	O
entities	O
.	O

ABSTRACT	O
:	O
Carbohydrate	O
structures	O
,	O
including	O
Lewis	O
X	O
(	O
Le	O
(	O
x	O
)),	O
which	O
is	O
not	O
synthesized	O
in	O
mutant	B-DISO
mice	O
that	O
lack	O
α1	O
,	O
3	O
-	O
fucosyltransferase	O
9	O
(	O
Fut9	O
(-/-)),	O
are	O
involved	O
in	O
cell	O
-	O
cell	O
recognition	O
and	O
inflammation	B-DISO
.	O

Thus	O
,	O
the	O
inflammatory	B-DISO
response	I-DISO
of	O
Fut9	O
(-/-)	O
mice	O
was	O
examined	O
using	O
the	O
highly	O
neurovirulent	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
JHMV	O
srr7	O
strain	O
.	O

Immunofluoresence	O
assays	O
indicated	O
that	O
inhibition	O
of	O
PEDV	O
infection	B-DISO
by	O
peptide	O
H	O
was	O
independent	O
of	O
pAPN	O
.	O

Rather	O
,	O
it	O
limits	O
CNS	O
inflammation	B-DISO
and	O
impairs	O
control	O
of	O
CNS	O
virus	O
replication	O
via	O
induction	O
of	O
IL	O
-	O
10	O
in	O
virus	O
-	O
specific	O
CD4	O
+	O
T	O
cells	O
.	O

ABSTRACT	O
:	O
Transfusion	B-DISO
-	I-DISO
related	I-DISO
acute	I-DISO
lung	I-DISO
injury	I-DISO
(	O
TRALI	B-DISO
)	O
is	O
defined	O
as	O
the	O
onset	O
or	O
the	O
worsening	O
of	O
respiratory	B-DISO
distress	I-DISO
within	O
6	O
h	O
of	O
the	O
transfusion	O
of	O
a	O
plasma	O
-	O
containing	O
blood	O
component	O
.	O

Understanding	O
of	O
the	O
pathogenesis	B-DISO
of	O
TRALI	B-DISO
has	O
resulted	O
in	O
the	O
development	O
of	O
preventive	O
measures	O
that	O
have	O
contributed	O
to	O
reducing	O
its	O
incidence	O
.	O

TITLE	O
:	O
US	O
-	O
like	O
strain	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
outbreaks	O
in	O
Taiwan	O
,	O
2013	O
-	O
2014	O
.	O

Suckling	O
piglets	O
under	O
2	O
weeks	O
of	O
age	O
showed	O
severe	O
vomiting	B-DISO
and	O
watery	O
yellowish	O
diarrhea	B-DISO
with	O
morbidity	O
and	O
mortality	O
ranging	O
from	O
80	O
to	O
100	O
%	O
and	O
90	O
to	O
100	O
%,	O
respectively	O
.	O

A	O
total	O
of	O
68	O
samples	O
from	O
25	O
pig	O
farms	O
were	O
confirmed	O
as	O
positive	O
for	O
PEDV	O
and	O
negative	O
for	O
rotavirus	O
and	O
transmissible	O
gastroenteritis	B-DISO
virus	O
by	O
reverse	O
transcription	O
PCR	O
,	O
and	O
the	O
partial	O
S	O
gene	O
of	O
PEDV	O
was	O
analyzed	O
.	O

However	O
,	O
the	O
contribution	O
of	O
the	O
innate	B-DISO
immune	I-DISO
response	I-DISO
to	O
allograft	O
rejection	O
in	O
a	O
model	O
of	O
viral	O
-	O
induced	O
neurological	B-DISO
disease	I-DISO
has	O
not	O
been	O
well	O
defined	O
.	O

RAE	O
-	O
1	O
(+)	O
NPCs	O
were	O
susceptible	O
to	O
NK	O
cell	O
-	O
mediated	O
killing	O
whereas	O
RAE	O
-	O
1	O
(-)	O
cells	O
were	O
resistant	O
to	O
lysis	B-DISO
.	O

Of	O
1	O
,	O
004	O
included	O
patients	O
(	O
86	O
%	O
with	O
hematological	B-DISO
malignancies	I-DISO
and	O
14	O
%	O
with	O
solid	B-DISO
tumors	I-DISO
),	O
444	O
(	O
44	O
.	O
2	O
%)	O
had	O
neutropenia	O
.	O

RESULTS	O
:	O
Of	O
1	O
,	O
004	O
included	O
patients	O
(	O
86	O
%	O
with	O
hematological	B-DISO
malignancies	I-DISO
and	O
14	O
%	O
with	O
solid	B-DISO
tumors	I-DISO
),	O
444	O
(	O
44	O
.	O
2	O
%)	O
had	O
neutropenia	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
emerged	O
in	O
2012	O
.	O

Gene	O
transcription	O
is	O
dynamic	O
and	O
condition	B-DISO
-	O
specific	O
;	O
therefore	O
,	O
to	O
better	O
understand	O
the	O
mouse	O
transcriptional	O
response	O
to	O
respiratory	B-DISO
virus	I-DISO
infection	I-DISO
,	O
we	O
infected	O
the	O
eight	O
founder	B-DISO
strains	O
of	O
the	O
Collaborative	O
Cross	O
with	O
either	O
influenza	B-DISO
A	O
virus	O
or	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
and	O
sequenced	O
lung	O
RNA	O
samples	O
at	O
2	O
and	O
4	O
days	O
after	O
infection	B-DISO
.	O

We	O
also	O
found	O
that	O
respiratory	B-DISO
virus	I-DISO
infection	I-DISO
induced	O
differential	O
expression	O
of	O
4287	O
splicing	O
junctions	O
,	O
resulting	O
in	O
strain	O
-	O
specific	O
isoform	O
expression	O
.	O

Here	O
,	O
we	O
show	O
that	O
GAPDH	O
has	O
an	O
anti	O
-	O
inflammatory	O
function	O
by	O
using	O
a	O
lipopolysaccharide	O
(	O
LPS	B-DISO
)-	O
induced	O
,	O
sepsis	B-DISO
-	O
related	O
severe	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
mouse	O
model	O
,	O
which	O
is	O
referred	O
to	O
as	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
humans	O
.	O

In	O
contrast	O
,	O
after	O
addition	O
of	O
iron	O
(	O
II	O
)	O
ions	O
to	O
the	O
CLOSE	O
state	O
a	O
bishomoleptic	O
dimeric	O
[	O
Fe	O
(	O
terpy	O
)	O
2	O
](	O
2	O
+)	O
complex	O
is	O
formed	O
with	O
the	O
copper	O
(	O
I	O
)	O
ions	O
placed	O
in	O
the	O
phenanthroline	O
cavities	B-DISO
(	O
OPEN	O
-	O
II	O
).	O

ABSTRACT	O
:	O
Guillain	O
-	O
Barré	O
Syndrome	B-DISO
is	O
one	O
of	O
the	O
most	O
common	O
causes	O
of	O
acute	B-DISO
polyneuropathy	I-DISO
in	O
adults	O
.	O

In	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
,	O
syndrome	B-DISO
of	I-DISO
inappropriate	I-DISO
antidiuretic	I-DISO
hormone	I-DISO
secretion	I-DISO
and	O
dysautonomy	O
are	O
generally	O
observed	O
after	O
maximal	O
motor	B-DISO
deficit	I-DISO
.	O

After	O
the	O
development	O
of	O
a	O
severe	B-DISO
headache	I-DISO
,	O
nausea	B-DISO
,	O
diplopia	B-DISO
,	O
and	O
attacks	O
of	O
hypertension	B-DISO
in	O
the	O
early	O
postoperative	O
period	O
,	O
a	O
computer	O
tomography	O
of	O
the	O
brain	O
was	O
normal	O
.	O

RESULTS	O
:	O
From	O
85	O
patients	O
with	O
CAP	B-DISO
,	O
at	O
least	O
one	O
pathogen	O
was	O
identified	O
in	O
81	O
cases	O
(	O
95	O
.	O
3	O
%),	O
including	O
4	O
bacterial	O
exclusive	O
infections	B-DISO
(	O
4	O
.	O
7	O
%),	O
53	O
viral	O
exclusive	O
infections	B-DISO
(	O
62	O
.	O
4	O
%)	O
and	O
24	O
mixed	B-DISO
infections	I-DISO
(	O
28	O
.	O
2	O
%).	O

Two	O
cousins	O
of	O
PI	O
had	O
the	O
same	O
hypomorphic	O
splice	O
site	O
mutation	O
leading	O
to	O
a	O
deletion	O
of	O
27	O
amino	O
acids	O
,	O
but	O
normal	O
FOXP3	O
protein	O
expression	O
and	O
normal	O
suppressive	O
capacity	O
of	O
T	O
reg	O
in	O
a	O
proliferation	B-DISO
inhibition	O
assay	O
.	O

Patient	O
IV	O
from	O
another	O
family	O
presented	O
with	O
chronic	B-DISO
diarrhea	I-DISO
without	O
autoimmune	B-DISO
manifestations	O
and	O
died	O
due	O
to	O
ARDS	B-DISO
.	O

CONCLUSIONS	O
:	O
The	O
most	O
common	O
CT	O
finding	O
in	O
hospitalized	O
patients	O
with	O
MERS	O
-	O
CoV	O
infection	B-DISO
is	O
that	O
of	O
bilateral	O
predominantly	O
subpleural	O
and	O
basilar	O
airspace	O
changes	O
,	O
with	O
more	O
extensive	O
ground	O
-	O
glass	O
opacities	B-DISO
than	O
consolidation	O
.	O

ABSTRACT	O
:	O
Previous	O
trials	O
of	O
higher	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
failed	O
to	O
demonstrate	O
mortality	O
benefit	O
,	O
possibly	O
because	O
of	O
differences	O
in	O
lung	O
recruitability	O
among	O
patients	O
with	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
represents	O
a	O
current	O
threat	O
to	O
the	O
Arabian	O
Peninsula	O
,	O
and	O
potential	O
pandemic	O
disease	O
.	O

All	O
of	O
them	O
received	O
VIPC	O
plan	B-DISO
for	O
early	O
stage	O
resuscitation	O
and	O
CRASHPLAN	O
for	O
further	O
evaluations	O
.	O

Human	O
coronavirus	O
and	O
human	O
bocavirus	O
were	O
the	O
most	O
common	O
pathogens	O
,	O
tending	O
to	O
occur	O
in	O
co	B-DISO
-	I-DISO
infection	I-DISO
with	O
other	O
respiratory	O
viruses	O
.	O

TITLE	O
:	O
Development	O
of	O
a	O
multiplex	O
TaqMan	O
probe	O
-	O
based	O
real	O
-	O
time	O
PCR	O
for	O
discrimination	O
of	O
variant	O
and	O
classical	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
.	O

Knowledge	O
related	O
to	O
the	O
structure	O
and	O
function	O
of	O
the	O
surfactant	O
proteins	O
and	O
their	O
roles	O
in	O
alveolar	O
homeostasis	O
has	O
provided	O
new	O
diagnostic	O
,	O
prognostic	O
and	O
therapeutic	O
tools	O
to	O
advance	O
our	O
understanding	O
of	O
the	O
causes	O
and	O
treatments	O
of	O
acute	O
and	O
chronic	O
lung	B-DISO
diseases	I-DISO
.	O

Mutations	O
in	O
genes	O
encoding	O
the	O
surfactant	O
proteins	O
,	O
transcription	O
factors	O
critical	O
for	O
alveolar	O
morphogenesis	O
and	O
surfactant	O
clearance	O
,	O
are	O
now	O
known	O
to	O
play	O
important	O
roles	O
in	O
the	O
pathogenesis	B-DISO
of	O
chronic	O
lung	B-DISO
diseases	I-DISO
.	O

In	O
the	O
one	O
case	O
in	O
which	O
cats	O
with	O
lesions	O
suspicious	O
for	O
dermatophytosis	B-DISO
were	O
cultured	O
for	O
Microsporum	O
canis	O
,	O
69	O
/	O
76	O
lesional	O
cats	O
were	O
culture	O
-	O
positive	O
;	O
of	O
these	O
,	O
half	O
were	O
believed	O
to	O
be	O
truly	O
infected	O
and	O
half	O
were	O
believed	O
to	O
be	O
fomite	O
carriers	O
.	O

These	O
data	O
suggested	O
that	O
SOCS3	O
may	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
pathogenesis	B-DISO
of	O
MHV	O
-	O
3	O
-	O
induced	O
acute	B-DISO
liver	I-DISO
failure	I-DISO
and	O
HBV	B-DISO
-	O
ACLF	O
.	O

PCP	B-DISO
is	O
responsible	O
for	O
pneumonia	B-DISO
in	O
56	O
.	O
6	O
%	O
HIV	B-DISO
-	O
positive	O
patients	O
in	O
Croatia	O
,	O
primarily	O
those	O
who	O
do	O
not	O
know	O
that	O
they	O
are	O
HIV	B-DISO
infected	O
.	O

The	O
search	O
keywords	O
were	O
:	O
""""	O
tako	B-DISO
-	I-DISO
tsubo	I-DISO
cardiomyopathy	I-DISO
""","	O
""""	O
takotsubo	O
""","	O
""""	O
takotsubo	B-DISO
cardiomyopathy	I-DISO
""","	O
""""	O
broken	B-DISO
heart	I-DISO
syndrome	I-DISO
""","	O
""""	O
stress	O
-	O
induced	O
cardiomyopathy	B-DISO
""","	O
""""	O
apical	B-DISO
ballooning	I-DISO
syndrome	I-DISO
""","	O
and	O
""""	O
ampulla	B-DISO
cardiomyopathy	I-DISO
in	O
combination	O
with	O
respiratory	B-DISO
diseases	I-DISO
,	O
lung	O
,	O
pulmonary	B-DISO
disease	I-DISO
.	O

CONCLUSIONS	O
:	O
An	O
association	O
between	O
respiratory	B-DISO
diseases	I-DISO
and	O
TTC	O
is	O
likely	O
to	O
exist	O
.	O

ABSTRACT	O
:	O
Acute	O
lower	O
respiratory	B-DISO
infections	I-DISO
(	O
ALRIs	O
)	O
are	O
an	O
important	O
cause	O
of	O
acute	O
illnesses	O
and	O
mortality	O
worldwide	O
and	O
in	O
China	O
.	O

PIV	O
,	O
hBoV	O
,	O
hMPV	O
and	O
ADV	O
infections	B-DISO
were	O
more	O
frequent	O
in	O
children	O
,	O
while	O
hCoV	O
infection	B-DISO
was	O
distributed	O
evenly	O
in	O
all	O
-	O
age	O
.	O

A	O
19	O
-	O
bed	B-DISO
Intensive	O
Care	O
Unit	O
of	O
a	O
tertiary	O
hospital	O
in	O
Hong	O
Kong	O
.	O

Complications	O
related	O
to	O
extracorporeal	O
membrane	O
oxygenation	O
included	O
severe	O
bleeding	B-DISO
(	O
n	O
=	O
2	O
;	O
6	O
.	O
5	O
%)	O
and	O
mechanical	O
complications	O
of	O
the	O
circuits	O
(	O
n	O
=	O
3	O
;	O
9	O
.	O
7	O
%).	O

Lung	O
ultrasound	O
maybe	O
a	O
first	O
-	O
line	O
alternative	O
to	O
chest	O
X	O
-	O
ray	O
and	O
CT	O
scan	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
respiratory	B-DISO
failure	I-DISO
.	O

Coexisting	O
consolidated	O
pneumonia	B-DISO
with	O
sonographic	O
air	O
bronchograms	O
was	O
noted	O
in	O
one	O
patient	O
who	O
did	O
not	O
survive	O
.	O

Coexisting	O
consolidated	O
pneumonia	B-DISO
with	O
sonographic	O
air	O
bronchograms	O
was	O
noted	O
in	O
one	O
patient	O
who	O
did	O
not	O
survive	O
.	O

TITLE	O
:	O
Clinical	O
and	O
epidemiological	O
analysis	O
of	O
the	O
first	O
case	O
of	O
human	O
infection	B-DISO
with	O
avian	B-DISO
influenza	I-DISO
A	O
(	O
H7N9	O
)	O
virus	O
in	O
Shenzhen	O
,	O
China	O
.	O

ABSTRACT	O
:	O
The	O
novel	O
influenza	B-DISO
A	O
(	O
H7N9	O
)	O
virus	O
can	O
cause	O
severe	O
illness	O
,	O
including	O
pneumonia	B-DISO
and	O
acute	O
respiratory	B-DISO
disorder	I-DISO
syndrome	B-DISO
(	O
ARDS	B-DISO
),	O
with	O
high	O
rates	O
of	O
intensive	O
care	O
unit	O
admission	O
and	O
death	O
.	O

We	O
detected	O
three	O
PEDV	O
strains	O
from	O
ten	O
small	O
intestine	O
samples	O
from	O
piglets	O
with	O
acute	B-DISO
diarrhea	I-DISO
and	O
we	O
determined	O
the	O
complete	O
genome	O
sequences	O
of	O
the	O
reemerging	O
Korean	O
PEDV	O
field	O
isolates	O
,	O
except	O
for	O
the	O
noncoding	O
regions	O
from	O
both	O
ends	O
.	O

ABSTRACT	O
:	O
A	O
prospective	O
study	O
of	O
a	O
dromedary	O
camel	O
herd	O
during	O
the	O
2013	O
-	O
14	O
calving	O
season	O
showed	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	B-DISO
infection	I-DISO
of	O
calves	O
and	O
adults	O
.	O

TITLE	O
:	O
EDs	B-DISO
on	O
heightened	O
alert	O
for	O
MERS	O
-	O
CoV	O
as	O
first	O
cases	O
reach	O
the	O
US	O
.	O

While	O
both	O
patients	O
have	O
since	O
recovered	O
from	O
the	O
virus	O
and	O
been	O
released	O
,	O
the	O
cases	O
have	O
raised	O
awareness	O
of	O
the	O
infectious	B-DISO
threat	O
of	O
MERS	O
-	O
CoV	O
,	O
and	O
they	O
have	O
put	O
EDs	B-DISO
and	O
other	O
frontline	O
providers	O
on	O
heightened	O
alert	O
for	O
patients	O
with	O
severe	O
respiratory	B-DISO
symptoms	I-DISO
and	O
other	O
risk	O
factors	O
.	O

We	O
collected	O
1	O
,	O
254	O
samples	O
from	O
patients	O
diagnosed	O
with	O
respiratory	B-DISO
infection	I-DISO
in	O
southern	O
Thailand	O
from	O
July	O
2009	O
to	O
January	O
2011	O
and	O
screened	O
for	O
HCoV	O
by	O
RT	O
-	O
PCR	O
and	O
genotyped	O
by	O
BLAST	O
analysis	O
of	O
nsp12	O
gene	O
.	O

The	O
etiology	O
of	O
severe	O
pneumonia	B-DISO
is	O
complex	O
and	O
includes	O
the	O
newly	O
emerged	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

TITLE	O
:	O
Surface	O
tension	B-DISO
in	O
situ	O
in	O
flooded	O
alveolus	O
unaltered	O
by	O
albumin	O
.	O

TITLE	O
:	O
Gene	O
-	O
expression	O
patterns	O
in	O
the	O
cerebral	O
cortex	O
of	O
mice	O
infected	O
with	O
porcine	O
haemagglutinating	O
encephalomyelitis	B-DISO
virus	O
detected	O
using	O
microarray	O
.	O

ABSTRACT	O
:	O
Porcine	O
haemagglutinating	O
encephalomyelitis	B-DISO
virus	O
(	O
PHEV	O
)	O
is	O
the	O
main	O
causative	O
agent	O
of	O
porcine	O
coronavirus	O
-	O
associated	O
disease	O
,	O
which	O
is	O
characterized	O
by	O
encephalomyelitis	B-DISO
and	O
involves	O
the	O
central	O
nervous	B-DISO
system	O
.	O

Following	O
the	O
outbreak	O
of	O
an	O
infectious	B-DISO
disease	I-DISO
,	O
syndromic	O
surveillance	O
can	O
be	O
reassuring	O
in	O
the	O
absence	O
of	O
an	O
epidemic	O
.	O

ABSTRACT	O
:	O
Early	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
characterized	O
by	O
protein	O
-	O
rich	O
inflammatory	O
lung	B-DISO
edema	I-DISO
often	O
associated	O
with	O
a	O
hydrostatic	O
component	O
.	O

Fluid	B-DISO
overload	I-DISO
must	O
be	O
avoided	O
.	O

Co	B-DISO
-	I-DISO
infections	I-DISO
with	O
more	O
than	O
one	O
agent	O
were	O
detected	O
in	O
47	O
.	O
9	O
%	O
of	O
B	O
.	O
bronchiseptica	O
-	O
positive	O
,	O
82	O
.	O
6	O
%	O
of	O
CPIV	O
-	O
positive	O
,	O
and	O
100	O
%	O
of	O
CRCoV	O
-	O
positive	O
dogs	O
.	O

Mixed	B-DISO
infections	I-DISO
with	O
several	O
pathogens	O
were	O
common	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
failure	I-DISO
with	O
diffuse	O
pulmonary	O
opacities	B-DISO
is	O
an	O
unusual	O
manifestation	O
following	O
influenza	B-DISO
vaccination	O
.	O

Bronchoalveolar	O
lavage	O
was	O
compatible	O
with	O
acute	B-DISO
eosinophilic	I-DISO
pneumonia	I-DISO
.	O

No	O
disease	O
recurrence	B-DISO
was	O
observed	O
at	O
the	O
6	O
-	O
month	O
follow	O
-	O
up	O
.	O

The	O
majority	O
of	O
these	O
centers	O
(	O
77	O
%)	O
reported	O
""""	O
lung	O
rest	O
""""	O
to	O
be	O
the	O
primary	O
goal	O
of	O
mechanical	O
ventilation	O
,	O
whereas	O
9	O
%	O
reported	O
""""	O
lung	O
recruitment	B-DISO
""""	O
to	O
be	O
their	O
ventilation	O
strategy	O
.	O

The	O
inflammasome	O
has	O
evolved	O
for	O
this	O
purpose	O
and	O
is	O
an	O
important	O
surveillance	O
system	O
that	O
,	O
when	O
triggered	O
,	O
fights	O
infection	B-DISO
and	O
eliminates	O
pathogens	O
.	O

ABSTRACT	O
:	O
Data	O
on	O
the	O
efficacy	O
of	O
Peg	O
-	O
interferon	O
/	O
ribavirin	O
therapy	O
for	O
chronic	B-DISO
hepatitis	I-DISO
C	I-DISO
are	O
mostly	O
derived	O
from	O
treatment	O
of	O
selected	O
patients	O
enrolled	O
in	O
clinical	O
trials	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
inhaled	O
nitric	O
oxide	O
beyond	O
ARDS	B-DISO
.	O

INO	O
was	O
given	O
for	O
ARDS	B-DISO
,	O
but	O
coincidentally	O
it	O
also	O
improved	O
the	O
raised	B-DISO
intracranial	I-DISO
pressure	I-DISO
(	O
ICP	B-DISO
)	O
and	O
patient	O
'	O
s	O
neurological	O
outcome	O
.	O

Activation	O
of	O
the	O
three	O
branches	O
of	O
UPR	O
modulates	O
a	O
wide	O
variety	O
of	O
signaling	O
pathways	O
,	O
such	O
as	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
activation	O
,	O
autophagy	O
,	O
apoptosis	O
,	O
and	O
innate	B-DISO
immune	I-DISO
response	I-DISO
.	O

We	O
demonstrated	O
that	O
nonstructural	O
protein	O
(	O
NSP	O
)	O
6	O
of	O
the	O
avian	O
coronavirus	O
,	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
),	O
generates	O
autophagosomes	O
from	O
the	O
ER	O
.	O

ABSTRACT	O
:	O
The	O
Middle	O
-	O
East	O
Respiratory	O
Syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
causes	O
severe	O
acute	B-DISO
pneumonia	I-DISO
and	O
renal	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Antiretroviral	O
activity	O
of	O
metal	O
-	O
chelating	O
HIV	B-DISO
-	O
1	O
integrase	O
inhibitors	O
.	O

TITLE	O
:	O
From	O
SARS	B-DISO
in	O
2003	O
to	O
H1N1	O
in	O
2009	O
:	O
lessons	O
learned	O
from	O
Taiwan	O
in	O
preparation	O
for	O
the	O
next	O
pandemic	O
.	O

ABSTRACT	O
:	O
In	O
anticipation	O
of	O
a	O
future	O
pandemic	O
potentially	O
arising	O
from	O
H5N1	B-DISO
,	O
H7N9	O
avian	B-DISO
influenza	I-DISO
or	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
,	O
and	O
in	O
large	O
part	O
in	O
response	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
2003	O
,	O
the	O
city	O
of	O
Taipei	O
,	O
Taiwan	O
,	O
has	O
developed	O
extensive	O
new	O
strategies	O
to	O
manage	O
pandemics	O
.	O

As	O
Taipei	O
'	O
s	O
experiences	O
with	O
these	O
cases	O
illustrate	O
,	O
in	O
mitigating	O
moderate	O
or	O
severe	O
pandemic	O
influenza	B-DISO
,	O
a	O
graduated	O
process	O
including	O
Traffic	O
Control	O
Bundles	O
accompanied	O
by	O
hospital	O
and	O
medical	O
interventions	O
,	O
as	O
well	O
as	O
school	O
-	O
and	O
community	O
-	O
focused	O
interventions	O
,	O
provides	O
an	O
effective	O
interim	O
response	O
while	O
awaiting	O
vaccine	O
development	O
.	O

ABSTRACT	O
:	O
Docetaxel	O
is	O
a	O
standard	O
therapy	O
for	O
patients	O
with	O
castration	O
-	O
resistant	O
prostate	B-DISO
cancer	I-DISO
(	O
CRPC	O
).	O

In	O
addition	O
,	O
severe	O
non	O
-	O
hematological	O
AEs	O
included	O
colonic	O
perforation	O
,	O
interstitial	B-DISO
pneumonia	I-DISO
,	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
1	O
patient	O
each	O
.	O

The	O
prophylactic	O
application	O
of	O
antibiotics	O
after	O
a	O
dog	O
bite	O
should	O
be	O
considered	O
in	O
high	O
-	O
risk	O
individuals	O
with	O
immune	B-DISO
deficiency	I-DISO
in	O
order	O
to	O
prevent	O
both	O
Capnocytophyga	O
canimorsus	O
sepsis	B-DISO
and	O
serious	O
nosocomial	O
complications	O
.	O

TITLE	O
:	O
Early	O
diagnosis	O
of	O
leptospirosis	B-DISO
.	O

ABSTRACT	O
:	O
A	O
25	O
-	O
years	O
old	O
man	O
from	O
Zagreb	O
,	O
Croatia	O
,	O
was	O
admitted	O
to	O
the	O
University	O
Hospital	O
for	O
Infectious	B-DISO
Diseases	I-DISO
four	O
days	O
after	O
the	O
onset	O
of	O
symptoms	O
such	O
as	O
fever	O
,	O
intense	O
pain	O
in	O
the	O
calves	O
and	O
anuria	B-DISO
.	O

This	O
report	O
highlights	O
the	O
benefits	O
of	O
combining	O
MAT	O
and	O
PCR	O
methods	O
in	O
early	O
diagnosis	O
of	O
leptospirosis	B-DISO
.	O

Here	O
we	O
evaluated	O
the	O
miR	O
-	O
125b	O
-	O
based	O
strategy	O
in	O
treatment	O
of	O
ARDS	B-DISO
using	O
the	O
murine	O
model	O
of	O
lipopolysaccharide	O
(	O
LPS	B-DISO
)-	O
induced	O
ALI	O
.	O

Our	O
findings	O
strongly	O
demonstrated	O
that	O
enforced	O
expression	O
of	O
miR	O
-	O
125b	O
could	O
effectively	O
ameliorate	O
the	O
LPS	B-DISO
-	O
induced	O
ALI	O
,	O
suggesting	O
a	O
potential	O
application	O
for	O
miR	O
-	O
125b	O
-	O
based	O
therapy	O
to	O
treat	O
clinical	O
ARDS	B-DISO
.	O

Prior	O
to	O
admission	O
,	O
patient	O
had	O
dry	B-DISO
cough	I-DISO
and	O
bilateral	O
pleuritic	B-DISO
chest	I-DISO
pain	I-DISO
for	O
the	O
last	O
three	O
days	O
.	O

Chest	O
X	O
-	O
ray	O
analysis	O
was	O
suggestive	O
of	O
non	O
-	O
cardiac	O
pulmonary	B-DISO
edema	I-DISO
in	O
view	O
of	O
bilateral	O
fluffy	O
opacity	B-DISO
without	O
cardiomegaly	O
.	O

Assessment	O
of	O
micturition	O
patterns	O
by	O
filter	O
paper	O
assay	O
determined	O
an	O
increase	O
in	O
the	O
number	O
of	O
small	O
and	O
large	O
urine	O
spots	B-DISO
in	O
CIE	B-DISO
mice	O
starting	O
from	O
the	O
second	O
week	O
after	O
inoculation	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
a	O
highly	O
contagious	O
enteric	O
pathogen	O
of	O
swine	O
.	O

Interestingly	O
,	O
mitochondrial	O
apoptosis	O
-	O
inducing	O
factor	O
(	O
AIF	O
)	O
was	O
found	O
to	O
translocate	O
to	O
the	O
nucleus	O
during	O
PEDV	O
infection	B-DISO
,	O
and	O
AIF	O
relocalization	O
was	O
completely	O
abrogated	O
by	O
the	O
presence	O
of	O
cyclosporin	O
A	O
(	O
CsA	B-DISO
),	O
an	O
inhibitor	O
of	O
cyclophilin	O
D	O
(	O
CypD	O
)	O
that	O
is	O
an	O
essential	O
component	O
of	O
the	O
mitochondrial	O
permeabilization	O
transition	B-DISO
pore	O
(	O
mPTP	O
)	O
complex	O
.	O

CsA	B-DISO
treatment	O
resulted	O
in	O
significant	O
inhibition	O
of	O
PEDV	O
-	O
triggered	O
apoptosis	O
and	O
suppressed	O
PEDV	O
replication	O
.	O

Furthermore	O
,	O
direct	O
inhibition	O
of	O
AIF	O
strongly	O
impaired	B-DISO
PEDV	O
infection	B-DISO
and	O
virus	O
-	O
induced	O
apoptosis	O
.	O

The	O
aim	O
of	O
present	O
studies	O
was	O
to	O
characterize	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
capable	O
of	O
inhibiting	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
replication	O
in	O
chicken	O
lungs	O
after	O
in	O
ovo	O
administration	O
of	O
CpG	O
ODN	O
.	O

In	O
our	O
experiments	O
,	O
CpG	O
ODN	O
2007	O
or	O
PBS	B-DISO
solution	O
was	O
injected	O
on	O
18th	O
embryonic	O
day	O
(	O
ED	O
)	O
via	O
the	O
chorioallontoic	O
route	O
.	O

It	O
is	O
expected	O
that	O
understanding	O
of	O
the	O
innate	O
immune	O
modulation	O
of	O
target	O
tissues	O
by	O
the	O
virus	O
and	O
innate	O
immune	O
stimulants	O
will	O
be	O
helpful	O
in	O
identification	O
of	O
valuable	O
targets	O
for	O
development	O
of	O
novel	O
,	O
safe	O
,	O
effective	O
and	O
economical	O
control	O
strategies	O
against	O
IBV	O
infection	B-DISO
in	O
chickens	O
.	O

Influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pdm09	O
virus	O
was	O
detected	O
in	O
58	O
.	O
3	O
%	O
of	O
specimens	O
,	O
with	O
a	O
case	O
fatality	O
rate	O
of	O
11	O
.	O
3	O
%.	O

Similarly	O
,	O
the	O
imidazo	O
[	O
4	O
,	O
5	O
-	O
c	O
]	O
pyridines	O
and	O
N	O
-	O
benzylidenequinolinamines	O
derivatives	O
resulted	O
active	O
against	O
Bovine	B-DISO
Viral	I-DISO
Diarrhoea	I-DISO
virus	O
(	O
BVDV	O
),	O
at	O
concentrations	O
ranging	O
from	O
1	O
.	O
2	O
to	O
28	O
μM	O
.	O
Above	O
all	O
compounds	O
1	O
,	O
3a	O
and	O
3f	O
showed	O
an	O
EC50	O
of	O
the	O
same	O
order	O
of	O
magnitude	O
of	O
the	O
reference	O
drug	O
,	O
the	O
2	O
'-	O
C	O
-	O
methyl	O
-	O
guanosine	O
.	O

Parainfluenza	B-DISO
Virus	O
type	O
3	O
and	O
M	O
.	O
pneumoniae	O
were	O
found	O
alone	O
or	O
together	O
as	O
the	O
most	O
common	O
microorganisms	O
while	O
no	O
cases	O
of	O
human	O
bocavirus	O
,	O
adenovirus	B-DISO
,	O
rhinovirus	O
,	O
or	O
coronavirus	O
were	O
detected	O
.	O

Our	O
results	O
demonstrated	O
that	O
,	O
during	O
the	O
study	O
period	O
,	O
most	O
of	O
our	O
patients	O
had	O
atypical	O
pneumonia	B-DISO
due	I-DISO
to	I-DISO
Parainfluenza	I-DISO
Virus	I-DISO
type	O
3	O
and	O
M	O
.	O
pneumoniae	O
co	B-DISO
-	I-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
spread	O
rapidly	O
after	O
being	O
diagnosed	O
in	O
the	O
USA	O
in	O
April	O
2013	O
.	O

TITLE	O
:	O
Development	O
and	O
evaluation	O
of	O
a	O
duplex	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
for	O
detection	O
and	O
differentiation	O
of	O
virulent	O
and	O
variant	O
strains	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
viruses	O
from	O
the	O
United	O
States	O
.	O

Bats	O
,	O
which	O
harbour	O
a	O
diverse	O
pool	O
of	O
SARS	B-DISO
-	O
like	O
CoVs	O
(	O
SL	O
-	O
CoVs	O
),	O
are	O
believed	O
to	O
be	O
the	O
natural	O
reservoir	O
.	O

TITLE	O
:	O
Etiology	O
and	O
clinical	O
outcomes	O
of	O
acute	O
respiratory	B-DISO
virus	I-DISO
infection	I-DISO
in	O
hospitalized	O
adults	O
.	O

A	O
retrospective	O
observational	O
study	O
at	O
a	O
single	O
,	O
university	O
-	O
affiliated	O
center	O
was	O
performed	O
to	O
evaluate	O
the	O
respiratory	B-DISO
viral	I-DISO
infection	I-DISO
etiologies	O
in	O
children	O
compared	O
to	O
that	O
in	O
adults	O
and	O
to	O
document	O
the	O
clinical	O
features	O
of	O
common	O
viral	B-DISO
infections	I-DISO
for	O
adults	O
from	O
July	O
2009	O
to	O
April	O
2012	O
.	O

In	O
comparison	O
,	O
influenza	B-DISO
virus	O
A	O
(	O
IFA	O
)	O
had	O
the	O
highest	O
isolation	O
rate	O
(	O
28	O
.	O
5	O
%),	O
followed	O
by	O
hRV	O
(	O
15	O
.	O
5	O
%),	O
influenza	B-DISO
virus	O
B	O
(	O
IFB	O
)	O
(	O
15	O
.	O
0	O
%),	O
and	O
hMPV	O
(	O
14	O
.	O
0	O
%),	O
in	O
adults	O
(	O
763	O
total	O
patients	O
).	O

RESULTS	O
:	O
The	O
common	O
viruses	O
detected	O
from	O
children	O
(	O
2	O
,	O
800	O
total	O
patients	O
)	O
were	O
human	O
rhinovirus	O
(	O
hRV	O
)	O
(	O
31	O
.	O
8	O
%),	O
adenovirus	B-DISO
(	O
AdV	O
)	O
(	O
19	O
.	O
2	O
%),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
A	O
(	O
17	O
.	O
4	O
%),	O
RSV	O
B	O
(	O
11	O
.	O
7	O
%),	O
and	O
human	O
metapneumovirus	O
(	O
hMPV	O
)	O
(	O
9	O
.	O
8	O
%).	O

Here	O
we	O
use	O
it	O
to	O
confirm	O
and	O
extend	O
current	O
knowledge	O
on	O
the	O
entry	O
process	O
of	O
two	O
enveloped	O
viruses	O
:	O
vesicular	B-DISO
stomatitis	I-DISO
virus	O
(	O
VSV	O
)	O
and	O
murine	B-DISO
hepatitis	I-DISO
coronavirus	O
(	O
MHV	O
).	O

ABSTRACT	O
:	O
Administration	O
of	O
convalescent	O
plasma	O
,	O
serum	O
,	O
or	O
hyperimmune	O
immunoglobulin	O
may	O
be	O
of	O
clinical	O
benefit	O
for	O
treatment	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
(	O
SARIs	O
)	O
of	O
viral	O
etiology	O
.	O

TITLE	O
:	O
Rooting	O
the	O
phylogenetic	O
tree	O
of	O
middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
by	O
characterization	O
of	O
a	O
conspecific	O
virus	O
from	O
an	O
African	O
bat	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
currently	O
the	O
focus	O
of	O
global	O
attention	O
.	O

Those	O
who	O
develop	O
ill	B-DISO
health	O
during	O
their	O
trip	O
or	O
soon	O
after	O
their	O
return	O
should	O
seek	O
medical	O
care	O
.	O

TITLE	O
:	O
Modified	O
vaccinia	B-DISO
virus	O
ankara	O
(	O
MVA	O
)	O
as	O
production	O
platform	O
for	O
vaccines	O
against	O
influenza	B-DISO
and	O
other	O
viral	O
respiratory	B-DISO
diseases	I-DISO
.	O

ABSTRACT	O
:	O
Previously	O
we	O
revealed	O
that	O
the	O
extra	O
domain	O
of	O
SARS	B-DISO
3CLpro	O
mediated	O
the	O
catalysis	O
via	O
different	O
mechanisms	O
.	O

Differences	O
between	O
dairy	O
and	O
beef	O
cows	O
in	O
the	O
number	O
of	O
cases	O
of	O
diarrhea	B-DISO
and	O
rates	O
of	O
infection	B-DISO
by	O
Salmonella	B-DISO
spp	O
.	O

TITLE	O
:	O
From	O
SARS	B-DISO
to	O
MERS	O
:	O
crystallographic	O
studies	O
on	O
coronaviral	O
proteases	O
enable	O
antiviral	O
drug	O
design	O
.	O

The	O
crystal	O
structure	O
of	O
the	O
free	O
SARS	B-DISO
coronavirus	O
M	O
(	O
pro	O
)	O
and	O
its	O
dependence	B-DISO
on	I-DISO
pH	O
is	O
discussed	O
,	O
as	O
are	O
efforts	O
to	O
design	O
inhibitors	O
on	O
the	O
basis	O
of	O
these	O
structures	O
.	O

The	O
crystal	O
structure	O
of	O
the	O
SARS	B-DISO
coronavirus	O
PL	O
(	O
pro	O
)	O
and	O
its	O
complex	O
with	O
ubiquitin	O
is	O
also	O
discussed	O
,	O
as	O
is	O
its	O
orthologue	O
from	O
MERS	O
coronavirus	O
.	O

death	O
,	O
O2	O
dependence	B-DISO
at	O
36	O
weeks	O
(	O
BPD36wks	O
),	O
IVH	O
III	O
/	O
IV	O
,	O
ROPsur	O
,	O
NECsur	O
,	O
and	O
death	O
/	O
BPD36wks	O
.	O

The	O
conservative	O
approach	O
of	O
PDA	B-DISO
was	O
associated	O
to	O
high	O
mortality	O
,	O
the	O
surgical	O
approach	O
to	O
the	O
occurrence	O
of	O
BPD36wks	O
and	O
ROPsur	O
,	O
and	O
the	O
pharmacological	O
treatment	O
was	O
protective	O
for	O
the	O
outcome	O
death	O
/	O
BPD36wks	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
association	O
of	O
early	O
sedation	B-DISO
strategies	O
with	O
outcomes	O
of	O
critically	B-DISO
ill	I-DISO
adult	O
patients	O
under	O
mechanical	O
ventilation	O
(	O
MV	O
).	O

Early	O
deep	O
sedation	B-DISO
is	O
associated	O
with	O
adverse	O
outcomes	O
and	O
constitutes	O
an	O
independent	O
predictor	O
of	O
hospital	O
mortality	O
in	O
mechanically	O
ventilated	O
patients	O
.	O

In	O
a	O
multivariate	O
analysis	O
,	O
age	O
(	O
Odds	O
Ratio	O
(	O
OR	O
)	O
1	O
.	O
02	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
00	O
to	O
1	O
.	O
03	O
),	O
Charlson	O
Comorbidity	O
Index	O
>	O
2	O
(	O
OR	O
2	O
.	O
06	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
44	O
to	O
2	O
.	O
94	O
),	O
Simplified	O
Acute	O
Physiology	O
Score	O
3	O
(	O
SAPS	O
3	O
)	O
score	O
(	O
OR	O
1	O
.	O
02	O
;	O
CI	O
95	O
%,	O
1	O
.	O
00	O
to	O
1	O
.	O
04	O
),	O
severe	O
ARDS	B-DISO
(	O
OR	O
1	O
.	O
44	O
;	O
CI	O
95	O
%,	O
1	O
.	O
09	O
to	O
1	O
.	O
91	O
)	O
and	O
deep	O
sedation	B-DISO
(	O
OR	O
2	O
.	O
36	O
;	O
CI	O
95	O
%,	O
1	O
.	O
31	O
to	O
4	O
.	O
25	O
)	O
were	O
independently	O
associated	O
with	O
increased	O
hospital	O
mortality	O
.	O

The	O
maximal	O
superimposed	O
pressure	O
was	O
12	O
±	O
3	O
,	O
12	O
±	O
2	O
,	O
and	O
13	O
±	O
1	O
cm	O
H2O	O
in	O
mild	O
,	O
moderate	O
,	O
and	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
respectively	O
,	O
(	O
P	O
=	O
0	O
.	O
0533	O
)	O
with	O
a	O
corresponding	O
CT	O
-	O
derived	O
PEEP	O
of	O
16	O
±	O
5	O
,	O
16	O
±	O
5	O
,	O
and	O
18	O
±	O
5	O
cm	O
H2O	O
(	O
P	O
=	O
0	O
.	O
48	O
).	O

Recently	O
turkey	O
integrators	O
in	O
the	O
Southeastern	O
United	O
States	O
and	O
Arkansas	O
experienced	O
an	O
outbreak	O
of	O
moderate	O
to	O
severe	O
enteritis	B-DISO
associated	O
with	O
turkey	O
enteric	O
coronavirus	O
(	O
TCoV	O
),	O
and	O
numerous	O
enteric	O
samples	O
collected	O
from	O
turkey	O
flocks	O
in	O
these	O
areas	O
tested	O
positive	O
for	O
TCoV	O
via	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	O
PCR	O
(	O
RRT	O
-	O
PCR	O
).	O

Quantitative	O
RT	O
-	O
PCR	O
revealed	O
higher	O
mean	O
viral	O
loads	O
in	O
dunked	O
sputum	O
samples	O
compared	O
to	O
NTS	O
samples	O
for	O
Flu	B-DISO
A	O
,	O
RSV	O
,	O
and	O
HMPV	O
(	O
P	O
=	O
0	O
.	O
0001	O
,	O
P	O
=	O
0	O
.	O
006	O
,	O
and	O
P	O
=	O
0	O
.	O
011	O
,	O
respectively	O
).	O

Several	O
studies	O
have	O
demonstrated	O
the	O
role	O
of	O
neutralizing	O
antibodies	O
induced	O
by	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	O
in	O
protecting	O
susceptible	O
hosts	O
from	O
lethal	O
infection	B-DISO
.	O

In	O
this	O
study	O
,	O
we	O
assessed	O
the	O
ability	O
of	O
virus	O
-	O
specific	O
memory	O
CD8	O
T	O
cells	O
to	O
mediate	O
protection	O
against	O
infection	B-DISO
in	O
the	O
absence	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
specific	O
memory	O
CD4	O
T	O
or	O
B	O
cells	O
.	O

In	O
this	O
study	O
,	O
using	O
a	O
prime	O
-	O
boost	O
immunization	O
approach	O
,	O
we	O
showed	O
that	O
virus	O
-	O
specific	O
CD8	O
T	O
cells	O
protect	O
susceptible	O
8	O
-	O
to	O
10	O
-	O
month	O
-	O
old	O
mice	O
from	O
lethal	O
SARS	B-DISO
-	O
CoV	O
challenge	O
.	O

Efforts	O
to	O
inhibit	O
MERS	O
-	O
CoV	O
infection	B-DISO
by	O
targeting	O
host	O
cell	O
proteases	O
should	O
therefore	O
focus	O
on	O
enzymes	O
that	O
process	O
MERS	O
-	O
S	O
during	O
viral	O
uptake	O
into	O
target	O
cells	O
.	O

The	O
trachea	B-DISO
,	O
jugular	O
vein	O
and	O
femoral	O
artery	O
of	O
anesthetized	O
adult	O
rats	O
were	O
cannulated	O
.	O

The	O
recovery	O
efficiencies	O
were	O
determined	O
for	O
bovine	B-DISO
viral	I-DISO
diarrhea	I-DISO
virus	O
types	O
1	O
and	O
2	O
,	O
bovine	O
rotavirus	O
group	O
A	O
,	O
bovine	O
coronavirus	O
,	O
poliovirus	O
Sabin	O
III	O
,	O
toxigenic	O
Escherichia	O
coli	O
,	O
and	O
Campylobacter	O
jejuni	O
seeded	O
into	O
water	O
with	O
three	O
different	O
turbidity	O
levels	O
(	O
0	O
.	O
5	O
,	O
215	O
,	O
and	O
447	O
NTU	O
).	O

ABSTRACT	O
:	O
The	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
(	O
ARF	B-DISO
)	O
in	O
adults	O
is	O
growing	O
rapidly	O
given	O
recent	O
advances	O
in	O
technology	O
,	O
even	O
though	O
there	O
is	O
controversy	O
regarding	O
the	O
evidence	O
justifying	O
its	O
use	O
.	O

Adenovirus	B-DISO
(	O
2	O
.	O
07	O
%),	O
hMPV	O
(	O
2	O
.	O
78	O
%)	O
and	O
bocaviruses	O
(	O
0	O
.	O
56	O
%)	O
appear	O
to	O
be	O
rare	O
causative	O
agents	O
of	O
AECOPD	O
.	O

However	O
,	O
relatively	O
early	O
,	O
after	O
the	O
first	O
short	O
-	O
term	O
reports	O
were	O
published	O
,	O
a	O
relatively	O
high	O
complication	B-DISO
rate	O
became	O
evident	O
.	O

Here	O
we	O
describe	O
our	O
observations	O
of	O
SARS	B-DISO
-	O
CoV	O
using	O
ADE	O
to	O
enhance	O
the	O
infectivity	O
of	O
a	O
HL	O
-	O
CZ	O
human	O
promonocyte	O
cell	O
line	O
.	O

According	O
to	O
flow	O
cytometry	O
data	O
,	O
the	O
HL	O
-	O
CZ	O
cells	O
also	O
expressed	O
angiotensin	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
,	O
a	O
SARS	B-DISO
-	O
CoV	O
receptor	O
)	O
and	O
higher	O
levels	O
of	O
the	O
FcγRII	O
receptor	O
.	O

In	O
patient	O
1	O
,	O
who	O
died	O
of	O
refractory	O
ARDS	B-DISO
and	O
renal	B-DISO
failure	I-DISO
,	O
MERS	O
-	O
CoV	O
RNA	O
was	O
detected	O
in	O
pharyngeal	O
and	O
tracheal	O
swabs	O
,	O
as	O
well	O
blood	O
samples	O
and	O
urine	O
samples	O
until	O
the	O
30th	O
day	O
.	O

ABSTRACT	O
:	O
Hemolytic	B-DISO
-	I-DISO
uremic	I-DISO
syndrome	I-DISO
(	O
HUS	O
)	O
is	O
a	O
leading	O
cause	O
of	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
in	O
infants	O
and	O
young	O
children	O
.	O

Severe	O
cases	O
can	O
also	O
be	O
presented	O
by	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
toxic	B-DISO
megacolon	I-DISO
with	O
ileus	B-DISO
,	O
pancreatitis	B-DISO
,	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
disorders	O
and	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
(	O
MOF	B-DISO
).	O

ABSTRACT	O
:	O
Dromedary	O
camels	O
are	O
a	O
putative	O
source	O
for	O
human	O
infections	B-DISO
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
.	O

TITLE	O
:	O
Placement	O
of	O
a	O
caudal	O
vena	O
cava	O
stent	O
for	O
treatment	O
of	O
Budd	O
-	O
Chiari	O
-	O
like	O
syndrome	B-DISO
in	O
a	O
4	O
-	O
month	O
-	O
old	O
Ragdoll	O
cat	O
.	O

Active	O
,	O
prospective	O
,	O
continuous	O
,	O
hospital	O
-	O
based	O
SARI	O
surveillance	O
is	O
useful	O
in	O
supporting	O
pandemic	O
preparedness	O
for	O
emerging	O
influenza	B-DISO
A	O
(	O
H7N9	O
)	O
virus	O
infections	B-DISO
and	O
seasonal	O
influenza	B-DISO
prevention	O
and	O
control	O
.	O

Our	O
study	O
shows	O
that	O
IAPV	O
is	O
established	O
as	O
a	O
persistent	B-DISO
infection	I-DISO
in	O
honey	O
bee	O
populations	O
,	O
likely	O
enabled	O
by	O
both	O
horizontal	O
and	O
vertical	B-DISO
transmission	I-DISO
pathways	O
.	O

Nasal	O
/	O
Nasopharyngeal	O
swabs	O
were	O
tested	O
for	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
HCoV	O
-	O
22E	O
,	O
HCoV	O
-	O
OC43	O
,	O
HCoV	O
-	O
NL63	O
and	O
HCoV	O
-	O
HKU1	O
using	O
Reverse	O
Transcriptase	O
Real	O
-	O
Time	O
Polymerase	O
Chain	O
Reaction	O
.	O

ABSTRACT	O
:	O
Antibody	O
titers	O
after	O
vaccination	O
against	O
Infectious	B-DISO
Bronchitis	B-DISO
Virus	O
(	O
IBV	O
),	O
Newcastle	B-DISO
Disease	I-DISO
Virus	O
(	O
NDV	O
)	O
and	O
after	O
natural	O
infection	B-DISO
with	O
Campylobacter	O
were	O
analyzed	O
in	O
five	O
trials	O
with	O
Lohmann	O
Silver	O
laying	O
hens	O
kept	O
in	O
two	O
different	O
housing	O
systems	O
.	O

TITLE	O
:	O
Clathrin	O
-	O
and	O
serine	O
proteases	O
-	O
dependent	O
uptake	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
into	O
Vero	O
cells	O
.	O

A	O
live	O
attenuated	O
duck	O
enteritis	B-DISO
virus	O
(	O
DEV	O
;	O
a	O
herpesvirus	O
)	O
vaccine	O
has	O
been	O
used	O
routinely	O
to	O
control	O
lethal	O
DEV	O
in	O
ducks	O
since	O
the	O
1960s	O
.	O

The	O
respiratory	O
viruses	O
detected	O
using	O
a	O
multiplex	O
real	O
-	O
time	O
-	O
polymerase	O
chain	O
reaction	O
kit	O
were	O
influenza	B-DISO
virus	O
(	O
A	O
/	O
H1N1	O
,	O
A	O
/	O
H3N2	O
,	O
A	O
/	O
H5N1	B-DISO
,	O
and	O
B	O
),	O
adenovirus	B-DISO
,	O
parainfluenza	B-DISO
virus	O
(	O
type	O
1	O
,	O
2	O
,	O
3	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
type	O
A	O
,	O
B	O
),	O
human	O
rhinovirus	O
,	O
human	O
coronavirus	O
(	O
OC43	O
/	O
229E	O
,	O
NL63	O
),	O
human	O
bocavirus	O
,	O
and	O
enterovirus	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
have	O
traditionally	O
been	O
associated	O
with	O
mild	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
throughout	O
the	O
world	O
.	O

In	O
contrast	O
,	O
MERS	O
is	O
relatively	O
inefficiently	O
transmitted	B-DISO
to	O
humans	O
but	O
has	O
a	O
high	O
mortality	O
rate	O
.	O

This	O
review	O
highlights	O
pathological	O
aspects	O
related	O
to	O
two	O
pre	O
-	O
clinical	O
viral	O
models	O
for	O
MS	O
;	O
data	O
are	O
consistent	O
between	O
these	O
two	O
models	O
as	O
experimental	O
infection	B-DISO
of	O
susceptible	O
mice	O
can	O
induce	O
axonal	O
degeneration	B-DISO
associated	O
with	O
demyelination	B-DISO
.	O

Clinical	O
signs	O
of	O
PEDV	O
infection	B-DISO
(	O
vomiting	B-DISO
and	O
diarrhea	B-DISO
)	O
and	O
viral	B-DISO
shedding	I-DISO
were	O
observed	O
in	O
both	O
the	O
Positive	O
control	O
and	O
Treatment	O
group	O
'	O
post	O
-	O
consumption	O
with	O
virus	O
and	O
microscopic	O
lesions	O
detected	O
in	O
intestinal	O
samples	O
No	O
evidence	O
of	O
infection	B-DISO
was	O
observed	O
in	O
the	O
Negative	O
controls	O
.	O

ABSTRACT	O
:	O
HIV	B-DISO
-	O
1	O
reverse	O
transcriptase	O
(	O
RT	O
)-	O
associated	O
RNase	O
H	O
activity	O
is	O
an	O
essential	O
function	O
in	O
viral	O
genome	O
retrotranscription	O
.	O

Overall	O
,	O
we	O
provide	O
the	O
first	O
demonstration	O
that	O
RNase	O
H	O
inhibition	O
by	O
DKAs	O
is	O
due	O
not	O
only	O
to	O
their	O
chelating	O
properties	O
but	O
also	O
to	O
specific	O
interactions	O
with	O
highly	O
conserved	O
amino	O
acid	O
residues	O
in	O
the	O
RNase	O
H	O
domain	O
,	O
leading	O
to	O
effective	O
targeting	O
of	O
HIV	B-DISO
retrotranscription	O
in	O
cells	O
and	O
hence	O
offering	O
important	O
insights	O
for	O
the	O
rational	O
design	O
of	O
RNase	O
H	O
inhibitors	O
.	O

It	O
has	O
been	O
shown	O
that	O
the	O
envelope	O
(	O
E	O
)	O
protein	O
plays	O
a	O
variable	O
role	O
in	O
CoV	O
morphogenesis	O
,	O
depending	O
on	O
the	O
CoV	O
genus	O
,	O
being	O
absolutely	O
essential	O
in	O
some	O
cases	O
(	O
genus	O
α	O
CoVs	O
such	O
as	O
TGEV	O
,	O
and	O
genus	O
β	O
CoVs	O
such	O
as	O
MERS	O
-	O
CoV	O
),	O
but	O
not	O
in	O
others	O
(	O
genus	O
β	O
CoVs	O
such	O
as	O
MHV	O
or	O
SARS	B-DISO
-	O
CoV	O
).	O

In	O
fact	O
,	O
E	O
protein	O
is	O
responsible	O
in	O
a	O
significant	O
proportion	O
of	O
the	O
inflammasome	O
activation	O
and	O
the	O
associated	O
inflammation	B-DISO
elicited	O
by	O
SARS	B-DISO
-	O
CoV	O
in	O
the	O
lung	O
parenchyma	O
.	O

This	O
exacerbated	O
inflammation	B-DISO
causes	O
edema	B-DISO
accumulation	O
leading	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
,	O
frequently	O
,	O
to	O
the	O
death	O
of	O
infected	O
animal	O
models	O
or	O
human	O
patients	O
.	O

TITLE	O
:	O
Sweet	B-DISO
'	I-DISO
s	I-DISO
syndrome	I-DISO
.	O

In	O
this	O
study	O
,	O
we	O
exploited	O
the	O
model	O
coronavirus	O
,	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
),	O
to	O
investigate	O
the	O
genotype	O
and	O
phenotype	O
of	O
MHV	O
quasispecies	O
selected	O
for	O
resistance	O
to	O
a	O
broad	O
-	O
spectrum	O
CoV	O
3C	O
-	O
like	O
protease	O
(	O
3CLpro	O
)	O
inhibitor	O
.	O

We	O
extended	O
the	O
chimeric	O
-	O
virus	O
platform	O
to	O
evaluate	O
the	O
papain	O
-	O
like	O
protease	O
/	O
deISGylating	O
activity	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
to	O
provide	O
a	O
small	O
-	O
animal	O
model	O
to	O
evaluate	O
PLpro	O
inhibitors	O
of	O
this	O
recently	O
emerged	O
pathogen	O
.	O

We	O
aimed	O
to	O
identify	O
the	O
epidemiological	O
and	O
microbiological	O
risk	O
factors	O
associated	O
with	O
noma	B-DISO
disease	O
.	O

At	O
24	O
h	O
post	O
-	O
infection	B-DISO
,	O
inflammatory	O
cytokines	O
related	O
genes	O
were	O
significantly	O
upregulated	O
,	O
including	O
peaks	O
of	O
TNFSF15	O
and	O
TGFβ	O
mRNA	O
production	O
,	O
although	O
no	O
tracheal	O
microscopic	O
alterations	O
were	O
observed	O
and	O
only	O
a	O
slightly	O
increase	O
in	O
viral	O
load	O
occurred	O
.	O

ABSTRACT	O
:	O
Mounting	O
reports	O
on	O
severe	O
Plasmodium	B-DISO
vivax	I-DISO
malaria	I-DISO
from	O
across	O
the	O
globe	O
have	O
raised	O
concerns	O
among	O
the	O
scientific	O
community	O
.	O

Plasmodium	O
falciparum	O
had	O
significantly	O
higher	O
odds	O
[	O
adjusted	O
odds	O
ratio	O
(	O
95	O
%	O
CI	O
),	O
2	O
.	O
80	O
(	O
2	O
.	O
04	O
-	O
3	O
.	O
83	O
)]	O
of	O
severe	O
malaria	B-DISO
than	O
P	O
.	O
vivax	O
.	O

Pulmonary	B-DISO
oedema	I-DISO
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
P	O
.	O
vivax	O
infection	B-DISO
could	O
lead	O
to	O
mortality	O
and	O
therefore	O
should	O
be	O
diagnosed	O
and	O
treated	O
promptly	O
.	O

RESULTS	O
:	O
Of	O
922	O
malaria	B-DISO
cases	O
included	O
in	O
the	O
study	O
,	O
P	O
.	O
vivax	O
was	O
the	O
largest	O
(	O
63	O
.	O
4	O
%,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
60	O
.	O
3	O
-	O
66	O
.	O
5	O
%)	O
infecting	O
species	O
,	O
followed	O
by	O
P	O
.	O
falciparum	O
(	O
34	O
.	O
4	O
%,	O
95	O
%	O
CI	O
31	O
.	O
3	O
-	O
37	O
.	O
5	O
%)	O
and	O
their	O
mixed	B-DISO
infection	I-DISO
(	O
2	O
.	O
2	O
%,	O
95	O
%	O
CI	O
1	O
.	O
3	O
-	O
3	O
.	O
2	O
%).	O

ABSTRACT	O
:	O
Current	O
teaching	O
and	O
guidelines	O
suggest	O
that	O
aggressive	B-DISO
fluid	O
resuscitation	O
is	O
the	O
best	O
initial	O
approach	O
to	O
the	O
patient	O
with	O
hemodynamic	B-DISO
instability	I-DISO
.	O

The	O
source	O
of	O
this	O
wisdom	O
is	O
difficult	O
to	O
discern	O
,	O
however	O
,	O
Early	O
Goal	O
Directed	O
therapy	O
(	O
EGDT	O
)	O
as	O
championed	O
by	O
Rivers	O
et	O
al	O
.	O
and	O
the	O
Surviving	O
Sepsis	B-DISO
Campaign	O
Guidelines	O
appears	O
to	O
have	O
established	O
this	O
as	O
the	O
irrefutable	O
truth	O
.	O

However	O
,	O
over	O
the	O
last	O
decade	O
it	O
has	O
become	O
clear	O
that	O
aggressive	B-DISO
fluid	O
resuscitation	O
leading	O
to	O
fluid	B-DISO
overload	I-DISO
is	O
associated	O
with	O
increased	O
morbidity	O
and	O
mortality	O
across	O
a	O
diverse	O
group	O
of	O
patients	O
,	O
including	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
as	O
well	O
as	O
elective	O
surgical	O
and	O
trauma	O
patients	O
and	O
those	O
with	O
pancreatitis	B-DISO
.	O

TITLE	O
:	O
Extracorporeal	O
support	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

Arterial	O
blood	O
gas	O
analysis	O
at	O
ICU	O
admission	O
revealed	O
profound	O
hypoxia	B-DISO
.	O

HAdV	O
-	O
55	O
may	O
cause	O
severe	O
ARDS	B-DISO
in	O
immunocompetent	O
young	O
men	O
.	O

RESULTS	O
:	O
The	O
results	O
for	O
a	O
total	O
of	O
five	O
consecutive	O
patients	O
with	O
severe	O
ARDS	B-DISO
with	O
confirmed	O
HAdV	O
-	O
55	O
infection	B-DISO
were	O
included	O
.	O

Respiratory	O
syndromes	B-DISO
caused	O
by	O
coronavirus	B-DISO
infections	I-DISO
in	O
humans	O
range	O
in	O
severity	O
from	O
the	O
common	B-DISO
cold	I-DISO
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
associated	O
with	O
human	O
coronavirus	O
OC43	O
and	O
other	O
viral	O
strains	O
.	O

We	O
describe	O
a	O
case	O
of	O
coronavirus	O
OC43	O
infection	B-DISO
in	O
an	O
infant	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
treated	O
with	O
heliox	O
inhalation	O
to	O
avoid	O
intubation	O
.	O

Silencing	O
of	O
syntenin	O
using	O
siRNAs	O
led	O
to	O
a	O
decrease	O
in	O
p38	O
MAPK	O
activation	O
in	O
SARS	B-DISO
-	O
CoV	O
infected	O
cells	O
,	O
further	O
reinforcing	O
their	O
functional	O
relationship	O
.	O

Therefore	O
,	O
the	O
E	O
protein	O
PBM	O
is	O
a	O
virulence	O
domain	O
that	O
activates	O
immunopathology	B-DISO
most	O
likely	O
by	O
using	O
syntenin	O
as	O
a	O
mediator	O
of	O
p38	O
MAPK	O
induced	O
inflammation	B-DISO
.	O

Expression	O
of	O
TMPRSS2	O
is	O
essential	O
for	O
the	O
spread	O
and	O
pathogenesis	B-DISO
of	O
H1N1	B-DISO
influenza	I-DISO
viruses	O
in	O
mice	O
.	O

ABSTRACT	O
:	O
To	O
compare	O
unilateral	O
lung	O
and	O
traditional	O
lung	O
recruitment	B-DISO
maneuver	O
(	O
RM	O
)	O
in	O
animals	O
with	O
unilateral	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
by	O
implementing	O
independent	O
lung	O
ventilation	O
,	O
and	O
to	O
explore	O
the	O
rational	O
mechanical	O
ventilation	O
strategy	O
for	O
unilateral	O
lung	O
lesions	O
.	O

MicroRNAs	O
are	O
likely	O
to	O
play	O
major	O
roles	O
in	O
regulating	O
virus	O
-	O
host	O
interaction	O
in	O
bats	O
,	O
via	O
dampening	O
of	O
inflammatory	B-DISO
responses	I-DISO
(	O
limiting	O
the	O
effects	O
of	O
immunopathology	B-DISO
),	O
and	O
directly	O
limiting	O
the	O
extent	O
of	O
viral	O
replication	O
,	O
either	O
through	O
restricting	O
the	O
availability	O
of	O
essential	O
factors	O
or	O
by	O
controlling	O
apoptosis	O
.	O

Infectious	B-DISO
diseases	I-DISO
associated	O
with	O
mass	O
gatherings	O
vary	O
depending	O
on	O
the	O
type	O
and	O
location	O
of	O
the	O
mass	O
gathering	O
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
examine	O
the	O
indications	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Two	O
waves	O
of	O
coronavirus	B-DISO
infections	I-DISO
were	O
identified	O
:	O
one	O
in	O
spring	O
(	O
April	O
and	O
May	O
)	O
and	O
another	O
in	O
late	O
autumn	O
(	O
October	O
to	O
December	O
).	O

Conditioned	O
medium	O
collected	O
from	O
an	O
in	O
vitro	O
lipopolysaccharide	O
-	O
induced	O
airway	O
epithelial	O
cell	B-DISO
injury	I-DISO
model	O
using	O
human	O
A549	O
alveolar	O
cells	O
was	O
subsequently	O
added	O
at	O
increasing	O
concentrations	O
(	O
no	O
conditioned	O
,	O
2	O
%,	O
5	O
%,	O
10	O
%,	O
15	O
%,	O
25	O
%,	O
and	O
50	O
%)	O
to	O
a	O
rat	O
mixed	O
brain	O
cell	O
culture	O
containing	O
both	O
astrocytes	O
and	O
neurons	O
.	O

The	O
severity	O
of	O
neuroinflammation	O
and	O
demyelination	B-DISO
in	O
FTY720	O
-	O
treated	O
mice	O
was	O
examined	O
by	O
flow	O
cytometry	O
and	O
histopathologically	O
,	O
respectively	O
,	O
in	O
the	O
spinal	O
cords	O
of	O
the	O
mice	O
.	O

In	O
this	O
study	O
,	O
we	O
inoculated	O
three	O
Japanese	O
draft	O
horses	O
with	O
an	O
ECoV	O
-	O
positive	O
diarrheic	O
fecal	O
sample	O
to	O
confirm	O
infection	B-DISO
after	O
inoculation	O
and	O
to	O
investigate	O
the	O
clinical	O
course	O
and	O
virus	B-DISO
shedding	I-DISO
patterns	O
of	O
ECoV	O
.	O
Virus	O
neutralization	O
tests	O
showed	O
that	O
all	O
three	O
horses	O
became	O
infected	O
with	O
ECoV	O
.	O
Two	O
of	O
the	O
three	O
horses	O
developed	O
clinical	O
signs	O
similar	O
to	O
those	O
observed	O
during	O
ECoV	O
outbreaks	O
,	O
including	O
fever	O
,	O
anorexia	B-DISO
,	O
and	O
gastrointestinal	O
dysfunction	O
.	O

Here	O
,	O
we	O
report	O
that	O
inositol	O
-	O
requiring	O
protein	O
1	O
alpha	O
(	O
IRE1α	O
),	O
a	O
key	O
sensor	O
of	O
ER	O
stress	O
,	O
is	O
activated	O
in	O
cells	O
infected	O
with	O
the	O
avian	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
).	O

We	O
prospectively	O
recruited	O
patients	O
consecutively	O
admitted	O
for	O
ARF	B-DISO
to	O
the	O
ICU	O
of	O
a	O
university	O
teaching	O
hospital	O
over	O
a	O
12	O
-	O
month	O
period	O
.	O

Inclusion	O
criteria	O
were	O
age	O
≥	O
18	O
years	O
and	O
the	O
presence	O
of	O
criteria	O
for	O
severe	O
ARF	B-DISO
justifying	O
ICU	O
admission	O
.	O

The	O
value	O
of	O
the	O
TUS	O
approach	O
was	O
particularly	O
important	O
to	O
disambiguate	O
cases	O
of	O
hemodynamic	O
pulmonary	B-DISO
edema	I-DISO
and	O
pneumonia	B-DISO
.	O

From	O
July	O
2012	O
to	O
July	O
2013	O
,	O
116	O
severe	O
ARDS	B-DISO
patients	O
sequentially	O
admitted	O
to	O
the	O
critical	O
department	O
of	O
Peking	O
Union	O
Medical	O
College	O
Hospital	O
were	O
enrolled	O
in	O
the	O
study	O
with	O
60	O
patients	O
assigned	O
to	O
the	O
control	O
group	O
and	O
56	O
patients	O
to	O
the	O
intervention	O
group	O
.	O

No	O
significant	O
difference	O
was	O
found	O
between	O
the	O
two	O
groups	O
in	O
the	O
demographics	O
including	O
the	O
median	O
patient	O
age	O
,	O
sex	O
ratio	O
,	O
initial	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
scores	O
,	O
initial	O
pulmonary	O
function	O
and	O
the	O
sources	O
of	O
ARDS	B-DISO
.	O

RESULTS	O
:	O
From	O
July	O
2012	O
to	O
July	O
2013	O
,	O
116	O
severe	O
ARDS	B-DISO
patients	O
sequentially	O
admitted	O
to	O
the	O
critical	O
department	O
of	O
Peking	O
Union	O
Medical	O
College	O
Hospital	O
were	O
enrolled	O
in	O
the	O
study	O
with	O
60	O
patients	O
assigned	O
to	O
the	O
control	O
group	O
and	O
56	O
patients	O
to	O
the	O
intervention	O
group	O
.	O

Application	O
of	O
BDNF	O
can	O
reverse	O
hyperexcitability	O
in	O
acute	O
brainstem	O
slices	O
from	O
Mecp2	O
-	O
null	O
mice	O
,	O
suggesting	O
that	O
therapies	O
targeting	O
BDNF	O
or	O
its	O
receptor	O
,	O
TrkB	O
,	O
could	O
be	O
effective	O
at	O
acute	O
reversal	O
of	O
respiratory	B-DISO
abnormalities	I-DISO
in	O
RTT	B-DISO
.	O

TITLE	O
:	O
Eculizumab	O
in	O
neonatal	O
hemolytic	B-DISO
uremic	I-DISO
syndrome	I-DISO
with	O
homozygous	O
factor	B-DISO
H	I-DISO
deficiency	I-DISO
.	O

Part	O
16	O
:	O
Structure	O
-	O
based	O
bioisosterism	O
design	O
,	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
novel	O
pyrimidinylthioacetanilides	O
as	O
potent	O
HIV	B-DISO
-	O
1	O
inhibitors	O
.	O

Most	O
of	O
the	O
tested	O
compounds	O
were	O
proved	O
to	O
be	O
effective	O
in	O
inhibiting	O
HIV	B-DISO
-	O
1	O
(	O
IIIB	O
)	O
replication	O
with	O
EC50	O
ranging	O
from	O
0	O
.	O
15	O
μM	O
to	O
24	O
.	O
2	O
μM	O
,	O
thereinto	O
compound	O
15	O
was	O
the	O
most	O
active	O
lead	O
with	O
favorable	O
inhibitory	O
activity	O
against	O
HIV	B-DISO
-	O
1	O
(	O
IIIB	O
)	O
(	O
EC50	O
=	O
0	O
.	O
15	O
μM	O
,	O
SI	O
=	O
684	O
).	O

Similarly	O
ORF3c	O
from	O
faecal	O
samples	O
of	O
the	O
cats	O
with	O
FIP	B-DISO
was	O
mostly	O
intact	O
and	O
showed	O
only	O
in	O
a	O
few	O
cases	O
the	O
same	O
mutations	O
found	O
in	O
the	O
respective	O
ascites	O
samples	O
.	O

If	O
iNO	O
was	O
initiated	O
for	O
severe	O
respiratory	B-DISO
failure	I-DISO
,	O
a	O
detailed	O
evaluation	O
by	O
the	O
ECMO	O
team	O
determined	O
if	O
ECMO	O
was	O
indicated	O
.	O

At	O
the	O
time	O
of	O
the	O
alert	O
,	O
the	O
median	O
PaO₂	O
-	O
to	O
-	O
FIO₂	O
ratio	O
was	O
64	O
mm	O
Hg	O
(	O
range	O
,	O
55	O
-	O
107	O
mm	O
Hg	O
),	O
the	O
median	O
age	O
-	O
adjusted	O
oxygenation	O
index	O
was	O
73	O
(	O
range	O
,	O
51	O
-	O
96	O
),	O
and	O
the	O
median	O
Murray	O
score	O
was	O
3	O
.	O
4	O
(	O
range	O
,	O
3	O
-	O
3	O
.	O
75	O
),	O
indicating	O
severe	O
respiratory	B-DISO
failure	I-DISO
.	O

We	O
studied	O
26	O
index	O
patients	O
with	O
MERS	O
-	O
CoV	O
infection	B-DISO
and	O
their	O
280	O
household	O
contacts	O
.	O

Maintenance	O
of	O
adequate	O
oxygenation	O
in	O
the	O
postoperative	O
period	O
is	O
of	O
major	O
importance	O
,	O
especially	O
when	O
pulmonary	B-DISO
complications	I-DISO
such	O
as	O
ARF	B-DISO
occur	O
.	O

Non	O
-	O
invasive	O
ventilation	O
(	O
NIV	O
)	O
does	O
not	O
require	O
endotracheal	O
tube	O
or	O
tracheotomy	O
and	O
its	O
use	O
is	O
well	O
established	O
to	O
prevent	O
ARF	B-DISO
occurrence	O
(	O
prophylactic	O
treatment	O
)	O
or	O
to	O
treat	O
ARF	B-DISO
to	O
avoid	O
reintubation	O
(	O
curative	O
treatment	O
).	O

Rationale	O
for	O
postoperative	O
NIV	O
use	O
is	O
the	O
same	O
as	O
the	O
post	O
-	O
extubation	O
NIV	O
use	O
plus	O
the	O
specificities	O
due	O
to	O
the	O
respiratory	O
modifications	O
induced	O
by	O
the	O
surgery	O
and	O
anesthesia	B-DISO
.	O

The	O
aims	O
of	O
this	O
article	O
are	O
(	O
1	O
)	O
to	O
review	O
the	O
main	O
respiratory	O
modifications	O
induced	O
by	O
surgery	O
and	O
anesthesia	B-DISO
which	O
justify	O
postoperative	O
NIV	O
use	O
(	O
2	O
)	O
to	O
offer	O
some	O
recommendations	O
to	O
apply	O
safely	O
postoperative	O
NIV	O
and	O
(	O
3	O
)	O
to	O
present	O
the	O
main	O
results	O
obtained	O
with	O
preventive	O
and	O
curative	O
NIV	O
in	O
a	O
surgical	O
context	O
.	O

TITLE	O
:	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
and	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	B-DISO
infection	I-DISO
induces	O
dramatic	O
changes	O
in	O
the	O
tight	O
junctions	O
and	O
microfilaments	O
of	O
polarized	O
IPEC	O
-	O
J2	O
cells	O
.	O

Eight	O
hospitals	O
were	O
selected	O
in	O
six	O
provinces	O
from	O
a	O
national	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
surveillance	O
network	O
.	O

RSV	O
,	O
influenza	B-DISO
,	O
PIV	O
,	O
hBoV	O
and	O
hMPV	O
all	O
showed	O
the	O
nature	O
of	O
seasonality	O
.	O

RESULTS	O
:	O
4	O
508	O
hospitalized	O
children	O
less	O
than	O
five	O
years	O
old	O
,	O
with	O
pneumonia	B-DISO
from	O
8	O
hospitals	O
were	O
included	O
,	O
and	O
2	O
688	O
(	O
59	O
.	O
6	O
%)	O
patients	O
were	O
positive	O
for	O
at	O
least	O
one	O
viral	O
etiology	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
zoonotic	B-DISO
infection	I-DISO
causing	O
severe	O
viral	B-DISO
pneumonia	I-DISO
,	O
with	O
index	O
cases	O
having	O
resided	O
in	O
or	O
recently	O
travelled	O
to	O
the	O
Arabian	O
peninsula	O
,	O
and	O
is	O
a	O
global	O
concern	O
for	O
public	O
health	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygen	O
(	O
ECMO	O
)	O
has	O
been	O
used	O
for	O
many	O
years	O
in	O
patients	O
with	O
life	O
-	O
threatening	O
hypoxaemia	O
and	O
/	O
or	O
hypercarbia	B-DISO
.	O

RESULTS	O
:	O
Viral	O
etiology	O
was	O
established	O
in	O
fifty	O
-	O
two	O
(	O
34	O
.	O
9	O
%)	O
of	O
149	O
CAP	B-DISO
patients	O
,	O
twenty	O
-	O
two	O
(	O
81	O
.	O
5	O
%)	O
of	O
27	O
influenza	B-DISO
like	I-DISO
illness	I-DISO
patients	O
,	O
and	O
none	O
of	O
75	O
volunteer	O
controls	O
.	O

CONCLUSIONS	O
:	O
Respiratory	O
virus	O
was	O
not	O
a	O
bystander	O
,	O
but	O
pathogenic	O
in	O
pneumonia	B-DISO
and	O
was	O
a	O
common	O
cause	O
of	O
CAP	B-DISO
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
associated	O
with	O
significant	O
mortality	O
and	O
morbidity	O
in	O
survivors	O
.	O

Sepsis	B-DISO
-	O
associated	O
cardiac	O
dysfunction	O
occurred	O
in	O
44	O
patients	O
(	O
36	O
.	O
1	O
%).	O

CD4	O
T	O
-	O
cell	O
depletion	O
before	O
infection	B-DISO
did	O
not	O
impair	O
peripheral	O
expansion	O
,	O
interferon	O
-	O
γ	O
production	O
,	O
CNS	O
recruitment	B-DISO
or	O
initial	O
CNS	O
effector	O
capacity	O
of	O
virus	O
-	O
specific	O
CD8	O
T	O
cells	O
ex	O
vivo	O
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
NL63	O
(	O
HCoV	O
-	O
NL63	O
)	O
is	O
an	O
alphacoronavirus	O
that	O
was	O
first	O
identified	O
in	O
2004	O
in	O
the	O
nasopharyngeal	O
aspirate	O
from	O
a	O
7	O
-	O
month	O
-	O
old	O
patient	O
with	O
a	O
respiratory	B-DISO
tract	I-DISO
infection	I-DISO
.	O

Conducted	O
research	O
showed	O
that	O
heparan	O
sulfate	O
proteoglycans	O
function	O
as	O
adhesion	B-DISO
molecules	O
,	O
increasing	O
the	O
virus	O
density	O
on	O
cell	O
surface	O
and	O
possibly	O
facilitating	O
the	O
interaction	O
between	O
HCoV	O
-	O
NL63	O
and	O
its	O
receptor	O
.	O

MERS	O
-	O
CoV	O
infection	B-DISO
actively	O
causes	O
disease	O
in	O
environments	O
with	O
low	O
relative	O
humidity	O
(<	O
20	O
%)	O
and	O
high	O
temperature	O
(	O
15	O
°	O
C	O
-	O
35	O
°	O
C	O
).	O

TITLE	O
:	O
Replacement	O
of	O
anesthesia	B-DISO
machines	O
improves	O
intraoperative	O
ventilation	O
parameters	O
associated	O
with	O
the	O
development	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

We	O
hypothesized	O
a	O
change	O
in	O
anesthesia	B-DISO
machines	O
would	O
be	O
associated	O
with	O
parameters	O
associated	O
with	O
lower	O
rates	O
of	O
ARDS	B-DISO
.	O

Since	O
then	O
,	O
we	O
have	O
witnessed	O
the	O
emergence	O
of	O
several	O
other	O
viral	O
respiratory	O
pathogens	O
including	O
influenza	B-DISO
viruses	O
(	O
avian	B-DISO
influenza	I-DISO
H5N1	B-DISO
,	O
H7N9	O
,	O
and	O
H10N8	O
;	O
variant	O
influenza	B-DISO
A	O
H3N2	O
virus	O
),	O
human	O
adenovirus	B-DISO
-	O
14	O
,	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

TITLE	O
:	O
Emerging	O
novel	O
and	O
antimicrobial	O
-	O
resistant	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
:	O
new	O
drug	O
development	O
and	O
therapeutic	O
options	O
.	O

New	O
viral	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
with	O
epidemic	O
potential	O
,	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
swine	O
-	O
origin	O
influenza	B-DISO
A	O
H1N1	O
,	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	B-DISO
infection	I-DISO
,	O
require	O
development	O
of	O
new	O
antiviral	O
agents	O
.	O

TITLE	O
:	O
Successful	O
treatment	O
of	O
Panton	O
-	O
Valentine	O
leukocidin	O
-	O
expressing	O
Staphylococcus	O
aureus	O
-	O
associated	O
pneumonia	B-DISO
co	O
-	O
infected	O
with	O
influenza	B-DISO
using	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

We	O
report	O
a	O
patient	O
with	O
life	O
-	O
threatening	O
PVL	O
-	O
expressing	O
S	O
.	O
aureus	O
-	O
associated	O
pneumonia	B-DISO
who	O
was	O
rescued	O
using	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
).	O

In	O
this	O
case	O
report	O
we	O
present	O
an	O
end	O
stage	O
patient	O
with	O
adenocarcinoma	B-DISO
of	I-DISO
ampulla	I-DISO
of	I-DISO
Vater	I-DISO
with	O
involvement	O
of	O
both	O
abdomen	O
and	O
thorax	O
who	O
presented	O
with	O
severe	O
intractable	O
abdominal	B-DISO
pain	I-DISO
.	O

Bilateral	O
celiac	O
plexus	O
block	O
in	O
this	O
patient	O
resulted	O
in	O
left	O
side	O
pneumothorax	B-DISO
and	O
subsequent	O
development	O
of	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Immunogenicity	O
of	O
an	O
adenoviral	O
-	O
based	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
coronavirus	O
vaccine	O
in	O
BALB	O
/	O
c	O
mice	O
.	O

In	O
an	O
initial	O
attempt	O
to	O
develop	O
a	O
MERS	O
-	O
CoV	O
vaccine	O
to	O
ultimately	O
target	O
dromedary	O
camels	O
,	O
we	O
constructed	O
two	O
recombinant	O
adenoviral	O
vectors	O
encoding	O
the	O
full	O
-	O
length	O
MERS	O
-	O
CoV	O
S	O
protein	O
(	O
Ad5	B-DISO
.	O
MERS	O
-	O
S	O
)	O
and	O
the	O
S1	O
extracellular	O
domain	O
of	O
S	O
protein	O
(	O
Ad5	B-DISO
.	O
MERS	O
-	O
S1	O
).	O

We	O
report	O
a	O
31	O
-	O
year	O
old	O
pregnant	O
woman	O
infected	O
with	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
virus	O
and	O
progressed	O
to	O
ARDS	B-DISO
.	O

The	O
patient	O
rapidly	O
developed	O
severe	O
complications	O
,	O
including	O
acute	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
,	I-DISO
acute	I-DISO
hepatitis	B-DISO
,	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
,	O
and	O
encephalopathy	B-DISO
.	O

Immunoglobulin	O
neutralize	O
virus	O
invasion	B-DISO
and	O
suppress	O
viremia	B-DISO
,	O
acting	O
synergistically	O
with	O
acyclovir	O
.	O

TITLE	O
:	O
Current	O
perspectives	O
in	O
transfusion	O
-	O
transmitted	B-DISO
infectious	B-DISO
diseases	I-DISO
:	O
emerging	O
and	O
re	O
-	O
emerging	O
infections	B-DISO
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrate	O
the	O
feasibility	O
of	O
highly	O
expressing	O
SARS	B-DISO
subunit	O
vaccine	O
RBD	O
,	O
indicating	O
its	O
potential	O
in	O
subsequent	O
development	O
of	O
a	O
plant	O
-	O
derived	O
recombinant	O
subunit	O
vaccine	O
and	O
reagents	O
production	O
for	O
antibody	O
detection	O
in	O
SARS	B-DISO
serological	O
tests	O
.	O

The	O
experience	O
of	O
integrative	O
TCM	O
/	O
WM	O
in	O
the	O
treatment	O
of	O
SARS	B-DISO
is	O
encouraging	O
.	O

The	O
level	O
of	O
serum	O
IL	O
-	O
8	O
was	O
positively	O
correlated	O
with	O
white	O
blood	O
cell	O
count	O
and	O
ISS	B-DISO
score	O
,	O
and	O
inversely	O
correlated	O
with	O
oxygen	O
index	O
.	O

The	O
patients	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
:	O
fluid	O
resuscitation	O
(	O
group	O
A	O
,	O
n	O
=	O
41	O
),	O
and	O
fluid	O
resuscitation	O
plus	O
high	O
-	O
volume	O
hemofiltration	O
(	O
group	B-DISO
B	I-DISO
,	O
n	O
=	O
48	O
).	O

Representative	O
strains	O
of	O
these	O
three	O
genetic	O
groups	O
were	O
passaged	O
serially	O
and	O
grew	O
to	O
titers	O
of	O
∼	O
5	O
-	O
6log10	O
plaque	B-DISO
forming	O
units	O
/	O
mL	O
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
the	O
isolation	O
in	O
cell	O
culture	O
of	O
an	O
S	O
INDEL	O
PEDV	O
strain	O
and	O
a	O
PEDV	O
strain	O
with	O
a	O
large	O
(	O
197aa	O
)	O
deletion	O
in	O
the	O
S	O
protein	O
.	O

RESULTS	O
:	O
Health	O
concerns	O
and	O
social	O
experiences	O
motivated	O
the	O
participants	O
to	O
practise	O
tai	O
chi	O
in	O
post	O
-	O
SARS	B-DISO
Hong	O
Kong	O
.	O

Consequently	O
,	O
we	O
have	O
hypothesized	O
that	O
germline	O
antibodies	O
may	O
not	O
bind	O
to	O
the	O
HIV	B-DISO
-	O
1	O
envelope	O
glycoprotein	O
(	O
Env	O
)	O
because	O
they	O
are	O
so	O
different	O
compared	O
to	O
the	O
highly	O
somatically	O
mutated	O
HIV	B-DISO
-	O
1	O
-	O
specific	O
bnAbs	O
.	O

The	O
new	O
assays	O
were	O
used	O
on	O
samples	O
of	O
lung	O
and	O
trachea	B-DISO
as	O
well	O
as	O
virus	O
from	O
allantoic	O
fluid	O
and	O
cell	O
culture	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
liver	I-DISO
failure	I-DISO
(	O
ALF	O
)	O
caused	O
by	O
viral	O
and	O
non	O
-	O
viral	B-DISO
hepatitis	I-DISO
is	O
often	O
accompanied	O
with	O
severe	O
metabolic	B-DISO
disorders	I-DISO
,	O
the	O
accumulation	O
of	O
toxic	O
substances	O
and	O
continuous	O
release	O
and	O
accumulation	O
of	O
a	O
large	O
number	O
of	O
endogenous	O
toxins	O
and	O
inflammatory	O
mediators	O
.	O

The	O
emergence	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
in	O
2002	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
2012	O
has	O
resulted	O
in	O
severe	O
human	O
respiratory	B-DISO
disease	I-DISO
with	O
high	O
death	O
rates	O
.	O

Of	O
a	O
total	O
of	O
922	O
malaria	B-DISO
cases	O
studied	O
,	O
more	O
than	O
seven	O
days	O
of	O
hospitalization	O
was	O
the	O
most	O
frequent	O
outcome	O
(	O
21	O
.	O
8	O
%	O
(	O
201	O
),	O
95	O
%	O
CI	O
=	O
19	O
.	O
1	O
-	O
24	O
.	O
5	O
%)	O
followed	O
by	O
intensive	O
care	O
requirement	O
(	O
8	O
.	O
6	O
%	O
(	O
79	O
),	O
95	O
%	O
CI	O
=	O
6	O
.	O
8	O
-	O
10	O
.	O
4	O
%)	O
and	O
in	O
-	O
hospital	O
mortality	O
(	O
1	O
.	O
2	O
%	O
(	O
11	O
),	O
95	O
%	O
CI	O
=	O
0	O
.	O
5	O
-	O
1	O
.	O
9	O
%).	O

This	O
study	O
was	O
the	O
first	O
to	O
identify	O
genetic	O
differences	O
of	O
the	O
M	O
gene	O
from	O
Korean	O
CCV	B-DISO
strains	O
and	O
provided	O
a	O
platform	O
for	O
molecular	O
identification	O
of	O
different	O
Korean	O
CCV	B-DISO
strains	O
.	O

TITLE	O
:	O
Characterization	O
of	O
the	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
codon	O
usage	O
bias	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
was	O
a	O
highly	O
virulent	O
atypical	B-DISO
pneumonia	I-DISO
caused	O
by	O
a	O
novel	O
coronavirus	O
that	O
resulted	O
in	O
a	O
pandemic	O
in	O
2003	O
.	O

NO	O
has	O
direct	O
antiviral	O
properties	O
against	O
some	O
viruses	O
,	O
whereas	O
during	O
other	O
virus	O
infections	B-DISO
NO	O
can	O
mediate	O
immunopathology	B-DISO
and	O
/	O
or	O
inhibit	O
the	O
antiviral	O
immune	O
response	O
to	O
promote	O
chronic	B-DISO
infection	I-DISO
.	O

In	O
this	O
review	O
,	O
we	O
will	O
discuss	O
a	O
variety	O
of	O
viral	B-DISO
infections	I-DISO
,	O
including	O
HIV	B-DISO
,	O
SARS	B-DISO
-	O
CoV	O
,	O
LCMV	O
,	O
HCV	O
,	O
RSV	O
,	O
and	O
others	O
,	O
where	O
myeloid	O
cells	O
influence	O
the	O
control	O
and	O
clearance	O
of	O
the	O
virus	O
from	O
the	O
host	O
,	O
as	O
well	O
as	O
the	O
severity	O
and	O
resolution	O
of	O
tissue	O
damage	O
,	O
via	O
the	O
activities	O
of	O
iNOS	O
and	O
/	O
or	O
Arg1	O
.	O

RAGE	O
and	O
cytokeratin	O
18	O
isoforms	O
have	O
the	O
potential	O
to	O
act	O
as	O
diagnostic	O
or	O
prognostic	O
biomarkers	O
of	O
lung	O
and	O
hepatic	B-DISO
dysfunction	I-DISO
.	O

There	O
are	O
several	O
animal	O
models	O
,	O
both	O
mouse	O
and	O
alternative	O
animals	O
,	O
for	O
the	O
study	O
of	O
severe	O
CoV	O
respiratory	B-DISO
disease	I-DISO
that	O
have	O
been	O
examined	O
,	O
each	O
with	O
different	O
pros	O
and	O
cons	O
relative	O
to	O
the	O
actual	O
pathogenesis	B-DISO
of	O
the	O
disease	O
in	O
humans	O
.	O

Furthermore	O
,	O
TRIM56	O
was	O
revealed	O
to	O
impair	O
YFV	O
and	O
DENV2	O
propagation	O
by	O
suppressing	O
intracellular	O
viral	O
RNA	O
accumulation	O
but	O
to	O
compromise	O
HCoV	O
-	O
OC43	O
infection	B-DISO
at	O
a	O
later	O
step	O
in	O
the	O
viral	O
life	O
cycle	O
,	O
suggesting	O
that	O
distinct	O
TRIM56	O
domains	O
accommodate	O
differing	O
antiviral	O
mechanisms	O
.	O

Herein	O
,	O
we	O
demonstrate	O
that	O
TRIM56	O
restricts	O
two	O
medically	O
important	O
flaviviruses	O
,	O
yellow	B-DISO
fever	I-DISO
virus	O
(	O
YFV	O
)	O
and	O
dengue	B-DISO
virus	O
serotype	O
2	O
(	O
DENV2	O
),	O
and	O
a	O
human	O
coronavirus	O
,	O
HCoV	O
-	O
OC43	O
,	O
but	O
not	O
encephalomyocarditis	O
virus	O
,	O
a	O
picornavirus	O
.	O

ABSTRACT	O
:	O
Emerging	O
canine	O
coronavirus	O
(	O
CCoV	O
)	O
variants	O
that	O
are	O
associated	O
with	O
systemic	B-DISO
infections	I-DISO
have	O
been	O
reported	O
in	O
the	O
European	O
Union	O
;	O
however	O
,	O
CCoV	O
-	O
associated	O
disease	O
in	O
the	O
United	O
States	O
is	O
incompletely	O
characterized	O
.	O

No	O
evidence	O
of	O
systemic	O
CCoV	O
infection	B-DISO
was	O
found	O
.	O

TITLE	O
:	O
Diagnostic	O
value	O
of	O
surfactant	O
protein	O
-	O
a	O
in	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
-	O
induced	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Serum	O
SP	O
-	O
A	O
levels	O
may	O
allow	O
the	O
detection	O
of	O
SAP	O
-	O
induced	O
ARDS	B-DISO
and	O
may	O
help	O
to	O
support	O
the	O
clinical	O
diagnosis	O
of	O
ARDS	B-DISO
.	O

CONCLUSIONS	O
:	O
Modern	O
extracorporeal	O
lung	O
support	O
devices	O
allow	O
an	O
effective	O
extracorporeal	O
gas	O
exchange	O
and	O
have	O
become	O
an	O
inherent	O
component	O
of	O
intensive	O
care	O
treatment	O
of	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

Chronic	B-DISO
GVHD	I-DISO
was	O
observed	O
in	O
five	O
(	O
55	O
.	O
6	O
%)	O
out	O
of	O
nine	O
evaluable	B-DISO
patients	O
.	O

Two	O
-	O
year	O
relapse	B-DISO
-	O
free	O
and	O
overall	O
survival	O
were	O
33	O
.	O
3	O
%	O
(	O
95	O
%	O
CI	O
:	O
2	O
.	O
5	O
-	O
64	O
.	O
1	O
%)	O
or	O
37	O
.	O
5	O
%	O
(	O
95	O
%	O
CI	O
:	O
5	O
.	O
9	O
-	O
69	O
.	O
1	O
%),	O
respectively	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
are	O
characterized	O
by	O
proteinaceous	O
pulmonary	B-DISO
edema	I-DISO
and	O
severe	O
arterial	O
hypoxemia	O
with	O
a	O
mortality	O
of	O
approximately	O
40	O
%.	O

RESULTS	O
:	O
Arterial	O
oxygen	O
tension	B-DISO
(	O
PaO2	O
),	O
oxygenation	O
index	O
(	O
OI	O
)	O
as	O
well	O
as	O
dynamic	O
pulmonary	O
compliance	O
were	O
all	O
elevated	O
significantly	O
,	O
whereas	O
peak	O
inspiratory	O
pressure	O
significantly	O
decreased	O
at	O
6h	O
,	O
12h	O
and	O
24h	O
after	O
CRRT	O
respectively	O
;	O
serum	O
cytokine	O
level	O
and	O
CRP	O
significantly	O
decreased	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
The	O
SARS	B-DISO
-	O
coronavirus	O
membrane	O
protein	O
induces	O
apoptosis	O
via	O
interfering	O
with	O
PDK1	O
-	O
PKB	O
/	O
Akt	O
signalling	O
.	O

We	O
previously	O
reported	O
the	O
pro	O
-	O
apoptotic	O
property	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
(	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
)	O
M	O
(	O
membrane	O
)-	O
protein	O
and	O
a	O
down	O
-	O
regulation	O
of	O
the	O
phosphorylation	O
level	O
of	O
the	O
cell	O
-	O
survival	O
protein	O
PKB	O
(	O
protein	O
kinase	O
B	O
)/	O
Akt	O
in	O
cells	O
expressing	O
M	O
-	O
protein	O
.	O

TITLE	O
:	O
[	O
Complete	O
genomic	O
analysis	O
of	O
a	O
novel	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
isolate	O
].	O

The	O
complete	O
genome	O
of	O
CK	O
/	O
CH	O
/	O
SD09	O
/	O
005	O
consisted	O
of	O
27691	O
nucleotides	O
(	O
nt	O
),	O
excluding	O
the	O
5	O
'	O
cap	B-DISO
and	O
3	O
'	O
poly	O
A	O
tail	O
.	O

Recent	O
disease	O
outbreaks	O
such	O
as	O
Nipah	O
virus	O
,	O
SARS	B-DISO
,	O
avian	B-DISO
influenza	I-DISO
H5N1	B-DISO
,	O
bluetongue	B-DISO
serotype	O
8	O
and	O
Schmallenberg	O
virus	O
have	O
led	O
to	O
realising	O
that	O
we	O
need	O
to	O
explicitly	O
take	O
into	O
account	O
the	O
underlying	O
complex	O
interactions	O
between	O
environmental	O
,	O
epidemiological	O
and	O
social	O
factors	O
which	O
are	O
often	O
also	O
spatially	O
and	O
temporally	O
heterogeneous	O
as	O
well	O
as	O
interconnected	O
across	O
affected	O
regions	O
and	O
beyond	O
.	O

Wild	O
-	O
type	O
(	O
WT	O
)	O
mice	O
and	O
Spred	O
-	O
2	O
(-/-)	O
mice	O
were	O
exposed	O
to	O
intratracheal	O
LPS	B-DISO
(	O
50	O
µg	O
in	O
50	O
µL	O
PBS	B-DISO
)	O
to	O
induce	O
pulmonary	B-DISO
inflammation	I-DISO
.	O

In	O
multivariable	O
analysis	O
,	O
high	O
T	O
-	O
reg	O
%	O
(	O
HR	O
0	O
.	O
41	O
,	O
95	O
%	O
CI	O
0	O
.	O
20	O
-	O
0	O
.	O
81	O
)	O
and	O
high	O
CMV	O
-	O
reactive	O
CD4	O
+	O
T	O
-	O
cell	O
%	O
(	O
HR	O
1	O
.	O
69	O
,	O
95	O
%	O
CI	O
1	O
.	O
03	O
-	O
2	O
.	O
78	O
)	O
were	O
predictive	O
of	O
respiratory	B-DISO
viral	I-DISO
infection	I-DISO
.	O

In	O
elderly	O
nursing	O
home	O
residents	O
,	O
high	O
CMV	O
-	O
reactive	O
CD4	O
+	O
T	O
-	O
cells	O
were	O
associated	O
with	O
an	O
increased	O
risk	O
and	O
high	O
T	O
-	O
regs	O
were	O
associated	O
with	O
a	O
reduced	O
risk	O
of	O
respiratory	B-DISO
viral	I-DISO
infection	I-DISO
.	O

Unlike	O
other	O
influenza	B-DISO
viruses	O
,	O
engineering	O
truncations	O
hypothesized	O
to	O
reduce	O
interferon	O
antagonism	O
into	O
the	O
NS1	B-DISO
protein	O
didn	O
'	O
t	O
attenuate	O
bat	O
-	O
influenza	B-DISO
.	O

Mini	O
-	O
genome	O
replication	O
studies	O
and	O
virus	O
reassortment	O
experiments	O
demonstrated	O
that	O
bat	O
-	O
influenza	B-DISO
has	O
very	O
limited	O
genetic	O
and	O
protein	O
compatibility	O
with	O
Type	O
A	O
or	O
Type	O
B	O
influenza	B-DISO
viruses	O
,	O
yet	O
it	O
readily	O
reassorts	O
with	O
another	O
divergent	O
bat	O
-	O
influenza	B-DISO
virus	O
,	O
suggesting	O
that	O
the	O
bat	O
-	O
influenza	B-DISO
lineage	O
may	O
represent	O
a	O
new	O
Genus	O
/	O
Species	O
within	O
the	O
Orthomyxoviridae	O
family	O
.	O

This	O
report	O
describes	O
timing	O
of	O
antibody	O
generation	O
and	O
disease	B-DISO
progression	I-DISO
following	O
infection	B-DISO
with	O
a	O
US	O
PEDV	O
isolate	O
by	O
assessing	O
fecal	O
viral	B-DISO
shedding	I-DISO
,	O
morphometric	O
analysis	O
of	O
intestinal	O
lesions	O
,	O
and	O
magnitude	O
of	O
immunohistochemical	O
staining	O
.	O

TITLE	O
:	O
Alcohol	O
consumption	O
and	O
prevalence	O
of	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
infection	B-DISO
among	O
US	O
men	O
in	O
the	O
HPV	O
in	O
Men	O
(	O
HIM	O
)	O
study	O
.	O

The	O
objective	O
of	O
this	O
cross	O
-	O
sectional	O
analysis	O
was	O
to	O
assess	O
the	O
association	O
between	O
alcohol	O
intake	O
and	O
prevalent	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
infection	B-DISO
among	O
US	O
men	O
enrolled	O
in	O
the	O
HPV	O
in	O
Men	O
(	O
HIM	O
)	O
study	O
using	O
quantitative	O
alcohol	O
intake	O
measured	O
from	O
a	O
Food	O
Frequency	O
Questionnaire	O
.	O

Multivariable	O
prevalence	O
ratios	O
(	O
mPRs	O
)	O
were	O
used	O
to	O
assess	O
the	O
association	O
between	O
alcohol	O
intake	O
and	O
HPV	O
infections	B-DISO
.	O

Prevalent	O
infections	B-DISO
were	O
significantly	O
higher	O
among	O
men	O
in	O
the	O
highest	O
quartile	O
of	O
alcohol	O
intake	O
and	O
multivariable	O
models	O
revealed	O
that	O
the	O
highest	O
quartile	O
of	O
alcohol	O
intake	O
was	O
associated	O
with	O
significantly	O
increased	O
risks	O
for	O
any	O
(	O
mPR	O
=	O
1	O
.	O
13	O
;	O
95	O
%	O
CI	O
1	O
.	O
00	O
to	O
1	O
.	O
27	O
)	O
HPV	O
types	O
and	O
oncogenic	O
(	O
mPR	O
=	O
1	O
.	O
35	O
;	O
95	O
%	O
CI	O
1	O
.	O
08	O
to	O
1	O
.	O
68	O
)	O
HPV	O
types	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
considered	O
an	O
emergent	O
pathogen	O
associated	O
with	O
high	O
economic	O
losses	O
in	O
many	O
pig	O
rearing	O
areas	O
.	O

In	O
the	O
RAW	O
-	O
PEDV	O
-	O
CONTROL	O
group	O
,	O
PEDV	O
RNA	O
was	O
present	O
in	O
feces	O
at	O
day	O
post	O
infection	B-DISO
(	O
dpi	O
)	O
3	O
and	O
the	O
pigs	O
seroconverted	O
by	O
dpi	O
14	O
.	O

Indeed	O
,	O
we	O
are	O
continually	O
faced	O
with	O
the	O
threat	O
of	O
morbidity	O
and	O
mortality	O
associated	O
with	O
annual	O
influenza	B-DISO
virus	O
infections	B-DISO
,	O
new	O
respiratory	O
viruses	O
(	O
e	O
.	O
g	O
.,	O
SARS	B-DISO
-	O
CoV	O
),	O
and	O
lung	O
infections	B-DISO
caused	O
by	O
antibiotic	O
-	O
resistant	O
""""	O
ESKAPE	O
pathogens	O
""""	O
(	O
three	O
of	O
which	O
target	O
the	O
lung	O
).	O

Herein	O
,	O
we	O
present	O
host	O
and	O
viral	O
factors	O
that	O
participate	O
in	O
the	O
regulation	O
of	O
the	O
possible	O
pathogenic	O
processes	O
associated	O
with	O
CNS	B-DISO
infection	I-DISO
by	O
human	O
coronaviruses	O
and	O
we	O
try	O
to	O
decipher	O
the	O
intricate	O
interplay	O
between	O
virus	O
and	O
host	O
target	O
cells	O
in	O
order	O
to	O
characterize	O
their	O
role	O
in	O
the	O
virus	O
life	O
cycle	O
as	O
well	O
as	O
in	O
the	O
capacity	O
of	O
the	O
cell	O
to	O
respond	O
to	O
viral	O
invasion	B-DISO
.	O

ABSTRACT	O
:	O
Optimal	O
ventilator	O
management	O
for	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
remains	O
uncertain	O
.	O

EPVent2	O
is	O
a	O
multicentre	O
,	O
prospective	O
,	O
randomised	O
,	O
phase	O
II	O
clinical	O
trial	O
testing	O
the	O
hypothesis	O
that	O
the	O
use	O
of	O
a	O
PTP	B-DISO
-	O
guided	O
ventilation	O
strategy	O
will	O
lead	O
to	O
improvement	O
in	O
composite	O
outcomes	O
of	O
mortality	O
and	O
time	O
off	O
the	O
ventilator	O
at	O
28	O
days	O
as	O
compared	O
with	O
a	O
high	O
-	O
PEEP	O
control	O
.	O

The	O
trial	O
will	O
utilise	O
a	O
primary	O
composite	O
end	O
point	O
that	O
incorporates	O
death	O
and	O
days	O
off	O
the	O
ventilator	O
at	O
28	O
days	O
to	O
test	O
the	O
primary	O
hypothesis	O
that	O
adjusting	O
ventilator	O
pressure	O
to	O
achieve	O
positive	O
PTP	B-DISO
values	O
will	O
result	O
in	O
improved	O
mortality	O
and	O
ventilator	O
-	O
free	O
days	O
.	O

Inhibition	O
of	O
furin	O
activity	O
was	O
shown	O
to	O
decrease	O
MERS	O
-	O
CoV	O
S	O
-	O
mediated	O
entry	O
,	O
as	O
well	O
as	O
infection	B-DISO
by	O
the	O
virus	O
.	O

ABSTRACT	O
:	O
The	O
serial	O
interval	O
of	O
an	O
infectious	B-DISO
disease	I-DISO
represents	O
the	O
duration	O
between	O
symptom	B-DISO
onset	O
of	O
a	O
primary	O
case	O
and	O
symptom	B-DISO
onset	O
of	O
its	O
secondary	O
cases	O
.	O

TITLE	O
:	O
Nucleocapsid	O
phosphorylation	O
and	O
RNA	O
helicase	O
DDX1	O
recruitment	B-DISO
enables	O
coronavirus	O
transition	B-DISO
from	O
discontinuous	O
to	O
continuous	O
transcription	O
.	O

The	O
gender	O
action	O
was	O
shown	O
on	O
isolated	O
blood	O
neutrophils	O
,	O
whole	O
blood	O
and	O
in	O
vivo	O
by	O
the	O
antiviral	O
activity	O
on	O
experimental	O
animals	O
,	O
contaminated	O
with	O
three	O
types	O
of	O
viruses	O
:	O
Herpes	B-DISO
simplex	I-DISO
type	O
1	O
,	O
the	O
virus	O
of	O
encephalomyocarditis	O
and	O
the	O
virus	O
of	O
hepatitis	B-DISO
of	O
mice	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	B-DISO
infection	I-DISO
:	O
inhibition	O
by	O
polysaccharide	O
from	O
Ginkgo	O
biloba	O
exocarp	O
and	O
mode	O
of	O
its	O
action	O
.	O

The	O
development	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
is	O
associated	O
with	O
increased	O
mortality	O
and	O
higher	O
prevalence	O
of	O
complications	O
,	O
representing	O
the	O
actual	O
challenge	O
in	O
the	O
management	O
of	O
children	O
with	O
severe	O
acute	B-DISO
viral	I-DISO
bronchiolitis	I-DISO
.	O

Fever	O
(	O
43	O
,	O
61	O
.	O
4	O
%),	O
dyspnea	B-DISO
(	O
42	O
,	O
60	O
%),	O
and	O
cough	B-DISO
(	O
38	O
,	O
54	O
.	O
3	O
%)	O
were	O
the	O
most	O
common	O
symptoms	O
.	O

Concomitant	O
infections	B-DISO
and	O
low	O
albumin	O
were	O
found	O
to	O
be	O
predictors	O
of	O
severe	O
infection	B-DISO
,	O
while	O
age	O
≥	O
65	O
years	O
was	O
the	O
only	O
predictor	O
of	O
increased	O
mortality	O
.	O

TITLE	O
:	O
Differential	O
response	O
of	O
porcine	O
immature	O
monocyte	O
-	O
derived	O
dendritic	O
cells	O
to	O
virulent	O
and	O
inactivated	O
transmissible	O
gastroenteritis	B-DISO
virus	O
.	O

In	O
this	O
study	O
50	O
clinically	O
normal	O
and	O
50	O
cats	O
with	O
cutaneous	O
and	O
/	O
or	O
systemic	O
signs	O
that	O
lived	O
in	O
an	O
endemic	O
area	O
and	O
had	O
been	O
previously	O
examined	O
for	O
infection	B-DISO
by	O
L	O
.	O
infantum	O
using	O
PCR	O
in	O
four	O
different	O
tissues	O
were	O
serologically	O
tested	O
for	O
the	O
presence	O
of	O
anti	O
-	O
Leishmania	O
IgG	O
(	O
IFAT	O
and	O
ELISA	O
)	O
and	O
IgM	O
(	O
IFAT	O
).	O

Interactions	O
of	O
the	O
viral	O
replicase	O
complex	O
with	O
cis	B-DISO
-	O
acting	O
RNA	O
elements	O
located	O
in	O
the	O
5	O
'	O
and	O
3	O
'-	O
terminal	O
genome	O
regions	O
ensure	O
the	O
specific	O
replication	O
of	O
viral	O
RNA	O
.	O

In	O
addition	O
,	O
and	O
despite	O
their	O
continued	O
use	O
,	O
pharmacotherapies	O
for	O
ARDS	B-DISO
disease	O
modulation	O
have	O
no	O
proven	O
benefit	O
in	O
improving	O
mortality	O
.	O

The	O
majority	O
of	O
respondents	O
set	O
permissive	O
blood	O
gas	O
targets	O
(	O
hypoxia	B-DISO
(	O
92	O
%),	O
hypercapnia	B-DISO
(	O
58	O
%)	O
and	O
pH	O
(	O
90	O
%)).	O

TITLE	O
:	O
[	O
Hantavirus	B-DISO
pulmonary	I-DISO
syndrome	I-DISO
with	O
multiple	O
organ	O
dysfunctions	O
:	O
case	O
report	O
].	O

He	O
developed	O
multiple	O
organ	O
dysfunction	O
syndromes	B-DISO
(	O
pulmonary	O
,	O
renal	O
,	O
coagulation	O
,	O
cardiovascular	O
and	O
metabolic	O
).	O

The	O
maximum	O
effect	O
of	O
EFS	O
was	O
not	O
significantly	O
different	O
between	O
CIE	B-DISO
and	O
control	O
bladders	O
.	O

Removal	O
of	O
the	O
mucosa	O
in	O
CIE	B-DISO
bladders	O
restored	O
the	O
cholinergic	O
component	O
.	O

ABSTRACT	O
:	O
The	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
is	O
a	O
healthy	O
-	O
world	O
problem	O
,	O
some	O
of	O
his	O
patients	O
develop	O
respiratory	B-DISO
failure	I-DISO
,	O
requiring	O
intubation	O
and	O
mechanical	O
ventilation	O
,	O
and	O
the	O
most	O
common	O
complications	O
are	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

The	O
methods	O
and	O
ventilatories	O
parameters	O
used	O
to	O
ventilate	O
the	O
patients	O
with	O
TBI	O
and	O
ARDS	B-DISO
has	O
been	O
evaluated	O
by	O
a	O
sample	O
of	O
physiotherapists	O
from	O
the	O
city	O
of	O
Salvador	O
,	O
BA	O
,	O
from	O
a	O
descriptive	O
study	O
.	O

The	O
data	O
were	O
collected	O
by	O
face	B-DISO
-	O
to	O
-	O
face	B-DISO
interviews	O
in	O
the	O
period	O
of	O
October	O
2005	O
to	O
March	O
2006	O
.	O

ABSTRACT	O
:	O
Malaria	B-DISO
is	O
still	O
considered	O
a	O
major	O
global	O
health	O
problem	O
.	O

Seventeen	O
isolates	O
of	O
Salmonella	B-DISO
spp	O
.	O
were	O
recovered	O
from	O
feces	O
of	O
11	O
calves	O
(	O
16	O
.	O
4	O
%),	O
and	O
statistical	O
analysis	O
revealed	O
no	O
association	O
between	O
the	O
presence	O
of	O
Salmonella	B-DISO
spp	O
.	O

and	O
clinical	O
signs	O
of	O
diarrhea	B-DISO
or	O
age	O
.	O

Intriguingly	O
,	O
PLP2	O
-	O
TM	O
induces	O
incomplete	O
autophagy	O
process	O
by	O
increasing	O
the	O
accumulation	O
of	O
autophagosomes	O
but	O
blocking	B-DISO
the	O
fusion	O
of	O
autophagosomes	O
with	O
lysosomes	O
.	O

H9N2	O
-	O
AIV	O
-	O
infected	O
mice	O
exhibited	O
severe	O
respiratory	O
syndrome	B-DISO
,	O
with	O
a	O
mortality	O
rate	O
of	O
50	O
%.	O

TITLE	O
:	O
How	O
infectious	B-DISO
disease	I-DISO
outbreaks	O
affect	O
community	O
-	O
based	O
primary	O
care	O
physicians	O
:	O
comparing	O
the	O
SARS	B-DISO
and	O
H1N1	O
epidemics	O
.	O

Physicians	O
made	O
changes	O
to	O
various	O
office	O
practices	O
in	O
order	O
to	O
manage	O
and	O
deal	O
with	O
patients	O
with	O
serious	O
infectious	B-DISO
diseases	I-DISO
.	O

Three	O
young	O
consecutive	O
patients	O
with	O
homozygous	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
were	O
admitted	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
due	O
to	O
ACS	O
.	O

An	O
area	O
under	O
the	O
curve	O
and	O
a	O
Hosmer	O
-	O
Lemeshow	O
goodness	O
-	O
of	O
-	O
fit	B-DISO
test	O
were	O
used	O
to	O
assess	O
discrimination	O
and	O
calibration	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
describe	O
the	O
epidemiological	O
and	O
clinical	O
features	O
of	O
two	O
outbreaks	O
of	O
ECoV	O
infection	B-DISO
that	O
were	O
associated	O
with	O
an	O
high	O
case	O
fatality	O
rate	O
.	O

In	O
addition	O
to	O
this	O
replicative	O
function	O
,	O
MERS	O
-	O
CoV	O
PL	O
(	O
pro	O
)	O
was	O
recently	O
shown	O
to	O
be	O
a	O
deubiquitinating	O
enzyme	O
(	O
DUB	O
)	O
and	O
to	O
possess	B-DISO
deISGylating	O
activity	O
,	O
as	O
previously	O
reported	O
for	O
other	O
coronaviral	O
PL	O
(	O
pro	O
)	O
domains	O
,	O
including	O
that	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

This	O
includes	O
enhancing	O
collaborations	O
between	O
countries	O
to	O
ensure	O
diagnostic	O
capabilities	O
for	O
surveillance	O
of	O
MERS	O
-	O
CoV	O
infections	B-DISO
across	O
the	O
European	O
Region	O
.	O

TITLE	O
:	O
An	O
observational	O
,	O
laboratory	O
-	O
based	O
study	O
of	O
outbreaks	O
of	O
middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
in	O
Jeddah	O
and	O
Riyadh	O
,	O
kingdom	O
of	O
Saudi	O
Arabia	O
,	O
2014	O
.	O

TITLE	O
:	O
Chronic	B-DISO
respiratory	I-DISO
failure	I-DISO
due	O
to	O
toxic	O
epidermal	B-DISO
necrosis	I-DISO
in	O
a	O
10	O
year	O
old	O
girl	O
.	O

Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
has	O
been	O
reported	O
to	O
be	O
the	O
most	O
devastating	O
complications	O
of	O
this	O
pathogen	O
.	O

First	O
,	O
it	O
describes	O
a	O
successful	O
use	O
of	O
a	O
dialysis	O
catheter	O
for	O
the	O
establishment	O
of	O
a	O
veno	O
-	O
venous	O
ECMO	O
in	O
an	O
emergency	B-DISO
case	O
by	O
child	O
.	O

More	O
comprehensive	O
research	O
into	O
sources	O
of	O
infection	B-DISO
in	O
the	O
Arabian	O
Peninsula	O
is	O
needed	O
to	O
strengthen	O
and	O
specify	O
the	O
prevention	O
of	O
MERS	O
-	O
CoV	O
infections	B-DISO
.	O

Necroptosis	B-DISO
and	O
subsequent	O
danger	O
signal	O
release	O
is	O
a	O
novel	O
mechanism	O
of	O
injury	O
following	O
transfusion	O
that	O
may	O
account	O
for	O
the	O
increased	O
risk	O
of	O
ARDS	B-DISO
in	O
critically	B-DISO
ill	I-DISO
transfused	O
patients	O
.	O

Likewise	O
,	O
the	O
presence	O
of	O
putative	O
G4	O
-	O
sequences	O
has	O
been	O
reported	O
in	O
various	O
viruses	O
genomes	O
[	O
e	O
.	O
g	O
.,	O
Human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
(	O
HIV	B-DISO
-	O
1	O
),	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
),	O
papillomavirus	O
(	O
HPV	O
)].	O

In	O
parallel	O
,	O
DNA	O
aptamers	O
that	O
form	O
G4s	O
have	O
been	O
described	O
as	O
inhibitors	O
and	O
diagnostic	O
tools	O
to	O
detect	O
viruses	O
[	O
e	O
.	O
g	O
.,	O
hepatitis	B-DISO
A	I-DISO
virus	O
(	O
HAV	B-DISO
),	O
EBV	O
,	O
cauliflower	O
mosaic	O
virus	O
(	O
CaMV	O
),	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
(	O
SARS	B-DISO
),	O
simian	O
virus	O
40	O
(	O
SV40	O
)].	O

The	O
results	O
showed	O
that	O
the	O
4	O
-	O
plex	O
iTRAQ	O
-	O
based	O
quantitative	O
approach	O
identified	O
4	O
,	O
112	O
proteins	O
,	O
146	O
of	O
which	O
showed	O
significant	O
changes	O
in	O
expression	O
48	O
h	O
after	O
infection	B-DISO
.	O

At	O
64	O
h	O
post	O
infection	B-DISO
,	O
219	O
of	O
these	O
proteins	O
showed	O
significant	O
change	O
,	O
further	O
indicating	O
that	O
a	O
larger	O
number	O
of	O
proteomic	O
changes	O
appear	O
to	O
occur	O
during	O
the	O
later	O
stages	O
of	O
infection	B-DISO
.	O

Advantages	O
and	O
disadvantages	O
of	O
the	O
available	O
techniques	O
for	O
measuring	O
protection	O
against	O
an	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
challenge	O
are	O
discussed	O
,	O
including	O
the	O
definition	O
of	O
protection	O
itself	O
.	O

However	O
,	O
sometimes	O
the	O
other	O
reasons	O
for	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
and	O
heart	B-DISO
failure	I-DISO
are	O
found	O
.	O

One	O
third	O
(	O
29	O
.	O
8	O
%)	O
of	O
the	O
participants	O
acquired	O
≥	O
1	O
virus	O
,	O
particularly	O
rhinovirus	O
(	O
14	O
.	O
0	O
%),	O
coronavirus	O
E229	O
(	O
12	O
.	O
4	O
%),	O
and	O
influenza	B-DISO
A	O
(	O
H3N2	O
)	O
virus	O
(	O
6	O
.	O
2	O
%)	O
while	O
in	O
Saudi	O
Arabia	O
.	O

Then	O
based	O
on	O
the	O
gene	O
expression	O
,	O
PPI	O
and	O
signalling	O
pathways	O
data	O
,	O
we	O
investigate	O
the	O
comorbidity	O
association	O
of	O
these	O
2	O
infective	O
pathologies	O
with	O
other	O
7	O
diseases	O
(	O
heart	O
failure	O
,	O
kidney	B-DISO
disorder	I-DISO
,	O
breast	B-DISO
cancer	I-DISO
,	O
neurodegenerative	B-DISO
disorders	I-DISO
,	O
bone	B-DISO
diseases	I-DISO
,	O
Type	O
1	O
and	O
Type	B-DISO
2	I-DISO
diabetes	I-DISO
).	O

ABSTRACT	O
:	O
Intra	B-DISO
-	I-DISO
abdominal	I-DISO
hypertension	I-DISO
and	O
abdominal	B-DISO
compartment	I-DISO
syndrome	I-DISO
are	O
frequent	O
findings	O
among	O
severe	O
surgical	O
ill	B-DISO
patients	O
.	O

Emodin	O
,	O
the	O
bio	O
-	O
active	O
coxund	O
of	O
herb	O
Radix	O
rhizoma	O
Rhei	O
,	O
shows	O
potent	O
anti	O
-	O
inflammatory	O
properties	O
through	O
inactivation	B-DISO
of	O
nuclear	O
factor	O
-	O
κB	O
(	O
NF	O
-	O
κB	O
).	O

Hence	O
,	O
in	O
addition	O
to	O
reducing	O
the	O
production	O
of	O
infectious	B-DISO
virions	O
,	O
inhibition	O
of	O
ER	O
glucosidases	O
also	O
impairs	O
the	O
entry	O
of	O
selected	O
viruses	O
via	O
a	O
post	O
-	O
receptor	O
-	O
binding	O
mechanism	O
.	O

In	O
contrast	O
,	O
current	O
transfusion	O
guidelines	O
for	O
critically	B-DISO
ill	I-DISO
patients	O
support	O
restrictive	O
transfusion	O
practice	O
.	O

We	O
retrospectively	O
analyzed	O
18	O
patients	O
receiving	O
vvECMO	O
due	O
to	O
severe	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Procalcitonin	O
as	O
a	O
predictor	O
of	O
moderate	O
to	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
after	O
cardiac	O
surgery	O
with	O
cardiopulmonary	O
bypass	O
:	O
a	O
study	O
protocol	O
for	O
a	O
prospective	O
cohort	O
study	O
.	O

ABSTRACT	O
:	O
Procalcitonin	O
(	O
PCT	B-DISO
)	O
is	O
activated	O
during	O
cardiopulmonary	O
bypass	O
(	O
CPB	O
)	O
and	O
may	O
be	O
a	O
predictor	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

ABSTRACT	O
:	O
The	O
low	O
toxicity	O
of	O
perfluorocarbons	O
(	O
PFCs	O
),	O
their	O
high	O
affinity	O
for	O
respiratory	O
gases	O
and	O
their	O
compatibility	O
with	O
lung	O
surfactant	O
have	O
made	O
them	O
useful	O
candidates	O
for	O
treating	O
respiratory	B-DISO
diseases	I-DISO
such	O
as	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Sheep	O
previously	O
sensitized	O
to	O
house	O
dust	O
mite	O
(	O
HDM	O
)	O
were	O
challenged	O
with	O
HDM	O
aerosols	O
to	O
induce	O
early	O
asthmatic	B-DISO
responses	O
.	O

The	O
formulation	O
has	O
potential	O
as	O
a	O
rescue	O
treatment	O
for	O
acute	B-DISO
severe	I-DISO
asthma	I-DISO
.	O

ABSTRACT	O
:	O
Surveillance	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
was	O
conducted	O
to	O
explore	O
the	O
possible	O
introduction	O
and	O
circulation	O
of	O
this	O
novel	O
virus	O
in	O
Catalonia	O
,	O
northeastern	O
Spain	O
.	O

Our	O
studies	O
lay	O
the	O
foundation	O
for	O
future	O
investigations	O
regarding	O
how	O
infection	B-DISO
source	O
,	O
vaccination	O
status	O
or	O
other	O
putative	O
transmissibility	O
traits	O
may	O
affect	O
self	O
-	O
limited	O
transmission	O
.	O

ABSTRACT	O
:	O
Four	O
healthy	O
adult	O
dogs	O
(	O
Golden	O
Retrievers	O
aged	O
6	O
years	O
and	O
9	O
years	O
,	O
Dalmatian	O
aged	O
13	O
years	O
,	O
and	O
Mastiff	O
aged	O
5	O
years	O
)	O
developed	O
clinical	O
signs	O
of	O
acute	B-DISO
respiratory	I-DISO
disease	I-DISO
and	O
died	O
within	O
2	O
to	O
7	O
days	O
of	O
onset	O
of	O
clinical	O
signs	O
.	O

Canid	O
herpesvirus	O
1	O
has	O
been	O
isolated	O
from	O
cases	O
of	O
acute	O
infectious	B-DISO
respiratory	B-DISO
disease	I-DISO
in	O
dogs	O
but	O
has	O
only	O
rarely	O
been	O
associated	O
with	O
fatal	O
primary	O
viral	B-DISO
pneumonia	I-DISO
in	O
adult	O
dogs	O
.	O

Data	O
suggest	O
that	O
activated	O
microglia	O
and	O
inflammatory	O
mediators	O
contribute	O
to	O
a	O
local	O
CNS	O
microenvironment	O
that	O
regulates	O
viral	O
replication	O
and	O
IFN	O
-	O
γ	O
production	O
during	O
the	O
acute	O
phase	O
of	O
infection	B-DISO
,	O
which	O
in	O
turn	O
can	O
cause	O
phagolysosome	O
maturation	O
and	O
phagocytosis	O
of	O
the	O
myelin	O
sheath	O
,	O
leading	O
to	O
demyelination	B-DISO
.	O

TITLE	O
:	O
Ultrasound	O
-	O
guided	O
lung	O
recruitment	B-DISO
in	O
a	O
3	O
-	O
month	O
-	O
old	O
infant	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

We	O
report	O
a	O
case	O
of	O
US	O
-	O
guided	O
lung	O
recruitment	B-DISO
procedure	O
applied	O
in	O
an	O
infant	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
advocate	O
that	O
the	O
lung	O
US	O
-	O
guided	O
RM	O
in	O
infants	O
is	O
a	O
feasible	O
and	O
safe	O
procedure	O
.	O

Twenty	O
-	O
four	O
patients	O
(	O
92	O
.	O
3	O
%)	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
and	O
10	O
(	O
38	O
.	O
5	O
%)	O
developed	O
septic	B-DISO
shock	I-DISO
quickly	O
after	O
the	O
onset	O
of	O
illness	O
.	O

Infection	B-DISO
with	O
novel	O
avian	O
-	O
origin	O
reassortment	O
influenza	B-DISO
A	O
(	O
H7N9	O
)	O
virus	O
is	O
characterized	O
by	O
high	O
fever	O
,	O
cough	B-DISO
,	O
and	O
severe	O
respiratory	B-DISO
failure	I-DISO
and	O
is	O
associated	O
with	O
a	O
high	O
mortality	O
.	O

The	O
issue	O
concludes	O
with	O
a	O
series	O
of	O
articles	O
reviewing	O
the	O
relationship	O
between	O
viruses	O
and	O
cancer	B-DISO
,	O
including	O
the	O
role	O
played	O
by	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
in	O
the	O
pathogenesis	B-DISO
of	O
lymphoma	B-DISO
and	O
carcinoma	B-DISO
;	O
how	O
human	O
papillomaviruses	O
(	O
HPVs	O
)	O
are	O
involved	O
in	O
the	O
development	O
of	O
skin	B-DISO
cancer	I-DISO
;	O
the	O
involvement	O
of	O
hepatitis	O
B	B-DISO
virus	I-DISO
infection	I-DISO
in	O
hepatocellular	B-DISO
carcinoma	I-DISO
;	O
and	O
the	O
mechanisms	O
by	O
which	O
Kaposi	B-DISO
'	I-DISO
s	I-DISO
sarcoma	I-DISO
-	O
associated	O
herpesvirus	O
(	O
KSHV	O
)	O
leads	O
to	O
Kaposi	B-DISO
'	I-DISO
s	I-DISO
sarcoma	I-DISO
.	O

We	O
conclude	O
that	O
HFNC	O
may	O
be	O
considered	O
as	O
first	O
-	O
line	O
therapy	O
in	O
ARF	B-DISO
,	O
including	O
patients	O
with	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Multiple	O
bilateral	O
branch	O
retinal	B-DISO
artery	I-DISO
occlusions	I-DISO
in	O
a	O
patient	O
with	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
with	O
vancomycin	O
red	B-DISO
man	I-DISO
syndrome	I-DISO
.	O

A	O
30	O
-	O
year	O
-	O
old	O
man	O
with	O
complicated	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
presented	O
with	O
pain	O
,	O
fever	O
,	O
and	O
hypoxia	B-DISO
.	O

When	O
the	O
patient	O
regained	O
consciousness	O
within	O
an	O
hour	O
,	O
he	O
complained	O
of	O
severe	O
vision	B-DISO
loss	I-DISO
and	O
demonstrated	O
multiple	O
bilateral	O
branch	O
retinal	B-DISO
artery	I-DISO
occlusions	I-DISO
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
virus	O
that	O
manifests	O
itself	O
in	O
viral	B-DISO
infection	I-DISO
with	O
fever	O
,	O
cough	B-DISO
,	O
shortness	B-DISO
of	I-DISO
breath	I-DISO
,	O
renal	B-DISO
failure	I-DISO
and	O
severe	O
acute	B-DISO
pneumonia	I-DISO
,	O
which	O
often	O
result	O
in	O
a	O
fatal	O
outcome	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
life	O
-	O
threatening	O
critical	B-DISO
illness	I-DISO
,	O
characterised	O
by	O
qualitative	O
and	O
quantitative	O
surfactant	O
compositional	O
changes	O
associated	O
with	O
premature	O
airway	O
collapse	B-DISO
,	O
gas	O
-	O
exchange	O
abnormalities	O
and	O
acute	O
hypoxic	B-DISO
respiratory	B-DISO
failure	I-DISO
.	O

Ten	O
patients	O
with	O
moderate	O
to	O
severe	O
ARDS	B-DISO
were	O
recruited	O
.	O

This	O
novel	O
approach	O
may	O
facilitate	O
biochemical	O
phenotyping	O
of	O
ARDS	B-DISO
patients	O
according	O
to	O
surfactant	O
synthesis	O
and	O
metabolism	O
,	O
enabling	O
individualised	O
treatment	O
approaches	O
for	O
the	O
management	O
of	O
ARDS	B-DISO
patients	O
in	O
the	O
future	O
.	O

RESULTS	O
:	O
BALF	O
of	O
patients	O
with	O
ARDS	B-DISO
consisted	O
of	O
diminished	O
total	O
PC	O
and	O
fractional	O
PC16	O
:	O
0	O
/	O
16	O
:	O
0	O
concentrations	O
compared	O
to	O
healthy	O
controls	O
.	O

ABSTRACT	O
:	O
Severe	O
thoracic	B-DISO
trauma	O
can	O
be	O
associated	O
with	O
immediate	O
life	O
-	O
threatening	O
injuries	O
including	O
major	O
air	O
leak	O
syndrome	B-DISO
that	O
can	O
lead	O
to	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
and	O
refractory	O
hypoxaemia	O
.	O

ABSTRACT	O
:	O
Based	O
on	O
a	O
bioinformatics	O
analysis	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavvirus	O
(	O
MERS	O
-	O
CoV	O
)	O
S	O
protein	O
,	O
we	O
synthesized	O
a	O
panel	O
of	O
peptides	O
coupled	O
to	O
keyhole	O
limpet	O
haemocyanin	O
and	O
used	O
them	O
to	O
raise	O
antibodies	O
in	O
rabbits	O
.	O

The	O
recent	O
emergence	O
of	O
virulent	O
enteric	O
coronaviruses	O
[	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)]	O
in	O
North	O
America	O
and	O
Asia	O
,	O
for	O
which	O
no	O
vaccines	O
are	O
available	O
,	O
remains	O
a	O
challenge	O
for	O
the	O
global	O
swine	O
industry	O
.	O

From	O
1998	O
to	O
2010	O
,	O
23	O
patients	O
at	O
our	O
institution	O
were	O
diagnosed	O
with	O
a	O
septic	O
thrombosis	B-DISO
of	O
the	O
internal	O
jugular	O
vein	O
.	O

The	O
primary	B-DISO
infection	I-DISO
sites	O
were	O
found	O
in	O
the	O
middle	O
ear	O
(	O
11	O
),	O
oropharynx	O
(	O
8	O
),	O
sinus	B-DISO
(	O
3	O
),	O
and	O
oral	O
cavity	B-DISO
(	O
1	O
).	O

Modern	O
imaging	O
techniques	O
allow	O
early	O
and	O
often	O
incidental	O
diagnosis	O
of	O
this	O
clinically	O
hidden	O
complication	B-DISO
.	O

Two	O
hypotheses	O
may	O
explain	O
temporal	O
and	O
spatial	O
pulses	O
of	O
virus	B-DISO
shedding	I-DISO
in	O
bat	O
populations	O
:	O
episodic	O
shedding	O
from	O
persistently	O
infected	O
bats	O
or	O
transient	O
epidemics	O
that	O
occur	O
as	O
virus	O
is	O
transmitted	B-DISO
among	O
bat	O
populations	O
.	O

ABSTRACT	O
:	O
The	O
emergence	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
in	O
2012	O
resulted	O
in	O
an	O
increased	O
concern	O
of	O
the	O
spread	O
of	O
the	O
infection	B-DISO
globally	O
.	O

Respiratory	O
syncytial	O
virus	O
was	O
isolated	O
in	O
33	O
patients	O
,	O
human	O
rhinovirus	O
(	O
hRV	O
)	O
in	O
22	O
,	O
adenovirus	B-DISO
(	O
AdV	O
)	O
in	O
19	O
,	O
human	O
metapneumovirus	O
in	O
13	O
,	O
influenza	B-DISO
virus	O
in	O
10	O
,	O
parainfluenza	B-DISO
virus	O
in	O
7	O
,	O
human	O
corona	O
virus	O
(	O
hCoV	O
)	O
in	O
4	O
,	O
and	O
human	O
bocavirus	O
in	O
one	O
.	O

TITLE	O
:	O
[	O
Risk	O
factors	O
of	O
the	O
occurence	O
and	O
death	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
a	O
prospective	O
multicenter	O
cohort	O
study	O
].	O

The	O
28	O
-	O
day	O
mortality	O
of	O
ARDS	B-DISO
group	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
severe	O
control	O
group	O
[	O
30	O
.	O
43	O
%	O
(	O
49	O
/	O
161	O
)	O
vs	O
.	O
18	O
.	O
99	O
%	O
(	O
34	O
/	O
179	O
),	O
χ²	O
=	O
6	O
.	O
013	O
,	O
P	O
=	O
0	O
.	O
014	O
].	O

Multivariate	O
COX	O
regression	O
analysis	O
showed	O
that	O
old	O
age	O
and	O
septic	B-DISO
shock	I-DISO
were	O
significantly	O
associated	O
with	O
the	O
increased	O
risk	O
of	O
in	O
28	O
-	O
day	O
death	O
of	O
ARDS	B-DISO
[	O
advanced	O
age	O
:	O
hazard	O
ratio	O
(	O
HR	O
)=	O
1	O
.	O
040	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
018	O
-	O
1	O
.	O
064	O
,	O
P	O
<	O
0	O
.	O
001	O
;	O
septic	B-DISO
shock	I-DISO
:	O
HR	O
=	O
3	O
.	O
209	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
676	O
-	O
6	O
.	O
146	O
,	O
P	O
<	O
0	O
.	O
001	O
].	O

High	O
APACHEII	O
score	O
at	O
admission	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
1	O
.	O
316	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
95	O
%	O
CI	O
)	O
=	O
1	O
.	O
040	O
-	O
1	O
.	O
633	O
,	O
P	O
=	O
0	O
.	O
022	O
]	O
and	O
increased	O
plasma	O
Ang	O
-	O
2	O
levels	O
(	O
OR	O
=	O
1	O
.	O
287	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
041	O
-	O
1	O
.	O
760	O
,	O
P	O
=	O
0	O
.	O
038	O
)	O
were	O
the	O
independent	O
prognostic	O
factors	O
for	O
the	O
28	O
-	O
day	O
mortality	O
in	O
ARDS	B-DISO
.	O

The	O
plasma	O
level	O
of	O
Ang	O
-	O
2	O
was	O
significantly	O
increased	O
in	O
patients	O
with	O
ARDS	B-DISO
.	O

In	O
contrast	O
,	O
absence	O
of	O
ATF3	O
in	O
parenchymal	O
cells	O
resulted	O
in	O
loss	O
of	O
alveolar	O
-	O
capillary	O
membrane	O
integrity	O
and	O
increased	O
exudative	O
edema	B-DISO
.	O

Finally	O
,	O
sequential	O
passage	O
of	O
MERS	O
-	O
CoV	O
in	O
permissive	O
bat	O
cells	O
established	O
persistent	B-DISO
infection	I-DISO
with	O
concomitant	O
downregulation	O
of	O
CD26	O
/	O
DPP4	O
surface	O
expression	O
.	O

TITLE	O
:	O
Acquisition	O
of	O
new	O
protein	O
domains	O
by	O
coronaviruses	O
:	O
analysis	O
of	O
overlapping	O
genes	O
coding	O
for	O
proteins	O
N	O
and	O
9b	O
in	O
SARS	B-DISO
coronavirus	O
.	O

Healthcare	O
workers	O
(	O
HCWs	O
)	O
are	O
vulnerable	O
to	O
exposure	O
to	O
these	O
agents	O
given	O
the	O
nature	O
of	O
their	O
jobs	O
,	O
and	O
as	O
a	O
result	O
,	O
risk	O
both	O
becoming	O
infected	O
,	O
and	O
spreading	O
the	O
infectious	B-DISO
agents	O
to	O
other	O
patients	O
.	O

To	O
avoid	O
transmission	O
of	O
these	O
infectious	B-DISO
diseases	I-DISO
to	O
(	O
HCWs	O
),	O
exposure	O
-	O
appropriate	O
respiratory	O
precautions	O
are	O
sometimes	O
necessary	O
to	O
protect	O
both	O
HCWs	O
and	O
the	O
patients	O
they	O
care	O
for	O
.	O

TITLE	O
:	O
Is	O
there	O
still	O
room	O
for	O
novel	O
viral	O
pathogens	O
in	O
pediatric	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
?	O

ABSTRACT	O
:	O
Viruses	O
are	O
the	O
most	O
frequent	O
cause	O
of	O
respiratory	B-DISO
disease	I-DISO
in	O
children	O
.	O

Forty	O
two	O
(	O
38	O
%)	O
pilgrims	O
had	O
laboratory	O
-	O
confirmed	O
viral	B-DISO
infections	I-DISO
;	O
28	O
(	O
25	O
%)	O
rhinovirus	O
,	O
5	O
(	O
4	O
%)	O
influenza	B-DISO
A	O
,	O
2	O
(	O
2	O
%)	O
adenovirus	B-DISO
,	O
2	O
(	O
2	O
%)	O
human	O
coronavirus	O
OC43	O
/	O
229E	O
,	O
2	O
(	O
2	O
%)	O
parainfluenza	B-DISO
virus	O
3	O
,	O
1	O
(	O
1	O
%)	O
parainfluenza	B-DISO
virus	O
1	O
,	O
and	O
2	O
(	O
2	O
%)	O
dual	O
infections	B-DISO
.	O

Neurological	O
examination	O
revealed	O
distal	O
weakness	B-DISO
and	O
loss	O
of	O
deep	O
tendon	O
reflexes	O
in	O
lower	O
extremities	O
.	O

Nerve	O
conduction	O
studies	O
displayed	O
severe	O
demyelinating	O
sensorimotor	B-DISO
polyneuropathy	I-DISO
,	O
and	O
plasmapheresis	O
was	O
therefore	O
applied	O
with	O
mild	O
improvement	O
.	O

ABSTRACT	O
:	O
In	O
2012	O
,	O
a	O
novel	O
coronavirus	O
associated	O
with	O
severe	O
respiratory	B-DISO
disease	I-DISO
in	O
humans	O
emerged	O
in	O
the	O
Middle	O
East	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
potential	O
transmission	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
to	O
health	O
care	O
workers	O
in	O
a	O
hospital	O
,	O
we	O
serologically	O
tested	O
hospital	O
contacts	O
of	O
the	O
index	O
case	O
-	O
patient	O
in	O
Saudi	O
Arabia	O
,	O
4	O
months	O
after	O
his	O
death	O
.	O

Among	O
the	O
45	O
cases	O
who	O
received	O
ECMO	O
for	O
pneumonia	B-DISO
(	O
n	O
=	O
19	O
),	O
exacerbation	O
of	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
(	O
n	O
=	O
11	O
),	O
ARDS	B-DISO
secondary	O
to	O
sepsis	B-DISO
(	O
n	O
=	O
8	O
),	O
aspiration	B-DISO
pneumonitis	I-DISO
(	O
n	O
=	O
2	O
),	O
postoperative	O
ARDS	B-DISO
(	O
n	O
=	O
3	O
),	O
and	O
others	O
(	O
n	O
=	O
2	O
),	O
21	O
(	O
46	O
.	O
7	O
%)	O
were	O
successfully	O
weaned	O
from	O
ECMO	O
.	O

Despite	O
this	O
initial	O
management	O
,	O
respiratory	B-DISO
failure	I-DISO
deteriorated	O
and	O
V	O
-	O
V	O
ECMO	O
was	O
introduced	O
.	O

RESULTS	O
:	O
Freedom	O
from	O
mechanical	O
ventilation	O
took	O
longer	O
in	O
the	O
lung	O
transplant	O
recipients	O
whose	O
donors	O
had	O
Heavy	B-DISO
Alcohol	I-DISO
Use	I-DISO
,	O
compared	O
with	O
those	O
whose	O
donors	O
had	O
No	O
Alcohol	O
Use	O
or	O
Moderate	O
Alcohol	O
Use	O
(	O
p	O
=	O
0	O
.	O
01	O
).	O

Nipah	O
virus	O
emerged	O
a	O
few	O
years	O
later	O
,	O
causing	O
respiratory	B-DISO
infections	I-DISO
and	O
encephalitis	B-DISO
in	O
Southeast	O
Asia	O
,	O
with	O
case	O
fatality	O
rates	O
ranging	O
from	O
40	O
%	O
to	O
more	O
than	O
90	O
%.	O

CONCLUSIONS	O
:	O
In	O
ARDS	B-DISO
patients	O
,	O
lung	O
barometry	O
method	O
cannot	O
be	O
used	O
instead	O
of	O
the	O
esophageal	O
pressure	O
measurement	O
to	O
assess	O
EL	O
.	O

Empiric	O
antifungal	O
therapy	O
comprising	O
voriconazole	O
was	O
also	O
initiated	O
owing	O
to	O
her	O
history	O
and	O
a	O
previous	O
case	O
report	O
of	O
aspergillosis	B-DISO
after	O
plant	O
mulch	O
exposure	O
,	O
though	O
there	O
was	O
no	O
microbiological	O
proof	O
at	O
the	O
time	O
.	O

Overall	O
,	O
these	O
results	O
indicate	O
that	O
the	O
BAC	O
-	O
based	O
MHV	O
reverse	O
genetics	O
system	O
will	O
be	O
useful	O
for	O
studies	O
of	O
JHMV	O
and	O
expand	O
upon	O
previous	O
studies	O
,	O
showing	O
that	O
the	O
macrodomain	O
is	O
critical	O
for	O
the	O
ability	O
of	O
coronaviruses	O
to	O
evade	O
the	O
immune	O
system	O
and	O
promote	O
viral	B-DISO
pathogenesis	I-DISO
.	O

The	O
coronavirus	O
macrodomain	O
has	O
ADP	O
-	O
ribose	O
-	O
1	O
"""-"	O
phosphatase	O
activity	O
;	O
however	O
,	O
its	O
function	O
during	O
infection	B-DISO
remains	O
unclear	O
as	O
does	O
the	O
reason	O
that	O
coronaviruses	O
have	O
maintained	O
this	O
enzymatic	O
activity	O
throughout	O
evolution	O
.	O

Understanding	O
the	O
mechanism	O
used	O
by	O
this	O
enzyme	O
to	O
promote	O
viral	B-DISO
pathogenesis	I-DISO
will	O
open	O
up	O
novel	O
avenues	O
for	O
therapies	O
and	O
may	O
give	O
further	O
insight	O
into	O
the	O
role	O
of	O
macrodomain	O
proteins	O
in	O
the	O
host	O
cell	O
since	O
these	O
proteins	O
are	O
found	O
in	O
all	O
living	O
organisms	O
.	O

It	O
is	O
an	O
important	O
determinant	O
of	O
viral	O
host	O
range	O
and	O
cross	O
-	O
species	O
infection	B-DISO
and	O
a	O
primary	O
target	O
for	O
antiviral	O
intervention	O
.	O

Before	O
combining	O
lung	O
recruitment	B-DISO
maneuver	O
,	O
24	O
h	O
after	O
combining	O
lung	O
recruitment	B-DISO
maneuver	O
,	O
and	O
at	O
the	O
end	O
of	O
combining	O
lung	O
recruitment	B-DISO
maneuver	O
,	O
the	O
EVLWI	O
values	O
of	O
4	O
patients	O
who	O
received	O
PiCCO	O
monitoring	O
were	O
respectively	O
(	O
13	O
.	O
5	O
±	O
1	O
.	O
3	O
),	O
(	O
10	O
.	O
2	O
±	O
1	O
.	O
0	O
),	O
(	O
7	O
.	O
0	O
±	O
0	O
.	O
8	O
)	O
mL	O
/	O
kg	O
(	O
F	O
=	O
117	O
.	O
00	O
,	O
P	O
<	O
0	O
.	O
01	O
).	O

In	O
'	O
under	O
-	O
fives	O
',	O
acute	B-DISO
asthma	I-DISO
and	O
pneumonia	B-DISO
have	O
similar	O
clinical	O
presentation	O
and	O
most	O
children	O
with	O
acute	O
respiratory	B-DISO
symptoms	I-DISO
are	O
diagnosed	O
with	O
pneumonia	B-DISO
according	O
to	O
the	O
WHO	O
criteria	O
.	O

Children	O
with	O
'	B-DISO
asthma	I-DISO
syndrome	B-DISO
'	O
had	O
a	O
significantly	O
shorter	O
hospital	O
stay	O
compared	O
to	O
those	O
with	O
pneumonia	B-DISO
(	O
p	O
<	O
0	O
.	O
001	O
).	O

This	O
may	O
be	O
related	O
to	O
focus	O
on	O
and	O
treatment	O
of	O
asthma	B-DISO
in	O
this	O
study	O
,	O
and	O
will	O
be	O
analysed	O
in	O
a	O
later	O
study	O
.	O

Hypoxemia	O
,	O
severe	B-DISO
malnutrition	I-DISO
,	O
and	O
being	O
an	O
infant	O
were	O
associated	O
with	O
poor	O
prognosis	O
among	O
children	O
with	O
acute	B-DISO
asthma	I-DISO
and	O
pneumonia	B-DISO
and	O
need	O
to	O
be	O
addressed	O
in	O
the	O
management	O
protocols	O
.	O

TITLE	O
:	O
Advances	O
in	O
prevention	O
and	O
therapy	O
of	O
neonatal	O
dairy	O
calf	O
diarrhoea	B-DISO
:	O
a	O
systematical	O
review	O
with	O
emphasis	O
on	O
colostrum	O
management	O
and	O
fluid	O
therapy	O
.	O

Histological	O
findings	O
associated	O
with	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
(	O
DAD	O
),	O
which	O
is	O
the	O
pathological	O
correlate	O
of	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
were	O
seen	O
in	O
approximately	O
42	O
%	O
of	O
autopsies	O
studied	O
.	O

The	O
aim	O
of	O
this	O
article	O
was	O
to	O
review	O
the	O
role	O
of	O
noninvasive	O
ventilation	O
(	O
NIV	O
)	O
in	O
acute	O
pulmonary	O
infectious	B-DISO
diseases	I-DISO
,	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
H1N1	O
and	O
tuberculosis	B-DISO
,	O
and	O
to	O
assess	O
the	O
risk	O
of	O
disease	B-DISO
transmission	I-DISO
with	O
the	O
use	O
of	O
NIV	O
from	O
patients	O
to	O
healthcare	O
workers	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
first	O
description	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
it	O
has	O
not	O
been	O
known	O
how	O
long	O
patients	O
shed	O
the	O
virus	O
in	O
respiratory	O
secretions	O
.	O

Contacts	O
cleared	O
MERS	O
-	O
CoV	O
earlier	O
than	O
ill	B-DISO
patients	O
.	O

IBV	O
causes	O
a	O
highly	O
contagious	B-DISO
disease	I-DISO
affecting	O
the	O
respiratory	O
tract	O
and	O
,	O
depending	O
on	O
the	O
strain	O
,	O
other	O
tissues	O
including	O
the	O
reproductive	O
and	O
urogenital	O
tract	O
.	O

TITLE	O
:	O
Insights	O
into	O
RNA	O
synthesis	O
,	O
capping	O
,	O
and	O
proofreading	O
mechanisms	O
of	O
SARS	B-DISO
-	O
coronavirus	O
.	O

ABSTRACT	O
:	O
The	O
successive	O
emergence	O
of	O
highly	O
pathogenic	O
coronaviruses	O
(	O
CoVs	O
)	O
such	O
as	O
the	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
)	O
in	O
2003	O
and	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
2012	O
has	O
stimulated	O
a	O
number	O
of	O
studies	O
on	O
the	O
molecular	O
biology	O
.	O

We	O
then	O
look	O
ahead	O
to	O
future	O
applications	O
of	O
these	O
viral	O
entry	O
/	O
fusion	O
inhibitors	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
specific	O
and	O
nonspecific	O
MERS	O
-	O
CoV	O
replication	O
inhibitors	O
,	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

TITLE	O
:	O
Porcine	B-DISO
reproductive	I-DISO
and	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
replication	O
and	O
quasispecies	O
evolution	O
in	O
pigs	O
that	O
lack	O
adaptive	O
immunity	O
.	O

Therefore	O
,	O
amino	O
acid	O
substitutions	O
that	O
appear	O
during	O
acute	B-DISO
infection	I-DISO
are	O
likely	O
the	O
result	O
of	O
the	O
adaptation	O
of	O
the	O
virus	O
to	O
replication	O
in	O
pigs	O
and	O
not	O
immune	O
selection	O
.	O

SHFV	O
infections	B-DISO
were	O
compared	O
in	O
macrophages	O
and	O
myeloid	O
dendritic	O
cells	O
from	O
baboons	O
and	O
macaques	O
.	O

SHFV	O
infection	B-DISO
induced	I-DISO
the	O
production	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
including	O
IL	O
-	O
1β	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
12	O
/	O
23	O
(	O
p40	O
),	O
TNF	O
-	O
α	O
and	O
MIP	B-DISO
-	O
1α	O
,	O
in	O
macaque	O
cells	O
but	O
not	O
baboon	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
outbreak	O
poses	O
a	O
serious	O
threat	O
to	O
public	O
health	O
.	O

As	O
of	O
28th	O
May	O
2014	O
,	O
636	O
laboratory	O
-	O
confirmed	O
cases	O
of	O
infection	B-DISO
with	O
MERS	O
-	O
CoV	O
have	O
been	O
reported	O
to	O
World	O
Health	O
Organization	O
including	O
14	O
cases	O
imported	O
by	O
travelers	O
.	O

The	O
patient	O
met	O
the	O
criteria	O
for	O
ARDS	B-DISO
with	O
a	O
PaO2	O
/	O
FiO2	O
ratio	O
of	O
94mmHg	O
.	O

An	O
investigation	O
of	O
the	O
dynamics	O
of	O
co	B-DISO
-	I-DISO
infections	I-DISO
revealed	O
a	O
synergistic	O
effect	O
between	O
CoV	O
and	O
IAV	O
,	O
whereby	O
CoV	O
prevalence	O
was	O
higher	O
given	O
that	O
the	O
birds	O
were	O
co	O
-	O
infected	O
with	O
IAV	O
.	O

Secondary	O
structure	O
predictions	O
for	O
5	O
'	O
regions	O
of	O
MHV	O
-	O
A59	O
,	O
BCoV	O
and	O
SARS	B-DISO
-	O
CoV	O
were	O
similar	O
despite	O
high	O
sequence	O
divergence	O
.	O

ABSTRACT	O
:	O
Human	O
coronaviruses	O
(	O
HCoVs	O
)	O
OC43	O
,	O
229E	O
,	O
NL63	O
and	O
HKU1	O
are	O
common	O
causes	O
of	O
respiratory	B-DISO
infections	I-DISO
.	O

There	O
is	O
a	O
need	O
to	O
increase	O
infection	B-DISO
control	O
capacity	O
in	O
affected	O
areas	O
and	O
areas	O
at	O
increased	O
risk	O
of	O
being	O
affected	O
to	O
prevent	O
transmission	O
in	O
health	O
care	O
settings	O
.	O

CONCLUSIONS	O
:	O
There	O
is	O
a	O
need	O
to	O
increase	O
infection	B-DISO
control	O
capacity	O
in	O
affected	O
areas	O
and	O
areas	O
at	O
increased	O
risk	O
of	O
being	O
affected	O
to	O
prevent	O
transmission	O
in	O
health	O
care	O
settings	O
.	O

ABSTRACT	O
:	O
Bovine	O
plasma	O
was	O
inoculated	O
with	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
at	O
an	O
average	O
final	O
titer	O
of	O
4	O
.	O
2	O
log10	O
TCID50	O
/	O
mL	O
to	O
determine	O
the	O
effect	O
of	O
spray	O
drying	O
on	O
viral	O
inactivation	B-DISO
.	O

Severity	O
and	O
further	O
characteristics	O
of	O
ALI	O
/	O
ARDS	B-DISO
may	O
be	O
detected	O
by	O
biomarkers	O
in	O
the	O
plasma	O
and	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
or	O
tracheal	O
aspirate	O
)	O
of	O
patients	O
.	O

This	O
chapter	O
reviews	O
various	O
biomarkers	O
of	O
acute	O
lung	O
injury	O
and	O
evaluates	O
their	O
usefulness	O
in	O
diagnostics	O
and	O
prognostication	O
of	O
ALI	O
/	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Newly	O
emerging	O
human	O
viruses	O
such	O
as	O
Ebola	O
virus	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
virus	O
,	O
and	O
HIV	B-DISO
likely	O
originate	O
within	O
an	O
extant	O
population	O
of	O
viruses	O
in	O
nonhuman	O
hosts	O
and	O
acquire	O
the	O
ability	O
to	O
infect	O
and	O
cause	O
disease	O
in	O
humans	O
.	O

Although	O
several	O
mechanisms	O
preventing	O
viral	B-DISO
infection	I-DISO
of	O
particular	O
hosts	O
have	O
been	O
described	O
,	O
the	O
mechanisms	O
and	O
constraints	O
on	O
viral	O
host	O
expansion	O
are	O
ill	B-DISO
defined	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
an	O
emerging	O
viral	O
pathogen	O
that	O
primarily	O
causes	O
respiratory	O
illness	O
.	O

Thus	O
,	O
obvious	O
positive	O
secondary	O
outcome	O
effects	O
with	O
intravenous	O
fish	O
oil	O
have	O
not	O
yet	O
been	O
shown	O
to	O
transfer	O
to	O
lower	O
mortality	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

There	O
is	O
a	O
need	O
for	O
adequately	O
powered	O
,	O
well	O
-	O
planned	O
and	O
well	O
-	O
conducted	O
randomized	O
trials	O
to	O
give	O
clear	O
recommendations	O
on	O
the	O
individual	O
utility	O
and	O
dosage	O
of	O
intravenous	O
omega	O
-	O
3	O
fatty	O
acids	O
in	O
critical	B-DISO
illness	I-DISO
.	O

Coronaviruses	O
induce	O
double	O
-	O
membrane	O
vesicles	B-DISO
(	O
DMVs	B-DISO
),	O
but	O
the	O
role	O
of	O
DMVs	B-DISO
in	O
replication	O
and	O
virus	O
fitness	O
remains	O
unclear	O
.	O

It	O
has	O
been	O
shown	O
previously	O
that	O
mutations	O
in	O
murine	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
nsp4	O
loop	O
1	O
that	O
alter	O
nsp4	O
glycosylation	O
are	O
associated	O
with	O
disrupted	O
DMV	O
formation	O
and	O
result	O
in	O
changes	O
in	O
virus	O
replication	O
and	O
RNA	O
synthesis	O
.	O

The	O
results	O
also	O
suggest	O
that	O
nsp4	O
glycosylation	O
serves	O
roles	O
in	O
replication	O
in	O
addition	O
to	O
the	O
organization	O
and	O
stability	O
of	O
MHV	O
-	O
induced	O
double	O
-	O
membrane	O
vesicles	B-DISO
.	O

In	O
contrast	O
with	O
H5N1	B-DISO
with	O
over	O
650	O
confirmed	O
cases	O
over	O
11	O
years	O
,	O
H7N9	O
has	O
infected	O
over	O
450	O
persons	O
within	O
2	O
years	O
.	O

Exposure	O
to	O
poultry	O
and	O
fomites	O
are	O
considered	O
the	O
likely	O
sources	O
of	O
infection	B-DISO
for	O
H7N9	O
,	O
H5N1	B-DISO
,	O
and	O
H10N8	O
,	O
with	O
limited	O
human	O
-	O
to	O
-	O
human	O
transmission	O
in	O
close	O
contacts	O
.	O

Vaccines	O
,	O
antivirals	O
,	O
and	O
other	O
therapeutics	O
remain	O
in	O
development	O
stage	O
or	O
of	O
modest	O
benefit	O
for	O
dangerous	O
infections	B-DISO
carrying	O
high	O
morbidity	O
and	O
mortality	O
.	O

FP	O
assumes	O
α	O
-	O
helical	O
conformation	O
with	O
significant	O
distortion	B-DISO
at	O
the	O
central	O
Gly	O
residues	O
;	O
enabling	O
a	O
close	O
packing	O
among	O
sidechains	O
of	O
aromatic	O
residues	O
including	O
W	O
,	O
Y	O
and	O
F	O
.	O
The	O
3	O
-	O
D	O
structure	O
of	O
PMT	B-DISO
is	O
characterized	O
by	O
a	O
helix	O
-	O
loop	O
-	O
helix	O
with	O
extensive	O
aromatic	O
interactions	O
within	O
the	O
helices	O
.	O

During	O
treatment	O
,	O
the	O
dehydration	B-DISO
speed	O
of	O
CVVHDF	O
was	O
set	O
at	O
50	O
ml	O
/	O
h	O
to	O
maintain	O
the	O
balance	O
of	O
fluid	O
input	O
and	O
output	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
assess	O
the	O
rate	O
of	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
(	O
DAD	O
)	O
on	O
open	O
lung	O
biopsy	O
(	O
OLB	O
)	O
performed	O
in	O
the	O
ICU	O
for	O
nonresolving	O
ARDS	B-DISO
.	O

The	O
secondary	O
endpoint	O
was	O
the	O
ability	O
of	O
DAD	O
to	O
predict	O
ARDS	B-DISO
among	O
all	O
the	O
patients	O
who	O
had	O
OLB	O
.	O

On	O
this	O
basis	O
,	O
the	O
systematic	O
use	O
of	O
steroids	O
in	O
nonresolving	O
ARDS	B-DISO
is	O
not	O
recommended	O
.	O

TITLE	O
:	O
The	O
SARS	B-DISO
coronavirus	O
papain	O
like	O
protease	O
can	O
inhibit	O
IRF3	O
at	O
a	O
post	O
activation	O
step	O
that	O
requires	O
deubiquitination	O
activity	O
.	O

Commercial	O
immunochromatography	O
testing	O
of	O
all	O
four	O
pathogens	O
and	O
molecular	O
analysis	O
of	O
C	O
.	O
parvum	O
with	O
diarrhea	B-DISO
in	O
calves	O
from	O
southernmost	O
Okinawa	O
and	O
northernmost	O
Hokkaido	O
,	O
Japan	O
,	O
were	O
conducted	O
.	O

In	O
a	O
recent	O
study	O
,	O
we	O
reported	O
a	O
promising	O
approach	O
to	O
study	O
FIP	B-DISO
pathogenesis	B-DISO
using	O
reverse	O
genetics	O
.	O

We	O
have	O
begun	O
to	O
extend	O
this	O
work	O
using	O
recombinant	O
IBVs	O
,	O
which	O
are	O
chimera	B-DISO
of	O
different	O
virus	O
strains	O
to	O
study	O
the	O
role	O
of	O
viral	O
proteins	O
in	O
the	O
induction	O
of	O
membrane	O
rearrangements	O
.	O

Viruses	O
were	O
detected	O
in	O
52	O
(	O
51	O
.	O
5	O
%)	O
of	O
samples	O
:	O
one	O
virus	O
(	O
25	O
EBV	O
,	O
8	O
PIV3	O
,	O
4	O
adenovirus	B-DISO
,	O
4	O
PIV2	O
,	O
1	O
PIV1	O
,	O
1	O
InVA	O
,	O
and	O
1	O
enterovirus	O
)	O
was	O
detected	O
in	O
44	O
patients	O
(	O
84	O
.	O
6	O
%),	O
two	O
viruses	O
in	O
7	O
patients	O
,	O
and	O
three	O
viruses	O
in	O
one	O
patient	O
.	O

The	O
timing	O
of	O
oral	O
-	O
sample	O
collection	O
is	O
crucial	O
to	O
correctly	O
interpret	O
the	O
negative	O
results	O
for	O
mumps	B-DISO
virus	O
RNA	O
,	O
especially	O
when	O
suspected	O
cases	O
occur	O
in	O
vaccinated	O
persons	O
.	O

ABSTRACT	O
:	O
This	O
article	O
reviews	O
the	O
use	O
of	O
noninvasive	O
ventilation	O
(	O
NIV	O
)	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
(	O
ARF	B-DISO
),	O
with	O
a	O
critical	O
review	O
of	O
the	O
most	O
recent	O
literature	O
in	O
this	O
setting	O
.	O

Despite	O
limited	O
evidence	O
,	O
NIV	O
may	O
improve	O
the	O
outcomes	O
of	O
patients	O
with	O
chest	O
trauma	O
and	O
severe	O
ARF	B-DISO
.	O

Although	O
patients	O
with	O
severe	O
hypoxemic	O
ARF	B-DISO
are	O
,	O
in	O
general	O
,	O
less	O
likely	O
to	O
be	O
intubated	O
when	O
NIV	O
is	O
used	O
,	O
the	O
efficacy	O
is	O
different	O
among	O
these	O
heterogeneous	O
populations	O
.	O

In	O
addition	O
,	O
analysis	O
of	O
the	O
effects	O
of	O
specific	O
kinase	O
inhibitors	O
on	O
MERS	O
-	O
CoV	O
infection	B-DISO
in	O
tissue	O
culture	O
models	O
confirmed	O
these	O
cellular	O
response	O
observations	O
.	O

Timing	O
of	O
thoracic	B-DISO
closure	O
is	O
based	O
on	O
physiology	O
.	O

Seven	O
patients	O
were	O
discharged	O
home	O
without	O
neurological	O
sequelae	O
,	O
while	O
2	O
patients	O
who	O
had	O
hypoxic	B-DISO
brain	I-DISO
damage	I-DISO
died	O
after	O
further	O
referral	O
.	O

ECMO	O
was	O
safe	O
and	O
effective	O
for	O
patients	O
with	O
ongoing	O
cardiac	B-DISO
arrest	I-DISO
or	O
ARDS	B-DISO
after	O
a	O
near	O
-	O
drowning	O
incident	O
and	O
can	O
be	O
used	O
as	O
a	O
resuscitative	O
strategy	O
in	O
near	O
-	O
drowning	O
patients	O
with	O
cardiac	O
or	O
pulmonary	B-DISO
failure	I-DISO
resistant	O
to	O
conventional	O
ventilator	O
therapy	O
.	O

Aiming	O
to	O
reduce	O
transfusion	O
requirements	O
,	O
we	O
implemented	O
a	O
blood	O
conservation	O
protocol	O
in	O
adults	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
receiving	O
ECMO	O
.	O

Implementation	O
of	O
a	O
blood	O
conservation	O
protocol	O
in	O
adults	O
receiving	O
ECMO	O
for	O
ARDS	B-DISO
resulted	O
in	O
lower	O
transfusion	O
requirements	O
and	O
bleeding	B-DISO
complications	O
than	O
previously	O
reported	O
in	O
the	O
literature	O
and	O
was	O
associated	O
with	O
comparable	O
survival	O
and	O
organ	O
recovery	O
.	O

Hypercapnia	B-DISO
-	O
mediated	O
NF	O
-	O
κB	O
inhibition	O
may	O
also	O
explain	O
several	O
deleterious	O
effects	O
,	O
including	O
delayed	O
epithelial	O
wound	O
healing	O
and	O
decreased	O
bacterial	O
killing	O
,	O
which	O
has	O
been	O
demonstrated	O
to	O
cause	O
worse	O
lung	O
injury	O
in	O
prolonged	O
untreated	O
pneumonia	B-DISO
models	O
.	O

We	O
prospectively	O
collected	O
and	O
reviewed	O
a	O
cohort	O
of	O
all	O
cases	O
of	O
severe	B-DISO
sepsis	I-DISO
and	O
septic	B-DISO
shock	I-DISO
admitted	O
to	O
the	O
medical	O
intensive	O
care	O
unit	O
from	O
the	O
ED	O
from	O
November	O
2009	O
to	O
March	O
2012	O
.	O

The	O
investigators	O
revealed	O
mutations	O
in	O
the	O
strain	O
isolated	O
from	O
the	O
bronchoalveolar	O
lavage	O
fluid	O
of	O
a	O
patient	O
with	O
severe	O
pneumonia	B-DISO
complicated	O
by	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

However	O
,	O
studies	O
are	O
required	O
to	O
assess	O
the	O
knowledge	O
and	O
attitude	O
of	O
HCWs	O
at	O
national	O
level	O
so	O
that	O
effective	O
interventions	O
could	O
be	O
designed	O
as	O
surveillance	O
and	O
infection	B-DISO
control	O
measures	O
are	O
critical	O
to	O
global	O
public	O
health	O
.	O

With	O
an	O
immune	O
-	O
mediated	O
disease	O
entity	O
,	O
host	O
genetic	O
variant	O
was	O
suggested	O
to	O
influence	O
the	O
occurrence	O
of	O
FIP	B-DISO
.	O

One	O
SNP	O
was	O
identified	O
in	O
the	O
extracellular	O
domain	O
(	O
ECD	B-DISO
)	O
of	O
fCD209	O
at	O
position	O
+	O
1900	O
,	O
a	O
G	O
to	O
A	O
substitution	O
,	O
and	O
the	O
A	O
allele	O
was	O
associated	O
with	O
FIP	B-DISO
susceptibility	O
.	O

Three	O
SNPs	O
located	O
in	O
the	O
introns	O
of	O
fCD209	O
,	O
at	O
positions	O
+	O
2276	O
,	O
+	O
2392	O
,	O
and	O
+	O
2713	O
,	O
were	O
identified	O
to	O
be	O
associated	O
with	O
the	O
outcome	O
of	O
FCoV	O
infection	B-DISO
,	O
with	O
statistical	O
relevance	O
.	O

In	O
contrast	O
,	O
among	O
the	O
five	O
Birman	O
FIP	B-DISO
cat	O
-	O
associated	O
SNPs	O
,	O
no	O
genotype	O
or	O
allele	O
showed	O
significant	O
differences	O
between	O
our	O
FIP	B-DISO
and	O
non	O
-	O
FIP	B-DISO
groups	O
.	O

At	O
clinical	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
11	O
±	O
3	O
cm	O
H2O	O
),	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
had	O
a	O
greater	O
lung	O
tissue	O
weight	O
and	O
recruitability	O
than	O
patients	O
with	O
mild	O
or	O
moderate	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
p	O
<	O
0	O
.	O
001	O
).	O

To	O
start	O
gaining	O
information	O
about	O
bat	O
-	O
transmitted	B-DISO
viruses	O
in	O
Hungary	O
,	O
we	O
tested	O
multiple	O
bat	O
species	O
for	O
several	O
virus	O
groups	O
between	O
2012	O
and	O
2013	O
.	O

We	O
performed	O
group	O
-	O
specific	O
RT	O
-	O
PCR	O
screening	O
for	O
astro	O
-,	O
calici	O
-,	O
corona	O
-,	O
lyssa	B-DISO
-,	O
othoreo	O
-,	O
paramyxo	O
-,	O
and	O
rotaviruses	O
.	O

Bat	O
-	O
transmitted	B-DISO
astroviruses	O
(	O
BtAstV	O
)	O
were	O
detected	O
in	O
eight	O
species	O
with	O
a	O
6	O
.	O
93	O
%	O
detection	O
rate	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
4	O
.	O
854	O
,	O
9	O
.	O
571	O
).	O

TITLE	O
:	O
A	O
retrospective	O
study	O
of	O
the	O
clinical	O
benefit	O
from	O
acetylsalicylic	O
acid	O
desensitization	O
in	O
patients	O
with	O
nasal	B-DISO
polyposis	I-DISO
and	O
asthma	B-DISO
.	O

The	O
practice	O
of	O
ASA	O
challenge	O
and	O
desensitization	O
in	O
Canada	O
is	O
infrequently	O
utilized	O
,	O
which	O
may	O
explain	O
its	O
omission	O
as	O
a	O
viable	O
therapeutic	O
option	O
in	O
the	O
latest	O
Canadian	O
clinical	O
practice	O
guidelines	O
for	O
acute	O
and	O
chronic	B-DISO
rhinosinusitis	I-DISO
(	O
AACI	O
7	O
:	O
1	O
-	O
38	O
,	O
2011	O
).	O

This	O
retrospective	O
study	O
assessed	O
111	O
patients	O
who	O
underwent	O
ASA	O
desensitization	O
in	O
the	O
Allergy	B-DISO
and	O
Immunology	O
clinic	O
at	O
St	O
.	O
Joseph	O
'	O
s	O
Healthcare	O
(	O
SJHC	O
)	O
in	O
London	O
,	O
Ontario	O
.	O

This	O
is	O
of	O
particular	O
benefit	O
in	O
those	O
who	O
require	O
these	O
medications	O
for	O
improved	O
quality	O
of	O
life	O
,	O
and	O
for	O
reduced	O
morbidity	O
and	O
mortality	O
,	O
such	O
as	O
those	O
with	O
cardiovascular	B-DISO
disease	I-DISO
or	O
chronic	B-DISO
pain	I-DISO
.	O

An	O
ongoing	O
randomized	O
controlled	O
trial	O
(	O
ECMO	O
to	O
rescue	O
lung	O
injury	O
in	O
severe	O
ARDS	B-DISO
)	O
will	O
contribute	O
valuable	O
data	O
to	O
guide	O
clinical	O
decisions	O
to	O
opt	O
for	O
this	O
supportive	O
therapy	O
.	O

ABSTRACT	O
:	O
Although	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
epidemic	O
was	O
controlled	O
by	O
nonvaccine	O
measures	O
,	O
coronaviruses	O
remain	O
a	O
major	O
threat	O
to	O
human	O
health	O
.	O

ABSTRACT	O
:	O
Hereditary	B-DISO
angioedema	I-DISO
(	O
HAE	O
)	O
is	O
a	O
rare	O
autosomal	O
dominant	O
disease	O
most	O
commonly	O
associated	O
with	O
defects	O
in	O
C1	O
esterase	O
inhibitor	O
(	O
C1	O
-	O
INH	O
).	O

Lung	O
-	O
protective	O
ventilation	O
is	O
still	O
the	O
key	O
of	O
better	O
outcome	O
in	O
ARDS	B-DISO
.	O

We	O
strongly	O
recommend	O
pressure	O
-	O
and	O
volume	O
limitation	O
and	O
suggest	O
using	O
higher	O
PEEP	O
and	O
prone	O
ventilation	O
in	O
patients	O
with	O
severe	O
respiratory	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Mesenchymal	O
stem	O
(	O
stromal	O
)	O
cells	O
for	O
treatment	O
of	O
ARDS	B-DISO
:	O
a	O
phase	O
1	O
clinical	O
trial	O
.	O

We	O
aimed	O
to	O
test	O
the	O
safety	O
of	O
a	O
single	O
dose	O
of	O
allogeneic	O
bone	O
marrow	O
-	O
derived	O
MSCs	O
in	O
patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	B-DISO
.	O

The	O
STem	O
cells	O
for	O
ARDS	B-DISO
Treatment	O
(	O
START	O
)	O
trial	O
was	O
a	O
multicentre	O
,	O
open	O
-	O
label	O
,	O
dose	O
-	O
escalation	O
,	O
phase	O
1	O
clinical	O
trial	O
.	O

A	O
profound	O
drop	O
in	O
the	O
absolute	O
count	O
of	O
blood	O
lymphocytes	O
occurred	O
around	O
2	O
weeks	O
post	O
-	O
infection	B-DISO
(	O
p	O
.	O
i	O
.)	O
in	O
cats	O
with	O
rapid	O
disease	O
,	O
while	O
the	O
decrease	O
was	O
delayed	O
in	O
the	O
one	O
cat	O
that	O
survived	O
for	O
6	O
weeks	O
.	O

Virus	O
was	O
usually	O
detected	O
at	O
relatively	O
low	O
levels	O
in	O
feces	O
and	O
there	O
was	O
no	O
evidence	O
of	O
enterocyte	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Elevated	O
cardiac	O
troponin	O
(	O
cTn	O
)	O
has	O
been	O
associated	O
with	O
worse	O
outcomes	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
,	O
but	O
few	O
studies	O
have	O
focused	O
on	O
whether	O
these	O
markers	O
are	O
related	O
to	O
outcomes	O
in	O
patients	O
with	O
severe	O
pneumonia	B-DISO
.	O

Patients	O
with	O
evidence	O
of	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
were	O
excluded	O
.	O

Bone	O
marrow	O
cytology	O
showed	O
prompted	O
bone	B-DISO
marrow	I-DISO
hyperplasia	I-DISO
,	O
and	O
the	O
phenomenon	O
of	O
phagocytosed	O
blood	O
cells	O
.	O

CT	O
scan	O
was	O
performed	O
for	O
all	O
the	O
cases	O
and	O
consolidation	O
with	O
pleural	B-DISO
effusion	I-DISO
were	O
shown	O
.	O

CONCLUSIONS	O
:	O
MP	O
-	O
HLH	B-DISO
is	O
a	O
rare	B-DISO
disease	I-DISO
in	O
children	O
,	O
and	O
had	O
acute	O
onset	O
,	O
rapid	O
progression	O
and	O
high	O
mortality	O
.	O

TITLE	O
:	O
A	O
comparison	O
of	O
smartphones	O
to	O
paper	O
-	O
based	O
questionnaires	O
for	O
routine	O
influenza	B-DISO
sentinel	O
surveillance	O
,	O
Kenya	O
,	O
2011	O
-	O
2012	O
.	O

Since	O
2006	O
,	O
the	O
Kenya	O
Ministry	O
of	O
Health	O
(	O
MoH	O
)	O
with	O
technical	O
support	O
from	O
the	O
Kenya	O
Medical	O
Research	O
Institute	O
/	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
KEMRI	O
/	O
CDC	O
)	O
conducted	O
hospital	O
-	O
based	O
sentinel	O
surveillance	O
for	O
influenza	B-DISO
in	O
Kenya	O
.	O

We	O
included	O
a	O
retrospective	O
cohort	O
study	O
of	O
patients	O
with	O
GBS	B-DISO
at	O
the	O
John	O
Radcliffe	O
Hospital	O
,	O
Oxford	O
2001	O
-	O
2012	O
and	O
determined	O
the	O
seasonal	O
variation	O
in	O
GBS	B-DISO
incidence	O
and	O
length	O
of	O
stay	O
.	O

To	O
study	O
MxA	O
protein	O
levels	O
in	O
healthy	O
state	O
and	O
during	O
respiratory	B-DISO
virus	I-DISO
infection	I-DISO
of	O
young	O
children	O
in	O
an	O
observational	O
prospective	O
cohort	O
.	O

Blood	O
MxA	O
protein	O
levels	O
are	O
increased	O
in	O
young	O
children	O
with	O
symptomatic	O
respiratory	O
virus	O
infections	B-DISO
,	O
including	O
rhinovirus	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
CoV	O
)	O
may	O
cause	O
severe	O
pneumonia	B-DISO
with	O
significant	O
morbidity	O
and	O
mortality	O
,	O
particularly	O
in	O
patients	O
with	O
multiple	O
comorbid	O
condition	B-DISO
.	O

Herein	O
,	O
we	O
report	O
a	O
case	O
of	O
MERS	O
CoV	O
pneumonia	B-DISO
with	O
a	O
successful	O
outcome	O
in	O
a	O
patient	O
recently	O
diagnosed	O
with	O
HIV	B-DISO
.	O

TITLE	O
:	O
Thiopurine	O
analogs	O
and	O
mycophenolic	O
acid	O
synergistically	O
inhibit	O
the	O
papain	O
-	O
like	O
protease	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
.	O

The	O
oxygenation	O
response	O
to	O
recruitment	B-DISO
maneuvers	O
was	O
associated	O
with	O
better	O
outcome	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
from	O
influenza	B-DISO
A	O
(	O
H1N1	O
).	O

These	O
results	O
suggest	O
that	O
intranasal	O
infection	B-DISO
of	O
MHV	O
-	O
A59	O
would	O
serve	O
as	O
a	O
surrogate	O
mouse	O
model	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
by	O
SARS	B-DISO
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
infections	B-DISO
.	O

Endotoxin	O
infusion	O
increased	O
serum	O
ET	O
-	O
1	O
,	O
and	O
INO	O
almost	O
doubled	O
the	O
ratio	O
between	O
mRNA	O
expression	O
of	O
endothelin	O
receptor	O
A	O
(	O
mediating	O
vasoconstriction	B-DISO
)	O
and	O
B	O
(	O
mediating	O
vasodilation	B-DISO
and	O
clearance	O
of	O
ET	O
-	O
1	O
)	O
(	O
ET	O
-	O
A	O
/	O
ET	O
-	O
B	O
)	O
in	O
atelectatic	O
lung	O
regions	O
.	O

In	O
Brazil	O
,	O
patients	O
with	O
severe	O
scorpion	O
envenoming	O
have	O
mainly	O
cardiovascular	O
events	O
,	O
including	O
acute	B-DISO
heart	I-DISO
failure	I-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
shock	O
,	O
death	O
is	O
rare	O
.	O

The	O
clinical	O
picture	O
in	O
this	O
scorpion	O
envenoming	O
is	O
mainly	O
characterized	O
by	O
an	O
acute	O
dysfunction	O
of	O
cerebellar	O
activities	O
and	O
abnormal	O
neuromuscular	B-DISO
manifestations	I-DISO
and	O
in	O
some	O
cases	O
muscle	O
injury	O
which	O
are	O
not	O
described	O
in	O
any	O
other	O
region	O
of	O
the	O
world	O
.	O

Here	O
,	O
we	O
report	O
that	O
development	O
of	O
a	O
transgenic	O
mouse	O
model	O
expressing	O
porcine	O
APN	O
which	O
is	O
susceptible	O
to	O
porcine	O
coronavirus	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Spatial	O
pattern	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
-	O
out	O
flow	O
in	O
2003	O
in	O
Mainland	O
China	O
.	O

There	O
were	O
5327	O
SARS	B-DISO
cases	O
from	O
November	O
2002	O
to	O
May	O
2003	O
in	O
Mainland	O
China	O
,	O
which	O
involved	O
29	O
provinces	O
,	O
resulted	O
in	O
349	O
deaths	O
,	O
and	O
directly	O
caused	O
economic	O
losses	O
of	O
$	O
18	O
.	O
3	O
billion	O
.	O

In	O
-	O
out	O
flow	O
is	O
measured	O
by	O
the	O
in	O
-	O
out	O
degree	O
and	O
clustering	O
coefficient	O
of	O
SARS	B-DISO
.	O

During	O
2002	O
-	O
2003	O
,	O
SARS	B-DISO
in	O
-	O
out	O
flow	O
played	O
an	O
important	O
role	O
in	O
countrywide	O
transmission	O
of	O
the	O
disease	O
in	O
Mainland	O
China	O
.	O

In	O
addition	O
,	O
the	O
Chinese	O
holiday	O
effect	O
led	O
to	O
irregular	O
spread	O
of	O
SARS	B-DISO
,	O
but	O
the	O
panic	O
effect	O
was	O
more	O
apparent	O
in	O
the	O
middle	O
and	O
late	O
stages	O
of	O
the	O
epidemic	O
.	O

Our	O
findings	O
suggest	O
that	O
both	O
EBOV	O
and	O
SARS	B-DISO
traffic	O
deep	O
into	O
the	O
endocytic	O
pathway	O
for	O
entry	O
and	O
that	O
they	O
do	O
so	O
to	O
access	O
higher	O
cathepsin	O
activity	O
.	O

Infection	B-DISO
by	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
causes	O
severe	O
respiratory	B-DISO
distress	I-DISO
in	O
infected	O
patients	O
.	O

Other	O
rats	O
,	O
including	O
Norway	O
rats	O
from	O
Hong	O
Kong	O
,	O
possessed	B-DISO
antibodies	O
only	O
against	O
N	O
protein	O
and	O
not	O
against	O
the	O
spike	O
polypeptide	O
,	O
suggesting	O
infection	B-DISO
by	O
βCoVs	O
different	O
from	O
ChRCoV	O
HKU24	O
.	O

ABSTRACT	O
:	O
Over	O
10	O
years	O
have	O
passed	O
since	O
the	O
deadly	O
human	O
coronavirus	O
that	O
causes	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
)	O
emerged	O
from	O
the	O
Guangdong	O
Province	O
of	O
China	O
.	O

From	O
September	O
29	O
,	O
2013	O
,	O
through	O
May	O
17	O
,	O
2014	O
,	O
17	O
pregnant	O
women	O
with	O
severe	O
influenza	B-DISO
were	O
reported	O
.	O

Influenza	B-DISO
remains	O
a	O
significant	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
pregnant	O
and	O
postpartum	O
women	O
;	O
in	O
our	O
series	O
,	O
a	O
majority	O
were	O
not	O
vaccinated	O
.	O

RESULTS	O
:	O
From	O
September	O
29	O
,	O
2013	O
,	O
through	O
May	O
17	O
,	O
2014	O
,	O
17	O
pregnant	O
women	O
with	O
severe	O
influenza	B-DISO
were	O
reported	O
.	O

ABSTRACT	O
:	O
Porcine	B-DISO
reproductive	I-DISO
and	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
PRRS	B-DISO
)	O
is	O
one	O
of	O
the	O
most	O
serious	O
diseases	O
affecting	O
the	O
swine	O
industry	O
worldwide	O
;	O
however	O
,	O
there	O
are	O
no	O
efficient	O
control	O
strategies	O
against	O
PRRS	B-DISO
virus	O
(	O
PRRSV	O
)	O
at	O
present	O
.	O

In	O
this	O
report	O
,	O
we	O
explored	O
whether	O
LiCl	O
had	O
the	O
potential	O
to	O
inhibit	O
PRRSV	O
infection	B-DISO
.	O

Overall	O
,	O
interest	O
in	O
this	O
elective	O
has	O
persisted	O
throughout	O
the	O
course	O
of	O
time	O
,	O
sometimes	O
temporarily	O
increasing	O
or	O
decreasing	O
with	O
outside	O
factors	O
,	O
such	O
as	O
the	O
events	O
of	O
11	O
September	O
2001	O
and	O
the	O
outbreak	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
in	O
Asia	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
mechanical	O
ventilation	O
settings	O
in	O
adult	O
patients	O
treated	O
for	O
an	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
with	O
extracorporeal	O
membrane	O
oxygenation	O
and	O
assess	O
the	O
potential	O
impact	O
of	O
mechanical	O
ventilation	O
settings	O
on	O
ICU	O
mortality	O
.	O

Since	O
CESAR	O
trial	O
,	O
the	O
clinical	O
application	O
of	O
ECLA	O
for	O
ARDS	B-DISO
as	O
a	O
method	O
to	O
achieve	O
lung	O
rest	O
has	O
wide	O
spread	O
.	O

The	O
effectiveness	O
is	O
further	O
appreciated	O
during	O
the	O
2009	O
H1N1	B-DISO
influenza	I-DISO
pandemic	O
.	O

The	O
present	O
study	O
suggested	O
the	O
potential	O
of	O
compounds	O
6	O
,	O
9	O
,	O
11	O
,	O
and	O
13	O
as	O
promising	O
scaffolds	O
for	O
treating	O
PEDV	O
infection	B-DISO
via	O
inhibiting	O
viral	O
replication	O
.	O

Moreover	O
,	O
the	O
system	O
newly	O
included	O
a	O
multivariable	O
logistic	O
regression	O
model	O
(	O
MLRM	O
)	O
to	O
determine	O
the	O
possibility	O
of	O
infection	B-DISO
.	O

TITLE	O
:	O
Levo	O
-	O
1	O
-	O
methyl	O
tryptophan	O
aggravates	O
the	O
effects	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
-	O
A59	O
)	O
infection	B-DISO
.	O

This	O
kind	O
of	O
empirically	O
validated	O
model	O
is	O
critical	O
to	O
exploring	O
strategies	O
for	O
public	O
health	O
intervention	O
,	O
increasing	O
our	O
ability	O
to	O
anticipate	O
the	O
response	O
to	O
infectious	B-DISO
disease	I-DISO
outbreaks	O
.	O

The	O
Betacoronavirus	O
genus	O
includes	O
human	O
pathogens	O
,	O
some	O
of	O
which	O
cause	O
severe	O
respiratory	B-DISO
disease	I-DISO
.	O

Murine	O
coronavirus	B-DISO
infection	I-DISO
of	O
mice	O
provides	O
a	O
useful	O
model	O
for	O
the	O
study	O
of	O
coronavirus	O
-	O
host	O
interactions	O
,	O
including	O
the	O
determinants	O
of	O
tropism	O
and	O
virulence	O
.	O

Infected	O
Tg	O
(+)	O
mice	O
developed	O
a	O
progressive	O
pneumonia	B-DISO
,	O
characterized	O
by	O
extensive	O
inflammatory	B-DISO
infiltration	I-DISO
.	O

The	O
standard	O
small	O
animals	O
,	O
mice	O
,	O
hamsters	O
,	O
and	O
ferrets	O
,	O
all	O
lack	O
the	O
functional	O
MERS	O
-	O
CoV	O
receptor	O
and	O
are	O
not	O
susceptible	O
to	O
infection	B-DISO
.	O

A	O
transversal	O
prospective	O
study	O
was	O
conducted	O
to	O
analyze	O
the	O
seasonality	O
of	O
CRS	B-DISO
using	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
to	O
detect	O
respiratory	O
virus	O
genomes	O
in	O
secretions	O
and	O
tissue	O
samples	O
from	O
patients	O
with	O
CRS	B-DISO
with	O
and	O
without	O
nasal	B-DISO
polyps	I-DISO
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
clinical	O
and	O
epidemiological	O
features	O
of	O
sarcoidosis	B-DISO
patients	O
in	O
a	O
referral	O
clinic	O
of	O
pulmonary	B-DISO
disease	I-DISO
in	O
city	O
of	O
Rasht	O
(	O
Guilan	O
-	O
Iran	O
).	O

ABSTRACT	O
:	O
Acute	B-DISO
eosinophilic	I-DISO
pneumonia	I-DISO
(	O
AEP	O
)	O
is	O
a	O
very	O
rare	O
condition	B-DISO
,	O
with	O
only	O
one	O
paper	O
published	O
so	O
far	O
discussing	O
histopathological	O
findings	O
at	O
surgical	O
biopsy	O
.	O

ABSTRACT	O
:	O
System	O
dynamics	O
approach	O
offers	O
great	O
potential	O
for	O
addressing	O
how	O
intervention	O
policies	O
can	O
affect	O
the	O
spread	O
of	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
in	O
complex	O
and	O
highly	O
networked	O
systems	O
.	O

Here	O
,	O
we	O
develop	O
a	O
model	O
that	O
explains	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
epidemic	O
that	O
occurred	O
in	O
Hong	O
Kong	O
in	O
2003	O
.	O

Attenuated	O
IB	O
virus	O
(	O
aIBV	O
group	O
)	O
or	O
its	O
vehicle	O
(	O
control	O
group	O
)	O
was	O
introduced	O
to	O
the	O
oviductal	O
magnum	O
lumen	O
of	O
White	O
Leghorn	O
hens	O
in	O
the	O
laying	O
and	O
molting	O
phase	O
,	O
as	O
well	O
as	O
molting	O
hens	O
injected	O
with	O
estradiol	O
benzoate	O
(	O
M	O
-	O
EB	O
hens	O
)	O
or	O
corn	B-DISO
oil	O
(	O
M	O
-	O
oil	O
hens	O
).	O

Compelling	O
pre	O
-	O
clinical	O
data	O
from	O
mouse	O
,	O
rat	O
,	O
sheep	O
and	O
ex	O
vivo	O
perfused	O
human	O
lung	O
models	O
support	O
the	O
use	O
of	O
human	O
mesenchymal	O
stem	O
(	O
stromal	O
)	O
cells	O
(	O
MSCs	O
)	O
as	O
a	O
novel	O
intravenous	O
therapy	O
for	O
the	O
early	O
treatment	O
of	O
ARDS	B-DISO
.	O

TITLE	O
:	O
The	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
from	O
mechanism	O
to	O
translation	O
.	O

ABSTRACT	O
:	O
The	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
form	O
of	O
severe	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
that	O
is	O
characterized	O
by	O
inflammatory	O
injury	O
to	O
the	O
alveolar	O
capillary	O
barrier	O
,	O
with	O
extravasation	B-DISO
of	O
protein	O
-	O
rich	O
edema	B-DISO
fluid	O
into	O
the	O
airspace	O
.	O

Data	O
was	O
retrospectively	O
collected	O
from	O
three	O
patients	O
admitted	O
with	O
MERS	O
-	O
CoV	O
infection	B-DISO
to	O
Intensive	O
Care	O
unit	O
(	O
ICU	O
)	O
at	O
King	O
Abdulaziz	O
Medical	O
City	O
,	O
Riyadh	O
.	O

Human	O
pDCs	O
are	O
the	O
immune	O
cell	O
population	O
sensing	O
MERS	O
-	O
CoV	O
but	O
secrete	O
significantly	O
larger	O
amounts	O
of	O
IFNs	O
,	O
especially	O
IFN	O
-	O
α	O
,	O
than	O
in	O
response	O
to	O
SARS	B-DISO
-	O
CoV	O
.	O
A	O
model	O
for	O
molecular	O
virus	O
-	O
host	O
interactions	O
is	O
presented	O
outlining	O
IFN	O
induction	O
in	O
pDCs	O
.	O

The	O
present	O
report	O
describes	O
a	O
case	O
of	O
Porcine	O
Circovirus	O
type	O
2	O
(	O
PCV2	O
),	O
infection	B-DISO
associated	O
with	O
lesions	O
of	O
PNES	O
at	O
the	O
weaning	O
stage	O
of	O
a	O
farrow	O
-	O
to	O
-	O
finish	O
pig	O
farm	O
.	O

The	O
present	O
study	O
based	O
on	O
the	O
clinical	O
signs	O
,	O
serological	O
and	O
pathological	O
examinations	O
,	O
indicates	O
that	O
weaners	O
suffered	B-DISO
by	O
sub	O
-	O
acute	O
PCV2	O
infection	B-DISO
resulting	O
in	O
PMWS	O
associated	O
with	O
PNES	O
.	O

TITLE	O
:	O
Molecular	O
detection	O
of	O
infectious	B-DISO
bronchitis	B-DISO
and	O
avian	O
metapneumoviruses	O
in	O
Oman	O
backyard	O
poultry	O
.	O

TITLE	O
:	O
CT	O
correlation	O
with	O
outcomes	O
in	O
15	O
patients	O
with	O
acute	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
.	O

CT	O
of	O
patients	O
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
predominantly	O
showed	O
ground	O
-	O
glass	O
opacities	B-DISO
,	O
with	O
peripheral	O
lower	O
lobe	O
preference	O
.	O

TITLE	O
:	O
Exchange	O
transfusion	O
in	O
patients	O
with	O
Down	B-DISO
syndrome	I-DISO
and	O
severe	O
transient	O
leukemia	B-DISO
.	O

Two	O
of	O
the	O
three	O
surviving	O
neonates	O
developed	O
acute	B-DISO
megakaryocytic	I-DISO
leukemia	I-DISO
at	O
age	O
90	O
days	O
and	O
222	O
days	O
.	O

ABSTRACT	O
:	O
Bovine	O
respiratory	B-DISO
disease	I-DISO
(	O
BRD	O
)	O
is	O
1	O
of	O
the	O
2	O
most	O
important	O
causes	O
of	O
morbidity	O
and	O
mortality	O
in	O
dairy	O
calves	O
.	O

ABSTRACT	O
:	O
In	O
response	O
to	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
pandemic	O
of	O
2003	O
and	O
the	O
influenza	B-DISO
pandemic	O
of	O
2009	O
,	O
many	O
countries	O
instituted	O
border	O
measures	O
as	O
a	O
means	O
of	O
stopping	O
or	O
slowing	O
the	O
spread	O
of	O
disease	O
.	O

The	O
measures	O
,	O
usually	O
consisting	O
of	O
a	O
combination	O
of	O
border	O
entry	O
/	O
exit	O
screening	O
,	O
quarantine	O
,	O
isolation	O
,	O
and	O
communications	O
,	O
were	O
resource	O
intensive	O
,	O
and	O
modeling	O
and	O
observational	O
studies	O
indicate	O
that	O
border	O
screening	O
is	O
not	O
effective	O
at	O
detecting	O
infectious	B-DISO
persons	O
.	O

ABSTRACT	O
:	O
The	O
development	O
of	O
HIV	B-DISO
-	O
1	O
dual	O
inhibitors	O
is	O
a	O
highly	O
innovative	O
approach	O
aimed	O
at	O
reducing	O
drug	O
toxic	O
side	O
effects	O
as	O
well	O
as	O
therapeutic	O
costs	O
.	O

We	O
suspected	O
that	O
his	O
symptoms	O
were	O
associated	O
with	O
a	O
pulmonary	O
lipiodol	O
embolism	B-DISO
after	O
TACE	O
,	O
and	O
we	O
began	O
intensive	O
treatment	O
.	O

Protective	O
mechanical	O
ventilation	O
has	O
emerged	O
as	O
the	O
comer	O
stone	O
of	O
the	O
management	O
of	O
ARDS	B-DISO
to	O
avoid	O
the	O
occurrence	O
of	O
ventilation	O
-	O
induced	O
lung	O
injuries	O
(	O
VILI	O
).	O

TITLE	O
:	O
Canine	O
adenovirus	B-DISO
type	O
1	O
in	O
a	O
fennec	O
fox	O
(	O
Vulpes	O
zerda	O
).	O

ABSTRACT	O
:	O
A	O
10	O
-	O
mo	O
-	O
old	O
female	O
fennec	O
fox	O
(	O
Vulpes	O
zerda	O
)	O
with	O
drooling	B-DISO
suddenly	O
died	O
and	O
was	O
examined	O
postmortem	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	B-DISO
),	O
an	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
caused	O
by	O
MERS	B-DISO
coronavirus	O
(	O
MERS	B-DISO
-	O
CoV	O
),	O
has	O
garnered	O
worldwide	O
attention	O
as	O
a	O
consequence	O
of	O
its	O
continuous	O
spread	O
and	O
pandemic	O
potential	O
,	O
making	O
the	O
development	O
of	O
effective	O
vaccines	O
a	O
high	O
priority	O
.	O

Despite	O
the	O
1	O
:	O
1	O
:	O
1	O
group	O
receiving	O
more	O
plasma	O
(	O
median	O
of	O
7	O
U	O
vs	O
5	O
U	O
,	O
P	O
<	O
.	O
001	O
)	O
and	O
platelets	O
(	O
12	O
U	O
vs	O
6	O
U	O
,	O
P	O
<	O
.	O
001	O
)	O
and	O
similar	O
amounts	O
of	O
red	O
blood	O
cells	O
(	O
9	O
U	O
)	O
over	O
the	O
first	O
24	O
hours	O
,	O
no	O
differences	O
between	O
the	O
2	O
groups	O
were	O
found	O
for	O
the	O
23	O
prespecified	O
complications	O
,	O
including	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
,	O
venous	B-DISO
thromboembolism	I-DISO
,	O
sepsis	B-DISO
,	O
and	O
transfusion	O
-	O
related	O
complications	O
.	O

Faecal	O
specimens	O
from	O
1283	O
calves	O
were	O
scored	O
as	O
liquid	O
,	O
semi	O
-	O
solid	O
or	O
solid	O
,	O
and	O
analysed	O
for	O
bovine	O
rotavirus	O
(	O
BRV	B-DISO
)	O
and	O
coronavirus	O
(	O
BCV	O
),	O
enterotoxigenic	O
K99	O
(+)	O
Escherichia	O
coli	O
(	O
K99	O
),	O
Salmonella	B-DISO
spp	O
.	O

TITLE	O
:	O
Severe	O
Falciparum	B-DISO
Malaria	I-DISO
-	O
Difference	O
in	O
Mortality	O
among	O
Male	O
and	O
Nonpregnant	O
Females	O
.	O

Our	O
objective	O
was	O
to	O
evaluate	O
the	O
prevalence	O
,	O
outcomes	O
,	O
and	O
risk	O
factors	O
associated	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
children	O
up	O
to	O
15	O
years	O
according	O
to	O
the	O
Berlin	O
definition	O
.	O

Among	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
according	O
to	O
the	O
Berlin	O
definition	O
,	O
nine	O
patients	O
(	O
16	O
%)	O
were	O
mild	O
,	O
21	O
(	O
37	O
%)	O
were	O
moderate	O
,	O
and	O
27	O
(	O
47	O
%)	O
were	O
severe	O
.	O

The	O
presence	O
of	O
two	O
or	O
more	O
comorbidities	O
and	O
admission	O
for	O
medical	O
reasons	O
were	O
associated	O
with	O
development	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Comparisons	O
across	O
the	O
three	O
the	O
Berlin	O
categories	O
showed	O
significant	O
differences	O
in	O
the	O
number	O
of	O
ventilator	O
-	O
free	O
days	O
(	O
21	O
,	O
20	O
,	O
and	O
5	O
d	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
and	O
mortality	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
41	O
%)	O
in	O
comparison	O
with	O
mild	O
(	O
0	O
)	O
and	O
moderate	O
(	O
15	O
%)	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
p	O
=	O
0	O
.	O
02	O
).	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
:	O
An	O
emerging	O
coronavirus	B-DISO
infection	I-DISO
tracked	O
by	O
the	O
crowd	O
.	O

TITLE	O
:	O
Plasma	O
levels	O
of	O
soluble	O
receptor	O
for	O
advanced	O
glycation	O
end	O
products	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Plasma	O
sRAGE	O
levels	O
were	O
significantly	O
elevated	O
in	O
the	O
plasma	O
samples	O
taken	O
from	O
patients	O
with	O
ARDS	B-DISO
(	O
1797	O
±	O
383	O
pg	O
/	O
ml	O
)	O
when	O
compared	O
with	O
both	O
ventilated	O
(	O
650	O
±	O
192	O
pg	O
/	O
ml	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
healthy	O
(	O
415	O
±	O
178	O
pg	O
/	O
ml	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
controls	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
gain	O
entry	O
into	O
cells	O
,	O
diverse	O
viruses	O
,	O
including	O
Ebola	O
virus	O
,	O
SARS	B-DISO
-	O
coronavirus	O
and	O
the	O
emerging	O
MERS	O
-	O
coronavirus	O
,	O
depend	O
on	O
activation	O
of	O
their	O
envelope	O
glycoproteins	O
by	O
host	O
cell	O
proteases	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
effects	O
of	O
different	O
tidal	O
volume	O
(	O
VT	O
)	O
ventilation	O
on	O
paraquat	O
-	O
induced	O
acute	O
lung	O
injury	O
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ALI	O
/	O
ARDS	B-DISO
)	O
in	O
piglets	O
.	O

The	O
piglets	O
showed	O
ALI	O
/	O
ARDS	B-DISO
in	O
4	O
.	O
5	O
±	O
0	O
.	O
8	O
hours	O
after	O
PQ	O
intraperitoneal	O
injection	O
.	O

TITLE	O
:	O
Preemptive	O
enteral	O
nutrition	O
enriched	O
with	O
eicosapentaenoic	O
acid	O
,	O
gamma	O
-	O
linolenic	O
acid	O
and	O
antioxidants	O
in	O
severe	O
multiple	O
trauma	O
:	O
a	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	B-DISO
study	O
.	O

ABSTRACT	O
:	O
Severe	O
injury	O
triggers	O
a	O
complex	O
systemic	O
immune	O
response	O
which	O
may	O
result	O
in	O
significant	O
respiratory	O
compromise	O
,	O
including	O
the	O
development	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

No	O
randomized	O
clinical	O
trial	O
has	O
assessed	O
the	O
role	O
of	O
nutritional	O
interventions	O
to	O
limit	O
respiratory	B-DISO
complications	I-DISO
.	O

The	O
development	O
of	O
infectious	B-DISO
complications	O
and	O
fatty	O
acid	O
red	O
blood	O
cell	O
membrane	O
composition	O
were	O
also	O
assessed	O
.	O

The	O
significantly	O
higher	O
incidence	O
of	O
bacteremia	B-DISO
noted	O
in	O
the	O
study	O
group	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
was	O
associated	O
with	O
a	O
higher	O
number	O
of	O
patients	O
with	O
multiple	O
trauma	O
and	O
a	O
higher	O
red	O
blood	O
cell	O
transfusion	O
requirement	O
(	O
P	O
=	O
0	O
.	O
008	O
).	O

RESULTS	O
:	O
In	O
this	O
intention	O
-	O
to	O
-	O
treat	O
population	O
,	O
no	O
significant	O
differences	O
between	O
the	O
control	O
and	O
study	O
groups	O
were	O
found	O
for	O
the	O
PF	O
ratio	O
at	O
day	O
4	O
(	O
213	O
.	O
7	O
±	O
85	O
.	O
6	O
vs	O
.	O
227	O
.	O
2	O
±	O
67	O
.	O
7	O
,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
24	O
)	O
and	O
day	O
8	O
(	O
187	O
.	O
8	O
±	O
65	O
.	O
2	O
vs	O
.	O
188	O
.	O
9	O
±	O
56	O
.	O
0	O
,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
82	O
),	O
the	O
incidence	O
of	O
ARDS	B-DISO
/	O
ALI	O
(	O
24	O
.	O
1	O
vs	O
.	O
29	O
.	O
0	O
%,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
68	O
),	O
length	O
of	O
ventilation	O
time	O
(	O
13	O
.	O
6	O
±	O
10	O
.	O
7	O
vs	O
.	O
17	O
.	O
0	O
±	O
15	O
.	O
1	O
days	O
,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
15	O
),	O
duration	O
of	O
ICU	O
stay	O
(	O
16	O
.	O
4	O
±	O
11	O
.	O
3	O
vs	O
.	O
19	O
.	O
5	O
±	O
15	O
.	O
3	O
days	O
,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
21	O
)	O
and	O
28	O
-	O
day	O
mortality	O
(	O
8	O
.	O
6	O
vs	O
.	O
12	O
.	O
9	O
%,	O
respectively	O
P	O
=	O
0	O
.	O
56	O
).	O

TITLE	O
:	O
Molecular	O
Epidemiology	O
of	O
the	O
Human	O
Rhinovirus	B-DISO
Infection	I-DISO
in	O
Mongolia	O
during	O
2008	O
-	O
2013	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
complications	O
,	O
particularly	O
in	O
the	O
respiratory	O
tract	O
of	O
critically	B-DISO
ill	I-DISO
patients	O
,	O
are	O
related	O
to	O
increased	O
mortality	O
.	O

TITLE	O
:	O
Positive	O
immunolabelling	O
for	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
in	O
an	O
African	O
lion	O
(	O
Panthera	O
leo	O
)	O
with	O
bilateral	O
panuveitis	B-DISO
.	O

ABSTRACT	O
:	O
A	O
15	O
-	O
year	O
-	O
old	O
male	O
African	O
lion	O
(	O
Panthera	O
leo	O
)	O
was	O
presented	O
with	O
blindness	B-DISO
due	O
to	O
bilateral	O
panuveitis	B-DISO
with	O
retinal	B-DISO
detachment	I-DISO
.	O

This	O
is	O
the	O
first	O
report	O
of	O
FIP	B-DISO
in	O
an	O
African	O
lion	O
and	O
the	O
first	O
report	O
of	O
ocular	O
FIP	B-DISO
in	O
a	O
non	O
-	O
domestic	O
felid	O
.	O

Eligible	O
participants	O
were	O
mechanically	O
ventilated	O
in	O
the	O
ICU	O
with	O
a	O
confirmed	O
diagnosis	O
of	O
H1N1	B-DISO
influenza	I-DISO
.	O

Health	O
-	O
related	O
quality	O
of	O
life	O
of	O
Australasian	O
survivors	O
of	O
severe	O
H1N1	B-DISO
influenza	I-DISO
was	O
comparable	O
to	O
the	O
healthy	O
population	O
1	O
year	O
after	O
ICU	O
discharge	O
.	O

TITLE	O
:	O
Porcine	O
aminopeptidase	O
N	O
mediated	O
polarized	O
infection	B-DISO
by	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
in	O
target	O
cells	O
.	O

These	O
results	O
imply	O
the	O
possibility	O
that	O
PEDV	O
infection	B-DISO
may	O
proceed	O
by	O
lateral	O
spread	O
of	O
virus	O
in	O
intestinal	O
epithelial	O
cells	O
.	O

TITLE	O
:	O
Rapid	O
detection	O
of	O
equine	O
coronavirus	O
by	O
reverse	O
transcription	O
loop	O
-	O
mediated	O
isothermal	O
amplification	B-DISO
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
was	O
initially	O
recognized	O
as	O
a	O
source	O
of	O
severe	O
respiratory	O
illness	O
and	O
renal	B-DISO
failure	I-DISO
in	O
2012	O
.	O

TITLE	O
:	O
Respiratory	B-DISO
infections	I-DISO
:	O
respiratory	B-DISO
infections	I-DISO
in	O
immigrants	O
to	O
the	O
United	O
States	O
.	O

Zoonotic	O
infections	B-DISO
,	O
such	O
as	O
influenza	B-DISO
A	O
,	O
and	O
novel	O
coronavirus	B-DISO
infections	I-DISO
also	O
are	O
of	O
increasing	O
concern	O
because	O
of	O
population	O
mobility	O
.	O

Symptoms	O
typically	O
associated	O
with	O
wet	B-DISO
feline	I-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
including	O
ascites	O
,	O
abdominal	O
distention	B-DISO
or	O
pleural	B-DISO
effusion	I-DISO
,	O
coupled	O
in	O
many	O
cases	O
with	O
non	O
-	O
antibiotic	O
responsive	O
fever	O
,	O
were	O
observed	O
in	O
19	O
%	O
(	O
32	O
/	O
169	O
)	O
of	O
cats	O
,	O
and	O
75	O
%	O
(	O
24	O
/	O
32	O
)	O
of	O
these	O
cats	O
were	O
FCoV	O
seropositive	O
.	O

Six	O
hundred	O
and	O
fifty	O
-	O
one	O
(	O
77	O
.	O
6	O
%)	O
pilgrims	O
had	O
respiratory	B-DISO
symptoms	I-DISO
.	O

The	O
prevalence	O
of	O
viral	O
respiratory	B-DISO
infections	I-DISO
among	O
Hajj	O
pilgrims	O
in	O
both	O
symptomatic	O
and	O
asymptomatic	O
subjects	O
was	O
high	O
.	O

TITLE	O
:	O
Aptamers	O
in	O
diagnostics	O
and	O
treatment	O
of	O
viral	B-DISO
infections	I-DISO
.	O

The	O
syndrome	B-DISO
is	O
thought	O
to	O
result	O
from	O
occlusion	B-DISO
of	O
the	O
artery	O
of	O
Percheron	O
,	O
which	O
arises	O
as	O
a	O
common	O
trunk	O
from	O
one	O
of	O
the	O
posterior	O
cerebral	O
arteries	O
to	O
supply	O
both	O
paramedian	O
thalamic	O
regions	O
.	O

In	O
the	O
present	O
study	O
,	O
11	O
complete	O
genomes	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
field	O
isolates	O
from	O
China	O
were	O
determined	O
and	O
analyzed	O
.	O

Since	O
3CLpro	O
is	O
functionally	O
and	O
structurally	O
conserved	O
among	O
these	O
viruses	O
and	O
essential	O
for	O
viral	O
replication	O
,	O
3CLpro	O
is	O
considered	O
a	O
potential	O
target	O
for	O
the	O
design	O
of	O
antiviral	O
drugs	O
with	O
broad	O
-	O
spectrum	O
activities	O
against	O
these	O
distinct	O
and	O
highly	O
important	O
viral	B-DISO
infections	I-DISO
.	O

Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
)	O
is	O
the	O
leading	O
cause	O
of	O
death	O
in	O
young	O
cats	O
,	O
and	O
virulent	O
,	O
systemic	O
feline	O
calicivirus	O
(	O
vs	O
-	O
FCV	O
)	O
causes	O
a	O
highly	O
fatal	O
disease	O
in	O
cats	O
for	O
which	O
no	O
preventive	O
or	O
therapeutic	O
measure	O
is	O
available	O
.	O

However	O
,	O
no	O
studies	O
have	O
previously	O
reported	O
a	O
structural	O
platform	O
for	O
the	O
design	O
of	O
antiviral	O
drugs	O
with	O
activities	O
against	O
these	O
viruses	O
or	O
on	O
the	O
efficacy	O
of	O
3CLpro	O
inhibitors	O
against	O
coronavirus	B-DISO
infection	I-DISO
in	O
experimental	O
animals	O
.	O

However	O
,	O
the	O
thermal	O
stability	O
of	O
the	O
Ubl	O
mutant	B-DISO
PLP2	O
was	O
significantly	O
reduced	O
at	O
30	O
°	O
C	O
,	O
thereby	O
reducing	O
the	O
total	O
enzymatic	O
activity	O
.	O

These	O
studies	O
revealed	O
that	O
modulating	O
the	O
Ubl	O
domain	O
adjacent	O
to	O
the	O
PLP	O
reduces	O
protease	O
stability	O
and	O
viral	B-DISO
pathogenesis	I-DISO
,	O
revealing	O
a	O
novel	O
approach	O
to	O
coronavirus	O
attenuation	O
.	O

ABSTRACT	O
:	O
In	O
January	O
,	O
2014	O
,	O
increased	O
mortality	O
was	O
reported	O
in	O
piglets	O
with	O
acute	B-DISO
diarrhea	I-DISO
on	O
an	O
Ontario	O
farm	O
.	O

ABSTRACT	O
:	O
Patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
hypercapnia	B-DISO
present	O
a	O
formidable	O
treatment	O
challenge	O
.	O

Bacteremia	B-DISO
was	O
documented	O
in	O
10	O
.	O
1	O
%	O
of	O
the	O
patients	O
.	O

This	O
is	O
in	O
stark	O
contrast	O
with	O
results	O
obtained	O
for	O
other	O
coronaviruses	O
,	O
except	O
for	O
the	O
SARS	B-DISO
-	O
CoV	O
.	O

US	O
clinicians	O
need	O
to	O
be	O
familiar	O
with	O
recommendations	O
regarding	O
when	O
to	O
suspect	O
MERS	O
-	O
CoV	O
,	O
how	O
to	O
make	O
a	O
diagnosis	O
,	O
and	O
what	O
infection	B-DISO
control	O
measures	O
need	O
to	O
be	O
instituted	O
when	O
a	O
case	O
is	O
suspected	O
.	O

Viruses	O
seem	O
common	O
in	O
adults	O
attending	O
emergency	B-DISO
departments	O
with	O
suspected	O
CAP	B-DISO
.	O

Episodes	O
of	O
ventilator	B-DISO
-	I-DISO
associated	I-DISO
pneumonia	I-DISO
were	O
recorded	O
on	O
days	O
5	O
and	O
12	O
.	O

Both	O
groups	O
were	O
further	O
subdivided	O
according	O
to	O
a	O
threshold	O
stroke	B-DISO
volume	O
variation	O
(	O
SVV	O
)	O
of	O
13	O
%	O
as	O
a	O
parameter	O
of	O
fluid	O
responsiveness	O
.	O

ABSTRACT	O
:	O
Here	O
,	O
we	O
measured	O
presepsins	O
(	O
PSPs	O
)	O
in	O
four	O
patients	O
with	O
acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
or	O
chronic	B-DISO
kidney	I-DISO
disease	I-DISO
(	O
CKD	O
)	O
and	O
discuss	O
the	O
relationship	O
between	O
PSP	B-DISO
and	O
kidney	B-DISO
dysfunction	I-DISO
.	O

PSP	B-DISO
level	O
(	O
pg	O
/	O
ml	O
)	O
on	O
day	O
2	O
was	O
2	O
,	O
745	O
without	O
elevation	O
of	O
other	O
conventional	O
biomarkers	O
.	O

Spatially	O
invariant	O
residues	O
in	O
the	O
N6	O
and	O
influenza	B-DISO
B	O
neuraminidase	O
active	O
sites	O
were	O
found	O
in	O
previously	O
unidentified	O
spatially	O
equivalent	O
sites	O
in	O
the	O
N10	O
and	O
N11	O
proteins	O
.	O

The	O
presentation	O
of	O
E2S	O
-	O
like	O
,	O
SARS	B-DISO
spike	O
protein	O
-	O
like	O
,	O
or	O
toxin	O
-	O
like	O
domains	O
by	O
the	O
N10	O
and	O
N11	O
proteins	O
in	O
these	O
emerging	O
viruses	O
may	O
indicate	O
that	O
H17N10	O
and	O
H18N11	O
sialidase	O
-	O
facilitated	O
cell	O
entry	O
has	O
been	O
supplemented	O
or	O
replaced	O
by	O
sialidase	O
-	O
independent	O
receptor	O
binding	O
to	O
an	O
expanded	O
cell	O
population	O
that	O
may	O
include	O
neurons	O
and	O
T	O
-	O
cells	O
.	O

Our	O
work	O
shows	O
that	O
fruit	O
bat	O
cells	O
have	O
homologs	O
of	O
cathepsin	O
and	O
furin	O
proteases	O
capable	O
of	O
cleaving	O
and	O
activating	O
both	O
the	O
cathepsin	O
-	O
dependent	O
Hendra	O
virus	O
F	O
and	O
the	O
furin	O
-	O
dependent	O
parainfluenza	B-DISO
virus	O
5	O
F	O
proteins	O
.	O

TITLE	O
:	O
Diagnostic	O
performance	O
of	O
a	O
rapid	O
in	O
-	O
clinic	O
test	O
for	O
the	O
detection	O
of	O
Canine	O
Parvovirus	B-DISO
under	O
different	O
storage	O
conditions	O
and	O
vaccination	O
status	O
.	O

TITLE	O
:	O
Association	O
of	O
bovine	O
respiratory	B-DISO
disease	I-DISO
or	O
vaccination	O
with	O
serologic	O
response	O
in	O
dairy	O
heifer	O
calves	O
up	O
to	O
three	O
months	O
of	O
age	O
.	O

Calves	O
with	O
initial	O
antibody	O
titers	O
against	O
BRSV	O
<	O
1	O
:	O
64	O
that	O
were	O
treated	O
for	O
BRD	O
had	O
a	O
slower	O
rate	O
of	O
anti	O
-	O
BRSV	O
antibody	O
decay	B-DISO
than	O
did	O
similar	O
calves	O
that	O
were	O
not	O
treated	O
for	O
BRD	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
the	O
short	O
-	O
term	O
(	O
days	O
to	O
weeks	O
)	O
support	O
of	O
patients	O
with	O
severe	O
respiratory	O
and	O
/	O
or	O
cardiac	B-DISO
failure	I-DISO
.	O

The	O
use	O
of	O
these	O
devices	O
has	O
been	O
well	O
established	O
in	O
paediatric	O
and	O
post	O
-	O
heart	O
and	O
lung	O
transplantation	O
patients	O
;	O
however	O
,	O
its	O
use	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
has	O
gained	O
acceptance	O
as	O
standard	O
clinical	O
practice	O
over	O
the	O
past	O
decade	O
.	O

Among	O
the	O
151	O
symptomatic	O
patients	O
who	O
were	O
not	O
health	O
care	O
personnel	O
,	O
112	O
(	O
74	O
.	O
2	O
%)	O
had	O
data	O
that	O
could	O
be	O
assessed	O
,	O
and	O
109	O
(	O
97	O
.	O
3	O
%)	O
of	O
these	O
patients	O
had	O
had	O
contact	O
with	O
a	O
health	O
care	O
facility	O
,	O
a	O
person	O
with	O
a	O
confirmed	O
case	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
,	O
or	O
someone	O
with	O
severe	O
respiratory	O
illness	O
in	O
the	O
14	O
days	O
before	O
the	O
onset	O
of	O
illness	O
.	O

We	O
report	O
two	O
cases	O
of	O
MERS	O
CoV	O
infections	B-DISO
in	O
two	O
renal	O
transplant	O
recipients	O
with	O
variable	O
clinical	O
presentations	O
and	O
outcomes	O
.	O

Further	O
data	O
are	O
needed	O
to	O
gain	O
better	O
understanding	O
of	O
the	O
impact	O
of	O
anti	O
-	O
rejection	O
immunosuppressive	O
therapy	O
on	O
the	O
clinical	O
presentation	O
,	O
severity	O
and	O
outcome	O
of	O
MERS	O
CoV	O
infections	B-DISO
in	O
solid	O
organ	O
transplant	O
recipients	O
.	O

TITLE	O
:	O
Quantification	O
of	O
infectious	B-DISO
bronchitis	B-DISO
coronavirus	O
by	O
titration	O
in	O
vitro	O
and	O
in	O
ovo	O
.	O

There	O
are	O
no	O
effective	O
vaccines	O
or	O
treatment	O
available	O
,	O
and	O
the	O
virus	O
virulence	O
determinants	O
and	O
pathogenesis	B-DISO
are	O
not	O
fully	O
understood	O
.	O

ABSTRACT	O
:	O
Transmission	O
electron	O
microscopy	O
(	O
TEM	B-DISO
)	O
is	O
an	O
invaluable	O
technique	O
used	O
for	O
imaging	O
the	O
ultrastructure	O
of	O
samples	O
and	O
it	O
is	O
particularly	O
useful	O
when	O
determining	O
virus	O
-	O
host	O
interactions	O
at	O
a	O
cellular	O
level	O
.	O

This	O
study	O
suggests	O
the	O
potential	O
role	O
of	O
the	O
TM	O
domain	O
in	O
nsp6	O
,	O
the	O
integrity	O
of	O
the	O
S2	O
protein	O
and	O
the	O
B	O
-	O
TRS	B-DISO
3	O
,	O
and	O
the	O
putative	O
accessory	O
protein	O
4b	O
,	O
as	O
well	O
as	O
the	O
3	O
'	O
untranslated	O
region	O
,	O
in	O
the	O
virulence	O
and	O
replication	O
of	O
IBV	O
and	O
has	O
provided	O
a	O
better	O
understanding	O
of	O
relationships	O
between	O
the	O
Australian	O
vaccine	O
strain	O
of	O
IBV	O
and	O
those	O
used	O
elsewhere	O
.	O

Severe	O
lung	O
injury	O
with	O
respiratory	B-DISO
failure	I-DISO
is	O
often	O
encountered	O
in	O
trauma	O
patients	O
.	O

TITLE	O
:	O
[	O
Severe	O
pulmonary	B-DISO
tuberculosis	I-DISO
in	O
the	O
ICU	O
,	O
diagnosis	O
and	O
treatment	O
].	O

ABSTRACT	O
:	O
Pulmonary	B-DISO
tuberculosis	I-DISO
can	O
rarely	O
lead	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
anti	O
-	O
tuberculous	B-DISO
therapy	O
initiation	O
depends	O
on	O
this	O
difficult	O
diagnosis	O
in	O
ICU	O
.	O

TITLE	O
:	O
Structure	O
-	O
activity	O
relationships	O
of	O
3	O
-	O
O	O
-	O
β	O
-	O
chacotriosyl	O
ursolic	O
acid	O
derivatives	O
as	O
novel	O
H5N1	B-DISO
entry	O
inhibitors	O
.	O

We	O
designed	O
and	O
synthesised	O
a	O
new	O
generation	O
of	O
HIV	B-DISO
-	O
1	O
RT	O
inhibitors	O
,	O
based	O
on	O
the	O
(	O
3Z	O
)-	O
3	O
-(	O
2	O
-[	O
4	O
-(	O
aryl	O
)-	O
1	O
,	O
3	O
-	O
thiazol	O
-	O
2	O
-	O
yl	O
]	O
hydrazin	O
-	O
1	O
-	O
ylidene	O
)-	O
2	O
,	O
3	O
-	O
dihydro	O
-	O
1H	O
-	O
indol	O
-	O
2	O
-	O
one	O
scaffold	O
.	O

Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
tests	O
are	O
often	O
used	O
to	O
detect	O
viruses	O
in	O
samples	O
,	O
it	O
is	O
difficult	O
to	O
interpret	O
the	O
clinical	O
significance	O
of	O
PCR	O
positivity	O
,	O
which	O
may	O
reflect	O
a	O
past	O
,	O
imminent	O
or	O
active	O
asymptomatic	B-DISO
infection	I-DISO
due	O
to	O
their	O
high	O
sensitivity	O
.	O

The	O
detection	O
limit	O
corresponds	O
to	O
a	O
cycle	O
treshold	O
value	O
of	O
∼	O
35	O
with	O
standard	O
upE	O
real	O
time	O
PCR	O
assays	O
on	O
RNA	O
isolated	O
from	O
MERS	O
-	O
CoV	O
EMC	B-DISO
.	O

We	O
collected	O
and	O
tested	O
73	O
nasopharyngeal	O
specimens	O
;	O
of	O
which	O
,	O
2	O
,	O
were	O
positive	O
for	O
human	O
Coronavirus	O
OC43	O
and	O
1	O
for	O
influenza	B-DISO
C	O
virus	O
.	O

SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
nonstructural	O
protein	O
nsp16	O
functions	O
as	O
a	O
methyltransferase	O
,	O
to	O
methylate	O
mRNA	O
cap	B-DISO
-	O
0	O
structure	O
at	O
the	O
ribose	O
2	O
'-	O
O	O
position	O
of	O
the	O
first	O
nucleotide	O
to	O
form	O
cap	B-DISO
-	O
1	O
structures	O
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
newly	O
identified	O
pathogen	O
able	O
of	O
human	O
transmission	O
that	O
causes	O
a	O
mortality	O
of	O
almost	O
40	O
%.	O

TITLE	O
:	O
Severe	O
morbidity	O
and	O
mortality	O
risk	O
from	O
malaria	B-DISO
in	O
the	O
United	O
States	O
,	O
1985	O
-	O
2011	O
.	O

A	O
total	O
of	O
315	O
respiratory	O
samples	O
from	O
children	O
under	O
6	O
years	O
of	O
age	O
suffering	B-DISO
from	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
,	O
were	O
studied	O
by	O
IF	O
for	O
8	O
respiratory	O
viruses	O
and	O
by	O
RT	O
-	O
PCR	O
for	O
rhinoviruses	O
.	O

ABSTRACT	O
:	O
Patients	O
with	O
respiratory	B-DISO
failure	I-DISO
may	O
benefit	O
from	O
veno	O
-	O
venous	O
and	O
veno	O
-	O
arterial	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
support	O
.	O

This	O
study	O
was	O
performed	O
on	O
an	O
experimental	O
model	O
of	O
ARDS	B-DISO
obtained	O
in	O
eight	O
anaesthetized	O
pigs	O
connected	O
to	O
a	O
volume	O
-	O
cycled	O
ventilator	O
.	O

ARDS	B-DISO
was	O
obtained	O
by	O
repeated	O
bronchoalveolar	O
lavage	O
.	O

CO2	O
removal	O
decreased	O
pulmonary	B-DISO
hypertension	I-DISO
and	O
improved	O
RV	O
function	O
.	O

RESULTS	O
:	O
ARDS	B-DISO
induced	O
severe	O
hypercapnic	B-DISO
acidosis	I-DISO
.	O

CONCLUSIONS	O
:	O
Veno	O
-	O
venous	O
CO2	O
removal	O
therapy	O
enabled	O
protective	O
ventilation	O
while	O
maintaining	O
normocarbia	O
during	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Advanced	O
testicular	B-DISO
cancer	I-DISO
associated	O
with	O
life	O
-	O
threatening	O
tumour	B-DISO
lysis	I-DISO
syndrome	I-DISO
and	O
choriocarcinoma	B-DISO
syndrome	B-DISO
.	O

TITLE	O
:	O
Isolation	O
and	O
characterization	O
of	O
porcine	O
deltacoronavirus	O
from	O
pigs	O
with	O
diarrhea	B-DISO
in	O
the	O
United	O
States	O
.	O

TITLE	O
:	O
Long	O
-	O
term	O
experience	O
with	O
rituximab	O
in	O
anti	O
-	O
synthetase	O
syndrome	B-DISO
-	O
related	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
To	O
retrospectively	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
rituximab	O
(	O
Rtx	O
)	O
treatment	O
in	O
patients	O
with	O
anti	O
-	O
synthetase	O
syndrome	B-DISO
(	O
ASS	O
)	O
and	O
severe	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
(	O
ILD	O
).	O

Moreover	O
,	O
CD107a	O
mobilisation	O
was	O
analysed	O
on	O
CTL	O
isolated	O
from	O
airways	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)-	O
infected	O
birds	O
direct	O
ex	O
vivo	O
and	O
upon	O
in	O
vitro	O
stimulation	O
.	O

Preceding	O
infection	B-DISO
was	O
detected	O
in	O
32	O
cases	O
(	O
80	O
%).	O

Six	O
patients	O
had	O
speech	B-DISO
impairment	I-DISO
.	O

The	O
diagnosis	O
of	O
ARDS	B-DISO
,	O
HIV	B-DISO
infection	I-DISO
and	O
MDR	O
bacterial	O
and	O
fungal	O
VAP	O
was	O
made	O
.	O

ABSTRACT	O
:	O
PET	O
with	O
[	O
18F	O
]	O
fluoro	O
-	O
2	O
-	O
deoxy	O
-	O
D	O
-	O
glucose	O
can	O
be	O
used	O
to	O
image	O
cellular	O
metabolism	O
,	O
which	O
during	O
lung	B-DISO
inflammation	I-DISO
mainly	O
reflects	O
neutrophil	O
activity	O
,	O
allowing	O
the	O
study	O
of	O
regional	O
lung	B-DISO
inflammation	I-DISO
in	O
vivo	O
.	O

The	O
global	O
lung	O
uptake	O
was	O
elevated	O
at	O
3	O
and	O
27	O
hours	O
,	O
suggesting	O
persisting	O
inflammation	B-DISO
.	O

The	O
prevalence	O
of	O
ARDS	B-DISO
was	O
34	O
%	O
(	O
n	O
=	O
304	O
)	O
for	O
the	O
entire	O
cohort	O
,	O
33	O
%	O
(	O
n	O
=	O
96	O
)	O
for	O
military	O
,	O
and	O
35	O
%	O
(	O
n	O
=	O
208	O
)	O
for	O
civilians	O
(	O
p	O
=	O
0	O
.	O
55	O
).	O

An	O
eschar	B-DISO
and	O
a	O
maculopapular	O
rash	B-DISO
each	O
were	O
observed	O
in	O
20	O
%	O
of	O
patients	O
.	O

Recombinant	O
human	O
interferon	O
alpha	O
2b	O
has	O
a	O
stronger	O
inhibitory	O
effect	O
on	O
different	O
influenza	B-DISO
A	O
virus	O
RNA	O
than	O
drug	O
control	O
.	O

Recombinant	O
human	O
interferon	O
alpha	O
2b	O
is	O
expected	O
to	O
become	O
the	O
efficient	O
medicine	O
in	O
clinical	O
against	O
respiratory	O
viruses	O
,	O
as	O
well	O
as	O
provide	O
better	O
services	O
for	O
prevention	O
and	O
treatment	O
of	O
respiratory	O
viruses	O
'	O
infections	B-DISO
.	O

Within	O
1	O
to	O
3	O
days	O
postinfection	O
,	O
profuse	O
watery	B-DISO
diarrhea	I-DISO
,	O
vomiting	B-DISO
,	O
and	O
dehydration	B-DISO
were	O
observed	O
.	O

We	O
found	O
that	O
PdCV	O
caused	O
severe	B-DISO
diarrhea	I-DISO
,	O
vomiting	B-DISO
,	O
and	O
dehydration	B-DISO
in	O
gnotobiotic	O
and	O
conventional	O
piglets	O
,	O
signs	O
that	O
were	O
clinically	O
indistinguishable	O
from	O
those	O
caused	O
by	O
PEDV	O
and	O
TGEV	O
.	O

ABSTRACT	O
:	O
A	O
32	O
-	O
nucleotide	O
(	O
nt	O
)	O
RNA	O
motif	O
located	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
transmissible	O
gastroenteritis	B-DISO
coronavirus	O
(	O
TGEV	O
)	O
genome	O
was	O
found	O
to	O
specifically	O
interact	O
with	O
the	O
host	O
proteins	O
glutamyl	O
-	O
prolyl	O
-	O
tRNA	O
synthetase	O
(	O
EPRS	O
)	O
and	O
arginyl	O
-	O
tRNA	O
synthetase	O
(	O
RRS	B-DISO
).	O

To	O
test	O
the	O
functional	O
role	O
of	O
the	O
GAIT	O
-	O
like	O
RNA	O
motif	O
during	O
TGEV	O
infection	B-DISO
,	O
a	O
recombinant	O
coronavirus	O
harboring	O
mutations	O
in	O
this	O
motif	O
was	O
engineered	O
and	O
characterized	O
.	O

Furthermore	O
,	O
the	O
mutant	B-DISO
virus	O
was	O
more	O
sensitive	O
to	O
beta	O
interferon	O
than	O
the	O
parental	O
virus	O
.	O

The	O
combination	O
of	O
anti	O
-	O
hepatitis	B-DISO
B	I-DISO
virus	O
(	O
HBV	B-DISO
)	O
immunoglobulin	O
and	O
entecavir	O
was	O
initiated	O
for	O
anti	O
-	O
HBV	B-DISO
therapy	O
.	O

The	O
use	O
of	O
these	O
brain	O
-	O
penetrating	O
gene	O
vectors	O
,	O
in	O
conjunction	O
with	O
CED	B-DISO
,	O
offers	O
an	O
avenue	O
to	O
improve	O
gene	O
therapy	O
for	O
CNS	B-DISO
diseases	I-DISO
.	O

Intragastric	O
administration	O
of	O
either	O
Ad5	B-DISO
-	O
S	O
or	O
Ad41	O
-	O
S	O
induced	O
antigen	O
-	O
specific	O
IgG	O
and	O
neutralizing	O
antibody	O
in	O
serum	O
;	O
however	O
,	O
antigen	O
-	O
specific	O
T	O
-	O
cell	O
responses	O
were	O
not	O
detected	O
.	O

The	O
ECG	O
only	O
revealed	O
type	O
1	O
Brugada	B-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
All	O
medical	O
staff	O
and	O
travellers	O
to	O
the	O
Arabian	O
Peninsula	O
should	O
be	O
aware	O
of	O
a	O
new	O
epidemic	O
caused	O
by	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
which	O
has	O
emerged	O
in	O
the	O
Arabian	O
Peninsula	O
(	O
2012	O
),	O
secondary	O
cases	O
have	O
been	O
seen	O
in	O
Africa	O
,	O
Europe	O
,	O
Asia	O
and	O
the	O
United	O
States	O
.	O

Avian	B-DISO
influenza	I-DISO
A	O
(	O
H5N1	B-DISO
)	O
and	O
A	O
(	O
H7N9	O
)	O
viruses	O
have	O
continued	O
to	O
circulate	O
widely	O
in	O
some	O
poultry	O
populations	O
and	O
infect	O
humans	O
sporadically	O
.	O

Secondly	O
,	O
MERS	O
PLpro	O
cleaves	O
polyUb	O
chains	O
in	O
a	O
'	B-DISO
mono	I-DISO
-	O
distributive	O
'	O
manner	O
(	O
one	O
Ub	O
at	O
a	O
time	O
)	O
and	O
SARS	B-DISO
PLpro	O
prefers	O
to	O
cleave	O
Lys48	O
-	O
linked	O
polyUb	O
chains	O
by	O
sensing	O
a	O
di	O
-	O
Ub	O
moiety	O
as	O
a	O
minimal	O
recognition	O
element	O
using	O
a	O
'	O
di	O
-	O
distributive	O
'	O
cleavage	O
mechanism	O
.	O

Here	O
,	O
a	O
retrospective	O
cohort	O
study	O
to	O
evaluate	O
the	O
impact	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDv	O
)	O
infection	B-DISO
on	O
growing	O
pigs	O
'	O
performance	O
,	O
as	O
indicated	O
by	O
mortality	O
,	O
average	O
daily	O
gain	O
(	O
ADG	O
),	O
average	O
daily	O
feed	O
intake	O
(	O
ADFI	O
),	O
and	O
feed	O
conversion	O
ratio	O
(	O
FCR	O
)	O
was	O
performed	O
using	O
production	O
records	O
from	O
weaned	O
pigs	O
in	O
nursery	O
and	O
wean	O
-	O
to	O
-	O
finish	O
sites	O
from	O
sow	O
farms	O
that	O
became	O
PEDv	O
-	O
infected	O
between	O
May	O
2013	O
and	O
June	O
2014	O
.	O

Recently	O
,	O
a	O
SAP	O
patient	O
in	O
our	O
intensive	O
care	O
unit	O
had	O
sudden	B-DISO
cardiac	I-DISO
arrest	I-DISO
.	O

Such	O
zoonotic	O
hepatitis	B-DISO
E	I-DISO
infection	B-DISO
has	O
particular	O
relevance	O
to	O
the	O
increasing	O
population	O
living	O
with	O
immunosuppression	O
,	O
due	O
to	O
the	O
risk	O
of	O
chronic	B-DISO
hepatitis	I-DISO
E	I-DISO
in	O
these	O
patients	O
.	O

Furthermore	O
,	O
pretreatment	O
with	O
400	O
mg	O
/	O
kg	O
eucalyptol	O
prevented	O
LPS	B-DISO
-	O
induced	O
histopathological	O
changes	O
.	O

The	O
former	O
is	O
HIV	B-DISO
-	O
1	O
specific	O
;	O
the	O
latter	O
is	O
broadly	O
reactive	O
and	O
is	O
able	O
to	O
neutralize	O
viruses	O
of	O
distinct	O
phylogenetic	O
origins	O
,	O
such	O
as	O
HIV	B-DISO
-	O
1	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
and	O
human	O
cytomegalovirus	O
(	O
HCMV	O
).	O

ABSTRACT	O
:	O
Community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
CAP	B-DISO
)	O
is	O
the	O
most	O
common	O
infectious	B-DISO
disease	I-DISO
cause	O
of	O
death	O
.	O

Outside	O
of	O
the	O
United	O
States	O
,	O
MDRO	O
are	O
relatively	O
uncommon	O
causes	O
of	O
CAP	B-DISO
,	O
and	O
the	O
increased	O
mortality	O
of	O
HCAP	O
category	O
patients	O
seems	O
to	O
be	O
related	O
to	O
their	O
comorbidities	O
and	O
age	O
rather	O
than	O
microbial	O
aetiology	O
.	O

Noroviruses	O
and	O
adenoviruses	O
are	O
common	O
causes	O
of	O
gastroenteritis	B-DISO
in	O
children	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
the	O
broad	O
caspase	O
inhibitor	O
Z	O
-	O
VAD	O
(	O
OMe	O
)-	O
FMK	O
(	O
zVAD	O
)	O
on	O
inflammation	B-DISO
and	O
lung	O
injury	O
in	O
a	O
mouse	O
pneumovirus	O
model	O
for	O
severe	O
RSV	O
disease	O
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
;	O
Coronaviridae	O
family	O
)	O
causes	O
huge	O
economic	O
losses	O
to	O
the	O
swine	O
industry	O
.	O

ABSTRACT	O
:	O
Recent	O
outbreaks	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
have	O
caused	O
widespread	O
concern	O
.	O

The	O
identification	O
of	O
proteins	O
associated	O
with	O
PEDV	O
infection	B-DISO
might	O
provide	O
insight	O
into	O
PEDV	O
pathogenesis	B-DISO
and	O
facilitate	O
the	O
development	O
of	O
novel	O
antiviral	O
strategies	O
.	O

Among	O
the	O
disease	O
-	O
related	O
functions	O
,	O
certain	O
anti	O
-	O
viral	O
pathways	O
and	O
proteins	O
,	O
such	O
as	O
the	O
RIG	O
-	O
I	O
-	O
like	O
receptor	O
,	O
Rap1	O
,	O
autophagy	O
,	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
,	O
PI3K	O
-	O
Akt	O
and	O
Jak	O
-	O
STAT	O
signaling	O
pathways	O
,	O
and	O
integrin	O
β2	O
/	O
β3	O
and	O
cystatin	O
-	O
C	O
proteins	O
,	O
represented	O
potential	O
factors	O
in	O
PEDV	O
infection	B-DISO
.	O

Peer	O
-	O
reviewed	O
articles	O
were	O
identified	O
through	O
searches	O
of	O
PubMed	O
using	O
the	O
terms	O
""""	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
","""	O
""""	O
coronavirus	O
respiratory	O
illness	O
in	O
Saudi	O
Arabia	O
","""	O
and	O
""""	O
novel	O
(	O
beta	O
)	O
coronavirus	O
and	O
human	O
coronavirus	O
Erasmus	O
Medical	O
Center	O
"""."	O

The	O
risk	O
of	O
CLD	B-DISO
in	O
survivors	O
at	O
term	O
equivalent	O
gestational	O
age	O
was	O
significantly	O
reduced	O
with	O
the	O
use	O
of	O
HFOV	O
but	O
this	O
effect	O
was	O
inconsistent	O
across	O
studies	O
,	O
even	O
after	O
the	O
meta	O
-	O
analysis	O
was	O
restricted	O
to	O
studies	O
that	O
applied	O
a	O
high	O
lung	O
volume	O
strategy	O
with	O
HFOV	O
.	O

The	O
short	O
-	O
term	O
neurological	B-DISO
morbidity	I-DISO
with	O
HFOV	O
was	O
only	O
found	O
in	O
the	O
subgroup	O
of	O
two	O
trials	O
not	O
using	O
a	O
high	O
volume	O
strategy	O
with	O
HFOV	O
.	O

Our	O
results	O
show	O
that	O
TK9	O
inhibits	O
the	O
fibrillation	B-DISO
of	O
hIAPP	O
,	O
a	O
37	O
amino	O
acid	O
peptide	O
implicated	O
in	O
the	O
pathology	B-DISO
of	O
type	O
-	O
II	O
diabetes	B-DISO
.	O

We	O
intended	O
to	O
demonstrate	O
the	O
incidence	O
of	O
respiratory	O
viral	B-DISO
infections	I-DISO
detected	O
by	O
PCR	O
and	O
real	O
-	O
time	O
PCR	O
in	O
adult	O
patients	O
with	O
CAP	B-DISO
.	O

We	O
searched	O
PubMed	O
and	O
Embase	O
for	O
studies	O
providing	O
the	O
incidence	O
of	O
respiratory	O
viral	B-DISO
infections	I-DISO
in	O
adult	O
patients	O
with	O
CAP	B-DISO
.	O

Incidences	O
ranged	O
from	O
8	O
.	O
6	O
to	O
56	O
.	O
2	O
%	O
for	O
overall	O
respiratory	O
viral	B-DISO
infections	I-DISO
.	O

The	O
combined	O
incidence	O
of	O
viral	O
coinfections	B-DISO
with	O
other	O
pathogens	O
was	O
12	O
.	O
4	O
%	O
(	O
95	O
%	O
CI	O
=	O
9	O
.	O
7	O
-	O
15	O
.	O
0	O
).	O

Moreover	O
,	O
the	O
influenza	B-DISO
virus	O
,	O
rhinovirus	O
and	O
coronavirus	O
were	O
the	O
3	O
most	O
frequently	O
detected	O
viral	O
pathogens	O
in	O
adult	O
patients	O
with	O
CAP	B-DISO
according	O
to	O
our	O
study	O
.	O

ABSTRACT	O
:	O
The	O
source	O
of	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
epidemic	O
was	O
traced	O
to	O
wildlife	O
market	O
civets	O
and	O
ultimately	O
to	O
bats	O
.	O

We	O
recently	O
managed	O
a	O
case	O
of	O
leptospirosis	B-DISO
with	O
isolated	O
lung	O
involvement	O
as	O
alveolar	O
hemorrhage	B-DISO
and	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
To	O
verify	O
whether	O
porcine	O
deltacoronavirus	O
infection	B-DISO
induces	O
disease	O
,	O
we	O
inoculated	O
gnotobiotic	O
pigs	O
with	O
2	O
virus	O
strains	O
(	O
OH	O
-	O
FD22	O
and	O
OH	O
-	O
FD100	O
)	O
identified	O
by	O
2	O
specific	O
reverse	O
transcription	O
PCRs	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Corona	O
Virus	O
(	O
MERS	O
CoV	O
):	O
The	O
next	O
steps	O
.	O

TITLE	O
:	O
Viral	O
etiology	O
of	O
community	O
-	O
acquired	O
pneumonia	B-DISO
among	O
adolescents	O
and	O
adults	O
with	O
mild	O
or	O
moderate	O
severity	O
and	O
its	O
relation	O
to	O
age	O
and	O
severity	O
.	O

Frequency	O
of	O
IFV	O
A	O
was	O
highest	O
among	O
patients	O
aged	O
between	O
45	O
-	O
64	O
years	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
while	O
adenovirus	B-DISO
among	O
patients	O
aged	O
14	O
-	O
17	O
years	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
no	O
differences	O
was	O
found	O
in	O
other	O
RVs	O
.	O

The	O
findings	O
contribute	O
baseline	O
data	O
on	O
viral	O
CAP	B-DISO
study	O
in	O
China	O
.	O

They	O
were	O
more	O
likely	O
to	O
have	O
complications	O
such	O
as	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
liver	O
and	O
renal	O
dysfunctions	O
,	O
and	O
had	O
a	O
significantly	O
higher	O
risk	O
of	O
death	O
.	O

TITLE	O
:	O
Aerosol	O
transmission	B-DISO
of	I-DISO
infectious	I-DISO
disease	I-DISO
.	O

TITLE	O
:	O
Pathogenicity	O
and	O
pathogenesis	B-DISO
of	O
a	O
United	O
States	O
porcine	O
deltacoronavirus	O
cell	O
culture	O
isolate	O
in	O
5	O
-	O
day	O
-	O
old	O
neonatal	O
piglets	O
.	O

The	O
PDCoV	O
-	O
inoculated	O
piglets	O
developed	O
mild	O
to	O
moderate	O
diarrhea	B-DISO
,	O
shed	O
increasing	O
amount	O
of	O
virus	O
in	O
rectal	O
swabs	O
from	O
2	O
to	O
7	O
days	O
post	O
inoculation	O
,	O
and	O
developed	O
macroscopic	O
and	O
microscopic	O
lesions	O
in	O
small	O
intestines	O
with	O
viral	O
antigen	O
confirmed	O
by	O
immunohistochemistry	O
staining	O
.	O

Most	O
of	O
these	O
viruses	O
are	O
genetically	O
simple	O
and	O
rely	O
heavily	O
on	O
co	O
-	O
opting	O
cellular	O
proteins	O
,	O
particularly	O
cellular	O
RNA	O
-	O
binding	O
proteins	O
,	O
into	O
new	O
roles	O
for	O
support	O
of	O
virus	B-DISO
infection	I-DISO
at	O
the	O
level	O
of	O
virus	O
-	O
specific	O
translation	O
,	O
and	O
building	O
RNA	O
replication	O
complexes	O
.	O

TITLE	O
:	O
Co	B-DISO
-	I-DISO
infections	I-DISO
with	O
respiratory	O
viruses	O
in	O
dogs	O
with	O
bacterial	B-DISO
pneumonia	I-DISO
.	O

Respiratory	O
viruses	O
were	O
found	O
frequently	O
in	O
dogs	O
with	O
BP	O
and	O
may	O
therefore	O
play	O
an	O
important	O
role	O
in	O
the	O
etiology	O
and	O
pathogenesis	B-DISO
of	O
BP	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
clinical	O
variables	O
between	O
BP	O
dogs	O
with	O
and	O
without	O
a	O
viral	O
co	B-DISO
-	I-DISO
infection	I-DISO
.	O

Additionally	O
,	O
no	O
association	O
was	O
observed	O
between	O
the	O
polymorphisms	O
and	O
severity	O
of	O
SARS	B-DISO
.	O

After	O
several	O
attempts	O
to	O
manage	O
the	O
patient	O
'	O
s	O
ARDS	B-DISO
by	O
adjusting	O
ventilatory	O
values	O
,	O
the	O
patient	O
required	O
the	O
reinitiation	O
of	O
an	O
NMBA	O
.	O

The	O
patient	O
died	O
due	O
to	O
his	O
complicated	O
hospital	O
course	O
that	O
included	O
quadriplegia	B-DISO
,	O
ARDS	B-DISO
,	O
cardiac	B-DISO
arrest	I-DISO
,	O
and	O
sepsis	B-DISO
secondary	O
to	O
a	O
gastric	B-DISO
perforation	I-DISO
.	O

End	O
-	O
expiratory	O
lung	O
volume	O
,	O
compliance	O
,	O
dead	O
space	O
,	O
volumetric	O
capnography	O
,	O
and	O
bedside	O
imaging	O
techniques	O
such	O
as	O
lung	O
ultrasound	O
and	O
electrical	O
impedance	O
tomography	O
have	O
all	O
different	O
strengths	O
and	O
weaknesses	B-DISO
.	O

The	O
MERS	O
CoV	O
infection	B-DISO
was	O
confirmed	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
detection	O
of	O
the	O
consensus	O
viral	O
RNA	O
targets	O
upstream	O
of	O
the	O
E	O
gene	O
(	O
UPE	O
)	O
and	O
open	O
reading	O
frame	O
(	O
ORF1b	O
)	O
on	O
a	O
sputum	O
sample	O
.	O

For	O
the	O
last	O
three	O
decades	O
,	O
PEDV	O
infection	B-DISO
has	O
resulted	O
in	O
significant	O
economic	O
losses	O
in	O
the	O
European	O
and	O
Asian	O
pig	O
industries	O
,	O
but	O
in	O
2013	O
-	O
2014	O
the	O
disease	O
was	O
also	O
reported	O
in	O
the	O
US	O
,	O
Canada	O
and	O
Mexico	O
.	O

Moderate	O
risk	O
of	O
importation	O
was	O
determined	O
for	O
poliomyelitis	B-DISO
due	O
to	O
wild	O
poliovirus	O
,	O
Lassa	B-DISO
fever	I-DISO
,	O
cholera	B-DISO
,	O
plague	B-DISO
,	O
and	O
the	O
minimal	O
--	O
for	O
Dengue	O
fever	B-DISO
,	I-DISO
yellow	I-DISO
fever	O
,	O
the	O
Middle	O
East	O
and	O
respiratory	O
syndrome	B-DISO
,	O
diseases	B-DISO
caused	I-DISO
by	I-DISO
viruses	I-DISO
Marburg	O
and	O
Ebola	O
.	O

Based	O
on	O
of	O
analysis	O
of	O
previous	O
Olympic	O
Games	O
and	O
subsequent	O
co	O
-	O
events	O
related	O
to	O
the	O
activity	O
of	O
the	O
infectious	B-DISO
diseases	I-DISO
in	O
the	O
world	O
,	O
mate	O
-	O
cluded	O
that	O
even	O
a	O
slight	O
risk	O
of	O
importation	O
of	O
infectious	B-DISO
diseases	I-DISO
requires	O
maximum	O
alertness	O
and	O
readiness	O
to	O
conduct	O
adequate	O
epidemiological	O
issues	O
incorporated	O
.	O

Our	O
results	O
suggest	O
a	O
possible	O
involvement	O
of	O
structurally	O
impaired	B-DISO
TJ	O
and	O
AJ	O
in	O
the	O
pathogenesis	B-DISO
of	O
PEDV	O
,	O
potentially	O
leading	O
to	O
secondary	O
bacterial	B-DISO
infections	I-DISO
.	O

It	O
offered	O
specific	O
recommendations	O
for	O
this	O
period	O
,	O
including	O
the	O
identification	O
of	O
clusters	O
of	O
severe	O
respiratory	B-DISO
disorders	I-DISO
and	O
deaths	O
.	O

Patients	O
satisfied	O
Berlin	O
criteria	O
for	O
severe	O
ARDS	B-DISO
with	O
trough	O
PaO2	O
/	O
F	O
i	O
O2	O
ratios	O
of	O
44	O
-	O
61	O
on	O
positive	O
end	O
-	O
expiratory	O
pressure	O
of	O
12	O
-	O
24	O
cm	O
H2O	O
.	O

ABSTRACT	O
:	O
Sepsis	B-DISO
is	O
a	O
common	O
disease	O
seen	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
pertinent	O
studies	O
that	O
inform	O
clinical	O
practice	O
on	O
providing	O
artificial	O
nutrition	O
to	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
and	O
make	O
recommendations	O
as	O
to	O
how	O
these	O
studies	O
influence	O
clinical	O
care	O
of	O
these	O
patients	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
126	O
children	O
were	O
included	O
,	O
and	O
23	O
(	O
18	O
.	O
6	O
%)	O
of	O
them	O
had	O
urine	O
SIADH	B-DISO
criteria	O
.	O

Prevalence	O
of	O
septic	B-DISO
shock	I-DISO
was	O
higher	O
in	O
the	O
group	O
with	O
moderate	O
-	O
to	O
-	O
large	O
TPBT	O
.	O

Moderate	O
-	O
to	O
-	O
large	O
TPBT	O
was	O
detected	O
with	O
contrast	O
echocardiography	O
in	O
26	O
%	O
of	O
patients	O
with	O
ARDS	B-DISO
.	O

Fifteen	O
patients	O
had	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
2	O
%),	O
199	O
(	O
27	O
.	O
75	O
%)	O
had	O
mild	O
transient	O
dysfunction	O
of	O
gas	O
exchange	O
,	O
402	O
(	O
56	O
.	O
1	O
%)	O
had	O
moderate	O
transient	O
dysfunction	O
of	O
gas	O
exchange	O
,	O
and	O
39	O
(	O
5	O
.	O
4	O
%)	O
had	O
severe	O
transient	O
dysfunction	O
of	O
gas	O
exchange	O
.	O

Diabetes	B-DISO
mellitus	I-DISO
was	O
also	O
a	O
risk	O
factor	O
for	O
transient	O
dysfunction	O
of	O
gas	O
exchange	O
(	O
P	O
=	O
0	O
.	O
03	O
).	O

Pneumonia	B-DISO
was	O
present	O
in	O
8	O
.	O
9	O
%	O
of	O
cases	O
and	O
correlated	O
with	O
the	O
presence	O
of	O
moderate	O
transient	O
dysfunction	O
of	O
gas	O
exchange	O
(	O
P	O
=	O
0	O
.	O
001	O
).	O

Severe	O
transient	O
dysfunction	O
of	O
gas	O
exchange	O
was	O
associated	O
with	O
patients	O
who	O
had	O
renal	O
replacement	O
therapy	O
(	O
P	O
=	O
0	O
.	O
0005	O
),	O
hemotherapy	O
(	O
P	O
=	O
0	O
.	O
0001	O
),	O
enteral	O
nutrition	O
(	O
P	O
=	O
0	O
.	O
0012	O
),	O
or	O
cardiac	B-DISO
arrhythmia	I-DISO
(	O
P	O
=	O
0	O
.	O
0451	O
).	O

Severe	O
transient	O
dysfunction	O
of	O
gas	O
exchange	O
was	O
associated	O
with	O
patients	O
who	O
had	O
renal	O
replacement	O
therapy	O
(	O
P	O
=	O
0	O
.	O
0005	O
),	O
hemotherapy	O
(	O
P	O
=	O
0	O
.	O
0001	O
),	O
enteral	O
nutrition	O
(	O
P	O
=	O
0	O
.	O
0012	O
),	O
or	O
cardiac	B-DISO
arrhythmia	I-DISO
(	O
P	O
=	O
0	O
.	O
0451	O
).	O

Using	O
a	O
simple	O
transmission	O
model	O
that	O
incorporates	O
age	O
-	O
stratified	O
social	O
mixing	O
patterns	O
,	O
we	O
present	O
a	O
novel	O
method	O
for	O
characterizing	O
the	O
transmission	O
potential	O
of	O
subcritical	O
infections	B-DISO
,	O
which	O
have	O
effective	O
reproduction	O
number	O
R	O
<	O
1	O
,	O
from	O
readily	O
available	O
data	O
on	O
the	O
size	O
of	O
outbreaks	O
.	O

ABSTRACT	O
:	O
Tracheal	O
injury	O
is	O
a	O
rare	O
but	O
highly	O
morbid	O
complication	B-DISO
of	O
endotracheal	O
intubation	O
.	O

Eight	O
patients	O
were	O
admitted	O
to	O
the	O
ICU	O
with	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

Samples	O
were	O
screened	O
by	O
recombinant	O
ELISA	O
and	O
MERS	O
-	O
CoV	O
seropositivity	O
was	O
confirmed	O
by	O
recombinant	O
immunofluorescence	O
and	O
plaque	B-DISO
reduction	O
neutralisation	O
tests	O
.	O

These	O
individuals	O
might	O
be	O
the	O
source	O
of	O
infection	B-DISO
for	O
patients	O
with	O
confirmed	O
MERS	O
who	O
had	O
no	O
previous	O
exposure	O
to	O
camels	O
.	O

TITLE	O
:	O
A	O
novel	O
strain	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
in	O
Vietnamese	O
pigs	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
form	O
of	O
acute	O
life	O
threatening	O
respiratory	B-DISO
failure	I-DISO
.	O

We	O
observed	O
delay	O
in	O
diagnostic	O
and	O
therapeutic	O
procedures	O
in	O
patients	O
with	O
clinical	O
signs	O
for	O
the	O
presence	O
of	O
severe	O
respiratory	B-DISO
disorders	I-DISO
.	O

These	O
results	O
suggest	O
that	O
this	O
RBD	O
-	O
based	O
subunit	O
MERS	O
vaccine	O
candidate	O
at	O
the	O
dose	O
as	O
low	O
as	O
one	O
μg	O
is	O
sufficiently	O
potent	O
to	O
induce	O
strong	O
humoral	O
and	O
cellular	O
immune	O
responses	O
,	O
including	O
neutralizing	O
antibodies	O
,	O
against	O
MERS	O
-	O
CoV	O
infection	B-DISO
,	O
thus	O
providing	O
guidance	O
for	O
determining	O
the	O
optimal	O
dosage	O
of	O
RBD	O
-	O
based	O
MERS	O
vaccines	O
in	O
the	O
future	O
clinical	O
trials	O
and	O
for	O
applying	O
the	O
dose	O
-	O
sparing	O
strategy	O
in	O
other	O
subunit	O
vaccine	O
trials	O
.	O

The	O
survived	O
10	O
patients	O
were	O
followed	O
up	O
for	O
1	O
year	O
,	O
1	O
patient	O
with	O
localized	O
pneumothorax	B-DISO
,	O
bronchopleural	B-DISO
fistula	I-DISO
,	O
1	O
case	O
of	O
mild	O
pulmonary	B-DISO
fibrosis	I-DISO
,	O
1	O
case	O
of	O
acute	B-DISO
laryngitis	I-DISO
with	O
persistent	O
hoarseness	B-DISO
,	O
and	O
mild	O
inspiratory	O
dyspnea	B-DISO
were	O
found	O
.	O

TITLE	O
:	O
Plasma	O
level	O
of	O
soluble	O
receptor	O
for	O
advanced	O
glycation	O
end	O
-	O
products	O
and	O
aquaporin	O
5	O
in	O
preterm	O
infants	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
plasma	O
level	O
of	O
soluble	O
receptors	O
for	O
advanced	O
glycation	O
end	O
-	O
products	O
(	O
sRAGE	O
)	O
and	O
aquaporin	O
5	O
(	O
AQP5	O
)	O
in	O
preterm	O
infants	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
RDS	O
).	O

Clinical	O
features	O
,	O
lab	O
parameters	O
,	O
and	O
outcome	O
were	O
evaluated	O
in	O
all	O
patients	O
with	O
scrub	B-DISO
typhus	I-DISO
.	O

Among	O
24	O
Scrub	B-DISO
typhus	I-DISO
patients	O
with	O
ARDS	B-DISO
,	O
22	O
patients	O
recovered	O
,	O
and	O
2	O
patients	O
died	O
.	O

TITLE	O
:	O
An	O
inactivated	O
vaccine	O
made	O
from	O
a	O
U	O
.	O
S	O
.	O
field	O
isolate	O
of	O
porcine	O
epidemic	B-DISO
disease	I-DISO
virus	O
is	O
immunogenic	O
in	O
pigs	O
as	O
demonstrated	O
by	O
a	O
dose	O
-	O
titration	O
.	O

Various	O
types	O
of	O
RMs	O
such	O
as	O
sustained	O
inflation	O
at	O
high	O
pressure	O
,	O
intermittent	O
sighs	B-DISO
and	O
stepwise	O
increases	O
of	O
PEEP	O
and	O
/	O
or	O
airway	O
plateau	O
inspiratory	O
pressure	O
have	O
been	O
proposed	O
.	O

Histologic	O
analysis	O
confirmed	O
diffuse	O
alveolar	O
congestion	B-DISO
and	O
moderate	O
-	O
to	O
-	O
severe	O
lung	B-DISO
edema	I-DISO
in	O
animals	O
with	O
HS	O
+	O
OA	O
.	O

This	O
model	O
allows	O
the	O
analysis	O
of	O
the	O
dynamics	O
of	O
sterile	B-DISO
lung	O
injury	O
and	O
associated	O
organ	O
dysfunction	O
.	O

Thirty	O
seven	O
alphacoronaviruses	O
,	O
nine	O
lineage	O
D	O
betacoronaviruses	O
,	O
and	O
one	O
lineage	O
B	O
betacoronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
related	O
)	O
were	O
identified	O
.	O

We	O
sought	O
to	O
describe	O
the	O
hemodynamic	O
profile	O
associated	O
with	O
either	O
ACP	B-DISO
or	O
PFO	O
,	O
or	O
both	O
,	O
during	O
the	O
early	O
course	O
of	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	B-DISO
using	O
echocardiography	O
.	O

ACP	B-DISO
was	O
defined	O
by	O
the	O
association	O
of	O
right	O
ventricular	O
(	O
RV	O
)	O
dilatation	B-DISO
and	O
systolic	O
paradoxical	O
ventricular	O
septal	O
motion	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
an	O
important	O
pig	O
pathogen	O
that	O
can	O
cause	O
vomiting	B-DISO
,	O
diarrhea	B-DISO
,	O
and	O
dehydration	B-DISO
,	O
leading	O
to	O
serious	O
damage	O
to	O
the	O
swine	O
industry	O
worldwide	O
.	O

Multivariate	O
logistic	O
regression	O
showed	O
Th17	O
/	O
Treg	O
ratio	O
>	O
0	O
.	O
79	O
(	O
odds	O
ratio	O
=	O
8	O
.	O
68	O
,	O
P	O
=	O
0	O
.	O
002	O
)	O
was	O
the	O
independent	O
predictor	O
for	O
28	O
-	O
day	O
mortality	O
in	O
patients	O
with	O
ARDS	B-DISO
.	O

The	O
pathological	O
changes	O
were	O
severe	O
,	O
and	O
general	O
hyperemia	B-DISO
,	O
hemorrhage	B-DISO
,	O
inflammatory	B-DISO
cell	I-DISO
infiltration	I-DISO
,	O
and	O
necrosis	O
were	O
evident	O
in	O
the	O
tissues	O
of	O
dead	O
swine	O
.	O

The	O
natural	O
co	B-DISO
-	I-DISO
infection	I-DISO
of	O
HEV	O
and	O
PCV2	O
in	O
pigs	O
in	O
China	O
has	O
rarely	O
been	O
reported	O
.	O

However	O
,	O
pretreatment	O
with	O
c26	O
attenuated	O
the	O
LPS	B-DISO
induced	O
increase	O
through	O
ERK	O
pathway	O
in	O
vivo	O
.	O

In	O
China	O
,	O
TGEV	O
has	O
caused	O
great	O
economic	O
losses	O
,	O
but	O
its	O
role	O
in	O
epidemic	B-DISO
diarrhea	I-DISO
is	O
unclear	O
.	O

Influenza	B-DISO
A	O
H3N2	O
,	O
human	O
metapneumovirus	O
(	O
HMPV	O
)	O
subtypes	O
A1	O
and	O
A2	O
,	O
the	O
influenza	B-DISO
B	O
virus	O
,	O
human	O
adenovirus	B-DISO
B	O
,	O
and	O
human	O
coronavirus	O
OC43	O
were	O
also	O
detected	O
.	O

ABSTRACT	O
:	O
Haemophilus	O
species	O
bacteria	O
(	O
HSB	O
)	O
are	O
known	O
pathogens	O
responsible	O
for	O
early	O
pneumonia	B-DISO
in	O
intubated	O
trauma	O
patients	O
.	O

Haemophilus	O
species	O
bacteria	O
pneumonia	B-DISO
in	O
trauma	O
patients	O
is	O
associated	O
with	O
high	O
rates	O
of	O
transient	O
hypoxemia	O
and	O
a	O
high	O
tracheostomy	O
rate	O
,	O
although	O
subsequent	O
outcomes	O
are	O
not	O
affected	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
uses	O
cell	O
-	O
surface	O
heparan	O
sulfate	O
as	O
an	O
attachment	O
factor	O
.	O

Western	O
blot	O
analysis	O
,	O
real	O
-	O
time	O
PCR	O
,	O
and	O
plaque	B-DISO
formation	O
assay	O
revealed	O
that	O
PEDV	O
infection	B-DISO
was	O
inhibited	O
when	O
the	O
virus	O
was	O
pretreated	O
with	O
heparin	O
(	O
an	O
analogue	O
of	O
heparan	O
sulfate	O
).	O

The	O
data	O
suggested	O
de	O
-	O
N	O
-	O
sulfated	O
heparin	O
,	O
but	O
not	O
N	O
-	O
acetyl	O
-	O
de	O
-	O
O	O
-	O
sulfated	O
heparin	O
,	O
inhibits	O
PEDV	O
infection	B-DISO
.	O

TITLE	O
:	O
IFN	O
-	O
α2a	O
or	O
IFN	O
-	O
β1a	O
in	O
combination	O
with	O
ribavirin	O
to	O
treat	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
pneumonia	B-DISO
:	O
a	O
retrospective	O
study	O
.	O

We	O
retrospectively	O
analysed	O
32	O
patients	O
with	O
confirmed	O
MERS	O
-	O
CoV	O
infection	B-DISO
,	O
admitted	O
between	O
April	O
2014	O
and	O
June	O
2014	O
,	O
by	O
positive	O
respiratory	O
sample	O
RT	O
-	O
PCR	O
.	O

At	O
35	O
days	O
of	O
age	O
,	O
birds	O
were	O
slaughtered	O
and	O
blood	O
was	O
collected	O
for	O
investigating	O
the	O
antibody	O
titre	O
against	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
and	O
clinical	O
chemical	O
parameters	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
98	O
specialist	O
registrars	O
(	O
in	O
Anesthesiology	O
,	O
n	O
=	O
51	O
;	O
in	O
Emergency	B-DISO
Medicine	O
(	O
EM	O
),	O
n	O
=	O
21	O
;	O
and	O
in	O
Intensive	O
Care	O
Medicine	O
(	O
ICM	O
)	O
n	O
=	O
26	O
)	O
completed	O
hand	O
-	O
delivered	O
surveys	O
.	O

ABSTRACT	O
:	O
The	O
Middle	O
Eastern	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
is	O
a	O
serious	O
and	O
emerging	O
issue	O
in	O
Saudi	O
Arabia	O
and	O
the	O
world	O
.	O

Data	O
was	O
gathered	O
on	O
gaps	O
in	O
participant	O
knowledge	O
and	O
a	O
plan	B-DISO
was	O
developed	O
to	O
address	O
the	O
gaps	O
.	O

The	O
antiviral	O
activity	O
was	O
confirmed	O
through	O
a	O
plaque	B-DISO
assay	O
where	O
viral	O
titer	O
reduction	O
was	O
observed	O
in	O
the	O
presence	O
of	O
selected	O
compounds	O
.	O

Molecular	O
modeling	O
and	O
competitive	O
S	O
-	O
adenosyl	O
-	O
l	O
-	O
methionine	O
(	O
SAM	B-DISO
)	O
binding	O
assay	O
suggest	O
that	O
these	O
compounds	O
likely	O
confer	O
antiviral	O
activity	O
via	O
binding	O
to	O
methyltransferase	O
(	O
MTase	O
).	O

ABSTRACT	O
:	O
Mortality	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
remains	O
high	O
.	O

The	O
multisystemic	O
granulomatous	B-DISO
lesions	I-DISO
were	O
suggestive	O
of	O
ferret	O
systemic	O
coronavirus	O
(	O
FRSCV	O
).	O

Systemic	O
coronavirus	O
disease	O
in	O
ferrets	O
closely	O
resembles	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
in	O
domestic	O
cats	O
,	O
which	O
can	O
manifest	O
with	O
anterior	B-DISO
uveitis	I-DISO
,	O
chorioretinitis	B-DISO
,	O
optic	B-DISO
neuritis	I-DISO
,	O
and	O
retinal	B-DISO
detachment	I-DISO
.	O

A	O
retrospective	O
study	O
was	O
performed	O
on	O
severe	O
COPD	B-DISO
patients	O
within	O
24	O
hours	O
of	O
the	O
onset	O
of	O
MODS	B-DISO
.	O

The	O
value	O
of	O
exacerbation	O
frequency	O
for	O
predicting	O
the	O
outcome	O
of	O
COPD	B-DISO
was	O
excellent	O
(	O
AUC	O
:	O
0	O
.	O
892	O
),	O
with	O
a	O
sensitivity	O
of	O
0	O
.	O
851	O
and	O
a	O
specificity	O
of	O
0	O
.	O
797	O
.	O

The	O
exacerbation	O
frequency	O
,	O
number	O
of	O
failing	O
organs	O
,	O
and	O
the	O
SOFA	O
score	O
were	O
risk	O
factors	O
of	O
a	O
poor	O
prognosis	O
,	O
and	O
the	O
exacerbation	O
frequency	O
could	O
also	O
effectively	O
predict	O
the	O
outcome	O
of	O
COPD	B-DISO
.	O

TITLE	O
:	O
The	O
efficacy	O
and	O
safety	O
of	O
prone	O
positioning	O
in	O
adults	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
a	O
meta	O
-	O
analysis	O
of	O
randomized	O
controlled	O
trials	O
.	O

We	O
evaluated	O
effects	O
of	O
prone	O
position	O
duration	O
and	O
protective	O
lung	O
strategies	O
on	O
mortality	O
rates	O
in	O
ARDS	B-DISO
.	O

Prone	O
positioning	O
was	O
not	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
cardiac	B-DISO
events	I-DISO
(	O
RR	O
1	O
.	O
01	O
,	O
95	O
%	O
CI	O
,	O
0	O
.	O
87	O
-	O
1	O
.	O
17	O
)	O
or	O
ventilator	B-DISO
associated	I-DISO
pneumonia	I-DISO
(	O
RR	O
0	O
.	O
88	O
,	O
95	O
%	O
CI	O
,	O
0	O
.	O
71	O
-	O
1	O
.	O
09	O
),	O
but	O
it	O
was	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
pressure	B-DISO
sores	I-DISO
(	O
RR	O
1	O
.	O
23	O
,	O
95	O
%	O
CI	O
,	O
1	O
.	O
07	O
-	O
1	O
.	O
41	O
)	O
and	O
endotracheal	O
dislocation	O
(	O
RR	O
1	O
.	O
33	O
,	O
95	O
%	O
CI	O
,	O
1	O
.	O
02	O
-	O
1	O
.	O
74	O
).	O

Prone	O
positioning	O
was	O
not	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
cardiac	B-DISO
events	I-DISO
(	O
RR	O
1	O
.	O
01	O
,	O
95	O
%	O
CI	O
,	O
0	O
.	O
87	O
-	O
1	O
.	O
17	O
)	O
or	O
ventilator	B-DISO
associated	I-DISO
pneumonia	I-DISO
(	O
RR	O
0	O
.	O
88	O
,	O
95	O
%	O
CI	O
,	O
0	O
.	O
71	O
-	O
1	O
.	O
09	O
),	O
but	O
it	O
was	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
pressure	B-DISO
sores	I-DISO
(	O
RR	O
1	O
.	O
23	O
,	O
95	O
%	O
CI	O
,	O
1	O
.	O
07	O
-	O
1	O
.	O
41	O
)	O
and	O
endotracheal	O
dislocation	O
(	O
RR	O
1	O
.	O
33	O
,	O
95	O
%	O
CI	O
,	O
1	O
.	O
02	O
-	O
1	O
.	O
74	O
).	O

The	O
incidence	O
of	O
healthcare	O
-	O
associated	O
infections	B-DISO
has	O
increased	O
.	O

Since	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
epidemic	O
in	O
2003	O
,	O
combating	O
infectious	B-DISO
diseases	I-DISO
has	O
become	O
a	O
key	O
issue	O
.	O

The	O
incidence	O
rates	O
of	O
methicillin	B-DISO
-	I-DISO
resistant	I-DISO
Staphylococcus	I-DISO
aureus	I-DISO
,	O
Clostridium	O
difficile	O
and	O
vancomycin	O
-	O
resistant	O
enterococci	O
at	O
the	O
study	O
site	O
decreased	O
,	O
but	O
remained	O
above	O
provincial	O
benchmarks	O
.	O

Infection	B-DISO
prevention	O
and	O
control	O
guidelines	O
and	O
procedures	O
should	O
be	O
established	O
provincially	O
and	O
nationally	O
.	O

We	O
provide	O
a	O
demonstration	O
of	O
the	O
features	O
of	O
plethy	O
using	O
a	O
dataset	O
assessing	O
the	O
respiratory	O
effects	O
over	O
time	O
of	O
SARS	B-DISO
and	O
Influenza	B-DISO
infection	B-DISO
in	O
mice	O
.	O

These	O
syndromes	B-DISO
are	O
reported	O
in	O
association	O
with	O
opioid	O
use	O
.	O

Respiratory	O
samples	O
from	O
735	O
hospitalized	O
patients	O
with	O
RTI	B-DISO
from	O
September	O
2010	O
to	O
April	O
2013	O
were	O
evaluated	O
for	O
the	O
presence	O
of	O
HCoV	O
-	O
NL63	O
,	O
hMPV	O
,	O
Boca	B-DISO
,	O
KIV	O
and	O
WUV	O
using	O
molecular	O
assays	O
,	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
reverse	O
-	O
transcription	O
PCR	O
.	O

These	O
newly	O
discovered	O
viruses	O
were	O
associated	O
with	O
the	O
development	O
of	O
RTI	B-DISO
in	O
Kuwait	O
.	O

TITLE	O
:	O
Prediction	O
of	O
respiratory	B-DISO
disease	I-DISO
and	O
diarrhea	B-DISO
in	O
veal	O
calves	O
based	O
on	O
immunoglobulin	O
levels	O
and	O
the	O
serostatus	O
for	O
respiratory	O
pathogens	O
measured	O
at	O
arrival	O
.	O

While	O
uninoculated	O
or	O
inoculated	O
27	O
-	O
31	O
-	O
day	O
-	O
old	O
pigs	O
showed	O
large	O
numbers	O
of	O
Ki67	O
-	O
or	O
LGR5	O
-	O
positive	O
cells	O
in	O
the	O
intestinal	O
crypts	O
,	O
there	O
was	O
a	O
lack	O
of	O
LGR5	O
-	O
positive	O
cells	O
and	O
low	O
proliferation	B-DISO
of	O
crypts	O
in	O
jejunum	O
of	O
uninoculated	O
10	O
-	O
14	O
-	O
day	O
-	O
old	O
piglets	O
,	O
possibly	O
causing	O
a	O
slower	O
turnover	O
of	O
enterocytes	O
;	O
however	O
,	O
the	O
number	O
of	O
LGR5	O
-	O
positive	O
cells	O
and	O
proliferation	B-DISO
of	O
intestinal	O
crypts	O
increased	O
remarkably	O
at	O
3	O
-	O
5	O
days	O
after	O
inoculation	O
.	O

Homologous	O
re	O
-	O
challenge	O
49	O
days	O
post	O
initial	O
PEDV	O
exposure	O
did	O
not	O
result	O
in	O
re	O
-	O
infection	B-DISO
of	O
the	O
pigs	O
.	O

None	O
of	O
the	O
vaccinated	O
patients	O
developed	O
serious	O
disease	O
,	O
supporting	O
the	O
role	O
of	O
vaccination	O
also	O
for	O
ESRD	B-DISO
patients	O
.	O

Viral	O
RNA	O
,	O
histopathological	O
changes	O
,	O
and	O
viral	O
nucleoprotein	O
were	O
observed	O
in	O
the	O
lung	O
,	O
trachea	B-DISO
and	O
sinus	B-DISO
of	O
all	O
inoculated	O
mice	O
.	O

TITLE	O
:	O
Differential	O
Effects	O
of	O
Endotracheal	O
Suctioning	O
on	O
Gas	O
Exchanges	O
in	O
Patients	O
with	O
Acute	B-DISO
Respiratory	I-DISO
Failure	I-DISO
under	O
Pressure	O
-	O
Controlled	O
and	O
Volume	O
-	O
Controlled	O
Ventilation	O
.	O

Ninety	O
-	O
six	O
ARF	B-DISO
patients	O
were	O
treated	O
with	O
open	O
endotracheal	O
suctioning	O
and	O
their	O
variations	O
in	O
respiratory	O
mechanics	O
and	O
gas	O
exchange	O
after	O
the	O
suctions	O
were	O
compared	O
.	O

TITLE	O
:	O
Progress	O
and	O
challenges	O
toward	O
the	O
development	O
of	O
vaccines	O
against	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
.	O

One	O
group	O
of	O
C57BL	O
/	O
6J	O
mice	O
received	O
LPS	B-DISO
via	O
intratracheal	O
injection	O
(	O
n	O
=	O
6	O
),	O
and	O
another	O
received	O
sterile	B-DISO
water	O
(	O
n	O
=	O
7	O
).	O

TITLE	O
:	O
Review	O
of	O
Non	O
-	O
Bacterial	B-DISO
Infections	I-DISO
in	O
Respiratory	O
Medicine	O
:	O
Viral	B-DISO
Pneumonia	I-DISO
.	O

However	O
,	O
in	O
recent	O
years	O
,	O
outbreaks	O
of	O
deadly	O
coronavirus	O
and	O
zoonotic	O
influenza	B-DISO
virus	O
have	O
demonstrated	O
the	O
need	O
for	O
constant	O
alert	O
in	O
the	O
face	B-DISO
of	O
new	O
emerging	O
pathogens	O
.	O

ABSTRACT	O
:	O
Bats	O
are	O
likely	O
natural	O
hosts	O
for	O
a	O
range	O
of	O
zoonotic	O
viruses	O
such	O
as	O
Marburg	O
,	O
Ebola	O
,	O
Rabies	B-DISO
,	O
as	O
well	O
as	O
for	O
various	O
Corona	O
-	O
and	O
Paramyxoviruses	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
serological	O
evidence	O
of	O
influenza	B-DISO
A	O
viruses	O
other	O
than	O
H17	O
and	O
H18	O
in	O
bats	O
.	O

TITLE	O
:	O
Muscle	B-DISO
pain	I-DISO
,	O
fever	O
,	O
cough	B-DISO
,	O
and	O
progressive	O
dyspnea	B-DISO
in	O
a	O
woman	O
with	O
eosinophilic	B-DISO
pneumonia	I-DISO
.	O

A	O
roundworm	B-DISO
identified	O
in	O
the	O
patient	O
'	O
s	O
stool	O
confirmed	O
the	O
precise	O
diagnosis	O
to	O
be	O
parasitic	O
EP	O
.	O

Psychological	B-DISO
autopsy	O
revealed	O
severe	O
depressive	B-DISO
disorder	I-DISO
and	O
solvent	O
(	O
inhalant	O
)	O
abuse	B-DISO
,	O
with	O
marital	O
disharmony	O
as	O
the	O
precipitating	O
stressor	O
for	O
suicide	O
.	O

TITLE	O
:	O
Coronavirus	B-DISO
Infections	I-DISO
in	O
Pediatric	O
Outpatients	O
with	O
Febrile	O
Respiratory	B-DISO
Tract	I-DISO
Infections	I-DISO
in	O
Hiroshima	O
,	O
Japan	O
,	O
over	O
a	O
3	O
-	O
Year	O
Period	O
.	O

The	O
multi	O
-	O
virus	O
infections	B-DISO
involved	O
6	O
adenoviruses	O
,	O
3	O
respiratory	O
syncytial	O
viruses	O
,	O
2	O
parainfluenza	B-DISO
viruses	O
,	O
and	O
1	O
rhinovirus	O
.	O

A	O
previously	O
healthy	O
35	O
-	O
year	O
-	O
old	O
Japanese	O
man	O
who	O
developed	O
severe	O
dyspnea	B-DISO
presented	O
to	O
our	O
hospital	O
.	O

A	O
literature	O
review	O
was	O
performed	O
to	O
survey	O
all	O
reported	O
cases	O
of	O
polytetrafluoroethylene	O
fume	O
-	O
induced	O
pulmonary	B-DISO
edema	I-DISO
.	O

Pathophysiological	O
and	O
radiological	O
features	O
were	O
consistent	O
with	O
the	O
exudative	O
phase	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
A	O
Single	O
Point	O
Mutation	O
Creating	O
a	O
Furin	O
Cleavage	O
Site	O
in	O
the	O
Spike	O
Protein	O
Renders	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Coronavirus	O
Trypsin	O
Independent	O
for	O
Cell	O
Entry	O
and	O
Fusion	O
.	O

TITLE	O
:	O
Transcriptome	O
Profiling	O
of	O
the	O
Virus	O
-	O
Induced	O
Innate	B-DISO
Immune	I-DISO
Response	I-DISO
in	O
Pteropus	O
vampyrus	O
and	O
Its	O
Attenuation	O
by	O
Nipah	O
Virus	O
Interferon	O
Antagonist	O
Functions	O
.	O

Viral	B-DISO
infections	I-DISO
are	O
reportedly	O
asymptomatic	O
or	O
heavily	O
attenuated	O
in	O
bat	O
populations	O
.	O

TITLE	O
:	O
In	O
vivo	O
assessment	O
of	O
equine	O
arteritis	B-DISO
virus	O
vaccine	O
improvement	O
by	O
disabling	O
the	O
deubiquitinase	O
activity	O
of	O
papain	O
-	O
like	O
protease	O
2	O
.	O

Taken	O
together	O
,	O
the	O
data	O
obtained	O
in	O
this	O
study	O
warrant	O
further	O
in	O
vivo	O
investigations	O
into	O
the	O
potential	O
of	O
using	O
DUB	O
-	O
mutant	B-DISO
viruses	O
for	O
the	O
improvement	O
of	O
arterivirus	O
vaccines	O
.	O

ABSTRACT	O
:	O
The	O
Systems	O
Biology	O
for	O
Infectious	B-DISO
Diseases	I-DISO
Research	O
program	O
was	O
established	O
by	O
the	O
U	O
.	O
S	O
.	O
National	O
Institute	O
of	O
Allergy	B-DISO
and	O
Infectious	B-DISO
Diseases	I-DISO
to	O
investigate	O
host	O
-	O
pathogen	O
interactions	O
at	O
a	O
systems	O
level	O
.	O

This	O
program	O
generated	O
47	O
transcriptomic	O
and	O
proteomic	O
datasets	O
from	O
30	O
studies	O
that	O
investigate	O
in	O
vivo	O
and	O
in	O
vitro	O
host	O
responses	O
to	O
viral	B-DISO
infections	I-DISO
.	O

TITLE	O
:	O
Genetic	O
manipulation	O
of	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
recovered	O
from	O
a	O
full	O
-	O
length	O
infectious	B-DISO
cDNA	O
clone	O
.	O

This	O
study	O
is	O
designed	O
to	O
investigate	O
the	O
role	O
of	O
DAD	O
in	O
ARDS	B-DISO
patients	O
who	O
underwent	O
open	O
lung	O
biopsy	O
.	O

A	O
pathological	O
finding	O
of	O
DAD	O
in	O
ARDS	B-DISO
patients	O
is	O
associated	O
with	O
hospital	O
mortality	O
and	O
there	O
are	O
no	O
clinical	O
characteristics	O
that	O
could	O
identify	O
DAD	O
patients	O
before	O
open	O
lung	O
biopsy	O
.	O

The	O
patient	O
survived	O
after	O
multiple	B-DISO
organ	I-DISO
failures	I-DISO
and	O
widespread	O
burns	O
despite	O
the	O
fact	O
that	O
it	O
has	O
been	O
observed	O
that	O
outcome	O
of	O
phenol	O
burns	O
with	O
>	O
60	O
(	O
2	O
)	O
inches	O
of	O
skin	O
affected	O
or	O
two	O
or	O
more	O
organs	O
failure	O
involving	O
renal	O
system	O
is	O
nearly	O
fatal	O
.	O

Pneumonia	B-DISO
and	O
bronchiolitis	B-DISO
were	O
the	O
most	O
frequent	O
reason	O
for	O
hospitalization	O
with	O
viral	O
mixed	O
detection	O
(	O
9	O
.	O
1	O
%).	O

We	O
have	O
studied	O
experimental	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
in	O
mice	O
following	O
airway	O
deposition	O
of	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	B-DISO
)	O
or	O
the	O
recombinant	O
mouse	O
complement	O
anaphylatoxin	O
,	O
C5a	O
.	O

ABSTRACT	O
:	O
Coyotes	O
(	O
Canis	O
latrans	O
)	O
have	O
expanded	O
recently	O
into	O
the	O
eastern	O
US	O
and	O
can	O
serve	O
as	O
a	O
source	O
of	O
pathogens	O
to	O
domestic	O
dogs	O
(	O
Canis	O
lupus	B-DISO
familiaris	O
),	O
livestock	O
,	O
and	O
humans	O
.	O

TITLE	O
:	O
Bleb	B-DISO
point	O
:	O
mimicker	O
of	O
pneumothorax	B-DISO
in	O
bullous	B-DISO
lung	I-DISO
disease	I-DISO
.	O

The	O
outbreak	O
in	O
West	O
Africa	O
of	O
highly	O
contagious	O
Ebola	O
viral	B-DISO
disease	I-DISO
(	O
EVD	B-DISO
)	O
that	O
started	O
in	O
Guinea	O
in	O
December	O
2013	O
,	O
assumed	O
global	O
proportions	O
to	O
become	O
the	O
largest	O
outbreak	O
of	O
EVD	B-DISO
and	O
the	O
most	O
prominent	O
international	O
health	O
concern	O
.	O

The	O
present	O
study	O
provides	O
a	O
platform	O
for	O
immediate	O
development	O
of	O
suitable	O
vaccines	O
and	O
diagnostics	O
to	O
prevent	O
and	O
control	O
porcine	O
orthoreovirus	O
diarrhea	B-DISO
.	O

Magnetic	O
resonance	O
imaging	O
of	O
lumbosacral	O
and	O
cervical	O
spine	O
showed	O
tumor	B-DISO
-	O
like	O
masses	O
mistaken	O
for	O
neurofibromatosis	B-DISO
(	O
axial	O
diameter	O
,	O
7	O
.	O
5	O
-	O
10	O
mm	O
).	O

ABSTRACT	O
:	O
Severe	O
adenovirus	B-DISO
infection	I-DISO
in	O
children	O
can	O
manifest	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
respiratory	B-DISO
failure	I-DISO
,	O
leading	O
to	O
the	O
need	O
for	O
prolonged	O
mechanical	O
support	O
in	O
the	O
form	O
of	O
either	O
mechanical	O
ventilation	O
or	O
extracorporeal	O
life	O
support	O
.	O

Because	O
conventional	O
ARDS	B-DISO
therapies	O
failed	O
,	O
we	O
initiated	O
ECMO	O
with	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
for	O
9	O
days	O
.	O

Pulmonary	O
plague	B-DISO
is	O
the	O
bacterial	B-DISO
infectious	I-DISO
disease	I-DISO
with	O
the	O
most	O
contagious	O
and	O
lethal	O
course	O
and	O
it	O
is	O
endemic	O
to	O
Madagascar	O
and	O
East	O
Africa	O
,	O
but	O
also	O
occurs	O
in	O
other	O
countries	O
(	O
e	O
.	O
g	O
.	O
India	O
,	O
USA	O
).	O

Monkey	B-DISO
pox	I-DISO
epidemics	O
have	O
occurred	O
in	O
remote	O
areas	O
of	O
the	O
Congo	O
Basin	O
.	O

Such	O
outbreaks	O
could	O
potentially	O
become	O
more	O
common	O
with	O
the	O
discontinuation	O
of	O
the	O
cross	O
-	O
protective	O
smallpox	B-DISO
vaccination	O
.	O

TITLE	O
:	O
Bats	O
as	O
reservoirs	O
of	O
severe	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
role	O
of	O
complement	O
-	O
derived	O
anaphylatoxins	O
in	O
the	O
pathogenesis	B-DISO
of	O
experimental	O
acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ALI	O
/	O
ARDS	B-DISO
)	O
in	O
C57BL	O
/	O
6J	O
mice	O
.	O

Intratracheal	O
administration	O
of	O
recombinant	O
mouse	O
complement	O
component	O
(	O
C5a	O
)	O
caused	O
alveolar	O
inflammation	B-DISO
with	O
abundant	O
recruitment	B-DISO
of	O
Ly6	O
-	O
G	O
(+)	O
CD11b	O
(+)	O
leukocytes	O
to	O
the	O
alveolar	O
spaces	O
and	O
severe	O
alveolar	O
-	O
capillary	O
barrier	O
dysfunction	O
(	O
C5a	O
-	O
ALI	O
;	O
EC	O
(	O
50	O
[	O
C5a	O
])	O
=	O
20	O
ng	O
/	O
g	O
body	O
weight	O
).	O

Mice	O
with	O
genetic	O
deficiency	O
of	O
CC	O
-	O
chemokine	O
receptor	O
(	O
CCR	O
)	O
type	O
5	O
,	O
the	O
common	O
receptor	O
of	O
chemokine	O
(	O
C	O
-	O
C	O
motif	O
)	O
ligand	O
(	O
CCL	B-DISO
)	O
3	O
,	O
CCL4	O
,	O
and	O
CCL5	O
,	O
displayed	O
reduced	O
lung	O
damage	O
.	O

When	O
analysis	O
was	O
restricted	O
to	O
preterms	O
born	O
at	O
33	O
-	O
34	O
wGA	O
the	O
following	O
variables	O
were	O
associated	O
to	O
higher	O
rates	O
of	O
bronchiolitis	B-DISO
hospitalization	O
:	O
male	O
gender	O
,	O
prenatal	O
exposure	O
to	O
maternal	O
smoking	O
,	O
neonatal	O
surfactant	O
therapy	O
,	O
having	O
siblings	O
<	O
10	O
years	O
old	O
,	O
living	O
in	O
crowded	O
conditions	O
and	O
being	O
exposed	O
to	O
epidemic	O
season	O
during	O
the	O
first	O
three	O
months	O
of	O
life	O
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
)	O
is	O
one	O
of	O
five	O
currently	O
circulating	O
human	O
coronaviruses	O
responsible	O
for	O
respiratory	B-DISO
infections	I-DISO
.	O

The	O
emergence	O
of	O
highly	O
pathogenic	O
coronaviruses	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
concern	O
for	O
global	O
public	O
health	O
,	O
as	O
there	O
is	O
a	O
lack	O
of	O
efficacious	O
vaccine	O
platforms	O
and	O
antiviral	O
therapeutic	O
strategies	O
.	O

Distinct	O
alterations	O
in	O
inflammation	B-DISO
were	O
present	O
in	O
TRIF	O
(-/-)	O
mice	O
infected	O
with	O
SARS	B-DISO
-	O
CoV	O
,	O
including	O
excess	O
infiltration	B-DISO
of	O
neutrophils	O
and	O
inflammatory	O
cell	O
types	O
that	O
correlate	O
with	O
increased	O
pathology	B-DISO
of	O
other	O
known	O
causes	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
including	O
influenza	B-DISO
virus	O
infections	B-DISO
.	O

Our	O
aim	O
is	O
to	O
investigate	O
the	O
early	O
prediction	O
and	O
outcome	O
of	O
SE	O
in	O
stroke	B-DISO
patients	O
with	O
nosocomial	O
coma	B-DISO
(	O
NC	O
).	O

Bocavirus	O
infection	B-DISO
in	O
50	O
%	O
of	O
cases	O
progresses	O
with	O
laryngo	O
-	O
tracheitis	B-DISO
and	O
bronchiolitis	B-DISO
.	O

TITLE	O
:	O
Respiratory	O
muscle	O
dysfunction	O
in	O
facioscapulohumeral	B-DISO
muscular	I-DISO
dystrophy	I-DISO
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
first	O
emerged	O
in	O
Vietnam	O
in	O
2009	O
.	O

We	O
report	O
for	O
the	O
first	O
time	O
that	O
the	O
levels	O
of	O
MIF	O
,	O
SCF	O
,	O
MCP	O
-	O
1	O
,	O
HGF	B-DISO
,	O
and	O
SCGF	O
-	O
β	O
are	O
highly	O
positively	O
linked	O
to	O
disease	O
severity	O
and	O
the	O
profile	O
of	O
mediators	O
MIF	O
,	O
SCF	O
,	O
MCP	O
-	O
1	O
,	O
HGF	B-DISO
,	O
SCGF	O
-	O
β	O
,	O
IP	O
-	O
10	O
,	O
IL	O
-	O
18	O
,	O
and	O
IFN	O
-	O
γ	O
is	O
an	O
independent	O
outcome	O
predictor	O
.	O

ABSTRACT	O
:	O
Previous	O
investigations	O
have	O
presumed	O
a	O
potential	O
therapeutic	O
effect	O
of	O
statin	O
therapy	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Statins	O
are	O
expected	O
to	O
attenuate	O
inflammation	B-DISO
in	O
the	O
lungs	O
of	O
patients	O
with	O
ARDS	B-DISO
due	O
to	O
their	O
anti	O
-	O
inflammatory	O
effects	O
.	O

Patients	O
with	O
severe	O
ARDS	B-DISO
who	O
received	O
statin	O
therapy	O
had	O
significantly	O
more	O
vasopressor	O
-	O
free	O
days	O
compared	O
with	O
those	O
without	O
statin	O
therapy	O
(	O
13	O
±	O
7	O
and	O
9	O
±	O
7	O
,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
0034	O
),	O
and	O
they	O
also	O
required	O
less	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
therapy	O
and	O
had	O
more	O
ECMO	O
-	O
free	O
days	O
(	O
18	O
±	O
9	O
and	O
15	O
±	O
9	O
,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
0873	O
).	O

This	O
investigation	O
suggests	O
a	O
beneficial	O
effect	O
of	O
continuous	O
statin	O
therapy	O
in	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
-	O
associated	O
ARDS	B-DISO
and	O
a	O
history	O
of	O
prior	O
statin	O
therapy	O
.	O

Patients	O
with	O
severe	O
ARDS	B-DISO
who	O
received	O
statin	O
therapy	O
had	O
significantly	O
more	O
vasopressor	O
-	O
free	O
days	O
compared	O
with	O
those	O
without	O
statin	O
therapy	O
(	O
13	O
±	O
7	O
and	O
9	O
±	O
7	O
,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
0034	O
),	O
and	O
they	O
also	O
required	O
less	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
therapy	O
and	O
had	O
more	O
ECMO	O
-	O
free	O
days	O
(	O
18	O
±	O
9	O
and	O
15	O
±	O
9	O
,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
0873	O
).	O

Influenza	B-DISO
infection	B-DISO
stimulated	O
the	O
secretion	O
of	O
IL	O
-	O
8	O
and	O
GM	O
-	O
CSF	O
by	O
AECs	O
plated	O
on	O
rat	O
-	O
tail	O
collagen	O
through	O
EGFR	O
activation	O
likely	O
by	O
TGF	O
-	O
α	O
released	O
from	O
AECs	O
and	O
through	O
c	O
-	O
Met	O
activated	O
by	O
HGF	B-DISO
secreted	O
from	O
lung	O
fibroblasts	O
.	O

Patients	O
with	O
fever	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
,	O
with	O
or	O
without	O
abnormal	O
CXR	O
,	O
were	O
treated	O
in	O
the	O
hospital	O
until	O
tests	O
proved	O
negative	O
for	O
MERS	O
-	O
CoV	O
.	O
The	O
protocol	O
successfully	O
reduced	O
the	O
number	O
of	O
patients	O
who	O
needed	O
to	O
be	O
tested	O
for	O
MERS	O
-	O
CoV	O
from	O
12	O
,	O
563	O
to	O
514	O
,	O
identified	O
seven	O
positive	O
cases	O
,	O
and	O
did	O
not	O
lead	O
to	O
apparent	O
cross	O
infectivity	O
that	O
resulted	O
in	O
serious	O
illness	O
or	O
death	O
.	O

Electronic	O
searches	O
were	O
made	O
in	O
PubMed	O
,	O
EMBASE	O
,	O
Web	B-DISO
of	O
Science	O
,	O
Cochrane	O
Library	O
,	O
and	O
Scopus	O
with	O
the	O
following	O
specific	O
keywords	O
:	O
noninvasive	O
ventilation	O
,	O
noninvasive	O
positive	O
pressure	O
ventilation	O
,	O
continuous	O
positive	O
airway	O
pressure	O
,	O
and	O
high	O
-	O
flow	O
nasal	O
cannula	O
.	O

CONCLUSIONS	O
:	O
Noninvasive	O
positive	O
pressure	O
ventilation	O
can	O
be	O
beneficial	O
in	O
children	O
with	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
particularly	O
in	O
those	O
with	O
milder	O
disease	O
.	O

There	O
was	O
weak	O
agreement	O
on	O
recommendations	O
concerning	O
approach	O
to	O
tidal	O
volume	O
and	O
inspiratory	O
pressure	O
limitation	O
(	O
88	O
%	O
to	O
72	O
%	O
agreement	O
,	O
respectively	O
),	O
whereas	O
strong	O
agreement	O
could	O
be	O
achieved	O
for	O
accepting	O
permissive	O
hypercapnia	B-DISO
.	O

All	O
clinical	O
studies	O
pertaining	O
to	O
pulmonary	O
-	O
specific	O
therapeutic	O
approaches	O
to	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
were	O
reviewed	O
.	O

If	O
clinical	O
pediatric	O
data	O
were	O
sparse	O
or	O
unavailable	O
,	O
the	O
findings	O
from	O
studies	O
of	O
adult	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
animal	O
models	O
that	O
might	O
be	O
relevant	O
to	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
were	O
examined	O
.	O

Future	O
studies	O
are	O
definitely	O
warranted	O
to	O
establish	O
the	O
role	O
,	O
if	O
any	O
,	O
of	O
these	O
ancillary	O
treatment	O
modalities	O
in	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Piles	B-DISO
of	O
economic	O
losses	O
are	O
encountered	O
due	O
to	O
these	O
diseases	O
.	O

TITLE	O
:	O
Prediction	O
and	O
biochemical	O
analysis	O
of	O
putative	O
cleavage	O
sites	O
of	O
the	O
3C	O
-	O
like	O
protease	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
.	O

More	O
intensive	O
surveillance	O
studies	O
in	O
bats	O
and	O
other	O
animals	O
may	O
reveal	O
the	O
natural	O
host	O
of	O
HCoV	O
-	O
EMC	B-DISO
.	O

In	O
this	O
review	O
,	O
we	O
highlight	O
some	O
key	O
advances	O
in	O
the	O
development	O
of	O
antiviral	O
vaccines	O
targeting	O
the	O
RBDs	O
of	O
spike	O
proteins	O
of	O
emerging	O
and	O
re	O
-	O
emerging	O
viruses	O
,	O
using	O
SARS	B-DISO
-	O
CoV	O
,	O
influenza	B-DISO
virus	O
,	O
Hendra	O
virus	O
(	O
HeV	O
)	O
and	O
Nipah	O
virus	O
(	O
NiV	O
)	O
as	O
examples	O
.	O

ABSTRACT	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
epidemic	O
started	O
in	O
late	O
2002	O
and	O
swiftly	O
spread	O
across	O
5	O
continents	O
with	O
a	O
mortality	O
rate	O
of	O
around	O
10	O
%.	O

ABSTRACT	O
:	O
To	O
identify	O
host	O
factors	O
relevant	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
replication	O
,	O
we	O
performed	O
a	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
library	O
screen	O
targeting	O
the	O
human	O
kinome	O
.	O

Depletion	O
of	O
the	O
antiviral	O
double	O
-	O
stranded	O
RNA	O
-	O
activated	O
protein	O
kinase	O
(	O
PKR	O
)	O
enhanced	O
virus	O
replication	O
in	O
the	O
primary	O
screen	O
,	O
and	O
validation	O
experiments	O
confirmed	O
increased	O
SARS	B-DISO
-	O
CoV	O
protein	O
expression	O
and	O
virus	O
production	O
upon	O
PKR	O
depletion	O
.	O

The	O
identified	O
factors	O
could	O
be	O
interesting	O
targets	O
for	O
the	O
development	O
of	O
host	O
-	O
directed	O
antiviral	O
therapy	O
to	O
treat	O
infections	B-DISO
with	O
SARS	B-DISO
-	O
CoV	O
or	O
other	O
pathogenic	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
The	O
5	O
'	O
cap	B-DISO
structures	O
of	O
eukaryotic	O
mRNAs	O
are	O
important	O
for	O
RNA	O
stability	O
and	O
protein	O
translation	O
.	O

Based	O
on	O
our	O
current	O
and	O
previous	O
studies	O
,	O
we	O
designed	O
a	O
peptide	O
(	O
TP29	O
)	O
from	O
the	O
sequence	O
of	O
the	O
interaction	O
interface	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
nsp10	O
and	O
demonstrated	O
that	O
the	O
peptide	O
inhibits	O
the	O
2	O
'-	O
O	O
-	O
MTase	O
activity	O
of	O
different	O
coronaviruses	O
in	O
biochemical	O
assays	O
and	O
the	O
viral	O
replication	O
in	O
MHV	O
infection	B-DISO
and	O
SARS	B-DISO
-	O
CoV	O
replicon	O
models	O
.	O

Interestingly	O
,	O
the	O
peptide	O
TP29	O
exerted	O
robust	O
inhibitory	O
effects	O
in	O
vivo	O
in	O
MHV	O
-	O
infected	O
mice	O
by	O
impairing	O
MHV	O
virulence	O
and	O
pathogenesis	B-DISO
through	O
suppressing	O
virus	O
replication	O
and	O
enhancing	O
type	O
I	O
interferon	O
production	O
at	O
an	O
early	O
stage	O
of	O
infection	B-DISO
.	O

Patients	O
with	O
advanced	O
(	O
cT2	O
-	O
cT4	O
or	O
node	O
positive	O
)	O
esophageal	O
or	O
gastroesophageal	O
junction	O
carcinoma	B-DISO
who	O
received	O
preoperative	O
carboplatin	O
/	O
paclitaxel	O
-	O
based	O
chemoradiotherapy	O
with	O
radiation	O
doses	O
of	O
greater	O
than	O
41	O
.	O
4	O
Gray	O
(	O
Gy	O
)	O
followed	O
by	O
esophagectomy	O
were	O
identified	O
from	O
an	O
institutional	O
database	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
.	O

Although	O
asymptomatic	O
HCPs	O
certainly	O
harbor	O
a	O
number	O
of	O
different	O
potentially	O
infectious	B-DISO
agents	O
,	O
future	O
studies	O
are	O
needed	O
to	O
determine	O
whether	O
colonized	O
pathogens	O
are	O
transmitted	B-DISO
or	O
initiate	O
infection	B-DISO
in	O
at	O
-	O
risk	O
patient	O
populations	O
.	O

There	O
is	O
accumulating	O
evidence	O
in	O
rodents	O
and	O
humans	O
suggesting	O
that	O
extracellular	O
histones	O
are	O
strong	O
drivers	O
of	O
inflammation	B-DISO
and	O
tissue	O
damage	O
.	O

Unregulated	O
complement	O
activation	O
is	O
likely	O
to	O
play	O
a	O
crucial	O
role	O
in	O
the	O
pathogenesis	B-DISO
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
induced	O
by	O
highly	O
pathogenic	O
virus	O
including	O
influenza	B-DISO
A	O
viruses	O
H5N1	B-DISO
,	O
H7N9	O
,	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
coronavirus	O
.	O

Further	O
comparative	O
pathology	B-DISO
study	O
indicated	O
that	O
the	O
FL2013	O
strain	O
had	O
reduced	O
virulence	O
to	O
newborn	O
piglets	O
.	O

ABSTRACT	O
:	O
Infection	B-DISO
with	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
causes	O
damage	O
to	O
intestinal	O
epithelial	O
cells	O
and	O
results	O
in	O
acute	B-DISO
diarrhea	I-DISO
and	O
dehydration	B-DISO
with	O
high	O
mortality	O
rates	O
in	O
swine	O
.	O

ABSTRACT	O
:	O
Livestock	O
animals	O
have	O
been	O
the	O
assumed	O
source	O
of	O
several	O
human	O
epidemics	O
in	O
recent	O
years	O
,	O
for	O
example	O
,	O
influenza	B-DISO
H1N1	O
,	O
rotavirus	O
G8	O
/	O
G9	O
,	O
and	O
MERS	O
-	O
CoV	O
.	O
Surveillance	O
of	O
novel	O
viruses	O
in	O
animals	O
is	O
essential	O
to	O
evaluate	O
the	O
risk	O
to	O
human	O
and	O
animal	O
health	O
and	O
to	O
determine	O
any	O
economic	O
impact	O
,	O
for	O
example	O
,	O
failure	B-DISO
to	I-DISO
thrive	I-DISO
.	O

There	O
is	O
a	O
paucity	O
of	O
data	O
regarding	O
detection	O
and	O
characterisation	O
of	O
gastroenteritis	B-DISO
viruses	O
,	O
particularly	O
novel	O
viruses	O
,	O
in	O
porcines	O
in	O
Ireland	O
.	O

In	O
this	O
study	O
,	O
the	O
presence	O
of	O
gastroenteritis	B-DISO
viruses	O
(	O
rotavirus	O
A	O
,	O
porcine	O
circovirus	O
,	O
adenovirus	B-DISO
,	O
and	O
porcine	O
bocavirus	O
)	O
was	O
investigated	O
in	O
a	O
selection	O
of	O
archived	O
faecal	O
samples	O
from	O
asymptomatic	O
piglets	O
from	O
a	O
commercial	O
farm	O
in	O
Ireland	O
.	O

Some	O
specimens	O
contained	O
>	O
1	O
virus	O
,	O
with	O
statistical	O
analysis	O
indicating	O
a	O
strong	O
correlation	O
for	O
mixed	B-DISO
infections	I-DISO
of	O
PBoV	O
and	O
PAdV	O
on	O
this	O
farm	O
.	O

The	O
leading	O
cause	O
of	O
lung	O
failure	O
was	O
pneumonia	B-DISO
.	O

Recently	O
,	O
we	O
showed	O
that	O
LeTx	O
inactivation	B-DISO
of	O
p38	O
MAP	O
kinase	O
signaling	O
via	O
degradation	O
of	O
MKK3	O
in	O
pulmonary	O
vascular	O
endothelial	O
cells	O
can	O
be	O
linked	O
to	O
compromise	O
of	O
the	O
endothelial	O
permeability	O
barrier	O
.	O

ABSTRACT	O
:	O
Compared	O
to	O
other	O
respiratory	O
viruses	O
,	O
relatively	O
little	O
is	O
known	O
about	O
the	O
clinical	O
impact	O
of	O
coronavirus	O
(	O
CoV	O
)	O
infection	B-DISO
after	O
hematopoietic	O
stem	O
cell	O
transplant	O
(	O
HSCT	O
)	O
or	O
in	O
patients	O
with	O
hematologic	B-DISO
malignancies	I-DISO
.	O

Possible	O
and	O
proven	O
lower	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
was	O
less	O
common	O
compared	O
to	O
other	O
respiratory	O
viruses	O
except	O
RhV	O
/	O
EnV	O
.	O

Vascular	O
cell	O
adhesion	B-DISO
molecule	O
-	O
1	O
(	O
VCAM	O
-	O
1	O
)	O
is	O
one	O
kind	O
of	O
adhesion	B-DISO
molecules	O
participating	O
in	O
the	O
process	O
of	O
polymorphonuclear	O
leukocyte	O
transmigration	O
and	O
regulating	O
the	O
occurrence	O
and	O
amplification	B-DISO
of	O
tissue	O
inflammation	B-DISO
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
compare	O
the	O
risk	O
-	O
recognition	O
of	O
avian	B-DISO
influenza	I-DISO
between	O
poultry	O
farmers	O
and	O
the	O
general	O
population	O
.	O

To	O
obtain	O
health	O
-	O
related	O
data	O
,	O
including	O
the	O
participants	O
'	O
awareness	O
of	O
avian	B-DISO
influenza	I-DISO
,	O
their	O
recognition	O
of	O
potential	O
infection	B-DISO
,	O
and	O
their	O
risk	O
image	O
,	O
or	O
their	O
level	O
of	O
fear	O
and	O
understanding	O
an	O
anonymous	O
self	O
-	O
reported	O
questionnaire	O
was	O
administered	O
.	O

The	O
two	O
groups	O
differed	O
significantly	O
in	O
terms	O
of	O
their	O
overall	O
awareness	O
and	O
understanding	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
odds	O
ratio	O
=	O
0	O
.	O
49	O
P	O
=.	O
003	O
),	O
with	O
the	O
general	O
population	O
scoring	O
significantly	O
lower	O
than	O
the	O
poultry	O
farmers	O
.	O

ABSTRACT	O
:	O
Novel	O
approaches	O
to	O
the	O
management	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
include	O
strategies	O
to	O
enhance	O
alveolar	O
liquid	O
clearance	O
,	O
promote	O
epithelial	O
cell	O
growth	O
and	O
recovery	O
after	O
acute	O
lung	O
injury	O
,	O
and	O
individualize	O
ventilator	O
care	O
on	O
the	O
basis	O
of	O
physiological	O
responses	O
.	O

There	O
was	O
no	O
association	O
with	O
parainfluenza	B-DISO
virus	O
,	O
human	O
enterovirus	O
or	O
rhinovirus	O
and	O
coronavirus	O
and	O
bocavirus	O
were	O
negatively	O
associated	O
with	O
CAP	B-DISO
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
seasonal	O
distribution	O
of	O
agent	O
viruses	O
in	O
childhood	O
respiratory	B-DISO
infections	I-DISO
in	O
our	O
region	O
.	O

Parainfluenza	B-DISO
and	O
respiratory	O
syncytial	O
virus	O
were	O
found	O
most	O
frequently	O
in	O
December	O
-	O
february	O
(	O
58	O
%	O
and	O
59	O
%,	O
respectively	O
,	O
influenza	B-DISO
viruses	O
were	O
found	O
most	O
frequently	O
in	O
November	O
-	O
december	O
(	O
72	O
%)	O
and	O
adenoviruses	O
were	O
found	O
most	O
frequently	O
in	O
may	O
-	O
september	O
(	O
56	O
%).	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
outcomes	O
of	O
ECMO	O
in	O
patients	O
with	O
severe	O
postoperative	O
ARDS	B-DISO
.	O

To	O
evaluate	O
transmission	O
risk	O
,	O
we	O
determined	O
the	O
type	O
,	O
duration	O
,	O
and	O
frequency	O
of	O
patient	O
contact	O
among	O
health	O
care	O
personnel	O
(	O
HCP	B-DISO
),	O
household	O
,	O
and	O
community	O
contacts	O
by	O
using	O
standard	O
questionnaires	O
and	O
,	O
for	O
HCP	B-DISO
,	O
global	O
positioning	O
system	O
(	O
GPS	B-DISO
)	O
tracer	O
tag	B-DISO
logs	O
.	O

HCP	B-DISO
exposures	O
occurred	O
most	O
frequently	O
in	O
the	O
emergency	B-DISO
department	O
(	O
69	O
%)	O
and	O
among	O
nurses	O
(	O
47	O
%);	O
some	O
HCP	B-DISO
had	O
contact	O
with	O
respiratory	O
secretions	O
.	O

TITLE	O
:	O
Hematologic	B-DISO
Disorders	I-DISO
:	O
Sickle	B-DISO
Cell	I-DISO
Disease	I-DISO
.	O

Prophylactic	O
penicillin	O
through	O
age	O
5	O
years	O
and	O
pneumococcal	O
immunization	O
lower	O
the	O
risk	O
of	O
serious	O
pneumococcal	B-DISO
infections	I-DISO
.	O

TITLE	O
:	O
[	O
Advances	O
in	O
the	O
researches	O
of	O
genomic	O
characterization	O
and	O
molecular	O
detection	O
of	O
Middel	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
].	O

Networks	O
discussed	O
include	O
global	O
intergovernmental	O
organizations	O
and	O
recent	O
combined	O
efforts	O
of	O
these	O
organizations	O
;	O
Web	B-DISO
-	O
based	O
nongovernmental	O
systems	O
(	O
e	O
.	O
g	O
.,	O
ProMED	O
,	O
the	O
Program	O
for	O
Monitoring	O
Emerging	O
Diseases	O
);	O
and	O
networks	O
of	O
bilateral	O
or	O
multilateral	O
government	O
programs	O
(	O
e	O
.	O
g	O
.,	O
the	O
CDC	O
'	O
s	O
Global	O
Disease	O
Detection	O
[	O
GDD	B-DISO
]	O
platform	O
;	O
the	O
U	O
.	O
S	O
.	O
Department	O
of	O
Defense	O
'	O
s	O
Global	O
Emerging	O
Infections	B-DISO
Surveillance	O
and	O
Response	O
System	O
[	O
GEIS	O
];	O
regional	O
and	O
subregional	O
networks	O
;	O
and	O
the	O
U	O
.	O
S	O
.	O
Agency	O
for	O
International	O
Development	O
'	O
s	O
Emerging	O
Pandemic	O
Threats	O
[	O
EPT	O
]	O
program	O
and	O
its	O
surveillance	O
component	O
,	O
PREDICT	O
).	O

Preincubation	O
of	O
HTBE	O
cells	O
with	O
a	O
truncated	O
HKU1	O
S	O
protein	O
that	O
includes	O
the	O
C	O
domain	O
blocked	O
infection	B-DISO
with	O
HKU1	O
virus	O
,	O
but	O
preincubation	O
of	O
cells	O
with	O
truncated	O
S	O
protein	O
containing	O
only	O
the	O
NTD	O
did	O
not	O
block	O
infection	B-DISO
.	O

We	O
identified	O
a	O
novel	O
VSR	O
from	O
coronaviruses	O
,	O
a	O
group	O
of	O
medically	O
important	O
mammalian	O
viruses	O
including	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
and	O
showed	O
that	O
the	O
nucleocapsid	O
protein	O
(	O
N	O
protein	O
)	O
of	O
coronaviruses	O
suppresses	O
RNAi	O
triggered	O
by	O
either	O
short	O
hairpin	O
RNAs	O
or	O
small	O
interfering	O
RNAs	O
in	O
mammalian	O
cells	O
.	O

ABSTRACT	O
:	O
Acute	O
histologic	O
chorioamnionitis	B-DISO
(	O
acute	O
-	O
HCA	O
)	O
is	O
known	O
to	O
be	O
associated	O
with	O
a	O
decreased	O
risk	O
of	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
(	O
RDS	O
)	O
in	O
newborns	O
.	O

However	O
,	O
there	O
is	O
no	O
information	O
about	O
whether	O
the	O
severity	O
of	O
acute	O
-	O
HCA	O
or	O
intra	O
-	O
amniotic	O
inflammation	B-DISO
(	O
IAI	O
)	O
is	O
associated	O
with	O
the	O
development	O
of	O
RDS	O
.	O

RESULTS	O
:	O
Mild	O
to	O
moderate	O
,	O
but	O
not	O
minimal	O
or	O
severe	O
,	O
acute	O
-	O
HCA	O
(	O
minimal	O
,	O
24	O
%;	O
mild	O
,	O
13	O
%;	O
moderate	O
,	O
19	O
%;	O
severe	O
,	O
41	O
%;	O
preterm	O
-	O
reference	O
group	O
,	O
26	O
%)	O
or	O
IAI	O
(	O
minimal	O
,	O
24	O
%;	O
mild	O
,	O
11	O
%;	O
moderate	O
,	O
17	O
%;	O
severe	O
,	O
25	O
%;	O
preterm	O
reference	O
group	O
,	O
23	O
%)	O
was	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
RDS	O
as	O
compared	O
with	O
the	O
preterm	O
reference	O
group	O
(	O
each	O
for	O
p	O
<	O
0	O
.	O
05	O
after	O
the	O
adjustment	O
of	O
gestational	O
age	O
at	O
delivery	O
,	O
antenatal	O
corticosteroid	O
use	O
,	O
newborn	O
gender	O
,	O
cesarean	O
delivery	O
and	O
preterm	O
-	O
PROM	O
as	O
a	O
cause	O
of	O
preterm	B-DISO
birth	I-DISO
).	O

Activation	O
of	O
SMAD3	O
by	O
TGFβ1	O
did	O
not	O
affect	O
either	O
collagen	O
I	O
or	O
α	O
-	O
SMA	B-DISO
in	O
HLF	O
cells	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
infection	I-DISO
(	O
ARI	O
)	O
is	O
a	O
leading	O
cause	O
of	O
morbidity	O
and	O
hospitalization	O
in	O
children	O
.	O

This	O
report	O
presents	O
two	O
cases	O
of	O
ARDS	B-DISO
due	O
to	O
influenza	B-DISO
in	O
Vietnam	O
.	O

In	O
conclusion	O
,	O
treatment	O
with	O
PMX	O
-	O
DHP	O
and	O
oseltamivir	O
is	O
effective	O
on	O
ARDS	B-DISO
due	O
to	O
influenza	B-DISO
but	O
only	O
if	O
initiated	O
early	O
.	O

He	O
presented	O
with	O
severe	O
respiratory	B-DISO
insufficiency	I-DISO
;	O
chest	O
computed	O
tomography	O
(	O
CT	O
)	O
revealed	O
extensive	O
ground	O
-	O
glass	O
opacity	B-DISO
in	O
lung	O
fields	O
on	O
both	O
sides	O
.	O

The	O
viruses	O
are	O
transmitted	B-DISO
to	O
humans	O
mainly	O
by	O
inhalation	O
of	O
virus	O
-	O
contaminated	O
aerosols	O
of	O
rodent	O
excreta	O
and	O
secreta	O
.	O

We	O
review	O
diagnosis	O
for	O
hantavirus	B-DISO
infections	I-DISO
based	O
on	O
serology	O
,	O
PCR	O
,	O
immunochemistry	O
and	O
virus	O
culture	O
.	O

The	O
infectious	B-DISO
titers	O
of	O
the	O
virus	O
during	O
the	O
first	O
10	O
passages	O
ranged	O
from	O
10	O
(	O
2	O
.	O
6	O
)	O
to	O
10	O
(	O
5	O
.	O
8	O
)	O
50	O
%	O
tissue	O
culture	O
infective	O
doses	O
(	O
TCID50	O
)/	O
ml	O
,	O
and	O
the	O
titers	O
of	O
20	O
-	O
95	O
passages	O
ranged	O
from	O
10	O
(	O
6	O
.	O
2	O
)	O
to	O
10	O
(	O
8	O
.	O
0	O
)	O
TCID50	O
/	O
ml	O
.	O

All	O
piglets	O
orally	O
inoculated	O
developed	O
severe	O
watery	O
diarrhea	B-DISO
and	I-DISO
vomiting	I-DISO
within	O
24	O
hours	O
post	O
-	O
inoculation	O
(	O
hpi	B-DISO
)	O
and	O
died	O
within	O
72	O
hpi	B-DISO
.	O

TITLE	O
:	O
Risks	O
to	O
healthcare	O
workers	O
with	O
emerging	O
diseases	O
:	O
lessons	O
from	O
MERS	O
-	O
CoV	O
,	O
Ebola	O
,	O
SARS	B-DISO
,	O
and	O
avian	B-DISO
flu	I-DISO
.	O

The	O
WHO	O
guidelines	O
for	O
the	O
global	O
surveillance	O
of	O
SARS	B-DISO
were	O
developed	O
in	O
2004	O
and	O
used	O
as	O
a	O
template	O
for	O
other	O
emerging	O
diseases	O
preparedness	O
.	O

Risks	O
to	O
HCPs	O
with	O
emerging	O
diseases	O
are	O
related	O
to	O
inappropriate	O
and	O
insufficient	O
infection	B-DISO
control	O
measures	O
during	O
an	O
initial	O
encounter	O
,	O
at	O
the	O
beginning	O
of	O
outbreak	O
and	O
with	O
an	O
overwhelming	O
number	O
of	O
patient	O
cases	O
.	O

632	O
ARDS	B-DISO
patients	O
were	O
included	O
.	O

There	O
are	O
no	O
current	O
pharmacological	O
therapies	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Although	O
the	O
study	O
was	O
not	O
specifically	O
designed	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
as	O
an	O
outcome	O
,	O
the	O
number	O
of	O
patients	O
who	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
was	O
small	O
(	O
2	O
/	O
77	O
).	O

Furthermore	O
,	O
results	O
of	O
this	O
early	O
-	O
phase	O
trial	O
may	O
aid	O
in	O
design	O
of	O
future	O
studies	O
aimed	O
at	O
prevention	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
other	O
organ	O
injury	O
.	O

The	O
objective	O
of	O
our	O
study	O
was	O
to	O
describe	O
lung	O
changes	O
on	O
serial	O
chest	O
radiographs	O
from	O
patients	O
infected	O
with	O
the	O
acute	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
corona	O
-	O
virus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
to	O
compare	O
the	O
chest	O
radiographic	O
findings	O
and	O
final	O
outcomes	O
with	O
those	O
of	O
health	O
care	O
workers	O
(	O
HCWs	O
)	O
infected	O
with	O
the	O
same	O
virus	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
Respiratory	I-DISO
Infections	I-DISO
(	O
ARIs	O
)	O
are	O
responsible	O
for	O
considerable	O
morbidity	O
and	O
mortality	O
worldwide	O
.	O

We	O
conducted	O
a	O
small	O
-	O
molecule	O
screen	O
to	O
identify	O
compounds	O
capable	O
of	O
inhibiting	O
cytotoxicity	B-DISO
caused	O
by	O
reovirus	O
,	O
a	O
prototype	O
double	O
-	O
stranded	O
RNA	O
virus	O
.	O

TITLE	O
:	O
The	O
Pattern	O
of	O
Brain	O
Microhemorrhages	O
After	O
Severe	O
Lung	O
Failure	O
Resembles	O
the	O
One	O
Seen	O
in	O
High	O
-	O
Altitude	O
Cerebral	B-DISO
Edema	I-DISO
.	O

This	O
report	O
demonstrates	O
that	O
patients	O
after	O
treatment	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
high	O
-	O
altitude	O
cerebral	B-DISO
edema	I-DISO
show	O
congruent	O
cerebral	O
injuries	O
.	O

This	O
study	O
compared	O
the	O
clinical	O
characteristics	O
of	O
HRV	O
to	O
other	O
common	O
viral	B-DISO
infections	I-DISO
and	O
investigated	O
the	O
molecular	O
epidemiology	O
of	O
HRV	O
in	O
hospitalized	O
children	O
with	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
(	O
ARIs	O
)	O
in	O
Vietnam	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
was	O
first	O
recognized	O
in	O
North	O
America	O
in	O
April	O
2013	O
and	O
has	O
since	O
caused	O
devastating	O
disease	O
.	O

The	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
that	O
serves	O
as	O
a	O
critical	O
component	O
of	O
cellular	O
signal	O
transduction	O
pathways	O
to	O
modulate	O
a	O
variety	O
of	O
cellular	O
functions	O
has	O
been	O
shown	O
to	O
regulate	O
several	O
viral	B-DISO
infections	I-DISO
.	O

TITLE	O
:	O
Severe	O
childhood	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
associated	O
with	O
Mycoplasma	B-DISO
pneumoniae	O
infection	B-DISO
:	O
a	O
case	O
series	O
.	O

ABSTRACT	O
:	O
We	O
report	O
seven	O
children	O
with	O
recent	O
Mycoplasma	B-DISO
pneumoniae	O
infection	B-DISO
and	O
severe	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
(	O
GBS	B-DISO
)	O
that	O
presented	O
to	O
two	O
European	O
medical	O
centres	O
from	O
1992	O
to	O
2012	O
.	O

The	O
five	O
patients	O
with	O
severe	O
GBS	B-DISO
were	O
derived	O
from	O
an	O
original	O
cohort	O
of	O
66	O
children	O
with	O
GBS	B-DISO
.	O

TITLE	O
:	O
New	O
Metrics	O
for	O
Evaluating	O
Viral	O
Respiratory	O
Pathogenesis	B-DISO
.	O

This	O
methodology	O
closely	O
tracked	O
with	O
traditional	O
pathogenesis	B-DISO
metrics	O
,	O
distinguished	O
both	O
virus	O
-	O
and	O
dose	O
-	O
specific	O
responses	O
,	O
and	O
identified	O
long	O
-	O
term	O
respiratory	O
changes	O
following	O
both	O
SARS	B-DISO
-	O
CoV	O
and	O
Influenza	B-DISO
A	I-DISO
Virus	I-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Respiratory	O
viral	B-DISO
infections	I-DISO
(	O
RVI	O
)	O
are	O
important	O
in	O
hematopoietic	O
stem	O
cell	O
transplantations	O
(	O
HSCT	O
)	O
and	O
knowledge	O
regarding	O
incidence	O
,	O
morbidity	O
,	O
mortality	O
,	O
and	O
long	O
-	O
term	O
pulmonary	B-DISO
complications	I-DISO
is	O
limited	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
relationships	O
between	O
xanthine	O
oxidase	O
(	O
XOD	O
)	O
and	O
nephropathogenic	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
NIBV	O
)	O
infection	B-DISO
,	O
240	O
growing	O
layers	O
(	O
35	O
days	O
old	O
)	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
(	O
infected	O
and	O
control	O
)	O
of	O
120	O
chickens	O
each	O
.	O

TITLE	O
:	O
Overwintering	O
Is	O
Associated	O
with	O
Reduced	O
Expression	O
of	O
Immune	O
Genes	O
and	O
Higher	O
Susceptibility	O
to	O
Virus	B-DISO
Infection	I-DISO
in	O
Honey	O
Bees	O
.	O

Infections	B-DISO
in	O
North	O
America	O
occur	O
most	O
frequently	O
during	O
the	O
spring	O
and	O
summer	O
months	O
in	O
the	O
Northeastern	O
and	O
Midwestern	O
United	O
States	O
.	O

But	O
with	O
the	O
use	O
of	O
Boussignac	O
CPAP	O
system	O
all	O
necessary	O
tests	O
were	O
successfully	O
completed	O
,	O
confirming	O
the	O
patient	O
'	O
s	O
brain	B-DISO
death	I-DISO
,	O
which	O
gave	O
us	O
the	O
opportunity	O
to	O
perform	O
procedures	O
for	O
organ	O
donation	O
.	O

TITLE	O
:	O
Dynamic	O
changes	O
of	O
virus	O
load	O
in	O
supernatant	O
of	O
primary	O
CEK	O
cell	O
culture	O
infected	O
with	O
different	O
generations	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
strains	O
Sczy3	O
as	O
revealed	O
by	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
.	O

ABSTRACT	O
:	O
In	O
this	O
report	O
,	O
we	O
describe	O
37	O
MERS	O
-	O
CoV	O
infection	B-DISO
cases	O
(	O
1	O
primary	O
,	O
25	O
secondary	O
,	O
11	O
tertiary	O
cases	O
)	O
in	O
a	O
single	O
hospital	O
in	O
South	O
Korea	O
.	O

The	O
median	O
incubation	O
period	O
was	O
six	O
days	O
(	O
95	O
%	O
CI	O
:	O
4	O
–	O
7	O
days	O
)	O
and	O
the	O
duration	O
between	O
suspected	O
symptom	B-DISO
onset	O
and	O
laboratory	O
confirmation	O
was	O
6	O
.	O
5	O
days	O
(	O
95	O
%	O
CI	O
:	O
4	O
–	O
9	O
).	O

TITLE	O
:	O
Brief	O
Report	O
:	O
Incubation	O
Period	O
Duration	O
and	O
Severity	O
of	O
Clinical	O
Disease	O
Following	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Coronavirus	B-DISO
Infection	I-DISO
.	O

We	O
estimated	O
the	O
incubation	O
period	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
based	O
on	O
a	O
subset	O
of	O
patients	O
with	O
available	O
data	O
on	O
exposure	O
periods	O
and	O
a	O
separate	O
subset	O
of	O
patients	O
in	O
a	O
putative	O
common	O
source	O
outbreak	O
,	O
and	O
we	O
found	O
associations	O
between	O
shorter	O
incubation	O
period	O
and	O
greater	O
severity	O
in	O
both	O
groups	O
after	O
adjusting	O
for	O
potential	O
confounders	O
.	O

RESULTS	O
:	O
We	O
estimated	O
the	O
incubation	O
period	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
based	O
on	O
a	O
subset	O
of	O
patients	O
with	O
available	O
data	O
on	O
exposure	O
periods	O
and	O
a	O
separate	O
subset	O
of	O
patients	O
in	O
a	O
putative	O
common	O
source	O
outbreak	O
,	O
and	O
we	O
found	O
associations	O
between	O
shorter	O
incubation	O
period	O
and	O
greater	O
severity	O
in	O
both	O
groups	O
after	O
adjusting	O
for	O
potential	O
confounders	O
.	O

Impaired	B-DISO
muscle	O
function	O
in	O
ARDS	B-DISO
is	O
associated	O
with	O
increased	O
mortality	O
,	O
increased	O
duration	O
of	O
mechanical	O
ventilation	O
,	O
and	O
functional	O
disability	O
in	O
survivors	O
.	O

Owing	O
to	O
these	O
underlying	O
mechanistic	O
differences	O
,	O
therapeutic	O
interventions	O
for	O
treating	O
muscle	O
dysfunction	O
in	O
ARDS	B-DISO
may	O
differ	O
during	O
the	O
early	O
and	O
late	O
phases	O
.	O

ABSTRACT	O
:	O
Over	O
the	O
last	O
years	O
,	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
has	O
caused	O
devastating	O
enteric	O
diseases	O
in	O
the	O
US	O
and	O
several	O
countries	O
in	O
Asia	O
,	O
while	O
outbreaks	O
in	O
Europe	O
have	O
only	O
been	O
reported	O
sporadically	O
since	O
the	O
1980s	O
.	O

Epidemic	O
outbreaks	O
of	O
diarrhea	B-DISO
affecting	O
pigs	O
of	O
all	O
age	O
groups	O
were	O
reported	O
in	O
three	O
farms	O
,	O
one	O
fattening	O
farm	O
and	O
two	O
piglet	O
producing	O
farms	O
,	O
in	O
South	O
-	O
Western	O
Germany	O
between	O
May	O
and	O
November	O
2014	O
.	O

ABSTRACT	O
:	O
Myd88	O
signaling	O
is	O
critical	O
to	O
the	O
control	O
of	O
numerous	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
infections	B-DISO
by	O
promoting	O
both	O
innate	O
and	O
adaptive	O
immune	O
responses	O
.	O

Infected	O
Myd88	O
(-/-)	O
mice	O
failed	O
to	O
control	O
virus	O
,	O
exhibited	O
enhanced	O
clinical	O
disease	O
coincident	O
with	O
increased	O
demyelination	B-DISO
,	O
and	O
succumbed	O
to	O
infection	B-DISO
within	O
3	O
weeks	O
.	O

Moreover	O
,	O
CD4	O
T	O
cells	O
but	O
not	O
CD8	O
T	O
cells	O
were	O
impaired	B-DISO
in	O
IFN	O
-	O
γ	O
production	O
.	O

Severe	O
infusion	O
-	O
associated	O
reactions	O
are	O
consistent	O
with	O
CRS	B-DISO
and	O
can	O
cause	O
serious	O
cardiac	O
or	O
respiratory	B-DISO
problems	I-DISO
,	O
or	O
in	O
certain	O
cases	O
,	O
mortality	O
.	O

Sequence	O
comparison	O
and	O
phylogenetic	O
studies	O
have	O
thus	O
clearly	O
showed	O
that	O
the	O
emergence	O
of	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
type	O
1	O
(	O
HIV	B-DISO
-	O
1	O
)	O
and	O
HIV	B-DISO
-	O
2	O
in	O
humans	O
have	O
resulted	O
from	O
several	O
independent	O
interspecies	O
transmissions	O
of	O
different	O
SIV	B-DISO
types	O
from	O
Chimpanzees	O
and	O
African	O
monkeys	O
(	O
including	O
sooty	O
mangabeys	O
),	O
respectively	O
,	O
probably	O
during	O
the	O
first	O
part	O
of	O
the	O
last	O
century	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
risk	O
factors	O
of	O
patients	O
with	O
acute	O
lung	O
injury	O
/	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ALI	O
/	O
ARDS	B-DISO
)	O
complicated	O
with	O
Yangming	O
Fushi	O
syndrome	B-DISO
.	O

The	O
incidence	O
of	O
sepsis	B-DISO
-	O
related	O
ARDS	B-DISO
was	O
11	O
.	O
2	O
%	O
(	O
35	O
/	O
312	O
).	O

It	O
was	O
shown	O
by	O
multivariate	O
logistic	O
regression	O
analysis	O
that	O
LIPS	O
[	O
odds	O
ratio	O
(	O
OR	O
)=	O
5	O
.	O
124	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
95	O
%	O
CI	O
)=	O
3	O
.	O
642	O
-	O
10	O
.	O
153	O
,	O
P	O
=	O
0	O
.	O
002	O
],	O
Lac	O
(	O
OR	O
=	O
18	O
.	O
180	O
,	O
95	O
%	O
CI	O
=	O
7	O
.	O
677	O
-	O
32	O
.	O
989	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
were	O
independent	O
risk	O
factors	O
for	O
ARDS	B-DISO
.	O

It	O
was	O
shown	O
by	O
area	O
under	O
ROC	O
(	O
AUC	O
)	O
that	O
the	O
predictive	O
value	O
of	O
LIPS	O
and	O
Lac	O
in	O
ARDS	B-DISO
occurrence	O
was	O
significant	O
.	O

LIPS	O
and	O
Lac	O
are	O
independent	O
risk	O
factors	O
of	O
ARDS	B-DISO
in	O
patients	O
with	O
sepsis	B-DISO
in	O
emergency	B-DISO
department	O
,	O
which	O
may	O
be	O
a	O
reference	O
for	O
the	O
early	O
clinical	O
diagnosis	O
of	O
ARDS	B-DISO
.	O

The	O
predictive	O
value	O
for	O
mild	O
ARDS	B-DISO
by	O
LUS	O
was	O
7	O
.	O
0	O
,	O
sensitivity	O
of	O
87	O
.	O
0	O
%,	O
specificity	O
of	O
89	O
.	O
0	O
%;	O
that	O
for	O
moderate	O
ARDS	B-DISO
was	O
11	O
.	O
0	O
,	O
sensitivity	O
of	O
89	O
.	O
0	O
%,	O
specificity	O
of	O
87	O
.	O
0	O
%;	O
that	O
for	O
severe	O
ARDS	B-DISO
was	O
8	O
.	O
0	O
,	O
sensitivity	O
of	O
90	O
.	O
0	O
%,	O
specificity	O
of	O
88	O
.	O
5	O
%.	O

Bedside	O
LUS	O
,	O
which	O
is	O
simple	O
and	O
easily	O
available	O
,	O
could	O
evaluate	O
the	O
changes	O
in	O
pulmonary	O
ventilation	O
area	O
of	O
ARDS	B-DISO
,	O
and	O
its	O
degree	O
of	O
severity	O
,	O
and	O
prognosis	O
including	O
prediction	O
of	O
mortality	O
of	O
the	O
patients	O
.	O

TITLE	O
:	O
[	O
A	O
multicenter	O
clinical	O
study	O
of	O
bundle	O
treatment	O
for	O
moderate	O
or	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
].	O

TITLE	O
:	O
Inability	O
of	O
rat	O
DPP4	O
to	O
allow	O
MERS	O
-	O
CoV	O
infection	B-DISO
revealed	O
by	O
using	O
a	O
VSV	O
pseudotype	O
bearing	O
truncated	O
MERS	O
-	O
CoV	O
spike	O
protein	O
.	O

Using	O
MERSpv	O
-	O
St16	O
,	O
we	O
demonstrated	O
the	O
inability	O
of	O
rat	O
DPP4	O
to	O
serve	O
as	O
a	O
functional	O
receptor	O
for	O
MERS	O
-	O
CoV	O
,	O
suggesting	O
that	O
rats	O
are	O
not	O
susceptible	O
to	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

TITLE	O
:	O
Risk	O
factors	O
and	O
outcomes	O
associated	O
with	O
new	O
-	O
onset	O
atrial	B-DISO
fibrillation	I-DISO
during	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

In	O
this	O
study	O
,	O
both	O
pathogenic	O
(	O
passage	O
3	O
,	O
P3	O
)	O
and	O
attenuated	O
(	O
P110	O
)	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
strains	O
were	O
used	O
to	O
study	O
the	O
immune	O
responses	O
of	O
chicken	O
to	O
IBV	O
infection	B-DISO
.	O

Our	O
findings	O
contribute	O
to	O
the	O
proposal	O
that	O
IBV	O
infection	B-DISO
induces	O
an	O
increase	O
in	O
the	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
expression	O
of	O
some	O
AvBDs	O
and	O
TLRs	O
,	O
which	O
suggests	O
that	O
AvBDs	O
may	O
play	O
significant	O
roles	O
in	O
the	O
resistance	O
of	O
chickens	O
to	O
IBV	O
replication	O
.	O

TITLE	O
:	O
Human	O
infection	B-DISO
with	O
a	O
novel	O
,	O
highly	O
pathogenic	O
avian	B-DISO
influenza	I-DISO
A	O
(	O
H5N6	O
)	O
virus	O
:	O
Virological	O
and	O
clinical	B-DISO
findings	I-DISO
.	O

ABSTRACT	O
:	O
Severe	O
infection	B-DISO
with	O
avian	B-DISO
influenza	I-DISO
A	O
(	O
H5N6	O
)	O
virus	O
in	O
humans	O
was	O
identified	O
first	O
in	O
2014	O
in	O
China	O
.	O

The	O
patient	O
,	O
who	O
presented	O
with	O
fever	O
,	O
severe	O
pneumonia	B-DISO
,	O
leucopenia	B-DISO
,	O
and	O
lymphopenia	B-DISO
,	O
developed	O
septic	B-DISO
shock	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
and	O
died	O
on	O
day	O
10	O
after	O
illness	O
onset	O
.	O

The	O
percent	O
of	O
SARI	O
cases	O
that	O
tested	O
positive	O
for	O
influenza	B-DISO
ranged	O
from	O
7	O
-	O
17	O
%	O
depending	O
on	O
age	O
group	O
,	O
year	O
,	O
province	O
and	O
HIV	B-DISO
status	O
.	O

In	O
2011	O
,	O
there	O
were	O
an	O
estimated	O
29	O
,	O
892	O
total	O
severe	O
influenza	B-DISO
cases	O
in	O
HIV	B-DISO
-	O
uninfected	O
individuals	O
and	O
17	O
,	O
289	O
in	O
HIV	B-DISO
-	O
infected	O
individuals	O
.	O

The	O
objective	O
of	O
the	O
study	O
was	O
to	O
define	O
the	O
presenting	O
features	O
and	O
etiology	O
of	O
infections	B-DISO
in	O
children	O
with	O
SCID	B-DISO
.	O

Polymorphisms	O
at	O
OAS1	O
have	O
been	O
shown	O
to	O
correlate	O
with	O
differential	O
susceptibility	O
to	O
several	O
infections	B-DISO
of	O
great	O
public	O
health	O
significance	O
,	O
including	O
hepatitis	B-DISO
C	I-DISO
virus	O
,	O
SARS	B-DISO
coronavirus	O
,	O
and	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
.	O

TITLE	O
:	O
Infectious	B-DISO
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
Excretion	O
and	O
Serotype	O
Variability	O
Based	O
on	O
Live	O
Virus	O
Isolates	O
from	O
Patients	O
in	O
Saudi	O
Arabia	O
.	O

ABSTRACT	O
:	O
This	O
report	O
includes	O
a	O
summary	O
of	O
a	O
current	O
outbreak	O
of	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	B-DISO
infection	I-DISO
in	O
the	O
Republic	O
of	O
Korea	O
as	O
of	O
June	O
23	O
,	O
2015	O
.	O

Sedation	B-DISO
level	O
was	O
controlled	O
according	O
to	O
the	O
Richmond	O
Agitation	B-DISO
Sedation	B-DISO
Scale	O
(	O
RASS	O
).	O

Underlying	O
diseases	O
in	O
48	O
%	O
were	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
/	O
acute	O
lung	O
injury	O
/	O
severe	O
pneumonia	B-DISO
or	O
acute	O
exacerbation	O
of	O
interstitial	B-DISO
pneumonia	I-DISO
.	O

Women	O
were	O
excluded	O
for	O
antepartum	O
stillbirth	B-DISO
and	O
highly	O
morbid	O
conditions	O
for	O
which	O
route	O
of	O
delivery	O
would	O
not	O
likely	O
impact	O
morbidity	O
including	O
nonreassuring	B-DISO
fetal	I-DISO
status	I-DISO
,	O
cord	B-DISO
prolapse	B-DISO
,	O
placenta	B-DISO
previa	I-DISO
,	O
placenta	B-DISO
accreta	I-DISO
,	O
placental	B-DISO
abruption	I-DISO
,	O
and	O
severe	O
and	O
unstable	O
maternal	O
conditions	O
(	O
cardiopulmonary	O
collapse	B-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
seizures	B-DISO
).	O

There	O
was	O
no	O
significant	O
difference	O
in	O
complication	B-DISO
rates	O
between	O
CCD	B-DISO
and	O
LTCD	O
(	O
aRR	O
,	O
1	O
.	O
37	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
95	O
-	O
1	O
.	O
97	O
)	O
or	O
between	O
CCD	B-DISO
and	O
LVCD	O
(	O
aRR	O
,	O
1	O
.	O
56	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
48	O
-	O
5	O
.	O
07	O
).	O

There	O
was	O
no	O
significant	O
difference	O
in	O
complication	B-DISO
rates	O
between	O
CCD	B-DISO
and	O
LTCD	O
(	O
aRR	O
,	O
1	O
.	O
37	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
95	O
-	O
1	O
.	O
97	O
)	O
or	O
between	O
CCD	B-DISO
and	O
LVCD	O
(	O
aRR	O
,	O
1	O
.	O
56	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
48	O
-	O
5	O
.	O
07	O
).	O

By	O
contrast	O
,	O
many	O
other	O
human	O
adenovirus	B-DISO
(	O
HAdV	B-DISO
)	O
types	O
(	O
e	O
.	O
g	O
.	O
HAdV	B-DISO
-	O
C5	O
)	O
are	O
associated	O
mainly	O
with	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
.	O

The	O
efficient	O
""""	O
apical	O
to	O
apical	O
""""	O
replication	O
cycle	O
of	O
HAdV	O
-	O
B14p1	O
can	O
promote	O
endobronchial	O
dissemination	O
of	O
the	O
infection	B-DISO
from	O
the	O
upper	O
to	O
the	O
lower	O
respiratory	O
tract	O
.	O

ABSTRACT	O
:	O
Supporting	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
using	O
a	O
protective	O
mechanical	O
ventilation	O
strategy	O
characterized	O
by	O
low	O
tidal	O
volume	O
and	O
limitation	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
is	O
a	O
standard	O
practice	O
in	O
the	O
intensive	O
care	O
unit	O
.	O

Nearly	O
half	O
(	O
46	O
.	O
6	O
%)	O
of	O
respondents	O
regularly	O
visited	O
bat	O
caves	O
;	O
37	O
.	O
4	O
%	O
had	O
been	O
bitten	O
,	O
scratched	O
,	O
or	O
exposed	O
to	O
bat	O
urine	O
;	O
and	O
45	O
.	O
6	O
%	O
ate	B-DISO
bat	O
meat	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
correlation	O
of	O
severity	O
classification	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
by	O
the	O
Berlin	O
definition	O
with	O
extra	O
vascular	O
lung	O
water	O
index	O
(	O
EVLWI	O
)	O
and	O
pulmonary	O
vascular	O
permeability	O
index	O
(	O
PVPI	O
).	O

This	O
study	O
offers	O
a	O
brief	O
update	O
of	O
the	O
most	O
salient	O
new	O
aspects	O
of	O
the	O
important	O
viral	B-DISO
infections	I-DISO
,	O
especially	O
those	O
with	O
known	O
orofacial	O
manifestations	O
or	O
other	O
implications	O
for	O
oral	O
health	O
care	O
.	O

A	O
sepsis	B-DISO
mortality	O
prediction	O
formula	O
(	O
AIIMS	O
Sepsis	B-DISO
Score	O
)	O
based	O
on	O
SAPS	O
II	O
,	O
SAPS	O
III	O
,	O
and	O
SOFA	O
scores	O
and	O
hemoglobin	O
has	O
greater	O
predictive	O
power	O
than	O
these	O
scoring	O
methods	O
individually	O
.	O

TITLE	O
:	O
Animal	O
models	O
for	O
SARS	B-DISO
and	O
MERS	O
coronaviruses	O
.	O

Lymphopenia	B-DISO
,	O
observed	O
significantly	O
more	O
often	O
with	O
effusion	B-DISO
,	O
was	O
documented	O
in	O
only	O
26	O
.	O
8	O
%	O
of	O
cats	O
without	O
effusion	B-DISO
.	O

The	O
low	O
prevalence	O
of	O
lymphopenia	B-DISO
in	O
cats	O
without	O
effusion	B-DISO
suggests	O
that	O
this	O
is	O
not	O
a	O
useful	O
parameter	O
in	O
non	O
-	O
effusive	O
FIP	B-DISO
.	O

The	O
frequent	O
occurrence	O
of	O
a	O
left	O
shift	O
in	O
the	O
absence	O
of	O
a	O
mature	O
neutrophilia	O
complicates	O
the	O
differentiation	O
of	O
effusive	O
FIP	B-DISO
and	O
septic	O
peritonitis	B-DISO
.	O

TITLE	O
:	O
Rapid	O
and	O
sensitive	O
detection	O
of	O
Feline	O
immunodeficiency	B-DISO
virus	O
using	O
an	O
insulated	O
isothermal	O
PCR	O
-	O
based	O
assay	O
with	O
a	O
point	O
-	O
of	O
-	O
need	O
PCR	O
detection	O
platform	O
.	O

In	O
order	O
to	O
complete	O
experimental	O
work	O
at	O
BSL	O
-	O
2	O
,	O
demonstration	O
or	O
proof	O
of	O
inactivation	B-DISO
is	O
required	O
before	O
removal	O
of	O
specimens	O
from	O
biocontainment	O
laboratories	O
.	O

According	O
to	O
Tile	O
classification	O
of	O
pelvic	O
fractures	O
,	O
16	O
cases	O
were	O
type	O
B	O
and	O
12	O
cases	O
were	O
type	O
C	O
.	O
Injury	O
severity	O
score	O
(	O
ISS	B-DISO
)	O
averaged	O
32	O
.	O
0	O
±	O
3	O
.	O
4	O
.	O

ABSTRACT	O
:	O
Severe	O
outbreaks	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
have	O
re	O
-	O
emerged	O
in	O
Korea	O
and	O
rapidly	O
swept	O
across	O
the	O
country	O
,	O
causing	O
tremendous	O
economic	O
losses	O
to	O
producers	O
and	O
customers	O
.	O

Antibodies	O
were	O
only	O
detected	O
in	O
those	O
with	O
contact	O
,	O
suggesting	O
dromedary	O
exposure	O
as	O
a	O
risk	O
factor	O
for	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
causes	O
severe	O
disease	O
in	O
human	O
with	O
an	O
overall	O
case	O
-	O
fatality	O
rate	O
of	O
>	O
35	O
%.	O

Mycoplasma	B-DISO
cynos	O
(	O
29	O
.	O
2	O
%),	O
B	O
.	O
bronchiseptica	O
(	O
19	O
.	O
5	O
%),	O
CAV	O
-	O
2	O
(	O
12	O
.	O
5	O
%),	O
CDV	O
(	O
7	O
.	O
4	O
%)	O
and	O
CPIV	O
(	O
3	O
.	O
2	O
%)	O
were	O
the	O
most	O
commonly	O
detected	O
pathogens	O
.	O

In	O
-	O
hospital	O
mortality	O
is	O
38	O
.	O
5	O
%	O
for	O
AL	O
,	O
and	O
41	O
.	O
1	O
%	O
for	O
ARDS	B-DISO
.	O

The	O
objectives	O
of	O
the	O
present	O
study	O
were	O
to	O
assess	O
the	O
mucosal	O
,	O
cellular	O
,	O
and	O
humoral	O
immune	O
responses	O
induced	O
by	O
two	O
different	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
vaccination	O
regimes	O
and	O
their	O
efficacy	O
against	O
challenge	O
by	O
a	O
variant	O
IBV	O
Q1	O
.	O

Here	O
,	O
we	O
further	O
investigated	O
the	O
interplay	O
between	O
human	O
primary	O
T	O
cells	O
and	O
MERS	O
-	O
CoV	O
in	O
disease	O
pathogenesis	B-DISO
.	O

We	O
further	O
demonstrated	O
that	O
MERS	O
-	O
CoV	O
infection	B-DISO
induced	I-DISO
apoptosis	O
in	O
T	O
cells	O
,	O
which	O
involved	O
the	O
activation	O
of	O
both	O
the	O
extrinsic	O
and	O
intrinsic	O
apoptosis	O
pathways	O
.	O

TITLE	O
:	O
Structure	O
-	O
activity	O
relationship	O
studies	O
on	O
quinoxalin	O
-	O
2	O
(	O
1H	O
)-	O
one	O
derivatives	O
containing	O
thiazol	O
-	O
2	O
-	O
amine	O
against	O
hepatitis	B-DISO
C	I-DISO
virus	O
leading	O
to	O
the	O
discovery	O
of	O
BH6870	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
):	O
A	O
cluster	O
analysis	O
with	O
implications	O
for	O
global	O
management	O
of	O
suspected	O
cases	O
.	O

TITLE	O
:	O
Quantitative	O
Proteomics	O
Identifies	O
Serum	O
Response	O
Factor	O
Binding	O
Protein	O
1	O
as	O
a	O
Host	O
Factor	O
for	O
Hepatitis	B-DISO
C	I-DISO
Virus	O
Entry	O
.	O

TITLE	O
:	O
Changes	O
in	O
the	O
Swine	O
Gut	O
Microbiota	O
in	O
Response	O
to	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Infection	B-DISO
.	O

The	O
most	O
common	O
risk	O
factor	O
of	O
acute	O
lung	O
injury	O
is	O
severe	B-DISO
sepsis	I-DISO
.	O

Patients	O
with	O
sepsis	B-DISO
-	O
related	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
have	O
higher	O
mortality	O
.	O

Male	O
Wistar	O
rats	O
were	O
intravenously	O
infused	O
with	O
saline	O
or	O
lipopolysaccharide	O
(	O
LPS	B-DISO
,	O
10	O
mg	O
/	O
kg	O
).	O

The	O
lung	O
from	O
rats	O
with	O
endotoxic	B-DISO
shock	I-DISO
exhibited	O
significant	O
decreases	O
in	O
the	O
levels	O
of	O
Wnt3a	O
,	O
Fzd1	O
,	O
Dsh1	B-DISO
,	O
phosphorylated	O
GSK	O
-	O
3β	O
at	O
Ser9	O
,	O
and	O
β	O
-	O
catenin	O
.	O

ABSTRACT	O
:	O
Polyvalent	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
vaccination	O
is	O
common	O
worldwide	O
.	O

RESULTS	O
:	O
More	O
than	O
half	O
of	O
the	O
dental	O
students	O
(	O
54	O
%)	O
interviewed	O
had	O
good	O
knowledge	O
about	O
the	O
etiology	O
,	O
symptoms	O
,	O
and	O
treatment	O
of	O
MERS	O
-	O
CoV	O
.	O
Measurements	O
for	O
infection	B-DISO
control	O
and	O
protection	O
were	O
also	O
known	O
(	O
79	O
%).	O

TITLE	O
:	O
Phylogenetic	O
analysis	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
S1	O
glycoprotein	O
regions	O
reveals	O
emergence	O
of	O
a	O
new	O
genotype	O
in	O
Moroccan	O
broiler	O
chicken	O
flocks	O
.	O

ABSTRACT	O
:	O
Immunoadhesins	O
are	O
recombinant	O
proteins	O
that	O
combine	O
the	O
ligand	O
-	O
binding	O
region	O
of	O
a	O
receptor	O
or	O
adhesion	B-DISO
molecule	O
with	O
immunoglobulin	O
constant	O
domains	O
.	O

All	O
FDA	O
-	O
approved	O
immunoadhesins	O
are	O
designed	O
to	O
modulate	O
the	O
interaction	O
of	O
a	O
human	O
receptor	O
with	O
its	O
normal	O
ligand	O
,	O
such	O
as	O
Etanercept	O
(	O
Enbrel	O
(®)	O
),	O
which	O
interferes	O
with	O
the	O
binding	O
of	O
tumour	B-DISO
necrosis	I-DISO
factor	O
(	O
TNF	O
)	O
to	O
the	O
TNF	O
-	O
alpha	O
receptor	O
and	O
is	O
used	O
to	O
treat	O
inflammatory	O
diseases	O
such	O
as	O
rheumatoid	B-DISO
arthritis	I-DISO
.	O

An	O
immunoadhesin	O
based	O
on	O
the	O
receptor	O
for	O
human	O
rhinovirus	O
,	O
ICAM	O
-	O
1	O
,	O
potently	O
blocks	O
infection	B-DISO
of	O
human	O
cells	O
by	O
one	O
of	O
the	O
major	O
causes	O
of	O
the	O
common	B-DISO
cold	I-DISO
.	O

He	O
had	O
no	O
chills	B-DISO
,	O
cough	B-DISO
,	O
expectoration	O
,	O
short	B-DISO
of	I-DISO
breath	I-DISO
,	O
abdominal	B-DISO
pain	I-DISO
,	O
diarrhea	B-DISO
,	O
frequent	O
micturition	O
,	O
or	O
urgency	O
or	O
pain	O
of	O
urination	O
,	O
and	O
no	O
sore	B-DISO
throat	I-DISO
.	O

(	O
4	O
)	O
Patient	O
began	O
to	O
cough	B-DISO
at	O
admission	O
,	O
and	O
it	O
disappeared	O
on	O
the	O
18th	O
day	O
.	O

This	O
study	O
provides	O
evidence	O
that	O
CaKVs	O
circulate	O
in	O
diarrhoetic	O
dogs	O
in	O
China	O
and	O
that	O
they	O
exhibit	O
substantial	O
genetic	O
diversity	O
and	O
high	O
co	B-DISO
-	I-DISO
infection	I-DISO
rates	O
with	O
other	O
enteric	O
viruses	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
an	O
existential	O
threat	O
to	O
global	O
public	O
health	O
.	O

Adjunctive	O
corticosteroids	O
were	O
associated	O
with	O
possible	O
reductions	O
in	O
all	O
-	O
cause	O
mortality	O
(	O
12	O
trials	O
;	O
1974	O
patients	O
;	O
risk	O
ratio	O
[	O
RR	O
],	O
0	O
.	O
67	O
[	O
95	O
%	O
CI	O
,	O
0	O
.	O
45	O
to	O
1	O
.	O
01	O
];	O
risk	O
difference	O
[	O
RD	O
],	O
2	O
.	O
8	O
%;	O
moderate	O
certainty	O
),	O
need	O
for	O
mechanical	O
ventilation	O
(	O
5	O
trials	O
;	O
1060	O
patients	O
;	O
RR	O
,	O
0	O
.	O
45	O
[	O
CI	O
,	O
0	O
.	O
26	O
to	O
0	O
.	O
79	O
];	O
RD	O
,	O
5	O
.	O
0	O
%;	O
moderate	O
certainty	O
),	O
and	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
4	O
trials	O
;	O
945	O
patients	O
;	O
RR	O
,	O
0	O
.	O
24	O
[	O
CI	O
,	O
0	O
.	O
10	O
to	O
0	O
.	O
56	O
];	O
RD	O
,	O
6	O
.	O
2	O
%;	O
moderate	O
certainty	O
).	O

A	O
high	O
sensitivity	O
to	O
polymer	O
of	O
swine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
virus	O
was	O
noted	O
.	O

A	O
high	O
sensitivity	O
to	O
polymer	O
of	O
swine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
virus	O
was	O
noted	O
.	O

Continuous	O
electrocardiac	O
monitoring	O
of	O
pulse	O
,	O
respiratory	O
rate	O
,	O
blood	O
pressure	O
,	O
and	O
heart	O
rate	O
;	O
invasive	O
hemodynamic	O
monitoring	O
;	O
ventilator	O
-	O
assisted	O
breathing	O
and	O
circulation	O
support	O
;	O
and	O
anti	O
-	O
infection	B-DISO
as	O
well	O
as	O
UTI	B-DISO
treatment	O
were	O
given	O
in	O
the	O
UTI	B-DISO
group	O
with	O
GS	O
treatment	O
added	O
for	O
7	O
consecutive	O
days	O
in	O
the	O
GS	B-DISO
+	I-DISO
UTI	I-DISO
group	O
.	O

The	O
ALI	O
score	O
in	O
the	O
GS	B-DISO
+	I-DISO
UTI	I-DISO
group	O
was	O
significantly	O
decreased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
compared	O
with	O
that	O
of	O
the	O
UTI	B-DISO
group	O
,	O
and	O
the	O
indicators	O
of	O
pulmonary	O
capillary	O
permeability	O
such	O
as	O
pulmonary	O
vascular	O
permeability	O
index	O
,	O
extravascular	O
lung	O
water	O
index	O
,	O
and	O
oxygenation	O
index	O
,	O
in	O
the	O
GS	B-DISO
+	I-DISO
UTI	I-DISO
group	O
improved	O
significantly	O
more	O
than	O
that	O
of	O
the	O
UTI	B-DISO
group	O
.	O

TITLE	O
:	O
Prone	O
positioning	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
condition	B-DISO
with	O
a	O
high	O
morbidity	O
and	O
mortality	O
rate	O
,	O
and	O
treatment	O
is	O
often	O
long	O
and	O
costly	O
.	O

A	O
literature	O
search	O
was	O
undertaken	O
to	O
examine	O
the	O
effects	O
of	O
prone	O
positioning	O
on	O
oxygenation	O
,	O
morbidity	O
and	O
mortality	O
in	O
patients	O
with	O
ARDS	B-DISO
.	O

TITLE	O
:	O
A	O
Novel	O
Noonan	B-DISO
Syndrome	I-DISO
RAF1	O
Mutation	O
:	O
Lethal	O
Course	O
in	O
a	O
Preterm	O
Infant	O
.	O

Malarial	O
retinopathy	B-DISO
includes	O
retinal	O
whitening	O
,	O
vessel	O
changes	O
,	O
retinal	B-DISO
hemorrhages	I-DISO
and	O
papilledema	B-DISO
.	O

Hereby	O
,	O
we	O
report	O
a	O
case	O
of	O
30	O
-	O
year	O
-	O
old	O
man	O
,	O
who	O
presented	O
with	O
fever	B-DISO
with	I-DISO
chills	I-DISO
and	O
diminution	O
of	O
vision	O
.	O

After	O
many	O
relapses	O
,	O
rituximab	O
achieved	O
remission	B-DISO
in	O
3	O
/	O
4	O
SGS	B-DISO
patients	O
.	O

Endoscopic	O
treatments	O
(	O
dilation	B-DISO
,	O
laser	O
,	O
corticosteroid	O
injection	O
,	O
etc	O
.)	O
had	O
only	O
transient	O
efficacy	O
.	O

Despite	O
limited	O
evidence	O
and	O
relatively	O
few	O
randomized	O
trials	O
in	O
children	O
,	O
ECMO	O
remains	O
the	O
safety	O
net	O
for	O
patients	O
with	O
severe	O
respiratory	B-DISO
failure	I-DISO
.	O

BCoV	O
was	O
detected	O
in	O
78	O
.	O
8	O
%	O
of	O
fecal	O
samples	O
from	O
symptomatic	O
cattle	O
and	O
three	O
nasal	O
and	O
paired	O
fecal	O
samples	O
from	O
calves	O
with	O
respiratory	B-DISO
symptoms	I-DISO
.	O

In	O
particular	O
,	O
SARSr	O
-	O
Rs	O
-	O
BatCoVs	O
from	O
Chinese	O
horseshoe	O
bats	O
(	O
Rhinolophus	O
sinicus	O
)	O
exhibited	O
<	O
40	O
%	O
amino	O
acid	O
identities	O
to	O
human	O
/	O
civet	O
SARS	B-DISO
-	O
CoV	O
in	O
the	O
ORF8	O
protein	O
.	O

All	O
three	O
isolates	O
were	O
genetically	O
similar	O
to	O
NC99	O
(	O
98	O
.	O
2	O
-	O
98	O
.	O
7	O
%),	O
but	O
deletions	O
and	O
insertions	O
were	O
observed	O
in	O
the	O
genes	O
nsp3	O
of	O
ORF1a	O
,	O
NS2	B-DISO
and	O
p4	O
.	O
7	O
.	O

Recruits	O
in	O
four	O
successive	O
Royal	O
Thai	O
Army	O
basic	O
training	O
classes	O
living	O
in	O
military	O
barracks	O
were	O
monitored	O
for	O
the	O
symptoms	O
of	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
(	O
ILI	O
)	O
or	O
upper	O
respiratory	O
illness	O
(	O
URI	O
).	O

We	O
report	O
a	O
28	O
-	O
year	O
-	O
old	O
pregnant	O
woman	O
(	O
26	O
weeks	O
gestation	O
)	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
whom	O
ECMO	O
support	O
was	O
necessary	O
for	O
survival	O
,	O
and	O
she	O
was	O
transported	O
to	O
another	O
facility	O
1	O
,	O
155	O
km	O
away	O
with	O
the	O
aid	O
of	O
the	O
portable	O
ECMO	O
system	O
.	O

Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
improved	O
gradually	O
until	O
the	O
patient	O
was	O
discharged	O
from	O
the	O
hospital	O
with	O
excellent	O
maternal	O
and	O
fetal	O
outcome	O
.	O

ABSTRACT	O
:	O
A	O
large	O
cluster	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
linked	O
to	O
healthcare	O
setting	O
occurred	O
from	O
May	O
to	O
July	O
2015	O
in	O
the	O
Republic	O
of	O
Korea	O
.	O

Taken	O
together	O
,	O
we	O
show	O
that	O
isotope	O
-	O
edited	O
FTIR	O
is	O
a	O
powerful	O
tool	O
to	O
analyze	O
small	O
membrane	O
proteins	O
in	O
their	O
native	O
environment	O
,	O
enabling	O
us	O
to	O
relate	O
the	O
unusual	O
structure	O
of	O
the	O
SARS	B-DISO
E	O
protein	O
to	O
its	O
function	O
.	O

Tremendous	O
and	O
successful	O
efforts	O
have	O
been	O
conducted	O
to	O
discover	O
the	O
genome	O
structure	O
,	O
epidemiology	O
,	O
clinical	O
signs	O
,	O
pathogenesis	B-DISO
,	O
diagnosis	O
and	O
antiviral	O
therapy	O
.	O

ABSTRACT	O
:	O
The	O
rhinoviruses	O
and	O
coronaviruses	O
are	O
the	O
most	O
common	O
causative	O
agents	O
of	O
the	O
acute	B-DISO
upper	I-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
in	O
humans	O
.	O

Taken	O
together	O
,	O
our	O
data	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
PEDV	O
infection	B-DISO
of	O
its	O
target	O
cell	O
line	O
,	O
IECs	O
,	O
inhibited	O
dsRNA	O
-	O
mediated	O
IFN	O
-	O
β	O
production	O
by	O
blocking	B-DISO
the	O
activation	O
of	O
IPS	B-DISO
-	O
1	O
in	O
RIG	O
-	O
I	O
-	O
mediated	O
pathway	O
.	O

TITLE	O
:	O
In	O
Vivo	O
Effects	O
of	O
Mesenchymal	O
Stromal	O
Cells	O
in	O
Two	O
Patients	O
With	O
Severe	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
.	O

This	O
article	O
describes	O
the	O
cases	O
of	O
two	O
patients	O
with	O
severe	O
refractory	O
adult	B-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
who	O
failed	O
to	O
improve	O
after	O
both	O
standard	O
life	O
support	O
measures	O
,	O
including	O
mechanical	O
ventilation	O
,	O
and	O
additional	O
measures	O
,	O
including	O
extracorporeal	O
ventilation	O
(	O
i	O
.	O
e	O
.,	O
in	O
a	O
heart	O
-	O
lung	O
machine	O
).	O

Despite	O
the	O
importance	O
of	O
this	O
information	O
,	O
the	O
size	O
distribution	O
of	O
particles	O
bearing	O
viruses	O
emitted	O
by	O
infectious	B-DISO
animals	O
remains	O
unknown	O
.	O

RESULTS	O
:	O
Fifteen	O
ED	O
patients	O
with	O
moderate	O
to	O
severe	O
opioid	O
-	O
induced	O
ventilatory	B-DISO
depression	I-DISO
(	O
median	O
RR	O
,	O
6	O
breaths	O
/	O
min	O
)	O
who	O
were	O
managed	O
using	O
low	O
-	O
dose	O
naloxone	O
strategy	O
were	O
identified	O
.	O

Taiwan	O
would	O
face	B-DISO
a	O
serious	O
threat	O
of	O
public	O
health	O
problems	O
if	O
another	O
SARS	B-DISO
epidemic	O
overlapped	O
with	O
a	O
flu	B-DISO
outbreak	O
.	O

The	O
capacity	O
of	O
influenza	B-DISO
A	O
to	O
cross	O
species	O
barriers	O
presents	O
a	O
potential	O
threat	O
to	O
human	O
health	O
.	O

TITLE	O
:	O
Acute	B-DISO
Respiratory	I-DISO
Infections	I-DISO
in	O
Travelers	O
Returning	O
from	O
MERS	O
-	O
CoV	O
-	O
Affected	O
Areas	O
.	O

ABSTRACT	O
:	O
We	O
examined	O
which	O
respiratory	O
pathogens	O
were	O
identified	O
during	O
screening	O
for	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
in	O
177	O
symptomatic	O
travelers	O
returning	O
to	O
Ontario	O
,	O
Canada	O
,	O
from	O
regions	O
affected	O
by	O
the	O
virus	O
.	O

TITLE	O
:	O
Laboratory	O
Testing	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
,	O
California	O
,	O
USA	O
,	O
2013	O
-	O
2014	O
.	O

ABSTRACT	O
:	O
Since	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
first	O
emerged	O
,	O
the	O
California	O
Department	O
of	O
Public	O
Health	O
has	O
coordinated	O
efforts	O
to	O
identify	O
possible	O
cases	O
in	O
travelers	O
to	O
California	O
,	O
USA	O
,	O
from	O
affected	O
areas	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
infection	I-DISO
is	O
a	O
frequently	O
transmitted	B-DISO
illness	O
of	O
concern	O
to	O
doctors	O
and	O
patients	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
syndrome	B-DISO
of	O
acute	O
lung	O
injury	O
that	O
is	O
characterized	O
by	O
noncardiogenic	O
pulmonary	B-DISO
edema	I-DISO
and	O
severe	O
hypoxemia	O
second	O
to	O
a	O
pathogenic	O
impairment	B-DISO
of	O
gas	O
exchange	O
.	O

Despite	O
the	O
lack	O
of	O
robust	O
evidence	O
,	O
SPVs	O
are	O
commonly	O
employed	O
for	O
their	O
therapeutic	O
role	O
in	O
improving	O
oxygenation	O
in	O
patients	O
who	O
have	O
developed	O
refractory	O
hypoxemia	O
in	O
ARDS	B-DISO
.	O

The	O
most	O
beneficial	O
effects	O
of	O
iEPO	O
have	O
been	O
seen	O
in	O
adult	O
patients	O
with	O
secondary	O
ARDS	B-DISO
as	O
compared	O
with	O
primary	O
ARDS	B-DISO
,	O
most	O
likely	O
due	O
to	O
the	O
difference	O
in	O
etiology	O
of	O
the	O
two	O
disease	O
states	O
,	O
and	O
in	O
patients	O
suffering	B-DISO
from	O
baseline	O
right	O
ventricular	O
heart	B-DISO
failure	I-DISO
.	O

No	O
postprocedural	O
rebleeding	O
from	O
the	O
gastric	B-DISO
varices	I-DISO
was	O
observed	O
during	O
a	O
median	O
follow	O
-	O
up	O
time	O
of	O
39	O
.	O
5	O
months	O
after	O
procedures	O
with	O
ethanolamine	O
oleate	O
and	O
34	O
months	O
after	O
procedures	O
with	O
polidocanol	O
foam	O
.	O

No	O
postprocedural	O
rebleeding	O
from	O
the	O
gastric	B-DISO
varices	I-DISO
was	O
observed	O
during	O
a	O
median	O
follow	O
-	O
up	O
time	O
of	O
39	O
.	O
5	O
months	O
after	O
procedures	O
with	O
ethanolamine	O
oleate	O
and	O
34	O
months	O
after	O
procedures	O
with	O
polidocanol	O
foam	O
.	O

These	O
should	O
include	O
histological	O
changes	O
in	O
parenchymal	O
tissue	O
,	O
altered	O
integrity	O
of	O
the	O
alveolar	O
capillary	O
barrier	O
,	O
inflammation	B-DISO
,	O
and	O
abnormal	O
pulmonary	O
function	O
.	O

Murine	O
ARDS	B-DISO
models	O
typically	O
are	O
defined	O
by	O
such	O
features	O
as	O
pulmonary	B-DISO
edema	I-DISO
and	O
leukocyte	O
infiltration	B-DISO
in	O
cytological	O
preparations	O
of	O
bronchoalveolar	O
lavage	O
fluid	O
and	O
/	O
or	O
lung	O
sections	O
.	O

TITLE	O
:	O
Construction	O
of	O
an	O
oral	O
vaccine	O
for	O
transmissible	O
gastroenteritis	B-DISO
virus	O
based	O
on	O
the	O
TGEV	O
N	O
gene	O
expressed	O
in	O
an	O
attenuated	O
Salmonella	B-DISO
typhimurium	O
vector	O
.	O

ABSTRACT	O
:	O
This	O
research	O
aimed	O
to	O
develop	O
an	O
oral	O
vaccine	O
for	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
based	O
on	O
the	O
TGEV	O
N	O
gene	O
expressed	O
in	O
an	O
attenuated	O
Salmonella	B-DISO
typhimurium	O
vector	O
and	O
aimed	O
to	O
evaluate	O
the	O
vaccine	O
'	O
s	O
immune	O
response	O
in	O
piglets	O
.	O

Humoral	O
(	O
neutralization	O
titer	O
and	O
specific	O
IgG	O
),	O
cellular	O
(	O
interleukin	O
-	O
4	O
,	O
γ	O
-	O
interferon	O
,	O
and	O
peripheral	O
lymphocyte	O
proliferation	B-DISO
),	O
and	O
mucosal	O
(	O
sIgA	O
)	O
immune	O
responses	O
were	O
detected	O
and	O
evaluated	O
.	O

TITLE	O
:	O
Role	O
of	O
Extracorporeal	O
Membrane	O
Oxygenation	O
in	O
Aluminum	O
Phosphide	O
Poisoning	O
-	O
Induced	O
Reversible	O
Myocardial	B-DISO
Dysfunction	I-DISO
:	O
A	O
Novel	O
Therapeutic	O
Modality	O
.	O

ABSTRACT	O
:	O
Aluminum	O
phosphide	O
(	O
AlP	O
)	O
poisoning	O
carries	O
a	O
high	O
rate	O
of	O
mortality	O
despite	O
intensive	O
care	O
management	O
,	O
primarily	O
because	O
of	O
refractory	O
myocardial	B-DISO
depression	I-DISO
,	O
resistant	O
hypotension	O
,	O
and	O
severe	O
metabolic	B-DISO
acidosis	I-DISO
as	O
well	O
as	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Since	O
his	O
symptoms	O
went	O
on	O
and	O
got	O
worse	O
,	O
he	O
returned	O
to	O
Turkey	O
,	O
and	O
hospitalized	O
in	O
a	O
hospital	O
'	O
s	O
intensive	O
care	O
unit	O
in	O
Hatay	O
on	O
6th	O
of	O
October	O
with	O
the	O
symptoms	O
of	O
fever	O
,	O
malaise	B-DISO
,	O
sweating	O
,	O
cough	B-DISO
and	O
respiratory	B-DISO
distress	I-DISO
.	O

Currently	O
,	O
no	O
drug	O
has	O
been	O
clinically	O
approved	O
to	O
control	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

TITLE	O
:	O
Two	O
novel	O
neutralizing	O
antigenic	O
epitopes	O
of	O
the	O
s1	O
subunit	O
protein	O
of	O
a	O
QX	O
-	O
like	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
strain	O
Sczy3	O
as	O
revealed	O
using	O
a	O
phage	O
display	O
peptide	O
library	O
.	O

The	O
novel	O
mAbs	O
and	O
the	O
epitopes	O
identified	O
will	O
be	O
useful	O
for	O
developing	O
diagnostic	O
assays	O
for	O
IBV	O
infections	B-DISO
.	O

TITLE	O
:	O
Regional	O
anesthesia	B-DISO
for	O
the	O
trauma	O
patient	O
:	O
improving	O
patient	O
outcomes	O
.	O

The	O
use	O
of	O
regional	O
anesthesia	B-DISO
in	O
patients	O
at	O
risk	O
for	O
compartment	B-DISO
syndrome	I-DISO
is	O
controversial	O
;	O
although	O
the	O
data	O
is	O
sparse	O
,	O
there	O
is	O
no	O
evidence	O
that	O
peripheral	O
nerve	O
blocks	O
delay	O
the	O
diagnosis	O
,	O
and	O
these	O
techniques	O
may	O
in	O
fact	O
facilitate	O
the	O
recognition	O
of	O
pathologic	O
breakthrough	B-DISO
pain	I-DISO
.	O

This	O
study	O
explored	O
the	O
effects	O
of	O
PPV	O
on	O
the	O
respiratory	O
and	O
circulatory	O
mechanics	O
of	O
H7N9	O
-	O
infected	O
patients	O
with	O
severe	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Glomerulonephritis	B-DISO
in	O
a	O
ferret	O
with	O
feline	O
coronavirus	B-DISO
infection	I-DISO
.	O

The	O
results	O
showed	O
that	O
the	O
abundance	O
of	O
four	O
dominant	O
phyla	O
(	O
Fusobacteria	O
,	O
Actinobacteria	O
,	O
Verrucomicrobia	O
,	O
and	O
Proteobacteria	O
)	O
in	O
feces	O
was	O
affected	O
greatly	O
by	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
.	O

TITLE	O
:	O
Plasmodium	B-DISO
vivax	I-DISO
infection	I-DISO
causes	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
a	O
case	O
report	O
.	O

The	O
data	O
indicated	O
the	O
presence	O
of	O
mono	B-DISO
-	O
Pv	O
infection	B-DISO
in	O
the	O
patient	O
'	O
s	O
blood	O
,	O
and	O
Pf	O
infection	B-DISO
was	O
specifically	O
ruled	O
out	O
.	O

In	O
this	O
work	O
,	O
mutants	O
of	O
nsp15	O
from	O
Human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
were	O
made	O
based	O
on	O
structural	O
analysis	O
of	O
the	O
homologous	O
nsp15s	O
in	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
Mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
).	O

The	O
I26A	O
/	O
N52A	O
mutant	B-DISO
of	O
nsp15	O
was	O
overexpressed	O
,	O
purified	O
and	O
crystallized	O
,	O
and	O
this	O
mutant	B-DISO
led	O
to	O
a	O
trimeric	O
form	O
rather	O
than	O
hexamers	O
or	O
monomers	O
.	O

TITLE	O
:	O
Therapeutic	O
strategies	O
in	O
pneumonia	B-DISO
:	O
going	O
beyond	O
antibiotics	O
.	O

However	O
,	O
at	O
present	O
specific	O
preventive	O
or	O
curative	O
strategies	O
for	O
the	O
treatment	O
of	O
lung	O
failure	O
in	O
pneumonia	B-DISO
in	O
addition	O
to	O
antibiotics	O
are	O
still	O
missing	O
.	O

The	O
cytopathic	B-DISO
effect	I-DISO
and	O
MTS	B-DISO
assays	O
demonstrated	O
that	O
two	O
shRNAs	O
(	O
pSilencer4	O
.	O
1	O
-	O
M1	O
and	O
pSilencer4	O
.	O
1	O
-	O
N	O
)	O
were	O
capable	O
of	O
protecting	O
cells	O
against	O
PEDV	O
invasion	B-DISO
with	O
very	O
high	O
specificity	O
and	O
efficiency	O
.	O

E	O
protein	O
ion	O
channel	O
(	O
IC	O
)	O
activity	O
is	O
specifically	O
correlated	O
with	O
enhanced	O
pulmonary	O
damage	O
,	O
edema	B-DISO
accumulation	O
and	O
death	O
.	O

Moreover	O
,	O
the	O
distributions	O
of	O
secondary	O
cases	O
per	O
single	O
primary	O
case	O
varied	O
highly	O
across	O
individual	O
hospital	O
outbreaks	O
(	O
Kruskal	O
-	O
Wallis	O
test	O
;	O
P	O
<	O
0	O
.	O
0001	O
),	O
with	O
significantly	O
higher	O
transmission	O
heterogeneity	O
in	O
the	O
distribution	O
of	O
secondary	O
cases	O
for	O
MERS	O
than	O
SARS	B-DISO
.	O

Our	O
study	O
suggests	O
that	O
the	O
South	O
Korean	O
outbreak	O
followed	O
a	O
similar	O
progression	O
to	O
previously	O
described	O
hospital	O
clusters	O
involving	O
coronaviruses	O
,	O
with	O
early	O
super	O
-	O
spreading	O
events	O
generating	O
a	O
disproportionately	O
large	O
number	O
of	O
secondary	B-DISO
infections	I-DISO
,	O
and	O
the	O
transmission	O
potential	O
diminishing	O
greatly	O
in	O
subsequent	O
generations	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
induced	O
by	O
severe	B-DISO
sepsis	I-DISO
can	O
trigger	O
persistent	B-DISO
inflammation	I-DISO
and	O
fibrosis	B-DISO
.	O

TITLE	O
:	O
The	O
ns12	O
.	O
9	O
Accessory	O
Protein	O
of	O
Human	O
Coronavirus	O
OC43	O
Is	O
a	O
Viroporin	O
Involved	O
in	O
Virion	O
Morphogenesis	O
and	O
Pathogenesis	B-DISO
.	O

Here	O
,	O
we	O
engineered	O
a	O
recombinant	O
mutant	B-DISO
virus	O
lacking	O
the	O
ns12	O
.	O
9	O
protein	O
(	O
HCoV	O
-	O
OC43	O
-	O
Δns12	O
.	O
9	O
)	O
to	O
characterize	O
the	O
contributions	O
of	O
ns12	O
.	O
9	O
in	O
HCoV	O
-	O
OC43	O
replication	O
.	O

Therefore	O
,	O
our	O
findings	O
revealed	O
that	O
the	O
ns12	O
.	O
9	O
viroporin	O
facilitates	O
virion	O
morphogenesis	O
to	O
enhance	O
viral	O
production	O
,	O
and	O
these	O
results	O
provided	O
a	O
deeper	O
understanding	O
of	O
HCoV	O
-	O
OC43	O
pathogenesis	B-DISO
.	O

ABSTRACT	O
:	O
ABO	O
blood	O
types	O
are	O
determined	O
by	O
antigen	O
modifications	O
on	O
glycoproteins	O
and	O
glycolipids	O
and	O
associated	O
with	O
altered	O
plasma	O
levels	O
of	O
inflammatory	O
and	O
endothelial	O
injury	O
markers	O
implicated	O
in	O
AKI	O
pathogenesis	B-DISO
.	O

Blood	O
type	O
A	O
is	O
independently	O
associated	O
with	O
AKI	O
risk	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
trauma	O
or	O
severe	B-DISO
sepsis	I-DISO
of	O
European	O
descent	O
,	O
suggesting	O
a	O
role	O
for	O
ABO	O
glycans	O
in	O
AKI	O
susceptibility	O
.	O

TITLE	O
:	O
A	O
novel	O
diagnostic	O
approach	O
to	O
detecting	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
:	O
The	O
lateral	O
immunochromatography	O
assay	O
.	O

TITLE	O
:	O
Growth	O
and	O
Quantification	O
of	O
MERS	O
-	O
CoV	O
Infection	B-DISO
.	O

ABSTRACT	O
:	O
The	O
first	O
ever	O
case	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
was	O
reported	O
in	O
September	O
2012	O
.	O

CDC	O
'	O
s	O
response	O
to	O
MERS	O
-	O
CoV	O
required	O
a	O
large	O
effort	O
,	O
deploying	O
at	O
least	O
353	O
staff	O
members	O
who	O
worked	O
in	O
the	O
areas	O
of	O
surveillance	O
,	O
laboratory	O
capacity	O
,	O
infection	B-DISO
control	O
guidance	O
,	O
and	O
travelers	O
'	O
health	O
.	O

ABSTRACT	O
:	O
To	O
trace	O
evolution	O
of	O
canine	O
parvovirus	B-DISO
-	O
2	O
(	O
CPV	O
-	O
2	O
),	O
a	O
total	O
of	O
201	O
stool	O
samples	O
were	O
collected	O
from	O
dogs	O
with	O
diarrhea	B-DISO
in	O
Heilongjiang	O
province	O
of	O
northeast	O
China	O
from	O
May	O
2014	O
to	O
April	O
2015	O
.	O

TITLE	O
:	O
Infectious	B-DISO
Risks	O
of	O
Traveling	O
Abroad	O
.	O

Empiric	O
treatment	O
is	O
sometimes	O
necessary	O
when	O
suspicion	O
of	O
a	O
certain	O
diagnosis	O
is	O
strong	O
and	O
confirmatory	O
tests	O
are	O
delayed	O
or	O
lacking	O
,	O
particularly	O
for	O
infections	B-DISO
that	O
are	O
rapidly	O
progressive	O
(	O
for	O
example	O
,	O
malaria	B-DISO
)	O
or	O
for	O
which	O
timing	O
of	O
testing	O
is	O
prolonged	O
(	O
such	O
as	O
leptospirosis	B-DISO
).	O

ABSTRACT	O
:	O
In	O
2012	O
,	O
the	O
first	O
cases	O
of	O
infection	B-DISO
with	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
were	O
identified	O
.	O

Replication	O
-	O
competent	O
recombinant	O
measles	B-DISO
virus	O
(	O
MV	O
)	O
expressing	O
foreign	O
antigens	O
constitutes	O
a	O
promising	O
tool	O
to	O
induce	O
protective	O
immunity	O
against	O
corresponding	O
pathogens	O
.	O

Subsequent	O
challenge	O
experiments	O
indicated	O
protection	O
of	O
vaccinated	O
animals	O
,	O
illustrating	O
the	O
potential	O
of	O
MV	O
as	O
a	O
vaccine	O
platform	O
with	O
the	O
potential	O
to	O
target	O
emerging	O
infections	B-DISO
,	O
such	O
as	O
MERS	O
-	O
CoV	O
.	O

ABSTRACT	O
:	O
Pulmonary	O
contusion	O
is	O
a	O
major	O
risk	O
factor	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
trauma	O
patients	O
.	O

The	O
main	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
performance	O
of	O
the	O
Thoracic	B-DISO
Trauma	O
Severity	O
(	O
TTS	O
)	O
score	O
upon	O
admission	O
in	O
predicting	O
delayed	O
ARDS	B-DISO
in	O
blunt	O
trauma	O
patients	O
with	O
pulmonary	O
contusion	O
.	O

The	O
global	O
ability	O
of	O
the	O
TTS	O
score	O
to	O
predict	O
ARDS	B-DISO
was	O
studied	O
by	O
ROC	O
curves	O
with	O
a	O
threshold	O
analysis	O
using	O
a	O
grey	O
zone	O
approach	O
.	O

RESULTS	O
:	O
Of	O
329	O
patients	O
studied	O
(	O
75	O
%	O
men	O
,	O
mean	O
age	O
36	O
.	O
9	O
years	O
[	O
SD	O
17	O
.	O
8	O
years	O
],	O
mean	O
Injury	O
Severity	O
Score	O
21	O
.	O
7	O
[	O
SD	O
16	O
.	O
0	O
]),	O
82	O
(	O
25	O
%)	O
presented	O
with	O
ARDS	B-DISO
(	O
mean	O
lowest	O
PaO2	O
/	O
FiO2	O
ratio	O
of	O
131	O
[	O
SD	O
34	O
]).	O

Of	O
the	O
patients	O
with	O
ALI	O
/	O
ARDS	B-DISO
,	O
18	O
had	O
mild	O
hypoxaemia	O
,	O
20	O
had	O
moderate	O
hypoxaemia	O
and	O
21	O
had	O
severe	O
hypoxaemia	O
.	O

The	O
mean	O
±	O
SD	O
BNP	O
level	O
was	O
significantly	O
higher	O
in	O
all	O
three	O
ALI	O
/	O
ARDS	B-DISO
groups	O
(	O
92	O
.	O
41	O
±	O
28	O
.	O
19	O
pg	O
/	O
ml	O
,	O
170	O
.	O
64	O
±	O
57	O
.	O
34	O
pg	O
/	O
ml	O
and	O
239	O
.	O
06	O
±	O
59	O
.	O
62	O
pg	O
/	O
ml	O
,	O
respectively	O
,	O
in	O
the	O
mild	O
,	O
moderate	O
and	O
severe	O
groups	O
)	O
than	O
in	O
the	O
non	O
-	O
ALI	O
/	O
ARDS	B-DISO
group	O
(	O
47	O
.	O
27	O
±	O
19	O
.	O
63	O
pg	O
/	O
ml	O
);	O
the	O
increase	O
in	O
BNP	O
level	O
with	O
increasing	O
severity	O
was	O
also	O
statistically	O
significant	O
.	O

Kuwanon	O
-	O
L	O
also	O
inhibited	O
HIV	B-DISO
-	O
1	O
replication	O
in	O
cell	O
cultures	O
.	O

In	O
this	O
study	O
,	O
we	O
presented	O
for	O
the	O
first	O
application	O
of	O
proteomic	O
analysis	O
to	O
compare	O
whole	O
cellular	O
protein	O
alterations	O
induced	O
by	O
virulent	O
and	O
CV777	O
vaccine	O
strain	O
-	O
like	O
PEDV	O
infections	B-DISO
,	O
which	O
might	O
contribute	O
to	O
understand	O
the	O
pathogenesis	B-DISO
of	O
PEDV	O
and	O
anti	O
-	O
viral	O
strategy	O
development	O
.	O

Multivariate	O
analysis	O
demonstrated	O
an	O
association	O
between	O
the	O
NL	O
group	O
and	O
development	O
of	O
pulmonary	B-DISO
complications	I-DISO
(	O
adjusted	O
odds	O
ratio	O
[	O
aOR	O
],	O
2	O
.	O
1	O
;	O
confidence	O
interval	O
[	O
CI	O
],	O
1	O
.	O
15	O
-	O
3	O
.	O
78	O
).	O

Emergency	B-DISO
department	O
mechanical	O
ventilation	O
was	O
independently	O
associated	O
with	O
development	O
of	O
ARDS	B-DISO
(	O
aOR	O
,	O
3	O
.	O
5	O
;	O
1	O
.	O
8	O
-	O
7	O
.	O
0	O
).	O

In	O
the	O
a	O
priori	O
subgroup	O
of	O
patients	O
mechanically	O
ventilated	O
in	O
the	O
ED	O
(	O
n	O
=	O
97	O
),	O
those	O
who	O
developed	O
ARDS	B-DISO
received	O
higher	O
tidal	O
volumes	O
compared	O
to	O
patients	O
who	O
did	O
not	O
develop	O
ARDS	B-DISO
(	O
8	O
.	O
7	O
mL	O
/	O
kg	O
predicted	O
body	O
weight	O
[	O
interquartile	O
range	O
,	O
7	O
.	O
6	O
-	O
9	O
.	O
5	O
]	O
vs	O
7	O
.	O
6	O
[	O
interquartile	O
range	O
,	O
6	O
.	O
8	O
-	O
9	O
.	O
0	O
];	O
P	O
<.	O
01	O
).	O

ABSTRACT	O
:	O
Three	O
years	O
after	O
its	O
first	O
discovery	O
in	O
Jeddah	O
Saudi	O
Arabia	O
,	O
the	O
novel	O
zoonotic	O
pathogen	O
of	O
humans	O
,	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
continues	O
to	O
be	O
a	O
major	O
threat	O
to	O
global	O
health	O
security	O
.(	O
1	O
)	O

ABSTRACT	O
:	O
The	O
household	O
is	O
important	O
in	O
influenza	B-DISO
transmission	O
due	O
to	O
intensity	O
of	O
contact	O
.	O

ABSTRACT	O
:	O
Viral	O
fulminant	B-DISO
hepatitis	I-DISO
(	O
FH	O
)	O
is	O
a	O
severe	O
disease	O
with	O
high	O
mortality	O
resulting	O
from	O
excessive	O
inflammation	B-DISO
in	O
the	O
infected	O
liver	O
.	O

Whereas	O
,	O
the	O
viral	B-DISO
infection	I-DISO
in	O
IL	O
-	O
1β	O
receptor	O
-	O
I	O
deficient	O
(	O
IL	O
-	O
1R1	O
-/-)	O
or	O
IL	O
-	O
1R	O
antagonist	O
(	O
IL	O
-	O
1Ra	O
)	O
treated	O
mice	O
,	O
show	O
reductions	O
in	O
virus	O
replication	O
,	O
disease	O
progress	O
and	O
mortality	O
.	O

Although	O
shifts	O
were	O
not	O
always	O
consistently	O
of	O
the	O
same	O
type	O
,	O
when	O
influenza	B-DISO
type	O
A	O
hit	O
early	O
,	O
RSV	O
outbreaks	O
tended	O
to	O
be	O
delayed	O
,	O
coronavirus	O
outbreaks	O
tended	O
to	O
be	O
intensified	O
,	O
and	O
influenza	B-DISO
virus	O
type	O
B	O
tended	O
not	O
to	O
occur	O
at	O
all	O
.	O

However	O
,	O
infectious	B-DISO
diseases	I-DISO
still	O
remain	O
a	O
major	O
population	O
health	O
issue	O
and	O
this	O
may	O
be	O
exacerbated	O
by	O
rapid	O
urbanization	O
and	O
unprecedented	O
impacts	O
of	O
climate	O
change	O
.	O

TITLE	O
:	O
Evolutionary	O
characterization	O
of	O
the	O
emerging	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
worldwide	O
and	O
2014	O
epidemic	O
in	O
Taiwan	O
.	O

Finally	O
,	O
we	O
also	O
show	O
that	O
SARS	B-DISO
-	O
CoV	O
ORF7a	O
blocks	O
the	O
restriction	O
activity	O
of	O
BST	O
-	O
2	O
by	O
blocking	B-DISO
the	O
glycosylation	O
of	O
BST	O
-	O
2	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
six	O
early	O
onset	O
moderate	O
or	O
severe	O
ARDS	B-DISO
patients	O
were	O
included	O
.	O

ABSTRACT	O
:	O
Apoptosis	O
has	O
been	O
postulated	O
to	O
play	O
an	O
important	O
role	O
during	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
)	O
infection	B-DISO
;	O
however	O
,	O
its	O
mechanism	O
is	O
not	O
well	O
characterized	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
Novel	O
Small	O
Molecule	O
Inhibitor	O
Against	O
SARS	B-DISO
Coronavirus	O
Helicase	O
.	O

Moreover	O
,	O
we	O
observed	O
that	O
the	O
compound	O
did	O
not	O
show	O
cytotoxicity	B-DISO
up	O
to	O
80	O
µMconcentration	O
.	O

TITLE	O
:	O
[	O
Treatment	O
in	O
adult	O
patients	O
with	O
acute	B-DISO
myeloid	I-DISO
leukemias	I-DISO
and	O
hyperleukocytosis	O
at	O
disease	O
onset	O
].	O

TITLE	O
:	O
Critical	O
role	O
of	O
phospholipase	O
A2	O
group	O
IID	O
in	O
age	O
-	O
related	O
susceptibility	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
CoV	O
infection	B-DISO
.	O

To	O
maintain	O
lung	O
homeostasis	O
,	O
chronic	B-DISO
inflammation	I-DISO
is	O
countered	O
by	O
enhanced	O
expression	O
of	O
proresolving	O
/	O
antiinflammatory	O
factors	O
.	O

These	O
samples	O
were	O
tested	O
by	O
reverse	O
transcription	O
loop	O
-	O
mediated	O
isothermal	O
amplification	B-DISO
and	O
a	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
.	O

In	O
2013	O
,	O
imported	O
human	O
H7N9	O
influenza	B-DISO
infected	O
cases	O
from	O
China	O
were	O
reported	O
.	O

63	O
%	O
of	O
time	O
spent	O
by	O
epidemiologists	O
on	O
surveillance	O
was	O
spent	O
on	O
pathogens	O
in	O
the	O
highest	O
priority	O
group	O
and	O
all	O
pathogens	O
in	O
the	O
highest	O
priority	O
group	O
,	O
except	O
for	O
Borrelia	B-DISO
and	O
varicella	B-DISO
-	O
zoster	B-DISO
virus	O
,	O
were	O
under	O
surveillance	O
through	O
notifications	O
.	O

Stochastic	O
simulations	O
of	O
dynamics	O
on	O
networks	O
are	O
performed	O
and	O
compared	O
to	O
output	O
of	O
pairwise	O
models	O
for	O
several	O
realistic	O
examples	O
of	O
infectious	B-DISO
diseases	I-DISO
to	O
illustrate	O
the	O
role	O
played	O
by	O
the	O
number	O
of	O
stages	O
in	O
the	O
disease	O
dynamics	O
.	O

New	O
ventilatory	O
approaches	O
are	O
needed	O
to	O
safely	O
treat	O
patients	O
with	O
ARDS	B-DISO
,	O
and	O
recent	O
studies	O
have	O
suggested	O
the	O
potential	O
utility	O
of	O
open	O
-	O
lung	O
strategies	O
.	O

ABSTRACT	O
:	O
Respiratory	B-DISO
tract	I-DISO
infections	I-DISO
(	O
RTIs	O
)	O
are	O
a	O
heavy	O
burden	O
on	O
society	O
.	O

ABSTRACT	O
:	O
The	O
infectious	B-DISO
dose	O
of	O
a	O
virus	O
pool	O
of	O
original	O
US	O
PEDV	O
strain	O
PC22A	O
was	O
determined	O
in	O
4	O
-	O
day	O
-	O
old	O
,	O
cesarean	O
-	O
derived	O
,	O
colostrum	O
-	O
deprived	O
(	O
CDCD	O
)	O
piglets	O
.	O

ABSTRACT	O
:	O
Veno	O
-	O
arterial	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
VA	O
-	O
ECMO	O
(	O
1	O
))	O
systems	O
are	O
a	O
life	O
-	O
saving	O
option	O
in	O
the	O
treatment	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
(	O
2	O
)),	O
but	O
may	O
be	O
encumbered	O
by	O
severe	O
vascular	O
complications	O
in	O
the	O
groin	O
.	O

Major	O
complications	O
of	O
using	O
VA	O
-	O
ECMO	O
devices	O
are	O
related	O
to	O
vascular	O
access	O
,	O
most	O
common	O
bleeding	B-DISO
at	O
the	O
puncture	O
site	O
and	O
acute	O
limb	O
ischemia	B-DISO
.	O

Exposure	O
factors	O
and	O
comorbid	O
conditions	O
were	O
analyzed	O
using	O
Epi	B-DISO
Info	O
.	O

Cough	B-DISO
,	O
fever	O
,	O
radiological	O
evidence	O
of	O
pneumonia	B-DISO
,	O
and	O
shortness	B-DISO
of	I-DISO
breath	I-DISO
were	O
identified	O
as	O
significant	O
risk	O
factors	O
for	O
a	O
diagnosis	O
of	O
MER	O
-	O
CoV	O
infection	B-DISO
.	O

Economic	O
losses	O
associated	O
with	O
NDV	O
and	O
IBV	O
infections	B-DISO
still	O
need	O
to	O
be	O
evaluated	O
.	O

ABSTRACT	O
:	O
The	O
outbreaks	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	B-DISO
)	O
previously	O
in	O
Middle	O
East	O
and	O
recently	O
in	O
South	O
Korea	O
have	O
raised	O
serious	O
concerns	O
worldwide	O
,	O
reinforcing	O
the	O
importance	O
of	O
developing	O
effective	O
and	O
safe	O
vaccines	O
against	O
MERS	B-DISO
-	O
coronavirus	O
(	O
MERS	B-DISO
-	O
CoV	O
).	O

ABSTRACT	O
:	O
Since	O
the	O
first	O
case	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
was	O
reported	O
in	O
2012	O
,	O
the	O
virus	O
has	O
infected	O
more	O
than	O
1300	O
individuals	O
in	O
26	O
countries	O
,	O
and	O
caused	O
more	O
than	O
480	O
deaths	O
.	O

Improved	O
global	O
awareness	O
,	O
together	O
with	O
improved	O
hygiene	O
practices	O
in	O
healthcare	O
facilities	O
,	O
has	O
been	O
highlighted	O
as	O
key	O
strategies	O
in	O
controlling	O
the	O
spread	O
of	O
MERS	O
-	O
CoV	O
.	O
This	O
study	O
tested	O
the	O
in	O
vitro	O
efficacy	O
of	O
three	O
formulations	O
of	O
povidone	O
iodine	O
(	O
PVP	O
-	O
I	O
:	O
4	O
%	O
PVP	O
-	O
I	O
skin	O
cleanser	O
,	O
7	O
.	O
5	O
%	O
PVP	O
-	O
I	O
surgical	O
scrub	O
,	O
and	O
1	O
%	O
PVP	O
-	O
I	O
gargle	O
/	O
mouthwash	O
)	O
against	O
a	O
reference	O
virus	O
(	O
Modified	O
vaccinia	B-DISO
virus	O
Ankara	O
,	O
MVA	O
)	O
and	O
MERS	O
-	O
CoV	O
.	O
According	O
to	O
EN14476	O
,	O
a	O
standard	O
suspension	O
test	O
was	O
used	O
to	O
assess	O
virucidal	O
activity	O
against	O
MVA	O
and	O
large	O
volume	O
plating	O
was	O
used	O
for	O
MERS	O
-	O
CoV	O
.	O
All	O
products	O
were	O
tested	O
under	O
clean	O
(	O
0	O
.	O
3	O
g	O
/	O
L	O
bovine	O
serum	O
albumin	O
,	O
BSA	O
)	O
and	O
dirty	O
conditions	O
(	O
3	O
.	O
0	O
g	O
/	O
L	O
BSA	O
+	O
3	O
.	O
0	O
mL	O
/	O
L	O
erythrocytes	O
),	O
with	O
application	O
times	O
of	O
15	O
,	O
30	O
,	O
and	O
60	O
s	O
for	O
MVA	O
,	O
and	O
15	O
s	O
for	O
MERS	O
-	O
CoV	O
.	O
The	O
products	O
were	O
tested	O
undiluted	O
,	O
1	O
:	O
10	O
and	O
1	O
:	O
100	O
diluted	O
against	O
MVA	O
,	O
and	O
undiluted	O
against	O
MERS	O
-	O
CoV	O
.	O
A	O
reduction	O
in	O
virus	O
titer	O
of	O
≥	O
4	O
log10	O
(	O
corresponding	O
to	O
an	O
inactivation	B-DISO
of	O
≥	O
99	O
.	O
99	O
%)	O
was	O
regarded	O
as	O
evidence	O
of	O
virucidal	O
activity	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
indicate	O
that	O
PVP	O
-	O
I	O
-	O
based	O
hand	O
wash	O
products	O
for	O
potentially	O
contaminated	O
skin	O
,	O
and	O
PVP	O
-	O
I	O
gargle	O
/	O
mouthwash	O
for	O
reduction	O
of	O
viral	O
load	O
in	O
the	O
oral	O
cavity	B-DISO
and	O
the	O
oropharynx	O
,	O
may	O
help	O
to	O
support	O
hygiene	O
measures	O
to	O
prevent	O
transmission	O
of	O
MERS	O
-	O
CoV	O
.	O

ABSTRACT	O
:	O
The	O
ongoing	O
moratorium	O
on	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
research	O
with	O
highly	O
pathogenic	O
avian	B-DISO
influenza	I-DISO
virus	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
,	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
has	O
drawn	O
attention	O
to	O
the	O
current	O
debate	O
on	O
these	O
research	O
practices	O
and	O
the	O
potential	O
benefits	O
and	O
risks	O
they	O
present	O
.	O

TITLE	O
:	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
:	O
clinical	O
profile	O
and	O
management	O
.	O

ABSTRACT	O
:	O
Since	O
its	O
emergence	O
in	O
2012	O
,	O
more	O
than	O
900	O
laboratory	O
-	O
confirmed	O
cases	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
have	O
been	O
reported	O
with	O
a	O
fatality	O
rate	O
of	O
more	O
than	O
30	O
%.	O

ABSTRACT	O
:	O
Infection	B-DISO
with	O
the	O
murine	O
coronavirus	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
activates	O
the	O
pattern	O
recognition	O
receptors	O
melanoma	B-DISO
differentiation	O
-	O
associated	O
gene	O
5	O
(	O
MDA5	O
)	O
and	O
Toll	O
-	O
like	O
receptor	O
7	O
(	O
TLR7	O
)	O
to	O
induce	O
transcription	O
of	O
type	O
I	O
interferon	O
.	O

Viral	O
replication	O
in	O
the	O
liver	O
was	O
similar	O
in	O
mice	O
with	O
and	O
without	O
MDA5	O
,	O
but	O
liver	B-DISO
damage	I-DISO
was	O
increased	O
in	O
MDA5	O
(-/-)	O
mice	O
,	O
suggesting	O
that	O
the	O
immune	O
response	O
is	O
causing	O
the	O
damage	O
.	O

Production	O
of	O
several	O
proinflammatory	O
cytokines	O
was	O
elevated	O
in	O
MDA5	O
(-/-)	O
mice	O
,	O
suggesting	O
that	O
MDA5	O
may	O
be	O
responsible	O
for	O
keeping	O
pathological	O
inflammatory	B-DISO
responses	I-DISO
in	O
check	O
.	O

STAT1	O
,	O
NS2	B-DISO
,	O
CD5	O
,	O
NCKX6	O
and	O
PDGFB	O
were	O
significant	O
DEPs	O
in	O
these	O
GO	O
terms	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
4	O
protein	O
groups	O
between	O
the	O
normal	O
cells	O
and	O
the	O
Calu	O
-	O
3	O
cells	O
infected	O
by	O
IAV	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
or	O
swine	B-DISO
influenza	I-DISO
were	O
identified	O
.	O

STAT1	O
,	O
NS2	B-DISO
,	O
CD5	O
,	O
NCKX6	O
and	O
PDGFB	O
were	O
significant	O
DEPs	O
in	O
these	O
GO	O
terms	O
.	O

In	O
addition	O
,	O
the	O
extracorporeal	O
removal	O
of	O
CO2	O
has	O
been	O
used	O
in	O
patients	O
with	O
exacerbated	O
hypercapnic	B-DISO
respiratory	I-DISO
failure	I-DISO
with	O
promising	O
results	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
)	O
is	O
an	O
enteric	O
coronaviral	O
infection	B-DISO
that	O
causes	O
severe	O
morbidity	O
and	O
mortality	O
in	O
suckling	O
pigs	O
,	O
but	O
less	O
severe	O
disease	O
in	O
older	O
pigs	O
.	O

The	O
PEDV	O
infected	O
suckling	O
pigs	O
showed	O
severe	O
diarrhea	B-DISO
and	I-DISO
vomiting	I-DISO
at	O
PID	B-DISO
1	O
,	O
whereas	O
the	O
PEDV	O
infected	O
weaned	O
pigs	O
showed	O
milder	O
clinical	O
signs	O
starting	O
at	O
PID	B-DISO
3	O
.	O

In	O
conclusion	O
,	O
the	O
observations	O
of	O
impaired	B-DISO
lytic	B-DISO
activity	O
and	O
IFN	O
-	O
γ	O
production	O
by	O
NK	O
cells	O
in	O
suckling	O
pigs	O
coincided	O
with	O
the	O
increased	O
severity	O
of	O
PEDV	O
infection	B-DISO
in	O
the	O
suckling	O
pigs	O
compared	O
with	O
the	O
weaned	O
pigs	O
.	O

Intracerebral	O
infection	B-DISO
with	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
JHMV	O
)	O
resulted	O
in	O
an	O
acute	O
encephalomyelitis	B-DISO
,	O
followed	O
by	O
demyelination	B-DISO
similar	O
in	O
pathology	B-DISO
to	O
the	O
human	O
demyelinating	B-DISO
disease	I-DISO
,	O
multiple	B-DISO
sclerosis	I-DISO
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
(	O
IB	O
)	O
is	O
a	O
common	O
,	O
highly	O
contagious	O
,	O
acute	O
,	O
and	O
economically	O
important	O
viral	B-DISO
disease	I-DISO
of	O
chickens	O
caused	O
by	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
,	O
sp	O
.	O
Avian	O
coronavirus	O
).	O

ABSTRACT	O
:	O
In	O
2012	O
,	O
a	O
nephrologist	O
reported	O
the	O
development	O
of	O
a	O
multiorgan	O
thrombotic	O
syndromic	O
complex	O
resembling	O
thrombotic	B-DISO
thrombocytopenic	I-DISO
purpura	I-DISO
(	O
TTP	B-DISO
)	O
in	O
patients	O
who	O
were	O
abusing	O
long	O
acting	O
oxymorphone	O
hydrochloride	O
;	O
all	O
patients	O
had	O
hemolytic	B-DISO
anemia	I-DISO
and	O
thrombocytopenia	O
.	O

The	O
patient	O
'	O
s	O
pre	O
and	O
post	O
eculizumab	O
skin	O
biopsies	O
showed	O
a	O
striking	O
pauci	O
-	O
inflammatory	O
thrombogenic	O
vasculopathy	O
associated	O
with	O
marked	O
endothelial	O
cell	B-DISO
injury	I-DISO
along	O
with	O
deposits	O
of	O
C3d	B-DISO
and	O
C4d	O
within	O
the	O
cutaneous	O
vasculature	O
;	O
the	O
C5b	O
-	O
9	O
deposits	O
were	O
limited	O
to	O
the	O
pre	O
-	O
eculizumab	O
biopsy	O
.	O

We	O
studied	O
patients	O
admitted	O
between	O
2005	O
and	O
2012	O
with	O
ALI	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
according	O
to	O
the	O
American	O
European	O
Consensus	O
Conference	O
(	O
AECC	O
)	O
criteria	O
and	O
recorded	O
clinical	O
variables	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
was	O
identified	O
in	O
the	O
United	O
States	O
(	O
U	O
.	O
S	O
.)	O
swine	O
population	O
for	O
the	O
first	O
time	O
in	O
April	O
2013	O
and	O
rapidly	O
spread	O
nationwide	O
.	O

We	O
then	O
computed	O
a	O
pooled	O
odds	O
ratio	O
and	O
virus	O
-	O
specific	O
attributable	O
fraction	O
among	O
the	O
exposed	O
of	O
8	O
common	O
viruses	O
-	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
influenza	B-DISO
(	O
IFV	O
),	O
parainfluenza	B-DISO
(	O
PIV	O
),	O
human	O
metapneumovirus	O
(	O
MPV	O
),	O
adenovirus	B-DISO
(	O
AdV	O
),	O
rhinovirus	O
(	O
RV	O
),	O
bocavirus	O
(	O
BoV	O
),	O
and	O
coronavirus	O
(	O
CoV	O
).	O

Persistent	O
inflammatory	O
infiltrates	B-DISO
were	O
seen	O
in	O
the	O
lungs	O
and	O
brain	O
stems	O
at	O
day	O
2	O
and	O
day	O
6	O
after	O
infection	B-DISO
,	O
respectively	O
.	O

We	O
experienced	O
a	O
patient	O
with	O
acute	B-DISO
cor	I-DISO
pulmonale	I-DISO
during	O
high	O
positive	O
-	O
pressure	O
ventilation	O
for	O
the	O
treatment	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Timing	O
of	O
termination	O
of	O
prone	O
positioning	O
and	O
ventilator	O
settings	O
such	O
as	O
lowering	O
positive	O
end	O
-	O
expiration	O
pressure	O
was	O
determined	O
to	O
maintain	O
dorsal	O
recruitment	B-DISO
as	O
seen	O
by	O
EIT	O
.	O

TITLE	O
:	O
Analysis	O
of	O
synonymous	O
codon	O
usage	O
in	O
spike	O
protein	O
gene	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

Using	O
genetically	O
diverse	O
animals	O
from	O
incipient	O
lines	O
of	O
the	O
Collaborative	O
Cross	O
mouse	O
panel	O
,	O
we	O
demonstrate	O
a	O
greatly	O
expanded	O
range	O
of	O
phenotypes	O
relative	O
to	O
classical	O
mouse	O
models	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
including	O
lung	O
pathology	B-DISO
,	O
weight	O
loss	O
and	O
viral	O
titer	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
):	O
what	O
lessons	O
can	O
we	O
learn	O
?	O

A	O
significant	O
proportion	O
of	O
patients	O
present	O
with	O
non	O
-	O
respiratory	B-DISO
symptoms	I-DISO
such	O
as	O
headache	B-DISO
,	O
myalgia	B-DISO
,	O
vomiting	B-DISO
and	O
diarrhoea	B-DISO
.	O

The	O
largest	O
outbreaks	O
have	O
been	O
driven	O
by	O
delayed	O
diagnosis	O
,	O
overcrowding	O
and	O
poor	O
infection	B-DISO
control	O
practices	O
.	O

TITLE	O
:	O
Risk	O
factor	O
analysis	O
and	O
molecular	O
epidemiology	O
of	O
respiratory	O
adenovirus	B-DISO
infections	I-DISO
among	O
children	O
in	O
northern	O
Taiwan	O
,	O
2009	O
-	O
2013	O
.	O

Patients	O
with	O
underlying	O
neurologic	B-DISO
diseases	I-DISO
(	O
OR	O
76	O
.	O
8	O
;	O
p	O
<	O
0	O
.	O
001	O
),	O
airway	O
anomaly	O
(	O
OR	O
15	O
.	O
1	O
;	O
p	O
=	O
0	O
.	O
033	O
),	O
chronic	O
lung	B-DISO
diseases	I-DISO
(	O
OR	O
12	O
.	O
5	O
;	O
p	O
=	O
0	O
.	O
047	O
),	O
weight	O
<	O
3	O
HAdV	O
infections	B-DISO
circulate	O
all	O
year	O
-	O
round	O
.	O

Underlying	O
neurologic	B-DISO
diseases	I-DISO
and	O
prematurity	O
are	O
risk	O
factors	O
for	O
severe	O
HAdV	O
infections	B-DISO
.	O

The	O
relationship	O
between	O
CCoV	O
infection	B-DISO
and	O
the	O
manifestation	O
of	O
diarrhea	B-DISO
symptoms	I-DISO
was	O
investigated	O
,	O
and	O
a	O
correlation	O
was	O
noted	O
(	O
df	O
=	O
1	O
,	O
χ	O
(	O
2	O
)=	O
8	O
.	O
90	O
,	O
P	O
<	O
0	O
.	O
005	O
).	O

We	O
searched	O
the	O
Scopus	O
database	O
for	O
all	O
literature	O
on	O
economic	O
evaluation	O
of	O
mask	O
or	O
respirator	O
use	O
to	O
control	O
respiratory	O
infection	B-DISO
transmission	I-DISO
.	O

RESULTS	O
:	O
Five	O
studies	O
considered	O
interventions	O
for	O
seasonal	O
and	O
/	O
or	O
pandemic	O
influenza	B-DISO
,	O
with	O
one	O
also	O
considering	O
SARS	B-DISO
(	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
).	O

IBV	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
were	O
generated	O
through	O
the	O
co	B-DISO
-	I-DISO
infection	I-DISO
with	O
three	O
recombinant	O
baculoviruses	O
separately	O
encoding	O
M	O
,	O
E	O
or	O
the	O
recombinant	O
S	O
genes	O
.	O

Of	O
the	O
2	O
studies	O
that	O
reported	O
hemodynamic	B-DISO
instability	I-DISO
during	O
the	O
prone	O
positioning	O
maneuvers	O
,	O
very	O
few	O
adverse	O
hemodynamic	O
episodes	O
were	O
reported	O
.	O

The	O
authors	O
who	O
reported	O
adverse	B-DISO
effects	I-DISO
stated	O
that	O
the	O
episodes	O
were	O
quickly	O
and	O
successfully	O
reversible	O
.	O

RESULTS	O
:	O
Seven	O
studies	O
fit	B-DISO
the	O
study	O
inclusion	O
criteria	O
(	O
1	O
prospective	O
cohort	O
study	O
,	O
3	O
retrospective	O
cohort	O
studies	O
,	O
and	O
3	O
case	O
series	O
).	O

ABSTRACT	O
:	O
It	O
is	O
often	O
difficult	O
for	O
a	O
physician	O
to	O
distinguish	O
between	O
viral	O
and	O
bacterial	O
causes	O
of	O
respiratory	B-DISO
infections	I-DISO
and	O
this	O
may	O
result	O
in	O
overuse	O
of	O
antibiotics	O
.	O

This	O
might	O
explain	O
why	O
the	O
Saudi	O
Ministry	O
of	O
Health	O
is	O
using	O
social	O
media	O
platforms	O
alongside	O
various	O
other	O
media	O
platforms	O
in	O
a	O
large	O
-	O
scale	O
public	O
awareness	O
campaign	O
to	O
educate	O
at	O
-	O
risk	O
communities	O
about	O
the	O
recently	O
emerged	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

Thorough	O
reprocessing	O
of	O
endoscopes	O
using	O
high	O
-	O
level	O
disinfection	O
and	O
sterilization	O
methods	O
may	O
be	O
essential	O
for	O
reducing	O
the	O
risk	O
of	O
infection	B-DISO
.	O

The	O
combined	O
infection	B-DISO
of	O
TAstV	O
and	O
TCoV	O
did	O
not	O
induce	O
more	O
severe	O
clinical	O
signs	O
and	O
pathology	B-DISO
than	O
the	O
TCoV	O
infection	B-DISO
alone	O
.	O

ABSTRACT	O
:	O
Objectives	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
whether	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
RNA	O
in	O
effusion	B-DISO
samples	O
can	O
be	O
used	O
as	O
a	O
diagnostic	O
marker	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
);	O
and	O
in	O
FCoV	O
RNA	O
-	O
positive	O
samples	O
to	O
examine	O
amino	O
acid	O
codons	O
in	O
the	O
FCoV	O
spike	O
protein	O
at	O
positions	O
1058	O
and	O
1060	O
where	O
leucine	O
and	O
alanine	O
,	O
respectively	O
,	O
have	O
been	O
associated	O
with	O
systemic	O
or	O
virulent	O
(	O
FIP	B-DISO
)	O
FCoV	O
infection	B-DISO
.	O

At	O
5	O
days	O
following	O
challenge	O
with	O
IBV	O
,	O
we	O
found	O
a	O
good	O
correlation	O
among	O
clinical	O
signs	O
,	O
ciliostasis	O
in	O
the	O
trachea	B-DISO
,	O
challenge	O
virus	O
detection	O
,	O
and	O
microscopic	O
lesions	O
in	O
the	O
trachea	B-DISO
,	O
with	O
all	O
four	O
criteria	O
being	O
negative	O
in	O
fully	O
protected	O
birds	O
and	O
positive	O
in	O
fully	O
susceptible	O
birds	O
.	O

In	O
patients	O
with	O
refractory	O
ARDS	B-DISO
immediately	O
before	O
ECMO	O
implantation	O
,	O
the	O
prevalence	O
of	O
acute	B-DISO
cor	I-DISO
pulmonale	I-DISO
is	O
low	O
(	O
9	O
.	O
5	O
%).	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	B-DISO
)	O
is	O
an	O
acute	B-DISO
infectious	I-DISO
disease	I-DISO
of	O
the	O
respiratory	O
system	O
caused	O
by	O
the	O
new	O
betacoronavirus	O
(	O
MERS	B-DISO
coronavirus	O
,	O
MERS	B-DISO
-	O
CoV	O
),	O
which	O
shows	O
high	O
mortality	O
rates	O
.	O

TITLE	O
:	O
Pulmonary	B-DISO
agenesis	I-DISO
and	O
respiratory	B-DISO
failure	I-DISO
in	O
childhood	O
.	O

Although	O
respiratory	B-DISO
symptoms	I-DISO
represent	O
frequent	O
complaints	O
in	O
pediatrics	O
,	O
the	O
aim	O
of	O
this	O
study	O
is	O
not	O
only	O
to	O
draw	O
attention	O
to	O
the	O
unilateral	O
pulmonary	B-DISO
agenesis	I-DISO
as	O
a	O
possible	O
underlying	O
malformation	B-DISO
in	O
children	O
who	O
present	O
recurrent	O
and	O
severe	O
respiratory	B-DISO
symptoms	I-DISO
,	O
but	O
also	O
to	O
report	O
a	O
case	O
diagnosed	O
at	O
autopsy	O
.	O

TITLE	O
:	O
Genetic	O
polymorphisms	O
of	O
IL28b	O
gene	O
as	O
predictors	O
of	O
response	O
to	O
dual	O
therapy	O
in	O
genotypes	O
1	O
and	O
4	O
-	O
HCV	O
and	O
HIV	B-DISO
/	O
HCV	O
-	O
infected	O
patients	O
.	O

IL28B	O
SNPs	O
,	O
HCV	O
mono	B-DISO
-	O
infection	B-DISO
and	O
HCV	O
RNA	O
load	O
were	O
associated	O
with	O
SVR	O
as	O
independent	O
predictors	O
in	O
the	O
two	O
study	O
groups	O
as	O
a	O
whole	O
.	O

The	O
SARS	B-DISO
CoV	O
receptor	O
-	O
binding	O
domain	O
(	O
amino	O
acids	O
N318	O
-	O
T509	O
of	O
S	O
protein	O
)	O
harbors	O
an	O
extended	O
excursion	O
along	O
its	O
periphery	O
that	O
contacts	O
ACE2	O
and	O
is	O
designated	O
the	O
receptor	O
-	O
binding	O
motif	O
(	O
RBM	O
,	O
amino	O
acids	O
S432	O
-	O
T486	O
).	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
causes	O
a	O
spectrum	O
of	O
illness	O
.	O

TITLE	O
:	O
Mortality	O
Risk	O
Factors	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Outbreak	O
,	O
South	O
Korea	O
,	O
2015	O
.	O

TITLE	O
:	O
Compounds	O
Derived	O
from	O
Epigallocatechin	O
-	O
3	O
-	O
Gallate	O
(	O
EGCG	O
)	O
as	O
a	O
Novel	O
Approach	O
to	O
the	O
Prevention	O
of	O
Viral	B-DISO
Infections	I-DISO
.	O

Outbreaks	O
of	O
emerging	O
lethal	O
viruses	O
,	O
such	O
as	O
Ebola	O
virus	O
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
virus	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
virus	O
,	O
could	O
lead	O
to	O
epidemics	O
or	O
even	O
pandemics	O
if	O
they	O
are	O
not	O
effectively	O
controlled	O
.	O

In	O
addition	O
to	O
a	O
short	O
duration	O
on	O
the	O
skin	O
surface	O
,	O
alcohol	O
is	O
ineffective	O
against	O
certain	O
viruses	O
such	O
as	O
norovirus	O
,	O
rabies	B-DISO
virus	O
,	O
and	O
polio	B-DISO
virus	O
.	O

TITLE	O
:	O
Low	O
-	O
Level	O
Expression	O
of	O
the	O
E1B	O
20	O
-	O
Kilodalton	O
Protein	O
by	O
Adenovirus	B-DISO
14p1	O
Enhances	O
Viral	O
Immunopathogenesis	O
.	O

ABSTRACT	O
:	O
Adenovirus	B-DISO
14p1	O
(	O
Ad14p1	O
)	O
is	O
an	O
emergent	O
variant	O
of	O
Ad	O
serotype	O
14	O
(	O
Ad14	B-DISO
)	O
that	O
has	O
caused	O
increased	O
severity	O
of	O
respiratory	O
illnesses	O
during	O
globally	O
distributed	O
outbreaks	O
,	O
including	O
cases	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
death	O
.	O

This	O
reduced	O
Ad14p1	O
E1B	O
20K	O
expression	O
caused	O
a	O
loss	O
-	O
of	O
-	O
function	O
phenotype	O
of	O
Ad	O
-	O
infected	O
cell	O
corpses	O
that	O
,	O
in	O
contrast	O
to	O
cells	O
infected	O
with	O
wt	O
Ad14	B-DISO
,	O
either	O
failed	O
to	O
repress	O
or	O
increased	O
NF	O
-	O
κB	O
-	O
dependent	O
,	O
proinflammatory	O
cytokine	O
responses	O
of	O
responder	O
human	O
alveolar	O
macrophages	O
.	O

The	O
study	O
was	O
an	O
analysis	O
of	O
the	O
safety	O
of	O
erythropoietin	O
administration	O
and	O
transfusion	O
threshold	O
on	O
the	O
incidence	O
of	O
ARDS	B-DISO
in	O
severe	O
TBI	O
patients	O
.	O

ARDS	B-DISO
by	O
either	O
definition	O
was	O
associated	O
with	O
increased	O
mortality	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
but	O
not	O
with	O
differences	O
in	O
functional	O
outcome	O
as	O
measured	O
by	O
the	O
GOS	O
score	O
at	O
6	O
months	O
.	O

ARDS	B-DISO
is	O
associated	O
with	O
increased	O
mortality	O
in	O
severe	O
TBI	O
patients	O
,	O
but	O
further	O
studies	O
are	O
needed	O
to	O
validate	O
these	O
findings	O
.	O

TITLE	O
:	O
Combination	O
therapy	O
with	O
lopinavir	O
/	O
ritonavir	O
,	O
ribavirin	O
and	O
interferon	O
-	O
α	O
for	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
.	O

This	O
is	O
a	O
case	O
report	O
of	O
use	O
of	O
lopinavir	O
/	O
ritonavir	O
-	O
based	O
combination	O
antiviral	O
therapy	O
for	O
a	O
patient	O
with	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

The	O
effects	O
of	O
high	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
FiO	O
The	O
aim	O
of	O
this	O
article	O
is	O
to	O
explore	O
the	O
current	O
opinion	O
concerning	O
optimal	O
mechanical	O
ventilation	O
support	O
techniques	O
for	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

There	O
is	O
also	O
evidence	O
that	O
this	O
syndrome	B-DISO
is	O
under	O
-	O
diagnosed	O
and	O
the	O
utilization	O
of	O
lung	O
protective	O
ventilation	O
is	O
still	O
variable	O
.	O

It	O
is	O
important	O
that	O
nurses	O
have	O
underlying	O
knowledge	O
of	O
both	O
aetiology	O
of	O
ARDS	B-DISO
and	O
ventilation	O
management	O
,	O
and	O
that	O
they	O
monitor	O
patients	O
very	O
closely	O
.	O

ABSTRACT	O
:	O
Prone	O
position	O
(	O
PP	O
)	O
has	O
been	O
used	O
since	O
the	O
1970s	O
to	O
treat	O
severe	O
hypoxemia	O
in	O
patients	O
with	O
ARDS	B-DISO
because	O
of	O
its	O
effectiveness	O
at	O
improving	O
gas	O
exchange	O
.	O

An	O
epidemiological	O
investigation	O
of	O
all	O
possible	O
infection	B-DISO
routes	O
indicated	O
two	O
likely	O
modes	O
of	O
transmission	O
:	O
exposure	O
to	O
MERS	O
in	O
Pyeongtaek	O
St	O
.	O
Mary	O
'	O
s	O
Hospital	O
during	O
a	O
visit	O
to	O
his	O
hospitalized	O
father	O
(	O
May	O
18	O
-	O
29	O
),	O
and	O
infection	B-DISO
through	O
frequent	O
contact	O
with	O
his	O
father	O
between	O
the	O
latter	O
'	O
s	O
referral	O
to	O
Pyeongtaek	O
Good	O
Samaritan	O
Bagae	O
Hospital	O
for	O
treatment	O
without	O
confirmatory	O
diagnosis	O
until	O
his	O
death	O
(	O
May	O
29	O
-	O
June	O
6	O
).	O

This	O
provoked	O
the	O
Korean	O
government	O
and	O
the	O
general	O
public	O
to	O
recognize	O
the	O
importance	O
of	O
having	O
a	O
well	O
-	O
established	O
system	O
against	O
infectious	B-DISO
diseases	I-DISO
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
the	O
size	O
and	O
location	O
of	O
homogeneous	O
inflamed	O
/	O
noninflamed	O
and	O
inhomogeneous	O
inflamed	O
/	O
noninflamed	O
lung	O
compartments	O
and	O
their	O
association	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
severity	O
.	O

Assessing	O
MRSA	B-DISO
,	O
emerging	O
and	O
re	O
-	O
emerging	O
pathogens	O
,	O
1963	O
-	O
2014	O
.	O

ABSTRACT	O
:	O
A	O
rapid	O
rise	O
in	O
PubMed	O
citations	O
on	O
methicillin	B-DISO
-	I-DISO
resistant	I-DISO
Staphylococcus	I-DISO
aureus	I-DISO
(	O
MRSA	B-DISO
)	O
occurred	O
after	O
2000	O
,	O
but	O
the	O
relationship	O
of	O
trends	O
in	O
citation	O
to	O
epidemiologic	O
trends	O
for	O
infectious	B-DISO
disease	I-DISO
is	O
not	O
known	O
.	O

MRSA	B-DISO
most	O
closely	O
resembled	O
a	O
Type	O
I	O
pathogen	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
reassortant	O
avian	O
-	O
origin	O
influenza	B-DISO
A	O
(	O
H7N9	O
)	O
virus	O
was	O
found	O
to	O
infect	O
three	O
Chinese	O
residents	O
,	O
the	O
first	O
H7N9	O
infection	B-DISO
in	O
humans	O
in	O
Asia	O
.	O

Eleven	O
patients	O
infected	O
with	O
H7N9	O
avian	B-DISO
influenza	I-DISO
who	O
developed	O
ARDS	B-DISO
were	O
diagnosed	O
by	O
lung	O
ultrasonography	O
.	O

RESULTS	O
:	O
Six	O
patients	O
who	O
had	O
severe	O
ARDS	B-DISO
showed	O
a	O
diffuse	O
comet	O
tail	O
sign	O
or	O
a	O
consolidation	O
score	O
≥	O
7	O
and	O
a	O
lung	O
ultrasound	O
score	O
≥	O
20	O
points	O
.	O

TITLE	O
:	O
Clinical	O
correlates	O
of	O
complicated	O
grief	O
among	O
individuals	O
with	O
acute	B-DISO
coronary	I-DISO
syndromes	I-DISO
.	O

ABSTRACT	O
:	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
(	O
GBS	B-DISO
)	O
has	O
a	O
cosmopolitan	O
distribution	O
.	O

The	O
aim	O
of	O
this	O
article	O
is	O
to	O
describe	O
the	O
characteristics	O
of	O
a	O
group	O
of	O
adults	O
with	O
GBS	B-DISO
diagnosed	O
and	O
treated	O
at	O
a	O
university	O
hospital	O
.	O

There	O
are	O
only	O
a	O
few	O
studies	O
in	O
English	O
that	O
describe	O
severe	O
respiratory	B-DISO
failure	I-DISO
treated	O
with	O
non	O
-	O
invasive	O
ventilation	O
,	O
but	O
all	O
of	O
them	O
have	O
had	O
good	O
outcomes	O
.	O

In	O
this	O
retrospective	O
study	O
70	O
polytraumatic	O
patients	O
with	O
severe	O
(	O
American	O
Association	O
for	O
the	O
Surgery	O
of	O
Trauma	O
[	O
AAST	O
]	O
grade	O
III	O
-	O
V	O
)	O
blunt	O
liver	O
injuries	O
were	O
operated	O
on	O
at	O
the	O
Clinic	O
for	O
Emergency	B-DISO
Surgery	O
.	O

FES	O
occurs	O
as	O
a	O
complication	B-DISO
after	O
trauma	O
or	O
procedures	O
such	O
as	O
surgery	O
.	O

The	O
most	O
common	O
viruses	O
were	O
rhinovirus	O
,	O
coronavirus	O
,	O
and	O
influenza	B-DISO
A	O
virus	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
the	O
incidence	O
,	O
in	O
-	O
hospital	O
mortality	O
,	O
and	O
1	O
-	O
year	O
mortality	O
of	O
ARDS	B-DISO
in	O
Taiwan	O
.	O

The	O
age	O
-	O
adjusted	O
incidence	O
of	O
ARDS	B-DISO
was	O
15	O
.	O
19	O
per	O
100	O
,	O
000	O
person	O
-	O
years	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
and	O
Medical	O
Students	O
:	O
Letter	O
from	O
China	O
.	O

TITLE	O
:	O
Comparative	O
Genomic	O
Analysis	O
of	O
Classical	O
and	O
Variant	O
Virulent	O
Parental	O
/	O
Attenuated	O
Strains	O
of	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
.	O

Further	O
,	O
these	O
viruses	O
fully	O
protected	O
mice	O
against	O
challenge	O
with	O
the	O
lethal	O
parental	O
virus	O
,	O
and	O
are	O
therefore	O
safe	O
and	O
stable	O
vaccine	O
candidates	O
for	O
protection	O
against	O
SARS	B-DISO
-	O
CoV	O
.	O

Ten	O
pigs	O
with	O
severe	O
lavage	O
-	O
induced	O
lung	O
injury	O
were	O
mechanically	O
ventilated	O
in	O
a	O
decremental	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
trial	O
that	O
was	O
reduced	O
from	O
20	O
to	O
6	O
cm	O
H2O	O
after	O
full	O
-	O
lung	O
recruitment	B-DISO
.	O

TITLE	O
:	O
Mortality	O
Predictors	O
in	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
Renal	O
Transplant	O
Recipients	O
With	O
ESKAPE	O
/	O
rESKAPE	O
Pneumonia	B-DISO
.	O

Recent	O
ongoing	O
zoonotic	O
epidemics	O
,	O
for	O
example	O
,	O
Ebola	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
,	O
demonstrate	O
that	O
human	O
-	O
to	O
-	O
human	O
transmission	O
is	O
a	O
distinct	O
reality	O
rather	O
than	O
an	O
obscure	O
possibility	O
.	O

ABSTRACT	O
:	O
Bovine	O
coronavirus	O
(	O
BCoV	O
)	O
is	O
an	O
important	O
viral	O
pathogen	O
associated	O
with	O
neonatal	B-DISO
calf	I-DISO
diarrhea	I-DISO
.	O

ABSTRACT	O
:	O
As	O
one	O
of	O
our	O
projects	O
,	O
we	O
here	O
report	O
some	O
new	O
molecular	O
modifications	O
of	O
2	O
,	O
4	O
,	O
6	O
-	O
trichloro	O
-	O
1	O
,	O
3	O
,	O
5	O
-	O
triazine	O
(	O
TCTAZ	O
:	O
1	O
)	O
to	O
symmetrical	O
2	O
,	O
4	O
,	O
6	O
-	O
trialkoxy	O
-	O
or	O
2	O
,	O
4	O
,	O
6	O
-	O
triaryloxy	O
-	O
substituted	O
1	O
,	O
3	O
,	O
5	O
-	O
triazine	O
(	O
TAZ	O
)	O
molecules	O
,	O
as	O
well	O
as	O
the	O
results	O
of	O
anti	O
-	O
herpes	B-DISO
simplex	I-DISO
virus	O
type	O
1	O
(	O
anti	O
-	O
HSV	O
-	O
1	O
)	O
activity	O
evaluation	O
of	O
synthesized	O
2	O
,	O
4	O
,	O
6	O
-	O
trisubstituted	O
TAZ	O
derivatives	O
.	O

We	O
performed	O
meta	O
-	O
analyses	O
of	O
studies	O
on	O
tuberculosis	B-DISO
,	O
influenza	B-DISO
,	O
respiratory	O
syncytial	O
virus	O
,	O
SARS	B-DISO
-	O
Coronavirus	O
and	O
pneumonia	B-DISO
.	O

TITLE	O
:	O
Non	O
-	O
Invasive	O
Detection	O
of	O
Lung	B-DISO
Inflammation	I-DISO
by	O
Near	O
-	O
Infrared	O
Fluorescence	O
Imaging	O
Using	O
Bimodal	O
Liposomes	O
.	O

A	O
positive	O
correlation	O
was	O
observed	O
between	O
NIRF	O
signals	O
and	O
lung	B-DISO
inflammation	I-DISO
markers	O
.	O

The	O
respiratory	O
virus	O
examination	O
was	O
determined	O
by	O
a	O
liquid	O
bead	O
array	O
xTAG	O
Respiratory	O
Virus	O
Panel	O
in	O
pharyngeal	O
swabs	O
,	O
while	O
bacterial	B-DISO
infection	I-DISO
was	O
studied	O
by	O
conventional	O
sputum	O
culture	O
.	O

TITLE	O
:	O
Comparison	O
of	O
community	O
-	O
acquired	O
,	O
hospital	O
-	O
acquired	O
,	O
and	O
intensive	O
care	O
unit	O
-	O
acquired	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
a	O
prospective	O
observational	O
cohort	O
study	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
syndrome	B-DISO
characterized	O
by	O
diffuse	O
pulmonary	B-DISO
edema	I-DISO
and	O
severe	O
hypoxemia	O
that	O
usually	O
occurs	O
after	O
an	O
injury	O
such	O
as	O
sepsis	B-DISO
,	O
aspiration	B-DISO
and	O
pneumonia	B-DISO
.	O

Of	O
the	O
3002	O
patients	O
screened	O
,	O
296	O
patients	O
had	O
a	O
diagnosis	O
of	O
ARDS	B-DISO
,	O
including	O
70	O
(	O
23	O
.	O
7	O
%)	O
with	O
community	O
-	O
acquired	O
ARDS	B-DISO
,	O
83	O
(	O
28	O
%)	O
with	O
hospital	O
-	O
acquired	O
ARDS	B-DISO
,	O
and	O
143	O
(	O
48	O
.	O
3	O
%)	O
with	O
ICU	O
-	O
acquired	O
ARDS	B-DISO
.	O

In	O
addition	O
,	O
the	O
ORF3	O
-	O
expressing	O
Vero	O
cells	O
had	O
more	O
vesicles	B-DISO
than	O
the	O
host	O
Vero	O
cells	O
.	O

ABSTRACT	O
:	O
In	O
2012	O
,	O
a	O
new	O
betacoronavirus	O
,	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
was	O
identified	O
in	O
humans	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
first	O
imported	O
case	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
was	O
reported	O
on	O
May	O
20	O
,	O
2015	O
in	O
Korea	O
,	O
there	O
have	O
been	O
186	O
laboratory	O
-	O
confirmed	O
cases	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
with	O
36	O
fatalities	O
.	O

The	O
index	O
case	O
was	O
a	O
35	O
-	O
yr	O
-	O
old	O
man	O
who	O
had	O
vigorous	O
coughing	B-DISO
while	O
staying	O
at	O
the	O
ER	O
for	O
58	O
hr	O
.	O

All	O
healthcare	O
facilities	O
should	O
establish	O
and	O
implement	O
infection	B-DISO
prevention	O
and	O
control	O
measure	O
as	O
well	O
as	O
triage	O
policies	O
and	O
procedures	O
for	O
early	O
detection	O
and	O
isolation	O
of	O
suspected	O
MERS	O
-	O
CoV	O
cases	O
.	O

We	O
also	O
showed	O
that	O
alstotides	O
are	O
antiviral	O
and	O
cell	O
-	O
permeable	O
to	O
inhibit	O
the	O
early	O
phase	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
and	O
Dengue	B-DISO
infection	B-DISO
,	O
in	O
addition	O
to	O
their	O
ability	O
to	O
inhibit	O
α	O
-	O
amylase	O
.	O

ABSTRACT	O
:	O
The	O
evolution	O
of	O
the	O
techniques	O
used	O
in	O
the	O
intensive	O
care	O
setting	O
over	O
the	O
past	O
decades	O
has	O
led	O
on	O
one	O
side	O
to	O
better	O
survival	O
rates	O
in	O
patients	O
with	O
acute	O
conditions	O
and	O
severely	O
impaired	B-DISO
vital	O
functions	O
.	O

Evaluation	O
of	O
available	O
SARS	B-DISO
-	O
based	O
immune	O
-	O
therapeutic	O
and	O
prophylactic	O
modalities	O
revealed	O
poor	O
efficacy	O
;	O
both	O
monoclonal	O
antibody	O
and	O
vaccine	O
approaches	O
failed	O
to	O
neutralize	O
and	O
protect	O
from	O
infection	B-DISO
with	O
CoVs	O
using	O
the	O
novel	O
spike	O
protein	O
.	O

Our	O
work	O
suggests	O
a	O
potential	O
risk	O
of	O
SARS	B-DISO
-	O
CoV	O
re	O
-	O
emergence	O
from	O
viruses	O
currently	O
circulating	O
in	O
bat	O
populations	O
.	O

Animal	O
coronaviruses	O
that	O
""""	O
host	O
jump	O
""""	O
to	O
humans	O
result	O
in	O
severe	O
infections	B-DISO
with	O
high	O
mortality	O
,	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
,	O
more	O
recently	O
,	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
).	O

In	O
this	O
study	O
,	O
pediatric	O
case	O
admitted	O
with	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
and	O
AFP	O
,	O
who	O
detected	O
for	O
HCoV	O
229E	O
and	O
OC43	O
co	B-DISO
-	I-DISO
infection	I-DISO
by	O
the	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
,	O
has	O
been	O
reported	O
for	O
the	O
first	O
time	O
.	O

Patients	O
were	O
divided	O
into	O
two	O
cohorts	O
:	O
the	O
treatment	O
group	O
received	O
therapeutic	O
temperature	O
modulation	O
(	O
TTM	B-DISO
)	O
with	O
continuous	O
surface	O
cooling	O
and	O
indwelling	O
bladder	O
temperature	O
probes	O
.	O

Exposure	O
to	O
TTM	B-DISO
is	O
associated	O
with	O
an	O
increase	O
in	O
pulmonary	B-DISO
complications	I-DISO
.	O

Serology	O
was	O
consistently	O
completed	O
for	O
feline	B-DISO
leukemia	I-DISO
virus	O
(	O
FeLV	O
),	O
feline	O
immunodeficiency	B-DISO
virus	O
(	O
FIV	O
),	O
feline	O
coronavirus	O
(	O
FCoV	O
),	O
Toxoplasma	O
gondii	O
,	O
and	O
Bartonella	O
spp	O
.	O

TITLE	O
:	O
Self	O
-	O
reactive	O
CD4	O
(+)	O
T	O
cells	O
activated	O
during	O
viral	O
-	O
induced	O
demyelination	B-DISO
do	O
not	O
prevent	O
clinical	O
recovery	O
.	O

While	O
both	O
the	O
CNS	O
-	O
infiltrating	B-DISO
myeloid	O
population	O
and	O
microglia	O
ingested	O
myelin	O
,	O
only	O
CNS	O
-	O
infiltrating	B-DISO
APC	B-DISO
were	O
capable	O
of	O
presenting	O
endogenous	O
myelin	O
antigen	O
to	O
SR	O
T	O
cells	O
ex	O
vivo	O
.	O

Their	O
gradual	O
decline	O
,	O
despite	O
ongoing	O
demyelination	B-DISO
,	O
suggested	O
minimal	O
re	O
-	O
stimulation	O
and	O
pathogenic	O
function	O
in	O
vivo	O
consistent	O
with	O
the	O
lack	O
of	O
autoimmune	B-DISO
symptoms	O
.	O

TITLE	O
:	O
Prone	O
position	O
for	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
in	O
adults	O
.	O

Risk	O
of	O
bias	O
,	O
although	O
acceptable	O
in	O
the	O
view	O
of	O
the	O
review	O
authors	O
,	O
was	O
inevitable	O
:	O
Blinding	O
of	O
participants	O
and	O
carers	O
to	O
treatment	O
allocation	O
was	O
not	O
possible	O
(	O
face	B-DISO
-	O
up	O
vs	O
face	B-DISO
-	O
down	O
).	O
Primary	O
analyses	O
of	O
short	O
-	O
and	O
longer	O
-	O
term	O
mortality	O
pooled	O
from	O
six	O
trials	O
demonstrated	O
an	O
RR	O
of	O
0	O
.	O
84	O
to	O
0	O
.	O
86	O
in	O
favour	O
of	O
the	O
prone	O
position	O
(	O
PP	O
),	O
but	O
findings	O
were	O
not	O
statistically	O
significant	O
:	O
In	O
the	O
short	O
term	O
,	O
mortality	O
for	O
those	O
ventilated	O
prone	O
was	O
33	O
.	O
4	O
%	O
(	O
363	O
/	O
1086	O
)	O
and	O
supine	O
38	O
.	O
3	O
%	O
(	O
395	O
/	O
1031	O
).	O

ABSTRACT	O
:	O
Leptospirosis	B-DISO
is	O
recognized	O
as	O
a	O
zoonotic	O
disease	O
that	O
is	O
emerging	O
worldwide	O
.	O

TITLE	O
:	O
Impact	O
of	O
Recruitment	B-DISO
on	O
Static	O
and	O
Dynamic	O
Lung	O
Strain	O
in	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
.	O

In	O
the	O
animal	O
model	O
,	O
recruitment	B-DISO
caused	O
a	O
significant	O
decrease	O
in	O
dynamic	O
strain	O
(	O
from	O
[	O
mean	O
±	O
SD	O
]	O
0	O
.	O
4	O
±	O
0	O
.	O
12	O
to	O
0	O
.	O
25	O
±	O
0	O
.	O
07	O
,	O
P	O
<	O
0	O
.	O
01	O
),	O
while	O
increasing	O
the	O
static	O
component	O
.	O

Systemic	O
examination	O
revealed	O
pyogenic	B-DISO
liver	I-DISO
abscess	I-DISO
and	O
percutaneous	O
drainage	O
of	O
abscess	B-DISO
disclosed	O
Klebsiella	O
pneumoniae	O
,	O
which	O
was	O
also	O
isolated	O
from	O
conjunctival	B-DISO
discharge	I-DISO
.	O

CONCLUSIONS	O
:	O
Severe	O
bacterial	B-DISO
endophthalmitis	I-DISO
may	O
cause	O
intracranial	O
infection	B-DISO
via	O
the	O
optic	O
nerve	O
.	O

TITLE	O
:	O
Evidence	O
for	O
zoonotic	O
origins	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
.	O

ABSTRACT	O
:	O
Design	O
of	O
inhibitors	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
chymotrypsin	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
)	O
)	O
is	O
a	O
potentially	O
important	O
approach	O
to	O
fight	O
against	O
SARS	B-DISO
.	O

TITLE	O
:	O
Kinetics	O
of	O
Serologic	O
Responses	O
to	O
MERS	O
Coronavirus	B-DISO
Infection	I-DISO
in	O
Humans	O
,	O
South	O
Korea	O
.	O

ABSTRACT	O
:	O
An	O
outbreak	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
occurred	O
in	O
the	O
summer	O
of	O
2014	O
in	O
Ukraine	O
,	O
severely	O
affecting	O
piglets	O
<	O
10	O
days	O
of	O
age	O
;	O
the	O
mortality	O
rate	O
approached	O
100	O
%.	O

TITLE	O
:	O
Failure	O
of	O
Noninvasive	O
Ventilation	O
for	O
De	O
Novo	O
Acute	O
Hypoxemic	O
Respiratory	B-DISO
Failure	I-DISO
:	O
Role	O
of	O
Tidal	O
Volume	O
.	O

Sixty	O
-	O
two	O
patients	O
were	O
enrolled	O
,	O
including	O
47	O
meeting	O
criteria	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
and	O
32	O
failed	O
noninvasive	O
ventilation	O
(	O
51	O
%).	O

ABSTRACT	O
:	O
Recently	O
several	O
infectious	B-DISO
agents	O
with	O
a	O
zoonotic	O
potential	O
have	O
been	O
detected	O
in	O
different	O
bat	O
species	O
.	O

TITLE	O
:	O
Spatial	O
and	O
temporal	O
epidemiology	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
)	O
in	O
the	O
Midwest	O
and	O
Southeast	O
regions	O
of	O
the	O
United	O
States	O
.	O

Even	O
though	O
the	O
role	O
of	O
potential	O
sources	O
of	O
infection	B-DISO
in	O
the	O
epidemiology	O
of	O
the	O
disease	O
at	O
the	O
farm	O
level	O
(	O
feed	O
,	O
fomites	O
)	O
has	O
been	O
extensively	O
investigated	O
,	O
there	O
is	O
a	O
lack	O
of	O
knowledge	O
about	O
the	O
dynamics	O
of	O
disease	O
spread	O
at	O
the	O
regional	O
level	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
dissemination	O
of	O
PEDV	O
infection	B-DISO
in	O
two	O
areas	O
located	O
in	O
the	O
regions	O
with	O
the	O
highest	O
swine	O
density	O
in	O
the	O
country	O
(	O
Southeast	O
and	O
Midwest	O
)	O
including	O
more	O
than	O
2400	O
farms	O
.	O

TITLE	O
:	O
Identify	O
-	O
Isolate	O
-	O
Inform	O
:	O
A	O
Modified	O
Tool	O
for	O
Initial	O
Detection	O
and	O
Management	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Patients	O
in	O
the	O
Emergency	B-DISO
Department	O
.	O

ABSTRACT	O
:	O
Although	O
the	O
original	O
US	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
was	O
confirmed	O
as	O
highly	O
virulent	O
by	O
multiple	O
studies	O
,	O
the	O
virulence	O
of	O
spike	O
-	O
insertion	O
deletion	O
(	O
S	O
-	O
INDEL	O
)	O
PEDV	O
strains	O
is	O
undefined	O
.	O

Two	O
of	O
four	O
S	O
-	O
INDEL	O
Iowa106	O
-	O
infected	O
sows	O
and	O
the	O
original	O
PC21A	O
-	O
infected	O
sow	O
showed	O
anorexia	B-DISO
and	O
watery	B-DISO
diarrhea	I-DISO
for	O
1	O
-	O
4	O
days	O
.	O

After	O
the	O
original	O
PC21A	O
challenge	O
,	O
a	O
subset	O
(	O
13	O
/	O
16	O
)	O
of	O
S	O
-	O
INDEL	O
Iowa106	O
-	O
inoculated	O
piglets	O
developed	O
diarrhea	B-DISO
,	O
whereas	O
all	O
(	O
5	O
/	O
5	O
)	O
and	O
no	O
(	O
0	O
/	O
4	O
)	O
pigs	O
in	O
the	O
mock	O
and	O
original	O
PC21A	O
-	O
inoculated	O
pigs	O
had	O
diarrhea	B-DISO
,	O
respectively	O
.	O

ABSTRACT	O
:	O
The	O
Binational	O
Border	O
Infectious	B-DISO
Disease	I-DISO
Surveillance	O
program	O
began	O
surveillance	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
(	O
SARI	O
)	O
on	O
the	O
US	O
-	O
Mexico	O
border	O
in	O
2009	O
.	O

We	O
aim	O
to	O
determine	O
the	O
viral	O
content	O
of	O
the	O
air	O
emitted	O
by	O
symptomatic	O
inpatients	O
or	O
long	O
-	O
term	O
care	O
residents	O
with	O
laboratory	O
-	O
confirmed	O
influenza	B-DISO
virus	B-DISO
infection	I-DISO
(	O
emitters	O
),	O
and	O
in	O
the	O
breathing	O
zones	O
of	O
healthcare	O
workers	O
who	O
attend	O
to	O
them	O
.	O

Of	O
the	O
patients	O
infected	O
with	O
influenza	B-DISO
A	O
,	O
viral	O
RNA	O
was	O
recovered	O
from	O
the	O
air	O
emitted	O
by	O
9	O
/	O
12	O
patients	O
using	O
the	O
low	O
-	O
volume	O
sampler	O
;	O
no	O
viral	O
RNA	O
was	O
detected	O
from	O
air	O
emitted	O
by	O
patients	O
with	O
influenza	B-DISO
B	O
(	O
n	O
=	O
3	O
).	O

Influenza	B-DISO
virus	O
RNA	O
was	O
recovered	O
from	O
one	O
HCW	O
'	O
s	O
sampler	O
.	O

Influenza	B-DISO
virus	O
RNA	O
was	O
recovered	O
from	O
one	O
HCW	O
'	O
s	O
sampler	O
.	O

ABSTRACT	O
:	O
Emerging	O
microbiological	O
threats	O
,	O
such	O
as	O
SARS	B-DISO
,	O
Ebola	O
,	O
MERS	O
-	O
CoV	O
,	O
anthrax	B-DISO
,	O
cause	O
necessity	O
of	O
considering	O
how	O
effectively	O
protect	O
laboratory	O
workers	O
against	O
dangerous	O
pathogens	O
which	O
might	O
be	O
present	O
in	O
clinical	O
samples	O
.	O

TITLE	O
:	O
Controversies	O
in	O
the	O
Management	O
of	O
Severe	O
ARDS	B-DISO
:	O

Among	O
174	O
nasopharyngeal	O
aspirates	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
was	O
detected	O
in	O
39	O
samples	O
(	O
22	O
.	O
41	O
%),	O
influenza	B-DISO
A	O
virus	O
in	O
34	O
(	O
19	O
.	O
54	O
%),	O
metapneumovirus	O
(	O
MPV	O
)	O
in	O
19	O
(	O
10	O
.	O
92	O
%),	O
coronaviruses	O
in	O
14	O
(	O
8	O
.	O
05	O
%),	O
and	O
parainfluenza	B-DISO
viruses	O
(	O
PIVs	O
)	O
in	O
11	O
(	O
6	O
.	O
32	O
%).	O

Multiple	O
antiepileptic	O
medications	O
were	O
attempted	O
,	O
including	O
drug	B-DISO
-	I-DISO
induced	I-DISO
coma	I-DISO
in	O
all	O
of	O
them	O
,	O
with	O
poor	O
response	O
.	O

RESULTS	O
:	O
Six	O
males	O
and	O
one	O
female	O
ranging	O
from	O
3	O
months	O
to	O
9	O
years	O
of	O
age	O
presented	O
with	O
status	B-DISO
epilepticus	I-DISO
preceded	O
by	O
a	O
febrile	B-DISO
illness	I-DISO
.	O

A	O
lack	O
of	O
autopsy	O
studies	O
from	O
MERS	O
fatalities	O
has	O
hindered	O
understanding	O
of	O
MERS	O
-	O
CoV	O
pathogenesis	B-DISO
.	O

In	O
the	O
future	O
also	O
new	O
approaches	O
like	O
mesenchymal	O
cell	O
therapy	O
,	O
activation	O
of	O
hypoxia	B-DISO
-	O
elicited	O
transcription	O
factors	O
or	O
targeting	O
of	O
purinergic	O
signaling	O
may	O
be	O
successful	O
outside	O
the	O
experimental	O
setting	O
.	O

Especially	O
,	O
use	O
of	O
low	O
tidal	O
volumes	O
,	O
avoiding	O
of	O
fluid	B-DISO
overload	I-DISO
and	O
restrictive	O
blood	O
transfusion	O
regimes	O
may	O
help	O
to	O
prevent	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
we	O
assessed	O
the	O
ability	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
to	O
replicate	O
and	O
induce	O
innate	O
immunity	O
in	O
human	O
monocyte	O
-	O
derived	O
macrophages	O
and	O
dendritic	O
cells	O
(	O
MDDCs	O
),	O
and	O
compared	O
it	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

Our	O
data	O
suggest	O
that	O
SARS	B-DISO
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
replicate	O
poorly	O
in	O
human	O
macrophages	O
and	O
MDDCs	O
,	O
but	O
MERS	O
-	O
CoV	O
is	O
nonetheless	O
capable	O
of	O
inducing	O
a	O
readily	O
detectable	O
host	O
innate	B-DISO
immune	I-DISO
response	I-DISO
.	O

We	O
present	O
a	O
39	O
-	O
year	O
-	O
old	O
man	O
who	O
presented	O
with	O
a	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
related	O
to	O
an	O
alveolar	O
hemorrhage	B-DISO
associated	O
with	O
a	O
persistent	O
penis	B-DISO
ulcer	I-DISO
and	O
a	O
genital	O
lymphedema	B-DISO
.	O

CONCLUSIONS	O
:	O
A	O
serious	O
alveolar	O
hemorrhage	B-DISO
in	O
a	O
young	O
patient	O
should	O
raise	O
suspicion	O
of	O
silicone	O
embolism	B-DISO
syndrome	B-DISO
,	O
especially	O
if	O
there	O
are	O
cutaneous	O
lesions	O
compatible	O
with	O
injections	O
.	O

ABSTRACT	O
:	O
During	O
the	O
2009	O
/	O
10	O
pandemic	O
,	O
a	O
national	O
surveillance	O
system	O
for	O
severe	O
influenza	B-DISO
cases	O
was	O
set	O
up	O
in	O
France	O
.	O

ARDS	B-DISO
occurred	O
more	O
frequently	O
in	O
patients	O
who	O
were	O
middle	O
-	O
aged	O
(	O
36	O
-	O
55	O
years	O
),	O
pregnant	O
,	O
obese	B-DISO
,	O
or	O
infected	O
with	O
A	O
(	O
H1N1	O
)	O
pdm09	O
.	O

Our	O
approach	O
is	O
implemented	O
as	O
a	O
web	B-DISO
server	O
that	O
can	O
be	O
accessed	O
at	O
http	O
://	O
bioinfo	O
.	O
ihb	O
.	O
ac	O
.	O
cn	O
/	O
seq2hosts	O
.	O

ABSTRACT	O
:	O
Influenza	B-DISO
A	O
and	O
B	O
,	O
and	O
many	O
unrelated	O
viruses	O
including	O
rhinovirus	O
,	O
RSV	O
,	O
adenovirus	B-DISO
,	O
metapneumovirus	O
and	O
coronavirus	O
share	O
the	O
same	O
seasonality	O
,	O
since	O
these	O
viral	O
acute	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
(	O
vARIs	O
)	O
are	O
much	O
more	O
common	O
in	O
winter	O
than	O
summer	O
.	O

ABSTRACT	O
:	O
OBJECT	O
Subarachnoid	B-DISO
hemorrhage	I-DISO
(	O
SAH	O
)	O
is	O
often	O
accompanied	O
by	O
pulmonary	B-DISO
complications	I-DISO
,	O
which	O
may	O
lead	O
to	O
poor	O
outcomes	O
and	O
death	O
.	O

Identifying	O
ARDS	B-DISO
patients	O
who	O
should	O
be	O
transferred	O
to	O
an	O
extracorporeal	O
membrane	O
oxygenation	O
center	O
is	O
an	O
important	O
task	O
for	O
emergency	B-DISO
providers	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
their	O
pathogenesis	B-DISO
.	O

The	O
lipid	O
profile	O
of	O
the	O
lung	O
tissue	O
from	O
mice	O
infected	O
with	O
Plasmodium	O
berghei	O
NK65	O
developing	O
MA	O
-	O
ALI	O
/	O
ARDS	B-DISO
,	O
but	O
not	O
that	O
from	O
mice	O
without	O
lung	O
pathology	B-DISO
or	O
controls	O
,	O
was	O
characterized	O
by	O
high	O
levels	O
of	O
phospholipids	O
-	O
mainly	O
phosphatidylcholine	O
-	O
and	O
esterified	O
cholesterol	O
.	O

Recruitment	B-DISO
manoeuvres	O
(	O
RMs	O
)	O
were	O
conducted	O
with	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
;	O
30	O
cm	O
H2O	O
for	O
40	O
seconds	O
).	O

ABSTRACT	O
:	O
Influenza	B-DISO
virus	O
(	O
IFV	O
)	O
infection	B-DISO
is	O
a	O
common	O
cause	O
of	O
severe	O
viral	B-DISO
pneumonia	I-DISO
associated	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
which	O
is	O
difficult	O
to	O
control	O
with	O
general	O
immunosuppressive	O
therapy	O
including	O
corticosteroids	O
due	O
to	O
the	O
unfavorable	O
effect	O
on	O
viral	O
replication	O
.	O

Syk	O
or	O
CARD9	O
-	O
deficient	O
DCs	B-DISO
but	O
not	O
macrophages	O
showed	O
impaired	B-DISO
cytokine	O
but	O
not	O
type	O
-	O
I	O
interferon	O
production	O
in	O
response	O
to	O
IFV	O
in	O
vitro	O
,	O
indicating	O
a	O
possible	O
role	O
for	O
the	O
Syk	O
-	O
CARD9	O
pathway	O
in	O
DCs	B-DISO
in	O
excessive	O
inflammation	B-DISO
of	O
IFV	O
-	O
infected	O
lungs	O
.	O

TITLE	O
:	O
Recombinant	O
Receptor	O
Binding	O
Domain	O
Protein	O
Induces	O
Partial	O
Protective	O
Immunity	O
in	O
Rhesus	O
Macaques	O
Against	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
Challenge	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
.	O

MERS	O
-	O
CoV	O
ORF4b	O
antagonizes	O
the	O
early	O
antiviral	O
response	O
,	O
which	O
may	O
contribute	O
to	O
MERS	O
-	O
CoV	O
pathogenesis	B-DISO
.	O

TITLE	O
:	O
A	O
phylogenetically	O
distinct	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
detected	O
in	O
a	O
dromedary	O
calf	O
from	O
a	O
closed	O
dairy	O
herd	O
in	O
Dubai	O
with	O
rising	O
seroprevalence	O
with	O
age	O
.	O

Instead	O
,	O
it	O
formed	O
a	O
unique	O
branch	O
more	O
closely	O
related	O
to	O
other	O
MERS	O
-	O
CoV	O
strains	O
from	O
patients	O
in	O
Qatar	O
and	O
Hafr	O
-	O
Al	O
-	O
Batin	O
in	O
Saudi	O
Arabia	O
,	O
as	O
well	O
as	O
the	O
MERS	O
-	O
CoV	O
strains	O
from	O
patients	O
in	O
the	O
recent	O
Korean	O
outbreak	O
,	O
in	O
which	O
the	O
index	O
patient	O
acquired	O
the	O
infection	B-DISO
during	O
travel	O
in	O
the	O
eastern	O
part	O
of	O
the	O
Arabian	O
Peninsula	O
.	O

However	O
,	O
infection	B-DISO
source	O
,	O
transmission	O
route	O
,	O
and	O
host	O
of	O
nCoV	O
have	O
not	O
yet	O
been	O
thoroughly	O
characterized	O
.	O

Hemodynamic	B-DISO
instability	I-DISO
or	O
significant	O
activation	O
of	O
the	O
plasmatic	O
coagulation	O
was	O
not	O
observed	O
.	O

ABSTRACT	O
:	O
The	O
role	O
of	O
viruses	O
in	O
chronic	B-DISO
rhinosinusitis	I-DISO
(	O
CRS	B-DISO
)	O
is	O
poorly	O
understood	O
.	O

In	O
this	O
prospective	O
study	O
,	O
13	O
patients	O
with	O
CRS	B-DISO
with	O
nasal	B-DISO
polyposis	I-DISO
(	O
CRSwNP	O
)	O
and	O
8	O
patients	O
without	O
nasal	B-DISO
polyposis	I-DISO
(	O
CRSsNP	O
)	O
were	O
enrolled	O
and	O
compared	O
with	O
14	O
healthy	O
controls	O
.	O

Moreover	O
,	O
viral	B-DISO
infection	I-DISO
may	O
play	O
a	O
greater	O
role	O
in	O
symptom	B-DISO
exacerbation	O
in	O
CRSsNP	O
than	O
in	O
CRSwNP	O
.	O

Overall	O
intensive	O
care	O
unit	O
mortality	O
was	O
63	O
(	O
37	O
.	O
1	O
%)	O
of	O
170	O
,	O
and	O
high	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
score	O
,	O
low	O
PaO2	O
/	O
FIO2	O
,	O
shock	O
,	O
and	O
ARDS	B-DISO
severity	O
were	O
associated	O
with	O
increased	O
mortality	O
.	O

Also	O
,	O
we	O
have	O
reviewed	O
the	O
data	O
on	O
survival	O
reported	O
in	O
observational	O
and	O
randomized	O
controlled	O
trials	O
,	O
discussed	O
how	O
the	O
current	O
ARDS	B-DISO
definition	O
modifies	O
the	O
true	O
incidence	O
of	O
ARDS	B-DISO
,	O
and	O
briefly	O
mentioned	O
recent	O
approaches	O
that	O
appear	O
to	O
improve	O
ARDS	B-DISO
outcome	O
.	O

On	O
the	O
basis	O
of	O
current	O
evidence	O
,	O
it	O
seems	O
that	O
the	O
incidence	O
and	O
overall	O
hospital	O
mortality	O
of	O
ARDS	B-DISO
has	O
not	O
changed	O
substantially	O
in	O
the	O
last	O
decade	O
.	O

During	O
the	O
first	O
5	O
days	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
therapy	O
,	O
prothrombin	O
fragment	O
1	O
.	O
2	O
(	O
F1	O
.	O
2	O
)	O
(	O
1	O
.	O
36	O
-	O
2	O
.	O
4	O
µM	O
),	O
thrombin	O
-	O
antithrombin	O
complex	O
(	O
14	O
.	O
5	O
-	O
50	O
µg	O
/	O
L	O
),	O
and	O
D	O
-	O
dimers	O
(	O
6	O
.	O
00	O
-	O
27	O
.	O
0	O
mg	O
/	O
L	O
)	O
increased	O
,	O
whereas	O
fibrinogen	O
values	O
dropped	O
from	O
5	O
.	O
8	O
to	O
4	O
.	O
1	O
g	O
/	O
L	O
.	O
The	O
three	O
different	O
extracorporeal	O
membrane	O
oxygenation	O
systems	O
did	O
not	O
show	O
any	O
differences	O
with	O
regard	O
to	O
hemostasis	O
,	O
anticoagulation	O
,	O
hemolysis	B-DISO
,	O
and	O
inflammatory	O
parameters	O
within	O
the	O
first	O
5	O
days	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
therapy	O
.	O

Here	O
we	O
show	O
in	O
Chinese	O
macaques	O
that	O
SARS	B-DISO
-	O
CoV	O
traversed	O
the	O
mucosa	O
through	O
the	O
respiratory	O
tract	O
within	O
2	O
days	O
,	O
resulting	O
in	O
extensive	O
mucosal	O
infiltration	B-DISO
by	O
T	O
cells	O
,	O
MAC387	O
(+),	O
and	O
CD163	O
(+)	O
monocytes	O
/	O
macrophages	O
followed	O
by	O
limited	O
viral	O
replication	O
in	O
the	O
lung	O
but	O
persistent	O
viral	B-DISO
shedding	I-DISO
into	O
the	O
upper	O
airway	O
.	O

This	O
study	O
provides	O
a	O
comprehensive	O
overview	O
of	O
the	O
spatiotemporal	O
interactions	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
monocytes	O
/	O
macrophages	O
,	O
and	O
the	O
DC	O
network	O
in	O
mucosal	O
tissues	O
and	O
highlights	O
the	O
fact	O
that	O
,	O
while	O
these	O
innate	O
cells	O
contribute	O
to	O
viral	O
clearance	O
,	O
they	O
probably	O
also	O
serve	O
as	O
shelters	O
and	O
vehicles	O
to	O
provide	O
a	O
mechanism	O
for	O
the	O
virus	O
to	O
escape	O
host	O
mucosal	O
innate	O
immunity	O
and	O
disseminate	O
systemically	O
.	O

In	O
the	O
derivation	O
cohort	O
,	O
the	O
ACP	B-DISO
risk	O
score	O
included	O
four	O
variables	O
[	O
pneumonia	B-DISO
as	O
a	O
cause	O
of	O
ARDS	B-DISO
,	O
driving	O
pressure	O
≥	O
18	O
cm	O
H2O	O
,	O
arterial	O
oxygen	O
partial	O
pressure	O
to	O
fractional	O
inspired	O
oxygen	O
(	O
PaO2	O
/	O
FiO2	O
)	O
ratio	O
<	O
150	O
mmHg	O
,	O
and	O
arterial	O
carbon	O
dioxide	O
partial	O
pressure	O
≥	O
48	O
mmHg	O
].	O

TITLE	O
:	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
3C	O
-	O
Like	O
Protease	O
Regulates	O
Its	O
Interferon	O
Antagonism	O
by	O
Cleaving	O
NEMO	O
.	O

NEMO	O
is	O
cleaved	O
at	O
glutamine	O
231	O
(	O
Q231	O
)	O
by	O
PEDV	O
,	O
and	O
this	O
cleavage	O
impaired	B-DISO
the	O
ability	O
of	O
NEMO	O
to	O
activate	O
downstream	O
IFN	O
production	O
and	O
to	O
act	O
as	O
a	O
signaling	O
adaptor	O
of	O
the	O
RIG	O
-	O
I	O
/	O
MDA5	O
pathway	O
.	O

Plasma	O
Ang	O
-	O
2	O
,	O
von	O
Willebrand	O
Factor	O
antigen	O
(	O
vWF	O
),	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
were	O
measured	O
on	O
ARDS	B-DISO
days	O
1	O
and	O
3	O
and	O
correlated	O
with	O
patient	O
outcomes	O
.	O

45	O
%	O
of	O
the	O
cohort	O
had	O
a	O
rising	O
Ang	O
-	O
2	O
between	O
ARDS	B-DISO
day	O
1	O
and	O
3	O
(	O
adjusted	O
mortality	O
OR	O
3	O
.	O
3	O
,	O
95	O
%	O
CI	O
1	O
.	O
2	O
-	O
9	O
.	O
2	O
,	O
P	O
=	O
0	O
.	O
026	O
).	O

ABSTRACT	O
:	O
The	O
severity	O
of	O
exacerbation	O
in	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
COPD	B-DISO
)	O
due	O
to	O
the	O
overlap	O
of	O
obstructive	B-DISO
sleep	I-DISO
apnea	I-DISO
syndrome	I-DISO
(	O
OSAS	B-DISO
)	O
is	O
not	O
known	O
.	O

To	O
find	O
out	O
the	O
1	O
)	O
severity	O
of	O
acute	O
exacerbation	O
of	O
COPD	B-DISO
(	O
AECOPD	O
)	O
in	O
patients	O
with	O
overlap	B-DISO
syndrome	I-DISO
compared	O
to	O
only	O
COPD	B-DISO
,	O
2	O
)	O
prevalence	O
of	O
overlap	B-DISO
syndrome	I-DISO
in	O
AECOPD	O
,	O
and	O
3	O
)	O
clinical	O
characteristics	O
of	O
COPD	B-DISO
compared	O
to	O
overlap	B-DISO
syndrome	I-DISO
.	O

Fifty	O
-	O
one	O
patients	O
admitted	O
with	O
AECOPD	O
were	O
classified	O
into	O
;	O
Mild	O
exacerbation	O
:	O
Normal	O
arterial	O
blood	O
gases	O
(	O
ABG	O
)	O
treated	O
with	O
antibiotics	O
,	O
Moderate	O
:	O
Normal	O
ABG	O
treated	O
with	O
parenteral	O
corticosteroids	O
,	O
Severe	O
:	O
Type	B-DISO
1	I-DISO
respiratory	I-DISO
failure	I-DISO
,	O
Very	O
severe	O
:	O
Type	B-DISO
2	I-DISO
respiratory	I-DISO
failure	I-DISO
with	O
normal	O
pH	O
and	O
Life	O
-	O
threatening	O
:	O
Type	B-DISO
2	I-DISO
respiratory	I-DISO
failure	I-DISO
with	O
pH	O
<	O
7	O
.	O
35	O
.	O

The	O
majority	O
of	O
only	O
COPD	B-DISO
cases	O
(	O
26	O
/	O
38	O
)	O
had	O
mild	O
and	O
moderate	O
exacerbations	O
whereas	O
majority	O
of	O
overlap	O
patients	O
(	O
9	O
/	O
13	O
)	O
had	O
severe	O
,	O
very	O
severe	O
and	O
life	O
-	O
threatening	O
exacerbations	O
(	O
statistically	O
significant	O
,	O
P	O
=	O
0	O
.	O
021	O
).	O

The	O
mean	O
BMI	O
in	O
only	O
COPD	B-DISO
and	O
overlap	B-DISO
syndrome	I-DISO
was	O
20	O
.	O
70	O
±	O
8	O
.	O
03	O
kg	O
/	O
m	O
(	O
2	O
)	O
and	O
31	O
.	O
82	O
±	O
5	O
.	O
80	O
kg	O
/	O
m	O
(	O
2	O
)	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
respectively	O
.	O

Metabolic	B-DISO
syndrome	I-DISO
was	O
recorded	O
in	O
2	O
/	O
36	O
(	O
5	O
.	O
3	O
%)	O
patients	O
in	O
only	O
COPD	B-DISO
and	O
6	O
/	O
13	O
(	O
46	O
.	O
2	O
%)	O
patients	O
in	O
overlap	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

Overlap	B-DISO
syndromes	I-DISO
are	O
more	O
likely	O
have	O
respiratory	B-DISO
failure	I-DISO
compared	O
to	O
only	O
COPD	B-DISO
during	O
AECOPD	O
.	O

Metabolic	B-DISO
syndrome	I-DISO
was	O
recorded	O
in	O
2	O
/	O
36	O
(	O
5	O
.	O
3	O
%)	O
patients	O
in	O
only	O
COPD	B-DISO
and	O
6	O
/	O
13	O
(	O
46	O
.	O
2	O
%)	O
patients	O
in	O
overlap	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

It	O
is	O
feasible	O
that	O
severe	O
acidosis	B-DISO
,	O
hypotension	O
,	O
azotemia	B-DISO
,	O
hypoalbuminemia	O
and	O
the	O
superimposed	O
aggressive	B-DISO
intravenous	O
fluid	O
administration	O
were	O
important	O
risk	O
factors	O
for	O
the	O
development	O
of	O
cerebral	B-DISO
edema	I-DISO
and	O
ARDS	B-DISO
in	O
the	O
index	O
patient	O
.	O

TITLE	O
:	O
Open	O
Lung	O
Approach	O
for	O
the	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
:	O
A	O
Pilot	O
,	O
Randomized	O
Controlled	O
Trial	O
.	O

In	O
patients	O
with	O
established	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
open	O
lung	O
approach	O
improved	O
oxygenation	O
and	O
driving	O
pressure	O
,	O
without	O
detrimental	O
effects	O
on	O
mortality	O
,	O
ventilator	O
-	O
free	O
days	O
,	O
or	O
barotrauma	O
.	O

This	O
pilot	O
study	O
supports	O
the	O
need	O
for	O
a	O
large	O
,	O
multicenter	O
trial	O
using	O
recruitment	B-DISO
maneuvers	O
and	O
a	O
decremental	O
positive	O
end	O
-	O
expiratory	O
pressure	O
trial	O
in	O
persistent	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Both	O
Cyp	O
and	O
FKBP	O
have	O
peptidyl	O
-	O
prolyl	O
cis	B-DISO
-	O
trans	O
isomerase	O
(	O
PPIase	O
)	O
activity	O
.	O

VDR	O
knockout	O
mice	O
exhibited	O
severe	O
lung	O
injuries	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
increased	O
alveolar	O
permeability	O
[	O
demonstrated	O
by	O
a	O
higher	O
wet	O
‑	O
dry	O
ratio	O
of	O
lung	O
weight	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
greater	O
expression	O
levels	O
of	O
BALF	O
protein	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
fluorescein	O
isothiocyanate	O
‑	O
conjugated	O
4	O
kDa	O
dextran	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
leakage	B-DISO
into	O
the	O
alveolar	O
space	O
],	O
elevated	O
proinflammatory	O
cytokine	O
and	O
chemokine	O
mRNA	O
levels	O
,	O
as	O
demonstrated	O
by	O
reverse	O
transcription	O
‑	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
decreased	O
protein	O
and	O
mRNA	O
expression	O
levels	O
of	O
occludin	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
zonula	O
occludens	O
‑	O
1	O
(	O
ZO	O
‑	O
1	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
compared	O
with	O
WT	O
mice	O
.	O

ABSTRACT	O
:	O
Evidence	O
of	O
current	O
and	O
past	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
in	O
dromedary	O
camels	O
slaughtered	O
at	O
an	O
abattoir	O
in	O
Kano	O
,	O
Nigeria	O
in	O
January	O
2015	O
,	O
was	O
sought	O
by	O
reverse	O
transcription	O
-	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
qPCR	O
)	O
and	O
serology	O
.	O

Mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
infection	B-DISO
-	O
induced	O
demyelination	B-DISO
is	O
one	O
of	O
the	O
best	O
-	O
studied	O
experimental	O
animal	O
models	O
for	O
MS	O
.	O

More	O
specifically	O
,	O
alteration	O
of	O
Cx43	O
may	O
be	O
the	O
basis	O
of	O
the	O
destabilization	O
of	O
Cx47	O
in	O
oligodendrocytes	O
seen	O
in	O
and	O
around	O
inflammatory	O
demyelinating	O
plaques	B-DISO
in	O
MS	O
patients	O
.	O

ABSTRACT	O
:	O
Outbreaks	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	B-DISO
)	O
raise	O
questions	O
about	O
the	O
prevalence	O
and	O
evolution	O
of	O
the	O
MERS	B-DISO
coronavirus	O
(	O
CoV	O
)	O
in	O
its	O
animal	O
reservoir	O
.	O

TITLE	O
:	O
An	O
orthopoxvirus	O
-	O
based	O
vaccine	O
reduces	O
virus	O
excretion	O
after	O
MERS	O
-	O
CoV	O
infection	B-DISO
in	O
dromedary	O
camels	O
.	O

Compared	O
with	O
results	O
for	O
control	O
animals	O
,	O
we	O
observed	O
a	O
significant	O
reduction	O
of	O
excreted	O
infectious	B-DISO
virus	O
and	O
viral	O
RNA	O
transcripts	O
in	O
vaccinated	O
animals	O
upon	O
MERS	O
-	O
CoV	O
challenge	O
.	O

Protection	O
correlated	O
with	O
the	O
presence	O
of	O
serum	O
neutralizing	O
antibodies	O
to	O
MERS	O
-	O
CoV	O
.	O
Induction	O
of	O
MVA	O
-	O
specific	O
antibodies	O
that	O
cross	O
-	O
neutralize	O
camelpox	B-DISO
virus	O
would	O
also	O
provide	O
protection	O
against	O
camelpox	B-DISO
.	O

ABSTRACT	O
:	O
Middle	O
Eastern	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
has	O
spread	O
rapidly	O
across	O
much	O
of	O
the	O
Middle	O
East	O
,	O
but	O
no	O
quantitative	O
mapping	O
of	O
transmission	O
risk	O
has	O
been	O
developed	O
to	O
date	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
has	O
been	O
detected	O
sporadically	O
in	O
Italy	O
since	O
the	O
1990s	O
.	O

Other	O
coronaviruses	O
such	O
as	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
are	O
also	O
known	O
to	O
cause	O
major	O
disease	O
epidemics	O
in	O
animals	O
with	O
huge	O
economic	O
loss	O
.	O

TITLE	O
:	O
Multifacility	O
Outbreak	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
in	O
Taif	O
,	O
Saudi	O
Arabia	O
.	O

Circulation	O
persisted	O
in	O
multiple	O
healthcare	O
settings	O
over	O
an	O
extended	O
period	O
,	O
underscoring	O
the	O
importance	O
of	O
strengthening	O
MERS	O
-	O
CoV	O
surveillance	O
and	O
infection	B-DISO
-	O
control	O
practices	O
.	O

Using	O
multivariable	O
analysis	O
,	O
we	O
found	O
that	O
direct	O
exposure	O
to	O
dromedary	O
camels	O
during	O
the	O
2	O
weeks	O
before	O
illness	O
onset	O
,	O
as	O
well	O
as	O
diabetes	B-DISO
mellitus	I-DISO
,	O
heart	B-DISO
disease	I-DISO
,	O
and	O
smoking	O
,	O
were	O
each	O
independently	O
associated	O
with	O
MERS	O
-	O
CoV	O
illness	O
.	O

ABSTRACT	O
:	O
The	O
first	O
known	O
cases	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
),	O
associated	O
with	O
infection	B-DISO
by	O
a	O
novel	O
coronavirus	O
(	O
CoV	O
),	O
occurred	O
in	O
2012	O
in	O
Jordan	O
but	O
were	O
reported	O
retrospectively	O
.	O

When	O
the	O
xiamycins	O
were	O
tested	O
for	O
inhibitory	O
activity	O
on	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
xiamycin	O
D	O
(	O
2	O
)	O
showed	O
the	O
strongest	O
inhibitory	O
effect	O
on	O
PEDV	O
replication	O
(	O
EC50	O
=	O
0	O
.	O
93	O
μM	O
)	O
with	O
low	O
cytotoxicity	B-DISO
(	O
CC50	O
=	O
56	O
.	O
03	O
μM	O
),	O
thus	O
displaying	O
a	O
high	O
selective	O
index	O
(	O
60	O
.	O
31	O
).	O

For	O
the	O
limited	O
number	O
of	O
autopsy	O
reports	O
,	O
small	O
animal	O
models	O
are	O
urgently	O
needed	O
to	O
study	O
the	O
mechanisms	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
and	O
pathogenesis	B-DISO
of	O
the	O
disease	O
and	O
to	O
evaluate	O
the	O
efficacy	O
of	O
therapeutics	O
against	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

In	O
addition	O
,	O
the	O
mice	O
exhibited	O
systemic	O
inflammation	B-DISO
with	O
mild	O
to	O
severe	O
pneumonia	B-DISO
accompanied	O
by	O
the	O
injury	O
of	O
liver	O
,	O
kidney	O
and	O
spleen	O
with	O
neutrophil	O
and	O
macrophage	O
infiltration	B-DISO
.	O

Subjects	O
had	O
a	O
critical	O
ICU	O
course	O
and	O
required	O
neuromuscular	B-DISO
blockade	I-DISO
(	O
n	O
=	O
11	O
;	O
79	O
%),	O
required	O
rescue	O
therapy	O
for	O
respiratory	B-DISO
failure	I-DISO
(	O
n	O
=	O
8	O
;	O
57	O
%),	O
developed	O
shock	O
(	O
n	O
=	O
10	O
;	O
71	O
%),	O
and	O
required	O
renal	O
replacement	O
therapy	O
(	O
n	O
=	O
8	O
;	O
57	O
%).	O

ABSTRACT	O
:	O
Objectives	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
is	O
an	O
important	O
cause	O
of	O
death	O
in	O
the	O
cat	O
population	O
worldwide	O
.	O

In	O
cats	O
without	O
effusion	B-DISO
,	O
a	O
definitive	O
diagnosis	O
can	O
only	O
be	O
achieved	O
post	O
mortem	O
or	O
with	O
invasive	O
methods	O
.	O

Results	O
Specificity	O
of	O
RT	O
-	O
nPCR	O
was	O
100	O
%	O
in	O
all	O
materials	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
in	O
serum	O
/	O
plasma	O
83	O
.	O
9	O
-	O
100	O
.	O
0	O
;	O
95	O
%	O
CI	O
in	O
effusion	B-DISO
93	O
.	O
0	O
-	O
100	O
.	O
0	O
).	O

Conclusions	O
and	O
relevance	O
A	O
positive	O
result	O
is	O
highly	O
indicative	O
of	O
the	O
presence	O
of	O
FIP	B-DISO
,	O
but	O
as	O
none	O
of	O
the	O
control	O
cats	O
tested	O
positive	O
by	O
RT	O
-	O
nPCR	O
,	O
it	O
was	O
not	O
possible	O
to	O
confirm	O
that	O
the	O
FCoV	O
mutant	B-DISO
described	O
can	O
only	O
be	O
found	O
in	O
cats	O
with	O
FIP	B-DISO
.	O

The	O
pulmonary	O
functions	O
of	O
SARS	B-DISO
patents	O
largely	O
returned	O
to	O
normal	O
after	O
10	O
years	O
of	O
convalescence	O
,	O
and	O
the	O
lung	O
function	O
damage	O
was	O
characterized	O
by	O
diffusing	O
and	O
restrictive	O
ventilatory	O
dysfunctions	O
.	O

Management	O
of	O
IL	O
-	O
17	O
could	O
modulate	O
LPS	B-DISO
-	O
induced	O
pulmonary	B-DISO
inflammation	I-DISO
,	O
as	O
reflected	O
by	O
the	O
total	O
cell	O
and	O
neutrophil	O
counts	O
,	O
proinflammatory	O
cytokines	O
,	O
as	O
well	O
as	O
chemokines	O
in	O
BAL	O
fluid	O
.	O

Our	O
results	O
show	O
that	O
clinical	O
laboratories	O
play	O
an	O
important	O
role	O
in	O
the	O
maintenance	O
and	O
enhancement	O
of	O
laboratory	O
response	O
in	O
preparation	O
for	O
future	O
emerging	O
infections	B-DISO
.	O

Spatial	O
analysis	O
showed	O
that	O
PEDv	O
was	O
clustered	O
rather	O
than	O
randomly	O
distributed	O
,	O
which	O
suggested	O
that	O
sites	O
near	O
a	O
positive	O
site	O
had	O
increased	O
risk	O
of	O
acquiring	O
PEDv	O
infection	B-DISO
.	O

TITLE	O
:	O
Molecular	O
detection	O
of	O
bovine	O
coronavirus	O
in	O
a	O
diarrhea	B-DISO
outbreak	O
in	O
pasture	O
-	O
feeding	O
Nellore	O
steers	O
in	O
southern	O
Brazil	O
.	O

ABSTRACT	O
:	O
Some	O
cases	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
-	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
presented	O
renal	O
function	O
impairment	B-DISO
after	O
the	O
first	O
MERS	O
-	O
CoV	O
patient	O
died	O
of	O
progressive	O
respiratory	O
and	O
renal	B-DISO
failure	I-DISO
.	O

Diabetes	B-DISO
,	O
AKI	O
,	O
and	O
the	O
application	O
of	O
a	O
continuous	O
renal	O
replacement	O
therapy	O
(	O
CRRT	O
)	O
were	O
risk	O
factors	O
for	O
mortality	O
in	O
the	O
univariate	O
analysis	O
(	O
HR	O
[	O
95	O
%	O
CI	O
]:	O
diabetes	B-DISO
;	O
10	O
.	O
133	O
[	O
1	O
.	O
692	O
-	O
60	O
.	O
697	O
],	O
AKI	O
;	O
12	O
.	O
744	O
[	O
1	O
.	O
418	O
-	O
114	O
.	O
565	O
],	O
CRRT	O
;	O
10	O
.	O
254	O
[	O
1	O
.	O
626	O
-	O
64	O
.	O
666	O
],	O
respectively	O
).	O

Despite	O
no	O
detectable	O
pulmonary	B-DISO
metastases	I-DISO
,	O
acute	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
developed	O
,	O
requiring	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
).	O

Reduced	O
feed	O
uptake	O
and	O
occasional	O
diarrhea	B-DISO
were	O
observed	O
in	O
December	O
2014	O
in	O
a	O
group	O
of	O
fattening	O
pigs	O
,	O
kept	O
on	O
an	O
Austrian	O
swine	O
farm	O
.	O

TITLE	O
:	O
[	O
Epidemiological	O
characteristics	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
outbreak	O
in	O
the	O
Republic	O
of	O
Korea	O
,	O
2015	O
].	O

Besides	O
the	O
index	O
case	O
,	O
other	O
12	O
patients	O
were	O
reported	O
to	O
cause	O
secondary	O
cases	O
,	O
in	O
which	O
1	O
caused	O
84	O
infections	B-DISO
.	O

TITLE	O
:	O
Pathosphere	O
.	O
org	O
:	O
pathogen	O
detection	O
and	O
characterization	O
through	O
a	O
web	B-DISO
-	O
based	O
,	O
open	O
source	O
informatics	O
platform	O
.	O

TITLE	O
:	O
Airway	B-DISO
hyperreactivity	I-DISO
is	O
frequent	O
in	O
non	O
-	O
asthmatic	B-DISO
children	O
with	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
Postobstructive	O
pulmonary	B-DISO
edema	I-DISO
(	O
POPE	O
),	O
sudden	O
pulmonary	B-DISO
edema	I-DISO
after	O
upper	B-DISO
airway	I-DISO
obstruction	I-DISO
,	O
is	O
an	O
important	O
disease	O
entity	O
for	O
pediatric	O
emergency	B-DISO
physicians	O
to	O
recognize	O
and	O
initiate	O
prompt	O
treatment	O
.	O

Type	O
1	O
POPE	O
occurs	O
after	O
a	O
sudden	O
,	O
severe	O
upper	B-DISO
airway	I-DISO
obstruction	I-DISO
,	O
whereas	O
type	O
2	O
POPE	O
develops	O
after	O
acute	O
relief	O
of	O
chronic	O
airway	O
obstructive	O
.	O

ABSTRACT	O
:	O
A	O
30	O
year	O
-	O
old	O
Hispanic	O
man	O
with	O
no	O
significant	O
previous	O
medical	O
history	O
presented	O
with	O
refractory	O
hypoxemia	O
after	O
flu	B-DISO
-	I-DISO
like	I-DISO
symptoms	I-DISO
.	O

Because	O
of	O
progressive	O
hypoxemia	O
despite	O
appropriate	O
ventilator	O
strategies	O
,	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
VV	O
-	O
ECMO	O
)	O
was	O
initiated	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Of	O
the	O
396	O
,	O
449	O
older	O
patients	O
at	O
293	O
trauma	O
centres	O
that	O
met	O
inclusion	O
criteria	O
,	O
30	O
,	O
761	O
(	O
8	O
%)	O
suffered	B-DISO
a	O
MC	O
.	O

To	O
elucidate	O
the	O
pathogenesis	B-DISO
of	O
this	O
virus	O
and	O
investigate	O
mechanisms	O
underlying	O
disease	O
severity	O
variation	O
in	O
the	O
absence	O
of	O
autopsy	O
data	O
,	O
a	O
rhesus	O
macaque	O
and	O
common	O
marmoset	O
model	O
of	O
MERS	O
-	O
CoV	O
disease	O
were	O
analyzed	O
.	O

TITLE	O
:	O
The	O
first	O
case	O
of	O
the	O
2015	O
Korean	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
outbreak	O
.	O

Platelet	O
count	O
did	O
not	O
always	O
correlate	O
well	O
with	O
the	O
severity	O
of	O
bleeding	B-DISO
.	O

Infection	B-DISO
of	O
H9N2	O
on	O
HPMECs	O
induced	O
a	O
high	O
level	O
of	O
chemokines	O
and	O
cytokines	O
production	O
including	O
IP	O
-	O
10	O
,	O
RANTES	O
,	O
IL	O
-	O
6	O
,	O
IFN	O
-	O
β	O
and	O
IFN	O
-	O
γ1	O
.	O

The	O
conjugation	O
of	O
double	O
strand	O
probes	O
onto	O
polymeric	O
microgels	O
allows	O
for	O
a	O
sensitive	O
detection	O
of	O
DNA	O
sequences	O
from	O
HIV	B-DISO
,	O
HCV	O
and	O
SARS	B-DISO
corona	O
viruses	O
with	O
a	O
LOD	O
of	O
1	O
.	O
4	O
fM	O
,	O
3	O
.	O
7	O
fM	O
and	O
1	O
.	O
4	O
fM	O
,	O
respectively	O
,	O
and	O
with	O
a	O
dynamic	O
range	O
of	O
10	O
(-	O
9	O
)-	O
10	O
(-	O
15	O
)	O
M	O
.	O
Such	O
combination	O
enhances	O
the	O
sensitivity	O
of	O
the	O
detection	O
of	O
almost	O
five	O
orders	O
of	O
magnitude	O
when	O
compared	O
to	O
the	O
only	O
probe	O
.	O

Finally	O
,	O
overexpression	O
of	O
RNase	O
L	O
is	O
not	O
sufficient	O
to	O
compensate	O
for	O
inadequate	O
basal	O
OAS	B-DISO
levels	O
.	O

Thus	O
,	O
our	O
data	O
suggest	O
that	O
cells	O
with	O
high	O
basal	O
Oas	B-DISO
gene	O
expression	O
levels	O
can	O
activate	O
RNase	O
L	O
and	O
thereby	O
inhibit	O
virus	O
replication	O
early	O
in	O
infection	B-DISO
upon	O
exposure	O
to	O
viral	O
double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	O
)	O
before	O
the	O
induction	O
of	O
interferon	O
and	O
prior	O
to	O
transcription	O
of	O
interferon	O
-	O
stimulated	O
antiviral	O
genes	O
.	O

Clinical	B-DISO
findings	I-DISO
and	O
further	O
diagnostic	O
work	O
up	O
revealed	O
a	O
diagnosis	O
of	O
perimyocarditis	O
,	O
and	O
adequate	O
therapy	O
was	O
initiated	O
.	O

ABSTRACT	O
:	O
The	O
newly	O
emerging	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
encodes	O
the	O
conserved	O
macro	O
domain	O
within	O
non	O
-	O
structural	O
protein	O
3	O
.	O

Importantly	O
,	O
clinicians	O
should	O
test	O
for	O
pneumonia	B-DISO
in	O
all	O
suspected	O
patients	O
with	O
MERS	O
-	O
CoV	O
infection	B-DISO
,	O
even	O
in	O
the	O
absence	O
of	O
respiratory	B-DISO
symptoms	I-DISO
.	O

A	O
shorter	O
incubation	O
period	O
was	O
associated	O
with	O
more	O
severe	O
disease	O
and	O
greater	O
risk	O
of	O
mortality	O
,	O
and	O
the	O
severity	O
of	O
fever	O
predicted	O
the	O
prognosis	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
-	O
related	O
pneumonia	B-DISO
.	O

Therefore	O
,	O
in	O
cases	O
of	O
lower	O
-	O
lobe	O
pneumonia	B-DISO
that	O
occur	O
during	O
an	O
MERS	O
-	O
CoV	O
outbreak	O
and	O
are	O
unesponsive	O
to	O
antibiotics	O
,	O
clinicians	O
should	O
consider	O
the	O
possibility	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

Induction	O
of	O
sepsis	B-DISO
using	O
LPS	B-DISO
is	O
a	O
known	O
experimental	O
model	O
,	O
but	O
LPS	B-DISO
treatment	O
in	O
rats	O
does	O
not	O
cause	O
the	O
severe	O
endothelial	O
and	O
epithelial	O
injury	O
that	O
occurs	O
in	O
humans	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Eighteen	O
male	O
Beagles	O
were	O
studied	O
under	O
mechanical	O
ventilation	O
with	O
anesthesia	B-DISO
.	O

ARDS	B-DISO
was	O
defined	O
by	O
PaO2	O
/	O
FiO2	O
lower	O
than	O
200	O
mmHg	O
under	O
ventilation	O
with	O
at	O
least	O
10	O
cm	O
H2O	O
of	O
PEEP	O
and	O
a	O
FiO2	O
higher	O
or	O
equal	O
than	O
0	O
.	O
5	O
.	O

CONCLUSIONS	O
:	O
In	O
this	O
cohort	O
,	O
including	O
patients	O
with	O
severe	O
hypoxemia	O
and	O
high	O
percentage	O
of	O
mayor	O
co	O
-	O
morbidities	O
,	O
ARDS	B-DISO
associated	O
mortality	O
was	O
lower	O
than	O
some	O
previous	O
studies	O
.	O

HCoV	O
-	O
NL63	O
infection	B-DISO
was	O
identified	O
in	O
8	O
.	O
4	O
%	O
(	O
9	O
/	O
107	O
)	O
of	O
hospitalized	O
patients	O
with	O
pneumonia	B-DISO
,	O
but	O
not	O
found	O
in	O
outpatients	O
with	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
.	O

CONCLUSIONS	O
:	O
Understanding	O
epidemiology	O
of	O
HCoV	O
-	O
NL63	O
in	O
Taiwan	O
provides	O
an	O
insight	O
for	O
worldwide	O
surveillance	O
of	O
HCoV	O
-	O
NL63	O
infection	B-DISO
.	O

TITLE	O
:	O
Production	O
impact	O
&	O
time	O
to	O
stability	O
in	O
sow	O
herds	O
infected	O
with	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
).	O

TITLE	O
:	O
Adult	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
for	O
severe	O
respiratory	B-DISO
failure	I-DISO
:	O
Current	O
status	O
and	O
future	O
perspectives	O
.	O

Clinical	O
management	O
of	O
the	O
patient	O
includes	O
comprehensive	O
critical	O
care	O
addressing	O
sedation	B-DISO
and	O
neurologic	O
issues	O
,	O
ensuring	O
lung	O
recruitment	B-DISO
,	O
diuresis	O
,	O
early	O
enteral	O
nutrition	O
,	O
treatment	O
and	O
surveillance	O
of	O
infections	B-DISO
,	O
and	O
multisystem	O
organ	O
support	O
.	O

ABSTRACT	O
:	O
Acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
is	O
common	O
in	O
critically	B-DISO
ill	I-DISO
children	O
and	O
is	O
associated	O
with	O
poor	O
outcome	O
.	O

All	O
bacterial	O
,	O
viral	O
,	O
protozoan	O
,	O
and	O
parasitic	O
agents	O
here	O
investigated	O
,	O
with	O
the	O
exception	O
of	O
Salmonella	B-DISO
spp	O
.	O

Compound	O
showed	O
selective	O
anti	O
-	O
HIV	B-DISO
-	O
1	O
activity	O
thanks	O
to	O
its	O
ability	O
to	O
inhibit	O
the	O
reverse	O
transcriptase	O
.	O

Rapid	O
and	O
strong	O
stiffening	O
of	O
primary	O
neutrophils	O
and	O
monocytes	O
was	O
induced	O
within	O
30	O
minutes	O
(	O
mean	O
ET	O
>	O
50	O
seconds	O
)	O
by	O
sera	O
from	O
the	O
ARDS	B-DISO
group	O
compared	O
with	O
both	O
the	O
healthy	O
subjects	O
and	O
the	O
ACPE	O
groups	O
(	O
mean	O
ET	O
<	O
1	O
second	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Strong	O
stiffening	O
was	O
induced	O
by	O
IL	O
-	O
1β	O
,	O
IL	O
-	O
8	O
,	O
and	O
TNF	O
-	O
α	O
but	O
not	O
by	O
IL	O
-	O
10	O
,	O
and	O
incubations	O
with	O
sera	O
and	O
blocking	B-DISO
antibodies	O
against	O
IL	O
-	O
1β	O
,	O
IL	O
-	O
8	O
,	O
or	O
TNF	O
-	O
α	O
significantly	O
diminished	O
the	O
stiffening	O
effect	O
of	O
serum	O
.	O

RESULTS	O
:	O
Rapid	O
and	O
strong	O
stiffening	O
of	O
primary	O
neutrophils	O
and	O
monocytes	O
was	O
induced	O
within	O
30	O
minutes	O
(	O
mean	O
ET	O
>	O
50	O
seconds	O
)	O
by	O
sera	O
from	O
the	O
ARDS	B-DISO
group	O
compared	O
with	O
both	O
the	O
healthy	O
subjects	O
and	O
the	O
ACPE	O
groups	O
(	O
mean	O
ET	O
<	O
1	O
second	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Prior	O
studies	O
have	O
demonstrated	O
that	O
the	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
A59	O
strain	O
ns2	B-DISO
protein	O
is	O
a	O
member	O
of	O
the	O
2H	O
phosphoesterase	O
family	O
and	O
exhibits	O
2	O
',	O
5	O
'-	O
phosphodiesterase	O
(	O
PDE	B-DISO
)	O
activity	O
.	O

(	O
4	O
)	O
Positive	O
rates	O
of	O
HCoVs	O
infection	B-DISO
in	O
<	O
1	O
year	O
group	O
,	O
1	O
-	O
3	O
years	O
group	O
,	O
3	O
-	O
6	O
years	O
group	O
and	O
≥	O
6	O
years	O
group	O
were	O
4	O
.	O
13	O
%,	O
5	O
.	O
08	O
%,	O
2	O
.	O
71	O
%	O
and	O
1	O
.	O
23	O
%,	O
respectively	O
.	O

(	O
5	O
)	O
There	O
were	O
16	O
hospitalized	O
cases	O
with	O
single	O
infection	B-DISO
of	O
HCoVs	O
in	O
this	O
study	O
,	O
of	O
which	O
12	O
cases	O
were	O
diagnosed	O
as	O
bronchopneumonia	B-DISO
,	O
3	O
cases	O
developed	O
acute	O
laryngeal	B-DISO
obstruction	I-DISO
,	O
2	O
cases	O
had	O
acute	O
bronchial	B-DISO
asthma	I-DISO
attack	O
.	O

TITLE	O
:	O
Hospitalised	O
Malaysian	O
children	O
with	O
pandemic	O
(	O
H1N1	O
)	O
2009	O
influenza	B-DISO
:	O
clinical	O
characteristics	O
,	O
risk	O
factors	O
for	O
severe	O
disease	O
and	O
comparison	O
with	O
the	O
2002	O
-	O
2007	O
seasonal	O
influenza	B-DISO
.	O

PEDV	O
nsp1	O
did	O
not	O
interfere	O
the	O
IRF3	O
phosphorylation	O
and	O
nuclear	O
translocation	B-DISO
but	O
interrupted	O
the	O
enhanceosome	O
assembly	O
of	O
IRF3	O
and	O
CREB	O
-	O
binding	O
protein	O
(	O
CBP	O
)	O
by	O
degrading	O
CBP	O
.	O

ABSTRACT	O
:	O
This	O
study	O
reports	O
the	O
results	O
of	O
a	O
systematic	O
screening	O
for	O
respiratory	O
viruses	O
in	O
pediatric	O
outpatients	O
from	O
an	O
emergency	B-DISO
department	O
(	O
ED	O
)	O
in	O
southern	O
Brazil	O
during	O
two	O
consecutive	O
influenza	B-DISO
seasons	O
.	O

Further	O
,	O
the	O
presence	O
of	O
asthma	B-DISO
(	O
OR	O
,	O
3	O
.	O
17	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
86	O
-	O
5	O
.	O
46	O
)	O
was	O
independently	O
associated	O
with	O
HRV	O
infection	B-DISO
,	O
whereas	O
fever	O
was	O
associated	O
with	O
AdV	O
(	O
OR	O
,	O
3	O
.	O
86	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
31	O
-	O
16	O
.	O
52	O
)	O
and	O
influenza	B-DISO
infections	B-DISO
(	O
OR	O
,	O
3	O
.	O
74	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
26	O
-	O
16	O
.	O
06	O
).	O

We	O
undertook	O
a	O
systematic	O
review	O
to	O
assess	O
the	O
evidence	O
that	O
air	O
,	O
ground	O
and	O
sea	O
mass	O
transportation	O
systems	O
or	O
hubs	O
are	O
associated	O
with	O
propagating	O
influenza	B-DISO
and	O
coronaviruses	O
.	O

A	O
paucity	O
of	O
evidence	O
was	O
identified	O
describing	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
transmission	O
events	O
associated	O
with	O
transportation	O
systems	O
or	O
hubs	O
.	O

Air	O
transportation	O
appears	O
important	O
in	O
accelerating	O
and	O
amplifying	O
influenza	B-DISO
propagation	O
.	O

Our	O
study	O
evaluates	O
the	O
accuracy	O
of	O
this	O
method	O
in	O
subjects	O
with	O
respiratory	B-DISO
failure	I-DISO
according	O
to	O
the	O
severity	O
of	O
hypercapnia	B-DISO
.	O

Infections	B-DISO
by	O
these	O
emerging	O
human	O
coronaviruses	O
are	O
characterized	O
by	O
less	O
robust	O
interferon	O
production	O
.	O

This	O
review	O
focuses	O
on	O
the	O
fierce	O
arms	B-DISO
race	O
between	O
host	O
innate	O
antiviral	O
immunity	O
and	O
emerging	O
human	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
Most	O
cases	O
of	O
severe	O
influenza	B-DISO
are	O
associated	O
with	O
pulmonary	B-DISO
complications	I-DISO
,	O
such	O
as	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
and	O
no	O
antiviral	O
drugs	O
of	O
proven	O
value	O
for	O
treating	O
such	O
complications	O
are	O
currently	O
available	O
.	O

However	O
,	O
the	O
mechanisms	O
of	O
action	O
of	O
these	O
antibodies	O
are	O
not	O
fully	O
understood	O
,	O
and	O
their	O
ability	O
to	O
mitigate	O
severe	O
complications	O
of	O
influenza	B-DISO
has	O
been	O
poorly	O
studied	O
.	O

TITLE	O
:	O
Clinical	O
and	O
laboratory	O
outcomes	O
after	O
umbilical	O
cord	B-DISO
blood	O
transplantation	O
in	O
a	O
patient	O
with	O
mucolipidosis	B-DISO
II	I-DISO
alpha	I-DISO
/	I-DISO
beta	I-DISO
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
:	O
a	O
comprehensive	O
review	O
.	O

During	O
coronavirus	O
encephalomyelitis	B-DISO
CXCL13	O
deficiency	O
impaired	B-DISO
CNS	O
accumulation	O
of	O
memory	O
B	O
cells	O
and	O
antibody	O
-	O
secreting	O
cells	O
(	O
ASC	O
)	O
but	O
not	O
naïve	O
/	O
early	O
-	O
activated	O
B	O
cells	O
.	O

Consequently	O
,	O
998	O
cases	O
(	O
43	O
.	O
3	O
%)	O
were	O
classified	O
as	O
MAP	O
,	O
937	O
cases	O
(	O
40	O
.	O
7	O
%)	O
as	O
moderately	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
(	O
MSAP	O
),	O
370	O
cases	O
(	O
16	O
.	O
1	O
%)	O
as	O
SAP	O
.	O

The	O
incidence	O
of	O
respiratory	B-DISO
failure	I-DISO
was	O
lower	O
than	O
that	O
of	O
the	O
old	O
standard	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
-	O
Coronavirus	B-DISO
Infection	I-DISO
:	O
A	O
Case	O
Report	O
of	O
Serial	O
Computed	O
Tomographic	O
Findings	O
in	O
a	O
Young	O
Male	O
Patient	O
.	O

The	O
other	O
four	O
coinfections	B-DISO
were	O
caused	O
by	O
:	O
adenovirus	B-DISO
and	O
hCoVOC43	O
,	O
adenovirus	B-DISO
,	O
and	O
rhinovirus	O
,	O
RSV	O
A	O
and	O
PIV	O
-	O
1	O
,	O
influenza	B-DISO
B	O
,	O
and	O
RSV	O
B	O
.	O
We	O
did	O
not	O
observe	O
any	O
significant	O
differences	O
in	O
the	O
clinical	O
course	O
of	O
infections	B-DISO
caused	O
either	O
by	O
a	O
single	O
or	O
multiple	O
viral	O
factors	O
.	O

Soon	O
after	O
the	O
deadly	O
disease	O
outbreak	O
,	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
was	O
identified	O
as	O
a	O
functional	O
cellular	O
receptor	O
in	O
vitro	O
and	O
in	O
vivo	O
for	O
SARS	B-DISO
-	O
CoV	O
spike	O
protein	O
.	O

Moreover	O
,	O
flow	O
cytometry	O
data	O
demonstrated	O
an	O
increase	O
of	O
the	O
cell	O
surface	O
vimentin	O
level	O
by	O
16	O
.	O
5	O
%	O
after	O
SARS	B-DISO
-	O
CoV	O
permissive	O
Vero	O
E6	O
cells	O
were	O
treated	O
with	O
SARS	B-DISO
-	O
CoV	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
).	O

TITLE	O
:	O
Can	O
lung	O
ultrasonography	O
predict	O
prone	O
positioning	O
response	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
?	O

TITLE	O
:	O
Epidemiology	O
of	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
Following	O
Hematopoietic	O
Stem	O
Cell	O
Transplantation	O
.	O

ABSTRACT	O
:	O
Pulmonary	B-DISO
complications	I-DISO
are	O
common	O
following	O
hematopoietic	O
stem	O
cell	O
transplantation	O
.	O

Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
adjudication	O
was	O
performed	O
in	O
accordance	O
with	O
the	O
2012	O
Berlin	O
criteria	O
.	O

A	O
total	O
of	O
44	O
patients	O
with	O
ARDS	B-DISO
from	O
October	O
2012	O
to	O
June	O
2014	O
admitted	O
in	O
the	O
Second	O
Affiliated	O
Hospital	O
of	O
Wenzhou	O
Medical	O
University	O
were	O
recruited	O
in	O
this	O
study	O
.	O

According	O
to	O
the	O
severity	O
,	O
patients	O
were	O
divided	O
into	O
three	O
groups	O
(	O
Mild	O
group	O
,	O
Moderate	O
group	O
and	O
Severe	O
group	O
);	O
the	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
system	O
II	O
score	O
(	O
APACHE	O
II	O
),	O
the	O
lung	O
injury	O
score	O
(	O
LIS	O
),	O
the	O
pulse	O
contour	O
curve	O
continuous	O
cardiac	O
output	O
(	O
PiCCO	O
)	O
and	O
other	O
clinical	O
indicators	O
were	O
respectively	O
monitored	O
in	O
the	O
period	O
of	O
24	O
,	O
48	O
,	O
72	O
hrs	B-DISO
after	O
admission	O
;	O
then	O
the	O
correlation	O
of	O
EVLWI	O
,	O
PVPI	O
and	O
oxygenation	O
index	O
(	O
OI	O
)	O
among	O
groups	O
were	O
analyzed	O
;	O
According	O
to	O
the	O
prognosis	O
,	O
patients	O
were	O
divided	O
into	O
the	O
survival	O
group	O
and	O
the	O
death	O
group	O
,	O
both	O
given	O
the	O
univariate	O
and	O
multivariate	O
Logistic	O
regression	O
analysis	O
;	O
EVLWI	O
,	O
PVPI	O
,	O
APACHE	O
II	O
score	O
,	O
LIS	O
and	O
lactic	O
acid	O
were	O
admitted	O
into	O
the	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curve	O
analysis	O
,	O
and	O
the	O
prognosis	O
was	O
evaluated	O
respectively	O
.	O

EVLWI	O
,	O
PVPI	O
were	O
positively	O
correlated	O
with	O
the	O
severity	O
of	O
ARDS	B-DISO
illness	O
;	O
EVLWI	O
can	O
be	O
used	O
as	O
an	O
independent	O
risk	O
factor	O
for	O
forecasting	O
ARDS	B-DISO
death	O
,	O
jointing	O
EVLWI	O
with	O
PVPI	O
could	O
improve	O
the	O
accuracy	O
of	O
ARDS	B-DISO
death	O
forecasting	O
.	O

Compared	O
with	O
baseline	O
,	O
after	O
guiding	O
MV	O
with	O
Ptp	B-DISO
,	O
the	O
Level	O
of	O
PEEP	O
(	O
14	O
.	O
6	O
±	O
4	O
.	O
2	O
)	O
cmH2O	O
vs	O
(	O
8	O
.	O
3	O
±	O
2	O
.	O
0	O
)	O
cmH2O	O
,	O
and	O
Ptp	B-DISO
-	O
e	O
(	O
1	O
.	O
5	O
±	O
0	O
.	O
5	O
)	O
cmH2O	O
vs	O
(-	O
2	O
.	O
3	O
±	O
1	O
.	O
4	O
)	O
cmH2O	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
Ptp	B-DISO
-	O
i	O
did	O
not	O
increase	O
significantly	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

Transpulmonary	O
pressure	O
-	O
directed	O
mechanical	O
ventilation	O
in	O
ARDS	B-DISO
secondary	O
to	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
patient	O
with	O
intraabdominal	B-DISO
hypertension	I-DISO
could	O
not	O
only	O
recruit	O
the	O
collapsed	O
alveoli	O
,	O
improve	O
lung	O
compliance	O
,	O
increase	O
oxygenation	O
index	O
and	O
decrease	O
dead	O
space	O
ventilation	O
but	O
also	O
monitor	O
lung	O
stress	O
to	O
avoid	O
alveoli	O
overinflation	O
,	O
which	O
might	O
be	O
lung	O
protective	O
.	O

Amongst	O
intubated	O
blunt	O
trauma	O
patients	O
with	O
confirmed	O
pulmonary	O
contusions	O
diagnosis	O
,	O
an	O
initial	O
chest	O
radiograph	O
that	O
reveals	O
immediate	O
pulmonary	O
contusion	O
is	O
associated	O
with	O
higher	O
mortality	O
and	O
ARDS	B-DISO
compared	O
with	O
the	O
absence	O
of	O
such	O
findings	O
.	O

In	O
multivariable	O
analyses	O
controlling	O
for	O
injury	O
severity	O
,	O
age	O
,	O
sex	O
and	O
head	O
injury	O
,	O
the	O
CXR	O
+	O
group	O
was	O
associated	O
with	O
significantly	O
increased	O
odds	O
of	O
mortality	O
and	O
ARDS	B-DISO
(	O
odds	O
ratio	O
for	O
CXR	O
+	O
vs	O
.	O
CXR	O
-	O
4	O
.	O
19	O
,	O
95	O
%	O
CI	O
1	O
.	O
54	O
-	O
11	O
.	O
45	O
,	O
p	O
<	O
0	O
.	O
01	O
).	O

The	O
analysis	O
of	O
risk	O
factors	O
of	O
associative	O
pathology	B-DISO
development	O
,	O
roentgenographic	O
study	O
,	O
investigation	O
of	O
the	O
function	O
of	O
external	O
respiration	O
(	O
FER	O
)	O
(	O
peak	O
flowmetry	O
,	O
spirometry	O
),	O
intracavitary	O
pH	O
-	O
metry	O
,	O
esophagofibrogastroduodenoscopy	O
(	O
EFGDS	O
)	O
and	O
ultrasonic	O
investigation	O
(	O
USI	O
)	O
of	O
the	O
organs	O
of	O
the	O
gastro	O
-	O
intestinal	O
tract	O
(	O
GIT	O
)	O
were	O
carried	O
out	O
.	O

RESULTS	O
:	O
Diseases	O
of	O
the	O
respiratory	O
organs	O
with	O
BOS	B-DISO
in	O
the	O
groups	O
of	O
the	O
patients	O
under	O
investigation	O
in	O
43	O
.	O
9	O
%	O
of	O
cases	O
on	O
an	O
average	O
associated	O
with	O
GERD	B-DISO
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
analyze	O
the	O
current	O
information	O
on	O
potentially	O
useful	O
prognostic	O
scales	O
and	O
markers	O
in	O
the	O
early	O
stage	O
of	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
.	O

Especially	O
patients	O
with	O
mild	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
seem	O
to	O
benefit	O
from	O
preserved	O
spontaneous	O
breathing	O
.	O

While	O
completely	O
disabling	O
spontaneous	O
ventilation	O
with	O
or	O
without	O
neuromuscular	B-DISO
blockade	I-DISO
is	O
not	O
a	O
standard	O
strategy	O
in	O
ARDS	B-DISO
,	O
it	O
might	O
be	O
temporarily	O
required	O
in	O
patients	O
with	O
severe	O
ARDS	B-DISO
,	O
who	O
have	O
substantial	O
dyssynchrony	O
or	O
persistent	O
hypoxaemia	O
.	O

ABSTRACT	O
:	O
Neuromuscular	O
blocking	B-DISO
agents	O
and	O
corticosteroids	O
are	O
widely	O
used	O
in	O
medicine	O
and	O
in	O
particular	O
in	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
).	O

TITLE	O
:	O
Detection	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
strains	O
similar	O
to	O
Japan	O
in	O
Taiwan	O
.	O

Since	O
many	O
virological	O
and	O
immunological	O
data	O
on	O
FECV	O
infections	B-DISO
are	O
lacking	O
,	O
the	O
present	O
study	O
investigated	O
these	O
missing	O
links	O
during	O
experimental	O
infection	B-DISO
of	O
three	O
SPF	O
cats	O
with	O
FECV	O
strain	O
UCD	O
.	O

Two	O
cats	O
showed	O
mild	O
clinical	O
signs	O
,	O
faecal	O
shedding	O
of	O
infectious	B-DISO
virus	O
from	O
4	O
dpi	O
,	O
a	O
cell	O
-	O
associated	O
viraemia	B-DISO
at	O
inconsistent	O
time	O
points	O
from	O
5	O
dpi	O
,	O
a	O
highly	O
neutralising	O
antibody	O
response	O
from	O
9	O
dpi	O
,	O
and	O
no	O
major	O
abnormalities	O
in	O
leukocyte	O
numbers	O
.	O

There	O
is	O
substantial	O
evidence	O
that	O
the	O
recent	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)-	O
CoV	O
outbreak	O
is	O
fueled	O
by	O
zoonotic	O
transmission	O
from	O
dromedary	O
camels	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
clinical	O
and	O
radiographic	O
changes	O
of	O
rhesus	O
monkeys	O
following	O
infection	B-DISO
with	O
5	O
×	O
10	O
(	O
6	O
)	O
PFU	O
MERS	O
-	O
CoV	O
Jordan	O
-	O
n3	O
/	O
2012	O
.	O

This	O
paper	O
reports	O
on	O
the	O
first	O
molecular	O
characterization	O
of	O
human	O
Coronaviruses	O
in	O
Kenya	O
,	O
which	O
play	O
an	O
important	O
role	O
in	O
causing	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
among	O
children	O
.	O

Acute	B-DISO
pancreatitis	I-DISO
was	O
induced	O
in	O
rats	O
with	O
repetitive	O
injections	O
of	O
cerulein	O
(	O
50	O
µg	O
/	O
kg	O
/	O
h	O
)	O
and	O
a	O
shot	O
of	O
lipopolysaccharide	O
(	O
7	O
.	O
5	O
mg	O
/	O
kg	O
).	O

TITLE	O
:	O
Small	O
interfering	O
RNA	O
expression	O
inhibits	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
replication	O
and	O
inflammatory	B-DISO
response	I-DISO
.	O

Expression	O
of	O
inflammatory	O
cytokines	O
,	O
Mx	O
protein	O
and	O
nitric	O
oxide	O
levels	O
were	O
lower	O
in	O
early	O
IBV	O
infection	B-DISO
in	O
Tg	O
.	O

The	O
inflammatory	B-DISO
responses	I-DISO
indicate	O
that	O
the	O
cellular	O
immune	O
response	O
is	O
most	O
effective	O
during	O
the	O
initial	O
stage	O
,	O
while	O
the	O
humoral	O
immune	O
response	O
is	O
more	O
significant	O
in	O
later	O
stages	O
of	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Attenuated	O
Salmonella	B-DISO
typhimurium	O
(	O
S	O
.	O
typhimurium	O
)	O
was	O
selected	O
as	O
a	O
transgenic	O
vehicle	O
for	O
the	O
development	O
of	O
live	O
mucosal	O
vaccines	O
against	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
based	O
on	O
the	O
M	O
gene	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
pathogenicity	O
differences	O
of	O
the	O
US	O
PEDV	O
prototype	O
and	O
S	O
-	O
INDEL	O
-	O
variant	O
strains	O
in	O
conventional	O
neonatal	O
piglets	O
under	O
experimental	O
infections	B-DISO
.	O

During	O
the	O
outbreak	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
the	O
Republic	O
of	O
Korea	O
in	O
2015	O
,	O
serious	O
challenges	O
emerged	O
regarding	O
important	O
ethical	O
issues	O
,	O
such	O
as	O
transparency	O
and	O
the	O
protection	O
of	O
privacy	O
.	O

The	O
MERS	O
-	O
CoV	O
epidemic	O
in	O
Korea	O
created	O
significant	O
public	O
support	O
for	O
more	O
aggressive	B-DISO
early	O
interventions	O
in	O
future	O
outbreaks	O
.	O

The	O
vast	O
majority	O
of	O
viral	O
respiratory	B-DISO
infections	I-DISO
in	O
pilgrims	O
returning	O
home	O
have	O
been	O
due	O
to	O
seasonal	O
influenza	B-DISO
viruses	O
,	O
rhinoviruses	O
,	O
and	O
other	O
known	O
coronaviruses	O
distinct	O
from	O
the	O
MERS	O
coronavirus	O
.	O

They	O
appreciated	O
recognition	O
of	O
their	O
efforts	O
by	O
hospital	O
management	O
and	O
expected	O
similar	O
acknowledgment	O
,	O
infection	B-DISO
control	O
guidance	O
,	O
and	O
equipment	O
would	O
entice	O
them	O
to	O
work	O
during	O
future	O
epidemics	O
.	O

TITLE	O
:	O
Veno	O
-	O
veno	O
-	O
arterial	O
ECMO	O
support	O
for	O
acute	B-DISO
myocarditis	I-DISO
combined	O
with	O
ARDS	B-DISO
:	O
a	O
case	O
report	O
.	O

ABSTRACT	O
:	O
In	O
patients	O
who	O
developed	O
a	O
combined	O
situation	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
with	O
refractory	O
hypoxemia	O
and	O
acute	B-DISO
cardiac	I-DISO
failure	I-DISO
with	O
circulatory	B-DISO
collapse	I-DISO
,	O
traditional	O
veno	O
-	O
venous	O
or	O
veno	O
-	O
arterial	O
extracorporeal	O
membrane	O
oxygenation	O
approach	O
alone	O
may	O
not	O
be	O
sufficient	O
enough	O
to	O
maintain	O
both	O
an	O
acceptable	O
range	O
of	O
gas	O
exchange	O
and	O
a	O
hemodynamic	O
stability	O
.	O

TITLE	O
:	O
Therapeutic	O
effect	O
of	O
anti	O
-	O
feline	O
TNF	O
-	O
alpha	O
monoclonal	O
antibody	O
for	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
.	O

ABSTRACT	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
)	O
replication	O
in	O
macrophages	O
/	O
monocytes	O
induced	O
tumor	B-DISO
necrosis	I-DISO
factor	O
(	O
TNF	O
)-	O
alpha	O
production	O
,	O
and	O
that	O
the	O
TNF	O
-	O
alpha	O
produced	O
was	O
involved	O
in	O
aggravating	O
the	O
pathology	B-DISO
of	O
FIP	B-DISO
.	O

A	O
derivative	O
was	O
created	O
,	O
additionally	O
harboring	O
the	O
TAM	B-DISO
K70R	O
and	O
the	O
reversions	O
M151Q	O
as	O
well	O
as	O
R65K	O
since	O
K65R	O
antagonizes	O
excision	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
clinical	O
course	O
and	O
outcomes	O
of	O
liver	O
functions	O
in	O
children	O
with	O
dengue	B-DISO
viral	B-DISO
infection	I-DISO
-	O
caused	O
acute	B-DISO
liver	I-DISO
failure	I-DISO
(	O
ALF	O
),	O
the	O
records	O
of	O
patients	O
aged	O
<	O
15	O
years	O
attending	O
our	O
institution	O
during	O
1989	O
-	O
2011	O
were	O
reviewed	O
.	O

(	O
Saururaceae	O
)	O
and	O
three	O
of	O
its	O
constituent	O
flavonoids	O
(	O
quercetin	O
,	O
quercitrin	O
and	O
rutin	O
)	O
against	O
murine	O
coronavirus	O
and	O
dengue	B-DISO
virus	O
(	O
DENV	O
).	O

When	O
quercetin	O
was	O
combined	O
with	O
quercitrin	O
,	O
enhancement	O
of	O
anti	O
-	O
DENV	O
-	O
2	O
activity	O
and	O
reduced	O
cytotoxicity	B-DISO
were	O
observed	O
.	O

After	O
retrieving	O
163	O
,	O
433	O
news	O
records	O
mentioning	O
the	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
H1N1	O
pandemics	O
,	O
a	O
maximum	O
entropy	O
model	O
for	O
inductive	O
machine	O
learning	O
was	O
used	O
to	O
identify	O
relationships	O
among	O
500	O
randomly	O
sampled	O
news	O
records	O
that	O
correlated	O
with	O
systematic	O
human	O
assessments	O
of	O
their	O
scientific	O
quality	O
and	O
sensationalism	O
.	O

Despite	O
high	O
incidence	O
,	O
HCoV	O
infections	B-DISO
are	O
grossly	O
understudied	O
.	O

We	O
here	O
report	O
a	O
case	O
of	O
HCoV	O
infection	B-DISO
in	O
a	O
leukemia	B-DISO
patient	O
with	O
fatal	O
ARDS	B-DISO
despite	O
successful	O
virus	O
elimination	O
by	O
pegylated	O
interferon	O
-	O
alpha	O
(	O
PEG	O
-	O
IFN	O
-	O
α	O
).	O

Evidence	O
of	O
chronic	B-DISO
disease	I-DISO
,	O
including	O
severe	O
peripheral	B-DISO
vascular	I-DISO
disease	I-DISO
,	O
patchy	O
cardiac	B-DISO
fibrosis	I-DISO
,	O
and	O
hepatic	B-DISO
steatosis	I-DISO
,	O
was	O
noted	O
in	O
the	O
other	O
organs	O
.	O

Primary	O
pulmonary	O
Kaposi	B-DISO
sarcoma	I-DISO
(	O
KS	B-DISO
)	O
without	O
mucocutaneous	O
involvement	O
accounts	O
for	O
only	O
0	O
-	O
15	O
%	O
of	O
all	O
AIDS	O
-	O
related	O
KS	B-DISO
.	O

This	O
case	O
underscores	O
the	O
importance	O
of	O
plasma	O
RNA	O
test	O
in	O
conjunction	O
with	O
HIV	B-DISO
antibody	O
test	O
for	O
some	O
rare	O
patients	O
with	O
HIV	B-DISO
infection	I-DISO
who	O
present	O
with	O
severe	O
immunodeficiency	B-DISO
and	O
opportunistic	B-DISO
infections	I-DISO
or	O
malignancy	B-DISO
.	O

ABSTRACT	O
:	O
Dysregulated	O
type	O
I	O
interferon	O
(	O
IFN	O
-	O
I	O
)	O
expression	O
can	O
lead	O
to	O
severe	O
pathology	B-DISO
and	O
disease	O
.	O

TITLE	O
:	O
Dysregulated	O
Type	O
I	O
Interferon	O
and	O
Inflammatory	O
Monocyte	O
-	O
Macrophage	O
Responses	O
Cause	O
Lethal	O
Pneumonia	B-DISO
in	O
SARS	B-DISO
-	O
CoV	O
-	O
Infected	O
Mice	O
.	O

However	O
,	O
the	O
factors	O
leading	O
to	O
lung	O
pathology	B-DISO
are	O
not	O
well	O
understood	O
.	O

Genetic	O
ablation	O
of	O
the	O
IFN	O
-	O
αβ	O
receptor	O
(	O
IFNAR	O
)	O
or	O
IMM	O
depletion	O
protects	O
mice	O
from	O
lethal	O
infection	B-DISO
,	O
without	O
affecting	O
viral	O
load	O
.	O

Of	O
102	O
cases	O
of	O
severe	O
CAP	B-DISO
,	O
samples	O
were	O
obtained	O
in	O
91	O
cases	O
and	O
48	O
(	O
52	O
.	O
7	O
%)	O
were	O
positive	O
for	O
respiratory	O
viruses	O
.	O

ABSTRACT	O
:	O
Rheumatic	B-DISO
diseases	I-DISO
are	O
commonly	O
considered	O
chronic	O
conditions	O
.	O

This	O
aim	O
of	O
this	O
paper	O
is	O
to	O
overview	O
emergency	B-DISO
situations	O
which	O
can	O
be	O
encountered	O
in	O
the	O
care	O
of	O
patients	O
with	O
autoimmune	B-DISO
systemic	O
diseases	O
and	O
vasculitides	B-DISO
.	O

Although	O
the	O
clinical	O
presentation	O
of	O
human	O
MERS	O
-	O
CoV	O
infection	B-DISO
has	O
been	O
documented	O
,	O
many	O
facets	O
of	O
this	O
emerging	O
disease	O
are	O
still	O
unknown	O
and	O
could	O
be	O
studied	O
with	O
animal	O
models	O
.	O

These	O
molecules	O
are	O
able	O
to	O
directly	O
inhibit	O
many	O
viruses	O
such	O
as	O
Human	B-DISO
Immunodeficiency	I-DISO
Virus	I-DISO
(	O
HIV	B-DISO
),	O
Hepatitis	B-DISO
C	I-DISO
Virus	O
(	O
HCV	O
),	O
Dengue	B-DISO
Virus	O
,	O
Ebola	O
Virus	O
or	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Coronavirus	O
through	O
binding	O
to	O
envelope	O
protein	O
N	O
-	O
glycans	O
.	O

ABSTRACT	O
:	O
The	O
International	O
Society	O
for	O
Influenza	B-DISO
and	O
other	O
Respiratory	O
Virus	B-DISO
Diseases	I-DISO
(	O
isirv	O
)	O
held	O
its	O
4th	O
Antiviral	O
Group	O
Conference	O
at	O
the	O
University	O
of	O
Texas	O
on	O
2	O
-	O
4	O
June	O
,	O
2015	O
.	O

Therapies	O
for	O
rhinoviruses	O
and	O
MERS	O
and	O
SARS	B-DISO
coronaviruses	O
were	O
also	O
discussed	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
(	O
IB	O
)	O
and	O
Newcastle	B-DISO
disease	I-DISO
(	O
ND	O
)	O
are	O
common	O
viral	B-DISO
diseases	I-DISO
of	O
chickens	O
,	O
which	O
are	O
caused	O
by	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
and	O
Newcastle	B-DISO
disease	I-DISO
virus	O
(	O
NDV	O
),	O
respectively	O
.	O

ABSTRACT	O
:	O
The	O
SARS	B-DISO
3C	O
-	O
like	O
proteinase	O
(	O
SARS	B-DISO
-	O
3CLpro	O
),	O
which	O
is	O
the	O
main	O
proteinase	O
of	O
the	O
SARS	B-DISO
coronavirus	O
,	O
is	O
essential	O
to	O
the	O
virus	O
life	O
cycle	O
.	O

These	O
inhibitors	O
showed	O
protease	O
selectivity	O
and	O
no	O
cytotoxicity	B-DISO
.	O

ABSTRACT	O
:	O
1	O
.	O
Malaria	B-DISO
is	O
the	O
tropical	B-DISO
disease	I-DISO
most	O
commonly	O
imported	O
into	O
the	O
UK	O
,	O
with	O
1300	O
-	O
1800	O
cases	O
reported	O
each	O
year	O
,	O
and	O
2	O
-	O
11	O
deaths	O
.	O

Malaria	B-DISO
in	O
children	O
(	O
and	O
sometimes	O
in	O
adults	O
)	O
may	O
present	O
with	O
misleading	O
symptoms	O
such	O
as	O
gastrointestinal	O
features	O
,	O
sore	B-DISO
throat	I-DISO
or	O
lower	O
respiratory	O
complaints	O
.	O

Uncomplicated	O
falciparum	B-DISO
malaria	I-DISO
in	O
the	O
second	O
and	O
third	O
trimester	O
of	O
pregnancy	O
should	O
be	O
treated	O
with	O
artemether	O
-	O
lumefantrine	O
(	O
Grade	O
2B	O
).	O

Uncomplicated	O
falciparum	B-DISO
malaria	I-DISO
in	O
the	O
first	O
trimester	O
of	O
pregnancy	O
should	O
usually	O
be	O
treated	O
with	O
quinine	O
and	O
clindamycin	O
but	O
specialist	O
advice	O
should	O
be	O
sought	O
.	O

Tie2	O
expression	O
declined	O
rapidly	O
in	O
wide	O
-	O
ranging	O
models	O
of	O
leak	O
-	O
associated	O
infections	B-DISO
,	O
including	O
anthrax	B-DISO
,	O
influenza	B-DISO
,	O
malaria	B-DISO
,	O
and	O
sepsis	B-DISO
.	O

Forced	O
Tie2	O
suppression	B-DISO
sufficed	O
to	O
attenuate	O
barrier	O
function	O
and	O
sensitize	O
endothelium	O
to	O
permeability	O
mediators	O
.	O

Compared	O
with	O
wild	O
-	O
type	O
littermates	O
,	O
mice	O
possessing	O
one	O
allele	O
of	O
Tie2	O
suffered	B-DISO
more	O
severe	O
vascular	O
leakage	B-DISO
and	O
higher	O
mortality	O
in	O
two	O
different	O
sepsis	B-DISO
models	O
.	O

Together	O
,	O
the	O
results	O
implicate	O
common	O
genetic	O
variation	O
at	O
the	O
TIE2	O
locus	O
as	O
a	O
determinant	O
of	O
vascular	O
leak	O
-	O
related	O
clinical	O
outcomes	O
from	O
common	O
infections	B-DISO
,	O
suggesting	O
new	O
tools	O
to	O
identify	O
individuals	O
at	O
unusual	O
risk	O
for	O
deleterious	O
complications	O
of	O
infection	B-DISO
.	O

At	O
least	O
one	O
respiratory	O
tract	O
pathogen	O
was	O
detected	O
by	O
polymerase	O
chain	O
reaction	O
in	O
78	O
.	O
6	O
%	O
(	O
n	O
=	O
140	O
)	O
of	O
the	O
patients	O
:	O
influenza	B-DISO
A	O
33	O
.	O
5	O
%,	O
influenza	B-DISO
B	O
16	O
.	O
4	O
%,	O
respiratory	O
syncytial	O
virus	O
9	O
.	O
2	O
%,	O
adenovirus	B-DISO
7	O
.	O
8	O
%,	O
rhinovirus	O
7	O
.	O
1	O
%,	O
coronavirus	O
7	O
.	O
1	O
%,	O
human	O
metapneumovirus	O
5	O
.	O
7	O
%,	O
human	O
bocavirus	O
5	O
.	O
7	O
%,	O
parainfluenza	B-DISO
virus	O
3	O
.	O
5	O
%,	O
coinfection	B-DISO
2	O
.	O
8	O
%.	O

Influenza	B-DISO
A	O
infection	B-DISO
was	O
observed	O
with	O
the	O
highest	O
rate	O
in	O
both	O
age	O
groups	O
.	O

Influenza	B-DISO
B	O
was	O
the	O
second	O
leading	O
agent	O
(	O
p	O
=	O
0	O
.	O
008	O
)	O
above	O
the	O
age	O
of	O
5	O
years	O
and	O
respiratory	O
syncytial	O
virus	O
was	O
the	O
second	O
leading	O
agent	O
in	O
the	O
2	O
-	O
5	O
year	O
age	O
group	O
(	O
p	O
=	O
0	O
.	O
003	O
).	O

In	O
this	O
study	O
,	O
it	O
was	O
concluded	O
that	O
influenza	B-DISO
and	O
other	O
respiratory	O
viruses	O
can	O
not	O
be	O
differentiated	O
definitely	O
by	O
clinical	O
and	O
radiological	O
findings	O
,	O
though	O
there	O
are	O
some	O
differences	O
.	O

TITLE	O
:	O
Genotyping	O
of	O
infectious	B-DISO
bronchitis	B-DISO
viruses	O
from	O
broiler	O
farms	O
in	O
Iraq	O
during	O
2014	O
-	O
2015	O
.	O

Melatonin	O
inhibits	O
the	O
activation	O
of	O
the	O
NLRP3	O
inflammasome	O
by	O
both	O
suppressing	O
the	O
release	O
of	O
extracellular	O
histones	O
and	O
directly	O
blocking	B-DISO
histone	O
-	O
induced	O
NLRP3	O
inflammasome	O
activation	O
.	O

In	O
order	O
to	O
further	O
define	O
M	O
-	O
M	O
and	O
M	O
-	O
N	O
interactions	O
,	O
we	O
constructed	O
mutants	O
of	O
the	O
model	O
coronavirus	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
in	O
which	O
all	O
or	O
part	O
of	O
the	O
M	O
protein	O
was	O
replaced	O
by	O
its	O
phylogenetically	O
divergent	O
counterpart	O
from	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

Here	O
,	O
we	O
show	O
that	O
TRIM56	O
puts	O
a	O
check	O
on	O
replication	O
of	O
influenza	B-DISO
A	O
and	O
B	O
viruses	O
in	O
cell	O
culture	O
but	O
does	O
not	O
inhibit	O
Sendai	O
virus	O
or	O
human	O
metapneumovirus	O
,	O
two	O
paramyxoviruses	O
.	O

Moreover	O
,	O
expression	O
of	O
this	O
short	O
C	O
-	O
terminal	O
segment	O
curtailed	O
the	O
replication	O
of	O
influenza	B-DISO
viruses	O
as	O
effectively	O
as	O
that	O
of	O
full	O
-	O
length	O
TRIM56	O
.	O

Together	O
,	O
these	O
data	O
reveal	O
a	O
novel	O
antiviral	O
activity	O
of	O
TRIM56	O
against	O
influenza	B-DISO
A	O
and	O
B	O
viruses	O
and	O
provide	O
insights	O
into	O
the	O
mechanism	O
by	O
which	O
TRIM56	O
restricts	O
these	O
medically	O
important	O
orthomyxoviruses	O
.	O

TITLE	O
:	O
Notes	O
from	O
the	O
Field	O
:	O
Nosocomial	O
Outbreak	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
in	O
a	O
Large	O
Tertiary	O
Care	O
Hospital	O
--	O
Riyadh	O
,	O
Saudi	O
Arabia	O
,	O
2015	O
.	O

ABSTRACT	O
:	O
Objectives	O
Feline	O
coronaviruses	O
(	O
FCoVs	O
)	O
exist	O
as	O
two	O
biotypes	O
,	O
feline	O
enteric	O
coronavirus	O
and	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
.	O

Although	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
is	O
a	O
very	O
common	O
disease	O
,	O
the	O
ante	O
-	O
mortem	O
diagnosis	O
of	O
this	O
disease	B-DISO
still	I-DISO
remains	O
a	O
challenge	O
.	O

Therefore	O
,	O
it	O
was	O
the	O
aim	O
of	O
this	O
study	O
to	O
evaluate	O
the	O
diagnostic	O
potential	O
of	O
an	O
immunocytochemical	O
(	O
ICC	B-DISO
)	O
assay	O
using	O
body	O
cavity	B-DISO
effusion	B-DISO
.	O

As	O
false	O
-	O
positive	O
results	O
might	O
lead	O
to	O
euthanasia	O
of	O
cats	O
suffering	B-DISO
from	O
potentially	O
treatable	O
diseases	O
,	O
the	O
diagnostic	O
specificity	O
of	O
a	O
diagnostic	O
tool	O
is	O
the	O
most	O
important	O
factor	O
in	O
a	O
fatal	O
disease	O
like	O
FIP	B-DISO
.	O

In	O
addition	O
,	O
the	O
antibody	O
treatment	O
induced	O
a	O
marked	O
reduction	O
in	O
the	O
number	O
of	O
the	O
infected	O
cells	O
at	O
24	O
hours	O
post	O
inoculation	O
,	O
without	O
changing	O
the	O
infected	O
cell	O
numbers	O
during	O
the	O
initial	O
phase	O
of	O
infection	B-DISO
.	O

Presentation	O
of	O
the	O
current	O
knowledge	O
on	O
indications	O
and	O
management	O
of	O
mechanical	O
ventilation	O
in	O
patients	O
with	O
hypercapnic	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

In	O
patients	O
with	O
severe	O
respiratory	B-DISO
acidosis	I-DISO
NIV	O
requires	O
a	O
skilled	O
and	O
experienced	O
team	O
and	O
close	O
monitoring	O
in	O
order	O
to	O
perceive	O
a	O
failure	O
of	O
NIV	O
.	O

The	O
use	O
of	O
NIV	O
is	O
the	O
predominant	O
treatment	O
in	O
patients	O
with	O
hypercapnic	B-DISO
respiratory	I-DISO
failure	I-DISO
but	O
close	O
monitoring	O
is	O
necessary	O
in	O
order	O
not	O
to	O
miss	O
the	O
indications	O
for	O
intubation	O
and	O
invasive	O
ventilation	O
.	O

The	O
Large	O
Observational	O
Study	O
to	O
Understand	O
the	O
Global	O
Impact	O
of	O
Severe	O
Acute	B-DISO
Respiratory	I-DISO
Failure	I-DISO
(	O
LUNG	O
SAFE	O
)	O
was	O
an	O
international	O
,	O
multicenter	O
,	O
prospective	O
cohort	O
study	O
of	O
patients	O
undergoing	O
invasive	O
or	O
noninvasive	O
ventilation	O
,	O
conducted	O
during	O
4	O
consecutive	O
weeks	O
in	O
the	O
winter	O
of	O
2014	O
in	O
a	O
convenience	O
sample	O
of	O
459	O
ICUs	O
from	O
50	O
countries	O
across	O
5	O
continents	O
.	O

Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

The	O
period	O
prevalence	O
of	O
mild	O
ARDS	B-DISO
was	O
30	O
.	O
0	O
%	O
(	O
95	O
%	O
CI	O
,	O
28	O
.	O
2	O
%-	O
31	O
.	O
9	O
%);	O
of	O
moderate	O
ARDS	B-DISO
,	O
46	O
.	O
6	O
%	O
(	O
95	O
%	O
CI	O
,	O
44	O
.	O
5	O
%-	O
48	O
.	O
6	O
%);	O
and	O
of	O
severe	O
ARDS	B-DISO
,	O
23	O
.	O
4	O
%	O
(	O
95	O
%	O
CI	O
,	O
21	O
.	O
7	O
%-	O
25	O
.	O
2	O
%).	O

Prone	O
positioning	O
was	O
used	O
in	O
16	O
.	O
3	O
%	O
(	O
95	O
%	O
CI	O
,	O
13	O
.	O
7	O
%-	O
19	O
.	O
2	O
%)	O
of	O
patients	O
with	O
severe	O
ARDS	B-DISO
.	O

We	O
retrospectively	O
analyzed	O
the	O
clinical	O
reports	O
of	O
10	O
patients	O
who	O
underwent	O
awake	O
ECMO	O
due	O
to	O
postoperative	O
ARDS	B-DISO
between	O
August	O
2012	O
and	O
May	O
2015	O
.	O

Additionally	O
,	O
it	O
is	O
possible	O
for	O
patients	O
to	O
breathe	O
spontaneously	O
,	O
which	O
might	O
prevents	O
respiratory	O
muscle	O
dystrophy	B-DISO
.	O

The	O
latter	O
two	O
are	O
pain	B-DISO
syndromes	I-DISO
that	O
provide	O
insight	O
into	O
the	O
pain	O
caused	O
by	O
systemic	O
pro	O
-	O
inflammatory	O
cytokines	O
and	O
direct	O
injury	O
to	O
nerves	O
(	O
e	O
.	O
g	O
.,	O
after	O
severe	O
burn	O
),	O
respectively	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
a	O
member	O
of	O
Alphacoronavirus	O
,	O
has	O
caused	O
huge	O
economic	O
losses	O
for	O
the	O
global	O
pork	O
industry	O
recently	O
.	O

Understanding	O
the	O
differences	O
in	O
receptor	O
binding	O
between	O
the	O
prototype	O
and	O
the	O
variant	O
strains	O
may	O
provide	O
insight	O
into	O
PEDV	O
pathogenesis	B-DISO
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
heterogeneous	O
transmission	O
patterns	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
in	O
the	O
Republic	O
of	O
Korea	O
,	O
with	O
a	O
particular	O
focus	O
on	O
epidemiological	O
characteristics	O
of	O
superspreaders	O
.	O

In	O
this	O
experimental	O
extrapulmonary	O
mild	O
ALI	O
model	O
,	O
prone	O
position	O
ventilation	O
for	O
1	O
h	O
,	O
when	O
compared	O
with	O
supine	O
position	O
ventilation	O
,	O
was	O
associated	O
with	O
lower	O
lung	B-DISO
inflammation	I-DISO
and	O
injury	O
.	O

The	O
dose	O
of	O
methylprednisolone	O
was	O
tapered	O
to	O
0	O
.	O
25	O
mg	O
/(	O
kg	O
·	O
d	O
)	O
after	O
4	O
weeks	O
and	O
was	O
adjusted	O
according	O
to	O
the	O
occurrence	O
and	O
severity	O
of	O
chronic	B-DISO
graft	I-DISO
-	I-DISO
versus	I-DISO
-	I-DISO
host	I-DISO
disease	I-DISO
(	O
cGVHD	B-DISO
).	O

CONCLUSIONS	O
:	O
MSC	O
combined	O
with	O
budesonide	O
,	O
almeterol	O
and	O
azithromycin	O
has	O
been	O
confirmed	O
to	O
be	O
generally	O
safe	O
and	O
can	O
reduce	O
the	O
dose	O
of	O
glucocorticoid	O
in	O
treatment	O
of	O
BOS	B-DISO
after	O
HSCT	O
.	O

Recently	O
,	O
the	O
new	O
Berlin	O
Definition	O
of	O
ARDS	B-DISO
has	O
been	O
developed	O
and	O
this	O
classified	O
ARDS	B-DISO
into	O
three	O
stages	O
(	O
mild	O
,	O
moderate	O
,	O
and	O
severe	O
ARDS	B-DISO
),	O
depending	O
on	O
the	O
PaO2	O
/	O
FiO2	O
.	O

After	O
this	O
new	O
definition	O
of	O
ARDS	B-DISO
,	O
each	O
treatment	O
to	O
the	O
patients	O
with	O
ARDS	B-DISO
should	O
be	O
considered	O
,	O
depending	O
on	O
the	O
severity	O
of	O
lung	O
injury	O
,	O
such	O
as	O
prone	O
position	O
to	O
the	O
patients	O
with	O
severe	O
ARDS	B-DISO
,	O
muscle	O
paralysis	O
to	O
the	O
patients	O
with	O
severe	O
ARDS	B-DISO
.	O

On	O
June	O
3	O
,	O
2015	O
,	O
the	O
Korean	O
Society	O
for	O
Laboratory	O
Medicine	O
(	O
KSLM	O
)	O
launched	O
a	O
MERS	O
-	O
CoV	O
Laboratory	O
Response	O
Task	O
Force	O
(	O
LR	O
-	O
TF	O
)	O
to	O
facilitate	O
clinical	O
laboratories	O
to	O
set	O
up	O
the	O
diagnosis	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

Many	O
studies	O
suggest	O
that	O
the	O
N	O
protein	O
interaction	O
with	O
nsp3	O
plays	O
a	O
critical	O
role	O
in	O
the	O
virus	O
replication	O
early	O
in	O
infection	B-DISO
.	O

The	O
amino	O
acid	O
sequences	O
of	O
MHV	O
N	O
and	O
nsp3	O
proteins	O
have	O
similarity	O
between	O
human	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

Data	O
from	O
the	O
GO	O
analysis	O
indicated	O
that	O
the	O
target	O
genes	O
of	O
ribavirin	O
and	O
interferon	O
-	O
α	O
as	O
well	O
as	O
the	O
genes	O
from	O
the	O
microarray	O
were	O
mainly	O
enriched	O
in	O
10	O
biological	O
processes	O
,	O
including	O
cellular	O
process	O
,	O
metabolic	O
process	O
,	O
immune	O
system	O
process	O
and	O
biological	O
regulation	O
,	O
et	O
al	O
.	O
Data	O
on	O
drug	O
target	O
genes	O
,	O
first	O
and	O
second	O
cluster	O
of	O
microarray	O
would	O
involve	O
9	O
,	O
3	O
and	O
23	O
signaling	O
pathways	O
respectively	O
,	O
and	O
only	O
the	O
former	O
two	O
showed	O
7	O
common	O
pathways	O
,	O
which	O
were	O
related	O
to	O
pathogen	O
recognition	O
,	O
cytokine	O
release	O
and	O
autoimmune	B-DISO
response	I-DISO
.	O

Data	O
from	O
the	O
GO	O
analysis	O
indicated	O
that	O
the	O
target	O
genes	O
of	O
ribavirin	O
and	O
interferon	O
-	O
α	O
as	O
well	O
as	O
the	O
genes	O
from	O
the	O
microarray	O
were	O
mainly	O
enriched	O
in	O
10	O
biological	O
processes	O
,	O
including	O
cellular	O
process	O
,	O
metabolic	O
process	O
,	O
immune	O
system	O
process	O
and	O
biological	O
regulation	O
,	O
et	O
al	O
.	O
Data	O
on	O
drug	O
target	O
genes	O
,	O
first	O
and	O
second	O
cluster	O
of	O
microarray	O
would	O
involve	O
9	O
,	O
3	O
and	O
23	O
signaling	O
pathways	O
respectively	O
,	O
and	O
only	O
the	O
former	O
two	O
showed	O
7	O
common	O
pathways	O
,	O
which	O
were	O
related	O
to	O
pathogen	O
recognition	O
,	O
cytokine	O
release	O
and	O
autoimmune	B-DISO
response	I-DISO
.	O

ABSTRACT	O
:	O
Pulmonary	O
vascular	O
endothelial	O
activation	O
has	O
been	O
implicated	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
yet	O
little	O
is	O
known	O
about	O
the	O
presence	O
and	O
role	O
of	O
endothelial	O
activation	O
markers	O
in	O
the	O
alveolar	O
space	O
in	O
ARDS	B-DISO
.	O

Median	O
bronchoalveolar	O
lavage	O
fluid	O
biomarker	O
levels	O
did	O
not	O
differ	O
between	O
patients	O
with	O
and	O
without	O
microbiologically	O
-	O
confirmed	O
ventilator	B-DISO
-	I-DISO
associated	I-DISO
pneumonia	I-DISO
.	O

TITLE	O
:	O
Sharing	O
experiences	O
from	O
a	O
reference	O
laboratory	O
in	O
the	O
public	O
health	O
response	O
for	O
Ebola	O
viral	B-DISO
disease	I-DISO
,	O
MERS	O
-	O
CoV	O
and	O
H7N9	O
influenza	B-DISO
virus	O
investigations	O
.	O

In	O
this	O
paper	O
we	O
share	O
our	O
experiences	O
in	O
recent	O
infectious	B-DISO
disease	I-DISO
outbreak	O
investigations	O
as	O
a	O
reference	O
laboratory	O
within	O
the	O
Ministry	O
of	O
Health	O
infectious	B-DISO
disease	I-DISO
surveillance	O
network	O
.	O

However	O
,	O
a	O
growing	O
body	O
of	O
experimental	O
evidence	O
supports	O
the	O
novel	O
concept	O
that	O
an	O
abnormally	O
enhanced	O
CB	O
chemosensory	O
input	O
to	O
the	O
brainstem	O
contributes	O
to	O
overactivation	O
of	O
the	O
sympathetic	O
nervous	B-DISO
system	O
,	O
and	O
consequent	O
pathology	B-DISO
.	O

These	O
include	O
hypertension	B-DISO
,	O
heart	B-DISO
failure	I-DISO
,	O
sleep	B-DISO
apnea	I-DISO
,	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
and	O
metabolic	B-DISO
syndrome	I-DISO
.	O

Indeed	O
,	O
ablation	O
of	O
the	O
CB	O
has	O
been	O
proposed	O
for	O
the	O
treatment	O
of	O
severe	O
and	O
resistant	O
hypertension	B-DISO
in	O
humans	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
2002	O
-	O
2003	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
outbreak	O
prompted	O
a	O
search	O
for	O
the	O
natural	O
reservoir	O
of	O
the	O
SARS	B-DISO
coronavirus	O
,	O
numerous	O
alpha	O
-	O
and	O
betacoronaviruses	O
have	O
been	O
discovered	O
in	O
bats	O
around	O
the	O
world	O
.	O

TITLE	O
:	O
Responses	O
of	O
the	O
Toll	O
-	O
like	O
receptor	O
and	O
melanoma	B-DISO
differentiation	O
-	O
associated	O
protein	O
5	O
signaling	O
pathways	O
to	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	B-DISO
infection	I-DISO
in	O
chicks	O
.	O

the	O
patient	O
had	O
all	O
criteria	O
specified	O
by	O
the	O
international	O
Consensus	O
Group	O
on	O
CMR	O
in	O
Myocarditis	B-DISO
that	O
make	O
a	O
clinical	O
suspicion	O
for	O
acute	B-DISO
myocarditis	I-DISO
.	O

ABSTRACT	O
:	O
Transmission	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
-	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
among	O
health	O
care	O
workers	O
(	O
HCWs	O
)	O
and	O
patients	O
has	O
been	O
documented	O
with	O
mortality	O
rate	O
approximating	O
36	O
%.	O

A	O
-	O
IC	O
measures	O
include	O
administrative	O
support	O
with	O
daily	O
rounds	O
;	O
infection	B-DISO
control	O
risk	O
assessment	O
;	O
timely	O
screening	O
,	O
isolation	O
,	O
and	O
specimen	O
analysis	O
;	O
collaboration	O
;	O
epidemic	O
planning	O
;	O
stockpiling	O
;	O
implementation	O
of	O
contingency	O
plans	O
;	O
full	O
personal	O
protective	O
equipment	O
use	O
for	O
advanced	O
airway	O
management	O
;	O
use	O
of	O
a	O
real	O
-	O
time	O
electronic	O
isolation	O
flagging	O
system	O
;	O
infection	B-DISO
prevention	O
and	O
control	O
team	O
on	O
-	O
call	O
protocols	O
;	O
pretransfer	O
MERS	O
-	O
CoV	O
testing	O
;	O
and	O
education	O
.	O

ABSTRACT	O
:	O
Appropriately	O
identifying	O
and	O
triaging	O
patients	O
with	O
newly	O
diagnosed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
who	O
may	O
progress	O
to	O
severe	O
ARDS	B-DISO
is	O
a	O
common	O
clinical	O
challenge	O
without	O
any	O
existing	O
tools	O
for	O
assistance	O
.	O

ABSTRACT	O
:	O
Although	O
a	O
globe	O
box	O
-	O
type	O
highly	O
contained	O
laboratory	O
with	O
the	O
internationally	O
-	O
recognized	O
biosafety	O
level	O
-	O
4	O
standards	O
has	O
been	O
constructed	O
in	O
the	O
Murayama	O
Annex	O
,	O
the	O
National	O
Institute	O
of	O
Infectious	B-DISO
Diseases	I-DISO
,	O
Tokyo	O
,	O
Japan	O
(	O
NIID	B-DISO
)	O
in	O
1981	O
,	O
the	O
laboratory	O
has	O
never	O
been	O
operated	O
as	O
BSL	O
-	O
4	O
laboratory	O
since	O
its	O
construction	O
.	O

TITLE	O
:	O
Modelling	O
input	O
-	O
output	O
flows	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
in	O
mainland	O
China	O
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
novel	O
enzootic	O
betacoronavirus	O
that	O
was	O
first	O
described	O
in	O
September	O
2012	O
.	O

As	O
a	O
test	O
case	O
,	O
we	O
calibrated	O
the	O
model	O
with	O
the	O
case	O
incidence	O
data	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
Beijing	O
in	O
2003	O
,	O
and	O
the	O
estimated	O
parameters	O
demonstrated	O
the	O
effectiveness	O
of	O
the	O
control	O
measures	O
taken	O
during	O
that	O
period	O
.	O

TITLE	O
:	O
Comparative	O
Epidemiology	O
of	O
Human	O
Infections	B-DISO
with	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
and	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Coronaviruses	O
among	O
Healthcare	O
Personnel	O
.	O

ABSTRACT	O
:	O
The	O
largest	O
nosocomial	O
outbreak	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
occurred	O
in	O
South	O
Korea	O
in	O
2015	O
.	O

This	O
study	O
described	O
the	O
similarities	O
and	O
differences	O
in	O
epidemiological	O
and	O
clinical	O
characteristics	O
of	O
183	O
confirmed	O
global	O
MERS	O
cases	O
and	O
98	O
SARS	B-DISO
cases	O
in	O
Taiwan	O
associated	O
with	O
HCP	B-DISO
.	O

In	O
conclusion	O
,	O
the	O
severity	O
of	O
MERS	O
-	O
HCP	B-DISO
and	O
SARS	B-DISO
-	O
HCP	B-DISO
was	O
lower	O
than	O
that	O
of	O
MERS	O
-	O
non	O
-	O
HCP	B-DISO
and	O
SARS	B-DISO
-	O
non	O
-	O
HCP	B-DISO
due	O
to	O
younger	O
age	O
and	O
early	O
confirmation	O
in	O
HCP	B-DISO
groups	O
.	O

We	O
found	O
that	O
4	O
%	O
(	O
10	O
%	O
of	O
those	O
less	O
than	O
5years	O
)	O
of	O
people	O
had	O
respiratory	B-DISO
disease	I-DISO
resulting	O
in	O
a	O
visit	O
to	O
a	O
healthcare	O
provider	O
in	O
the	O
past	O
2weeks	O
;	O
these	O
episodes	O
were	O
most	O
commonly	O
treated	O
at	O
government	O
(	O
33	O
%)	O
or	O
private	O
(	O
44	O
%)	O
clinics	O
.	O

Only	O
39	O
/	O
200	O
(	O
20	O
%)	O
had	O
a	O
healthcare	O
visit	O
(	O
2	O
/	O
9	O
individuals	O
with	O
influenza	B-DISO
).	O

ABSTRACT	O
:	O
Viral	O
respiratory	B-DISO
infections	I-DISO
continue	O
to	O
pose	O
a	O
major	O
global	O
healthcare	O
burden	O
.	O

Examinations	O
on	O
transbronchial	O
specimens	O
obtained	O
by	O
bronchoscopy	O
permitted	O
to	O
reach	O
the	O
diagnosis	O
of	O
sarcoidosis	B-DISO
and	O
steroid	O
therapy	O
improved	O
rapidly	O
clinical	O
conditions	O
.	O

TITLE	O
:	O
The	O
epidermal	O
growth	O
factor	O
receptor	O
regulates	O
cofilin	O
activity	O
and	O
promotes	O
transmissible	O
gastroenteritis	B-DISO
virus	O
entry	O
into	O
intestinal	O
epithelial	O
cells	O
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
),	O
a	O
coronavirus	O
,	O
causes	O
severe	B-DISO
diarrhea	I-DISO
and	O
high	O
mortality	O
in	O
newborn	O
piglets	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
a	O
laboratory	O
-	O
confirmed	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
in	O
a	O
pregnant	O
woman	O
.	O

TITLE	O
:	O
Prophylaxis	O
With	O
a	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)-	O
Specific	O
Human	O
Monoclonal	O
Antibody	O
Protects	O
Rabbits	O
From	O
MERS	O
-	O
CoV	O
Infection	B-DISO
.	O

Patients	O
infected	O
by	O
HCoV	O
-	O
NL63	O
are	O
typically	O
young	O
children	O
with	O
upper	O
and	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
,	O
presenting	O
with	O
symptoms	O
including	O
croup	B-DISO
,	O
bronchiolitis	B-DISO
,	O
and	O
pneumonia	B-DISO
.	O

41	O
(	O
98	O
%)	O
patients	O
with	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
had	O
anti	O
-	O
Zika	O
virus	O
IgM	O
or	O
IgG	O
,	O
and	O
all	O
(	O
100	O
%)	O
had	O
neutralising	O
antibodies	O
against	O
Zika	O
virus	O
compared	O
with	O
54	O
(	O
56	O
%)	O
of	O
98	O
in	O
control	O
group	O
1	O
(	O
p	O
<	O
0	O
.	O
0001	O
).	O

ABSTRACT	O
:	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
is	O
the	O
most	O
common	O
and	O
most	O
severe	O
acute	O
paralytic	O
neuropathy	B-DISO
,	O
with	O
about	O
100	O
,	O
000	O
people	O
developing	O
the	O
disorder	O
every	O
year	O
worldwide	O
.	O

Such	O
studies	O
are	O
transforming	O
the	O
clinical	O
and	O
scientific	O
landscape	O
of	O
acute	B-DISO
autoimmune	I-DISO
neuropathies	I-DISO
.	O

TITLE	O
:	O
Glycopeptide	O
Antibiotics	O
Potently	O
Inhibit	O
Cathepsin	O
L	O
in	O
the	O
Late	O
Endosome	O
/	O
Lysosome	O
and	O
Block	O
the	O
Entry	O
of	O
Ebola	O
Virus	O
,	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
and	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

Notably	O
,	O
given	O
that	O
teicoplanin	O
has	O
routinely	O
been	O
used	O
in	O
the	O
clinic	O
with	O
low	O
toxicity	O
,	O
our	O
work	O
provides	O
a	O
promising	O
prospect	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
Ebola	O
,	O
MERS	O
,	O
and	O
SARS	B-DISO
virus	B-DISO
infection	I-DISO
.	O

Influenza	B-DISO
A	O
viruses	O
were	O
detected	O
in	O
co	O
-	O
circulation	O
with	O
influenza	B-DISO
B	O
viruses	O
;	O
the	O
latter	O
amounted	O
to	O
34	O
.	O
1	O
%	O
of	O
all	O
influenza	B-DISO
detections	O
.	O

Other	O
detected	O
causes	O
of	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
consisted	O
of	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
being	O
predominant	O
,	O
and	O
,	O
sporadically	O
,	O
human	O
coronavirus	O
,	O
parainfluenza	B-DISO
1	O
-	O
3	O
,	O
rhinovirus	O
,	O
and	O
adenovirus	B-DISO
.	O

TITLE	O
:	O
Coronavirus	O
Host	O
Range	O
Expansion	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
Emergence	O
:	O
Biochemical	O
Mechanisms	O
and	O
Evolutionary	O
Perspectives	O
.	O

GBS	B-DISO
should	O
be	O
considered	O
as	O
a	O
differential	O
diagnosis	O
in	O
acute	O
onset	O
respiratory	B-DISO
failure	I-DISO
with	O
neuromuscular	B-DISO
weakness	I-DISO
in	O
infants	O
.	O

TITLE	O
:	O
Infections	B-DISO
in	O
travellers	O
returning	O
to	O
Turkey	O
from	O
the	O
Arabian	O
peninsula	O
:	O
a	O
retrospective	O
cross	O
-	O
sectional	O
multicenter	O
study	O
.	O

We	O
did	O
a	O
retrospective	O
cross	O
-	O
sectional	O
multicenter	O
study	O
in	O
Turkey	O
to	O
explore	O
the	O
range	O
of	O
infections	B-DISO
among	O
inpatients	O
who	O
had	O
recently	O
returned	O
from	O
the	O
Arabian	O
Peninsula	O
.	O

Therefore	O
,	O
survival	O
after	O
both	O
primary	O
and	O
secondary	B-DISO
infection	I-DISO
was	O
decreased	O
rather	O
than	O
increased	O
by	O
positive	O
selection	O
for	O
resistance	O
.	O

We	O
also	O
briefly	O
describe	O
common	O
clinical	O
manifestations	O
of	O
respiratory	B-DISO
viral	I-DISO
infection	I-DISO
and	O
morphological	O
correlates	O
.	O

TITLE	O
:	O
Severe	O
Community	O
-	O
Acquired	O
Pneumonia	B-DISO
Caused	O
by	O
Human	O
Adenovirus	B-DISO
in	O
Immunocompetent	O
Adults	O
:	O
A	O
Multicenter	O
Case	O
Series	O
.	O

Here	O
we	O
report	O
the	O
case	O
of	O
a	O
45	O
year	O
old	O
male	O
who	O
was	O
a	O
victim	O
of	O
severe	O
Plasmodium	B-DISO
vivax	I-DISO
malaria	I-DISO
culminating	O
into	O
ARDS	B-DISO
,	O
prior	O
to	O
the	O
initiation	O
of	O
anti	O
-	O
malarial	O
therapy	O
.	O

Ingredients	O
imported	O
to	O
the	O
USA	O
from	O
China	O
,	O
including	O
organic	O
&	O
conventional	O
soybeans	O
and	O
meal	O
,	O
lysine	O
hydrochloride	O
,	O
D	O
-	O
L	O
methionine	O
,	O
tryptophan	O
,	O
Vitamins	O
A	O
,	O
D	O
&	O
E	O
,	O
choline	O
,	O
carriers	O
(	O
rice	O
hulls	O
,	O
corn	B-DISO
cobs	O
)	O
and	O
feed	O
grade	O
tetracycline	O
,	O
were	O
inoculated	O
with	O
PEDV	O
.	O

AIVs	O
capable	O
of	O
infecting	O
humans	O
include	O
a	O
highly	O
pathogenic	O
AIV	O
H5N1	B-DISO
,	O
first	O
detected	O
in	O
humans	O
in	O
1997	O
,	O
and	O
a	O
low	O
pathogenic	O
AIV	O
H7N9	O
,	O
reported	O
in	O
humans	O
in	O
2013	O
.	O

TITLE	O
:	O
The	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
:	O
Mechanisms	O
and	O
Perspective	O
Therapeutic	O
Approaches	O
.	O

However	O
,	O
in	O
vivo	O
attenuation	O
suggests	O
additional	O
adaptation	O
is	O
required	O
for	O
epidemic	B-DISO
disease	I-DISO
.	O

Moreover	O
,	O
the	O
docking	O
study	O
of	O
all	O
synthesized	O
compounds	O
inside	O
the	O
HLA	O
-	O
A	O
protein	O
(	O
PDB	B-DISO
ID	O
:	O
3OX8	O
)	O
active	O
site	O
was	O
carried	O
out	O
to	O
explore	O
the	O
molecular	O
interactions	O
and	O
a	O
molecular	O
target	O
for	O
activity	O
and	O
a	O
modified	O
assay	O
method	O
measuring	O
the	O
interaction	O
between	O
our	O
derivatives	O
and	O
HBcAg	O
was	O
investigated	O
,	O
indicating	O
that	O
the	O
HBV	B-DISO
core	O
protein	O
might	O
be	O
their	O
potential	O
target	O
for	O
anti	O
-	O
HBV	B-DISO
.	O

This	O
study	O
identified	O
a	O
new	O
class	O
of	O
potent	O
non	O
-	O
nucleoside	O
anti	O
-	O
HBV	B-DISO
agents	O
.	O

In	O
this	O
study	O
,	O
a	O
DNA	O
vaccine	O
SL7207	O
(	O
pVAXD	O
-	O
PS1	O
-	O
TS	O
)	O
co	O
-	O
expressing	O
S	O
proteins	O
of	O
TGEV	O
and	O
PEDV	O
delivered	O
by	O
attenuated	O
Salmonella	B-DISO
typhimurium	O
was	O
constructed	O
and	O
its	O
immunogenicity	O
in	O
piglets	O
was	O
investigated	O
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
Middle	O
Eastern	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
was	O
one	O
of	O
the	O
major	O
events	O
in	O
South	O
Korea	O
in	O
2015	O
.	O

Co	B-DISO
-	I-DISO
infections	I-DISO
with	O
PKV	O
and	O
the	O
other	O
three	O
viruses	O
were	O
very	O
common	O
.	O

Co	B-DISO
-	I-DISO
infection	I-DISO
of	O
PKV	O
and	O
PEDV	O
was	O
detected	O
in	O
15	O
.	O
0	O
%	O
(	O
47	O
/	O
314	O
)	O
of	O
the	O
samples	O
.	O

This	O
argues	O
against	O
low	O
levels	O
of	O
adiponectin	O
as	O
a	O
mechanism	O
explaining	O
the	O
association	O
of	O
obesity	B-DISO
with	O
ARDS	B-DISO
.	O

The	O
issue	O
was	O
addressed	O
by	O
comparing	O
the	O
effects	O
on	O
lung	O
function	O
of	O
CMV	O
and	O
HFJV	O
in	O
two	O
rabbit	O
models	O
of	O
neonatal	O
acute	O
lung	O
injury	O
:	O
repetitive	O
saline	O
lung	O
lavage	O
(	O
LAV	O
)	O
and	O
meconium	B-DISO
aspiration	I-DISO
syndrome	I-DISO
(	O
MAS	B-DISO
)	O
induced	O
by	O
intratracheal	O
meconium	O
instillation	O
.	O

TITLE	O
:	O
Immune	O
responses	O
induced	O
by	O
recombinant	O
Bacillus	O
subtilis	O
expressing	O
the	O
spike	O
protein	O
of	O
transmissible	O
gastroenteritis	B-DISO
virus	O
in	O
pigs	O
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	B-DISO
(	O
TGE	B-DISO
)	O
causes	O
severe	B-DISO
diarrhea	I-DISO
in	O
suckling	O
piglets	O
,	O
results	O
in	O
enormous	O
economic	O
loss	O
in	O
swine	O
-	O
producing	O
areas	O
of	O
the	O
world	O
.	O

CONCLUSIONS	O
:	O
This	O
guideline	O
emphasizes	O
the	O
paucity	O
of	O
evidence	O
of	O
benefit	O
-	O
and	O
potential	O
for	O
harm	O
-	O
of	O
common	O
interventions	O
in	O
adults	O
with	O
ARDS	B-DISO
and	O
highlights	O
the	O
need	O
for	O
prudence	O
when	O
considering	O
use	O
of	O
non	O
-	O
licensed	O
interventions	O
in	O
this	O
patient	O
population	O
.	O

α	O
-	O
1	O
antitrypsin	O
was	O
shown	O
to	O
reduce	O
Pseudomonas	O
aeruginosa	O
burden	O
in	O
the	O
airways	O
of	O
cystic	B-DISO
fibrosis	I-DISO
patients	O
.	O

TITLE	O
:	O
Studies	O
on	O
Cycloheptathiophene	O
-	O
3	O
-	O
carboxamide	O
Derivatives	O
as	O
Allosteric	O
HIV	B-DISO
-	O
1	O
Ribonuclease	O
H	O
Inhibitors	O
.	O

The	O
animals	O
were	O
free	O
of	O
eight	O
other	O
microorganisms	O
tested	O
,	O
but	O
some	O
were	O
seropositive	O
for	O
porcine	O
circovirus	O
2	O
(	O
PCV2	O
),	O
porcine	B-DISO
reproductive	I-DISO
and	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
(	O
PRRSV	O
),	O
and	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
).	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
and	O
evaluation	O
of	O
novel	O
HIV	B-DISO
-	O
1	O
NNRTIs	O
with	O
dual	O
structural	O
conformations	O
targeting	O
the	O
entrance	O
channel	O
of	O
the	O
NNRTI	O
binding	O
pocket	O
.	O

In	O
addition	O
,	O
preliminary	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	B-DISO
)	O
and	O
molecular	O
simulation	O
studies	O
were	O
discussed	O
,	O
which	O
may	O
provide	O
valuable	O
insights	O
for	O
further	O
optimization	O
.	O

Successful	O
treatment	O
of	O
Legionnaires	B-DISO
disease	I-DISO
requires	O
a	O
high	O
degree	O
of	O
clinical	O
suspicion	O
and	O
prompt	O
empirical	O
treatment	O
when	O
severe	O
community	O
-	O
acquired	O
pneumonia	B-DISO
is	O
encountered	O
.	O

CONCLUSIONS	O
:	O
Successful	O
treatment	O
of	O
Legionnaires	B-DISO
disease	I-DISO
requires	O
a	O
high	O
degree	O
of	O
clinical	O
suspicion	O
and	O
prompt	O
empirical	O
treatment	O
when	O
severe	O
community	O
-	O
acquired	O
pneumonia	B-DISO
is	O
encountered	O
.	O

It	O
was	O
indicated	O
that	O
patients	O
who	O
were	O
male	O
,	O
of	O
IgG	O
type	O
,	O
with	O
a	O
relapse	B-DISO
status	O
and	O
a	O
previous	O
history	O
of	O
auto	O
-	O
PBSCT	O
had	O
a	O
higher	O
possibility	O
of	O
developing	O
bortezomib	O
-	O
induced	O
severe	O
pulmonary	B-DISO
complications	I-DISO
.	O

An	O
increased	O
awareness	O
of	O
MERS	O
-	O
CoV	O
and	O
an	O
understanding	O
of	O
the	O
radiologic	O
features	O
of	O
MERS	O
-	O
CoV	O
can	O
improve	O
the	O
early	O
assessment	O
and	O
monitoring	O
of	O
this	O
new	O
infection	B-DISO
.	O

In	O
this	O
issue	O
of	O
the	O
JCI	O
,	O
Peteranderl	O
and	O
colleagues	O
define	O
a	O
paracrine	O
communication	O
between	O
macrophages	O
and	O
type	O
II	O
alveolar	O
epithelial	O
cells	O
during	O
influenza	B-DISO
infection	B-DISO
where	O
IFNα	O
induces	O
macrophage	O
secretion	O
of	O
TRAIL	O
that	O
causes	O
endocytosis	O
of	O
Na	O
,	O
K	O
-	O
ATPase	O
by	O
the	O
alveolar	O
epithelium	O
.	O

Inhibition	O
of	O
the	O
TRAIL	O
signaling	O
pathway	O
has	O
been	O
shown	O
to	O
improve	O
lung	O
injury	O
after	O
influenza	B-DISO
infection	B-DISO
,	O
and	O
future	O
studies	O
will	O
be	O
needed	O
to	O
determine	O
if	O
blocking	B-DISO
this	O
pathway	O
is	O
a	O
viable	O
option	O
in	O
the	O
treatment	O
of	O
ARDS	B-DISO
.	O

RESULTS	O
:	O
Our	O
results	O
reveal	O
that	O
an	O
initial	O
rise	O
in	O
the	O
levels	O
of	O
serum	O
endocan	O
from	O
baseline	O
in	O
all	O
patients	O
after	O
induction	O
of	O
anaesthesia	B-DISO
.	O

TITLE	O
:	O
Non	O
Susceptibility	O
of	O
Neonatal	O
and	O
Adult	O
Rats	O
against	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
.	O

TITLE	O
:	O
Severe	O
alcohol	B-DISO
withdrawal	I-DISO
syndrome	I-DISO
:	O
Evolution	O
of	O
care	O
and	O
impact	O
of	O
adjunctive	O
therapy	O
on	O
course	O
and	O
complications	O
of	O
171	O
intensive	O
care	O
unit	O
patients	O
.	O

Clinical	O
management	O
was	O
similar	O
for	O
both	O
intervals	O
,	O
as	O
well	O
as	O
prevalence	O
of	O
alcohol	B-DISO
withdrawal	I-DISO
syndrome	I-DISO
versus	O
total	O
adult	O
hospital	O
admissions	O
and	O
comorbid	O
conditions	O
.	O

TITLE	O
:	O
[	O
Prophylaxis	O
of	O
Pulmonary	B-DISO
Aspiration	I-DISO
during	O
General	O
Anesthesia	B-DISO
].	O

Patients	O
with	O
ARDS	B-DISO
treated	O
by	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
can	O
also	O
benefit	O
from	O
prone	O
positioning	O
;	O
however	O
,	O
the	O
procedure	O
is	O
associated	O
with	O
a	O
possible	O
higher	O
risk	O
of	O
serious	O
adverse	O
events	O
.	O

We	O
observed	O
6	O
,	O
452	O
animals	O
listed	O
by	O
Lao	O
PDR	B-DISO
as	O
near	O
extinct	O
or	O
threatened	O
with	O
extinction	O
.	O

The	O
combined	O
risks	O
of	O
wildlife	O
trade	O
in	O
Lao	O
PDR	B-DISO
to	O
human	O
health	O
and	O
biodiversity	O
highlight	O
the	O
need	O
for	O
a	O
multi	O
-	O
sector	O
approach	O
to	O
effectively	O
protect	O
public	O
health	O
,	O
economic	O
interests	O
and	O
biodiversity	O
.	O

Consequently	O
,	O
the	O
mutant	B-DISO
triggered	O
a	O
reduced	O
antiviral	O
response	O
,	O
which	O
was	O
confirmed	O
by	O
evaluating	O
different	O
stages	O
of	O
the	O
dsRNA	O
-	O
induced	O
antiviral	O
pathway	O
.	O

Early	O
blood	O
purification	O
therapy	O
improves	O
respiratory	O
function	O
and	O
inflammatory	O
markers	O
in	O
patients	O
with	O
SAP	O
complicated	O
by	O
ALI	O
,	O
and	O
decreases	O
the	O
occurrence	O
of	O
MODS	B-DISO
and	O
ARDS	B-DISO
.	O

TITLE	O
:	O
A	O
clinical	O
perspective	O
of	O
sepsis	B-DISO
-	O
associated	O
delirium	B-DISO
.	O

ABSTRACT	O
:	O
The	O
term	O
sepsis	B-DISO
-	I-DISO
associated	I-DISO
encephalopathy	I-DISO
(	O
SAE	O
)	O
has	O
been	O
applied	O
to	O
animal	O
models	O
,	O
postmortem	O
studies	O
in	O
patients	O
,	O
and	O
severe	O
cases	O
of	O
sepsis	B-DISO
.	O

Prospective	O
clinic	O
surveillance	O
was	O
conducted	O
to	O
identify	O
hospitalized	O
children	O
aged	O
≤	O
15	O
years	O
presenting	O
with	O
respiratory	B-DISO
symptoms	I-DISO
≤	O
5	O
-	O
day	O
duration	O
.	O

ABSTRACT	O
:	O
Stray	O
cats	O
in	O
the	O
city	O
of	O
Milan	O
,	O
Italy	O
,	O
were	O
tested	O
for	O
Leishmania	O
infantum	O
and	O
other	O
selected	O
infections	B-DISO
.	O

Feline	O
immunodeficiency	B-DISO
virus	O
,	O
feline	B-DISO
leukemia	I-DISO
virus	O
,	O
and	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
seroprevalence	O
determined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
was	O
6	O
.	O
1	O
,	O
6	O
.	O
1	O
,	O
and	O
39	O
.	O
0	O
%,	O
respectively	O
.	O

Malarial	O
hepatopathy	B-DISO
was	O
associated	O
with	O
a	O
higher	O
incidence	O
of	O
cerebral	B-DISO
malaria	I-DISO
,	O
shock	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
acute	O
kidney	O
injury	O
in	O
both	O
overall	O
(	O
p	O
<	O
0	O
.	O
05	O
each	O
)	O
and	O
falciparum	B-DISO
malaria	I-DISO
(	O
p	O
<	O
0	O
.	O
05	O
each	O
)	O
and	O
hyponatremia	O
and	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
only	O
in	O
overall	O
malaria	B-DISO
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Thus	O
,	O
hepatocellular	O
dysfunction	O
is	O
common	O
in	O
malaria	B-DISO
but	O
that	O
qualifying	O
as	O
malarial	O
hepatopathy	B-DISO
is	O
not	O
common	O
.	O

It	O
is	O
an	O
epiphenomenon	O
in	O
severe	O
malaria	B-DISO
and	O
indicative	O
of	O
severe	O
disease	O
.	O

An	O
oral	O
Lactobacillus	O
casei	O
(	O
L	O
.	O
casei	O
)	O
vaccine	O
against	O
anti	O
-	O
transmissible	O
gastroenteritis	B-DISO
virus	O
developed	O
in	O
our	O
laboratory	O
was	O
used	O
to	O
study	O
mucosal	O
immune	O
responses	O
.	O

We	O
found	O
that	O
the	O
recombinant	O
Lactobacillus	O
stimulated	O
IL	O
-	O
17	O
expression	O
in	O
both	O
the	O
systemic	O
and	O
mucosal	O
immune	O
responses	O
against	O
TGEV	O
infection	B-DISO
.	O

TITLE	O
:	O
Detection	O
of	O
variant	O
infectious	B-DISO
bronchitis	B-DISO
viruses	O
in	O
Sri	O
Lanka	O
(	O
2012	O
-	O
2015	O
).	O

TITLE	O
:	O
Characteristics	O
and	O
outcomes	O
of	O
patients	O
treated	O
with	O
airway	O
pressure	O
release	O
ventilation	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O

ABSTRACT	O
:	O
The	O
optimal	O
mode	O
of	O
ventilation	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
remains	O
uncertain	O
.	O

This	O
was	O
a	O
prospective	O
,	O
single	O
blind	B-DISO
cohort	O
study	O
in	O
which	O
children	O
younger	O
than	O
two	O
years	O
presenting	O
to	O
the	O
emergency	B-DISO
department	O
(	O
ED	O
)	O
with	O
bronchiolitis	B-DISO
were	O
included	O
.	O

We	O
found	O
that	O
MERS	O
-	O
CoV	O
NS4b	O
and	O
homologs	O
from	O
related	O
lineage	O
C	O
bat	O
betacoronaviruses	O
BtCoV	O
-	O
SC2013	O
(	O
SC2013	O
)	O
and	O
BtCoV	O
-	O
HKU5	O
(	O
HKU5	O
)	O
are	O
members	O
of	O
the	O
2H	O
-	O
phosphoesterase	O
(	O
2H	O
-	O
PE	O
)	O
enzyme	O
family	O
with	O
phosphodiesterase	O
(	O
PDE	B-DISO
)	O
activity	O
.	O

Feline	O
enteric	O
coronavirus	O
(	O
FECV	O
)	O
causes	O
inapparent	O
or	O
mild	O
enteritis	B-DISO
in	O
cats	O
,	O
but	O
a	O
highly	O
fatal	O
disease	O
,	O
called	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
),	O
can	O
arise	O
through	O
mutation	O
of	O
FECV	O
to	O
FIP	B-DISO
virus	O
(	O
FIPV	O
).	O

We	O
observe	O
that	O
TGEV	O
infection	B-DISO
induce	O
mitochondrial	O
injury	O
,	O
abnormal	O
morphology	O
,	O
complete	O
mitophagy	O
,	O
and	O
without	O
obvious	O
apoptosis	O
after	O
TGEV	O
infection	B-DISO
.	O

TITLE	O
:	O
Infection	B-DISO
site	I-DISO
is	O
predictive	O
of	O
outcome	O
in	O
acute	O
lung	O
injury	O
associated	O
with	O
severe	B-DISO
sepsis	I-DISO
and	O
septic	B-DISO
shock	I-DISO
.	O

Compliance	O
with	O
a	O
set	O
of	O
sepsis	B-DISO
management	O
bundles	O
was	O
associated	O
with	O
better	O
outcomes	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
regulatory	O
role	O
of	O
autophagy	O
in	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
replication	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
location	O
and	O
amino	O
acid	O
sequences	O
of	O
the	O
FPs	O
of	O
S	O
glycoproteins	O
of	O
3	O
β	O
-	O
CoVs	O
,	O
MERS	O
-	O
CoV	O
,	O
SARS	B-DISO
-	O
CoV	O
,	O
and	O
MHV	O
,	O
and	O
demonstrated	O
that	O
they	O
were	O
essential	O
for	O
mediating	O
cell	O
-	O
cell	O
fusion	O
and	O
virus	O
entry	O
.	O

The	O
protease	O
contains	O
an	O
alternative	O
active	O
site	O
motif	O
,	O
(	O
475	O
)	O
NVCWAK	O
(	O
480	O
),	O
which	O
differs	O
from	O
papain	O
'	O
s	O
(	O
CGS	O
(	O
25	O
)	O
CWAFS	O
),	O
and	O
the	O
enzyme	O
lacks	O
a	O
transition	B-DISO
state	O
-	O
stabilizing	O
residue	O
homologous	O
to	O
Gln	O
-	O
19	O
in	O
papain	O
.	O

The	O
peptide	O
-	O
like	O
E64d	O
inhibitor	O
was	O
found	O
to	O
bind	O
beneath	O
a	O
β	O
-	O
hairpin	O
at	O
the	O
interface	O
of	O
the	O
SAM	B-DISO
MTase	O
and	O
protease	O
domains	O
.	O

Consistent	O
with	O
our	O
substrate	O
-	O
bound	O
models	O
,	O
the	O
SAM	B-DISO
MTase	O
domain	O
K706A	O
mutation	O
increased	O
Km	O
4	O
.	O
5	O
-	O
fold	O
to	O
500	O
μM	O
.	O
Within	O
the	O
β	O
-	O
hairpin	O
,	O
the	O
N545A	O
mutation	O
slightly	O
but	O
not	O
significantly	O
increased	O
kcat	O
and	O
Km	O
.	O

TITLE	O
:	O
Human	O
infection	B-DISO
with	O
a	O
highly	O
pathogenic	O
avian	B-DISO
influenza	I-DISO
A	O
(	O
H5N6	O
)	O
virus	O
in	O
Yunnan	O
province	O
,	O
China	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
expanding	O
and	O
enhancing	O
of	O
surveillance	O
in	O
both	O
avian	O
and	O
humans	O
are	O
necessary	O
to	O
monitor	O
the	O
evolution	O
of	O
H5	O
influenza	B-DISO
virus	O
and	O
to	O
facilitate	O
early	O
detection	O
of	O
suspected	O
cases	O
.	O

Co	B-DISO
-	I-DISO
infections	I-DISO
with	O
up	O
to	O
four	O
pathogens	O
occurred	O
in	O
60	O
%	O
of	O
the	O
samples	O
.	O

It	O
is	O
likely	O
that	O
co	B-DISO
-	I-DISO
infections	I-DISO
increase	O
the	O
severity	O
of	O
the	O
disease	O
.	O

ABSTRACT	O
:	O
The	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
in	O
the	O
trauma	O
population	O
has	O
been	O
reported	O
to	O
have	O
a	O
mortality	O
benefit	O
in	O
patients	O
with	O
severe	O
refractory	O
hypoxic	B-DISO
respiratory	B-DISO
failure	I-DISO
.	O

CONCLUSIONS	O
:	O
Patients	O
who	O
were	O
treated	O
with	O
ECMO	O
for	O
severe	O
ARDS	B-DISO
had	O
an	O
improved	O
mortality	O
compared	O
with	O
historical	O
controls	O
.	O

ECMO	O
should	O
be	O
considered	O
at	O
the	O
early	O
onset	O
of	O
severe	O
ARDS	B-DISO
to	O
improve	O
survival	O
.	O

ABSTRACT	O
:	O
A	O
79	O
-	O
year	O
-	O
old	O
man	O
experienced	O
severe	B-DISO
chronic	I-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
COPD	B-DISO
)	O
and	O
was	O
receiving	O
treatment	O
for	O
ischemic	B-DISO
heart	I-DISO
disease	I-DISO
.	O

He	O
was	O
taken	O
to	O
our	O
emergency	B-DISO
department	O
.	O

TITLE	O
:	O
Experimental	O
infection	B-DISO
of	O
IS	O
/	O
885	O
/	O
00	O
-	O
like	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
in	O
specific	O
pathogen	O
free	O
and	O
commercial	O
broiler	O
chicks	O
.	O

Chicks	O
were	O
humanely	O
euthanized	O
at	O
3	O
,	O
6	O
,	O
9	O
,	O
12	O
,	O
15	O
,	O
21	O
and	O
28	O
days	O
post	O
infection	B-DISO
(	O
dpi	O
)	O
for	O
necropsy	O
examination	O
,	O
and	O
tissues	O
were	O
collected	O
for	O
histopathology	O
and	O
virus	O
detection	O
by	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

ABSTRACT	O
:	O
Although	O
there	O
is	O
general	O
agreement	O
on	O
the	O
characteristic	O
features	O
of	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
we	O
lack	O
a	O
scoring	O
system	O
that	O
predicts	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
outcome	O
with	O
high	O
probability	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
a	O
highly	O
contagious	O
virus	O
infecting	O
pigs	O
of	O
all	O
ages	O
with	O
high	O
morbidity	O
and	O
mortality	O
among	O
newborn	O
piglets	O
.	O

TITLE	O
:	O
Crisis	O
prevention	O
and	O
management	O
by	O
infection	B-DISO
control	O
nurses	O
during	O
the	O
Middle	O
East	O
respiratory	O
coronavirus	O
outbreak	O
in	O
Korea	O
.	O

For	O
mechanical	O
ventilation	O
specific	O
settings	O
are	O
recommended	O
:	O
limitation	O
of	O
tidal	O
volume	O
(	O
6	O
ml	O
/	O
kg	O
predicted	O
body	O
weight	O
),	O
adequate	O
high	O
PEEP	O
(>	O
12	O
cmH2O	O
),	O
a	O
recruitment	B-DISO
manoeuvre	O
in	O
special	O
situations	O
,	O
and	O
a	O
'	O
balanced	O
'	O
respiratory	O
rate	O
(	O
20	O
-	O
30	O
/	O
min	O
).	O

Prone	O
positioning	O
[	O
early	O
(≤	O
48	O
hrs	B-DISO
after	O
onset	O
of	O
severe	O
ARDS	B-DISO
)	O
and	O
prolonged	O
(	O
repetition	O
of	O
16	O
-	O
hr	O
-	O
sessions	O
)]	O
improves	O
survival	O
.	O

Randomized	O
controlled	O
trials	O
(	O
RCTs	O
)	O
comparing	O
treatment	O
using	O
HFO	O
with	O
conventional	O
mechanical	O
ventilation	O
for	O
children	O
and	O
adults	O
diagnosed	O
with	O
ARDS	B-DISO
.	O

The	O
findings	O
of	O
this	O
systematic	O
review	O
suggest	O
that	O
HFO	O
does	O
not	O
reduce	O
hospital	O
and	O
30	O
-	O
day	O
mortality	O
due	O
to	O
ARDS	B-DISO
;	O
the	O
quality	O
of	O
evidence	O
was	O
very	O
low	O
.	O

ABSTRACT	O
:	O
Avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
(	O
IB	O
),	O
caused	O
by	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
),	O
is	O
a	O
worldwide	O
endemic	B-DISO
disease	I-DISO
of	O
chickens	O
that	O
affects	O
all	O
branches	O
of	O
the	O
poultry	O
industry	O
.	O

Five	O
consecutive	O
patients	O
undergoing	O
single	O
-	O
site	O
LFVV	O
-	O
ECLS	O
for	O
severe	O
hypercapnic	B-DISO
respiratory	I-DISO
failure	I-DISO
were	O
included	O
in	O
this	O
study	O
.	O

TITLE	O
:	O
Does	O
Circulating	O
Antibody	O
Play	O
a	O
Role	O
in	O
the	O
Protection	O
of	O
Piglets	O
against	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
?	O

TITLE	O
:	O
A	O
Case	O
Report	O
of	O
a	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Survivor	O
with	O
Kidney	O
Biopsy	O
Results	O
.	O

Acute	B-DISO
tubular	I-DISO
necrosis	I-DISO
was	O
the	O
main	O
finding	O
,	O
and	O
proteinaceous	O
cast	O
formation	O
and	O
acute	B-DISO
tubulointerstitial	I-DISO
nephritis	I-DISO
were	O
found	O
.	O

Recent	O
works	O
have	O
also	O
demonstrated	O
the	O
crucial	O
impact	O
of	O
lung	O
inflation	O
and	O
driving	O
pressure	O
on	O
RV	O
afterload	O
,	O
and	O
have	O
confirmed	O
the	O
deleterious	O
effect	O
of	O
severe	O
RV	O
failure	O
,	O
described	O
as	O
acute	B-DISO
cor	I-DISO
pulmonale	I-DISO
.	O

TITLE	O
:	O
Roles	O
of	O
neurally	O
adjusted	O
ventilatory	O
assist	O
in	O
improving	O
gas	O
exchange	O
in	O
a	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patient	O
after	O
weaning	O
from	O
extracorporeal	O
membrane	O
oxygenation	O
:	O
a	O
case	O
report	O
.	O

The	O
patient	O
was	O
a	O
63	O
-	O
year	O
-	O
old	O
Japanese	O
man	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
secondary	O
to	O
respiratory	B-DISO
infection	I-DISO
.	O

However	O
,	O
weaning	O
from	O
mechanical	O
ventilation	O
using	O
a	O
flow	O
trigger	O
failed	O
repeatedly	O
because	O
of	O
patient	O
-	O
ventilator	O
asynchrony	O
with	O
hypercapnic	B-DISO
acidosis	I-DISO
during	O
partial	O
ventilator	O
support	O
despite	O
using	O
different	O
types	O
of	O
ventilators	O
and	O
different	O
trigger	O
levels	O
.	O

Our	O
experience	O
showed	O
that	O
NAVA	O
improved	O
not	O
only	O
patient	O
-	O
ventilator	O
synchrony	O
but	O
also	O
regional	O
ventilation	O
distribution	O
in	O
an	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
patient	O
with	O
sustained	O
low	O
lung	O
compliance	O
.	O

We	O
aimed	O
to	O
determine	O
the	O
predictive	O
validity	O
of	O
the	O
stabilized	O
ratio	O
of	O
partial	O
pressure	O
arterial	O
oxygen	O
and	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
PaO2	O
/	O
FiO2	O
ratio	O
)	O
following	O
standard	O
ventilator	O
setting	O
in	O
the	O
prognosis	O
of	O
patients	O
with	O
ARDS	B-DISO
.	O
This	O
prospective	O
observational	O
study	O
was	O
conducted	O
in	O
a	O
single	O
tertiary	O
medical	O
center	O
in	O
Taiwan	O
and	O
compared	O
the	O
stabilized	O
PaO2	O
/	O
FiO2	O
ratio	O
(	O
Day	O
1	O
)	O
following	O
standard	O
ventilator	O
settings	O
and	O
the	O
PaO2	O
/	O
FiO2	O
ratio	O
on	O
the	O
day	O
patients	O
met	O
ARDS	B-DISO
Berlin	O
criteria	O
(	O
Day	O
0	O
).	O

Twelve	O
(	O
5	O
%)	O
patients	O
who	O
originally	O
were	O
classified	O
as	O
ARDS	B-DISO
did	O
not	O
continually	O
meet	O
the	O
Berlin	O
definition	O
,	O
and	O
a	O
total	O
of	O
134	O
(	O
56	O
%)	O
patients	O
had	O
the	O
changes	O
regarding	O
the	O
severity	O
of	O
ARDS	B-DISO
from	O
Day	O
0	O
to	O
Day	O
1	O
.	O

Patients	O
with	O
an	O
Injury	O
Severity	O
Score	O
(	O
ISS	B-DISO
)	O
at	O
least	O
16	O
and	O
Abbreviated	O
Injury	O
Scale	O
of	O
head	O
(	O
AIS	B-DISO
-	O
head	O
)	O
at	O
least	O
3	O
were	O
included	O
upon	O
arrival	O
in	O
the	O
emergency	B-DISO
room	O
and	O
grouped	O
according	O
to	O
positive	O
BAC	O
(>	O
0	O
.	O
5	O
‰,	O
BAC	O
)	O
vs	O
.	O
less	O
than	O
0	O
.	O
5	O
‰	O
alcohol	O
(	O
no	O
BAC	O
).	O

In	O
addition	O
,	O
our	O
data	O
emphasized	O
that	O
the	O
HMPV	O
prevalence	O
was	O
high	O
in	O
children	O
0	O
-	O
5	O
years	O
old	O
,	O
and	O
coinfections	B-DISO
were	O
common	O
with	O
the	O
other	O
respiratory	O
viruses	O
such	O
as	O
respiratory	O
syncytial	O
virus	O
,	O
coronavirus	O
,	O
parainfluenza	B-DISO
virus	O
3	O
,	O
rhinovirus	O
and	O
enterovirus	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
was	O
first	O
recognized	O
in	O
pigs	O
in	O
the	O
United	O
States	O
(	O
US	O
)	O
in	O
May	O
2013	O
.	O

ABSTRACT	O
:	O
Recent	O
outbreaks	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
and	O
porcine	O
deltacoronavirus	O
(	O
PDCoV	O
)	O
in	O
multiple	O
countries	O
have	O
caused	O
significant	O
economic	O
losses	O
and	O
remain	O
a	O
serious	O
challenge	O
to	O
the	O
swine	O
industry	O
.	O

Furthermore	O
,	O
when	O
platelet	O
functions	O
were	O
defective	O
because	O
of	O
administration	O
of	O
aspirin	O
or	O
clopidogrel	O
,	O
or	O
because	O
of	O
glycoprotein	O
(	O
GP	O
)	O
IIbIIIa	O
deficiency	O
,	O
TRALI	B-DISO
still	O
developed	O
but	O
no	O
lung	O
hemorrhages	B-DISO
were	O
observed	O
.	O

Although	O
they	O
do	O
not	O
protect	O
against	O
the	O
disruption	O
of	O
the	O
vascular	O
endothelial	O
cell	O
barrier	O
and	O
the	O
subsequent	O
plasma	O
leakage	B-DISO
and	O
edema	B-DISO
formation	O
,	O
platelets	O
are	O
essential	O
to	O
prevent	O
more	O
serious	O
damage	O
resulting	O
in	O
hemorrhages	B-DISO
in	O
alveoli	O
.	O

TITLE	O
:	O
The	O
effect	O
of	O
porcine	B-DISO
reproductive	I-DISO
and	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
and	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
challenge	O
on	O
growing	O
pigs	O
I	O
:	O
Growth	O
performance	O
and	O
digestibility	O
.	O

Additional	O
reductions	O
in	O
ADG	O
and	O
G	O
:	O
F	O
were	O
detected	O
in	O
PRP	O
pigs	O
compared	O
with	O
singular	O
PED	O
or	O
PRRS	B-DISO
treatments	O
(	O
33	O
and	O
16	O
%,	O
respectively	O
).	O

TITLE	O
:	O
The	O
effect	O
of	O
porcine	B-DISO
reproductive	I-DISO
and	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
and	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
challenge	O
on	O
growing	O
pigs	O
II	O
:	O
Intestinal	O
integrity	O
and	O
function	O
.	O

Compared	O
with	O
the	O
CON	O
,	O
intestinal	O
morphology	O
was	O
unaffected	O
by	O
PRRS	B-DISO
.	O

We	O
report	O
on	O
the	O
successful	O
long	O
-	O
term	O
use	O
of	O
ECMO	O
in	O
a	O
postpartum	O
patient	O
with	O
recurrent	O
pulmonary	O
decompensation	O
after	O
peripartum	O
uterine	B-DISO
rupture	I-DISO
with	O
extensive	O
blood	B-DISO
loss	I-DISO
.	O

TITLE	O
:	O
Sepsis	B-DISO
and	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
:	O
Recent	O
Update	O
.	O

Advances	O
in	O
treatment	O
modalities	O
including	O
lung	O
protective	O
ventilation	O
,	O
prone	O
positioning	O
,	O
use	O
of	O
neuromuscular	B-DISO
blockade	I-DISO
,	O
and	O
extracorporeal	O
membrane	O
oxygenation	O
,	O
have	O
improved	O
the	O
outcome	O
over	O
recent	O
decades	O
,	O
nevertheless	O
,	O
the	O
mortality	O
rate	O
still	O
remains	O
high	O
.	O

Chronic	O
pulmonary	O
deficiencies	O
in	O
survivors	O
appear	O
to	O
be	O
caused	O
by	O
inappropriate	O
injury	O
repair	O
,	O
with	O
fibrosis	B-DISO
and	O
predisposition	O
to	O
emphysema	B-DISO
arising	O
as	O
irreversible	O
secondary	O
events	O
that	O
can	O
severely	O
compromise	O
pulmonary	O
development	O
and	O
function	O
,	O
as	O
well	O
as	O
the	O
overall	O
health	O
of	O
the	O
patient	O
.	O

Infection	B-DISO
control	O
in	O
healthcare	O
settings	O
,	O
in	O
which	O
patients	O
with	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
such	O
as	O
MERS	O
,	O
Ebola	B-DISO
virus	I-DISO
disease	I-DISO
,	O
and	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
are	O
diagnosed	O
and	O
treated	O
,	O
are	O
often	O
imperfect	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
Berlin	O
definition	O
to	O
the	O
American	O
-	O
European	O
Consensus	O
Conference	O
(	O
AECC	O
)	O
definition	O
in	O
determining	O
the	O
prevalence	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
associated	O
mortality	O
in	O
the	O
critically	B-DISO
ill	I-DISO
burn	O
population	O
.	O

Arteriviruses	O
(	O
order	O
Nidovirales	O
)	O
belong	O
to	O
the	O
subset	O
of	O
+	O
RNA	O
viruses	O
that	O
induce	O
double	O
-	O
membrane	O
vesicles	B-DISO
(	O
DMVs	O
),	O
similar	O
to	O
the	O
structures	O
induced	O
by	O
e	O
.	O
g	O
.	O
coronaviruses	O
,	O
picornaviruses	O
and	O
hepatitis	B-DISO
C	I-DISO
virus	O
.	O

Co	O
-	O
expression	O
of	O
the	O
third	O
EAV	O
transmembrane	O
protein	O
(	O
nsp5	O
),	O
expressed	O
as	O
part	O
of	O
a	O
self	O
-	O
cleaving	O
polypeptide	O
that	O
mimics	O
viral	O
polyprotein	O
processing	O
in	O
infected	O
cells	O
,	O
led	O
to	O
the	O
formation	O
of	O
DMVs	O
whose	O
size	O
was	O
more	O
homogenous	O
and	O
closer	O
to	O
what	O
is	O
observed	O
upon	O
EAV	O
infection	B-DISO
,	O
suggesting	O
a	O
regulatory	O
role	O
for	O
nsp5	O
in	O
modulating	O
membrane	O
curvature	O
and	O
DMV	O
formation	O
.	O

The	O
transport	O
of	O
mechanically	O
ventilated	O
patients	O
with	O
respiratory	B-DISO
failure	I-DISO
in	O
the	O
prone	O
position	O
is	O
feasible	O
and	O
safe	O
,	O
with	O
minimal	O
complications	O
identified	O
in	O
this	O
case	O
series	O
.	O

RESULTS	O
:	O
Seven	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
were	O
transported	O
in	O
the	O
prone	O
position	O
.	O

This	O
chapter	O
describes	O
the	O
use	O
of	O
an	O
insect	O
cell	O
expression	O
system	O
for	O
rapid	O
production	O
of	O
a	O
recombinant	O
vaccine	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
).	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
efficacy	O
of	O
lung	O
volume	O
recruitment	B-DISO
maneuver	O
(	O
LVRM	O
)	O
with	O
high	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
on	O
oxygenation	O
,	O
hemodynamic	O
alteration	O
,	O
and	O
clinical	O
outcomes	O
when	O
compared	O
to	O
conventional	O
mechanical	O
ventilation	O
(	O
CV	O
)	O
in	O
children	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

We	O
performed	O
a	O
randomized	O
controlled	O
trial	O
and	O
enrolled	O
pediatric	O
patients	O
who	O
were	O
diagnosed	O
to	O
have	O
severe	O
ARDS	B-DISO
upon	O
pediatric	O
intensive	O
care	O
unit	O
(	O
PICU	O
)	O
admission	O
.	O

Eighteen	O
children	O
with	O
severe	O
ARDS	B-DISO
were	O
enrolled	O
in	O
our	O
study	O
.	O

HFOV	O
combined	O
with	O
LVRM	O
in	O
severe	O
pediatric	O
ARDS	B-DISO
had	O
superior	O
oxygenation	O
and	O
tended	O
to	O
have	O
better	O
clinical	O
effect	O
over	O
CV	O
.	O

TITLE	O
:	O
A	O
rare	O
aspect	O
of	O
Crohn	B-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
:	O
Pulmonary	B-DISO
involvement	I-DISO
in	O
a	O
child	O
.	O

In	O
the	O
pediatric	O
population	O
,	O
CD	O
associated	O
pulmonary	B-DISO
involvement	I-DISO
is	O
very	O
rare	O
,	O
mainly	O
in	O
the	O
form	O
of	O
subclinical	O
alterations	O
and	O
the	O
data	O
are	O
limited	O
mostly	O
to	O
case	O
reports	O
.	O

Therefore	O
,	O
we	O
hypothesized	O
that	O
RA	O
could	O
induce	O
DCs	B-DISO
to	O
form	O
an	O
immature	O
mucosal	O
phenotype	O
and	O
could	O
recruit	O
them	O
to	O
the	O
small	O
intestinal	O
submucosa	O
.	O

TITLE	O
:	O
Pulmonary	O
Angiotensin	O
-	O
Converting	O
Enzyme	O
2	O
(	O
ACE2	O
)	O
and	O
Inflammatory	O
Lung	B-DISO
Disease	I-DISO
.	O

The	O
renin	O
-	O
angiotensin	O
system	O
(	O
RAS	O
),	O
one	O
of	O
the	O
primary	O
cardiovascular	O
regulatory	O
systems	O
,	O
has	O
been	O
proposed	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	B-DISO
of	O
inflammatory	O
lung	B-DISO
disease	I-DISO
.	O

Angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
a	O
relatively	O
new	O
member	O
of	O
the	O
RAS	O
,	O
has	O
drawn	O
extensive	O
attention	O
since	O
2003	O
,	O
because	O
of	O
the	O
findings	O
that	O
ACE2	O
is	O
the	O
receptor	O
for	O
SARS	B-DISO
Corona	O
virus	O
and	O
that	O
maintenance	O
of	O
normal	O
ACE2	O
levels	O
in	O
the	O
lung	O
is	O
beneficial	O
for	O
the	O
host	O
to	O
combat	O
inflammatory	O
lung	B-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
Few	O
studies	O
,	O
each	O
limited	O
to	O
a	O
single	O
major	O
city	O
,	O
have	O
investigated	O
the	O
prevalence	O
and	O
seasonal	O
patterns	O
of	O
different	O
viruses	O
among	O
children	O
with	O
low	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
(	O
LRTI	B-DISO
)	O
in	O
Northeastern	O
Brazil	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
frequency	O
of	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
and	O
of	O
7	O
other	O
viruses	O
in	O
children	O
for	O
LRTI	B-DISO
in	O
4	O
capitals	O
from	O
this	O
region	O
,	O
and	O
investigate	O
their	O
association	O
with	O
several	O
risk	O
factors	O
,	O
including	O
meteorological	O
data	O
.	O

Sodium	O
dodecyl	O
sulfate	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	B-DISO
-	O
PAGE	O
)	O
results	O
showed	O
that	O
rNPs	O
of	O
CCoV	O
and	O
CRCoV	O
were	O
expressed	O
efficiently	O
and	O
isolated	O
with	O
a	O
final	O
purity	O
of	O
over	O
95	O
%.	O

Mechanical	O
ventilation	O
is	O
the	O
first	O
-	O
line	O
intervention	O
in	O
case	O
of	O
respiratory	B-DISO
failure	I-DISO
,	O
but	O
in	O
most	O
severe	O
cases	O
may	O
,	O
itself	O
,	O
cause	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

TITLE	O
:	O
Porcine	O
deltacoronavirus	O
infection	B-DISO
:	O
Etiology	O
,	O
cell	O
culture	O
for	O
virus	O
isolation	O
and	O
propagation	O
,	O
molecular	O
epidemiology	O
and	O
pathogenesis	B-DISO
.	O

ABSTRACT	O
:	O
During	O
March	O
-	O
May	O
2014	O
,	O
a	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
outbreak	O
occurred	O
in	O
Jeddah	O
,	O
Saudi	O
Arabia	O
,	O
that	O
included	O
many	O
persons	O
who	O
worked	O
or	O
received	O
medical	O
treatment	O
at	O
King	O
Fahd	O
General	O
Hospital	O
.	O

To	O
evaluate	O
which	O
type	O
or	O
component	O
of	O
full	O
-	O
body	O
PPE	O
and	O
which	O
method	O
of	O
donning	O
or	O
removing	O
(	O
doffing	O
)	O
PPE	O
have	O
the	O
least	O
risk	O
of	O
self	O
-	O
contamination	O
or	O
infection	B-DISO
for	O
HCWs	O
,	O
and	O
which	O
training	O
methods	O
most	O
increase	O
compliance	O
with	O
PPE	O
protocols	O
.	O

In	O
one	O
study	O
,	O
PPE	O
made	O
of	O
more	O
breathable	O
material	O
did	O
not	O
lead	O
to	O
a	O
statistically	O
significantly	O
different	O
number	O
of	O
spots	B-DISO
with	O
contamination	O
but	O
did	O
have	O
greater	O
user	O
satisfaction	O
(	O
Mean	O
Difference	O
(	O
MD	O
)	O
-	O
0	O
.	O
46	O
(	O
95	O
%	O
Confidence	O
Interval	O
(	O
CI	O
)	O
-	O
0	O
.	O
84	O
to	O
-	O
0	O
.	O
08	O
,	O
range	O
1	O
to	O
5	O
,	O
very	O
low	O
quality	O
evidence	O
).	O

Different	O
methods	O
of	O
donning	O
and	O
doffing	O
procedures	O
versus	O
each	O
otherTwo	O
cross	O
-	O
over	O
simulation	O
studies	O
(	O
one	O
RCT	O
,	O
one	O
CCT	B-DISO
)	O
compared	O
different	O
methods	O
for	O
donning	O
and	O
doffing	O
against	O
each	O
other	O
.	O

The	O
patients	O
who	O
developed	O
AHF	O
/	O
ARDS	B-DISO
had	O
a	O
higher	O
incidence	O
of	O
lung	O
contusion	O
(	O
P	O
=	O
0	O
.	O
04	O
)	O
and	O
the	O
surgical	O
stabilization	O
was	O
performed	O
earlier	O
(	O
5	O
versus	O
10	O
days	O
)	O
in	O
these	O
patients	O
(	O
P	O
=	O
0	O
.	O
03	O
).	O

We	O
found	O
that	O
the	O
incidence	O
of	O
respiratory	B-DISO
failure	I-DISO
in	O
ICU	O
treated	O
patients	O
with	O
pelvis	O
fractures	O
was	O
high	O
,	O
that	O
the	O
procedure	O
around	O
surgical	O
stabilization	O
seems	O
to	O
be	O
associated	O
with	O
a	O
worsening	O
in	O
the	O
respiratory	O
function	O
in	O
patients	O
with	O
lung	O
contusion	O
,	O
and	O
that	O
mortality	O
was	O
low	O
and	O
was	O
probably	O
not	O
related	O
to	O
the	O
respiratory	O
condition	B-DISO
.	O

RESULTS	O
:	O
The	O
incidence	O
of	O
AHF	O
/	O
ARDS	B-DISO
was	O
67	O
%	O
(	O
75	O
/	O
112	O
patients	O
),	O
i	O
.	O
e	O
.,	O
the	O
percentage	O
of	O
patients	O
that	O
at	O
any	O
period	O
during	O
the	O
ICU	O
stay	O
fulfilled	O
the	O
AHF	O
/	O
ARDS	B-DISO
criteria	O
.	O

The	O
patients	O
who	O
developed	O
AHF	O
/	O
ARDS	B-DISO
had	O
a	O
higher	O
incidence	O
of	O
lung	O
contusion	O
(	O
P	O
=	O
0	O
.	O
04	O
)	O
and	O
the	O
surgical	O
stabilization	O
was	O
performed	O
earlier	O
(	O
5	O
versus	O
10	O
days	O
)	O
in	O
these	O
patients	O
(	O
P	O
=	O
0	O
.	O
03	O
).	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
heterogeneous	O
syndrome	B-DISO
that	O
occurs	O
as	O
a	O
result	O
of	O
various	O
risk	O
factors	O
,	O
including	O
either	O
direct	O
or	O
indirect	O
lung	O
injury	O
,	O
and	O
systemic	O
inflammation	B-DISO
triggered	O
also	O
by	O
severe	O
pneumonia	B-DISO
(	O
SP	O
).	O

Plasma	O
was	O
sampled	O
from	O
the	O
healthy	O
as	O
controls	O
or	O
patients	O
with	O
SP	O
infected	O
with	O
bacteria	O
or	O
infection	B-DISO
-	O
associated	O
SP	O
-	O
ARDS	B-DISO
on	O
the	O
day	O
of	O
admission	O
,	O
day	O
3	O
,	O
and	O
day	O
7	O
.	O

ABSTRACT	O
:	O
Nitazoxanide	O
is	O
a	O
broad	O
-	O
spectrum	O
antiviral	O
agent	O
undergoing	O
clinical	O
development	O
for	O
treatment	O
of	O
influenza	B-DISO
and	O
other	O
viral	O
respiratory	B-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
A	O
recent	O
study	O
provides	O
a	O
platform	O
for	O
generating	O
infectious	B-DISO
coronavirus	O
genomes	O
using	O
sequence	O
data	O
,	O
examining	O
their	O
capabilities	O
of	O
replicating	O
in	O
human	O
cells	O
and	O
causing	O
diseases	O
in	O
animal	O
models	O
,	O
and	O
evaluating	O
therapeutics	O
and	O
vaccines	O
.	O

Enterovirus	O
/	O
rhinovirus	O
was	O
detected	O
in	O
51	O
.	O
7	O
%	O
patients	O
,	O
followed	O
by	O
parainfluenza	B-DISO
virus	O
type	O
III	O
(	O
8	O
.	O
3	O
%),	O
and	O
RSV	O
(	O
5	O
.	O
7	O
%).	O

Here	O
,	O
we	O
present	O
a	O
case	O
of	O
a	O
thoracic	B-DISO
trauma	O
patient	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
requiring	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
via	O
a	O
right	O
internal	O
jugular	O
double	O
lumen	O
cannula	O
due	O
to	O
a	O
previously	O
inserted	O
inferior	O
vena	O
cava	O
filter	O
caused	O
by	O
distal	O
bilateral	O
calf	O
muscle	O
vein	O
deep	B-DISO
vein	I-DISO
thrombosis	I-DISO
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
having	O
a	O
severe	O
effect	O
on	O
the	O
pig	O
breeding	O
industry	O
in	O
central	O
China	O
.	O

Almost	O
a	O
quarter	O
of	O
the	O
patients	O
were	O
healthcare	O
workers	O
(	O
23	O
.	O
5	O
%)	O
and	O
41	O
%	O
had	O
a	O
known	O
exposure	O
to	O
another	O
person	O
with	O
MERS	O
-	O
CoV	O
.	O
Survival	O
was	O
associated	O
with	O
male	O
gender	O
,	O
working	O
as	O
a	O
healthcare	O
worker	O
,	O
history	O
of	O
hypertension	B-DISO
,	O
vomiting	B-DISO
on	O
admission	O
,	O
elevated	O
respiratory	O
rate	O
,	O
abnormal	O
lung	O
exam	O
,	O
elevated	O
alanine	O
transaminase	O
(	O
ALT	O
),	O
clearance	O
of	O
MERS	O
-	O
CoV	O
on	O
repeat	O
PCR	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
testing	O
,	O
and	O
mycophenolate	O
mofetil	O
treatment	O
.	O

Currently	O
,	O
the	O
LCA60	O
antibody	O
is	O
being	O
considered	O
for	O
clinical	O
development	O
,	O
which	O
includes	O
prophylaxis	O
in	O
individuals	O
at	O
risk	O
and	O
a	O
treatment	O
for	O
severe	O
MERS	O
-	O
CoV	O
infections	B-DISO
.	O

Since	O
December	O
2010	O
,	O
a	O
large	O
-	O
scale	O
outbreak	O
of	O
diarrhea	B-DISO
has	O
been	O
observed	O
in	O
swine	O
farms	O
in	O
China	O
.	O

ABSTRACT	O
:	O
The	O
recent	O
outbreak	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
in	O
Korea	O
was	O
unexpected	O
that	O
laboratory	O
response	O
had	O
to	O
be	O
built	O
up	O
urgently	O
during	O
the	O
outbreak	O
.	O

To	O
investigate	O
the	O
antiviral	O
activity	O
of	O
graphene	O
oxide	O
(	O
GO	O
)	O
sheets	O
and	O
GO	O
sheets	O
with	O
silver	O
particles	O
(	O
GO	O
-	O
Ag	O
)	O
against	O
enveloped	O
and	O
non	O
-	O
enveloped	O
viruses	O
,	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
with	O
an	O
envelope	O
and	O
infectious	B-DISO
bursal	I-DISO
disease	I-DISO
virus	O
(	O
IBDV	O
)	O
without	O
an	O
envelope	O
were	O
chosen	O
.	O

TITLE	O
:	O
Comparison	O
of	O
SYBR	O
green	O
I	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
with	O
conventional	O
agarose	O
gel	O
-	O
based	O
RT	O
-	O
PCR	O
for	O
the	O
diagnosis	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	B-DISO
infection	I-DISO
in	O
chickens	O
in	O
Morocco	O
.	O

TITLE	O
:	O
Serological	O
Study	O
of	O
An	O
Imported	O
Case	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
and	O
His	O
Close	O
Contacts	O
in	O
China	O
,	O
2015	O
.	O

TITLE	O
:	O
Effects	O
of	O
acute	B-DISO
hemorrhage	I-DISO
on	O
intrapulmonary	O
shunt	O
in	O
a	O
pig	O
model	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
-	O
like	O
syndrome	B-DISO
.	O

We	O
performed	O
a	O
secondary	O
analysis	O
of	O
a	O
previous	O
study	O
including	O
8	O
pigs	O
with	O
ARDS	B-DISO
-	O
like	O
syndrome	B-DISO
induced	O
by	O
lung	O
lavage	O
and	O
surfactant	O
depletion	O
method	O
(	O
ARDS	B-DISO
group	O
)	O
and	O
10	O
mechanically	O
ventilated	O
pigs	O
with	O
no	O
intervention	O
(	O
CTRL	O
group	O
).	O

Our	O
results	O
strengthen	O
the	O
importance	O
to	O
integrate	O
the	O
circulatory	O
condition	B-DISO
in	O
the	O
analysis	O
of	O
the	O
state	O
of	O
the	O
respiratory	O
system	O
.	O

TITLE	O
:	O
Dexmedetomidine	O
as	O
an	O
adjunct	O
for	O
sedation	B-DISO
in	O
patients	O
with	O
traumatic	O
brain	O
injury	O
.	O

Sedative	O
agents	O
were	O
titrated	O
using	O
the	O
Richmond	O
Agitation	B-DISO
Sedation	B-DISO
Scale	O
(	O
RASS	O
)	O
while	O
maintaining	O
intracranial	O
pressure	O
of	O
less	O
than	O
20	O
mm	O
Hg	O
and	O
cerebral	O
perfusion	O
pressure	O
of	O
greater	O
than	O
60	O
mm	O
Hg	O
.	O

TITLE	O
:	O
Active	O
screening	O
and	O
surveillance	O
in	O
the	O
United	O
Kingdom	O
for	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
in	O
returning	O
travellers	O
and	O
pilgrims	O
from	O
the	O
Middle	O
East	O
:	O
a	O
prospective	O
descriptive	O
study	O
for	O
the	O
period	O
2013	O
-	O
2015	O
.	O

A	O
viral	O
aetiology	O
was	O
detected	O
in	O
half	O
(	O
50	O
.	O
3	O
%)	O
of	O
the	O
cases	O
,	O
with	O
rhinoviruses	O
,	O
influenza	B-DISO
A	O
(	O
H1N1	O
and	O
H3N2	O
),	O
and	O
influenza	B-DISO
B	O
being	O
most	O
frequent	O
.	O

These	O
infections	B-DISO
are	O
usually	O
asymptomatic	O
in	O
bats	O
but	O
the	O
mechanism	O
of	O
this	O
tolerance	B-DISO
is	O
not	O
yet	O
understood	O
.	O

At	O
48	O
hpi	B-DISO
,	O
the	O
passage	O
was	O
found	O
to	O
be	O
constructed	O
by	O
ER	O
-	O
TR7	O
antigen	O
(	O
ERag	O
)-	O
positive	O
fibers	O
(	O
ERfibs	O
)	O
associated	O
with	O
laminin	O
and	O
collagen	O
III	O
between	O
the	O
fourth	O
ventricle	O
and	O
meninges	O
at	O
the	O
cerebellopontine	O
angle	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
the	O
more	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
are	O
common	O
and	O
complex	O
inflammatory	O
lung	B-DISO
diseases	I-DISO
.	O

This	O
protein	O
was	O
expressed	O
by	O
induction	O
of	O
IPTG	O
at	O
concentration	O
of	O
1mM	O
and	O
it	O
was	O
confirmed	O
by	O
Ni	O
-	O
NTA	O
column	O
,	O
dot	O
-	O
blotting	O
analysis	O
and	O
SDS	B-DISO
-	O
PAGE	O
electrophoresis	O
.	O

It	O
is	O
crucial	O
to	O
provide	O
nursing	O
students	O
with	O
information	O
or	O
knowledge	O
,	O
but	O
it	O
is	O
also	O
important	O
to	O
help	O
those	O
in	O
nursing	O
education	O
recognize	O
that	O
active	O
preventive	O
behavior	O
can	O
prevent	O
this	O
infectious	B-DISO
disease	I-DISO
and	O
stop	O
its	O
spread	O
.	O

CONCLUSIONS	O
:	O
Preventive	O
behavior	O
against	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
such	O
as	O
MERS	O
-	O
CoV	O
was	O
found	O
to	O
be	O
affected	O
most	O
significantly	O
by	O
attitude	O
and	O
risk	O
perception	O
.	O

TITLE	O
:	O
Complete	O
Genome	O
Sequence	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
Isolated	O
from	O
a	O
Dromedary	O
Camel	O
in	O
Egypt	O
.	O

Bats	O
have	O
been	O
suggested	O
to	O
act	O
as	O
natural	O
reservoirs	O
for	O
both	O
these	O
viruses	O
,	O
and	O
periodic	O
monitoring	O
of	O
coronaviruses	O
in	O
bats	O
may	O
thus	O
provide	O
important	O
clues	O
about	O
emergent	O
infectious	B-DISO
viruses	O
.	O

TITLE	O
:	O
Inverted	O
stress	O
-	O
induced	O
cardiomyopathy	B-DISO
as	O
a	O
unusual	O
variant	O
of	O
acute	B-DISO
heart	I-DISO
failure	I-DISO
after	O
cesarean	O
delivery	O
-	O
a	O
case	O
report	O
.	O

TITLE	O
:	O
Effect	O
of	O
Extracorporeal	O
Membrane	O
Oxygenation	O
Use	O
on	O
Sedative	O
Requirements	O
in	O
Patients	O
with	O
Severe	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
.	O

ABSTRACT	O
:	O
A	O
telephone	O
survey	O
involving	O
200	O
household	O
members	O
in	O
and	O
around	O
Seoul	O
,	O
South	O
Korea	O
,	O
was	O
completed	O
during	O
the	O
maturity	O
stage	O
of	O
the	O
outbreak	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
in	O
Korea	O
during	O
June	O
2015	O
.	O

No	O
significant	O
difference	O
in	O
Crs	B-DISO
(	O
mL	O
/	O
cmH2O	O
)	O
before	O
PPV	O
treatment	O
was	O
found	O
between	O
non	O
-	O
ILD	O
and	O
ILD	O
groups	O
[	O
24	O
.	O
3	O
(	O
15	O
.	O
9	O
,	O
48	O
.	O
9	O
)	O
vs	O
.	O
18	O
.	O
9	O
(	O
12	O
.	O
7	O
,	O
27	O
.	O
3	O
),	O
P	O
>	O
0	O
.	O
05	O
],	O
and	O
Crs	B-DISO
was	O
lower	O
after	O
PPV	O
treatment	O
in	O
both	O
groups	O
,	O
but	O
without	O
significant	O
difference	O
[	O
non	O
-	O
ILD	O
group	O
:	O
22	O
.	O
7	O
(	O
15	O
.	O
2	O
,	O
27	O
.	O
1	O
)	O
vs	O
.	O
24	O
.	O
3	O
(	O
15	O
.	O
9	O
,	O
48	O
.	O
9	O
);	O
ILD	O
group	O
:	O
16	O
.	O
2	O
(	O
12	O
.	O
8	O
,	O
25	O
.	O
6	O
)	O
vs	O
.	O
18	O
.	O
9	O
(	O
12	O
.	O
7	O
,	O
27	O
.	O
3	O
),	O
both	O
P	O
>	O
0	O
.	O
05	O
].	O

The	O
clinical	O
data	O
in	O
two	O
groups	O
were	O
recorded	O
as	O
following	O
:	O
gender	O
,	O
age	O
;	O
respiratory	O
rate	O
,	O
heart	O
rate	O
,	O
and	O
systolic	O
blood	O
pressure	O
at	O
admission	O
;	O
the	O
lowest	O
values	O
of	O
serum	O
creatinine	O
(	O
SCr	O
),	O
white	O
blood	O
cell	O
count	O
(	O
WBC	O
),	O
platelet	O
count	O
(	O
PLT	O
),	O
hematocrit	O
(	O
Hct	O
),	O
respectively	O
,	O
within	O
24	O
hours	O
after	O
admission	O
;	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHE	O
II	O
)	O
score	O
,	O
Glasgow	O
coma	B-DISO
scale	O
(	O
GCS	O
)	O
score	O
,	O
sequential	O
organ	B-DISO
failure	I-DISO
assessment	O
(	O
SOFA	O
),	O
systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
syndrome	I-DISO
(	O
SIRS	B-DISO
)	O
score	O
,	O
injury	O
severity	O
score	O
(	O
ISS	B-DISO
)	O
within	O
24	O
hours	O
of	O
final	O
diagnosis	O
;	O
the	O
performance	O
of	O
emergency	B-DISO
operation	O
or	O
intubation	O
within	O
24	O
hours	O
;	O
incidence	O
of	O
sepsis	B-DISO
,	O
and	O
clinical	O
outcomes	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
gender	O
,	O
respiratory	O
rate	O
,	O
heart	O
rate	O
,	O
systolic	O
blood	O
pressure	O
,	O
WBC	O
,	O
Hct	O
,	O
SIRS	B-DISO
score	O
,	O
ISS	B-DISO
,	O
or	O
emergency	B-DISO
operation	O
between	O
two	O
groups	O
.	O

In	O
the	O
late	O
group	O
,	O
it	O
was	O
shown	O
by	O
single	O
factor	O
analysis	O
that	O
the	O
age	O
,	O
the	O
case	O
history	O
of	O
chronic	B-DISO
disease	I-DISO
,	O
infection	B-DISO
sites	I-DISO
,	O
WBC	O
,	O
pH	O
value	O
,	O
Lac	O
,	O
and	O
ScvO₂	O
before	O
treatment	O
,	O
6	O
-	O
hour	O
urine	O
output	O
after	O
treatment	O
,	O
the	O
number	O
of	O
organ	O
with	O
failure	O
,	O
the	O
use	O
of	O
antibiotics	O
within	O
1	O
hour	O
,	O
and	O
incidence	O
of	O
AKI	O
or	O
ALI	O
/	O
ARDS	B-DISO
within	O
24	O
hours	O
were	O
risk	O
factors	O
of	O
28	O
-	O
day	O
death	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
Management	O
of	O
infections	B-DISO
in	O
critically	B-DISO
ill	I-DISO
returning	O
travellers	O
in	O
the	O
intensive	O
care	O
unit	O
-	O
I	O
:	O
considerations	O
on	O
infection	B-DISO
control	O
and	O
transmission	O
of	O
resistance	O
.	O

The	O
emergence	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
and	O
more	O
recently	O
Ebola	B-DISO
haemorrhagic	I-DISO
fever	I-DISO
,	O
has	O
highlighted	O
the	O
risks	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
today	O
a	O
leading	O
cause	O
of	O
hospitalization	O
in	O
intensive	O
care	O
unit	O
(	O
ICU	O
).	O

This	O
study	O
aims	O
to	O
characterize	O
mechanically	O
ventilated	O
patients	O
in	O
the	O
emergency	B-DISO
department	O
(	O
ED	O
),	O
describe	O
the	O
initial	O
ED	O
ventilator	O
settings	O
,	O
and	O
assess	O
for	O
associations	O
between	O
lung	O
protective	O
ventilation	O
strategies	O
in	O
the	O
ED	O
and	O
outcomes	O
.	O

Altered	B-DISO
mental	I-DISO
status	I-DISO
without	O
respiratory	O
pathology	B-DISO
was	O
the	O
most	O
common	O
reason	O
for	O
intubation	O
,	O
followed	O
by	O
trauma	O
and	O
respiratory	B-DISO
failure	I-DISO
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
the	O
review	O
of	O
WHO	O
and	O
ECDC	O
notifications	O
received	O
by	O
National	O
IHR	O
Focal	O
Point	O
in	O
Poland	O
in	O
the	O
period	O
from	O
2010	O
to	O
2015	O
which	O
were	O
related	O
to	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
not	O
covered	O
by	O
routine	O
vaccination	O
programs	O
or	O
for	O
which	O
there	O
are	O
no	O
effective	O
vaccines	O
that	O
have	O
occurred	O
in	O
the	O
WHO	O
European	O
Region	O
.	O

The	O
review	O
includes	O
verotoxin	O
-	O
producing	O
Escherichia	O
coli	O
O104	O
:	O
H4	O
infections	B-DISO
,	O
MERS	O
-	O
CoV	O
infections	B-DISO
,	O
Ebola	B-DISO
virus	I-DISO
disease	I-DISO
,	O
malaria	B-DISO
,	O
dengue	B-DISO
fever	I-DISO
,	O
West	B-DISO
Nile	I-DISO
fever	I-DISO
,	O
chikungunya	B-DISO
and	O
cholera	B-DISO
.	O

The	O
patients	O
developed	O
similar	O
clinical	O
symptoms	B-DISO
and	I-DISO
signs	I-DISO
,	O
such	O
as	O
fever	O
,	O
loss	O
of	O
consciousness	O
,	O
and	O
multiple	O
organ	O
dysfunction	O
.	O

Further	O
collection	O
of	O
blood	O
samples	O
from	O
endemic	O
areas	O
is	O
warranted	O
for	O
the	O
prevention	O
of	O
SFTSV	O
infection	B-DISO
.	O

Importantly	O
,	O
Nanotrap	O
particle	O
can	O
efficiently	O
capture	O
and	O
concentrate	O
multiple	O
viral	O
pathogens	O
during	O
a	O
coinfection	B-DISO
scenario	O
.	O

As	O
new	O
infectious	B-DISO
diseases	I-DISO
such	O
as	O
avian	B-DISO
influenza	I-DISO
and	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
have	O
been	O
emerging	O
,	O
threatening	O
people	O
'	O
s	O
health	O
worldwide	O
,	O
and	O
because	O
facemasks	O
have	O
been	O
documented	O
to	O
have	O
substantial	O
efficacy	O
in	O
the	O
prevention	O
of	O
infection	B-DISO
transmission	I-DISO
,	O
understanding	O
the	O
sociocultural	O
meanings	O
of	O
facemasks	O
has	O
significant	O
implications	O
for	O
public	O
health	O
policymakers	O
and	O
health	O
care	O
providers	O
in	O
designing	O
a	O
socially	O
and	O
culturally	O
responsive	O
public	O
health	O
and	O
infection	B-DISO
control	O
policy	O
for	O
the	O
community	O
.	O

Leukocytosis	B-DISO
,	O
primarily	O
due	O
to	O
increased	O
neutrophils	O
and	O
monocytes	O
,	O
was	O
generally	O
observed	O
in	O
more	O
severe	O
and	O
fatal	O
cases	O
.	O

It	O
is	O
associated	O
with	O
a	O
number	O
of	O
conditions	O
including	O
diabetes	B-DISO
,	O
Parkinson	B-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
,	O
multiple	B-DISO
sclerosis	I-DISO
,	O
previous	O
abdominal	O
surgeries	O
and	O
connective	B-DISO
tissue	I-DISO
disorders	I-DISO
,	O
including	O
scleroderma	B-DISO
and	O
Ehlers	B-DISO
-	I-DISO
Danlos	I-DISO
syndrome	I-DISO
.	O

This	O
occurred	O
due	O
to	O
opiate	O
toxicity	O
confounded	O
by	O
gastroparesis	B-DISO
.	O

ABSTRACT	O
:	O
Since	O
the	O
beginning	O
of	O
this	O
century	O
,	O
humanity	O
has	O
been	O
facing	O
a	O
new	O
emerging	O
,	O
or	O
re	O
-	O
emerging	O
,	O
virus	O
threat	O
almost	O
every	O
year	O
:	O
West	O
Nile	O
,	O
Influenza	B-DISO
A	O
,	O
avian	B-DISO
flu	I-DISO
,	O
dengue	B-DISO
,	O
Chikungunya	B-DISO
,	O
SARS	B-DISO
,	O
MERS	O
,	O
Ebola	O
,	O
and	O
now	O
Zika	O
,	O
the	O
latest	O
newcomer	O
.	O

The	O
virus	O
was	O
mainly	O
confined	O
to	O
the	O
African	O
continent	O
until	O
it	O
was	O
detected	O
in	O
south	O
-	O
east	O
Asia	O
the	O
1980	O
'	O
s	O
,	O
then	O
in	O
the	O
Micronesia	O
in	O
2007	O
and	O
,	O
more	O
recently	O
in	O
the	O
Americas	O
in	O
2014	O
,	O
where	O
it	O
has	O
displayed	O
an	O
explosive	O
spread	O
,	O
as	O
advised	O
by	O
the	O
World	O
Health	O
Organization	O
,	O
which	O
resulted	O
in	O
the	O
infection	B-DISO
of	O
hundreds	O
of	O
thousands	O
of	O
people	O
.	O

Here	O
,	O
we	O
describe	O
a	O
novel	O
approach	O
for	O
the	O
production	O
of	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
against	O
nucleocapsid	O
protein	O
(	O
NP	O
)	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

Optimal	O
management	O
remains	O
unknown	O
,	O
including	O
the	O
roles	O
of	O
adjunctive	O
corticosteroids	O
and	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
).	O
We	O
conducted	O
a	O
retrospective	O
chart	O
review	O
of	O
patients	O
with	O
ARDS	B-DISO
caused	O
by	O
blastomycosis	B-DISO
,	O
managed	O
in	O
intensive	O
care	O
units	O
in	O
Manitoba	O
,	O
Canada	O
,	O
from	O
1992	O
to	O
2014	O
.	O

ARDS	B-DISO
was	O
defined	O
using	O
the	O
Berlin	O
definition	O
.	O

At	O
lower	O
TPCK	O
concentration	O
(	O
3	O
-	O
10	O
μg	O
/	O
inoculum	O
),	O
no	O
changes	O
at	O
the	O
cellular	O
level	O
were	O
observed	O
,	O
while	O
cells	O
activated	O
with	O
25	O
-	O
30	O
μg	O
of	O
trypsin	O
/	O
inoculums	O
,	O
they	O
degenerated	B-DISO
and	O
trypsin	O
cytotoxicity	B-DISO
was	O
enhanced	O
.	O

TITLE	O
:	O
Serum	O
antibody	O
responses	O
to	O
vaccinal	O
antigens	O
in	O
lean	O
and	O
obese	B-DISO
geriatric	O
dogs	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
syndrome	B-DISO
with	O
heterogeneous	O
underlying	O
pathological	B-DISO
processes	I-DISO
.	O

Although	O
extensive	O
studies	O
have	O
been	O
carried	O
out	O
to	O
investigate	O
the	O
regulation	O
of	O
interferon	O
(	O
IFN	O
)	O
responses	O
by	O
alphacoronaviruses	O
,	O
betacoronaviruses	O
,	O
and	O
gammacoronaviruses	O
,	O
little	O
is	O
known	O
about	O
this	O
process	O
during	O
deltacoronavirus	O
infection	B-DISO
.	O

We	O
also	O
found	O
that	O
PDCoV	O
infection	B-DISO
significantly	O
suppresses	O
the	O
activation	O
of	O
IFN	O
-	O
β	O
promoter	O
stimulated	O
by	O
IRF3	O
or	O
its	O
upstream	O
molecules	O
(	O
RIG	O
-	O
I	O
,	O
MDA5	O
,	O
IPS	B-DISO
-	O
1	O
,	O
TBK1	O
,	O
IKKε	O
)	O
in	O
the	O
RIG	O
-	O
I	O
signaling	O
pathway	O
,	O
but	O
does	O
not	O
counteract	O
its	O
activation	O
by	O
the	O
constitutively	O
active	O
mutant	B-DISO
of	O
IRF3	O
(	O
IRF3	O
-	O
5D	O
).	O

Cough	B-DISO
and	O
tachypnea	B-DISO
were	O
reported	O
in	O
all	O
patients	O
;	O
22	O
(	O
77	O
.	O
4	O
%)	O
patients	O
had	O
bilateral	B-DISO
pulmonary	I-DISO
infiltrates	I-DISO
.	O

The	O
pathogenesis	B-DISO
of	O
BRD	O
is	O
complex	O
and	O
includes	O
contributions	O
from	O
microbial	O
pathogens	O
as	O
well	O
as	O
host	O
,	O
environmental	O
and	O
animal	O
management	O
factors	O
.	O

Twenty	O
-	O
one	O
viruses	O
were	O
detected	O
,	O
with	O
bovine	O
rhinitis	B-DISO
A	O
(	O
52	O
.	O
7	O
%)	O
and	O
B	O
(	O
23	O
.	O
7	O
%)	O
virus	O
,	O
and	O
bovine	O
coronavirus	O
(	O
24	O
.	O
7	O
%)	O
being	O
the	O
most	O
commonly	O
identified	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
coronavirus	O
is	O
the	O
most	O
recent	O
among	O
the	O
Coronaviridae	O
family	O
to	O
jump	O
species	O
and	O
infect	O
humans	O
.	O

No	O
evidence	O
for	O
infection	B-DISO
resulted	O
from	O
inoculation	O
of	O
pigs	O
with	O
the	O
German	O
sample	O
that	O
contained	O
high	O
levels	O
of	O
PEDV	O
RNA	O
;	O
there	O
were	O
no	O
clinical	O
signs	O
,	O
excretion	O
of	O
viral	O
RNA	O
or	O
anti	O
-	O
PEDV	O
antibody	O
production	O
.	O

TITLE	O
:	O
Ten	O
years	O
of	O
a	O
hantavirus	O
disease	O
emergency	B-DISO
in	O
the	O
Federal	O
District	O
,	O
Brazil	O
.	O

Acute	B-DISO
respiratory	I-DISO
failure	I-DISO
was	O
reported	O
in	O
47	O
.	O
5	O
%	O
of	O
cases	O
,	O
and	O
the	O
fatality	O
rate	O
was	O
40	O
%.	O

The	O
study	O
investigated	O
the	O
inhibitory	O
effect	O
and	O
its	O
antagonistic	O
mechanism	O
of	O
SARS	B-DISO
-	O
CoV	O
PLPro	O
on	O
TLR7	O
-	O
mediated	O
cytokine	O
production	O
.	O

The	O
results	O
revealed	O
that	O
the	O
antagonism	O
of	O
SARS	B-DISO
-	O
CoV	O
PLPro	O
on	O
TLR7	O
-	O
mediated	O
innate	O
immunity	O
was	O
associated	O
with	O
the	O
negative	O
regulation	O
of	O
TRAF3	O
/	O
6	O
-	O
TBK1	O
-	O
IRF3	O
/	O
NF	O
-	O
κB	O
/	O
AP1	O
signals	O
.	O

However	O
,	O
ZZ2004	O
,	O
a	O
Chinese	O
isolate	O
of	O
IBV	O
,	O
was	O
obtained	O
from	O
ducks	O
with	O
clinical	O
growth	B-DISO
suppression	I-DISO
and	O
mild	O
respiratory	B-DISO
symptoms	I-DISO
that	O
had	O
been	O
reared	O
with	O
chickens	O
in	O
the	O
central	O
region	O
of	O
China	O
.	O

An	O
alternate	O
diagnosis	O
of	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
with	O
acute	B-DISO
pulmonary	I-DISO
oedema	I-DISO
was	O
made	O
and	O
his	O
asthma	B-DISO
treatment	O
was	O
stopped	O
.	O

SILA	O
is	O
a	O
relatively	O
common	O
complication	B-DISO
of	O
salbutamol	O
therapy	O
in	O
moderate	O
/	O
severe	O
asthma	B-DISO
exacerbations	O
.	O

TITLE	O
:	O
Correction	O
:	O
Reversal	O
of	O
the	O
Progression	O
of	O
Fatal	O
Coronavirus	B-DISO
Infection	I-DISO
in	O
Cats	O
by	O
a	O
Broad	O
-	O
Spectrum	O
Coronavirus	O
Protease	O
Inhibitor	O
.	O

TITLE	O
:	O
Patient	O
characteristics	O
infected	O
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	B-DISO
infection	I-DISO
in	O
a	O
tertiary	O
hospital	O
.	O

MERS	O
-	O
CoV	O
presentation	O
varies	O
from	O
asymptomatic	B-DISO
infection	I-DISO
to	O
severe	O
respiratory	B-DISO
disease	I-DISO
causing	O
death	O
.	O

Thirty	O
sedated	O
patients	O
with	O
ARDS	B-DISO
(	O
10	O
mild	O
,	O
14	O
moderate	O
,	O
6	O
severe	O
)	O
underwent	O
decremental	O
PEEP	O
testing	O
(	O
20	O
,	O
15	O
,	O
10	O
,	O
5	O
cm	O
H2O	O
)	O
for	O
up	O
to	O
7	O
days	O
after	O
inclusion	O
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
was	O
a	O
great	O
global	O
concern	O
in	O
2014	O
.	O

Two	O
of	O
these	O
patients	O
had	O
leukopenia	B-DISO
,	O
and	O
none	O
had	O
renal	B-DISO
failure	I-DISO
.	O

A	O
virus	B-DISO
infection	I-DISO
assay	O
showed	O
that	O
rWIV1	O
-	O
ΔX	O
replicated	O
as	O
efficiently	O
as	O
rWIV1	O
in	O
Vero	O
E6	O
,	O
Calu	O
-	O
3	O
,	O
and	O
HeLa	O
-	O
hACE2	O
cells	O
.	O

TITLE	O
:	O
The	O
Role	O
of	O
Human	O
Coronaviruses	O
in	O
Children	O
Hospitalized	O
for	O
Acute	B-DISO
Bronchiolitis	I-DISO
,	O
Acute	B-DISO
Gastroenteritis	I-DISO
,	O
and	O
Febrile	B-DISO
Seizures	I-DISO
:	O
A	O
2	O
-	O
Year	O
Prospective	O
Study	O
.	O

According	O
to	O
the	O
number	O
of	O
organ	O
failures	O
,	O
ACLF	O
is	O
graded	O
into	O
three	O
stages	O
:	O
ACLF	O
-	O
1	O
=	O
single	O
renal	B-DISO
failure	I-DISO
or	O
single	O
nonrenal	O
organ	B-DISO
failure	I-DISO
if	O
associated	O
with	O
renal	O
dysfunction	O
and	O
/	O
or	O
cerebral	B-DISO
dysfunction	I-DISO
;	O
ACLF	O
-	O
2	O
=	O
two	O
organ	O
failures	O
;	O
and	O
ACLF	O
-	O
3	O
=	O
three	O
to	O
six	O
organ	O
failures	O
,	O
with	O
increasing	O
28	O
-	O
day	O
mortality	O
rate	O
(	O
from	O
23	O
%-	O
74	O
%).	O

In	O
a	O
mouse	O
model	O
with	O
a	O
direct	O
pulmonary	O
injection	O
,	O
PLpro	O
stimulated	O
macrophage	O
infiltration	B-DISO
into	O
lung	O
,	O
up	O
-	O
regulating	O
Egr	O
-	O
1	O
,	O
TSP	O
-	O
1	O
,	O
TGF	O
-	O
β1	O
and	O
vimentin	O
expression	O
in	O
lung	O
tissues	O
.	O

TITLE	O
:	O
X	O
-	O
Ray	O
Structure	O
and	O
Inhibition	O
of	O
3C	O
-	O
like	O
Protease	O
from	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
.	O

Qingfei	O
Xiaoyan	O
Wan	O
(	O
QF	O
),	O
a	O
traditional	O
Chinese	O
medicine	O
(	O
TCM	O
)	O
formula	O
,	O
has	O
been	O
used	O
clinically	O
in	O
China	O
for	O
the	O
treatment	O
of	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
,	O
acute	O
or	O
chronic	B-DISO
bronchitis	I-DISO
and	O
pulmonary	B-DISO
infection	I-DISO
.	O

In	O
this	O
study	O
,	O
the	O
effects	O
of	O
QF	O
on	O
Pseudomonas	O
aeruginosa	O
-	O
induced	O
acute	B-DISO
pneumonia	I-DISO
in	O
mice	O
were	O
evaluated	O
.	O

ABSTRACT	O
:	O
Among	O
Plasmodium	O
species	O
the	O
causative	O
agent	O
of	O
malaria	B-DISO
in	O
Turkey	O
is	O
P	B-DISO
.	I-DISO
vivax	I-DISO
,	O
however	O
the	O
incidence	O
of	O
imported	O
falciparum	B-DISO
malaria	I-DISO
cases	O
is	O
steadily	O
increasing	O
.	O

Due	O
to	O
the	O
development	O
of	O
acute	B-DISO
tubular	I-DISO
necrosis	I-DISO
,	O
the	O
patient	O
have	O
undergone	O
hemodialysis	O
.	O

As	O
a	O
result	O
,	O
it	O
should	O
be	O
keep	O
in	O
mind	O
that	O
both	O
the	O
African	O
students	O
who	O
have	O
come	O
to	O
our	O
country	O
for	O
education	O
from	O
endemic	O
regions	O
and	O
as	O
well	O
as	O
the	O
returned	O
citizens	O
of	O
our	O
country	O
who	O
have	O
gone	O
to	O
work	O
in	O
endemic	O
areas	O
,	O
are	O
under	O
risk	O
of	O
malaria	B-DISO
and	O
it	O
is	O
very	O
important	O
to	O
consider	O
malaria	B-DISO
in	O
the	O
distinctive	O
diagnosis	O
of	O
patients	O
with	O
the	O
complaints	O
of	O
fever	O
,	O
headache	B-DISO
,	O
nausea	B-DISO
,	O
vomiting	B-DISO
and	O
muscle	B-DISO
pain	I-DISO
.	O

TITLE	O
:	O
Resolution	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
through	O
reversing	O
the	O
imbalance	B-DISO
of	O
Treg	O
/	O
Th17	O
by	O
targeting	O
the	O
cAMP	O
signaling	O
pathway	O
.	O

Pre	O
-	O
treatment	O
with	O
the	O
phosphodiesterase	O
antagonist	O
pentoxifyllinum	O
(	O
PTX	O
)	O
obviously	O
attenuated	O
lung	O
injury	O
and	O
reduced	O
the	O
mortality	O
of	O
mice	O
with	O
cecal	O
ligature	O
and	O
puncture	O
(	O
CLP	O
)‑	O
induced	O
ARDS	B-DISO
,	O
while	O
raising	O
cAMP	O
levels	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
provided	O
a	O
novel	O
treatment	O
strategy	O
for	O
ARDS	B-DISO
by	O
modulating	O
the	O
balance	O
of	O
Treg	O
/	O
Th17	O
and	O
the	O
subsequent	O
immune	O
response	O
via	O
cAMP	O
signaling	O
,	O
which	O
requires	O
pre	O
-	O
clinical	O
and	O
clinical	O
validation	O
.	O

ABSTRACT	O
:	O
We	O
present	O
a	O
rare	O
cause	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
due	O
to	O
an	O
accidental	O
intravascular	O
injection	O
of	O
paraffin	O
oil	O
.	O

The	O
current	O
piece	O
reviews	O
a	O
thematic	O
series	O
on	O
surveillance	O
-	O
response	O
systems	O
for	O
elimination	O
of	O
tropical	B-DISO
diseases	I-DISO
.	O

TITLE	O
:	O
Efficacy	O
of	O
an	O
inactivated	O
genotype	O
2b	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
vaccine	O
in	O
neonatal	O
piglets	O
.	O

Altogether	O
,	O
our	O
data	O
demonstrated	O
that	O
durable	O
lactogenic	O
immunity	O
was	O
present	O
in	O
dams	O
administrated	O
with	O
the	O
inactivated	O
vaccine	O
and	O
subsequently	O
conferred	O
critical	O
passive	O
immune	O
protection	O
to	O
their	O
own	O
litters	O
against	O
virulent	O
PEDV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Respiratory	O
viruses	O
are	O
well	O
-	O
known	O
causes	O
of	O
acute	O
exacerbation	O
of	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
AE	O
-	O
COPD	B-DISO
)	O
and	O
also	O
important	O
pathogens	O
for	O
concomitant	O
pneumonia	B-DISO
in	O
COPD	B-DISO
(	O
CP	O
-	O
COPD	B-DISO
).	O

Influenza	B-DISO
virus	O
was	O
significantly	O
more	O
common	O
in	O
the	O
AE	O
-	O
ACOPD	O
group	O
than	O
in	O
the	O
CP	O
-	O
COPD	B-DISO
group	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Respiratory	O
viruses	O
were	O
commonly	O
identified	O
in	O
both	O
AE	O
-	O
COPD	B-DISO
and	O
CP	O
-	O
COPD	B-DISO
,	O
influenza	B-DISO
virus	O
and	O
human	O
coronavirus	O
were	O
the	O
most	O
common	O
viruses	O
identified	O
in	O
AE	O
-	O
COPD	B-DISO
and	O
CP	O
-	O
COPD	B-DISO
patients	O
,	O
respectively	O
.	O

Forty	O
-	O
six	O
of	O
these	O
flocks	O
were	O
clinically	O
healthy	O
with	O
no	O
enteric	O
disease	O
,	O
and	O
the	O
other	O
55	O
flocks	O
were	O
clinically	O
suffering	B-DISO
from	O
diarrhea	B-DISO
.	O

There	O
was	O
no	O
statistical	O
evidence	O
to	O
link	O
these	O
viruses	O
as	O
the	O
main	O
cause	O
of	O
diarrhea	B-DISO
in	O
the	O
flocks	O
tested	O
.	O

Mice	O
were	O
instilled	O
with	O
increasing	O
doses	O
of	O
LPS	B-DISO
intratracheally	O
to	O
induce	O
different	O
degrees	O
of	O
ARDS	B-DISO
.	O

Results	O
showed	O
that	O
in	O
high	O
dose	O
LPS	B-DISO
(	O
30mg	O
/	O
kg	O
and	O
40mg	O
/	O
kg	O
)	O
-	O
induced	O
severe	O
ARDS	B-DISO
,	O
RIP3	O
protein	O
was	O
increased	O
significantly	O
,	O
accompanied	O
by	O
increases	O
of	O
p	O
-	O
RIP3	O
and	O
MLKL	O
,	O
while	O
in	O
low	O
dose	O
LPS	B-DISO
(	O
10mg	O
/	O
kg	O
and	O
20mg	O
/	O
kg	O
)	O
-	O
induced	O
mild	O
ARDS	B-DISO
,	O
apoptosis	O
was	O
remarkably	O
increased	O
.	O

Three	O
patients	O
infected	O
with	O
HCoV	O
(	O
9	O
%)	O
died	O
from	O
respiratory	B-DISO
infection	I-DISO
.	O

Prevalence	O
of	O
CCV	B-DISO
antibodies	O
suggested	O
a	O
seasonal	O
pattern	O
with	O
higher	O
prevalence	O
during	O
spring	O
(	O
43	O
%)	O
than	O
in	O
fall	O
(	O
11	O
%).	O

People	O
drugged	B-DISO
before	O
assault	O
also	O
need	O
to	O
promptly	O
notify	O
authorities	O
because	O
the	O
period	O
to	O
detect	O
the	O
drug	O
in	O
the	O
urine	O
or	O
blood	O
is	O
brief	O
and	O
the	O
ultimate	O
metabolites	O
are	O
carbon	O
dioxide	O
and	O
water	O
.	O

Acute	O
motor	O
axonal	B-DISO
neuropathy	I-DISO
,	O
a	O
subtype	O
of	O
GBS	B-DISO
,	O
was	O
diagnosed	O
by	O
cerebrospinal	O
fluid	O
and	O
nerve	O
conduction	O
velocity	O
testing	O
.	O

Inhaled	O
nitric	O
oxide	O
might	O
improve	O
outcomes	O
in	O
a	O
subset	O
of	O
patients	O
with	O
postoperative	O
pulmonary	B-DISO
hypertension	I-DISO
who	O
had	O
cardiac	O
surgery	O
;	O
however	O
,	O
it	O
has	O
not	O
been	O
shown	O
to	O
provide	O
long	O
-	O
term	O
benefit	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Aerosolised	O
bronchodilators	O
are	O
useful	O
in	O
mechanically	O
ventilated	O
patients	O
with	O
asthma	B-DISO
and	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
,	O
but	O
are	O
not	O
recommended	O
for	O
those	O
with	O
ARDS	B-DISO
.	O

PVD	B-DISO
and	O
ACP	B-DISO
were	O
assessed	O
by	O
echocardiography	O
.	O

To	O
evaluate	O
independent	O
factors	O
associated	O
with	O
ACP	B-DISO
,	O
significant	O
univariable	O
risk	O
factors	O
were	O
examined	O
using	O
logistic	O
regression	O
and	O
propensity	O
score	O
analyses	O
.	O

Both	O
the	O
crude	O
(	O
odds	O
ratio	O
[	O
OR	O
],	O
19	O
.	O
9	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
6	O
.	O
6	O
-	O
60	O
;	O
P	O
<	O
0	O
.	O
0001	O
),	O
multivariable	O
adjustment	O
(	O
OR	O
,	O
27	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
8	O
.	O
2	O
-	O
91	O
.	O
5	O
;	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
propensity	O
-	O
matched	O
(	O
OR	O
,	O
11	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
110	O
.	O
8	O
;	O
P	O
=	O
0	O
.	O
03	O
)	O
analyses	O
found	O
a	O
significant	O
association	O
between	O
ACS	O
-	O
ARDS	B-DISO
and	O
ACP	B-DISO
.	O

ABSTRACT	O
:	O
Emergence	O
of	O
the	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
as	O
a	O
global	O
threat	O
to	O
the	O
swine	O
industry	O
underlies	O
the	O
urgent	O
need	O
for	O
deeper	O
understanding	O
of	O
this	O
virus	O
.	O

TITLE	O
:	O
Neonatal	O
Mortality	O
,	O
Vesicular	O
Lesions	O
and	O
Lameness	B-DISO
Associated	O
with	O
Senecavirus	O
A	O
in	O
a	O
U	O
.	O
S	O
.	O
Sow	O
Farm	O
.	O

Veterinarians	O
and	O
animal	O
caretakers	O
must	O
remain	O
vigilant	O
for	O
vesicular	O
foreign	O
animal	B-DISO
diseases	I-DISO
and	O
report	O
suspicious	O
clinical	O
signs	O
and	O
lesions	O
to	O
state	O
animal	O
health	O
authorities	O
for	O
diagnostic	O
testing	O
and	O
further	O
investigation	O
.	O

TITLE	O
:	O
JNK	O
and	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
pathways	O
contribute	O
to	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	B-DISO
infection	I-DISO
.	O

The	O
EqCoV	O
S	O
protein	O
-	O
based	O
ELISA	O
could	O
be	O
used	O
effectively	O
for	O
seroepidemiologic	O
studies	O
in	O
order	O
to	O
better	O
characterize	O
the	O
overall	O
infection	B-DISO
rate	O
of	O
EqCoV	O
in	O
various	O
horse	O
populations	O
.	O

TITLE	O
:	O
Factors	O
influencing	O
emergency	B-DISO
nurses	O
'	O
ethical	O
problems	O
during	O
the	O
outbreak	O
of	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Whenever	O
there	O
has	O
been	O
a	O
worldwide	O
contagious	B-DISO
disease	I-DISO
outbreak	O
,	O
there	O
have	O
been	O
reports	O
of	O
infection	B-DISO
and	O
death	O
of	O
healthcare	O
workers	O
.	O

Data	O
were	O
collected	O
from	O
169	O
emergency	B-DISO
nurses	O
in	O
Korea	O
during	O
August	O
2015	O
.	O

The	O
findings	O
of	O
this	O
study	O
suggest	O
that	O
during	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
-	O
coronavirus	O
outbreak	O
,	O
emergency	B-DISO
nurses	O
experienced	O
ethical	O
problems	O
tied	O
to	O
a	O
mind	O
-	O
set	O
of	O
avoiding	O
patients	O
.	O

CONCLUSIONS	O
:	O
Through	O
this	O
study	O
,	O
we	O
obtained	O
information	O
on	O
emergency	B-DISO
nurses	O
'	O
ethical	O
problems	O
during	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
-	O
coronavirus	O
outbreak	O
and	O
identified	O
the	O
factors	O
that	O
influence	O
them	O
.	O

ABSTRACT	O
:	O
Knowledge	O
about	O
immunity	O
to	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
dromedary	O
camels	O
is	O
essential	O
for	O
infection	B-DISO
control	O
and	O
vaccination	O
.	O

A	O
longitudinal	O
study	O
of	O
11	O
dam	O
-	O
calf	O
pairs	O
showed	O
that	O
calves	O
lose	O
maternal	O
MERS	O
-	O
CoV	O
antibodies	O
5	O
-	O
6	O
months	O
postparturition	O
and	O
are	O
left	O
susceptible	O
to	O
infection	B-DISO
,	O
indicating	O
a	O
short	O
window	O
of	O
opportunity	O
for	O
vaccination	O
.	O

Interactions	O
between	O
Mo	O
-	O
DCs	B-DISO
and	O
UV	O
-	O
PEDV	O
significantly	O
stimulate	O
T	O
-	O
cell	O
proliferation	B-DISO
in	O
vitro	O
.	O

In	O
the	O
last	O
decade	O
,	O
interfering	O
with	O
microtubule	O
polymerization	O
,	O
a	O
potential	O
orientation	O
to	O
cause	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
has	O
become	O
a	O
promising	O
method	O
for	O
cancer	B-DISO
therapy	O
.	O

TITLE	O
:	O
Neurological	O
Complications	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
:	O
A	O
Report	O
of	O
Two	O
Cases	O
and	O
Review	O
of	O
the	O
Literature	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
was	O
first	O
discovered	O
in	O
September	O
2012	O
in	O
Saudi	O
Arabia	O
.	O

Five	O
suggestions	O
are	O
extracted	O
for	O
medical	O
schools	O
to	O
consider	O
in	O
infection	B-DISO
outbreaks	O
:	O
instant	O
cessation	O
of	O
clinical	O
clerkships	O
;	O
rational	O
decision	O
making	O
on	O
a	O
school	O
closure	O
;	O
use	O
of	O
information	O
technology	O
;	O
constant	O
communication	O
with	O
hospitals	O
;	O
and	O
open	O
communication	O
with	O
faculty	O
,	O
staff	O
,	O
and	O
students	O
.	O

CONCLUSIONS	O
:	O
FOB	O
under	O
NIV	O
could	O
be	O
considered	O
as	O
a	O
feasible	O
tool	O
for	O
diagnosis	O
and	O
guide	O
for	O
treatment	O
of	O
patients	O
with	O
ARDS	B-DISO
treated	O
via	O
NIV	O
in	O
intensive	O
care	O
units	O
.	O

The	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
in	O
severe	O
ARDS	B-DISO
is	O
increasing	O
worldwide	O
,	O
but	O
because	O
of	O
a	O
lack	O
of	O
randomized	O
trials	O
is	O
still	O
considered	O
a	O
rescue	O
therapy	O
.	O

CONCLUSIONS	O
:	O
Severe	O
ARDS	B-DISO
patients	O
should	O
receive	O
a	O
holistic	O
framework	O
of	O
respiratory	O
and	O
hemodynamic	O
support	O
aimed	O
to	O
ensure	O
adequate	O
gas	O
exchange	O
while	O
minimizing	O
the	O
risk	O
of	O
VILI	O
,	O
by	O
promoting	O
lung	O
recruitment	B-DISO
and	O
setting	O
protective	O
mechanical	O
ventilation	O
.	O

TITLE	O
:	O
The	O
proteome	O
of	O
the	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
Beau	O
-	O
R	O
virion	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
is	O
a	O
highly	O
contagious	O
respiratory	B-DISO
disease	I-DISO
of	O
poultry	O
caused	O
by	O
the	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
).	O

Lung	O
mononuclear	O
infiltrates	B-DISO
occurred	O
in	O
all	O
groups	O
after	O
virus	O
challenge	O
but	O
with	O
increased	O
infiltrates	B-DISO
that	O
contained	O
eosinophils	O
and	O
increases	O
in	O
the	O
eosinophil	O
promoting	O
IL	O
-	O
5	O
and	O
IL	O
-	O
13	O
cytokines	O
only	O
in	O
the	O
vaccine	O
groups	O
.	O

Rapid	O
diagnosis	O
is	O
critical	O
for	O
the	O
implementation	O
of	O
efficient	O
control	O
strategies	O
against	O
PDCoV	O
.	O
Developing	O
high	O
-	O
quality	O
diagnostic	O
methods	O
and	O
understanding	O
PDCoV	O
infection	B-DISO
dynamics	O
to	O
collect	O
appropriate	O
specimens	O
at	O
the	O
appropriate	O
time	O
window	O
are	O
important	O
to	O
obtain	O
reliable	O
diagnostic	O
results	O
.	O

Observational	O
trial	O
over	O
a	O
3	O
-	O
year	O
period	O
on	O
outcome	O
in	O
trauma	O
patients	O
(	O
Injury	O
Severity	O
Score	O
,	O
ISS	B-DISO
≥	O
16	O
)	O
with	O
severe	O
thoracic	B-DISO
injury	O
(	O
Abbreviated	O
Injury	O
Scale	O
,	O
AIS	B-DISO
Over	O
the	O
3	O
-	O
year	O
period	O
76	O
patients	O
with	O
ISS	B-DISO
≥	O
16	O
/	O
AIS	B-DISO
CLRT	O
remains	O
a	O
therapeutic	O
option	O
to	O
reduce	O
pulmonary	B-DISO
complications	I-DISO
after	O
severe	O
chest	O
trauma	O
in	O
our	O
center	O
.	O

Middle	O
East	O
respiratory	O
syndrome	B-DISO
-	O
related	O
risk	O
perception	O
was	O
significantly	O
different	O
according	O
to	O
gender	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
education	O
.	O

Enhancing	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
-	O
related	O
knowledge	O
by	O
considering	O
cooperation	O
between	O
hospitals	O
and	O
universities	O
will	O
sharpen	O
nursing	O
students	O
'	O
risk	O
perception	O
of	O
the	O
disease	O
and	O
effectively	O
increase	O
their	O
preventive	O
behaviours	O
.	O

ABSTRACT	O
:	O
Viral	O
replication	O
in	O
the	O
liver	O
is	O
generally	O
detected	O
by	O
cellular	O
endosomal	O
Toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
and	O
cytosolic	O
helicase	O
sensors	O
that	O
trigger	O
antiviral	O
inflammatory	B-DISO
responses	I-DISO
.	O

ABSTRACT	O
:	O
Only	O
a	O
few	O
reports	O
have	O
been	O
published	O
on	O
women	O
with	O
an	O
infectious	B-DISO
respiratory	O
viral	O
pathogen	O
,	O
such	O
as	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
Coronavirus	O
delivering	O
a	O
baby	O
.	O

Primary	O
and	O
secondary	O
bronchi	O
,	O
epithelial	B-DISO
hyperplasia	I-DISO
and	O
mononuclear	O
inflammatory	O
cell	O
infiltrate	B-DISO
of	O
the	O
lamina	O
propria	O
were	O
also	O
observed	O
.	O

ABSTRACT	O
:	O
Fecal	O
calprotectin	O
and	O
immunoglobulin	O
A	O
(	O
IgA	O
)	O
are	O
markers	O
of	O
intestinal	O
inflammation	B-DISO
and	O
immunity	O
in	O
adult	O
dogs	O
.	O

Giardia	B-DISO
intestinalis	O
antigen	O
was	O
quantified	O
by	O
ELISA	O
.	O

Fidelity	O
-	O
altering	O
mutations	O
previously	O
identified	O
in	O
coxsackie	B-DISO
virus	I-DISO
B3	O
(	O
CVB3	O
)	O
were	O
mapped	O
onto	O
the	O
nsp12	O
-	O
RdRp	O
model	O
structure	O
and	O
then	O
engineered	O
into	O
the	O
MHV	O
genome	O
with	O
[	O
nsp14	O
-	O
ExoN	O
(+)]	O
or	O
without	O
[	O
nsp14	O
-	O
ExoN	O
(-)]	O
ExoN	O
activity	O
.	O

The	O
nanoparticle	O
-	O
assisted	O
RT	O
-	O
PCR	O
assay	O
we	O
describe	O
here	O
can	O
be	O
used	O
to	O
distinguish	O
field	O
strains	O
from	O
vaccine	O
strains	O
of	O
PEDV	O
,	O
and	O
it	O
shows	O
promise	O
for	O
reducing	O
economic	O
loss	O
due	O
to	O
PEDV	O
infection	B-DISO
.	O

TITLE	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
detection	O
and	O
antibody	O
response	O
in	O
commercial	O
growing	O
pigs	O
.	O

TITLE	O
:	O
Characterization	O
of	O
anti	O
-	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
neutralizing	O
activity	O
in	O
mammary	O
secretions	O
.	O

ABSTRACT	O
:	O
Infection	B-DISO
of	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
by	O
neurotropic	O
viruses	O
represents	O
an	O
increasing	O
worldwide	O
problem	O
in	O
terms	O
of	O
morbidity	O
and	O
mortality	O
for	O
people	O
of	O
all	O
ages	O
.	O

More	O
recently	O
,	O
myeloid	O
cells	O
e	O
.	O
g	O
.	O
neutrophils	O
have	O
been	O
implicated	O
in	O
contributing	O
to	O
both	O
host	O
defense	O
and	O
disease	O
in	O
response	O
to	O
viral	B-DISO
infection	I-DISO
of	O
the	O
CNS	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
mechanism	O
by	O
which	O
a	O
large	O
outbreak	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	B-DISO
)	O
occurred	O
in	O
Japan	O
,	O
where	O
the	O
majority	O
of	O
sows	O
are	O
vaccinated	O
,	O
we	O
isolated	O
two	O
new	O
strains	O
of	O
PED	B-DISO
virus	O
(	O
PEDV	O
)	O
from	O
the	O
intestines	O
of	O
piglets	O
and	O
found	O
that	O
they	O
showed	O
greater	O
similarity	O
to	O
US	O
isolates	O
(	O
group	O
II	O
PEDV	O
)	O
than	O
to	O
the	O
Japanese	O
vaccine	O
strain	O
(	O
group	O
I	O
PEDV	O
).	O

ABSTRACT	O
:	O
Typhoid	B-DISO
fever	I-DISO
is	O
commonly	O
characterized	O
by	O
fever	O
and	O
abdominal	B-DISO
pain	I-DISO
.	O

This	O
case	O
details	O
severe	O
complications	O
of	O
typhoid	B-DISO
fever	I-DISO
that	O
are	O
uncommonly	O
seen	O
in	O
developed	O
countries	O
,	O
and	O
the	O
successful	O
response	O
to	O
high	O
-	O
dose	O
dexamethasone	O
as	O
adjunct	O
therapy	O
.	O

TITLE	O
:	O
[	O
Visual	O
Detection	O
of	O
Human	O
Coronavirus	O
NL63	O
by	O
Reverse	O
Transcription	O
Loop	O
-	O
Mediated	O
Isothermal	O
Amplification	B-DISO
].	O

ABSTRACT	O
:	O
We	O
wished	O
to	O
ascertain	O
the	O
prevalence	O
as	O
well	O
as	O
the	O
genetic	O
and	O
antigenic	O
variation	O
of	O
infectious	B-DISO
bronchitis	B-DISO
viruses	O
(	O
IBVs	O
)	O
circulating	O
in	O
the	O
Guangxi	O
Province	O
of	O
China	O
in	O
recent	O
years	O
.	O

ABSTRACT	O
:	O
Numerous	O
viral	B-DISO
infections	I-DISO
have	O
arisen	O
and	O
affected	O
global	O
healthcare	O
facilities	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	B-DISO
),	O
a	O
pandemic	O
threat	O
to	O
human	O
beings	O
,	O
has	O
aroused	O
huge	O
concern	O
worldwide	O
,	O
but	O
no	O
bibliometric	O
studies	O
have	O
been	O
conducted	O
on	O
MERS	B-DISO
research	O
.	O

Recent	O
efforts	O
of	O
antiviral	O
lead	O
discovery	O
for	O
RNA	O
targets	O
have	O
provided	O
drug	O
-	O
like	O
small	O
molecules	O
that	O
inhibit	O
viral	O
replication	O
and	O
include	O
inhibitors	O
of	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
(	O
HIV	B-DISO
),	O
hepatitis	B-DISO
C	I-DISO
virus	O
(	O
HCV	O
),	O
severe	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
SARS	B-DISO
CoV	O
),	O
and	O
influenza	B-DISO
A	O
virus	O
.	O

In	O
this	O
study	O
,	O
chickens	O
vaccinated	O
with	O
a	O
low	O
dose	O
(	O
1	O
.	O
6	O
×	O
10	O
(	O
3	O
)	O
EID50	O
/	O
bird	O
,	O
where	O
EID50	O
is	O
50	O
%	O
embryo	O
infectious	B-DISO
dose	O
)	O
of	O
CEK	O
-	O
adapted	O
Ark	O
vaccine	O
at	O
5	O
days	O
of	O
age	O
showed	O
a	O
significant	O
reduction	O
of	O
IBV	O
RNA	O
in	O
lachrymal	O
fluids	O
and	O
decreased	O
incidence	O
of	O
IBV	O
RNA	O
detection	O
in	O
tracheal	O
swabs	O
5	O
days	O
after	O
challenge	O
compared	O
to	O
unvaccinated	O
challenged	O
chickens	O
.	O

Here	O
we	O
describe	O
the	O
detection	O
and	O
isolation	O
of	O
an	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
-	O
like	O
coronavirus	O
from	O
the	O
intestines	O
of	O
a	O
flock	O
of	O
60	O
,	O
000	O
14	O
-	O
day	O
-	O
old	O
brown	O
/	O
red	O
broiler	O
chicks	O
.	O

There	O
were	O
no	O
lesions	O
in	O
the	O
respiratory	O
system	O
,	O
and	O
no	O
IBV	O
antigen	O
was	O
detected	O
in	O
trachea	B-DISO
,	O
lung	O
,	O
air	O
sac	O
,	O
conjunctiva	O
,	O
and	O
cecal	O
tonsils	O
.	O

TITLE	O
:	O
Frequent	O
Respiratory	O
Viral	B-DISO
Infections	I-DISO
in	O
Children	O
with	O
Febrile	B-DISO
Neutropenia	I-DISO
-	O
A	O
Prospective	O
Follow	O
-	O
Up	O
Study	O
.	O

Although	O
respiratory	O
viruses	O
are	O
commonly	O
associated	O
with	O
this	O
condition	B-DISO
,	O
the	O
etiologic	O
significance	O
of	O
this	O
finding	O
remains	O
unclear	O
and	O
is	O
therefore	O
the	O
subject	O
of	O
this	O
study	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
continuously	O
spreading	O
and	O
causing	O
severe	O
and	O
fatal	O
acute	B-DISO
respiratory	I-DISO
disease	I-DISO
in	O
humans	O
.	O

Prophylactic	O
and	O
therapeutic	O
strategies	O
are	O
therefore	O
urgently	O
needed	O
to	O
control	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

In	O
this	O
review	O
,	O
we	O
will	O
discuss	O
the	O
strategy	O
of	O
concerted	O
activation	O
of	O
Nrf2	O
and	O
autophagy	O
as	O
a	O
preventive	O
and	O
therapeutic	O
intervention	O
to	O
ameliorate	O
ALI	O
/	O
ARDS	B-DISO
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
antioxidant	O
,	O
antimicrobial	O
,	O
anti	O
-	O
HIV	B-DISO
,	O
and	O
cholinesterase	O
inhibitory	O
activities	O
of	O
aqueous	O
and	O
alcoholic	O
extracts	O
from	O
leaves	O
,	O
stems	O
,	O
and	O
flowers	O
of	O
Euphorbia	O
characias	O
.	O

We	O
observe	O
that	O
clinical	O
signs	B-DISO
and	I-DISO
symptoms	I-DISO
alone	O
are	O
often	O
insufficient	O
to	O
recognize	O
index	O
cases	O
of	O
diseases	O
of	O
global	O
concern	O
against	O
the	O
considerable	O
background	O
infectious	B-DISO
disease	I-DISO
burden	O
that	O
is	O
present	O
throughout	O
the	O
developing	O
world	O
.	O

CONCLUSIONS	O
:	O
Veno	O
-	O
arterial	O
ECMO	O
has	O
been	O
shown	O
to	O
improve	O
the	O
short	O
-	O
term	O
survival	O
of	O
patients	O
with	O
AlP	O
poisoning	O
having	O
severe	O
LV	O
myocardial	B-DISO
dysfunction	I-DISO
.	O

ABSTRACT	O
:	O
Prone	O
position	O
(	O
PP	O
)	O
improves	O
oxygenation	O
and	O
outcome	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
patients	O
with	O
a	O
PaO2	O
/	O
FiO2	O
ratio	O
<	O
150	O
mmHg	O
.	O

We	O
conducted	O
a	O
prospective	O
multicenter	O
study	O
that	O
included	O
adult	O
patients	O
with	O
severe	O
and	O
moderate	O
ARDS	B-DISO
.	O

TITLE	O
:	O
From	O
SARS	B-DISO
to	O
Avian	B-DISO
Influenza	I-DISO
:	O
The	O
Role	O
of	O
International	O
Factors	O
in	O
China	O
'	O
s	O
Approach	O
to	O
Infectious	B-DISO
Disease	I-DISO
Control	O
.	O

Medical	O
records	O
of	O
eligible	O
pregnant	O
women	O
with	O
HELLP	B-DISO
syndrome	I-DISO
were	O
reviewed	O
retrospectively	O
.	O

TITLE	O
:	O
Identify	O
-	O
Isolate	O
-	O
Inform	O
:	O
A	O
Tool	O
for	O
Initial	O
Detection	O
and	O
Management	O
of	O
Zika	O
Virus	O
Patients	O
in	O
the	O
Emergency	B-DISO
Department	O
.	O

TITLE	O
:	O
Persistence	O
of	O
Antibodies	O
against	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
how	O
long	O
antibodies	O
against	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
persist	O
,	O
we	O
measured	O
long	O
-	O
term	O
antibody	O
responses	O
among	O
persons	O
serologically	O
positive	O
or	O
indeterminate	O
after	O
a	O
2012	O
outbreak	O
in	O
Jordan	O
.	O

TITLE	O
:	O
A	O
Highly	O
Sensitive	O
Molecular	O
Detection	O
Platform	O
for	O
Robust	O
and	O
Facile	O
Diagnosis	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
Corona	O
Virus	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
increasingly	O
being	O
applied	O
as	O
life	O
support	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
patients	O
.	O

ABSTRACT	O
:	O
Status	B-DISO
asthmaticus	I-DISO
can	O
develop	O
into	O
a	O
life	O
-	O
threatening	O
disorder	O
that	O
requires	O
mechanical	O
ventilation	O
.	O

Previous	O
case	O
studies	O
have	O
demonstrated	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
as	O
a	O
life	O
-	O
saving	O
measure	O
for	O
pregnant	O
women	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
as	O
well	O
as	O
non	O
-	O
pregnant	O
patients	O
with	O
status	B-DISO
asthmaticus	I-DISO
.	O

ABSTRACT	O
:	O
Infection	B-DISO
with	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
causes	O
diarrhea	B-DISO
,	O
vomiting	B-DISO
,	O
and	O
high	O
mortality	O
in	O
suckling	O
pigs	O
.	O

Scientific	O
advancements	O
since	O
the	O
2002	O
-	O
2003	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
pandemic	O
allowed	O
for	O
rapid	O
progress	O
in	O
our	O
understanding	O
of	O
the	O
epidemiology	O
and	O
pathogenesis	B-DISO
of	O
MERS	O
-	O
CoV	O
and	O
the	O
development	O
of	O
therapeutics	O
.	O

In	O
this	O
Review	O
,	O
we	O
detail	O
our	O
present	O
understanding	O
of	O
the	O
transmission	O
and	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
,	O
and	O
discuss	O
the	O
current	O
state	O
of	O
development	O
of	O
measures	O
to	O
combat	O
emerging	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
Since	O
outbreaks	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
in	O
the	O
United	O
States	O
in	O
2013	O
,	O
explosive	O
outbreaks	O
of	O
PED	O
in	O
South	O
Korea	O
have	O
infected	O
all	O
age	O
groups	O
of	O
pigs	O
in	O
2014	O
-	O
2015year	O
.	O

We	O
showed	O
that	O
this	O
peptide	O
ameliorates	O
collagen	O
-	O
induced	O
arthritis	B-DISO
in	O
DBA	B-DISO
/	O
1J	O
mice	O
and	O
protects	O
against	O
bone	O
and	O
cartilage	O
damage	O
.	O

ABSTRACT	O
:	O
Human	O
adenoviruses	O
(	O
HAdVs	O
)	O
cause	O
a	O
wide	O
spectrum	O
of	O
clinical	O
syndromes	B-DISO
,	O
depending	O
on	O
species	O
and	O
types	O
,	O
from	O
mild	O
respiratory	B-DISO
infections	I-DISO
to	O
deadly	O
pneumonia	B-DISO
:	O
in	O
particular	O
,	O
severe	O
infections	B-DISO
occur	O
in	O
immunocompromised	O
patients	O
.	O

Leukopenia	B-DISO
and	O
subsequent	O
bacterial	B-DISO
infection	I-DISO
occurred	O
,	O
but	O
the	O
patient	O
recovered	O
completely	O
and	O
was	O
discharged	O
from	O
the	O
hospital	O
after	O
54days	O
.	O

In	O
Mexico	O
,	O
an	O
outbreak	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
,	O
characterized	O
by	O
100	O
%	O
mortality	O
in	O
piglets	O
,	O
began	O
in	O
March	O
2014	O
in	O
the	O
State	O
of	O
Mexico	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	B-DISO
Infection	I-DISO
During	O
Pregnancy	O
:	O
A	O
Report	O
of	O
5	O
Cases	O
From	O
Saudi	O
Arabia	O
.	O

To	O
better	O
understand	O
the	O
antigenicity	O
and	O
pathogenesis	B-DISO
of	O
this	O
genotype	O
,	O
the	O
characteristics	O
of	O
the	O
ck	O
/	O
CH	O
/	O
LDL	O
/	O
140520	O
strain	O
were	O
compared	O
to	O
those	O
of	O
four	O
commercial	O
IB	O
vaccine	O
strains	O
that	O
are	O
used	O
commonly	O
in	O
China	O
,	O
as	O
well	O
as	O
four	O
attenuated	O
viruses	O
that	O
represent	O
two	O
types	O
of	O
IBV	O
strains	O
,	O
which	O
are	O
believed	O
to	O
have	O
originated	O
in	O
China	O
and	O
are	O
the	O
predominant	O
IBV	O
types	O
circulating	O
in	O
chicken	O
flocks	O
in	O
China	O
and	O
many	O
other	O
parts	O
of	O
the	O
world	O
.	O

Our	O
results	O
showed	O
that	O
strain	O
ck	O
/	O
CH	O
/	O
LDL	O
/	O
140520	O
is	O
very	O
pathogenic	O
,	O
and	O
that	O
it	O
is	O
able	O
to	O
cause	O
cystic	O
oviducts	O
in	O
a	O
high	O
percentage	O
of	O
birds	O
,	O
as	O
well	O
as	O
mortality	O
due	O
to	O
nephritis	B-DISO
and	O
respiratory	B-DISO
distress	I-DISO
with	O
complete	O
tracheal	O
ciliostasis	O
,	O
especially	O
in	O
chickens	O
infected	O
at	O
1day	O
of	O
age	O
.	O

TITLE	O
:	O
Pressure	O
-	O
controlled	O
inverse	O
ratio	O
ventilation	O
as	O
a	O
rescue	O
therapy	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Over	O
the	O
6	O
-	O
year	O
period	O
,	O
1169	O
CPV	O
-	O
positive	O
cases	O
were	O
identified	O
and	O
the	O
morbidity	O
of	O
CPV	O
infection	B-DISO
ranged	O
from	O
4	O
.	O
16	O
to	O
8	O
.	O
06	O
%,	O
although	O
morbidity	O
was	O
not	O
significant	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
between	O
2009	O
and	O
2014	O
.	O

There	O
is	O
evidence	O
from	O
in	O
vitro	O
and	O
in	O
vivo	O
experiments	O
in	O
various	O
animal	O
models	O
and	O
in	O
patients	O
that	O
endotoxin	O
or	O
sepsis	B-DISO
may	O
directly	O
and	O
indirectly	O
alter	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
response	O
to	O
severe	O
infection	B-DISO
.	O

We	O
have	O
classified	O
three	O
phases	O
,	O
ranging	O
from	O
sepsis	B-DISO
to	O
organ	O
dysfunction	O
,	O
characterizing	O
the	O
interaction	O
between	O
neutrophils	O
and	O
platelets	O
.	O

TITLE	O
:	O
Immunotherapeutic	O
implications	O
of	O
IL	O
-	O
6	O
blockade	O
for	O
cytokine	B-DISO
storm	I-DISO
.	O

The	O
hypothesis	O
of	O
rickettsiosis	B-DISO
was	O
made	O
on	O
the	O
basis	O
of	O
a	O
comprehensive	O
medical	O
history	O
and	O
was	O
confirmed	O
by	O
serological	O
tests	O
.	O

TNF	O
-	O
α	O
and	O
IL	O
-	O
10	O
concentrations	O
in	O
the	O
alveolar	O
lavage	O
,	O
probability	O
of	O
survival	O
and	O
days	O
without	O
organ	B-DISO
failure	I-DISO
were	O
similar	O
in	O
both	O
groups	O
.	O

Here	O
,	O
we	O
review	O
the	O
strategies	O
exploited	O
by	O
coronavirus	O
to	O
modulate	O
cellular	B-DISO
stress	I-DISO
response	O
pathways	O
.	O

In	O
this	O
case	O
,	O
only	O
ATRA	O
was	O
administered	O
for	O
APL	B-DISO
treatment	O
.	O

Presepsin	O
and	O
procalcitonin	O
(	O
PCT	B-DISO
)	O
levels	O
were	O
determined	O
for	O
patients	O
at	O
admission	O
to	O
ICU	O
.	O

In	O
view	O
of	O
the	O
rapid	O
onset	O
and	O
extent	O
of	O
hemorrhage	B-DISO
which	O
may	O
culminate	O
quickly	O
into	O
asphyxiation	B-DISO
and	O
death	O
,	O
HFOV	O
may	O
indeed	O
be	O
lifesaving	O
in	O
severe	O
LPHS	O
.	O

ABSTRACT	O
:	O
Two	O
critical	O
steps	O
when	O
investigating	O
an	O
animal	O
model	O
of	O
a	O
virus	B-DISO
infection	I-DISO
are	O
consistently	O
successfully	O
infecting	O
animals	O
and	O
accurately	O
determining	O
viral	O
titers	O
in	O
tissue	O
throughout	O
the	O
course	O
of	O
infection	B-DISO
.	O

Here	O
we	O
discuss	O
in	O
detail	O
how	O
to	O
infect	O
mice	O
with	O
SARS	B-DISO
-	O
CoV	O
and	O
then	O
quantify	O
the	O
titer	O
of	O
virus	O
in	O
the	O
lung	O
.	O

Positioning	O
a	O
patient	O
in	O
a	O
prone	O
position	O
increases	O
the	O
risk	O
of	O
medical	O
device	O
-	O
related	O
pressure	B-DISO
ulcers	I-DISO
in	O
the	O
facial	O
area	O
.	O

The	O
results	O
indicated	O
the	O
virus	O
showed	O
the	O
characters	O
of	O
inducing	O
dwarf	B-DISO
embryo	O
after	O
inocubation	O
,	O
the	O
sensibility	O
to	O
lipid	O
solvent	O
and	O
the	O
hemagglutination	O
capacity	O
after	O
pancreatic	O
enzyme	O
treatment	O
,	O
the	O
typical	O
morphology	O
of	O
coronavirus	O
,	O
the	O
interference	O
to	O
NDV	O
replication	O
and	O
the	O
homology	O
among	O
84	O
.	O
7	O
%	O
-	O
99	O
%	O
of	O
the	O
particial	O
N	O
gene	O
sequences	O
to	O
the	O
reference	O
IBV	O
(	O
Avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
)	O
strains	O
.	O

In	O
2014	O
,	O
porcine	O
deltacoronavirus	O
(	O
PDCoV	O
)	O
infection	B-DISO
spread	O
rapidly	O
in	O
the	O
USA	O
.	O

This	O
review	O
is	O
focused	O
in	O
the	O
host	O
cell	O
responses	O
to	O
enteric	O
porcine	O
CoV	O
infection	B-DISO
and	O
the	O
viral	O
proteins	O
involved	O
in	O
pathogenesis	B-DISO
.	O

Veno	O
-	O
venous	O
ECMO	O
was	O
started	O
at	O
the	O
end	O
of	O
lung	O
injury	O
induction	O
with	O
a	O
flow	O
>	O
60	O
ml	O
/	O
kg	O
/	O
min	O
resulting	O
in	O
rapid	O
reversal	O
of	O
hypoxemia	O
and	O
pulmonary	B-DISO
hypertension	I-DISO
.	O

It	O
is	O
presented	O
as	O
it	O
was	O
seldom	O
reported	O
in	O
children	O
to	O
cause	O
distinct	O
pulmonary	B-DISO
complications	I-DISO
.	O

It	O
should	O
be	O
kept	O
in	O
mind	O
that	O
severe	O
pulmonary	B-DISO
complications	I-DISO
can	O
develop	O
in	O
patients	O
with	O
chemical	B-DISO
pneumonia	I-DISO
.	O

TITLE	O
:	O
MERS	O
-	O
CoV	O
outbreak	O
following	O
a	O
single	O
patient	O
exposure	O
in	O
an	O
emergency	B-DISO
room	O
in	O
South	O
Korea	O
:	O
an	O
epidemiological	O
outbreak	O
study	O
.	O

Patients	O
were	O
categorised	O
on	O
the	O
basis	O
of	O
their	O
exposure	O
in	O
the	O
emergency	B-DISO
room	O
:	O
in	O
the	O
same	O
zone	O
as	O
the	O
index	O
case	O
(	O
group	O
A	O
),	O
in	O
different	O
zones	O
except	O
for	O
overlap	O
at	O
the	O
registration	O
area	O
or	O
the	O
radiology	O
suite	O
(	O
group	B-DISO
B	I-DISO
),	O
and	O
in	O
different	O
zones	O
(	O
group	O
C	O
).	O

Medically	O
critically	B-DISO
ill	I-DISO
patients	O
who	O
require	O
urgent	O
bedside	O
diagnostic	O
assessment	O
fall	O
into	O
2	O
categories	O
:	O
(	O
1	O
)	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
and	O
(	O
2	O
)	O
hemodynamic	O
derangements	O
.	O

Different	O
respiratory	O
system	O
pathologies	O
that	O
result	O
in	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
(	O
such	O
as	O
increased	O
interstitial	O
fluid	O
,	O
alveolar	O
consolidation	O
,	O
pleural	B-DISO
effusion	I-DISO
)	O
cause	O
characteristic	O
ultrasonographic	O
findings	O
;	O
diaphragmatic	O
assessment	O
may	O
also	O
add	B-DISO
information	O
.	O

It	O
has	O
not	O
been	O
found	O
useful	O
in	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
due	O
to	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
and	O
diffuse	O
interstitial	B-DISO
pneumonia	I-DISO
.	O

Although	O
considerable	O
translational	O
challenges	O
,	O
such	O
as	O
concerns	O
regarding	O
cell	O
manufacture	O
scale	O
-	O
up	O
and	O
issues	O
regarding	O
cell	O
potency	O
and	O
batch	O
variability	O
,	O
must	O
be	O
overcome	O
,	O
MSCs	O
constitute	O
a	O
highly	O
promising	O
potential	O
therapy	O
for	O
ARDS	B-DISO
.	O

ECMO	O
can	O
stabilize	O
gas	O
exchange	O
and	O
haemodynamic	O
compromise	O
,	O
consequently	O
preventing	O
further	O
hypoxic	B-DISO
organ	O
damage	O
.	O

Because	O
ARDS	B-DISO
has	O
multiple	O
causes	O
,	O
the	O
diagnosis	O
should	O
be	O
investigated	O
and	O
treatment	O
should	O
be	O
commenced	O
during	O
ECMO	O
.	O

A	O
retrospective	O
case	O
study	O
was	O
performed	O
,	O
including	O
twenty	O
-	O
three	O
severe	O
ARDS	B-DISO
patients	O
who	O
received	O
ECMO	O
from	O
January	O
2009	O
to	O
July	O
2015	O
.	O

The	O
RESP	O
,	O
APCHAE	O
II	O
,	O
and	O
SOFA	O
scorings	O
systems	O
show	O
good	O
predictive	O
value	O
for	O
intra	O
-	O
hospital	O
survival	O
of	O
ARDS	B-DISO
patients	O
treated	O
with	O
ECMO	O
in	O
our	O
single	O
-	O
center	O
evaluation	O
.	O

Five	O
patients	O
were	O
discharged	O
after	O
giving	O
up	O
of	O
treatment	O
by	O
parents	O
due	O
to	O
poor	O
efficacy	O
on	O
primary	B-DISO
disease	I-DISO
;	O
3	O
cases	O
were	O
transferred	O
to	O
other	O
departments	O
for	O
further	O
treatment	O
;	O
15	O
cases	O
were	O
discharged	O
with	O
a	O
feeding	O
tube	O
for	O
family	O
nutrition	O
and	O
specialist	O
out	O
-	O
patient	O
treatment	O
.	O

EN	O
is	O
suitable	O
for	O
a	O
variety	O
of	O
children	O
'	O
s	O
digestive	B-DISO
diseases	I-DISO
,	O
which	O
can	O
improve	O
the	O
nutritional	O
status	O
of	O
the	O
patients	O
and	O
was	O
safe	O
for	O
clinical	O
application	O
.	O

ABSTRACT	O
:	O
Idiopathic	B-DISO
pneumonia	I-DISO
syndrome	I-DISO
(	O
IPS	B-DISO
)	O
is	O
an	O
acute	O
lung	O
dysfunction	O
of	O
non	O
-	O
infectious	B-DISO
aetiology	O
and	O
a	O
severe	O
complication	B-DISO
following	O
haematopoietic	O
stem	O
cell	O
transplantation	O
(	O
HSCT	O
).	O

Since	O
the	O
therapeutic	O
strategies	O
for	O
IPS	B-DISO
are	O
clearly	O
different	O
from	O
those	O
of	O
infectious	B-DISO
diseases	I-DISO
,	O
and	O
therapeutic	O
delay	O
causes	O
a	O
poor	O
prognosis	O
,	O
radiologists	O
should	O
be	O
aware	O
of	O
some	O
characteristic	O
HRCT	O
findings	O
of	O
IPS	B-DISO
,	O
which	O
includes	O
a	O
wide	O
spectrum	O
of	O
entities	O
.	O

The	O
second	O
advance	O
introduces	O
a	O
nicking	O
enzyme	O
that	O
allows	O
a	O
single	O
target	O
molecule	O
to	O
activate	O
more	O
than	O
one	O
beacon	O
,	O
allowing	O
""""	O
signal	O
amplification	B-DISO
"""."	O

Time	O
course	O
experiments	O
show	O
that	O
griffithsin	O
inhibits	O
MERS	O
-	O
CoV	O
infection	B-DISO
at	O
the	O
binding	O
step	O
.	O

In	O
conclusion	O
,	O
we	O
identify	O
griffithsin	O
as	O
a	O
potent	O
inhibitor	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
at	O
the	O
entry	O
step	O
.	O

Impairments	O
in	O
chromosome	O
maintenance	O
are	O
linked	O
to	O
rare	O
chromosome	B-DISO
breakage	I-DISO
disorders	O
.	O

Here	O
,	O
we	O
have	O
identified	O
a	O
chromosome	B-DISO
breakage	I-DISO
syndrome	B-DISO
associated	O
with	O
severe	O
lung	B-DISO
disease	I-DISO
in	O
early	O
childhood	O
.	O

Four	O
children	O
from	O
two	O
unrelated	O
kindreds	O
died	O
of	O
severe	O
pulmonary	B-DISO
disease	I-DISO
during	O
infancy	O
following	O
viral	B-DISO
pneumonia	I-DISO
with	O
evidence	O
of	O
combined	O
T	O
and	O
B	O
cell	O
immunodeficiency	B-DISO
.	O

Whole	O
exome	O
sequencing	O
revealed	O
biallelic	O
missense	O
mutations	O
in	O
the	O
NSMCE3	O
(	O
also	O
known	O
as	O
NDNL2	O
)	O
gene	O
,	O
which	O
encodes	O
a	O
subunit	O
of	O
the	O
SMC5	O
/	O
6	O
complex	O
that	O
is	O
essential	O
for	O
DNA	B-DISO
damage	I-DISO
response	O
and	O
chromosome	O
segregation	O
.	O

This	O
work	O
associates	O
missense	O
mutations	O
in	O
NSMCE3	O
with	O
an	O
autosomal	O
recessive	O
chromosome	B-DISO
breakage	I-DISO
syndrome	B-DISO
that	O
leads	O
to	O
defective	O
T	O
and	O
B	O
cell	O
function	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
early	O
childhood	O
.	O

The	O
two	O
suggested	O
mechanisms	O
are	O
as	O
follows	O
:	O
(	O
1	O
)	O
apnea	B-DISO
due	O
to	O
muscle	B-DISO
rigidity	I-DISO
and	O
paroxysmal	O
muscle	B-DISO
spasms	I-DISO
,	O
and	O
(	O
2	O
)	O
paroxysmal	O
autonomic	O
hyperactivity	O
.	O

Cats	O
were	O
classified	O
as	O
having	O
or	O
not	O
having	O
FIP	B-DISO
based	O
on	O
immunohistochemistry	O
(	O
if	O
available	O
)	O
or	O
a	O
sophisticated	O
statistical	O
method	O
using	O
machine	O
learning	O
methodology	O
with	O
concepts	O
from	O
game	O
theory	O
.	O

ABSTRACT	O
:	O
Three	O
experiments	O
were	O
conducted	O
to	O
evaluate	O
the	O
effect	O
of	O
yeast	O
-	O
derived	O
carbohydrates	O
(	O
YDC	O
),	O
and	O
a	O
blend	O
of	O
probiotics	O
and	O
YDC	O
(	O
synbiotic	O
,	O
SNB	O
)	O
on	O
serum	O
IgG	O
concentration	O
,	O
maternal	O
-	O
derived	O
antibody	O
(	O
MDA	O
)	O
decay	B-DISO
,	O
and	O
specific	O
antibody	O
-	O
mediated	O
immune	O
response	O
in	O
chick	O
pullets	O
following	O
immunization	O
with	O
T	O
-	O
cell	O
dependent	O
antigens	O
.	O

Recently	O
,	O
the	O
Korean	O
Asthma	B-DISO
Guideline	O
has	O
been	O
updated	O
by	O
The	O
Korean	O
Academy	O
of	O
Tuberculosis	B-DISO
and	O
Respiratory	B-DISO
Diseases	I-DISO
(	O
KATRD	O
)	O
in	O
an	O
effort	O
to	O
improve	O
the	O
clinical	O
management	O
of	O
asthma	B-DISO
.	O

This	O
guideline	O
focuses	O
on	O
adult	O
patients	O
with	O
asthma	B-DISO
and	O
aims	O
to	O
deliver	O
up	O
to	O
date	O
scientific	O
evidence	O
and	O
recommendations	O
to	O
general	O
physicians	O
for	O
the	O
management	O
of	O
asthma	B-DISO
.	O

Although	O
it	O
is	O
usually	O
associated	O
with	O
elevated	O
creatine	O
phosphokinase	O
level	O
,	O
some	O
patients	O
may	O
have	O
amyopathic	B-DISO
dermatomyositis	I-DISO
(	O
ADM	O
)	O
like	O
presentation	O
with	O
predominant	O
skin	O
involvement	O
.	O

It	O
may	O
rarely	O
present	O
with	O
a	O
very	O
aggressive	B-DISO
course	O
resulting	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Differentiation	O
between	O
ADM	O
-	O
ILD	O
and	O
AS	O
syndrome	B-DISO
may	O
be	O
difficult	O
in	O
the	O
absence	O
of	O
positive	O
serology	O
and	O
clinical	O
presentation	O
may	O
help	O
in	O
clinching	O
the	O
diagnosis	O
.	O

2	O
)	O
Visit	O
hospitals	O
that	O
were	O
exposed	O
to	O
MERS	O
-	O
CoV	O
infected	O
patients	O
,	O
and	O
to	O
provide	O
advice	O
regarding	O
infection	B-DISO
control	O
strategy	O
for	O
rehabilitating	O
of	O
the	O
exposed	O
hospitals	O
.	O

The	O
first	O
Korean	O
patient	O
infected	O
by	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
was	O
diagnosed	O
on	O
May	O
20	O
,	O
2015	O
,	O
after	O
he	O
returned	O
from	O
Qatar	O
and	O
Bahrain	O
.	O

TITLE	O
:	O
Outbreaks	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
in	O
Two	O
Hospitals	O
Initiated	O
by	O
a	O
Single	O
Patient	O
in	O
Daejeon	O
,	O
South	O
Korea	O
.	O

Korea	O
experienced	O
an	O
outbreak	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
in	O
2015	O
,	O
which	O
was	O
characterized	O
by	O
superspreading	O
events	O
in	O
healthcare	O
settings	O
.	O

TITLE	O
:	O
Clinical	O
Presentation	O
and	O
Outcomes	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
in	O
the	O
Republic	O
of	O
Korea	O
.	O

ABSTRACT	O
:	O
From	O
May	O
to	O
July	O
2015	O
,	O
the	O
Republic	O
of	O
Korea	O
experienced	O
the	O
largest	O
outbreak	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
outside	O
the	O
Arabian	O
Peninsula	O
.	O

Here	O
,	O
we	O
hypothesized	O
that	O
absence	O
of	O
C5	O
is	O
correlated	O
with	O
a	O
decreased	O
inflammatory	B-DISO
response	I-DISO
in	O
trauma	O
induced	O
septic	O
acute	O
lung	O
injury	O
.	O

Oesophagectomy	O
is	O
associated	O
with	O
high	O
rates	O
of	O
ARDS	B-DISO
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
characterize	O
patients	O
and	O
identify	O
risk	O
factors	O
for	O
developing	O
ARDS	B-DISO
after	O
oesophagectomy	O
.	O

ABSTRACT	O
:	O
ADP	O
-	O
ribosylation	O
is	O
a	O
posttranslational	O
protein	O
modification	O
in	O
which	O
ADP	O
-	O
ribose	O
is	O
transferred	O
from	O
NAD	B-DISO
(+)	O
to	O
specific	O
acceptors	O
to	O
regulate	O
a	O
wide	O
variety	O
of	O
cellular	O
processes	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
macro	O
domain	O
from	O
hepatitis	B-DISO
E	I-DISO
virus	O
(	O
HEV	O
)	O
serves	O
as	O
an	O
ADP	O
-	O
ribose	O
-	O
protein	O
hydrolase	O
for	O
mono	B-DISO
-	O
ADP	O
-	O
ribose	O
(	O
MAR	B-DISO
)	O
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
(	O
PAR	O
)	O
chain	O
removal	O
(	O
de	O
-	O
MARylation	O
and	O
de	O
-	O
PARylation	O
,	O
respectively	O
)	O
from	O
mono	B-DISO
-	O
and	O
poly	O
(	O
ADP	O
)-	O
ribosylated	O
proteins	O
,	O
respectively	O
.	O

TITLE	O
:	O
Relationship	O
between	O
elevated	O
soluble	O
CD74	O
and	O
severity	O
of	O
experimental	O
and	O
clinical	O
ALI	O
/	O
ARDS	B-DISO
.	O

The	O
elevated	O
levels	O
of	O
sCD74	O
in	O
BALF	O
positively	O
correlated	O
with	O
lung	O
permeability	O
and	O
inflammation	B-DISO
.	O

A	O
total	O
of	O
62	O
patients	O
with	O
ARDS	B-DISO
secondary	O
to	O
severe	O
chest	O
trauma	O
were	O
divided	O
into	O
the	O
observation	O
and	O
control	O
groups	O
.	O

Human	O
HeLa	O
cells	O
expressing	O
pAPN	O
and	O
pAPN	O
-	O
positive	O
porcine	O
CPK	O
cells	O
failed	O
to	O
support	O
PEDV	O
infection	B-DISO
,	O
but	O
were	O
susceptible	O
to	O
infection	B-DISO
by	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
),	O
which	O
utilizes	O
pAPN	O
as	O
a	O
functional	O
receptor	O
.	O

ABSTRACT	O
:	O
A	O
67	O
-	O
year	O
-	O
old	O
woman	O
was	O
diagnosed	O
as	O
having	O
scrub	B-DISO
typhus	I-DISO
with	O
pneumonitis	B-DISO
.	O

Primary	O
outcomes	O
included	O
acute	O
(	O
5	O
-	O
minute	O
Apgar	O
score	O
<	O
5	O
,	O
cardiopulmonary	O
resuscitation	O
and	O
ventilator	O
support	O
<	O
24	O
hours	O
,	O
neonatal	O
injury	O
,	O
and	O
/	O
or	O
transient	B-DISO
tachypnea	I-DISO
of	I-DISO
the	I-DISO
newborn	I-DISO
)	O
and	O
severe	O
(	O
grade	O
3	O
or	O
4	O
intraventricular	B-DISO
hemorrhage	I-DISO
,	O
necrotizing	B-DISO
enterocolitis	I-DISO
,	O
seizure	B-DISO
,	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
,	O
hypoxic	B-DISO
ischemic	I-DISO
encephalopathy	I-DISO
,	O
meconium	B-DISO
aspiration	I-DISO
,	O
ventilator	O
support	O
≥	O
2	O
days	O
,	O
sepsis	B-DISO
and	O
/	O
or	O
neonatal	B-DISO
death	I-DISO
)	O
neonatal	O
morbidity	O
.	O

The	O
2003	O
SARS	B-DISO
-	O
CoV	O
outbreak	O
began	O
in	O
Guangdong	O
Province	O
in	O
China	O
and	O
spread	O
to	O
humans	O
via	O
civet	O
cats	O
and	O
raccoon	O
dogs	O
in	O
the	O
wet	O
markets	O
before	O
spreading	O
to	O
37	O
countries	O
.	O

In	O
this	O
study	O
,	O
the	O
molecular	O
cloning	O
,	O
expression	O
,	O
and	O
antiporcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
activity	O
of	O
porcine	O
IFN	O
-	O
λ3	O
(	O
poIFN	O
-	O
λ3	O
)	O
were	O
reported	O
.	O

ABSTRACT	O
:	O
Parenchymal	O
lung	O
involvement	O
(	O
PLI	O
)	O
in	O
adult	B-DISO
-	I-DISO
onset	I-DISO
Still	I-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
(	O
AOSD	O
)	O
has	O
seldom	O
,	O
if	O
ever	O
,	O
been	O
studied	O
.	O

TITLE	O
:	O
Viral	O
etiology	O
in	O
adult	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
/	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
and	O
predictivity	O
of	O
C	O
-	O
reactive	O
protein	O
.	O

Patients	O
with	O
rhinovirus	O
had	O
lower	O
rates	O
(	O
20	O
%)	O
of	O
myalgia	B-DISO
(	O
p	O
=	O
0	O
.	O
043	O
).	O

TITLE	O
:	O
Parainfluenza	B-DISO
Virus	I-DISO
Infection	I-DISO
.	O

Seasonal	O
HPIV	O
epidemics	O
result	O
in	O
a	O
significant	O
burden	O
of	O
disease	O
in	O
children	O
and	O
account	O
for	O
40	O
%	O
of	O
pediatric	O
hospitalizations	O
for	O
lower	O
respiratory	O
tract	O
illnesses	O
(	O
LRTIs	O
)	O
and	O
75	O
%	O
of	O
croup	B-DISO
cases	O
.	O

HPIV	O
pneumonia	B-DISO
in	O
recipients	O
of	O
hematopoietic	O
stem	O
cell	O
transplant	O
(	O
HSCT	O
)	O
is	O
associated	O
with	O
50	O
%	O
acute	O
mortality	O
and	O
75	O
%	O
mortality	O
at	O
6	O
months	O
.	O

The	O
hCoVs	O
only	O
occasionally	O
induce	O
lower	O
respiratory	B-DISO
tract	I-DISO
disease	I-DISO
,	O
including	O
bronchitis	B-DISO
,	O
bronchiolitis	B-DISO
,	O
and	O
pneumonia	B-DISO
.	O

A	O
decade	O
later	O
(	O
June	O
2012	O
),	O
another	O
novel	O
CoV	O
was	O
implicated	O
as	O
the	O
cause	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
in	O
Saudi	O
Arabia	O
.	O

TITLE	O
:	O
Hemodiafiltration	O
Decreases	O
Serum	O
Levels	O
of	O
Inflammatory	O
Mediators	O
in	O
Severe	O
Leptospirosis	B-DISO
:	O
A	O
Prospective	O
Study	O
.	O

ABSTRACT	O
:	O
Leptospirosis	B-DISO
is	O
a	O
health	O
problem	O
worldwide	O
.	O

Therefore	O
,	O
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effects	O
of	O
SLED	O
with	O
traditional	O
(	O
diffusive	O
)	O
clearance	O
,	O
via	O
hemodialysis	O
,	O
and	O
SLED	O
with	O
convective	O
clearance	O
,	O
via	O
hemodiafiltration	O
(	O
SLEDf	O
),	O
in	O
patients	O
with	O
severe	O
leptospirosis	B-DISO
.	O

Direct	O
bilirubin	O
and	O
the	O
arterial	O
oxygen	O
tension	B-DISO
/	O
fraction	O
of	O
inspired	O
oxygen	O
ratio	O
were	O
significantly	O
higher	O
in	O
the	O
SLED	O
group	O
.	O

Disrupting	O
the	O
interaction	O
between	O
CEACAM5	O
and	O
MERS	O
-	O
CoV	O
spike	O
with	O
anti	O
-	O
CEACAM5	O
antibody	O
,	O
recombinant	O
CEACAM5	O
protein	O
,	O
or	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
knockdown	O
of	O
CEACAM5	O
significantly	O
inhibited	O
the	O
entry	O
of	O
MERS	O
-	O
CoV	O
.	O
Recombinant	O
expression	O
of	O
CEACAM5	O
did	O
not	O
render	O
nonpermissive	O
baby	O
hamster	O
kidney	O
(	O
BHK21	O
)	O
cells	O
susceptible	O
to	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

A	O
highly	O
pathogenic	O
avian	B-DISO
influenza	I-DISO
A	O
H5N6	O
virus	O
was	O
isolated	O
from	O
the	O
tracheal	O
aspirate	O
specimen	O
of	O
the	O
patient	O
.	O

This	O
prospective	O
cohort	O
study	O
investigated	O
the	O
prevalence	O
of	O
SDB	O
and	O
determined	O
risk	O
factors	O
for	O
the	O
presence	O
of	O
SDB	O
in	O
a	O
large	O
CAD	B-DISO
cohort	O
undergoing	O
cardiac	O
rehabilitation	O
.	O

The	O
prevalence	O
of	O
SDB	O
(	O
apnea	B-DISO
-	O
hypopnea	O
index	O
[	O
AHI	O
]	O
≥	O
5	O
/	O
h	O
)	O
was	O
83	O
%.	O

CONCLUSIONS	O
:	O
This	O
study	O
highlights	O
important	O
inflammatory	O
chemokines	O
involved	O
in	O
regulating	O
neutrophil	B-DISO
migration	I-DISO
,	O
which	O
may	O
have	O
potential	O
value	O
as	O
therapeutic	O
targets	O
for	O
the	O
treatment	O
of	O
ARDS	B-DISO
.	O

To	O
investigate	O
the	O
prevalence	O
of	O
PDCoV	O
in	O
this	O
region	O
and	O
compare	O
its	O
activity	O
to	O
other	O
enteric	O
disease	O
of	O
swine	O
caused	O
by	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
transmissible	O
gastroenteritis	B-DISO
coronavirus	O
(	O
TGEV	O
),	O
and	O
porcine	O
rotavirus	O
group	O
C	O
(	O
Rota	O
C	O
),	O
390	O
fecal	O
samples	O
were	O
collected	O
from	O
swine	O
of	O
various	O
ages	O
from	O
15	O
swine	O
farms	O
with	O
reported	O
diarrhea	B-DISO
.	O

Our	O
data	O
suggest	O
that	O
S1	O
protein	O
fused	O
to	O
the	O
HA2	O
or	O
TM	O
proteins	O
from	O
hemagglutinin	O
of	O
H3N2	O
influenza	B-DISO
virus	O
may	O
provide	O
a	O
new	O
strategy	O
for	O
high	O
efficacy	O
recombinant	O
vaccine	O
development	O
against	O
IBV	O
.	O

RESULTS	O
:	O
On	O
histologic	O
analysis	O
,	O
left	O
pneumonectomy	O
followed	O
by	O
LPS	B-DISO
administration	O
induced	O
both	O
severe	O
inflammatory	O
cellular	O
infiltration	B-DISO
and	O
alveolar	O
wall	O
congestion	B-DISO
with	O
hemorrhage	B-DISO
.	O

Children	O
with	O
enterovirus	O
D68	O
were	O
more	O
likely	O
to	O
have	O
asthma	B-DISO
(	O
62	O
%	O
vs	O
23	O
%;	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
present	O
with	O
reactive	B-DISO
airway	I-DISO
disease	I-DISO
exacerbations	O
,	O
with	O
greater	O
receipt	O
of	O
albuterol	O
(	O
94	O
%	O
vs	O
49	O
%)	O
and	O
steroids	O
(	O
89	O
%	O
vs	O
40	O
%;	O
p	O
<	O
0	O
.	O
0001	O
for	O
both	O
).	O

Critically	B-DISO
ill	I-DISO
children	O
with	O
enterovirus	O
D68	O
were	O
more	O
likely	O
to	O
present	O
with	O
reactive	B-DISO
airway	I-DISO
disease	I-DISO
exacerbations	O
,	O
whereas	O
children	O
with	O
H1N1	B-DISO
influenza	I-DISO
were	O
more	O
likely	O
to	O
present	O
with	O
pneumonia	B-DISO
.	O

TITLE	O
:	O
Leptospirosis	B-DISO
Presenting	O
with	O
Rapidly	O
Progressing	O
Acute	B-DISO
Renal	I-DISO
Failure	I-DISO
and	O
Conjugated	B-DISO
Hyperbilirubinemia	I-DISO
:	O
A	O
Case	O
Report	O
.	O

Broad	O
-	O
spectrum	O
antibiotics	O
were	O
administered	O
,	O
including	O
doxycycline	O
,	O
due	O
to	O
a	O
high	O
suspicion	O
of	O
leptospirosis	B-DISO
.	O

CONCLUSIONS	O
As	O
world	O
travel	O
becomes	O
more	O
economically	O
feasible	O
,	O
we	O
will	O
continue	O
to	O
encounter	O
foreign	O
endemic	B-DISO
diseases	I-DISO
.	O

TITLE	O
:	O
Assessment	O
of	O
the	O
risk	O
posed	O
to	O
Singapore	O
by	O
the	O
2015	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
outbreak	O
in	O
the	O
Republic	O
of	O
Korea	O
.	O

Literature	O
on	O
the	O
epidemiology	O
and	O
contextual	O
factors	O
associated	O
with	O
MERS	O
coronavirus	B-DISO
infection	I-DISO
was	O
collected	O
and	O
reviewed	O
.	O

The	O
MERS	O
outbreak	O
was	O
sparked	O
by	O
an	O
exported	O
case	O
from	O
the	O
Middle	O
East	O
,	O
which	O
remains	O
a	O
concern	O
as	O
the	O
reservoir	O
of	O
infection	B-DISO
(	O
thought	O
to	O
be	O
camels	O
)	O
continues	O
to	O
exist	O
in	O
the	O
Middle	O
East	O
,	O
and	O
sporadic	O
cases	O
in	O
the	O
community	O
and	O
outbreaks	O
in	O
health	O
-	O
care	O
settings	O
continue	O
to	O
occur	O
there	O
.	O

Neuromuscular	B-DISO
blockade	I-DISO
is	O
associated	O
with	O
an	O
improvement	O
in	O
oxygenation	O
and	O
a	O
reduction	O
in	O
mortality	O
in	O
ARDS	B-DISO
.	O

This	O
evaluation	O
demonstrates	O
that	O
the	O
use	O
of	O
TOF	B-DISO
monitoring	O
for	O
neuromuscular	B-DISO
blockade	I-DISO
does	O
not	O
correlate	O
with	O
gas	O
exchange	O
markers	O
in	O
moderate	O
to	O
severe	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Eosinophilic	B-DISO
lung	I-DISO
diseases	O
especially	O
comprise	O
eosinophilic	B-DISO
pneumonia	I-DISO
or	O
as	O
the	O
more	O
transient	O
Löffler	O
syndrome	B-DISO
,	O
which	O
is	O
most	O
often	O
due	O
to	O
parasitic	O
infections	B-DISO
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
there	O
is	O
an	O
association	O
between	O
Cryptosporidium	O
infections	B-DISO
in	O
calves	O
and	O
immunological	O
factors	O
,	O
as	O
well	O
as	O
farm	O
-	O
related	O
factors	O
or	O
the	O
application	O
of	O
the	O
anti	O
-	O
cryptosporidiosis	B-DISO
drug	O
Halofuginone	O
.	O

The	O
identified	O
predictive	O
factors	O
for	O
pneumonia	B-DISO
development	O
included	O
age	O
≥	O
45	O
years	O
,	O
fever	O
≥	O
37	O
.	O
5	O
°	O
C	O
,	O
thrombocytopenia	O
,	O
lymphopenia	B-DISO
,	O
CRP	O
≥	O
2	O
mg	O
/	O
dL	O
,	O
and	O
a	O
threshold	O
cycle	O
value	O
of	O
PCR	O
less	O
than	O
28	O
.	O
5	O
.	O

With	O
≥	O
two	O
predictive	O
factors	O
for	O
pneumonia	B-DISO
development	O
,	O
100	O
%	O
of	O
patients	O
developed	O
pneumonia	B-DISO
.	O

RESULTS	O
:	O
A	O
total	O
of	O
45	O
patients	O
were	O
included	O
in	O
the	O
study	O
:	O
13	O
patients	O
(	O
28	O
.	O
9	O
%)	O
did	O
not	O
develop	O
pneumonia	B-DISO
,	O
19	O
developed	O
pneumonia	B-DISO
without	O
respiratory	B-DISO
failure	I-DISO
(	O
42	O
.	O
2	O
%),	O
and	O
13	O
progressed	O
to	O
respiratory	O
failures	O
(	O
28	O
.	O
9	O
%).	O

The	O
SARS	B-DISO
-	O
CoV	O
papain	O
-	O
like	O
protease	O
is	O
encoded	O
next	O
to	O
SUD	O
within	O
nonstructural	O
protein	O
3	O
.	O

TITLE	O
:	O
The	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
mechanically	O
ventilated	O
burn	O
patients	O
:	O
An	O
analysis	O
of	O
risk	O
factors	O
,	O
clinical	O
features	O
,	O
and	O
outcomes	O
using	O
the	O
Berlin	O
ARDS	B-DISO
definition	O
.	O

The	O
incidence	O
of	O
ARDS	B-DISO
was	O
43	O
%.	O

Neither	O
moderate	O
ARDS	B-DISO
nor	O
severe	O
ARDS	B-DISO
were	O
significant	O
predictors	O
of	O
death	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
failure	I-DISO
(	O
ARF	B-DISO
)	O
is	O
a	O
leading	O
indication	O
for	O
performing	O
critical	O
care	O
ultrasonography	O
(	O
CCUS	O
)	O
which	O
,	O
in	O
these	O
patients	O
,	O
combines	O
critical	O
care	O
echocardiography	O
(	O
CCE	O
)	O
and	O
chest	O
ultrasonography	O
.	O

ABSTRACT	O
:	O
Over	O
the	O
recent	O
decades	O
,	O
China	O
experienced	O
several	O
emerging	O
virus	O
outbreaks	O
including	O
those	O
caused	O
by	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
(	O
SARS	B-DISO
-)	O
coronavirus	O
(	O
Cov	O
),	O
H5N1	B-DISO
virus	O
,	O
and	O
H7N9	O
virus	O
.	O

The	O
system	O
is	O
buttressed	O
by	O
three	O
fundamental	O
,	O
mutually	O
reinforcing	O
components	O
:	O
(	O
1	O
)	O
enduring	O
government	O
administration	O
reforms	O
,	O
including	O
legislation	O
establishing	O
a	O
unified	O
public	O
health	O
emergency	B-DISO
management	O
system	O
;	O
(	O
2	O
)	O
prioritized	O
funding	O
for	O
biotechnology	O
and	O
biomedicine	O
industrialization	O
,	O
especially	O
in	O
the	O
areas	O
of	O
pathogen	O
identification	O
,	O
drug	O
production	O
,	O
and	O
the	O
development	O
of	O
vaccines	O
and	O
diagnostics	O
;	O
and	O
(	O
3	O
)	O
increasing	O
investment	O
for	O
public	O
health	O
and	O
establishment	O
of	O
a	O
rapid	O
-	O
response	O
infectious	B-DISO
diseases	I-DISO
prevention	O
and	O
control	O
system	O
.	O

Live	O
isolates	O
of	O
dromedary	O
229E	O
viruses	O
were	O
obtained	O
and	O
studied	O
to	O
assess	O
human	O
infection	B-DISO
risks	O
.	O

Results	O
show	O
that	O
Hx	O
-	O
XO	O
-	O
derived	O
ROS	O
induced	O
an	O
increase	O
in	O
HUVEC	O
adhesion	B-DISO
in	O
the	O
early	O
stages	O
of	O
the	O
process	O
(	O
less	O
than	O
30	O
min	O
),	O
followed	O
by	O
a	O
decrease	O
in	O
adhesion	B-DISO
in	O
the	O
later	O
stages	O
of	O
the	O
process	O
.	O

In	O
addition	O
,	O
NF	O
-	O
κB	O
-	O
mediated	O
signaling	O
plays	O
a	O
significant	O
role	O
in	O
mechanical	O
ventilation	O
-	O
induced	O
diaphragmatic	O
atrophy	B-DISO
and	O
contractile	O
dysfunction	O
.	O

We	O
assessed	O
the	O
prophylactic	O
and	O
therapeutic	O
efficacy	O
of	O
m336	O
by	O
using	O
well	O
-	O
characterized	O
transgenic	O
mice	O
shown	O
to	O
be	O
highly	O
sensitive	O
to	O
MERS	O
-	O
CoV	O
infection	B-DISO
and	O
disease	O
.	O

Taken	O
together	O
,	O
these	O
results	O
support	O
further	O
development	O
of	O
m336	O
and	O
other	O
human	O
monoclonal	O
antibodies	O
as	O
potential	O
therapeutics	O
for	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

Next	O
,	O
we	O
showed	O
that	O
feline	O
venous	O
ECs	O
become	O
activated	O
when	O
exposed	O
to	O
supernatant	O
from	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
)-	O
infected	O
monocytes	O
,	O
as	O
indicated	O
by	O
increased	O
adhesion	B-DISO
molecule	O
expression	O
.	O

The	O
overall	O
perioperative	O
complication	B-DISO
rate	O
was	O
19	O
.	O
3	O
%	O
and	O
in	O
-	O
patient	O
mortality	O
was	O
3	O
.	O
0	O
%.	O

RESULTS	O
:	O
The	O
overall	O
perioperative	O
complication	B-DISO
rate	O
was	O
19	O
.	O
3	O
%	O
and	O
in	O
-	O
patient	O
mortality	O
was	O
3	O
.	O
0	O
%.	O

TITLE	O
:	O
Inoculation	O
of	O
Goats	O
,	O
Sheep	O
,	O
and	O
Horses	O
with	O
MERS	O
-	O
CoV	O
Does	O
Not	O
Result	O
in	O
Productive	O
Viral	B-DISO
Shedding	I-DISO
.	O

Dromedary	O
camels	O
are	O
the	O
reservoir	O
for	O
the	O
virus	O
,	O
although	O
,	O
other	O
than	O
nasal	B-DISO
discharge	I-DISO
,	O
these	O
animals	O
do	O
not	O
display	O
any	O
overt	O
clinical	O
disease	O
.	O

ABSTRACT	O
:	O
The	O
ongoing	O
battle	O
against	O
current	O
and	O
rising	O
viral	O
infectious	B-DISO
threats	O
has	O
prompted	O
increasing	O
effort	O
in	O
the	O
development	O
of	O
vaccine	O
technology	O
.	O

The	O
study	O
demonstrates	O
a	O
simple	O
yet	O
robust	O
method	O
in	O
bridging	O
viral	O
antigens	O
with	O
synthetic	O
nanoparticles	O
for	O
improved	O
vaccine	O
application	O
;	O
it	O
has	O
practical	O
implications	O
in	O
the	O
management	O
of	O
human	O
viral	B-DISO
infections	I-DISO
as	O
well	O
as	O
in	O
animal	O
agriculture	O
.	O

The	O
NS2	B-DISO

Our	O
objective	O
was	O
to	O
describe	O
the	O
characteristics	O
of	O
the	O
patients	O
treated	O
for	O
influenza	B-DISO
suspicion	O
at	O
Hospital	O
de	O
Especialidades	O
in	O
Centro	O
Médico	O
Nacional	O
Siglo	O
XXI	O
during	O
a	O
new	O
epidemic	O
.	O

Of	O
patients	O
with	O
a	O
confirmed	O
influenza	B-DISO
A	O
(	O
H3N2	O
),	O
10	O
(	O
91	O
%)	O
were	O
vaccinated	O
against	O
influenza	B-DISO
during	O
the	O
2014	O
-	O
2015	O
season	O
.	O

Clinical	O
presentations	O
included	O
pain	O
abdomen	O
(	O
42	O
,	O
42	O
%),	O
nausea	B-DISO
and	I-DISO
vomiting	I-DISO
(	O
35	O
,	O
35	O
%),	O
jaundice	B-DISO
(	O
34	O
,	O
34	O
%),	O
oliguria	B-DISO
(	O
24	O
,	O
24	O
%),	O
altered	O
sensorium	O
(	O
24	O
,	O
24	O
%),	O
breathing	B-DISO
difficulty	I-DISO
(	O
10	O
,	O
10	O
%),	O
and	O
seizures	B-DISO
(	O
5	O
,	O
5	O
%).	O

We	O
collected	O
the	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
and	O
plasma	O
from	O
ARDS	B-DISO
patients	O
with	O
differing	O
degrees	O
of	O
ARDS	B-DISO
severity	O
.	O

Pathological	O
examinations	O
of	O
the	O
kidneys	O
revealed	O
inflammation	B-DISO
,	O
distention	B-DISO
with	O
uric	O
acid	O
deposits	O
,	O
and	O
tubular	O
degeneration	B-DISO
.	O

We	O
explored	O
how	O
early	O
and	O
aggressive	B-DISO
management	O
measures	O
,	O
implemented	O
within	O
24	O
hours	O
of	O
recognition	O
of	O
severe	O
CAP	B-DISO
and	O
carried	O
out	O
both	O
in	O
the	O
emergency	B-DISO
department	O
and	O
in	O
the	O
ICU	O
,	O
decrease	O
mortality	O
in	O
severe	O
CAP	B-DISO
.	O
These	O
measures	O
begin	O
with	O
the	O
use	O
of	O
severity	O
assessment	O
tools	O
and	O
the	O
application	O
of	O
care	O
bundles	O
via	O
clinical	O
decision	O
support	O
tools	O
.	O

Here	O
,	O
we	O
demonstrated	O
renal	B-DISO
infection	I-DISO
and	O
apoptotic	O
induction	O
by	O
MERS	O
-	O
CoV	O
in	O
human	O
ex	O
vivo	O
organ	O
culture	O
and	O
a	O
nonhuman	O
primate	O
model	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
:	O
Emergence	O
of	O
a	O
Pathogenic	O
Human	O
Coronavirus	O
.	O

Ten	O
patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	B-DISO
were	O
included	O
.	O

The	O
transition	B-DISO
from	O
prefusion	O
to	O
postfusion	O
conformation	O
of	O
the	O
spike	O
protein	O
must	O
be	O
triggered	O
,	O
leading	O
to	O
membrane	O
fusion	O
.	O

Various	O
stressors	O
,	O
including	O
intense	O
physical	O
activity	O
,	O
severe	O
infection	B-DISO
,	O
and	O
emotional	B-DISO
stress	I-DISO
are	O
reported	O
in	O
the	O
medical	O
history	O
of	O
ME	O
/	O
CFS	B-DISO
patients	O
which	O
raises	O
the	O
question	O
whether	O
any	O
physiological	O
and	O
biological	O
abnormalities	O
usually	O
found	O
in	O
these	O
patients	O
could	O
be	O
indicative	O
of	O
the	O
etiology	O
and	O
/	O
or	O
the	O
quality	O
-	O
of	O
-	O
life	O
impairment	B-DISO
.	O

We	O
observed	O
that	O
:	O
(	O
1	O
)	O
there	O
were	O
striking	O
differences	O
between	O
cases	O
and	O
controls	O
with	O
regard	O
to	O
three	O
biological	O
variables	O
:	O
post	O
-	O
exercise	O
M	O
-	O
wave	O
,	O
TBARS	O
variations	O
and	O
CD26	O
-	O
expression	O
at	O
rest	O
;	O
(	O
2	O
)	O
each	O
of	O
these	O
three	O
variables	O
correlated	O
with	O
the	O
other	O
two	O
;	O
(	O
3	O
)	O
abnormalities	O
in	O
the	O
biomarkers	O
associated	O
with	O
health	O
-	O
related	O
quality	O
of	O
life	O
:	O
the	O
LHS	O
score	O
was	O
negatively	O
correlated	O
with	O
the	O
exercise	O
-	O
induced	O
TBARS	O
increase	O
and	O
positively	O
correlated	O
with	O
CD26	O
-	O
expression	O
while	O
the	O
pain	O
component	O
of	O
SF	O
-	O
36	O
was	O
negatively	O
correlated	O
with	O
CD26	O
-	O
expression	O
;	O
(	O
4	O
)	O
the	O
TBARS	O
increase	O
and	O
the	O
M	O
-	O
wave	O
decrease	O
were	O
the	O
highest	O
,	O
and	O
the	O
CD26	O
-	O
expression	O
level	O
the	O
lowest	O
in	O
patients	O
who	O
had	O
been	O
submitted	O
to	O
infectious	B-DISO
stressors	O
.	O

Nine	O
months	O
after	O
admission	O
,	O
she	O
showed	O
totally	O
-	O
locked	B-DISO
in	I-DISO
syndrome	I-DISO
.	O

Severe	O
pregnancy	B-DISO
-	I-DISO
induced	I-DISO
hypertension	I-DISO
/	O
eclampsia	B-DISO
,	O
massive	B-DISO
haemorrhage	I-DISO
and	O
sepsis	B-DISO
were	O
the	O
common	O
obstetric	O
complications	O
.	O

We	O
analyzed	O
200	O
nasal	O
swab	O
samples	O
,	O
collected	O
by	O
the	O
Arkansas	O
Department	O
of	O
Health	O
in	O
2010	O
,	O
for	O
influenza	B-DISO
diagnosis	O
.	O

All	O
samples	O
were	O
from	O
patients	O
showing	O
acute	O
respiratory	B-DISO
symptoms	I-DISO
while	O
testing	O
negative	O
for	O
influenza	B-DISO
.	O

ABSTRACT	O
:	O
Since	O
the	O
2003	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
epidemic	O
,	O
scientific	O
exploration	O
of	O
infection	B-DISO
control	O
is	O
no	O
longer	O
restricted	O
to	O
microbiologists	O
or	O
medical	O
scientists	O
.	O

We	O
have	O
shown	O
the	O
opportunities	O
for	O
infection	B-DISO
control	O
at	O
different	O
stages	O
of	O
the	O
spread	O
.	O

Titer	O
against	O
Newcastle	B-DISO
disease	I-DISO
virus	O
(	O
NDV	O
:	O
)	O
and	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
:	O
)	O
was	O
found	O
to	O
be	O
greater	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
SI	O
and	O
FR	O
,	O
respectively	O
.	O

TITLE	O
:	O
PaO	O
ABSTRACT	O
:	O
During	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
),	O
arterial	O
oxygen	O
partial	O
pressure	O
to	O
fractional	O
inspired	O
oxygen	O
(	O
PaO	O
This	O
was	O
a	O
single	O
-	O
center	O
observational	O
study	O
of	O
adult	O
patients	O
(	O
n	O
=	O
81	O
)	O
undergoing	O
veno	O
-	O
venous	O
ECMO	O
support	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

In	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
PF	O
ratio	O
deterioration	O
during	O
stable	O
ECMO	O
associates	O
with	O
protracted	O
recovery	O
and	O
increased	O
mortality	O
,	O
not	O
accounted	O
for	O
by	O
patient	O
baseline	O
characteristics	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
severity	O
,	O
or	O
pre	O
-	O
ECMO	O
management	O
.	O

TITLE	O
:	O
High	O
correlation	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
spread	O
with	O
Google	O
search	O
and	O
Twitter	O
trends	O
in	O
Korea	O
.	O

TITLE	O
:	O
[	O
Complex	O
control	O
of	O
the	O
source	O
of	O
infection	B-DISO
in	O
sepsis	B-DISO
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
as	O
a	O
bridging	O
concept	O
for	O
tracheal	B-DISO
fistula	I-DISO
repair	O
in	O
sepsis	B-DISO
-	O
associated	O
ARDS	B-DISO
].	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
one	O
of	O
the	O
most	O
severe	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
of	O
the	O
21st	O
century	O
so	O
far	O
.	O

Lower	O
Vts	O
during	O
VC	O
ventilation	O
result	O
in	O
higher	O
patient	O
-	O
ventilator	O
dyssynchrony	O
in	O
most	O
patients	O
with	O
or	O
at	O
risk	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Media	O
and	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
attention	O
on	O
Zika	O
virus	O
transmission	O
at	O
the	O
2016	O
Rio	O
Olympic	O
Games	O
and	O
the	O
2015	O
Ebola	O
virus	O
outbreak	O
in	O
West	O
Africa	O
diverted	O
the	O
attention	O
of	O
global	O
public	O
health	O
authorities	O
from	O
other	O
lethal	O
infectious	B-DISO
diseases	I-DISO
with	O
epidemic	O
potential	O
.	O

Hence	O
,	O
continuous	O
follow	O
-	O
up	O
of	O
the	O
current	O
vaccine	O
strategy	O
is	O
highly	O
recommended	O
for	O
better	O
control	O
and	O
prevention	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
in	O
the	O
poultry	O
sector	O
in	O
Egypt	O
.	O

Acute	O
encephalomyelitis	B-DISO
and	O
immune	O
-	O
mediated	O
demyelination	B-DISO
were	O
induced	O
by	O
intracranial	O
injection	O
with	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
JHMV	O
)	O
into	O
C57BL	O
/	O
6	O
miR	O
-	O
155	O
(+/+)	O
wildtype	O
(	O
WT	O
)	O
mice	O
or	O
miR	O
-	O
155	O
(-/-)	O
mice	O
.	O

These	O
findings	O
support	O
a	O
novel	O
role	O
for	O
miR	O
-	O
155	O
in	O
host	O
defense	O
in	O
a	O
model	O
of	O
viral	O
-	O
induced	O
encephalomyelitis	B-DISO
.	O

TITLE	O
:	O
Multivariable	O
fractional	O
polynomial	O
interaction	O
to	O
investigate	O
continuous	O
effect	O
modifiers	O
in	O
a	O
meta	O
-	O
analysis	O
on	O
higher	O
versus	O
lower	O
PEEP	O
for	O
patients	O
with	O
ARDS	B-DISO
.	O

RESULTS	O
:	O
The	O
hospitalization	O
rate	O
for	O
all	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
was	O
significantly	O
higher	O
in	O
the	O
DS	O
cohort	O
than	O
in	O
the	O
non	O
-	O
DS	O
cohort	O
(	O
44	O
.	O
1	O
%	O
vs	O
7	O
.	O
7	O
%,	O
P	O
<.	O
0001	O
).	O

TITLE	O
:	O
Intravascular	B-DISO
haemolysis	I-DISO
with	O
haemoglobinuria	B-DISO
in	O
a	O
splenectomized	O
patient	O
with	O
severe	O
Plasmodium	O
knowlesi	O
malaria	B-DISO
.	O

ABSTRACT	O
:	O
Bat	O
-	O
borne	O
viral	B-DISO
diseases	I-DISO
are	O
a	O
major	O
public	O
health	O
concern	O
among	O
newly	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
which	O
includes	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
,	O
Nipah	O
,	O
Marburg	O
and	O
Ebola	B-DISO
virus	I-DISO
disease	I-DISO
.	O

However	O
,	O
further	O
analyses	O
,	O
using	O
other	O
TGEV	O
-	O
and	O
PEDV	O
-	O
specific	O
RT	O
-	O
qPCR	O
assays	O
,	O
provided	O
results	O
inconsistent	O
with	O
infection	B-DISO
by	O
either	O
of	O
these	O
viruses	O
.	O

Pigs	O
(	O
n	O
=	O
3	O
)	O
were	O
euthanized	O
for	O
pathologic	O
examination	O
at	O
post	O
-	O
inoculation	O
day	O
(	O
PID	B-DISO
)	O
3	O
,	O
and	O
the	O
remainder	O
were	O
monitored	O
for	O
clinical	O
signs	O
,	O
virus	B-DISO
shedding	I-DISO
,	O
and	O
serum	O
antibody	O
responses	O
until	O
PID	B-DISO
28	O
.	O

Chikungunya	B-DISO
represented	O
a	O
substantial	O
risk	O
for	O
neonates	O
born	O
to	O
symptomatic	O
parturients	O
during	O
the	O
chikungunya	B-DISO
outbreak	O
in	O
the	O
Americas	O
Region	O
,	O
with	O
important	O
clinical	O
and	O
public	O
health	O
implications	O
.	O

TITLE	O
:	O
Clinically	O
Profiling	O
Pediatric	O
Patients	O
with	O
Dengue	B-DISO
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
clinical	O
profile	O
and	O
outcome	O
of	O
dengue	B-DISO
fever	I-DISO
in	O
children	O
at	O
a	O
tertiary	O
care	O
hospital	O
in	O
Puducherry	O
.	O

The	O
most	O
common	O
complications	O
were	O
liver	B-DISO
dysfunction	I-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
encephalopathy	B-DISO
,	O
pleural	B-DISO
effusion	I-DISO
,	O
ascites	O
,	O
myocarditis	B-DISO
,	O
myositis	B-DISO
,	O
acute	O
kidney	O
injury	O
,	O
and	O
disseminated	O
intravascular	O
coagulopathy	B-DISO
.	O

There	O
were	O
six	O
deaths	O
(	O
2	O
.	O
3	O
%)	O
and	O
out	O
of	O
them	O
four	O
presented	O
with	O
impaired	B-DISO
consciousness	I-DISO
(	O
66	O
.	O
6	O
%).	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
causes	O
infectious	B-DISO
bronchitis	B-DISO
in	O
poultry	O
,	O
a	O
respiratory	B-DISO
disease	I-DISO
that	O
is	O
a	O
source	O
of	O
major	O
economic	O
loss	O
to	O
the	O
poultry	O
industry	O
.	O

At	O
the	O
time	O
of	O
hospital	O
admission	O
,	O
there	O
were	O
non	O
-	O
specific	O
ST	O
-	O
changes	O
on	O
the	O
ecg	O
,	O
coronary	O
enzymes	O
were	O
increased	O
,	O
and	O
the	O
patient	O
was	O
concluded	O
to	O
have	O
a	O
non	O
-	O
ST	O
-	O
elevation	O
myocardial	B-DISO
infarction	I-DISO
,	O
and	O
treated	O
as	O
such	O
.	O

At	O
the	O
time	O
,	O
no	O
connection	O
to	O
patient	O
'	O
s	O
diagnosis	O
of	O
severe	O
asthma	B-DISO
was	O
made	O
.	O

At	O
this	O
point	O
,	O
there	O
was	O
increasing	O
pain	O
in	O
both	O
legs	O
and	O
the	O
patient	O
had	O
difficulty	O
walking	O
and	O
experienced	O
increasing	O
dyspnea	B-DISO
.	O

Heart	O
involvement	O
is	O
the	O
most	O
critical	O
and	O
potentially	O
lethal	O
systemic	O
manifestation	O
in	O
eosinophilic	O
granulomatosis	B-DISO
with	O
polyangiitis	O
(	O
EGPA	O
,	O
formerly	O
known	O
as	O
Churg	B-DISO
-	I-DISO
Strauss	I-DISO
syndrome	I-DISO
),	O
which	O
makes	O
a	O
quick	O
diagnosis	O
and	O
prompt	O
initiation	O
of	O
correct	O
treatment	O
imperative	O
.	O

Using	O
antibodies	O
from	O
SARS	B-DISO
patients	O
,	O
we	O
identified	O
and	O
characterized	O
SARS	B-DISO
-	O
CoV	O
B	O
-	O
cell	O
peptide	O
epitopes	O
with	O
disparate	O
functions	O
.	O

In	O
contrast	O
,	O
peptide	O
S597	O
-	O
603	O
induced	O
antibodies	O
that	O
enhanced	O
infection	B-DISO
both	O
in	O
vitro	O
and	O
in	O
non	O
-	O
human	O
primates	O
by	O
using	O
an	O
epitope	O
sequence	O
-	O
dependent	O
(	O
ESD	O
)	O
mechanism	O
.	O

Clinicians	O
should	O
be	O
aware	O
of	O
expanding	O
use	O
of	O
this	O
breakthrough	O
therapy	O
and	O
implications	O
for	O
critical	O
care	O
units	O
in	O
cancer	B-DISO
centers	O
.	O

Our	O
studies	O
demonstrated	O
that	O
PEDV	O
infection	B-DISO
resulted	O
in	O
the	O
up	O
-	O
regulation	O
of	O
proinflammatory	O
cytokines	O
.	O

Meanwhile	O
,	O
PEDV	O
infection	B-DISO
and	O
overexpression	O
of	O
viral	O
nucleoprotein	O
resulted	O
in	O
the	O
acetylation	O
and	O
release	O
of	O
high	O
mobility	O
group	O
box	O
1	O
proteins	O
in	O
vitro	O
,	O
an	O
important	O
proinflammatory	O
response	O
mediator	O
,	O
which	O
contributes	O
to	O
the	O
pathogenesis	B-DISO
of	O
various	O
inflammatory	O
diseases	O
.	O

Calibration	O
was	O
moderate	O
using	O
the	O
original	O
cutoff	O
values	O
(	O
Hosmer	O
-	O
Lemeshow	O
goodness	O
of	O
fit	B-DISO
P	O
<	O
0	O
.	O
001	O
),	O
and	O
recalibration	O
was	O
performed	O
for	O
the	O
cutoff	O
value	O
for	O
age	O
and	O
plateau	O
pressure	O
.	O

ABSTRACT	O
:	O
Recently	O
,	O
the	O
outbreak	O
of	O
MERS	O
-	O
CoV	O
infections	B-DISO
caused	O
worldwide	O
attention	O
to	O
Saudi	O
Arabia	O
.	O

ABSTRACT	O
:	O
Legionnaires	B-DISO
'	I-DISO
disease	I-DISO
is	O
a	O
bacterial	B-DISO
disease	I-DISO
of	O
the	O
respiratory	O
system	O
caused	O
by	O
a	O
gram	O
-	O
negative	O
germ	O
whose	O
clinical	O
manifestation	O
can	O
be	O
benign	O
limiting	O
to	O
flu	B-DISO
-	O
like	O
syndrome	B-DISO
or	O
can	O
be	O
more	O
severe	O
being	O
characterized	O
by	O
pneumonia	B-DISO
which	O
may	O
be	O
complicated	O
by	O
multisystem	O
disease	O
that	O
can	O
lead	O
to	O
death	O
.	O

ABSTRACT	O
:	O
The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
first	O
emerged	O
in	O
2003	O
,	O
causing	O
the	O
SARS	B-DISO
epidemic	O
which	O
resulted	O
in	O
a	O
10	O
%	O
fatality	O
rate	O
.	O

The	O
advancements	O
in	O
metagenomic	O
techniques	O
have	O
allowed	O
the	O
identification	O
of	O
SARS	B-DISO
-	O
like	O
coronaviruses	O
(	O
SL	O
-	O
CoVs	O
)	O
sequences	O
that	O
share	O
high	O
homology	O
to	O
the	O
human	O
SARS	B-DISO
-	O
CoV	O
epidemic	O
strains	O
from	O
wildlife	O
bats	O
,	O
presenting	O
concrete	O
evidence	O
that	O
bats	O
are	O
the	O
origin	O
and	O
natural	O
reservoir	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
The	O
application	O
of	O
reverse	O
genetics	O
further	O
enabled	O
that	O
characterization	O
of	O
these	O
bat	O
CoVs	O
and	O
the	O
prediction	O
of	O
their	O
potential	O
to	O
cause	O
disease	O
in	O
humans	O
.	O

CONCLUSIONS	O
:	O
The	O
Polio	B-DISO
Eradication	O
Initiative	O
(	O
PEI	O
)	O
is	O
a	O
good	O
example	O
of	O
contribution	O
in	O
strengthening	O
public	O
health	O
laboratories	O
systems	O
in	O
the	O
African	O
region	O
.	O

TITLE	O
:	O
Available	O
Evidence	O
of	O
Association	O
between	O
Zika	O
Virus	O
and	O
Microcephaly	B-DISO
.	O

Studies	O
were	O
included	O
and	O
analyzed	O
if	O
they	O
met	O
all	O
of	O
the	O
following	O
criteria	O
:	O
""""	O
probable	O
or	O
confirmed	O
infant	O
microcephaly	B-DISO
""""	O
and	O
""""	O
probable	O
or	O
confirmed	O
ZIKV	O
infection	B-DISO
among	O
mothers	O
or	O
infants	O
"""."	O

RESULTS	O
:	O
We	O
emphasize	O
the	O
diagnosis	O
of	O
ZIKV	O
infection	B-DISO
,	O
including	O
maternal	O
clinical	O
manifestations	O
,	O
maternal	O
and	O
fetal	O
laboratory	O
confirmation	O
,	O
and	O
possible	O
autopsy	O
if	O
need	O
.	O

An	O
association	O
between	O
gluten	O
and	O
schizophrenia	B-DISO
was	O
described	O
for	O
the	O
first	O
time	O
in	O
1950	O
by	O
Bender	O
et	O
al	O
.	O
In	O
the	O
1950	O
'	O
s	O
,	O
Dicke	O
noted	O
that	O
gluten	O
-	O
free	O
diet	O
improved	O
mood	O
in	O
celiac	O
patients	O
.	O

TITLE	O
:	O
Liquid	O
extracorporeal	O
carbon	O
dioxide	O
removal	O
:	O
use	O
of	O
THAM	O
(	O
tris	O
-	O
hydroxymethyl	O
aminomethane	O
)	O
coupled	O
to	O
hemofiltration	O
to	O
control	O
hypercapnic	B-DISO
acidosis	I-DISO
in	O
a	O
porcine	O
model	O
of	O
protective	O
mechanical	O
ventilation	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
THAM	O
infusion	O
coupled	O
to	O
hemofiltration	O
for	O
the	O
management	O
of	O
hypercapnic	B-DISO
acidosis	I-DISO
.	O

Thereafter	O
PaCO2	O
remained	O
stable	O
between	O
60	O
-	O
70	O
mmHg	O
,	O
while	O
pH	B-DISO
increased	I-DISO
above	O
7	O
.	O
4	O
.	O

The	O
patterns	O
of	O
parenchymal	O
lesions	O
,	O
involved	O
segments	O
and	O
presence	O
of	O
cavity	B-DISO
,	O
bronchiectasis	B-DISO
and	O
bronchogenic	O
spread	O
of	O
the	O
lesions	O
with	O
computed	O
tomography	O
(	O
CT	O
)	O
and	O
chest	O
/	O
X	O
-	O
ray	O
(	O
CXR	O
)	O
were	O
recorded	O
and	O
analyzed	O
.	O

ARDS	B-DISO
,	O
interstitial	O
involvement	O
,	O
and	O
Parenchymal	O
nodular	O
infiltration	B-DISO
are	O
the	O
most	O
common	O
manifestations	O
of	O
pulmonary	B-DISO
TB	I-DISO
.	O

ABSTRACT	O
:	O
In	O
Réunion	O
Island	O
,	O
despite	O
an	O
influenza	B-DISO
surveillance	O
established	O
since	O
1996	O
by	O
the	O
sentinel	O
general	O
practitioner	O
'	O
s	O
network	O
,	O
little	O
is	O
known	O
about	O
the	O
etiology	O
of	O
Influenza	B-DISO
like	O
-	O
illness	O
(	O
ILI	O
)	O
that	O
differs	O
from	O
influenza	B-DISO
viruses	O
in	O
a	O
tropical	O
area	O
.	O

Dexmedetomidine	O
as	O
a	O
secondary	O
agent	O
does	O
not	O
appear	O
to	O
add	B-DISO
benefit	O
.	O

Together	O
,	O
our	O
results	O
identify	O
the	O
NS6	B-DISO
sgRNA	O
and	O
demonstrate	O
its	O
expression	O
in	O
PDCoV	O
-	O
infected	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
complex	O
interplay	O
between	O
viral	O
replication	O
and	O
host	O
immune	O
response	O
during	O
infection	B-DISO
remains	O
poorly	O
understood	O
.	O

We	O
validated	O
our	O
predictions	O
in	O
18	O
different	O
knockout	O
(	O
KO	O
)	O
mouse	O
strains	O
,	O
showing	O
that	O
network	O
topology	O
provides	O
significant	O
predictive	O
power	O
to	O
identify	O
genes	O
that	O
are	O
important	O
for	O
viral	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Estimates	O
of	O
the	O
risk	O
of	O
large	O
or	O
long	O
-	O
lasting	O
outbreaks	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
after	O
importations	O
outside	O
the	O
Arabian	O
Peninsula	O
.	O

TITLE	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
poly	O
-	O
epitope	O
-	O
based	O
vaccine	O
protects	O
chickens	O
from	O
acute	B-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Respiratory	O
viruses	O
and	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
:	O
Epidemiology	O
and	O
outcomes	O
in	O
children	O
aged	O
6	O
months	O
to	O
10	O
years	O
in	O
a	O
multi	O
-	O
country	O
population	O
sample	O
.	O

The	O
epidemiology	O
of	O
respiratory	O
viruses	O
among	O
healthy	O
children	O
(	O
6	O
months	O
to	O
<	O
10	O
years	O
)	O
with	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
(	O
ILI	O
)	O
was	O
determined	O
in	O
a	O
population	O
sample	O
derived	O
from	O
an	O
influenza	B-DISO
vaccine	O
trial	O
(	O
NCT01051661	O
)	O
in	O
17	O
centers	O
in	O
eight	O
countries	O
(	O
Australia	O
,	O
South	O
East	O
Asia	O
and	O
Latin	O
America	O
).	O

Rhinovirus	O
/	O
enterovirus	O
had	O
the	O
highest	O
prevalence	O
(	O
41	O
.	O
5	O
%),	O
followed	O
by	O
influenza	B-DISO
(	O
15	O
.	O
8	O
%),	O
adenovirus	B-DISO
(	O
9	O
.	O
8	O
%),	O
parainfluenza	B-DISO
and	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
(	O
both	O
9	O
.	O
7	O
%),	O
coronavirus	O
(	O
5	O
.	O
6	O
%),	O
human	O
metapneumovirus	O
(	O
5	O
.	O
5	O
%)	O
and	O
human	O
bocavirus	O
(	O
HBov	O
)	O
(	O
2	O
.	O
0	O
%).	O

Overall	O
,	O
results	O
indicated	O
5	O
.	O
6	O
×	O
10	O
(	O
1	O
)	O
TCID50	O
/	O
g	O
was	O
the	O
minimum	O
PEDV	O
dose	O
in	O
feed	O
that	O
can	O
lead	O
to	O
infection	B-DISO
in	O
10	O
-	O
day	O
-	O
old	O
pigs	O
under	O
the	O
conditions	O
of	O
this	O
study	O
.	O

This	O
allowed	O
demonstrating	O
,	O
by	O
accomplishing	O
all	O
Hill	O
'	O
s	O
criteria	O
for	O
causation	O
,	O
the	O
cause	O
-	O
effect	O
relationship	O
between	O
the	O
vaccine	O
administration	O
/	O
withdrawal	B-DISO
and	O
the	O
variation	O
in	O
viral	O
population	O
dynamics	O
and	O
,	O
above	O
all	O
,	O
IBV	O
related	O
outbreaks	O
.	O

Diagnoses	O
were	O
status	B-DISO
asthmaticus	I-DISO
(	O
2	O
),	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
due	O
to	O
septic	B-DISO
shock	I-DISO
(	O
1	O
),	O
aspergillus	B-DISO
pneumonia	I-DISO
(	O
1	O
),	O
and	O
respiratory	B-DISO
failure	I-DISO
due	O
to	O
parainfluenza	B-DISO
(	O
1	O
).	O

RNA	O
was	O
extracted	O
and	O
tested	O
by	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
for	O
the	O
presence	O
of	O
rotavirus	O
,	O
norovirus	O
,	O
astrovirus	O
,	O
torovirus	O
,	O
coronavirus	O
and	O
bovine	B-DISO
viral	I-DISO
diarrhea	I-DISO
virus	O
.	O

Awareness	O
of	O
the	O
clinical	O
syndrome	B-DISO
with	O
the	O
rare	O
complication	B-DISO
of	O
compartment	B-DISO
syndrome	I-DISO
may	O
help	O
guide	O
investigations	O
and	O
diagnoses	O
of	O
these	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

ABSTRACT	O
:	O
The	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
plays	O
important	O
roles	O
in	O
the	O
replication	O
and	O
translation	O
of	O
viral	O
RNA	O
.	O

The	O
accepted	O
definition	O
of	O
'	B-DISO
influenza	I-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
'	O
includes	O
fever	O
and	O
may	O
be	O
insensitive	O
for	O
surveillance	O
when	O
high	O
case	O
-	O
finding	O
is	O
required	O
.	O

TITLE	O
:	O
Scrub	B-DISO
typhus	I-DISO
associated	O
with	O
hemophagocytic	B-DISO
lymphohistiocytosis	I-DISO
:	O
A	O
report	O
of	O
six	O
pediatric	O
patients	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
highlight	O
the	O
clinical	O
features	O
of	O
scrub	B-DISO
typhus	I-DISO
-	O
associated	O
HLH	B-DISO
in	O
children	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aimed	O
to	O
determine	O
knowledge	O
,	O
attitude	O
and	O
practice	O
of	O
airborne	O
and	O
droplet	O
isolation	O
precautions	O
among	O
Dental	O
Health	O
Professionals	O
(	O
DHPs	O
)	O
(	O
dental	O
students	O
,	O
interns	O
,	O
practitioners	O
and	O
auxiliaries	O
)	O
during	O
the	O
outbreak	O
of	O
MERS	O
(	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
),	O
corona	B-DISO
virus	I-DISO
infection	I-DISO
in	O
Riyadh	O
city	O
,	O
Saudi	O
Arabia	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
describe	O
epidemiology	O
,	O
clinical	O
features	O
,	O
laboratory	O
data	O
and	O
severity	O
of	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
acute	O
lower	B-DISO
respiratory	I-DISO
infection	I-DISO
(	O
ALRI	O
)	O
in	O
Malaysian	O
children	O
and	O
to	O
determine	O
risk	O
factors	O
associated	O
with	O
prolonged	O
hospital	O
stay	O
,	O
paediatric	O
intensive	O
care	O
unit	O
(	O
PICU	O
)	O
admission	O
and	O
mortality	O
.	O

We	O
show	O
that	O
human	B-DISO
influenza	I-DISO
virus	B-DISO
infection	I-DISO
is	O
blocked	O
during	O
the	O
early	O
stages	O
of	O
virus	O
entry	O
,	O
which	O
is	O
likely	O
due	O
to	O
the	O
relatively	O
high	O
expression	O
of	O
the	O
host	O
antiviral	O
factors	O
IFITMs	O
(	O
interferon	O
-	O
induced	O
transmembrane	O
proteins	O
)	O
located	O
in	O
membrane	O
-	O
bound	O
compartments	O
inside	O
cells	O
.	O

Our	O
data	O
shows	O
that	O
clinical	O
condition	B-DISO
may	O
suddenly	O
deteriorate	O
around	O
7	O
days	O
of	O
illness	O
and	O
the	O
serum	O
levels	O
of	O
IL	O
-	O
6	O
and	O
CXCL	O
-	O
10	O
was	O
significantly	O
elevated	O
in	O
MERS	O
-	O
CoV	O
patients	O
who	O
developed	O
severe	O
diseases	O
.	O

Recent	O
bioinformatic	O
,	O
biochemical	O
,	O
and	O
genetic	O
studies	O
suggest	O
a	O
previously	O
unknown	O
level	O
of	O
conservation	O
of	O
cis	B-DISO
-	O
acting	O
RNA	O
structures	O
among	O
different	O
coronavirus	O
genera	O
and	O
,	O
in	O
some	O
cases	O
,	O
even	O
beyond	O
genus	O
boundaries	O
.	O

We	O
discuss	O
the	O
structural	O
and	O
functional	O
features	O
of	O
these	O
cis	B-DISO
-	O
acting	O
RNA	O
elements	O
and	O
their	O
specific	O
functions	O
in	O
coronavirus	O
RNA	O
synthesis	O
.	O

TITLE	O
:	O
Interaction	O
of	O
SARS	B-DISO
and	O
MERS	O
Coronaviruses	O
with	O
the	O
Antiviral	O
Interferon	O
Response	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
are	O
the	O
most	O
severe	O
coronavirus	O
(	O
CoV	O
)-	O
associated	O
diseases	O
in	O
humans	O
.	O

To	O
meet	O
these	O
requirements	O
,	O
vaccine	O
studies	O
need	O
to	O
provide	O
a	O
comprehensive	O
understanding	O
of	O
(	O
i	O
)	O
the	O
protective	O
roles	O
of	O
antiviral	O
B	O
and	O
T	O
-	O
cell	O
-	O
mediated	O
immune	O
responses	O
,	O
(	O
ii	O
)	O
the	O
complexity	O
and	O
plasticity	O
of	O
major	O
viral	O
antigens	O
,	O
and	O
(	O
iii	O
)	O
virus	O
molecular	O
biology	O
and	O
pathogenesis	B-DISO
.	O

TITLE	O
:	O
An	O
outbreak	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
due	O
to	O
coronavirus	O
in	O
Al	O
-	O
Ahssa	O
Region	O
,	O
Saudi	O
Arabia	O
,	O
2015	O
.	O

ABSTRACT	O
:	O
Between	O
19	O
April	O
and	O
23	O
June	O
2015	O
,	O
52	O
laboratory	O
-	O
confirmed	O
cases	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
due	O
to	O
coronavirus	O
(	O
MERS	O
)	O
were	O
reported	O
from	O
Al	O
-	O
Ahssa	O
region	O
,	O
eastern	O
Saudi	O
Arabia	O
.	O

The	O
cluster	O
of	O
cases	O
appeared	O
to	O
be	O
due	O
to	O
high	O
exposure	O
to	O
MERS	O
,	O
delayed	O
diagnosis	O
,	O
inadequate	O
risk	O
communication	O
and	O
inadequate	O
compliance	O
of	O
hospital	O
health	O
workers	O
and	O
visitors	O
with	O
infection	B-DISO
prevention	O
and	O
control	O
measures	O
.	O

Influenza	B-DISO
A	O
(	O
H1N1	O
)	O
was	O
an	O
important	O
cause	O
of	O
morbidity	O
during	O
the	O
2009	O
pandemic	O
.	O

ABSTRACT	O
:	O
Guangzhou	O
reported	O
its	O
first	O
laboratory	O
-	O
confirmed	O
case	O
of	O
influenza	B-DISO
A	O
(	O
H7N9	O
)	O
on	O
January	O
10	O
,	O
2014	O
.	O

This	O
dichotomy	O
is	O
exemplified	O
by	O
cathepsin	O
L	O
(	O
CTSL	O
),	O
which	O
helps	O
Hendra	O
virus	O
and	O
SARS	B-DISO
coronavirus	O
to	O
invade	O
cells	O
,	O
but	O
is	O
essential	O
for	O
survival	O
in	O
mice	O
with	O
mycoplasma	B-DISO
pneumonia	I-DISO
.	O

In	O
contrast	O
to	O
mycoplasma	B-DISO
pneumonia	I-DISO
,	O
infiltrating	B-DISO
cells	O
were	O
predominantly	O
mononuclear	O
rather	O
than	O
polymorphonuclear	O
.	O

This	O
critically	B-DISO
ill	I-DISO
patient	O
was	O
treated	O
in	O
a	O
special	O
care	O
unit	O
,	O
and	O
she	O
fully	O
recovered	O
with	O
supportive	O
measures	O
.	O

In	O
2012	O
,	O
the	O
infectious	B-DISO
outbreak	O
caused	O
by	O
MERS	O
-	O
CoV	O
in	O
Saudi	O
Arabia	O
has	O
spread	O
to	O
more	O
than	O
1600	O
patients	O
in	O
26	O
countries	O
,	O
resulting	O
in	O
over	O
600	O
deaths	O
.	O

Examples	O
of	O
viruses	O
that	O
have	O
emerged	O
in	O
this	O
manner	O
are	O
influenza	B-DISO
,	O
coronaviruses	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
,	O
and	O
the	O
Nipah	O
virus	O
.	O

Non	O
-	O
acutely	O
ill	B-DISO
children	O
undergoing	O
tonsillectomy	O
and	O
adenoidectomy	O
(	O
T	O
&	O
A	O
)	O
for	O
various	O
reasons	O
were	O
enrolled	O
prospectively	O
in	O
a	O
study	O
to	O
determine	O
the	O
frequency	O
of	O
asymptomatic	O
respiratory	O
viral	B-DISO
infections	I-DISO
in	O
each	O
lymphoid	O
tissue	O
and	O
to	O
relate	O
the	O
number	O
and	O
types	O
of	O
virus	O
to	O
the	O
degree	O
of	O
airway	B-DISO
obstruction	I-DISO
.	O

Also	O
,	O
PEDV	O
harvested	O
from	O
pAPN	O
or	O
domain	O
VII	O
expressing	O
NIH3T3	O
cells	O
was	O
induced	O
indirect	O
plaques	B-DISO
in	O
Vero	O
cells	O
confirming	O
successful	O
entry	O
and	O
replication	O
.	O

Here	O
,	O
we	O
found	O
that	O
clinical	O
isolates	O
of	O
HCoV	O
-	O
229E	O
preferentially	O
utilize	O
the	O
cell	O
surface	O
protease	O
TMPRSS2	O
rather	O
than	O
endosomal	O
cathepsin	O
L	O
.	O
The	O
endosome	O
is	O
a	O
main	O
site	O
of	O
Toll	O
-	O
like	O
receptor	O
recognition	O
,	O
which	O
then	O
triggers	O
an	O
innate	B-DISO
immune	I-DISO
response	I-DISO
;	O
therefore	O
,	O
HCoV	O
-	O
229E	O
presumably	O
evolved	O
to	O
bypass	O
the	O
endosome	O
by	O
entering	O
the	O
cell	O
via	O
TMPRSS2	O
.	O

Therefore	O
,	O
therapeutic	O
agents	O
for	O
coronavirus	O
-	O
mediated	O
diseases	O
,	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
),	O
should	O
target	O
cell	O
surface	O
TMPRSS2	O
rather	O
than	O
endosomal	O
cathepsin	O
.	O

ABSTRACT	O
:	O
The	O
disease	O
course	O
of	O
acute	B-DISO
pancreatitis	I-DISO
(	O
AP	O
)	O
ranges	O
from	O
mild	O
and	O
self	O
-	O
limiting	O
to	O
severe	O
inflammation	B-DISO
,	O
associated	O
with	O
significant	O
morbidity	O
and	O
mortality	O
.	O

They	O
were	O
also	O
significantly	O
higher	O
in	O
patients	O
with	O
versus	O
without	O
organ	B-DISO
failure	I-DISO
(	O
p	O
<	O
0	O
.	O
05	O
for	O
all	O
).	O

With	O
this	O
manuscript	O
,	O
we	O
want	O
to	O
explore	O
and	O
emphasize	O
the	O
critical	O
aspect	O
of	O
acute	B-DISO
gastroenteritis	I-DISO
in	O
Middle	O
-	O
East	O
Countries	O
and	O
its	O
correlation	O
with	O
the	O
clinical	O
aspect	O
of	O
gut	O
microbiota	O
modification	O
and	O
intestinal	O
homeostasis	O
.	O

The	O
single	O
most	O
common	O
diarrheal	B-DISO
disorder	I-DISO
observed	O
in	O
the	O
Emergency	B-DISO
Department	O
and	O
general	O
practice	O
is	O
viral	B-DISO
gastroenteritis	I-DISO
.	O

AIV	O
infection	B-DISO
of	O
macrophages	O
was	O
required	O
to	O
activate	O
T	O
lymphocytes	O
and	O
prior	O
in	O
vivo	O
exposure	O
of	O
chickens	O
to	O
NP	O
AIV	O
plasmid	O
enhanced	O
responses	O
to	O
infected	O
macrophages	O
.	O

ABSTRACT	O
:	O
To	O
further	O
explore	O
the	O
chemical	O
space	O
around	O
the	O
entrance	O
channel	O
of	O
HIV	B-DISO
-	O
1	O
reverse	O
transcriptase	O
(	O
RT	O
),	O
a	O
series	O
of	O
novel	O
indolylarylsulfones	O
(	O
IASs	O
)	O
bearing	O
N	O
-	O
substituted	O
piperidine	O
at	O
indole	O
-	O
2	O
-	O
carboxamide	O
were	O
identified	O
as	O
potent	O
HIV	B-DISO
NNRTIs	O
by	O
structure	O
-	O
guided	O
scaffold	O
morphing	O
and	O
fragment	O
rearrangement	O
.	O

The	O
evidence	O
supporting	O
NIV	O
use	O
in	O
patients	O
with	O
ARDS	B-DISO
remains	O
relatively	O
sparse	O
.	O

For	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
blood	O
culture	O
,	O
serum	O
procalcitonin	O
,	O
serum	O
antibodies	O
to	O
Mycoplasma	B-DISO
and	O
Chlamydia	O
and	O
urinary	O
Streptococcus	O
pneumoniae	O
antigen	O
were	O
also	O
assayed	O
.	O

The	O
large	O
observational	O
study	O
to	O
understand	O
the	O
global	O
impact	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
(	O
LUNG	O
SAFE	O
)	O
was	O
an	O
international	O
,	O
multicenter	O
,	O
prospective	O
cohort	O
study	O
of	O
patients	O
with	O
severe	O
respiratory	B-DISO
failure	I-DISO
,	O
conducted	O
in	O
the	O
winter	O
of	O
2014	O
in	O
a	O
convenience	O
sample	O
of	O
459	O
ICUs	O
from	O
50	O
countries	O
across	O
five	O
continents	O
.	O

Potentially	O
modifiable	O
factors	O
associated	O
with	O
increased	O
hospital	O
mortality	O
in	O
multivariable	O
analyses	O
include	O
lower	O
PEEP	O
,	O
higher	O
peak	O
inspiratory	O
,	O
plateau	O
,	O
and	O
driving	O
pressures	O
,	O
and	O
increased	B-DISO
respiratory	I-DISO
rate	I-DISO
.	O

Severity	O
of	O
illness	O
indices	O
including	O
lower	O
pH	O
,	O
lower	O
PaO	O
Higher	O
PEEP	O
,	O
lower	O
peak	O
,	O
plateau	O
,	O
and	O
driving	O
pressures	O
,	O
and	O
lower	O
respiratory	O
rate	O
are	O
associated	O
with	O
improved	O
survival	O
from	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Chest	O
radiographic	O
manifestations	O
of	O
scrub	B-DISO
typhus	I-DISO
.	O

Breathlessness	B-DISO
,	O
presence	O
of	O
an	O
eschar	B-DISO
,	O
platelet	O
counts	O
of	O
<	O
20	O
,	O
000	O
cells	O
/	O
cumm	O
,	O
and	O
total	O
serum	O
bilirubin	O
>	O
2	O
mg	O
/	O
dL	O
had	O
the	O
highest	O
odds	O
of	O
having	O
an	O
abnormal	O
chest	O
radiograph	O
.	O

Chemo	O
/	O
radiation	O
therapy	O
-	O
induced	O
toxicity	O
(	O
6	O
%),	O
venous	B-DISO
thromboembolism	I-DISO
(	O
5	O
%),	O
respiratory	B-DISO
failure	I-DISO
(	O
4	O
%),	O
gastrointestinal	O
involvement	O
(	O
3	O
%)	O
and	O
vena	B-DISO
cava	I-DISO
syndrome	I-DISO
(	O
VCS	O
)	O
(	O
2	O
%)	O
were	O
the	O
most	O
frequent	O
cancer	B-DISO
-	O
related	O
complications	O
.	O

LPS	B-DISO
-	O
induced	O
phosphorylation	O
and	O
nuclear	O
translocation	B-DISO
of	O
NF	O
-	O
κB	O
and	O
p38	O
MAPK	O
were	O
blocked	O
by	O
Nur77	O
overexpression	O
and	O
augmented	O
by	O
Nur77	O
knockdown	O
in	O
A549	O
cells	O
.	O

Pharmacological	O
activation	O
of	O
Nur77	O
by	O
cytosporone	O
B	O
(	O
CsnB	O
)	O
inhibited	O
ET	O
-	O
1	O
expression	O
in	O
ARDS	B-DISO
rats	O
,	O
decreased	O
LPS	B-DISO
-	O
induced	O
phosphorylation	O
of	O
NF	O
-	O
κB	O
and	O
p38	O
MAPK	O
,	O
and	O
relieved	O
lung	O
,	O
liver	O
,	O
and	O
kidney	O
injury	O
.	O

Infection	B-DISO
status	O
was	O
determined	O
by	O
the	O
presence	O
of	O
antibodies	O
against	O
MERS	O
-	O
CoV	O
.	O
To	O
assess	O
risk	O
factors	O
,	O
we	O
compared	O
infected	O
and	O
uninfected	O
participants	O
.	O

Clinical	O
signs	B-DISO
and	I-DISO
symptoms	I-DISO
may	O
overlap	O
among	O
the	O
different	O
forms	O
of	O
HUS	O
.	O

The	O
presence	O
of	O
potential	O
pathogens	O
however	O
,	O
does	O
not	O
prove	O
a	O
causal	O
relationship	O
with	O
diarrhoea	B-DISO
.	O

Faecal	O
samples	O
from	O
puppies	O
with	O
(	O
n	O
=	O
113	O
)	O
and	O
without	O
(	O
n	O
=	O
56	O
)	O
acute	B-DISO
diarrhoea	I-DISO
were	O
collected	O
and	O
screened	O
for	O
Canine	O
Parvovirus	B-DISO
(	O
CPV	O
),	O
Canine	O
Coronavirus	O
(	O
CCoV	O
),	O
Salmonella	B-DISO
spp	O
.,	O
Campylobacter	O
spp	O
.,	O
Clostridium	O
perfringens	O
,	O
Clostridium	O
difficile	O
,	O
β	O
-	O
hemolytic	O
Eschericha	O
coli	O
(	O
hEC	O
),	O
Giardia	B-DISO
spp	O
.,	O
Toxocara	O
spp	O
.,	O
Cystoisospora	O
spp	O
.,	O
and	O
Cyniclomyces	O
guttulatus	O
.	O

Significant	O
positive	O
associations	O
were	O
found	O
between	O
CPV	O
and	O
CCoV	O
,	O
CPV	O
and	O
Cystoisospora	O
spp	O
.,	O
Toxocara	O
spp	O
.	O
and	O
hEC	O
,	O
Giardia	B-DISO
spp	O
.	O

TITLE	O
:	O
Amiodarone	O
-	O
Induced	O
Pulmonary	B-DISO
Toxicity	I-DISO
-	O
A	O
Frequently	O
Missed	O
Complication	B-DISO
.	O

We	O
examined	O
the	O
incubation	O
period	O
distribution	O
of	O
MERS	O
coronavirus	B-DISO
infection	I-DISO
for	O
cases	O
in	O
South	O
Korea	O
and	O
in	O
Saudi	O
Arabia	O
.	O

Ventilation	O
with	O
low	O
tidal	O
volumes	O
and	O
pressure	O
limitation	O
at	O
30cmH	O
Demographic	O
data	O
,	O
risk	O
factors	O
and	O
severity	O
of	O
ARDS	B-DISO
,	O
APACHE	O
II	O
and	O
SOFA	O
scores	O
,	O
daily	O
Lung	O
Injury	O
Score	O
,	O
ventilatory	O
measurements	O
,	O
ICU	O
and	O
hospital	O
stay	O
,	O
organ	B-DISO
failure	I-DISO
and	O
mortality	O
at	O
day	O
28	O
and	O
90	O
after	O
inclusion	O
.	O

Patients	O
with	O
moderate	O
ARDS	B-DISO
did	O
not	O
show	O
these	O
effects	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
for	O
adult	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
trauma	O
patients	O
:	O
A	O
case	O
series	O
and	O
systematic	O
literature	O
review	O
.	O

We	O
performed	O
a	O
systematic	O
review	O
of	O
the	O
available	O
literature	O
to	O
investigate	O
the	O
safety	O
and	O
efficacy	O
of	O
vv	O
-	O
ECMO	O
in	O
posttraumatic	O
ARDS	B-DISO
,	O
focusing	O
on	O
the	O
use	O
of	O
different	O
anticoagulation	O
strategies	O
and	O
risk	O
of	O
bleeding	B-DISO
on	O
patients	O
with	O
multiple	O
injuries	O
.	O

Eleven	O
patients	O
developed	O
complications	O
during	O
treatment	O
with	O
ECMO	O
with	O
three	O
cases	O
of	O
major	O
bleeding	B-DISO
.	O

Our	O
experience	O
and	O
our	O
literature	O
review	O
suggest	O
that	O
vv	O
-	O
ECMO	O
should	O
be	O
considered	O
as	O
a	O
rescue	O
treatment	O
for	O
the	O
management	O
of	O
severe	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
secondary	O
to	O
ARDS	B-DISO
in	O
trauma	O
patients	O
.	O

For	O
patients	O
with	O
a	O
moderate	O
risk	O
of	O
bleeding	B-DISO
,	O
use	O
of	O
a	O
heparin	O
infusion	O
keeping	O
an	O
ACT	O
target	O
shorter	O
than	O
150	O
seconds	O
can	O
be	O
appropriate	O
.	O

TITLE	O
:	O
Clinical	O
predictors	O
of	O
early	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
trauma	O
patients	O
.	O

Distribution	O
of	O
V	O
RESULTS	O
:	O
Twenty	O
-	O
two	O
patients	O
were	O
studied	O
(	O
N	O
=	O
18	O
met	O
the	O
criteria	O
for	O
pediatric	O
ARDS	B-DISO
).	O

TITLE	O
:	O
Fifty	O
Years	O
of	O
Research	O
in	O
ARDS	B-DISO
.	O

Additionally	O
,	O
infections	B-DISO
with	O
typical	O
bacteria	O
were	O
more	O
common	O
in	O
patients	O
with	O
chronic	B-DISO
lung	I-DISO
disease	I-DISO
(	O
p	O
=	O
0	O
.	O
029	O
),	O
and	O
typical	O
bacterial	B-DISO
infections	I-DISO
showed	O
a	O
trend	O
towards	O
a	O
higher	O
prevalence	O
with	O
older	O
age	O
(	O
p	O
=	O
0	O
.	O
001	O
).	O

These	O
mutations	O
severely	O
compromised	O
MERS	O
-	O
CoV	O
infection	B-DISO
into	O
human	O
lung	O
-	O
derived	O
cells	O
,	O
but	O
had	O
little	O
effect	O
on	O
infection	B-DISO
into	O
several	O
other	O
cell	O
types	O
.	O

TITLE	O
:	O
Antiviral	O
Compounds	O
Against	O
Nucleocapsid	O
Protein	O
of	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
.	O

nsp11	O
is	O
associated	O
with	O
multiple	O
functions	O
,	O
such	O
as	O
RNA	O
processing	O
and	O
suppression	B-DISO
of	O
the	O
infected	O
host	O
innate	O
immunity	O
system	O
.	O

There	O
were	O
68	O
penguins	O
that	O
were	O
seropositive	O
for	O
at	O
least	O
one	O
of	O
seven	O
pathogens	O
tested	O
:	O
avian	B-DISO
encephalomyelitis	I-DISO
virus	O
,	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
,	O
avian	O
reovirus	O
,	O
infectious	B-DISO
bursal	I-DISO
disease	I-DISO
virus	O
,	O
Newcastle	B-DISO
disease	I-DISO
virus	O
,	O
Mycoplasma	B-DISO
gallisepticum	O
and	O
Mycoplasma	B-DISO
synoviae	O
.	O

TITLE	O
:	O
Fibroblastic	O
reticular	O
cells	O
regulate	O
intestinal	O
inflammation	B-DISO
via	O
IL	O
-	O
15	O
-	O
mediated	O
control	O
of	O
group	O
1	O
ILCs	O
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
(	O
HCoV	O
)	O
NL63	O
is	O
recognized	O
as	O
a	O
common	O
cause	O
of	O
upper	B-DISO
respiratory	I-DISO
infections	I-DISO
and	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
.	O

In	O
screening	O
children	O
with	O
acute	O
undifferentiated	O
febrile	B-DISO
illness	I-DISO
in	O
a	O
school	O
cohort	O
in	O
rural	O
Haiti	O
,	O
we	O
identified	O
HCoV	O
-	O
NL63	O
in	O
blood	O
samples	O
from	O
four	O
children	O
.	O

However	O
,	O
the	O
rescue	O
effects	O
of	O
HFOV	O
on	O
severe	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
PARDS	O
)	O
with	O
hypoxemia	O
refractory	O
to	O
conventional	O
mechanical	O
ventilation	O
(	O
CMV	O
)	O
remain	O
unclear	O
.	O

General	O
mortality	O
rates	O
ranged	O
from	O
11	O
to	O
87	O
%	O
in	O
studies	O
including	O
subjects	O
with	O
ARDS	B-DISO
of	O
all	O
etiologies	O
(	O
mixed	O
group	O
).	O

TITLE	O
:	O
Molecular	O
Detection	O
of	O
Circovirus	O
and	O
Adenovirus	B-DISO
in	O
Feces	O
of	O
Fur	O
Seals	O
(	O
Arctocephalus	O
spp	O
.).	O

MERS	O
-	O
CoV	O
(	O
EMC	B-DISO
strain	O
)	O
was	O
used	O
to	O
inoculate	O
plasma	O
units	O
that	O
then	O
underwent	O
treatment	O
with	O
riboflavin	O
and	O
UV	O
light	O
.	O

Frequently	O
,	O
patients	O
with	O
severe	O
ARDS	B-DISO
also	O
show	O
signs	O
of	O
severe	B-DISO
sepsis	I-DISO
.	O

Despite	O
the	O
preactivated	O
status	O
of	O
the	O
septic	O
blood	O
,	O
no	O
further	O
increase	O
of	O
coagulation	O
activity	O
,	O
inflammatory	B-DISO
response	I-DISO
or	O
increased	O
oxygenator	O
resistance	O
was	O
observed	O
in	O
comparison	O
to	O
the	O
control	O
experiments	O
.	O

There	O
are	O
no	O
treatment	O
options	O
against	O
MERS	O
-	O
CoV	O
for	O
humans	O
or	O
animals	O
,	O
and	O
there	O
are	O
no	O
large	O
-	O
scale	O
clinical	O
trials	O
for	O
therapies	O
against	O
MERS	O
-	O
CoV	O
.	O
To	O
address	O
this	O
need	O
,	O
we	O
developed	O
an	O
inactivated	O
rabies	B-DISO
virus	O
(	O
RABV	O
)	O
that	O
contains	O
the	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
expressed	O
on	O
its	O
surface	O
.	O

Our	O
results	O
indicate	O
that	O
this	O
vaccine	O
approach	O
can	O
prevent	O
disease	O
,	O
and	O
the	O
RABV	O
-	O
based	O
vaccine	O
platform	O
may	O
be	O
a	O
valuable	O
tool	O
for	O
timely	O
vaccine	O
development	O
against	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

The	O
highest	O
mRNA	O
levels	O
were	O
observed	O
in	O
the	O
most	O
severely	O
ill	B-DISO
patients	O
(	O
p	O
<	O
0	O
.	O
028	O
).	O

In	O
this	O
pilot	O
study	O
,	O
we	O
show	O
for	O
the	O
first	O
time	O
that	O
blood	O
neutrophils	O
from	O
patients	O
with	O
ARDS	B-DISO
can	O
express	O
GILZ	O
,	O
in	O
keeping	O
with	O
an	O
anti	O
-	O
inflammatory	O
and	O
regulatory	O
endogenous	O
role	O
of	O
GILZ	O
in	O
humans	O
.	O

Contrary	O
to	O
some	O
markers	O
of	O
inflammation	B-DISO
or	O
its	O
resolution	O
,	O
the	O
levels	O
of	O
gilz	O
gene	O
expression	O
were	O
related	O
to	O
ARDS	B-DISO
severity	O
.	O

In	O
addition	O
,	O
common	O
directional	O
changes	O
in	O
human	B-DISO
influenza	I-DISO
A	O
viruses	O
were	O
observed	O
for	O
three	O
subtypes	O
,	O
whose	O
epidemics	O
started	O
independently	O
.	O

The	O
demographics	O
,	O
clinical	O
and	O
laboratory	O
characteristics	O
and	O
clinical	O
outcomes	O
of	O
patients	O
with	O
RT	O
-	O
PCR	O
confirmed	O
MERS	O
-	O
CoV	O
infection	B-DISO
was	O
compared	O
with	O
those	O
testing	O
negative	O
MERS	O
-	O
CoV	O
PCR	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
a	O
novel	O
duplex	O
nanoparticle	O
-	O
assisted	O
polymerase	O
chain	O
reaction	O
(	O
nanoPCR	O
)	O
assay	O
was	O
developed	O
to	O
detect	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
and	O
porcine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
virus	O
(	O
TGEV	O
).	O

Respiratory	O
syncytial	O
virus	O
and	O
influenza	B-DISO
virus	O
are	O
frequently	O
transmitted	B-DISO
in	O
the	O
hospital	O
setting	O
.	O

Weaning	O
occurred	O
over	O
5d	O
,	O
and	O
during	O
this	O
weaning	O
period	O
,	O
ACD	B-DISO
calves	O
had	O
access	O
to	O
milk	O
replacer	O
for	O
12h	O
/	O
d	O
and	O
RES	O
calves	O
were	O
offered	O
only	O
one	O
feeding	O
of	O
milk	O
replacer	O
(	O
3	O
L	O
)	O
daily	O
.	O

The	O
ACD	B-DISO
feeding	O
treatment	O
supported	O
greater	O
preweaning	O
average	O
daily	O
gain	O
(	O
0	O
.	O
59	O
vs	O
.	O
0	O
.	O
43kg	O
/	O
d	O
)	O
and	O
structural	O
growth	O
than	O
RES	O
feeding	O
.	O

Using	O
a	O
three	O
-	O
step	O
search	O
strategy	O
,	O
the	O
following	O
databases	O
from	O
1997	O
-	O
2009	O
were	O
accessed	O
:	O
CINAHL	O
,	O
PubMed	O
,	O
SCOPUS	O
,	O
ScienceDirect	O
,	O
Sociological	O
Abstracts	O
,	O
PsycINFO	O
,	O
and	O
Web	B-DISO
of	O
Science	O
.	O

Findings	O
indicated	O
that	O
although	O
health	O
care	O
workers	O
perceived	O
personal	O
and	O
familial	O
health	O
risks	O
and	O
stigmatization	O
from	O
their	O
exposure	O
to	O
emerging	O
acute	O
respiratory	O
infectious	B-DISO
diseases	I-DISO
,	O
the	O
majority	O
were	O
accepting	O
of	O
these	O
risks	O
.	O

Here	O
we	O
adapted	O
a	O
solvent	O
-	O
based	O
method	O
,	O
widely	O
applied	O
for	O
extracting	O
lipids	O
and	O
metabolites	O
,	O
to	O
add	B-DISO
proteomics	O
to	O
mass	O
spectrometry	O
-	O
based	O
multi	O
-	O
omics	O
measurements	O
.	O

In	O
summary	O
,	O
we	O
describe	O
a	O
rapid	O
,	O
universal	O
standard	O
operating	O
procedure	O
that	O
generates	O
high	O
-	O
quality	O
NGS	O
libraries	O
free	O
of	O
infectious	B-DISO
virus	O
and	O
infectious	B-DISO
viral	O
RNA	O
.	O

Variables	O
associated	O
with	O
mortality	O
included	O
immunosuppression	O
,	O
shock	O
at	O
time	O
of	O
admission	O
,	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
occurrence	O
of	O
heparin	B-DISO
-	I-DISO
induced	I-DISO
thrombocytopenia	I-DISO
antibodies	O
,	O
nosocomial	O
sepsis	B-DISO
and	O
duration	O
of	O
ECMO	O
.	O

ABSTRACT	O
:	O
Hyponatremia	O
is	O
commonly	O
noted	O
with	O
cardiovascular	B-DISO
disorders	I-DISO
,	O
but	O
its	O
role	O
in	O
infective	B-DISO
endocarditis	I-DISO
(	O
IE	O
)	O
is	O
limited	O
to	O
being	O
a	O
marker	O
of	O
increased	O
morbidity	O
in	O
IE	O
patients	O
with	O
intravenous	O
drug	B-DISO
use	I-DISO
.	O

ABSTRACT	O
:	O
Recent	O
pandemics	O
of	O
influenza	B-DISO
A	O
H1N1pdm09	O
virus	O
have	O
caused	O
severe	O
illness	O
,	O
especially	O
in	O
young	O
people	O
.	O

Very	O
few	O
studies	O
on	O
influenza	B-DISO
A	O
H1N1pdm09	O
in	O
post	O
-	O
pandemic	O
periods	O
exist	O
,	O
and	O
there	O
is	O
no	O
information	O
on	O
the	O
severity	O
of	O
both	O
seasonal	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
and	O
A	O
(	O
H3N2	O
)	O
from	O
the	O
same	O
season	O
,	O
adjusting	O
for	O
potential	O
confounders	O
,	O
including	O
vaccine	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
remains	O
a	O
common	O
organ	O
dysfunction	O
in	O
the	O
critically	B-DISO
ill	I-DISO
patient	O
.	O

ARDS	B-DISO
was	O
induced	O
in	O
mice	O
by	O
hemorrhagic	B-DISO
shock	I-DISO
(	O
day	O
1	O
)	O
followed	O
by	O
poly	O
-	O
microbial	O
sepsis	B-DISO
(	O
day	O
2	O
).	O

ABSTRACT	O
:	O
The	O
economic	O
losses	O
of	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
(	O
PED	O
)	O
and	O
the	O
net	O
benefits	O
of	O
strategies	O
to	O
control	O
the	O
virus	O
are	O
calculated	O
for	O
individual	O
farrow	O
-	O
to	O
-	O
finish	O
herds	O
.	O

ABSTRACT	O
:	O
Dermatomyositis	B-DISO
associated	O
with	O
anti	O
-	O
MDA	O
-	O
5	O
autoantibodies	O
is	O
a	O
recently	O
-	O
described	O
clinical	O
entity	O
.	O

TITLE	O
:	O
Alisporivir	O
inhibits	O
MERS	O
-	O
and	O
SARS	B-DISO
-	O
coronavirus	O
replication	O
in	O
cell	O
culture	O
,	O
but	O
not	O
SARS	B-DISO
-	O
coronavirus	B-DISO
infection	I-DISO
in	O
a	O
mouse	O
model	O
.	O

We	O
here	O
report	O
that	O
in	O
cultured	O
cells	O
low	O
-	O
micromolar	O
concentrations	O
of	O
alisporivir	O
,	O
a	O
non	O
-	O
immunosuppressive	O
cyclosporin	O
A	O
-	O
analog	O
,	O
inhibit	O
the	O
replication	O
of	O
four	O
different	O
coronaviruses	O
,	O
including	O
MERS	O
-	O
and	O
SARS	B-DISO
-	O
coronavirus	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
appropriateness	O
of	O
the	O
screening	O
strategy	O
for	O
healthcare	O
personnel	O
(	O
HCP	B-DISO
)	O
during	O
a	O
hospital	O
-	O
associated	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	B-DISO
)	O
outbreak	O
,	O
we	O
performed	O
a	O
serologic	O
investigation	O
in	O
189	O
rRT	O
-	O
PCR	O
-	O
negative	O
HCP	B-DISO
exposed	O
and	O
assigned	O
to	O
MERS	B-DISO
patients	O
.	O

TITLE	O
:	O
Extracorporeal	O
Gas	O
Exchange	O
:	O
The	O
Expanding	O
Role	O
of	O
Extracorporeal	O
Support	O
in	O
Respiratory	B-DISO
Failure	I-DISO
.	O

Extracorporeal	O
gas	O
exchange	O
is	O
an	O
accepted	O
rescue	O
therapy	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
select	O
patients	O
.	O

A	O
67	O
-	O
year	O
-	O
old	O
man	O
with	O
a	O
normal	O
platelet	O
count	O
(	O
220	O
K	O
/	O
uL	O
)	O
developed	O
atrial	B-DISO
fibrillation	I-DISO
,	O
left	B-DISO
bundle	I-DISO
branch	I-DISO
block	I-DISO
,	O
and	O
respiratory	B-DISO
insufficiency	I-DISO
consistent	O
with	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
two	O
days	O
after	O
colectomy	O
.	O

In	O
this	O
case	O
,	O
discontinuation	O
of	O
eptifibatide	O
and	O
transfusion	O
of	O
apheresis	O
platelets	B-DISO
increased	I-DISO
the	O
platelet	O
count	O
(	O
137	O
K	O
/	O
uL	O
)	O
the	O
following	O
day	O
,	O
and	O
the	O
patient	O
subsequently	O
underwent	O
successful	O
coronary	O
artery	O
surgery	O
using	O
cardiopulmonary	O
bypass	O
.	O

The	O
link	O
between	O
steroid	O
treatment	O
and	O
the	O
risk	O
of	O
osteonecrosis	B-DISO
in	O
SARS	B-DISO
patients	O
remains	O
unknown	O
.	O

Two	O
authors	O
independently	O
extracted	O
the	O
data	O
from	O
the	O
individual	O
studies	O
,	O
and	O
the	O
rate	O
ratio	O
(	O
RR	O
)	O
of	O
osteonecrosis	B-DISO
was	O
calculated	O
using	O
random	O
-	O
effect	O
models	O
.	O

Our	O
findings	O
suggest	O
that	O
it	O
is	O
important	O
to	O
reduce	O
osteonecrosis	B-DISO
risk	O
by	O
modifying	O
the	O
cumulative	O
dose	O
and	O
the	O
treatment	O
duration	O
of	O
steroids	O
in	O
SARS	B-DISO
patients	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
celastrol	O
exhibits	O
antiviral	O
activity	O
against	O
HIV	B-DISO
and	O
SARS	B-DISO
-	O
CoV	O
.	O
To	O
date	O
,	O
no	O
investigations	O
of	O
the	O
anti	O
-	O
DENV	O
activity	O
of	O
celastrol	O
have	O
been	O
reported	O
.	O

For	O
every	O
centimeter	O
H	O
Our	O
results	O
suggest	O
that	O
PEEP	O
can	O
be	O
applied	O
safely	O
in	O
patients	O
with	O
acute	O
brain	O
injury	O
as	O
it	O
does	O
not	O
have	O
a	O
clinically	O
significant	O
effect	O
on	O
ICP	B-DISO
or	O
CPP	O
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
is	O
a	O
coronavirus	O
that	O
causes	O
villus	O
atrophy	B-DISO
,	O
followed	O
by	O
crypt	O
hyperplasia	B-DISO
,	O
reduces	O
the	O
activities	O
of	O
intestinal	O
digestive	O
enzymes	O
,	O
and	O
disrupts	O
the	O
absorption	O
of	O
intestinal	O
nutrients	O
.	O

However	O
,	O
the	O
transmission	O
of	O
PEEP	O
into	O
the	O
thoracic	B-DISO
cavity	B-DISO
depends	O
on	O
the	O
properties	O
of	O
the	O
lungs	O
and	O
the	O
chest	O
wall	O
.	O

TITLE	O
:	O
Long	O
-	O
term	O
impact	O
after	O
fulminant	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
,	O
case	O
report	O
and	O
literature	O
review	O
.	O

The	O
higher	O
detection	O
of	O
rhinoviruses	O
both	O
in	O
patient	O
and	O
control	O
groups	O
give	O
rise	O
to	O
thought	O
that	O
these	O
viruses	O
may	O
be	O
responsible	O
for	O
asthma	B-DISO
exacerbations	O
and	O
may	O
be	O
related	O
with	O
long	O
duration	O
of	O
virus	B-DISO
shedding	I-DISO
.	O

ABSTRACT	O
:	O
A	O
54	O
-	O
year	O
-	O
old	O
man	O
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
was	O
transferred	O
to	O
our	O
hospital	O
.	O

We	O
report	O
two	O
immunocompetent	O
patients	O
with	O
severe	O
ARDS	B-DISO
complicating	O
HAdV	O
pneumonia	B-DISO
who	O
were	O
treated	O
successfully	O
and	O
survived	O
to	O
discharge	O
.	O

Influenza	B-DISO
A	O
virus	O
accounted	O
for	O
half	O
the	O
isolated	O
viruses	O
,	O
especially	O
subtype	O
A	O
(	O
H1N1	O
)	O
pdm09	O
among	O
patients	O
aged	O
20	O
-	O
59	O
years	O
old	O
,	O
and	O
subtype	O
A	O
(	O
H3N2	O
)	O
in	O
those	O
aged	O
60	O
or	O
over	O
;	O
the	O
most	O
frequently	O
identified	O
respiratory	O
virus	O
among	O
children	O
under	O
five	O
years	O
old	O
was	O
respiratory	O
syncytial	O
virus	O
(	O
65	O
.	O
6	O
%),	O
followed	O
by	O
influenza	B-DISO
A	O
virus	O
(	O
21	O
.	O
2	O
%);	O
influenza	B-DISO
virus	O
circulated	O
in	O
all	O
seasons	O
of	O
the	O
year	O
and	O
its	O
periods	O
of	O
greatest	O
incidence	O
were	O
interspersed	O
with	O
those	O
of	O
higher	O
Respiratory	O
Syncytial	O
Virus	O
activity	O
.	O

The	O
patient	O
was	O
initially	O
diagnosed	O
with	O
simple	O
acute	B-DISO
pancreatitis	I-DISO
.	O

Though	O
the	O
symptoms	O
were	O
rapidly	O
relieved	O
after	O
initiation	O
of	O
treatment	O
,	O
severe	O
hyperglycemia	B-DISO
(	O
575	O
mg	O
/	O
dL	O
),	O
severe	O
metabolic	B-DISO
acidosis	I-DISO
(	O
pH	O
6	O
.	O
9	O
),	O
and	O
ketonuria	B-DISO
developed	O
at	O
four	O
days	O
after	O
hospitalization	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aimed	O
to	O
assess	O
whether	O
a	O
management	O
algorithm	O
using	O
data	O
obtained	O
with	O
a	O
PiCCO	O
system	O
can	O
improve	O
clinical	O
outcomes	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

The	O
PaO	O
This	O
study	O
investigated	O
the	O
usefulness	O
of	O
the	O
PiCCO	O
system	O
in	O
improving	O
outcomes	O
for	O
patient	O
with	O
severe	O
thoracic	B-DISO
trauma	O
and	O
ARDS	B-DISO
and	O
provided	O
new	O
evidence	O
for	O
fluid	O
management	O
in	O
critical	O
care	O
settings	O
.	O

TITLE	O
:	O
Human	O
Coronavirus	O
in	O
the	O
2014	O
Winter	O
Season	O
as	O
a	O
Cause	O
of	O
Lower	B-DISO
Respiratory	I-DISO
Tract	I-DISO
Infection	I-DISO
.	O

Interestingly	O
,	O
in	O
2014	O
,	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
caused	O
not	O
only	O
upper	B-DISO
respiratory	I-DISO
infections	I-DISO
but	O
also	O
LRTIs	O
more	O
commonly	O
than	O
in	O
other	O
years	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
:	O
beyond	O
rescue	O
therapy	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
?	O

In	O
addition	O
,	O
early	O
and	O
prolonged	O
viral	B-DISO
shedding	I-DISO
and	O
rapid	O
viral	O
dissemination	O
were	O
observed	O
.	O

Although	O
cocaine	O
might	O
be	O
expected	O
more	O
frequently	O
to	O
cause	O
oesophageal	B-DISO
necrosis	I-DISO
through	O
sympathomimetic	O
vasoconstriction	B-DISO
,	O
this	O
is	O
only	O
the	O
second	O
known	O
case	O
report	O
of	O
AEN	O
in	O
a	O
patient	O
with	O
cocaine	B-DISO
abuse	I-DISO
.	O

His	O
symptoms	O
at	O
presentation	O
included	O
epigastric	O
abdominal	B-DISO
pain	I-DISO
,	O
haematemesis	B-DISO
and	O
generalised	O
weakness	B-DISO
.	O

OSAS	B-DISO
is	O
characterized	O
by	O
repeated	O
occlusions	B-DISO
of	O
the	O
pharyngeal	O
airway	O
during	O
sleep	O
.	O

Dysfunction	O
of	O
the	O
upper	O
airway	O
muscles	O
controlling	O
airway	O
calibre	O
and	O
collapsibility	O
is	O
implicated	O
in	O
the	O
pathophysiology	O
of	O
OSAS	B-DISO
,	O
and	O
sex	O
differences	O
in	O
the	O
neuro	O
-	O
mechanical	O
control	O
of	O
upper	O
airway	O
patency	O
are	O
described	O
.	O

Conversely	O
,	O
exposure	O
to	O
CIH	O
in	O
early	O
life	O
,	O
results	O
in	O
upper	O
airway	O
muscle	B-DISO
weakness	I-DISO
equivalent	O
between	O
the	O
two	O
sexes	O
at	O
3	O
and	O
6	O
weeks	O
of	O
age	O
.	O

Intriguingly	O
,	O
female	O
advantage	O
intrinsic	O
to	O
upper	O
airway	O
muscle	O
exists	O
with	O
evidence	O
of	O
substantially	O
greater	O
loss	O
of	O
performance	O
in	O
male	O
muscle	O
during	O
acute	O
exposure	O
to	O
severe	O
hypoxic	B-DISO
stress	O
.	O

We	O
examined	O
the	O
association	O
between	O
influenza	B-DISO
vaccination	O
and	O
school	O
absence	O
among	O
children	O
with	O
RT	O
-	O
PCR	O
-	O
confirmed	O
influenza	B-DISO
.	O

Although	O
controversial	O
,	O
obesity	B-DISO
may	O
also	O
cause	O
poorer	O
outcomes	O
in	O
acute	B-DISO
asthma	I-DISO
.	O

IL	O
-	O
17	O
is	O
associated	O
with	O
neutrophilic	O
inflammation	B-DISO
,	O
steroid	O
resistance	O
and	O
severe	O
asthma	B-DISO
,	O
but	O
its	O
importance	O
in	O
the	O
association	O
between	O
asthma	B-DISO
and	O
obesity	B-DISO
is	O
unknown	O
.	O

Effects	O
of	O
adiposity	B-DISO
on	O
acute	B-DISO
asthma	I-DISO
remain	O
uncertain	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	B-DISO
)	O
is	O
a	O
highly	O
lethal	O
pulmonary	B-DISO
infection	I-DISO
caused	O
by	O
a	O
coronavirus	O
(	O
CoV	O
),	O
MERS	B-DISO
-	O
CoV	O
.	O
With	O
the	O
continuing	O
spread	O
of	O
MERS	O
-	O
CoV	O
,	O
prophylactic	O
and	O
therapeutic	O
treatments	O
are	O
urgently	O
needed	O
.	O

Here	O
we	O
employed	O
differential	O
scanning	O
calorimetry	O
(	O
DSC	O
)	O
and	O
electron	O
spin	O
resonance	O
(	O
ESR	O
)	O
to	O
gather	O
information	O
on	O
the	O
membrane	O
fusion	O
mechanism	O
promoted	O
by	O
two	O
putative	O
SARS	B-DISO
FPs	O
.	O

The	O
significance	O
of	O
the	O
ordering	O
effect	O
,	O
membrane	O
dehydration	B-DISO
,	O
changes	O
in	O
the	O
curvature	O
properties	O
and	O
the	O
possible	O
role	O
of	O
negatively	O
charged	O
phospholipids	O
in	O
helping	O
to	O
overcome	O
the	O
high	O
kinetic	O
barrier	O
involved	O
in	O
the	O
different	O
stages	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
-	O
mediated	O
membrane	O
fusion	O
are	O
discussed	O
.	O

Limited	O
clinical	O
studies	O
indicate	O
that	O
humans	O
infected	O
with	O
MERS	O
-	O
CoV	O
exhibit	O
pathology	B-DISO
consistent	O
with	O
the	O
late	O
stages	O
of	O
ARDS	B-DISO
,	O
which	O
is	O
reminiscent	O
of	O
the	O
disease	O
observed	O
in	O
patients	O
infected	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

Serial	O
MERS	O
-	O
CoV	O
passage	O
in	O
these	O
engineered	O
mice	O
was	O
then	O
used	O
to	O
generate	O
a	O
mouse	O
-	O
adapted	O
virus	O
that	O
replicated	O
efficiently	O
within	O
the	O
lungs	O
and	O
evoked	O
symptoms	O
indicative	O
of	O
severe	O
ARDS	B-DISO
,	O
including	O
decreased	O
survival	O
,	O
extreme	O
weight	O
loss	O
,	O
decreased	O
pulmonary	O
function	O
,	O
pulmonary	B-DISO
haemorrhage	I-DISO
and	O
pathological	O
signs	O
indicative	O
of	O
end	O
-	O
stage	O
lung	B-DISO
disease	I-DISO
.	O

Importantly	O
,	O
therapeutic	O
countermeasures	O
comprising	O
MERS	O
-	O
CoV	O
neutralizing	O
antibody	O
treatment	O
or	O
a	O
MERS	O
-	O
CoV	O
spike	O
protein	O
vaccine	O
protected	O
the	O
engineered	O
mice	O
against	O
MERS	O
-	O
CoV	O
-	O
induced	O
ARDS	B-DISO
.	O

Description	O
of	O
the	O
case	O
:	O
A	O
17	O
-	O
year	O
-	O
old	O
male	O
was	O
transferred	O
to	O
the	O
emergency	B-DISO
department	O
unconscious	O
(	O
Glasgow	O
coma	B-DISO
scale	O
:	O
6	O
/	O
15	O
)	O
after	O
heroin	O
inhalation	O
.	O

Heroin	O
inhalation	O
may	O
cause	O
severe	O
complications	O
,	O
such	O
as	O
non	B-DISO
-	I-DISO
cardiogenic	I-DISO
pulmonary	I-DISO
edema	I-DISO
,	O
rhabdomyolysis	B-DISO
or	O
myocardial	O
injury	O
.	O

ABSTRACT	O
:	O
Severe	O
respiratory	B-DISO
failure	I-DISO
due	O
to	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
might	O
require	O
rescue	O
therapy	O
measures	O
beyond	O
even	O
extended	O
standard	O
care	O
to	O
ensure	O
adequate	O
oxygenation	O
and	O
survival	O
.	O

Early	O
involvement	O
of	O
an	O
ARDS	B-DISO
or	O
extracorporeal	O
membrane	O
oxygenation	O
center	O
should	O
be	O
considered	O
to	O
ensure	O
optimal	O
care	O
.	O

A	O
well	O
timed	O
,	O
multimodal	O
approach	O
is	O
required	O
for	O
patients	O
with	O
ARDS	B-DISO
suffering	B-DISO
from	O
life	O
-	O
threatening	O
hypoxemia	O
.	O

ABSTRACT	O
:	O
While	O
the	O
risk	O
of	O
severe	O
complications	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
and	O
its	O
determinants	O
have	O
been	O
explored	O
in	O
previous	O
studies	O
,	O
a	O
systematic	O
analysis	O
of	O
published	O
articles	O
with	O
different	O
designs	O
and	O
populations	O
has	O
yet	O
to	O
be	O
conducted	O
.	O

In	O
this	O
prospective	O
study	O
,	O
45	O
patients	O
with	O
ARDS	B-DISO
were	O
included	O
for	O
the	O
assessment	O
of	O
PPP	B-DISO
.	O

The	O
PLUE	O
protocol	O
can	O
be	O
used	O
to	O
predict	O
PPP	B-DISO
and	O
assess	O
prognosis	O
in	O
patients	O
with	O
ARDS	B-DISO
.	O

However	O
,	O
the	O
mechanism	O
underlying	O
the	O
regulation	O
of	O
coronavirus	O
replication	O
by	O
CsA	B-DISO
is	O
unknown	O
.	O

Furthermore	O
,	O
the	O
proteins	O
expressed	O
by	O
CypA	O
and	O
CypB	O
harbouring	O
mutations	O
in	O
their	O
respective	O
predicted	O
peptidyl	O
-	O
prolyl	O
cis	B-DISO
-	O
transisomerase	O
active	O
sites	O
,	O
which	O
also	O
alter	O
the	O
affinities	O
between	O
Cyps	O
and	O
CsA	B-DISO
,	O
inhibited	O
FCoV	O
replication	O
.	O

TITLE	O
:	O
Early	O
experience	O
of	O
a	O
new	O
extracorporeal	O
carbon	O
dioxide	O
removal	O
device	O
for	O
acute	O
hypercapnic	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Protective	O
T	O
Cell	O
Responses	O
Featured	O
by	O
Concordant	O
Recognition	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
-	O
Derived	O
CD8	O
+	O
T	O
Cell	O
Epitopes	O
and	O
Host	O
MHC	O
.	O

In	O
this	O
study	O
,	O
utilizing	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
-	O
infected	O
mouse	O
model	O
,	O
we	O
observed	O
that	O
through	O
the	O
unusual	O
secondary	O
anchor	O
Ile5	O
,	O
a	O
CD8	O

TITLE	O
:	O
Treatment	O
of	O
Adenoviral	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
Using	O
Cidofovir	O
With	O
Extracorporeal	O
Membrane	O
Oxygenation	O
.	O

Although	O
rare	O
in	O
adults	O
,	O
severe	O
lower	O
respiratory	O
adenovirus	B-DISO
infections	I-DISO
including	O
pneumonia	B-DISO
are	O
reported	O
in	O
specific	O
populations	O
,	O
such	O
as	O
military	O
recruits	O
and	O
immunocompromised	O
patients	O
.	O

Of	O
these	O
55	O
plants	O
,	O
only	O
six	O
plants	O
have	O
been	O
studied	O
in	O
vitro	O
against	O
viral	O
pathogens	O
causing	O
bronchitis	B-DISO
.	O

We	O
invite	O
the	O
attention	O
of	O
researchers	O
for	O
detailed	O
ethnopharmacological	O
and	O
phytochemical	O
studies	O
on	O
unexplored	O
plants	O
used	O
to	O
treat	O
bronchitis	B-DISO
for	O
the	O
development	O
of	O
novel	O
antiviral	O
drugs	O
.	O

This	O
paper	O
examines	O
the	O
effect	O
of	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
epidemic	O
on	O
the	O
labor	O
market	O
to	O
investigate	O
whether	O
vulnerable	O
groups	O
become	O
more	O
vulnerable	O
due	O
to	O
an	O
interaction	O
between	O
the	O
socio	O
-	O
economic	O
structure	O
and	O
physical	O
risk	O
.	O

ABSTRACT	O
:	O
Legionella	O
pneumophila	O
,	O
a	O
major	O
cause	O
of	O
Legionnaires	B-DISO
'	I-DISO
disease	I-DISO
,	O
accounts	O
for	O
2	O
-	O
15	O
%	O
of	O
all	O
community	O
-	O
acquired	O
pneumonia	B-DISO
requiring	O
hospitalization	O
and	O
up	O
to	O
30	O
%	O
of	O
community	O
-	O
acquired	O
pneumonia	B-DISO
requiring	O
intensive	O
care	O
unit	O
admission	O
.	O

We	O
sought	O
to	O
describe	O
hospitalized	O
community	O
-	O
acquired	O
Legionnaires	B-DISO
'	I-DISO
disease	I-DISO
to	O
increase	O
awareness	O
of	O
this	O
important	O
and	O
potentially	O
lethal	O
disease	O
.	O

In	O
our	O
cohort	O
,	O
Legionnaires	B-DISO
'	I-DISO
disease	I-DISO
was	O
diagnosed	O
with	O
a	O
combination	O
of	O
a	O
urinary	O
Legionella	O
antigen	O
test	O
and	O
a	O
Legionella	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
assay	O
.	O

In	O
addition	O
,	O
antimicrobial	O
therapy	O
with	O
newer	O
macrolides	O
or	O
respiratory	O
fluoroquinolones	O
should	O
be	O
initiated	O
for	O
severe	O
community	O
-	O
acquired	O
pneumonia	B-DISO
requiring	O
intensive	O
care	O
unit	O
admission	O
,	O
prior	O
to	O
laboratory	O
confirmation	O
of	O
diagnosis	O
,	O
especially	O
when	O
a	O
clinical	O
suspicion	O
of	O
Legionella	B-DISO
infection	I-DISO
exists	O
.	O

TITLE	O
:	O
Getting	O
Rid	O
of	O
Weakness	B-DISO
in	O
the	O
ICU	O
:	O
An	O
Updated	O
Approach	O
to	O
the	O
Acute	O
Management	O
of	O
Myasthenia	B-DISO
Gravis	I-DISO
and	O
Guillain	O
-	O
Barré	O
Syndrome	B-DISO
.	O

Clinical	O
,	O
epidemiological	O
,	O
and	O
laboratory	O
data	O
of	O
patients	O
hospitalized	O
with	O
acute	O
respiratory	O
syndrome	B-DISO
in	O
a	O
tertiary	O
care	O
hospital	O
from	O
2012	O
to	O
2013	O
were	O
reviewed	O
.	O

Overall	O
,	O
patients	O
infected	O
with	O
HRV	O
had	O
a	O
lower	O
frequency	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
than	O
those	O
infected	O
with	O
other	O
CRVs	O
(	O
60	O
%	O
and	O
84	O
%,	O
respectively	O
,	O
p	O
=	O
0	O
.	O
006	O
),	O
but	O
had	O
more	O
comorbidities	O
(	O
40	O
%	O
and	O
27	O
%,	O
respectively	O
;	O
p	O
=	O
0	O
.	O
043	O
).	O

Comorbidities	O
are	O
closely	O
associated	O
with	O
HRV	O
infections	B-DISO
.	O

RESULTS	O
:	O
HRV	O
was	O
the	O
most	O
common	O
CRV	B-DISO
observed	O
(	O
36	O
%,	O
162	O
/	O
444	O
)	O
and	O
was	O
present	O
in	O
the	O
majority	O
of	O
viral	O
co	O
-	O
detections	O
(	O
69	O
%,	O
88	O
/	O
128	O
),	O
mainly	O
in	O
association	O
with	O
human	O
enterovirus	O
(	O
45	O
%).	O

CONCLUSIONS	O
:	O
HRV	O
is	O
usually	O
detected	O
in	O
hospitalized	O
children	O
with	O
respiratory	B-DISO
infections	I-DISO
and	O
is	O
often	O
present	O
in	O
viral	O
co	O
-	O
detections	O
.	O

TITLE	O
:	O
Drivers	O
of	O
airborne	O
human	O
-	O
to	O
-	O
human	O
pathogen	B-DISO
transmission	I-DISO
.	O

However	O
,	O
ECMO	O
is	O
still	O
marred	O
by	O
frequent	O
and	O
significant	O
complications	O
such	O
as	O
bleeding	B-DISO
and	O
nosocomial	B-DISO
infections	I-DISO
.	O

TITLE	O
:	O
Severe	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
during	O
Infliximab	O
Therapy	O
in	O
a	O
Patient	O
with	O
Crohn	B-DISO
Disease	I-DISO
.	O

ABSTRACT	O
:	O
Inflammatory	O
lung	B-DISO
diseases	I-DISO
like	O
asthma	B-DISO
bronchiale	O
,	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
and	O
allergic	O
airway	O
inflammation	B-DISO
are	O
widespread	O
public	O
diseases	O
that	O
constitute	O
an	O
enormous	O
burden	O
to	O
the	O
health	O
systems	O
.	O

These	O
life	O
-	O
threatening	O
syndromes	B-DISO
are	O
caused	O
by	O
increased	O
permeability	O
of	O
the	O
alveolar	O
and	O
airway	O
epithelium	O
and	O
exudate	O
formation	O
.	O

We	O
present	O
six	O
cases	O
of	O
severe	O
dengue	B-DISO
,	O
malaria	B-DISO
,	O
and	O
acute	O
Chagas	B-DISO
disease	I-DISO
that	O
were	O
treated	O
with	O
ECMO	O
from	O
September	O
2007	O
to	O
September	O
2015	O
.	O

ABSTRACT	O
:	O
Infection	B-DISO
with	O
nidoviruses	O
like	O
corona	O
-	O
and	O
arteriviruses	O
induces	O
a	O
reticulovesicular	O
network	O
of	O
interconnected	O
endoplasmic	O
reticulum	O
(	O
ER	O
)-	O
derived	O
double	O
-	O
membrane	O
vesicles	B-DISO
(	O
DMVs	O
)	O
and	O
other	O
membrane	O
structures	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
occupies	O
a	O
great	O
deal	O
of	O
attention	O
in	O
intensive	O
care	O
units	O
.	O

We	O
also	O
observed	O
that	O
the	O
parasites	O
Plasmodium	O
falciparum	O
and	O
PbA	O
induced	O
the	O
formation	O
of	O
neutrophil	O
extracellular	O
traps	B-DISO
(	O
NETs	O
)	O
ex	O
vivo	O
,	O
which	O
were	O
associated	O
with	O
inflammation	B-DISO
and	O
tissue	O
injury	O
.	O

Validated	O
prediction	O
scores	O
for	O
pneumonia	B-DISO
severity	O
can	O
guide	O
the	O
decision	O
between	O
outpatient	O
and	O
inpatient	O
therapy	O
.	O

Using	O
procalcitonin	O
as	O
a	O
biomarker	O
for	O
severe	O
infection	B-DISO
may	O
further	O
assist	O
with	O
risk	O
stratification	O
.	O

Patients	O
with	O
risk	O
factors	O
for	O
methicillin	B-DISO
-	I-DISO
resistant	I-DISO
Staphylococcus	I-DISO
aureus	I-DISO
should	O
be	O
given	O
vancomycin	O
or	O
linezolid	O
,	O
or	O
ceftaroline	O
in	O
resistant	O
cases	O
.	O

Non	O
-	O
specific	O
abnormalities	O
such	O
as	O
left	O
atrial	O
(	O
LA	O
)	O
dilatation	B-DISO
were	O
present	O
in	O
two	O
patients	O
,	O
while	O
LV	B-DISO
hypertrophy	I-DISO
was	O
seen	O
only	O
in	O
one	O
.	O

After	O
a	O
median	O
follow	O
-	O
up	O
of	O
25	O
(	O
11	O
-	O
29	O
)	O
months	O
,	O
only	O
one	O
cardiovascular	O
event	O
occurred	O
:	O
one	O
of	O
the	O
LGE	O
-	O
positive	O
patients	O
with	O
a	O
high	O
cardiovascular	O
risk	O
profile	O
suffered	B-DISO
an	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
.	O

A	O
43	O
-	O
year	O
-	O
old	O
man	O
with	O
liver	B-DISO
cirrhosis	I-DISO
due	O
to	O
hepatitis	B-DISO
C	I-DISO
virus	O
underwent	O
living	O
-	O
donor	O
liver	O
transplantation	O
.	O

We	O
highlighted	O
the	O
presence	O
and	O
the	O
high	O
diversity	O
of	O
coronaviruses	O
circulating	O
in	O
bats	O
from	O
Cambodia	O
and	O
Lao	O
PDR	B-DISO
.	O

Disembarking	O
passengers	O
(	O
n	O
=	O
8753	O
)	O
from	O
Saudi	O
Arabia	O
(	O
October	O
2014	O
to	O
April	O
2015	O
)	O
were	O
interviewed	O
for	O
the	O
presence	O
of	O
respiratory	B-DISO
symptoms	I-DISO
;	O
977	O
(	O
11	O
%)	O
reported	O
symptoms	O
and	O
300	O
(	O
age	O
26	O
-	O
90	O
,	O
median	O
60	O
years	O
;	O
140	O
male	O
)	O
consented	O
to	O
participate	O
in	O
the	O
study	O
.	O

Despite	O
a	O
high	O
prevalence	O
of	O
acute	O
respiratory	B-DISO
symptoms	I-DISO
,	O
MERS	O
coV	O
was	O
not	O
seen	O
in	O
returning	O
pilgrims	O
from	O
Hajj	O
and	O
Umrah	O
.	O

Despite	O
a	O
proven	O
survival	O
benefit	O
in	O
patients	O
with	O
severe	O
ARDS	B-DISO
,	O
studies	O
have	O
also	O
shown	O
underutilization	O
of	O
prone	O
positioning	O
.	O

In	O
light	O
of	O
this	O
,	O
there	O
is	O
a	O
need	O
to	O
integrate	O
basic	O
and	O
clinical	O
research	O
for	O
investigating	O
the	O
connections	O
between	O
molecular	O
and	O
clinical	O
pathogenesis	B-DISO
and	O
for	O
therapeutic	O
development	O
strategies	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
the	O
main	O
causative	O
agent	O
of	O
porcine	O
diarrhea	B-DISO
,	O
which	O
has	O
resulted	O
in	O
devastating	O
damage	O
to	O
swine	O
industry	O
and	O
become	O
a	O
perplexed	O
global	O
problem	O
.	O

PEDV	O
infection	B-DISO
causes	O
lesions	O
and	O
clinical	O
symptoms	O
,	O
and	O
infected	O
pigs	O
often	O
succumb	O
to	O
severe	B-DISO
dehydration	I-DISO
.	O

ABSTRACT	O
:	O
The	O
continual	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	B-DISO
)	O
threat	O
highlights	O
the	O
importance	O
of	O
developing	O
effective	O
antiviral	O
therapeutics	O
to	O
prevent	O
and	O
treat	O
MERS	B-DISO
coronavirus	O
(	O
MERS	B-DISO
-	O
CoV	O
)	O
infection	B-DISO
.	O

However	O
,	O
emergence	O
of	O
escape	O
mutant	B-DISO
viruses	O
and	O
mAb	O
'	O
s	O
limitations	O
make	O
it	O
necessary	O
for	O
combining	O
neutralizing	O
mAbs	O
recognizing	O
different	O
neutralizing	O
epitopes	O
and	O
engineering	O
them	O
with	O
improved	O
efficacy	O
and	O
reduced	O
cost	O
.	O

TITLE	O
:	O
Inter	O
-	O
laboratory	O
study	O
to	O
characterize	O
the	O
detection	O
of	O
serum	O
antibodies	O
against	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
.	O

TITLE	O
:	O
Quantifying	O
the	O
effect	O
of	O
lactogenic	O
antibody	O
on	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	B-DISO
infection	I-DISO
in	O
neonatal	O
piglets	O
.	O

The	O
pathogenicity	O
of	O
CHN	B-DISO
-	O
HN	O
-	O
2014	O
was	O
further	O
investigated	O
in	O
5	O
-	O
day	O
-	O
old	O
and	O
21	O
-	O
day	O
-	O
old	O
piglets	O
.	O

These	O
data	O
demonstrate	O
that	O
Chinese	O
PDCoV	O
strain	O
CHN	B-DISO
-	O
HN	O
-	O
2014	O
shares	O
high	O
nucleotide	O
identity	O
with	O
previously	O
reported	O
PDCoV	O
strains	O
and	O
is	O
pathogenic	O
in	O
5	O
-	O
day	O
-	O
old	O
and	O
21	O
-	O
day	O
-	O
old	O
piglets	O
.	O

These	O
relationships	O
highlight	O
the	O
importance	O
of	O
rapidly	O
enforcing	O
infection	B-DISO
control	O
measures	O
to	O
prevent	O
outbreaks	O
.	O

TITLE	O
:	O
Viral	O
pathogens	O
among	O
elderly	O
people	O
with	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
in	O
Shanghai	O
,	O
China	O
:	O
Preliminary	O
results	O
from	O
a	O
laboratory	O
-	O
based	O
surveillance	O
,	O
2012	O
-	O
2015	O
.	O

An	O
influenza	B-DISO
vaccination	O
strategy	O
needs	O
to	O
be	O
advocated	O
for	O
the	O
elderly	O
population	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
established	O
a	O
novel	O
function	O
for	O
the	O
SARS	B-DISO
-	O
CoV	O
macrodomain	O
that	O
implicates	O
ADP	O
-	O
ribose	O
in	O
the	O
regulation	O
of	O
the	O
innate	B-DISO
immune	I-DISO
response	I-DISO
and	O
helps	O
to	O
demonstrate	O
why	O
this	O
domain	O
is	O
conserved	O
in	O
CoVs	O
.	O

Our	O
data	O
suggest	O
that	O
an	O
early	O
innate	B-DISO
immune	I-DISO
response	I-DISO
can	O
protect	O
mice	O
from	O
lethal	O
disease	O
.	O

RESULTS	O
:	O
Of	O
24	O
patients	O
at	O
risk	O
,	O
6	O
developed	O
mild	O
ARDS	B-DISO
and	O
4	O
of	O
each	O
moderate	O
or	O
severe	O
ARDS	B-DISO
,	O
respectively	O
,	O
3	O
±	O
2	O
(	O
mean	O
±	O
SD	O
)	O
days	O
after	O
inclusion	O
.	O

TITLE	O
:	O
The	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
-	O
A	O
Continuing	O
Risk	O
to	O
Global	O
Health	O
Security	O
.	O

(	O
2	O
)	O
The	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
new	O
corona	O
virus	O
isolated	O
for	O
the	O
first	O
time	O
in	O
a	O
patients	O
who	O
died	O
of	O
severe	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
in	O
Jeddah	O
(	O
Saudi	O
Arabia	O
)	O
in	O
June	O
2012	O
(	O
Zaki	O
et	O
al	O
.	O
2012	O
).	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
in	O
the	O
time	O
to	O
recovery	O
of	O
respiratory	O
muscle	O
paralysis	O
,	O
time	O
to	O
an	O
improvement	O
in	O
muscle	O
strength	O
of	O
one	O
grade	O
,	O
time	O
to	O
recovery	O
of	O
sensory	B-DISO
disturbance	I-DISO
,	O
and	O
length	O
of	O
hospital	O
stay	O
.	O

Previous	O
studies	O
have	O
reported	O
that	O
circulating	O
levels	O
of	O
soluble	O
thrombomodulin	O
(	O
TM	O
)	O
reflect	O
endothelial	O
injuries	O
,	O
which	O
play	O
key	O
roles	O
in	O
the	O
development	O
of	O
ARDS	B-DISO
.	O

These	O
findings	O
underscore	O
the	O
importance	O
of	O
pulmonary	O
endothelial	O
injuries	O
in	O
the	O
pathogenesis	B-DISO
of	O
severe	O
DLI	O
.	O

The	O
overall	O
early	B-DISO
complication	I-DISO
rate	O
was	O
8	O
.	O
3	O
%.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
a	O
highly	O
contagious	O
coronavirus	O
that	O
causes	O
severe	B-DISO
diarrhea	I-DISO
and	O
death	O
,	O
particularly	O
in	O
neonatal	O
piglets	O
.	O

However	O
,	O
the	O
lack	O
of	O
a	O
vaccine	O
,	O
together	O
with	O
the	O
increasing	O
resistance	O
to	O
the	O
highly	O
active	O
anti	O
-	O
retroviral	O
therapy	O
(	O
HAART	O
),	O
make	O
HIV	B-DISO
-	I-DISO
1	I-DISO
infection	I-DISO
still	O
a	O
serious	O
global	O
emergency	B-DISO
.	O

The	O
present	O
review	O
is	O
focused	O
on	O
the	O
elucidation	O
of	O
immunothrombosis	O
in	O
ARDS	B-DISO
and	O
the	O
potential	O
therapeutic	O
implications	O
.	O

TITLE	O
:	O
From	O
plague	B-DISO
to	O
MERS	O
:	O
coordinating	O
Australia	O
'	O
s	O
response	O
to	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

Nonetheless	O
,	O
active	O
GRFT	O
capable	O
of	O
neutralizing	O
HIV	B-DISO
-	O
Env	O
pseudoviruses	O
was	O
detected	O
in	O
rat	O
fecal	O
extracts	O
after	O
chronic	O
oral	O
dosing	O
.	O

As	O
these	O
propositions	O
require	O
evidence	O
-	O
based	O
demonstration	O
,	O
the	O
reader	O
is	O
reminded	O
that	O
the	O
accepted	O
practice	O
remains	O
,	O
in	O
2016	O
,	O
controlled	O
mechanical	O
ventilation	O
,	O
muscle	B-DISO
relaxation	I-DISO
and	O
prone	O
position	O
.	O

The	O
accumulated	O
surveillance	O
data	O
,	O
including	O
temporal	O
,	O
spatial	O
,	O
clinical	O
,	O
and	O
demographic	O
information	O
can	O
provide	O
valuable	O
information	O
that	O
can	O
be	O
exploited	O
to	O
better	O
understand	O
and	O
model	O
the	O
dynamics	O
of	O
infectious	B-DISO
disease	I-DISO
spread	O
.	O

ABSTRACT	O
:	O
Dilmapimod	O
is	O
a	O
potent	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
inhibitor	O
and	O
was	O
investigated	O
in	O
a	O
study	O
(	O
NCT00996840	O
)	O
for	O
its	O
anti	O
-	O
inflammatory	O
effect	O
in	O
non	O
-	O
head	O
injury	O
trauma	O
patients	O
at	O
risk	O
for	O
developing	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Here	O
,	O
we	O
present	O
highly	O
potent	O
and	O
selective	O
fluorescent	O
inhibitors	O
that	O
we	O
show	O
to	O
be	O
useful	O
chemical	O
biology	O
tools	O
especially	O
in	O
determination	O
of	O
dissociation	B-DISO
constants	O
.	O

Patients	O
with	O
asthma	B-DISO
had	O
a	O
high	O
prevalence	O
of	O
OSA	B-DISO
,	O
which	O
was	O
an	O
important	O
factor	O
associated	O
with	O
severe	O
asthma	B-DISO
exacerbations	O
.	O

In	O
this	O
report	O
,	O
we	O
present	O
four	O
Kawasaki	B-DISO
disease	I-DISO
patients	O
infected	O
with	O
adenovirus	B-DISO
,	O
coronavirus	O
OC43	O
/	O
HKU1	O
and	O
parainfluenza	B-DISO
virus	O
type	O
3	O
.	O

Here	O
we	O
aim	O
to	O
characterize	O
the	O
causative	O
agent	O
of	O
visceral	B-DISO
gout	I-DISO
suspected	O
for	O
astrovirus	O
infection	B-DISO
in	O
broiler	O
breeder	O
chickens	O
.	O

The	O
purpose	O
of	O
this	O
survey	O
is	O
to	O
describe	O
providers	O
'	O
knowledge	O
and	O
perceived	O
efficacy	O
and	O
safety	O
of	O
NMBAs	O
in	O
patients	O
with	O
ARDS	B-DISO
.	O

All	O
patients	O
were	O
monitored	O
by	O
means	O
of	O
an	O
oesophageal	O
catheter	O
and	O
followed	O
up	O
for	O
48	O
h	O
.	O
Moderate	O
ARDS	B-DISO
patients	O
were	O
randomised	O
into	O
two	O
groups	O
according	O
to	O
whether	O
they	O
were	O
given	O
a	O
48	O
-	O
h	O
continuous	O
infusion	O
of	O
cisatracurium	O
besylate	O
or	O
not	O
(	O
control	O
group	O
).	O

ABSTRACT	O
:	O
Acute	O
exacerbation	O
(	O
AE	O
)	O
is	O
a	O
severe	O
complication	B-DISO
of	O
idiopathic	B-DISO
pulmonary	I-DISO
fibrosis	I-DISO
(	O
IPF	O
),	O
which	O
shares	O
some	O
common	O
pathological	O
features	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

The	O
study	O
involved	O
an	O
analysis	O
of	O
the	O
treatment	O
results	O
in	O
267	O
patients	O
with	O
STBI	O
followed	O
by	O
severe	B-DISO
sepsis	I-DISO
and	O
ARDS	B-DISO
,	O
who	O
were	O
treated	O
with	O
and	O
without	O
CS	O
.	O

TITLE	O
:	O
Binding	O
of	O
the	O
Methyl	O
Donor	O
ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
nonstructural	O
protein	O
16	O
(	O
nsp16	O
)	O
is	O
an	O

Both	O
28	O
-	O
day	O
and	O
60	O
-	O
day	O
survival	O
times	O
after	O
ARDS	B-DISO
onset	O
were	O
analyzed	O
.	O

We	O
estimated	O
the	O
hazard	O
ratio	O
(	O
HR	O
)	O
and	O
odds	O
ratio	O
(	O
OR	O
)	O
of	O
late	O
-	O
onset	O
ARDS	B-DISO
using	O
a	O
multivariate	O
Cox	O
proportional	O
hazards	O
model	O
of	O
survival	O
time	O
and	O
a	O
multivariate	O
logistic	O
regression	O
model	O
of	O
mortality	O
rate	O
,	O
respectively	O
.	O

Late	O
-	O
onset	O
ARDS	B-DISO
,	O
defined	O
as	O
onset	O
over	O
48	O
h	O
after	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
admission	O
(	O
N	O
=	O
273	O
,	O
31	O
%),	O
was	O
associated	O
with	O
shorter	O
28	O
-	O
day	O
survival	O
time	O
:	O
HR	O
=	O
2	O
.	O
24	O
,	O
95	O
%	O
CI	O
1	O
.	O
48	O
-	O
3	O
.	O
39	O
,	O
P	O
=	O
1	O
.	O
24	O
×	O
10	O
Late	O
-	O
onset	O
moderate	O
to	O
severe	O
ARDS	B-DISO
patients	O
had	O
both	O
shorter	O
survival	O
time	O
and	O
higher	O
mortality	O
rate	O
in	O
28	O
-	O
day	O
and	O
60	O
-	O
day	O
observations	O
.	O

RESULTS	O
:	O
Late	O
-	O
onset	O
ARDS	B-DISO
,	O
defined	O
as	O
onset	O
over	O
48	O
h	O
after	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
admission	O
(	O
N	O
=	O
273	O
,	O
31	O
%),	O
was	O
associated	O
with	O
shorter	O
28	O
-	O
day	O
survival	O
time	O
:	O
HR	O
=	O
2	O
.	O
24	O
,	O
95	O
%	O
CI	O
1	O
.	O
48	O
-	O
3	O
.	O
39	O
,	O
P	O
=	O
1	O
.	O
24	O
×	O
10	O

ABSTRACT	O
:	O
Hosts	O
and	O
pathogens	O
are	O
locked	O
in	O
an	O
evolutionary	O
arms	B-DISO
race	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
characterized	O
by	O
the	O
acute	O
onset	O
of	O
pulmonary	B-DISO
edema	I-DISO
of	O
non	O
-	O
cardiogenic	O
origin	O
,	O
along	O
with	O
bilateral	B-DISO
pulmonary	I-DISO
infiltrates	I-DISO
and	O
reduction	O
in	O
respiratory	O
system	O
compliance	O
.	O

TITLE	O
:	O
Noninvasive	O
ventilation	O
during	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
patients	O
with	O
cancer	B-DISO
:	O
Trends	O
in	O
use	O
and	O
outcome	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
1004	O
met	O
the	O
Berlin	O
definition	O
of	O
ARDS	B-DISO
.	O

CONCLUSIONS	O
:	O
Noninvasive	O
ventilation	O
failure	O
in	O
ARDS	B-DISO
patients	O
with	O
malignancies	B-DISO
is	O
frequent	O
and	O
related	O
to	O
ARDS	B-DISO
severity	O
,	O
SOFA	O
score	O
,	O
and	O
pulmonary	B-DISO
infection	I-DISO
-	O
related	O
ARDS	B-DISO
.	O

The	O
mechanism	O
of	O
nuclear	O
translocation	B-DISO
,	O
and	O
whether	O
N	O
protein	O
associates	O
with	O
particular	O
nucleolar	O
components	O
,	O
is	O
unknown	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	B-DISO
)	O
is	O
caused	O
by	O
MERS	B-DISO
coronavirus	O
(	O
MERS	B-DISO
-	O
CoV	O
).	O

The	O
majority	O
of	O
respondents	O
(	O
70	O
.	O
4	O
%)	O
felt	O
at	O
risk	O
of	O
contracting	O
a	O
MERS	O
-	O
CoV	O
infection	B-DISO
at	O
work	O
,	O
69	O
.	O
1	O
%	O
felt	O
threatened	O
if	O
a	O
colleague	O
contracted	O
MERS	O
-	O
CoV	O
,	O
60	O
.	O
9	O
%	O
felt	O
obliged	O
to	O
care	O
for	O
patients	O
infected	O
with	O
MERS	O
-	O
CoV	O
and	O
87	O
.	O
8	O
%	O
did	O
not	O
feel	O
safe	O
at	O
work	O
using	O
standard	O
precautions	O
.	O

The	O
majority	O
of	O
respondents	O
reported	O
concern	O
regarding	O
MERS	O
-	O
CoV	O
infection	B-DISO
from	O
exposure	O
at	O
work	O
.	O

Concurrent	O
infections	B-DISO
of	O
dengue	B-DISO
and	O
malaria	B-DISO
are	O
rare	O
due	O
to	O
the	O
different	O
habitats	O
of	O
its	O
vectors	O
and	O
activities	O
of	O
different	O
carrier	O
mosquitoes	O
.	O

Since	O
then	O
,	O
several	O
concurrent	O
infections	B-DISO
have	O
been	O
reported	O
between	O
the	O
dengue	B-DISO
virus	O
(	O
DENV	O
)	O
and	O
the	O
malaria	B-DISO
protozoans	O
,	O
Plasmodium	O
falciparum	O
and	O
Plasmodium	O
vivax	O
.	O

Symptoms	O
of	O
each	O
infection	B-DISO
may	O
be	O
masked	O
by	O
a	O
simultaneous	O
second	O
infection	B-DISO
,	O
resulting	O
in	O
late	O
treatment	O
and	O
severe	O
complications	O
.	O

This	O
case	O
contributes	O
to	O
the	O
body	O
of	O
literature	O
on	O
co	B-DISO
-	I-DISO
infection	I-DISO
between	O
DENV	O
and	O
P	O
.	O
knowlesi	O
and	O
highlights	O
the	O
clinical	O
consequences	O
,	O
which	O
can	O
be	O
severe	O
.	O

Further	O
research	O
is	O
required	O
to	O
determine	O
the	O
real	O
incidence	O
and	O
risk	O
of	O
co	B-DISO
-	I-DISO
infection	I-DISO
in	O
order	O
to	O
improve	O
the	O
management	O
of	O
acute	O
febrile	B-DISO
illness	I-DISO
.	O

TITLE	O
:	O
Social	O
Big	O
Data	O
Analysis	O
of	O
Information	O
Spread	O
and	O
Perceived	O
Infection	B-DISO
Risk	O
During	O
the	O
2015	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Outbreak	O
in	O
South	O
Korea	O
.	O

TITLE	O
:	O
[	O
Role	O
of	O
imaging	O
procedures	O
in	O
clarification	O
of	O
complications	O
of	O
pneumonia	B-DISO
].	O

If	O
complications	O
or	O
disease	B-DISO
progression	I-DISO
are	O
suspected	O
or	O
the	O
clinical	O
course	O
differs	O
from	O
the	O
X	O
‑	O
ray	O
interpretation	O
,	O
a	O
subsequent	O
CT	O
of	O
the	O
chest	O
should	O
be	O
performed	O
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
is	O
proposed	O
to	O
be	O
a	O
zoonotic	O
disease	O
.	O

Furthermore	O
,	O
fever	O
with	O
cough	B-DISO
and	O
shortness	B-DISO
of	I-DISO
breath	I-DISO
(	O
SOB	B-DISO
)	O
(	O
n	O
=	O
39	O
;	O
20	O
.	O
5	O
%),	O
fever	O
with	O
cough	B-DISO
(	O
n	O
=	O
29	O
;	O
15	O
.	O
3	O
%),	O
fever	O
(	O
n	O
=	O
18	O
;	O
9	O
.	O
5	O
%),	O
and	O
fever	O
with	O
SOB	B-DISO
(	O
n	O
=	O
13	O
;	O
6	O
.	O
8	O
%),	O
were	O
the	O
most	O
common	O
clinical	O
manifestations	O
associated	O
with	O
confirmed	O
MERS	O
-	O
CoV	O
cases	O
.	O

TITLE	O
:	O
Understanding	O
the	O
early	O
dynamics	O
of	O
the	O
2014	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
outbreak	O
in	O
Ontario	O
using	O
the	O
incidence	O
decay	B-DISO
and	O
exponential	O
adjustment	O
(	O
IDEA	O
)	O
model	O
.	O

ABSTRACT	O
:	O
Human	O
infections	B-DISO
with	O
highly	O
pathogenic	O
avian	B-DISO
influenza	I-DISO
A	O
(	O
H5N1	B-DISO
)	O
virus	O
are	O
frequently	O
fatal	O
but	O
the	O
mechanisms	O
of	O
disease	O
remain	O
ill	B-DISO
-	O
defined	O
.	O

H5N1	B-DISO
infection	B-DISO
is	O
associated	O
with	O
intense	O
production	O
of	O
proinflammatory	O
cytokines	O
,	O
but	O
whether	O
this	O
cytokine	B-DISO
storm	I-DISO
is	O
the	O
main	O
cause	O
of	O
fatality	O
or	O
is	O
a	O
consequence	O
of	O
extensive	O
virus	O
replication	O
that	O
itself	O
drives	O
disease	O
remains	O
controversial	O
.	O

Charting	O
the	O
decline	O
in	O
PaO2	O
/	O
FiO2	O
ratio	O
in	O
a	O
mechanically	O
ventilated	O
pig	O
confirmed	O
that	O
ricin	O
-	O
induced	O
respiratory	O
damage	O
complies	O
with	O
the	O
accepted	O
diagnostic	O
criteria	O
for	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Bovine	B-DISO
respiratory	I-DISO
disease	I-DISO
complex	I-DISO
(	O
BRDC	O
)	O
is	O
frequently	O
found	O
in	O
cattle	O
worldwide	O
.	O

Since	O
the	O
resulting	O
morphology	O
closely	O
resembles	O
the	O
3	O
-	O
dimensional	O
fibrous	O
network	O
of	O
an	O
extracellular	O
matrix	O
(	O
ECM	O
),	O
the	O
capability	O
of	O
the	O
TMV	O
assemblies	O
to	O
support	O
the	O
adhesion	B-DISO
of	O
NIH	O
-	O
3T3	O
fibroblast	O
cells	O
was	O
investigated	O
,	O
demonstrating	O
potential	O
utility	O
in	O
regenerative	O
medicine	O
.	O

Electrocardiogram	O
(	O
EKG	O
)	O
showed	O
no	O
apparent	O
ST	O
segment	O
elevation	O
or	O
depression	B-DISO
that	O
would	O
be	O
consistent	O
with	O
pericarditis	B-DISO
,	O
or	O
acute	O
ischemia	B-DISO
or	I-DISO
infarct	I-DISO
.	O

ABSTRACT	O
:	O
Over	O
the	O
past	O
two	O
decades	O
a	O
number	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
outbreaks	O
such	O
as	O
the	O
2009	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
and	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
have	O
emerged	O
and	O
presented	O
a	O
considerable	O
global	O
public	O
health	O
threat	O
.	O

Influenza	B-DISO
,	O
coronavirus	O
or	O
rhinovirus	O
were	O
detected	O
in	O
three	O
participants	O
;	O
all	O
in	O
the	O
placebo	O
group	O
.	O

ARMS	B-DISO
-	O
I	O
significantly	O
reduced	O
the	O
frequency	O
and	O
severity	O
of	O
cough	B-DISO
and	O
sore	B-DISO
throat	I-DISO
,	O
and	O
duration	O
of	O
cough	B-DISO
(	O
P	O
≤	O
.	O
019	O
for	O
all	O
comparisons	O
).	O

Prior	O
influenza	B-DISO
vaccination	O
had	O
no	O
effect	O
on	O
study	O
outcome	O
.	O

TITLE	O
:	O
Propofol	O
as	O
a	O
Risk	O
Factor	O
for	O
ICU	O
-	O
Acquired	O
Weakness	B-DISO
in	O
Septic	O
Patients	O
with	O
Acute	B-DISO
Respiratory	I-DISO
Failure	I-DISO
.	O

ABSTRACT	O
:	O
The	O
continued	O
emergence	O
and	O
spread	O
of	O
infectious	B-DISO
agents	O
is	O
of	O
great	O
concern	O
,	O
and	O
systems	O
biology	O
approaches	O
to	O
infectious	B-DISO
disease	I-DISO
research	O
can	O
advance	O
our	O
understanding	O
of	O
host	O
-	O
pathogen	O
relationships	O
and	O
facilitate	O
the	O
development	O
of	O
new	O
therapies	O
and	O
vaccines	O
.	O

Molecular	O
characterization	O
of	O
infectious	B-DISO
samples	O
outside	O
of	O
appropriate	O
biosafety	O
containment	O
can	O
take	O
place	O
only	O
subsequent	O
to	O
pathogen	O
inactivation	B-DISO
.	O

Herein	O
,	O
we	O
describe	O
a	O
modified	O
Folch	O
extraction	O
using	O
chloroform	O
/	O
methanol	O
that	O
facilitates	O
the	O
molecular	O
characterization	O
of	O
infectious	B-DISO
samples	O
by	O
enabling	O
simultaneous	O
pathogen	O
inactivation	B-DISO
and	O
extraction	O
of	O
proteins	O
,	O
metabolites	O
,	O
and	O
lipids	O
for	O
subsequent	O
mass	O
spectrometry	O
-	O
based	O
multi	O
-	O
omics	O
measurements	O
.	O

This	O
single	O
-	O
sample	O
metabolite	O
,	O
protein	O
and	O
lipid	O
extraction	O
(	O
MPLEx	O
)	O
method	O
resulted	O
in	O
complete	O
inactivation	B-DISO
of	O
clinically	O
important	O
bacterial	O
and	O
viral	O
pathogens	O
with	O
exposed	O
lipid	O
membranes	O
,	O
including	O
Yersinia	B-DISO
pestis	O
,	O
Salmonella	B-DISO
Typhimurium	O
,	O
and	O
Campylobacter	O
jejuni	O
in	O
pure	O
culture	O
,	O
and	O
Yersinia	B-DISO
pestis	O
,	O
Campylobacter	O
jejuni	O
,	O
and	O
West	O
Nile	O
,	O
MERS	O
-	O
CoV	O
,	O
Ebola	O
,	O
and	O
influenza	B-DISO
H7N9	O
viruses	O
in	O
infection	B-DISO
studies	O
.	O

The	O
overall	O
pipeline	O
of	O
inactivation	B-DISO
and	O
subsequent	O
proteomic	O
,	O
metabolomic	O
,	O
and	O
lipidomic	O
analyses	O
was	O
evaluated	O
using	O
a	O
human	O
epithelial	O
lung	O
cell	O
line	O
infected	O
with	O
wild	O
-	O
type	O
and	O
mutant	B-DISO
influenza	B-DISO
H7N9	O
viruses	O
,	O
thereby	O
demonstrating	O
that	O
MPLEx	O
yields	O
biomaterial	O
of	O
sufficient	O
quality	O
for	O
subsequent	O
multi	O
-	O
omics	O
analyses	O
.	O

TITLE	O
:	O
Novel	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
(	O
PEDV	O
)	O
Variants	O
with	O
Large	O
Deletions	O
in	O
the	O
Spike	O
(	O
S	O
)	O
Gene	O
Coexist	O
with	O
PEDV	O
Strains	O
Possessing	O
an	O
Intact	O
S	O
Gene	O
in	O
Domestic	O
Pigs	O
in	O
Japan	O
:	O
A	O
New	O
Disease	O
Situation	O
.	O

ABSTRACT	O
:	O
A	O
previously	O
healthy	O
young	O
man	O
with	O
a	O
rare	O
genetic	B-DISO
condition	I-DISO
presented	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
secondary	O
to	O
pneumonia	B-DISO
with	O
septic	B-DISO
shock	I-DISO
.	O

Treatment	O
was	O
started	O
once	O
the	O
diagnosis	O
of	O
disseminated	O
adenovirus	B-DISO
infection	I-DISO
was	O
made	O
;	O
however	O
,	O
at	O
that	O
time	O
patient	O
was	O
suffering	B-DISO
from	O
refractory	O
hypoxaemia	O
,	O
respiratory	B-DISO
acidosis	I-DISO
,	O
right	B-DISO
heart	I-DISO
failure	I-DISO
and	O
septic	B-DISO
shock	I-DISO
.	O

TITLE	O
:	O
Rhodoccocus	O
Equi	O
Pneumonia	B-DISO
and	O
Paradoxical	O
Immune	B-DISO
Reconstitution	I-DISO
Inflammatory	I-DISO
Syndrome	I-DISO
in	O
a	O
Patient	O
with	O
Acquired	B-DISO
Immune	I-DISO
Deficiency	I-DISO
Syndrome	I-DISO
(	O
AIDS	O
).	O

This	O
review	O
discusses	O
novel	O
insights	O
on	O
control	O
of	O
self	O
-	O
reactive	O
(	O
SR	O
)	O
T	O
cells	O
activated	O
during	O
neurotropic	O
coronavirus	O
-	O
induced	O
demyelination	B-DISO
.	O

TITLE	O
:	O
Severe	O
hypercapnia	B-DISO
and	O
outcome	O
of	O
mechanically	O
ventilated	O
patients	O
with	O
moderate	O
or	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
The	O
Feline	O
coronavirus	O
(	O
FCoV	O
)	O
is	O
the	O
etiological	O
agent	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
),	O
a	O
lethal	O
disease	O
of	O
felids	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
novel	O
recombinant	O
virulent	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
.	O

Ischemic	B-DISO
necrosis	I-DISO
of	O
the	O
mucosal	O
side	O
of	O
the	O
cecal	O
wall	O
with	O
various	O
degrees	O
of	O
neutrophilic	O
inflammation	B-DISO
of	O
subjacent	O
tissues	O
was	O
found	O
consistently	O
,	O
and	O
thrombosis	B-DISO
and	O
vascular	B-DISO
occlusion	I-DISO
within	O
the	O
areas	O
of	O
necrosis	O
and	O
inflammation	B-DISO
was	O
found	O
in	O
21	O
of	O
34	O
cases	O
.	O

TITLE	O
:	O
Comparative	O
genomics	O
of	O
QX	O
-	O
like	O
infectious	B-DISO
bronchitis	B-DISO
viruses	O
in	O
Korea	O
.	O

The	O
recent	O
prevalence	O
of	O
recurrent	O
viruses	O
with	O
different	O
genomic	O
backgrounds	O
and	O
spike	O
genes	O
from	O
the	O
early	O
and	O
the	O
NC1	O
viruses	O
may	O
indicate	O
the	O
repeated	O
introduction	O
of	O
different	O
infectious	B-DISO
bronchitis	B-DISO
viruses	O
from	O
other	O
countries	O
and	O
their	O
successful	O
evasion	O
of	O
vaccine	O
immunity	O
in	O
the	O
field	O
.	O

ABSTRACT	O
:	O
Low	O
-	O
dose	O
hydrocortisone	O
is	O
recommended	O
in	O
patients	O
with	O
septic	B-DISO
shock	I-DISO
unresponsive	O
to	O
fluid	O
and	O
vasopressor	O
therapy	O
.	O

The	O
objective	O
of	O
this	O
review	O
is	O
to	O
summarize	O
and	O
comment	O
recent	O
findings	O
on	O
low	O
-	O
dose	O
corticosteroids	O
(	O
LDC	O
)	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

Retrospective	O
propensity	O
-	O
score	O
analyses	O
also	O
suggest	O
that	O
LDC	O
administered	O
in	O
severe	O
septic	B-DISO
shock	I-DISO
or	O
in	O
septic	B-DISO
shock	I-DISO
due	O
to	O
community	O
-	O
acquired	O
pneumonia	B-DISO
or	O
intestinal	B-DISO
perforation	I-DISO
may	O
improve	O
survival	O
.	O

We	O
reviewed	O
severe	O
ARDS	B-DISO
patients	O
who	O
received	O
ECMO	O
due	O
to	O
refractory	O
hypoxemia	O
from	O
May	O
2006	O
to	O
October	O
2015	O
.	O

A	O
total	O
of	O
158	O
severe	O
ARDS	B-DISO
patients	O
received	O
ECMO	O
were	O
finally	O
analyzed	O
.	O

Cox	O
proportional	O
hazards	O
regression	O
model	O
revealed	O
that	O
immunocompromised	O
[	O
hazard	O
ratio	O
1	O
.	O
957	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
216	O
-	O
3	O
.	O
147	O
;	O
p	O
=	O
0	O
.	O
006	O
],	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
(	O
APACHE	O
)	O
II	O
score	O
(	O
hazard	O
ratio	O
1	O
.	O
039	O
;	O
95	O
%	O
CI	O
1	O
.	O
005	O
-	O
1	O
.	O
073	O
;	O
p	O
=	O
0	O
.	O
023	O
),	O
ARDS	B-DISO
duration	O
before	O
ECMO	O
(	O
hazard	O
ratio	O
1	O
.	O
002	O
;	O
95	O
%	O
CI	O
1	O
.	O
000	O
-	O
1	O
.	O
003	O
;	O
p	O
=	O
0	O
.	O
029	O
)	O
and	O
mean	O
dynamic	O
driving	O
pressure	O
from	O
day	O
1	O
to	O
3	O
on	O
ECMO	O
(	O
hazard	O
ratio	O
1	O
.	O
070	O
;	O
95	O
%	O
CI	O
1	O
.	O
026	O
-	O
1	O
.	O
116	O
;	O
p	O
=	O
0	O
.	O
002	O
)	O
were	O
independently	O
associated	O
with	O
ICU	O
mortality	O
.	O

TITLE	O
:	O
High	O
flow	O
nasal	O
cannula	O
(	O
HFNC	O
)	O
versus	O
nasal	O
continuous	O
positive	O
airway	O
pressure	O
(	O
nCPAP	O
)	O
for	O
the	O
initial	O
respiratory	O
management	O
of	O
acute	B-DISO
viral	I-DISO
bronchiolitis	I-DISO
in	O
young	O
infants	O
:	O
a	O
multicenter	O
randomized	O
controlled	O
trial	O
(	O
TRAMONTANE	O
study	O
).	O

ABSTRACT	O
:	O
Emerging	O
pathogenic	O
viruses	O
such	O
as	O
Ebola	O
and	O
Middle	O
Eastern	O
Respiratory	O
Syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
can	O
cause	O
acute	B-DISO
infections	I-DISO
through	O
the	O
evasion	O
of	O
the	O
host	O
'	O
s	O
antiviral	O
immune	O
responses	O
and	O
by	O
inducing	O
the	O
upregulation	O
of	O
inflammatory	O
cytokines	O
.	O

This	O
review	O
aims	O
to	O
explore	O
alternative	O
experimental	O
strategies	O
for	O
treating	O
hypercytokinemia	O
induced	O
by	O
the	O
Ebola	O
,	O
avian	B-DISO
influenza	I-DISO
and	O
Dengue	B-DISO
viruses	O
;	O
outlining	O
their	O
modes	O
of	O
action	O
,	O
summarizing	O
their	O
preclinical	O
assessments	O
and	O
potential	O
clinical	O
applications	O
.	O

Human	O
rhinovirus	O
is	O
the	O
most	O
commonly	O
encountered	O
respiratory	O
viral	O
pathogen	O
in	O
CF	O
although	O
adenovirus	B-DISO
,	O
bocavirus	O
,	O
coronavirus	O
,	O
influenza	B-DISO
,	O
parainfluenza	B-DISO
,	O
metapneumovirus	O
and	O
respiratory	O
syncytial	O
virus	O
are	O
all	O
also	O
responsible	O
for	O
infections	B-DISO
in	O
this	O
population	O
.	O

Areas	O
covered	O
:	O
This	O
article	O
reviews	O
the	O
epidemiology	O
,	O
clinical	O
impact	O
and	O
therapeutic	O
options	O
for	O
respiratory	B-DISO
virus	I-DISO
infection	I-DISO
in	O
both	O
children	O
and	O
adults	O
with	O
CF	O
.	O

We	O
describe	O
an	O
unusual	O
case	O
of	O
a	O
42	O
year	O
old	O
healthcare	O
worker	O
who	O
was	O
admitted	O
to	O
our	O
Intensive	O
Care	O
Unit	O
(	O
ICU	O
)	O
King	O
Abdul	O
-	O
Aziz	O
Medical	O
City	O
,	O
with	O
MERS	O
-	O
CoV	O
and	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
Syndrome	I-DISO
and	O
developed	O
a	O
sudden	O
-	O
onset	O
diabetes	B-DISO
insipidus	I-DISO
and	O
spontaneous	O
massive	O
intracranial	B-DISO
hemorrhage	I-DISO
with	O
intra	O
-	O
ventricular	O
extension	O
and	O
tonsillar	B-DISO
herniation	I-DISO
.	O

The	O
purpose	O
of	O
this	O
scoping	O
review	O
was	O
to	O
determine	O
what	O
is	O
known	O
about	O
the	O
impact	O
of	O
infectious	B-DISO
disease	I-DISO
on	O
the	O
health	O
of	O
paramedics	O
.	O

Contraction	B-DISO
of	O
infectious	B-DISO
diseases	I-DISO
is	O
generally	O
low	O
;	O
exceptions	O
to	O
this	O
are	O
MRSA	B-DISO
colonization	O
,	O
influenza	B-DISO
,	O
and	O
SARS	B-DISO
.	O

The	O
majority	O
of	O
patients	O
were	O
admitted	O
with	O
acute	B-DISO
leukemia	I-DISO
(	O
n	O
=	O
60	O
,	O
76	O
%),	O
8	O
(	O
10	O
%)	O
with	O
lymphoma	B-DISO
,	O
and	O
11	O
(	O
14	O
%)	O
with	O
chronic	B-DISO
leukemia	I-DISO
,	O
multiple	B-DISO
myeloma	I-DISO
,	O
or	O
myelodysplastic	B-DISO
syndrome	I-DISO
.	O

Compared	O
with	O
patients	O
who	O
avoided	O
ETI	O
,	O
those	O
who	O
failed	O
NIV	O
or	O
had	O
a	O
DNI	O
order	O
and	O
died	O
were	O
more	O
likely	O
to	O
have	O
acute	B-DISO
leukemia	I-DISO
(	O
84	O
%	O
vs	O
61	O
%;	O
P	O
=	O
.	O
02	O
)	O
and	O
at	O
baseline	O
had	O
higher	O
Paco	O
Two	O
-	O
thirds	O
of	O
patients	O
with	O
HM	O
and	O
respiratory	B-DISO
failure	I-DISO
failed	O
NIV	O
and	O
required	O
ETI	O
,	O
and	O
had	O
high	O
subsequent	O
mortality	O
.	O

the	O
short	O
-	O
term	O
survival	O
rate	O
of	O
ARDS	B-DISO
in	O
developing	O
countries	O
including	O
Indonesia	O
is	O
still	O
low	O
and	O
early	O
management	O
with	O
optimal	O
treatment	O
provided	O
within	O
the	O
first	O
week	O
may	O
improve	O
the	O
survival	O
rate	O
.	O

ABSTRACT	O
:	O
Acute	O
exacerbations	O
of	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
AECOPD	O
)	O
cause	O
significant	O
morbidity	O
,	O
mortality	O
,	O
and	O
an	O
inexorable	O
decline	O
of	O
lung	O
function	O
.	O

Three	O
patients	O
with	O
A	O
/	O
H3N2	O
infection	B-DISO
died	O
during	O
hospitalization	O
.	O

Appropriate	O
preventive	O
strategies	O
like	O
influenza	B-DISO
vaccination	O
also	O
need	O
to	O
be	O
employed	O
routinely	O
.	O

This	O
case	O
illustrates	O
the	O
possible	O
relationship	O
between	O
infection	B-DISO
and	O
humoral	B-DISO
rejection	I-DISO
.	O

Studies	O
of	O
long	O
-	O
term	O
SJS	B-DISO
/	O
TEN	O
outcomes	O
mostly	O
focus	O
on	O
mucocutaneous	O
and	O
ocular	O
complications	O
.	O

TITLE	O
:	O
The	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Coronavirus	O
Nucleocapsid	O
Inhibits	O
Type	O
I	O
Interferon	O
Production	O
by	O
Interfering	O
with	O
TRIM25	O
-	O
Mediated	O
RIG	O
-	O
I	O
Ubiquitination	O
.	O

It	O
is	O
the	O
first	O
comprehensive	O
study	O
on	O
determination	O
of	O
the	O
role	O
of	O
human	O
coronaviruses	O
in	O
respiratory	B-DISO
infections	I-DISO
in	O
Iran	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
outbreak	O
in	O
South	O
Korea	O
,	O
2015	O
:	O
epidemiology	O
,	O
characteristics	O
and	O
public	O
health	O
implications	O
.	O

The	O
main	O
underlying	O
diseases	O
were	O
respiratory	B-DISO
diseases	I-DISO
,	O
cancer	B-DISO
and	O
hypertension	B-DISO
.	O

Although	O
not	O
first	O
-	O
line	O
,	O
HFOV	O
remains	O
a	O
tool	O
in	O
the	O
armamentarium	O
of	O
the	O
intensivist	O
managing	O
the	O
patient	O
with	O
severe	O
ARDS	B-DISO
and	O
refractory	O
hypoxemia	O
.	O

Although	O
antiviral	O
therapy	O
is	O
available	O
for	O
some	O
respiratory	O
viral	B-DISO
infections	I-DISO
,	O
further	O
research	O
is	O
needed	O
to	O
determine	O
which	O
groups	O
of	O
patients	O
would	O
benefit	O
.	O

ABSTRACT	O
:	O
Polymerase	O
chain	O
reaction	O
-	O
based	O
diagnosis	O
has	O
become	O
the	O
standard	O
for	O
viral	B-DISO
pneumonia	I-DISO
and	O
other	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
.	O

The	O
relative	O
plasma	O
miR	O
-	O
155	O
and	O
miR	O
-	O
146a	O
concentrations	O
were	O
significantly	O
increased	O
in	O
severe	B-DISO
sepsis	I-DISO
and	O
sepsis	B-DISO
-	O
induced	O
cases	O
of	O
ALI	O
,	O
compared	O
with	O
control	O
subjects	O
.	O

RESULTS	O
:	O
The	O
relative	O
plasma	O
miR	O
-	O
155	O
and	O
miR	O
-	O
146a	O
concentrations	O
were	O
significantly	O
increased	O
in	O
severe	B-DISO
sepsis	I-DISO
and	O
sepsis	B-DISO
-	O
induced	O
cases	O
of	O
ALI	O
,	O
compared	O
with	O
control	O
subjects	O
.	O

Stress	O
induced	O
gastric	B-DISO
ulcers	I-DISO
should	O
be	O
suspected	O
in	O
a	O
neonate	O
presenting	O
with	O
massive	O
gastrointestinal	B-DISO
bleeding	I-DISO
after	O
difficult	O
delivery	O
and	O
birth	B-DISO
asphyxia	I-DISO
.	O

Peak	O
PEDV	O
infection	B-DISO
was	O
noted	O
at	O
3	O
dpi	O
compared	O
with	O
4	O
dpi	O
for	O
PDCoV	O
pigs	O
as	O
determined	O
by	O
fecal	O
swab	O
quantitative	O
real	O
-	O
time	O
PCR	O
(	O
RT	O
-	O
PCR	O
).	O

During	O
the	O
first	O
week	O
of	O
mechanical	O
ventilation	O
,	O
patients	O
were	O
categorized	O
as	O
:	O
no	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
or	O
mild	O
,	O
moderate	O
,	O
or	O
severe	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
based	O
on	O
oxygenation	O
index	O
or	O
oxygen	O
saturation	O
index	O
.	O

TITLE	O
:	O
Immunological	O
aspects	O
of	O
the	O
efficiency	O
of	O
protectotype	O
vaccination	O
strategy	O
against	O
chicken	O
infectious	B-DISO
bronchitis	B-DISO
.	O

TITLE	O
:	O
Hemodynamic	O
effects	O
of	O
lung	O
recruitment	B-DISO
maneuvers	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Two	O
peaks	O
of	O
publications	O
,	O
an	O
early	O
one	O
for	O
SARS	B-DISO
and	O
a	O
late	O
one	O
for	O
Ebola	O
,	O
were	O
observed	O
.	O

We	O
developed	O
a	O
simplified	O
ECMO	O
transport	O
system	O
without	O
mechanical	O
ventilation	O
for	O
use	O
by	O
public	O
emergency	B-DISO
medical	O
services	O
.	O

TITLE	O
:	O
Comparison	O
and	O
evaluation	O
of	O
conventional	O
RT	O
-	O
PCR	O
,	O
SYBR	O
green	O
I	O
and	O
TaqMan	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assays	O
for	O
the	O
detection	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
.	O

ABSTRACT	O
:	O
The	O
shrinking	B-DISO
lung	I-DISO
syndrome	I-DISO
(	O
SLS	B-DISO
)	O
is	O
a	O
rare	O
complication	B-DISO
of	O
systemic	B-DISO
lupus	I-DISO
erythematosus	I-DISO
.	O

ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
is	O
a	O
zoonotic	O
viral	B-DISO
disease	I-DISO
that	O
can	O
be	O
transmitted	B-DISO
from	O
dromedaries	O
to	O
human	O
beings	O
.	O

TITLE	O
:	O
Seroprevalence	O
and	O
risk	O
factors	O
for	O
infection	B-DISO
with	O
equine	O
coronavirus	O
in	O
healthy	O
horses	O
in	O
the	O
USA	O
.	O

ABSTRACT	O
:	O
In	O
addition	O
to	O
severe	O
hypoxia	B-DISO
and	O
hypercapnia	B-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
can	O
present	O
with	O
substantial	O
hemodynamic	O
compromise	O
,	O
requiring	O
inotropic	O
or	O
vasopressor	O
support	O
or	O
both	O
.	O

Although	O
lower	O
than	O
other	O
RNA	O
viruses	O
such	O
as	O
hepatitis	B-DISO
C	I-DISO
virus	O
,	O
HCoV	O
-	O
OC43	O
did	O
exhibit	O
quasi	O
-	O
species	O
.	O

Here	O
,	O
we	O
report	O
a	O
case	O
of	O
acute	B-DISO
necrotizing	I-DISO
pancreatitis	I-DISO
in	O
a	O
29	O
-	O
year	O
-	O
old	O
man	O
who	O
presented	O
with	O
severe	O
abdominal	B-DISO
pain	I-DISO
,	O
nausea	B-DISO
and	I-DISO
vomiting	I-DISO
.	O

She	O
suffered	B-DISO
significant	O
hemorrhage	B-DISO
requiring	O
transfusion	O
of	O
platelets	O
and	O
multidrug	O
-	O
resistant	O
Acinetobacter	O
Baumannii	O
infection	B-DISO
during	O
ECMO	O
support	O
.	O

Mechanical	O
circulatory	O
support	O
was	O
the	O
only	O
chance	O
for	O
our	O
patient	O
with	O
H7N9	O
-	O
associated	O
ARDS	B-DISO
to	O
survive	O
until	O
respiratory	O
function	B-DISO
recovery	I-DISO
.	O

ABSTRACT	O
:	O
Lungs	O
are	O
easily	O
damaged	O
by	O
the	O
inflammatory	B-DISO
responses	I-DISO
induced	O
after	O
extensive	O
burns	O
.	O

Intravenous	O
administration	O
of	O
mtDNA	O
significantly	O
increased	O
concentrations	O
of	O
inflammatory	O
mediators	O
and	O
caused	O
severe	O
ARDS	B-DISO
(	O
P	O
<	O
.	O
05	O
).	O

Our	O
results	O
suggest	O
that	O
mtDNA	O
is	O
important	O
for	O
thermal	O
injury	O
-	O
induced	O
inflammation	B-DISO
and	O
associated	O
ARDS	B-DISO
.	O

This	O
differential	O
pattern	O
of	O
early	O
immune	O
responses	O
developed	O
after	O
challenge	O
with	O
IBV	O
B	O
isolate	O
,	O
related	O
to	O
the	O
downregulation	O
of	O
TLR7	O
,	O
leading	O
to	O
insufficient	O
pro	O
-	O
inflammatory	B-DISO
response	I-DISO
and	O
lower	O
CMI	O
responses	O
,	O
seem	O
to	O
have	O
an	O
association	O
with	O
a	O
most	O
severe	O
renal	O
lesion	O
and	O
an	O
enhanced	O
capability	O
of	O
replication	O
of	O
this	O
isolate	O
in	O
chicken	O
.	O

Poor	O
prognosis	O
of	O
severe	O
adenovirus	B-DISO
pneumonia	B-DISO
in	O
children	O
is	O
associated	O
with	O
anemia	B-DISO
,	O
low	O
serum	O
albumin	O
,	O
inflammatory	B-DISO
response	I-DISO
,	O
concurrent	O
multiple	O
complications	O
and	O
underlying	O
lung	B-DISO
diseases	I-DISO
.	O

ABSTRACT	O
:	O
The	O
development	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
antibody	O
-	O
based	O
assays	O
is	O
important	O
for	O
detecting	O
infected	O
animals	O
,	O
confirming	O
previous	O
virus	O
exposure	O
,	O
and	O
monitoring	O
sow	O
herd	O
immunity	O
.	O

ABSTRACT	O
:	O
Legionnaires	B-DISO
'	I-DISO
disease	I-DISO
(	O
LD	O
)	O
is	O
an	O
important	O
cause	O
of	O
community	O
-	O
acquired	O
pneumonia	B-DISO
with	O
high	O
mortality	O
rates	O
in	O
the	O
most	O
severe	O
cases	O
.	O

The	O
ARF	B-DISO
and	O
hematologic	O
parameters	O
improved	O
with	O
conservative	O
treatment	O
.	O

Multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
was	O
defined	O
as	O
respiratory	B-DISO
dysfunction	I-DISO
one	O
or	O
more	O
extrapulmonary	O
organ	O
dysfunctions	O
.	O

Diarrhetic	O
fecal	O
samples	O
from	O
20	O
Hunan	O
farm	O
piglets	O
were	O
tested	O
and	O
found	O
to	O
be	O
positive	O
for	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
by	O
RT	O
-	O
PCR	O
,	O
although	O
incubation	O
with	O
porcine	O
kidney	O
(	O
PK	O
-	O
15	O
)	O
cells	O
failed	O
to	O
produce	O
infectious	B-DISO
PEDV	O
.	O

Phylogenetic	O
analyses	O
based	O
on	O
full	O
-	O
length	O
and	O
partial	O
VP1	O
gene	O
sequences	O
showed	O
that	O
3	O
of	O
the	O
PSV	O
-	O
HuN	O
strains	O
(	O
HuN2	O
,	O
3	O
and	O
4	O
)	O
clustered	O
within	O
a	O
clade	O
distinct	O
from	O
HuN1	O
as	O
well	O
as	O
from	O
all	O
PSVs	B-DISO
previously	O
isolated	O
in	O
China	O
,	O
thereby	O
showing	O
that	O
genetic	O
diversity	O
exists	O
within	O
Chinese	O
PSVs	B-DISO
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
development	O
of	O
an	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
program	O
for	O
the	O
treatment	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
adults	O
.	O

Our	O
results	O
endorse	O
the	O
use	O
of	O
ECMO	O
as	O
a	O
rescue	O
therapy	O
in	O
adults	O
with	O
ARDS	B-DISO
,	O
although	O
there	O
are	O
some	O
risks	O
associated	O
with	O
a	O
learning	O
curve	O
as	O
well	O
as	O
an	O
important	O
increase	O
in	O
the	O
days	O
of	O
patient	O
stay	O
.	O

TITLE	O
:	O
Questionnaire	O
-	O
based	O
analysis	O
of	O
infection	B-DISO
prevention	O
and	O
control	O
in	O
healthcare	O
facilities	O
in	O
Saudi	O
Arabia	O
in	O
regards	O
to	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
.	O

TITLE	O
:	O
The	O
17th	O
International	O
Congress	O
on	O
Infectious	B-DISO
Diseases	I-DISO
workshop	O
on	O
developing	O
infection	B-DISO
prevention	O
and	O
control	O
resources	O
for	O
low	O
-	O
and	O
middle	O
-	O
income	O
countries	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
svRNAs	O
contribute	O
to	O
SARS	B-DISO
-	O
CoV	O
pathogenesis	B-DISO
and	O
highlight	O
the	O
potential	O
of	O
svRNA	O
-	O
N	O
antagomirs	O
as	O
antivirals	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
performance	O
of	O
laboratory	O
methods	O
and	O
clinical	O
case	O
definitions	O
in	O
detecting	O
the	O
viral	O
pathogens	O
for	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
(	O
ARIs	B-DISO
)	O
from	O
a	O
prospective	O
community	O
cohort	O
and	O
hospital	O
inpatients	O
,	O
nasopharyngeal	O
swabs	O
from	O
cohort	O
members	O
reporting	O
ARIs	B-DISO
(	O
community	O
-	O
ARI	O
)	O
and	O
inpatients	O
admitted	O
with	O
ARIs	B-DISO
(	O
inpatient	O
-	O
ARI	O
)	O
were	O
tested	O
by	O
Singleplex	O
Real	O
Time	O
-	O
Polymerase	O
Chain	O
Reaction	O
(	O
SRT	O
-	O
PCR	O
),	O
multiplex	O
RT	O
-	O
PCR	O
(	O
MRT	O
-	O
PCR	O
)	O
and	O
pathogen	O
-	O
chip	O
system	O
(	O
PathChip	O
)	O
between	O
April	O
2012	O
and	O
December	O
2013	O
.	O

No	O
such	O
patterns	O
were	O
observed	O
for	O
non	O
-	O
influenza	B-DISO
respiratory	O
virus	O
infections	B-DISO
.	O

TITLE	O
:	O
Intravenous	O
vitamin	O
C	O
as	O
adjunctive	O
therapy	O
for	O
enterovirus	O
/	O
rhinovirus	O
induced	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ECMO	O
and	O
mechanical	O
ventilation	O
were	O
discontinued	O
by	O
day	O
-	O
7	O
and	O
the	O
patient	O
recovered	O
with	O
no	O
long	O
-	O
term	O
ARDS	B-DISO
sequelae	O
.	O

Infusing	O
high	O
dose	O
intravenous	O
vitamin	O
C	O
into	O
this	O
patient	O
with	O
virus	O
-	O
induced	O
ARDS	B-DISO
was	O
associated	O
with	O
rapid	O
resolution	O
of	O
lung	O
injury	O
with	O
no	O
evidence	O
of	O
post	O
-	O
ARDS	B-DISO
fibroproliferative	O
sequelae	O
.	O

Faecal	O
samples	O
from	O
184	O
dogs	O
with	O
diarrhoea	B-DISO
and	O
from	O
82	O
clinically	O
healthy	O
dogs	O
(	O
control	O
group	O
)	O
were	O
analysed	O
for	O
the	O
presence	O
of	O
DogCV	O
by	O
PCR	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
presence	O
of	O
viruses	O
and	O
bacteria	O
in	O
middle	O
ear	O
and	O
adenoids	O
of	O
patients	O
with	O
and	O
without	O
otitis	B-DISO
media	I-DISO
with	I-DISO
effusion	I-DISO
(	O
OME	O
).	O

Specific	O
DNA	O
or	O
RNA	O
of	O
9	O
respiratory	O
viruses	O
(	O
rhinovirus	O
,	O
influenza	B-DISO
virus	O
,	O
picornavirus	O
,	O
syncytial	O
respiratory	O
virus	O
,	O
metapneumovirus	O
,	O
coronavirus	O
,	O
enterovirus	O
,	O
adenovirus	B-DISO
and	O
bocavirus	O
)	O
and	O
5	O
bacteria	O
(	O
S	O
.	O
pneumoniae	O
,	O
H	O
.	O
influenzae	O
,	O
M	O
.	O
catarrhalis	O
,	O
P	O
.	O
aeruginosa	O
and	O
S	O
.	O
aureus	O
)	O
were	O
extracted	O
and	O
quantified	O
by	O
real	O
-	O
time	O
PCR	O
.	O

TITLE	O
:	O
Comparative	O
pathology	B-DISO
of	O
rhesus	O
macaque	O
and	O
common	O
marmoset	O
animal	O
models	O
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
.	O

However	O
,	O
the	O
pathogenesis	B-DISO
,	O
comparative	O
pathology	B-DISO
and	O
inflammatory	O
cell	O
response	O
of	O
rhesus	O
macaques	O
and	O
common	O
marmosets	O
experimentally	O
infected	O
with	O
MERS	O
-	O
CoV	O
are	O
unknown	O
.	O

The	O
main	O
histopathological	O
findings	O
in	O
the	O
lungs	O
of	O
rhesus	O
macaques	O
and	O
common	O
marmosets	O
were	O
varying	O
degrees	O
of	O
pulmonary	O
lesions	O
,	O
including	O
pneumonia	B-DISO
,	O
pulmonary	B-DISO
oedema	I-DISO
,	O
haemorrhage	B-DISO
,	O
degeneration	B-DISO
and	O
necrosis	O
of	O
the	O
pneumocytes	O
and	O
bronchial	O
epithelial	O
cells	O
,	O
and	O
inflammatory	B-DISO
cell	I-DISO
infiltration	I-DISO
.	O

It	O
has	O
been	O
suggested	O
that	O
administration	O
of	O
buprenorphine	O
,	O
a	O
partial	O
μ	O
-	O
opioid	O
receptor	O
agonist	O
,	O
to	O
an	O
opioid	O
-	O
intoxicated	O
patient	O
may	O
result	O
in	O
reversal	O
of	O
respiratory	B-DISO
depression	I-DISO
with	O
less	O
severe	O
withdrawal	B-DISO
signs	B-DISO
and	I-DISO
symptoms	I-DISO
.	O

We	O
describe	O
a	O
case	O
of	O
a	O
previously	O
healthy	O
8	O
-	O
month	O
-	O
old	O
female	O
who	O
presented	O
with	O
progressive	O
purpura	B-DISO
in	O
a	O
nondependent	O
distribution	O
,	O
low	O
-	O
grade	O
fevers	O
,	O
and	O
extremity	B-DISO
swelling	I-DISO
.	O

Understanding	O
the	O
dynamic	O
changes	O
in	O
the	O
genome	O
and	O
the	O
related	O
functional	O
changes	O
induced	O
by	O
H1N1	B-DISO
influenza	I-DISO
virus	B-DISO
infection	I-DISO
is	O
essential	O
to	O
elucidating	O
the	O
pathogenesis	B-DISO
of	O
this	O
virus	O
and	O
thereby	O
determining	O
strategies	O
to	O
prevent	O
future	O
outbreaks	O
.	O

As	O
such	O
,	O
laboratories	O
face	B-DISO
challenges	O
in	O
assay	O
development	O
,	O
test	O
evaluation	O
,	O
and	O
subsequent	O
quality	O
assurance	O
.	O

ABSTRACT	O
:	O
The	O
new	O
emerging	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
CoV	O
)	O
encodes	O
several	O
resistance	O
proteins	O
against	O
the	O
innate	B-DISO
immune	I-DISO
response	I-DISO
of	O
the	O
host	O
,	O
including	O
interferon	O
(	O
IFN	O
)	O
resistance	O
.	O

ABSTRACT	O
:	O
IFIT1	O
(	O
IFN	O
-	O
induced	O
protein	O
with	O
tetratricopeptide	O
repeats	O
-	O
1	O
)	O
is	O
an	O
effector	O
of	O
the	O
host	O
innate	O
immune	O
antiviral	O
response	O
that	O
prevents	O
propagation	O
of	O
virus	B-DISO
infection	I-DISO
by	O
selectively	O
inhibiting	O
translation	O
of	O
viral	O
mRNA	O
.	O

We	O
studied	O
778	O
patients	O
with	O
moderate	O
to	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Single	O
-	O
factor	O
analysis	O
of	O
variance	O
revealed	O
factors	O
influencing	O
the	O
course	O
of	O
flu	B-DISO
-	O
like	O
syndrome	B-DISO
and	O
identified	O
risk	O
groups	O
:	O
children	O
younger	O
than	O
2	O
years	O
old	O
and	O
adults	O
over	O
65	O
,	O
pregnant	O
women	O
,	O
and	O
people	O
with	O
chronic	O
somatic	O
diseases	O
and	O
obesity	B-DISO
.	O

The	O
incidence	O
of	O
complications	O
was	O
higher	O
,	O
especially	O
in	O
the	O
under	O
2	O
-	O
year	O
-	O
year	O
-	O
old	O
children	O
and	O
in	O
patients	O
with	O
endocrine	O
,	O
metabolic	O
,	O
or	O
respiratory	B-DISO
diseases	I-DISO
,	O
with	O
a	O
large	O
proportion	O
of	O
complications	O
being	O
pneumonia	B-DISO
.	O

Patients	O
with	O
endocrine	O
,	O
eating	O
,	O
metabolic	O
(	O
including	O
obesity	B-DISO
),	O
circulatory	O
,	O
and	O
respiratory	B-DISO
disorders	I-DISO
are	O
at	O
high	O
risk	O
for	O
influenza	B-DISO
and	O
ARVI	O
complications	O
.	O

TITLE	O
:	O
Sagittal	O
-	O
lung	O
CT	O
measurements	O
in	O
the	O
evaluation	O
of	O
asthma	B-DISO
-	O
COPD	B-DISO
overlap	B-DISO
syndrome	I-DISO
:	O
a	O
distinctive	O
phenotype	O
from	O
COPD	B-DISO
alone	O
.	O

Sagittal	O
-	O
lung	O
CT	O
measurements	O
in	O
terms	O
of	O
bilateral	O
lung	O
height	O
(	O
LH	O
),	O
anterior	O
-	O
posterior	O
lung	O
diameter	O
(	O
APLD	B-DISO
),	O
diaphragm	O
height	O
(	O
DH	O
),	O
and	O
anterior	O
sterno	O
-	O
diaphragmatic	O
angle	O
(	O
ASDA	O
),	O
as	O
well	O
as	O
inter	O
-	O
pulmonary	O
septum	O
length	O
(	O
IPSL	O
)	O
on	O
axial	O
images	O
were	O
measured	O
both	O
before	O
and	O
after	O
bronchodilator	O
(	O
BD	O
)	O
administration	O
.	O

TITLE	O
:	O
Multidisciplinary	O
Approach	O
to	O
Complicated	B-DISO
Pregnancy	I-DISO
.	O

She	O
had	O
an	O
uneventful	O
medical	O
history	O
;	O
however	O
,	O
the	O
physical	O
examination	O
upon	O
hospital	O
admission	O
revealed	O
a	O
hypertensive	B-DISO
emergency	I-DISO
,	O
papilledema	B-DISO
,	O
and	O
2	O
+	O
dipstick	O
proteinuria	O
.	O

CONCLUSIONS	O
:	O
Although	O
correlations	O
between	O
CT	O
values	O
and	O
clinical	O
parameters	O
in	O
patients	O
with	O
single	O
and	O
multiple	O
viral	B-DISO
infection	I-DISO
were	O
found	O
,	O
the	O
clinical	O
importance	O
of	O
these	O
findings	O
is	O
limited	O
because	O
individual	O
differences	O
in	O
host	O
-,	O
viral	O
and	O
laboratory	O
factors	O
complicate	O
the	O
interpretation	O
of	O
statistically	O
significant	O
findings	O
.	O

There	O
are	O
three	O
accepted	O
methods	O
of	O
surgical	O
intervension	O
:	O
needle	O
aspiration	B-DISO
,	O
incision	O
and	O
drainage	O
(	O
ID	O
),	O
and	O
acute	O
tonsillectomy	O
(	O
á	O
chaud	O
).	O

The	O
trend	O
towards	O
de	O
-	O
escalated	O
surgical	O
intervention	O
and	O
increasing	O
reliance	O
on	O
antibiotic	O
treatment	O
,	O
require	O
studies	O
defining	O
the	O
significant	O
pathogens	O
in	O
PTA	B-DISO
in	O
order	O
to	O
determine	O
optimal	O
antibiotic	O
regimens	O
.	O

The	O
identification	O
and	O
quantification	O
of	O
risk	O
factors	O
for	O
PTA	B-DISO
development	O
constitutes	O
another	O
approach	O
to	O
reduce	O
the	O
incidence	O
of	O
PTA	B-DISO
.	O

To	O
characterize	O
patients	O
with	O
PPA	B-DISO
,	O
explore	O
the	O
relationship	O
between	O
PPA	B-DISO
and	O
PTA	B-DISO
,	O
identify	O
the	O
pathogens	O
associated	O
with	O
PPA	B-DISO
,	O
and	O
review	O
our	O
management	O
of	O
PPA	B-DISO
.	O

In	O
a	O
retrospective	O
study	O
on	O
all	O
847	O
PTA	B-DISO
patients	O
admitted	O
to	O
the	O
ENT	O
department	O
at	O
Aarhus	O
University	O
Hospital	O
(	O
AUH	O
)	O
from	O
2001	O
to	O
2006	O
,	O
we	O
found	O
that	O
FN	O
was	O
the	O
most	O
prevalent	O
(	O
23	O
%)	O
bacterial	O
strain	O
in	O
pus	O
specimens	O
.	O

FN	O
-	O
positive	O
patients	O
displayed	O
significantly	O
higher	O
infection	B-DISO
markers	O
(	O
CRP	O
and	O
neutrophil	O
counts	O
)	O
than	O
patients	O
infected	O
with	O
other	O
bacteria	O
(	O
P	O
=	O
0	O
.	O
01	O
and	O
P	O
<	O
0	O
.	O
001	O
,	O
respectively	O
).	O

However	O
,	O
our	O
results	O
did	O
not	O
indicate	O
that	O
any	O
of	O
these	O
viruses	O
are	O
involved	O
in	O
the	O
development	O
of	O
PTA	B-DISO
.	O

Development	O
of	O
anti	O
-	O
FN	O
antibodies	O
in	O
FN	O
-	O
positive	O
patients	O
with	O
PTA	B-DISO
.	O

The	O
incidence	O
of	O
PTA	B-DISO
was	O
highly	O
related	O
to	O
age	O
and	O
gender	O
.	O

However	O
,	O
the	O
microbiology	O
of	O
PTA	B-DISO
fluctuated	O
with	O
seasons	O
:	O
GAS	O
-	O
positive	O
PTA	B-DISO
cases	O
were	O
significantly	O
more	O
prevalent	O
in	O
the	O
winter	O
and	O
spring	O
compared	O
to	O
the	O
summer	O
,	O
while	O
FN	O
-	O
positive	O
PTA	B-DISO
patients	O
exhibited	O
a	O
more	O
even	O
distribution	O
over	O
the	O
year	O
,	O
but	O
with	O
a	O
trend	O
towards	O
higher	O
prevalence	O
in	O
the	O
summer	O
than	O
in	O
the	O
winter	O
.	O

We	O
therefore	O
suggest	O
that	O
combined	O
tonsillectomy	O
and	O
intrapharyngeal	O
incision	O
in	O
cases	O
where	O
PTA	B-DISO
is	O
present	O
or	O
suspected	O
.	O

Based	O
on	O
our	O
findings	O
suggesting	O
that	O
FN	O
is	O
a	O
frequent	O
pathogen	O
in	O
PTA	B-DISO
,	O
we	O
recommend	O
clindamycin	O
instead	O
of	O
a	O
macrolide	O
in	O
penicillin	O
-	O
allergic	O
patients	O
with	O
PTA	B-DISO
.	O

Future	O
studies	O
of	O
patients	O
with	O
FN	O
-	O
positive	O
acute	B-DISO
tonsillitis	I-DISO
focusing	O
on	O
the	O
optimal	O
methods	O
(	O
clinical	O
characteristics	O
,	O
culture	O
,	O
polymerase	O
chain	O
reaction	O
,	O
or	O
other	O
)	O
for	O
diagnosis	O
and	O
whether	O
antibiotics	O
(	O
and	O
which	O
)	O
can	O
reduce	O
symptoms	O
and	O
avoid	O
complications	O
are	O
warranted	O
.	O

FN	O
is	O
a	O
significant	O
and	O
prevalent	O
pathogen	O
in	O
PTA	B-DISO
.	O

The	O
epidemiology	O
of	O
the	O
infection	B-DISO
is	O
compatible	O
with	O
multiple	O
introductions	O
of	O
the	O
virus	O
into	O
humans	O
from	O
an	O
animal	O
reservoir	O
,	O
probably	O
dromedary	O
camels	O
.	O

TITLE	O
:	O
Severe	O
Fever	O
with	O
Thrombocytopenia	O
Syndrome	B-DISO
Presenting	O
with	O
Rhabdomyolysis	B-DISO
.	O

TITLE	O
:	O
Characterization	O
of	O
Chinese	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
with	O
Novel	O
Insertions	O
and	O
Deletions	O
in	O
Genome	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
continues	O
to	O
raise	O
worldwide	O
concerns	O
due	O
to	O
its	O
pandemic	O
potential	O
.	O

Lumbar	O
puncture	O
revealed	O
albuminocytologic	O
dissociation	B-DISO
that	O
was	O
consistent	O
with	O
a	O
diagnosis	O
of	O
GBS	B-DISO
.	O

In	O
patients	O
presenting	O
with	O
refractory	O
bradycardia	B-DISO
and	O
hypotension	O
,	O
GBS	B-DISO
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
.	O

ABSTRACT	O
:	O
Open	O
lung	O
strategy	O
during	O
ARDS	B-DISO
aims	O
to	O
decrease	O
the	O
ventilator	O
-	O
induced	O
lung	O
injury	O
by	O
minimizing	O
the	O
atelectrauma	O
and	O
stress	O
/	O
strain	O
maldistribution	O
.	O

Advanced	O
treatment	O
strategies	O
,	O
which	O
complement	O
lung	O
protective	O
ventilation	O
,	O
include	O
short	O
-	O
term	O
neuromuscular	B-DISO
blockade	I-DISO
,	O
prone	O
positioning	O
,	O
and	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

TITLE	O
:	O
Attenuation	O
of	O
an	O
original	O
US	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
strain	O
PC22A	O
via	O
serial	O
cell	O
culture	O
passage	O
.	O

In	O
this	O
study	O
we	O
report	O
the	O
detection	O
of	O
RVA	O
from	O
calves	O
with	O
severe	B-DISO
diarrhea	I-DISO
in	O
a	O
herd	O
regularly	O
vaccinated	O
to	O
prevent	O
enteric	O
infections	B-DISO
including	O
RVA	O
.	O

ABSTRACT	O
:	O
Observational	O
research	O
focused	O
upon	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
such	O
as	O
Ebola	O
virus	O
,	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
,	O
and	O
Zika	O
virus	O
has	O
been	O
challenging	O
to	O
quickly	O
initiate	O
.	O

Mortality	O
associated	O
with	O
severe	O
malaria	B-DISO
remains	O
high	O
.	O

These	O
results	O
show	O
that	O
PHEV	O
infection	B-DISO
induces	O
atypical	O
autophagy	O
and	O
causes	O
the	O
appearance	O
of	O
autophagosomes	O
but	O
blocks	O
the	O
fusion	O
with	O
lysosomes	O
,	O
which	O
is	O
necessary	O
for	O
the	O
replication	O
of	O
PHEV	O
in	O
nerve	O
cells	O
.	O

McNemar	O
'	O
s	O
test	O
was	O
significant	O
only	O
for	O
BCV	O
,	O
indicating	O
that	O
for	O
this	O
pathogen	O
the	O
proportion	O
of	O
positive	O
results	O
from	O
NS	O
and	O
NPS	B-DISO
could	O
not	O
be	O
considered	O
comparable	O
to	O
TTW	O
.	O

We	O
reviewed	O
the	O
cases	O
of	O
RVI	O
in	O
allo	O
-	O
HSCT	O
recipients	O
and	O
explored	O
the	O
predictive	O
value	O
of	O
the	O
immunodeficiency	B-DISO
scoring	O
index	O
(	O
ISI	O
)	O
established	O
for	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
and	O
its	O
applicability	O
for	O
RVI	O
caused	O
by	O
other	O
respiratory	O
viruses	O
.	O

So	O
far	O
,	O
data	O
on	O
ECoV	O
infection	B-DISO
in	O
horses	O
remain	O
limited	O
to	O
the	O
USA	O
,	O
France	O
and	O
Japan	O
and	O
its	O
geographic	O
distribution	O
is	O
not	O
well	O
understood	O
.	O

We	O
document	O
evidence	O
of	O
infection	B-DISO
with	O
ECoV	O
and	O
HKU23	O
coronavirus	O
by	O
RT	O
-	O
PCR	O
.	O

TITLE	O
:	O
A	O
novel	O
benzo	O
-	O
heterocyclic	O
amine	O
derivative	O
N30	O
inhibits	O
influenza	B-DISO
virus	O
replication	O
by	O
depression	B-DISO
of	O
Inosine	O
-	O
5	O
'-	O
Monophospate	O
Dehydrogenase	O
activity	O
.	O

TITLE	O
:	O
miR	O
-	O
21a	O
-	O
5p	O
Contributes	O
to	O
Porcine	O
Hemagglutinating	O
Encephalomyelitis	B-DISO
Virus	O
Proliferation	B-DISO
via	O
Targeting	O
CASK	O
-	O
Interactive	O
Protein1	O
ABSTRACT	O
:	O
Porcine	O
hemagglutinating	O
encephalomyelitis	B-DISO
virus	O
(	O
PHEV	O
)	O
is	O
a	O
highly	O
neurovirulent	O
coronavirus	O
that	O
can	O
cause	O
nervous	B-DISO
symptoms	O
in	O
piglets	O
with	O
muscle	B-DISO
tremors	I-DISO
,	O
hind	O
limb	O
paralysis	O
,	O
and	O
nystagmus	B-DISO
.	O

TITLE	O
:	O
ORF3a	O
deletion	O
in	O
field	O
strains	O
of	O
porcine	O
-	O
transmissible	O
gastroenteritis	B-DISO
virus	O
in	O
China	O
:	O
A	O
hint	O
of	O
association	O
with	O
porcine	O
respiratory	O
coronavirus	O
.	O

For	O
this	O
study	O
,	O
we	O
aimed	O
to	O
determine	O
the	O
minimum	O
infectious	B-DISO
dose	O
for	O
the	O
spray	O
-	O
administered	O
ArkDPI	O
vaccine	O
,	O
which	O
we	O
designate	O
as	O
the	O
dose	O
that	O
achieves	O
the	O
same	O
level	O
of	O
infection	B-DISO
and	O
replication	O
as	O
the	O
eye	O
drop	O
-	O
administered	O
ArkDPI	O
vaccine	O
.	O

,	O
there	O
are	O
still	O
no	O
Food	O
and	O
Drug	O
Administration	O
-	O
approved	O
drugs	O
that	O
improve	O
mortality	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

TITLE	O
:	O
DNA	O
vaccine	O
encoding	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
S1	O
protein	O
induces	O
protective	O
immune	O
responses	O
in	O
mice	O
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
is	O
an	O
emerging	O
pathogen	O
that	O
continues	O
to	O
cause	O
outbreaks	O
in	O
the	O
Arabian	O
peninsula	O
and	O
in	O
travelers	O
from	O
this	O
region	O
,	O
raising	O
the	O
concern	O
that	O
a	O
global	O
pandemic	O
could	O
occur	O
.	O

TITLE	O
:	O
The	O
papain	O
-	O
like	O
protease	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
has	O
deubiquitinating	O
activity	O
.	O

We	O
enrolled	O
61	O
patients	O
who	O
met	O
the	O
Berlin	O
criteria	O
for	O
ARDS	B-DISO
:	O
7	O
were	O
classified	O
as	O
mild	O
,	O
29	O
as	O
moderate	O
,	O
and	O
25	O
as	O
severe	O
.	O

Lung	O
-	O
morphology	O
is	O
one	O
of	O
the	O
ARDS	B-DISO
-	O
phenotypes	O
and	O
physiological	O
studies	O
suggest	O
different	O
responses	O
in	O
terms	O
of	O
positive	O
-	O
end	O
-	O
expiratory	O
-	O
pressure	O
(	O
PEEP	O
)	O
and	O
recruitment	B-DISO
-	O
manoeuvres	O
(	O
RM	O
)	O
according	O
to	O
loss	O
of	O
aeration	O
.	O

Patients	O
will	O
be	O
enrolled	O
within	O
the	O
first	O
12hours	O
of	O
ARDS	B-DISO
onset	O
.	O

In	O
both	O
groups	O
,	O
volume	O
-	O
controlled	O
ventilation	O
with	O
low	O
tidal	O
-	O
volumes	O
(	O
Vt	O
)	O
will	O
be	O
used	O
to	O
target	O
a	O
plateau	O
pressure	O
≤	O
30	O
cmH	B-DISO

TITLE	O
:	O
Venovenous	O
Extracorporeal	O
Membrane	O
Oxygenation	O
as	O
a	O
Treatment	O
for	O
Obesity	B-DISO
Hypoventilation	I-DISO
Syndrome	I-DISO
.	O

We	O
describe	O
a	O
case	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
resulting	O
from	O
obesity	B-DISO
hypoventilation	I-DISO
syndrome	I-DISO
(	O
BMI	O
,	O
60	O
.	O
2	O
kg	O
/	O
m	O

It	O
is	O
estimated	O
that	O
1	O
to	O
10	O
%	O
of	O
the	O
population	O
suffers	B-DISO
annually	O
from	O
cold	B-DISO
-	O
like	O
symptoms	O
related	O
to	O
infection	B-DISO
with	O
human	O
coronavirus	O
NL63	O
(	O
HCoV	O
-	O
NL63	O
),	O
an	O
alphacoronavirus	O
.	O

A	O
fillable	O
online	O
questionnaire	O
was	O
sent	O
to	O
the	O
zoonoses	B-DISO
programme	O
managers	O
of	O
the	O
Ministries	O
of	O
Health	O
(	O
MOH	O
)	O
and	O
Ministries	O
of	O
Agriculture	O
(	O
MAg	O
)	O
of	O
33	O
LAC	O
countries	O
from	O
January	O
to	O
April	O
of	O
2015	O
.	O

ARI	O
severity	O
was	O
measured	O
using	O
the	O
validated	O
Wisconsin	O
Upper	B-DISO
Respiratory	I-DISO
Symptom	I-DISO
Survey	O
(	O
WURSS	O
-	O
24	O
)	O
until	O
the	O
ARI	O
episode	O
resolved	O
.	O

Our	O
findings	O
might	O
accelerate	O
our	O
understanding	O
of	O
the	O
pathogenesis	B-DISO
of	O
PEDV	O
infection	B-DISO
and	O
provide	O
new	O
insights	O
into	O
the	O
development	O
of	O
effective	O
therapeutic	O
strategies	O
.	O

PDCoV	O
has	O
been	O
experimentally	O
proved	O
to	O
lead	O
to	O
diarrhoea	B-DISO
in	O
swine	O
and	O
it	O
was	O
detected	O
positive	O
in	O
pigs	O
in	O
Guangdong	O
,	O
southern	O
China	O
.	O

In	O
our	O
study	O
,	O
252	O
faecal	O
and	O
intestinal	O
samples	O
from	O
sucking	O
piglets	O
and	O
sows	O
with	O
diarrhoea	B-DISO
were	O
surveyed	O
for	O
common	O
enteric	O
viruses	O
.	O

As	O
mice	O
are	O
restricted	O
to	O
infection	B-DISO
at	O
the	O
level	O
of	O
DPP4	O
,	O
the	O
MERS	O
-	O
CoV	O
receptor	O
,	O
we	O
generated	O
mice	O
with	O
humanized	O
exons	O
10	O
-	O
12	O
of	O
the	O
mouse	O

TITLE	O
:	O
Effects	O
of	O
operational	O
decisions	O
on	O
the	O
diffusion	O
of	O
epidemic	B-DISO
disease	I-DISO
:	O
A	O
system	O
dynamics	O
modeling	O
of	O
the	O
MERS	O
-	O
CoV	O
outbreak	O
in	O
South	O
Korea	O
.	O

ABSTRACT	O
:	O
We	O
evaluated	O
the	O
nosocomial	O
outbreak	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
Coronavirus	O
(	O
CoV	O
)	O
in	O
the	O
Republic	O
of	O
Korea	O
,	O
2015	O
,	O
from	O
a	O
healthcare	O
operations	O
management	O
perspective	O
.	O

The	O
success	O
of	O
these	O
nonpharmaceutical	O
strategies	O
will	O
depend	O
on	O
not	O
only	O
the	O
effectiveness	O
of	O
isolation	O
measures	O
but	O
also	O
the	O
epidemiological	O
characteristics	O
of	O
the	O
infection	B-DISO
.	O

The	O
benefit	O
of	O
quarantine	O
over	O
symptom	B-DISO
monitoring	O
is	O
generally	O
maximized	O
for	O
fast	O
-	O
course	O
diseases	O
,	O
but	O
we	O
show	O
the	O
conditions	O
under	O
which	O
symptom	B-DISO
monitoring	O
alone	O
can	O
control	O
certain	O
outbreaks	O
.	O

Seven	O
CoVs	O
belonging	O
to	O
distinct	O
groups	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
like	O
CoVs	O
and	O
α	O
-	O
CoVs	O
were	O
detected	O
in	O
samples	O
from	O
least	O
horseshoe	O
bats	O
.	O

Therefore	O
,	O
a	O
VLP	O
-	O
based	O
vaccine	O
has	O
the	O
potential	O
to	O
prevent	O
PEDV	O
infection	B-DISO
.	O

Using	O
our	O
established	O
rat	O
primary	O
type	O
I	O
-	O
like	O
alveolar	O
epithelial	O
cell	O
monolayer	O
stretch	O
model	O
and	O
in	O
vivo	O
rat	O
mechanical	O
ventilation	O
that	O
mimics	O
the	O
alveolar	O
overdistension	O
seen	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
we	O
studied	O
epithelial	O
responses	O
to	O
mechanical	O
stress	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
an	O
emerging	O
pathogenic	O
coronavirus	O
that	O
causes	O
a	O
significant	O
economic	O
burden	O
to	O
the	O
swine	O
industry	O
.	O

The	O
combined	O
observations	O
indicated	O
that	O
APN	O
is	O
not	O
required	O
for	O
PEDV	O
infection	B-DISO
.	O

Endobronchial	O
valves	O
(	O
EBV	O
)	O
are	O
frequently	O
deployed	O
after	O
pulmonary	O
resection	O
in	O
noncritically	O
ill	B-DISO
patients	O
to	O
reduce	O
and	O
eliminate	O
bronchopleural	O
fistulas	B-DISO
(	O
BPFs	O
)	O
with	O
persistent	B-DISO
air	I-DISO
leak	I-DISO
(	O
PAL	O
).	O

Information	O
regarding	O
EBV	O
placement	O
in	O
mechanically	O
ventilated	O
patients	O
with	O
ARDS	B-DISO
and	O
high	O
volume	O
persistent	O
air	O
leaks	O
is	O
rare	O
and	O
limited	O
to	O
case	O
reports	O
.	O

We	O
believe	O
endobronchial	O
valve	O
placement	O
is	O
a	O
safe	O
method	O
treating	O
persistent	B-DISO
air	I-DISO
leak	I-DISO
with	O
severe	O
respiratory	B-DISO
failure	I-DISO
and	O
may	O
reduce	O
days	O
on	O
mechanical	O
ventilation	O
.	O

Severe	O
pediatric	O
pneumonia	B-DISO
accounts	O
for	O
a	O
significant	O
number	O
of	O
PICU	O
admissions	O
and	O
is	O
associated	O
with	O
significant	O
mortality	O
risk	O
.	O

The	O
aggravation	O
of	O
loss	O
of	O
function	O
of	O
SCN5A	O
caused	O
by	O
VCL	O
-	O
D841H	O
under	O
acidosis	B-DISO
supports	O
that	O
nocturnal	O
sleep	O
respiratory	B-DISO
disorders	I-DISO
with	O
acidosis	B-DISO
may	O
play	O
a	O
key	O
role	O
in	O
the	O
pathogenesis	B-DISO
of	O
SUNDS	B-DISO
.	O

During	O
the	O
pandemic	O
,	O
different	O
sanitary	O
responses	O
were	O
documented	O
between	O
Europe	O
and	O
North	O
America	O
in	O
terms	O
of	O
vaccination	O
and	O
compliance	O
with	O
infection	B-DISO
prevention	O
and	O
control	O
measures	O
.	O

These	O
themes	O
fit	B-DISO
within	O
safety	O
cultures	O
described	O
by	O
participants	O
:	O
individual	O
culture	O
,	O
blame	O
culture	O
,	O
and	O
collaborative	O
culture	O
.	O

ABSTRACT	O
:	O
The	O
evolutionary	O
origins	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	B-DISO
)	O
coronavirus	O
(	O
MERS	B-DISO
-	O
CoV	O
)	O
are	O
unknown	O
.	O

ABSTRACT	O
:	O
Nosocomial	O
transmission	O
is	O
an	O
important	O
characteristic	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Advances	O
in	O
diagnostic	O
techniques	O
have	O
led	O
to	O
better	O
distinction	O
between	O
types	O
of	O
vasculitis	B-DISO
,	O
potentially	O
affecting	O
the	O
utility	O
of	O
the	O
1990	O
ACR	O
classification	O
criteria	O
for	O
vasculitis	B-DISO
.	O

Fulfilment	O
of	O
six	O
ACR	O
criteria	O
sets	O
and	O
their	O
diagnostic	O
performance	O
was	O
evaluated	O
in	O
patients	O
with	O
a	O
given	O
type	O
of	O
vasculitis	B-DISO
and	O
its	O
comparator	O
conditions	O
.	O

Since	O
publication	O
of	O
the	O
ACR	O
criteria	O
for	O
vasculitis	B-DISO
,	O
the	O
sensitivity	O
for	O
each	O
type	O
of	O
vasculitis	B-DISO
,	O
except	O
GCA	B-DISO
,	O
has	O
diminished	O
,	O
although	O
the	O
specificities	O
have	O
remained	O
high	O
,	O
highlighting	O
the	O
need	O
for	O
updated	O
classification	O
criteria	O
.	O

Because	O
of	O
its	O
heat	B-DISO
sensitivity	I-DISO
,	O
we	O
hypothesized	O
that	O
a	O
steam	O
conditioner	O
and	O
pellet	O
mill	O
mimicking	O
traditional	O
commercial	O
thermal	O
processing	O
may	O
mitigate	O
PEDV	O
infectivity	O
.	O

A	O
prominent	O
regulator	O
of	O
disease	O
outcome	O
,	O
especially	O
in	O
-	O
but	O
not	O
limited	O
to	O
-	O
respiratory	B-DISO
viral	I-DISO
infection	I-DISO
,	O
is	O
the	O
IFN	O
-	O
dependent	O
mediator	O
TRAIL	O
(	O
TNF	O
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	O
)	O
produced	O
by	O
several	O
cell	O
types	O
including	O
immune	O
cells	O
such	O
as	O
macrophages	O
or	O
T	O
cells	O
.	O

Interestingly	O
,	O
the	O
lack	O
of	O
a	O
strictly	O
controlled	O
and	O
well	O
balanced	O
IFN	O
/	O
TRAIL	O
signaling	O
response	O
has	O
not	O
only	O
been	O
implicated	O
in	O
viral	B-DISO
infection	I-DISO
but	O
might	O
furthermore	O
be	O
an	O
important	O
determinant	O
of	O
disease	B-DISO
progression	I-DISO
in	O
bacterial	O
superinfections	B-DISO
and	O
in	O
chronic	O
respiratory	O
illness	O
.	O

ABSTRACT	O
:	O
The	O
transmission	O
routes	O
and	O
risk	O
factors	O
for	O
zoonotic	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infections	B-DISO
are	O
still	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
BRCoV	O
strain	O
(	O
BR	O
-	O
UEL11	O
)	O
derived	O
from	O
an	O
outbreak	O
of	O
respiratory	B-DISO
disease	I-DISO
in	O
feedlot	O
cattle	O
in	O
southern	O
Brazil	O
,	O
and	O
compared	O
the	O
partial	O
sequence	O
of	O
the	O
polymorphic	O
region	O
of	O
Spike	O
(	O
which	O
was	O
detected	O
and	O
sequenced	O
by	O
two	O
distinct	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reactions	O
)	O
with	O
those	O
of	O
other	O
BCoV	O
strains	O
.	O

The	O
phylogenetic	O
relationship	O
of	O
BR	O
-	O
UEL11	O
with	O
Brazilian	O
BCoV	O
,	O
which	O
is	O
associated	O
with	O
calf	O
diarrhea	B-DISO
and	O
winter	B-DISO
dysentery	I-DISO
(	O
enteric	O
,	O
BECoV	O
;	O
respiratory	O
,	O
BRCoV	O
),	O
and	O
classical	O
reference	O
prototypes	O
was	O
analyzed	O
.	O

The	O
analysis	O
showed	O
that	O
the	O
BRCoV	O
strains	O
from	O
Brazil	O
clustered	O
with	O
a	O
clade	O
that	O
was	O
distinct	O
from	O
most	O
isolates	O
associated	O
with	O
calf	O
diarrhea	B-DISO
(	O
BECoV	O
)	O
and	O
ancestral	O
prototype	O
strains	O
such	O
as	O
Mebus	O
,	O
Nebraska	O
,	O
and	O
LYVB	O
.	O

This	O
study	O
provides	O
an	O
insight	O
on	O
the	O
various	O
immune	O
mediators	O
detected	O
in	O
FCoV	O
-	O
positive	O
cats	O
which	O
may	O
be	O
responsible	O
for	O
the	O
development	O
of	O
FIP	B-DISO
.	O

AstVs	O
(	O
12	O
.	O
83	O
%),	O
CoVs	O
(	O
3	O
.	O
97	O
%),	O
PMV	B-DISO
(	O
2	O
.	O
4	O
%),	O
ADV	O
(	O
2	O
.	O
26	O
%),	O
PYV	O
(	O
1	O
.	O
65	O
%),	O
CalVs	O
(	O
0	O
.	O
29	O
%),	O
rotavirus	O
(	O
0	O
.	O
19	O
%)	O
and	O
flavivirus	O
(	O
0	O
.	O
19	O
%).	O

TITLE	O
:	O
Offering	O
patients	O
more	O
:	O
how	O
the	O
West	O
Africa	O
Ebola	O
outbreak	O
can	O
shape	O
innovation	O
in	O
therapeutic	O
research	O
for	O
emerging	O
and	O
epidemic	O
infections	B-DISO
.	O

Therefore	O
,	O
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
frequency	O
of	O
thoracic	B-DISO
trauma	O
and	O
ARDS	B-DISO
in	O
polytraumatized	O
patients	O
,	O
and	O
to	O
evaluate	O
the	O
impact	O
of	O
thoracic	B-DISO
trauma	O
on	O
the	O
occurrence	O
and	O
the	O
onset	O
of	O
ARDS	B-DISO
.	O

Independent	O
of	O
the	O
ISS	B-DISO
,	O
the	O
presence	O
of	O
thoracic	B-DISO
trauma	O
increased	O
the	O
odds	O
of	O
ARDS	B-DISO
occurrence	O
(	O
OR	O
=	O
2	O
.	O
242	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
381	O
-	O
3	O
.	O
640	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
resulted	O
in	O
a	O
significantly	O
earlier	O
onset	O
of	O
ARDS	B-DISO
(	O
median	O
,	O
day	O
2	O
vs	O
.	O
day	O
3	O
;	O
P	O
<	O
0	O
.	O
01	O
).	O

Finally	O
,	O
an	O
overall	O
mortality	O
rate	O
of	O
21	O
.	O
2	O
%	O
was	O
observed	O
,	O
which	O
was	O
neither	O
affected	O
by	O
thoracic	B-DISO
trauma	O
nor	O
ARDS	B-DISO
.	O

A	O
total	O
of	O
343	O
clinical	O
specimens	O
as	O
well	O
as	O
29	O
external	O
quality	O
assessment	O
(	O
EQA	O
)	O
specimens	O
and	O
2	O
different	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
isolates	O
have	O
been	O
assessed	O
in	O
this	O
study	O
.	O

After	O
infection	B-DISO
with	O
SARS	B-DISO
-	O
CoV	O
,	O
the	O
acute	O
lung	O
injury	O
caused	O
by	O
the	O
virus	O
must	O
be	O
repaired	O
to	O
regain	O
lung	O
function	O
.	O

Importantly	O
,	O
we	O
show	O
that	O
during	O
infection	B-DISO
,	O
the	O
EGFR	O
ligands	O
amphiregulin	O
and	O
heparin	O
-	O
binding	O
EGF	O
-	O
like	O
growth	O
factor	O
(	O
HB	O
-	O
EGF	O
)	O
are	O
upregulated	O
,	O
and	O
exogenous	O
addition	O
of	O
these	O
ligands	O
during	O
infection	B-DISO
leads	O
to	O
enhanced	O
lung	B-DISO
disease	I-DISO
and	O
altered	O
wound	O
healing	O
dynamics	O
.	O

TITLE	O
:	O
Three	O
Hypothetical	O
Inflammation	B-DISO
Pathobiology	O
Phenotypes	O
and	O
Pediatric	O
Sepsis	B-DISO
-	O
Induced	O
Multiple	B-DISO
Organ	I-DISO
Failure	I-DISO
Outcome	O
.	O

Discouraging	O
survival	O
rates	O
in	O
patients	O
treated	O
early	O
after	O
allogeneic	O
hematopoietic	O
stem	O
cell	O
transplantation	O
do	O
not	O
support	O
the	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
this	O
group	O
.	O

Overall	O
yearly	O
incidence	O
of	O
infectious	B-DISO
disease	I-DISO
was	O
higher	O
among	O
males	O
than	O
females	O
and	O
was	O
highest	O
among	O
children	O
younger	O
than	O
10	O
years	O
.	O

TITLE	O
:	O
SARS	B-DISO
coronavirus	O
papain	O
-	O
like	O
protease	O
up	O
-	O
regulates	O
the	O
collagen	O
expression	O
through	O
non	O
-	O
Samd	O
TGF	O
-	O
β1	O
signaling	O
.	O

Specific	O
inhibitors	O
for	O
TGF	O
-	O
βRI	O
,	O
p38	O
MAPK	O
,	O
MEK	O
,	O
and	O
STAT3	O
proved	O
that	O
SARS	B-DISO
-	O
CoV	O
PLpro	O
induced	O
TGF	O
-	O
β1	O
-	O
dependent	O
up	O
-	O
regulation	O
of	O
Type	O
I	O
collagen	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Comprehensive	O
analysis	O
of	O
ubiquitin	O
-	O
conjugated	O
proteins	O
using	O
immunoprecipitation	O
and	O
nanoLC	O
-	O
MS	O
/	O
MS	O
indicated	O
that	O
SARS	B-DISO
-	O
CoV	O
PLpro	O
caused	O
the	O
change	O
in	O
the	O
ubiquitination	O
profile	O
of	O
Rho	O
GTPase	O
family	O
proteins	O
,	O
in	O
which	O
linked	O
with	O
the	O
increase	O
of	O
Rho	O
-	O
like	O
GTPase	O
family	O
proteins	O
.	O

After	O
the	O
SARS	B-DISO
outbreak	O
,	O
Taiwan	O
'	O
s	O
Centers	O
for	O
Disease	O
Control	O
(	O
Taiwan	O
CDC	O
)	O
followed	O
the	O
WHO	O
outbreak	O
communication	O
guidelines	O
on	O
trust	O
,	O
early	O
announcements	O
,	O
transparency	O
,	O
informing	O
the	O
public	O
,	O
and	O
planning	O
,	O
in	O
order	O
to	O
reform	O
its	O
risk	O
communication	O
systems	O
.	O

Furthermore	O
,	O
the	O
potential	O
emergence	O
of	O
highly	O
pathogenic	O
strains	O
of	O
influenza	B-DISO
virus	O
poses	O
a	O
significant	O
public	O
health	O
threat	O
.	O

TITLE	O
:	O
C	O
-	O
C	O
Motif	O
Chemokine	O
Ligand	O
2	O
(	O
CCL2	O
)	O
Mediates	O
Acute	O
Lung	O
Injury	O
Induced	O
by	O
Lethal	O
Influenza	B-DISO
H7N9	O
Virus	O
.	O

IL	O
-	O
6KO	O
In	O
a	O
double	O
-	O
hit	O
murine	O
model	O
of	O
ARDS	B-DISO
,	O
IL	O
-	O
6	O
deficient	O
mice	O
experienced	O
more	O
severe	O
bronchoalveolar	O
cellular	O
inflammation	B-DISO
as	O
compared	O
to	O
wild	O
-	O
type	O
littermates	O
.	O

TITLE	O
:	O
Kaposi	B-DISO
Sarcoma	I-DISO
Inflammatory	O
Cytokine	O
Syndrome	B-DISO
(	O
KICS	O
):	O
A	O
Rare	O
but	O
Potentially	O
Treatable	O
Condition	B-DISO
.	O

We	O
analyzed	O
40	O
clinical	O
specimens	O
from	O
hospitalized	O
children	O
diagnosed	O
with	O
acute	B-DISO
bronchiolitis	I-DISO
,	O
croup	B-DISO
,	O
or	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
in	O
which	O
virus	O
identification	O
by	O
viral	O
culture	O
or	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
was	O
unsuccessful	O
.	O

Two	O
dominant	O
populations	O
within	O
the	O
detected	O
viruses	O
were	O
human	O
rhinoviruses	O
(	O
HRVs	O
;	O
n	O
=	O
14	O
)	O
and	O
human	O
coronavirus	O
NL63	O
(	O
n	O
=	O
8	O
),	O
followed	O
by	O
human	O
parainfluenza	B-DISO
virus	O
(	O
HPIV	O
),	O
human	O
parechovirus	O
,	O
influenza	B-DISO
A	O
virus	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
and	O
human	O
metapneumovirus	O
.	O

TITLE	O
:	O
Cross	O
-	O
sectional	O
quantitative	O
RT	O
-	O
PCR	O
study	O
of	O
feline	O
coronavirus	O
viremia	B-DISO
and	O
replication	O
in	O
peripheral	O
blood	O
of	O
healthy	O
shelter	O
cats	O
in	O
Southern	O
California	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
determine	O
the	O
prevalence	O
of	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
viremia	B-DISO
,	O
and	O
its	O
replication	O
in	O
peripheral	O
blood	O
using	O
quantitative	O
RT	O
-	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
methodology	O
in	O
a	O
population	O
of	O
205	O
healthy	O
shelter	O
cats	O
in	O
Southern	O
California	O
,	O
as	O
well	O
as	O
to	O
assess	O
any	O
possible	O
connection	O
to	O
longitudinal	O
development	O
of	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
).	O

ABSTRACT	O
:	O
The	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
typically	O
manifested	O
by	O
refractory	O
hypoxemia	O
with	O
high	O
mortality	O
.	O

A	O
constellation	O
of	O
physical	O
and	O
psychological	B-DISO
problems	O
can	O
develop	O
or	O
persist	O
for	O
up	O
to	O
5	O
years	O
in	O
patients	O
with	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
encode	O
multifunctional	O
papain	O
-	O
like	O
proteases	O
(	O
PLPs	O
)	O
that	O
have	O
the	O
ability	O
to	O
process	O
the	O
viral	O
polyprotein	O
to	O
facilitate	O
RNA	O
replication	O
and	O
antagonize	O
the	O
host	O
innate	B-DISO
immune	I-DISO
response	I-DISO
.	O

Sixty	O
-	O
two	O
percent	O
of	O
the	O
patients	O
(	O
n	O
=	O
62	O
)	O
had	O
chronic	B-DISO
diseases	I-DISO
.	O

Seven	O
patients	O
were	O
transferred	O
to	O
the	O
intensive	O
care	O
unit	O
with	O
diagnoses	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
n	O
=	O
4	O
),	O
encephalitis	B-DISO
(	O
n	O
=	O
2	O
),	O
and	O
bronchiolitis	B-DISO
(	O
n	O
=	O
1	O
).	O

Influenza	B-DISO
A	O
/	O
H1N1	O
infection	B-DISO
represented	O
more	O
severe	O
clinical	O
disease	O
.	O

ABSTRACT	O
:	O
GATA2	O
mutations	O
have	O
been	O
identified	O
in	O
various	O
diseases	O
,	O
such	O
as	O
MonoMAC	B-DISO
syndrome	B-DISO
,	O
Emberger	B-DISO
syndrome	I-DISO
,	O
familial	O
myelodysplastic	B-DISO
syndrome	I-DISO
,	O
acute	B-DISO
myeloid	I-DISO
leukaemia	I-DISO
and	O
dendritic	O
cell	O
,	O
monocyte	O
,	O
B	O
-	O
cell	O
and	O
natural	O
killer	O
-	O
cell	O
deficiency	O
.	O

We	O
report	O
three	O
patients	O
presenting	O
with	O
common	O
dermatological	O
and	O
haematological	O
features	O
leading	O
to	O
the	O
diagnosis	O
of	O
GATA2	O
deficiency	O
,	O
but	O
also	O
with	O
skin	B-DISO
manifestations	I-DISO
that	O
have	O
not	O
been	O
previously	O
described	O
:	O
gingival	B-DISO
hypertrophy	I-DISO
,	O
macroglossitis	O
and	O
glossitis	B-DISO
and	O
granulomatous	O
lupoid	O
facial	O
lesions	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
is	O
characterized	O
by	O
diffuse	O
inflammatory	O
lung	O
injury	O
and	O
is	O
classified	O
as	O
mild	O
,	O
moderate	O
,	O
and	O
severe	O
.	O

We	O
present	O
a	O
case	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
after	O
accidental	O
inhalation	O
of	O
chlorine	O
in	O
a	O
swimming	O
pool	O
,	O
with	O
noninvasive	O
ventilation	O
used	O
as	O
a	O
treatment	O
with	O
good	O
response	O
in	O
this	O
case	O
.	O

There	O
are	O
no	O
longitudinal	O
data	O
on	O
the	O
changes	O
in	O
hematologic	O
,	O
hepatic	O
,	O
and	O
renal	O
function	O
findings	O
in	O
patients	O
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
.	O

Lymphopenia	B-DISO
was	O
a	O
prominent	O
feature	O
with	O
a	O
rate	O
of	O
44	O
%	O
(	O
7	O
/	O
16	O
)	O
of	O
the	O
patients	O
on	O
day	O
1	O
and	O
60	O
%	O
(	O
3	O
/	O
5	O
)	O
on	O
day	O
21	O
.	O

Lymphocytosis	B-DISO
was	O
not	O
a	O
feature	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
is	O
a	O
porcine	O
enteric	O
coronavirus	O
which	O
causes	O
lethal	O
severe	O
watery	B-DISO
diarrhea	I-DISO
in	O
piglets	O
.	O

TITLE	O
:	O
Characteristics	O
and	O
provision	O
of	O
care	O
of	O
patients	O
with	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
descriptive	O
findings	O
from	O
the	O
DACAPO	O
cohort	O
baseline	O
and	O
comparison	O
with	O
international	O
findings	O
.	O

Additionally	O
,	O
characteristics	O
of	O
other	O
large	O
ARDS	B-DISO
cohorts	O
identified	O
by	O
a	O
systematic	O
literature	O
search	O
were	O
extracted	O
into	O
evidence	O
tables	O
.	O

Other	O
ARDS	B-DISO
cohorts	O
revealed	O
a	O
high	O
heterogeneity	O
in	O
reported	O
concomitant	O
diseases	O
,	O
but	O
sepsis	B-DISO
and	O
pneumonia	B-DISO
were	O
most	O
frequently	O
reported	O
.	O

Zika	O
virus	O
(	O
ZIKV	O
),	O
Ebola	O
virus	O
(	O
EBOV	O
),	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
as	O
(	O
re	O
-)	O
emerging	O
viral	O
pathogens	O
and	O
other	O
enveloped	O
viruses	O
could	O
be	O
efficiently	O
inactivated	O
by	O
both	O
WHO	O
formulations	O
,	O
implicating	O
their	O
use	O
in	O
healthcare	O
systems	O
and	O
viral	O
outbreak	O
situations	O
.	O

TITLE	O
:	O
Meningococcal	B-DISO
disease	I-DISO
in	O
the	O
Middle	O
East	O
and	O
Africa	O
:	O
Findings	O
and	O
updates	O
from	O
the	O
Global	O
Meningococcal	O
Initiative	O
.	O

Differences	O
exist	O
between	O
Middle	O
Eastern	O
and	O
African	O
countries	O
regarding	O
case	O
and	O
syndrome	B-DISO
definitions	O
,	O
surveillance	O
,	O
and	O
epidemiologic	O
data	O
gaps	O
.	O

A	O
panel	O
of	O
characterization	O
tests	O
indicated	O
that	O
the	O
process	O
is	O
reproducible	O
and	O
that	O
the	O
purified	O
,	O
tag	B-DISO
-	O
free	O
RBD219	O
-	O
N1	O
protein	O
has	O
high	O
purity	O
and	O
a	O
well	O
-	O
defined	O
structure	O
and	O
is	O
therefore	O
a	O
suitable	O
candidate	O
for	O
production	O
under	O
current	O
Good	O
Manufacturing	O
Practice	O
and	O
future	O
phase	O
-	O
1	O
clinical	O
trials	O
.	O

TITLE	O
:	O
An	O
Official	O
American	O
Thoracic	B-DISO
Society	O
/	O
European	O
Society	O
of	O
Intensive	O
Care	O
Medicine	O
/	O
Society	O
of	O
Critical	O
Care	O
Medicine	O
Clinical	O
Practice	O
Guideline	O
:	O
Mechanical	O
Ventilation	O
in	O
Adult	O
Patients	O
with	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
.	O

RESULTS	O
:	O
For	O
all	O
patients	O
with	O
ARDS	B-DISO
,	O
the	O
recommendation	O
is	O
strong	O
for	O
mechanical	O
ventilation	O
using	O
lower	O
tidal	O
volumes	O
(	O
4	O
-	O
8	O
ml	O
/	O
kg	O
predicted	O
body	O
weight	O
)	O
and	O
lower	O
inspiratory	O
pressures	O
(	O
plateau	O
pressure	O
<	O
30	O
cm	O
H	O

APACHE	O
II	O
score	O
and	O
serum	O
PCT	B-DISO
in	O
non	O
-	O
survival	O
group	O
(	O
n	O
=	O
38	O
)	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
the	O
survival	O
group	O
[	O
n	O
=	O
51	O
;	O
APACHE	O
II	O
score	O
:	O
26	O
.	O
00	O
(	O
23	O
.	O
00	O
,	O
28	O
.	O
50	O
)	O
vs	O
.	O
21	O
.	O
00	O
(	O
17	O
.	O
00	O
,	O
25	O
.	O
00	O
),	O
PCT	B-DISO
(	O
μg	O
/	O
L	O
):	O
6	O
.	O
38	O
(	O
2	O
.	O
82	O
,	O
9	O
.	O
49	O
)	O
vs	O
.	O
3	O
.	O
09	O
(	O
1	O
.	O
08	O
,	O
3	O
.	O
57	O
),	O
both	O
P	O
<	O
0	O
.	O
01	O
],	O
but	O
Murray	O
score	O
and	O
CRP	O
level	O
were	O
similar	O
between	O
survivors	O
and	O
non	O
-	O
survivors	O
.	O

In	O
vitro	O
,	O
both	O
pharmacological	O
inhibitors	O
(	O
AG1478	O
and	O
451	O
)	O
and	O
si	O
-	O
RNA	O
silencing	O
of	O
EGFR	O
significantly	O
inhibited	O
LPS	B-DISO
-	O
induced	O
EGFR	O
signaling	O
activation	O
and	O
inflammatory	B-DISO
response	I-DISO
in	O
human	O
lung	O
epithelial	O
cells	O
or	O
macrophages	O
.	O

In	O
a	O
cohort	O
of	O
82	O
VV	O
-	O
ECMO	O
patients	O
(	O
PRedicting	O
dEath	O
for	O
SEvere	O
ARDS	B-DISO
on	O
VV	O
-	O
ECMO	O
[	O
PRESERVE	O
]	O
score	O
:	O
4	O
,	O
Interquartile	O
range	O
[	O
IQR	O
]:	O
3	O
-	O
5	O
,	O
Respiratory	O
Extracorporeal	O
Membrane	O
Oxygenation	O
Survival	O
Prediction	O
[	O
RESP	O
]	O
score	O
:	O
2	O
,	O
IQR	O
:	O
2	O
-	O
4	O
),	O
76	O
(	O
92	O
.	O
7	O
%)	O
patients	O
received	O
at	O
least	O
1	O
unit	O
of	O
packed	O
red	O
blood	O
cells	O
(	O
PRBCs	O
)	O
during	O
the	O
intensive	O
care	O
unit	O
stay	O
related	O
to	O
ECMO	O
(	O
median	O
PRBC	O
/	O
d	O
156	O
mL	O
,	O
IQR	O
:	O
93	O
-	O
218	O
;	O
median	O
ECMO	O
duration	O
14	O
days	O
,	O
IQR	O
:	O
8	O
-	O
22	O
).	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
has	O
two	O
genotypes	O
,	O
G1	O
and	O
G2	O
.	O

TITLE	O
:	O
Pulmonary	O
strongyloidiasis	B-DISO
:	O
assessment	O
between	O
manifestation	O
and	O
radiological	O
findings	O
in	O
16	O
severe	O
strongyloidiasis	B-DISO
cases	O
.	O

Severe	O
cases	O
such	O
as	O
,	O
hyperinfection	O
syndrome	B-DISO
(	O
HS	O
)	O
and	O
disseminated	B-DISO
strongyloidiasis	I-DISO
(	O
DS	O
),	O
can	O
involve	O
pulmonary	O
manifestations	O
.	O

Sixteen	O
severe	O
strongyloidiasis	B-DISO
cases	O
were	O
included	O
.	O

RESULTS	O
:	O
Bivariate	O
logistic	O
analysis	O
showed	O
that	O
mortality	O
and	O
worse	O
outcomes	O
were	O
correlated	O
with	O
FFP	O
transfusion	O
and	O
Glasgow	O
Coma	B-DISO
Scale	O
score	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Pathogenic	O
human	O
coronavirus	B-DISO
infections	I-DISO
:	O
causes	O
and	O
consequences	O
of	O
cytokine	B-DISO
storm	I-DISO
and	O
immunopathology	B-DISO
.	O

TITLE	O
:	O
Characterization	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
infectivity	O
in	O
human	O
embryonic	O
kidney	O
cells	O
.	O

However	O
,	O
since	O
the	O
production	O
of	O
interferon	O
in	O
these	O
cells	O
is	O
defective	O
,	O
Vero	O
cells	O
are	O
not	O
the	O
ideal	O
cell	O
type	O
to	O
study	O
the	O
molecular	O
mechanisms	O
of	O
PEDV	O
infection	B-DISO
and	O
the	O
host	O
antiviral	O
innate	B-DISO
immune	I-DISO
response	I-DISO
.	O

RESULTS	O
:	O
The	O
overall	O
positivity	O
for	O
viruses	O
in	O
the	O
study	O
was	O
found	O
to	O
be	O
72	O
.	O
9	O
per	O
cent	O
with	O
a	O
co	B-DISO
-	I-DISO
infection	I-DISO
rate	O
of	O
19	O
.	O
5	O
per	O
cent	O
.	O

Moreover	O
,	O
following	O
stimulation	O
with	O
LPS	B-DISO
,	O
p47phox	O
was	O
expressed	O
at	O
lower	O
levels	O
in	O
miR	O
-	O
19	O
-	O
deficient	O
murine	O
pulmonary	O
inflammatory	O
cells	O
than	O
in	O
those	O
in	O
wild	O
-	O
type	O
rats	O
.	O

In	O
LPS	B-DISO
-	O
treated	O
Raw264	O
.	O
7	O
macrophages	O
,	O
miR	O
-	O
19	O
mimics	O
blocking	B-DISO
the	O
down	O
-	O
regulation	O
of	O
LPS	B-DISO
-	O
induced	O
p47phox	O
expression	O
,	O
the	O
accumulation	O
of	O
ROS	O
,	O
and	O
the	O
release	O
of	O
inflammatory	O
cytokines	O
.	O

Thus	O
,	O
NIV	O
may	O
lower	O
the	O
risk	O
of	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
after	O
bariatric	O
surgery	O
.	O

We	O
present	O
two	O
cases	O
highlighting	O
the	O
diagnostic	O
and	O
clinical	O
challenges	O
of	O
BMP	O
infarction	B-DISO
.	O

Initial	O
examination	O
findings	O
included	O
bulbar	B-DISO
weakness	I-DISO
,	O
dysphagia	B-DISO
,	O
hyporeflexia	O
,	O
and	O
generalized	B-DISO
weakness	I-DISO
.	O

Acute	O
BMP	O
infarction	B-DISO
may	O
present	O
with	O
flaccid	B-DISO
tetraplegia	I-DISO
mimicking	O
neuromuscular	B-DISO
disorders	I-DISO
.	O

When	O
the	O
infarction	B-DISO
is	O
recognized	O
early	O
,	O
intravenous	O
thrombolysis	O
can	O
be	O
considered	O
to	O
reduce	O
morbidity	O
of	O
this	O
rare	O
stroke	B-DISO
subtype	O
.	O

She	O
required	O
tracheostomy	O
and	O
percutaneous	O
gastrostomy	B-DISO
tube	O
placement	O
,	O
with	O
no	O
paralysis	O
resolution	O
.	O

Of	O
the	O
severe	O
ARDS	B-DISO
survivors	O
enrolled	O
,	O
1	O
-	O
year	O
postdischarge	O
,	O
HRQoL	O
assessment	O
using	O
the	O
Short	O
-	O
Form	O
36	O
(	O
SF	O
-	O
36	O
)	O
and	O
EuroQol	O
questionnaire	O
dimensions	O
,	O
6	O
-	O
min	O
walking	O
distance	O
,	O
chest	O
computed	O
tomography	O
scan	O
,	O
pulmonary	O
function	O
,	O
and	O
arterial	O
blood	O
gas	O
analysis	O
were	O
compared	O
for	O
ARDS	B-DISO
patients	O
with	O
or	O
without	O
ECMO	O
.	O

ARDS	B-DISO
patients	O
receiving	O
ECMO	O
had	O
a	O
significantly	O
higher	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
score	O
(	O
30	O
.	O
3	O
±	O
6	O
.	O
7	O
vs	O
.	O
26	O
.	O
5	O
±	O
7	O
.	O
3	O
,	O
P	O
=	O
0	O
.	O
036	O
),	O
lung	O
injury	O
score	O
(	O
3	O
.	O
3	O
±	O
0	O
.	O
4	O
vs	O
.	O
2	O
.	O
8	O
±	O
0	O
.	O
5	O
,	O
P	O
=	O
0	O
.	O
000	O
),	O
Sequential	O
Organ	B-DISO
Failure	I-DISO
Assessment	O
score	O
(	O
10	O
.	O
8	O
±	O
3	O
.	O
5	O
vs	O
.	O
7	O
.	O
9	O
±	O
3	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
000	O
),	O
lower	O
PaO2	O
/	O
FiO2ratio	O
([	O
mmHg	O
,	O
1	O
mmHg	O
=	O
0	O
.	O
133	O
kPa	O
],	O
68	O
.	O
3	O
±	O
16	O
.	O
1	O
vs	O
.	O
84	O
.	O
8	O
±	O
16	O
.	O
5	O
,	O
P	O
=	O
0	O
.	O
000	O
),	O
and	O
increased	O
extrapulmonary	O
organ	B-DISO
failure	I-DISO
(	O
2	O
[	O
1	O
,	O
3	O
]	O
vs	O
.	O
1	O
[	O
1	O
,	O
1	O
],	O
P	O
=	O
0	O
.	O
025	O
)	O
compared	O
with	O
patients	O
not	O
receiving	O
ECMO	O
.	O

One	O
-	O
year	O
posthospital	O
discharge	O
,	O
severe	O
ARDS	B-DISO
survivors	O
receiving	O
ECMO	O
or	O
MV	O
demonstrated	O
comparable	O
outcomes	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
developed	O
a	O
novel	O
porcine	O
model	O
of	O
septic	B-DISO
shock	I-DISO
induced	O
by	O
ARDS	B-DISO
due	O
to	O
severe	O
MRSA	B-DISO
pneumonia	I-DISO
with	O
characteristic	O
hyperdynamic	O
and	O
hypodynamic	O
phases	O
in	O
24	O
h	O
,	O
which	O
mimicked	O
the	O
hemodynamic	O
changing	O
of	O
septic	B-DISO
shock	I-DISO
in	O
human	O
.	O

ABSTRACT	O
:	O
Anastomotic	B-DISO
leak	I-DISO
was	O
a	O
potentially	O
severe	O
life	O
-	O
threatening	O
complication	B-DISO
of	O
esophagectomy	O
,	O
which	O
drew	O
attention	O
in	O
consequence	O
of	O
progressive	O
dyspnea	B-DISO
until	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
due	O
to	O
the	O
early	O
asymptomatic	O
presentation	O
.	O

Respiratory	B-DISO
failure	I-DISO
,	O
caused	O
by	O
ARDS	B-DISO
as	O
the	O
severe	O
presentation	O
of	O
anastomotic	B-DISO
leak	I-DISO
,	O
is	O
the	O
most	O
common	O
organ	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Specific	O
detection	O
of	O
GII	O
-	O
1	O
lineage	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

The	O
assay	O
was	O
proven	O
to	O
be	O
a	O
valuable	O
tool	O
for	O
rapid	O
diagnosis	O
of	O
GII	O
-	O
1	O
lineage	O
of	O
IBV	O
strains	O
and	O
moreover	O
it	O
enabled	O
the	O
monitoring	O
of	O
viral	O
loads	O
which	O
can	O
be	O
used	O
to	O
assess	O
disease	B-DISO
progression	I-DISO
.	O

Moreover	O
,	O
this	O
new	O
assay	O
enables	O
the	O
assessment	O
of	O
viral	O
load	O
measurement	O
which	O
might	O
be	O
useful	O
for	O
epidemiology	O
and	O
pathogenesis	B-DISO
studies	O
.	O

The	O
study	O
included	O
26	O
cats	O
with	O
immunohistochemically	O
confirmed	O
FIP	B-DISO
and	O
12	O
control	O
cats	O
for	O
which	O
FIP	B-DISO
was	O
suspected	O
due	O
to	O
similar	O
clinical	O
or	O
laboratory	O
changes	O
,	O
but	O
which	O
suffered	B-DISO
from	O
other	O
diseases	O
confirmed	O
via	O
histopathology	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
an	O
increase	O
in	O
FGL2	O
is	O
diagnostic	O
of	O
FH	O
and	O
liver	B-DISO
necrosis	I-DISO
,	O
and	O
animals	O
with	O
no	O
FGL2	O
had	O
better	O
survivorship	O
during	O
FH	O
.	O

Using	O
a	O
viral	O
encephalomyelitis	B-DISO
model	O
we	O
developed	O
a	O
modified	O
limiting	O
dilution	O
in	O
vitro	O
stimulation	O
assay	O
to	O
convert	O
CNS	O
-	O
derived	O
virus	O
specific	O
Bmem	O
into	O
ASC	O
.	O

TITLE	O
:	O
Intrapulmonary	O
Percussive	O
Ventilation	O
as	O
an	O
Airway	O
Clearance	O
Technique	O
during	O
Venoarterial	O
Extracorporeal	O
Life	O
Support	O
in	O
an	O
Infant	O
with	O
Pertussis	B-DISO
.	O

We	O
present	O
a	O
case	O
of	O
a	O
4	O
-	O
week	O
old	O
infant	O
who	O
developed	O
a	O
severe	O
pertussis	B-DISO
infection	B-DISO
requiring	O
ECLS	O
.	O

In	O
addition	O
to	O
lung	O
protection	O
ventilator	O
strategies	O
and	O
bronchoscopy	O
,	O
intrapulmonary	O
percussive	O
ventilation	O
was	O
initiated	O
to	O
facilitate	O
lung	O
recruitment	B-DISO
.	O

The	O
identification	O
of	O
risk	O
factors	O
for	O
increased	O
viral	B-DISO
shedding	I-DISO
that	O
may	O
potentially	O
result	O
in	O
increased	O
interspecies	O
transmission	O
is	O
important	O
to	O
prevent	O
viral	O
spillovers	O
from	O
bats	O
to	O
other	O
animals	O
,	O
including	O
humans	O
.	O

ABSTRACT	O
:	O
Veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
for	O
refractory	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
rapidly	O
expanding	O
technique	O
.	O

Twelve	O
studies	O
fulfilled	O
inclusion	O
criteria	O
,	O
representing	O
a	O
population	O
of	O
1042	O
patients	O
with	O
refractory	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
is	O
a	O
rare	O
acute	O
polyradiculoneuropathy	B-DISO
.	O

ABSTRACT	O
:	O
Ten	O
and	O
seven	O
years	O
ago	O
respectively	O
,	O
the	O
two	O
high	O
-	O
isolation	O
units	O
in	O
Denmark	O
became	O
prepared	O
to	O
receive	O
highly	O
contagious	O
and	O
potential	O
severely	O
ill	B-DISO
patients	O
.	O

Accumulated	O
evidence	O
indicates	O
that	O
this	O
large	O
-	O
scale	O
outbreak	O
of	O
diarrhea	B-DISO
was	O
caused	O
by	O
variants	O
of	O
the	O
highly	O
virulent	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
).	O

Expression	O
of	O
GPC3	O
leads	O
to	O
an	O
increased	O
apoptosis	O
response	O
in	O
human	O
lung	B-DISO
carcinoma	I-DISO
tumor	B-DISO
cells	O
,	O
and	O
is	O
considered	O
to	O
be	O
a	O
candidate	O
lung	B-DISO
tumor	I-DISO
suppressor	O
gene	O
.	O

Increased	O
serum	O
levels	O
of	O
GPC3	O
have	O
been	O
demonstrated	O
in	O
ARDS	B-DISO
patients	O
with	O
severe	O
pneumonia	B-DISO
.	O

Patients	O
were	O
inspected	O
for	O
the	O
presence	O
of	O
PPP	B-DISO
,	O
localization	O
,	O
and	O
association	O
with	O
human	O
papilloma	B-DISO
virus	O
(	O
HPV	O
).	O

ABSTRACT	O
:	O
Porcine	O
hemagglutinating	O
encephalomyelitis	B-DISO
virus	O
(	O
PHEV	O
)	O
invades	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
and	O
causes	O
neurodegenerative	B-DISO
disease	I-DISO
in	O
suckling	O
piglets	O
,	O
but	O
the	O
understanding	O
of	O
its	O
neuropathogenicity	O
for	O
neurological	O
dysfunction	O
remains	O
limited	O
.	O

Here	O
,	O
we	O
report	O
that	O
miR	O
-	O
142	O
-	O
5p	O
is	O
localized	O
to	O
neurons	O
and	O
negatively	O
regulates	O
neuronal	O
morphogenesis	O
in	O
porcine	O
hemagglutinating	O
encephalomyelitis	B-DISO
(	O
PHE	O
).	O

TITLE	O
:	O
Respiratory	O
viral	B-DISO
infections	I-DISO
are	O
underdiagnosed	O
in	O
patients	O
with	O
suspected	O
sepsis	B-DISO
.	O

Epithelial	O
cell	O
cultures	O
were	O
induced	O
to	O
express	O
LIF	O
by	O
bacteria	O
and	O
by	O
sterile	B-DISO
bronchoalveolar	O
lavage	O
fluid	O
from	O
pneumonic	O
mice	O
.	O

TITLE	O
:	O
TMPRSS2	O
and	O
MSPL	O
Facilitate	O
Trypsin	O
-	O
Independent	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
Replication	O
in	O
Vero	O
Cells	O
.	O

ABSTRACT	O
:	O
Type	O
II	O
transmembrane	O
serine	O
proteases	O
(	O
TTSPs	O
)	O
facilitate	O
the	O
spread	O
and	O
replication	O
of	O
viruses	O
such	O
as	O
influenza	B-DISO
and	O
human	O
coronaviruses	O
,	O
although	O
it	O
remains	O
unclear	O
whether	O
TTSPs	O
play	O
a	O
role	O
in	O
the	O
progression	O
of	O
animal	O
coronavirus	B-DISO
infections	I-DISO
,	O
such	O
as	O
that	O
by	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
).	O

We	O
did	O
a	O
double	O
-	O
blind	B-DISO
,	O
allocation	O
concealed	O
,	O
randomised	O
,	O
placebo	O
-	O
controlled	O
phase	O
2	O
trial	O
in	O
two	O
intensive	O
care	O
units	O
in	O
the	O
UK	O
,	O
involving	O
patients	O
fulfilling	O
the	O
American	O
-	O
European	O
Consensus	O
Conference	O
Definition	O
of	O
ARDS	B-DISO
.	O

KGF	O
did	O
not	O
improve	O
physiological	O
or	O
clinical	O
outcomes	O
in	O
ARDS	B-DISO
and	O
might	O
be	O
harmful	O
to	O
patient	O
health	O
.	O

Information	O
on	O
71	O
patients	O
at	O
>	O
25	O
weeks	O
gestation	O
in	O
the	O
ICU	O
with	O
respiratory	B-DISO
failure	I-DISO
was	O
recorded	O
between	O
2009	O
and	O
2013	O
.	O

RESULTS	O
:	O
The	O
leading	O
causes	O
of	O
respiratory	B-DISO
failure	I-DISO
were	O
postpartum	B-DISO
hemorrhage	I-DISO
and	O
severe	B-DISO
preeclampsia	I-DISO
in	O
the	O
obstetric	O
causes	O
group	O
and	O
pneumonia	B-DISO
in	O
the	O
nonobstetric	O
causes	O
group	O
during	O
pregnancy	O
and	O
the	O
peripartum	O
period	O
.	O

TITLE	O
:	O
Persistent	O
infections	B-DISO
support	O
maintenance	O
of	O
a	O
coronavirus	O
in	O
a	O
population	O
of	O
Australian	O
bats	O
(	O
Myotis	O
macropus	O
).	O

We	O
found	O
that	O
the	O
CMR	O
data	O
analysis	O
supported	O
grouping	O
of	O
infectious	B-DISO
bats	O
into	O
persistently	O
and	O
transiently	O
infectious	B-DISO
bats	O
.	O

These	O
findings	O
,	O
using	O
rare	O
CMR	O
data	O
from	O
longitudinal	O
samples	O
of	O
individual	O
bats	O
,	O
increase	O
our	O
understanding	O
of	O
transmission	O
dynamics	O
of	O
bat	O
viral	O
infectious	B-DISO
diseases	I-DISO
.	O

ABSTRACT	O
:	O
Reverse	O
transcriptase	O
(	O
RT	O
)-	O
associated	O
DNA	O
polymerase	O
(	O
RDDP	O
)	O
and	O
ribonucleaser	O
H	O
(	O
RNase	O
H	O
)	O
functions	O
are	O
both	O
essential	O
for	O
HIV	B-DISO
-	O
1	O
genome	O
replication	O
,	O
and	O
the	O
identification	O
of	O
new	O
inhibitors	O
to	O
block	O
both	O
of	O
them	O
is	O
a	O
goal	O
actively	O
pursued	O
by	O
the	O
scientific	O
community	O
.	O

Plasma	O
kallistatin	O
levels	O
on	O
day	O
1	O
of	O
ICU	O
admission	O
were	O
lower	O
in	O
patients	O
with	O
septic	B-DISO
shock	I-DISO
compared	O
with	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
(	O
p	O
=	O
0	O
.	O
004	O
).	O

Phosphine	O
is	O
a	O
respiratory	O
toxin	O
that	O
inhibits	O
cytochrome	O
C	O
oxidase	O
system	O
resulting	O
in	O
renal	B-DISO
failure	I-DISO
and	O
liver	B-DISO
failure	I-DISO
.	O

The	O
renal	O
biopsy	O
revealed	O
acute	B-DISO
tubulointerstitial	I-DISO
nephritis	I-DISO
with	O
acute	B-DISO
tubular	I-DISO
necrosis	I-DISO
.	O

Case	O
1	O
showed	O
delayed	O
symptom	B-DISO
development	O
after	O
a	O
four	O
-	O
day	O
asymptomatic	O
period	O
,	O
Case	O
2	O
experienced	O
a	O
20	O
-	O
day	O
incubation	O
period	O
,	O
and	O
Case	O
3	O
exhibited	O
persistent	O
viral	B-DISO
shedding	I-DISO
without	O
clinical	O
deterioration	O
.	O

In	O
this	O
retrospective	O
observational	O
study	O
,	O
83	O
patients	O
with	O
ARDS	B-DISO
and	O
129	O
non	O
-	O
ARDS	B-DISO
patients	O
on	O
ICU	O
admission	O
were	O
enrolled	O
.	O

RESULTS	O
:	O
The	O
serum	O
CC16	O
levels	O
in	O
ARDS	B-DISO
patients	O
were	O
significantly	O
higher	O
than	O
that	O
in	O
non	O
-	O
ARDS	B-DISO
patients	O
(	O
54	O
.	O
44	O
±	O
19	O
.	O
62	O
vs	O
24	O
.	O
13	O
±	O
12	O
.	O
32	O
ng	O
/	O
mL	O
,	O
P	O
=.	O
001	O
).	O

TITLE	O
:	O
The	O
Epidemiology	O
of	O
Hospital	O
Death	O
Following	O
Pediatric	O
Severe	B-DISO
Sepsis	I-DISO
:	O
When	O
,	O
Why	O
,	O
and	O
How	O
Children	O
With	O
Sepsis	B-DISO
Die	O
.	O

The	O
median	O
time	O
to	O
death	O
was	O
8	O
days	O
(	O
interquartile	O
range	O
,	O
1	O
-	O
12	O
d	O
)	O
with	O
25	O
%,	O
35	O
%,	O
and	O
49	O
%	O
of	O
cumulative	O
deaths	O
within	O
1	O
,	O
3	O
,	O
and	O
7	O
days	O
of	O
sepsis	B-DISO
recognition	O
,	O
respectively	O
.	O

Later	O
deaths	O
were	O
mostly	O
attributable	O
to	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
,	O
neurologic	O
,	O
and	O
respiratory	B-DISO
failure	I-DISO
after	O
life	O
-	O
sustaining	O
therapies	O
were	O
limited	O
.	O

Neutrophils	O
increase	O
in	O
the	O
respiratory	O
tract	O
during	O
infection	B-DISO
with	O
mild	O
seasonal	O
IAV	O
,	O
moderate	O
and	O
severe	O
epidemic	O
IAV	O
infection	B-DISO
,	O
and	O
emerging	O
highly	O
pathogenic	O
avian	B-DISO
influenza	I-DISO
(	O
HPAI	O
).	O

Thus	O
,	O
comparative	O
analyses	O
of	O
the	O
relationship	O
between	O
IAV	O
infection	B-DISO
and	O
neutrophils	O
provide	O
insights	O
into	O
the	O
relative	O
contribution	O
of	O
host	O
and	O
viral	O
factors	O
that	O
contribute	O
to	O
disease	O
severity	O
.	O

Despite	O
limited	O
scientific	O
evidence	O
these	O
systems	O
are	O
increasingly	O
used	O
in	O
the	O
intensive	O
care	O
unit	O
for	O
treatment	O
of	O
different	O
types	O
of	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

Therefore	O
,	O
in	O
acute	O
cases	O
of	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
,	O
when	O
rapid	O
diagnostics	O
of	O
the	O
causative	O
agent	O
are	O
not	O
readily	O
available	O
,	O
an	O
antiviral	O
drug	O
with	O
properties	O
like	O
FA	O
-	O
613	O
could	O
prove	O
to	O
be	O
very	O
valuable	O
.	O

The	O
assessed	O
BDR	O
criteria	O
included	O
the	O
Global	O
Initiative	O
for	O
Chronic	B-DISO
Obstructive	I-DISO
Lung	I-DISO
Disease	I-DISO
(	O
GOLD	O
),	O
American	O
Thoracic	B-DISO
Society	O
(	O
ATS	B-DISO
),	O
American	O
College	O
of	O
Chest	O
Physicians	O
,	O
(	O
ACCP	O
),	O
major	O
criteria	O
of	O
the	O
Spanish	O
definition	O
of	O
asthma	B-DISO
-	O
COPD	B-DISO
overlap	B-DISO
syndrome	I-DISO
(	O
ACOS	B-DISO
),	O
criteria	O
compatible	O
with	O
ACOS	B-DISO
in	O
the	O
Global	O
Initiative	O
for	O
Asthma	B-DISO
(	O
GINA	O
),	O
and	O
European	O
Respiratory	O
Society	O
(	O
ERS	B-DISO
).	O

Among	O
different	O
criteria	O
for	O
positive	O
BDR	O
,	O
the	O
use	O
of	O
the	O
GOLD	O
ones	O
was	O
significantly	O
associated	O
with	O
a	O
decreased	O
risk	O
of	O
severe	O
AE	O
in	O
COPD	B-DISO
patients	O
.	O

For	O
severity	O
of	O
ARDS	B-DISO
,	O
subjects	O
were	O
stratified	O
according	O
to	O
P	O
A	O
total	O
of	O
2	O
,	O
914	O
subjects	O
were	O
included	O
in	O
these	O
trials	O
.	O

Outcomes	O
were	O
modeled	O
with	O
multivariable	O
regressions	B-DISO
adjusted	O
for	O
baseline	O
covariates	O
,	O
age	O
,	O
sex	O
,	O
race	O
,	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
III	O
(	O
APACHE	O
III	O
),	O
vasopressor	O
use	O
,	O
modified	O
lung	O
injury	O
score	O
,	O
diabetes	B-DISO
mellitus	I-DISO
,	O
cancer	B-DISO
status	O
,	O
body	O
mass	O
index	O
,	O
pre	O
-	O
ICU	O
location	O
,	O
ICU	O
location	O
,	O
and	O
study	O
.	O

Subjects	O
with	O
trauma	O
,	O
compared	O
with	O
other	O
etiologies	O
of	O
ARDS	B-DISO
,	O
had	O
significantly	O
lower	O
mortality	O
at	O
28	O
d	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
0	O
.	O
47	O
,	O
95	O
%	O
CI	O
0	O
.	O
26	O
-	O
0	O
.	O
83	O
,	O
Severity	O
of	O
ARDS	B-DISO
based	O
on	O
P	O
RESULTS	O
:	O
A	O
total	O
of	O
2	O
,	O
914	O
subjects	O
were	O
included	O
in	O
these	O
trials	O
.	O

Multivariate	O
analyses	O
demonstrated	O
increased	O
risk	O
of	O
MODS	B-DISO
(	O
P	O
=	O
0	O
.	O
03	O
),	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
at	O
48	O
hours	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
pneumonia	B-DISO
(	O
P	O
=	O
0	O
.	O
01	O
),	O
prolonged	O
ventilator	O
dependence	B-DISO
(	O
P	O
=	O
0	O
.	O
03	O
),	O
and	O
a	O
trend	O
toward	O
mortality	O
(	O
P	O
=	O
0	O
.	O
08	O
)	O
with	O
higher	O
AIS	B-DISO
groups	O
.	O

HFRS	B-DISO
is	O
endemic	O
in	O
Europe	O
and	O
Russia	O
,	O
where	O
the	O
mild	O
form	O
of	O
the	O
disease	O
is	O
prevalent	O
in	O
the	O
Tatarstan	O
region	O
.	O

Furthermore	O
,	O
HPS	B-DISO
was	O
strictly	O
characterized	O
by	O
the	O
upregulation	O
of	O
cytokine	O
levels	O
,	O
in	O
contrast	O
to	O
HFRS	B-DISO
where	O
cases	O
were	O
distinguished	O
by	O
a	O
dichotomy	O
in	O
serum	O
cytokine	O
levels	O
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
-	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
South	O
Korea	O
in	O
April	O
2015	O
led	O
to	O
186	O
infections	B-DISO
and	O
37	O
deaths	O
by	O
the	O
end	O
of	O
October	O
2015	O
.	O

The	O
envelope	O
(	O
E	O
)	O
protein	O
,	O
a	O
small	O
structural	O
protein	O
of	O
MERS	O
-	O
CoV	O
,	O
plays	O
an	O
important	O
role	O
in	O
host	O
recognition	O
and	O
infection	B-DISO
.	O

RV1B	O
infection	B-DISO
caused	O
numerous	O
gene	O
expression	O
changes	O
,	O
but	O
the	O
differential	O
effect	O
peaked	O
at	O
12	O
hours	O
post	O
-	O
infection	B-DISO
.	O

We	O
present	O
a	O
case	O
of	O
a	O
12	O
-	O
year	O
-	O
old	O
girl	O
who	O
developed	O
severe	O
ARDS	B-DISO
(	O
PO	O

TITLE	O
:	O
MERS	O
-	O
CoV	O
Antibody	O
Responses	O
1	O
Year	O
after	O
Symptom	B-DISO
Onset	O
,	O
South	O
Korea	O
,	O
2015	O
.	O

TITLE	O
:	O
Rapid	O
and	O
sensitive	O
insulated	O
isothermal	O
PCR	O
for	O
point	O
-	O
of	O
-	O
need	O
feline	O
leukaemia	B-DISO
virus	O
detection	O
.	O

The	O
N	O
-	O
PACT	B-DISO
interaction	O
sequestered	O
the	O
association	O
of	O
PACT	B-DISO
and	O
RIG	O
-	O
I	O
/	O
MDA5	O
,	O
which	O
in	O
turn	O
inhibited	O
IFN	O
-	O
β	O
production	O
.	O

Time	O
since	O
respiratory	B-DISO
symptom	I-DISO
onset	O
was	O
2	O
(	O
1	O
-	O
3	O
)	O
days	O
.	O

We	O
generated	O
264	O
F2	O
mice	O
between	O
these	O
strains	O
,	O
and	O
infected	O
them	O
with	O
SARS	B-DISO
-	O
CoV	O
.	O
Weight	O
loss	O
,	O
pulmonary	B-DISO
hemorrhage	I-DISO
,	O
and	O
viral	O
load	O
were	O
all	O
highly	O
correlated	O
disease	O
phenotypes	O
.	O

TITLE	O
:	O
Targeting	O
endosomal	O
acidification	O
by	O
chloroquine	O
analogs	O
as	O
a	O
promising	O
strategy	O
for	O
the	O
treatment	O
of	O
emerging	O
viral	B-DISO
diseases	I-DISO
.	O

Majority	O
of	O
these	O
viruses	O
are	O
responsible	O
for	O
the	O
outbreaks	O
of	O
pathogenic	O
lethal	O
infections	B-DISO
.	O

It	O
is	O
characterized	O
by	O
acute	O
onset	O
of	O
diarrhea	B-DISO
,	O
fever	O
,	O
depression	B-DISO
,	O
and	O
reduced	O
milk	O
yield	O
in	O
adult	O
cattle	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
with	O
a	O
recombinant	O
S	O
gene	O
detected	O
in	O
Hungary	O
,	O
2016	O
.	O

ABSTRACT	O
:	O
In	O
South	O
Korea	O
,	O
an	O
outbreak	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
occurred	O
in	O
2015	O
.	O

Sedation	B-DISO
managed	O
per	O
usual	O
care	O
or	O
Randomized	O
Evaluation	O
of	O
Sedation	B-DISO
Titration	O
for	O
Respiratory	B-DISO
Failure	I-DISO
protocol	O
.	O

Sixty	O
-	O
one	O
Randomized	O
Evaluation	O
of	O
Sedation	B-DISO
Titration	O
for	O
Respiratory	B-DISO
Failure	I-DISO
patients	O
(	O
5	O
%)	O
with	O
moderate	O
/	O
severe	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
were	O
supported	O
on	O
extracorporeal	O
membrane	O
oxygenation	O
,	O
including	O
29	O
managed	O
per	O
Randomized	O
Evaluation	O
of	O
Sedation	B-DISO
Titration	O
for	O
Respiratory	B-DISO
Failure	I-DISO
protocol	O
.	O

TITLE	O
:	O
Moxifloxacin	O
monotherapy	O
versus	O
combination	O
therapy	O
in	O
patients	O
with	O
severe	O
community	O
-	O
acquired	O
pneumonia	B-DISO
evoked	O
ARDS	B-DISO
.	O

In	O
2	O
(	O
15	O
%)	O
CoV	O
-	O
HKU1	O
-	O
positive	O
adults	O
,	O
the	O
only	O
viral	O
coinfection	B-DISO
detected	O
was	O
influenza	B-DISO
A	O
.	O
Coronavirus	O
-	O
HKU1	O
accounted	O
for	O
1	O
.	O
6	O
%	O
of	O
adult	O
respiratory	B-DISO
infections	I-DISO
and	O
should	O
be	O
considered	O
in	O
differential	O
diagnosis	O
of	O
severe	O
respiratory	O
illnesses	O
among	O
adults	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
still	O
causes	O
outbreaks	O
despite	O
public	O
awareness	O
and	O
implementation	O
of	O
health	O
care	O
measures	O
,	O
such	O
as	O
rapid	O
viral	O
diagnosis	O
and	O
patient	O
quarantine	O
.	O

In	O
comparison	O
,	O
for	O
the	O
PBS	B-DISO
group	O
as	O
the	O
negative	O
group	O
and	O
the	O
NDV	O
-	O
infected	O
group	O
as	O
the	O
positive	O
group	O
,	O
the	O
histological	O
changes	O
showed	O
that	O
the	O
lesions	O
of	O
the	O
AIV	O
+	O
IBV	O
co	O
-	O
infected	O
group	O
were	O
more	O
serious	O
compared	O
to	O
the	O
AIV	O
-	O
infected	O
group	O
and	O
the	O
IBV	O
-	O
infected	O
group	O
.	O

Imaging	O
investigations	O
revealed	O
tension	B-DISO
enterothorax	O
and	O
hepatothorax	O
with	O
tracheal	B-DISO
deviation	I-DISO
.	O

ABSTRACT	O
:	O
In	O
the	O
past	O
20	O
years	O
,	O
our	O
understanding	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
management	O
has	O
improved	O
,	O
but	O
the	O
worldwide	O
incidence	O
and	O
current	O
outcomes	O
are	O
unclear	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
904	O
adult	O
patients	O
were	O
admitted	O
to	O
ICU	O
during	O
the	O
study	O
period	O
and	O
15	O
patients	O
met	O
ARDS	B-DISO
criteria	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
link	O
HSP27	O
to	O
PEDV	O
replication	O
via	O
the	O
innate	O
immunity	O
response	O
,	O
which	O
contributed	O
to	O
further	O
clarify	O
the	O
mechanism	O
of	O
PEDV	O
infection	B-DISO
and	O
the	O
development	O
of	O
novel	O
antiviral	O
therapies	O
.	O

Isolating	O
PEDV	O
neutralizing	O
antibodies	O
from	O
porcine	O
B	O
cells	O
is	O
critical	O
to	O
elucidate	O
the	O
development	O
of	O
PEDV	O
neutralizing	O
antibodies	O
and	O
the	O
protective	O
mechanism	O
of	O
PEDV	O
infection	B-DISO
.	O

The	O
proportion	O
of	O
patients	O
with	O
severe	O
ARDS	B-DISO
or	O
with	O
ratios	O
of	O
the	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
(	O
PaO	O
Important	O
geo	O
-	O
economic	O
differences	O
exist	O
in	O
the	O
severity	O
,	O
clinician	O
recognition	O
,	O
and	O
management	O
of	O
ARDS	B-DISO
,	O
and	O
in	O
patients	O
'	O
outcomes	O
.	O

These	O
were	O
older	O
,	O
had	O
more	O
frequent	O
chronic	B-DISO
diseases	I-DISO
and	O
presented	O
with	O
less	O
severe	O
SOFA	O
and	O
non	O
-	O
pulmonary	O
SOFA	O
scores	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

Fifty	O
-	O
one	O
patients	O
with	O
moderate	O
-	O
severe	O
ARDS	B-DISO
were	O
included	O
.	O

Severe	O
pulmonary	B-DISO
hypertension	I-DISO
was	O
seen	O
in	O
two	O
patients	O
and	O
no	O
case	O
of	O
cerebral	B-DISO
edema	I-DISO
was	O
observed	O
.	O

ABSTRACT	O
:	O
The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
effects	O
of	O
tea	O
saponins	O
on	O
oxidative	B-DISO
stress	I-DISO
induced	O
by	O
cyclophosphamide	O
in	O
chickens	O
.	O

In	O
experimental	O
studies	O
,	O
regions	O
of	O
lung	O
with	O
unstable	O
inflation	O
(	O
ie	O
,	O
partial	O
or	O
reversible	O
airspace	O
filling	O
reflecting	O
local	O
strain	O
)	O
were	O
the	O
areas	O
in	O
which	O
subsequent	O
progression	O
of	O
injury	O
was	O
greatest	O
in	O
terms	O
of	O
progressive	O
infiltrates	B-DISO
(	O
R	O
=	O
0	O
.	O
77	O
)	O
and	O
impaired	B-DISO
compliance	O
(	O
R	O
=	O
0	O
.	O
67	O
,	O
p	O
<	O
0	O
.	O
01	O
).	O

RESULTS	O
:	O
In	O
experimental	O
studies	O
,	O
regions	O
of	O
lung	O
with	O
unstable	O
inflation	O
(	O
ie	O
,	O
partial	O
or	O
reversible	O
airspace	O
filling	O
reflecting	O
local	O
strain	O
)	O
were	O
the	O
areas	O
in	O
which	O
subsequent	O
progression	O
of	O
injury	O
was	O
greatest	O
in	O
terms	O
of	O
progressive	O
infiltrates	B-DISO
(	O
R	O
=	O
0	O
.	O
77	O
)	O
and	O
impaired	B-DISO
compliance	O
(	O
R	O
=	O
0	O
.	O
67	O
,	O
p	O
<	O
0	O
.	O
01	O
).	O

The	O
detection	O
of	O
Coronavirus	O
HKU15	O
in	O
respiratory	O
tracts	O
of	O
pigs	O
implies	O
that	O
in	O
addition	O
to	O
enteric	O
infections	B-DISO
,	I-DISO
Coronavirus	I-DISO
HKU15	O
may	O
be	O
able	O
to	O
cause	O
respiratory	B-DISO
infections	I-DISO
in	O
pigs	O
and	O
that	O
in	O
addition	O
to	O
fecal	O
-	O
oral	O
transmission	O
,	O
the	O
virus	O
could	O
possibly	O
spread	O
through	O
the	O
respiratory	O
route	O
.	O

Each	O
patient	O
was	O
assessed	O
for	O
signs	B-DISO
and	I-DISO
symptoms	I-DISO
,	O
clinical	O
features	O
,	O
treatment	O
,	O
complications	O
and	O
outcome	O
of	O
ILI	O
and	O
SARI	O
.	O

Throat	O
or	O
nasopharyngeal	O
swabs	O
were	O
obtained	O
from	O
36	O
patient	O
and	O
analyzed	O
for	O
the	O
presence	O
of	O
Influenza	B-DISO
virus	O
by	O
quantitative	O
PCR	O
.	O

We	O
found	O
that	O
SARS	B-DISO
S	O
residue	O
R667	O
,	O
a	O
previously	O
identified	O
trypsin	O
cleavage	O
site	O
,	O
is	O
also	O
required	O
for	O
S	O
protein	O
cleavage	O
by	O
TMPRSS2	O
.	O

Conversely	O
,	O
residue	O
R797	O
,	O
previously	O
reported	O
to	O
be	O
required	O
for	O
SARS	B-DISO
S	O
activation	O
by	O
trypsin	O
,	O
was	O
dispensable	O
for	O
S	O
protein	O
cleavage	O
but	O
required	O
for	O
S	O
protein	O
activation	O
by	O
TMPRSS2	O
.	O

On	O
the	O
bases	O
of	O
these	O
results	O
and	O
searching	O
for	O
potential	O
multitarget	O
active	O
drug	O
supplement	O
,	O
we	O
also	O
investigated	O
the	O
anti	O
-	O
HIV	B-DISO
-	O
1	O
activity	O
of	O
Hemidesmus	O
indicus	O
,	O
an	O
Ayurveda	O
medicinal	O
plant	O
containing	O
Lupeol	O
.	O

Unfractionated	O
heparin	O
has	O
traditionally	O
been	O
used	O
in	O
this	O
setting	O
as	O
a	O
systemic	O
form	O
of	O
anticoagulation	O
to	O
prevent	O
thrombosis	B-DISO
of	O
the	O
circuit	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
27	O
-	O
year	O
-	O
old	O
man	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
who	O
developed	O
HIT	O
while	O
on	O
venovenous	O
ECMO	O
with	O
continuous	O
venovenous	O
hemofiltration	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
know	O
the	O
viral	O
aetiology	O
of	O
wheezing	B-DISO
among	O
the	O
children	O
less	O
than	O
five	O
years	O
of	O
age	O
,	O
admitted	O
to	O
a	O
tertiary	O
care	O
hospital	O
in	O
eastern	O
India	O
.	O

NF	O
-	O
κB	O
activation	O
induced	O
by	O
TGEV	O
infection	B-DISO
was	O
found	O
to	O
be	O
associated	O
with	O
two	O
convergent	O
pathways	O
,	O
IKK	O
-	O
2_IκBα	O
/	O
p65	O
and	O
JAK2	O
mediated	O
p65	O
phosphorylation	O
,	O
in	O
swine	O
testicular	O
cells	O
.	O

The	O
protocol	O
below	O
regards	O
exclusively	O
veno	O
-	O
venous	O
ECMO	O
treatment	O
as	O
a	O
support	O
for	O
blood	O
gas	O
conditioning	O
by	O
means	O
of	O
extracorporeal	O
circuit	O
in	O
adult	O
patients	O
with	O
severe	O
ARDS	B-DISO
.	O

Recent	O
experience	O
of	O
ECMO	O
treatment	O
since	O
the	O
outbreak	O
of	O
AH1N1	O
influenza	B-DISO
pandemic	O
in	O
2009	O
,	O
along	O
with	O
technical	O
progress	O
and	O
advancement	O
in	O
understanding	O
pathophysiology	O
of	O
ventilator	O
-	O
induced	O
lung	O
injury	O
,	O
have	O
contributed	O
to	O
significant	O
improvement	O
of	O
the	O
results	O
of	O
ECMO	O
treatment	O
.	O

The	O
aim	O
of	O
presenting	O
this	O
revised	O
protocol	O
was	O
to	O
improve	O
the	O
effects	O
of	O
ECMO	O
treatment	O
in	O
patients	O
with	O
severe	O
ARDS	B-DISO
,	O
to	O
enhance	O
ECMO	O
accessibility	O
for	O
patients	O
who	O
might	O
possibly	O
benefit	O
from	O
this	O
treatment	O
,	O
to	O
reduce	O
time	O
until	O
patient	O
'	O
s	O
connection	O
to	O
ECMO	O
,	O
and	O
to	O
avoid	O
ECMO	O
treatment	O
in	O
futile	O
cases	O
.	O

The	O
xTAG	O
RVP	O
Fast	O
v2	O
assay	O
showed	O
comparable	O
capabilities	O
compared	O
with	O
the	O
other	O
assays	O
;	O
it	O
will	O
be	O
useful	O
for	O
identifying	O
respiratory	O
viral	B-DISO
infections	I-DISO
in	O
patients	O
with	O
respiratory	B-DISO
symptoms	I-DISO
.	O

TITLE	O
:	O
Use	O
of	O
Sequence	O
-	O
Independent	O
,	O
Single	O
-	O
Primer	O
-	O
Amplification	B-DISO
(	O
SISPA	O
)	O
for	O
rapid	O
detection	O
,	O
identification	O
,	O
and	O
characterization	O
of	O
avian	O
RNA	O
viruses	O
.	O

To	O
achieve	O
the	O
non	O
-	O
selective	O
amplification	B-DISO
and	O
recovery	O
of	O
low	O
abundance	O
genetic	O
sequences	O
,	O
a	O
simplified	O
Sequence	O
-	O
Independent	O
,	O
Single	O
-	O
Primer	O
Amplification	B-DISO
(	O
SISPA	O
)	O
technique	O
in	O
combination	O
with	O
MiSeq	O
platform	O
was	O
applied	O
to	O
target	O
negative	O
-	O
and	O
positive	O
-	O
sense	O
single	O
-	O
stranded	O
RNA	O
viral	O
sequences	O
.	O

Moreover	O
,	O
SISPA	O
analysis	O
applied	O
to	O
unknown	O
clinical	O
cases	O
of	O
mixed	O
viral	B-DISO
infections	I-DISO
produced	O
genome	O
assemblies	O
comprising	O
98	O
%	O
NDV	O
and	O
99	O
%	O
of	O
IBV	O
genomes	O
.	O

TITLE	O
:	O
Crystal	O
structure	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
helicase	O
.	O

TITLE	O
:	O
Aortic	B-DISO
stenosis	I-DISO
concomitant	O
with	O
microscopic	B-DISO
polyangiitis	I-DISO
:	O
a	O
challenge	O
in	O
medical	O
reasoning	O
and	O
thinking	O
.	O

ABSTRACT	O
:	O
Microscopic	B-DISO
polyangiitis	I-DISO
(	O
MPA	O
)	O
is	O
part	O
of	O
the	O
anti	O
-	O
neutrophil	O
cytoplasmic	O
antibodies	O
(	O
ANCA	O
)-	O
related	O
vasculitis	B-DISO
,	O
which	O
usually	O
presents	O
as	O
renal	B-DISO
pulmonary	I-DISO
syndrome	I-DISO
.	O

The	O
patient	O
had	O
been	O
recently	O
diagnosed	O
with	O
pneumonia	B-DISO
.	O

Imaging	O
studies	O
showed	O
bilateral	O
diaphragmatic	O
paralysis	O
,	O
and	O
electromyography	O
(	O
EMG	O
)	O
confirmed	O
neuropathy	B-DISO
of	O
both	O
phrenic	O
nerves	O
.	O

Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
CoV	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
CoV	O
(	O
MERS	O
-	O
CoV	O
)	O
successively	O
emerged	O
,	O
causing	O
severe	O
epidemic	O
respiratory	B-DISO
disease	I-DISO
in	O
immunologically	O
naïve	O
human	O
populations	O
throughout	O
the	O
globe	O
.	O

TITLE	O
:	O
Variability	O
in	O
biological	O
behaviour	O
,	O
pathogenicity	O
,	O
protectotype	O
and	O
induction	O
of	O
virus	O
neutralizing	O
antibodies	O
by	O
different	O
vaccination	O
programmes	O
to	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
genotype	O
Q1	O
strains	O
from	O
Chile	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
common	O
sequela	O
of	O
severe	O
burns	O
and	O
inhalation	O
injury	O
.	O

TITLE	O
:	O
Frequent	O
respiratory	O
viral	B-DISO
infections	I-DISO
in	O
a	O
young	O
child	O
in	O
a	O
27	O
-	O
month	O
follow	O
-	O
up	O
study	O
.	O

Young	O
children	O
living	O
in	O
a	O
group	O
context	O
have	O
a	O
high	O
risk	O
of	O
respiratory	O
virus	O
infections	B-DISO
,	O
especially	O
rhinovirus	O
.	O

A	O
65	O
-	O
year	O
-	O
old	O
man	O
presented	O
twice	O
with	O
severe	B-DISO
headache	I-DISO
.	O

Since	O
week	O
40	O
/	O
2015	O
,	O
weekly	O
updated	O
anonymized	O
data	O
on	O
discharged	O
patients	O
overall	O
and	O
on	O
patients	O
with	O
respiratory	O
illness	O
including	O
ICD	B-DISO
-	O
10	O
codes	O
of	O
primary	O
and	O
secondary	O
diagnoses	O
are	O
transferred	O
from	O
the	O
network	O
data	O
center	O
to	O
RKI	O
.	O

The	O
patients	O
fulfilling	O
the	O
TCD	B-DISO
had	O
been	O
completely	O
reported	O
after	O
3	O
weeks	O
,	O
which	O
was	O
fastest	O
among	O
the	O
CD	O
.	O

The	O
International	O
Extracorporeal	O
Membrane	O
Oxygenation	O
Network	O
recommends	O
regionalization	O
of	O
extracorporeal	O
life	O
support	O
(	O
ECLS	O
)	O
to	O
high	O
-	O
volume	O
centers	O
and	O
development	O
of	O
mobile	O
ECLS	O
teams	O
to	O
rescue	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
In	O
patients	O
with	O
severe	O
neurologic	O
conditions	O
,	O
percutaneous	O
endoscopic	O
gastrostomy	B-DISO
(	O
PEG	O
)	O
is	O
typically	O
performed	O
either	O
alone	O
or	O
with	O
a	O
tracheostomy	O
.	O

Within	O
the	O
participants	O
'	O
rich	O
and	O
illuminating	O
experiences	O
,	O
four	O
themes	O
were	O
identified	O
:	O
caring	O
for	O
others	O
in	O
the	O
defining	O
moments	O
,	O
perceived	O
prejudice	O
behaviours	O
and	O
stigmatization	O
,	O
lived	O
moments	O
of	O
traumatic	O
fear	O
and	O
despair	B-DISO
,	O
and	O
denial	B-DISO
and	O
underestimation	O
of	O
the	O
seriousness	O
of	O
the	O
disease	O
at	O
the	O
individual	O
and	O
organizational	O
levels	O
.	O

TITLE	O
:	O
Asthma	B-DISO
-	O
COPD	B-DISO
Overlap	O
Shows	O
Favorable	O
Clinical	O
Outcomes	O
Compared	O
to	O
Pure	O
COPD	B-DISO
in	O
a	O
Korean	O
COPD	B-DISO
Cohort	O
.	O

Among	O
1	O
,	O
504	O
patients	O
with	O
COPD	B-DISO
,	O
223	O
(	O
14	O
.	O
8	O
%)	O
were	O
diagnosed	O
with	O
ACO	O
.	O

We	O
suggest	O
that	O
ACO	O
is	O
characterized	O
by	O
less	O
severe	O
symptoms	O
,	O
and	O
therefore	O
it	O
might	O
lead	O
to	O
rare	O
severe	O
exacerbation	O
and	O
the	O
possibility	O
of	O
lung	O
function	B-DISO
recovery	I-DISO
.	O

Patients	O
with	O
ACO	O
showed	O
a	O
higher	O
likelihood	O
of	O
FEV1	O
recovery	O
than	O
those	O
with	O
pure	O
COPD	B-DISO
(	O
P	O
<	O
0	O
.	O
001	O
).	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
)	O
is	O
an	O
acute	O
and	O
highly	O
contagious	O
enteric	O
disease	O
of	O
swine	O
caused	O
by	O
the	O
eponymous	O
virus	O
(	O
PEDV	O
)	O
which	O
belongs	O
to	O
the	O
genus	O

RESULTS	O
:	O
Observational	O
studies	O
of	O
ZIKV	O
face	B-DISO
an	O
array	O
of	O
challenges	O
,	O
including	O
measurement	O
of	O
exposure	O
and	O
outcomes	O
(	O
microcephaly	B-DISO
and	O
Guillain	O
-	O
Barré	O
Syndrome	B-DISO
).	O

TITLE	O
:	O
miRNA	O
-	O
200c	O
-	O
3p	O
is	O
crucial	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
Influenza	B-DISO
infection	B-DISO
and	O
pneumonia	B-DISO
are	O
known	O
to	O
cause	O
much	O
of	O
their	O
mortality	O
by	O
inducing	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
which	O
is	O
the	O
most	O
severe	O
form	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

Then	O
,	O
we	O
found	O
that	O
nonstructural	O
protein	O
1	O
and	O
viral	O
RNA	O
of	O
H5N1	B-DISO
contributed	O
to	O
the	O
induction	O
of	O
miR	O
-	O
200c	O
-	O
3p	O
during	O
viral	B-DISO
infection	I-DISO
.	O

Histopathologically	O
,	O
tracheal	O
congestion	B-DISO
,	O
severe	O
degeneration	B-DISO
,	O
and	O
deciliation	O
were	O
noticed	O
in	O
all	O
groups	O
of	O
mixed	B-DISO
infection	I-DISO
.	O

In	O
diagnosis	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
,	O
ELISA	O
IgG	O
exhibited	O
optimal	O
performance	O
using	O
sera	O
collected	O
after	O
28	O
dpex	O
,	O
at	O
a	O
cut	O
-	O
off	O
value	O
of	O
OD	O
ratio	O
0	O
.	O
2	O
(	O
sensitivity	O
97	O
.	O
3	O
%	O
and	O
specificity	O
92	O
.	O
9	O
%).	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
one	O
of	O
the	O
most	O
lethal	O
diseases	O
encountered	O
in	O
the	O
pediatric	O
intensive	O
care	O
unit	O
(	O
PICU	O
).	O

Demographic	O
data	O
,	O
type	O
of	O
infection	B-DISO
,	O
risk	O
factors	O
,	O
clinical	O
presentation	O
,	O
analytical	O
data	O
at	O
admission	O
,	O
treatment	O
,	O
need	O
for	O
admission	O
to	O
a	O
pediatric	O
intensive	O
care	O
unit	O
,	O
microbiological	O
data	O
,	O
hospital	O
stay	O
and	O
evolution	O
were	O
collected	O
.	O

Skin	O
and	O
soft	B-DISO
tissue	I-DISO
infections	I-DISO
were	O
diagnosed	O
in	O
14	O
patients	O
(	O
26	O
.	O
9	O
%),	O
14	O
(	O
26	O
.	O
9	O
%)	O
pneumonias	B-DISO
,	O
12	O
(	O
23	O
.	O
1	O
%)	O
bones	O
and	O
joints	O
infections	B-DISO
,	O
10	O
(	O
19	O
.	O
2	O
%)	O
SSTS	O
,	O
6	O
(	O
11	O
.	O
5	O
%)	O
occult	O
bacteremia	B-DISO
,	O
4	O
(	O
7	O
.	O
7	O
%)	O
meningitis	B-DISO
and	O
2	O
(	O
3	O
.	O
8	O
%)	O
sepsis	B-DISO
.	O

The	O
complete	O
genome	O
of	O
the	O
GI	O
-	O
11	O
and	O
GI	O
-	O
16	O
strains	O
have	O
27	O
,	O
621	O
and	O
27	O
,	O
638	O
nucleotides	O
,	O
respectively	O
,	O
and	O
possess	B-DISO
the	O
same	O
genomic	O
organization	O
.	O

ABSTRACT	O
:	O
Hypercapnic	B-DISO
respiratory	I-DISO
failure	I-DISO
is	O
a	O
frequent	O
problem	O
in	O
critical	O
care	O
and	O
mainly	O
affects	O
patients	O
with	O
acute	O
exacerbation	O
of	O
COPD	B-DISO
(	O
AECOPD	O
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

In	O
these	O
patients	O
,	O
ECCO	O
Optimized	O
use	O
of	O
NIV	O
and	O
lung	O
-	O
protective	O
ventilation	O
remains	O
standard	O
of	O
care	O
in	O
the	O
management	O
of	O
hypercapnic	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Healthcare	O
infrastructure	O
capacity	O
to	O
respond	O
to	O
severe	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
(	O
SARI	O
)	O
and	O
sepsis	B-DISO
in	O
Vietnam	O
:	O
A	O
low	O
-	O
middle	O
income	O
country	O
.	O

Arrived	O
on	O
16th	O
December	O
2012	O
,	O
mostly	O
stayed	O
at	O
daughter	O
'	O
s	O
house	O
,	O
visited	O
by	O
relatives	O
,	O
on	O
19th	O
January	O
,	O
left	O
for	O
KSA	O
accompanied	O
by	O
daughter	O
,	O
developed	O
fever	B-DISO
with	I-DISO
chills	I-DISO
and	O
body	O
aches	B-DISO
on	O
23rd	O
January	O
.	O

The	O
present	O
study	O
aimed	O
to	O
identify	O
the	O
potential	O
roles	O
of	O
miRNAs	O
in	O
the	O
pathogenesis	B-DISO
and	O
progression	O
of	O
ARDS	B-DISO
.	O

A	O
total	O
of	O
19	O
miRNAs	O
were	O
differentially	O
expressed	O
between	O
ARDS	B-DISO
and	O
normal	O
lung	O
tissue	O
were	O
identified	O
.	O

TITLE	O
:	O
Anasarca	B-DISO
,	O
Fever	O
,	O
Thrombocytopenia	O
,	O
Organomegaly	O
,	O
and	O
Multiorgan	B-DISO
Failure	I-DISO
in	O
a	O
24	O
-	O
Year	O
-	O
Old	O
Pregnant	O
Woman	O
.	O

As	O
systemic	O
inflammatory	O
manifestations	O
are	O
important	O
,	O
TAFRO	O
syndrome	B-DISO
can	O
be	O
mistaken	O
with	O
severe	O
autoimmune	B-DISO
diseases	I-DISO
,	O
systemic	B-DISO
infections	I-DISO
,	O
hematological	B-DISO
malignancies	I-DISO
,	O
or	O
hemophagocytic	B-DISO
lymphohistiocytosis	I-DISO
.	O

An	O
effective	O
strategy	O
to	O
control	O
emergency	B-DISO
center	O
visits	O
by	O
non	O
-	O
urgent	O
febrile	O
patients	O
and	O
provide	O
proper	O
medical	O
services	O
is	O
urgently	O
needed	O
.	O

ABSTRACT	O
:	O
Asthma	B-DISO
affects	O
about	O
7	O
.	O
5	O
%	O
of	O
the	O
adult	O
population	O
.	O

The	O
diagnosis	O
of	O
asthma	B-DISO
requires	O
these	O
symptoms	O
and	O
demonstration	O
of	O
reversible	O
airway	B-DISO
obstruction	I-DISO
using	O
spirometry	O
.	O

Other	O
controller	O
medications	O
,	O
such	O
as	O
long	O
-	O
acting	O
bronchodilators	O
and	O
biologics	O
,	O
may	O
be	O
required	O
in	O
moderate	O
and	O
severe	O
asthma	B-DISO
.	O

Using	O
in	O
vitro	O
pull	O
-	O
down	O
experiments	O
and	O
density	O
glycerol	O
gradients	O
,	O
we	O
found	O
that	O
at	O
least	O
3	O
regions	O
distributed	O
over	O
its	O
entire	O
length	O
mediate	O
the	O
self	O
-	O
interaction	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
N	O
protein	O
.	O

It	O
was	O
thought	O
that	O
the	O
source	O
of	O
the	O
exotoxin	O
that	O
mediated	O
her	O
TSS	B-DISO
was	O
her	O
skin	O
,	O
given	O
the	O
temporal	O
relationship	O
of	O
the	O
skin	O
biopsy	O
to	O
her	O
TSS	B-DISO
.	O

Recently	O
,	O
we	O
are	O
witnessing	O
the	O
increased	O
priority	O
given	O
to	O
the	O
GHD	B-DISO
because	O
the	O
issue	O
of	O
health	O
is	O
discussed	O
by	O
various	O
actors	O
outside	O
the	O
WHO	O
to	O
shape	O
the	O
global	O
policy	O
for	O
health	O
determinants	O
.	O

TITLE	O
:	O
Vero	O
cell	O
technology	O
for	O
rapid	O
development	O
of	O
inactivated	O
whole	O
virus	O
vaccines	O
for	O
emerging	O
viral	B-DISO
diseases	I-DISO
.	O

TITLE	O
:	O
Role	O
of	O
fomites	O
in	O
SARS	B-DISO
transmission	O
during	O
the	O
largest	O
hospital	O
outbreak	O
in	O
Hong	O
Kong	O
.	O

ABSTRACT	O
:	O
Liberal	O
late	O
fluid	O
management	O
(	O
LFM	O
)	O
is	O
associated	O
with	O
higher	O
morbi	O
-	O
mortality	O
in	O
critically	B-DISO
ill	I-DISO
populations	O
.	O

TITLE	O
:	O
No	O
.	O
225	O
-	O
Management	O
Guidelines	O
for	O
Obstetric	O
Patients	O
and	O
Neonates	O
Born	O
to	O
Mothers	O
With	O
Suspected	O
or	O
Probable	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
).	O

Our	O
findings	O
support	O
the	O
view	O
that	O
well	O
-	O
selected	O
candidates	O
with	O
acutely	O
decompensated	O
end	O
-	O
stage	O
lung	B-DISO
disease	I-DISO
may	O
be	O
safely	O
bridged	O
until	O
a	O
suitable	O
donor	O
is	O
identified	O
.	O

ECMO	O
is	O
not	O
able	O
to	O
reverse	O
the	O
course	O
of	O
patients	O
;	O
however	O
,	O
it	O
could	O
be	O
a	O
life	O
-	O
saving	O
option	O
for	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
requiring	O
lung	O
transplantation	O
.	O

ABSTRACT	O
:	O
An	O
analysis	O
of	O
cardiac	O
injury	O
markers	O
in	O
patients	O
with	O
OSA	B-DISO
who	O
sustain	O
an	O
episode	O
of	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
(	O
ACS	B-DISO
)	O
may	O
contribute	O
to	O
a	O
better	O
understanding	O
of	O
the	O
interactions	O
and	O
impact	O
of	O
OSA	B-DISO
in	O
subjects	O
with	O
ACS	B-DISO
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
OSA	B-DISO
has	O
a	O
protective	O
effect	O
in	O
the	O
context	O
of	O
myocardial	B-DISO
infarction	I-DISO
and	O
that	O
patients	O
with	O
OSA	B-DISO
may	O
experience	O
less	O
severe	O
myocardial	O
injury	O
.	O

TITLE	O
:	O
SARS	B-DISO
,	O
MERS	O
and	O
other	O
Viral	O
Lung	O
Infections	B-DISO
ABSTRACT	O
:	O
Respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
infection	B-DISO
has	O
an	O
estimated	O
global	O
incidence	O
of	O
33	O
million	O
cases	O
in	O
children	O
younger	O
than	O
5	O
years	O
,	O
with	O
10	O
%	O
requiring	O
hospital	O
admission	O
and	O
up	O
to	O
199	O
,	O
000	O
dying	O
of	O
the	O
disease	O
.	O

There	O
is	O
growing	O
evidence	O
that	O
severe	O
infantile	O
RSV	O
bronchiolitis	B-DISO
,	O
a	O
condition	B-DISO
characterised	O
by	O
an	O
inflammatory	B-DISO
reaction	I-DISO
to	O
the	O
virus	O
,	O
is	O
associated	O
with	O
later	O
childhood	O
wheeze	B-DISO
in	O
some	O
vulnerable	O
children	O
;	O
however	O
,	O
a	O
direct	O
causal	O
relationship	O
with	O
asthma	B-DISO
has	O
not	O
yet	O
been	O
established	O
.	O

It	O
is	O
also	O
increasingly	O
recognised	O
as	O
a	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
those	O
with	O
underlying	O
airway	B-DISO
disease	I-DISO
,	O
immunocompromise	O
and	O
frail	O
elderly	O
persons	O
.	O

ABSTRACT	O
:	O
Prone	O
position	O
ventilation	O
(	O
PPV	O
)	O
has	O
been	O
shown	O
to	O
improve	O
oxygenation	O
and	O
decrease	O
pulmonary	O
vascular	O
resistance	O
and	O
mortality	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

ABSTRACT	O
:	O
The	O
Pediatric	O
Acute	O
Lung	O
Injury	O
Consensus	O
Conference	O
developed	O
a	O
pediatric	O
specific	O
definition	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
PARDS	O
).	O

The	O
most	O
common	O
risk	O
factor	O
for	O
PARDS	O
was	O
pneumonia	B-DISO
/	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
(	O
309	O
[	O
82	O
.	O
8	O
%]).	O

TITLE	O
:	O
Comprehensive	O
structural	O
analysis	O
of	O
designed	O
incomplete	O
polypeptide	O
chains	O
of	O
the	O
replicase	O
nonstructural	O
protein	O
1	O
from	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
.	O

TITLE	O
:	O
A	O
Comprehensive	O
Review	O
of	O
Common	O
Bacterial	O
,	O
Parasitic	O
and	O
Viral	O
Zoonoses	B-DISO
at	O
the	O
Human	O
-	O
Animal	O
Interface	O
in	O
Egypt	O
.	O

Its	O
95	O
amino	O
acids	O
are	O
divided	O
into	O
two	O
structural	O
domains	O
(	O
SD	O
),	O
the	O
first	O
spanning	O
amino	O
acids	O
1	O
-	O
48	O
(	O
SD1	B-DISO
)	O
and	O
the	O
second	O
49	O
-	O
95	O
(	O
SD2	O
).	O

Contrary	O
to	O
other	O
reports	O
,	O
binding	O
free	O
energy	O
results	O
suggest	O
that	O
Man4	O
can	O
bind	O
simultaneously	O
to	O
SD1	B-DISO
and	O
SD2	O
binding	O
regions	O
,	O
but	O
SD1	B-DISO
individually	O
has	O
the	O
best	O
values	O
of	O
energy	O
and	O
the	O
best	O
affinity	O
for	O
Man4	O
.	O

Decomposition	O
of	O
the	O
binding	O
free	O
energy	O
showed	O
that	O
the	O
residues	O
that	O
interact	O
with	O
Man4	O
were	O
different	O
in	O
the	O
three	O
systems	O
,	O
suggesting	O
that	O
the	O
binding	O
mechanism	O
of	O
Man4	O
varies	O
between	O
full	O
-	O
length	O
protein	O
,	O
SD1	B-DISO
and	O
SD2	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
has	O
emerged	O
or	O
re	O
-	O
emerged	O
worldwide	O
,	O
posing	O
a	O
significant	O
financial	O
threat	O
to	O
major	O
pig	O
-	O
producing	O
countries	O
.	O

ABSTRACT	O
:	O
Infection	B-DISO
by	O
enveloped	O
coronaviruses	O
(	O
CoVs	O
)	O
initiates	O
with	O
viral	O
spike	O
(	O
S	O
)	O
proteins	O
binding	O
to	O
cellular	O
receptors	O
,	O
and	O
is	O
followed	O
by	O
proteolytic	O
cleavage	O
of	O
receptor	O
-	O
bound	O
S	O
proteins	O
,	O
which	O
prompts	O
S	O
protein	O
-	O
mediated	O
virus	O
-	O
cell	O
membrane	O
fusion	O
.	O

It	O
was	O
hypothesized	O
that	O
this	O
test	O
would	O
correctly	O
discriminate	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
)	O
and	O
feline	O
enteric	O
coronavirus	O
(	O
FECV	O
).	O

RESULTS	O
:	O
FIPV	O
was	O
detected	O
in	O
the	O
effusion	B-DISO
of	O
25	O
/	O
59	O
cats	O
,	O
one	O
of	O
them	O
being	O
a	O
control	O
cat	O
with	O
chronic	B-DISO
kidney	I-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
Incidences	O
of	O
emerging	O
/	O
re	O
-	O
emerging	O
deadly	O
viral	B-DISO
infections	I-DISO
have	O
significantly	O
affected	O
human	O
health	O
despite	O
extraordinary	O
progress	O
in	O
the	O
area	O
of	O
biomedical	O
knowledge	O
.	O

Prevention	O
of	O
arboviral	O
infections	B-DISO
using	O
vector	O
control	O
methods	O
has	O
not	O
been	O
very	O
successful	O
.	O

The	O
Korea	O
reported	O
its	O
first	O
laboratory	O
-	O
confirmed	O
case	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
coronavirus	O
on	O
May	O
20	O
,	O
2015	O
.	O

The	O
aim	O
would	O
be	O
to	O
develop	O
a	O
structure	O
that	O
specifies	O
the	O
roles	O
of	O
each	O
level	O
of	O
government	O
,	O
and	O
facilitates	O
the	O
close	O
collaboration	O
among	O
them	O
,	O
then	O
enacting	O
this	O
in	O
law	O
for	O
the	O
prevention	O
and	O
response	O
of	O
infectious	B-DISO
disease	I-DISO
.	O

TITLE	O
:	O
Airway	O
and	O
parenchyma	O
immune	O
cells	O
in	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pdm09	O
viral	O
and	O
non	O
-	O
viral	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
.	O

TITLE	O
:	O
Viridans	O
group	O
streptococci	O
bloodstream	O
infections	B-DISO
in	O
neutropenic	O
adult	O
patients	O
with	O
hematologic	B-DISO
malignancy	I-DISO
:	O
Single	O
center	O
experience	O
.	O

Retrospective	O
analysis	O
of	O
all	O
microbiologically	O
documented	O
bloodstream	O
infections	B-DISO
caused	O
by	O
VGS	O
during	O
the	O
9	O
-	O
year	O
time	O
period	O
(	O
from	O
January	O
2006	O
until	O
December	O
2014	O
)	O
was	O
carried	O
out	O
.	O

The	O
causative	O
agent	O
,	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
is	O
an	O
RNA	O
virus	O
with	O
great	O
ability	O
for	O
mutation	O
and	O
recombination	O
;	O
thus	O
,	O
capable	O
of	O
generating	O
new	O
virus	O
strains	O
that	O
are	O
difficult	O
to	O
control	O
.	O

PPCs	O
were	O
defined	O
as	O
one	O
or	O
more	O
of	O
the	O
following	O
postoperative	O
morbidities	O
grade	O
≥	O
2	O
(	O
as	O
per	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
v3	O
.	O
0	O
):	O
pneumonia	B-DISO
,	O
atelectasis	B-DISO
,	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Again	O
lower	O
titers	O
in	O
co	B-DISO
-	I-DISO
infection	I-DISO
groups	O
indicated	O
an	O
interference	O
of	O
the	O
two	O
RNA	O
viruses	O
.	O

HDACi	O
has	O
been	O
reported	O
to	O
revert	O
U18666A	O
-	O
induced	O
dysfunction	O
of	O
Niemann	O
-	O
Pick	O
C1	O
(	O
NPC1	B-DISO
).	O

Currently	O
,	O
the	O
recovery	O
goal	O
in	O
sow	O
units	O
infected	O
with	O
PEDV	O
is	O
to	O
become	O
fully	O
naive	O
again	O
or	O
use	O
natural	O
virus	B-DISO
infection	I-DISO
to	O
develop	O
immune	O
gilts	O
through	O
a	O
feedback	O
program	O
before	O
introduction	O
into	O
the	O
sow	O
herd	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
patient	O
characteristics	O
,	O
clinical	O
manifestations	O
,	O
disease	O
course	O
including	O
viral	O
replication	O
patterns	O
,	O
and	O
outcomes	O
of	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
from	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
and	O
to	O
compare	O
these	O
features	O
with	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
due	O
to	O
other	O
etiologies	O
.	O

Patients	O
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
severe	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
had	O
more	O
severe	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
(	O
PaO2	O
/	O
FIO2	O
:	O
106	O
[	O
66	O
,	O
160	O
]	O
vs	O
176	O
[	O
104	O
,	O
252	O
];	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
more	O
frequent	O
nonrespiratory	O
organ	B-DISO
failure	I-DISO
(	O
nonrespiratory	O
Sequential	O
Organ	B-DISO
Failure	I-DISO
Assessment	O
score	O
:	O
6	O
[	O
4	O
,	O
9	O
]	O
vs	O
5	O
[	O
3	O
,	O
7	O
];	O
p	O
=	O
0	O
.	O
002	O
),	O
thus	O
required	O
more	O
frequently	O
invasive	O
mechanical	O
ventilation	O
(	O
85	O
.	O
2	O
%	O
vs	O
73	O
.	O
0	O
%;	O
p	O
<	O
0	O
.	O
001	O
),	O
oxygen	O
rescue	O
therapies	O
(	O
extracorporeal	O
membrane	O
oxygenation	O
5	O
.	O
8	O
%	O
vs	O
0	O
.	O
9	O
%;	O
p	O
=	O
0	O
.	O
003	O
),	O
vasopressor	O
support	O
(	O
79	O
.	O
4	O
%	O
vs	O
55	O
.	O
0	O
%;	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
renal	O
replacement	O
therapy	O
(	O
48	O
.	O
8	O
%	O
vs	O
22	O
.	O
1	O
%;	O
p	O
<	O
0	O
.	O
001	O
).	O

Spread	O
of	O
the	O
infection	B-DISO
occurred	O
worldwide	O
;	O
however	O
,	O
most	O
cases	O
of	O
mortality	O
have	O
occurred	O
in	O
the	O
Middle	O
East	O
.	O

ABSTRACT	O
:	O
Benign	O
acute	O
childhood	O
myositis	B-DISO
(	O
BACM	O
)	O
is	O
a	O
syndrome	B-DISO
classically	O
occurring	O
in	O
children	O
during	O
the	O
convalescent	O
phase	O
from	O
a	O
febrile	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
,	O
most	O
commonly	O
after	O
influenza	B-DISO
B	O
.	O
BACM	O
can	O
cause	O
difficulty	O
walking	O
due	O
to	O
severe	O
calf	B-DISO
pain	I-DISO
.	O

These	O
data	O
help	O
to	O
appreciate	O
the	O
range	O
of	O
disease	O
severity	O
observed	O
in	O
vivo	O
and	O
the	O
occurrence	O
of	O
chronic	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
in	O
immunocompromised	O
hosts	O
.	O

TITLE	O
:	O
Practical	O
approach	O
to	O
the	O
patient	O
with	O
acute	O
neuromuscular	B-DISO
weakness	I-DISO
.	O

Respiratory	B-DISO
failure	I-DISO
caused	O
by	O
neuromuscular	B-DISO
weakness	I-DISO
is	O
considered	O
as	O
more	O
critical	O
than	O
lung	B-DISO
disease	I-DISO
because	O
its	O
development	O
may	O
be	O
insidious	O
or	O
subtle	O
until	O
sudden	O
decompensation	O
leads	O
to	O
life	O
threatening	O
hypoxia	B-DISO
.	O

TITLE	O
:	O
Genome	O
characterization	O
,	O
antigenicity	O
and	O
pathogenicity	O
of	O
a	O
novel	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
type	O
isolated	O
from	O
south	O
China	O
.	O

TITLE	O
:	O
Isolation	O
,	O
molecular	O
characterization	O
and	O
an	O
artificial	O
infection	B-DISO
model	O
for	O
a	O
variant	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
strain	O
from	O
Jiangsu	O
Province	O
,	O
China	O
.	O

The	O
isolated	O
virus	O
was	O
confirmed	O
to	O
be	O
PEDV	O
via	O
RT	O
-	O
PCR	O
,	O
electron	O
microscopy	O
,	O
a	O
cytopathic	B-DISO
effect	I-DISO
assay	O
and	O
sequence	O
analysis	O
.	O

There	O
are	O
10	O
case	O
reports	O
in	O
the	O
literature	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
use	O
in	O
HIV	B-DISO
-	O
positive	O
patients	O
,	O
of	O
whom	O
seven	O
survived	O
to	O
hospital	O
discharge	O
.	O

ABSTRACT	O
:	O
This	O
communication	O
reports	O
fatal	O
Peste	B-DISO
des	I-DISO
petits	I-DISO
ruminants	I-DISO
(	O
PPR	B-DISO
)	O
disease	O
in	O
Chowsingha	O
(	O
Tetracerus	O
quadricornis	O
),	O
a	O
member	O
of	O
the	O
subfamily	O
Bovinae	O
and	O
family	O
Bovidae	O
captured	O
in	O
a	O
Zoological	O
Park	B-DISO
.	O

Sequence	O
analysis	O
of	O
complete	O
H	O
gene	O
and	O
partial	O
N	O
gene	O
confirmed	O
the	O
aetiological	O
agent	O
as	O
PPR	B-DISO
virus	O
lineage	O
IV	O
.	O

This	O
report	O
extends	O
host	O
range	O
and	O
demands	O
enhanced	O
surveillance	O
among	O
subfamily	O
bovinae	O
to	O
strengthen	O
PPR	B-DISO
eradication	O
programme	O
.	O

All	O
had	O
excessive	B-DISO
daytime	I-DISO
sleepiness	I-DISO
,	O
high	O
arousal	O
index	O
and	O
Apnoea	B-DISO
-	O
Hypopnoea	O
Index	O
(	O
AHI	O
)	O
<	O
5	O
.	O

TITLE	O
:	O
What	O
We	O
Are	O
Watching	O
-	O
Top	O
Global	O
Infectious	B-DISO
Disease	I-DISO
Threats	O
,	O
2013	O
-	O
2016	O
:	O
An	O
Update	O
from	O
CDC	O
'	O
s	O
Global	O
Disease	O
Detection	O
Operations	O
Center	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
is	O
an	O
emerging	O
zoonotic	O
viral	O
respiratory	B-DISO
disease	I-DISO
that	O
was	O
first	O
identified	O
in	O
Saudi	O
Arabia	O
in	O
2012	O
.	O

A	O
real	O
-	O
time	O
reverse	O
transcription	O
RPA	O
(	O
RT	O
-	O
RPA	O
)	O
assay	O
for	O
the	O
detection	O
of	O
canine	B-DISO
distemper	I-DISO
virus	O
(	O
CDV	O
)	O
using	O
primers	O
and	O
exo	O
probe	O
targeting	O
the	O
CDV	O
nucleocapsid	O
protein	O
gene	O
was	O
developed	O
.	O

In	O
fact	O
,	O
reinfection	O
resulted	O
in	O
enhanced	O
pulmonary	B-DISO
inflammation	I-DISO
,	O
without	O
an	O
associated	O
increase	O
in	O
viral	O
RNA	O
titers	O
.	O

We	O
further	O
found	O
this	O
inflammation	B-DISO
was	O
accompanied	O
by	O
increased	O
recruitment	B-DISO
of	O
complement	O
proteins	O
compared	O
to	O
primary	B-DISO
infection	I-DISO
.	O

We	O
identified	O
two	O
critical	O
phases	O
of	O
respiratory	B-DISO
dysfunction	I-DISO
in	O
SAD	B-DISO
mice	O
;	O
the	O
first	O
prior	O
to	O
weaning	O
and	O
the	O
second	O
in	O
adulthood	O
.	O

This	O
report	O
suggests	O
that	O
ECMO	O
currently	O
allows	O
treatment	O
of	O
severe	O
ARDS	B-DISO
with	O
presumed	O
improved	O
survival	O
.	O

ABSTRACT	O
:	O
We	O
evaluated	O
serologic	O
response	O
of	O
42	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)-	O
infected	O
patients	O
according	O
to	O
4	O
severity	O
groups	O
:	O
asymptomatic	B-DISO
infection	I-DISO
(	O
Group	O
0	O
),	O
symptomatic	O
infection	B-DISO
without	O
pneumonia	B-DISO
(	O
Group	O
1	O
),	O
pneumonia	B-DISO
without	O
respiratory	B-DISO
failure	I-DISO
(	O
Group	O
2	O
),	O
and	O
pneumonia	B-DISO
progressing	O
to	O
respiratory	B-DISO
failure	I-DISO
(	O
Group	O
3	O
).	O

ABSTRACT	O
:	O
In	O
the	O
past	O
five	O
years	O
,	O
there	O
have	O
been	O
1	O
,	O
936	O
laboratory	O
-	O
confirmed	O
cases	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
27	O
countries	O
,	O
with	O
a	O
mortality	O
rate	O
of	O
35	O
.	O
6	O
%.	O

At	O
14	O
,	O
28	O
,	O
and	O
42	O
days	O
after	O
the	O
first	O
vaccination	O
,	O
serum	O
anti	O
-	O
IBV	O
antibody	O
titers	O
;	O
peripheral	O
lymphocyte	O
proliferation	B-DISO
;	O
and	O
the	O
mRNA	O
expression	O
of	O
IL	O
-	O
1β	O
,	O
IL	O
-	O
2	O
,	O
IL	O
-	O
8	O
,	O
and	O
TNF	O
-	O
α	O
in	O
the	O
spleen	O
were	O
assessed	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
the	O
cell	O
counting	O
kit	O
-	O
8	O
(	O
CCK	O
-	O
8	O
),	O
and	O
real	O
time	O
quantitative	O
RT	O
-	O
PCR	O
(	O
qRT	O
-	O
PCR	O
),	O
respectively	O
.	O

At	O
most	O
time	O
points	O
,	O
the	O
titer	O
of	O
IBV	O
-	O
specific	O
antibodies	O
,	O
lymphocyte	O
proliferation	B-DISO
,	O
and	O
IL	O
-	O
1β	O
,	O
IL	O
-	O
2	O
,	O
IL	O
-	O
8	O
,	O
and	O
TNF	O
-	O
α	O
mRNA	O
expression	O
levels	O
were	O
higher	O
in	O
three	O
APS	B-DISO
groups	O
than	O
in	O
the	O
vaccine	O
control	O
group	O
,	O
and	O
these	O
increases	O
were	O
dose	O
-	O
dependent	O
.	O

TITLE	O
:	O
Antibiotics	O
for	O
persistent	B-DISO
cough	I-DISO
or	O
wheeze	B-DISO
following	O
acute	B-DISO
bronchiolitis	I-DISO
in	O
children	O
.	O

We	O
illustrate	O
the	O
potential	O
of	O
Internet	O
data	O
streams	O
to	O
improve	O
preparedness	O
and	O
response	O
in	O
outbreak	O
situations	O
by	O
drawing	O
from	O
recent	O
work	O
on	O
the	O
2014	O
-	O
2015	O
Ebola	O
epidemic	O
in	O
West	O
Africa	O
and	O
the	O
2015	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
outbreak	O
in	O
South	O
Korea	O
.	O

Importantly	O
,	O
attenuation	O
of	O
the	O
dORF3	O
-	O
5	O
mutant	B-DISO
is	O
primarily	O
driven	O
by	O
dysregulated	O
host	O
responses	O
,	O
including	O
disrupted	O
cell	O
processes	O
,	O
augmented	O
interferon	O
(	O
IFN	O
)	O
pathway	O
activation	O
,	O
and	O
robust	O
inflammation	B-DISO
.	O

ABSTRACT	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
is	O
the	O
most	O
common	O
infectious	B-DISO
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
disease	O
in	O
the	O
cat	O
and	O
is	O
invariably	O
fatal	O
.	O

It	O
typically	O
manifests	O
as	O
an	O
acute	O
episode	O
of	O
headache	B-DISO
,	O
visual	B-DISO
disturbance	I-DISO
,	O
mental	B-DISO
status	I-DISO
changes	I-DISO
,	O
cranial	B-DISO
nerve	I-DISO
palsy	I-DISO
,	O
and	O
endocrine	O
pituitary	B-DISO
dysfunction	I-DISO
.	O

An	O
83	O
-	O
year	O
-	O
old	O
Japanese	O
man	O
developed	O
acute	O
anterior	O
hypopituitarism	B-DISO
;	O
he	O
showed	O
anorexia	B-DISO
,	O
fatigue	B-DISO
,	O
lethargy	B-DISO
,	O
severe	O
bilateral	O
periorbital	B-DISO
edema	I-DISO
,	O
and	O
mild	O
cardiac	O
dysfunction	O
in	O
the	O
absence	O
of	O
headache	B-DISO
,	O
visual	B-DISO
disturbance	I-DISO
,	O
altered	B-DISO
mental	I-DISO
status	I-DISO
,	O
and	O
cranial	B-DISO
nerve	I-DISO
palsy	I-DISO
.	O

Common	O
causes	O
of	O
periorbital	B-DISO
edema	I-DISO
include	O
infections	B-DISO
,	O
inflammation	B-DISO
,	O
trauma	O
,	O
allergy	B-DISO
,	O
kidney	O
or	O
cardiac	O
dysfunction	O
,	O
and	O
endocrine	B-DISO
disorders	I-DISO
such	O
as	O
primary	B-DISO
hypothyroidism	I-DISO
.	O

ABSTRACT	O
:	O
Viral	B-DISO
infection	I-DISO
of	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
is	O
complicated	O
by	O
the	O
mostly	O
irreplaceable	O
nature	O
of	O
neurons	O
,	O
as	O
the	O
loss	O
of	O
neurons	O
has	O
the	O
potential	O
to	O
result	O
in	O
permanent	O
damage	O
to	O
brain	O
function	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
indicated	O
that	O
some	O
neurons	O
are	O
resistant	O
to	O
virus	O
-	O
mediated	O
cell	O
death	O
and	O
provide	O
a	O
framework	O
for	O
studying	O
the	O
effects	O
of	O
prior	O
coronavirus	B-DISO
infection	I-DISO
on	O
neuron	O
function	O
.	O

ABSTRACT	O
:	O
Lemierre	B-DISO
'	I-DISO
s	I-DISO
syndrome	I-DISO
cause	O
by	O
methicillin	O
-	O
sensitive	O
In	O
this	O
report	O
we	O
present	O
a	O
12	O
year	O
old	O
male	O
who	O
presented	O
with	O
Lemierre	B-DISO
'	I-DISO
s	I-DISO
syndrome	I-DISO
from	O
which	O
he	O
developed	O
septic	B-DISO
shock	I-DISO
and	O
severe	O
necrotizing	B-DISO
pneumonia	I-DISO
.	O

Using	O
a	O
prospectively	O
maintained	O
database	O
of	O
patients	O
with	O
acute	B-DISO
pancreatitis	I-DISO
admitted	O
to	O
a	O
tertiary	O
medical	O
center	O
between	O
2003	O
and	O
2016	O
,	O
those	O
with	O
evidence	O
of	O
persistent	O
OF	O
were	O
classified	O
to	O
renal	O
,	O
respiratory	O
,	O
cardiovascular	O
,	O
or	O
multi	O
-	O
organ	O
(	O
2	O
or	O
more	O
organs	O
).	O

Differences	O
in	O
clinical	O
outcomes	O
after	O
development	O
of	O
isolated	O
RF	O
in	O
comparison	O
to	O
other	O
forms	O
of	O
OF	O
were	O
determined	O
using	O
independent	O
t	O
and	O
Mann	O
-	O
Whitney	O
Among	O
500	O
patients	O
with	O
acute	B-DISO
pancreatitis	I-DISO
,	O
111	O
patients	O
developed	O
persistent	O
OF	O
:	O
mean	O
age	O
was	O
54	O
years	O
,	O
and	O
75	O
(	O
67	O
.	O
6	O
%)	O
were	O
male	O
.	O

No	O
differences	O
in	O
demographics	O
,	O
etiology	O
of	O
acute	B-DISO
pancreatitis	I-DISO
,	O
systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
syndrome	I-DISO
scores	O
,	O
or	O
development	O
of	O
pancreatic	B-DISO
necrosis	I-DISO
were	O
seen	O
between	O
patients	O
with	O
isolated	O
RF	O
CONCLUSIONS	O
:	O
Among	O
patients	O
with	O
SAP	O
per	O
the	O
Revised	O
Atlanta	O
Classification	O
,	O
approximately	O
15	O
%	O
develop	O
isolated	O
RF	O
.	O

Subsequent	O
examination	O
of	O
sputum	O
later	O
on	O
day	O
3	O
confirmed	O
MERS	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Asthma	B-DISO
is	O
a	O
syndrome	B-DISO
of	O
chronic	O
bronchial	O
inflammation	B-DISO
and	O
airway	O
remodelling	O
.	O

This	O
study	O
examines	O
the	O
profiles	O
of	O
upregulation	O
and	O
downregulation	O
of	O
various	O
cytokines	O
and	O
chemokines	O
in	O
relation	O
to	O
asthmatic	B-DISO
control	O
status	O
.	O

TITLE	O
:	O
Rapamycin	O
-	O
induced	O
autophagy	O
restricts	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
infectivity	O
in	O
porcine	O
intestinal	O
epithelial	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
past	O
decade	O
and	O
a	O
half	O
has	O
been	O
characterized	O
by	O
numerous	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

Male	O
BABL	O
/	O
c	O
mice	O
were	O
injected	O
through	O
tail	O
vein	O
using	O
lipopolysaccharide	O
(	O
LPS	B-DISO
,	O
5	O
mg	O
/	O
kg	O
)	O
with	O
or	O
without	O
5	O
mg	O
/	O
kg	O
MP	O
.	O

An	O
assessment	O
of	O
a	O
prospectively	O
collected	O
cohort	O
of	O
441	O
patients	O
with	O
ARDS	B-DISO
admitted	O
to	O
three	O
intensive	O
care	O
units	O
at	O
the	O
University	O
Medical	O
Centre	O
identified	O
274	O
patients	O
with	O
ARDS	B-DISO
due	O
to	O
pneumonia	B-DISO
.	O

ABSTRACT	O
:	O
Porcine	O
deltacoronavirus	O
(	O
PDCoV	O
)	O
has	O
been	O
recently	O
recognized	O
as	O
an	O
emerging	O
viral	O
pathogen	O
that	O
causes	O
diarrhea	B-DISO
in	O
newborn	O
piglets	O
.	O

Herein	O
,	O
PEDV	O
isolate	O
85	O
-	O
7	O
could	O
proliferate	O
and	O
induce	O
cell	O
-	O
cell	O
fusion	O
in	O
a	O
trypsin	O
independent	O
manner	O
on	O
Vero	O
cells	O
,	O
and	O
eight	O
homologous	O
mutation	O
strains	O
were	O
screened	O
by	O
continuous	O
proliferation	B-DISO
in	O
the	O
absence	O
of	O
trypsin	O
on	O
Vero	O
cells	O
.	O

This	O
change	O
resulted	O
in	O
weaker	O
cell	O
-	O
cell	O
fusion	O
,	O
smaller	O
plaque	B-DISO
morphology	O
,	O
higher	O
virus	O
titer	O
and	O
serious	O
microfilament	O
condensation	B-DISO
.	O

The	O
current	O
therapies	O
have	O
mainly	O
been	O
adapted	O
from	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
-	O
CoV	O
)	O
treatments	O
,	O
including	O
broad	O
-	O
spectrum	O
antibiotics	O
,	O
corticosteroids	O
,	O
interferons	O
,	O
ribavirin	O
,	O
lopinavir	O
-	O
ritonavir	O
or	O
mycophenolate	O
mofetil	O
,	O
and	O
have	O
not	O
been	O
subject	O
to	O
well	O
-	O
organized	O
clinical	O
trials	O
.	O

The	O
control	O
group	O
deteriorated	O
in	O
arterial	O
oxygen	O
tension	B-DISO
/	O
inspired	O
oxygen	O
fraction	O
,	O
whereas	O
the	O
protective	O
group	O
was	O
unchanged	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

Use	O
of	O
daily	O
sedation	B-DISO
interruption	O
and	O
a	O
sedation	B-DISO
/	O
analgesia	B-DISO
protocol	O
was	O
reported	O
by	O
51	O
%	O
and	O
39	O
%,	O
respectively	O
.	O

The	O
most	O
frequently	O
perceived	O
barriers	O
to	O
mobilization	O
were	O
hemodynamic	B-DISO
instability	I-DISO
,	O
hypoxemia	O
,	O
and	O
dependency	O
on	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
support	O
.	O

There	O
is	O
considerable	O
variability	O
surrounding	O
early	O
physical	O
therapy	O
and	O
mobilization	O
goals	O
for	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
supported	O
by	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

TITLE	O
:	O
Neurologic	O
Injury	O
With	O
Severe	O
Adult	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
in	O
Patients	O
Undergoing	O
Extracorporeal	O
Membrane	O
Oxygenation	O
:	O
A	O
Single	O
-	O
Center	O
Retrospective	O
Analysis	O
.	O

ABSTRACT	O
:	O
This	O
retrospective	O
single	O
-	O
center	O
study	O
investigated	O
the	O
incidence	O
of	O
neurologic	O
injury	O
as	O
determined	O
by	O
autopsy	O
or	O
cerebral	O
imaging	O
in	O
74	O
patients	O
undergoing	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ECMO	O
-	O
associated	O
intracerebral	B-DISO
hemorrhage	I-DISO
was	O
diagnosed	O
in	O
10	O
.	O
8	O
%	O
of	O
patients	O
.	O

Six	O
-	O
month	O
survival	O
was	O
13	O
%	O
(	O
Wilson	O
confidence	O
interval	O
,	O
2	O
%-	O
47	O
%)	O
in	O
patients	O
with	O
severe	O
intracerebral	B-DISO
hemorrhage	I-DISO
compared	O
to	O
an	O
overall	O
survival	O
rate	O
of	O
57	O
%	O
(	O
Wilson	O
confidence	O
interval	O
,	O
45	O
%-	O
67	O
%).	O

We	O
suggest	O
that	O
antimicrobial	O
peptides	O
(	O
AMPs	O
)	O
may	O
be	O
used	O
as	O
alternative	O
therapeutic	O
agents	O
against	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
The	O
emergence	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
-	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
resulted	O
in	O
multiple	O
healthcare	O
associated	O
outbreaks	O
.	O

TITLE	O
:	O
Type	O
II	O
transmembrane	O
serine	O
proteases	O
as	O
potential	O
target	O
for	O
anti	O
-	O
influenza	B-DISO
drug	O
discovery	O
.	O

ABSTRACT	O
:	O
The	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
a	O

ABSTRACT	O
:	O
Changes	O
occurred	O
in	O
the	O
patterns	O
of	O
utilization	O
of	O
emergency	B-DISO
medical	O
services	O
during	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
outbreak	O
.	O

We	O
compared	O
and	O
analyzed	O
the	O
patients	O
'	O
characteristics	O
,	O
emergency	B-DISO
severity	O
index	O
(	O
ESI	O
)	O
level	O
at	O
the	O
visit	O
,	O
cause	O
of	O
visit	O
,	O
diagnosis	O
,	O
final	O
dispositions	O
,	O
injury	O
/	O
non	O
-	O
injury	O
,	O
length	O
of	O
stay	O
at	O
the	O
ED	O
(	O
EDLOS	O
),	O
and	O
hospitalization	O
rate	O
.	O

TITLE	O
:	O
MERS	O
-	O
CoV	O
Infection	B-DISO
in	O
a	O
Pregnant	O
Woman	O
in	O
Korea	O
.	O

Her	O
condition	B-DISO
was	O
improved	O
only	O
with	O
conservative	O
treatment	O
.	O

After	O
a	O
full	O
recovery	O
of	O
MERS	O
,	O
the	O
patient	O
manifested	O
abrupt	O
vaginal	B-DISO
bleeding	I-DISO
with	O
rupture	O
of	O
membrane	O
.	O

ABSTRACT	O
:	O
An	O
increasing	O
number	O
of	O
publications	O
describe	O
the	O
potential	O
of	O
ionic	O
liquids	O
(	O
ILs	B-DISO
)	O
as	O
novel	O
antimicrobials	O
,	O
antibacterial	O
coatings	O
and	O
even	O
as	O
active	O
pharmaceutical	O
ingredients	O
.	O

All	O
structure	O
activity	O
relationships	O
(	O
SARs	B-DISO
)	O
were	O
tested	O
on	O
the	O
human	O
norovirus	O
surrogate	O
phage	O
MS2	O
and	O
phage	O
P100	O
representing	O
non	O
-	O
enveloped	O
DNA	O
viruses	O
.	O

Overall	O
,	O
four	O
ILs	B-DISO
,	O
covering	O
different	O
structural	O
elements	O
,	O
were	O
found	O
to	O
reduce	O
phage	O
P100	O
infectivity	O
by	O
≥	O
4	O
log	O

ABSTRACT	O
:	O
Porcine	B-DISO
reproductive	I-DISO
and	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
(	O
PRRSV	O
)	O
and	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
are	O
porcine	O
nidoviruses	O
that	O
are	O
considered	O
emerging	O
and	O
re	O
-	O
emerging	O
viral	O
pathogens	O
of	O
pigs	O
that	O
pose	O
a	O
significant	O
economic	O
threat	O
to	O
the	O
global	O
pork	O
industry	O
.	O

HPeV	O
coinfection	B-DISO
might	O
associate	O
with	O
convulsion	B-DISO
and	O
aggravate	O
other	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
.	O

Our	O
objective	O
was	O
to	O
compare	O
the	O
rate	O
of	O
respiratory	B-DISO
complications	I-DISO
in	O
patients	O
with	O
COPD	B-DISO
with	O
severe	O
aortic	B-DISO
stenosis	I-DISO
who	O
underwent	O
transcatheter	O
aortic	O
valve	O
implantation	O
(	O
TAVI	O
)	O
versus	O
surgical	O
aortic	O
valve	O
replacement	O
(	O
SAVR	O
).	O

A	O
total	O
of	O
321	O
patients	O
(	O
mean	O
age	O
72	O
.	O
4	O
±	O
9	O
.	O
3	O
years	O
old	O
,	O
74	O
.	O
5	O
%	O
male	O
,	O
mean	O
Society	O
of	O
Thoracic	B-DISO
Surgeons	O
predicted	O
risk	O
of	O
mortality	O
3	O
.	O
8	O
±	O
1	O
.	O
9	O
%,	O
mean	O
forced	O
expiratory	O
volume	O
1	O
:	O
59	O
±	O
13	O
%)	O
were	O
included	O
in	O
the	O
analysis	O
.	O

Part	O
of	O
the	O
current	O
critical	O
care	O
knowledge	O
base	O
must	O
include	O
an	O
understanding	O
of	O
how	O
extracorporeal	O
membrane	O
oxygenation	O
fits	B-DISO
into	O
the	O
paradigm	O
of	O
ARDS	B-DISO
management	O
without	O
using	O
it	O
as	O
a	O
""""	O
salvage	O
therapy	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
support	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
has	O
been	O
increasing	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
does	O
not	O
replicate	O
in	O
porcine	O
monocyte	O
-	O
derived	O
dendritic	O
cells	O
,	O
but	O
activates	O
the	O
transcription	O
of	O
type	O
I	O
interferon	O
and	O
chemokine	O
.	O

TITLE	O
:	O
Role	O
of	O
biomarkers	O
in	O
acute	O
traumatic	B-DISO
lung	I-DISO
injury	O
.	O

We	O
present	O
this	O
case	O
with	O
literature	O
review	O
for	O
the	O
CMV	B-DISO
infection	I-DISO
associated	O
morbidity	O
and	O
mortality	O
among	O
immunocompetent	O
children	O
.	O

Reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
tests	O
for	O
bovine	B-DISO
viral	I-DISO
diarrhea	I-DISO
virus	O
,	O
rotavirus	O
and	O
coronavirus	O
were	O
all	O
negative	O
.	O

Severe	O
malaria	B-DISO
was	O
diagnosed	O
in	O
34	O
(	O
17	O
.	O
9	O
%)	O
patients	O
and	O
ICU	O
admittance	O
was	O
required	O
in	O
2	O
.	O
6	O
%	O
of	O
them	O
.	O

In	O
this	O
paper	O
,	O
a	O
class	O
of	O
novel	O
four	O
-	O
dimensional	O
dynamic	O
model	O
describing	O
the	O
infection	B-DISO
of	O
MERS	O
-	O
CoV	O
is	O
given	O
,	O
and	O
then	O
global	O
stability	O
of	O
the	O
equilibria	O
of	O
the	O
model	O
is	O
discussed	O
.	O

These	O
data	O
suggest	O
that	O
inflammasome	O
signaling	O
is	O
largely	O
protective	O
during	O
murine	O
coronavirus	B-DISO
infection	I-DISO
,	O
in	O
large	O
part	O
due	O
to	O
the	O
pro	O
-	O
inflammatory	O
effects	O
of	O
IL	O
-	O
18	O
.	O

We	O
also	O
characterized	O
the	O
antigenicity	O
,	O
pathogenesis	B-DISO
,	O
tissue	O
tropism	O
and	O
spreading	O
of	O
three	O
IBV	O
isolates	O
by	O
experimental	O
infection	B-DISO
of	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
chickens	O
and	O
contact	O
sentinel	O
birds	O
.	O

We	O
used	O
a	O
publically	O
available	O
case	O
line	O
list	O
to	O
explore	O
the	O
effect	O
of	O
relevant	O
factors	O
,	O
notably	O
underlying	O
comorbidities	O
,	O
on	O
fatal	O
outcome	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
cases	O
up	O
to	O
the	O
end	O
of	O
October	O
2016	O
.	O

Cats	O
with	O
neurologic	B-DISO
signs	I-DISO
were	O
excluded	O
from	O
the	O
study	O
.	O

Severe	O
neurologic	O
disease	O
occurred	O
in	O
8	O
/	O
13	O
cats	O
that	O
failed	O
treatment	O
and	O
five	O
cats	O
had	O
recurrences	B-DISO
of	O
abdominal	O
lesions	O
.	O

Five	O
kittens	O
aged	O
3	O
.	O
3	O
-	O
4	O
.	O
4	O
months	O
with	O
wet	B-DISO
FIP	I-DISO
were	O
treated	O
for	O
12	O
weeks	O
and	O
have	O
been	O
in	O
disease	O
remission	B-DISO
after	O
stopping	O
treatment	O
and	O
at	O
the	O
time	O
of	O
writing	O
for	O
5	O
-	O
14	O
months	O
(	O
mean	O
11	O
.	O
2	O
months	O
).	O

The	O
seventh	O
was	O
a	O
6	O
.	O
8	O
-	O
year	O
-	O
old	O
cat	O
with	O
only	O
mesenteric	O
lymph	O
node	O
involvement	O
that	O
went	O
into	O
remission	B-DISO
after	O
three	O
relapses	O
that	O
required	O
progressively	O
longer	O
repeat	O
treatments	O
over	O
a	O
10	O
month	O
period	O
.	O

Side	O
effects	O
of	O
treatment	O
included	O
transient	O
stinging	B-DISO
upon	O
injection	O
and	O
occasional	O
foci	O
of	O
subcutaneous	B-DISO
fibrosis	I-DISO
and	O
hair	O
loss	O
.	O

There	O
was	O
retarded	O
development	O
and	O
abnormal	O
eruption	B-DISO
of	O
permanent	O
teeth	O
in	O
cats	O
treated	O
before	O
16	O
-	O
18	O
weeks	O
of	O
age	O
.	O

TITLE	O
:	O
In	O
-	O
Hospital	O
Outcomes	O
of	O
Tumor	B-DISO
Lysis	I-DISO
Syndrome	I-DISO
:	O

The	O
most	O
common	O
malignancies	B-DISO
were	O
non	B-DISO
-	I-DISO
Hodgkin	I-DISO
lymphoma	I-DISO
(	O
30	O
%),	O
solid	B-DISO
tumors	I-DISO
(	O
20	O
%),	O
acute	B-DISO
myeloid	I-DISO
leukemia	I-DISO
(	O
19	O
%),	O
and	O
acute	B-DISO
lymphocytic	I-DISO
leukemia	I-DISO
(	O
13	O
%).	O

ABSTRACT	O
:	O
A	O
22	O
-	O
year	O
-	O
old	O
Asian	O
woman	O
presented	O
with	O
respiratory	B-DISO
distress	I-DISO
,	O
cough	B-DISO
,	O
and	O
wheezing	B-DISO
for	O
1	O
week	O
.	O

Study	O
subjects	O
were	O
5	O
,	O
298	O
patients	O
,	O
who	O
underwent	O
multiplex	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
for	O
simultaneous	O
detection	O
of	O
respiratory	O
viruses	O
,	O
among	O
who	O
visited	O
the	O
emergency	B-DISO
department	O
or	O
outpatient	O
clinic	O
with	O
respiratory	B-DISO
symptoms	I-DISO
at	O
Ulsan	O
University	O
Hospital	O
between	O
April	O
2013	O
and	O
March	O
2016	O
.	O

TITLE	O
:	O
Inclusion	O
of	O
MERS	O
-	O
spike	O
protein	O
ELISA	O
in	O
algorithm	O
to	O
determine	O
serologic	O
evidence	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

This	O
was	O
a	O
prospective	O
cohort	O
study	O
(	O
March	O
2014	O
-	O
February	O
2015	O
)	O
of	O
mechanically	O
ventilated	O
adults	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	B-DISO
requiring	O
an	O
Fi	O
We	O
enrolled	O
664	O
patients	O
:	O
222	O
(	O
33	O
%)	O
with	O
moderate	O
and	O
442	O
(	O
67	O
%)	O
with	O
severe	O
ARDS	B-DISO
.	O

Drill	O
scenarios	O
presented	O
a	O
patient	O
reporting	O
signs	O
or	O
symptoms	O
and	O
travel	O
history	O
consistent	O
with	O
possible	O
measles	B-DISO
or	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
).	O

Evaluators	O
captured	O
key	O
infection	B-DISO
control	O
performance	O
measures	O
,	O
including	O
time	O
to	O
patient	O
masking	O
and	O
isolation	O
.	O

Ninety	O
-	O
five	O
drills	O
(	O
53	O
measles	B-DISO
and	O
42	O
MERS	O
)	O
were	O
conducted	O
in	O
49	O
EDs	B-DISO
with	O
patients	O
masked	O
and	O
isolated	O
in	O
78	O
%	O
of	O
drills	O
.	O

Local	O
septic	O
complications	O
were	O
higher	O
,	O
as	O
expected	O
,	O
in	O
all	O
patients	O
with	O
external	O
fixation	O
and	O
we	O
observed	O
a	O
very	O
low	O
incidence	O
in	O
the	O
ETC	O
group	O
(	O
8	O
.	O
3	O
%	O
-	O
DCO	B-DISO
shock	O
group	O
versus	O
1	O
.	O
9	O
%	O
-	O
ETC	O
group	O
and	O
6	O
.	O
7	O
%	O
-	O
DCO	B-DISO
no	O
shock	O
group	O
;	O
p	O
=	O
0	O
.	O
18	O
/	O
0	O
.	O
009	O
).	O

ABSTRACT	O
:	O
Extracorporeal	O
respiratory	O
support	O
,	O
also	O
known	O
as	O
extracorporeal	O
gas	O
exchange	O
,	O
may	O
be	O
used	O
to	O
rescue	O
the	O
most	O
severe	O
forms	O
of	O
acute	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
with	O
high	O
blood	O
flow	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

However	O
,	O
in	O
patients	O
with	O
syndromic	O
CIDs	O
,	O
autosomal	O
recessive	O
mutations	O
in	O
ataxia	B-DISO
-	I-DISO
telangiectasia	I-DISO
mutated	O
(	O
ATM	O
),	O
autosomal	O
dominant	O
mutations	O
in	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
STAT3	O
),	O
and	O
microdeletions	O
in	O
22q11	O
.	O
21	O
were	O
the	O
most	O
commonly	O
affected	O
genomic	O
loci	O
.	O

Our	O
data	O
suggest	O
that	O
rSPV	O
-	O
St	O
is	O
potentially	O
an	O
effective	O
vaccine	O
against	O
infection	B-DISO
with	O
emerging	O
PEDV	O
strains	O
.	O

TITLE	O
:	O
Interstitial	B-DISO
pneumonia	I-DISO
with	O
autoimmune	B-DISO
features	O
:	O
an	O
additional	O
risk	O
factor	O
for	O
ARDS	B-DISO
?	O

This	O
diagnosis	O
should	O
be	O
considered	O
in	O
any	O
critically	B-DISO
ill	I-DISO
patient	O
with	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
of	O
unknown	O
origin	O
.	O

Driven	O
by	O
recent	O
disease	O
epidemics	O
like	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
),	O
and	O
Ebola	O
,	O
bats	O
have	O
gained	O
special	O
interest	O
as	O
reservoirs	O
of	O
emerging	O
viruses	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
analyze	O
,	O
using	O
a	O
decision	O
analysis	O
approach	O
,	O
the	O
probability	O
of	O
severity	O
of	O
illness	O
due	O
to	O
delayed	O
utilization	O
of	O
health	O
services	O
and	O
inappropriate	O
hospital	O
medical	O
treatment	O
during	O
the	O
2009	O
AH1N1	O
influenza	B-DISO
epidemic	I-DISO
in	O
Mexico	O
.	O

TITLE	O
:	O
Identification	O
of	O
sialic	O
acid	O
-	O
binding	O
function	O
for	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
spike	O
glycoprotein	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
serious	O
complication	B-DISO
of	O
acute	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
The	O
life	O
cycle	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
involves	O
a	O
unique	O
process	O
called	O
discontinuous	O
transcription	O
by	O
which	O
a	O
set	O
of	O
3	O
'	O
coterminal	O
subgenomic	O
mRNAs	O
(	O
sgmRNA	O
)	O
with	O
identical	O
5	O
'	O
leader	O
sequences	O
can	O
be	O
generated	O
.	O

TITLE	O
:	O
Protective	O
Humoral	O
Immunity	O
in	O
the	O
Central	O
Nervous	B-DISO
System	O
Requires	O
Peripheral	O
CD19	O
-	O
Dependent	O
Germinal	O
Center	O
Formation	O
following	O
Coronavirus	O
Encephalomyelitis	B-DISO
.	O

In	O
the	O
past	O
14	O
years	O
,	O
the	O
onset	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
have	O
thrust	O
HCoVs	O
into	O
spotlight	O
of	O
the	O
research	O
community	O
due	O
to	O
their	O
high	O
pathogenicity	O
in	O
humans	O
.	O

In	O
this	O
study	O
,	O
chicken	O
macrophage	O
HD11	O
cells	O
were	O
established	O
as	O
a	O
cellular	O
model	O
that	O
is	O
permissive	O
to	O
IBV	O
infection	B-DISO
.	O

TITLE	O
:	O
A	O
simple	O
and	O
rapid	O
identification	O
method	O
for	O
newly	O
emerged	O
porcine	O
Deltacoronavirus	O
with	O
loop	O
-	O
mediated	O
isothermal	O
amplification	B-DISO
.	O

RESULTS	O
:	O
In	O
this	O
study	O
,	O
we	O
developed	O
a	O
single	O
-	O
tube	O
one	O
-	O
step	O
reverse	O
transcription	O
loop	O
-	O
mediated	O
isothermal	O
amplification	B-DISO
(	O
RT	O
-	O
LAMP	O
)	O
assay	O
specific	O
for	O
nucleocapsid	O
gene	O
to	O
diagnose	O
and	O
monitor	O
PDCoV	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
Maternal	O
hemorrhage	B-DISO
,	O
defined	O
as	O
a	O
cumulative	O
blood	B-DISO
loss	I-DISO
of	O
greater	O
than	O
or	O
equal	O
to	O
1	O
,	O
000	O
mL	O
or	O
blood	B-DISO
loss	I-DISO
accompanied	O
by	O
signs	O
or	O
symptoms	O
of	O
hypovolemia	O
within	O
24	O
hours	O
after	O
the	O
birth	O
process	O
,	O
remains	O
the	O
leading	O
cause	O
of	O
maternal	O
mortality	O
worldwide	O
(	O
1	O
).	O

In	O
the	O
United	O
States	O
,	O
the	O
rate	O
of	O
postpartum	B-DISO
hemorrhage	I-DISO
increased	O
26	O
%	O
between	O
1994	O
and	O
2006	O
primarily	O
because	O
of	O
increased	O
rates	O
of	O
atony	O
(	O
3	O
).	O

For	O
treatment	O
of	O
specific	O
conditions	O
,	O
we	O
suggest	O
using	O
IV	O
hydrocortisone	O
<	O
400	O
mg	O
/	O
day	O
for	O
≥	O
3	O
days	O
at	O
full	O
dose	O
in	O
patients	O
with	O
septic	B-DISO
shock	I-DISO
that	O
is	O
not	O
responsive	O
to	O
fluid	O
and	O
moderate	O
-	O
to	O
high	O
-	O
dose	O
vasopressor	O
therapy	O
(	O
conditional	O
,	O
low	O
quality	O
of	O
evidence	O
).	O

TITLE	O
:	O
Guidelines	O
for	O
the	O
diagnosis	O
and	O
management	O
of	O
critical	B-DISO
illness	I-DISO
-	O
related	O
corticosteroid	O
insufficiency	O
(	O
CIRCI	O
)	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
(	O
Part	O
I	O
):	O
Society	O
of	O
Critical	O
Care	O
Medicine	O
(	O
SCCM	O
)	O
and	O
European	O
Society	O
of	O
Intensive	O
Care	O
Medicine	O
(	O
ESICM	O
)	O
2017	O
.	O

We	O
suggest	O
the	O
use	O
of	O
IV	O
methylprednisolone	O
1	O
mg	O
/	O
kg	O
/	O
day	O
in	O
patients	O
with	O
early	O
moderate	O
to	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
PaO	O
Evidence	O
-	O
based	O
recommendations	O
for	O
the	O
use	O
of	O
corticosteroids	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
sepsis	B-DISO
and	O
septic	B-DISO
shock	I-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
and	O
major	O
trauma	O
have	O
been	O
developed	O
by	O
a	O
multispecialty	O
task	O
force	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
whether	O
,	O
and	O
by	O
which	O
mechanism	O
,	O
vitamin	O
D	O
alleviates	O
lipopolysaccharide	O
(	O
LPS	B-DISO
)‑	O
induced	O
ALI	O
.	O

ABSTRACT	O
:	O
Porcine	B-DISO
transmissible	I-DISO
gastroenteritis	I-DISO
virus	O
(	O
TGEV	O
)	O
and	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
are	O
the	O
causative	O
agents	O
of	O
highly	O
fatal	O
acute	B-DISO
diarrhea	I-DISO
in	O
pigs	O
,	O
resulting	O
in	O
enormous	O
losses	O
in	O
the	O
pig	O
industry	O
worldwide	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
causes	O
devastating	O
impact	O
on	O
global	O
pig	O
-	O
breeding	O
industry	O
and	O
current	O
vaccines	O
have	O
become	O
not	O
effective	O
against	O
the	O
circulating	O
PEDV	O
variants	O
since	O
2011	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
well	O
known	O
to	O
cause	O
severe	O
respiratory	B-DISO
infection	I-DISO
and	O
was	O
first	O
reported	O
in	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
in	O
2012	O
.	O

We	O
report	O
here	O
the	O
first	O
confirmed	O
MERS	O
-	O
CoV	O
infection	B-DISO
in	O
the	O
Kingdom	O
of	O
Bahrain	O
in	O
a	O
Saudi	O
gentleman	O
who	O
was	O
admitted	O
electively	O
for	O
coronary	O
bypass	O
surgery	O
,	O
postoperatively	O
developed	O
an	O
acute	O
respiratory	O
illness	O
,	O
and	O
tested	O
positive	O
for	O
MERS	O
-	O
CoV	O
.	O
40	O
close	O
contacts	O
,	O
all	O
healthcare	O
workers	O
,	O
were	O
traced	O
and	O
followed	O
with	O
no	O
documented	O
secondary	O
cases	O
.	O

She	O
had	O
significantly	O
improved	O
at	O
six	O
months	O
follow	O
-	O
up	O
,	O
though	O
she	O
continued	O
to	O
have	O
moderate	O
airflow	O
obstruction	B-DISO
on	O
pulmonary	O
function	O
testing	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
here	O
the	O
case	O
of	O
a	O
73	O
-	O
year	O
-	O
old	O
woman	O
who	O
presented	O
a	O
recurrent	O
macular	B-DISO
rash	I-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
,	O
and	O
hemoptysis	B-DISO
.	O

TITLE	O
:	O
Porcine	O
Hemagglutinating	O
Encephalomyelitis	B-DISO
Virus	O
Enters	O
Neuro	O
-	O
2a	O
Cells	O
via	O
Clathrin	O
-	O
Mediated	O
Endocytosis	O
in	O
a	O
Rab5	O
-,	O
Cholesterol	O
-,	O
and	O
pH	O
-	O
Dependent	O
Manner	O
.	O

Here	O
we	O
dissected	O
the	O
molecular	O
mechanism	O
underlying	O
cellular	O
entry	O
and	O
intracellular	O
trafficking	O
of	O
PHEV	O
in	O
mouse	B-DISO
neuroblastoma	I-DISO
(	O
Neuro	O
-	O
2a	O
)	O
cells	O
.	O

TITLE	O
:	O
Understanding	O
Immune	O
Resistance	O
to	O
Infectious	B-DISO
Bronchitis	B-DISO
Using	O
Major	O
Histocompatibility	O
Complex	O
Chicken	O
Lines	O
.	O

We	O
found	O
that	O
respiratory	O
signs	O
,	O
tracheal	O
deciliation	O
and	O
inflammation	B-DISO
,	O
airsacculitis	B-DISO
,	O
viral	B-DISO
shedding	I-DISO
in	O
tears	O
,	O
and	O
local	O
humoral	O
responses	O
were	O
good	O
parameters	O
to	O
determine	O
resistance	O
or	O
susceptibility	O
.	O

These	O
two	O
lines	O
will	O
be	O
used	O
as	O
an	O
animal	O
model	O
in	O
subsequent	O
experiments	O
to	O
understand	O
the	O
mechanisms	O
by	O
which	O
the	O
immune	O
system	O
in	O
chickens	O
generates	O
resistance	O
to	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
.	O

Chickens	O
primed	O
with	O
attenuated	O
Mass	O
IBV	O
at	O
1	O
day	O
of	O
age	O
and	O
boosted	O
with	O
rLS	B-DISO
/	O
IBV	O
.	O
S2	O
-	O
4	O
/	O
91	O
at	O
14	O
days	O
of	O
age	O
were	O
challenged	O
with	O
a	O
virulent	O
Ark	O
IBV	O
strain	O
at	O
28	O
days	O
of	O
age	O
.	O

ABSTRACT	O
:	O
The	O
present	O
study	O
aimed	O
to	O
determine	O
the	O
molecular	O
characteristics	O
of	O
circulating	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
strains	O
in	O
vaccinated	O
broiler	O
flocks	O
in	O
the	O
Giza	O
and	O
Fayoum	O
governorates	O
.	O

ABSTRACT	O
:	O
Infections	B-DISO
caused	O
by	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
are	O
a	O
serious	O
health	O
issue	O
due	O
to	O
their	O
prevalence	O
and	O
associated	O
mortality	O
.	O

LncRNA	O
-	O
IL7R	O
was	O
isolated	O
from	O
the	O
plasma	O
of	O
patients	O
with	O
ARDS	B-DISO
and	O
healthy	O
controls	O
and	O
clinical	O
indexes	O
were	O
obtained	O
within	O
24	O
h	O
after	O
admission	O
.	O

A	O
total	O
of	O
85	O
ARDS	B-DISO
patients	O
and	O
49	O
healthy	O
controls	O
were	O
included	O
.	O

Lnc	O
-	O
IL7R	O
is	O
a	O
novel	O
biomarker	O
for	O
the	O
diagnosis	O
of	O
ARDS	B-DISO
and	O
predicts	O
the	O
severity	O
of	O
ARDS	B-DISO
and	O
28	O
-	O
day	O
mortality	O
in	O
this	O
patients	O
cohort	O
.	O

Neither	O
the	O
addition	O
of	O
inspiratory	O
pauses	O
or	O
the	O
alveolar	O
recruitment	B-DISO
maneuver	O
followed	O
by	O
decremental	O
PEEP	O
titration	O
resulted	O
in	O
further	O
reductions	O
in	O
VT	O
.	O

TITLE	O
:	O
Risk	O
factors	O
and	O
outcomes	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
requiring	O
invasive	O
mechanical	O
ventilation	O
in	O
cancer	B-DISO
patients	O
:	O
A	O
retrospective	O
cohort	O
study	O
.	O

HELLP	B-DISO
syndrome	I-DISO
is	O
a	O
life	O
-	O
threatening	O
condition	B-DISO
frequently	O
associated	O
with	O
severe	B-DISO
preeclampsia	I-DISO
-	O
eclampsia	B-DISO
and	O
is	O
characterized	O
by	O
three	O
hallmark	O
features	O
of	O
hemolysis	B-DISO
,	O
elevated	O
liver	O
enzymes	O
and	O
low	O
platelets	O
.	O

Early	O
diagnosis	O
and	O
management	O
of	O
preeclampsia	B-DISO
,	O
eclampsia	B-DISO
and	O
HELLP	B-DISO
syndrome	I-DISO
are	O
critical	O
with	O
involvement	O
of	O
a	O
multidisciplinary	O
team	O
that	O
includes	O
Obstetrics	O
,	O
Maternal	O
Fetal	O
Medicine	O
and	O
Critical	O
Care	O
.	O

ABSTRACT	O
:	O
To	O
gather	O
recent	O
data	O
regarding	O
the	O
infectious	B-DISO
bronchitis	B-DISO
(	O
IB	O
)	O
and	O
infectious	B-DISO
bursal	I-DISO
disease	I-DISO
(	O
IBD	B-DISO
)	O
situation	O
in	O
Europe	O
,	O
a	O
large	O
-	O
scale	O
field	O
epidemiological	O
survey	O
using	O
diagnostic	O
samples	O
has	O
been	O
implemented	O
in	O
2013	O
for	O
about	O
six	O
months	O
in	O
several	O
European	O
countries	O
:	O
France	O
,	O
Germany	O
,	O
Greece	O
,	O
Italy	O
,	O
the	O
Netherlands	O
,	O
Poland	O
,	O
Portugal	O
,	O
the	O
Republic	O
of	O
Ireland	O
,	O
Spain	O
and	O
the	O
UK	O
.	O

The	O
data	O
of	O
this	O
survey	O
also	O
provided	O
valuable	O
information	O
about	O
the	O
replication	O
of	O
IBD	B-DISO
vaccines	O
and	O
subsequent	O
infectious	B-DISO
bursal	I-DISO
disease	I-DISO
virus	O
(	O
IBDV	O
)	O
antibody	O
responses	O
under	O
field	O
conditions	O
.	O

The	O
detection	O
of	O
five	O
non	O
-	O
vvIBDV	O
field	O
strains	O
of	O
two	O
different	O
genotypes	O
shows	O
the	O
presence	O
of	O
non	O
-	O
vvIBDV	O
non	O
-	O
vaccine	O
strains	O
,	O
which	O
can	O
easily	O
be	O
undetected	O
in	O
Europe	O
due	O
to	O
the	O
focus	O
on	O
sampling	O
of	O
clinically	O
ill	B-DISO
birds	O
.	O

Detection	O
of	O
vaccine	O
virus	O
in	O
the	O
bursa	O
and	O
antibody	O
response	O
to	O
the	O
IBD	B-DISO
vaccination	O
in	O
flocks	O
that	O
had	O
been	O
vaccinated	O
by	O
the	O
drinking	O
water	O
with	O
a	O
live	O
attenuated	O
vaccine	O
compared	O
to	O
a	O
vaccination	O
in	O
the	O
hatchery	O
using	O
an	O
immune	O
-	O
complex	O
vaccine	O
showed	O
a	O
delayed	O
replication	O
of	O
the	O
vaccines	O
that	O
had	O
been	O
applied	O
by	O
the	O
drinking	O
water	O
,	O
indicating	O
mistakes	O
in	O
the	O
timing	O
and	O
/	O
or	O
application	O
of	O
the	O
vaccines	O
.	O

The	O
clinical	O
manifestation	O
of	O
pulmonary	O
ricin	O
intoxication	O
in	O
animal	O
models	O
is	O
closely	O
related	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
which	O
involves	O
pulmonary	O
proinflammatory	O
cytokine	O
upregulation	O
,	O
massive	O
neutrophil	O
infiltration	B-DISO
and	O
severe	B-DISO
edema	I-DISO
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
its	O
severe	O
form	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
remain	O
the	O
leading	O
cause	O
of	O
morbidity	O
and	O
mortality	O
.	O

Multicenter	O
,	O
randomized	O
trial	O
conducted	O
at	O
120	O
intensive	O
care	O
units	O
(	O
ICUs	O
)	O
from	O
9	O
countries	O
from	O
November	O
17	O
,	O
2011	O
,	O
through	O
April	O
25	O
,	O
2017	O
,	O
enrolling	O
adults	O
with	O
moderate	O
to	O
severe	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
This	O
report	O
aimed	O
to	O
describe	O
the	O
outcomes	O
of	O
the	O
patients	O
with	O
severe	O
H1N1	O
associated	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
who	O
were	O
treated	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
therapy	O
.	O

Limiting	O
tidal	O
volume	O
has	O
a	O
demonstrated	O
survival	O
benefit	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
is	O
recognized	O
as	O
the	O
cornerstone	O
of	O
protective	O
ventilation	O
.	O

Measurement	O
of	O
syndecan	O
-	O
1	O
levels	O
in	O
sepsis	B-DISO
patients	O
might	O
be	O
useful	O
for	O
identifying	O
patients	O
at	O
high	O
risk	O
of	O
organ	O
dysfunction	O
and	O
mortality	O
as	O
well	O
as	O
those	O
who	O
could	O
benefit	O
from	O
therapies	O
targeted	O
at	O
protecting	O
or	O
restoring	O
the	O
glycocalyx	O
.	O

ABSTRACT	O
:	O
The	O
lethal	O
Coronaviruses	O
(	O
CoVs	O
),	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
-	O
associated	O
Coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
most	O
recently	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
,	O
(	O
MERS	O
-	O
CoV	O
)	O
are	O
serious	O
human	O
health	O
hazard	O
.	O

Across	O
the	O
three	O
countries	O
,	O
there	O
was	O
some	O
inconsistency	O
with	O
regard	O
to	O
the	O
types	O
of	O
products	O
(	O
i	O
.	O
e	O
.	O
masks	O
vs	O
.	O
respirators	O
)	O
recommended	O
for	O
influenza	B-DISO
,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
tuberculosis	B-DISO
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
newly	O
emerged	O
coronavirus	O
that	O
is	O
associated	O
with	O
a	O
severe	O
respiratory	B-DISO
disease	I-DISO
in	O
humans	O
in	O
the	O
Middle	O
East	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
animal	O
herds	O
associated	O
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)-	O
infected	O
patients	O
in	O
Saudi	O
Arabia	O
,	O
during	O
the	O
last	O
three	O
years	O
(	O
2014	O
-	O
2016	O
).	O

ABSTRACT	O
:	O
We	O
report	O
two	O
cases	O
of	O
severe	O
influenza	B-DISO
infection	B-DISO
imported	O
by	O
tourist	O
patients	O
from	O
their	O
country	O
of	O
origin	O
and	O
developed	O
during	O
travel	O
.	O

Influenza	B-DISO
is	O
a	O
very	O
common	O
infection	B-DISO
that	O
is	O
often	O
benign	O
,	O
but	O
sometimes	O
very	O
severe	O
.	O

A	O
""""	O
second	O
hit	O
""""	O
from	O
surgery	O
during	O
this	O
time	O
frame	O
often	O
results	O
in	O
acute	O
lung	O
injury	O
,	O
along	O
with	O
deterioration	O
of	O
the	O
patient	O
'	O
s	O
clinical	O
condition	B-DISO
.	O

We	O
used	O
the	O
electronic	O
medical	O
record	O
to	O
track	O
SIRS	B-DISO
criteria	O
in	O
patients	O
days	O
1	O
to	O
4	O
posttrauma	O
.	O

Patients	O
in	O
the	O
orthopaedic	O
cohort	O
were	O
further	O
examined	O
for	O
pulmonary	B-DISO
complications	I-DISO
and	O
death	O
.	O

81	O
.	O
4	O
%	O
(	O
OI	O
)	O
and	O
69	O
.	O
1	O
%	O
no	O
orthopaedic	O
injury	O
reached	O
the	O
threshold	O
for	O
SIRS	B-DISO
within	O
their	O
first	O
4	O
days	O
of	O
hospitalization	O
.	O

TITLE	O
:	O
Detection	O
and	O
phylogenetic	O
analyses	O
of	O
spike	O
genes	O
in	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
strains	O
circulating	O
in	O
China	O
in	O
2016	O
-	O
2017	O
.	O

In	O
smokers	O
and	O
subjects	O
with	O
COPD	B-DISO
,	O
both	O
DPP4	O
mRNA	O
and	O
protein	O
expression	O
were	O
significantly	O
higher	O
compared	O
to	O
never	O
-	O
smokers	O
.	O

ABSTRACT	O
:	O
Recent	O
zoonotic	O
outbreaks	O
,	O
such	O
as	O
Zika	O
,	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
and	O
Ebola	O
,	O
have	O
highlighted	O
the	O
need	O
for	O
rapid	O
and	O
accurate	O
diagnostic	O
assays	O
that	O
can	O
be	O
used	O
to	O
aid	O
pathogen	O
control	O
.	O

TITLE	O
:	O
Occurrence	O
of	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
across	O
the	O
Gulf	O
Corporation	O
Council	O
countries	O
:	O
Four	O
years	O
update	O
.	O

GCC	O
countries	O
including	O
Saudi	O
Arabia	O
now	O
have	O
the	O
infrastructure	O
in	O
place	O
that	O
allows	O
physicians	O
and	O
scientific	O
community	O
to	O
identify	O
and	O
immediately	O
respond	O
to	O
the	O
potential	O
risks	O
posed	O
by	O
new	O
outbreaks	O
of	O
MERS	O
-	O
CoV	O
infections	B-DISO
in	O
the	O
region	O
.	O

Deadly	O
infectious	B-DISO
diseases	I-DISO
such	O
as	O
MERS	O
have	O
significant	O
direct	O
and	O
indirect	O
social	O
impacts	O
,	O
which	O
include	O
disease	O
-	O
induced	O
mortality	O
and	O
economic	O
losses	O
.	O

In	O
this	O
paper	O
,	O
we	O
propose	O
a	O
class	O
of	O
nonlinear	O
susceptible	O
-	O
infectious	B-DISO
-	O
quarantined	O
(	O
SIQ	O
)	O
models	O
for	O
analyzing	O
and	O
controlling	O
the	O
MERS	O
outbreak	O
in	O
Korea	O
.	O

For	O
the	O
SIQ	O
based	O
ordinary	O
differential	O
equation	O
(	O
ODE	O
)	O
model	O
,	O
we	O
perform	O
the	O
task	O
of	O
parameter	O
estimation	O
,	O
and	O
apply	O
optimal	O
control	O
theory	O
to	O
the	O
controlled	O
SIQ	O
model	O
,	O
with	O
the	O
goal	O
of	O
minimizing	O
the	O
infectious	B-DISO
compartment	O
population	O
and	O
the	O
cost	O
of	O
implementing	O
the	O
quarantine	O
and	O
isolation	O
strategies	O
.	O

During	O
2013	O
-	O
2016	O
,	O
a	O
total	O
of	O
42351	O
throat	O
swabs	O
were	O
examined	O
for	O
presence	O
of	O
influenza	B-DISO
viruses	O
and	O
MERS	O
-	O
CoV	O
in	O
Iranian	O
general	O
population	O
and	O
pilgrims	O
returning	O
from	O
Mecca	O
and	O
Karbala	O
with	O
SARI	O
by	O
using	O
one	O
step	O
RT	O
-	O
PCR	O
kit	O
.	O

The	O
detected	O
influenza	B-DISO
viruses	O
were	O
Influenza	B-DISO
A	O
(	O
107	O
,	O
6	O
.	O
5	O
%),	O
pandemic	O
2009	O
H1N1	O
(	O
n	O
=	O
120	O
,	O
7	O
.	O
3	O
%),	O
and	O
Influenza	B-DISO
B	O
(	O
n	O
=	O
44	O
,	O
2	O
.	O
7	O
%).	O

Cigarette	O
smoke	O
exposure	O
(	O
quantified	O
using	O
plasma	O
cotinine	O
),	O
ARDS	B-DISO
development	O
,	O
and	O
other	O
clinical	O
parameters	O
were	O
correlated	O
with	O
lung	O
microbiota	O
composition	O
.	O

The	O
Hajj	O
and	O
Umrah	O
vaccine	O
requirements	O
include	O
mandatory	O
vaccinations	O
against	O
yellow	B-DISO
fever	I-DISO
,	O
quadrivalent	O
meningococcal	O
polysaccharide	O
(	O
every	O
3	O
years	O
)	O
or	O
conjugated	O
(	O
every	O
5	O
years	O
)	O
vaccines	O
and	O
poliomyelitis	B-DISO
vaccine	O
.	O

RESULTS	O
:	O
The	O
Hajj	O
and	O
Umrah	O
vaccine	O
requirements	O
include	O
mandatory	O
vaccinations	O
against	O
yellow	B-DISO
fever	I-DISO
,	O
quadrivalent	O
meningococcal	O
polysaccharide	O
(	O
every	O
3	O
years	O
)	O
or	O
conjugated	O
(	O
every	O
5	O
years	O
)	O
vaccines	O
and	O
poliomyelitis	B-DISO
vaccine	O
.	O

TITLE	O
:	O
The	O
viral	O
aetiology	O
of	O
influenza	B-DISO
-	O
like	O
illnesses	O
in	O
Kampala	O
and	O
Entebbe	O
,	O
Uganda	O
,	O
2008	O
.	O

Medications	O
administered	O
(	O
sedative	O
,	O
analgesic	O
,	O
paralytic	O
,	O
and	O
antipsychotic	O
),	O
sedation	B-DISO
depth	O
(	O
Sedation	B-DISO
Agitation	B-DISO
Scale	O
[	O
SAS	O
]	O
score	O
)	O
delirium	B-DISO
assessments	O
,	O
and	O
mobilization	O
were	O
recorded	O
daily	O
.	O

Forty	O
-	O
five	O
adults	O
(	O
33	O
males	O
,	O
median	O
age	O
47	O
years	O
;	O
interquartile	O
range	O
[	O
IQR	O
],	O
35	O
-	O
56	O
])	O
with	O
ARDS	B-DISO
(	O
median	O
PaO2	O
/	O
FiO2	O
71	O
;	O
IQR	O
59	O
-	O
83	O
)	O
because	O
of	O
respiratory	B-DISO
infection	I-DISO
(	O
91	O
%)	O
were	O
treated	O
with	O
VV	O
-	O
ECMO	O
for	O
a	O
median	O
of	O
11	O
days	O
(	O
IQR	O
,	O
7	O
-	O
17	O
).	O

Patients	O
were	O
deeply	O
sedated	O
for	O
a	O
median	O
of	O
6	O
days	O
(	O
IQR	O
,	O
3	O
-	O
10	O
)	O
after	O
cannulation	O
before	O
transitioning	O
to	O
intermediate	O
or	O
light	O
sedation	B-DISO
(	O
SAS	O
score	O
≥	O
3	O
).	O

In	O
conclusion	O
,	O
we	O
found	O
that	O
although	O
patients	O
were	O
deeply	O
sedated	O
for	O
a	O
prolonged	O
duration	O
after	O
VV	O
-	O
ECMO	O
initiation	O
,	O
many	O
were	O
able	O
to	O
safely	O
achieve	O
light	O
sedation	B-DISO
and	O
active	O
mobilization	O
.	O

CoVs	O
encode	O
several	O
innate	O
immune	O
antagonists	O
that	O
counteract	O
the	O
host	O
innate	B-DISO
immune	I-DISO
response	I-DISO
to	O
facilitate	O
efficient	O
viral	O
replication	O
.	O

These	O
processes	O
all	O
have	O
a	O
redox	O
component	O
,	O
and	O
this	O
chapter	O
focuses	O
on	O
the	O
role	O
played	O
by	O
ROS	O
during	O
the	O
development	O
of	O
ALI	O
/	O
ARDS	B-DISO
.	O

We	O
discuss	O
the	O
origins	O
of	O
ROS	O
within	O
the	O
cell	O
,	O
cellular	O
defense	O
mechanisms	O
against	O
oxidative	O
damage	O
,	O
the	O
role	O
of	O
ROS	O
in	O
the	O
development	O
of	O
endothelial	O
permeability	O
,	O
and	O
potential	O
therapies	O
targeted	O
at	O
oxidative	B-DISO
stress	I-DISO
.	O

TITLE	O
:	O
Difficulties	O
in	O
using	O
personal	O
protective	O
equipment	O
:	O
Training	O
experiences	O
with	O
the	O
2015	O
outbreak	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
in	O
Korea	O
.	O

Difficulties	O
observed	O
were	O
ill	B-DISO
-	O
fitting	B-DISO
sizes	O
,	O
anxiety	O
,	O
confusion	B-DISO
from	O
unstandardized	O
protocols	O
,	O
doubts	O
about	O
PPE	O
quality	O
and	O
effectiveness	O
,	O
and	O
complexity	O
of	O
using	O
several	O
PPE	O
items	O
together	O
.	O

ABSTRACT	O
:	O
Although	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
(	O
DAD	O
)	O
is	O
considered	O
the	O
typical	O
histological	O
pattern	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
only	O
half	O
of	O
patients	O
exhibit	O
this	O
morphological	O
hallmark	O
.	O

Therefore	O
,	O
we	O
aimed	O
to	O
identify	O
the	O
factors	O
associated	O
with	O
DAD	O
in	O
patients	O
with	O
ARDS	B-DISO
.	O

TITLE	O
:	O
MERS	O
,	O
SARS	B-DISO
and	O
other	O
coronaviruses	O
as	O
causes	O
of	O
pneumonia	B-DISO
.	O

Entry	O
of	O
CoVs	O
into	O
host	O
cells	O
is	O
mediated	O
by	O
the	O
viral	O
spike	O
(	O
S	O
)	O
protein	O
,	O
which	O
is	O
structurally	O
categorized	O
as	O
a	O
class	O
I	O
viral	O
fusion	O
protein	O
,	O
within	O
the	O
same	O
group	O
as	O
influenza	B-DISO
virus	O
and	O
HIV	B-DISO
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
caused	O
by	O
a	O
novel	O
coronavirus	O
discovered	O
in	O
2012	O
.	O

The	O
results	O
of	O
current	O
study	O
would	O
be	O
helpful	O
for	O
evaluation	O
of	O
future	O
progression	O
of	O
MERS	O
-	O
CoV	O
infections	B-DISO
,	O
better	O
understanding	O
and	O
control	O
interventions	O
.	O

ABSTRACT	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
is	O
a	O
serious	O
,	O
widely	O
distributed	O
systemic	B-DISO
disease	I-DISO
caused	O
by	O
feline	O
coronavirus	O
(	O
FCoV	O
),	O
in	O
which	O
ocular	O
disease	O
is	O
common	O
.	O

TITLE	O
:	O
Early	O
Antibody	O
Response	O
Contributes	O
to	O
the	O
Virus	O
Eradication	O
and	O
Clinical	O
Recovery	O
of	O
H7N9	O
Influenza	B-DISO
Infection	B-DISO
.	O

Meta	O
-	O
analysis	O
revealed	O
no	O
difference	O
in	O
mortality	O
(	O
risk	O
ratio	O
[	O
RR	O
],	O
0	O
.	O
84	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
0	O
.	O
68	O
-	O
1	O
.	O
04	O
),	O
but	O
subgroup	O
analyses	O
found	O
lower	O
mortality	O
with	O
12	O
hours	O
or	O
greater	O
duration	O
prone	O
(	O
five	O
trials	O
;	O
RR	O
,	O
0	O
.	O
74	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
56	O
-	O
0	O
.	O
99	O
)	O
and	O
for	O
patients	O
with	O
moderate	O
to	O
severe	O
ARDS	B-DISO
(	O
five	O
trials	O
;	O
RR	O
,	O
0	O
.	O
74	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
56	O
-	O
0	O
.	O
99	O
).	O

IBV	O
titres	O
in	O
the	O
supernatant	O
were	O
significantly	O
increased	O
when	O
CD59	O
proteins	O
were	O
overexpressed	O
in	O
cells	O
followed	O
by	O
IBV	O
infection	B-DISO
,	O
and	O
this	O
observation	O
was	O
further	O
supported	O
by	O
knockdown	O
or	O
cleavage	O
of	O
CD59	O
.	O

ABSTRACT	O
:	O
Idiopathic	B-DISO
pulmonary	I-DISO
fibrosis	I-DISO
(	O
IPF	O
)	O
is	O
a	O
chronic	O
and	O
ultimately	O
fatal	O
lung	B-DISO
disease	I-DISO
.	O

The	O
patient	O
had	O
severe	O
bilateral	O
iris	O
transillumination	O
defects	O
with	O
posterior	B-DISO
synechiae	I-DISO
formation	O
and	O
3	O
+	O
pigment	O
with	O
rare	O
cell	O
in	O
the	O
anterior	O
chamber	O
.	O

Ophthalmologists	O
should	O
remain	O
aware	O
of	O
the	O
association	O
between	O
systemic	O
fluoroquinolones	O
and	O
acute	O
pigmentary	O
dispersion	O
that	O
can	O
progress	O
to	O
glaucoma	B-DISO
.	O

TITLE	O
:	O
Risk	O
stratification	O
using	O
SpO	O
ABSTRACT	O
:	O
We	O
assessed	O
the	O
potential	O
of	O
risk	O
stratification	O
of	O
ARDS	B-DISO
patients	O
using	O
SpO	O
We	O
used	O
data	O
from	O
a	O
prospective	O
observational	O
study	O
in	O
patients	O
admitted	O
to	O
a	O
mixed	O
medical	O
-	O
surgical	O
intensive	O
care	O
unit	O
of	O
a	O
university	O
hospital	O
in	O
the	O
Netherlands	O
.	O

ABSTRACT	O
:	O
Veno	O
-	O
venous	O
ECMO	O
is	O
increasingly	O
used	O
for	O
the	O
management	O
of	O
refractory	O
ARDS	B-DISO
.	O

In	O
this	O
context	O
,	O
acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
is	O
a	O
major	O
and	O
frequent	O
complication	B-DISO
,	O
often	O
associated	O
with	O
poor	O
outcome	O
.	O

TITLE	O
:	O
[	O
ACUTE	B-DISO
RESPIRATORY	I-DISO
DISTRESS	I-DISO
SYNDROME	I-DISO
AND	O
OTHER	B-DISO
RESPIRATORY	I-DISO
DISORDERS	I-DISO
IN	O
SEPSIS	B-DISO
].	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
develops	O
in	O
patients	O
with	O
predisposing	O
conditions	O
that	O
induce	O
systemic	O
inflammatory	O
response	O
such	O
as	O
sepsis	B-DISO
,	O
pneumonia	B-DISO
,	O
acute	B-DISO
pancreatitis	I-DISO
,	O
major	O
trauma	O
,	O
or	O
multiple	O
transfusions	O
.	O

Sepsis	B-DISO
-	O
related	O
ARDS	B-DISO
patients	O
have	O
significantly	O
lower	O
PaO2	O
/	O
FiO2	O
ratios	O
than	O
patients	O
with	O
non	O
-	O
sepsis	B-DISO
-	O
related	O
ARDS	B-DISO
.	O

TITLE	O
:	O
The	O
8	O
-	O
Year	O
Experience	O
of	O
the	O
Florence	O
Referral	O
ECMO	O
Center	O
and	O
Retrieval	O
Team	O
for	O
Acute	B-DISO
Respiratory	I-DISO
Failure	I-DISO
.	O

The	O
authors	O
therefore	O
described	O
the	O
experience	O
of	O
their	O
referral	O
ECMO	O
center	O
for	O
severe	O
respiratory	B-DISO
failure	I-DISO
from	O
2009	O
to	O
2016	O
and	O
gave	O
a	O
comprehensive	O
report	O
of	O
transfers	O
performed	O
by	O
their	O
mobile	O
ECMO	O
team	O
.	O

One	O
hundred	O
and	O
sixty	O
consecutive	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
refractory	O
to	O
conventional	O
treatment	O
requiring	O
veno	O
-	O
venous	O
(	O
VV	O
)-	O
ECMO	O
.	O

For	O
these	O
reasons	O
,	O
such	O
viral	O
vectors	O
provide	O
an	O
attractive	O
platform	O
for	O
stockpiling	O
vaccines	O
for	O
emergency	B-DISO
deployment	O
in	O
response	O
to	O
a	O
threatened	O
outbreak	O
of	O
an	O
emerging	O
pathogen	O
.	O

ABSTRACT	O
:	O
Over	O
the	O
past	O
decade	O
,	O
there	O
has	O
been	O
growing	O
interest	O
in	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
as	O
a	O
rescue	O
therapy	O
for	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
cardiogenic	B-DISO
shock	I-DISO
.	O

ABSTRACT	O
:	O
The	O
immunoinflammatory	O
response	O
is	O
central	O
to	O
the	O
pathogenesis	B-DISO
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Higher	O
cytokine	O
levels	O
are	O
associated	O
with	O
extrapulmonary	O
causes	O
of	O
ARDS	B-DISO
,	O
more	O
aggressive	B-DISO
mechanical	O
ventilation	O
before	O
VV	O
ECMO	O
,	O
and	O
mortality	O
.	O

ABSTRACT	O
:	O
Extracorporeal	O
Membrane	O
Oxygenation	O
(	O
ECMO	O
)	O
is	O
now	O
a	O
recognized	O
revolutionary	O
technology	O
,	O
which	O
has	O
emerged	O
as	O
a	O
life	O
-	O
saving	O
therapeutic	O
option	O
for	O
patients	O
with	O
potentially	O
reversible	O
severe	O
respiratory	B-DISO
failure	I-DISO
who	O
fail	O
to	O
respond	O
positively	O
with	O
the	O
conventional	O
ventilation	O
therapy	O
.	O

Using	O
the	O
influenza	B-DISO
virus	O
as	O
a	O
model	O
,	O
erythrocyte	O
membrane	O
cloaked	O
nanoparticles	O
are	O
prepared	O
and	O
modified	O
with	O
magnetic	O
functionalities	O
(	O
RBC	O
-	O
mNP	O
)	O
for	O
virus	O
targeting	O
and	O
isolation	O
.	O

To	O
maximize	O
targeting	O
and	O
isolation	O
efficiency	O
,	O
density	O
gradient	O
centrifugation	O
and	O
nanoparticle	O
tracking	O
analysis	O
were	O
applied	O
to	O
minimize	O
the	O
presence	O
of	O
uncoated	O
particles	O
and	O
membrane	O
vesicles	B-DISO
.	O

Magnetic	O
functionality	O
is	O
bestowed	O
to	O
the	O
nanoparticles	O
through	O
encapsulation	O
of	O
superparamagnetic	O
iron	O
-	O
oxide	O
particles	O
,	O
which	O
enable	O
influenza	B-DISO
virus	O
enrichment	O
via	O
magnetic	O
extraction	O
.	O

In	O
TGEV	O
pre	O
-	O
infected	O
IPEC	O
-	O
J2	O
cells	O
,	O
ETEC	O
K88	O
adhesion	B-DISO
is	O
enhanced	O
over	O
uninfected	O
cells	O
.	O

Based	O
on	O
these	O
data	O
,	O
the	O
authors	O
suspect	O
that	O
integrin	O
α5	O
might	O
enable	O
TGEV	O
to	O
promote	O
ETEC	O
K88	O
adhesion	B-DISO
.	O

ABSTRACT	O
:	O
Coronaviruses	O
recently	O
emerged	O
as	O
major	O
human	O
pathogens	O
causing	O
outbreaks	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
.	O

ABSTRACT	O
:	O
The	O
Eastern	O
Mediterranean	O
Region	O
(	O
EMR	O
)	O
of	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
continues	O
to	O
be	O
a	O
hotspot	O
for	O
emerging	O
and	O
reemerging	B-DISO
infectious	I-DISO
diseases	I-DISO
and	O
the	O
need	O
to	O
prevent	O
,	O
detect	O
,	O
and	O
respond	O
to	O
any	O
infectious	B-DISO
diseases	I-DISO
that	O
pose	O
a	O
threat	O
to	O
global	O
health	O
security	O
remains	O
a	O
priority	O
.	O

In	O
EMR	O
,	O
several	O
infectious	B-DISO
disease	I-DISO
outbreaks	O
were	O
detected	O
,	O
investigated	O
,	O
and	O
rapidly	O
contained	O
over	O
the	O
past	O
5	O
years	O
including	O
:	O
yellow	B-DISO
fever	I-DISO
in	O
Sudan	O
,	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
in	O
Bahrain	O
,	O
Oman	O
,	O
Qatar	O
,	O
Saudi	O
Arabia	O
,	O
United	O
Arab	O
Emirates	O
,	O
and	O
Yemen	O
,	O
cholera	B-DISO
in	O
Iraq	O
,	O
avian	B-DISO
influenza	I-DISO
A	O
(	O
H5N1	B-DISO
)	O
infection	B-DISO
in	O
Egypt	O
,	O
and	O
dengue	B-DISO
fever	I-DISO
in	O
Yemen	O
,	O
Sudan	O
,	O
and	O
Pakistan	O
.	O

In	O
addition	O
,	O
PEDV	O
pigs	O
had	O
increased	O
stem	O
cell	O
proliferation	B-DISO
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
a	O
numerical	O
increase	O
in	O
DNA	O
fragmentation	B-DISO
compared	O
with	O
controls	O
through	O
dpi	O
7	O
which	O
coincided	O
with	O
an	O
observed	O
return	O
of	O
digestive	O
function	O
to	O
that	O
of	O
controls	O
.	O

TITLE	O
:	O
Genetic	O
and	O
biological	O
characterization	O
of	O
a	O
Porcine	B-DISO
Reproductive	I-DISO
and	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Virus	O
2	O
(	O
PRRSV	O
-	O
2	O
)	O
causing	O
significant	O
clinical	O
disease	O
in	O
the	O
field	O
.	O

In	O
November	O
2010	O
,	O
a	O
pig	O
herd	O
in	O
the	O
Northern	O
part	O
of	O
Denmark	O
experienced	O
an	O
infection	B-DISO
with	O
PRRSV	O
-	O
2	O
with	O
clinical	O
signs	O
that	O
were	O
much	O
more	O
severe	O
than	O
normally	O
reported	O
from	O
current	O
Danish	O
PRRSV	O
-	O
2	O
affected	O
herds	O
.	O

ABSTRACT	O
:	O
Two	O
different	O
genotypes	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
the	O
classical	O
and	O
variant	O
strains	O
,	O
are	O
classified	O
by	O
multiple	O
insertions	O
and	O
deletions	O
in	O
their	O
S	O
genes	O
.	O

Fibrinous	O
bronchopneumonia	B-DISO
was	O
diagnosed	O
in	O
one	O
steer	O
that	O
died	O
;	O
samples	O
were	O
positive	O
for	O
H	O
.	O
somni	O
and	O
M	O
.	O
haemolytica	O
by	O
PCR	O
.	O

Here	O
,	O
we	O
provide	O
a	O
comprehensive	O
overview	O
of	O
the	O
covalent	O
NCp7	O
inhibitors	O
that	O
have	O
emerged	O
over	O
the	O
past	O
25	O
years	O
of	O
drug	O
discovery	O
campaigns	O
,	O
emphasising	O
,	O
where	O
possible	O
,	O
their	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	B-DISO
)	O
and	O
pharmacophoric	O
features	O
.	O

TITLE	O
:	O
Single	O
primer	O
isothermal	O
amplification	B-DISO
(	O
SPIA	O
)	O
combined	O
with	O
next	O
generation	O
sequencing	O
provides	O
complete	O
bovine	O
coronavirus	O
genome	O
coverage	O
and	O
higher	O
sequence	O
depth	O
compared	O
to	O
sequence	O
-	O
independent	O
single	O
primer	O
amplification	B-DISO
(	O
SISPA	O
).	O

With	O
the	O
emergence	O
of	O
novel	O
coronaviruses	O
such	O
as	O
SARS	B-DISO
and	O
MERS	O
,	O
the	O
need	O
for	O
fast	O
genome	O
characterisation	O
is	O
ever	O
so	O
important	O
.	O

It	O
was	O
clear	O
that	O
the	O
Saudi	O
pilgrims	O
were	O
more	O
oriented	O
about	O
different	O
aspects	O
of	O
MERS	O
-	O
CoV	O
including	O
the	O
nature	O
of	O
the	O
causative	O
agent	O
,	O
the	O
signs	O
,	O
the	O
severity	O
of	O
the	O
disease	O
,	O
the	O
animals	O
that	O
can	O
transmit	O
the	O
infection	B-DISO
to	O
humans	O
,	O
the	O
risk	O
groups	O
,	O
and	O
when	O
one	O
need	O
to	O
be	O
screened	O
for	O
infection	B-DISO
.	O

The	O
clinical	O
signs	O
,	O
the	O
gross	O
,	O
and	O
histopathological	O
lesions	O
scores	O
of	O
the	O
adenovirus	B-DISO
vaccine	O
constructs	O
were	O
not	O
significantly	O
different	O
from	O
that	O
of	O
the	O
attenuated	O
commercial	O
IBV	O
or	O
MG	O
vaccines	O
(	O
positive	O
controls	O
)	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Messenger	O
RNA	O
sequencing	O
reveals	O
similar	O
mechanisms	O
between	O
neonatal	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
No	O
evidence	O
of	O
enteric	O
viral	O
involvement	O
in	O
the	O
new	O
neonatal	O
porcine	O
diarrhoea	B-DISO
syndrome	B-DISO
in	O
Danish	O
pigs	O
.	O

Microarray	O
analyses	O
performed	O
on	O
a	O
total	O
of	O
18	O
animals	O
were	O
all	O
negative	O
,	O
as	O
were	O
eight	O
animals	O
examined	O
by	O
Transmission	O
Electron	O
Microscopy	O
(	O
TEM	B-DISO
).	O

ABSTRACT	O
:	O
The	O
MERS	O
-	O
CoV	O
is	O
a	O
novel	O
human	O
coronavirus	O
causing	O
respiratory	O
syndrome	B-DISO
since	O
April	O
2012	O
.	O

Potential	O
siRNA	O
can	O
be	O
designed	O
to	O
silence	B-DISO
a	O
desired	O
gene	O
by	O
considering	O
many	O
factors	O
like	O
target	O
site	O
,	O
specificity	O
,	O
length	O
and	O
nucleotide	O
content	O
of	O
siRNA	O
,	O
removal	O
of	O
potential	O
off	O
-	O
target	O
sites	O
,	O
toxicity	O
and	O
immunogenic	O
responses	O
.	O

ABSTRACT	O
:	O
To	O
report	O
the	O
clinical	O
features	O
and	O
prognosis	O
of	O
drug	O
-	O
associatedacute	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Although	O
more	O
severe	O
lung	O
damage	O
with	O
fibroproliferation	O
was	O
observed	O
in	O
patients	O
with	O
drug	O
-	O
associated	O
ARDS	B-DISO
,	O
ventilator	O
weaning	O
was	O
earlier	O
,	O
and	O
their	O
prognosis	O
was	O
better	O
than	O
the	O
others	O
.	O

RESULTS	O
:	O
The	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
scores	O
were	O
significantly	O
lower	O
in	O
the	O
drug	O
-	O
associated	O
ARDS	B-DISO
group	O
than	O
in	O
the	O
non	O
-	O
drug	O
-	O
associated	O
ARDS	B-DISO
group	O
(	O
median	O
(	O
IQR	O
):	O
18	O
.	O
0	O
(	O
16	O
.	O
5	O
-	O
21	O
.	O
0	O
)	O
vs	O
23	O
.	O
0	O
(	O
18	O
.	O
0	O
-	O
26	O
.	O
0	O
),	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
the	O
arterial	O
oxygen	O
tension	B-DISO
/	O
fractional	O
inspired	O
oxygen	O
ratio	O
was	O
higher	O
(	O
148	O
.	O
0	O
(	O
114	O
.	O
1	O
-	O
177	O
.	O
5	O
)	O
vs	O
101	O
.	O
0	O
(	O
71	O
.	O
5	O
-	O
134	O
.	O
0	O
),	O
p	O
=	O
0	O
.	O
003	O
).	O

After	O
adjusting	O
for	O
potentially	O
confounding	O
covariates	O
,	O
drug	O
-	O
associated	O
ARDS	B-DISO
group	O
was	O
associated	O
with	O
lower	O
28	O
-	O
day	O
mortality	O
(	O
adjusted	O
HR	O
(	O
HR	O
)	O
0	O
.	O
275	O
;	O
95	O
%	O
CI	O
0	O
.	O
106	O
to	O
0	O
.	O
711	O
;	O
p	O
=	O
0	O
.	O
008	O
).	O

It	O
comprises	O
various	O
domains	O
,	O
the	O
organization	O
of	O
which	O
differs	O
between	O
CoV	O
genera	O
,	O
due	O
to	O
duplication	B-DISO
or	O
absence	O
of	O
some	O
domains	O
.	O

TITLE	O
:	O
Hepatitis	B-DISO
B	I-DISO
core	O
antigen	O
based	O
novel	O
vaccine	O
against	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
.	O

Secondary	O
endpoints	O
include	O
:	O
all	O
-	O
cause	O
mortality	O
at	O
28	O
,	O
90	O
,	O
180	O
and	O
360	O
days	O
;	O
organ	B-DISO
failure	I-DISO
-	O
free	O
days	O
;	O
length	O
of	O
hospital	O
stay	O
;	O
pharmacodynamic	O
assessment	O
including	O
measurement	O
of	O
myxovirus	O
resistance	O
protein	O
A	O
concentrations	O
;	O
and	O
measures	O
of	O
quality	O
of	O
life	O
,	O
respiratory	O
and	O
neurological	O
function	O
at	O
180	O
and	O
360	O
days	O
.	O

Acute	O
kidney	O
injury	O
,	O
liver	B-DISO
dysfunction	I-DISO
,	O
thrombocytopenia	O
,	O
disseminated	O
intravascular	O
coagulopathy	B-DISO
(	O
DIC	B-DISO
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
are	O
also	O
common	O
in	O
severe	O
malaria	B-DISO
.	O

SCIs	O
have	O
significantly	O
decreased	O
since	O
2005	O
,	O
except	O
for	O
upper	O
cervical	O
central	O
cord	B-DISO
syndrome	B-DISO
.	O

These	O
include	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
),	O
Hendra	O
virus	O
,	O
Nipah	O
virus	O
,	O
influenza	B-DISO
viruses	O
,	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
coronavirus	O
,	O
and	O
ebola	O
.	O

We	O
suggest	O
creating	O
a	O
MeSH	O
term	O
for	O
One	O
Health	O
in	O
the	O
PubMed	O
database	O
to	O
support	O
more	O
specific	O
research	O
on	O
zoonoses	B-DISO
,	O
and	O
exploring	O
the	O
possibility	O
of	O
a	O
patent	O
of	O
the	O
term	O
One	O
Health	O
to	O
support	O
global	O
health	O
and	O
evidence	O
based	O
public	O
health	O
.	O

Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
within	O
the	O
first	O
8	O
days	O
of	O
admission	O
was	O
adjudicated	O
using	O
Berlin	O
criteria	O
.	O

Regression	O
analyses	O
were	O
used	O
to	O
assess	O
the	O
relationship	O
between	O
(	O
1	O
)	O
platelet	O
aggregation	O
and	O
ARDS	B-DISO
and	O
(	O
2	O
)	O
cigarette	O
smoke	O
exposure	O
and	O
platelet	O
aggregation	O
.	O

Cigarette	O
smoke	O
exposure	O
was	O
associated	O
with	O
increased	B-DISO
platelet	I-DISO
aggregation	O
upon	O
arrival	O
to	O
the	O
emergency	B-DISO
department	O
.	O

However	O
,	O
at	O
24	O
hours	O
,	O
cigarette	O
smoke	O
exposure	O
was	O
associated	O
with	O
increased	O
impairment	B-DISO
in	O
platelet	O
aggregation	O
,	O
reflecting	O
a	O
statistically	O
significant	O
decline	O
in	O
platelet	O
aggregation	O
over	O
the	O
initial	O
24	O
hours	O
after	O
trauma	O
.	O

Impaired	B-DISO
platelet	O
aggregation	O
at	O
0	O
hour	O
and	O
24	O
hours	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
developing	O
ARDS	B-DISO
after	O
severe	O
blunt	O
trauma	O
.	O

The	O
relationship	O
between	O
this	O
decline	O
in	O
platelet	O
aggregation	O
and	O
ARDS	B-DISO
differed	O
by	O
cigarette	O
smoke	O
exposure	O
status	O
,	O
suggesting	O
that	O
impaired	B-DISO
platelet	O
activation	O
differentially	O
affects	O
the	O
risk	O
of	O
ARDS	B-DISO
in	O
those	O
with	O
cigarette	O
smoke	O
exposure	O
(	O
arachidonic	O
acid	O
,	O
p	O
for	O
interaction	O
:	O
0	O
.	O
005	O
,	O
collagen	O
p	O
for	O
interaction	O
:	O
0	O
.	O
02	O
,	O
adenosine	O
diphosphate	O
,	O
p	O
for	O
interaction	O
:	O
0	O
.	O
05	O
).	O

A	O
literature	O
search	O
was	O
performed	O
covering	O
pathogenesis	B-DISO
,	O
clinical	O
features	O
and	O
therapeutics	O
,	O
clinically	O
developed	O
drugs	O
for	O
repurposing	O
and	O
novel	O
drug	O
targets	O
.	O

miR	O
-	O
223	O
expression	O
is	O
increased	O
in	O
the	O
lungs	O
of	O
MTD	O
-	O
induced	O
mice	O
or	O
ARDS	B-DISO
patients	O
following	O
trauma	O
/	O
transfusion	O
or	O
following	O
the	O
physiological	O
remission	B-DISO
of	O
ALI	O
/	O
ARDS	B-DISO
.	O

Viral	O
pathogens	O
were	O
detected	O
in	O
342	O
(	O
91	O
.	O
93	O
%)	O
of	O
the	O
samples	O
of	O
which	O
28	O
.	O
76	O
%	O
were	O
single	O
positive	O
and	O
63	O
.	O
17	O
%	O
had	O
multiple	O
infections	B-DISO
.	O

Adenovirus	B-DISO
was	O
statistically	O
associated	O
to	O
the	O
manifestation	O
of	O
gastroenteritis	B-DISO
(	O
p	O
=	O
0	O
.	O
004	O
).	O

Unfortunately	O
,	O
former	O
trials	O
of	O
ECMO	O
in	O
ARDS	B-DISO
were	O
negative	O
or	O
highly	O
criticized	O
due	O
to	O
many	O
technical	O
and	O
methodological	O
shortcomings	O
.	O

Therefore	O
,	O
the	O
international	O
multicenter	O
randomized	O
EOLIA	O
(	O
ECMO	O
to	O
rescue	O
Lung	O
Injury	O
in	O
severe	O
ARDS	B-DISO
)	O
trial	O
was	O
designed	O
to	O
test	O
the	O
benefit	O
of	O
systematic	O
and	O
early	O
installation	O
of	O
the	O
latest	O
-	O
generation	O
ECMO	O
circuits	O
in	O
patients	O
with	O
very	O
severe	O
ARDS	B-DISO
.	O

Antihistamine	O
and	O
epinephrine	O
were	O
required	O
and	O
symptom	B-DISO
resolution	O
occurred	O
.	O

CONCLUSIONS	O
:	O
Children	O
who	O
are	O
highly	O
sensitive	O
to	O
milk	O
may	O
have	O
severe	O
allergic	B-DISO
reactions	I-DISO
also	O
after	O
exposure	O
to	O
CMP	O
through	O
a	O
different	O
administration	O
route	O
than	O
the	O
oral	O
one	O
.	O

The	O
clinical	O
data	O
of	O
17	O
patients	O
who	O
were	O
diagnosed	O
as	O
ARDS	B-DISO
caused	O
by	O
severe	O
pneumonia	B-DISO
after	O
kidney	O
transplantation	O
and	O
treated	O
with	O
NIV	O
in	O
Sichuan	O
Provincial	O
People	O
'	O
s	O
Hospital	O
from	O
January	O
1st	O
,	O
2014	O
to	O
June	O
1st	O
,	O
2016	O
were	O
collected	O
and	O
retrospectively	O
analyzed	O
.	O

The	O
fewer	O
tacrolimus	O
daily	O
dosage	O
,	O
the	O
lower	O
APACHE	O
II	O
score	O
and	O
levels	O
of	O
PCT	B-DISO
and	O
BNP	O
,	O
the	O
more	O
effective	O
promotion	O
of	O
PaO	O
RESULTS	O
:	O
The	O
two	O
groups	O
were	O
similar	O
in	O
gender	O
,	O
age	O
,	O
and	O
underlying	O
diseases	O
.	O

TITLE	O
:	O
Severe	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
after	O
Laparoscopic	O
Appendectomy	O
in	O
a	O
Young	O
Adult	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
after	O
laparoscopic	O
appendectomy	O
for	O
acute	B-DISO
appendicitis	I-DISO
in	O
a	O
young	O
adult	O
is	O
an	O
uncommon	O
complication	B-DISO
.	O

Histological	O
examination	O
revealed	O
MERS	O
-	O
CoV	O
enteric	O
infection	B-DISO
in	O
all	O
inoculated	O
mice	O
,	O
as	O
shown	O
by	O
the	O
presence	O
of	O
virus	O
-	O
positive	O
cells	O
,	O
progressive	B-DISO
inflammation	I-DISO
,	O
and	O
epithelial	O
degeneration	B-DISO
in	O
small	O
intestines	O
,	O
which	O
were	O
exaggerated	O
in	O
the	O
mice	O
pretreated	O
with	O
the	O
proton	O
pump	O
inhibitor	O
pantoprazole	O
.	O

These	O
findings	O
suggest	O
that	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
who	O
require	O
transport	O
to	O
a	O
referral	O
center	O
for	O
extracorporeal	O
life	O
support	O
may	O
benefit	O
from	O
the	O
availability	O
of	O
a	O
mobile	O
extracorporeal	O
life	O
support	O
team	O
.	O

These	O
findings	O
imply	O
that	O
for	O
infection	B-DISO
control	O
strategy	O
to	O
be	O
properly	O
performed	O
,	O
education	O
should	O
be	O
strengthened	O
so	O
that	O
HCP	B-DISO
can	O
accurately	O
recognize	O
the	O
risk	O
situation	O
and	O
properly	O
notify	O
the	O
infection	B-DISO
control	O
officer	O
.	O

RESULTS	O
:	O
Of	O
the	O
333	O
HCP	B-DISO
who	O
participated	O
in	O
MERS	O
patient	O
care	O
,	O
35	O
HCP	B-DISO
(	O
10	O
.	O
5	O
%)	O
visited	O
the	O
MSC	O
for	O
MERS	O
-	O
like	O
symptoms	O
.	O

ABSTRACT	O
:	O
Duchenne	B-DISO
muscular	I-DISO
dystrophy	I-DISO
(	O
DMD	B-DISO
)	O
is	O
characterized	O
by	O
respiratory	O
and	O
heart	O
involvements	O
.	O

We	O
sought	O
to	O
describe	O
clinical	O
and	O
genetic	O
profiles	O
and	O
to	O
determine	O
prognosis	O
of	O
DMD	B-DISO
and	O
Becker	B-DISO
muscular	I-DISO
dystrophy	I-DISO
(	O
BMD	B-DISO
)	O
patients	O
on	O
home	O
MV	O
(	O
HMV	O
),	O
hospitalized	O
for	O
AHF	O
.	O

Cardiogenic	B-DISO
shock	I-DISO
presentation	O
was	O
found	O
in	O
six	O
patients	O
(	O
46	O
%).	O

TITLE	O
:	O
Macrophage	O
scavenger	O
receptor	O
1	O
contributes	O
to	O
pathogenesis	B-DISO
of	O
fulminant	B-DISO
hepatitis	I-DISO
via	O
neutrophil	O
-	O
mediated	O
complement	O
activation	O
.	O

ABSTRACT	O
:	O
Published	O
guidance	O
recommends	O
controlled	O
movement	O
for	O
persons	O
with	O
higher	O
-	O
risk	O
exposures	O
(	O
HREs	O
)	O
to	O
communicable	B-DISO
diseases	I-DISO
of	O
public	O
health	O
concern	O
;	O
US	O
federal	O
public	O
health	O
travel	O
restrictions	O
(	O
PHTRs	O
)	O
might	O
be	O
implemented	O
to	O
enforce	O
these	O
measures	O
.	O

PHTR	O
enforced	O
controlled	O
movement	O
and	O
removed	O
risk	O
for	O
disease	B-DISO
transmission	I-DISO
among	O
travelers	O
who	O
had	O
contacts	O
who	O
refused	O
to	O
comply	O
with	O
public	O
health	O
recommendations	O
.	O

PHTRs	O
are	O
mechanisms	O
to	O
mitigate	O
spread	O
of	O
communicable	B-DISO
diseases	I-DISO
and	O
might	O
be	O
critical	O
in	O
enhancing	O
health	O
security	O
during	O
epidemics	O
.	O

TITLE	O
:	O
Spectrum	O
of	O
pathogen	O
-	O
and	O
model	O
-	O
specific	O
histopathologies	O
in	O
mouse	O
models	O
of	O
acute	B-DISO
pneumonia	I-DISO
.	O

Here	O
,	O
we	O
systematically	O
describe	O
and	O
compare	O
the	O
distinctive	O
histopathological	O
features	O
of	O
established	O
models	O
of	O
acute	B-DISO
pneumonia	I-DISO
in	O
mice	O
induced	O
by	O
Streptococcus	O
(	O
S	O
.)	O
pneumoniae	O
,	O
Staphylococcus	O
aureus	O
,	O
Klebsiella	O
pneumoniae	O
,	O
Acinetobacter	O
baumannii	O
,	O
Legionella	O
pneumophila	O
,	O
Escherichia	O
coli	O
,	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
coronavirus	O
,	O
influenza	B-DISO
A	O
virus	O
(	O
IAV	O
)	O
and	O
superinfection	B-DISO
of	O
IAV	O
-	O
incuced	O
pneumonia	B-DISO
with	O
S	O
.	O
pneumoniae	O
.	O

To	O
investigate	O
the	O
association	O
of	O
corticosteroid	O
therapy	O
on	O
mortality	O
and	O
on	O
MERS	O
coronavirus	O
RNA	O
clearance	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
MERS	O
.	O

Moving	O
from	O
the	O
nondependent	O
to	O
the	O
dependent	O
lung	O
regions	O
,	O
the	O
not	O
inflated	O
lung	O
tissue	O
significantly	O
increased	O
,	O
while	O
the	O
well	O
inflated	O
tissue	O
decreased	O
(	O
ρ	O
=	O
0	O
.	O
96	O
-	O
1	O
.	O
00	O
,	O
Both	O
ARDS	B-DISO
and	O
CPE	O
are	O
characterized	O
by	O
a	O
similar	O
presence	O
of	O
ground	O
-	O
glass	O
attenuation	O
and	O
different	O
airspace	O
consolidation	O
regions	O
.	O

Following	O
on	O
from	O
the	O
previous	O
conference	O
,	O
there	O
were	O
ongoing	O
discussions	O
on	O
appropriate	O
endpoints	O
for	O
severe	O
influenza	B-DISO
in	O
clinical	O
trials	O
from	O
regulators	O
and	O
clinicians	O
,	O
an	O
issue	O
which	O
remains	O
unresolved	O
.	O

TITLE	O
:	O
Interleukin	O
-	O
36γ	O
and	O
IL	O
-	O
36	O
receptor	O
signaling	O
mediate	O
impaired	B-DISO
host	O
immunity	O
and	O
lung	O
injury	O
in	O
cytotoxic	O
Pseudomonas	O
aeruginosa	O
pulmonary	B-DISO
infection	I-DISO
:	O
Role	O
of	O
prostaglandin	O
E2	O
.	O

Neuroimaging	O
of	O
brain	O
and	O
spine	O
and	O
NCSs	O
were	O
unremarkable	O
;	O
cerebrospinal	O
fluid	O
analysis	O
revealed	O
no	O
albuminocytologic	O
dissociation	B-DISO
.	O

The	O
diagnosis	O
of	O
acute	O
motor	O
and	O
sensory	O
axonal	B-DISO
neuropathy	I-DISO
was	O
made	O
.	O

TITLE	O
:	O
The	O
French	O
Infectious	B-DISO
Diseases	I-DISO
Society	O
'	O
s	O
readiness	O
and	O
response	O
to	O
epidemic	O
or	O
biological	O
risk	O
-	O
the	O
current	O
situation	O
following	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
and	O
Ebola	B-DISO
virus	I-DISO
disease	I-DISO
alerts	O
.	O

However	O
,	O
inflammation	B-DISO
-	O
directed	O
therapies	O
have	O
yet	O
failed	O
to	O
improve	O
the	O
outcome	O
in	O
ARDS	B-DISO
patients	O
.	O

One	O
of	O
the	O
reasons	O
may	O
be	O
the	O
underestimated	O
complexity	O
of	O
inflammation	B-DISO
.	O

We	O
suggest	O
that	O
therapeutic	O
interventions	O
in	O
ARDS	B-DISO
should	O
be	O
based	O
on	O
a	O
systems	O
approach	O
to	O
inflammation	B-DISO
.	O

ABSTRACT	O
:	O
Viral	O
aerosol	O
infection	B-DISO
through	O
cough	B-DISO
generates	O
large	O
amounts	O
of	O
viral	O
aerosol	O
and	O
can	O
result	O
in	O
many	O
adverse	O
health	O
effects	O
such	O
as	O
influenza	B-DISO
flu	B-DISO
and	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
).	O

To	O
characterize	O
the	O
coughed	O
viral	O
aerosol	O
,	O
the	O
sampler	O
needs	O
to	O
sample	O
at	O
higher	O
flow	O
rate	O
and	O
possess	B-DISO
high	O
physical	O
collection	O
efficiency	O
as	O
well	O
as	O
high	O
viral	O
preservation	O
.	O

TITLE	O
:	O
Gastrointestinal	B-DISO
tuberculosis	I-DISO
following	O
renal	O
transplantation	O
accompanied	O
with	O
septic	B-DISO
shock	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
a	O
survival	O
case	O
presentation	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
and	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
is	O
characterized	O
by	O
uncontrolled	O
inflammation	B-DISO
of	O
the	O
lungs	O
after	O
a	O
severe	O
inflammatory	O
stimulus	O
.	O

We	O
first	O
explain	O
how	O
the	O
statistics	O
data	O
of	O
infectious	B-DISO
diseases	I-DISO
,	O
such	O
as	O
influenza	B-DISO
and	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
in	O
Korea	O
,	O
can	O
be	O
collected	O
for	O
reference	O
data	O
.	O

In	O
other	O
species	O
,	O
vaccination	O
is	O
associated	O
with	O
an	O
immediate	O
acute	B-DISO
-	I-DISO
phase	I-DISO
response	I-DISO
.	O

ABSTRACT	O
:	O
Coronaviruses	O
are	O
closely	O
monitored	O
in	O
the	O
context	O
of	O
emerging	O
diseases	O
and	O
,	O
as	O
illustrated	O
with	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
-	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
are	O
known	O
to	O
cross	O
the	O
species	O
barrier	O
and	O
eventually	O
to	O
move	O
from	O
wildlife	O
to	O
humans	O
.	O

We	O
studied	O
the	O
effect	O
of	O
neutralizing	O
monoclonal	O
antibodies	O
(	O
MAb	O
)	O
against	O
IL	O
-	O
17A	O
in	O
our	O
model	O
of	O
mouse	O
MHV	O
-	O
A59	O
-	O
infection	B-DISO
.	O

TITLE	O
:	O
Type	O
III	O
Interferon	O
Restriction	O
by	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
and	O
the	O
Role	O
of	O
Viral	O
Protein	O
nsp1	O
in	O
IRF1	O
Signaling	O
.	O

To	O
study	O
the	O
possible	O
immune	O
evasion	O
of	O
the	O
type	O
III	O
IFN	O
response	O
by	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
a	O
line	O
of	O
porcine	O
intestinal	O
epithelial	O
cells	O
was	O
developed	O
as	O
a	O
cell	O
model	O
for	O
PEDV	O
replication	O
.	O

PEDV	O
nsp1	O
blocked	O
the	O
nuclear	O
translocation	B-DISO
of	O
IRF1	O
and	O
reduced	O
the	O
number	O
of	O
peroxisomes	O
to	O
suppress	O
IRF1	O
-	O
mediated	O
type	O
III	O
IFNs	O
.	O

LTPL	O
may	O
be	O
considered	O
as	O
a	O
therapeutic	O
option	O
in	O
a	O
select	O
group	O
of	O
patients	O
with	O
severe	O
ARDS	B-DISO
.	O

RESULTS	O
:	O
Fourteen	O
patients	O
were	O
listed	O
for	O
LTPL	O
due	O
to	O
severe	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
A	O
large	O
number	O
of	O
SARS	B-DISO
-	O
related	O
coronaviruses	O
(	O
SARSr	O
-	O
CoV	O
)	O
have	O
been	O
detected	O
in	O
horseshoe	O
bats	O
since	O
2005	O
in	O
different	O
areas	O
of	O
China	O
.	O

However	O
,	O
these	O
bat	O
SARSr	O
-	O
CoVs	O
show	O
sequence	O
differences	O
from	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
in	O
different	O
genes	O
(	O
S	O
,	O
ORF8	O
,	O
ORF3	O
,	O
etc	O
)	O
and	O
are	O
considered	O
unlikely	O
to	O
represent	O
the	O
direct	O
progenitor	O
of	O
SARS	B-DISO
-	O
CoV	O
.	O
Herein	O
,	O
we	O
report	O
the	O
findings	O
of	O
our	O
5	O
-	O
year	O
surveillance	O
of	O
SARSr	O
-	O
CoVs	O
in	O
a	O
cave	O
inhabited	O
by	O
multiple	O
species	O
of	O
horseshoe	O
bats	O
in	O
Yunnan	O
Province	O
,	O
China	O
.	O

In	O
addition	O
,	O
we	O
report	O
the	O
first	O
discovery	O
of	O
bat	O
SARSr	O
-	O
CoVs	O
highly	O
similar	O
to	O
human	O
SARS	B-DISO
-	O
CoV	O
in	O
ORF3b	O
and	O
in	O
the	O
split	O
ORF8a	O
and	O
8b	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
test	O
the	O
efficacy	O
of	O
an	O
accelerated	O
hydrogen	O
peroxide	O
(	O
AHP	B-DISO
)	O
disinfectant	O
for	O
inactivating	O
PEDV	O
in	O
swine	O
feces	O
on	O
metal	O
surfaces	O
under	O
freezing	O
conditions	O
.	O

This	O
study	O
also	O
suggests	O
that	O
a	O
positive	O
RT	O
-	O
qPCR	O
result	O
for	O
PEDV	O
on	O
an	O
environmental	O
sample	O
should	O
be	O
expected	O
when	O
the	O
AHP	B-DISO
disinfectant	O
is	O
applied	O
under	O
freezing	O
conditions	O
,	O
but	O
does	O
not	O
necessarily	O
indicate	O
that	O
an	O
infectious	B-DISO
dose	O
of	O
PEDV	O
remains	O
after	O
disinfection	O
.	O

The	O
N	O
proteins	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
CoV	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)-	O
CoV	O
were	O
also	O
ADP	O
-	O
ribosylated	O
.	O

ADP	O
-	O
ribosylation	O
of	O
N	O
protein	O
was	O
also	O
observed	O
in	O
cells	O
exogenously	O
expressing	O
N	O
protein	O
by	O
transduction	O
using	O
Venezuelan	B-DISO
equine	I-DISO
encephalitis	I-DISO
virus	O
replicon	O
particles	O
(	O
VRPs	O
).	O

However	O
,	O
plasmid	O
-	O
derived	O
N	O
protein	O
was	O
not	O
ADP	O
-	O
ribosylated	O
following	O
transient	O
transfection	O
but	O
was	O
ADP	O
-	O
ribosylated	O
after	O
MHV	O
infection	B-DISO
,	O
indicating	O
that	O
this	O
modification	O
requires	O
virus	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Over	O
the	O
last	O
decade	O
,	O
capacity	O
for	O
influenza	B-DISO
surveillance	O
and	O
research	O
in	O
West	O
Africa	O
has	O
strengthened	O
.	O

Among	O
influenza	B-DISO
-	O
positive	O
ILI	O
patients	O
,	O
1431	O
(	O
63	O
%)	O
were	O
influenza	B-DISO
A	O
[	O
820	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pdm09	O
,	O
611	O
influenza	B-DISO
A	O
(	O
H3N2	O
)]	O
and	O
847	O
(	O
37	O
%)	O
were	O
influenza	B-DISO
B	O
.	O
A	O
majority	O
of	O
SARI	O
and	O
ILI	O
case	O
-	O
patients	O
who	O
tested	O
positive	O
for	O
influenza	B-DISO
(	O
72	O
%	O
SARI	O
and	O
59	O
%	O
ILI	O
)	O
were	O
children	O
aged	O
0	O
-	O
4	O
years	O
,	O
as	O
were	O
a	O
majority	O
of	O
those	O
enrolled	O
in	O
surveillance	O
.	O

The	O
seasonality	O
of	O
influenza	B-DISO
and	O
the	O
predominant	O
influenza	B-DISO
type	O
or	O
subtype	O
varied	O
by	O
country	O
and	O
year	O
.	O

The	O
viral	O
component	O
of	O
the	O
microbiome	O
(	O
the	O
virome	O
)	O
is	O
receiving	O
increasing	O
attention	O
for	O
its	O
role	O
in	O
neonatal	B-DISO
calf	I-DISO
diarrhea	I-DISO
(	O
NCD	O
).	O

Most	O
studies	O
have	O
involved	O
epidemiologic	O
investigations	O
seeking	O
to	O
show	O
association	O
with	O
diarrhea	B-DISO
for	O
each	O
virus	O
alone	O
or	O
in	O
combination	O
with	O
potential	O
pathogens	O
.	O

TITLE	O
:	O
Human	O
Infection	B-DISO
with	O
ABSTRACT	O
:	O
Lemierre	B-DISO
'	I-DISO
s	I-DISO
syndrome	I-DISO
is	O
also	O
known	O
as	O
postangina	O
septicemia	B-DISO
,	O
which	O
is	O
commonly	O
caused	O
by	O

TITLE	O
:	O
Etiology	O
of	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
in	O
the	O
community	O
and	O
clinic	O
in	O
Ilorin	O
,	O
Nigeria	O
.	O

However	O
,	O
it	O
remains	O
unclear	O
how	O
SIVcpz	O
has	O
evolved	O
into	O
pandemic	O
HIV	B-DISO
-	O
1	O
in	O
humans	O
.	O

ABSTRACT	O
:	O
Human	O
coronaviruses	O
(	O
HCoV	O
)	O
OC43	O
,	O
229E	O
,	O
NL63	O
,	O
and	O
HKU1	O
are	O
common	O
respiratory	O
viruses	O
which	O
cause	O
various	O
respiratory	B-DISO
diseases	I-DISO
,	O
including	O
pneumonia	B-DISO
.	O

The	O
peak	O
seasons	O
of	O
infection	B-DISO
varied	O
depending	O
on	O
the	O
HCoV	O
strain	O
.	O

TITLE	O
:	O
A	O
prospective	O
international	O
observational	O
prevalence	O
study	O
on	O
prone	O
positioning	O
of	O
ARDS	B-DISO
patients	O
:	O
the	O
APRONET	O
(	O
ARDS	B-DISO
Prone	O
Position	O
Network	O
)	O
study	O
.	O

ABSTRACT	O
:	O
While	O
prone	O
positioning	O
(	O
PP	O
)	O
has	O
been	O
shown	O
to	O
improve	O
patient	O
survival	O
in	O
moderate	O
to	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
patients	O
,	O
the	O
rate	O
of	O
application	O
of	O
PP	O
in	O
clinical	O
practice	O
still	O
appears	O
low	O
.	O

The	O
indication	O
of	O
VV	O
-	O
ECMO	O
was	O
severe	O
hypoxemia	O
(	O
P	O
The	O
causes	O
of	O
ARDS	B-DISO
were	O
bacterial	B-DISO
pneumonia	I-DISO
(	O
n	O
=	O
41	O
),	O
viral	B-DISO
pneumonia	I-DISO
(	O
n	O
=	O
24	O
),	O
aspiration	B-DISO
pneumonitis	I-DISO
(	O
n	O
=	O
3	O
),	O
and	O
others	O
(	O
n	O
=	O
38	O
).	O

We	O
recruited	O
246	O
consecutive	O
adult	O
ischemic	B-DISO
stroke	I-DISO
patients	O
.	O

Patients	O
underwent	O
cardiorespiratory	O
sleep	O
study	O
with	O
portable	O
three	O
-	O
channel	O
device	O
during	O
the	O
first	O
48	O
h	O
after	O
the	O
symptom	B-DISO
onset	O
of	O
ischemic	B-DISO
stroke	I-DISO
.	O

We	O
enrolled	O
110	O
(	O
65	O
.	O
5	O
%	O
male	O
)	O
stroke	B-DISO
patients	O
in	O
the	O
thrombolysis	O
group	O
and	O
94	O
(	O
59	O
.	O
6	O
%	O
male	O
)	O
in	O
the	O
nonthrombolysis	O
group	O
.	O

These	O
findings	O
illustrate	O
a	O
striking	O
intrafamilial	O
phenotypic	O
variability	O
in	O
patients	O
with	O
AGS6	O
and	O
describe	O
the	O
first	O
case	O
of	O
a	O
full	O
recovery	O
from	O
an	O
acute	B-DISO
encephalopathy	I-DISO
in	O
an	O
AGS	B-DISO
patient	O
.	O

Our	O
findings	O
also	O
suggest	O
that	O
AGS	B-DISO
should	O
be	O
considered	O
as	O
an	O
important	O
differential	O
diagnosis	O
of	O
an	O
infection	B-DISO
-	O
triggered	O
encephalopathy	B-DISO
in	O
infancy	O
despite	O
the	O
absence	O
of	O
typical	O
neuroimaging	O
findings	O
.	O

TITLE	O
:	O
Diagnostic	O
and	O
Prognostic	O
Plasma	O
Biomarkers	O
for	O
Idiopathic	B-DISO
Pneumonia	I-DISO
Syndrome	I-DISO
after	O
Hematopoietic	O
Cell	O
Transplantation	O
.	O

Based	O
on	O
an	O
assumed	O
prevalence	O
of	O
8	O
%,	O
a	O
positive	O
ST2	O
test	O
increased	O
likelihood	O
of	O
IPS	B-DISO
to	O
50	O
%.	O

We	O
conclude	O
that	O
a	O
prospective	O
validation	O
study	O
is	O
warranted	O
to	O
determine	O
whether	O
a	O
plasma	O
biomarker	O
panel	O
can	O
aid	O
the	O
noninvasive	O
diagnosis	O
and	O
prognosis	O
of	O
IPS	B-DISO
.	O

In	O
a	O
multivariate	O
analysis	O
,	O
history	O
of	O
autologous	O
stem	O
cell	O
transplantation	O
(	O
HR	O
,	O
31	O
.	O
151	O
;	O
95	O
%	O
CI	O
,	O
5	O
.	O
447	O
-	O
178	O
.	O
145	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
tachypnea	B-DISO
at	O
ED	O
(	O
HR	O
,	O
4	O
.	O
392	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
402	O
-	O
13	O
.	O
761	O
;	O
P	O
=	O
0	O
.	O
011	O
)	O
were	O
significantly	O
associated	O
with	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

The	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
according	O
to	O
four	O
indicators	O
(	O
resuscitation	O
,	O
acute	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
,	I-DISO
acute	I-DISO
kidney	O
injury	O
,	O
septic	B-DISO
shock	I-DISO
).	O

We	O
collected	O
several	O
types	O
of	O
data	O
for	O
the	O
patients	O
and	O
divided	O
the	O
patients	O
into	O
a	O
complication	B-DISO
group	O
and	O
non	O
-	O
complication	B-DISO
group	O
according	O
to	O
the	O
diagnostic	O
criteria	O
.	O

TITLE	O
:	O
Estradiol	O
mediates	O
the	O
long	O
-	O
lasting	O
lung	B-DISO
inflammation	I-DISO
induced	O
by	O
intestinal	B-DISO
ischemia	I-DISO
and	O
reperfusion	O
.	O

ABSTRACT	O
:	O
Lung	B-DISO
inflammation	I-DISO
is	O
one	O
of	O
the	O
main	O
consequences	O
of	O
intestinal	B-DISO
ischemia	I-DISO
reperfusion	O
(	O
intestinal	O
IR	O
)	O
and	O
,	O
in	O
severe	O
cases	O
,	O
can	O
lead	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
death	O
.	O

Seven	O
-	O
days	O
-	O
ovariectomized	O
rats	O
were	O
subjected	O
to	O
intestinal	O
IR	O
by	O
occlusion	B-DISO
of	O
the	O
superior	O
mesenteric	O
artery	O
for	O
45	O
min	O
.	O

In	O
this	O
study	O
ATII	O
cells	O
(	O
2	O
.	O
5	O
×	O
10	O
ATII	O
cell	O
transplantation	O
promoted	O
recovery	O
of	O
lung	O
function	O
,	O
decrease	O
mortality	O
and	O
lung	B-DISO
inflammation	I-DISO
of	O
the	O
animals	O
with	O
ALI	O
.	O

While	O
no	O
MERS	O
-	O
CoV	O
was	O
detected	O
,	O
other	O
respiratory	O
viruses	O
were	O
identified	O
in	O
12	O
cases	O
and	O
Mycoplasma	B-DISO
pneumoniae	O
in	O
1	O
case	O
.	O

Here	O
,	O
using	O
the	O
Illumina	O
MiSeq	O
platform	O
,	O
we	O
examined	O
and	O
compared	O
the	O
impact	O
of	O
PEDV	O
infection	B-DISO
on	O
the	O
GM	O
of	O
sows	O
and	O
their	O
piglets	O
less	O
than	O
10	O
days	O
old	O
.	O

Interestingly	O
,	O
pro	O
-	O
apoptotic	O
activity	O
of	O
JNK	O
was	O
not	O
mediated	O
via	O
c	O
-	O
Jun	O
,	O
but	O
involved	O
modulation	O
of	O
the	O
anti	O
-	O
apoptotic	O
protein	O
B	B-DISO
-	I-DISO
cell	I-DISO
lymphoma	I-DISO
2	O
(	O
Bcl2	O
).	O

TITLE	O
:	O
Zoonotic	O
origin	O
and	O
transmission	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
in	O
the	O
UAE	O
.	O

TITLE	O
:	O
Inactivation	B-DISO
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
-	O
coronavirus	O
in	O
human	O
plasma	O
using	O
amotosalen	O
and	O
ultraviolet	O
A	O
light	O
.	O

In	O
addition	O
,	O
residual	O
replicating	O
or	O
live	O
virus	O
after	O
inactivation	B-DISO
was	O
examined	O
by	O
passaging	O
in	O
the	O
permissive	O
Vero	O
E6	O
cells	O
.	O

Our	O
data	O
show	O
that	O
amotosalen	O
/	O
UVA	O
treatment	O
is	O
a	O
potent	O
and	O
effective	O
way	O
to	O
inactivate	O
MERS	O
-	O
CoV	O
infectious	B-DISO
particles	O
in	O
FFP	O
to	O
undetectable	O
levels	O
and	O
to	O
minimize	O
the	O
risk	O
of	O
any	O
possible	O
transfusion	O
-	O
related	O
MERS	O
-	O
CoV	O
transmission	O
.	O

Using	O
a	O
nationally	O
representative	O
database	O
,	O
patients	O
who	O
were	O
admitted	O
to	O
the	O
ICU	O
with	O
a	O
diagnosis	O
of	O
ARDS	B-DISO
or	O
an	O
ARDS	B-DISO
risk	O
factor	O
,	O
received	O
mechanical	O
ventilation	O
,	O
and	O
were	O
treated	O
with	O
a	O
continuous	O
infusion	O
of	O
neuromuscular	O
blocking	B-DISO
agent	O
for	O
at	O
least	O
2	O
days	O
within	O
2	O
days	O
of	O
hospital	O
admission	O
were	O
included	O
.	O

TITLE	O
:	O
Routes	O
of	O
transmission	O
of	O
influenza	B-DISO
A	O
H1N1	O
,	O
SARS	B-DISO
CoV	O
,	O
and	O
norovirus	O
in	O
air	O
cabin	O
:	O
Comparative	O
analyses	O
.	O

ABSTRACT	O
:	O
Mobile	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
retrieval	O
teams	O
(	O
MERTs	O
)	O
assure	O
ECMO	O
implantation	O
and	O
under	O
-	O
ECMO	O
retrieval	O
of	O
patients	O
with	O
most	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
(	O
ARF	B-DISO
)	O
to	O
experienced	O
ECMO	O
centers	O
.	O

Among	O
157	O
VV	O
-	O
ECMO	O
implantations	O
from	O
2008	O
to	O
2012	O
,	O
the	O
MERT	O
hooked	O
up	O
118	O
(	O
75	O
%)	O
patients	O
with	O
refractory	O
ARF	B-DISO
,	O
as	O
reflected	O
by	O
their	O
median	O
partial	O
pressure	O
of	O
O	O
ICU	O
mortality	O
and	O
ECMO	O
-	O
related	O
complications	O
of	O
patients	O
with	O
MERT	O
-	O
implanted	O
VV	O
-	O
ECMO	O
who	O
were	O
transferred	O
to	O
our	O
ECMO	O
referral	O
center	O
were	O
comparable	O
with	O
those	O
implanted	O
on	O
site	O
by	O
the	O
same	O
team	O
,	O
thereby	O
supporting	O
this	O
strategy	O
to	O
manage	O
patients	O
with	O
severe	O
ARF	B-DISO
.	O

The	O
psychological	B-DISO
impact	O
of	O
SARS	B-DISO
on	O
employees	O
appeared	O
to	O
be	O
associated	O
with	O
occupational	O
role	O
;	O
training	O
/	O
preparedness	O
;	O
high	O
-	O
risk	O
work	O
environments	O
;	O
quarantine	O
;	O
role	O
-	O
related	O
stressors	O
;	O
perceived	O
risk	O
;	O
social	O
support	O
;	O
social	O
rejection	O
/	O
isolation	O
;	O
and	O
impact	O
of	O
SARS	B-DISO
on	O
personal	O
or	O
professional	O
life	O
.	O

It	O
provides	O
a	O
description	O
of	O
key	O
epidemiologic	O
events	O
and	O
news	O
released	O
from	O
a	O
prime	O
daily	O
newspaper	O
and	O
main	O
Emergency	B-DISO
Risk	O
Communication	O
(	O
ERC	O
)	O
actions	O
that	O
were	O
undertaken	O
by	O
public	O
health	O
authorities	O
.	O

The	O
collected	O
media	O
stories	O
were	O
then	O
assessed	O
against	O
the	O
practiced	O
emergency	B-DISO
risk	O
communication	O
(	O
ERC	O
)	O
activities	O
during	O
the	O
same	O
time	O
frame	O
.	O

TITLE	O
:	O
Detection	O
and	O
full	O
genome	O
characterization	O
of	O
two	O
beta	O
CoV	O
viruses	O
related	O
to	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
from	O
bats	O
in	O
Italy	O
.	O

The	O
three	O
dimensional	O
macromolecular	O
structure	O
(	O
3DMMS	O
)	O
of	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
in	O
the	O
S	O
protein	O
was	O
predicted	O
by	O
sequence	O
-	O
homology	O
method	O
using	O
the	O
protein	O
data	O
bank	O
(	O
PDB	B-DISO
).	O

He	O
had	O
hypoxemia	O
with	O
diffuse	O
ground	O
glass	O
opacity	B-DISO
evident	O
on	O
chest	O
radiography	O
,	O
which	O
progressed	O
and	O
required	O
mechanical	O
ventilation	O
.	O

Under	O
the	O
diagnosis	O
of	O
respiratory	O
syncytial	O
virus	O
-	O
induced	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
orally	O
administered	O
ribavirin	O
was	O
administered	O
and	O
he	O
recuperated	O
completely	O
without	O
complications	O
.	O

CONCLUSIONS	O
:	O
This	O
case	O
demonstrates	O
the	O
potential	O
usefulness	O
of	O
orally	O
administered	O
ribavirin	O
as	O
a	O
therapeutic	O
option	O
for	O
severe	O
respiratory	B-DISO
syncytial	I-DISO
virus	I-DISO
infection	I-DISO
,	O
at	O
least	O
in	O
an	O
immunocompetent	O
host	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
bilateral	O
central	B-DISO
retinal	I-DISO
artery	I-DISO
occlusion	I-DISO
with	O
both	O
anterior	O
and	O
posterior	B-DISO
ischemic	I-DISO
optic	I-DISO
neuropathy	I-DISO
,	O
presumed	O
due	O
to	O
the	O
combination	O
of	O
severe	O
systemic	O
hypotension	O
,	O
hypoxemia	O
due	O
to	O
the	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
,	O
and	O
prolonged	O
prone	O
positioning	O
.	O

ABSTRACT	O
:	O
Among	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
apart	O
from	O
acute	B-DISO
cor	I-DISO
pulmonale	I-DISO
(	O
ACP	B-DISO
),	O
the	O
frequency	O
and	O
prognostic	O
impact	O
of	O
basic	O
critical	O
care	O
echocardiography	O
(	O
BCCE	O
)	O
abnormalities	O
are	O
not	O
well	O
defined	O
.	O

On	O
multivariate	O
analysis	O
,	O
only	O
severe	O
ACP	B-DISO
remained	O
significantly	O
associated	O
with	O
ICU	O
/	O
hospital	O
mortality	O
.	O

ABCA3	O
-	O
related	O
lung	O
dysfunction	O
was	O
associated	O
with	O
surfactant	O
deficiency	O
,	O
inflammation	B-DISO
,	O
and	O
alveolar	O
-	O
capillary	O
leak	O
.	O

The	O
remarkable	O
and	O
selective	O
regeneration	O
of	O
ABCA3	O
-	O
sufficient	O
AT2	O
progenitor	O
cells	O
provides	O
plausible	O
approaches	O
for	O
future	O
correction	O
of	O
ABCA3	O
and	O
other	O
genetic	B-DISO
disorders	I-DISO
associated	O
with	O
surfactant	O
deficiency	O
and	O
acute	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
.	O

TITLE	O
:	O
Attenuated	O
accumulation	O
of	O
regulatory	O
T	O
cells	O
and	O
reduced	O
production	O
of	O
interleukin	O
10	O
lead	O
to	O
the	O
exacerbation	O
of	O
tissue	O
injury	O
in	O
a	O
mouse	O
model	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

We	O
have	O
established	O
a	O
mouse	O
model	O
of	O
severe	O
ARDS	B-DISO
,	O
developed	O
by	O
intratracheal	O
injection	O
of	O
α	O
-	O
galactosylceramide	O
(	O
α	O
-	O
GalCer	O
),	O
an	O
activator	O
of	O
natural	O
killer	O
T	O
(	O
NKT	O
)	O
cells	O
,	O
followed	O
by	O
LPS	B-DISO
.	O

Identification	O
of	O
ARDS	B-DISO
from	O
patients	O
with	O
severe	O
pneumonia	B-DISO
remains	O
a	O
significant	O
clinical	O
problem	O
due	O
to	O
the	O
overlap	O
of	O
clinical	O
presentations	O
and	O
symptoms	O
.	O

Multivariate	O
logistic	O
regression	O
and	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curves	O
were	O
performed	O
to	O
screen	O
independent	O
risk	O
factors	O
and	O
identify	O
their	O
sensitivity	O
in	O
predicting	O
ARDS	B-DISO
development	O
and	O
prognosis	O
.	O

Her	O
hospital	O
course	O
was	O
rapidly	O
complicated	O
by	O
respiratory	B-DISO
failure	I-DISO
and	O
shock	O
requiring	O
intubation	O
and	O
vasopressors	O
.	O

CoV	O
RNA	O
was	O
found	O
in	O
36	O
bats	O
belonging	O
to	O
eight	O
species	O
,	O
while	O
PMV	B-DISO
RNA	O
in	O
three	O
Pipistrellus	O
spp	O
.	O

Considering	O
the	O
amount	O
of	O
novel	O
bat	O
-	O
borne	O
PMVs	O
associated	O
with	O
the	O
emergence	O
of	O
zoonotic	O
infections	B-DISO
in	O
animals	O
and	O
humans	O
in	O
the	O
last	O
years	O
,	O
the	O
definition	O
of	O
viral	O
diversity	O
within	O
European	O
bat	O
species	O
is	O
needed	O
.	O

ABSTRACT	O
:	O
The	O
electrical	O
activity	O
of	O
the	O
diaphragm	O
(	O
EAdi	O
)	O
shows	O
global	O
diaphragmatic	O
activation	O
and	O
power	O
output	O
from	O
the	O
central	O
nervous	B-DISO
system	O
.	O

We	O
sought	O
to	O
identify	O
current	O
practice	O
patterns	O
of	O
HFOV	O
,	O
investigate	O
parameters	O
during	O
HFOV	O
and	O
their	O
association	O
with	O
mortality	O
,	O
and	O
compare	O
the	O
use	O
of	O
HFOV	O
to	O
conventional	O
mechanical	O
ventilation	O
in	O
severe	O
pediatric	O
ARDS	B-DISO
.	O

Patients	O
may	O
present	O
with	O
ACS	O
or	O
may	O
develop	O
this	O
complication	B-DISO
during	O
the	O
course	O
of	O
a	O
hospitalization	O
for	O
acute	O
vaso	O
-	O
occlusive	O
crises	O
(	O
VOC	O
).	O

ACS	O
in	O
SCD	B-DISO
is	O
defined	O
as	O
the	O
presence	O
of	O
fever	O
and	O
/	O
or	O
new	O
respiratory	B-DISO
symptoms	I-DISO
accompanied	O
by	O
the	O
presence	O
of	O
a	O
new	O
pulmonary	B-DISO
infiltrate	I-DISO
on	O
chest	O
X	O
-	O
ray	O
.	O

Infection	B-DISO
is	O
a	O
common	O
cause	O
in	O
children	O
,	O
whereas	O
adults	O
usually	O
present	O
with	O
pain	O
crises	O
.	O

These	O
include	O
younger	O
age	O
,	O
severe	O
SCD	B-DISO
genotypes	O
(	O
SS	O
or	O
Sβ	O

This	O
Account	O
will	O
build	O
toward	O
examples	O
of	O
in	O
vivo	O
studies	O
in	O
cardiovascular	B-DISO
disease	I-DISO
and	O
cancer	B-DISO
models	O
,	O
including	O
diagnostic	O
studies	O
by	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
),	O
computed	O
tomography	O
(	O
CT	O
),	O
and	O
positron	O
emission	O
tomography	O
(	O
PET	O
).	O

Secondary	O
outcomes	O
were	O
rate	O
of	O
bronchopulmonary	B-DISO
dysplasia	I-DISO
(	O
BDP	O
),	O
air	O
leaks	O
,	O
nasal	O
injury	O
,	O
late	O
onset	O
sepsis	B-DISO
(	O
LOS	O
),	O
intraventricular	B-DISO
hemorrhage	I-DISO
(	O
IVH	O
),	O
retinopathy	B-DISO
(	O
ROP	B-DISO
),	O
necrotizing	B-DISO
enterocolitis	I-DISO
(	O
NEC	O
),	O
hemodynamically	O
-	O
significant	O
patent	B-DISO
ductus	I-DISO
arteriosus	I-DISO
(	O
PDA	B-DISO
)	O
and	O
death	O
.	O

In	O
subgroup	O
analysis	O
,	O
BPD	B-DISO
was	O
diagnosed	O
in	O
53	O
.	O
9	O
%	O
of	O
newborns	O
with	O
GA	O
<	O
29	O
weeks	O
,	O
in	O
53	O
.	O
3	O
%	O
of	O
ELBW	O
newborns	O
and	O
in	O
11	O
.	O
1	O
%	O
of	O
small	B-DISO
for	I-DISO
gestational	I-DISO
age	I-DISO
(	O
SGA	O
)	O
newborns	O
.	O

LOS	O
,	O
IVH	O
,	O
ROP	B-DISO
,	O
NEC	O
and	O
PDA	B-DISO
occurred	O
respectively	O
in	O
16	O
.	O
1	O
%,	O
0	O
%,	O
7	O
.	O
8	O
%,	O
and	O
1	O
.	O
6	O
%	O
of	O
newborns	O
.	O

Traditional	O
diagnostic	O
criteria	O
for	O
pulmonary	B-DISO
hypertension	I-DISO
(	O
PH	O
),	O
in	O
this	O
situation	O
,	O
may	O
be	O
unreliable	O
due	O
to	O
the	O
effects	O
of	O
positive	O
pressure	O
ventilation	O
and	O
vasoactive	O
agents	O
.	O

Furthermore	O
,	O
we	O
examined	O
numerous	O
epidemiologic	O
correlates	O
of	O
febrile	B-DISO
illness	I-DISO
,	O
and	O
conducted	O
demographic	O
,	O
clinical	O
,	O
and	O
behavioral	O
domain	O
-	O
specific	O
multivariate	O
regression	O
to	O
statistically	O
establish	O
associations	O
with	O
agent	O
detection	O
.	O

AFI	O
TAC	O
detected	O
nucleic	O
acid	O
for	O
one	O
or	O
more	O
of	O
seven	O
microbial	O
agents	O
in	O
49	O
%	O
of	O
AFI	O
blood	O
samples	O
,	O
including	O
:	O
Plasmodium	O
(	O
47	O
%),	O
Leptospira	O
(	O
3	O
%),	O
Bartonella	O
(	O
1	O
%),	O
Salmonella	B-DISO
enterica	O
(	O
1	O
%),	O
Coxiella	O
burnetii	O
(	O
1	O
%),	O
Rickettsia	O
(	O
1	O
%),	O
and	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
(	O
1	O
%).	O

The	O
most	O
common	O
agents	O
detected	O
among	O
our	O
surveyed	O
population	O
were	O
:	O
Haemophilus	O
influenzae	O
(	O
67	O
%),	O
Streptococcus	O
pneumoniae	O
(	O
55	O
%),	O
Moraxella	O
catarrhalis	O
(	O
39	O
%),	O
Staphylococcus	O
aureus	O
(	O
37	O
%),	O
Pseudomonas	O
aeruginosa	O
(	O
36	O
%),	O
Human	O
Rhinovirus	O
(	O
25	O
%),	O
influenza	B-DISO
A	O
(	O
24	O
%),	O
Klebsiella	O
pneumoniae	O
(	O
14	O
%),	O
Enterovirus	O
(	O
15	O
%)	O
and	O
group	O
A	O
Streptococcus	O
(	O
12	O
%).	O

Workup	O
for	O
glomerulonephritis	B-DISO
and	O
vasculitis	B-DISO
was	O
negative	O
.	O

TITLE	O
:	O
Pathogenicity	O
differences	O
between	O
QX	O
-	O
like	O
and	O
Mass	O
-	O
type	O
infectious	B-DISO
bronchitis	B-DISO
viruses	O
.	O

The	O
results	O
showed	O
that	O
the	O
viral	O
genome	O
copy	O
numbers	O
in	O
the	O
tissues	O
of	O
chickens	O
inoculated	O
with	O
SD	O
strain	O
were	O
higher	O
than	O
those	O
in	O
chickens	O
inoculated	O
with	O
M41	O
strain	O
,	O
with	O
the	O
exception	O
of	O
the	O
trachea	B-DISO
and	O
lung	O
.	O

Fifteen	O
CRRT	O
patients	O
required	O
transition	B-DISO
to	O
intermittent	O
hemodialysis	O
.	O

TITLE	O
:	O
Memory	O
CD8	O
T	O
cells	O
mediate	O
severe	O
immunopathology	B-DISO
following	O
respiratory	B-DISO
syncytial	I-DISO
virus	I-DISO
infection	I-DISO
.	O

Herein	O
,	O
we	O
summarize	O
the	O
current	O
updates	O
on	O
the	O
characteristics	O
of	O
human	O
T	O
-	O
cell	O
immunological	O
responses	O
against	O
recently	O
emerged	O
or	O
re	O
-	O
emerged	O
viruses	O
,	O
and	O
emphasize	O
the	O
necessity	O
for	O
timely	O
investigation	O
on	O
the	O
T	O
-	O
cell	O
features	O
of	O
these	O
viral	B-DISO
diseases	I-DISO
,	O
which	O
may	O
provide	O
beneficial	O
recommendations	O
for	O
clinical	O
diagnosis	O
and	O
vaccine	O
development	O
.	O

TITLE	O
:	O
Accessory	O
proteins	O
8b	O
and	O
8ab	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
suppress	O
the	O
interferon	O
signaling	O
pathway	O
by	O
mediating	O
ubiquitin	O
-	O
dependent	O
rapid	O
degradation	O
of	O
interferon	O
regulatory	O
factor	O
3	O
.	O

Patients	O
with	O
hematological	B-DISO
malignancies	I-DISO
had	O
significantly	O
poorer	O
outcomes	O
than	O
others	O
(	O
log	O
-	O
rank	O
P	O
=	O
0	O
.	O
02	O
).	O

We	O
previously	O
determined	O
the	O
immunogenicity	O
of	O
a	O
novel	O
dendritic	O
cell	O
(	O
DC	O
)-	O
targeted	O
PEDV	O
S1	O
protein	O
-	O
based	O
subunit	O
vaccine	O
in	O
weaned	O
piglets	O
in	O
which	O
the	O
PEDV	O
antigen	O
was	O
targeted	O
to	O
DCs	B-DISO
through	O
a	O
porcine	O
Langerin	O
-	O
specific	O
antibody	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
rates	O
of	O
both	O
symptomatic	O
and	O
asymptomatic	B-DISO
infection	I-DISO
among	O
ambulatory	O
adults	O
,	O
we	O
collected	O
nasopharyngeal	O
swab	O
specimens	O
,	O
demographic	O
characteristics	O
,	O
and	O
survey	O
information	O
from	O
1477	O
adult	O
visitors	O
to	O
a	O
New	O
York	O
City	O
tourist	O
attraction	O
during	O
April	O
-	O
July	O
2016	O
.	O

TITLE	O
:	O
The	O
burden	O
of	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
associated	O
acute	O
lower	O
respiratory	B-DISO
infections	I-DISO
in	O
children	O
with	O
Down	B-DISO
syndrome	I-DISO
:	O
A	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
.	O

Down	B-DISO
syndrome	I-DISO
(	O
DS	O
),	O
a	O
common	O
genetic	B-DISO
disorder	I-DISO
associated	O
with	O
congenital	O
and	O
dysmorphic	B-DISO
features	I-DISO
,	O
has	O
recently	O
been	O
identified	O
as	O
an	O
independent	O
risk	O
factor	O
for	O
RSV	O
-	O
associated	O
ALRI	O
requiring	O
hospitalisation	O
;	O
however	O
,	O
the	O
disease	O
burden	O
of	O
RSV	O
-	O
associated	O
ALRI	O
in	O
this	O
population	O
has	O
not	O
yet	O
been	O
established	O
.	O

ABSTRACT	O
:	O
To	O
establish	O
an	O
association	O
between	O
mitochondrial	O
dysfunction	O
and	O
apoptosis	O
following	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
infection	B-DISO
,	O
HD11	O
avian	O
macrophage	O
cells	O
were	O
infected	O
with	O
the	O
Massachusetts	O
41	O
(	O
M41	O
)	O
strain	O
.	O

Our	O
results	O
show	O
that	O
the	O
M41	O
strain	O
of	O
IBV	O
induced	O
cytopathic	B-DISO
effects	I-DISO
followed	O
by	O
the	O
release	O
of	O
new	O
viral	O
particles	O
.	O

Elevated	O
numbers	O
of	O
apoptotic	O
cells	O
were	O
observed	O
at	O
24	O
,	O
48	O
and	O
72	O
h	O
post	O
-	O
infection	B-DISO
(	O
p	O
.	O
i	O
.).	O

Viral	B-DISO
infection	I-DISO
was	O
associated	O
with	O
mitochondrial	O
membrane	O
depolarization	O
and	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
production	O
at	O
all	O
of	O
the	O
examined	O
timepoints	O
p	O
.	O
i	O
.	O

Bundle	O
treatment	O
group	O
was	O
given	O
bundle	O
treatment	O
on	O
the	O
basis	O
of	O
conventional	O
treatment	O
,	O
including	O
isolation	O
,	O
anti	O
-	O
virus	O
,	O
respiratory	O
support	O
,	O
restrictive	O
fluid	O
management	O
,	O
immunotherapy	O
,	O
inhibition	O
of	O
inflammation	B-DISO
,	O
antibiotic	O
therapy	O
,	O
nutritional	O
support	O
,	O
prevention	O
of	O
hospital	B-DISO
acquired	I-DISO
infection	I-DISO
(	O
HAP	O
),	O
individual	O
sedation	B-DISO
,	O
continuous	O
blood	O
purification	O
(	O
CBP	O
)	O
for	O
acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
and	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
patients	O
,	O
and	O
intensive	O
care	O
.	O

As	O
the	O
main	O
hormones	O
during	O
sepsis	B-DISO
,	O
catecholamines	O
(	O
CA	O
),	O
including	O
epinephrine	O
and	O
NE	O
,	O
could	O
bind	O
to	O
adrenergic	O
receptor	O
(	O
AR	O
).	O

The	O
following	O
data	O
were	O
collected	O
:	O
demographics	O
,	O
hemodynamic	O
data	O
,	O
coagulation	O
samples	O
,	O
transfusion	O
requirements	O
,	O
change	O
of	O
ECMO	O
-	O
circuit	O
during	O
treatment	O
and	O
adverse	B-DISO
effects	I-DISO
,	O
including	O
hemorrhage	B-DISO
and	O
thrombosis	B-DISO
.	O

RESULTS	O
:	O
We	O
analyzed	O
278	O
patients	O
(	O
M	O
age	O
=	O
43	O
years	O
,	O
SD	O
19	O
;	O
M	O
ISS	B-DISO
=	O
32	O
.	O
8	O
,	O
SD	O
10	O
.	O
7	O
).	O

The	O
greater	O
number	O
of	O
CFs	B-DISO
in	O
the	O
ALI	O
/	O
ARDS	B-DISO
group	O
implied	O
higher	O
degree	O
of	O
lung	O
injury	O
and	O
more	O
severe	O
pulmonary	B-DISO
fibrosis	I-DISO
.	O

ROC	O
curve	O
analysis	O
indicated	O
the	O
counts	O
of	O
CFs	B-DISO
greater	O
than	O
5	O
.	O
85	O
%	O
can	O
predict	O
death	O
rates	O
with	O
AUC	O
=	O
0	O
.	O
928	O
.	O

Ventilatory	O
and	O
mechanical	O
parameters	O
,	O
arterial	O
blood	O
gases	O
,	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
score	O
,	O
epithelial	O
integrity	O
measured	O
by	O
E	O
-	O
cadherin	O
tissue	O
expression	O
,	O
and	O
biological	O
markers	O
associated	O
with	O
inflammation	B-DISO
(	O
IL	O
-	O
6	O
and	O
cytokine	O
-	O
induced	O
neutrophil	O
chemoattractant	O
,	O
CINC	O
-	O
1	O
)	O
and	O
type	O
II	O
epithelial	O
cell	B-DISO
damage	I-DISO
(	O
surfactant	O
protein	O
-	O
B	O
)	O
were	O
evaluated	O
.	O

In	O
PSV	O
,	O
PEEP	O
=	O
5	O
cmH2O	O
compared	O
with	O
PEEP	O
=	O
2	O
cmH2O	O
was	O
associated	O
with	O
significantly	O
reduced	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
score	O
[	O
median	O
(	O
interquartile	O
range	O
),	O
11	O
(	O
8	O
.	O
5	O
to	O
13	O
.	O
5	O
)	O
vs	O
.	O
23	O
(	O
19	O
to	O
26	O
),	O
P	O
=	O
0	O
.	O
005	O
]	O
and	O
expressions	O
of	O
IL	O
-	O
6	O
and	O
CINC	O
-	O
1	O
(	O
P	O
=	O
0	O
.	O
02	O
for	O
both	O
),	O
whereas	O
surfactant	O
protein	O
-	O
B	O
mRNA	O
expression	O
increased	O
(	O
P	O
=	O
0	O
.	O
03	O
).	O

Male	O
C56BL	O
/	O
6	O
mice	O
were	O
administered	O
UTI	B-DISO
intravenously	O
1	O
h	O
before	O
and	O
6	O
h	O
after	O
exposure	O
to	O
LPS	B-DISO
by	O
intratracheal	O
instillation	O
.	O

ABSTRACT	O
:	O
Most	O
patients	O
with	O
severe	O
infection	B-DISO
with	O
influenza	B-DISO
A	O
virus	O
(	O
IAV	O
)	O
progress	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
even	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
(	O
MODS	B-DISO
).	O

The	O
different	O
subtypes	O
,	O
preceding	O
infection	B-DISO
and	O
age	O
of	O
onset	O
can	O
partially	O
determine	O
the	O
disease	B-DISO
progression	I-DISO
,	O
severity	O
and	O
short	O
-	O
term	O
recovery	O
speed	O
of	O
GBS	B-DISO
.	O

Till	O
date	O
,	O
it	O
is	O
not	O
known	O
if	O
viral	B-DISO
infection	I-DISO
can	O
modulate	O
Cx43	O
expression	O
and	O
function	O
in	O
cells	O
of	O
the	O
brain	O
meninges	O
and	O
thus	O
affect	O
BBB	O
permeability	O
.	O

This	O
protein	O
is	O
also	O
involved	O
in	O
FCoV	O
tropism	O
and	O
virulence	O
,	O
as	O
well	O
as	O
in	O
the	O
switch	O
from	O
enteric	O
disease	O
to	O
FIP	B-DISO
.	O

TITLE	O
:	O
Safety	O
and	O
tolerability	O
of	O
a	O
novel	O
,	O
polyclonal	O
human	O
anti	O
-	O
MERS	O
coronavirus	O
antibody	O
produced	O
from	O
transchromosomic	O
cattle	O
:	O
a	O
phase	O
1	O
randomised	O
,	O
double	O
-	O
blind	B-DISO
,	O
single	O
-	O
dose	O
-	O
escalation	O
study	O
.	O

We	O
collected	O
data	O
retrospectively	O
on	O
MERS	O
-	O
CoV	O
patients	O
with	O
refractory	O
respiratory	B-DISO
failure	I-DISO
from	O
April	O
2014	O
to	O
December	O
2015	O
in	O
5	O
intensive	O
care	O
units	O
(	O
ICUs	O
)	O
in	O
Saudi	O
Arabia	O
.	O

ABSTRACT	O
:	O
The	O
ability	O
of	O
commercial	O
vaccines	O
H120	O
and	O
4	O
/	O
91	O
to	O
protect	O
against	O
Moroccan	O
-	O
Italy	O
02	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
Mor	O
-	O
It02	O
)	O
was	O
investigated	O
in	O
specific	O
-	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
chickens	O
and	O
commercial	O
broiler	O
chickens	O
.	O

Importantly	O
,	O
epigenetic	O
analysis	O
suggested	O
that	O
DNA	O
methylation	O
,	O
rather	O
than	O
histone	O
modification	O
,	O
plays	O
a	O
crucial	O
role	O
in	O
MERS	O
-	O
CoV	O
-	O
mediated	O
antagonism	O
of	O
antigen	O
-	O
presentation	O
gene	O
expression	O
;	O
in	O
contrast	O
,	O
H5N1	B-DISO
-	O
VN1203	O
likely	O
utilizes	O
a	O
combination	O
of	O
epigenetic	O
mechanisms	O
to	O
target	O
antigen	O
presentation	O
.	O

A	O
higher	O
white	O
blood	O
cell	O
count	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
and	O
the	O
complications	O
of	O
ARDS	B-DISO
(	O
P	O
=	O
0	O
.	O
004	O
)	O
and	O
encephalopathy	B-DISO
(	O
P	O
=	O
0	O
.	O
004	O
)	O
were	O
associated	O
with	O
mortality	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
clinical	O
characteristics	O
and	O
outcomes	O
of	O
ARDS	B-DISO
in	O
patients	O
with	O
hematological	B-DISO
malignancies	I-DISO
admitted	O
to	O
the	O
ICU	O
.	O

During	O
the	O
8	O
-	O
year	O
study	O
period	O
,	O
among	O
a	O
total	O
of	O
821	O
patients	O
with	O
ARDS	B-DISO
admitted	O
to	O
the	O
ICU	O
,	O
all	O
185	O
patients	O
with	O
hematological	B-DISO
malignancies	I-DISO
were	O
included	O
in	O
the	O
analysis	O
.	O

RESULTS	O
:	O
During	O
the	O
8	O
-	O
year	O
study	O
period	O
,	O
among	O
a	O
total	O
of	O
821	O
patients	O
with	O
ARDS	B-DISO
admitted	O
to	O
the	O
ICU	O
,	O
all	O
185	O
patients	O
with	O
hematological	B-DISO
malignancies	I-DISO
were	O
included	O
in	O
the	O
analysis	O
.	O

Most	O
of	O
the	O
patients	O
(	O
88	O
.	O
1	O
%)	O
had	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	B-DISO
,	O
and	O
the	O
median	O
PaO	O
CONCLUSIONS	O
:	O
The	O
outcome	O
of	O
ARDS	B-DISO
in	O
patients	O
with	O
hematological	B-DISO
malignancies	I-DISO
is	O
associated	O
with	O
the	O
severity	O
of	O
the	O
underlying	O
diseases	O
,	O
the	O
presence	O
of	O
multidrug	O
-	O
resistance	O
pathogens	O
,	O
and	O
the	O
amount	O
of	O
transfusion	O
;	O
however	O
,	O
strict	O
application	O
of	O
low	O
tidal	O
volume	O
ventilation	O
may	O
improve	O
the	O
outcome	O
of	O
these	O
patients	O
at	O
the	O
time	O
of	O
diagnosis	O
.	O

Our	O
findings	O
showing	O
a	O
novel	O
role	O
for	O
SPC	O
in	O
regulating	O
inflammation	B-DISO
via	O
JAK	O
/	O
STAT	O
may	O
have	O
clinical	O
applications	O
.	O

TITLE	O
:	O
Receptor	O
Usage	O
of	O
a	O
Novel	O
Bat	O
Lineage	O
C	O
Betacoronavirus	O
Reveals	O
Evolution	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
-	O
Related	O
Coronavirus	O
Spike	O
Proteins	O
for	O
Human	O
Dipeptidyl	O
Peptidase	O
4	O
Binding	O
.	O

Extending	O
our	O
analysis	O
to	O
smallpox	B-DISO
and	O
MERS	O
-	O
CoV	O
,	O
we	O
found	O
that	O
the	O
optimal	O
length	O
of	O
active	O
monitoring	O
relative	O
to	O
the	O
median	O
incubation	O
period	O
was	O
reduced	O
compared	O
to	O
Ebola	O
due	O
to	O
less	O
variable	O
incubation	O
periods	O
.	O

ABSTRACT	O
:	O
The	O
optimal	O
strategy	O
for	O
initiation	O
of	O
renal	O
replacement	O
therapy	O
(	O
RRT	O
)	O
in	O
patients	O
with	O
severe	O
acute	O
kidney	O
injury	O
in	O
the	O
context	O
of	O
septic	B-DISO
shock	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
unknown	O
.	O

We	O
found	O
no	O
significant	O
influence	O
of	O
the	O
baseline	O
sepsis	B-DISO
status	O
(	O
P	O
=	O
0	O
.	O
28	O
),	O
baseline	O
ARDS	B-DISO
status	O
(	O
P	O
=	O
0	O
.	O
94	O
),	O
and	O
baseline	O
severity	O
scores	O
(	O
P	O
=	O
0	O
.	O
77	O
and	O
P	O
=	O
0	O
.	O
46	O
for	O
SAPS	O
3	O
and	O
SOFA	O
,	O
respectively	O
)	O
on	O
the	O
comparison	O
of	O
60	O
-	O
day	O
mortality	O
according	O
to	O
RRT	O
initiation	O
strategy	O
.	O

This	O
innovation	O
analysis	O
article	O
outlines	O
the	O
promise	O
of	O
Omics	O
systems	O
science	O
biotechnologies	O
,	O
for	O
example	O
,	O
to	O
deploy	O
rapid	O
fire	O
diagnostics	O
for	O
health	O
security	O
crises	O
at	O
GCBR	O
level	O
,	O
possibly	O
involving	O
neopathogens	O
and	O
/	O
or	O
incurring	O
epidemics	O
(	O
e	O
.	O
g	O
.,	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
[	O
SARS	B-DISO
]	O
and	O
Ebola	O
)	O
that	O
collectively	O
threaten	O
the	O
lives	O
of	O
global	O
society	O
and	O
interdependent	O
biological	O
ecosystems	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
potential	O
of	O
hemoglobin	O
modification	O
as	O
a	O
novel	O
therapy	O
for	O
ARDS	B-DISO
-	O
induced	O
hypoxemia	O
.	O

The	O
AKI	O
group	O
showed	O
a	O
greater	O
incidence	O
of	O
complications	O
during	O
ECMO	O
,	O
including	O
liver	B-DISO
failure	I-DISO
(	O
38	O
%	O
vs	O
.	O
5	O
%,	O
p	O
=	O
0	O
.	O
002	O
)	O
and	O
hemorrhage	B-DISO
(	O
94	O
%	O
vs	O
.	O
45	O
%,	O
p	O
=	O
0	O
.	O
0008	O
).	O

ABSTRACT	O
:	O
Sepsis	B-DISO
as	O
a	O
process	O
has	O
been	O
recognized	O
since	O
the	O
time	O
of	O
the	O
Ancient	O
Greeks	O
.	O

Acute	O
,	O
life	O
-	O
threatening	O
but	O
potentially	O
reversible	O
organ	O
dysfunction	O
is	O
its	O
hallmark	O
,	O
and	O
unresolving	O
organ	O
dysfunction	O
is	O
the	O
dominant	O
cause	O
of	O
death	O
in	O
critical	B-DISO
illness	I-DISO
.	O

This	O
virus	O
causes	O
enteric	O
disease	O
in	O
piglets	O
that	O
is	O
characterized	O
by	O
enteritis	B-DISO
and	O
diarrhoea	B-DISO
.	O

An	O
association	O
was	O
also	O
observed	O
between	O
galectin	O
-	O
3	O
and	O
NLRP3	O
/	O
apoptosis	O
-	O
associated	O
speck	O
-	O
like	O
proteins	O
containing	O
caspase	O
-	O
associated	O
recruitment	B-DISO
domain	O
complex	O
.	O

Understanding	O
both	O
the	O
assumptions	O
of	O
lung	O
mechanics	O
and	O
the	O
scope	O
of	O
injury	O
mechanisms	O
operating	O
during	O
ARDS	B-DISO
is	O
necessary	O
to	O
interpret	O
the	O
results	O
of	O
clinical	O
trials	O
that	O
inform	O
prevailing	O
ventilator	O
-	O
management	O
guidelines	O
.	O

Abnormal	O
findings	O
on	O
radiographic	O
imagine	O
was	O
similar	O
in	O
both	O
syndromes	B-DISO
.	O

Most	O
patients	O
with	O
EP	O
were	O
treated	O
with	O
steroids	O
with	O
a	O
higher	O
rate	O
of	O
relapse	B-DISO
observed	O
in	O
patients	O
with	O
CEP	B-DISO
.	O

AEP	O
is	O
a	O
much	O
more	O
fulminant	O
and	O
severe	O
disease	O
than	O
the	O
gradual	O
onset	O
and	O
slowly	O
progressive	O
nature	O
of	O
CEP	B-DISO
.	O

The	O
pathogenesis	B-DISO
of	O
AEP	O
and	O
CEP	B-DISO
remains	O
unclear	O
.	O

This	O
indicates	O
that	O
NF	O
-	O
κB	O
repression	O
required	O
the	O
nuclear	O
import	O
of	O
4b	O
mediated	O
by	O
a	O
specific	O
NLS	B-DISO
.	O

However	O
,	O
the	O
2015	O
outbreak	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
revealed	O
limitations	O
in	O
the	O
existing	O
systems	O
of	O
management	O
of	O
field	O
epidemiologists	O
and	O
communicable	B-DISO
diseases	I-DISO
.	O

TITLE	O
:	O
Microglia	O
are	O
required	O
for	O
protection	O
against	O
lethal	O
coronavirus	O
encephalitis	B-DISO
in	O
mice	O
.	O

A	O
better	O
understanding	O
of	O
the	O
specific	O
role	O
of	O
microglia	O
in	O
responding	O
to	O
viral	B-DISO
infection	I-DISO
is	O
complicated	O
by	O
the	O
presence	O
of	O
nonmicroglial	O
myeloid	O
cells	O
with	O
potentially	O
overlapping	O
function	O
in	O
the	O
healthy	O
brain	O
and	O
by	O
the	O
rapid	O
infiltration	B-DISO
of	O
hematopoietic	O
myeloid	O
cells	O
into	O
the	O
brain	O
in	O
diseased	O
states	O
.	O

TITLE	O
:	O
Pathogenic	O
mechanisms	O
of	O
invasive	O
group	O
A	O
Streptococcus	O
infections	B-DISO
by	O
influenza	B-DISO
virus	O
-	O
group	O
A	O
Streptococcus	O
superinfection	B-DISO
.	O

ABSTRACT	O
:	O
Group	O
A	O
Streptococcus	O
(	O
GAS	O
)	O
are	O
pathogenic	O
bacteria	O
of	O
the	O
genus	O
Streptococcus	O
and	O
cause	O
severe	O
invasive	O
infections	B-DISO
that	O
comprise	O
a	O
wide	O
range	O
of	O
diverse	O
diseases	O
,	O
including	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
renal	B-DISO
failure	I-DISO
,	O
toxic	B-DISO
shock	I-DISO
-	O
like	O
syndrome	B-DISO
,	I-DISO
sepsis	I-DISO
,	O
cellulitis	B-DISO
and	O
necrotizing	B-DISO
fasciitis	I-DISO
.	O

The	O
present	O
review	O
describes	O
the	O
current	O
knowledge	O
about	O
invasive	O
GAS	O
infections	B-DISO
by	O
superinfection	B-DISO
.	O

TITLE	O
:	O
Hepatitis	B-DISO
E	I-DISO
virus	O
seroprevalence	O
,	O
seroincidence	O
and	O
seroreversion	O
in	O
the	O
German	O
adult	O
population	O
.	O

ABSTRACT	O
:	O
A	O
steep	O
rise	O
in	O
Hepatitis	B-DISO
E	I-DISO
diagnoses	O
is	O
currently	O
being	O
observed	O
in	O
Germany	O
and	O
other	O
European	O
countries	O
.	O

At	O
both	O
time	O
points	O
,	O
seroprevalence	O
increased	O
with	O
age	O
and	O
peaked	O
in	O
persons	O
born	O
between	O
1935	O
and	O
1959	O
suggesting	O
a	O
past	O
period	O
of	O
increased	O
infection	B-DISO
pressure	O
.	O

Continuously	O
rising	O
numbers	O
of	O
Hepatitis	B-DISO
E	I-DISO
diagnoses	O
in	O
Europe	O
are	O
likely	O
due	O
to	O
an	O
increased	O
awareness	O
of	O
clinicians	O
and	O
indicate	O
that	O
still	O
there	O
is	O
a	O
gap	O
between	O
incident	O
and	O
diagnosed	O
cases	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
reduces	O
feed	O
efficiency	O
in	O
nursery	O
pigs	O
.	O

TITLE	O
:	O
The	O
calm	O
before	O
the	O
storm	O
:	O
clinical	O
observations	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
patients	O
.	O

The	O
clinical	O
course	O
for	O
these	O
patients	O
started	O
with	O
a	O
febrile	O
period	O
lasting	O
five	O
days	O
,	O
a	O
reduction	O
in	O
fever	O
was	O
coinciding	O
with	O
increased	B-DISO
respiratory	I-DISO
rate	I-DISO
and	O
oxygen	O
requirements	O
.	O

Therefore	O
,	O
we	O
determined	O
whether	O
EGFR	O
activation	O
affected	O
PEDV	O
infection	B-DISO
by	O
using	O
an	O
activator	O
or	O
overexpression	O
assay	O
.	O

TITLE	O
:	O
Case	O
report	O
:	O
Guillain	B-DISO
-	I-DISO
Barre	I-DISO
syndrome	I-DISO
with	O
pneumococcus	O
-	O
A	O
new	O
association	O
in	O
pediatrics	O
.	O

Spike	O
gene	O
is	O
divergent	O
and	O
important	O
for	O
understanding	O
the	O
genetic	O
relations	O
of	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
field	O
strains	O
,	O
the	O
epidemiological	O
status	O
of	O
the	O
virus	O
and	O
vaccine	O
development	O
.	O

A	O
32	O
-	O
year	O
-	O
old	O
woman	O
from	O
the	O
Philippines	O
first	O
diagnosed	O
with	O
upper	O
airway	O
infection	B-DISO
,	O
was	O
subsequently	O
hospitalized	O
in	O
infectious	B-DISO
disease	I-DISO
department	O
and	O
treated	O
for	O
community	B-DISO
acquired	I-DISO
pneumonia	I-DISO
.	O

The	O
diagnosis	O
is	O
often	O
challenging	O
and	O
not	O
all	O
of	O
the	O
diagnostic	O
criteria	O
may	O
be	O
present	O
at	O
the	O
same	O
time	O
;	O
this	O
case	O
shows	O
how	O
complex	O
the	O
diagnosis	O
could	O
be	O
,	O
how	O
hematic	O
ferritin	O
levels	O
could	O
help	O
in	O
following	O
the	O
course	O
of	O
the	O
disease	O
,	O
and	O
the	O
possibility	O
of	O
severe	O
pulmonary	B-DISO
complication	I-DISO
either	O
due	O
to	O
the	O
disease	O
itself	O
and	O
to	O
possible	O
sovra	O
infections	B-DISO
.	O

""""	O
Age	O
""","	O
""""	O
HMPV	O
""""	O
and	O
""""	O
Respiratory	B-DISO
disease	I-DISO
""""	O
showed	O
an	O
association	O
with	O
severe	O
infection	B-DISO
.	O

The	O
challenged	O
piglets	O
exhibited	O
watery	B-DISO
diarrhea	I-DISO
with	O
or	O
without	O
vaccination	O
.	O

BAIT	O
syndrome	B-DISO
is	O
a	O
new	O
clinical	O
condition	B-DISO
characterised	O
by	O
severe	O
transillumination	O
of	O
the	O
iris	O
,	O
acute	O
onset	O
of	O
pigment	O
dispersion	O
in	O
the	O
anterior	O
chamber	O
,	O
and	O
a	O
medial	O
mydriatic	B-DISO
pupil	I-DISO
that	O
is	O
unresponsive	O
or	O
poorly	O
responsive	O
to	O
light	O
,	O
due	O
to	O
a	O
sphincter	O
paralysis	O
.	O

As	O
far	O
as	O
is	O
known	O
this	O
is	O
the	O
first	O
case	O
reported	O
in	O
Navarra	O
,	O
but	O
more	O
case	O
reports	O
are	O
needed	O
to	O
establish	O
clear	O
patterns	O
about	O
this	O
condition	B-DISO
.	O

ALI	O
is	O
frequently	O
observed	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
.	O

This	O
study	O
tested	O
the	O
hypothesis	O
that	O
treatment	O
with	O
simvastatin	O
would	O
improve	O
clinical	O
outcomes	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Patients	O
in	O
intensive	O
care	O
units	O
were	O
eligible	O
if	O
they	O
were	O
intubated	O
and	O
mechanically	O
ventilated	O
and	O
had	O
ARDS	B-DISO
as	O
defined	O
by	O
a	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
to	O
fraction	O
of	O
inspired	O
oxygen	O
concentration	O
(	O
Patients	O
were	O
randomised	O
in	O
a	O
1	O
:	O
1	O
ratio	O
to	O
receive	O
enteral	O
simvastatin	O
80	O
mg	O
or	O
identical	O
placebo	O
tablets	O
once	O
daily	O
for	O
up	O
to	O
28	O
days	O
.	O

The	O
heterogenous	O
cohort	O
of	O
patients	O
with	O
ARDS	B-DISO
was	O
an	O
attempt	O
to	O
ensure	O
that	O
our	O
findings	O
would	O
be	O
generalisable	O
;	O
however	O
,	O
it	O
may	O
be	O
more	O
appropriate	O
to	O
target	O
potential	O
therapies	O
based	O
on	O
their	O
proposed	O
biological	O
mechanism	O
for	O
a	O
specific	O
population	O
of	O
patients	O
.	O

There	O
is	O
a	O
need	O
to	O
confirm	O
if	O
ARDS	B-DISO
endotypes	O
that	O
are	O
more	O
likely	O
to	O
benefit	O
from	O
targeted	O
treatment	O
with	O
simvastatin	O
exist	O
.	O

Our	O
study	O
was	O
designed	O
to	O
provide	O
a	O
concise	O
and	O
east	O
-	O
to	O
-	O
apply	O
set	O
of	O
criteria	O
that	O
could	O
be	O
used	O
by	O
NATO	O
nations	O
to	O
evaluate	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
threats	O
with	O
respect	O
to	O
their	O
weaponization	O
potential	O
.	O

TITLE	O
:	O
Intensive	O
care	O
admission	O
for	O
Coronavirus	O
OC43	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
.	O

One	O
patient	O
died	O
from	O
Haemophilus	O
influenzae	O
co	B-DISO
-	I-DISO
infection	I-DISO
.	O

CONCLUSIONS	O
:	O
As	O
for	O
MERS	O
Co	O
-	O
V	O
infections	B-DISO
,	O
underlying	O
comorbidities	O
impacted	B-DISO
the	O
clinical	O
outcomes	O
of	O
OC43	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
The	O
first	O
case	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	B-DISO
)	O
in	O
Canada	O
was	O
diagnosed	O
in	O
January	O
2014	O
in	O
Ontario	O
,	O
approximately	O
9	O
months	O
after	O
PED	B-DISO
emerged	O
in	O
the	O
United	O
States	O
.	O

TITLE	O
:	O
Investigation	O
of	O
three	O
outbreaks	O
of	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
in	O
Germany	O
in	O
2016	O
demonstrates	O
age	O
dependent	O
differences	O
in	O
the	O
development	O
of	O
humoral	O
immune	O
response	O
.	O

TITLE	O
:	O
Genome	O
-	O
wide	O
analysis	O
of	O
differentially	O
expressed	O
genes	O
and	O
the	O
modulation	O
of	O
PEDV	O
infection	B-DISO
in	O
Vero	O
E6	O
cells	O
.	O

Clinical	O
neurologic	B-DISO
signs	I-DISO
were	O
noted	O
in	O
22	O
cases	O
,	O
and	O
rabies	B-DISO
was	O
clinically	O
suspected	O
in	O
11	O
cases	O
.	O

Gross	O
neuropathologic	O
changes	O
occurred	O
in	O
15	O
cases	O
and	O
consisted	O
of	O
hydrocephalus	B-DISO
(	O
10	O
cases	O
),	O
cerebellar	B-DISO
herniation	I-DISO
through	O
the	O
foramen	O
magnum	O
(	O
6	O
cases	O
),	O
cerebral	O
swelling	B-DISO
with	O
flattening	O
of	O
gyri	O
(	O
2	O
cases	O
),	O
and	O
accumulation	O
of	O
fibrin	O
within	O
ventricles	O
(	O
2	O
cases	O
)	O
or	O
leptomeninges	O
(	O
1	O
case	O
).	O

The	O
most	O
cited	O
causes	O
of	O
ARI	O
were	O
flu	B-DISO
syndrome	I-DISO
(	O
78	O
.	O
6	O
%),	O
common	B-DISO
cold	I-DISO
(	O
73	O
.	O
9	O
%),	O
pharyngitis	B-DISO
(	O
64	O
.	O
1	O
%),	O
and	O
pneumonia	B-DISO
(	O
54	O
.	O
5	O
%).	O

In	O
this	O
study	O
,	O
we	O
have	O
analyzed	O
the	O
profile	O
of	O
cytokine	O
responses	O
in	O
plasma	O
samples	O
from	O
patients	O
with	O
confirmed	O
MERS	O
-	O
CoV	O
infections	B-DISO
(	O
n	O
=	O
7	O
)	O
compared	O
to	O
healthy	O
controls	O
(	O
n	O
=	O
13	O
).	O

Our	O
results	O
demonstrate	O
a	O
marked	O
pro	O
-	O
inflammatory	O
cytokine	O
response	O
during	O
the	O
acute	O
phase	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
in	O
humans	O
.	O

Here	O
,	O
we	O
detected	O
NETs	O
in	O
abundance	O
in	O
mouse	O
models	O
of	O
severe	O
bacterial	B-DISO
pneumonia	I-DISO
/	O
acute	O
lung	O
injury	O
and	O
in	O
human	O
subjects	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
from	O
pneumonia	B-DISO
or	O
sepsis	B-DISO
.	O

ABSTRACT	O
:	O
Overall	O
mortality	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
is	O
a	O
composite	O
endpoint	O
because	O
it	O
includes	O
death	O
from	O
multiple	O
causes	O
.	O

Causes	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
modified	O
the	O
risk	O
of	O
death	O
.	O

TITLE	O
:	O
[	O
ARDS	B-DISO
-	O
An	O
Update	O
-	O
Part	O
1	O
:	O
Epidemiology	O
,	O
Pathophysiology	O
and	O
Diagnosis	O
].	O

ABSTRACT	O
:	O
The	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
defined	O
by	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
caused	O
by	O
inflammatory	B-DISO
response	I-DISO
within	O
the	O
lung	O
usually	O
requiring	O
invasive	O
mechanical	O
ventilation	O
.	O

Despite	O
more	O
than	O
50	O
years	O
of	O
research	O
numerous	O
issues	O
regarding	O
epidemiology	O
,	O
pathophysiology	O
and	O
diagnosis	O
remain	O
unclear	O
until	O
today	O
:	O
Due	O
to	O
rather	O
unspecific	O
clinical	O
diagnostic	O
criteria	O
incidence	O
of	O
ARDS	B-DISO
varies	O
considerably	O
in	O
clinical	O
trials	O
with	O
a	O
range	O
from	O
4	O
to	O
79	O
cases	O
per	O
100	O
000	O
persons	O
per	O
year	O
.	O

The	O
intestinal	O
M	O
cells	O
-	O
and	O
DCs	B-DISO
-	O
targeting	O
oral	O
delivery	O
of	O
genetically	O
engineered	O
Lactobacillus	O
expressing	O
the	O
COE	O
antigen	O
of	O
PEDV	O
can	O
efficiently	O
induce	O
anti	O
-	O
PEDV	O
mucosal	O
,	O
humoral	O
,	O
and	O
cellular	O
immune	O
responses	O
via	O
oral	O
administration	O
,	O
suggesting	O
a	O
promising	O
vaccine	O
strategy	O
against	O
PEDV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
infection	B-DISO
is	O
a	O
major	O
cause	O
of	O
economic	O
losses	O
to	O
the	O
poultry	O
industry	O
.	O

As	O
one	O
of	O
the	O
key	O
component	O
of	O
the	O
avian	O
immune	O
system	O
,	O
the	O
innate	O
immune	O
system	O
has	O
a	O
crucial	O
role	O
in	O
limiting	O
virus	O
replication	O
at	O
the	O
initial	O
stage	O
of	O
the	O
infection	B-DISO
.	O

To	O
meet	O
the	O
pressing	O
need	O
of	O
developing	O
a	O
safe	O
and	O
cost	O
-	O
efficient	O
PED	O
maternal	O
vaccine	O
,	O
we	O
generated	O
three	O
PED	O
subunit	O
vaccine	O
candidates	O
,	O
using	O
recombined	O
Salmonella	B-DISO
flagellin	O
(	O
rSF	O
)	O
as	O
a	O
mucosal	O
molecular	O
adjuvant	O
.	O

ABSTRACT	O
:	O
Acute	O
,	O
infectious	B-DISO
,	O
diarrhea	B-DISO
in	O
adult	O
horses	O
is	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
is	O
associated	O
with	O
numerous	O
complications	O
.	O

Common	O
causes	O
include	O
salmonellosis	B-DISO
,	O
clostridiosis	O
,	O
Coronavirus	O
,	O
and	O
infection	B-DISO
with	O
Neorickettsia	O
risticii	O
(	O
Potomac	B-DISO
horse	I-DISO
fever	I-DISO
).	O

TITLE	O
:	O
Heart	O
-	O
lung	O
interactions	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
pathophysiology	O
,	O
detection	O
and	O
management	O
strategies	O
.	O

The	O
effect	O
of	O
PVD	B-DISO
on	O
RV	O
function	O
is	O
not	O
only	O
a	O
consequence	O
of	O
increased	O
pulmonary	O
vascular	O
resistance	O
as	O
afterload	O
is	O
a	O
much	O
more	O
complex	O
phenomenon	O
that	O
includes	O
all	O
factors	O
that	O
oppose	O
efficient	O
ventricular	O
ejection	O
.	O

Impaired	B-DISO
pulmonary	O
vascular	O
mechanics	O
including	O
increased	O
arterial	O
elastance	O
and	O
augmented	O
wave	O
-	O
reflection	O
phenomena	O
are	O
commonly	O
seen	O
in	O
ARDS	B-DISO
and	O
can	O
additionally	O
affect	O
RV	O
afterload	O
.	O

ABSTRACT	O
:	O
A	O
50	O
-	O
year	O
-	O
old	O
man	O
with	O
acute	B-DISO
myelogenous	I-DISO
leukemia	I-DISO
underwent	O
allogeneic	O
bone	O
-	O
marrow	O
transplantation	O
(	O
BMT	O
).	O

We	O
retrospectively	O
analyzed	O
280	O
patients	O
with	O
newly	O
diagnosed	O
AML	B-DISO
in	O
order	O
to	O
describe	O
the	O
incidence	O
,	O
risk	O
factors	O
and	O
early	O
mortality	O
associated	O
with	O
ARDS	B-DISO
within	O
15	O
d	O
.	O
Univariate	O
and	O
then	O
multivariate	O
analysis	O
were	O
performed	O
.	O

TITLE	O
:	O
An	O
Exploratory	O
Reanalysis	O
of	O
the	O
Randomized	O
Trial	O
on	O
Efficacy	O
of	O
Corticosteroids	O
as	O
Rescue	O
Therapy	O
for	O
the	O
Late	O
Phase	O
of	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
.	O

Our	O
findings	O
support	O
rapid	O
glucocorticoid	O
discontinuation	O
post	O
extubation	O
as	O
likely	O
cause	O
of	O
disease	O
relapse	B-DISO
.	O

Morphological	O
changes	O
are	O
observed	O
with	O
ARDS	B-DISO
progression	O
.	O

He	O
developed	O
an	O
acute	O
kidney	O
injury	O
requiring	O
supportive	O
treatment	O
and	O
on	O
day	O
3	O
of	O
his	O
illness	O
was	O
noted	O
to	O
have	O
developed	O
severe	O
rhabdomyolysis	B-DISO
(	O
creatine	O
kinase	O
level	O
132	O
040	O
U	O
/	O
L	O
(	O
normal	O
<	O
320	O
U	O
/	O
L	O
)).	O

TITLE	O
:	O
Discovery	O
of	O
Hydrocarbon	O
-	O
Stapled	O
Short	O
α	O
-	O
Helical	O
Peptides	O
as	O
Promising	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
Fusion	O
Inhibitors	O
.	O

For	O
the	O
purpose	O
of	O
this	O
study	O
,	O
only	O
non	O
-	O
sleepy	O
patients	O
with	O
moderate	O
or	O
severe	O
OSA	B-DISO
and	O
randomized	O
to	O
receive	O
CPAP	O
treatment	O
were	O
analysed	O
(	O
n	O
=	O
357	O
).	O

The	O
median	O
ages	O
of	O
85	O
immunocompromised	O
and	O
1152	O
nonimmunocompromised	O
children	O
with	O
HCoV	O
infection	B-DISO
were	O
6	O
.	O
3	O
and	O
1	O
.	O
6	O
years	O
,	O
respectively	O
.	O

Despite	O
significant	O
improvements	O
,	O
the	O
patient	O
expired	O
on	O
postoperative	O
day	O
15	O
,	O
due	O
to	O
an	O
overwhelming	O
intra	O
-	O
abdominal	B-DISO
sepsis	I-DISO
.	O

The	O
role	O
of	O
angiopoietin	O
-	O
1	O
/-	O
2	O
in	O
pneumonia	B-DISO
remains	O
unidentified	O
.	O

Human	O
postmortem	O
lung	O
tissue	O
,	O
pneumolysin	O
-	O
or	O
angiopoietin	O
-	O
2	O
-	O
stimulated	O
endothelial	O
cells	O
,	O
isolated	O
perfused	O
and	O
ventilated	O
mouse	O
lungs	O
,	O
and	O
mice	O
with	O
pneumococcal	B-DISO
pneumonia	I-DISO
were	O
investigated	O
.	O

Influenza	B-DISO
virus	O
,	O
human	O
parainfluenza	B-DISO
viruses	O
and	O
human	O
respiratory	O
syncytial	O
virus	O
as	O
well	O
as	O
human	O
rhinovirus	O
,	O
human	O
coronavirus	O
and	O
human	O
metapneumovirus	O
were	O
detected	O
significantly	O
more	O
frequently	O
in	O
LRTI	B-DISO
patients	O
than	O
in	O
controls	O
.	O

Viral	O
sequences	O
similar	O
to	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
corona	O
virus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
have	O
been	O
detected	O
in	O
bats	O
,	O
and	O
filoviruses	O
such	O
as	O
Marburg	O
virus	O
have	O
been	O
isolated	O
from	O
bats	O
,	O
providing	O
definitive	O
evidence	O
for	O
the	O
role	O
of	O
bats	O
as	O
the	O
natural	O
host	O
reservoir	O
.	O

Patients	O
who	O
developed	O
ARDS	B-DISO
had	O
a	O
higher	O
ΔP	O
(	O
15	O
mmHg	O
[	O
5	O
]	O
vs	O
.	O
12	O
mmHg	O
[	O
4	O
],	O
p	O
=	O
0	O
.	O
016	O
)	O
and	O
lower	O
lung	O
compliance	O
(	O
35	O
ml	O
/	O
cmH2O	O
[	O
10	O
]	O
vs	O
.	O
49	O
ml	O
/	O
cmH2O	O
[	O
18	O
],	O
p	O
=	O
0	O
.	O
024	O
)	O
versus	O
those	O
who	O
did	O
not	O
.	O

In	O
this	O
study	O
,	O
the	O
HRs	B-DISO
sequences	O
were	O
designed	O
and	O
connected	O
with	O
a	O
flexible	O
linker	O
.	O

Knowledge	O
about	O
age	O
-	O
specific	O
pattern	O
of	O
CoV	O
infection	B-DISO
in	O
P	O
.	O
lylei	O
,	O
prevalence	O
,	O
and	O
viral	B-DISO
shedding	I-DISO
at	O
roosts	O
and	O
foraging	O
sites	O
may	O
have	O
an	O
impact	O
on	O
infection	B-DISO
-	O
age	O
-	O
structure	O
model	O
to	O
control	O
CoV	O
outbreak	O
.	O

No	O
gender	O
difference	O
related	O
to	O
infection	B-DISO
was	O
found	O
at	O
the	O
sites	O
.	O

The	O
Berlin	O
definition	O
proposed	O
3	O
categories	O
of	O
ARDS	B-DISO
based	O
on	O
the	O
severity	O
of	O
hypoxemia	O
:	O
mild	O
(	O
200	O
mm	O
Hg	O
<	O
Pao2	O
/	O
Fio2	O
≤	O
300	O
mm	O
Hg	O
),	O
moderate	O
(	O
100	O
mm	O
Hg	O
<	O
Pao2	O
/	O
Fio2	O
≤	O
200	O
mm	O
Hg	O
),	O
and	O
severe	O
(	O
Pao2	O
/	O
Fio2	O
≤	O
100	O
mm	O
Hg	O
),	O
along	O
with	O
explicit	O
criteria	O
related	O
to	O
timing	O
of	O
the	O
syndrome	B-DISO
'	O
s	O
onset	O
,	O
origin	O
of	O
edema	B-DISO
,	O
and	O
the	O
chest	O
radiograph	O
findings	O
.	O

Clinician	O
interpretation	O
of	O
the	O
origin	O
of	O
edema	B-DISO
and	O
chest	O
radiograph	O
criteria	O
may	O
be	O
less	O
reliable	O
in	O
making	O
a	O
diagnosis	O
of	O
ARDS	B-DISO
.	O

No	O
pharmacologic	O
treatments	O
aimed	O
at	O
the	O
underlying	O
pathology	B-DISO
have	O
been	O
shown	O
to	O
be	O
effective	O
,	O
and	O
management	O
remains	O
supportive	O
with	O
lung	O
-	O
protective	O
mechanical	O
ventilation	O
.	O

TITLE	O
:	O
Identification	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
variant	O
with	O
a	O
large	O
spike	O
gene	B-DISO
deletion	I-DISO
from	O
a	O
clinical	O
swine	O
sample	O
in	O
the	O
United	O
States	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
detecting	O
PEDV	O
bearing	O
large	O
spike	O
gene	B-DISO
deletion	I-DISO
in	O
clinical	O
swine	O
samples	O
in	O
the	O
USA	O
.	O

RESULTS	O
:	O
A	O
25	O
-	O
year	O
-	O
old	O
pregnant	O
woman	O
was	O
initiated	O
with	O
ECMO	O
due	O
to	O
severe	O
ARDS	B-DISO
caused	O
by	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
virus	O
.	O

Patients	O
with	O
resolving	O
AKI	O
were	O
less	O
likely	O
to	O
have	O
oliguria	B-DISO
or	O
moderate	O
/	O
severe	O
ARDS	B-DISO
on	O
the	O
day	O
AKI	O
criteria	O
were	O
met	O
.	O

In	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
sepsis	B-DISO
-	O
associated	O
ARDS	B-DISO
and	O
AKI	O
,	O
the	O
impact	O
of	O
short	O
and	O
medium	O
duration	O
AKI	O
on	O
clinical	O
outcomes	O
was	O
modest	O
.	O

Initial	O
studies	O
detected	O
a	O
single	O
major	O
body	O
TRS	B-DISO
for	O
each	O
3	O
'	O
sg	O
mRNA	O
with	O
a	O
few	O
alternative	O
functional	O
TRSs	O
reported	O
.	O

TITLE	O
:	O
Metalloprotease	O
ADAM17	O
regulates	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	B-DISO
infection	I-DISO
by	O
modifying	O
aminopeptidase	O
N	O
.	O
ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
a	O
causative	O
agent	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
).	O

Furthermore	O
,	O
overexpression	O
of	O
ADAM17	O
suppressed	O
PEDV	O
infection	B-DISO
in	O
HEK293	O
and	O
IPEC	O
-	O
J2	O
cells	O
,	O
whereas	O
ablation	O
of	O
ADAM17	O
expression	O
using	O
ADAM17	O
specific	O
siRNA	O
resulted	O
in	O
a	O
corresponding	O
increase	O
of	O
PEDV	O
infection	B-DISO
and	O
an	O
upregulation	O
of	O
cell	O
surface	O
APN	O
expression	O
.	O

Hence	O
,	O
the	O
reduction	O
in	O
APN	O
expression	O
represents	O
another	O
component	O
of	O
the	O
anti	O
-	O
PEDV	O
infection	B-DISO
response	O
initiated	O
by	O
ADAM17	O
.	O

In	O
addition	O
,	O
mirroring	O
data	O
from	O
murine	O
models	O
of	O
lung	O
injury	O
/	O
regeneration	O
,	O
peribronchiolar	O
basaloid	O
pods	O
(	O
previously	O
described	O
as	O
squamous	B-DISO
metaplasia	I-DISO
)	O
and	O
ciliated	O
bronchiolarization	O
were	O
identified	O
in	O
these	O
patients	O
and	O
in	O
39	O
%	O
of	O
57	O
historical	O
cases	O
with	O
diffuse	B-DISO
alveolar	I-DISO
damage	I-DISO
.	O

Up	O
to	O
10	O
%	O
of	O
FCoV	O
infections	B-DISO
,	O
however	O
,	O
result	O
in	O
the	O
fatal	O
disease	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
).	O

Ten	O
alphacoronaviruses	O
in	O
eleven	O
bat	O
species	O
belonging	O
to	O
the	O
Miniopteridae	O
,	O
Vespertilionidae	O
and	O
Rhinolophidae	O
families	O
and	O
,	O
a	O
SARS	B-DISO
-	O
CoV	O
-	O
related	O
Betacoronavirus	O
in	O
Rhinolophus	O
ferrumequinum	O
were	O
identified	O
.	O

The	O
diversity	O
and	O
prevalence	O
of	O
bat	O
coronaviruses	O
presently	O
reported	O
from	O
western	O
Europe	O
is	O
much	O
higher	O
than	O
previously	O
described	O
and	O
includes	O
a	O
SARS	B-DISO
-	O
CoV	O
sister	O
group	O
.	O

Analysis	O
of	O
gene	O
expression	O
associated	O
with	O
IFN	O
-	O
α	O
/	O
β	O
function	O
,	O
e	O
.	O
g	O
.,	O
pattern	O
recognition	O
receptors	O
(	O
PRRs	B-DISO
)	O
and	O
interferon	O
-	O
stimulated	O
genes	O
(	O
ISGs	O
),	O
revealed	O
lower	O
basal	O
mRNA	O
levels	O
in	O
brain	O
-	O
derived	O
astrocytes	O
than	O
in	O
microglia	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
)	O
is	O
a	O
highly	O
contagious	B-DISO
disease	I-DISO
in	O
newborn	O
piglets	O
.	O

Furthermore	O
,	O
by	O
integrating	O
multi	O
-	O
channel	O
design	O
,	O
simultaneous	O
phenotyping	O
of	O
various	O
infective	O
pathogens	O
(	O
i	O
.	O
e	O
.,	O
Ebola	O
,	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
),	O
and	O
others	O
)	O
in	O
biological	O
specimens	O
can	O
be	O
performed	O
at	O
a	O
point	O
-	O
of	O
-	O
care	O
.	O

ABSTRACT	O
:	O
Human	O
coronaviruses	O
cause	O
both	O
upper	O
and	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
in	O
humans	O
.	O

The	O
60	O
-	O
year	O
-	O
old	O
man	O
died	O
as	O
a	O
result	O
of	O
renal	O
and	O
respiratory	B-DISO
failure	I-DISO
after	O
admission	O
to	O
a	O
hospital	O
in	O
Jeddah	O
,	O
Saudi	O
Arabia	O
.	O

Evasion	O
of	O
IFN	O
signaling	O
by	O
Ebola	O
viral	O
protein	O
24	O
(	O
VP24	O
)	O
is	O
a	O
critical	O
event	O
in	O
the	O
pathogenesis	B-DISO
of	O
the	O
infection	B-DISO
and	O
,	O
hence	O
,	O
VP24	O
is	O
a	O
potential	O
target	O
for	O
drug	O
development	O
.	O

ARDS	B-DISO
patients	O
suffer	B-DISO
from	O
severe	O
hypoxemia	O
,	O
and	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
therapy	O
may	O
be	O
necessary	O
to	O
ensure	O
oxygenation	O
.	O

ARDS	B-DISO
has	O
various	O
etiologies	O
,	O
including	O
trauma	O
,	O
ischemia	B-DISO
-	O
reperfusion	O
injury	O
or	O
infections	B-DISO
of	O
various	O
origins	O
,	O
and	O
the	O
associated	O
immunological	O
responses	O
may	O
vary	O
.	O

ARDS	B-DISO
patients	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
who	O
were	O
placed	O
on	O
ECMO	O
and	O
treated	O
with	O
(	O
IVIG	O
group	O
;	O
The	O
baseline	O
characteristics	O
did	O
not	O
differ	O
between	O
the	O
groups	O
,	O
although	O
the	O
IVIG	O
group	O
showed	O
a	O
significantly	O
reduced	O
oxygenation	O
index	O
compared	O
to	O
the	O
control	O
group	O
.	O

TITLE	O
:	O
Aminopeptidase	O
-	O
N	O
-	O
independent	O
entry	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
into	O
Vero	O
or	O
porcine	O
small	O
intestine	O
epithelial	O
cells	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
:	O
what	O
we	O
learned	O
from	O
the	O
2015	O
outbreak	O
in	O
the	O
Republic	O
of	O
Korea	O
.	O

This	O
outbreak	O
provides	O
a	O
unique	O
opportunity	O
to	O
fill	O
the	O
gap	O
in	O
our	O
knowledge	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

BCoV	O
infection	B-DISO
was	O
also	O
evident	O
in	O
captive	O
wild	O
ruminants	O
.	O

hMPV	O
was	O
further	O
detected	O
in	O
several	O
cases	O
of	O
SARS	B-DISO
and	O
it	O
was	O
the	O
only	O
virus	O
detected	O
in	O
three	O
deaths	O
.	O

Robust	O
national	O
emergency	B-DISO
preparedness	O
is	O
vital	O
to	O
mitigate	O
the	O
transmission	O
of	O
infectious	B-DISO
diseases	I-DISO
agents	O
domestically	O
and	O
to	O
prevent	O
onward	O
spread	O
to	O
other	O
countries	O
.	O

Replacement	O
of	O
H209	O
with	O
Ala	O
had	O
no	O
effect	O
on	O
receptor	O
binding	O
,	O
but	O
in	O
murine	O
17Cl	O
.	O
1	O
cells	O
mutant	B-DISO
H209A	O
MHV	O
-	O
A59	O
showed	O
delayed	B-DISO
growth	I-DISO
kinetics	O
and	O
was	O
readily	O
outcompeted	O
by	O
wild	O
-	O
type	O
virus	O
when	O
mixed	O
together	O
,	O
indicating	O
that	O
the	O
H209A	O
mutation	O
caused	O
a	O
defect	O
in	O
virus	O
fitness	O
.	O

All	O
AvCoV	O
isolates	O
induced	O
clinical	O
signs	O
,	O
gross	O
lesions	O
in	O
the	O
trachea	B-DISO
,	O
moderate	O
histopathological	O
changes	O
in	O
the	O
respiratory	O
tract	O
,	O
and	O
mild	O
changes	O
in	O
other	O
tissues	O
.	O

TITLE	O
:	O
Weekend	O
Effect	O
in	O
Acute	B-DISO
Pancreatitis	I-DISO
-	O
Related	O
Hospital	O
Admissions	O
in	O
the	O
United	O
States	O
:	O
An	O
Analysis	O
of	O
the	O
Nationwide	O
Inpatient	O
Sample	O
.	O

Exclusion	O
criteria	O
were	O
applied	O
for	O
chronic	B-DISO
pancreatitis	I-DISO
and	O
other	O
pancreatic	O
and	O
biliary	O
malignancies	B-DISO
.	O

TITLE	O
:	O
Immunohistochemical	O
characterization	O
of	O
feline	O
lymphoplasmacytic	O
anterior	B-DISO
uveitis	I-DISO
.	O

The	O
numbers	O
of	O
FoxP3	O
RESULTS	O
:	O
Cells	O
stained	O
positive	O
for	O
IL	O
-	O
17A	O
in	O
idiopathic	O
uveitis	B-DISO
but	O
not	O
in	O
FIP	B-DISO
samples	O
.	O

The	O
patients	O
in	O
both	O
groups	O
received	O
etiological	O
treatment	O
,	O
protective	O
ventilation	O
strategy	O
,	O
sensitive	O
antibiotics	O
for	O
anti	O
-	O
infection	B-DISO
,	O
and	O
calefacient	O
and	O
humidifying	O
treatment	O
.	O

Mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
have	O
the	O
ability	O
to	O
regulate	O
immune	O
responses	O
,	O
and	O
many	O
researches	O
showed	O
that	O
MSCs	O
had	O
potential	O
therapeutic	O
effects	O
on	O
autoimmune	B-DISO
diseases	I-DISO
and	O
graft	O
versus	O
host	O
diseases	O
.	O

TITLE	O
:	O
A	O
highly	O
pathogenic	O
porcine	B-DISO
reproductive	I-DISO
and	I-DISO
respiratory	I-DISO
syndrome	I-DISO
virus	O
type	O
1	O
(	O
PRRSV	O
-	O
1	O
)	O
strongly	O
modulates	O
cellular	O
innate	O
and	O
adaptive	O
immune	O
subsets	O
upon	O
experimental	O
infection	B-DISO
.	O

PR40	O
infected	O
animals	O
showed	O
an	O
early	O
and	O
marked	O
reduction	O
of	O
pro	O
-	O
inflammatory	O
CD172α	O
+	O
CD14	O
+	O
CD16	O
+	O
and	O
CD14	O
+	O
CD163	O
+	O
monocytes	O
and	O
TCRγδ	O
+	O
CD8α	O
+/	O
CD8α	O
-	O
lymphocytes	O
when	O
pigs	O
were	O
most	O
infected	O
,	O
possibly	O
due	O
to	O
a	O
recruitment	B-DISO
sustaining	O
an	O
acute	B-DISO
inflammatory	I-DISO
response	I-DISO
in	O
target	O
tissues	O
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
a	O
systematic	O
analysis	O
to	O
determine	O
the	O
effect	O
of	O
specific	O
structural	O
motifs	O
of	O
ILs	B-DISO
on	O
three	O
different	O
biological	O
test	O
systems	O
(	O
viruses	O
,	O
bacteria	O
and	O
enzymes	O
).	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
NMB	O
may	O
improve	O
outcome	O
for	O
ARDS	B-DISO
patients	O
remains	O
unclear	O
.	O

TITLE	O
:	O
Transfusion	O
-	O
transmitted	B-DISO
malaria	B-DISO
masquerading	O
as	O
sickle	B-DISO
cell	I-DISO
crisis	I-DISO
with	O
multisystem	B-DISO
organ	I-DISO
failure	I-DISO
.	O

A	O
look	O
-	O
back	O
investigation	O
involving	O
two	O
hospitals	O
,	O
multiple	O
blood	O
suppliers	O
,	O
and	O
state	O
and	O
federal	O
public	O
health	O
departments	O
identified	O
the	O
source	O
of	O
malaria	B-DISO
as	O
a	O
unit	O
of	O
RBCs	O
transfused	O
2	O
weeks	O
prior	O
to	O
admission	O
.	O

Clinical	O
suspicion	O
for	O
transfusion	O
-	O
related	O
adverse	O
events	O
,	O
including	O
hemolytic	O
transfusion	B-DISO
reactions	I-DISO
and	O
transfusion	O
-	O
transmitted	B-DISO
infections	B-DISO
,	O
should	O
be	O
high	O
in	O
typically	O
and	O
atypically	O
immunocompromised	O
patient	O
populations	O
(	O
like	O
SCD	B-DISO
),	O
especially	O
those	O
on	O
chronic	O
transfusion	O
protocols	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
belongs	O
to	O
the	O
family	O
Coronaviridae	O
,	O
and	O
is	O
named	O
for	O
the	O
crown	O
-	O
like	O
spikes	O
on	O
its	O
surface	O
.	O

Regarding	O
MERS	O
-	O
CoV	O
clinical	O
features	O
,	O
76	O
.	O
4	O
%	O
(	O
n	O
=	O
259	O
)	O
recognized	O
the	O
presence	O
of	O
sub	O
-	O
clinical	B-DISO
infection	I-DISO
,	O
64	O
.	O
7	O
%	O
(	O
n	O
=	O
218	O
)	O
indicated	O
that	O
cases	O
should	O
be	O
immediately	O
isolated	O
,	O
and	O
46	O
.	O
9	O
%	O
(	O
n	O
=	O
159	O
)	O
identified	O
the	O
main	O
cause	O
of	O
mortality	O
as	O
respiratory	B-DISO
failure	I-DISO
.	O

Regarding	O
MERS	O
-	O
CoV	O
clinical	O
features	O
,	O
76	O
.	O
4	O
%	O
(	O
n	O
=	O
259	O
)	O
recognized	O
the	O
presence	O
of	O
sub	O
-	O
clinical	B-DISO
infection	I-DISO
,	O
64	O
.	O
7	O
%	O
(	O
n	O
=	O
218	O
)	O
indicated	O
that	O
cases	O
should	O
be	O
immediately	O
isolated	O
,	O
and	O
46	O
.	O
9	O
%	O
(	O
n	O
=	O
159	O
)	O
identified	O
the	O
main	O
cause	O
of	O
mortality	O
as	O
respiratory	B-DISO
failure	I-DISO
.	O

This	O
study	O
investigates	O
the	O
prevalence	O
and	O
pattern	O
of	O
CAM	B-DISO
use	O
by	O
Saudi	O
cancer	B-DISO
patients	O
.	O

The	O
prevalence	O
of	O
CAM	B-DISO
use	O
was	O
69	O
.	O
9	O
%;	O
the	O
most	O
prominent	O
types	O
of	O
CAM	B-DISO
were	O
those	O
of	O
a	O
religious	O
nature	O
,	O
such	O
as	O
supplication	O
(	O
95	O
.	O
4	O
%),	O
Quran	O
recitation	O
(	O
88	O
.	O
1	O
%),	O
consuming	O
Zamzam	O
water	O
(	O
84	O
.	O
4	O
%),	O
and	O
water	O
upon	O
which	O
the	O
Quran	O
has	O
been	O
read	O
(	O
63	O
.	O
3	O
%).	O

Association	O
is	O
known	O
between	O
camel	O
products	O
and	O
brucellosis	B-DISO
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

Doctor	O
-	O
patient	O
communication	O
regarding	O
CAM	B-DISO
use	O
is	O
of	O
paramount	O
importance	O
in	O
cancer	B-DISO
care	O
.	O

Thirty	O
percent	O
of	O
CAM	B-DISO
users	O
had	O
discussed	O
the	O
issue	O
with	O
their	O
doctors	O
;	O
only	O
7	O
.	O
7	O
%	O
had	O
done	O
so	O
with	O
their	O
nurses	O
.	O

A	O
total	O
of	O
1023	O
adults	O
with	O
intellectual	B-DISO
disabilities	I-DISO
underwent	O
comprehensive	O
health	O
assessments	O
.	O

METHODS	O
:	O
A	O
total	O
of	O
1023	O
adults	O
with	O
intellectual	B-DISO
disabilities	I-DISO
underwent	O
comprehensive	O
health	O
assessments	O
.	O

Ischaemic	B-DISO
heart	I-DISO
disease	I-DISO
increased	O
the	O
risk	O
of	O
problem	O
behaviours	O
approximately	O
threefold	O
(	O
OR	O
:	O
3	O
.	O
29	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
02	O
-	O
10	O
.	O
60	O
).	O

TITLE	O
:	O
Cellular	O
hnRNP	O
A1	O
Interacts	O
with	O
Nucleocapsid	O
Protein	O
of	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
and	O
Impairs	O
Viral	O
Replication	O
.	O

TITLE	O
:	O
Clinical	O
characteristics	O
from	O
co	B-DISO
-	I-DISO
infection	I-DISO
with	O
avian	B-DISO
influenza	I-DISO
A	O
H7N9	O
and	O
Mycoplasma	B-DISO
pneumoniae	O
:	O
a	O
case	O
report	O
.	O

ABSTRACT	O
:	O
More	O
and	O
more	O
cases	O
of	O
human	O
infections	B-DISO
with	O
avian	B-DISO
influenza	I-DISO
A	O
H7N9	O
have	O
been	O
reported	O
since	O
it	O
was	O
first	O
mentioned	O
in	O
2013	O
in	O
China	O
,	O
but	O
concurrence	O
of	O
influenza	B-DISO
A	O
H7N9	O
with	O
Mycoplasma	B-DISO
pneumoniae	O
,	O
however	O
,	O
has	O
never	O
been	O
described	O
.	O

She	O
was	O
reasonably	O
considered	O
to	O
be	O
infected	O
with	O
Mycoplasma	B-DISO
pneumoniae	O
as	O
well	O
,	O
and	O
azithromycin	O
and	O
moxifloxacin	O
were	O
added	O
to	O
her	O
treatment	O
.	O

RNA	O
was	O
extracted	O
from	O
body	O
cavity	B-DISO
effusion	B-DISO
samples	O
of	O
71	O
cats	O
,	O
including	O
34	O
samples	O
from	O
cats	O
with	O
a	O
definitive	O
diagnosis	O
of	O
FIP	B-DISO
,	O
and	O
37	O
samples	O
of	O
control	O
cats	O
with	O
similar	O
clinical	O
signs	O
but	O
other	O
confirmed	O
diseases	O
.	O

TITLE	O
:	O
Detection	O
of	O
feline	O
coronavirus	O
mutations	O
in	O
paraffin	O
-	O
embedded	O
tissues	O
in	O
cats	O
with	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
and	O
controls	O
.	O

The	O
study	O
population	O
consisted	O
of	O
64	O
cats	O
,	O
34	O
of	O
which	O
were	O
diagnosed	O
with	O
FIP	B-DISO
and	O
30	O
control	O
cats	O
.	O

TITLE	O
:	O
Cigarette	O
smoke	O
exposure	O
worsens	O
acute	O
lung	O
injury	O
in	O
antibiotic	O
-	O
treated	O
bacterial	B-DISO
pneumonia	I-DISO
in	O
mice	O
.	O

Streptococcus	O
pneumoniae	O
is	O
the	O
most	O
common	O
cause	O
of	O
bacterial	B-DISO
pneumonia	I-DISO
,	O
which	O
in	O
turn	O
is	O
the	O
leading	O
cause	O
of	O
ARDS	B-DISO
.	O

The	O
inclusion	O
of	O
antibiotic	O
treatment	O
in	O
preclinical	O
studies	O
of	O
acute	O
lung	O
injury	O
in	O
bacterial	B-DISO
pneumonia	I-DISO
may	O
enhance	O
clinical	O
relevance	O
,	O
particularly	O
for	O
future	O
studies	O
of	O
current	O
or	O
emerging	O
tobacco	O
products	O
.	O

This	O
study	O
assessed	O
the	O
efficacy	O
and	O
safety	O
of	O
bivalirudin	O
compared	O
with	O
UFH	O
with	O
or	O
without	O
GPIs	O
in	O
patients	O
with	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
(	O
ACS	O
)	O
who	O
underwent	O
invasive	O
management	O
.	O

The	O
30	O
-	O
day	O
coprimary	O
outcomes	O
were	O
major	O
adverse	O
cardiovascular	O
events	O
(	O
MACEs	O
)	O
(	O
a	O
composite	O
of	O
death	O
,	O
myocardial	B-DISO
infarction	I-DISO
,	O
or	O
stroke	B-DISO
),	O
and	O
net	O
adverse	O
clinical	O
events	O
(	O
NACEs	O
)	O
(	O
a	O
composite	O
of	O
MACEs	O
or	O
major	O
bleeding	B-DISO
).	O

At	O
30	O
days	O
,	O
the	O
2	O
coprimary	O
endpoints	O
of	O
MACEs	O
and	O
NACEs	O
,	O
as	O
well	O
as	O
individual	O
endpoints	O
of	O
mortality	O
,	O
myocardial	B-DISO
infarction	I-DISO
,	O
stent	O
thrombosis	B-DISO
or	O
stroke	B-DISO
did	O
not	O
differ	O
among	O
the	O
3	O
groups	O
after	O
adjustment	O
.	O

ABSTRACT	O
:	O
Morbidity	O
and	O
mortality	O
associated	O
with	O
infectious	B-DISO
diseases	I-DISO
are	O
always	O
on	O
the	O
rise	O
,	O
especially	O
in	O
poorer	O
countries	O
and	O
in	O
the	O
aging	O
population	O
.	O

ABSTRACT	O
:	O
Disseminated	B-DISO
intravascular	I-DISO
coagulations	I-DISO
(	O
DIC	B-DISO
),	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
and	O
acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
are	O
major	O
organ	O
dysfunctions	O
that	O
occur	O
in	O
patients	O
with	O
sepsis	B-DISO
.	O

DIC	B-DISO
(	O
hazard	O
ratio	O
2	O
.	O
58	O
,	O
95	O
%	O
CI	O
1	O
.	O
53	O
-	O
4	O
.	O
55	O
)	O
and	O
AKI	O
stage	O
3	O
(	O
hazard	O
ratio	O
1	O
.	O
73	O
,	O
95	O
%	O
CI	O
1	O
.	O
07	O
-	O
2	O
.	O
80	O
)	O
were	O
also	O
significantly	O
associated	O
with	O
longer	O
survival	O
durations	O
.	O

TITLE	O
:	O
Rapid	O
detection	O
of	O
transmissible	O
gastroenteritis	B-DISO
virus	O
in	O
swine	O
small	O
intestine	O
samples	O
using	O
real	O
-	O
time	O
reverse	O
transcription	O
recombinase	O
polymerase	O
amplification	B-DISO
.	O

ABSTRACT	O
:	O
The	O
rapid	O
and	O
accurate	O
identification	O
of	O
individuals	O
who	O
are	O
at	O
high	O
risk	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
remains	O
a	O
major	O
challenge	O
for	O
the	O
medical	O
and	O
scientific	O
communities	O
.	O

The	O
model	O
included	O
male	O
sex	O
,	O
contact	O
with	O
a	O
sick	O
patient	O
or	O
camel	O
,	O
diabetes	B-DISO
,	O
severe	O
illness	O
,	O
low	O
white	O
blood	O
cell	O
(	O
WBC	O
)	O
count	O
,	O
low	O
alanine	O
aminotransferase	O
(	O
ALT	O
),	O
and	O
high	O
aspartate	O
aminotransferase	O
(	O
AST	O
).	O

Further	O
validation	O
of	O
the	O
prediction	O
model	O
on	O
a	O
large	O
prospective	O
cohort	O
of	O
representative	O
patients	O
with	O
pneumonia	B-DISO
is	O
necessary	O
.	O

SARS	B-DISO
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
are	O
classified	O
as	O
BSL	O
-	O
3	O
viruses	O
,	O
which	O
makes	O
experimentation	O
into	O
the	O
cellular	O
mechanisms	O
involved	O
in	O
infection	B-DISO
more	O
challenging	O
.	O

Encouragingly	O
,	O
all	O
the	O
tested	O
compounds	O
showed	O
good	O
activities	O
against	O
wild	O
-	O
type	O
(	O
WT	O
)	O
HIV	B-DISO
-	O
1	O
(	O
IIIB	O
)	O
with	O
EC	O

ABSTRACT	O
:	O
Influenza	B-DISO
virus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
human	O
metapneumovirus	O
,	O
parainfluenza	B-DISO
virus	O
,	O
coronaviruses	O
,	O
and	O
rhinoviruses	O
are	O
among	O
the	O
most	O
common	O
viruses	O
causing	O
mild	O
seasonal	O
colds	B-DISO
.	O

Young	O
children	O
,	O
the	O
elderly	O
,	O
and	O
patients	O
with	O
compromised	O
cardiac	O
,	O
pulmonary	O
,	O
or	O
immune	O
systems	O
are	O
at	O
greatest	O
risk	O
for	O
serious	O
disease	O
associated	O
with	O
these	O
RNA	O
virus	O
respiratory	B-DISO
infections	I-DISO
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
the	O
current	O
medical	O
need	O
resulting	O
from	O
respiratory	B-DISO
infections	I-DISO
caused	O
by	O
RNA	O
viruses	O
,	O
which	O
justifies	O
drug	O
discovery	O
efforts	O
to	O
identify	O
new	O
therapeutic	O
agents	O
.	O

In	O
the	O
second	O
part	O
of	O
the	O
conference	O
,	O
which	O
took	O
place	O
on	O
October	O
11	O
and	O
12	O
,	O
the	O
clinical	O
trials	O
pipeline	O
,	O
design	O
and	O
recruitment	B-DISO
of	O
volunteers	O
,	O
and	O
economic	O
impact	O
of	O
clinical	O
trials	O
were	O
discussed	O
.	O

TITLE	O
:	O
MERS	O
-	O
CoV	O
pathogenesis	B-DISO
and	O
antiviral	O
efficacy	O
of	O
licensed	O
drugs	O
in	O
human	O
monocyte	O
-	O
derived	O
antigen	O
-	O
presenting	O
cells	O
.	O

To	O
further	O
evaluate	O
the	O
antiviral	O
activity	O
of	O
well	O
-	O
defined	O
drugs	O
in	O
primary	O
antigen	O
presenting	O
cells	O
(	O
APCs	B-DISO
),	O
three	O
compounds	O
(	O
chloroquine	O
,	O
chlorpromazine	O
and	O
toremifine	O
),	O
each	O
with	O
broad	O
-	O
spectrum	O
antiviral	O
activity	O
in	O
immortalized	O
cell	O
lines	O
,	O
were	O
evaluated	O
in	O
MDMs	O
and	O
MDDCs	O
to	O
determine	O
their	O
antiviral	O
effect	O
on	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

TITLE	O
:	O
Assessment	O
of	O
reproductive	O
performance	O
in	O
F	O
ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
)	O
occurred	O
in	O
Japan	O
in	O
2013	O
after	O
an	O
interval	O
of	O
7	O
years	O
.	O

ABSTRACT	O
:	O
BACKGROUND	O
Babesiosis	B-DISO
is	O
an	O
emerging	O
,	O
tick	O
-	O
borne	O
zoonosis	B-DISO
caused	O
by	O
intraerythrocytic	O
protozoa	O
of	O
the	O
genus	O
Babesia	O
.	O

Splenic	O
rupture	O
(	O
SR	O
)	O
is	O
a	O
very	O
rare	O
but	O
life	O
-	O
threatening	O
complication	B-DISO
of	O
severe	O
B	O
.	O
microti	O
infection	B-DISO
.	O

She	O
was	O
promptly	O
diagnosed	O
with	O
babesiosis	B-DISO
and	O
Lyme	B-DISO
disease	I-DISO
co	B-DISO
-	I-DISO
infection	I-DISO
.	O

TITLE	O
:	O
A	O
Highly	O
Pathogenic	O
Strain	O
of	O
Porcine	O
Deltacoronavirus	O
Caused	O
Watery	B-DISO
Diarrhea	I-DISO
in	O
Newborn	O
Piglets	O
.	O

Intensivists	O
should	O
be	O
aware	O
of	O
this	O
rare	O
but	O
rapid	O
complication	B-DISO
on	O
extracorporeal	O
membrane	O
oxygenation	O
support	O
that	O
may	O
directly	O
impact	O
outcome	O
.	O

Regarding	O
respiratory	B-DISO
failure	I-DISO
cause	O
,	O
NIV	O
was	O
delivered	O
in	O
pneumonia	B-DISO
(	O
97	O
.	O
3	O
%),	O
bronchiolitis	B-DISO
(	O
94	O
.	O
6	O
%),	O
bronchospasm	B-DISO
(	O
75	O
.	O
2	O
%),	O
acute	B-DISO
pulmonary	I-DISO
edema	I-DISO
(	O
84	O
.	O
1	O
%),	O
upper	B-DISO
airway	I-DISO
obstruction	I-DISO
(	O
76	O
.	O
1	O
%),	O
and	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
91	O
%	O
if	O
mild	O
,	O
53	O
.	O
1	O
%	O
if	O
moderate	O
,	O
and	O
5	O
.	O
3	O
%	O
if	O
severe	O
).	O

TITLE	O
:	O
Ventilator	O
-	O
induced	O
lung	O
injury	O
during	O
controlled	O
ventilation	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
less	O
is	O
probably	O
better	O
.	O

Oesophageal	O
Doppler	O
monitor	O
-	O
guided	O
GDHT	O
reduced	O
postoperative	B-DISO
complications	I-DISO
and	O
hospital	O
length	O
of	O
stay	O
in	O
low	O
-	O
moderate	O
risk	O
patients	O
undergoing	O
intermediate	O
risk	O
surgery	O
,	O
with	O
no	O
difference	O
in	O
mortality	O
at	O
180	O
days	O
.	O

TITLE	O
:	O
DYSFUNCTION	O
OF	O
VARIOUS	O
ORGAN	O
SYSTEMS	O
INDUCED	O
BY	O
SEPSIS	B-DISO
WITH	O
UNDERLYING	O
SEVERE	O
MYELOMIC	O
DISEASES	O
AND	O
PROSTATE	B-DISO
CANCER	I-DISO
(	O
CASE	O
REPORT	O
).	O

It	O
is	O
also	O
noteworthy	O
that	O
for	O
the	O
last	O
three	O
months	O
dysfunction	O
of	O
musculoskeletal	O
system	O
with	O
muscle	B-DISO
weakness	I-DISO
,	O
restricted	O
motion	O
has	O
been	O
present	O
.	O

TITLE	O
:	O
Coronavirus	B-DISO
infection	I-DISO
retards	O
the	O
development	O
of	O
the	O
cortico	O
-	O
medullary	O
capillary	O
network	O
in	O
the	O
bursa	O
of	O
Fabricius	O
of	O
chicken	O
.	O

TITLE	O
:	O
Reduction	O
of	O
soluble	O
dipeptidyl	O
peptidase	O
4	O
levels	O
in	O
plasma	O
of	O
patients	O
infected	O
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
.	O

Emerging	O
evidence	O
has	O
revealed	O
that	O
alveolar	O
macrophage	O
(	O
AM	O
)	O
death	O
plays	O
important	O
roles	O
in	O
the	O
progression	O
of	O
lung	B-DISO
inflammation	I-DISO
through	O
its	O
influence	O
on	O
other	O
immune	O
cell	O
populations	O
in	O
the	O
lung	O
.	O

There	O
is	O
a	O
large	O
population	O
of	O
nonimmunized	O
dogs	O
and	O
few	O
studies	O
about	O
the	O
identification	O
of	O
the	O
viruses	O
associated	O
with	O
diarrhea	B-DISO
.	O

Presence	O
of	O
a	O
severe	O
ARDS	B-DISO
was	O
identified	O
as	O
independent	O
risk	O
factor	O
for	O
the	O
occurrence	O
of	O
NRBCs	O
>	O
220	O
/	O
µl	O
(	O
OR	O
1	O
.	O
81	O
;	O
95	O
%	O
CI	O
1	O
.	O
1	O
-	O
2	O
.	O
97	O
;	O
p	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
The	O
FilmArray	O
Respiratory	O
Panel	O
2	O
(	O
RP2	B-DISO
)	O
is	O
a	O
multiplex	O

Chest	O
computed	O
tomography	O
(	O
CT	O
)	O
showed	O
new	O
diffuse	O
ground	O
-	O
glass	O
opacities	B-DISO
(	O
GGOs	O
)	O
with	O
slight	O
consolidations	O
along	O
with	O
bronchovascular	O
bundle	O
were	O
observed	O
in	O
addition	O
to	O
pre	O
-	O
existing	O
reticular	O
shadows	O
in	O
both	O
lungs	O
with	O
lower	O
lobe	O
-	O
predominance	O
.	O

From	O
August	O
2003	O
to	O
June	O
2015	O
,	O
five	O
patients	O
(	O
ten	O
hips	O
)	O
of	O
ONFH	O
in	O
ARCO	O
stage	O
I	O
,	O
after	O
SARS	B-DISO
and	O
Interstitial	B-DISO
pneumonia	I-DISO
,	O
were	O
treated	O
by	O
combined	O
pharmacotherapy	O
.	O

Lung	O
protective	O
strategies	O
with	O
low	O
tidal	O
volume	O
(	O
VT	O
)	O
and	O
lung	O
recruitment	B-DISO
should	O
consider	O
the	O
physiology	O
of	O
ARDS	B-DISO
because	O
ARDS	B-DISO
presents	O
lung	O
inhomogeneity	O
;	O
the	O
same	O
low	O
VT	O
might	O
increase	O
local	O
stress	O
and	O
strain	O
in	O
some	O
patients	O
with	O
low	O
compliance	O
,	O
and	O
lung	O
recruitment	B-DISO
could	O
injure	O
lungs	O
in	O
ARDS	B-DISO
patients	O
with	O
low	O
recruitability	O
and	O
hemodynamic	B-DISO
instability	I-DISO
.	O

Mice	O
subjected	O
to	O
VILI	O
after	O
HCl	O
or	O
LPS	B-DISO
instillation	O
displayed	O
augmented	O
lung	O
injury	O
,	O
compared	O
to	O
singular	O
lung	O
injury	O
.	O

LPS	B-DISO
prior	O
to	O
VILI	O
showed	O
significantly	O
increased	O
inflammatory	O
lung	O
injury	O
compared	O
to	O
animals	O
that	O
underwent	O
i	O
.	O
t	O
.	O

TITLE	O
:	O
Prenylated	O
phloroglucinols	O
from	O
Hypericum	O
scruglii	O
,	O
an	O
endemic	O
species	O
of	O
Sardinia	O
(	O
Italy	O
),	O
as	O
new	O
dual	O
HIV	B-DISO
-	O
1	O
inhibitors	O
effective	O
on	O
HIV	B-DISO
-	O
1	O
replication	O
.	O

Furthermore	O
,	O
phloroglucinols	O
compounds	O
,	O
included	O
the	O
newly	O
identified	O
compound	O
,	O
were	O
able	O
to	O
inhibit	O
the	O
HIV	B-DISO
-	O
1	O
replication	O
in	O
cell	O
based	O
assays	O
.	O

Oxidative	B-DISO
stress	I-DISO
and	O
inflammation	B-DISO
were	O
found	O
to	O
be	O
linked	O
with	O
most	O
of	O
the	O
diseases	O
in	O
recent	O
times	O
.	O

Herbal	O
medicines	O
or	O
plant	O
products	O
were	O
traditionally	O
being	O
used	O
for	O
treating	O
the	O
oxidative	B-DISO
stress	I-DISO
and	O
inflammation	B-DISO
related	O
diseases	O
in	O
diverse	O
communities	O
across	O
the	O
world	O
.	O

Phyto	O
-	O
constituents	O
such	O
as	O
afzelin	O
,	O
hyperoside	O
and	O
quercitrin	O
have	O
shown	O
to	O
reduce	O
inflammation	B-DISO
both	O
in	O
vitro	O
and	O
in	O
vivo	O
models	O
.	O

TITLE	O
:	O
Herd	O
-	O
level	O
prevalence	O
and	O
incidence	O
of	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
(	O
PEDV	O
)	O
and	O
porcine	O
deltacoronavirus	O
(	O
PDCoV	O
)	O
in	O
swine	O
herds	O
in	O
Ontario	O
,	O
Canada	O
.	O

ABSTRACT	O
:	O
Although	O
Plasmodium	O
ovale	O
is	O
considered	O
the	O
cause	O
of	O
only	O
mild	O
malaria	B-DISO
,	O
a	O
case	O
of	O
severe	O
malaria	B-DISO
due	O
to	O
P	O
.	O
ovale	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
is	O
reported	O
.	O

TITLE	O
:	O
Isolation	O
and	O
Characteristics	O
of	O
the	O
Arkansas	O
-	O
Type	O
Infectious	B-DISO
Bronchitis	B-DISO
Virus	O
in	O
China	O
.	O

The	O
virus	O
was	O
shed	O
from	O
the	O
trachea	B-DISO
for	O
at	O
least	O
a	O
week	O
and	O
from	O
the	O
cloaca	O
for	O
only	O
a	O
day	O
.	O

The	O
IBV	O
infection	B-DISO
leads	O
to	O
respiratory	O
and	O
nephrogenic	O
symptoms	O
in	O
broiler	O
chickens	O
.	O

The	O
PDCoV	O
-	O
inoculated	O
piglets	O
showed	O
acute	O
,	O
watery	B-DISO
diarrhoea	I-DISO
,	O
but	O
all	O
recovered	O
and	O
survived	O
.	O

Variables	O
of	O
patient	O
background	O
and	O
infectious	B-DISO
episode	O
were	O
studied	O
in	O
association	O
with	O
the	O
main	O
outcome	O
through	O
multiple	O
logistic	O
regression	O
.	O

Age	O
,	O
previous	O
comorbidities	O
,	O
and	O
functional	O
status	O
and	O
infection	B-DISO
by	O
an	O
ESKAPE	O
pathogen	O
were	O
consistently	O
associated	O
with	O
long	O
-	O
term	O
prognosis	O
.	O

To	O
review	O
indications	O
and	O
outcome	O
of	O
ECMO	O
in	O
severe	O
pulmonary	B-DISO
coccidioidomycosis	I-DISO
.	O

Three	O
cases	O
of	O
severe	O
ARDS	B-DISO
caused	O
by	O
coccidioidomycosis	B-DISO
are	O
presented	O
.	O

Common	O
complications	O
included	O
pneumonia	B-DISO
,	O
encephalopathy	B-DISO
and	O
critical	B-DISO
illness	I-DISO
myopathy	I-DISO
.	O

The	O
purified	O
recombinant	O
N	O
protein	O
conjugated	O
with	O
colloidal	O
gold	O
was	O
dispensed	O
on	O
a	O
conjugate	O
pad	B-DISO
as	O
the	O
detector	O
.	O

Our	O
results	O
show	O
that	O
Phi6	O
survived	O
best	O
at	O
high	O
(>	O
85	O
%)	O
and	O
low	O
(<	O
60	O
%)	O
RHs	B-DISO
,	O
with	O
a	O
significant	O
decrease	O
in	O
infectivity	O
at	O
mid	O
-	O
range	O
RHs	B-DISO
(∼	O
60	O
to	O
85	O
%).	O

Besides	O
the	O
severity	O
of	O
the	O
acute	O
organ	B-DISO
failure	I-DISO
,	O
it	O
is	O
important	O
to	O
thoroughly	O
evaluate	O
etiology	O
and	O
treatment	O
options	O
of	O
the	O
underlying	O
disease	O
,	O
comorbidities	O
,	O
and	O
the	O
functional	O
status	O
of	O
the	O
patients	O
in	O
an	O
interdisciplinary	O
team	O
.	O

Veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
can	O
be	O
utilized	O
for	O
severe	O
ACS	O
in	O
adult	O
patients	O
with	O
sickle	B-DISO
cell	I-DISO
disease	I-DISO
.	O

Here	O
,	O
we	O
report	O
the	O
effect	O
of	O
R	O
-	O
848	O
when	O
adjuvanted	O
with	O
live	O
or	O
inactivated	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
vaccines	O
with	O
special	O
emphasis	O
on	O
mucosal	O
immunity	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
caused	O
by	O
many	O
factors	O
including	O
inhalation	O
of	O
toxicants	O
,	O
acute	O
barotrauma	O
,	O
acid	O
aspiration	B-DISO
,	O
and	O
burns	O
.	O

The	O
concentration	O
of	O
multiple	O
plasma	O
lipids	O
is	O
associated	O
with	O
mortality	O
in	O
this	O
group	O
of	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
ARDS	B-DISO
.	O

pAPN	O
knockout	O
in	O
IPI	O
-	O
2I	O
cells	O
completely	O
blocked	O
TGEV	O
infection	B-DISO
but	O
only	O
slightly	O
decreased	O
PDCoV	O
infection	B-DISO
.	O

Accordingly	O
,	O
early	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
-	O
bronchoalveolar	O
lavage	O
fluid	O
drives	O
an	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
-	O
specific	O
anti	O
-	O
inflammatory	O
macrophage	O
polarization	O
in	O
vitro	O
,	O
close	O
to	O
that	O
induced	O
by	O
recombinant	O
interleukin	O
-	O
10	O
.	O

Two	O
negative	O
results	O
for	O
MERS	O
-	O
CoV	O
obtained	O
3days	O
apart	O
and	O
being	O
free	O
of	O
any	O
suggestive	O
signs	B-DISO
and	I-DISO
symptoms	I-DISO
were	O
used	O
to	O
end	O
the	O
isolation	O
of	O
the	O
HCWs	O
and	O
allow	O
their	O
return	O
to	O
duty	O
.	O

TITLE	O
:	O
A	O
novel	O
mechanism	O
of	O
RNase	O
L	O
inhibition	O
:	O
Theiler	O
'	O
s	O
virus	O
L	O
*	O
protein	O
prevents	O
2	O
-	O
5A	O
from	O
binding	O
to	O
RNase	O
L	O
.	O
ABSTRACT	O
:	O
The	O
OAS	B-DISO
/	O
RNase	O
L	O
pathway	O
is	O
one	O
of	O
the	O
best	O
-	O
characterized	O
effector	O
pathways	O
of	O
the	O
IFN	O
antiviral	O
response	O
.	O

The	O
results	O
indicated	O
that	O
IBV	O
-	O
CS	O
vaccine	O
administered	O
alone	O
or	O
associated	O
with	O
a	O
live	O
attenuated	O
heterologous	O
vaccine	O
induced	O
both	O
humoral	O
and	O
cell	O
-	O
mediated	O
immune	O
responses	O
at	O
the	O
primary	O
site	O
of	O
viral	O
replication	O
,	O
and	O
provided	O
an	O
effective	O
protection	O
against	O
IBV	O
infection	B-DISO
at	O
local	O
(	O
trachea	B-DISO
)	O
and	O
systemic	O
(	O
kidney	O
)	O
sites	O
.	O

For	O
an	O
IQR	O
increase	O
in	O
previous	O
day	O
pollutant	O
concentration	O
,	O
the	O
percentage	O
increases	O
(	O
95	O
%	O
CI	O
)	O
in	O
SIDS	B-DISO
were	O
16	O
(	O
6	O
to	O
27	O
)	O
for	O
PM	O
The	O
results	O
indicated	O
ambient	O
air	O
pollutants	O
,	O
particularly	O
PM	O
RESULTS	O
:	O
For	O
an	O
IQR	O
increase	O
in	O
previous	O
day	O
pollutant	O
concentration	O
,	O
the	O
percentage	O
increases	O
(	O
95	O
%	O
CI	O
)	O
in	O
SIDS	B-DISO
were	O
16	O
(	O
6	O
to	O
27	O
)	O
for	O
PM	O

ABSTRACT	O
:	O
To	O
identify	O
the	O
genetic	O
aetiology	O
of	O
a	O
distinct	O
leukoencephalopathy	B-DISO
causing	O
acute	O
neurological	O
regression	O
in	O
infancy	O
with	O
apparently	O
complete	O
clinical	O
recovery	O
.	O

ABSTRACT	O
:	O
The	O
rates	O
of	O
asymptomatic	B-DISO
infection	I-DISO
with	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
coronavirus	O
vary	O
.	O

Of	O
the	O
1499	O
patients	O
included	O
in	O
the	O
analysis	O
,	O
237	O
(	O
15	O
.	O
8	O
%)	O
had	O
infection	B-DISO
without	O
SIRS	B-DISO
,	O
163	O
(	O
10	O
.	O
8	O
%)	O
had	O
infection	B-DISO
with	O
SIRS	B-DISO
,	O
260	O
(	O
17	O
.	O
3	O
%)	O
had	O
severe	B-DISO
sepsis	I-DISO
without	O
shock	O
,	O
and	O
203	O
(	O
13	O
.	O
5	O
%)	O
had	O
septic	B-DISO
shock	I-DISO
.	O

The	O
mortality	O
rates	O
were	O
higher	O
in	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
(	O
55	O
.	O
7	O
%)	O
and	O
septic	B-DISO
shock	I-DISO
(	O
70	O
.	O
4	O
%)	O
than	O
those	O
with	O
infection	B-DISO
alone	O
(	O
24	O
.	O
8	O
%)	O
and	O
infection	B-DISO
+	O
SIRS	B-DISO
(	O
31	O
.	O
2	O
%)	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

Age	O
,	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
score	O
at	O
ICU	O
admission	O
,	O
sequential	O
organ	B-DISO
failure	I-DISO
assessment	O
score	O
on	O
study	O
day	O
,	O
solid	O
organ	O
malignancy	B-DISO
,	O
presence	O
of	O
severe	B-DISO
sepsis	I-DISO
or	O
shock	O
,	O
Candida	O
spp	O
.	O

This	O
was	O
a	O
retrospective	O
,	O
observational	O
study	O
of	O
patients	O
with	O
severe	O
varicella	B-DISO
pneumonia	I-DISO
attending	O
a	O
tertiary	O
care	O
teaching	O
hospital	O
.	O

During	O
this	O
period	O
,	O
137	O
patients	O
got	O
admitted	O
with	O
varicella	B-DISO
of	O
which	O
22	O
had	O
severe	O
varicella	B-DISO
pneumonia	I-DISO
.	O

The	O
various	O
factors	O
associated	O
with	O
the	O
need	O
for	O
mechanical	O
ventilation	O
were	O
partial	O
pressure	O
of	O
oxygen	O
:	O
fraction	O
of	O
inspired	O
oxygen	O
ratio	O
<	O
150	O
,	O
quick	O
sequential	O
(	O
sepsis	B-DISO
-	O
related	O
)	O
organ	B-DISO
failure	I-DISO
assessment	O
(	O
qSOFA	O
)	O
>	O
2	O
,	O
and	O
early	O
bacterial	O
coinfection	B-DISO
.	O

ABSTRACT	O
:	O
Literature	O
data	O
concerning	O
risk	O
factors	O
for	O
severe	O
influenza	B-DISO
in	O
post	O
-	O
2009	O
pandemic	O
period	O
,	O
from	O
low	O
-	O
and	O
middle	O
-	O
income	O
Central	O
and	O
Eastern	O
European	O
countries	O
are	O
very	O
limited	O
.	O

The	O
study	O
indicated	O
three	O
statistically	O
significant	O
risk	O
factors	O
of	O
influenza	B-DISO
severity	O
,	O
including	O
presence	O
of	O
chronic	O
underlying	O
illness	O
/	O
condition	B-DISO
[	O
odds	O
ratio	O
(	O
OR	O
)	O
of	O
15	O
.	O
2	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
of	O
1	O
.	O
8	O
–	O
125	O
.	O
4	O
,	O
p	O
=	O
0	O
.	O
001	O
),	O
age	O
≥	O
15	O
years	O
(	O
OR	O
9	O
.	O
2	O
,	O
95	O
%	O
CI	O
3	O
.	O
5	O
–	O
24	O
.	O
1	O
,	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
delay	O
in	O
medical	O
care	O
of	O
more	O
than	O
two	O
days	O
after	O
the	O
symptoms	O
onset	O
(	O
OR	O
3	O
.	O
2	O
,	O
95	O
%	O
CI	O
1	O
.	O
6	O
–	O
6	O
.	O
4	O
,	O
p	O
=	O
0	O
.	O
001	O
).	O

Human	O
coronaviruses	O
(	O
HCoVs	O
[	O
22	O
.	O
0	O
%;	O
55	O
/	O
250	O
]),	O
rhinovirus	O
(	O
7	O
.	O
6	O
%;	O
19	O
/	O
250	O
),	O
and	O
influenza	B-DISO
A	O
(	O
6	O
.	O
4	O
%;	O
16	O
/	O
250	O
)	O
were	O
most	O
prevalent	O
.	O

Symptoms	O
changed	O
significantly	O
over	O
time	O
among	O
ARI	O
participants	O
with	O
HCoV	O
:	O
the	O
prevalence	O
of	O
cough	B-DISO
and	O
chills	B-DISO
decreased	O
over	O
6	O
days	O
(	O
P	O
=	O
.	O
04	O
,	O
and	O
P	O
=	O
.	O
01	O
,	O
respectively	O
),	O
while	O
runny	B-DISO
nose	I-DISO
increased	O
over	O
the	O
same	O
period	O
(	O
P	O
=	O
.	O
02	O
).	O

Dromedary	O
camels	O
are	O
considered	O
as	O
potential	O
reservoirs	O
for	O
the	O
virus	O
and	O
seem	O
to	O
be	O
the	O
only	O
animal	O
host	O
which	O
may	O
transmit	O
the	O
infection	B-DISO
to	O
human	O
.	O

Further	O
studies	O
are	O
required	O
to	O
better	O
understand	O
the	O
animal	O
sources	O
of	O
zoonotic	O
transmission	O
route	O
and	O
the	O
risks	O
of	O
this	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	B-DISO
)	O
is	O
a	O
respiratory	B-DISO
disease	I-DISO
caused	O
by	O
MERS	B-DISO
coronavirus	O
.	O

TITLE	O
:	O
Effect	O
of	O
selected	O
gastrointestinal	B-DISO
parasites	I-DISO
and	O
viral	O
agents	O
on	O
fecal	O
S100A12	O
concentrations	O
in	O
puppies	O
as	O
a	O
potential	O
comparative	O
model	O
.	O

An	O
infection	B-DISO
with	O
any	O
single	O
enteropathogen	O
tested	O
in	O
this	O
study	O
is	O
unlikely	O
to	O
alter	O
fecal	O
S100A12	O
concentrations	O
,	O
and	O
these	O
preliminary	O
data	O
are	O
important	O
for	O
further	O
studies	O
evaluating	O
fecal	O
S100A12	O
concentrations	O
in	O
dogs	O
or	O
when	O
using	O
fecal	O
S100A12	O
concentrations	O
as	O
a	O
biomarker	O
in	O
patients	O
with	O
chronic	O
idiopathic	O
gastrointestinal	B-DISO
inflammation	I-DISO
.	O

ABSTRACT	O
:	O
Metabolic	B-DISO
syndrome	I-DISO
(	O
MS	O
)	O
is	O
an	O
increasing	O
public	O
health	O
concern	O
because	O
of	O
rapid	O
lifestyle	O
changes	O
.	O

MS	O
was	O
defined	O
according	O
to	O
the	O
criteria	O
of	O
the	O
China	O
Diabetes	B-DISO
Society	O
.	O

The	O
individual	O
risk	O
of	O
infection	B-DISO
over	O
the	O
6	O
-	O
month	O
period	O
was	O
93	O
.	O
4	O
%,	O
80	O
.	O
1	O
%,	O
71	O
.	O
6	O
%,	O
61	O
.	O
5	O
%,	O
and	O
37	O
.	O
1	O
%	O
for	O
any	O
virus	O
,	O
RV	O
,	O
HCoV	O
,	O
AdV	O
,	O
and	O
RSV	O
,	O
respectively	O
.	O

In	O
this	O
household	O
setting	O
,	O
respiratory	O
virus	O
infections	B-DISO
and	O
associated	O
illness	O
are	O
ubiquitous	O
.	O

The	O
construction	O
of	O
mutations	O
in	O
the	O
fusion	O
protein	O
transmembrane	O
domains	O
(	O
TMDs	O
)	O
or	O
the	O
replacement	O
of	O
these	O
domains	O
with	O
lipid	O
anchors	O
has	O
implicated	O
the	O
TMD	B-DISO
in	O
the	O
fusion	O
process	O
.	O

However	O
,	O
the	O
spread	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDv	O
)	O
in	O
U	O
.	O
S	O
.	O
swine	O
represents	O
one	O
of	O
the	O
best	O
documented	O
emergences	O
of	O
a	O
highly	O
infectious	B-DISO
pathogen	O
in	O
the	O
U	O
.	O
S	O
.	O
livestock	O
industry	O
,	O
providing	O
an	O
opportunity	O
to	O
parameterize	O
models	O
of	O
pathogen	O
spread	O
via	O
direct	O
and	O
indirect	O
transmission	O
mechanisms	O
in	O
swine	O
.	O

Moderate	O
or	O
severe	O
OSA	B-DISO
was	O
significantly	O
(	O
p	O
=	O
0	O
.	O
006	O
)	O
more	O
frequent	O
among	O
intermediate	O
-	O
and	O
high	O
-	O
risk	O
PE	O
patients	O
(	O
81	O
.	O
0	O
%)	O
compared	O
to	O
the	O
low	O
-	O
risk	O
PE	O
cohort	O
(	O
16	O
.	O
3	O
%).	O

TITLE	O
:	O
Recovery	O
of	O
pulmonary	O
functions	O
,	O
exercise	O
capacity	O
,	O
and	O
quality	O
of	O
life	O
after	O
pulmonary	O
rehabilitation	O
in	O
survivors	O
of	O
ARDS	B-DISO
due	O
to	O
severe	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pneumonitis	B-DISO
.	O

The	O
recovery	O
of	O
pulmonary	O
functions	O
,	O
exercise	O
capacity	O
,	O
and	O
HRQoL	O
in	O
the	O
survivors	O
of	O
ARDS	B-DISO
due	O
to	O
2009	O
pandemic	O
influenza	B-DISO
A	O
H1N1	O
pneumonitis	B-DISO
(	O
H1N1	O
-	O
ARDS	B-DISO
)	O
was	O
evaluated	O
in	O
a	O
tertiary	O
teaching	O
hospital	O
in	O
northern	O
Taiwan	O
between	O
May	O
2010	O
and	O
June	O
2011	O
.	O

Regarding	O
the	O
Injury	O
Severity	O
Score	O
and	O
Abbreviated	O
Injury	O
Scale	O
(	O
AIS	B-DISO
),	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
,	O
except	O
for	O
the	O
AIS	B-DISO
CONCLUSIONS	O
:	O
In	O
polytraumatized	O
patients	O
,	O
entrapment	O
has	O
a	O
minor	O
influence	O
on	O
the	O
outcome	O
and	O
treatment	O
in	O
the	O
prehospital	O
and	O
hospital	O
setting	O
when	O
using	O
physician	O
-	O
based	O
air	O
rescue	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
lethal	O
zoonosis	B-DISO
that	O
causes	O
death	O
in	O
35	O
·	O
7	O
%	O
of	O
cases	O
.	O

ABSTRACT	O
:	O
Veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
VV	O
-	O
ECMO	O
)	O
is	O
increasingly	O
utilized	O
in	O
the	O
management	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Chugging	O
is	O
a	O
common	O
complication	B-DISO
for	O
patients	O
on	O
VV	O
ECMO	O
.	O

The	O
objective	O
of	O
the	O
study	O
was	O
to	O
report	O
the	O
feasibility	O
and	O
results	O
of	O
superior	O
mesenteric	O
artery	O
(	O
SMA	B-DISO
)	O
stenting	O
using	O
embolic	O
protection	O
devices	O
(	O
EPDs	O
)	O
to	O
treat	O
acute	B-DISO
mesenteric	I-DISO
ischemia	I-DISO
(	O
AMI	B-DISO
)	O
and	O
chronic	B-DISO
mesenteric	I-DISO
ischemia	I-DISO
(	O
CMI	O
).	O

A	O
retrospective	O
review	O
was	O
conducted	O
of	O
consecutive	O
patients	O
who	O
underwent	O
SMA	B-DISO
stenting	O
with	O
EPDs	O
from	O
2007	O
to	O
2016	O
.	O

Use	O
of	O
EPDs	O
during	O
SMA	B-DISO
stenting	O
is	O
safe	O
and	O
feasible	O
with	O
a	O
two	O
-	O
wire	O
technique	O
.	O

ABSTRACT	O
:	O
This	O
study	O
was	O
aiming	O
to	O
investigate	O
the	O
knowledge	O
,	O
practice	O
and	O
attitudes	O
of	O
secondary	O
school	O
and	O
university	O
students	O
toward	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

In	O
comparison	O
to	O
Berlin	O
definition	O
,	O
the	O
PALICC	O
criteria	O
identified	O
more	O
number	O
of	O
patients	O
with	O
ARDS	B-DISO
.	O

In	O
addition	O
to	O
SARS	B-DISO
,	O
other	O
respiratory	O
pathogens	O
have	O
also	O
emerged	O
recently	O
,	O
contributing	O
to	O
the	O
high	O
burden	O
of	O
respiratory	B-DISO
tract	I-DISO
infection	I-DISO
-	O
related	O
morbidity	O
and	O
mortality	O
.	O

Two	O
years	O
old	O
patient	O
was	O
successfully	O
disconnected	O
from	O
ECMO	O
and	O
in	O
stabile	O
condition	B-DISO
is	O
treated	O
in	O
Paediatric	O
Department	O
.	O

This	O
article	O
focuses	O
on	O
the	O
utilization	O
of	O
neuromuscular	O
blocking	B-DISO
agents	O
in	O
this	O
entity	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
gravida	O
in	O
fulminant	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
mechanically	O
ventilated	O
at	O
27	O
weeks	O
estimated	O
gestational	O
age	O
,	O
who	O
further	O
deteriorated	O
into	O
severe	O
combined	O
hypercarbic	O
,	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
.	O

ABSTRACT	O
:	O
Autophagy	O
signaling	O
pathway	O
is	O
involved	O
in	O
cellular	O
homeostasis	O
,	O
developmental	O
processes	O
,	O
cellular	B-DISO
stress	I-DISO
responses	O
,	O
and	O
immune	O
pathways	O
.	O

A	O
high	O
level	O
of	O
vigilance	O
and	O
proper	O
disposition	O
will	O
enable	O
the	O
emergency	B-DISO
clinician	O
to	O
effectively	O
diagnose	O
,	O
manage	O
,	O
and	O
contain	O
these	O
diseases	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
high	O
resolution	O
oesophageal	O
manometry	O
in	O
occult	O
respiratory	B-DISO
symptoms	I-DISO
.	O

TITLE	O
:	O
Passive	O
immunity	O
to	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
following	O
immunization	O
of	O
pregnant	O
gilts	O
with	O
a	O
recombinant	O
orf	O
virus	O
vector	O
expressing	O
the	O
spike	O
protein	O
.	O

RESULTS	O
:	O
UVC	O
reduced	O
EBOV	O
(≥	O
4	O
.	O
5	O
log	O
)	O
and	O
MERS	O
-	O
CoV	O
(≥	O
3	O
.	O
7	O
log	O
)	O
infectivity	O
in	O
PCs	B-DISO
to	O
the	O
limit	O
of	O
detection	O
,	O
and	O
MB	O
/	O
light	O
decreased	O
EBOV	O
(≥	O
4	O
.	O
6	O
log	O
)	O
and	O
MERS	O
-	O
CoV	O
(≥	O
3	O
.	O
3	O
log	O
)	O
titers	O
in	O
plasma	O
to	O
nondetectable	O
levels	O
.	O

Emergency	B-DISO
Health	O
Services	O
Life	O
Flight	O
,	O
the	O
primary	O
critical	O
care	O
transport	O
program	O
in	O
Eastern	O
Canada	O
,	O
developed	O
a	O
prone	O
position	O
protocol	O
to	O
meet	O
this	O
clinical	O
need	O
.	O

Despite	O
evidence	O
-	O
based	O
guidelines	O
,	O
antibiotics	O
are	O
still	O
commonly	O
used	O
to	O
treat	O
infections	B-DISO
likely	O
caused	O
by	O
respiratory	O
viruses	O
.	O

ABSTRACT	O
:	O
Evidence	O
for	O
benefit	O
of	O
high	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
is	O
largely	O
lacking	O
for	O
invasively	O
ventilated	O
,	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
uninjured	O
lungs	O
.	O

Interestingly	O
,	O
Th1	O
cell	O
activation	O
was	O
induced	O
by	O
immunization	O
schedules	O
including	O
Ad5	B-DISO
/	O
MERS	O
,	O
but	O
not	O
by	O
those	O
including	O
only	O
spike	O
protein	O
nanoparticles	O
.	O

Our	O
results	O
demonstrate	O
that	O
heterologous	O
immunization	O
by	O
priming	O
with	O
Ad5	B-DISO
/	O
MERS	O
and	O
boosting	O
with	O
spike	O
protein	O
nanoparticles	O
could	O
be	O
an	O
efficient	O
prophylactic	O
strategy	O
against	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

Using	O
confocal	O
microscopy	O
and	O
molecular	O
biology	O
tools	O
we	O
visualized	O
early	O
events	O
during	O
infection	B-DISO
.	O

Additionally	O
,	O
paired	O
samples	O
from	O
25	O
individuals	O
with	O
evidence	O
of	O
repeat	O
HCoV	O
-	O
NL63	O
infection	B-DISO
were	O
selected	O
for	O
whole	O
-	O
genome	O
virus	O
sequencing	O
.	O

ABSTRACT	O
:	O
This	O
report	O
describes	O
the	O
successful	O
use	O
of	O
a	O
new	O
intervention	O
to	O
improve	O
respiratory	O
mechanics	O
and	O
gas	O
exchange	O
in	O
a	O
relatively	O
homogeneous	O
group	O
of	O
infants	O
with	O
severe	O
bronchiolitis	B-DISO
-	O
induced	O
PARDS	O
after	O
failure	O
of	O
conventional	O
treatment	O
.	O

TITLE	O
:	O
Effects	O
of	O
respiratory	O
viruses	O
on	O
febrile	B-DISO
neutropenia	I-DISO
attacks	O
in	O
children	O
.	O

TITLE	O
:	O
Axonal	O
chronic	O
injury	O
in	O
treatment	O
-	O
naïve	O
HIV	O
+	O
adults	O
with	O
asymptomatic	O
neurocognitive	O
impairment	B-DISO
and	O
its	O
relationship	O
with	O
clinical	O
variables	O
and	O
cognitive	O
status	O
.	O

Diffusion	O
tensor	O
imaging	O
(	O
DTI	O
)	O
was	O
performed	O
in	O
20	O
antiretroviral	O
-	O
naïve	O
HIV	B-DISO
-	O
positive	O
asymptomatic	O
neurocognitive	O
impairment	B-DISO
(	O
ANI	O
)	O
adults	O
and	O
20	O
healthy	O
volunteers	O
.	O

In	O
addition	O
,	O
elevated	O
levels	O
of	O
TLR3	O
,	O
MDA5	O
and	O
IFN	O
-	O
β	O
expression	O
occurred	O
concurrently	O
with	O
greater	O
lesion	O
severity	O
in	O
IBV	O
infected	O
trachea	B-DISO
and	O
kidney	O
tissues	O
.	O

TITLE	O
:	O
A	O
fatal	O
case	O
associated	O
with	O
respiratory	B-DISO
syncytial	I-DISO
virus	I-DISO
infection	I-DISO
in	O
a	O
young	O
child	O
.	O

Although	O
a	O
definite	O
diagnosis	O
cannot	O
be	O
achieved	O
on	O
the	O
basis	O
of	O
imaging	O
features	O
alone	O
,	O
recognition	O
of	O
viral	B-DISO
pneumonia	I-DISO
patterns	O
may	O
aid	O
in	O
differentiating	O
viral	O
pathogens	O
,	O
thus	O
reducing	O
the	O
use	O
of	O
antibiotics	O
.	O

The	O
first	O
goal	O
of	O
this	O
review	O
is	O
to	O
indicate	O
that	O
there	O
are	O
imaging	O
features	O
that	O
should	O
raise	O
the	O
possibility	O
of	O
viral	B-DISO
infections	I-DISO
.	O

TITLE	O
:	O
Early	O
Pulmonary	B-DISO
Interstitial	I-DISO
Emphysema	I-DISO
in	O
Preterm	O
Neonates	O
-	O
Respiratory	O
Management	O
and	O
Case	O
Report	O
in	O
Nonventilated	O
Very	O
Low	O
Birth	O
Weight	O
Twins	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
derived	O
and	O
validated	O
a	O
biomarker	O
panel	O
in	O
three	O
independent	O
cohorts	O
and	O
compared	O
the	O
diagnostic	O
performance	O
to	O
clinician	O
recognition	O
of	O
ARDS	B-DISO
.	O

Controls	O
were	O
subjects	O
without	O
ARDS	B-DISO
during	O
the	O
first	O
4	O
days	O
of	O
study	O
enrollment	O
.	O

Among	O
11	O
biomarkers	O
,	O
the	O
combination	O
of	O
the	O
endothelial	O
injury	O
marker	O
angiopoietin	O
-	O
2	O
(	O
Ang	O
-	O
2	O
)	O
and	O
the	O
lung	O
epithelial	O
injury	O
marker	O
receptor	O
for	O
advanced	O
glycation	O
endproducts	O
(	O
RAGE	O
)	O
provided	O
good	O
discrimination	O
for	O
ARDS	B-DISO
in	O
the	O
derivation	O
cohort	O
(	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)=	O
0	O
.	O
74	O
(	O
95	O
%	O
CI	O
0	O
.	O
67	O
to	O
0	O
.	O
80	O
).	O

A	O
two	O
-	O
biomarker	O
panel	O
consisting	O
of	O
Ang	O
-	O
2	O
and	O
RAGE	O
performed	O
well	O
across	O
multiple	O
patient	O
cohorts	O
and	O
outperformed	O
clinical	O
providers	O
for	O
diagnosing	O
ARDS	B-DISO
in	O
severe	O
trauma	O
.	O

Clinical	O
application	O
of	O
this	O
model	O
could	O
improve	O
both	O
diagnosis	O
and	O
treatment	O
of	O
ARDS	B-DISO
in	O
patients	O
with	O
severe	O
trauma	O
.	O

The	O
fragmentation	B-DISO
of	O
the	O
HIV	B-DISO
/	I-DISO
AIDS	I-DISO
community	O
would	O
further	O
hinder	O
the	O
development	O
,	O
preventing	O
from	O
NGOs	O
with	O
the	O
same	O
interest	O
forming	O
alliances	O
to	O
call	O
for	O
changes	O
in	O
current	O
political	O
environment	O
.	O

ABSTRACT	O
:	O
Pneumoperitoneum	B-DISO
in	O
preterm	O
infants	O
is	O
a	O
surgical	O
emergency	B-DISO
as	O
it	O
is	O
usually	O
indicative	O
of	O
intestinal	B-DISO
perforation	I-DISO
.	O

The	O
pneumoperitoneum	B-DISO
occurred	O
in	O
isolation	O
.	O

Here	O
,	O
we	O
found	O
that	O
ectopic	O
expression	O
of	O
accessory	O
protein	O
NS6	B-DISO
significantly	O
inhibits	O
Sendai	O
virus	O
-	O
induced	O
interferon	O
beta	O
(	O
IFN	O
-	O
β	O
)	O
production	O
as	O
well	O
as	O
the	O
activation	O
of	O
transcription	O
factors	O
IRF3	O
and	O
NF	O
-	O
κB	O
.	O
Interestingly	O
,	O
NS6	B-DISO
does	O
not	O
impede	O
the	O
IFN	O
-	O
β	O
promoter	O
activation	O
mediated	O
via	O
key	O
molecules	O
in	O
the	O
RIG	O
-	O
I	O
-	O
like	O
receptor	O
(	O
RLR	O
)	O
signaling	O
pathway	O
,	O
specifically	O
RIG	O
-	O
I	O
,	O
MDA5	O
,	O
and	O
their	O
downstream	O
molecules	O
MAVS	O
,	O
TBK1	O
,	O
IKKε	O
,	O
and	O
IRF3	O
.	O

The	O
percentage	O
of	O
AMs	B-DISO
that	O
were	O
classified	O
into	O
one	O
of	O
the	O
3	O
AM	O
subtypes	O
was	O
significantly	O
different	O
between	O
healthy	O
and	O
mechanically	O
ventilated	O
subjects	O
.	O

A	O
web	B-DISO
-	O
based	O
program	O
aggregates	O
data	O
based	O
on	O
an	O
algorithm	O
that	O
provides	O
potential	O
signals	O
of	O
emerging	O
public	O
health	O
events	O
which	O
are	O
then	O
reviewed	O
by	O
a	O
multilingual	O
,	O
multidisciplinary	O
team	O
.	O

The	O
GPHIN	O
identified	O
the	O
early	O
SARS	B-DISO
outbreak	O
in	O
China	O
,	O
was	O
credited	O
with	O
the	O
first	O
alert	O
on	O
MERS	O
-	O
CoV	O
and	O
has	O
played	O
a	O
significant	O
role	O
in	O
the	O
monitoring	O
of	O
the	O
Ebola	O
outbreak	O
in	O
West	O
Africa	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
a	O
globally	O
emerging	O
and	O
re	O
-	O
emerging	O
enteric	O
coronavirus	O
in	O
pigs	O
causing	O
serious	O
economic	O
threats	O
to	O
the	O
world	O
swine	O
industry	O
.	O

Recent	O
studies	O
of	O
diseases	O
caused	O
by	O
several	O
RNA	O
viruses	O
in	O
people	O
and	O
other	O
species	O
indicate	O
that	O
antiviral	O
therapy	O
may	O
be	O
effective	O
against	O
FIP	B-DISO
in	O
cats	O
.	O

On	O
d	O
56	O
,	O
the	O
risk	O
of	O
respiratory	B-DISO
disease	I-DISO
was	O
lower	O
for	O
MAB	O
compared	O
with	O
MEP	O
(	O
RR	O
=	O
0	O
.	O
40	O
;	O
confidence	O
interval	O
=	O
0	O
.	O
16	O
-	O
0	O
.	O
99	O
).	O

Using	O
Au	O
NP	O
-	O
modified	O
graphene	O
nanosheet	O
(	O
Au	O
-	O
GN	O
)	O
as	O
the	O
substrate	O
,	O
antibody	O
-	O
antigen	O
reaction	O
as	O
the	O
recognition	O
unit	O
,	O
rolling	O
circle	O
amplification	B-DISO
(	O
RCA	O
)	O
for	O
signal	O
enhancement	O
,	O
and	O
assembled	O
cascade	O
Ru	O
-	O
DNA	O
nanotags	O
as	O
signal	O
label	O
,	O
the	O
proposed	O
platform	O
behaved	O
with	O
good	O
specificity	O
and	O
sensitivity	O
.	O

In	O
the	O
current	O
editorial	O
,	O
we	O
discuss	O
the	O
mechanisms	O
of	O
action	O
of	O
acetylcholine	O
receptor	O
antagonists	O
beyond	O
neuromuscular	B-DISO
blockade	I-DISO
.	O

In	O
the	O
present	O
work	O
,	O
a	O
comparative	O
study	O
of	O
the	O
functional	O
motifs	O
included	O
within	O
the	O
SARS	B-DISO
-	O
CoV	O
viroporins	O
was	O
performed	O
,	O
mostly	O
focusing	O
on	O
the	O
roles	O
of	O
the	O
IC	O
and	O
PBM	O
of	O
E	O
and	O
3a	O
proteins	O
.	O

Our	O
results	O
showed	O
that	O
the	O
full	O
-	O
length	O
E	O
and	O
3a	O
proteins	O
were	O
required	O
for	O
maximal	O
SARS	B-DISO
-	O
CoV	O
replication	O
and	O
virulence	O
,	O
whereas	O
viroporin	O
8a	O
had	O
only	O
a	O
minor	O
impact	O
on	O
these	O
activities	O
.	O

TITLE	O
:	O
New	O
variants	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
with	O
large	O
deletions	O
in	O
the	O
spike	O
protein	O
,	O
identified	O
in	O
the	O
United	O
States	O
,	O
2016	O
-	O
2017	O
.	O

The	O
cyclopropylquinoline	O
derivative	O
IV	O
displayed	O
high	O
potency	O
towards	O
Rift	B-DISO
Valley	I-DISO
fever	I-DISO
virus	O
(	O
RVFV	O
)	O
and	O
Tacaribe	O
virus	O
(	O
TCRV	O
)	O
towards	O
Rift	B-DISO
Valley	I-DISO
fever	I-DISO
virus	O
(	O
RVFV	O
).	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
consists	O
of	O
a	O
positive	O
-	O
sense	O
,	O
single	O
-	O
stranded	O
RNA	O
genome	O
and	O
four	O
structural	O
proteins	O
:	O
the	O
spike	O
,	O
envelope	O
,	O
membrane	O
,	O
and	O
nucleocapsid	O
protein	O
.	O

The	O
efficiency	O
of	O
poliomyelitis	B-DISO
,	O
measles	B-DISO
and	O
HPA	O
vaccines	O
is	O
shown	O
.	O

Several	O
important	O
pathogenic	O
mechanisms	O
common	O
for	O
various	O
hemorrhagic	B-DISO
fevers	I-DISO
were	O
studied	O
on	O
experimental	O
SHF	O
of	O
macaques	O
.	O

TITLE	O
:	O
Systematic	O
detection	O
of	O
positive	O
selection	O
in	O
the	O
human	O
-	O
pathogen	O
interactome	O
and	O
lasting	O
effects	O
on	O
infectious	B-DISO
disease	I-DISO
susceptibility	O
.	O

For	O
HIV	B-DISO
-	O
1	O
,	O
GWAS	O
demonstrate	O
that	O
some	O
naturally	O
selected	O
variants	O
in	O
the	O
host	O
-	O
pathogen	O
protein	O
interaction	O
networks	O
continue	O
to	O
have	O
functional	O
consequences	O
for	O
susceptibility	O
to	O
these	O
pathogens	O
.	O

The	O
cohorts	O
were	O
diverse	O
in	O
enrollment	O
criteria	O
,	O
demographics	O
(	O
median	O
ages	O
,	O
29	O
-	O
54	O
years	O
;	O
males	O
range	O
,	O
36	O
%-	O
76	O
%),	O
HIV	B-DISO
prevalence	O
(	O
range	O
,	O
2	O
%-	O
43	O
%),	O
cause	O
of	O
infection	B-DISO
,	O
and	O
hospital	O
mortality	O
(	O
range	O
,	O
1	O
%-	O
39	O
%).	O

High	O
,	O
vs	O
low	O
or	O
moderate	O
,	O
SIRS	B-DISO
criteria	O
were	O
associated	O
with	O
a	O
smaller	O
increase	O
in	O
risk	O
of	O
death	O
overall	O
(	O
13	O
%	O
vs	O
8	O
%;	O
difference	O
,	O
5	O
%	O
[	O
95	O
%	O
CI	O
,	O
3	O
%-	O
6	O
%];	O
odds	O
ratio	O
,	O
1	O
.	O
7	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
4	O
-	O
2	O
.	O
0	O
])	O
and	O
across	O
cohorts	O
(	O
P	O
<	O
.	O
05	O
for	O
4	O
of	O
9	O
cohorts	O
).	O

qSOFA	O
discrimination	O
(	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
[	O
AUROC	O
],	O
0	O
.	O
70	O
[	O
95	O
%	O
CI	O
,	O
0	O
.	O
68	O
-	O
0	O
.	O
72	O
])	O
was	O
superior	O
to	O
that	O
of	O
both	O
the	O
baseline	O
model	O
(	O
AUROC	O
,	O
0	O
.	O
56	O
[	O
95	O
%	O
CI	O
,	O
0	O
.	O
53	O
-	O
0	O
.	O
58	O
;	O
P	O
<	O
.	O
001	O
)	O
and	O
SIRS	B-DISO
(	O
AUROC	O
,	O
0	O
.	O
59	O
[	O
95	O
%	O
CI	O
,	O
0	O
.	O
57	O
-	O
0	O
.	O
62	O
];	O
P	O
<	O
.	O
001	O
).	O

When	O
assessed	O
among	O
hospitalized	O
adults	O
with	O
suspected	O
infection	B-DISO
in	O
9	O
LMIC	O
cohorts	O
,	O
the	O
qSOFA	O
score	O
identified	O
infected	O
patients	O
at	O
risk	O
of	O
death	O
beyond	O
that	O
explained	O
by	O
baseline	O
factors	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
through	O
p53	O
-	O
dependent	O
pathway	O
causes	O
cell	O
cycle	O
arrest	O
in	O
the	O
G0	O
/	O
G1	O
phase	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
PEDV	O
infection	B-DISO
on	O
the	O
cell	O
cycle	O
of	O
Vero	O
cells	O
and	O
p53	O
activation	O
.	O

PEDV	O
infection	B-DISO
up	O
-	O
regulates	O
the	O
levels	O
of	O
p21	O
,	O
cdc2	O
,	O
cdk2	O
,	O
cdk4	O
,	O
Cyclin	O
A	O
protein	O
and	O
down	O
-	O
regulates	O
Cyclin	O
E	O
protein	O
.	O

ABSTRACT	O
:	O
Self	O
-	O
binding	O
peptides	O
containing	O
zipper	O
-	O
like	O
sequences	O
,	O
such	O
as	O
the	O
Leu	O
/	O
Ile	O
zipper	O
sequence	O
within	O
the	O
coiled	O
coil	O
regions	O
of	O
proteins	O
and	O
the	O
cross	O
-	O
β	O
spine	O
steric	O
zippers	O
within	O
the	O
amyloid	B-DISO
-	O
like	O
fibrils	O
,	O
could	O
bind	O
to	O
the	O
protein	O
-	O
of	O
-	O
origin	O
through	O
homophilic	O
sequence	O
-	O
specific	O
zipper	O
motifs	O
.	O

Here	O
,	O
we	O
report	O
on	O
the	O
identification	O
of	O
a	O
putative	O
self	O
-	O
binding	O
β	O
-	O
zipper	O
-	O
forming	O
peptide	O
within	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
associated	O
coronavirus	O
spike	O
(	O
S	O
)	O
protein	O
and	O
its	O
application	O
in	O
viral	O
detection	O
.	O

The	O
data	O
suggest	O
that	O
short	O
β	O
-	O
zipper	O
-	O
like	O
self	O
-	O
binding	O
peptides	O
within	O
the	O
S	O
protein	O
could	O
be	O
identified	O
through	O
combining	O
the	O
peptide	O
scanning	O
and	O
predictive	O
methods	O
,	O
and	O
could	O
be	O
exploited	O
as	O
biochemical	O
detection	O
reagents	O
for	O
viral	B-DISO
infection	I-DISO
.	O

In	O
contrast	O
to	O
S2	O
trimer	O
,	O
S2	O
monomer	O
was	O
unstable	O
,	O
having	O
high	O
RMSDs	O
with	O
major	O
drifts	O
above	O
8	O
Å	O
.	O
Fluctuation	B-DISO
of	O
HR	O
residue	O
positions	O
revealed	O
major	O
changes	O
in	O
the	O
C	O
-	O
terminal	O
of	O
HR2	O
and	O
the	O
linker	O
coil	O
between	O
HR1	O
and	O
HR2	O
in	O
both	O
monomer	O
and	O
trimer	O
.	O

ABSTRACT	O
:	O
Chimeric	O
antigen	O
receptor	O
(	O
CAR	B-DISO
)	O
therapy	O
targeting	O
CD19	O
is	O
an	O
effective	O
treatment	O
for	O
refractory	O
B	O
cell	O
malignancies	B-DISO
,	O
especially	O
acute	B-DISO
lymphoblastic	I-DISO
leukemia	I-DISO
(	O
ALL	O
)	O

TITLE	O
:	O
Modeling	O
the	O
spread	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
in	O
Saudi	O
Arabia	O
.	O

TITLE	O
:	O
An	O
episode	O
of	O
acute	B-DISO
encephalopathy	I-DISO
with	O
biphasic	O
seizures	B-DISO
and	O
late	O
reduced	O
diffusion	O
followed	O
by	O
hemiplegia	B-DISO
and	O
intractable	B-DISO
epilepsy	I-DISO
observed	O
in	O
a	O
patient	O
with	O
a	O
novel	O
frameshift	B-DISO
mutation	I-DISO
in	O
HNRNPU	O
.	O

Sczy3C100	O
effectively	O
reduced	O
the	O
morbidity	O
,	O
mortality	O
,	O
mean	O
lesion	O
scores	O
(	O
MLSs	O
),	O
and	O
viral	O
load	O
of	O
trachea	B-DISO
of	O
chickens	O
challenged	O
by	O
GI	O
-	O
19	O
/	O
QX	O
and	O
GI	O
-	O
7	O
/	O
TWI	O
strains	O
.	O

However	O
,	O
mortality	O
and	O
severe	B-DISO
sepsis	I-DISO
were	O
unchanged	O
following	O
statin	O
treatment	O
.	O

Healthcare	O
-	O
acquired	O
MERS	O
infection	B-DISO
has	O
become	O
a	O
well	O
-	O
known	O
characteristic	O
of	O
the	O
disease	O
and	O
a	O
leading	O
means	O
of	O
spread	O
.	O

Repeated	O
assessments	O
of	O
infection	B-DISO
control	O
and	O
monitoring	O
of	O
corrective	O
measures	O
contribute	O
to	O
changing	O
the	O
course	O
of	O
an	O
outbreak	O
.	O

ABSTRACT	O
:	O
Every	O
year	O
,	O
there	O
are	O
about	O
20	O
Mio	O
hepatitis	B-DISO
E	I-DISO
virus	O
(	O
HEV	O
)	O
infections	B-DISO
and	O
60	O
,	O
000	O
deaths	O
that	O
are	O
associated	O
with	O
HEV	O
worldwide	O
.	O

TITLE	O
:	O
Chaperna	O
-	O
Mediated	O
Assembly	O
of	O
Ferritin	O
-	O
Based	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
-	O
Coronavirus	O
Nanoparticles	O
.	O

After	O
excluding	O
the	O
causes	O
of	O
obstructive	O
apnea	B-DISO
,	O
a	O
cerebral	O
CT	O
scan	O
was	O
performed	O
,	O
revealing	O
isolated	O
fourth	O
ventricle	O
compressing	O
the	O
brainstem	O
.	O

Antigen	O
positivity	O
lasted	O
3	O
to	O
6	O
days	O
in	O
secondary	B-DISO
infections	I-DISO
and	O
13	O
days	O
in	O
primary	B-DISO
infection	I-DISO
.	O

We	O
report	O
that	O
Unc51	O
-	O
like	O
kinase	O
1	O
(	O
Ulk1	O
/	O
Unc51	O
.	O
1	O
)	O
is	O
a	O
pivotal	O
regulator	O
of	O
PHEV	O
-	O
induced	O
neurological	B-DISO
disorders	I-DISO
and	O
functions	O
to	O
selectively	O
control	O
the	O
initiation	O
of	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)/	O
TrkA	O
endosome	O
trafficking	O
.	O

Further	O
investigation	O
determined	O
that	O
the	O
ectopic	O
expression	O
of	O
Rab5	O
mutants	O
induces	O
aberrant	O
endosomal	O
accumulation	O
of	O
activated	O
pTrkA	O
,	O
proving	O
that	O
targeting	O
of	O
Ulk1	O
-	O
TrkA	O
-	O
NGF	O
signaling	O
to	O
the	O
retrograde	O
transport	O
route	O
in	O
the	O
neurodegenerative	O
process	O
that	O
underlies	O
PHEV	O
infection	B-DISO
is	O
dependent	O
on	O
Rab5	O
GTPase	O
activity	O
.	O

A	O
literature	O
search	O
was	O
conducted	O
using	O
Ovid	O
Medline	O
and	O
the	O
exploded	O
MeSH	O
terms	O
ARDS	B-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
neuromuscular	B-DISO
blockade	I-DISO
,	O
neuromuscular	O
blocking	B-DISO
agents	O
,	O
and	O
paralytics	O
.	O

With	O
limitations	O
applied	O
,	O
three	O
original	O
randomized	O
controlled	O
trials	O
investigating	O
the	O
use	O
of	O
neuromuscular	O
blocking	B-DISO
agents	O
(	O
NMBAs	O
)	O
in	O
severe	O
ARDS	B-DISO
were	O
identified	O
and	O
reviewed	O
.	O

The	O
results	O
of	O
phylogenetic	O
and	O
recombination	O
analyses	O
showed	O
that	O
GDS10	O
strain	O
shared	O
a	O
common	O
ancestor	O
with	O
CO13	O
strain	O
,	O
which	O
was	O
obtained	O
from	O
a	O
piglet	O
with	O
severe	B-DISO
diarrhea	I-DISO
in	O
USA	O
.	O

TITLE	O
:	O
Epidermal	O
growth	O
factor	O
receptor	O
is	O
a	O
co	O
-	O
factor	O
for	O
transmissible	O
gastroenteritis	B-DISO
virus	O
entry	O
.	O

COPD	B-DISO
,	O
HIV	B-DISO
infection	I-DISO
,	O
and	O
hematological	B-DISO
malignancy	I-DISO
were	O
associated	O
with	O
a	O
lower	O
likelihood	O
of	O
invasive	O
mechanical	O
ventilation	O
on	O
the	O
admission	O
day	O
.	O

Mortality	O
was	O
independently	O
associated	O
with	O
P	O
Half	O
the	O
patients	O
with	O
ARDS	B-DISO
had	O
major	O
comorbidities	O
,	O
which	O
were	O
associated	O
with	O
severe	O
ARDS	B-DISO
,	O
multiple	O
organ	O
dysfunction	O
,	O
and	O
day	O
-	O
28	O
mortality	O
.	O

His	O
cortisol	O
level	O
was	O
undetectable	O
;	O
he	O
was	O
diagnosed	O
with	O
adrenal	B-DISO
insufficiency	I-DISO
and	O
fludrocortisone	O
was	O
initiated	O
.	O

Fully	O
differentiated	O
3D	O
nasal	O
epithelium	O
cultures	O
were	O
inoculated	O
with	O
picornaviruses	O
,	O
a	O
coronavirus	O
and	O
influenza	B-DISO
A	O
viruses	O
in	O
the	O
absence	O
or	O
in	O
the	O
presence	O
of	O
reference	O
antiviral	O
drugs	O
.	O

Results	O
showed	O
that	O
,	O
rupintrivir	O
efficiently	O
inhibits	O
the	O
replication	O
of	O
respiratory	O
picornaviruses	O
in	O
a	O
dose	O
dependent	O
manner	O
and	O
prevents	O
the	O
impairment	B-DISO
of	O
the	O
mucociliary	O
clearance	O
.	O

Similarly	O
,	O
oseltamivir	O
reduced	O
the	O
replication	O
of	O
influenza	B-DISO
A	O
viruses	O
in	O
a	O
dose	O
dependent	O
manner	O
and	O
prevented	O
the	O
impairment	B-DISO
of	O
the	O
epithelial	O
barrier	O
function	O
and	O
cytotoxicity	B-DISO
until	O
4	O
days	O
of	O
infection	B-DISO
.	O

These	O
results	O
reveal	O
that	O
a	O
large	O
panel	O
of	O
epithelial	O
functions	O
is	O
modified	O
upon	O
viral	B-DISO
infection	I-DISO
and	O
validate	O
MucilAir	O
™	O
as	O
a	O
pertinent	O
tool	O
for	O
pre	O
-	O
clinical	O
antiviral	O
drug	O
testing	O
.	O

Moreover	O
,	O
rSF	O
-	O
COE	O
-	O
3D	O
could	O
provide	O
a	O
better	O
protection	O
against	O
the	O
challenge	O
of	O
a	O
high	O
pathogenic	O
PEDV	O
variant	O
,	O
with	O
less	O
diarrhea	B-DISO
pigs	O
,	O
less	O
pigs	O
with	O
detectable	O
PEDV	O
shed	O
,	O
lower	O
rank	O
values	O
of	O
feces	O
and	O
less	O
apparent	O
lesions	O
and	O
inflammation	B-DISO
in	O
duodenum	O
of	O
the	O
PEDV	O
infected	O
pigs	O
.	O

TITLE	O
:	O
Correlation	O
between	O
Pneumonia	B-DISO
Severity	O
and	O
Pulmonary	B-DISO
Complications	I-DISO
in	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
.	O

TITLE	O
:	O
The	O
ADRP	O
domain	O
from	O
a	O
virulent	O
strain	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
is	O
not	O
sufficient	O
to	O
confer	O
a	O
pathogenic	O
phenotype	O
to	O
the	O
attenuated	O
Beaudette	O
strain	O
.	O

TITLE	O
:	O
A	O
Rapid	O
and	O
Specific	O
Assay	O
for	O
the	O
Detection	O
of	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
novel	O
human	O
coronavirus	O
that	O
can	O
cause	O
human	O
respiratory	B-DISO
disease	I-DISO
.	O

Broiler	O
farming	O
is	O
even	O
more	O
problematic	O
given	O
the	O
short	O
and	O
intense	O
productive	O
cycle	O
,	O
which	O
requires	O
an	O
early	O
onset	O
of	O
protection	O
against	O
most	O
of	O
the	O
infectious	B-DISO
threats	O
,	O
possibly	O
with	O
limited	O
respiratory	O
post	O
-	O
vaccination	O
reactions	O
that	O
would	O
have	O
a	O
direct	O
impact	O
on	O
the	O
bird	O
health	O
and	O
productivity	O
.	O

Factors	O
attributable	O
for	O
ARDS	B-DISO
were	O
malaria	B-DISO
in	O
31	O
patients	O
(	O
26	O
.	O
72	O
%),	O
pneumonia	B-DISO
in	O
23	O
(	O
19	O
.	O
82	O
%),	O
sepsis	B-DISO
in	O
20	O
(	O
17	O
.	O
2	O
%),	O
dengue	B-DISO
in	O
15	O
(	O
12	O
.	O
96	O
%),	O
undiagnosed	O
fever	O
in	O
13	O
(	O
11	O
.	O
1	O
%),	O
leptospirosis	B-DISO
in	O
7	O
(	O
6	O
.	O
03	O
%),	O
pancreatitis	B-DISO
in	O
3	O
(	O
2	O
.	O
58	O
%),	O
H1N1	O
infection	B-DISO
in	O
2	O
(	O
1	O
.	O
72	O
%),	O
urinary	O
tract	O
infection	B-DISO
(	O
UTI	B-DISO
)	O
in	O
1	O
(	O
0	O
.	O
86	O
%)	O
and	O
UTI	B-DISO
with	O
pyelonephritis	B-DISO
and	O
Dengue	B-DISO
in	O
1	O
(	O
0	O
.	O
86	O
%)	O
patients	O
.	O

Tropical	B-DISO
diseases	I-DISO
in	O
present	O
study	O
constituted	O
66	O
(	O
56	O
.	O
89	O
%)	O
cases	O
of	O
which	O
31	O
(	O
47	O
%)	O
died	O
.	O

Likewise	O
,	O
underlying	O
causing	O
factors	O
such	O
as	O
venous	B-DISO
congestion	I-DISO
due	O
to	O
OCCP	O
-	O
related	O
DVT	B-DISO
should	O
be	O
considered	O
in	O
the	O
diagnosis	O
.	O

ABSTRACT	O
:	O
Although	O
there	O
is	O
evidence	O
of	O
person	O
-	O
to	O
-	O
person	O
transmission	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
household	O
and	O
healthcare	O
settings	O
,	O
more	O
data	O
are	O
needed	O
to	O
describe	O
and	O
better	O
understand	O
the	O
risk	O
factors	O
and	O
transmission	O
routes	O
in	O
both	O
settings	O
,	O
as	O
well	O
as	O
the	O
extent	O
to	O
which	O
disease	O
severity	O
affects	O
transmission	O
.	O

ABSTRACT	O
:	O
This	O
essay	O
focuses	O
on	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
),	O
which	O
is	O
an	O
enteropathogenic	O
virus	O
related	O
to	O
contagious	O
and	O
acute	B-DISO
diseases	I-DISO
in	O
suckling	O
piglets	O
.	O

ABSTRACT	O
:	O
During	O
the	O
2016	O
-	O
17	O
influenza	B-DISO
season	O
in	O
Spain	O
,	O
we	O
tested	O
specimens	O
from	O
57	O
elderly	O
deceased	O
persons	O
for	O
respiratory	O
viruses	O
.	O

FHS	B-DISO
-	O
1	O
cells	O
had	O
phagocytic	O
and	O
antigen	O
uptake	O
/	O
processing	O
activities	O
.	O

Although	O
FHS	B-DISO
-	O
1	O
cells	O
lost	O
the	O
expression	O
of	O
MHC	O
class	O
II	O
and	O
CD163	O
,	O
our	O
findings	O
indicate	O
that	O
FHS	B-DISO
-	O
1	O
is	O
a	O
feline	O
HS	O
cell	O
line	O
that	O
retains	O
functional	O
properties	O
of	O
dendritic	O
cells	O
/	O
macrophages	O
in	O
terms	O
of	O
phagocytic	O
and	O
antigen	O
uptake	O
/	O
processing	O
activities	O
.	O

TITLE	O
:	O
Epitope	O
selection	O
and	O
their	O
placement	O
for	O
increased	O
virus	O
neutralization	O
in	O
a	O
novel	O
vaccination	O
strategy	O
for	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
utilizing	O
the	O
Hepatitis	B-DISO
B	I-DISO
virus	O
core	O
antigen	O
.	O

This	O
report	O
details	O
several	O
design	O
changes	O
made	O
to	O
a	O
Hepatitis	B-DISO
B	I-DISO
virus	O
core	O
antigen	O
(	O
HBcAg	O
)-	O
based	O
recombinant	O
vaccine	O
strategy	O
,	O
and	O
their	O
effect	O
in	O
vivo	O
.	O

TITLE	O
:	O
Molecular	O
characteristic	O
and	O
pathogenicity	O
analysis	O
of	O
a	O
virulent	O
recombinant	O
avain	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
isolated	O
in	O
China	O
.	O

ABSTRACT	O
:	O
A	O
virulent	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
),	O
designated	O
as	O
CK	O
/	O
CH	O
/	O
GD	O
/	O
QY16	O
(	O
referred	O
as	O
QY16	O
),	O
was	O
isolated	O
from	O
a	O
diseased	O
chicken	O
farm	O
in	O
Guangdong	O
province	O
,	O
China	O
,	O
in	O
2016	O
.	O

It	O
has	O
been	O
further	O
confirmed	O
by	O
the	O
RDP	B-DISO
and	O
SimPlot	O
analysis	O
that	O
QY16	O
is	O
a	O
recombinant	O
strain	O
deriving	O
from	O
YX10	O
(	O
as	O
the	O
major	O
parental	O
sequence	O
)	O
and	O
4	O
/	O
91	O
(	O
as	O
the	O
minor	O
parental	O
sequence	O
),	O
and	O
that	O
the	O
recombination	O
occurs	O
in	O
a	O
region	O
which	O
includes	O
the	O
3	O
'-	O
terminal	O
1b	O
sequence	O
(	O
85	O
nt	O
)	O
and	O
the	O
5	O
'-	O
terminal	O
S1	O
protein	O
gene	O
sequence	O
(	O
1	O
,	O
466	O
nt	O
).	O

The	O
incidence	O
of	O
ARDS	B-DISO
,	O
AKI	O
,	O
and	O
cardiac	B-DISO
insufficiency	I-DISO
was	O
80	O
.	O
9	O
％	O
(	O
414	O
/	O
512	O
),	O
71	O
.	O
3	O
％	O
(	O
365	O
/	O
512	O
),	O
and	O
61	O
.	O
9	O
％	O
(	O
317	O
/	O
512	O
)	O
respectively	O
.	O

To	O
assess	O
whether	O
a	O
GBF1	O
/	O
class	O
II	O
Arf	B-DISO
pathway	O
is	O
conserved	O
among	O
positive	O
-	O
sense	O
single	O
-	O
stranded	O
RNA	O
viruses	O
,	O
we	O
investigated	O
yellow	B-DISO
fever	I-DISO
virus	O
(	O
YFV	O
),	O
Sindbis	O
virus	O
(	O
SINV	O
),	O
coxsackievirus	O
B4	O
(	O
CVB4	O
)	O
and	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
).	O

In	O
addition	O
,	O
another	O
Arf	B-DISO
pair	O
,	O
Arf1	O
and	O
Arf4	O
,	O
appears	O
to	O
be	O
essential	O
for	O
YFV	O
and	O
SINV	O
infection	B-DISO
,	O
but	O
not	O
for	O
infection	B-DISO
by	O
other	O
viruses	O
.	O

We	O
searched	O
major	O
databases	O
and	O
included	O
randomized	O
trials	O
comparing	O
at	O
least	O
NIV	O
with	O
HFNC	O
or	O
NIV	O
+	O
HFNC	O
with	O
NIV	O
in	O
ARF	B-DISO
.	O

Telocytes	O
(	O
TCs	B-DISO
)	O
can	O
promote	O
tissue	O
repair	O
following	O
injury	O
in	O
the	O
heart	O
,	O
kidneys	O
,	O
and	O
other	O
organs	O
.	O

The	O
percentages	O
of	O
H7N9	O
-	O
specific	O
IFN	O
-	O
γ	O
-	O
secreting	O
T	O
cells	O
tended	O
to	O
increase	O
over	O
time	O
in	O
patients	O
≥	O
60	O
years	O
or	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
requiring	O
ventilation	O
.	O

Spatial	O
structures	O
of	O
microbial	O
communities	O
were	O
more	O
disordered	O
in	O
the	O
0	O
-	O
4	O
age	O
group	O
and	O
those	O
with	O
recent	O
RTI	B-DISO
.	O

Overexpression	O
of	O
wild	O
-	O
type	O
or	O
dominant	O
-	O
negative	O
ULK1	O
constructs	O
does	O
not	O
affect	O
virus	O
replication	O
,	O
indicating	O
that	O
ULK1	O
degradation	O
may	O
be	O
a	O
side	B-DISO
effect	I-DISO
of	O
the	O
ULK1	O
-	O
independent	O
signaling	O
mechanism	O
used	O
by	O
PV	O
,	O
inducing	O
complex	O
instability	O
.	O

TITLE	O
:	O
Alk5	O
/	O
Runx1	O
signaling	O
mediated	O
by	O
extracellular	O
vesicles	B-DISO
promotes	O
vascular	O
repair	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

RESULTS	O
:	O
The	O
EVs	O
were	O
isolated	O
from	O
the	O
blood	O
of	O
ARDS	B-DISO
and	O
control	O
subjects	O
.	O

This	O
retrospective	O
study	O
examined	O
patients	O
with	O
suspected	O
leptospirosis	B-DISO
admitted	O
to	O
En	O
-	O
Chu	O
-	O
Kong	O
Hospital	O
,	O
a	O
regional	O
teaching	O
hospital	O
in	O
northern	O
Taiwan	O
.	O

Leptospira	O
santarosai	O
serova	O
Shermani	O
was	O
present	O
in	O
42	O
(	O
74	O
%)	O
patients	O
and	O
37	O
(	O
58	O
%)	O
patients	O
had	O
severe	O
leptospirosis	B-DISO
.	O

These	O
results	O
indicate	O
that	O
shock	O
is	O
a	O
predictor	O
of	O
severe	O
leptospirosis	B-DISO
,	O
and	O
prior	O
steroid	O
use	O
and	O
hemorrhage	B-DISO
are	O
predictors	O
of	O
death	O
from	O
leptospirosis	B-DISO
.	O

The	O
factors	O
independently	O
related	O
to	O
mortality	O
were	O
prior	O
steroid	O
use	O
(	O
OR	O
20	O
.	O
2	O
,	O
95	O
%	O
CI	O
1	O
.	O
9	O
-	O
217	O
.	O
5	O
)	O
and	O
hemorrhage	B-DISO
(	O
OR	O
71	O
.	O
2	O
,	O
95	O
%	O
CI	O
4	O
.	O
9	O
-	O
>	O
999	O
.	O
9	O
).	O

ABSTRACT	O
:	O
The	O
ability	O
to	O
infect	O
and	O
replicate	O
in	O
monocytes	O
/	O
macrophages	O
is	O
a	O
critically	O
distinguishing	O
feature	O
between	O
the	O
two	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
pathotypes	O
:	O
feline	O
enteric	O
coronavirus	O
(	O
FECV	O
;	O
low	O
-	O
virulent	O
)	O
and	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
;	O
lethal	O
).	O

While	O
some	O
of	O
the	O
single	O
mutations	O
had	O
a	O
significant	O
effect	O
,	O
none	O
of	O
them	O
fully	O
reverted	O
the	O
infection	B-DISO
phenotype	O
.	O

TITLE	O
:	O
Development	O
of	O
a	O
real	O
time	O
reverse	O
transcription	O
loop	O
-	O
mediated	O
isothermal	O
amplification	B-DISO
method	O
(	O
RT	O
-	O
LAMP	O
)	O
for	O
detection	O
of	O
a	O
novel	O
swine	O
acute	B-DISO
diarrhea	I-DISO
syndrome	B-DISO
coronavirus	O
(	O
SADS	O
-	O
CoV	O
).	O

The	O
sample	O
types	O
included	O
nasopharyngeal	O
swabs	O
(	O
n	O
=	O
677	O
),	O
expectorated	O
deep	O
cough	B-DISO
sputum	O
(	O
n	O
=	O
32	O
),	O
induced	O
sputum	O
(	O
n	O
=	O
17	O
),	O
and	O
tracheal	O
aspirates	O
(	O
n	O
=	O
23	O
).	O

ABSTRACT	O
:	O
Porcine	O
deltacoronavirus	O
(	O
PDCoV	O
),	O
a	O
newly	O
discovered	O
enteric	O
coronavirus	O
,	O
is	O
a	O
causative	O
agent	O
of	O
severe	O
clinical	O
diarrhea	B-DISO
and	O
intestinal	O
pathological	O
damage	O
in	O
piglets	O
.	O

Quantitative	O
results	O
of	O
AIV	O
and	O
IBV	O
co	B-DISO
-	I-DISO
infection	I-DISO
showed	O
that	O
interferences	O
between	O
the	O
two	O
viruses	O
yielded	O
decreased	O
viral	O
growth	O
.	O

The	O
ELISA	O
results	O
showed	O
that	O
higher	O
level	O
of	O
secreted	O
IL	O
-	O
1beta	O
varies	O
,	O
depending	O
on	O
the	O
viral	O
interference	O
conditions	O
between	O
both	O
viruses	O
,	O
during	O
mixed	B-DISO
infections	I-DISO
.	O

RESULTS	O
:	O
Quantitative	O
results	O
of	O
AIV	O
and	O
IBV	O
co	B-DISO
-	I-DISO
infection	I-DISO
showed	O
that	O
interferences	O
between	O
the	O
two	O
viruses	O
yielded	O
decreased	O
viral	O
growth	O
.	O

As	O
demyelination	B-DISO
is	O
caused	O
by	O
multifactorial	O
insults	O
,	O
our	O
results	O
highlight	O
the	O
plasticity	O
of	O
microglia	O
in	O
responding	O
to	O
distinct	O
inflammatory	O
settings	O
,	O
which	O
may	O
be	O
relevant	O
for	O
MS	O
pathogenesis	B-DISO
.	O

ABSTRACT	O
:	O
High	O
morbidity	O
and	O
mortality	O
due	O
to	O
community	O
-	O
acquired	O
pneumonia	B-DISO
(	O
CAP	B-DISO
)	O
is	O
seen	O
in	O
children	O
under	O
5	O
years	O
of	O
age	O
in	O
India	O
.	O

Included	O
were	O
children	O
between	O
2	O
and	O
59	O
months	O
of	O
age	O
hospitalized	O
with	O
WHO	O
-	O
defined	O
severe	O
CAP	B-DISO
with	O
consistent	O
radiological	O
abnormalities	O
.	O

Higher	O
serum	O
levels	O
of	O
IL1RA	O
were	O
found	O
in	O
A2A2	O
genotype	O
indicating	O
possibly	O
enhanced	O
inflammatory	B-DISO
response	I-DISO
resulting	O
in	O
AO	O
of	O
CAP	B-DISO
.	O

RESULTS	O
:	O
From	O
2014	O
to	O
2016	O
,	O
of	O
420	O
screened	O
cases	O
,	O
350	O
were	O
eligible	O
and	O
included	O
,	O
of	O
which	O
132	O
(	O
37	O
.	O
7	O
%)	O
had	O
no	O
complication	B-DISO
and	O
218	O
(	O
62	O
.	O
3	O
%)	O
had	O
AO	O
,	O
which	O
included	O
complications	O
like	O
empyema	B-DISO
,	O
pyopneumothorax	B-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
and	O
septic	B-DISO
shock	I-DISO
of	O
these	O
24	O
(	O
6	O
.	O
9	O
%)	O
expired	O
.	O

The	O
effects	O
of	O
dietary	O
yeast	O
nucleotides	O
supplementation	O
on	O
intestinal	O
development	O
,	O
expression	O
of	O
intestinal	O
barrier	O
-	O
related	O
genes	O
,	O
intestinal	O
microbiota	O
,	O
and	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
antibody	O
titer	O
of	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
chickens	O
were	O
investigated	O
.	O

Recent	O
data	O
indicate	O
that	O
dromedaries	O
represent	O
an	O
important	O
source	O
of	O
infection	B-DISO
,	O
although	O
information	O
regarding	O
viral	O
cell	O
tropism	O
and	O
pathogenesis	B-DISO
is	O
sparse	O
.	O

The	O
obtained	O
results	O
promote	O
a	O
better	O
understanding	O
of	O
coronavirus	B-DISO
infections	I-DISO
,	O
which	O
pose	O
major	O
health	O
challenges	O
.	O

Information	O
was	O
collected	O
on	O
demographics	O
,	O
severity	O
scores	O
at	O
admission	O
using	O
RAC	O
and	O
DBC	O
,	O
organ	B-DISO
failure	I-DISO
,	O
mechanical	O
ventilation	O
,	O
continuous	O
renal	O
replacement	O
therapy	O
(	O
CRRT	O
),	O
surgery	O
and	O
mortality	O
.	O

TITLE	O
:	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
and	O
Porcine	O
Deltacoronavirus	O
not	O
Detected	O
in	O
Waterfowl	O
in	O
the	O
North	O
American	O
Mississippi	O
Migratory	O
Bird	O
Flyway	O
in	O
2013	O
.	O

Our	O
results	O
demonstrated	O
that	O
the	O
S	O
-	O
Bac	O
could	O
serve	O
as	O
a	O
safe	O
,	O
easy	O
to	O
manipulate	O
,	O
and	O
effective	O
vaccine	O
candidate	O
against	O
the	O
PEDV	O
infection	B-DISO
.	O

In	O
the	O
current	O
study	O
,	O
recombinant	O
baculoviruses	O
co	O
-	O
expressing	O
the	O
S1	O
and	O
N	O
proteins	O
and	O
mono	B-DISO
-	O
expressing	O
S1	O
or	O
N	O
proteins	O
of	O
the	O
GX	O
-	O
YL5	O
strain	O
of	O
IBV	O
were	O
constructed	O
and	O
prepared	O
into	O
subunit	O
vaccines	O
rHBM	O
-	O
S1	O
-	O
N	O
,	O
rHBM	O
-	O
S1	O
and	O
rHBM	O
-	O
N	O
.	O
The	O
levels	O
of	O
immune	O
protection	O
of	O
these	O
subunit	O
vaccines	O
were	O
evaluated	O
by	O
inoculating	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
chickens	O
at	O
14	O
days	O
of	O
age	O
,	O
giving	O
them	O
a	O
booster	O
with	O
the	O
same	O
dose	O
14	O
days	O
later	O
and	O
challenging	O
them	O
with	O
a	O
virulent	O
GX	O
-	O
YL5	O
strain	O
of	O
IBV	O
14	O
days	O
post	O
-	O
booster	O
(	O
dpb	B-DISO
).	O

Clinical	O
presentation	O
ranges	O
from	O
asymptomatic	B-DISO
infection	I-DISO
to	O
severe	O
infection	B-DISO
including	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
disseminated	O
intravascular	O
coagulopathy	B-DISO
(	O
DIC	B-DISO
)	O
or	O
death	O
.	O

RESULTS	O
:	O
Among	O
24	O
patients	O
,	O
9	O
(	O
37	O
.	O
5	O
%)	O
additionally	O
had	O
at	O
least	O
one	O
of	O
the	O
MAAs	O
examined	O
in	O
this	O
study	O
:	O
1	O
patient	O
was	O
positive	O
for	O
ANA	O
,	O
5	O
for	O
anti	O
-	O
CCP	B-DISO
,	O
5	O
for	O
either	O
anti	O
-	O
SSA	O
or	O
anti	O
-	O
SSB	O
,	O
1	O
for	O
anti	O
-	O
cardiolipin	O
,	O
and	O
1	O
for	O
anti	O
-	O
Scl	O
-	O
70	O
.	O

The	O
relationship	O
between	O
posttraumatic	O
ARDS	B-DISO
severity	O
and	O
financial	O
burden	O
has	O
not	O
been	O
previously	O
studied	O
.	O

By	O
ARDS	B-DISO
severity	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
age	O
,	O
mechanism	O
,	O
or	O
rate	O
of	O
traumatic	O
brain	O
injury	O
.	O

Standardized	O
total	O
hospital	O
charges	O
were	O
fourfold	O
higher	O
for	O
patients	O
who	O
developed	O
ARDS	B-DISO
compared	O
with	O
those	O
who	O
did	O
not	O
develop	O
ARDS	B-DISO
(	O
US	O
$	O
434	O
,	O
000	O
vs	O
.	O
US	O
$	O
96	O
,	O
000	O
;	O
p	O
<	O
0	O
.	O
01	O
).	O

RESULTS	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
occurred	O
in	O
13	O
%	O
(	O
203	O
of	O
1	O
,	O
586	O
).	O

ABSTRACT	O
:	O
Devastating	O
outbreaks	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
)	O
started	O
in	O
China	O
in	O
late	O
2010	O
and	O
rapidly	O
spread	O
to	O
North	O
America	O
and	O
Asia	O
causing	O
severe	B-DISO
diarrhea	I-DISO
and	O
high	O
mortality	O
in	O
neonatal	O
piglets	O
,	O
indicating	O
that	O
a	O
new	O
generation	O
of	O
vaccine	O
against	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
urgently	O
needed	O
.	O

TITLE	O
:	O
Characterization	O
of	O
and	O
factors	O
associated	O
with	O
causes	O
of	O
pleural	B-DISO
effusion	I-DISO
in	O
cats	O
.	O

A	O
chest	O
X	O
-	O
ray	O
showed	O
bilateral	O
infiltration	B-DISO
.	O

The	O
diagnosis	O
of	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
(	O
MODS	B-DISO
)	O
caused	O
by	O
C	O
.	O
pauculus	O
was	O
made	O
.	O

ABSTRACT	O
:	O
Newly	O
approved	O
immunotherapeutic	O
agents	O
,	O
like	O
CTLA	O
-	O
4	O
inhibitors	O
and	O
antibodies	O
against	O
PD	O
-	O
1	O
,	O
are	O
a	O
promising	O
therapeutic	O
option	O
in	O
cancer	B-DISO
therapy	O
.	O

Serum	O
cytokine	O
interleukin	O
(	O
IL	O
)-	O
2	O
and	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
α	O
concentrations	O
were	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
both	O
the	O
4	O
%	O
and	O
6	O
%	O
FVW	O
grousp	O
than	O
in	O
the	O
control	O
and	O
antibiotic	O
groups	O
;	O
IL	O
-	O
4	O
was	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
FVW	O
groups	O
than	O
in	O
the	O
control	O
group	O
;	O
and	O
IL	O
-	O
6	O
was	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
6	O
%	O
FVW	O
group	O
than	O
in	O
the	O
control	O
and	O
antibiotic	O
groups	O
.	O

TITLE	O
:	O
Nucleocapsid	O
protein	O
from	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
isolates	O
can	O
antagonize	O
interferon	O
-	O
λ	O
production	O
by	O
blocking	B-DISO
the	O
nuclear	O
factor	O
-	O
κB	O
nuclear	O
translocation	B-DISO
.	O

hvKp	O
represent	O
a	O
potentially	O
underestimated	O
cause	O
of	O
fatal	O
infections	B-DISO
in	O
the	O
Western	O
world	O
.	O

RESULTS	O
:	O
Over	O
a	O
53	O
-	O
month	O
period	O
,	O
a	O
total	O
of	O
59	O
infections	B-DISO
due	O
to	O
K	O
.	O
pneumoniae	O
were	O
identified	O
including	O
26	O
community	O
-	O
onset	O
infections	B-DISO
.	O

TITLE	O
:	O
Heartfelt	O
sepsis	B-DISO
:	O
microvascular	O
injury	O
due	O
to	O
genomic	O
storm	O
.	O

Microvas	O
-	O
cular	O
endothelial	O
injury	O
in	O
sepsis	B-DISO
due	O
to	O
microbial	O
inflammation	B-DISO
encompasses	O
small	O
blood	O
vessels	O
(<	O
100	O
μm	O
in	O
diameter	O
).	O

This	O
review	O
analyses	O
both	O
new	O
advances	O
in	O
understanding	O
the	O
septic	O
mechanism	O
and	O
possible	O
resolutions	O
of	O
sepsis	B-DISO
.	O

While	O
very	O
early	O
control	O
of	O
sepsis	B-DISO
-	O
causing	O
bacterial	O
,	O
fungal	O
and	O
viral	B-DISO
infections	I-DISO
remains	O
crucial	O
for	O
the	O
treatment	O
of	O
sepsis	B-DISO
,	O
supportive	O
measures	O
are	O
likewise	O
necessary	O
to	O
maintain	O
blood	O
pressure	O
,	O
respiration	O
,	O
and	O
kidney	O
function	O
.	O

The	O
fundamental	O
role	O
of	O
nuclear	O
signalling	O
in	O
the	O
progres	O
-	O
sion	O
and	O
resolution	O
of	O
sepsis	B-DISO
was	O
established	O
with	O
a	O
new	O
class	O
of	O
cell	O
-	O
penetrating	O
nuclear	O
transport	O
modifiers	O
(	O
NTMs	O
).	O

The	O
result	O
is	O
a	O
700	O
-	O
fold	O
reduction	O
in	O
the	O
bacterial	O
burden	O
of	O
the	O
lungs	O
and	O
improvement	O
of	O
sepsis	B-DISO
-	O
associated	O
thrombocytopaenia	O
and	O
blood	O
markers	O
of	O
endothelial	O
injury	O
.	O

ABSTRACT	O
:	O
EU	O
Decision	O
1082	O
/	O
2013	O
/	O
EU	O
on	O
serious	O
cross	O
-	O
border	O
health	O
threats	O
provides	O
a	O
legal	O
basis	O
for	O
collaboration	O
between	O
EU	O
Member	O
States	O
,	O
and	O
between	O
international	O
and	O
European	O
level	O
institutions	O
on	O
preparedness	O
,	O
prevention	O
,	O
and	O
mitigation	O
in	O
the	O
event	O
of	O
a	O
public	O
health	O
emergency	B-DISO
.	O

Based	O
on	O
a	O
documentary	O
review	O
,	O
followed	O
by	O
five	O
week	O
-	O
long	O
country	O
visits	O
involving	O
a	O
total	O
of	O
61	O
interviews	O
and	O
group	O
discussions	O
with	O
experts	O
from	O
both	O
the	O
health	O
and	O
non	O
-	O
health	O
sectors	O
,	O
this	O
qualitative	O
case	O
study	O
has	O
investigated	O
six	O
issues	O
related	O
to	O
preparedness	O
and	O
response	O
to	O
MERS	O
and	O
poliomyelitis	B-DISO
:	O
national	O
plans	O
and	O
overall	O
preparedness	O
capacity	O
;	O
training	O
and	O
exercises	O
;	O
risk	O
communication	O
;	O
linking	O
policy	O
and	O
implementation	O
;	O
interoperability	O
between	O
the	O
health	O
and	O
non	O
-	O
health	O
sectors	O
;	O
and	O
cross	O
-	O
border	O
collaboration	O
.	O

Infectious	B-DISO
disease	I-DISO
outbreaks	O
remain	O
as	O
an	O
ongoing	O
threat	O
.	O

Although	O
preventive	O
measures	O
and	O
the	O
development	O
of	O
drugs	O
have	O
provided	O
some	O
relief	O
from	O
the	O
burden	O
of	O
malaria	B-DISO
,	O
dengue	B-DISO
,	O
and	O
HIV	B-DISO
,	O
the	O
US	O
military	O
continues	O
to	O
fund	O
research	O
and	O
development	O
of	O
prophylactic	O
vaccines	O
that	O
will	O
contribute	O
to	O
force	O
health	O
protection	O
and	O
global	O
health	O
.	O

A	O
logistic	O
regression	O
model	O
identified	O
risk	O
factors	O
associated	O
with	O
developing	O
ARDS	B-DISO
and	O
with	O
worsening	O
severity	O
of	O
disease	O
.	O

Of	O
2704	O
total	O
patients	O
,	O
432	O
(	O
16	O
%)	O
developed	O
ARDS	B-DISO
.	O

Male	O
gender	O
,	O
blunt	O
trauma	O
,	O
severe	O
head	O
and	O
chest	O
injuries	O
,	O
and	O
red	O
blood	O
cell	O
as	O
well	O
as	O
total	O
blood	O
product	O
transfusions	O
are	O
independent	O
risk	O
factors	O
associated	O
with	O
ARDS	B-DISO
.	O

In	O
the	O
present	O
study	O
,	O
we	O
isolated	O
a	O
new	O
Korean	O
PEDV	O
epidemic	O
strain	O
,	O
PED	O
-	O
CUP	B-DISO
-	O
B2014	O
,	O
in	O
Vero	O
cells	O
.	O

Higher	O
serum	O
/	O
colostrum	O
PEDV	O
-	O
specific	O
antibodies	O
and	O
higher	O
neutralizing	O
titers	O
were	O
shown	O
in	O
sows	O
vaccinated	O
with	O
PED	O
-	O
CUP	B-DISO
-	O
B2014	O
compared	O
to	O
unvaccinated	O
sows	O
or	O
sows	O
administered	O
commercial	O
PEDV	O
vaccine	O
.	O

Cytopathic	B-DISO
effects	I-DISO
(	O
CPE	O
)	O
that	O
consisted	O
of	O
enlarged	O
and	O
rounded	O
cells	O
followed	O
by	O
cell	O
shrinkage	O
and	O
detachment	B-DISO
,	O
were	O
identified	O
by	O
the	O
3rd	O
viral	O
passage	O
in	O
the	O
IPEC	O
-	O
J2	O
cells	O
.	O

Given	O
that	O
PEDV	O
infection	B-DISO
occurs	O
in	O
gut	O
epithelial	O
cells	O
mainly	O
via	O
the	O
fecal	O
-	O
oral	O
route	O
,	O
induction	O
of	O
PEDV	O
-	O
specific	O
immune	O
responses	O
in	O
the	O
mucosal	O
compartment	O
is	O
required	O
for	O
protective	O
immunity	O
against	O
viral	B-DISO
infection	I-DISO
.	O

He	O
was	O
diagnosed	O
with	O
pulmonary	B-DISO
blastomycosis	I-DISO
and	O
started	O
therapy	O
with	O
liposomal	O
amphotericin	O
.	O

Whether	O
the	O
gut	O
microbiota	O
plays	O
any	O
role	O
in	O
the	O
development	O
of	O
TRALI	B-DISO
is	O
currently	O
unknown	O
.	O

BF	O
fecal	O
matter	O
transferred	O
into	O
SPF	O
mice	O
significantly	O
restored	O
TRALI	B-DISO
susceptibility	O
in	O
SPF	O
mice	O
.	O

Moreover	O
,	O
ARDS	B-DISO
RCTs	O
strictly	O
adhere	O
to	O
lung	O
-	O
protective	O
strategies	O
,	O
while	O
ARDS	B-DISO
observational	O
studies	O
continually	O
demonstrate	O
variable	O
compliance	O
.	O

Neurologic	B-DISO
signs	I-DISO
,	O
petechial	O
hemorrhages	B-DISO
and	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
constitute	O
the	O
characteristic	O
presenting	O
triad	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
effect	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
on	O
microRNA	O
expression	O
profiles	O
of	O
porcine	O
kidney	O
15cell	O
(	O
PK	O
-	O
15	O
),	O
total	O
RNA	O
was	O
isolated	O
from	O
PK	O
-	O
15	O
cells	O
with	O
or	O
without	O
PEDV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
The	O
major	O
mechanism	O
of	O
antibody	O
-	O
mediated	O
neutralization	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
involves	O
competition	O
with	O
the	O
cellular	O
receptor	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
)	O
for	O
binding	O
to	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
epidemiology	O
in	O
domestic	O
pigs	O
,	O
virus	O
isolation	O
and	O
identification	O
were	O
carried	O
out	O
in	O
pig	O
herds	O
in	O
Shanghai	O
and	O
Jiangsu	O
province	O
.	O

TITLE	O
:	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
in	O
the	O
Operating	O
Room	O
and	O
Prone	O
Ventilation	O
:	O
A	O
Case	O
Report	O
.	O

This	O
case	O
report	O
describes	O
an	O
example	O
in	O
which	O
intraoperative	O
prone	O
positioning	O
improved	O
oxygenation	O
in	O
a	O
patient	O
after	O
aspiration	B-DISO
of	O
gastric	O
contents	O
on	O
induction	O
of	O
general	O
anesthesia	B-DISO
.	O

Influenza	B-DISO
A	O
""""	O
equivocal	O
""""	O
and	O
""""	O
no	O
-	O
subtype	O
""""	O
samples	O
by	O
FilmArray	O
were	O
further	O
compared	O
to	O
a	O
laboratory	O
-	O
developed	O
Influenza	B-DISO
A	O
/	O
B	O
test	O
.	O

Equivocal	O
""""	O
and	O
""""	O
no	O
-	O
subtype	O
""""	O
samples	O
by	O
FilmArray	O
mostly	O
represented	O
weak	O
Influenza	B-DISO
A	O
by	O
laboratory	O
-	O
developed	O
test	O
.	O

TITLE	O
:	O
Comparison	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
outcome	O
for	O
influenza	B-DISO
-	O
associated	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
in	O
Japan	O
between	O
2009	O
and	O
2016	O
.	O

This	O
project	O
involves	O
adequate	O
respiratory	O
management	O
for	O
severe	O
respiratory	B-DISO
failure	I-DISO
using	O
ECMO	O
.	O

ABSTRACT	O
:	O
Hand	O
washing	O
is	O
an	O
effective	O
way	O
to	O
prevent	O
transmission	O
of	O
infectious	B-DISO
diseases	I-DISO
.	O

Our	O
study	O
aimed	O
to	O
examine	O
associations	O
between	O
hand	O
-	O
washing	O
education	O
and	O
self	O
-	O
reported	O
hand	O
-	O
washing	O
behaviors	O
among	O
Korean	O
adults	O
during	O
the	O
year	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
outbreak	O
.	O

Well	O
-	O
organized	O
campaigns	O
that	O
consider	O
these	O
factors	O
are	O
needed	O
to	O
prevent	O
infectious	B-DISO
diseases	I-DISO
.	O

CONCLUSIONS	O
:	O
The	O
management	O
of	O
patients	O
with	O
possible	O
MERS	O
-	O
CoV	O
infection	B-DISO
requires	O
medical	O
facilities	O
with	O
trained	O
personnel	O
,	O
and	O
rapid	O
access	O
to	O
virological	O
results	O
.	O

However	O
,	O
MERS	O
-	O
CoV	O
-	O
induced	O
severe	O
respiratory	B-DISO
disease	I-DISO
in	O
humans	O
is	O
associated	O
with	O
high	O
viral	O
loads	O
in	O
the	O
lower	O
respiratory	O
tract	O
,	O
which	O
may	O
be	O
difficult	O
to	O
achieve	O
in	O
nonhuman	O
primate	O
models	O
.	O

Considering	O
this	O
limitation	O
,	O
we	O
wanted	O
to	O
ascertain	O
the	O
effectiveness	O
of	O
using	O
a	O
MERS	O
-	O
CoV	O
infectious	B-DISO
clone	O
(	O
icMERS	O
-	O
0	O
)	O
previously	O
shown	O
to	O
replicate	O
to	O
higher	O
titers	O
than	O
the	O
wild	O
-	O
type	O
EMC	B-DISO
2012	O
strain	O
.	O

Overall	O
,	O
respiratory	B-DISO
disease	I-DISO
was	O
mild	O
and	O
transient	O
,	O
resolving	O
by	O
day	O
30	O
post	O
-	O
infection	B-DISO
.	O

It	O
has	O
been	O
used	O
for	O
more	O
than	O
50	O
years	O
for	O
the	O
treatment	O
of	O
nasal	B-DISO
congestion	I-DISO
caused	O
by	O
rhinitis	B-DISO
/	O
sinusitis	B-DISO
.	O

In	O
42	O
samples	O
(	O
15	O
.	O
6	O
%),	O
coinfections	B-DISO
with	O
2	O
or	O
more	O
respiratory	O
viruses	O
were	O
detected	O
,	O
with	O
enterovirus	O
/	O
rhinovirus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
human	O
metapneumovirus	O
,	O
and	O
adenovirus	B-DISO
being	O
identified	O
as	O
the	O
most	O
common	O
agents	O
in	O
viral	O
coinfections	B-DISO
in	O
these	O
patients	O
.	O

A	O
total	O
of	O
96	O
laboratories	O
from	O
79	O
countries	O
participating	O
in	O
the	O
PTP	B-DISO
,	O
with	O
76	O
of	O
96	O
(	O
79	O
.	O
2	O
%)	O
reporting	O
correct	O
MERS	O
-	O
CoV	O
results	O
for	O
all	O
nine	O
scored	O
specimens	O
.	O

A	O
further	O
10	O
laboratories	O
(	O
10	O
.	O
4	O
%)	O
scored	O
correctly	O
in	O
eight	O
of	O
nine	O
specimens	O
of	O
the	O
PTP	B-DISO
.	O

The	O
data	O
analyzed	O
refer	O
to	O
the	O
patient	O
,	O
event	O
,	O
type	O
of	O
resuscitation	O
performed	O
,	O
and	O
clinical	O
situation	O
after	O
resuscitation	O
and	O
at	O
arrival	O
to	O
the	O
PICU	O
;	O
results	O
of	O
additional	O
tests	O
;	O
and	O
clinical	O
evolution	O
and	O
neurological	O
status	O
at	O
discharge	O
from	O
the	O
PICU	O
(	O
categorized	O
as	O
death	O
,	O
severe	O
encephalopathy	B-DISO
,	O
or	O
normal	O
).	O

The	O
considered	O
potential	O
prognostic	O
factors	O
were	O
whether	O
drowning	O
was	O
witnessed	O
,	O
the	O
type	O
of	O
initial	O
resuscitation	O
,	O
Glasgow	O
Coma	B-DISO
Scale	O
score	O
at	O
admission	O
,	O
pupil	O
status	O
and	O
reactivity	O
,	O
and	O
pH	O
.	O
One	O
hundred	O
thirty	O
-	O
one	O
patients	O
were	O
registered	O
.	O

TIMP	O
-	O
3	O
was	O
significantly	O
higher	O
among	O
subjects	O
who	O
developed	O
ARDS	B-DISO
compared	O
with	O
those	O
who	O
did	O
not	O
(	O
median	O
2810	O
pg	O
/	O
mL	O
vs	O
.	O
2260	O
pg	O
/	O
mL	O
,	O
p	O
=	O
0	O
.	O
008	O
),	O
and	O
significantly	O
higher	O
among	O
subjects	O
who	O
died	O
than	O
among	O
those	O
who	O
survived	O
to	O
discharge	O
(	O
median	O
2960	O
pg	O
/	O
mL	O
vs	O
.	O
2080	O
pg	O
/	O
mL	O
,	O
p	O
<	O
0	O
.	O
001	O
).	O

TITLE	O
:	O
Hepatitis	B-DISO
C	I-DISO
virus	O
enters	O
liver	O
cells	O
using	O
the	O
CD81	O
receptor	O
complex	O
proteins	O
calpain	O
-	O
5	O
and	O
CBLB	O
.	O

ABSTRACT	O
:	O
Hepatitis	B-DISO
C	I-DISO
virus	O
(	O
HCV	O
)	O
and	O
the	O
malaria	B-DISO
parasite	O
Plasmodium	O
use	O
the	O
membrane	O
protein	O
CD81	O
to	O
invade	O
human	O
liver	O
cells	O
.	O

Knockout	O
of	O
CAPN5	O
and	O
CBLB	O
reduced	O
susceptibility	O
to	O
all	O
tested	O
HCV	O
genotypes	O
,	O
but	O
not	O
to	O
other	O
enveloped	O
viruses	O
such	O
as	O
vesicular	B-DISO
stomatitis	I-DISO
virus	O
and	O
human	O
coronavirus	O
.	O

However	O
,	O
the	O
increased	O
airway	O
pressures	O
resulting	O
from	O
the	O
recruitment	B-DISO
maneuver	O
may	O
induce	O
cardiac	O
dysfunction	O
,	O
limiting	O
the	O
benefit	O
of	O
this	O
maneuver	O
.	O

At	O
peak	O
positive	O
end	O
-	O
expiratory	O
pressure	O
during	O
the	O
recruitment	B-DISO
maneuver	O
,	O
the	O
arterial	O
pressure	O
,	O
cardiac	O
output	O
,	O
left	O
ventricular	O
size	O
decreased	O
and	O
right	O
ventricular	O
size	O
increased	O
.	O

Fifty	O
percent	O
of	O
patients	O
were	O
nonresponders	O
and	O
demonstrated	O
a	O
lower	O
hemodynamic	O
tolerance	B-DISO
to	O
the	O
recruitment	B-DISO
maneuver	O
than	O
responders	O
.	O

All	O
hemodynamic	O
variables	O
returned	O
to	O
their	O
baseline	O
value	O
after	O
the	O
recruitment	B-DISO
maneuver	O
despite	O
a	O
higher	O
positive	O
end	O
-	O
expiratory	O
pressure	O
.	O

TITLE	O
:	O
Etoposide	O
and	O
Corticosteroid	O
Combination	O
Therapy	O
Improves	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
in	O
Mice	O
.	O

However	O
,	O
interruption	O
of	O
inflammatory	O
cytokine	O
activation	O
failed	O
to	O
attenuate	O
ARDS	B-DISO
,	O
suggesting	O
that	O
other	O
therapies	O
are	O
required	O
to	O
treat	O
this	O
illness	O
and	O
improve	O
survival	O
.	O

Leptospirosis	B-DISO
is	O
an	O
infectious	B-DISO
vasculitis	B-DISO
,	O
which	O
can	O
occur	O
with	O
different	O
clinical	O
features	O
.	O

A	O
six	O
-	O
year	O
-	O
old	O
boy	O
presented	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
shock	O
,	O
thrombocytopenia	O
-	O
associated	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
,	O
and	O
persistent	O
high	O
fever	O
secondary	O
to	O
leptospirosis	B-DISO
.	O

After	O
adjustment	O
for	O
age	O
,	O
injury	O
complexity	O
,	O
injury	O
mechanism	O
,	O
and	O
physiologic	O
variables	O
,	O
PT	O
-	O
ARDS	B-DISO
was	O
found	O
to	O
be	O
independently	O
associated	O
with	O
higher	O
mortality	O
(	O
adjusted	O
OR	O
1	O
.	O
33	O
,	O
95	O
%	O
CI	O
1	O
.	O
18	O
-	O
1	O
.	O
51	O
,	O
p	O
<	O
0	O
.	O
001	O
).	O

RESULTS	O
:	O
PT	O
-	O
ARDS	B-DISO
was	O
identified	O
in	O
0	O
.	O
5	O
%	O
(	O
2660	O
/	O
488	O
,	O
381	O
)	O
of	O
the	O
analysis	O
cohort	O
,	O
with	O
an	O
associated	O
mortality	O
of	O
18	O
.	O
6	O
%	O
(	O
494	O
/	O
2660	O
).	O

After	O
adjustment	O
for	O
age	O
,	O
injury	O
complexity	O
,	O
injury	O
mechanism	O
,	O
and	O
physiologic	O
variables	O
,	O
PT	O
-	O
ARDS	B-DISO
was	O
found	O
to	O
be	O
independently	O
associated	O
with	O
higher	O
mortality	O
(	O
adjusted	O
OR	O
1	O
.	O
33	O
,	O
95	O
%	O
CI	O
1	O
.	O
18	O
-	O
1	O
.	O
51	O
,	O
p	O
<	O
0	O
.	O
001	O
).	O

Consequently	O
,	O
cardiac	O
glycosides	O
have	O
emerged	O
as	O
potential	O
broad	O
-	O
spectrum	O
antiviral	O
drugs	O
,	O
with	O
the	O
great	O
advantage	O
of	O
targeting	O
cell	O
host	O
proteins	O
,	O
which	O
help	O
to	O
minimize	O
resistance	O
to	O
antiviral	O
treatments	O
,	O
making	O
them	O
a	O
very	O
promising	O
strategy	O
against	O
human	O
viral	B-DISO
infections	I-DISO
.	O

Therefore	O
,	O
understanding	O
how	O
hCoV	O
-	O
host	O
interactions	O
cause	O
pathogenic	O
outcomes	O
relies	O
upon	O
mammalian	O
models	O
that	O
closely	O
recapitulate	O
the	O
pathogenesis	B-DISO
of	O
hCoVs	O
in	O
humans	O
.	O

HVHF	O
is	O
a	O
potential	O
method	O
for	O
improvement	O
of	O
chlorine	O
-	O
induced	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
and	O
worsening	O
hypoxemia	O
.	O

TITLE	O
:	O
Time	O
-	O
calibrated	O
phylogenomics	O
of	O
the	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
:	O
genome	O
-	O
wide	O
insights	O
into	O
the	O
spatio	O
-	O
temporal	O
dynamics	O
.	O

TITLE	O
:	O
Periodic	O
Fluctuation	B-DISO
of	O
Tidal	O
Volumes	O
Further	O
Improves	O
Variable	O
Ventilation	O
in	O
Experimental	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
.	O

ABSTRACT	O
:	O
In	O
experimental	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
random	O
variation	O
of	O
tidal	O
volumes	O
(	O

ABSTRACT	O
:	O
Epidemics	O
such	O
as	O
SARS	B-DISO
and	O
H7N9	O
have	O
caused	O
huge	O
negative	O
impacts	O
on	O
population	O
health	O
and	O
the	O
economy	O
in	O
China	O
.	O

To	O
provide	O
the	O
results	O
of	O
an	O
analysis	O
of	O
impacts	O
of	O
SARS	B-DISO
and	O
H7N9	O
based	O
on	O
feedback	O
from	O
documents	O
,	O
informants	O
,	O
and	O
focus	O
groups	O
on	O
events	O
during	O
the	O
SARS	B-DISO
and	O
H7N9	O
outbreaks	O
.	O

The	O
rRT	O
-	O
PCR	O
results	O
were	O
positive	O
for	O
PDCoV	O
(	O
29	O
/	O
172	O
,	O
16	O
.	O
9	O
%),	O
PEDV	O
(	O
36	O
/	O
172	O
,	O
20	O
.	O
9	O
%),	O
TGEV	O
(	O
2	O
/	O
172	O
,	O
1	O
.	O
2	O
%),	O
and	O
coinfections	B-DISO
(	O
16	O
/	O
172	O
,	O
9	O
.	O
3	O
%).	O

Our	O
results	O
showed	O
that	O
depletion	O
of	O
cholesterol	O
from	O
cells	O
or	O
virions	O
by	O
treating	O
them	O
with	O
methyl	O
-	O
β	O
-	O
cyclodextrin	O
(	O
MβCD	O
)	O
diminished	O
PDCoV	O
infection	B-DISO
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

TITLE	O
:	O
Overview	O
of	O
three	O
influenza	B-DISO
seasons	O
in	O
Georgia	O
,	O
2014	O
-	O
2017	O
.	O

In	O
Georgia	O
influenza	B-DISO
virus	O
activity	O
occurred	O
mainly	O
from	O
December	O
through	O
March	O
in	O
all	O
seasons	O
,	O
with	O
varying	O
peak	O
weeks	O
and	O
predominating	O
viruses	O
.	O

Around	O
one	O
third	O
of	O
ILI	O
/	O
SARI	O
cases	O
were	O
associated	O
with	O
influenza	B-DISO
caused	O
by	O
antigenically	O
and	O
genetically	O
distinct	O
influenza	B-DISO
viruses	O
over	O
the	O
course	O
of	O
the	O
three	O
seasons	O
.	O

CONCLUSIONS	O
:	O
In	O
Georgia	O
influenza	B-DISO
virus	O
activity	O
occurred	O
mainly	O
from	O
December	O
through	O
March	O
in	O
all	O
seasons	O
,	O
with	O
varying	O
peak	O
weeks	O
and	O
predominating	O
viruses	O
.	O

Overall	O
,	O
the	O
use	O
of	O
rice	O
hull	O
flushes	B-DISO
effectively	O
reduced	O
the	O
quantity	O
of	O
detectible	O
RNA	O
present	O
after	O
mixing	O
a	O
batch	O
of	O
PEDV	O
-	O
positive	O
feed	O
.	O

Their	O
cytotoxicity	B-DISO
and	O
the	O
underlying	O
mechanistic	O
signaling	O
axes	O
have	O
been	O
extensively	O
documented	O
,	O
but	O
only	O
a	O
few	O
anti	O
-	O
viral	O
activities	O
of	O
cardenolides	O
and	O
the	O
associated	O
signaling	O
pathways	O
have	O
been	O
reported	O
.	O

An	O
84	O
-	O
year	O
-	O
old	O
man	O
underwent	O
reperfusion	O
therapy	O
for	O
acute	O
left	O
internal	O
carotid	B-DISO
artery	I-DISO
occlusion	I-DISO
;	O
complete	O
reperfusion	O
was	O
achieved	O
.	O

Urosepsis	B-DISO
was	O
diagnosed	O
,	O
and	O
computed	O
tomography	O
revealed	O
massive	O
hemorrhagic	B-DISO
infarction	I-DISO
in	O
the	O
left	O
frontal	O
lobe	O
and	O
diffuse	O
subarachnoid	B-DISO
hemorrhage	I-DISO
.	O

Initial	O
ischemic	O
damage	O
following	O
reperfusion	O
therapy	O
and	O
damage	O
secondary	O
to	O
sepsis	B-DISO
and	O
subarachnoid	B-DISO
hemorrhage	I-DISO
may	O
have	O
led	O
to	O
rapid	O
malignant	O
brain	B-DISO
swelling	I-DISO
in	O
this	O
patient	O
.	O

ABSTRACT	O
:	O
Six	O
years	O
have	O
passed	O
since	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	B-DISO
)	O
coronavirus	O
(	O
MERS	B-DISO
-	O
CoV	O
),	O
a	O
newly	O
emerging	O
infectious	B-DISO
virus	O
,	O
was	O
first	O
reported	O
in	O
2012	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
spectrum	O
of	O
immune	O
responses	O
occurring	O
in	O
patients	O
with	O
MERS	O
during	O
the	O
early	O
period	O
of	O
infection	B-DISO
.	O

Our	O
findings	O
show	O
an	O
association	O
between	O
the	O
early	O
CD8	O
+	O
T	O
-	O
cell	O
response	O
and	O
the	O
severity	O
of	O
the	O
infection	B-DISO
,	O
and	O
also	O
provide	O
basic	O
information	O
that	O
may	O
help	O
to	O
prepare	O
effective	O
control	O
strategies	O
for	O
MERS	O
in	O
humans	O
.	O

ORF3	O
and	O
S	O
proteins	O
were	O
also	O
co	O
-	O
localized	O
at	O
perinuclear	O
compartments	O
and	O
in	O
the	O
vesicle	B-DISO
-	O
like	O
structures	O
in	O
transfected	O
and	O
infected	O
cells	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
risk	O
factors	O
,	O
management	O
,	O
and	O
outcome	O
of	O
postpneumonectomy	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Mortality	O
was	O
higher	O
in	O
severe	O
(	O
25	O
/	O
36	O
,	O
69	O
.	O
4	O
%)	O
than	O
in	O
mild	O
or	O
moderate	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
9	O
/	O
24	O
,	O
37	O
.	O
5	O
%,	O
P	O
=	O
.	O
014	O
).	O

FIPVs	O
are	O
suggested	O
to	O
emerge	O
from	O
feline	O
enteric	O
coronaviruses	O
(	O
FECVs	O
)	O
by	O
acquiring	O
mutations	O
in	O
specific	O
genes	O
in	O
the	O
course	O
of	O
persistent	O
infections	B-DISO
.	O

Several	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
-	O
approved	O
therapies	O
exist	O
that	O
impede	O
activated	O
lymphocytes	O
from	O
entering	O
the	O
CNS	O
thereby	O
limiting	O
new	O
lesion	O
formation	O
in	O
patients	O
with	O
relapse	B-DISO
-	O
remitting	O
forms	O
of	O
MS	O
.	O

ABSTRACT	O
:	O
Exposure	O
to	O
air	O
pollution	O
has	O
molecular	O
and	O
physiologic	O
effects	O
on	O
the	O
lung	O
that	O
may	O
increase	O
the	O
risk	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
after	O
injury	O
.	O

Mice	O
were	O
immunized	O
intranasally	O
with	O
the	O
inactivated	O
split	O
influenza	B-DISO
A	O
(	O
H7N9	O
)	O
virus	O
(	O
A	O
/	O
Shanghai	O
/	O
02	O
/	O
2013	O
)	O
vaccine	O
with	O
or	O
without	O
JY	O
.	O

ABSTRACT	O
:	O
Porcine	O
hemagglutinating	O
encephalomyelitis	B-DISO
virus	O
(	O
PHEV	O
)	O
is	O
a	O
member	O
of	O
the	O
genus	O
betacoronavirus	O
within	O
the	O
family	O
coronaviridae	O
,	O
which	O
invades	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
via	O
peripheral	O
nervous	B-DISO
system	O
and	O
causes	O
encephalomyelitis	B-DISO
or	O
vomiting	B-DISO
and	O
wasting	B-DISO
disease	I-DISO
(	O
VWD	O
)	O
in	O
sucking	O
piglets	O
.	O

TITLE	O
:	O
Safety	O
and	O
efficacy	O
of	O
attenuated	O
classic	O
and	O
variant	O
2	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
candidate	O
vaccines	O
.	O

ABSTRACT	O
:	O
Vaccination	O
programs	O
against	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
in	O
Egypt	O
depend	O
on	O
both	O
classical	O
and	O
/	O
or	O
imported	O
variant	O
IBV	O
strain	O
vaccines	O
.	O

When	O
HBD	B-DISO
2	O
-	O
conjugated	O
S	O
RBD	O
was	O
used	O
to	O
treat	O
THP	O
-	O
1	O
human	O
monocytic	O
cells	O
,	O
the	O
expression	O
levels	O
of	O
antiviral	O
(	O
IFN	O
-	O
β	O
,	O
IFN	O
-	O
γ	O
,	O
MxA	O
,	O
PKR	O
,	O
and	O
RNaseL	O
)	O
and	O
primary	O
immune	O
-	O
inducing	O
(	O
NOD2	O
,	O
TNF	O
-	O
α	O
,	O
IL	O
-	O
1β	O
,	O
and	O
IL	O
-	O
6	O
)	O
molecules	O
were	O
enhanced	O
compared	O
to	O
those	O
expressed	O
after	O
treatment	O
with	O
S	O
RBD	O
only	O
.	O

TITLE	O
:	O
Different	O
intestinal	O
tropism	O
of	O
the	O
G2b	O
Taiwan	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
-	O
Pintung	O
52	O
strain	O
in	O
conventional	O
7	O
-	O
day	O
-	O
old	O
piglets	O
.	O

We	O
describe	O
our	O
experience	O
with	O
three	O
consecutive	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
supported	O
with	O
right	O
jugular	O
-	O
femoral	O
configuration	O
of	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
without	O
therapeutic	O
anticoagulation	O
as	O
an	O
alternative	O
to	O
lung	O
-	O
protective	O
mechanical	O
ventilation	O
.	O

TITLE	O
:	O
Intraoperative	O
initiation	O
of	O
a	O
modified	O
ARDSNet	O
protocol	O
increases	O
survival	O
of	O
septic	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
A	O
Recombinant	O
Newcastle	B-DISO
Disease	I-DISO
Virus	O
(	O
NDV	O
)	O
Expressing	O
S	O
Protein	O
of	O
Infectious	B-DISO
Bronchitis	B-DISO
Virus	O
(	O
IBV	O
)	O
Protects	O
Chickens	O
against	O
IBV	O
and	O
NDV	O
.	O

These	O
derivatives	O
were	O
first	O
evaluated	O
for	O
their	O
inhibitory	O
effect	O
on	O
HIV	B-DISO
-	O
1	O
Reverse	O
Transcriptase	O
(	O
RT	O
)	O
enzyme	O
activity	O
.	O

TITLE	O
:	O
Feed	O
batch	O
sequencing	O
to	O
decrease	O
the	O
risk	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
cross	O
-	O
contamination	O
during	O
feed	O
manufacturing	O
.	O

The	O
results	O
demonstrate	O
sequenced	O
batches	O
had	O
reduced	O
quantities	O
of	O
PEDV	O
RNA	O
although	O
sequenced	O
feed	O
without	O
detectible	O
PEDV	O
RNA	O
by	O
rRT	O
-	O
PCR	O
can	O
be	O
infectious	B-DISO
.	O

Therefore	O
,	O
a	O
sequencing	O
protocol	O
can	O
reduce	O
but	O
not	O
eliminate	O
the	O
risk	O
of	O
producing	O
infectious	B-DISO
PEDV	O
carryover	O
from	O
the	O
first	O
sequenced	O
batch	O
of	O
feed	O
.	O

In	O
contrast	O
to	O
humans	O
,	O
MERS	O
-	O
CoV	O
-	O
exposed	O
dromedaries	O
develop	O
only	O
very	O
mild	O
infections	B-DISO
and	O
exceptionally	O
potent	O
virus	O
-	O
neutralizing	O
antibody	O
responses	O
.	O

Among	O
these	O
seven	O
synthesized	O
compounds	O
,	O
linear	O
reniochalistatin	O
B	O
was	O
found	O
to	O
have	O
potent	O
activity	O
against	O
several	O
cancer	B-DISO
cell	O
lines	O
not	O
shown	O
by	O
the	O
cyclic	O
reniochalistatin	O
B	O
counterpart	O
.	O

It	O
leads	O
to	O
significant	O
respiratory	B-DISO
disease	I-DISO
and	O
among	O
patients	O
with	O
co	O
-	O
morbidities	O
is	O
associated	O
with	O
high	O
mortality	O
.	O

Many	O
patients	O
had	O
underlying	O
co	O
-	O
morbidities	O
,	O
including	O
diabetes	B-DISO
mellitus	I-DISO
(	O
51	O
.	O
9	O
%),	O
hypertension	B-DISO
(	O
46	O
.	O
2	O
%),	O
and	O
chronic	B-DISO
renal	I-DISO
disease	I-DISO
(	O
21	O
.	O
2	O
%).	O

MERS	O
-	O
CoV	O
ICU	O
mortality	O
remains	O
markedly	O
high	O
due	O
to	O
a	O
combination	O
of	O
factors	O
;	O
the	O
disease	O
process	O
of	O
MERS	O
-	O
CoV	O
leads	O
to	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
,	O
particularly	O
respiratory	O
and	O
renal	B-DISO
failure	I-DISO
.	O

RESULTS	O
:	O
The	O
total	O
sample	O
consisted	O
of	O
52	O
laboratory	O
-	O
confirmed	O
MERS	O
-	O
CoV	O
infection	B-DISO
patients	O
.	O

ABSTRACT	O
:	O
The	O
trimeric	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
surface	O
spike	O
(	O
S	O
)	O
glycoprotein	O
consisting	O
of	O
three	O
S1	O
-	O
S2	O
heterodimers	O
binds	O
the	O
cellular	O
receptor	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
and	O
mediates	O
fusion	O
of	O
the	O
viral	O
and	O
cellular	O
membranes	O
through	O
a	O
pre	O
-	O
to	O
postfusion	O
conformation	O
transition	B-DISO
.	O

The	O
BED	B-DISO
multiplex	O
PCR	O
-	O
microarray	O
-	O
assay	O
was	O
able	O
to	O
detect	O
and	O
differentiate	O
four	O
bacteria	O
(	O
Clostridium	O
perfringens	O
,	O
Escherichia	O
coli	O
,	O
Salmonella	B-DISO
enterica	O
Dublin	O
,	O
and	O
Salmonella	B-DISO
enterica	O
Typhimurium	O
),	O
three	O
protozoa	O
(	O
Eimeria	O
zuernii	O
,	O
Eimeria	O
bovis	O
,	O
and	O
Cryptosporidium	O
parvum	O
),	O
and	O
four	O
viruses	O
(	O
bovine	O
torovirus	O
,	O
bovine	O
rotavirus	O
,	O
BCoV	O
,	O
and	O
BVDV	O
)	O
associated	O
with	O
the	O
BED	B-DISO
.	O

TITLE	O
:	O
Arch	O
-	O
shaped	O
multiple	O
-	O
target	O
sensing	O
for	O
rapid	O
diagnosis	O
and	O
identification	O
of	O
emerging	O
infectious	B-DISO
pathogens	O
.	O

Here	O
,	O
we	O
present	O
a	O
novel	O
arch	O
-	O
shaped	O
multiple	O
-	O
target	O
sensor	O
capable	O
of	O
rapid	O
pathogen	O
identification	O
using	O
direct	O
amplification	B-DISO
in	O
clinical	O
samples	O
.	O

In	O
this	O
study	O
,	O
an	O
arch	O
-	O
shaped	O
amplification	B-DISO
containing	O
primer	O
sequences	O
was	O
designed	O
to	O
rapidly	O
amplify	O
multiple	O
targets	O
.	O

TITLE	O
:	O
Isolation	O
and	O
characterization	O
of	O
a	O
highly	O
pathogenic	O
strain	O
of	O
Porcine	O
enteric	O
alphacoronavirus	O
causing	O
watery	B-DISO
diarrhoea	I-DISO
and	O
high	O
mortality	O
in	O
newborn	O
piglets	O
.	O

Genomic	O
analysis	O
reveals	O
that	O
PEAV	O
GDS04	O
shares	O
a	O
close	O
relationship	O
with	O
SADS	O
-	O
CoV	O
and	O
SeACoV	O
.	O
Furthermore	O
,	O
newborn	O
piglets	O
orally	O
challenged	O
with	O
PEAV	O
GDS04	O
developed	O
typical	O
clinical	O
symptoms	O
as	O
watery	B-DISO
diarrhoea	I-DISO
in	O
neonatal	O
piglets	O
.	O

Intracranial	O
inoculation	O
of	O
the	O
CNS	O
of	O
susceptible	O
mice	O
with	O
JHMV	O
results	O
in	O
an	O
acute	O
encephalomyelitis	B-DISO
characterized	O
by	O
widespread	O
dissemination	O
of	O
virus	O
throughout	O
the	O
parenchyma	O
.	O

Sterile	B-DISO
immunity	O
is	O
not	O
acquired	O
,	O
and	O
virus	O
will	O
persist	O
primarily	O
in	O
white	O
matter	O
tracts	O
leading	O
to	O
chronic	O
neuroinflammation	O
and	O
demyelination	B-DISO
.	O

TITLE	O
:	O
The	O
Endonucleolytic	O
RNA	O
Cleavage	O
Function	O
of	O
nsp1	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
Promotes	O
the	O
Production	O
of	O
Infectious	B-DISO
Virus	O
Particles	O
in	O
Specific	O
Human	O
Cell	O
Lines	O
.	O

We	O
examined	O
the	O
biological	O
functions	O
of	O
nsp1	O
in	O
infected	O
cells	O
and	O
its	O
role	O
in	O
virus	O
replication	O
by	O
using	O
wild	O
-	O
type	O
MERS	O
-	O
CoV	O
and	O
two	O
mutant	B-DISO
viruses	O
with	O
specific	O
mutations	O
in	O
the	O
nsp1	O
;	O
one	O
mutant	B-DISO
lacked	O
both	O
biological	O
functions	O
,	O
while	O
the	O
other	O
lacked	O
the	O
RNA	O
cleavage	O
function	O
but	O
retained	O
the	O
translation	O
inhibition	O
function	O
.	O

ABSTRACT	O
:	O
MMPs	O
(	O
Matrix	O
metalloproteinases	O
)	O
and	O
their	O
endogenous	O
tissue	O
inhibitors	O
may	O
contribute	O
to	O
lung	O
injury	O
through	O
extracellular	O
matrix	O
degradation	O
and	O
modulation	O
of	O
inflammation	B-DISO
and	O
fibrosis	B-DISO
.	O

All	O
but	O
9	O
/	O
3	O
patients	O
suffered	B-DISO
from	O
leuco	O
-/	O
thrombocytopenia	O
due	O
to	O
anti	O
-	O
cancer	B-DISO
treatment	O
or	O
underlying	O
disease	O
.	O

All	O
patients	O
after	O
recent	O
allogeneic	O
(	O
allo	O
-)	O
SCT	B-DISO
have	O
died	O
.	O

Discouraging	O
survival	O
rates	O
in	O
patients	O
treated	O
after	O
allo	O
-	O
SCT	B-DISO
do	O
not	O
support	O
the	O
use	O
of	O
ECMO	O
for	O
ARDS	B-DISO
in	O
this	O
patient	O
subgroup	O
.	O

We	O
evaluated	O
the	O
clinical	O
characteristics	O
,	O
management	O
and	O
outcomes	O
of	O
patients	O
that	O
received	O
tracheostomy	O
,	O
in	O
the	O
cohort	O
of	O
patients	O
that	O
developed	O
ARDS	B-DISO
on	O
day	O
1	O
-	O
2	O
of	O
acute	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
,	O
and	O
in	O
a	O
subsequent	O
propensity	O
-	O
matched	O
cohort	O
.	O

Only	O
86	O
/	O
309	O
(	O
27	O
.	O
8	O
%)	O
underwent	O
tracheostomy	O
on	O
or	O
before	O
day	O
7	O
,	O
while	O
the	O
median	O
timing	O
of	O
tracheostomy	O
was	O
14	O
(	O
Q1	O
-	O
Q3	O
,	O
7	O
-	O
21	O
)	O
days	O
after	O
onset	O
of	O
ARDS	B-DISO
.	O

TITLE	O
:	O
NAADP	O
-	O
dependent	O
Ca	O
ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infections	B-DISO
are	O
associated	O
with	O
a	O
significant	O
mortality	O
rate	O
,	O
and	O
existing	O
drugs	O
show	O
poor	O
efficacy	O
.	O

According	O
to	O
Berlin	O
definition	O
of	O
ARDS	B-DISO
,	O
this	O
is	O
defined	O
based	O
on	O
the	O
timings	O
,	O
radiographic	O
changes	O
,	O
edema	B-DISO
formation	O
,	O
and	O
severity	O
on	O
the	O
PaO	O

ABSTRACT	O
:	O
Infectious	B-DISO
Bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
genotype	O
Q1	O
was	O
detected	O
for	O
the	O
first	O
time	O
in	O
China	O
in	O
1996	O
,	O
and	O
then	O
spread	O
worldwide	O
.	O

In	O
this	O
study	O
,	O
we	O
screened	O
egg	O
layer	O
flocks	O
,	O
in	O
the	O
provinces	O
of	O
Alberta	O
(	O
AB	O
)	O
and	O
Saskatchewan	O
(	O
SK	O
),	O
with	O
and	O
without	O
a	O
history	O
of	O
SES	O
for	O
the	O
presence	O
of	O
IBV	O
infection	B-DISO
.	O

Finally	O
,	O
the	O
S1	O
indirect	O
ELISA	O
was	O
applied	O
to	O
detect	O
serum	O
antibodies	O
of	O
3304	O
field	O
samples	O
collected	O
from	O
different	O
pig	O
farms	O
in	O
eastern	O
China	O
,	O
and	O
it	O
presented	O
an	O
overall	O
substantial	O
agreement	O
on	O
the	O
PEDV	O
infection	B-DISO
status	O
.	O

TITLE	O
:	O
γδ	O
T	O
Cells	O
Contribute	O
to	O
the	O
Outcome	O
of	O
Murine	O
Fulminant	O
Viral	B-DISO
Hepatitis	I-DISO
via	O
Effector	O
Cytokines	O
TNF	O
-	O
α	O
and	O
IFN	O
-	O
γ	O
.	O

These	O
results	O
demonstrated	O
that	O
γδ	O
T	O
cells	O
might	O
contribute	O
to	O
the	O
pathogenesis	B-DISO
of	O
MHV	O
-	O
3	O
-	O
induced	O
FVH	O
through	O
the	O
effector	O
cytokines	O
TNF	O
-	O
α	O
and	O
IFN	O
-	O
γ	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
severe	O
form	O
of	O
lung	O
injury	O
characterized	O
by	O
damage	O
to	O
the	O
epithelial	O
barrier	O
with	O
subsequent	O
pulmonary	B-DISO
edema	I-DISO
and	O
hypoxic	B-DISO
respiratory	B-DISO
failure	I-DISO
.	O

TITLE	O
:	O
Structural	O
and	O
Biochemical	O
Characterization	O
of	O
Endoribonuclease	O
Nsp15	O
Encoded	O
by	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
.	O

In	O
this	O
study	O
,	O
we	O
constructed	O
scIAV	O
-	O
S	O
,	O
a	O
single	O
-	O
cycle	O
influenza	B-DISO
A	O
virus	O
pseudotyped	O
with	O
the	O
spike	O
protein	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
and	O
demonstrated	O
that	O
this	O
virus	O
could	O
infect	O
cultured	O
cells	O
and	O
trigger	O
massive	O
syncytium	O
formation	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
infections	I-DISO
are	O
a	O
major	O
cause	O
of	O
morbidity	O
in	O
children	O
and	O
are	O
often	O
caused	O
by	O
viruses	O
.	O

The	O
adjusted	O
odds	O
ratio	O
for	O
hospitalization	O
was	O
estimated	O
in	O
children	O
with	O
infections	B-DISO
caused	O
by	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
metapneumovirus	O
,	O
bocavirus	O
,	O
parainfluenza	B-DISO
viruses	O
,	O
rhinovirus	O
/	O
enterovirus	O
,	O
coronavirus	O
,	O
adenovirus	B-DISO
,	O
and	O
influenza	B-DISO
.	O

Children	O
presenting	O
with	O
ILI	O
caused	O
by	O
RSV	O
and	O
metapneumovirus	O
were	O
at	O
greatest	O
risk	O
for	O
hospitalization	O
,	O
while	O
children	O
with	O
rhinovirus	O
/	O
enterovirus	O
,	O
parainfluenza	B-DISO
,	O
coronavirus	O
,	O
adenovirus	B-DISO
,	O
and	O
influenza	B-DISO
were	O
at	O
lower	O
risk	O
of	O
hospitalization	O
.	O

We	O
report	O
a	O
case	O
of	O
ARDS	B-DISO
after	O
an	O
infection	B-DISO
with	O
H1N1	B-DISO
influenza	I-DISO
A	O
in	O
a	O
33	O
-	O
year	O
-	O
old	O
patient	O
pregnant	O
at	O
27	O
-	O
weeks	O
.	O

Between	O
December	O
2016	O
and	O
December	O
2017	O
,	O
6121	O
samples	O
were	O
collected	O
,	O
and	O
submitted	O
to	O
viral	O
culture	O
and	O
genomic	O
quantification	O
,	O
specifically	O
Parainfluenza	B-DISO
1	O
-	O
4	O
(	O
PIV1	O
-	O
4	O
),	O
Influenza	B-DISO
A	O
and	O
B	O
,	O
Respiratory	O
Syncytial	O
Virus	O
(	O
RSV	O
)	O
A	O
and	O
B	O
,	O
Adenovirus	B-DISO
,	O
Metapneumovirus	O
,	O
Coronavirus	O
,	O
Rhinovirus	O
,	O
and	O
Enterovirus	O
.	O

Little	O
information	O
is	O
available	O
on	O
the	O
role	O
of	O
major	O
traffic	O
hubs	O
,	O
such	O
as	O
airports	O
,	O
in	O
the	O
transmission	O
of	O
respiratory	B-DISO
infections	I-DISO
,	O
including	O
seasonal	O
influenza	B-DISO
and	O
a	O
pandemic	O
threat	O
.	O

Those	O
with	O
a	O
body	O
temperature	O
of	O
>	O
38	O
°	O
C	O
and	O
respiratory	B-DISO
symptoms	I-DISO
were	O
sent	O
to	O
the	O
airport	O
clinic	O
to	O
have	O
an	O
oropharyngeal	O
swab	O
and	O
a	O
bacterial	O
culture	O
.	O

This	O
patient	O
'	O
s	O
GBS	B-DISO
manifested	O
slightly	O
differently	O
,	O
with	O
both	O
sensory	O
and	O
motor	B-DISO
symptoms	I-DISO
of	O
her	O
thoracic	B-DISO
region	O
and	O
lower	O
extremities	O
,	O
with	O
no	O
preceding	O
history	O
indicative	O
of	O
infection	B-DISO
.	O

The	O
main	O
pulmonary	O
side	O
effects	O
are	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
essentially	O
caused	O
by	O
crizotinib	O
,	O
respiratory	B-DISO
infections	I-DISO
,	O
pneumothorax	B-DISO
,	O
and	O
alveolar	O
hemorrhage	B-DISO
.	O

TITLE	O
:	O
Structure	O
-	O
activity	O
relationship	O
studies	O
of	O
lipophilic	O
teicoplanin	O
pseudoaglycon	O
derivatives	O
as	O
new	O
anti	O
-	O
influenza	B-DISO
virus	O
agents	O
.	O

Minor	O
differences	O
in	O
the	O
side	O
chain	O
length	O
as	O
well	O
as	O
lipophilicity	O
appeared	O
to	O
have	O
significant	O
impact	O
on	O
antiviral	O
activity	O
and	O
cytotoxicity	B-DISO
.	O

TITLE	O
:	O
A	O
new	O
severe	O
mutation	O
in	O
the	O
SLC5A7	O
gene	O
related	O
to	O
congenital	B-DISO
myasthenic	I-DISO
syndrome	I-DISO
type	O
20	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
HPV	O
infection	B-DISO
of	O
the	O
external	O
genitalia	O
in	O
men	O
whose	O
female	O
partners	O
have	O
cervical	O
HPV	O
infection	B-DISO
.	O

We	O
obtained	O
samples	O
with	O
nylon	O
swabs	O
from	O
the	O
glans	O
penis	O
,	O
corona	O
,	O
inner	O
layer	O
of	O
the	O
prepuce	O
and	O
penile	O
body	O
and	O
detected	O
different	O
types	O
of	O
HPV	O
infection	B-DISO
using	O
the	O
Hybribio	O
HPV	O
typing	O
kit	O
,	O
PCR	O
and	O
membrane	O
hybridization	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
viruses	O
(	O
IBVs	O
)	O
circulating	O
in	O
Malaysia	O
are	O
classified	O
into	O
two	O
groups	O
as	O
Malaysian	O
QX	O
-	O
like	O
and	O
variant	O
strains	O
.	O

Both	O
strains	O
caused	O
respiratory	O
and	O
kidney	B-DISO
infections	I-DISO
based	O
on	O
immunohistochemistry	O
(	O
IHC	O
),	O
real	O
-	O
time	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
qPCR	O
)	O
and	O
a	O
ciliostasis	O
study	O
;	O
however	O
,	O
the	O
results	O
showed	O
that	O
the	O
QX	O
-	O
like	O
strain	O
was	O
more	O
pathogenic	O
,	O
caused	O
higher	O
mortality	O
and	O
showed	O
higher	O
tissue	O
tropism	O
for	O
the	O
kidney	O
than	O
the	O
variant	O
strain	O
.	O

Our	O
aim	O
was	O
to	O
investigate	O
risk	O
factors	O
and	O
outcome	O
of	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
severe	O
burn	O
patients	O
.	O

Results	O
showed	O
that	O
45	O
patients	O
developed	O
ARDS	B-DISO
(	O
28	O
.	O
3	O
%).	O

Severe	O
ARDS	B-DISO
was	O
recorded	O
in	O
30	O
of	O
these	O
patients	O
,	O
accounting	O
for	O
66	O
.	O
7	O
%.	O

An	O
enrolment	O
system	O
was	O
established	O
for	O
monitoring	O
the	O
CAP	B-DISO
patients	O
with	O
fever	O
.	O

Nowadays	O
,	O
they	O
are	O
easily	O
transmitted	B-DISO
among	O
the	O
continents	O
via	O
vehicles	O
,	O
equipment	O
,	O
and	O
cargo	O
.	O

Both	O
viruses	O
establish	O
an	O
infection	B-DISO
in	O
porcine	O
enterocytes	O
in	O
the	O
small	O
intestine	O
,	O
and	O
their	O
spike	O
(	O
S	O
)	O
proteins	O
play	O
a	O
key	O
role	O
in	O
the	O
virus	O
-	O
cell	O
binding	O
process	O
under	O
unfavorable	O
conditions	O
when	O
the	O
intestine	O
with	O
a	O
low	O
pH	O
is	O
filled	O
with	O
a	O
thick	O
layer	O
of	O
mucus	O
and	O
proteases	O
.	O

Univariate	O
and	O
multivariate	O
analyses	O
tested	O
the	O
association	O
between	O
ΔP	O
(	O
measured	O
at	O
ICU	O
admission	O
(	O
baseline	O
)	O
or	O
24	O
h	O
later	O
(	O
day	O
1	O
))	O
and	O
the	O
development	O
of	O
ARDS	B-DISO
.	O

These	O
patients	O
had	O
higher	O
baseline	O
ΔP	O
than	O
those	O
who	O
did	O
not	O
(	O
mean	O
±	O
SD	O
:	O
12	O
.	O
5	O
±	O
3	O
.	O
1	O
vs	O
9	O
.	O
8	O
±	O
3	O
.	O
4	O
cm	O
H	O
CONCLUSIONS	O
:	O
Among	O
at	O
-	O
risk	O
ICU	O
patients	O
,	O
higher	O
ΔP	O
may	O
identify	O
those	O
who	O
are	O
more	O
likely	O
to	O
develop	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Beginning	O
in	O
December	O
2013	O
,	O
an	O
epidemic	O
of	O
chikungunya	B-DISO
virus	O
(	O
CHIKV	O
)	O
infection	B-DISO
spread	O
across	O
the	O
Caribbean	O
and	O
into	O
virtually	O
all	O
countries	O
in	O
the	O
Western	O
hemisphere	O
,	O
with	O
>	O
2	O
.	O
4	O
million	O
cases	O
reported	O
through	O
the	O
end	O
of	O
2017	O
.	O

TITLE	O
:	O
DPP4	O
inhibition	O
by	O
sitagliptin	O
attenuates	O
LPS	B-DISO
-	O
induced	O
lung	O
injury	O
in	O
mice	O
.	O

Pulmonary	O
vascular	O
endothelial	O
cells	O
(	O
PVECs	O
)	O
function	O
as	O
an	O
important	O
pro	O
-	O
inflammatory	O
source	O
in	O
ARDS	B-DISO
,	O
suggesting	O
that	O
modulation	O
of	O
inflammatory	O
events	O
at	O
the	O
endothelial	O
level	O
may	O
have	O
a	O
therapeutic	O
benefit	O
.	O

Therefore	O
,	O
we	O
evaluated	O
the	O
effects	O
of	O
sitagliptin	O
,	O
a	O
DPP4	O
inhibitor	O
in	O
wide	O
clinical	O
use	O
,	O
on	O
LPS	B-DISO
-	O
induced	O
lung	O
injury	O
in	O
mice	O
and	O
in	O
human	O
lung	O
ECs	O
in	O
vitro	O
.	O

LPS	B-DISO
induced	O
the	O
release	O
of	O
TNFα	O
,	O
IL	O
-	O
6	O
,	O
and	O
IL	O
-	O
8	O
by	O
HLMVECs	O
that	O
were	O
inhibited	O
by	O
sitagliptin	O
.	O

Chlorine	O
,	O
phosgene	O
,	O
hydrogen	O
sulfide	O
,	O
and	O
ammonia	O
are	O
either	O
of	O
intermediate	O
or	O
high	O
water	O
solubility	O
leading	O
to	O
immediate	O
reactions	O
with	O
mucous	O
membranes	O
of	O
the	O
face	B-DISO
,	O
throat	O
,	O
and	O
lungs	O
and	O
rapid	O
symptoms	O
onset	O
after	O
exposure	O
.	O

Management	O
of	O
these	O
patients	O
includes	O
early	O
airway	O
management	O
,	O
lung	O
-	O
protective	O
ventilator	O
strategies	O
,	O
aggressive	B-DISO
pulmonary	O
toilet	O
,	O
and	O
avoidance	O
of	O
volume	B-DISO
overload	I-DISO
.	O

First	O
Discovered	O
from	O
SARS	B-DISO
Coronavirus	O
.	O

Using	O
this	O
joint	O
analysis	O
of	O
the	O
molecular	O
function	O
and	O
phylogeny	O
,	O
our	O
results	O
suggested	O
that	O
SARS	B-DISO
-	O
CoV	O
-	O
cpsR	O
-	O
19	O
could	O
play	O
a	O
role	O
in	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
infection	I-DISO
or	O
pathogenesis	B-DISO
.	O

The	O
discovery	O
of	O
cpsRNAs	O
has	O
paved	O
a	O
way	O
to	O
find	O
novel	O
markers	O
for	O
pathogen	O
detection	O
and	O
to	O
reveal	O
the	O
mechanisms	O
underlying	B-DISO
infection	I-DISO
or	O
pathogenesis	B-DISO
from	O
a	O
different	O
point	O
of	O
view	O
.	O

Based	O
on	O
the	O
symptoms	O
'	O
progress	O
,	O
the	O
cause	O
of	O
ARDS	B-DISO
was	O
thought	O
to	O
be	O
lung	O
injury	O
due	O
to	O
waterproofing	O
spray	O
inhalation	O
,	O
and	O
treatment	O
was	O
accordingly	O
initiated	O
.	O

RESULTS	O
:	O
We	O
observed	O
significantly	O
decreased	O
plasma	O
HRG	O
levels	O
in	O
an	O
acute	B-DISO
pancreatitis	I-DISO
mouse	O
model	O
.	O

ABSTRACT	O
:	O
While	O
general	O
medical	O
practitioners	O
(	O
GPs	B-DISO
)	O
and	O
veterinarians	O
are	O
often	O
the	O
first	O
line	O
responders	O
in	O
the	O
face	B-DISO
of	O
a	O
disease	O
outbreak	O
,	O
pathways	O
to	O
improving	O
the	O
One	O
Health	O
efficacy	O
of	O
these	O
clinicians	O
remain	O
unclear	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
of	O
lung	O
ultrasound	O
in	O
out	O
-	O
of	O
-	O
hospital	O
non	O
-	O
traumatic	O
respiratory	B-DISO
insufficiency	I-DISO
.	O

We	O
planned	O
a	O
case	O
-	O
controlled	O
study	O
in	O
the	O
ULSS	O
5	O
ovest	O
vicentino	O
area	O
(	O
Vicenza	O
-	O
Italy	O
)	O
enrolling	O
subjects	O
with	O
severe	O
dyspnea	B-DISO
caused	O
by	O
cardiac	O
heart	B-DISO
failure	I-DISO
or	O
acute	O
exacerbation	O
of	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
.	O

Our	O
study	O
suggests	O
that	O
cardiac	O
heart	B-DISO
failure	I-DISO
and	O
acute	O
exacerbation	O
of	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
can	O
be	O
considered	O
two	O
indications	O
for	O
pre	O
-	O
hospital	O
ultrasound	O
,	O
and	O
can	O
improve	O
the	O
management	O
of	O
patient	O
with	O
acute	B-DISO
respiratory	I-DISO
insufficiency	I-DISO
.	O

RESULTS	O
:	O
Pre	O
-	O
hospital	O
lung	O
ultrasound	O
had	O
a	O
high	O
specificity	O
(	O
94	O
.	O
4	O
%)	O
and	O
sensitivity	O
(	O
100	O
%)	O
for	O
the	O
correct	O
identification	O
of	O
alveolar	O
interstitial	O
syndrome	B-DISO
using	O
B	O
lines	O
,	O
whereas	O
the	O
percentages	O
obtained	O
with	O
pleural	B-DISO
effusion	I-DISO
were	O
lower	O
(	O
83	O
.	O
3	O
,	O
53	O
.	O
3	O
%,	O
respectively	O
).	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
usually	O
causes	O
mild	O
upper	B-DISO
respiratory	I-DISO
infections	I-DISO
in	O
heathy	O
adults	O
,	O
but	O
may	O
lead	O
to	O
severe	O
complications	O
or	O
mortality	O
in	O
individuals	O
with	O
weakened	O
immune	O
systems	O
.	O

In	O
this	O
study	O
,	O
the	O
Bayesian	O
phylogeography	O
framework	O
was	O
used	O
to	O
investigate	O
the	O
origins	O
and	O
patterns	O
in	O
spatial	O
dissemination	O
of	O
HBV	B-DISO
/	O
C	O
by	O
analyzing	O
East	O
Asian	O
sequences	O
obtained	O
from	O
1992	O
to	O
2010	O
.	O

TITLE	O
:	O
S1	O
Subunit	O
of	O
Spike	O
Protein	O
from	O
a	O
Current	O
Highly	O
Virulent	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
Is	O
an	O
Important	O
Determinant	O
of	O
Virulence	O
in	O
Piglets	O
.	O

TITLE	O
:	O
Upper	B-DISO
respiratory	I-DISO
infections	I-DISO
in	O
a	O
rural	O
area	O
with	O
reduced	O
malaria	B-DISO
transmission	O
in	O
Senegal	O
:	O
a	O
pathogens	O
community	O
study	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
Respiratory	I-DISO
Infections	I-DISO
(	O
ARI	O
)	O
are	O
common	O
causes	O
of	O
febrile	O
illnesses	O
in	O
many	O
settings	O
in	O
Senegal	O
.	O

This	O
study	O
was	O
conducted	O
to	O
explore	O
the	O
pathogens	O
community	O
among	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
in	O
a	O
rural	O
area	O
in	O
Senegal	O
.	O

This	O
could	O
be	O
explained	O
by	O
an	O
HFO	O
-	O
induced	O
right	O
ventricular	O
(	O
RV	O
)	O
dysfunction	O
/	O
failure	O
due	O
to	O
high	O
intrathoracic	O
pressures	O
and	O
hypercapnia	B-DISO
.	O

Patients	O
with	O
aMDA	O
-	O
5	O
dermato	O
-	O
pulmonary	O
syndrome	B-DISO
had	O
a	O
higher	O
hospital	O
mortality	O
than	O
those	O
with	O
AS	O
syndrome	B-DISO
(	O
n	O
=	O
16	O
/	O
19	O
,	O
84	O
%	O
vs	O
.	O
n	O
=	O
8	O
/	O
28	O
,	O
29	O
%;	O
p	O
=	O
0	O
.	O
001	O
).	O

Mortality	O
is	O
high	O
,	O
especially	O
in	O
aMDA	O
-	O
5	O
dermato	O
-	O
pulmonary	O
syndrome	B-DISO
.	O

Patients	O
with	O
aMDA	O
-	O
5	O
dermato	O
-	O
pulmonary	O
syndrome	B-DISO
had	O
a	O
higher	O
hospital	O
mortality	O
than	O
those	O
with	O
AS	O
syndrome	B-DISO
(	O
n	O
=	O
16	O
/	O
19	O
,	O
84	O
%	O
vs	O
.	O
n	O
=	O
8	O
/	O
28	O
,	O
29	O
%;	O
p	O
=	O
0	O
.	O
001	O
).	O

Although	O
fatalities	O
from	O
septicemia	B-DISO
after	O
uterine	O
artery	O
embolization	O
have	O
been	O
reported	O
,	O
aseptic	O
inflammatory	B-DISO
responses	I-DISO
to	O
uterine	O
degeneration	B-DISO
can	O
also	O
lead	O
to	O
multiorgan	B-DISO
failure	I-DISO
.	O

ABSTRACT	O
:	O
SARS	B-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
the	O
causative	O
agent	O
of	O
the	O
large	O
SARS	B-DISO
outbreak	O
in	O
2003	O
,	O
originated	O
in	O
bats	O
.	O

These	O
results	O
revealed	O
81	O
%	O
shared	O
nucleotide	O
identity	O
with	O
human	O
/	O
civet	O
SARS	B-DISO
CoVs	O
,	O
which	O
was	O
more	O
distant	O
than	O
that	O
observed	O
previously	O
for	O
bat	O
SL	O
-	O
CoVs	O
in	O
China	O
.	O

Failure	O
of	O
clinical	O
therapeutic	O
trials	O
prompted	O
the	O
investigation	O
and	O
subsequent	O
discovery	O
of	O
two	O
distinct	O
phenotypes	O
of	O
ARDS	B-DISO
(	O
hyper	O
-	O
inflammatory	O
and	O
hypo	O
-	O
inflammatory	O
)	O
that	O
have	O
different	O
biomarker	O
profiles	O
and	O
clinical	O
courses	O
and	O
respond	O
differently	O
to	O
the	O
random	O
application	O
of	O
positive	O
end	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
and	O
fluid	O
management	O
strategies	O
.	O

High	O
-	O
frequency	O
oscillatory	O
ventilation	O
,	O
application	O
of	O
recruitment	B-DISO
maneuvers	O
,	O
higher	O
PEEP	O
,	O
extracorporeal	O
membrane	O
oxygenation	O
,	O
and	O
alternate	O
modes	O
of	O
mechanical	O
ventilation	O
have	O
failed	O
to	O
show	O
benefit	O
.	O

Hence	O
,	O
infectious	B-DISO
diseases	I-DISO
will	O
remain	O
a	O
major	O
threat	O
to	O
humankind	O
,	O
especially	O
in	O
LMICs	O
,	O
requiring	O
vigilance	O
,	O
surveillance	O
,	O
and	O
new	O
interventions	O
of	O
all	O
types	O
.	O

TITLE	O
:	O
Disease	O
Control	O
Priorities	O
:	O
Improving	O
Health	O
and	O
Reducing	O
Poverty	O
ABSTRACT	O
:	O
Pandemics	O
are	O
large	O
-	O
scale	O
outbreaks	O
of	O
infectious	B-DISO
disease	I-DISO
that	O
can	O
greatly	O
increase	O
morbidity	O
and	O
mortality	O
over	O
a	O
wide	O
geographic	O
area	O
and	O
cause	O
significant	O
economic	O
,	O
social	O
,	O
and	O
political	O
disruption	O
.	O

The	O
2003	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
pandemic	O
and	O
growing	O
concerns	O
about	O
the	O
threat	O
posed	O
by	O
avian	B-DISO
influenza	I-DISO
led	O
many	O
countries	O
to	O
devise	O
pandemic	O
plans	O
(	O
U	O
.	O
S	O
.	O
Department	O
of	O
Health	O
and	O
Human	O
Services	O
2005	O
).	O

TITLE	O
:	O
A	O
review	O
on	O
current	O
trends	O
in	O
the	O
treatment	O
of	O
human	O
infection	B-DISO
with	O
H7N9	O
-	O
avian	B-DISO
influenza	I-DISO
A	O
.	O
ABSTRACT	O
:	O
The	O
H7N9	O
subtype	O
of	O
avian	B-DISO
influenza	I-DISO
is	O
an	O
enzootic	O
and	O
airborne	O
virus	O
which	O
caused	O
an	O
influenza	B-DISO
outbreak	O
in	O
China	O
.	O

Infected	O
individuals	O
mostly	O
worked	O
with	O
poultry	O
,	O
suggesting	O
H7N9	O
virus	O
-	O
infected	O
poultry	O
as	O
the	O
primary	O
source	O
of	O
human	O
infection	B-DISO
.	O

Severe	O
cases	O
are	O
marked	O
by	O
fulminant	O
pneumonia	B-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
encephalopathy	B-DISO
.	O

Subjects	O
at	O
high	O
risk	O
of	O
contracting	O
avian	B-DISO
influenza	I-DISO
H7N9	O
infection	B-DISO
are	O
recommended	O
to	O
receive	O
annual	O
seasonal	O
influenza	B-DISO
vaccination	O
.	O

TITLE	O
:	O
Stimulant	O
and	O
Designer	O
Drug	B-DISO
Use	I-DISO
:	O
Primary	O
Care	O
Management	O
.	O

2	O
)	O
Mutations	O
on	O
the	O
extra	O
domain	O
of	O
SARS	B-DISO
3C	O
-	O
like	O
protease	O
can	O
transform	O
the	O
active	O
catalytic	O
machinery	O
into	O
the	O
inactive	O
collapsed	O
state	O
by	O
structurally	O
-	O
driven	O
allostery	O
.	O

4	O
)	O
Global	O
networks	O
of	O
correlated	O
motions	O
have	O
been	O
identified	O
:	O
for	O
SARS	B-DISO
3C	O
-	O
like	O
protease	O
,	O
N214A	O
inactivates	O
the	O
catalytic	O
machinery	O
by	O
decoupling	O
the	O
network	O
,	O
while	O
STI	O
/	O
A	O
and	O
STIF	O
/	O
A	O
enhance	O
by	O
altering	O
the	O
patterns	O
of	O
the	O
network	O
.	O

TITLE	O
:	O
A	O
convenient	O
colorimetric	O
assay	O
for	O
the	O
quantification	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
and	O
neutralizing	O
antibodies	O
.	O

However	O
,	O
the	O
visual	O
assessment	O
of	O
viral	B-DISO
cytopathic	I-DISO
effects	I-DISO
by	O
operators	O
to	O
determine	O
antibody	O
titers	O
or	O
for	O
viral	O
quantification	O
is	O
a	O
tedious	O
,	O
subjective	O
and	O
time	O
-	O
consuming	O
process	O
,	O
especially	O
when	O
high	O
volume	O
testing	O
is	O
involved	O
.	O

Currently	O
,	O
the	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
in	O
patients	O
with	O
hematologic	B-DISO
malignancies	I-DISO
who	O
develop	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
remains	O
controversial	O
.	O

ABSTRACT	O
:	O
Recently	O
,	O
the	O
use	O
of	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
for	O
adult	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
has	O
increased	O
.	O

In	O
2017	O
the	O
Saudi	O
Ministry	O
of	O
Health	O
released	O
a	O
visual	O
triage	O
system	O
with	O
scoring	O
to	O
alert	O
healthcare	O
workers	O
in	O
emergency	B-DISO
departments	O
(	O
EDs	B-DISO
)	O
and	O
haemodialysis	O
units	O
for	O
the	O
possibility	O
of	O
occurrence	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
scoring	O
system	O
were	O
low	O
,	O
and	O
further	O
refinement	O
of	O
the	O
score	O
is	O
needed	O
for	O
better	O
prediction	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Influenza	B-DISO
viruses	O
and	O
rhinoviruses	O
are	O
responsible	O
for	O
a	O
large	O
number	O
of	O
acute	O
respiratory	O
viral	B-DISO
infections	I-DISO
in	O
human	O
populations	O
and	O
are	O
detected	O
as	O
copathogens	O
within	O
hosts	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
has	O
catastrophic	O
impacts	O
on	O
the	O
global	O
pig	O
industry	O
.	O

TITLE	O
:	O
Extended	O
use	O
of	O
the	O
modified	O
Berlin	O
Definition	O
based	O
on	O
age	O
-	O
related	O
subgroup	O
analysis	O
in	O
pediatric	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Neurotropic	O
strains	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
)	O
induce	O
acute	O
inflammation	B-DISO
and	O
chronic	O
demyelination	B-DISO
in	O
the	O
spinal	O
cord	B-DISO
and	O
optic	O
nerves	O
mediated	O
by	O
axonal	O
spread	O
following	O
intracranial	O
inoculation	O
in	O
mice	O
,	O
with	O
pathologic	O
features	O
similar	O
to	O
the	O
human	O
demyelinating	B-DISO
disease	I-DISO
multiple	B-DISO
sclerosis	I-DISO
.	O

A	O
respiratory	O
multiplex	O
array	O
was	O
performed	O
to	O
detect	O
for	O
influenza	B-DISO
A	O
and	O
B	O
;	O
respiratory	O
syncytial	O
virus	O
A	O
and	O
B	O
;	O
human	O
parainfluenza	B-DISO
virus	O
1	O
-	O
2	O
-	O
3	O
and	O
4	O
;	O
human	O
coronavirus	O
229E	O
and	O
OC43	O
;	O
human	O
rhinovirus	O
;	O
human	O
enterovirus	O
;	O
human	O
adenovirus	B-DISO
;	O
human	O
bocavirus	O
;	O
human	O
metapneumovirus	O
.	O

Influenza	B-DISO
B	O
virus	O
was	O
the	O
most	O
common	O
virus	O
identified	O
in	O
children	O
who	O
were	O
experiencing	O
their	O
first	O
incidence	O
of	O
FS	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Widespread	O
use	O
of	O
the	O
existing	O
quadrivalent	O
influenza	B-DISO
vaccine	O
might	O
be	O
useful	O
for	O
the	O
prevention	O
of	O
FS	O
related	O
to	O
the	O
flu	B-DISO
.	O

ABSTRACT	O
:	O
Electrical	O
impedance	O
tomography	O
(	O
EIT	O
)	O
has	O
been	O
used	O
to	O
guide	O
mechanical	O
ventilation	O
in	O
ICU	O
patients	O
with	O
lung	B-DISO
collapse	I-DISO
.	O

High	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
analyses	O
showed	O
that	O
TGEV	O
infection	B-DISO
leads	O
to	O
reduced	O
arginine	O
uptake	O
at	O
48	O
hours	O
post	O
-	O
infection	B-DISO
(	O
hpi	B-DISO
).	O

TGEV	O
infection	B-DISO
induced	I-DISO
activation	O
of	O
phospho	O
-	O
protein	O
kinase	O
C	O
α	O
(	O
p	O
-	O
PKC	B-DISO
α	O
),	O
phospho	O
-	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
p	O
-	O
EGFR	O
),	O
and	O
enhanced	O
the	O
expression	O
of	O
caveolin	O
-	O
1	O
,	O
all	O
of	O
which	O
appear	O
to	O
be	O
involved	O
in	O
down	O
-	O
regulating	O
arginine	O
uptake	O
and	O
CAT	O
-	O
1	O
expression	O
.	O

TITLE	O
:	O
Knowledge	O
and	O
practices	O
regarding	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
among	O
camel	O
handlers	O
in	O
a	O
Slaughterhouse	O
,	O
Kenya	O
,	O
2015	O
.	O

ABSTRACT	O
:	O
Dromedary	O
camels	O
are	O
implicated	O
as	O
reservoirs	O
for	O
the	O
zoonotic	O
transmission	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
with	O
the	O
respiratory	O
route	O
thought	O
to	O
be	O
the	O
main	O
mode	O
of	O
transmission	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
significant	O
changes	O
in	O
the	O
miRNA	O
composition	O
of	O
EVs	O
in	O
the	O
bronchoalveolar	O
lavage	O
fluid	O
from	O
patients	O
with	O
IAV	O
-	O
induced	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Genetics	O
,	O
antigenicity	O
and	O
virulence	O
properties	O
of	O
three	O
infectious	B-DISO
bronchitis	B-DISO
viruses	O
isolated	O
from	O
a	O
single	O
tracheal	O
sample	O
in	O
a	O
chicken	O
with	O
respiratory	B-DISO
problems	I-DISO
.	O

Lipopolysaccharide	O
was	O
intratracheally	O
administered	O
to	O
rats	O
to	O
establish	O
experimental	O
ARDS	B-DISO
.	O

Even	O
after	O
RM	O
in	O
both	O
groups	O
,	O
the	O
differences	O
in	O
these	O
parameters	O
between	O
the	O
two	O
groups	O
persisted	O
,	O
indicating	O
that	O
the	O
atelectasis	B-DISO
-	O
induced	O
respiratory	B-DISO
dysfunction	I-DISO
observed	O
in	O
the	O
control	O
group	O
is	O
not	O
an	O
easily	O
reversible	O
functional	O
problem	O
.	O

In	O
order	O
to	O
prevent	O
P	O
-	O
SILI	O
,	O
patients	O
are	O
generally	O
heavily	O
sedated	O
and	O
receive	O
muscle	B-DISO
relaxation	I-DISO
,	O
resulting	O
in	O
a	O
slower	O
weaning	O
process	O
.	O

TITLE	O
:	O
Beyond	O
Low	O
Tidal	O
Volume	O
Ventilation	O
:	O
Treatment	O
Adjuncts	O
for	O
Severe	O
Respiratory	B-DISO
Failure	I-DISO
in	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
.	O

The	O
objective	O
of	O
the	O
study	O
reported	O
here	O
was	O
to	O
measure	O
the	O
burden	O
of	O
exposure	O
to	O
infectious	B-DISO
bursal	I-DISO
disease	I-DISO
virus	O
(	O
IBDV	O
),	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
),	O
Newcastle	B-DISO
disease	I-DISO
virus	O
(	O
NDV	O
),	O
Mycoplasma	B-DISO
gallisepticum	O
(	O
MG	O
),	O
and	O
intestinal	B-DISO
parasites	I-DISO
in	O
a	O
sample	O
of	O
broiler	O
chickens	O
on	O
13	O
farms	O
on	O
Santa	O
Cruz	O
Island	O
and	O
San	O
Cristobal	O
Island	O
in	O
July	O
2017	O
.	O

In	O
addition	O
,	O
fecal	O
samples	O
and	O
pen	O
bedding	O
environmental	O
samples	O
were	O
processed	O
and	O
analyzed	O
for	O
diagnosis	O
of	O
intestinal	B-DISO
parasite	I-DISO
eggs	O
under	O
a	O
compound	O
light	O
microscope	O
.	O

In	O
order	O
to	O
determine	O
if	O
TGEV	O
was	O
circulating	O
before	O
the	O
official	O
report	O
,	O
a	O
retrospective	O
study	O
on	O
cases	O
of	O
neonatal	B-DISO
diarrhea	I-DISO
was	O
performed	O
.	O

Data	O
regarding	O
clinical	O
characteristics	O
and	O
infectious	B-DISO
events	O
were	O
recorded	O
.	O

The	O
coinfections	B-DISO
of	O
AIV	O
/	O
NDV	O
,	O
AIV	O
/	O
IBV	O
,	O
NDV	O
/	O
IBV	O
,	O
and	O
AIV	O
/	O
NDV	O
/	O
IBV	O
were	O
observed	O
in	O
13	O
%,	O
4	O
%,	O
23	O
%,	O
and	O
7	O
%	O
of	O
the	O
sampled	O
chickens	O
,	O
respectively	O
.	O

hDPP4	O
+/+	O
mice	O
were	O
unexpectedly	O
more	O
resistant	O
than	O
hDPP4	O
+/-	O
mice	O
to	O
MERS	O
-	O
CoV	O
infection	B-DISO
,	O
as	O
judged	O
by	O
increased	O
LD50	O
,	O
reduced	O
lung	O
viral	B-DISO
infection	I-DISO
,	O
attenuated	O
morbidity	O
and	O
mortality	O
,	O
and	O
reduced	O
histopathology	O
.	O

ABSTRACT	O
:	O
Inhalation	O
of	O
ricin	O
toxin	O
is	O
associated	O
with	O
the	O
onset	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
characterized	O
by	O
hemorrhage	B-DISO
,	O
inflammatory	O
exudates	O
,	O
and	O
tissue	O
edema	B-DISO
,	O
as	O
well	O
as	O
the	O
nearly	O
complete	O
destruction	O
of	O
the	O
lung	O
epithelium	O
.	O

The	O
Research	O
and	O
Development	O
(	O
R	O
&	O
D	O
)	O
Blueprint	O
is	O
a	O
World	O
Health	O
Organization	O
initiative	O
to	O
reduce	O
the	O
time	O
between	O
the	O
declaration	O
of	O
a	O
public	O
health	O
emergency	B-DISO
and	O
the	O
availability	O
of	O
effective	O
diagnostic	O
tests	O
,	O
vaccines	O
,	O
and	O
treatments	O
that	O
can	O
save	O
lives	O
and	O
avert	O
a	O
public	O
health	O
crisis	O
.	O

This	O
report	O
describes	O
a	O
case	O
of	O
a	O
coronavirus	O
-	O
associated	O
cutaneous	B-DISO
nodule	I-DISO
in	O
which	O
the	O
evidence	O
of	O
amino	O
acid	O
changes	O
in	O
the	O
spike	O
protein	O
gene	O
identified	O
by	O
RT	O
-	O
PCR	O
were	O
consistent	O
with	O
an	O
FCoV	O
genotype	O
commonly	O
seen	O
in	O
cases	O
of	O
FIP	B-DISO
.	O

Then	O
,	O
the	O
extended	O
period	O
of	O
controlled	O
mechanical	O
ventilation	O
with	O
paralysis	O
under	O
general	O
anaesthesia	B-DISO
leads	O
to	O
CCU	O
-	O
acquired	O
pathology	B-DISO
,	O
including	O
low	O
cardiac	O
output	O
,	O
myoneuropathy	O
,	O
emergence	O
delirium	B-DISO
and	O
nosocomial	B-DISO
infection	I-DISO
.	O

When	O
the	O
IFNβ	O
expression	O
level	O
in	O
FCoV	O
-	O
infected	O
fcwf	O
-	O
4	O
cells	O
was	O
semi	O
-	O
quantitatively	O
analyzed	O
,	O
infection	B-DISO
with	O
type	O
I	O
FIPV	O
,	O
excluding	O
type	O
I	O
FIPV	O
UCD	O
-	O
1	O
,	O
highly	O
induced	O
IFNβ	O
expression	O
.	O

In	O
contrast	O
,	O
induction	O
of	O
IFNβ	O
by	O
type	O
II	O
FCoV	O
infection	B-DISO
was	O
significantly	O
lower	O
than	O
that	O
by	O
type	O
I	O
FIPV	O
.	O

Also	O
,	O
the	O
proliferation	B-DISO
of	O
type	O
I	O
FIPV	O
was	O
enhanced	O
by	O
a	O
IFN	O
inhibitor	O
.	O

TITLE	O
:	O
Hepatopulmonary	B-DISO
syndrome	I-DISO
-	O
attributed	O
extreme	O
hypoxemia	O
and	O
polycythemia	B-DISO
revealing	O
liver	B-DISO
cirrhosis	I-DISO
.	O

ABSTRACT	O
:	O
With	O
outbreaks	O
of	O
new	O
respiratory	O
viruses	O
such	O
as	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
and	O
swine	O
-	O
origin	O
influenza	B-DISO
A	O
/	O
H1N1	O
,	O
the	O
nucleic	O
acid	O
-	O
based	O
amplification	B-DISO
test	O
was	O
introduced	O
to	O
identify	O
causative	O
agents	O
.	O

The	O
S1	O
subunit	O
from	O
Spike	O
(	O
S	O
)	O
protein	O
plays	O
the	O
major	O
role	O
in	O
protective	O
immunity	O
and	O
is	O
involved	O
in	O
the	O
host	O
-	O
virus	O
interactions	O
,	O
as	O
well	O
as	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
serotyping	O
.	O

Chlordecone	O
targets	O
,	O
and	O
mainly	O
accumulates	O
in	O
,	O
the	O
liver	O
,	O
leading	O
to	O
hepatomegaly	B-DISO
and	O
neurological	O
signs	O
in	O
mammals	O
.	O

Comparing	O
to	O
the	O
parental	O
PEDVPT	O
-	O
P96	O
virus	O
,	O
the	O
iPEDVPT	O
-	O
P96	O
virus	O
showed	O
efficient	O
replication	O
kinetics	O
with	O
a	O
delayed	O
decline	O
of	O
viral	O
load	O
and	O
similar	O
but	O
much	O
more	O
uniform	O
plaque	B-DISO
sizes	O
in	O
Vero	O
cells	O
.	O

TITLE	O
:	O
Corticosteroids	O
in	O
the	O
Management	O
of	O
Severe	O
Coccidioidomycosis	B-DISO
.	O

One	O
was	O
a	O
69	O
-	O
year	O
-	O
old	O
man	O
who	O
had	O
been	O
treated	O
with	O
combination	O
fluconazole	O
and	O
liposomal	O
amphotericin	O
for	O
over	O
6	O
weeks	O
,	O
with	O
persistent	B-DISO
fever	I-DISO
and	O
pneumonia	B-DISO
.	O

The	O
other	O
was	O
a	O
61	O
-	O
year	O
-	O
old	O
man	O
treated	O
with	O
fluconazole	O
and	O
then	O
amphotericin	O
for	O
3	O
weeks	O
,	O
with	O
progression	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
shock	O
.	O

Our	O
study	O
suggest	O
that	O
MERS	O
patients	O
with	O
radiographic	O
score	O
>	O
10	O
on	O
day	O
10	O
from	O
viral	O
exposure	O
require	O
aggressive	B-DISO
therapy	O
with	O
careful	O
surveillance	O
and	O
follow	O
-	O
up	O
evaluation	O
.	O

TITLE	O
:	O
Temporal	O
dynamics	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
in	O
the	O
Arabian	O
Peninsula	O
,	O
2012	O
-	O
2017	O
.	O

EVLW	O
index	O
was	O
measured	O
by	O
the	O
TPTD	O
method	O
,	O
and	O
an	O
index	O
of	O
≥	O
10	O
mL	O
/	O
kg	O
was	O
considered	O
diagnostic	O
of	O
pulmonary	B-DISO
edema	I-DISO
.	O

In	O
ARDS	B-DISO
,	O
the	O
L	O
-	O
US	O
28	O
-	O
zone	O
protocol	O
was	O
more	O
accurate	O
than	O
the	O
4	O
-	O
and	O
8	O
-	O
zone	O
protocols	O
in	O
predicting	O
EVLW	O
.	O

TITLE	O
:	O
Going	O
to	O
Bat	O
(	O
s	O
)	O
for	O
Studies	O
of	O
Disease	O
Tolerance	B-DISO
.	O

Their	O
physiology	O
likely	O
impacted	B-DISO
their	O
history	O
of	O
pathogen	O
exposure	O
and	O
necessitated	O
adaptations	O
that	O
may	O
have	O
also	O
affected	O
immune	O
signaling	O
pathways	O
.	O

ABSTRACT	O
:	O
Speckle	O
tracking	O
echocardiography	O
is	O
a	O
novel	O
echocardiographic	O
technique	O
to	O
assess	O
RV	O
myocardial	O
function	O
but	O
no	O
data	O
are	O
so	O
far	O
available	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
and	O
we	O
aimed	O
at	O
assessing	O
the	O
feasibility	O
of	O
2	O
dimensional	O
(	O
2D	O
)	O
speckle	O
tracking	O
echocardiography	O
and	O
the	O
prognostic	O
role	O
of	O
RV	O
free	O
wall	O
speckle	O
tracking	O
strain	O
in	O
30	O
consecutive	O
patients	O
with	O
moderate	O
-	O
severe	O
ARDS	B-DISO
MATERIALS	O
AND	O
METHODS	O
:	O
In	O
an	O
observational	O
prospective	O
study	O
,	O
30	O
consecutive	O
patients	O
with	O
moderate	O
-	O
severe	O
ARDS	B-DISO
were	O
enrolled	O
.	O

Our	O
study	O
using	O
murine	B-DISO
hepatitis	I-DISO
virus	O
as	O
a	O
model	O
CoV	O
showed	O
that	O
CoV	O
mRNAs	O
are	O
recognized	O
by	O
the	O
NMD	O
pathway	O
as	O
a	O
substrate	O
,	O
resulting	O
in	O
their	O
degradation	O
.	O

Furthermore	O
,	O
CoV	O
replication	O
induced	O
the	O
inhibition	O
of	O
the	O
NMD	O
pathway	O
,	O
and	O
N	O
protein	O
(	O
a	O
viral	O
structural	O
protein	O
)	O
had	O
an	O
NMD	O
inhibitory	O
function	O
that	O
protected	O
viral	O
mRNAs	O
from	O
rapid	O
decay	B-DISO
.	O

ABSTRACT	O
:	O
A	O
61	O
-	O
year	O
-	O
old	O
man	O
presented	O
by	O
ambulance	O
with	O
dyspnea	B-DISO
.	O

Although	O
he	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
on	O
the	O
21st	O
day	O
after	O
operation	O
,	O
he	O
was	O
successfully	O
treated	O
with	O
corticosteroid	O
pulse	O
therapy	O
and	O
artificial	O
ventilation	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
zoonotic	O
pathogen	O
capable	O
of	O
causing	O
severe	O
respiratory	B-DISO
disease	I-DISO
in	O
humans	O
.	O

However	O
,	O
whether	O
ncRNAs	O
participate	O
in	O
TGEV	O
-	O
induced	O
inflammation	B-DISO
in	O
porcine	O
intestinal	O
epithelial	O
cells	O
is	O
largely	O
unknown	O
.	O

TITLE	O
:	O
Early	O
initiation	O
of	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
in	O
a	O
mechanically	O
ventilated	O
patient	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

ABSTRACT	O
:	O
A	O
49	O
-	O
year	O
-	O
old	O
man	O
presented	O
to	O
the	O
emergency	B-DISO
department	O
with	O
acute	O
-	O
onset	O
dyspnoea	B-DISO
and	O
hypoxaemia	O
1	O
day	O
following	O
nasal	O
surgery	O
for	O
obstructive	B-DISO
sleep	I-DISO
apnoea	I-DISO
.	O

Considering	O
both	O
the	O
presence	O
of	O
key	O
ARDS	B-DISO
risk	O
factors	O
and	O
hypoxemia	O
severity	O
can	O
help	O
guide	O
clinicians	O
in	O
identifying	O
patients	O
with	O
diagnosis	O
of	O
ARDS	B-DISO
agreed	O
upon	O
by	O
a	O
consensus	O
of	O
physicians	O
.	O

RESULTS	O
:	O
Among	O
738	O
patients	O
reviewed	O
,	O
110	O
(	O
15	O
%)	O
had	O
consensus	O
-	O
ARDS	B-DISO
,	O
100	O
(	O
14	O
%)	O
had	O
disagreement	O
,	O
and	O
528	O
(	O
72	O
%)	O
did	O
not	O
have	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
infection	B-DISO
causes	O
acute	O
enteritis	B-DISO
in	O
swine	O
of	O
all	O
ages	O
,	O
and	O
especially	O
in	O
suckling	O
piglets	O
.	O

Takotsubo	B-DISO
cardiomyopathy	I-DISO
(	O
TTC	O
),	O
which	O
is	O
typically	O
triggered	O
by	O
psychological	B-DISO
or	O
physical	B-DISO
stress	I-DISO
,	O
is	O
characterized	O
by	O
transient	O
myocardial	B-DISO
dysfunction	I-DISO
affecting	O
the	O
left	O
ventricular	O
apex	O
.	O

Recent	O
reports	O
have	O
suggested	O
that	O
seizures	B-DISO
can	O
also	O
trigger	O
TTC	O
.	O

Underlying	O
causes	O
for	O
pulmonary	B-DISO
edema	I-DISO
and	O
aberrant	O
fluid	O
regulation	O
largely	O
remain	O
unknown	O
,	O
particularly	O
regarding	O
the	O
role	O
of	O
viral	O
-	O
mediated	O
mechanisms	O
.	O

ABSTRACT	O
:	O
The	O
present	O
study	O
describes	O
the	O
association	O
between	O
inflammatory	O
cell	O
types	O
and	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
)	O
antigen	O
in	O
the	O
brain	O
of	O
4	O
cats	O
diagnosed	O
as	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
).	O

Therefore	O
,	O
hospital	O
crisis	O
management	O
should	O
implement	O
efforts	O
to	O
improve	O
hospital	O
workers	O
'	O
preparedness	O
in	O
responding	O
to	O
public	O
health	O
emergencies	B-DISO
caused	O
by	O
infectious	B-DISO
diseases	I-DISO
.	O

A	O
47	O
-	O
year	O
-	O
old	O
man	O
was	O
admitted	O
with	O
progressive	O
shortness	B-DISO
of	I-DISO
breath	I-DISO
.	O

In	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
patients	O
with	O
HIV	B-DISO
/	I-DISO
AIDS	I-DISO
refractory	O
to	O
treatment	O
,	O
ECMO	O
should	O
be	O
considered	O
.	O

Echocardiographic	O
changes	O
due	O
to	O
common	O
chest	O
pathology	B-DISO
.	O

TITLE	O
:	O
Prolyl	O
Hydroxylase	O
Domain	O
-	O
2	O
Protein	O
Regulates	O
Lipopolysaccharide	O
-	O
Induced	O
Vascular	B-DISO
Inflammation	I-DISO
.	O

The	O
local	O
and	O
international	O
response	O
to	O
infectious	B-DISO
disease	I-DISO
epidemics	O
,	O
such	O
as	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
west	O
African	O
Ebola	O
virus	O
epidemic	O
,	O
revealed	O
serious	O
shortcomings	O
which	O
bioterrorists	O
might	O
exploit	O
when	O
intentionally	O
initiating	O
an	O
epidemic	O
.	O

Increased	O
viral	O
RNA	O
in	O
the	O
intestines	O
correlated	O
with	O
the	O
severity	O
of	O
fungus	O
-	O
related	O
pathology	B-DISO
.	O

Our	O
results	O
suggest	O
that	O
the	O
systemic	O
effects	O
of	O
WNS	B-DISO
may	O
down	O
-	O
regulate	O
anti	O
-	O
viral	O
responses	O
in	O
bats	O
persistently	O
infected	O
with	O
M	O
.	O
lucifugus	O
coronavirus	O
and	O
increase	O
the	O
potential	O
of	O
virus	B-DISO
shedding	I-DISO
.	O

TITLE	O
:	O
Transferrin	O
receptor	O
1	O
is	O
a	O
supplementary	O
receptor	O
that	O
assists	O
transmissible	O
gastroenteritis	B-DISO
virus	O
entry	O
into	O
porcine	O
intestinal	O
epithelium	O
.	O

Our	O
study	O
investigated	O
the	O
possibility	O
that	O
TfR1	O
can	O
serve	O
as	O
a	O
receptor	O
for	O
TGEV	O
infection	B-DISO
and	O
enables	O
the	O
invasion	B-DISO
and	O
replication	O
of	O
TGEV	O
.	O

In	O
recent	O
years	O
,	O
however	O
,	O
systemic	O
fatal	O
coronavirus	B-DISO
infection	I-DISO
has	O
emerged	O
in	O
ferrets	O
,	O
which	O
resembles	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
in	O
cats	O
.	O

The	O
results	O
of	O
this	O
study	O
provide	O
support	O
for	O
further	O
research	O
to	O
develop	O
broad	O
-	O
spectrum	O
antiviral	O
agents	O
for	O
multiple	O
coronavirus	B-DISO
infections	I-DISO
.	O

The	O
Mini	O
International	O
Neuropsychiatric	O
Interview	O
and	O
Hospital	O
Anxiety	O
and	O
Depression	B-DISO
Scale	O
were	O
administered	O
to	O
patients	O
undergoing	O
hemodialysis	O
.	O

ABSTRACT	O
:	O
High	O
-	O
flow	O
nasal	O
cannula	O
(	O
HFNC	O
)	O
therapy	O
is	O
increasingly	O
proposed	O
as	O
first	O
-	O
line	O
respiratory	O
support	O
for	O
infants	O
with	O
acute	B-DISO
viral	I-DISO
bronchiolitis	I-DISO
(	O
AVB	O
).	O

Finally	O
,	O
we	O
used	O
this	O
method	O
to	O
refine	O
carbohydrates	O
of	O
the	O
human	O
coronavirus	O
NL63	O
spike	O
glycoprotein	O
and	O
of	O
an	O
HIV	B-DISO
envelope	O
glycoprotein	O
,	O
demonstrating	O
its	O
usefulness	O
for	O
cryoEM	O
refinement	O
.	O

HTG	O
is	O
the	O
third	O
most	O
common	O
cause	O
of	O
acute	B-DISO
pancreatitis	I-DISO
and	O
has	O
been	O
established	O
in	O
the	O
literature	O
as	O
a	O
risk	O
factor	O
when	O
levels	O
are	O
greater	O
than	O
1000	O
mg	O
/	O
dL	O
.	O
A	O
43	O
-	O
year	O
-	O
old	O
patient	O
presented	O
to	O
the	O
hospital	O
with	O
severe	O
epigastric	O
abdominal	B-DISO
pain	I-DISO
.	O

Post	O
hoc	O
Bayesian	O
analysis	O
of	O
data	O
from	O
a	O
randomized	O
clinical	O
trial	O
of	O
early	O
extracorporeal	O
membrane	O
oxygenation	O
compared	O
with	O
conventional	O
lung	O
-	O
protective	O
ventilation	O
with	O
the	O
option	O
for	O
rescue	O
extracorporeal	O
membrane	O
oxygenation	O
among	O
patients	O
with	O
very	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
provides	O
information	O
about	O
the	O
posterior	O
probability	O
of	O
mortality	O
benefit	O
under	O
a	O
broad	O
set	O
of	O
assumptions	O
that	O
may	O
help	O
inform	O
interpretation	O
of	O
the	O
study	O
findings	O
.	O

Herein	O
,	O
we	O
employed	O
a	O
bioinorganic	O
perspective	O
to	O
develop	O
an	O
SAR	O
for	O
inhibition	O
of	O
the	O
metalloenzyme	O
influenza	B-DISO
RNA	O
polymerase	O
PA	O

TITLE	O
:	O
Recombinant	O
infectious	B-DISO
bronchitis	B-DISO
viruses	O
expressing	O
heterologous	O
S1	O
subunits	O
:	O
potential	O
for	O
a	O
new	O
generation	O
of	O
vaccines	O
that	O
replicate	O
in	O
Vero	O
cells	O
.	O

Furthermore	O
,	O
the	O
506	O
-	O
2G10G5	O
monoclonal	O
antibody	O
significantly	O
reduced	O
plaque	B-DISO
formation	O
in	O
MERS	O
-	O
CoV	O
infected	O
Vero	O
cells	O
compared	O
to	O
normal	O
mouse	O
IgG	O
and	O
492	O
-	O
1G10E4E2	O
.	O

We	O
recently	O
developed	O
stabilizing	O
mutations	O
for	O
coronavirus	O
spikes	O
that	O
prevent	O
the	O
transition	B-DISO
from	O
the	O
pre	O
-	O
fusion	O
to	O
post	O
-	O
fusion	O
states	O
.	O

ABSTRACT	O
:	O
It	O
remains	O
uncertain	O
whether	O
invasive	O
ventilation	O
should	O
use	O
low	O
tidal	O
volumes	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
without	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Of	O
the	O
63	O
samples	O
tested	O
for	O
other	O
viruses	O
,	O
58	O
were	O
positive	O
:	O
influenza	B-DISO
H1N1	O
(	O
43	O
.	O
1	O
%	O
of	O
positive	O
samples	O
),	O
rhinovirus	O
/	O
enterovirus	O
(	O
41	O
.	O
4	O
%),	O
respiratory	O
syncytial	O
vírus	O
(	O
12	O
.	O
1	O
%),	O
human	O
metapneumovirus	O
(	O
12	O
.	O
1	O
%),	O
adenovirus	B-DISO
(	O
6	O
.	O
9	O
%),	O
and	O
bocavirus	O
(	O
3	O
.	O
5	O
%).	O

Comparing	O
the	O
groups	O
with	O
mono	B-DISO
-	O
detection	O
and	O
co	O
-	O
dection	O
of	O
any	O
virus	O
,	O
no	O
difference	O
was	O
found	O
regarding	O
the	O
association	O
with	O
any	O
clinical	O
variable	O
.	O

Tissues	O
of	O
small	O
intestines	O
from	O
CHN	B-DISO
-	O
HG	O
-	O
2017	O
-	O
infected	O
piglets	O
at	O
4	O
DPI	O
displayed	O
significant	O
macroscopic	O
and	O
microscopic	O
lesions	O
with	O
clear	O
viral	O
antigen	O
expression	O
.	O

Thus	O
,	O
the	O
permanent	O
monitoring	O
of	O
cases	O
that	O
have	O
occurred	O
and	O
the	O
review	O
of	O
vaccination	O
plans	O
of	O
affected	O
flocks	O
every	O
year	O
are	O
some	O
of	O
the	O
necessary	O
measures	O
needed	O
for	O
strategic	O
control	O
of	O
respiratory	O
syndrome	B-DISO
in	O
broilers	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
characteristics	O
and	O
outcomes	O
of	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
with	O
or	O
without	O
spontaneous	O
breathing	O
and	O
to	O
investigate	O
whether	O
the	O
effects	O
of	O
spontaneous	O
breathing	O
on	O
outcome	O
depend	O
on	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
severity	O
.	O

Patients	O
with	O
spontaneous	O
breathing	O
were	O
older	O
and	O
had	O
lower	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
severity	O
,	O
Sequential	O
Organ	B-DISO
Failure	I-DISO
Assessment	O
scores	O
,	O
ICU	O
and	O
hospital	O
mortality	O
,	O
and	O
were	O
less	O
likely	O
to	O
be	O
diagnosed	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
by	O
clinicians	O
.	O

Previous	O
studies	O
reported	O
miRNA	O
involvement	O
in	O
viral	B-DISO
infection	I-DISO
;	O
however	O
,	O
their	O
role	O
in	O
regulating	O
PEDV	O
infection	B-DISO
remains	O
unknown	O
.	O

The	O
models	O
are	O
applied	O
to	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
and	O
measles	B-DISO
.	O

We	O
conclude	O
that	O
HCoV	O
is	O
common	O
and	O
clinically	O
significant	O
in	O
HSCT	O
recipients	O
,	O
with	O
nearly	O
one	O
-	O
third	O
of	O
patients	O
progressing	O
to	O
proven	O
or	O
probable	O
LRTI	B-DISO
.	O

TITLE	O
:	O
Research	O
agenda	O
on	O
persistent	O
and	O
unpredictable	O
threat	O
of	O
influenza	B-DISO
and	O
emerging	O
respiratory	B-DISO
infections	I-DISO
:	O
a	O
public	O
health	O
necessity	O
in	O
the	O
Eastern	O
Mediterranean	O
Region	O
(	O
Guest	O
Editorial	O
).	O

In	O
addition	O
,	O
the	O
appearance	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
in	O
2003	O
,	O
widespread	O
and	O
continued	O
outbreaks	O
of	O
avian	B-DISO
influenza	I-DISO
A	O
(	O
H5N1	B-DISO
)	O
since	O
2004	O
,	O
the	O
H1N1	O
pandemic	O
in	O
2009	O
and	O
emergence	O
of	O
MERS	O
CoV	O
in	O
2012	O
reflect	O
the	O
seriousness	O
of	O
public	O
health	O
challenges	O
posed	O
by	O
influenza	B-DISO
and	O
emerging	O
respiratory	B-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
ARDS	B-DISO
is	O
an	O
acute	O
inflammatory	O
pulmonary	O
process	O
triggered	O
by	O
severe	O
pulmonary	O
and	O
systemic	O
insults	O
to	O
the	O
alveolar	O
-	O
capillary	O
membrane	O
.	O

TITLE	O
:	O
Hypothesis	O
:	O
Fever	O
control	O
,	O
a	O
niche	O
for	O
alpha	O
-	O
2	O
agonists	O
in	O
the	O
setting	O
of	O
septic	B-DISO
shock	I-DISO
and	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
?	O

Furthermore	O
,	O
after	O
a	O
rigorous	O
control	O
of	O
systemic	O
acidosis	B-DISO
,	O
alpha	O
-	O
2	O
agonists	O
will	O
allow	O
for	O
accelerated	O
emergence	O
without	O
delirium	B-DISO
,	O
early	O
spontaneous	O
ventilation	O
,	O
improved	O
cardiac	O
output	O
and	O
micro	O
-	O
circulation	O
,	O
lowered	O
vasopressor	O
requirements	O
and	O
inflammation	B-DISO
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
life	O
-	O
threatening	O
respiratory	B-DISO
disease	I-DISO
with	O
a	O
high	O
case	O
fatality	O
rate	O
;	O
however	O
,	O
its	O
risk	O
factors	O
remain	O
unclear	O
.	O

Bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
was	O
collected	O
at	O
day	O
3	O
(	O
and	O
day	O
7	O
when	O
the	O
patients	O
were	O
still	O
receiving	O
invasive	O
mechanical	O
ventilation	O
)	O
from	O
the	O
onset	O
of	O
ARDS	B-DISO
.	O

Pulmonary	O
levels	O
of	O
TGF	O
-	O
β1	O
during	O
the	O
first	O
week	O
of	O
ARDS	B-DISO
were	O
not	O
associated	O
nor	O
with	O
the	O
presence	O
of	O
fibroproliferation	O
neither	O
with	O
death	O
.	O

A	O
large	O
multicenter	O
,	O
prospective	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
is	O
ongoing	O
to	O
confirm	O
benefit	O
of	O
NMBAs	O
in	O
early	O
,	O
severe	O
ARDS	B-DISO
when	O
adjusting	O
for	O
limitations	O
of	O
the	O
previous	O
studies	O
.	O

TITLE	O
:	O
Weaning	O
from	O
Mechanical	O
Ventilation	O
in	O
ARDS	B-DISO
:	O
Aspects	O
to	O
Think	O
about	O
for	O
Better	O
Understanding	O
,	O
Evaluation	O
,	O
and	O
Management	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
characterized	O
by	O
severe	O
inflammatory	B-DISO
response	I-DISO
and	O
hypoxemia	O
.	O

These	O
results	O
can	O
be	O
used	O
to	O
develop	O
vaccines	O
against	O
this	O
infection	B-DISO
by	O
employing	O
TGEV	O
antigen	O
coupled	O
to	O
gold	O
nanoparticles	O
as	O
a	O
carrier	O
.	O

ABSTRACT	O
:	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
(	O
PED	B-DISO
)	O
is	O
an	O
acute	O
and	O
highly	O
contagious	O
enteric	O
disease	O
caused	O
by	O
PED	B-DISO
virus	O
(	O
PEDV	O
),	O
characterized	O
by	O
vomitting	O
,	O
watery	B-DISO
diarrhea	I-DISO
and	O
fatal	O
dehydration	B-DISO
with	O
high	O
mortality	O
in	O
sucking	O
piglets	O
of	O
one	O
week	O
of	O
age	O
.	O

A	O
22	O
-	O
year	O
-	O
old	O
male	O
with	O
past	O
medical	O
history	O
of	O
ATD	O
and	O
severe	O
kyphoscoliosis	B-DISO
presented	O
with	O
progressively	O
worsening	O
shortness	B-DISO
of	I-DISO
breath	I-DISO
for	O
several	O
days	O
.	O

LPS	B-DISO
-	O
induced	O
IL	O
-	O
33	O
autocrine	O
upregulated	O
the	O
expression	O
of	O
MMP2	O
and	O
MMP9	O
through	O
activating	O
STAT3	O
.	O

TITLE	O
:	O
MERS	O
coronavirus	O
outbreak	O
:	O
Implications	O
for	O
emerging	O
viral	B-DISO
infections	I-DISO
.	O

Among	O
these	O
neuropathological	O
viruses	O
are	O
the	O
human	O
respiratory	O
syncytial	O
virus	O
(	O
hRSV	O
),	O
the	O
influenza	B-DISO
virus	O
(	O
IV	O
),	O
the	O
coronavirus	O
(	O
CoV	O
)	O
and	O
the	O
human	O
metapneumovirus	O
(	O
hMPV	O
).	O

TITLE	O
:	O
Practice	O
of	O
diagnosis	O
and	O
management	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
mainland	O
China	O
:	O
a	O
cross	O
-	O
sectional	O
study	O
.	O

However	O
,	O
in	O
recent	O
years	O
,	O
cell	O
therapy	O
has	O
shown	O
great	O
promise	O
in	O
preclinical	O
ARDS	B-DISO
studies	O
.	O

This	O
protocol	O
was	O
specifically	O
designed	O
to	O
reach	O
precise	O
and	O
controlled	O
concentrations	O
of	O
sevoflurane	O
or	O
isoflurane	O
in	O
vitro	O
to	O
improve	O
our	O
understanding	O
of	O
mechanisms	O
involved	O
in	O
epithelial	O
lung	O
injury	O
during	O
ARDS	B-DISO
and	O
to	O
test	O
novel	O
therapies	O
for	O
the	O
syndrome	B-DISO
.	O

HCoV	O
was	O
present	O
in	O
9	O
.	O
1	O
%	O
(	O
313	O
/	O
3458	O
)	O
of	O
all	O
RTI	B-DISO
episodes	O
:	O
46	O
.	O
6	O
%	O
OC43	O
,	O
32	O
.	O
3	O
%	O
NL63	O
,	O
16	O
.	O
0	O
%	O
HKU1	O
,	O
and	O
5	O
.	O
8	O
%	O
229E	O
.	O

We	O
highlight	O
the	O
ways	O
in	O
which	O
lung	O
architecture	O
and	O
function	O
is	O
stressed	O
by	O
pregnancy	O
,	O
increasing	O
baseline	O
inflammation	B-DISO
prior	O
to	O
infection	B-DISO
.	O

Thus	O
,	O
we	O
highlight	O
advancements	O
in	O
the	O
field	O
of	O
reproductive	O
immunology	O
in	O
response	O
to	O
viral	B-DISO
infection	I-DISO
and	O
illustrate	O
how	O
that	O
knowledge	O
might	O
be	O
used	O
to	O
develop	O
more	O
effective	O
post	O
-	O
infection	B-DISO
therapies	O
and	O
vaccination	O
strategies	O
.	O

Following	O
this	O
,	O
he	O
was	O
diagnosed	O
with	O
bacterial	B-DISO
pneumonia	I-DISO
and	O
treated	O
with	O
tazobactam	O
/	O
piperacillin	O
;	O
however	O
,	O
he	O
showed	O
little	O
clinical	O
improvement	O
with	O
this	O
treatment	O
approach	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
an	O
emerging	O
zoonotic	O
pathogen	O
discovered	O
in	O
2012	O
.	O

Risk	O
factors	O
for	O
initial	O
and	O
repeated	O
respiratory	O
viral	B-DISO
infections	I-DISO
in	O
young	O
infants	O
in	O
resource	O
-	O
limited	O
settings	O
have	O
not	O
been	O
well	O
described	O
.	O

From	O
2011	O
to	O
2014	O
,	O
a	O
birth	O
cohort	O
of	O
infants	O
in	O
rural	O
Nepal	O
was	O
enrolled	O
and	O
followed	O
with	O
weekly	O
household	O
-	O
based	O
active	O
surveillance	O
for	O
respiratory	B-DISO
symptoms	I-DISO
until	O
6	O
months	O
of	O
age	O
.	O

The	O
risk	O
of	O
primary	O
and	O
repeated	O
infections	B-DISO
with	O
the	O
same	O
virus	O
was	O
evaluated	O
using	O
Poisson	O
regression	O
.	O

Of	O
3528	O
infants	O
,	O
1726	O
(	O
49	O
%)	O
had	O
a	O
primary	B-DISO
infection	I-DISO
,	O
and	O
419	O
(	O
12	O
%)	O
had	O
a	O
repeated	O
infection	B-DISO
.	O

We	O
report	O
the	O
possible	O
association	O
of	O
rhinovirus	O
C	O
and	O
myocarditis	B-DISO
in	O
a	O
child	O
presenting	O
with	O
acute	O
onset	O
of	O
dilated	B-DISO
cardiomyopathy	I-DISO
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
complication	B-DISO
that	O
affects	O
approximately	O
40	O
%	O
of	O
burn	O
patients	O
and	O
is	O
associated	O
with	O
high	O
mortality	O
rates	O
.	O

We	O
retrospectively	O
reviewed	O
all	O
patients	O
treated	O
with	O
ECMO	O
for	O
ARDS	B-DISO
who	O
received	O
their	O
burn	O
care	O
at	O
a	O
single	O
regional	O
burn	O
center	O
between	O
9	O
/	O
1	O
/	O
2006	O
and	O
8	O
/	O
31	O
/	O
2016	O
.	O

Mortality	O
in	O
burn	O
patients	O
with	O
ARDS	B-DISO
who	O
are	O
managed	O
with	O
ECMO	O
is	O
extremely	O
low	O
.	O

Areas	O
covered	O
:	O
This	O
article	O
reviews	O
the	O
evolution	O
of	O
the	O
currently	O
used	O
definition	O
,	O
established	O
pathophysiological	O
mechanism	O
,	O
highlights	O
the	O
current	O
best	O
clinical	O
practice	O
to	O
treat	O
ARDS	B-DISO
,	O
gives	O
a	O
brief	O
outlook	O
on	O
cutting	O
edge	O
trends	O
in	O
ARDS	B-DISO
research	O
and	O
closes	O
with	O
an	O
expert	O
opinion	O
on	O
the	O
subject	O
.	O

The	O
data	O
of	O
3	O
176	O
critically	B-DISO
ill	I-DISO
patients	O
aged	O
≥	O
14	O
years	O
old	O
admitted	O
to	O
the	O
emergency	B-DISO
room	O
of	O
Xuanwu	O
Hospital	O
Capital	O
Medical	O
University	O
from	O
January	O
1st	O
to	O
December	O
31st	O
in	O
2017	O
were	O
analyzed	O
,	O
including	O
gender	O
,	O
age	O
,	O
clinical	O
time	O
,	O
discharge	O
diagnosis	O
,	O
outcomes	O
,	O
etc	O
.	O

Among	O
the	O
3	O
176	O
cases	O
of	O
acute	O
critical	B-DISO
illness	I-DISO
,	O
there	O
were	O
more	O
males	O
than	O
females	O
(	O
1	O
824	O
vs	O
.	O
1	O
352	O
,	O
1	O
.	O
35	O
:	O
1	O
);	O
the	O
age	O
ranged	O
from	O
14	O
to	O
100	O
years	O
old	O
,	O
with	O
an	O
average	O
of	O
(	O
66	O
.	O
52	O
±	O
17	O
.	O
18	O
)	O
years	O
old	O
;	O
the	O
highest	O
incidence	O
age	O
was	O
75	O
-	O
89	O
years	O
old	O
(	O
35	O
.	O
2	O
%,	O
516	O
males	O
and	O
603	O
females	O
),	O
followed	O
by	O
60	O
-	O
70	O
years	O
old	O
(	O
30	O
.	O
0	O
%,	O
572	O
males	O
and	O
381	O
females	O
).	O

Long	O
-	O
term	O
repercussions	O
of	O
critical	B-DISO
illness	I-DISO
due	O
to	O
MERS	O
on	O
HCWs	O
in	O
particular	O
,	O
and	O
patients	O
in	O
general	O
,	O
remain	O
unknown	O
and	O
should	O
be	O
investigated	O
in	O
larger	O
studies	O
.	O

Dengue	B-DISO
Fever	I-DISO
Detecting	O
System	O
Using	O
Peak	O
-	O
detection	O
of	O
Data	O
from	O
Contactless	O
Doppler	O
Radar	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
diseases	I-DISO
,	O
such	O
as	O
dengue	B-DISO
fever	I-DISO
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
,	O
have	O
become	O
prevalent	O
worldwide	O
in	O
recent	O
times	O
.	O

In	O
this	O
study	O
,	O
heartbeat	O
rate	O
(	O
HR	O
),	O
respiration	O
rate	O
(	O
RR	O
),	O
and	O
standard	O
deviation	O
of	O
heartbeat	O
interval	O
(	O
SDHI	O
)	O
were	O
used	O
to	O
quantify	O
the	O
infection	B-DISO
screening	O
system	O
without	O
using	O
facial	O
temperature	O
as	O
a	O
parameter	O
.	O

We	O
found	O
that	O
respiratory	O
sinus	B-DISO
arrhythmia	B-DISO
(	O
RSA	O
)	O
diminished	O
in	O
patients	O
who	O
had	O
dengue	B-DISO
fever	I-DISO
.	O

ABSTRACT	O
:	O
The	O
in	O
ovo	O
delivery	O
of	O
cytosine	O
-	O
guanosine	O
(	O
CpG	O
)	O
oligodeoxynucleotides	O
(	O
ODNs	O
)	O
protects	O
chickens	O
against	O
many	O
bacterial	O
and	O
viral	B-DISO
infections	I-DISO
,	O
by	O
activating	O
the	O
toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
21	O
signaling	O
pathway	O
.	O

Early	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
requiring	I-DISO
reintubation	I-DISO
remains	O
a	O
severe	O
complication	B-DISO
of	O
pneumonectomy	O
with	O
a	O
poor	O
outcome	O
.	O

Four	O
patients	O
had	O
mild	O
OSA	B-DISO
(	O
apnea	B-DISO
-	O
hypopnea	O
index	O
[	O
AHI	O
]	O
≥	O
1	O
.	O
5	O
and	O
<	O
5	O
events	O
/	O
hr	O
),	O
three	O
patients	O
had	O
moderate	O
OSA	B-DISO
(	O
AHI	O
≥	O
5	O
and	O
<	O
10	O
events	O
/	O
hr	O
),	O
and	O
three	O
patients	O
had	O
severe	O
OSA	B-DISO
(	O
AHI	O
≥	O
10	O
events	O
/	O
hr	O
).	O

CPAP	O
and	O
NIV	O
are	O
efficient	O
and	O
well	O
accepted	O
for	O
treating	O
sleep	B-DISO
-	I-DISO
disordered	I-DISO
breathing	I-DISO
.	O

Safety	O
has	O
not	O
been	O
established	O
for	O
administration	O
of	O
MSCs	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
is	O
endemic	O
in	O
South	O
China	O
and	O
is	O
continuing	O
to	O
spread	O
worldwide	O
since	O
the	O
2003	O
outbreak	O
,	O
affecting	O
human	O
population	O
of	O
37	O
countries	O
till	O
present	O
.	O

TITLE	O
:	O
Pathobiological	O
and	O
Genomic	O
Characterization	O
of	O
a	O
Cold	B-DISO
-	O
Adapted	O
Infectious	B-DISO
Bronchitis	B-DISO
Virus	O
(	O
BP	O
-	O
caKII	O
).	O

However	O
,	O
the	O
role	O
of	O
T	O
cells	O
on	O
pulmonary	O
dysfunctions	O
in	O
immune	O
-	O
competent	O
patients	O
with	O
ARDS	B-DISO
is	O
only	O
incompletely	O
understood	O
.	O

TITLE	O
:	O
Characteristics	O
,	O
management	O
,	O
and	O
in	O
-	O
hospital	O
mortality	O
among	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
in	O
intensive	O
care	O
units	O
in	O
Japan	O
:	O
the	O
FORECAST	O
study	O
.	O

ABSTRACT	O
:	O
Upon	O
viral	B-DISO
infection	I-DISO
,	O
the	O
interferon	O
(	O
IFN	O
)	O
system	O
triggers	O
potent	O
antiviral	O
mechanisms	O
limiting	O
viral	O
growth	O
and	O
spread	O
.	O

Hence	O
,	O
to	O
sustain	O
their	O
infection	B-DISO
,	O
viruses	O
evolved	O
efficient	O
counteracting	O
strategies	O
to	O
evade	O
IFN	O
control	O
.	O

Particularly	O
,	O
the	O
efficacious	O
suppression	B-DISO
of	O
the	O
IFN	O
cascade	O
contributes	O
to	O
disease	B-DISO
progression	I-DISO
and	O
severity	O
.	O

ABSTRACT	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
is	O
a	O
fatal	O
infectious	B-DISO
disease	I-DISO
of	O
wild	O
and	O
domestic	O
cats	O
,	O
and	O
the	O
occurrence	O
of	O
FIP	B-DISO
is	O
frequently	O
reported	O
in	O
China	O
.	O

The	O
results	O
revealed	O
that	O
a	O
total	O
of	O
126	O
(	O
74	O
.	O
6	O
%,	O
126	O
/	O
169	O
)	O
samples	O
were	O
positive	O
for	O
FCoV	O
:	O
75	O
.	O
7	O
%	O
(	O
87	O
/	O
115	O
)	O
of	O
the	O
FIP	B-DISO
-	O
suspected	O
samples	O
were	O
positive	O
for	O
FCoV	O
,	O
and	O
72	O
.	O
2	O
%	O
(	O
39	O
/	O
54	O
)	O
of	O
the	O
clinically	O
healthy	O
samples	O
were	O
positive	O
for	O
FCoV	O
.	O
Of	O
the	O
126	O
FCoV	O
-	O
positive	O
samples	O
,	O
95	O
partial	O
S	O
genes	O
were	O
successfully	O
sequenced	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
lncRNA	O
expression	O
profiles	O
during	O
PEDV	O
infection	B-DISO
in	O
intestinal	O
porcine	O
epithelial	O
cell	O
-	O
jejunum	O
2	O
(	O
IPEC	O
-	O
J2	O
)	O
cell	O
lines	O
by	O
next	O
-	O
generation	O
sequencing	O
and	O
identified	O
6188	O
novel	O
lncRNAs	O
.	O

TITLE	O
:	O
Virus	O
neutralization	O
study	O
using	O
H120	O
,	O
H52	O
,	O
793	O
/	O
B	O
antisera	O
against	O
Iranian	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
genotypes	O
.	O

ABSTRACT	O
:	O
BACKGROUND	O
Severe	O
pneumonia	B-DISO
requiring	O
admission	O
to	O
an	O
intensive	O
care	O
unit	O
carries	O
high	O
morbidity	O
and	O
mortality	O
.	O

CASE	O
REPORT	O
A	O
previously	O
healthy	O
,	O
21	O
-	O
year	O
-	O
old	O
man	O
presented	O
with	O
neck	B-DISO
pain	I-DISO
and	O
fever	O
and	O
rapidly	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
requiring	O
mechanical	O
ventilation	O
.	O

TITLE	O
:	O
Trans	O
-	O
Esophageal	O
Doppler	O
Assessment	O
of	O
Acute	O
Hemodynamic	O
Changes	O
Due	O
to	O
Prone	O
Positioning	O
in	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
Patients	O
.	O

It	O
is	O
concluded	O
that	O
inherited	O
metabolic	B-DISO
diseases	I-DISO
may	O
be	O
main	O
causes	O
of	O
Reye	B-DISO
syndrome	I-DISO
and	O
sudden	B-DISO
death	I-DISO
,	O
and	O
biochemical	O
and	O
genetic	O
analyses	O
are	O
the	O
key	O
to	O
identifying	O
underlying	O
diseases	O
.	O

Early	O
empirical	O
systemic	O
heparin	O
anticoagulation	O
for	O
all	O
severe	O
ARDS	B-DISO
patients	O
with	O
possible	O
H1N1	O
viral	B-DISO
pneumonia	I-DISO
was	O
initiated	O
as	O
a	O
VTE	O
preventive	O
strategy	O
.	O

Preparedness	O
and	O
contingency	O
plans	O
for	O
infectious	B-DISO
disease	I-DISO
control	O
for	O
the	O
hotel	O
industry	O
requires	O
continuous	O
engagement	O
and	O
dialogue	O
.	O

Most	O
patients	O
with	O
initial	O
mild	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
continue	O
to	O
fulfill	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
criteria	O
in	O
the	O
first	O
week	O
,	O
and	O
nearly	O
half	O
worsen	O
in	O
severity	O
.	O

RESULTS	O
:	O
Among	O
580	O
patients	O
with	O
initial	O
mild	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
18	O
%	O
(	O
103	O
of	O
580	O
)	O
continuously	O
improved	O
,	O
36	O
%	O
(	O
210	O
of	O
580	O
)	O
had	O
persisting	O
mild	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
and	O
46	O
%	O
(	O
267	O
of	O
580	O
)	O
worsened	O
in	O
the	O
first	O
week	O
after	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
onset	O
.	O

ABSTRACT	O
:	O
In	O
2013	O
,	O
the	O
outbreak	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
)	O
in	O
Taiwan	O
caused	O
serious	O
economic	O
losses	O
.	O

We	O
studied	O
the	O
infection	B-DISO
control	O
influence	O
of	O
MERS	O
-	O
CoV	O
using	O
a	O
hospital	O
-	O
based	O
analysis	O
.	O

Asthma	B-DISO
development	O
has	O
been	O
modeled	O
by	O
administration	O
of	O
virus	O
to	O
immature	O
animals	O
.	O

Nasopharyngeal	O
swabs	O
were	O
tested	O
for	O
influenza	B-DISO
and	O
other	O
common	O
respiratory	O
pathogens	O
.	O

Adults	O
with	O
influenza	B-DISO
were	O
more	O
likely	O
to	O
be	O
hospitalized	O
if	O
they	O
were	O
underweight	O
(	O
OR	O
:	O
5	O
.	O
20	O
),	O
obese	B-DISO
(	O
OR	O
:	O
3	O
.	O
18	O
),	O
or	O
morbidly	O
obese	B-DISO
(	O
OR	O
:	O
18	O
.	O
40	O
)	O
compared	O
to	O
normal	O
-	O
weight	O
adults	O
.	O

There	O
is	O
an	O
increased	O
risk	O
of	O
being	O
hospitalized	O
in	O
adult	O
participants	O
that	O
are	O
underweight	O
or	O
morbidly	O
obese	B-DISO
,	O
regardless	O
of	O
their	O
viral	O
pathogen	O
status	O
.	O

Having	O
influenza	B-DISO
,	O
however	O
,	O
significantly	O
increases	O
the	O
odds	O
of	O
hospitalization	O
in	O
those	O
who	O
are	O
underweight	O
or	O
morbidly	O
obese	B-DISO
.	O

ABSTRACT	O
:	O
In	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
airway	O
pressure	O
release	O
ventilation	O
(	O
APRV	O
)	O
has	O
been	O
purported	O
to	O
have	O
several	O
physiological	O
benefits	O
.	O

Physical	O
examination	O
,	O
laboratory	O
analysis	O
,	O
thoracic	B-DISO
radiography	O
,	O
echocardiography	O
,	O
a	O
computed	O
tomography	O
scan	O
and	O
an	O
ante	O
mortem	O
lung	O
biopsy	O
demonstrated	O
severe	O
arterial	O
hypoxemia	O
and	O
severe	O
PH	O
but	O
were	O
not	O
diagnostic	O
for	O
a	O
known	O
disease	O
syndrome	B-DISO
.	O

Low	O
-	O
dose	O
inhaled	O
carbon	O
monoxide	O
(	O
iCO	O
)	O
confers	O
cytoprotection	O
in	O
preclinical	O
models	O
of	O
sepsis	B-DISO
and	O
ARDS	B-DISO
.	O

We	O
conducted	O
a	O
phase	O
I	O
dose	O
escalation	O
trial	O
to	O
assess	O
feasibility	O
and	O
safety	O
of	O
low	O
-	O
dose	O
iCO	O
administration	O
in	O
patients	O
with	O
sepsis	B-DISO
-	O
induced	O
ARDS	B-DISO
.	O

We	O
recommend	O
the	O
development	O
of	O
pain	O
and	O
sedation	B-DISO
assessment	O
tools	O
specific	O
to	O
this	O
patient	O
population	O
.	O

Suppressing	O
TRIM8	O
markedly	O
ameliorated	O
LPS	B-DISO
-	O
elicited	O
inflammatory	B-DISO
response	I-DISO
,	O
as	O
evidenced	O
by	O
the	O
down	O
-	O
regulated	O
mRNA	O
levels	O
of	O
interleukin	O
-	O
1β	O
(	O
IL	O
-	O
1β	O
),	O
IL	O
-	O
6	O
and	O
tumor	B-DISO
necrosis	I-DISO
factor	O
-	O
α	O
(	O
TNF	O
-	O
α	O
)	O
in	O
cells	O
mainly	O
through	O
inactivating	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
κB	O
)	O
signaling	O
pathway	O
;	O
however	O
,	O
over	O
-	O
expressing	O
TRIM8	O
markedly	O
promoted	O
inflammation	B-DISO
in	O
LPS	B-DISO
-	O
challenged	O
cells	O
.	O

In	O
addition	O
,	O
LPS	B-DISO
-	O
induced	O
oxidative	B-DISO
stress	I-DISO
was	O
accelerated	O
by	O
TRIM8	O
over	O
-	O
expression	O
,	O
while	O
being	O
alleviated	O
by	O
TRIM8	O
knockdown	O
by	O
regulating	O
Nrf2	O
signaling	O
.	O

TITLE	O
:	O
Profile	O
analysis	O
of	O
circRNAs	O
induced	O
by	O
porcine	O
endemic	O
diarrhea	B-DISO
virus	B-DISO
infection	I-DISO
in	O
porcine	O
intestinal	O
epithelial	O
cells	O
.	O

The	O
infant	O
'	O
s	O
initial	O
course	O
was	O
significant	O
for	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
,	O
grade	O
III	O
-	O
IV	O
intraventricular	B-DISO
hemorrhage	I-DISO
(	O
IVH	O
),	O
acute	O
kidney	O
injury	O
,	O
and	O
large	O
PDA	B-DISO
.	O

Serum	O
sodium	O
and	O
urine	B-DISO
output	I-DISO
decreased	I-DISO
and	O
urine	O
osmolality	O
increased	O
after	O
subcutaneous	O
DDAVP	O
administration	O
.	O

ABSTRACT	O
:	O
Previous	O
findings	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)-	O
related	O
viruses	O
in	O
bats	O
,	O
and	O
the	O
ability	O
of	O
Tylonycteris	O
-	O
BatCoV	O
HKU4	O
spike	O
protein	O
to	O
utilize	O
MERS	O
-	O
CoV	O
receptor	O
,	O
human	O
dipeptidyl	O
peptidase	O
4	O
hDPP4	O
,	O
suggest	O
a	O
bat	O
ancestral	O
origin	O
of	O
MERS	O
-	O
CoV	O
.	O
We	O
developed	O
12	O
primary	O
bat	O
cell	O
lines	O
from	O
seven	O
bat	O
species	O
,	O
including	O
Tylonycteris	O
pachypus	O
,	O
Pipistrellus	O
abramus	O
and	O
Rhinolophus	O
sinicus	O
(	O
hosts	O
of	O
Tylonycteris	O
-	O
BatCoV	O
HKU4	O
,	O
Pipistrellus	O
-	O
BatCoV	O
HKU5	O
,	O
and	O
SARS	B-DISO
-	O
related	O
-	O
CoV	O
respectively	O
),	O
and	O
tested	O
their	O
susceptibilities	O
to	O
MERS	O
-	O
CoVs	O
,	O
SARS	B-DISO
-	O
CoV	O
,	O
and	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
).	O

Five	O
cell	O
lines	O
,	O
including	O
P	O
.	O
abramus	O
and	O
R	O
.	O
sinicus	O
but	O
not	O
T	O
.	O
pachypus	O
cells	O
,	O
were	O
susceptible	O
to	O
human	O
MERS	O
-	O
CoV	O
EMC	B-DISO
/	O
2012	O
.	O

While	O
pharmacokinetics	O
of	O
the	O
encapsulated	O
drug	O
is	O
drastically	O
altered	O
resulting	O
in	O
favorable	O
circulation	O
time	O
,	O
improved	O
tumor	B-DISO
accumulation	O
,	O
and	O
better	O
manageable	O
or	O
reduced	O
side	O
effects	O
,	O
therapeutic	O
efficacy	O
has	O
been	O
disappointing	O
.	O

Major	O
drawbacks	O
are	O
a	O
failure	O
to	O
reach	O
the	O
tumor	B-DISO
cell	O
,	O
limited	O
penetration	O
depth	O
,	O
and	O
impaired	B-DISO
uptake	O
by	O
tumor	B-DISO
cells	O
.	O

TITLE	O
:	O
A	O
fatal	O
complication	B-DISO
of	O
tirofiban	O
in	O
an	O
octogenarian	O
:	O
Diffuse	O
alveolar	O
hemorrhage	B-DISO
.	O

TITLE	O
:	O
Evaluation	O
of	O
preparedness	O
of	O
healthcare	O
student	O
volunteers	O
against	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
Makkah	O
,	O
Saudi	O
Arabia	O
:	O
a	O
cross	O
-	O
sectional	O
study	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
knowledge	O
and	O
attitude	O
of	O
senior	O
medical	O
,	O
dental	O
,	O
nursing	O
and	O
pharmacy	O
students	O
toward	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
-	O
corona	O
virus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
Saudi	O
Arabia	O
.	O

It	O
causes	O
watery	B-DISO
diarrhea	I-DISO
,	O
vomiting	B-DISO
,	O
and	O
dehydration	B-DISO
in	O
newborn	O
piglets	O
.	O

A	O
sensitive	O
RT	O
-	O
PCR	O
method	O
is	O
urgently	O
required	O
to	O
detect	O
PDCoV	O
infection	B-DISO
.	O

In	O
extubation	O
day	O
an	O
association	O
between	O
driving	O
pressure	O
and	O
NT	O
-	O
PCP	B-DISO
-	O
III	O
was	O
observed	O
.	O

Screened	O
CTL	O
and	O
HTL	B-DISO
epitopes	O
were	O
found	O
to	O
have	O
high	O
propensity	O
for	O
stable	O
molecular	O
interaction	O
with	O
HLA	O
alleles	O
molecules	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
point	O
-	O
of	O
-	O
care	O
lung	O
ultrasound	O
as	O
a	O
novel	O
tool	O
to	O
determine	O
the	O
prevalence	O
and	O
early	O
signs	O
of	O
ARDS	B-DISO
in	O
a	O
resource	O
-	O
limited	O
setting	O
among	O
patients	O
with	O
severe	O
malaria	B-DISO
or	O
sepsis	B-DISO
.	O

ARDS	B-DISO
was	O
defined	O
according	O
to	O
the	O
Kigali	O
Modification	O
of	O
the	O
Berlin	O
Definition	O
.	O

Of	O
102	O
patients	O
enrolled	O
,	O
71	O
had	O
sepsis	B-DISO
and	O
31	O
had	O
malaria	B-DISO
.	O

Two	O
patients	O
developing	O
ARDS	B-DISO
during	O
hospitalisation	O
already	O
had	O
reduced	O
aeration	O
patterns	O
on	O
enrolment	O
.	O

Such	O
technology	O
allows	O
for	O
real	O
-	O
time	O
evaluation	O
of	O
disease	B-DISO
progression	I-DISO
and	O
when	O
applied	O
to	O
studying	O
infectious	B-DISO
diseases	I-DISO
may	O
provide	O
insight	O
into	O
pathogenesis	B-DISO
.	O

The	O
human	O
sodium	O
iodide	O
symporter	O
(	O
hNIS	O
),	O
a	O
SPECT	O
and	O
positron	O
emission	O
tomography	O
reporter	O
gene	O
,	O
was	O
inserted	O
into	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
a	O
recently	O
emerged	O
virus	O
that	O
can	O
cause	O
severe	O
respiratory	B-DISO
disease	I-DISO
and	O
death	O
in	O
afflicted	O
humans	O
to	O
obtain	O
a	O
quantifiable	O
and	O
sensitive	O
marker	O
for	O
viral	O
replication	O
to	O
further	O
MERS	O
-	O
CoV	O
animal	O
model	O
development	O
.	O

In	O
conclusion	O
,	O
we	O
demonstrate	O
that	O
PHEV	O
utilizes	O
the	O
integrin	O
α5β1	O
-	O
FAK	O
-	O
Rac1	O
/	O
Cdc42	O
-	O
PAK	O
-	O
LIMK	O
-	O
cofilin	O
pathway	O
to	O
cause	O
an	O
actin	O
cytoskeletal	O
rearrangement	O
to	O
promote	O
its	O
own	O
invasion	B-DISO
,	O
providing	O
theoretical	O
support	O
for	O
the	O
development	O
of	O
PHEV	O
pathogenic	O
mechanisms	O
and	O
new	O
antiviral	O
targets	O
.	O

TITLE	O
:	O
[	O
Etiological	O
structure	O
of	O
influenza	B-DISO
and	O
other	O
ARVI	O
in	O
St	O
.	O
Petersburg	O
during	O
epidemic	O
seasons	O
2012	O
-	O
2016	O
.]	O
ABSTRACT	O
:	O
The	O
etiological	O
structure	O
of	O
influenza	B-DISO
and	O
other	O
acute	O
respiratory	O
viral	B-DISO
infections	I-DISO
including	O
their	O
rate	O
of	O
incidence	O
in	O
St	O
.	O
Petersburg	O
and	O
Leningrad	O
region	O
during	O
4	O
epidemic	O
seasons	O
has	O
been	O
studied	O
.	O

In	O
2013	O
,	O
China	O
WHO	O
reported	O
new	O
avian	B-DISO
influenza	I-DISO
virus	O
H7N9	O
infected	O
to	O
human	O
.	O

A	O
patholog	O
-	O
ical	O
study	O
of	O
post	O
-	O
mortem	O
biopsied	O
lung	O
tissues	O
revealed	O
that	O
H5N1	B-DISO
infected	O
alveolar	O
epithe	O
-	O
lial	O
cells	O
and	O
caused	O
primary	O
viral	B-DISO
pneumonia	I-DISO
,	O
which	O
subsequently	O
developed	O
into	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Case	O
management	O
of	O
ill	B-DISO
travelers	O
with	O
infectious	B-DISO
diseases	I-DISO
.	O

Malaria	B-DISO
is	O
most	O
common	O
in	O
travelers	O
returning	O
from	O
sub	O
-	O
Saharan	O
Africa	O
while	O
dengue	B-DISO
is	O
most	O
common	O
those	O
returning	O
from	O
Southeast	O
Asia	O
and	O
Latin	O
America	O
.	O

TITLE	O
:	O
Asymptomatic	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
:	O
Extent	O
and	O
implications	O
for	O
infection	B-DISO
control	O
:	O
A	O
systematic	O
review	O
.	O

The	O
MEDLINE	O
/	O
PubMed	O
and	O
Scopus	O
databases	O
were	O
searched	O
for	O
relevant	O
papers	O
published	O
till	O
August	O
2018	O
describing	O
asymptomatic	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

METHODS	O
:	O
The	O
MEDLINE	O
/	O
PubMed	O
and	O
Scopus	O
databases	O
were	O
searched	O
for	O
relevant	O
papers	O
published	O
till	O
August	O
2018	O
describing	O
asymptomatic	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Anti	O
-	O
neutrophil	O
cytoplasmic	O
antibody	O
(	O
ANCA	O
)-	O
associated	O
vasculitis	B-DISO
(	O
AAV	O
)	O
is	O
a	O
systemic	O
vasculitis	B-DISO
resulting	O
in	O
severe	O
organ	O
injuries	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
only	O
two	O
cases	O
of	O
coexistence	O
of	O
AAV	O
and	O
takotsubo	B-DISO
syndrome	I-DISO
have	O
been	O
reported	O
.	O

Intraoperative	O
transesophageal	O
echocardiography	O
was	O
performed	O
and	O
hypertrophic	B-DISO
obstructive	I-DISO
cardiomyopathy	I-DISO
with	O
systolic	O
anterior	O
motion	O
of	O
the	O
mitral	O
valve	O
was	O
discovered	O
as	O
an	O
underlying	O
pathology	B-DISO
,	O
undetected	O
on	O
preoperative	O
imaging	O
.	O

A	O
2	O
-	O
month	O
-	O
old	O
preterm	O
male	O
was	O
admitted	O
for	O
severe	O
Bordetella	O
pertussis	B-DISO
infection	B-DISO
.	O

Symptoms	O
leading	O
to	O
a	O
diagnosis	O
of	O
hemolytic	B-DISO
uremic	I-DISO
syndrome	I-DISO
(	O
HUS	O
)	O
rapidly	O
appeared	O
:	O
hemolytic	B-DISO
anemia	I-DISO
,	O
thrombocytopenia	O
,	O
and	O
acute	O
kidney	O
injury	O
.	O

TITLE	O
:	O
Airflow	O
as	O
a	O
Possible	O
Transmission	O
Route	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
at	O
an	O
Initial	O
Outbreak	O
Hospital	O
in	O
Korea	O
.	O

TITLE	O
:	O
Estimating	O
severity	O
of	O
influenza	B-DISO
epidemics	O
from	O
severe	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
(	O
SARI	O
)	O
in	O
intensive	O
care	O
units	O
.	O

In	O
the	O
ICU	O
there	O
is	O
great	O
variation	O
between	O
the	O
yearly	O
influenza	B-DISO
epidemic	I-DISO
periods	O
in	O
terms	O
of	O
different	O
influenza	B-DISO
severity	O
parameters	O
.	O

ABSTRACT	O
:	O
Viral	B-DISO
infections	I-DISO
trigger	O
robust	O
secretion	O
of	O
interferons	O
and	O
other	O
antiviral	O
cytokines	O
by	O
infected	O
and	O
bystander	O
cells	O
,	O
which	O
in	O
turn	O
can	O
tune	O
the	O
immune	O
response	O
and	O
may	O
lead	O
to	O
viral	O
clearance	O
or	O
immune	B-DISO
suppression	I-DISO
.	O

ABSTRACT	O
:	O
The	O
genetic	O
variability	O
of	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
is	O
one	O
of	O
the	O
main	O
challenges	O
for	O
its	O
control	O
,	O
hindering	O
not	O
only	O
the	O
development	O
of	O
effective	O
vaccination	O
strategies	O
but	O
also	O
its	O
classification	O
and	O
,	O
consequently	O
,	O
epidemiology	O
understanding	O
.	O

Infected	O
patients	O
frequently	O
present	O
with	O
pneumonia	B-DISO
and	O
acute	O
respiratory	B-DISO
disorder	I-DISO
syndrome	B-DISO
with	O
high	O
rates	O
of	O
intensive	O
care	O
unit	O
admission	O
and	O
death	O
.	O

A	O
56	O
-	O
year	O
-	O
old	O
female	O
patient	O
(	O
case	O
1	O
)	O
and	O
a	O
78	O
-	O
year	O
-	O
old	O
female	O
patient	O
(	O
case	O
2	O
)	O
were	O
admitted	O
because	O
of	O
fever	O
,	O
cough	B-DISO
,	O
chest	B-DISO
tightness	I-DISO
and	O
shortness	B-DISO
of	I-DISO
breath	I-DISO
.	O

However	O
,	O
based	O
on	O
results	O
from	O
electrophysiological	O
testing	O
and	O
needle	O
electromyography	O
of	O
these	O
2	O
patients	O
,	O
it	O
is	O
difficult	O
to	O
differentiate	O
critical	B-DISO
illness	I-DISO
polyneuropathy	I-DISO
from	O
GBS	B-DISO
,	O
since	O
no	O
lumbar	O
puncture	O
or	O
muscle	O
and	O
nerve	O
biopsy	O
were	O
conducted	O
during	O
hospitalization	O
.	O

Following	O
a	O
long	O
-	O
term	O
comprehensive	O
treatment	O
,	O
the	O
patients	O
'	O
neurological	O
condition	B-DISO
improved	O
gradually	O
.	O

Although	O
there	O
is	O
great	O
improvement	O
in	O
saving	O
severe	O
patients	O
'	O
lives	O
from	O
fatal	O
respiratory	O
and	O
blood	O
infections	B-DISO
,	O
it	O
is	O
necessary	O
to	O
pay	O
sufficient	O
attention	O
and	O
to	O
use	O
more	O
methods	O
to	O
differentiate	O
GBS	B-DISO
from	O
intensive	O
care	O
unit	O
-	O
acquired	O
weakness	B-DISO
.	O

ABSTRACT	O
:	O
Multiple	B-DISO
sclerosis	I-DISO
(	O
MS	O
)	O
is	O
a	O
disease	O
of	O
the	O
central	O
nervous	B-DISO
system	O
(	O
CNS	O
)	O
characterized	O
by	O
chronic	O
neuroinflammation	O
,	O
axonal	O
damage	O
,	O
and	O
demyelination	B-DISO
.	O

In	O
this	O
review	O
,	O
we	O
have	O
summarized	O
some	O
of	O
the	O
recent	O
advancements	O
made	O
in	O
the	O
area	O
of	O
nucleic	O
acid	O
based	O
therapeutics	O
and	O
highlighted	O
the	O
emerging	O
roles	O
of	O
nucleic	O
acids	O
in	O
the	O
management	O
of	O
some	O
of	O
the	O
severe	O
respiratory	O
viral	B-DISO
infections	I-DISO
.	O

Our	O
investigation	O
also	O
revealed	O
that	O
patients	O
with	O
an	O
HA	O
-	O
MERS	O
infection	B-DISO
experienced	O
a	O
significantly	O
longer	O
hospital	O
stay	O
and	O
were	O
more	O
likely	O
to	O
die	O
from	O
the	O
disease	O
.	O

CONCLUSIONS	O
:	O
Our	O
investigation	O
also	O
revealed	O
that	O
patients	O
with	O
an	O
HA	O
-	O
MERS	O
infection	B-DISO
experienced	O
a	O
significantly	O
longer	O
hospital	O
stay	O
and	O
were	O
more	O
likely	O
to	O
die	O
from	O
the	O
disease	O
.	O

TITLE	O
:	O
Ventilator	O
-	O
associated	O
events	O
versus	O
ventilator	O
-	O
associated	O
respiratory	B-DISO
infections	I-DISO
-	O
moving	O
into	O
a	O
new	O
paradigm	O
or	O
merging	O
both	O
concepts	O
,	O
instead	O
?	O

The	O
new	O
classification	O
of	O
ventilator	O
-	O
associated	O
events	O
(	O
VAE	O
)	O
proposed	O
by	O
the	O
centers	O
for	O
disease	O
control	O
and	O
prevention	O
(	O
CDC	O
)	O
enhance	O
the	O
spectra	O
of	O
complications	O
due	O
to	O
MV	O
including	O
both	O
infection	B-DISO
-	O
related	O
and	O
non	O
-	O
infectious	B-DISO
events	O
.	O

Noninfective	O
events	O
explain	O
up	O
to	O
30	O
%	O
of	O
VAEs	O
,	O
the	O
main	O
causes	O
being	O
atelectasis	B-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
pulmonary	B-DISO
edema	I-DISO
and	O
pulmonary	B-DISO
embolism	I-DISO
.	O

With	O
the	O
LVAD	O
in	O
place	O
,	O
the	O
patient	O
developed	O
transfusion	B-DISO
-	I-DISO
related	I-DISO
acute	I-DISO
lung	I-DISO
injury	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
with	O
right	B-DISO
ventricular	I-DISO
dysfunction	I-DISO
requiring	O
VA	O
ECMO	O
once	O
again	O
.	O

There	O
is	O
a	O
paucity	O
of	O
data	O
regarding	O
the	O
differentiating	O
characteristics	O
of	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
and	O
those	O
negative	O
for	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
South	O
Korea	O
.	O

Patients	O
with	O
flail	B-DISO
chest	I-DISO
more	O
often	O
had	O
lung	O
contusions	O
(	O
70	O
vs	O
.	O
50	O
%,	O
p	O
=	O
0	O
.	O
04	O
)	O
and	O
pneumo	O
-/	O
hematothorax	O
(	O
93	O
vs	O
.	O
71	O
%,	O
p	O
=	O
0	O
.	O
005	O
).	O

TITLE	O
:	O
MMI	O
-	O
0100	O
ameliorates	O
lung	B-DISO
inflammation	I-DISO
in	O
a	O
mouse	O
model	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
by	O
reducing	O
endothelial	O
expression	O
of	O
ICAM	O
-	O
1	O
.	O

Compared	O
with	O
the	O
LPS	B-DISO
group	O
,	O
the	O
LPS	B-DISO
plus	O
MMI	O
-	O
0100	O
group	O
of	O
mice	O
showed	O
less	O
severe	O
inflammation	B-DISO
,	O
including	O
a	O
lower	O
W	O
/	O
D	O
and	O
neutrophil	O
count	O
.	O

1	O
973	O
patients	O
with	O
AP	O
in	O
Hunan	O
People	O
'	O
s	O
Hospital	O
from	O
2012	O
to	O
2017	O
were	O
retrospectively	O
enrolled	O
and	O
divided	O
by	O
SIRS	B-DISO
duration	O
into	O
the	O
persistent	O
SIRS	B-DISO
group	O
,	O
temporary	O
SIRS	B-DISO
group	O
and	O
non	O
-	O
SIRS	B-DISO
group	O
.	O

Moreover	O
,	O
The	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHE	O
II	O
),	O
CT	O
severity	O
index	O
(	O
CTSI	O
),	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
(	O
MOF	B-DISO
)	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
incidence	O
,	O
mortality	O
and	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
),	O
white	O
blood	O
cell	O
count	O
(	O
WBC	O
),	O
procalcitonin	O
(	O
PCT	B-DISO
)	O
and	O
immature	O
granulocytes	O
in	O
persistent	O
SIRS	B-DISO
group	O
were	O
further	O
higher	O
than	O
those	O
in	O
the	O
temporary	O
SIRS	B-DISO
group	O
[	O
APACHE	O
II	O
:	O
9	O
(	O
6	O
,	O
12	O
)	O
vs	O
.	O
5	O
(	O
3	O
,	O
7	O
),	O
CTSI	O
:	O
6	O
(	O
4	O
,	O
6	O
)	O
vs	O
.	O
4	O
(	O
3	O
,	O
6	O
),	O
MOF	B-DISO
incidence	O
:	O
92	O
.	O
0	O
%	O
vs	O
.	O
32	O
.	O
8	O
%,	O
ARDS	B-DISO
incidence	O
:	O
39	O
.	O
9	O
%	O
vs	O
.	O
10	O
.	O
1	O
%,	O
morbidity	O
:	O
11	O
.	O
1	O
%	O
vs	O
.	O
4	O
.	O
2	O
%,	O
CRP	O
(	O
mg	O
/	O
L	O
):	O
25	O
.	O
00	O
(	O
0	O
.	O
80	O
,	O
212	O
.	O
25	O
)	O
vs	O
.	O
0	O
.	O
80	O
(	O
0	O
.	O
80	O
,	O
123	O
.	O
50	O
),	O
WBC	O
(×	O
10	O
Immature	O
granulocyte	O
in	O
peripheral	O
blood	O
is	O
a	O
potential	O
indicator	O
for	O
persistent	O
SIRS	B-DISO
in	O
AP	O
patients	O
.	O

RESULTS	O
:	O
These	O
1	O
973	O
AP	O
patients	O
(	O
1	O
165	O
males	O
,	O
59	O
.	O
0	O
%)	O
with	O
an	O
average	O
age	O
of	O
49	O
(	O
40	O
,	O
60	O
)	O
years	O
old	O
,	O
including	O
288	O
persistent	O
SIRS	B-DISO
,	O
189	O
temporary	O
SIRS	B-DISO
and	O
1	O
496	O
non	O
-	O
SIRS	B-DISO
cases	O
.	O

These	O
results	O
indicated	O
that	O
the	O
replication	O
of	O
the	O
S	O
-	O
intact	O
PEDV	O
was	O
enhanced	O
during	O
coinfection	B-DISO
in	O
piglets	O
.	O

ABSTRACT	O
:	O
Porcine	O
deltacoronavirus	O
(	O
PDCoV	O
)	O
is	O
a	O
newly	O
identified	O
swine	O
enteropathogenic	O
coronavirus	O
that	O
causes	O
watery	B-DISO
diarrhea	I-DISO
in	O
piglets	O
and	O
results	O
in	O
significant	O
economic	O
losses	O
to	O
the	O
pig	O
industry	O
.	O

ABSTRACT	O
:	O
Sudden	B-DISO
Infant	I-DISO
Death	I-DISO
Syndrome	I-DISO
(	O
SIDS	B-DISO
)	O
mechanisms	O
of	O
death	O
remains	O
obscured	O
.	O

The	O
cardiovascular	O
/	O
cardiorespiratory	O
control	O
of	O
the	O
vulnerable	O
infant	O
during	O
a	O
critical	O
developmental	O
period	O
may	O
be	O
impaired	B-DISO
.	O

A	O
severe	O
decrease	O
in	O
SVR	O
is	O
associated	O
with	O
hyper	O
-	O
dynamic	O
state	O
,	O
high	O
output	O
failure	O
and	O
distributive	B-DISO
shock	I-DISO
.	O

SADS	O
-	O
CoV	O
was	O
first	O
detected	O
and	O
identified	O
as	O
the	O
causative	O
agent	O
of	O
a	O
devastating	O
swine	B-DISO
disease	I-DISO
outbreak	O
in	O
southern	O
China	O
in	O
2017	O
.	O

We	O
describe	O
a	O
patient	O
with	O
rapidly	O
progressing	O
ARDS	B-DISO
and	O
myocarditis	B-DISO
secondary	O
to	O
spotted	B-DISO
fever	I-DISO
caused	O
by	O
Rickettsia	O
conorii	O
.	O

Moreover	O
,	O
4	O
cases	O
were	O
associated	O
with	O
superspreading	O
events	O
(	O
any	O
interaction	O
where	O
a	O
case	O
patient	O
transmitted	B-DISO
to	O
≥	O
5	O
subsequent	O
case	O
patients	O
).	O

All	O
4	O
of	O
these	O
patients	O
were	O
severely	O
ill	B-DISO
,	O
were	O
initially	O
not	O
recognized	O
as	O
MERS	O
-	O
CoV	O
cases	O
,	O
and	O
subsequently	O
died	O
.	O

Prompt	O
contact	O
tracing	O
,	O
repeated	O
testing	O
,	O
HCP	B-DISO
furloughing	O
,	O
and	O
implementation	O
of	O
recommended	O
transmission	O
-	O
based	O
precautions	O
for	O
suspected	O
cases	O
ultimately	O
halted	O
transmission	O
.	O

TITLE	O
:	O
An	O
Atypical	O
Case	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
in	O
a	O
Returning	O
Traveler	O
to	O
Korea	O
from	O
Kuwait	O
,	O
2018	O
.	O

Chest	O
radiography	O
revealed	O
interstitial	O
infiltrates	B-DISO
in	O
the	O
lungs	O
,	O
and	O
he	O
was	O
immediately	O
transferred	O
to	O
an	O
isolation	O
unit	O
.	O

Pulmonary	B-DISO
complications	I-DISO
occurred	O
in	O
47	O
.	O
24	O
%	O
of	O
cases	O
.	O

The	O
frequency	O
of	O
pulmonary	B-DISO
complications	I-DISO
in	O
acute	O
kidney	O
injury	O
is	O
very	O
high	O
and	O
has	O
a	O
negative	O
impact	O
on	O
the	O
evolution	O
and	O
prognosis	O
.	O

The	O
etiology	O
of	O
the	O
pulmonary	B-DISO
complications	I-DISO
is	O
complex	O
,	O
as	O
these	O
are	O
caused	O
by	O
the	O
agents	O
that	O
induced	O
the	O
acute	O
kidney	O
injury	O
in	O
the	O
first	O
place	O
,	O
most	O
frequently	O
by	O
septic	B-DISO
shock	I-DISO
.	O

High	O
ISS	B-DISO
(	O
OR	O
1	O
.	O
047	O
,	O
95	O
%	O
CI	O
1	O
.	O
02	O
-	O
1	O
.	O
08	O
),	O
TBI	O
(	O
OR	O
8	O
.	O
922	O
,	O
95	O
%	O
CI	O
2	O
.	O
57	O
-	O
31	O
.	O
00	O
),	O
sepsis	B-DISO
(	O
OR	O
4	O
.	O
956	O
,	O
95	O
%	O
CI	O
1	O
.	O
99	O
-	O
12	O
.	O
36	O
),	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
(	O
OR	O
8	O
.	O
036	O
,	O
95	O
%	O
CI	O
1	O
.	O
85	O
-	O
34	O
.	O
84	O
),	O
respiratory	B-DISO
failure	I-DISO
(	O
OR	O
9	O
.	O
630	O
,	O
95	O
%	O
CI	O
2	O
.	O
64	O
-	O
35	O
.	O
14	O
),	O
renal	B-DISO
failure	I-DISO
(	O
OR	O
74	O
.	O
803	O
,	O
95	O
%	O
CI	O
11	O
.	O
34	O
-	O
493	O
.	O
43	O
),	O
and	O
multiple	B-DISO
organ	I-DISO
failure	I-DISO
[	O
MOF	B-DISO
]	O
(	O
OR	O
10	O
.	O
415	O
,	O
95	O
%	O
CI	O
4	O
.	O
48	O
-	O
24	O
.	O
24	O
)	O
were	O
risk	O
factors	O
for	O
late	O
in	O
-	O
hospital	O
mortality	O
.	O

High	O
Glasgow	O
Coma	B-DISO
Scale	O
(	O
GCS	O
)	O
was	O
a	O
good	O
predictor	O
for	O
survival	O
at	O
2	O
,	O
7	O
,	O
and	O
28	O
or	O
more	O
days	O
of	O
hospitalization	O
(	O
OR	O
0	O
.	O
708	O
and	O
95	O
%	O
CI	O
0	O
.	O
56	O
-	O
0	O
.	O
09	O
;	O
OR	O
0	O
.	O
835	O
and	O
95	O
%	O
CI	O
0	O
.	O
73	O
-	O
0	O
.	O
95	O
;	O
OR	O
0	O
.	O
798	O
and	O
95	O
%	O
CI	O
0	O
.	O
71	O
-	O
0	O
.	O
90	O
,	O
resp	O
.).	O

For	O
this	O
patient	O
group	O
,	O
ISS	B-DISO
and	O
APACHE	O
II	O
scores	O
might	O
be	O
helpful	O
for	O
stratifying	O
by	O
mortality	O
risk	O
,	O
and	O
GCS	O
might	O
be	O
a	O
good	O
predictor	O
for	O
survival	O
.	O

As	O
erythrocytes	O
mature	O
,	O
the	O
surfaces	O
of	O
Ery	O
-	O
C	O
cells	O
and	O
mature	O
erythrocytes	O
also	O
acquire	O
an	O
additional	O
distinct	O
CASD1	O
-	O
dependent	O
9	O
-	O
O	O
-	O
acetyl	O
sialic	O
acid	O
moiety	O
that	O
can	O
be	O
recognized	O
by	O
virolectins	O
from	O
both	O
influenza	B-DISO
C	O
and	O
bovine	O
coronavirus	O
.	O

Even	O
if	O
rasburicase	O
induced	O
methemoglobinemia	B-DISO
and	O
hemolysis	B-DISO
are	O
not	O
very	O
common	O
complications	O
,	O
clinicians	O
who	O
prescribe	O
and	O
follow	O
patients	O
should	O
detect	O
this	O
serious	O
complication	B-DISO
early	O
and	O
manage	O
it	O
accordingly	O
.	O

The	O
results	O
of	O
the	O
trial	O
have	O
led	O
some	O
to	O
believe	O
that	O
the	O
widespread	O
adoption	O
of	O
ECMO	O
as	O
a	O
feasible	O
treatment	O
for	O
severe	O
respiratory	B-DISO
failure	I-DISO
is	O
forthcoming	O
[	O
MacLaren	O
2012	O
;	O
Del	O
Sorbo	O
2014	O
].	O

ABSTRACT	O
:	O
The	O
relationship	O
among	O
chronic	O
fatigue	B-DISO
,	O
depressive	B-DISO
symptoms	I-DISO
,	O
and	O
post	O
-	O
traumatic	O
stress	B-DISO
symptoms	I-DISO
(	O
PTSSs	O
)	O
among	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
survivors	O
is	O
poorly	O
understood	O
.	O

Of	O
148	O
survivors	O
who	O
consented	O
to	O
be	O
registered	O
and	O
underwent	O
assessments	O
at	O
12	O
months	O
(	O
T1	O
)	O
and	O
18	O
months	O
(	O
T2	O
)	O
after	O
the	O
MERS	O
outbreak	O
,	O
72	O
(	O
48	O
.	O
65	O
%)	O
were	O
evaluated	O
for	O
chronic	O
fatigue	B-DISO
,	O
depressive	B-DISO
symptoms	I-DISO
,	O
and	O
PTSSs	O
based	O
on	O
the	O
Impact	O
of	O
Event	O
ScaleRevised	O
(	O
IES	O
-	O
R	O
),	O
the	O
Patient	O
Health	O
Questionnaire	O
-	O
9	O
(	O
PHQ	O
-	O
9	O
),	O
and	O
the	O
Fatigue	B-DISO
Severity	O
Scale	O
(	O
FSS	B-DISO
).	O

He	O
developed	O
a	O
high	O
fever	O
soon	O
after	O
lymphography	O
,	O
followed	O
by	O
severe	O
ARDS	B-DISO
requiring	O
artificial	O
respiration	O
5	O
days	O
later	O
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
describe	O
recent	O
evidence	O
regarding	O
the	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
as	O
salvage	O
therapy	O
for	O
severe	O
cardiac	O
or	O
respiratory	B-DISO
failure	I-DISO
in	O
patients	O
with	O
trauma	O
.	O

The	O
recent	O
findings	O
suggest	O
that	O
venous	O
-	O
venous	O
ECMO	O
can	O
be	O
feasible	O
in	O
the	O
treatment	O
of	O
refractory	O
respiratory	B-DISO
failure	I-DISO
and	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
trauma	O
-	O
related	O
.	O

Therefore	O
,	O
ADAM	O
-	O
17	O
should	O
be	O
considered	O
as	O
a	O
potential	O
target	O
molecule	O
for	O
novel	O
antiviral	O
drug	O
discovery	O
that	O
would	O
regulate	O
host	O
reactivity	O
to	O
infection	B-DISO
and	O
thereby	O
limit	O
or	O
prevent	O
fatal	B-DISO
outcomes	I-DISO
.	O

Here	O
,	O
we	O
report	O
that	O
coronavirus	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
produces	O
a	O
novel	O
ncRNA	B-DISO
in	O
virus	O
-	O
infected	O
cells	O
.	O

We	O
compared	O
the	O
diagnostic	O
value	O
of	O
indices	O
derived	O
from	O
Tcap	O
and	O
Vcap	O
following	O
ventilation	O
to	O
perfusion	O
ratio	O
()	O
mismatch	O
subsequent	O
to	O
experimentally	O
induced	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
and	O
alveolar	O
recruitment	B-DISO
by	O
elevating	O
the	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
).	O

Infections	B-DISO
are	O
a	O
major	O
complication	B-DISO
of	O
cancer	B-DISO
and	O
its	O
treatment	O
.	O

Community	O
acquired	O
respiratory	O
viral	B-DISO
infections	I-DISO
(	O
CRV	B-DISO
)	O
in	O
these	O
patients	O
increase	O
morbidity	O
,	O
mortality	O
and	O
can	O
lead	O
to	O
delay	O
in	O
chemotherapy	O
.	O

These	O
are	O
the	O
result	O
of	O
infections	B-DISO
with	O
a	O
heterogeneous	O
group	O
of	O
viruses	O
including	O
RNA	O
viruses	O
,	O
such	O
as	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
influenza	B-DISO
virus	O
(	O
IV	O
),	O
parainfluenza	B-DISO
virus	O
(	O
PIV	O
),	O
metapneumovirus	O
(	O
HMPV	O
),	O
rhinovirus	O
(	O
RhV	O
),	O
and	O
coronavirus	O
(	O
CoV	O
).	O

Thus	O
,	O
effective	O
coordination	O
of	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
cytokines	O
is	O
essential	O
during	O
MHV	O
induced	O
encephalomyelitis	B-DISO
in	O
order	O
to	O
protect	O
the	O
host	O
against	O
viral	B-DISO
infection	I-DISO
at	O
a	O
limited	O
cost	O
.	O

Three	O
hypotheses	O
were	O
evaluated	O
by	O
assessing	O
:	O
1	O
)	O
whether	O
feed	O
supplier	O
,	O
semen	O
supplier	O
and	O
/	O
or	O
animal	O
transportation	O
company	O
networks	O
contained	O
a	O
higher	O
proportion	O
of	O
case	O
herds	O
compared	O
to	O
randomly	O
permuted	O
networks	O
,	O
2	O
)	O
whether	O
the	O
proportion	O
of	O
case	O
herds	O
in	O
the	O
giant	B-DISO
weak	O
component	O
differed	O
from	O
randomly	O
permuted	O
networks	O
,	O
and	O
3	O
)	O
whether	O
external	O
herd	O
biosecurity	O
,	O
defined	O
as	O
the	O
number	O
of	O
mean	O
contacts	O
with	O
other	O
herds	O
in	O
a	O
one	O
-	O
mode	O
network	O
,	O
was	O
different	O
between	O
case	O
and	O
control	O
herds	O
.	O

Here	O
,	O
the	O
role	O
of	O
Poldip2	O
in	O
regulating	O
vascular	O
permeability	O
and	O
inflammation	B-DISO
in	O
a	O
mouse	O
model	O
of	O
ARDS	B-DISO
was	O
assessed	O
.	O

The	O
present	O
study	O
aimed	O
to	O
define	O
the	O
role	O
of	O
RIPK1	O
in	O
hepatocytes	O
during	O
fulminant	O
viral	B-DISO
hepatitis	I-DISO
,	O
a	O
worldwide	O
syndrome	B-DISO
mainly	O
observed	O
in	O
hepatitis	B-DISO
B	I-DISO
virus	O
(	O
HBV	B-DISO
)	O
infected	O
patients	O
.	O

Transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
is	O
main	O
pathogens	O
responsible	O
for	O
piglets	O
viral	B-DISO
diarrhea	I-DISO
.	O

We	O
examined	O
a	O
set	O
of	O
selected	O
variables	O
early	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
to	O
determine	O
accurate	O
prognostic	O
predictors	O
for	O
selecting	O
high	O
-	O
risk	O
patients	O
for	O
randomized	O
controlled	O
trials	O
.	O

We	O
studied	O
1	O
,	O
200	O
patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
managed	O
with	O
lung	O
-	O
protective	O
ventilation	O
.	O

Combined	O
thresholds	O
for	O
patient	O
'	O
s	O
age	O
,	O
PaO2	O
/	O
FIO2	O
,	O
plateau	O
pressure	O
,	O
and	O
extrapulmonary	O
organ	B-DISO
failure	I-DISO
provides	O
prognostic	O
enrichment	O
accuracy	O
for	O
stratifying	O
and	O
selecting	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
for	O
randomized	O
controlled	O
trials	O
.	O

We	O
describe	O
patients	O
with	O
dengue	B-DISO
infection	B-DISO
confirmed	O
by	O
dengue	B-DISO
serology	O
or	O
NS1	B-DISO
antigen	O
in	O
Cali	O
,	O
Colombia	O
.	O

Two	O
patients	O
suffered	B-DISO
postpartum	B-DISO
hemorrhage	I-DISO
despite	O
the	O
management	O
.	O

We	O
concluded	O
that	O
although	O
tocolysis	O
is	O
not	O
regularly	O
used	O
in	O
patients	O
with	O
dengue	B-DISO
fever	I-DISO
,	O
our	O
results	O
suggest	O
that	O
our	O
protocol	O
could	O
benefit	O
pregnant	O
patients	O
with	O
thrombocytopenia	O
due	O
to	O
dengue	B-DISO
;	O
however	O
,	O
prospective	O
studies	O
which	O
determine	O
the	O
safety	O
and	O
effectiveness	O
of	O
our	O
intervention	O
are	O
needed	O
.	O

Intranasal	O
inoculation	O
of	O
young	O
and	O
adult	O
Tg	O
mice	O
with	O
MERS	O
-	O
CoV	O
led	O
to	O
infection	B-DISO
of	O
the	O
lower	O
respiratory	O
tract	O
and	O
pathological	O
evidence	O
of	O
acute	O
multifocal	O
interstitial	B-DISO
pneumonia	I-DISO
within	O
7	O
days	O
,	O
with	O
only	O
transient	O
loss	O
of	O
body	O
weight	O
.	O

ABSTRACT	O
:	O
Legionella	O
community	O
-	O
acquired	O
pneumonia	B-DISO
necessitating	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
has	O
been	O
reported	O
in	O
adults	O
.	O

Here	O
,	O
by	O
exploring	O
a	O
lipid	O
library	O
,	O
we	O
show	O
that	O
AM580	O
,	O
a	O
retinoid	O
derivative	O
and	O
RAR	O
-	O
α	O
agonist	O
,	O
is	O
highly	O
potent	O
in	O
interrupting	O
the	O
life	O
cycle	O
of	O
diverse	O
viruses	O
including	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
and	O
influenza	B-DISO
A	O
virus	O
.	O

TITLE	O
:	O
Nasal	O
virome	O
of	O
dogs	O
with	O
respiratory	B-DISO
infection	I-DISO
signs	O
include	O
novel	O
taupapillomaviruses	O
.	O

ABSTRACT	O
:	O
Using	O
viral	O
metagenomics	O
,	O
we	O
characterized	O
the	O
mammalian	O
virome	O
of	O
nasal	O
swabs	O
from	O
57	O
dogs	O
with	O
unexplained	O
signs	O
of	O
respiratory	B-DISO
infection	I-DISO
showing	O
mostly	O
negative	O
results	O
using	O
the	O
IDEXX	O
Canine	O
Respiratory	B-DISO
Disease	I-DISO
RealPCR	O
™	O
Panel	O
.	O

Horses	O
with	O
Salmonella	B-DISO
had	O
significantly	O
lower	O
mean	O
leukocyte	O
counts	O
compared	O
to	O
those	O
with	O
UNK	O
.	O

RESULTS	O
:	O
Most	O
common	O
presenting	O
complaints	O
were	O
fever	O
and	O
colic	B-DISO
and	O
were	O
similar	O
across	O
groups	O
.	O

These	O
results	O
will	O
further	O
our	O
understanding	O
of	O
the	O
pathogenesis	B-DISO
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

A	O
prospective	O
cross	O
-	O
sectional	O
observational	O
study	O
was	O
conducted	O
in	O
infants	O
hospitalized	O
with	O
a	O
diagnosis	O
of	O
acute	B-DISO
lower	I-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
(	O
ALRTI	O
),	O
in	O
a	O
tertiary	O
care	O
hospital	O
in	O
a	O
metropolitan	O
city	O
of	O
Western	O
India	O
.	O

Influenza	B-DISO
A	O
(	O
other	O
than	O
H1N1	O
),	O
Influenza	B-DISO
B	O
,	O
Human	O
Coronavirus	O
229E	O
and	O
Enterovirus	O
were	O
not	O
detected	O
.	O

The	O
rate	O
of	O
coinfection	B-DISO
was	O
34	O
%	O
and	O
rhinovirus	O
was	O
the	O
most	O
common	O
of	O
the	O
multiple	O
pathogens	O
.	O

The	O
results	O
showed	O
that	O
Griffithsin	O
reduced	O
PEDV	O
infection	B-DISO
of	O
Vero	O
cells	O
by	O
approximately	O
82	O
.	O
8	O
%.	O

In	O
conclusion	O
,	O
Griffithsin	O
was	O
identified	O
as	O
a	O
potent	O
PEDV	O
inhibitor	O
and	O
may	O
represent	O
a	O
candidate	O
drug	O
for	O
preventing	O
PEDV	O
infection	B-DISO
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
these	O
viruses	O
in	O
hospitalized	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
infection	I-DISO
(	O
SARI	O
).	O

A	O
retrospective	O
study	O
was	O
conducted	O
with	O
251	O
patients	O
,	O
from	O
April	O
2009	O
to	O
November	O
2010	O
,	O
using	O
nasopharyngeal	O
aspirates	O
,	O
naso	O
-	O
and	O
oropharyngeal	O
swab	O
samples	O
from	O
hospitalized	O
patients	O
(	O
children	O
<	O
12	O
years	O
and	O
adults	O
)	O
who	O
had	O
SARI	O
within	O
7	O
days	O
of	O
the	O
onset	O
of	O
symptoms	O
,	O
including	O
fever	O
(>	O
38	O
.	O
8	O
°	O
C	O
),	O
dyspnea	B-DISO
,	O
and	O
cough	B-DISO
.	O

TITLE	O
:	O
Evaluation	O
on	O
the	O
efficacy	O
and	O
immunogenicity	O
of	O
recombinant	O
DNA	O
plasmids	O
expressing	O
S	O
gene	O
from	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
and	O
VP7	O
gene	O
from	O
porcine	O
rotavirus	O
.	O

ABSTRACT	O
:	O
To	O
compare	O
the	O
clinical	O
profile	O
and	O
short	O
-	O
term	O
outcome	O
of	O
children	O
with	O
axonal	O
and	O
demyelinating	O
subtypes	O
of	O
childhood	O
Guillain	O
Barré	O
syndrome	B-DISO
(	O
GBS	B-DISO
).	O

Among	O
9847	O
children	O
admitted	O
to	O
the	O
emergency	B-DISO
,	O
95	O
had	O
acute	O
flaccid	B-DISO
paralysis	I-DISO
;	O
57	O
of	O
whom	O
had	O
GBS	B-DISO
.	O

Electrophysiological	O
studies	O
were	O
completed	O
in	O
57	O
;	O
of	O
whom	O
20	O
had	O
acute	B-DISO
inflammatory	I-DISO
demyelinating	I-DISO
polyneuropathy	I-DISO
(	O
AIDP	B-DISO
);	O
19	O
had	O
acute	O
motor	O
axonal	B-DISO
neuropathy	I-DISO
(	O
AMAN	O
);	O
12	O
had	O
non	O
-	O
reactive	O
nerves	O
;	O
five	O
were	O
unclassifiable	O
;	O
1	O
had	O
acute	O
motor	O
sensory	O
axonal	B-DISO
neuropathy	I-DISO
(	O
AMSAN	O
).	O

Ataxia	B-DISO
was	O
only	O
seen	O
in	O
AIDP	B-DISO
subtype	O
while	O
wrist	B-DISO
drop	I-DISO
,	O
foot	B-DISO
drop	I-DISO
and	O
hyperreflexia	O
were	O
seen	O
only	O
with	O
AMAN	O
subtype	O
.	O

Children	O
with	O
AMAN	O
appear	O
to	O
have	O
a	O
more	O
severe	O
clinical	O
course	O
;	O
higher	O
short	O
-	O
term	O
morbidity	O
;	O
and	O
slower	O
recovery	O
than	O
those	O
with	O
AIDP	B-DISO
.	O

We	O
investigated	O
the	O
impact	O
of	O
tidal	O
volume	O
on	O
mortality	O
and	O
probability	O
of	O
extubation	O
in	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
using	O
ideal	O
body	O
weight	O
-	O
adjusted	O
tidal	O
volume	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
viruses	O
(	O
IBVs	O
)	O
of	O
GI	O
-	O
13	O
(	O
793	O
/	O
B	O
)	O
and	O
GI	O
-	O
19	O
(	O
QX	O
/	O
LX4	O
)	O
lineages	O
have	O
been	O
frequently	O
detected	O
in	O
China	O
in	O
recent	O
years	O
.	O

Some	O
of	O
the	O
strains	O
showed	O
comparable	O
antigenic	O
relatedness	O
,	O
pathogenicity	O
,	O
and	O
affinity	O
for	O
the	O
trachea	B-DISO
and	O
kidneys	O
among	O
each	O
other	O
and	O
with	O
their	O
parental	O
viruses	O
;	O
however	O
,	O
some	O
of	O
them	O
showed	O
varying	O
biological	O
characteristics	O
.	O

Although	O
respiratory	B-DISO
infection	I-DISO
is	O
a	O
major	O
cause	O
of	O
AE	O
-	O
IPF	O
,	O
no	O
reports	O
have	O
indicated	O
pertussis	B-DISO
infection	B-DISO
as	O
a	O
cause	O
.	O

Since	O
pertussis	B-DISO
can	O
be	O
prevented	O
with	O
vaccination	O
and	O
is	O
expected	O
to	O
be	O
affected	O
by	O
antibiotics	O
,	O
consideration	O
of	O
pertussis	B-DISO
infection	B-DISO
as	O
a	O
causative	O
virulent	O
factor	O
of	O
AE	O
-	O
IPF	O
may	O
be	O
important	O
for	O
management	O
of	O
subjects	O
with	O
IPF	O
.	O

ABSTRACT	O
:	O
To	O
gain	O
insight	O
into	O
the	O
mechanism	O
of	O
Lactobacillus	O
acidophilus	O
(	O
L	O
.	O
acidophilus	O
)	O
S	O
-	O
layer	O
protein	O
antiviral	O
activity	O
,	O
we	O
examined	O
how	O
S	O
-	O
layer	O
protein	O
impacts	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
infection	B-DISO
and	O
PEDV	O
-	O
induced	O
apoptosis	O
of	O
Vero	O
cells	O
.	O

In	O
Vero	O
cells	O
infected	O
with	O
PEDV	O
,	O
we	O
found	O
that	O
apoptosis	O
was	O
mediated	O
by	O
activation	O
of	O
caspase	O
-	O
8	O
and	O
caspase	O
-	O
3	O
in	O
the	O
late	O
stage	O
of	O
infection	B-DISO
.	O

When	O
PEDV	O
-	O
infected	O
Vero	O
cells	O
were	O
pretreated	O
with	O
S	O
-	O
layer	O
protein	O
,	O
rates	O
of	O
Vero	O
cell	O
apoptosis	O
were	O
markedly	O
decreased	O
and	O
cell	B-DISO
damage	I-DISO
was	O
significantly	O
reduced	O
,	O
as	O
evaluated	O
by	O
flow	O
cytometry	O
and	O
microscopy	O
.	O

In	O
addition	O
,	O
the	O
findings	O
suggest	O
that	O
L	O
.	O
acidophilus	O
S	O
-	O
layer	O
protein	O
protects	O
against	O
PEDV	O
-	O
induced	O
apoptosis	O
through	O
reduced	O
caspase	O
-	O
8	O
and	O
caspase	O
-	O
3	O
activation	O
in	O
the	O
later	O
stages	O
of	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Use	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
in	O
adults	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
has	O
increased	O
in	O
the	O
past	O
10	O
years	O
.	O

We	O
aimed	O
to	O
estimate	O
the	O
effect	O
of	O
venovenous	O
ECMO	O
on	O
mortality	O
from	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Using	O
the	O
papain	O
-	O
like	O
deISGylase	O
from	O
Severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
as	O
a	O
probe	O
,	O
the	O
biochemical	O
importance	O
of	O
this	O
motif	O
in	O
ISG15	O
-	O
protein	O
engagements	O
was	O
illuminated	O
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
emerged	O
in	O
2012	O
and	O
caused	O
continual	O
outbreaks	O
worldwide	O
with	O
high	O
mortality	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
a	O
highly	O
contagious	O
coronavirus	O
that	O
causes	O
severe	B-DISO
diarrhea	I-DISO
and	O
death	O
in	O
neonatal	O
piglets	O
.	O

For	O
building	O
up	O
more	O
suitable	O
animal	O
models	O
,	O
we	O
compare	O
the	O
current	O
animal	O
models	O
recapitulating	O
pathogenesis	B-DISO
and	O
summarize	O
the	O
potential	O
role	O
of	O
host	O
receptors	O
contributing	O
to	O
diverse	O
host	O
affinity	O
in	O
various	O
species	O
.	O

The	O
MERS	O
-	O
CoV	O
genome	O
encodes	O
four	O
major	O
structural	O
proteins	O
,	O
among	O
which	O
the	O
spike	O
(	O
S	O
)	O
protein	O
has	O
a	O
key	O
role	O
in	O
viral	B-DISO
infection	I-DISO
and	O
pathogenesis	B-DISO
.	O

Furthermore	O
,	O
the	O
PEDV	O
N	O
protein	O
harbouring	O
truncations	O
of	O
amino	O
acids	O
(	O
aa	O
)	O
1	O
to	O
170	O
or	O
aa	O
125	O
to	O
301	O
was	O
demonstrated	O
to	O
cross	O
-	O
react	O
with	O
the	O
anti	O
-	O
TGEV	O
N	O
polyclonal	O
antibody	O
(	O
PAb	O
),	O
whereas	O
the	O
truncation	B-DISO
-	O
expressing	O
aa	O
302	O
to	O
401	O
resulted	O
in	O
a	O
specific	O
reaction	O
with	O
the	O
anti	O
-	O
PEDV	O
N	O
PAb	O
but	O
not	O
with	O
the	O
anti	O
-	O
TGEV	O
N	O
PAb	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
porcine	O
deltacoronavirus	O
(	O
PDCoV	O
),	O
and	O
swine	O
acute	B-DISO
diarrhea	I-DISO
syndrome	B-DISO
-	O
coronavirus	O
(	O
SADS	O
-	O
CoV	O
)	O
are	O
emerging	O
/	O
reemerging	O
coronaviruses	O
(	O
CoVs	O
).	O

TITLE	O
:	O
Hypersensitivity	B-DISO
Reactions	I-DISO
in	O
Serious	O
Adverse	O
Events	O
Reported	O
for	O
Paracetamol	O
in	O
the	O
EudraVigilance	O
Database	O
,	O
2007	O
⁻	O
2018	O
.	O

We	O
recorded	O
58	O
AE	O
reports	O
with	O
fatal	B-DISO
outcomes	I-DISO
,	O
including	O
9	O
Stevens	B-DISO
-	I-DISO
Johnson	I-DISO
syndrome	I-DISO
/	O
toxic	B-DISO
epidermal	I-DISO
necrolysis	I-DISO
cases	O
(	O
SJS	B-DISO
/	O
TEN	O
),	O
10	O
anaphylactic	B-DISO
reactions	I-DISO
,	O
21	O
cases	O
of	O
hepatic	B-DISO
failure	I-DISO
and	O
a	O
further	O
18	O
cases	O
which	O
occurred	O
for	O
other	O
reasons	O
.	O

380	O
AE	O
reports	O
pointed	O
to	O
a	O
diagnosis	O
of	O
anaphylaxis	B-DISO
.	O

Plasma	O
sVE	O
-	O
cadherin	O
is	O
elevated	O
in	O
sepsis	B-DISO
,	O
malignancy	B-DISO
,	O
autoimmune	B-DISO
diseases	I-DISO
,	O
and	O
coronary	B-DISO
atherosclerosis	I-DISO
.	O

Plasma	O
sVE	O
-	O
cadherin	O
levels	O
by	O
quartile	O
were	O
significantly	O
higher	O
in	O
severe	B-DISO
sepsis	I-DISO
patients	O
with	O
acute	O
kidney	O
injury	O
stage	O
3	O
(	O
p	O
=	O
0	O
.	O
044	O
)	O
as	O
defined	O
by	O
Kidney	B-DISO
Disease	I-DISO
Improving	O
Global	O
Outcomes	O
(	O
KDIGO	O
)	O
criteria	O
.	O

TITLE	O
:	O
Antiviral	O
activity	O
of	O
itraconazole	O
against	O
type	O
I	O
feline	O
coronavirus	B-DISO
infection	I-DISO
.	O

Frequencies	O
≥	O
8	O
Hz	O
and	O
high	O
∆	O
P	O
This	O
is	O
the	O
first	O
study	O
reporting	O
the	O
feasibility	O
of	O
an	O
alternative	O
,	O
individualized	O
,	O
physiology	O
-	O
based	O
open	O
-	O
lung	O
HFOV	O
strategy	O
targeting	O
high	O
F	O
and	O
high	O
∆	O
P	O
RESULTS	O
:	O
Data	O
from	O
115	O
non	O
-	O
cardiac	O
patients	O
were	O
analysed	O
,	O
of	O
whom	O
53	O
had	O
moderate	O
-	O
to	O
-	O
severe	O
paediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
PARDS	O
).	O

Inspite	O
of	O
the	O
active	O
medications	O
it	O
is	O
associated	O
with	O
severe	O
weakness	B-DISO
,	O
incomplete	O
recovery	O
and	O
pain	O
.	O

The	O
pipeline	O
has	O
been	O
validated	O
on	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
,	O
human	O
parainfluenza	B-DISO
virus	O
1	O
-	O
4	O
,	O
human	O
metapneumovirus	O
,	O
human	O
coronaviruses	O
(	O
229E	O
/	O
OC43	O
/	O
NL63	O
/	O
HKU1	O
/	O
SARS	B-DISO
/	O
MERS	O
),	O
human	O
enteroviruses	O
/	O
rhinoviruses	O
,	O
measles	B-DISO
virus	O
,	O
mumps	B-DISO
virus	O
,	O
Hepatitis	B-DISO
A	I-DISO
-	O
E	O
Virus	O
,	O
Chikungunya	B-DISO
virus	O
,	O
dengue	B-DISO
virus	O
,	O
and	O
West	B-DISO
Nile	I-DISO
virus	I-DISO
,	O
as	O
well	O
the	O
human	O
polyomaviruses	O
BK	O
/	O
JC	O
/	O
MCV	O
,	O
human	O
adenoviruses	O
,	O
and	O
human	O
papillomaviruses	O
.	O

Biomarker	O
panels	O
have	O
potential	O
applications	O
in	O
molecular	O
phenotyping	O
for	O
identifying	O
patients	O
at	O
risk	O
of	O
developing	O
ARDS	B-DISO
,	O
diagnosis	O
of	O
ARDS	B-DISO
,	O
risk	O
stratification	O
and	O
monitoring	O
.	O

Two	O
subphenotypes	O
of	O
ARDS	B-DISO
have	O
been	O
identified	O
on	O
the	O
basis	O
of	O
blood	O
biomarkers	O
:	O
hypo	O
-	O
inflammatory	O
and	O
hyper	O
-	O
inflammatory	O
.	O

During	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
influenza	B-DISO
A	O
/	O
H1N1	O
pandemic	O
outbreaks	O
in	O
2003	O
and	O
2009	O
,	O
respectively	O
,	O
customs	O
officers	O
had	O
a	O
fundamental	O
front	O
-	O
line	O
input	O
in	O
the	O
establishment	O
of	O
the	O
recommended	O
at	O
that	O
time	O
border	O
measures	O
.	O

Finally	O
,	O
we	O
extracted	O
the	O
number	O
of	O
swine	O
with	O
PEDV	O
infection	B-DISO
from	O
the	O
obtained	O
studies	O
and	O
provided	O
information	O
that	O
permitted	O
us	O
to	O
estimate	O
the	O
prevalence	O
of	O
PEDV	O
infection	B-DISO
in	O
pigs	O
in	O
mainland	O
China	O
.	O

It	O
usually	O
presents	O
as	O
a	O
severe	O
acute	B-DISO
abdominal	I-DISO
pain	I-DISO
,	O
which	O
prompts	O
surgical	O
exploration	O
.	O

This	O
study	O
was	O
to	O
investigate	O
the	O
relationship	O
between	O
complete	O
blood	O
count	O
(	O
CBC	O
)	O
parameters	O
and	O
the	O
incidence	O
of	O
ARDS	B-DISO
in	O
severe	O
burn	O
patients	O
.	O

Every	O
1	O
%	O
increase	O
in	O
RDW	O
was	O
associated	O
with	O
a	O
29	O
%	O
increase	O
in	O
the	O
risk	O
to	O
develop	O
ARDS	B-DISO
.	O

RESULTS	O
:	O
Of	O
these	O
610	O
patients	O
,	O
143	O
developed	O
ARDS	B-DISO
giving	O
a	O
rate	O
of	O
23	O
.	O
44	O
%.	O

TITLE	O
:	O
A	O
3	O
-	O
Year	O
Retrospective	O
Study	O
of	O
the	O
Epidemiology	O
of	O
Acute	O
Respiratory	O
Viral	B-DISO
Infections	I-DISO
in	O
Pediatric	O
Patients	O
With	O
Cancer	B-DISO
Undergoing	O
Chemotherapy	O
.	O

The	O
first	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
viral	O
etiology	O
and	O
seasonality	O
of	O
acute	O
viral	B-DISO
respiratory	I-DISO
infection	I-DISO
in	O
pediatric	O
patients	O
with	O
cancer	B-DISO
in	O
a	O
3	O
-	O
year	O
study	O
.	O

Nasopharyngeal	O
aspirates	O
were	O
analyzed	O
in	O
patients	O
younger	O
than	O
21	O
years	O
with	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
.	O

The	O
mean	O
duration	O
of	O
neutropenia	O
for	O
patients	O
with	O
viral	B-DISO
respiratory	I-DISO
infection	I-DISO
was	O
17	O
.	O
1	O
±	O
13	O
.	O
8	O
(	O
range	O
:	O
2	O
to	O
90	O
)	O
days	O
.	O

This	O
study	O
investigated	O
the	O
association	O
of	O
macrolides	O
with	O
90	O
-	O
day	O
mortality	O
and	O
MERS	O
coronavirus	O
(	O
CoV	O
)	O
RNA	O
clearance	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
MERS	O
.	O

Polymerase	O
chain	O
reaction	O
-	O
amplified	O
784	O
-	O
bp	O
specific	O
ORT	O
DNA	O
fragments	O
were	O
found	O
in	O
7	O
ORT	O
isolates	O
from	O
lungs	O
,	O
air	O
sacs	B-DISO
,	O
and	O
tracheas	O
of	O
commercial	O
broilers	O
or	O
layers	O
in	O
Egypt	O
in	O
2015	O
.	O

This	O
reveals	O
that	O
the	O
use	O
of	O
live	O
infectious	B-DISO
bronchitic	O
vaccines	O
,	O
which	O
is	O
a	O
common	O
practice	O
in	O
the	O
local	O
Egyptian	O
field	O
of	O
production	O
,	O
may	O
concomitantly	O
increase	O
the	O
pathogenicity	O
of	O
ORT	O
in	O
broiler	O
chickens	O
.	O

Expression	O
of	O
genes	O
encoding	O
inflammatory	O
cytokines	O
and	O
chemokines	O
,	O
including	O
interleukin	O
(	O
IL	O
)-	O
1β	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
15	O
,	O
tumour	B-DISO
necrosis	I-DISO
factor	O
(	O
TNF	O
)-	O
α	O
,	O
CXCL10	O
,	O
CCL8	O
,	O
interferon	O
(	O
IFN	O
)-	O
α	O
,	O
IFN	O
-	O
β	O
and	O
IFN	O
-	O
γ	O
,	O
was	O
higher	O
in	O
cats	O
with	O
FIP	B-DISO
,	O
consistent	O
with	O
inflammatory	O
pathway	O
activation	O
.	O

ABSTRACT	O
:	O
Immunohistochemistry	O
(	O
IHC	O
)	O
of	O
tissue	O
samples	O
is	O
considered	O
the	O
gold	O
standard	O
for	O
diagnosing	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
),	O
and	O
,	O
in	O
cats	O
without	O
body	O
cavity	B-DISO
effusion	B-DISO
,	O
IHC	O
is	O
the	O
only	O
method	O
available	O
to	O
establish	O
definitive	O
antemortem	O
diagnosis	O
.	O

ICC	B-DISO
was	O
positive	O
in	O
17	O
of	O
30	O
cats	O
with	O
FIP	B-DISO
,	O
but	O
also	O
in	O
1	O
of	O
11	O
control	O
cats	O
that	O
was	O
diagnosed	O
with	O
lymphoma	B-DISO
.	O

Sensitivity	O
of	O
ICC	B-DISO
was	O
53	O
%	O
(	O
95	O
%	O
CI	O
:	O
34	O
-	O
72	O
);	O
specificity	O
91	O
%	O
(	O
95	O
%	O
CI	O
:	O
59	O
-	O
100	O
);	O
NPV	O
42	O
%	O
(	O
95	O
%	O
CI	O
:	O
22	O
-	O
63	O
);	O
and	O
PPV	O
94	O
%	O
(	O
95	O
%	O
CI	O
:	O
71	O
-	O
100	O
).	O

Focusing	O
on	O
the	O
mechanism	O
of	O
transmission	O
and	O
infection	B-DISO
for	O
emerging	O
and	O
re	O
-	O
emerging	O
zoonosis	B-DISO
,	O
this	O
research	O
will	O
provide	O
an	O
important	O
.	O

TITLE	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
in	O
a	O
cat	O
presented	O
because	O
of	O
papular	O
skin	O
lesions	O
.	O

A	O
diaphragmatic	O
electromyogram	O
showed	O
bilateral	O
axonal	O
polyneuropathy	B-DISO
of	O
the	O
phrenic	O
nerves	O
.	O

IgG	O
and	O
IgM	O
antibodies	O
to	O
Borrelia	B-DISO
burgdorferi	O
were	O
detectable	O
in	O
serum	O
and	O
cerebrospinal	O
fluid	O
,	O
leading	O
to	O
the	O
diagnosis	O
of	O
Lyme	B-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
Recent	O
outbreaks	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
,	O
along	O
with	O
the	O
threat	O
of	O
a	O
future	O
coronavirus	O
-	O
mediated	O
pandemic	O
,	O
underscore	O
the	O
importance	O
of	O
finding	O
ways	O
to	O
combat	O
these	O
viruses	O
.	O

To	O
understand	O
the	O
humoral	O
immune	O
response	O
elicited	O
upon	O
natural	O
infections	B-DISO
with	O
coronaviruses	O
,	O
we	O
structurally	O
characterized	O
the	O
SARS	B-DISO
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
S	O
glycoproteins	O
in	O
complex	O
with	O
neutralizing	O
antibodies	O
isolated	O
from	O
human	O
survivors	O
.	O

TITLE	O
:	O
Tension	B-DISO
pneumoperitoneum	B-DISO
:	O
Case	O
report	O
of	O
a	O
rare	O
form	O
of	O
acute	O
abdominal	B-DISO
compartment	I-DISO
syndrome	I-DISO
.	O

Because	O
of	O
the	O
need	O
to	O
protect	O
long	O
-	O
lived	O
poultry	O
against	O
respiratory	O
tract	O
pathogens	O
from	O
an	O
early	O
age	O
,	O
vaccination	O
programs	O
for	O
pullets	O
typically	O
involve	O
serial	O
administration	O
of	O
a	O
variety	O
of	O
vaccines	O
,	O
including	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
),	O
Newcastle	B-DISO
disease	I-DISO
virus	O
(	O
NDV	O
),	O
and	O
infectious	B-DISO
laryngotracheitis	B-DISO
virus	O
(	O
ILTV	O
).	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
endemic	O
in	O
dromedary	O
camels	O
in	O
the	O
Arabian	O
Peninsula	O
,	O
and	O
zoonotic	O
transmission	O
to	O
people	O
is	O
a	O
sporadic	O
event	O
.	O

This	O
study	O
aimed	O
to	O
identify	O
meteorological	O
factors	O
that	O
may	O
increase	O
the	O
risk	O
of	O
primary	O
MERS	O
infections	B-DISO
in	O
humans	O
.	O

Cases	O
with	O
symptom	B-DISO
onset	O
between	O
January	O
2015	O
-	O
December	O
2017	O
were	O
obtained	O
from	O
a	O
publicly	O
available	O
line	O
list	O
of	O
human	O
MERS	O
cases	O
maintained	O
by	O
the	O
World	O
Health	O
Organization	O
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
describe	O
the	O
beneficial	O
and	O
deleterious	O
effects	O
of	O
spontaneous	O
breathing	O
in	O
ARDS	B-DISO
,	O
explain	O
potential	O
mechanisms	O
for	O
harm	O
,	O
and	O
provide	O
contemporary	O
suggestions	O
for	O
clinical	O
management	O
.	O

Finally	O
,	O
several	O
approaches	O
to	O
minimize	O
P	O
-	O
SILI	O
while	O
maintaining	O
some	O
diaphragm	O
activity	O
(	O
e	O
.	O
g	O
.	O
partial	O
neuromuscular	B-DISO
blockade	I-DISO
,	O
high	O
PEEP	O
)	O
appear	O
promising	O
.	O

TITLE	O
:	O
Evidence	O
for	O
Cross	O
-	O
Protection	O
Against	O
Subsequent	O
Febrile	O
Respiratory	O
Illness	O
Episodes	O
From	O
Prior	O
Infections	B-DISO
by	O
Different	O
Viruses	O
Among	O
Singapore	O
Military	O
Recruits	O
2009	O
-	O
2014	O
.	O

Adenovirus	B-DISO
-	O
positive	O
participants	O
with	O
FRI	O
episodes	O
tended	O
to	O
be	O
protected	O
against	O
subsequent	O
infection	B-DISO
with	O
adenovirus	B-DISO
,	O
coronavirus	O
,	O
enterovirus	O
/	O
rhinovirus	O
,	O
and	O
influenza	B-DISO
virus	O
(	O
P	O
=	O
.	O
062	O
-.	O
093	O
),	O
while	O
men	O
with	O
influenza	B-DISO
virus	O
-	O
positive	O
FRI	O
episodes	O
tended	O
be	O
protected	O
against	O
subsequent	O
infection	B-DISO
with	O
adenovirus	B-DISO
(	O
P	O
=	O
.	O
044	O
)	O
and	O
influenza	B-DISO
virus	O
(	O
P	O
=	O
.	O
081	O
).	O

TITLE	O
:	O
Mechanical	O
Ventilation	O
and	O
Extracorporeal	O
Membrane	O
Oxygena	O
tion	O
in	O
Acute	B-DISO
Respiratory	I-DISO
Insufficiency	I-DISO
.	O

In	O
a	O
German	O
prevalence	O
study	O
,	O
13	O
.	O
6	O
%	O
of	O
patients	O
in	O
intensive	O
care	O
units	O
received	O
mechanical	O
ventilation	O
for	O
more	O
than	O
12	O
hours	O
;	O
20	O
%	O
of	O
these	O
patients	O
received	O
mechanical	O
ventilation	O
as	O
treatment	O
for	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Pairwise	O
identity	O
analysis	O
of	O
the	O
whole	O
genome	O
sequences	O
revealed	O
that	O
PEDV	O
/	O
Belgorod	O
/	O
dom	O
/	O
2008	O
is	O
an	O
intermediate	O
between	O
PEDV	O
and	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
strains	O
.	O

There	O
are	O
many	O
diseases	O
that	O
are	O
evaluated	O
using	O
an	O
ABG	O
which	O
include	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
severe	B-DISO
sepsis	I-DISO
,	O
septic	O
shock	B-DISO
,	I-DISO
hypovolemic	I-DISO
shock	O
,	O
diabetic	B-DISO
ketoacidosis	I-DISO
,	O
renal	B-DISO
tubular	I-DISO
acidosis	I-DISO
,	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
,	O
heart	B-DISO
failure	I-DISO
,	O
cardiac	B-DISO
arrest	I-DISO
,	O
asthma	B-DISO
and	O
inborn	B-DISO
errors	I-DISO
of	I-DISO
metabolism	I-DISO
.	O

However	O
,	O
when	O
one	O
-	O
lung	O
ventilation	O
is	O
complicated	O
by	O
traumatic	B-DISO
wet	I-DISO
lung	I-DISO
,	O
the	O
mortality	O
rate	O
is	O
likely	O
to	O
be	O
much	O
higher	O
.	O

ABSTRACT	O
:	O
Identifying	O
viral	O
antagonists	O
of	O
innate	O
immunity	O
and	O
determining	O
if	O
they	O
contribute	O
to	O
pathogenesis	B-DISO
are	O
critical	O
for	O
developing	O
effective	O
strategies	O
to	O
control	O
emerging	O
viruses	O
.	O

These	O
results	O
demonstrate	O
that	O
EndoU	O
activity	O
is	O
not	O
required	O
for	O
PEDV	O
replication	O
in	O
immortalized	O
,	O
IFN	O
-	O
deficient	O
Vero	O
cells	O
,	O
but	O
is	O
important	O
for	O
suppressing	O
the	O
IFN	O
response	O
in	O
epithelial	O
cells	O
and	O
macrophages	O
,	O
which	O
facilitates	O
replication	O
,	O
shedding	O
,	O
and	O
pathogenesis	B-DISO

These	O
results	O
indicate	O
that	O
scFv	O
antibodies	O
provide	O
protection	O
against	O
viral	B-DISO
infection	I-DISO
in	O
vitro	O
and	O
may	O
be	O
a	O
therapeutic	O
candidate	O
for	O
both	O
prevention	O
and	O
treatment	O
of	O
TGEV	O
infection	B-DISO
in	O
swine	O
.	O

TITLE	O
:	O
Platelets	O
inhibit	O
apoptotic	O
lung	O
epithelial	O
cell	O
death	O
and	O
protect	O
mice	O
against	O
infection	B-DISO
-	O
induced	O
lung	O
injury	O
.	O

Each	O
of	O
the	O
reviews	O
is	O
authored	O
by	O
experts	O
in	O
their	O
fields	O
and	O
our	O
intention	O
is	O
to	O
provide	O
comprehensive	O
updates	O
in	O
specific	O
areas	O
of	O
pathology	B-DISO
in	O
which	O
there	O
has	O
been	O
considerable	O
recent	O
progress	O
.	O

ABSTRACT	O
:	O
Dakshina	O
Kannada	O
district	O
in	O
the	O
Southwestern	O
region	O
of	O
Karnataka	O
state	O
,	O
India	O
,	O
including	O
Mangaluru	O
city	O
is	O
endemic	O
to	O
malaria	B-DISO
.	O

<	O
strong	O
>	O
RESULTS	O
</	O
strong	O
>	O
We	O
found	O
the	O
HIPK1	O
was	O
elevated	O
in	O
ALI	O
model	O
mice	O
while	O
interference	O
of	O
HIPK1	O
by	O
siRNA	O
attenuated	O
the	O
inflammation	B-DISO
and	O
oxidative	B-DISO
stress	I-DISO
indicators	O
(	O
H2O2	O
,	O
O	O
-	O
2	O
,	O
and	O
NO	O
).	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
(	O
IB	O
)	O
generated	O
by	O
the	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
causes	O
economic	O
difficulties	O
for	O
livestock	O
farmers	O
.	O

Patients	O
with	O
common	O
medical	O
comorbidities	O
are	O
at	O
higher	O
risk	O
for	O
life	O
-	O
threatening	O
complications	O
in	O
the	O
setting	O
of	O
severe	O
ovarian	B-DISO
hyperstimulation	I-DISO
syndrome	I-DISO
.	O

RESULTS	O
:	O
A	O
total	O
of	O
11	O
,	O
562	O
patients	O
were	O
hospitalized	O
with	O
severe	O
ovarian	B-DISO
hyperstimulation	I-DISO
syndrome	I-DISO
from	O
2002	O
to	O
2011	O
.	O

This	O
article	O
reviews	O
neuromuscular	O
emergencies	B-DISO
by	O
localization	O
in	O
the	O
peripheral	O
nervous	B-DISO
system	O
of	O
the	O
underlying	O
disorder	O
,	O
as	O
well	O
as	O
the	O
identification	O
and	O
management	O
of	O
neuromuscular	O
respiratory	B-DISO
failure	I-DISO
.	O

Laboratory	O
examination	O
indicated	O
severe	B-DISO
sepsis	I-DISO
with	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
,	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
while	O
the	O
Doppler	O
ultrasonography	O
of	O
the	O
carotids	O
revealed	O
left	O
internal	O
jugular	O
venous	B-DISO
thrombosis	I-DISO
.	O

The	O
patient	O
was	O
administered	O
piperacillin	O
/	O
tazobactam	O
and	O
vancomycin	O
intravenously	O
,	O
doxycycline	O
orally	O
,	O
and	O
anti	O
-	O
coagulation	O
by	O
enoxaparin	O
based	O
on	O
the	O
diagnosis	O
of	O
Lemierre	B-DISO
syndrome	I-DISO
.	O

Meanwhile	O
,	O
he	O
was	O
complicated	O
by	O
bilateral	O
diffuse	O
pulmonary	O
cavities	B-DISO
and	O
encapsulated	O
pleural	B-DISO
effusions	I-DISO
and	O
so	O
transcutaneous	O
drainage	O
was	O
performed	O
.	O

TITLE	O
:	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Coronavirus	O
Viroporin	O
3a	O
Activates	O
the	O
NLRP3	O
Inflammasome	O
.	O

Nasopharyngeal	O
swabs	O
along	O
with	O
clinical	O
and	O
demographic	O
data	O
were	O
collected	O
from	O
patients	O
with	O
pediatric	B-DISO
cancer	I-DISO
presenting	O
febrile	O
episodes	O
with	O
upper	O
respiratory	O
tract	O
symptoms	O
.	O

Total	O
nucleic	O
acid	O
was	O
extracted	O
from	O
specimens	O
followed	O
by	O
the	O
real	O
-	O
time	O
PCR	O
analysis	O
targeting	O
14	O
respiratory	O
viruses	O
to	O
estimate	O
the	O
frequency	O
of	O
infections	B-DISO
.	O

HCoV	O
was	O
associated	O
with	O
bronchiolitis	B-DISO
;	O
rhinovirus	O
was	O
associated	O
with	O
hospital	O
admission	O
.	O

CONCLUSIONS	O
:	O
Patients	O
with	O
pediatric	B-DISO
cancer	I-DISO
have	O
a	O
high	O
burden	O
of	O
respiratory	O
viral	B-DISO
infections	I-DISO
and	O
a	O
high	O
incidence	O
of	O
coinfections	B-DISO
.	O

ABSTRACT	O
:	O
Vaccination	O
programs	O
are	O
implemented	O
in	O
poultry	O
farms	O
to	O
limit	O
outbreaks	O
and	O
spread	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
),	O
which	O
is	O
a	O
substantial	O
economic	O
burden	O
in	O
the	O
poultry	O
industry	O
.	O

By	O
combining	O
metabolic	O
endotypes	O
with	O
clinical	O
based	O
mortality	O
score	O
(	O
APACHE	O
and	O
SOFA	O
)	O
added	O
to	O
their	O
predictive	O
performance	O
as	O
ARDS	B-DISO
mortality	O
predictors	O
.	O

TITLE	O
:	O
Kaempferol	O
reduces	O
K63	O
-	O
linked	O
polyubiquitination	O
to	O
inhibit	O
nuclear	O
factor	O
-	O
κB	O
and	O
inflammatory	B-DISO
responses	I-DISO
in	O
acute	O
lung	O
injury	O
in	O
mice	O
.	O

ABSTRACT	O
:	O
Respiratory	O
viral	B-DISO
infections	I-DISO
are	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
worldwide	O
.	O

We	O
combined	O
personal	O
information	O
with	O
weekly	O
nasal	O
swab	O
collection	O
to	O
investigate	O
the	O
prevalence	O
of	O
18	O
respiratory	O
viruses	O
among	O
different	O
age	O
groups	O
and	O
to	O
assess	O
risk	O
factors	O
associated	O
with	O
infection	B-DISO
susceptibility	O
.	O

The	O
observations	O
identify	O
children	O
as	O
the	O
principal	O
source	O
of	O
respiratory	B-DISO
infections	I-DISO
.	O

TITLE	O
:	O
Forecasting	O
herd	O
-	O
level	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
(	O
PED	O
)	O
frequency	O
trends	O
in	O
Ontario	O
(	O
Canada	O
).	O

These	O
findings	O
do	O
not	O
support	O
PES	O
-	O
guided	O
PEEP	O
titration	O
in	O
ARDS	B-DISO
.	O

TITLE	O
:	O
The	O
Cost	O
-	O
Effectiveness	O
of	O
Interventions	O
to	O
Increase	O
Utilization	O
of	O
Prone	O
Positioning	O
for	O
Severe	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
.	O

This	O
study	O
determines	O
the	O
cost	O
-	O
effectiveness	O
of	O
interventions	O
to	O
increase	O
utilization	O
of	O
proning	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

If	O
society	O
was	O
willing	O
to	O
pay	O
$	O
100	O
,	O
000	O
per	O
quality	O
-	O
adjusted	O
life	O
year	O
,	O
any	O
intervention	O
costing	O
less	O
than	O
$	O
51	O
,	O
328	O
per	O
patient	O
with	O
moderate	O
to	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
would	O
represent	O
good	O
value	O
.	O

Specific	O
products	O
related	O
to	O
hypoxia	B-DISO
may	O
serve	O
as	O
early	O
biomarkers	O
for	O
ARDS	B-DISO
prediction	O
,	O
while	O
the	O
metabolites	O
with	O
significant	O
correlations	O
with	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
(	O
PaO	O
RESULTS	O
:	O
A	O
total	O
of	O
222	O
metabolites	O
were	O
identified	O
in	O
our	O
study	O
,	O
of	O
which	O
128	O
were	O
significantly	O
altered	O
in	O
patients	O
with	O
ARDS	B-DISO
compared	O
with	O
healthy	O
controls	O
.	O

TITLE	O
:	O
Interferon	O
Regulatory	O
Factor	O
3	O
-	O
Mediated	O
Signaling	O
Limits	O
Middle	O
-	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
Coronavirus	O
Propagation	O
in	O
Cells	O
from	O
an	O
Insectivorous	O
Bat	O
.	O

Japanese	O
patients	O
aged	O
0	O
-	O
74	O
years	O
diagnosed	O
with	O
influenza	B-DISO
by	O
a	O
rapid	O
test	O
in	O
employment	O
-	O
related	O
health	O
insurance	O
records	O
.	O

There	O
were	O
statistically	O
significant	O
decreasing	O
trends	O
over	O
the	O
years	O
in	O
the	O
incidence	O
of	O
all	O
-	O
cause	O
hospitalisations	O
,	O
pneumonia	B-DISO
and	O
febrile	B-DISO
seizures	I-DISO
.	O

Strikingly	O
,	O
6	O
-	O
5	O
exhibited	O
a	O
promising	O
inhibitory	O
activity	O
against	O
SARS	B-DISO
-	O
CoV	O
M	O

ABSTRACT	O
:	O
With	O
rapidly	O
increasing	O
animal	O
pathogen	O
surveillance	O
requirements	O
,	O
new	O
technologies	O
are	O
needed	O
for	O
a	O
comprehensive	O
understanding	O
of	O
the	O
roles	O
of	O
pathogens	O
in	O
the	O
occurrence	O
and	O
development	O
of	O
animal	B-DISO
diseases	I-DISO
.	O

The	O
results	O
showed	O
that	O
the	O
method	O
could	O
simultaneously	O
detect	O
major	O
viruses	O
infecting	O
farms	O
,	O
including	O
avian	B-DISO
influenza	I-DISO
virus	O
,	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
,	O
Newcastle	B-DISO
disease	I-DISO
virus	O
,	O
rotavirus	O
G	O
,	O
duck	O
hepatitis	B-DISO
B	I-DISO
virus	O
,	O
and	O
avian	O
leukemia	B-DISO
virus	O
subgroup	O
J	O
in	O
several	O
farms	O
.	O

ABSTRACT	O
:	O
In	O
2015	O
,	O
a	O
One	O
Health	O
Working	O
Group	O
was	O
established	O
in	O
Qatar	O
to	O
conduct	O
a	O
survey	O
in	O
the	O
Gulf	O
Cooperation	O
Council	O
countries	O
,	O
Egypt	O
,	O
and	O
Jordan	O
to	O
monitor	O
preparedness	O
of	O
public	O
health	O
and	O
veterinary	O
health	O
authorities	O
in	O
response	O
to	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
epidemic	O
.	O

Adult	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
based	O
on	O
Sepsis	B-DISO
-	O
2	O
were	O
enrolled	O
and	O
divided	O
into	O
three	O
categories	O
(	O
body	O
temperature	O
<	O
36	O
°	O
C	O
,	O
36	O
-	O
38	O
°	O
C	O
,	O
>	O
38	O
°	O
C	O
),	O
using	O
the	O
core	O
body	O
temperature	O
at	O
ICU	O
admission	O
.	O

TITLE	O
:	O
Moderate	O
to	O
Severe	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
Management	O
Strategies	O
:	O
A	O
Narrative	O
Review	O
.	O

Occurrence	O
,	O
risk	O
factors	O
,	O
and	O
outcomes	O
of	O
early	O
onset	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
were	O
also	O
evaluated	O
.	O

Independent	O
predictors	O
of	O
early	O
onset	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
were	O
determined	O
by	O
multiple	O
logistic	O
regression	O
analysis	O
based	O
on	O
clinical	O
characteristics	O
and	O
initial	O
management	O
.	O

Early	O
onset	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
appeared	O
to	O
be	O
associated	O
with	O
lung	O
contusion	O
of	O
>	O
20	O
%	O
of	O
total	O
lung	O
volume	O
and	O
early	O
onset	O
pneumonia	B-DISO
.	O

Either	O
in	O
conjunction	O
with	O
or	O
in	O
the	O
absence	O
of	O
CRS	B-DISO
,	O
a	O
subset	O
of	O
patients	O
may	O
also	O
develop	O
mild	O
to	O
severe	O
neurotoxicity	O
.	O

Risk	O
adaptive	O
modeling	O
incorporating	O
disease	O
profile	O
,	O
patient	O
demographics	O
,	O
lymphodepletion	O
,	O
cell	O
dosing	O
,	O
CAR	B-DISO
T	O
construct	O
,	O
and	O
potentially	O
cytokine	O
gene	O
polymorphisms	O
may	O
be	O
instructive	O
to	O
assess	O
individualized	O
risk	O
and	O
optimal	O
CRS	B-DISO
/	O
neurotoxicity	O
management	O
.	O

A	O
sensitive	O
diagnostic	O
method	O
would	O
be	O
beneficial	O
to	O
the	O
prevention	O
and	O
control	O
of	O
PDCoV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Evaluation	O
of	O
the	O
thermal	O
and	O
physical	O
conditions	O
for	O
inactivation	B-DISO
of	O
adenovirus	B-DISO
(	O
AdV	O
),	O
porcine	O
sapelovirus	O
1	O
(	O
PSV1	O
)	O
and	O
the	O
economically	O
important	O
viruses	O
porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
virus	O
(	O
PEDV	O
)	O
and	O
porcine	O
circovirus	O
2	O
(	O
PCV2	O
)	O
in	O
the	O
production	O
of	O
spray	O
-	O
dried	O
porcine	O
plasma	O
(	O
SDPP	O
).	O

TITLE	O
:	O
Correction	O
to	O
:	O
Genetic	O
Evidence	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
Cov	O
)	O
and	O
Widespread	O
Seroprevalence	O
among	O
Camels	O
in	O
Kenya	O
.	O

ABSTRACT	O
:	O
Despite	O
recent	O
advances	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
remains	O
a	O
severe	O
and	O
often	O
fatal	O
disease	O
for	O
which	O
there	O
is	O
no	O
therapy	O
able	O
to	O
reduce	O
the	O
underlying	O
excessive	O
lung	B-DISO
inflammation	I-DISO
or	O
enhance	O
resolution	O
of	O
injury	O
.	O

Metabolic	O
programming	O
plays	O
a	O
critical	O
role	O
in	O
regulating	O
inflammatory	B-DISO
responses	I-DISO
.	O

Rhinovirus	O
was	O
the	O
most	O
prevalent	O
virus	O
(	O
66	O
%),	O
followed	O
by	O
parainfluenza	B-DISO
(	O
19	O
%),	O
and	O
coronavirus	O
(	O
16	O
%).	O

Future	O
investigations	O
examining	O
longitudinal	O
relationships	O
between	O
viral	B-DISO
infections	I-DISO
,	O
airway	O
microbiome	O
,	O
and	O
antibiotic	O
use	O
will	O
allow	O
us	O
to	O
elucidate	O
the	O
interplay	O
between	O
these	O
factors	O
in	O
young	O
children	O
with	O
CF	O
.	O

ABSTRACT	O
:	O
Genotyping	O
of	O
avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
virus	O
(	O
IBV	O
)	O
was	O
performed	O
on	O
trachea	B-DISO
and	O
kidney	O
samples	O
of	O
six	O
chickens	O
obtained	O
from	O
a	O
single	O
farm	O
in	O
Japan	O
.	O

TITLE	O
:	O
Successful	O
extracorporeal	O
life	O
support	O
in	O
respiratory	B-DISO
failure	I-DISO
after	O
copper	O
sulphate	O
ingestion	O
.	O

She	O
had	O
minimal	O
intravascular	B-DISO
haemolysis	I-DISO
and	O
methemoglobinaemia	O
but	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
4	O
hours	O
after	O
acute	O
copper	O
sulphate	O
poisoning	O
.	O

Acute	O
copper	O
sulphate	O
poisoning	O
can	O
cause	O
severe	O
pulmonary	B-DISO
toxicity	I-DISO
even	O
in	O
the	O
absence	O
of	O
other	O
serious	O
symptoms	O
.	O

We	O
suggest	O
early	O
initiation	O
of	O
venovenous	O
ECMO	O
in	O
those	O
with	O
ARDS	B-DISO
following	O
copper	O
sulphate	O
poisoning	O
.	O

The	O
presence	O
of	O
S	O
-	O
IgG	O
prior	O
to	O
viral	O
clearance	O
,	O
however	O
,	O
abrogated	O
wound	O
-	O
healing	O
responses	O
and	O
promoted	O
MCP1	O
and	O
IL	O
-	O
8	O
production	O
and	O
proinflammatory	O
monocyte	O
/	O
macrophage	O
recruitment	B-DISO
and	O
accumulation	O
.	O

Our	O
findings	O
reveal	O
a	O
mechanism	O
responsible	O
for	O
virus	O
-	O
mediated	O
ALI	O
,	O
define	O
a	O
pathological	O
consequence	O
of	O
viral	O
specific	O
antibody	O
response	O
,	O
and	O
provide	O
a	O
potential	O
target	O
for	O
treatment	O
of	O
SARS	B-DISO
-	O
CoV	O
or	O
other	O
virus	O
-	O
mediated	O
lung	O
injury	O
.	O

Rapid	O
diagnosis	O
of	O
these	O
multiple	O
infections	B-DISO
is	O
important	O
for	O
providing	O
timely	O
and	O
effective	O
treatment	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
Standardized	O
Mortality	O
Ratio	O
(	O
SMR	O
)	O
for	O
ARDS	B-DISO
in	O
leptospirosis	B-DISO
based	O
on	O
the	O
quartiles	O
of	O
the	O
SAPS2	O
score	O
in	O
the	O
reference	O
population	O
of	O
1683	O
patients	O
hospitalized	O
for	O
ARDS	B-DISO
.	O

The	O
second	O
outcomes	O
were	O
to	O
determine	O
the	O
risk	O
factors	O
of	O
mortality	O
of	O
ARDS	B-DISO
in	O
leptospirosis	B-DISO
and	O
to	O
describe	O
the	O
cases	O
requiring	O
Extracorporeal	O
Membrane	O
Oxygenation	O
(	O
ECMO	O
).	O

Here	O
we	O
show	O
that	O
vaccination	O
with	O
an	O
adjuvanted	O
MERS	O
-	O
CoV	O
Spike	O
protein	O
subunit	O
vaccine	O
confers	O
complete	O
protection	O
from	O
MERS	O
-	O
CoV	O
disease	O
in	O
alpaca	O
and	O
results	O
in	O
reduced	O
and	O
delayed	O
viral	B-DISO
shedding	I-DISO
in	O
the	O
upper	O
airways	O
of	O
dromedary	O
camels	O
.	O

ABSTRACT	O
:	O
Mouse	B-DISO
hepatitis	I-DISO
virus	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
is	O
a	O
representative	O
member	O
of	O
the	O
genus	O
betacoronavirus	O
within	O
the	O
subfamily	O
Coronavirinae	O
,	O
which	O
infects	O
the	O
liver	O
,	O
brain	O
and	O
respiratory	O
tract	O
.	O

ABSTRACT	O
:	O
Pneumonia	B-DISO
severity	O
index	O
(	O
PSI	O
)	O
is	O
an	O
important	O
scoring	O
system	O
that	O
can	O
assess	O
the	O
severity	O
of	O
community	B-DISO
acquired	I-DISO
pneumonia	I-DISO
and	O
determine	O
admission	O
status	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
usefulness	O
of	O
PSI	O
in	O
viral	O
community	B-DISO
acquired	I-DISO
pneumonia	I-DISO
.	O

Viral	B-DISO
infections	I-DISO
were	O
diagnosed	O
by	O
multiplex	O
PCR	O
.	O

Patients	O
diagnosed	O
with	O
non	O
-	O
viral	O
community	O
-	O
acquired	O
pneumonia	B-DISO
were	O
included	O
in	O
the	O
control	O
group	O
(	O
N	O
=	O
1	O
,	O
173	O
).	O

CONCLUSIONS	O
:	O
Extended	O
indications	O
of	O
ECMO	O
implementation	O
coupled	O
with	O
protective	O
ventilator	O
settings	O
may	O
improve	O
the	O
clinical	O
outcome	O
of	O
patients	O
with	O
ARDS	B-DISO
.	O

TITLE	O
:	O
An	O
electrochemical	O
immunosensor	O
for	O
the	O
corona	O
virus	O
associated	O
with	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
using	O
an	O
array	O
of	O
gold	O
nanoparticle	O
-	O
modified	O
carbon	O
electrodes	O
.	O

The	O
various	O
prevalence	O
factors	O
associated	O
with	O
ECoV	O
qPCR	O
-	O
positive	O
status	O
likely	O
relate	O
to	O
the	O
high	O
infectious	B-DISO
nature	O
of	O
ECoV	O
and	O
breed	O
-	O
specific	O
differences	O
in	O
management	O
and	O
husbandry	O
practices	O
.	O

ECoV	O
infection	B-DISO
should	O
be	O
suspected	O
and	O
tested	O
for	O
in	O
horses	O
presenting	O
with	O
acute	O
onset	O
of	O
fever	O
,	O
lethargy	B-DISO
and	O
anorexia	B-DISO
with	O
no	O
respiratory	O
signs	O
.	O

ABSTRACT	O
:	O
The	O
epidemiology	O
and	O
genetic	O
diversity	O
of	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
in	O
the	O
United	O
States	O
(	O
US	O
)	O
was	O
investigated	O
by	O
testing	O
clinical	O
cases	O
for	O
TGEV	O
by	O
real	O
time	O
RT	O
-	O
PCR	O
between	O
January	O
2008	O
and	O
November	O
2016	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
ICU	O
and	O
hospital	O
mortality	O
rates	O
of	O
the	O
ARDS	B-DISO
and	O
non	O
-	O
ARDS	B-DISO
patients	O
.	O

Logistic	O
regression	O
analysis	O
revealed	O
that	O
a	O
high	O
tidal	O
volume	O
(	O
odds	O
ratio	O
=	O
1	O
.	O
448	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
033	O
-	O
2	O
.	O
030	O
;	O
p	O
=	O
0	O
.	O
032	O
)	O
and	O
sequential	O
organ	B-DISO
failure	I-DISO
assessment	O
(	O
SOFA	O
)	O
score	O
(	O
odds	O
ratio	O
=	O
1	O
.	O
233	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
029	O
-	O
1	O
.	O
478	O
;	O
p	O
=	O
0	O
.	O
023	O
)	O
were	O
the	O
risk	O
factors	O
of	O
hospital	O
mortality	O
.	O

TITLE	O
:	O
N	O
-	O
Linked	O
glycosylation	O
of	O
the	O
membrane	O
protein	O
ectodomain	O
regulates	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
-	O
induced	O
ER	O
stress	O
response	O
,	O
apoptosis	O
and	O
pathogenesis	B-DISO
.	O

TITLE	O
:	O
Construction	O
of	O
a	O
Recombinant	O
Lactococcus	O
lactis	O
Strain	O
Expressing	O
a	O
Variant	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
S1	O
Gene	O
and	O
Its	O
Immunogenicity	O
Analysis	O
in	O
Mice	O
.	O

Lymphocyte	O
proliferation	B-DISO
assay	O
results	O
showed	O
that	O
the	O
recombinant	O
L	O
.	O
lactis	O
pNZ8149	O
-	O
S1	O
/	O
NZ3900	O
significantly	O
stimulated	O
the	O
proliferation	B-DISO
of	O
splenic	O
lymphocytes	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
incidence	O
of	O
cannula	O
-	O
related	O
thrombosis	B-DISO
and	O
its	O
risk	O
factors	O
after	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

We	O
analyzed	O
consecutive	O
patients	O
with	O
severe	O
respiratory	B-DISO
failure	I-DISO
(	O
PaO2	O
/	O
FIO2	O
<	O
85	O
mm	O
Hg	O
and	O
/	O
or	O
respiratory	B-DISO
acidosis	I-DISO
with	O
pH	O
<	O
7	O
.	O
25	O
)	O
who	O
were	O
successfully	O
treated	O
with	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
in	O
a	O
medical	O
ICU	O
between	O
2010	O
and	O
2017	O
.	O

Thrombosis	B-DISO
was	O
classified	O
as	O
a	O
large	O
thrombosis	B-DISO
by	O
vein	B-DISO
occlusion	I-DISO
of	O
greater	O
than	O
50	O
%.	O

One	O
-	O
hundred	O
six	O
patients	O
(	O
62	O
%)	O
showed	O
thrombosis	B-DISO
that	O
was	O
considered	O
large	O
in	O
48	O
of	O
172	O
(	O
28	O
%).	O

The	O
incidence	O
of	O
thrombosis	B-DISO
was	O
higher	O
in	O
patients	O
with	O
a	O
mean	O
aPTT	O
of	O
less	O
than	O
or	O
equal	O
to	O
50	O
seconds	O
(	O
odds	O
ratio	O
,	O
1	O
.	O
02	O
;	O
p	O
=	O
0	O
.	O
013	O
)	O
and	O
in	O
patients	O
with	O
a	O
decline	O
in	O
D	O
-	O
dimer	O
less	O
than	O
or	O
equal	O
to	O
50	O
%	O
(	O
odds	O
ratio	O
,	O
2	O
.	O
76	O
;	O
p	O
=	O
0	O
.	O
041	O
)	O
the	O
day	O
after	O
decannulation	O
following	O
adjustment	O
for	O
risk	O
factors	O
.	O

Reduced	O
systemic	O
anticoagulation	O
may	O
enhance	O
the	O
risk	O
of	O
thrombosis	B-DISO
.	O

Sustained	O
elevation	O
of	O
D	O
-	O
dimer	O
after	O
decannulation	O
may	O
indicate	O
thrombosis	B-DISO
.	O

5	O
.	O
5	O
%	O
of	O
pre	O
-	O
Hajj	O
,	O
95	O
.	O
2	O
%	O
of	O
per	O
-	O
Hajj	O
(	O
at	O
symptom	B-DISO
onset	O
)	O
and	O
46	O
.	O
5	O
%	O
of	O
post	O
-	O
Hajj	O
samples	O
tested	O
positive	O
(	O
p	O
<	O
0	O
.	O
0001	O
).	O

TITLE	O
:	O
Acute	O
hypoxic	B-DISO
respiratory	B-DISO
failure	I-DISO
secondary	O
to	O
antisynthetase	B-DISO
syndrome	I-DISO
:	O
A	O
case	O
report	O
and	O
review	O
of	O
literature	O
.	O

The	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
of	O
this	O
syndrome	B-DISO
can	O
vary	O
in	O
severity	O
and	O
if	O
not	O
identified	O
soon	O
enough	O
,	O
can	O
lead	O
to	O
severe	O
respiratory	B-DISO
failure	I-DISO
.	O

CT	O
chest	O
revealed	O
interval	O
improvement	O
in	O
his	O
bilateral	O
ground	O
glass	O
and	O
reticular	O
opacities	B-DISO
but	O
residual	O
fibrotic	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
.	O

We	O
have	O
performed	O
a	O
comprehensive	O
review	O
of	O
30	O
cases	O
of	O
antisynthetase	B-DISO
syndrome	I-DISO
in	O
the	O
literature	O
(	O
including	O
our	O
case	O
).	O

By	O
using	O
a	O
representative	O
arenavirus	O
,	O
bunyavirus	O
,	O
coronavirus	O
,	O
filovirus	O
,	O
flavivirus	O
,	O
orthomyxovirus	O
,	O
and	O
paramyxovirus	O
,	O
we	O
found	O
that	O
these	O
enveloped	O
viruses	O
differed	O
in	O
their	O
susceptibility	O
to	O
irradiation	O
treatment	O
with	O
adsorbed	O
doses	O
for	O
inactivation	B-DISO
of	O
a	O
target	O
dose	O
of	O
1	O
×	O
10	O

TITLE	O
:	O
Endemic	O
infection	B-DISO
can	O
shape	O
exposure	O
to	O
novel	O
pathogens	O
:	O
Pathogen	O
co	O
-	O
occurrence	O
networks	O
in	O
the	O
Serengeti	O
lions	O
.	O

We	O
recruited	O
60	O
febrile	O
pediatric	O
patients	O
with	O
a	O
positive	O
scrub	B-DISO
typhus	I-DISO
rapid	O
diagnostic	O
test	O
result	O
and	O
40	O
healthy	O
controls	O
from	O
Chiang	O
Rai	O
Province	O
in	O
northern	O
Thailand	O
.	O

Only	O
4	O
(	O
11	O
%)	O
of	O
35	O
patients	O
received	O
appropriate	O
antibiotic	O
treatment	O
for	O
scrub	B-DISO
typhus	I-DISO
before	O
admission	O
.	O

ABSTRACT	O
:	O
Dromedary	O
camels	O
are	O
natural	O
host	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

TITLE	O
:	O
Evaluation	O
of	O
the	O
Serologic	O
Cross	O
-	O
Reactivity	O
between	O
Transmissible	O
Gastroenteritis	B-DISO
Coronavirus	O
and	O
Porcine	O
Respiratory	O
Coronavirus	O
Using	O
Commercial	O
Blocking	B-DISO
Enzyme	O
-	O
Linked	O
Immunosorbent	O
Assay	O
Kits	O
.	O

The	O
seroprevalence	O
of	O
MERS	O
-	O
CoV	O
antibodies	O
increases	O
with	O
age	O
in	O
camels	O
,	O
while	O
the	O
prevalence	O
of	O
viral	B-DISO
shedding	I-DISO
as	O
determined	O
by	O
MERS	O
-	O
CoV	O
RNA	O
detection	O
in	O
nasal	O
swabs	O
decreases	O
.	O

The	O
match	O
-	O
point	O
for	O
UHBI	O
vs	O
.	O
LHBI	O
was	O
set	O
at	O
1	O
cm	O
above	O
the	O
iliac	O
crest	B-DISO
.	O

Future	O
directions	O
include	O
efforts	O
to	O
facilitate	O
earlier	O
recognition	O
of	O
ARDS	B-DISO
,	O
identifying	O
responsive	O
subsets	O
of	O
patients	O
and	O
ongoing	O
efforts	O
to	O
understand	O
fundamental	O
mechanisms	O
of	O
lung	O
injury	O
to	O
design	O
specific	O
treatments	O
.	O

ABSTRACT	O
:	O
Bovine	O
respiratory	B-DISO
disease	I-DISO
(	O
BRD	O
)	O
causes	O
considerable	O
economic	O
losses	O
in	O
North	O
America	O
.	O

Despite	O
more	O
severe	O
respiratory	B-DISO
failure	I-DISO
at	O
admission	O
,	O
1	O
-	O
yr	O
survival	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
patients	O
was	O
not	O
different	O
from	O
that	O
of	O
non	O
-	O
extracorporeal	O
membrane	O
oxygenation	O
patients	O
;	O
each	O
group	O
had	O
almost	O
full	O
recovery	O
of	O
lung	O
function	O
,	O
but	O
non	O
-	O
extracorporeal	O
membrane	O
oxygenation	O
patients	O
had	O
greater	O
impairment	B-DISO
of	O
health	O
-	O
related	O
quality	O
of	O
life	O
.	O

It	O
is	O
critically	O
important	O
and	O
urgent	O
to	O
develop	O
tools	O
for	O
detection	O
of	O
PEDV	O
infection	B-DISO
.	O

In	O
addition	O
,	O
immunoregulated	O
agents	O
,	O
such	O
as	O
asthymosin	O
α1	O
,	O
are	O
also	O
of	O
great	O
value	O
in	O
renal	O
transplant	O
recipients	O
in	O
the	O
setting	O
of	O
opportunistic	O
pathogen	O
infections	B-DISO
.	O

We	O
found	O
that	O
diabetes	B-DISO
mellitus	I-DISO
among	O
survivors	O
was	O
associated	O
with	O
prolonged	O
MERS	O
-	O
CoV	O
RNA	O
detection	O
in	O
the	O
respiratory	O
tract	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aims	O
to	O
explore	O
the	O
dynamic	O
changes	O
of	O
pulmonary	O
arterial	O
pressure	O
(	O
PAP	B-DISO
)	O
and	O
its	O
clinical	O
significance	O
in	O
prenatal	O
neonates	O
with	O
pulmonary	O
and	O
extra	O
-	O
pulmonary	O
acute	O
lung	O
injury	O
/	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ALI	O
/	O
ARDS	B-DISO
).	O
A	O
prospective	O
study	O
was	O
conducted	O
in	O
the	O
Neonate	O
Intensive	O
Care	O
Unit	O
(	O
NICU	O
)	O
between	O
May	O
2015	O
and	O
April	O
2017	O
.	O

A	O
total	O
of	O
78	O
prenatal	O
neonates	O
with	O
ALI	O
/	O
ARDS	B-DISO
were	O
selected	O
and	O
divided	O
into	O
2	O
groups	O
:	O
pulmonary	O
group	O
(	O
n	O
=	O
37	O
)	O
and	O
extra	O
-	O
pulmonary	O
group	O
(	O
n	O
=	O
41	O
).	O

Furthermore	O
,	O
PAP	B-DISO
was	O
higher	O
in	O
neonates	O
with	O
ALI	O
/	O
ADDSp	O
in	O
the	O
severe	O
group	O
,	O
compared	O
with	O
those	O
in	O
the	O
moderate	O
group	O
(	O
t	O
=	O
2	O
.	O
420	O
,	O
P	O
<	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
is	O
a	O
rescue	O
treatment	O
for	O
respiratory	O
or	O
cardiac	B-DISO
failure	I-DISO
.	O

One	O
patient	O
with	O
cardiac	B-DISO
arrest	I-DISO
developed	O
a	O
liver	O
laceration	O
during	O
resuscitation	O
.	O

TITLE	O
:	O
Noninvasive	O
ventilation	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
.	O

TITLE	O
:	O
The	O
battle	O
against	O
SARS	B-DISO
and	O
MERS	O
coronaviruses	O
:	O
Reservoirs	O
and	O
Animal	O
Models	O
.	O

TITLE	O
:	O
Host	O
Determinants	O
of	O
MERS	O
-	O
CoV	O
Transmission	O
and	O
Pathogenesis	B-DISO
.	O

Differences	O
in	O
the	O
behavior	O
of	O
the	O
virus	O
observed	O
between	O
individuals	O
,	O
as	O
well	O
as	O
between	O
humans	O
and	O
dromedary	O
camels	O
,	O
highlight	O
the	O
role	O
of	O
host	O
factors	O
in	O
MERS	O
-	O
CoV	O
pathogenesis	B-DISO
and	O
transmission	O
.	O

Older	O
(>	O
40	O
years	O
of	O
age	O
)	O
and	O
more	O
experienced	O
(>	O
10	O
years	O
)	O
HCWs	O
had	O
the	O
highest	O
PMS	B-DISO
for	O
knowledge	O
(	O
73	O
.	O
4	O
±	O
18	O
.	O
9	O
,	O
P	O
=	O
0	O
.	O
005	O
and	O
76	O
.	O
9	O
±	O
15	O
.	O
7	O
,	O
P	O
<	O
0	O
.	O
001	O
respectively	O
).	O

The	O
National	O
Inpatient	O
Sample	O
(	O
NIS	O
)	O
from	O
years	O
2002	O
to	O
2012	O
was	O
queried	O
for	O
patients	O
aged	O
15	O
and	O
older	O
treated	O
with	O
ECMO	O
who	O
had	O
one	O
or	O
more	O
acute	O
traumatic	O
injuries	O
as	O
defined	O
by	O
the	O
International	O
Diagnostic	O
Codes	O
,	O
Ninth	O
Edition	O
(	O
ICD	B-DISO
-	O
9	O
).	O

A	O
total	O
of	O
1347	O
patients	O
were	O
identified	O
in	O
the	O
NIS	O
database	O
who	O
had	O
both	O
ECMO	O
performed	O
and	O
ICD	B-DISO
-	O
9	O
codes	O
consistent	O
with	O
trauma	O
.	O

The	O
peak	O
-	O
to	O
-	O
low	O
ratio	O
for	O
FLU	B-DISO
was	O
2	O
.	O
26	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
1	O
.	O
52	O
-	O
3	O
.	O
35	O
).	O

The	O
optimized	O
procedure	O
was	O
applied	O
to	O
detect	O
naturally	O
occurring	O
HAV	B-DISO
and	O
coronaviruses	O
in	O
surface	O
water	O
of	O
Wadi	O
Hanifa	O
,	O
Riyadh	O
.	O

Several	O
approaches	O
exist	O
:	O
thoracic	B-DISO
trauma	O
,	O
pulmonary	O
contusion	O
,	O
pulmonary	O
laceration	O
,	O
lung	O
contusion	O
;	O
although	O
these	O
may	O
show	O
similar	O
clinical	O
signs	O
,	O
manifest	O
in	O
different	O
pathologies	O
.	O

ABSTRACT	O
:	O
Infection	B-DISO
with	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
could	O
be	O
asymptomatic	O
or	O
cause	O
mild	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
.	O

We	O
extended	O
and	O
optimized	O
our	O
previous	O
recombinant	O
adenovirus	B-DISO
5	O
(	O
rAd5	O
)-	O
based	O
vaccine	O
platform	O
characterized	O
by	O
in	O
vivo	O
amplified	O
and	O
CD40	O
-	O
mediated	O
specific	O
responses	O
to	O
generate	O
MERS	O
-	O
CoV	O
S1	O
subunit	O
-	O
based	O
vaccine	O
.	O

Among	O
cranial	B-DISO
nerve	I-DISO
palsies	I-DISO
in	O
Guillain	O
-	O
Barré	O
syndrome	B-DISO
,	O
facial	B-DISO
nerve	I-DISO
palsy	I-DISO
is	O
the	O
most	O
common	O
affecting	O
around	O
half	O
of	O
the	O
cases	O
.	O

A	O
5	O
-	O
year	O
-	O
old	O
boy	O
had	O
progressive	O
lower	B-DISO
extremity	I-DISO
weakness	I-DISO
and	O
pain	O
3	O
days	O
prior	O
to	O
onset	O
of	O
unilateral	O
peripheral	B-DISO
facial	I-DISO
palsy	I-DISO
.	O

Importantly	O
,	O
we	O
show	O
that	O
the	O
macrodomain	O
and	O
PLP2	O
mutant	B-DISO
viruses	O
trigger	O
production	O
of	O
type	O
I	O
interferon	O

TITLE	O
:	O
Hemoadsorption	O
in	O
isolated	O
conjugated	B-DISO
hyperbilirubinemia	I-DISO
after	O
extracorporeal	O
membrane	O
oxygenation	O
support	O
.	O

Viral	B-DISO
hepatitis	I-DISO
was	O
excluded	O
.	O

By	O
analyzing	O
simulated	O
outbreaks	O
under	O
various	O
contact	O
tracing	O
scenarios	O
,	O
we	O
demonstrate	O
that	O
contact	O
data	O
significantly	O
improves	O
our	O
ability	O
to	O
reconstruct	O
transmission	O
trees	O
,	O
even	O
under	O
realistic	O
limitations	O
on	O
the	O
coverage	O
of	O
the	O
contact	O
tracing	O
effort	O
and	O
the	O
amount	O
of	O
non	O
-	O
infectious	B-DISO
mixing	O
between	O
cases	O
.	O

TITLE	O
:	O
Lower	O
Extremity	O
Necrotizing	B-DISO
Fasciitis	I-DISO
in	O
Diabetic	O
and	O
Nondiabetic	O
Patients	O
:	O
Mortality	O
and	O
Amputation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
patient	O
factors	O
predictive	O
of	O
amputation	O
and	O
mortality	O
in	O
diabetes	B-DISO
mellitus	I-DISO
(	O
DM	B-DISO
)	O
and	O
non	O
-	O
DM	B-DISO
patients	O
with	O
lower	O
extremity	O
NF	O
.	O

In	O
this	O
case	O
study	O
we	O
aim	O
to	O
describe	O
the	O
importance	O
of	O
considering	O
mycoplasma	B-DISO
pneumonia	I-DISO
in	O
high	O
-	O
risk	O
groups	O
.	O

Delayed	O
treatment	O
can	O
result	O
in	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
,	O
which	O
requires	O
intensive	O
care	O
and	O
long	O
hospital	O
stays	O
.	O

RESULTS	O
:	O
Seventeen	O
patients	O
were	O
treated	O
with	O
VV	O
-	O
ECMO	O
(	O
nine	O
males	O
,	O
median	O
age	O
33	O
years	O
,	O
range	O
14	O
-	O
74	O
),	O
the	O
indication	O
for	O
16	O
patients	O
was	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
most	O
often	O
following	O
pneumonia	B-DISO
(	O
n	O
=	O
6	O
),	O
H1N1	O
-	O
infection	B-DISO
(	O
n	O
=	O
3	O
)	O
or	O
drowning	O
(	O
n	O
=	O
2	O
).	O

ABSTRACT	O
:	O
The	O
4a	O
and	O
4b	O
proteins	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
have	O
been	O
described	O
for	O
their	O
antagonism	O
on	O
host	O
innate	O
immunity	O
.	O

Glucocorticoids	O
such	O
as	O
methylprednisolone	O
(	O
MP	O
)	O
are	O
commonly	O
used	O
to	O
treat	O
patients	O
with	O
inflammatory	O
diseases	O
;	O
however	O
,	O
the	O
management	O
of	O
ALI	O
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
remains	O
controversial	O
.	O

A	O
medium	O
dose	O
significantly	O
attenuated	O
lung	O
injury	O
,	O
and	O
reduced	O
proinflammatory	O
cytokine	O
production	O
and	O
neutrophil	O
infiltration	B-DISO
into	O
alveoli	O
.	O

TITLE	O
:	O
A	O
study	O
on	O
the	O
protective	O
effects	O
of	O
CpG	O
oligodeoxynucleotide	O
-	O
induced	O
mucosal	O
immunity	O
against	O
lung	O
injury	O
in	O
a	O
mouse	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
model	O
.	O

In	O
contrast	O
,	O
the	O
nasal	O
and	O
rectal	O
administration	O
of	O
CpG	O
ODN	O
in	O
BALB	O
/	O
c	O
mice	O
before	O
LPS	B-DISO
immunization	O
did	O
not	O
appear	O
to	O
exhibit	O
any	O
significant	O
protective	O
effects	O
.	O

Compared	O
with	O
other	O
FS	O
patients	O
,	O
H	O
.	O
influenzae	O
-	O
seropositive	O
FS	O
patients	O
more	O
frequently	O
had	O
a	O
history	O
of	O
prior	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
;	O
double	B-DISO
vision	I-DISO
as	O
the	O
initial	O
symptom	B-DISO
;	O
and	O
,	O
except	O
for	O
oculomotor	O
disturbance	O
,	O
more	O
rarely	O
showed	O
cranial	O
nerve	O
involvement	O
.	O

CMV	O
-	O
related	O
FS	O
appeared	O
to	O
be	O
similar	O
to	O
H	O
.	O
influenzae	O
-	O
and	O
C	O
.	O
jejuni	O
-	O
related	O
FS	O
regarding	O
anti	O
-	O
GQ1b	O
antibody	O
-	O
mediated	O
pathogenesis	B-DISO
,	O
as	O
opposed	O
to	O
CMV	O
-	O
related	O
GBS	B-DISO
.	O

TITLE	O
:	O
Assessment	O
of	O
the	O
safety	O
and	O
efficacy	O
of	O
an	O
attenuated	O
live	O
vaccine	O
based	O
on	O
highly	O
virulent	O
genotype	O
2b	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
in	O
nursing	O
piglets	O
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
reported	O
the	O
generation	O
of	O
the	O
attenuated	O
KNU	O
-	O
141112	O
-	O
S	O
DEL5	O
/	O
ORF3	O
virus	O
by	O
continuous	O
propagation	O
of	O
highly	O
virulent	O
G2b	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
in	O
Vero	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
explored	O
the	O
antiviral	O
effect	O
of	O
CH25H	O
and	O
25HC	O
on	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
which	O
causes	O
high	O
mortality	O
rates	O
in	O
newborn	O
piglets	O
with	O
severe	B-DISO
diarrhea	I-DISO
,	O
and	O
considerable	O
financial	O
loss	O
in	O
the	O
swine	O
industry	O
worldwide	O
.	O

TITLE	O
:	O
Construction	O
of	O
Lentivirus	O
-	O
Based	O
Reference	O
Material	O
for	O
RT	O
-	O
PCR	O
Detection	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
and	O
Its	O
Application	O
in	O
External	O
Quality	O
Assessment	O
.	O

“	B-DISO
Mendelson	I-DISO
syndrome	O
”	O
was	O
initially	O
described	O
as	O
aspiration	B-DISO
of	O
gastric	O
contents	O
causing	O
a	O
chemical	B-DISO
pneumonitis	I-DISO
characterized	O
by	O
fever	O
,	O
cyanosis	B-DISO
,	O
hypoxia	B-DISO
,	O
pulmonary	B-DISO
edema	I-DISO
,	O
and	O
potential	O
death	O
.	O

Amongst	O
the	O
patients	O
studied	O
,	O
there	O
were	O
66	O
cases	O
of	O
aspiration	B-DISO
(	O
0	O
.	O
15	O
%)	O
and	O
two	O
deaths	O
(	O
0	O
.	O
0045	O
%).	O

The	O
remaining	O
64	O
patients	O
experienced	O
aspiration	B-DISO
of	O
liquid	O
material	O
,	O
and	O
they	O
often	O
went	O
unrecognized	O
with	O
complete	O
recovery	O
.[	O
1	O
]	O
Through	O
his	O
animal	O
model	O
,	O
Mendelson	O
replicated	O
the	O
gastric	O
acid	O
in	O
the	O
respiratory	B-DISO
distress	I-DISO
syndrome	I-DISO
he	O
witnessed	O
in	O
human	O
patients	O
.	O

During	O
Mendelson	O
’	O
s	O
time	O
,	O
the	O
induction	O
of	O
general	O
anesthesia	B-DISO
was	O
not	O
limited	O
to	O
parturients	O
undergoing	O
a	O
cesarean	O
section	O
but	O
was	O
also	O
the	O
method	O
for	O
spontaneous	O
or	O
operative	O
vaginal	O
deliveries	O
.	O

At	O
present	O
,	O
there	O
is	O
almost	O
no	O
research	O
on	O
lncRNA	O
related	O
to	O
PDCoV	O
infection	B-DISO
.	O

A	O
54	O
-	O
year	O
-	O
old	O
man	O
was	O
referred	O
to	O
our	O
hospital	O
because	O
of	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

The	O
patient	O
had	O
severe	O
delirium	B-DISO
and	O
was	O
confined	O
to	O
a	O
long	O
-	O
term	O
supine	O
position	O
to	O
maintain	O
circuit	O
safety	O
.	O

This	O
case	O
underscores	O
the	O
importance	O
of	O
obtaining	O
a	O
thorough	O
epidemiological	O
exposure	O
and	O
travel	O
history	O
and	O
being	O
aware	O
of	O
areas	O
of	O
endemicity	O
for	O
life	O
-	O
threatening	O
infections	B-DISO
.	O

For	O
comparative	O
analyses	O
,	O
two	O
eS770	O
proteins	O
lacking	O
the	O
IgG4	O
Fc	O
domain	O
were	O
generated	O
using	O
the	O
IdeS	O
protease	O
(	O
eS770	O
-	O
ΔFc	O
)	O
or	O
His	O
tag	B-DISO
attachment	O
(	O
eS770	O
-	O
His	O
)	O
and	O
the	O
immunogenicity	O
of	O
the	O
above	O
constructs	O
were	O
examined	O
following	O
intramuscular	O
immunization	O
in	O
mice	O
.	O

All	O
participants	O
stated	O
that	O
the	O
most	O
important	O
standard	O
precaution	O
that	O
should	O
be	O
applied	O
when	O
seeing	O
a	O
case	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
is	O
hand	O
washing	O
,	O
whereas	O
97	O
.	O
6	O
%	O
stated	O
that	O
the	O
most	O
important	O
respiratory	O
precaution	O
to	O
prevent	O
transmission	O
of	O
respiratory	B-DISO
infections	I-DISO
in	O
PHC	O
setting	O
when	O
seeing	O
a	O
case	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
is	O
masking	O
and	O
separation	B-DISO
of	O
suspected	O
MERS	O
-	O
CoV	O
patients	O
,	O
and	O
81	O
.	O
2	O
%	O
stated	O
that	O
upon	O
exit	O
from	O
the	O
room	O
of	O
a	O
MERS	O
-	O
CoV	O
patient	O
,	O
the	O
physician	O
should	O
remove	O
and	O
discard	O
personal	O
protective	O
equipment	O
.	O

These	O
emerging	O
infections	B-DISO
,	O
including	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
the	O
pandemic	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
and	O
avian	B-DISO
influenza	I-DISO
(	O
AI	O
)	O
viruses	O
,	O
have	O
seriously	O
threatened	O
global	O
health	O
and	O
the	O
economy	O
.	O

These	O
infections	B-DISO
with	O
epidemic	O
or	O
pandemic	O
potential	O
present	O
a	O
persistent	O
threat	O
to	O
public	O
health	O
and	O
a	O
huge	O
burden	O
on	O
healthcare	O
services	O
in	O
the	O
Asia	O
-	O
Pacific	O
region	O
.	O

Survival	O
in	O
ALI	O
patients	O
appear	O
to	O
be	O
influenced	O
by	O
the	O
stress	O
generated	O
by	O
mechanical	O
ventilation	O
and	O
by	O
ALI	O
-	O
associated	O
factors	O
that	O
initiate	O
the	O
inflammatory	B-DISO
response	I-DISO
.	O

TITLE	O
:	O
Exposure	O
to	O
Atmospheric	O
Ultrafine	O
Particles	O
Induces	O
Severe	O
Lung	O
Inflammatory	B-DISO
Response	I-DISO
and	O
Tissue	O
Remodeling	O
in	O
Mice	O
.	O

In	O
this	O
case	O
series	O
,	O
we	O
present	O
our	O
experiences	O
with	O
NIV	O
-	O
facilitated	O
diagnostic	O
and	O
therapeutic	O
BF	O
performed	O
in	O
patients	O
with	O
respiratory	B-DISO
failure	I-DISO
that	O
was	O
associated	O
with	O
acute	O
interstitial	O
pulmonary	B-DISO
disease	I-DISO
,	I-DISO
chronic	I-DISO
obstructive	I-DISO
pulmonary	B-DISO
disease	I-DISO
,	O
cystic	B-DISO
fibrosis	I-DISO
exacerbation	O
,	O
foreign	O
body	O
aspiration	B-DISO
,	O
tracheal	B-DISO
stenosis	I-DISO
,	O
pneumonia	B-DISO
,	O
and	O
in	O
a	O
patient	O
with	O
a	O
neuromuscular	B-DISO
disease	I-DISO
.	O

We	O
also	O
recognized	O
a	O
high	O
amount	O
of	O
excreted	O
PEDV	O
in	O
its	O
rectal	O
swabs	O
and	O
villus	O
atrophy	B-DISO
of	O
the	O
small	O
intestine	O
.	O

This	O
study	O
was	O
aimed	O
to	O
investigate	O
the	O
roles	O
of	O
host	O
differentially	O
expressed	O
genes	O
on	O
metabolic	O
pathways	O
in	O
PDCoV	O
infections	B-DISO
.	O

The	O
differential	O
expressed	O
genes	O
were	O
associated	O
with	O
appetite	B-DISO
decrease	I-DISO
and	O
weight	O
loss	O
of	O
PDCoV	O
-	O
affected	O
piglets	O
.	O

The	O
host	O
differentially	O
expressed	O
genes	O
were	O
associated	O
with	O
infection	B-DISO
response	O
,	O
metabolism	O
signaling	O
and	O
organismal	O
systems	O
signaling	O
pathways	O
.	O

Our	O
results	O
provided	O
new	O
insights	O
into	O
the	O
metabolic	O
mechanisms	O
and	O
pathogenesis	B-DISO
of	O
PDCoV	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
The	O
Berlin	O
definition	O
of	O
ARDS	B-DISO
does	O
not	O
account	O
for	O
nonpulmonary	O
organ	B-DISO
failure	I-DISO
,	O
which	O
is	O
a	O
major	O
determinant	O
of	O
outcome	O
.	O

The	O
most	O
abnormal	O
laboratory	O
values	O
at	O
ARDS	B-DISO
onset	O
were	O
analyzed	O
as	O
cutoff	O
values	O
to	O
assess	O
organ	O
dysfunction	O
.	O

Nonpulmonary	O
organ	O
dysfunction	O
was	O
present	O
in	O
at	O
least	O
1	O
system	O
at	O
ARDS	B-DISO
onset	O
that	O
increased	O
with	O
severity	O
:	O
80	O
%	O
(	O
mild	O
),	O
83	O
%	O
(	O
moderate	O
),	O
and	O
90	O
%	O
(	O
severe	O
).	O

ARDS	B-DISO
etiologies	O
varied	O
as	O
severity	O
increased	O
:	O
trauma	O
-	O
associated	O
lung	O
injury	O
steadily	O
decreased	O
,	O
whereas	O
lung	O
injury	O
associated	O
with	O
aspiration	B-DISO
and	O
pneumonia	B-DISO
steadily	O
increased	O
.	O

Normal	O
hematologic	O
function	O
and	O
the	O
absence	O
of	O
standard	O
exclusion	O
criteria	O
used	O
for	O
therapeutic	O
clinical	O
trials	O
in	O
ARDS	B-DISO
were	O
protective	O
.	O

In	O
these	O
cases	O
,	O
early	O
and	O
aggressive	B-DISO
treatment	O
with	O
bronchodilatators	O
,	O
steroids	O
,	O
antihistamines	O
and	O
epinephrine	O
should	O
be	O
considered	O
.	O

ABSTRACT	O
:	O
Besides	O
fatigue	B-DISO
,	O
many	O
Q	B-DISO
fever	I-DISO
fatigue	B-DISO
syndrome	B-DISO
(	O
QFS	O
)	O
patients	O
also	O
complain	O
of	O
frequently	O
recurring	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
with	O
severe	O
symptoms	O
.	O

Cytokine	O
and	O
chemokine	O
production	O
was	O
measured	O
after	O
stimulating	O
monocytes	O
of	O
QFS	O
patients	O
and	O
age	O
-	O
and	O
sex	O
-	O
matched	O
healthy	O
controls	O
with	O
LPS	B-DISO
and	O
several	O
viral	O
ligands	O
.	O

After	O
ruling	O
out	O
other	O
causes	O
,	O
the	O
diagnosis	O
of	O
gabapentin	O
withdrawal	B-DISO
was	O
considered	O
.	O

We	O
concluded	O
that	O
severe	O
gabapentin	O
withdrawal	B-DISO
should	O
be	O
considered	O
in	O
patients	O
on	O
higher	O
doses	O
of	O
gabapentin	O
when	O
it	O
is	O
stopped	O
abruptly	O
.	O

As	O
the	O
results	O
conducted	O
meta	O
-	O
analyses	O
to	O
comprehensively	O
analyze	O
the	O
correlations	O
of	O
factors	O
influencing	O
disaster	O
response	O
from	O
a	O
Korean	O
context	O
,	O
the	O
findings	O
show	O
that	O
the	O
legislative	O
factor	O
had	O
direct	O
and	O
indirect	O
influence	O
on	O
the	O
overall	O
process	O
of	O
infectious	B-DISO
disease	I-DISO
response	O
and	O
that	O
Leadership	O
of	O
the	O
central	O
government	O
,	O
establishment	O
of	O
an	O
intergovernmental	O
response	O
system	O
,	O
the	O
need	O
for	O
communication	O
,	O
information	O
sharing	O
and	O
disclosure	O
and	O
onsite	O
response	O
were	O
identified	O
as	O
key	O
factors	O
influencing	O
effective	O
infectious	B-DISO
disease	I-DISO
response	O
.	O

This	O
retrospective	O
study	O
included	O
207	O
ARDS	B-DISO
patients	O
admitted	O
to	O
the	O
general	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
in	O
the	O
Second	O
Affiliated	O
Hospital	O
of	O
Harbin	O
Medical	O
University	O
from	O
Jan	O
1st	O
,	O
2016	O
to	O
Jan	O
1st	O
,	O
2017	O
.	O

TITLE	O
:	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
(	O
PEDV	O
)	O
ORF3	O
Interactome	O
Reveals	O
Inhibition	O
of	O
Virus	O
Replication	O
by	O
Cellular	O
VPS36	O
Protein	O
.	O

Here	O
,	O
a	O
mouse	O
model	O
of	O
ARDS	B-DISO
was	O
established	O
by	O
an	O
intratracheal	O
injection	O
of	O
LPS	B-DISO
.	O

We	O
found	O
that	O
the	O
gene	O
expression	O
of	O
col3a1	O
and	O
hydroxyproline	O
contents	O
in	O
the	O
lungs	O
were	O
significantly	O
increased	O
24	O
h	O
after	O
LPS	B-DISO
injection	O
.	O

IL	O
-	O
17RC	O
rather	O
than	O
IL	O
-	O
17RA	O
was	O
increased	O
in	O
the	O
lungs	O
of	O
mice	O
with	O
ARDS	B-DISO
.	O

In	O
order	O
to	O
obtain	O
detailed	O
information	O
about	O
the	O
pathogenesis	B-DISO
and	O
host	O
immune	O
response	O
in	O
a	O
PEDV	O
-	O
infected	O
host	O
for	O
first	O
In	O
vivo	O
study	O
we	O
used	O
high	O
-	O
throughput	O
sequencing	O
to	O
analyze	O
the	O
gene	O
expression	O
differences	O
of	O
the	O
small	O
intestinal	O
mucosa	O
after	O
infection	B-DISO
with	O
PEDV	O
.	O

TITLE	O
:	O
Veno	O
-	O
venous	O
extracorporeal	O
life	O
support	O
for	O
blastomycosis	B-DISO
-	O
associated	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

TITLE	O
:	O
Current	O
epidemiological	O
status	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
in	O
the	O
world	O
from	O
1	O
.	O
1	O
.	O
2017	O
to	O
17	O
.	O
1	O
.	O
2018	O
:	O
a	O
cross	O
-	O
sectional	O
study	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
infections	B-DISO
induce	O
apoptosis	O
in	O
Vero	O
cells	O
via	O
a	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)/	O
p53	O
,	O
but	O
not	O
p38	O
MAPK	O
and	O
SAPK	O
/	O
JNK	O
signalling	O
pathways	O
.	O

In	O
this	O
study	O
,	O
the	O
pro	O
-	O
apoptotic	O
effect	O
of	O
PEDV	O
was	O
examined	O
in	O
Vero	O
cells	O
and	O
we	O
observed	O
that	O
PEDV	O
infection	B-DISO
increased	O
MDM2	O
and	O
CBP	O
,	O
promoted	O
p53	O
phosphorylation	O
at	O
serine	O
20	O
and	O
,	O
promoted	O
p53	O
nuclear	O
translocation	B-DISO
,	O
leading	O
to	O
p53	O
activation	O
in	O
Vero	O
cells	O
.	O

We	O
also	O
observed	O
PEDV	O
infection	B-DISO
induced	I-DISO
time	O
-	O
dependent	O
ROS	O
accumulation	O
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
activated	O
p53	O
and	O
accumulated	O
ROS	O
participated	O
in	O
PEDV	O
-	O
induced	O
apoptosis	O
and	O
p53	O
could	O
be	O
regulated	O
by	O
ROS	O
during	O
PEDV	O
infection	B-DISO
.	O

CS	O
was	O
first	O
described	O
as	O
a	O
syndrome	B-DISO
with	O
hemorrhage	B-DISO
from	O
metastatic	O
sites	O
in	O
patients	O
with	O
TGCTs	O
with	O
significantly	O
high	O
choriogonadotropin	O
level	O
.	O

Acute	B-DISO
hemorrhage	I-DISO
to	O
lung	B-DISO
metastases	I-DISO
is	O
typical	O
,	O
but	O
hemorrhage	B-DISO
can	O
occur	O
from	O
any	O
metastatic	O
site	O
.	O

This	O
can	O
lead	O
to	O
a	O
consecutive	O
superinfection	B-DISO
,	O
furthered	O
with	O
neutropenia	O
after	O
chemotherapy	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
rising	O
to	O
systemic	O
inflammatory	B-DISO
response	I-DISO
,	O
resulting	O
in	O
multiorgan	B-DISO
failure	I-DISO
and	O
death	O
.	O

A	O
reasonably	O
effective	O
approach	O
in	O
patients	O
with	O
extensive	B-DISO
disease	I-DISO
could	O
be	O
a	O
shortened	O
course	O
of	O
chemotherapy	O
as	O
well	O
as	O
a	O
reduction	O
of	O
dosage	O
in	O
induction	O
chemotherapy	O
before	O
full	O
-	O
dose	O
chemotherapeutical	O
regimen	O
;	O
however	O
,	O
current	O
data	O
regarding	O
optimal	O
treatment	O
approach	O
are	O
limited	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
is	O
known	O
to	O
be	O
transmitted	B-DISO
through	O
close	O
contact	O
.	O

The	O
study	O
results	O
do	O
not	O
imply	O
that	O
the	O
infection	B-DISO
pathway	O
of	O
MERS	O
is	O
airborne	O
.	O

TITLE	O
:	O
Inhaled	O
Nitric	O
Oxide	O
as	O
an	O
Adjunct	O
to	O
Thrombolytic	O
Therapy	O
in	O
a	O
Patient	O
with	O
Submassive	O
Pulmonary	B-DISO
Embolism	I-DISO
and	O
Severe	O
Hypoxemia	O
.	O

A	O
29	O
-	O
year	O
-	O
old	O
male	O
was	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
for	O
alcohol	B-DISO
intoxication	I-DISO
complicated	O
with	O
aspiration	B-DISO
pneumonia	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
requiring	O
mechanical	O
ventilation	O
.	O

Inhaled	O
NO	O
has	O
been	O
used	O
to	O
improve	O
ventilation	O
-	O
perfusion	O
matching	O
and	O
also	O
to	O
reduce	O
pulmonary	O
vascular	O
resistance	O
(	O
PVR	B-DISO
).	O

The	O
most	O
frequent	O
complications	O
were	O
pneumonia	B-DISO
(	O
25	O
%),	O
chylothorax	B-DISO
(	O
20	O
%),	O
anastomotic	B-DISO
leakage	I-DISO
(	O
17	O
.	O
5	O
%)	O
and	O
vocal	B-DISO
cord	I-DISO
paralysis	I-DISO
(	O
17	O
.	O
5	O
%)	O
which	O
was	O
grade	O
1	O
in	O
72	O
%	O
of	O
the	O
patients	O
.	O

Commonest	O
Influenza	B-DISO
subtype	O
in	O
age	O
group	O
-	O
IV	O
was	O
H3N2	O
found	O
in	O
20	O
(	O
32	O
.	O
8	O
%)	O
patients	O
,	O
followed	O
by	O
H1N1	O
in	O
15	O
(	O
12	O
.	O
5	O
%)	O
patients	O
.	O

CONCLUSIONS	O
:	O
The	O
dominant	O
subtype	O
in	O
our	O
set	O
-	O
up	O
,	O
during	O
winter	O
of	O
2017	O
-	O
2018	O
,	O
was	O
Influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pdm09	O
.	O

TITLE	O
:	O
[	O
The	O
Clinical	O
Study	O
of	O
Comorbidities	O
and	O
Systemic	O
Inflammation	B-DISO
in	O
COPD	B-DISO
].	O

TITLE	O
:	O
Genes	O
involved	O
in	O
mitochondrial	O
biogenesis	O
and	O
function	O
may	O
not	O
show	O
synchronised	O
responses	O
to	O
mitochondria	O
in	O
shell	O
gland	O
of	O
laying	O
chickens	O
under	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
challenge	O
.	O

TITLE	O
:	O
Differential	O
recognition	O
of	O
peptides	O
within	O
feline	O
coronavirus	O
polyprotein	O
1	O
ab	O
by	O
sera	O
from	O
healthy	O
cats	O
and	O
cats	O
with	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
.	O

The	O
value	O
of	O
antibody	O
tests	O
based	O
on	O
these	O
peptides	O
in	O
differentiating	O
between	O
the	O
enteric	O
and	O
FIP	B-DISO
forms	O
of	O
feline	O
coronavirus	B-DISO
infection	I-DISO
remains	O
to	O
be	O
determined	O
.	O

To	O
evade	O
further	O
complications	O
,	O
identifying	O
the	O
abdominal	B-DISO
compartment	I-DISO
syndrome	I-DISO
(	O
ACS	O
)	O
and	O
Intra	B-DISO
-	I-DISO
abdominal	I-DISO
hypertension	I-DISO
(	O
IAH	O
),	O
in	O
critically	B-DISO
ill	I-DISO
individuals	O
and	O
hospitalised	O
in	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
is	O
obligated	O
.	O

Intra	O
-	O
abdominal	O
pressure	O
test	O
,	O
as	O
a	O
valuable	O
prognosis	O
test	O
for	O
the	O
abdominal	B-DISO
compartment	I-DISO
syndrome	I-DISO
(	O
ACS	O
)	O
and	O
Intra	B-DISO
-	I-DISO
abdominal	I-DISO
hypertension	I-DISO
(	O
IAH	O
),	O
may	O
offer	O
better	O
results	O
when	O
added	O
to	O
the	O
routine	O
medical	O
checkup	O
of	O
ICU	O
patients	O
.	O

CONCLUSIONS	O
:	O
Current	O
findings	O
showed	O
a	O
correlation	O
between	O
IAP	O
hospitalised	O
patients	O
in	O
ICU	O
and	O
shock	O
,	O
SIRS	B-DISO
,	O
APACHE	O
II	O
,	O
central	O
venous	O
oxygen	O
saturation	O
and	O
GCS	O
.	O

Viral	O
RNA	O
was	O
detected	O
from	O
the	O
air	O
emitted	O
by	O
37	O
.	O
5	O
%	O
of	O
the	O
16	O
participants	O
infected	O
with	O
influenza	B-DISO
virus	O
and	O
distributed	O
both	O
in	O
near	O
and	O
far	O
fields	O
and	O
in	O
all	O
tested	O
particle	O
sizes	O
(<	O
1	O
µm	O
,	O
1	O
-	O
4	O
µm	O
,	O
and	O
>	O
4	O
µm	O
).	O

Conclusions	O
:	O
Changes	O
in	O
antioxidant	O
system	O
happend	O
due	O
to	O
the	O
activation	O
of	O
lipid	O
peroxidation	O
,	O
and	O
because	O
of	O
the	O
inability	O
to	O
neutralize	O
toxic	O
metabolites	O
in	O
the	O
children	O
`	O
body	O
the	O
intoxication	O
syndrome	B-DISO
developed	O
.	O

ABSTRACT	O
:	O
Disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
(	O
DIC	B-DISO
)	O
associated	O
with	O
multiple	B-DISO
organ	I-DISO
dysfunction	I-DISO
syndrome	I-DISO
(	O
MODS	B-DISO
)	O
plays	O
pivotal	O
roles	O
in	O
severe	B-DISO
sepsis	I-DISO
.	O

DIC	B-DISO
patients	O
also	O
showed	O
a	O
lower	O
survival	O
probability	O
than	O
non	O
-	O
DIC	B-DISO
patients	O
(	O
Log	O
rank	O
p	O
=	O
0	O
.	O
028	O
).	O

Although	O
we	O
perhaps	O
most	O
frequently	O
think	O
of	O
viruses	O
when	O
discussing	O
emerging	O
respiratory	B-DISO
infections	I-DISO
,	O
bacteria	O
have	O
not	O
been	O
left	O
out	O
of	O
the	O
mix	O
,	O
as	O
we	O
have	O
witnessed	O
an	O
increase	O
in	O
the	O
number	O
of	O
infections	B-DISO
from	O
Legionella	O
spp	O
.	O

Year	O
of	O
infection	B-DISO
(	O
2013	O
-	O
2018	O
)	O
and	O
having	O
no	O
comorbidities	O
were	O
independent	O
protective	O
factors	O
against	O
death	O
among	O
secondary	O
healthcare	O
workers	O
cases	O
.	O

The	O
most	O
common	O
use	O
of	O
this	O
tool	O
is	O
to	O
determine	O
whether	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
(	O
ACS	O
)	O
is	O
occurring	O
,	O
but	O
other	O
differentials	O
include	O
cardiomyopathy	B-DISO
,	O
pulmonary	B-DISO
embolism	I-DISO
,	O
and	O
even	O
acute	B-DISO
heart	I-DISO
failure	I-DISO
.	O

In	O
the	O
emergency	B-DISO
room	O
(	O
ER	O
),	O
the	O
patient	O
was	O
found	O
to	O
have	O
an	O
elevated	O
serum	O
troponin	O
of	O
15	O
.	O
61	O
ng	O
/	O
L	O
(	O
normal	O
<	O
0	O
.	O
05	O
ng	O
/	O
L	O
).	O

Despite	O
this	O
improved	O
understanding	O
,	O
no	O
pharmacologic	O
therapies	O
aimed	O
at	O
the	O
underlying	O
biology	O
have	O
been	O
proven	O
effective	O
in	O
ARDS	B-DISO
.	O

Despite	O
a	O
disappointing	O
lack	O
of	O
benefit	O
(	O
and	O
possible	O
harm	O
)	O
in	O
patients	O
with	O
moderate	O
or	O
severe	O
ARDS	B-DISO
,	O
possibly	O
due	O
to	O
lung	O
hyperdistention	B-DISO
and	O
right	B-DISO
ventricular	I-DISO
dysfunction	I-DISO
,	O
high	O
-	O
frequency	O
oscillation	O
may	O
improve	O
outcome	O
in	O
patients	O
with	O
very	O
severe	O
hypoxemia	O
.	O

ABSTRACT	O
:	O
This	O
study	O
examines	O
perceptions	O
of	O
the	O
operational	O
and	O
organisational	O
management	O
of	O
a	O
major	O
outbreak	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	B-DISO
)	O
caused	O
by	O
a	O
novel	O
coronavirus	O
(	O
MERS	B-DISO
-	O
CoV	O
)	O
in	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
(	O
KSA	O
).	O

While	O
the	O
outbreak	O
was	O
controlled	O
successfully	O
in	O
6	O
weeks	O
,	O
progress	O
in	O
management	O
was	O
inhibited	O
by	O
a	O
lack	O
of	O
institutional	O
readiness	O
to	O
implement	O
infection	B-DISO
control	O
(	O
IC	O
)	O
measures	O
and	O
reduce	O
patient	O
flow	O
,	O
low	O
staff	O
morale	O
and	O
high	O
anxiety	O
.	O

ABSTRACT	O
:	O
Worldwide	O
outbreaks	O
of	O
infectious	B-DISO
diseases	I-DISO
necessitate	O
the	O
development	O
of	O
rapid	O
and	O
accurate	O
diagnostic	O
methods	O
.	O

The	O
12	O
-	O
bed	B-DISO
intensive	O
care	O
unit	O
of	O
Careggi	O
Hospital	O
in	O
Florence	O
,	O
the	O
ECMO	O
referral	O
center	O
for	O
Tuscany	O
,	O
and	O
the	O
center	O
of	O
Italy	O
,	O
with	O
a	O
mobile	O
ECMO	O
team	O
.	O

Pediatric	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
were	O
categorized	O
into	O
those	O
who	O
had	O
recent	O
surgery	O
(	O
postsurgical	O
sepsis	B-DISO
)	O
versus	O
those	O
that	O
did	O
not	O
(	O
medical	O
sepsis	B-DISO
)	O
before	O
sepsis	B-DISO
onset	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
whole	O
genomic	O
sequence	O
of	O
a	O
SARS	B-DISO
-	O
like	O
bat	O
CoV	O
(	O
16BO133	O
)	O
and	O
found	O
it	O
to	O
be	O
29	O
,	O
075	O
nt	O
in	O
length	O
with	O
a	O
40	O
.	O
9	O
%	O
G	O
+	O
C	O
content	O
.	O

However	O
,	O
16BO133	O
was	O
distinctly	O
located	O
in	O
the	O
phylogenetic	O
topology	O
of	O
the	O
human	O
SARS	B-DISO
CoV	O
strain	O
(	O
Tor2	O
).	O

The	O
spike	O
region	O
of	O
16BO133	O
showed	O
84	O
.	O
7	O
%	O
and	O
75	O
.	O
2	O
%	O
amino	O
acid	O
identity	O
with	O
Rf1	O
(	O
SARS	B-DISO
-	O
like	O
bat	O
CoV	O
)	O
and	O
Tor2	O
(	O
human	O
SARS	B-DISO
CoV	O
),	O
respectively	O
.	O

In	O
addition	O
,	O
the	O
S	O
gene	O
of	O
16BO133	O
was	O
found	O
to	O
contain	O
the	O
amino	O
acid	O
substitution	O
of	O
two	O
critical	O
residues	O
(	O
N479S	O
and	O
T487	O
V	O
)	O
associated	O
with	O
human	O
infection	B-DISO
.	O

ABSTRACT	O
:	O
Canine	O
parvovirus	B-DISO
(	O
CPV	O
)	O
and	O
feline	O
parvovirus	B-DISO
(	O
FPV	O
)	O
are	O
causative	O
agents	O
of	O
diarrhea	B-DISO
in	O
dogs	O
and	O
cats	O
,	O
which	O
manifests	O
as	O
depression	B-DISO
,	O
vomiting	B-DISO
,	O
fever	O
,	O
loss	B-DISO
of	I-DISO
appetite	I-DISO
,	O
leucopenia	B-DISO
,	O
and	O
diarrhea	B-DISO
in	O
young	O
animals	O
.	O

In	O
this	O
study	O
,	O
a	O
total	O
of	O
190	O
faecal	O
samples	O
from	O
dairy	O
calves	O
with	O
diarrhoea	B-DISO
were	O
collected	O
from	O
14	O
farms	O
in	O
six	O
Chinese	O
provinces	O
,	O
and	O
BCoV	O
was	O
detected	O
in	O
18	O
.	O
95	O
%	O
(	O
36	O
/	O
190	O
)	O
of	O
the	O
samples	O
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
fatal	O
disease	O
that	O
includes	O
inflammation	B-DISO
formed	O
by	O
septic	O
and	O
non	O
-	O
septic	O
causes	O
.	O

Antioxidant	O
vitamins	O
may	O
be	O
useful	O
for	O
premedication	O
of	O
ARDS	B-DISO
and	O
similar	O
disorders	O
.	O

However	O
,	O
methylprednisolone	O
was	O
not	O
found	O
sufficient	O
for	O
being	O
a	O
therapeutic	O
agent	O
for	O
ARDS	B-DISO
.	O

And	O
the	O
individuals	O
with	O
different	O
viral	B-DISO
infection	I-DISO
varied	O
significantly	O
in	O
terms	O
of	O
clinical	O
profiles	O
.	O

Secondary	O
bacterial	B-DISO
infections	I-DISO
are	O
common	O
and	O
have	O
a	O
serious	O
economic	O
and	O
welfare	O
impact	O
.	O

Many	O
genotypic	O
and	O
serotypic	O
variants	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
exist	O
worldwide	O
,	O
making	O
diagnosis	O
difficult	O
,	O
and	O
challenging	O
control	O
strategies	O
.	O

Vaccination	O
,	O
requiring	O
the	O
use	O
of	O
both	O
live	O
-	O
attenuated	O
and	O
inactivated	O
vaccines	O
,	O
is	O
needed	O
to	O
control	O
IBV	O
infections	B-DISO
;	O
to	O
date	O
,	O
attempts	O
to	O
develop	O
vectored	O
vaccines	O
as	O
effective	O
as	O
the	O
traditional	O
vaccines	O
have	O
been	O
unsuccessful	O
.	O

ABSTRACT	O
:	O
A	O
flock	O
of	O
54	O
wk	O
-	O
old	O
layer	O
birds	O
exhibiting	O
signs	O
of	O
respiratory	B-DISO
distress	I-DISO
,	O
greenish	O
diarrhea	B-DISO
,	O
and	O
drop	O
in	O
egg	O
production	O
was	O
investigated	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
):	O
Infection	B-DISO
,	O
Immunological	O
Response	O
,	O
and	O
Vaccine	O
Development	O
.	O

We	O
believe	O
this	O
study	O
will	O
increase	O
our	O
understanding	O
of	O
the	O
mechanisms	O
that	O
enhance	O
the	O
MERS	O
-	O
CoV	O
immune	O
response	O
and	O
subsequently	O
contribute	O
to	O
the	O
control	O
of	O
MERS	O
-	O
CoV	O
infections	B-DISO
.	O

In	O
this	O
study	O
we	O
aimed	O
to	O
verify	O
clinical	O
ND	O
suspicions	O
in	O
poultry	O
holdings	O
in	O
Egypt	O
suffering	B-DISO
from	O
respiratory	B-DISO
distress	I-DISO
and	O
elevated	O
mortality	O
,	O
comparing	O
two	O
groups	O
of	O
ND	O
-	O
vaccinated	O
poultry	O
holdings	O
in	O
three	O
governorates	O
.	O

Venous	O
-	O
venous	O
-	O
ECMO	O
support	O
potentially	O
relieves	O
hypoxic	B-DISO
pulmonary	O
vasoconstriction	B-DISO
.	O

TITLE	O
:	O
Synthesis	O
and	O
biological	O
evaluation	O
of	O
dihydroquinazoline	O
-	O
2	O
-	O
amines	O
as	O
potent	O
non	O
-	O
nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
of	O
wild	O
-	O
type	O
and	O
mutant	B-DISO
HIV	B-DISO
-	O
1	O
strains	O
.	O

ABSTRACT	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
is	O
caused	O
by	O
infection	B-DISO
with	O
feline	O
coronavirus	O
(	O
FCoV	O
).	O

In	O
the	O
field	O
study	O
,	O
there	O
appeared	O
to	O
be	O
less	O
virus	B-DISO
shedding	I-DISO
on	O
one	O
Fuller	O
'	O
s	O
earth	O
-	O
based	O
cat	O
litter	O
.	O

Here	O
we	O
show	O
that	O
pan	O
-	O
PARP	O
inhibition	O
enhanced	O
replication	O
and	O
inhibited	O
interferon	O
production	O
in	O
primary	O
macrophages	O
infected	O
with	O
macrodomain	O
-	O
mutant	B-DISO
but	O
not	O
wild	O
-	O
type	O
coronavirus	O
.	O

Successful	O
combination	O
of	O
ECMO	O
with	O
VATS	O
of	O
pulmonary	O
bullae	B-DISO
resection	O
was	O
performed	O
and	O
pneumothorax	B-DISO
was	O
cured	O
.	O

However	O
,	O
the	O
patient	O
finally	O
developed	O
multiorgan	B-DISO
failure	I-DISO
(	O
MOF	B-DISO
)	O
complicated	O
by	O
refractory	O
hypoxemia	O
due	O
to	O
progressive	O
lung	B-DISO
fibrosis	I-DISO
and	O
died	O
36	O
days	O
after	O
admission	O
.	O

In	O
this	O
study	O
,	O
a	O
series	O
of	O
heptad	O
repeat	O
1	O
(	O
HR1	O
)	O
peptide	O
inhibitors	O
have	O
been	O
developed	O
to	O
inhibit	O
HR1	O
/	O
HR2	O
-	O
mediated	O
membrane	O
fusion	O
between	O
MERS	O
-	O
CoV	O
and	O
host	O
cells	O
,	O
which	O
is	O
the	O
major	O
pathway	O
of	O
MERS	O
-	O
CoV	O
-	O
induced	O
host	O
infections	B-DISO
.	O

Plasmodium	O
berghei	O
NK65	O
-	O
E	O
(	O
PbNK65	O
)	O
parasites	O
were	O
injected	O
in	O
Vwf	O
In	O
accordance	O
with	O
patients	O
with	O
severe	O
malaria	B-DISO
,	O
plasma	O
VWF	O
levels	O
were	O
increased	O
and	O
ADAMTS13	O
activity	O
levels	O
were	O
reduced	O
in	O
experimental	O
MA	O
-	O
ARDS	B-DISO
.	O

TITLE	O
:	O
The	O
effects	O
of	O
past	O
SARS	B-DISO
experience	O
and	O
proximity	O
on	O
declines	O
in	O
numbers	O
of	O
travelers	O
to	O
the	O
Republic	O
of	O
Korea	O
during	O
the	O
2015	O
MERS	O
outbreak	O
:	O
A	O
retrospective	O
study	O
.	O

The	O
percentage	O
changes	O
in	O
visitors	O
from	O
areas	O
with	O
a	O
previous	O
SARS	B-DISO
outbreak	O
of	O
≥	O
100	O
cases	O
decreased	O
more	O
than	O
the	O
percentage	O
changes	O
in	O
visitors	O
from	O
their	O
counterparts	O
in	O
June	O
(	O
52	O
.	O
4	O
%	O
vs	O
.	O
23	O
.	O
3	O
%)	O
and	O
July	O
(	O
60	O
.	O
0	O
%	O
vs	O
.	O
31	O
.	O
4	O
%)	O
during	O
the	O
2015	O
MERS	O
outbreak	O
.	O

In	O
patients	O
with	O
lower	O
respiratory	B-DISO
symptoms	I-DISO
,	O
development	O
of	O
respiratory	B-DISO
insufficiency	I-DISO
should	O
trigger	O
rapid	O
and	O
thorough	O
clinical	O
evaluation	O
,	O
in	O
particular	O
in	O
cases	O
of	O
suspected	O
ARDS	B-DISO
,	O
including	O
electrocardiography	O
and	O
echocardiography	O
to	O
exclude	O
cardiac	O
dysfunction	O
,	O
arrhythmias	B-DISO
and	O
ischaemia	B-DISO
.	O

To	O
decrease	O
the	O
burden	O
of	O
influenza	B-DISO
-	O
related	O
illness	O
,	O
vaccination	O
is	O
of	O
utmost	O
importance	O
,	O
specifically	O
in	O
patients	O
with	O
co	O
-	O
morbidities	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
effects	O
of	O
alveolar	O
macrophage	O
phagocytosis	O
on	O
prognosis	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
caused	O
by	O
abdominal	B-DISO
infection	I-DISO
.	O

The	O
neutral	O
red	O
phagocytosis	O
ability	O
of	O
alveolar	O
macrophages	O
in	O
ARDS	B-DISO
patients	O
caused	O
by	O
abdominal	B-DISO
infection	I-DISO
was	O
negatively	O
correlated	O
with	O
age	O
,	O
APACHE	O
II	O
score	O
and	O
the	O
length	O
of	O
ICU	O
stay	O
(	O
r	O
value	O
was	O
-	O
0	O
.	O
328	O
,	O
-	O
0	O
.	O
572	O
,	O
-	O
0	O
.	O
809	O
,	O
respectively	O
,	O
all	O
P	O
<	O
0	O
.	O
05	O
);	O
alkaline	O
phosphatase	O
activity	O
was	O
negatively	O
correlated	O
with	O
age	O
,	O
APACHE	O
II	O
score	O
,	O
the	O
length	O
of	O
ICU	O
stay	O
and	O
hospitalization	O
expenses	O
(	O
r	O
value	O
was	O
-	O
0	O
.	O
334	O
,	O
-	O
0	O
.	O
583	O
,	O
-	O
0	O
.	O
470	O
,	O
-	O
0	O
.	O
517	O
,	O
respectively	O
,	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

A	O
2	O
-	O
year	O
-	O
old	O
child	O
presented	O
with	O
severe	O
respiratory	B-DISO
distress	I-DISO
and	O
progressed	O
to	O
develop	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
necessitating	O
high	O
-	O
pressure	O
mechanical	O
ventilation	O
.	O

ABSTRACT	O
:	O
Feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
)	O
is	O
considered	O
highly	O
fatal	O
in	O
its	O
naturally	O
occurring	O
form	O
,	O
although	O
up	O
to	O
36	O
%	O
of	O
cats	O
resist	O
disease	O
after	O
experimental	O
infection	B-DISO
,	O
suggesting	O
that	O
cats	O
in	O
nature	O
may	O
also	O
resist	O
development	O
of	O
FIP	B-DISO
in	O
the	O
face	B-DISO
of	O
infection	B-DISO
with	O
FIP	B-DISO
virus	O
(	O
FIPV	O
).	O

This	O
experimental	O
FIPV	O
infection	B-DISO
study	O
in	O
specific	O
pathogen	O
free	O
(	O
SPF	O
)	O
kittens	O
describes	O
longitudinal	O
antiviral	O
T	O
cell	O
responses	O
and	O
clinical	O
outcomes	O
ranging	O
from	O
rapid	O
progression	O
,	O
slow	O
progression	O
,	O
and	O
resistance	O
to	O
disease	O
.	O

Recovery	O
of	O
antiviral	O
T	O
cell	O
responses	O
during	O
the	O
later	O
phase	O
of	O
acute	B-DISO
infection	I-DISO
was	O
observed	O
in	O
a	O
subset	O
of	O
cats	O
that	O
survived	O
longer	O
or	O
resisted	O
disease	O
compared	O
to	O
cats	O
showing	O
rapid	O
disease	B-DISO
progression	I-DISO
.	O

In	O
summary	O
,	O
definitive	O
adaptive	O
T	O
cell	O
responses	O
predictive	O
of	O
disease	O
outcome	O
were	O
not	O
detected	O
during	O
the	O
early	O
phase	O
of	O
primary	O
FIPV	O
infection	B-DISO
.	O

RESULTS	O
:	O
Differences	O
in	O
disease	O
outcome	O
provided	O
an	O
opportunity	O
to	O
investigate	O
the	O
role	O
of	O
T	O
cell	O
immunity	O
to	O
FIP	B-DISO
determined	O
by	O
T	O
cell	O
subset	O
proliferation	B-DISO
after	O
stimulation	O
with	O
different	O
viral	O
antigens	O
.	O

TITLE	O
:	O
The	O
Role	O
of	O
Stress	O
Granules	O
and	O
the	O
Nonsense	O
-	O
mediated	O
mRNA	O
Decay	B-DISO
Pathway	O
in	O
Antiviral	O
Defence	O
.	O

AKI	O
is	O
a	O
frequent	O
complication	B-DISO
of	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
and	O
develops	O
late	O
in	O
the	O
course	O
of	O
the	O
disease	O
,	O
usually	O
after	O
the	O
failure	O
of	O
other	O
organs	O
.	O

TITLE	O
:	O
Engineering	O
a	O
Live	O
Attenuated	O
Porcine	O
Epidemic	B-DISO
Diarrhea	I-DISO
Virus	O
Vaccine	O
Candidate	O
via	O
Inactivation	B-DISO
of	O
the	O
Viral	O
2	O
'-	O
ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
causes	O
high	O
mortality	O
in	O
neonatal	O
piglets	O
;	O
however	O
,	O
effective	O
and	O
safe	O
vaccines	O
are	O
still	O
not	O
available	O
.	O

ABSTRACT	O
:	O
The	O
original	O
discouraging	O
results	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
application	O
in	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
caused	O
the	O
technique	O
to	O
be	O
almost	O
abandoned	O
.	O

ABSTRACT	O
:	O
Recent	O
outbreaks	O
of	O
SARS	B-DISO
-	O
Coronavirus	O
and	O
MERS	O
-	O
Coronavirus	O
(	O
CoV	O
)	O
have	O
heightened	O
awareness	O
about	O
the	O
lack	O
of	O
vaccines	O
or	O
antiviral	O
compounds	O
approved	O
for	O
prevention	O
or	O
treatment	O
of	O
human	O
or	O
potential	O
zoonotic	O
CoVs	O
.	O

TITLE	O
:	O
Human	O
β	O
-	O
defensin	O
2	O
is	O
involved	O
in	O
CCR2	O
-	O
mediated	O
Nod2	O
signal	O
transduction	O
,	O
leading	O
to	O
activation	O
of	O
the	O
innate	B-DISO
immune	I-DISO
response	I-DISO
in	O
macrophages	O
.	O

S	O
RBD	O
-	O
HBD	B-DISO
2	O
treatment	O
also	O
enhanced	O
phosphorylation	O
and	O
activation	O
of	O
receptor	O
-	O
interacting	O
serine	O
/	O
threonine	O
-	O
protein	O
kinase	O
2	O
and	O
IFN	O
regulatory	O
factor	O
3	O
compared	O
to	O
S	O
RBD	O
alone	O
.	O

TITLE	O
:	O
Porcine	O
deltacoronavirus	O
nucleocapsid	O
protein	O
antagonizes	O
IFN	O
-	O
β	O
production	O
by	O
impairing	O
dsRNA	O
and	O
PACT	B-DISO
binding	O
to	O
RIG	O
-	O
I	O
.	O
ABSTRACT	O
:	O
Porcine	O
deltacoronavirus	O
(	O
PDCoV	O
)	O
is	O
an	O
emerging	O
swine	O
enteropathogenic	O
coronavirus	O
that	O
causes	O
watery	B-DISO
diarrhea	I-DISO
,	O
vomiting	B-DISO
and	O
mortality	O
in	O
newborn	O
piglets	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
PDCoV	O
infection	B-DISO
antagonizes	O
RIG	O
-	O
I	O
-	O
like	O
receptor	O
(	O
RLR	O
)-	O
mediated	O
IFN	O
-	O
β	O
production	O
to	O
evade	O
host	O
innate	O
immune	O
defense	O
,	O
and	O
PDCoV	O
-	O
encoded	O
nonstructural	O
protein	O
nsp5	O
and	O
accessory	O
protein	O
NS6	B-DISO
are	O
associated	O
with	O
this	O
process	O
.	O

These	O
results	O
show	O
that	O
AdC68	O
-	O
S	O
can	O
induce	O
protective	O
immune	O
responses	O
in	O
mice	O
and	O
represent	O
a	O
promising	O
candidate	O
for	O
further	O
development	O
against	O
MERS	O
-	O
CoV	O
infection	B-DISO
in	O
both	O
dromedaries	O
and	O
humans	O
.	O

In	O
101	O
(	O
12	O
.	O
1	O
%)	O
cases	O
infections	B-DISO
caused	O
by	O
two	O
or	O
three	O
agents	O
were	O
diagnosed	O
.	O

Infections	B-DISO
with	O
three	O
causative	O
agents	O
were	O
detected	O
completely	O
among	O
1	O
month	O
-	O
18	O
year	O
age	O
[	O
3	O
%	O
(	O
18	O
/	O
593	O
)]	O
group	O
.	O

In	O
our	O
study	O
,	O
318	O
(	O
38	O
.	O
1	O
%)	O
cases	O
had	O
no	O
signs	O
of	O
infection	B-DISO
in	O
the	O
postmortem	O
histopathological	O
examination	O
of	O
the	O
lung	O
tissues	O
,	O
while	O
the	O
most	O
common	O
finding	O
was	O
lobular	B-DISO
pneumonia	I-DISO
/	O
purulent	B-DISO
bronchitis	I-DISO
in	O
233	O
(	O
28	O
%)	O
cases	O
and	O
the	O
second	O
was	O
interstitial	B-DISO
pneumonia	I-DISO
in	O
168	O
(	O
20	O
.	O
1	O
%)	O
cases	O
.	O

Furthermore	O
,	O
we	O
have	O
shown	O
that	O
the	O
RNA	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
),	O
SARS	B-DISO
-	O
Nsp12	O
,	O
can	O
enhance	O
the	O
helicase	O
activity	O
of	O
SARS	B-DISO
-	O
Nsp13	O
through	O
interacting	O
with	O
it	O
directly	O
.	O

The	O
CoV	O
envelope	O
(	O
E	O
)	O
protein	O
is	O
a	O
small	O
,	O
integral	O
membrane	O
protein	O
involved	O
in	O
several	O
aspects	O
of	O
the	O
virus	O
'	O
life	O
cycle	O
,	O
such	O
as	O
assembly	O
,	O
budding	O
,	O
envelope	O
formation	O
,	O
and	O
pathogenesis	B-DISO
.	O

TITLE	O
:	O
The	O
viral	O
protein	O
corona	O
directs	O
viral	B-DISO
pathogenesis	I-DISO
and	O
amyloid	B-DISO
aggregation	O
.	O

Importantly	O
,	O
we	O
show	O
that	O
HSV	O
-	O
1	O
catalyzes	O
the	O
aggregation	O
of	O
the	O
amyloid	B-DISO
β	O
-	O
peptide	O
(	O
Aβ	O

This	O
study	O
aims	O
to	O
determine	O
the	O
proportions	O
of	O
influenza	B-DISO
and	O
noninfluenza	O
viruses	O
among	O
SARI	O
patients	O
and	O
to	O
determine	O
the	O
severity	O
of	O
SARI	O
and	O
its	O
associated	O
factors	O
.	O

ABSTRACT	O
:	O
Recent	O
history	O
is	O
punctuated	O
by	O
the	O
emergence	O
of	O
highly	O
pathogenic	O
coronaviruses	O
such	O
as	O
SARS	B-DISO
-	O
and	O
MERS	O
-	O
CoV	O
into	O
human	O
circulation	O
.	O

Epidemiological	O
studies	O
conducted	O
over	O
the	O
last	O
three	O
decades	O
have	O
indicated	O
that	O
viruses	O
are	O
responsible	O
for	O
the	O
majority	O
of	O
these	O
infections	B-DISO
.	O

However	O
,	O
we	O
contend	O
that	O
other	O
camel	O
-	O
borne	O
diseases	O
such	O
as	O
Yersinia	B-DISO
pestis	O
,	O
Coxiella	O
burnetii	O
,	O
and	O
Crimean	B-DISO
-	I-DISO
Congo	I-DISO
hemorrhagic	I-DISO
fever	I-DISO
are	O
just	O
as	O
important	O
to	O
include	O
in	O
surveillance	O
efforts	O
.	O

Our	O
results	O
showed	O
that	O
the	O
chimeric	O
antigen	O
could	O
induce	O
specific	O
neutralizing	O
antibodies	O
against	O
both	O
strains	O
leading	O
to	O
protection	O
of	O
immunized	O
mice	O
against	O
H1N1pdm09	O
and	O
efficient	O
neutralization	O
of	O
MERS	O
-	O
CoV	O
.	O
This	O
study	O
demonstrate	O
that	O
OMVs	O
-	O
based	O
vaccines	O
presenting	O
viral	O
antigens	O
provide	O
a	O
safe	O
and	O
reliable	O
approach	O
to	O
protect	O
against	O
two	O
different	O
viral	B-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
Avian	B-DISO
infectious	I-DISO
bronchitis	I-DISO
(	O
IB	O
)	O
is	O
a	O
disease	O
that	O
can	O
result	O
in	O
huge	O
economic	O
losses	O
in	O
the	O
poultry	O
industry	O
.	O

RESULTS	O
:	O
Extracts	O
of	O
S	O
.	O
montana	O
,	O
O	O
.	O
vulgare	O
,	O
M	O
.	O
piperita	O
,	O
M	O
.	O
officinalis	O
,	O
T	O
.	O
vulgaris	O
,	O
H	O
.	O
officinalis	O
,	O
S	O
.	O
officinalis	O
and	O
D	O
.	O
canadense	O
showed	O
anti	O
-	O
IBV	O
activity	O
prior	O
to	O
and	O
during	O
infection	B-DISO
,	O
while	O
S	O
.	O
montana	O
showed	O
activity	O
prior	O
to	O
and	O
after	O
infection	B-DISO
.	O

Clinical	O
examination	O
revealed	O
high	O
fever	O
,	O
jaundice	B-DISO
,	O
cyanosis	B-DISO
,	O
tachypnea	B-DISO
and	O
bilateral	O
rales	B-DISO
on	O
pulmonary	O
auscultation	O
.	O

ABSTRACT	O
:	O
The	O
increase	O
in	O
international	O
travel	O
,	O
the	O
growing	O
presence	O
of	O
arbovirus	O
vectors	O
in	O
our	O
country	O
,	O
and	O
notifications	O
of	O
haemorrhagic	B-DISO
fever	I-DISO
such	O
as	O
the	O
current	O
outbreak	O
of	O
Ebola	O
in	O
D	O
.	O
R	O
.	O
Congo	O
and	O
the	O
cases	O
of	O
Crimea	O
-	O
Congo	B-DISO
haemorrhagic	I-DISO
fever	I-DISO
in	O
our	O
country	O
have	O
again	O
cast	O
the	O
spotlight	O
on	O
tropical	B-DISO
diseases	I-DISO
Isolating	O
suspected	O
cases	O
of	O
highly	O
contagious	O
and	O
lethal	O
diseases	O
must	O
be	O
a	O
priority	O
(	O
Haemorrhagic	B-DISO
fever	I-DISO
,	O
MERS	O
-	O
CoV	O
).	O

Malaria	B-DISO
should	O
be	O
ruled	O
out	O
because	O
of	O
its	O
frequency	O
,	O
without	O
forgetting	B-DISO
other	O
common	O
causes	O
of	O
fever	O
familiar	O
to	O
emergency	B-DISO
doctors	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
cause	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
in	O
humans	O
and	O
outbreaks	O
of	O
deadly	O
pneumonia	B-DISO
worldwide	O
.	O

Patients	O
with	O
a	O
glomerular	O
filtration	O
rate	O
greater	O
than	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73	O
m	O
prior	O
to	O
admission	O
who	O
fulfilled	O
criteria	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
on	O
day	O
1	O
and	O
day	O
2	O
of	O
acute	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
.	O

The	O
primary	O
outcome	O
was	O
hospital	O
mortality	O
,	O
whereas	O
secondary	O
outcomes	O
included	O
prevalence	O
of	O
acute	O
kidney	O
injury	O
and	O
characterization	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
risk	O
factors	O
and	O
illness	O
severity	O
patterns	O
,	O
in	O
patients	O
with	O
acute	O
kidney	O
injury	O
versus	O
no	O
acute	O
kidney	O
injury	O
.	O

In	O
total	O
,	O
915	O
out	O
of	O
2336	O
adult	O
patients	O
with	O
viral	B-DISO
infection	I-DISO
were	O
enrolled	O
in	O
the	O
analysis	O
,	O
with	O
influenza	B-DISO
virus	O
(	O
28	O
.	O
4	O
%)	O
the	O
most	O
frequently	O
detected	O
virus	O
,	O
followed	O
by	O
respiratory	O
syncytial	O
virus	O
(	O
3	O
.	O
6	O
%),	O
adenovirus	B-DISO
(	O
3	O
.	O
3	O
%),	O
human	O
coronavirus	O
(	O
3	O
.	O
0	O
%),	O
parainfluenza	B-DISO
virus	O
(	O
2	O
.	O
2	O
%),	O
human	O
rhinovirus	O
(	O
1	O
.	O
8	O
%)	O
and	O
human	O
metapneumovirus	O
(	O
1	O
.	O
5	O
%).	O

However	O
,	O
there	O
is	O
no	O
compelling	O
evidence	O
supporting	O
the	O
use	O
of	O
direct	O
oral	O
anticoagulant	O
in	O
individuals	O
who	O
are	O
intubated	O
or	O
have	O
a	O
percutaneous	O
endoscopic	O
gastrostomy	B-DISO
(	O
PEG	O
):	O
patients	O
with	O
several	O
co	O
-	O
morbidities	O
are	O
underrepresented	O
in	O
clinical	O
trials	O
,	O
so	O
the	O
best	O
long	O
-	O
term	O
strategy	O
for	O
anticoagulation	O
is	O
difficult	O
to	O
ascertain	O
.	O

Years	O
later	O
the	O
diagnostics	O
industry	O
provided	O
commercial	O
HCV	O
and	O
HIV	B-DISO
-	O
1	O
and	O
later	O
HBV	B-DISO
NAT	O
tests	O
on	O
automated	O
platforms	O
.	O

Mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
are	O
able	O
to	O
modulate	O
proliferation	B-DISO
,	O
activation	O
,	O
and	O
effector	O
function	O
of	O
all	O
immune	O
cells	O
that	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	B-DISO
of	O
acute	O
and	O
chronic	O
inflammatory	O
lung	B-DISO
diseases	I-DISO
.	O

Risk	O
factors	O
for	O
known	O
causes	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
included	O
a	O
witnessed	O
aspiration	B-DISO
event	O
and	O
RSV	O
pneumonia	B-DISO
.	O

On	O
review	O
of	O
the	O
literature	O
,	O
severe	O
hypothermia	O
has	O
been	O
found	O
to	O
cause	O
pulmonary	B-DISO
edema	I-DISO
in	O
post	O
-	O
mortem	O
studies	O
,	O
but	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
has	O
not	O
yet	O
been	O
recognized	O
as	O
a	O
known	O
complication	B-DISO
.	O

Other	O
findings	O
during	O
the	O
initial	O
evaluation	O
of	O
the	O
patient	O
may	O
include	O
a	O
lack	O
of	O
acute	O
cardiac	B-DISO
disease	I-DISO
or	O
inappropriate	O
fluid	O
balance	O
,	O
flat	O
neck	O
veins	O
,	O
and	O
the	O
absence	O
of	O
peripheral	O
edema	B-DISO
.	O

Clinical	O
context	O
also	O
necessitates	O
no	O
evidence	O
of	O
acute	B-DISO
heart	I-DISO
failure	I-DISO
or	O
hypervolemia	B-DISO
in	O
the	O
setting	O
of	O
ARDS	B-DISO
.	O

All	O
samples	O
were	O
tested	O
for	O
influenza	B-DISO
viruses	O
,	O
whereas	O
about	O
38	O
,	O
000	O
samples	O
were	O
tested	O
for	O
influenza	B-DISO
and	O
a	O
panel	O
of	O
respiratory	O
viruses	O
using	O
Fast	O
Track	O
Diagnostics	O
(	O
FTD	B-DISO
)	O
RT	O
-	O
PCR	O
kit	O
.	O

A	O
detection	O
rate	O
of	O
2	O
-	O
3	O
%	O
was	O
recorded	O
for	O
mycoplasma	B-DISO
pneumonia	I-DISO
,	O
adenoviruses	O
,	O
human	O
parainfluenza	B-DISO
viruses	O
(	O
HPIVs	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
and	O
human	O
metapneumovirus	O
(	O
HMPV	O
).	O

TITLE	O
:	O
[	O
Prognostic	O
value	O
of	O
the	O
dynamic	O
changes	O
in	O
extra	O
vascular	O
lung	O
water	O
index	O
and	O
angiopoietin	O
-	O
2	O
in	O
severe	O
multiple	O
trauma	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
].	O

ABSTRACT	O
:	O
To	O
observe	O
the	O
dynamic	O
changes	O
in	O
extra	O
vascular	O
lung	O
water	O
index	O
(	O
EVLWI	O
)	O
and	O
angiopoietin	O
-	O
2	O
(	O
Ang	O
-	O
2	O
)	O
in	O
severe	O
multiple	O
trauma	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
analyze	O
the	O
risk	O
factor	O
for	O
short	O
-	O
term	O
mortality	O
,	O
and	O
to	O
evaluate	O
their	O
prognostic	O
values	O
for	O
prognosis	O
.	O

The	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHE	O
II	O
),	O
injury	O
severity	O
score	O
(	O
ISS	B-DISO
)	O
and	O
oxygenation	O
index	O
(	O
PaO	O
115	O
patients	O
were	O
enrolled	O
in	O
the	O
final	O
analysis	O
,	O
72	O
survived	O
in	O
28	O
days	O
,	O
43	O
died	O
,	O
and	O
the	O
mortality	O
rate	O
was	O
37	O
.	O
4	O
%.	O

The	O
inflammatory	O
factors	O
play	O
an	O
important	O
role	O
in	O
the	O
formation	O
of	O
traumatic	O
ARDS	B-DISO
.	O

This	O
article	O
reports	O
the	O
spleen	O
-	O
mediated	O
systemic	O
inflammatory	B-DISO
response	I-DISO
,	O
the	O
role	O
of	O
inflammatory	O
mediators	O
in	O
the	O
development	O
of	O
ARDS	B-DISO
,	O
and	O
the	O
current	O
state	O
of	O
research	O
on	O
ARDS	B-DISO
treatment	O
to	O
explore	O
new	O
approaches	O
to	O
the	O
prevention	O
and	O
treatment	O
of	O
traumatic	O
ARDS	B-DISO
.	O

We	O
describe	O
the	O
case	O
of	O
a	O
17	O
-	O
year	O
-	O
old	O
male	O
who	O
was	O
admitted	O
in	O
our	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
for	O
severe	O
hypoxemia	O
due	O
to	O
fat	B-DISO
embolism	I-DISO
.	O

In	O
this	O
study	O
,	O
we	O
reported	O
the	O
recent	O
diarrhoea	B-DISO
outbreak	O
of	O
SADS	O
-	O
CoV	O
in	O
Southern	O
China	O
on	O
February	O
2019	O
.	O

Asymptomatic	O
shedding	O
among	O
pediatric	O
surgery	O
patients	O
(	O
PSPs	O
)	O
could	O
potentially	O
lead	O
to	O
progression	O
of	O
symptomatic	O
diseases	O
and	O
cause	O
outbreaks	O
of	O
respiratory	B-DISO
diseases	I-DISO
.	O

We	O
collected	O
the	O
induced	O
sputum	O
from	O
enrolled	O
1629	O
children	O
(	O
under	O
18	O
years	O
of	O
age	O
)	O
with	O
no	O
respiratory	B-DISO
symptom	I-DISO
prior	O
to	O
pediatric	O
surgery	O
between	O
March	O
2017	O
and	O
February	O
2019	O
.	O

CoV	O
(	O
OC43	O
,	O
HKU1	O
)	O
infections	B-DISO
with	O
a	O
higher	O
viral	O
load	O
were	O
mostly	O
observed	O
in	O
asymptomatic	O
PSPs	O
progressing	O
to	O
alveolar	O
or	O
interstitial	O
infiltration	B-DISO
.	O

TITLE	O
:	O
Impact	O
of	O
""""	O
opening	O
the	O
lung	O
""""	O
ventilatory	O
strategy	O
on	O
burn	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Opening	O
the	O
lung	O
procedure	O
was	O
safe	O
in	O
all	O
patients	O
with	O
optimal	O
PEEP	O
of	O
14	O
.	O
8	O
±	O
1	O
.	O
8	O
cmH	B-DISO
It	O
is	O
necessary	O
to	O
conduct	O
further	O
trials	O
to	O
find	O
out	O
the	O
effectiveness	O
of	O
this	O
ventilation	O
strategy	O
on	O
burns	O
injury	O
induced	O
ARDS	B-DISO
.	O

TITLE	O
:	O
A	O
shared	O
protocol	O
for	O
porcine	O
surfactant	O
use	O
in	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
a	O
feasibility	O
study	O
.	O

Using	O
biochemical	O
methods	O
we	O
identify	O
RNA	O
as	O
a	O
novel	O
target	O
of	O
reversible	O
mono	B-DISO
-	O
ADP	O
-	O
ribosylation	O
.	O

Finally	O
,	O
we	O
show	O
that	O
TRPT1	O
and	O
MACROD	O
homologues	O
in	O
bacteria	O
possess	B-DISO
activities	O
equivalent	O
to	O
the	O
human	O
proteins	O
.	O

ABSTRACT	O
:	O
Autosomal	O
recessive	O
IRF7	O
and	O
IRF9	O
deficiencies	O
impair	O
type	O
I	O
and	O
III	O
IFN	O
immunity	O
and	O
underlie	O
severe	O
influenza	B-DISO
pneumonitis	B-DISO
.	O

We	O
report	O
three	O
unrelated	O
children	O
with	O
influenza	B-DISO
A	O
virus	O
(	O
IAV	O
)	O
infection	B-DISO
manifesting	O
as	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
IAV	O
-	O
ARDS	B-DISO
),	O
heterozygous	O
for	O
rare	O

Here	O
,	O
to	O
better	O
understand	O
the	O
epidemiology	O
and	O
pathogenicity	O
of	O
IBV	O
in	O
China	O
and	O
control	O
the	O
spread	O
of	O
infectious	B-DISO
bronchitis	B-DISO
(	O
IB	O
),	O
we	O
conducted	O
sequence	O
analyses	O
and	O
examined	O
the	O
pathogenicity	O
of	O
5	O
field	O
isolates	O
from	O
diseased	O
flocks	O
in	O
2017	O
and	O
2018	O
.	O

ABSTRACT	O
:	O
Prader	B-DISO
-	I-DISO
Willi	I-DISO
syndrome	I-DISO
(	O
PWS	B-DISO
)	O
is	O
generally	O
due	O
to	O
sporadic	O
paternal	O
deletions	O
of	O
the	O
chromosome	O
15q11	O
-	O
q13	O
region	O
followed	O
by	O
maternal	O
disomy	O
15	O
.	O

Experimental	O
work	O
carried	O
on	O
to	O
determine	O
the	O
mode	O
of	O
action	O
of	O
the	O
most	O
potent	O
IIa	O
,	O
containing	O
tetravalent	O
branched	O
arms	B-DISO
,	O
demonstrated	O
that	O
it	O
interacts	O
with	O
the	O
viral	O
envelopes	O
of	O
HIV	B-DISO
,	O
EV71	O
and	O
HSV	O
-	O
2	O
and	O
thus	O
may	O
prevent	O
virus	O
attachment	O
to	O
the	O
host	O
cell	O
.	O

New	O
strategies	O
for	O
prevention	O
and	O
treatment	O
of	O
viral	O
respiratory	B-DISO
infections	I-DISO
,	O
mainly	O
rhinovirus	O
and	O
RSV	B-DISO
infections	I-DISO
,	O
are	O
necessary	O
.	O

In	O
ST	O
cells	O
,	O
caspase	O
activity	O
assay	O
showed	O
that	O
the	O
activity	O
of	O
caspase	O
3	O
,	O
caspase	O
8	O
and	O
caspase	O
9	O
increased	O
significantly	O
with	O
the	O
infection	B-DISO
of	O
PDCoV	O
,	O
but	O
not	O
observed	O
in	O
UV	O
irradiated	O
PDCoV	O
-	O
infected	O
cells	O
,	O
indicating	O
that	O
PDCoV	O
infection	B-DISO
activated	O
both	O
endogenous	O
and	O
exogenous	O
apoptotic	O
pathways	O
in	O
ST	O
cells	O
,	O
and	O
the	O
induction	O
of	O
apoptosis	O
depended	O
on	O
viral	O
replication	O
.	O

ABSTRACT	O
:	O
Advances	O
in	O
molecular	O
laboratory	O
techniques	O
are	O
changing	O
the	O
prospects	O
for	O
the	O
diagnosis	O
of	O
viral	O
infectious	B-DISO
diseases	I-DISO
.	O

Eleven	O
common	O
respiratory	O
pathogens	O
were	O
tested	O
in	O
hospitalized	O
children	O
<	O
13	O
years	O
of	O
age	O
who	O
met	O
the	O
criteria	O
for	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
by	O
GeXP	O
-	O
based	O
multiplex	O
-	O
PCR	O
of	O
paired	O
OPS	B-DISO
and	O
sputum	O
.	O

From	O
January	O
to	O
June	O
2018	O
,	O
440	O
children	O
with	O
paired	O
OPS	B-DISO
and	O
sputum	O
were	O
tested	O
.	O

ABSTRACT	O
:	O
The	O
identification	O
and	O
analysis	O
of	O
viral	O
etiological	O
agents	O
from	O
suspected	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
cases	O
admitted	O
to	O
Prof	O
.	O
Dr	O
.	O
Sulianti	O
Saroso	O
Infectious	B-DISO
Disease	I-DISO
Hospital	O
(	O
IDH	O
)	O
using	O
molecular	O
assays	O
.	O

TITLE	O
:	O
Avian	O
coronavirus	B-DISO
infection	I-DISO
induces	O
mannose	O
-	O
binding	O
lectin	O
production	O
in	O
dendritic	O
cell	O
precursors	O
of	O
chicken	O
lymphoid	O
organs	O
.	O

Analysis	O
of	O
differential	O
gene	O
expression	O
in	O
infected	O
primary	O
chick	O
kidney	O
cells	O
indicated	O
that	O
the	O
host	O
cell	O
response	O
to	O
IBV	O
occurs	O
primarily	O
at	O
the	O
level	O
of	O
transcription	O
,	O
with	O
global	O
upregulation	O
of	O
immune	O
-	O
related	O
mRNA	O
transcripts	O
following	O
infection	B-DISO
and	O
comparatively	O
modest	O
changes	O
in	O
the	O
translation	O
efficiencies	O
of	O
host	O
genes	O
.	O

Cellular	O
genes	O
and	O
gene	O
networks	O
differentially	O
expressed	O
during	O
virus	B-DISO
infection	I-DISO
were	O
also	O
identified	O
,	O
giving	O
insights	O
into	O
the	O
host	O
cell	O
response	O
to	O
IBV	O
infection	B-DISO
.	O

Early	O
management	O
of	O
ARDS	B-DISO
has	O
been	O
difficult	O
due	O
to	O
the	O
lack	O
of	O
sensitive	O
imaging	O
tools	O
and	O
robust	O
analysis	O
software	O
.	O

The	O
decrease	O
in	O
the	O
PAV	O
was	O
more	O
prominent	O
in	O
the	O
animals	O
that	O
developed	O
ARDS	B-DISO
after	O
24	O
hours	O
after	O
the	O
injury	O
.	O

TITLE	O
:	O
Early	O
Vaccination	O
of	O
Chickens	O
Induces	O
Suboptimal	O
Immunity	O
Against	O
Infectious	B-DISO
Bronchitis	B-DISO
Virus	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
is	O
highly	O
prevalent	O
in	O
broiler	O
chickens	O
despite	O
extensive	O
vaccination	O
commonly	O
conducted	O
early	O
after	O
hatch	O
.	O

There	O
were	O
no	O
randomized	O
clinical	O
trials	O
to	O
recommend	O
specific	O
therapy	O
for	O
the	O
treatment	O
of	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

In	O
conclusion	O
,	O
NETs	O
promote	O
ARDS	B-DISO
inflammation	B-DISO
during	O
the	O
acute	O
phase	O
by	O
promoting	O
macrophage	O
polarization	O
to	O
the	O
M1	O
phenotype	O
.	O

Nasopharyngeal	O
swabs	O
and	O
broncho	O
-	O
alveolar	O
lavage	O
samples	O
from	O
inpatients	O
with	O
respiratory	B-DISO
infection	I-DISO
symptoms	O
at	O
the	O
Uludag	O
University	O
Hospital	O
between	O
December	O
1	O
,	O
2015	O
and	O
March	O
31	O
,	O
2018	O
were	O
investigated	O
.	O

ABSTRACT	O
:	O
The	O
Faculty	O
of	O
Intensive	O
Care	O
Medicine	O
and	O
Intensive	O
Care	O
Society	O
Guideline	O
Development	O
Group	O
have	O
used	O
GRADE	O
methodology	O
to	O
make	O
the	O
following	O
recommendations	O
for	O
the	O
management	O
of	O
adult	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Where	O
mechanical	O
ventilation	O
is	O
required	O
,	O
the	O
use	O
of	O
low	O
tidal	O
volumes	O
(<	O
6	O
ml	O
/	O
kg	O
ideal	O
body	O
weight	O
)	O
and	O
airway	O
pressures	O
(	O
plateau	O
pressure	O
<	O
30	O
cmH	B-DISO

In	O
one	O
study	O
HCW	O
were	O
exposed	O
to	O
Ebola	O
and	O
in	O
another	O
to	O
SARS	B-DISO
.	O
Evidence	O
for	O
all	O
outcomes	O
is	O
based	O
on	O
single	O
studies	O
and	O
is	O
very	O
low	O
quality	O
.	O

TITLE	O
:	O
Controversy	O
around	O
airborne	O
versus	O
droplet	O
transmission	O
of	O
respiratory	O
viruses	O
:	O
implication	O
for	O
infection	B-DISO
prevention	O
.	O

TITLE	O
:	O
Epidemiology	O
of	O
Pediatric	O
Severe	B-DISO
Sepsis	I-DISO
in	O
Main	O
PICU	O
Centers	O
in	O
Southwest	O
China	O
.	O

Here	O
we	O
review	O
emerging	B-DISO
infectious	I-DISO
disease	I-DISO
biological	O
standards	O
development	O
,	O
vaccine	O
clinical	O
assay	O
development	O
and	O
trial	O
execution	O
with	O
the	O
recent	O
experiences	O
of	O
MERS	O
-	O
CoV	O
and	O
Zika	O
virus	O
as	O
examples	O
.	O

These	O
data	O
suggest	O
that	O
the	O
expression	O
of	O
these	O
six	O
tight	O
junction	O
proteins	O
,	O
especially	O
Occludin	O
and	O
Claudin	O
-	O
4	O
,	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
the	O
integrity	O
of	O
the	O
intestinal	O
mucosal	O
barrier	O
and	O
resistance	O
to	O
PEDV	O
infection	B-DISO
in	O
piglets	O
.	O

Both	O
entities	O
are	O
well	O
known	O
to	O
be	O
associated	O
with	O
severe	O
post	O
-	O
traumatic	O
complications	O
,	O
including	O
pneumonia	B-DISO
,	O
a	O
common	O
complication	B-DISO
with	O
a	O
significant	O
impact	O
on	O
the	O
further	O
clinical	O
course	O
.	O

Complications	O
(	O
i	O
.	O
e	O
.	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
),	O
multi	O
-	O
organ	B-DISO
dysfunction	I-DISO
syndrome	I-DISO
(	O
MODS	B-DISO
)	O
and	O
pneumonia	B-DISO
)	O
were	O
documented	O
by	O
a	O
review	O
of	O
the	O
medical	O
records	O
.	O

Pneumonia	B-DISO
(	O
OR	O
5	O
.	O
142	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
represented	O
the	O
strongest	O
independent	O
predictor	O
of	O
in	O
-	O
hospital	O
mortality	O
,	O
followed	O
by	O
the	O
combination	O
of	O
chest	O
injury	O
and	O
TBI	O
(	O
OR	O
3	O
.	O
784	O
,	O
p	O
=	O
0	O
.	O
008	O
)	O
and	O
TBI	O
(	O
OR	O
3	O
.	O
028	O
,	O
p	O
=	O
0	O
.	O
010	O
).	O

ABSTRACT	O
:	O
To	O
set	O
priorities	O
for	O
efficient	O
control	O
of	O
acute	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
(	O
ARTI	O
)	O
in	O
Africa	O
,	O
it	O
is	O
necessary	O
to	O
have	O
accurate	O
estimate	O
of	O
its	O
burden	O
,	O
especially	O
among	O
HIV	B-DISO
-	O
infected	O
populations	O
.	O

We	O
searched	O
PubMed	O
,	O
EMBASE	O
,	O
Web	B-DISO
of	O
Knowledge	O
,	O
Africa	O
Journal	O
Online	O
,	O
and	O
Global	O
Index	O
Medicus	O
to	O
identify	O
studies	O
published	O
from	O
January	O
2000	O
to	O
April	O
2018	O
.	O

ARTI	O
deserves	O
more	O
attention	O
from	O
HIV	B-DISO
health	O
-	O
care	O
providers	O
for	O
efficient	O
control	O
.	O

TITLE	O
:	O
Prevalence	O
of	O
and	O
risk	O
factors	O
for	O
pulmonary	B-DISO
complications	I-DISO
after	O
curative	O
resection	O
in	O
otherwise	O
healthy	O
elderly	O
patients	O
with	O
early	O
stage	O
lung	B-DISO
cancer	I-DISO
.	O

We	O
aimed	O
to	O
determine	O
the	O
prevalence	O
of	O
and	O
risk	O
factors	O
for	O
postoperative	O
pulmonary	B-DISO
complications	I-DISO
(	O
PPCs	O
)	O
in	O
healthy	O
elderly	O
patients	O
with	O
non	B-DISO
-	I-DISO
small	I-DISO
cell	I-DISO
lung	I-DISO
cancer	I-DISO
(	O
NSCLC	B-DISO
)	O
to	O
select	O
optimal	O
candidates	O
for	O
surgical	O
resection	O
in	O
this	O
subpopulation	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
severe	O
acute	B-DISO
disease	I-DISO
that	O
threatens	O
human	O
health	O
,	O
and	O
few	O
drugs	O
that	O
can	O
effectively	O
treat	O
this	O
disease	O
are	O
available	O
.	O

TITLE	O
:	O
Severity	O
and	O
Mortality	O
Predictors	O
of	O
Pediatric	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
According	O
to	O
the	O
Pediatric	O
Acute	O
Lung	O
Injury	O
Consensus	O
Conference	O
Definition	O
.	O

Children	O
1	O
month	O
to	O
15	O
years	O
old	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
admitted	O
to	O
the	O
PICU	O
from	O
January	O
2013	O
to	O
December	O
2016	O
.	O

After	O
multivariable	O
analysis	O
was	O
performed	O
,	O
factors	O
significantly	O
associated	O
with	O
moderate	O
to	O
severe	O
disease	O
at	O
the	O
initial	O
diagnosis	O
were	O
Pediatric	O
Risk	O
of	O
Mortality	O
III	O
score	O
(	O
odds	O
ratio	O
,	O
1	O
.	O
08	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
03	O
-	O
1	O
.	O
15	O
;	O
p	O
=	O
0	O
.	O
004	O
),	O
underlying	O
oncologic	O
/	O
hematologic	B-DISO
disorder	I-DISO
(	O
odds	O
ratio	O
,	O
0	O
.	O
32	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
12	O
-	O
0	O
.	O
77	O
;	O
p	O
=	O
0	O
.	O
012	O
),	O
and	O
serum	O
albumin	O
level	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
46	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
27	O
-	O
0	O
.	O
80	O
;	O
p	O
=	O
0	O
.	O
006	O
),	O
whereas	O
underlying	O
oncologic	O
/	O
hematologic	B-DISO
disorder	I-DISO
(	O
odds	O
ratio	O
,	O
5	O
.	O
33	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
33	O
-	O
21	O
.	O
4	O
)	O
and	O
hemoglobin	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
63	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
44	O
-	O
0	O
.	O
89	O
)	O
predicted	O
the	O
progression	O
of	O
this	O
syndrome	B-DISO
within	O
7	O
days	O
.	O

The	O
predictors	O
of	O
mortality	O
were	O
the	O
Pediatric	O
Risk	O
of	O
Mortality	O
III	O
score	O
(	O
odds	O
ratio	O
,	O
1	O
.	O
12	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
02	O
-	O
1	O
.	O
24	O
;	O
p	O
=	O
0	O
.	O
017	O
),	O
underlying	O
oncologic	O
/	O
hematologic	B-DISO
disorder	I-DISO
(	O
odds	O
ratio	O
,	O
7	O
.	O
81	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
18	O
-	O
27	O
.	O
94	O
;	O
p	O
=	O
0	O
.	O
002	O
),	O
receiving	O
systemic	O
steroids	O
(	O
odds	O
ratio	O
,	O
4	O
.	O
04	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
25	O
-	O
13	O
.	O
03	O
;	O
p	O
=	O
0	O
.	O
019	O
),	O
having	O
air	O
leak	O
syndrome	B-DISO
(	O
odds	O
ratio	O
,	O
5	O
.	O
45	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
57	O
-	O
18	O
.	O
96	O
;	O
p	O
=	O
0	O
.	O
008	O
),	O
and	O
presenting	O
with	O
multiple	O
organ	O
dysfunction	O
(	O
odds	O
ratio	O
,	O
7	O
.	O
41	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
00	O
-	O
27	O
.	O
36	O
;	O
p	O
=	O
0	O
.	O
003	O
).	O

TITLE	O
:	O
Overview	O
of	O
Current	O
Therapeutics	O
and	O
Novel	O
Candidates	O
Against	O
Influenza	B-DISO
,	O
Respiratory	O
Syncytial	O
Virus	O
,	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	B-DISO
Infections	I-DISO
.	O

Respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
may	O
cause	O
a	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
characterized	O
by	O
bronchiolitis	B-DISO
and	O
pneumonia	B-DISO
mainly	O
in	O
children	O
and	O
the	O
elderly	O
.	O

These	O
findings	O
provide	O
a	O
new	O
model	O
of	O
developing	O
safe	O
and	O
effective	O
immunizations	O
for	O
newborn	O
animals	O
against	O
established	O
and	O
emerging	O
enteric	O
infections	B-DISO
.	O

TITLE	O
:	O
A	O
48	O
-	O
Year	O
-	O
Old	O
Man	O
With	O
Excessive	O
Drooling	B-DISO
and	O
Descending	O
Paralysis	O
Requiring	O
Mechanical	O
Ventilation	O
.	O

He	O
denied	O
fevers	O
,	O
stridor	B-DISO
,	O
dyspnea	B-DISO
,	O
rash	B-DISO
,	O
odynophagia	B-DISO
,	O
nausea	B-DISO
,	O
vomiting	B-DISO
,	O
or	O
diarrhea	B-DISO
.	O

An	O
inadequate	O
extracorporeal	O
membrane	O
oxygenation	O
output	O
flow	O
was	O
observed	O
,	O
possibly	O
because	O
of	O
severe	O
polycythemia	B-DISO
and	O
hyperviscosity	O
.	O

Clinicians	O
should	O
be	O
aware	O
that	O
polycythemia	B-DISO
and	O
hyperviscosity	O
may	O
impair	O
extracorporeal	O
membrane	O
oxygenation	O
support	O
and	O
that	O
acute	O
normovolemic	O
hemodilution	O
may	O
be	O
a	O
safe	O
and	O
efficient	O
procedure	O
to	O
address	O
such	O
matter	O
.	O

ABSTRACT	O
:	O
Severe	O
influenza	B-DISO
infections	B-DISO
are	O
often	O
associated	O
with	O
the	O
excessive	O
induction	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
which	O
is	O
also	O
referred	O
to	O
as	O
""""	O
cytokine	O
storms	O
"""."	O

We	O
demonstrated	O
that	O
the	O
U937	O
cell	O
model	O
is	O
robust	O
and	O
suitable	O
for	O
the	O
high	O
-	O
throughput	O
screening	O
of	O
immunomodulators	O
and	O
antivirals	O
against	O
influenza	B-DISO
infection	B-DISO
.	O

We	O
identified	O
1093	O
up	O
-	O
regulated	O
and	O
845	O
down	O
-	O
regulated	O
mRNAs	O
in	O
IBV	O
-	O
infected	O
avian	O
DCs	B-DISO
.	O

Best	O
management	O
practices	O
of	O
MERS	O
-	O
CoV	O
patients	O
were	O
significantly	O
higher	O
among	O
dentists	O
with	O
better	O
knowledge	O
of	O
virus	O
transmission	O
(	O
odd	O
ration	O
[	O
OR	O
]=	O
1	O
.	O
16	O
,	O
p	O
less	O
than	O
0	O
.	O
0001	O
),	O
patients	O
'	O
identification	O
(	O
OR	O
=	O
1	O
.	O
40	O
,	O
p	O
less	O
than	O
0	O
.	O
0001	O
)	O
and	O
those	O
knowing	O
that	O
corona	O
infection	B-DISO
can	O
be	O
fatal	O
(	O
OR	O
=	O
2	O
.	O
44	O
,	O
p	O
=	O
0	O
.	O
02	O
).	O

Conditions	O
at	O
the	O
time	O
of	O
death	O
were	O
sepsis	B-DISO
(	O
25	O
),	O
pneumonia	B-DISO
(	O
16	O
),	O
AKI	O
(	O
15	O
),	O
bleeding	B-DISO
disorders	I-DISO
(	O
11	O
),	O
neurological	O
complications	O
(	O
10	O
),	O
ARDS	B-DISO
(	O
10	O
),	O
CKD	O
(	O
4	O
),	O
AKI	O
in	O
addition	O
to	O
CKD	O
(	O
3	O
).	O

TITLE	O
:	O
Fatty	O
acid	O
synthase	O
downregulation	O
contributes	O
to	O
acute	O
lung	O
injury	O
in	O
murine	O
diet	O
-	O
induced	O
obesity	B-DISO
.	O

Here	O
,	O
we	O
showed	O
that	O
recombinant	O
staphylococcal	O
PI	O
-	O
PLC	O
possesses	B-DISO
enzyme	O
activity	O
that	O
causes	O
shedding	O
of	O
glycosylphosphatidylinositol	O
-	O
anchored	O
CD55	O
and	O
CD59	O
from	O
human	O
umbilical	O
vein	O
endothelial	O
cell	O
surfaces	O
and	O
triggers	O
cell	O
lysis	B-DISO
via	O
complement	O
activity	O
.	O

ABSTRACT	O
:	O
Influenza	B-DISO
A	O
(	O
H1N1	O
)	O
infection	B-DISO
has	O
a	O
propensity	O
to	O
infect	O
an	O
immunocompromised	O
host	O
(	O
ICH	B-DISO
).	O

Cox	O
regression	O
showed	O
that	O
ZM	O
and	O
ZS	O
-	O
treated	O
calves	O
had	O
a	O
14	O
.	O
7	O
%	O
(	O
P	O
=	O
0	O
.	O
015	O
)	O
and	O
13	O
.	O
9	O
%	O
(	O
P	O
=	O
0	O
.	O
022	O
)	O
reduced	O
hazard	O
of	O
diarrhea	B-DISO
,	O
respectively	O
,	O
compared	O
to	O
placebo	O
-	O
treated	O
calves	O
.	O

Calves	O
supplemented	O
for	O
at	O
least	O
the	O
first	O
five	O
days	O
of	O
diarrhea	B-DISO
with	O
ZM	O
and	O
ZS	O
had	O
a	O
21	O
.	O
4	O
%	O
(	O
P	O
=	O
0	O
.	O
027	O
)	O
and	O
13	O
.	O
0	O
%	O
(	O
P	O
=	O
0	O
.	O
040	O
)	O
increased	O
hazard	O
of	O
cure	O
from	O
diarrhea	B-DISO
,	O
respectively	O
,	O
compared	O
to	O
placebo	O
-	O
treated	O
calves	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
role	O
of	O
endocan	O
in	O
the	O
control	O
of	O
acute	O
lung	B-DISO
inflammation	I-DISO
.	O

Treatment	O
with	O
endocan	O
1	O
h	O
after	O
intratracheal	O
LPS	B-DISO
challenge	O
reduced	O
the	O
alveolar	O
inflammatory	B-DISO
response	I-DISO
,	O
diminished	O
histological	O
features	O
of	O
acute	O
lung	O
injury	O
,	O
and	O
improved	O
respiratory	O
function	O
.	O

Infants	O
with	O
more	O
severe	O
CDH	B-DISO
had	O
a	O
statistically	O
significant	O
increase	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
in	O
serum	O
SP	O
-	O
D	O
over	O
their	O
first	O
month	O
of	O
life	O
.	O

TITLE	O
:	O
Complete	O
Genome	O
Sequence	O
of	O
a	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
-	O
Related	O
Coronavirus	O
from	O
Kenyan	O
Bats	O
.	O

TITLE	O
:	O
Stochastic	O
and	O
spatio	O
-	O
temporal	O
analysis	O
of	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
outbreak	O
in	O
South	O
Korea	O
,	O
2015	O
.	O

Serum	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
levels	O
have	O
been	O
studied	O
in	O
non	O
-	O
trauma	O
-	O
related	O
ARDS	B-DISO
.	O

A	O
total	O
of	O
48	O
thoracic	B-DISO
trauma	O
patients	O
were	O
included	O
in	O
the	O
study	O
.	O

The	O
results	O
proposed	O
that	O
infection	B-DISO
with	O
heterologous	O
virus	O
may	O
result	O
in	O
temporary	O
competition	O
for	O
cell	O
receptors	O
or	O
competent	O
cells	O
for	O
replication	O
,	O
most	O
likely	O
interferon	O
-	O
mediated	O
.	O

In	O
the	O
short	O
-	O
term	O
,	O
colonies	O
under	O
nutritional	O
stress	O
(	O
which	O
consumed	O
mainly	O
E	O
.	O
grandis	O
pollen	O
)	O
showed	O
higher	O
infection	B-DISO
level	O
with	O
Nosema	O
spp	O
.	O

TITLE	O
:	O
Scaffold	O
hybridization	O
strategy	O
towards	O
potent	O
hydroxamate	O
-	O
based	O
inhibitors	O
of	O
ABSTRACT	O
:	O
Infections	B-DISO
with	O

TITLE	O
:	O
Respiratory	O
Virus	O
Epidemiology	O
Among	O
US	O
Infants	O
With	O
Severe	O
Bronchiolitis	B-DISO
:	O
Analysis	O
of	O
2	O
Multicenter	O
,	O
Multiyear	O
Cohort	O
Studies	O
.	O

Eligible	O
patients	O
were	O
randomized	O
into	O
(	O
1	O
)	O
SGMT	O
,	O
comprised	O
a	O
sleep	O
study	O
during	O
the	O
index	O
admission	O
and	O
continuous	O
positive	O
airway	O
pressure	O
and	O
behavioral	O
therapy	O
for	O
those	O
with	O
at	O
least	O
mild	O
OSA	B-DISO
or	O
(	O
2	O
)	O
standard	O
therapy	O
.	O

Of	O
the	O
70	O
patients	O
randomized	O
to	O
SGMT	O
,	O
21	O
(	O
30	O
%),	O
15	O
(	O
22	O
%)	O
and	O
27	O
(	O
39	O
%)	O
were	O
diagnosed	O
with	O
mild	O
,	O
moderate	O
and	O
severe	O
OSA	B-DISO
,	O
respectively	O
.	O

The	O
abundance	O
of	O
pathogenic	O
bacteria	O
associated	O
with	O
diseases	O
,	O
including	O
diarrhea	B-DISO
,	O
was	O
increased	O
.	O

The	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
is	O
still	O
a	O
very	O
severe	O
condition	B-DISO
in	O
intensive	O
care	O
patients	O
.	O

Temporal	O
,	O
seasonal	O
,	O
spatial	O
and	O
spatiotemporal	O
cluster	O
analyses	O
were	O
performed	O
using	O
Kulldorff	O
'	O
s	O
spatial	O
scan	O
statistics	O
to	O
determine	O
the	O
time	O
period	O
and	O
geographical	O
areas	O
with	O
the	O
highest	O
MERS	O
-	O
CoV	O
infection	B-DISO
risk	O
.	O

Most	O
MERS	O
-	O
CoV	O
infections	B-DISO
occurred	O
during	O
the	O
spring	O
season	O
(	O
41	O
.	O
88	O
%),	O
with	O
April	O
and	O
May	O
showing	O
significant	O
seasonal	O
clusters	O
.	O

MATERIAL	O
AND	O
METHODS	O
The	O
pathological	O
morphology	O
of	O
lung	O
tissue	O
and	O
degree	O
of	O
pulmonary	B-DISO
edema	I-DISO
were	O
assessed	O
by	O
hematoxylin	O
-	O
eosin	O
staining	O
and	O
pulmonary	B-DISO
edema	I-DISO
score	O
,	O
respectively	O
.	O

TITLE	O
:	O
PEEP	O
titration	O
in	O
moderate	O
to	O
severe	O
ARDS	B-DISO
:	O
plateau	O
versus	O
transpulmonary	O
pressure	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
clinical	O
correlations	O
between	O
mechanical	O
power	O
(	O
MP	O
)	O
and	O
lung	O
ultrasound	O
score	O
(	O
LUS	O
),	O
and	O
analyze	O
their	O
evaluation	O
value	O
of	O
prognosis	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

The	O
MP	O
and	O
LUS	O
could	O
be	O
used	O
early	O
to	O
evaluate	O
the	O
28	O
-	O
day	O
prognosis	O
of	O
patients	O
with	O
moderate	O
to	O
severe	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
A	O
fusion	O
protein	O
expressed	O
on	O
the	O
surface	O
of	O
enveloped	O
viruses	O
mediates	O
fusion	O
of	O
the	O
viral	O
and	O
cellular	O
membranes	O
to	O
facilitate	O
virus	B-DISO
infection	I-DISO
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhoea	I-DISO
(	O
PED	O
)	O
is	O
an	O
emergent	O
/	O
re	O
-	O
emergent	O
viral	O
pig	O
disease	O
(	O
caused	O
by	O
the	O
virus	O
belonging	O
to	O
the	O
Coronaviridae	O
family	O
,	O
in	O
specific	O
the	O
Alphacoronavirus	O
genus	O
)	O
of	O
global	O
importance	O
.	O

Clinical	O
presentation	O
is	O
characterized	O
with	O
acute	B-DISO
diarrhoea	I-DISO
,	O
vomiting	B-DISO
and	O
dehydration	B-DISO
in	O
pigs	O
of	O
all	O
ages	O
,	O
with	O
a	O
possible	O
high	O
mortality	O
in	O
suckling	O
piglets	O
.	O

In	O
a	O
pregnant	O
patient	O
with	O
severe	O
respiratory	B-DISO
failure	I-DISO
,	O
when	O
other	O
interventions	O
fail	O
,	O
initiation	O
of	O
VV	O
-	O
ECMO	O
should	O
not	O
be	O
delayed	O
.	O

TITLE	O
:	O
Influenza	B-DISO
virus	O
-	O
related	O
critical	B-DISO
illness	I-DISO
:	O
pathophysiology	O
and	O
epidemiology	O
.	O

The	O
inability	O
of	O
the	O
lung	O
to	O
perform	O
its	O
primary	O
function	O
of	O
gas	O
exchange	O
can	O
result	O
from	O
multiple	O
mechanisms	O
,	O
including	O
obstruction	B-DISO
of	O
the	O
airways	O
,	O
loss	O
of	O
alveolar	O
structure	O
,	O
loss	O
of	O
lung	O
epithelial	O
integrity	O
from	O
direct	O
epithelial	O
cell	O
killing	O
,	O
and	O
degradation	O
of	O
the	O
critical	O
extracellular	O
matrix	O
.	O

Approximately	O
30	O
-	O
40	O
%	O
of	O
hospitalized	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
influenza	B-DISO
are	O
diagnosed	O
with	O
acute	B-DISO
pneumonia	I-DISO
.	O

Influenza	B-DISO
can	O
primarily	O
cause	O
severe	O
pneumonia	B-DISO
,	O
but	O
it	O
can	O
also	O
present	O
in	O
conjunction	O
with	O
or	O
be	O
followed	O
by	O
a	O
secondary	O
bacterial	B-DISO
infection	I-DISO
,	O
most	O
commonly	O
by	O
Staphylococcus	O
aureus	O
and	O
Streptococcus	O
pneumoniae	O
.	O

We	O
included	O
1103	O
adult	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
based	O
on	O
the	O
Sepsis	B-DISO
-	O
2	O
criteria	O
.	O

Similarly	O
,	O
the	O
decreased	O
levels	O
of	O
the	O
two	O
markers	O
non	O
-	O
linearly	O
correlated	O
with	O
the	O
elevation	O
of	O
DIC	B-DISO
score	O
.	O

RESULTS	O
:	O
One	O
hundred	O
-	O
thirteen	O
critical	O
ill	B-DISO
patients	O
were	O
studied	O
.	O

Literature	O
confirmed	O
high	O
risk	O
of	O
biliar	O
reflux	B-DISO
after	O
OAGB	O
-	O
MGB	O
procedure	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
describe	O
the	O
epidemiologic	O
,	O
clinical	O
and	O
laboratory	O
changes	O
,	O
and	O
outcomes	O
of	O
viral	B-DISO
pneumonia	I-DISO
caused	O
by	O
influenza	B-DISO
and	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
-	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infections	B-DISO
.	O

The	O
predictors	O
of	O
death	O
were	O
age	O
>	O
65	O
years	O
,	O
male	O
gender	O
,	O
and	O
associated	O
comorbidities	O
particularly	O
diabetes	B-DISO
mellitus	I-DISO
,	O
hypertension	B-DISO
,	O
and	O
chronic	B-DISO
kidney	I-DISO
diseases	I-DISO
.	O

Routine	O
testing	O
for	O
newly	O
emergent	O
viruses	O
is	O
warranted	O
for	O
adults	O
who	O
have	O
been	O
hospitalized	O
with	O
pneumonia	B-DISO
.	O

ABSTRACT	O
:	O
Acute	B-DISO
interstitial	I-DISO
pneumonia	I-DISO
(	O
AIP	B-DISO
)	O
is	O
a	O
rare	O
and	O
severe	O
form	O
of	O
diffuse	O
lung	O
injury	O
that	O
affects	O
previously	O
healthy	O
individuals	O
.	O

ABSTRACT	O
:	O
Leigh	B-DISO
Syndrome	I-DISO
is	O
a	O
neurodegenerative	B-DISO
disorder	I-DISO
caused	O
by	O
mitochondrial	O
dysfunction	O
,	O
with	O
significant	O
phenotypic	O
and	O
genetic	O
heterogeneity	O
.	O

In	O
ARDS	B-DISO
patients	O
on	O
ECMO	O
,	O
temporal	O
trends	O
of	O
specific	O
physiologic	O
parameters	O
differentiate	O
survivors	O
from	O
non	O
-	O
survivors	O
and	O
could	O
be	O
used	O
to	O
monitor	O
the	O
evolution	O
of	O
lung	O
injury	O
.	O

This	O
retrospective	O
study	O
involved	O
270	O
patients	O
who	O
underwent	O
surgical	O
repair	O
for	O
acute	O
type	B-DISO
A	I-DISO
aortic	I-DISO
dissection	I-DISO
between	O
January	O
2009	O
and	O
December	O
2015	O
.	O

Ninety	O
-	O
five	O
patients	O
with	O
moderate	O
or	O
severe	O
ARDS	B-DISO
,	O
who	O
required	O
mechanical	O
ventilation	O
therapy	O
,	O
were	O
randomly	O
selected	O
among	O
hospitalized	O
patients	O
from	O
January	O
2017	O
to	O
February	O
2019	O
.	O

Mechanical	O
power	O
,	O
TGF	O
-	O
β1	O
,	O
and	O
CTGF	O
were	O
clinically	O
evaluated	O
for	O
the	O
assessment	O
of	O
lung	O
structural	O
remodeling	O
,	O
such	O
as	O
ARDS	B-DISO
pulmonary	B-DISO
fibrosis	I-DISO
.	O

RESULTS	O
:	O
A	O
significant	O
positive	O
correlation	O
between	O
mechanical	O
power	O
and	O
serum	O
TGF	O
-	O
β1	O
and	O
CTGF	O
in	O
patients	O
with	O
ARDS	B-DISO
was	O
found	O
and	O
the	O
correlation	O
coefficients	O
were	O
0	O
.	O
424	O
and	O
0	O
.	O
581	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Lung	O
endothelial	O
barrier	O
dysfunction	O
leads	O
to	O
severe	O
pathologies	O
,	O
including	O
the	O
lethal	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
.	O

TITLE	O
:	O
Tuberculosis	B-DISO
-	O
induced	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
treated	O
with	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

ABSTRACT	O
:	O
Bovine	O
coronavirus	O
(	O
BCoV	O
)	O
is	O
associated	O
with	O
severe	B-DISO
diarrhea	I-DISO
in	O
calves	O
,	O
winter	B-DISO
dysentery	I-DISO
in	O
adult	O
cattle	O
,	O
and	O
respiratory	B-DISO
diseases	I-DISO
in	O
cattle	O
of	O
all	O
ages	O
.	O

In	O
comparison	O
with	O
post	O
-	O
weaned	O
calves	O
with	O
diarrhea	B-DISO
,	O
in	O
diarrhea	B-DISO
-	O
recovered	O
calves	O
,	O
the	O
lymphocyte	O
count	O
was	O
significantly	O
higher	O
(	O
P	O
=	O
0	O
.	O
018	O
),	O
and	O
the	O
monocyte	O
count	O
was	O
significantly	O
lower	O
(	O
P	O
=	O
0	O
.	O
001	O
);	O
however	O
,	O
the	O
number	O
of	O
monocytes	O
was	O
still	O
high	O
.	O

Of	O
2377	O
patients	O
with	O
ARDS	B-DISO
,	O
905	O
(	O
38	O
%)	O
were	O
female	O
and	O
1472	O
(	O
62	O
%)	O
were	O
male	O
.	O

ABSTRACT	O
:	O
Mechanical	O
ventilation	O
is	O
a	O
life	O
-	O
saving	O
therapy	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

ABSTRACT	O
:	O
In	O
May	O
2015	O
,	O
South	O
Korea	O
experienced	O
an	O
epidemic	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
).	O

The	O
decrease	O
was	O
observed	O
in	O
all	O
age	O
,	O
sex	O
,	O
and	O
income	O
groups	O
,	O
and	O
was	O
more	O
pronounced	O
for	O
low	O
-	O
acuity	O
diseases	O
(	O
acute	B-DISO
otitis	I-DISO
media	I-DISO
:	O
53	O
.	O
0	O
%;	O
upper	B-DISO
respiratory	I-DISO
infections	I-DISO
:	O
45	O
.	O
2	O
%)	O
than	O
for	O
high	O
-	O
acuity	O
diseases	O
(	O
myocardial	B-DISO
infarctions	I-DISO
:	O
14	O
.	O
0	O
%;	O
ischemic	B-DISO
stroke	I-DISO
:	O
16	O
.	O
6	O
%).	O

Mechanical	O
ventilation	O
and	O
bronchoscopy	O
were	O
effective	O
treatments	O
for	O
severe	O
ARDS	B-DISO
caused	O
by	O
aspiration	B-DISO
of	O
this	O
drug	O
.	O

In	O
this	O
line	O
,	O
we	O
engineered	O
an	O
attenuated	O
virus	O
based	O
on	O
the	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
)	O
genome	O
,	O
expressing	O
a	O
chimeric	O
spike	O
protein	O
from	O
a	O
virulent	O
United	O
States	O
(	O
US	O
)	O
PEDV	O
strain	O
.	O

The	O
rTGEV	O
-	O
RS	O
-	O
SPEDV	O
vaccine	O
candidate	O
was	O
also	O
attenuated	O
in	O
three	O
-	O
week	O
-	O
old	O
animals	O
that	O
were	O
used	O
to	O
evaluate	O
the	O
protection	O
conferred	O
by	O
this	O
virus	O
,	O
compared	O
with	O
the	O
protection	O
induced	O
by	O
infection	B-DISO
with	O
a	O
virulent	O
PEDV	O
US	O
strain	O
(	O
PEDV	O
-	O
NVSL	O
).	O

Altogether	O
,	O
the	O
data	O
indicated	O
that	O
rTGEV	O
-	O
RS	O
-	O
SPEDV	O
is	O
a	O
promising	O
vaccine	O
candidate	O
against	O
virulent	O
PEDV	O
infection	B-DISO
.	O

Our	O
earlier	O
studies	O
have	O
identified	O
that	O
3	O
-	O
O	O
-	O
β	O
-	O
chacotriosyl	O
ursolic	O
acid	O
(	O
1	O
)	O
could	O
inhibit	O
H5N1	B-DISO
pseudovirus	O
by	O
targeting	O
hemagglutinin	O
(	O
HA	O
).	O

The	O
SARs	B-DISO
analysis	O
of	O
these	O
compounds	O
revealed	O
that	O
introduction	O
of	O
certain	O
amide	O
structures	O
at	O
the	O
17	O
-	O
COOH	O
of	O
ursolic	O
acid	O
could	O
significantly	O
enhance	O
both	O
their	O
antiviral	O
activity	O
and	O
selective	O
index	O
.	O

They	O
include	O
transmissible	O
gastroenteritis	B-DISO
virus	O
(	O
TGEV	O
),	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
and	O
the	O
human	O
coronaviruses	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
many	O
of	O
which	O
seriously	O
endanger	O
human	O
health	O
and	O
well	O
-	O
being	O
.	O

In	O
vitro	O
contractility	O
studies	O
determined	O
a	O
decreased	O
basal	O
detrusor	O
tone	O
and	O
reduced	O
amplitude	O
of	O
nerve	O
-	O
mediated	O
contractions	B-DISO
in	O
C	O
-	O
RELAP	O
group	O
,	O
whereas	O
C	O
-	O
PRO	O
group	O
had	O
elevated	O
muscle	O
-	O
mediated	O
contractions	B-DISO
.	O

TITLE	O
:	O
Complete	O
genome	O
sequences	O
of	O
novel	O
S	O
-	O
deletion	O
variants	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
identified	O
from	O
a	O
recurrent	O
outbreak	O
on	O
Jeju	O
Island	O
,	O
South	O
Korea	O
.	O

ABSTRACT	O
:	O
Porcine	O
deltacoronavirus	O
(	O
PDCoV	O
)	O
is	O
an	O
emerging	O
swine	O
coronavirus	O
causing	O
diarrhea	B-DISO
and	O
intestinal	O
damage	O
in	O
nursing	O
piglets	O
.	O

PDCoV	O
nsp15	O
disrupts	O
the	O
phosphorylation	O
and	O
nuclear	O
translocation	B-DISO
of	O
NF	O
-	O
κB	O
p65	O
subunit	O
,	O
but	O
not	O
antagonizes	O
the	O
activation	O
of	O
transcription	O
factor	O
IRF3	O
.	O

Overall	O
,	O
73	O
participants	O
(	O
97	O
%)	O
of	O
75	O
reported	O
at	O
least	O
one	O
solicited	O
adverse	O
event	O
;	O
the	O
most	O
common	O
systemic	O
symptoms	O
were	O
headache	B-DISO
(	O
five	O
[	O
20	O
%]	O
with	O
0	O
·	O
67	O
mg	O
,	O
11	O
[	O
44	O
%]	O
with	O
2	O
mg	O
,	O
and	O
seven	O
[	O
28	O
%]	O
with	O
6	O
mg	O
),	O
and	O
malaise	B-DISO
or	O
fatigue	B-DISO
(	O
five	O
[	O
20	O
%]	O
with	O
0	O
·	O
67	O
mg	O
,	O
seven	O
[	O
28	O
%]	O
with	O
2	O
mg	O
,	O
and	O
two	O
[	O
8	O
%]	O
with	O
6	O
mg	O
).	O

ABSTRACT	O
:	O
BACKGROUND	O
This	O
study	O
investigated	O
the	O
risk	O
factors	O
affecting	O
development	O
and	O
prognosis	O
of	O
acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

MATERIAL	O
AND	O
METHODS	O
A	O
total	O
of	O
501	O
ARDS	B-DISO
cases	O
were	O
retrospectively	O
enrolled	O
(	O
296	O
males	O
and	O
205	O
females	O
)	O
admitted	O
to	O
the	O
First	O
People	O
'	O
s	O
Hospital	O
of	O
Lianyungang	O
from	O
Aug	O
2015	O
to	O
Aug	O
2017	O
.	O

In	O
this	O
retrospective	O
study	O
,	O
22	O
children	O
with	O
laboratory	O
confirmed	O
severe	O
dengue	B-DISO
admitted	O
to	O
pediatric	O
intensive	O
care	O
unit	O
(	O
PICU	O
)	O
were	O
enrolled	O
.	O

Half	O
(	O
n	O
=	O
11	O
,	O
50	O
%)	O
had	O
dengue	B-DISO
shock	I-DISO
syndrome	I-DISO
.	O

HLH	B-DISO
was	O
noted	O
in	O
7	O
(	O
32	O
%)	O
cases	O
at	O
a	O
median	O
(	O
IQR	O
)	O
hospital	O
stay	O
of	O
5	O
(	O
2	O
-	O
8	O
)	O
d	O
.	O
Children	O
with	O
HLH	B-DISO
had	O
significantly	O
higher	O
Pediatric	O
Index	O
of	O
Mortality	O
2	O
(	O
PIM	O
2	O
)	O
score	O
at	O
admission	O
and	O
higher	O
frequency	O
of	O
pain	O
abdomen	O
,	O
anemia	B-DISO
,	O
hypoalbuminemia	O
,	O
elevated	O
alanine	O
aminotransferase	O
(	O
ALT	O
)	O
and	O
ARDS	B-DISO
.	O

Length	O
of	O
PICU	O
stay	O
(	O
5	O
.	O
1	O
vs	O
.	O
2	O
.	O
9	O
d	O
)	O
and	O
mortality	O
(	O
28	O
.	O
6	O
%	O
vs	O
.	O
6	O
.	O
7	O
%)	O
were	O
higher	O
in	O
HLH	B-DISO
group	O
,	O
however	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

RESULTS	O
:	O
Median	O
(	O
IQR	O
)	O
age	O
was	O
8	O
(	O
5	O
-	O
10	O
.	O
3	O
)	O
y	O
.	O
Fever	O
was	O
present	O
for	O
mean	O
(	O
SD	O
)	O
duration	O
of	O
5	O
.	O
3	O
(	O
2	O
.	O
1	O
)	O
d	O
.	O
Vomiting	B-DISO
,	O
respiratory	B-DISO
distress	I-DISO
,	O
pain	O
abdomen	O
and	O
hepatomegaly	B-DISO
were	O
other	O
clinical	O
features	O
.	O

TITLE	O
:	O
Peptide	O
-	O
Protein	O
Interaction	O
Studies	O
of	O
Antimicrobial	O
Peptides	O
Targeting	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
Spike	O
Protein	O
:	O

ABSTRACT	O
:	O
There	O
is	O
no	O
effective	O
therapeutic	O
or	O
vaccine	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
and	O
this	O
study	O
attempts	O
to	O
find	O
therapy	O
using	O
peptide	O
by	O
establishing	O
a	O
basis	O
for	O
the	O
peptide	O
-	O
protein	O
interactions	O
through	O
in	O
silico	O
docking	O
studies	O
for	O
the	O
spike	O
protein	O
of	O
MERS	O
-	O
CoV	O
.	O
The	O
antimicrobial	O
peptides	O
(	O
AMPs	O
)	O
were	O
retrieved	O
from	O
the	O
antimicrobial	O
peptide	O
database	O
(	O
APD3	O
)	O
and	O
shortlisted	O
based	O
on	O
certain	O
important	O
physicochemical	O
properties	O
.	O

TITLE	O
:	O
IFN	O
-	O
I	O
response	O
timing	O
relative	O
to	O
virus	O
replication	O
determines	O
MERS	O
coronavirus	B-DISO
infection	I-DISO
outcomes	O
.	O

Because	O
IFN	O
-	O
I	O
is	O
protective	O
,	O
it	O
is	O
commonly	O
used	O
to	O
treat	O
virus	O
infections	B-DISO
for	O
which	O
no	O
specific	O
approved	O
drug	O
or	O
vaccine	O
is	O
available	O
.	O

Here	O
,	O
we	O
show	O
that	O
IFN	O
-	O
I	O
signaling	O
is	O
protective	O
during	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
spike	O
(	O
S	O
)	O
proteins	O
of	O
the	O
prototypic	O
Arabian	O
MERS	O
-	O
CoV	O
strain	O
,	O
human	O
betacoronavirus	O
2c	O
EMC	B-DISO
/	O
2012	O
,	O
and	O
the	O
above	O
stated	O
African	O
MERS	O
-	O
CoV	O
variants	O
do	O
not	O
appreciably	O
differ	O
in	O
expression	O
,	O
DPP4	O
binding	O
and	O
ability	O
to	O
drive	O
entry	O
into	O
target	O
cells	O
.	O

The	O
obtained	O
results	O
gave	O
us	O
ground	O
to	O
assume	O
that	O
the	O
removal	O
of	O
bioactive	O
molecules	O
can	O
be	O
a	O
useful	O
adjunct	O
to	O
protective	O
mechanical	O
ventilation	O
in	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Successful	O
Extracorporeal	O
Membrane	O
Oxygenation	O
(	O
ECMO	O
)	O
Use	O
without	O
Systemic	O
Anticoagulation	O
for	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
in	O
a	O
Patient	O
with	O
Aneurysmal	B-DISO
Subarachnoid	I-DISO
Hemorrhage	I-DISO
.	O

We	O
also	O
discuss	O
important	O
limitations	O
and	O
considerations	O
for	O
future	O
successful	O
use	O
of	O
ECMO	O
in	O
hemorrhagic	B-DISO
stroke	I-DISO
.	O

The	O
treatment	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
using	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
an	O
example	O
of	O
these	O
considerations	O
.	O

Although	O
ECMO	O
has	O
rarely	O
been	O
prospectively	O
evaluated	O
according	O
to	O
scientific	O
criteria	O
,	O
it	O
is	O
still	O
used	O
with	O
an	O
increasing	O
tendency	O
,	O
not	O
least	O
since	O
the	O
documented	O
register	O
survival	O
rates	O
in	O
ECMO	O
patients	O
with	O
severe	O
ARDS	B-DISO
are	O
60	O
%.	O

The	O
oral	O
homologous	O
prime	O
-	O
boost	O
vaccination	O
of	O
P29	O
-	O
CA	O
significantly	O
improved	O
the	O
survival	O
rate	O
of	O
the	O
piglets	O
and	O
notably	O
mitigated	O
the	O
severity	O
of	O
diarrhea	B-DISO
and	O
PEDV	O
fecal	O
shedding	O
after	O
the	O
challenge	O
.	O

These	O
results	O
demonstrated	O
that	O
the	O
cold	B-DISO
-	O
adapted	O
attenuated	O
virus	O
can	O
be	O
used	O
as	O
a	O
live	O
vaccine	O
in	O
maternal	O
vaccination	O
strategies	O
to	O
provide	O
durable	O
lactogenic	O
immunity	O
and	O
confer	O
passive	O
protection	O
to	O
litters	O
against	O
PEDV	O
.	O

TITLE	O
:	O
Using	O
routine	O
testing	O
data	O
to	O
understand	O
circulation	O
patterns	O
of	O
influenza	B-DISO
A	O
,	O
respiratory	O
syncytial	O
virus	O
and	O
other	O
respiratory	O
viruses	O
in	O
Victoria	O
,	O
Australia	O
.	O

TITLE	O
:	O
Assessment	O
of	O
Therapeutic	O
Interventions	O
and	O
Lung	O
Protective	O
Ventilation	O
in	O
Patients	O
With	O
Moderate	O
to	O
Severe	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
:	O
A	O
Systematic	O
Review	O
and	O
Network	O
Meta	O
-	O
analysis	O
.	O

Hypoxia	B-DISO
,	O
oxidative	B-DISO
stress	I-DISO
and	O
systemic	O
inflammation	B-DISO
link	O
OSA	B-DISO
and	O
cardiovascular	O
and	O
metabolic	O
consequences	O
,	O
including	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
.	O

Fewer	O
data	O
are	O
available	O
in	O
subjects	O
with	O
ACS	O
and	O
OSA	B-DISO
,	O
and	O
results	O
of	O
randomised	O
controlled	O
studies	O
on	O
the	O
effects	O
of	O
CPAP	O
are	O
expected	O
shortly	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
significant	O
need	O
for	O
early	O
,	O
rapid	O
detection	O
and	O
diagnosis	O
as	O
well	O
as	O
clinical	O
trajectory	O
monitoring	O
of	O
ARDS	B-DISO
.	O

The	O
high	O
overall	O
accuracy	O
and	O
high	O
positive	O
predicative	O
value	O
suggest	O
that	O
the	O
breath	O
analysis	O
method	O
can	O
accurately	O
diagnose	O
ARDS	B-DISO
.	O

A	O
total	O
of	O
324	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
were	O
enrolled	O
.	O

TITLE	O
:	O
Emergence	O
and	O
genetic	O
analysis	O
of	O
variant	O
pathogenic	O
4	O
/	O
91	O
(	O
serotype	O
793	O
/	O
B	O
)	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
in	O
Egypt	O
during	O
2019	O
.	O

ABSTRACT	O
:	O
Despite	O
their	O
being	O
uncommon	O
,	O
severe	O
cutaneous	O
adverse	O
drug	O
reactions	O
(	O
SCARs	B-DISO
)	O
result	O
in	O
a	O
very	O
great	O
burden	O
of	O
disease	O
.	O

ABSTRACT	O
:	O
Ventilator	O
settings	O
for	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
supported	O
by	O
venovenous	O
extracorporeal	O
membrane	O
oxygenation	O
are	O
currently	O
set	O
arbitrarily	O
.	O

Personalisation	O
of	O
mechanical	O
ventilation	O
did	O
not	O
decrease	O
mortality	O
in	O
patients	O
with	O
ARDS	B-DISO
,	O
possibly	O
because	O
of	O
the	O
misclassification	O
of	O
21	O
%	O
of	O
patients	O
.	O

TITLE	O
:	O
Extracorporeal	O
Life	O
Support	O
for	O
Adults	O
With	O
Respiratory	B-DISO
Failure	I-DISO
and	O
Related	O
Indications	O
:	O
A	O
Review	O
.	O

TITLE	O
:	O
Identifying	O
Sepsis	B-DISO
Populations	O
Benefitting	O
from	O
Anticoagulant	O
Therapy	O
:	O
A	O
Prospective	O
Cohort	O
Study	O
Incorporating	O
a	O
Restricted	O
Cubic	O
Spline	O
Regression	O
Model	O
.	O

ABSTRACT	O
:	O
Acute	O
left	O
ventricular	O
(	O
LV	O
)	O
systolic	O
failure	O
as	O
a	O
consequence	O
of	O
acute	O
severe	O
brain	O
injury	O
with	O
status	B-DISO
epilepticus	I-DISO
in	O
a	O
young	O
infant	O
is	O
not	O
common	O
;	O
managing	O
such	O
a	O
patient	O
on	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
),	O
which	O
requires	O
proper	O
anticoagulation	O
adds	O
further	O
substrate	O
to	O
a	O
particularly	O
intriguing	O
and	O
novel	O
case	O
worthy	O
of	O
reporting	O
.	O

Takotsubo	B-DISO
syndrome	I-DISO
and	O
its	O
peculiar	O
clinical	O
presentation	O
is	O
not	O
commonly	O
reported	O
in	O
the	O
paediatric	O
population	O
,	O
yet	O
the	O
high	O
likelihood	O
of	O
this	O
diagnosis	O
joining	O
the	O
dots	O
up	O
for	O
this	O
case	O
invites	O
our	O
curiosity	O
and	O
reflection	O
through	O
the	O
clinical	O
management	O
of	O
this	O
case	O
.	O

A	O
previously	O
healthy	O
9	O
-	O
month	O
-	O
old	O
local	O
Chinese	O
boy	O
presented	O
with	O
generalised	O
seizures	B-DISO
secondary	O
to	O
acute	O
severe	O
brain	O
injury	O
,	O
with	O
signs	O
of	O
sympathetic	O
overdrive	O
,	O
followed	O
by	O
rapidly	O
progressive	O
cardiogenic	B-DISO
shock	I-DISO
and	O
respiratory	B-DISO
failure	I-DISO
,	O
eventually	O
requiring	O
ECMO	O
support	O
.	O

For	O
this	O
purpose	O
,	O
30	O
children	O
with	O
recurrent	O
respiratory	B-DISO
infections	I-DISO
and	O
10	O
healthy	O
children	O
were	O
included	O
.	O

TITLE	O
:	O
Severe	O
Immune	B-DISO
Thrombocytopenia	I-DISO
Complicated	O
by	O
Intracerebral	B-DISO
Haemorrhage	I-DISO
Associated	O
with	O
Coronavirus	B-DISO
Infection	I-DISO
:	O
A	O
Case	O
Report	O
and	O
Literature	O
Review	O
.	O

Many	O
viruses	O
have	O
been	O
identified	O
as	O
triggering	O
the	O
autoimmune	B-DISO
process	I-DISO
,	O
including	O
HIV	B-DISO
,	O
MCV	O
,	O
EBV	O
,	O
parvovirus	B-DISO
,	O
rubella	B-DISO
and	O
measles	B-DISO
.	O

In	O
cats	O
,	O
infections	B-DISO
with	O
feline	O
coronaviruses	O
(	O
FCoVs	O
)	O
are	O
common	O
.	O

TITLE	O
:	O
Infectious	B-DISO
Disease	I-DISO
Management	O
and	O
Control	O
with	O
Povidone	O
Iodine	O
.	O

Among	O
the	O
findings	O
of	O
computed	O
tomography	O
(	O
CT	O
)	O
of	O
the	O
chest	O
,	O
bronchial	B-DISO
wall	I-DISO
thickening	I-DISO
,	O
cystic	O
bronchiectasis	B-DISO
,	O
and	O
emphysema	B-DISO
did	O
not	O
differ	O
significantly	O
(	O
p	O
>	O
0	O
.	O
05	O
).	O

Among	O
126	O
eligible	O
patients	O
with	O
ARDS	B-DISO
admitted	O
to	O
the	O
central	O
tertiary	O
hospital	O
in	O
Vietnam	O
,	O
we	O
observed	O
high	O
mortality	O
(	O
57	O
.	O
1	O
%).	O

Logistic	O
regression	O
revealed	O
that	O
PaO2	O
/	O
FiO2	O
on	O
day	O
3	O
[	O
odds	O
ratio	O
(	O
OR	O
),	O
1	O
.	O
010	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
),	O
1	O
.	O
003	O
-	O
1	O
.	O
017	O
],	O
length	O
of	O
stay	O
in	O
a	O
local	O
hospital	O
before	O
admission	O
to	O
the	O
central	O
hospital	O
(	O
OR	O
,	O
1	O
.	O
122	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
042	O
-	O
1	O
.	O
210	O
)	O
due	O
to	O
stable	O
condition	B-DISO
,	O
and	O
SOFA	O
score	O
on	O
Day	O
1	O
(	O
OR	O
,	O
0	O
.	O
842	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
708	O
-	O
1	O
.	O
002	O
)	O
were	O
independent	O
factors	O
in	O
patient	O
survival	O
.	O

Tertiary	O
referral	O
severe	O
respiratory	B-DISO
failure	I-DISO
center	O
in	O
a	O
university	O
hospital	O
in	O
the	O
United	O
Kingdom	O
.	O

Forty	O
-	O
seven	O
adults	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
requiring	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

Patients	O
with	O
high	O
potential	O
for	O
lung	O
recruitment	B-DISO
had	O
a	O
shorter	O
ICU	O
stay	O
and	O
shorter	O
extracorporeal	O
membrane	O
oxygenation	O
duration	O
.	O

The	O
key	O
measures	O
taken	O
on	O
lung	O
recruitment	B-DISO
was	O
postural	O
drainage	O
on	O
this	O
case	O
with	O
a	O
low	O
cost	O
but	O
a	O
qualified	O
effectiveness	O
.	O

This	O
case	O
report	O
aimed	O
to	O
deepen	O
the	O
understanding	O
of	O
AMAN	O
and	O
acquaint	O
the	O
cutting	O
-	O
edge	O
advances	O
on	O
the	O
treatment	O
of	O
GBS	B-DISO
,	O
as	O
well	O
as	O
providing	O
successful	O
treatment	O
experience	O
for	O
the	O
prevention	O
on	O
similar	O
cases	O
.	O

Better	O
adherence	O
was	O
associated	O
with	O
more	O
severe	O
OSA	B-DISO
(	O
P	O
=.	O
04	O
)	O
and	O
greater	O
CPAP	O
use	O
in	O
the	O
first	O
week	O
(	O
P	O
<.	O
01	O
).	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infections	B-DISO
in	O
humans	O
can	O
cause	O
asymptomatic	O
to	O
fatal	O
lower	O
respiratory	O
lung	B-DISO
disease	I-DISO
.	O

Using	O
in	O
-	O
house	O
S1	O
ELISA	O
and	O
protein	O
microarray	O
,	O
we	O
demonstrate	O
that	O
most	O
PCR	O
-	O
confirmed	O
MERS	O
-	O
CoV	O
case	O
-	O
patients	O
with	O
mild	O
infections	B-DISO
seroconverted	O
;	O
nonetheless	O
,	O
some	O
of	O
these	O
samples	O
did	O
not	O
have	O
detectable	O
levels	O
of	O
virus	O
-	O
neutralizing	O
antibodies	O
.	O

TITLE	O
:	O
Transmissibility	O
of	O
MERS	O
-	O
CoV	O
Infection	B-DISO
in	O
Closed	O
Setting	O
,	O
Riyadh	O
,	O
Saudi	O
Arabia	O
,	O
2015	O
.	O

For	O
9	O
women	O
from	O
whom	O
a	O
second	O
serum	O
sample	O
was	O
collected	O
,	O
antibodies	O
remained	O
detectable	O
at	O
titers	O
>	O
1	O
:	O
20	O
by	O
pseudoparticle	O
neutralization	O
tests	O
(	O
n	O
=	O
8	O
)	O
and	O
90	O
%	O
plaque	B-DISO
-	O
reduction	O
neutralization	O
tests	O
(	O
n	O
=	O
2	O
).	O

To	O
date	O
,	O
there	O
is	O
no	O
specific	O
treatment	O
proven	O
effective	O
against	O
this	O
viral	B-DISO
disease	I-DISO
.	O

The	O
incidence	O
of	O
ROP	B-DISO
is	O
considered	O
a	O
relatively	O
low	O
percentage	O
compared	O
to	O
neighboring	O
countries	O
that	O
have	O
higher	O
levels	O
of	O
human	O
development	O
index	O
.	O

However	O
,	O
when	O
a	O
multivariate	O
analysis	O
was	O
performed	O
,	O
only	O
low	O
gestational	O
age	O
,	O
total	O
days	O
on	O
oxygen	O
supplement	O
and	O
high	O
bilirubin	O
levels	O
were	O
significant	O
regarding	O
the	O
development	O
of	O
ROP	B-DISO
.	O

ABSTRACT	O
:	O
We	O
characterized	O
exposures	O
and	O
demographics	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
cases	O
reported	O
to	O
the	O
Saudi	O
Arabia	O
Ministry	O
of	O
Health	O
during	O
July	O
1	O
-	O
October	O
31	O
,	O
2017	O
,	O
and	O
June	O
1	O
-	O
September	O
16	O
,	O
2018	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
is	O
a	O
viral	O
respiratory	O
illness	O
that	O
was	O
recently	O
recognized	O
in	O
humans	O
.	O

ABSTRACT	O
:	O
India	O
is	O
one	O
of	O
the	O
seven	O
identified	O
countries	O
in	O
South	O
-	O
East	O
Asia	O
region	O
regularly	O
reporting	O
dengue	B-DISO
fever	I-DISO
(	O
DF	O
)/	O
dengue	B-DISO
hemorrhagic	I-DISO
fever	I-DISO
(	O
DHF	O
)	O
outbreaks	O
.	O

We	O
studied	O
the	O
clinical	O
manifestations	O
,	O
outcome	O
and	O
factors	O
predicting	O
mortality	O
of	O
serology	O
confirmed	O
dengue	B-DISO
fever	I-DISO
cases	O
admitted	O
in	O
Multidisciplinary	O
Intensive	O
Care	O
Unit	O
(	O
MICU	O
)	O
of	O
a	O
high	O
acuity	O
healthcare	O
facility	O
in	O
India	O
.	O

ABSTRACT	O
:	O
Antiphospholipid	B-DISO
syndrome	I-DISO
(	O
APLS	O
)	O
is	O
characterised	O
by	O
venous	O
or	O
arterial	B-DISO
thrombosis	I-DISO
and	O
/	O
or	O
adverse	O
pregnancy	O
outcome	O
in	O
the	O
presence	O
of	O
persistent	O
laboratory	O
evidence	O
of	O
antiphospholipid	O
antibodies	O
.	O

To	O
investigate	O
and	O
describe	O
the	O
clinical	O
features	O
and	O
outcome	O
of	O
C	O
.	O
psittaci	O
infection	B-DISO
in	O
neonatal	O
foals	O
.	O

ABSTRACT	O
:	O
A	O
number	O
of	O
compounds	O
targeting	O
different	O
processes	O
of	O
the	O
Human	B-DISO
Immunodeficiency	I-DISO
Virus	I-DISO
type	O
1	O
(	O
HIV	B-DISO
-	O
1	O
)	O
life	O
cycle	O
have	O
been	O
developed	O
in	O
the	O
continuing	O
fight	O
against	O
AIDS	O
.	O

Although	O
supported	O
with	O
mechanical	O
ventilation	O
,	O
she	O
still	O
had	O
severe	O
hypoxia	B-DISO
.	O

In	O
spite	O
of	O
a	O
bedside	O
abdominocentesis	O
,	O
her	O
abdomen	O
was	O
still	O
tense	B-DISO
and	O
her	O
hemodynamics	O
was	O
unstable	O
.	O

To	O
review	O
,	O
the	O
mainstay	O
of	O
ARDS	B-DISO
management	O
includes	O
mechanical	O
ventilation	O
with	O
low	O
tidal	O
volumes	O
to	O
decrease	O
barotrauma	O
,	O
prone	O
ventilation	O
,	O
conservative	O
fluid	O
management	O
,	O
and	O
neuromuscular	B-DISO
blockade	I-DISO
.	O

These	O
novel	O
findings	O
will	O
facilitate	O
elucidation	O
of	O
mechanisms	O
of	O
virus	O
-	O
encoded	O
evasion	O
strategies	O
,	O
thus	O
helping	O
design	O
rationale	O
antiviral	O
countermeasures	O
against	O
deadly	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

RESULTS	O
:	O
The	O
four	O
endemic	O
human	O
CoVs	O
(	O
HCoV	O
-	O
NL63	O
,	O
HCoV	O
-	O
229E	O
,	O
HCoV	O
-	O
OC43	O
and	O
HCoV	O
-	O
HKU1	O
)	O
mainly	O
cause	O
mild	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
.	O

Currently	O
,	O
there	O
are	O
no	O
effective	O
treatments	O
or	O
vaccines	O
available	O
to	O
control	O
PDCoV	O
.	O
To	O
study	O
the	O
potential	O
of	O
RNA	O
interference	O
(	O
RNAi	O
)	O
as	O
a	O
strategy	O
against	O
PDCoV	O
infection	B-DISO
,	O
two	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)-	O
expressing	O
plasmids	O
(	O
pGenesil	O
-	O
M	O
and	O
pGenesil	O
-	O
N	O
)	O
that	O
targeted	O
the	O
M	O
and	O
N	O
genes	O
of	O
PDCoV	O
were	O
constructed	O
and	O
transfected	O
separately	O
into	O
swine	O
testicular	O
(	O
ST	O
)	O
cells	O
,	O
which	O
were	O
then	O
infected	O
with	O
PDCoV	O
strain	O
HB	O
-	O
BD	O
.	O

Exacerbation	O
of	O
COPD	B-DISO
and	O
bronchial	B-DISO
asthma	I-DISO
occurred	O
in	O
23	O
(	O
16	O
.	O
1	O
%)	O
patients	O
,	O
paresis	B-DISO
of	O
the	O
diaphragm	O
-	O
in	O
15	O
(	O
11	O
.	O
7	O
%).	O

CONCLUSIONS	O
:	O
Acute	B-DISO
respiratory	I-DISO
failure	I-DISO
developed	O
in	O
3	O
.	O
5	O
%	O
of	O
cardiac	O
patients	O
and	O
was	O
common	O
thoracic	B-DISO
and	O
thoracoabdominal	O
aortic	O
surgery	O
.	O

Nosocomial	B-DISO
pneumonia	I-DISO
was	O
diagnosed	O
in	O
1	O
.	O
4	O
%	O
of	O
patients	O
and	O
was	O
not	O
fatal	O
.	O

Inclusion	O
criteria	O
were	O
Glasgow	O
Coma	B-DISO
Scale	O
score	O
less	O
than	O
8	O
on	O
postinjury	O
Day	O
2	O
,	O
all	O
paraplegic	O
and	O
quadriplegic	O
patients	O
,	O
and	O
patients	O
older	O
than	O
55	O
years	O
with	O
central	O
cord	B-DISO
syndrome	B-DISO
who	O
underwent	O
tracheostomy	O
.	O

In	O
the	O
year	O
following	O
the	O
initiation	O
of	O
the	O
mPATH	O
team	O
,	O
we	O
observed	O
earlier	O
time	O
to	O
occupational	O
,	O
physical	O
,	O
and	O
speech	O
therapist	O
evaluation	O
,	O
decreased	O
length	O
of	O
stay	O
,	O
and	O
cost	O
savings	O
in	O
severe	O
traumatic	O
brain	O
and	O
spinal	O
cord	B-DISO
injury	O
patients	O
requiring	O
tracheostomy	O
compared	O
with	O
our	O
historical	O
control	O
.	O

CONCLUSIONS	O
:	O
In	O
the	O
year	O
following	O
the	O
initiation	O
of	O
the	O
mPATH	O
team	O
,	O
we	O
observed	O
earlier	O
time	O
to	O
occupational	O
,	O
physical	O
,	O
and	O
speech	O
therapist	O
evaluation	O
,	O
decreased	O
length	O
of	O
stay	O
,	O
and	O
cost	O
savings	O
in	O
severe	O
traumatic	O
brain	O
and	O
spinal	O
cord	B-DISO
injury	O
patients	O
requiring	O
tracheostomy	O
compared	O
with	O
our	O
historical	O
control	O
.	O

Older	O
age	O
,	O
oxygen	O
saturation	O
level	O
of	O
<	O
90	O
%	O
at	O
admission	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
pneumorrhagia	O
,	O
influenza	B-DISO
-	O
associated	O
encephalopathy	B-DISO
(	O
IEA	O
),	O
septic	B-DISO
shock	I-DISO
,	O
low	O
ratio	O
of	O
partial	O
pressure	O
of	O
oxygen	O
in	O
arterial	O
blood	O
(	O
PaO2	O
,	O
<	O
60	O
mm	O
Hg	O
)	O
to	O
the	O
fraction	O
concentration	O
of	O
oxygen	O
in	O
inspired	O
air	O
(	O
FiO2	O
;	O
P	O
/	O
F	O
),	O
higher	O
oxygenation	O
index	O
,	O
increased	O
alanine	O
aminotransferase	O
level	O
(>	O
100	O
IU	O
/	O
L	O
),	O
increased	O
aspartate	O
aminotransferase	O
level	O
(>	O
100	O
IU	O
/	O
L	O
),	O
increased	O
lactate	O
dehydrogenase	O
level	O
(>	O
500	O
IU	O
/	O
L	O
),	O
high	O
fraction	O
concentration	O
of	O
oxygen	O
in	O
inspired	O
air	O
(	O
FiO2	O
>	O
60	O
%),	O
and	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(>	O
8	O
cmH2O	O
)	O
were	O
associated	O
with	O
poor	O
outcome	O
.	O

ABSTRACT	O
:	O
To	O
report	O
results	O
of	O
a	O
national	O
survey	O
of	O
provider	O
attitudes	O
,	O
observations	O
,	O
and	O
opinions	O
regarding	O
the	O
use	O
of	O
extracorporeal	O
membranous	O
oxygenation	O
(	O
ECMO	O
)	O
to	O
manage	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
in	O
trauma	O
patients	O
.	O

Trauma	O
patients	O
with	O
refractory	O
ARDS	B-DISO
.	O

Ranking	O
the	O
preferred	O
modality	O
of	O
treatments	O
for	O
refractory	O
ARDS	B-DISO
from	O
most	O
to	O
least	O
preferable	O
is	O
as	O
follows	O
:	O
airway	O
pressure	O
release	O
ventilation	O
,	O
bilevel	O
ventilation	O
,	O
paralysis	O
,	O
prone	O
positioning	O
,	O
inhaled	O
nitric	O
oxide	O
,	O
epoprostenol	O
,	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
,	O
corticosteroids	O
,	O
surfactant	O
.	O

Data	O
of	O
weekly	O
incident	O
RA	O
(	O
2012	O
-	O
2013	O
)	O
were	O
obtained	O
from	O
the	O
Korean	O
National	O
Health	O
Insurance	O
claims	O
database	O
,	O
and	O
those	O
of	O
weekly	O
observations	O
on	O
eight	O
respiratory	O
viral	B-DISO
infections	I-DISO
were	O
obtained	O
from	O
the	O
Korea	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
database	O
.	O

We	O
estimated	O
the	O
percentage	O
change	O
in	O
incident	O
RA	O
associated	O
with	O
ambient	O
mean	O
respiratory	O
viral	B-DISO
infections	I-DISO
using	O
a	O
generalized	O
linear	O
model	O
,	O
after	O
adjusting	O
for	O
time	O
trend	O
,	O
air	O
pollution	O
,	O
and	O
meteorological	O
data	O
.	O

TITLE	O
:	O
Porcine	O
IL	O
-	O
12	O
plasmid	O
as	O
an	O
adjuvant	O
improves	O
the	O
cellular	O
and	O
humoral	O
immune	O
responses	O
of	O
DNA	O
vaccine	O
targeting	O
transmissible	O
gastroenteritis	B-DISO
virus	O
spike	O
gene	O
in	O
a	O
mouse	O
model	O
.	O

TITLE	O
:	O
[	O
Influenza	B-DISO
].	O

ABSTRACT	O
:	O
Viral	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
are	O
common	O
during	O
early	O
childhood	O
.	O

Forty	O
-	O
four	O
respiratory	B-DISO
tract	I-DISO
infections	I-DISO
(	O
69	O
%)	O
were	O
associated	O
with	O
virus	O
:	O
rhinovirus	O
and	O
enterovirus	O
(	O
RV	O
/	O
EV	O
)	O
were	O
implied	O
in	O
61	O
%	O
of	O
them	O
and	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
in	O
14	O
%.	O

RSV	B-DISO
infections	I-DISO
(	O
n	O
=	O
6	O
)	O
were	O
usually	O
of	O
mild	O
severity	O
.	O

RSV	B-DISO
infections	I-DISO
(	O
n	O
=	O
6	O
)	O
were	O
usually	O
of	O
mild	O
severity	O
.	O

ABSTRACT	O
:	O
Severe	O
,	O
organ	O
-	O
threatening	O
and	O
life	O
-	O
threatening	O
manifestations	O
of	O
inflammatory	O
rheumatic	B-DISO
diseases	I-DISO
,	O
such	O
as	O
diffuse	O
alveolar	O
hemorrhage	B-DISO
in	O
the	O
context	O
of	O
small	O
vessel	O
vasculitis	B-DISO
,	O
sometimes	O
inadequately	O
respond	O
to	O
immunosuppressive	O
treatment	O
.	O

In	O
the	O
case	O
of	O
an	O
immanent	O
or	O
already	O
occurring	O
organ	B-DISO
failure	I-DISO
,	O
immunosuppressive	O
treatment	O
may	O
need	O
to	O
be	O
supplemented	O
with	O
rapidly	O
effective	O
rescue	O
treatment	O
procedures	O
.	O

Some	O
predisposing	O
genetic	O
factors	O
favor	O
MERS	O
-	O
CoV	O
infection	B-DISO
in	O
some	O
patients	O
,	O
which	O
is	O
worth	O
investigating	O
in	O
the	O
near	O
future	O
.	O

A	O
50	O
-	O
year	O
-	O
old	O
man	O
with	O
hyperthermia	O
and	O
general	B-DISO
malaise	I-DISO
presented	O
to	O
our	O
hospital	O
and	O
was	O
clinically	O
diagnosed	O
with	O
B	O
-	O
lymphoblastic	B-DISO
leukemia	I-DISO
(	O
B	B-DISO
-	I-DISO
ALL	I-DISO
)	O
and	O
febrile	B-DISO
neutropenia	I-DISO
accompanied	O
by	O
septic	B-DISO
shock	I-DISO
.	O

The	O
chest	O
X	O
-	O
ray	O
revealed	O
signs	O
of	O
bipulmonary	O
infiltration	B-DISO
.	O

Due	O
to	O
progressive	O
respiratory	B-DISO
failure	I-DISO
the	O
patient	O
required	O
mechanical	O
ventilation	O
.	O

The	O
diagnostic	O
potentials	O
of	O
specific	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
accessory	O
and	O
nonstructural	O
proteins	O
,	O
if	O
any	O
,	O
have	O
not	O
yet	O
been	O
investigated	O
.	O

PEDV	O
causes	O
severe	B-DISO
diarrhoea	I-DISO
and	O
dehydration	B-DISO
in	O
nursing	O
piglets	O
,	O
which	O
leads	O
to	O
significant	O
economic	O
losses	O
to	O
the	O
swine	O
industry	O
worldwide	O
.	O

Using	O
this	O
ancient	O
therapy	O
as	O
a	O
complementary	O
medicine	O
,	O
the	O
management	O
of	O
serious	O
medical	O
conditions	O
,	O
such	O
as	O
SARS	B-DISO
,	O
acute	O
heart	B-DISO
diseases	I-DISO
,	O
and	O
ischemic	O
cerebral	B-DISO
stroke	I-DISO
,	O
are	O
presented	O
.	O

ABSTRACT	O
:	O
Our	O
Cooling	O
to	O
Help	O
Injured	O
Lungs	O
(	O
CHILL	B-DISO
)	O
trial	O
of	O
therapeutic	O
hypothermia	O
in	O
ARDS	B-DISO
includes	O
neuromuscular	B-DISO
blockade	I-DISO
(	O
NMB	O
)	O
as	O
an	O
inclusion	O
criterion	O
to	O
avoid	O
shivering	O
.	O

NMB	O
has	O
been	O
used	O
to	O
facilitate	O
mechanical	O
ventilation	O
in	O
ARDS	B-DISO
and	O
was	O
shown	O
to	O
reduce	O
mortality	O
in	O
the	O
ACURASYS	O
trial	O
.	O

To	O
assess	O
the	O
feasibility	O
of	O
a	O
multi	O
-	O
center	O
CHILL	B-DISO
trial	O
,	O
we	O
conducted	O
a	O
survey	O
of	O
academic	O
intensivists	O
about	O
their	O
NMB	O
use	O
in	O
patients	O
with	O
ARDS	B-DISO
.	O

We	O
conclude	O
that	O
NMB	O
is	O
frequently	O
used	O
by	O
academic	O
intensivists	O
to	O
facilitate	O
mechanical	O
ventilation	O
in	O
patients	O
with	O
moderate	O
to	O
severe	O
ARDS	B-DISO
.	O

Severe	O
pneumonia	B-DISO
is	O
a	O
common	O
cause	O
of	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Due	O
to	O
the	O
immediate	O
and	O
severe	O
nature	O
of	O
ARDS	B-DISO
,	O
medical	O
practitioners	O
may	O
seek	O
after	O
other	O
aetiologies	O
other	O
than	O
MRI	O
-	O
contrast	O
-	O
induced	O
ARDS	B-DISO
for	O
patients	O
'	O
clinical	O
manifestations	O
such	O
as	O
acute	O
-	O
onset	O
difficulty	O
of	O
breathing	O
.	O

RESULTS	O
:	O
While	O
no	O
differences	O
were	O
found	O
in	O
terms	O
of	O
nonadherence	O
and	O
use	O
problems	O
between	O
the	O
current	O
and	O
the	O
redesigned	O
gown	O
,	O
differences	O
in	O
usability	O
and	O
task	O
load	O
ratings	O
suggested	O
that	O
the	O
redesigned	O
gown	O
is	O
perceived	O
more	O
favorably	O
by	O
HCP	B-DISO
.	O

ABSTRACT	O
:	O
A	O
swine	O
acute	B-DISO
diarrhea	I-DISO
syndrome	B-DISO
coronavirus	O
(	O
SADS	O
-	O
CoV	O
)	O
that	O
causes	O
severe	B-DISO
diarrhea	I-DISO
in	O
suckling	O
piglets	O
was	O
identified	O
in	O
Southern	O
China	O
in	O
2017	O
.	O

The	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
emerged	O
in	O
2002	O
and	O
was	O
responsible	O
for	O
an	O
epidemic	O
that	O
spread	O
to	O
five	O
continents	O
with	O
a	O
fatality	O
rate	O
of	O
10	O
%	O
before	O
being	O
contained	O
in	O
2003	O
(	O
with	O
additional	O
cases	O
reported	O
in	O
2004	O
).	O

Here	O
,	O
we	O
review	O
our	O
understanding	O
of	O
the	O
infection	B-DISO
mechanism	O
used	O
by	O
coronaviruses	O
derived	O
from	O
recent	O
structural	O
and	O
biochemical	O
studies	O
.	O

The	O
incidence	O
of	O
influenza	B-DISO
-	I-DISO
like	I-DISO
illness	I-DISO
(	O
ILI	O
)	O
was	O
analysed	O
.	O

Among	O
the	O
>	O
64	O
-	O
year	O
age	O
group	O
,	O
18	O
out	O
of	O
26	O
ICU	O
-	O
ARDS	B-DISO
cases	O
(	O
69	O
.	O
2	O
%)	O
were	O
caused	O
by	O
IBV	O
,	O
and	O
14	O
of	O
these	O
(	O
77	O
.	O
8	O
%)	O
were	O
B	O
/	O
Yamagata	O
lineage	O
.	O

The	O
2017	O
-	O
2018	O
influenza	B-DISO
season	O
was	O
one	O
of	O
the	O
most	O
severe	O
in	O
a	O
decade	O
in	O
Southern	O
Italy	O
.	O

Influenza	B-DISO
D	O
virus	O
was	O
detected	O
in	O
two	O
(	O
0	O
.	O
07	O
%)	O
samples	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
is	O
an	O
alphacoronavirus	O
that	O
has	O
a	O
significant	O
agricultural	O
and	O
economic	O
impact	O
due	O
to	O
the	O
high	O
mortality	O
rate	O
associated	O
with	O
infection	B-DISO
of	O
neonatal	O
piglets	O
.	O

ABSTRACT	O
:	O
This	O
report	O
describes	O
a	O
cat	O
with	O
chronic	O
,	O
progressive	O
,	O
non	O
-	O
painful	B-DISO
,	O
non	O
-	O
lateralizing	O
multifocal	O
neurologic	O
clinical	O
signs	O
associated	O
with	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
(	O
FIP	B-DISO
).	O

He	O
was	O
treated	O
as	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
secondary	O
to	O
exposure	O
to	O
welding	O
metal	O
fumes	O
in	O
a	O
closed	O
container	O
.	O

Welding	O
metal	O
fumes	O
related	O
ARDS	B-DISO
remains	O
the	O
diagnosis	O
of	O
exclusion	O
and	O
all	O
other	O
causes	O
must	O
be	O
ruled	O
out	O
.	O

Among	O
them	O
,	O
the	O
indole	O
scaffold	O
widely	O
distributes	O
in	O
natural	O
products	O
and	O
bioactive	O
molecules	O
including	O
anti	O
-	O
cancer	B-DISO
agents	O
.	O

So	O
far	O
,	O
many	O
natural	O
and	O
synthetic	O
indole	O
derivatives	O
have	O
been	O
discovered	O
as	O
promising	O
anti	O
-	O
cancer	B-DISO
agents	O
used	O
in	O
clinic	O
or	O
clinical	O
evaluations	O
,	O
suggesting	O
its	O
prominent	O
place	O
in	O
anti	O
-	O
cancer	B-DISO
drugs	O
development	O
.	O

TITLE	O
:	O
Oseltamivir	O
resistance	O
in	O
severe	O
influenza	B-DISO
A	O
(	O
H1N1	O
)	O
pdm09	O
pneumonia	B-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
a	O
French	O
multicenter	O
observational	O
cohort	O
study	O
.	O

Patients	O
infected	O
with	O
the	O
H275Y	O
mutant	B-DISO
virus	O
had	O
higher	O
day	O
-	O
28	O
mortality	O
than	O
others	O
(	O
80	O
%	O
vs	O
12	O
%;	O
p	O
=	O
0	O
.	O
011	O
).	O

A	O
single	O
-	O
center	O
,	O
observational	O
cohort	O
,	O
retrospective	O
study	O
was	O
undertaken	O
of	O
patients	O
with	O
severe	O
respiratory	B-DISO
failure	I-DISO
managed	O
with	O
conventional	O
ventilation	O
or	O
requiring	O
ECMO	O
in	O
a	O
tertiary	O
referral	O
university	O
teaching	O
hospital	O
.	O

RESULTS	O
:	O
We	O
identified	O
343	O
patients	O
with	O
severe	O
respiratory	B-DISO
failure	I-DISO
between	O
January	O
2014	O
and	O
December	O
2017	O
.	O

TITLE	O
:	O
A	O
quantitative	O
approach	O
for	O
the	O
analysis	O
of	O
clinician	O
recognition	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
using	O
electronic	O
health	O
record	O
data	O
.	O

The	O
recognition	O
model	O
yielded	O
a	O
mean	O
(	O
99	O
%	O
confidence	O
interval	O
)	O
physician	O
recognition	O
of	O
ARDS	B-DISO
of	O
22	O
%	O
(	O
9	O
%-	O
42	O
%)	O
for	O
mild	O
,	O
34	O
%	O
(	O
19	O
%-	O
49	O
%)	O
for	O
moderate	O
,	O
and	O
67	O
%	O
(	O
41	O
%-	O
100	O
%)	O
for	O
severe	O
ARDS	B-DISO
.	O

In	O
this	O
study	O
,	O
patient	O
characteristics	O
and	O
physician	O
behaviors	O
were	O
demonstrated	O
to	O
be	O
associated	O
with	O
differences	O
in	O
ventilator	O
management	O
in	O
both	O
ARDS	B-DISO
and	O
control	O
patients	O
.	O

TITLE	O
:	O
Generating	O
and	O
evaluating	O
type	O
I	O
interferon	O
receptor	O
-	O
deficient	O
and	O
feline	O
TMPRSS2	O
-	O
expressing	O
cells	O
for	O
propagating	O
serotype	O
I	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
.	O

ABSTRACT	O
:	O
Feline	O
coronavirus	B-DISO
infection	I-DISO
can	O
progress	O
to	O
a	O
fatal	O
infectious	B-DISO
peritonitis	I-DISO
,	O
which	O
is	O
a	O
widespread	O
feline	B-DISO
disease	I-DISO
without	O
an	O
effective	O
vaccine	O
.	O

The	O
ICU	O
mortality	O
rate	O
was	O
30	O
.	O
4	O
%	O
(	O
14	O
/	O
46	O
),	O
with	O
no	O
difference	O
between	O
patients	O
with	O
RV	B-DISO
hypertrophy	I-DISO
and	O
those	O
without	O
.	O

Highresolution	O
two	O
-	O
dimensional	O
gel	O
electrophoresis	O
initially	O
identified	O
48	O
protein	O
spots	B-DISO
which	O
were	O
differentially	O
expressed	O
in	O
the	O
presence	O
of	O
NS7	B-DISO
.	O

These	O
proteomic	O
data	O
will	O
provide	O
insights	O
into	O
the	O
understanding	O
of	O
specific	O
cellular	O
responses	O
to	O
the	O
accessory	O
protein	O
during	O
PDCoV	O
infection	B-DISO
.	O

TITLE	O
:	O
Feasibility	O
and	O
safety	O
of	O
ultra	O
-	O
low	O
tidal	O
volume	O
ventilation	O
without	O
extracorporeal	O
circulation	O
in	O
moderately	O
severe	O
and	O
severe	O
ARDS	B-DISO
patients	O
.	O

ABSTRACT	O
:	O
The	O
efficacy	O
of	O
ustekinumab	O
,	O
an	O
antagonist	O
of	O
the	O
p40	O
subunit	O
of	O
interleukin	O
-	O
12	O
and	O
interleukin	O
-	O
23	O
,	O
as	O
induction	O
and	O
maintenance	O
therapy	O
in	O
patients	O
with	O
ulcerative	B-DISO
colitis	I-DISO
is	O
unknown	O
.	O

We	O
evaluated	O
ustekinumab	O
as	O
8	O
-	O
week	O
induction	O
therapy	O
and	O
44	O
-	O
week	O
maintenance	O
therapy	O
in	O
patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
ulcerative	B-DISO
colitis	I-DISO
.	O

Through	O
52	O
weeks	O
of	O
exposure	O
,	O
there	O
were	O
two	O
deaths	O
(	O
one	O
each	O
from	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
and	O
hemorrhage	B-DISO
from	O
esophageal	B-DISO
varices	I-DISO
)	O
and	O
seven	O
cases	O
of	O
cancer	B-DISO
(	O
one	O
each	O
of	O
prostate	O
,	O
colon	O
,	O
renal	O
papillary	O
,	O
and	O
rectal	B-DISO
cancer	I-DISO
and	O
three	O
nonmelanoma	O
skin	B-DISO
cancers	I-DISO
)	O
among	O
825	O
patients	O
who	O
received	O
ustekinumab	O
and	O
no	O
deaths	O
and	O
one	O
case	O
of	O
cancer	B-DISO
(	O
testicular	B-DISO
cancer	I-DISO
)	O
among	O
319	O
patients	O
who	O
received	O
placebo	O
.	O

RESULTS	O
:	O
The	O
percentage	O
of	O
patients	O
who	O
had	O
clinical	O
remission	B-DISO
at	O
week	O
8	O
among	O
patients	O
who	O
received	O
intravenous	O
ustekinumab	O
at	O
a	O
dose	O
of	O
130	O
mg	O
(	O
15	O
.	O
6	O
%)	O
or	O
6	O
mg	O
per	O
kilogram	O
(	O
15	O
.	O
5	O
%)	O
was	O
significantly	O
higher	O
than	O
that	O
among	O
patients	O
who	O
received	O
placebo	O
(	O
5	O
.	O
3	O
%)	O
(	O
P	O
<	O
0	O
.	O
001	O
for	O
both	O
comparisons	O
).	O

Due	O
to	O
the	O
absence	O
of	O
live	O
dromedary	O
movement	O
to	O
Europe	O
,	O
the	O
more	O
likely	O
way	O
of	O
entry	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
is	O
through	O
the	O
infected	O
people	O
movement	O
from	O
Saudi	O
Arabia	O
,	O
Kuwait	O
,	O
Qatar	O
and	O
Oman	O
.	O

ABSTRACT	O
:	O
This	O
study	O
reports	O
the	O
prevalence	O
of	O
potential	O
faecal	O
pathogens	O
in	O
the	O
microbiome	O
detected	O
in	O
a	O
cohort	O
of	O
cats	O
and	O
dogs	O
with	O
diarrhoea	B-DISO
in	O
Perth	O
,	O
Western	O
Australia	O
.	O

The	O
extract	O
was	O
less	O
cytotoxic	O
and	O
concentration	O
-	O
dependently	O
increased	O
anti	O
-	O
HCoV	O
-	O
NL63	O
activities	O
,	O
including	O
cytopathicity	O
,	O
sub	O
-	O
G1	O
fraction	O
,	O
virus	O
yield	O
(	O
IC50	O
=	O
1	O
.	O
17	O
μg	O
/	O
ml	O
),	O
plaque	B-DISO
formation	O
(	O
IC50	O
=	O
4	O
.	O
67	O
μg	O
/	O
ml	O
)	O
and	O
virus	O
attachment	O
(	O
IC50	O
=	O
15	O
.	O
75	O
μg	O
/	O
ml	O
).	O

The	O
potential	O
signaling	O
pathways	O
were	O
manipulated	O
individually	O
by	O
pharmacological	O
inhibition	O
,	O
small	O
interfering	O
ribonucleic	O
acid	O
(	O
siRNA	O
)	O
depletion	O
,	O
and	O
antibody	O
blocking	B-DISO
.	O

Taking	O
into	O
account	O
the	O
fact	O
that	O
the	O
majority	O
of	O
emerging	O
pathogens	O
(	O
e	O
.	O
g	O
.	O
highly	O
pathogenic	O
avian	B-DISO
influenza	I-DISO
[	O
HPAI	O
],	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
,	O
Nipah	O
virus	O
,	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
)	O
are	O
zoonotic	O
diseases	O
,	O
Egypt	O
has	O
established	O
a	O
national	O
One	O
Health	O
coordination	O
mechanism	O
.	O

There	O
are	O
multiple	O
obstacles	O
in	O
the	O
region	O
to	O
overcome	O
,	O
including	O
a	O
lack	O
of	O
transparency	O
as	O
governments	O
in	O
the	O
Middle	O
East	O
generally	O
do	O
not	O
disclose	O
detailed	O
information	O
on	O
animal	B-DISO
diseases	I-DISO
.	O

However	O
,	O
with	O
the	O
support	O
of	O
the	O
Food	O
and	O
Agriculture	O
Organization	O
of	O
the	O
United	O
Nations	O
(	O
FAO	O
),	O
the	O
World	O
Organisation	O
for	O
Animal	O
Health	O
(	O
OIE	O
),	O
and	O
other	O
partners	O
,	O
the	O
responsibility	O
of	O
the	O
Mediterranean	O
Zoonosis	B-DISO
Control	O
Centre	O
in	O
Athens	O
,	O
Greece	O
,	O
could	O
be	O
widened	O
to	O
include	O
the	O
countries	O
of	O
the	O
Middle	O
East	O
.	O

This	O
study	O
will	O
provide	O
up	O
-	O
to	O
-	O
date	O
evidence	O
of	O
BP	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
SP	O
and	O
ARDS	B-DISO
.	O

RESULTS	O
:	O
This	O
systematic	O
review	O
will	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
BP	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
SP	O
and	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Mucosal	O
Immune	O
Response	O
to	O
Feline	O
Enteric	O
Coronavirus	B-DISO
Infection	I-DISO
.	O

Infection	B-DISO
by	O
FECV	O
is	O
generally	O
subclinical	O
,	O
and	O
little	O
is	O
known	O
about	O
the	O
mucosal	O
immune	O
response	O
that	O
controls	O
and	O
eliminates	O
the	O
virus	O
.	O

Results	O
showed	O
that	O
cats	O
with	O
active	O
FECV	O
infections	B-DISO
have	O
strong	O
systemic	O
IgG	O
and	O
mucosal	O
IgA	O
responses	O
that	O
wane	O
after	O
virus	O
clearance	O
.	O

Data	O
was	O
collected	O
by	O
face	B-DISO
-	O
to	O
-	O
face	B-DISO
interview	O
using	O
standardised	O
questionnaire	O
,	O
and	O
analyzed	O
using	O
SPSS	O
.	O

About	O
29	O
%	O
reported	O
avoiding	O
touching	O
their	O
eyes	O
,	O
noses	O
,	O
and	O
mouths	O
directly	O
with	O
their	O
hands	O
;	O
63	O
.	O
5	O
%	O
covered	O
their	O
noses	O
and	O
mouths	O
with	O
tissue	O
paper	O
when	O
sneezing	O
or	O
coughing	B-DISO
.	O

A	O
high	O
proportion	O
(	O
62	O
.	O
8	O
%)	O
did	O
not	O
take	O
the	O
seasonal	O
flu	B-DISO
vaccine	O
.	O

About	O
1	O
-	O
day	O
-	O
old	O
specific	O
pathogen	O
-	O
free	O
White	O
Leghorn	O
chickens	O
inoculated	O
with	O
CK	O
/	O
CH	O
/	O
JS	O
/	O
TAHY	O
at	O
105	O
.	O
5	O
EID50	O
exhibited	O
clinical	O
signs	O
including	O
coughing	B-DISO
,	O
sneezing	O
,	O
nasal	B-DISO
discharge	I-DISO
,	O
and	O
tracheal	O
vocalization	O
accompanied	O
by	O
depression	B-DISO
with	O
84	O
%	O
mortality	O
and	O
100	O
%	O
morbidity	O
.	O

The	O
CITRIS	O
-	O
ALI	O
trial	O
was	O
a	O
randomized	O
,	O
double	O
-	O
blind	B-DISO
,	O
placebo	O
-	O
controlled	O
,	O
multicenter	O
trial	O
conducted	O
in	O
7	O
medical	O
intensive	O
care	O
units	O
in	O
the	O
United	O
States	O
,	O
enrolling	O
patients	O
(	O
N	O
=	O
167	O
)	O
with	O
sepsis	B-DISO
and	O
ARDS	B-DISO
present	O
for	O
less	O
than	O
24	O
hours	O
.	O

Further	O
research	O
is	O
needed	O
to	O
evaluate	O
the	O
potential	O
role	O
of	O
vitamin	O
C	O
for	O
other	O
outcomes	O
in	O
sepsis	B-DISO
and	O
ARDS	B-DISO
.	O

Although	O
our	O
study	O
did	O
not	O
have	O
the	O
precision	O
to	O
rule	O
out	O
a	O
small	O
,	O
clinically	O
relevant	O
effect	O
,	O
the	O
benefit	O
is	O
insufficient	O
to	O
justify	O
the	O
use	O
of	O
immune	O
plasma	O
for	O
treating	O
patients	O
with	O
severe	O
influenza	B-DISO
A	O
.	O
National	O
Institute	O
of	O
Allergy	B-DISO
and	O
Infectious	B-DISO
Diseases	I-DISO
of	O
the	O
National	O
Institutes	O
of	O
Health	O
(	O
Bethesda	O
,	O
MD	O
,	O
USA	O
).	O

TITLE	O
:	O
Invasive	B-DISO
Pulmonary	I-DISO
Aspergillosis	I-DISO
in	O
Nonimmunocompromised	O
Hosts	O
.	O

TITLE	O
:	O
Prevalence	O
of	O
enteric	O
pathogens	O
in	O
diarrheic	O
and	O
non	O
-	O
diarrheic	O
samples	O
from	O
pig	O
farms	O
with	O
neonatal	B-DISO
diarrhea	I-DISO
in	O
the	O
North	O
East	O
of	O
Spain	O
.	O

In	O
the	O
present	O
study	O
,	O
31	O
pig	O
farms	O
with	O
outbreaks	O
of	O
neonatal	B-DISO
diarrhea	I-DISO
were	O
investigated	O
in	O
Catalonia	O
(	O
NE	O
Spain	O
)	O
from	O
February	O
2017	O
until	O
June	O
2018	O
.	O

ABSTRACT	O
:	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
are	O
two	O
coronaviruses	O
with	O
demonstrated	O
potential	O
to	O
generate	O
significant	O
nosocomial	O
outbreaks	O
.	O

Our	O
modeling	O
results	O
informed	O
by	O
historic	O
outbreak	O
data	O
for	O
SARS	B-DISO
and	O
MERS	O
suggest	O
that	O
vaccination	O
strategies	O
targeting	O
patients	O
could	O
be	O
an	O
effective	O
measure	O
to	O
mitigate	O
and	O
prevent	O
outbreaks	O
in	O
the	O
healthcare	O
setting	O
.	O

In	O
total	O
,	O
29	O
HKIA	O
staff	O
of	O
diverse	O
ranks	O
and	O
working	O
locations	O
were	O
infected	O
with	O
measles	B-DISO
within	O
1	O
month	O
.	O

We	O
observed	O
no	O
rabies	B-DISO
-	O
associated	O
signs	O
or	O
symptoms	O
in	O
mice	O
inoculated	O
with	O
RVΔP	O
-	O
MERS	O
/	O
S1	O
.	O

ABSTRACT	O
:	O
The	O
present	O
study	O
attempted	O
to	O
verify	O
the	O
prevalence	O
of	O
and	O
risk	O
factors	O
for	O
diarrhea	B-DISO
-	O
causing	O
agents	O
in	O
dairy	O
calves	O
from	O
Brazil	O
.	O

(	O
P	O
<	O
0	O
.	O
0001	O
),	O
as	O
well	O
as	O
developing	O
infection	B-DISO
by	O
nematodes	O
(	O
P	O
<	O
0	O
.	O
0001	O
).	O

In	O
our	O
previous	O
study	O
,	O
we	O
have	O
demonstrated	O
that	O
circular	O
RNA	O
circEZH2	O
was	O
down	O
-	O
regulated	O
during	O
TGEV	O
infection	B-DISO
and	O
promoted	O
the	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
-	O
light	O
-	O
chain	O
-	O
enhancer	O
of	O
activated	O
B	O
cells	O
(	O
NF	O
-	O
κB	O
)	O
via	O
targeting	O
miR	O
-	O
22	O
in	O
porcine	O
intestinal	O
epithelial	O
cell	O
line	O
(	O
IPEC	O
-	O
J2	O
).	O

Activation	O
of	O
NF	O
-	O
κB	O
is	O
an	O
important	O
factor	O
for	O
mitochondrial	B-DISO
damage	I-DISO
.	O

These	O
data	O
emphasize	O
the	O
plasticity	O
of	O
the	O
MERS	O
-	O
CoV	O
genome	O
during	O
human	O
infection	B-DISO
.	O

However	O
,	O
the	O
utilization	O
of	O
CURB	B-DISO
-	O
65	O
score	O
was	O
low	O
and	O
there	O
is	O
a	O
need	O
for	O
wider	O
implementation	O
of	O
pneumonia	B-DISO
severity	O
index	O
for	O
patients	O
presenting	O
with	O
CAP	B-DISO
.	O

The	O
mortality	O
rates	O
for	O
CURB	B-DISO
-	O
65	O
scores	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
4	O
/	O
5	O
were	O
1	O
.	O
8	O
%,	O
4	O
.	O
3	O
%,	O
10	O
.	O
2	O
%,	O
14	O
%,	O
and	O
21	O
.	O
9	O
%,	O
respectively	O
.	O

IFI204	O
and	O
other	O
p200	O
family	O
proteins	O
are	O
highly	O
expressed	O
in	O
mouse	B-DISO
hepatitis	I-DISO
coronavirus	O
-	O
infected	O
bone	O
marrow	O
-	O
derived	O
dendritic	O
cells	O
.	O

ABSTRACT	O
:	O
Drug	O
reaction	O
with	O
eosinophilia	B-DISO
and	O
systemic	O
symptoms	O
(	O
DRESS	O
)	O
syndrome	B-DISO
represents	O
a	O
severe	O
adverse	O
drug	O
reaction	O
driven	O
by	O
eosinophilia	B-DISO
.	O

Vaccine	O
derived	O
virus	O
interference	O
was	O
significantly	O
associated	O
with	O
coronavirus	O
and	O
human	O
metapneumovirus	O
;	O
however	O
,	O
significant	O
protection	O
with	O
vaccination	O
was	O
associated	O
not	O
only	O
with	O
most	O
influenza	B-DISO
viruses	O
,	O
but	O
also	O
parainfluenza	B-DISO
,	O
RSV	O
,	O
and	O
non	O
-	O
influenza	B-DISO
virus	O
coinfections	B-DISO
.	O

RESULTS	O
:	O
We	O
compared	O
vaccination	O
status	O
of	O
2880	O
people	O
with	O
non	O
-	O
influenza	B-DISO
respiratory	O
viruses	O
to	O
3240	O
people	O
with	O
pan	O
-	O
negative	O
results	O
.	O

In	O
this	O
context	O
and	O
not	O
withstanding	O
significant	O
recent	O
progress	O
in	O
the	O
field	O
of	O
mechanical	O
ventilation	O
and	O
extra	O
-	O
corporeal	O
respiratory	O
assistance	O
,	O
early	O
diagnosis	O
remains	O
essential	O
to	O
identify	O
patients	O
with	O
ARDS	B-DISO
in	O
order	O
to	O
offer	O
them	O
the	O
most	O
appropriate	O
therapy	O
.	O

The	O
affected	O
innate	B-DISO
immune	I-DISO
response	I-DISO
also	O
impacts	O
subsequent	O
adaptive	O
responses	O
,	O
and	O
therefore	O
viral	O
innate	O
immune	O
evasion	O
often	O
undermines	O
fully	O
protective	O
immunity	O
.	O

In	O
this	O
review	O
,	O
innate	B-DISO
immune	I-DISO
responses	I-DISO
relevant	O
for	O
respiratory	O
viruses	O
with	O
an	O
RNA	O
genome	O
will	O
briefly	O
be	O
summarized	O
,	O
and	O
viral	O
innate	O
immune	O
evasion	O
based	O
on	O
shielding	O
viral	O
RNA	O
species	O
away	O
from	O
cellular	O
innate	O
immune	O
sensors	O
will	O
be	O
discussed	O
from	O
different	O
angles	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
induces	O
severe	O
aggravating	O
respiratory	B-DISO
failure	I-DISO
in	O
infected	O
patients	O
,	O
frequently	O
resulting	O
in	O
mechanical	O
ventilation	O
.	O

Identifying	O
the	O
underlying	O
mechanisms	O
of	O
variability	O
in	O
pathogenicity	O
is	O
a	O
critical	O
task	O
for	O
understanding	O
influenza	B-DISO
virus	B-DISO
infection	I-DISO
and	O
effective	O
management	O
of	O
highly	O
pathogenic	O
influenza	B-DISO
virus	B-DISO
disease	I-DISO
.	O

Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Coronavirus	O
(	O
SARS	B-DISO
).	O

The	O
role	O
of	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
in	O
influenza	B-DISO
pathogenesis	B-DISO
,	O
one	O
of	O
the	O
bottleneck	O
regulators	O
with	O
corroborating	O
signals	O
across	O
transcript	O
and	O
protein	O
expression	O
data	O
,	O
was	O
tested	O
and	O
validated	O
in	O
additional	O
mouse	O
infection	B-DISO
experiments	O
.	O

Our	O
results	O
show	O
that	O
by	O
using	O
association	O
networks	O
,	O
bottleneck	O
genes	O
that	O
lack	O
hub	O
characteristics	O
can	O
be	O
used	O
to	O
predict	O
a	O
gene	O
'	O
s	O
involvement	O
in	O
influenza	B-DISO
virus	O
pathogenicity	O
.	O

In	O
addition	O
,	O
the	O
patients	O
were	O
managed	O
for	O
concomitant	O
multidrug	O
-	O
resistant	O
bacterial	B-DISO
infections	I-DISO
,	O
with	O
infection	B-DISO
resolution	O
confirmed	O
with	O
blood	O
cultures	O
.	O

After	O
Severe	O
Carbon	O
Monoxide	O
Poisoning	O
Is	O
Likely	O
Due	O
to	O
Cytopathic	O
Hypoxia	B-DISO
:	O
A	O
Case	O
Report	O
and	O
Discussion	O
.	O

We	O
then	O
used	O
comprehensive	O
preinfection	O
immunophenotyping	O
to	O
identify	O
global	O
baseline	O
immune	O
correlates	O
of	O
protection	O
from	O
mortality	O
to	O
virus	B-DISO
infection	I-DISO
.	O

RESULTS	O
:	O
Ten	O
pathogens	O
were	O
detected	O
in	O
this	O
assay	O
,	O
of	O
which	O
rhinovirus	O
,	O
adenovirus	B-DISO
,	O
and	O
influenza	B-DISO
virus	O
A	O
pdmH1N1	O
(	O
2009	O
)	O
were	O
the	O
most	O
common	O
.	O

CONCLUSIONS	O
:	O
The	O
ResP	O
assay	O
demonstrated	O
a	O
highly	O
concordant	O
performance	O
comparing	O
with	O
pathogen	O
-	O
specific	O
PCRs	O
for	O
detection	O
of	O
respiratory	O
pathogens	O
in	O
oropharyngeal	O
swabs	O
from	O
outpatients	O
and	O
could	O
aid	O
in	O
the	O
diagnosis	O
of	O
respiratory	B-DISO
infections	I-DISO
in	O
a	O
variety	O
of	O
clinical	O
scenarios	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
frequency	O
of	O
detection	O
and	O
molecular	O
characteristics	O
of	O
enteric	O
coronavirus	O
(	O
CoV	O
)	O
infections	B-DISO
in	O
cattle	O
,	O
alpaca	O
,	O
and	O
llama	O
herds	O
bred	O
in	O
family	O
-	O
based	O
farms	O
in	O
Brazil	O
and	O
Peru	O
.	O

ABSTRACT	O
:	O
Epidemic	O
intelligence	O
(	O
EI	O
)	O
for	O
emerging	O
infections	B-DISO
is	O
the	O
process	O
of	O
identifying	O
key	O
information	O
on	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
and	O
specific	O
incidents	O
.	O

Ebola	O
entries	O
dominated	O
the	O
database	O
,	O
making	O
up	O
23	O
.	O
7	O
%	O
of	O
the	O
total	O
,	O
followed	O
by	O
Zika	O
(	O
11	O
.	O
8	O
%),	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
6	O
.	O
7	O
%),	O
cholera	B-DISO
(	O
5	O
.	O
5	O
%),	O
and	O
yellow	B-DISO
fever	I-DISO
and	O
undiagnosed	O
morbidity	O
(	O
both	O
3	O
.	O
3	O
%).	O

In	O
the	O
dacryocystorhinostomy	O
samples	O
,	O
viral	O
genomes	O
were	O
detected	O
in	O
four	O
(	O
8	O
.	O
3	O
%)	O
cases	O
,	O
including	O
respiratory	O
syncytial	O
virus	O
(	O
two	O
cases	O
),	O
coronavirus	O
HKU1	O
(	O
one	O
case	O
),	O
and	O
adenovirus	B-DISO
(	O
one	O
case	O
).	O

There	O
was	O
a	O
statistically	O
significant	O
agreement	O
between	O
nasal	O
mucosal	O
swab	O
and	O
dacryocystorhinostomy	O
biopsy	O
samples	O
in	O
terms	O
of	O
respiratory	O
syncytial	O
virus	O
positivity	O
(	O
kappa	O
=	O
1	O
.	O
000	O
,	O
Although	O
the	O
viral	O
genome	O
was	O
detected	O
in	O
the	O
samples	O
,	O
a	O
direct	O
relationship	O
between	O
viruses	O
and	O
pathogenesis	B-DISO
of	O
primary	B-DISO
acquired	I-DISO
nasolacrimal	I-DISO
duct	I-DISO
obstruction	I-DISO
could	O
not	O
be	O
revealed	O
because	O
of	O
the	O
low	O
number	O
of	O
positive	O
results	O
.	O

However	O
,	O
considering	O
the	O
profibrotic	O
characteristics	O
of	O
specific	O
viruses	O
such	O
as	O
respiratory	O
syncytial	O
virus	O
and	O
adenovirus	B-DISO
,	O
viral	B-DISO
infections	I-DISO
may	O
be	O
one	O
of	O
the	O
many	O
predisposing	O
factors	O
of	O
primary	B-DISO
acquired	I-DISO
nasolacrimal	I-DISO
duct	I-DISO
obstruction	I-DISO
.	O

ECMO	O
for	O
adult	O
respiratory	B-DISO
failure	I-DISO
was	O
associated	O
with	O
overall	O
survival	O
of	O
62	O
%	O
in	O
2018	O
,	O
according	O
to	O
the	O
Extracorporeal	O
Life	O
Support	O
Organization	O
(	O
ELSO	O
)	O
January	O
2019	O
registry	O
report	O
.	O

ABSTRACT	O
:	O
Therapeutic	O
options	O
for	O
the	O
highly	O
pathogenic	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
infections	B-DISO
are	O
urgently	O
needed	O
.	O

These	O
nanostructures	O
showed	O
a	O
concentration	O
-	O
dependent	O
virus	O
inactivation	B-DISO
with	O
an	O
estimated	O
EC	O

TITLE	O
:	O
Feline	O
coronavirus	O
-	O
associated	O
myocarditis	B-DISO
in	O
a	O
domestic	O
longhair	O
cat	O
.	O

Given	O
the	O
persistent	O
anorexia	B-DISO
and	O
worsening	O
of	O
the	O
clinical	O
signs	O
,	O
the	O
cat	O
was	O
humanely	O
euthanized	O
and	O
a	O
post	O
-	O
mortem	O
examination	O
was	O
performed	O
.	O

Immunohistochemistry	O
performed	O
on	O
the	O
myocardium	O
revealed	O
feline	O
coronavirus	O
-	O
positive	O
macrophages	O
associated	O
with	O
pyogranulomatous	O
lesions	O
,	O
justifying	O
a	O
diagnosis	O
of	O
feline	O
coronavirus	O
-	O
associated	O
myocarditis	B-DISO
.	O

To	O
the	O
authors	O
'	O
knowledge	O
,	O
the	O
case	O
described	O
here	O
represents	O
the	O
first	O
published	O
report	O
of	O
feline	O
coronavirus	O
-	O
associated	O
myocarditis	B-DISO
.	O

ABSTRACT	O
:	O
Mortality	O
is	O
high	O
among	O
patients	O
with	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
.	O

Patients	O
who	O
were	O
admitted	O
with	O
septic	B-DISO
shock	I-DISO
and	O
/	O
or	O
organ	B-DISO
failure	I-DISO
were	O
significantly	O
more	O
likely	O
to	O
die	O
than	O
patients	O
who	O
were	O
admitted	O
with	O
pneumonia	B-DISO
and	O
/	O
or	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
OR	O
=	O
47	O
.	O
9	O
,	O
95	O
%	O
CI	O
=	O
3	O
.	O
9	O
,	O
585	O
.	O
5	O
,	O
p	O
-	O
value	O
0	O
.	O
002	O
).	O

Hospital	O
mortality	O
was	O
25	O
%;	O
septic	B-DISO
shock	I-DISO
/	O
organ	B-DISO
failure	I-DISO
at	O
admittance	O
was	O
a	O
significant	O
predictor	O
of	O
mortality	O
.	O

The	O
opioids	O
are	O
highly	O
potent	O
and	O
effective	O
analgesics	O
,	O
but	O
most	O
have	O
a	O
high	O
potential	O
for	O
dependency	O
and	O
abuse	B-DISO
.	O

Engagement	O
of	O
the	O
opiate	O
receptors	O
generates	O
a	O
series	O
of	O
intracellular	O
signals	O
,	O
including	O
inhibition	O
of	O
adenylate	O
cyclase	O
,	O
decreased	O
opening	O
of	O
calcium	O
channels	O
,	O
increased	O
potassium	O
currents	O
and	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	B-DISO
).	O

The	O
opioids	O
can	O
be	O
categorized	O
into	O
subclasses	O
on	O
the	O
basis	O
of	O
their	O
chemical	O
structure	O
as	O
opium	O
alkaloids	O
(	O
opiates	B-DISO
:	O
codeine	O
,	O
morphine	O
),	O
semisynthetic	O
derivatives	O
of	O
the	O
natural	O
alkaloids	O
(	O
hydrocodone	O
,	O
hydromorphone	O
,	O
oxycodone	O
,	O
buprenorphine	O
),	O
and	O
various	O
classes	O
of	O
synthetic	O
opioids	O
such	O
as	O
the	O
anililopiperidines	O
(	O
fentanyl	O
,	O
alfentanil	O
,	O
sufentanil	O
,	O
remifentanil	O
),	O
diphenylpropylamine	O
derivatives	O
(	O
propoxyphene	O
,	O
dextropropoxyphene	O
,	O
methadone	O
,	O
diphenoxylate	O
,	O
loperamide	O
),	O
and	O
others	O
(	O
pentazocine	O
,	O
butorphanol	O
,	O
nalbupine	O
,	O
levorphanol	O
,	O
tramadol	O
),	O
and	O
,	O
the	O
opioid	O
antagonists	O
(	O
nalmefene	O
,	O
naloxone	O
and	O
naltrexone	O
).	O

They	O
can	O
also	O
be	O
informally	O
classified	O
based	O
upon	O
their	O
major	O
use	O
such	O
as	O
anesthesia	B-DISO
(	O
fentanyl	O
,	O
alfentanil	O
,	O
remifentanil	O
,	O
sufentanil	O
),	O
severe	B-DISO
pain	I-DISO
(	O
morphine	O
,	O
hydromorphone	O
,	O
levorphanol	O
,	O
merperidine	O
),	O
moderate	O
to	O
severe	O
acute	O
or	O
chronic	B-DISO
pain	I-DISO
(	O
transdermal	O
or	O
transbuccal	O
fentanyl	O
,	O
codeine	O
,	O
oxycodone	O
,	O
hydrocodone	O
,	O
levorphanol	O
,	O
methadone	O
),	O
diarrhea	B-DISO
(	O
loperamide	O
,	O
diphenoxylate	O
),	O
and	O
cough	B-DISO
(	O
codeine	O
,	O
hydrocodone	O
).	O

ABSTRACT	O
:	O
Dromedary	O
camels	O
are	O
important	O
reservoir	O
hosts	O
of	O
various	O
coronaviruses	O
,	O
including	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
that	O
cause	O
human	O
infections	B-DISO
.	O

In	O
this	O
study	O
,	O
we	O
present	O
evidence	O
suggesting	O
that	O
recombinant	O
IBV	O
with	O
a	O
mutant	B-DISO
S2	O
'	O
site	O
(	O
furin	O
-	O
S2	O
'	O
site	O
)	O
leads	O
to	O
higher	O
mortality	O
.	O

Infection	B-DISO
with	O
mutant	B-DISO
IBV	O
induces	O
severe	O
encephalitis	B-DISO
and	O
breaks	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

ABSTRACT	O
:	O
Porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
)	O
has	O
caused	O
enormous	O
economic	O
losses	O
to	O
the	O
global	O
pig	O
industry	O
.	O

TITLE	O
:	O
Extracorporeal	O
Life	O
Support	O
:	O
The	O
Next	O
Step	O
in	O
Moderate	O
to	O
Severe	O
ARDS	B-DISO
-	O
A	O
Review	O
and	O
Meta	O
-	O
Analysis	O
of	O
the	O
Literature	O
.	O

The	O
reaction	O
commonly	O
manifests	O
as	O
a	O
febrile	O
skin	B-DISO
eruption	I-DISO
with	O
lymphadenopathy	O
and	O
malaise	B-DISO
between	O
two	O
and	O
eight	O
weeks	O
following	O
drug	O
exposure	O
.	O

Pulmonary	O
symptoms	O
may	O
precede	O
development	O
of	O
the	O
other	O
more	O
common	O
symptoms	B-DISO
and	I-DISO
signs	I-DISO
of	O
the	O
syndrome	B-DISO
,	O
or	O
they	O
might	O
develop	O
later	O
in	O
the	O
course	O
of	O
the	O
disease	O
.	O

The	O
most	O
common	O
pulmonary	O
radiographic	O
findings	O
in	O
DRESS	O
were	O
interstitial	O
infiltrates	B-DISO
in	O
50	O
%	O
of	O
cases	O
,	O
followed	O
by	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
31	O
%.	O

In	O
a	O
multivariate	O
regression	O
,	O
a	O
latency	O
of	O
30	O
days	O
or	O
less	O
and	O
an	O
age	O
of	O
60	O
or	O
less	O
were	O
associated	O
with	O
development	O
of	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Risk	O
of	O
transmission	O
via	O
medical	O
employees	O
and	O
importance	O
of	O
routine	O
infection	B-DISO
-	O
prevention	O
policy	O
in	O
a	O
nosocomial	O
outbreak	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
):	O
a	O
descriptive	O
analysis	O
from	O
a	O
tertiary	O
care	O
hospital	O
in	O
South	O
Korea	O
.	O

A	O
24	O
-	O
year	O
-	O
old	O
man	O
suffered	B-DISO
from	O
extensive	O
hydrofluoric	O
acid	O
burns	O
covering	O
60	O
%	O
of	O
the	O
total	O
body	O
surface	O
area	O
(	O
TBSA	O
),	O
including	O
deep	O
second	O
degree	O
burns	O
on	O
47	O
%	O
and	O
third	O
degree	O
burns	O
on	O
13	O
%	O
of	O
the	O
TBSA	O
,	O
after	O
he	O
fell	O
into	O
a	O
pickling	O
pool	O
containing	O
15	O
%	O
HF	O
.	O

Ventricular	B-DISO
fibrillation	I-DISO
occurred	O
9	O
times	O
within	O
the	O
first	O
2	O
h	O
,	O
and	O
the	O
lowest	O
serum	O
Ca	O
Extensive	O
HF	O
burns	O
combined	O
with	O
an	O
inhalation	O
injury	O
led	O
to	O
a	O
potentially	O
fatal	O
electrolyte	B-DISO
imbalance	I-DISO
and	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
Duck	B-DISO
viral	I-DISO
enteritis	I-DISO
(	O
DEV	O
)	O
is	O
a	O
DNA	O
virus	O
that	O
leads	O
to	O
heavy	O
economic	O
losses	O
in	O
the	O
commercial	O
duck	O
industry	O
.	O

However	O
,	O
the	O
role	O
of	O
MDA5	O
in	O
DEV	O
infection	B-DISO
remains	O
unclear	O
.	O

ABSTRACT	O
:	O
Haemorrhagic	B-DISO
enteritis	I-DISO
(	O
HE	O
)	O
of	O
turkeys	O
was	O
first	O
described	O
in	O
1937	O
in	O
the	O
USA	O
,	O
while	O
in	O
Poland	O
it	O
was	O
first	O
diagnosed	O
in	O
1987	O
.	O

Unfortunately	O
,	O
even	O
the	O
low	O
-	O
pathogenic	O
HEV	O
strains	O
cause	O
severe	O
immunosuppression	O
leading	O
to	O
secondary	O
bacterial	B-DISO
infections	I-DISO
and	O
huge	O
economic	O
losses	O
.	O

TITLE	O
:	O
Comprehensive	O
analysis	O
of	O
synonymous	O
codon	O
usage	O
patterns	O
in	O
orf3	O
gene	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
in	O
China	O
.	O

ABSTRACT	O
:	O
Infectious	B-DISO
bronchitis	B-DISO
virus	O
(	O
IBV	O
)	O
causes	O
respiratory	B-DISO
diseases	I-DISO
in	O
chickens	O
and	O
poses	O
an	O
economic	O
threat	O
to	O
the	O
poultry	O
industry	O
worldwide	O
.	O

The	O
LRN	O
for	O
biological	O
threats	O
(	O
LRN	O
-	O
B	O
)	O
provides	O
a	O
laboratory	O
infrastructure	O
to	O
respond	O
to	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
.	O

Meanwhile	O
,	O
we	O
found	O
that	O
the	O
differentially	O
expressed	O
lncRNA	O
TCONS_00058367	O
might	O
lead	O
to	O
a	O
reduction	O
of	O
phosphorylation	O
of	O
transcription	O
factor	O
p65	O
(	O
p	O
-	O
p65	O
)	O
in	O
TGEV	O
-	O
infected	O
IPEC	O
-	O
J2	O
cells	O
by	O
negatively	O
regulating	O
its	O
antisense	O
gene	O
promyelocytic	B-DISO
leukemia	I-DISO
(	O
PML	B-DISO
).	O

TITLE	O
:	O
Evaluation	O
of	O
serological	O
assays	O
available	O
in	O
a	O
biosafety	O
level	O
2	O
laboratory	O
and	O
their	O
application	O
for	O
survey	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
among	O
livestock	O
in	O
Ethiopia	O
.	O

In	O
spite	O
of	O
multi	O
-	O
modality	O
critical	O
care	O
treatment	O
and	O
resuscitation	O
,	O
including	O
milrinone	O
,	O
multiple	O
vasopressors	O
,	O
anti	O
-	O
pseudomonal	O
antibiotics	O
,	O
and	O
prone	O
positioning	O
,	O
the	O
patient	O
progressed	O
to	O
cardiorespiratory	B-DISO
failure	I-DISO
and	O
died	O
.	O

Therefore	O
,	O
in	O
this	O
study	O
,	O
a	O
new	O
type	O
of	O
recombinant	O
adenovirus	B-DISO
expressing	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
porcine	O
epidemic	B-DISO
diarrhea	I-DISO
virus	O
(	O
PEDV	O
),	O
rAd	O
-	O
PEDV	O
-	O
S	O
,	O
was	O
generated	O
,	O
and	O
its	O
characteristics	O
were	O
determined	O
.	O

TITLE	O
:	O
Prevalence	O
of	O
selected	O
cardiotropic	O
pathogens	O
in	O
the	O
myocardium	O
of	O
adult	O
dogs	O
with	O
unexplained	O
myocardial	O
and	O
rhythm	O
disorders	O
or	O
with	O
congenital	B-DISO
heart	I-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
prevalence	O
of	O
nucleic	O
acid	O
from	O
selected	O
cardiotropic	O
pathogens	O
in	O
endomyocardial	O
biopsy	O
samples	O
from	O
dogs	O
with	O
unexplained	O
myocardial	O
and	O
rhythm	O
disorders	O
(	O
UMRD	O
)	O
and	O
compare	O
prevalence	O
with	O
that	O
for	O
a	O
group	O
of	O
control	O
dogs	O
with	O
congenital	B-DISO
heart	I-DISO
disease	I-DISO
(	O
CHD	O
).	O

TITLE	O
:	O
Gold	O
nanoparticle	O
-	O
adjuvanted	O
S	O
protein	O
induces	O
a	O
strong	O
antigen	O
-	O
specific	O
IgG	O
response	O
against	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
related	O
coronavirus	B-DISO
infection	I-DISO
,	O
but	O
fails	O
to	O
induce	O
protective	O
antibodies	O
and	O
limit	O
eosinophilic	B-DISO
infiltration	I-DISO
in	O
lungs	O
.	O

While	O
opioid	O
-	O
induced	O
hearing	B-DISO
loss	I-DISO
is	O
uncommon	O
,	O
methadone	O
toxicity	O
should	O
be	O
taken	O
into	O
account	O
for	O
any	O
previously	O
healthy	O
patient	O
presenting	O
with	O
acute	O
hearing	B-DISO
loss	I-DISO
with	O
or	O
without	O
rhabdomyolysis	B-DISO
.	O

Here	O
,	O
we	O
show	O
that	O
AhR	O
is	O
activated	O
in	O
cells	O
infected	O
with	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
),	O
a	O
coronavirus	O
(	O
CoV	O
),	O
and	O
contributes	O
to	O
the	O
upregulation	O
of	O
downstream	O
effector	O
TCDD	O
-	O
inducible	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
TiPARP	O
)	O
during	O
infection	B-DISO
.	O

This	O
study	O
assesses	O
whether	O
co	B-DISO
-	I-DISO
infection	I-DISO
with	O
2	O
viruses	O
as	O
compared	O
with	O
1	O
is	O
associated	O
with	O
increased	O
hospitalization	O
in	O
those	O
with	O
acute	B-DISO
respiratory	I-DISO
infections	I-DISO
.	O

In	O
this	O
study	O
,	O
detection	O
of	O
2	O
viruses	O
did	O
not	O
significantly	O
increase	O
hospitalizations	O
compared	O
with	O
single	O
virus	O
infections	B-DISO
.	O

ABSTRACT	O
:	O
This	O
study	O
aimed	O
to	O
assess	O
the	O
efficacy	O
of	O
the	O
INTERCEPT	O
™	O
Blood	O
System	O
[	O
amotosalen	O
/	O
ultraviolet	O
A	O
(	O
UVA	O
)	O
light	O
]	O
to	O
reduce	O
the	O
risk	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
-	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
transmission	O
by	O
human	O
platelet	O
concentrates	O
.	O

RESULTS	O
:	O
Complete	O
inactivation	B-DISO
of	O
MERS	O
-	O
CoV	O
in	O
spiked	O
platelet	O
units	O
was	O
achieved	O
by	O
treatment	O
with	O
Amotosalen	O
/	O
UVA	O
light	O
with	O
a	O
mean	O
log	O
reduction	O
of	O
4	O
·	O
48	O
±	O
0	O
·	O
3	O
.	O

Active	O
malignancy	B-DISO
,	O
male	O
gender	O
,	O
PaO	O

ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
(	O
MERS	O
-	O
COV	O
)	O
is	O
the	O
main	O
cause	O
of	O
lung	O
and	O
kidney	B-DISO
infections	I-DISO
in	O
developing	O
countries	O
such	O
as	O
Saudi	O
Arabia	O
and	O
South	O
Korea	O
.	O

ABSTRACT	O
:	O
Human	O
coronaviruses	O
(	O
HCoVs	O
)	O
are	O
important	O
pathogens	O
that	O
cause	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
and	O
have	O
neuroinvasive	O
abilities	O
;	O
however	O
,	O
little	O
is	O
known	O
about	O
the	O
dynamic	O
infection	B-DISO
process	O
of	O
CoVs	O
in	O
vivo	O
,	O
and	O
there	O
are	O
currently	O
no	O
specific	O
antiviral	O
drugs	O
to	O
prevent	O
or	O
treat	O
HCoV	O
infection	B-DISO
.	O

Inflammatory	B-DISO
responses	I-DISO
have	O
a	O
significant	O
impact	O
on	O
MERS	O
-	O
CoV	O
pathogenesis	B-DISO
and	O
disease	O
outcome	O
.	O

TITLE	O
:	O
Evolution	O
of	O
infectious	B-DISO
bronchitis	B-DISO
virus	O
in	O
the	O
field	O
after	O
homologous	O
vaccination	O
introduction	O
.	O

Diverse	O
severity	O
of	O
neurological	O
sequelae	O
remains	O
inevitable	O
among	O
acute	O
flaccid	O
myelitis	B-DISO
patients	O
,	O
but	O
no	O
curable	O
treatment	O
is	O
available	O
currently	O
.	O

According	O
to	O
the	O
management	O
suggestions	O
of	O
the	O
American	O
Centers	O
of	O
Disease	O
Control	O
,	O
uses	O
of	O
corticosteroids	O
and	O
plasmapheresis	O
are	O
either	O
preferred	O
or	O
avoided	O
and	O
intravenous	O
immunoglobulin	O
also	O
has	O
no	O
clear	O
indication	O
in	O
the	O
treatment	O
for	O
acute	O
flaccid	O
myelitis	B-DISO
.	O

Bronchoalveolar	O
lavage	O
on	O
admission	O
revealed	O
diffuse	O
alveolar	O
hemorrhage	B-DISO
.	O

Therefore	O
,	O
we	O
also	O
initiated	O
intravenous	O
immunoglobulin	O
(	O
IVIG	O
)	O
therapy	O
for	O
the	O
treatment	O
of	O
potential	O
vasculitis	B-DISO
.	O

TITLE	O
:	O
[	O
A	O
Rare	O
Complication	B-DISO
of	O
Acute	O
Diarrhae	O
Caused	O
by	O
Cryptosporidium	O
:	O
Possible	O
Hepatobiliary	O
System	O
Involvement	O
in	O
a	O
Child	O
without	O
Immunodeficiency	B-DISO
].	O

The	O
severity	O
and	O
duration	O
of	O
the	O
disease	O
may	O
be	O
a	O
reflection	O
of	O
the	O
immune	B-DISO
deficiency	I-DISO
.	O

Factors	O
such	O
as	O
developmental	O
level	O
of	O
the	O
countries	O
,	O
immune	O
system	O
,	O
nutritional	O
status	O
,	O
living	O
in	O
crowded	O
environments	O
,	O
contact	O
with	O
contaminated	O
water	O
,	O
close	O
contact	O
with	O
animals	O
,	O
working	O
at	O
a	O
hospital	O
and	O
hot	O
and	O
humid	O
climate	O
affect	O
the	O
incidence	O
of	O
Cryptosporidiosis	B-DISO
.	O

Immunodeficiency	B-DISO
was	O
not	O
considered	O
with	O
her	O
resume	O
and	O
laboratuary	O
examinations	O
.	O

In	O
contrast	O
to	O
naïve	O
animals	O
,	O
in	O
-	O
contact	O
vaccinated	O
llamas	O
did	O
not	O
shed	O
infectious	B-DISO
virus	O
upon	O
exposure	O
to	O
directly	O
inoculated	O
llamas	O
,	O
consistent	O
with	O
the	O
induction	O
of	O
strong	O
virus	O
neutralizing	O
antibody	O
responses	O
.	O

The	O
rescued	O
virus	O
(	O
rAJ1102	O
)	O
exhibited	O
similar	O
proliferation	B-DISO
characteristics	O
in	O
vitro	O
to	O
the	O
wildtype	O
AJ1102	O
.	O

An	O
improved	O
accessibility	O
to	O
early	O
diagnosis	O
and	O
treatment	O
and	O
prevention	O
of	O
TB	O
infection	B-DISO
should	O
reduce	O
its	O
prevalence	O
.	O

ΔEVLWI2	O
,	O
rather	O
than	O
EVLWI	O
on	O
2	O
days	O
after	O
ARDS	B-DISO
onset	O
,	O
was	O
identified	O
as	O
an	O
independent	O
prognostic	O
factor	O
even	O
after	O
adjusting	O
other	O
significant	O
factors	O
by	O
Cox	O
proportional	O
hazard	O
analysis	O
.	O

TITLE	O
:	O
Timing	O
and	O
Associated	O
Factors	O
for	O
Sepsis	B-DISO
-	O
3	O
in	O
Severe	O
Trauma	O
Patients	O
:	O
A	O
3	O
-	O
Year	O
Single	O
Trauma	O
Center	O
Experience	O
.	O

Moreover	O
,	O
we	O
investigated	O
factors	O
associated	O
with	O
sepsis	B-DISO
according	O
to	O
the	O
sepsis	B-DISO
-	O
3	O
definition	O
.	O

A	O
binary	O
logistic	O
regression	O
test	O
was	O
used	O
to	O
identify	O
the	O
risk	O
factors	O
for	O
sepsis	B-DISO
-	O
3	O
.	O

Sepsis	B-DISO
defined	O
by	O
sepsis	B-DISO
-	O
3	O
remains	O
a	O
critical	O
issue	O
in	O
severe	O
trauma	O
patients	O
.	O

ABSTRACT	O
:	O
Managing	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
after	O
severe	O
blunt	O
traumatic	B-DISO
lung	I-DISO
injury	O
can	O
be	O
challenging	O
.	O

Here	O
,	O
we	O
applied	O
a	O
flavonoid	O
library	O
to	O
systematically	O
probe	O
inhibitory	O
compounds	O
against	O
SARS	B-DISO
-	O
CoV	O
3CLpro	O
.	O

An	O
induced	O
-	O
fit	B-DISO
docking	O
analysis	O
indicated	O
that	O
S1	O
,	O
S2	O
and	O
S3	O
'	O
sites	O
are	O
involved	O
in	O
binding	O
with	O
flavonoids	O
.	O

We	O
believe	O
that	O
the	O
findings	O
of	O
this	O
study	O
will	O
shed	O
light	O
about	O
the	O
burden	O
of	O
premature	O
mortality	O
due	O
to	O
MERS	O
infection	B-DISO
in	O
the	O
world	O
and	O
the	O
results	O
may	O
provide	O
necessary	O
information	O
for	O
policy	O
-	O
makers	O
to	O
prevent	O
,	O
control	O
,	O
and	O
make	O
a	O
quick	O
response	O
to	O
the	O
outbreak	O
of	O
MERS	O
-	O
CoV	O
disease	O
.	O

TITLE	O
:	O
Compound	O
heterozygous	O
LPIN2	O
pathogenic	O
variants	O
in	O
a	O
patient	O
with	O
Majeed	B-DISO
syndrome	I-DISO
with	O
recurrent	B-DISO
fever	I-DISO
and	O
severe	O
neutropenia	O
:	O
case	O
report	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
first	O
case	O
of	O
human	O
infection	B-DISO
by	O
the	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
Saudi	O
Arabia	O
in	O
June	O
2012	O
,	O
more	O
than	O
2260	O
cases	O
of	O
confirmed	O
MERS	O
-	O
CoV	O
infection	B-DISO
and	O
803	O
related	O
deaths	O
have	O
been	O
reported	O
since	O
the	O
16th	O
of	O
October	O
2018	O
.	O

While	O
there	O
are	O
no	O
published	O
guidelines	O
for	O
use	O
of	O
ECMO	O
in	O
PARDS	O
,	O
in	O
particular	O
no	O
clearly	O
defined	O
inclusion	O
and	O
exclusion	O
criteria	O
,	O
current	O
evidence	O
suggests	O
that	O
children	O
with	O
severe	O
ARDS	B-DISO
may	O
benefit	O
from	O
ECMO	O
support	O
,	O
with	O
survival	O
to	O
hospital	O
discharge	O
equivalent	O
or	O
better	O
than	O
conventional	O
management	O
in	O
children	O
with	O
severe	O
ARDS	B-DISO
.	O

Additionally	O
,	O
diagnostic	O
trees	O
depict	O
recommended	O
diagnostic	O
steps	O
that	O
should	O
be	O
performed	O
in	O
cats	O
suspected	O
of	O
having	O
FIP	B-DISO
based	O
on	O
their	O
clinical	O
signs	O
or	O
clinicopathologic	O
abnormalities	O
.	O

TITLE	O
:	O
An	O
Unsettled	O
Promise	O
:	O
The	O
Newborn	O
Piglet	O
Model	O
of	O
Neonatal	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
(	O
NARDS	O
).	O

While	O
many	O
studies	O
assessed	O
lung	O
injury	O
scores	O
,	O
leukocyte	O
infiltration	B-DISO
,	O
and	O
protein	O
/	O
cytokine	O
concentrations	O
in	O
bronchoalveolar	O
fluid	O
,	O
a	O
systematic	O
approach	O
to	O
tackle	O
major	O
upstream	O
pro	O
-	O
inflammatory	O
pathways	O
of	O
the	O
innate	O
immune	O
system	O
is	O
still	O
in	O
the	O
fledgling	O
stages	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
Coronavirus	O
Seropositivity	O
in	O
Camel	O
Handlers	O
and	O
Their	O
Families	O
,	O
Pakistan	O
.	O

ABSTRACT	O
:	O
We	O
tested	O
samples	O
collected	O
from	O
camels	O
,	O
camel	O
workers	O
,	O
and	O
other	O
animals	O
in	O
Sudan	O
and	O
Qatar	O
in	O
2015	O
and	O
2017	O
for	O
evidence	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	B-DISO
.	O

TITLE	O
:	O
Membrane	O
Cholesterol	O
Modulates	O
Oligomeric	O
Status	O
and	O
Peptide	O
-	O
Membrane	O
Interaction	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Coronavirus	O
Fusion	O
Peptide	O
.	O

We	O
compared	O
the	O
characteristics	O
and	O
in	O
-	O
hospital	O
mortality	O
of	O
patients	O
administered	O
with	O
antibiotics	O
at	O
varying	O
durations	O
after	O
sepsis	B-DISO
recognition	O
,	O
i	O
.	O
e	O
.,	O
0	O
-	O
60	O
,	O
61	O
-	O
120	O
,	O
121	O
-	O
180	O
,	O
181	O
-	O
240	O
,	O
241	O
-	O
360	O
,	O
and	O
361	O
-	O
1440	O
min	O
,	O
and	O
estimated	O
the	O
impact	O
of	O
antibiotic	O
timing	O
on	O
risk	O
-	O
adjusted	O
in	O
-	O
hospital	O
mortality	O
using	O
the	O
generalized	O
estimating	O
equation	O
model	O
(	O
GEE	O
)	O
with	O
an	O
exchangeable	O
,	O
within	O
-	O
group	O
correlation	O
matrix	O
,	O
with	O
""""	O
hospital	O
""""	O
as	O
the	O
grouping	O
variable	O
.	O

We	O
could	O
not	O
find	O
any	O
association	O
between	O
earlier	O
antibiotic	O
administration	O
and	O
reduction	O
in	O
in	O
-	O
hospital	O
mortality	O
in	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
.	O

TITLE	O
:	O
Clinical	O
features	O
and	O
haematological	O
parameters	O
among	O
malaria	B-DISO
patients	O
in	O
Mangaluru	O
city	O
area	O
in	O
the	O
southwestern	O
coastal	O
region	O
of	O
India	O
.	O

Among	O
the	O
total	O
579	O
patients	O
recruited	O
in	O
this	O
study	O
,	O
the	O
distribution	O
of	O
P	O
.	O
vivax	O
,	O
P	O
.	O
falciparum	O
and	O
mixed	B-DISO
infections	I-DISO
were	O
364	O
(	O
62	O
.	O
9	O
%),	O
150	O
(	O
25	O
.	O
9	O
%)	O
and	O
65	O
(	O
11	O
.	O
2	O
%),	O
respectively	O
.	O

Among	O
these	O
,	O
506	O
(	O
87	O
.	O
4	O
%)	O
had	O
mild	O
malaria	B-DISO
,	O
whereas	O
73	O
(	O
12	O
.	O
6	O
%)	O
had	O
severe	O
malaria	B-DISO
.	O

Overall	O
,	O
the	O
clinical	O
features	O
and	O
severity	O
of	O
malaria	B-DISO
in	O
P	O
.	O
vivax	O
and	O
mixed	B-DISO
infection	I-DISO
patients	O
were	O
comparable	O
to	O
P	O
.	O
falciparum	O
patients	O
,	O
albeit	O
with	O
some	O
significant	O
differences	O
.	O

After	O
1	O
:	O
1	O
matching	O
by	O
year	O
,	O
there	O
were	O
three	O
thousand	O
three	O
hundred	O
and	O
forty	O
patients	O
(	O
1670	O
cases	O
;	O
1670	O
controls	O
)	O
diagnosed	O
with	O
sepsis	B-DISO
.	O

Sepsis	B-DISO
in	O
solid	O
organ	O
transplants	O
and	O
non	O
-	O
solid	O
organ	O
transplant	O
patients	O
have	O
similar	O
mortality	O
;	O
however	O
,	O
the	O
subset	O
of	O
heart	O
and	O
lung	O
transplant	O
recipients	O
with	O
sepsis	B-DISO
has	O
a	O
higher	O
rate	O
of	O
mortality	O
compared	O
with	O
the	O
non	O
-	O
solid	O
organ	O
transplant	O
recipients	O
.	O

RESULTS	O
:	O
Overall	O
,	O
there	O
were	O
18	O
632	O
admission	O
encounters	O
with	O
a	O
discharge	O
diagnosis	O
of	O
sepsis	B-DISO
in	O
14	O
780	O
unique	O
patients	O
.	O

Systolic	O
and	O
diastolic	O
function	O
was	O
studied	O
assessing	O
,	O
respectively	O
:	O
right	O
ventricular	O
systolic	O
longitudinal	O
function	O
(	O
tricuspid	O
annular	O
plane	O
systolic	O
excursion	O
)	O
and	O
systolic	O
contraction	B-DISO
duration	O
(	O
tricuspid	O
annular	O
plane	O
systolic	O
excursion	O
length	O
);	O
right	O
ventricular	O
diastolic	O
filling	O
time	O
and	O
right	O
ventricular	O
diastolic	O
restrictive	O
pattern	O
(	O
presence	O
of	O
pulmonary	O
valve	O
presystolic	O
ejection	O
wave	O
).	O

RESULTS	O
:	O
In	O
98	O
patients	O
studied	O
,	O
systolic	B-DISO
dysfunction	I-DISO
(	O
tricuspid	O
annular	O
plane	O
systolic	O
excursion	O
<	O
16	O
mm	O
)	O
was	O
present	O
in	O
33	O
.	O
6	O
%	O
while	O
diastolic	O
restrictive	O
pattern	O
was	O
present	O
in	O
64	O
%.	O

A	O
24	O
-	O
year	O
-	O
old	O
man	O
was	O
admitted	O
to	O
our	O
Internal	O
Medicine	O
Department	O
due	O
to	O
dyspnea	B-DISO
,	O
ascites	O
,	O
and	O
leg	B-DISO
swelling	I-DISO
.	O

Hilar	O
congestion	B-DISO
was	O
highlighted	O
on	O
chest	O
x	O
-	O
ray	O
.	O

Recurrent	O
acute	B-DISO
decompensated	I-DISO
heart	I-DISO
failure	I-DISO
with	O
reduced	O
ejection	O
fraction	O
despite	O
optimal	O
medical	O
therapy	O
in	O
Marfan	O
-	O
related	O
cardiomyopathy	B-DISO
.	O

TITLE	O
:	O
Exit	O
and	O
Entry	O
Screening	O
Practices	O
for	O
Infectious	B-DISO
Diseases	I-DISO
among	O
Travelers	O
at	O
Points	O
of	O
Entry	O
:	O
Looking	O
for	O
Evidence	O
on	O
Public	O
Health	O
Impact	O
.	O

ABSTRACT	O
:	O
Clathrin	O
-	O
mediated	O
endocytosis	O
is	O
a	O
mechanism	O
used	O
for	O
the	O
invasion	B-DISO
of	O
cells	O
by	O
a	O
variety	O
of	O
viruses	O
.	O

The	O
target	O
molecules	O
5a	O
-	O
q	O
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
anti	O
-	O
HIV	B-DISO
activities	O
and	O
cytotoxicities	O
in	O
MT	O
-	O
4	O
cells	O
.	O

Slum	O
populations	O
stand	O
out	O
from	O
other	O
settings	O
and	O
may	O
present	O
differences	O
in	O
the	O
epidemiology	O
of	O
acute	O
viral	B-DISO
infections	I-DISO
.	O

We	O
observed	O
seasonality	O
of	O
hRSV	O
,	O
HRV	O
and	O
human	O
coronavirus	B-DISO
infections	I-DISO
,	O
more	O
severe	O
symptoms	O
in	O
hRSV	O
and	O
influenza	B-DISO
virus	O
(	O
FLU	B-DISO
)	O
infections	B-DISO
and	O
prolonged	O
circulation	O
of	O
seven	O
HRV	O
clusters	O
likely	O
representing	O
distinct	O
serotypes	O
according	O
to	O
genomic	O
sequence	O
distances	O
.	O

Investigations	O
revealed	O
an	O
extremely	O
high	O
serum	O
myogenic	O
enzyme	O
levels	O
and	O
impaired	B-DISO
renal	I-DISO
function	I-DISO
with	O
serum	O
creatinine	O
level	O
of	O
510	O
μmol	O
/	O
L	O
,	O
consistent	O
with	O
the	O
diagnosis	O
of	O
rhabdomyolysis	B-DISO
,	O
AKI	O
stage	O
3	O
,	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

In	O
many	O
instances	O
these	O
outbreaks	O
have	O
been	O
newly	O
emerging	O
(	O
SARS	B-DISO
coronavirus	O
),	O
re	O
-	O
emerging	O
(	O
Ebola	O
virus	O
,	O
Zika	O
virus	O
)	O
or	O
zoonotic	O
(	O
avian	B-DISO
influenza	I-DISO
H5N1	B-DISO
)	O
virus	O
infections	B-DISO
.	O

Given	O
the	O
direct	O
antiviral	O
effects	O
of	O
type	O
I	O
interferons	O
(	O
IFNs	O
)	O
in	O
inhibiting	O
the	O
replication	O
of	O
both	O
DNA	O
and	O
RNA	O
viruses	O
at	O
different	O
stages	O
of	O
their	O
replicative	O
cycles	O
,	O
and	O
the	O
effects	O
of	O
type	O
I	O
IFNs	O
on	O
activating	O
immune	O
cell	O
populations	O
to	O
clear	O
virus	O
infections	B-DISO
,	O
IFNs	O
-	O
α	O
/	O
β	O
present	O
as	O
ideal	O
candidate	O
broad	O
-	O
spectrum	O
antivirals	O
.	O

ABSTRACT	O
:	O
Calf	O
diarrhea	B-DISO
caused	O
by	O
infectious	B-DISO
agents	O
is	O
associated	O
with	O
economic	O
losses	O
in	O
the	O
cattle	O
industry	O
.	O

ABSTRACT	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
life	O
-	O
threatening	O
noncardiogenic	O
circulatory	B-DISO
disorder	I-DISO
of	O
the	O
lungs	O
associated	O
with	O
critical	B-DISO
illnesses	I-DISO
such	O
as	O
sepsis	B-DISO
,	O
trauma	O
,	O
and	O
immune	O
and	O
collagen	B-DISO
vascular	I-DISO
disease	I-DISO
.	O

The	O
demise	O
occurs	O
due	O
to	O
progressive	O
pulmonary	B-DISO
hypoxia	I-DISO
and	O
multi	O
-	O
organ	B-DISO
dysfunction	I-DISO
syndrome	I-DISO
(	O
MODS	B-DISO
)	O
with	O
severe	O
inflammation	B-DISO
.	O

It	O
has	O
been	O
shown	O
that	O
N	O
proteins	O
are	O
important	O
for	O
viral	O
replication	O
and	O
that	O
the	O
one	O
of	O
mouse	B-DISO
hepatitis	I-DISO
virus	O
(	O
MHV	O
),	O
a	O
commonly	O
used	O
model	O
CoV	O
,	O
interacts	O
with	O
nonstructural	O
protein	O
3	O
(	O
nsp3	O
),	O
a	O
component	O
of	O
the	O
RTCs	O
.	O

An	O
appropriate	O
immune	O
response	O
requires	O
controlling	O
the	O
viral	B-DISO
infection	I-DISO
through	O
activation	O
of	O
antiviral	O
defenses	O
,	O
which	O
involves	O
cells	O
of	O
the	O
lung	O
and	O
immune	O
system	O
.	O

In	O
the	O
multivariable	O
logistic	O
regression	O
analysis	O
,	O
bronchiolitis	B-DISO
with	O
multiple	O
viral	B-DISO
infections	I-DISO
was	O
associated	O
with	O
higher	O
odds	O
of	O
PICU	O
admission	O
(	O
adjusted	O
odds	O
ratio	O
:	O
2	O
.	O
56	O
,	O
95	O
%	O
confidence	O
interval	O
:	O
1	O
.	O
17	O
-	O
5	O
.	O
57	O
,	O
P	O
=	O
0	O
.	O
02	O
).	O

While	O
the	O
literature	O
describing	O
the	O
use	O
of	O
oesophageal	O
pressure	O
-	O
guided	O
ARDS	B-DISO
management	O
continues	O
to	O
evolve	O
,	O
there	O
are	O
no	O
reported	O
cases	O
demonstrating	O
use	O
in	O
patients	O
with	O
ARDS	B-DISO
and	O
intractable	O
intracranial	B-DISO
hypertension	I-DISO
due	O
to	O
TBI	O
.	O

The	O
rate	O
of	O
complication	B-DISO
is	O
lowering	O
with	O
the	O
increase	O
in	O
center	O
expertise	O
.	O

Twenty	O
-	O
three	O
patients	O
developed	O
pressure	B-DISO
sores	I-DISO
after	O
prone	O
position	O
(	O
14	O
%).	O

Moderate	O
to	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
developed	O
in	O
37	O
/	O
55	O
(	O
67	O
%),	O
32	O
/	O
55	O
(	O
58	O
%)	O
had	O
pulmonary	B-DISO
haemorrhage	I-DISO
,	O
and	O
mechanical	O
ventilation	O
was	O
required	O
in	O
27	O
/	O
55	O
(	O
49	O
%).	O

In	O
this	O
case	O
report	O
,	O
we	O
aimed	O
to	O
give	O
information	O
about	O
perioperative	O
anesthesia	B-DISO
and	O
surgical	O
management	O
of	O
pulmonary	O
endarterectomy	O
which	O
was	O
successfully	O
managed	O
without	O
Cardiopulmonary	O
Bypass	O
.	O

ABSTRACT	O
:	O
Acute	O
hypoxic	B-DISO
respiratory	B-DISO
failure	I-DISO
can	O
be	O
caused	O
by	O
severe	O
pneumonia	B-DISO
,	O
cardiogenic	B-DISO
pulmonary	I-DISO
edema	I-DISO
(	O
CPE	O
),	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Currently	O
over	O
3	O
,	O
000	O
cases	O
of	O
ECLS	O
(	O
ECMO	O
and	O
ECCO2R	O
)	O
in	O
adults	O
with	O
respiratory	B-DISO
failure	I-DISO
are	O
reported	O
annually	O
to	O
the	O
Extracorporeal	O
Life	O
Support	O
Organization	O
registry	O
.	O

Advances	O
in	O
the	O
care	O
of	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
technological	O
innovations	O
in	O
extracorporeal	O
circuitry	O
,	O
and	O
insights	O
from	O
modern	O
clinical	O
trials	O
of	O
ECLS	O
have	O
led	O
to	O
favorable	O
outcomes	O
and	O
a	O
renewed	O
interest	O
in	O
the	O
use	O
of	O
this	O
technology	O
.	O

Finally	O
,	O
we	O
found	O
that	O
the	O
addition	O
of	O
exogenous	O
trypsin	O
also	O
rescues	O
HKU5	O
-	O
CoV	O
,	O
a	O
second	O
bat	O
group	O
2c	O
CoV	O
.	O
Together	O
,	O
these	O
results	O
indicate	O
that	O
proteolytic	O
cleavage	O
of	O
the	O
spike	O
,	O
not	O
receptor	O
binding	O
,	O
is	O
the	O
primary	B-DISO
infection	I-DISO
barrier	O
for	O
these	O
two	O
group	O
2c	O
CoVs	O
.	O

ABSTRACT	O
:	O
Bats	O
living	O
in	O
close	O
contact	O
with	O
people	O
in	O
Rwanda	O
were	O
tested	O
for	O
evidence	O
of	O
infection	B-DISO
with	O
viruses	O
of	O
zoonotic	O
potential	O
.	O

TITLE	O
:	O
Choking	B-DISO
agents	O
and	O
chlorine	O
gas	O
-	O
History	O
,	O
pathophysiology	O
,	O
clinical	O
effects	O
and	O
treatment	O
.	O

ABSTRACT	O
:	O
Choking	B-DISO
agent	O
exposure	O
,	O
among	O
them	O
chlorine	O
gas	O
,	O
occurs	O
in	O
household	O
or	O
industrial	O
accidents	O
,	O
chemical	O
warfare	O
and	O
terrorist	O
attacks	O
.	O

An	O
EKG	O
,	O
cardiac	O
enzymes	O
and	O
complete	O
-	O
blood	O
-	O
count	O
should	O
be	O
obtained	O
if	O
there	O
is	O
retrosternal	B-DISO
pain	I-DISO
.	O

Laryngoscopy	O
should	O
be	O
performed	O
if	O
glottis	B-DISO
edema	I-DISO
is	O
suspected	O
.	O

Glucocorticoids	O
for	O
prevention	O
of	O
pulmonary	B-DISO
edema	I-DISO
should	O
be	O
applied	O
restrictively	O
.	O

Docking	O
and	O
site	O
-	O
directed	O
mutagenesis	O
studies	O
have	O
suggested	O
that	O
compound	O
5	O
binds	O
to	O
a	O
previously	O
described	O
HIV	B-DISO
-	O
1	O
IN	O
allosteric	O
pocket	O
.	O

Crucial	O
to	O
halting	O
PDCoV	O
transmission	O
and	O
infection	B-DISO
is	O
the	O
development	O
of	O
effective	O
therapies	O
and	O
vaccines	O
.	O

TITLE	O
:	O
Spontaneous	O
breathing	O
in	O
patients	O
with	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
receiving	O
prolonged	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

ABSTRACT	O
:	O
The	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
in	O
awake	O
,	O
spontaneously	O
breathing	O
and	O
non	O
-	O
intubated	O
patients	O
(	O
awake	O
ECMO	O
)	O
may	O
be	O
a	O
novel	O
therapeutic	O
strategy	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
patients	O
.	O

This	O
was	O
in	O
contrast	O
to	O
high	O
viral	O
RNA	O
titers	O
and	O
abundant	O
lesions	O
in	O
the	O
kidney	O
after	O
IBV	O
D388	O
infection	B-DISO
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
-	O
syndrome	B-DISO
in	O
the	O
general	O
complications	O
of	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
.	O

ABSTRACT	O
:	O
Improvement	O
of	O
efficiency	O
of	O
treatment	O
of	O
patients	O
with	O
severe	O
acute	B-DISO
pancreatitis	I-DISO
(	O
SAP	O
),	O
complicated	O
by	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
-	O
syndrome	B-DISO
(	O
ARDS	B-DISO
).	O

The	O
basic	O
criterion	O
of	O
patient	O
inclusion	O
was	O
stable	O
respiration	O
impairment	B-DISO
leading	O
to	O
hypoxia	B-DISO
with	O
PaO	O
Pancreatitis	B-DISO
-	O
associated	O
ARDS	B-DISO
was	O
diagnosed	O
in	O
36	O
cases	O
(	O
53	O
.	O
7	O
%).	O

Early	O
recognition	O
of	O
the	O
complication	B-DISO
and	O
application	O
of	O
ventilatory	O
support	O
techniques	O
resulted	O
in	O
fast	O
restoration	O
of	O
oxygenation	O
and	O
improvement	O
of	O
treatment	O
efficiency	O
.	O

Results	O
have	O
suggested	O
that	O
these	O
tissues	O
alone	O
may	O
not	O
be	O
sufficient	O
to	O
induce	O
the	O
observed	O
inflammation	B-DISO
.	O

In	O
conclusion	O
,	O
MERS	O
-	O
CoV	O
infection	B-DISO
caused	O
a	O
substantial	O
health	O
burden	O
in	O
Saudi	O
Arabia	O
.	O

Respiratory	O
viruses	O
can	O
also	O
exacerbate	O
asthma	B-DISO
and	O
lead	O
to	O
various	O
types	O
of	O
respiratory	B-DISO
distress	I-DISO
syndromes	B-DISO
.	O

However	O
,	O
little	O
is	O
known	O
of	O
the	O
role	O
of	O
IL	O
-	O
11	O
during	O
viral	B-DISO
infections	I-DISO
.	O

Pretreatment	O
with	O
recombinant	O
porcine	O
IL	O
-	O
11	O
(	O
pIL	O
-	O
11	O
)	O
was	O
found	O
to	O
suppress	O
PEDV	O
replication	O
in	O
Vero	O
E6	O
cells	O
,	O
while	O
IL	O
-	O
11	O
knockdown	O
promoted	O
viral	B-DISO
infection	I-DISO
.	O

Nine	O
(	O
81	O
.	O
8	O
%)	O
pregnant	O
women	O
had	O
pneumonia	B-DISO
(	O
six	O
had	O
interstitial	O
and	O
three	O
had	O
bacterial	B-DISO
pneumonia	I-DISO
).	O

Pregnant	O
women	O
developed	O
pneumonia	B-DISO
more	O
often	O
than	O
other	O
women	O
in	O
the	O
reproductive	O
period	O
,	O
but	O
without	O
statistical	O
significance	O
(	O
81	O
.	O
8	O
%	O
vs	O
.	O
65	O
.	O
7	O
%,	O
p	O
=	O
0	O
.	O
330	O
,	O
OR	O
(	O
95	O
%	O
CI	O
)	O
2	O
.	O
35	O
(	O
0	O
.	O
47	O
-	O
11	O
.	O
80	O
)).	O

All	O
tested	O
samples	O
which	O
were	O
originally	O
found	O
negative	O
for	O
influenza	B-DISO
A	O
H1N1	O
virus	O
were	O
also	O
found	O
to	O
be	O
negative	O
for	O
MERS	O
-	O
CoV	O
.	O
These	O
results	O
suggest	O
that	O
circulation	O
of	O
MERS	O
-	O
CoV	O
was	O
uncommon	O
among	O
patients	O
with	O
acute	O
respiratory	B-DISO
symptoms	I-DISO
in	O
Western	O
Saudi	O
Arabia	O
between	O
2010	O
and	O
2012	O
.	O

ABSTRACT	O
:	O
Herpesviridae	O
reactivation	O
among	O
non	O
-	O
immunocompromised	O
critically	B-DISO
ill	I-DISO
patients	O
is	O
associated	O
with	O
impaired	B-DISO
prognosis	O
,	O
especially	O
during	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Herpesviridae	O
reactivation	O
is	O
frequent	O
among	O
patients	O
with	O
severe	O
ARDS	B-DISO
under	O
veno	O
-	O
venous	O
ECMO	O
and	O
is	O
associated	O
with	O
a	O
longer	O
duration	O
of	O
mechanical	O
ventilation	O
.	O

However	O
,	O
conventional	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assays	O
require	O
large	O
laboratory	O
instruments	O
,	O
and	O
amplification	B-DISO
takes	O
approximately	O
2	O
h	O
.	O
These	O
are	O
disadvantages	O
for	O
rapid	O
diagnosis	O
.	O

There	O
is	O
scarcity	O
of	O
literature	O
on	O
the	O
use	O
of	O
prone	O
ventilation	O
in	O
H1N1	O
-	O
associated	O
ARDS	B-DISO
patients	O
.	O

TITLE	O
:	O
Prevalence	O
and	O
phylogenetic	O
analysis	O
of	O
porcine	O
diarrhea	B-DISO
associated	O
viruses	O
in	O
southern	O
China	O
from	O
2012	O
to	O
2018	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
an	O
emerging	O
zoonotic	O
pathogen	O
with	O
a	O
broad	O
host	O
range	O
.	O

Quickly	O
after	O
the	O
identification	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
-	O
CoV	O
(	O
MERS	O
-	O
CoV	O
),	O
both	O
in	O
vitro	O
ligation	O
and	O
BAC	O
-	O
based	O
reverse	O
genetic	O
technologies	O
were	O
engineered	O
for	O
MERS	O
-	O
CoV	O
to	O
study	O
its	O
basic	O
biological	O
properties	O
,	O
develop	O
live	O
-	O
attenuated	O
vaccines	O
,	O
and	O
test	O
antiviral	O
drugs	O
.	O

Rapid	O
laboratory	O
diagnosis	O
of	O
MERS	O
-	O
CoV	O
is	O
the	O
key	O
to	O
successful	O
containment	O
and	O
prevention	O
of	O
the	O
spread	O
of	O
infection	B-DISO
.	O

MERS	O
-	O
CoV	O
infection	B-DISO
leads	O
to	O
a	O
variety	O
of	O
clinical	O
outcomes	O
in	O
humans	O
ranging	O
from	O
asymptomatic	O
and	O
mild	O
infection	B-DISO
to	O
severe	O
acute	O
lung	O
injury	O
and	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
and	O
death	O
.	O

Precise	O
molecular	O
engineering	O
of	O
mouse	O
DPP4	O
(	O
mDPP4	O
)	O
with	O
clustered	O
regularly	O
interspaced	O
short	O
palindromic	O
repeats	O
(	O
CRISPR	O
)/	O
Cas9	O
technology	O
maintained	O
inherent	O
expression	O
profiles	O
,	O
and	O
limited	O
MERS	O
-	O
CoV	O
susceptibility	O
to	O
tissues	O
that	O
naturally	O
express	O
mDPP4	O
,	O
notably	O
the	O
lower	O
respiratory	O
tract	O
wherein	O
MERS	O
-	O
CoV	O
elicits	O
severe	O
pulmonary	B-DISO
pathology	I-DISO
.	O

However	O
,	O
a	O
dysregulated	O
cytokine	O
response	O
can	O
promote	O
excessive	O
infiltration	B-DISO
and	O
robust	O
pro	O
-	O
inflammatory	O
activity	O
of	O
neutrophils	O
and	O
monocyte	O
-	O
macrophages	O
,	O
leading	O
to	O
fatal	O
disease	O
.	O

ABSTRACT	O
:	O
Emergent	O
coronaviruses	O
such	O
as	O
MERS	O
-	O
CoV	O
and	O
SARS	B-DISO
-	O
CoV	O
can	O
cause	O
significant	O
morbidity	O
and	O
mortality	O
in	O
infected	O
individuals	O
.	O

We	O
present	O
the	O
case	O
of	O
an	O
11	O
year	O
old	O
male	O
who	O
was	O
found	O
to	O
have	O
a	O
right	O
-	O
sided	O
,	O
post	O
-	O
obstructive	B-DISO
pneumonia	I-DISO
secondary	O
to	O
an	O
aspirated	B-DISO
FB	O
obstructing	O
the	O
bronchus	O
intermedius	O
.	O

Positive	O
adenovirus	B-DISO
polymerase	O
chain	O
reaction	O
results	O
can	O
support	O
a	O
diagnosis	O
of	O
severe	O
lower	O
respiratory	O
tract	O
adenovirus	B-DISO
infection	I-DISO
in	O
patients	O
with	O
a	O
clinically	O
compatible	O
syndrome	B-DISO
and	O
no	O
other	O
identified	O
aetiology	O
,	O
with	O
higher	O
viral	O
loads	O
being	O
associated	O
with	O
worse	O
prognosis	O
.	O

We	O
hypothesized	O
that	O
increases	O
in	O
children	O
hospitalized	O
with	O
severe	O
respiratory	O
illnesses	O
might	O
be	O
associated	O
with	O
increase	O
in	O
acute	O
flaccid	O
myelitis	B-DISO
also	O
in	O
autumn	O
2018	O
.	O

The	O
other	O
questionnaire	O
explored	O
the	O
monthly	O
numbers	O
of	O
children	O
hospitalized	O
with	O
respiratory	O
illnesses	O
associated	O
with	O
wheezing	B-DISO
.	O

A	O
correlation	O
between	O
the	O
monthly	O
numbers	O
of	O
children	O
with	O
acute	O
flaccid	O
myelitis	B-DISO
and	O
those	O
with	O
respiratory	O
illness	O
was	O
analyzed	O
by	O
the	O
Pearson	O
correlation	O
test	O
.	O

Here	O
,	O
we	O
present	O
a	O
case	O
,	O
and	O
explore	O
the	O
outcomes	O
for	O
a	O
patient	O
who	O
had	O
two	O
separate	O
admissions	O
with	O
life	O
-	O
threatening	O
illnesses	O
,	O
but	O
had	O
distinct	O
differences	O
in	O
the	O
psychological	B-DISO
outcomes	O
following	O
each	O
illness	O
.	O

Enterovirus	O
/	O
rhinovirus	O
and	O
RSV	O
constituted	O
most	O
of	O
the	O
viral	O
respiratory	B-DISO
infections	I-DISO
among	O
young	O
children	O
,	O
especially	O
among	O
children	O
less	O
than	O
1	O
year	O
old	O
.	O

However	O
,	O
whether	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
virus	O
(	O
FIPV	O
)	O
antagonizes	O
the	O
type	O
I	O
IFN	O
signaling	O
remains	O
unclear	O
.	O

Our	O
research	O
provides	O
new	O
insights	O
into	O
the	O
mechanism	O
for	O
FIPV	O
to	O
counteract	O
host	O
innate	B-DISO
immune	I-DISO
response	I-DISO
.	O

While	O
hepatic	B-DISO
dysfunction	I-DISO
has	O
been	O
focused	O
on	O
the	O
later	O
stages	O
of	O
HCC	B-DISO
,	O
the	O
management	O
of	O
symptoms	O
in	O
PTTM	O
is	O
important	O
for	O
supportive	O
care	O
of	O
the	O
cases	O
.	O

We	O
diagnosed	O
his	O
condition	B-DISO
as	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
caused	O
by	O
the	O
lung	B-DISO
metastases	I-DISO
and	O
involvement	O
of	O
the	O
pulmonary	O
vessels	O
by	O
tumor	B-DISO
thrombus	I-DISO
.	O

As	O
such	O
,	O
optimizing	O
oxygenation	O
to	O
allow	O
for	O
transport	O
should	O
continue	O
to	O
be	O
a	O
priority	O
for	O
critical	O
care	O
transport	O
(	O
CCT	B-DISO
)	O
services	O
.	O

ABSTRACT	O
:	O
Leptospirosis	B-DISO
,	O
one	O
of	O
the	O
most	O
important	O
of	O
neglected	O
tropical	B-DISO
diseases	I-DISO
,	O
is	O
a	O
common	O
zoonosis	B-DISO
in	O
the	O
tropics	O
.	O

Recent	O
reports	O
have	O
demonstrated	O
that	O
pulmonary	B-DISO
haemorrhage	I-DISO
is	O
one	O
of	O
the	O
fatal	O
complications	O
of	O
severe	O
leptospirosis	B-DISO
.	O

With	O
rapid	O
progression	O
of	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
in	O
6	O
hours	O
,	O
he	O
was	O
intubated	O
and	O
a	O
litre	O
of	O
fresh	O
blood	O
was	O
suctioned	O
.	O

All	O
patients	O
died	O
of	O
respiratory	B-DISO
failure	I-DISO
.	O

There	O
were	O
35	O
deaths	O
,	O
17	O
cases	O
of	O
lung	B-DISO
cancer	I-DISO
and	O
11	O
cases	O
related	O
to	O
interstitial	B-DISO
pneumonias	I-DISO
.	O

METHODS	O
:	O
Patients	O
with	O
lung	B-DISO
cancer	I-DISO
with	O
dorsal	O
subpleural	O
fibrotic	O
changes	O
occupying	O
three	O
or	O
more	O
segments	O
of	O
both	O
lower	O
lobes	O
and	O
planned	O
anatomical	O
lung	O
resection	O
were	O
enrolled	O
.	O

In	O
mice	O
,	O
both	O
prophylactic	O
and	O
therapeutic	O
RDV	O
improve	O
pulmonary	O
function	O
and	O
reduce	O
lung	O
viral	O
loads	O
and	O
severe	O
lung	O
pathology	B-DISO
.	O

This	O
is	O
a	O
retrospective	O
cohort	O
study	O
of	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
laboratory	O
-	O
confirmed	O
MERS	O
from	O
14	O
hospitals	O
in	O
Saudi	O
Arabia	O
diagnosed	O
between	O
September	O
2012	O
and	O
January	O
2018	O
.	O

Thirty	O
-	O
four	O
children	O
with	O
pediatric	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
PARDS	O
)	O
managed	O
with	O
HFOV	O
were	O
included	O
.	O

ABSTRACT	O
:	O
Severe	O
leptospirosis	B-DISO
(	O
Weil	B-DISO
'	I-DISO
s	I-DISO
disease	I-DISO
)	O
can	O
give	O
rise	O
to	O
multiorgan	B-DISO
failure	I-DISO
such	O
as	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
,	O
liver	B-DISO
dysfunction	I-DISO
,	O
coagulopathy	B-DISO
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
pulmonary	B-DISO
haemorrhage	I-DISO
,	O
and	O
myocarditis	B-DISO
.	O

We	O
report	O
a	O
rare	O
case	O
of	O
posterior	B-DISO
reversible	I-DISO
encephalopathy	I-DISO
syndrome	I-DISO
(	O
PRES	B-DISO
)	O
in	O
a	O
patient	O
with	O
severe	O
leptospirosis	B-DISO
during	O
recovery	O
phase	O
of	O
the	O
illness	O
.	O

TITLE	O
:	O
Inactivation	B-DISO
of	O
three	O
emerging	O
viruses	O
-	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
,	O
Crimean	B-DISO
-	I-DISO
Congo	I-DISO
haemorrhagic	I-DISO
fever	I-DISO
virus	O
and	O
Nipah	O
virus	O
-	O
in	O
platelet	O
concentrates	O
by	O
ultraviolet	O
C	O
light	O
and	O
in	O
plasma	O
by	O
methylene	O
blue	O
plus	O
visible	O
light	O
.	O

ABSTRACT	O
:	O
Emerging	O
viruses	O
like	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
),	O
Crimean	B-DISO
-	I-DISO
Congo	I-DISO
haemorrhagic	I-DISO
fever	I-DISO
virus	O
(	O
CCHFV	O
)	O
and	O
Nipah	O
virus	O
(	O
NiV	O
)	O
have	O
been	O
identified	O
to	O
pose	O
a	O
potential	O
threat	O
to	O
transfusion	O
safety	O
.	O

In	O
this	O
study	O
,	O
the	O
ability	O
of	O
the	O
THERAFLEX	O
UV	O
-	O
Platelets	O
and	O
THERAFLEX	O
MB	O
-	O
Plasma	O
pathogen	O
inactivation	B-DISO
systems	O
to	O
inactivate	O
these	O
viruses	O
in	O
platelet	O
concentrates	O
and	O
plasma	O
,	O
respectively	O
,	O
was	O
investigated	O
.	O

Treatment	O
with	O
half	O
to	O
three	O
-	O
fourths	O
of	O
the	O
full	O
UVC	O
dose	O
(	O
0	O
·	O
2	O
J	O
/	O
cm	O
Our	O
study	O
demonstrates	O
that	O
both	O
THERAFLEX	O
UV	O
-	O
Platelets	O
(	O
UVC	O
)	O
and	O
THERAFLEX	O
MB	O
-	O
Plasma	O
(	O
MB	O
/	O
light	O
)	O
effectively	O
reduce	O
the	O
infectivity	O
of	O
SARS	B-DISO
-	O
CoV	O
,	O
CCHFV	O
and	O
NiV	O
in	O
platelet	O
concentrates	O
and	O
plasma	O
,	O
respectively	O
.	O

Adverse	O
events	O
included	O
cardiac	B-DISO
arrhythmias	I-DISO
(	O
44	O
.	O
7	O
%,	O
mostly	O
atrial	B-DISO
fibrillation	I-DISO
),	O
respiratory	B-DISO
failure	I-DISO
(	O
22	O
.	O
9	O
%),	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
requiring	O
temporary	O
renal	O
replacement	O
therapy	O
(	O
12	O
.	O
9	O
%),	O
and	O
low	B-DISO
cardiac	I-DISO
output	I-DISO
syndrome	I-DISO
(	O
3	O
.	O
3	O
%).	O

The	O
strain	O
CHN	B-DISO
-	O
JS	O
-	O
2017	O
was	O
isolated	O
and	O
identified	O
by	O
cytopathology	O
,	O
immunofluorescence	O
assays	O
,	O
transmission	O
electron	O
microscopy	O
,	O
and	O
sequence	O
analysis	O
.	O

After	O
applying	O
inclusion	O
and	O
exclusion	O
criteria	O
,	O
594	O
patients	O
with	O
non	O
-	O
pulmonary	B-DISO
sepsis	I-DISO
were	O
enrolled	O
,	O
among	O
whom	O
85	O
(	O
14	O
.	O
3	O
%)	O
had	O
ARDS	B-DISO
.	O

Septic	B-DISO
shock	I-DISO
was	O
diagnosed	O
in	O
80	O
%	O
of	O
patients	O
with	O
ARDS	B-DISO
and	O
66	O
%	O
of	O
those	O
without	O
ARDS	B-DISO
(	O
Soft	B-DISO
tissue	I-DISO
infection	I-DISO
,	O
ICU	O
admission	O
from	O
an	O
emergency	B-DISO
department	O
,	O
and	O
a	O
higher	O
APACHE	O
II	O
score	O
appear	O
to	O
be	O
the	O
risk	O
modifiers	O
of	O
ARDS	B-DISO
in	O
patients	O
with	O
non	O
-	O
pulmonary	B-DISO
sepsis	I-DISO
.	O

We	O
share	O
the	O
infection	B-DISO
prevention	O
measures	O
for	O
surgical	O
procedures	O
during	O
the	O
unexpected	O
outbreak	O
at	O
our	O
hospital	O
.	O

TITLE	O
:	O
The	O
characteristics	O
of	O
hDPP4	O
transgenic	O
mice	O
subjected	O
to	O
aerosol	O
MERS	O
coronavirus	B-DISO
infection	I-DISO
via	O
an	O
animal	O
nose	O
-	O
only	O
exposure	O
device	O
.	O

There	O
is	O
currently	O
an	O
outbreak	O
of	O
pneumonia	B-DISO
of	O
unknown	O
aetiology	O
in	O
Wuhan	O
,	O
China	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
there	O
are	O
no	O
appropriate	O
diagnostic	O
models	O
that	O
can	O
differentiate	O
human	O
MERS	O
-	O
CoV	O
infection	B-DISO
among	O
other	O
respiratory	B-DISO
infections	I-DISO
.	O

ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
causes	O
severe	O
pulmonary	B-DISO
infection	I-DISO
,	O
with	O
∼	O
35	O
%	O
mortality	O
.	O

We	O
developed	O
77	O
hybridomas	O
and	O
selected	O
five	O
neutralizing	O
mAbs	O
by	O
immunization	O
with	O
SΔTM	O
against	O
MERS	O
-	O
CoV	O
EMC	B-DISO
/	O
2012	O
strain	O
S	O
-	O
pseudotyped	O
lentivirus	O
.	O

TITLE	O
:	O
Prevalence	O
and	O
mutation	O
analysis	O
of	O
the	O
spike	O
protein	O
in	O
feline	O
enteric	O
coronavirus	O
and	O
feline	B-DISO
infectious	I-DISO
peritonitis	I-DISO
detected	O
in	O
household	O
and	O
shelter	O
cats	O
in	O
western	O
Canada	O
.	O

To	O
protect	O
against	O
PEDV	O
invasion	B-DISO
,	O
a	O
mucosal	O
vaccine	O
is	O
utilized	O
effectively	O
.	O

The	O
fusion	O
protein	O
LTB	O
-	O
COE	O
was	O
successfully	O
expressed	O
by	O
the	O
recombinant	O
adenovirus	B-DISO
in	O
HEK293	O
cells	O
,	O
and	O
the	O
immunogenicity	O
of	O
the	O
vaccine	O
candidate	O
was	O
assessed	O
in	O
BALB	O
/	O
c	O
mice	O
and	O
piglets	O
.	O

No	O
difference	O
was	O
found	O
for	O
mortality	O
and	O
hospitalization	O
duration	O
between	O
the	O
DCO	B-DISO
-	O
ST	O
and	O
DCO	B-DISO
-	O
EF	O
groups	O
.	O

No	O
difference	O
was	O
found	O
for	O
mortality	O
and	O
hospitalization	O
duration	O
between	O
the	O
DCO	B-DISO
-	O
ST	O
and	O
DCO	B-DISO
-	O
EF	O
groups	O
.	O

Mycoplasma	B-DISO
bovis	O
,	O
Mannheimia	O
haemolytica	O
,	O
Pasteurella	O
multocida	O
,	O
and	O
Histophilus	O
somni	O
were	O
detected	O
in	O
33	O
.	O
3	O
,	O
41	O
.	O
2	O
,	O
89	O
.	O
1	O
,	O
and	O
36	O
.	O
4	O
%	O
of	O
the	O
herds	O
,	O
respectively	O
.	O

TITLE	O
:	O
Specificity	O
,	O
kinetics	O
and	O
longevity	O
of	O
antibody	O
responses	O
to	O
avian	B-DISO
influenza	I-DISO
A	O
(	O
H7N9	O
)	O
virus	B-DISO
infection	I-DISO
in	O
humans	O
.	O

In	O
detail	O
,	O
the	O
new	O
evidence	O
for	O
treating	O
severe	O
ARDS	B-DISO
with	O
ECMO	O
,	O
phenotyping	O
of	O
ARDS	B-DISO
,	O
early	O
neuromuscular	B-DISO
blockade	I-DISO
and	O
the	O
application	O
of	O
non	O
-	O
invasive	O
ventilation	O
and	O
high	O
-	O
flow	O
oxygen	O
therapy	O
are	O
discussed	O
.	O

TITLE	O
:	O
Illness	O
Severity	O
in	O
Hospitalized	O
Influenza	B-DISO
Patients	O
by	O
Virus	O
Type	O
and	O
Subtype	O
,	O
Spain	O
,	O
2010	O
-	O
2017	O
.	O

We	O
analyzed	O
the	O
cases	O
of	O
8	O
,	O
985	O
laboratory	O
-	O
confirmed	O
case	O
-	O
patients	O
hospitalized	O
for	O
severe	O
influenza	B-DISO
by	O
using	O
data	O
from	O
a	O
national	O
surveillance	O
system	O
for	O
the	O
period	O
2010	O
-	O
2017	O
.	O

The	O
secondary	O
outcomes	O
were	O
the	O
ratio	O
of	O
the	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
to	O
the	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
PaO2	O
/	O
FIO2	O
),	O
total	O
positive	O
end	O
expiratory	O
pressure	O
(	O
PEEP	O
),	O
plateau	O
pressure	O
(	O
Pplat	O
),	O
days	O
free	O
of	O
ventilator	O
at	O
day	O
28	O
,	O
barotrauma	O
and	O
ICU	O
-	O
acquired	O
weakness	B-DISO
.	O

Compared	O
with	O
matched	O
controls	O
,	O
serious	O
infections	B-DISO
were	O
significantly	O
increased	O
(	O
rate	O
ratio	O
2	O
.	O
58	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
53	O
,	O
4	O
.	O
37	O
,	O
P	O
=	O
0	O
.	O
0004	O
),	O
while	O
hyperlipidaemia	B-DISO
(	O
0	O
.	O
54	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
35	O
,	O
0	O
.	O
85	O
;	O
P	O
=	O
0	O
.	O
008	O
)	O
and	O
obesity	B-DISO
(	O
0	O
.	O
30	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
15	O
,	O
0	O
.	O
62	O
;	O
P	O
=	O
0	O
.	O
001	O
)	O
were	O
significantly	O
decreased	O
in	O
AOSD	O
patients	O
.	O

TITLE	O
:	O
Association	O
between	O
electromyographical	O
findings	O
and	O
intensive	O
care	O
unit	O
mortality	O
among	O
mechanically	O
ventilated	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
under	O
profound	O
sedation	B-DISO
.	O

CONCLUSIONS	O
:	O
Electromyographical	O
signs	O
of	O
critical	B-DISO
illness	I-DISO
myopathy	I-DISO
or	O
neuropathy	B-DISO
between	O
the	O
7th	O
and	O
the	O
10th	O
day	O
of	O
mechanical	O
ventilation	O
may	O
be	O
associated	O
with	O
intensive	O
care	O
unit	O
mortality	O
among	O
moderate	O
-	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
patients	O
under	O
profound	O
sedation	B-DISO
,	O
in	O
whom	O
clinical	O
strength	O
assessment	O
is	O
not	O
possible	O
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
for	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
in	O
adult	O
patients	O
:	O
a	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
.	O

ABSTRACT	O
:	O
The	O
evidence	O
of	O
improved	O
survival	O
with	O
the	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
is	O
still	O
uncertain	O
.	O

The	O
most	O
common	O
reason	O
for	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
was	O
pneumonia	B-DISO
(	O
60	O
%	O
-	O
65	O
%).	O

When	O
transmitted	B-DISO
to	O
humans	O
,	O
they	O
cause	O
hemorrhagic	B-DISO
fever	I-DISO
with	I-DISO
renal	I-DISO
syndrome	I-DISO
(	O
HFRS	B-DISO
)	O
in	O
Asia	O
and	O
Europe	O
and	O
hantavirus	O
(	O
cardio	O
)	O
pulmonary	O
syndrome	B-DISO
(	O
HPS	B-DISO
)	O
in	O
the	O
Americas	O
.	O

Interestingly	O
,	O
several	O
2	O
-	O
phenyl	O
-	O
benzotriazoles	O
resulted	O
in	O
fairly	O
potent	O
inhibitors	O
of	O
the	O
Hantaan	O
virus	O
in	O
a	O
chemiluminescence	O
focus	O
reduction	O
assay	O
(	O
C	O
-	O
FRA	B-DISO
)	O
showing	O
an	O
EC	O

We	O
have	O
also	O
used	O
the	O
rabies	B-DISO
virus	O
(	O
RV	O
)	O
as	O
a	O
viral	O
vector	O
to	O
design	O
a	O
recombinant	O
vaccine	O
by	O
expressing	O
the	O
MERS	O
-	O
CoV	O
S1	O
(	O
spike	O
)	O
protein	O
on	O
the	O
surface	O
of	O
the	O
RV	O
.	O

The	O
results	O
show	O
that	O
the	O
rabies	B-DISO
virus	O
vector	O
-	O
based	O
vaccine	O
can	O
induce	O
remarkably	O
earlier	O
antibody	O
response	O
and	O
higher	O
levels	O
of	O
cellular	O
immunity	O
than	O
the	O
GEM	O
particles	O
vector	O
.	O

However	O
,	O
a	O
recent	O
study	O
revealed	O
that	O
direct	O
inoculation	O
of	O
Bactrian	O
camels	O
intranasally	O
with	O
MERS	O
-	O
CoV	O
can	O
lead	O
to	O
infection	B-DISO
with	O
abundant	O
virus	B-DISO
shedding	I-DISO
and	O
seroconversion	O
.	O

TITLE	O
:	O
Gga	O
-	O
miR	O
-	O
30d	O
regulates	O
infectious	B-DISO
bronchitis	B-DISO
virus	B-DISO
infection	I-DISO
by	O
targeting	O
USP47	O
in	O
HD11	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
characterized	O
by	O
pulmonary	O
epithelial	O
and	O
endothelial	O
barrier	O
dysfunction	O
and	O
injury	O
.	O

The	O
latter	O
group	O
of	O
patients	O
with	O
persistent	O
severe	O
ARDS	B-DISO
poses	O
challenges	O
to	O
clinicians	O
.	O

Mortality	O
at	O
60	O
days	O
[	O
95	O
/	O
232	O
(	O
41	O
%)	O
versus	O
233	O
/	O
1299	O
(	O
18	O
%);	O
p	O
<	O
0	O
.	O
001	O
]	O
was	O
higher	O
,	O
and	O
ventilator	O
-	O
free	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
intensive	O
care	O
unit	O
-	O
free	O
[	O
0	O
(	O
0	O
-	O
14	O
)	O
versus	O
19	O
(	O
7	O
-	O
23	O
);	O
p	O
<	O
0	O
.	O
001	O
]	O
and	O
non	O
-	O
pulmonary	O
organ	B-DISO
failure	I-DISO
-	O
free	O
[	O
3	O
(	O
0	O
-	O
21	O
)	O
versus	O
20	O
(	O
1	O
-	O
26	O
);	O
p	O
<	O
0	O
.	O
001	O
]	O
days	O
were	O
fewer	O
in	O
patients	O
with	O
versus	O
without	O
persistent	O
severe	O
ARDS	B-DISO
.	O

Older	O
patients	O
(	O
aged	O
>	O
60	O
years	O
)	O
had	O
more	O
systemic	O
symptoms	O
,	O
extensive	O
radiological	O
ground	O
-	O
glass	O
lung	O
changes	O
,	O
lymphopenia	B-DISO
,	O
thrombocytopenia	O
,	O
and	O
increased	O
C	O
-	O
reactive	O
protein	O
and	O
lactate	O
dehydrogenase	O
levels	O
.	O

Phylogenetic	O
analysis	O
of	O
these	O
five	O
patients	O
'	O
RT	O
-	O
PCR	O
amplicons	O
and	O
two	O
full	O
genomes	O
by	O
next	O
-	O
generation	O
sequencing	O
showed	O
that	O
this	O
is	O
a	O
novel	O
coronavirus	O
,	O
which	O
is	O
closest	O
to	O
the	O
bat	O
severe	O
acute	O
respiatory	O
syndrome	B-DISO
(	O
SARS	B-DISO
)-	O
related	O
coronaviruses	O
found	O
in	O
Chinese	O
horseshoe	O
bats	O
.	O

Data	O
were	O
obtained	O
with	O
standardised	O
data	O
collection	O
forms	O
shared	O
by	O
WHO	O
and	O
the	O
International	O
Severe	O
Acute	O
Respiratory	O
and	O
Emerging	O
Infection	B-DISO
Consortium	O
from	O
electronic	O
medical	O
records	O
.	O

Common	O
symptoms	O
at	O
onset	O
of	O
illness	O
were	O
fever	O
(	O
40	O
[	O
98	O
%]	O
of	O
41	O
patients	O
),	O
cough	B-DISO
(	O
31	O
[	O
76	O
%]),	O
and	O
myalgia	B-DISO
or	O
fatigue	B-DISO
(	O
18	O
[	O
44	O
%]);	O
less	O
common	O
symptoms	O
were	O
sputum	O
production	O
(	O
11	O
[	O
28	O
%]	O
of	O
39	O
),	O
headache	B-DISO
(	O
three	O
[	O
8	O
%]	O
of	O
38	O
),	O
haemoptysis	B-DISO
(	O
two	O
[	O
5	O
%]	O
of	O
39	O
),	O
and	O
diarrhoea	B-DISO
(	O
one	O
[	O
3	O
%]	O
of	O
38	O
).	O

We	O
performed	O
bioinformatics	O
analysis	O
on	O
a	O
virus	O
genome	O
from	O
a	O
patient	O
with	O
2019	B-DISO
-	I-DISO
nCoV	I-DISO
infection	I-DISO
and	O
compared	O
it	O
with	O
other	O
related	O
coronavirus	O
genomes	O
.	O

Learning	O
from	O
the	O
roles	O
of	O
civet	O
in	O
SARS	B-DISO
and	O
camel	O
in	O
MERS	O
,	O
hunting	O
for	O
the	O
animal	O
source	O
of	O
2019	O
-	O
nCoV	O
and	O
its	O
more	O
ancestral	O
virus	O
would	O
be	O
important	O
for	O
understanding	O
the	O
origin	O
and	O
evolution	O
of	O
this	O
novel	O
lineage	O
B	O

Reye	B-DISO
'	I-DISO
s	I-DISO
syndrome	I-DISO
is	O
most	O
common	O
in	O
children	O
and	O
rarely	O
occurs	O
in	O
adults	O
.	O

She	O
had	O
taken	O
ibuprofen	O
for	O
headache	B-DISO
.	O

TITLE	O
:	O
Return	O
of	O
the	O
Coronavirus	O
:	O
2019	O
-	O
nCoV	O
.	O
ABSTRACT	O
:	O
The	O
emergence	O
of	O
a	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
)	O
has	O
awakened	O
the	O
echoes	O
of	O
SARS	B-DISO
-	O
CoV	O
from	O
nearly	O
two	O
decades	O
ago	O
.	O

The	O
most	O
plausible	O
number	O
of	O
infections	B-DISO
is	O
in	O
the	O
order	O
of	O
thousands	O
,	O
rather	O
than	O
hundreds	O
,	O
and	O
there	O
is	O
a	O
strong	O
indication	O
that	O
untraced	O
exposures	O
other	O
than	O
the	O
one	O
in	O
the	O
epidemiologically	O
linked	O
seafood	O
market	O
in	O
Wuhan	O
have	O
occurred	O
.	O

The	O
workflow	O
reliably	O
detects	O
2019	O
-	O
nCoV	O
,	O
and	O
further	O
discriminates	O
2019	O
-	O
nCoV	O
from	O
SARS	B-DISO
-	O
CoV	O
.	O
Through	O
coordination	O
between	O
academic	O
and	O
public	O
laboratories	O
,	O
we	O
confirmed	O
assay	O
exclusivity	O
based	O
on	O
297	O
original	O
clinical	O
specimens	O
containing	O
a	O
full	O
spectrum	O
of	O
human	O
respiratory	O
viruses	O
.	O

The	O
median	O
number	O
of	O
days	O
from	O
the	O
occurence	O
of	O
the	O
first	O
symptom	B-DISO
to	O
death	O
was	O
14	O
.	O
0	O
(	O
range	O
6	O
-	O
41	O
)	O
days	O
,	O
and	O
it	O
tended	O
to	O
be	O
shorter	O
among	O
people	O
aged	O
70	O
years	O
or	O
more	O
(	O
11	O
.	O
5	O
[	O
range	O
6	O
-	O
19	O
]	O
days	O
)	O
than	O
those	O
aged	O
less	O
than	O
70	O
years	O
(	O
20	O
[	O
range	O
10	O
-	O
41	O
]	O
days	O
;	O
P	O
=	O
.	O
033	O
).	O

ABSTRACT	O
:	O
The	O
initial	O
cases	O
of	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
)-	O
infected	O
pneumonia	B-DISO
(	O
NCIP	O
)	O
occurred	O
in	O
Wuhan	O
,	O
Hubei	O
Province	O
,	O
China	O
,	O
in	O
December	O
2019	O
and	O
January	O
2020	O
.	O

ABSTRACT	O
:	O
Recently	O
,	O
a	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
)	O
has	O
emerged	O
from	O
Wuhan	O
,	O
China	O
,	O
causing	O
symptoms	O
in	O
humans	O
similar	O
to	O
those	O
caused	O
by	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
).	O

Last	O
,	O
while	O
phylogenetic	O
analysis	O
indicates	O
a	O
bat	O
origin	O
of	O
2019	O
-	O
nCoV	O
,	O
2019	O
-	O
nCoV	O
also	O
potentially	O
recognizes	O
ACE2	O
from	O
a	O
diversity	O
of	O
animal	O
species	O
(	O
except	O
mice	O
and	O
rats	O
),	O
implicating	O
these	O
animal	O
species	O
as	O
possible	O
intermediate	O
hosts	O
or	O
animal	O
models	O
for	O
2019	O
-	O
nCoV	O
infections	B-DISO
.	O

There	O
is	O
a	O
paucity	O
of	O
studies	O
on	O
the	O
progression	O
and	O
outcome	O
of	O
Systemic	B-DISO
Inflammatory	I-DISO
Response	I-DISO
Syndrome	I-DISO
(	O
SIRS	B-DISO
)	O
with	O
its	O
determinants	O
.	O

In	O
the	O
last	O
decade	O
,	O
there	O
is	O
a	O
growing	O
body	O
of	O
evidence	O
that	O
veno	O
-	O
venous	O
ECMO	O
(	O
VV	O
-	O
ECMO	O
)	O
is	O
lifesaving	O
in	O
multiple	O
trauma	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
thanks	O
to	O
technical	O
improvements	O
in	O
ECMO	O
devices	O
.	O

We	O
decided	O
to	O
start	O
heparin	O
-	O
free	O
VV	O
-	O
ECMO	O
after	O
cardiac	B-DISO
arrest	I-DISO
considering	O
risk	O
of	O
hemorrhage	B-DISO
.	O

Even	O
in	O
cases	O
in	O
which	O
life	O
-	O
threatening	O
hypoxemia	O
and	O
severe	O
hypercapnia	B-DISO
/	O
acidosis	B-DISO
last	O
for	O
>	O
1	O
hours	O
during	O
CPR	O
for	O
cardiac	B-DISO
arrest	I-DISO
,	O
VV	O
-	O
ECMO	O
could	O
be	O
considered	O
a	O
potential	O
lifesaving	O
treatment	O
.	O

Participants	O
had	O
a	O
mean	O
GAD	B-DISO
score	O
of	O
2	O
.	O
7	O
±	O
3	O
.	O
1	O
and	O
a	O
median	O
of	O
2	O
.	O

Our	O
results	O
highlight	O
the	O
need	O
to	O
establish	O
psychological	B-DISO
support	O
programs	O
for	O
medical	O
students	O
during	O
an	O
infectious	B-DISO
disease	I-DISO
outbreak	O
.	O

ABSTRACT	O
:	O
Hypoxaemia	O
is	O
a	O
common	O
presentation	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
,	O
with	O
the	O
potential	O
for	O
severe	O
harm	O
if	O
not	O
addressed	O
appropriately	O
.	O

It	O
is	O
important	O
that	O
each	O
new	O
scenario	O
is	O
approached	O
in	O
a	O
structured	O
manner	O
with	O
an	O
open	O
diagnostic	O
mind	O
and	O
a	O
clear	O
escalation	O
plan	B-DISO
.	O

ABSTRACT	O
:	O
Human	O
infections	B-DISO
with	O
zoonotic	O
coronaviruses	O
(	O
CoVs	O
),	O
including	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)-	O
CoV	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)-	O
CoV	O
,	O
have	O
raised	O
great	O
public	O
health	O
concern	O
globally	O
.	O

A	O
novel	O
bat	O
-	O
borne	O
CoV	O
was	O
identified	O
that	O
is	O
associated	O
with	O
severe	O
and	O
fatal	O
respiratory	B-DISO
disease	I-DISO
in	O
humans	O
.	O

Retrospective	O
data	O
were	O
collected	O
for	O
returning	O
travellers	O
from	O
the	O
Middle	O
East	O
fitting	B-DISO
the	O
PHE	O
MERS	O
case	O
definition	O
.	O

Of	O
the	O
99	O
patients	O
with	O
2019	O
-	O
nCoV	O
pneumonia	B-DISO
,	O
49	O
(	O
49	O
%)	O
had	O
a	O
history	O
of	O
exposure	O
to	O
the	O
Huanan	O
seafood	O
market	O
.	O

Viral	O
contigs	O
were	O
connected	O
using	O
Sanger	O
sequencing	O
to	O
obtain	O
the	O
full	O
-	O
length	O
genomes	O
,	O
with	O
the	O
terminal	O
regions	O
determined	O
by	O
rapid	O
amplification	B-DISO
of	O
cDNA	O
ends	O
.	O

We	O
enrolled	O
119	O
patients	O
with	O
acute	O
ischemic	B-DISO
stroke	I-DISO
and	O
assigned	O
them	O
into	O
WUS	O
(	O
n	O
=	O
34	O
)	O
and	O
non	O
-	O
WUS	O
(	O
n	O
=	O
85	O
)	O
groups	O
.	O

TITLE	O
:	O
Epstein	O
-	O
Barr	O
virus	O
-	O
associated	O
hemophagocytic	B-DISO
lymphohistiocytosis	I-DISO
in	O
a	O
small	O
child	O
:	O
A	O
case	O
report	O
.	O

ABSTRACT	O
:	O
Hemodialysis	O
(	O
HD	O
)	O
patients	O
had	O
a	O
high	O
rate	O
of	O
infection	B-DISO
transmission	I-DISO
and	O
mortality	O
during	O
the	O
middle	O
east	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
outbreak	O
in	O
Saudi	O
Arabia	O
.	O

During	O
the	O
2015	O
MERS	O
-	O
CoV	O
outbreak	O
in	O
Korea	O
,	O
116	O
patients	O
in	O
3	O
HD	O
units	O
were	O
incidentally	O
exposed	O
to	O
individuals	O
with	O
confirmed	O
MERS	O
-	O
CoV	O
infection	B-DISO
and	O
underwent	O
different	O
types	O
of	O
isolation	O
,	O
which	O
were	O
as	O
follows	O
:	O
single	O
-	O
room	O
isolation	O
(	O
n	O
=	O
54	O
,	O
47	O
%),	O
cohort	O
isolation	O
(	O
n	O
=	O
46	O
,	O
40	O
%),	O
and	O
self	O
-	O
imposed	O
quarantine	O
(	O
n	O
=	O
16	O
,	O
13	O
%).	O

TITLE	O
:	O
Mast	O
cells	O
contribute	O
to	O
coronavirus	O
-	O
induced	O
inflammation	B-DISO
:	O
new	O
anti	O
-	O
inflammatory	O
strategy	O
.	O

ABSTRACT	O
:	O
Since	O
Dec	O
31	O
,	O
2019	O
,	O
the	O
Chinese	O
city	O
of	O
Wuhan	O
has	O
reported	O
an	O
outbreak	O
of	O
atypical	B-DISO
pneumonia	I-DISO
caused	O
by	O
the	O
2019	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
).	O

The	O
purified	O
protein	O
also	O
showed	O
potent	O
in	O
-	O
vitro	O
antiviral	O
activity	O
against	O
Camelpox	B-DISO
Virus	O
in	O
kidney	O
cells	O
.	O

The	O
identified	O
camel	O
IFN	O
-	O
α	O
protein	O
and	O
the	O
subtypes	O
will	O
facilitate	O
a	O
better	O
understanding	O
of	O
the	O
host	O
immune	O
response	O
to	O
viral	B-DISO
infections	I-DISO
in	O
camel	O
and	O
the	O
development	O
of	O
potential	O
antiviral	O
biologicals	O
for	O
zoonotic	O
diseases	O
for	O
which	O
camel	O
act	O
as	O
a	O
reservoir	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
outbreak	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
18	O
years	O
ago	O
,	O
a	O
large	O
number	O
of	O
SARS	B-DISO
-	O
related	O
coronaviruses	O
(	O
SARSr	O
-	O
CoVs	O
)	O
have	O
been	O
discovered	O
in	O
their	O
natural	O
reservoir	O
host	O
,	O
bats	O

TITLE	O
:	O
Neuromuscular	B-DISO
blockade	I-DISO
in	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
a	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
of	O
randomized	O
controlled	O
trials	O
.	O

ABSTRACT	O
:	O
Neuromuscular	O
blocking	B-DISO
agent	O
(	O
NMBA	O
)	O
has	O
been	O
proposed	O
by	O
medical	O
guidelines	O
for	O
early	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
because	O
of	O
its	O
survival	O
benefits	O
.	O

Median	O
(	O
IQR	O
)	O
optimal	O
PEEP	O
decreased	O
from	O
14	O
(	O
12	O
-	O
16	O
)	O
to	O
10	O
(	O
8	O
-	O
14	O
)	O
cmH	B-DISO
CONCLUSIONS	O
:	O
Although	O
baseline	O
tidal	O
volume	O
distribution	O
on	O
EIT	O
may	O
predict	O
static	O
compliance	O
improvement	O
after	O
PP	O
on	O
ECMO	O
,	O
our	O
results	O
support	O
physiological	O
benefits	O
of	O
PP	O
in	O
all	O
ECMO	O
patients	O
,	O
by	O
modifying	O
lung	O
mechanics	O
and	O
potentially	O
reducing	O
VILI	O
.	O

,	O
China	O
has	O
been	O
experiencing	O
a	O
large	O
outbreak	O
of	O
a	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
)	O
which	O
can	O
cause	O
respiratory	B-DISO
disease	I-DISO
and	O
severe	O
pneumonia	B-DISO
.	O

TITLE	O
:	O
RNA	O
based	O
mNGS	O
approach	O
identifies	O
a	O
novel	O
human	O
coronavirus	O
from	O
two	O
individual	O
pneumonia	B-DISO
cases	O
in	O
2019	O
Wuhan	O
outbreak	O
.	O

We	O
investigated	O
two	O
patients	O
who	O
developed	O
acute	O
respiratory	O
syndromes	B-DISO
after	O
independent	O
contact	O
history	O
with	O
this	O
market	O
.	O

The	O
two	O
patients	O
shared	O
common	O
clinical	O
features	O
including	O
fever	O
,	O
cough	B-DISO
,	O
and	O
multiple	O
ground	O
-	O
glass	O
opacities	B-DISO
in	O
the	O
bilateral	O
lung	O
field	O
with	O
patchy	O
infiltration	B-DISO
.	O

In	O
this	O
short	O
report	O
,	O
phylogenetic	O
reconstruction	O
was	O
used	O
to	O
better	O
understand	O
the	O
transmission	O
dynamics	O
of	O
the	O
virus	O
from	O
its	O
first	O
introduction	O
in	O
China	O
focusing	O
on	O
the	O
more	O
recent	O
evidence	O
of	O
infection	B-DISO
in	O
a	O
couple	O
of	O
Chinese	O
tourists	O
arrived	O
in	O
Italy	O
on	O
23rd	O
January	O
2020	O
and	O
labeled	O
as	O
Coronavirus	O
Italian	O
cases	O
.	O

Other	O
key	O
drug	O
targets	O
,	O
including	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
and	O
coronavirus	O
main	O
proteinase	O
(	O
3CLpro	O
),	O
share	O
a	O
strikingly	O
high	O
(>	O
95	O
%)	O
homology	O
to	O
SARS	B-DISO
-	O
CoV	O
.	O
Herein	O
,	O
we	O
suggest	O
four	O
potential	O
drug	O
candidates	O
(	O
an	O
ACE2	O
-	O
based	O
peptide	O
,	O
remdesivir	O
,	O
3CLpro	O
-	O
1	O
and	O
a	O
novel	O
vinylsulfone	O
protease	O
inhibitor	O
)	O
that	O
could	O
be	O
used	O
to	O
treat	O
patients	O
suffering	B-DISO
with	O
the	O
2019	O
-	O
nCoV	O
.	O
We	O
also	O
summarize	O
previous	O
efforts	O
into	O
drugging	O
these	O
targets	O
and	O
hope	O
to	O
help	O
in	O
the	O
development	O
of	O
broad	O
-	O
spectrum	O
anti	O
-	O
coronaviral	O
agents	O
for	O
future	O
epidemics	O
.	O

But	O
the	O
efficacy	O
and	O
safety	O
of	O
these	O
drugs	O
for	O
2019	O
-	O
nCoV	O
pneumonia	B-DISO
patients	O
need	O
to	O
be	O
assessed	O
by	O
further	O
clinical	O
trials	O
.	O

TITLE	O
:	O
[	O
Early	O
detection	O
and	O
disease	O
assessment	O
of	O
patients	O
with	O
novel	O
coronavirus	O
pneumonia	B-DISO
].	O

ABSTRACT	O
:	O
A	O
recent	O
epidemic	O
of	O
pneumonia	B-DISO
cases	O
in	O
Wuhan	O
China	O
was	O
caused	O
by	O
a	O
novel	O
coronavirus	O
with	O
strong	O
infectivity	O
,	O
the	O
2019	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
).	O

We	O
used	O
the	O
serial	O
intervals	O
(	O
SI	O
)	O
of	O
infection	B-DISO
caused	O
by	O
two	O
other	O
well	O
-	O
known	O
coronaviruses	O
(	O
CoV	O
),	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
CoVs	O
,	O
as	O
approximations	O
of	O
the	O
unknown	O
SI	O
for	O
2019	O
-	O
nCoV	O
to	O
estimate	O
We	O
confirmed	O
that	O
the	O
initial	O
growth	O
phase	O
followed	O
an	O
exponential	O
growth	O
pattern	O
.	O

The	O
cellular	O
regulation	O
of	O
IBV	O
pathogenesis	B-DISO
and	O
the	O
host	O
immune	O
responses	O
involved	O
remain	O
to	O
be	O
fully	O
elucidated	O
.	O

PurposeTo	O
investigate	O
the	O
clinical	O
,	O
laboratory	O
,	O
and	O
imaging	O
findings	O
of	O
emerging	O
2019	O
-	O
nCoV	O
pneumonia	B-DISO
in	O
humans	O
.	O

ABSTRACT	O
:	O
Autoimmune	B-DISO
hemolytic	O
AQ5	O
anemia	B-DISO
(	O
AIHA	O
)	O
is	O
an	O
immune	B-DISO
disorder	I-DISO
caused	O
by	O
antibodies	O
directed	O
against	O
unmodified	O
autologous	O
red	O
blood	O
cells	O
.	O

These	O
multiple	O
autoimmune	B-DISO
mechanisms	O
are	O
referred	O
to	O
as	O
""""	O
immunological	B-DISO
tolerance	I-DISO
loss	O
","""	O
which	O
is	O
known	O
as	O
a	O
characteristic	O
autoimmunity	B-DISO
specific	O
for	O
AIHA	O
.	O

ITP	B-DISO
and	O
mixed	O
-	O
type	O
AIHA	O
.	O

Although	O
infrequent	O
,	O
comorbid	O
thromboembolism	B-DISO
to	O
AIHA	O
is	O
well	O
documented	O
;	O
however	O
,	O
a	O
mixed	O
-	O
type	O
AIHA	O
case	O
complicated	O
with	O
thromboembolism	B-DISO
has	O
not	O
been	O
previously	O
reported	O
.	O

The	O
combined	O
pathophysiology	O
of	O
AIHA	O
and	O
thromboembolism	B-DISO
should	O
be	O
considered	O
in	O
the	O
clinical	O
course	O
of	O
hemolysis	B-DISO
.	O

ABSTRACT	O
:	O
In	O
December	O
2019	O
,	O
a	O
new	O
type	O
viral	B-DISO
pneumonia	I-DISO
cases	O
occurred	O
in	O
Wuhan	O
,	O
Hubei	O
Province	O
;	O
and	O
then	O
named	O
""""	O
2019	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
")"""	O
by	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
on	O
12	O
January	O
2020	O
.	O

For	O
it	O
is	O
a	O
never	O
been	O
experienced	O
respiratory	B-DISO
disease	I-DISO
before	O
and	O
with	O
infection	B-DISO
ability	O
widely	O
and	O
quickly	O
,	O
it	O
attracted	O
the	O
world	O
'	O
s	O
attention	O
but	O
without	O
treatment	O
and	O
control	O
manual	O
.	O

ABSTRACT	O
:	O
Acute	O
severe	O
ammonia	O
inhalation	O
can	O
seriously	O
affect	O
oxygenation	O
and	O
ventilation	O
function	O
of	O
patients	O
,	O
and	O
even	O
cause	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
).	O

Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
technology	O
is	O
increasingly	O
used	O
in	O
treating	O
patients	O
with	O
ARDS	B-DISO
caused	O
by	O
infection	B-DISO
,	O
cardiogenic	B-DISO
shock	I-DISO
,	O
trauma	O
,	O
and	O
drowning	O
with	O
achieved	O
certain	O
effects	O
,	O
but	O
its	O
usage	O
for	O
ARDS	B-DISO
caused	O
by	O
ammonia	O
is	O
rarely	O
reported	O
.	O

TITLE	O
:	O
The	O
First	O
Case	O
of	O
2019	O
Novel	O
Coronavirus	O
Pneumonia	B-DISO
Imported	O
into	O
Korea	O
from	O
Wuhan	O
,	O
China	O
:	O
Implication	O
for	O
Infection	B-DISO
Prevention	O
and	O
Control	O
Measures	O
.	O

We	O
report	O
the	O
epidemiological	O
and	O
clinical	O
features	O
of	O
the	O
first	O
patient	O
with	O
2019	O
-	O
nCoV	O
pneumonia	B-DISO
imported	O
into	O
Korea	O
from	O
Wuhan	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
coronavirus	O
of	O
zoonotic	O
origin	O
(	O
2019	O
-	O
nCoV	O
)	O
has	O
recently	O
been	O
identified	O
in	O
patients	O
with	O
acute	B-DISO
respiratory	I-DISO
disease	I-DISO
.	O

ABSTRACT	O
:	O
In	O
our	O
increasingly	O
interconnected	O
world	O
,	O
the	O
potential	O
for	O
emerging	B-DISO
infectious	I-DISO
diseases	I-DISO
(	O
EIDs	O
)	O
to	O
spread	O
globally	O
is	O
of	O
paramount	O
concern	O
.	O

ABSTRACT	O
:	O
Influenza	B-DISO
is	O
a	O
generally	O
self	O
-	O
limited	O
infection	B-DISO
agent	O
that	O
only	O
rarely	O
causes	O
severe	O
complications	O
.	O

Supportive	O
treatment	O
and	O
oseltamivir	O
did	O
not	O
prevent	O
the	O
development	O
of	O
chronic	B-DISO
renal	I-DISO
failure	I-DISO
.	O

All	O
passengers	O
were	O
screened	O
upon	O
arrival	O
in	O
Japan	O
for	O
symptoms	O
consistent	O
with	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
)	O
infection	B-DISO
and	O
tested	O
for	O
presence	O
of	O
the	O
virus	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
or	O
its	O
most	O
advanced	O
form	O
,	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
is	O
a	O
severe	O
inflammatory	O
pulmonary	O
process	O
triggered	O
by	O
varieties	O
of	O
pathophysiological	O
factors	O
,	O
among	O
which	O
apoptosis	O
of	O
pulmonary	O
endothelial	O
cells	O
plays	O
a	O
critical	O
role	O
in	O
the	O
progression	O
of	O
ALI	O
/	O
ARDS	B-DISO
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
underlying	O
mechanism	O
in	O
which	O
RUS	O
attenuates	O
LPS	B-DISO
-	O
induced	O
pulmonary	O
endothelial	O
cell	O
apoptosis	O
.	O

The	O
scientific	O
interest	O
on	O
coronaviruses	O
increased	O
after	O
the	O
emergence	O
of	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
outbreaks	O
in	O
2002	O
-	O
2003	O
followed	O
by	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
CoV	O
(	O
MERS	O
-	O
CoV	O
).	O

The	O
recently	O
characterized	O
E	O
protein	O
ion	O
channel	O
activity	O
(	O
EIC	O
)	O
has	O
also	O
been	O
implicated	O
in	O
modulating	O
viral	B-DISO
pathogenesis	I-DISO
.	O

In	O
this	O
study	O
,	O
we	O
used	O
infectious	B-DISO
bronchitis	B-DISO
coronavirus	O
(	O
IBV	O
)	O
as	O
a	O
model	O
to	O
study	O
EIC	O
.	O

EIC	O
-	O
defective	O
mutants	O
also	O
formed	O
smaller	O
plaques	B-DISO
,	O
released	O
significantly	O
less	O
infectious	B-DISO
virions	O
into	O
the	O
culture	O
supernatant	O
,	O
and	O
had	O
lower	O
levels	O
of	O
viral	O
fitness	O
in	O
cell	O
culture	O
.	O

Significant	O
complications	O
include	O
variceal	O
bleeding	B-DISO
,	O
hepatic	B-DISO
encephalopathy	I-DISO
,	O
hepatorenal	B-DISO
syndrome	I-DISO
,	O
and	O
infection	B-DISO
.	O

It	O
identifies	O
key	O
behavioural	O
risk	O
factors	O
that	O
can	O
be	O
targeted	O
for	O
development	O
of	O
tailored	O
risk	O
-	O
mitigation	O
strategies	O
to	O
reduce	O
the	O
threat	O
of	O
novel	O
zoonoses	B-DISO
.	O

In	O
addition	O
,	O
novel	O
pathogens	O
including	O
zoonotic	O
coronaviruses	O
like	O
the	O
agents	O
causing	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
),	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
and	O
the	O
2019	O
novel	O
coronavirus	O
(	O
2019	O
nCoV	O
)	O
are	O
still	O
being	O
identified	O
.	O

Oseltamivir	O
is	O
the	O
most	O
widely	O
used	O
neuraminidase	O
inhibitor	O
for	O
treatment	O
of	O
influenza	B-DISO
;	O
data	O
suggest	O
that	O
early	O
use	O
is	O
associated	O
with	O
reduced	O
mortality	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
influenza	B-DISO
.	O

TITLE	O
:	O
Dexamethasone	O
treatment	O
for	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
a	O
multicentre	O
,	O
randomised	O
controlled	O
trial	O
.	O

TITLE	O
:	O
Functional	O
respiratory	O
imaging	O
of	O
the	O
airways	O
in	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Immunoglobulin	O
G	O
was	O
delivered	O
to	O
some	O
critically	B-DISO
ill	I-DISO
patients	O
according	O
to	O
their	O
conditions	O
.	O

The	O
risk	O
of	O
death	O
was	O
primarily	O
associated	O
with	O
age	O
,	O
underlying	O
chronic	B-DISO
diseases	I-DISO
,	O
and	O
median	O
interval	O
from	O
the	O
appearance	O
of	O
initial	O
symptoms	O
to	O
dyspnea	B-DISO
.	O

As	O
this	O
bivalent	O
binding	O
may	O
enable	O
broad	O
zoonotic	O
CoV	O
infection	B-DISO
,	O
we	O
aimed	O
to	O
identify	O
roles	O
for	O
each	O
receptor	O
in	O
distinct	O
infection	B-DISO
stages	O
.	O

In	O
this	O
paper	O
,	O
the	O
authors	O
introduce	O
their	O
experience	O
on	O
treating	O
severe	O
2019	O
-	O
nCoV	O
pneumonia	B-DISO
,	O
it	O
is	O
hopeful	O
for	O
current	O
fighting	O
against	O
2019	O
-	O
nCoV	O
in	O
China	O
.	O

A	O
Maximum	O
Clade	O
Credibility	O
tree	O
has	O
been	O
built	O
using	O
the	O
29	O
available	O
whole	O
genome	O
sequences	O
of	O
2019	O
-	O
nCoV	O
and	O
two	O
whole	O
genome	O
sequences	O
that	O
are	O
highly	O
similar	O
sequences	O
from	O
Bat	O
SARS	B-DISO
-	O
like	O
Coronavirus	O
available	O
in	O
GeneBank	O
.	O

TITLE	O
:	O
Facilitating	O
ventilator	O
weaning	O
through	O
rib	O
fixation	O
combined	O
with	O
video	O
-	O
assisted	O
thoracoscopic	O
surgery	O
in	O
severe	O
blunt	O
chest	O
injury	O
with	O
acute	B-DISO
respiratory	I-DISO
failure	I-DISO
.	O

The	O
rate	O
of	O
pneumonia	B-DISO
was	O
higher	O
in	O
group	O
2	O
(	O
38	O
.	O
1	O
%	O
vs	O
.	O
75	O
.	O
0	O
%,	O
P	O
=	O
0	O
.	O
005	O
).	O

CONCLUSIONS	O
:	O
Rib	O
fixation	O
combined	O
with	O
VATS	O
could	O
shorten	O
the	O
length	O
of	O
ventilator	O
use	O
and	O
reduce	O
the	O
pneumonia	B-DISO
rate	O
in	O
patients	O
with	O
severe	O
chest	O
blunt	O
injury	O
with	O
ARF	B-DISO
.	O

TITLE	O
:	O
[	O
Emergency	B-DISO
response	O
plan	B-DISO
for	O
the	O
neonatal	O
intensive	O
care	O
unit	O
during	O
epidemic	O
of	O
2019	O
novel	O
coronavirus	O
].	O

ABSTRACT	O
:	O
2019	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
)	O
infection	B-DISO
has	O
been	O
spreading	O
in	O
China	O
since	O
December	O
2019	O
.	O

The	O
emergency	B-DISO
response	O
plan	B-DISO
enables	O
the	O
efficient	O
response	O
capability	O
of	O
NICU	O
.	O

TITLE	O
:	O
[	O
Recommendation	O
for	O
the	O
diagnosis	O
and	O
treatment	O
of	O
novel	O
coronavirus	B-DISO
infection	I-DISO
in	O
children	O
in	O
Hubei	O
(	O
Trial	O
version	O
1	O
)].	O

We	O
suggest	O
that	O
the	O
nutritional	O
status	O
of	O
each	O
infected	O
patient	O
should	O
be	O
evaluated	O
before	O
the	O
administration	O
of	O
general	O
treatments	O
and	O
the	O
current	O
children	O
'	O
s	O
RNA	O
-	O
virus	O
vaccines	O
including	O
influenza	B-DISO
vaccine	O
should	O
be	O
immunized	O
for	O
uninfected	O
people	O
and	O
health	O
care	O
workers	O
.	O

Purpose	O
To	O
determine	O
the	O
change	O
in	O
chest	O
CT	O
findings	O
associated	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pneumonia	I-DISO
from	O
initial	O
diagnosis	O
until	O
patient	O
recovery	O
.	O

Based	O
on	O
quartiles	O
of	O
patients	O
from	O
day	O
0	O
to	O
day	O
26	O
involvement	O
,	O
4	O
stages	O
of	O
lung	O
CT	O
were	O
defined	O
:	O
Stage	O
1	O
(	O
0	O
-	O
4	O
days	O
):	O
ground	O
glass	O
opacities	B-DISO
(	O
GGO	O
)	O
in	O
18	O
/	O
24	O
(	O
75	O
%)	O
patients	O
with	O
the	O
total	O
CT	O
score	O
of	O
2	O
±	O
2	O
;	O
(	O
2	O
)	O
Stage	O
-	O
2	O
(	O
5	O
-	O
8d	O
days	O
):	O
increased	O
crazy	O
-	O
paving	O
pattern	O
9	O
/	O
17	O
patients	O
(	O
53	O
%)	O
with	O
a	O
increase	O
in	O
total	O
CT	O
score	O
(	O
6	O
±	O
4	O
,	O
p	O
=	O
0	O
.	O
002	O
);	O
(	O
3	O
)	O
Stage	O
-	O
3	O
(	O
9	O
-	O
13days	O
):	O
consolidation	O
19	O
/	O
21	O
(	O
91	O
%)	O
patients	O
with	O
the	O
peak	O
of	O
total	O
CT	O
score	O
(	O
7	O
±	O
4	O
);	O
(	O
4	O
)	O
Stage	O
-	O
4	O
(≥	O
14	O
days	O
):	O
gradual	O
resolution	O
of	O
consolidation	O
15	O
/	O
20	O
(	O
75	O
%)	O
patients	O
with	O
a	O
decreased	O
total	O
CT	O
score	O
(	O
6	O
±	O
4	O
)	O
without	O
crazy	O
-	O
paving	O
pattern	O
.	O

Guided	O
by	O
CDC	O
criteria	O
for	O
the	O
evaluation	O
of	O
persons	O
under	O
investigation	O
(	O
PUIs	O
)	O
(	O
5	O
),	O
210	O
symptomatic	O
persons	O
were	O
tested	O
for	O
2019	O
-	O
nCoV	O
;	O
among	O
these	O
persons	O
,	O
148	O
(	O
70	O
%)	O
had	O
travel	O
-	O
related	O
risk	O
only	O
,	O
42	O
(	O
20	O
%)	O
had	O
close	O
contact	O
with	O
an	O
ill	B-DISO
laboratory	O
-	O
confirmed	O
2019	O
-	O
nCoV	O
patient	O
or	O
PUI	O
,	O
and	O
18	O
(	O
9	O
%)	O
had	O
both	O
travel	O
-	O
and	O
contact	O
-	O
related	O
risks	O
.	O

ABSTRACT	O
:	O
Respiratory	O
virome	O
is	O
an	O
integral	O
part	O
of	O
the	O
human	O
microbiome	O
and	O
its	O
characterization	O
may	O
contribute	O
to	O
a	O
better	O
understanding	O
of	O
the	O
changes	O
that	O
arise	O
in	O
the	O
disease	O
and	O
,	O
consequently	O
,	O
influence	O
the	O
approach	O
and	O
treatment	O
of	O
patients	O
with	O
acute	O
lower	O
respiratory	B-DISO
infections	I-DISO
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
presence	O
of	O
respiratory	O
viruses	O
in	O
the	O
lower	O
airways	O
of	O
individuals	O
undergoing	O
invasive	O
mechanical	O
ventilation	O
,	O
with	O
and	O
without	O
acute	O
lower	B-DISO
respiratory	I-DISO
infection	I-DISO
(	O
respectively	O
WRI	O
and	O
WORI	O
groups	O
).	O

Imaging	O
changes	O
in	O
novel	O
viral	B-DISO
pneumonia	I-DISO
are	O
rapid	O
.	O

•	O
High	O
-	O
resolution	O
CT	O
(	O
HRCT	O
)	O
of	O
the	O
chest	O
is	O
critical	O
for	O
early	O
detection	O
,	O
evaluation	O
of	O
disease	O
severity	O
and	O
follow	O
-	O
up	O
of	O
patients	O
with	O
the	O
novel	O
coronavirus	O
pneumonia	B-DISO
.	O

•	O
The	O
manifestations	O
of	O
the	O
novel	O
coronavirus	O
pneumonia	B-DISO
are	O
diverse	O
and	O
change	O
rapidly	O
.	O

However	O
,	O
data	O
are	O
scarce	O
regarding	O
its	O
use	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
its	O
feasibility	O
and	O
clinical	O
usefulness	O
in	O
moderate	O
-	O
severe	O
ARDS	B-DISO
patients	O
.	O

ROC	O
curve	O
analysis	O
showed	O
that	O
lateral	O
,	O
inferior	O
,	O
global	O
(	O
average	O
of	O
the	O
3	O
RV	O
walls	O
)	O
longitudinal	O
systolic	O
strain	O
(	O
LSS	B-DISO
)	O
and	O
global	O
strain	O
rate	O
demonstrated	O
significant	O
diagnostic	O
values	O
when	O
compared	O
to	O
several	O
conventional	O
indices	O
(	O
TAPSE	O
,	O
S	O
',	O
RV	O
FAC	B-DISO
).	O

RESULTS	O
:	O
Among	O
1421	O
patients	O
enrolled	O
,	O
influenza	B-DISO
virus	O
was	O
detected	O
in	O
535	O
(	O
38	O
%),	O
and	O
NIRV	O
in	O
215	O
(	O
15	O
%),	O
mostly	O
picornavirus	O
(	O
n	O
=	O
61	O
),	O
RSV	O
(	O
n	O
=	O
53	O
),	O
coronavirus	O
229E	O
(	O
n	O
=	O
48	O
),	O
and	O
human	O
metapneumovirus	O
(	O
n	O
=	O
40	O
).	O

TITLE	O
:	O
Novel	O
Coronavirus	O
Pneumonia	B-DISO
Outbreak	O
in	O
2019	O
:	O
Computed	O
Tomographic	O
Findings	O
in	O
Two	O
Cases	O
.	O

As	O
secondary	O
transmissions	O
have	O
occurred	O
and	O
the	O
speed	O
of	O
transmission	O
is	O
accelerating	O
,	O
there	O
are	O
rising	O
concerns	O
about	O
community	O
infections	B-DISO
.	O

TITLE	O
:	O
Systemic	O
BK	B-DISO
Virus	I-DISO
Infection	I-DISO
in	O
a	O
Pediatric	O
Patient	O
With	O
Severe	B-DISO
Combined	I-DISO
Immunodeficiency	I-DISO
.	O

Coronavirus	O
has	O
caused	O
several	O
epidemic	O
situations	O
world	O
widely	O
,	O
but	O
the	O
present	O
contagious	B-DISO
disease	I-DISO
caused	O
by	O
2019	O
new	O
Coronavirus	O
is	O
unprecedentedly	O
fulminating	O
.	O

Despite	O
a	O
high	O
similarity	O
with	O
the	O
genome	O
sequence	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
SARS	B-DISO
-	O
like	O
CoVs	O
,	O
we	O
identified	O
a	O
peculiar	O
furin	O
-	O
like	O
cleavage	O
site	O
in	O
the	O
Spike	O
protein	O
of	O
the	O
2019	O
-	O
nCoV	O
,	O
lacking	O
in	O
the	O
other	O
SARS	B-DISO
-	O
like	O
CoVs	O
.	O

Since	O
their	O
trading	O
provides	O
a	O
potential	O
risk	O
for	O
spreading	O
zoonoses	B-DISO
,	O
a	O
change	O
in	O
these	O
practices	O
is	O
highly	O
recommended	O
.	O

ACE2	O
plays	O
an	O
important	O
role	O
in	O
the	O
RAS	O
,	O
and	O
the	O
imbalance	B-DISO
between	O
ACE	O
/	O
Ang	O
II	O
/	O
AT1R	O
pathway	O
and	O
ACE2	O
/	O
Ang	O
(	O
1	O
-	O
7	O
)/	O
Mas	B-DISO
receptor	O
pathway	O
in	O
the	O
RAS	O
system	O
will	O
lead	O
to	O
multi	O
-	O
system	O
inflammation	B-DISO
.	O

The	O
binding	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
and	O
ACE2	O
resulted	O
in	O
the	O
exhaustion	B-DISO
of	O
ACE2	O
,	O
and	O
then	O
ACE2	O
/	O
Ang	O
(	O
1	O
-	O
7	O
)/	O
Mas	B-DISO
receptor	O
pathway	O
was	O
inhibited	O
.	O

Additionally	O
we	O
explored	O
spatio	O
-	O
temporal	O
patterns	O
of	O
virus	O
occurrence	O
in	O
Canis	O
lupus	B-DISO
.	O

Although	O
China	O
has	O
made	O
great	O
efforts	O
to	O
strengthen	O
the	O
ability	O
to	O
quickly	O
respond	O
to	O
public	O
health	O
emergencies	B-DISO
since	O
the	O
SARS	B-DISO
outbreak	O
in	O
2003	O
and	O
it	O
has	O
clarified	O
requirements	O
for	O
emergency	B-DISO
supplies	O
through	O
legislation	O
,	O
the	O
emergency	B-DISO
reserve	O
supplies	O
program	O
has	O
not	O
been	O
effectively	O
implemented	O
,	O
and	O
there	O
are	O
also	O
deficiencies	O
in	O
the	O
types	O
,	O
quantity	O
,	O
and	O
availability	O
of	O
emergency	B-DISO
medical	O
supplies	O
.	O

TITLE	O
:	O
Role	O
of	O
Neuromuscular	O
Blocking	B-DISO
Agents	O
in	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
:	O
An	O
Updated	O
Meta	O
-	O
Analysis	O
of	O
Randomized	O
Controlled	O
Trials	O
.	O

TITLE	O
:	O
[	O
Analysis	O
of	O
the	O
first	O
cluster	O
of	O
cases	O
in	O
a	O
family	O
of	O
novel	O
coronavirus	O
pneumonia	B-DISO
in	O
Gansu	O
Province	O
].	O

Except	O
for	O
the	O
discharged	O
cases	O
,	O
5	O
cases	O
were	O
positive	O
for	O
COVID	B-DISO
-	I-DISO
19	I-DISO
specific	O
IgM	O
antibody	O
and	O
1	O
case	O
was	O
negative	O
.	O

ABSTRACT	O
:	O
In	O
December	O
2019	O
,	O
novel	O
coronavirus	O
pneumonia	B-DISO
epidemic	O
occurred	O
in	O
Wuhan	O
,	O
Hubei	O
Province	O
,	O
and	O
spread	O
rapidly	O
across	O
the	O
country	O
.	O

The	O
infection	B-DISO
rate	O
of	O
H1N1	B-DISO
influenza	I-DISO
in	O
the	O
CM	O
group	O
was	O
significantly	O
lower	O
than	O
the	O
non	O
-	O
CM	O
group	O
(	O
relative	O
risk	O
0	O
.	O
36	O
,	O
95	O
%	O
confidence	O
interval	O
0	O
.	O
24	O
-	O
0	O
.	O
52	O
;	O
n	O
=	O
4	O
).	O

Based	O
on	O
historical	O
records	O
and	O
human	O
evidence	O
of	O
SARS	B-DISO
and	O
H1N1	B-DISO
influenza	I-DISO
prevention	O
,	O
Chinese	O
herbal	O
formula	O
could	O
be	O
an	O
alternative	O
approach	O
for	O
prevention	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
high	O
-	O
risk	O
population	O
.	O

RESULTS	O
:	O
The	O
use	O
of	O
CM	O
to	O
prevent	O
epidemics	O
of	O
infectious	B-DISO
diseases	I-DISO
was	O
traced	O
back	O
to	O
ancient	O
Chinese	O
practice	O
cited	O
in	O
Huangdi	O
'	O
s	O
Internal	O
Classic	O
(	O
Huang	O
Di	O
Nei	O
Jing	O
)	O
where	O
preventive	O
effects	O
were	O
recorded	O
.	O

The	O
radiological	O
and	O
partial	O
pressure	O
of	O
oxygen	O
,	O
arterial	O
(	O
Pao2	O
)/	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
Fio2	O
)	O
criteria	O
for	O
ARDS	B-DISO
had	O
to	O
be	O
met	O
within	O
a	O
24	O
-	O
hour	O
period	O
,	O
and	O
the	O
administration	O
of	O
the	O
first	O
dose	O
of	O
the	O
study	O
drug	O
had	O
to	O
occur	O
within	O
48	O
hours	O
of	O
the	O
diagnosis	O
of	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Effect	O
of	O
TLR	O
agonist	O
on	O
infections	B-DISO
bronchitis	B-DISO
virus	O
replication	O
and	O
cytokine	O
expression	O
in	O
embryonated	O
chicken	O
eggs	O
.	O

The	O
toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
are	O
a	O
major	O
class	O
of	O
innate	O
immune	O
pattern	O
recognition	O
receptors	O
that	O
have	O
a	O
key	O
role	O
in	O
immune	O
response	O
and	O
defense	O
against	O
various	O
infections	B-DISO
.	O

TITLE	O
:	O
Fatal	O
encephalitis	B-DISO
associated	O
with	O
coronavirus	O
OC43	O
in	O
an	O
immunocompromised	O
child	O
.	O

In	O
ARDS	B-DISO
patients	O
,	O
a	O
trial	O
assessing	O
the	O
effects	O
of	O
a	O
driving	O
pressure	O
-	O
limited	O
strategy	O
using	O
very	O
low	O
tidal	O
volumes	O
versus	O
a	O
conventional	O
ventilation	O
strategy	O
on	O
clinical	O
outcomes	O
is	O
feasible	O
.	O

Postobstructive	O
pulmonary	B-DISO
edema	I-DISO
,	O
also	O
known	O
as	O
negative	B-DISO
pressure	I-DISO
pulmonary	I-DISO
edema	I-DISO
,	O
can	O
result	O
in	O
severe	O
respiratory	O
compromise	O
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Three	O
cases	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
were	O
confirmed	O
on	O
24	O
January	O
,	O
the	O
first	O
cases	O
in	O
Europe	O
.	O

Receptor	O
-	O
interacting	O
protein	O
3	O
(	O
RIPK3	O
)	O
regulates	O
a	O
newly	O
discovered	O
programmed	O
form	O
of	O
necrosis	O
called	O
necroptosis	B-DISO
.	O

Focusing	O
on	O
the	O
health	O
emergency	B-DISO
scenario	O
of	O
severe	O
virus	O
infectious	B-DISO
diseases	I-DISO
and	O
atypical	O
places	O
where	O
NPC	B-DISO
patients	O
with	O
mild	O
symptom	B-DISO
gather	O
,	O
from	O
perspectives	O
of	O
functional	O
zones	O
,	O
hygiene	O
facilities	O
,	O
personal	O
protection	O
,	O
and	O
management	O
system	O
,	O
health	O
risk	O
protection	O
recommendations	O
and	O
countermeasures	O
are	O
comprehensively	O
proposed	O
to	O
mainly	O
protect	O
staffs	O
and	O
surrounding	O
environment	O
.	O

Antibodies	O
against	O
common	O
HCoV	O
strains	O
were	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
neutralization	O
assay	O
comparing	O
older	O
adults	O
with	O
cardiopulmonary	B-DISO
diseases	I-DISO
(	O
99	O
subjects	O
)	O
to	O
younger	O
,	O
healthy	O
adults	O
(	O
101	O
subjects	O
).	O

Functional	O
neutralizing	O
antibodies	O
were	O
not	O
stimulated	O
as	O
often	O
as	O
binding	O
antibodies	O
,	O
explaining	O
in	O
part	O
a	O
susceptibility	O
to	O
reinfection	O
with	O
HCoV	O
.	O
Monitoring	O
binding	O
antibodies	O
may	O
be	O
more	O
sensitive	O
for	O
the	O
serologic	O
detection	O
of	O
HCoV	O
infections	B-DISO
.	O

As	O
of	O
8	O
February	O
2020	O
,	O
the	O
assays	O
developed	O
have	O
successfully	O
detected	O
25	O
positive	O
cases	O
of	O
infection	B-DISO
in	O
Japan	O
.	O

The	O
radical	O
operation	O
of	O
colorectal	B-DISO
cancer	I-DISO
is	O
confine	O
operation	O
.	O

Patients	O
with	O
colorectal	B-DISO
cancer	I-DISO
should	O
receive	O
operation	O
as	O
soon	O
as	O
possible	O
after	O
elective	O
operation	O
is	O
resumed	O
in	O
each	O
hospital	O
.	O

Based	O
onLaparoscopic	O
colorectal	O
operation	O
experiences	O
,	O
the	O
author	O
suggests	O
that	O
the	O
surgery	O
strategy	O
for	O
colorectal	B-DISO
cancer	I-DISO
patients	O
under	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
situation	O
.	O

TITLE	O
:	O
[	O
Treatment	O
strategy	O
for	O
gastrointestinal	B-DISO
tumor	I-DISO
under	O
the	O
outbreak	O
of	O
novel	O
coronavirus	O
pneumonia	B-DISO
in	O
China	O
].	O

For	O
colorectal	O
malignancy	B-DISO
with	O
simple	O
intestinal	B-DISO
obstruction	I-DISO
,	O
stent	O
placement	O
can	O
achieve	O
a	O
high	O
success	O
rate	O
,	O
which	O
not	O
only	O
helps	O
avoid	O
emergency	B-DISO
surgery	O
,	O
but	O
also	O
creates	O
a	O
better	O
condition	B-DISO
for	O
subsequent	O
surgery	O
.	O

However	O
,	O
emergency	B-DISO
operation	O
still	O
must	O
be	O
performed	O
for	O
patients	O
with	O
acute	O
uncontrolled	O
bleeding	B-DISO
,	O
obstruction	B-DISO
or	O
after	O
other	O
alternative	O
treatment	O
measures	O
fail	O
.	O

Fever	O
after	O
surgery	O
must	O
be	O
carefully	O
differentiated	O
whether	O
it	O
'	O
s	O
caused	O
by	O
post	O
-	O
surgery	O
abdominal	B-DISO
infection	I-DISO
/	O
inflammation	B-DISO
or	O
NCP	O
.	O

ABSTRACT	O
:	O
The	O
exported	O
cases	O
of	O
2019	O
novel	O
coronavirus	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
infection	B-DISO
that	O
were	O
confirmed	O
outside	O
China	O
provide	O
an	O
opportunity	O
to	O
estimate	O
the	O
cumulative	O
incidence	O
and	O
confirmed	O
case	O
fatality	O
risk	O
(	O
cCFR	O
)	O
in	O
mainland	O
China	O
.	O

62	O
patients	O
admitted	O
to	O
hospital	O
with	O
laboratory	O
confirmed	O
SARS	B-DISO
-	I-DISO
Cov	I-DISO
-	I-DISO
2	I-DISO
infection	I-DISO
.	O

An	O
approximately	O
1	O
:	O
1	O
ratio	O
of	O
male	O
(	O
50	O
.	O
7	O
%)	O
and	O
female	O
COVID	B-DISO
-	I-DISO
19	I-DISO
patients	O
was	O
found	O
,	O
with	O
an	O
overall	O
median	O
age	O
of	O
57	O
.	O
0	O
years	O
.	O

Chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
COPD	B-DISO
,	O
1	O
.	O
4	O
%)	O
patients	O
and	O
current	O
smokers	O
(	O
1	O
.	O
4	O
%)	O
were	O
rare	O
.	O

TITLE	O
:	O
[	O
Clinical	O
Management	O
of	O
Lung	B-DISO
Cancer	I-DISO
Patients	O
during	O
the	O
Outbreak	O
of	O
2019	B-DISO
Novel	I-DISO
Coronavirus	I-DISO
Disease	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)].	O

ABSTRACT	O
:	O
For	O
effective	O
resistance	O
to	O
virus	O
attack	O
and	O
infection	B-DISO
,	O
reducing	O
virus	O
transmission	O
chance	O
,	O
it	O
is	O
extremely	O
important	O
for	O
the	O
medical	O
staff	O
and	O
related	O
workers	O
to	O
have	O
their	O
own	O
safe	O
protection	O
.	O

TITLE	O
:	O
[	O
Technologies	O
and	O
requirements	O
of	O
protection	O
and	O
disinfection	O
in	O
key	O
places	O
during	O
the	O
novel	O
coronavirus	O
pneumonia	B-DISO
(	O
NCP	O
)	O
outbreak	O
].	O

ABSTRACT	O
:	O
Novel	O
coronavirus	O
pneumonia	B-DISO
(	O
NCP	O
),	O
a	O
new	O
respiratory	O
infectious	B-DISO
disease	I-DISO
,	O
has	O
become	O
an	O
important	O
public	O
health	O
problem	O
.	O

ABSTRACT	O
:	O
The	O
prevention	O
and	O
control	O
of	O
novel	O
coronavirus	O
pneumonia	B-DISO
(	O
NCP	O
)	O
has	O
already	O
entered	O
a	O
key	O
period	O
.	O

The	O
patients	O
treated	O
in	O
the	O
burn	O
and	O
wound	O
care	O
ward	O
are	O
susceptible	O
to	O
viral	B-DISO
infection	I-DISO
because	O
of	O
disease	O
,	O
age	O
and	O
other	O
factors	O
,	O
so	O
it	O
is	O
very	O
important	O
to	O
manage	O
the	O
burn	O
and	O
wound	O
care	O
ward	O
during	O
the	O
prevention	O
and	O
control	O
of	O
NCP	O
epidemic	O
.	O

Current	O
data	O
do	O
not	O
support	O
the	O
routine	O
use	O
of	O
corticosteroids	O
in	O
patients	O
with	O
influenza	B-DISO
severe	O
pneumonia	B-DISO
or	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Viral	O
Load	O
Kinetics	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
-	I-DISO
2	I-DISO
Infection	I-DISO
in	O
First	O
Two	O
Patients	O
in	O
Korea	O
.	O

This	O
report	O
suggests	O
that	O
viral	O
load	O
kinetics	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
may	O
be	O
different	O
from	O
that	O
of	O
previously	O
reported	O
other	O
coronavirus	B-DISO
infections	I-DISO
such	O
as	O
SARS	B-DISO
-	O
CoV	O
.	O

TITLE	O
:	O
[	O
Emergency	B-DISO
management	O
of	O
prevention	O
and	O
control	O
of	O
novel	O
coronavirus	O
pneumonia	B-DISO
in	O
departments	O
of	O
stomatology	O
].	O

On	O
30	O
January	O
2020	O
,	O
the	O
WHO	O
declared	O
COVID	B-DISO
-	I-DISO
19	I-DISO
as	O
the	O
sixth	O
public	O
health	O
emergency	B-DISO
of	O
international	O
concern	O
.	O

SARS	B-DISO
-	O
CoV	O
-	O
2	O
is	O
closely	O
related	O
to	O
two	O
bat	O
-	O
derived	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
-	O
like	O
coronaviruses	O
,	O
bat	O
-	O
SL	O
-	O
CoVZC45	O
and	O
bat	O
-	O
SL	O
-	O
CoVZXC21	O
.	O

ABSTRACT	O
:	O
Last	O
December	O
2019	O
,	O
a	O
new	O
virus	O
,	O
named	O
novel	O
Coronavirus	O
(	O
COVID	O
-	O
2019	O
)	O
causing	O
many	O
cases	O
of	O
severe	O
pneumonia	B-DISO
was	O
reported	O
in	O
Wuhan	O
,	O
China	O
.	O

A	O
significant	O
proportion	O
of	O
HCWs	O
expressed	O
anxiety	O
about	O
the	O
risk	O
of	O
acquiring	O
MERS	O
-	O
CoV	O
infection	B-DISO
.	O

Referring	O
to	O
the	O
""""	O
Diagnosis	O
and	O
Treatment	O
Scheme	O
for	O
NCP	O
(	O
Trial	O
Version	O
4	O
and	O
5	O
")"""	O
and	O
combining	O
the	O
actual	O
practice	O
situation	O
in	O
our	O
hospital	O
with	O
the	O
""""	O
Summary	O
of	O
New	O
Coronavirus	O
Files	O
of	O
Shanghai	O
Renji	O
Hospital	O
""","	O
we	O
summarize	O
how	O
to	O
carry	O
out	O
the	O
clinical	O
practice	O
of	O
colorectal	O
surgery	O
under	O
the	O
situation	O
of	O
the	O
prevention	O
and	O
control	O
of	O
the	O
NCP	O
epidemiology	O
,	O
meanwhile	O
under	O
such	O
situation	O
aiming	O
the	O
procedure	O
of	O
diagnose	O
and	O
treatment	O
for	O
emergency	B-DISO
patients	O
with	O
colorectal	B-DISO
tumor	I-DISO
,	O
we	O
share	O
the	O
experiences	O
of	O
the	O
diagnosis	O
of	O
colorectal	B-DISO
tumor	I-DISO
,	O
the	O
management	O
of	O
patients	O
with	O
colorectal	B-DISO
cancer	I-DISO
who	O
are	O
scheduled	O
to	O
be	O
admitted	O
for	O
surgery	O
,	O
the	O
protection	O
of	O
wards	O
,	O
the	O
perioperative	O
management	O
.	O

(	O
2	O
)	O
Colonoscopy	O
examination	O
may	O
cause	O
cross	B-DISO
infection	I-DISO
of	O
NCP	O
to	O
patients	O
and	O
doctors	O
.	O

Through	O
literature	O
review	O
,	O
this	O
paper	O
reviewed	O
the	O
oral	O
psychosomatic	O
diseases	O
closely	O
related	O
to	O
patients	O
'	O
psychological	B-DISO
state	O
,	O
such	O
as	O
oral	O
mucosal	O
disease	B-DISO
,	I-DISO
temporomandibular	I-DISO
joint	I-DISO
disease	O
,	O
bruxism	B-DISO
,	O
periodontal	B-DISO
disease	I-DISO
and	O
so	O
on	O
.	O

TITLE	O
:	O
The	O
SARS	B-DISO
,	O
MERS	O
and	O
novel	O
coronavirus	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
epidemics	O
,	O
the	O
newest	O
and	O
biggest	O
global	O
health	O
threats	O
:	O
what	O
lessons	O
have	O
we	O
learned	O
?	O

Utilizing	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
CDC	O
,	O
USA	O
)	O
website	O
,	O
and	O
a	O
comprehensive	O
review	O
of	O
PubMed	O
literature	O
,	O
we	O
obtained	O
information	O
regarding	O
clinical	O
signs	B-DISO
and	I-DISO
symptoms	I-DISO
,	O
treatment	O
and	O
diagnosis	O
,	O
transmission	O
methods	O
,	O
protection	O
methods	O
and	O
risk	O
factors	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
),	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
and	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

The	O
management	O
and	O
control	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
importations	O
heavily	O
rely	O
on	O
a	O
country	O
'	O
s	O
health	O
capacity	O
.	O

We	O
determined	O
the	O
country	O
'	O
s	O
capacity	O
to	O
detect	O
and	O
respond	O
to	O
cases	O
with	O
two	O
indicators	O
:	O
preparedness	O
,	O
using	O
the	O
WHO	O
International	O
Health	O
Regulations	O
Monitoring	O
and	O
Evaluation	O
Framework	O
;	O
and	O
vulnerability	O
,	O
using	O
the	O
Infectious	B-DISO
Disease	I-DISO
Vulnerability	O
Index	O
.	O

We	O
wished	O
to	O
determine	O
the	O
frequency	O
and	O
patterns	O
of	O
use	O
of	O
adjunctive	O
strategies	O
in	O
patients	O
with	O
moderate	O
-	O
severe	O
ARDS	B-DISO
(	O
P	O
/	O
F	O
ratio	O
<	O
150	O
)	O
enrolled	O
into	O
the	O
Large	O
observational	O
study	O
to	O
UNderstand	O
the	O
Global	O
impact	O
of	O
Severe	O
Acute	B-DISO
respiratory	I-DISO
FailurE	I-DISO
(	O
LUNG	O
SAFE	O
)	O
study	O
.	O

The	O
primary	O
objective	O
of	O
this	O
substudy	O
was	O
to	O
determine	O
the	O
frequency	O
of	O
use	O
of	O
widely	O
available	O
(	O
neuromuscular	B-DISO
blockade	I-DISO
,	O
prone	O
position	O
)	O
adjuncts	O
versus	O
adjuncts	O
requiring	O
specialized	O
equipment	O
(	O
ECMO	O
,	O
Inhaled	O
vasodilators	O
,	O
HFOV	O
)	O
in	O
patients	O
in	O
the	O
first	O
48	O
hours	O
of	O
moderate	O
-	O
severe	O
ARDS	B-DISO
(	O
P	O
/	O
F	O
ratio	O
<	O
150	O
).	O

RESULTS	O
:	O
Of	O
1	O
,	O
151	O
invasively	O
ventilated	O
patients	O
with	O
moderate	O
-	O
severe	O
ARDS	B-DISO
,	O
818	O
pts	O
(	O
71	O
%)	O
received	O
no	O
adjunct	O
within	O
48h	O
of	O
ARDS	B-DISO
onset	O
.	O

TITLE	O
:	O
Lessons	O
learned	O
from	O
the	O
2019	O
-	O
nCoV	O
epidemic	O
on	O
prevention	O
of	O
future	O
infectious	B-DISO
diseases	I-DISO
.	O

According	O
to	O
current	O
information	O
,	O
an	O
exceptionally	O
wide	O
contamination	O
of	O
seafood	O
market	O
might	O
explain	O
the	O
initiation	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
outbreak	O
.	O

TITLE	O
:	O
Coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
:	O
Implications	O
of	O
emerging	O
infections	B-DISO
for	O
transplantation	O
.	O

Our	O
work	O
underscores	O
the	O
need	O
for	O
measures	O
to	O
limit	O
transmission	O
by	O
individuals	O
who	O
become	O
ill	B-DISO
after	O
being	O
missed	O
by	O
a	O
screening	O
program	O
.	O

Study	O
sample	O
consisted	O
of	O
80	O
patients	O
diagnosed	O
as	O
COVID	B-DISO
-	I-DISO
19	I-DISO
from	O
January	O
to	O
February	O
2020	O
.	O

The	O
most	O
frequent	O
CT	O
abnormalities	O
observed	O
were	O
ground	O
glass	O
opacity	B-DISO
(	O
GGO	O
)	O
(	O
73	O
/	O
80	O
cases	O
,	O
91	O
%),	O
consolidation	O
(	O
50	O
/	O
80	O
cases	O
,	O
63	O
%)	O
and	O
interlobular	O
septal	O
thickening	O
(	O
47	O
/	O
80	O
,	O
59	O
%).	O

The	O
average	O
pulmonary	B-DISO
inflammation	I-DISO
index	O
(	O
PII	O
)	O
value	O
was	O
(	O
34	O
%±	O
20	O
%)	O
for	O
all	O
the	O
patients	O
.	O

TITLE	O
:	O
Coronavirus	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
Outbreak	O
:	O
What	O
the	O
Department	O
of	O
Radiology	O
Should	O
Know	O
.	O

The	O
purpose	O
of	O
the	O
present	O
review	O
is	O
to	O
briefly	O
discuss	O
the	O
known	O
epidemiology	O
and	O
the	O
imaging	O
findings	O
of	O
coronavirus	O
syndromes	B-DISO
,	O
with	O
a	O
focus	O
on	O
the	O
reported	O
imaging	O
findings	O
of	O
NCIP	O
.	O

TITLE	O
:	O
Genetic	O
diversity	O
and	O
evolution	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
.	O

The	O
World	O
Health	O
Organization	O
declared	O
the	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
outbreak	O
a	O
global	O
public	O
health	O
emergency	B-DISO
.	O

We	O
performed	O
genetic	O
analyses	O
of	O
eighty	O
-	O
six	O
complete	O
or	O
near	O
-	O
complete	O
genomes	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
and	O
revealed	O
many	O
mutations	O
and	O
deletions	O
on	O
coding	O
and	O
non	O
-	O
coding	O
regions	O
.	O

TITLE	O
:	O
Is	O
COVID	B-DISO
-	I-DISO
19	I-DISO
receiving	O
ADE	O
from	O
other	O
coronaviruses	O
?	O

TITLE	O
:	O
Rigidity	B-DISO
of	O
the	O
Outer	O
Shell	O
Predicted	O
by	O
a	O
Protein	O
Intrinsic	O
Disorder	O
Model	O
Sheds	O
Light	O
on	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
(	O
Wuhan	O
-	O
2019	O
-	O
nCoV	O
)	O
Infectivity	O
.	O

A	O
novel	O
coronavirus	O
,	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
,	O
was	O
identified	O
to	O
be	O
accountable	O
for	O
this	O
disease	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
),	O
one	O
of	O
the	O
causes	O
of	O
the	O
common	B-DISO
cold	I-DISO
,	O
exacerbates	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
COPD	B-DISO
)	O
and	O
bronchial	B-DISO
asthma	I-DISO
.	O

Remdesivir	O
(	O
RDV	O
)	O
is	O
an	O
investigational	O
compound	O
with	O
a	O
broad	O
spectrum	O
of	O
antiviral	O
activities	O
against	O
RNA	O
viruses	O
,	O
including	O
SARS	B-DISO
-	O
CoV	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
-	O
CoV	O
).	O

As	O
the	O
National	O
Clinical	O
Research	O
Center	O
for	O
Infectious	B-DISO
Diseases	I-DISO
,	O
the	O
First	O
Affiliated	O
Hospital	O
of	O
Zhejiang	O
University	O
School	O
of	O
Medicine	O
is	O
the	O
primary	O
medical	O
care	O
center	O
for	O
COVID	B-DISO
-	I-DISO
19	I-DISO
inZhejiang	O
Province	O
.	O

The	O
artificial	O
liver	O
blood	O
purification	O
system	O
could	O
rapidly	O
remove	O
inflammatory	O
mediators	O
and	O
block	O
cytokine	B-DISO
storm	I-DISO
.	O

The	O
digestive	O
systemic	O
cancer	B-DISO
is	O
the	O
most	O
common	O
malignancy	B-DISO
.	O

TITLE	O
:	O
Understanding	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
based	O
on	O
current	O
evidence	O
.	O

The	O
COVID	B-DISO
-	I-DISO
19	I-DISO
epidemic	O
is	O
spreading	O
all	O
over	O
the	O
world	O
,	O
especially	O
in	O
China	O
.	O

The	O
Maximum	O
-	O
Likelihood	O
(	O
ML	O
)	O
value	O
of	O
R0	O
was	O
2	O
.	O
28	O
for	O
COVID	B-DISO
-	I-DISO
19	I-DISO
outbreak	O
at	O
the	O
early	O
stage	O
on	O
the	O
ship	O
.	O

The	O
median	O
with	O
95	O
%	O
CI	O
of	O
R0	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
was	O
about	O
2	O
.	O
28	O
(	O
2	O
.	O
06	O
-	O
2	O
.	O
52	O
)	O
during	O
the	O
early	O
stage	O
experienced	O
on	O
the	O
Diamond	O
Princess	O
cruise	O
ship	O
.	O

RESULTS	O
:	O
The	O
Maximum	O
-	O
Likelihood	O
(	O
ML	O
)	O
value	O
of	O
R0	O
was	O
2	O
.	O
28	O
for	O
COVID	B-DISO
-	I-DISO
19	I-DISO
outbreak	O
at	O
the	O
early	O
stage	O
on	O
the	O
ship	O
.	O

Specifically	O
,	O
we	O
generate	O
forecasts	O
using	O
a	O
generalized	O
logistic	O
growth	O
model	O
,	O
the	O
Richards	O
growth	O
model	O
,	O
and	O
a	O
sub	O
-	O
epidemic	O
wave	O
model	O
,	O
which	O
have	O
each	O
been	O
previously	O
used	O
to	O
forecast	O
outbreaks	O
due	O
to	O
different	O
infectious	B-DISO
diseases	I-DISO
.	O

Due	O
to	O
the	O
increasing	O
number	O
of	O
cases	O
in	O
China	O
and	O
outside	O
China	O
,	O
the	O
WHO	O
declared	O
coronavirus	O
as	O
a	O
global	O
health	O
emergency	B-DISO
.	O

TITLE	O
:	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
Australia	O
:	O
Epidemiology	O
Report	O
4	O
(	O
Reporting	O
week	O
ending	O
19	O
:	O
00	O
AEDT	O
22	O
February	O
2020	O
).	O

As	O
part	O
of	O
a	O
multi	O
-	O
institutional	O
collaboration	O
coordinated	O
by	O
the	O
Korean	O
Society	O
of	O
Thoracic	B-DISO
Radiology	O
,	O
we	O
collected	O
nine	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
infections	B-DISO
who	O
had	O
undergone	O
chest	O
radiography	O
and	O
CT	O
scans	O
.	O

A	O
considerable	O
proportion	O
of	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pneumonia	I-DISO
had	O
normal	O
chest	O
radiographs	O
.	O

TITLE	O
:	O
Composition	O
and	O
divergence	O
of	O
coronavirus	O
spike	O
proteins	O
and	O
host	O
ACE2	O
receptors	O
predict	O
potential	O
intermediate	O
hosts	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
.	O

ABSTRACT	O
:	O
The	O
critical	O
period	O
for	O
the	O
prevention	O
and	O
control	O
of	O
novel	O
coronavirus	O
pneumonia	B-DISO
(	O
NCP	O
)	O
in	O
China	O
,	O
in	O
response	O
to	O
requirements	O
for	O
accelerating	O
the	O
modernization	O
of	O
the	O
disease	O
prevention	O
and	O
control	O
system	O
,	O
we	O
analyzed	O
and	O
summarized	O
the	O
current	O
situation	O
,	O
existing	O
problems	O
,	O
and	O
deficiencies	O
in	O
China	O
'	O
s	O
modernization	O
of	O
disease	O
prevention	O
and	O
control	O
system	O
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
2019	B-DISO
novel	I-DISO
coronavirus	I-DISO
disease	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
is	O
spreading	O
rapidly	O
.	O

TITLE	O
:	O
[	O
Chemotherapy	O
strategy	O
for	O
colorectal	B-DISO
cancer	I-DISO
under	O
the	O
outbreak	O
of	O
novel	O
coronavirus	O
pneumonia	B-DISO
].	O

Chest	O
CT	O
may	O
be	O
considered	O
as	O
a	O
primary	O
tool	O
for	O
the	O
current	O
COVID	B-DISO
-	I-DISO
19	I-DISO
detection	O
in	O
epidemic	O
areas	O
.	O

Among	O
severe	O
trauma	O
patients	O
,	O
median	O
ISS	B-DISO
was	O
34	O
,	O
and	O
AIS	B-DISO
thorax	O
was	O
3	O
.	O

RESULTS	O
:	O
Among	O
141	O
included	O
patients	O
(	O
84	O
%	O
military	O
;	O
median	O
age	O
,	O
30	O
years	O
),	O
57	O
(	O
42	O
%)	O
developed	O
ARDS	B-DISO
.	O

ABSTRACT	O
:	O
The	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
)	O
infection	B-DISO
caused	O
pneumonia	B-DISO
.	O

ABSTRACT	O
:	O
Coronavirus	B-DISO
Disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
),	O
caused	O
by	O
a	O
novel	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
),	O
is	O
a	O
highly	O
contagious	B-DISO
disease	I-DISO
.	O

But	O
in	O
severe	O
cases	O
,	O
patients	O
can	O
progress	O
rapidly	O
and	O
develop	O
to	O
the	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
septic	B-DISO
shock	I-DISO
,	O
metabolic	B-DISO
acidosis	I-DISO
and	O
coagulopathy	B-DISO
.	O

In	O
fact	O
,	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
-	I-DISO
2	I-DISO
infection	I-DISO
of	O
anesthesiologists	O
after	O
endotracheal	O
intubation	O
for	O
confirmed	O
COVID	B-DISO
-	I-DISO
19	I-DISO
patients	O
have	O
been	O
reported	O
in	O
hospitals	O
in	O
Wuhan	O
.	O

TITLE	O
:	O
Negative	O
Nasopharyngeal	O
and	O
Oropharyngeal	O
Swab	O
Does	O
Not	O
Rule	O
Out	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

By	O
deeply	O
investigating	O
and	O
analyzing	O
the	O
problems	O
existed	O
in	O
the	O
current	O
Chinese	O
disease	O
control	O
and	O
prevention	O
system	O
,	O
and	O
learning	O
the	O
experiences	O
from	O
the	O
disease	O
control	O
and	O
prevention	O
systems	O
of	O
other	O
countries	O
,	O
the	O
expert	O
group	O
suggested	O
the	O
following	O
recommendations	O
,	O
included	O
the	O
enhance	O
and	O
update	O
the	O
laws	O
related	O
to	O
public	O
health	O
,	O
build	O
up	O
advanced	O
institution	O
mechanisms	O
that	O
meet	O
current	O
social	O
status	O
,	O
reform	O
current	O
emergency	B-DISO
response	O
system	O
,	O
clarify	O
the	O
dominance	O
and	O
function	O
of	O
disease	O
control	O
and	O
prevention	O
system	O
in	O
Health	O
China	O
developing	O
,	O
and	O
speed	O
up	O
the	O
construction	O
of	O
a	O
modern	O
information	O
system	O
,	O
talented	O
professional	O
groups	O
,	O
and	O
advanced	O
culture	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
literature	O
on	O
the	O
efficacy	O
of	O
LPV	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
especially	O
in	O
patients	O
with	O
SARS	B-DISO
and	O
MERS	O
,	O
so	O
that	O
we	O
might	O
clarify	O
the	O
potential	O
for	O
the	O
use	O
of	O
LPV	O
in	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

Based	O
on	O
Bayesian	O
time	O
-	O
scaled	O
phylogenetic	O
analysis	O
using	O
the	O
tip	O
-	O
dating	O
method	O
,	O
we	O
estimated	O
the	O
time	O
to	O
the	O
most	O
recent	O
common	O
ancestor	O
and	O
evolutionary	O
rate	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
,	O
which	O
ranged	O
from	O
22	O
to	O
24	O
November	O
2019	O
and	O
1	O
.	O
19	O
to	O
1	O
.	O
31	O
×	O
10	O

This	O
virus	O
shares	O
highly	O
homological	O
sequence	O
with	O
SARS	B-DISO
-	O
CoV	O
,	O
and	O
causes	O
acute	O
,	O
highly	O
lethal	O
pneumonia	B-DISO
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
with	O
clinical	O
symptoms	O
similar	O
to	O
those	O
reported	O
for	O
SARS	B-DISO
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
.	O
The	O
most	O
characteristic	O
symptom	B-DISO
of	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
is	O
respiratory	B-DISO
distress	I-DISO
,	O
and	O
most	O
of	O
the	O
patients	O
admitted	O
to	O
the	O
intensive	O
care	O
could	O
not	O
breathe	O
spontaneously	O
.	O

It	O
can	O
be	O
used	O
for	O
the	O
rapid	O
screening	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
carriers	O
,	O
symptomatic	O
or	O
asymptomatic	O
,	O
in	O
hospitals	O
,	O
clinics	O
,	O
and	O
test	O
laboratories	O
.	O

The	O
COVID	B-DISO
-	I-DISO
19	I-DISO
has	O
brought	O
huge	O
impacts	O
to	O
all	O
the	O
people	O
and	O
walks	O
of	O
life	O
,	O
especially	O
to	O
the	O
medical	O
and	O
health	O
systems	O
.	O

The	O
selection	O
of	O
surgical	O
procedures	O
and	O
perioperative	O
managements	O
of	O
esophageal	B-DISO
cancer	I-DISO
require	O
all	O
thoracic	B-DISO
surgeons	O
work	O
together	O
to	O
figure	O
out	O
a	O
reasonable	O
system	O
of	O
surgical	O
treatment	O
and	O
emergency	B-DISO
response	O
.	O

ABSTRACT	O
:	O
Recent	O
evidence	O
suggest	O
that	O
dysregulation	O
of	O
the	O
tumor	B-DISO
suppressor	O
P53	O
,	O
in	O
combination	O
with	O
disharmonious	O
activities	O
of	O
the	O
small	O
GTPase	O
RhoA	O
,	O
may	O
lead	O
to	O
irreversible	O
progression	O
of	O
human	O
disease	O
.	O

Secondary	O
outcomes	O
included	O
incidence	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
-	O
related	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
and	O
the	O
proportion	O
of	O
patients	O
requiring	O
mechanical	O
ventilation	O
.	O

Compared	O
with	O
survivors	O
,	O
non	O
-	O
survivors	O
were	O
older	O
(	O
64	O
·	O
6	O
years	O
[	O
11	O
·	O
2	O
]	O
vs	O
51	O
·	O
9	O
years	O
[	O
12	O
·	O
9	O
]),	O
more	O
likely	O
to	O
develop	O
ARDS	B-DISO
(	O
26	O
[	O
81	O
%]	O
patients	O
vs	O
9	O
[	O
45	O
%]	O
patients	O
),	O
and	O
more	O
likely	O
to	O
receive	O
mechanical	O
ventilation	O
(	O
30	O
[	O
94	O
%]	O
patients	O
vs	O
7	O
[	O
35	O
%]	O
patients	O
),	O
either	O
invasively	O
or	O
non	O
-	O
invasively	O
.	O

Hospital	O
-	O
acquired	O
infection	B-DISO
occurred	O
in	O
seven	O
(	O
13	O
·	O
5	O
%)	O
patients	O
.	O

Thereafter	O
,	O
the	O
prevalence	O
of	O
ground	O
-	O
glass	O
opacities	B-DISO
continued	O
to	O
decrease	O
(	O
17	O
[	O
57	O
%]	O
of	O
30	O
patients	O
in	O
group	O
3	O
,	O
and	O
five	O
[	O
33	O
%]	O
of	O
15	O
in	O
group	O
4	O
),	O
and	O
consolidation	O
and	O
mixed	O
patterns	O
became	O
more	O
frequent	O
(	O
12	O
[	O
40	O
%]	O
in	O
group	O
3	O
,	O
eight	O
[	O
53	O
%]	O
in	O
group	O
4	O
).	O

TITLE	O
:	O
Update	O
:	O
Public	O
Health	O
Response	O
to	O
the	O
Coronavirus	B-DISO
Disease	I-DISO
2019	I-DISO
Outbreak	O
-	O
United	O
States	O
,	O
February	O
24	O
,	O
2020	O
.	O

ABSTRACT	O
:	O
An	O
outbreak	O
of	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
caused	O
by	O
the	O
2019	O
novel	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
)	O
began	O
in	O
Wuhan	O
,	O
Hubei	O
Province	O
,	O
China	O
in	O
December	O
2019	O
,	O
and	O
has	O
spread	O
throughout	O
China	O
and	O
to	O
31	O
other	O
countries	O
and	O
territories	O
,	O
including	O
the	O
United	O
States	O
(	O
1	O
).	O

This	O
report	O
summarizes	O
the	O
aggressive	B-DISO
measures	O
(	O
2	O
,	O
3	O
)	O
that	O
CDC	O
,	O
state	O
and	O
local	O
health	O
departments	O
,	O
multiple	O
other	O
federal	O
agencies	O
,	O
and	O
other	O
partners	O
are	O
implementing	O
to	O
slow	O
and	O
try	O
to	O
contain	O
transmission	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
the	O
United	O
States	O
.	O

Although	O
these	O
measures	O
might	O
not	O
prevent	O
widespread	O
transmission	O
of	O
the	O
virus	O
in	O
the	O
United	O
States	O
,	O
they	O
are	O
being	O
implemented	O
to	O
1	O
)	O
slow	O
the	O
spread	O
of	O
illness	O
;	O
2	O
)	O
provide	O
time	O
to	O
better	O
prepare	O
state	O
and	O
local	O
health	O
departments	O
,	O
health	O
care	O
systems	O
,	O
businesses	O
,	O
educational	O
organizations	O
,	O
and	O
the	O
general	O
public	O
in	O
the	O
event	O
that	O
widespread	O
transmission	O
occurs	O
;	O
and	O
3	O
)	O
better	O
characterize	O
COVID	B-DISO
-	I-DISO
19	I-DISO
to	O
guide	O
public	O
health	O
recommendations	O
and	O
the	O
development	O
and	O
deployment	O
of	O
medical	O
countermeasures	O
,	O
including	O
diagnostics	O
,	O
therapeutics	O
,	O
and	O
vaccines	O
.	O

Based	O
on	O
the	O
analysis	O
of	O
the	O
milling	O
process	O
,	O
metal	O
adhesion	B-DISO
studies	O
,	O
and	O
COMSOL	O
MultiPhysics	O
heat	O
transfer	O
simulations	O
,	O
the	O
first	O
batch	O
of	O
chips	O
has	O
been	O
fabricated	O
and	O
successful	O
multiple	O
displacement	O
amplification	B-DISO
reactions	O
are	O
performed	O
inside	O
these	O
chips	O
.	O

This	O
research	O
is	O
the	O
first	O
step	O
towards	O
the	O
development	O
of	O
an	O
early	O
-	O
stage	O
zoonoses	B-DISO
detection	O
device	O
.	O

ABSTRACT	O
:	O
With	O
the	O
outbreak	O
of	O
unknown	O
pneumonia	B-DISO
in	O
Wuhan	O
,	O
China	O
,	O
in	O
December	O
2019	O
,	O
a	O
new	O
coronavirus	O
,	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Coronavirus	O
2	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
),	O
aroused	O
the	O
attention	O
of	O
the	O
entire	O
world	O
.	O

Multiple	O
patchy	O
ground	O
glass	O
opacities	B-DISO
in	O
bilateral	O
multiple	O
lobular	O
with	O
periphery	O
distribution	O
are	O
typical	O
chest	O
CT	O
imaging	O
features	O
of	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pneumonia	I-DISO
.	O

ABSTRACT	O
:	O
We	O
aim	O
to	O
summarize	O
reliable	O
evidence	O
of	O
evidence	O
-	O
based	O
medicine	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
the	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
Coronavirus	O
2	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
)	O
by	O
analyzing	O
all	O
the	O
published	O
studies	O
on	O
the	O
clinical	O
characteristics	O
of	O
patients	O
with	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
.	O

The	O
incidence	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
was	O
0	O
.	O
148	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
046	O
,	O
0	O
.	O
296	O
),	O
the	O
incidence	O
of	O
abnormal	O
chest	O
computer	O
tomography	O
(	O
CT	O
)	O
was	O
0	O
.	O
966	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
921	O
,	O
0	O
.	O
993	O
),	O
the	O
percentage	O
of	O
severe	O
cases	O
in	O
all	O
infected	O
cases	O
was	O
0	O
.	O
181	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
127	O
,	O
0	O
.	O
243	O
),	O
and	O
the	O
case	O
fatality	O
rate	O
of	O
patients	O
with	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
-	I-DISO
2	I-DISO
infection	I-DISO
was	O
0	O
.	O
043	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
027	O
,	O
0	O
.	O
061	O
).	O

CONCLUSIONS	O
:	O
Fever	O
and	O
cough	B-DISO
are	O
the	O
most	O
common	O
symptoms	O
in	O
patients	O
with	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
-	I-DISO
2	I-DISO
infection	I-DISO
,	O
and	O
most	O
of	O
these	O
patients	O
have	O
abnormal	O
chest	O
CT	O
examination	O
.	O

ABSTRACT	O
:	O
So	O
far	O
,	O
there	O
is	O
a	O
lack	O
of	O
effective	O
drugs	O
for	O
the	O
new	O
coronavirus	O
pneumonia	B-DISO
.	O

TITLE	O
:	O
[	O
Discussion	O
on	O
diagnosis	O
and	O
treatment	O
of	O
hepatobiliary	O
malignancies	B-DISO
during	O
the	O
outbreak	O
of	O
novel	O
coronavirus	O
pneumonia	B-DISO
].	O

On	O
January	O
20	O
,	O
2020	O
,	O
the	O
National	O
Health	O
Committee	O
classified	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pneumonia	I-DISO
as	O
one	O
of	O
B	O
class	O
infectious	B-DISO
diseases	I-DISO
and	O
treated	O
it	O
as	O
class	O
A	O
infectious	B-DISO
disease	I-DISO
.	O

During	O
the	O
epidemic	O
period	O
,	O
the	O
routine	O
diagnosis	O
and	O
treatment	O
of	O
tumor	B-DISO
patients	O
was	O
affected	O
with	O
varying	O
degrees	O
.	O

We	O
extracted	O
data	O
regarding	O
1099	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
Covid	B-DISO
-	I-DISO
19	I-DISO
from	O
552	O
hospitals	O
in	O
30	O
provinces	O
,	O
autonomous	O
regions	O
,	O
and	O
municipalities	O
in	O
China	O
through	O
January	O
29	O
,	O
2020	O
.	O

Diarrhea	B-DISO
was	O
uncommon	O
(	O
3	O
.	O
8	O
%).	O

On	O
admission	O
,	O
ground	O
-	O
glass	O
opacity	B-DISO
was	O
the	O
most	O
common	O
radiologic	O
finding	O
on	O
chest	O
computed	O
tomography	O
(	O
CT	O
)	O
(	O
56	O
.	O
4	O
%).	O

Lymphocytopenia	B-DISO
was	O
present	O
in	O
83	O
.	O
2	O
%	O
of	O
the	O
patients	O
on	O
admission	O
.	O

ABSTRACT	O
:	O
Over	O
the	O
past	O
decade	O
,	O
outbreaks	O
of	O
new	O
or	O
reemergent	O
viruses	O
such	O
as	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
(	O
SARS	B-DISO
)	O
virus	O
,	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	O
)	O
virus	O
,	O
and	O
Zika	O
have	O
claimed	O
thousands	O
of	O
lives	O
and	O
cost	O
governments	O
and	O
healthcare	O
systems	O
billions	O
of	O
dollars	O
.	O

By	O
4	O
February	O
,	O
public	O
health	O
measures	O
such	O
as	O
removal	O
and	O
isolation	O
of	O
ill	B-DISO
passengers	O
and	O
quarantine	O
of	O
non	O
-	O
ill	B-DISO
passengers	O
were	O
implemented	O
.	O

TITLE	O
:	O
Clinical	O
Characteristics	O
of	O
Imported	O
Cases	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
Jiangsu	O
Province	O
:	O
A	O
Multicenter	O
Descriptive	O
Study	O
.	O

CT	O
imaging	O
presentations	O
of	O
NCP	O
are	O
mostly	O
patchy	O
ground	O
glass	O
opacities	B-DISO
in	O
the	O
peripheral	O
areas	O
under	O
the	O
pleura	O
with	O
partial	O
consolidation	O
which	O
will	O
be	O
absorbed	O
with	O
formation	O
of	O
fibrotic	O
stripes	O
if	O
improved	O
.	O

TITLE	O
:	O
Real	O
-	O
time	O
forecasts	O
of	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
epidemic	O
in	O
China	O
from	O
February	O
5th	O
to	O
February	O
24th	O
,	O
2020	O
.	O

The	O
risk	O
of	O
venous	B-DISO
thromboembolism	I-DISO
(	O
VTE	O
)	O
needs	O
to	O
be	O
assessed	O
,	O
and	O
effective	O
prevention	O
should	O
be	O
carried	O
out	O
for	O
high	O
-	O
risk	O
patients	O
.	O

It	O
is	O
necessary	O
to	O
consider	O
the	O
possibility	O
of	O
pulmonary	B-DISO
thromboembolism	I-DISO
(	O
PTE	O
)	O
in	O
patients	O
with	O
sudden	O
onset	O
of	O
oxygenation	O
deterioration	O
,	O
respiratory	B-DISO
distress	I-DISO
,	O
reduced	O
blood	O
pressure	O
.	O

ABSTRACT	O
:	O
2019	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
)	O
is	O
one	O
of	O
the	O
beta	O
coronaviruses	O
and	O
was	O
identified	O
as	O
the	O
pathogen	O
of	O
the	O
severe	O
""""	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
")"""	O
in	O
2019	O
.	O

ABSTRACT	O
:	O
We	O
first	O
described	O
the	O
2019	B-DISO
novel	I-DISO
coronavirus	I-DISO
infection	I-DISO
in	O
10	O
children	O
occurring	O
in	O
areas	O
other	O
than	O
Wuhan	O
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
a	O
preliminary	O
risk	O
assessment	O
of	O
prioritization	O
measures	O
to	O
control	O
the	O
transmission	O
of	O
infection	B-DISO
from	O
camels	O
to	O
humans	O
.	O

Combining	O
the	O
guidelines	O
for	O
diagnosis	O
and	O
treatment	O
of	O
tumors	B-DISO
with	O
our	O
clinical	O
experience	O
,	O
in	O
this	O
epidemic	O
period	O
,	O
we	O
discuss	O
the	O
strategies	O
for	O
diagnosis	O
,	O
treatment	O
,	O
and	O
follow	O
-	O
up	O
of	O
malignant	B-DISO
tumors	I-DISO
of	O
the	O
digestive	O
system	O
in	O
this	O
article	O
.	O

The	O
aim	O
of	O
this	O
paper	O
was	O
to	O
describe	O
the	O
clinical	O
characteristics	O
and	O
imaging	O
manifestations	O
of	O
hospitalized	O
patients	O
with	O
confirmed	O
COVID	B-DISO
-	I-DISO
19	I-DISO
infection	I-DISO
in	O
Wenzhou	O
,	O
Zhejiang	O
,	O
China	O
.	O

TITLE	O
:	O
Characteristics	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
infection	I-DISO
in	O
Beijing	O
.	O

ABSTRACT	O
:	O
Several	O
recent	O
case	O
reports	O
have	O
described	O
common	O
early	O
chest	O
imaging	O
findings	O
of	O
lung	O
pathology	B-DISO
caused	O
by	O
2019	O
novel	O
Coronavirus	O
(	O
SARS	B-DISO
-	O
COV2	O
)	O
which	O
appear	O
to	O
be	O
similar	O
to	O
those	O
seen	O
previously	O
in	O
SARS	B-DISO
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
infected	O
patients	O
.	O

A	O
novel	O
coronavirus	O
was	O
identified	O
as	O
the	O
causative	O
agent	O
and	O
was	O
subsequently	O
termed	O
COVID	B-DISO
-	I-DISO
19	I-DISO
by	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
).	O

Network	O
pharmacology	O
analysis	O
predicted	O
that	O
the	O
general	O
in	O
vivo	O
roles	O
of	O
these	O
26	O
herbal	O
plants	O
were	O
related	O
to	O
regulating	O
viral	B-DISO
infection	I-DISO
,	O
immune	O
/	O
inflammation	B-DISO
reactions	O
and	O
hypoxia	B-DISO
response	O
.	O

Two	O
patients	O
who	O
recently	O
underwent	O
lung	O
lobectomies	O
for	O
adenocarcinoma	B-DISO
were	O
retrospectively	O
found	O
to	O
have	O
had	O
COVID	B-DISO
-	I-DISO
19	I-DISO
at	O
the	O
time	O
of	O
the	O
operation	O
.	O

These	O
two	O
cases	O
thus	O
provide	O
important	O
first	O
opportunities	O
to	O
study	O
the	O
pathology	B-DISO
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

This	O
article	O
reviews	O
the	O
influences	O
of	O
cytokine	B-DISO
storm	I-DISO
syndrome	O
on	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
and	O
the	O
corresponding	O
immunotherapies	O
to	O
resist	O
cytokine	B-DISO
storm	I-DISO
.	O

TITLE	O
:	O
Effect	O
of	O
corticosteroid	O
therapy	O
in	O
the	O
early	O
phase	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
:	O
a	O
propensity	O
-	O
matched	O
cohort	O
study	O
.	O

A	O
total	O
of	O
565	O
patients	O
admitted	O
with	O
moderate	O
to	O
severe	O
ARDS	B-DISO
were	O
eligible	O
.	O

ABSTRACT	O
:	O
Controversy	O
remains	O
over	O
whether	O
the	O
novel	O
coronavirus	O
2019	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
virus	O
may	O
have	O
infectivity	O
during	O
the	O
incubation	O
period	O
before	O
the	O
onset	O
of	O
symptoms	O
.	O

TITLE	O
:	O
Autophagy	O
Protects	O
Against	O
Developing	O
Increased	O
Lung	O
Permeability	O
and	O
Hypoxemia	O
by	O
Down	O
Regulating	O
Inflammasome	O
Activity	O
and	O
IL	O
-	O
1β	O
in	O
LPS	B-DISO
Plus	O
Mechanical	O
Ventilation	O
-	O
Induced	O
Acute	O
Lung	O
Injury	O
.	O

TITLE	O
:	O
The	O
Clinical	O
and	O
Chest	O
CT	O
Features	O
Associated	O
with	O
Severe	O
and	O
Critical	O
COVID	B-DISO
-	I-DISO
19	I-DISO
Pneumonia	I-DISO
.	O

Besides	O
,	O
severe	O
/	O
critical	O
patients	O
showed	O
higher	O
incidences	O
of	O
lymph	O
node	O
enlargement	B-DISO
,	O
pericardial	B-DISO
effusion	I-DISO
and	O
pleural	B-DISO
effusion	I-DISO
than	O
the	O
ordinary	O
patients	O
.	O

TITLE	O
:	O
Persistence	O
and	O
clearance	O
of	O
viral	O
RNA	O
in	O
2019	B-DISO
novel	I-DISO
coronavirus	I-DISO
disease	I-DISO
rehabilitation	O
patients	O
.	O

Patients	O
tested	O
positive	O
for	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
based	O
on	O
nucleic	O
acid	O
detection	O
were	O
included	O
in	O
this	O
study	O
.	O

Logistic	O
regression	O
analysis	O
was	O
performed	O
to	O
explore	O
the	O
risk	O
factors	O
for	O
disease	B-DISO
progression	I-DISO
.	O

Even	O
before	O
extracorporeal	O
membrane	O
oxygenation	O
,	O
plasmatic	O
coagulation	O
and	O
platelet	O
aggregation	O
were	O
impaired	B-DISO
due	O
to	O
systemic	O
inflammation	B-DISO
,	O
liver	B-DISO
failure	I-DISO
,	O
anticoagulants	O
(	O
heparins	O
,	O
phenprocoumon	O
,	O
apixaban	O
),	O
and	O
antiplatelet	O
medication	O
.	O

ABSTRACT	O
:	O
Isolation	O
of	O
cases	O
and	O
contact	O
tracing	O
is	O
used	O
to	O
control	O
outbreaks	O
of	O
infectious	B-DISO
diseases	I-DISO
,	O
and	O
has	O
been	O
used	O
for	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
).	O

A	O
backcalculation	O
method	O
was	O
employed	O
to	O
estimate	O
the	O
incidence	O
of	O
infection	B-DISO
.	O

The	O
estimated	O
number	O
of	O
new	O
infections	B-DISO
among	O
passengers	O
without	O
close	O
contact	O
was	O
very	O
small	O
from	O
5	O
February	O
on	O
which	O
a	O
movement	O
restriction	O
policy	O
was	O
imposed	O
.	O

TITLE	O
:	O
Stepping	B-DISO
up	O
infection	B-DISO
control	O
measures	O
in	O
ophthalmology	O
during	O
the	O
novel	O
coronavirus	O
outbreak	O
:	O
an	O
experience	O
from	O
Hong	O
Kong	O
.	O

The	O
measures	O
are	O
based	O
on	O
detailed	O
risk	O
assessment	O
by	O
both	O
local	O
ophthalmologists	O
and	O
infection	B-DISO
control	O
experts	O
.	O

ABSTRACT	O
:	O
In	O
December	O
2019	O
,	O
the	O
2019	O
novel	O
coronavirus	O
pneumonia	B-DISO
(	O
NCP	O
,	O
officially	O
named	O
Coronavirus	B-DISO
Disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
by	O
the	O
World	O
Health	O
Organization	O
)	O
broke	O
out	O
in	O
Wuhan	O
,	O
Hubei	O
,	O
and	O
it	O
quickly	O
spread	O
to	O
the	O
whole	O
country	O
and	O
abroad	O
.	O

How	O
to	O
effectively	O
control	O
the	O
spread	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
?	O

With	O
the	O
deeper	O
cognition	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
and	O
accumulation	O
of	O
clinical	O
experience	O
,	O
we	O
proposed	O
the	O
recommendations	O
for	O
pulmonary	O
rehabilitation	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
adults	O
based	O
on	O
the	O
opinions	O
of	O
front	O
-	O
line	O
clinical	O
experts	O
involved	O
in	O
the	O
management	O
of	O
this	O
epidemic	O
and	O
a	O
review	O
of	O
the	O
relevant	O
literature	O
and	O
evidences	O
:	O
1	O
.	O

for	O
the	O
inpatients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
pulmonary	O
rehabilitation	O
would	O
relieve	O
the	O
symptoms	O
of	O
dyspnea	B-DISO
,	O
anxiety	O
,	O
and	O
depression	B-DISO
;	O
eventually	O
improve	O
physical	O
function	O
and	O
the	O
quality	O
of	O
life	O
;	O
2	O
.	O

ABSTRACT	O
:	O
Since	O
December	O
2019	O
,	O
corona	B-DISO
virus	I-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
,	O
an	O
emerging	O
infection	B-DISO
disease	O
occurred	O
in	O
Wuhan	O
,	O
has	O
spread	O
in	O
the	O
mainland	O
China	O
.	O

The	O
epidemic	O
factors	O
on	O
the	O
basis	O
of	O
knowledge	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
were	O
discussed	O
in	O
this	O
paper	O
.	O

Source	O
of	O
infection	B-DISO
including	O
the	O
patients	O
,	O
asymptomatic	O
carrier	O
and	O
patients	O
in	O
the	O
incubation	O
period	O
are	O
contagious	O
.	O

Among	O
the	O
infected	O
cancer	B-DISO
patients	O
,	O
lung	B-DISO
cancer	I-DISO
is	O
the	O
most	O
common	O
type	O
.	O

During	O
epidemic	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
a	O
guideline	O
for	O
the	O
optimal	O
management	O
of	O
patients	O
with	O
advanced	O
lung	B-DISO
cancer	I-DISO
urgently	O
needs	O
to	O
be	O
proposed	O
to	O
distinguish	O
the	O
symptoms	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
and	O
the	O
side	O
effects	O
of	O
antitumor	O
drugs	O
.	O

Stronger	O
personal	O
protection	O
should	O
be	O
made	O
for	O
advanced	O
NSCLC	B-DISO
patients	O
;	O
An	O
intentional	O
postponing	O
of	O
antitumor	O
treatment	O
should	O
be	O
considered	O
according	O
to	O
patient	O
performance	O
status	O
.	O

ABSTRACT	O
:	O
Since	O
early	O
January	O
2020	O
,	O
after	O
the	O
outbreak	O
of	O
2019	B-DISO
novel	I-DISO
coronavirus	I-DISO
infection	I-DISO
in	O
Wuhan	O
,	O
China	O
,	O
≈	O
365	O
confirmed	O
cases	O
have	O
been	O
reported	O
in	O
Shenzhen	O
,	O
China	O
.	O

TITLE	O
:	O
Epidemiologic	O
Features	O
and	O
Clinical	O
Course	O
of	O
Patients	O
Infected	O
With	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
in	O
Singapore	O
.	O

Among	O
the	O
first	O
18	O
patients	O
diagnosed	O
with	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
-	I-DISO
2	I-DISO
infection	I-DISO
in	O
Singapore	O
,	O
clinical	O
presentation	O
was	O
frequently	O
a	O
mild	O
respiratory	B-DISO
tract	I-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Understanding	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
-	O
Mediated	O
Inflammatory	B-DISO
Responses	I-DISO
:	O
From	O
Mechanisms	O
to	O
Potential	O
Therapeutic	O
Tools	O
.	O

Potential	O
therapeutic	O
tools	O
to	O
reduce	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
-	O
induced	O
inflammatory	B-DISO
responses	I-DISO
include	O
various	O
methods	O
to	O
block	O
FcR	O
activation	O
.	O

Macrolide	O
/	O
ketolide	O
antibiotics	O
are	O
reported	O
to	O
possess	B-DISO
immunomodulatory	O
activity	O
;	O
as	O
a	O
result	O
improved	O
survival	O
has	O
been	O
noted	O
in	O
pneumonia	B-DISO
patients	O
.	O

Some	O
differences	O
were	O
found	O
between	O
the	O
CO	O
and	O
DC	O
groups	O
regarding	O
age	O
(	O
mean	O
[	O
standard	O
deviation	O
(	O
SD	O
)]:	O
47	O
.	O
9	O
years	O
[	O
22	O
.	O
8	O
]	O
versus	O
39	O
.	O
6	O
years	O
[	O
20	O
.	O
1	O
];	O
CONCLUSIONS	O
:	O
Although	O
most	O
of	O
the	O
patients	O
underwent	O
CO	O
for	O
acute	O
SDH	B-DISO
,	O
no	O
significant	O
differences	O
were	O
observed	O
in	O
the	O
incidence	O
of	O
ARDS	B-DISO
,	O
pneumonia	B-DISO
,	O
PE	O
,	O
or	O
systemic	O
sepsis	B-DISO
when	O
compared	O
with	O
patients	O
who	O
underwent	O
DC	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
)	O
has	O
been	O
identified	O
as	O
the	O
causative	O
pathogen	O
of	O
an	O
ongoing	O
outbreak	O
of	O
respiratory	B-DISO
disease	I-DISO
,	O
now	O
named	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

TITLE	O
:	O
Early	O
transmission	O
patterns	O
of	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
in	O
travellers	O
from	O
Wuhan	O
to	O
Thailand	O
,	O
January	O
2020	O
.	O

Developing	O
vaccines	O
against	O
the	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
virus	O
may	O
take	O
many	O
months	O
.	O

Effective	O
prevention	O
and	O
control	O
strategies	O
must	O
be	O
compulsorily	O
implemented	O
to	O
prevent	O
nosocomial	B-DISO
infection	I-DISO
.	O

The	O
microbiota	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
infected	O
patients	O
was	O
similar	O
to	O
those	O
in	O
CAP	B-DISO
,	O
either	O
dominated	O
by	O
the	O
pathogens	O
or	O
with	O
elevated	O
levels	O
of	O
oral	O
and	O
upper	O
respiratory	O
commensal	O
bacteria	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
present	O
a	O
new	O
forecasting	O
model	O
to	O
estimate	O
and	O
forecast	O
the	O
number	O
of	O
confirmed	O
cases	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
the	O
upcoming	O
ten	O
days	O
based	O
on	O
the	O
previously	O
confirmed	O
cases	O
recorded	O
in	O
China	O
.	O

Structural	O
equation	O
modeling	O
(	O
SEM	B-DISO
)	O
is	O
a	O
multivariate	O
analysis	O
method	O
to	O
determine	O
the	O
structural	O
relationship	O
between	O
measured	O
variables	O
.	O

TITLE	O
:	O
Phase	O
-	O
adjusted	O
estimation	O
of	O
the	O
number	O
of	O
Coronavirus	B-DISO
Disease	I-DISO
2019	I-DISO
cases	O
in	O
Wuhan	O
,	O
China	O
.	O

TITLE	O
:	O
Review	O
of	O
the	O
Clinical	O
Characteristics	O
of	O
Coronavirus	B-DISO
Disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
).	O

ABSTRACT	O
:	O
Endotracheal	O
intubation	O
is	O
an	O
independent	O
risk	O
factor	O
for	O
respiratory	O
infectious	B-DISO
diseases	I-DISO
.	O

We	O
conducted	O
a	O
retrospective	O
study	O
in	O
12	O
cases	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
who	O
underwent	O
endotracheal	O
intubation	O
at	O
ICU	O
of	O
the	O
Guangzhou	O
eighth	O
hospital	O
from	O
January	O
20	O
to	O
February	O
10	O
,	O
2020	O
.	O

The	O
mean	O
change	O
in	O
Pao	O
Fixed	O
-	O
dose	O
iEPO	O
was	O
comparable	O
to	O
iNO	O
in	O
patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	B-DISO
for	O
oxygenation	O
and	O
ventilation	O
parameters	O
as	O
well	O
as	O
clinical	O
outcomes	O
.	O

Fever	O
(	O
12	O
/	O
20	O
,	O
60	O
%)	O
and	O
cough	B-DISO
(	O
13	O
/	O
20	O
,	O
65	O
%)	O
were	O
the	O
most	O
common	O
symptoms	O
.	O

Here	O
,	O
we	O
summarize	O
the	O
potential	O
monoclonal	O
antibody	O
based	O
therapeutic	O
intervention	O
for	O
COVID	B-DISO
-	I-DISO
19	I-DISO
by	O
considering	O
the	O
existing	O
knowledge	O
on	O
the	O
neutralizing	O
monoclonal	O
antibodies	O
against	O
similar	O
coronaviruses	O
SARS	B-DISO
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
.	O
Further	O
research	O
on	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pathogenesis	B-DISO
could	O
identify	O
appropriate	O
therapeutic	O
targets	O
to	O
develop	O
specific	O
anti	O
-	O
virals	O
against	O
this	O
newly	O
emerging	O
pathogen	O
.	O

The	O
initial	O
and	O
follow	O
-	O
up	O
CT	O
obtained	O
a	O
mean	O
of	O
4	O
.	O
5	O
days	O
and	O
11	O
.	O
6	O
days	O
from	O
the	O
illness	O
onset	O
were	O
retrospectively	O
assessed	O
for	O
the	O
severity	O
and	O
progression	O
of	O
pneumonia	B-DISO
.	O

Presence	O
of	O
bilateral	O
ground	O
glass	O
opacity	B-DISO
and	O
consolidation	O
on	O
imaging	O
in	O
appropriate	O
clinical	O
background	O
should	O
raise	O
a	O
suspicion	O
about	O
COVID	B-DISO
19	I-DISO
.	O

Standard	O
infection	B-DISO
control	O
and	O
prevention	O
techniques	O
should	O
be	O
followed	O
.	O

Subsequent	O
investigations	O
revealed	O
a	O
novel	O
coronavirus	O
,	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
,	O
as	O
the	O
causative	O
agent	O
now	O
at	O
the	O
heart	O
of	O
a	O
major	O
outbreak	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aimed	O
to	O
assess	O
the	O
affective	O
and	O
cognitive	O
risk	O
perceptions	O
in	O
the	O
general	O
population	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
(	O
MERS	B-DISO
)	O
during	O
the	O
2015	O
MERS	B-DISO
coronavirus	O
(	O
MERS	B-DISO
-	O
CoV	O
)	O
outbreak	O
in	O
South	O
Korea	O
and	O
the	O
influencing	O
factors	O
.	O

In	O
this	O
article	O
,	O
we	O
aim	O
to	O
highlight	O
the	O
necessity	O
of	O
implementing	O
protective	O
measures	O
,	O
and	O
recommend	O
how	O
to	O
set	O
proper	O
emergency	B-DISO
management	O
plans	O
for	O
preventing	O
and	O
controlling	O
nosocomial	B-DISO
infection	I-DISO
of	O
2019	O
-	O
nCoV	O
in	O
dermatology	O
departments	O
.	O

Although	O
several	O
animals	O
have	O
been	O
speculated	O
to	O
be	O
a	O
reservoir	O
for	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
no	O
animal	O
reservoir	O
has	O
been	O
already	O
confirmed	O
.	O

ABSTRACT	O
:	O
2019	O
novel	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
),	O
which	O
originated	O
in	O
Wuhan	O
,	O
China	O
,	O
has	O
attracted	O
the	O
world	O
'	O
s	O
attention	O
over	O
the	O
last	O
month	O
.	O

TITLE	O
:	O
Transmission	O
dynamics	O
of	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
outbreak	O
and	O
effectiveness	O
of	O
government	O
interventions	O
:	O
A	O
data	O
-	O
driven	O
analysis	O
.	O

Finally	O
,	O
we	O
show	O
that	O
the	O
sera	O
from	O
convalescent	O
SARS	B-DISO
patients	O
cross	O
-	O
neutralized	O
SARS	B-DISO
-	O
2	O
-	O
S	O
-	O
driven	O
entry	O
.	O

The	O
continuous	O
evolution	O
of	O
coronaviruses	O
was	O
further	O
highlighted	O
with	O
the	O
emergence	O
of	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
-	O
CoV	O
(	O
MERS	O
-	O
CoV	O
)	O
outbreak	O
in	O
2012	O
.	O

While	O
human	O
strains	O
of	O
Coronavirus	O
are	O
associated	O
with	O
about	O
15	O
%	O
of	O
cases	O
of	O
the	O
common	B-DISO
cold	I-DISO
,	O
the	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
may	O
present	O
with	O
varying	O
degrees	O
of	O
severity	O
,	O
from	O
flu	B-DISO
-	I-DISO
like	I-DISO
symptoms	I-DISO
to	O
death	O
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
lethal	O
zoonotic	O
pathogen	O
that	O
was	O
first	O
identified	O
in	O
humans	O
in	O
Saudi	O
Arabia	O
and	O
Jordan	O
in	O
2012	O
.	O

This	O
Seminar	O
provides	O
an	O
update	O
on	O
the	O
current	O
knowledge	O
and	O
perspectives	O
on	O
MERS	O
epidemiology	O
,	O
virology	O
,	O
mode	O
of	O
transmission	O
,	O
pathogenesis	B-DISO
,	O
diagnosis	O
,	O
clinical	O
features	O
,	O
management	O
,	O
infection	B-DISO
control	O
,	O
development	O
of	O
new	O
therapeutics	O
and	O
vaccines	O
,	O
and	O
highlights	O
unanswered	O
questions	O
and	O
priorities	O
for	O
research	O
,	O
improved	O
management	O
,	O
and	O
prevention	O
.	O

ABSTRACT	O
:	O
To	O
date	O
,	O
the	O
controlling	O
of	O
outbreak	O
of	O
corona	B-DISO
virus	I-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
has	O
entered	O
into	O
a	O
critical	O
period	O
in	O
China	O
.	O

Travel	O
-	O
related	O
cases	O
were	O
the	O
main	O
source	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
cases	O
during	O
the	O
early	O
stages	O
of	O
the	O
current	O
epidemic	O
in	O
Italy	O
.	O

RESULTS	O
:	O
The	O
data	O
showed	O
that	O
58	O
.	O
73	O
%	O
of	O
imported	O
camels	O
and	O
25	O
%	O
of	O
traders	O
had	O
antibodies	O
specific	O
to	O
MERS	O
-	O
CoV	O
.	O
Interestingly	O
,	O
like	O
seroreactive	O
camels	O
,	O
all	O
seropositive	O
humans	O
were	O
apparently	O
healthy	O
without	O
any	O
history	O
of	O
developing	O
severe	O
respiratory	B-DISO
disease	I-DISO
in	O
the	O
14	O
days	O
prior	O
to	O
sampling	O
.	O

Asymptomatic	O
carriers	O
were	O
laboratory	O
-	O
confirmed	O
positive	O
for	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
virus	O
by	O
testing	O
the	O
nucleic	O
acid	O
of	O
the	O
pharyngeal	O
swab	O
samples	O
.	O

Currently	O
patients	O
are	O
the	O
main	O
source	O
of	O
infection	B-DISO
.	O

TITLE	O
:	O
Diagnosis	O
and	O
Management	O
of	O
First	O
Case	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
Canada	O
:	O
Lessons	O
applied	O
from	O
SARS	B-DISO
.	O

ABSTRACT	O
:	O
We	O
report	O
diagnosis	O
and	O
management	O
of	O
the	O
first	O
laboratory	O
-	O
confirmed	O
case	O
of	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
hospitalized	O
in	O
Toronto	O
,	O
Canada	O
.	O

TITLE	O
:	O
Clarithromycin	O
-	O
Associated	O
Acute	B-DISO
Liver	I-DISO
Failure	I-DISO
Leading	O
to	O
Fatal	O
,	O
Massive	O
Upper	B-DISO
Gastrointestinal	I-DISO
Hemorrhage	I-DISO
from	O
Profound	O
Coagulopathy	B-DISO
:	O
Case	O
Report	O
and	O
Systematic	O
Literature	O
Review	O
.	O

AST	O
and	O
ALT	O
each	O
rose	O
to	O
about	O
1	O
,	O
000	O
U	O
/	O
L	O
on	O
day	O
-	O
2	O
of	O
admission	O
,	O
and	O
rose	O
to	O
≥	O
6	O
,	O
000	O
U	O
/	O
L	O
on	O
day	O
-	O
3	O
,	O
with	O
development	O
of	O
severe	O
hepatic	B-DISO
encephalopathy	I-DISO
and	O
severe	O
coagulopathy	B-DISO
.	O

TITLE	O
:	O
Identification	O
of	O
Coronavirus	O
Isolated	O
from	O
a	O
Patient	O
in	O
Korea	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

Three	O
patients	O
were	O
asymptomatic	O
,	O
however	O
,	O
18	O
developed	O
pneumonia	B-DISO
.	O

Radioprotective	O
effect	O
of	O
curcumin	O
enables	O
it	O
to	O
attenuate	O
radiation	O
-	O
induced	O
inflammation	B-DISO
and	O
fibrosis	B-DISO
.	O

This	O
study	O
aims	O
to	O
repurpose	O
the	O
clinically	O
approved	O
drugs	O
for	O
the	O
treatment	O
of	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
in	O
a	O
2019	O
-	O
nCoV	O
related	O
coronavirus	O
model	O
.	O

However	O
,	O
a	O
significant	O
fraction	O
of	O
these	O
patients	O
goes	O
on	O
to	O
subsequently	O
develop	O
serious	O
lower	O
respiratory	B-DISO
disease	I-DISO
.	O

The	O
CoVs	O
have	O
become	O
the	O
major	O
pathogens	O
of	O
emerging	O
respiratory	B-DISO
disease	I-DISO
outbreaks	O
.	O

TITLE	O
:	O
The	O
Incubation	O
Period	O
of	O
Coronavirus	B-DISO
Disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
From	O
Publicly	O
Reported	O
Confirmed	O
Cases	O
:	O
Estimation	O
and	O
Application	O
.	O

Persons	O
with	O
confirmed	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
-	I-DISO
2	I-DISO
infection	I-DISO
outside	O
Hubei	O
province	O
,	O
China	O
.	O

Our	O
results	O
support	O
current	O
proposals	O
for	O
the	O
length	O
of	O
quarantine	O
or	O
active	O
monitoring	O
of	O
persons	O
potentially	O
exposed	O
to	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
,	O
although	O
longer	O
monitoring	O
periods	O
might	O
be	O
justified	O
in	O
extreme	O
cases	O
.	O

TITLE	O
:	O
1	O
,	O
2	O
,	O
4	O
-	O
Triazolo	O
[	O
1	O
,	O
5	O
-	O
ABSTRACT	O
:	O
Despite	O
great	O
efforts	O
have	O
been	O
made	O
in	O
the	O
prevention	O
and	O
therapy	O
of	O
human	B-DISO
immunodeficiency	I-DISO
virus	I-DISO
(	O
HIV	B-DISO
-	O
1	O
)	O
infection	B-DISO
,	O
however	O
the	O
difficulty	O
to	O
eradicate	O
latent	O
viral	O
reservoirs	O
together	O
with	O
the	O
emergence	O
of	O
multi	O
-	O
drug	O
-	O
resistant	O
strains	O
require	O
the	O
search	O
for	O
innovative	O
agents	O
,	O
possibly	O
exploiting	O
novel	O
mechanisms	O
of	O
action	O
.	O

Clinical	O
records	O
,	O
laboratory	O
results	O
,	O
and	O
chest	O
CT	O
scans	O
were	O
retrospectively	O
reviewed	O
for	O
nine	O
pregnant	O
women	O
with	O
laboratory	O
-	O
confirmed	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pneumonia	I-DISO
(	O
ie	O
,	O
with	O
maternal	O
throat	O
swab	O
samples	O
that	O
were	O
positive	O
for	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
2	O
[	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
])	O
who	O
were	O
admitted	O
to	O
Zhongnan	O
Hospital	O
of	O
Wuhan	O
University	O
,	O
Wuhan	O
,	O
China	O
,	O
from	O
Jan	O
20	O
to	O
Jan	O
31	O
,	O
2020	O
.	O

Evidence	O
of	O
intrauterine	O
vertical	B-DISO
transmission	I-DISO
was	O
assessed	O
by	O
testing	O
for	O
the	O
presence	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
in	O
amniotic	O
fluid	O
,	O
cord	B-DISO
blood	O
,	O
and	O
neonatal	O
throat	O
swab	O
samples	O
.	O

Five	O
of	O
nine	O
patients	O
had	O
lymphopenia	B-DISO
(<	O
1	O
·	O
0	O
×	O
10⁹	O
cells	O
per	O
L	O
).	O

No	O
neonatal	B-DISO
asphyxia	I-DISO
was	O
observed	O
in	O
newborn	O
babies	O
.	O

This	O
study	O
aims	O
to	O
investigate	O
the	O
spread	O
of	O
diseases	O
among	O
individuals	O
over	O
contact	O
networks	O
by	O
exploring	O
the	O
2015	O
Middle	O
East	O
Respiratory	O
Syndrome	B-DISO
(	O
MERS	O
)	O
outbreak	O
in	O
Korea	O
.	O

ABSTRACT	O
:	O
Novel	O
coronavirus	O
pneumonia	B-DISO
was	O
novel	O
coronavirus	B-DISO
infection	I-DISO
that	O
has	O
dominated	O
pulmonary	B-DISO
infection	I-DISO
since	O
December	O
2019	O
.	O

Patients	O
with	O
novel	O
coronavirus	O
pneumonia	B-DISO
usually	O
had	O
history	O
of	O
travelling	O
or	O
living	O
in	O
the	O
epidemic	O
area	O
including	O
Wuhan	O
within	O
14	O
days	O
before	O
onset	O
,	O
or	O
have	O
been	O
exposed	O
to	O
patients	O
who	O
had	O
fever	O
or	O
respiratory	B-DISO
symptoms	I-DISO
from	O
the	O
epidemic	O
area	O
,	O
or	O
had	O
clustering	O
diseases	O
.	O

In	O
this	O
article	O
,	O
the	O
clinical	O
and	O
chest	O
imaging	O
features	O
of	O
the	O
novel	O
coronavirus	O
pneumonia	B-DISO
were	O
reviewed	O
and	O
compared	O
with	O
other	O
infections	B-DISO
and	O
non	O
-	O
infectious	B-DISO
diffuse	O
pulmonary	B-DISO
diseases	I-DISO
.	O

TITLE	O
:	O
[	O
Study	O
on	O
issues	O
for	O
stomatological	O
institutions	O
responding	O
to	O
state	O
public	O
health	O
emergencies	B-DISO
].	O

Epidemiological	O
data	O
showed	O
that	O
the	O
older	O
patients	O
with	O
chronic	O
commodities	O
were	O
at	O
high	O
risk	O
of	O
the	O
involvement	O
of	O
the	O
severe	O
and	O
critical	O
type	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
especially	O
patients	O
with	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
COPD	B-DISO
)	O
resulting	O
in	O
high	O
mortalities	O
.	O

In	O
most	O
cases	O
,	O
fever	O
and	O
a	O
cough	B-DISO
were	O
the	O
first	O
symptoms	O
experienced	O
,	O
and	O
1	O
patient	O
also	O
had	O
diarrhea	B-DISO
.	O

Clinically	O
,	O
the	O
first	O
symptom	B-DISO
in	O
the	O
neonates	O
was	O
shortness	B-DISO
of	I-DISO
breath	I-DISO
(	O
n	O
=	O
6	O
),	O
but	O
other	O
initial	O
symptoms	O
such	O
as	O
fever	O
(	O
n	O
=	O
2	O
),	O
thrombocytopenia	O
accompanied	O
by	O
abnormal	B-DISO
liver	I-DISO
function	I-DISO
(	O
n	O
=	O
2	O
),	O
rapid	O
heart	O
rate	O
(	O
n	O
=	O
1	O
),	O
vomiting	B-DISO
(	O
n	O
=	O
1	O
),	O
and	O
pneumothorax	B-DISO
(	O
n	O
=	O
1	O
)	O
were	O
observed	O
.	O

Up	O
to	O
now	O
,	O
5	O
neonates	O
have	O
been	O
cured	O
and	O
discharged	O
,	O
1	O
has	O
died	O
,	O
and	O
4	O
neonates	O
remain	O
in	O
hospital	O
in	O
a	O
stable	O
condition	B-DISO
.	O

A	O
total	O
of	O
205	O
patients	O
with	O
positive	O
Respiratory	O
Pathogen	O
Panel	O
for	O
viral	B-DISO
pneumonia	I-DISO
and	O
CT	O
findings	O
consistent	O
with	O
or	O
highly	O
suspicious	O
for	O
pneumonia	B-DISO
by	O
original	O
radiology	O
interpretation	O
within	O
7	O
days	O
of	O
each	O
other	O
were	O
identified	O
from	O
Rhode	O
Island	O
Hospital	O
in	O
Providence	O
,	O
RI	O
.	O

Results	O
For	O
all	O
chest	O
CTs	B-DISO
,	O
three	O
Chinese	O
radiologists	O
correctly	O
differentiated	O
COVID	B-DISO
-	I-DISO
19	I-DISO
from	O
non	O
-	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pneumonia	I-DISO
83	O
%	O
(	O
350	O
/	O
424	O
),	O
80	O
%	O
(	O
338	O
/	O
424	O
),	O
and	O
60	O
%	O
(	O
255	O
/	O
424	O
)	O
of	O
the	O
time	O
,	O
respectively	O
.	O

We	O
propose	O
a	O
cost	O
-	O
effective	O
,	O
quick	O
-	O
and	O
-	O
easy	O
method	O
for	O
early	O
detection	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
at	O
any	O
conventional	O
Biosafety	O
Level	O
II	O
laboratories	O
that	O
are	O
equipped	O
with	O
a	O
rtPCR	O
machine	O
.	O

TITLE	O
:	O
Potential	O
scenarios	O
for	O
the	O
progression	O
of	O
a	O
COVID	B-DISO
-	I-DISO
19	I-DISO
epidemic	O
in	O
the	O
European	O
Union	O
and	O
the	O
European	O
Economic	O
Area	O
,	O
March	O
2020	O
.	O

ABSTRACT	O
:	O
Two	O
months	O
after	O
the	O
emergence	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
2	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
),	O
the	O
possibility	O
of	O
established	O
and	O
widespread	O
community	O
transmission	O
in	O
the	O
European	O
Union	O
and	O
European	O
Economic	O
Area	O
(	O
EU	O
/	O
EEA	O
)	O
is	O
becoming	O
more	O
likely	O
.	O

Binary	O
logistic	O
regression	O
analysis	O
showed	O
that	O
age	O
,	O
not	O
gender	O
,	O
was	O
the	O
risk	O
factor	O
for	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
-	I-DISO
2	I-DISO
infection	I-DISO
in	O
fever	O
clinics	O
.	O

The	O
currently	O
available	O
literature	O
was	O
reviewed	O
for	O
microbiologically	O
confirmed	O
infections	B-DISO
by	O
2019	O
-	O
nCoV	O
or	O
COVID	B-DISO
-	I-DISO
19	I-DISO
at	O
the	O
time	O
of	O
writing	O
(	O
13	O
February	O
2020	O
).	O

Fever	O
was	O
present	O
in	O
all	O
of	O
the	O
case	O
series	O
available	O
,	O
flanked	O
by	O
cough	B-DISO
,	O
dyspnoea	B-DISO
,	O
myalgia	B-DISO
and	O
fatigue	B-DISO
.	O

The	O
use	O
of	O
mAb	O
therapeutics	O
has	O
also	O
revealed	O
a	O
""""	O
scaffolding	O
""""	O
role	O
for	O
FcγR	O
which	O
,	O
in	O
different	O
contexts	O
,	O
may	O
either	O
underpin	O
the	O
therapeutic	O
mAb	O
action	O
such	O
as	O
immune	O
agonism	O
or	O
may	O
trigger	O
catastrophic	O
adverse	B-DISO
effects	I-DISO
.	O

The	O
still	O
unmet	O
therapeutic	O
need	O
in	O
many	O
cancers	B-DISO
,	O
inflammatory	O
diseases	O
or	O
emerging	O
infections	B-DISO
such	O
as	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
,	O
requires	O
increased	O
effort	O
on	O
the	O
development	O
of	O
improved	O
and	O
novel	O
mAbs	O
.	O

Chest	O
computed	O
tomography	O
offers	O
fast	O
and	O
convenient	O
evaluation	O
of	O
patients	O
with	O
suspected	O
2019	O
-	O
novel	O
coronavirus	O
pneumonia	B-DISO
.	O

ABSTRACT	O
:	O
Similar	O
to	O
outbreaks	O
of	O
many	O
other	B-DISO
infectious	I-DISO
diseases	I-DISO
,	O
success	O
in	O
controlling	O
the	O
novel	O
2019	O
coronavirus	B-DISO
infection	I-DISO
requires	O
a	O
timely	O
and	O
accurate	O
monitoring	O
of	O
the	O
epidemic	O
,	O
particularly	O
during	O
its	O
early	O
period	O
with	O
rather	O
limited	O
data	O
while	O
the	O
need	O
for	O
information	O
increases	O
explosively	O
.	O

Most	O
high	O
-	O
frequency	O
codons	O
were	O
ending	O
with	O
A	O
or	O
T	O
,	O
while	O
the	O
low	O
frequency	O
and	O
rare	O
codons	O
were	O
ending	O
with	O
G	O
or	O
C	O
.	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
structural	O
proteins	O
showed	O
5	O
to	O
20	O
lower	O
ENc	O
values	O
,	O
compared	O
with	O
SARS	B-DISO
,	O
bat	O
SARS	B-DISO
,	O
and	O
MERS	O
CoVs	O
.	O

A	O
greater	O
emphasis	O
on	O
severity	O
,	O
such	O
that	O
pandemics	O
are	O
defined	O
as	O
severe	O
and	O
rapidly	O
spreading	O
infectious	B-DISO
disease	I-DISO
outbreaks	O
,	O
would	O
make	O
them	O
""""	O
true	O
global	O
health	O
emergencies	B-DISO
","""	O
allowing	O
for	O
priority	O
resource	O
allocation	O
and	O
effective	O
collective	O
actions	O
in	O
emergency	B-DISO
response	O
efforts	O
.	O

Results	O
show	O
that	O
camels	O
are	O
one	O
of	O
the	O
most	O
important	O
sources	O
of	O
infections	B-DISO
and	O
diseases	O
in	O
human	O
;	O
therefore	O
,	O
continuous	O
monitoring	O
and	O
inspection	O
programs	O
are	O
necessary	O
to	O
prevent	O
the	O
outbreak	O
of	O
zoonotic	O
diseases	O
caused	O
by	O
this	O
animal	O
in	O
humans	O
.	O

Viral	B-DISO
infections	I-DISO
were	O
detected	O
in	O
44	O
%	O
of	O
cases	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
the	O
isolation	O
of	O
HCoV	O
-	O
OC43	O
from	O
respiratory	B-DISO
infections	I-DISO
in	O
Alexandria	O
,	O
Egypt	O
.	O

Given	O
the	O
current	O
growing	O
spread	O
of	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
around	O
the	O
world	O
,	O
it	O
is	O
imperative	O
that	O
businesses	O
review	O
their	O
pandemic	O
plans	O
and	O
be	O
prepared	O
in	O
case	O
this	O
epidemic	O
expands	O
and	O
affects	O
more	O
people	O
and	O
communities	O
.	O

Businesses	O
that	O
regularly	O
test	O
and	O
update	O
their	O
pandemic	O
plan	B-DISO
can	O
significantly	O
reduce	O
harmful	O
impacts	O
to	O
the	O
business	O
,	O
play	O
a	O
key	O
role	O
in	O
protecting	O
employees	O
'	O
and	O
customers	O
'	O
health	O
and	O
safety	O
,	O
and	O
limit	O
the	O
negative	O
impact	O
of	O
a	O
pandemic	O
on	O
the	O
community	O
and	O
economy	O
.	O

TITLE	O
:	O
The	O
emergence	O
of	O
a	O
novel	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
),	O
their	O
biology	O
and	O
therapeutic	O
options	O
.	O

TITLE	O
:	O
A	O
high	O
ATP	O
concentration	O
enhances	O
the	O
cooperative	O
translocation	B-DISO
of	O
the	O
SARS	B-DISO
coronavirus	O
helicase	O
nsP13	O
in	O
the	O
unwinding	O
of	O
duplex	O
RNA	O
.	O

Despite	O
its	O
putative	O
role	O
in	O
viral	O
RNA	O
replication	O
,	O
nsP13	O
readily	O
unwinds	O
duplex	O
DNA	O
by	O
cooperative	O
translocation	B-DISO
.	O

ABSTRACT	O
:	O
In	O
December	O
2019	O
,	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
emerged	O
in	O
Wuhan	O
and	O
rapidly	O
spread	O
throughout	O
China	O
.	O

TITLE	O
:	O
Prevalence	O
and	O
impact	O
of	O
cardiovascular	O
metabolic	B-DISO
diseases	I-DISO
on	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
China	O
.	O

We	O
studied	O
children	O
at	O
a	O
large	O
tertiary	O
-	O
care	O
hospital	O
in	O
China	O
,	O
during	O
the	O
period	O
from	O
28	O
January	O
2019	O
to	O
8	O
February	O
2020	O
,	O
who	O
had	O
positive	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
for	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

Along	O
these	O
efforts	O
,	O
the	O
structure	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
main	O
protease	O
(	O
Mpro	O
)	O
has	O
been	O
rapidly	O
resolved	O
and	O
made	O
publicly	O
available	O
to	O
facilitate	O
global	O
efforts	O
to	O
develop	O
novel	O
drug	O
candidates	O
.	O

ABSTRACT	O
:	O
Coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
caused	O
by	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
2	O
has	O
become	O
an	O
important	O
public	O
health	O
issue	O
in	O
the	O
world	O
.	O

The	O
main	O
clinical	O
manifestations	O
were	O
respiratory	B-DISO
symptoms	I-DISO
and	O
occasional	O
gastrointestinal	B-DISO
symptoms	I-DISO
.	O

However	O
,	O
there	O
is	O
no	O
unified	O
standard	O
for	O
the	O
diagnosis	O
and	O
treatment	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

We	O
statistically	O
analyzed	O
the	O
clinical	O
symptoms	O
and	O
laboratory	O
results	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
patients	O
and	O
explained	O
the	O
discharge	O
rate	O
and	O
fatality	O
rate	O
with	O
a	O
single	O
-	O
arm	O
meta	O
-	O
analysis	O
.	O

The	O
main	O
clinical	O
symptoms	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
patients	O
were	O
fever	O
(	O
88	O
.	O
5	O
%),	O
cough	B-DISO
(	O
68	O
.	O
6	O
%),	O
myalgia	B-DISO
or	O
fatigue	B-DISO
(	O
35	O
.	O
8	O
%),	O
expectoration	O
(	O
28	O
.	O
2	O
%),	O
and	O
dyspnea	B-DISO
(	O
21	O
.	O
9	O
%).	O

Minor	O
symptoms	O
include	O
headache	B-DISO
or	O
dizziness	B-DISO
(	O
12	O
.	O
1	O
%),	O
diarrhea	B-DISO
(	O
4	O
.	O
8	O
%),	O
nausea	B-DISO
and	I-DISO
vomiting	I-DISO
(	O
3	O
.	O
9	O
%).	O

The	O
results	O
of	O
single	O
-	O
arm	O
meta	O
-	O
analysis	O
showed	O
that	O
the	O
male	O
took	O
a	O
larger	O
percentage	O
in	O
the	O
gender	O
distribution	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
patients	O
60	O
%	O
(	O
95	O
%	O
CI	O
[	O
0	O
.	O
54	O
,	O
0	O
.	O
65	O
]),	O
the	O
discharge	O
rate	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
patients	O
was	O
42	O
%	O
(	O
95	O
%	O
CI	O
[	O
0	O
.	O
29	O
,	O
0	O
.	O
55	O
]),	O
and	O
the	O
fatality	O
rate	O
was	O
7	O
%	O
(	O
95	O
%	O
CI	O
[	O
0	O
.	O
04	O
,	O
0	O
.	O
10	O
]).	O

As	O
of	O
February	O
26	O
,	O
2020	O
,	O
COVID	B-DISO
-	I-DISO
19	I-DISO
has	O
been	O
recognized	O
in	O
34	O
countries	O
,	O
with	O
a	O
total	O
of	O
80	O
,	O
239	O
laboratory	O
-	O
confirmed	O
cases	O
and	O
2	O
,	O
700	O
deaths	O
.	O

This	O
study	O
analyzed	O
global	O
COVID	B-DISO
-	I-DISO
19	I-DISO
epidemiological	O
trends	O
,	O
examined	O
impact	O
of	O
the	O
pandemic	O
on	O
global	O
health	O
security	O
,	O
diplomacy	O
,	O
and	O
social	O
environment	O
in	O
China	O
,	O
and	O
provided	O
short	O
-	O
and	O
long	O
-	O
term	O
strategic	O
policy	O
recommendations	O
for	O
China	O
'	O
s	O
subsequent	O
preparedness	O
and	O
responses	O
.	O

Cancellation	O
or	O
suspension	O
of	O
MGs	B-DISO
would	O
be	O
critical	O
to	O
pandemic	O
mitigation	O
.	O

These	O
events	O
included	O
environmental	O
crises	O
,	O
like	O
forest	O
fires	O
and	O
hurricanes	O
,	O
and	O
infectious	B-DISO
disease	I-DISO
crises	O
,	O
like	O
the	O
SARS	B-DISO
(	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
)	O
and	O
H1N1	O
outbreaks	O
.	O

On	O
this	O
note	O
,	O
travel	O
restrictions	O
to	O
and	O
from	O
high	O
risk	O
areas	O
and	O
/	O
or	O
14	O
days	O
quarantine	O
of	O
travelers	O
coming	O
from	O
high	O
risk	O
areas	O
are	O
recommended	O
to	O
prevent	O
possible	O
importation	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

ABSTRACT	O
:	O
To	O
describe	O
a	O
pediatric	O
case	O
of	O
cytokine	B-DISO
release	I-DISO
syndrome	I-DISO
secondary	O
to	O
chimeric	O
antigen	O
receptor	O
-	O
modified	O
T	O
cells	O
associated	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

He	O
was	O
admitted	O
to	O
PICU	O
with	O
a	O
clinical	O
picture	O
of	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
requiring	O
mechanical	O
ventilation	O
,	O
and	O
secondary	O
hemophagocytic	B-DISO
lymphohistiocytosis	I-DISO
.	O

TITLE	O
:	O
A	O
Review	O
of	O
Coronavirus	O
Disease	O
-	O
2019	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
).	O

According	O
to	O
the	O
guidelines	O
drafted	O
by	O
China	O
'	O
s	O
Center	O
for	O
Disease	O
prevention	O
and	O
Control	O
(	O
CDC	O
),	O
the	O
positive	O
nucleic	O
acid	O
test	O
is	O
need	O
to	O
the	O
diagnosis	O
of	O
patient	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

It	O
was	O
found	O
that	O
among	O
all	O
the	O
upper	O
respiratory	O
sampling	O
methods	O
,	O
nasopharyngeal	O
aspirate	O
(	O
NPA	O
)	O
had	O
a	O
higher	O
positive	O
rate	O
within	O
2	O
weeks	O
of	O
symptom	B-DISO
onset	O
,	O
while	O
combined	O
nasal	O
and	O
oropharyngeal	O
swabs	O
(	O
NS	O
+	O
OPS	B-DISO
)	O
was	O
the	O
least	O
harmful	O
to	O
medical	O
staff	O
during	O
sampling	O
.	O

We	O
wish	O
this	O
review	O
is	O
helpful	O
for	O
the	O
prevention	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

TITLE	O
:	O
Soluble	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
:	O
a	O
potential	O
approach	O
for	O
coronavirus	B-DISO
infection	I-DISO
therapy	O
?	O

It	O
has	O
been	O
known	O
since	O
the	O
2003	O
SARS	B-DISO
epidemic	O
that	O
the	O
receptor	O
critical	O
for	O
SARS	B-DISO
-	O
CoV	O
entry	O
into	O
host	O
cells	O
is	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
).	O

We	O
thought	O
that	O
it	O
is	O
timely	O
to	O
explain	O
the	O
connection	O
between	O
the	O
SARS	B-DISO
-	O
CoV	O
,	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
,	O
ACE2	O
and	O
the	O
rationale	O
for	O
soluble	O
ACE2	O
as	O
a	O
potential	O
therapy	O
.	O

We	O
found	O
that	O
theaflavin	O
has	O
a	O
lower	O
idock	O
score	O
in	O
the	O
catalytic	O
pocket	O
of	O
RdRp	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
(-	O
9	O
.	O
11	O
kcal	O
/	O
mol	O
),	O
SARS	B-DISO
-	O
CoV	O
(-	O
8	O
.	O
03	O
kcal	O
/	O
mol	O
),	O
and	O
MERS	O
-	O
CoV	O
(-	O
8	O
.	O
26	O
kcal	O
/	O
mol	O
)	O
from	O
idock	O
.	O

TITLE	O
:	O
Risk	O
Factors	O
Associated	O
With	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
and	O
Death	O
in	O
Patients	O
With	O
Coronavirus	B-DISO
Disease	I-DISO
2019	I-DISO
Pneumonia	B-DISO
in	O
Wuhan	O
,	O
China	O
.	O

To	O
describe	O
the	O
clinical	O
characteristics	O
and	O
outcomes	O
in	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pneumonia	I-DISO
who	O
developed	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
or	O
died	O
.	O

In	O
bivariate	O
Cox	O
regression	O
analysis	O
,	O
risk	O
factors	O
associated	O
with	O
the	O
development	O
of	O
ARDS	B-DISO
and	O
progression	O
from	O
ARDS	B-DISO
to	O
death	O
included	O
older	O
age	O
(	O
hazard	O
ratio	O
[	O
HR	O
],	O
3	O
.	O
26	O
;	O
95	O
%	O
CI	O
2	O
.	O
08	O
-	O
5	O
.	O
11	O
;	O
and	O
HR	O
,	O
6	O
.	O
17	O
;	O
95	O
%	O
CI	O
,	O
3	O
.	O
26	O
-	O
11	O
.	O
67	O
,	O
respectively	O
),	O
neutrophilia	O
(	O
HR	O
,	O
1	O
.	O
14	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
09	O
-	O
1	O
.	O
19	O
;	O
and	O
HR	O
,	O
1	O
.	O
08	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
01	O
-	O
1	O
.	O
17	O
,	O
respectively	O
),	O
and	O
organ	O
and	O
coagulation	O
dysfunction	O
(	O
eg	O
,	O
higher	O
lactate	O
dehydrogenase	O
[	O
HR	O
,	O
1	O
.	O
61	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
44	O
-	O
1	O
.	O
79	O
;	O
and	O
HR	O
,	O
1	O
.	O
30	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
11	O
-	O
1	O
.	O
52	O
,	O
respectively	O
]	O
and	O
D	O
-	O
dimer	O
[	O
HR	O
,	O
1	O
.	O
03	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
01	O
-	O
1	O
.	O
04	O
;	O
and	O
HR	O
,	O
1	O
.	O
02	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
01	O
-	O
1	O
.	O
04	O
,	O
respectively	O
]).	O

Here	O
,	O
we	O
investigate	O
the	O
density	O
of	O
the	O
expression	O
levels	O
of	O
ACE2	O
in	O
the	O
CNS	O
,	O
the	O
host	O
-	O
virus	O
interaction	O
and	O
relate	O
it	O
to	O
the	O
pathogenesis	B-DISO
and	O
complications	O
seen	O
in	O
the	O
recent	O
cases	O
resulting	O
from	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
outbreak	O
.	O

ABSTRACT	O
:	O
We	O
estimated	O
the	O
case	O
-	O
fatality	O
risk	O
for	O
2019	B-DISO
novel	I-DISO
coronavirus	I-DISO
disease	I-DISO
cases	O
in	O
China	O
(	O
3	O
.	O
5	O
%);	O
China	O
,	O
excluding	O
Hubei	O
Province	O
(	O
0	O
.	O
8	O
%);	O
82	O
countries	O
,	O
territories	O
,	O
and	O
areas	O
(	O
4	O
.	O
2	O
%);	O
and	O
on	O
a	O
cruise	O
ship	O
(	O
0	O
.	O
6	O
%).	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
epidemiology	O
of	O
2019	B-DISO
novel	I-DISO
coronavirus	I-DISO
disease	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
in	O
a	O
remote	O
region	O
of	O
China	O
,	O
far	O
from	O
Wuhan	O
,	O
we	O
analyzed	O
the	O
epidemiology	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
Gansu	O
Province	O
.	O

Spatial	O
distribution	O
pattern	O
analysis	O
indicated	O
hot	B-DISO
spots	I-DISO
and	O
spatial	O
outliers	O
in	O
Gansu	O
Province	O
.	O

As	O
a	O
result	O
of	O
adequate	O
interventions	O
,	O
transmission	O
of	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
virus	O
in	O
Gansu	O
Province	O
is	O
decreasing	O
.	O

The	O
emergence	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
,	O
since	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
)	O
in	O
2002	O
and	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
2012	O
,	O
marked	O
the	O
third	O
introduction	O
of	O
a	O
highly	O
pathogenic	O
and	O
large	O
-	O
scale	O
epidemic	O
coronavirus	O
into	O
the	O
human	O
population	O
in	O
the	O
twenty	O
-	O
first	O
century	O
.	O

Meanwhile	O
,	O
several	O
independent	O
research	O
groups	O
have	O
identified	O
that	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
belongs	O
to	O
β	O
-	O
coronavirus	O
,	O
with	O
highly	O
identical	O
genome	O
to	O
bat	O
coronavirus	O
,	O
pointing	O
to	O
bat	O
as	O
the	O
natural	O
host	O
.	O

TITLE	O
:	O
COVID	B-DISO
-	I-DISO
19	I-DISO
spike	O
-	O
host	O
cell	O
receptor	O
GRP78	O
binding	O
site	O
prediction	O
.	O

In	O
this	O
study	O
,	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
spike	O
binding	O
site	O
to	O
the	O
cell	O
-	O
surface	O
receptor	O
(	O
Glucose	O
Regulated	O
Protein	O
78	O
(	O
GRP78	O
))	O
is	O
predicted	O
using	O
combined	O
molecular	O
modeling	O
docking	O
and	O
structural	O
bioinformatics	O
.	O

Therefore	O
,	O
increased	O
attention	O
should	O
be	O
paid	O
to	O
the	O
psychological	B-DISO
problems	O
of	O
the	O
medical	O
staff	O
,	O
especially	O
non	O
-	O
front	O
-	O
line	O
nurses	O
,	O
and	O
general	O
public	O
under	O
the	O
situation	O
of	O
the	O
spread	O
and	O
control	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

ABSTRACT	O
:	O
The	O
Corona	B-DISO
Virus	I-DISO
Disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
caused	O
by	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
2	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
)	O
is	O
a	O
Public	O
Health	O
Emergency	B-DISO
of	O
International	O
Concern	O
.	O

ABSTRACT	O
:	O
The	O
novel	O
coronavirus	O
outbreak	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
in	O
mainland	O
China	O
has	O
rapidly	O
spread	O
across	O
the	O
globe	O
.	O

TITLE	O
:	O
Single	O
-	O
cell	O
RNA	O
-	O
seq	O
data	O
analysis	O
on	O
the	O
receptor	O
ACE2	O
expression	O
reveals	O
the	O
potential	O
risk	O
of	O
different	O
human	O
organs	O
vulnerable	O
to	O
2019	B-DISO
-	I-DISO
nCoV	I-DISO
infection	I-DISO
.	O

This	O
study	O
is	O
aimed	O
to	O
score	O
the	O
outbreak	O
of	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
Saudi	O
Arabia	O
using	O
both	O
the	O
original	O
GFT	O
and	O
mGFT	O
.	O

ABSTRACT	O
:	O
Health	O
professions	O
preventing	O
and	O
controlling	O
Coronavirus	B-DISO
Disease	I-DISO
2019	I-DISO
are	O
prone	O
to	O
skin	O
and	O
mucous	O
membrane	O
injury	O
,	O
which	O
may	O
cause	O
acute	B-DISO
and	I-DISO
chronic	I-DISO
dermatitis	I-DISO
,	O
secondary	B-DISO
infection	I-DISO
and	O
aggravation	O
of	O
underlying	O
skin	B-DISO
diseases	I-DISO
.	O

The	O
WHO	O
has	O
declared	O
the	O
outbreak	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
-	I-DISO
2	I-DISO
infection	I-DISO
an	O
international	O
public	O
health	O
emergency	B-DISO
.	O

In	O
this	O
review	O
,	O
the	O
characteristics	O
and	O
mechanism	O
of	O
liver	O
injury	O
caused	O
by	O
SARS	B-DISO
-	O
CoV	O
,	O
MERS	O
-	O
CoV	O
,	O
as	O
well	O
as	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
-	I-DISO
2	I-DISO
infection	I-DISO
were	O
summarized	O
,	O
which	O
may	O
provide	O
help	O
for	O
further	O
studies	O
on	O
the	O
liver	O
injury	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

ABSTRACT	O
:	O
In	O
late	O
December	O
2019	O
,	O
a	O
cluster	O
of	O
unexplained	O
pneumonia	B-DISO
cases	O
has	O
been	O
reported	O
in	O
Wuhan	O
,	O
China	O
.	O

TITLE	O
:	O
Early	O
dynamics	O
of	O
transmission	O
and	O
control	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
:	O
a	O
mathematical	O
modelling	O
study	O
.	O

Understanding	O
the	O
early	O
transmission	O
dynamics	O
of	O
the	O
infection	B-DISO
and	O
evaluating	O
the	O
effectiveness	O
of	O
control	O
measures	O
is	O
crucial	O
for	O
assessing	O
the	O
potential	O
for	O
sustained	O
transmission	O
to	O
occur	O
in	O
new	O
areas	O
.	O

We	O
estimated	O
that	O
the	O
median	O
daily	O
reproduction	O
number	O
(	O
R	O
Our	O
results	O
show	O
that	O
COVID	B-DISO
-	I-DISO
19	I-DISO
transmission	O
probably	O
declined	O
in	O
Wuhan	O
during	O
late	O
January	O
,	O
2020	O
,	O
coinciding	O
with	O
the	O
introduction	O
of	O
travel	O
control	O
measures	O
.	O

Epidemiological	O
and	O
clinical	O
characteristics	O
of	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
have	O
been	O
reported	O
but	O
risk	O
factors	O
for	O
mortality	O
and	O
a	O
detailed	O
clinical	O
course	B-DISO
of	I-DISO
illness	I-DISO
,	O
including	O
viral	B-DISO
shedding	I-DISO
,	O
have	O
not	O
been	O
well	O
described	O
.	O

Cytokine	O
IL	O
-	O
37	O
has	O
the	O
ability	O
to	O
suppress	O
innate	O
and	O
acquired	O
immune	O
response	O
and	O
also	O
has	O
the	O
capacity	O
to	O
inhibit	O
inflammation	B-DISO
by	O
acting	O
on	O
IL	O
-	O
18Rα	O
receptor	O
.	O

The	O
suppression	B-DISO
of	O
IL	O
-	O
1β	O
by	O
IL	O
-	O
37	O
in	O
inflammatory	O
state	O
induced	O
by	O
coronavirus	B-DISO
-	I-DISO
19	I-DISO
can	O
have	O
a	O
new	O
therapeutic	O
effect	O
previously	O
unknown	O
.	O

IL	O
-	O
38	O
is	O
a	O
potential	O
therapeutic	O
cytokine	O
which	O
inhibits	O
inflammation	B-DISO
in	O
viral	B-DISO
infections	I-DISO
including	O
that	O
caused	O
by	O
coronavirus	B-DISO
-	I-DISO
19	I-DISO
,	O
providing	O
a	O
new	O
relevant	O
strategy	O
.	O

Clinical	O
and	O
CT	O
data	O
of	O
59	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
from	O
January	O
27	O
to	O
February	O
14	O
,	O
2020	O
were	O
retrospectively	O
reviewed	O
,	O
including	O
14	O
laboratory	O
-	O
confirmed	O
non	O
-	O
pregnant	O
adults	O
,	O
16	O
laboratory	O
-	O
confirmed	O
and	O
25	O
clinically	O
-	O
diagnosed	O
pregnant	O
women	O
,	O
and	O
4	O
laboratory	O
-	O
confirmed	O
children	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
clinical	O
characteristics	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
reactivation	O
.	O

We	O
investigated	O
the	O
temporal	O
progression	O
in	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

The	O
estimated	O
median	O
duration	O
of	O
fever	O
in	O
all	O
the	O
patients	O
with	O
fever	O
was	O
10	O
days	O
(	O
95	O
confidential	O
intervals	O
[	O
CIs	B-DISO
]:	O
8	O
-	O
11	O
days	O
)	O
after	O
onset	O
of	O
symptoms	O
.	O

The	O
median	O
duration	O
to	O
negative	O
reverse	O
-	O
transcriptase	O
PCR	O
tests	O
of	O
upper	O
respiratory	O
tract	O
samples	O
was	O
11	O
days	O
(	O
95	O
CIs	B-DISO
:	O
10	O
-	O
12	O
days	O
).	O

TITLE	O
:	O
Arbidol	O
combined	O
with	O
LPV	O
/	O
r	O
versus	O
LPV	O
/	O
r	O
alone	O
against	O
Corona	B-DISO
Virus	I-DISO
Disease	I-DISO
2019	I-DISO
:	O
A	O
retrospective	O
cohort	O
study	O
.	O

In	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
the	O
apparent	O
favorable	O
clinical	O
response	O
with	O
arbidol	O
and	O
LPV	O
/	O
r	O
supports	O
further	O
LPV	O
/	O
r	O
only	O
.	O

ABSTRACT	O
:	O
As	O
of	O
1	O
March	O
2020	O
,	O
Iran	O
has	O
reported	O
987	O
COVID	B-DISO
-	I-DISO
19	I-DISO
cases	O
and	O
including	O
54	O
associated	O
deaths	O
.	O

At	O
least	O
six	O
neighboring	O
countries	O
(	O
Bahrain	O
,	O
Iraq	O
,	O
Kuwait	O
,	O
Oman	O
,	O
Afghanistan	O
and	O
Pakistan	O
)	O
have	O
reported	O
imported	O
COVID	B-DISO
-	I-DISO
19	I-DISO
cases	O
from	O
Iran	O
.	O

The	O
values	O
of	O
D	O
-	O
dimer	O
,	O
fibrin	O
/	O
fibrinogen	O
degradation	O
products	O
(	O
FDP	O
),	O
and	O
fibrinogen	O
(	O
FIB	O
)	O
in	O
all	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
cases	O
were	O
substantially	O
higher	O
than	O
those	O
in	O
healthy	O
controls	O
.	O

TITLE	O
:	O
A	O
tug	O
-	O
of	O
-	O
war	O
between	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
2	O
and	O
host	O
antiviral	O
defence	O
:	O
lessons	O
from	O
other	O
pathogenic	O
viruses	O
.	O

ABSTRACT	O
:	O
World	O
Health	O
Organization	O
has	O
declared	O
the	O
ongoing	O
outbreak	O
of	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
a	O
Public	O
Health	O
Emergency	B-DISO
of	O
International	O
Concern	O
.	O

The	O
severe	O
cases	O
present	O
with	O
pneumonia	B-DISO
,	O
which	O
can	O
progress	O
to	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

We	O
summarize	O
current	O
understanding	O
of	O
the	O
induction	O
of	O
a	O
proinflammatory	O
cytokine	B-DISO
storm	I-DISO
by	O
other	O
highly	O
pathogenic	O
human	O
coronaviruses	O
,	O
their	O
adaptation	O
to	O
humans	O
and	O
their	O
usurpation	O
of	O
the	O
cell	O
death	O
programmes	O
.	O

ABSTRACT	O
:	O
Equine	O
coronavirus	O
(	O
ECoV	O
)	O
is	O
a	O
known	O
cause	O
of	O
fever	O
,	O
anorexia	B-DISO
,	O
and	O
lethargy	B-DISO
in	O
adult	O
horses	O
.	O

Interestingly	O
,	O
4	O
of	O
5	O
horses	O
had	O
moderate	O
to	O
severe	B-DISO
diarrhea	I-DISO
,	O
3	O
had	O
abnormal	O
large	O
colon	O
ultrasonography	O
,	O
2	O
had	O
transient	O
ventricular	B-DISO
tachycardia	I-DISO
and	O
2	O
had	O
clinicopathologic	O
evidence	O
of	O
liver	B-DISO
dysfunction	I-DISO
.	O

TITLE	O
:	O
A	O
systematic	O
review	O
on	O
the	O
efficacy	O
and	O
safety	O
of	O
chloroquine	O
for	O
the	O
treatment	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

PubMed	O
,	O
EMBASE	O
,	O
and	O
three	O
trial	O
Registries	O
were	O
searched	O
for	O
studies	O
on	O
the	O
use	O
of	O
chloroquine	O
in	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

On	O
7	O
January	O
2020	O
,	O
the	O
Chinese	O
authorities	O
identified	O
that	O
the	O
agent	O
causing	O
the	O
outbreak	O
was	O
a	O
new	O
type	O
of	O
virus	O
of	O
the	O
Coronaviridae	O
family	O
,	O
temporarily	O
called	O
«	O
new	O
coronavirus	O
»,	O
2019	O
-	O
nCoV	O
.	O
On	O
January	O
30th	O
,	O
2020	O
,	O
the	O
World	O
Health	O
Organisation	O
(	O
WHO	O
)	O
declared	O
the	O
outbreak	O
an	O
International	O
Emergency	B-DISO
.	O

ABSTRACT	O
:	O
Since	O
the	O
emergence	O
of	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
(	O
formerly	O
known	O
as	O
the	O
2019	O
novel	O
coronavirus	O
[	O
2019	O
-	O
nCoV	O
])	O
in	O
Wuhan	O
,	O
China	O
in	O
December	O
2019	O
,	O
which	O
is	O
caused	O
by	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
2	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
),	O
more	O
than	O
75	O
,	O
000	O
cases	O
have	O
been	O
reported	O
in	O
32	O
countries	O
/	O
regions	O
,	O
resulting	O
in	O
more	O
than	O
2000	O
deaths	O
worldwide	O
.	O

Despite	O
the	O
fact	O
that	O
most	O
COVID	B-DISO
-	I-DISO
19	I-DISO
cases	O
and	O
mortalities	O
were	O
reported	O
in	O
China	O
,	O
the	O
WHO	O
has	O
declared	O
this	O
outbreak	O
as	O
the	O
sixth	O
public	O
health	O
emergency	B-DISO
of	O
international	O
concern	O
.	O

The	O
COVID	B-DISO
-	I-DISO
19	I-DISO
can	O
present	O
as	O
an	O
asymptomatic	O
carrier	O
state	O
,	O
acute	B-DISO
respiratory	I-DISO
disease	I-DISO
,	O
and	O
pneumonia	B-DISO
.	O

Adults	O
represent	O
the	O
population	O
with	O
the	O
highest	O
infection	B-DISO
rate	O
;	O
however	O
,	O
neonates	O
,	O
children	O
,	O
and	O
elderly	O
patients	O
can	O
also	O
be	O
infected	O
by	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
.	O

In	O
addition	O
,	O
nosocomial	B-DISO
infection	I-DISO
of	O
hospitalized	O
patients	O
and	O
healthcare	O
workers	O
,	O
and	O
viral	O
transmission	O
from	O
asymptomatic	O
carriers	O
are	O
possible	O
.	O

Indeed	O
,	O
age	O
and	O
disease	O
severity	O
may	O
be	O
correlated	O
with	O
the	O
outcomes	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

Moreover	O
,	O
high	O
to	O
moderate	O
correlations	O
between	O
Google	O
relative	O
search	O
volume	O
(	O
RSV	O
)	O
and	O
COVID	B-DISO
-	I-DISO
19	I-DISO
cases	O
were	O
found	O
in	O
Taipei	O
(	O
lag	O
-	O
3	O
),	O
New	O
Taipei	O
(	O
lag	O
-	O
2	O
),	O
Taoyuan	O
(	O
lag	O
-	O
2	O
),	O
Tainan	O
(	O
lag	O
-	O
1	O
),	O
Taichung	O
(	O
lag0	O
),	O
and	O
Kaohsiung	O
(	O
lag0	O
).	O

Compared	O
with	O
the	O
Non	O
-	O
severe	O
patient	O
,	O
the	O
pooled	O
odds	O
ratio	O
of	O
hypertension	B-DISO
,	O
respiratory	B-DISO
system	I-DISO
disease	I-DISO
,	O
cardiovascular	B-DISO
disease	I-DISO
in	O
severe	O
patients	O
were	O
(	O
OR	O
2	O
.	O
36	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
46	O
-	O
3	O
.	O
83	O
),	O
(	O
OR	O
2	O
.	O
46	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
76	O
-	O
3	O
.	O
44	O
)	O
and	O
(	O
OR	O
3	O
.	O
42	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
88	O
-	O
6	O
.	O
22	O
)	O
respectively	O
.	O

This	O
study	O
aimed	O
to	O
clarify	O
the	O
characteristics	O
of	O
patients	O
with	O
refractory	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

Nearly	O
50	O
%	O
COVID	B-DISO
-	I-DISO
19	I-DISO
patients	O
could	O
not	O
reach	O
obvious	O
clinical	O
and	O
radiological	O
remission	B-DISO
within	O
10	O
days	O
after	O
hospitalization	O
.	O

ABSTRACT	O
:	O
Recently	O
,	O
some	O
global	O
cases	O
of	O
2019	O
novel	O
coronavirus	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
pneumonia	B-DISO
have	O
been	O
caused	O
by	O
second	O
-	O
or	O
third	O
-	O
generation	O
transmission	O
of	O
the	O
viral	B-DISO
infection	I-DISO
,	O
resulting	O
in	O
no	O
traceable	O
epidemiological	O
history	O
.	O

TITLE	O
:	O
Characterization	O
and	O
evaluation	O
of	O
the	O
pathogenicity	O
of	O
a	O
natural	O
recombinant	O
transmissible	O
gastroenteritis	B-DISO
virus	O
in	O
China	O
.	O

Our	O
findings	O
provide	O
valuable	O
information	O
about	O
genetic	O
diversity	O
and	O
infection	B-DISO
mechanism	O
of	O
the	O
coronavirus	O
family	O
.	O

TITLE	O
:	O
Early	O
estimation	O
of	O
the	O
case	O
fatality	O
rate	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
mainland	O
China	O
:	O
a	O
data	O
-	O
driven	O
analysis	O
.	O

Daily	O
numbers	O
of	O
laboratory	O
-	O
confirmed	O
COVID	B-DISO
-	I-DISO
19	I-DISO
cases	O
and	O
deaths	O
were	O
collected	O
from	O
January	O
10	O
to	O
February	O
3	O
,	O
2020	O
and	O
divided	O
into	O
three	O
clusters	O
:	O

This	O
challenge	O
will	O
now	O
be	O
faced	O
by	O
the	O
whole	O
global	O
health	O
community	O
dealing	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
since	O
both	O
coronaviruses	O
have	O
similar	O
presentation	O
.	O

Those	O
patients	O
should	O
now	O
be	O
tested	O
for	O
both	O
MERS	O
-	O
CoV	O
and	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
simultaneously	O
,	O
and	O
with	O
the	O
continuing	O
wide	O
international	O
spread	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
,	O
the	O
travel	O
history	O
to	O
China	O
in	O
the	O
last	O
14	O
days	O
will	O
be	O
of	O
less	O
significance	O
.	O

ABSTRACT	O
:	O
In	O
December	O
2019	O
,	O
a	O
novel	O
coronavirus	O
(	O
CoV	O
)	O
epidemic	O
,	O
caused	O
by	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
-	O
2	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
)	O
emerged	O
from	O
China	O
.	O

In	O
this	O
article	O
,	O
the	O
current	O
evidence	O
suggesting	O
possible	O
human	O
CoV	O
infection	B-DISO
of	O
ocular	O
tissue	O
is	O
reviewed	O
.	O

We	O
hope	O
that	O
this	O
article	O
will	O
serve	O
as	O
a	O
start	O
for	O
further	O
research	O
into	O
the	O
ocular	O
implications	O
of	O
human	O
CoV	O
infections	B-DISO
.	O

The	O
most	O
common	O
symptoms	O
were	O
fever	O
(	O
60	O
[	O
87	O
%]),	O
cough	B-DISO
(	O
38	O
[	O
55	O
%]),	O
and	O
fatigue	B-DISO
(	O
29	O
[	O
42	O
%]).	O

ABSTRACT	O
:	O
The	O
recent	O
outbreak	O
of	O
pneumonia	B-DISO
-	O
causing	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
China	O
is	O
an	O
urgent	O
global	O
public	O
health	O
issue	O
with	O
an	O
increase	O
in	O
mortality	O
and	O
morbidity	O
.	O

One	O
week	O
later	O
,	O
she	O
was	O
hospitalised	O
with	O
pneumonia	B-DISO
and	O
tested	O
positive	O
for	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
.	O

Person	O
-	O
to	O
-	O
person	O
transmission	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
occurred	O
between	O
two	O
people	O
with	O
prolonged	O
,	O
unprotected	O
exposure	O
while	O
Patient	O
1	O
was	O
symptomatic	O
.	O

Despite	O
active	O
symptom	B-DISO
monitoring	O
and	O
testing	O
of	O
symptomatic	O
and	O
some	O
asymptomatic	O
contacts	O
,	O
no	O
further	O
transmission	O
was	O
detected	O
.	O

10	O
(	O
27	O
%)	O
patients	O
had	O
chronic	O
medical	O
illnesses	O
,	O
including	O
4	O
(	O
11	O
%)	O
with	O
diabetes	B-DISO
,	O
8	O
(	O
22	O
%)	O
with	O
hypertension	B-DISO
,	O
and	O
8	O
(	O
22	O
%)	O
with	O
digestive	B-DISO
system	I-DISO
disease	I-DISO
.	O

TITLE	O
:	O
Composition	O
of	O
human	O
-	O
specific	O
slow	O
codons	O
and	O
slow	O
di	O
-	O
codons	O
in	O
SARS	B-DISO
-	O
CoV	O
and	O
2019	O
-	O
nCoV	O
are	O
lower	O
than	O
other	O
coronaviruses	O
suggesting	O
a	O
faster	O
protein	O
synthesis	O
rate	O
of	O
SARS	B-DISO
-	O
CoV	O
and	O
2019	O
-	O
nCoV	O
.	O
ABSTRACT	O
:	O
Translation	O
of	O
a	O
genetic	O
codon	O
without	O
a	O
cognate	O
tRNA	O
gene	O
is	O
affected	O
by	O
both	O
the	O
cognate	O
tRNA	O
availability	O
and	O
the	O
interaction	O
with	O
non	O
-	O
cognate	O
isoacceptor	O
tRNAs	O
.	O

The	O
pooled	O
analysis	O
revealed	O
that	O
platelet	O
count	O
was	O
significantly	O
lower	O
in	O
patients	O
with	O
more	O
severe	O
COVID	B-DISO
-	I-DISO
19	I-DISO
(	O
WMD	O
-	O
31	O
×	O
10	O
Low	O
platelet	O
count	O
is	O
associated	O
with	O
increased	O
risk	O
of	O
severe	O
disease	O
and	O
mortality	O
in	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
and	O
thus	O
should	O
serve	O
as	O
clinical	O
indicator	O
of	O
worsening	O
illness	O
during	O
hospitalization	O
.	O

Since	O
that	O
time	O
,	O
Italy	O
and	O
nations	O
throughout	O
the	O
world	O
have	O
adopted	O
very	O
stringent	O
and	O
severe	O
measures	O
to	O
protect	O
populations	O
from	O
spread	O
of	O
infection	B-DISO
.	O

As	O
this	O
virus	O
spreads	O
globally	O
,	O
countries	O
need	O
to	O
urgently	O
prepare	O
human	O
resources	O
,	O
infrastructure	O
and	O
facilities	O
to	O
treat	O
severe	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

Some	O
13	O
.	O
9	O
%	O
(	O
95	O
%	O
CI	O
6	O
.	O
2	O
-	O
21	O
.	O
5	O
%)	O
of	O
hospitalized	O
patients	O
had	O
fatal	B-DISO
outcomes	I-DISO
(	O
case	O
fatality	O
rate	O
,	O
CFR	O
).	O

TITLE	O
:	O
Testing	O
the	O
repatriated	O
for	O
SARS	B-DISO
-	O
Cov2	O
:	O
Should	O
laboratory	O
-	O
based	O
quarantine	O
replace	O
traditional	O
quarantine	O
?	O

The	O
CT	O
scan	O
showed	O
that	O
most	O
patients	O
had	O
bilateral	B-DISO
pneumonia	I-DISO
in	O
the	O
three	O
groups	O
(	O
80	O
.	O
00	O
%,	O
76	O
.	O
47	O
%,	O
and	O
73	O
.	O
68	O
%,	O
respectively	O
).	O

This	O
activity	O
is	O
conserved	O
on	O
the	O
SARS	B-DISO
-	O
Cov	O
-	O
2	O
,	O
thus	O
placing	O
teicoplanin	O
as	O
a	O
potential	O
treatment	O
for	O
patients	O
with	O
this	O
virus	O
.	O

Additionally	O
,	O
we	O
report	O
that	O
GA	O
inhibits	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
genome	O
replication	O
and	O
Zika	O
virus	O
(	O
ZIKV	O
)	O
infection	B-DISO
of	O
normal	O
human	O
astrocytes	O
(	O
NHA	O
).	O

Thus	O
,	O
in	O
light	O
of	O
the	O
strong	O
effect	O
of	O
GA	O
on	O
viral	B-DISO
infection	I-DISO
,	O
even	O
after	O
the	O
infection	B-DISO
begins	O
,	O
it	O
may	O
potentially	O
be	O
used	O
to	O
treat	O
acute	B-DISO
infections	I-DISO
(	O
e	O
.	O
g	O
.	O
Coronavirus	O
,	O
EBOV	O
,	O
ZIKV	O
,	O
IAV	O
and	O
measles	B-DISO
),	O
and	O
also	O
topically	O
for	O
the	O
successful	O
treatment	O
of	O
active	O
lesions	O
(	O
e	O
.	O
g	O
.	O
HSV	O
-	O
1	O
,	O
HSV	O
-	O
2	O
and	O
varicella	B-DISO
-	O
zoster	B-DISO
virus	O
(	O
VZV	O
)).	O

TITLE	O
:	O
A	O
55	O
-	O
Day	O
-	O
Old	O
Female	O
Infant	O
infected	O
with	O
COVID	B-DISO
19	I-DISO
:	O
presenting	O
with	O
pneumonia	B-DISO
,	O
liver	O
injury	O
,	O
and	O
heart	O
damage	O
.	O

RESULTS	O
:	O
The	O
two	O
confirmed	O
children	O
only	O
presented	O
with	O
mild	O
respiratory	O
or	O
gastrointestinal	B-DISO
symptoms	I-DISO
.	O

TITLE	O
:	O
Safety	O
and	O
efficacy	O
of	O
different	O
anesthetic	O
regimens	O
for	O
parturients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
undergoing	O
Cesarean	O
delivery	O
:	O
a	O
case	O
series	O
of	O
17	O
patients	O
.	O

We	O
also	O
recorded	O
the	O
patients	O
'	O
demographic	O
and	O
clinical	O
characteristics	O
,	O
anesthesia	B-DISO
and	O
surgery	O
-	O
related	O
data	O
,	O
maternal	O
and	O
neonatal	O
complications	O
,	O
as	O
well	O
as	O
the	O
health	O
status	O
of	O
the	O
involved	O
medical	O
staff	O
.	O

ABSTRACT	O
:	O
The	O
emergence	O
of	O
a	O
novel	O
coronavirus	O
,	O
termed	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
,	O
and	O
the	O
potentially	O
life	O
-	O
threating	O
respiratory	B-DISO
disease	I-DISO
that	O
it	O
can	O
produce	O
,	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
has	O
rapidly	O
spread	O
across	O
the	O
globe	O
creating	O
a	O
massive	O
public	O
health	O
problem	O
.	O

ABSTRACT	O
:	O
SinceDecember	O
2019	O
,	O
novelcoronavirus	O
infected	O
pneumonia	B-DISO
emerged	O
in	O
Wuhan	O
city	O
and	O
rapidly	O
spread	O
throughout	O
China	O
.	O

CONCLUSIONS	O
:	O
Single	O
-	O
center	O
case	O
series	O
of	O
the	O
30	O
hospitalized	O
patients	O
with	O
confirmed	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
Huizhou	O
municipal	O
central	O
hospital	O
,	O
presumed	O
that	O
the	O
number	O
of	O
platelets	O
and	O
their	O
dynamic	O
changes	O
during	O
the	O
treatment	O
may	O
have	O
suggestion	O
on	O
the	O
severity	O
and	O
prognosis	O
of	O
disease	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
look	O
for	O
the	O
warning	O
index	O
in	O
severe	O
COVID	B-DISO
-	I-DISO
19	I-DISO
patients	O
.	O

ABSTRACT	O
:	O
Since	O
December	O
2019	O
,	O
world	O
healthcare	O
community	O
faced	O
with	O
Coronavirus	B-DISO
Disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
outbreak	O
caused	O
by	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
.	O

ABSTRACT	O
:	O
The	O
current	O
outbreak	O
of	O
Coronavirus	B-DISO
Disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
has	O
raised	O
great	O
concern	O
worldwide	O
,	O
but	O
its	O
impact	O
on	O
transplant	O
recipients	O
is	O
unknown	O
.	O

We	O
report	O
here	O
the	O
clinical	O
features	O
and	O
therapeutic	O
course	O
of	O
the	O
first	O
reported	O
renal	O
transplant	O
recipient	O
with	O
confirmed	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pneumonia	I-DISO
.	O

TITLE	O
:	O
Perinatal	O
Transmission	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
Associated	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
:	O
Should	O
We	O
Worry	O
?	O

The	O
application	O
of	O
the	O
model	O
is	O
illustrated	O
with	O
a	O
case	O
study	O
based	O
on	O
the	O
outbreak	O
of	O
the	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
in	O
Wuhan	O
,	O
China	O
.	O

ABSTRACT	O
:	O
We	O
believe	O
a	O
point	O
-	O
of	O
-	O
care	O
(	O
PoC	O
)	O
device	O
for	O
the	O
rapid	O
detection	O
of	O
the	O
2019	O
novel	O
Coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
)	O
is	O
crucial	O
and	O
urgently	O
needed	O
.	O

Reported	O
symptoms	O
include	O
fever	O
,	O
cough	B-DISO
,	O
fatigue	B-DISO
,	O
pneumonia	B-DISO
,	O
headache	B-DISO
,	O
diarrhea	B-DISO
,	O
hemoptysis	B-DISO
,	O
and	O
dyspnea	B-DISO
.	O

TITLE	O
:	O
The	O
difference	O
in	O
the	O
incubation	O
period	O
of	O
2019	O
novel	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
)	O
infection	B-DISO
between	O
travelers	O
to	O
Hubei	O
and	O
non	O
-	O
travelers	O
:	O
The	O
need	O
of	O
a	O
longer	O
quarantine	O
period	O
.	O

However	O
,	O
little	O
information	O
is	O
available	O
about	O
the	O
targets	O
of	O
immune	O
responses	O
to	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
.	O

TITLE	O
:	O
Diagnosis	O
of	O
chronic	B-DISO
thromboembolic	I-DISO
pulmonary	I-DISO
hypertension	I-DISO
after	O
acute	O
pulmonary	B-DISO
embolism	I-DISO
.	O

Untreated	O
,	O
CTEPH	B-DISO
is	O
fatal	O
,	O
but	O
,	O
if	O
diagnosed	O
in	O
time	O
,	O
successful	O
surgical	O
(	O
pulmonary	O
endarterectomy	O
),	O
medical	O
(	O
pulmonary	B-DISO
hypertension	I-DISO
drugs	O
)	O
and	O
/	O
or	O
interventional	O
(	O
balloon	O
pulmonary	O
angioplasty	O
)	O
therapies	O
have	O
been	O
shown	O
to	O
improve	O
clinical	O
outcomes	O
,	O
especially	O
in	O
case	O
of	O
successful	O
pulmonary	O
endarterectomy	O
.	O

TITLE	O
:	O
Novel	O
Resolution	O
Mediators	O
of	O
Severe	O
Systemic	O
Inflammation	B-DISO
.	O

Thus	O
,	O
increasing	O
evidence	O
indicates	O
that	O
resolution	O
of	O
an	O
acute	B-DISO
inflammatory	I-DISO
response	I-DISO
,	O
considered	O
an	O
active	O
process	O
,	O
is	O
the	O
ideal	O
outcome	O
that	O
leads	O
to	O
tissue	O
restoration	O
and	O
organ	O
function	O
.	O

CT	O
imaging	O
is	O
helpful	O
for	O
the	O
evaluation	O
of	O
the	O
novel	B-DISO
coronavirus	I-DISO
disease	I-DISO
2019	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
pneumonia	B-DISO
.	O

TITLE	O
:	O
Rapidly	O
increasing	O
cumulative	O
incidence	O
of	O
coronavirus	O
disease	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
in	O
the	O
European	O
Union	O
/	O
European	O
Economic	O
Area	O
and	O
the	O
United	O
Kingdom	O
,	O
1	O
January	O
to	O
15	O
March	O
2020	O
.	O

TITLE	O
:	O
Influenza	B-DISO
-	O
associated	O
pneumonia	B-DISO
as	O
reference	O
to	O
assess	O
seriousness	O
of	O
coronavirus	O
disease	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
).	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
safety	O
,	O
feasibility	O
,	O
and	O
possible	O
adverse	O
events	O
of	O
single	O
-	O
dose	O
human	O
umbilical	O
cord	B-DISO
-	O
derived	O
mesenchymal	O
stem	O
cells	O
in	O
patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
.	O

Scaling	O
for	O
doses	O
was	O
required	O
by	O
Taiwan	O
Food	O
and	O
Drug	O
Administration	O
as	O
follows	O
:	O
the	O
first	O
three	O
patients	O
received	O
low	O
-	O
dose	O
human	O
umbilical	O
cord	B-DISO
-	O
derived	O
mesenchymal	O
stem	O
cells	O
(	O
1	O
.	O
0	O
×	O
10	O
cells	O
/	O
kg	O
),	O
the	O
next	O
three	O
patients	O
with	O
intermediate	O
dose	O
(	O
5	O
.	O
0	O
×	O
10	O
cells	O
/	O
kg	O
),	O
and	O
the	O
final	O
three	O
patients	O
with	O
high	O
dose	O
(	O
1	O
.	O
0	O
×	O
10	O
cells	O
/	O
kg	O
)	O
between	O
December	O
2017	O
and	O
August	O
2019	O
.	O

ABSTRACT	O
:	O
The	O
reliable	O
detection	O
of	O
transcription	O
events	O
via	O
the	O
quantification	O
of	O
the	O
corresponding	O
mRNA	O
is	O
of	O
paramount	O
importance	O
for	O
the	O
diagnostics	O
of	O
infections	B-DISO
and	O
diseases	O
.	O

The	O
disease	O
caused	O
by	O
SARSCoV	O
-	O
2	O
is	O
called	O
Corona	O
Virus	B-DISO
Disease	I-DISO
(	O
COVID	O
-	O
2019	O
).	O

Finally	O
,	O
we	O
drafted	O
the	O
prevention	O
and	O
control	O
strategies	O
and	O
recommendations	O
to	O
make	O
a	O
reference	O
for	O
medical	O
staff	O
of	O
general	O
surgery	O
to	O
fight	O
against	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

Susceptible	O
transitions	O
to	O
Infected	O
every	O
hour	O
with	O
a	O
probability	O
determined	O
by	O
the	O
ratio	O
of	O
Infected	O
and	O
the	O
congestion	B-DISO
of	O
area	O
.	O

Departments	O
of	O
Anaesthesia	B-DISO
,	O
Intensive	O
Care	O
and	O
emergency	B-DISO
medicine	O
will	O
envisage	O
major	O
challenges	O
.	O

ABSTRACT	O
:	O
The	O
novel	O
coronavirus	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
outbreak	O
,	O
which	O
was	O
identified	O
in	O
late	O
2019	O
,	O
requires	O
special	O
attention	O
because	O
of	O
its	O
future	O
epidemics	O
and	O
possible	O
global	O
threats	O
.	O

RESULTS	O
:	O
Multiple	O
patchy	O
ground	O
-	O
glass	O
opacities	B-DISO
(	O
GGOs	O
)	O
were	O
seen	O
in	O
bilateral	O
lung	O
,	O
mostly	O
in	O
subpleural	O
areas	O
.	O

A	O
15	O
-	O
year	O
-	O
old	O
Japanese	O
girl	O
with	O
a	O
history	O
of	O
atopic	B-DISO
asthma	I-DISO
and	O
dermatitis	B-DISO
was	O
admitted	O
to	O
the	O
emergency	B-DISO
department	O
with	O
the	O
anaphylactic	O
symptoms	O
of	O
urticaria	B-DISO
,	O
skin	O
flushing	B-DISO
,	O
throat	B-DISO
discomfort	I-DISO
,	O
acute	B-DISO
dyspnea	I-DISO
and	O
severe	O
wheezing	B-DISO
that	O
developed	O
shortly	O
after	O
the	O
ingestion	O
of	O
home	O
-	O
cooked	O
buchimgae	O
(	O
Korean	O
pancake	O
)	O
prepared	O
with	O
commercial	O
mixed	O
wheat	O
flour	O
.	O

The	O
patient	O
'	O
s	O
serum	O
specific	O
IgE	B-DISO
analysis	O
was	O
positive	O
for	O
antibodies	O
to	O
dust	O
mite	O
allergens	O
.	O

The	O
shortage	O
of	O
complete	O
genomic	O
sequences	O
available	O
impairs	O
our	O
understanding	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
introduction	O
and	O
establishment	O
in	O
the	O
country	O
.	O

To	O
better	O
understand	O
its	O
dynamics	O
in	O
Italy	O
,	O
we	O
analysed	O
complete	O
genomes	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
isolates	O
,	O
obtained	O
directly	O
from	O
clinical	O
samples	O
.	O

ABSTRACT	O
:	O
We	O
read	O
with	O
great	O
interest	O
a	O
recent	O
editorial	O
by	O
Liang	O
et	O
al	O
.	O
on	O
the	O
management	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
pregnancy	O
.	O

TITLE	O
:	O
The	O
critical	O
role	O
of	O
laboratory	O
medicine	O
during	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
and	O
other	O
viral	O
outbreaks	O
.	O

ABSTRACT	O
:	O
Coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
,	O
abbreviated	O
to	O
COVID	B-DISO
-	I-DISO
19	I-DISO
and	O
sustained	O
by	O
the	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
2	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
),	O
is	O
the	O
latest	O
biological	O
hazard	O
to	O
assume	O
the	O
relevance	O
of	O
insidious	O
worldwide	O
threat	O
.	O

The	O
predominant	O
CT	O
characteristics	O
consisted	O
of	O
ground	O
glass	O
opacity	B-DISO
(	O
67	O
%),	O
bilateral	O
sides	O
involved	O
(	O
86	O
%),	O
both	O
peripheral	O
and	O
central	O
distribution	O
(	O
74	O
%),	O
and	O
lower	O
zone	O
involvement	O
(	O
96	O
%).	O

Testing	O
on	O
its	O
own	O
will	O
not	O
stop	O
the	O
spread	O
of	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
.	O

Spreading	O
mainly	O
through	O
the	O
droplet	O
route	O
,	O
the	O
virus	O
causes	O
mild	O
symptoms	O
in	O
the	O
majority	O
of	O
cases	O
,	O
the	O
most	O
common	O
being	O
:	O
fever	O
(	O
80	O
%),	O
dry	B-DISO
cough	I-DISO
(	O
56	O
%),	O
fatigue	B-DISO
(	O
22	O
%)	O
and	O
muscle	B-DISO
pain	I-DISO
(	O
7	O
%);	O
less	O
common	O
symptoms	O
include	O
a	O
sore	B-DISO
throat	I-DISO
,	O
a	O
runny	B-DISO
nose	I-DISO
,	O
diarrhea	B-DISO
,	O
hemoptysis	B-DISO
and	O
chills	B-DISO
.	O

Due	O
to	O
the	O
fact	O
that	O
effective	O
causal	O
treatment	O
is	O
not	O
yet	O
available	O
and	O
the	O
number	O
of	O
infections	B-DISO
and	O
deaths	O
increases	O
day	O
by	O
day	O
,	O
infection	B-DISO
prevention	O
and	O
strict	O
adherence	O
to	O
recommendations	O
of	O
infection	B-DISO
control	O
organizations	O
remain	O
the	O
basis	O
for	O
fighting	O
the	O
virus	O
.	O

Besides	O
that	O
,	O
hypercapnic	B-DISO
respiratory	I-DISO
failure	I-DISO
in	O
patients	O
with	O
acute	O
exacerbation	O
of	O
COPD	B-DISO
(	O
AECOPD	O
)	O
or	O
acute	O
respiratory	O
syndrome	B-DISO
(	O
ARDS	B-DISO
)	O
is	O
common	O
and	O
may	O
require	O
extracorporeal	O
elimination	O
of	O
carbon	O
dioxide	O
by	O
ECCO	O

Misdiagnosed	O
infection	B-DISO
can	O
progress	O
to	O
a	O
wide	O
range	O
of	O
life	O
-	O
threatening	O
pathologies	O
,	O
including	O
severe	B-DISO
anemia	I-DISO
and	O
cerebral	B-DISO
malaria	I-DISO
which	O
can	O
lead	O
to	O
death	O
even	O
few	O
days	O
after	O
first	O
symptoms	O
appearance	O
.	O

Prolonged	O
anemia	B-DISO
after	O
treatment	O
can	O
be	O
a	O
consequence	O
of	O
artemisine	O
usage	O
as	O
well	O
as	O
a	O
severe	O
malaria	B-DISO
sequel	O
.	O

TITLE	O
:	O
Co	B-DISO
-	I-DISO
infection	I-DISO
with	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
and	O
Human	O
Metapneumovirus	O
.	O

TITLE	O
:	O
[	O
Standardized	O
diagnosis	O
and	O
treatment	O
of	O
colorectal	B-DISO
cancer	I-DISO
during	O
the	O
outbreak	O
of	O
corona	B-DISO
virus	I-DISO
disease	I-DISO
2019	I-DISO
in	O
Renji	O
hospital	O
].	O

It	O
has	O
been	O
proven	O
that	O
COVID	B-DISO
-	I-DISO
19	I-DISO
can	O
be	O
transmitted	B-DISO
from	O
human	O
to	O
human	O
and	O
cause	O
hospital	B-DISO
infection	I-DISO
,	O
which	O
seriously	O
threatens	O
surgical	O
staffs	O
and	O
inpatients	O
.	O

ABSTRACT	O
:	O
Three	O
clusters	O
of	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
linked	O
to	O
a	O
tour	O
group	O
from	O
China	O
,	O
a	O
company	O
conference	O
,	O
and	O
a	O
church	O
were	O
identified	O
in	O
Singapore	O
in	O
February	O
,	O
2020	O
.	O

All	O
43	O
patients	O
(	O
59	O
%)	O
with	O
common	O
type	O
presented	O
unique	O
or	O
multiple	O
ground	O
-	O
glass	O
opacities	B-DISO
(	O
GGO	O
)	O
in	O
the	O
periphery	O
of	O
the	O
lungs	O
,	O
with	O
or	O
without	O
interlobular	O
septal	O
thickening	O
.	O

Traditional	O
respiratory	O
support	O
consists	O
mainly	O
of	O
mechanical	O
ventilation	O
,	O
but	O
the	O
prognosis	O
of	O
this	O
condition	B-DISO
is	O
still	O
poor	O
.	O

Awake	O
""""	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
maintains	O
oxygenation	O
,	O
improves	O
ventilation	O
,	O
adequately	O
allows	O
the	O
injured	O
lungs	O
to	O
rest	O
,	O
and	O
avoids	O
complications	O
associated	O
with	O
sedation	B-DISO
,	O
intubation	O
,	O
and	O
mechanical	O
ventilation	O
.	O

Two	O
critically	B-DISO
ill	I-DISO
patients	O
underwent	O
invasive	O
mechanical	O
ventilation	O
.	O

In	O
this	O
series	O
of	O
severe	O
pediatric	O
patients	O
in	O
Wuhan	O
,	O
polypnea	B-DISO
was	O
the	O
most	O
common	O
symptom	B-DISO
,	O
followed	O
by	O
fever	O
and	O
cough	B-DISO
.	O

ABSTRACT	O
:	O
As	O
the	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
outbreak	O
is	O
ongoing	O
,	O
the	O
number	O
of	O
individuals	O
to	O
be	O
tested	O
for	O
COVID	B-DISO
-	I-DISO
19	I-DISO
is	O
rapidly	O
increasing	O
.	O

Herein	O
,	O
we	O
present	O
the	O
overall	O
concept	O
,	O
advantages	O
,	O
and	O
limitations	O
of	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
DT	O
screening	O
centers	O
.	O

In	O
this	O
report	O
,	O
we	O
present	O
mild	O
clinical	O
course	O
of	O
her	O
pneumonia	B-DISO
that	O
did	O
not	O
require	O
antiviral	O
treatment	O
and	O
serial	O
viral	O
test	O
results	O
from	O
multiple	O
specimens	O
.	O

TITLE	O
:	O
Social	O
Capital	O
and	O
Sleep	O
Quality	O
in	O
Individuals	O
Who	O
Self	O
-	O
Isolated	O
for	O
14	O
Days	O
During	O
the	O
Coronavirus	B-DISO
Disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
Outbreak	O
in	O
January	O
2020	O
in	O
China	O
.	O

TITLE	O
:	O
Prediction	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
(	O
2019	O
-	O
nCoV	O
)	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
ABSTRACT	O
:	O
We	O
prepared	O
the	O
three	O
-	O
dimensional	O
model	O
of	O
the	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
(	O
aka	O
2019	O
-	O
nCoV	O
)	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O

Patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
can	O
progress	O
from	O
asymptomatic	O
or	O
mild	O
illness	O
to	O
hypoxemic	O
respiratory	B-DISO
failure	I-DISO
or	O
multisystem	B-DISO
organ	I-DISO
failure	I-DISO
,	O
necessitating	O
intubation	O
and	O
intensive	O
care	O
management	O
.	O

So	O
far	O
,	O
actions	O
have	O
been	O
taken	O
including	O
but	O
not	O
limited	O
to	O
nationwide	O
actions	O
and	O
online	O
education	O
regarding	O
special	O
procedures	O
of	O
airway	O
management	O
,	O
oxygen	O
therapy	O
,	O
ventilation	O
support	O
,	O
hemodynamic	O
management	O
,	O
sedation	B-DISO
,	O
and	O
analgesia	B-DISO
.	O

However	O
,	O
PMX	O
-	O
HP	O
has	O
seldom	O
achieved	O
expectations	O
in	O
randomized	O
trials	O
targeting	O
nonspecific	O
overall	O
sepsis	B-DISO
patients	O
.	O

We	O
used	O
a	O
prospective	O
nationwide	O
cohort	O
targeting	O
consecutive	O
adult	O
patients	O
with	O
severe	B-DISO
sepsis	I-DISO
(	O
Sepsis	B-DISO
-	O
2	O
)	O
in	O
59	O
intensive	O
care	O
units	O
in	O
Japan	O
.	O

To	O
identify	O
best	O
targets	O
for	O
PMX	O
-	O
HP	O
,	O
we	O
developed	O
a	O
non	O
-	O
linear	O
restricted	O
cubic	O
spline	O
model	O
including	O
two	O
-	O
way	O
interaction	O
term	O
(	O
treatment	O
×	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
[	O
APACHE	O
]	O
II	O
score	O
/	O
Sequential	O
Organ	B-DISO
Failure	I-DISO
Assessment	O
[	O
SOFA	O
]	O
score	O
)	O
and	O
three	O
-	O
way	O
interaction	O
term	O
(	O
treatment	O
×	O
age	O
×	O
each	O
score	O
).	O

Three	O
-	O
way	O
interaction	O
analysis	O
revealed	O
suppressed	O
risk	O
hazard	O
in	O
the	O
PMX	O
-	O
HP	O
group	O
versus	O
control	O
group	O
only	O
in	O
septic	B-DISO
shock	I-DISO
patients	O
with	O
high	O
age	O
and	O
in	O
the	O
most	O
severe	O
subset	O
of	O
both	O
scores	O
,	O
whereas	O
increased	O
risk	O
hazard	O
was	O
observed	O
in	O
those	O
with	O
high	O
age	O
but	O
in	O
the	O
lower	O
severity	O
subset	O
of	O
both	O
scores	O
.	O

Our	O
patients	O
had	O
some	O
severe	O
complications	O
such	O
as	O
septic	B-DISO
shock	I-DISO
,	O
respiratory	B-DISO
failure	I-DISO
and	O
obliterans	O
bronchiolitis	B-DISO
(	O
BO	O
)	O
etc	O
.	O

They	O
all	O
died	O
because	O
of	O
out	O
-	O
of	O
-	O
control	O
severe	O
infections	B-DISO
.	O

In	O
-	O
droplet	O
infection	B-DISO
of	O
host	O
cells	O
by	O
the	O
virus	O
was	O
first	O
demonstrated	O
,	O
followed	O
by	O
demonstration	O
of	O
in	O
-	O
droplet	O
neutralization	O
by	O
nAbs	O
produced	O
from	O
a	O
single	O
Ab	O
-	O
producing	O
hybridoma	O
cell	O
.	O

TITLE	O
:	O
COVID	B-DISO
-	I-DISO
19	I-DISO
:	O
a	O
recommendation	O
to	O
examine	O
the	O
effect	O
of	O
hydroxychloroquine	O
in	O
preventing	O
infection	B-DISO
and	O
progression	O
.	O

The	O
aim	O
of	O
the	O
present	O
review	O
of	O
the	O
European	O
Dialysis	O
(	O
EUDIAL	O
)	O
Working	O
Group	O
of	O
ERA	O
-	O
EDTA	O
is	O
to	O
provide	O
recommendations	O
for	O
the	O
prevention	O
,	O
mitigation	O
and	O
containment	O
in	O
haemodialysis	O
centres	O
of	O
the	O
emerging	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pandemic	O
.	O

The	O
management	O
of	O
patients	O
on	O
dialysis	O
affected	O
by	O
COVID	B-DISO
-	I-DISO
19	I-DISO
must	O
be	O
carried	O
out	O
according	O
to	O
strict	O
protocols	O
to	O
minimize	O
the	O
risk	O
for	O
other	O
patients	O
and	O
personnel	O
taking	O
care	O
of	O
these	O
patients	O
.	O

Only	O
patients	O
with	O
confirmed	O
infection	B-DISO
were	O
included	O
.	O

Sixteen	O
patients	O
(	O
80	O
%)	O
were	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
;	O
13	O
patients	O
(	O
81	O
%)	O
had	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
11	O
were	O
intubated	O
(	O
68	O
.	O
75	O
%),	O
9	O
had	O
acute	O
renal	O
injury	O
(	O
56	O
.	O
25	O
%),	O
and	O
3	O
required	O
dialysis	O
(	O
18	O
.	O
75	O
%).	O

Only	O
3	O
patients	O
(	O
15	O
.	O
8	O
%)	O
with	O
early	O
-	O
stage	O
cancers	B-DISO
survived	O
.	O

Patients	O
with	O
hematologic	B-DISO
malignancies	I-DISO
and	O
advanced	O
solid	B-DISO
tumors	I-DISO
had	O
a	O
100	O
%	O
case	O
fatality	O
rate	O
.	O

The	O
majority	O
of	O
the	O
causes	O
of	O
death	O
were	O
due	O
to	O
multi	B-DISO
-	I-DISO
organ	I-DISO
failure	I-DISO
and	O
septic	B-DISO
shock	I-DISO
.	O

TITLE	O
:	O
Hypothesis	O
for	O
potential	O
pathogenesis	B-DISO
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
-	I-DISO
2	I-DISO
infection	I-DISO
--	O
a	O
review	O
of	O
immune	O
changes	O
in	O
patients	O
with	O
viral	B-DISO
pneumonia	I-DISO
.	O

More	O
recent	O
research	O
highlights	O
the	O
importance	O
of	O
the	O
environmental	O
factors	O
,	O
especially	O
temperature	O
and	O
humidity	O
,	O
in	O
modulating	O
host	O
intrinsic	O
,	O
innate	O
,	O
and	O
adaptive	O
immune	O
responses	O
to	O
viral	B-DISO
infections	I-DISO
in	O
the	O
respiratory	O
tract	O
.	O

The	O
laboratory	O
diagnostic	O
methods	O
for	O
human	O
coronavirus	B-DISO
infections	I-DISO
have	O
evolved	O
substantially	O
,	O
with	O
the	O
development	O
of	O
novel	O
assays	O
as	O
well	O
as	O
the	O
availability	O
of	O
updated	O
tests	O
for	O
emerging	O
ones	O
.	O

Currently	O
,	O
there	O
is	O
no	O
clear	O
evidence	O
regarding	O
optimal	O
delivery	O
timing	O
,	O
the	O
safety	O
of	O
vaginal	O
delivery	O
,	O
or	O
whether	O
cesarean	O
delivery	O
prevents	O
vertical	B-DISO
transmission	I-DISO
at	O
the	O
time	O
of	O
delivery	O
;	O
therefore	O
,	O
route	O
of	O
delivery	O
and	O
delivery	O
timing	O
should	O
be	O
individualized	O
based	O
on	O
obstetrical	O
indications	O
and	O
maternal	O
-	O
fetal	O
status	O
.	O

One	O
of	O
the	O
five	O
patients	O
had	O
transient	O
hemostatic	O
medication	O
for	O
hemoptysis	B-DISO
.	O

However	O
,	O
it	O
is	O
worth	O
noting	O
that	O
the	O
symptoms	O
of	O
nasal	O
tampon	O
and	O
pharyngalgia	O
may	O
be	O
more	O
prone	O
to	O
appear	O
for	O
those	O
co	B-DISO
-	I-DISO
infection	I-DISO
patients	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
a	O
patient	O
in	O
Wuhan	O
,	O
China	O
,	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
2	O
infection	B-DISO
who	O
had	O
progressive	O
pulmonary	O
lesions	O
and	O
rhabdomyolysis	B-DISO
with	O
manifestations	O
of	O
lower	B-DISO
limb	I-DISO
pain	I-DISO
and	O
fatigue	B-DISO
.	O

Rapid	O
clinical	O
recognition	O
of	O
rhabdomyolysis	B-DISO
symptoms	O
in	O
patients	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
2	O
infection	B-DISO
can	O
be	O
lifesaving	O
.	O

Therefore	O
,	O
we	O
reinvestigated	O
published	O
data	O
from	O
pangolin	O
lung	O
samples	O
from	O
which	O
SARS	B-DISO
-	O
CoV	O
-	O
like	O

Aside	O
from	O
RaTG13	O
,	O
Pangolin	O
-	O
CoV	O
is	O
the	O
most	O
closely	O
related	O
CoV	O
to	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
.	O

Both	O
Pangolin	O
-	O
CoV	O
and	O
RaTG13	O
lost	O
the	O
putative	O
furin	O
recognition	O
sequence	O
motif	O
at	O
S1	O
/	O
S2	O
cleavage	O
site	O
that	O
can	O
be	O
observed	O
in	O
the	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
.	O

Clinical	O
trials	O
are	O
needed	O
to	O
determine	O
whether	O
this	O
drug	O
combination	O
might	O
be	O
used	O
to	O
treat	O
patients	O
with	O
severe	O
COVID	B-DISO
-	I-DISO
19	I-DISO
infection	I-DISO
.	O

TITLE	O
:	O
Practical	O
laboratory	O
considerations	O
amidst	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
outbreak	O
:	O
early	O
experience	O
from	O
Singapore	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
is	O
a	O
zoonotic	O
viral	B-DISO
infection	I-DISO
originating	O
from	O
Wuhan	O
,	O
China	O
in	O
December	O
2019	O
.	O

We	O
here	O
aim	O
to	O
describe	O
the	O
time	O
kinetics	O
of	O
various	O
antibodies	O
produced	O
against	O
the	O
2019	O
novel	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
)	O
and	O
evaluate	O
the	O
potential	O
of	O
antibody	O
testing	O
to	O
diagnose	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

The	O
host	O
humoral	O
response	O
against	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
including	O
IgA	O
,	O
IgM	O
and	O
IgG	O
response	O
were	O
examined	O
by	O
using	O
an	O
ELISA	O
based	O
assay	O
on	O
the	O
recombinant	O
viral	O
nucleocapsid	O
protein	O
.	O

RESULTS	O
:	O
In	O
Washington	O
State	O
,	O
the	O
first	O
week	O
of	O
March	O
started	O
with	O
4	O
confirmed	O
cases	O
and	O
ended	O
with	O
150	O
;	O
by	O
the	O
end	O
of	O
the	O
second	O
week	O
of	O
March	O
there	O
were	O
more	O
than	O
700	O
cases	O
of	O
confirmed	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

This	O
study	O
was	O
conducted	O
to	O
provide	O
the	O
international	O
community	O
with	O
a	O
deeper	O
understanding	O
of	O
this	O
new	O
infectious	B-DISO
disease	I-DISO
.	O

Kaletra	O
and	O
traditional	O
Chinese	O
medicine	O
played	O
an	O
important	O
role	O
in	O
the	O
treatment	O
of	O
the	O
viral	B-DISO
pneumonia	I-DISO
.	O

RESULTS	O
:	O
A	O
total	O
of	O
135	O
hospitalized	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
were	O
enrolled	O
.	O

ABSTRACT	O
:	O
In	O
December	O
2019	O
,	O
a	O
new	O
type	O
of	O
coronavirus	O
pneumonia	B-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
emerged	O
in	O
Wuhan	O
,	O
Hubei	O
,	O
and	O
spread	O
rapidly	O
to	O
China	O
and	O
over	O
100	O
countries	O
around	O
the	O
world	O
.	O

The	O
COVID	B-DISO
-	I-DISO
19	I-DISO
,	O
as	O
same	O
as	O
SARS	B-DISO
and	O
MERS	O
,	O
is	O
caused	O
by	O
coronaviruses	O
and	O
can	O
cause	O
viral	B-DISO
pneumonia	I-DISO
.	O

ABSTRACT	O
:	O
Public	O
health	O
measures	O
to	O
prevent	O
,	O
detect	O
,	O
and	O
respond	O
to	O
events	O
are	O
essential	O
to	O
control	O
public	O
health	O
risks	O
,	O
including	O
infectious	B-DISO
disease	I-DISO
outbreaks	O
,	O
as	O
highlighted	O
in	O
the	O
International	O
Health	O
Regulations	O
(	O
IHR	O
).	O

ABSTRACT	O
:	O
A	O
novel	O
form	O
of	O
Coronavirus	O
(	O
2019	O
-	O
nCoV	O
)	O
in	O
Wuhan	O
has	O
created	O
a	O
confused	B-DISO
and	O
rapidly	O
evolving	O
situation	O
.	O

ABSTRACT	O
:	O
The	O
new	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
)	O
outbreak	O
from	O
December	O
2019	O
in	O
Wuhan	O
,	O
Hubei	O
,	O
China	O
,	O
has	O
been	O
declared	O
a	O
global	O
public	O
health	O
emergency	B-DISO
.	O

Of	O
the	O
80	O
cases	O
,	O
76	O
patients	O
(	O
95	O
%)	O
had	O
bilateral	O
lung	B-DISO
disease	I-DISO
,	O
four	O
(	O
5	O
%)	O
patients	O
had	O
unilateral	O
lung	B-DISO
disease	I-DISO
,	O
and	O
eight	O
(	O
10	O
%)	O
patients	O
had	O
cord	B-DISO
shadow	O
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
Coronavirus	B-DISO
Disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
causing	O
novel	O
coronavirus	O
-	O
infected	O
pneumonia	B-DISO
(	O
NCIP	O
),	O
has	O
affected	O
the	O
lives	O
of	O
71	O
,	O
429	O
people	O
globally	O
.	O

Research	O
suggests	O
remarkable	O
genomic	O
resemblance	O
of	O
2019	O
-	O
nCoV	O
with	O
Severe	B-DISO
Acute	I-DISO
Respiratory	I-DISO
Syndrome	I-DISO
(	O
SARS	B-DISO
)	O
which	O
has	O
a	O
history	O
of	O
a	O
pandemic	O
in	O
2002	O
.	O

So	O
far	O
,	O
COVID	B-DISO
-	I-DISO
19	I-DISO
has	O
affected	O
84	O
,	O
503	O
patients	O
in	O
57	O
countries	O
/	O
territories	O
and	O
caused	O
2	O
,	O
924	O
deaths	O
in	O
nine	O
countries	O
.	O

The	O
daily	O
cumulative	O
index	O
(	O
DCI	B-DISO
)	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
(	O
cumulative	O
cases	O
/	O
no	O
.	O

Most	O
often	O
at	O
the	O
origin	O
of	O
a	O
mild	O
infectious	B-DISO
syndrome	B-DISO
,	O
associating	O
mild	O
symptoms	O
(	O
fever	O
,	O
cough	B-DISO
,	O
myalgia	B-DISO
,	O
headache	B-DISO
and	O
possible	O
digestive	B-DISO
disorders	I-DISO
)	O
to	O
different	O
degrees	O
,	O
SARS	B-DISO
-	O
Covid	O
-	O
2	O
can	O
cause	O
serious	O
pulmonary	O
pathologies	O
and	O
sometimes	O
death	O
.	O

Current	O
evidence	O
suggests	O
that	O
patients	O
with	O
advanced	O
age	O
,	O
pre	O
-	O
existing	O
comorbidities	O
or	O
dyspnoea	B-DISO
should	O
be	O
closely	O
monitored	O
,	O
especially	O
at	O
1	O
-	O
2	O
weeks	O
after	O
symptom	B-DISO
onset	O
.	O

TITLE	O
:	O
Cardiovascular	O
Considerations	O
for	O
Patients	O
,	O
Health	O
Care	O
Workers	O
,	O
and	O
Health	O
Systems	O
During	O
the	O
Coronavirus	B-DISO
Disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
Pandemic	O
.	O

TITLE	O
:	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
:	O
fear	O
versus	O
data	O
.	O

This	O
article	O
compares	O
the	O
incidence	O
and	O
mortality	O
rates	O
of	O
these	O
four	O
common	O
coronaviruses	O
with	O
those	O
of	O
SARS	B-DISO
-	O
COV	O
-	O
2	O
in	O
Organisation	O
for	O
Economic	O
Co	O
-	O
operation	O
and	O
Development	O
countries	O
.	O

ABSTRACT	O
:	O
Up	O
to	O
November	O
2014	O
,	O
Middle	O
East	O
respiratory	O
syndrome	B-DISO
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
has	O
infected	O
935	O
individuals	O
and	O
killed	O
371	O
,	O
all	O
originating	O
in	O
or	O
with	O
links	O
to	O
the	O
Middle	O
East	O
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
the	O
current	O
knowledge	O
on	O
PTMs	O
of	O
CoV	O
proteins	O
,	O
with	O
an	O
emphasis	O
on	O
their	O
impact	O
on	O
viral	O
replication	O
and	O
pathogenesis	B-DISO
.	O

An	O
activated	O
STAT3	O
translocates	O
into	O
the	O
nucleus	O
and	O
combines	O
with	O
DNA	O
to	O
regulate	O
the	O
expression	O
of	O
target	O
genes	O
involved	O
in	O
cell	O
proliferation	B-DISO
,	O
differentiation	O
,	O
apoptosis	O
and	O
metastasis	B-DISO
.	O

Dermatologists	O
in	O
China	O
have	O
participated	O
in	O
the	O
fight	O
against	O
Covid	B-DISO
-	I-DISO
19	I-DISO
.	O

In	O
the	O
pessimistic	O
scenario	O
of	O
R0	O
=	O
4	O
,	O
and	O
asymptomatic	B-DISO
infections	I-DISO
being	O
half	O
as	O
infectious	B-DISO
as	O
symptomatic	O
,	O
this	O
projected	O
impact	O
falls	O
to	O
two	O
per	O
cent	O
.	O

Model	O
projections	O
are	O
subject	O
to	O
substantial	O
uncertainty	O
and	O
can	O
be	O
further	O
refined	O
as	O
more	O
is	O
understood	O
about	O
the	O
natural	O
history	O
of	O
infection	B-DISO
of	O
this	O
novel	O
virus	O
.	O

TITLE	O
:	O
Factors	O
Associated	O
With	O
Mental	O
Health	O
Outcomes	O
Among	O
Health	O
Care	O
Workers	O
Exposed	O
to	O
Coronavirus	B-DISO
Disease	I-DISO
2019	I-DISO
.	O

A	O
considerable	O
proportion	O
of	O
participants	O
reported	O
symptoms	B-DISO
of	I-DISO
depression	I-DISO
(	O
634	O
[	O
50	O
.	O
4	O
%]),	O
anxiety	O
(	O
560	O
[	O
44	O
.	O
6	O
%]),	O
insomnia	B-DISO
(	O
427	O
[	O
34	O
.	O
0	O
%]),	O
and	O
distress	O
(	O
899	O
[	O
71	O
.	O
5	O
%]).	O

The	O
number	O
of	O
patients	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
infection	I-DISO
who	O
might	O
develop	O
severe	O
ARDS	B-DISO
that	O
is	O
refractory	O
to	O
maximal	O
medical	O
management	O
and	O
require	O
this	O
level	O
of	O
support	O
is	O
currently	O
unknown	O
.	O

Ensuring	O
that	O
systems	O
enable	O
safe	O
and	O
coordinated	O
movement	O
of	O
critically	B-DISO
ill	I-DISO
patients	O
,	O
staff	O
,	O
and	O
equipment	O
is	O
important	O
to	O
improve	O
ECMO	O
access	O
.	O

TITLE	O
:	O
Should	O
COVID	B-DISO
-	I-DISO
19	I-DISO
Concern	O
Nephrologists	O
?	O

Lastly	O
,	O
we	O
discuss	O
the	O
clinical	O
management	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
patients	O
with	O
existing	O
chronic	O
renal	B-DISO
disorders	I-DISO
,	O
particularly	O
those	O
in	O
dialysis	O
and	O
with	O
kidney	O
transplants	O
.	O

ABSTRACT	O
:	O
COVID	B-DISO
-	I-DISO
19	I-DISO
(	O
Corona	B-DISO
Virus	I-DISO
Disease	I-DISO
2019	I-DISO
)	O
has	O
significantly	O
resulted	O
in	O
a	O
large	O
number	O
of	O
psychological	B-DISO
consequences	O
.	O

The	O
sentiment	O
analysis	O
and	O
the	O
paired	O
sample	O
t	O
-	O
test	O
were	O
performed	O
to	O
examine	O
the	O
differences	O
in	O
the	O
same	O
group	O
before	O
and	O
after	O
the	O
declaration	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
on	O
20	O
January	O
,	O
2020	O
.	O

Interferons	O
(	O
IFNs	O
),	O
especially	O
type	O
I	O
IFNs	O
(	O
IFN	O
-	O
α	O
,	O
IFN	O
-	O
β	O
,	O
and	O
interferon	O
omega	O
(	O
IFN	O
-	O
ω	O
)),	O
have	O
been	O
explored	O
as	O
effective	O
therapeutic	O
drugs	O
against	O
viral	B-DISO
diseases	I-DISO
in	O
cats	O
.	O

The	O
children	O
with	O
hematological	B-DISO
tumors	I-DISO
are	O
a	O
special	O
population	O
with	O
immunosuppression	O
and	O
special	O
therapeutic	O
characteristics	O
.	O

In	O
order	O
to	O
define	O
an	O
effective	O
and	O
safe	O
treatment	O
for	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
-	O
associated	O
disease	O
,	O
we	O
provide	O
considerations	O
on	O
the	O
actual	O
treatments	O
,	O
on	O
how	O
to	O
avoid	O
complications	O
and	O
the	O
undesirable	O
side	O
effects	O
related	O
to	O
them	O
and	O
to	O
select	O
and	O
apply	O
earlier	O
the	O
most	O
appropriate	O
treatment	O
.	O

Perinatal	O
and	O
neonatal	O
management	O
plan	B-DISO
for	O
prevention	O
and	O
control	O
of	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
-	I-DISO
2	I-DISO
infection	I-DISO
(	O
2nd	O
Edition	O
)	O
has	O
been	O
worked	O
out	O
by	O
the	O
Editorial	O
Committee	O
of	O
Chinese	O
Journal	O
of	O
Contemporary	O
Pediatrics	O
.	O

TITLE	O
:	O
[	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
-	I-DISO
2	I-DISO
infection	I-DISO
with	O
gastrointestinal	B-DISO
symptoms	I-DISO
as	O
the	O
first	O
manifestation	O
in	O
a	O
neonate	O
].	O

Most	O
children	O
with	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
-	I-DISO
2	I-DISO
infection	I-DISO
present	O
mainly	O
with	O
respiratory	B-DISO
symptoms	I-DISO
,	O
but	O
less	O
commonly	O
with	O
gastrointestinal	B-DISO
symptoms	I-DISO
,	O
and	O
tend	O
to	O
have	O
mild	O
clinical	O
symptoms	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
clinical	O
features	O
and	O
chest	O
CT	O
findings	O
of	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
in	O
infants	O
and	O
young	O
children	O
.	O

The	O
twin	O
girls	O
,	O
aged	O
1	O
year	O
and	O
2	O
months	O
,	O
were	O
admitted	O
on	O
January	O
29	O
,	O
2020	O
due	O
to	O
fever	O
for	O
one	O
day	O
and	O
cough	B-DISO
and	O
sneezing	O
for	O
two	O
days	O
respectively	O
.	O

The	O
two	O
girls	O
had	O
mild	O
symptoms	O
and	O
rapid	O
recovery	O
,	O
suggesting	O
that	O
children	O
with	O
SARS	B-DISO
-	I-DISO
CoV	I-DISO
-	I-DISO
2	I-DISO
infection	I-DISO
may	O
be	O
mild	O
and	O
have	O
a	O
good	O
prognosis	O
.	O

,	O
the	O
outbreak	O
of	O
coronavirus	O
disease	O
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
)	O
has	O
become	O
the	O
most	O
serious	O
public	O
health	O
issue	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
disease	O
is	O
an	O
emerging	O
infection	B-DISO
caused	O
by	O
a	O
novel	O
coronavirus	O
that	O
is	O
moving	O
rapidly	O
.	O

TITLE	O
:	O
Imaging	O
Features	O
of	O
Coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
):	O
Evaluation	O
on	O
Thin	O
-	O
Section	O
CT	O
.	O

COVID	B-DISO
-	I-DISO
19	I-DISO
showed	O
the	O
pulmonary	O
lesions	O
in	O
patients	O
infected	O
with	O
COVID	B-DISO
-	I-DISO
19	I-DISO
were	O
predominantly	O
distributed	O
peripherally	O
in	O
the	O
subpleural	O
area	O
.	O

While	O
COVID	B-DISO
-	I-DISO
19	I-DISO
cases	O
with	O
travel	O
history	O
to	O
China	O
seem	O
to	O
peak	O
for	O
each	O
HAQ	O
-	O
cohort	O
,	O
the	O
number	O
of	O
non	O
-	O
travel	O
related	O
COVID	B-DISO
-	I-DISO
19	I-DISO
cases	O
seem	O
to	O
continuously	O
increase	O
in	O
the	O
HAQ	O
-	O
cohort	O
of	O
countries	O
with	O
higher	O
medical	O
standards	O
.	O

ABSTRACT	O
:	O
COVID	B-DISO
-	I-DISO
19	I-DISO
emerges	O
as	O
a	O
pandemic	O
disease	O
with	O
high	O
mortality	O
.	O

We	O
reviewed	O
TH17	O
responses	O
in	O
patients	O
with	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
and	O
proposed	O
an	O
FDA	O
approved	O
JAK2	O
inhibitor	O
Fedratinib	O
for	O
reducing	O
mortality	O
of	O
patients	O
with	O
TH17	O
type	O
immune	O
profiles	O
.	O

TITLE	O
:	O
COVID	B-DISO
-	I-DISO
19	I-DISO
infection	I-DISO
and	O
rheumatoid	B-DISO
arthritis	I-DISO
:	O
Faraway	O
,	O
so	O
close	O
!	O

Given	O
the	O
lack	O
of	O
specific	O
anti	O
-	O
viral	O
therapies	O
,	O
the	O
current	O
management	O
of	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronaviruses	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
)	O
is	O
mainly	O
supportive	O
,	O
even	O
though	O
several	O
compounds	O
are	O
now	O
under	O
investigation	O
for	O
the	O
treatment	O
of	O
this	O
life	O
-	O
threatening	O
disease	O
.	O

RESULTS	O
:	O
Six	O
patients	O
were	O
asymptomatic	O
,	O
22	O
had	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
symptoms	O
and	O
eight	O
had	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
symptoms	O
.	O

TITLE	O
:	O
Lianhuaqingwen	O
exerts	O
anti	O
-	O
viral	O
and	O
anti	O
-	O
inflammatory	O
activity	O
against	O
novel	O
coronavirus	O
(	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
).	O

ABSTRACT	O
:	O
Lianhuaqingwen	O
(	O
LH	O
)	O
as	O
traditional	O
Chinese	O
medicine	O
(	O
TCM	O
)	O
formula	O
has	O
been	O
used	O
to	O
treat	O
influenza	B-DISO
and	O
exerted	O
broad	O
-	O
spectrum	O
antiviral	O
effects	O
on	O
a	O
series	O
of	O
influenza	B-DISO
viruses	O
and	O
immune	O
regulatory	O
effects	O
[	O
1	O
].	O

LH	O
significantly	O
inhibits	O
the	O
SARS	B-DISO
-	O
COV	O
-	O
2	O
replication	O
,	O
affects	O
virus	O
morphology	O
and	O
exerts	O
anti	O
-	O
inflammatory	O
activity	O
in	O
vitro	O
.	O

RESULTS	O
:	O
LH	O
significantly	O
inhibited	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
replication	O
in	O
Vero	O
E6	O
cells	O
and	O
markedly	O
reduced	O
pro	O
-	O
inflammatory	O
cytokines	O
(	O
TNF	O
-	O
α	O
,	O
IL	O
-	O
6	O
,	O
CCL	B-DISO
-	O
2	O
/	O
MCP	O
-	O
1	O
and	O
CXCL	O
-	O
10	O
/	O
IP	O
-	O
10	O
)	O
production	O
at	O
the	O
mRNA	O
levels	O
.	O

In	O
this	O
study	O
,	O
Swedish	O
privately	O
-	O
owned	O
dogs	O
with	O
characteristic	O
signs	O
of	O
canine	O
infectious	B-DISO
respiratory	B-DISO
disease	I-DISO
(	O
n	O
=	O
88	O
)	O
were	O
screened	O
for	O
CRCoV	O
and	O
13	O
positive	O
samples	O
(	O
14	O
.	O
7	O
%,	O
8	O
.	O
4	O
-	O
23	O
.	O
7	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)])	O
were	O
further	O
sequenced	O
.	O

Over	O
our	O
study	O
period	O
,	O
no	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
was	O
detected	O
.	O

TITLE	O
:	O
Acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
-	O
attributable	O
mortality	O
in	O
critically	B-DISO
ill	I-DISO
patients	O
with	O
sepsis	B-DISO
.	O

The	O
attributable	O
mortality	O
of	O
ARDS	B-DISO
was	O
27	O
%	O
(	O
CI	O
14	O
%,	O
37	O
%)	O
in	O
EARLI	O
and	O
37	O
%	O
(	O
CI	O
10	O
%,	O
51	O
%)	O
in	O
VALID	O
.	O

Clinical	O
diagnoses	O
included	O
upper	B-DISO
respiratory	I-DISO
tract	I-DISO
infection	I-DISO
(	O
n	O
=	O
8	O
),	O
mild	O
pneumonia	B-DISO
(	O
n	O
=	O
15	O
),	O
and	O
critical	O
cases	O
(	O
n	O
=	O
2	O
).	O

When	O
tested	O
against	O
the	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
pseudovirus	O
,	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
convalescent	O
patient	O
sera	O
showed	O
high	O
neutralizing	O
potency	O
,	O
which	O
underscore	O
its	O
potential	O
as	O
therapeutics	O
.	O

ABSTRACT	O
:	O
To	O
analyze	O
the	O
CT	O
findings	O
of	O
patients	O
with	O
different	O
clinical	O
types	O
of	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
(	O
COVID	B-DISO
-	I-DISO
19	I-DISO
).	O

Consolidation	O
shadow	O
as	O
the	O
main	O
lesion	O
was	O
observed	O
in	O
7	O
cases	O
,	O
and	O
all	O
of	O
them	O
were	O
severe	O
or	O
critical	O
ill	B-DISO
patients	O
.	O

Strategic	O
planning	O
and	O
adequate	O
protections	O
can	O
help	O
protect	O
patients	O
and	O
staff	O
against	O
a	O
highly	O
infectious	B-DISO
disease	I-DISO
while	O
allow	O
normal	O
functioning	O
at	O
a	O
high	O
-	O
volume	O
capacity	O
.	O

We	O
outline	O
the	O
design	O
and	O
implementation	O
of	O
EHR	O
based	O
rapid	O
screening	O
processes	O
,	O
laboratory	O
testing	O
,	O
clinical	O
decision	O
support	O
,	O
reporting	O
tools	O
,	O
and	O
patient	O
-	O
facing	O
technology	O
related	O
to	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

The	O
EHR	O
is	O
an	O
essential	O
tool	O
in	O
supporting	O
the	O
clinical	O
needs	O
of	O
a	O
health	O
system	O
managing	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pandemic	O
.	O

RESULTS	O
:	O
We	O
outline	O
the	O
design	O
and	O
implementation	O
of	O
EHR	O
based	O
rapid	O
screening	O
processes	O
,	O
laboratory	O
testing	O
,	O
clinical	O
decision	O
support	O
,	O
reporting	O
tools	O
,	O
and	O
patient	O
-	O
facing	O
technology	O
related	O
to	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

CONCLUSIONS	O
:	O
The	O
EHR	O
is	O
an	O
essential	O
tool	O
in	O
supporting	O
the	O
clinical	O
needs	O
of	O
a	O
health	O
system	O
managing	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
pandemic	O
.	O

Professor	O
Wenhong	O
Zhang	O
is	O
responsible	O
for	O
Shanghai	O
'	O
s	O
overall	O
clinical	O
management	O
of	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
cases	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aims	O
to	O
analyze	O
the	O
different	O
clinical	O
characteristics	O
between	O
children	O
and	O
their	O
families	O
infected	O
with	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
2	O
.	O

COVID	B-DISO
-	I-DISO
19	I-DISO
in	O
children	O
is	O
mainly	O
caused	O
by	O
family	O
transmission	O
,	O
and	O
their	O
symptoms	O
are	O
mild	O
and	O
prognosis	O
is	O
better	O
than	O
adult	O
.	O

Because	O
the	O
ACE2	O
(	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
)	O
protein	O
is	O
the	O
receptor	O
that	O
facilitates	O
coronavirus	O
entry	O
into	O
cells	O
,	O
the	O
notion	O
has	O
been	O
popularized	O
that	O
treatment	O
with	O
renin	O
-	O
angiotensin	O
system	O
blockers	O
might	O
increase	O
the	O
risk	O
of	O
developing	O
a	O
severe	O
and	O
fatal	O
severe	B-DISO
acute	I-DISO
respiratory	I-DISO
syndrome	I-DISO
coronavirus	O
-	O
2	O
infection	B-DISO
.	O

The	O
smooth	O
distance	O
curve	O
for	O
SARS	B-DISO
-	O
CoV	O
suggests	O
that	O
its	O
close	O
relatives	O
still	O
exist	O
in	O
nature	O
and	O
public	O
health	O
is	O
challenged	O
as	O
usual	O
.	O

Current	O
discharge	O
criteria	O
and	O
the	O
impact	O
of	O
extra	O
-	O
pulmonary	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
samples	O
are	O
discussed	O
.	O

Our	O
study	O
enrolled	O
109	O
COVID	B-DISO
-	I-DISO
19	I-DISO
patients	O
who	O
died	O
during	O
hospitalization	O
and	O
116	O
recovered	O
patients	O
.	O

The	O
patients	O
in	O
the	O
death	O
group	O
had	O
more	O
complications	O
such	O
as	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
89	O
.	O
9	O
%	O
vs	O
.	O
7	O
.	O
6	O
%,	O
χ	O
=	O
148	O
.	O
105	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
acute	O
cardiac	O
injury	O
(	O
59	O
.	O
6	O
%	O
vs	O
.	O
0	O
.	O
8	O
%,	O
χ	O
=	O
93	O
.	O
222	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
acute	O
kidney	O
injury	O
(	O
18	O
.	O
3	O
%	O
vs	O
.	O
0	O
,	O
χ	O
=	O
23	O
.	O
257	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
shock	O
(	O
11	O
.	O
9	O
%	O
vs	O
.	O
0	O
,	O
χ	O
=	O
14	O
.	O
618	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
disseminated	B-DISO
intravascular	I-DISO
coagulation	I-DISO
(	O
DIC	B-DISO
)	O
(	O
6	O
.	O
4	O
%	O
vs	O
.	O
0	O
,	O
χ	O
=	O
7	O
.	O
655	O
,	O
P	O
=	O
0	O
.	O
006	O
).	O

To	O
aid	O
the	O
analysis	O
and	O
tracking	O
of	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
epidemic	O
we	O
collected	O
and	O
curated	O
individual	O
-	O
level	O
data	O
from	O
national	O
,	O
provincial	O
,	O
and	O
municipal	O
health	O
reports	O
,	O
as	O
well	O
as	O
additional	O
information	O
from	O
online	O
reports	O
.	O

TITLE	O
:	O
Invasive	B-DISO
Aspergillosis	I-DISO
After	O
Non	O
-	O
Fatal	O
Drowning	O
.	O

TITLE	O
:	O
Role	O
of	O
changes	O
in	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
spike	O
protein	O
in	O
the	O
interaction	O
with	O
the	O
human	O
ACE2	O
receptor	O
:	O
An	O
ABSTRACT	O
:	O
Many	O
human	O
viral	B-DISO
diseases	I-DISO
are	O
a	O
consequence	O
of	O
a	O
zoonotic	O
event	O
.	O

TITLE	O
:	O
A	O
numerical	O
study	O
of	O
ventilation	O
strategies	O
for	O
infection	B-DISO
risk	O
mitigation	O
in	O
general	O
inpatient	O
wards	O
.	O

The	O
outcome	O
of	O
this	O
study	O
can	O
serve	O
as	O
a	O
source	O
of	O
reference	O
for	O
hospital	O
management	O
to	O
better	O
ventilation	O
design	O
strategies	O
for	O
mitigating	O
the	O
risk	O
of	O
infection	B-DISO
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
incidence	O
of	O
moderate	O
and	O
severe	O
ARDS	B-DISO
and	O
its	O
risk	O
factors	O
among	O
burn	O
-	O
related	O
demographic	O
variables	O
and	O
clinical	O
interventions	O
in	O
mechanically	O
ventilated	O
burn	O
patients	O
.	O

Current	O
tidal	O
volume	O
,	O
driving	O
pressure	O
,	O
red	O
blood	O
cell	O
transfusion	O
,	O
acute	O
renal	O
injury	O
,	O
and	O
FB	O
were	O
not	O
predictors	O
of	O
ARDS	B-DISO
.	O

TITLE	O
:	O
Epidemiological	O
and	O
Clinical	O
Predictors	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
.	O

Rapidly	O
ascertainable	O
clinical	O
and	O
laboratory	O
data	O
could	O
identify	O
individuals	O
at	O
high	O
risk	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
and	O
enable	O
prioritization	O
of	O
PCR	O
-	O
testing	O
and	O
containment	O
efforts	O
.	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
the	O
COVID	B-DISO
-	I-DISO
19	I-DISO
caused	O
by	O
Coronavirus	O
SARS	B-DISO
-	O
CoV2	O
,	O
is	O
rapidly	O
spreading	O
worldwide	O
.	O

No	O
data	O
are	O
available	O
on	O
the	O
risk	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
and	O
outcomes	O
in	O
inflammatory	B-DISO
bowel	I-DISO
disease	I-DISO
(	O
IBD	B-DISO
)	O
patients	O
.	O

As	O
the	O
number	O
of	O
imported	O
SARS	B-DISO
-	O
CoV	O
-	O
2	O
cases	O
is	O
on	O
the	O
rise	O
in	O
Brazil	O
,	O
we	O
use	O
incidence	O
and	O
historical	O
air	O
travel	O
data	O
to	O
estimate	O
the	O
most	O
important	O
routes	O
of	O
importation	O
into	O
the	O
country	O
.	O

Complications	O
were	O
more	O
common	O
in	O
patients	O
with	O
cardiac	O
injury	O
than	O
those	O
without	O
cardiac	O
injury	O
and	O
included	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
48	O
of	O
82	O
[	O
58	O
.	O
5	O
%]	O
vs	O
49	O
of	O
334	O
[	O
14	O
.	O
7	O
%];	O
P	O
<	O
.	O
001	O
),	O
acute	O
kidney	O
injury	O
(	O
7	O
of	O
82	O
[	O
8	O
.	O
5	O
%]	O
vs	O
1	O
of	O
334	O
[	O
0	O
.	O
3	O
%];	O
P	O
<	O
.	O
001	O
),	O
electrolyte	O
disturbances	O
(	O
13	O
of	O
82	O
[	O
15	O
.	O
9	O
%]	O
vs	O
17	O
of	O
334	O
[	O
5	O
.	O
1	O
%];	O
P	O
=	O
.	O
003	O
),	O
hypoproteinemia	B-DISO
(	O
11	O
of	O
82	O
[	O
13	O
.	O
4	O
%]	O
vs	O
16	O
of	O
334	O
[	O
4	O
.	O
8	O
%];	O
P	O
=	O
.	O
01	O
),	O
and	O
coagulation	B-DISO
disorders	I-DISO
(	O
6	O
of	O
82	O
[	O
7	O
.	O
3	O
%]	O
vs	O
6	O
of	O
334	O
[	O
1	O
.	O
8	O
%];	O
P	O
=	O
.	O
02	O
).	O

In	O
a	O
Cox	O
regression	O
model	O
,	O
patients	O
with	O
vs	O
those	O
without	O
cardiac	O
injury	O
were	O
at	O
a	O
higher	O
risk	O
of	O
death	O
,	O
both	O
during	O
the	O
time	O
from	O
symptom	B-DISO
onset	O
(	O
hazard	O
ratio	O
,	O
4	O
.	O
26	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
92	O
-	O
9	O
.	O
49	O
])	O
and	O
from	O
admission	O
to	O
end	O
point	O
(	O
hazard	O
ratio	O
,	O
3	O
.	O
41	O
[	O
95	O
%	O
CI	O
,	O
1	O
.	O
62	O
-	O
7	O
.	O
16	O
]).	O

ABSTRACT	O
:	O
The	O
outbreak	O
of	O
COVID	B-DISO
-	I-DISO
19	I-DISO
has	O
become	O
a	O
big	O
threat	O
to	O
China	O
,	O
with	O
high	O
contagious	O
capacity	O
and	O
varied	O
mortality	O
.	O

Total	O
788	O
patients	O
with	O
confirmed	O
COVID	B-DISO
-	I-DISO
19	I-DISO
were	O
selected	O
,	O
where	O
136	O
were	O
older	O
patients	O
with	O
corresponding	O
age	O
of	O
68	O
.	O
28y	O
±	O
7	O
.	O
314y	O
.	O

ABSTRACT	O
:	O
To	O
systematically	O
analyze	O
CT	O
findings	O
during	O
the	O
early	O
and	O
progressive	O
stages	O
of	O
natural	O
course	O
of	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
and	O
also	O
to	O
explore	O
possible	O
changes	O
in	O
pulmonary	O
parenchymal	O
abnormalities	O
during	O
these	O
two	O
stages	O
.	O

In	O
our	O
study	O
,	O
the	O
major	O
characteristic	O
of	O
coronavirus	B-DISO
disease	I-DISO
2019	I-DISO
was	O
ground	O
-	O
glass	O
opacity	B-DISO
(	O
61	O
.	O
3	O
%),	O
followed	O
by	O
ground	O
-	O
glass	O
opacity	B-DISO
with	O
consolidation	O
(	O
35	O
.	O
5	O
%),	O
rounded	O
opacities	B-DISO
(	O
25	O
.	O
8	O
%),	O
a	O
crazy	O
-	O
paving	O
pattern	O
(	O
25	O
.	O
8	O
%),	O
and	O
an	O
air	O
bronchogram	O
(	O
22	O
.	O
6	O
%).	O

The	O
experience	O
and	O
lessons	O
learned	O
should	O
be	O
a	O
valuable	O
asset	O
for	O
international	O
health	O
community	O
to	O
contain	O
the	O
ongoing	O
COVID	B-DISO
-	I-DISO
19	I-DISO
epidemic	O
around	O
the	O
world	O
.	O

Having	O
a	O
well	O
thought	O
out	O
regional	O
anesthesia	B-DISO
plan	B-DISO
to	O
manage	O
these	O
patients	O
in	O
this	O
new	O
normal	O
will	O
ensure	O
the	O
best	O
possible	O
outcome	O
for	O
both	O
the	O
patient	O
and	O
the	O
perioperative	O
management	O
team	O
.	O

ABSTRACT	O
:	O
This	O
commentary	O
seeks	O
to	O
share	O
some	O
key	O
insights	O
relevant	O
to	O
optimizing	O
COVID	B-DISO
-	I-DISO
19	I-DISO
candidate	O
therapeutics	O
that	O
were	O
learned	O
from	O
attempts	O
to	O
optimize	O
anti	O
-	O
infective	O
posology	O
in	O
settings	O
where	O
quality	O
and	O
timely	O
availability	O
of	O
data	O
is	O
challenging	O
,	O
with	O
particular	O
focus	O
on	O
influenza	B-DISO
,	O
including	O
experiences	O
from	O
H5N1	B-DISO
and	O
pH1N1	O
outbreaks	O
.	O

The	O
group	O
most	O
susceptible	O
to	O
COVID	B-DISO
-	I-DISO
19	I-DISO
are	O
older	O
adults	O
and	O
those	O
with	O
chronic	O
underlying	O
chronic	O
medical	O
disorders	O
.	O

Viral	B-DISO
infections	I-DISO
often	O
affected	O
the	O
heart	O
and	O
gastrointestinal	O
tract	O
.	O

The	O
dosage	O
used	O
according	O
to	O
current	O
clinical	O
recommended	O
dosage	O
and	O
course	O
of	O
treatment	O
are	O
larger	O
than	O
that	O
of	O
previous	O
treatment	O
of	O
malaria	B-DISO
.	O

